After BC2GM086731573 IN O
control BC2GM086731573 NN O
for BC2GM086731573 IN O
body BC2GM086731573 NN O
mass BC2GM086731573 NN O
index BC2GM086731573 NN O
, BC2GM086731573 , O
trait BC2GM086731573 NN O
anxiety BC2GM086731573 NN O
and BC2GM086731573 CC O
anger-in BC2GM086731573 JJ O
remained BC2GM086731573 JJ O
independent BC2GM086731573 JJ O
predictors BC2GM086731573 NNS O
of BC2GM086731573 IN O
diastolic BC2GM086731573 JJ O
blood BC2GM086731573 NN O
pressure BC2GM086731573 NN O
among BC2GM086731573 IN O
the BC2GM086731573 DT O
women BC2GM086731573 NNS O
. BC2GM086731573 . O
. . O O

We BC2GM062908561 PRP O
used BC2GM062908561 VBD O
high-resolution BC2GM062908561 NN O
ultrasound BC2GM062908561 NN O
to BC2GM062908561 TO O
characterize BC2GM062908561 VB O
postprandial BC2GM062908561 JJ O
antral BC2GM062908561 JJ O
excursion BC2GM062908561 NN O
characteristics BC2GM062908561 NNS O
in BC2GM062908561 IN O
15 BC2GM062908561 CD O
healthy BC2GM062908561 JJ O
volunteers BC2GM062908561 NNS O
. BC2GM062908561 . O
. . O O

In BC2GM034854345 IN O
this BC2GM034854345 DT O
study BC2GM034854345 NN O
, BC2GM034854345 , O
a BC2GM034854345 DT O
site BC2GM034854345 NN O
of BC2GM034854345 IN O
PDGF-induced BC2GM034854345 NNP O
tyrosine BC2GM034854345 NN O
phosphorylation BC2GM034854345 NN O
was BC2GM034854345 VBD O
mapped BC2GM034854345 VBN O
to BC2GM034854345 TO O
Tyr BC2GM034854345 VB O
138 BC2GM034854345 CD O
in BC2GM034854345 IN O
the BC2GM034854345 DT O
SH3 BC2GM034854345 NNP O
domain BC2GM034854345 NN O
; BC2GM034854345 : O
Tyr BC2GM034854345 NNP O
138 BC2GM034854345 CD O
is BC2GM034854345 VBZ O
exposed BC2GM034854345 VBN O
on BC2GM034854345 IN O
the BC2GM034854345 DT O
SH3 BC2GM034854345 NNP O
peptide BC2GM034854345 NN O
binding BC2GM034854345 VBG O
surface BC2GM034854345 NN O
. BC2GM034854345 . O
. . O O

Reversal BC2GM001688677 NNP O
of BC2GM001688677 IN O
biliary BC2GM001688677 JJ O
sphincter BC2GM001688677 NN O
spasm BC2GM001688677 NN O
with BC2GM001688677 IN O
low BC2GM001688677 JJ O
dose BC2GM001688677 JJ O
glucagon BC2GM001688677 NN O
during BC2GM001688677 IN O
operative BC2GM001688677 JJ O
cholangiography BC2GM001688677 NN O
. BC2GM001688677 . O
. . O O

Rewarding BC2GM058058644 VBG O
properties BC2GM058058644 NNS O
of BC2GM058058644 IN O
methylphenidate BC2GM058058644 NN O
: BC2GM058058644 : O
sensitization BC2GM058058644 NN O
by BC2GM058058644 IN O
prior BC2GM058058644 JJ O
exposure BC2GM058058644 NN O
to BC2GM058058644 TO O
the BC2GM058058644 DT O
drug BC2GM058058644 NN O
and BC2GM058058644 CC O
effects BC2GM058058644 NNS O
of BC2GM058058644 IN O
dopamine BC2GM058058644 JJ O
D1- BC2GM058058644 NNP O
and BC2GM058058644 CC O
D2-receptor BC2GM058058644 NNP O
antagonists BC2GM058058644 NNS O
. BC2GM058058644 . O
. . O O

Sequence BC2GM046184202 NN O
analysis BC2GM046184202 NN O
and BC2GM046184202 CC O
electrophoretic BC2GM046184202 JJ O
mobility BC2GM046184202 NN O
shift BC2GM046184202 NN O
experiments BC2GM046184202 NNS O
suggest BC2GM046184202 VBP O
that BC2GM046184202 IN O
GnSE BC2GM046184202 NNP O
response BC2GM046184202 NN O
elements BC2GM046184202 NNS O
interact BC2GM046184202 JJ O
, BC2GM046184202 , O
in BC2GM046184202 IN O
these BC2GM046184202 DT O
two BC2GM046184202 CD O
regions BC2GM046184202 NNS O
, BC2GM046184202 , O
with BC2GM046184202 IN O
GATA- BC2GM046184202 NNP O
and BC2GM046184202 CC O
LIM-related BC2GM046184202 JJ O
factors BC2GM046184202 NNS O
, BC2GM046184202 , O
respectively BC2GM046184202 RB O
. BC2GM046184202 . O
. . O O

The BC2GM058847965 DT O
disorders BC2GM058847965 NNS O
are BC2GM058847965 VBP O
accompanied BC2GM058847965 VBN O
by BC2GM058847965 IN O
consistent BC2GM058847965 JJ O
, BC2GM058847965 , O
but BC2GM058847965 CC O
similarly BC2GM058847965 RB O
reversible BC2GM058847965 JJ O
, BC2GM058847965 , O
electroencephalographic BC2GM058847965 JJ O
changes BC2GM058847965 NNS O
. BC2GM058847965 . O
. . O O

In BC2GM097504248 IN O
vitro BC2GM097504248 JJ O
binding BC2GM097504248 NN O
studies BC2GM097504248 NNS O
previously BC2GM097504248 RB O
showed BC2GM097504248 VBD O
that BC2GM097504248 IN O
NF-kappa BC2GM097504248 NNP O
B BC2GM097504248 NNP O
p50 BC2GM097504248 NN O
homodimer BC2GM097504248 NN O
binds BC2GM097504248 VBZ O
the BC2GM097504248 DT O
switch BC2GM097504248 JJ O
nuclear BC2GM097504248 JJ O
B-site BC2GM097504248 JJ O
protein BC2GM097504248 NN O
( BC2GM097504248 ( O
SNIP BC2GM097504248 NNP O
) BC2GM097504248 ) O
of BC2GM097504248 IN O
the BC2GM097504248 DT O
S BC2GM097504248 NNP O
gamma BC2GM097504248 NN O
3 BC2GM097504248 CD O
tandem BC2GM097504248 NN O
repeat BC2GM097504248 NN O
. BC2GM097504248 . O
. . O O

We BC2GM063229471 PRP O
have BC2GM063229471 VBP O
isolated BC2GM063229471 VBN O
two BC2GM063229471 CD O
H19 BC2GM063229471 NNP O
cDNAs BC2GM063229471 NN O
( BC2GM063229471 ( O
AP BC2GM063229471 NNP O
and BC2GM063229471 CC O
ES BC2GM063229471 NNP O
) BC2GM063229471 ) O
that BC2GM063229471 WDT O
contain BC2GM063229471 VBP O
this BC2GM063229471 DT O
ORF4 BC2GM063229471 NNP O
and BC2GM063229471 CC O
correspond BC2GM063229471 NN O
to BC2GM063229471 TO O
incomplete BC2GM063229471 VB O
copies BC2GM063229471 NNS O
of BC2GM063229471 IN O
the BC2GM063229471 DT O
unique BC2GM063229471 JJ O
2.3 BC2GM063229471 CD O
kb BC2GM063229471 NN O
H19 BC2GM063229471 NNP O
RNA BC2GM063229471 NNP O
. BC2GM063229471 . O
. . O O

The BC2GM020320741 DT O
gag-myc BC2GM020320741 JJ O
proteins BC2GM020320741 NNS O
encoded BC2GM020320741 VBN O
by BC2GM020320741 IN O
these BC2GM020320741 DT O
variants BC2GM020320741 NNS O
efficiently BC2GM020320741 RB O
localized BC2GM020320741 VBN O
to BC2GM020320741 TO O
the BC2GM020320741 DT O
cell BC2GM020320741 NN O
nucleus BC2GM020320741 NN O
. BC2GM020320741 . O
. . O O

We BC2GM016290576 PRP O
hypothesized BC2GM016290576 VBD O
that BC2GM016290576 IN O
subjects BC2GM016290576 NNS O
would BC2GM016290576 MD O
demonstrate BC2GM016290576 VB O
PKAR BC2GM016290576 NNP O
during BC2GM016290576 IN O
both BC2GM016290576 DT O
hopping BC2GM016290576 VBG O
and BC2GM016290576 CC O
stepping BC2GM016290576 VBG O
, BC2GM016290576 , O
adding BC2GM016290576 VBG O
support BC2GM016290576 NN O
to BC2GM016290576 TO O
the BC2GM016290576 DT O
hypothesis BC2GM016290576 NN O
that BC2GM016290576 IN O
PKAR BC2GM016290576 NNP O
is BC2GM016290576 VBZ O
a BC2GM016290576 DT O
centrally BC2GM016290576 RB O
mediated BC2GM016290576 VBN O
adaptation BC2GM016290576 NN O
of BC2GM016290576 IN O
general BC2GM016290576 JJ O
locomotor BC2GM016290576 NN O
trajectory BC2GM016290576 NN O
that BC2GM016290576 WDT O
is BC2GM016290576 VBZ O
not BC2GM016290576 RB O
specific BC2GM016290576 JJ O
to BC2GM016290576 TO O
the BC2GM016290576 DT O
form BC2GM016290576 NN O
of BC2GM016290576 IN O
locomotion BC2GM016290576 NN O
used BC2GM016290576 VBN O
while BC2GM016290576 IN O
on BC2GM016290576 IN O
the BC2GM016290576 DT O
rotating BC2GM016290576 VBG O
disk BC2GM016290576 NN O
. BC2GM016290576 . O
. . O O

BACKGROUND BC2GM065749861 NN O
: BC2GM065749861 : O
In BC2GM065749861 IN O
lung BC2GM065749861 NN O
protective BC2GM065749861 JJ O
strategy BC2GM065749861 NN O
, BC2GM065749861 , O
positive BC2GM065749861 JJ O
end-expiratory BC2GM065749861 JJ O
pressure BC2GM065749861 NN O
( BC2GM065749861 ( O
PEEP BC2GM065749861 NNP O
) BC2GM065749861 ) O
slightly BC2GM065749861 RB O
higher BC2GM065749861 JJR O
than BC2GM065749861 IN O
the BC2GM065749861 DT O
Pflex BC2GM065749861 NNP O
( BC2GM065749861 ( O
the BC2GM065749861 DT O
airway BC2GM065749861 NN O
pressure BC2GM065749861 NN O
corresponding BC2GM065749861 VBG O
to BC2GM065749861 TO O
the BC2GM065749861 DT O
lower BC2GM065749861 JJR O
inflection BC2GM065749861 NN O
point BC2GM065749861 NN O
( BC2GM065749861 ( O
LIP BC2GM065749861 NNP O
) BC2GM065749861 ) O
on BC2GM065749861 IN O
the BC2GM065749861 DT O
inspiratory BC2GM065749861 JJ O
pressure-volume BC2GM065749861 JJ O
( BC2GM065749861 ( O
P-V BC2GM065749861 NNP O
) BC2GM065749861 ) O
curve BC2GM065749861 NN O
measured BC2GM065749861 VBN O
with BC2GM065749861 IN O
ZEEP BC2GM065749861 NNP O
) BC2GM065749861 ) O
is BC2GM065749861 VBZ O
generally BC2GM065749861 RB O
recommended BC2GM065749861 VBN O
. BC2GM065749861 . O
. . O O

The BC2GM081648973 DT O
unusual BC2GM081648973 JJ O
properties BC2GM081648973 NNS O
of BC2GM081648973 IN O
TRAC BC2GM081648973 NNP O
activity BC2GM081648973 NN O
and BC2GM081648973 CC O
its BC2GM081648973 PRP$ O
relationship BC2GM081648973 NN O
, BC2GM081648973 , O
if BC2GM081648973 IN O
any BC2GM081648973 DT O
, BC2GM081648973 , O
with BC2GM081648973 IN O
the BC2GM081648973 DT O
enigmatic BC2GM081648973 JJ O
Ku BC2GM081648973 NNP O
protein BC2GM081648973 NN O
, BC2GM081648973 , O
are BC2GM081648973 VBP O
discussed BC2GM081648973 VBN O
. BC2GM081648973 . O
. . O O

We BC2GM065517718 PRP O
propose BC2GM065517718 VBP O
2 BC2GM065517718 CD O
separate BC2GM065517718 JJ O
PAI-1 BC2GM065517718 NNP O
inductory BC2GM065517718 NN O
pathways BC2GM065517718 NNS O
for BC2GM065517718 IN O
PMA BC2GM065517718 NNP O
and BC2GM065517718 CC O
IL-1alpha BC2GM065517718 NNP O
in BC2GM065517718 IN O
HepG2 BC2GM065517718 NNP O
, BC2GM065517718 , O
both BC2GM065517718 DT O
involving BC2GM065517718 VBG O
protein BC2GM065517718 NN O
tyrosine BC2GM065517718 JJ O
kinase BC2GM065517718 NN O
activation BC2GM065517718 NN O
; BC2GM065517718 : O
the BC2GM065517718 DT O
serum-induced BC2GM065517718 JJ O
signaling BC2GM065517718 VBG O
pathway BC2GM065517718 NN O
may BC2GM065517718 MD O
( BC2GM065517718 ( O
partially BC2GM065517718 RB O
) BC2GM065517718 ) O
overlap BC2GM065517718 NN O
with BC2GM065517718 IN O
the BC2GM065517718 DT O
PMA-activated BC2GM065517718 JJ O
protein BC2GM065517718 NN O
kinase BC2GM065517718 NN O
C BC2GM065517718 NNP O
/ BC2GM065517718 NNP O
mitogen-activated BC2GM065517718 JJ O
protein BC2GM065517718 NN O
kinase BC2GM065517718 NN O
kinase BC2GM065517718 VB O
pathway BC2GM065517718 NN O
, BC2GM065517718 , O
leading BC2GM065517718 VBG O
to BC2GM065517718 TO O
c-Jun BC2GM065517718 JJ O
homodimer BC2GM065517718 NN O
binding BC2GM065517718 NN O
to BC2GM065517718 TO O
the BC2GM065517718 DT O
PAI-1 BC2GM065517718 NNP O
TRE BC2GM065517718 NNP O
. BC2GM065517718 . O
. . O O

The BC2GM063604617 DT O
complete BC2GM063604617 JJ O
nucleotide BC2GM063604617 JJ O
sequence BC2GM063604617 NN O
of BC2GM063604617 IN O
odontoglossum BC2GM063604617 JJ O
ringspot BC2GM063604617 NN O
virus BC2GM063604617 NN O
( BC2GM063604617 ( O
Cy-1 BC2GM063604617 NNP O
strain BC2GM063604617 NN O
) BC2GM063604617 ) O
genomic BC2GM063604617 NN O
RNA BC2GM063604617 NNP O
. BC2GM063604617 . O
. . O O

The BC2GM084598125 DT O
effects BC2GM084598125 NNS O
on BC2GM084598125 IN O
survival BC2GM084598125 NN O
of BC2GM084598125 IN O
adjuvant BC2GM084598125 JJ O
treatments BC2GM084598125 NNS O
, BC2GM084598125 , O
including BC2GM084598125 VBG O
pre- BC2GM084598125 NN O
or BC2GM084598125 CC O
postoperative BC2GM084598125 JJ O
systemic BC2GM084598125 NN O
or BC2GM084598125 CC O
postoperative BC2GM084598125 JJ O
intra-arterial BC2GM084598125 JJ O
chemotherapy BC2GM084598125 NN O
, BC2GM084598125 , O
are BC2GM084598125 VBP O
currently BC2GM084598125 RB O
under BC2GM084598125 IN O
evaluation BC2GM084598125 NN O
. BC2GM084598125 . O
. . O O

A BC2GM080339050 DT O
new BC2GM080339050 JJ O
model BC2GM080339050 NN O
for BC2GM080339050 IN O
objective BC2GM080339050 JJ O
assessment BC2GM080339050 NN O
of BC2GM080339050 IN O
cervical BC2GM080339050 JJ O
ripening BC2GM080339050 NN O
: BC2GM080339050 : O
the BC2GM080339050 DT O
effect BC2GM080339050 NN O
of BC2GM080339050 IN O
prostaglandin BC2GM080339050 NN O
E2 BC2GM080339050 NNP O
and BC2GM080339050 CC O
prelabor BC2GM080339050 NN O
contractility BC2GM080339050 NN O
. BC2GM080339050 . O
. . O O

Genomic BC2GM006714669 NNP O
Southern BC2GM006714669 NNP O
analysis BC2GM006714669 NN O
reveals BC2GM006714669 NNS O
10 BC2GM006714669 CD O
to BC2GM006714669 TO O
15 BC2GM006714669 CD O
hybridising BC2GM006714669 NN O
fragments BC2GM006714669 NNS O
, BC2GM006714669 , O
suggesting BC2GM006714669 VBG O
that BC2GM006714669 IN O
maize BC2GM006714669 NN O
contains BC2GM006714669 VBZ O
a BC2GM006714669 DT O
small BC2GM006714669 JJ O
gene BC2GM006714669 NN O
family BC2GM006714669 NN O
. BC2GM006714669 . O
. . O O

Based BC2GM079186021 VBN O
on BC2GM079186021 IN O
the BC2GM079186021 DT O
requirement BC2GM079186021 NN O
for BC2GM079186021 IN O
CREM BC2GM079186021 NNP O
/ BC2GM079186021 NNP O
ICER BC2GM079186021 NNP O
and BC2GM079186021 CC O
Rad6B BC2GM079186021 NNP O
proteins BC2GM079186021 NNS O
in BC2GM079186021 IN O
spermatogenesis BC2GM079186021 NN O
, BC2GM079186021 , O
we BC2GM079186021 PRP O
determined BC2GM079186021 VBD O
expression BC2GM079186021 NN O
of BC2GM079186021 IN O
Cdc34 BC2GM079186021 NNP O
, BC2GM079186021 , O
Rad6B BC2GM079186021 NNP O
, BC2GM079186021 , O
CREM BC2GM079186021 NNP O
/ BC2GM079186021 NNP O
ICER BC2GM079186021 NNP O
isoforms BC2GM079186021 NNS O
, BC2GM079186021 , O
and BC2GM079186021 CC O
the BC2GM079186021 DT O
Skp1-Cullin-F-box BC2GM079186021 NNP O
ubiquitin BC2GM079186021 JJ O
protein BC2GM079186021 NN O
ligase BC2GM079186021 VBD O
subunits BC2GM079186021 JJ O
Cul-1 BC2GM079186021 NNP O
and BC2GM079186021 CC O
Cul-2 BC2GM079186021 NNP O
, BC2GM079186021 , O
which BC2GM079186021 WDT O
are BC2GM079186021 VBP O
associated BC2GM079186021 VBN O
with BC2GM079186021 IN O
Cdc34 BC2GM079186021 NNP O
activity BC2GM079186021 NN O
during BC2GM079186021 IN O
murine BC2GM079186021 NN O
testicular BC2GM079186021 NN O
development BC2GM079186021 NN O
. BC2GM079186021 . O
. . O O

VAV BC2GM008088904 NNP O
and BC2GM008088904 CC O
SOCS1 BC2GM008088904 NNP O
form BC2GM008088904 VBP O
a BC2GM008088904 DT O
protein BC2GM008088904 NN O
complex BC2GM008088904 NN O
through BC2GM008088904 IN O
interactions BC2GM008088904 NNS O
between BC2GM008088904 IN O
the BC2GM008088904 DT O
VAV BC2GM008088904 NNP O
NH BC2GM008088904 NNP O
( BC2GM008088904 ( O
2 BC2GM008088904 CD O
) BC2GM008088904 ) O
-terminal BC2GM008088904 JJ O
regulatory BC2GM008088904 JJ O
region BC2GM008088904 NN O
and BC2GM008088904 CC O
the BC2GM008088904 DT O
SH2 BC2GM008088904 NNP O
domain BC2GM008088904 NN O
of BC2GM008088904 IN O
SOCS1 BC2GM008088904 NNP O
in BC2GM008088904 IN O
a BC2GM008088904 DT O
phosphotyrosine-independent BC2GM008088904 JJ O
manner BC2GM008088904 NN O
. BC2GM008088904 . O
. . O O

In BC2GM023802177 IN O
a BC2GM023802177 DT O
pilot BC2GM023802177 NN O
study BC2GM023802177 NN O
in BC2GM023802177 IN O
which BC2GM023802177 WDT O
two BC2GM023802177 CD O
dogs BC2GM023802177 NNS O
were BC2GM023802177 VBD O
given BC2GM023802177 VBN O
parenteral BC2GM023802177 JJ O
rifampin BC2GM023802177 NN O
before BC2GM023802177 IN O
and BC2GM023802177 CC O
after BC2GM023802177 IN O
operation BC2GM023802177 NN O
and BC2GM023802177 CC O
grafts BC2GM023802177 NNS O
were BC2GM023802177 VBD O
preclotted BC2GM023802177 VBN O
with BC2GM023802177 IN O
blood BC2GM023802177 NN O
that BC2GM023802177 WDT O
contained BC2GM023802177 VBD O
rifampin BC2GM023802177 NN O
, BC2GM023802177 , O
it BC2GM023802177 PRP O
was BC2GM023802177 VBD O
suggested BC2GM023802177 VBN O
that BC2GM023802177 IN O
there BC2GM023802177 EX O
was BC2GM023802177 VBD O
a BC2GM023802177 DT O
slight BC2GM023802177 JJ O
increase BC2GM023802177 NN O
in BC2GM023802177 IN O
inhibition BC2GM023802177 NN O
at BC2GM023802177 IN O
24 BC2GM023802177 CD O
hours BC2GM023802177 NNS O
( BC2GM023802177 ( O
93 BC2GM023802177 CD O
% BC2GM023802177 NN O
) BC2GM023802177 ) O
. BC2GM023802177 . O
. . O O

Plasmid BC2GM078586075 NNP O
pNK21 BC2GM078586075 NN O
, BC2GM078586075 , O
in BC2GM078586075 IN O
which BC2GM078586075 WDT O
2.05-kb BC2GM078586075 JJ O
sequence BC2GM078586075 NN O
covering BC2GM078586075 VBG O
the BC2GM078586075 DT O
region BC2GM078586075 NN O
encoding BC2GM078586075 VBG O
the BC2GM078586075 DT O
nitrilase BC2GM078586075 NN O
was BC2GM078586075 VBD O
was BC2GM078586075 VBD O
placed BC2GM078586075 VBN O
under BC2GM078586075 IN O
the BC2GM078586075 DT O
control BC2GM078586075 NN O
of BC2GM078586075 IN O
the BC2GM078586075 DT O
lac BC2GM078586075 NN O
promoter BC2GM078586075 NN O
, BC2GM078586075 , O
directed BC2GM078586075 VBD O
overproduction BC2GM078586075 NN O
of BC2GM078586075 IN O
enzymatically BC2GM078586075 RB O
active BC2GM078586075 JJ O
nitrilase BC2GM078586075 NN O
in BC2GM078586075 IN O
response BC2GM078586075 NN O
to BC2GM078586075 TO O
addition BC2GM078586075 NN O
of BC2GM078586075 IN O
isopropyl BC2GM078586075 JJ O
beta-D-thiogalactopyranoside BC2GM078586075 NN O
in BC2GM078586075 IN O
Escherichia BC2GM078586075 NNP O
coli BC2GM078586075 NN O
. BC2GM078586075 . O
. . O O

Coronary BC2GM043696971 JJ O
arteries BC2GM043696971 NNS O
were BC2GM043696971 VBD O
found BC2GM043696971 VBN O
in BC2GM043696971 IN O
the BC2GM043696971 DT O
biopsy BC2GM043696971 NN O
tissue BC2GM043696971 NN O
of BC2GM043696971 IN O
30 BC2GM043696971 CD O
( BC2GM043696971 ( O
76 BC2GM043696971 CD O
% BC2GM043696971 NN O
) BC2GM043696971 ) O
of BC2GM043696971 IN O
the BC2GM043696971 DT O
39 BC2GM043696971 CD O
patients BC2GM043696971 NNS O
who BC2GM043696971 WP O
formed BC2GM043696971 VBD O
the BC2GM043696971 DT O
study BC2GM043696971 NN O
group BC2GM043696971 NN O
. BC2GM043696971 . O
. . O O

Both BC2GM072208661 DT O
parameters BC2GM072208661 NNS O
were BC2GM072208661 VBD O
determined BC2GM072208661 VBN O
in BC2GM072208661 IN O
an BC2GM072208661 DT O
individual BC2GM072208661 JJ O
eye BC2GM072208661 NN O
by BC2GM072208661 IN O
applying BC2GM072208661 VBG O
the BC2GM072208661 DT O
dye BC2GM072208661 NN O
first BC2GM072208661 RB O
by BC2GM072208661 IN O
iontophoresis BC2GM072208661 NN O
and BC2GM072208661 CC O
then BC2GM072208661 RB O
by BC2GM072208661 IN O
intravitreal BC2GM072208661 JJ O
injection BC2GM072208661 NN O
, BC2GM072208661 , O
which BC2GM072208661 WDT O
allows BC2GM072208661 VBZ O
the BC2GM072208661 DT O
influence BC2GM072208661 NN O
of BC2GM072208661 IN O
fluorescein BC2GM072208661 NN O
glucuronide BC2GM072208661 NN O
on BC2GM072208661 IN O
the BC2GM072208661 DT O
fluorophotometric BC2GM072208661 JJ O
measurements BC2GM072208661 NNS O
to BC2GM072208661 TO O
be BC2GM072208661 VB O
excluded BC2GM072208661 VBN O
. BC2GM072208661 . O
. . O O

A BC2GM031723678 DT O
significant BC2GM031723678 JJ O
difference BC2GM031723678 NN O
in BC2GM031723678 IN O
the BC2GM031723678 DT O
distribution BC2GM031723678 NN O
of BC2GM031723678 IN O
antibodies BC2GM031723678 NNS O
to BC2GM031723678 TO O
thyroglobulin BC2GM031723678 VB O
and BC2GM031723678 CC O
thyroid BC2GM031723678 VB O
peroxidase BC2GM031723678 NN O
was BC2GM031723678 VBD O
found BC2GM031723678 VBN O
in BC2GM031723678 IN O
subgroup BC2GM031723678 NN O
2 BC2GM031723678 CD O
. BC2GM031723678 . O
. . O O

Together BC2GM055239754 RB O
with BC2GM055239754 IN O
the BC2GM055239754 DT O
up-regulation BC2GM055239754 NN O
of BC2GM055239754 IN O
the BC2GM055239754 DT O
cAMP BC2GM055239754 NN O
response BC2GM055239754 NN O
element BC2GM055239754 NN O
modulator BC2GM055239754 NN O
protein BC2GM055239754 NN O
( BC2GM055239754 ( O
CREM BC2GM055239754 NNP O
) BC2GM055239754 ) O
mRNA BC2GM055239754 NN O
and BC2GM055239754 CC O
protein BC2GM055239754 NN O
levels BC2GM055239754 NNS O
demonstrated BC2GM055239754 VBD O
previously BC2GM055239754 RB O
in BC2GM055239754 IN O
CREB BC2GM055239754 NNP O
mutant BC2GM055239754 JJ O
mice BC2GM055239754 NN O
, BC2GM055239754 , O
we BC2GM055239754 PRP O
suggest BC2GM055239754 VBP O
that BC2GM055239754 IN O
the BC2GM055239754 DT O
up-regulation BC2GM055239754 NN O
of BC2GM055239754 IN O
CREB BC2GM055239754 NNP O
beta BC2GM055239754 NN O
may BC2GM055239754 MD O
also BC2GM055239754 RB O
contribute BC2GM055239754 VB O
to BC2GM055239754 TO O
compensation BC2GM055239754 NN O
within BC2GM055239754 IN O
the BC2GM055239754 DT O
CREB BC2GM055239754 NNP O
/ BC2GM055239754 NNP O
ATF BC2GM055239754 NNP O
family BC2GM055239754 NN O
of BC2GM055239754 IN O
transcription BC2GM055239754 NN O
factors BC2GM055239754 NNS O
, BC2GM055239754 , O
when BC2GM055239754 WRB O
CREB BC2GM055239754 NNP O
delta BC2GM055239754 NN O
and BC2GM055239754 CC O
CREB BC2GM055239754 NNP O
alpha BC2GM055239754 NNS O
are BC2GM055239754 VBP O
absent BC2GM055239754 JJ O
. BC2GM055239754 . O
. . O O

Messenger BC2GM019484817 NNP O
RNA BC2GM019484817 NNP O
for BC2GM019484817 IN O
the BC2GM019484817 DT O
Ad2 BC2GM019484817 NNP O
DNA BC2GM019484817 NNP O
binding BC2GM019484817 VBG O
protein BC2GM019484817 NN O
: BC2GM019484817 : O
DNA BC2GM019484817 NN O
sequences BC2GM019484817 NNS O
encoding BC2GM019484817 VBG O
the BC2GM019484817 DT O
first BC2GM019484817 JJ O
leader BC2GM019484817 NN O
and BC2GM019484817 CC O
heterogenity BC2GM019484817 NN O
at BC2GM019484817 IN O
the BC2GM019484817 DT O
mRNA BC2GM019484817 NN O
5 BC2GM019484817 CD O
' BC2GM019484817 POS O
end BC2GM019484817 NN O
. BC2GM019484817 . O
. . O O

The BC2GM065898705 DT O
contractile BC2GM065898705 JJ O
effects BC2GM065898705 NNS O
of BC2GM065898705 IN O
oxytocin BC2GM065898705 NN O
, BC2GM065898705 , O
prostaglandin BC2GM065898705 NN O
F2 BC2GM065898705 NNP O
alpha BC2GM065898705 NN O
and BC2GM065898705 CC O
their BC2GM065898705 PRP$ O
combined BC2GM065898705 VBN O
use BC2GM065898705 NN O
on BC2GM065898705 IN O
human BC2GM065898705 JJ O
pregnant BC2GM065898705 JJ O
myometrium BC2GM065898705 NN O
were BC2GM065898705 VBD O
studied BC2GM065898705 VBN O
in BC2GM065898705 IN O
vitro BC2GM065898705 NN O
. BC2GM065898705 . O
. . O O

Within BC2GM030169999 IN O
the BC2GM030169999 DT O
last BC2GM030169999 JJ O
few BC2GM030169999 JJ O
years BC2GM030169999 NNS O
, BC2GM030169999 , O
the BC2GM030169999 DT O
WWW BC2GM030169999 NNP O
has BC2GM030169999 VBZ O
grown BC2GM030169999 VBN O
enormously BC2GM030169999 RB O
. BC2GM030169999 . O
. . O O

Estrogen BC2GM065203942 NN O
has BC2GM065203942 VBZ O
positive BC2GM065203942 JJ O
effects BC2GM065203942 NNS O
on BC2GM065203942 IN O
mood BC2GM065203942 NN O
, BC2GM065203942 , O
sexual BC2GM065203942 JJ O
function BC2GM065203942 NN O
, BC2GM065203942 , O
target BC2GM065203942 VB O
end BC2GM065203942 JJ O
organs BC2GM065203942 NNS O
and BC2GM065203942 CC O
cognitive BC2GM065203942 JJ O
function BC2GM065203942 NN O
, BC2GM065203942 , O
and BC2GM065203942 CC O
may BC2GM065203942 MD O
play BC2GM065203942 VB O
an BC2GM065203942 DT O
important BC2GM065203942 JJ O
role BC2GM065203942 NN O
in BC2GM065203942 IN O
the BC2GM065203942 DT O
etiology BC2GM065203942 NN O
of BC2GM065203942 IN O
Alzheimer BC2GM065203942 NNP O
's BC2GM065203942 POS O
Disease BC2GM065203942 NNP O
by BC2GM065203942 IN O
acting BC2GM065203942 VBG O
to BC2GM065203942 TO O
prevent BC2GM065203942 VB O
amyloid BC2GM065203942 JJ O
plaque BC2GM065203942 NN O
formation BC2GM065203942 NN O
, BC2GM065203942 , O
oxidative BC2GM065203942 JJ O
stress BC2GM065203942 NN O
, BC2GM065203942 , O
or BC2GM065203942 CC O
deterioration BC2GM065203942 NN O
of BC2GM065203942 IN O
the BC2GM065203942 DT O
cholinergic BC2GM065203942 NN O
neurotransmitter BC2GM065203942 NN O
system BC2GM065203942 NN O
. BC2GM065203942 . O
. . O O

Allergen-stimulated BC2GM079950529 JJ O
levels BC2GM079950529 NNS O
of BC2GM079950529 IN O
PGD2 BC2GM079950529 NNP O
were BC2GM079950529 VBD O
1274 BC2GM079950529 CD O
+ BC2GM079950529 NNP O
/ BC2GM079950529 NNP O
- BC2GM079950529 : O
565 BC2GM079950529 CD O
versus BC2GM079950529 NN O
1468 BC2GM079950529 CD O
+ BC2GM079950529 NN O
/ BC2GM079950529 NNP O
- BC2GM079950529 : O
679 BC2GM079950529 CD O
after BC2GM079950529 IN O
prednisone BC2GM079950529 NN O
; BC2GM079950529 : O
likewise BC2GM079950529 RB O
, BC2GM079950529 , O
allergen-stimulated BC2GM079950529 JJ O
5-HETE BC2GM079950529 JJ O
levels BC2GM079950529 NNS O
were BC2GM079950529 VBD O
95 BC2GM079950529 CD O
+ BC2GM079950529 NNP O
/ BC2GM079950529 NNP O
- BC2GM079950529 : O
21 BC2GM079950529 CD O
versus BC2GM079950529 NN O
82 BC2GM079950529 CD O
+ BC2GM079950529 NN O
/ BC2GM079950529 NNP O
- BC2GM079950529 : O
21 BC2GM079950529 CD O
; BC2GM079950529 : O
those BC2GM079950529 DT O
of BC2GM079950529 IN O
LTE4 BC2GM079950529 NNP O
were BC2GM079950529 VBD O
54 BC2GM079950529 CD O
+ BC2GM079950529 NNP O
/ BC2GM079950529 NNP O
- BC2GM079950529 : O
20 BC2GM079950529 CD O
versus BC2GM079950529 NN O
91 BC2GM079950529 CD O
+ BC2GM079950529 NN O
/ BC2GM079950529 NNP O
- BC2GM079950529 : O
51 BC2GM079950529 CD O
; BC2GM079950529 : O
and BC2GM079950529 CC O
those BC2GM079950529 DT O
of BC2GM079950529 IN O
15-HETE BC2GM079950529 JJ O
were BC2GM079950529 VBD O
63 BC2GM079950529 CD O
+ BC2GM079950529 NNP O
/ BC2GM079950529 NNP O
- BC2GM079950529 : O
19 BC2GM079950529 CD O
versus BC2GM079950529 NN O
60 BC2GM079950529 CD O
+ BC2GM079950529 NN O
/ BC2GM079950529 NNP O
- BC2GM079950529 : O
25 BC2GM079950529 CD O
. BC2GM079950529 . O
. . O O

Nonlinearities BC2GM024464549 NNS O
in BC2GM024464549 IN O
cochlear BC2GM024464549 JJ O
hydrodynamics BC2GM024464549 NNS O
. BC2GM024464549 . O
. . O O

Value BC2GM049242982 NNP O
of BC2GM049242982 IN O
bone BC2GM049242982 NN O
scintigraphy BC2GM049242982 NN O
with BC2GM049242982 IN O
Tc99MDP BC2GM049242982 NNP O
in BC2GM049242982 IN O
the BC2GM049242982 DT O
early BC2GM049242982 JJ O
diagnosis BC2GM049242982 NN O
of BC2GM049242982 IN O
mobilization BC2GM049242982 NN O
of BC2GM049242982 IN O
the BC2GM049242982 DT O
total BC2GM049242982 JJ O
hip BC2GM049242982 NN O
prosthesis BC2GM049242982 NN O
. BC2GM049242982 . O
. . O O

The BC2GM067531031 DT O
revaluation BC2GM067531031 NN O
at BC2GM067531031 IN O
the BC2GM067531031 DT O
end BC2GM067531031 NN O
of BC2GM067531031 IN O
the BC2GM067531031 DT O
study BC2GM067531031 NN O
showed BC2GM067531031 VBD O
a BC2GM067531031 DT O
good BC2GM067531031 JJ O
compliance BC2GM067531031 NN O
for BC2GM067531031 IN O
the BC2GM067531031 DT O
proposed BC2GM067531031 VBN O
diet BC2GM067531031 JJ O
scheme BC2GM067531031 NN O
by BC2GM067531031 IN O
children BC2GM067531031 NNS O
, BC2GM067531031 , O
but BC2GM067531031 CC O
a BC2GM067531031 DT O
poor BC2GM067531031 JJ O
compliance BC2GM067531031 NN O
by BC2GM067531031 IN O
their BC2GM067531031 PRP$ O
families BC2GM067531031 NNS O
. BC2GM067531031 . O
. . O O

Phosphorylated BC2GM023060026 VBN O
tyrosine BC2GM023060026 NN O
residues BC2GM023060026 NNS O
were BC2GM023060026 VBD O
subsequently BC2GM023060026 RB O
identified BC2GM023060026 VBN O
by BC2GM023060026 IN O
sequencing BC2GM023060026 VBG O
the BC2GM023060026 DT O
separated BC2GM023060026 VBN O
phosphopeptides BC2GM023060026 NNS O
by BC2GM023060026 IN O
matrix BC2GM023060026 NN O
assisted BC2GM023060026 VBN O
laser BC2GM023060026 JJR O
desorption BC2GM023060026 NN O
ionization BC2GM023060026 NN O
mass BC2GM023060026 NN O
spectrometry BC2GM023060026 NN O
( BC2GM023060026 ( O
MALDI-MS BC2GM023060026 NNP O
) BC2GM023060026 ) O
and BC2GM023060026 CC O
Edman BC2GM023060026 NNP O
degradation BC2GM023060026 NN O
. BC2GM023060026 . O
. . O O

In BC2GM001799055 IN O
the BC2GM001799055 DT O
yeast BC2GM001799055 JJ O
two-hybrid BC2GM001799055 JJ O
assays BC2GM001799055 NNS O
, BC2GM001799055 , O
PNRC BC2GM001799055 NNP O
interacted BC2GM001799055 VBD O
with BC2GM001799055 IN O
the BC2GM001799055 DT O
orphan BC2GM001799055 JJ O
receptors BC2GM001799055 NNS O
SF1 BC2GM001799055 NNP O
and BC2GM001799055 CC O
ERRalpha1 BC2GM001799055 NNP O
in BC2GM001799055 IN O
a BC2GM001799055 DT O
ligand-independent BC2GM001799055 JJ O
manner BC2GM001799055 NN O
. BC2GM001799055 . O
. . O O

In BC2GM008859713 IN O
serial BC2GM008859713 JJ O
recall BC2GM008859713 NN O
from BC2GM008859713 IN O
short-term BC2GM008859713 JJ O
memory BC2GM008859713 NN O
, BC2GM008859713 , O
repeated BC2GM008859713 VBN O
items BC2GM008859713 NNS O
are BC2GM008859713 VBP O
recalled BC2GM008859713 VBN O
well BC2GM008859713 RB O
when BC2GM008859713 WRB O
close BC2GM008859713 JJ O
together BC2GM008859713 RB O
( BC2GM008859713 ( O
repetition BC2GM008859713 NN O
facilitation BC2GM008859713 NN O
) BC2GM008859713 ) O
, BC2GM008859713 , O
but BC2GM008859713 CC O
not BC2GM008859713 RB O
when BC2GM008859713 WRB O
far BC2GM008859713 RB O
apart BC2GM008859713 RB O
( BC2GM008859713 ( O
repetition BC2GM008859713 NN O
inhibition BC2GM008859713 NN O
; BC2GM008859713 : O
the BC2GM008859713 DT O
Ranschburg BC2GM008859713 NNP O
effect BC2GM008859713 NN O
) BC2GM008859713 ) O
. BC2GM008859713 . O
. . O O

The BC2GM033658965 DT O
essential BC2GM033658965 JJ O
questions BC2GM033658965 NNS O
about BC2GM033658965 IN O
hepatitis BC2GM033658965 NN O
C BC2GM033658965 NNP O
. BC2GM033658965 . O
. . O O

Fli-1 BC2GM036162857 NNP O
is BC2GM036162857 VBZ O
a BC2GM036162857 DT O
proto-oncogene BC2GM036162857 JJ O
which BC2GM036162857 WDT O
is BC2GM036162857 VBZ O
rearranged BC2GM036162857 VBN O
in BC2GM036162857 IN O
tumors BC2GM036162857 NNS O
induced BC2GM036162857 VBN O
by BC2GM036162857 IN O
three BC2GM036162857 CD O
different BC2GM036162857 JJ O
retroviruses BC2GM036162857 NNS O
, BC2GM036162857 , O
Cas-Br-E BC2GM036162857 NNP O
, BC2GM036162857 , O
F-MuLV BC2GM036162857 NNP O
, BC2GM036162857 , O
and BC2GM036162857 CC O
10A1 BC2GM036162857 CD O
. BC2GM036162857 . O
. . O O

An BC2GM043724689 DT O
atypical BC2GM043724689 JJ O
form BC2GM043724689 NN O
of BC2GM043724689 IN O
juvenile BC2GM043724689 NN O
myasthenia BC2GM043724689 NN O
gravis BC2GM043724689 NN O
associated BC2GM043724689 VBN O
with BC2GM043724689 IN O
severe BC2GM043724689 JJ O
emaciation BC2GM043724689 NN O
, BC2GM043724689 , O
muscle BC2GM043724689 NN O
atrophy BC2GM043724689 NN O
, BC2GM043724689 , O
ophthalmoplegia BC2GM043724689 NN O
, BC2GM043724689 , O
bulbar BC2GM043724689 NN O
signs BC2GM043724689 NNS O
and BC2GM043724689 CC O
joint BC2GM043724689 JJ O
contracture BC2GM043724689 NN O
. BC2GM043724689 . O
. . O O

All BC2GM050589731 DT O
such BC2GM050589731 JJ O
polypeptides BC2GM050589731 NNS O
containing BC2GM050589731 VBG O
263 BC2GM050589731 CD O
or BC2GM050589731 CC O
more BC2GM050589731 JJR O
residues BC2GM050589731 NNS O
derived BC2GM050589731 VBN O
from BC2GM050589731 IN O
the BC2GM050589731 DT O
C-terminus BC2GM050589731 NNP O
of BC2GM050589731 IN O
P130gag-fps BC2GM050589731 NNP O
( BC2GM050589731 ( O
i.e BC2GM050589731 NN O
. BC2GM050589731 . O
residues BC2GM050589731 NNS O
920-1182 BC2GM050589731 CD O
) BC2GM050589731 ) O
were BC2GM050589731 VBD O
enzymatically BC2GM050589731 RB O
active BC2GM050589731 JJ O
as BC2GM050589731 IN O
tyrosine BC2GM050589731 NN O
kinases BC2GM050589731 NNS O
. BC2GM050589731 . O
. . O O

Donehower BC2GM016417962 NNP O
and BC2GM016417962 CC O
H BC2GM016417962 NNP O
. BC2GM016417962 . O
. . O O

Especially BC2GM075850023 RB O
if BC2GM075850023 IN O
the BC2GM075850023 DT O
number BC2GM075850023 NN O
of BC2GM075850023 IN O
dimensions BC2GM075850023 NNS O
of BC2GM075850023 IN O
the BC2GM075850023 DT O
samples BC2GM075850023 NNS O
is BC2GM075850023 VBZ O
large BC2GM075850023 JJ O
, BC2GM075850023 , O
it BC2GM075850023 PRP O
can BC2GM075850023 MD O
be BC2GM075850023 VB O
said BC2GM075850023 VBD O
that BC2GM075850023 IN O
BPN BC2GM075850023 NNP O
is BC2GM075850023 VBZ O
better BC2GM075850023 JJR O
than BC2GM075850023 IN O
k-NN BC2GM075850023 NN O
in BC2GM075850023 IN O
classification BC2GM075850023 NN O
ability BC2GM075850023 NN O
. BC2GM075850023 . O
. . O O

Mouse BC2GM049302974 NNP O
GRK6-C BC2GM049302974 NNP O
displays BC2GM049302974 VBZ O
none BC2GM049302974 NN O
of BC2GM049302974 IN O
these BC2GM049302974 DT O
motifs BC2GM049302974 NNS O
. BC2GM049302974 . O
. . O O

The BC2GM013416504 DT O
glyoxysomal BC2GM013416504 NN O
and BC2GM013416504 CC O
plastid BC2GM013416504 NN O
molecular BC2GM013416504 JJ O
chaperones BC2GM013416504 NNS O
( BC2GM013416504 ( O
70-kDa BC2GM013416504 JJ O
heat BC2GM013416504 NN O
shock BC2GM013416504 NN O
protein BC2GM013416504 NN O
) BC2GM013416504 ) O
of BC2GM013416504 IN O
watermelon BC2GM013416504 NN O
cotyledons BC2GM013416504 NNS O
are BC2GM013416504 VBP O
encoded BC2GM013416504 VBN O
by BC2GM013416504 IN O
a BC2GM013416504 DT O
single BC2GM013416504 JJ O
gene BC2GM013416504 NN O
. BC2GM013416504 . O
. . O O

Transcription BC2GM083080586 NN O
of BC2GM083080586 IN O
FN BC2GM083080586 NNP O
promoter-chloramphenicol BC2GM083080586 JJ O
acetyltransferase BC2GM083080586 NN O
fusion BC2GM083080586 NN O
genes BC2GM083080586 NNS O
carrying BC2GM083080586 VBG O
the BC2GM083080586 DT O
base BC2GM083080586 NN O
substitution BC2GM083080586 NN O
in BC2GM083080586 IN O
one BC2GM083080586 CD O
or BC2GM083080586 CC O
more BC2GM083080586 JJR O
of BC2GM083080586 IN O
these BC2GM083080586 DT O
G-rich BC2GM083080586 JJ O
sequences BC2GM083080586 NNS O
both BC2GM083080586 DT O
in BC2GM083080586 IN O
vivo BC2GM083080586 NN O
and BC2GM083080586 CC O
in BC2GM083080586 IN O
vitro BC2GM083080586 NN O
revealed BC2GM083080586 VBD O
that BC2GM083080586 IN O
the BC2GM083080586 DT O
base BC2GM083080586 NN O
substitution BC2GM083080586 NN O
in BC2GM083080586 IN O
any BC2GM083080586 DT O
G-rich BC2GM083080586 JJ O
sequence BC2GM083080586 NN O
results BC2GM083080586 NNS O
in BC2GM083080586 IN O
reduction BC2GM083080586 NN O
of BC2GM083080586 IN O
promoter BC2GM083080586 NN O
activity BC2GM083080586 NN O
, BC2GM083080586 , O
although BC2GM083080586 IN O
the BC2GM083080586 DT O
downstream BC2GM083080586 NN O
GC BC2GM083080586 NNP O
box BC2GM083080586 NN O
( BC2GM083080586 ( O
GCd BC2GM083080586 NNP O
) BC2GM083080586 ) O
plays BC2GM083080586 VBZ O
a BC2GM083080586 DT O
primary BC2GM083080586 JJ O
role BC2GM083080586 NN O
. BC2GM083080586 . O
. . O O

Appl BC2GM034370454 NNP O
. BC2GM034370454 . O
. . O O

In BC2GM021380457 IN O
several BC2GM021380457 JJ O
steps BC2GM021380457 NNS O
we BC2GM021380457 PRP O
converted BC2GM021380457 VBD O
the BC2GM021380457 DT O
retinoid BC2GM021380457 NN O
specific BC2GM021380457 JJ O
response BC2GM021380457 NN O
element BC2GM021380457 NN O
of BC2GM021380457 IN O
the BC2GM021380457 DT O
human BC2GM021380457 JJ O
retinoic BC2GM021380457 NN O
acid BC2GM021380457 NN O
receptor BC2GM021380457 NN O
beta BC2GM021380457 NN O
promoter BC2GM021380457 NN O
into BC2GM021380457 IN O
the BC2GM021380457 DT O
vitamin BC2GM021380457 NN O
D BC2GM021380457 NNP O
/ BC2GM021380457 NNP O
retinoic BC2GM021380457 VBD O
acid BC2GM021380457 JJ O
response BC2GM021380457 NN O
element BC2GM021380457 NN O
of BC2GM021380457 IN O
the BC2GM021380457 DT O
human BC2GM021380457 JJ O
osteocalcin BC2GM021380457 NN O
promoter BC2GM021380457 NN O
. BC2GM021380457 . O
. . O O

Phylogenetic BC2GM025848591 JJ O
analysis BC2GM025848591 NN O
of BC2GM025848591 IN O
yeast BC2GM025848591 NN O
, BC2GM025848591 , O
invertebrate BC2GM025848591 NN O
, BC2GM025848591 , O
and BC2GM025848591 CC O
multiple BC2GM025848591 JJ O
mammalian BC2GM025848591 JJ O
isoforms BC2GM025848591 NNS O
of BC2GM025848591 IN O
SNF4 BC2GM025848591 NNP O
shows BC2GM025848591 VBZ O
that BC2GM025848591 IN O
the BC2GM025848591 DT O
gene BC2GM025848591 NN O
duplication BC2GM025848591 NN O
likely BC2GM025848591 RB O
occurred BC2GM025848591 VBD O
early BC2GM025848591 RB O
in BC2GM025848591 IN O
the BC2GM025848591 DT O
metazoan BC2GM025848591 NN O
lineage BC2GM025848591 NN O
, BC2GM025848591 , O
as BC2GM025848591 IN O
the BC2GM025848591 DT O
protein BC2GM025848591 NN O
products BC2GM025848591 NNS O
of BC2GM025848591 IN O
the BC2GM025848591 DT O
different BC2GM025848591 JJ O
loci BC2GM025848591 NN O
are BC2GM025848591 VBP O
relatively BC2GM025848591 RB O
divergent BC2GM025848591 JJ O
. BC2GM025848591 . O
. . O O

A BC2GM093503103 DT O
. BC2GM093503103 . O
. . O O

This BC2GM037203130 DT O
gene BC2GM037203130 NN O
is BC2GM037203130 VBZ O
divided BC2GM037203130 VBN O
into BC2GM037203130 IN O
six BC2GM037203130 CD O
exons BC2GM037203130 NNS O
spanning BC2GM037203130 VBG O
about BC2GM037203130 IN O
3kb BC2GM037203130 CD O
, BC2GM037203130 , O
and BC2GM037203130 CC O
encodes BC2GM037203130 VBZ O
a BC2GM037203130 DT O
175 BC2GM037203130 CD O
amino BC2GM037203130 NN O
acid BC2GM037203130 NN O
protein BC2GM037203130 NN O
with BC2GM037203130 IN O
40-52 BC2GM037203130 JJ O
% BC2GM037203130 NN O
identity BC2GM037203130 NN O
with BC2GM037203130 IN O
the BC2GM037203130 DT O
other BC2GM037203130 JJ O
five BC2GM037203130 CD O
mouse BC2GM037203130 NN O
Reg BC2GM037203130 NNP O
( BC2GM037203130 ( O
regenerating BC2GM037203130 VBG O
gene BC2GM037203130 NN O
product BC2GM037203130 NN O
) BC2GM037203130 ) O
proteins BC2GM037203130 VBZ O
. BC2GM037203130 . O
. . O O

We BC2GM034609623 PRP O
have BC2GM034609623 VBP O
thus BC2GM034609623 RB O
cloned BC2GM034609623 VBN O
two BC2GM034609623 CD O
yeast BC2GM034609623 JJ O
homologs BC2GM034609623 NNS O
of BC2GM034609623 IN O
mammalian BC2GM034609623 JJ O
p220 BC2GM034609623 NN O
. BC2GM034609623 . O
. . O O

CONCLUSIONS BC2GM027384741 NN O
: BC2GM027384741 : O
The BC2GM027384741 DT O
system BC2GM027384741 NN O
developed BC2GM027384741 VBD O
in BC2GM027384741 IN O
this BC2GM027384741 DT O
study BC2GM027384741 NN O
can BC2GM027384741 MD O
be BC2GM027384741 VB O
used BC2GM027384741 VBN O
as BC2GM027384741 IN O
a BC2GM027384741 DT O
method BC2GM027384741 NN O
to BC2GM027384741 TO O
detect BC2GM027384741 VB O
air-trapping BC2GM027384741 JJ O
during BC2GM027384741 IN O
TGI BC2GM027384741 NNP O
. BC2GM027384741 . O
. . O O

However BC2GM084592604 RB O
, BC2GM084592604 , O
in BC2GM084592604 IN O
each BC2GM084592604 DT O
case BC2GM084592604 NN O
in BC2GM084592604 IN O
which BC2GM084592604 WDT O
either BC2GM084592604 CC O
the BC2GM084592604 DT O
DQ BC2GM084592604 NNP O
alpha- BC2GM084592604 NN O
or BC2GM084592604 CC O
DQ BC2GM084592604 NNP O
beta-chain BC2GM084592604 NN O
was BC2GM084592604 VBD O
exchanged BC2GM084592604 VBN O
, BC2GM084592604 , O
major BC2GM084592604 JJ O
alterations BC2GM084592604 NNS O
or BC2GM084592604 CC O
reversals BC2GM084592604 NNS O
of BC2GM084592604 IN O
this BC2GM084592604 DT O
pattern BC2GM084592604 NN O
of BC2GM084592604 IN O
interaction BC2GM084592604 NN O
were BC2GM084592604 VBD O
observed BC2GM084592604 VBN O
. BC2GM084592604 . O
. . O O

A BC2GM095082528 DT O
mouse BC2GM095082528 NN O
brain BC2GM095082528 NN O
cDNA BC2GM095082528 NN O
library BC2GM095082528 NN O
in BC2GM095082528 IN O
lambdagt11 BC2GM095082528 NN O
was BC2GM095082528 VBD O
screened BC2GM095082528 VBN O
for BC2GM095082528 IN O
this BC2GM095082528 DT O
association BC2GM095082528 NN O
, BC2GM095082528 , O
and BC2GM095082528 CC O
two BC2GM095082528 CD O
positive BC2GM095082528 JJ O
clones BC2GM095082528 NNS O
encoding BC2GM095082528 VBG O
tyrosine BC2GM095082528 JJ O
phosphatase BC2GM095082528 NN O
SH-PTP2 BC2GM095082528 NNP O
were BC2GM095082528 VBD O
isolated BC2GM095082528 VBN O
. BC2GM095082528 . O
. . O O

Cell BC2GM058154023 NNP O
sloughing BC2GM058154023 VBG O
with BC2GM058154023 IN O
proparacaine BC2GM058154023 NN O
. BC2GM058154023 . O
. . O O

In BC2GM033019840 IN O
contrast BC2GM033019840 NN O
to BC2GM033019840 TO O
the BC2GM033019840 DT O
effect BC2GM033019840 NN O
on BC2GM033019840 IN O
DNA BC2GM033019840 NNP O
replication BC2GM033019840 NN O
, BC2GM033019840 , O
the BC2GM033019840 DT O
L13V BC2GM033019840 NNP O
substitution BC2GM033019840 NN O
in BC2GM033019840 IN O
large BC2GM033019840 JJ O
T BC2GM033019840 NNP O
antigen BC2GM033019840 NN O
did BC2GM033019840 VBD O
not BC2GM033019840 RB O
prevent BC2GM033019840 VB O
complex BC2GM033019840 JJ O
formation BC2GM033019840 NN O
with BC2GM033019840 IN O
Hsc70 BC2GM033019840 NNP O
and BC2GM033019840 CC O
the BC2GM033019840 DT O
Rb BC2GM033019840 NNP O
protein BC2GM033019840 NN O
. BC2GM033019840 . O
. . O O

These BC2GM010800143 DT O
results BC2GM010800143 NNS O
demonstrate BC2GM010800143 VBP O
that BC2GM010800143 IN O
the BC2GM010800143 DT O
entire BC2GM010800143 JJ O
E3L BC2GM010800143 NNP O
gene BC2GM010800143 NN O
is BC2GM010800143 VBZ O
required BC2GM010800143 VBN O
for BC2GM010800143 IN O
pathogenesis BC2GM010800143 NN O
in BC2GM010800143 IN O
the BC2GM010800143 DT O
mouse BC2GM010800143 NN O
model BC2GM010800143 NN O
. BC2GM010800143 . O
. . O O

Studies BC2GM065749452 NNS O
on BC2GM065749452 IN O
recurrences BC2GM065749452 NNS O
in BC2GM065749452 IN O
gingival BC2GM065749452 JJ O
hyperplasia BC2GM065749452 NN O
. BC2GM065749452 . O
. . O O

Recombinant BC2GM057201448 JJ O
caspases BC2GM057201448 NNS O
are BC2GM057201448 VBP O
typically BC2GM057201448 RB O
produced BC2GM057201448 VBN O
in BC2GM057201448 IN O
Escherichia BC2GM057201448 NNP O
coli BC2GM057201448 JJ O
expression BC2GM057201448 NN O
systems BC2GM057201448 NNS O
with BC2GM057201448 IN O
the BC2GM057201448 DT O
attendant BC2GM057201448 JJ O
problems BC2GM057201448 NNS O
of BC2GM057201448 IN O
solubilization BC2GM057201448 NN O
, BC2GM057201448 , O
re-folding BC2GM057201448 NN O
and BC2GM057201448 CC O
activation BC2GM057201448 NN O
of BC2GM057201448 IN O
the BC2GM057201448 DT O
protease BC2GM057201448 NN O
. BC2GM057201448 . O
. . O O

Pseudotumor BC2GM040216592 NNP O
form BC2GM040216592 NN O
of BC2GM040216592 IN O
pulmonary BC2GM040216592 JJ O
nocardia BC2GM040216592 JJ O
infection BC2GM040216592 NN O
( BC2GM040216592 ( O
Nocardia BC2GM040216592 NNP O
nova BC2GM040216592 RB O
) BC2GM040216592 ) O
in BC2GM040216592 IN O
a BC2GM040216592 DT O
renal BC2GM040216592 JJ O
transplant BC2GM040216592 NN O
patient BC2GM040216592 NN O
. BC2GM040216592 . O
. . O O

To BC2GM064288538 TO O
quantify BC2GM064288538 VB O
the BC2GM064288538 DT O
normal BC2GM064288538 JJ O
coupling BC2GM064288538 NN O
patterns BC2GM064288538 NNS O
, BC2GM064288538 , O
fresh BC2GM064288538 JJ O
cadaveric BC2GM064288538 JJ O
human BC2GM064288538 JJ O
lumbar BC2GM064288538 NN O
spine BC2GM064288538 NN O
specimens BC2GM064288538 NNS O
( BC2GM064288538 ( O
L1-S1 BC2GM064288538 NNP O
) BC2GM064288538 ) O
were BC2GM064288538 VBD O
used BC2GM064288538 VBN O
. BC2GM064288538 . O
. . O O

The BC2GM099236530 DT O
lamina BC2GM099236530 NN O
densa BC2GM099236530 NN O
was BC2GM099236530 VBD O
always BC2GM099236530 RB O
interrupted BC2GM099236530 VBN O
by BC2GM099236530 IN O
numerous BC2GM099236530 JJ O
small BC2GM099236530 JJ O
gaps BC2GM099236530 NNS O
and BC2GM099236530 CC O
in BC2GM099236530 IN O
some BC2GM099236530 DT O
areas BC2GM099236530 NNS O
the BC2GM099236530 DT O
basement BC2GM099236530 NN O
membrane BC2GM099236530 NN O
could BC2GM099236530 MD O
not BC2GM099236530 RB O
be BC2GM099236530 VB O
identified BC2GM099236530 VBN O
over BC2GM099236530 IN O
a BC2GM099236530 DT O
long BC2GM099236530 JJ O
distance BC2GM099236530 NN O
. BC2GM099236530 . O
. . O O

Our BC2GM029234966 PRP$ O
results BC2GM029234966 NNS O
suggest BC2GM029234966 VBP O
a BC2GM029234966 DT O
dose-dependent BC2GM029234966 JJ O
activity BC2GM029234966 NN O
of BC2GM029234966 IN O
lysine BC2GM029234966 NN O
vasopressin BC2GM029234966 NN O
on BC2GM029234966 IN O
the BC2GM029234966 DT O
EEG BC2GM029234966 NNP O
, BC2GM029234966 , O
which BC2GM029234966 WDT O
might BC2GM029234966 MD O
be BC2GM029234966 VB O
similar BC2GM029234966 JJ O
to BC2GM029234966 TO O
that BC2GM029234966 DT O
observed BC2GM029234966 VBN O
in BC2GM029234966 IN O
animal BC2GM029234966 NN O
and BC2GM029234966 CC O
man BC2GM029234966 NN O
after BC2GM029234966 IN O
administration BC2GM029234966 NN O
of BC2GM029234966 IN O
nicotine BC2GM029234966 NN O
. BC2GM029234966 . O
. . O O

We BC2GM014111333 PRP O
found BC2GM014111333 VBD O
that BC2GM014111333 IN O
the BC2GM014111333 DT O
PRP20 BC2GM014111333 NNP O
gene BC2GM014111333 NN O
is BC2GM014111333 VBZ O
identical BC2GM014111333 JJ O
to BC2GM014111333 TO O
the BC2GM014111333 DT O
yeast BC2GM014111333 NN O
SRM1 BC2GM014111333 NNP O
gene BC2GM014111333 NN O
( BC2GM014111333 ( O
Clark BC2GM014111333 NNP O
and BC2GM014111333 CC O
Sprague BC2GM014111333 NNP O
1989 BC2GM014111333 CD O
) BC2GM014111333 ) O
. BC2GM014111333 . O
. . O O

When BC2GM093619245 WRB O
linked BC2GM093619245 VBN O
to BC2GM093619245 TO O
the BC2GM093619245 DT O
herpes BC2GM093619245 NNS O
simplex BC2GM093619245 JJ O
thymidine BC2GM093619245 JJ O
kinase BC2GM093619245 NN O
minimal BC2GM093619245 JJ O
promoter BC2GM093619245 NN O
, BC2GM093619245 , O
this BC2GM093619245 DT O
fragment BC2GM093619245 JJ O
acts BC2GM093619245 VBZ O
as BC2GM093619245 IN O
an BC2GM093619245 DT O
enhancing BC2GM093619245 VBG O
element BC2GM093619245 NN O
in BC2GM093619245 IN O
Rcho BC2GM093619245 NNP O
but BC2GM093619245 CC O
not BC2GM093619245 RB O
GC BC2GM093619245 NNP O
cells BC2GM093619245 NNS O
. BC2GM093619245 . O
. . O O

It BC2GM093150217 PRP O
has BC2GM093150217 VBZ O
been BC2GM093150217 VBN O
shown BC2GM093150217 VBN O
that BC2GM093150217 IN O
renin BC2GM093150217 NN O
secretion BC2GM093150217 NN O
is BC2GM093150217 VBZ O
stimulated BC2GM093150217 VBN O
by BC2GM093150217 IN O
endothelin BC2GM093150217 NN O
, BC2GM093150217 , O
a BC2GM093150217 DT O
recently BC2GM093150217 RB O
discovered BC2GM093150217 VBN O
peptide BC2GM093150217 NN O
with BC2GM093150217 IN O
strong BC2GM093150217 JJ O
vasoconstrictive BC2GM093150217 JJ O
properties BC2GM093150217 NNS O
and BC2GM093150217 CC O
stimulating BC2GM093150217 VBG O
effects BC2GM093150217 NNS O
on BC2GM093150217 IN O
renin BC2GM093150217 NN O
secretion BC2GM093150217 NN O
. BC2GM093150217 . O
. . O O

Effect BC2GM045767677 NN O
of BC2GM045767677 IN O
capsaicin BC2GM045767677 NN O
on BC2GM045767677 IN O
hexobarbital-anesthetized BC2GM045767677 JJ O
rats BC2GM045767677 NNS O
. BC2GM045767677 . O
. . O O

Metastatic BC2GM045159577 JJ O
tumours BC2GM045159577 NNS O
of BC2GM045159577 IN O
bone BC2GM045159577 NN O
in BC2GM045159577 IN O
Nigerians BC2GM045159577 NNP O
. BC2GM045159577 . O
. . O O

When BC2GM032286416 WRB O
yeast BC2GM032286416 NN O
cells BC2GM032286416 NNS O
reach BC2GM032286416 VBP O
a BC2GM032286416 DT O
critical BC2GM032286416 JJ O
size BC2GM032286416 NN O
in BC2GM032286416 IN O
late BC2GM032286416 JJ O
G1 BC2GM032286416 NNP O
they BC2GM032286416 PRP O
simultaneously BC2GM032286416 RB O
start BC2GM032286416 VBP O
budding BC2GM032286416 VBG O
, BC2GM032286416 , O
initiate BC2GM032286416 JJ O
DNA BC2GM032286416 NNP O
synthesis BC2GM032286416 NN O
, BC2GM032286416 , O
and BC2GM032286416 CC O
activate BC2GM032286416 JJ O
transcription BC2GM032286416 NN O
of BC2GM032286416 IN O
a BC2GM032286416 DT O
set BC2GM032286416 NN O
of BC2GM032286416 IN O
genes BC2GM032286416 NNS O
that BC2GM032286416 WDT O
includes BC2GM032286416 VBZ O
G1 BC2GM032286416 NNP O
cyclins BC2GM032286416 NNS O
CLN1 BC2GM032286416 NNP O
, BC2GM032286416 , O
CLN2 BC2GM032286416 NNP O
, BC2GM032286416 , O
and BC2GM032286416 CC O
many BC2GM032286416 JJ O
DNA BC2GM032286416 NNP O
synthesis BC2GM032286416 NN O
genes BC2GM032286416 NNS O
. BC2GM032286416 . O
. . O O

Furthermore BC2GM047640437 RB O
, BC2GM047640437 , O
disruption BC2GM047640437 NN O
of BC2GM047640437 IN O
pcr1 BC2GM047640437 NN O
reduced BC2GM047640437 VBN O
expression BC2GM047640437 NN O
of BC2GM047640437 IN O
fbp1 BC2GM047640437 NN O
, BC2GM047640437 , O
a BC2GM047640437 DT O
glucose-repressible BC2GM047640437 JJ O
gene BC2GM047640437 NN O
negatively BC2GM047640437 RB O
regulated BC2GM047640437 VBN O
by BC2GM047640437 IN O
PKA BC2GM047640437 NNP O
. BC2GM047640437 . O
. . O O

Recently BC2GM034941243 RB O
, BC2GM034941243 , O
we BC2GM034941243 PRP O
reported BC2GM034941243 VBD O
that BC2GM034941243 IN O
SMRT BC2GM034941243 NNP O
also BC2GM034941243 RB O
directly BC2GM034941243 RB O
associates BC2GM034941243 VBZ O
with BC2GM034941243 IN O
LAZ3 BC2GM034941243 NNP O
( BC2GM034941243 ( O
BCL-6 BC2GM034941243 NNP O
) BC2GM034941243 ) O
, BC2GM034941243 , O
a BC2GM034941243 DT O
POZ BC2GM034941243 NNP O
/ BC2GM034941243 NNP O
Zn BC2GM034941243 NNP O
finger BC2GM034941243 VBD O
transcriptional BC2GM034941243 JJ O
repressor BC2GM034941243 NN O
involvedin BC2GM034941243 VBP O
the BC2GM034941243 DT O
pathogenesis BC2GM034941243 NN O
of BC2GM034941243 IN O
non-Hodgkin BC2GM034941243 JJ O
lymphomas BC2GM034941243 NN O
. BC2GM034941243 . O
. . O O

The BC2GM093309719 DT O
rifampicin BC2GM093309719 NN O
resistance BC2GM093309719 NN O
of BC2GM093309719 IN O
uvsW-repressed BC2GM093309719 JJ O
replication BC2GM093309719 NN O
suggests BC2GM093309719 VBZ O
that BC2GM093309719 IN O
it BC2GM093309719 PRP O
involves BC2GM093309719 VBZ O
either BC2GM093309719 CC O
tertiary BC2GM093309719 JJ O
initiation BC2GM093309719 NN O
or BC2GM093309719 CC O
some BC2GM093309719 DT O
novel BC2GM093309719 JJ O
mode BC2GM093309719 NN O
of BC2GM093309719 IN O
initiation BC2GM093309719 NN O
. BC2GM093309719 . O
. . O O

Both BC2GM028667009 DT O
merR BC2GM028667009 JJ O
genes BC2GM028667009 NNS O
consist BC2GM028667009 NN O
of BC2GM028667009 IN O
a BC2GM028667009 DT O
408 BC2GM028667009 CD O
bp BC2GM028667009 NN O
ORF BC2GM028667009 NNP O
coding BC2GM028667009 NN O
for BC2GM028667009 IN O
135 BC2GM028667009 CD O
amino BC2GM028667009 JJ O
acids BC2GM028667009 NNS O
. BC2GM028667009 . O
. . O O

The BC2GM074656896 DT O
optimum BC2GM074656896 JJ O
cooling BC2GM074656896 NN O
rate BC2GM074656896 NN O
from BC2GM074656896 IN O
RT BC2GM074656896 NNP O
to BC2GM074656896 TO O
5 BC2GM074656896 CD O
degrees BC2GM074656896 NNS O
C BC2GM074656896 NNP O
resulting BC2GM074656896 VBG O
in BC2GM074656896 IN O
maximum BC2GM074656896 JJ O
survival BC2GM074656896 NN O
of BC2GM074656896 IN O
human BC2GM074656896 JJ O
spermatozoa BC2GM074656896 NN O
was BC2GM074656896 VBD O
found BC2GM074656896 VBN O
to BC2GM074656896 TO O
be BC2GM074656896 VB O
0.5 BC2GM074656896 CD O
to BC2GM074656896 TO O
1 BC2GM074656896 CD O
degree BC2GM074656896 NN O
per BC2GM074656896 IN O
minute BC2GM074656896 NN O
when BC2GM074656896 WRB O
cooled BC2GM074656896 VBN O
from BC2GM074656896 IN O
RT BC2GM074656896 NNP O
to BC2GM074656896 TO O
5 BC2GM074656896 CD O
degrees BC2GM074656896 NNS O
C BC2GM074656896 NNP O
and BC2GM074656896 CC O
subsequently BC2GM074656896 RB O
frozen-thawed BC2GM074656896 VBN O
in BC2GM074656896 IN O
liquid BC2GM074656896 NN O
nitrogen BC2GM074656896 NN O
( BC2GM074656896 ( O
LN2 BC2GM074656896 NNP O
) BC2GM074656896 ) O
. BC2GM074656896 . O
. . O O

These BC2GM084813234 DT O
clones BC2GM084813234 NNS O
contain BC2GM084813234 VBP O
most BC2GM084813234 JJS O
of BC2GM084813234 IN O
the BC2GM084813234 DT O
exon BC2GM084813234 NN O
of BC2GM084813234 IN O
cyclin BC2GM084813234 NN O
D2 BC2GM084813234 NNP O
except BC2GM084813234 IN O
exon BC2GM084813234 RB O
5 BC2GM084813234 CD O
. BC2GM084813234 . O
. . O O

The BC2GM097604426 DT O
cyclin-dependent BC2GM097604426 JJ O
kinase BC2GM097604426 NN O
Cdk2 BC2GM097604426 NNP O
associates BC2GM097604426 VBZ O
with BC2GM097604426 IN O
cyclins BC2GM097604426 NNS O
A BC2GM097604426 NNP O
, BC2GM097604426 , O
D BC2GM097604426 NNP O
, BC2GM097604426 , O
and BC2GM097604426 CC O
E BC2GM097604426 NNP O
and BC2GM097604426 CC O
has BC2GM097604426 VBZ O
been BC2GM097604426 VBN O
implicated BC2GM097604426 VBN O
in BC2GM097604426 IN O
the BC2GM097604426 DT O
control BC2GM097604426 NN O
of BC2GM097604426 IN O
the BC2GM097604426 DT O
G1 BC2GM097604426 NNP O
to BC2GM097604426 TO O
S BC2GM097604426 NNP O
phase BC2GM097604426 NN O
transition BC2GM097604426 NN O
in BC2GM097604426 IN O
mammals BC2GM097604426 NNS O
. BC2GM097604426 . O
. . O O

Our BC2GM056335260 PRP$ O
findings BC2GM056335260 NNS O
suggest BC2GM056335260 VBP O
that BC2GM056335260 IN O
resting BC2GM056335260 VBG O
Tl-201 BC2GM056335260 NNP O
scintigraphy BC2GM056335260 NN O
has BC2GM056335260 VBZ O
limited BC2GM056335260 VBN O
value BC2GM056335260 NN O
in BC2GM056335260 IN O
the BC2GM056335260 DT O
detection BC2GM056335260 NN O
of BC2GM056335260 IN O
coronary BC2GM056335260 JJ O
artery BC2GM056335260 NN O
disease BC2GM056335260 NN O
in BC2GM056335260 IN O
patients BC2GM056335260 NNS O
with BC2GM056335260 IN O
Hurler BC2GM056335260 NNP O
syndrome BC2GM056335260 NN O
. BC2GM056335260 . O
. . O O

In BC2GM076042408 IN O
contrast BC2GM076042408 NN O
to BC2GM076042408 TO O
the BC2GM076042408 DT O
restricted BC2GM076042408 VBN O
tissue BC2GM076042408 NN O
expression BC2GM076042408 NN O
of BC2GM076042408 IN O
gonadotropin BC2GM076042408 NN O
and BC2GM076042408 CC O
TSH BC2GM076042408 NNP O
receptors BC2GM076042408 NNS O
in BC2GM076042408 IN O
gonads BC2GM076042408 NNS O
and BC2GM076042408 CC O
thyroid BC2GM076042408 NN O
, BC2GM076042408 , O
respectively BC2GM076042408 RB O
, BC2GM076042408 , O
LGR4 BC2GM076042408 NNP O
is BC2GM076042408 VBZ O
expressed BC2GM076042408 VBN O
in BC2GM076042408 IN O
diverse BC2GM076042408 NN O
tissues BC2GM076042408 NNS O
including BC2GM076042408 VBG O
ovary BC2GM076042408 JJ O
, BC2GM076042408 , O
testis BC2GM076042408 NN O
, BC2GM076042408 , O
adrenal BC2GM076042408 JJ O
, BC2GM076042408 , O
placenta BC2GM076042408 NN O
, BC2GM076042408 , O
thymus BC2GM076042408 NN O
, BC2GM076042408 , O
spinal BC2GM076042408 JJ O
cord BC2GM076042408 NN O
, BC2GM076042408 , O
and BC2GM076042408 CC O
thyroid BC2GM076042408 NN O
, BC2GM076042408 , O
whereas BC2GM076042408 JJ O
LGR5 BC2GM076042408 NNP O
is BC2GM076042408 VBZ O
found BC2GM076042408 VBN O
in BC2GM076042408 IN O
muscle BC2GM076042408 NN O
, BC2GM076042408 , O
placenta BC2GM076042408 NN O
, BC2GM076042408 , O
spinal BC2GM076042408 JJ O
cord BC2GM076042408 NN O
, BC2GM076042408 , O
and BC2GM076042408 CC O
brain BC2GM076042408 NN O
. BC2GM076042408 . O
. . O O

However BC2GM092761606 RB O
, BC2GM092761606 , O
only BC2GM092761606 RB O
plasma BC2GM092761606 JJ O
fibrinogen BC2GM092761606 NN O
concentrations BC2GM092761606 NNS O
showed BC2GM092761606 VBD O
statistically BC2GM092761606 RB O
significant BC2GM092761606 JJ O
positive BC2GM092761606 JJ O
associations BC2GM092761606 NNS O
with BC2GM092761606 IN O
IMT BC2GM092761606 NNP O
in BC2GM092761606 IN O
both BC2GM092761606 DT O
groups BC2GM092761606 NNS O
. BC2GM092761606 . O
. . O O

In BC2GM085419447 IN O
the BC2GM085419447 DT O
second BC2GM085419447 JJ O
group BC2GM085419447 NN O
the BC2GM085419447 DT O
untreated BC2GM085419447 JJ O
fellow BC2GM085419447 NN O
eye BC2GM085419447 NN O
was BC2GM085419447 VBD O
microscopically BC2GM085419447 RB O
intact BC2GM085419447 JJ O
, BC2GM085419447 , O
but BC2GM085419447 CC O
was BC2GM085419447 VBD O
shown BC2GM085419447 VBN O
( BC2GM085419447 ( O
as BC2GM085419447 IN O
the BC2GM085419447 DT O
treated BC2GM085419447 JJ O
eye BC2GM085419447 NN O
) BC2GM085419447 ) O
to BC2GM085419447 TO O
alter BC2GM085419447 VB O
the BC2GM085419447 DT O
concentration BC2GM085419447 NN O
of BC2GM085419447 IN O
uronic BC2GM085419447 JJ O
acid BC2GM085419447 NN O
in BC2GM085419447 IN O
different BC2GM085419447 JJ O
parts BC2GM085419447 NNS O
of BC2GM085419447 IN O
the BC2GM085419447 DT O
sclera BC2GM085419447 NN O
. BC2GM085419447 . O
. . O O

Direct BC2GM031921056 JJ O
saturation BC2GM031921056 NN O
analysis BC2GM031921056 NN O
. BC2GM031921056 . O
. . O O

CNS BC2GM014747695 NNP O
preventive BC2GM014747695 JJ O
treatment BC2GM014747695 NN O
without BC2GM014747695 IN O
cranial BC2GM014747695 JJ O
irradiation BC2GM014747695 NN O
was BC2GM014747695 VBD O
effective BC2GM014747695 JJ O
in BC2GM014747695 IN O
all BC2GM014747695 PDT O
the BC2GM014747695 DT O
groups BC2GM014747695 NNS O
of BC2GM014747695 IN O
ALL BC2GM014747695 DT O
patients BC2GM014747695 NNS O
. BC2GM014747695 . O
. . O O

The BC2GM083941161 DT O
data BC2GM083941161 NNS O
obtained BC2GM083941161 VBN O
with BC2GM083941161 IN O
cellular BC2GM083941161 JJ O
RNA BC2GM083941161 NNP O
from BC2GM083941161 IN O
HepG2 BC2GM083941161 NNP O
cells BC2GM083941161 NNS O
demonstrated BC2GM083941161 VBD O
that BC2GM083941161 IN O
transcription BC2GM083941161 NN O
is BC2GM083941161 VBZ O
initiated BC2GM083941161 VBN O
891 BC2GM083941161 CD O
bases BC2GM083941161 NNS O
upstream BC2GM083941161 RB O
of BC2GM083941161 IN O
the BC2GM083941161 DT O
translation-start BC2GM083941161 JJ O
site BC2GM083941161 NN O
and BC2GM083941161 CC O
that BC2GM083941161 IN O
the BC2GM083941161 DT O
polyadenylation BC2GM083941161 NN O
site BC2GM083941161 NN O
is BC2GM083941161 VBZ O
located BC2GM083941161 VBN O
550 BC2GM083941161 CD O
bases BC2GM083941161 NNS O
downstream BC2GM083941161 NN O
of BC2GM083941161 IN O
the BC2GM083941161 DT O
stop BC2GM083941161 NN O
codon BC2GM083941161 NN O
. BC2GM083941161 . O
. . O O

At BC2GM065683949 IN O
9 BC2GM065683949 CD O
months BC2GM065683949 NNS O
postpartum BC2GM065683949 NN O
, BC2GM065683949 , O
serum BC2GM065683949 NN O
fT4 BC2GM065683949 NN O
and BC2GM065683949 CC O
fT3 BC2GM065683949 NN O
levels BC2GM065683949 NNS O
were BC2GM065683949 VBD O
low BC2GM065683949 JJ O
normal BC2GM065683949 JJ O
( BC2GM065683949 ( O
8.0 BC2GM065683949 CD O
and BC2GM065683949 CC O
1.7 BC2GM065683949 CD O
pmol BC2GM065683949 NN O
/ BC2GM065683949 NNP O
L BC2GM065683949 NNP O
, BC2GM065683949 , O
respectively BC2GM065683949 RB O
) BC2GM065683949 ) O
, BC2GM065683949 , O
but BC2GM065683949 CC O
TSH BC2GM065683949 NNP O
was BC2GM065683949 VBD O
not BC2GM065683949 RB O
raised BC2GM065683949 VBN O
( BC2GM065683949 ( O
0.4 BC2GM065683949 CD O
mU BC2GM065683949 NN O
/ BC2GM065683949 NNP O
L BC2GM065683949 NNP O
) BC2GM065683949 ) O
. BC2GM065683949 . O
. . O O

One BC2GM074053029 CD O
new BC2GM074053029 JJ O
ORF BC2GM074053029 NNP O
, BC2GM074053029 , O
YBR0224 BC2GM074053029 NNP O
, BC2GM074053029 , O
was BC2GM074053029 VBD O
detected BC2GM074053029 VBN O
, BC2GM074053029 , O
coding BC2GM074053029 VBG O
for BC2GM074053029 IN O
a BC2GM074053029 DT O
protein BC2GM074053029 NN O
with BC2GM074053029 IN O
918 BC2GM074053029 CD O
amino BC2GM074053029 JJ O
acids BC2GM074053029 NNS O
. BC2GM074053029 . O
. . O O

Subclones BC2GM008312798 NNS O
stably BC2GM008312798 RB O
expressing BC2GM008312798 VBG O
alpha1A- BC2GM008312798 JJ O
, BC2GM008312798 , O
alpha1B- BC2GM008312798 JJ O
, BC2GM008312798 , O
and BC2GM008312798 CC O
alpha1D-ARs BC2GM008312798 JJ O
under BC2GM008312798 IN O
control BC2GM008312798 NN O
of BC2GM008312798 IN O
an BC2GM008312798 DT O
inducible BC2GM008312798 JJ O
promoter BC2GM008312798 NN O
, BC2GM008312798 , O
or BC2GM008312798 CC O
at BC2GM008312798 IN O
high BC2GM008312798 JJ O
and BC2GM008312798 CC O
low BC2GM008312798 JJ O
receptor BC2GM008312798 NN O
density BC2GM008312798 NN O
, BC2GM008312798 , O
were BC2GM008312798 VBD O
isolated BC2GM008312798 VBN O
and BC2GM008312798 CC O
characterized BC2GM008312798 VBN O
. BC2GM008312798 . O
. . O O

Greer BC2GM053348868 NNP O
, BC2GM053348868 , O
and BC2GM053348868 CC O
L.A BC2GM053348868 NNP O
. BC2GM053348868 . O
. . O O

The BC2GM063202569 DT O
identification BC2GM063202569 NN O
of BC2GM063202569 IN O
SRP54sc BC2GM063202569 NNP O
and BC2GM063202569 CC O
SRP54sp BC2GM063202569 NNP O
provides BC2GM063202569 VBZ O
the BC2GM063202569 DT O
first BC2GM063202569 JJ O
evidence BC2GM063202569 NN O
for BC2GM063202569 IN O
SRP BC2GM063202569 NNP O
related BC2GM063202569 JJ O
proteins BC2GM063202569 NNS O
in BC2GM063202569 IN O
yeast BC2GM063202569 NN O
. BC2GM063202569 . O
. . O O

Enhanced BC2GM012329811 NNP O
quantum BC2GM012329811 NN O
correlations BC2GM012329811 NNS O
in BC2GM012329811 IN O
bound BC2GM012329811 JJ O
higher-order BC2GM012329811 JJ O
solitons BC2GM012329811 NNS O
Quantum BC2GM012329811 NNP O
effects BC2GM012329811 NNS O
in BC2GM012329811 IN O
N-bound BC2GM012329811 JJ O
solitons BC2GM012329811 NNS O
can BC2GM012329811 MD O
be BC2GM012329811 VB O
drastically BC2GM012329811 RB O
enhanced BC2GM012329811 VBN O
compared BC2GM012329811 VBN O
to BC2GM012329811 TO O
the BC2GM012329811 DT O
fundamental BC2GM012329811 JJ O
soliton BC2GM012329811 NN O
. BC2GM012329811 . O
. . O O

The BC2GM060839599 DT O
enigma BC2GM060839599 NN O
of BC2GM060839599 IN O
aging BC2GM060839599 VBG O
bone BC2GM060839599 NN O
loss BC2GM060839599 NN O
. BC2GM060839599 . O
. . O O

Derepression BC2GM052718596 NN O
of BC2GM052718596 IN O
RAR BC2GM052718596 NNP O
signaling BC2GM052718596 VBG O
by BC2GM052718596 IN O
expressing BC2GM052718596 VBG O
a BC2GM052718596 DT O
dominant-negative BC2GM052718596 JJ O
corepressor BC2GM052718596 NN O
resulted BC2GM052718596 VBD O
in BC2GM052718596 IN O
embryos BC2GM052718596 NN O
that BC2GM052718596 WDT O
exhibited BC2GM052718596 VBD O
phenotypes BC2GM052718596 NNS O
similar BC2GM052718596 JJ O
to BC2GM052718596 TO O
those BC2GM052718596 DT O
treated BC2GM052718596 VBN O
by BC2GM052718596 IN O
RA BC2GM052718596 NNP O
. BC2GM052718596 . O
. . O O

It BC2GM025336946 PRP O
appears BC2GM025336946 VBZ O
to BC2GM025336946 TO O
be BC2GM025336946 VB O
useful BC2GM025336946 JJ O
in BC2GM025336946 IN O
untreated BC2GM025336946 JJ O
patients BC2GM025336946 NNS O
with BC2GM025336946 IN O
stage BC2GM025336946 NN O
I BC2GM025336946 PRP O
or BC2GM025336946 CC O
II BC2GM025336946 NNP O
NHL BC2GM025336946 NNP O
but BC2GM025336946 CC O
no BC2GM025336946 DT O
definite BC2GM025336946 JJ O
radiographic BC2GM025336946 JJ O
abnormalities BC2GM025336946 NNS O
, BC2GM025336946 , O
or BC2GM025336946 CC O
with BC2GM025336946 IN O
abnormal BC2GM025336946 JJ O
radiographs BC2GM025336946 NNS O
but BC2GM025336946 CC O
no BC2GM025336946 DT O
extrathoracic BC2GM025336946 JJ O
spread BC2GM025336946 NN O
, BC2GM025336946 , O
and BC2GM025336946 CC O
in BC2GM025336946 IN O
treated BC2GM025336946 JJ O
patients BC2GM025336946 NNS O
with BC2GM025336946 IN O
questionable BC2GM025336946 JJ O
radiographs BC2GM025336946 NN O
. BC2GM025336946 . O
. . O O

Peak BC2GM017555562 NNP O
insulin BC2GM017555562 NN O
response BC2GM017555562 NN O
to BC2GM017555562 TO O
glucose BC2GM017555562 VB O
infusion BC2GM017555562 NN O
declined BC2GM017555562 VBD O
from BC2GM017555562 IN O
Groups BC2GM017555562 NNP O
1 BC2GM017555562 CD O
to BC2GM017555562 TO O
3 BC2GM017555562 CD O
( BC2GM017555562 ( O
51 BC2GM017555562 CD O
+ BC2GM017555562 NN O
/ BC2GM017555562 NNP O
- BC2GM017555562 : O
14 BC2GM017555562 CD O
, BC2GM017555562 , O
42.4 BC2GM017555562 CD O
+ BC2GM017555562 NN O
/ BC2GM017555562 NNP O
- BC2GM017555562 : O
31 BC2GM017555562 CD O
, BC2GM017555562 , O
20.4 BC2GM017555562 CD O
+ BC2GM017555562 NN O
/ BC2GM017555562 NNP O
- BC2GM017555562 : O
6.8 BC2GM017555562 CD O
microU BC2GM017555562 NN O
/ BC2GM017555562 NNP O
ml BC2GM017555562 NN O
, BC2GM017555562 , O
respectively BC2GM017555562 RB O
) BC2GM017555562 ) O
with BC2GM017555562 IN O
Group BC2GM017555562 NNP O
3 BC2GM017555562 CD O
exhibiting BC2GM017555562 VBG O
a BC2GM017555562 DT O
significantly BC2GM017555562 RB O
decreased BC2GM017555562 VBN O
mean BC2GM017555562 JJ O
peak BC2GM017555562 NN O
level BC2GM017555562 NN O
compared BC2GM017555562 VBN O
to BC2GM017555562 TO O
the BC2GM017555562 DT O
other BC2GM017555562 JJ O
groups BC2GM017555562 NNS O
. BC2GM017555562 . O
. . O O

CONCLUSIONS BC2GM071513043 NNS O
: BC2GM071513043 : O
Results BC2GM071513043 NNS O
of BC2GM071513043 IN O
this BC2GM071513043 DT O
study BC2GM071513043 NN O
suggest BC2GM071513043 VBP O
that BC2GM071513043 IN O
both BC2GM071513043 DT O
male BC2GM071513043 NN O
and BC2GM071513043 CC O
female BC2GM071513043 JJ O
soldiers BC2GM071513043 NNS O
who BC2GM071513043 WP O
are BC2GM071513043 VBP O
diagnosed BC2GM071513043 VBN O
with BC2GM071513043 IN O
chlamydia BC2GM071513043 NN O
infections BC2GM071513043 NNS O
have BC2GM071513043 VBP O
relatively BC2GM071513043 RB O
high BC2GM071513043 JJ O
risks BC2GM071513043 NNS O
of BC2GM071513043 IN O
reinfection BC2GM071513043 NN O
through BC2GM071513043 IN O
their BC2GM071513043 PRP$ O
20s BC2GM071513043 CD O
. BC2GM071513043 . O
. . O O

Magnification-corrected BC2GM028646260 JJ O
planimetry BC2GM028646260 NN O
of BC2GM028646260 IN O
the BC2GM028646260 DT O
parapapillary BC2GM028646260 JJ O
region BC2GM028646260 NN O
was BC2GM028646260 VBD O
performed BC2GM028646260 VBN O
according BC2GM028646260 VBG O
to BC2GM028646260 TO O
Littmann BC2GM028646260 NNP O
's BC2GM028646260 POS O
method BC2GM028646260 NN O
in BC2GM028646260 IN O
312 BC2GM028646260 CD O
unselected BC2GM028646260 JJ O
eyes BC2GM028646260 NNS O
with BC2GM028646260 IN O
chronic BC2GM028646260 JJ O
primary BC2GM028646260 JJ O
open-angle BC2GM028646260 JJ O
glaucoma BC2GM028646260 NN O
and BC2GM028646260 CC O
in BC2GM028646260 IN O
125 BC2GM028646260 CD O
normal BC2GM028646260 JJ O
eyes BC2GM028646260 NNS O
of BC2GM028646260 IN O
an BC2GM028646260 DT O
age- BC2GM028646260 JJ O
and BC2GM028646260 CC O
refraction-matched BC2GM028646260 JJ O
control BC2GM028646260 NN O
group BC2GM028646260 NN O
using BC2GM028646260 VBG O
optic BC2GM028646260 JJ O
disk BC2GM028646260 NN O
photographs BC2GM028646260 NN O
. BC2GM028646260 . O
. . O O

Clinical BC2GM031995468 JJ O
findings BC2GM031995468 NNS O
plaque BC2GM031995468 NN O
index BC2GM031995468 NN O
, BC2GM031995468 , O
PI BC2GM031995468 NNP O
; BC2GM031995468 : O
gingival BC2GM031995468 JJ O
index BC2GM031995468 NN O
, BC2GM031995468 , O
GI BC2GM031995468 NNP O
; BC2GM031995468 : O
bleeding BC2GM031995468 VBG O
on BC2GM031995468 IN O
probing BC2GM031995468 VBG O
, BC2GM031995468 , O
BOP BC2GM031995468 NNP O
; BC2GM031995468 : O
pus BC2GM031995468 NN O
discharge BC2GM031995468 NN O
, BC2GM031995468 , O
pus BC2GM031995468 NN O
; BC2GM031995468 : O
and BC2GM031995468 CC O
probing BC2GM031995468 VBG O
depth BC2GM031995468 NN O
, BC2GM031995468 , O
PD BC2GM031995468 NNP O
at BC2GM031995468 IN O
both BC2GM031995468 DT O
PT-01 BC2GM031995468 NNP O
and BC2GM031995468 CC O
control BC2GM031995468 VB O
sites BC2GM031995468 NNS O
were BC2GM031995468 VBD O
measured BC2GM031995468 VBN O
at BC2GM031995468 IN O
every BC2GM031995468 DT O
visit BC2GM031995468 NN O
for BC2GM031995468 IN O
4 BC2GM031995468 CD O
weeks BC2GM031995468 NNS O
. BC2GM031995468 . O
. . O O

Stability BC2GM087637002 NN O
of BC2GM087637002 IN O
125 BC2GM087637002 CD O
I-labeled BC2GM087637002 JJ O
insulin BC2GM087637002 NN O
used BC2GM087637002 VBN O
in BC2GM087637002 IN O
radioimmunoassay BC2GM087637002 NN O
of BC2GM087637002 IN O
insulin BC2GM087637002 NN O
. BC2GM087637002 . O
. . O O

Subgroup BC2GM089485975 NNP O
analysis BC2GM089485975 NN O
failed BC2GM089485975 VBD O
to BC2GM089485975 TO O
show BC2GM089485975 VB O
any BC2GM089485975 DT O
benefit BC2GM089485975 NN O
for BC2GM089485975 IN O
etoposide BC2GM089485975 NN O
in BC2GM089485975 IN O
patients BC2GM089485975 NNS O
with BC2GM089485975 IN O
monocytic BC2GM089485975 JJ O
or BC2GM089485975 CC O
myelomonocytic BC2GM089485975 JJ O
disease BC2GM089485975 NN O
, BC2GM089485975 , O
or BC2GM089485975 CC O
in BC2GM089485975 IN O
any BC2GM089485975 DT O
other BC2GM089485975 JJ O
diagnostic BC2GM089485975 JJ O
subgroup BC2GM089485975 NN O
. BC2GM089485975 . O
. . O O

The BC2GM027269907 DT O
difference BC2GM027269907 NN O
between BC2GM027269907 IN O
the BC2GM027269907 DT O
effects BC2GM027269907 NNS O
of BC2GM027269907 IN O
the BC2GM027269907 DT O
two BC2GM027269907 CD O
dose BC2GM027269907 JJ O
levels BC2GM027269907 NNS O
of BC2GM027269907 IN O
Z BC2GM027269907 NNP O
. BC2GM027269907 . O
. . O O

Raman BC2GM091583660 NNP O
scattering BC2GM091583660 VBG O
from BC2GM091583660 IN O
VO2 BC2GM091583660 NNP O
single BC2GM091583660 JJ O
crystals BC2GM091583660 NNS O
: BC2GM091583660 : O
A BC2GM091583660 DT O
study BC2GM091583660 NN O
of BC2GM091583660 IN O
the BC2GM091583660 DT O
effects BC2GM091583660 NNS O
of BC2GM091583660 IN O
surface BC2GM091583660 NN O
oxidation BC2GM091583660 NN O
. BC2GM091583660 . O
. . O O

The BC2GM031523666 DT O
starting BC2GM031523666 VBG O
dose BC2GM031523666 NN O
was BC2GM031523666 VBD O
8 BC2GM031523666 CD O
mg BC2GM031523666 NN O
/ BC2GM031523666 NNP O
m2 BC2GM031523666 NN O
administered BC2GM031523666 VBD O
intravenously BC2GM031523666 RB O
( BC2GM031523666 ( O
IV BC2GM031523666 NNP O
) BC2GM031523666 ) O
as BC2GM031523666 IN O
a BC2GM031523666 DT O
short BC2GM031523666 JJ O
infusion BC2GM031523666 NN O
daily BC2GM031523666 RB O
for BC2GM031523666 IN O
5 BC2GM031523666 CD O
days BC2GM031523666 NNS O
, BC2GM031523666 , O
repeated BC2GM031523666 VBD O
every BC2GM031523666 DT O
3 BC2GM031523666 CD O
weeks BC2GM031523666 NNS O
with BC2GM031523666 IN O
dose BC2GM031523666 JJ O
adjustments BC2GM031523666 NNS O
depending BC2GM031523666 VBG O
on BC2GM031523666 IN O
patient BC2GM031523666 JJ O
tolerance BC2GM031523666 NN O
. BC2GM031523666 . O
. . O O

Mycobacterium BC2GM039052742 NNP O
tuberculosis BC2GM039052742 NN O
inhibits BC2GM039052742 VBZ O
IFN-gamma BC2GM039052742 NNP O
transcriptional BC2GM039052742 JJ O
responses BC2GM039052742 NNS O
without BC2GM039052742 IN O
inhibiting BC2GM039052742 VBG O
activation BC2GM039052742 NN O
of BC2GM039052742 IN O
STAT1 BC2GM039052742 NNP O
. BC2GM039052742 . O
. . O O

The BC2GM082788210 DT O
lack BC2GM082788210 NN O
of BC2GM082788210 IN O
heterozygous BC2GM082788210 JJ O
positions BC2GM082788210 NNS O
essentially BC2GM082788210 RB O
facilitates BC2GM082788210 VBZ O
on BC2GM082788210 IN O
the BC2GM082788210 DT O
one BC2GM082788210 CD O
hand BC2GM082788210 NN O
the BC2GM082788210 DT O
data BC2GM082788210 NN O
analysis BC2GM082788210 NN O
and BC2GM082788210 CC O
on BC2GM082788210 IN O
the BC2GM082788210 DT O
other BC2GM082788210 JJ O
hand BC2GM082788210 NN O
the BC2GM082788210 DT O
detection BC2GM082788210 NN O
of BC2GM082788210 IN O
new BC2GM082788210 JJ O
alleles BC2GM082788210 NNS O
. BC2GM082788210 . O
. . O O

Serum BC2GM067694313 NNP O
estriol BC2GM067694313 NN O
levels BC2GM067694313 NNS O
during BC2GM067694313 IN O
beta-receptor BC2GM067694313 JJ O
agonist BC2GM067694313 JJ O
infusion BC2GM067694313 NN O
in BC2GM067694313 IN O
the BC2GM067694313 DT O
third BC2GM067694313 JJ O
trimester BC2GM067694313 NN O
of BC2GM067694313 IN O
pregnancy BC2GM067694313 NN O
. BC2GM067694313 . O
. . O O

BAG-1 BC2GM062596008 NNP O
also BC2GM062596008 RB O
prevented BC2GM062596008 VBD O
growth BC2GM062596008 NN O
arrest BC2GM062596008 IN O
following BC2GM062596008 VBG O
UV-irradiation-induced BC2GM062596008 JJ O
genotoxic BC2GM062596008 JJ O
injury BC2GM062596008 NN O
without BC2GM062596008 IN O
interfering BC2GM062596008 VBG O
with BC2GM062596008 IN O
accumulation BC2GM062596008 NN O
of BC2GM062596008 IN O
p53 BC2GM062596008 NN O
protein BC2GM062596008 NN O
or BC2GM062596008 CC O
p21 BC2GM062596008 NN O
( BC2GM062596008 ( O
waf-1 BC2GM062596008 JJ O
) BC2GM062596008 ) O
expression BC2GM062596008 NN O
. BC2GM062596008 . O
. . O O

UVB-induced BC2GM098731910 JJ O
association BC2GM098731910 NN O
of BC2GM098731910 IN O
tumor BC2GM098731910 NN O
necrosis BC2GM098731910 NN O
factor BC2GM098731910 NN O
( BC2GM098731910 ( O
TNF BC2GM098731910 NNP O
) BC2GM098731910 ) O
receptor BC2GM098731910 NN O
1 BC2GM098731910 CD O
/ BC2GM098731910 JJ O
TNF BC2GM098731910 NNP O
receptor-associated BC2GM098731910 JJ O
factor-2 BC2GM098731910 JJ O
mediates BC2GM098731910 NNS O
activation BC2GM098731910 NN O
of BC2GM098731910 IN O
Rel BC2GM098731910 NNP O
proteins BC2GM098731910 NNS O
. BC2GM098731910 . O
. . O O

Ciprofloxacin BC2GM097798916 NNP O
attained BC2GM097798916 VBD O
a BC2GM097798916 DT O
peak BC2GM097798916 JJ O
serum BC2GM097798916 JJ O
concentration BC2GM097798916 NN O
of BC2GM097798916 IN O
1.2 BC2GM097798916 CD O
mg BC2GM097798916 NNS O
/ BC2GM097798916 JJ O
l BC2GM097798916 NN O
and BC2GM097798916 CC O
a BC2GM097798916 DT O
serum BC2GM097798916 JJ O
half-life BC2GM097798916 NN O
of BC2GM097798916 IN O
34 BC2GM097798916 CD O
min BC2GM097798916 NN O
. BC2GM097798916 . O
. . O O

The BC2GM078517067 DT O
orf2 BC2GM078517067 JJ O
gene BC2GM078517067 NN O
product BC2GM078517067 NN O
is BC2GM078517067 VBZ O
a BC2GM078517067 DT O
protein BC2GM078517067 NN O
of BC2GM078517067 IN O
79 BC2GM078517067 CD O
amino BC2GM078517067 JJ O
acids BC2GM078517067 NNS O
with BC2GM078517067 IN O
characteristics BC2GM078517067 NNS O
similar BC2GM078517067 JJ O
to BC2GM078517067 TO O
those BC2GM078517067 DT O
of BC2GM078517067 IN O
the BC2GM078517067 DT O
Tat BC2GM078517067 NNP O
( BC2GM078517067 ( O
transactivator BC2GM078517067 NN O
) BC2GM078517067 ) O
proteins BC2GM078517067 VBZ O
of BC2GM078517067 IN O
the BC2GM078517067 DT O
ungulate BC2GM078517067 JJ O
lentiviruses BC2GM078517067 NNS O
. BC2GM078517067 . O
. . O O

To BC2GM012511616 TO O
test BC2GM012511616 VB O
this BC2GM012511616 DT O
hypothesis BC2GM012511616 NN O
, BC2GM012511616 , O
we BC2GM012511616 PRP O
developed BC2GM012511616 VBD O
a BC2GM012511616 DT O
system BC2GM012511616 NN O
of BC2GM012511616 IN O
transient BC2GM012511616 JJ O
transfection BC2GM012511616 NN O
of BC2GM012511616 IN O
rat BC2GM012511616 NN O
adipocytes BC2GM012511616 NNS O
with BC2GM012511616 IN O
constructs BC2GM012511616 NNS O
containing BC2GM012511616 VBG O
glyceraldehyde-3-phosphate BC2GM012511616 JJ O
dehydrogenase BC2GM012511616 NN O
( BC2GM012511616 ( O
GAPDH BC2GM012511616 NNP O
) BC2GM012511616 ) O
and BC2GM012511616 CC O
fatty BC2GM012511616 JJ O
acid BC2GM012511616 JJ O
synthetase BC2GM012511616 NN O
( BC2GM012511616 ( O
FAS BC2GM012511616 NNP O
) BC2GM012511616 ) O
promoters BC2GM012511616 NNS O
fused BC2GM012511616 VBN O
to BC2GM012511616 TO O
gene BC2GM012511616 NN O
reporter BC2GM012511616 NN O
CAT BC2GM012511616 NNP O
. BC2GM012511616 . O
. . O O

MRI BC2GM014167322 NNP O
visualization BC2GM014167322 NN O
of BC2GM014167322 IN O
proteoglycan BC2GM014167322 JJ O
depletion BC2GM014167322 NN O
in BC2GM014167322 IN O
articular BC2GM014167322 JJ O
cartilage BC2GM014167322 NN O
via BC2GM014167322 IN O
intravenous BC2GM014167322 JJ O
administration BC2GM014167322 NN O
of BC2GM014167322 IN O
Gd-DTPA BC2GM014167322 NNP O
. BC2GM014167322 . O
. . O O

The BC2GM014656011 DT O
long BC2GM014656011 JJ O
terminal BC2GM014656011 JJ O
repeat BC2GM014656011 NN O
is BC2GM014656011 VBZ O
590 BC2GM014656011 CD O
bp BC2GM014656011 NN O
in BC2GM014656011 IN O
length BC2GM014656011 NN O
, BC2GM014656011 , O
with BC2GM014656011 IN O
the BC2GM014656011 DT O
U3 BC2GM014656011 NNP O
region BC2GM014656011 NN O
containing BC2GM014656011 VBG O
consensus BC2GM014656011 NN O
sequences BC2GM014656011 NNS O
likely BC2GM014656011 JJ O
to BC2GM014656011 TO O
be BC2GM014656011 VB O
involved BC2GM014656011 VBN O
in BC2GM014656011 IN O
viral BC2GM014656011 JJ O
gene BC2GM014656011 NN O
expression BC2GM014656011 NN O
. BC2GM014656011 . O
. . O O

The BC2GM090237633 DT O
N-terminal BC2GM090237633 JJ O
sequences BC2GM090237633 NNS O
of BC2GM090237633 IN O
isoforms BC2GM090237633 NNS O
beta BC2GM090237633 VBP O
to BC2GM090237633 TO O
epsilon BC2GM090237633 VB O
contain BC2GM090237633 VB O
a BC2GM090237633 DT O
PEST BC2GM090237633 NNP O
region BC2GM090237633 NN O
which BC2GM090237633 WDT O
could BC2GM090237633 MD O
induce BC2GM090237633 VB O
rapid BC2GM090237633 JJ O
intracellular BC2GM090237633 JJ O
degradation BC2GM090237633 NN O
of BC2GM090237633 IN O
isoforms BC2GM090237633 NNS O
beta BC2GM090237633 NN O
and BC2GM090237633 CC O
delta BC2GM090237633 NN O
. BC2GM090237633 . O
. . O O

These BC2GM057124014 DT O
observations BC2GM057124014 NNS O
demonstrate BC2GM057124014 VBP O
that BC2GM057124014 IN O
KSR BC2GM057124014 NNP O
is BC2GM057124014 VBZ O
capable BC2GM057124014 JJ O
of BC2GM057124014 IN O
uncoupling BC2GM057124014 VBG O
the BC2GM057124014 DT O
MAP BC2GM057124014 NNP O
kinase BC2GM057124014 NN O
activation BC2GM057124014 NN O
from BC2GM057124014 IN O
its BC2GM057124014 PRP$ O
target BC2GM057124014 NN O
phosphorylation BC2GM057124014 NN O
, BC2GM057124014 , O
and BC2GM057124014 CC O
thus BC2GM057124014 RB O
provide BC2GM057124014 VB O
a BC2GM057124014 DT O
novel BC2GM057124014 JJ O
mechanism BC2GM057124014 NN O
for BC2GM057124014 IN O
modulating BC2GM057124014 VBG O
the BC2GM057124014 DT O
Ras-MAP BC2GM057124014 JJ O
kinase BC2GM057124014 NN O
signaling BC2GM057124014 VBG O
pathway BC2GM057124014 NN O
. BC2GM057124014 . O
. . O O

In BC2GM040092989 IN O
patients BC2GM040092989 NNS O
in BC2GM040092989 IN O
which BC2GM040092989 WDT O
these BC2GM040092989 DT O
criteria BC2GM040092989 NNS O
were BC2GM040092989 VBD O
not BC2GM040092989 RB O
met BC2GM040092989 VBN O
only BC2GM040092989 RB O
the BC2GM040092989 DT O
reproducibility BC2GM040092989 NN O
of BC2GM040092989 IN O
the BC2GM040092989 DT O
VO2 BC2GM040092989 NNP O
obtained BC2GM040092989 VBN O
in BC2GM040092989 IN O
both BC2GM040092989 DT O
the BC2GM040092989 DT O
P-MET BC2GM040092989 NNP O
and BC2GM040092989 CC O
the BC2GM040092989 DT O
C-MET BC2GM040092989 NNP O
indicated BC2GM040092989 VBD O
that BC2GM040092989 IN O
the BC2GM040092989 DT O
maximal BC2GM040092989 JJ O
VO2 BC2GM040092989 NNP O
for BC2GM040092989 IN O
these BC2GM040092989 DT O
4 BC2GM040092989 CD O
patients BC2GM040092989 NNS O
had BC2GM040092989 VBD O
been BC2GM040092989 VBN O
reached BC2GM040092989 VBN O
. BC2GM040092989 . O
. . O O

More BC2GM002607371 JJR O
than BC2GM002607371 IN O
80 BC2GM002607371 CD O
% BC2GM002607371 NN O
appropriate BC2GM002607371 JJ O
lever BC2GM002607371 NN O
responding BC2GM002607371 NN O
was BC2GM002607371 VBD O
established BC2GM002607371 VBN O
after BC2GM002607371 IN O
27 BC2GM002607371 CD O
, BC2GM002607371 , O
38 BC2GM002607371 CD O
and BC2GM002607371 CC O
44 BC2GM002607371 CD O
daily BC2GM002607371 JJ O
training BC2GM002607371 NN O
sessions BC2GM002607371 NNS O
with BC2GM002607371 IN O
DN-2327 BC2GM002607371 NNP O
, BC2GM002607371 , O
diazepam BC2GM002607371 NN O
and BC2GM002607371 CC O
PTZ BC2GM002607371 NNP O
, BC2GM002607371 , O
respectively BC2GM002607371 RB O
, BC2GM002607371 , O
as BC2GM002607371 IN O
the BC2GM002607371 DT O
training BC2GM002607371 NN O
drug BC2GM002607371 NN O
. BC2GM002607371 . O
. . O O

The BC2GM015319491 DT O
maximum BC2GM015319491 JJ O
levels BC2GM015319491 NNS O
of BC2GM015319491 IN O
reporter BC2GM015319491 NN O
proteins BC2GM015319491 NNS O
attained BC2GM015319491 VBN O
in BC2GM015319491 IN O
transformed BC2GM015319491 JJ O
cells BC2GM015319491 NNS O
after BC2GM015319491 IN O
prolonged BC2GM015319491 JJ O
induction BC2GM015319491 NN O
represented BC2GM015319491 VBD O
from BC2GM015319491 IN O
1 BC2GM015319491 CD O
% BC2GM015319491 NN O
to BC2GM015319491 TO O
7 BC2GM015319491 CD O
% BC2GM015319491 NN O
of BC2GM015319491 IN O
total BC2GM015319491 JJ O
cellular BC2GM015319491 JJ O
protein BC2GM015319491 NN O
. BC2GM015319491 . O
. . O O

4 BC2GM029173033 CD O
382 BC2GM029173033 CD O
new BC2GM029173033 JJ O
mothers BC2GM029173033 NNS O
were BC2GM029173033 VBD O
examined BC2GM029173033 VBN O
retrospectively BC2GM029173033 RB O
with BC2GM029173033 IN O
the BC2GM029173033 DT O
enzyme-linked BC2GM029173033 JJ O
immunosorbent BC2GM029173033 NN O
assay BC2GM029173033 NN O
( BC2GM029173033 ( O
ELISA BC2GM029173033 NNP O
) BC2GM029173033 ) O
for BC2GM029173033 IN O
IgG BC2GM029173033 NNP O
activity BC2GM029173033 NN O
to BC2GM029173033 TO O
cytomegalovirus BC2GM029173033 VB O
( BC2GM029173033 ( O
CMV BC2GM029173033 NNP O
) BC2GM029173033 ) O
during BC2GM029173033 IN O
pregnancy BC2GM029173033 NN O
. BC2GM029173033 . O
. . O O

Synthesis BC2GM082670974 NN O
of BC2GM082670974 IN O
2- BC2GM082670974 JJ O
( BC2GM082670974 ( O
2'-thiazolyl BC2GM082670974 JJ O
) BC2GM082670974 ) O
alkanebenzimidazoles BC2GM082670974 NNS O
-- BC2GM082670974 : O
potential BC2GM082670974 JJ O
anthelmintics BC2GM082670974 NNS O
. BC2GM082670974 . O
. . O O

Diffusion BC2GM001873364 NNP O
epidemic BC2GM001873364 JJ O
models BC2GM001873364 NNS O
with BC2GM001873364 IN O
incubation BC2GM001873364 NN O
and BC2GM001873364 CC O
crisscross BC2GM001873364 NN O
dynamics BC2GM001873364 NNS O
. BC2GM001873364 . O
. . O O

To BC2GM015170864 TO O
test BC2GM015170864 VB O
whether BC2GM015170864 IN O
Cd BC2GM015170864 NN O
exposure BC2GM015170864 NN O
would BC2GM015170864 MD O
increase BC2GM015170864 VB O
Ca BC2GM015170864 NNP O
release BC2GM015170864 NN O
from BC2GM015170864 IN O
bone BC2GM015170864 NN O
during BC2GM015170864 IN O
pregnancy BC2GM015170864 NN O
and BC2GM015170864 CC O
lactation BC2GM015170864 NN O
in BC2GM015170864 IN O
relation BC2GM015170864 NN O
to BC2GM015170864 TO O
the BC2GM015170864 DT O
etiological BC2GM015170864 JJ O
mechanism BC2GM015170864 NN O
of BC2GM015170864 IN O
Itai-Itai BC2GM015170864 NNP O
disease BC2GM015170864 NN O
, BC2GM015170864 , O
virgin BC2GM015170864 JJ O
female BC2GM015170864 JJ O
mice BC2GM015170864 NN O
with BC2GM015170864 IN O
45Ca BC2GM015170864 CD O
prelabeled BC2GM015170864 JJ O
skeletons BC2GM015170864 NNS O
( BC2GM015170864 ( O
15 BC2GM015170864 CD O
microCi BC2GM015170864 NN O
/ BC2GM015170864 NNP O
mouse BC2GM015170864 NN O
) BC2GM015170864 ) O
were BC2GM015170864 VBD O
subjected BC2GM015170864 VBN O
to BC2GM015170864 TO O
one BC2GM015170864 CD O
round BC2GM015170864 NN O
of BC2GM015170864 IN O
pregnancy BC2GM015170864 NN O
/ BC2GM015170864 NNP O
lactation BC2GM015170864 NN O
and BC2GM015170864 CC O
were BC2GM015170864 VBD O
exposed BC2GM015170864 VBN O
to BC2GM015170864 TO O
a BC2GM015170864 DT O
Ca-deficient BC2GM015170864 JJ O
diet BC2GM015170864 JJ O
containing BC2GM015170864 VBG O
0 BC2GM015170864 CD O
, BC2GM015170864 , O
5 BC2GM015170864 CD O
, BC2GM015170864 , O
or BC2GM015170864 CC O
25 BC2GM015170864 CD O
ppm BC2GM015170864 JJ O
Cd BC2GM015170864 NNP O
or BC2GM015170864 CC O
25 BC2GM015170864 CD O
ppm BC2GM015170864 NNS O
Pb BC2GM015170864 NNP O
for BC2GM015170864 IN O
32 BC2GM015170864 CD O
days BC2GM015170864 NNS O
, BC2GM015170864 , O
from BC2GM015170864 IN O
conception BC2GM015170864 NN O
until BC2GM015170864 IN O
Lactation BC2GM015170864 NNP O
Day BC2GM015170864 NNP O
14 BC2GM015170864 CD O
. BC2GM015170864 . O
. . O O

Extragonadal BC2GM082967002 NNP O
endodermal BC2GM082967002 JJ O
sinus BC2GM082967002 NN O
tumors BC2GM082967002 NNS O
in BC2GM082967002 IN O
the BC2GM082967002 DT O
head BC2GM082967002 NN O
and BC2GM082967002 CC O
neck BC2GM082967002 NN O
are BC2GM082967002 VBP O
very BC2GM082967002 RB O
rare BC2GM082967002 JJ O
. BC2GM082967002 . O
. . O O

It BC2GM030008462 PRP O
is BC2GM030008462 VBZ O
important BC2GM030008462 JJ O
to BC2GM030008462 TO O
understand BC2GM030008462 VB O
the BC2GM030008462 DT O
etiology BC2GM030008462 NN O
of BC2GM030008462 IN O
HITT BC2GM030008462 NNP O
because BC2GM030008462 IN O
of BC2GM030008462 IN O
its BC2GM030008462 PRP$ O
devastating BC2GM030008462 VBG O
clinical BC2GM030008462 JJ O
consequences BC2GM030008462 NNS O
. BC2GM030008462 . O
. . O O

Though BC2GM077208182 IN O
it BC2GM077208182 PRP O
has BC2GM077208182 VBZ O
been BC2GM077208182 VBN O
established BC2GM077208182 VBN O
that BC2GM077208182 IN O
skinfold BC2GM077208182 JJ O
anthropometry BC2GM077208182 NN O
has BC2GM077208182 VBZ O
severe BC2GM077208182 JJ O
limitations BC2GM077208182 NNS O
as BC2GM077208182 IN O
a BC2GM077208182 DT O
method BC2GM077208182 NN O
of BC2GM077208182 IN O
deriving BC2GM077208182 VBG O
total BC2GM077208182 JJ O
body BC2GM077208182 NN O
fat BC2GM077208182 NN O
( BC2GM077208182 ( O
TBF BC2GM077208182 NNP O
) BC2GM077208182 ) O
, BC2GM077208182 , O
the BC2GM077208182 DT O
possibility BC2GM077208182 NN O
that BC2GM077208182 IN O
the BC2GM077208182 DT O
problem BC2GM077208182 NN O
might BC2GM077208182 MD O
be BC2GM077208182 VB O
related BC2GM077208182 VBN O
more BC2GM077208182 JJR O
to BC2GM077208182 TO O
the BC2GM077208182 DT O
assumptions BC2GM077208182 NNS O
implicit BC2GM077208182 VBP O
in BC2GM077208182 IN O
densitometry BC2GM077208182 NN O
has BC2GM077208182 VBZ O
to BC2GM077208182 TO O
be BC2GM077208182 VB O
addressed BC2GM077208182 VBN O
. BC2GM077208182 . O
. . O O

These BC2GM081669747 DT O
data BC2GM081669747 NNS O
suggest BC2GM081669747 VBP O
that BC2GM081669747 IN O
multiple BC2GM081669747 JJ O
genetic BC2GM081669747 JJ O
recombination BC2GM081669747 NN O
among BC2GM081669747 IN O
bacteriophages BC2GM081669747 NNS O
with BC2GM081669747 IN O
different BC2GM081669747 JJ O
immunities BC2GM081669747 NNS O
took BC2GM081669747 VBD O
place BC2GM081669747 NN O
to BC2GM081669747 TO O
generate BC2GM081669747 VB O
the BC2GM081669747 DT O
prophage BC2GM081669747 NN O
VT1-Sakai BC2GM081669747 NNP O
. BC2GM081669747 . O
. . O O

Plasma BC2GM017854624 NNP O
insulin BC2GM017854624 NN O
responses BC2GM017854624 NNS O
to BC2GM017854624 TO O
glucose BC2GM017854624 VB O
in BC2GM017854624 IN O
femoral BC2GM017854624 JJ O
, BC2GM017854624 , O
hepatic BC2GM017854624 JJ O
, BC2GM017854624 , O
and BC2GM017854624 CC O
pancreatic BC2GM017854624 JJ O
veins BC2GM017854624 NNS O
in BC2GM017854624 IN O
dogs BC2GM017854624 NNS O
. BC2GM017854624 . O
. . O O

However BC2GM064552901 RB O
, BC2GM064552901 , O
H19 BC2GM064552901 NNP O
and BC2GM064552901 CC O
IGF2 BC2GM064552901 NNP O
lie BC2GM064552901 VBP O
within BC2GM064552901 IN O
a BC2GM064552901 DT O
larger BC2GM064552901 JJR O
imprinted BC2GM064552901 JJ O
domain BC2GM064552901 NN O
, BC2GM064552901 , O
and BC2GM064552901 CC O
the BC2GM064552901 DT O
gene BC2GM064552901 NN O
specificity BC2GM064552901 NN O
of BC2GM064552901 IN O
H19 BC2GM064552901 NNP O
epimutation BC2GM064552901 NN O
has BC2GM064552901 VBZ O
been BC2GM064552901 VBN O
a BC2GM064552901 DT O
persistent BC2GM064552901 JJ O
question BC2GM064552901 NN O
. BC2GM064552901 . O
. . O O

It BC2GM011253634 PRP O
has BC2GM011253634 VBZ O
been BC2GM011253634 VBN O
confirmed BC2GM011253634 VBN O
in BC2GM011253634 IN O
animal BC2GM011253634 NN O
experiments BC2GM011253634 NNS O
that BC2GM011253634 IN O
the BC2GM011253634 DT O
number BC2GM011253634 NN O
of BC2GM011253634 IN O
microspheres BC2GM011253634 NNS O
in BC2GM011253634 IN O
a BC2GM011253634 DT O
myocardial BC2GM011253634 JJ O
sample BC2GM011253634 NN O
approximately BC2GM011253634 RB O
follows BC2GM011253634 VBZ O
a BC2GM011253634 DT O
Poisson BC2GM011253634 NNP O
distribution BC2GM011253634 NN O
, BC2GM011253634 , O
under BC2GM011253634 IN O
adequate BC2GM011253634 JJ O
experimental BC2GM011253634 JJ O
conditions BC2GM011253634 NNS O
. BC2GM011253634 . O
. . O O

Diet BC2GM015550026 NNP O
imbalances BC2GM015550026 NNS O
and BC2GM015550026 CC O
aflatoxicosis BC2GM015550026 NN O
. BC2GM015550026 . O
. . O O

Function BC2GM030750070 NN O
was BC2GM030750070 VBD O
retained BC2GM030750070 VBN O
when BC2GM030750070 WRB O
one BC2GM030750070 CD O
copy BC2GM030750070 NN O
of BC2GM030750070 IN O
the BC2GM030750070 DT O
sequence BC2GM030750070 NN O
was BC2GM030750070 VBD O
present BC2GM030750070 JJ O
, BC2GM030750070 , O
suggesting BC2GM030750070 VBG O
that BC2GM030750070 IN O
this BC2GM030750070 DT O
sequence BC2GM030750070 NN O
represents BC2GM030750070 VBZ O
an BC2GM030750070 DT O
essential BC2GM030750070 JJ O
element BC2GM030750070 NN O
. BC2GM030750070 . O
. . O O

The BC2GM063898512 DT O
expression BC2GM063898512 NN O
pattern BC2GM063898512 NN O
of BC2GM063898512 IN O
the BC2GM063898512 DT O
reporter BC2GM063898512 NN O
gene BC2GM063898512 NN O
was BC2GM063898512 VBD O
compared BC2GM063898512 VBN O
to BC2GM063898512 TO O
that BC2GM063898512 DT O
of BC2GM063898512 IN O
the BC2GM063898512 DT O
endogenous BC2GM063898512 JJ O
PDGFbeta BC2GM063898512 NNP O
r BC2GM063898512 NN O
gene BC2GM063898512 NN O
. BC2GM063898512 . O
. . O O

The BC2GM086750845 DT O
predicted BC2GM086750845 JJ O
vav BC2GM086750845 NN O
oncogene BC2GM086750845 NN O
protein BC2GM086750845 NN O
sequence BC2GM086750845 NN O
exhibits BC2GM086750845 VBZ O
several BC2GM086750845 JJ O
motifs BC2GM086750845 NNS O
reminiscent BC2GM086750845 NN O
of BC2GM086750845 IN O
transcriptional BC2GM086750845 JJ O
factors BC2GM086750845 NNS O
. BC2GM086750845 . O
. . O O

Constructs BC2GM057244424 NNS O
containing BC2GM057244424 VBG O
fragments BC2GM057244424 NNS O
of BC2GM057244424 IN O
the BC2GM057244424 DT O
upstream BC2GM057244424 JJ O
region BC2GM057244424 NN O
of BC2GM057244424 IN O
the BC2GM057244424 DT O
cytotactin BC2GM057244424 NN O
gene BC2GM057244424 NN O
fused BC2GM057244424 VBD O
to BC2GM057244424 TO O
a BC2GM057244424 DT O
promoterless BC2GM057244424 JJ O
gene BC2GM057244424 NN O
for BC2GM057244424 IN O
chloramphenicol BC2GM057244424 JJ O
acetyltransferase BC2GM057244424 NN O
were BC2GM057244424 VBD O
transiently BC2GM057244424 RB O
transfected BC2GM057244424 VBN O
into BC2GM057244424 IN O
chicken BC2GM057244424 JJ O
embryo BC2GM057244424 NN O
fibroblasts BC2GM057244424 NNS O
to BC2GM057244424 TO O
define BC2GM057244424 VB O
functional BC2GM057244424 JJ O
promoter BC2GM057244424 NN O
sequences BC2GM057244424 NNS O
. BC2GM057244424 . O
. . O O

132 BC2GM074517332 CD O
varix BC2GM074517332 JJ O
ligations BC2GM074517332 NNS O
were BC2GM074517332 VBD O
performed BC2GM074517332 VBN O
during BC2GM074517332 IN O
44 BC2GM074517332 CD O
separate BC2GM074517332 JJ O
EVL BC2GM074517332 NNP O
sessions BC2GM074517332 NNS O
. BC2GM074517332 . O
. . O O

The BC2GM034608401 DT O
leukotriene BC2GM034608401 NN O
receptor BC2GM034608401 NN O
antagonist BC2GM034608401 NN O
zafirlukast BC2GM034608401 NN O
inhibits BC2GM034608401 NNS O
sulfur BC2GM034608401 VBP O
dioxide-induced BC2GM034608401 JJ O
bronchoconstriction BC2GM034608401 NN O
in BC2GM034608401 IN O
patients BC2GM034608401 NNS O
with BC2GM034608401 IN O
asthma BC2GM034608401 NN O
. BC2GM034608401 . O
. . O O

We BC2GM043376689 PRP O
identified BC2GM043376689 VBD O
clones BC2GM043376689 NNS O
of BC2GM043376689 IN O
Chlamydomonas BC2GM043376689 NNP O
genomic BC2GM043376689 JJ O
DNA BC2GM043376689 NN O
that BC2GM043376689 WDT O
rescued BC2GM043376689 VBD O
the BC2GM043376689 DT O
Ca BC2GM043376689 NNP O
( BC2GM043376689 ( O
2+ BC2GM043376689 CD O
) BC2GM043376689 ) O
-dependent BC2GM043376689 NN O
axonemal BC2GM043376689 JJ O
microtubule BC2GM043376689 NN O
severing BC2GM043376689 VBG O
defect BC2GM043376689 NN O
of BC2GM043376689 IN O
fa1 BC2GM043376689 JJ O
mutants BC2GM043376689 NNS O
. BC2GM043376689 . O
. . O O

The BC2GM035223840 DT O
use BC2GM035223840 NN O
of BC2GM035223840 IN O
the BC2GM035223840 DT O
two BC2GM035223840 CD O
pharmacokinetic BC2GM035223840 JJ O
parameters BC2GM035223840 NNS O
, BC2GM035223840 , O
t1 BC2GM035223840 EX O
/ BC2GM035223840 $ O
2 BC2GM035223840 CD O
and BC2GM035223840 CC O
Cltp BC2GM035223840 NNP O
, BC2GM035223840 , O
as BC2GM035223840 IN O
indices BC2GM035223840 NNS O
of BC2GM035223840 IN O
drug BC2GM035223840 NN O
elimination BC2GM035223840 NN O
ability BC2GM035223840 NN O
are BC2GM035223840 VBP O
discussed BC2GM035223840 VBN O
. BC2GM035223840 . O
. . O O

METHODS BC2GM039494188 NN O
: BC2GM039494188 : O
Autocapture BC2GM039494188 NN O
devices BC2GM039494188 NNS O
( BC2GM039494188 ( O
Pacesetter BC2GM039494188 NNP O
Microny BC2GM039494188 NNP O
SR+ BC2GM039494188 NNP O
/ BC2GM039494188 NNP O
- BC2GM039494188 : O
and BC2GM039494188 CC O
Regency BC2GM039494188 NNP O
SR+ BC2GM039494188 NNP O
/ BC2GM039494188 NNP O
- BC2GM039494188 : O
; BC2GM039494188 : O
Pacesetter BC2GM039494188 NNP O
, BC2GM039494188 , O
Solna BC2GM039494188 NNP O
, BC2GM039494188 , O
Sweden BC2GM039494188 NNP O
) BC2GM039494188 ) O
and BC2GM039494188 CC O
steroid-eluting BC2GM039494188 JJ O
epicardial BC2GM039494188 JJ O
pacing BC2GM039494188 NN O
leads BC2GM039494188 NNS O
( BC2GM039494188 ( O
Medtronic BC2GM039494188 JJ O
CapSure BC2GM039494188 NNP O
Epi BC2GM039494188 NNP O
10366 BC2GM039494188 CD O
; BC2GM039494188 : O
Medtronic BC2GM039494188 NNP O
, BC2GM039494188 , O
Inc BC2GM039494188 NNP O
, BC2GM039494188 , O
Minneapolis BC2GM039494188 NNP O
, BC2GM039494188 , O
MN BC2GM039494188 NNP O
) BC2GM039494188 ) O
were BC2GM039494188 VBD O
implanted BC2GM039494188 VBN O
in BC2GM039494188 IN O
14 BC2GM039494188 CD O
children BC2GM039494188 NNS O
. BC2GM039494188 . O
. . O O

The BC2GM072699759 DT O
Tat BC2GM072699759 NNP O
protein BC2GM072699759 NN O
coded BC2GM072699759 VBN O
by BC2GM072699759 IN O
human BC2GM072699759 JJ O
immunodeficiency BC2GM072699759 NN O
virus BC2GM072699759 NN O
( BC2GM072699759 ( O
HIV BC2GM072699759 NNP O
) BC2GM072699759 ) O
is BC2GM072699759 VBZ O
a BC2GM072699759 DT O
strong BC2GM072699759 JJ O
activator BC2GM072699759 NN O
of BC2GM072699759 IN O
viral BC2GM072699759 JJ O
gene BC2GM072699759 NN O
expression BC2GM072699759 NN O
from BC2GM072699759 IN O
the BC2GM072699759 DT O
long BC2GM072699759 JJ O
terminal BC2GM072699759 JJ O
repeat BC2GM072699759 NN O
( BC2GM072699759 ( O
LTR BC2GM072699759 NNP O
) BC2GM072699759 ) O
. BC2GM072699759 . O
. . O O

The BC2GM051960304 DT O
1-year BC2GM051960304 JJ O
and BC2GM051960304 CC O
2-year BC2GM051960304 JJ O
survival BC2GM051960304 NN O
rates BC2GM051960304 NNS O
for BC2GM051960304 IN O
the BC2GM051960304 DT O
patients BC2GM051960304 NNS O
with BC2GM051960304 IN O
N0-3 BC2GM051960304 NNP O
significantly BC2GM051960304 RB O
exceeded BC2GM051960304 VBD O
those BC2GM051960304 DT O
of BC2GM051960304 IN O
N4 BC2GM051960304 NNP O
patients BC2GM051960304 NNS O
. BC2GM051960304 . O
. . O O

HGF BC2GM071845732 NNP O
treatment BC2GM071845732 NN O
increased BC2GM071845732 VBD O
cyclin BC2GM071845732 NN O
A BC2GM071845732 NNP O
, BC2GM071845732 , O
cyclin BC2GM071845732 NN O
G1 BC2GM071845732 NNP O
and BC2GM071845732 CC O
nuclear BC2GM071845732 JJ O
transcriptional BC2GM071845732 JJ O
factor BC2GM071845732 NN O
( BC2GM071845732 ( O
NFkappaB BC2GM071845732 NNP O
) BC2GM071845732 ) O
protein BC2GM071845732 NN O
expression BC2GM071845732 NN O
. BC2GM071845732 . O
. . O O

Stress BC2GM057075557 NNP O
thallium-201 BC2GM057075557 JJ O
myocardial BC2GM057075557 NN O
imaging BC2GM057075557 NN O
was BC2GM057075557 VBD O
used BC2GM057075557 VBN O
in BC2GM057075557 IN O
two BC2GM057075557 CD O
angina-free BC2GM057075557 JJ O
patients BC2GM057075557 NNS O
with BC2GM057075557 IN O
severe BC2GM057075557 JJ O
congestive BC2GM057075557 JJ O
heart BC2GM057075557 NN O
failure BC2GM057075557 NN O
to BC2GM057075557 TO O
identify BC2GM057075557 VB O
clinically BC2GM057075557 RB O
silent BC2GM057075557 JJ O
areas BC2GM057075557 NNS O
of BC2GM057075557 IN O
ischemic BC2GM057075557 JJ O
myocardium BC2GM057075557 NN O
and BC2GM057075557 CC O
to BC2GM057075557 TO O
distinguish BC2GM057075557 VB O
between BC2GM057075557 IN O
scar BC2GM057075557 NN O
and BC2GM057075557 CC O
reversibly BC2GM057075557 RB O
ischemic BC2GM057075557 JJ O
myocardium BC2GM057075557 NN O
as BC2GM057075557 IN O
a BC2GM057075557 DT O
cause BC2GM057075557 NN O
for BC2GM057075557 IN O
akinesia BC2GM057075557 NN O
of BC2GM057075557 IN O
left BC2GM057075557 JJ O
ventricular BC2GM057075557 JJ O
wall BC2GM057075557 NN O
segments BC2GM057075557 NNS O
. BC2GM057075557 . O
. . O O

Defects BC2GM080881152 NNS O
in BC2GM080881152 IN O
RT6 BC2GM080881152 NNP O
expression BC2GM080881152 NN O
coincide BC2GM080881152 NN O
with BC2GM080881152 IN O
increased BC2GM080881152 JJ O
susceptibility BC2GM080881152 NN O
in BC2GM080881152 IN O
animal BC2GM080881152 JJ O
models BC2GM080881152 NNS O
for BC2GM080881152 IN O
insulin-dependent BC2GM080881152 JJ O
diabetes BC2GM080881152 NNS O
mellitus BC2GM080881152 NNS O
and BC2GM080881152 CC O
other BC2GM080881152 JJ O
autoimmune BC2GM080881152 NN O
diseases BC2GM080881152 NNS O
. BC2GM080881152 . O
. . O O

Nickel BC2GM062555785 NNP O
release BC2GM062555785 NN O
from BC2GM062555785 IN O
tools BC2GM062555785 NNS O
on BC2GM062555785 IN O
the BC2GM062555785 DT O
Swedish BC2GM062555785 JJ O
market BC2GM062555785 NN O
. BC2GM062555785 . O
. . O O

Co-operativity BC2GM032693967 NN O
of BC2GM032693967 IN O
functional BC2GM032693967 JJ O
domains BC2GM032693967 NNS O
in BC2GM032693967 IN O
the BC2GM032693967 DT O
muscle-specific BC2GM032693967 JJ O
transcription BC2GM032693967 NN O
factor BC2GM032693967 NN O
Myf-5 BC2GM032693967 NNP O
. BC2GM032693967 . O
. . O O

Consequently BC2GM031882943 RB O
, BC2GM031882943 , O
during BC2GM031882943 IN O
the BC2GM031882943 DT O
evolution BC2GM031882943 NN O
of BC2GM031882943 IN O
mammals BC2GM031882943 NNS O
, BC2GM031882943 , O
it BC2GM031882943 PRP O
is BC2GM031882943 VBZ O
the BC2GM031882943 DT O
CKbeta4GT-I BC2GM031882943 JJ O
gene BC2GM031882943 NN O
lineage BC2GM031882943 NN O
that BC2GM031882943 WDT O
has BC2GM031882943 VBZ O
been BC2GM031882943 VBN O
recruited BC2GM031882943 VBN O
for BC2GM031882943 IN O
the BC2GM031882943 DT O
biosynthesis BC2GM031882943 NN O
of BC2GM031882943 IN O
lactose BC2GM031882943 NN O
. BC2GM031882943 . O
. . O O

In BC2GM062242948 IN O
this BC2GM062242948 DT O
study BC2GM062242948 NN O
we BC2GM062242948 PRP O
cloned BC2GM062242948 VBD O
the BC2GM062242948 DT O
cDNA BC2GM062242948 NN O
of BC2GM062242948 IN O
AD1 BC2GM062242948 NNP O
Ag BC2GM062242948 NNP O
from BC2GM062242948 IN O
a BC2GM062242948 DT O
rat BC2GM062242948 NN O
basophilic BC2GM062242948 JJ O
leukemia BC2GM062242948 NN O
2H3 BC2GM062242948 CD O
cDNA BC2GM062242948 NN O
library BC2GM062242948 NN O
. BC2GM062242948 . O
. . O O

Galactorrhoea BC2GM055311228 NNP O
is BC2GM055311228 VBZ O
a BC2GM055311228 DT O
rare BC2GM055311228 JJ O
presentation BC2GM055311228 NN O
of BC2GM055311228 IN O
an BC2GM055311228 DT O
empty BC2GM055311228 JJ O
sella BC2GM055311228 NN O
syndrome BC2GM055311228 NN O
. BC2GM055311228 . O
. . O O

Other BC2GM038859248 JJ O
similar BC2GM038859248 JJ O
patients BC2GM038859248 NNS O
must BC2GM038859248 MD O
be BC2GM038859248 VB O
found BC2GM038859248 VBN O
before BC2GM038859248 IN O
it BC2GM038859248 PRP O
is BC2GM038859248 VBZ O
established BC2GM038859248 VBN O
that BC2GM038859248 IN O
the BC2GM038859248 DT O
colloid BC2GM038859248 JJ O
cyst BC2GM038859248 NN O
is BC2GM038859248 VBZ O
part BC2GM038859248 NN O
of BC2GM038859248 IN O
the BC2GM038859248 DT O
nevoid BC2GM038859248 JJ O
basal BC2GM038859248 NN O
cell BC2GM038859248 NN O
carcinoma BC2GM038859248 VBZ O
syndrome BC2GM038859248 NN O
. BC2GM038859248 . O
. . O O

We BC2GM081878560 PRP O
have BC2GM081878560 VBP O
previously BC2GM081878560 RB O
described BC2GM081878560 VBN O
the BC2GM081878560 DT O
partial BC2GM081878560 JJ O
purification BC2GM081878560 NN O
of BC2GM081878560 IN O
Ap4A BC2GM081878560 NNP O
hydrolase BC2GM081878560 NN O
from BC2GM081878560 IN O
S. BC2GM081878560 NNP O
pombe BC2GM081878560 NN O
[ BC2GM081878560 NNP O
Robinson BC2GM081878560 NNP O
, BC2GM081878560 , O
de BC2GM081878560 FW O
la BC2GM081878560 FW O
Pena BC2GM081878560 NNP O
and BC2GM081878560 CC O
Barnes BC2GM081878560 NNP O
( BC2GM081878560 ( O
1993 BC2GM081878560 CD O
) BC2GM081878560 ) O
Biochim BC2GM081878560 NNP O
. BC2GM081878560 . O
. . O O

The BC2GM013148295 DT O
recombinant BC2GM013148295 NN O
containing BC2GM013148295 VBG O
the BC2GM013148295 DT O
full-length BC2GM013148295 JJ O
polyhedrin BC2GM013148295 NN O
leader BC2GM013148295 NN O
sequence BC2GM013148295 NN O
gave BC2GM013148295 VBD O
levels BC2GM013148295 NNS O
of BC2GM013148295 IN O
N BC2GM013148295 NNP O
mRNA BC2GM013148295 RBS O
comparable BC2GM013148295 JJ O
to BC2GM013148295 TO O
those BC2GM013148295 DT O
of BC2GM013148295 IN O
AcNPV BC2GM013148295 NNP O
polyhedrin BC2GM013148295 NN O
mRNA BC2GM013148295 NN O
. BC2GM013148295 . O
. . O O

Conservation BC2GM081733719 NN O
of BC2GM081733719 IN O
this BC2GM081733719 DT O
zinc BC2GM081733719 NN O
finger BC2GM081733719 NN O
motif BC2GM081733719 NN O
from BC2GM081733719 IN O
yeast BC2GM081733719 NN O
to BC2GM081733719 TO O
mouse BC2GM081733719 VB O
and BC2GM081733719 CC O
human BC2GM081733719 JJ O
implies BC2GM081733719 NNS O
functional BC2GM081733719 JJ O
importance BC2GM081733719 NN O
. BC2GM081733719 . O
. . O O

We BC2GM097970761 PRP O
previously BC2GM097970761 RB O
described BC2GM097970761 VBD O
the BC2GM097970761 DT O
upregulation BC2GM097970761 NN O
of BC2GM097970761 IN O
the BC2GM097970761 DT O
MT2 BC2GM097970761 NNP O
antigen BC2GM097970761 NN O
during BC2GM097970761 IN O
urodele BC2GM097970761 JJ O
limb BC2GM097970761 JJ O
regeneration BC2GM097970761 NN O
and BC2GM097970761 CC O
characterized BC2GM097970761 VBD O
the BC2GM097970761 DT O
MT2 BC2GM097970761 NNP O
antigen BC2GM097970761 NN O
as BC2GM097970761 IN O
a BC2GM097970761 DT O
310- BC2GM097970761 JJ O
to BC2GM097970761 TO O
325-kDa BC2GM097970761 JJ O
chondroitin-sulfated BC2GM097970761 JJ O
glycoprotein BC2GM097970761 NN O
with BC2GM097970761 IN O
a BC2GM097970761 DT O
core BC2GM097970761 NN O
protein BC2GM097970761 NN O
of BC2GM097970761 IN O
285-300 BC2GM097970761 JJ O
kDa BC2GM097970761 NN O
. BC2GM097970761 . O
. . O O

Comparison BC2GM095725237 NNP O
of BC2GM095725237 IN O
bioreactive BC2GM095725237 JJ O
and BC2GM095725237 CC O
immunoreactive BC2GM095725237 JJ O
gastrin BC2GM095725237 NN O
. BC2GM095725237 . O
. . O O

We BC2GM033411061 PRP O
conclude BC2GM033411061 VBP O
that BC2GM033411061 IN O
GRF1 BC2GM033411061 NNP O
and BC2GM033411061 CC O
GRF2 BC2GM033411061 NNP O
can BC2GM033411061 MD O
form BC2GM033411061 VB O
homo- BC2GM033411061 JJ O
and BC2GM033411061 CC O
hetero-oligomers BC2GM033411061 NNS O
via BC2GM033411061 IN O
their BC2GM033411061 PRP$ O
DH BC2GM033411061 NNP O
domains BC2GM033411061 NNS O
, BC2GM033411061 , O
that BC2GM033411061 IN O
mutational BC2GM033411061 JJ O
inactivation BC2GM033411061 NN O
of BC2GM033411061 IN O
oligomer BC2GM033411061 JJ O
formation BC2GM033411061 NN O
by BC2GM033411061 IN O
GRF1 BC2GM033411061 NNP O
is BC2GM033411061 VBZ O
associated BC2GM033411061 VBN O
with BC2GM033411061 IN O
impaired BC2GM033411061 JJ O
biological BC2GM033411061 JJ O
and BC2GM033411061 CC O
signaling BC2GM033411061 JJ O
activities BC2GM033411061 NNS O
, BC2GM033411061 , O
and BC2GM033411061 CC O
that BC2GM033411061 IN O
in BC2GM033411061 IN O
293T BC2GM033411061 CD O
cells BC2GM033411061 NNS O
GRF1 BC2GM033411061 NNP O
mediates BC2GM033411061 NNS O
at BC2GM033411061 IN O
least BC2GM033411061 JJS O
two BC2GM033411061 CD O
pathways BC2GM033411061 NNS O
for BC2GM033411061 IN O
Raf BC2GM033411061 NNP O
activation BC2GM033411061 NN O
: BC2GM033411061 : O
one BC2GM033411061 CD O
a BC2GM033411061 DT O
constitutive BC2GM033411061 JJ O
signal BC2GM033411061 NN O
that BC2GM033411061 WDT O
is BC2GM033411061 VBZ O
mainly BC2GM033411061 RB O
Ras-dependent BC2GM033411061 JJ O
, BC2GM033411061 , O
and BC2GM033411061 CC O
one BC2GM033411061 CD O
an BC2GM033411061 DT O
ionomycin-induced BC2GM033411061 JJ O
signal BC2GM033411061 NN O
that BC2GM033411061 WDT O
cooperates BC2GM033411061 VBZ O
with BC2GM033411061 IN O
the BC2GM033411061 DT O
constitutive BC2GM033411061 JJ O
signal BC2GM033411061 NN O
without BC2GM033411061 IN O
further BC2GM033411061 JJ O
augmenting BC2GM033411061 VBG O
the BC2GM033411061 DT O
level BC2GM033411061 NN O
of BC2GM033411061 IN O
GTP-Ras BC2GM033411061 NNP O
. BC2GM033411061 . O
. . O O

The BC2GM075752604 DT O
results BC2GM075752604 NNS O
can BC2GM075752604 MD O
be BC2GM075752604 VB O
summarized BC2GM075752604 VBN O
as BC2GM075752604 IN O
follows BC2GM075752604 VBZ O
. BC2GM075752604 . O
. . O O

Northern BC2GM017211898 NNP O
blot BC2GM017211898 NN O
analysis BC2GM017211898 NN O
of BC2GM017211898 IN O
liver BC2GM017211898 NN O
, BC2GM017211898 , O
muscle BC2GM017211898 NN O
, BC2GM017211898 , O
fat BC2GM017211898 NN O
, BC2GM017211898 , O
and BC2GM017211898 CC O
pituitary BC2GM017211898 JJ O
RNA BC2GM017211898 NNP O
from BC2GM017211898 IN O
normal BC2GM017211898 JJ O
( BC2GM017211898 ( O
DwDw BC2GM017211898 NNP O
) BC2GM017211898 ) O
chickens BC2GM017211898 VBZ O
shows BC2GM017211898 VBZ O
a BC2GM017211898 DT O
major BC2GM017211898 JJ O
transcript BC2GM017211898 NN O
of BC2GM017211898 IN O
4.3 BC2GM017211898 CD O
kilobases BC2GM017211898 NNS O
( BC2GM017211898 ( O
kb BC2GM017211898 NN O
) BC2GM017211898 ) O
and BC2GM017211898 CC O
three BC2GM017211898 CD O
minor BC2GM017211898 JJ O
transcripts BC2GM017211898 NNS O
( BC2GM017211898 ( O
0.8 BC2GM017211898 CD O
, BC2GM017211898 , O
1.7 BC2GM017211898 CD O
, BC2GM017211898 , O
and BC2GM017211898 CC O
3.2 BC2GM017211898 CD O
kb BC2GM017211898 NN O
) BC2GM017211898 ) O
, BC2GM017211898 , O
which BC2GM017211898 WDT O
correspond BC2GM017211898 NN O
to BC2GM017211898 TO O
the BC2GM017211898 DT O
cGHR BC2GM017211898 NN O
. BC2GM017211898 . O
. . O O

These BC2GM086254445 DT O
include BC2GM086254445 VBP O
the BC2GM086254445 DT O
genes BC2GM086254445 NNS O
, BC2GM086254445 , O
undefined BC2GM086254445 VBD O
1 BC2GM086254445 CD O
( BC2GM086254445 ( O
UD1 BC2GM086254445 NNP O
) BC2GM086254445 ) O
, BC2GM086254445 , O
UD2 BC2GM086254445 NNP O
, BC2GM086254445 , O
and BC2GM086254445 CC O
UD3 BC2GM086254445 NNP O
, BC2GM086254445 , O
each BC2GM086254445 DT O
coding BC2GM086254445 VBG O
for BC2GM086254445 IN O
proteins BC2GM086254445 NNS O
of BC2GM086254445 IN O
unknown BC2GM086254445 JJ O
function BC2GM086254445 NN O
, BC2GM086254445 , O
the BC2GM086254445 DT O
ken BC2GM086254445 JJ O
gene BC2GM086254445 NN O
encoding BC2GM086254445 VBG O
a BC2GM086254445 DT O
new BC2GM086254445 JJ O
Kruppel-like BC2GM086254445 NNP O
putative BC2GM086254445 JJ O
transcription BC2GM086254445 NN O
factor BC2GM086254445 NN O
, BC2GM086254445 , O
the BC2GM086254445 DT O
fly BC2GM086254445 NN O
homologues BC2GM086254445 NNS O
of BC2GM086254445 IN O
the BC2GM086254445 DT O
mammalian BC2GM086254445 JJ O
mitochondrial BC2GM086254445 JJ O
trifunctional BC2GM086254445 JJ O
enzyme BC2GM086254445 NN O
( BC2GM086254445 ( O
thiolase BC2GM086254445 NN O
) BC2GM086254445 ) O
, BC2GM086254445 , O
and BC2GM086254445 CC O
the BC2GM086254445 DT O
TAR BC2GM086254445 NNP O
DNA-binding BC2GM086254445 NNP O
protein-43 BC2GM086254445 NN O
( BC2GM086254445 ( O
TBPH BC2GM086254445 NNP O
) BC2GM086254445 ) O
, BC2GM086254445 , O
the BC2GM086254445 DT O
first BC2GM086254445 JJ O
nonvertebrate BC2GM086254445 JJ O
member BC2GM086254445 NN O
of BC2GM086254445 IN O
the BC2GM086254445 DT O
transmembrane BC2GM086254445 NN O
4 BC2GM086254445 CD O
superfamily BC2GM086254445 RB O
( BC2GM086254445 ( O
TM4SF BC2GM086254445 NNP O
) BC2GM086254445 ) O
gene BC2GM086254445 NN O
, BC2GM086254445 , O
a BC2GM086254445 DT O
new BC2GM086254445 JJ O
homeodomain BC2GM086254445 NN O
gene BC2GM086254445 NN O
, BC2GM086254445 , O
and BC2GM086254445 CC O
a BC2GM086254445 DT O
gene BC2GM086254445 NN O
coding BC2GM086254445 VBG O
for BC2GM086254445 IN O
a BC2GM086254445 DT O
putative BC2GM086254445 JJ O
nuclear BC2GM086254445 JJ O
binding BC2GM086254445 NN O
protein BC2GM086254445 NN O
( BC2GM086254445 ( O
PNBP BC2GM086254445 NNP O
) BC2GM086254445 ) O
that BC2GM086254445 WDT O
is BC2GM086254445 VBZ O
homologous BC2GM086254445 JJ O
to BC2GM086254445 TO O
maleless BC2GM086254445 VB O
, BC2GM086254445 , O
and BC2GM086254445 CC O
a BC2GM086254445 DT O
Copia-like BC2GM086254445 JJ O
element BC2GM086254445 NN O
. BC2GM086254445 . O
. . O O

Finally BC2GM071926370 RB O
, BC2GM071926370 , O
there BC2GM071926370 EX O
is BC2GM071926370 VBZ O
now BC2GM071926370 RB O
appropriate BC2GM071926370 JJ O
recognition BC2GM071926370 NN O
of BC2GM071926370 IN O
the BC2GM071926370 DT O
pivotal BC2GM071926370 JJ O
role BC2GM071926370 NN O
of BC2GM071926370 IN O
BP BC2GM071926370 NNP O
reduction BC2GM071926370 NN O
in BC2GM071926370 IN O
forestalling BC2GM071926370 VBG O
pressure-related BC2GM071926370 JJ O
cardiovascular BC2GM071926370 JJ O
complications BC2GM071926370 NNS O
, BC2GM071926370 , O
even BC2GM071926370 RB O
among BC2GM071926370 IN O
high-risk BC2GM071926370 JJ O
persons BC2GM071926370 NNS O
with BC2GM071926370 IN O
diabetes BC2GM071926370 NNS O
mellitus BC2GM071926370 NNS O
and BC2GM071926370 CC O
renal BC2GM071926370 JJ O
insufficiency BC2GM071926370 NN O
. BC2GM071926370 . O
. . O O

Virol BC2GM013081581 NNP O
. BC2GM013081581 . O
. . O O

Activation BC2GM023386484 NN O
of BC2GM023386484 IN O
HIV-1 BC2GM023386484 NNP O
requires BC2GM023386484 VBZ O
the BC2GM023386484 DT O
binding BC2GM023386484 NN O
of BC2GM023386484 IN O
host BC2GM023386484 NN O
cell BC2GM023386484 NN O
transcription BC2GM023386484 NN O
factors BC2GM023386484 NNS O
to BC2GM023386484 TO O
cis BC2GM023386484 VB O
elements BC2GM023386484 NNS O
in BC2GM023386484 IN O
the BC2GM023386484 DT O
proviral BC2GM023386484 JJ O
long BC2GM023386484 JJ O
terminal BC2GM023386484 JJ O
repeat BC2GM023386484 NN O
( BC2GM023386484 ( O
LTR BC2GM023386484 NNP O
) BC2GM023386484 ) O
. BC2GM023386484 . O
. . O O

Checking BC2GM018712064 VBG O
for BC2GM018712064 IN O
patient BC2GM018712064 JJ O
compliance BC2GM018712064 NN O
, BC2GM018712064 , O
samples BC2GM018712064 NNS O
( BC2GM018712064 ( O
n BC2GM018712064 JJ O
= BC2GM018712064 NNP O
10 BC2GM018712064 CD O
) BC2GM018712064 ) O
with BC2GM018712064 IN O
a BC2GM018712064 DT O
FK BC2GM018712064 NNP O
I BC2GM018712064 PRP O
concentration BC2GM018712064 NN O
of BC2GM018712064 IN O
0 BC2GM018712064 CD O
ng BC2GM018712064 JJ O
/ BC2GM018712064 NNS O
mL BC2GM018712064 NNS O
were BC2GM018712064 VBD O
re-analyzed BC2GM018712064 JJ O
. BC2GM018712064 . O
. . O O

Regardless BC2GM008520158 NNP O
of BC2GM008520158 IN O
muscle BC2GM008520158 NN O
tensioning BC2GM008520158 NN O
or BC2GM008520158 CC O
marination BC2GM008520158 NN O
treatments BC2GM008520158 NNS O
, BC2GM008520158 , O
aging BC2GM008520158 VBG O
of BC2GM008520158 IN O
the BC2GM008520158 DT O
carcass BC2GM008520158 NN O
for BC2GM008520158 IN O
24 BC2GM008520158 CD O
h BC2GM008520158 NN O
( BC2GM008520158 ( O
T1 BC2GM008520158 NNP O
, BC2GM008520158 , O
T2 BC2GM008520158 NNP O
, BC2GM008520158 , O
and BC2GM008520158 CC O
T3 BC2GM008520158 NNP O
) BC2GM008520158 ) O
produced BC2GM008520158 VBD O
meats BC2GM008520158 NNS O
with BC2GM008520158 IN O
lower BC2GM008520158 JJR O
shear BC2GM008520158 NN O
values BC2GM008520158 NNS O
than BC2GM008520158 IN O
those BC2GM008520158 DT O
from BC2GM008520158 IN O
hot-boned BC2GM008520158 JJ O
carcasses BC2GM008520158 NNS O
( BC2GM008520158 ( O
T4 BC2GM008520158 NNP O
and BC2GM008520158 CC O
T5 BC2GM008520158 NNP O
) BC2GM008520158 ) O
. BC2GM008520158 . O
. . O O

Thus BC2GM058484539 RB O
the BC2GM058484539 DT O
Hi-RARE BC2GM058484539 JJ O
represents BC2GM058484539 VBZ O
a BC2GM058484539 DT O
new BC2GM058484539 JJ O
type BC2GM058484539 NN O
of BC2GM058484539 IN O
RA BC2GM058484539 NNP O
response BC2GM058484539 NN O
element BC2GM058484539 NN O
with BC2GM058484539 IN O
a BC2GM058484539 DT O
role BC2GM058484539 NN O
in BC2GM058484539 IN O
the BC2GM058484539 DT O
modulation BC2GM058484539 NN O
of BC2GM058484539 IN O
the BC2GM058484539 DT O
expression BC2GM058484539 NN O
of BC2GM058484539 IN O
MHC BC2GM058484539 NNP O
class BC2GM058484539 NN O
1 BC2GM058484539 CD O
family BC2GM058484539 NN O
genes BC2GM058484539 NNS O
. BC2GM058484539 . O
. . O O

Measuring BC2GM013705035 VBG O
the BC2GM013705035 DT O
dim BC2GM013705035 NN O
light BC2GM013705035 JJ O
melatonin BC2GM013705035 NN O
onset BC2GM013705035 NN O
( BC2GM013705035 ( O
DLMO BC2GM013705035 NNP O
) BC2GM013705035 ) O
is BC2GM013705035 VBZ O
a BC2GM013705035 DT O
useful BC2GM013705035 JJ O
and BC2GM013705035 CC O
practical BC2GM013705035 JJ O
way BC2GM013705035 NN O
to BC2GM013705035 TO O
assess BC2GM013705035 VB O
circadian BC2GM013705035 JJ O
phase BC2GM013705035 NN O
position BC2GM013705035 NN O
in BC2GM013705035 IN O
humans BC2GM013705035 NNS O
. BC2GM013705035 . O
. . O O

Reduced BC2GM022449738 VBN O
risk BC2GM022449738 NN O
of BC2GM022449738 IN O
upper BC2GM022449738 JJ O
gastrointestinal BC2GM022449738 JJ O
ulcer BC2GM022449738 NN O
complications BC2GM022449738 NNS O
with BC2GM022449738 IN O
celecoxib BC2GM022449738 NN O
, BC2GM022449738 , O
a BC2GM022449738 DT O
novel BC2GM022449738 JJ O
COX-2 BC2GM022449738 NNP O
inhibitor BC2GM022449738 NN O
. BC2GM022449738 . O
. . O O

Due BC2GM009503758 JJ O
to BC2GM009503758 TO O
significant BC2GM009503758 JJ O
homology BC2GM009503758 NN O
to BC2GM009503758 TO O
the BC2GM009503758 DT O
C-terminus BC2GM009503758 NNP O
of BC2GM009503758 IN O
the BC2GM009503758 DT O
Mutator BC2GM009503758 NNP O
transposase BC2GM009503758 NN O
this BC2GM009503758 DT O
alternative BC2GM009503758 JJ O
gene BC2GM009503758 NN O
product BC2GM009503758 NN O
was BC2GM009503758 VBD O
named BC2GM009503758 VBN O
Trap BC2GM009503758 NNP O
( BC2GM009503758 ( O
transposon-associated BC2GM009503758 JJ O
protein BC2GM009503758 NN O
) BC2GM009503758 ) O
. BC2GM009503758 . O
. . O O

To BC2GM083666450 TO O
investigate BC2GM083666450 VB O
whether BC2GM083666450 IN O
the BC2GM083666450 DT O
two BC2GM083666450 CD O
RPG-boxes BC2GM083666450 JJ O
mediate BC2GM083666450 NN O
transcription BC2GM083666450 NN O
activation BC2GM083666450 NN O
of BC2GM083666450 IN O
both BC2GM083666450 CC O
the BC2GM083666450 DT O
L46 BC2GM083666450 NNP O
and BC2GM083666450 CC O
S24 BC2GM083666450 NNP O
gene BC2GM083666450 NN O
, BC2GM083666450 , O
two BC2GM083666450 CD O
experimental BC2GM083666450 JJ O
strategies BC2GM083666450 NNS O
were BC2GM083666450 VBD O
followed BC2GM083666450 VBN O
: BC2GM083666450 : O
cloning BC2GM083666450 NN O
of BC2GM083666450 IN O
the BC2GM083666450 DT O
respective BC2GM083666450 JJ O
genes BC2GM083666450 NNS O
on BC2GM083666450 IN O
multicopy BC2GM083666450 NN O
vectors BC2GM083666450 NNS O
and BC2GM083666450 CC O
construction BC2GM083666450 NN O
of BC2GM083666450 IN O
fusion BC2GM083666450 NN O
genes BC2GM083666450 NNS O
. BC2GM083666450 . O
. . O O

The BC2GM094780513 DT O
stress BC2GM094780513 NN O
/ BC2GM094780513 VBD O
BHV-1 BC2GM094780513 NNP O
model BC2GM094780513 NN O
resulted BC2GM094780513 VBD O
in BC2GM094780513 IN O
a BC2GM094780513 DT O
mild BC2GM094780513 JJ O
respiratory BC2GM094780513 JJ O
infection BC2GM094780513 NN O
in BC2GM094780513 IN O
all BC2GM094780513 DT O
calves BC2GM094780513 NNS O
with BC2GM094780513 IN O
no BC2GM094780513 DT O
difference BC2GM094780513 NN O
observed BC2GM094780513 VBD O
between BC2GM094780513 IN O
treatment BC2GM094780513 NN O
groups BC2GM094780513 NNS O
. BC2GM094780513 . O
. . O O

The BC2GM006294419 DT O
human BC2GM006294419 JJ O
BRCA1 BC2GM006294419 NNP O
promoter BC2GM006294419 NN O
also BC2GM006294419 RB O
contains BC2GM006294419 VBZ O
a BC2GM006294419 DT O
conserved BC2GM006294419 JJ O
E2F BC2GM006294419 NNP O
site BC2GM006294419 NN O
and BC2GM006294419 CC O
is BC2GM006294419 VBZ O
similarly BC2GM006294419 RB O
regulated BC2GM006294419 VBN O
by BC2GM006294419 IN O
E2F1 BC2GM006294419 NNP O
and BC2GM006294419 CC O
Rb BC2GM006294419 NNP O
. BC2GM006294419 . O
. . O O

It BC2GM028090853 PRP O
is BC2GM028090853 VBZ O
dangerous BC2GM028090853 JJ O
to BC2GM028090853 TO O
label BC2GM028090853 VB O
such BC2GM028090853 JJ O
conditions BC2GM028090853 NNS O
as BC2GM028090853 IN O
'inappropriate BC2GM028090853 NN O
' BC2GM028090853 POS O
secretion BC2GM028090853 NN O
of BC2GM028090853 IN O
ADH BC2GM028090853 NNP O
since BC2GM028090853 IN O
the BC2GM028090853 DT O
maintenance BC2GM028090853 NN O
of BC2GM028090853 IN O
circulating BC2GM028090853 VBG O
volume BC2GM028090853 NN O
is BC2GM028090853 VBZ O
at BC2GM028090853 IN O
least BC2GM028090853 JJS O
as BC2GM028090853 IN O
important BC2GM028090853 JJ O
a BC2GM028090853 DT O
physiological BC2GM028090853 JJ O
requirement BC2GM028090853 NN O
as BC2GM028090853 IN O
the BC2GM028090853 DT O
defence BC2GM028090853 NN O
of BC2GM028090853 IN O
tonicity BC2GM028090853 NN O
. BC2GM028090853 . O
. . O O

Our BC2GM003819880 PRP$ O
analysis BC2GM003819880 NN O
indicates BC2GM003819880 VBZ O
that BC2GM003819880 IN O
a BC2GM003819880 DT O
gene BC2GM003819880 NN O
correction BC2GM003819880 NN O
mechanism BC2GM003819880 NN O
has BC2GM003819880 VBZ O
been BC2GM003819880 VBN O
operating BC2GM003819880 VBG O
on BC2GM003819880 IN O
the BC2GM003819880 DT O
Hbbs BC2GM003819880 NNP O
chromosome BC2GM003819880 NN O
to BC2GM003819880 TO O
keep BC2GM003819880 VB O
beta BC2GM003819880 NN O
s BC2GM003819880 NN O
and BC2GM003819880 CC O
beta BC2GM003819880 NN O
t BC2GM003819880 NN O
evolving BC2GM003819880 VBG O
in BC2GM003819880 IN O
concert BC2GM003819880 NN O
, BC2GM003819880 , O
whereas BC2GM003819880 NNS O
on BC2GM003819880 IN O
the BC2GM003819880 DT O
Hbbd BC2GM003819880 NNP O
chromosome BC2GM003819880 NN O
, BC2GM003819880 , O
beta BC2GM003819880 NN O
dmin BC2GM003819880 NN O
has BC2GM003819880 VBZ O
diverged BC2GM003819880 VBN O
considerably BC2GM003819880 RB O
from BC2GM003819880 IN O
beta BC2GM003819880 NN O
dmaj BC2GM003819880 NN O
. BC2GM003819880 . O
. . O O

Western BC2GM043622260 JJ O
and BC2GM043622260 CC O
immunocytochemical BC2GM043622260 JJ O
analysis BC2GM043622260 NN O
implied BC2GM043622260 VBD O
that BC2GM043622260 IN O
PREB BC2GM043622260 NNP O
accumulates BC2GM043622260 VBZ O
specifically BC2GM043622260 RB O
in BC2GM043622260 IN O
GH3 BC2GM043622260 NNP O
cell BC2GM043622260 NN O
nuclei BC2GM043622260 NN O
. BC2GM043622260 . O
. . O O

The BC2GM022806510 DT O
pressure BC2GM022806510 NN O
measurements BC2GM022806510 NNS O
under BC2GM022806510 IN O
steady BC2GM022806510 JJ O
flow BC2GM022806510 NN O
conditions BC2GM022806510 NNS O
showed BC2GM022806510 VBD O
that BC2GM022806510 IN O
the BC2GM022806510 DT O
hemodynamic BC2GM022806510 JJ O
performance BC2GM022806510 NN O
( BC2GM022806510 ( O
including BC2GM022806510 VBG O
pressure BC2GM022806510 NN O
gradient BC2GM022806510 NN O
and BC2GM022806510 CC O
effective BC2GM022806510 JJ O
orifice BC2GM022806510 NNP O
area BC2GM022806510 NN O
) BC2GM022806510 ) O
of BC2GM022806510 IN O
SPAB BC2GM022806510 NNP O
is BC2GM022806510 VBZ O
superior BC2GM022806510 JJ O
to BC2GM022806510 TO O
that BC2GM022806510 DT O
of BC2GM022806510 IN O
its BC2GM022806510 PRP$ O
stented BC2GM022806510 JJ O
counterpart BC2GM022806510 NN O
, BC2GM022806510 , O
especially BC2GM022806510 RB O
in BC2GM022806510 IN O
the BC2GM022806510 DT O
smaller BC2GM022806510 JJR O
sizes BC2GM022806510 NN O
. BC2GM022806510 . O
. . O O

This BC2GM079219786 DT O
is BC2GM079219786 VBZ O
the BC2GM079219786 DT O
first BC2GM079219786 JJ O
description BC2GM079219786 NN O
of BC2GM079219786 IN O
an BC2GM079219786 DT O
integron BC2GM079219786 NN O
located BC2GM079219786 VBN O
on BC2GM079219786 IN O
a BC2GM079219786 DT O
composite BC2GM079219786 JJ O
transposon BC2GM079219786 NN O
. BC2GM079219786 . O
. . O O

An BC2GM049816389 DT O
exception BC2GM049816389 NN O
is BC2GM049816389 VBZ O
the BC2GM049816389 DT O
Bcl-6 BC2GM049816389 JJ O
gene BC2GM049816389 NN O
, BC2GM049816389 , O
encoding BC2GM049816389 VBG O
a BC2GM049816389 DT O
transcription BC2GM049816389 NN O
factor BC2GM049816389 NN O
, BC2GM049816389 , O
which BC2GM049816389 WDT O
was BC2GM049816389 VBD O
found BC2GM049816389 VBN O
to BC2GM049816389 TO O
be BC2GM049816389 VB O
mutated BC2GM049816389 VBN O
in BC2GM049816389 IN O
normal BC2GM049816389 JJ O
human BC2GM049816389 JJ O
memory BC2GM049816389 NN O
B BC2GM049816389 NNP O
cells BC2GM049816389 NNS O
. BC2GM049816389 . O
. . O O

Ten BC2GM081134768 CD O
patients BC2GM081134768 NNS O
( BC2GM081134768 ( O
aged BC2GM081134768 VBN O
28-76 BC2GM081134768 CD O
years BC2GM081134768 NNS O
) BC2GM081134768 ) O
with BC2GM081134768 IN O
a BC2GM081134768 DT O
terminal BC2GM081134768 JJ O
jejunostomy BC2GM081134768 NN O
located BC2GM081134768 VBN O
within BC2GM081134768 IN O
the BC2GM081134768 DT O
first BC2GM081134768 JJ O
meter BC2GM081134768 NN O
of BC2GM081134768 IN O
jejunum BC2GM081134768 NN O
were BC2GM081134768 VBD O
treated BC2GM081134768 VBN O
by BC2GM081134768 IN O
infusion BC2GM081134768 NN O
of BC2GM081134768 IN O
an BC2GM081134768 DT O
elemental BC2GM081134768 JJ O
diet BC2GM081134768 NN O
into BC2GM081134768 IN O
the BC2GM081134768 DT O
distal BC2GM081134768 JJ O
small BC2GM081134768 JJ O
bowel BC2GM081134768 NN O
( BC2GM081134768 ( O
IEDDSB BC2GM081134768 NNP O
) BC2GM081134768 ) O
. BC2GM081134768 . O
. . O O

Seizure BC2GM039883635 NN O
recurrence BC2GM039883635 NN O
( BC2GM039883635 ( O
HR BC2GM039883635 NNP O
1.30 BC2GM039883635 CD O
; BC2GM039883635 : O
95 BC2GM039883635 CD O
% BC2GM039883635 NN O
CI BC2GM039883635 NNP O
= BC2GM039883635 NNP O
0.84 BC2GM039883635 CD O
, BC2GM039883635 , O
2.01 BC2GM039883635 CD O
) BC2GM039883635 ) O
and BC2GM039883635 CC O
antiepileptic BC2GM039883635 JJ O
drug BC2GM039883635 NN O
treatment BC2GM039883635 NN O
( BC2GM039883635 ( O
HR BC2GM039883635 NNP O
0.97 BC2GM039883635 CD O
; BC2GM039883635 : O
95 BC2GM039883635 CD O
% BC2GM039883635 NN O
CI BC2GM039883635 NNP O
= BC2GM039883635 NNP O
0.67 BC2GM039883635 CD O
, BC2GM039883635 , O
1.38 BC2GM039883635 CD O
) BC2GM039883635 ) O
did BC2GM039883635 VBD O
not BC2GM039883635 RB O
influence BC2GM039883635 VB O
mortality BC2GM039883635 NN O
rate BC2GM039883635 NN O
. BC2GM039883635 . O
. . O O

Effects BC2GM029322086 NNS O
of BC2GM029322086 IN O
prolonged BC2GM029322086 JJ O
inhibition BC2GM029322086 NN O
of BC2GM029322086 IN O
labour BC2GM029322086 NN O
pains BC2GM029322086 NNS O
with BC2GM029322086 IN O
Th BC2GM029322086 NNP O
1165a BC2GM029322086 CD O
and BC2GM029322086 CC O
Isoptin BC2GM029322086 NNP O
on BC2GM029322086 IN O
the BC2GM029322086 DT O
heart BC2GM029322086 NN O
, BC2GM029322086 , O
circulation BC2GM029322086 NN O
, BC2GM029322086 , O
organ- BC2GM029322086 JJ O
and BC2GM029322086 CC O
metabolic BC2GM029322086 JJ O
parameters BC2GM029322086 NNS O
of BC2GM029322086 IN O
the BC2GM029322086 DT O
mother BC2GM029322086 NN O
. BC2GM029322086 . O
. . O O

This BC2GM064070437 DT O
demonstrates BC2GM064070437 VBZ O
the BC2GM064070437 DT O
presence BC2GM064070437 NN O
of BC2GM064070437 IN O
a BC2GM064070437 DT O
PKC-dependent BC2GM064070437 NNP O
pathway BC2GM064070437 NN O
which BC2GM064070437 WDT O
functions BC2GM064070437 NNS O
independently BC2GM064070437 RB O
from BC2GM064070437 IN O
Lck BC2GM064070437 NNP O
in BC2GM064070437 IN O
MAP BC2GM064070437 NNP O
kinase BC2GM064070437 NN O
activation BC2GM064070437 NN O
. BC2GM064070437 . O
. . O O

A BC2GM095746583 DT O
significant BC2GM095746583 JJ O
reduction BC2GM095746583 NN O
in BC2GM095746583 IN O
total BC2GM095746583 JJ O
cellular BC2GM095746583 JJ O
p27 BC2GM095746583 NN O
protein BC2GM095746583 NN O
levels BC2GM095746583 NNS O
and BC2GM095746583 CC O
a BC2GM095746583 DT O
moderate BC2GM095746583 JJ O
reduction BC2GM095746583 NN O
in BC2GM095746583 IN O
p27 BC2GM095746583 NN O
mRNA BC2GM095746583 NN O
are BC2GM095746583 VBP O
observed BC2GM095746583 VBN O
, BC2GM095746583 , O
but BC2GM095746583 CC O
no BC2GM095746583 DT O
changes BC2GM095746583 NNS O
in BC2GM095746583 IN O
Cdk BC2GM095746583 NNP O
regulatory BC2GM095746583 JJ O
kinases BC2GM095746583 NNS O
and BC2GM095746583 CC O
phosphatases BC2GM095746583 NNS O
occur BC2GM095746583 VBP O
. BC2GM095746583 . O
. . O O

The BC2GM087596425 DT O
strongly BC2GM087596425 RB O
DNA BC2GM087596425 NNP O
binding BC2GM087596425 VBG O
p50 BC2GM087596425 NN O
subunit BC2GM087596425 NN O
showed BC2GM087596425 VBD O
only BC2GM087596425 RB O
very BC2GM087596425 RB O
weak BC2GM087596425 JJ O
, BC2GM087596425 , O
if BC2GM087596425 IN O
any BC2GM087596425 DT O
, BC2GM087596425 , O
induction BC2GM087596425 NN O
of BC2GM087596425 IN O
gene BC2GM087596425 NN O
expression BC2GM087596425 NN O
. BC2GM087596425 . O
. . O O

Enoxacin BC2GM045174565 NNP O
has BC2GM045174565 VBZ O
been BC2GM045174565 VBN O
shown BC2GM045174565 VBN O
to BC2GM045174565 TO O
be BC2GM045174565 VB O
an BC2GM045174565 DT O
effective BC2GM045174565 JJ O
well BC2GM045174565 NN O
tolerated BC2GM045174565 VBN O
and BC2GM045174565 CC O
convenient BC2GM045174565 JJ O
treatment BC2GM045174565 NN O
for BC2GM045174565 IN O
gonorrhoea BC2GM045174565 NN O
. BC2GM045174565 . O
. . O O

DNA BC2GM051328807 NN O
elements BC2GM051328807 NNS O
recognizing BC2GM051328807 VBG O
NF-Y BC2GM051328807 NNP O
and BC2GM051328807 CC O
Sp1 BC2GM051328807 NNP O
regulate BC2GM051328807 VB O
the BC2GM051328807 DT O
human BC2GM051328807 JJ O
multidrug-resistance BC2GM051328807 NN O
gene BC2GM051328807 NN O
promoter BC2GM051328807 NN O
. BC2GM051328807 . O
. . O O

The BC2GM037875786 DT O
extent BC2GM037875786 NN O
of BC2GM037875786 IN O
myocardial BC2GM037875786 JJ O
ischemia BC2GM037875786 NN O
in BC2GM037875786 IN O
the BC2GM037875786 DT O
coronary BC2GM037875786 JJ O
sinus BC2GM037875786 NN O
study BC2GM037875786 NN O
was BC2GM037875786 VBD O
significantly BC2GM037875786 RB O
correlated BC2GM037875786 VBN O
to BC2GM037875786 TO O
the BC2GM037875786 DT O
coronary BC2GM037875786 JJ O
diameters BC2GM037875786 NNS O
of BC2GM037875786 IN O
the BC2GM037875786 DT O
proximal BC2GM037875786 NN O
and BC2GM037875786 CC O
middle BC2GM037875786 JJ O
segments BC2GM037875786 NNS O
of BC2GM037875786 IN O
the BC2GM037875786 DT O
Ramus BC2GM037875786 NNP O
interventricularis BC2GM037875786 NN O
anterior BC2GM037875786 NN O
and BC2GM037875786 CC O
the BC2GM037875786 DT O
middle BC2GM037875786 JJ O
segment BC2GM037875786 NN O
of BC2GM037875786 IN O
the BC2GM037875786 DT O
Ramus BC2GM037875786 NNP O
circumflexus BC2GM037875786 NN O
( BC2GM037875786 ( O
r BC2GM037875786 JJ O
= BC2GM037875786 NN O
0.87 BC2GM037875786 CD O
, BC2GM037875786 , O
p BC2GM037875786 NN O
< BC2GM037875786 NNP O
0.02 BC2GM037875786 CD O
) BC2GM037875786 ) O
. BC2GM037875786 . O
. . O O

We BC2GM080497809 PRP O
compared BC2GM080497809 VBN O
these BC2GM080497809 DT O
responses BC2GM080497809 NNS O
for BC2GM080497809 IN O
six BC2GM080497809 CD O
hatchling BC2GM080497809 NN O
and BC2GM080497809 CC O
eight BC2GM080497809 CD O
adult BC2GM080497809 NN O
Chrysemys BC2GM080497809 NNP O
picta BC2GM080497809 NN O
from BC2GM080497809 IN O
an BC2GM080497809 DT O
Ohio BC2GM080497809 NNP O
population BC2GM080497809 NN O
. BC2GM080497809 . O
. . O O

We BC2GM038751995 PRP O
were BC2GM038751995 VBD O
able BC2GM038751995 JJ O
to BC2GM038751995 TO O
demonstrate BC2GM038751995 VB O
a BC2GM038751995 DT O
significant BC2GM038751995 JJ O
statistical BC2GM038751995 JJ O
interaction BC2GM038751995 NN O
effect BC2GM038751995 NN O
between BC2GM038751995 IN O
gender BC2GM038751995 NN O
and BC2GM038751995 CC O
globulin BC2GM038751995 NN O
protein BC2GM038751995 NN O
concentration BC2GM038751995 NN O
on BC2GM038751995 IN O
Vu BC2GM038751995 NNP O
( BC2GM038751995 ( O
p BC2GM038751995 JJ O
= BC2GM038751995 NNP O
0.022 BC2GM038751995 CD O
) BC2GM038751995 ) O
. BC2GM038751995 . O
. . O O

Murine BC2GM037968390 NNP O
ELAM-1 BC2GM037968390 NNP O
is BC2GM037968390 VBZ O
encoded BC2GM037968390 VBN O
by BC2GM037968390 IN O
a BC2GM037968390 DT O
single-copy BC2GM037968390 JJ O
gene BC2GM037968390 NN O
, BC2GM037968390 , O
spanning BC2GM037968390 VBG O
about BC2GM037968390 IN O
13 BC2GM037968390 CD O
kb BC2GM037968390 NNS O
, BC2GM037968390 , O
which BC2GM037968390 WDT O
is BC2GM037968390 VBZ O
structurally BC2GM037968390 RB O
organized BC2GM037968390 VBN O
into BC2GM037968390 IN O
14 BC2GM037968390 CD O
exons BC2GM037968390 NNS O
and BC2GM037968390 CC O
13 BC2GM037968390 CD O
introns BC2GM037968390 NNS O
; BC2GM037968390 : O
very BC2GM037968390 RB O
similar BC2GM037968390 JJ O
to BC2GM037968390 TO O
that BC2GM037968390 DT O
of BC2GM037968390 IN O
its BC2GM037968390 PRP$ O
human BC2GM037968390 JJ O
counterpart BC2GM037968390 NN O
. BC2GM037968390 . O
. . O O

Model BC2GM080794726 NNP O
experiments BC2GM080794726 NNS O
on BC2GM080794726 IN O
pheasants BC2GM080794726 NNS O
using BC2GM080794726 VBG O
single BC2GM080794726 JJ O
doses BC2GM080794726 NNS O
of BC2GM080794726 IN O
the BC2GM080794726 DT O
insecticide BC2GM080794726 NN O
( BC2GM080794726 ( O
Lindane BC2GM080794726 NNP O
) BC2GM080794726 ) O
the BC2GM080794726 DT O
herbicide BC2GM080794726 NN O
( BC2GM080794726 ( O
Terbutryn BC2GM080794726 NNP O
) BC2GM080794726 ) O
a BC2GM080794726 DT O
mineral BC2GM080794726 JJ O
fertilizer BC2GM080794726 NN O
( BC2GM080794726 ( O
calcium BC2GM080794726 JJ O
ammonium BC2GM080794726 NN O
nitrate BC2GM080794726 NN O
) BC2GM080794726 ) O
and BC2GM080794726 CC O
the BC2GM080794726 DT O
fungicide BC2GM080794726 NN O
( BC2GM080794726 ( O
HCB BC2GM080794726 NNP O
) BC2GM080794726 ) O
. BC2GM080794726 . O
. . O O

Programmed BC2GM059465323 NNP O
peritoneal BC2GM059465323 JJ O
lavage BC2GM059465323 NN O
in BC2GM059465323 IN O
suppurative BC2GM059465323 JJ O
complications BC2GM059465323 NNS O
of BC2GM059465323 IN O
perforated BC2GM059465323 JJ O
ulcer BC2GM059465323 NN O
of BC2GM059465323 IN O
the BC2GM059465323 DT O
stomach BC2GM059465323 NN O
. BC2GM059465323 . O
. . O O

The BC2GM039562937 DT O
predicted BC2GM039562937 JJ O
amino-acid BC2GM039562937 JJ O
sequence BC2GM039562937 NN O
includes BC2GM039562937 VBZ O
an BC2GM039562937 DT O
N-terminal BC2GM039562937 JJ O
signal BC2GM039562937 JJ O
sequence BC2GM039562937 NN O
of BC2GM039562937 IN O
27 BC2GM039562937 CD O
amino BC2GM039562937 NN O
acids BC2GM039562937 NNS O
, BC2GM039562937 , O
a BC2GM039562937 DT O
27 BC2GM039562937 CD O
amino-acid BC2GM039562937 JJ O
pro-region BC2GM039562937 NN O
, BC2GM039562937 , O
a BC2GM039562937 DT O
251 BC2GM039562937 CD O
amino-acid BC2GM039562937 JJ O
catalytic BC2GM039562937 JJ O
domain BC2GM039562937 NN O
typical BC2GM039562937 JJ O
of BC2GM039562937 IN O
a BC2GM039562937 DT O
serine BC2GM039562937 JJ O
protease BC2GM039562937 NN O
with BC2GM039562937 IN O
trypsin-like BC2GM039562937 JJ O
specificity BC2GM039562937 NN O
, BC2GM039562937 , O
and BC2GM039562937 CC O
a BC2GM039562937 DT O
C-terminal BC2GM039562937 JJ O
hydrophobic BC2GM039562937 NN O
extension BC2GM039562937 NN O
which BC2GM039562937 WDT O
is BC2GM039562937 VBZ O
predicted BC2GM039562937 VBN O
to BC2GM039562937 TO O
function BC2GM039562937 VB O
as BC2GM039562937 IN O
a BC2GM039562937 DT O
membrane BC2GM039562937 NN O
anchor BC2GM039562937 NN O
. BC2GM039562937 . O
. . O O

It BC2GM029913363 PRP O
is BC2GM029913363 VBZ O
concluded BC2GM029913363 VBN O
that BC2GM029913363 IN O
the BC2GM029913363 DT O
atherogenic BC2GM029913363 JJ O
process BC2GM029913363 NN O
includes BC2GM029913363 VBZ O
stimulation BC2GM029913363 NN O
of BC2GM029913363 IN O
collagen BC2GM029913363 NN O
and BC2GM029913363 CC O
elastin BC2GM029913363 JJ O
synthesis BC2GM029913363 NN O
. BC2GM029913363 . O
. . O O

The BC2GM099775528 DT O
survival BC2GM099775528 NN O
of BC2GM099775528 IN O
patients BC2GM099775528 NNS O
with BC2GM099775528 IN O
a BC2GM099775528 DT O
short BC2GM099775528 JJ O
bowel BC2GM099775528 NN O
, BC2GM099775528 , O
even BC2GM099775528 RB O
if BC2GM099775528 IN O
they BC2GM099775528 PRP O
need BC2GM099775528 VBP O
long-term BC2GM099775528 JJ O
parenteral BC2GM099775528 JJ O
nutrition BC2GM099775528 NN O
, BC2GM099775528 , O
is BC2GM099775528 VBZ O
good BC2GM099775528 JJ O
. BC2GM099775528 . O
. . O O

After BC2GM043977767 IN O
at BC2GM043977767 IN O
least BC2GM043977767 JJS O
one BC2GM043977767 CD O
year BC2GM043977767 NN O
follow-up BC2GM043977767 NN O
, BC2GM043977767 , O
argon BC2GM043977767 NN O
laser BC2GM043977767 NN O
showed BC2GM043977767 VBD O
a BC2GM043977767 DT O
statistically BC2GM043977767 RB O
significant BC2GM043977767 JJ O
effect BC2GM043977767 NN O
( BC2GM043977767 ( O
p BC2GM043977767 JJ O
less BC2GM043977767 NN O
of BC2GM043977767 IN O
0,01 BC2GM043977767 CD O
; BC2GM043977767 : O
Kolmogorow-Smirnov BC2GM043977767 NNP O
test BC2GM043977767 NN O
) BC2GM043977767 ) O
on BC2GM043977767 IN O
the BC2GM043977767 DT O
stabilization BC2GM043977767 NN O
or BC2GM043977767 CC O
the BC2GM043977767 DT O
amelioration BC2GM043977767 NN O
of BC2GM043977767 IN O
visual BC2GM043977767 JJ O
acuity BC2GM043977767 NN O
compared BC2GM043977767 VBN O
with BC2GM043977767 IN O
the BC2GM043977767 DT O
non BC2GM043977767 NN O
treated BC2GM043977767 VBD O
group BC2GM043977767 NN O
. BC2GM043977767 . O
. . O O

Experiments BC2GM048317669 NNS O
were BC2GM048317669 VBD O
performed BC2GM048317669 VBN O
without BC2GM048317669 IN O
polarization BC2GM048317669 NN O
or BC2GM048317669 CC O
with BC2GM048317669 IN O
cathodic BC2GM048317669 JJ O
and BC2GM048317669 CC O
anodic BC2GM048317669 JJ O
polarization BC2GM048317669 NN O
of BC2GM048317669 IN O
the BC2GM048317669 DT O
adsorbent BC2GM048317669 NN O
. BC2GM048317669 . O
. . O O

Glutathione BC2GM043140660 NNP O
reductase BC2GM043140660 NN O
( BC2GM043140660 ( O
GR BC2GM043140660 NNP O
) BC2GM043140660 ) O
was BC2GM043140660 VBD O
purified BC2GM043140660 VBN O
from BC2GM043140660 IN O
the BC2GM043140660 DT O
cyanobacterium BC2GM043140660 NN O
Anabaena BC2GM043140660 NNP O
PCC BC2GM043140660 NNP O
7120 BC2GM043140660 CD O
. BC2GM043140660 . O
. . O O

These BC2GM046888921 DT O
results BC2GM046888921 NNS O
induce BC2GM046888921 VBP O
that BC2GM046888921 IN O
the BC2GM046888921 DT O
putative BC2GM046888921 JJ O
TATA BC2GM046888921 NNP O
box BC2GM046888921 NN O
and BC2GM046888921 CC O
initiator BC2GM046888921 NN O
are BC2GM046888921 VBP O
not BC2GM046888921 RB O
involved BC2GM046888921 VBN O
in BC2GM046888921 IN O
the BC2GM046888921 DT O
promoter BC2GM046888921 NN O
activity BC2GM046888921 NN O
, BC2GM046888921 , O
and BC2GM046888921 CC O
that BC2GM046888921 IN O
the BC2GM046888921 DT O
vitronectin BC2GM046888921 NN O
promoter BC2GM046888921 NN O
lacks BC2GM046888921 VBZ O
the BC2GM046888921 DT O
TATA BC2GM046888921 NNP O
box BC2GM046888921 NN O
, BC2GM046888921 , O
initiator BC2GM046888921 NN O
and BC2GM046888921 CC O
GC BC2GM046888921 NNP O
box BC2GM046888921 NN O
. BC2GM046888921 . O
. . O O

This BC2GM027529733 DT O
paper BC2GM027529733 NN O
describes BC2GM027529733 VBZ O
a BC2GM027529733 DT O
course BC2GM027529733 NN O
of BC2GM027529733 IN O
therapy BC2GM027529733 NN O
with BC2GM027529733 IN O
an BC2GM027529733 DT O
agoraphobic BC2GM027529733 JJ O
female BC2GM027529733 NN O
patient BC2GM027529733 NN O
. BC2GM027529733 . O
. . O O

For BC2GM021169148 IN O
economical BC2GM021169148 JJ O
reasons BC2GM021169148 NNS O
, BC2GM021169148 , O
we BC2GM021169148 PRP O
could BC2GM021169148 MD O
not BC2GM021169148 RB O
send BC2GM021169148 VB O
a BC2GM021169148 DT O
questionnaire BC2GM021169148 NN O
to BC2GM021169148 TO O
all BC2GM021169148 PDT O
the BC2GM021169148 DT O
35,779 BC2GM021169148 CD O
individuals BC2GM021169148 NNS O
, BC2GM021169148 , O
but BC2GM021169148 CC O
based BC2GM021169148 VBN O
the BC2GM021169148 DT O
investigation BC2GM021169148 NN O
on BC2GM021169148 IN O
a BC2GM021169148 DT O
SRS BC2GM021169148 NNP O
of BC2GM021169148 IN O
4,000 BC2GM021169148 CD O
men BC2GM021169148 NNS O
, BC2GM021169148 , O
post-stratified BC2GM021169148 JJ O
in BC2GM021169148 IN O
a BC2GM021169148 DT O
high-risk BC2GM021169148 JJ O
and BC2GM021169148 CC O
a BC2GM021169148 DT O
low-risk BC2GM021169148 JJ O
group BC2GM021169148 NN O
. BC2GM021169148 . O
. . O O

ATF BC2GM049324626 NNP O
is BC2GM049324626 VBZ O
formulated BC2GM049324626 VBN O
from BC2GM049324626 IN O
the BC2GM049324626 DT O
prothrombin BC2GM049324626 NN O
time BC2GM049324626 NN O
( BC2GM049324626 ( O
PT BC2GM049324626 NNP O
) BC2GM049324626 ) O
, BC2GM049324626 , O
fibrinogen BC2GM049324626 JJ O
transformation BC2GM049324626 NN O
rate BC2GM049324626 NN O
( BC2GM049324626 ( O
FTR BC2GM049324626 NNP O
) BC2GM049324626 ) O
( BC2GM049324626 ( O
a BC2GM049324626 DT O
representation BC2GM049324626 NN O
of BC2GM049324626 IN O
thrombin BC2GM049324626 JJ O
activity BC2GM049324626 NN O
) BC2GM049324626 ) O
, BC2GM049324626 , O
and BC2GM049324626 CC O
a BC2GM049324626 DT O
consideration BC2GM049324626 NN O
of BC2GM049324626 IN O
the BC2GM049324626 DT O
fibrinogen BC2GM049324626 NN O
( BC2GM049324626 ( O
FBG BC2GM049324626 NNP O
) BC2GM049324626 ) O
content BC2GM049324626 NN O
of BC2GM049324626 IN O
blood BC2GM049324626 NN O
plasma BC2GM049324626 NN O
. BC2GM049324626 . O
. . O O

Alcohol BC2GM052318281 NNP O
abuse BC2GM052318281 NN O
and BC2GM052318281 CC O
treatment BC2GM052318281 NN O
resistance BC2GM052318281 NN O
in BC2GM052318281 IN O
skin BC2GM052318281 JJ O
disease BC2GM052318281 NN O
. BC2GM052318281 . O
. . O O

Gold BC2GM065051600 NNP O
flaxseed BC2GM065051600 NN O
( BC2GM065051600 ( O
whole BC2GM065051600 JJ O
or BC2GM065051600 CC O
ground BC2GM065051600 NN O
) BC2GM065051600 ) O
fed BC2GM065051600 NN O
at BC2GM065051600 IN O
levels BC2GM065051600 NNS O
of BC2GM065051600 IN O
5 BC2GM065051600 CD O
or BC2GM065051600 CC O
15 BC2GM065051600 CD O
% BC2GM065051600 NN O
were BC2GM065051600 VBD O
compared BC2GM065051600 VBN O
to BC2GM065051600 TO O
a BC2GM065051600 DT O
1.5 BC2GM065051600 CD O
% BC2GM065051600 NN O
menhaden BC2GM065051600 JJ O
oil BC2GM065051600 NN O
or BC2GM065051600 CC O
a BC2GM065051600 DT O
typical BC2GM065051600 JJ O
control BC2GM065051600 NN O
layer BC2GM065051600 NN O
ration BC2GM065051600 NN O
. BC2GM065051600 . O
. . O O

Acute BC2GM014858349 NNP O
renal BC2GM014858349 JJ O
vein BC2GM014858349 NN O
thrombosis BC2GM014858349 NN O
in BC2GM014858349 IN O
renal BC2GM014858349 JJ O
allografts BC2GM014858349 NNS O
: BC2GM014858349 : O
detection BC2GM014858349 NN O
with BC2GM014858349 IN O
duplex BC2GM014858349 JJ O
Doppler BC2GM014858349 NNP O
US BC2GM014858349 NNP O
. BC2GM014858349 . O
. . O O

Urease BC2GM063249278 NNP O
activity BC2GM063249278 NN O
, BC2GM063249278 , O
judged BC2GM063249278 VBN O
as BC2GM063249278 IN O
the BC2GM063249278 DT O
amount BC2GM063249278 NN O
of BC2GM063249278 IN O
ammonia BC2GM063249278 JJ O
production BC2GM063249278 NN O
from BC2GM063249278 IN O
urea BC2GM063249278 JJ O
, BC2GM063249278 , O
could BC2GM063249278 MD O
be BC2GM063249278 VB O
measured BC2GM063249278 VBN O
at BC2GM063249278 IN O
25 BC2GM063249278 CD O
ng BC2GM063249278 JJ O
per BC2GM063249278 IN O
tube BC2GM063249278 NN O
( BC2GM063249278 ( O
S BC2GM063249278 NNP O
/ BC2GM063249278 NNP O
N BC2GM063249278 NNP O
= BC2GM063249278 NNP O
1.5 BC2GM063249278 CD O
) BC2GM063249278 ) O
with BC2GM063249278 IN O
Jack BC2GM063249278 NNP O
bean BC2GM063249278 JJ O
meal BC2GM063249278 NN O
urease BC2GM063249278 NN O
. BC2GM063249278 . O
. . O O

The BC2GM091384124 DT O
biological BC2GM091384124 JJ O
functions BC2GM091384124 NNS O
of BC2GM091384124 IN O
rat BC2GM091384124 NN O
surfactant BC2GM091384124 JJ O
protein BC2GM091384124 NN O
A BC2GM091384124 NNP O
( BC2GM091384124 ( O
SP-A BC2GM091384124 NNP O
) BC2GM091384124 ) O
, BC2GM091384124 , O
an BC2GM091384124 DT O
oligomer BC2GM091384124 NN O
composed BC2GM091384124 VBD O
of BC2GM091384124 IN O
18 BC2GM091384124 CD O
polypeptide BC2GM091384124 JJ O
subunits BC2GM091384124 NNS O
derived BC2GM091384124 VBN O
from BC2GM091384124 IN O
a BC2GM091384124 DT O
single BC2GM091384124 JJ O
gene BC2GM091384124 NN O
, BC2GM091384124 , O
are BC2GM091384124 VBP O
dependent BC2GM091384124 JJ O
on BC2GM091384124 IN O
intact BC2GM091384124 JJ O
disulfide BC2GM091384124 JJ O
bonds BC2GM091384124 NNS O
. BC2GM091384124 . O
. . O O

Between BC2GM088426730 JJ O
1988 BC2GM088426730 CD O
and BC2GM088426730 CC O
1994 BC2GM088426730 CD O
, BC2GM088426730 , O
data BC2GM088426730 NNS O
from BC2GM088426730 IN O
3 BC2GM088426730 CD O
large BC2GM088426730 JJ O
sites BC2GM088426730 NNS O
revealed BC2GM088426730 VBD O
a BC2GM088426730 DT O
3-5 BC2GM088426730 JJ O
fold BC2GM088426730 JJ O
increase BC2GM088426730 NN O
in BC2GM088426730 IN O
the BC2GM088426730 DT O
prevalence BC2GM088426730 NN O
of BC2GM088426730 IN O
antidepressant BC2GM088426730 NN O
( BC2GM088426730 ( O
ATD BC2GM088426730 NNP O
) BC2GM088426730 ) O
treatment BC2GM088426730 NN O
for BC2GM088426730 IN O
U.S. BC2GM088426730 NNP O
youths BC2GM088426730 NNS O
aged BC2GM088426730 VBN O
2-19 BC2GM088426730 CD O
years BC2GM088426730 NNS O
. BC2GM088426730 . O
. . O O

Enterobius BC2GM094581342 NNP O
vermicularis BC2GM094581342 NN O
eggs BC2GM094581342 NNS O
were BC2GM094581342 VBD O
demonstrated BC2GM094581342 VBN O
during BC2GM094581342 IN O
microscopic BC2GM094581342 JJ O
examination BC2GM094581342 NN O
of BC2GM094581342 IN O
a BC2GM094581342 DT O
smear BC2GM094581342 JJ O
taken BC2GM094581342 VBN O
from BC2GM094581342 IN O
the BC2GM094581342 DT O
posterior BC2GM094581342 JJ O
fornix BC2GM094581342 NN O
of BC2GM094581342 IN O
the BC2GM094581342 DT O
vagina BC2GM094581342 NN O
. BC2GM094581342 . O
. . O O

Conversely BC2GM089791646 RB O
the BC2GM089791646 DT O
rate BC2GM089791646 NN O
of BC2GM089791646 IN O
bioavailability BC2GM089791646 NN O
was BC2GM089791646 VBD O
significantly BC2GM089791646 RB O
different BC2GM089791646 JJ O
, BC2GM089791646 , O
because BC2GM089791646 IN O
from BC2GM089791646 IN O
the BC2GM089791646 DT O
Reference BC2GM089791646 NNP O
patch BC2GM089791646 NN O
the BC2GM089791646 DT O
release BC2GM089791646 NN O
rate BC2GM089791646 NN O
is BC2GM089791646 VBZ O
fast BC2GM089791646 VBN O
in BC2GM089791646 IN O
the BC2GM089791646 DT O
first BC2GM089791646 JJ O
24 BC2GM089791646 CD O
h BC2GM089791646 NN O
, BC2GM089791646 , O
leading BC2GM089791646 VBG O
to BC2GM089791646 TO O
an BC2GM089791646 DT O
E2 BC2GM089791646 NNP O
peak BC2GM089791646 NN O
at BC2GM089791646 IN O
8 BC2GM089791646 CD O
h BC2GM089791646 NN O
and BC2GM089791646 CC O
to BC2GM089791646 TO O
a BC2GM089791646 DT O
Cmax BC2GM089791646 NNP O
in BC2GM089791646 IN O
average BC2GM089791646 NN O
at BC2GM089791646 IN O
23 BC2GM089791646 CD O
h BC2GM089791646 NN O
. BC2GM089791646 . O
. . O O

Chronic BC2GM084680436 NNP O
granulocytic BC2GM084680436 JJ O
leukemia BC2GM084680436 NN O
in BC2GM084680436 IN O
children BC2GM084680436 NNS O
. BC2GM084680436 . O
. . O O

Region-specific BC2GM002040357 JJ O
enhancers BC2GM002040357 NNS O
near BC2GM002040357 IN O
two BC2GM002040357 CD O
mammalian BC2GM002040357 JJ O
homeo BC2GM002040357 NN O
box BC2GM002040357 NN O
genes BC2GM002040357 NNS O
define BC2GM002040357 VBP O
adjacent BC2GM002040357 JJ O
rostrocaudal BC2GM002040357 NN O
domains BC2GM002040357 NNS O
in BC2GM002040357 IN O
the BC2GM002040357 DT O
central BC2GM002040357 JJ O
nervous BC2GM002040357 JJ O
system BC2GM002040357 NN O
. BC2GM002040357 . O
. . O O

At BC2GM061934161 IN O
a BC2GM061934161 DT O
cutoff BC2GM061934161 NN O
point BC2GM061934161 NN O
for BC2GM061934161 IN O
KISA BC2GM061934161 NNP O
% BC2GM061934161 NN O
of BC2GM061934161 IN O
100 BC2GM061934161 CD O
, BC2GM061934161 , O
280 BC2GM061934161 CD O
of BC2GM061934161 IN O
281 BC2GM061934161 CD O
participants BC2GM061934161 NNS O
( BC2GM061934161 ( O
99.6 BC2GM061934161 CD O
% BC2GM061934161 NN O
) BC2GM061934161 ) O
were BC2GM061934161 VBD O
correctly BC2GM061934161 RB O
classified BC2GM061934161 VBN O
. BC2GM061934161 . O
. . O O

The BC2GM099480245 DT O
levels BC2GM099480245 NNS O
of BC2GM099480245 IN O
TPAR1 BC2GM099480245 NNP O
mRNAs BC2GM099480245 NN O
were BC2GM099480245 VBD O
dramatically BC2GM099480245 RB O
down-regulated BC2GM099480245 VBN O
in BC2GM099480245 IN O
regenerating BC2GM099480245 VBG O
rat BC2GM099480245 NN O
liver BC2GM099480245 NN O
when BC2GM099480245 WRB O
compared BC2GM099480245 VBN O
to BC2GM099480245 TO O
normal BC2GM099480245 JJ O
adult BC2GM099480245 NN O
liver BC2GM099480245 NN O
. BC2GM099480245 . O
. . O O

A BC2GM002201420 DT O
29.425 BC2GM002201420 CD O
kb BC2GM002201420 NN O
segment BC2GM002201420 NN O
on BC2GM002201420 IN O
the BC2GM002201420 DT O
left BC2GM002201420 JJ O
arm BC2GM002201420 NN O
of BC2GM002201420 IN O
yeast BC2GM002201420 JJ O
chromosome BC2GM002201420 NN O
XV BC2GM002201420 NN O
contains BC2GM002201420 VBZ O
more BC2GM002201420 JJR O
than BC2GM002201420 IN O
twice BC2GM002201420 RB O
as BC2GM002201420 IN O
many BC2GM002201420 JJ O
unknown BC2GM002201420 JJ O
as BC2GM002201420 IN O
known BC2GM002201420 VBN O
open BC2GM002201420 JJ O
reading BC2GM002201420 NN O
frames BC2GM002201420 NNS O
. BC2GM002201420 . O
. . O O

E2A-HLF-mediated BC2GM000692061 JJ O
cell BC2GM000692061 NN O
transformation BC2GM000692061 NN O
requires BC2GM000692061 VBZ O
both BC2GM000692061 DT O
the BC2GM000692061 DT O
trans-activation BC2GM000692061 NN O
domains BC2GM000692061 NNS O
of BC2GM000692061 IN O
E2A BC2GM000692061 NNP O
and BC2GM000692061 CC O
the BC2GM000692061 DT O
leucine BC2GM000692061 JJ O
zipper BC2GM000692061 NN O
dimerization BC2GM000692061 NN O
domain BC2GM000692061 NN O
of BC2GM000692061 IN O
HLF BC2GM000692061 NNP O
. BC2GM000692061 . O
. . O O

BACKGROUND BC2GM027774736 NN O
: BC2GM027774736 : O
Recent BC2GM027774736 JJ O
iterative BC2GM027774736 JJ O
methods BC2GM027774736 NNS O
for BC2GM027774736 IN O
sequence BC2GM027774736 NN O
alignment BC2GM027774736 NN O
have BC2GM027774736 VBP O
indicated BC2GM027774736 VBN O
that BC2GM027774736 IN O
the BC2GM027774736 DT O
380 BC2GM027774736 CD O
kDa BC2GM027774736 NNS O
motor BC2GM027774736 NN O
unit BC2GM027774736 NN O
of BC2GM027774736 IN O
dynein BC2GM027774736 JJ O
belongs BC2GM027774736 NNS O
to BC2GM027774736 TO O
the BC2GM027774736 DT O
AAA BC2GM027774736 NNP O
class BC2GM027774736 NN O
of BC2GM027774736 IN O
chaperone-like BC2GM027774736 JJ O
ATPases BC2GM027774736 NNS O
. BC2GM027774736 . O
. . O O

In BC2GM014585915 IN O
the BC2GM014585915 DT O
conscious BC2GM014585915 JJ O
animals BC2GM014585915 NNS O
the BC2GM014585915 DT O
increase BC2GM014585915 NN O
reached BC2GM014585915 VBD O
statistical BC2GM014585915 JJ O
significance BC2GM014585915 NN O
when BC2GM014585915 WRB O
the BC2GM014585915 DT O
animals BC2GM014585915 NNS O
were BC2GM014585915 VBD O
exposed BC2GM014585915 VBN O
to BC2GM014585915 TO O
12 BC2GM014585915 CD O
% BC2GM014585915 NN O
oxygen BC2GM014585915 NN O
in BC2GM014585915 IN O
nitrogen BC2GM014585915 NN O
, BC2GM014585915 , O
which BC2GM014585915 WDT O
produced BC2GM014585915 VBD O
a BC2GM014585915 DT O
fall BC2GM014585915 NN O
in BC2GM014585915 IN O
arterial BC2GM014585915 JJ O
PaO2 BC2GM014585915 NNP O
of BC2GM014585915 IN O
44.7 BC2GM014585915 CD O
+ BC2GM014585915 NNS O
/ BC2GM014585915 SYM O
- BC2GM014585915 : O
5.0 BC2GM014585915 CD O
% BC2GM014585915 NN O
. BC2GM014585915 . O
. . O O

Infra-red BC2GM095688766 JJ O
spectroscopy BC2GM095688766 NN O
of BC2GM095688766 IN O
tissues BC2GM095688766 NNS O
in BC2GM095688766 IN O
the BC2GM095688766 DT O
700-400 BC2GM095688766 JJ O
cm-1 BC2GM095688766 JJ O
region BC2GM095688766 NN O
. BC2GM095688766 . O
. . O O

We BC2GM084179136 PRP O
found BC2GM084179136 VBD O
that BC2GM084179136 IN O
in BC2GM084179136 IN O
anesthetized BC2GM084179136 JJ O
, BC2GM084179136 , O
paralyzed BC2GM084179136 JJ O
cats BC2GM084179136 NNS O
, BC2GM084179136 , O
the BC2GM084179136 DT O
visual BC2GM084179136 JJ O
evoked BC2GM084179136 JJ O
potential BC2GM084179136 NN O
( BC2GM084179136 ( O
VEP BC2GM084179136 NNP O
) BC2GM084179136 ) O
was BC2GM084179136 VBD O
dependent BC2GM084179136 JJ O
only BC2GM084179136 RB O
on BC2GM084179136 IN O
magnitude BC2GM084179136 NN O
of BC2GM084179136 IN O
delta BC2GM084179136 JJ O
C BC2GM084179136 NNP O
at BC2GM084179136 IN O
each BC2GM084179136 DT O
pattern BC2GM084179136 NN O
transition BC2GM084179136 NN O
, BC2GM084179136 , O
and BC2GM084179136 CC O
was BC2GM084179136 VBD O
independent BC2GM084179136 JJ O
of BC2GM084179136 IN O
the BC2GM084179136 DT O
starting BC2GM084179136 NN O
or BC2GM084179136 CC O
ending BC2GM084179136 VBG O
contrast BC2GM084179136 JJ O
level BC2GM084179136 NN O
. BC2GM084179136 . O
. . O O

Effects BC2GM032107617 NNS O
were BC2GM032107617 VBD O
studied BC2GM032107617 VBN O
of BC2GM032107617 IN O
extremely BC2GM032107617 RB O
high-frequency BC2GM032107617 JJ O
electromagnetic BC2GM032107617 JJ O
radiation BC2GM032107617 NN O
( BC2GM032107617 ( O
EHF BC2GM032107617 NNP O
EMR BC2GM032107617 NNP O
) BC2GM032107617 ) O
on BC2GM032107617 IN O
indices BC2GM032107617 NNS O
for BC2GM032107617 IN O
the BC2GM032107617 DT O
immune BC2GM032107617 NN O
and BC2GM032107617 CC O
endocrine BC2GM032107617 JJ O
systems BC2GM032107617 NNS O
in BC2GM032107617 IN O
a BC2GM032107617 DT O
series BC2GM032107617 NN O
of BC2GM032107617 IN O
48 BC2GM032107617 CD O
patients BC2GM032107617 NNS O
presenting BC2GM032107617 VBG O
with BC2GM032107617 IN O
hyperplastic BC2GM032107617 JJ O
processes BC2GM032107617 NNS O
in BC2GM032107617 IN O
endometrium BC2GM032107617 NN O
. BC2GM032107617 . O
. . O O

The BC2GM083514944 DT O
slope BC2GM083514944 NN O
of BC2GM083514944 IN O
QD BC2GM083514944 NNP O
versus BC2GM083514944 NN O
QEMF BC2GM083514944 NNP O
for BC2GM083514944 IN O
the BC2GM083514944 DT O
four BC2GM083514944 CD O
tubes BC2GM083514944 NN O
was BC2GM083514944 VBD O
near BC2GM083514944 JJ O
unity BC2GM083514944 NN O
. BC2GM083514944 . O
. . O O

Risk BC2GM011611657 NN O
factors BC2GM011611657 NNS O
for BC2GM011611657 IN O
atherosclerosis BC2GM011611657 NN O
related BC2GM011611657 VBN O
to BC2GM011611657 TO O
nutrition BC2GM011611657 NN O
are BC2GM011611657 VBP O
hypercholesterolemia BC2GM011611657 VBN O
, BC2GM011611657 , O
hyperglycemia-diabetes BC2GM011611657 NNS O
, BC2GM011611657 , O
and BC2GM011611657 CC O
for BC2GM011611657 IN O
hypertension BC2GM011611657 NN O
, BC2GM011611657 , O
obesity BC2GM011611657 NN O
, BC2GM011611657 , O
high BC2GM011611657 JJ O
salt BC2GM011611657 NN O
intake BC2GM011611657 NN O
, BC2GM011611657 , O
and BC2GM011611657 CC O
excessive BC2GM011611657 JJ O
use BC2GM011611657 NN O
of BC2GM011611657 IN O
alcohol BC2GM011611657 NN O
. BC2GM011611657 . O
. . O O

Overexpression BC2GM040128143 NN O
of BC2GM040128143 IN O
either BC2GM040128143 DT O
Sp1 BC2GM040128143 NNP O
or BC2GM040128143 CC O
phosphorylated BC2GM040128143 VBN O
CREB BC2GM040128143 NNP O
transactivated BC2GM040128143 VBD O
the BC2GM040128143 DT O
mCgA BC2GM040128143 NN O
promoter BC2GM040128143 NN O
dose BC2GM040128143 NN O
dependently BC2GM040128143 RB O
, BC2GM040128143 , O
while BC2GM040128143 IN O
coexpression BC2GM040128143 NN O
of BC2GM040128143 IN O
both BC2GM040128143 DT O
transcription BC2GM040128143 NN O
factors BC2GM040128143 NNS O
resulted BC2GM040128143 VBD O
in BC2GM040128143 IN O
an BC2GM040128143 DT O
additive BC2GM040128143 JJ O
mCgA BC2GM040128143 NN O
promoter BC2GM040128143 NN O
response BC2GM040128143 NN O
. BC2GM040128143 . O
mCgA BC2GM040128143 NN O
-92 BC2GM040128143 NN O
to BC2GM040128143 TO O
-64 BC2GM040128143 VB O
bp BC2GM040128143 NN O
, BC2GM040128143 , O
comprising BC2GM040128143 VBG O
the BC2GM040128143 DT O
Sp1 BC2GM040128143 NNP O
/ BC2GM040128143 NNP O
Egr-1 BC2GM040128143 NNP O
site BC2GM040128143 NN O
and BC2GM040128143 CC O
the BC2GM040128143 DT O
CRE BC2GM040128143 NNP O
motif BC2GM040128143 NN O
, BC2GM040128143 , O
conferred BC2GM040128143 VBD O
gastrin BC2GM040128143 JJ O
responsiveness BC2GM040128143 NN O
to BC2GM040128143 TO O
a BC2GM040128143 DT O
heterologous BC2GM040128143 JJ O
thymidine BC2GM040128143 NN O
kinase BC2GM040128143 NN O
promoter BC2GM040128143 NN O
system BC2GM040128143 NN O
, BC2GM040128143 , O
and BC2GM040128143 CC O
therefore BC2GM040128143 RB O
functions BC2GM040128143 NNS O
as BC2GM040128143 IN O
a BC2GM040128143 DT O
`` BC2GM040128143 `` O
true BC2GM040128143 JJ O
'' BC2GM040128143 '' O
enhancer BC2GM040128143 NN O
element BC2GM040128143 NN O
. BC2GM040128143 . O
. . O O

There BC2GM055423276 EX O
is BC2GM055423276 VBZ O
little BC2GM055423276 JJ O
supportive BC2GM055423276 JJ O
evidence BC2GM055423276 NN O
that BC2GM055423276 IN O
ACE BC2GM055423276 NNP O
inhibitors BC2GM055423276 NNS O
( BC2GM055423276 ( O
captopril BC2GM055423276 NN O
or BC2GM055423276 CC O
enalapril BC2GM055423276 NN O
) BC2GM055423276 ) O
are BC2GM055423276 VBP O
teratogenic BC2GM055423276 JJ O
. BC2GM055423276 . O
. . O O

The BC2GM024261949 DT O
nucleotide BC2GM024261949 JJ O
sequence BC2GM024261949 NN O
of BC2GM024261949 IN O
a BC2GM024261949 DT O
PCR-amplified BC2GM024261949 JJ O
SMT3A BC2GM024261949 NNP O
genomic BC2GM024261949 JJ O
DNA BC2GM024261949 NNP O
fragment BC2GM024261949 NN O
was BC2GM024261949 VBD O
found BC2GM024261949 VBN O
to BC2GM024261949 TO O
be BC2GM024261949 VB O
identical BC2GM024261949 JJ O
to BC2GM024261949 TO O
that BC2GM024261949 DT O
of BC2GM024261949 IN O
SMT3A BC2GM024261949 NNP O
cDNA BC2GM024261949 NN O
, BC2GM024261949 , O
indicating BC2GM024261949 VBG O
the BC2GM024261949 DT O
absence BC2GM024261949 NN O
of BC2GM024261949 IN O
intron BC2GM024261949 NN O
( BC2GM024261949 ( O
s BC2GM024261949 NN O
) BC2GM024261949 ) O
in BC2GM024261949 IN O
its BC2GM024261949 PRP$ O
protein BC2GM024261949 NN O
coding BC2GM024261949 VBG O
region BC2GM024261949 NN O
. BC2GM024261949 . O
. . O O

These BC2GM009218919 DT O
mutants BC2GM009218919 NNS O
, BC2GM009218919 , O
assayed BC2GM009218919 VBN O
by BC2GM009218919 IN O
injection BC2GM009218919 NN O
into BC2GM009218919 IN O
Xenopus BC2GM009218919 NNP O
oocyte BC2GM009218919 MD O
nuclei BC2GM009218919 RB O
, BC2GM009218919 , O
delimit BC2GM009218919 VBP O
the BC2GM009218919 DT O
promoter BC2GM009218919 NN O
to BC2GM009218919 TO O
36 BC2GM009218919 CD O
bp BC2GM009218919 NN O
of BC2GM009218919 IN O
DNA BC2GM009218919 NNP O
upstream BC2GM009218919 NN O
of BC2GM009218919 IN O
the BC2GM009218919 DT O
cap BC2GM009218919 NN O
site BC2GM009218919 NN O
and BC2GM009218919 CC O
73 BC2GM009218919 CD O
bp BC2GM009218919 NN O
of BC2GM009218919 IN O
the BC2GM009218919 DT O
untranslated BC2GM009218919 JJ O
mRNA BC2GM009218919 NN O
leader BC2GM009218919 NN O
. BC2GM009218919 . O
. . O O

These BC2GM023906400 DT O
three BC2GM023906400 CD O
groups BC2GM023906400 NNS O
were BC2GM023906400 VBD O
further BC2GM023906400 RB O
examined BC2GM023906400 VBN O
with BC2GM023906400 IN O
regard BC2GM023906400 NN O
to BC2GM023906400 TO O
the BC2GM023906400 DT O
modulation BC2GM023906400 NN O
of BC2GM023906400 IN O
discharge BC2GM023906400 NN O
rate BC2GM023906400 NN O
i BC2GM023906400 NN O
) BC2GM023906400 ) O
during BC2GM023906400 IN O
motor BC2GM023906400 NN O
activity BC2GM023906400 NN O
in BC2GM023906400 IN O
W BC2GM023906400 NNP O
, BC2GM023906400 , O
ii BC2GM023906400 NN O
) BC2GM023906400 ) O
at BC2GM023906400 IN O
the BC2GM023906400 DT O
transitional BC2GM023906400 JJ O
phase BC2GM023906400 NN O
from BC2GM023906400 IN O
SS BC2GM023906400 NNP O
to BC2GM023906400 TO O
paradoxical BC2GM023906400 JJ O
sleep BC2GM023906400 NN O
( BC2GM023906400 ( O
PS BC2GM023906400 NNP O
) BC2GM023906400 ) O
, BC2GM023906400 , O
iii BC2GM023906400 JJ O
) BC2GM023906400 ) O
during BC2GM023906400 IN O
rapid BC2GM023906400 JJ O
eye BC2GM023906400 NN O
movements BC2GM023906400 NNS O
( BC2GM023906400 ( O
REMs BC2GM023906400 NNP O
) BC2GM023906400 ) O
in BC2GM023906400 IN O
PS BC2GM023906400 NNP O
, BC2GM023906400 , O
and BC2GM023906400 CC O
iv BC2GM023906400 NN O
) BC2GM023906400 ) O
following BC2GM023906400 VBG O
electrical BC2GM023906400 JJ O
stimulation BC2GM023906400 NN O
of BC2GM023906400 IN O
the BC2GM023906400 DT O
midbrain BC2GM023906400 NN O
reticular BC2GM023906400 JJ O
formation BC2GM023906400 NN O
( BC2GM023906400 ( O
MRF BC2GM023906400 NNP O
) BC2GM023906400 ) O
. BC2GM023906400 . O
. . O O

Level BC2GM095775239 NNP O
II BC2GM095775239 NNP O
mosaicism BC2GM095775239 NN O
occurred BC2GM095775239 VBD O
in BC2GM095775239 IN O
0.9 BC2GM095775239 CD O
per BC2GM095775239 IN O
cent BC2GM095775239 NN O
of BC2GM095775239 IN O
CVS BC2GM095775239 NNP O
mesenchyme BC2GM095775239 NN O
and BC2GM095775239 CC O
1.5 BC2GM095775239 CD O
per BC2GM095775239 IN O
cent BC2GM095775239 NN O
of BC2GM095775239 IN O
amniotic BC2GM095775239 JJ O
fluid BC2GM095775239 NN O
cultures BC2GM095775239 NNS O
and BC2GM095775239 CC O
in BC2GM095775239 IN O
general BC2GM095775239 JJ O
was BC2GM095775239 VBD O
not BC2GM095775239 RB O
perceived BC2GM095775239 VBN O
to BC2GM095775239 TO O
be BC2GM095775239 VB O
of BC2GM095775239 IN O
sufficient BC2GM095775239 JJ O
concern BC2GM095775239 NN O
to BC2GM095775239 TO O
warrant BC2GM095775239 VB O
cytogenetic BC2GM095775239 JJ O
follow-up BC2GM095775239 JJ O
studies BC2GM095775239 NNS O
. BC2GM095775239 . O
. . O O

The BC2GM043225423 DT O
mammalian BC2GM043225423 JJ O
UPR BC2GM043225423 NNP O
is BC2GM043225423 VBZ O
mediated BC2GM043225423 VBN O
by BC2GM043225423 IN O
the BC2GM043225423 DT O
cis-acting BC2GM043225423 JJ O
ER BC2GM043225423 NNP O
stress BC2GM043225423 NN O
response BC2GM043225423 NN O
element BC2GM043225423 NN O
consisting BC2GM043225423 VBG O
of BC2GM043225423 IN O
19 BC2GM043225423 CD O
nt BC2GM043225423 NNS O
( BC2GM043225423 ( O
CCAATN BC2GM043225423 NNP O
( BC2GM043225423 ( O
9 BC2GM043225423 CD O
) BC2GM043225423 ) O
CCACG BC2GM043225423 NNP O
) BC2GM043225423 ) O
, BC2GM043225423 , O
the BC2GM043225423 DT O
CCACG BC2GM043225423 NNP O
part BC2GM043225423 NN O
of BC2GM043225423 IN O
which BC2GM043225423 WDT O
is BC2GM043225423 VBZ O
considered BC2GM043225423 VBN O
to BC2GM043225423 TO O
provide BC2GM043225423 VB O
specificity BC2GM043225423 NN O
. BC2GM043225423 . O
. . O O

This BC2GM011826716 DT O
seems BC2GM011826716 VBZ O
to BC2GM011826716 TO O
take BC2GM011826716 VB O
place BC2GM011826716 NN O
in BC2GM011826716 IN O
the BC2GM011826716 DT O
same BC2GM011826716 JJ O
nuclear BC2GM011826716 JJ O
compartment BC2GM011826716 NN O
as BC2GM011826716 IN O
normal BC2GM011826716 JJ O
cis BC2GM011826716 NN O
splicing BC2GM011826716 NN O
and BC2GM011826716 CC O
proceeds BC2GM011826716 NNS O
through BC2GM011826716 IN O
Y-branched BC2GM011826716 JJ O
intermediates BC2GM011826716 NNS O
analogous BC2GM011826716 JJ O
to BC2GM011826716 TO O
the BC2GM011826716 DT O
lariats BC2GM011826716 NNS O
formed BC2GM011826716 VBN O
in BC2GM011826716 IN O
cis BC2GM011826716 NN O
splicing BC2GM011826716 NN O
. BC2GM011826716 . O
. . O O

We BC2GM020267089 PRP O
functionally BC2GM020267089 RB O
characterised BC2GM020267089 VBD O
AtXPO1 BC2GM020267089 NNP O
by BC2GM020267089 IN O
its BC2GM020267089 PRP$ O
interaction BC2GM020267089 NN O
with BC2GM020267089 IN O
NESs BC2GM020267089 NNP O
of BC2GM020267089 IN O
animal BC2GM020267089 NN O
and BC2GM020267089 CC O
plant BC2GM020267089 NN O
proteins BC2GM020267089 NNS O
, BC2GM020267089 , O
which BC2GM020267089 WDT O
is BC2GM020267089 VBZ O
inhibited BC2GM020267089 VBN O
by BC2GM020267089 IN O
the BC2GM020267089 DT O
cytotoxin BC2GM020267089 NN O
leptomycin BC2GM020267089 NN O
B BC2GM020267089 NNP O
( BC2GM020267089 ( O
LMB BC2GM020267089 NNP O
) BC2GM020267089 ) O
, BC2GM020267089 , O
and BC2GM020267089 CC O
also BC2GM020267089 RB O
by BC2GM020267089 IN O
its BC2GM020267089 PRP$ O
interaction BC2GM020267089 NN O
with BC2GM020267089 IN O
the BC2GM020267089 DT O
small BC2GM020267089 JJ O
GTPase BC2GM020267089 NNP O
Ran1 BC2GM020267089 NNP O
in BC2GM020267089 IN O
the BC2GM020267089 DT O
yeast BC2GM020267089 NN O
two-hybrid BC2GM020267089 JJ O
system BC2GM020267089 NN O
. BC2GM020267089 . O
. . O O

Coimmunoprecipitation BC2GM049247911 NN O
analysis BC2GM049247911 NN O
suggests BC2GM049247911 VBZ O
that BC2GM049247911 IN O
these BC2GM049247911 DT O
residues BC2GM049247911 NNS O
likely BC2GM049247911 RB O
contribute BC2GM049247911 VBP O
to BC2GM049247911 TO O
the BC2GM049247911 DT O
multimerization BC2GM049247911 NN O
function BC2GM049247911 NN O
required BC2GM049247911 VBN O
for BC2GM049247911 IN O
homomeric BC2GM049247911 JJ O
complex BC2GM049247911 JJ O
formation BC2GM049247911 NN O
or BC2GM049247911 CC O
heteromeric BC2GM049247911 JJ O
complex BC2GM049247911 JJ O
formation BC2GM049247911 NN O
with BC2GM049247911 IN O
p50 BC2GM049247911 NN O
in BC2GM049247911 IN O
that BC2GM049247911 DT O
no BC2GM049247911 DT O
association BC2GM049247911 NN O
of BC2GM049247911 IN O
p65 BC2GM049247911 NN O
delta BC2GM049247911 NN O
with BC2GM049247911 IN O
itself BC2GM049247911 PRP O
or BC2GM049247911 CC O
with BC2GM049247911 IN O
p50 BC2GM049247911 NN O
was BC2GM049247911 VBD O
evident BC2GM049247911 JJ O
. BC2GM049247911 . O
. . O O

Sonography BC2GM028865518 NNP O
depicted BC2GM028865518 VBD O
the BC2GM028865518 DT O
true BC2GM028865518 JJ O
morphology BC2GM028865518 NN O
of BC2GM028865518 IN O
these BC2GM028865518 DT O
cystic BC2GM028865518 JJ O
lesions BC2GM028865518 NNS O
more BC2GM028865518 RBR O
clearly BC2GM028865518 RB O
than BC2GM028865518 IN O
CT BC2GM028865518 NNP O
, BC2GM028865518 , O
and BC2GM028865518 CC O
the BC2GM028865518 DT O
sonographic BC2GM028865518 JJ O
findings BC2GM028865518 NNS O
virtually BC2GM028865518 RB O
excluded BC2GM028865518 VBD O
uncomplicated BC2GM028865518 JJ O
hepatic BC2GM028865518 JJ O
cyst BC2GM028865518 NN O
as BC2GM028865518 IN O
a BC2GM028865518 DT O
diagnosis BC2GM028865518 NN O
. BC2GM028865518 . O
. . O O

The BC2GM021990815 DT O
prototype BC2GM021990815 NN O
now BC2GM021990815 RB O
structures BC2GM021990815 VBZ O
oncology-related BC2GM021990815 JJ O
information BC2GM021990815 NN O
available BC2GM021990815 JJ O
on BC2GM021990815 IN O
the BC2GM021990815 DT O
Internet BC2GM021990815 NNP O
and BC2GM021990815 CC O
also BC2GM021990815 RB O
places BC2GM021990815 NNS O
resources BC2GM021990815 NNS O
maintained BC2GM021990815 VBD O
locally BC2GM021990815 RB O
at BC2GM021990815 IN O
users BC2GM021990815 NNS O
' BC2GM021990815 POS O
disposal BC2GM021990815 NN O
. BC2GM021990815 . O
. . O O

The BC2GM025821174 DT O
STS BC2GM025821174 NNP O
sequence BC2GM025821174 NN O
WI-14920 BC2GM025821174 NNP O
is BC2GM025821174 VBZ O
in BC2GM025821174 IN O
fact BC2GM025821174 NN O
derived BC2GM025821174 VBN O
from BC2GM025821174 IN O
the BC2GM025821174 DT O
3'-untranslated BC2GM025821174 JJ O
region BC2GM025821174 NN O
of BC2GM025821174 IN O
the BC2GM025821174 DT O
human BC2GM025821174 JJ O
PUNC BC2GM025821174 NNP O
gene BC2GM025821174 NN O
. BC2GM025821174 . O
. . O O

Superovulation BC2GM023079382 NN O
with BC2GM023079382 IN O
intrauterine BC2GM023079382 JJ O
insemination BC2GM023079382 NN O
( BC2GM023079382 ( O
SO-IUI BC2GM023079382 NNP O
) BC2GM023079382 ) O
has BC2GM023079382 VBZ O
been BC2GM023079382 VBN O
suggested BC2GM023079382 VBN O
as BC2GM023079382 IN O
an BC2GM023079382 DT O
alternative BC2GM023079382 NN O
to BC2GM023079382 TO O
gamete BC2GM023079382 VB O
intrafallopian BC2GM023079382 JJ O
transfer BC2GM023079382 NN O
( BC2GM023079382 ( O
GIFT BC2GM023079382 NNP O
) BC2GM023079382 ) O
, BC2GM023079382 , O
despite BC2GM023079382 IN O
the BC2GM023079382 DT O
absence BC2GM023079382 NN O
of BC2GM023079382 IN O
controlled BC2GM023079382 VBN O
or BC2GM023079382 CC O
comparative BC2GM023079382 JJ O
trials BC2GM023079382 NNS O
. BC2GM023079382 . O
. . O O

Magnetic BC2GM046486714 JJ O
force BC2GM046486714 NN O
and BC2GM046486714 CC O
torque BC2GM046486714 NN O
at BC2GM046486714 IN O
1.5 BC2GM046486714 CD O
T BC2GM046486714 NNP O
did BC2GM046486714 VBD O
not BC2GM046486714 RB O
dislodge BC2GM046486714 VB O
the BC2GM046486714 DT O
GF BC2GM046486714 NNP O
or BC2GM046486714 CC O
result BC2GM046486714 NN O
in BC2GM046486714 IN O
perforation BC2GM046486714 NN O
of BC2GM046486714 IN O
canine BC2GM046486714 NN O
IVC BC2GM046486714 NNP O
by BC2GM046486714 IN O
the BC2GM046486714 DT O
GF BC2GM046486714 NNP O
. BC2GM046486714 . O
. . O O

Binding BC2GM057764341 VBG O
sites BC2GM057764341 NNS O
were BC2GM057764341 VBD O
mapped BC2GM057764341 VBN O
for BC2GM057764341 IN O
each BC2GM057764341 DT O
factor BC2GM057764341 NN O
. BC2GM057764341 . O
. . O O

Paradoxically BC2GM000522836 RB O
, BC2GM000522836 , O
loop BC2GM000522836 VBD O
3i BC2GM000522836 CD O
from BC2GM000522836 IN O
the BC2GM000522836 DT O
M1Ach-muscarinic BC2GM000522836 NNP O
receptor BC2GM000522836 NN O
also BC2GM000522836 RB O
maximally BC2GM000522836 RB O
inhibited BC2GM000522836 JJ O
GnRH BC2GM000522836 NNP O
agonist-stimulated BC2GM000522836 JJ O
cAMP BC2GM000522836 NN O
accumulation BC2GM000522836 NN O
and BC2GM000522836 CC O
PRL BC2GM000522836 NNP O
release BC2GM000522836 NN O
by BC2GM000522836 IN O
40 BC2GM000522836 CD O
% BC2GM000522836 NN O
( BC2GM000522836 ( O
both BC2GM000522836 DT O
effects BC2GM000522836 NNS O
mediated BC2GM000522836 VBN O
through BC2GM000522836 IN O
activation BC2GM000522836 NN O
of BC2GM000522836 IN O
the BC2GM000522836 DT O
Gs BC2GM000522836 NNP O
protein BC2GM000522836 NN O
) BC2GM000522836 ) O
. BC2GM000522836 . O
. . O O

Conversion BC2GM023833000 NN O
of BC2GM023833000 IN O
glucose BC2GM023833000 JJ O
phosphate-14C BC2GM023833000 JJ O
to BC2GM023833000 TO O
glucose-14C BC2GM023833000 JJ O
in BC2GM023833000 IN O
passage BC2GM023833000 NN O
through BC2GM023833000 IN O
human BC2GM023833000 JJ O
brain BC2GM023833000 NN O
in BC2GM023833000 IN O
vivo BC2GM023833000 NN O
. BC2GM023833000 . O
. . O O

Usher BC2GM037491850 NNP O
syndrome BC2GM037491850 VBD O
1C BC2GM037491850 CD O
( BC2GM037491850 ( O
USH1C BC2GM037491850 NNP O
) BC2GM037491850 ) O
is BC2GM037491850 VBZ O
a BC2GM037491850 DT O
congenital BC2GM037491850 JJ O
condition BC2GM037491850 NN O
manifesting BC2GM037491850 VBG O
profound BC2GM037491850 JJ O
hearing BC2GM037491850 NN O
loss BC2GM037491850 NN O
, BC2GM037491850 , O
the BC2GM037491850 DT O
absence BC2GM037491850 NN O
of BC2GM037491850 IN O
vestibular BC2GM037491850 JJ O
function BC2GM037491850 NN O
, BC2GM037491850 , O
and BC2GM037491850 CC O
eventual BC2GM037491850 JJ O
retinal BC2GM037491850 JJ O
degeneration BC2GM037491850 NN O
. BC2GM037491850 . O
. . O O

For BC2GM050531748 IN O
the BC2GM050531748 DT O
first BC2GM050531748 JJ O
time BC2GM050531748 NN O
also BC2GM050531748 RB O
a BC2GM050531748 DT O
genomic BC2GM050531748 JJ O
sequence BC2GM050531748 NN O
for BC2GM050531748 IN O
a BC2GM050531748 DT O
red BC2GM050531748 JJ O
algal BC2GM050531748 NN O
lhc BC2GM050531748 NN O
gene BC2GM050531748 NN O
is BC2GM050531748 VBZ O
presented BC2GM050531748 VBN O
. BC2GM050531748 . O
. . O O

In BC2GM000772761 IN O
this BC2GM000772761 DT O
report BC2GM000772761 NN O
, BC2GM000772761 , O
several BC2GM000772761 JJ O
health BC2GM000772761 NN O
behaviors BC2GM000772761 NNS O
were BC2GM000772761 VBD O
investigated BC2GM000772761 VBN O
in BC2GM000772761 IN O
relation BC2GM000772761 NN O
to BC2GM000772761 TO O
maintaining BC2GM000772761 VBG O
mobility BC2GM000772761 NN O
during BC2GM000772761 IN O
4 BC2GM000772761 CD O
years BC2GM000772761 NNS O
of BC2GM000772761 IN O
follow-up BC2GM000772761 NN O
among BC2GM000772761 IN O
6,981 BC2GM000772761 CD O
men BC2GM000772761 NNS O
and BC2GM000772761 CC O
women BC2GM000772761 NNS O
aged BC2GM000772761 VBN O
65 BC2GM000772761 CD O
years BC2GM000772761 NNS O
and BC2GM000772761 CC O
older BC2GM000772761 JJR O
with BC2GM000772761 IN O
intact BC2GM000772761 JJ O
mobility BC2GM000772761 NN O
at BC2GM000772761 IN O
baseline BC2GM000772761 NN O
between BC2GM000772761 IN O
1981 BC2GM000772761 CD O
and BC2GM000772761 CC O
1983 BC2GM000772761 CD O
who BC2GM000772761 WP O
lived BC2GM000772761 VBD O
in BC2GM000772761 IN O
one BC2GM000772761 CD O
of BC2GM000772761 IN O
three BC2GM000772761 CD O
communities BC2GM000772761 NNS O
: BC2GM000772761 : O
East BC2GM000772761 NNP O
Boston BC2GM000772761 NNP O
, BC2GM000772761 , O
Massachusetts BC2GM000772761 NNP O
; BC2GM000772761 : O
Iowa BC2GM000772761 NNP O
and BC2GM000772761 CC O
Washington BC2GM000772761 NNP O
counties BC2GM000772761 NNS O
, BC2GM000772761 , O
Iowa BC2GM000772761 NNP O
; BC2GM000772761 : O
and BC2GM000772761 CC O
New BC2GM000772761 NNP O
Haven BC2GM000772761 NNP O
, BC2GM000772761 , O
Connecticut BC2GM000772761 NNP O
. BC2GM000772761 . O
. . O O

The BC2GM025563582 DT O
Mer1 BC2GM025563582 NNP O
protein BC2GM025563582 NN O
contains BC2GM025563582 VBZ O
the BC2GM025563582 DT O
KH BC2GM025563582 NNP O
motif BC2GM025563582 NN O
found BC2GM025563582 VBD O
in BC2GM025563582 IN O
some BC2GM025563582 DT O
RNA-binding BC2GM025563582 JJ O
proteins BC2GM025563582 NNS O
, BC2GM025563582 , O
and BC2GM025563582 CC O
RNA BC2GM025563582 NNP O
gel BC2GM025563582 VBP O
mobility BC2GM025563582 NN O
shift BC2GM025563582 NN O
assays BC2GM025563582 NNS O
demonstrate BC2GM025563582 VBP O
that BC2GM025563582 IN O
Mer1 BC2GM025563582 NNP O
binds BC2GM025563582 VBZ O
specifically BC2GM025563582 RB O
to BC2GM025563582 TO O
MER2 BC2GM025563582 NNP O
RNA BC2GM025563582 NNP O
. BC2GM025563582 . O
. . O O

The BC2GM018717311 DT O
Robert BC2GM018717311 NNP O
Wood BC2GM018717311 NNP O
Johnson BC2GM018717311 NNP O
Foundation BC2GM018717311 NNP O
: BC2GM018717311 : O
billion BC2GM018717311 CD O
dollar BC2GM018717311 NN O
force BC2GM018717311 NN O
for BC2GM018717311 IN O
health-care BC2GM018717311 JJ O
change BC2GM018717311 NN O
. BC2GM018717311 . O
. . O O

Glutathione BC2GM083916737 NNP O
reductase BC2GM083916737 NN O
activities BC2GM083916737 NNS O
in BC2GM083916737 IN O
liver BC2GM083916737 NN O
, BC2GM083916737 , O
kidney BC2GM083916737 NN O
, BC2GM083916737 , O
lung BC2GM083916737 NN O
, BC2GM083916737 , O
and BC2GM083916737 CC O
brain BC2GM083916737 NN O
were BC2GM083916737 VBD O
not BC2GM083916737 RB O
affected BC2GM083916737 VBN O
by BC2GM083916737 IN O
diet BC2GM083916737 NN O
. BC2GM083916737 . O
. . O O

Measurement BC2GM038824735 NN O
of BC2GM038824735 IN O
the BC2GM038824735 DT O
spectral BC2GM038824735 JJ O
sensitivity BC2GM038824735 NN O
and BC2GM038824735 CC O
the BC2GM038824735 DT O
ERG BC2GM038824735 NNP O
can BC2GM038824735 MD O
thus BC2GM038824735 RB O
help BC2GM038824735 VB O
in BC2GM038824735 IN O
the BC2GM038824735 DT O
diagnosis BC2GM038824735 NN O
of BC2GM038824735 IN O
these BC2GM038824735 DT O
three BC2GM038824735 CD O
hereditary BC2GM038824735 NN O
diseases BC2GM038824735 NNS O
. BC2GM038824735 . O
. . O O

Pulse BC2GM082666535 JJ O
monitors BC2GM082666535 NNS O
in BC2GM082666535 IN O
outpatient BC2GM082666535 JJ O
dental BC2GM082666535 JJ O
anaesthesia BC2GM082666535 NN O
. BC2GM082666535 . O
. . O O

The BC2GM072322164 DT O
homeodomain BC2GM072322164 NN O
transcription BC2GM072322164 NN O
factor BC2GM072322164 NN O
CDP BC2GM072322164 NNP O
/ BC2GM072322164 NNP O
cut BC2GM072322164 VBD O
interacts BC2GM072322164 NNS O
with BC2GM072322164 IN O
the BC2GM072322164 DT O
cell BC2GM072322164 NN O
cycle BC2GM072322164 NN O
regulatory BC2GM072322164 JJ O
element BC2GM072322164 NN O
of BC2GM072322164 IN O
histone BC2GM072322164 NN O
H4 BC2GM072322164 NNP O
genes BC2GM072322164 NNS O
packaged BC2GM072322164 VBD O
into BC2GM072322164 IN O
nucleosomes BC2GM072322164 NNS O
. BC2GM072322164 . O
. . O O

Efficacy BC2GM057454173 NN O
of BC2GM057454173 IN O
probiotic BC2GM057454173 JJ O
feed BC2GM057454173 NN O
additives BC2GM057454173 NNS O
: BC2GM057454173 : O
guidelines BC2GM057454173 NNS O
for BC2GM057454173 IN O
the BC2GM057454173 DT O
evaluation BC2GM057454173 NN O
of BC2GM057454173 IN O
the BC2GM057454173 DT O
efficiency BC2GM057454173 NN O
of BC2GM057454173 IN O
microorganisms BC2GM057454173 NNS O
in BC2GM057454173 IN O
dogs BC2GM057454173 NNS O
, BC2GM057454173 , O
cats BC2GM057454173 NNS O
, BC2GM057454173 , O
and BC2GM057454173 CC O
horses BC2GM057454173 NNS O
] BC2GM057454173 NNP O
Probiotic BC2GM057454173 NNP O
microorganisms BC2GM057454173 NNS O
are BC2GM057454173 VBP O
frequently BC2GM057454173 RB O
in BC2GM057454173 IN O
use BC2GM057454173 NN O
as BC2GM057454173 IN O
feed BC2GM057454173 NN O
additives BC2GM057454173 NNS O
for BC2GM057454173 IN O
farm BC2GM057454173 NN O
and BC2GM057454173 CC O
pet BC2GM057454173 NN O
animals BC2GM057454173 NNS O
. BC2GM057454173 . O
. . O O

A BC2GM063896502 DT O
phylogenetic BC2GM063896502 JJ O
comparison BC2GM063896502 NN O
of BC2GM063896502 IN O
32 BC2GM063896502 CD O
species BC2GM063896502 NNS O
showed BC2GM063896502 VBD O
minor BC2GM063896502 JJ O
differences BC2GM063896502 NNS O
in BC2GM063896502 IN O
the BC2GM063896502 DT O
apoB BC2GM063896502 NN O
mRNA BC2GM063896502 NN O
sequence BC2GM063896502 NN O
, BC2GM063896502 , O
and BC2GM063896502 CC O
the BC2GM063896502 DT O
apoB BC2GM063896502 JJ O
mRNA BC2GM063896502 NN O
from BC2GM063896502 IN O
31 BC2GM063896502 CD O
species BC2GM063896502 NNS O
was BC2GM063896502 VBD O
robustly BC2GM063896502 RB O
edited BC2GM063896502 VBN O
in BC2GM063896502 IN O
vitro BC2GM063896502 NN O
. BC2GM063896502 . O
. . O O

They BC2GM088129513 PRP O
represent BC2GM088129513 VBP O
a BC2GM088129513 DT O
physiologically BC2GM088129513 RB O
more BC2GM088129513 RBR O
meaningful BC2GM088129513 JJ O
pattern BC2GM088129513 NN O
than BC2GM088129513 IN O
the BC2GM088129513 DT O
arithmetic BC2GM088129513 JJ O
mean BC2GM088129513 NN O
with BC2GM088129513 IN O
standard BC2GM088129513 JJ O
deviation BC2GM088129513 NN O
. BC2GM088129513 . O
. . O O

The BC2GM096080543 DT O
recovery BC2GM096080543 NN O
of BC2GM096080543 IN O
xanthomegnin BC2GM096080543 NN O
added BC2GM096080543 VBN O
to BC2GM096080543 TO O
corn BC2GM096080543 NN O
samples BC2GM096080543 NNS O
at BC2GM096080543 IN O
levels BC2GM096080543 NNS O
of BC2GM096080543 IN O
0.75 BC2GM096080543 CD O
-- BC2GM096080543 : O
9.6 BC2GM096080543 CD O
mg BC2GM096080543 NN O
/ BC2GM096080543 NNP O
kg BC2GM096080543 VBD O
averaged BC2GM096080543 VBD O
41 BC2GM096080543 CD O
% BC2GM096080543 NN O
with BC2GM096080543 IN O
a BC2GM096080543 DT O
coefficient BC2GM096080543 NN O
of BC2GM096080543 IN O
variation BC2GM096080543 NN O
of BC2GM096080543 IN O
25 BC2GM096080543 CD O
% BC2GM096080543 NN O
. BC2GM096080543 . O
. . O O

From BC2GM003217917 IN O
a BC2GM003217917 DT O
chromosomal BC2GM003217917 JJ O
cosmid BC2GM003217917 NN O
library BC2GM003217917 NN O
of BC2GM003217917 IN O
Streptomyces BC2GM003217917 NNP O
argillaceus BC2GM003217917 NN O
, BC2GM003217917 , O
a BC2GM003217917 DT O
Mtm BC2GM003217917 NNP O
producer BC2GM003217917 NN O
, BC2GM003217917 , O
a BC2GM003217917 DT O
clone BC2GM003217917 NN O
( BC2GM003217917 ( O
cosAR7 BC2GM003217917 NN O
) BC2GM003217917 ) O
was BC2GM003217917 VBD O
isolated BC2GM003217917 VBN O
by BC2GM003217917 IN O
homology BC2GM003217917 NN O
to BC2GM003217917 TO O
the BC2GM003217917 DT O
actI BC2GM003217917 NN O
/ BC2GM003217917 NNP O
III BC2GM003217917 NNP O
region BC2GM003217917 NN O
of BC2GM003217917 IN O
S. BC2GM003217917 NNP O
coelicolor BC2GM003217917 NN O
and BC2GM003217917 CC O
the BC2GM003217917 DT O
strDEM BC2GM003217917 JJ O
genes BC2GM003217917 NNS O
of BC2GM003217917 IN O
S. BC2GM003217917 NNP O
griseus BC2GM003217917 NN O
. BC2GM003217917 . O
. . O O

Polyglutamine-containing BC2GM006411333 JJ O
protein BC2GM006411333 NN O
fragments BC2GM006411333 NNS O
have BC2GM006411333 VBP O
been BC2GM006411333 VBN O
shown BC2GM006411333 VBN O
to BC2GM006411333 TO O
accumulate BC2GM006411333 VB O
as BC2GM006411333 IN O
aggregates BC2GM006411333 NNS O
in BC2GM006411333 IN O
the BC2GM006411333 DT O
nucleus BC2GM006411333 NN O
and BC2GM006411333 CC O
in BC2GM006411333 IN O
the BC2GM006411333 DT O
cytoplasm BC2GM006411333 NN O
, BC2GM006411333 , O
and BC2GM006411333 CC O
to BC2GM006411333 TO O
induce BC2GM006411333 VB O
cell BC2GM006411333 NN O
death BC2GM006411333 NN O
when BC2GM006411333 WRB O
expressed BC2GM006411333 VBN O
in BC2GM006411333 IN O
cultured BC2GM006411333 JJ O
cells BC2GM006411333 NNS O
, BC2GM006411333 , O
leading BC2GM006411333 VBG O
to BC2GM006411333 TO O
the BC2GM006411333 DT O
proposal BC2GM006411333 NN O
that BC2GM006411333 IN O
polyglutamine BC2GM006411333 JJ O
aggregation BC2GM006411333 NN O
is BC2GM006411333 VBZ O
an BC2GM006411333 DT O
important BC2GM006411333 JJ O
step BC2GM006411333 NN O
in BC2GM006411333 IN O
the BC2GM006411333 DT O
pathogenesis BC2GM006411333 NN O
. BC2GM006411333 . O
. . O O

Our BC2GM044501927 PRP$ O
case BC2GM044501927 NN O
, BC2GM044501927 , O
however BC2GM044501927 RB O
, BC2GM044501927 , O
had BC2GM044501927 VBD O
no BC2GM044501927 DT O
histologic BC2GM044501927 JJ O
evidence BC2GM044501927 NN O
of BC2GM044501927 IN O
malignancy BC2GM044501927 NN O
, BC2GM044501927 , O
no BC2GM044501927 DT O
serum BC2GM044501927 NN O
alpha BC2GM044501927 RB O
fetoprotein BC2GM044501927 RB O
at BC2GM044501927 IN O
7 BC2GM044501927 CD O
months BC2GM044501927 NNS O
of BC2GM044501927 IN O
age BC2GM044501927 NN O
, BC2GM044501927 , O
and BC2GM044501927 CC O
no BC2GM044501927 DT O
recurrence BC2GM044501927 NN O
at BC2GM044501927 IN O
1 BC2GM044501927 CD O
years BC2GM044501927 NNS O
. BC2GM044501927 . O
. . O O

Analysis BC2GM028069237 NN O
of BC2GM028069237 IN O
pseudo BC2GM028069237 NN O
VH BC2GM028069237 NNP O
gene BC2GM028069237 NN O
segment BC2GM028069237 NN O
recombination BC2GM028069237 NN O
products BC2GM028069237 NNS O
reveals BC2GM028069237 VBZ O
no BC2GM028069237 DT O
bias BC2GM028069237 NN O
in BC2GM028069237 IN O
D BC2GM028069237 NNP O
gene BC2GM028069237 NN O
segment BC2GM028069237 NN O
reading BC2GM028069237 VBG O
frame BC2GM028069237 JJ O
utilization BC2GM028069237 NN O
. BC2GM028069237 . O
. . O O

DESIGN BC2GM054764143 NNP O
-- BC2GM054764143 : O
A BC2GM054764143 DT O
randomised BC2GM054764143 JJ O
double BC2GM054764143 JJ O
blind BC2GM054764143 NN O
placebo BC2GM054764143 NN O
controlled BC2GM054764143 VBD O
parallel BC2GM054764143 JJ O
arm BC2GM054764143 NN O
trial BC2GM054764143 NN O
. BC2GM054764143 . O
. . O O

Binding BC2GM027985903 NNP O
of BC2GM027985903 IN O
transformed BC2GM027985903 JJ O
Ah BC2GM027985903 NNP O
receptor BC2GM027985903 NN O
complex BC2GM027985903 NN O
to BC2GM027985903 TO O
a BC2GM027985903 DT O
dioxin BC2GM027985903 NN O
responsive BC2GM027985903 JJ O
transcriptional BC2GM027985903 JJ O
enhancer BC2GM027985903 NN O
: BC2GM027985903 : O
evidence BC2GM027985903 NN O
for BC2GM027985903 IN O
two BC2GM027985903 CD O
distinct BC2GM027985903 JJ O
heteromeric BC2GM027985903 JJ O
DNA-binding BC2GM027985903 NN O
forms BC2GM027985903 NNS O
. BC2GM027985903 . O
. . O O

( BC2GM051172236 ( O
control BC2GM051172236 VB O
hearts BC2GM051172236 NNS O
) BC2GM051172236 ) O
. BC2GM051172236 . O
. . O O

This BC2GM068538767 DT O
report BC2GM068538767 NN O
describes BC2GM068538767 VBZ O
the BC2GM068538767 DT O
isolation BC2GM068538767 NN O
and BC2GM068538767 CC O
recombinant BC2GM068538767 JJ O
expression BC2GM068538767 NN O
of BC2GM068538767 IN O
a BC2GM068538767 DT O
cDNA BC2GM068538767 NN O
clone BC2GM068538767 NN O
encoding BC2GM068538767 VBG O
HER4 BC2GM068538767 NNP O
, BC2GM068538767 , O
the BC2GM068538767 DT O
fourth BC2GM068538767 JJ O
member BC2GM068538767 NN O
of BC2GM068538767 IN O
the BC2GM068538767 DT O
human BC2GM068538767 JJ O
epidermal BC2GM068538767 JJ O
growth BC2GM068538767 NN O
factor BC2GM068538767 NN O
receptor BC2GM068538767 NN O
( BC2GM068538767 ( O
EGFR BC2GM068538767 NNP O
) BC2GM068538767 ) O
family BC2GM068538767 NN O
. BC2GM068538767 . O
. . O O

Cefminox BC2GM008125101 NN O
shows BC2GM008125101 NNS O
greater BC2GM008125101 JJR O
in BC2GM008125101 IN O
vivo BC2GM008125101 NN O
activity BC2GM008125101 NN O
than BC2GM008125101 IN O
that BC2GM008125101 DT O
expected BC2GM008125101 VBN O
for BC2GM008125101 IN O
the BC2GM008125101 DT O
MICs BC2GM008125101 NNP O
, BC2GM008125101 , O
excellent BC2GM008125101 JJ O
efficacy BC2GM008125101 NN O
and BC2GM008125101 CC O
safety BC2GM008125101 NN O
. BC2GM008125101 . O
. . O O

We BC2GM040314258 PRP O
report BC2GM040314258 VBP O
that BC2GM040314258 IN O
Nim1 BC2GM040314258 NNP O
possesses BC2GM040314258 VBZ O
intrinsic BC2GM040314258 JJ O
serine-kinase BC2GM040314258 NN O
, BC2GM040314258 , O
threonine-kinase BC2GM040314258 JJ O
and BC2GM040314258 CC O
tyrosine-kinase BC2GM040314258 JJ O
activities BC2GM040314258 NNS O
. BC2GM040314258 . O
. . O O

Studies BC2GM075740515 NNS O
on BC2GM075740515 IN O
the BC2GM075740515 DT O
reaction BC2GM075740515 NN O
of BC2GM075740515 IN O
cytochrome BC2GM075740515 JJ O
c BC2GM075740515 NN O
with BC2GM075740515 IN O
corticosteroids BC2GM075740515 NNS O
. BC2GM075740515 . O
. . O O

Hence BC2GM093832681 RB O
, BC2GM093832681 , O
it BC2GM093832681 PRP O
is BC2GM093832681 VBZ O
perhaps BC2GM093832681 RB O
not BC2GM093832681 RB O
necessary BC2GM093832681 JJ O
to BC2GM093832681 TO O
perform BC2GM093832681 VB O
spinal BC2GM093832681 JJ O
puncture BC2GM093832681 NN O
if BC2GM093832681 IN O
the BC2GM093832681 DT O
only BC2GM093832681 JJ O
purpose BC2GM093832681 NN O
is BC2GM093832681 VBZ O
to BC2GM093832681 TO O
determine BC2GM093832681 VB O
the BC2GM093832681 DT O
CSF BC2GM093832681 NNP O
/ BC2GM093832681 NNP O
serum BC2GM093832681 NN O
ratio BC2GM093832681 NN O
. BC2GM093832681 . O
. . O O

In BC2GM057936039 IN O
this BC2GM057936039 DT O
report BC2GM057936039 NN O
, BC2GM057936039 , O
we BC2GM057936039 PRP O
have BC2GM057936039 VBP O
examined BC2GM057936039 VBN O
whether BC2GM057936039 IN O
PTP1B BC2GM057936039 NNP O
effects BC2GM057936039 NNS O
transformation BC2GM057936039 NN O
induced BC2GM057936039 VBN O
by BC2GM057936039 IN O
p210 BC2GM057936039 JJ O
bcr-abl BC2GM057936039 NN O
. BC2GM057936039 . O
. . O O

A BC2GM083615175 DT O
flow BC2GM083615175 NN O
probe BC2GM083615175 NN O
for BC2GM083615175 IN O
direct BC2GM083615175 JJ O
measurement BC2GM083615175 NN O
of BC2GM083615175 IN O
blood BC2GM083615175 NN O
flow BC2GM083615175 NN O
of BC2GM083615175 IN O
the BC2GM083615175 DT O
mitral BC2GM083615175 JJ O
valve BC2GM083615175 NN O
was BC2GM083615175 VBD O
devised BC2GM083615175 VBN O
. BC2GM083615175 . O
. . O O

Hematological BC2GM004334399 JJ O
parameters BC2GM004334399 NNS O
( BC2GM004334399 ( O
leukocyte BC2GM004334399 NN O
, BC2GM004334399 , O
neutrophil BC2GM004334399 NN O
and BC2GM004334399 CC O
platelet BC2GM004334399 NN O
counts BC2GM004334399 NNS O
) BC2GM004334399 ) O
and BC2GM004334399 CC O
liver BC2GM004334399 JJ O
function BC2GM004334399 NN O
tests BC2GM004334399 NNS O
were BC2GM004334399 VBD O
determined BC2GM004334399 VBN O
by BC2GM004334399 IN O
standard BC2GM004334399 JJ O
procedures BC2GM004334399 NNS O
. BC2GM004334399 . O
. . O O

Accordingly BC2GM005118324 RB O
, BC2GM005118324 , O
superpeptide BC2GM005118324 JJ O
antigenic BC2GM005118324 JJ O
material BC2GM005118324 NN O
was BC2GM005118324 VBD O
readily BC2GM005118324 RB O
detected BC2GM005118324 VBN O
by BC2GM005118324 IN O
immunoblotting BC2GM005118324 VBG O
cell BC2GM005118324 NN O
extracts BC2GM005118324 NNS O
and BC2GM005118324 CC O
enriched BC2GM005118324 VBN O
in BC2GM005118324 IN O
vacuolar BC2GM005118324 JJ O
preparations BC2GM005118324 NNS O
of BC2GM005118324 IN O
PrA BC2GM005118324 NNP O
deficient BC2GM005118324 NN O
mutant BC2GM005118324 NN O
cells BC2GM005118324 NNS O
. BC2GM005118324 . O
. . O O

The BC2GM011333437 DT O
predicted BC2GM011333437 JJ O
product BC2GM011333437 NN O
exhibits BC2GM011333437 VBZ O
91 BC2GM011333437 CD O
% BC2GM011333437 NN O
amino BC2GM011333437 NN O
acid BC2GM011333437 NN O
identity BC2GM011333437 NN O
to BC2GM011333437 TO O
the BC2GM011333437 DT O
murine BC2GM011333437 JJ O
voltage-gated BC2GM011333437 JJ O
potassium BC2GM011333437 NN O
channel BC2GM011333437 NN O
protein BC2GM011333437 NN O
Kv1.7 BC2GM011333437 NNP O
( BC2GM011333437 ( O
Kcna7 BC2GM011333437 NNP O
) BC2GM011333437 ) O
, BC2GM011333437 , O
which BC2GM011333437 WDT O
plays BC2GM011333437 VBZ O
an BC2GM011333437 DT O
important BC2GM011333437 JJ O
role BC2GM011333437 NN O
in BC2GM011333437 IN O
the BC2GM011333437 DT O
repolarization BC2GM011333437 NN O
of BC2GM011333437 IN O
cell BC2GM011333437 NN O
membranes BC2GM011333437 NNS O
. BC2GM011333437 . O
. . O O

The BC2GM015832871 DT O
average BC2GM015832871 JJ O
progression BC2GM015832871 NN O
was BC2GM015832871 VBD O
11.6 BC2GM015832871 CD O
( BC2GM015832871 ( O
SD BC2GM015832871 NNP O
9.0 BC2GM015832871 CD O
) BC2GM015832871 ) O
. BC2GM015832871 . O
. . O O

The BC2GM016588295 DT O
translated BC2GM016588295 JJ O
sequence BC2GM016588295 NN O
of BC2GM016588295 IN O
the BC2GM016588295 DT O
FLI BC2GM016588295 NNP O
LRR BC2GM016588295 NNP O
associated BC2GM016588295 VBD O
protein BC2GM016588295 NN O
( BC2GM016588295 ( O
FLAP BC2GM016588295 NNP O
) BC2GM016588295 ) O
encodes BC2GM016588295 VBZ O
a BC2GM016588295 DT O
novel BC2GM016588295 JJ O
protein BC2GM016588295 NN O
not BC2GM016588295 RB O
represented BC2GM016588295 VBN O
in BC2GM016588295 IN O
the BC2GM016588295 DT O
data BC2GM016588295 NN O
base BC2GM016588295 NN O
. BC2GM016588295 . O
. . O O

A BC2GM044977015 DT O
new BC2GM044977015 JJ O
simple BC2GM044977015 JJ O
identification BC2GM044977015 NN O
of BC2GM044977015 IN O
rheumatoid BC2GM044977015 JJ O
factor BC2GM044977015 NN O
on BC2GM044977015 IN O
nitrocellulose BC2GM044977015 NN O
was BC2GM044977015 VBD O
developed BC2GM044977015 VBN O
that BC2GM044977015 IN O
allows BC2GM044977015 VBZ O
quantitative BC2GM044977015 JJ O
detection BC2GM044977015 NN O
. BC2GM044977015 . O
. . O O

cDNA BC2GM008847096 NN O
cloning BC2GM008847096 NN O
, BC2GM008847096 , O
sequencing BC2GM008847096 VBG O
and BC2GM008847096 CC O
chromosome BC2GM008847096 JJ O
mapping BC2GM008847096 NN O
of BC2GM008847096 IN O
a BC2GM008847096 DT O
non-erythroid BC2GM008847096 JJ O
spectrin BC2GM008847096 NN O
, BC2GM008847096 , O
human BC2GM008847096 JJ O
alpha-fodrin BC2GM008847096 NN O
. BC2GM008847096 . O
. . O O

We BC2GM010215483 PRP O
conclude BC2GM010215483 VBP O
that BC2GM010215483 DT O
clonidine BC2GM010215483 VBP O
3 BC2GM010215483 CD O
micrograms BC2GM010215483 NNS O
/ BC2GM010215483 JJ O
kg BC2GM010215483 JJ O
produces BC2GM010215483 VBZ O
sedation BC2GM010215483 NN O
comparable BC2GM010215483 JJ O
to BC2GM010215483 TO O
diazepam BC2GM010215483 VB O
0.2 BC2GM010215483 CD O
mg BC2GM010215483 NN O
/ BC2GM010215483 NNP O
kg BC2GM010215483 NN O
and BC2GM010215483 CC O
also BC2GM010215483 RB O
attenuates BC2GM010215483 VBZ O
the BC2GM010215483 DT O
intubation BC2GM010215483 NN O
response BC2GM010215483 NN O
without BC2GM010215483 IN O
increasing BC2GM010215483 VBG O
the BC2GM010215483 DT O
incidence BC2GM010215483 NN O
of BC2GM010215483 IN O
complications BC2GM010215483 NNS O
. BC2GM010215483 . O
. . O O

Here BC2GM059925570 RB O
we BC2GM059925570 PRP O
demonstrate BC2GM059925570 VBP O
the BC2GM059925570 DT O
ability BC2GM059925570 NN O
of BC2GM059925570 IN O
oligonucleotides BC2GM059925570 NNS O
containing BC2GM059925570 VBG O
the BC2GM059925570 DT O
C4T BC2GM059925570 NNP O
sequence BC2GM059925570 NN O
to BC2GM059925570 TO O
confer BC2GM059925570 VB O
heat BC2GM059925570 NN O
shock BC2GM059925570 NN O
inducibility BC2GM059925570 NN O
on BC2GM059925570 IN O
the BC2GM059925570 DT O
reporter BC2GM059925570 NN O
gene BC2GM059925570 NN O
and BC2GM059925570 CC O
show BC2GM059925570 VB O
that BC2GM059925570 IN O
the BC2GM059925570 DT O
presence BC2GM059925570 NN O
of BC2GM059925570 IN O
two BC2GM059925570 CD O
such BC2GM059925570 JJ O
elements BC2GM059925570 NNS O
produces BC2GM059925570 VBZ O
more BC2GM059925570 JJR O
than BC2GM059925570 IN O
additive BC2GM059925570 JJ O
effects BC2GM059925570 NNS O
on BC2GM059925570 IN O
induction BC2GM059925570 NN O
. BC2GM059925570 . O
. . O O

The BC2GM037366873 DT O
false BC2GM037366873 JJ O
positive BC2GM037366873 JJ O
fraction BC2GM037366873 NN O
( BC2GM037366873 ( O
FPF BC2GM037366873 NNP O
) BC2GM037366873 ) O
decreased BC2GM037366873 VBD O
significantly BC2GM037366873 RB O
if BC2GM037366873 IN O
the BC2GM037366873 DT O
count BC2GM037366873 NN O
density BC2GM037366873 NN O
increased BC2GM037366873 VBD O
; BC2GM037366873 : O
no BC2GM037366873 DT O
difference BC2GM037366873 NN O
in BC2GM037366873 IN O
FPF BC2GM037366873 NNP O
was BC2GM037366873 VBD O
found BC2GM037366873 VBN O
for BC2GM037366873 IN O
a BC2GM037366873 DT O
change BC2GM037366873 NN O
in BC2GM037366873 IN O
lesion BC2GM037366873 NN O
tracer BC2GM037366873 NN O
concentration BC2GM037366873 NN O
. BC2GM037366873 . O
. . O O

LAC9 BC2GM053926612 NNP O
is BC2GM053926612 VBZ O
a BC2GM053926612 DT O
DNA-binding BC2GM053926612 JJ O
protein BC2GM053926612 NN O
that BC2GM053926612 WDT O
regulates BC2GM053926612 VBZ O
transcription BC2GM053926612 NN O
of BC2GM053926612 IN O
the BC2GM053926612 DT O
lactose-galactose BC2GM053926612 JJ O
regulon BC2GM053926612 NN O
in BC2GM053926612 IN O
Kluyveromyces BC2GM053926612 NNP O
lactis BC2GM053926612 NN O
. BC2GM053926612 . O
. . O O

Hormonal BC2GM047468980 JJ O
replacement BC2GM047468980 NN O
therapy BC2GM047468980 NN O
for BC2GM047468980 IN O
women BC2GM047468980 NNS O
with BC2GM047468980 IN O
a BC2GM047468980 DT O
personal BC2GM047468980 JJ O
history BC2GM047468980 NN O
of BC2GM047468980 IN O
breast BC2GM047468980 NN O
cancer BC2GM047468980 NN O
? BC2GM047468980 . O
. BC2GM047468980 . O
. . O O

This BC2GM062867525 DT O
is BC2GM062867525 VBZ O
the BC2GM062867525 DT O
most BC2GM062867525 RBS O
northern BC2GM062867525 JJ O
and BC2GM062867525 CC O
, BC2GM062867525 , O
at BC2GM062867525 IN O
the BC2GM062867525 DT O
same BC2GM062867525 JJ O
time BC2GM062867525 NN O
largest BC2GM062867525 JJS O
, BC2GM062867525 , O
Q BC2GM062867525 NNP O
fever BC2GM062867525 RB O
epidemic BC2GM062867525 RB O
recorded BC2GM062867525 VBN O
in BC2GM062867525 IN O
Germany BC2GM062867525 NNP O
over BC2GM062867525 IN O
the BC2GM062867525 DT O
last BC2GM062867525 JJ O
28 BC2GM062867525 CD O
years BC2GM062867525 NNS O
. BC2GM062867525 . O
. . O O

Both BC2GM083581791 DT O
viruses BC2GM083581791 NNS O
express BC2GM083581791 VBP O
the BC2GM083581791 DT O
mil BC2GM083581791 NN O
/ BC2GM083581791 NNP O
raf BC2GM083581791 NN O
oncogene BC2GM083581791 NN O
product BC2GM083581791 NN O
as BC2GM083581791 IN O
a BC2GM083581791 DT O
gag-fusion BC2GM083581791 NN O
polyprotein BC2GM083581791 NN O
, BC2GM083581791 , O
while BC2GM083581791 IN O
the BC2GM083581791 DT O
myc BC2GM083581791 JJ O
oncogene BC2GM083581791 NN O
of BC2GM083581791 IN O
MH2 BC2GM083581791 NNP O
is BC2GM083581791 VBZ O
expressed BC2GM083581791 VBN O
via BC2GM083581791 IN O
a BC2GM083581791 DT O
subgenomic BC2GM083581791 JJ O
mRNA BC2GM083581791 NN O
. BC2GM083581791 . O
. . O O

To BC2GM065023987 TO O
this BC2GM065023987 DT O
end BC2GM065023987 NN O
we BC2GM065023987 PRP O
generated BC2GM065023987 VBD O
a BC2GM065023987 DT O
detailed BC2GM065023987 JJ O
physical BC2GM065023987 JJ O
map BC2GM065023987 NN O
of BC2GM065023987 IN O
the BC2GM065023987 DT O
genomic BC2GM065023987 JJ O
region BC2GM065023987 NN O
spanning BC2GM065023987 VBG O
between BC2GM065023987 IN O
sequence-tagged BC2GM065023987 JJ O
site BC2GM065023987 NN O
markers BC2GM065023987 NNS O
D16S518 BC2GM065023987 NNP O
and BC2GM065023987 CC O
D16S516 BC2GM065023987 NNP O
. BC2GM065023987 . O
. . O O

Several BC2GM018871077 JJ O
components BC2GM018871077 NNS O
in BC2GM018871077 IN O
cytokine BC2GM018871077 NN O
signaling BC2GM018871077 VBG O
remain BC2GM018871077 VBP O
unidentified BC2GM018871077 JJ O
. BC2GM018871077 . O
. . O O

A BC2GM049023434 DT O
backward BC2GM049023434 JJ O
look BC2GM049023434 NN O
at BC2GM049023434 IN O
urinary BC2GM049023434 JJ O
tract BC2GM049023434 NN O
infections BC2GM049023434 NNS O
. BC2GM049023434 . O
. . O O

The BC2GM062583466 DT O
receptor BC2GM062583466 NN O
for BC2GM062583466 IN O
CSF-1 BC2GM062583466 NNP O
, BC2GM062583466 , O
c-Fms BC2GM062583466 NN O
, BC2GM062583466 , O
is BC2GM062583466 VBZ O
expressed BC2GM062583466 VBN O
in BC2GM062583466 IN O
osteoclasts BC2GM062583466 NNS O
, BC2GM062583466 , O
possesses BC2GM062583466 NNS O
intrinsic BC2GM062583466 JJ O
tyrosine-kinase BC2GM062583466 JJ O
activity BC2GM062583466 NN O
, BC2GM062583466 , O
and BC2GM062583466 CC O
signals BC2GM062583466 NNS O
via BC2GM062583466 IN O
rapid BC2GM062583466 JJ O
phosphorylation BC2GM062583466 NN O
of BC2GM062583466 IN O
selected BC2GM062583466 VBN O
proteins BC2GM062583466 NNS O
. BC2GM062583466 . O
. . O O

Cross-talk BC2GM052598708 NN O
between BC2GM052598708 IN O
transcription BC2GM052598708 NN O
factors BC2GM052598708 NNS O
NF-kappa BC2GM052598708 NNP O
B BC2GM052598708 NNP O
and BC2GM052598708 CC O
C BC2GM052598708 NNP O
/ BC2GM052598708 NNP O
EBP BC2GM052598708 NNP O
in BC2GM052598708 IN O
the BC2GM052598708 DT O
transcriptional BC2GM052598708 JJ O
regulation BC2GM052598708 NN O
of BC2GM052598708 IN O
genes BC2GM052598708 NNS O
. BC2GM052598708 . O
. . O O

Overexpression BC2GM080154101 NN O
of BC2GM080154101 IN O
p50 BC2GM080154101 NN O
in BC2GM080154101 IN O
transient BC2GM080154101 JJ O
cotransfection BC2GM080154101 NN O
studies BC2GM080154101 NNS O
using BC2GM080154101 VBG O
the BC2GM080154101 DT O
proximal BC2GM080154101 JJ O
CRP BC2GM080154101 NNP O
promoter BC2GM080154101 NN O
( BC2GM080154101 ( O
-125 BC2GM080154101 JJ O
/ BC2GM080154101 NNP O
+9 BC2GM080154101 NNP O
) BC2GM080154101 ) O
linked BC2GM080154101 VBD O
to BC2GM080154101 TO O
a BC2GM080154101 DT O
luciferase BC2GM080154101 NN O
reporter BC2GM080154101 NN O
caused BC2GM080154101 VBD O
a BC2GM080154101 DT O
3-fold BC2GM080154101 JJ O
increase BC2GM080154101 NN O
of BC2GM080154101 IN O
luciferase BC2GM080154101 JJ O
activity BC2GM080154101 NN O
, BC2GM080154101 , O
while BC2GM080154101 IN O
C BC2GM080154101 NNP O
/ BC2GM080154101 NNP O
EBPbeta BC2GM080154101 NNP O
overexpression BC2GM080154101 NN O
caused BC2GM080154101 VBD O
an BC2GM080154101 DT O
18-fold BC2GM080154101 JJ O
increase BC2GM080154101 NN O
; BC2GM080154101 : O
simultaneous BC2GM080154101 JJ O
overexpression BC2GM080154101 NN O
of BC2GM080154101 IN O
both BC2GM080154101 DT O
transcription BC2GM080154101 JJ O
factors BC2GM080154101 NNS O
increased BC2GM080154101 VBD O
luciferase BC2GM080154101 NN O
activity BC2GM080154101 NN O
approximately BC2GM080154101 RB O
600-fold BC2GM080154101 JJ O
. BC2GM080154101 . O
. . O O

These BC2GM045996206 DT O
observed BC2GM045996206 VBN O
changes BC2GM045996206 NNS O
were BC2GM045996206 VBD O
not BC2GM045996206 RB O
found BC2GM045996206 VBN O
when BC2GM045996206 WRB O
assessing BC2GM045996206 VBG O
NPY BC2GM045996206 NNP O
level BC2GM045996206 NN O
in BC2GM045996206 IN O
plasma BC2GM045996206 JJ O
fluid BC2GM045996206 NN O
. BC2GM045996206 . O
. . O O

The BC2GM031584591 DT O
cerebellar BC2GM031584591 JJ O
cortical BC2GM031584591 JJ O
vessels BC2GM031584591 NNS O
: BC2GM031584591 : O
they BC2GM031584591 PRP O
are BC2GM031584591 VBP O
compared BC2GM031584591 VBN O
to BC2GM031584591 TO O
the BC2GM031584591 DT O
cerebral BC2GM031584591 JJ O
vessels BC2GM031584591 NNS O
. BC2GM031584591 . O
. . O O

Oncogenic BC2GM021225439 JJ O
activation BC2GM021225439 NN O
of BC2GM021225439 IN O
RET BC2GM021225439 NNP O
is BC2GM021225439 VBZ O
detected BC2GM021225439 VBN O
in BC2GM021225439 IN O
human BC2GM021225439 JJ O
papillary BC2GM021225439 JJ O
thyroid BC2GM021225439 NN O
tumours BC2GM021225439 NN O
and BC2GM021225439 CC O
in BC2GM021225439 IN O
multiple BC2GM021225439 JJ O
endocrine BC2GM021225439 NN O
neoplasia BC2GM021225439 NN O
type BC2GM021225439 NN O
2 BC2GM021225439 CD O
syndromes BC2GM021225439 NNS O
. BC2GM021225439 . O
. . O O

These BC2GM095551237 DT O
results BC2GM095551237 NNS O
demonstrate BC2GM095551237 VBP O
that BC2GM095551237 IN O
m2 BC2GM095551237 NN O
receptors BC2GM095551237 NNS O
couple BC2GM095551237 NN O
to BC2GM095551237 TO O
both BC2GM095551237 DT O
G BC2GM095551237 NNP O
alpha BC2GM095551237 NN O
i2 BC2GM095551237 NN O
and BC2GM095551237 CC O
G BC2GM095551237 NNP O
alpha BC2GM095551237 VBP O
i3 BC2GM095551237 NN O
in BC2GM095551237 IN O
vivo BC2GM095551237 NN O
and BC2GM095551237 CC O
that BC2GM095551237 IN O
this BC2GM095551237 DT O
interaction BC2GM095551237 NN O
is BC2GM095551237 VBZ O
integral BC2GM095551237 JJ O
to BC2GM095551237 TO O
both BC2GM095551237 DT O
positive BC2GM095551237 JJ O
and BC2GM095551237 CC O
negative BC2GM095551237 JJ O
regulatory BC2GM095551237 JJ O
pathways BC2GM095551237 NNS O
leading BC2GM095551237 VBG O
to BC2GM095551237 TO O
activation BC2GM095551237 NN O
of BC2GM095551237 IN O
PLC BC2GM095551237 NNP O
and BC2GM095551237 CC O
desensitization BC2GM095551237 NN O
of BC2GM095551237 IN O
receptor BC2GM095551237 NN O
signaling BC2GM095551237 NN O
. BC2GM095551237 . O
. . O O

This BC2GM029041456 DT O
alternative BC2GM029041456 JJ O
splice BC2GM029041456 NN O
acceptor BC2GM029041456 NN O
site BC2GM029041456 NN O
is BC2GM029041456 VBZ O
also BC2GM029041456 RB O
used BC2GM029041456 VBN O
by BC2GM029041456 IN O
a BC2GM029041456 DT O
biologically BC2GM029041456 RB O
active BC2GM029041456 JJ O
provirus BC2GM029041456 NN O
with BC2GM029041456 IN O
an BC2GM029041456 DT O
efficiency BC2GM029041456 NN O
of BC2GM029041456 IN O
approximately BC2GM029041456 RB O
5 BC2GM029041456 CD O
% BC2GM029041456 NN O
compared BC2GM029041456 VBN O
with BC2GM029041456 IN O
the BC2GM029041456 DT O
upstream BC2GM029041456 JJ O
site BC2GM029041456 NN O
. BC2GM029041456 . O
. . O O

Screening BC2GM073047103 VBG O
of BC2GM073047103 IN O
a BC2GM073047103 DT O
human BC2GM073047103 JJ O
foetal BC2GM073047103 NN O
brain BC2GM073047103 NN O
genomic BC2GM073047103 JJ O
DNA BC2GM073047103 NNP O
library BC2GM073047103 NN O
allowed BC2GM073047103 VBD O
us BC2GM073047103 PRP O
to BC2GM073047103 TO O
isolate BC2GM073047103 VB O
an BC2GM073047103 DT O
EcoRI-EcoRI BC2GM073047103 JJ O
fragment BC2GM073047103 NN O
containing BC2GM073047103 VBG O
6 BC2GM073047103 CD O
kb BC2GM073047103 NN O
of BC2GM073047103 IN O
the BC2GM073047103 DT O
5'-flanking BC2GM073047103 JJ O
region BC2GM073047103 NN O
, BC2GM073047103 , O
the BC2GM073047103 DT O
open BC2GM073047103 JJ O
reading BC2GM073047103 NN O
frame BC2GM073047103 NN O
and BC2GM073047103 CC O
4 BC2GM073047103 CD O
kb BC2GM073047103 NN O
of BC2GM073047103 IN O
the BC2GM073047103 DT O
3'-flanking BC2GM073047103 JJ O
region BC2GM073047103 NN O
of BC2GM073047103 IN O
the BC2GM073047103 DT O
alpha2C4 BC2GM073047103 JJ O
gene BC2GM073047103 NN O
. BC2GM073047103 . O
. . O O

The BC2GM093550976 DT O
regulatory BC2GM093550976 JJ O
genes BC2GM093550976 NNS O
cnrYXH BC2GM093550976 NNS O
have BC2GM093550976 VBP O
been BC2GM093550976 VBN O
cloned BC2GM093550976 VBN O
, BC2GM093550976 , O
overexpressed BC2GM093550976 VBN O
, BC2GM093550976 , O
and BC2GM093550976 CC O
purified BC2GM093550976 VBD O
in BC2GM093550976 IN O
Escherichia BC2GM093550976 NNP O
coli BC2GM093550976 NN O
. BC2GM093550976 . O
. . O O

Arg-130 BC2GM010467864 NNP O
, BC2GM010467864 , O
Gly-132 BC2GM010467864 NNP O
and BC2GM010467864 CC O
Lys-167 BC2GM010467864 NNP O
are BC2GM010467864 VBP O
conserved BC2GM010467864 VBN O
in BC2GM010467864 IN O
all BC2GM010467864 DT O
members BC2GM010467864 NNS O
of BC2GM010467864 IN O
the BC2GM010467864 DT O
type BC2GM010467864 NN O
IB BC2GM010467864 NNP O
topoisomerase BC2GM010467864 NN O
family BC2GM010467864 NN O
. BC2GM010467864 . O
. . O O

It BC2GM036120565 PRP O
is BC2GM036120565 VBZ O
hypothesized BC2GM036120565 VBN O
this BC2GM036120565 DT O
occurs BC2GM036120565 VBZ O
through BC2GM036120565 IN O
antagonism BC2GM036120565 NN O
of BC2GM036120565 IN O
PML BC2GM036120565 NNP O
/ BC2GM036120565 NNP O
RAR BC2GM036120565 NNP O
alpha BC2GM036120565 JJ O
actions BC2GM036120565 NNS O
in BC2GM036120565 IN O
these BC2GM036120565 DT O
leukemic BC2GM036120565 JJ O
cells BC2GM036120565 NNS O
. BC2GM036120565 . O
. . O O

Nonlethal BC2GM009645672 NNP O
sec71-1 BC2GM009645672 JJ O
and BC2GM009645672 CC O
sec72-1 BC2GM009645672 JJ O
mutations BC2GM009645672 NNS O
eliminate BC2GM009645672 VBP O
proteins BC2GM009645672 NNS O
associated BC2GM009645672 VBN O
with BC2GM009645672 IN O
the BC2GM009645672 DT O
Sec63p-BiP BC2GM009645672 NNP O
complex BC2GM009645672 NN O
from BC2GM009645672 IN O
S. BC2GM009645672 NNP O
cerevisiae BC2GM009645672 NN O
. BC2GM009645672 . O
. . O O

Inhibition BC2GM005485785 NN O
of BC2GM005485785 IN O
Raf-1 BC2GM005485785 NNP O
signaling BC2GM005485785 NN O
by BC2GM005485785 IN O
a BC2GM005485785 DT O
monoclonal BC2GM005485785 JJ O
antibody BC2GM005485785 NN O
, BC2GM005485785 , O
which BC2GM005485785 WDT O
interferes BC2GM005485785 VBZ O
with BC2GM005485785 IN O
Raf-1 BC2GM005485785 NNP O
activation BC2GM005485785 NN O
and BC2GM005485785 CC O
with BC2GM005485785 IN O
Mek BC2GM005485785 NNP O
substrate BC2GM005485785 NN O
binding BC2GM005485785 NN O
. BC2GM005485785 . O
. . O O

The BC2GM054091501 DT O
sequences BC2GM054091501 NNS O
at BC2GM054091501 IN O
-10 BC2GM054091501 NNP O
and BC2GM054091501 CC O
-35 BC2GM054091501 NNP O
relative BC2GM054091501 VBP O
to BC2GM054091501 TO O
the BC2GM054091501 DT O
transcriptional BC2GM054091501 JJ O
starting BC2GM054091501 NN O
site BC2GM054091501 NN O
showed BC2GM054091501 VBD O
55 BC2GM054091501 CD O
% BC2GM054091501 NN O
homology BC2GM054091501 NN O
with BC2GM054091501 IN O
the BC2GM054091501 DT O
consensus BC2GM054091501 NN O
sequences BC2GM054091501 NNS O
of BC2GM054091501 IN O
the BC2GM054091501 DT O
Escherichia BC2GM054091501 NNP O
coli BC2GM054091501 JJ O
sigma BC2GM054091501 NN O
70-type BC2GM054091501 JJ O
promoter BC2GM054091501 NN O
. BC2GM054091501 . O
. . O O

Unlike BC2GM067463780 IN O
LANA1 BC2GM067463780 NNP O
, BC2GM067463780 , O
LANA2 BC2GM067463780 NNP O
does BC2GM067463780 VBZ O
not BC2GM067463780 RB O
elicit BC2GM067463780 VB O
a BC2GM067463780 DT O
serologic BC2GM067463780 JJ O
response BC2GM067463780 NN O
from BC2GM067463780 IN O
patients BC2GM067463780 NNS O
with BC2GM067463780 IN O
KS BC2GM067463780 NNP O
, BC2GM067463780 , O
PEL BC2GM067463780 NNP O
, BC2GM067463780 , O
or BC2GM067463780 CC O
CD BC2GM067463780 NN O
as BC2GM067463780 IN O
measured BC2GM067463780 VBN O
by BC2GM067463780 IN O
Western BC2GM067463780 JJ O
blot BC2GM067463780 NN O
hybridization BC2GM067463780 NN O
. BC2GM067463780 . O
. . O O

Here BC2GM078543266 RB O
, BC2GM078543266 , O
we BC2GM078543266 PRP O
analyzed BC2GM078543266 VBD O
the BC2GM078543266 DT O
interaction BC2GM078543266 NN O
of BC2GM078543266 IN O
the BC2GM078543266 DT O
Lactococcus BC2GM078543266 NNP O
lactis BC2GM078543266 NN O
Ll.LtrB BC2GM078543266 NNP O
group BC2GM078543266 NN O
II BC2GM078543266 NNP O
intron BC2GM078543266 VBZ O
endonuclease BC2GM078543266 NN O
with BC2GM078543266 IN O
its BC2GM078543266 PRP$ O
DNA BC2GM078543266 NNP O
target BC2GM078543266 NN O
site BC2GM078543266 NN O
by BC2GM078543266 IN O
DNA BC2GM078543266 NNP O
footprinting BC2GM078543266 NN O
and BC2GM078543266 CC O
modification-interference BC2GM078543266 NN O
approaches BC2GM078543266 NNS O
. BC2GM078543266 . O
. . O O

Secretogranin BC2GM069147613 NNP O
II BC2GM069147613 NNP O
( BC2GM069147613 ( O
SgII BC2GM069147613 NNP O
) BC2GM069147613 ) O
is BC2GM069147613 VBZ O
a BC2GM069147613 DT O
secretory BC2GM069147613 JJ O
polypeptide BC2GM069147613 NN O
stored BC2GM069147613 VBN O
in BC2GM069147613 IN O
large BC2GM069147613 JJ O
dense BC2GM069147613 NN O
core BC2GM069147613 NN O
vesicles BC2GM069147613 NNS O
of BC2GM069147613 IN O
neuroendocrine BC2GM069147613 NN O
and BC2GM069147613 CC O
neuronal BC2GM069147613 JJ O
cells BC2GM069147613 NNS O
. BC2GM069147613 . O
. . O O

The BC2GM057409363 DT O
average BC2GM057409363 JJ O
cumulative BC2GM057409363 JJ O
UVA BC2GM057409363 NNP O
dose BC2GM057409363 NN O
was BC2GM057409363 VBD O
65 BC2GM057409363 CD O
J BC2GM057409363 NNP O
/ BC2GM057409363 NNP O
cm2 BC2GM057409363 NN O
; BC2GM057409363 : O
40 BC2GM057409363 CD O
patients BC2GM057409363 NNS O
had BC2GM057409363 VBD O
received BC2GM057409363 VBN O
more BC2GM057409363 JJR O
than BC2GM057409363 IN O
200 BC2GM057409363 CD O
J BC2GM057409363 NNP O
/ BC2GM057409363 NNP O
cm2 BC2GM057409363 NN O
. BC2GM057409363 . O
. . O O

Papillomavirus BC2GM062065726 NNP O
type BC2GM062065726 VBD O
16 BC2GM062065726 CD O
oncogenes BC2GM062065726 NNS O
downregulate BC2GM062065726 JJ O
expression BC2GM062065726 NN O
of BC2GM062065726 IN O
interferon-responsive BC2GM062065726 JJ O
genes BC2GM062065726 NNS O
and BC2GM062065726 CC O
upregulate BC2GM062065726 JJ O
proliferation-associated BC2GM062065726 JJ O
and BC2GM062065726 CC O
NF-kappaB-responsive BC2GM062065726 JJ O
genes BC2GM062065726 NNS O
in BC2GM062065726 IN O
cervical BC2GM062065726 JJ O
keratinocytes BC2GM062065726 NNS O
. BC2GM062065726 . O
. . O O

This BC2GM096793174 DT O
radiolabeled BC2GM096793174 VBD O
, BC2GM096793174 , O
900-bp BC2GM096793174 JJ O
amplicon BC2GM096793174 NN O
was BC2GM096793174 VBD O
used BC2GM096793174 VBN O
as BC2GM096793174 IN O
a BC2GM096793174 DT O
hybridization BC2GM096793174 NN O
probe BC2GM096793174 NN O
to BC2GM096793174 TO O
screen BC2GM096793174 VB O
a BC2GM096793174 DT O
cDNA BC2GM096793174 NN O
library BC2GM096793174 NN O
constructed BC2GM096793174 VBD O
from BC2GM096793174 IN O
poly BC2GM096793174 NN O
( BC2GM096793174 ( O
A BC2GM096793174 DT O
) BC2GM096793174 ) O
( BC2GM096793174 ( O
+ BC2GM096793174 $ O
) BC2GM096793174 ) O
RNA BC2GM096793174 NNP O
isolated BC2GM096793174 VBN O
from BC2GM096793174 IN O
induced BC2GM096793174 JJ O
Taxus BC2GM096793174 NNP O
cells BC2GM096793174 NNS O
, BC2GM096793174 , O
from BC2GM096793174 IN O
which BC2GM096793174 WDT O
a BC2GM096793174 DT O
full-length BC2GM096793174 JJ O
transacetylase BC2GM096793174 NN O
sequence BC2GM096793174 NN O
was BC2GM096793174 VBD O
obtained BC2GM096793174 VBN O
. BC2GM096793174 . O
. . O O

The BC2GM017175901 DT O
flanking BC2GM017175901 NN O
open BC2GM017175901 JJ O
reading BC2GM017175901 NN O
frames BC2GM017175901 NNS O
in BC2GM017175901 IN O
pARGC2 BC2GM017175901 NN O
showed BC2GM017175901 VBD O
no BC2GM017175901 DT O
homologies BC2GM017175901 NNS O
to BC2GM017175901 TO O
arginine BC2GM017175901 VB O
biosynthetic BC2GM017175901 JJ O
genes BC2GM017175901 NNS O
. BC2GM017175901 . O
. . O O

Postheparin BC2GM032327372 NNP O
lipoprotein BC2GM032327372 NN O
lipase BC2GM032327372 NN O
, BC2GM032327372 , O
measured BC2GM032327372 VBN O
using BC2GM032327372 VBG O
fat BC2GM032327372 JJ O
emulsion BC2GM032327372 NN O
as BC2GM032327372 IN O
substrate BC2GM032327372 NN O
, BC2GM032327372 , O
also BC2GM032327372 RB O
was BC2GM032327372 VBD O
significantly BC2GM032327372 RB O
greater BC2GM032327372 JJR O
in BC2GM032327372 IN O
female BC2GM032327372 JJ O
rats BC2GM032327372 NNS O
compared BC2GM032327372 VBN O
with BC2GM032327372 IN O
males BC2GM032327372 NNS O
. BC2GM032327372 . O
. . O O

Avian BC2GM017445898 JJ O
EMILIN BC2GM017445898 NNP O
was BC2GM017445898 VBD O
extracted BC2GM017445898 VBN O
from BC2GM017445898 IN O
19-day-old BC2GM017445898 JJ O
embryonic BC2GM017445898 JJ O
chick BC2GM017445898 NN O
aortas BC2GM017445898 NNS O
and BC2GM017445898 CC O
associated BC2GM017445898 VBN O
blood BC2GM017445898 NN O
vessels BC2GM017445898 NNS O
and BC2GM017445898 CC O
purified BC2GM017445898 VBN O
by BC2GM017445898 IN O
ion-exchange BC2GM017445898 JJ O
chromatography BC2GM017445898 NN O
and BC2GM017445898 CC O
gel BC2GM017445898 JJ O
filtration BC2GM017445898 NN O
. BC2GM017445898 . O
. . O O

Detonation-traumatic BC2GM031485809 JJ O
load BC2GM031485809 NN O
during BC2GM031485809 IN O
military BC2GM031485809 JJ O
service BC2GM031485809 NN O
. BC2GM031485809 . O
. . O O

Total BC2GM056629834 JJ O
body BC2GM056629834 NN O
water BC2GM056629834 NN O
and BC2GM056629834 CC O
distribution BC2GM056629834 NN O
space BC2GM056629834 NN O
of BC2GM056629834 IN O
Na24 BC2GM056629834 NNP O
in BC2GM056629834 IN O
women BC2GM056629834 NNS O
with BC2GM056629834 IN O
various BC2GM056629834 JJ O
body BC2GM056629834 NN O
weight BC2GM056629834 NN O
. BC2GM056629834 . O
. . O O

For BC2GM057439987 IN O
routine BC2GM057439987 JJ O
medical BC2GM057439987 JJ O
applications BC2GM057439987 NNS O
, BC2GM057439987 , O
no BC2GM057439987 DT O
sophisticated BC2GM057439987 JJ O
adjustment BC2GM057439987 NN O
of BC2GM057439987 IN O
the BC2GM057439987 DT O
CHESS BC2GM057439987 NNP O
pulse BC2GM057439987 NN O
is BC2GM057439987 VBZ O
needed BC2GM057439987 VBN O
, BC2GM057439987 , O
as BC2GM057439987 IN O
reported BC2GM057439987 VBN O
in BC2GM057439987 IN O
previous BC2GM057439987 JJ O
methods BC2GM057439987 NNS O
. BC2GM057439987 . O
. . O O

The BC2GM043099285 DT O
5'-flanking BC2GM043099285 JJ O
region BC2GM043099285 NN O
of BC2GM043099285 IN O
the BC2GM043099285 DT O
gene BC2GM043099285 NN O
, BC2GM043099285 , O
approximately BC2GM043099285 RB O
1.1 BC2GM043099285 CD O
kbp BC2GM043099285 NNS O
long BC2GM043099285 RB O
, BC2GM043099285 , O
had BC2GM043099285 VBD O
no BC2GM043099285 DT O
known BC2GM043099285 VBN O
regulatory BC2GM043099285 JJ O
elements BC2GM043099285 NNS O
for BC2GM043099285 IN O
transcription BC2GM043099285 NN O
such BC2GM043099285 JJ O
as BC2GM043099285 IN O
TATA BC2GM043099285 NNP O
, BC2GM043099285 , O
GC BC2GM043099285 NNP O
, BC2GM043099285 , O
and BC2GM043099285 CC O
CCAAT BC2GM043099285 NNP O
boxes BC2GM043099285 NNS O
. BC2GM043099285 . O
. . O O

KU-1257 BC2GM062157969 NNP O
also BC2GM062157969 RB O
significantly BC2GM062157969 RB O
accelerated BC2GM062157969 VBD O
the BC2GM062157969 DT O
healing BC2GM062157969 NN O
of BC2GM062157969 IN O
acetic BC2GM062157969 JJ O
acid-induced BC2GM062157969 JJ O
duodenal BC2GM062157969 JJ O
ulcers BC2GM062157969 NNS O
as BC2GM062157969 RB O
well BC2GM062157969 RB O
as BC2GM062157969 IN O
famotidine BC2GM062157969 NN O
and BC2GM062157969 CC O
roxatidine BC2GM062157969 NN O
acetate BC2GM062157969 NN O
. BC2GM062157969 . O
. . O O

In BC2GM032311862 IN O
situ BC2GM032311862 JJ O
localization BC2GM032311862 NN O
of BC2GM032311862 IN O
PCP-A1 BC2GM032311862 NNP O
transcripts BC2GM032311862 NNS O
revealed BC2GM032311862 VBD O
that BC2GM032311862 IN O
they BC2GM032311862 PRP O
accumulate BC2GM032311862 VBP O
specifically BC2GM032311862 RB O
in BC2GM032311862 IN O
pollen BC2GM032311862 NN O
at BC2GM032311862 IN O
the BC2GM032311862 DT O
late BC2GM032311862 JJ O
binucleate BC2GM032311862 NN O
/ BC2GM032311862 NN O
trinucleate BC2GM032311862 NN O
stage BC2GM032311862 NN O
of BC2GM032311862 IN O
development BC2GM032311862 NN O
rather BC2GM032311862 RB O
than BC2GM032311862 IN O
in BC2GM032311862 IN O
the BC2GM032311862 DT O
tapetum BC2GM032311862 NN O
, BC2GM032311862 , O
which BC2GM032311862 WDT O
previously BC2GM032311862 RB O
was BC2GM032311862 VBD O
taken BC2GM032311862 VBN O
to BC2GM032311862 TO O
be BC2GM032311862 VB O
the BC2GM032311862 DT O
principal BC2GM032311862 JJ O
source BC2GM032311862 NN O
of BC2GM032311862 IN O
the BC2GM032311862 DT O
pollen BC2GM032311862 NN O
coat BC2GM032311862 NN O
. BC2GM032311862 . O
. . O O

The BC2GM066006503 DT O
fate BC2GM066006503 NN O
of BC2GM066006503 IN O
ochratoxin BC2GM066006503 NN O
A BC2GM066006503 NNP O
during BC2GM066006503 IN O
malting BC2GM066006503 NN O
and BC2GM066006503 CC O
brewing BC2GM066006503 NN O
. BC2GM066006503 . O
. . O O

Both BC2GM081881949 DT O
flavoproteins BC2GM081881949 NNS O
are BC2GM081881949 VBP O
active BC2GM081881949 JJ O
as BC2GM081881949 IN O
AhpC BC2GM081881949 NNP O
reductases BC2GM081881949 NNS O
and BC2GM081881949 CC O
mediate BC2GM081881949 VB O
electron BC2GM081881949 NN O
transfer BC2GM081881949 NN O
, BC2GM081881949 , O
resulting BC2GM081881949 VBG O
in BC2GM081881949 IN O
the BC2GM081881949 DT O
NADH-dependent BC2GM081881949 JJ O
reduction BC2GM081881949 NN O
of BC2GM081881949 IN O
hydrogen BC2GM081881949 NN O
peroxide BC2GM081881949 NN O
and BC2GM081881949 CC O
cumene BC2GM081881949 NN O
hydroperoxide BC2GM081881949 NN O
. BC2GM081881949 . O
. . O O

Up BC2GM098621694 RB O
to BC2GM098621694 TO O
1988 BC2GM098621694 CD O
, BC2GM098621694 , O
145 BC2GM098621694 CD O
cases BC2GM098621694 NNS O
had BC2GM098621694 VBD O
been BC2GM098621694 VBN O
reported BC2GM098621694 VBN O
in BC2GM098621694 IN O
literature BC2GM098621694 NN O
and BC2GM098621694 CC O
32 BC2GM098621694 CD O
cases BC2GM098621694 NNS O
in BC2GM098621694 IN O
our BC2GM098621694 PRP$ O
country BC2GM098621694 NN O
. BC2GM098621694 . O
. . O O

Disruption BC2GM032675979 NN O
and BC2GM032675979 CC O
reconstruction BC2GM032675979 NN O
: BC2GM032675979 : O
narrative BC2GM032675979 JJ O
insights BC2GM032675979 NNS O
into BC2GM032675979 IN O
the BC2GM032675979 DT O
experience BC2GM032675979 NN O
of BC2GM032675979 IN O
family BC2GM032675979 NN O
members BC2GM032675979 NNS O
caring BC2GM032675979 VBG O
for BC2GM032675979 IN O
a BC2GM032675979 DT O
relative BC2GM032675979 JJ O
diagnosed BC2GM032675979 VBN O
with BC2GM032675979 IN O
serious BC2GM032675979 JJ O
mental BC2GM032675979 JJ O
illness BC2GM032675979 NN O
. BC2GM032675979 . O
. . O O

A BC2GM080113467 DT O
proposed BC2GM080113467 VBN O
method BC2GM080113467 NN O
. BC2GM080113467 . O
. . O O

Frequency BC2GM062475449 NN O
of BC2GM062475449 IN O
recurrence BC2GM062475449 NN O
of BC2GM062475449 IN O
fibroids BC2GM062475449 NNS O
after BC2GM062475449 IN O
myomectomy BC2GM062475449 NN O
has BC2GM062475449 VBZ O
been BC2GM062475449 VBN O
evaluated BC2GM062475449 VBN O
in BC2GM062475449 IN O
145 BC2GM062475449 CD O
women BC2GM062475449 NNS O
( BC2GM062475449 ( O
median BC2GM062475449 JJ O
age BC2GM062475449 NN O
38 BC2GM062475449 CD O
years BC2GM062475449 NNS O
, BC2GM062475449 , O
range BC2GM062475449 VB O
21-52 BC2GM062475449 JJ O
) BC2GM062475449 ) O
who BC2GM062475449 WP O
underwent BC2GM062475449 JJ O
myomectomy BC2GM062475449 NN O
. BC2GM062475449 . O
. . O O

Plasma BC2GM085771334 NNP O
colony-stimulating BC2GM085771334 JJ O
factor BC2GM085771334 NN O
analysis BC2GM085771334 NN O
and BC2GM085771334 CC O
the BC2GM085771334 DT O
clinical BC2GM085771334 JJ O
significance BC2GM085771334 NN O
. BC2GM085771334 . O
. . O O

Phenazopyridine-induced BC2GM059503446 NNP O
hemolytic BC2GM059503446 JJ O
anemia BC2GM059503446 NN O
in BC2GM059503446 IN O
a BC2GM059503446 DT O
patient BC2GM059503446 NN O
with BC2GM059503446 IN O
G6PD BC2GM059503446 NNP O
deficiency BC2GM059503446 NN O
. BC2GM059503446 . O
. . O O

Mad3 BC2GM084355616 NNP O
and BC2GM084355616 CC O
Mad4 BC2GM084355616 NNP O
: BC2GM084355616 : O
novel BC2GM084355616 JJ O
Max-interacting BC2GM084355616 NNP O
transcriptional BC2GM084355616 NN O
repressors BC2GM084355616 NNS O
that BC2GM084355616 WDT O
suppress BC2GM084355616 VBP O
c-myc BC2GM084355616 JJ O
dependent BC2GM084355616 JJ O
transformation BC2GM084355616 NN O
and BC2GM084355616 CC O
are BC2GM084355616 VBP O
expressed BC2GM084355616 VBN O
during BC2GM084355616 IN O
neural BC2GM084355616 JJ O
and BC2GM084355616 CC O
epidermal BC2GM084355616 JJ O
differentiation BC2GM084355616 NN O
. BC2GM084355616 . O
. . O O

However BC2GM084116601 RB O
, BC2GM084116601 , O
a BC2GM084116601 DT O
few BC2GM084116601 JJ O
sites BC2GM084116601 NNS O
in BC2GM084116601 IN O
the BC2GM084116601 DT O
genomes BC2GM084116601 NNS O
of BC2GM084116601 IN O
EC BC2GM084116601 NNP O
cells BC2GM084116601 NNS O
permit BC2GM084116601 VBP O
M-MuLVneo BC2GM084116601 NNP O
delta BC2GM084116601 NN O
Enh BC2GM084116601 NNP O
proviral BC2GM084116601 JJ O
expression BC2GM084116601 NN O
. BC2GM084116601 . O
. . O O

1 BC2GM089252708 CD O
. BC2GM089252708 . O
. . O O

For BC2GM085332953 IN O
the BC2GM085332953 DT O
P BC2GM085332953 NNP O
transcript BC2GM085332953 NN O
from BC2GM085332953 IN O
phage BC2GM085332953 NN O
with BC2GM085332953 IN O
the BC2GM085332953 DT O
G BC2GM085332953 NNP O
( BC2GM085332953 ( O
- BC2GM085332953 : O
) BC2GM085332953 ) O
orientation BC2GM085332953 NN O
, BC2GM085332953 , O
full BC2GM085332953 JJ O
termination BC2GM085332953 NN O
activity BC2GM085332953 NN O
required BC2GM085332953 VBN O
both BC2GM085332953 DT O
the BC2GM085332953 DT O
region BC2GM085332953 NN O
containing BC2GM085332953 VBG O
the BC2GM085332953 DT O
stem-loop BC2GM085332953 JJ O
structure BC2GM085332953 NN O
and BC2GM085332953 CC O
upstream BC2GM085332953 JJ O
sequences BC2GM085332953 NNS O
. BC2GM085332953 . O
. . O O

Directional BC2GM095437250 NNP O
growth BC2GM095437250 NN O
of BC2GM095437250 IN O
a BC2GM095437250 DT O
smectic-A-smectic-B BC2GM095437250 JJ O
interface BC2GM095437250 NN O
lying BC2GM095437250 VBG O
along BC2GM095437250 IN O
a BC2GM095437250 DT O
forbidden BC2GM095437250 JJ O
orientation BC2GM095437250 NN O
. BC2GM095437250 . O
. . O O

Denaturing BC2GM049276320 VBG O
gradient BC2GM049276320 NN O
gel BC2GM049276320 NN O
electrophoresis BC2GM049276320 NN O
( BC2GM049276320 ( O
DGGE BC2GM049276320 NNP O
) BC2GM049276320 ) O
with BC2GM049276320 IN O
sequence BC2GM049276320 NN O
analysis BC2GM049276320 NN O
showed BC2GM049276320 VBD O
that BC2GM049276320 IN O
PGCL4 BC2GM049276320 NNP O
is BC2GM049276320 VBZ O
a BC2GM049276320 DT O
major BC2GM049276320 JJ O
member BC2GM049276320 NN O
in BC2GM049276320 IN O
the BC2GM049276320 DT O
female BC2GM049276320 JJ O
mammary BC2GM049276320 JJ O
gland BC2GM049276320 NN O
, BC2GM049276320 , O
and BC2GM049276320 CC O
in BC2GM049276320 IN O
the BC2GM049276320 DT O
submaxillary BC2GM049276320 JJ O
and BC2GM049276320 CC O
lachrymal BC2GM049276320 JJ O
glands BC2GM049276320 NNS O
of BC2GM049276320 IN O
both BC2GM049276320 DT O
sexes BC2GM049276320 NNS O
, BC2GM049276320 , O
while BC2GM049276320 IN O
the BC2GM049276320 DT O
counterpart BC2GM049276320 NN O
in BC2GM049276320 IN O
male BC2GM049276320 JJ O
liver BC2GM049276320 NN O
and BC2GM049276320 CC O
the BC2GM049276320 DT O
coagulate BC2GM049276320 NN O
glands BC2GM049276320 NNS O
was BC2GM049276320 VBD O
found BC2GM049276320 VBN O
to BC2GM049276320 TO O
be BC2GM049276320 VB O
PGCL1 BC2GM049276320 NNP O
. BC2GM049276320 . O
. . O O

These BC2GM011710885 DT O
psoralens BC2GM011710885 NNS O
are BC2GM011710885 VBP O
being BC2GM011710885 VBG O
used BC2GM011710885 VBN O
in BC2GM011710885 IN O
research BC2GM011710885 NN O
projects BC2GM011710885 NNS O
sponsored BC2GM011710885 VBN O
by BC2GM011710885 IN O
the BC2GM011710885 DT O
National BC2GM011710885 NNP O
Toxicology BC2GM011710885 NNP O
Program BC2GM011710885 NNP O
. BC2GM011710885 . O
. . O O

We BC2GM032430456 PRP O
examined BC2GM032430456 VBD O
the BC2GM032430456 DT O
contribution BC2GM032430456 NN O
of BC2GM032430456 IN O
a BC2GM032430456 DT O
cryptic BC2GM032430456 JJ O
plasmid BC2GM032430456 NN O
, BC2GM032430456 , O
pRmeGR4b BC2GM032430456 NN O
, BC2GM032430456 , O
to BC2GM032430456 TO O
the BC2GM032430456 DT O
nodulation BC2GM032430456 NN O
of BC2GM032430456 IN O
Medicago BC2GM032430456 NNP O
sativa BC2GM032430456 NN O
by BC2GM032430456 IN O
strain BC2GM032430456 NN O
GR4 BC2GM032430456 NNP O
of BC2GM032430456 IN O
Rhizobium BC2GM032430456 NNP O
meliloti BC2GM032430456 NN O
. BC2GM032430456 . O
. . O O

There BC2GM053284567 EX O
is BC2GM053284567 VBZ O
an BC2GM053284567 DT O
overall BC2GM053284567 JJ O
functional BC2GM053284567 JJ O
similarity BC2GM053284567 NN O
between BC2GM053284567 IN O
IL-6 BC2GM053284567 NNP O
and BC2GM053284567 CC O
c-fos BC2GM053284567 JJ O
promoters BC2GM053284567 NNS O
, BC2GM053284567 , O
since BC2GM053284567 IN O
transfection BC2GM053284567 NN O
of BC2GM053284567 IN O
excess BC2GM053284567 JJ O
amounts BC2GM053284567 NNS O
of BC2GM053284567 IN O
either BC2GM053284567 DT O
promoter BC2GM053284567 NN O
DNA BC2GM053284567 NNP O
into BC2GM053284567 IN O
intact BC2GM053284567 JJ O
HeLa BC2GM053284567 NNP O
cells BC2GM053284567 NNS O
modulates BC2GM053284567 VBZ O
the BC2GM053284567 DT O
function BC2GM053284567 NN O
of BC2GM053284567 IN O
the BC2GM053284567 DT O
heterologous BC2GM053284567 JJ O
promoter BC2GM053284567 NN O
construct BC2GM053284567 NN O
. BC2GM053284567 . O
. . O O

At BC2GM051214920 IN O
the BC2GM051214920 DT O
same BC2GM051214920 JJ O
acoustic BC2GM051214920 JJ O
power BC2GM051214920 NN O
, BC2GM051214920 , O
the BC2GM051214920 DT O
rate BC2GM051214920 NN O
of BC2GM051214920 IN O
chloride BC2GM051214920 NN O
formation BC2GM051214920 NN O
with BC2GM051214920 IN O
20 BC2GM051214920 CD O
kHz BC2GM051214920 NNS O
ultrasound BC2GM051214920 NN O
was BC2GM051214920 VBD O
greater BC2GM051214920 JJR O
when BC2GM051214920 WRB O
a BC2GM051214920 DT O
probe BC2GM051214920 NN O
with BC2GM051214920 IN O
a BC2GM051214920 DT O
larger BC2GM051214920 JJR O
tip BC2GM051214920 JJ O
area BC2GM051214920 NN O
was BC2GM051214920 VBD O
used BC2GM051214920 VBN O
, BC2GM051214920 , O
but BC2GM051214920 CC O
significantly BC2GM051214920 RB O
less BC2GM051214920 JJR O
than BC2GM051214920 IN O
the BC2GM051214920 DT O
rate BC2GM051214920 NN O
with BC2GM051214920 IN O
900 BC2GM051214920 CD O
kHz BC2GM051214920 NNS O
. BC2GM051214920 . O
. . O O

In BC2GM016645087 IN O
the BC2GM016645087 DT O
plant BC2GM016645087 NN O
malate BC2GM016645087 NN O
synthases BC2GM016645087 NNS O
, BC2GM016645087 , O
the BC2GM016645087 DT O
extension BC2GM016645087 NN O
is BC2GM016645087 VBZ O
probably BC2GM016645087 RB O
involved BC2GM016645087 VBN O
in BC2GM016645087 IN O
routing BC2GM016645087 VBG O
to BC2GM016645087 TO O
the BC2GM016645087 DT O
microbodies BC2GM016645087 NNS O
, BC2GM016645087 , O
since BC2GM016645087 IN O
it BC2GM016645087 PRP O
contains BC2GM016645087 VBZ O
the BC2GM016645087 DT O
potential BC2GM016645087 JJ O
peroxisomal BC2GM016645087 NN O
targeting BC2GM016645087 VBG O
signal BC2GM016645087 JJ O
, BC2GM016645087 , O
Ser-Arg BC2GM016645087 JJ O
/ BC2GM016645087 NNP O
Lys-Leu BC2GM016645087 NNP O
, BC2GM016645087 , O
at BC2GM016645087 IN O
the BC2GM016645087 DT O
carboxy BC2GM016645087 JJ O
terminus BC2GM016645087 NN O
. BC2GM016645087 . O
. . O O

The BC2GM041159775 DT O
proteins BC2GM041159775 NNS O
encoded BC2GM041159775 VBN O
by BC2GM041159775 IN O
these BC2GM041159775 DT O
genes BC2GM041159775 NNS O
, BC2GM041159775 , O
called BC2GM041159775 VBD O
GF14 BC2GM041159775 NNP O
proteins BC2GM041159775 NNS O
, BC2GM041159775 , O
participate BC2GM041159775 VB O
in BC2GM041159775 IN O
protein BC2GM041159775 JJ O
/ BC2GM041159775 NNP O
DNA BC2GM041159775 NNP O
complexes BC2GM041159775 NNS O
and BC2GM041159775 CC O
show BC2GM041159775 VB O
more BC2GM041159775 JJR O
than BC2GM041159775 IN O
60 BC2GM041159775 CD O
% BC2GM041159775 NN O
identity BC2GM041159775 NN O
with BC2GM041159775 IN O
a BC2GM041159775 DT O
highly BC2GM041159775 RB O
conserved BC2GM041159775 VBN O
, BC2GM041159775 , O
widely BC2GM041159775 RB O
distributed BC2GM041159775 VBN O
protein BC2GM041159775 NN O
family BC2GM041159775 NN O
, BC2GM041159775 , O
collectively BC2GM041159775 RB O
referred BC2GM041159775 VBD O
to BC2GM041159775 TO O
as BC2GM041159775 IN O
14-3-3 BC2GM041159775 JJ O
proteins BC2GM041159775 NNS O
. BC2GM041159775 . O
. . O O

Correlation BC2GM057155678 NN O
of BC2GM057155678 IN O
alpha BC2GM057155678 JJ O
activity BC2GM057155678 NN O
between BC2GM057155678 IN O
the BC2GM057155678 DT O
frontal BC2GM057155678 NN O
and BC2GM057155678 CC O
occipital BC2GM057155678 JJ O
cortex BC2GM057155678 NN O
. BC2GM057155678 . O
. . O O

Replacement BC2GM081729559 NN O
of BC2GM081729559 IN O
Val20-Leu21 BC2GM081729559 NNP O
with BC2GM081729559 IN O
Ala-Ala BC2GM081729559 NNP O
produced BC2GM081729559 VBD O
a BC2GM081729559 DT O
dimeric BC2GM081729559 JJ O
RII BC2GM081729559 NNP O
beta BC2GM081729559 NN O
protein BC2GM081729559 NN O
that BC2GM081729559 WDT O
binds BC2GM081729559 VBZ O
AKAP75 BC2GM081729559 NNP O
approximately BC2GM081729559 RB O
4 BC2GM081729559 CD O
% BC2GM081729559 NN O
as BC2GM081729559 RB O
avidly BC2GM081729559 RB O
as BC2GM081729559 IN O
wild-type BC2GM081729559 JJ O
RII BC2GM081729559 NNP O
beta BC2GM081729559 NN O
. BC2GM081729559 . O
. . O O

The BC2GM038012165 DT O
three BC2GM038012165 CD O
more BC2GM038012165 JJR O
slower BC2GM038012165 JJR O
migrating BC2GM038012165 NN O
Stat5B BC2GM038012165 NNP O
bands BC2GM038012165 VBZ O
observed BC2GM038012165 VBN O
in BC2GM038012165 IN O
response BC2GM038012165 NN O
to BC2GM038012165 TO O
GH BC2GM038012165 NNP O
contain BC2GM038012165 NN O
phosphorylated BC2GM038012165 VBD O
tyrosyl BC2GM038012165 JJ O
residues BC2GM038012165 NNS O
. BC2GM038012165 . O
. . O O

CRKL BC2GM001917913 NNP O
, BC2GM001917913 , O
an BC2GM001917913 DT O
SH2-SH3-SH3 BC2GM001917913 JJ O
adapter BC2GM001917913 NN O
protein BC2GM001917913 NN O
, BC2GM001917913 , O
is BC2GM001917913 VBZ O
one BC2GM001917913 CD O
of BC2GM001917913 IN O
the BC2GM001917913 DT O
major BC2GM001917913 JJ O
tyrosine BC2GM001917913 NN O
phosphoproteins BC2GM001917913 NNS O
detected BC2GM001917913 VBN O
in BC2GM001917913 IN O
primary BC2GM001917913 JJ O
leukemic BC2GM001917913 JJ O
neutrophils BC2GM001917913 NNS O
from BC2GM001917913 IN O
patients BC2GM001917913 NNS O
with BC2GM001917913 IN O
CML BC2GM001917913 NNP O
. BC2GM001917913 . O
. . O O

Lysates BC2GM025314354 NNS O
of BC2GM025314354 IN O
COS BC2GM025314354 NNP O
cells BC2GM025314354 NNS O
transfected BC2GM025314354 VBD O
with BC2GM025314354 IN O
modified BC2GM025314354 JJ O
hGrzB BC2GM025314354 NN O
cDNA BC2GM025314354 NN O
were BC2GM025314354 VBD O
able BC2GM025314354 JJ O
to BC2GM025314354 TO O
hydrolyze BC2GM025314354 VB O
tert-butyloxycarbonyl-Ala-Ala-Asp-thiobenzyl BC2GM025314354 JJ O
ester BC2GM025314354 NN O
( BC2GM025314354 ( O
Boc-Ala-Ala-Asp-SBzl BC2GM025314354 NNP O
) BC2GM025314354 ) O
, BC2GM025314354 , O
whereas BC2GM025314354 JJ O
lysates BC2GM025314354 NNS O
transfected BC2GM025314354 VBN O
with BC2GM025314354 IN O
unmodified BC2GM025314354 JJ O
hGrzB BC2GM025314354 NN O
cDNA BC2GM025314354 NN O
were BC2GM025314354 VBD O
inactive BC2GM025314354 JJ O
. BC2GM025314354 . O
. . O O

We BC2GM072405160 PRP O
now BC2GM072405160 RB O
report BC2GM072405160 VBP O
identification BC2GM072405160 NN O
and BC2GM072405160 CC O
analysis BC2GM072405160 NN O
of BC2GM072405160 IN O
transcriptional BC2GM072405160 JJ O
activities BC2GM072405160 NNS O
mediated BC2GM072405160 VBN O
by BC2GM072405160 IN O
three BC2GM072405160 CD O
cis-acting BC2GM072405160 NN O
sites BC2GM072405160 NNS O
within BC2GM072405160 IN O
a BC2GM072405160 DT O
90-bp BC2GM072405160 JJ O
portion BC2GM072405160 NN O
of BC2GM072405160 IN O
the BC2GM072405160 DT O
rDNA BC2GM072405160 NN O
enhancer BC2GM072405160 NN O
designated BC2GM072405160 VBD O
the BC2GM072405160 DT O
modulator BC2GM072405160 NN O
region BC2GM072405160 NN O
. BC2GM072405160 . O
. . O O

This BC2GM067528741 DT O
preliminary BC2GM067528741 JJ O
study BC2GM067528741 NN O
reports BC2GM067528741 NNS O
an BC2GM067528741 DT O
initial BC2GM067528741 JJ O
evaluation BC2GM067528741 NN O
of BC2GM067528741 IN O
HMPAO-SPECT BC2GM067528741 NNP O
imaging BC2GM067528741 VBG O
for BC2GM067528741 IN O
assessing BC2GM067528741 VBG O
regional BC2GM067528741 JJ O
alterations BC2GM067528741 NNS O
in BC2GM067528741 IN O
brain BC2GM067528741 NN O
function BC2GM067528741 NN O
during BC2GM067528741 IN O
opiate BC2GM067528741 JJ O
dependence BC2GM067528741 NN O
and BC2GM067528741 CC O
withdrawal BC2GM067528741 NN O
. BC2GM067528741 . O
. . O O

Antinuclear BC2GM076094656 JJ O
antibodies BC2GM076094656 NNS O
, BC2GM076094656 , O
rheumatoid BC2GM076094656 JJ O
factor BC2GM076094656 NN O
and BC2GM076094656 CC O
C-reactive BC2GM076094656 JJ O
protein BC2GM076094656 NN O
in BC2GM076094656 IN O
serum BC2GM076094656 NN O
of BC2GM076094656 IN O
normal BC2GM076094656 JJ O
women BC2GM076094656 NNS O
using BC2GM076094656 VBG O
oral BC2GM076094656 JJ O
contraceptives BC2GM076094656 NNS O
. BC2GM076094656 . O
. . O O

The BC2GM051237837 DT O
R260A BC2GM051237837 NNP O
mutant BC2GM051237837 NN O
, BC2GM051237837 , O
as BC2GM051237837 IN O
expected BC2GM051237837 VBN O
, BC2GM051237837 , O
was BC2GM051237837 VBD O
unable BC2GM051237837 JJ O
to BC2GM051237837 TO O
support BC2GM051237837 VB O
mRNA BC2GM051237837 JJ O
synthesis BC2GM051237837 NN O
in BC2GM051237837 IN O
vitro BC2GM051237837 NN O
in BC2GM051237837 IN O
a BC2GM051237837 DT O
transcription BC2GM051237837 NN O
reconstitution BC2GM051237837 NN O
reaction BC2GM051237837 NN O
as BC2GM051237837 RB O
well BC2GM051237837 RB O
as BC2GM051237837 IN O
transcription BC2GM051237837 NN O
in BC2GM051237837 IN O
vivo BC2GM051237837 NN O
of BC2GM051237837 IN O
a BC2GM051237837 DT O
minigenome BC2GM051237837 NN O
using BC2GM051237837 VBG O
a BC2GM051237837 DT O
reverse BC2GM051237837 NN O
genetic BC2GM051237837 JJ O
approach BC2GM051237837 NN O
. BC2GM051237837 . O
. . O O

MRI BC2GM023032582 NNP O
measurements BC2GM023032582 NNS O
of BC2GM023032582 IN O
the BC2GM023032582 DT O
brain BC2GM023032582 NN O
. BC2GM023032582 . O
. . O O

These BC2GM004333942 DT O
changes BC2GM004333942 NNS O
persisted BC2GM004333942 VBD O
during BC2GM004333942 IN O
the BC2GM004333942 DT O
first BC2GM004333942 JJ O
week BC2GM004333942 NN O
. BC2GM004333942 . O
. . O O

This BC2GM026058529 DT O
report BC2GM026058529 NN O
establishes BC2GM026058529 VBZ O
that BC2GM026058529 IN O
the BC2GM026058529 DT O
effect BC2GM026058529 NN O
of BC2GM026058529 IN O
homozygous BC2GM026058529 JJ O
sickle BC2GM026058529 NN O
cell BC2GM026058529 NN O
disease BC2GM026058529 NN O
on BC2GM026058529 IN O
growth BC2GM026058529 NN O
patterns BC2GM026058529 NNS O
in BC2GM026058529 IN O
childhood BC2GM026058529 NN O
is BC2GM026058529 VBZ O
apparent BC2GM026058529 JJ O
before BC2GM026058529 IN O
the BC2GM026058529 DT O
age BC2GM026058529 NN O
of BC2GM026058529 IN O
6 BC2GM026058529 CD O
years BC2GM026058529 NNS O
. BC2GM026058529 . O
. . O O

An BC2GM089431747 DT O
incorrect BC2GM089431747 JJ O
response BC2GM089431747 NN O
on BC2GM089431747 IN O
the BC2GM089431747 DT O
previous BC2GM089431747 JJ O
trial BC2GM089431747 NN O
enhanced BC2GM089431747 VBD O
the BC2GM089431747 DT O
accuracy BC2GM089431747 NN O
in BC2GM089431747 IN O
the BC2GM089431747 DT O
current BC2GM089431747 JJ O
trial BC2GM089431747 NN O
only BC2GM089431747 RB O
in BC2GM089431747 IN O
the BC2GM089431747 DT O
left BC2GM089431747 JJ O
visual BC2GM089431747 JJ O
field BC2GM089431747 NN O
( BC2GM089431747 ( O
LVF BC2GM089431747 NNP O
) BC2GM089431747 ) O
. BC2GM089431747 . O
. . O O

MsEPV BC2GM076238232 NNP O
genes BC2GM076238232 NNS O
with BC2GM076238232 IN O
putative BC2GM076238232 JJ O
functions BC2GM076238232 NNS O
in BC2GM076238232 IN O
prevention BC2GM076238232 NN O
and BC2GM076238232 CC O
repair BC2GM076238232 NN O
of BC2GM076238232 IN O
DNA BC2GM076238232 NNP O
damage BC2GM076238232 NN O
include BC2GM076238232 VBP O
a BC2GM076238232 DT O
complete BC2GM076238232 JJ O
base BC2GM076238232 NN O
excision BC2GM076238232 NN O
repair BC2GM076238232 NN O
pathway BC2GM076238232 NN O
( BC2GM076238232 ( O
uracil BC2GM076238232 JJ O
DNA BC2GM076238232 NNP O
glycosylase BC2GM076238232 NN O
, BC2GM076238232 , O
AP BC2GM076238232 NNP O
endonuclease BC2GM076238232 NN O
, BC2GM076238232 , O
DNA BC2GM076238232 NNP O
polymerase BC2GM076238232 NN O
beta BC2GM076238232 NN O
, BC2GM076238232 , O
and BC2GM076238232 CC O
an BC2GM076238232 DT O
NAD+-dependent BC2GM076238232 JJ O
DNA BC2GM076238232 NNP O
ligase BC2GM076238232 NN O
) BC2GM076238232 ) O
, BC2GM076238232 , O
a BC2GM076238232 DT O
photoreactivation BC2GM076238232 NN O
repair BC2GM076238232 NN O
pathway BC2GM076238232 NN O
( BC2GM076238232 ( O
cyclobutane BC2GM076238232 JJ O
pyrimidine BC2GM076238232 NN O
dimer BC2GM076238232 NN O
photolyase BC2GM076238232 NN O
) BC2GM076238232 ) O
, BC2GM076238232 , O
a BC2GM076238232 DT O
LINE-type BC2GM076238232 JJ O
reverse BC2GM076238232 NN O
transcriptase BC2GM076238232 NN O
, BC2GM076238232 , O
and BC2GM076238232 CC O
a BC2GM076238232 DT O
mutT BC2GM076238232 NN O
homologue BC2GM076238232 NN O
. BC2GM076238232 . O
. . O O

As BC2GM032150077 IN O
a BC2GM032150077 DT O
member BC2GM032150077 NN O
of BC2GM032150077 IN O
the BC2GM032150077 DT O
uncoupling BC2GM032150077 JJ O
protein BC2GM032150077 NN O
family BC2GM032150077 NN O
, BC2GM032150077 , O
UCP2 BC2GM032150077 NNP O
is BC2GM032150077 VBZ O
ubiquitously BC2GM032150077 RB O
expressed BC2GM032150077 VBN O
in BC2GM032150077 IN O
rodents BC2GM032150077 NNS O
and BC2GM032150077 CC O
humans BC2GM032150077 NNS O
, BC2GM032150077 , O
implicating BC2GM032150077 VBG O
a BC2GM032150077 DT O
major BC2GM032150077 JJ O
role BC2GM032150077 NN O
in BC2GM032150077 IN O
thermogenesis BC2GM032150077 NN O
. BC2GM032150077 . O
. . O O

The BC2GM033756854 DT O
dominant BC2GM033756854 JJ O
inhibitory BC2GM033756854 JJ O
biological BC2GM033756854 JJ O
activity BC2GM033756854 NN O
of BC2GM033756854 IN O
the BC2GM033756854 DT O
N BC2GM033756854 NNP O
terminus BC2GM033756854 NN O
correlated BC2GM033756854 VBD O
with BC2GM033756854 IN O
its BC2GM033756854 PRP$ O
ability BC2GM033756854 NN O
to BC2GM033756854 TO O
impair BC2GM033756854 VB O
EGF-dependent BC2GM033756854 JJ O
activation BC2GM033756854 NN O
of BC2GM033756854 IN O
GTP-Ras BC2GM033756854 NNP O
and BC2GM033756854 CC O
of BC2GM033756854 IN O
MAP BC2GM033756854 NNP O
kinase BC2GM033756854 NN O
, BC2GM033756854 , O
as BC2GM033756854 IN O
well BC2GM033756854 RB O
with BC2GM033756854 IN O
the BC2GM033756854 DT O
ability BC2GM033756854 NN O
of BC2GM033756854 IN O
endogenous BC2GM033756854 JJ O
Sos BC2GM033756854 NNP O
to BC2GM033756854 TO O
form BC2GM033756854 VB O
a BC2GM033756854 DT O
stable BC2GM033756854 JJ O
complex BC2GM033756854 NN O
with BC2GM033756854 IN O
activated BC2GM033756854 JJ O
EGF BC2GM033756854 NNP O
receptors BC2GM033756854 NNS O
. BC2GM033756854 . O
. . O O

On BC2GM008813180 IN O
the BC2GM008813180 DT O
sixth BC2GM008813180 JJ O
postirradiation BC2GM008813180 NN O
day BC2GM008813180 NN O
the BC2GM008813180 DT O
absorption BC2GM008813180 NN O
of BC2GM008813180 IN O
phenobarbitone BC2GM008813180 NN O
, BC2GM008813180 , O
sulphafurazole BC2GM008813180 NN O
and BC2GM008813180 CC O
mecamylamine BC2GM008813180 NN O
had BC2GM008813180 VBD O
returned BC2GM008813180 VBN O
to BC2GM008813180 TO O
the BC2GM008813180 DT O
control BC2GM008813180 NN O
level BC2GM008813180 NN O
, BC2GM008813180 , O
but BC2GM008813180 CC O
the BC2GM008813180 DT O
absorption BC2GM008813180 NN O
of BC2GM008813180 IN O
quinidine BC2GM008813180 NN O
and BC2GM008813180 CC O
isoniazid BC2GM008813180 NN O
was BC2GM008813180 VBD O
still BC2GM008813180 RB O
retarded BC2GM008813180 VBN O
. BC2GM008813180 . O
. . O O

The BC2GM075516743 DT O
Sensititre BC2GM075516743 NNP O
MIC BC2GM075516743 NNP O
panels BC2GM075516743 NNS O
containing BC2GM075516743 VBG O
meropenem BC2GM075516743 NN O
offer BC2GM075516743 VBP O
a BC2GM075516743 DT O
convenient BC2GM075516743 NN O
and BC2GM075516743 CC O
valid BC2GM075516743 JJ O
alternative BC2GM075516743 NN O
to BC2GM075516743 TO O
the BC2GM075516743 DT O
NCCLS BC2GM075516743 NNP O
reference BC2GM075516743 NN O
method BC2GM075516743 NN O
for BC2GM075516743 IN O
the BC2GM075516743 DT O
susceptibility BC2GM075516743 NN O
testing BC2GM075516743 NN O
of BC2GM075516743 IN O
potential BC2GM075516743 JJ O
pathogens BC2GM075516743 NNS O
likely BC2GM075516743 JJ O
to BC2GM075516743 TO O
be BC2GM075516743 VB O
recovered BC2GM075516743 VBN O
from BC2GM075516743 IN O
mixed BC2GM075516743 JJ O
infections BC2GM075516743 NNS O
. BC2GM075516743 . O
. . O O

To BC2GM083962510 TO O
investigate BC2GM083962510 VB O
the BC2GM083962510 DT O
role BC2GM083962510 NN O
of BC2GM083962510 IN O
bHLH BC2GM083962510 JJ O
proteins BC2GM083962510 NNS O
in BC2GM083962510 IN O
MC3T3-E1 BC2GM083962510 NNP O
osteoblasts BC2GM083962510 NNS O
, BC2GM083962510 , O
which BC2GM083962510 WDT O
undergo BC2GM083962510 VBP O
a BC2GM083962510 DT O
developmental BC2GM083962510 JJ O
sequence BC2GM083962510 NN O
in BC2GM083962510 IN O
vitro BC2GM083962510 NN O
, BC2GM083962510 , O
we BC2GM083962510 PRP O
analyzed BC2GM083962510 VBD O
the BC2GM083962510 DT O
transcriptional BC2GM083962510 JJ O
control BC2GM083962510 NN O
of BC2GM083962510 IN O
osteocalcin BC2GM083962510 JJ O
gene BC2GM083962510 NN O
expression BC2GM083962510 NN O
by BC2GM083962510 IN O
stable BC2GM083962510 JJ O
transfection BC2GM083962510 NN O
of BC2GM083962510 IN O
an BC2GM083962510 DT O
osteocalcin BC2GM083962510 JJ O
promoter-luciferase BC2GM083962510 NN O
chimeric BC2GM083962510 JJ O
gene BC2GM083962510 NN O
( BC2GM083962510 ( O
p637OC-luc BC2GM083962510 JJ O
) BC2GM083962510 ) O
and BC2GM083962510 CC O
assessed BC2GM083962510 VBD O
the BC2GM083962510 DT O
role BC2GM083962510 NN O
of BC2GM083962510 IN O
E-box BC2GM083962510 NNP O
cis-acting BC2GM083962510 JJ O
elements BC2GM083962510 NNS O
in BC2GM083962510 IN O
osteocalcin BC2GM083962510 JJ O
promoter BC2GM083962510 NN O
by BC2GM083962510 IN O
DNA BC2GM083962510 NNP O
binding BC2GM083962510 VBG O
assays BC2GM083962510 NNS O
. BC2GM083962510 . O
. . O O

Thus BC2GM077447825 RB O
, BC2GM077447825 , O
transgene BC2GM077447825 JJ O
expression BC2GM077447825 NN O
directed BC2GM077447825 VBN O
by BC2GM077447825 IN O
both BC2GM077447825 DT O
the BC2GM077447825 DT O
human BC2GM077447825 JJ O
and BC2GM077447825 CC O
mouse BC2GM077447825 NN O
Rb BC2GM077447825 NNP O
promoters BC2GM077447825 NNS O
is BC2GM077447825 VBZ O
restricted BC2GM077447825 VBN O
to BC2GM077447825 TO O
a BC2GM077447825 DT O
subset BC2GM077447825 NN O
of BC2GM077447825 IN O
tissues BC2GM077447825 NNS O
in BC2GM077447825 IN O
which BC2GM077447825 WDT O
Rb BC2GM077447825 NNP O
is BC2GM077447825 VBZ O
normally BC2GM077447825 RB O
expressed BC2GM077447825 VBN O
during BC2GM077447825 IN O
embryogenesis BC2GM077447825 NN O
. BC2GM077447825 . O
. . O O

A BC2GM055232950 DT O
kinetic BC2GM055232950 JJ O
model BC2GM055232950 NN O
for BC2GM055232950 IN O
99mTc-DMSA BC2GM055232950 CD O
in BC2GM055232950 IN O
the BC2GM055232950 DT O
rat BC2GM055232950 NN O
. BC2GM055232950 . O
. . O O

Minor BC2GM070919106 JJ O
changes BC2GM070919106 NNS O
within BC2GM070919106 IN O
the BC2GM070919106 DT O
transmembrane BC2GM070919106 NN O
domains BC2GM070919106 NNS O
( BC2GM070919106 ( O
TMs BC2GM070919106 NNP O
) BC2GM070919106 ) O
sometimes BC2GM070919106 RB O
produced BC2GM070919106 VBN O
major BC2GM070919106 JJ O
effects BC2GM070919106 NNS O
and BC2GM070919106 CC O
more BC2GM070919106 RBR O
drastic BC2GM070919106 JJ O
changes BC2GM070919106 NNS O
in BC2GM070919106 IN O
the BC2GM070919106 DT O
TMs BC2GM070919106 NNP O
ablated BC2GM070919106 VBD O
surface BC2GM070919106 NN O
expression BC2GM070919106 NN O
entirely BC2GM070919106 RB O
. BC2GM070919106 . O
. . O O

The BC2GM082631911 DT O
psi BC2GM082631911 NN O
zeta BC2GM082631911 NN O
gene BC2GM082631911 NN O
has BC2GM082631911 VBZ O
a BC2GM082631911 DT O
nonsense BC2GM082631911 JJ O
mutation BC2GM082631911 NN O
in BC2GM082631911 IN O
exon BC2GM082631911 JJ O
1 BC2GM082631911 CD O
but BC2GM082631911 CC O
has BC2GM082631911 VBZ O
identical BC2GM082631911 JJ O
promoter BC2GM082631911 NN O
sequence BC2GM082631911 NN O
and BC2GM082631911 CC O
RNA BC2GM082631911 NNP O
processing BC2GM082631911 NN O
sites BC2GM082631911 NNS O
to BC2GM082631911 TO O
the BC2GM082631911 DT O
zeta BC2GM082631911 NN O
gene BC2GM082631911 NN O
, BC2GM082631911 , O
raising BC2GM082631911 VBG O
the BC2GM082631911 DT O
possibility BC2GM082631911 NN O
that BC2GM082631911 IN O
both BC2GM082631911 DT O
psi BC2GM082631911 JJ O
zeta BC2GM082631911 NN O
and BC2GM082631911 CC O
zeta BC2GM082631911 NN O
are BC2GM082631911 VBP O
transcriptionally BC2GM082631911 RB O
active BC2GM082631911 JJ O
. BC2GM082631911 . O
. . O O

In BC2GM090043718 IN O
the BC2GM090043718 DT O
green BC2GM090043718 JJ O
unicellular BC2GM090043718 JJ O
alga BC2GM090043718 NN O
Chlamydomonas BC2GM090043718 NNP O
eugametos BC2GM090043718 NN O
, BC2GM090043718 , O
cellular BC2GM090043718 JJ O
division BC2GM090043718 NN O
is BC2GM090043718 VBZ O
readily BC2GM090043718 RB O
synchronized BC2GM090043718 VBN O
by BC2GM090043718 IN O
light BC2GM090043718 JJ O
/ BC2GM090043718 NNP O
dark BC2GM090043718 NN O
cycles BC2GM090043718 NNS O
. BC2GM090043718 . O
. . O O

The BC2GM013302577 DT O
herpesvirus BC2GM013302577 NN O
entry BC2GM013302577 NN O
mediator BC2GM013302577 NN O
C BC2GM013302577 NNP O
( BC2GM013302577 ( O
HveC BC2GM013302577 NNP O
) BC2GM013302577 ) O
, BC2GM013302577 , O
previously BC2GM013302577 RB O
known BC2GM013302577 VBN O
as BC2GM013302577 IN O
poliovirus BC2GM013302577 NN O
receptor-related BC2GM013302577 JJ O
protein BC2GM013302577 NN O
1 BC2GM013302577 CD O
( BC2GM013302577 ( O
PRR1 BC2GM013302577 NNP O
) BC2GM013302577 ) O
, BC2GM013302577 , O
and BC2GM013302577 CC O
the BC2GM013302577 DT O
herpesvirus BC2GM013302577 NN O
Ig-like BC2GM013302577 NNP O
receptor BC2GM013302577 NN O
( BC2GM013302577 ( O
HIgR BC2GM013302577 NNP O
) BC2GM013302577 ) O
are BC2GM013302577 VBP O
the BC2GM013302577 DT O
bona BC2GM013302577 JJ O
fide BC2GM013302577 NN O
receptors BC2GM013302577 NNS O
employed BC2GM013302577 VBN O
by BC2GM013302577 IN O
herpes BC2GM013302577 NNS O
simplex BC2GM013302577 JJ O
virus-1 BC2GM013302577 JJ O
and BC2GM013302577 CC O
-2 BC2GM013302577 JJ O
( BC2GM013302577 ( O
HSV-1 BC2GM013302577 NNP O
and BC2GM013302577 CC O
-2 BC2GM013302577 NNP O
) BC2GM013302577 ) O
for BC2GM013302577 IN O
entry BC2GM013302577 NN O
into BC2GM013302577 IN O
the BC2GM013302577 DT O
human BC2GM013302577 JJ O
cell BC2GM013302577 NN O
lines BC2GM013302577 NNS O
most BC2GM013302577 RBS O
frequently BC2GM013302577 RB O
used BC2GM013302577 VBN O
in BC2GM013302577 IN O
HSV BC2GM013302577 NNP O
studies BC2GM013302577 NNS O
. BC2GM013302577 . O
. . O O

Nearly BC2GM060497618 RB O
1.5 BC2GM060497618 CD O
million BC2GM060497618 CD O
American BC2GM060497618 JJ O
men BC2GM060497618 NNS O
age BC2GM060497618 NN O
65 BC2GM060497618 CD O
and BC2GM060497618 CC O
older BC2GM060497618 JJR O
have BC2GM060497618 VBP O
osteoporosis BC2GM060497618 VBN O
, BC2GM060497618 , O
and BC2GM060497618 CC O
another BC2GM060497618 DT O
3.5 BC2GM060497618 CD O
million BC2GM060497618 CD O
are BC2GM060497618 VBP O
at BC2GM060497618 IN O
risk BC2GM060497618 NN O
. BC2GM060497618 . O
. . O O

A. BC2GM061835240 NN O
nidulans BC2GM061835240 NNS O
transformants BC2GM061835240 NNS O
secreted BC2GM061835240 VBD O
high BC2GM061835240 JJ O
amounts BC2GM061835240 NNS O
of BC2GM061835240 IN O
PGI BC2GM061835240 NNP O
and BC2GM061835240 CC O
PGII BC2GM061835240 NNP O
in BC2GM061835240 IN O
comparison BC2GM061835240 NN O
to BC2GM061835240 TO O
the BC2GM061835240 DT O
previously BC2GM061835240 RB O
characterized BC2GM061835240 VBN O
A. BC2GM061835240 NN O
niger BC2GM061835240 NN O
transformants BC2GM061835240 NNS O
and BC2GM061835240 CC O
a BC2GM061835240 DT O
novel BC2GM061835240 JJ O
polygalacturonase BC2GM061835240 NN O
( BC2GM061835240 ( O
PGC BC2GM061835240 NNP O
) BC2GM061835240 ) O
was BC2GM061835240 VBD O
produced BC2GM061835240 VBN O
at BC2GM061835240 IN O
high BC2GM061835240 JJ O
levels BC2GM061835240 NNS O
by BC2GM061835240 IN O
A. BC2GM061835240 NN O
nidulans BC2GM061835240 NNS O
transformed BC2GM061835240 VBN O
with BC2GM061835240 IN O
the BC2GM061835240 DT O
subcloned BC2GM061835240 VBN O
pgaC BC2GM061835240 NN O
gene BC2GM061835240 NN O
. BC2GM061835240 . O
. . O O

Their BC2GM011436488 PRP$ O
main BC2GM011436488 JJ O
representatives BC2GM011436488 NNS O
are BC2GM011436488 VBP O
the BC2GM011436488 DT O
American BC2GM011436488 NNP O
diagnostic BC2GM011436488 NN O
and BC2GM011436488 CC O
statistical BC2GM011436488 JJ O
manual BC2GM011436488 NN O
of BC2GM011436488 IN O
mental BC2GM011436488 JJ O
disorders BC2GM011436488 NNS O
, BC2GM011436488 , O
DSM-III BC2GM011436488 NNP O
, BC2GM011436488 , O
its BC2GM011436488 PRP$ O
revised BC2GM011436488 VBN O
version BC2GM011436488 NN O
DSM-III-R BC2GM011436488 NNP O
and BC2GM011436488 CC O
the BC2GM011436488 DT O
new BC2GM011436488 JJ O
international BC2GM011436488 JJ O
classification BC2GM011436488 NN O
of BC2GM011436488 IN O
mental BC2GM011436488 JJ O
disorders BC2GM011436488 NNS O
iCD-10 BC2GM011436488 JJ O
. BC2GM011436488 . O
. . O O

Functional BC2GM099369048 JJ O
importance BC2GM099369048 NN O
of BC2GM099369048 IN O
a BC2GM099369048 DT O
properly BC2GM099369048 RB O
folded BC2GM099369048 VBN O
surface BC2GM099369048 NN O
loop BC2GM099369048 NN O
covering BC2GM099369048 VBG O
the BC2GM099369048 DT O
catalytic BC2GM099369048 JJ O
center BC2GM099369048 NN O
. BC2GM099369048 . O
. . O O

The BC2GM044941923 DT O
actual BC2GM044941923 JJ O
placement BC2GM044941923 NN O
of BC2GM044941923 IN O
the BC2GM044941923 DT O
lesions BC2GM044941923 NNS O
was BC2GM044941923 VBD O
determined BC2GM044941923 VBN O
after BC2GM044941923 IN O
mapping BC2GM044941923 NN O
of BC2GM044941923 IN O
the BC2GM044941923 DT O
GPi BC2GM044941923 NNP O
by BC2GM044941923 IN O
microrecording BC2GM044941923 VBG O
, BC2GM044941923 , O
using BC2GM044941923 VBG O
stimulation BC2GM044941923 NN O
to BC2GM044941923 TO O
identify BC2GM044941923 VB O
the BC2GM044941923 DT O
sensorimotor BC2GM044941923 NN O
region BC2GM044941923 NN O
and BC2GM044941923 CC O
its BC2GM044941923 PRP$ O
somatotopic BC2GM044941923 NN O
organization BC2GM044941923 NN O
. BC2GM044941923 . O
. . O O

Glucose BC2GM030524461 NNP O
consumption BC2GM030524461 NN O
of BC2GM030524461 IN O
the BC2GM030524461 DT O
human BC2GM030524461 JJ O
brain BC2GM030524461 NN O
under BC2GM030524461 IN O
the BC2GM030524461 DT O
influence BC2GM030524461 NN O
of BC2GM030524461 IN O
intravenous BC2GM030524461 JJ O
infusions BC2GM030524461 NNS O
of BC2GM030524461 IN O
glucose BC2GM030524461 NN O
, BC2GM030524461 , O
glucagon BC2GM030524461 NN O
and BC2GM030524461 CC O
glucose-insulin BC2GM030524461 NN O
. BC2GM030524461 . O
. . O O

These BC2GM056216898 DT O
data BC2GM056216898 NNS O
also BC2GM056216898 RB O
suggest BC2GM056216898 VBP O
the BC2GM056216898 DT O
existence BC2GM056216898 NN O
of BC2GM056216898 IN O
a BC2GM056216898 DT O
mechanism BC2GM056216898 NN O
by BC2GM056216898 IN O
which BC2GM056216898 WDT O
regulatory BC2GM056216898 JJ O
subunits BC2GM056216898 NNS O
modulate BC2GM056216898 VBP O
the BC2GM056216898 DT O
PI BC2GM056216898 NNP O
3-kinase-mediated BC2GM056216898 JJ O
signals BC2GM056216898 NNS O
, BC2GM056216898 , O
independent BC2GM056216898 JJ O
of BC2GM056216898 IN O
the BC2GM056216898 DT O
kinase BC2GM056216898 NN O
activity BC2GM056216898 NN O
, BC2GM056216898 , O
possibly BC2GM056216898 RB O
through BC2GM056216898 IN O
subcellular BC2GM056216898 JJ O
localization BC2GM056216898 NN O
of BC2GM056216898 IN O
the BC2GM056216898 DT O
catalytic BC2GM056216898 JJ O
subunit BC2GM056216898 NN O
or BC2GM056216898 CC O
interaction BC2GM056216898 NN O
with BC2GM056216898 IN O
additional BC2GM056216898 JJ O
signaling BC2GM056216898 NN O
molecules BC2GM056216898 NNS O
. BC2GM056216898 . O
. . O O

The BC2GM066867028 DT O
results BC2GM066867028 NNS O
of BC2GM066867028 IN O
this BC2GM066867028 DT O
study BC2GM066867028 NN O
suggest BC2GM066867028 VBP O
that BC2GM066867028 IN O
in BC2GM066867028 IN O
patients BC2GM066867028 NNS O
with BC2GM066867028 IN O
syndrome BC2GM066867028 JJ O
X BC2GM066867028 NNP O
, BC2GM066867028 , O
myocardial BC2GM066867028 JJ O
ischemia BC2GM066867028 NN O
frequently BC2GM066867028 RB O
develops BC2GM066867028 VBZ O
during BC2GM066867028 IN O
daily BC2GM066867028 JJ O
life BC2GM066867028 NN O
; BC2GM066867028 : O
silent BC2GM066867028 JJ O
ischemia BC2GM066867028 NN O
is BC2GM066867028 VBZ O
an BC2GM066867028 DT O
important BC2GM066867028 JJ O
component BC2GM066867028 NN O
of BC2GM066867028 IN O
this BC2GM066867028 DT O
syndrome BC2GM066867028 NN O
; BC2GM066867028 : O
and BC2GM066867028 CC O
increased BC2GM066867028 VBD O
oxygen BC2GM066867028 NN O
demand BC2GM066867028 NN O
in BC2GM066867028 IN O
the BC2GM066867028 DT O
presence BC2GM066867028 NN O
of BC2GM066867028 IN O
impaired BC2GM066867028 JJ O
coronary BC2GM066867028 JJ O
vasodilatory BC2GM066867028 NN O
capacity BC2GM066867028 NN O
is BC2GM066867028 VBZ O
not BC2GM066867028 RB O
the BC2GM066867028 DT O
only BC2GM066867028 JJ O
cause BC2GM066867028 NN O
of BC2GM066867028 IN O
myocardial BC2GM066867028 JJ O
ischemia BC2GM066867028 NN O
. BC2GM066867028 . O
. . O O

These BC2GM049401430 DT O
properties BC2GM049401430 NNS O
prompted BC2GM049401430 VBD O
us BC2GM049401430 PRP O
to BC2GM049401430 TO O
investigate BC2GM049401430 VB O
Ets-1 BC2GM049401430 NNP O
expression BC2GM049401430 NN O
in BC2GM049401430 IN O
32 BC2GM049401430 CD O
human BC2GM049401430 JJ O
astroglial BC2GM049401430 JJ O
tumors BC2GM049401430 NNS O
of BC2GM049401430 IN O
WHO BC2GM049401430 NNP O
grades BC2GM049401430 VBZ O
I-IV BC2GM049401430 NNP O
and BC2GM049401430 CC O
to BC2GM049401430 TO O
correlate BC2GM049401430 VB O
the BC2GM049401430 DT O
data BC2GM049401430 NN O
with BC2GM049401430 IN O
the BC2GM049401430 DT O
expression BC2GM049401430 NN O
pattern BC2GM049401430 NN O
of BC2GM049401430 IN O
VEGF BC2GM049401430 NNP O
, BC2GM049401430 , O
Flt-1 BC2GM049401430 NNP O
, BC2GM049401430 , O
and BC2GM049401430 CC O
KDR BC2GM049401430 NNP O
. BC2GM049401430 . O
. . O O

Effect BC2GM063513672 NN O
of BC2GM063513672 IN O
choline BC2GM063513672 NN O
magnesium BC2GM063513672 NN O
trisalicylate BC2GM063513672 NN O
on BC2GM063513672 IN O
prostacyclin BC2GM063513672 NN O
production BC2GM063513672 NN O
by BC2GM063513672 IN O
isolated BC2GM063513672 JJ O
vascular BC2GM063513672 JJ O
tissue BC2GM063513672 NN O
of BC2GM063513672 IN O
the BC2GM063513672 DT O
rat BC2GM063513672 NN O
. BC2GM063513672 . O
. . O O

In BC2GM073488635 IN O
this BC2GM073488635 DT O
study BC2GM073488635 NN O
, BC2GM073488635 , O
we BC2GM073488635 PRP O
show BC2GM073488635 VBP O
that BC2GM073488635 IN O
HNF-4 BC2GM073488635 NNP O
, BC2GM073488635 , O
a BC2GM073488635 DT O
member BC2GM073488635 NN O
of BC2GM073488635 IN O
the BC2GM073488635 DT O
steroid BC2GM073488635 NN O
hormone BC2GM073488635 NN O
receptor BC2GM073488635 NN O
superfamily BC2GM073488635 RB O
, BC2GM073488635 , O
binds BC2GM073488635 VBZ O
the BC2GM073488635 DT O
AF-1 BC2GM073488635 NNP O
site BC2GM073488635 NN O
on BC2GM073488635 IN O
the BC2GM073488635 DT O
apoB BC2GM073488635 NN O
promoter BC2GM073488635 NN O
and BC2GM073488635 CC O
through BC2GM073488635 IN O
it BC2GM073488635 PRP O
activates BC2GM073488635 VBZ O
transcription BC2GM073488635 NN O
in BC2GM073488635 IN O
transient BC2GM073488635 JJ O
transfection BC2GM073488635 NN O
assays BC2GM073488635 NNS O
in BC2GM073488635 IN O
both BC2GM073488635 DT O
liver BC2GM073488635 NN O
and BC2GM073488635 CC O
non-liver BC2GM073488635 RB O
cell BC2GM073488635 NN O
lines BC2GM073488635 NNS O
, BC2GM073488635 , O
HepG2 BC2GM073488635 NNP O
and BC2GM073488635 CC O
HeLa BC2GM073488635 NNP O
, BC2GM073488635 , O
respectively BC2GM073488635 RB O
. BC2GM073488635 . O
. . O O

The BC2GM085880360 DT O
JNK BC2GM085880360 NNP O
/ BC2GM085880360 NNP O
SAPK BC2GM085880360 NNP O
activator BC2GM085880360 NN O
mixed BC2GM085880360 JJ O
lineage BC2GM085880360 NN O
kinase BC2GM085880360 VBD O
3 BC2GM085880360 CD O
( BC2GM085880360 ( O
MLK3 BC2GM085880360 NNP O
) BC2GM085880360 ) O
transforms BC2GM085880360 VBZ O
NIH BC2GM085880360 $ O
3T3 BC2GM085880360 CD O
cells BC2GM085880360 NNS O
in BC2GM085880360 IN O
a BC2GM085880360 DT O
MEK-dependent BC2GM085880360 JJ O
fashion BC2GM085880360 NN O
. BC2GM085880360 . O
. . O O

Thus BC2GM072333569 RB O
, BC2GM072333569 , O
IF-laser BC2GM072333569 NNP O
therapy BC2GM072333569 NN O
has BC2GM072333569 VBZ O
a BC2GM072333569 DT O
certain BC2GM072333569 JJ O
antioxidative BC2GM072333569 JJ O
effect BC2GM072333569 NN O
by BC2GM072333569 IN O
increasing BC2GM072333569 VBG O
SOD BC2GM072333569 NNP O
activity BC2GM072333569 NN O
in BC2GM072333569 IN O
RA BC2GM072333569 NNP O
patients BC2GM072333569 NNS O
' BC2GM072333569 POS O
blood BC2GM072333569 NN O
cells BC2GM072333569 NNS O
and BC2GM072333569 CC O
reducing BC2GM072333569 VBG O
the BC2GM072333569 DT O
production BC2GM072333569 NN O
of BC2GM072333569 IN O
highly BC2GM072333569 RB O
reactive BC2GM072333569 JJ O
oxygen BC2GM072333569 NN O
and BC2GM072333569 CC O
nitrogen BC2GM072333569 NN O
forms BC2GM072333569 NNS O
. BC2GM072333569 . O
. . O O

The BC2GM043328446 DT O
effects BC2GM043328446 NNS O
of BC2GM043328446 IN O
inoculum BC2GM043328446 NN O
size BC2GM043328446 NN O
, BC2GM043328446 , O
medium BC2GM043328446 NN O
, BC2GM043328446 , O
temperature BC2GM043328446 NN O
, BC2GM043328446 , O
and BC2GM043328446 CC O
duration BC2GM043328446 NN O
of BC2GM043328446 IN O
growth BC2GM043328446 NN O
on BC2GM043328446 IN O
the BC2GM043328446 DT O
in BC2GM043328446 IN O
vitro BC2GM043328446 JJ O
susceptibility BC2GM043328446 NN O
testing BC2GM043328446 NN O
of BC2GM043328446 IN O
Aspergillus BC2GM043328446 NNP O
fumigatus BC2GM043328446 NN O
were BC2GM043328446 VBD O
investigated BC2GM043328446 VBN O
using BC2GM043328446 VBG O
broth BC2GM043328446 DT O
micro- BC2GM043328446 JJ O
and BC2GM043328446 CC O
macro-dilution BC2GM043328446 NN O
techniques BC2GM043328446 NNS O
. BC2GM043328446 . O
. . O O

Development BC2GM070690502 NNP O
of BC2GM070690502 IN O
P BC2GM070690502 NNP O
carinii BC2GM070690502 NN O
pneumonia BC2GM070690502 NN O
was BC2GM070690502 VBD O
associated BC2GM070690502 VBN O
with BC2GM070690502 IN O
the BC2GM070690502 DT O
stage BC2GM070690502 NN O
of BC2GM070690502 IN O
Kaposi BC2GM070690502 NNP O
's BC2GM070690502 POS O
sarcoma BC2GM070690502 NN O
, BC2GM070690502 , O
B BC2GM070690502 NNP O
subtype BC2GM070690502 NN O
disease BC2GM070690502 NN O
, BC2GM070690502 , O
and BC2GM070690502 CC O
the BC2GM070690502 DT O
presence BC2GM070690502 NN O
of BC2GM070690502 IN O
0.20 BC2GM070690502 CD O
X BC2GM070690502 NNS O
10 BC2GM070690502 CD O
( BC2GM070690502 ( O
9 BC2GM070690502 CD O
) BC2GM070690502 ) O
/ BC2GM070690502 NN O
L BC2GM070690502 NNP O
( BC2GM070690502 ( O
200 BC2GM070690502 CD O
/ BC2GM070690502 NNP O
mm3 BC2GM070690502 NN O
) BC2GM070690502 ) O
or BC2GM070690502 CC O
fewer BC2GM070690502 JJR O
CD4 BC2GM070690502 NNP O
cells BC2GM070690502 NNS O
at BC2GM070690502 IN O
study BC2GM070690502 NN O
entry BC2GM070690502 NN O
. BC2GM070690502 . O
. . O O

CONCLUSION BC2GM020487228 NN O
: BC2GM020487228 : O
high BC2GM020487228 JJ O
resolution BC2GM020487228 NN O
MF-ERG BC2GM020487228 NNP O
seems BC2GM020487228 VBZ O
more BC2GM020487228 RBR O
sensitive BC2GM020487228 JJ O
than BC2GM020487228 IN O
low BC2GM020487228 JJ O
resolution BC2GM020487228 NN O
MF-ERG BC2GM020487228 NNP O
. BC2GM020487228 . O
. . O O

As BC2GM084904030 IN O
much BC2GM084904030 JJ O
thrombin BC2GM084904030 NN O
was BC2GM084904030 VBD O
formed BC2GM084904030 VBN O
during BC2GM084904030 IN O
cardiopulmonary BC2GM084904030 JJ O
bypass BC2GM084904030 NN O
( BC2GM084904030 ( O
measured BC2GM084904030 VBN O
by BC2GM084904030 IN O
the BC2GM084904030 DT O
prothrombin BC2GM084904030 NN O
activation BC2GM084904030 NN O
fragment BC2GM084904030 NN O
F1 BC2GM084904030 NNP O
+ BC2GM084904030 VBZ O
2 BC2GM084904030 CD O
and BC2GM084904030 CC O
thrombin-antithrombin BC2GM084904030 JJ O
complexes BC2GM084904030 NNS O
) BC2GM084904030 ) O
as BC2GM084904030 IN O
in BC2GM084904030 IN O
normal BC2GM084904030 JJ O
patients BC2GM084904030 NNS O
, BC2GM084904030 , O
showing BC2GM084904030 VBG O
that BC2GM084904030 IN O
factor BC2GM084904030 NN O
XII BC2GM084904030 NNP O
was BC2GM084904030 VBD O
not BC2GM084904030 RB O
necessary BC2GM084904030 JJ O
for BC2GM084904030 IN O
thrombin BC2GM084904030 JJ O
generation BC2GM084904030 NN O
. BC2GM084904030 . O
. . O O

Both BC2GM008128545 DT O
the BC2GM008128545 DT O
p38 BC2GM008128545 NN O
kinase BC2GM008128545 NN O
inhibitor BC2GM008128545 NN O
SB205380 BC2GM008128545 NNP O
( BC2GM008128545 ( O
SB BC2GM008128545 NNP O
) BC2GM008128545 ) O
and BC2GM008128545 CC O
cotransfection BC2GM008128545 NN O
of BC2GM008128545 IN O
a BC2GM008128545 DT O
dominant-negative BC2GM008128545 JJ O
mutant BC2GM008128545 NN O
of BC2GM008128545 IN O
p38 BC2GM008128545 NN O
kinase BC2GM008128545 NN O
reduced BC2GM008128545 VBD O
IL-1beta BC2GM008128545 NNP O
stimulation BC2GM008128545 NN O
of BC2GM008128545 IN O
the BC2GM008128545 DT O
hBNP BC2GM008128545 NN O
promoter BC2GM008128545 NN O
. BC2GM008128545 . O
. . O O

Four BC2GM068106933 CD O
multicannulated BC2GM068106933 VBD O
Holstein BC2GM068106933 NNP O
steers BC2GM068106933 NNS O
( BC2GM068106933 ( O
initial BC2GM068106933 JJ O
BW BC2GM068106933 NNP O
424 BC2GM068106933 CD O
+ BC2GM068106933 NNP O
/ BC2GM068106933 NNP O
- BC2GM068106933 : O
16 BC2GM068106933 CD O
kg BC2GM068106933 NN O
) BC2GM068106933 ) O
were BC2GM068106933 VBD O
used BC2GM068106933 VBN O
in BC2GM068106933 IN O
a BC2GM068106933 DT O
4 BC2GM068106933 CD O
x BC2GM068106933 NN O
4 BC2GM068106933 CD O
Latin BC2GM068106933 NNP O
square BC2GM068106933 NN O
to BC2GM068106933 TO O
determine BC2GM068106933 VB O
the BC2GM068106933 DT O
influence BC2GM068106933 NN O
of BC2GM068106933 IN O
protein BC2GM068106933 NN O
supplementation BC2GM068106933 NN O
on BC2GM068106933 IN O
forage BC2GM068106933 NN O
intake BC2GM068106933 NN O
, BC2GM068106933 , O
site BC2GM068106933 NN O
and BC2GM068106933 CC O
extent BC2GM068106933 NN O
of BC2GM068106933 IN O
digestion BC2GM068106933 NN O
, BC2GM068106933 , O
and BC2GM068106933 CC O
nutrient BC2GM068106933 JJ O
flow BC2GM068106933 NN O
in BC2GM068106933 IN O
steers BC2GM068106933 NNS O
consuming BC2GM068106933 VBG O
dormant BC2GM068106933 JJ O
bluestem-range BC2GM068106933 JJ O
forage BC2GM068106933 NN O
( BC2GM068106933 ( O
2.3 BC2GM068106933 CD O
% BC2GM068106933 NN O
CP BC2GM068106933 NNP O
) BC2GM068106933 ) O
. BC2GM068106933 . O
. . O O

Teboroxime BC2GM083082153 NNP O
is BC2GM083082153 VBZ O
a BC2GM083082153 DT O
new BC2GM083082153 JJ O
boronic BC2GM083082153 JJ O
acid BC2GM083082153 NN O
adduct BC2GM083082153 NN O
of BC2GM083082153 IN O
technetium BC2GM083082153 NN O
dioxime BC2GM083082153 NN O
( BC2GM083082153 ( O
BATO BC2GM083082153 NNP O
) BC2GM083082153 ) O
compound BC2GM083082153 NN O
that BC2GM083082153 IN O
demonstrates BC2GM083082153 VBZ O
favorable BC2GM083082153 JJ O
characteristics BC2GM083082153 NNS O
in BC2GM083082153 IN O
preliminary BC2GM083082153 JJ O
studies BC2GM083082153 NNS O
. BC2GM083082153 . O
. . O O

The BC2GM038427842 DT O
data BC2GM038427842 NN O
obtained BC2GM038427842 VBD O
included BC2GM038427842 VBD O
1 BC2GM038427842 CD O
) BC2GM038427842 ) O
the BC2GM038427842 DT O
mean BC2GM038427842 JJ O
frequency BC2GM038427842 NN O
of BC2GM038427842 IN O
abnormal BC2GM038427842 JJ O
teased BC2GM038427842 VBN O
myelinated BC2GM038427842 JJ O
fibers BC2GM038427842 NNS O
and BC2GM038427842 CC O
its BC2GM038427842 PRP$ O
upper BC2GM038427842 JJ O
limit BC2GM038427842 NN O
value BC2GM038427842 NN O
of BC2GM038427842 IN O
95 BC2GM038427842 CD O
% BC2GM038427842 NN O
confidence BC2GM038427842 NN O
interval BC2GM038427842 NN O
, BC2GM038427842 , O
and BC2GM038427842 CC O
2 BC2GM038427842 CD O
) BC2GM038427842 ) O
the BC2GM038427842 DT O
mean BC2GM038427842 JJ O
densities BC2GM038427842 NNS O
of BC2GM038427842 IN O
total BC2GM038427842 JJ O
, BC2GM038427842 , O
large BC2GM038427842 JJ O
and BC2GM038427842 CC O
small BC2GM038427842 JJ O
myelinated BC2GM038427842 VBD O
fibers BC2GM038427842 NNS O
and BC2GM038427842 CC O
of BC2GM038427842 IN O
unmyelinated BC2GM038427842 JJ O
fibers BC2GM038427842 NNS O
and BC2GM038427842 CC O
their BC2GM038427842 PRP$ O
lower BC2GM038427842 JJR O
limit BC2GM038427842 NN O
value BC2GM038427842 NN O
of BC2GM038427842 IN O
95 BC2GM038427842 CD O
% BC2GM038427842 NN O
confidence BC2GM038427842 NN O
interval BC2GM038427842 NN O
for BC2GM038427842 IN O
each BC2GM038427842 DT O
decade BC2GM038427842 NN O
. BC2GM038427842 . O
. . O O

The BC2GM047934950 DT O
University BC2GM047934950 NNP O
of BC2GM047934950 IN O
North BC2GM047934950 NNP O
Carolina BC2GM047934950 NNP O
caries BC2GM047934950 NNS O
risk BC2GM047934950 VBP O
assessment BC2GM047934950 NN O
was BC2GM047934950 VBD O
conducted BC2GM047934950 VBN O
between BC2GM047934950 IN O
1986 BC2GM047934950 CD O
and BC2GM047934950 CC O
1989 BC2GM047934950 CD O
with BC2GM047934950 IN O
5000 BC2GM047934950 CD O
children BC2GM047934950 NNS O
initially BC2GM047934950 RB O
in BC2GM047934950 IN O
grades BC2GM047934950 NNS O
1 BC2GM047934950 CD O
and BC2GM047934950 CC O
5 BC2GM047934950 CD O
from BC2GM047934950 IN O
low BC2GM047934950 JJ O
fluoride BC2GM047934950 NN O
sites BC2GM047934950 NNS O
in BC2GM047934950 IN O
South BC2GM047934950 NNP O
Carolina BC2GM047934950 NNP O
and BC2GM047934950 CC O
Maine BC2GM047934950 NNP O
. BC2GM047934950 . O
. . O O

The BC2GM015948167 DT O
delta BC2GM015948167 NN O
G BC2GM015948167 NNP O
values BC2GM015948167 NNS O
of BC2GM015948167 IN O
these BC2GM015948167 DT O
regions BC2GM015948167 NNS O
were BC2GM015948167 VBD O
higher BC2GM015948167 JJR O
, BC2GM015948167 , O
i.e BC2GM015948167 NN O
. BC2GM015948167 . O
potential BC2GM015948167 JJ O
secondary BC2GM015948167 JJ O
structural BC2GM015948167 JJ O
elements BC2GM015948167 NNS O
were BC2GM015948167 VBD O
fewer BC2GM015948167 JJR O
, BC2GM015948167 , O
than BC2GM015948167 IN O
in BC2GM015948167 IN O
TIR BC2GM015948167 NNP O
of BC2GM015948167 IN O
genes BC2GM015948167 NNS O
from BC2GM015948167 IN O
E. BC2GM015948167 NNP O
coli BC2GM015948167 NNS O
. BC2GM015948167 . O
. . O O

Although BC2GM004396508 IN O
analysis BC2GM004396508 NN O
of BC2GM004396508 IN O
the BC2GM004396508 DT O
similarity BC2GM004396508 NN O
between BC2GM004396508 IN O
the BC2GM004396508 DT O
44-kDa BC2GM004396508 JJ O
protein BC2GM004396508 NN O
and BC2GM004396508 CC O
the BC2GM004396508 DT O
E. BC2GM004396508 NNP O
coli BC2GM004396508 NNS O
RecA BC2GM004396508 NNP O
protein BC2GM004396508 NN O
did BC2GM004396508 VBD O
not BC2GM004396508 RB O
show BC2GM004396508 VB O
any BC2GM004396508 DT O
significant BC2GM004396508 JJ O
homology BC2GM004396508 NN O
between BC2GM004396508 IN O
them BC2GM004396508 PRP O
, BC2GM004396508 , O
it BC2GM004396508 PRP O
revealed BC2GM004396508 VBD O
their BC2GM004396508 PRP$ O
identity BC2GM004396508 NN O
by BC2GM004396508 IN O
five BC2GM004396508 CD O
amino-acid BC2GM004396508 JJ O
residues BC2GM004396508 NNS O
involved BC2GM004396508 VBN O
in BC2GM004396508 IN O
the BC2GM004396508 DT O
formation BC2GM004396508 NN O
of BC2GM004396508 IN O
the BC2GM004396508 DT O
epitope BC2GM004396508 NN O
that BC2GM004396508 WDT O
recognized BC2GM004396508 VBD O
the BC2GM004396508 DT O
paratope BC2GM004396508 NN O
of BC2GM004396508 IN O
the BC2GM004396508 DT O
RecA BC2GM004396508 NNP O
protein BC2GM004396508 NN O
antibody BC2GM004396508 NN O
for BC2GM004396508 IN O
subsequent BC2GM004396508 JJ O
epitope-paratope BC2GM004396508 JJ O
binding BC2GM004396508 NN O
of BC2GM004396508 IN O
these BC2GM004396508 DT O
proteins BC2GM004396508 NNS O
. BC2GM004396508 . O
. . O O

Perception BC2GM076945603 NN O
of BC2GM076945603 IN O
sweetness BC2GM076945603 NN O
can BC2GM076945603 MD O
not BC2GM076945603 RB O
be BC2GM076945603 VB O
used BC2GM076945603 VBN O
to BC2GM076945603 TO O
accurately BC2GM076945603 RB O
meter BC2GM076945603 VB O
the BC2GM076945603 DT O
metabolizable BC2GM076945603 JJ O
energy BC2GM076945603 NN O
or BC2GM076945603 CC O
nutritive BC2GM076945603 JJ O
value BC2GM076945603 NN O
of BC2GM076945603 IN O
a BC2GM076945603 DT O
food BC2GM076945603 NN O
. BC2GM076945603 . O
. . O O

The BC2GM075883505 DT O
sequence BC2GM075883505 NN O
immediately BC2GM075883505 RB O
upstream BC2GM075883505 JJ O
of BC2GM075883505 IN O
the BC2GM075883505 DT O
translation BC2GM075883505 NN O
start BC2GM075883505 NN O
site BC2GM075883505 NN O
was BC2GM075883505 VBD O
G BC2GM075883505 NNP O
+ BC2GM075883505 NNP O
C BC2GM075883505 NNP O
rich BC2GM075883505 NN O
( BC2GM075883505 ( O
greater BC2GM075883505 JJR O
than BC2GM075883505 IN O
75 BC2GM075883505 CD O
% BC2GM075883505 NN O
) BC2GM075883505 ) O
and BC2GM075883505 CC O
contained BC2GM075883505 VBD O
a BC2GM075883505 DT O
consensus BC2GM075883505 NN O
CCAAT BC2GM075883505 NNP O
sequence BC2GM075883505 NN O
despite BC2GM075883505 IN O
the BC2GM075883505 DT O
absence BC2GM075883505 NN O
of BC2GM075883505 IN O
a BC2GM075883505 DT O
TATA BC2GM075883505 NNP O
box BC2GM075883505 NN O
. BC2GM075883505 . O
. . O O

1 BC2GM014918843 CD O
. BC2GM014918843 . O
. . O O

Reversal BC2GM065583903 NNP O
of BC2GM065583903 IN O
'refractory BC2GM065583903 NNP O
septic BC2GM065583903 JJ O
shock BC2GM065583903 NN O
' BC2GM065583903 '' O
by BC2GM065583903 IN O
infusion BC2GM065583903 NN O
of BC2GM065583903 IN O
amrinone BC2GM065583903 NN O
and BC2GM065583903 CC O
angiotensin BC2GM065583903 NN O
II BC2GM065583903 NNP O
in BC2GM065583903 IN O
an BC2GM065583903 DT O
anthracycline-treated BC2GM065583903 JJ O
patient BC2GM065583903 NN O
. BC2GM065583903 . O
. . O O

NF-kappaB BC2GM063578385 JJ O
DNA-protein BC2GM063578385 NNP O
binding BC2GM063578385 NN O
and BC2GM063578385 CC O
ICAM-1 BC2GM063578385 JJ O
promoter BC2GM063578385 NN O
activity BC2GM063578385 NN O
were BC2GM063578385 VBD O
enhanced BC2GM063578385 VBN O
by BC2GM063578385 IN O
IL-1beta BC2GM063578385 NNP O
and BC2GM063578385 CC O
these BC2GM063578385 DT O
effects BC2GM063578385 NNS O
were BC2GM063578385 VBD O
inhibited BC2GM063578385 VBN O
by BC2GM063578385 IN O
tyrphostin BC2GM063578385 NN O
23 BC2GM063578385 CD O
, BC2GM063578385 , O
but BC2GM063578385 CC O
not BC2GM063578385 RB O
by BC2GM063578385 IN O
PD BC2GM063578385 NNP O
98059 BC2GM063578385 CD O
or BC2GM063578385 CC O
SB BC2GM063578385 NNP O
203580 BC2GM063578385 CD O
. BC2GM063578385 . O
. . O O

Developmental BC2GM096226765 NNP O
regulation BC2GM096226765 NN O
of BC2GM096226765 IN O
expression BC2GM096226765 NN O
of BC2GM096226765 IN O
the BC2GM096226765 DT O
malate BC2GM096226765 NN O
synthase BC2GM096226765 NN O
gene BC2GM096226765 NN O
in BC2GM096226765 IN O
transgenic BC2GM096226765 JJ O
plants BC2GM096226765 NNS O
. BC2GM096226765 . O
. . O O

The BC2GM009205276 DT O
combined BC2GM009205276 VBN O
in BC2GM009205276 IN O
vitro BC2GM009205276 JJ O
effects BC2GM009205276 NNS O
of BC2GM009205276 IN O
ethanol BC2GM009205276 JJ O
wih BC2GM009205276 NN O
methaqualone BC2GM009205276 NN O
, BC2GM009205276 , O
phenobarbital BC2GM009205276 NN O
, BC2GM009205276 , O
pyrazole BC2GM009205276 NN O
or BC2GM009205276 CC O
disulfiram BC2GM009205276 NN O
were BC2GM009205276 VBD O
studied BC2GM009205276 VBN O
using BC2GM009205276 VBG O
rat BC2GM009205276 NN O
brain BC2GM009205276 NN O
microsomal BC2GM009205276 JJ O
NA-K-ATPase BC2GM009205276 NNP O
. BC2GM009205276 . O
. . O O

By BC2GM097091019 IN O
contrast BC2GM097091019 NN O
, BC2GM097091019 , O
clonidine BC2GM097091019 NN O
( BC2GM097091019 ( O
1 BC2GM097091019 CD O
micrograms BC2GM097091019 NNS O
/ BC2GM097091019 NNP O
kg BC2GM097091019 NN O
) BC2GM097091019 ) O
elicited BC2GM097091019 VBD O
an BC2GM097091019 DT O
immediate BC2GM097091019 JJ O
and BC2GM097091019 CC O
prolonged BC2GM097091019 JJ O
fall BC2GM097091019 NN O
in BC2GM097091019 IN O
blood BC2GM097091019 NN O
pressure BC2GM097091019 NN O
and BC2GM097091019 CC O
heart BC2GM097091019 NN O
rate BC2GM097091019 NN O
when BC2GM097091019 WRB O
given BC2GM097091019 VBN O
into BC2GM097091019 IN O
the BC2GM097091019 DT O
vertebral BC2GM097091019 JJ O
artery BC2GM097091019 NN O
, BC2GM097091019 , O
but BC2GM097091019 CC O
not BC2GM097091019 RB O
intravenously BC2GM097091019 RB O
. BC2GM097091019 . O
. . O O

Comparison BC2GM001536665 NNP O
of BC2GM001536665 IN O
the BC2GM001536665 DT O
encoded BC2GM001536665 JJ O
ERCC3Dm BC2GM001536665 NNP O
protein BC2GM001536665 NN O
with BC2GM001536665 IN O
the BC2GM001536665 DT O
homologous BC2GM001536665 JJ O
proteins BC2GM001536665 NNS O
of BC2GM001536665 IN O
mouse BC2GM001536665 NN O
and BC2GM001536665 CC O
man BC2GM001536665 NN O
shows BC2GM001536665 VBZ O
a BC2GM001536665 DT O
strong BC2GM001536665 JJ O
amino BC2GM001536665 NN O
acid BC2GM001536665 NN O
conservation BC2GM001536665 NN O
( BC2GM001536665 ( O
71 BC2GM001536665 CD O
% BC2GM001536665 NN O
identity BC2GM001536665 NN O
) BC2GM001536665 ) O
, BC2GM001536665 , O
especially BC2GM001536665 RB O
in BC2GM001536665 IN O
the BC2GM001536665 DT O
postulated BC2GM001536665 JJ O
DNA BC2GM001536665 NNP O
binding BC2GM001536665 NN O
region BC2GM001536665 NN O
and BC2GM001536665 CC O
seven BC2GM001536665 CD O
'helicase BC2GM001536665 NNP O
' BC2GM001536665 POS O
domains BC2GM001536665 NNS O
. BC2GM001536665 . O
. . O O

A BC2GM099320794 DT O
score BC2GM099320794 NN O
( BC2GM099320794 ( O
APACHE BC2GM099320794 NNP O
II BC2GM099320794 NNP O
) BC2GM099320794 ) O
was BC2GM099320794 VBD O
calculated BC2GM099320794 VBN O
to BC2GM099320794 TO O
assess BC2GM099320794 VB O
the BC2GM099320794 DT O
severity BC2GM099320794 NN O
of BC2GM099320794 IN O
disease BC2GM099320794 NN O
. BC2GM099320794 . O
. . O O

Instead BC2GM005729141 RB O
, BC2GM005729141 , O
the BC2GM005729141 DT O
large BC2GM005729141 JJ O
difference BC2GM005729141 NN O
in BC2GM005729141 IN O
ssDNA-binding BC2GM005729141 JJ O
affinities BC2GM005729141 NNS O
reflects BC2GM005729141 VBZ O
the BC2GM005729141 DT O
loss BC2GM005729141 NN O
of BC2GM005729141 IN O
hexamerization BC2GM005729141 NN O
ability BC2GM005729141 NN O
by BC2GM005729141 IN O
uvsY BC2GM005729141 NN O
, BC2GM005729141 , O
suggesting BC2GM005729141 VBG O
that BC2GM005729141 IN O
a BC2GM005729141 DT O
form BC2GM005729141 NN O
of BC2GM005729141 IN O
intrahexamer BC2GM005729141 JJ O
synergism BC2GM005729141 NN O
or BC2GM005729141 CC O
cooperativity BC2GM005729141 NN O
between BC2GM005729141 IN O
binding BC2GM005729141 VBG O
sites BC2GM005729141 NNS O
within BC2GM005729141 IN O
the BC2GM005729141 DT O
uvsY BC2GM005729141 JJ O
hexamer BC2GM005729141 NN O
leads BC2GM005729141 VBZ O
to BC2GM005729141 TO O
its BC2GM005729141 PRP$ O
high BC2GM005729141 JJ O
observed BC2GM005729141 VBN O
affinity BC2GM005729141 NN O
for BC2GM005729141 IN O
ssDNA BC2GM005729141 NN O
. BC2GM005729141 . O
. . O O

Consistent BC2GM041776531 JJ O
with BC2GM041776531 IN O
the BC2GM041776531 DT O
large BC2GM041776531 JJ O
pocket BC2GM041776531 NN O
of BC2GM041776531 IN O
Rb BC2GM041776531 NNP O
binding BC2GM041776531 VBG O
to BC2GM041776531 TO O
TAF BC2GM041776531 NNP O
( BC2GM041776531 ( O
II BC2GM041776531 NNP O
) BC2GM041776531 ) O
250 BC2GM041776531 CD O
, BC2GM041776531 , O
the BC2GM041776531 DT O
large BC2GM041776531 JJ O
pocket BC2GM041776531 NN O
domains BC2GM041776531 NNS O
of BC2GM041776531 IN O
both BC2GM041776531 DT O
p107 BC2GM041776531 NNS O
and BC2GM041776531 CC O
p130 BC2GM041776531 NNS O
are BC2GM041776531 VBP O
able BC2GM041776531 JJ O
to BC2GM041776531 TO O
bind BC2GM041776531 VB O
to BC2GM041776531 TO O
TAF BC2GM041776531 NNP O
( BC2GM041776531 ( O
II BC2GM041776531 NNP O
) BC2GM041776531 ) O
250 BC2GM041776531 CD O
in BC2GM041776531 IN O
vivo BC2GM041776531 NN O
. BC2GM041776531 . O
. . O O

This BC2GM024718949 DT O
selective BC2GM024718949 JJ O
squelching BC2GM024718949 NN O
activity BC2GM024718949 NN O
suggests BC2GM024718949 VBZ O
that BC2GM024718949 IN O
GRIM BC2GM024718949 NNP O
can BC2GM024718949 MD O
interact BC2GM024718949 VB O
with BC2GM024718949 IN O
an BC2GM024718949 DT O
essential BC2GM024718949 JJ O
component BC2GM024718949 NN O
of BC2GM024718949 IN O
the BC2GM024718949 DT O
RNA BC2GM024718949 NNP O
polymerase BC2GM024718949 NN O
II BC2GM024718949 NNP O
transcription BC2GM024718949 NN O
machinery BC2GM024718949 NN O
. BC2GM024718949 . O
. . O O

Mutation BC2GM021723092 NN O
of BC2GM021723092 IN O
the BC2GM021723092 DT O
HNF3 BC2GM021723092 NNP O
element BC2GM021723092 NN O
significantly BC2GM021723092 RB O
reduced BC2GM021723092 VBN O
promoter BC2GM021723092 NN O
activity BC2GM021723092 NN O
in BC2GM021723092 IN O
HepG2 BC2GM021723092 NNP O
cells BC2GM021723092 NNS O
, BC2GM021723092 , O
whereas BC2GM021723092 IN O
this BC2GM021723092 DT O
element BC2GM021723092 NN O
in BC2GM021723092 IN O
isolation BC2GM021723092 NN O
conferred BC2GM021723092 VBD O
HNF3beta BC2GM021723092 NNP O
responsiveness BC2GM021723092 NN O
to BC2GM021723092 TO O
a BC2GM021723092 DT O
heterologous BC2GM021723092 JJ O
promoter BC2GM021723092 NN O
. BC2GM021723092 . O
. . O O

Our BC2GM012491320 PRP$ O
objective BC2GM012491320 NN O
was BC2GM012491320 VBD O
to BC2GM012491320 TO O
find BC2GM012491320 VB O
possible BC2GM012491320 JJ O
predictors BC2GM012491320 NNS O
for BC2GM012491320 IN O
the BC2GM012491320 DT O
expression BC2GM012491320 NN O
and BC2GM012491320 CC O
progression BC2GM012491320 NN O
of BC2GM012491320 IN O
LJM BC2GM012491320 NNP O
and BC2GM012491320 CC O
to BC2GM012491320 TO O
evaluate BC2GM012491320 VB O
the BC2GM012491320 DT O
relationship BC2GM012491320 NN O
between BC2GM012491320 IN O
LJM BC2GM012491320 NNP O
and BC2GM012491320 CC O
other BC2GM012491320 JJ O
long-term BC2GM012491320 JJ O
complications BC2GM012491320 NNS O
of BC2GM012491320 IN O
insulin-dependent BC2GM012491320 JJ O
diabetes BC2GM012491320 NNS O
mellitus BC2GM012491320 NN O
. BC2GM012491320 . O
. . O O

Cell BC2GM035990949 NNP O
lines BC2GM035990949 NNS O
expressing BC2GM035990949 VBG O
single BC2GM035990949 JJ O
amino BC2GM035990949 NN O
acid BC2GM035990949 JJ O
substitutions BC2GM035990949 NNS O
of BC2GM035990949 IN O
the BC2GM035990949 DT O
carboxyl-terminal BC2GM035990949 JJ O
asparagine BC2GM035990949 NN O
of BC2GM035990949 IN O
CD2 BC2GM035990949 NNP O
are BC2GM035990949 VBP O
incapable BC2GM035990949 JJ O
of BC2GM035990949 IN O
avidity BC2GM035990949 NN O
regulation BC2GM035990949 NN O
by BC2GM035990949 IN O
TCR BC2GM035990949 NNP O
signaling BC2GM035990949 VBG O
, BC2GM035990949 , O
PMA BC2GM035990949 NNP O
treatment BC2GM035990949 NN O
, BC2GM035990949 , O
or BC2GM035990949 CC O
elevation BC2GM035990949 NN O
of BC2GM035990949 IN O
intracellular BC2GM035990949 JJ O
cAMP BC2GM035990949 NN O
levels BC2GM035990949 NNS O
, BC2GM035990949 , O
demonstrating BC2GM035990949 VBG O
that BC2GM035990949 IN O
each BC2GM035990949 DT O
of BC2GM035990949 IN O
these BC2GM035990949 DT O
stimuli BC2GM035990949 NNS O
utilizes BC2GM035990949 VBP O
a BC2GM035990949 DT O
common BC2GM035990949 JJ O
structural BC2GM035990949 JJ O
element BC2GM035990949 NN O
for BC2GM035990949 IN O
regulating BC2GM035990949 VBG O
CD2 BC2GM035990949 NNP O
avidity BC2GM035990949 NN O
. BC2GM035990949 . O
. . O O

Oscillatory BC2GM093671894 NNP O
flow BC2GM093671894 NN O
is BC2GM093671894 VBZ O
reestablished BC2GM093671894 VBN O
in BC2GM093671894 IN O
the BC2GM093671894 DT O
model BC2GM093671894 NN O
at BC2GM093671894 IN O
the BC2GM093671894 DT O
capillary-cerebrospinal BC2GM093671894 JJ O
fluid BC2GM093671894 NN O
and BC2GM093671894 CC O
capillary-venous BC2GM093671894 JJ O
interfaces BC2GM093671894 NNS O
. BC2GM093671894 . O
. . O O

The BC2GM092851466 DT O
control BC2GM092851466 NN O
of BC2GM092851466 IN O
human BC2GM092851466 JJ O
aromatase BC2GM092851466 NN O
expression BC2GM092851466 NN O
is BC2GM092851466 VBZ O
complex BC2GM092851466 JJ O
in BC2GM092851466 IN O
that BC2GM092851466 DT O
several BC2GM092851466 JJ O
promoters BC2GM092851466 NNS O
drive BC2GM092851466 VBP O
aromatase BC2GM092851466 JJ O
expression BC2GM092851466 NN O
in BC2GM092851466 IN O
a BC2GM092851466 DT O
tissue-specific BC2GM092851466 JJ O
manner BC2GM092851466 NN O
. BC2GM092851466 . O
. . O O

The BC2GM038250262 DT O
RPC31 BC2GM038250262 NNP O
gene BC2GM038250262 NN O
encoding BC2GM038250262 VBG O
the BC2GM038250262 DT O
C31 BC2GM038250262 NNP O
subunit BC2GM038250262 NN O
of BC2GM038250262 IN O
Saccharomyces BC2GM038250262 NNP O
cerevisiae BC2GM038250262 NN O
RNA BC2GM038250262 NNP O
polymerase BC2GM038250262 NN O
C BC2GM038250262 NNP O
( BC2GM038250262 ( O
III BC2GM038250262 NNP O
) BC2GM038250262 ) O
has BC2GM038250262 VBZ O
been BC2GM038250262 VBN O
isolated BC2GM038250262 VBN O
, BC2GM038250262 , O
starting BC2GM038250262 VBG O
from BC2GM038250262 IN O
a BC2GM038250262 DT O
C-terminal BC2GM038250262 JJ O
fragment BC2GM038250262 NN O
cloned BC2GM038250262 VBN O
on BC2GM038250262 IN O
a BC2GM038250262 DT O
lambda BC2GM038250262 JJ O
gt11 BC2GM038250262 NN O
library BC2GM038250262 NN O
. BC2GM038250262 . O
. . O O

The BC2GM063455036 DT O
strategy BC2GM063455036 NN O
uses BC2GM063455036 VBZ O
RNA BC2GM063455036 NNP O
ligase BC2GM063455036 NN O
to BC2GM063455036 TO O
add BC2GM063455036 VB O
DNA BC2GM063455036 NNP O
oligonucleotide BC2GM063455036 IN O
priming BC2GM063455036 VBG O
sites BC2GM063455036 NNS O
to BC2GM063455036 TO O
the BC2GM063455036 DT O
RNA BC2GM063455036 NNP O
for BC2GM063455036 IN O
subsequent BC2GM063455036 JJ O
reverse BC2GM063455036 NN O
transcription BC2GM063455036 NN O
and BC2GM063455036 CC O
PCR BC2GM063455036 NNP O
( BC2GM063455036 ( O
RNA BC2GM063455036 NNP O
ligase BC2GM063455036 NN O
, BC2GM063455036 , O
reverse BC2GM063455036 VB O
transcription-PCR BC2GM063455036 NN O
, BC2GM063455036 , O
or BC2GM063455036 CC O
RL BC2GM063455036 NNP O
/ BC2GM063455036 NNP O
RT BC2GM063455036 NNP O
/ BC2GM063455036 NNP O
PCR BC2GM063455036 NNP O
) BC2GM063455036 ) O
. BC2GM063455036 . O
. . O O

The BC2GM012490279 DT O
cumulative BC2GM012490279 JJ O
experience BC2GM012490279 NN O
in BC2GM012490279 IN O
liver BC2GM012490279 NN O
transplantation BC2GM012490279 NN O
since BC2GM012490279 IN O
the BC2GM012490279 DT O
introduction BC2GM012490279 NN O
of BC2GM012490279 IN O
cyclosporine BC2GM012490279 NN O
A BC2GM012490279 NNP O
has BC2GM012490279 VBZ O
confirmed BC2GM012490279 VBN O
its BC2GM012490279 PRP$ O
efficacy BC2GM012490279 NN O
in BC2GM012490279 IN O
the BC2GM012490279 DT O
treatment BC2GM012490279 NN O
of BC2GM012490279 IN O
diverse BC2GM012490279 JJ O
liver BC2GM012490279 NN O
diseases BC2GM012490279 NNS O
in BC2GM012490279 IN O
children BC2GM012490279 NNS O
and BC2GM012490279 CC O
adults BC2GM012490279 NNS O
. BC2GM012490279 . O
. . O O

We BC2GM037323939 PRP O
found BC2GM037323939 VBD O
that BC2GM037323939 IN O
secretion BC2GM037323939 NN O
of BC2GM037323939 IN O
chitinolytic BC2GM037323939 JJ O
enzymes BC2GM037323939 NNS O
by BC2GM037323939 IN O
cultured BC2GM037323939 VBD O
L. BC2GM037323939 NNP O
major BC2GM037323939 JJ O
parasites BC2GM037323939 NNS O
is BC2GM037323939 VBZ O
inhibited BC2GM037323939 VBN O
by BC2GM037323939 IN O
blood BC2GM037323939 NN O
or BC2GM037323939 CC O
hemoglobin BC2GM037323939 NN O
, BC2GM037323939 , O
and BC2GM037323939 CC O
hence BC2GM037323939 RB O
these BC2GM037323939 DT O
enzymes BC2GM037323939 NNS O
are BC2GM037323939 VBP O
apparently BC2GM037323939 RB O
absent BC2GM037323939 JJ O
from BC2GM037323939 IN O
the BC2GM037323939 DT O
blood-fed BC2GM037323939 NN O
infected BC2GM037323939 JJ O
flies BC2GM037323939 NNS O
, BC2GM037323939 , O
where BC2GM037323939 WRB O
the BC2GM037323939 DT O
cardiac BC2GM037323939 NN O
valve BC2GM037323939 NN O
appears BC2GM037323939 VBZ O
undamaged BC2GM037323939 JJ O
. BC2GM037323939 . O
. . O O

These BC2GM080743687 DT O
8-oxoguanine BC2GM080743687 JJ O
DNA BC2GM080743687 NN O
glycosylases BC2GM080743687 NNS O
, BC2GM080743687 , O
hOgg1 BC2GM080743687 NN O
( BC2GM080743687 ( O
human BC2GM080743687 JJ O
) BC2GM080743687 ) O
and BC2GM080743687 CC O
mOgg1 BC2GM080743687 $ O
( BC2GM080743687 ( O
murine BC2GM080743687 NN O
) BC2GM080743687 ) O
, BC2GM080743687 , O
are BC2GM080743687 VBP O
homologous BC2GM080743687 JJ O
to BC2GM080743687 TO O
each BC2GM080743687 DT O
other BC2GM080743687 JJ O
and BC2GM080743687 CC O
to BC2GM080743687 TO O
yeast BC2GM080743687 VB O
Ogg1 BC2GM080743687 NNP O
. BC2GM080743687 . O
. . O O

Temporal BC2GM095302327 JJ O
recruitment BC2GM095302327 NN O
of BC2GM095302327 IN O
the BC2GM095302327 DT O
mSin3A-histone BC2GM095302327 JJ O
deacetylase BC2GM095302327 NN O
corepressor BC2GM095302327 NN O
complex BC2GM095302327 NN O
to BC2GM095302327 TO O
the BC2GM095302327 DT O
ETS BC2GM095302327 NNP O
domain BC2GM095302327 VBP O
transcription BC2GM095302327 NN O
factor BC2GM095302327 NN O
Elk-1 BC2GM095302327 NNP O
. BC2GM095302327 . O
. . O O

When BC2GM029694123 WRB O
expressed BC2GM029694123 VBN O
in BC2GM029694123 IN O
thymidine BC2GM029694123 JJ O
kinase-deficient BC2GM029694123 JJ O
L BC2GM029694123 NNP O
cells BC2GM029694123 NNS O
or BC2GM029694123 CC O
3T3 BC2GM029694123 CD O
cells BC2GM029694123 NNS O
, BC2GM029694123 , O
C BC2GM029694123 NNP O
/ BC2GM029694123 NNP O
EBPalpha BC2GM029694123 NNP O
is BC2GM029694123 VBZ O
detected BC2GM029694123 VBN O
in BC2GM029694123 IN O
a BC2GM029694123 DT O
protein BC2GM029694123 NN O
complex BC2GM029694123 NN O
which BC2GM029694123 WDT O
binds BC2GM029694123 VBZ O
to BC2GM029694123 TO O
the BC2GM029694123 DT O
E2F BC2GM029694123 NNP O
binding BC2GM029694123 NN O
sites BC2GM029694123 NNS O
found BC2GM029694123 VBN O
in BC2GM029694123 IN O
the BC2GM029694123 DT O
promoters BC2GM029694123 NNS O
of BC2GM029694123 IN O
the BC2GM029694123 DT O
genes BC2GM029694123 NNS O
for BC2GM029694123 IN O
E2F-1 BC2GM029694123 NNP O
and BC2GM029694123 CC O
dihydrofolate BC2GM029694123 VB O
reductase BC2GM029694123 NN O
( BC2GM029694123 ( O
DHFR BC2GM029694123 NNP O
) BC2GM029694123 ) O
. BC2GM029694123 . O
. . O O

The BC2GM038291943 DT O
same BC2GM038291943 JJ O
slice BC2GM038291943 NN O
was BC2GM038291943 VBD O
imaged BC2GM038291943 VBN O
three BC2GM038291943 CD O
times BC2GM038291943 NNS O
each BC2GM038291943 DT O
with BC2GM038291943 IN O
sequences BC2GM038291943 NNS O
using BC2GM038291943 VBG O
spatial BC2GM038291943 JJ O
presaturation BC2GM038291943 NN O
or BC2GM038291943 CC O
not BC2GM038291943 RB O
. BC2GM038291943 . O
. . O O

Measurement BC2GM065990339 NN O
of BC2GM065990339 IN O
protein BC2GM065990339 NN O
in BC2GM065990339 IN O
natural BC2GM065990339 JJ O
rubber BC2GM065990339 NN O
latex BC2GM065990339 NN O
. BC2GM065990339 . O
. . O O

Interestingly BC2GM094094269 RB O
, BC2GM094094269 , O
VDR BC2GM094094269 NNP O
was BC2GM094094269 VBD O
able BC2GM094094269 JJ O
to BC2GM094094269 TO O
bind BC2GM094094269 VB O
to BC2GM094094269 TO O
VDREs BC2GM094094269 NNP O
with BC2GM094094269 IN O
high BC2GM094094269 JJ O
affinity BC2GM094094269 NN O
and BC2GM094094269 CC O
to BC2GM094094269 TO O
fully BC2GM094094269 RB O
activate BC2GM094094269 VB O
transcription BC2GM094094269 NN O
in BC2GM094094269 IN O
intact BC2GM094094269 JJ O
yeast BC2GM094094269 JJ O
cells BC2GM094094269 NNS O
in BC2GM094094269 IN O
the BC2GM094094269 DT O
presence BC2GM094094269 NN O
of BC2GM094094269 IN O
the BC2GM094094269 DT O
retinoid BC2GM094094269 NN O
X BC2GM094094269 NNP O
receptor BC2GM094094269 NN O
( BC2GM094094269 ( O
RXR BC2GM094094269 NNP O
) BC2GM094094269 ) O
. BC2GM094094269 . O
. . O O

The BC2GM063528560 DT O
magnitude BC2GM063528560 NN O
of BC2GM063528560 IN O
all BC2GM063528560 DT O
four BC2GM063528560 CD O
parameters BC2GM063528560 NNS O
increased BC2GM063528560 VBD O
in BC2GM063528560 IN O
an BC2GM063528560 DT O
exponential BC2GM063528560 JJ O
fashion BC2GM063528560 NN O
with BC2GM063528560 IN O
increasing BC2GM063528560 VBG O
sperm BC2GM063528560 NN O
number BC2GM063528560 NN O
up BC2GM063528560 IN O
to BC2GM063528560 TO O
400 BC2GM063528560 CD O
x BC2GM063528560 NNS O
10 BC2GM063528560 CD O
( BC2GM063528560 ( O
6 BC2GM063528560 CD O
) BC2GM063528560 ) O
per BC2GM063528560 IN O
ejaculate BC2GM063528560 NN O
. BC2GM063528560 . O
. . O O

It BC2GM027790254 PRP O
is BC2GM027790254 VBZ O
suggested BC2GM027790254 VBN O
that BC2GM027790254 IN O
death BC2GM027790254 NN O
of BC2GM027790254 IN O
S. BC2GM027790254 NNP O
mansoni BC2GM027790254 NNP O
cercariae BC2GM027790254 NN O
during BC2GM027790254 IN O
penetration BC2GM027790254 NN O
of BC2GM027790254 IN O
mammalian BC2GM027790254 JJ O
host BC2GM027790254 NN O
skin BC2GM027790254 NN O
is BC2GM027790254 VBZ O
probably BC2GM027790254 RB O
due BC2GM027790254 JJ O
to BC2GM027790254 TO O
exhaustion BC2GM027790254 NN O
of BC2GM027790254 IN O
their BC2GM027790254 PRP$ O
energy BC2GM027790254 NN O
reserves BC2GM027790254 NNS O
. BC2GM027790254 . O
. . O O

One BC2GM059714682 CD O
day BC2GM059714682 NN O
postoperatively BC2GM059714682 RB O
, BC2GM059714682 , O
the BC2GM059714682 DT O
mononuclear BC2GM059714682 JJ O
leukocyte BC2GM059714682 JJ O
beta BC2GM059714682 NN O
2-receptor BC2GM059714682 JJ O
density BC2GM059714682 NN O
decreased BC2GM059714682 VBN O
maximally BC2GM059714682 RB O
by BC2GM059714682 IN O
45 BC2GM059714682 CD O
+ BC2GM059714682 NNS O
/ BC2GM059714682 SYM O
- BC2GM059714682 : O
11 BC2GM059714682 CD O
% BC2GM059714682 NN O
in BC2GM059714682 IN O
the BC2GM059714682 DT O
enflurane BC2GM059714682 NN O
patients BC2GM059714682 NNS O
, BC2GM059714682 , O
and BC2GM059714682 CC O
by BC2GM059714682 IN O
53 BC2GM059714682 CD O
+ BC2GM059714682 NNS O
/ BC2GM059714682 SYM O
- BC2GM059714682 : O
6 BC2GM059714682 CD O
% BC2GM059714682 NN O
in BC2GM059714682 IN O
the BC2GM059714682 DT O
neurolept BC2GM059714682 JJ O
patients BC2GM059714682 NNS O
. BC2GM059714682 . O
. . O O

The BC2GM032772191 DT O
general BC2GM032772191 JJ O
concept BC2GM032772191 NN O
of BC2GM032772191 IN O
RARE-cleavage BC2GM032772191 JJ O
mapping BC2GM032772191 NN O
as BC2GM032772191 RB O
well BC2GM032772191 RB O
as BC2GM032772191 IN O
its BC2GM032772191 PRP$ O
applications BC2GM032772191 NNS O
and BC2GM032772191 CC O
limitations BC2GM032772191 NNS O
are BC2GM032772191 VBP O
discussed BC2GM032772191 VBN O
. BC2GM032772191 . O
. . O O

As BC2GM067276643 IN O
the BC2GM067276643 DT O
mechanism BC2GM067276643 NN O
of BC2GM067276643 IN O
the BC2GM067276643 DT O
intractability BC2GM067276643 NN O
, BC2GM067276643 , O
cell BC2GM067276643 NN O
function BC2GM067276643 NN O
involved BC2GM067276643 VBN O
in BC2GM067276643 IN O
the BC2GM067276643 DT O
defense BC2GM067276643 NN O
against BC2GM067276643 IN O
infection BC2GM067276643 NN O
was BC2GM067276643 VBD O
evaluated BC2GM067276643 VBN O
. BC2GM067276643 . O
. . O O

The BC2GM003643024 DT O
failure BC2GM003643024 NN O
suggests BC2GM003643024 VBZ O
that BC2GM003643024 IN O
these BC2GM003643024 DT O
assembly BC2GM003643024 RB O
competent BC2GM003643024 NN O
but BC2GM003643024 CC O
complementation-negative BC2GM003643024 JJ O
alpha BC2GM003643024 NN O
mutants BC2GM003643024 NNS O
lack BC2GM003643024 VBP O
an BC2GM003643024 DT O
as BC2GM003643024 IN O
yet BC2GM003643024 RB O
unidentified BC2GM003643024 JJ O
function BC2GM003643024 NN O
( BC2GM003643024 ( O
s BC2GM003643024 NN O
) BC2GM003643024 ) O
. BC2GM003643024 . O
. . O O

On BC2GM077617268 IN O
the BC2GM077617268 DT O
basis BC2GM077617268 NN O
of BC2GM077617268 IN O
the BC2GM077617268 DT O
physical BC2GM077617268 JJ O
interactions BC2GM077617268 NNS O
between BC2GM077617268 IN O
Sxl BC2GM077617268 NNP O
and BC2GM077617268 CC O
Snf BC2GM077617268 NNP O
, BC2GM077617268 , O
we BC2GM077617268 PRP O
present BC2GM077617268 VBP O
a BC2GM077617268 DT O
model BC2GM077617268 NN O
for BC2GM077617268 IN O
Sxl BC2GM077617268 NNP O
splicing BC2GM077617268 VBG O
regulation BC2GM077617268 NN O
. BC2GM077617268 . O
. . O O

The BC2GM050125975 DT O
STP1 BC2GM050125975 NNP O
locus BC2GM050125975 NN O
is BC2GM050125975 VBZ O
located BC2GM050125975 VBN O
on BC2GM050125975 IN O
chromosome BC2GM050125975 NN O
IV BC2GM050125975 NNP O
close BC2GM050125975 NN O
to BC2GM050125975 TO O
at BC2GM050125975 IN O
least BC2GM050125975 JJS O
two BC2GM050125975 CD O
other BC2GM050125975 JJ O
genes BC2GM050125975 NNS O
involved BC2GM050125975 VBN O
in BC2GM050125975 IN O
RNA BC2GM050125975 NNP O
splicing BC2GM050125975 NN O
: BC2GM050125975 : O
PRP3 BC2GM050125975 NNP O
and BC2GM050125975 CC O
SPP41 BC2GM050125975 NNP O
. BC2GM050125975 . O
. . O O

Strains BC2GM091067876 NNS O
lacking BC2GM091067876 VBG O
a BC2GM091067876 DT O
functional BC2GM091067876 JJ O
RPL16A BC2GM091067876 NNP O
gene BC2GM091067876 NN O
grow BC2GM091067876 NN O
as BC2GM091067876 RB O
rapidly BC2GM091067876 RB O
as BC2GM091067876 IN O
wild BC2GM091067876 JJ O
type BC2GM091067876 NN O
, BC2GM091067876 , O
whereas BC2GM091067876 VBP O
those BC2GM091067876 DT O
containing BC2GM091067876 VBG O
a BC2GM091067876 DT O
null BC2GM091067876 JJ O
allele BC2GM091067876 NN O
of BC2GM091067876 IN O
RPL16B BC2GM091067876 NNP O
grow BC2GM091067876 VB O
more BC2GM091067876 RBR O
slowly BC2GM091067876 RB O
than BC2GM091067876 IN O
wild BC2GM091067876 JJ O
type BC2GM091067876 NN O
. BC2GM091067876 . O
. . O O

A BC2GM075464288 DT O
retrospective BC2GM075464288 JJ O
study BC2GM075464288 NN O
of BC2GM075464288 IN O
clozapine BC2GM075464288 NN O
and BC2GM075464288 CC O
electroencephalographic BC2GM075464288 JJ O
abnormalities BC2GM075464288 NNS O
in BC2GM075464288 IN O
schizophrenic BC2GM075464288 JJ O
patients BC2GM075464288 NNS O
. BC2GM075464288 . O
. . O O

Blood BC2GM011728728 NNP O
coagulation BC2GM011728728 NN O
Factor BC2GM011728728 NNP O
X BC2GM011728728 NNP O
and BC2GM011728728 CC O
its BC2GM011728728 PRP$ O
activated BC2GM011728728 JJ O
form BC2GM011728728 NN O
Factor BC2GM011728728 NNP O
Xa BC2GM011728728 NNP O
play BC2GM011728728 VBD O
an BC2GM011728728 DT O
essential BC2GM011728728 JJ O
role BC2GM011728728 NN O
in BC2GM011728728 IN O
the BC2GM011728728 DT O
midphase BC2GM011728728 NN O
of BC2GM011728728 IN O
the BC2GM011728728 DT O
clotting BC2GM011728728 NN O
cascade BC2GM011728728 NN O
. BC2GM011728728 . O
. . O O

In BC2GM059940131 IN O
the BC2GM059940131 DT O
other BC2GM059940131 JJ O
two BC2GM059940131 CD O
groups BC2GM059940131 NNS O
( BC2GM059940131 ( O
NAAR BC2GM059940131 NNP O
and BC2GM059940131 CC O
PLA BC2GM059940131 NNP O
) BC2GM059940131 ) O
, BC2GM059940131 , O
no BC2GM059940131 DT O
variation BC2GM059940131 NN O
in BC2GM059940131 IN O
this BC2GM059940131 DT O
serum BC2GM059940131 NN O
protease BC2GM059940131 NN O
was BC2GM059940131 VBD O
observed BC2GM059940131 VBN O
. BC2GM059940131 . O
. . O O

Northern BC2GM042845952 NNP O
blot BC2GM042845952 NN O
analysis BC2GM042845952 NN O
with BC2GM042845952 IN O
GPR37 BC2GM042845952 NNP O
probes BC2GM042845952 NNS O
revealed BC2GM042845952 VBD O
a BC2GM042845952 DT O
main BC2GM042845952 JJ O
3.8-kb BC2GM042845952 JJ O
mRNA BC2GM042845952 NN O
and BC2GM042845952 CC O
a BC2GM042845952 DT O
less BC2GM042845952 RBR O
abundant BC2GM042845952 JJ O
8-kb BC2GM042845952 JJ O
mRNA BC2GM042845952 NN O
, BC2GM042845952 , O
both BC2GM042845952 DT O
expressed BC2GM042845952 VBN O
in BC2GM042845952 IN O
human BC2GM042845952 JJ O
brain BC2GM042845952 NN O
tissues BC2GM042845952 NNS O
, BC2GM042845952 , O
particularly BC2GM042845952 RB O
in BC2GM042845952 IN O
corpus BC2GM042845952 NN O
callosum BC2GM042845952 NN O
, BC2GM042845952 , O
medulla BC2GM042845952 NN O
, BC2GM042845952 , O
putamen BC2GM042845952 NNS O
, BC2GM042845952 , O
and BC2GM042845952 CC O
caudate BC2GM042845952 NN O
nucleus BC2GM042845952 NNS O
. BC2GM042845952 . O
. . O O

Successful BC2GM095166166 JJ O
resolution BC2GM095166166 NN O
of BC2GM095166166 IN O
progressive BC2GM095166166 JJ O
multifocal BC2GM095166166 JJ O
leukoencephalopathy BC2GM095166166 NN O
after BC2GM095166166 IN O
combination BC2GM095166166 NN O
therapy BC2GM095166166 NN O
with BC2GM095166166 IN O
cidofovir BC2GM095166166 NN O
and BC2GM095166166 CC O
cytosine BC2GM095166166 NN O
arabinoside BC2GM095166166 NN O
. BC2GM095166166 . O
. . O O

4 BC2GM088433679 CD O
. BC2GM088433679 . O
. . O O

Radiation BC2GM075993463 NNP O
sensitivity BC2GM075993463 NN O
of BC2GM075993463 IN O
rats BC2GM075993463 NNS O
irradiated BC2GM075993463 VBN O
in BC2GM075993463 IN O
a BC2GM075993463 DT O
condition BC2GM075993463 NN O
of BC2GM075993463 IN O
hypoxia BC2GM075993463 NN O
. BC2GM075993463 . O
. . O O

Recently BC2GM014257511 RB O
, BC2GM014257511 , O
we BC2GM014257511 PRP O
and BC2GM014257511 CC O
other BC2GM014257511 JJ O
laboratories BC2GM014257511 NNS O
have BC2GM014257511 VBP O
identified BC2GM014257511 VBN O
a BC2GM014257511 DT O
family BC2GM014257511 NN O
of BC2GM014257511 IN O
caveolin-related BC2GM014257511 JJ O
proteins BC2GM014257511 NNS O
; BC2GM014257511 : O
caveolin BC2GM014257511 NN O
has BC2GM014257511 VBZ O
been BC2GM014257511 VBN O
re-termed BC2GM014257511 JJ O
caveolin-1 BC2GM014257511 NN O
. BC2GM014257511 . O
. . O O

On BC2GM000288103 IN O
the BC2GM000288103 DT O
other BC2GM000288103 JJ O
hand BC2GM000288103 NN O
hypokalemia BC2GM000288103 NN O
, BC2GM000288103 , O
induced BC2GM000288103 VBN O
by BC2GM000288103 IN O
diuretics BC2GM000288103 NNS O
, BC2GM000288103 , O
may BC2GM000288103 MD O
also BC2GM000288103 RB O
be BC2GM000288103 VB O
accompanied BC2GM000288103 VBN O
by BC2GM000288103 IN O
a BC2GM000288103 DT O
significant BC2GM000288103 JJ O
depletion BC2GM000288103 NN O
of BC2GM000288103 IN O
total BC2GM000288103 JJ O
body BC2GM000288103 NN O
K BC2GM000288103 NNP O
, BC2GM000288103 , O
bringing BC2GM000288103 VBG O
about BC2GM000288103 IN O
more BC2GM000288103 JJR O
general BC2GM000288103 JJ O
consequences BC2GM000288103 NNS O
. BC2GM000288103 . O
. . O O

We BC2GM011894137 PRP O
determined BC2GM011894137 VBD O
their BC2GM011894137 PRP$ O
N-terminal BC2GM011894137 JJ O
amino BC2GM011894137 NN O
acid BC2GM011894137 NN O
sequence BC2GM011894137 NN O
and BC2GM011894137 CC O
found BC2GM011894137 VBD O
that BC2GM011894137 IN O
these BC2GM011894137 DT O
polypeptides BC2GM011894137 NNS O
were BC2GM011894137 VBD O
CotT BC2GM011894137 NNP O
, BC2GM011894137 , O
YeeK BC2GM011894137 NNP O
, BC2GM011894137 , O
YxeE BC2GM011894137 NNP O
, BC2GM011894137 , O
CotF BC2GM011894137 NNP O
, BC2GM011894137 , O
YrbA BC2GM011894137 NNP O
( BC2GM011894137 ( O
31 BC2GM011894137 CD O
and BC2GM011894137 CC O
45 BC2GM011894137 CD O
kDa BC2GM011894137 NN O
) BC2GM011894137 ) O
, BC2GM011894137 , O
and BC2GM011894137 CC O
SpoIVA BC2GM011894137 NNP O
, BC2GM011894137 , O
respectively BC2GM011894137 RB O
. BC2GM011894137 . O
. . O O

Previously BC2GM075603170 RB O
, BC2GM075603170 , O
we BC2GM075603170 PRP O
identified BC2GM075603170 VBD O
two BC2GM075603170 CD O
human BC2GM075603170 JJ O
SMC BC2GM075603170 NNP O
family BC2GM075603170 NN O
proteins BC2GM075603170 NNS O
, BC2GM075603170 , O
hCAP-C BC2GM075603170 JJ O
and BC2GM075603170 CC O
hCAP-E BC2GM075603170 NN O
, BC2GM075603170 , O
which BC2GM075603170 WDT O
form BC2GM075603170 VBP O
a BC2GM075603170 DT O
heterodimeric BC2GM075603170 NN O
complex BC2GM075603170 NN O
( BC2GM075603170 ( O
hCAP-C-hCAP-E BC2GM075603170 NN O
) BC2GM075603170 ) O
in BC2GM075603170 IN O
the BC2GM075603170 DT O
cell BC2GM075603170 NN O
. BC2GM075603170 . O
. . O O

John BC2GM098133751 NNP O
's BC2GM098133751 POS O
wort BC2GM098133751 NN O
. BC2GM098133751 . O
. . O O

Increased BC2GM074464938 VBN O
trabecular BC2GM074464938 JJ O
spacing BC2GM074464938 NN O
, BC2GM074464938 , O
such BC2GM074464938 JJ O
as BC2GM074464938 IN O
it BC2GM074464938 PRP O
occurs BC2GM074464938 VBZ O
in BC2GM074464938 IN O
osteoporosis BC2GM074464938 NN O
, BC2GM074464938 , O
reduces BC2GM074464938 VBZ O
the BC2GM074464938 DT O
spatial BC2GM074464938 JJ O
field BC2GM074464938 NN O
inhomogeneity BC2GM074464938 NN O
and BC2GM074464938 CC O
thus BC2GM074464938 RB O
prolongs BC2GM074464938 NNS O
T2* BC2GM074464938 NNP O
, BC2GM074464938 , O
which BC2GM074464938 WDT O
has BC2GM074464938 VBZ O
been BC2GM074464938 VBN O
shown BC2GM074464938 VBN O
both BC2GM074464938 DT O
in BC2GM074464938 IN O
vitro BC2GM074464938 NN O
and BC2GM074464938 CC O
in BC2GM074464938 IN O
vivo BC2GM074464938 NN O
. BC2GM074464938 . O
. . O O

Mean BC2GM088125251 JJ O
24 BC2GM088125251 CD O
h BC2GM088125251 NN O
urinary BC2GM088125251 JJ O
excretion BC2GM088125251 NN O
values BC2GM088125251 NNS O
confirmed BC2GM088125251 VBD O
this BC2GM088125251 DT O
observation BC2GM088125251 NN O
. BC2GM088125251 . O
. . O O

All BC2GM057171148 DT O
other BC2GM057171148 JJ O
cysts BC2GM057171148 NNS O
showed BC2GM057171148 VBD O
a BC2GM057171148 DT O
unilocular BC2GM057171148 JJ O
, BC2GM057171148 , O
purely BC2GM057171148 RB O
cystic BC2GM057171148 JJ O
pattern BC2GM057171148 NN O
, BC2GM057171148 , O
with BC2GM057171148 IN O
homogeneous BC2GM057171148 JJ O
fluids BC2GM057171148 NNS O
, BC2GM057171148 , O
although BC2GM057171148 IN O
the BC2GM057171148 DT O
T2 BC2GM057171148 NNP O
relaxation BC2GM057171148 NN O
times BC2GM057171148 NNS O
of BC2GM057171148 IN O
four BC2GM057171148 CD O
lesions BC2GM057171148 NNS O
overlapped BC2GM057171148 VBD O
those BC2GM057171148 DT O
of BC2GM057171148 IN O
odontogenic BC2GM057171148 JJ O
keratocysts BC2GM057171148 NNS O
. BC2GM057171148 . O
. . O O

RESULTS BC2GM060854323 NN O
: BC2GM060854323 : O
After BC2GM060854323 IN O
lavage BC2GM060854323 NN O
, BC2GM060854323 , O
a BC2GM060854323 DT O
rapid BC2GM060854323 JJ O
decrease BC2GM060854323 NN O
in BC2GM060854323 IN O
arterial BC2GM060854323 JJ O
pH BC2GM060854323 NN O
and BC2GM060854323 CC O
PaO2 BC2GM060854323 NNP O
, BC2GM060854323 , O
and BC2GM060854323 CC O
an BC2GM060854323 DT O
increase BC2GM060854323 NN O
in BC2GM060854323 IN O
PaCO2 BC2GM060854323 NNP O
and BC2GM060854323 CC O
PIP BC2GM060854323 NNP O
were BC2GM060854323 VBD O
observed BC2GM060854323 VBN O
in BC2GM060854323 IN O
all BC2GM060854323 DT O
animals BC2GM060854323 NNS O
. BC2GM060854323 . O
. . O O

Partial BC2GM000627922 JJ O
hepatectomy BC2GM000627922 NN O
in BC2GM000627922 IN O
metastatic BC2GM000627922 JJ O
Wilms BC2GM000627922 NNP O
' BC2GM000627922 POS O
tumor BC2GM000627922 NN O
. BC2GM000627922 . O
. . O O

GBF1 BC2GM069162607 NNP O
and BC2GM069162607 CC O
GBF2 BC2GM069162607 NNP O
mRNA BC2GM069162607 NN O
is BC2GM069162607 VBZ O
present BC2GM069162607 JJ O
in BC2GM069162607 IN O
light BC2GM069162607 JJ O
and BC2GM069162607 CC O
dark BC2GM069162607 JJ O
grown BC2GM069162607 JJ O
leaves BC2GM069162607 NNS O
as BC2GM069162607 RB O
well BC2GM069162607 RB O
as BC2GM069162607 IN O
in BC2GM069162607 IN O
roots BC2GM069162607 NNS O
. BC2GM069162607 . O
. . O O

Because BC2GM041136178 IN O
the BC2GM041136178 DT O
variation BC2GM041136178 NN O
in BC2GM041136178 IN O
the BC2GM041136178 DT O
carbohydrate BC2GM041136178 NN O
content BC2GM041136178 NN O
of BC2GM041136178 IN O
human BC2GM041136178 JJ O
milk BC2GM041136178 NN O
is BC2GM041136178 VBZ O
very BC2GM041136178 RB O
small BC2GM041136178 JJ O
, BC2GM041136178 , O
a BC2GM041136178 DT O
more BC2GM041136178 JJR O
simple BC2GM041136178 JJ O
alternative BC2GM041136178 JJ O
approach BC2GM041136178 NN O
would BC2GM041136178 MD O
be BC2GM041136178 VB O
to BC2GM041136178 TO O
include BC2GM041136178 VB O
only BC2GM041136178 RB O
an BC2GM041136178 DT O
average BC2GM041136178 JJ O
carbohydrate BC2GM041136178 NN O
value BC2GM041136178 NN O
for BC2GM041136178 IN O
an BC2GM041136178 DT O
estimate BC2GM041136178 NN O
of BC2GM041136178 IN O
energy BC2GM041136178 NN O
content BC2GM041136178 NN O
. BC2GM041136178 . O
. . O O

The BC2GM044963002 DT O
0.018-inch BC2GM044963002 JJ O
FloWire BC2GM044963002 NNP O
provides BC2GM044963002 VBZ O
a BC2GM044963002 DT O
high-fidelity BC2GM044963002 NN O
continuous BC2GM044963002 JJ O
Doppler BC2GM044963002 NNP O
signal BC2GM044963002 NN O
. BC2GM044963002 . O
. . O O

80 BC2GM049012897 CD O
bp BC2GM049012897 NN O
) BC2GM049012897 ) O
surrounding BC2GM049012897 VBG O
the BC2GM049012897 DT O
site BC2GM049012897 NN O
of BC2GM049012897 IN O
transcription BC2GM049012897 NN O
initiation BC2GM049012897 NN O
. BC2GM049012897 . O
. . O O

Using BC2GM090231645 VBG O
the BC2GM090231645 DT O
yeast BC2GM090231645 JJS O
two-hybrid BC2GM090231645 JJ O
system BC2GM090231645 NN O
, BC2GM090231645 , O
we BC2GM090231645 PRP O
have BC2GM090231645 VBP O
isolated BC2GM090231645 VBN O
an BC2GM090231645 DT O
835 BC2GM090231645 CD O
amino BC2GM090231645 NN O
acid BC2GM090231645 NN O
RING BC2GM090231645 NNP O
finger BC2GM090231645 NN O
( BC2GM090231645 ( O
C3HC4 BC2GM090231645 NNP O
zinc BC2GM090231645 NNP O
finger BC2GM090231645 NN O
) BC2GM090231645 ) O
protein BC2GM090231645 NN O
, BC2GM090231645 , O
TIF1 BC2GM090231645 NNP O
beta BC2GM090231645 NN O
( BC2GM090231645 ( O
also BC2GM090231645 RB O
named BC2GM090231645 VBN O
KAP-1 BC2GM090231645 NNP O
) BC2GM090231645 ) O
, BC2GM090231645 , O
that BC2GM090231645 WDT O
specifically BC2GM090231645 RB O
interacts BC2GM090231645 VBZ O
with BC2GM090231645 IN O
the BC2GM090231645 DT O
KRAB BC2GM090231645 NNP O
domain BC2GM090231645 NN O
of BC2GM090231645 IN O
the BC2GM090231645 DT O
human BC2GM090231645 JJ O
zinc BC2GM090231645 NN O
finger BC2GM090231645 NN O
factor BC2GM090231645 NN O
KOX1 BC2GM090231645 NNP O
/ BC2GM090231645 NNP O
ZNF10 BC2GM090231645 NNP O
. BC2GM090231645 . O
. . O O

We BC2GM017902303 PRP O
discuss BC2GM017902303 VBP O
the BC2GM017902303 DT O
possibility BC2GM017902303 NN O
that BC2GM017902303 IN O
DNA-protein BC2GM017902303 NNP O
interactions BC2GM017902303 NNS O
at BC2GM017902303 IN O
homologous BC2GM017902303 JJ O
nucleotide BC2GM017902303 JJ O
sequences BC2GM017902303 NNS O
like BC2GM017902303 IN O
those BC2GM017902303 DT O
identified BC2GM017902303 VBN O
in BC2GM017902303 IN O
PII BC2GM017902303 NNP O
are BC2GM017902303 VBP O
part BC2GM017902303 NN O
of BC2GM017902303 IN O
a BC2GM017902303 DT O
regulatory BC2GM017902303 JJ O
gene BC2GM017902303 NN O
cascade BC2GM017902303 NN O
that BC2GM017902303 WDT O
participates BC2GM017902303 VBZ O
in BC2GM017902303 IN O
timing BC2GM017902303 VBG O
fla BC2GM017902303 JJ O
gene BC2GM017902303 NN O
expression BC2GM017902303 NN O
in BC2GM017902303 IN O
the BC2GM017902303 DT O
C. BC2GM017902303 NNP O
crescentus BC2GM017902303 NN O
cell BC2GM017902303 NN O
cycle BC2GM017902303 NN O
. BC2GM017902303 . O
. . O O

Expression BC2GM080942212 NN O
of BC2GM080942212 IN O
the BC2GM080942212 DT O
bacteriophage BC2GM080942212 NN O
T4 BC2GM080942212 NNP O
DNA BC2GM080942212 NNP O
terminase BC2GM080942212 NN O
genes BC2GM080942212 NNS O
16 BC2GM080942212 CD O
and BC2GM080942212 CC O
17 BC2GM080942212 CD O
yields BC2GM080942212 NNS O
multiple BC2GM080942212 JJ O
proteins BC2GM080942212 NNS O
. BC2GM080942212 . O
. . O O

This BC2GM091451815 DT O
new BC2GM091451815 JJ O
receptor BC2GM091451815 NN O
, BC2GM091451815 , O
TOR BC2GM091451815 NNP O
( BC2GM091451815 ( O
thymus BC2GM091451815 JJ O
orphan BC2GM091451815 IN O
receptor BC2GM091451815 NN O
) BC2GM091451815 ) O
, BC2GM091451815 , O
is BC2GM091451815 VBZ O
most BC2GM091451815 RBS O
closely BC2GM091451815 RB O
related BC2GM091451815 VBN O
in BC2GM091451815 IN O
both BC2GM091451815 DT O
its BC2GM091451815 PRP$ O
DNA-binding BC2GM091451815 NN O
domain BC2GM091451815 NN O
and BC2GM091451815 CC O
ligand-binding BC2GM091451815 JJ O
domain BC2GM091451815 NN O
, BC2GM091451815 , O
90 BC2GM091451815 CD O
% BC2GM091451815 NN O
and BC2GM091451815 CC O
53 BC2GM091451815 CD O
% BC2GM091451815 NN O
, BC2GM091451815 , O
respectively BC2GM091451815 RB O
, BC2GM091451815 , O
to BC2GM091451815 TO O
ROR BC2GM091451815 NNP O
alpha BC2GM091451815 NN O
/ BC2GM091451815 NNP O
RZR BC2GM091451815 NNP O
alpha BC2GM091451815 NN O
and BC2GM091451815 CC O
clusters BC2GM091451815 NNS O
with BC2GM091451815 IN O
these BC2GM091451815 DT O
two BC2GM091451815 CD O
receptors BC2GM091451815 NNS O
and BC2GM091451815 CC O
RZR BC2GM091451815 NNP O
beta BC2GM091451815 NN O
in BC2GM091451815 IN O
a BC2GM091451815 DT O
phylogenetic BC2GM091451815 JJ O
tree BC2GM091451815 NN O
, BC2GM091451815 , O
when BC2GM091451815 WRB O
both BC2GM091451815 DT O
the BC2GM091451815 DT O
DNA-binding BC2GM091451815 NNP O
domain BC2GM091451815 NN O
and BC2GM091451815 CC O
the BC2GM091451815 DT O
ligand-binding BC2GM091451815 JJ O
domain BC2GM091451815 NN O
sequences BC2GM091451815 NNS O
of BC2GM091451815 IN O
nuclear BC2GM091451815 JJ O
receptors BC2GM091451815 NNS O
are BC2GM091451815 VBP O
compared BC2GM091451815 VBN O
. BC2GM091451815 . O
. . O O

The BC2GM021097776 DT O
equation BC2GM021097776 NN O
for BC2GM021097776 IN O
mean BC2GM021097776 JJ O
trabecular BC2GM021097776 JJ O
number BC2GM021097776 NN O
passed BC2GM021097776 VBD O
the BC2GM021097776 DT O
test BC2GM021097776 NN O
, BC2GM021097776 , O
whereas BC2GM021097776 IN O
the BC2GM021097776 DT O
validity BC2GM021097776 NN O
of BC2GM021097776 IN O
the BC2GM021097776 DT O
equations BC2GM021097776 NNS O
for BC2GM021097776 IN O
mean BC2GM021097776 JJ O
trabecular BC2GM021097776 JJ O
separation BC2GM021097776 NN O
and BC2GM021097776 CC O
Tb.Wi BC2GM021097776 NNP O
appeared BC2GM021097776 VBD O
limited BC2GM021097776 JJ O
. BC2GM021097776 . O
. . O O

However BC2GM010976531 RB O
, BC2GM010976531 , O
at BC2GM010976531 IN O
the BC2GM010976531 DT O
time BC2GM010976531 NN O
of BC2GM010976531 IN O
salvage BC2GM010976531 NN O
treatment BC2GM010976531 NN O
, BC2GM010976531 , O
the BC2GM010976531 DT O
mean BC2GM010976531 JJ O
serum BC2GM010976531 NN O
PSA BC2GM010976531 NNP O
levels BC2GM010976531 NNS O
were BC2GM010976531 VBD O
9.1 BC2GM010976531 CD O
and BC2GM010976531 CC O
1.1 BC2GM010976531 CD O
ng BC2GM010976531 JJ O
/ BC2GM010976531 NNP O
mL BC2GM010976531 NN O
for BC2GM010976531 IN O
the BC2GM010976531 DT O
salvage BC2GM010976531 NN O
RP BC2GM010976531 NNP O
and BC2GM010976531 CC O
salvage BC2GM010976531 NN O
RT BC2GM010976531 NNP O
groups BC2GM010976531 NNS O
, BC2GM010976531 , O
respectively BC2GM010976531 RB O
( BC2GM010976531 ( O
P BC2GM010976531 NNP O
= BC2GM010976531 NNP O
0.0001 BC2GM010976531 CD O
) BC2GM010976531 ) O
. BC2GM010976531 . O
. . O O

Furthermore BC2GM027223397 RB O
, BC2GM027223397 , O
the BC2GM027223397 DT O
data BC2GM027223397 NN O
suggest BC2GM027223397 VBP O
an BC2GM027223397 DT O
immunological BC2GM027223397 JJ O
non-responsiveness BC2GM027223397 NN O
to BC2GM027223397 TO O
enterotoxin BC2GM027223397 VB O
A BC2GM027223397 NNP O
in BC2GM027223397 IN O
a BC2GM027223397 DT O
considerable BC2GM027223397 JJ O
portion BC2GM027223397 NN O
of BC2GM027223397 IN O
the BC2GM027223397 DT O
patients BC2GM027223397 NNS O
. BC2GM027223397 . O
. . O O

Interaction BC2GM053757906 NN O
between BC2GM053757906 IN O
the BC2GM053757906 DT O
tobacco BC2GM053757906 NN O
DNA-binding BC2GM053757906 NNP O
activity BC2GM053757906 NN O
CBF BC2GM053757906 NNP O
and BC2GM053757906 CC O
the BC2GM053757906 DT O
cyt-1 BC2GM053757906 JJ O
promoter BC2GM053757906 NN O
element BC2GM053757906 NN O
of BC2GM053757906 IN O
the BC2GM053757906 DT O
Agrobacterium BC2GM053757906 NNP O
tumefaciens BC2GM053757906 VBZ O
T-DNA BC2GM053757906 JJ O
gene BC2GM053757906 NN O
T-CYT BC2GM053757906 NNP O
correlates BC2GM053757906 NNS O
with BC2GM053757906 IN O
cyt-1 BC2GM053757906 JJ O
directed BC2GM053757906 JJ O
gene BC2GM053757906 NN O
expression BC2GM053757906 NN O
in BC2GM053757906 IN O
multiple BC2GM053757906 JJ O
tobacco BC2GM053757906 NN O
tissue BC2GM053757906 NN O
types BC2GM053757906 NNS O
. BC2GM053757906 . O
. . O O

Overexpression BC2GM037400518 NN O
of BC2GM037400518 IN O
SNURF BC2GM037400518 NNP O
in BC2GM037400518 IN O
cultured BC2GM037400518 JJ O
mammalian BC2GM037400518 JJ O
cells BC2GM037400518 NNS O
enhanced BC2GM037400518 VBD O
not BC2GM037400518 RB O
only BC2GM037400518 RB O
androgen BC2GM037400518 NN O
, BC2GM037400518 , O
glucocorticoid BC2GM037400518 NN O
, BC2GM037400518 , O
and BC2GM037400518 CC O
progesterone BC2GM037400518 RB O
receptor-dependent BC2GM037400518 JJ O
transactivation BC2GM037400518 NN O
but BC2GM037400518 CC O
also BC2GM037400518 RB O
basal BC2GM037400518 JJ O
transcription BC2GM037400518 NN O
from BC2GM037400518 IN O
steroid-regulated BC2GM037400518 JJ O
promoters BC2GM037400518 NNS O
. BC2GM037400518 . O
. . O O

EMBO BC2GM038054598 NNP O
( BC2GM038054598 ( O
Eur BC2GM038054598 NNP O
. BC2GM038054598 . O
. . O O

The BC2GM002734773 DT O
predictive BC2GM002734773 JJ O
value BC2GM002734773 NN O
of BC2GM002734773 IN O
the BC2GM002734773 DT O
remotely BC2GM002734773 RB O
sensed BC2GM002734773 VBN O
map BC2GM002734773 NN O
based BC2GM002734773 VBN O
on BC2GM002734773 IN O
NDVI BC2GM002734773 NNP O
data BC2GM002734773 NN O
appears BC2GM002734773 VBZ O
to BC2GM002734773 TO O
be BC2GM002734773 VB O
better BC2GM002734773 JJR O
than BC2GM002734773 IN O
that BC2GM002734773 DT O
from BC2GM002734773 IN O
forecast BC2GM002734773 NN O
indices BC2GM002734773 NNS O
based BC2GM002734773 VBN O
only BC2GM002734773 RB O
on BC2GM002734773 IN O
climatic BC2GM002734773 JJ O
data BC2GM002734773 NNS O
. BC2GM002734773 . O
. . O O

Like BC2GM092988766 IN O
other BC2GM092988766 JJ O
known BC2GM092988766 VBN O
GCD BC2GM092988766 NNP O
genes BC2GM092988766 NNS O
, BC2GM092988766 , O
GCD14 BC2GM092988766 NNP O
and BC2GM092988766 CC O
GCD15 BC2GM092988766 NNP O
are BC2GM092988766 VBP O
therefore BC2GM092988766 RB O
probably BC2GM092988766 RB O
required BC2GM092988766 VBN O
for BC2GM092988766 IN O
general BC2GM092988766 JJ O
translation BC2GM092988766 NN O
initiation BC2GM092988766 NN O
in BC2GM092988766 IN O
addition BC2GM092988766 NN O
to BC2GM092988766 TO O
their BC2GM092988766 PRP$ O
roles BC2GM092988766 NNS O
in BC2GM092988766 IN O
GCN4-specific BC2GM092988766 NNP O
translational BC2GM092988766 JJ O
control BC2GM092988766 NN O
. BC2GM092988766 . O
. . O O

In BC2GM044146778 IN O
HepG2 BC2GM044146778 NNP O
cells BC2GM044146778 NNS O
, BC2GM044146778 , O
SREBP-1c BC2GM044146778 NNP O
mRNA BC2GM044146778 NN O
and BC2GM044146778 CC O
precursor BC2GM044146778 NN O
protein BC2GM044146778 NN O
levels BC2GM044146778 NNS O
were BC2GM044146778 VBD O
induced BC2GM044146778 VBN O
by BC2GM044146778 IN O
treatment BC2GM044146778 NN O
with BC2GM044146778 IN O
22 BC2GM044146778 CD O
( BC2GM044146778 ( O
R BC2GM044146778 NNP O
) BC2GM044146778 ) O
-hydroxycholesterol BC2GM044146778 NN O
and BC2GM044146778 CC O
9-cis-retinoic BC2GM044146778 JJ O
acid BC2GM044146778 NN O
, BC2GM044146778 , O
confirming BC2GM044146778 VBG O
that BC2GM044146778 IN O
endogenous BC2GM044146778 JJ O
LXR-RXR BC2GM044146778 JJ O
activation BC2GM044146778 NN O
can BC2GM044146778 MD O
induce BC2GM044146778 VB O
endogenous BC2GM044146778 JJ O
SREBP-1c BC2GM044146778 JJ O
expression BC2GM044146778 NN O
. BC2GM044146778 . O
. . O O

The BC2GM097492255 DT O
presence BC2GM097492255 NN O
of BC2GM097492255 IN O
chloroquine BC2GM097492255 NN O
in BC2GM097492255 IN O
saliva BC2GM097492255 NN O
from BC2GM097492255 IN O
seven BC2GM097492255 CD O
healthy BC2GM097492255 JJ O
volunteers BC2GM097492255 NNS O
for BC2GM097492255 IN O
21 BC2GM097492255 CD O
days BC2GM097492255 NNS O
after BC2GM097492255 IN O
a BC2GM097492255 DT O
single BC2GM097492255 JJ O
600 BC2GM097492255 CD O
mg BC2GM097492255 JJ O
oral BC2GM097492255 JJ O
dose BC2GM097492255 NN O
of BC2GM097492255 IN O
the BC2GM097492255 DT O
drug BC2GM097492255 NN O
was BC2GM097492255 VBD O
established BC2GM097492255 VBN O
by BC2GM097492255 IN O
chromatographic BC2GM097492255 JJ O
and BC2GM097492255 CC O
spectroscopic BC2GM097492255 JJ O
methods BC2GM097492255 NNS O
. BC2GM097492255 . O
. . O O

Pathophysiologic BC2GM027306792 NNP O
mechanisms BC2GM027306792 NNS O
underlying BC2GM027306792 VBG O
spatial BC2GM027306792 JJ O
disorientation BC2GM027306792 NN O
in BC2GM027306792 IN O
patients BC2GM027306792 NNS O
with BC2GM027306792 IN O
Alzheimer BC2GM027306792 NNP O
's BC2GM027306792 POS O
disease BC2GM027306792 NN O
. BC2GM027306792 . O
. . O O

Other BC2GM044964847 JJ O
recommendations BC2GM044964847 NNS O
for BC2GM044964847 IN O
enhancing BC2GM044964847 VBG O
the BC2GM044964847 DT O
safety BC2GM044964847 NN O
of BC2GM044964847 IN O
potent BC2GM044964847 JJ O
antiplatelet BC2GM044964847 NN O
agents BC2GM044964847 NNS O
in BC2GM044964847 IN O
a BC2GM044964847 DT O
variety BC2GM044964847 NN O
of BC2GM044964847 IN O
clinical BC2GM044964847 JJ O
situations BC2GM044964847 NNS O
are BC2GM044964847 VBP O
provided BC2GM044964847 VBN O
. BC2GM044964847 . O
. . O O

In BC2GM049951633 IN O
conclusion BC2GM049951633 NN O
, BC2GM049951633 , O
ANH BC2GM049951633 NNP O
had BC2GM049951633 VBD O
no BC2GM049951633 DT O
negative BC2GM049951633 JJ O
effects BC2GM049951633 NNS O
on BC2GM049951633 IN O
the BC2GM049951633 DT O
endocrine BC2GM049951633 JJ O
stress BC2GM049951633 NN O
response BC2GM049951633 NN O
during BC2GM049951633 IN O
orthopedic BC2GM049951633 JJ O
surgery BC2GM049951633 NN O
under BC2GM049951633 IN O
epidural BC2GM049951633 JJ O
anesthesia BC2GM049951633 NN O
. BC2GM049951633 . O
. . O O

Time BC2GM040359047 NNP O
between BC2GM040359047 IN O
tests BC2GM040359047 NNS O
( BC2GM040359047 ( O
usually BC2GM040359047 RB O
less BC2GM040359047 JJR O
than BC2GM040359047 IN O
one BC2GM040359047 CD O
year BC2GM040359047 NN O
) BC2GM040359047 ) O
did BC2GM040359047 VBD O
not BC2GM040359047 RB O
affect BC2GM040359047 VB O
the BC2GM040359047 DT O
correlations BC2GM040359047 NNS O
, BC2GM040359047 , O
but BC2GM040359047 CC O
MMPI BC2GM040359047 NNP O
response-set BC2GM040359047 JJ O
variables BC2GM040359047 NNS O
( BC2GM040359047 ( O
L BC2GM040359047 NNP O
, BC2GM040359047 , O
F BC2GM040359047 NNP O
, BC2GM040359047 , O
K BC2GM040359047 NNP O
, BC2GM040359047 , O
F-K BC2GM040359047 NNP O
) BC2GM040359047 ) O
did BC2GM040359047 VBD O
. BC2GM040359047 . O
. . O O

Pharmacokinetics BC2GM057666669 NNS O
of BC2GM057666669 IN O
skin BC2GM057666669 JJ O
penetration BC2GM057666669 NN O
. BC2GM057666669 . O
. . O O

The BC2GM007092490 DT O
sulfur BC2GM007092490 NN O
species BC2GM007092490 NNS O
could BC2GM007092490 MD O
be BC2GM007092490 VB O
separated BC2GM007092490 VBN O
within BC2GM007092490 IN O
less BC2GM007092490 JJR O
than BC2GM007092490 IN O
4 BC2GM007092490 CD O
min BC2GM007092490 NN O
by BC2GM007092490 IN O
CZE BC2GM007092490 NNP O
with BC2GM007092490 IN O
a BC2GM007092490 DT O
pyromellitic BC2GM007092490 JJ O
acid BC2GM007092490 NN O
electrolyte BC2GM007092490 NN O
at BC2GM007092490 IN O
pH BC2GM007092490 $ O
3.5 BC2GM007092490 CD O
to BC2GM007092490 TO O
5.0 BC2GM007092490 CD O
. BC2GM007092490 . O
. . O O

Isolates BC2GM023576851 NNS O
of BC2GM023576851 IN O
B. BC2GM023576851 NNP O
burgdorferi BC2GM023576851 NN O
from BC2GM023576851 IN O
humans BC2GM023576851 NNS O
, BC2GM023576851 , O
rodents BC2GM023576851 NNS O
, BC2GM023576851 , O
and BC2GM023576851 CC O
I. BC2GM023576851 NNP O
dammini BC2GM023576851 NNS O
are BC2GM023576851 VBP O
usually BC2GM023576851 RB O
indistinguishable BC2GM023576851 JJ O
, BC2GM023576851 , O
but BC2GM023576851 CC O
strains BC2GM023576851 NNS O
of BC2GM023576851 IN O
B. BC2GM023576851 NNP O
burgdorferi BC2GM023576851 NN O
with BC2GM023576851 IN O
different BC2GM023576851 JJ O
major BC2GM023576851 JJ O
proteins BC2GM023576851 NNS O
have BC2GM023576851 VBP O
been BC2GM023576851 VBN O
identified BC2GM023576851 VBN O
. BC2GM023576851 . O
. . O O

Recombinant BC2GM084701019 JJ O
apoA-I BC2GM084701019 JJ O
protein BC2GM084701019 NN O
recovered BC2GM084701019 VBD O
from BC2GM084701019 IN O
the BC2GM084701019 DT O
soluble BC2GM084701019 JJ O
fraction BC2GM084701019 NN O
of BC2GM084701019 IN O
the BC2GM084701019 DT O
bacterial BC2GM084701019 JJ O
cell BC2GM084701019 NN O
pellet BC2GM084701019 NN O
was BC2GM084701019 VBD O
purified BC2GM084701019 VBN O
to BC2GM084701019 TO O
greater BC2GM084701019 JJR O
than BC2GM084701019 IN O
95 BC2GM084701019 CD O
% BC2GM084701019 NN O
homogeneity BC2GM084701019 NN O
by BC2GM084701019 IN O
reversed-phase BC2GM084701019 JJ O
high-performance BC2GM084701019 NN O
liquid BC2GM084701019 NN O
chromatography BC2GM084701019 NN O
. BC2GM084701019 . O
. . O O

Rat BC2GM021543883 NNP O
cholesterol BC2GM021543883 NN O
side-chain BC2GM021543883 JJ O
cleavage BC2GM021543883 NN O
cytochrome BC2GM021543883 JJ O
P-450 BC2GM021543883 NNP O
( BC2GM021543883 ( O
P-450scc BC2GM021543883 NNP O
) BC2GM021543883 ) O
gene BC2GM021543883 NN O
. BC2GM021543883 . O
. . O O

These BC2GM076960951 DT O
results BC2GM076960951 NNS O
suggest BC2GM076960951 VBP O
that BC2GM076960951 IN O
termination BC2GM076960951 NN O
is BC2GM076960951 VBZ O
a BC2GM076960951 DT O
highly BC2GM076960951 RB O
specific BC2GM076960951 JJ O
event BC2GM076960951 NN O
, BC2GM076960951 , O
and BC2GM076960951 CC O
not BC2GM076960951 RB O
merely BC2GM076960951 RB O
a BC2GM076960951 DT O
consequence BC2GM076960951 NN O
of BC2GM076960951 IN O
decreased BC2GM076960951 JJ O
stability BC2GM076960951 NN O
of BC2GM076960951 IN O
the BC2GM076960951 DT O
EC BC2GM076960951 NNP O
. BC2GM076960951 . O
. . O O

We BC2GM031143223 PRP O
used BC2GM031143223 VBD O
event-related BC2GM031143223 JJ O
functional BC2GM031143223 JJ O
magnetic BC2GM031143223 JJ O
resonance BC2GM031143223 NN O
imaging BC2GM031143223 NN O
( BC2GM031143223 ( O
fMRI BC2GM031143223 JJ O
) BC2GM031143223 ) O
during BC2GM031143223 IN O
a BC2GM031143223 DT O
cued BC2GM031143223 VBN O
spatial-attention BC2GM031143223 NN O
task BC2GM031143223 NN O
to BC2GM031143223 TO O
dissociate BC2GM031143223 VB O
brain BC2GM031143223 NN O
activity BC2GM031143223 NN O
related BC2GM031143223 VBN O
to BC2GM031143223 TO O
attentional BC2GM031143223 JJ O
control BC2GM031143223 NN O
from BC2GM031143223 IN O
that BC2GM031143223 DT O
related BC2GM031143223 VBN O
to BC2GM031143223 TO O
selective BC2GM031143223 JJ O
processing BC2GM031143223 NN O
of BC2GM031143223 IN O
target BC2GM031143223 NN O
stimuli BC2GM031143223 NNS O
. BC2GM031143223 . O
. . O O

In BC2GM010650292 IN O
contrast BC2GM010650292 NN O
, BC2GM010650292 , O
inhibition BC2GM010650292 NN O
of BC2GM010650292 IN O
MAPK BC2GM010650292 NNP O
activity BC2GM010650292 NN O
by BC2GM010650292 IN O
MAPK BC2GM010650292 NNP O
kinase BC2GM010650292 NNP O
inhibitor BC2GM010650292 NN O
( BC2GM010650292 ( O
PD BC2GM010650292 NNP O
98059 BC2GM010650292 CD O
) BC2GM010650292 ) O
or BC2GM010650292 CC O
by BC2GM010650292 IN O
overexpression BC2GM010650292 NN O
of BC2GM010650292 IN O
kinase-deficient BC2GM010650292 JJ O
MAPKs BC2GM010650292 NNP O
activated BC2GM010650292 VBD O
basal BC2GM010650292 NN O
and BC2GM010650292 CC O
GnRH-A-stimulated BC2GM010650292 JJ O
GnRHR-Luc BC2GM010650292 NNP O
activity BC2GM010650292 NN O
. BC2GM010650292 . O
. . O O

Cloning BC2GM089696492 VBG O
and BC2GM089696492 CC O
characterization BC2GM089696492 NN O
of BC2GM089696492 IN O
the BC2GM089696492 DT O
5 BC2GM089696492 CD O
' BC2GM089696492 POS O
flanking BC2GM089696492 JJ O
region BC2GM089696492 NN O
of BC2GM089696492 IN O
human BC2GM089696492 JJ O
ATP-citrate BC2GM089696492 NNP O
lyase BC2GM089696492 NN O
gene BC2GM089696492 NN O
. BC2GM089696492 . O
. . O O

Steady-state BC2GM019597390 JJ O
levels BC2GM019597390 NNS O
of BC2GM019597390 IN O
murine BC2GM019597390 NN O
MMR BC2GM019597390 NNP O
mRNA BC2GM019597390 NN O
were BC2GM019597390 VBD O
measured BC2GM019597390 VBN O
in BC2GM019597390 IN O
the BC2GM019597390 DT O
macrophage BC2GM019597390 NN O
cell BC2GM019597390 NN O
line BC2GM019597390 NN O
J774E BC2GM019597390 NNP O
, BC2GM019597390 , O
which BC2GM019597390 WDT O
is BC2GM019597390 VBZ O
known BC2GM019597390 VBN O
to BC2GM019597390 TO O
express BC2GM019597390 VB O
the BC2GM019597390 DT O
protein BC2GM019597390 NN O
at BC2GM019597390 IN O
the BC2GM019597390 DT O
cell BC2GM019597390 NN O
surface BC2GM019597390 NN O
. BC2GM019597390 . O
. . O O

Seasonal BC2GM003946891 JJ O
variation BC2GM003946891 NN O
of BC2GM003946891 IN O
the BC2GM003946891 DT O
cadmium BC2GM003946891 NN O
content BC2GM003946891 NN O
of BC2GM003946891 IN O
Murex BC2GM003946891 NNP O
trunculus BC2GM003946891 NN O
in BC2GM003946891 IN O
a BC2GM003946891 DT O
non-cadmium BC2GM003946891 JJ O
polluted BC2GM003946891 JJ O
environment BC2GM003946891 NN O
. BC2GM003946891 . O
. . O O

Previously BC2GM077951036 RB O
, BC2GM077951036 , O
we BC2GM077951036 PRP O
reported BC2GM077951036 VBD O
the BC2GM077951036 DT O
identification BC2GM077951036 NN O
of BC2GM077951036 IN O
a BC2GM077951036 DT O
23-kD BC2GM077951036 JJ O
protein BC2GM077951036 NN O
that BC2GM077951036 WDT O
interacts BC2GM077951036 VBZ O
with BC2GM077951036 IN O
zyxin BC2GM077951036 NN O
in BC2GM077951036 IN O
vitro BC2GM077951036 NN O
( BC2GM077951036 ( O
Sadler BC2GM077951036 NNP O
et BC2GM077951036 RB O
al. BC2GM077951036 RB O
, BC2GM077951036 , O
1992 BC2GM077951036 CD O
) BC2GM077951036 ) O
. BC2GM077951036 . O
. . O O

Critical BC2GM035321349 NNP O
review BC2GM035321349 NN O
of BC2GM035321349 IN O
general BC2GM035321349 JJ O
results BC2GM035321349 NNS O
. BC2GM035321349 . O
. . O O

Periarteritis BC2GM059318256 NNP O
nodosa BC2GM059318256 NN O
with BC2GM059318256 IN O
ruptures BC2GM059318256 NNS O
of BC2GM059318256 IN O
the BC2GM059318256 DT O
renal BC2GM059318256 JJ O
vessels BC2GM059318256 NNS O
and BC2GM059318256 CC O
the BC2GM059318256 DT O
persistence BC2GM059318256 NN O
of BC2GM059318256 IN O
the BC2GM059318256 DT O
hepatitis BC2GM059318256 NN O
B BC2GM059318256 NNP O
and BC2GM059318256 CC O
C BC2GM059318256 NNP O
viruses BC2GM059318256 NNS O
in BC2GM059318256 IN O
the BC2GM059318256 DT O
blood BC2GM059318256 NN O
. BC2GM059318256 . O
. . O O

A BC2GM054116094 DT O
clinical BC2GM054116094 JJ O
double-blind BC2GM054116094 JJ O
trial BC2GM054116094 NN O
of BC2GM054116094 IN O
topical BC2GM054116094 JJ O
miconazole BC2GM054116094 NN O
and BC2GM054116094 CC O
clotrimazole BC2GM054116094 NN O
against BC2GM054116094 IN O
superficial BC2GM054116094 JJ O
fungal BC2GM054116094 JJ O
infections BC2GM054116094 NNS O
and BC2GM054116094 CC O
erythrasma BC2GM054116094 NN O
. BC2GM054116094 . O
. . O O

To BC2GM061963337 TO O
evaluate BC2GM061963337 VB O
the BC2GM061963337 DT O
effect BC2GM061963337 NN O
of BC2GM061963337 IN O
selective BC2GM061963337 JJ O
thromboxane BC2GM061963337 NN O
A2 BC2GM061963337 NNP O
blockade BC2GM061963337 NN O
on BC2GM061963337 IN O
clinical BC2GM061963337 JJ O
findings BC2GM061963337 NNS O
and BC2GM061963337 CC O
platelet BC2GM061963337 NN O
reactivity BC2GM061963337 NN O
in BC2GM061963337 IN O
refractory BC2GM061963337 NN O
unstable BC2GM061963337 JJ O
angina BC2GM061963337 NN O
, BC2GM061963337 , O
OKY-046 BC2GM061963337 NNP O
( BC2GM061963337 ( O
600 BC2GM061963337 CD O
mg BC2GM061963337 NNS O
/ BC2GM061963337 JJ O
day BC2GM061963337 NN O
, BC2GM061963337 , O
p.o BC2GM061963337 NN O
. BC2GM061963337 . O
) BC2GM061963337 ) O
was BC2GM061963337 VBD O
administered BC2GM061963337 VBN O
to BC2GM061963337 TO O
another BC2GM061963337 DT O
14 BC2GM061963337 CD O
patients BC2GM061963337 NNS O
with BC2GM061963337 IN O
refractory BC2GM061963337 JJ O
unstable BC2GM061963337 JJ O
angina BC2GM061963337 NN O
in BC2GM061963337 IN O
addition BC2GM061963337 NN O
to BC2GM061963337 TO O
the BC2GM061963337 DT O
conventional BC2GM061963337 JJ O
therapy BC2GM061963337 NN O
. BC2GM061963337 . O
. . O O

The BC2GM015390020 DT O
c-Jun BC2GM015390020 JJ O
delta-domain BC2GM015390020 JJ O
inhibits BC2GM015390020 NNS O
neuroendocrine BC2GM015390020 JJ O
promoter BC2GM015390020 NN O
activity BC2GM015390020 NN O
in BC2GM015390020 IN O
a BC2GM015390020 DT O
DNA BC2GM015390020 NN O
sequence- BC2GM015390020 JJ O
and BC2GM015390020 CC O
pituitary-specific BC2GM015390020 JJ O
manner BC2GM015390020 NN O
. BC2GM015390020 . O
. . O O

The BC2GM019190601 DT O
dermatoglyphic BC2GM019190601 JJ O
pattern BC2GM019190601 NN O
demostrates BC2GM019190601 VBZ O
a BC2GM019190601 DT O
distal BC2GM019190601 JJ O
triradius BC2GM019190601 NN O
and BC2GM019190601 CC O
small BC2GM019190601 JJ O
whorl BC2GM019190601 NN O
abnormalities BC2GM019190601 NNS O
. BC2GM019190601 . O
. . O O

TGF-beta1 BC2GM030264277 NNP O
induced BC2GM030264277 JJ O
phosphorylation BC2GM030264277 NN O
of BC2GM030264277 IN O
Smad2 BC2GM030264277 NNP O
and BC2GM030264277 CC O
Smad3 BC2GM030264277 NNP O
in BC2GM030264277 IN O
Mv1Lu BC2GM030264277 NNP O
mink BC2GM030264277 NN O
lung BC2GM030264277 NN O
epithelial BC2GM030264277 JJ O
cells BC2GM030264277 NNS O
. BC2GM030264277 . O
. . O O

Total BC2GM066457601 JJ O
meso-pore BC2GM066457601 NN O
volume BC2GM066457601 NN O
and BC2GM066457601 CC O
surface BC2GM066457601 JJ O
area BC2GM066457601 NN O
ranged BC2GM066457601 VBD O
from BC2GM066457601 IN O
0.004-0.08 BC2GM066457601 JJ O
cm3 BC2GM066457601 NN O
g BC2GM066457601 NN O
( BC2GM066457601 ( O
-1 BC2GM066457601 NNP O
) BC2GM066457601 ) O
and BC2GM066457601 CC O
from BC2GM066457601 IN O
0.33-6.9 BC2GM066457601 JJ O
m2 BC2GM066457601 NN O
g BC2GM066457601 NN O
( BC2GM066457601 ( O
-1 BC2GM066457601 NNP O
) BC2GM066457601 ) O
respectively BC2GM066457601 RB O
, BC2GM066457601 , O
accounting BC2GM066457601 VBG O
for BC2GM066457601 IN O
up BC2GM066457601 RB O
33 BC2GM066457601 CD O
% BC2GM066457601 NN O
of BC2GM066457601 IN O
the BC2GM066457601 DT O
BET BC2GM066457601 NNP O
surface BC2GM066457601 NN O
area BC2GM066457601 NN O
. BC2GM066457601 . O
. . O O

We BC2GM027749985 PRP O
conclude BC2GM027749985 VBP O
that BC2GM027749985 DT O
transcription BC2GM027749985 NN O
of BC2GM027749985 IN O
both BC2GM027749985 DT O
SCD1 BC2GM027749985 NNP O
and BC2GM027749985 CC O
SCD2 BC2GM027749985 NNP O
genes BC2GM027749985 NNS O
is BC2GM027749985 VBZ O
responsive BC2GM027749985 JJ O
to BC2GM027749985 TO O
cellular BC2GM027749985 VB O
sterol BC2GM027749985 NN O
levels BC2GM027749985 NNS O
and BC2GM027749985 CC O
to BC2GM027749985 TO O
the BC2GM027749985 DT O
levels BC2GM027749985 NNS O
of BC2GM027749985 IN O
nuclear BC2GM027749985 JJ O
SREBP BC2GM027749985 NNP O
/ BC2GM027749985 NNP O
ADD1 BC2GM027749985 NNP O
and BC2GM027749985 CC O
that BC2GM027749985 IN O
transcriptional BC2GM027749985 JJ O
induction BC2GM027749985 NN O
requires BC2GM027749985 VBZ O
three BC2GM027749985 CD O
spatially BC2GM027749985 RB O
conserved BC2GM027749985 VBN O
cis BC2GM027749985 JJ O
elements BC2GM027749985 NNS O
, BC2GM027749985 , O
that BC2GM027749985 IN O
bind BC2GM027749985 NN O
SREBP BC2GM027749985 NNP O
and BC2GM027749985 CC O
NF-Y BC2GM027749985 NNP O
. BC2GM027749985 . O
. . O O

Zonography BC2GM059503308 NN O
in BC2GM059503308 IN O
urology BC2GM059503308 NN O
( BC2GM059503308 ( O
author BC2GM059503308 NN O
's BC2GM059503308 POS O
transl BC2GM059503308 NN O
) BC2GM059503308 ) O
. BC2GM059503308 . O
. . O O

Both BC2GM043977711 DT O
v-Myb BC2GM043977711 JJ O
and BC2GM043977711 CC O
c-Myb BC2GM043977711 JJ O
bind BC2GM043977711 NN O
specifically BC2GM043977711 RB O
to BC2GM043977711 TO O
delta BC2GM043977711 VB O
E3 BC2GM043977711 NNP O
. BC2GM043977711 . O
. . O O

Melioidosis BC2GM065471552 NN O
in BC2GM065471552 IN O
Sika BC2GM065471552 NNP O
deer BC2GM065471552 NN O
( BC2GM065471552 ( O
Cervus BC2GM065471552 NNP O
nippon BC2GM065471552 RB O
nippon BC2GM065471552 RB O
) BC2GM065471552 ) O
. BC2GM065471552 . O
. . O O

Motilin BC2GM042231510 NNP O
serum BC2GM042231510 NN O
levels BC2GM042231510 NNS O
were BC2GM042231510 VBD O
measured BC2GM042231510 VBN O
for BC2GM042231510 IN O
one BC2GM042231510 CD O
hour BC2GM042231510 NN O
. BC2GM042231510 . O
. . O O

ER BC2GM008677402 NNP O
and BC2GM008677402 CC O
DR BC2GM008677402 NNP O
were BC2GM008677402 VBD O
significantly BC2GM008677402 RB O
correlated BC2GM008677402 VBN O
with BC2GM008677402 IN O
MIB-1 BC2GM008677402 NNP O
LI BC2GM008677402 NNP O
( BC2GM008677402 ( O
P BC2GM008677402 NNP O
< BC2GM008677402 NNP O
0.01 BC2GM008677402 CD O
and BC2GM008677402 CC O
P BC2GM008677402 NNP O
< BC2GM008677402 NNP O
0.05 BC2GM008677402 CD O
, BC2GM008677402 , O
respectively BC2GM008677402 RB O
) BC2GM008677402 ) O
, BC2GM008677402 , O
but BC2GM008677402 CC O
RI BC2GM008677402 NNP O
and BC2GM008677402 CC O
Td BC2GM008677402 NNP O
/ BC2GM008677402 NNP O
Te BC2GM008677402 NNP O
were BC2GM008677402 VBD O
not BC2GM008677402 RB O
. BC2GM008677402 . O
. . O O

Examination BC2GM048575101 NN O
of BC2GM048575101 IN O
the BC2GM048575101 DT O
Coomassie-stained BC2GM048575101 JJ O
gels BC2GM048575101 NNS O
revealed BC2GM048575101 VBD O
that BC2GM048575101 IN O
the BC2GM048575101 DT O
capsid-like BC2GM048575101 JJ O
particles BC2GM048575101 NNS O
composed BC2GM048575101 VBN O
of BC2GM048575101 IN O
the BC2GM048575101 DT O
N11-VP1 BC2GM048575101 NNP O
protein BC2GM048575101 NN O
did BC2GM048575101 VBD O
not BC2GM048575101 RB O
contain BC2GM048575101 VB O
any BC2GM048575101 DT O
host-derived BC2GM048575101 JJ O
histones BC2GM048575101 NNS O
. BC2GM048575101 . O
. . O O

OBJECTIVE BC2GM033383172 NN O
: BC2GM033383172 : O
To BC2GM033383172 TO O
assess BC2GM033383172 VB O
laboratory BC2GM033383172 NN O
practice BC2GM033383172 NN O
in BC2GM033383172 IN O
the BC2GM033383172 DT O
examination BC2GM033383172 NN O
of BC2GM033383172 IN O
blood BC2GM033383172 NN O
films BC2GM033383172 NNS O
for BC2GM033383172 IN O
malarial BC2GM033383172 JJ O
parasites BC2GM033383172 NNS O
. BC2GM033383172 . O
. . O O

Residues BC2GM045448639 NNP O
crucial BC2GM045448639 NN O
for BC2GM045448639 IN O
Ras BC2GM045448639 NNP O
interaction BC2GM045448639 NN O
with BC2GM045448639 IN O
GDP-GTP BC2GM045448639 NNP O
exchangers BC2GM045448639 NNS O
. BC2GM045448639 . O
. . O O

Any BC2GM036804417 DT O
respectative BC2GM036804417 JJ O
material BC2GM036804417 NN O
( BC2GM036804417 ( O
class BC2GM036804417 NN O
0 BC2GM036804417 CD O
) BC2GM036804417 ) O
was BC2GM036804417 VBD O
not BC2GM036804417 RB O
obtained BC2GM036804417 VBN O
from BC2GM036804417 IN O
334 BC2GM036804417 CD O
patients BC2GM036804417 NNS O
( BC2GM036804417 ( O
4.2 BC2GM036804417 CD O
% BC2GM036804417 NN O
) BC2GM036804417 ) O
, BC2GM036804417 , O
class BC2GM036804417 NN O
I-II BC2GM036804417 NNP O
findings BC2GM036804417 NNS O
belonged BC2GM036804417 VBD O
to BC2GM036804417 TO O
6m141 BC2GM036804417 CD O
patients BC2GM036804417 NNS O
( BC2GM036804417 ( O
76.7 BC2GM036804417 CD O
% BC2GM036804417 NN O
) BC2GM036804417 ) O
, BC2GM036804417 , O
950 BC2GM036804417 CD O
patients BC2GM036804417 NNS O
( BC2GM036804417 ( O
11.9 BC2GM036804417 CD O
% BC2GM036804417 NN O
) BC2GM036804417 ) O
were BC2GM036804417 VBD O
classified BC2GM036804417 VBN O
as BC2GM036804417 IN O
class BC2GM036804417 NN O
HII BC2GM036804417 NNP O
and BC2GM036804417 CC O
IV BC2GM036804417 NNP O
, BC2GM036804417 , O
578 BC2GM036804417 CD O
patients BC2GM036804417 NNS O
( BC2GM036804417 ( O
7.2 BC2GM036804417 CD O
% BC2GM036804417 NN O
) BC2GM036804417 ) O
as BC2GM036804417 IN O
class BC2GM036804417 NN O
V BC2GM036804417 NNP O
. BC2GM036804417 . O
. . O O

Immunoblot BC2GM005703373 NN O
analyses BC2GM005703373 NNS O
revealed BC2GM005703373 VBD O
that BC2GM005703373 IN O
the BC2GM005703373 DT O
loss BC2GM005703373 NN O
of BC2GM005703373 IN O
activator BC2GM005703373 NN O
function BC2GM005703373 NN O
coincides BC2GM005703373 NNS O
with BC2GM005703373 IN O
selective BC2GM005703373 JJ O
removal BC2GM005703373 NN O
of BC2GM005703373 IN O
the BC2GM005703373 DT O
C-terminal BC2GM005703373 JJ O
domain BC2GM005703373 NN O
( BC2GM005703373 ( O
CTD BC2GM005703373 NNP O
) BC2GM005703373 ) O
-hyperphosphorylated BC2GM005703373 VBD O
RNAP BC2GM005703373 NNP O
IIO BC2GM005703373 NNP O
along BC2GM005703373 IN O
with BC2GM005703373 IN O
NC2 BC2GM005703373 NNP O
. BC2GM005703373 . O
. . O O

A BC2GM019076970 DT O
novel BC2GM019076970 JJ O
zinc BC2GM019076970 NN O
finger-containing BC2GM019076970 JJ O
RNA-binding BC2GM019076970 NNP O
protein BC2GM019076970 NN O
conserved BC2GM019076970 VBD O
from BC2GM019076970 IN O
fruitflies BC2GM019076970 NNS O
to BC2GM019076970 TO O
humans BC2GM019076970 NNS O
. BC2GM019076970 . O
. . O O

Two BC2GM084593857 CD O
methods BC2GM084593857 NNS O
for BC2GM084593857 IN O
the BC2GM084593857 DT O
routine BC2GM084593857 JJ O
determination BC2GM084593857 NN O
of BC2GM084593857 IN O
blood BC2GM084593857 NN O
hemoglobin BC2GM084593857 NN O
oxygen BC2GM084593857 NN O
affinity BC2GM084593857 NN O
are BC2GM084593857 VBP O
described BC2GM084593857 VBN O
. BC2GM084593857 . O
. . O O

Among BC2GM031419699 IN O
the BC2GM031419699 DT O
different BC2GM031419699 JJ O
epithelial BC2GM031419699 NN O
cell BC2GM031419699 NN O
lines BC2GM031419699 NNS O
tested BC2GM031419699 VBD O
, BC2GM031419699 , O
only BC2GM031419699 RB O
RTS3b BC2GM031419699 NNP O
cells BC2GM031419699 NNS O
allowed BC2GM031419699 VBD O
an BC2GM031419699 DT O
expression BC2GM031419699 NN O
pattern BC2GM031419699 NN O
similar BC2GM031419699 JJ O
to BC2GM031419699 TO O
that BC2GM031419699 DT O
observed BC2GM031419699 VBN O
in BC2GM031419699 IN O
naturally BC2GM031419699 RB O
infected BC2GM031419699 VBN O
benign BC2GM031419699 JJ O
condylomas BC2GM031419699 NN O
. BC2GM031419699 . O
. . O O

All BC2GM091440565 DT O
depressive BC2GM091440565 JJ O
groups BC2GM091440565 NNS O
showed BC2GM091440565 VBD O
improved BC2GM091440565 JJ O
error BC2GM091440565 NN O
measures BC2GM091440565 VBZ O
post-treatment BC2GM091440565 NN O
. BC2GM091440565 . O
. . O O

Microscopic BC2GM001871340 NNP O
examination BC2GM001871340 NN O
of BC2GM001871340 IN O
these BC2GM001871340 DT O
colonies BC2GM001871340 NNS O
showed BC2GM001871340 VBD O
a BC2GM001871340 DT O
high BC2GM001871340 JJ O
percentage BC2GM001871340 NN O
of BC2GM001871340 IN O
histiocytes BC2GM001871340 NNS O
identical BC2GM001871340 JJ O
to BC2GM001871340 TO O
those BC2GM001871340 DT O
seen BC2GM001871340 VBN O
in BC2GM001871340 IN O
the BC2GM001871340 DT O
patient BC2GM001871340 NN O
's BC2GM001871340 POS O
bone BC2GM001871340 NN O
marrow BC2GM001871340 NN O
. BC2GM001871340 . O
. . O O

Thus BC2GM056444302 RB O
in BC2GM056444302 IN O
this BC2GM056444302 DT O
study BC2GM056444302 NN O
we BC2GM056444302 PRP O
used BC2GM056444302 VBD O
in BC2GM056444302 IN O
vitro BC2GM056444302 JJ O
methods BC2GM056444302 NNS O
to BC2GM056444302 TO O
directly BC2GM056444302 RB O
evaluate BC2GM056444302 VB O
whether BC2GM056444302 IN O
isolated BC2GM056444302 JJ O
human BC2GM056444302 JJ O
saphenous BC2GM056444302 JJ O
vein BC2GM056444302 NN O
segments BC2GM056444302 NNS O
respond BC2GM056444302 VBP O
to BC2GM056444302 TO O
vasoconstrictor BC2GM056444302 VB O
agents BC2GM056444302 NNS O
at BC2GM056444302 IN O
arterial BC2GM056444302 JJ O
pressure BC2GM056444302 NN O
levels BC2GM056444302 NNS O
. BC2GM056444302 . O
. . O O

Here BC2GM080568509 RB O
we BC2GM080568509 PRP O
show BC2GM080568509 VBP O
that BC2GM080568509 IN O
the BC2GM080568509 DT O
nucleotide BC2GM080568509 NN O
in BC2GM080568509 IN O
the BC2GM080568509 DT O
middle BC2GM080568509 NN O
of BC2GM080568509 IN O
the BC2GM080568509 DT O
anticodon BC2GM080568509 NN O
( BC2GM080568509 ( O
i.e. BC2GM080568509 FW O
, BC2GM080568509 , O
psi BC2GM080568509 FW O
35 BC2GM080568509 CD O
) BC2GM080568509 ) O
also BC2GM080568509 RB O
contributes BC2GM080568509 VBZ O
to BC2GM080568509 TO O
the BC2GM080568509 DT O
suppressor BC2GM080568509 NN O
efficiency BC2GM080568509 NN O
displayed BC2GM080568509 VBN O
by BC2GM080568509 IN O
cytoplasmic BC2GM080568509 JJ O
tRNA BC2GM080568509 NN O
( BC2GM080568509 ( O
Tyr BC2GM080568509 NNP O
) BC2GM080568509 ) O
. BC2GM080568509 . O
. . O O

The BC2GM065065002 DT O
study BC2GM065065002 NN O
drugs BC2GM065065002 NNS O
( BC2GM065065002 ( O
combination BC2GM065065002 NN O
vinblastine-CCNU BC2GM065065002 NN O
and BC2GM065065002 CC O
single-agent BC2GM065065002 JJ O
triazinate BC2GM065065002 NN O
or BC2GM065065002 CC O
dactinomycin BC2GM065065002 NN O
) BC2GM065065002 ) O
failed BC2GM065065002 VBD O
to BC2GM065065002 TO O
provide BC2GM065065002 VB O
any BC2GM065065002 DT O
meaningful BC2GM065065002 JJ O
antitumor BC2GM065065002 NN O
activity BC2GM065065002 NN O
for BC2GM065065002 IN O
these BC2GM065065002 DT O
patients BC2GM065065002 NNS O
with BC2GM065065002 IN O
advanced BC2GM065065002 JJ O
renal BC2GM065065002 JJ O
cell BC2GM065065002 NN O
cancer BC2GM065065002 NN O
. BC2GM065065002 . O
. . O O

Each BC2GM051097875 DT O
fusion BC2GM051097875 NN O
leads BC2GM051097875 VBZ O
, BC2GM051097875 , O
in BC2GM051097875 IN O
principle BC2GM051097875 NN O
, BC2GM051097875 , O
to BC2GM051097875 TO O
the BC2GM051097875 DT O
same BC2GM051097875 JJ O
effect BC2GM051097875 NN O
: BC2GM051097875 : O
The BC2GM051097875 DT O
ret BC2GM051097875 JJ O
tyrosine BC2GM051097875 NN O
kinase BC2GM051097875 NN O
is BC2GM051097875 VBZ O
uncoupled BC2GM051097875 VBN O
from BC2GM051097875 IN O
its BC2GM051097875 PRP$ O
stringent BC2GM051097875 JJ O
physiological BC2GM051097875 JJ O
regulation BC2GM051097875 NN O
by BC2GM051097875 IN O
replacement BC2GM051097875 NN O
of BC2GM051097875 IN O
its BC2GM051097875 PRP$ O
5 BC2GM051097875 CD O
' BC2GM051097875 POS O
end BC2GM051097875 NN O
and BC2GM051097875 CC O
is BC2GM051097875 VBZ O
aberrantly BC2GM051097875 RB O
activated BC2GM051097875 VBN O
by BC2GM051097875 IN O
the BC2GM051097875 DT O
5 BC2GM051097875 CD O
' BC2GM051097875 POS O
parts BC2GM051097875 NNS O
of BC2GM051097875 IN O
fused BC2GM051097875 VBN O
genes BC2GM051097875 NNS O
in BC2GM051097875 IN O
thyrocytes BC2GM051097875 NNS O
that BC2GM051097875 WDT O
do BC2GM051097875 VBP O
not BC2GM051097875 RB O
normally BC2GM051097875 RB O
express BC2GM051097875 VB O
ret BC2GM051097875 JJ O
tyrosine BC2GM051097875 NN O
kinase BC2GM051097875 NN O
. BC2GM051097875 . O
. . O O

5 BC2GM010251771 CD O
Intravenous BC2GM010251771 JJ O
prizidilol BC2GM010251771 NNS O
hydrochloride BC2GM010251771 VBP O
decreases BC2GM010251771 VBZ O
resting BC2GM010251771 VBG O
blood BC2GM010251771 NN O
pressure BC2GM010251771 NN O
and BC2GM010251771 CC O
left BC2GM010251771 VBD O
ventricular BC2GM010251771 JJ O
area BC2GM010251771 NN O
, BC2GM010251771 , O
increases BC2GM010251771 VBZ O
pulse BC2GM010251771 JJ O
rate BC2GM010251771 NN O
and BC2GM010251771 CC O
has BC2GM010251771 VBZ O
virtually BC2GM010251771 RB O
no BC2GM010251771 DT O
effect BC2GM010251771 NN O
on BC2GM010251771 IN O
left BC2GM010251771 NN O
ventricular BC2GM010251771 JJ O
ejection BC2GM010251771 NN O
fraction BC2GM010251771 NN O
. BC2GM010251771 . O
. . O O

The BC2GM042679394 DT O
system BC2GM042679394 NN O
consists BC2GM042679394 VBZ O
of BC2GM042679394 IN O
a BC2GM042679394 DT O
TV BC2GM042679394 NN O
unit BC2GM042679394 NN O
compatible BC2GM042679394 JJ O
to BC2GM042679394 TO O
IBM BC2GM042679394 NNP O
PC BC2GM042679394 NNP O
/ BC2GM042679394 NN O
AT BC2GM042679394 NNP O
and BC2GM042679394 CC O
software BC2GM042679394 NN O
. BC2GM042679394 . O
. . O O

Although BC2GM097601782 IN O
paclitaxel BC2GM097601782 JJ O
alone BC2GM097601782 RB O
failed BC2GM097601782 VBD O
to BC2GM097601782 TO O
induce BC2GM097601782 VB O
p38 BC2GM097601782 JJ O
MAPK BC2GM097601782 NNP O
activation BC2GM097601782 NN O
, BC2GM097601782 , O
subsequent BC2GM097601782 JJ O
( BC2GM097601782 ( O
but BC2GM097601782 CC O
not BC2GM097601782 RB O
prior BC2GM097601782 RB O
) BC2GM097601782 ) O
exposure BC2GM097601782 NN O
to BC2GM097601782 TO O
PD98059 BC2GM097601782 NNP O
induced BC2GM097601782 VBD O
a BC2GM097601782 DT O
dramatic BC2GM097601782 JJ O
increase BC2GM097601782 NN O
in BC2GM097601782 IN O
p38 BC2GM097601782 JJ O
MAPK BC2GM097601782 NNP O
phosphorylation BC2GM097601782 NN O
. BC2GM097601782 . O
. . O O

Otosclerosis BC2GM047597727 NN O
in BC2GM047597727 IN O
monozygotic BC2GM047597727 JJ O
twins BC2GM047597727 NNS O
: BC2GM047597727 : O
clinical BC2GM047597727 JJ O
and BC2GM047597727 CC O
genetical BC2GM047597727 JJ O
analysis BC2GM047597727 NN O
. BC2GM047597727 . O
. . O O

Role BC2GM077137738 NNP O
of BC2GM077137738 IN O
the BC2GM077137738 DT O
CCAAT BC2GM077137738 NNP O
/ BC2GM077137738 NNP O
enhancer BC2GM077137738 NN O
binding BC2GM077137738 VBG O
protein-alpha BC2GM077137738 JJ O
transcription BC2GM077137738 NN O
factor BC2GM077137738 NN O
in BC2GM077137738 IN O
the BC2GM077137738 DT O
glucocorticoid BC2GM077137738 JJ O
stimulation BC2GM077137738 NN O
of BC2GM077137738 IN O
p21waf1 BC2GM077137738 NN O
/ BC2GM077137738 NNP O
cip1 BC2GM077137738 NN O
gene BC2GM077137738 NN O
promoter BC2GM077137738 NN O
activity BC2GM077137738 NN O
in BC2GM077137738 IN O
growth-arrested BC2GM077137738 JJ O
rat BC2GM077137738 NN O
hepatoma BC2GM077137738 NN O
cells BC2GM077137738 NNS O
. BC2GM077137738 . O
. . O O

A BC2GM014660271 DT O
pathogenetic BC2GM014660271 JJ O
relation BC2GM014660271 NN O
with BC2GM014660271 IN O
the BC2GM014660271 DT O
Eisenmenger BC2GM014660271 NNP O
's BC2GM014660271 POS O
syndrome BC2GM014660271 NN O
is BC2GM014660271 VBZ O
discussed BC2GM014660271 VBN O
. BC2GM014660271 . O
. . O O

Statistical BC2GM026957766 JJ O
aspects BC2GM026957766 NNS O
of BC2GM026957766 IN O
the BC2GM026957766 DT O
relation BC2GM026957766 NN O
of BC2GM026957766 IN O
the BC2GM026957766 DT O
radioprotective BC2GM026957766 JJ O
action BC2GM026957766 NN O
of BC2GM026957766 IN O
mercaptoethylamine BC2GM026957766 NN O
derivatives BC2GM026957766 NNS O
and BC2GM026957766 CC O
analogs BC2GM026957766 NNS O
to BC2GM026957766 TO O
their BC2GM026957766 PRP$ O
electron BC2GM026957766 NN O
parameters BC2GM026957766 NNS O
. BC2GM026957766 . O
. . O O

Saturated BC2GM065395717 VBN O
fatty BC2GM065395717 JJ O
acids BC2GM065395717 NNS O
induce BC2GM065395717 VB O
a BC2GM065395717 DT O
1.6-fold BC2GM065395717 JJ O
increase BC2GM065395717 NN O
in BC2GM065395717 IN O
transcription BC2GM065395717 NN O
activity BC2GM065395717 NN O
, BC2GM065395717 , O
whereas BC2GM065395717 IN O
a BC2GM065395717 DT O
large BC2GM065395717 JJ O
family BC2GM065395717 NN O
of BC2GM065395717 IN O
unsaturated BC2GM065395717 JJ O
fatty BC2GM065395717 JJ O
acids BC2GM065395717 NNS O
repress BC2GM065395717 NN O
OLE1 BC2GM065395717 NNP O
transcription BC2GM065395717 NN O
as BC2GM065395717 RB O
much BC2GM065395717 JJ O
as BC2GM065395717 IN O
60-fold BC2GM065395717 JJ O
. BC2GM065395717 . O
. . O O

Furthermore BC2GM034696553 RB O
, BC2GM034696553 , O
the BC2GM034696553 DT O
induction BC2GM034696553 NN O
of BC2GM034696553 IN O
cytochrome BC2GM034696553 JJ O
P-450 BC2GM034696553 NNP O
1A1 BC2GM034696553 CD O
observed BC2GM034696553 VBN O
in BC2GM034696553 IN O
the BC2GM034696553 DT O
cormorant BC2GM034696553 NN O
indicates BC2GM034696553 VBZ O
that BC2GM034696553 IN O
the BC2GM034696553 DT O
Ah BC2GM034696553 NNP O
receptor-mediated BC2GM034696553 JJ O
process BC2GM034696553 NN O
, BC2GM034696553 , O
by BC2GM034696553 IN O
which BC2GM034696553 WDT O
TCDD BC2GM034696553 NNP O
and BC2GM034696553 CC O
related BC2GM034696553 JJ O
chemicals BC2GM034696553 NNS O
exert BC2GM034696553 VBP O
many BC2GM034696553 JJ O
of BC2GM034696553 IN O
their BC2GM034696553 PRP$ O
toxicities BC2GM034696553 NNS O
, BC2GM034696553 , O
has BC2GM034696553 VBZ O
been BC2GM034696553 VBN O
activated BC2GM034696553 VBN O
. BC2GM034696553 . O
. . O O

Apoptosis BC2GM073208468 NN O
triggered BC2GM073208468 VBD O
through BC2GM073208468 IN O
Fas BC2GM073208468 NNP O
and BC2GM073208468 CC O
F BC2GM073208468 NNP O
/ BC2GM073208468 NNP O
F BC2GM073208468 NNP O
was BC2GM073208468 VBD O
inhibited BC2GM073208468 VBN O
by BC2GM073208468 IN O
coexpression BC2GM073208468 NN O
of BC2GM073208468 IN O
CrmA BC2GM073208468 NNP O
and BC2GM073208468 CC O
p35 BC2GM073208468 NN O
, BC2GM073208468 , O
but BC2GM073208468 CC O
not BC2GM073208468 RB O
Bcl-xL BC2GM073208468 NNP O
. BC2GM073208468 . O
. . O O

One BC2GM080435021 CD O
patient BC2GM080435021 NN O
had BC2GM080435021 VBD O
chronic BC2GM080435021 JJ O
dysphoria BC2GM080435021 NNS O
and BC2GM080435021 CC O
one BC2GM080435021 CD O
encephalopatia BC2GM080435021 NN O
toxica BC2GM080435021 NN O
. BC2GM080435021 . O
. . O O

The BC2GM093413177 DT O
differential BC2GM093413177 JJ O
diagnosis BC2GM093413177 NN O
of BC2GM093413177 IN O
mineral BC2GM093413177 JJ O
oil BC2GM093413177 NN O
lipidosis BC2GM093413177 NN O
in BC2GM093413177 IN O
lymph BC2GM093413177 NN O
nodes BC2GM093413177 NNS O
with BC2GM093413177 IN O
reaction BC2GM093413177 NN O
to BC2GM093413177 TO O
radiopaque BC2GM093413177 VB O
oils BC2GM093413177 NNS O
and BC2GM093413177 CC O
Whipple BC2GM093413177 NNP O
's BC2GM093413177 POS O
disease BC2GM093413177 NN O
is BC2GM093413177 VBZ O
discussed BC2GM093413177 VBN O
. BC2GM093413177 . O
. . O O

Thus BC2GM050323538 RB O
, BC2GM050323538 , O
CARP BC2GM050323538 NNP O
is BC2GM050323538 VBZ O
a BC2GM050323538 DT O
YB-1 BC2GM050323538 JJ O
associated BC2GM050323538 JJ O
factor BC2GM050323538 NN O
and BC2GM050323538 CC O
represents BC2GM050323538 VBZ O
the BC2GM050323538 DT O
first BC2GM050323538 JJ O
identified BC2GM050323538 VBN O
cardiac-restricted BC2GM050323538 JJ O
downstream BC2GM050323538 NN O
regulatory BC2GM050323538 JJ O
gene BC2GM050323538 NN O
in BC2GM050323538 IN O
the BC2GM050323538 DT O
homeobox BC2GM050323538 JJ O
gene BC2GM050323538 NN O
Nkx2-5 BC2GM050323538 NNP O
pathway BC2GM050323538 NN O
and BC2GM050323538 CC O
may BC2GM050323538 MD O
serve BC2GM050323538 VB O
as BC2GM050323538 IN O
a BC2GM050323538 DT O
negative BC2GM050323538 JJ O
regulator BC2GM050323538 NN O
of BC2GM050323538 IN O
HF-1-dependent BC2GM050323538 NNP O
pathways BC2GM050323538 NNS O
for BC2GM050323538 IN O
ventricular BC2GM050323538 JJ O
muscle BC2GM050323538 NN O
gene BC2GM050323538 NN O
expression BC2GM050323538 NN O
. BC2GM050323538 . O
. . O O

Not BC2GM052108283 RB O
only BC2GM052108283 RB O
will BC2GM052108283 MD O
it BC2GM052108283 PRP O
substantially BC2GM052108283 RB O
reduce BC2GM052108283 VB O
incident BC2GM052108283 JJ O
cases BC2GM052108283 NNS O
of BC2GM052108283 IN O
hepatitis BC2GM052108283 NN O
B BC2GM052108283 NNP O
for BC2GM052108283 IN O
the BC2GM052108283 DT O
next BC2GM052108283 JJ O
decade BC2GM052108283 NN O
, BC2GM052108283 , O
it BC2GM052108283 PRP O
will BC2GM052108283 MD O
also BC2GM052108283 RB O
provide BC2GM052108283 VB O
a BC2GM052108283 DT O
framework BC2GM052108283 NN O
for BC2GM052108283 IN O
the BC2GM052108283 DT O
successful BC2GM052108283 JJ O
introduction BC2GM052108283 NN O
of BC2GM052108283 IN O
future BC2GM052108283 JJ O
adolescent BC2GM052108283 JJ O
vaccine BC2GM052108283 NN O
initiatives BC2GM052108283 NNS O
in BC2GM052108283 IN O
Australia BC2GM052108283 NNP O
. BC2GM052108283 . O
. . O O

This BC2GM030553104 DT O
study BC2GM030553104 NN O
was BC2GM030553104 VBD O
undertaken BC2GM030553104 VBN O
to BC2GM030553104 TO O
evaluate BC2GM030553104 VB O
the BC2GM030553104 DT O
physical BC2GM030553104 JJ O
and BC2GM030553104 CC O
biological BC2GM030553104 JJ O
characteristics BC2GM030553104 NNS O
of BC2GM030553104 IN O
nebulized BC2GM030553104 JJ O
interleukin BC2GM030553104 JJ O
2 BC2GM030553104 CD O
liposomes BC2GM030553104 NNS O
. BC2GM030553104 . O
. . O O

The BC2GM030760863 DT O
data BC2GM030760863 NN O
also BC2GM030760863 RB O
suggest BC2GM030760863 VBP O
that BC2GM030760863 IN O
gamma BC2GM030760863 NN O
CACCC BC2GM030760863 NNP O
box BC2GM030760863 NN O
binding BC2GM030760863 VBG O
factors BC2GM030760863 NNS O
mediate BC2GM030760863 VBP O
LCR-gamma BC2GM030760863 NNP O
interactions BC2GM030760863 NNS O
which BC2GM030760863 WDT O
normally BC2GM030760863 RB O
enhance BC2GM030760863 VB O
gamma-globin BC2GM030760863 NN O
and BC2GM030760863 CC O
suppress BC2GM030760863 JJ O
beta-globin BC2GM030760863 JJ O
gene BC2GM030760863 NN O
expression BC2GM030760863 NN O
in BC2GM030760863 IN O
fetal BC2GM030760863 JJ O
erythroid BC2GM030760863 JJ O
cells BC2GM030760863 NNS O
. BC2GM030760863 . O
. . O O

Together BC2GM081882075 RB O
, BC2GM081882075 , O
these BC2GM081882075 DT O
results BC2GM081882075 NNS O
indicate BC2GM081882075 VBP O
that BC2GM081882075 IN O
YTS1 BC2GM081882075 NNP O
is BC2GM081882075 VBZ O
a BC2GM081882075 DT O
bifunctional BC2GM081882075 JJ O
protein BC2GM081882075 NN O
active BC2GM081882075 JJ O
in BC2GM081882075 IN O
both BC2GM081882075 DT O
splicing BC2GM081882075 NN O
and BC2GM081882075 CC O
protein BC2GM081882075 JJ O
synthesis BC2GM081882075 NN O
. BC2GM081882075 . O
. . O O

PURPOSE BC2GM036717390 NN O
: BC2GM036717390 : O
To BC2GM036717390 TO O
evaluate BC2GM036717390 VB O
the BC2GM036717390 DT O
effect BC2GM036717390 NN O
of BC2GM036717390 IN O
adding BC2GM036717390 VBG O
a BC2GM036717390 DT O
pulsating BC2GM036717390 NN O
bristle BC2GM036717390 JJ O
action BC2GM036717390 NN O
to BC2GM036717390 TO O
the BC2GM036717390 DT O
established BC2GM036717390 VBN O
oscillating BC2GM036717390 NN O
/ BC2GM036717390 NN O
rotating BC2GM036717390 VBG O
action BC2GM036717390 NN O
of BC2GM036717390 IN O
the BC2GM036717390 DT O
Braun BC2GM036717390 NNP O
Oral-B BC2GM036717390 NNP O
Ultra BC2GM036717390 NNP O
Plaque BC2GM036717390 NNP O
Remover BC2GM036717390 NNP O
( BC2GM036717390 ( O
D9 BC2GM036717390 NNP O
) BC2GM036717390 ) O
on BC2GM036717390 IN O
plaque BC2GM036717390 NN O
removal BC2GM036717390 NN O
. BC2GM036717390 . O
. . O O

The BC2GM039881960 DT O
liver-specific BC2GM039881960 JJ O
sequence BC2GM039881960 NN O
contains BC2GM039881960 NNS O
unique BC2GM039881960 JJ O
consensus BC2GM039881960 NN O
sites BC2GM039881960 NNS O
for BC2GM039881960 IN O
phosphorylation BC2GM039881960 NN O
by BC2GM039881960 IN O
cyclic BC2GM039881960 JJ O
AMP-dependent BC2GM039881960 JJ O
protein BC2GM039881960 NN O
kinase BC2GM039881960 NN O
and BC2GM039881960 CC O
by BC2GM039881960 IN O
protein BC2GM039881960 JJ O
kinase BC2GM039881960 NN O
C BC2GM039881960 NNP O
. BC2GM039881960 . O
. . O O

Adenocarcinoma BC2GM070747884 NNP O
and BC2GM070747884 CC O
large BC2GM070747884 JJ O
cell BC2GM070747884 NN O
carcinoma BC2GM070747884 NNS O
have BC2GM070747884 VBP O
a BC2GM070747884 DT O
worse BC2GM070747884 JJR O
prognosis BC2GM070747884 NN O
than BC2GM070747884 IN O
squamous BC2GM070747884 JJ O
cell BC2GM070747884 NN O
carcinoma BC2GM070747884 NN O
in BC2GM070747884 IN O
the BC2GM070747884 DT O
T1N1 BC2GM070747884 NNP O
and BC2GM070747884 CC O
T2N1 BC2GM070747884 NNP O
subsets BC2GM070747884 NNS O
. BC2GM070747884 . O
. . O O

This BC2GM050680877 DT O
is BC2GM050680877 VBZ O
the BC2GM050680877 DT O
first BC2GM050680877 JJ O
report BC2GM050680877 NN O
which BC2GM050680877 WDT O
clearly BC2GM050680877 RB O
proved BC2GM050680877 VBD O
CEA BC2GM050680877 NNP O
synthesis BC2GM050680877 NN O
in BC2GM050680877 IN O
the BC2GM050680877 DT O
cells BC2GM050680877 NNS O
of BC2GM050680877 IN O
HCC BC2GM050680877 NNP O
. BC2GM050680877 . O
. . O O

Sera BC2GM056659741 NN O
from BC2GM056659741 IN O
33 BC2GM056659741 CD O
newborn BC2GM056659741 JJ O
infants BC2GM056659741 NNS O
with BC2GM056659741 IN O
gestational BC2GM056659741 JJ O
ages BC2GM056659741 NNS O
ranging BC2GM056659741 VBG O
from BC2GM056659741 IN O
27 BC2GM056659741 CD O
to BC2GM056659741 TO O
41 BC2GM056659741 CD O
weeks BC2GM056659741 NNS O
were BC2GM056659741 VBD O
tested BC2GM056659741 VBN O
by BC2GM056659741 IN O
radioimmunoassay BC2GM056659741 NN O
for BC2GM056659741 IN O
IgG BC2GM056659741 NNP O
antibodies BC2GM056659741 NNS O
to BC2GM056659741 TO O
surface BC2GM056659741 VB O
antigens BC2GM056659741 NNS O
of BC2GM056659741 IN O
group BC2GM056659741 NN O
B BC2GM056659741 NNP O
streptococci BC2GM056659741 NN O
( BC2GM056659741 ( O
GBS BC2GM056659741 NNP O
) BC2GM056659741 ) O
types BC2GM056659741 VBZ O
Ia BC2GM056659741 NNP O
, BC2GM056659741 , O
Ib BC2GM056659741 NNP O
, BC2GM056659741 , O
II BC2GM056659741 NNP O
and BC2GM056659741 CC O
III BC2GM056659741 NNP O
. BC2GM056659741 . O
. . O O

In BC2GM092138955 IN O
this BC2GM092138955 DT O
second BC2GM092138955 JJ O
clinical BC2GM092138955 JJ O
paper BC2GM092138955 NN O
, BC2GM092138955 , O
the BC2GM092138955 DT O
genetic BC2GM092138955 JJ O
features BC2GM092138955 NNS O
of BC2GM092138955 IN O
the BC2GM092138955 DT O
case BC2GM092138955 NN O
of BC2GM092138955 IN O
microphthalmia BC2GM092138955 NN O
in BC2GM092138955 IN O
sheep BC2GM092138955 NN O
reported BC2GM092138955 VBN O
by BC2GM092138955 IN O
Wagenaar BC2GM092138955 NNP O
is BC2GM092138955 VBZ O
discussed BC2GM092138955 VBN O
in BC2GM092138955 IN O
greater BC2GM092138955 JJR O
detail BC2GM092138955 NN O
. BC2GM092138955 . O
. . O O

In BC2GM043735377 IN O
this BC2GM043735377 DT O
system BC2GM043735377 NN O
, BC2GM043735377 , O
enhancers BC2GM043735377 NNS O
act BC2GM043735377 VBP O
primarily BC2GM043735377 RB O
to BC2GM043735377 TO O
increase BC2GM043735377 VB O
the BC2GM043735377 DT O
probability BC2GM043735377 NN O
of BC2GM043735377 IN O
rapid BC2GM043735377 JJ O
and BC2GM043735377 CC O
efficient BC2GM043735377 JJ O
transcription BC2GM043735377 NN O
complex BC2GM043735377 JJ O
formation BC2GM043735377 NN O
and BC2GM043735377 CC O
initiation BC2GM043735377 NN O
. BC2GM043735377 . O
. . O O

( BC2GM043837371 ( O
i BC2GM043837371 NN O
) BC2GM043837371 ) O
p60 BC2GM043837371 NN O
bound BC2GM043837371 IN O
fast-migrating BC2GM043837371 NN O
, BC2GM043837371 , O
underprocessed BC2GM043837371 JJ O
wild-type BC2GM043837371 JJ O
ICP22 BC2GM043837371 NNP O
and BC2GM043837371 CC O
ICP22 BC2GM043837371 NNP O
lacking BC2GM043837371 VBG O
the BC2GM043837371 DT O
carboxyl-terminal BC2GM043837371 JJ O
24 BC2GM043837371 CD O
amino BC2GM043837371 JJ O
acids BC2GM043837371 NNS O
but BC2GM043837371 CC O
not BC2GM043837371 RB O
ICP22 BC2GM043837371 NNP O
lacking BC2GM043837371 VBG O
the BC2GM043837371 DT O
carboxyl-terminal BC2GM043837371 JJ O
40 BC2GM043837371 CD O
amino BC2GM043837371 NN O
acids BC2GM043837371 NNS O
, BC2GM043837371 , O
whereas BC2GM043837371 IN O
the BC2GM043837371 DT O
previously BC2GM043837371 RB O
identified BC2GM043837371 VBN O
cellular BC2GM043837371 JJ O
protein BC2GM043837371 NN O
p78 BC2GM043837371 NN O
( BC2GM043837371 ( O
R BC2GM043837371 NNP O
. BC2GM043837371 . O
. . O O

To BC2GM002844887 TO O
identify BC2GM002844887 VB O
the BC2GM002844887 DT O
GRK6 BC2GM002844887 NNP O
homologue BC2GM002844887 NN O
on BC2GM002844887 IN O
chromsome BC2GM002844887 NN O
13 BC2GM002844887 CD O
, BC2GM002844887 , O
several BC2GM002844887 JJ O
sets BC2GM002844887 NNS O
of BC2GM002844887 IN O
closely-spaced BC2GM002844887 JJ O
primers BC2GM002844887 NNS O
were BC2GM002844887 VBD O
designed BC2GM002844887 VBN O
based BC2GM002844887 VBN O
on BC2GM002844887 IN O
the BC2GM002844887 DT O
GRK6 BC2GM002844887 NNP O
cDNA BC2GM002844887 NN O
sequence BC2GM002844887 NN O
and BC2GM002844887 CC O
then BC2GM002844887 RB O
used BC2GM002844887 VBD O
to BC2GM002844887 TO O
amplify BC2GM002844887 VB O
human BC2GM002844887 JJ O
genomic BC2GM002844887 JJ O
DNA BC2GM002844887 NN O
by BC2GM002844887 IN O
PCR BC2GM002844887 NNP O
. BC2GM002844887 . O
. . O O

This BC2GM038644769 DT O
surface BC2GM038644769 NN O
in BC2GM038644769 IN O
specimens BC2GM038644769 NNS O
from BC2GM038644769 IN O
unfertilized BC2GM038644769 JJ O
eggs BC2GM038644769 NNS O
is BC2GM038644769 VBZ O
almost BC2GM038644769 RB O
flat BC2GM038644769 JJ O
. BC2GM038644769 . O
. . O O

Physical BC2GM061275857 JJ O
mapping BC2GM061275857 NN O
220 BC2GM061275857 CD O
kb BC2GM061275857 NN O
centromeric BC2GM061275857 NN O
of BC2GM061275857 IN O
the BC2GM061275857 DT O
human BC2GM061275857 JJ O
MHC BC2GM061275857 NNP O
and BC2GM061275857 CC O
DNA BC2GM061275857 NNP O
sequence BC2GM061275857 NN O
analysis BC2GM061275857 NN O
of BC2GM061275857 IN O
the BC2GM061275857 DT O
43-kb BC2GM061275857 JJ O
segment BC2GM061275857 NN O
including BC2GM061275857 VBG O
the BC2GM061275857 DT O
RING1 BC2GM061275857 NNP O
, BC2GM061275857 , O
HKE6 BC2GM061275857 NNP O
, BC2GM061275857 , O
and BC2GM061275857 CC O
HKE4 BC2GM061275857 NNP O
genes BC2GM061275857 NNS O
. BC2GM061275857 . O
. . O O

The BC2GM052576426 DT O
central BC2GM052576426 JJ O
venous BC2GM052576426 JJ O
O2 BC2GM052576426 NNP O
saturation BC2GM052576426 NN O
test BC2GM052576426 NN O
in BC2GM052576426 IN O
acute BC2GM052576426 JJ O
pulmonary BC2GM052576426 JJ O
fat BC2GM052576426 NN O
embolism BC2GM052576426 NN O
. BC2GM052576426 . O
. . O O

Influence BC2GM072421473 NN O
of BC2GM072421473 IN O
copper BC2GM072421473 NN O
addition BC2GM072421473 NN O
. BC2GM072421473 . O
. . O O

The BC2GM051853385 DT O
nutraceuticals BC2GM051853385 NNS O
of BC2GM051853385 IN O
specific BC2GM051853385 JJ O
vitamins BC2GM051853385 NNS O
, BC2GM051853385 , O
minerals BC2GM051853385 NNS O
, BC2GM051853385 , O
phytoestrogens BC2GM051853385 NNS O
, BC2GM051853385 , O
and BC2GM051853385 CC O
essential BC2GM051853385 JJ O
fatty BC2GM051853385 JJ O
acid BC2GM051853385 NN O
supplementations BC2GM051853385 NNS O
are BC2GM051853385 VBP O
a BC2GM051853385 DT O
vital BC2GM051853385 JJ O
component BC2GM051853385 NN O
of BC2GM051853385 IN O
the BC2GM051853385 DT O
risk BC2GM051853385 NN O
reduction BC2GM051853385 NN O
health BC2GM051853385 NN O
program BC2GM051853385 NN O
. BC2GM051853385 . O
. . O O

After BC2GM085157618 IN O
multivariate BC2GM085157618 JJ O
analysis BC2GM085157618 NN O
, BC2GM085157618 , O
TWA BC2GM085157618 NNP O
correlated BC2GM085157618 VBD O
with BC2GM085157618 IN O
age BC2GM085157618 NN O
( BC2GM085157618 ( O
P BC2GM085157618 NNP O
= BC2GM085157618 NNP O
0.02 BC2GM085157618 CD O
) BC2GM085157618 ) O
and BC2GM085157618 CC O
LV BC2GM085157618 NNP O
function BC2GM085157618 NN O
( BC2GM085157618 ( O
P BC2GM085157618 NNP O
= BC2GM085157618 NNP O
0.002 BC2GM085157618 CD O
) BC2GM085157618 ) O
and BC2GM085157618 CC O
occurred BC2GM085157618 VBD O
more BC2GM085157618 RBR O
often BC2GM085157618 RB O
in BC2GM085157618 IN O
patients BC2GM085157618 NNS O
after BC2GM085157618 IN O
nonanterior BC2GM085157618 JJ O
MI BC2GM085157618 NNP O
( BC2GM085157618 ( O
P BC2GM085157618 NNP O
= BC2GM085157618 NNP O
0.03 BC2GM085157618 CD O
) BC2GM085157618 ) O
. BC2GM085157618 . O
. . O O

Deletion BC2GM064298943 NN O
mutations BC2GM064298943 NNS O
were BC2GM064298943 VBD O
constructed BC2GM064298943 VBN O
, BC2GM064298943 , O
removing BC2GM064298943 VBG O
residues BC2GM064298943 NNS O
2-30 BC2GM064298943 JJ O
, BC2GM064298943 , O
31-60 BC2GM064298943 JJ O
, BC2GM064298943 , O
61-90 BC2GM064298943 JJ O
, BC2GM064298943 , O
and BC2GM064298943 CC O
49-78 BC2GM064298943 CD O
of BC2GM064298943 IN O
the BC2GM064298943 DT O
N-terminal BC2GM064298943 JJ O
cytoplasmic BC2GM064298943 JJ O
domain BC2GM064298943 NN O
, BC2GM064298943 , O
as BC2GM064298943 RB O
well BC2GM064298943 RB O
as BC2GM064298943 IN O
a BC2GM064298943 DT O
missense BC2GM064298943 JJ O
mutation BC2GM064298943 NN O
of BC2GM064298943 IN O
a BC2GM064298943 DT O
dileucine BC2GM064298943 NN O
motif BC2GM064298943 NN O
. BC2GM064298943 . O
. . O O

Furthermore BC2GM003309537 RB O
, BC2GM003309537 , O
we BC2GM003309537 PRP O
detect BC2GM003309537 VBP O
hCoch-5B2 BC2GM003309537 JJ O
on BC2GM003309537 IN O
three BC2GM003309537 CD O
overlapping BC2GM003309537 VBG O
YACs BC2GM003309537 NNP O
, BC2GM003309537 , O
two BC2GM003309537 CD O
of BC2GM003309537 IN O
which BC2GM003309537 WDT O
also BC2GM003309537 RB O
contain BC2GM003309537 VBP O
one BC2GM003309537 CD O
of BC2GM003309537 IN O
the BC2GM003309537 DT O
markers BC2GM003309537 NNS O
linked BC2GM003309537 VBD O
to BC2GM003309537 TO O
DFNA9 BC2GM003309537 NNP O
. BC2GM003309537 . O
mCoch-5B2 BC2GM003309537 NN O
was BC2GM003309537 VBD O
genetically BC2GM003309537 RB O
mapped BC2GM003309537 VBN O
in BC2GM003309537 IN O
the BC2GM003309537 DT O
mouse BC2GM003309537 NN O
to BC2GM003309537 TO O
chromosome BC2GM003309537 VB O
12 BC2GM003309537 CD O
, BC2GM003309537 , O
in BC2GM003309537 IN O
a BC2GM003309537 DT O
region BC2GM003309537 NN O
of BC2GM003309537 IN O
homologous BC2GM003309537 JJ O
synteny BC2GM003309537 NN O
with BC2GM003309537 IN O
human BC2GM003309537 JJ O
14q11.2-q13 BC2GM003309537 CD O
, BC2GM003309537 , O
which BC2GM003309537 WDT O
contains BC2GM003309537 VBZ O
the BC2GM003309537 DT O
asp1 BC2GM003309537 NN O
( BC2GM003309537 ( O
audiogenic BC2GM003309537 JJ O
seizure BC2GM003309537 NN O
prone BC2GM003309537 NN O
) BC2GM003309537 ) O
locus BC2GM003309537 NN O
in BC2GM003309537 IN O
the BC2GM003309537 DT O
mouse BC2GM003309537 NN O
. BC2GM003309537 . O
. . O O

Insulin-secreting BC2GM080360058 JJ O
islet-cell BC2GM080360058 JJ O
tumours BC2GM080360058 NN O
of BC2GM080360058 IN O
the BC2GM080360058 DT O
pancreas BC2GM080360058 NNS O
. BC2GM080360058 . O
. . O O

All BC2GM039889670 DT O
patients BC2GM039889670 NNS O
whose BC2GM039889670 WP$ O
PSA BC2GM039889670 NNP O
levels BC2GM039889670 NNS O
reached BC2GM039889670 VBD O
0.1 BC2GM039889670 CD O
ng BC2GM039889670 NN O
. BC2GM039889670 . O
/ BC2GM039889670 JJ O
ml BC2GM039889670 NN O
. BC2GM039889670 . O
. . O O

HNF4alpha7 BC2GM019547641 NNP O
mRNA BC2GM019547641 NN O
is BC2GM019547641 VBZ O
also BC2GM019547641 RB O
found BC2GM019547641 VBN O
in BC2GM019547641 IN O
totipotent BC2GM019547641 JJ O
embryonic BC2GM019547641 JJ O
stem BC2GM019547641 NN O
cells BC2GM019547641 NNS O
. BC2GM019547641 . O
. . O O

Tax BC2GM082753569 NN O
and BC2GM082753569 CC O
the BC2GM082753569 DT O
active BC2GM082753569 JJ O
Tax BC2GM082753569 NN O
mutants BC2GM082753569 NNS O
were BC2GM082753569 VBD O
able BC2GM082753569 JJ O
to BC2GM082753569 TO O
abrogate BC2GM082753569 VB O
the BC2GM082753569 DT O
G1 BC2GM082753569 NNP O
arrest BC2GM082753569 NN O
and BC2GM082753569 CC O
apoptosis BC2GM082753569 NN O
induced BC2GM082753569 VBN O
by BC2GM082753569 IN O
p53 BC2GM082753569 NN O
, BC2GM082753569 , O
and BC2GM082753569 CC O
this BC2GM082753569 DT O
effect BC2GM082753569 NN O
does BC2GM082753569 VBZ O
not BC2GM082753569 RB O
correlate BC2GM082753569 VB O
with BC2GM082753569 IN O
an BC2GM082753569 DT O
altered BC2GM082753569 JJ O
localization BC2GM082753569 NN O
of BC2GM082753569 IN O
nuclear BC2GM082753569 JJ O
p53 BC2GM082753569 NN O
or BC2GM082753569 CC O
with BC2GM082753569 IN O
the BC2GM082753569 DT O
disruption BC2GM082753569 NN O
of BC2GM082753569 IN O
p53-DNA BC2GM082753569 NN O
complexes BC2GM082753569 NNS O
. BC2GM082753569 . O
. . O O

In BC2GM069951819 IN O
addition BC2GM069951819 NN O
, BC2GM069951819 , O
the BC2GM069951819 DT O
findings BC2GM069951819 NNS O
confirmed BC2GM069951819 VBD O
previous BC2GM069951819 JJ O
studies BC2GM069951819 NNS O
which BC2GM069951819 WDT O
showed BC2GM069951819 VBD O
that BC2GM069951819 IN O
monkeys BC2GM069951819 NNS O
with BC2GM069951819 IN O
total BC2GM069951819 JJ O
bilateral BC2GM069951819 JJ O
striatectomies BC2GM069951819 NNS O
could BC2GM069951819 MD O
require BC2GM069951819 VB O
the BC2GM069951819 DT O
ability BC2GM069951819 NN O
to BC2GM069951819 TO O
execute BC2GM069951819 VB O
accurate BC2GM069951819 JJ O
visually BC2GM069951819 RB O
guided BC2GM069951819 VBN O
reaches BC2GM069951819 NNS O
. BC2GM069951819 . O
. . O O

Adhesion BC2GM037459381 NN O
was BC2GM037459381 VBD O
inhibited BC2GM037459381 VBN O
by BC2GM037459381 IN O
mAbs BC2GM037459381 NN O
against BC2GM037459381 IN O
the BC2GM037459381 DT O
COOH-terminus BC2GM037459381 NNP O
and BC2GM037459381 CC O
central BC2GM037459381 JJ O
cell BC2GM037459381 NN O
binding BC2GM037459381 VBG O
domains BC2GM037459381 NNS O
of BC2GM037459381 IN O
fibronectin BC2GM037459381 NN O
, BC2GM037459381 , O
as BC2GM037459381 RB O
well BC2GM037459381 RB O
as BC2GM037459381 IN O
by BC2GM037459381 IN O
the BC2GM037459381 DT O
corresponding BC2GM037459381 JJ O
CS1 BC2GM037459381 NNP O
and BC2GM037459381 CC O
RGD BC2GM037459381 NNP O
peptides BC2GM037459381 NNS O
. BC2GM037459381 . O
. . O O

The BC2GM095336401 DT O
gene BC2GM095336401 NN O
is BC2GM095336401 VBZ O
predicted BC2GM095336401 VBN O
to BC2GM095336401 TO O
encode BC2GM095336401 VB O
an BC2GM095336401 DT O
880-amino-acid BC2GM095336401 JJ O
protein BC2GM095336401 NN O
which BC2GM095336401 WDT O
contains BC2GM095336401 VBZ O
two BC2GM095336401 CD O
C2H2 BC2GM095336401 NNP O
zinc BC2GM095336401 NN O
fingers BC2GM095336401 NNS O
, BC2GM095336401 , O
a BC2GM095336401 DT O
nuclear BC2GM095336401 JJ O
localization BC2GM095336401 NN O
sequence BC2GM095336401 NN O
and BC2GM095336401 CC O
two BC2GM095336401 CD O
transcriptional BC2GM095336401 JJ O
activation BC2GM095336401 NN O
domains BC2GM095336401 NNS O
. BC2GM095336401 . O
. . O O

The BC2GM065728074 DT O
most BC2GM065728074 RBS O
frequent BC2GM065728074 JJ O
abnormality BC2GM065728074 NN O
was BC2GM065728074 VBD O
GH BC2GM065728074 NNP O
deficiency BC2GM065728074 NN O
( BC2GM065728074 ( O
six BC2GM065728074 CD O
cases BC2GM065728074 NNS O
) BC2GM065728074 ) O
, BC2GM065728074 , O
followed BC2GM065728074 VBN O
by BC2GM065728074 IN O
gonadotropin BC2GM065728074 NN O
( BC2GM065728074 ( O
four BC2GM065728074 CD O
cases BC2GM065728074 NNS O
) BC2GM065728074 ) O
, BC2GM065728074 , O
cortisol BC2GM065728074 FW O
( BC2GM065728074 ( O
four BC2GM065728074 CD O
cases BC2GM065728074 NNS O
) BC2GM065728074 ) O
, BC2GM065728074 , O
and BC2GM065728074 CC O
TSH BC2GM065728074 NNP O
( BC2GM065728074 ( O
one BC2GM065728074 CD O
case BC2GM065728074 NN O
) BC2GM065728074 ) O
, BC2GM065728074 , O
whereas BC2GM065728074 RB O
four BC2GM065728074 CD O
patients BC2GM065728074 NNS O
showed BC2GM065728074 VBD O
high BC2GM065728074 JJ O
serum BC2GM065728074 NN O
PRL BC2GM065728074 NNP O
values BC2GM065728074 NNS O
. BC2GM065728074 . O
. . O O

These BC2GM023252709 DT O
studies BC2GM023252709 NNS O
define BC2GM023252709 VBP O
a BC2GM023252709 DT O
class BC2GM023252709 NN O
of BC2GM023252709 IN O
DNA BC2GM023252709 NNP O
elements BC2GM023252709 NNS O
with BC2GM023252709 IN O
a BC2GM023252709 DT O
mode BC2GM023252709 NN O
of BC2GM023252709 IN O
action BC2GM023252709 NN O
that BC2GM023252709 WDT O
has BC2GM023252709 VBZ O
not BC2GM023252709 RB O
been BC2GM023252709 VBN O
heretofore BC2GM023252709 RB O
described BC2GM023252709 VBN O
. BC2GM023252709 . O
. . O O

To BC2GM009275309 TO O
obtain BC2GM009275309 VB O
information BC2GM009275309 NN O
on BC2GM009275309 IN O
the BC2GM009275309 DT O
functional BC2GM009275309 JJ O
role BC2GM009275309 NN O
of BC2GM009275309 IN O
the BC2GM009275309 DT O
Rac1 BC2GM009275309 NNP O
/ BC2GM009275309 NNP O
p38 BC2GM009275309 NN O
/ BC2GM009275309 NNP O
MAPKAPK-2 BC2GM009275309 NNP O
pathway BC2GM009275309 NN O
in BC2GM009275309 IN O
RA BC2GM009275309 NNP O
signaling BC2GM009275309 NN O
, BC2GM009275309 , O
the BC2GM009275309 DT O
effects BC2GM009275309 NNS O
of BC2GM009275309 IN O
pharmacological BC2GM009275309 JJ O
inhibition BC2GM009275309 NN O
of BC2GM009275309 IN O
p38 BC2GM009275309 NN O
on BC2GM009275309 IN O
RA-induced BC2GM009275309 NNP O
gene BC2GM009275309 NN O
transcription BC2GM009275309 NN O
and BC2GM009275309 CC O
cell BC2GM009275309 NN O
differentiation BC2GM009275309 NN O
were BC2GM009275309 VBD O
determined BC2GM009275309 VBN O
. BC2GM009275309 . O
. . O O

Few BC2GM069360294 JJ O
triers BC2GM069360294 NNS O
or BC2GM069360294 CC O
users BC2GM069360294 NNS O
had BC2GM069360294 VBD O
received BC2GM069360294 VBN O
SLT BC2GM069360294 NNP O
counseling BC2GM069360294 VBG O
from BC2GM069360294 IN O
their BC2GM069360294 PRP$ O
dentist BC2GM069360294 NN O
despite BC2GM069360294 IN O
high BC2GM069360294 JJ O
dental BC2GM069360294 JJ O
utilization BC2GM069360294 NN O
rates BC2GM069360294 NNS O
. BC2GM069360294 . O
. . O O

After BC2GM032122398 IN O
dialysis BC2GM032122398 NN O
online BC2GM032122398 NN O
, BC2GM032122398 , O
lactate BC2GM032122398 NN O
was BC2GM032122398 VBD O
converted BC2GM032122398 VBN O
by BC2GM032122398 IN O
means BC2GM032122398 NNS O
of BC2GM032122398 IN O
lactate BC2GM032122398 JJ O
oxidase BC2GM032122398 NN O
immobilized BC2GM032122398 VBN O
to BC2GM032122398 TO O
porous BC2GM032122398 JJ O
glass BC2GM032122398 NN O
, BC2GM032122398 , O
and BC2GM032122398 CC O
the BC2GM032122398 DT O
depletion BC2GM032122398 NN O
of BC2GM032122398 IN O
oxygen BC2GM032122398 NN O
was BC2GM032122398 VBD O
registered BC2GM032122398 VBN O
by BC2GM032122398 IN O
means BC2GM032122398 NNS O
of BC2GM032122398 IN O
a BC2GM032122398 DT O
Clark BC2GM032122398 NNP O
electrode BC2GM032122398 NN O
. BC2GM032122398 . O
. . O O

Genetic BC2GM062872922 JJ O
analysis BC2GM062872922 NN O
of BC2GM062872922 IN O
the BC2GM062872922 DT O
role BC2GM062872922 NN O
of BC2GM062872922 IN O
herpes BC2GM062872922 NNS O
simplex BC2GM062872922 JJ O
virus BC2GM062872922 NN O
type BC2GM062872922 NN O
1 BC2GM062872922 CD O
glycoprotein BC2GM062872922 NN O
K BC2GM062872922 NNP O
in BC2GM062872922 IN O
infectious BC2GM062872922 JJ O
virus BC2GM062872922 NN O
production BC2GM062872922 NN O
and BC2GM062872922 CC O
egress BC2GM062872922 NN O
. BC2GM062872922 . O
. . O O

RESULTS BC2GM081228563 NN O
: BC2GM081228563 : O
In BC2GM081228563 IN O
patients BC2GM081228563 NNS O
with BC2GM081228563 IN O
necrotising BC2GM081228563 JJ O
fasciitis BC2GM081228563 NN O
the BC2GM081228563 DT O
arterial BC2GM081228563 JJ O
PO2 BC2GM081228563 NNP O
rose BC2GM081228563 VBD O
about BC2GM081228563 IN O
7-fold BC2GM081228563 JJ O
whereas BC2GM081228563 NNS O
the BC2GM081228563 DT O
arterial BC2GM081228563 JJ O
PCO2 BC2GM081228563 NNP O
increased BC2GM081228563 VBD O
only BC2GM081228563 RB O
slightly BC2GM081228563 RB O
during BC2GM081228563 IN O
exposure BC2GM081228563 NN O
to BC2GM081228563 TO O
2.5 BC2GM081228563 CD O
absolute BC2GM081228563 NN O
atmospheres BC2GM081228563 NNS O
( BC2GM081228563 ( O
ATA BC2GM081228563 NNP O
) BC2GM081228563 ) O
of BC2GM081228563 IN O
oxygen BC2GM081228563 NN O
. BC2GM081228563 . O
. . O O

TAF-1 BC2GM012798293 JJ O
activates BC2GM012798293 NNS O
transcription BC2GM012798293 NN O
constitutively BC2GM012798293 RB O
and BC2GM012798293 CC O
was BC2GM012798293 VBD O
mapped BC2GM012798293 VBN O
to BC2GM012798293 TO O
the BC2GM012798293 DT O
first BC2GM012798293 JJ O
32 BC2GM012798293 CD O
amino BC2GM012798293 JJ O
acids BC2GM012798293 NNS O
of BC2GM012798293 IN O
the BC2GM012798293 DT O
A-region BC2GM012798293 NNP O
. BC2GM012798293 . O
. . O O

Positive BC2GM064911802 JJ O
linear BC2GM064911802 JJ O
correlations BC2GM064911802 NNS O
were BC2GM064911802 VBD O
found BC2GM064911802 VBN O
when BC2GM064911802 WRB O
the BC2GM064911802 DT O
AUC BC2GM064911802 NNP O
( BC2GM064911802 ( O
0-12 BC2GM064911802 NN O
) BC2GM064911802 ) O
( BC2GM064911802 ( O
r BC2GM064911802 JJ O
= BC2GM064911802 VBZ O
0.68 BC2GM064911802 CD O
; BC2GM064911802 : O
P BC2GM064911802 NNP O
less BC2GM064911802 JJR O
than BC2GM064911802 IN O
0.01 BC2GM064911802 CD O
) BC2GM064911802 ) O
, BC2GM064911802 , O
the BC2GM064911802 DT O
maximum BC2GM064911802 JJ O
plasma BC2GM064911802 JJ O
concentration BC2GM064911802 NN O
( BC2GM064911802 ( O
r BC2GM064911802 JJ O
= BC2GM064911802 VBZ O
0.34 BC2GM064911802 CD O
; BC2GM064911802 : O
P BC2GM064911802 NNP O
less BC2GM064911802 JJR O
than BC2GM064911802 IN O
0.01 BC2GM064911802 CD O
) BC2GM064911802 ) O
, BC2GM064911802 , O
the BC2GM064911802 DT O
minimum BC2GM064911802 JJ O
plasma BC2GM064911802 NN O
concentration BC2GM064911802 NN O
( BC2GM064911802 ( O
r BC2GM064911802 JJ O
= BC2GM064911802 VBZ O
0.55 BC2GM064911802 CD O
; BC2GM064911802 : O
P BC2GM064911802 NNP O
less BC2GM064911802 JJR O
than BC2GM064911802 IN O
0.01 BC2GM064911802 CD O
) BC2GM064911802 ) O
, BC2GM064911802 , O
and BC2GM064911802 CC O
the BC2GM064911802 DT O
elimination BC2GM064911802 NN O
t1 BC2GM064911802 NN O
/ BC2GM064911802 $ O
2 BC2GM064911802 CD O
( BC2GM064911802 ( O
r BC2GM064911802 NN O
= BC2GM064911802 VBZ O
0.46 BC2GM064911802 CD O
; BC2GM064911802 : O
P BC2GM064911802 NNP O
less BC2GM064911802 JJR O
than BC2GM064911802 IN O
0.01 BC2GM064911802 CD O
) BC2GM064911802 ) O
were BC2GM064911802 VBD O
regressed BC2GM064911802 VBN O
with BC2GM064911802 IN O
age BC2GM064911802 NN O
. BC2GM064911802 . O
. . O O

In BC2GM011982866 IN O
alfalfa BC2GM011982866 NN O
, BC2GM011982866 , O
the BC2GM011982866 DT O
insecticides BC2GM011982866 NNS O
caused BC2GM011982866 VBD O
significant BC2GM011982866 JJ O
mortality BC2GM011982866 NN O
to BC2GM011982866 TO O
most BC2GM011982866 JJS O
of BC2GM011982866 IN O
the BC2GM011982866 DT O
insects BC2GM011982866 NNS O
evaluated BC2GM011982866 VBN O
. BC2GM011982866 . O
. . O O

Plasma BC2GM073658017 NNP O
renin BC2GM073658017 NN O
activity BC2GM073658017 NN O
in BC2GM073658017 IN O
essential BC2GM073658017 JJ O
arterial BC2GM073658017 JJ O
hypertension BC2GM073658017 NN O
. BC2GM073658017 . O
. . O O

Disruption BC2GM065997756 NN O
of BC2GM065997756 IN O
PML BC2GM065997756 NNP O
subnuclear BC2GM065997756 VBP O
domains BC2GM065997756 NNS O
by BC2GM065997756 IN O
the BC2GM065997756 DT O
acidic BC2GM065997756 JJ O
IE1 BC2GM065997756 NNP O
protein BC2GM065997756 NN O
of BC2GM065997756 IN O
human BC2GM065997756 JJ O
cytomegalovirus BC2GM065997756 NN O
is BC2GM065997756 VBZ O
mediated BC2GM065997756 VBN O
through BC2GM065997756 IN O
interaction BC2GM065997756 NN O
with BC2GM065997756 IN O
PML BC2GM065997756 NNP O
and BC2GM065997756 CC O
may BC2GM065997756 MD O
modulate BC2GM065997756 VB O
a BC2GM065997756 DT O
RING BC2GM065997756 NNP O
finger-dependent BC2GM065997756 JJ O
cryptic BC2GM065997756 JJ O
transactivator BC2GM065997756 NN O
function BC2GM065997756 NN O
of BC2GM065997756 IN O
PML BC2GM065997756 NNP O
. BC2GM065997756 . O
. . O O

These BC2GM041461171 DT O
results BC2GM041461171 NNS O
strongly BC2GM041461171 RB O
suggest BC2GM041461171 VBP O
that BC2GM041461171 IN O
HSV-1 BC2GM041461171 NNP O
infection BC2GM041461171 NN O
inhibits BC2GM041461171 VBZ O
host BC2GM041461171 NN O
cell BC2GM041461171 NN O
splicing BC2GM041461171 VBG O
through BC2GM041461171 IN O
the BC2GM041461171 DT O
action BC2GM041461171 NN O
of BC2GM041461171 IN O
ICP27 BC2GM041461171 NNP O
. BC2GM041461171 . O
. . O O

The BC2GM086476863 DT O
majority BC2GM086476863 NN O
of BC2GM086476863 IN O
the BC2GM086476863 DT O
human BC2GM086476863 JJ O
Ig BC2GM086476863 NNP O
heavy BC2GM086476863 NN O
chain BC2GM086476863 NN O
( BC2GM086476863 ( O
IgH BC2GM086476863 NNP O
) BC2GM086476863 ) O
constant BC2GM086476863 NN O
( BC2GM086476863 ( O
C BC2GM086476863 NNP O
) BC2GM086476863 ) O
region BC2GM086476863 NN O
locus BC2GM086476863 NN O
has BC2GM086476863 VBZ O
been BC2GM086476863 VBN O
cloned BC2GM086476863 VBN O
and BC2GM086476863 CC O
mapped BC2GM086476863 VBN O
. BC2GM086476863 . O
. . O O

Analysis BC2GM096526647 NN O
of BC2GM096526647 IN O
replicative BC2GM096526647 JJ O
intermediates BC2GM096526647 NNS O
shows BC2GM096526647 VBZ O
that BC2GM096526647 IN O
plasmid BC2GM096526647 NN O
YRp7 BC2GM096526647 NNP O
, BC2GM096526647 , O
which BC2GM096526647 WDT O
contains BC2GM096526647 VBZ O
the BC2GM096526647 DT O
chromosomal BC2GM096526647 JJ O
replicator BC2GM096526647 NN O
ARS1 BC2GM096526647 NNP O
, BC2GM096526647 , O
initiates BC2GM096526647 VBZ O
bidirectional BC2GM096526647 JJ O
replication BC2GM096526647 NN O
in BC2GM096526647 IN O
a BC2GM096526647 DT O
100 BC2GM096526647 CD O
bp BC2GM096526647 NN O
region BC2GM096526647 NN O
within BC2GM096526647 IN O
the BC2GM096526647 DT O
sequence BC2GM096526647 NN O
required BC2GM096526647 VBN O
for BC2GM096526647 IN O
autonomous BC2GM096526647 JJ O
replication BC2GM096526647 NN O
in BC2GM096526647 IN O
vivo BC2GM096526647 NN O
. BC2GM096526647 . O
. . O O

We BC2GM017819030 PRP O
then BC2GM017819030 RB O
supplemented BC2GM017819030 VBD O
these BC2GM017819030 DT O
spliceosomes BC2GM017819030 NNS O
with BC2GM017819030 IN O
purified BC2GM017819030 JJ O
proteins BC2GM017819030 NNS O
or BC2GM017819030 CC O
yeast BC2GM017819030 VB O
extract BC2GM017819030 JJ O
fractions BC2GM017819030 NNS O
as BC2GM017819030 IN O
a BC2GM017819030 DT O
functional BC2GM017819030 JJ O
assay BC2GM017819030 NN O
for BC2GM017819030 IN O
second-step BC2GM017819030 JJ O
splicing BC2GM017819030 NN O
factors BC2GM017819030 NNS O
. BC2GM017819030 . O
. . O O

Primary BC2GM073185216 JJ O
TJRs BC2GM073185216 NNP O
were BC2GM073185216 VBD O
clinically BC2GM073185216 RB O
evaluated BC2GM073185216 VBN O
for BC2GM073185216 IN O
degree BC2GM073185216 NN O
of BC2GM073185216 IN O
osteoarthrosis BC2GM073185216 NN O
. BC2GM073185216 . O
. . O O

Likewise BC2GM031241503 RB O
, BC2GM031241503 , O
epidural BC2GM031241503 JJ O
morphine BC2GM031241503 NN O
does BC2GM031241503 VBZ O
not BC2GM031241503 RB O
modify BC2GM031241503 VB O
the BC2GM031241503 DT O
intraoperative BC2GM031241503 JJ O
metabolic BC2GM031241503 NN O
and BC2GM031241503 CC O
hormonal BC2GM031241503 JJ O
responses BC2GM031241503 NNS O
. BC2GM031241503 . O
. . O O

Pendulin BC2GM084941902 NNP O
, BC2GM084941902 , O
a BC2GM084941902 DT O
Drosophila BC2GM084941902 NNP O
protein BC2GM084941902 NN O
with BC2GM084941902 IN O
cell BC2GM084941902 NN O
cycle-dependent BC2GM084941902 JJ O
nuclear BC2GM084941902 JJ O
localization BC2GM084941902 NN O
, BC2GM084941902 , O
is BC2GM084941902 VBZ O
required BC2GM084941902 VBN O
for BC2GM084941902 IN O
normal BC2GM084941902 JJ O
cell BC2GM084941902 NN O
proliferation BC2GM084941902 NN O
. BC2GM084941902 . O
. . O O

Hence BC2GM065338169 RB O
the BC2GM065338169 DT O
GAP1 BC2GM065338169 NNP O
gene BC2GM065338169 NN O
encodes BC2GM065338169 VBZ O
a BC2GM065338169 DT O
protein BC2GM065338169 NN O
with BC2GM065338169 IN O
characteristics BC2GM065338169 NNS O
typical BC2GM065338169 JJ O
of BC2GM065338169 IN O
integral BC2GM065338169 JJ O
membrane BC2GM065338169 NN O
proteins BC2GM065338169 NNS O
translocating BC2GM065338169 VBG O
ligants BC2GM065338169 NNS O
across BC2GM065338169 IN O
cellular BC2GM065338169 JJ O
membranes BC2GM065338169 NNS O
. BC2GM065338169 . O
. . O O

A BC2GM004292158 DT O
rabbit BC2GM004292158 NN O
antiserum BC2GM004292158 NN O
raised BC2GM004292158 VBN O
against BC2GM004292158 IN O
a BC2GM004292158 DT O
unique BC2GM004292158 JJ O
( BC2GM004292158 ( O
V3 BC2GM004292158 NNP O
domain BC2GM004292158 NN O
) BC2GM004292158 ) O
bacterially BC2GM004292158 RB O
expressed BC2GM004292158 VBN O
PKC BC2GM004292158 NNP O
theta BC2GM004292158 NN O
fragment BC2GM004292158 NN O
immunoprecipitated BC2GM004292158 VBN O
specifically BC2GM004292158 RB O
an BC2GM004292158 DT O
82-kDa BC2GM004292158 JJ O
protein BC2GM004292158 NN O
from BC2GM004292158 IN O
Jurkat BC2GM004292158 NNP O
cell BC2GM004292158 NN O
lysates BC2GM004292158 NNS O
. BC2GM004292158 . O
. . O O

Growth BC2GM095899932 NNP O
factors BC2GM095899932 NNS O
promote BC2GM095899932 VBP O
cell BC2GM095899932 NN O
survival BC2GM095899932 NN O
through BC2GM095899932 IN O
phosphorylation BC2GM095899932 NN O
of BC2GM095899932 IN O
Bad BC2GM095899932 NNP O
, BC2GM095899932 , O
resulting BC2GM095899932 VBG O
in BC2GM095899932 IN O
its BC2GM095899932 PRP$ O
dissociation BC2GM095899932 NN O
from BC2GM095899932 IN O
Bcl-2 BC2GM095899932 NNP O
and BC2GM095899932 CC O
Bcl-x BC2GM095899932 NNP O
( BC2GM095899932 ( O
L BC2GM095899932 NNP O
) BC2GM095899932 ) O
and BC2GM095899932 CC O
its BC2GM095899932 PRP$ O
association BC2GM095899932 NN O
with BC2GM095899932 IN O
14-3-3tau BC2GM095899932 JJ O
. BC2GM095899932 . O
. . O O

BACKGROUND BC2GM084651011 NNP O
-- BC2GM084651011 : O
Platelet BC2GM084651011 NNP O
activating BC2GM084651011 VBG O
factor BC2GM084651011 NN O
( BC2GM084651011 ( O
PAF BC2GM084651011 NNP O
) BC2GM084651011 ) O
has BC2GM084651011 VBZ O
been BC2GM084651011 VBN O
implicated BC2GM084651011 VBN O
in BC2GM084651011 IN O
the BC2GM084651011 DT O
pathogenesis BC2GM084651011 NN O
of BC2GM084651011 IN O
airway BC2GM084651011 NN O
hyperresponsiveness BC2GM084651011 NN O
in BC2GM084651011 IN O
asthma BC2GM084651011 NN O
. BC2GM084651011 . O
. . O O

The BC2GM071336386 DT O
impairment BC2GM071336386 NN O
of BC2GM071336386 IN O
the BC2GM071336386 DT O
nocturnal BC2GM071336386 JJ O
secretion BC2GM071336386 NN O
was BC2GM071336386 VBD O
related BC2GM071336386 VBN O
to BC2GM071336386 TO O
the BC2GM071336386 DT O
subjects BC2GM071336386 NNS O
' BC2GM071336386 POS O
age BC2GM071336386 NN O
and BC2GM071336386 CC O
, BC2GM071336386 , O
for BC2GM071336386 IN O
the BC2GM071336386 DT O
GH BC2GM071336386 NNP O
secretory BC2GM071336386 NN O
pattern BC2GM071336386 NN O
only BC2GM071336386 RB O
, BC2GM071336386 , O
also BC2GM071336386 RB O
to BC2GM071336386 TO O
the BC2GM071336386 DT O
MMSE BC2GM071336386 NNP O
score BC2GM071336386 NN O
. BC2GM071336386 . O
. . O O

The BC2GM058638697 DT O
genes BC2GM058638697 NNS O
expressed BC2GM058638697 VBD O
during BC2GM058638697 IN O
the BC2GM058638697 DT O
embryonic BC2GM058638697 JJ O
( BC2GM058638697 ( O
zeta BC2GM058638697 NN O
) BC2GM058638697 ) O
or BC2GM058638697 CC O
fetal BC2GM058638697 JJ O
and BC2GM058638697 CC O
adult BC2GM058638697 JJ O
stage BC2GM058638697 NN O
( BC2GM058638697 ( O
alpha BC2GM058638697 JJ O
2 BC2GM058638697 CD O
and BC2GM058638697 CC O
alpha BC2GM058638697 RB O
1 BC2GM058638697 CD O
) BC2GM058638697 ) O
can BC2GM058638697 MD O
be BC2GM058638697 VB O
modified BC2GM058638697 VBN O
by BC2GM058638697 IN O
point BC2GM058638697 NN O
mutations BC2GM058638697 NNS O
which BC2GM058638697 WDT O
affect BC2GM058638697 VBP O
either BC2GM058638697 DT O
the BC2GM058638697 DT O
processing-translation BC2GM058638697 NN O
of BC2GM058638697 IN O
mRNA BC2GM058638697 NN O
or BC2GM058638697 CC O
make BC2GM058638697 VB O
the BC2GM058638697 DT O
polypeptide BC2GM058638697 NN O
chains BC2GM058638697 VBZ O
extremely BC2GM058638697 RB O
unstable BC2GM058638697 JJ O
. BC2GM058638697 . O
. . O O

The BC2GM087369574 DT O
yeast BC2GM087369574 NN O
mitochondrial BC2GM087369574 JJ O
Hsp70 BC2GM087369574 NNP O
, BC2GM087369574 , O
Ssc1p BC2GM087369574 NNP O
, BC2GM087369574 , O
functions BC2GM087369574 NNS O
as BC2GM087369574 IN O
a BC2GM087369574 DT O
molecular BC2GM087369574 JJ O
chaperone BC2GM087369574 NN O
with BC2GM087369574 IN O
its BC2GM087369574 PRP$ O
partner BC2GM087369574 NN O
proteins BC2GM087369574 NNS O
, BC2GM087369574 , O
Mdj1p BC2GM087369574 NNP O
( BC2GM087369574 ( O
DnaJ BC2GM087369574 NNP O
homologue BC2GM087369574 NN O
) BC2GM087369574 ) O
and BC2GM087369574 CC O
Yge1p BC2GM087369574 NNP O
( BC2GM087369574 ( O
GrpE BC2GM087369574 NNP O
homologue BC2GM087369574 NN O
) BC2GM087369574 ) O
. BC2GM087369574 . O
. . O O

Oct-1 BC2GM096950581 NNP O
is BC2GM096950581 VBZ O
a BC2GM096950581 DT O
ubiquitously BC2GM096950581 RB O
expressed BC2GM096950581 VBN O
regulatory BC2GM096950581 JJ O
gene BC2GM096950581 NN O
of BC2GM096950581 IN O
the BC2GM096950581 DT O
POU BC2GM096950581 NNP O
domain BC2GM096950581 NN O
family BC2GM096950581 NN O
. BC2GM096950581 . O
. . O O

Use BC2GM032297282 NNP O
of BC2GM032297282 IN O
ELISAs BC2GM032297282 NNP O
for BC2GM032297282 IN O
the BC2GM032297282 DT O
diagnosis BC2GM032297282 NN O
of BC2GM032297282 IN O
canine BC2GM032297282 NN O
atopy BC2GM032297282 NN O
. BC2GM032297282 . O
. . O O

The BC2GM065259412 DT O
system BC2GM065259412 NN O
consists BC2GM065259412 VBZ O
of BC2GM065259412 IN O
a BC2GM065259412 DT O
microcomputer BC2GM065259412 NN O
and BC2GM065259412 CC O
six BC2GM065259412 CD O
laboratory BC2GM065259412 NN O
analyzers BC2GM065259412 NNS O
: BC2GM065259412 : O
a BC2GM065259412 DT O
blood BC2GM065259412 NN O
gas BC2GM065259412 NN O
analyzer BC2GM065259412 NN O
, BC2GM065259412 , O
a BC2GM065259412 DT O
flame BC2GM065259412 NN O
photometer BC2GM065259412 NN O
, BC2GM065259412 , O
a BC2GM065259412 DT O
plasma BC2GM065259412 JJ O
osmotic BC2GM065259412 JJ O
pressure BC2GM065259412 NN O
meter BC2GM065259412 NN O
, BC2GM065259412 , O
a BC2GM065259412 DT O
chloride BC2GM065259412 JJ O
ion BC2GM065259412 NN O
titrator BC2GM065259412 NN O
, BC2GM065259412 , O
a BC2GM065259412 DT O
blood BC2GM065259412 NN O
sugar BC2GM065259412 NN O
analyzer BC2GM065259412 NN O
, BC2GM065259412 , O
and BC2GM065259412 CC O
a BC2GM065259412 DT O
hemoglobin BC2GM065259412 JJ O
concentration BC2GM065259412 NN O
and BC2GM065259412 CC O
saturation BC2GM065259412 NN O
meter BC2GM065259412 NN O
. BC2GM065259412 . O
. . O O

RESULTS BC2GM073538623 NN O
: BC2GM073538623 : O
In BC2GM073538623 IN O
76 BC2GM073538623 CD O
trials BC2GM073538623 NNS O
, BC2GM073538623 , O
5,351 BC2GM073538623 CD O
patients BC2GM073538623 NNS O
received BC2GM073538623 VBD O
24 BC2GM073538623 CD O
different BC2GM073538623 JJ O
regimens BC2GM073538623 NNS O
of BC2GM073538623 IN O
droperidol BC2GM073538623 NN O
. BC2GM073538623 . O
. . O O

The BC2GM041728644 DT O
remaining BC2GM041728644 VBG O
77 BC2GM041728644 CD O
nucleotides BC2GM041728644 NNS O
at BC2GM041728644 IN O
the BC2GM041728644 DT O
3 BC2GM041728644 CD O
' BC2GM041728644 POS O
end BC2GM041728644 NN O
of BC2GM041728644 IN O
domain BC2GM041728644 NN O
II BC2GM041728644 NNP O
and BC2GM041728644 CC O
all BC2GM041728644 DT O
of BC2GM041728644 IN O
domains BC2GM041728644 NNS O
III BC2GM041728644 NNP O
( BC2GM041728644 ( O
655 BC2GM041728644 CD O
nucleotides BC2GM041728644 NNS O
) BC2GM041728644 ) O
and BC2GM041728644 CC O
IV BC2GM041728644 NNP O
( BC2GM041728644 ( O
770 BC2GM041728644 CD O
nucleotides BC2GM041728644 NNS O
) BC2GM041728644 ) O
are BC2GM041728644 VBP O
not BC2GM041728644 RB O
present BC2GM041728644 JJ O
in BC2GM041728644 IN O
DIssE BC2GM041728644 NNP O
RNA BC2GM041728644 NNP O
. BC2GM041728644 . O
. . O O

Cell BC2GM058610366 NNP O
rounding BC2GM058610366 NN O
was BC2GM058610366 VBD O
abrogated BC2GM058610366 VBN O
by BC2GM058610366 IN O
expression BC2GM058610366 NN O
of BC2GM058610366 IN O
either BC2GM058610366 DT O
kinase-dead BC2GM058610366 JJ O
forms BC2GM058610366 NNS O
of BC2GM058610366 IN O
US3 BC2GM058610366 NNP O
PK BC2GM058610366 NNP O
or BC2GM058610366 CC O
a BC2GM058610366 DT O
mutant BC2GM058610366 JJ O
protein BC2GM058610366 NN O
lacking BC2GM058610366 VBG O
the BC2GM058610366 DT O
acidic BC2GM058610366 JJ O
cluster BC2GM058610366 NN O
in BC2GM058610366 IN O
the BC2GM058610366 DT O
kinase BC2GM058610366 NN O
regulatory BC2GM058610366 JJ O
domain BC2GM058610366 NN O
. BC2GM058610366 . O
. . O O

The BC2GM043951266 DT O
generation BC2GM043951266 NN O
of BC2GM043951266 IN O
dorso-ventral BC2GM043951266 JJ O
polarity BC2GM043951266 NN O
during BC2GM043951266 IN O
Drosophila BC2GM043951266 NNP O
embryogenesis BC2GM043951266 NN O
is BC2GM043951266 VBZ O
regulated BC2GM043951266 VBN O
by BC2GM043951266 IN O
the BC2GM043951266 DT O
action BC2GM043951266 NN O
of BC2GM043951266 IN O
12 BC2GM043951266 CD O
maternally BC2GM043951266 RB O
expressed BC2GM043951266 VBN O
gene BC2GM043951266 NN O
products BC2GM043951266 NNS O
, BC2GM043951266 , O
the BC2GM043951266 DT O
dorsal BC2GM043951266 NN O
group BC2GM043951266 NN O
. BC2GM043951266 . O
. . O O

In BC2GM073702043 IN O
vitro BC2GM073702043 NN O
, BC2GM073702043 , O
cytokine- BC2GM073702043 JJ O
or BC2GM073702043 CC O
hypoxia-induced BC2GM073702043 JJ O
up-regulation BC2GM073702043 NN O
of BC2GM073702043 IN O
Fas BC2GM073702043 NNP O
expression BC2GM073702043 NN O
is BC2GM073702043 VBZ O
associated BC2GM073702043 VBN O
with BC2GM073702043 IN O
RTC BC2GM073702043 NNP O
apoptosis BC2GM073702043 NN O
. BC2GM073702043 . O
. . O O

The BC2GM046228270 DT O
NrfC BC2GM046228270 NNP O
polypeptide BC2GM046228270 NN O
, BC2GM046228270 , O
M BC2GM046228270 NNP O
( BC2GM046228270 ( O
r BC2GM046228270 NN O
) BC2GM046228270 ) O
24,567 BC2GM046228270 CD O
, BC2GM046228270 , O
contains BC2GM046228270 VBZ O
16 BC2GM046228270 CD O
cysteine BC2GM046228270 NN O
residues BC2GM046228270 NNS O
arranged BC2GM046228270 VBN O
in BC2GM046228270 IN O
four BC2GM046228270 CD O
clusters BC2GM046228270 NNS O
typical BC2GM046228270 JJ O
of BC2GM046228270 IN O
the BC2GM046228270 DT O
CooF BC2GM046228270 NNP O
super-family BC2GM046228270 NN O
of BC2GM046228270 IN O
non-haem BC2GM046228270 JJ O
iron-sulphur BC2GM046228270 JJ O
proteins BC2GM046228270 NNS O
. BC2GM046228270 . O
. . O O

The BC2GM016077661 DT O
brains BC2GM016077661 NNS O
were BC2GM016077661 VBD O
bisected BC2GM016077661 VBN O
and BC2GM016077661 CC O
T1 BC2GM016077661 NNP O
and BC2GM016077661 CC O
T2 BC2GM016077661 NNP O
relaxation BC2GM016077661 NN O
times BC2GM016077661 NNS O
were BC2GM016077661 VBD O
determined BC2GM016077661 VBN O
for BC2GM016077661 IN O
the BC2GM016077661 DT O
right BC2GM016077661 NN O
and BC2GM016077661 CC O
left BC2GM016077661 VBD O
hemispheres BC2GM016077661 NNS O
by BC2GM016077661 IN O
MR BC2GM016077661 NNP O
spectroscopy BC2GM016077661 NN O
immediately BC2GM016077661 RB O
after BC2GM016077661 IN O
dissection BC2GM016077661 NN O
. BC2GM016077661 . O
. . O O

Such BC2GM014357950 JJ O
simple BC2GM014357950 JJ O
injuries BC2GM014357950 NNS O
may BC2GM014357950 MD O
however BC2GM014357950 RB O
be BC2GM014357950 VB O
accompanied BC2GM014357950 VBN O
by BC2GM014357950 IN O
far BC2GM014357950 RB O
reaching BC2GM014357950 VBG O
consequences BC2GM014357950 NNS O
. BC2GM014357950 . O
. . O O

The BC2GM061492332 DT O
amount BC2GM061492332 NN O
of BC2GM061492332 IN O
ERCC1 BC2GM061492332 NNP O
detectable BC2GM061492332 JJ O
by BC2GM061492332 IN O
immunoblotting BC2GM061492332 VBG O
is BC2GM061492332 VBZ O
reduced BC2GM061492332 VBN O
in BC2GM061492332 IN O
group BC2GM061492332 NN O
1 BC2GM061492332 CD O
, BC2GM061492332 , O
group BC2GM061492332 NN O
4 BC2GM061492332 CD O
and BC2GM061492332 CC O
XP-F BC2GM061492332 JJ O
extracts BC2GM061492332 NNS O
. BC2GM061492332 . O
. . O O

Incorporation BC2GM013509506 NN O
of BC2GM013509506 IN O
this BC2GM013509506 DT O
information BC2GM013509506 NN O
in BC2GM013509506 IN O
the BC2GM013509506 DT O
data BC2GM013509506 NNS O
brought BC2GM013509506 VBD O
about BC2GM013509506 IN O
a BC2GM013509506 DT O
revised BC2GM013509506 JJ O
five-year BC2GM013509506 JJ O
survival BC2GM013509506 JJ O
estimate BC2GM013509506 NN O
of BC2GM013509506 IN O
55 BC2GM013509506 CD O
percent BC2GM013509506 NN O
. BC2GM013509506 . O
. . O O

Thus BC2GM045265175 RB O
, BC2GM045265175 , O
Tax1 BC2GM045265175 NNP O
activates BC2GM045265175 VBZ O
CArG-mediated BC2GM045265175 JJ O
transcription BC2GM045265175 NN O
without BC2GM045265175 IN O
mitogenic BC2GM045265175 JJ O
signals BC2GM045265175 NNS O
through BC2GM045265175 IN O
interaction BC2GM045265175 NN O
with BC2GM045265175 IN O
a BC2GM045265175 DT O
CArG-binding BC2GM045265175 JJ O
factor BC2GM045265175 NN O
, BC2GM045265175 , O
p67SRF BC2GM045265175 NN O
. BC2GM045265175 . O
. . O O

In BC2GM033020504 IN O
contrast BC2GM033020504 NN O
, BC2GM033020504 , O
the BC2GM033020504 DT O
tail BC2GM033020504 NN O
deviated BC2GM033020504 VBN O
ipsilaterally BC2GM033020504 RB O
in BC2GM033020504 IN O
cats BC2GM033020504 NNS O
with BC2GM033020504 IN O
a BC2GM033020504 DT O
hemisection BC2GM033020504 NN O
, BC2GM033020504 , O
and BC2GM033020504 CC O
the BC2GM033020504 DT O
tail BC2GM033020504 NN O
was BC2GM033020504 VBD O
ventroflexed BC2GM033020504 VBN O
in BC2GM033020504 IN O
cats BC2GM033020504 NNS O
with BC2GM033020504 IN O
a BC2GM033020504 DT O
transection BC2GM033020504 NN O
. BC2GM033020504 . O
. . O O

The BC2GM009462696 DT O
sequence BC2GM009462696 NN O
contained BC2GM009462696 VBD O
five BC2GM009462696 CD O
repeats BC2GM009462696 NNS O
of BC2GM009462696 IN O
the BC2GM009462696 DT O
hypothetical BC2GM009462696 JJ O
leucine BC2GM009462696 NN O
zipper BC2GM009462696 NN O
motif BC2GM009462696 NN O
: BC2GM009462696 : O
one BC2GM009462696 CD O
is BC2GM009462696 VBZ O
in BC2GM009462696 IN O
the BC2GM009462696 DT O
N-terminal BC2GM009462696 JJ O
globular BC2GM009462696 NN O
domain BC2GM009462696 NN O
, BC2GM009462696 , O
and BC2GM009462696 CC O
four BC2GM009462696 CD O
are BC2GM009462696 VBP O
in BC2GM009462696 IN O
the BC2GM009462696 DT O
central BC2GM009462696 JJ O
alpha-helical BC2GM009462696 JJ O
stalk BC2GM009462696 NN O
. BC2GM009462696 . O
. . O O

It BC2GM004444068 PRP O
would BC2GM004444068 MD O
seem BC2GM004444068 VB O
that BC2GM004444068 IN O
caution BC2GM004444068 NN O
should BC2GM004444068 MD O
be BC2GM004444068 VB O
exercised BC2GM004444068 VBN O
in BC2GM004444068 IN O
using BC2GM004444068 VBG O
HPL BC2GM004444068 NNP O
values BC2GM004444068 NNS O
as BC2GM004444068 IN O
an BC2GM004444068 DT O
index BC2GM004444068 NN O
of BC2GM004444068 IN O
placental BC2GM004444068 JJ O
function BC2GM004444068 NN O
in BC2GM004444068 IN O
anaemic BC2GM004444068 JJ O
women BC2GM004444068 NNS O
. BC2GM004444068 . O
. . O O

The BC2GM076533289 DT O
ATF BC2GM076533289 NNP O
/ BC2GM076533289 NNP O
CRE BC2GM076533289 NNP O
site BC2GM076533289 NN O
is BC2GM076533289 VBZ O
also BC2GM076533289 RB O
essential BC2GM076533289 JJ O
for BC2GM076533289 IN O
CD4 BC2GM076533289 NNP O
promoter BC2GM076533289 NN O
activation BC2GM076533289 NN O
by BC2GM076533289 IN O
forskolin BC2GM076533289 NN O
, BC2GM076533289 , O
an BC2GM076533289 DT O
activator BC2GM076533289 NN O
of BC2GM076533289 IN O
adenylate BC2GM076533289 JJ O
cyclase BC2GM076533289 NN O
. BC2GM076533289 . O
. . O O

Such BC2GM025980637 JJ O
saturation BC2GM025980637 NN O
often BC2GM025980637 RB O
occurs BC2GM025980637 VBZ O
for BC2GM025980637 IN O
several BC2GM025980637 JJ O
recording BC2GM025980637 VBG O
sweeps BC2GM025980637 NNS O
after BC2GM025980637 IN O
large BC2GM025980637 JJ O
amplitude BC2GM025980637 JJ O
signals BC2GM025980637 NNS O
such BC2GM025980637 JJ O
as BC2GM025980637 IN O
eye BC2GM025980637 NN O
blinks BC2GM025980637 NNS O
are BC2GM025980637 VBP O
rejected BC2GM025980637 VBN O
. BC2GM025980637 . O
. . O O

The BC2GM081841697 DT O
Caenorhabditis BC2GM081841697 NNP O
elegans BC2GM081841697 VBZ O
NK-2 BC2GM081841697 JJ O
class BC2GM081841697 NN O
homeoprotein BC2GM081841697 NN O
CEH-22 BC2GM081841697 NNP O
is BC2GM081841697 VBZ O
involved BC2GM081841697 VBN O
in BC2GM081841697 IN O
combinatorial BC2GM081841697 JJ O
activation BC2GM081841697 NN O
of BC2GM081841697 IN O
gene BC2GM081841697 NN O
expression BC2GM081841697 NN O
in BC2GM081841697 IN O
pharyngeal BC2GM081841697 JJ O
muscle BC2GM081841697 NN O
. BC2GM081841697 . O
. . O O

No BC2GM000478841 DT O
patient BC2GM000478841 NN O
demonstrated BC2GM000478841 VBD O
a BC2GM000478841 DT O
decrease BC2GM000478841 NN O
in BC2GM000478841 IN O
bone BC2GM000478841 NN O
marrow BC2GM000478841 NN O
fibrosis BC2GM000478841 NN O
as BC2GM000478841 IN O
determined BC2GM000478841 VBN O
by BC2GM000478841 IN O
serial BC2GM000478841 JJ O
procollagen BC2GM000478841 NN O
( BC2GM000478841 ( O
PC BC2GM000478841 NNP O
III BC2GM000478841 NNP O
) BC2GM000478841 ) O
serum BC2GM000478841 VBP O
level BC2GM000478841 JJ O
analysis BC2GM000478841 NN O
. BC2GM000478841 . O
. . O O

We BC2GM064062109 PRP O
previously BC2GM064062109 RB O
demonstrated BC2GM064062109 VBD O
that BC2GM064062109 IN O
AKT2 BC2GM064062109 NNP O
, BC2GM064062109 , O
a BC2GM064062109 DT O
member BC2GM064062109 NN O
of BC2GM064062109 IN O
protein BC2GM064062109 NN O
kinase BC2GM064062109 NN O
B BC2GM064062109 NNP O
family BC2GM064062109 NN O
, BC2GM064062109 , O
is BC2GM064062109 VBZ O
activated BC2GM064062109 VBN O
by BC2GM064062109 IN O
a BC2GM064062109 DT O
number BC2GM064062109 NN O
of BC2GM064062109 IN O
growth BC2GM064062109 NN O
factors BC2GM064062109 NNS O
via BC2GM064062109 IN O
Ras BC2GM064062109 NNP O
and BC2GM064062109 CC O
PI BC2GM064062109 NNP O
3-kinase BC2GM064062109 JJ O
signaling BC2GM064062109 NN O
pathways BC2GM064062109 NNS O
. BC2GM064062109 . O
. . O O

The BC2GM052870770 DT O
prominent BC2GM052870770 JJ O
fracture BC2GM052870770 NN O
of BC2GM052870770 IN O
women BC2GM052870770 NNS O
older BC2GM052870770 JJR O
than BC2GM052870770 IN O
75 BC2GM052870770 CD O
years BC2GM052870770 NNS O
is BC2GM052870770 VBZ O
the BC2GM052870770 DT O
hip BC2GM052870770 NN O
fracture BC2GM052870770 NN O
( BC2GM052870770 ( O
type BC2GM052870770 JJ O
II BC2GM052870770 NNP O
osteoporosis BC2GM052870770 NN O
) BC2GM052870770 ) O
. BC2GM052870770 . O
. . O O

Biochemical BC2GM085890702 JJ O
analyses BC2GM085890702 NNS O
revealed BC2GM085890702 VBD O
that BC2GM085890702 IN O
the BC2GM085890702 DT O
concentration BC2GM085890702 NN O
of BC2GM085890702 IN O
norepinephrine BC2GM085890702 NN O
was BC2GM085890702 VBD O
reduced BC2GM085890702 VBN O
significantly BC2GM085890702 RB O
in BC2GM085890702 IN O
cortex-hippocampus BC2GM085890702 NN O
and BC2GM085890702 CC O
olfactory BC2GM085890702 JJ O
bulb BC2GM085890702 NN O
but BC2GM085890702 CC O
not BC2GM085890702 RB O
in BC2GM085890702 IN O
other BC2GM085890702 JJ O
regions BC2GM085890702 NNS O
, BC2GM085890702 , O
while BC2GM085890702 IN O
dopamine BC2GM085890702 NN O
and BC2GM085890702 CC O
serotonin BC2GM085890702 NN O
levels BC2GM085890702 NNS O
were BC2GM085890702 VBD O
not BC2GM085890702 RB O
altered BC2GM085890702 VBN O
in BC2GM085890702 IN O
any BC2GM085890702 DT O
brain BC2GM085890702 NN O
region BC2GM085890702 NN O
examined BC2GM085890702 VBD O
. BC2GM085890702 . O
. . O O

The BC2GM018310054 DT O
coding BC2GM018310054 VBG O
sequence BC2GM018310054 NN O
of BC2GM018310054 IN O
rat BC2GM018310054 NN O
MEK BC2GM018310054 NNP O
kinase BC2GM018310054 NN O
1 BC2GM018310054 CD O
( BC2GM018310054 ( O
MEKK1 BC2GM018310054 NNP O
) BC2GM018310054 ) O
has BC2GM018310054 VBZ O
been BC2GM018310054 VBN O
determined BC2GM018310054 VBN O
from BC2GM018310054 IN O
multiple BC2GM018310054 JJ O
, BC2GM018310054 , O
independent BC2GM018310054 JJ O
cDNA BC2GM018310054 NN O
clones BC2GM018310054 NNS O
. BC2GM018310054 . O
. . O O

In BC2GM025023094 IN O
this BC2GM025023094 DT O
work BC2GM025023094 NN O
, BC2GM025023094 , O
we BC2GM025023094 PRP O
determined BC2GM025023094 VBD O
the BC2GM025023094 DT O
sequences BC2GM025023094 NNS O
of BC2GM025023094 IN O
eight BC2GM025023094 CD O
VirF-binding BC2GM025023094 JJ O
sites BC2GM025023094 NNS O
from BC2GM025023094 IN O
four BC2GM025023094 CD O
different BC2GM025023094 JJ O
genes BC2GM025023094 NNS O
, BC2GM025023094 , O
by BC2GM025023094 IN O
DNase BC2GM025023094 NNP O
I BC2GM025023094 PRP O
or BC2GM025023094 CC O
hydroxyl BC2GM025023094 VB O
radical BC2GM025023094 JJ O
footprinting BC2GM025023094 NN O
. BC2GM025023094 . O
. . O O

Through BC2GM013273874 IN O
genomic BC2GM013273874 JJ O
library BC2GM013273874 JJ O
screening BC2GM013273874 NN O
and BC2GM013273874 CC O
PCR-based BC2GM013273874 JJ O
genomic BC2GM013273874 JJ O
walking BC2GM013273874 NN O
we BC2GM013273874 PRP O
have BC2GM013273874 VBP O
now BC2GM013273874 RB O
cloned BC2GM013273874 VBN O
the BC2GM013273874 DT O
mouse BC2GM013273874 NN O
E-Tmod BC2GM013273874 NNP O
gene BC2GM013273874 NN O
, BC2GM013273874 , O
whose BC2GM013273874 WP$ O
coding BC2GM013273874 VBG O
region BC2GM013273874 NN O
spans BC2GM013273874 NNS O
approximately BC2GM013273874 RB O
60kb BC2GM013273874 CD O
containing BC2GM013273874 VBG O
nine BC2GM013273874 CD O
exons BC2GM013273874 NNS O
and BC2GM013273874 CC O
eight BC2GM013273874 CD O
introns BC2GM013273874 NNS O
. BC2GM013273874 . O
. . O O

With BC2GM013473921 IN O
stimulation BC2GM013473921 NN O
beyond BC2GM013473921 IN O
the BC2GM013473921 DT O
theta-range BC2GM013473921 JJ O
three BC2GM013473921 CD O
phenomena BC2GM013473921 NNS O
occurred BC2GM013473921 VBD O
: BC2GM013473921 : O
shift BC2GM013473921 NN O
of BC2GM013473921 IN O
the BC2GM013473921 DT O
burst BC2GM013473921 NN O
frequencies BC2GM013473921 NNS O
to BC2GM013473921 TO O
higher BC2GM013473921 JJR O
or BC2GM013473921 CC O
lower BC2GM013473921 JJR O
harmonics BC2GM013473921 NNS O
of BC2GM013473921 IN O
stimulation BC2GM013473921 NN O
frequencies BC2GM013473921 NNS O
; BC2GM013473921 : O
complex BC2GM013473921 JJ O
interactions BC2GM013473921 NNS O
of BC2GM013473921 IN O
basic BC2GM013473921 JJ O
background BC2GM013473921 NN O
frequency BC2GM013473921 NN O
with BC2GM013473921 IN O
rhythm BC2GM013473921 NN O
of BC2GM013473921 IN O
stimulation BC2GM013473921 NN O
( BC2GM013473921 ( O
`` BC2GM013473921 `` O
beating BC2GM013473921 NN O
'' BC2GM013473921 '' O
) BC2GM013473921 ) O
; BC2GM013473921 : O
return BC2GM013473921 NN O
to BC2GM013473921 TO O
background BC2GM013473921 VB O
theta-burst BC2GM013473921 JJ O
frequency BC2GM013473921 NN O
in BC2GM013473921 IN O
spite BC2GM013473921 NN O
of BC2GM013473921 IN O
continuing BC2GM013473921 VBG O
stimulation BC2GM013473921 NN O
( BC2GM013473921 ( O
`` BC2GM013473921 `` O
escape BC2GM013473921 NN O
'' BC2GM013473921 '' O
) BC2GM013473921 ) O
. BC2GM013473921 . O
. . O O

METHODS BC2GM095454246 NNS O
: BC2GM095454246 : O
We BC2GM095454246 PRP O
performed BC2GM095454246 VBD O
nasal BC2GM095454246 JJ O
mupirocin BC2GM095454246 FW O
treatment BC2GM095454246 NN O
on BC2GM095454246 IN O
10 BC2GM095454246 CD O
infants BC2GM095454246 NNS O
who BC2GM095454246 WP O
were BC2GM095454246 VBD O
MRSA-positive BC2GM095454246 JJ O
either BC2GM095454246 RB O
in BC2GM095454246 IN O
the BC2GM095454246 DT O
nose BC2GM095454246 NN O
or BC2GM095454246 CC O
the BC2GM095454246 DT O
pharynx BC2GM095454246 NN O
and BC2GM095454246 CC O
evaluated BC2GM095454246 VBD O
the BC2GM095454246 DT O
effect BC2GM095454246 NN O
of BC2GM095454246 IN O
mupirocin BC2GM095454246 NN O
on BC2GM095454246 IN O
the BC2GM095454246 DT O
eradication BC2GM095454246 NN O
of BC2GM095454246 IN O
MRSA BC2GM095454246 NNP O
. BC2GM095454246 . O
. . O O

The BC2GM069293246 DT O
testes BC2GM069293246 NNS O
of BC2GM069293246 IN O
8 BC2GM069293246 CD O
specimens BC2GM069293246 NNS O
of BC2GM069293246 IN O
Triturus BC2GM069293246 NNP O
marmoratus BC2GM069293246 NN O
were BC2GM069293246 VBD O
collected BC2GM069293246 VBN O
during BC2GM069293246 IN O
each BC2GM069293246 DT O
month BC2GM069293246 NN O
of BC2GM069293246 IN O
1987 BC2GM069293246 CD O
and BC2GM069293246 CC O
processed BC2GM069293246 VBD O
for BC2GM069293246 IN O
electron BC2GM069293246 NN O
microscopy BC2GM069293246 NN O
and BC2GM069293246 CC O
light BC2GM069293246 JJ O
microscopy BC2GM069293246 NN O
demonstration BC2GM069293246 NN O
of BC2GM069293246 IN O
testosterone BC2GM069293246 NN O
( BC2GM069293246 ( O
T BC2GM069293246 NNP O
) BC2GM069293246 ) O
following BC2GM069293246 VBG O
the BC2GM069293246 DT O
ABC BC2GM069293246 NNP O
( BC2GM069293246 ( O
avidin-biotin BC2GM069293246 JJ O
peroxidase BC2GM069293246 NN O
complex BC2GM069293246 NN O
) BC2GM069293246 ) O
method BC2GM069293246 NN O
. BC2GM069293246 . O
. . O O

Characterization BC2GM024036486 NN O
of BC2GM024036486 IN O
an BC2GM024036486 DT O
unusual BC2GM024036486 JJ O
tRNA-like BC2GM024036486 JJ O
sequence BC2GM024036486 NN O
found BC2GM024036486 VBD O
inserted BC2GM024036486 VBN O
in BC2GM024036486 IN O
a BC2GM024036486 DT O
Neurospora BC2GM024036486 NNP O
retroplasmid BC2GM024036486 NN O
. BC2GM024036486 . O
. . O O

Comparative BC2GM000828997 JJ O
analyses BC2GM000828997 NNS O
indicate BC2GM000828997 VBP O
that BC2GM000828997 IN O
the BC2GM000828997 DT O
5'-peripheral BC2GM000828997 JJ O
domain BC2GM000828997 NN O
exhibits BC2GM000828997 VBZ O
a BC2GM000828997 DT O
75-bp BC2GM000828997 JJ O
length BC2GM000828997 NN O
polymorphism BC2GM000828997 NN O
near BC2GM000828997 IN O
sequences BC2GM000828997 NNS O
associated BC2GM000828997 VBN O
with BC2GM000828997 IN O
the BC2GM000828997 DT O
termination BC2GM000828997 NN O
of BC2GM000828997 IN O
the BC2GM000828997 DT O
H-strand BC2GM000828997 NNP O
replication BC2GM000828997 NN O
. BC2GM000828997 . O
. . O O

None BC2GM058457481 NN O
of BC2GM058457481 IN O
the BC2GM058457481 DT O
19 BC2GM058457481 CD O
women BC2GM058457481 NNS O
with BC2GM058457481 IN O
probable BC2GM058457481 JJ O
RA BC2GM058457481 NNP O
and BC2GM058457481 CC O
100 BC2GM058457481 CD O
of BC2GM058457481 IN O
the BC2GM058457481 DT O
116 BC2GM058457481 CD O
women BC2GM058457481 NNS O
with BC2GM058457481 IN O
definite BC2GM058457481 JJ O
RA BC2GM058457481 NNP O
met BC2GM058457481 VBD O
the BC2GM058457481 DT O
1987 BC2GM058457481 CD O
criteria BC2GM058457481 NNS O
. BC2GM058457481 . O
. . O O

In BC2GM088237349 IN O
conclusion BC2GM088237349 NN O
, BC2GM088237349 , O
when BC2GM088237349 WRB O
pulmonary BC2GM088237349 JJ O
abnormalities BC2GM088237349 NNS O
are BC2GM088237349 VBP O
found BC2GM088237349 VBN O
in BC2GM088237349 IN O
HTLV-1 BC2GM088237349 NNP O
carriers BC2GM088237349 NNS O
, BC2GM088237349 , O
we BC2GM088237349 PRP O
should BC2GM088237349 MD O
be BC2GM088237349 VB O
careful BC2GM088237349 JJ O
in BC2GM088237349 IN O
determining BC2GM088237349 VBG O
whether BC2GM088237349 IN O
such BC2GM088237349 JJ O
pulmonary BC2GM088237349 JJ O
involvements BC2GM088237349 NNS O
are BC2GM088237349 VBP O
etiologically BC2GM088237349 RB O
related BC2GM088237349 VBN O
to BC2GM088237349 TO O
HTLV-1 BC2GM088237349 NNP O
infection BC2GM088237349 NN O
. BC2GM088237349 . O
. . O O

This BC2GM092540760 DT O
high BC2GM092540760 JJ O
dose BC2GM092540760 JJ O
5-FU BC2GM092540760 JJ O
+ BC2GM092540760 JJ O
Act-D BC2GM092540760 NNP O
protocol BC2GM092540760 NN O
was BC2GM092540760 VBD O
effective BC2GM092540760 JJ O
for BC2GM092540760 IN O
drug BC2GM092540760 NN O
resistant BC2GM092540760 JJ O
cases BC2GM092540760 NNS O
with BC2GM092540760 IN O
MEA BC2GM092540760 NNP O
protocol BC2GM092540760 NN O
. BC2GM092540760 . O
. . O O

Anesthesia BC2GM012342232 NNP O
in BC2GM012342232 IN O
the BC2GM012342232 DT O
radical BC2GM012342232 JJ O
surgery BC2GM012342232 NN O
of BC2GM012342232 IN O
arteriosclerotic BC2GM012342232 JJ O
coronary BC2GM012342232 JJ O
disease BC2GM012342232 NN O
. BC2GM012342232 . O
. . O O

Twelve BC2GM091307930 CD O
patients BC2GM091307930 NNS O
of BC2GM091307930 IN O
leprosy BC2GM091307930 JJ O
with BC2GM091307930 IN O
arthritis BC2GM091307930 NN O
and BC2GM091307930 CC O
161 BC2GM091307930 CD O
patients BC2GM091307930 NNS O
without BC2GM091307930 IN O
arthritis BC2GM091307930 NN O
were BC2GM091307930 VBD O
studied BC2GM091307930 VBN O
for BC2GM091307930 IN O
immunological BC2GM091307930 JJ O
parameters BC2GM091307930 NNS O
like BC2GM091307930 IN O
immunoglobulins BC2GM091307930 NNS O
( BC2GM091307930 ( O
IgG BC2GM091307930 NNP O
, BC2GM091307930 , O
IgM BC2GM091307930 NNP O
, BC2GM091307930 , O
IgA BC2GM091307930 NNP O
) BC2GM091307930 ) O
, BC2GM091307930 , O
C-reactive BC2GM091307930 JJ O
proteins BC2GM091307930 NNS O
and BC2GM091307930 CC O
rheumatoid BC2GM091307930 JJ O
factor BC2GM091307930 NN O
. BC2GM091307930 . O
. . O O

Following BC2GM058306655 VBG O
immunization BC2GM058306655 NN O
of BC2GM058306655 IN O
transgenic BC2GM058306655 JJ O
mice BC2GM058306655 NN O
, BC2GM058306655 , O
hybrid BC2GM058306655 JJ O
molecules BC2GM058306655 NNS O
were BC2GM058306655 VBD O
isolated BC2GM058306655 VBN O
from BC2GM058306655 IN O
B BC2GM058306655 NNP O
cell BC2GM058306655 NN O
DNA BC2GM058306655 NNP O
which BC2GM058306655 WDT O
contained BC2GM058306655 VBD O
the BC2GM058306655 DT O
transgene BC2GM058306655 NN O
recombined BC2GM058306655 VBD O
with BC2GM058306655 IN O
the BC2GM058306655 DT O
endogenous BC2GM058306655 JJ O
IgH BC2GM058306655 NNP O
locus BC2GM058306655 NN O
. BC2GM058306655 . O
. . O O

In BC2GM046884524 IN O
T BC2GM046884524 NNP O
cells BC2GM046884524 NNS O
these BC2GM046884524 DT O
two BC2GM046884524 CD O
signal BC2GM046884524 NN O
pathways BC2GM046884524 NNS O
are BC2GM046884524 VBP O
critical BC2GM046884524 JJ O
for BC2GM046884524 IN O
interleukin-2 BC2GM046884524 JJ O
production BC2GM046884524 NN O
. BC2GM046884524 . O
. . O O

In BC2GM089987435 IN O
situ BC2GM089987435 JJ O
hybridization BC2GM089987435 NN O
of BC2GM089987435 IN O
whole-mount BC2GM089987435 NN O
mouse BC2GM089987435 NN O
embryos BC2GM089987435 NN O
with BC2GM089987435 IN O
Mex5 BC2GM089987435 NNP O
antisense BC2GM089987435 NN O
RNA BC2GM089987435 NNP O
provide BC2GM089987435 VBP O
no BC2GM089987435 DT O
evidence BC2GM089987435 NN O
for BC2GM089987435 IN O
the BC2GM089987435 DT O
exclusion BC2GM089987435 NN O
of BC2GM089987435 IN O
Mex5 BC2GM089987435 NNP O
during BC2GM089987435 IN O
embryonic BC2GM089987435 JJ O
development BC2GM089987435 NN O
. BC2GM089987435 . O
. . O O

Copyright BC2GM079897140 JJ O
1999 BC2GM079897140 CD O
Academic BC2GM079897140 NNP O
Press BC2GM079897140 NNP O
. BC2GM079897140 . O
. . O O

After BC2GM004581999 IN O
3 BC2GM004581999 CD O
months BC2GM004581999 NNS O
of BC2GM004581999 IN O
intervention BC2GM004581999 NN O
, BC2GM004581999 , O
sustained BC2GM004581999 VBD O
physical BC2GM004581999 JJ O
training BC2GM004581999 NN O
was BC2GM004581999 VBD O
associated BC2GM004581999 VBN O
with BC2GM004581999 IN O
the BC2GM004581999 DT O
decrease BC2GM004581999 NN O
of BC2GM004581999 IN O
FVII BC2GM004581999 NNP O
and BC2GM004581999 CC O
PAI-1 BC2GM004581999 NNP O
levels BC2GM004581999 NNS O
. BC2GM004581999 . O
. . O O

Fourteen BC2GM029006862 NNP O
samples BC2GM029006862 NNS O
, BC2GM029006862 , O
seven BC2GM029006862 CD O
each BC2GM029006862 DT O
of BC2GM029006862 IN O
IR64 BC2GM029006862 NNP O
and BC2GM029006862 CC O
IR66 BC2GM029006862 NNP O
were BC2GM029006862 VBD O
studied BC2GM029006862 VBN O
with BC2GM029006862 IN O
regard BC2GM029006862 NN O
to BC2GM029006862 TO O
moisture BC2GM029006862 VB O
content BC2GM029006862 NN O
, BC2GM029006862 , O
germination BC2GM029006862 NN O
test BC2GM029006862 NN O
, BC2GM029006862 , O
abnormal BC2GM029006862 JJ O
seedlings BC2GM029006862 NNS O
, BC2GM029006862 , O
speed BC2GM029006862 NN O
of BC2GM029006862 IN O
germination BC2GM029006862 NN O
, BC2GM029006862 , O
conductance BC2GM029006862 NN O
of BC2GM029006862 IN O
leachates BC2GM029006862 NNS O
, BC2GM029006862 , O
total BC2GM029006862 JJ O
dehydrogenase BC2GM029006862 NN O
activity BC2GM029006862 NN O
, BC2GM029006862 , O
total BC2GM029006862 JJ O
free BC2GM029006862 JJ O
amino BC2GM029006862 NN O
acids BC2GM029006862 NNS O
, BC2GM029006862 , O
total BC2GM029006862 JJ O
soluble BC2GM029006862 JJ O
sugar BC2GM029006862 NN O
, BC2GM029006862 , O
fat BC2GM029006862 JJ O
acidity BC2GM029006862 NN O
, BC2GM029006862 , O
gelatinization BC2GM029006862 NN O
temperature BC2GM029006862 NN O
, BC2GM029006862 , O
gel BC2GM029006862 JJ O
consistency BC2GM029006862 NN O
, BC2GM029006862 , O
amylose BC2GM029006862 JJ O
content BC2GM029006862 NN O
, BC2GM029006862 , O
translucency BC2GM029006862 NN O
, BC2GM029006862 , O
and BC2GM029006862 CC O
per BC2GM029006862 IN O
cent BC2GM029006862 NN O
whiteness BC2GM029006862 NN O
. BC2GM029006862 . O
. . O O

Long BC2GM021744852 RB O
chain BC2GM021744852 NN O
acyl-CoA BC2GM021744852 JJ O
esters BC2GM021744852 NNS O
are BC2GM021744852 VBP O
important BC2GM021744852 JJ O
intermediates BC2GM021744852 NNS O
in BC2GM021744852 IN O
degradation BC2GM021744852 NN O
and BC2GM021744852 CC O
synthesis BC2GM021744852 NN O
of BC2GM021744852 IN O
fatty BC2GM021744852 JJ O
acids BC2GM021744852 NNS O
, BC2GM021744852 , O
as BC2GM021744852 RB O
well BC2GM021744852 RB O
as BC2GM021744852 IN O
having BC2GM021744852 VBG O
important BC2GM021744852 JJ O
functions BC2GM021744852 NNS O
in BC2GM021744852 IN O
regulation BC2GM021744852 NN O
of BC2GM021744852 IN O
intermediary BC2GM021744852 JJ O
metabolism BC2GM021744852 NN O
and BC2GM021744852 CC O
gene BC2GM021744852 NN O
expression BC2GM021744852 NN O
. BC2GM021744852 . O
. . O O

Nosographic BC2GM007116849 JJ O
problems BC2GM007116849 NNS O
. BC2GM007116849 . O
. . O O

The BC2GM045550408 DT O
expression BC2GM045550408 NN O
of BC2GM045550408 IN O
CAPL BC2GM045550408 NNP O
, BC2GM045550408 , O
a BC2GM045550408 DT O
second BC2GM045550408 JJ O
protein BC2GM045550408 NN O
involved BC2GM045550408 VBN O
in BC2GM045550408 IN O
calcium BC2GM045550408 NN O
metabolism BC2GM045550408 NN O
, BC2GM045550408 , O
was BC2GM045550408 VBD O
only BC2GM045550408 RB O
moderately BC2GM045550408 RB O
elevated BC2GM045550408 VBN O
in BC2GM045550408 IN O
the BC2GM045550408 DT O
doxorubicin-resistant BC2GM045550408 JJ O
cells BC2GM045550408 NNS O
. BC2GM045550408 . O
. . O O

Association BC2GM035585393 NNP O
of BC2GM035585393 IN O
Smads BC2GM035585393 NNP O
with BC2GM035585393 IN O
lymphoid BC2GM035585393 JJ O
enhancer BC2GM035585393 NN O
binding BC2GM035585393 VBG O
factor BC2GM035585393 NN O
1 BC2GM035585393 CD O
/ BC2GM035585393 JJ O
T BC2GM035585393 NNP O
cell-specific BC2GM035585393 JJ O
factor BC2GM035585393 NN O
mediates BC2GM035585393 NNS O
cooperative BC2GM035585393 VBP O
signaling BC2GM035585393 VBG O
by BC2GM035585393 IN O
the BC2GM035585393 DT O
transforming BC2GM035585393 VBG O
growth BC2GM035585393 NN O
factor-beta BC2GM035585393 JJ O
and BC2GM035585393 CC O
wnt BC2GM035585393 JJ O
pathways BC2GM035585393 NNS O
. BC2GM035585393 . O
. . O O

Blood BC2GM010424307 NN O
and BC2GM010424307 CC O
whole-brain BC2GM010424307 JJ O
mercury BC2GM010424307 NN O
concentrations BC2GM010424307 NNS O
were BC2GM010424307 VBD O
determined BC2GM010424307 VBN O
in BC2GM010424307 IN O
pups BC2GM010424307 NNS O
on BC2GM010424307 IN O
PN BC2GM010424307 NNP O
0 BC2GM010424307 CD O
( BC2GM010424307 ( O
birth BC2GM010424307 NN O
) BC2GM010424307 ) O
and BC2GM010424307 CC O
PN BC2GM010424307 $ O
21 BC2GM010424307 CD O
( BC2GM010424307 ( O
weaning BC2GM010424307 VBG O
) BC2GM010424307 ) O
. BC2GM010424307 . O
. . O O

These BC2GM067333955 DT O
results BC2GM067333955 NNS O
indicate BC2GM067333955 VBP O
that BC2GM067333955 IN O
patients BC2GM067333955 NNS O
with BC2GM067333955 IN O
SS BC2GM067333955 NNP O
and BC2GM067333955 CC O
evidence BC2GM067333955 NN O
of BC2GM067333955 IN O
exercise-induced BC2GM067333955 JJ O
ST-segment BC2GM067333955 JJ O
depression BC2GM067333955 NN O
may BC2GM067333955 MD O
have BC2GM067333955 VB O
decreased BC2GM067333955 VBN O
myocardial BC2GM067333955 JJ O
oxygen BC2GM067333955 NN O
supply BC2GM067333955 NN O
due BC2GM067333955 JJ O
to BC2GM067333955 TO O
low BC2GM067333955 JJ O
hemoglobin BC2GM067333955 NN O
levels BC2GM067333955 NNS O
and BC2GM067333955 CC O
increased BC2GM067333955 VBD O
myocardial BC2GM067333955 JJ O
oxygen BC2GM067333955 NN O
demand BC2GM067333955 NN O
( BC2GM067333955 ( O
elevated BC2GM067333955 VBN O
double BC2GM067333955 RB O
products BC2GM067333955 NNS O
) BC2GM067333955 ) O
when BC2GM067333955 WRB O
compared BC2GM067333955 VBN O
to BC2GM067333955 TO O
subjects BC2GM067333955 NNS O
with BC2GM067333955 IN O
SS BC2GM067333955 NNP O
who BC2GM067333955 WP O
do BC2GM067333955 VBP O
not BC2GM067333955 RB O
have BC2GM067333955 VB O
exercise-induced BC2GM067333955 JJ O
ST-segment BC2GM067333955 JJ O
depression BC2GM067333955 NN O
. BC2GM067333955 . O
. . O O

The BC2GM037013975 DT O
human BC2GM037013975 JJ O
sequence BC2GM037013975 NN O
contains BC2GM037013975 VBZ O
the BC2GM037013975 DT O
element BC2GM037013975 NN O
TGACTCT BC2GM037013975 NNP O
that BC2GM037013975 IN O
also BC2GM037013975 RB O
is BC2GM037013975 VBZ O
found BC2GM037013975 VBN O
in BC2GM037013975 IN O
a BC2GM037013975 DT O
murine BC2GM037013975 JJ O
ras-responsive BC2GM037013975 JJ O
enhancer BC2GM037013975 NN O
. BC2GM037013975 . O
. . O O

The BC2GM083628661 DT O
adoption BC2GM083628661 NN O
of BC2GM083628661 IN O
a BC2GM083628661 DT O
twisted BC2GM083628661 JJ O
structure BC2GM083628661 NN O
of BC2GM083628661 IN O
importin-beta BC2GM083628661 NN O
is BC2GM083628661 VBZ O
essential BC2GM083628661 JJ O
for BC2GM083628661 IN O
the BC2GM083628661 DT O
protein-protein BC2GM083628661 JJ O
interaction BC2GM083628661 NN O
required BC2GM083628661 VBN O
for BC2GM083628661 IN O
nuclear BC2GM083628661 JJ O
transport BC2GM083628661 NN O
. BC2GM083628661 . O
. . O O

Protease BC2GM049336360 NNP O
digestion BC2GM049336360 NN O
and BC2GM049336360 CC O
alkaline BC2GM049336360 JJ O
extraction BC2GM049336360 NN O
of BC2GM049336360 IN O
microsomes BC2GM049336360 NNS O
containing BC2GM049336360 VBG O
labeled BC2GM049336360 VBD O
mutant BC2GM049336360 JJ O
proteins BC2GM049336360 NNS O
further BC2GM049336360 RBR O
showed BC2GM049336360 VBD O
that BC2GM049336360 IN O
segment BC2GM049336360 NN O
3 BC2GM049336360 CD O
was BC2GM049336360 VBD O
sufficient BC2GM049336360 JJ O
for BC2GM049336360 IN O
stable BC2GM049336360 JJ O
membrane BC2GM049336360 NN O
anchoring BC2GM049336360 NN O
of BC2GM049336360 IN O
the BC2GM049336360 DT O
glycoproteins BC2GM049336360 NNS O
, BC2GM049336360 , O
indicating BC2GM049336360 VBG O
that BC2GM049336360 IN O
this BC2GM049336360 DT O
segment BC2GM049336360 NN O
may BC2GM049336360 MD O
specify BC2GM049336360 VB O
the BC2GM049336360 DT O
transmembrane BC2GM049336360 NN O
domain BC2GM049336360 NN O
of BC2GM049336360 IN O
the BC2GM049336360 DT O
gB BC2GM049336360 NN O
glycoprotein BC2GM049336360 NN O
. BC2GM049336360 . O
. . O O

Thallium-201 BC2GM025927345 NNP O
scintigraphy BC2GM025927345 NN O
after BC2GM025927345 IN O
dipyridamole BC2GM025927345 JJ O
infusion BC2GM025927345 NN O
with BC2GM025927345 IN O
low BC2GM025927345 JJ O
level BC2GM025927345 NN O
exercise BC2GM025927345 NN O
. BC2GM025927345 . O
. . O O

1988 BC2GM004818954 CD O
) BC2GM004818954 ) O
. BC2GM004818954 . O
. . O O

Second BC2GM053041112 JJ O
, BC2GM053041112 , O
CGGA-containing BC2GM053041112 JJ O
sequences BC2GM053041112 NNS O
placed BC2GM053041112 VBN O
at BC2GM053041112 IN O
-88 BC2GM053041112 NN O
in BC2GM053041112 IN O
the BC2GM053041112 DT O
delta BC2GM053041112 JJ O
MTV-CAT BC2GM053041112 NNP O
reporter BC2GM053041112 NN O
plasmid BC2GM053041112 NN O
conferred BC2GM053041112 VBD O
insulin BC2GM053041112 JJ O
responsiveness BC2GM053041112 NN O
to BC2GM053041112 TO O
the BC2GM053041112 DT O
mammary BC2GM053041112 JJ O
tumor BC2GM053041112 NN O
virus BC2GM053041112 NN O
promoter BC2GM053041112 NN O
. BC2GM053041112 . O
. . O O

Thus BC2GM081931379 RB O
, BC2GM081931379 , O
STK1 BC2GM081931379 NNP O
is BC2GM081931379 VBZ O
most BC2GM081931379 RBS O
likely BC2GM081931379 JJ O
the BC2GM081931379 DT O
human BC2GM081931379 JJ O
homologue BC2GM081931379 NN O
of BC2GM081931379 IN O
MO15 BC2GM081931379 NNP O
. BC2GM081931379 . O
. . O O

However BC2GM080092738 RB O
, BC2GM080092738 , O
an BC2GM080092738 DT O
analogous BC2GM080092738 JJ O
myristoylated BC2GM080092738 VBN O
peptide BC2GM080092738 RB O
derived BC2GM080092738 VBN O
from BC2GM080092738 IN O
c-Yes BC2GM080092738 NN O
also BC2GM080092738 RB O
has BC2GM080092738 VBZ O
no BC2GM080092738 DT O
inhibitory BC2GM080092738 NN O
activity BC2GM080092738 NN O
. BC2GM080092738 . O
. . O O

Inhibition BC2GM069816957 NN O
of BC2GM069816957 IN O
DNA BC2GM069816957 NNP O
topoisomerase BC2GM069816957 NN O
II BC2GM069816957 NNP O
alpha BC2GM069816957 VBZ O
gene BC2GM069816957 NN O
expression BC2GM069816957 NN O
by BC2GM069816957 IN O
the BC2GM069816957 DT O
p53 BC2GM069816957 NN O
tumor BC2GM069816957 NN O
suppressor BC2GM069816957 NN O
. BC2GM069816957 . O
. . O O

Corresponding BC2GM060603409 VBG O
oligonucleotides BC2GM060603409 NNS O
were BC2GM060603409 VBD O
used BC2GM060603409 VBN O
to BC2GM060603409 TO O
screen BC2GM060603409 VB O
a BC2GM060603409 DT O
rat BC2GM060603409 NN O
liver BC2GM060603409 NN O
cDNA BC2GM060603409 NN O
library BC2GM060603409 NN O
constructed BC2GM060603409 VBN O
in BC2GM060603409 IN O
the BC2GM060603409 DT O
plasmid BC2GM060603409 NN O
cloning BC2GM060603409 VBG O
vector BC2GM060603409 NN O
, BC2GM060603409 , O
pcDV BC2GM060603409 NN O
. BC2GM060603409 . O
. . O O

Presently BC2GM092797387 RB O
, BC2GM092797387 , O
we BC2GM092797387 PRP O
made BC2GM092797387 VBD O
chain BC2GM092797387 NN O
pair BC2GM092797387 NN O
switch BC2GM092797387 NN O
, BC2GM092797387 , O
chimeric BC2GM092797387 NN O
, BC2GM092797387 , O
and BC2GM092797387 CC O
site BC2GM092797387 NN O
mutant BC2GM092797387 JJ O
gamma BC2GM092797387 NN O
delta BC2GM092797387 NN O
TCRs BC2GM092797387 NNP O
and BC2GM092797387 CC O
transfected BC2GM092797387 VBD O
them BC2GM092797387 PRP O
into BC2GM092797387 IN O
TCR- BC2GM092797387 NNP O
mutant BC2GM092797387 JJ O
Jurkat BC2GM092797387 NNP O
T BC2GM092797387 NNP O
cells BC2GM092797387 NNS O
to BC2GM092797387 TO O
examine BC2GM092797387 VB O
the BC2GM092797387 DT O
effects BC2GM092797387 NNS O
of BC2GM092797387 IN O
changing BC2GM092797387 VBG O
the BC2GM092797387 DT O
TCR BC2GM092797387 NNP O
gamma BC2GM092797387 NN O
junctional BC2GM092797387 JJ O
region BC2GM092797387 NN O
sequences BC2GM092797387 NNS O
on BC2GM092797387 IN O
reactivity BC2GM092797387 NN O
to BC2GM092797387 TO O
prenyl BC2GM092797387 VB O
pyrophosphate BC2GM092797387 NN O
Ags BC2GM092797387 NNP O
. BC2GM092797387 . O
. . O O

Simulation BC2GM010769407 NN O
results BC2GM010769407 NNS O
based BC2GM010769407 VBN O
on BC2GM010769407 IN O
the BC2GM010769407 DT O
presented BC2GM010769407 VBN O
model BC2GM010769407 NN O
are BC2GM010769407 VBP O
compared BC2GM010769407 VBN O
with BC2GM010769407 IN O
the BC2GM010769407 DT O
experimental BC2GM010769407 JJ O
data BC2GM010769407 NNS O
for BC2GM010769407 IN O
two BC2GM010769407 CD O
types BC2GM010769407 NNS O
of BC2GM010769407 IN O
cMUTs BC2GM010769407 NN O
reported BC2GM010769407 VBN O
in BC2GM010769407 IN O
the BC2GM010769407 DT O
recent BC2GM010769407 JJ O
literature BC2GM010769407 NN O
. BC2GM010769407 . O
. . O O

TAAG BC2GM038794623 NNP O
sites BC2GM038794623 VBZ O
that BC2GM038794623 DT O
serve BC2GM038794623 NN O
as BC2GM038794623 IN O
functional BC2GM038794623 JJ O
late BC2GM038794623 JJ O
promoters BC2GM038794623 NNS O
in BC2GM038794623 IN O
OpMNPV BC2GM038794623 NNP O
were BC2GM038794623 VBD O
found BC2GM038794623 VBN O
to BC2GM038794623 TO O
mediate BC2GM038794623 VB O
transcription BC2GM038794623 NN O
initiation BC2GM038794623 NN O
at BC2GM038794623 IN O
only BC2GM038794623 RB O
basal BC2GM038794623 NN O
levels BC2GM038794623 NNS O
in BC2GM038794623 IN O
the BC2GM038794623 DT O
context BC2GM038794623 NN O
of BC2GM038794623 IN O
the BC2GM038794623 DT O
AcMNPV BC2GM038794623 NNP O
genome BC2GM038794623 NN O
, BC2GM038794623 , O
suggesting BC2GM038794623 VBG O
that BC2GM038794623 IN O
late BC2GM038794623 JJ O
promoter BC2GM038794623 NN O
activation BC2GM038794623 NN O
may BC2GM038794623 MD O
be BC2GM038794623 VB O
virus BC2GM038794623 NN O
specific BC2GM038794623 JJ O
within BC2GM038794623 IN O
the BC2GM038794623 DT O
family BC2GM038794623 NN O
Baculoviridae BC2GM038794623 NNP O
. BC2GM038794623 . O
. . O O

Membrane BC2GM002487539 NNP O
extraction BC2GM002487539 NN O
has BC2GM002487539 VBZ O
been BC2GM002487539 VBN O
interfaced BC2GM002487539 VBN O
with BC2GM002487539 IN O
gas BC2GM002487539 NN O
chromatography BC2GM002487539 NN O
and BC2GM002487539 CC O
mass BC2GM002487539 NN O
spectroscopy BC2GM002487539 NN O
for BC2GM002487539 IN O
the BC2GM002487539 DT O
analysis BC2GM002487539 NN O
of BC2GM002487539 IN O
volatile BC2GM002487539 JJ O
organics BC2GM002487539 NNS O
in BC2GM002487539 IN O
water BC2GM002487539 NN O
. BC2GM002487539 . O
. . O O

The BC2GM081194969 DT O
kinetics BC2GM081194969 NNS O
of BC2GM081194969 IN O
[ BC2GM081194969 $ O
14C BC2GM081194969 CD O
] BC2GM081194969 NNP O
NG BC2GM081194969 NNP O
in BC2GM081194969 IN O
the BC2GM081194969 DT O
blood BC2GM081194969 NN O
of BC2GM081194969 IN O
the BC2GM081194969 DT O
dosed BC2GM081194969 JJ O
animals BC2GM081194969 NNS O
was BC2GM081194969 VBD O
followed BC2GM081194969 VBN O
. BC2GM081194969 . O
. . O O

Here BC2GM060824736 RB O
RFX BC2GM060824736 NNP O
/ BC2GM060824736 NNP O
X2BP BC2GM060824736 NNP O
/ BC2GM060824736 NNP O
DNA BC2GM060824736 NNP O
complexes BC2GM060824736 NNS O
were BC2GM060824736 VBD O
formed BC2GM060824736 VBN O
on BC2GM060824736 IN O
all BC2GM060824736 DT O
class BC2GM060824736 NN O
II BC2GM060824736 NNP O
isotypes BC2GM060824736 VBZ O
regardless BC2GM060824736 RB O
of BC2GM060824736 IN O
the BC2GM060824736 DT O
ability BC2GM060824736 NN O
of BC2GM060824736 IN O
the BC2GM060824736 DT O
X BC2GM060824736 NNP O
box BC2GM060824736 NN O
region BC2GM060824736 NN O
to BC2GM060824736 TO O
bind BC2GM060824736 VB O
either BC2GM060824736 DT O
factor BC2GM060824736 NN O
individually BC2GM060824736 RB O
. BC2GM060824736 . O
. . O O

A BC2GM038520766 DT O
short BC2GM038520766 JJ O
conserved BC2GM038520766 NN O
motif BC2GM038520766 NN O
is BC2GM038520766 VBZ O
required BC2GM038520766 VBN O
for BC2GM038520766 IN O
repressor BC2GM038520766 NN O
domain BC2GM038520766 NN O
function BC2GM038520766 NN O
in BC2GM038520766 IN O
the BC2GM038520766 DT O
myeloid-specific BC2GM038520766 JJ O
transcription BC2GM038520766 NN O
factor BC2GM038520766 NN O
CCAAT BC2GM038520766 NNP O
/ BC2GM038520766 NNP O
enhancer-binding BC2GM038520766 JJ O
protein BC2GM038520766 NN O
epsilon BC2GM038520766 NN O
. BC2GM038520766 . O
. . O O

Chromaffin BC2GM007028303 NNP O
cells BC2GM007028303 NNS O
transfected BC2GM007028303 VBN O
with BC2GM007028303 IN O
a BC2GM007028303 DT O
plasmid BC2GM007028303 NN O
with BC2GM007028303 IN O
the BC2GM007028303 DT O
entire BC2GM007028303 JJ O
coding BC2GM007028303 NN O
sequence BC2GM007028303 NN O
of BC2GM007028303 IN O
c-Rabphilin3a BC2GM007028303 JJ O
inserted BC2GM007028303 VBN O
in BC2GM007028303 IN O
the BC2GM007028303 DT O
antisense BC2GM007028303 JJ O
orientation BC2GM007028303 NN O
inhibited BC2GM007028303 VBN O
secretion BC2GM007028303 NN O
of BC2GM007028303 IN O
co-expressed BC2GM007028303 JJ O
GH BC2GM007028303 NNP O
by BC2GM007028303 IN O
approximately BC2GM007028303 RB O
30 BC2GM007028303 CD O
% BC2GM007028303 NN O
. BC2GM007028303 . O
. . O O

The BC2GM061191789 DT O
standardized BC2GM061191789 JJ O
incidence BC2GM061191789 NN O
in BC2GM061191789 IN O
Europeans BC2GM061191789 NNPS O
has BC2GM061191789 VBZ O
risen BC2GM061191789 VBN O
significantly BC2GM061191789 RB O
to BC2GM061191789 TO O
4.7 BC2GM061191789 CD O
/ BC2GM061191789 NNS O
10 BC2GM061191789 CD O
( BC2GM061191789 ( O
5 BC2GM061191789 CD O
) BC2GM061191789 ) O
/ BC2GM061191789 CD O
year BC2GM061191789 NN O
from BC2GM061191789 IN O
3.4 BC2GM061191789 CD O
/ BC2GM061191789 NNS O
10 BC2GM061191789 CD O
( BC2GM061191789 ( O
5 BC2GM061191789 CD O
) BC2GM061191789 ) O
/ BC2GM061191789 CD O
year BC2GM061191789 NN O
in BC2GM061191789 IN O
the BC2GM061191789 DT O
1970s BC2GM061191789 CD O
( BC2GM061191789 ( O
chi BC2GM061191789 JJ O
2 BC2GM061191789 CD O
= BC2GM061191789 JJ O
8.1 BC2GM061191789 CD O
, BC2GM061191789 , O
p BC2GM061191789 NN O
less BC2GM061191789 JJR O
than BC2GM061191789 IN O
0.005 BC2GM061191789 CD O
) BC2GM061191789 ) O
. BC2GM061191789 . O
. . O O

The BC2GM017195942 DT O
interaction BC2GM017195942 NN O
of BC2GM017195942 IN O
different BC2GM017195942 JJ O
protein BC2GM017195942 NNS O
systems BC2GM017195942 NNS O
with BC2GM017195942 IN O
microtubules BC2GM017195942 NNS O
is BC2GM017195942 VBZ O
a BC2GM017195942 DT O
critical BC2GM017195942 JJ O
step BC2GM017195942 NN O
in BC2GM017195942 IN O
the BC2GM017195942 DT O
cellular BC2GM017195942 JJ O
function BC2GM017195942 NN O
of BC2GM017195942 IN O
these BC2GM017195942 DT O
organelles BC2GM017195942 NNS O
. BC2GM017195942 . O
. . O O

Possibilities BC2GM012924248 NNS O
and BC2GM012924248 CC O
limints BC2GM012924248 NNS O
of BC2GM012924248 IN O
immunofluorescence BC2GM012924248 NN O
in BC2GM012924248 IN O
the BC2GM012924248 DT O
laboratory BC2GM012924248 JJ O
diagnosis BC2GM012924248 NN O
of BC2GM012924248 IN O
rabies BC2GM012924248 NNS O
. BC2GM012924248 . O
. . O O

The BC2GM095731252 DT O
claustrocortical BC2GM095731252 JJ O
connection BC2GM095731252 NN O
was BC2GM095731252 VBD O
investigated BC2GM095731252 VBN O
in BC2GM095731252 IN O
13 BC2GM095731252 CD O
cats BC2GM095731252 NNS O
with BC2GM095731252 IN O
selective BC2GM095731252 JJ O
injections BC2GM095731252 NNS O
of BC2GM095731252 IN O
30 BC2GM095731252 CD O
% BC2GM095731252 NN O
HRP BC2GM095731252 NNP O
in BC2GM095731252 IN O
the BC2GM095731252 DT O
three BC2GM095731252 CD O
subdivisions BC2GM095731252 NNS O
of BC2GM095731252 IN O
the BC2GM095731252 DT O
auditory BC2GM095731252 NN O
cortex BC2GM095731252 NN O
. BC2GM095731252 . O
( BC2GM095731252 ( O
ABSTRACT BC2GM095731252 NNP O
TRUNCATED BC2GM095731252 NNP O
AT BC2GM095731252 NNP O
400 BC2GM095731252 CD O
WORDS BC2GM095731252 NNP O
) BC2GM095731252 ) O
. BC2GM095731252 . O
. . O O

A BC2GM066302060 DT O
series BC2GM066302060 NN O
of BC2GM066302060 IN O
sequence BC2GM066302060 NN O
fragments BC2GM066302060 NNS O
were BC2GM066302060 VBD O
placed BC2GM066302060 VBN O
5 BC2GM066302060 CD O
' BC2GM066302060 '' O
to BC2GM066302060 TO O
the BC2GM066302060 DT O
chloramphenicol BC2GM066302060 NN O
acetyltransferase BC2GM066302060 NN O
( BC2GM066302060 ( O
CAT BC2GM066302060 NNP O
) BC2GM066302060 ) O
reporter BC2GM066302060 NN O
gene BC2GM066302060 NN O
and BC2GM066302060 CC O
ability BC2GM066302060 NN O
to BC2GM066302060 TO O
mediate BC2GM066302060 VB O
transcription BC2GM066302060 NN O
of BC2GM066302060 IN O
CAT BC2GM066302060 NNP O
in BC2GM066302060 IN O
response BC2GM066302060 NN O
to BC2GM066302060 TO O
IFN BC2GM066302060 NNP O
gamma BC2GM066302060 NN O
or BC2GM066302060 CC O
LPS BC2GM066302060 NNP O
treatment BC2GM066302060 NN O
was BC2GM066302060 VBD O
studied BC2GM066302060 VBN O
following BC2GM066302060 VBG O
transient BC2GM066302060 JJ O
transfection BC2GM066302060 NN O
in BC2GM066302060 IN O
the BC2GM066302060 DT O
macrophage-like BC2GM066302060 JJ O
cell BC2GM066302060 NN O
line BC2GM066302060 NN O
RAW BC2GM066302060 NNP O
264.7 BC2GM066302060 CD O
. BC2GM066302060 . O
. . O O

IGF-I BC2GM064435872 JJ O
levels BC2GM064435872 NNS O
were BC2GM064435872 VBD O
measured BC2GM064435872 VBN O
in BC2GM064435872 IN O
the BC2GM064435872 DT O
CSF BC2GM064435872 NNP O
of BC2GM064435872 IN O
11 BC2GM064435872 CD O
children BC2GM064435872 NNS O
with BC2GM064435872 IN O
autism BC2GM064435872 NN O
( BC2GM064435872 ( O
4 BC2GM064435872 CD O
females BC2GM064435872 NNS O
, BC2GM064435872 , O
7 BC2GM064435872 CD O
males BC2GM064435872 NNS O
; BC2GM064435872 : O
mean BC2GM064435872 JJ O
age BC2GM064435872 NN O
3.8 BC2GM064435872 CD O
years BC2GM064435872 NNS O
, BC2GM064435872 , O
SD BC2GM064435872 NNP O
1.1 BC2GM064435872 CD O
) BC2GM064435872 ) O
using BC2GM064435872 VBG O
a BC2GM064435872 DT O
sensitive BC2GM064435872 JJ O
radioimmunoassay BC2GM064435872 NN O
method BC2GM064435872 NN O
and BC2GM064435872 CC O
compared BC2GM064435872 VBN O
with BC2GM064435872 IN O
levels BC2GM064435872 NNS O
in BC2GM064435872 IN O
11 BC2GM064435872 CD O
control BC2GM064435872 NN O
participants BC2GM064435872 NNS O
( BC2GM064435872 ( O
6 BC2GM064435872 CD O
females BC2GM064435872 NNS O
, BC2GM064435872 , O
5 BC2GM064435872 CD O
males BC2GM064435872 NNS O
; BC2GM064435872 : O
mean BC2GM064435872 JJ O
age BC2GM064435872 NN O
3.8 BC2GM064435872 CD O
years BC2GM064435872 NNS O
) BC2GM064435872 ) O
. BC2GM064435872 . O
. . O O

The BC2GM005330146 DT O
sequence BC2GM005330146 NN O
of BC2GM005330146 IN O
LZ321 BC2GM005330146 NNP O
matched BC2GM005330146 VBD O
that BC2GM005330146 IN O
of BC2GM005330146 IN O
RREB1 BC2GM005330146 NNP O
, BC2GM005330146 , O
a BC2GM005330146 DT O
transcription BC2GM005330146 NN O
factor BC2GM005330146 NN O
that BC2GM005330146 WDT O
bound BC2GM005330146 NN O
to BC2GM005330146 TO O
a BC2GM005330146 DT O
Ras BC2GM005330146 NNP O
responsive BC2GM005330146 JJ O
element BC2GM005330146 NN O
( BC2GM005330146 ( O
RRE BC2GM005330146 NNP O
) BC2GM005330146 ) O
very BC2GM005330146 RB O
different BC2GM005330146 JJ O
from BC2GM005330146 IN O
the BC2GM005330146 DT O
sequence BC2GM005330146 NN O
with BC2GM005330146 IN O
which BC2GM005330146 WDT O
we BC2GM005330146 PRP O
isolated BC2GM005330146 VBD O
LZ321 BC2GM005330146 NNP O
. BC2GM005330146 . O
. . O O

The BC2GM056370942 DT O
effect BC2GM056370942 NN O
of BC2GM056370942 IN O
buthionine BC2GM056370942 NN O
sulfoximine BC2GM056370942 NN O
( BC2GM056370942 ( O
BSO BC2GM056370942 NNP O
) BC2GM056370942 ) O
and BC2GM056370942 CC O
disulfiram BC2GM056370942 NN O
( BC2GM056370942 ( O
DSF BC2GM056370942 NNP O
) BC2GM056370942 ) O
on BC2GM056370942 IN O
the BC2GM056370942 DT O
urotoxicity BC2GM056370942 NN O
induced BC2GM056370942 VBN O
by BC2GM056370942 IN O
cyclophosphamide BC2GM056370942 NN O
( BC2GM056370942 ( O
CPA BC2GM056370942 NNP O
) BC2GM056370942 ) O
was BC2GM056370942 VBD O
examined BC2GM056370942 VBN O
in BC2GM056370942 IN O
mice BC2GM056370942 NN O
. BC2GM056370942 . O
. . O O

In BC2GM000487648 IN O
four BC2GM000487648 CD O
calves BC2GM000487648 NNS O
given BC2GM000487648 VBN O
Haemonchus BC2GM000487648 NNP O
contortus BC2GM000487648 NN O
larvae BC2GM000487648 NN O
, BC2GM000487648 , O
the BC2GM000487648 DT O
serum BC2GM000487648 NN O
pepsinogen BC2GM000487648 NN O
concentration BC2GM000487648 NN O
rose BC2GM000487648 VBD O
quickly BC2GM000487648 RB O
to BC2GM000487648 TO O
reach BC2GM000487648 VB O
a BC2GM000487648 DT O
mean BC2GM000487648 NN O
of BC2GM000487648 IN O
3.5 BC2GM000487648 CD O
iu BC2GM000487648 JJ O
tyrosine BC2GM000487648 NN O
on BC2GM000487648 IN O
day BC2GM000487648 NN O
14 BC2GM000487648 CD O
after BC2GM000487648 IN O
infection BC2GM000487648 NN O
. BC2GM000487648 . O
. . O O

The BC2GM064373042 DT O
temporal BC2GM064373042 JJ O
sequence BC2GM064373042 NN O
of BC2GM064373042 IN O
organ BC2GM064373042 JJ O
failure BC2GM064373042 NN O
was BC2GM064373042 VBD O
lung BC2GM064373042 NN O
, BC2GM064373042 , O
clotting BC2GM064373042 VBG O
system BC2GM064373042 NN O
, BC2GM064373042 , O
kidney BC2GM064373042 NN O
, BC2GM064373042 , O
and BC2GM064373042 CC O
liver BC2GM064373042 RB O
. BC2GM064373042 . O
. . O O

Real-time BC2GM011866603 JJ O
two-dimensional BC2GM011866603 JJ O
echocardiographic BC2GM011866603 JJ O
studies BC2GM011866603 NNS O
of BC2GM011866603 IN O
the BC2GM011866603 DT O
mitral BC2GM011866603 JJ O
valve BC2GM011866603 NN O
in BC2GM011866603 IN O
short-axis BC2GM011866603 JJ O
view BC2GM011866603 NN O
were BC2GM011866603 VBD O
obtained BC2GM011866603 VBN O
from BC2GM011866603 IN O
10 BC2GM011866603 CD O
normal BC2GM011866603 JJ O
subjects BC2GM011866603 NNS O
. BC2GM011866603 . O
. . O O

Comparison BC2GM044153984 NNP O
of BC2GM044153984 IN O
the BC2GM044153984 DT O
footprint BC2GM044153984 NN O
patterns BC2GM044153984 NNS O
of BC2GM044153984 IN O
the BC2GM044153984 DT O
mouse BC2GM044153984 NN O
and BC2GM044153984 CC O
human BC2GM044153984 JJ O
HPRT BC2GM044153984 NNP O
genes BC2GM044153984 NNS O
demonstrated BC2GM044153984 VBD O
that BC2GM044153984 IN O
the BC2GM044153984 DT O
in BC2GM044153984 IN O
vivo BC2GM044153984 JJ O
binding BC2GM044153984 NN O
of BC2GM044153984 IN O
regulatory BC2GM044153984 JJ O
proteins BC2GM044153984 NNS O
between BC2GM044153984 IN O
these BC2GM044153984 DT O
species BC2GM044153984 NNS O
is BC2GM044153984 VBZ O
generally BC2GM044153984 RB O
conserved BC2GM044153984 VBN O
but BC2GM044153984 CC O
not BC2GM044153984 RB O
identical BC2GM044153984 JJ O
. BC2GM044153984 . O
. . O O

After BC2GM072049758 IN O
institution BC2GM072049758 NN O
of BC2GM072049758 IN O
insulin BC2GM072049758 NN O
treatment BC2GM072049758 NN O
, BC2GM072049758 , O
diabetic BC2GM072049758 JJ O
control BC2GM072049758 NN O
was BC2GM072049758 VBD O
improved BC2GM072049758 VBN O
as BC2GM072049758 IN O
demonstrated BC2GM072049758 VBN O
by BC2GM072049758 IN O
decreasing BC2GM072049758 VBG O
levels BC2GM072049758 NNS O
of BC2GM072049758 IN O
HbA1 BC2GM072049758 NNP O
. BC2GM072049758 . O
. . O O

In BC2GM038818397 IN O
3 BC2GM038818397 CD O
of BC2GM038818397 IN O
the BC2GM038818397 DT O
5 BC2GM038818397 CD O
patients BC2GM038818397 NNS O
with BC2GM038818397 IN O
AVNRT BC2GM038818397 NNP O
and BC2GM038818397 CC O
AJR BC2GM038818397 NNP O
, BC2GM038818397 , O
junctional BC2GM038818397 JJ O
beats BC2GM038818397 NNS O
served BC2GM038818397 VBD O
as BC2GM038818397 IN O
a BC2GM038818397 DT O
trigger BC2GM038818397 NN O
for BC2GM038818397 IN O
reentry BC2GM038818397 NN O
. BC2GM038818397 . O
. . O O

In BC2GM096521893 IN O
contrast BC2GM096521893 NN O
, BC2GM096521893 , O
corticotropin BC2GM096521893 NN O
releasing BC2GM096521893 VBG O
factor BC2GM096521893 NN O
( BC2GM096521893 ( O
CRF BC2GM096521893 NNP O
) BC2GM096521893 ) O
, BC2GM096521893 , O
injected BC2GM096521893 VBN O
centrally BC2GM096521893 RB O
produces BC2GM096521893 VBZ O
a BC2GM096521893 DT O
suppression BC2GM096521893 NN O
of BC2GM096521893 IN O
punished BC2GM096521893 JJ O
and BC2GM096521893 CC O
non-punished BC2GM096521893 JJ O
responding BC2GM096521893 NN O
in BC2GM096521893 IN O
the BC2GM096521893 DT O
conflict BC2GM096521893 NN O
test BC2GM096521893 NN O
consistent BC2GM096521893 NN O
with BC2GM096521893 IN O
its BC2GM096521893 PRP$ O
hypothesized BC2GM096521893 JJ O
role BC2GM096521893 NN O
in BC2GM096521893 IN O
mediating BC2GM096521893 VBG O
behavioral BC2GM096521893 JJ O
responses BC2GM096521893 NNS O
to BC2GM096521893 TO O
stress BC2GM096521893 VB O
. BC2GM096521893 . O
. . O O

A BC2GM031220752 DT O
V1 BC2GM031220752 NNP O
mutant BC2GM031220752 NN O
generated BC2GM031220752 VBD O
in BC2GM031220752 IN O
vivo BC2GM031220752 NN O
with BC2GM031220752 IN O
11 BC2GM031220752 CD O
of BC2GM031220752 IN O
the BC2GM031220752 DT O
14 BC2GM031220752 CD O
N-terminal BC2GM031220752 JJ O
amino BC2GM031220752 NN O
acids BC2GM031220752 NNS O
altered BC2GM031220752 VBD O
, BC2GM031220752 , O
was BC2GM031220752 VBD O
viable BC2GM031220752 JJ O
and BC2GM031220752 CC O
produced BC2GM031220752 VBD O
symptoms BC2GM031220752 NNS O
typical BC2GM031220752 JJ O
of BC2GM031220752 IN O
a BC2GM031220752 DT O
wild-type BC2GM031220752 JJ O
infection BC2GM031220752 NN O
. BC2GM031220752 . O
. . O O

Before BC2GM066387134 IN O
therapy BC2GM066387134 NN O
was BC2GM066387134 VBD O
started BC2GM066387134 VBN O
, BC2GM066387134 , O
trabecular BC2GM066387134 JJ O
bone BC2GM066387134 NN O
alterations BC2GM066387134 NNS O
could BC2GM066387134 MD O
be BC2GM066387134 VB O
observed BC2GM066387134 VBN O
which BC2GM066387134 WDT O
were BC2GM066387134 VBD O
typical BC2GM066387134 JJ O
for BC2GM066387134 IN O
Paget BC2GM066387134 NNP O
's BC2GM066387134 POS O
disease BC2GM066387134 NN O
of BC2GM066387134 IN O
bone BC2GM066387134 NN O
as BC2GM066387134 IN O
there BC2GM066387134 EX O
were BC2GM066387134 VBD O
bulky BC2GM066387134 NNS O
trabeculare BC2GM066387134 JJ O
, BC2GM066387134 , O
increased BC2GM066387134 VBD O
remodelling BC2GM066387134 NN O
surfaces BC2GM066387134 NNS O
and BC2GM066387134 CC O
giant BC2GM066387134 JJ O
osteoclasts BC2GM066387134 NNS O
. BC2GM066387134 . O
. . O O

In BC2GM038738146 IN O
contrast BC2GM038738146 NN O
to BC2GM038738146 TO O
the BC2GM038738146 DT O
reciprocal BC2GM038738146 JJ O
effects BC2GM038738146 NNS O
of BC2GM038738146 IN O
Gab1 BC2GM038738146 NNP O
and BC2GM038738146 CC O
Gab2 BC2GM038738146 NNP O
in BC2GM038738146 IN O
mediating BC2GM038738146 VBG O
Elk-1 BC2GM038738146 JJ O
induction BC2GM038738146 NN O
, BC2GM038738146 , O
these BC2GM038738146 DT O
two BC2GM038738146 CD O
molecules BC2GM038738146 NNS O
have BC2GM038738146 VBP O
a BC2GM038738146 DT O
similar BC2GM038738146 JJ O
function BC2GM038738146 NN O
in BC2GM038738146 IN O
extracellular BC2GM038738146 JJ O
signal-regulated BC2GM038738146 JJ O
kinase BC2GM038738146 NN O
activation BC2GM038738146 NN O
induced BC2GM038738146 VBN O
by BC2GM038738146 IN O
either BC2GM038738146 DT O
oncogenic BC2GM038738146 JJ O
Ras BC2GM038738146 NNP O
or BC2GM038738146 CC O
growth BC2GM038738146 NN O
factor BC2GM038738146 NN O
stimulation BC2GM038738146 NN O
. BC2GM038738146 . O
. . O O

The BC2GM069151821 DT O
results BC2GM069151821 NNS O
show BC2GM069151821 VBP O
that BC2GM069151821 IN O
while BC2GM069151821 IN O
a BC2GM069151821 DT O
larger BC2GM069151821 JJR O
polypeptide BC2GM069151821 JJ O
substrate BC2GM069151821 NN O
carrying BC2GM069151821 VBG O
the BC2GM069151821 DT O
HD1 BC2GM069151821 NNP O
/ BC2GM069151821 NNP O
3C BC2GM069151821 CD O
site BC2GM069151821 NN O
was BC2GM069151821 VBD O
processed BC2GM069151821 VBN O
more BC2GM069151821 RBR O
efficiently BC2GM069151821 RB O
than BC2GM069151821 IN O
a BC2GM069151821 DT O
polypeptide BC2GM069151821 JJ O
substrate BC2GM069151821 NN O
carrying BC2GM069151821 VBG O
the BC2GM069151821 DT O
POL BC2GM069151821 NNP O
/ BC2GM069151821 NNP O
Zn BC2GM069151821 NNP O
site BC2GM069151821 NN O
, BC2GM069151821 , O
cleavage BC2GM069151821 NN O
of BC2GM069151821 IN O
the BC2GM069151821 DT O
synthetic BC2GM069151821 JJ O
peptide BC2GM069151821 NN O
substrates BC2GM069151821 VBZ O
containing BC2GM069151821 VBG O
these BC2GM069151821 DT O
two BC2GM069151821 CD O
cleavage BC2GM069151821 NN O
sites BC2GM069151821 NNS O
occurred BC2GM069151821 VBD O
at BC2GM069151821 IN O
similar BC2GM069151821 JJ O
efficiencies BC2GM069151821 NNS O
. BC2GM069151821 . O
. . O O

Sgs-4 BC2GM073091634 NNP O
is BC2GM073091634 VBZ O
one BC2GM073091634 CD O
of BC2GM073091634 IN O
the BC2GM073091634 DT O
eight BC2GM073091634 CD O
known BC2GM073091634 VBN O
genes BC2GM073091634 NNS O
coding BC2GM073091634 VBG O
for BC2GM073091634 IN O
larval BC2GM073091634 JJ O
secretion BC2GM073091634 NN O
proteins BC2GM073091634 NNS O
in BC2GM073091634 IN O
Drosophila BC2GM073091634 NNP O
melanogaster BC2GM073091634 NN O
. BC2GM073091634 . O
. . O O

During BC2GM002848058 IN O
the BC2GM002848058 DT O
burst BC2GM002848058 JJ O
period BC2GM002848058 NN O
( BC2GM002848058 ( O
approximately BC2GM002848058 RB O
5-10 BC2GM002848058 JJ O
min BC2GM002848058 NN O
) BC2GM002848058 ) O
, BC2GM002848058 , O
local BC2GM002848058 JJ O
blood BC2GM002848058 NN O
H2O2 BC2GM002848058 NNP O
concentrations BC2GM002848058 NNS O
and BC2GM002848058 CC O
xanthine BC2GM002848058 JJ O
oxidase BC2GM002848058 NN O
activities BC2GM002848058 NNS O
were BC2GM002848058 VBD O
highly BC2GM002848058 RB O
correlated BC2GM002848058 VBN O
( BC2GM002848058 ( O
r BC2GM002848058 VB O
= BC2GM002848058 RB O
0.999 BC2GM002848058 CD O
) BC2GM002848058 ) O
. BC2GM002848058 . O
. . O O

Each BC2GM011438021 DT O
received BC2GM011438021 VBD O
20 BC2GM011438021 CD O
mL BC2GM011438021 NN O
of BC2GM011438021 IN O
one BC2GM011438021 CD O
of BC2GM011438021 IN O
three BC2GM011438021 CD O
test BC2GM011438021 JJS O
solutions BC2GM011438021 NNS O
: BC2GM011438021 : O
levobupivacaine BC2GM011438021 NN O
control BC2GM011438021 NN O
, BC2GM011438021 , O
levobupivacaine BC2GM011438021 NN O
and BC2GM011438021 CC O
fentanyl BC2GM011438021 $ O
2 BC2GM011438021 CD O
microg BC2GM011438021 NN O
/ BC2GM011438021 NNP O
mL BC2GM011438021 NN O
, BC2GM011438021 , O
or BC2GM011438021 CC O
levobupivacaine BC2GM011438021 NN O
and BC2GM011438021 CC O
fentanyl BC2GM011438021 $ O
3 BC2GM011438021 CD O
microg BC2GM011438021 NN O
/ BC2GM011438021 NNP O
mL BC2GM011438021 NN O
. BC2GM011438021 . O
. . O O

Self-consistent BC2GM017504057 JJ O
calculation BC2GM017504057 NN O
of BC2GM017504057 IN O
the BC2GM017504057 DT O
surface BC2GM017504057 NN O
electronic BC2GM017504057 JJ O
structure BC2GM017504057 NN O
of BC2GM017504057 IN O
the BC2GM017504057 DT O
( BC2GM017504057 ( O
1 BC2GM017504057 CD O
x BC2GM017504057 RB O
2 BC2GM017504057 CD O
) BC2GM017504057 ) O
reconstructed BC2GM017504057 VBN O
Au BC2GM017504057 NNP O
( BC2GM017504057 ( O
110 BC2GM017504057 CD O
) BC2GM017504057 ) O
surface BC2GM017504057 NN O
. BC2GM017504057 . O
. . O O

But BC2GM035600571 CC O
, BC2GM035600571 , O
when BC2GM035600571 WRB O
mated BC2GM035600571 VBN O
males BC2GM035600571 NNS O
built BC2GM035600571 VBN O
nests BC2GM035600571 NNS O
in BC2GM035600571 IN O
the BC2GM035600571 DT O
absence BC2GM035600571 NN O
of BC2GM035600571 IN O
young BC2GM035600571 JJ O
, BC2GM035600571 , O
T BC2GM035600571 JJ O
levels BC2GM035600571 NNS O
were BC2GM035600571 VBD O
higher BC2GM035600571 JJR O
than BC2GM035600571 IN O
in BC2GM035600571 IN O
all BC2GM035600571 DT O
other BC2GM035600571 JJ O
conditions BC2GM035600571 NNS O
, BC2GM035600571 , O
though BC2GM035600571 IN O
only BC2GM035600571 RB O
for BC2GM035600571 IN O
early BC2GM035600571 JJ O
broods BC2GM035600571 NNS O
. BC2GM035600571 . O
. . O O

The BC2GM087801805 DT O
striking BC2GM087801805 JJ O
similarity BC2GM087801805 NN O
in BC2GM087801805 IN O
preference BC2GM087801805 NN O
for BC2GM087801805 IN O
mismatched BC2GM087801805 VBN O
and BC2GM087801805 CC O
weakly BC2GM087801805 RB O
paired BC2GM087801805 VBD O
nucleotides BC2GM087801805 NNS O
for BC2GM087801805 IN O
binding BC2GM087801805 NN O
and BC2GM087801805 CC O
for BC2GM087801805 IN O
excision BC2GM087801805 NN O
suggests BC2GM087801805 VBZ O
a BC2GM087801805 DT O
functional BC2GM087801805 JJ O
relationship BC2GM087801805 NN O
between BC2GM087801805 IN O
binding BC2GM087801805 VBG O
and BC2GM087801805 CC O
cleavage BC2GM087801805 JJ O
reactions BC2GM087801805 NNS O
. BC2GM087801805 . O
. . O O

Results BC2GM007595336 NNS O
of BC2GM007595336 IN O
this BC2GM007595336 DT O
study BC2GM007595336 NN O
indicate BC2GM007595336 VBP O
that BC2GM007595336 IN O
when BC2GM007595336 WRB O
amniotic BC2GM007595336 JJ O
fluid BC2GM007595336 NN O
samples BC2GM007595336 NNS O
are BC2GM007595336 VBP O
stored BC2GM007595336 VBN O
frozen BC2GM007595336 JJ O
and BC2GM007595336 CC O
strict BC2GM007595336 JJ O
quality BC2GM007595336 NN O
control BC2GM007595336 NN O
is BC2GM007595336 VBZ O
maintained BC2GM007595336 VBN O
in BC2GM007595336 IN O
analytic BC2GM007595336 JJ O
procedures BC2GM007595336 NNS O
, BC2GM007595336 , O
only BC2GM007595336 RB O
minimal BC2GM007595336 JJ O
changes BC2GM007595336 NNS O
occur BC2GM007595336 VBP O
in BC2GM007595336 IN O
phospholipid BC2GM007595336 JJ O
concentrations BC2GM007595336 NNS O
over BC2GM007595336 IN O
12 BC2GM007595336 CD O
months BC2GM007595336 NNS O
. BC2GM007595336 . O
. . O O

CONCLUSIONS BC2GM003488368 NN O
: BC2GM003488368 : O
These BC2GM003488368 DT O
findings BC2GM003488368 NNS O
imply BC2GM003488368 VBP O
that BC2GM003488368 IN O
the BC2GM003488368 DT O
spinal BC2GM003488368 JJ O
cord BC2GM003488368 NN O
is BC2GM003488368 VBZ O
not BC2GM003488368 RB O
a BC2GM003488368 DT O
simple BC2GM003488368 JJ O
command-carrying BC2GM003488368 JJ O
medium BC2GM003488368 NN O
from BC2GM003488368 IN O
the BC2GM003488368 DT O
brain BC2GM003488368 NN O
to BC2GM003488368 TO O
the BC2GM003488368 DT O
limbs BC2GM003488368 NNS O
, BC2GM003488368 , O
and BC2GM003488368 CC O
implies BC2GM003488368 NNS O
that BC2GM003488368 IN O
some BC2GM003488368 DT O
computational BC2GM003488368 JJ O
activities BC2GM003488368 NNS O
take BC2GM003488368 VBP O
place BC2GM003488368 NN O
at BC2GM003488368 IN O
the BC2GM003488368 DT O
spinal BC2GM003488368 JJ O
cord BC2GM003488368 NN O
level BC2GM003488368 NN O
. BC2GM003488368 . O
. . O O

Flux BC2GM052748917 NNP O
of BC2GM052748917 IN O
the BC2GM052748917 DT O
paramyxovirus BC2GM052748917 NN O
hemagglutinin-neuraminidase BC2GM052748917 NN O
glycoprotein BC2GM052748917 NN O
through BC2GM052748917 IN O
the BC2GM052748917 DT O
endoplasmic BC2GM052748917 JJ O
reticulum BC2GM052748917 NN O
activates BC2GM052748917 VBZ O
transcription BC2GM052748917 NN O
of BC2GM052748917 IN O
the BC2GM052748917 DT O
GRP78-BiP BC2GM052748917 NNP O
gene BC2GM052748917 NN O
. BC2GM052748917 . O
. . O O

Newly BC2GM042698596 RB O
hatched BC2GM042698596 VBN O
F1 BC2GM042698596 NNP O
nymphs BC2GM042698596 NN O
of BC2GM042698596 IN O
Aiolopus BC2GM042698596 NNP O
thalassinus BC2GM042698596 NN O
( BC2GM042698596 ( O
Fabr BC2GM042698596 NNP O
. BC2GM042698596 . O
) BC2GM042698596 ) O
were BC2GM042698596 VBD O
fed BC2GM042698596 VBN O
on BC2GM042698596 IN O
food BC2GM042698596 NN O
treated BC2GM042698596 VBN O
with BC2GM042698596 IN O
various BC2GM042698596 JJ O
concentrations BC2GM042698596 NNS O
of BC2GM042698596 IN O
HgCl2 BC2GM042698596 NNP O
, BC2GM042698596 , O
CdCl2 BC2GM042698596 NNP O
, BC2GM042698596 , O
and BC2GM042698596 CC O
PbCl2 BC2GM042698596 NNP O
until BC2GM042698596 IN O
the BC2GM042698596 DT O
end BC2GM042698596 NN O
of BC2GM042698596 IN O
adult BC2GM042698596 JJ O
life BC2GM042698596 NN O
. BC2GM042698596 . O
. . O O

The BC2GM071924862 DT O
aim BC2GM071924862 NN O
of BC2GM071924862 IN O
the BC2GM071924862 DT O
present BC2GM071924862 JJ O
study BC2GM071924862 NN O
was BC2GM071924862 VBD O
to BC2GM071924862 TO O
investigate BC2GM071924862 VB O
the BC2GM071924862 DT O
influence BC2GM071924862 NN O
of BC2GM071924862 IN O
long BC2GM071924862 JJ O
term BC2GM071924862 NN O
intravenous BC2GM071924862 JJ O
administration BC2GM071924862 NN O
of BC2GM071924862 IN O
naftidrofuryl BC2GM071924862 JJ O
( BC2GM071924862 ( O
Dusodril-Lipha BC2GM071924862 NNP O
Arzn BC2GM071924862 NNP O
) BC2GM071924862 ) O
twice BC2GM071924862 RB O
daily BC2GM071924862 RB O
in BC2GM071924862 IN O
a BC2GM071924862 DT O
dose BC2GM071924862 NN O
of BC2GM071924862 IN O
200 BC2GM071924862 CD O
mg BC2GM071924862 NNS O
in BC2GM071924862 IN O
continuous BC2GM071924862 JJ O
, BC2GM071924862 , O
4-hour BC2GM071924862 JJ O
infusion BC2GM071924862 NN O
in BC2GM071924862 IN O
500 BC2GM071924862 CD O
ml BC2GM071924862 NNS O
0.9 BC2GM071924862 CD O
% BC2GM071924862 NN O
NaCl BC2GM071924862 NNP O
to BC2GM071924862 TO O
the BC2GM071924862 DT O
patients BC2GM071924862 NNS O
suffering BC2GM071924862 VBG O
from BC2GM071924862 IN O
a BC2GM071924862 DT O
peripheral BC2GM071924862 JJ O
arterial BC2GM071924862 JJ O
occlusive BC2GM071924862 JJ O
disease BC2GM071924862 NN O
( BC2GM071924862 ( O
PAOD BC2GM071924862 NNP O
) BC2GM071924862 ) O
in BC2GM071924862 IN O
a BC2GM071924862 DT O
clinical BC2GM071924862 JJ O
condition BC2GM071924862 NN O
with BC2GM071924862 IN O
special BC2GM071924862 JJ O
attention BC2GM071924862 NN O
paid BC2GM071924862 VBN O
to BC2GM071924862 TO O
transcutaneous BC2GM071924862 JJ O
partial BC2GM071924862 JJ O
oxygen BC2GM071924862 NN O
pressure BC2GM071924862 NN O
measurements BC2GM071924862 NNS O
( BC2GM071924862 ( O
tcPO2 BC2GM071924862 NN O
) BC2GM071924862 ) O
and BC2GM071924862 CC O
rheographic BC2GM071924862 JJ O
parameters BC2GM071924862 NNS O
. BC2GM071924862 . O
. . O O

Controversy BC2GM062732556 NN O
exists BC2GM062732556 VBZ O
regarding BC2GM062732556 VBG O
both BC2GM062732556 DT O
the BC2GM062732556 DT O
natural BC2GM062732556 JJ O
life BC2GM062732556 NN O
cycle BC2GM062732556 NN O
for BC2GM062732556 IN O
this BC2GM062732556 DT O
parasite BC2GM062732556 NN O
as BC2GM062732556 RB O
well BC2GM062732556 RB O
as BC2GM062732556 IN O
the BC2GM062732556 DT O
species BC2GM062732556 NNS O
identity BC2GM062732556 NN O
of BC2GM062732556 IN O
opossum BC2GM062732556 JJ O
Sarcocystis BC2GM062732556 NNP O
. BC2GM062732556 . O
. . O O

Solution BC2GM086236532 NN O
of BC2GM086236532 IN O
the BC2GM086236532 DT O
Boltzmann BC2GM086236532 NNP O
equation BC2GM086236532 NN O
in BC2GM086236532 IN O
a BC2GM086236532 DT O
random BC2GM086236532 JJ O
magnetic BC2GM086236532 JJ O
field BC2GM086236532 NN O
. BC2GM086236532 . O
. . O O

Cross-species BC2GM088289193 JJ O
characterization BC2GM088289193 NN O
of BC2GM088289193 IN O
the BC2GM088289193 DT O
promoter BC2GM088289193 NN O
region BC2GM088289193 NN O
of BC2GM088289193 IN O
the BC2GM088289193 DT O
cystic BC2GM088289193 JJ O
fibrosis BC2GM088289193 NN O
transmembrane BC2GM088289193 NN O
conductance BC2GM088289193 NN O
regulator BC2GM088289193 NN O
gene BC2GM088289193 NN O
reveals BC2GM088289193 NNS O
multiple BC2GM088289193 JJ O
levels BC2GM088289193 NNS O
of BC2GM088289193 IN O
regulation BC2GM088289193 NN O
. BC2GM088289193 . O
. . O O

Extra BC2GM026399698 NNP O
dose BC2GM026399698 NN O
due BC2GM026399698 JJ O
to BC2GM026399698 TO O
extravehicular BC2GM026399698 JJ O
activity BC2GM026399698 NN O
during BC2GM026399698 IN O
the BC2GM026399698 DT O
NASA4 BC2GM026399698 NNP O
mission BC2GM026399698 NN O
measured BC2GM026399698 VBN O
by BC2GM026399698 IN O
an BC2GM026399698 DT O
on-board BC2GM026399698 JJ O
TLD BC2GM026399698 NNP O
system BC2GM026399698 NN O
. BC2GM026399698 . O
. . O O

Module BC2GM008224119 NNP O
2 BC2GM008224119 CD O
of BC2GM008224119 IN O
RifA BC2GM008224119 NNP O
lacks BC2GM008224119 VBZ O
a BC2GM008224119 DT O
beta-ketoacyl BC2GM008224119 NN O
: BC2GM008224119 : O
acyl BC2GM008224119 NN O
carrier BC2GM008224119 NN O
protein BC2GM008224119 NN O
reductase BC2GM008224119 NN O
( BC2GM008224119 ( O
KR BC2GM008224119 NNP O
) BC2GM008224119 ) O
domain BC2GM008224119 NN O
and BC2GM008224119 CC O
the BC2GM008224119 DT O
one BC2GM008224119 CD O
in BC2GM008224119 IN O
module BC2GM008224119 NN O
3 BC2GM008224119 CD O
has BC2GM008224119 VBZ O
an BC2GM008224119 DT O
apparently BC2GM008224119 RB O
inactive BC2GM008224119 JJ O
NADPH BC2GM008224119 NNP O
binding BC2GM008224119 NN O
motif BC2GM008224119 NN O
, BC2GM008224119 , O
similar BC2GM008224119 JJ O
to BC2GM008224119 TO O
one BC2GM008224119 CD O
found BC2GM008224119 NN O
in BC2GM008224119 IN O
the BC2GM008224119 DT O
Er BC2GM008224119 NNP O
PKS BC2GM008224119 NNP O
, BC2GM008224119 , O
while BC2GM008224119 IN O
the BC2GM008224119 DT O
other BC2GM008224119 JJ O
eight BC2GM008224119 CD O
KR BC2GM008224119 NNP O
domains BC2GM008224119 NNS O
of BC2GM008224119 IN O
the BC2GM008224119 DT O
Rf BC2GM008224119 NNP O
PKS BC2GM008224119 NNP O
should BC2GM008224119 MD O
be BC2GM008224119 VB O
functional BC2GM008224119 JJ O
. BC2GM008224119 . O
. . O O

Plasma BC2GM062836340 NNP O
hemopexin BC2GM062836340 NN O
homeostasis BC2GM062836340 NN O
during BC2GM062836340 IN O
the BC2GM062836340 DT O
acute BC2GM062836340 JJ O
phase BC2GM062836340 NN O
response BC2GM062836340 NN O
. BC2GM062836340 . O
. . O O

In BC2GM029087061 IN O
turn BC2GM029087061 NN O
, BC2GM029087061 , O
production BC2GM029087061 NN O
of BC2GM029087061 IN O
sufficient BC2GM029087061 JJ O
amounts BC2GM029087061 NNS O
of BC2GM029087061 IN O
TraR BC2GM029087061 NNP O
apparently BC2GM029087061 RB O
is BC2GM029087061 VBZ O
sensitive BC2GM029087061 JJ O
to BC2GM029087061 TO O
a BC2GM029087061 DT O
cellular BC2GM029087061 JJ O
function BC2GM029087061 NN O
requiring BC2GM029087061 VBG O
RNase BC2GM029087061 NNP O
D BC2GM029087061 NNP O
. BC2GM029087061 . O
. . O O

The BC2GM047037521 DT O
gene BC2GM047037521 NN O
set BC2GM047037521 VBN O
in BC2GM047037521 IN O
this BC2GM047037521 DT O
mitochondrial BC2GM047037521 JJ O
genome BC2GM047037521 NN O
is BC2GM047037521 VBZ O
a BC2GM047037521 DT O
subset BC2GM047037521 NN O
of BC2GM047037521 IN O
that BC2GM047037521 DT O
of BC2GM047037521 IN O
Reclinomonas BC2GM047037521 NNP O
americana BC2GM047037521 NN O
, BC2GM047037521 , O
an BC2GM047037521 DT O
amoeboid BC2GM047037521 JJ O
protozoan BC2GM047037521 NN O
. BC2GM047037521 . O
. . O O

The BC2GM023848611 DT O
sequence BC2GM023848611 NN O
of BC2GM023848611 IN O
the BC2GM023848611 DT O
gene BC2GM023848611 NN O
upstream BC2GM023848611 NN O
to BC2GM023848611 TO O
the BC2GM023848611 DT O
cap BC2GM023848611 NN O
site BC2GM023848611 NN O
contains BC2GM023848611 VBZ O
characteristic BC2GM023848611 JJ O
RNA BC2GM023848611 NNP O
polymerase BC2GM023848611 NN O
II BC2GM023848611 NNP O
promoter-binding BC2GM023848611 NN O
sites BC2GM023848611 NNS O
: BC2GM023848611 : O
a BC2GM023848611 DT O
putative BC2GM023848611 JJ O
TATA BC2GM023848611 NNP O
box BC2GM023848611 NN O
at BC2GM023848611 IN O
position BC2GM023848611 NN O
-29 BC2GM023848611 NN O
and BC2GM023848611 CC O
a BC2GM023848611 DT O
Sp BC2GM023848611 NNP O
1 BC2GM023848611 CD O
binding BC2GM023848611 VBG O
site BC2GM023848611 NN O
( BC2GM023848611 ( O
GGGGCGGAGA BC2GM023848611 NNP O
) BC2GM023848611 ) O
at BC2GM023848611 IN O
position BC2GM023848611 NN O
-48 BC2GM023848611 NN O
. BC2GM023848611 . O
. . O O

A BC2GM045923805 DT O
major BC2GM045923805 JJ O
feature BC2GM045923805 NN O
of BC2GM045923805 IN O
this BC2GM045923805 DT O
genomic BC2GM045923805 JJ O
sequence BC2GM045923805 NN O
is BC2GM045923805 VBZ O
the BC2GM045923805 DT O
presence BC2GM045923805 NN O
of BC2GM045923805 IN O
a BC2GM045923805 DT O
first BC2GM045923805 JJ O
intron BC2GM045923805 NN O
( BC2GM045923805 ( O
Il BC2GM045923805 NNP O
) BC2GM045923805 ) O
, BC2GM045923805 , O
215 BC2GM045923805 CD O
bp BC2GM045923805 NN O
long BC2GM045923805 RB O
, BC2GM045923805 , O
located BC2GM045923805 VBN O
48 BC2GM045923805 CD O
bp BC2GM045923805 JJ O
downstream BC2GM045923805 NN O
of BC2GM045923805 IN O
the BC2GM045923805 DT O
translation BC2GM045923805 NN O
start BC2GM045923805 NN O
ATG BC2GM045923805 NNP O
codon BC2GM045923805 NN O
. BC2GM045923805 . O
. . O O

The BC2GM030135043 DT O
effect BC2GM030135043 NN O
of BC2GM030135043 IN O
lung BC2GM030135043 NN O
edema BC2GM030135043 NN O
on BC2GM030135043 IN O
pulmonary BC2GM030135043 JJ O
vasoactivity BC2GM030135043 NN O
of BC2GM030135043 IN O
furosemide BC2GM030135043 NN O
. BC2GM030135043 . O
. . O O

Vasodilator BC2GM034468940 NNP O
and BC2GM034468940 CC O
hypotensive BC2GM034468940 JJ O
effects BC2GM034468940 NNS O
of BC2GM034468940 IN O
the BC2GM034468940 DT O
optical BC2GM034468940 JJ O
isomers BC2GM034468940 NNS O
of BC2GM034468940 IN O
nicardipine BC2GM034468940 NN O
( BC2GM034468940 ( O
YC-93 BC2GM034468940 NNP O
) BC2GM034468940 ) O
, BC2GM034468940 , O
a BC2GM034468940 DT O
new BC2GM034468940 JJ O
Ca2+-antagonist BC2GM034468940 NN O
. BC2GM034468940 . O
. . O O

Snails BC2GM075306454 NNS O
infected BC2GM075306454 VBN O
with BC2GM075306454 IN O
three BC2GM075306454 CD O
or BC2GM075306454 CC O
five BC2GM075306454 CD O
miracidia BC2GM075306454 NNS O
produced BC2GM075306454 VBD O
more BC2GM075306454 JJR O
metacercariae BC2GM075306454 NN O
than BC2GM075306454 IN O
those BC2GM075306454 DT O
infected BC2GM075306454 VBN O
with BC2GM075306454 IN O
a BC2GM075306454 DT O
single BC2GM075306454 JJ O
miracidium BC2GM075306454 NN O
. BC2GM075306454 . O
. . O O

Taking BC2GM020722431 VBG O
into BC2GM020722431 IN O
account BC2GM020722431 NN O
certain BC2GM020722431 JJ O
well BC2GM020722431 RB O
defined BC2GM020722431 VBN O
conditions BC2GM020722431 NNS O
( BC2GM020722431 ( O
frequent BC2GM020722431 JJ O
feedings BC2GM020722431 NNS O
, BC2GM020722431 , O
no BC2GM020722431 DT O
supplementary BC2GM020722431 JJ O
feeding BC2GM020722431 NN O
before BC2GM020722431 IN O
4-6 BC2GM020722431 JJ O
months BC2GM020722431 NNS O
, BC2GM020722431 , O
method BC2GM020722431 VBZ O
only BC2GM020722431 RB O
to BC2GM020722431 TO O
be BC2GM020722431 VB O
used BC2GM020722431 VBN O
in BC2GM020722431 IN O
the BC2GM020722431 DT O
absence BC2GM020722431 NN O
of BC2GM020722431 IN O
menstruation BC2GM020722431 NN O
) BC2GM020722431 ) O
, BC2GM020722431 , O
LAM BC2GM020722431 NNP O
can BC2GM020722431 MD O
be BC2GM020722431 VB O
relied BC2GM020722431 VBN O
on BC2GM020722431 IN O
for BC2GM020722431 IN O
contraceptive BC2GM020722431 JJ O
protection BC2GM020722431 NN O
for BC2GM020722431 IN O
up BC2GM020722431 IN O
to BC2GM020722431 TO O
1 BC2GM020722431 CD O
year BC2GM020722431 NN O
post BC2GM020722431 NN O
partum BC2GM020722431 NN O
. BC2GM020722431 . O
. . O O

In BC2GM019598575 IN O
this BC2GM019598575 DT O
work BC2GM019598575 NN O
, BC2GM019598575 , O
we BC2GM019598575 PRP O
have BC2GM019598575 VBP O
used BC2GM019598575 VBN O
Xenopus BC2GM019598575 NNP O
oocyte BC2GM019598575 JJ O
maturation BC2GM019598575 NN O
as BC2GM019598575 IN O
a BC2GM019598575 DT O
read-out BC2GM019598575 NN O
for BC2GM019598575 IN O
examining BC2GM019598575 VBG O
the BC2GM019598575 DT O
ability BC2GM019598575 NN O
of BC2GM019598575 IN O
the BC2GM019598575 DT O
neu BC2GM019598575 JJ O
tyrosine BC2GM019598575 NN O
kinase BC2GM019598575 NN O
( BC2GM019598575 ( O
p185neu BC2GM019598575 NN O
) BC2GM019598575 ) O
to BC2GM019598575 TO O
participate BC2GM019598575 VB O
with BC2GM019598575 IN O
the BC2GM019598575 DT O
epidermal BC2GM019598575 JJ O
growth BC2GM019598575 NN O
factor BC2GM019598575 NN O
( BC2GM019598575 ( O
EGF BC2GM019598575 NNP O
) BC2GM019598575 ) O
receptor BC2GM019598575 NN O
in BC2GM019598575 IN O
a BC2GM019598575 DT O
common BC2GM019598575 JJ O
signal BC2GM019598575 JJ O
transduction BC2GM019598575 NN O
pathway BC2GM019598575 NN O
. BC2GM019598575 . O
. . O O

Rats BC2GM004901699 NNS O
on BC2GM004901699 IN O
the BC2GM004901699 DT O
multiple BC2GM004901699 JJ O
oral BC2GM004901699 JJ O
dosage BC2GM004901699 NN O
regimen BC2GM004901699 NNS O
were BC2GM004901699 VBD O
given BC2GM004901699 VBN O
unlabelled BC2GM004901699 JJ O
HMCF BC2GM004901699 NNP O
in BC2GM004901699 IN O
their BC2GM004901699 PRP$ O
drinking BC2GM004901699 NN O
water BC2GM004901699 NN O
for BC2GM004901699 IN O
13 BC2GM004901699 CD O
days BC2GM004901699 NNS O
before BC2GM004901699 IN O
the BC2GM004901699 DT O
administration BC2GM004901699 NN O
of BC2GM004901699 IN O
a BC2GM004901699 DT O
bolus BC2GM004901699 NN O
dose BC2GM004901699 NN O
of BC2GM004901699 IN O
[ BC2GM004901699 $ O
14C BC2GM004901699 CD O
] BC2GM004901699 NNP O
HMCF BC2GM004901699 NNP O
on BC2GM004901699 IN O
day BC2GM004901699 NN O
14 BC2GM004901699 CD O
. BC2GM004901699 . O
. . O O

The BC2GM088061371 DT O
Ixodes BC2GM088061371 NNP O
fauna BC2GM088061371 NN O
in BC2GM088061371 IN O
the BC2GM088061371 DT O
Michourin BC2GM088061371 NNP O
region BC2GM088061371 NN O
, BC2GM088061371 , O
where BC2GM088061371 WRB O
the BC2GM088061371 DT O
pastures BC2GM088061371 NNS O
in BC2GM088061371 IN O
1971 BC2GM088061371 CD O
were BC2GM088061371 VBD O
grazed BC2GM088061371 VBN O
only BC2GM088061371 RB O
by BC2GM088061371 IN O
sheep BC2GM088061371 NN O
, BC2GM088061371 , O
shows BC2GM088061371 VBZ O
the BC2GM088061371 DT O
following BC2GM088061371 JJ O
trends BC2GM088061371 NNS O
: BC2GM088061371 : O
H. BC2GM088061371 NNP O
punctata BC2GM088061371 NN O
and BC2GM088061371 CC O
R. BC2GM088061371 NNP O
turanicus BC2GM088061371 NN O
ticks BC2GM088061371 NNS O
, BC2GM088061371 , O
which BC2GM088061371 WDT O
are BC2GM088061371 VBP O
preferably BC2GM088061371 RB O
parasitising BC2GM088061371 VBG O
in BC2GM088061371 IN O
sheep BC2GM088061371 NN O
, BC2GM088061371 , O
increase BC2GM088061371 VB O
their BC2GM088061371 PRP$ O
relative BC2GM088061371 JJ O
share BC2GM088061371 NN O
. BC2GM088061371 . O
. . O O

Sixtieth BC2GM012008422 NNP O
anniversary BC2GM012008422 NN O
of BC2GM012008422 IN O
Angiotensin BC2GM012008422 NNP O
. BC2GM012008422 . O
. . O O

In BC2GM011492237 IN O
the BC2GM011492237 DT O
HIV BC2GM011492237 NNP O
LTR BC2GM011492237 NNP O
, BC2GM011492237 , O
this BC2GM011492237 DT O
region BC2GM011492237 NN O
has BC2GM011492237 VBZ O
been BC2GM011492237 VBN O
demonstrated BC2GM011492237 VBN O
to BC2GM011492237 TO O
have BC2GM011492237 VB O
both BC2GM011492237 DT O
positive BC2GM011492237 JJ O
and BC2GM011492237 CC O
negative BC2GM011492237 JJ O
regulatory BC2GM011492237 JJ O
effects BC2GM011492237 NNS O
on BC2GM011492237 IN O
HIV BC2GM011492237 NNP O
gene BC2GM011492237 NN O
expression BC2GM011492237 NN O
. BC2GM011492237 . O
. . O O

A BC2GM095236565 DT O
high BC2GM095236565 JJ O
titer BC2GM095236565 NN O
of BC2GM095236565 IN O
anti-HBc BC2GM095236565 JJ O
, BC2GM095236565 , O
thus BC2GM095236565 RB O
suggested BC2GM095236565 VBN O
to BC2GM095236565 TO O
be BC2GM095236565 VB O
an BC2GM095236565 DT O
indicator BC2GM095236565 NN O
of BC2GM095236565 IN O
persistent BC2GM095236565 JJ O
hepatitis BC2GM095236565 NN O
B BC2GM095236565 NNP O
virus BC2GM095236565 NN O
infection BC2GM095236565 NN O
, BC2GM095236565 , O
was BC2GM095236565 VBD O
found BC2GM095236565 VBN O
rarely BC2GM095236565 RB O
in BC2GM095236565 IN O
seronegative BC2GM095236565 JJ O
patients BC2GM095236565 NNS O
with BC2GM095236565 IN O
chronic BC2GM095236565 JJ O
hepatitis BC2GM095236565 NN O
, BC2GM095236565 , O
non-alcoholic BC2GM095236565 JJ O
cirrhosis BC2GM095236565 NN O
, BC2GM095236565 , O
or BC2GM095236565 CC O
alcoholic BC2GM095236565 JJ O
liver BC2GM095236565 NN O
diseases BC2GM095236565 NNS O
. BC2GM095236565 . O
. . O O

Despite BC2GM056896938 IN O
the BC2GM056896938 DT O
same BC2GM056896938 JJ O
decreases BC2GM056896938 VBZ O
or BC2GM056896938 CC O
increases BC2GM056896938 VBZ O
in BC2GM056896938 IN O
MAP BC2GM056896938 NNP O
, BC2GM056896938 , O
RSNA BC2GM056896938 NNP O
was BC2GM056896938 VBD O
attenuated BC2GM056896938 VBN O
after BC2GM056896938 IN O
15 BC2GM056896938 CD O
and BC2GM056896938 CC O
30 BC2GM056896938 CD O
min BC2GM056896938 NN O
of BC2GM056896938 IN O
propofol BC2GM056896938 JJ O
infusion BC2GM056896938 NN O
in BC2GM056896938 IN O
both BC2GM056896938 DT O
groups BC2GM056896938 NNS O
compared BC2GM056896938 VBN O
with BC2GM056896938 IN O
control BC2GM056896938 NN O
( BC2GM056896938 ( O
P BC2GM056896938 NNP O
< BC2GM056896938 NNP O
0.05 BC2GM056896938 CD O
) BC2GM056896938 ) O
. BC2GM056896938 . O
. . O O

CONCLUSION BC2GM020930043 NN O
: BC2GM020930043 : O
Ultrasound BC2GM020930043 NN O
biomicroscopy BC2GM020930043 NN O
is BC2GM020930043 VBZ O
a BC2GM020930043 DT O
useful BC2GM020930043 JJ O
tool BC2GM020930043 NN O
for BC2GM020930043 IN O
the BC2GM020930043 DT O
evaluation BC2GM020930043 NN O
of BC2GM020930043 IN O
APVR BC2GM020930043 NNP O
, BC2GM020930043 , O
which BC2GM020930043 WDT O
is BC2GM020930043 VBZ O
difficult BC2GM020930043 JJ O
by BC2GM020930043 IN O
ordinary BC2GM020930043 JJ O
methods BC2GM020930043 NNS O
. BC2GM020930043 . O
. . O O

Transfer BC2GM090485804 NN O
of BC2GM090485804 IN O
health BC2GM090485804 NN O
care BC2GM090485804 NN O
to BC2GM090485804 TO O
natives BC2GM090485804 VB O
holds BC2GM090485804 VBZ O
much BC2GM090485804 RB O
promise BC2GM090485804 NN O
, BC2GM090485804 , O
lecturers BC2GM090485804 NNS O
say BC2GM090485804 VBP O
. BC2GM090485804 . O
. . O O

An BC2GM060767735 DT O
hcr1 BC2GM060767735 NN O
null BC2GM060767735 NN O
mutant BC2GM060767735 NN O
was BC2GM060767735 VBD O
viable BC2GM060767735 JJ O
, BC2GM060767735 , O
but BC2GM060767735 CC O
showed BC2GM060767735 VBD O
slight BC2GM060767735 JJ O
reduction BC2GM060767735 NN O
of BC2GM060767735 IN O
growth BC2GM060767735 NN O
when BC2GM060767735 WRB O
compared BC2GM060767735 VBN O
with BC2GM060767735 IN O
the BC2GM060767735 DT O
wild-type BC2GM060767735 JJ O
strain BC2GM060767735 NN O
. BC2GM060767735 . O
. . O O

The BC2GM040518813 DT O
Ick BC2GM040518813 NNP O
protein BC2GM040518813 NN O
tyrosine BC2GM040518813 NN O
kinase BC2GM040518813 NN O
is BC2GM040518813 VBZ O
not BC2GM040518813 RB O
involved BC2GM040518813 VBN O
in BC2GM040518813 IN O
antibody-mediated BC2GM040518813 JJ O
CD4 BC2GM040518813 NNP O
( BC2GM040518813 ( O
CDR3-loop BC2GM040518813 NNP O
) BC2GM040518813 ) O
signal BC2GM040518813 NN O
transduction BC2GM040518813 NN O
that BC2GM040518813 IN O
inhibits BC2GM040518813 VBZ O
HIV-1 BC2GM040518813 NNP O
transcription BC2GM040518813 NN O
. BC2GM040518813 . O
. . O O

At BC2GM056070197 IN O
1 BC2GM056070197 CD O
min BC2GM056070197 NN O
postalfentanil BC2GM056070197 NN O
, BC2GM056070197 , O
N2O BC2GM056070197 NNP O
caused BC2GM056070197 VBD O
significantly BC2GM056070197 RB O
more BC2GM056070197 JJR O
rigidity BC2GM056070197 NN O
than BC2GM056070197 IN O
100 BC2GM056070197 CD O
% BC2GM056070197 NN O
O2 BC2GM056070197 NNP O
( BC2GM056070197 ( O
p BC2GM056070197 JJ O
< BC2GM056070197 NNP O
0.001 BC2GM056070197 CD O
) BC2GM056070197 ) O
. BC2GM056070197 . O
. . O O

Parelaphostrongylus BC2GM010819774 NNP O
odocoilei BC2GM010819774 PRP O
is BC2GM010819774 VBZ O
redescribed BC2GM010819774 VBN O
from BC2GM010819774 IN O
worms BC2GM010819774 NNS O
collected BC2GM010819774 VBN O
from BC2GM010819774 IN O
the BC2GM010819774 DT O
type BC2GM010819774 NN O
host BC2GM010819774 NN O
( BC2GM010819774 ( O
Odocoileus BC2GM010819774 NNP O
hemionus BC2GM010819774 NNP O
columbianus BC2GM010819774 NN O
) BC2GM010819774 ) O
in BC2GM010819774 IN O
California BC2GM010819774 NNP O
, BC2GM010819774 , O
as BC2GM010819774 RB O
well BC2GM010819774 RB O
as BC2GM010819774 IN O
material BC2GM010819774 NN O
from BC2GM010819774 IN O
experimentally BC2GM010819774 RB O
infected BC2GM010819774 VBN O
mule BC2GM010819774 NN O
deer BC2GM010819774 NN O
( BC2GM010819774 ( O
O. BC2GM010819774 NNP O
h. BC2GM010819774 NNP O
heminus BC2GM010819774 NN O
) BC2GM010819774 ) O
in BC2GM010819774 IN O
Alberta BC2GM010819774 NNP O
. BC2GM010819774 . O
. . O O

The BC2GM062891050 DT O
5 BC2GM062891050 CD O
' BC2GM062891050 POS O
half BC2GM062891050 NN O
of BC2GM062891050 IN O
the BC2GM062891050 DT O
EWS BC2GM062891050 NNP O
gene BC2GM062891050 NN O
has BC2GM062891050 VBZ O
recently BC2GM062891050 RB O
been BC2GM062891050 VBN O
described BC2GM062891050 VBN O
to BC2GM062891050 TO O
be BC2GM062891050 VB O
fused BC2GM062891050 VBN O
to BC2GM062891050 TO O
the BC2GM062891050 DT O
3 BC2GM062891050 CD O
' BC2GM062891050 POS O
regions BC2GM062891050 NNS O
of BC2GM062891050 IN O
genes BC2GM062891050 NNS O
encoding BC2GM062891050 VBG O
the BC2GM062891050 DT O
DNA-binding BC2GM062891050 NNP O
domain BC2GM062891050 NN O
of BC2GM062891050 IN O
several BC2GM062891050 JJ O
transcriptional BC2GM062891050 JJ O
regulators BC2GM062891050 NNS O
, BC2GM062891050 , O
including BC2GM062891050 VBG O
ATF1 BC2GM062891050 NNP O
, BC2GM062891050 , O
FLI-1 BC2GM062891050 NNP O
, BC2GM062891050 , O
and BC2GM062891050 CC O
ERG BC2GM062891050 NNP O
, BC2GM062891050 , O
in BC2GM062891050 IN O
several BC2GM062891050 JJ O
human BC2GM062891050 JJ O
tumors BC2GM062891050 NNS O
. BC2GM062891050 . O
. . O O

Here BC2GM081758402 RB O
, BC2GM081758402 , O
we BC2GM081758402 PRP O
provide BC2GM081758402 VBP O
direct BC2GM081758402 JJ O
evidence BC2GM081758402 NN O
that BC2GM081758402 IN O
the BC2GM081758402 DT O
meiotic BC2GM081758402 JJ O
defect BC2GM081758402 NN O
caused BC2GM081758402 VBN O
by BC2GM081758402 IN O
either BC2GM081758402 DT O
unregulated BC2GM081758402 JJ O
cAPK BC2GM081758402 NN O
activity BC2GM081758402 NN O
or BC2GM081758402 CC O
unregulated BC2GM081758402 JJ O
ran1+ BC2GM081758402 JJ O
kinase BC2GM081758402 NN O
activity BC2GM081758402 NN O
is BC2GM081758402 VBZ O
due BC2GM081758402 JJ O
to BC2GM081758402 TO O
inability BC2GM081758402 NN O
to BC2GM081758402 TO O
induce BC2GM081758402 VB O
transcription BC2GM081758402 NN O
of BC2GM081758402 IN O
the BC2GM081758402 DT O
mei2+ BC2GM081758402 NN O
gene BC2GM081758402 NN O
, BC2GM081758402 , O
which BC2GM081758402 WDT O
is BC2GM081758402 VBZ O
required BC2GM081758402 VBN O
for BC2GM081758402 IN O
meiotic BC2GM081758402 JJ O
initiation BC2GM081758402 NN O
. BC2GM081758402 . O
. . O O

We BC2GM014154951 PRP O
found BC2GM014154951 VBD O
that BC2GM014154951 IN O
the BC2GM014154951 DT O
frequency BC2GM014154951 NN O
spectrum BC2GM014154951 NN O
of BC2GM014154951 IN O
physiologic BC2GM014154951 JJ O
chest BC2GM014154951 JJS O
sounds BC2GM014154951 NNS O
is BC2GM014154951 VBZ O
contained BC2GM014154951 VBN O
entirely BC2GM014154951 RB O
within BC2GM014154951 IN O
that BC2GM014154951 DT O
of BC2GM014154951 IN O
jet BC2GM014154951 NN O
rotocraft BC2GM014154951 NN O
noise BC2GM014154951 NN O
. BC2GM014154951 . O
. . O O

The BC2GM033802791 DT O
Giessener BC2GM033802791 NNP O
Tumordokumentationssystem BC2GM033802791 NNP O
( BC2GM033802791 ( O
GTDS BC2GM033802791 NNP O
) BC2GM033802791 ) O
is BC2GM033802791 VBZ O
such BC2GM033802791 JJ O
a BC2GM033802791 DT O
disease BC2GM033802791 NN O
specific BC2GM033802791 JJ O
system BC2GM033802791 NN O
. BC2GM033802791 . O
. . O O

After BC2GM021619038 IN O
15 BC2GM021619038 CD O
min BC2GM021619038 NN O
of BC2GM021619038 IN O
hemorrhage BC2GM021619038 NN O
the BC2GM021619038 DT O
cardiovascular BC2GM021619038 JJ O
parameters BC2GM021619038 NNS O
were BC2GM021619038 VBD O
the BC2GM021619038 DT O
same BC2GM021619038 JJ O
in BC2GM021619038 IN O
fed BC2GM021619038 NN O
and BC2GM021619038 CC O
starved BC2GM021619038 VBD O
animals BC2GM021619038 NNS O
, BC2GM021619038 , O
but BC2GM021619038 CC O
at BC2GM021619038 IN O
45 BC2GM021619038 CD O
min BC2GM021619038 NNS O
striking BC2GM021619038 VBG O
differences BC2GM021619038 NNS O
were BC2GM021619038 VBD O
observed BC2GM021619038 VBN O
. BC2GM021619038 . O
. . O O

The BC2GM089434490 DT O
SEC27 BC2GM089434490 NNP O
gene BC2GM089434490 NN O
was BC2GM089434490 VBD O
cloned BC2GM089434490 VBN O
, BC2GM089434490 , O
and BC2GM089434490 CC O
the BC2GM089434490 DT O
sequence BC2GM089434490 NN O
predicts BC2GM089434490 VBZ O
a BC2GM089434490 DT O
99.4-kDa BC2GM089434490 JJ O
protein BC2GM089434490 NN O
with BC2GM089434490 IN O
45 BC2GM089434490 CD O
% BC2GM089434490 NN O
sequence BC2GM089434490 NN O
identity BC2GM089434490 NN O
to BC2GM089434490 TO O
mammalian BC2GM089434490 JJ O
beta'-COP BC2GM089434490 NN O
. BC2GM089434490 . O
. . O O

Tre BC2GM047781094 NNP O
during BC2GM047781094 IN O
exercise BC2GM047781094 NN O
at BC2GM047781094 IN O
35 BC2GM047781094 CD O
W BC2GM047781094 NNP O
at BC2GM047781094 IN O
23 BC2GM047781094 CD O
degrees BC2GM047781094 NNS O
C BC2GM047781094 NNP O
correlated BC2GM047781094 VBD O
r BC2GM047781094 NN O
= BC2GM047781094 NNP O
-70 BC2GM047781094 NN O
with BC2GM047781094 IN O
Vo2max BC2GM047781094 NNP O
and BC2GM047781094 CC O
r BC2GM047781094 VB O
= BC2GM047781094 JJ O
0.80 BC2GM047781094 CD O
with BC2GM047781094 IN O
Tre BC2GM047781094 NNP O
during BC2GM047781094 IN O
exercise BC2GM047781094 NN O
in BC2GM047781094 IN O
heat BC2GM047781094 NN O
. BC2GM047781094 . O
. . O O

First BC2GM092196424 NNP O
aid BC2GM092196424 NN O
. BC2GM092196424 . O
. . O O

IENF BC2GM009453021 NNP O
density BC2GM009453021 NN O
at BC2GM009453021 IN O
the BC2GM009453021 DT O
calf BC2GM009453021 NN O
was BC2GM009453021 VBD O
lower BC2GM009453021 JJR O
than BC2GM009453021 IN O
that BC2GM009453021 DT O
obtained BC2GM009453021 VBN O
from BC2GM009453021 IN O
skin BC2GM009453021 NN O
at BC2GM009453021 IN O
more BC2GM009453021 RBR O
proximal BC2GM009453021 JJ O
sites BC2GM009453021 NNS O
, BC2GM009453021 , O
indicating BC2GM009453021 VBG O
the BC2GM009453021 DT O
length BC2GM009453021 NN O
dependency BC2GM009453021 NN O
of BC2GM009453021 IN O
small-fiber BC2GM009453021 JJ O
loss BC2GM009453021 NN O
in BC2GM009453021 IN O
these BC2GM009453021 DT O
neuropathies BC2GM009453021 NNS O
. BC2GM009453021 . O
. . O O

METHODS BC2GM069895813 NNS O
: BC2GM069895813 : O
Levels BC2GM069895813 NNS O
of BC2GM069895813 IN O
sIL-2R BC2GM069895813 NN O
were BC2GM069895813 VBD O
measured BC2GM069895813 VBN O
simultaneously BC2GM069895813 RB O
in BC2GM069895813 IN O
plasma BC2GM069895813 NN O
and BC2GM069895813 CC O
pleural BC2GM069895813 JJ O
fluid BC2GM069895813 NN O
in BC2GM069895813 IN O
111 BC2GM069895813 CD O
patients BC2GM069895813 NNS O
with BC2GM069895813 IN O
pleural BC2GM069895813 JJ O
effusions BC2GM069895813 NNS O
of BC2GM069895813 IN O
unknown BC2GM069895813 JJ O
causes BC2GM069895813 NNS O
. BC2GM069895813 . O
. . O O

The BC2GM045577252 DT O
reconstituted BC2GM045577252 JJ O
enzyme BC2GM045577252 NN O
binds BC2GM045577252 NNS O
DNA BC2GM045577252 NNP O
with BC2GM045577252 IN O
an BC2GM045577252 DT O
affinity BC2GM045577252 NN O
that BC2GM045577252 WDT O
is BC2GM045577252 VBZ O
approximately BC2GM045577252 RB O
20-fold BC2GM045577252 JJ O
lower BC2GM045577252 JJR O
than BC2GM045577252 IN O
that BC2GM045577252 DT O
of BC2GM045577252 IN O
the BC2GM045577252 DT O
intact BC2GM045577252 JJ O
topo70 BC2GM045577252 NN O
. BC2GM045577252 . O
. . O O

Control BC2GM086016998 NNP O
oligomers BC2GM086016998 NNS O
of BC2GM086016998 IN O
scrambled BC2GM086016998 JJ O
sequence BC2GM086016998 NN O
but BC2GM086016998 CC O
identical BC2GM086016998 JJ O
base BC2GM086016998 NN O
composition BC2GM086016998 NN O
were BC2GM086016998 VBD O
ineffective BC2GM086016998 JJ O
, BC2GM086016998 , O
and BC2GM086016998 CC O
no BC2GM086016998 DT O
TFO-induced BC2GM086016998 NNP O
recombination BC2GM086016998 NN O
was BC2GM086016998 VBD O
seen BC2GM086016998 VBN O
in BC2GM086016998 IN O
a BC2GM086016998 DT O
control BC2GM086016998 NN O
LTK BC2GM086016998 NNP O
( BC2GM086016998 ( O
- BC2GM086016998 : O
) BC2GM086016998 ) O
cell BC2GM086016998 NN O
line BC2GM086016998 NN O
carrying BC2GM086016998 VBG O
an BC2GM086016998 DT O
otherwise BC2GM086016998 RB O
identical BC2GM086016998 JJ O
dual BC2GM086016998 JJ O
TK BC2GM086016998 NNP O
gene BC2GM086016998 NN O
construct BC2GM086016998 NN O
lacking BC2GM086016998 VBG O
the BC2GM086016998 DT O
30-bp BC2GM086016998 JJ O
polypurine BC2GM086016998 NN O
target BC2GM086016998 NN O
site BC2GM086016998 NN O
. BC2GM086016998 . O
. . O O

We BC2GM022990188 PRP O
describe BC2GM022990188 VBP O
a BC2GM022990188 DT O
novel BC2GM022990188 JJ O
stat-related BC2GM022990188 JJ O
factor BC2GM022990188 NN O
, BC2GM022990188 , O
p93 BC2GM022990188 NN O
, BC2GM022990188 , O
that BC2GM022990188 WDT O
is BC2GM022990188 VBZ O
found BC2GM022990188 VBN O
in BC2GM022990188 IN O
EGF-treated BC2GM022990188 JJ O
A431 BC2GM022990188 NNP O
cell BC2GM022990188 NN O
extracts BC2GM022990188 NNS O
but BC2GM022990188 CC O
appears BC2GM022990188 VBZ O
to BC2GM022990188 TO O
be BC2GM022990188 VB O
absent BC2GM022990188 JJ O
in BC2GM022990188 IN O
bovine BC2GM022990188 NN O
fibroblast BC2GM022990188 NN O
growth BC2GM022990188 NN O
factor BC2GM022990188 NN O
( BC2GM022990188 ( O
bFGF BC2GM022990188 NN O
) BC2GM022990188 ) O
, BC2GM022990188 , O
IFN-gamma BC2GM022990188 NNP O
, BC2GM022990188 , O
tumor BC2GM022990188 NN O
necrosis BC2GM022990188 NN O
factor-alpha BC2GM022990188 JJ O
( BC2GM022990188 ( O
TNF-alpha BC2GM022990188 NNP O
) BC2GM022990188 ) O
, BC2GM022990188 , O
and BC2GM022990188 CC O
untreated BC2GM022990188 JJ O
cells BC2GM022990188 NNS O
. BC2GM022990188 . O
p93 BC2GM022990188 NN O
appears BC2GM022990188 VBZ O
to BC2GM022990188 TO O
be BC2GM022990188 VB O
antigenically BC2GM022990188 RB O
related BC2GM022990188 VBN O
to BC2GM022990188 TO O
stat91 BC2GM022990188 VB O
. BC2GM022990188 . O
p185c-neu+ BC2GM022990188 NN O
, BC2GM022990188 , O
EGFr+ BC2GM022990188 NNP O
( BC2GM022990188 ( O
M1 BC2GM022990188 NNP O
) BC2GM022990188 ) O
, BC2GM022990188 , O
and BC2GM022990188 CC O
p185c-neu- BC2GM022990188 JJ O
kinase BC2GM022990188 NN O
inactive BC2GM022990188 NN O
, BC2GM022990188 , O
EGFr+ BC2GM022990188 NNP O
( BC2GM022990188 ( O
NEN757 BC2GM022990188 NNP O
) BC2GM022990188 ) O
expressing BC2GM022990188 VBG O
cells BC2GM022990188 NNS O
undergo BC2GM022990188 JJ O
different BC2GM022990188 JJ O
mitotic BC2GM022990188 JJ O
responses BC2GM022990188 NNS O
to BC2GM022990188 TO O
EGF BC2GM022990188 NNP O
. BC2GM022990188 . O
. . O O

Although BC2GM070189689 IN O
cardiac BC2GM070189689 JJ O
output BC2GM070189689 NN O
decreased BC2GM070189689 VBD O
slightly BC2GM070189689 RB O
with BC2GM070189689 IN O
PCF BC2GM070189689 NNP O
, BC2GM070189689 , O
hemodynamic BC2GM070189689 JJ O
changes BC2GM070189689 NNS O
due BC2GM070189689 JJ O
to BC2GM070189689 TO O
PCF BC2GM070189689 NNP O
were BC2GM070189689 VBD O
unlikely BC2GM070189689 JJ O
to BC2GM070189689 TO O
account BC2GM070189689 VB O
for BC2GM070189689 IN O
the BC2GM070189689 DT O
observed BC2GM070189689 JJ O
fall BC2GM070189689 NN O
in BC2GM070189689 IN O
PaO2 BC2GM070189689 NNP O
. BC2GM070189689 . O
. . O O

Three BC2GM060327510 CD O
patients BC2GM060327510 NNS O
with BC2GM060327510 IN O
Mirizzi BC2GM060327510 NNP O
type BC2GM060327510 NN O
II BC2GM060327510 NNP O
syndrome BC2GM060327510 NN O
and BC2GM060327510 CC O
two BC2GM060327510 CD O
patients BC2GM060327510 NNS O
with BC2GM060327510 IN O
Mirizzi BC2GM060327510 NNP O
type BC2GM060327510 NN O
I BC2GM060327510 PRP O
syndrome BC2GM060327510 VBP O
were BC2GM060327510 VBD O
treated BC2GM060327510 VBN O
laparoscopically BC2GM060327510 RB O
. BC2GM060327510 . O
. . O O

In BC2GM033841968 IN O
humans BC2GM033841968 NNS O
, BC2GM033841968 , O
there BC2GM033841968 EX O
was BC2GM033841968 VBD O
a BC2GM033841968 DT O
statistically BC2GM033841968 RB O
significant BC2GM033841968 JJ O
decrease BC2GM033841968 NN O
of BC2GM033841968 IN O
TEWL BC2GM033841968 NNP O
on BC2GM033841968 IN O
both BC2GM033841968 DT O
forearm BC2GM033841968 NN O
and BC2GM033841968 CC O
thigh BC2GM033841968 NN O
in BC2GM033841968 IN O
CS-treated BC2GM033841968 JJ O
patients BC2GM033841968 NNS O
compared BC2GM033841968 VBN O
to BC2GM033841968 TO O
non-CS-treated BC2GM033841968 JJ O
patients BC2GM033841968 NNS O
and BC2GM033841968 CC O
controls BC2GM033841968 NNS O
( BC2GM033841968 ( O
p BC2GM033841968 NN O
less BC2GM033841968 JJR O
than BC2GM033841968 IN O
0.05 BC2GM033841968 CD O
) BC2GM033841968 ) O
. BC2GM033841968 . O
. . O O

Octamer BC2GM064636435 NNP O
recognition BC2GM064636435 NN O
is BC2GM064636435 VBZ O
mediated BC2GM064636435 VBN O
by BC2GM064636435 IN O
the BC2GM064636435 DT O
POU BC2GM064636435 NNP O
domain BC2GM064636435 NN O
, BC2GM064636435 , O
a BC2GM064636435 DT O
conserved BC2GM064636435 JJ O
structural BC2GM064636435 JJ O
motif BC2GM064636435 NN O
which BC2GM064636435 WDT O
-- BC2GM064636435 : O
like BC2GM064636435 IN O
the BC2GM064636435 DT O
zinc BC2GM064636435 NN O
finger BC2GM064636435 NN O
and BC2GM064636435 CC O
leucine BC2GM064636435 JJ O
zipper BC2GM064636435 NN O
-- BC2GM064636435 : O
defines BC2GM064636435 VBZ O
a BC2GM064636435 DT O
family BC2GM064636435 NN O
of BC2GM064636435 IN O
related BC2GM064636435 JJ O
transcription BC2GM064636435 NN O
factors BC2GM064636435 NNS O
. BC2GM064636435 . O
. . O O

Although BC2GM047756282 IN O
indomethacin BC2GM047756282 NN O
is BC2GM047756282 VBZ O
useful BC2GM047756282 JJ O
for BC2GM047756282 IN O
examining BC2GM047756282 VBG O
the BC2GM047756282 DT O
role BC2GM047756282 NN O
of BC2GM047756282 IN O
cyclooxygenase BC2GM047756282 NN O
products BC2GM047756282 NNS O
in BC2GM047756282 IN O
asthmatic BC2GM047756282 JJ O
responses BC2GM047756282 NNS O
, BC2GM047756282 , O
it BC2GM047756282 PRP O
should BC2GM047756282 MD O
not BC2GM047756282 RB O
be BC2GM047756282 VB O
considered BC2GM047756282 VBN O
in BC2GM047756282 IN O
the BC2GM047756282 DT O
treatment BC2GM047756282 NN O
of BC2GM047756282 IN O
asthma BC2GM047756282 NN O
. BC2GM047756282 . O
. . O O

Kerstin BC2GM043523673 NNP O
takes BC2GM043523673 VBZ O
the BC2GM043523673 DT O
abbreviated BC2GM043523673 JJ O
medical BC2GM043523673 JJ O
education BC2GM043523673 NN O
. BC2GM043523673 . O
. . O O

The BC2GM039301722 DT O
response BC2GM039301722 NN O
sequences BC2GM039301722 NNS O
were BC2GM039301722 VBD O
localized BC2GM039301722 VBN O
between BC2GM039301722 IN O
-67 BC2GM039301722 NNP O
and BC2GM039301722 CC O
+30 BC2GM039301722 NNP O
in BC2GM039301722 IN O
the BC2GM039301722 DT O
simian BC2GM039301722 JJ O
cytomegalovirus BC2GM039301722 NN O
IE94 BC2GM039301722 NNP O
promoter BC2GM039301722 NN O
and BC2GM039301722 CC O
upstream BC2GM039301722 NN O
of BC2GM039301722 IN O
position BC2GM039301722 NN O
+9 BC2GM039301722 NN O
in BC2GM039301722 IN O
the BC2GM039301722 DT O
HCMV BC2GM039301722 NNP O
IE68 BC2GM039301722 NNP O
promoter BC2GM039301722 NN O
. BC2GM039301722 . O
. . O O

Upstream BC2GM062194979 NNP O
stimulatory BC2GM062194979 NN O
factor BC2GM062194979 NN O
USF BC2GM062194979 NNP O
is BC2GM062194979 VBZ O
a BC2GM062194979 DT O
human BC2GM062194979 JJ O
transcriptional BC2GM062194979 JJ O
activation BC2GM062194979 NN O
factor BC2GM062194979 NN O
, BC2GM062194979 , O
which BC2GM062194979 WDT O
uses BC2GM062194979 VBZ O
a BC2GM062194979 DT O
basic BC2GM062194979 JJ O
/ BC2GM062194979 JJ O
helix-loop-helix BC2GM062194979 NN O
/ BC2GM062194979 NNP O
leucin BC2GM062194979 VBZ O
zipper BC2GM062194979 NNP O
( BC2GM062194979 ( O
b BC2GM062194979 SYM O
/ BC2GM062194979 NNP O
HLH BC2GM062194979 NNP O
/ BC2GM062194979 NNP O
Z BC2GM062194979 NNP O
) BC2GM062194979 ) O
motif BC2GM062194979 NN O
to BC2GM062194979 TO O
homodimerize BC2GM062194979 VB O
and BC2GM062194979 CC O
recognize BC2GM062194979 VB O
specific BC2GM062194979 JJ O
sequences BC2GM062194979 NNS O
in BC2GM062194979 IN O
the BC2GM062194979 DT O
promoter BC2GM062194979 NN O
region BC2GM062194979 NN O
of BC2GM062194979 IN O
both BC2GM062194979 DT O
nuclear BC2GM062194979 JJ O
and BC2GM062194979 CC O
viral BC2GM062194979 JJ O
genes BC2GM062194979 NNS O
transcribed BC2GM062194979 VBN O
by BC2GM062194979 IN O
RNA BC2GM062194979 NNP O
polymerase BC2GM062194979 NN O
II BC2GM062194979 NNP O
. BC2GM062194979 . O
. . O O

Thus BC2GM069413294 RB O
, BC2GM069413294 , O
apoptosis BC2GM069413294 NN O
in BC2GM069413294 IN O
hematopoietic BC2GM069413294 JJ O
cells BC2GM069413294 NNS O
is BC2GM069413294 VBZ O
the BC2GM069413294 DT O
end BC2GM069413294 NN O
result BC2GM069413294 NN O
of BC2GM069413294 IN O
a BC2GM069413294 DT O
conflict BC2GM069413294 NN O
between BC2GM069413294 IN O
death BC2GM069413294 NN O
and BC2GM069413294 CC O
survival BC2GM069413294 NN O
signals BC2GM069413294 NNS O
, BC2GM069413294 , O
rather BC2GM069413294 RB O
than BC2GM069413294 IN O
a BC2GM069413294 DT O
simple BC2GM069413294 JJ O
death BC2GM069413294 NN O
by BC2GM069413294 IN O
default BC2GM069413294 NN O
. BC2GM069413294 . O
. . O O

The BC2GM040660386 DT O
transcriptional BC2GM040660386 JJ O
initiation BC2GM040660386 NN O
site BC2GM040660386 NN O
of BC2GM040660386 IN O
RAG1 BC2GM040660386 NNP O
was BC2GM040660386 VBD O
localized BC2GM040660386 VBN O
at BC2GM040660386 IN O
A BC2GM040660386 NNP O
, BC2GM040660386 , O
26 BC2GM040660386 CD O
bp BC2GM040660386 NN O
upstream BC2GM040660386 NN O
of BC2GM040660386 IN O
the BC2GM040660386 DT O
putative BC2GM040660386 JJ O
translational BC2GM040660386 JJ O
initiation BC2GM040660386 NN O
codon BC2GM040660386 NN O
, BC2GM040660386 , O
ATG BC2GM040660386 NNP O
, BC2GM040660386 , O
by BC2GM040660386 IN O
the BC2GM040660386 DT O
primer BC2GM040660386 NN O
extension BC2GM040660386 NN O
assay BC2GM040660386 NN O
. BC2GM040660386 . O
. . O O

We BC2GM002874950 PRP O
demonstrate BC2GM002874950 VBP O
that BC2GM002874950 IN O
the BC2GM002874950 DT O
WRM-1 BC2GM002874950 NNP O
protein BC2GM002874950 NN O
binds BC2GM002874950 VBZ O
to BC2GM002874950 TO O
LIT-1 BC2GM002874950 NNP O
in BC2GM002874950 IN O
vivo BC2GM002874950 NN O
and BC2GM002874950 CC O
that BC2GM002874950 IN O
WRM-1 BC2GM002874950 NNP O
can BC2GM002874950 MD O
activate BC2GM002874950 VB O
the BC2GM002874950 DT O
LIT-1 BC2GM002874950 NNP O
protein BC2GM002874950 NN O
kinase BC2GM002874950 NN O
when BC2GM002874950 WRB O
coexpressed BC2GM002874950 VBN O
in BC2GM002874950 IN O
vertebrate BC2GM002874950 JJ O
tissue BC2GM002874950 NN O
culture BC2GM002874950 NN O
cells BC2GM002874950 NNS O
. BC2GM002874950 . O
. . O O

The BC2GM079401550 DT O
Brassica BC2GM079401550 NNP O
BTH1 BC2GM079401550 NNP O
gene BC2GM079401550 NN O
may BC2GM079401550 MD O
correspond BC2GM079401550 VB O
to BC2GM079401550 TO O
the BC2GM079401550 DT O
Arabidopsis BC2GM079401550 NNP O
TH-1 BC2GM079401550 NNP O
gene BC2GM079401550 NN O
. BC2GM079401550 . O
. . O O

These BC2GM097347861 DT O
results BC2GM097347861 NNS O
indicate BC2GM097347861 VBP O
that BC2GM097347861 IN O
( BC2GM097347861 ( O
1 BC2GM097347861 CD O
) BC2GM097347861 ) O
RXR-TR BC2GM097347861 NN O
heterodimers BC2GM097347861 NNS O
play BC2GM097347861 VBP O
a BC2GM097347861 DT O
role BC2GM097347861 NN O
in BC2GM097347861 IN O
basal BC2GM097347861 JJ O
transactivation BC2GM097347861 NN O
and BC2GM097347861 CC O
T3 BC2GM097347861 NNP O
suppression BC2GM097347861 NN O
of BC2GM097347861 IN O
negatively BC2GM097347861 RB O
regulated BC2GM097347861 VBN O
genes BC2GM097347861 NNS O
, BC2GM097347861 , O
and BC2GM097347861 CC O
( BC2GM097347861 ( O
2 BC2GM097347861 CD O
) BC2GM097347861 ) O
RXRs BC2GM097347861 NNP O
increase BC2GM097347861 VB O
the BC2GM097347861 DT O
dominant BC2GM097347861 JJ O
negative BC2GM097347861 JJ O
effect BC2GM097347861 NN O
of BC2GM097347861 IN O
some BC2GM097347861 DT O
mutant BC2GM097347861 JJ O
TRs BC2GM097347861 NNP O
on BC2GM097347861 IN O
specific BC2GM097347861 JJ O
negative BC2GM097347861 JJ O
TREs BC2GM097347861 NNP O
. BC2GM097347861 . O
. . O O

It BC2GM093402905 PRP O
is BC2GM093402905 VBZ O
suggested BC2GM093402905 VBN O
that BC2GM093402905 IN O
the BC2GM093402905 DT O
loss BC2GM093402905 NN O
of BC2GM093402905 IN O
weight BC2GM093402905 NN O
, BC2GM093402905 , O
the BC2GM093402905 DT O
decrease BC2GM093402905 NN O
in BC2GM093402905 IN O
food BC2GM093402905 NN O
intake BC2GM093402905 NN O
and BC2GM093402905 CC O
the BC2GM093402905 DT O
increase BC2GM093402905 NN O
in BC2GM093402905 IN O
brain BC2GM093402905 NN O
MOPEG-SO4 BC2GM093402905 NNP O
induced BC2GM093402905 VBN O
by BC2GM093402905 IN O
cyanamide BC2GM093402905 NN O
reflect BC2GM093402905 NN O
possible BC2GM093402905 JJ O
anorectic BC2GM093402905 JJ O
properties BC2GM093402905 NNS O
of BC2GM093402905 IN O
the BC2GM093402905 DT O
drug BC2GM093402905 NN O
. BC2GM093402905 . O
. . O O

Like BC2GM093717157 IN O
the BC2GM093717157 DT O
nuclear BC2GM093717157 JJ O
envelope BC2GM093717157 NN O
, BC2GM093717157 , O
the BC2GM093717157 DT O
intranuclear BC2GM093717157 JJ O
double BC2GM093717157 JJ O
membrane BC2GM093717157 NN O
lamellae BC2GM093717157 NN O
enclosed BC2GM093717157 VBD O
a BC2GM093717157 DT O
defined BC2GM093717157 JJ O
cisterna BC2GM093717157 NN O
that BC2GM093717157 WDT O
was BC2GM093717157 VBD O
interrupted BC2GM093717157 VBN O
by BC2GM093717157 IN O
pores BC2GM093717157 NNS O
but BC2GM093717157 CC O
, BC2GM093717157 , O
unlike BC2GM093717157 IN O
the BC2GM093717157 DT O
nuclear BC2GM093717157 JJ O
envelope BC2GM093717157 NN O
pores BC2GM093717157 NNS O
, BC2GM093717157 , O
they BC2GM093717157 PRP O
lacked BC2GM093717157 VBD O
NPCs BC2GM093717157 NNP O
. BC2GM093717157 . O
. . O O

A BC2GM078212435 DT O
search BC2GM078212435 NN O
was BC2GM078212435 VBD O
conducted BC2GM078212435 VBN O
for BC2GM078212435 IN O
suppressors BC2GM078212435 NNS O
of BC2GM078212435 IN O
the BC2GM078212435 DT O
inositol BC2GM078212435 NN O
auxotrophic BC2GM078212435 JJ O
phenotype BC2GM078212435 NN O
of BC2GM078212435 IN O
the BC2GM078212435 DT O
ino4-8 BC2GM078212435 JJ O
mutant BC2GM078212435 NN O
of BC2GM078212435 IN O
yeast BC2GM078212435 NN O
. BC2GM078212435 . O
. . O O

The BC2GM007534249 DT O
effect BC2GM007534249 NN O
of BC2GM007534249 IN O
stimulation BC2GM007534249 NN O
of BC2GM007534249 IN O
the BC2GM007534249 DT O
entopeduncular BC2GM007534249 JJ O
nucleus BC2GM007534249 NN O
( BC2GM007534249 ( O
EP BC2GM007534249 NNP O
) BC2GM007534249 ) O
on BC2GM007534249 IN O
the BC2GM007534249 DT O
jaw-opening BC2GM007534249 NN O
reflex BC2GM007534249 NN O
( BC2GM007534249 ( O
JOR BC2GM007534249 NNP O
) BC2GM007534249 ) O
was BC2GM007534249 VBD O
studied BC2GM007534249 VBN O
in BC2GM007534249 IN O
the BC2GM007534249 DT O
cat BC2GM007534249 NN O
anesthetized BC2GM007534249 VBN O
with BC2GM007534249 IN O
sodium BC2GM007534249 NN O
pentobarbital BC2GM007534249 NN O
. BC2GM007534249 . O
. . O O

Myocardial BC2GM096046498 JJ O
technetium-99m-teboroxime BC2GM096046498 JJ O
uptake BC2GM096046498 NN O
during BC2GM096046498 IN O
adenosine-induced BC2GM096046498 JJ O
hyperemia BC2GM096046498 NN O
in BC2GM096046498 IN O
dogs BC2GM096046498 NNS O
with BC2GM096046498 IN O
either BC2GM096046498 DT O
a BC2GM096046498 DT O
critical BC2GM096046498 JJ O
or BC2GM096046498 CC O
mild BC2GM096046498 JJ O
coronary BC2GM096046498 JJ O
stenosis BC2GM096046498 NN O
: BC2GM096046498 : O
comparison BC2GM096046498 NN O
to BC2GM096046498 TO O
thallium-201 BC2GM096046498 JJ O
and BC2GM096046498 CC O
regional BC2GM096046498 JJ O
blood BC2GM096046498 NN O
flow BC2GM096046498 NN O
. BC2GM096046498 . O
. . O O

Indeed BC2GM088701024 RB O
, BC2GM088701024 , O
after BC2GM088701024 IN O
a BC2GM088701024 DT O
single BC2GM088701024 JJ O
oral BC2GM088701024 JJ O
dose BC2GM088701024 NN O
, BC2GM088701024 , O
the BC2GM088701024 DT O
role BC2GM088701024 NN O
of BC2GM088701024 IN O
the BC2GM088701024 DT O
mu-receptor BC2GM088701024 JJ O
agonist BC2GM088701024 JJ O
component BC2GM088701024 NN O
of BC2GM088701024 IN O
the BC2GM088701024 DT O
antinociceptive BC2GM088701024 JJ O
effect BC2GM088701024 NN O
of BC2GM088701024 IN O
tramadol BC2GM088701024 NN O
appears BC2GM088701024 VBZ O
to BC2GM088701024 TO O
be BC2GM088701024 VB O
minor BC2GM088701024 JJ O
, BC2GM088701024 , O
with BC2GM088701024 IN O
most BC2GM088701024 JJS O
of BC2GM088701024 IN O
the BC2GM088701024 DT O
analgesic BC2GM088701024 JJ O
effect BC2GM088701024 NN O
being BC2GM088701024 VBG O
attributable BC2GM088701024 JJ O
to BC2GM088701024 TO O
nonopioid BC2GM088701024 JJ O
properties BC2GM088701024 NNS O
of BC2GM088701024 IN O
the BC2GM088701024 DT O
parent BC2GM088701024 NN O
compound BC2GM088701024 NN O
. BC2GM088701024 . O
. . O O

The BC2GM028672992 DT O
1.3-kb BC2GM028672992 JJ O
DNA BC2GM028672992 NNP O
, BC2GM028672992 , O
when BC2GM028672992 WRB O
placed BC2GM028672992 VBN O
upstream BC2GM028672992 NN O
of BC2GM028672992 IN O
the BC2GM028672992 DT O
chloramphenicol BC2GM028672992 NN O
acetyltransferase BC2GM028672992 NN O
gene BC2GM028672992 NN O
, BC2GM028672992 , O
was BC2GM028672992 VBD O
shown BC2GM028672992 VBN O
to BC2GM028672992 TO O
be BC2GM028672992 VB O
functionally BC2GM028672992 RB O
active BC2GM028672992 JJ O
. BC2GM028672992 . O
. . O O

These BC2GM060083809 DT O
results BC2GM060083809 NNS O
suggest BC2GM060083809 VBP O
an BC2GM060083809 DT O
essential BC2GM060083809 JJ O
role BC2GM060083809 NN O
of BC2GM060083809 IN O
the BC2GM060083809 DT O
binding BC2GM060083809 NN O
of BC2GM060083809 IN O
HNF-4 BC2GM060083809 NNP O
and BC2GM060083809 CC O
/ BC2GM060083809 NNP O
or BC2GM060083809 CC O
HNF-4-related BC2GM060083809 JJ O
nuclear BC2GM060083809 JJ O
factors BC2GM060083809 NNS O
to BC2GM060083809 TO O
the BC2GM060083809 DT O
6 BC2GM060083809 CD O
beta BC2GM060083809 NN O
A-A BC2GM060083809 NNP O
site BC2GM060083809 NN O
on BC2GM060083809 IN O
the BC2GM060083809 DT O
basal BC2GM060083809 JJ O
transcriptional BC2GM060083809 JJ O
activation BC2GM060083809 NN O
of BC2GM060083809 IN O
the BC2GM060083809 DT O
CYP3A2 BC2GM060083809 NNP O
gene BC2GM060083809 NN O
in BC2GM060083809 IN O
liver BC2GM060083809 JJ O
cells BC2GM060083809 NNS O
. BC2GM060083809 . O
. . O O

50-nucleotide BC2GM007186546 JJ O
) BC2GM007186546 ) O
intron BC2GM007186546 NN O
to BC2GM007186546 TO O
AA BC2GM007186546 NNP O
. BC2GM007186546 . O
. . O O

A BC2GM035149396 DT O
definition BC2GM035149396 NN O
of BC2GM035149396 IN O
bias BC2GM035149396 NN O
founded BC2GM035149396 VBN O
on BC2GM035149396 IN O
the BC2GM035149396 DT O
concept BC2GM035149396 NN O
of BC2GM035149396 IN O
the BC2GM035149396 DT O
study BC2GM035149396 NN O
base BC2GM035149396 NN O
. BC2GM035149396 . O
. . O O

Thirty-three BC2GM046604998 CD O
small BC2GM046604998 JJ O
glottic BC2GM046604998 JJ O
carcinomas BC2GM046604998 NN O
( BC2GM046604998 ( O
T1 BC2GM046604998 NNP O
and BC2GM046604998 CC O
small BC2GM046604998 JJ O
T2 BC2GM046604998 NNP O
; BC2GM046604998 : O
UICC BC2GM046604998 NNP O
, BC2GM046604998 , O
1978 BC2GM046604998 CD O
) BC2GM046604998 ) O
were BC2GM046604998 VBD O
examined BC2GM046604998 VBN O
by BC2GM046604998 IN O
malignancy BC2GM046604998 NN O
grading BC2GM046604998 VBG O
using BC2GM046604998 VBG O
the BC2GM046604998 DT O
8-factor BC2GM046604998 JJ O
system BC2GM046604998 NN O
proposed BC2GM046604998 VBN O
by BC2GM046604998 IN O
Jakobsson BC2GM046604998 NNP O
et BC2GM046604998 CC O
al BC2GM046604998 NN O
. BC2GM046604998 . O
. . O O

To BC2GM020893421 TO O
test BC2GM020893421 VB O
the BC2GM020893421 DT O
role BC2GM020893421 NN O
of BC2GM020893421 IN O
myb BC2GM020893421 JJ O
family BC2GM020893421 NN O
members BC2GM020893421 NNS O
in BC2GM020893421 IN O
progression BC2GM020893421 NN O
through BC2GM020893421 IN O
the BC2GM020893421 DT O
cell BC2GM020893421 NN O
cycle BC2GM020893421 NN O
, BC2GM020893421 , O
we BC2GM020893421 PRP O
comicroinjected BC2GM020893421 VBD O
c-myc BC2GM020893421 NN O
and BC2GM020893421 CC O
myb BC2GM020893421 JJ O
expression BC2GM020893421 NN O
vectors BC2GM020893421 NNS O
into BC2GM020893421 IN O
serum-deprived BC2GM020893421 JJ O
quiescent BC2GM020893421 NN O
SMCs BC2GM020893421 NNP O
. BC2GM020893421 . O
. . O O

Also BC2GM067919797 RB O
, BC2GM067919797 , O
anti-HIV BC2GM067919797 JJ O
gp120 BC2GM067919797 NN O
and BC2GM067919797 CC O
anti-CD4 BC2GM067919797 JJ O
crosslinking BC2GM067919797 NN O
induced BC2GM067919797 VBD O
a BC2GM067919797 DT O
10-15-fold BC2GM067919797 JJ O
increase BC2GM067919797 NN O
in BC2GM067919797 IN O
levels BC2GM067919797 NNS O
of BC2GM067919797 IN O
both BC2GM067919797 DT O
PI BC2GM067919797 NNP O
3- BC2GM067919797 CD O
and BC2GM067919797 CC O
PI BC2GM067919797 NNP O
4-kinase BC2GM067919797 JJ O
activity BC2GM067919797 NN O
in BC2GM067919797 IN O
anti-CD4 BC2GM067919797 JJ O
precipitates BC2GM067919797 NNS O
. BC2GM067919797 . O
. . O O

The BC2GM019191435 DT O
experimental BC2GM019191435 JJ O
results BC2GM019191435 NNS O
suggest BC2GM019191435 VBP O
equilibrium BC2GM019191435 NN O
complex BC2GM019191435 JJ O
formation BC2GM019191435 NN O
between BC2GM019191435 IN O
OTC BC2GM019191435 NNP O
and BC2GM019191435 CC O
PVP BC2GM019191435 NNP O
, BC2GM019191435 , O
it BC2GM019191435 PRP O
being BC2GM019191435 VBG O
mainly BC2GM019191435 RB O
the BC2GM019191435 DT O
complex BC2GM019191435 NN O
which BC2GM019191435 WDT O
is BC2GM019191435 VBZ O
i.v BC2GM019191435 NN O
. BC2GM019191435 . O
injected BC2GM019191435 VBN O
when BC2GM019191435 WRB O
both BC2GM019191435 DT O
products BC2GM019191435 NNS O
are BC2GM019191435 VBP O
combined BC2GM019191435 VBN O
in BC2GM019191435 IN O
an BC2GM019191435 DT O
injection BC2GM019191435 NN O
formulation BC2GM019191435 NN O
. BC2GM019191435 . O
. . O O

Shields BC2GM048840420 NNS O
needed BC2GM048840420 VBN O
for BC2GM048840420 IN O
pacemakers BC2GM048840420 NNS O
. BC2GM048840420 . O
. . O O

There BC2GM005914798 EX O
was BC2GM005914798 VBD O
no BC2GM005914798 DT O
difference BC2GM005914798 NN O
in BC2GM005914798 IN O
the BC2GM005914798 DT O
day-42 BC2GM005914798 JJ O
cure BC2GM005914798 NN O
rates BC2GM005914798 NNS O
between BC2GM005914798 IN O
the BC2GM005914798 DT O
QC7 BC2GM005914798 NNP O
( BC2GM005914798 ( O
n BC2GM005914798 JJ O
= BC2GM005914798 NNP O
65 BC2GM005914798 CD O
) BC2GM005914798 ) O
and BC2GM005914798 CC O
A7 BC2GM005914798 NNP O
( BC2GM005914798 ( O
n BC2GM005914798 JJ O
= BC2GM005914798 NNP O
64 BC2GM005914798 CD O
) BC2GM005914798 ) O
regimens BC2GM005914798 NNS O
with BC2GM005914798 IN O
an BC2GM005914798 DT O
efficacy BC2GM005914798 NN O
of BC2GM005914798 IN O
100 BC2GM005914798 CD O
% BC2GM005914798 NN O
in BC2GM005914798 IN O
both BC2GM005914798 DT O
, BC2GM005914798 , O
confirmed BC2GM005914798 VBN O
by BC2GM005914798 IN O
parasite BC2GM005914798 NN O
genotyping BC2GM005914798 NN O
. BC2GM005914798 . O
. . O O

Microenvironments BC2GM065388195 NNS O
dominated BC2GM065388195 VBN O
by BC2GM065388195 IN O
cyanobacteria BC2GM065388195 NN O
( BC2GM065388195 ( O
BPC BC2GM065388195 NNP O
) BC2GM065388195 ) O
had BC2GM065388195 VBD O
a BC2GM065388195 DT O
higher BC2GM065388195 JJR O
pH BC2GM065388195 NN O
( BC2GM065388195 ( O
pH BC2GM065388195 JJ O
7-8 BC2GM065388195 NNS O
) BC2GM065388195 ) O
than BC2GM065388195 IN O
those BC2GM065388195 DT O
dominated BC2GM065388195 VBN O
by BC2GM065388195 IN O
lichen BC2GM065388195 NN O
( BC2GM065388195 ( O
LTL BC2GM065388195 NNP O
) BC2GM065388195 ) O
( BC2GM065388195 ( O
pH BC2GM065388195 JJ O
4.5-5.5 BC2GM065388195 NN O
) BC2GM065388195 ) O
. BC2GM065388195 . O
. . O O

A BC2GM059554638 DT O
preformed BC2GM059554638 JJ O
SREBP-1a BC2GM059554638 JJ O
: BC2GM059554638 : O
[ BC2GM059554638 JJ O
32P BC2GM059554638 CD O
] BC2GM059554638 JJ O
DNA BC2GM059554638 NNP O
complex BC2GM059554638 NN O
bound BC2GM059554638 NN O
specifically BC2GM059554638 RB O
to BC2GM059554638 TO O
membrane-immobilized BC2GM059554638 JJ O
GST-CBP BC2GM059554638 NNP O
fusion BC2GM059554638 NN O
proteins BC2GM059554638 VBZ O
that BC2GM059554638 IN O
contained BC2GM059554638 VBD O
amino-terminal BC2GM059554638 JJ O
portions BC2GM059554638 NNS O
of BC2GM059554638 IN O
CBP BC2GM059554638 NNP O
. BC2GM059554638 . O
. . O O

Lastly BC2GM033021196 RB O
, BC2GM033021196 , O
several BC2GM033021196 JJ O
restriction BC2GM033021196 NN O
length BC2GM033021196 NN O
polymorphisms BC2GM033021196 NNS O
were BC2GM033021196 VBD O
identified BC2GM033021196 VBN O
and BC2GM033021196 CC O
mapped BC2GM033021196 VBN O
within BC2GM033021196 IN O
a BC2GM033021196 DT O
1 BC2GM033021196 CD O
kb BC2GM033021196 JJ O
region BC2GM033021196 NN O
located BC2GM033021196 VBN O
immediately BC2GM033021196 RB O
upstream BC2GM033021196 JJ O
from BC2GM033021196 IN O
the BC2GM033021196 DT O
JH BC2GM033021196 NNP O
cluster BC2GM033021196 NN O
. BC2GM033021196 . O
. . O O

The BC2GM036342195 DT O
results BC2GM036342195 NNS O
of BC2GM036342195 IN O
these BC2GM036342195 DT O
studies BC2GM036342195 NNS O
indicate BC2GM036342195 VBP O
that BC2GM036342195 IN O
EHV-1 BC2GM036342195 NNP O
gp13 BC2GM036342195 NN O
is BC2GM036342195 VBZ O
the BC2GM036342195 DT O
structural BC2GM036342195 JJ O
homolog BC2GM036342195 NN O
of BC2GM036342195 IN O
herpes BC2GM036342195 NNS O
simplex BC2GM036342195 JJ O
virus BC2GM036342195 NN O
glycoprotein BC2GM036342195 NN O
C BC2GM036342195 NNP O
and BC2GM036342195 CC O
further BC2GM036342195 RB O
suggest BC2GM036342195 VBP O
that BC2GM036342195 IN O
the BC2GM036342195 DT O
epitope-containing BC2GM036342195 JJ O
N-terminal BC2GM036342195 JJ O
amino BC2GM036342195 NN O
acid BC2GM036342195 NN O
sequences BC2GM036342195 NNS O
of BC2GM036342195 IN O
the BC2GM036342195 DT O
herpesvirus BC2GM036342195 NN O
gC-like BC2GM036342195 NN O
glycoproteins BC2GM036342195 NNS O
have BC2GM036342195 VBP O
undergone BC2GM036342195 VBN O
more BC2GM036342195 RBR O
extensive BC2GM036342195 JJ O
evolutionary BC2GM036342195 JJ O
divergence BC2GM036342195 NN O
than BC2GM036342195 IN O
the BC2GM036342195 DT O
C-terminal BC2GM036342195 JJ O
sequences BC2GM036342195 NNS O
. BC2GM036342195 . O
. . O O

In-111-BLMC BC2GM086467089 JJ O
uptake BC2GM086467089 NN O
was BC2GM086467089 VBD O
directly BC2GM086467089 RB O
proportional BC2GM086467089 JJ O
to BC2GM086467089 TO O
Ki-67 BC2GM086467089 NNP O
/ BC2GM086467089 NNP O
MIB-1 BC2GM086467089 NNP O
activity BC2GM086467089 NN O
and BC2GM086467089 CC O
number BC2GM086467089 NN O
of BC2GM086467089 IN O
mitoses BC2GM086467089 NNS O
in BC2GM086467089 IN O
tumor BC2GM086467089 NN O
tissue BC2GM086467089 NN O
. BC2GM086467089 . O
. . O O

The BC2GM022481867 DT O
transfer BC2GM022481867 NN O
by BC2GM022481867 IN O
conjugation BC2GM022481867 NN O
to BC2GM022481867 TO O
E. BC2GM022481867 NNP O
coli BC2GM022481867 NNS O
K12 BC2GM022481867 NNP O
of BC2GM022481867 IN O
ampicillin BC2GM022481867 NN O
and BC2GM022481867 CC O
carbenicillin BC2GM022481867 NN O
resistance BC2GM022481867 NN O
was BC2GM022481867 VBD O
obtained BC2GM022481867 VBN O
with BC2GM022481867 IN O
14 BC2GM022481867 CD O
strains BC2GM022481867 NNS O
: BC2GM022481867 : O
( BC2GM022481867 ( O
E. BC2GM022481867 NNP O
coli BC2GM022481867 NNS O
: BC2GM022481867 : O
9 BC2GM022481867 CD O
, BC2GM022481867 , O
C. BC2GM022481867 NNP O
freundii BC2GM022481867 NN O
: BC2GM022481867 : O
1 BC2GM022481867 CD O
, BC2GM022481867 , O
K. BC2GM022481867 NNP O
pneumoniae BC2GM022481867 NN O
: BC2GM022481867 : O
1 BC2GM022481867 CD O
, BC2GM022481867 , O
E. BC2GM022481867 NNP O
cloacae BC2GM022481867 NN O
: BC2GM022481867 : O
2 BC2GM022481867 CD O
, BC2GM022481867 , O
P. BC2GM022481867 NNP O
stuartii BC2GM022481867 NN O
: BC2GM022481867 : O
1 BC2GM022481867 CD O
) BC2GM022481867 ) O
. BC2GM022481867 . O
. . O O

Microscopically BC2GM030303279 RB O
, BC2GM030303279 , O
cartilage BC2GM030303279 NN O
showed BC2GM030303279 VBD O
markedly BC2GM030303279 RB O
stunted BC2GM030303279 VBN O
and BC2GM030303279 CC O
disorganized BC2GM030303279 VBN O
endochondral BC2GM030303279 JJ O
ossification BC2GM030303279 NN O
. BC2GM030303279 . O
. . O O

In BC2GM046362536 IN O
addition BC2GM046362536 NN O
, BC2GM046362536 , O
both BC2GM046362536 DT O
inhibitors BC2GM046362536 NNS O
blocked BC2GM046362536 VBD O
phosphatidylcholine BC2GM046362536 JJ O
hydrolysis BC2GM046362536 NN O
and BC2GM046362536 CC O
protein BC2GM046362536 NN O
kinase BC2GM046362536 NN O
C BC2GM046362536 NNP O
translocation BC2GM046362536 NN O
. BC2GM046362536 . O
. . O O

However BC2GM024210872 RB O
, BC2GM024210872 , O
the BC2GM024210872 DT O
safety BC2GM024210872 NN O
of BC2GM024210872 IN O
design BC2GM024210872 NN O
4 BC2GM024210872 CD O
was BC2GM024210872 VBD O
assured BC2GM024210872 VBN O
as BC2GM024210872 RB O
long BC2GM024210872 RB O
as BC2GM024210872 IN O
all BC2GM024210872 DT O
patients BC2GM024210872 NNS O
received BC2GM024210872 VBD O
three BC2GM024210872 CD O
courses BC2GM024210872 NNS O
of BC2GM024210872 IN O
chemotherapy BC2GM024210872 NN O
, BC2GM024210872 , O
which BC2GM024210872 WDT O
is BC2GM024210872 VBZ O
unusual BC2GM024210872 JJ O
in BC2GM024210872 IN O
phase BC2GM024210872 NN O
I BC2GM024210872 PRP O
studies BC2GM024210872 NNS O
in BC2GM024210872 IN O
Japan BC2GM024210872 NNP O
. BC2GM024210872 . O
. . O O

Lasting BC2GM065029145 VBG O
paraplegia BC2GM065029145 NN O
caused BC2GM065029145 VBN O
by BC2GM065029145 IN O
loss BC2GM065029145 NN O
of BC2GM065029145 IN O
lumbar BC2GM065029145 JJ O
spinal BC2GM065029145 JJ O
cord BC2GM065029145 NN O
interneurons BC2GM065029145 NNS O
in BC2GM065029145 IN O
rats BC2GM065029145 NNS O
: BC2GM065029145 : O
no BC2GM065029145 DT O
direct BC2GM065029145 JJ O
correlation BC2GM065029145 NN O
with BC2GM065029145 IN O
motor BC2GM065029145 NN O
neuron BC2GM065029145 JJ O
loss BC2GM065029145 NN O
. BC2GM065029145 . O
. . O O

A BC2GM037103656 DT O
gene BC2GM037103656 NN O
with BC2GM037103656 IN O
a BC2GM037103656 DT O
high BC2GM037103656 JJ O
degree BC2GM037103656 NN O
of BC2GM037103656 IN O
sequence BC2GM037103656 NN O
identity BC2GM037103656 NN O
with BC2GM037103656 IN O
mammalian BC2GM037103656 JJ O
ADP-ribosylation BC2GM037103656 NN O
factors BC2GM037103656 NNS O
( BC2GM037103656 ( O
ARFs BC2GM037103656 NNP O
) BC2GM037103656 ) O
, BC2GM037103656 , O
believed BC2GM037103656 VBN O
to BC2GM037103656 TO O
be BC2GM037103656 VB O
important BC2GM037103656 JJ O
in BC2GM037103656 IN O
vesicular BC2GM037103656 JJ O
transport BC2GM037103656 NN O
, BC2GM037103656 , O
was BC2GM037103656 VBD O
identified BC2GM037103656 VBN O
. BC2GM037103656 . O
. . O O

Northern BC2GM019562705 NNP O
( BC2GM019562705 ( O
RNA BC2GM019562705 NNP O
) BC2GM019562705 ) O
blot BC2GM019562705 NN O
hybridization BC2GM019562705 NN O
analysis BC2GM019562705 NN O
with BC2GM019562705 IN O
the BC2GM019562705 DT O
p68c-ets-1 BC2GM019562705 JJ O
-specific BC2GM019562705 JJ O
sequence BC2GM019562705 NN O
and BC2GM019562705 CC O
RNase BC2GM019562705 NNP O
protection BC2GM019562705 NN O
experiments BC2GM019562705 NNS O
showed BC2GM019562705 VBD O
that BC2GM019562705 IN O
the BC2GM019562705 DT O
corresponding BC2GM019562705 JJ O
mRNA BC2GM019562705 NN O
was BC2GM019562705 VBD O
expressed BC2GM019562705 VBN O
in BC2GM019562705 IN O
normal BC2GM019562705 JJ O
chicken BC2GM019562705 NN O
spleen BC2GM019562705 NN O
and BC2GM019562705 CC O
not BC2GM019562705 RB O
in BC2GM019562705 IN O
normal BC2GM019562705 JJ O
chicken BC2GM019562705 NN O
thymus BC2GM019562705 NN O
or BC2GM019562705 CC O
in BC2GM019562705 IN O
various BC2GM019562705 JJ O
T BC2GM019562705 NNP O
lymphoid BC2GM019562705 NN O
cell BC2GM019562705 NN O
lines BC2GM019562705 NNS O
. BC2GM019562705 . O
. . O O

Here BC2GM064685099 RB O
, BC2GM064685099 , O
we BC2GM064685099 PRP O
characterize BC2GM064685099 VBP O
TCR BC2GM064685099 NNP O
/ BC2GM064685099 NNP O
CD48 BC2GM064685099 NNP O
and BC2GM064685099 CC O
TCR BC2GM064685099 NNP O
/ BC2GM064685099 NNP O
CD28 BC2GM064685099 NNP O
costimulation BC2GM064685099 NN O
in BC2GM064685099 IN O
T BC2GM064685099 NNP O
cells BC2GM064685099 NNS O
expressing BC2GM064685099 VBG O
Lck BC2GM064685099 NNP O
Src BC2GM064685099 NNP O
homology BC2GM064685099 NN O
3 BC2GM064685099 CD O
( BC2GM064685099 ( O
SH3 BC2GM064685099 NNP O
) BC2GM064685099 ) O
mutants BC2GM064685099 NNS O
. BC2GM064685099 . O
. . O O

The BC2GM022719960 DT O
results BC2GM022719960 NNS O
of BC2GM022719960 IN O
a BC2GM022719960 DT O
study BC2GM022719960 NN O
to BC2GM022719960 TO O
investigate BC2GM022719960 VB O
the BC2GM022719960 DT O
effectiveness BC2GM022719960 NN O
of BC2GM022719960 IN O
a BC2GM022719960 DT O
propolis-containing BC2GM022719960 JJ O
mouthrinse BC2GM022719960 NN O
in BC2GM022719960 IN O
the BC2GM022719960 DT O
inhibition BC2GM022719960 NN O
of BC2GM022719960 IN O
de BC2GM022719960 FW O
novo BC2GM022719960 FW O
plaque BC2GM022719960 NN O
formation BC2GM022719960 NN O
are BC2GM022719960 VBP O
presented BC2GM022719960 VBN O
. BC2GM022719960 . O
. . O O

Organization BC2GM053778229 NN O
of BC2GM053778229 IN O
exons BC2GM053778229 NNS O
suggests BC2GM053778229 NNS O
that BC2GM053778229 IN O
, BC2GM053778229 , O
similar BC2GM053778229 JJ O
to BC2GM053778229 TO O
the BC2GM053778229 DT O
human BC2GM053778229 JJ O
VEGF BC2GM053778229 NNP O
gene BC2GM053778229 NN O
, BC2GM053778229 , O
alternative BC2GM053778229 JJ O
splicing BC2GM053778229 NN O
generates BC2GM053778229 VBZ O
the BC2GM053778229 DT O
120- BC2GM053778229 JJ O
, BC2GM053778229 , O
164- BC2GM053778229 JJ O
, BC2GM053778229 , O
and BC2GM053778229 CC O
188-amino BC2GM053778229 JJ O
acid BC2GM053778229 NN O
isoforms BC2GM053778229 NNS O
, BC2GM053778229 , O
but BC2GM053778229 CC O
does BC2GM053778229 VBZ O
not BC2GM053778229 RB O
predict BC2GM053778229 VB O
a BC2GM053778229 DT O
fourth BC2GM053778229 JJ O
VEGF BC2GM053778229 NNP O
isoform BC2GM053778229 NN O
corresponding BC2GM053778229 VBG O
to BC2GM053778229 TO O
human BC2GM053778229 JJ O
VEGF206 BC2GM053778229 NNP O
. BC2GM053778229 . O
. . O O

The BC2GM096642340 DT O
IFNAR BC2GM096642340 NNP O
chain BC2GM096642340 NN O
interacts BC2GM096642340 NNS O
with BC2GM096642340 IN O
both BC2GM096642340 DT O
IFN-alpha BC2GM096642340 NNP O
2 BC2GM096642340 CD O
and BC2GM096642340 CC O
IFN-beta BC2GM096642340 NNP O
, BC2GM096642340 , O
as BC2GM096642340 IN O
demonstrated BC2GM096642340 VBN O
by BC2GM096642340 IN O
cross-linking BC2GM096642340 NN O
. BC2GM096642340 . O
. . O O

To BC2GM068206281 TO O
determine BC2GM068206281 VB O
cis-acting BC2GM068206281 JJ O
elements BC2GM068206281 NNS O
controlling BC2GM068206281 VBG O
the BC2GM068206281 DT O
rat BC2GM068206281 NN O
B-50 BC2GM068206281 NNP O
/ BC2GM068206281 NNP O
GAP-43 BC2GM068206281 NNP O
gene BC2GM068206281 NN O
expression BC2GM068206281 NN O
, BC2GM068206281 , O
the BC2GM068206281 DT O
genomic BC2GM068206281 JJ O
DNA BC2GM068206281 NNP O
encoding BC2GM068206281 VBG O
exon BC2GM068206281 RB O
1 BC2GM068206281 CD O
and BC2GM068206281 CC O
the BC2GM068206281 DT O
5 BC2GM068206281 CD O
' BC2GM068206281 POS O
flanking BC2GM068206281 VBG O
sequence BC2GM068206281 NN O
was BC2GM068206281 VBD O
isolated BC2GM068206281 VBN O
. BC2GM068206281 . O
. . O O

Heart BC2GM033901476 NNP O
rate BC2GM033901476 NN O
during BC2GM033901476 IN O
the BC2GM033901476 DT O
behavioral BC2GM033901476 JJ O
avoidance BC2GM033901476 NN O
test BC2GM033901476 NN O
was BC2GM033901476 VBD O
shown BC2GM033901476 VBN O
to BC2GM033901476 TO O
be BC2GM033901476 VB O
as BC2GM033901476 IN O
susceptible BC2GM033901476 JJ O
to BC2GM033901476 TO O
experimental BC2GM033901476 JJ O
demand BC2GM033901476 NN O
as BC2GM033901476 IN O
other BC2GM033901476 JJ O
studies BC2GM033901476 NNS O
have BC2GM033901476 VBP O
shown BC2GM033901476 VBN O
approach BC2GM033901476 NN O
behaviors BC2GM033901476 NNS O
to BC2GM033901476 TO O
be BC2GM033901476 VB O
influenced BC2GM033901476 VBN O
. BC2GM033901476 . O
. . O O

We BC2GM007582543 PRP O
cloned BC2GM007582543 VBD O
the BC2GM007582543 DT O
BamHI-F BC2GM007582543 NNP O
fragment BC2GM007582543 NN O
from BC2GM007582543 IN O
the BC2GM007582543 DT O
left BC2GM007582543 JJ O
end BC2GM007582543 NN O
of BC2GM007582543 IN O
Ad4 BC2GM007582543 NNP O
in BC2GM007582543 IN O
pUC13-1 BC2GM007582543 NN O
between BC2GM007582543 IN O
the BC2GM007582543 DT O
SalI BC2GM007582543 NNP O
and BC2GM007582543 CC O
BamHI BC2GM007582543 NNP O
sites BC2GM007582543 NNS O
in BC2GM007582543 IN O
order BC2GM007582543 NN O
to BC2GM007582543 TO O
carry BC2GM007582543 VB O
out BC2GM007582543 RP O
the BC2GM007582543 DT O
structural BC2GM007582543 JJ O
analysis BC2GM007582543 NN O
of BC2GM007582543 IN O
the BC2GM007582543 DT O
E1A BC2GM007582543 NNP O
region BC2GM007582543 NN O
of BC2GM007582543 IN O
Ad4 BC2GM007582543 NNP O
. BC2GM007582543 . O
. . O O

The BC2GM046535575 DT O
formation BC2GM046535575 NN O
of BC2GM046535575 IN O
a BC2GM046535575 DT O
D-loop BC2GM046535575 NNP O
is BC2GM046535575 VBZ O
an BC2GM046535575 DT O
essential BC2GM046535575 JJ O
step BC2GM046535575 NN O
in BC2GM046535575 IN O
DNA BC2GM046535575 NNP O
double-strand BC2GM046535575 JJ O
break BC2GM046535575 NN O
repair BC2GM046535575 NN O
through BC2GM046535575 IN O
recombination BC2GM046535575 NN O
. BC2GM046535575 . O
. . O O

Expression BC2GM042454699 NN O
of BC2GM042454699 IN O
the BC2GM042454699 DT O
Hox BC2GM042454699 NNP O
genes BC2GM042454699 NNS O
egl-5 BC2GM042454699 JJ O
and BC2GM042454699 CC O
mab-5 BC2GM042454699 NN O
is BC2GM042454699 VBZ O
reduced BC2GM042454699 VBN O
in BC2GM042454699 IN O
lin-49 BC2GM042454699 JJ O
and BC2GM042454699 CC O
lin-59 BC2GM042454699 JJ O
mutants BC2GM042454699 NNS O
, BC2GM042454699 , O
suggesting BC2GM042454699 VBG O
lin-49 BC2GM042454699 JJ O
and BC2GM042454699 CC O
lin-59 BC2GM042454699 JJ O
regulate BC2GM042454699 NN O
HOM-C BC2GM042454699 NNP O
gene BC2GM042454699 NN O
expression BC2GM042454699 NN O
in BC2GM042454699 IN O
C. BC2GM042454699 NNP O
elegans BC2GM042454699 NNS O
as BC2GM042454699 IN O
the BC2GM042454699 DT O
trx-G BC2GM042454699 JJ O
genes BC2GM042454699 NNS O
do BC2GM042454699 VBP O
in BC2GM042454699 IN O
Drosophila BC2GM042454699 NNP O
. BC2GM042454699 . O
lin-49 BC2GM042454699 JJ O
and BC2GM042454699 CC O
lin-59 BC2GM042454699 JJ O
transgenes BC2GM042454699 NNS O
are BC2GM042454699 VBP O
expressed BC2GM042454699 VBN O
widely BC2GM042454699 RB O
throughout BC2GM042454699 IN O
C. BC2GM042454699 NNP O
elegans BC2GM042454699 VBZ O
animals BC2GM042454699 NNS O
. BC2GM042454699 . O
. . O O

Overexpression BC2GM042145005 NN O
of BC2GM042145005 IN O
N-terminal BC2GM042145005 JJ O
mutations BC2GM042145005 NNS O
disturbs BC2GM042145005 VBP O
mitosis BC2GM042145005 NN O
and BC2GM042145005 CC O
produces BC2GM042145005 VBZ O
elongated BC2GM042145005 JJ O
cells BC2GM042145005 NNS O
, BC2GM042145005 , O
Using BC2GM042145005 VBG O
a BC2GM042145005 DT O
PCR BC2GM042145005 NNP O
approach BC2GM042145005 NN O
, BC2GM042145005 , O
we BC2GM042145005 PRP O
isolated BC2GM042145005 VBD O
a BC2GM042145005 DT O
putative BC2GM042145005 JJ O
homologue BC2GM042145005 NN O
of BC2GM042145005 IN O
Prp4 BC2GM042145005 NNP O
from BC2GM042145005 IN O
human BC2GM042145005 JJ O
and BC2GM042145005 CC O
mouse BC2GM042145005 NN O
cells BC2GM042145005 NNS O
. BC2GM042145005 . O
. . O O

The BC2GM051590745 DT O
second BC2GM051590745 JJ O
system BC2GM051590745 NN O
( BC2GM051590745 ( O
VacFix BC2GM051590745 NNP O
) BC2GM051590745 ) O
uses BC2GM051590745 VBZ O
a BC2GM051590745 DT O
0.15 BC2GM051590745 CD O
mm BC2GM051590745 NN O
thick BC2GM051590745 JJ O
plastic BC2GM051590745 NN O
bag BC2GM051590745 NN O
loosely BC2GM051590745 RB O
filled BC2GM051590745 VBN O
with BC2GM051590745 IN O
1 BC2GM051590745 CD O
mm BC2GM051590745 NNS O
polysterol BC2GM051590745 NN O
spheres BC2GM051590745 NNS O
. BC2GM051590745 . O
. . O O

These BC2GM090751169 DT O
findings BC2GM090751169 NNS O
suggest BC2GM090751169 VBP O
that BC2GM090751169 IN O
eIF5-eIF2beta BC2GM090751169 JJ O
interaction BC2GM090751169 NN O
plays BC2GM090751169 VBZ O
an BC2GM090751169 DT O
essential BC2GM090751169 JJ O
role BC2GM090751169 NN O
in BC2GM090751169 IN O
eIF5 BC2GM090751169 JJ O
function BC2GM090751169 NN O
in BC2GM090751169 IN O
eukaryotic BC2GM090751169 JJ O
cells BC2GM090751169 NNS O
. BC2GM090751169 . O
. . O O

In BC2GM002635728 IN O
the BC2GM002635728 DT O
present BC2GM002635728 JJ O
study BC2GM002635728 NN O
, BC2GM002635728 , O
we BC2GM002635728 PRP O
have BC2GM002635728 VBP O
investigated BC2GM002635728 VBN O
the BC2GM002635728 DT O
effects BC2GM002635728 NNS O
of BC2GM002635728 IN O
SDZ BC2GM002635728 NNP O
ENA BC2GM002635728 NNP O
713 BC2GM002635728 CD O
on BC2GM002635728 IN O
spatial BC2GM002635728 JJ O
learning BC2GM002635728 VBG O
deficits BC2GM002635728 NNS O
in BC2GM002635728 IN O
aged BC2GM002635728 JJ O
rats BC2GM002635728 NNS O
. BC2GM002635728 . O
. . O O

BCR-ABL BC2GM018588140 JJ O
expression BC2GM018588140 NN O
confers BC2GM018588140 NNS O
cross-resistance BC2GM018588140 NN O
to BC2GM018588140 TO O
multiple BC2GM018588140 VB O
genotoxic BC2GM018588140 JJ O
anticancer BC2GM018588140 NN O
drugs BC2GM018588140 NNS O
by BC2GM018588140 IN O
inhibition BC2GM018588140 NN O
of BC2GM018588140 IN O
the BC2GM018588140 DT O
apoptotic BC2GM018588140 JJ O
response BC2GM018588140 NN O
to BC2GM018588140 TO O
DNA BC2GM018588140 NNP O
damage BC2GM018588140 NN O
in BC2GM018588140 IN O
association BC2GM018588140 NN O
with BC2GM018588140 IN O
cell BC2GM018588140 NN O
cycle BC2GM018588140 NN O
arrest BC2GM018588140 NN O
at BC2GM018588140 IN O
the BC2GM018588140 DT O
G2-M BC2GM018588140 NNP O
restriction BC2GM018588140 NN O
point BC2GM018588140 NN O
. BC2GM018588140 . O
. . O O

Two BC2GM060268532 CD O
cases BC2GM060268532 NNS O
of BC2GM060268532 IN O
Paraquat BC2GM060268532 NNP O
poisoning BC2GM060268532 NN O
of BC2GM060268532 IN O
anticonservative BC2GM060268532 JJ O
origin BC2GM060268532 NN O
are BC2GM060268532 VBP O
described BC2GM060268532 VBN O
. BC2GM060268532 . O
. . O O

The BC2GM046935375 DT O
role BC2GM046935375 NN O
of BC2GM046935375 IN O
PORT BC2GM046935375 NNP O
in BC2GM046935375 IN O
the BC2GM046935375 DT O
treatment BC2GM046935375 NN O
of BC2GM046935375 IN O
N2 BC2GM046935375 NNP O
tumours BC2GM046935375 NN O
is BC2GM046935375 VBZ O
not BC2GM046935375 RB O
clear BC2GM046935375 JJ O
and BC2GM046935375 CC O
may BC2GM046935375 MD O
justify BC2GM046935375 VB O
further BC2GM046935375 JJ O
research BC2GM046935375 NN O
. BC2GM046935375 . O
. . O O

The BC2GM020418673 DT O
best-studied BC2GM020418673 JJ O
neurotrophin BC2GM020418673 NN O
, BC2GM020418673 , O
nerve BC2GM020418673 NN O
growth BC2GM020418673 NN O
factor BC2GM020418673 NN O
( BC2GM020418673 ( O
NGF BC2GM020418673 NNP O
) BC2GM020418673 ) O
, BC2GM020418673 , O
is BC2GM020418673 VBZ O
a BC2GM020418673 DT O
major BC2GM020418673 JJ O
survival BC2GM020418673 NN O
factor BC2GM020418673 NN O
in BC2GM020418673 IN O
sympathetic BC2GM020418673 JJ O
and BC2GM020418673 CC O
sensory BC2GM020418673 JJ O
neurons BC2GM020418673 NNS O
and BC2GM020418673 CC O
promotes BC2GM020418673 NNS O
differentiation BC2GM020418673 NN O
in BC2GM020418673 IN O
a BC2GM020418673 DT O
well-studied BC2GM020418673 JJ O
model BC2GM020418673 NN O
system BC2GM020418673 NN O
, BC2GM020418673 , O
PC12 BC2GM020418673 NNP O
cells BC2GM020418673 NNS O
. BC2GM020418673 . O
. . O O

Incidence BC2GM063825132 NN O
of BC2GM063825132 IN O
beta-thalassemia BC2GM063825132 JJ O
carriers BC2GM063825132 NNS O
and BC2GM063825132 CC O
those BC2GM063825132 DT O
deficient BC2GM063825132 NN O
in BC2GM063825132 IN O
erythrocyte BC2GM063825132 JJ O
glucose-6-phosphate BC2GM063825132 JJ O
dehydrogenase BC2GM063825132 NN O
in BC2GM063825132 IN O
the BC2GM063825132 DT O
greater BC2GM063825132 JJR O
Buenos BC2GM063825132 NNP O
Aires BC2GM063825132 NNP O
area BC2GM063825132 NN O
. BC2GM063825132 . O
. . O O

Electrophoretic BC2GM085283124 JJ O
mobility-shift BC2GM085283124 NN O
assays BC2GM085283124 NNS O
using BC2GM085283124 VBG O
oligonucleotides BC2GM085283124 NNS O
derived BC2GM085283124 VBN O
from BC2GM085283124 IN O
these BC2GM085283124 DT O
sites BC2GM085283124 NNS O
demonstrated BC2GM085283124 VBD O
formation BC2GM085283124 NN O
of BC2GM085283124 IN O
specific BC2GM085283124 JJ O
DNA-protein BC2GM085283124 NNP O
complexes BC2GM085283124 NN O
. BC2GM085283124 . O
. . O O

In BC2GM070573613 IN O
this BC2GM070573613 DT O
report BC2GM070573613 NN O
, BC2GM070573613 , O
we BC2GM070573613 PRP O
investigated BC2GM070573613 VBD O
whether BC2GM070573613 IN O
the BC2GM070573613 DT O
cleavage BC2GM070573613 NN O
of BC2GM070573613 IN O
the BC2GM070573613 DT O
RRKR BC2GM070573613 NNP O
motif BC2GM070573613 NN O
of BC2GM070573613 IN O
MT-MMP1 BC2GM070573613 NNP O
by BC2GM070573613 IN O
Golgi-associated BC2GM070573613 NNP O
furin BC2GM070573613 NN O
is BC2GM070573613 VBZ O
analogous BC2GM070573613 JJ O
to BC2GM070573613 TO O
a BC2GM070573613 DT O
similar BC2GM070573613 JJ O
enzyme BC2GM070573613 NN O
activation BC2GM070573613 NN O
mechanism BC2GM070573613 NN O
observed BC2GM070573613 VBN O
with BC2GM070573613 IN O
stromelysin-3 BC2GM070573613 NN O
. BC2GM070573613 . O
. . O O

Some BC2GM077245777 DT O
of BC2GM077245777 IN O
these BC2GM077245777 DT O
physiological BC2GM077245777 JJ O
responses BC2GM077245777 NNS O
are BC2GM077245777 VBP O
regulated BC2GM077245777 VBN O
via BC2GM077245777 IN O
activation BC2GM077245777 NN O
of BC2GM077245777 IN O
transcription BC2GM077245777 NN O
factors BC2GM077245777 NNS O
such BC2GM077245777 JJ O
as BC2GM077245777 IN O
activator BC2GM077245777 NN O
protein BC2GM077245777 NN O
1 BC2GM077245777 CD O
( BC2GM077245777 ( O
AP-1 BC2GM077245777 NNP O
) BC2GM077245777 ) O
. BC2GM077245777 . O
. . O O

With BC2GM042078510 IN O
BCPP BC2GM042078510 NNP O
protocol BC2GM042078510 NN O
, BC2GM042078510 , O
12 BC2GM042078510 CD O
achieved BC2GM042078510 VBD O
a BC2GM042078510 DT O
complete BC2GM042078510 JJ O
response BC2GM042078510 NN O
, BC2GM042078510 , O
11 BC2GM042078510 CD O
evidenced BC2GM042078510 VBD O
a BC2GM042078510 DT O
75 BC2GM042078510 CD O
% BC2GM042078510 NN O
response BC2GM042078510 NN O
, BC2GM042078510 , O
and BC2GM042078510 CC O
7 BC2GM042078510 CD O
displayed BC2GM042078510 VBD O
a BC2GM042078510 DT O
50 BC2GM042078510 CD O
% BC2GM042078510 NN O
response BC2GM042078510 NN O
. BC2GM042078510 . O
. . O O

However BC2GM088483359 RB O
, BC2GM088483359 , O
the BC2GM088483359 DT O
addition BC2GM088483359 NN O
of BC2GM088483359 IN O
intravenous BC2GM088483359 JJ O
injection BC2GM088483359 NN O
of BC2GM088483359 IN O
FPFD BC2GM088483359 NNP O
101 BC2GM088483359 CD O
resulted BC2GM088483359 VBD O
in BC2GM088483359 IN O
a BC2GM088483359 DT O
marked BC2GM088483359 JJ O
improvement BC2GM088483359 NN O
in BC2GM088483359 IN O
their BC2GM088483359 PRP$ O
symptoms BC2GM088483359 NNS O
. BC2GM088483359 . O
. . O O

Swarming BC2GM070216905 VBG O
of BC2GM070216905 IN O
Moraxella BC2GM070216905 NNP O
. BC2GM070216905 . O
. . O O

The BC2GM086105729 DT O
results BC2GM086105729 NNS O
were BC2GM086105729 VBD O
compared BC2GM086105729 VBN O
with BC2GM086105729 IN O
the BC2GM086105729 DT O
findings BC2GM086105729 NNS O
in BC2GM086105729 IN O
pair-fed BC2GM086105729 JJ O
non-treated BC2GM086105729 JJ O
animals BC2GM086105729 NNS O
( BC2GM086105729 ( O
Control BC2GM086105729 NNP O
Group BC2GM086105729 NNP O
) BC2GM086105729 ) O
. BC2GM086105729 . O
. . O O

An BC2GM060654368 DT O
anoerxiant BC2GM060654368 NN O
, BC2GM060654368 , O
mazindol BC2GM060654368 NN O
suppresses BC2GM060654368 NNS O
food BC2GM060654368 NN O
intake BC2GM060654368 NN O
by BC2GM060654368 IN O
1 BC2GM060654368 CD O
) BC2GM060654368 ) O
stimulating BC2GM060654368 VBG O
beta-adrenergic BC2GM060654368 JJ O
receptors BC2GM060654368 NNS O
, BC2GM060654368 , O
2 BC2GM060654368 CD O
) BC2GM060654368 ) O
inhibiting BC2GM060654368 VBG O
the BC2GM060654368 DT O
feeding BC2GM060654368 NN O
center BC2GM060654368 NN O
and BC2GM060654368 CC O
, BC2GM060654368 , O
3 BC2GM060654368 CD O
) BC2GM060654368 ) O
stimulating BC2GM060654368 VBG O
the BC2GM060654368 DT O
satiety BC2GM060654368 NN O
center BC2GM060654368 NN O
in BC2GM060654368 IN O
the BC2GM060654368 DT O
hypothalamus BC2GM060654368 NN O
. BC2GM060654368 . O
. . O O

Serum BC2GM014230016 NNP O
prolactin BC2GM014230016 NN O
rapidly BC2GM014230016 RB O
decreased BC2GM014230016 VBD O
after BC2GM014230016 IN O
institution BC2GM014230016 NN O
of BC2GM014230016 IN O
treatment BC2GM014230016 NN O
, BC2GM014230016 , O
with BC2GM014230016 IN O
actual BC2GM014230016 JJ O
normalization BC2GM014230016 NN O
( BC2GM014230016 ( O
less BC2GM014230016 JJR O
than BC2GM014230016 IN O
20 BC2GM014230016 CD O
ng BC2GM014230016 JJ O
/ BC2GM014230016 NNP O
ml BC2GM014230016 NN O
) BC2GM014230016 ) O
by BC2GM014230016 IN O
the BC2GM014230016 DT O
3rd BC2GM014230016 CD O
month BC2GM014230016 NN O
. BC2GM014230016 . O
. . O O

A BC2GM060645160 DT O
. BC2GM060645160 . O
. . O O

A BC2GM051832821 DT O
protein BC2GM051832821 NN O
which BC2GM051832821 WDT O
promotes BC2GM051832821 VBZ O
DNA BC2GM051832821 NNP O
strand BC2GM051832821 NN O
transfer BC2GM051832821 NN O
between BC2GM051832821 IN O
linear BC2GM051832821 JJ O
double-stranded BC2GM051832821 JJ O
M13mp19 BC2GM051832821 NNP O
DNA BC2GM051832821 NNP O
and BC2GM051832821 CC O
single-stranded BC2GM051832821 JJ O
viral BC2GM051832821 JJ O
M13mp19 BC2GM051832821 NNP O
DNA BC2GM051832821 NNP O
has BC2GM051832821 VBZ O
been BC2GM051832821 VBN O
isolated BC2GM051832821 VBN O
from BC2GM051832821 IN O
recA- BC2GM051832821 JJ O
E.coli BC2GM051832821 NNP O
. BC2GM051832821 . O
. . O O

Overexpression BC2GM091594657 NN O
of BC2GM091594657 IN O
wild BC2GM091594657 JJ O
type BC2GM091594657 NN O
and BC2GM091594657 CC O
SeCys BC2GM091594657 NNP O
/ BC2GM091594657 NNP O
Cys BC2GM091594657 NNP O
mutant BC2GM091594657 NN O
of BC2GM091594657 IN O
human BC2GM091594657 JJ O
thioredoxin BC2GM091594657 NN O
reductase BC2GM091594657 NN O
in BC2GM091594657 IN O
E. BC2GM091594657 NNP O
coli BC2GM091594657 NNS O
: BC2GM091594657 : O
the BC2GM091594657 DT O
role BC2GM091594657 NN O
of BC2GM091594657 IN O
selenocysteine BC2GM091594657 NN O
in BC2GM091594657 IN O
the BC2GM091594657 DT O
catalytic BC2GM091594657 JJ O
activity BC2GM091594657 NN O
. BC2GM091594657 . O
. . O O

Here BC2GM029365587 RB O
we BC2GM029365587 PRP O
describe BC2GM029365587 VBP O
the BC2GM029365587 DT O
cloning BC2GM029365587 NN O
and BC2GM029365587 CC O
initial BC2GM029365587 JJ O
characterization BC2GM029365587 NN O
of BC2GM029365587 IN O
IPP BC2GM029365587 NNP O
, BC2GM029365587 , O
a BC2GM029365587 DT O
novel BC2GM029365587 JJ O
human BC2GM029365587 JJ O
gene BC2GM029365587 NN O
that BC2GM029365587 WDT O
predicts BC2GM029365587 VBZ O
a BC2GM029365587 DT O
kelch BC2GM029365587 JJ O
family BC2GM029365587 NN O
protein BC2GM029365587 RB O
homologous BC2GM029365587 JJ O
to BC2GM029365587 TO O
the BC2GM029365587 DT O
mouse BC2GM029365587 NN O
Ipp BC2GM029365587 NNP O
gene BC2GM029365587 NN O
, BC2GM029365587 , O
a BC2GM029365587 DT O
previously BC2GM029365587 RB O
described BC2GM029365587 VBN O
kelch BC2GM029365587 JJ O
family BC2GM029365587 NN O
member BC2GM029365587 NN O
. BC2GM029365587 . O
. . O O

The BC2GM032924091 DT O
pineal BC2GM032924091 NN O
hormone BC2GM032924091 NN O
melatonin BC2GM032924091 NN O
( BC2GM032924091 ( O
MLT BC2GM032924091 NNP O
) BC2GM032924091 ) O
is BC2GM032924091 VBZ O
able BC2GM032924091 JJ O
to BC2GM032924091 TO O
exert BC2GM032924091 VB O
an BC2GM032924091 DT O
oncostatic BC2GM032924091 JJ O
action BC2GM032924091 NN O
. BC2GM032924091 . O
. . O O

Peripheral BC2GM049338650 JJ O
visual BC2GM049338650 JJ O
acuity BC2GM049338650 NN O
with BC2GM049338650 IN O
monovision BC2GM049338650 NN O
and BC2GM049338650 CC O
other BC2GM049338650 JJ O
contact BC2GM049338650 NN O
lens BC2GM049338650 VBZ O
corrections BC2GM049338650 NNS O
for BC2GM049338650 IN O
presbyopia BC2GM049338650 NN O
. BC2GM049338650 . O
. . O O

Whether BC2GM040580909 NNP O
or BC2GM040580909 CC O
not BC2GM040580909 RB O
these BC2GM040580909 DT O
novel BC2GM040580909 NNS O
repeated BC2GM040580909 VBD O
sequences BC2GM040580909 NNS O
throughout BC2GM040580909 IN O
the BC2GM040580909 DT O
SMA BC2GM040580909 NNP O
region BC2GM040580909 NN O
are BC2GM040580909 VBP O
involved BC2GM040580909 VBN O
in BC2GM040580909 IN O
the BC2GM040580909 DT O
disease BC2GM040580909 NN O
remains BC2GM040580909 VBZ O
to BC2GM040580909 TO O
be BC2GM040580909 VB O
determined BC2GM040580909 VBN O
. BC2GM040580909 . O
. . O O

Serum BC2GM049845600 NNP O
PRL BC2GM049845600 NNP O
concentrations BC2GM049845600 NNS O
significantly BC2GM049845600 RB O
increased BC2GM049845600 VBD O
after BC2GM049845600 IN O
MCP BC2GM049845600 NNP O
administration BC2GM049845600 NN O
in BC2GM049845600 IN O
normal BC2GM049845600 JJ O
women BC2GM049845600 NNS O
, BC2GM049845600 , O
hyperprolactinemic BC2GM049845600 JJ O
patients BC2GM049845600 NNS O
with BC2GM049845600 IN O
normal BC2GM049845600 JJ O
sella BC2GM049845600 NN O
and BC2GM049845600 CC O
patients BC2GM049845600 NNS O
with BC2GM049845600 IN O
microadenoma BC2GM049845600 NN O
, BC2GM049845600 , O
but BC2GM049845600 CC O
not BC2GM049845600 RB O
in BC2GM049845600 IN O
macroadenoma BC2GM049845600 NN O
patients BC2GM049845600 NNS O
with BC2GM049845600 IN O
and BC2GM049845600 CC O
without BC2GM049845600 IN O
suprasellar BC2GM049845600 JJ O
expansion BC2GM049845600 NN O
( BC2GM049845600 ( O
SSE BC2GM049845600 NNP O
) BC2GM049845600 ) O
. BC2GM049845600 . O
. . O O

The BC2GM031955724 DT O
results BC2GM031955724 NNS O
of BC2GM031955724 IN O
the BC2GM031955724 DT O
neural BC2GM031955724 JJ O
network BC2GM031955724 NN O
were BC2GM031955724 VBD O
compared BC2GM031955724 VBN O
with BC2GM031955724 IN O
those BC2GM031955724 DT O
of BC2GM031955724 IN O
a BC2GM031955724 DT O
density BC2GM031955724 NN O
mask BC2GM031955724 NN O
( BC2GM031955724 ( O
thresholds BC2GM031955724 NNS O
, BC2GM031955724 , O
-750 BC2GM031955724 NNP O
/ BC2GM031955724 NNP O
-300 BC2GM031955724 NNP O
H BC2GM031955724 NNP O
) BC2GM031955724 ) O
, BC2GM031955724 , O
with BC2GM031955724 IN O
a BC2GM031955724 DT O
radiologist BC2GM031955724 NN O
serving BC2GM031955724 NN O
as BC2GM031955724 IN O
the BC2GM031955724 DT O
gold BC2GM031955724 JJ O
standard BC2GM031955724 NN O
. BC2GM031955724 . O
. . O O

Although BC2GM029364330 IN O
CB-4 BC2GM029364330 NNP O
isolates BC2GM029364330 NNS O
were BC2GM029364330 VBD O
less BC2GM029364330 RBR O
resistant BC2GM029364330 JJ O
to BC2GM029364330 TO O
chlorine BC2GM029364330 VB O
than BC2GM029364330 IN O
CB-5 BC2GM029364330 NNP O
isolates BC2GM029364330 NNS O
, BC2GM029364330 , O
after BC2GM029364330 IN O
1,000 BC2GM029364330 CD O
min BC2GM029364330 NN O
of BC2GM029364330 IN O
contact BC2GM029364330 JJ O
0.01 BC2GM029364330 CD O
% BC2GM029364330 NN O
of BC2GM029364330 IN O
the BC2GM029364330 DT O
input BC2GM029364330 NN O
virus BC2GM029364330 NN O
was BC2GM029364330 VBD O
still BC2GM029364330 RB O
infectious BC2GM029364330 JJ O
. BC2GM029364330 . O
. . O O

With BC2GM059623461 IN O
rats BC2GM059623461 NNS O
fed BC2GM059623461 VBN O
on BC2GM059623461 IN O
the BC2GM059623461 DT O
Zn-sufficient BC2GM059623461 JJ O
diet BC2GM059623461 NN O
, BC2GM059623461 , O
NaFe3+EDTA BC2GM059623461 NNP O
and BC2GM059623461 CC O
Na2EDTA BC2GM059623461 NNP O
similarly BC2GM059623461 RB O
increased BC2GM059623461 VBD O
the BC2GM059623461 DT O
absorption BC2GM059623461 NN O
, BC2GM059623461 , O
urinary BC2GM059623461 JJ O
excretion BC2GM059623461 NN O
and BC2GM059623461 CC O
retention BC2GM059623461 NN O
of BC2GM059623461 IN O
Zn BC2GM059623461 NNP O
but BC2GM059623461 CC O
to BC2GM059623461 TO O
a BC2GM059623461 DT O
lesser BC2GM059623461 JJR O
extent BC2GM059623461 NN O
. BC2GM059623461 . O
. . O O

Glycoprotein BC2GM052205120 NNP O
biosynthesis BC2GM052205120 NN O
in BC2GM052205120 IN O
Saccharomyces BC2GM052205120 NNP O
cerevisiae BC2GM052205120 NN O
: BC2GM052205120 : O
ngd29 BC2GM052205120 NN O
, BC2GM052205120 , O
an BC2GM052205120 DT O
N-glycosylation BC2GM052205120 NNP O
mutant BC2GM052205120 NN O
allelic BC2GM052205120 NN O
to BC2GM052205120 TO O
och1 BC2GM052205120 VB O
having BC2GM052205120 VBG O
a BC2GM052205120 DT O
defect BC2GM052205120 NN O
in BC2GM052205120 IN O
the BC2GM052205120 DT O
initiation BC2GM052205120 NN O
of BC2GM052205120 IN O
outer BC2GM052205120 NN O
chain BC2GM052205120 NN O
formation BC2GM052205120 NN O
. BC2GM052205120 . O
. . O O

These BC2GM045312914 DT O
aa BC2GM045312914 JJ O
residues BC2GM045312914 NNS O
correspond BC2GM045312914 VBP O
to BC2GM045312914 TO O
codons BC2GM045312914 NNS O
59 BC2GM045312914 CD O
and BC2GM045312914 CC O
108 BC2GM045312914 CD O
in BC2GM045312914 IN O
the BC2GM045312914 DT O
P. BC2GM045312914 NNP O
falciparum BC2GM045312914 NN O
DHFR BC2GM045312914 NNP O
active BC2GM045312914 JJ O
site BC2GM045312914 NN O
in BC2GM045312914 IN O
which BC2GM045312914 WDT O
similar BC2GM045312914 JJ O
aa BC2GM045312914 NN O
substitutions BC2GM045312914 NNS O
( BC2GM045312914 ( O
Cys BC2GM045312914 NNP O
Arg-59 BC2GM045312914 NNP O
and BC2GM045312914 CC O
Ser BC2GM045312914 NNP O
Asn-108 BC2GM045312914 NNP O
) BC2GM045312914 ) O
are BC2GM045312914 VBP O
associated BC2GM045312914 VBN O
with BC2GM045312914 IN O
pyrimethamine BC2GM045312914 NN O
resistance BC2GM045312914 NN O
. BC2GM045312914 . O
. . O O

It BC2GM026130174 PRP O
is BC2GM026130174 VBZ O
suggested BC2GM026130174 VBN O
that BC2GM026130174 IN O
on BC2GM026130174 IN O
presentation BC2GM026130174 NN O
of BC2GM026130174 IN O
tail BC2GM026130174 NN O
tip BC2GM026130174 NN O
necrosis BC2GM026130174 NN O
in BC2GM026130174 IN O
kittens BC2GM026130174 VBZ O
a BC2GM026130174 DT O
diagnosis BC2GM026130174 NN O
of BC2GM026130174 IN O
neonatal BC2GM026130174 JJ O
isoerythrolysis BC2GM026130174 NN O
or BC2GM026130174 CC O
isoagglutination BC2GM026130174 NN O
should BC2GM026130174 MD O
be BC2GM026130174 VB O
considered BC2GM026130174 VBN O
. BC2GM026130174 . O
. . O O

Maximum BC2GM075112019 JJ O
baroreceptor BC2GM075112019 NN O
activity BC2GM075112019 NN O
measured BC2GM075112019 VBN O
at BC2GM075112019 IN O
140 BC2GM075112019 CD O
mm BC2GM075112019 NN O
Hg BC2GM075112019 NNP O
and BC2GM075112019 CC O
the BC2GM075112019 DT O
slope BC2GM075112019 NN O
of BC2GM075112019 IN O
the BC2GM075112019 DT O
pressure-activity BC2GM075112019 NN O
curve BC2GM075112019 NN O
were BC2GM075112019 VBD O
reduced BC2GM075112019 VBN O
in BC2GM075112019 IN O
atherosclerotic BC2GM075112019 JJ O
( BC2GM075112019 ( O
n BC2GM075112019 JJ O
= BC2GM075112019 NNP O
15 BC2GM075112019 CD O
) BC2GM075112019 ) O
compared BC2GM075112019 VBN O
with BC2GM075112019 IN O
normal BC2GM075112019 JJ O
( BC2GM075112019 ( O
n BC2GM075112019 JJ O
= BC2GM075112019 NNP O
13 BC2GM075112019 CD O
) BC2GM075112019 ) O
rabbits BC2GM075112019 NNS O
( BC2GM075112019 ( O
425 BC2GM075112019 CD O
+ BC2GM075112019 NN O
/ BC2GM075112019 NNP O
- BC2GM075112019 : O
34 BC2GM075112019 CD O
versus BC2GM075112019 NN O
721 BC2GM075112019 CD O
+ BC2GM075112019 NN O
/ BC2GM075112019 NNP O
- BC2GM075112019 : O
30 BC2GM075112019 CD O
spikes BC2GM075112019 NNS O
per BC2GM075112019 IN O
second BC2GM075112019 NN O
and BC2GM075112019 CC O
6.2 BC2GM075112019 CD O
+ BC2GM075112019 NN O
/ BC2GM075112019 NNP O
- BC2GM075112019 : O
0.6 BC2GM075112019 CD O
versus BC2GM075112019 NN O
10.8 BC2GM075112019 CD O
+ BC2GM075112019 NN O
/ BC2GM075112019 NNP O
- BC2GM075112019 : O
0.8 BC2GM075112019 CD O
spikes BC2GM075112019 NNS O
per BC2GM075112019 IN O
second BC2GM075112019 JJ O
per BC2GM075112019 IN O
mm BC2GM075112019 NN O
Hg BC2GM075112019 NNP O
, BC2GM075112019 , O
respectively BC2GM075112019 RB O
, BC2GM075112019 , O
P BC2GM075112019 NNP O
< BC2GM075112019 NNP O
.05 BC2GM075112019 NNP O
) BC2GM075112019 ) O
. BC2GM075112019 . O
. . O O

A BC2GM060157872 DT O
vascular BC2GM060157872 JJ O
component BC2GM060157872 NN O
to BC2GM060157872 TO O
impotence BC2GM060157872 NN O
was BC2GM060157872 VBD O
shown BC2GM060157872 VBN O
to BC2GM060157872 TO O
be BC2GM060157872 VB O
common BC2GM060157872 JJ O
in BC2GM060157872 IN O
those BC2GM060157872 DT O
with BC2GM060157872 IN O
neurological BC2GM060157872 JJ O
impairment BC2GM060157872 NN O
, BC2GM060157872 , O
and BC2GM060157872 CC O
may BC2GM060157872 MD O
alter BC2GM060157872 VB O
management BC2GM060157872 NN O
. BC2GM060157872 . O
. . O O

The BC2GM055959438 DT O
rat BC2GM055959438 NN O
anococcygeus BC2GM055959438 JJ O
muscle BC2GM055959438 NN O
was BC2GM055959438 VBD O
used BC2GM055959438 VBN O
in BC2GM055959438 IN O
postsynaptic BC2GM055959438 JJ O
studies BC2GM055959438 NNS O
. BC2GM055959438 . O
. . O O

The BC2GM088713745 DT O
mRNA BC2GM088713745 NN O
for BC2GM088713745 IN O
this BC2GM088713745 DT O
protein BC2GM088713745 NN O
is BC2GM088713745 VBZ O
expressed BC2GM088713745 VBN O
in BC2GM088713745 IN O
the BC2GM088713745 DT O
T-ALL BC2GM088713745 NNP O
cell BC2GM088713745 NN O
line BC2GM088713745 NN O
Jurkat BC2GM088713745 NNP O
and BC2GM088713745 CC O
has BC2GM088713745 VBZ O
been BC2GM088713745 VBN O
designated BC2GM088713745 VBN O
HUG1 BC2GM088713745 NNP O
, BC2GM088713745 , O
for BC2GM088713745 IN O
HOX11 BC2GM088713745 NNP O
Upstream BC2GM088713745 NNP O
Gene BC2GM088713745 NNP O
. BC2GM088713745 . O
. . O O

From BC2GM061536305 IN O
the BC2GM061536305 DT O
frozen BC2GM061536305 JJ O
specimen BC2GM061536305 NNS O
, BC2GM061536305 , O
a BC2GM061536305 DT O
large BC2GM061536305 JJ O
number BC2GM061536305 NN O
of BC2GM061536305 IN O
sections BC2GM061536305 NNS O
with BC2GM061536305 IN O
good BC2GM061536305 JJ O
morphologic BC2GM061536305 NNS O
characteristics BC2GM061536305 NNS O
may BC2GM061536305 MD O
be BC2GM061536305 VB O
produced BC2GM061536305 VBN O
. BC2GM061536305 . O
. . O O

Accordingly BC2GM034973771 RB O
, BC2GM034973771 , O
constitutive BC2GM034973771 JJ O
downregulation BC2GM034973771 NN O
of BC2GM034973771 IN O
expression BC2GM034973771 NN O
of BC2GM034973771 IN O
accessory BC2GM034973771 JJ O
molecules BC2GM034973771 NNS O
of BC2GM034973771 IN O
the BC2GM034973771 DT O
MHC BC2GM034973771 NNP O
class BC2GM034973771 NN O
I BC2GM034973771 PRP O
pathway BC2GM034973771 VBP O
can BC2GM034973771 MD O
reveal BC2GM034973771 VB O
differences BC2GM034973771 NNS O
between BC2GM034973771 IN O
H2 BC2GM034973771 NNP O
class BC2GM034973771 NN O
I BC2GM034973771 PRP O
alleles BC2GM034973771 VBP O
in BC2GM034973771 IN O
antigen BC2GM034973771 NN O
presentation BC2GM034973771 NN O
not BC2GM034973771 RB O
encountered BC2GM034973771 VBD O
when BC2GM034973771 WRB O
the BC2GM034973771 DT O
expression BC2GM034973771 NN O
levels BC2GM034973771 NNS O
are BC2GM034973771 VBP O
augmented BC2GM034973771 VBN O
. BC2GM034973771 . O
. . O O

Immunogenicity BC2GM058529129 NNP O
tested BC2GM058529129 VBD O
in BC2GM058529129 IN O
experiments BC2GM058529129 NNS O
on BC2GM058529129 IN O
guinea BC2GM058529129 NN O
pigs BC2GM058529129 NNS O
and BC2GM058529129 CC O
rabbits BC2GM058529129 NNS O
was BC2GM058529129 VBD O
not BC2GM058529129 RB O
reduced BC2GM058529129 VBN O
and BC2GM058529129 CC O
corresponded BC2GM058529129 VBN O
to BC2GM058529129 TO O
that BC2GM058529129 DT O
of BC2GM058529129 IN O
the BC2GM058529129 DT O
reference BC2GM058529129 NN O
STI-1 BC2GM058529129 NNP O
vaccine BC2GM058529129 NN O
. BC2GM058529129 . O
. . O O

As BC2GM008619056 IN O
well BC2GM008619056 RB O
, BC2GM008619056 , O
variation BC2GM008619056 NN O
in BC2GM008619056 IN O
capillary BC2GM008619056 JJ O
size BC2GM008619056 NN O
and BC2GM008619056 CC O
density BC2GM008619056 NN O
was BC2GM008619056 VBD O
apparent BC2GM008619056 JJ O
between BC2GM008619056 IN O
ventricles BC2GM008619056 NNS O
in BC2GM008619056 IN O
the BC2GM008619056 DT O
fetal BC2GM008619056 NN O
and BC2GM008619056 CC O
neonatal BC2GM008619056 JJ O
periods BC2GM008619056 NNS O
. BC2GM008619056 . O
. . O O

In BC2GM020209849 IN O
contrast BC2GM020209849 NN O
, BC2GM020209849 , O
NF-kappa BC2GM020209849 NNP O
B BC2GM020209849 NNP O
activation BC2GM020209849 NN O
was BC2GM020209849 VBD O
observed BC2GM020209849 VBN O
in BC2GM020209849 IN O
these BC2GM020209849 DT O
cells BC2GM020209849 NNS O
after BC2GM020209849 IN O
PMA BC2GM020209849 NNP O
stimulation BC2GM020209849 NN O
. BC2GM020209849 . O
. . O O

Diethyldithiocarbamate BC2GM096939334 NNP O
and BC2GM096939334 CC O
amphetamine BC2GM096939334 VB O
stereotype BC2GM096939334 JJ O
behavior BC2GM096939334 NN O
. BC2GM096939334 . O
. . O O

The BC2GM024708623 DT O
predicted BC2GM024708623 VBN O
amino BC2GM024708623 NN O
acid BC2GM024708623 JJ O
sequence BC2GM024708623 NN O
of BC2GM024708623 IN O
Pst1p BC2GM024708623 NNP O
possessed BC2GM024708623 VBD O
high BC2GM024708623 JJ O
sequence BC2GM024708623 NN O
homology BC2GM024708623 NN O
with BC2GM024708623 IN O
the BC2GM024708623 DT O
Sin3 BC2GM024708623 NNP O
family BC2GM024708623 NN O
of BC2GM024708623 IN O
proteins BC2GM024708623 NNS O
, BC2GM024708623 , O
known BC2GM024708623 VBN O
for BC2GM024708623 IN O
their BC2GM024708623 PRP$ O
interaction BC2GM024708623 NN O
with BC2GM024708623 IN O
histone BC2GM024708623 NN O
deacetylases BC2GM024708623 NNS O
. BC2GM024708623 . O
. . O O

An BC2GM066617414 DT O
association BC2GM066617414 NN O
was BC2GM066617414 VBD O
found BC2GM066617414 VBN O
between BC2GM066617414 IN O
zafirlukast BC2GM066617414 NN O
plasma BC2GM066617414 NN O
concentrations BC2GM066617414 NNS O
and BC2GM066617414 CC O
increases BC2GM066617414 NNS O
in BC2GM066617414 IN O
PC8SRaw BC2GM066617414 NNP O
10 BC2GM066617414 CD O
h BC2GM066617414 NN O
after BC2GM066617414 IN O
treatment BC2GM066617414 NN O
( BC2GM066617414 ( O
p BC2GM066617414 JJ O
= BC2GM066617414 NNP O
0.001 BC2GM066617414 CD O
) BC2GM066617414 ) O
. BC2GM066617414 . O
. . O O

The BC2GM007281515 DT O
most BC2GM007281515 RBS O
distal BC2GM007281515 JJ O
active BC2GM007281515 JJ O
site BC2GM007281515 NN O
in BC2GM007281515 IN O
TIGA BC2GM007281515 NNP O
is BC2GM007281515 VBZ O
created BC2GM007281515 VBN O
by BC2GM007281515 IN O
excision BC2GM007281515 NN O
of BC2GM007281515 IN O
a BC2GM007281515 DT O
66-bp BC2GM007281515 JJ O
intron BC2GM007281515 NN O
. BC2GM007281515 . O
. . O O

Enterotoxin BC2GM057684207 NN O
production BC2GM057684207 NN O
by BC2GM057684207 IN O
staphylococci BC2GM057684207 NN O
isolated BC2GM057684207 VBN O
from BC2GM057684207 IN O
foods BC2GM057684207 NNS O
in BC2GM057684207 IN O
France BC2GM057684207 NNP O
. BC2GM057684207 . O
. . O O

139La BC2GM070272053 CD O
NQR BC2GM070272053 NNP O
relaxation BC2GM070272053 NN O
and BC2GM070272053 CC O
microSR BC2GM070272053 NN O
study BC2GM070272053 NN O
of BC2GM070272053 IN O
Zn-doping BC2GM070272053 NNP O
effects BC2GM070272053 NNS O
in BC2GM070272053 IN O
La2CuO4 BC2GM070272053 NNP O
. BC2GM070272053 . O
. . O O

The BC2GM057243625 DT O
effect BC2GM057243625 NN O
of BC2GM057243625 IN O
deferoxamine BC2GM057243625 NN O
B BC2GM057243625 NNP O
on BC2GM057243625 IN O
the BC2GM057243625 DT O
blood BC2GM057243625 NN O
sugar BC2GM057243625 NN O
behavior BC2GM057243625 NN O
in BC2GM057243625 IN O
intravenous BC2GM057243625 JJ O
glucose BC2GM057243625 JJ O
loading BC2GM057243625 NN O
in BC2GM057243625 IN O
healthy BC2GM057243625 JJ O
persons BC2GM057243625 NNS O
. BC2GM057243625 . O
. . O O

Soggy BC2GM064060868 NNP O
, BC2GM064060868 , O
a BC2GM064060868 DT O
spermatocyte-specific BC2GM064060868 JJ O
gene BC2GM064060868 NN O
, BC2GM064060868 , O
lies BC2GM064060868 VBZ O
3.8 BC2GM064060868 CD O
kb BC2GM064060868 NN O
upstream BC2GM064060868 NN O
of BC2GM064060868 IN O
and BC2GM064060868 CC O
antipodal BC2GM064060868 VB O
to BC2GM064060868 TO O
TEAD-2 BC2GM064060868 NNP O
, BC2GM064060868 , O
a BC2GM064060868 DT O
transcription BC2GM064060868 NN O
factor BC2GM064060868 NN O
expressed BC2GM064060868 VBD O
at BC2GM064060868 IN O
the BC2GM064060868 DT O
beginning BC2GM064060868 NN O
of BC2GM064060868 IN O
mouse BC2GM064060868 NN O
development BC2GM064060868 NN O
. BC2GM064060868 . O
. . O O

Quasidiatomic BC2GM070228927 NNP O
study BC2GM070228927 NN O
of BC2GM070228927 IN O
Ly- BC2GM070228927 NNP O
alpha BC2GM070228927 NN O
-producing BC2GM070228927 VBG O
H2 BC2GM070228927 NNP O
+-Ne BC2GM070228927 JJ O
collisions BC2GM070228927 NNS O
at BC2GM070228927 IN O
keV BC2GM070228927 JJ O
energies BC2GM070228927 NNS O
. BC2GM070228927 . O
. . O O

When BC2GM018485716 WRB O
using BC2GM018485716 VBG O
the BC2GM018485716 DT O
high-impedance BC2GM018485716 NN O
testing BC2GM018485716 VBG O
device BC2GM018485716 NN O
, BC2GM018485716 , O
the BC2GM018485716 DT O
post BC2GM018485716 NN O
shock BC2GM018485716 NN O
rhythm BC2GM018485716 NN O
was BC2GM018485716 VBD O
initially BC2GM018485716 RB O
displayed BC2GM018485716 VBN O
as BC2GM018485716 IN O
'no BC2GM018485716 JJ O
signal BC2GM018485716 NN O
' BC2GM018485716 POS O
( BC2GM018485716 ( O
Hewlett BC2GM018485716 NNP O
Packard BC2GM018485716 NNP O
XL BC2GM018485716 NNP O
) BC2GM018485716 ) O
or BC2GM018485716 CC O
'asystole BC2GM018485716 $ O
' BC2GM018485716 '' O
( BC2GM018485716 ( O
Physio-Control BC2GM018485716 NNP O
LIFEPAK BC2GM018485716 NNP O
9 BC2GM018485716 CD O
) BC2GM018485716 ) O
. BC2GM018485716 . O
. . O O

The BC2GM033262913 DT O
cleft BC2GM033262913 NN O
walls BC2GM033262913 NNS O
are BC2GM033262913 VBP O
lined BC2GM033262913 VBN O
with BC2GM033262913 IN O
highly BC2GM033262913 RB O
conserved BC2GM033262913 VBN O
residues BC2GM033262913 NNS O
and BC2GM033262913 CC O
NADP BC2GM033262913 NNP O
is BC2GM033262913 VBZ O
bound BC2GM033262913 VBN O
along BC2GM033262913 IN O
one BC2GM033262913 CD O
wall BC2GM033262913 NN O
. BC2GM033262913 . O
. . O O

Mutations BC2GM055384901 NNS O
away BC2GM055384901 RB O
from BC2GM055384901 IN O
splice BC2GM055384901 JJ O
site BC2GM055384901 NN O
recognition BC2GM055384901 NN O
sequences BC2GM055384901 NNS O
might BC2GM055384901 MD O
cis-modulate BC2GM055384901 VB O
alternative BC2GM055384901 JJ O
splicing BC2GM055384901 NN O
of BC2GM055384901 IN O
goat BC2GM055384901 NN O
alpha BC2GM055384901 IN O
s1-casein BC2GM055384901 JJ O
transcripts BC2GM055384901 NNS O
. BC2GM055384901 . O
. . O O

The BC2GM093465825 DT O
data BC2GM093465825 NN O
when BC2GM093465825 WRB O
used BC2GM093465825 VBN O
to BC2GM093465825 TO O
stimulate BC2GM093465825 VB O
the BC2GM093465825 DT O
collection BC2GM093465825 NN O
of BC2GM093465825 IN O
the BC2GM093465825 DT O
information BC2GM093465825 NN O
at BC2GM093465825 IN O
antenatal BC2GM093465825 NN O
or BC2GM093465825 CC O
postnatal BC2GM093465825 JJ O
visits BC2GM093465825 NNS O
, BC2GM093465825 , O
nonetheless BC2GM093465825 RB O
provide BC2GM093465825 IN O
an BC2GM093465825 DT O
accurate BC2GM093465825 JJ O
description BC2GM093465825 NN O
of BC2GM093465825 IN O
under-3 BC2GM093465825 JJ O
mortality BC2GM093465825 NN O
trends BC2GM093465825 NNS O
and BC2GM093465825 CC O
differences BC2GM093465825 NNS O
for BC2GM093465825 IN O
the BC2GM093465825 DT O
two BC2GM093465825 CD O
periods BC2GM093465825 NNS O
examined BC2GM093465825 VBN O
-- BC2GM093465825 : O
before BC2GM093465825 IN O
1984 BC2GM093465825 CD O
and BC2GM093465825 CC O
before BC2GM093465825 IN O
1989 BC2GM093465825 CD O
. BC2GM093465825 . O
. . O O

We BC2GM040125018 PRP O
found BC2GM040125018 VBD O
multiple BC2GM040125018 JJ O
transcription BC2GM040125018 NN O
start BC2GM040125018 NN O
sites BC2GM040125018 VBZ O
located BC2GM040125018 VBN O
within BC2GM040125018 IN O
a BC2GM040125018 DT O
15-base BC2GM040125018 JJ O
pair BC2GM040125018 NN O
region BC2GM040125018 NN O
, BC2GM040125018 , O
205 BC2GM040125018 CD O
base BC2GM040125018 NN O
pairs BC2GM040125018 NNS O
upstream BC2GM040125018 NN O
of BC2GM040125018 IN O
the BC2GM040125018 DT O
translation BC2GM040125018 NN O
start BC2GM040125018 NN O
codon BC2GM040125018 NN O
. BC2GM040125018 . O
. . O O

Comment BC2GM042287909 NN O
on BC2GM042287909 IN O
`` BC2GM042287909 `` O
Critical BC2GM042287909 JJ O
behavior BC2GM042287909 NN O
of BC2GM042287909 IN O
a BC2GM042287909 DT O
binary BC2GM042287909 JJ O
mixture BC2GM042287909 NN O
of BC2GM042287909 IN O
protein BC2GM042287909 NN O
and BC2GM042287909 CC O
salt BC2GM042287909 NN O
water BC2GM042287909 NN O
'' BC2GM042287909 '' O
. BC2GM042287909 . O
. . O O

In BC2GM025679566 IN O
cells BC2GM025679566 NNS O
co-expressing BC2GM025679566 JJ O
high BC2GM025679566 JJ O
levels BC2GM025679566 NNS O
of BC2GM025679566 IN O
the BC2GM025679566 DT O
p38 BC2GM025679566 NN O
( BC2GM025679566 ( O
MAPK BC2GM025679566 NNP O
) BC2GM025679566 ) O
kinase BC2GM025679566 NN O
( BC2GM025679566 ( O
MKK3 BC2GM025679566 NNP O
) BC2GM025679566 ) O
together BC2GM025679566 RB O
with BC2GM025679566 IN O
the BC2GM025679566 DT O
p38 BC2GM025679566 NN O
( BC2GM025679566 ( O
MAPK BC2GM025679566 NNP O
) BC2GM025679566 ) O
, BC2GM025679566 , O
a BC2GM025679566 DT O
significant BC2GM025679566 JJ O
inhibition BC2GM025679566 NN O
of BC2GM025679566 IN O
mitogen-induced BC2GM025679566 JJ O
cyclin BC2GM025679566 NN O
D1 BC2GM025679566 NNP O
expression BC2GM025679566 NN O
was BC2GM025679566 VBD O
observed BC2GM025679566 VBN O
. BC2GM025679566 . O
. . O O

The BC2GM058182434 DT O
possibility BC2GM058182434 NN O
to BC2GM058182434 TO O
use BC2GM058182434 VB O
this BC2GM058182434 DT O
method BC2GM058182434 NN O
for BC2GM058182434 IN O
common BC2GM058182434 JJ O
diagnostic BC2GM058182434 JJ O
problems BC2GM058182434 NNS O
is BC2GM058182434 VBZ O
indicated BC2GM058182434 VBN O
. BC2GM058182434 . O
. . O O

This BC2GM099666829 DT O
mechanism BC2GM099666829 NN O
seems BC2GM099666829 VBZ O
to BC2GM099666829 TO O
be BC2GM099666829 VB O
involved BC2GM099666829 VBN O
in BC2GM099666829 IN O
VIP-induced BC2GM099666829 NNP O
PRL BC2GM099666829 NNP O
gene BC2GM099666829 NN O
regulation BC2GM099666829 NN O
. BC2GM099666829 . O
. . O O

Sequence BC2GM081056774 NNP O
divergence BC2GM081056774 NN O
of BC2GM081056774 IN O
approximately BC2GM081056774 RB O
16 BC2GM081056774 CD O
% BC2GM081056774 NN O
reduced BC2GM081056774 VBN O
transformation BC2GM081056774 NN O
frequencies BC2GM081056774 NNS O
by BC2GM081056774 IN O
at BC2GM081056774 IN O
least BC2GM081056774 JJS O
10-fold BC2GM081056774 JJ O
. BC2GM081056774 . O
. . O O

Symptoms BC2GM071783264 NNS O
, BC2GM071783264 , O
skin-prick BC2GM071783264 JJ O
tests BC2GM071783264 NNS O
( BC2GM071783264 ( O
SPT BC2GM071783264 NNP O
) BC2GM071783264 ) O
with BC2GM071783264 IN O
environmental BC2GM071783264 JJ O
allergens BC2GM071783264 NNS O
and BC2GM071783264 CC O
Pt BC2GM071783264 NNP O
salt BC2GM071783264 NN O
, BC2GM071783264 , O
total BC2GM071783264 JJ O
serum BC2GM071783264 NN O
IgE BC2GM071783264 NNP O
, BC2GM071783264 , O
lung BC2GM071783264 NN O
function BC2GM071783264 NN O
, BC2GM071783264 , O
and BC2GM071783264 CC O
bronchial BC2GM071783264 JJ O
hyperresponsiveness BC2GM071783264 NN O
were BC2GM071783264 VBD O
assessed BC2GM071783264 VBN O
by BC2GM071783264 IN O
standard BC2GM071783264 JJ O
procedures BC2GM071783264 NNS O
. BC2GM071783264 . O
. . O O

An BC2GM052174865 DT O
evaluation BC2GM052174865 NN O
of BC2GM052174865 IN O
a BC2GM052174865 DT O
positive BC2GM052174865 JJ O
control BC2GM052174865 NN O
for BC2GM052174865 IN O
platelet BC2GM052174865 NN O
neutralization BC2GM052174865 NN O
procedure BC2GM052174865 NN O
testing BC2GM052174865 VBG O
with BC2GM052174865 IN O
seven BC2GM052174865 CD O
commercial BC2GM052174865 JJ O
activated BC2GM052174865 VBN O
partial BC2GM052174865 JJ O
thromboplastin BC2GM052174865 NN O
time BC2GM052174865 NN O
reagents BC2GM052174865 NNS O
. BC2GM052174865 . O
. . O O

A BC2GM023547323 DT O
constructed BC2GM023547323 VBN O
phylogenetic BC2GM023547323 JJ O
tree BC2GM023547323 NN O
suggests BC2GM023547323 VBZ O
that BC2GM023547323 IN O
the BC2GM023547323 DT O
UbcP1 BC2GM023547323 NNP O
protein BC2GM023547323 NN O
may BC2GM023547323 MD O
represent BC2GM023547323 VB O
a BC2GM023547323 DT O
member BC2GM023547323 NN O
of BC2GM023547323 IN O
a BC2GM023547323 DT O
distinct BC2GM023547323 JJ O
subfamily BC2GM023547323 NN O
of BC2GM023547323 IN O
E2s BC2GM023547323 NNP O
. BC2GM023547323 . O
. . O O

Intraspinal BC2GM036933937 NNP O
and BC2GM036933937 CC O
mediastinal BC2GM036933937 JJ O
foregut BC2GM036933937 NN O
cyst BC2GM036933937 NN O
compressing BC2GM036933937 VBG O
the BC2GM036933937 DT O
spinal BC2GM036933937 JJ O
cord BC2GM036933937 NN O
. BC2GM036933937 . O
. . O O

Before BC2GM050319569 IN O
and BC2GM050319569 CC O
6 BC2GM050319569 CD O
and BC2GM050319569 CC O
12 BC2GM050319569 CD O
months BC2GM050319569 NNS O
after BC2GM050319569 IN O
H. BC2GM050319569 NNP O
pylori BC2GM050319569 CC O
eradication BC2GM050319569 NN O
the BC2GM050319569 DT O
patients BC2GM050319569 NNS O
were BC2GM050319569 VBD O
evaluated BC2GM050319569 VBN O
for BC2GM050319569 IN O
fasting BC2GM050319569 VBG O
gastrinemia BC2GM050319569 NN O
and BC2GM050319569 CC O
pepsinogen BC2GM050319569 NN O
I BC2GM050319569 PRP O
, BC2GM050319569 , O
basal BC2GM050319569 NN O
and BC2GM050319569 CC O
peak BC2GM050319569 JJ O
acid BC2GM050319569 NN O
output BC2GM050319569 NN O
, BC2GM050319569 , O
and BC2GM050319569 CC O
detailed BC2GM050319569 JJ O
histological BC2GM050319569 JJ O
assessment BC2GM050319569 NN O
including BC2GM050319569 VBG O
the BC2GM050319569 DT O
ECL BC2GM050319569 NNP O
cell BC2GM050319569 NN O
proliferative BC2GM050319569 NN O
patterns BC2GM050319569 NNS O
. BC2GM050319569 . O
. . O O

Our BC2GM039351888 PRP$ O
results BC2GM039351888 NNS O
suggest BC2GM039351888 VBP O
that BC2GM039351888 IN O
it BC2GM039351888 PRP O
might BC2GM039351888 MD O
be BC2GM039351888 VB O
possible BC2GM039351888 JJ O
to BC2GM039351888 TO O
augment BC2GM039351888 VB O
IN BC2GM039351888 NNP O
function BC2GM039351888 NN O
in BC2GM039351888 IN O
vivo BC2GM039351888 NN O
through BC2GM039351888 IN O
a BC2GM039351888 DT O
heterologous BC2GM039351888 JJ O
domain BC2GM039351888 NN O
. BC2GM039351888 . O
. . O O

The BC2GM021445348 DT O
plasmid BC2GM021445348 NN O
was BC2GM021445348 VBD O
found BC2GM021445348 VBN O
to BC2GM021445348 TO O
confer BC2GM021445348 VB O
drug BC2GM021445348 NN O
resistance BC2GM021445348 NN O
specifically BC2GM021445348 RB O
to BC2GM021445348 TO O
LMB BC2GM021445348 NNP O
. BC2GM021445348 . O
. . O O

Although BC2GM021103469 IN O
the BC2GM021103469 DT O
only BC2GM021103469 JJ O
authoritative BC2GM021103469 JJ O
way BC2GM021103469 NN O
to BC2GM021103469 TO O
determine BC2GM021103469 VB O
the BC2GM021103469 DT O
effect BC2GM021103469 NN O
of BC2GM021103469 IN O
diet BC2GM021103469 NN O
on BC2GM021103469 IN O
urinary BC2GM021103469 JJ O
pH BC2GM021103469 NN O
is BC2GM021103469 VBZ O
a BC2GM021103469 DT O
feeding BC2GM021103469 JJ O
trial BC2GM021103469 NN O
, BC2GM021103469 , O
there BC2GM021103469 EX O
is BC2GM021103469 VBZ O
no BC2GM021103469 DT O
universally BC2GM021103469 RB O
accepted BC2GM021103469 VBN O
protocol BC2GM021103469 NN O
for BC2GM021103469 IN O
measuring BC2GM021103469 VBG O
urinary BC2GM021103469 JJ O
pH BC2GM021103469 NN O
. BC2GM021103469 . O
. . O O

Cells BC2GM035196654 NNS O
were BC2GM035196654 VBD O
co-infected BC2GM035196654 JJ O
simultaneously BC2GM035196654 RB O
with BC2GM035196654 IN O
IBV BC2GM035196654 NNP O
, BC2GM035196654 , O
the BC2GM035196654 DT O
recombinant BC2GM035196654 JJ O
FPV BC2GM035196654 NNP O
( BC2GM035196654 ( O
rFPV BC2GM035196654 NN O
) BC2GM035196654 ) O
containing BC2GM035196654 VBG O
the BC2GM035196654 DT O
D-RNA BC2GM035196654 NNP O
sequence BC2GM035196654 NN O
and BC2GM035196654 CC O
a BC2GM035196654 DT O
second BC2GM035196654 JJ O
rFPV BC2GM035196654 NN O
expressing BC2GM035196654 VBG O
T7 BC2GM035196654 NNP O
RNA BC2GM035196654 NNP O
polymerase BC2GM035196654 NN O
for BC2GM035196654 IN O
the BC2GM035196654 DT O
initial BC2GM035196654 JJ O
expression BC2GM035196654 NN O
of BC2GM035196654 IN O
the BC2GM035196654 DT O
D-RNA BC2GM035196654 NNP O
transcript BC2GM035196654 NN O
, BC2GM035196654 , O
subsequently BC2GM035196654 RB O
rescued BC2GM035196654 VBN O
by BC2GM035196654 IN O
helper BC2GM035196654 JJR O
IBV BC2GM035196654 NNP O
. BC2GM035196654 . O
. . O O

As BC2GM015090389 IN O
regards BC2GM015090389 NNS O
the BC2GM015090389 DT O
short BC2GM015090389 JJ O
stature BC2GM015090389 NN O
, BC2GM015090389 , O
they BC2GM015090389 PRP O
have BC2GM015090389 VBP O
proved BC2GM015090389 VBN O
that BC2GM015090389 IN O
the BC2GM015090389 DT O
syndrome BC2GM015090389 NN O
is BC2GM015090389 VBZ O
related BC2GM015090389 VBN O
to BC2GM015090389 TO O
low BC2GM015090389 JJ O
levels BC2GM015090389 NNS O
of BC2GM015090389 IN O
somatomedin BC2GM015090389 NN O
C BC2GM015090389 NNP O
( BC2GM015090389 ( O
SmC BC2GM015090389 NNP O
) BC2GM015090389 ) O
. BC2GM015090389 . O
. . O O

The BC2GM095215988 DT O
differences BC2GM095215988 NNS O
in BC2GM095215988 IN O
binding BC2GM095215988 NN O
( BC2GM095215988 ( O
Kdapp BC2GM095215988 NNP O
) BC2GM095215988 ) O
, BC2GM095215988 , O
incorporation BC2GM095215988 NN O
, BC2GM095215988 , O
and BC2GM095215988 CC O
extension BC2GM095215988 NN O
kinetics BC2GM095215988 NNS O
of BC2GM095215988 IN O
8-oxo-dGTP BC2GM095215988 JJ O
compared BC2GM095215988 VBN O
to BC2GM095215988 TO O
normal BC2GM095215988 JJ O
dNTP BC2GM095215988 JJ O
incorporation BC2GM095215988 NN O
at BC2GM095215988 IN O
template BC2GM095215988 JJ O
8-oxo-G BC2GM095215988 JJ O
adducts BC2GM095215988 NNS O
indicate BC2GM095215988 VBP O
that BC2GM095215988 IN O
polymerase BC2GM095215988 NN O
fidelity BC2GM095215988 NN O
does BC2GM095215988 VBZ O
not BC2GM095215988 RB O
depend BC2GM095215988 VB O
solely BC2GM095215988 RB O
upon BC2GM095215988 IN O
the BC2GM095215988 DT O
overall BC2GM095215988 JJ O
geometry BC2GM095215988 NN O
of BC2GM095215988 IN O
Watson-Crick BC2GM095215988 NNP O
base BC2GM095215988 NN O
pairs BC2GM095215988 NN O
and BC2GM095215988 CC O
reflects BC2GM095215988 VBZ O
the BC2GM095215988 DT O
asymmetry BC2GM095215988 NN O
of BC2GM095215988 IN O
the BC2GM095215988 DT O
enzyme BC2GM095215988 NN O
active BC2GM095215988 JJ O
site BC2GM095215988 NN O
. BC2GM095215988 . O
. . O O

Foreign BC2GM094374885 NNP O
DNA BC2GM094374885 NNP O
inserts BC2GM094374885 NNS O
contained BC2GM094374885 VBD O
within BC2GM094374885 IN O
the BC2GM094374885 DT O
fowlpox BC2GM094374885 JJ O
virus BC2GM094374885 NN O
sequence BC2GM094374885 NN O
were BC2GM094374885 VBD O
transferred BC2GM094374885 VBN O
to BC2GM094374885 TO O
the BC2GM094374885 DT O
viral BC2GM094374885 JJ O
genome BC2GM094374885 NN O
by BC2GM094374885 IN O
homologous BC2GM094374885 JJ O
recombination BC2GM094374885 NN O
occurring BC2GM094374885 VBG O
in BC2GM094374885 IN O
cells BC2GM094374885 NNS O
infected BC2GM094374885 VBN O
with BC2GM094374885 IN O
a BC2GM094374885 DT O
fowlpox BC2GM094374885 JJ O
virus BC2GM094374885 NN O
temperature-sensitive BC2GM094374885 JJ O
mutant BC2GM094374885 NN O
and BC2GM094374885 CC O
transfected BC2GM094374885 VBN O
with BC2GM094374885 IN O
both BC2GM094374885 DT O
wild-type BC2GM094374885 JJ O
viral BC2GM094374885 JJ O
DNA BC2GM094374885 NNP O
and BC2GM094374885 CC O
plasmid BC2GM094374885 JJ O
DNA BC2GM094374885 NNP O
. BC2GM094374885 . O
. . O O

These BC2GM085041109 DT O
findings BC2GM085041109 NNS O
indicate BC2GM085041109 VBP O
that BC2GM085041109 IN O
KCTG BC2GM085041109 NNP O
can BC2GM085041109 MD O
contribute BC2GM085041109 VB O
to BC2GM085041109 TO O
improved BC2GM085041109 VBN O
monitoring BC2GM085041109 NN O
in BC2GM085041109 IN O
high-risk BC2GM085041109 JJ O
pregnancies BC2GM085041109 NNS O
. BC2GM085041109 . O
. . O O

The BC2GM067873375 DT O
use BC2GM067873375 NN O
of BC2GM067873375 IN O
bentonite BC2GM067873375 NN O
in BC2GM067873375 IN O
the BC2GM067873375 DT O
compounding BC2GM067873375 NN O
of BC2GM067873375 IN O
hydrogels BC2GM067873375 NNS O
. BC2GM067873375 . O
. . O O

Contraindications BC2GM066466622 NNS O
to BC2GM066466622 TO O
adenosine BC2GM066466622 VB O
and BC2GM066466622 CC O
drug BC2GM066466622 NN O
interactions BC2GM066466622 NNS O
are BC2GM066466622 VBP O
noted BC2GM066466622 VBN O
in BC2GM066466622 IN O
this BC2GM066466622 DT O
article BC2GM066466622 NN O
. BC2GM066466622 . O
. . O O

However BC2GM077515790 RB O
, BC2GM077515790 , O
both BC2GM077515790 DT O
RAR- BC2GM077515790 NNP O
and BC2GM077515790 CC O
RXR-specific BC2GM077515790 NNP O
ligands BC2GM077515790 VBZ O
increase BC2GM077515790 VB O
CaSki BC2GM077515790 NNP O
number BC2GM077515790 NN O
by BC2GM077515790 IN O
> BC2GM077515790 NNP O
or BC2GM077515790 CC O
= BC2GM077515790 VB O
20 BC2GM077515790 CD O
% BC2GM077515790 NN O
. BC2GM077515790 . O
. . O O

The BC2GM006220127 DT O
results BC2GM006220127 NNS O
of BC2GM006220127 IN O
the BC2GM006220127 DT O
transient-transfection BC2GM006220127 NN O
assay BC2GM006220127 NN O
showed BC2GM006220127 VBD O
that BC2GM006220127 IN O
the BC2GM006220127 DT O
Sp1 BC2GM006220127 NNP O
binding BC2GM006220127 NN O
element BC2GM006220127 NN O
located BC2GM006220127 VBN O
in BC2GM006220127 IN O
the BC2GM006220127 DT O
core BC2GM006220127 NN O
region BC2GM006220127 NN O
( BC2GM006220127 ( O
positions BC2GM006220127 NNS O
-- BC2GM006220127 : O
64 BC2GM006220127 CD O
to BC2GM006220127 TO O
+1 BC2GM006220127 NNP O
) BC2GM006220127 ) O
of BC2GM006220127 IN O
the BC2GM006220127 DT O
alpha2-integrin BC2GM006220127 JJ O
promoter BC2GM006220127 NN O
plays BC2GM006220127 VBZ O
an BC2GM006220127 DT O
essential BC2GM006220127 JJ O
role BC2GM006220127 NN O
in BC2GM006220127 IN O
the BC2GM006220127 DT O
alpha2-integrin BC2GM006220127 JJ O
promoter BC2GM006220127 NN O
activity BC2GM006220127 NN O
and BC2GM006220127 CC O
its BC2GM006220127 PRP$ O
downregulation BC2GM006220127 NN O
by BC2GM006220127 IN O
Erb-B2 BC2GM006220127 NNP O
. BC2GM006220127 . O
. . O O

In BC2GM016180513 IN O
normal BC2GM016180513 JJ O
B BC2GM016180513 NNP O
cells BC2GM016180513 NNS O
stimulated BC2GM016180513 VBN O
by BC2GM016180513 IN O
LPS BC2GM016180513 NNP O
or BC2GM016180513 CC O
IL-4 BC2GM016180513 NNP O
, BC2GM016180513 , O
new BC2GM016180513 JJ O
complexes BC2GM016180513 NNS O
appear BC2GM016180513 VBP O
that BC2GM016180513 IN O
bind BC2GM016180513 NN O
to BC2GM016180513 TO O
C BC2GM016180513 NNP O
/ BC2GM016180513 NNP O
EBP BC2GM016180513 NNP O
and BC2GM016180513 CC O
NF-IL-4 BC2GM016180513 NNP O
elements BC2GM016180513 NNS O
, BC2GM016180513 , O
respectively BC2GM016180513 RB O
, BC2GM016180513 , O
located BC2GM016180513 VBN O
within BC2GM016180513 IN O
the BC2GM016180513 DT O
-125 BC2GM016180513 NNP O
/ BC2GM016180513 NNP O
-101 BC2GM016180513 NNP O
region BC2GM016180513 NN O
. BC2GM016180513 . O
. . O O

We BC2GM008579133 PRP O
also BC2GM008579133 RB O
show BC2GM008579133 VBP O
that BC2GM008579133 IN O
in BC2GM008579133 IN O
fusions BC2GM008579133 NNS O
with BC2GM008579133 IN O
the BC2GM008579133 DT O
DNA BC2GM008579133 NN O
binding BC2GM008579133 VBG O
domain BC2GM008579133 NN O
of BC2GM008579133 IN O
GAL4 BC2GM008579133 NNP O
, BC2GM008579133 , O
full BC2GM008579133 JJ O
activity BC2GM008579133 NN O
requires BC2GM008579133 VBZ O
the BC2GM008579133 DT O
entire BC2GM008579133 JJ O
BHV-alpha BC2GM008579133 NNP O
TIF BC2GM008579133 NNP O
, BC2GM008579133 , O
although BC2GM008579133 IN O
both BC2GM008579133 DT O
amino BC2GM008579133 NN O
and BC2GM008579133 CC O
carboxyl BC2GM008579133 NN O
termini BC2GM008579133 NN O
display BC2GM008579133 VB O
some BC2GM008579133 DT O
activity BC2GM008579133 NN O
on BC2GM008579133 IN O
their BC2GM008579133 PRP$ O
own BC2GM008579133 JJ O
. BC2GM008579133 . O
. . O O

Pig BC2GM025711637 NNP O
uPA BC2GM025711637 JJ O
promoter-CAT BC2GM025711637 JJ O
constructs BC2GM025711637 NNS O
were BC2GM025711637 VBD O
more BC2GM025711637 RBR O
active BC2GM025711637 JJ O
than BC2GM025711637 IN O
mouse BC2GM025711637 NN O
constructs BC2GM025711637 NNS O
in BC2GM025711637 IN O
this BC2GM025711637 DT O
assay BC2GM025711637 NN O
. BC2GM025711637 . O
. . O O

Analysis BC2GM054689635 NN O
of BC2GM054689635 IN O
the BC2GM054689635 DT O
DNA-binding BC2GM054689635 NNP O
and BC2GM054689635 CC O
transcriptional BC2GM054689635 JJ O
activation BC2GM054689635 NN O
functions BC2GM054689635 NNS O
of BC2GM054689635 IN O
human BC2GM054689635 JJ O
Fli-1 BC2GM054689635 NNP O
protein BC2GM054689635 NN O
. BC2GM054689635 . O
. . O O

Among BC2GM018119295 IN O
these BC2GM018119295 DT O
, BC2GM018119295 , O
four BC2GM018119295 CD O
patients BC2GM018119295 NNS O
had BC2GM018119295 VBD O
the BC2GM018119295 DT O
AIDS BC2GM018119295 NNP O
syndrome BC2GM018119295 NN O
, BC2GM018119295 , O
while BC2GM018119295 IN O
42 BC2GM018119295 CD O
individuals BC2GM018119295 NNS O
were BC2GM018119295 VBD O
HIV BC2GM018119295 NNP O
carriers BC2GM018119295 NNS O
. BC2GM018119295 . O
. . O O

Analysis BC2GM090387828 NN O
of BC2GM090387828 IN O
the BC2GM090387828 DT O
MCV-1 BC2GM090387828 NNP O
RPO1 BC2GM090387828 NNP O
revealed BC2GM090387828 VBD O
high BC2GM090387828 JJ O
amino BC2GM090387828 NN O
acid BC2GM090387828 NN O
homologies BC2GM090387828 NNS O
to BC2GM090387828 TO O
the BC2GM090387828 DT O
corresponding BC2GM090387828 JJ O
polypeptides BC2GM090387828 NNS O
of BC2GM090387828 IN O
vaccinia BC2GM090387828 NN O
and BC2GM090387828 CC O
variola BC2GM090387828 NN O
virus BC2GM090387828 NN O
. BC2GM090387828 . O
. . O O

The BC2GM033643051 DT O
kinase BC2GM033643051 NN O
domains BC2GM033643051 VBZ O
encoded BC2GM033643051 VBN O
in BC2GM033643051 IN O
the BC2GM033643051 DT O
COOH-terminal BC2GM033643051 JJ O
moiety BC2GM033643051 NN O
are BC2GM033643051 VBP O
94 BC2GM033643051 CD O
% BC2GM033643051 NN O
conserved BC2GM033643051 VBN O
; BC2GM033643051 : O
the BC2GM033643051 DT O
NH2-terminal BC2GM033643051 JJ O
moieties BC2GM033643051 NNS O
are BC2GM033643051 VBP O
approximately BC2GM033643051 RB O
65 BC2GM033643051 CD O
% BC2GM033643051 NN O
homologous BC2GM033643051 JJ O
, BC2GM033643051 , O
suggesting BC2GM033643051 VBG O
this BC2GM033643051 DT O
region BC2GM033643051 NN O
may BC2GM033643051 MD O
encode BC2GM033643051 VB O
sequences BC2GM033643051 NNS O
conferring BC2GM033643051 VBG O
differential BC2GM033643051 JJ O
regulation BC2GM033643051 NN O
of BC2GM033643051 IN O
the BC2GM033643051 DT O
two BC2GM033643051 CD O
kinases BC2GM033643051 NNS O
. BC2GM033643051 . O
. . O O

The BC2GM044203528 DT O
cats BC2GM044203528 NNS O
with BC2GM044203528 IN O
stage-2 BC2GM044203528 JJ O
lymphomas BC2GM044203528 NNS O
that BC2GM044203528 WDT O
were BC2GM044203528 VBD O
FeLV-test BC2GM044203528 NNP O
negative BC2GM044203528 JJ O
had BC2GM044203528 VBD O
the BC2GM044203528 DT O
best BC2GM044203528 JJS O
response BC2GM044203528 NN O
to BC2GM044203528 TO O
treatment BC2GM044203528 NN O
. BC2GM044203528 . O
. . O O

One BC2GM033982048 CD O
month BC2GM033982048 NN O
after BC2GM033982048 IN O
administration BC2GM033982048 NN O
of BC2GM033982048 IN O
131I BC2GM033982048 CD O
, BC2GM033982048 , O
the BC2GM033982048 DT O
29 BC2GM033982048 CD O
cats BC2GM033982048 NNS O
evaluated BC2GM033982048 VBN O
were BC2GM033982048 VBD O
clinically BC2GM033982048 RB O
improved BC2GM033982048 VBN O
, BC2GM033982048 , O
and BC2GM033982048 CC O
24 BC2GM033982048 CD O
( BC2GM033982048 ( O
83 BC2GM033982048 CD O
% BC2GM033982048 NN O
) BC2GM033982048 ) O
of BC2GM033982048 IN O
the BC2GM033982048 DT O
29 BC2GM033982048 CD O
cats BC2GM033982048 NNS O
evaluated BC2GM033982048 VBN O
had BC2GM033982048 VBD O
normal BC2GM033982048 JJ O
serum BC2GM033982048 JJ O
T4 BC2GM033982048 NNP O
concentrations BC2GM033982048 NNS O
, BC2GM033982048 , O
3 BC2GM033982048 CD O
cats BC2GM033982048 NNS O
( BC2GM033982048 ( O
10 BC2GM033982048 CD O
% BC2GM033982048 NN O
) BC2GM033982048 ) O
remained BC2GM033982048 VBD O
hyperthyroxinemic BC2GM033982048 JJ O
, BC2GM033982048 , O
and BC2GM033982048 CC O
2 BC2GM033982048 CD O
cats BC2GM033982048 NNS O
( BC2GM033982048 ( O
7 BC2GM033982048 CD O
% BC2GM033982048 NN O
) BC2GM033982048 ) O
were BC2GM033982048 VBD O
hypothyroxinemic BC2GM033982048 JJ O
. BC2GM033982048 . O
. . O O

Induction BC2GM051120604 NN O
of BC2GM051120604 IN O
interferon-alpha BC2GM051120604 NN O
( BC2GM051120604 ( O
IFNalpha BC2GM051120604 NNP O
) BC2GM051120604 ) O
gene BC2GM051120604 NN O
expression BC2GM051120604 NN O
in BC2GM051120604 IN O
virus-infected BC2GM051120604 JJ O
cells BC2GM051120604 NNS O
requires BC2GM051120604 VBZ O
phosphorylation-induced BC2GM051120604 JJ O
activation BC2GM051120604 NN O
of BC2GM051120604 IN O
the BC2GM051120604 DT O
transcription BC2GM051120604 NN O
factors BC2GM051120604 NNS O
IRF3 BC2GM051120604 NNP O
and BC2GM051120604 CC O
IRF7 BC2GM051120604 NNP O
. BC2GM051120604 . O
. . O O

AMPK BC2GM063781276 NNP O
is BC2GM063781276 VBZ O
a BC2GM063781276 DT O
heterotrimer BC2GM063781276 NN O
composed BC2GM063781276 VBN O
of BC2GM063781276 IN O
a BC2GM063781276 DT O
catalytic BC2GM063781276 JJ O
subunit BC2GM063781276 NN O
( BC2GM063781276 ( O
alpha BC2GM063781276 NN O
) BC2GM063781276 ) O
and BC2GM063781276 CC O
two BC2GM063781276 CD O
regulatory BC2GM063781276 JJ O
subunits BC2GM063781276 NNS O
( BC2GM063781276 ( O
beta BC2GM063781276 NN O
and BC2GM063781276 CC O
gamma BC2GM063781276 NN O
) BC2GM063781276 ) O
. BC2GM063781276 . O
. . O O

Basal BC2GM014796441 NNP O
urinary BC2GM014796441 JJ O
17-hydroxycorticoid BC2GM014796441 JJ O
( BC2GM014796441 ( O
17-OHCS BC2GM014796441 JJ O
) BC2GM014796441 ) O
values BC2GM014796441 NNS O
were BC2GM014796441 VBD O
elevated BC2GM014796441 VBN O
in BC2GM014796441 IN O
9 BC2GM014796441 CD O
/ BC2GM014796441 JJ O
12 BC2GM014796441 CD O
patients BC2GM014796441 NNS O
and BC2GM014796441 CC O
low BC2GM014796441 JJ O
dose BC2GM014796441 NN O
dexamethasone BC2GM014796441 NN O
suppression BC2GM014796441 NN O
test BC2GM014796441 NN O
favoured BC2GM014796441 VBD O
Cushing BC2GM014796441 NNP O
's BC2GM014796441 POS O
syndrome BC2GM014796441 NN O
in BC2GM014796441 IN O
8 BC2GM014796441 CD O
/ BC2GM014796441 JJ O
9 BC2GM014796441 CD O
patients BC2GM014796441 NNS O
. BC2GM014796441 . O
. . O O

Using BC2GM026306487 VBG O
lasers BC2GM026306487 NNS O
in BC2GM026306487 IN O
diabetic BC2GM026306487 JJ O
wound BC2GM026306487 NN O
healing BC2GM026306487 NN O
. BC2GM026306487 . O
. . O O

Evidence BC2GM068839310 NN O
for BC2GM068839310 IN O
a BC2GM068839310 DT O
role BC2GM068839310 NN O
of BC2GM068839310 IN O
Smad6 BC2GM068839310 NNP O
in BC2GM068839310 IN O
chick BC2GM068839310 JJ O
cardiac BC2GM068839310 NN O
development BC2GM068839310 NN O
. BC2GM068839310 . O
. . O O

The BC2GM091729767 DT O
DF3 BC2GM091729767 NNP O
/ BC2GM091729767 NNP O
MUC1 BC2GM091729767 NNP O
gene BC2GM091729767 NN O
encodes BC2GM091729767 VBZ O
a BC2GM091729767 DT O
high BC2GM091729767 JJ O
molecular BC2GM091729767 JJ O
weight BC2GM091729767 VBD O
mucin-like BC2GM091729767 NN O
glycoprotein BC2GM091729767 NN O
which BC2GM091729767 WDT O
is BC2GM091729767 VBZ O
overexpressed BC2GM091729767 VBN O
at BC2GM091729767 IN O
the BC2GM091729767 DT O
transcriptional BC2GM091729767 JJ O
level BC2GM091729767 NN O
in BC2GM091729767 IN O
the BC2GM091729767 DT O
majority BC2GM091729767 NN O
of BC2GM091729767 IN O
human BC2GM091729767 JJ O
breast BC2GM091729767 NN O
cancers BC2GM091729767 NNS O
. BC2GM091729767 . O
. . O O

Finally BC2GM064070438 RB O
, BC2GM064070438 , O
transfection BC2GM064070438 NN O
of BC2GM064070438 IN O
Grb10 BC2GM064070438 NNP O
genes BC2GM064070438 NNS O
with BC2GM064070438 IN O
specific BC2GM064070438 JJ O
mutations BC2GM064070438 NNS O
in BC2GM064070438 IN O
their BC2GM064070438 PRP$ O
SH2 BC2GM064070438 NNP O
domains BC2GM064070438 VBZ O
induces BC2GM064070438 NNS O
apoptosis BC2GM064070438 NN O
in BC2GM064070438 IN O
HTC-IR BC2GM064070438 NNP O
and BC2GM064070438 CC O
COS-7 BC2GM064070438 NNP O
cells BC2GM064070438 NNS O
. BC2GM064070438 . O
. . O O

Genetic BC2GM074994659 JJ O
polymorphisms BC2GM074994659 NNS O
in BC2GM074994659 IN O
the BC2GM074994659 DT O
5'-flanking BC2GM074994659 JJ O
region BC2GM074994659 NN O
change BC2GM074994659 NN O
transcriptional BC2GM074994659 JJ O
regulation BC2GM074994659 NN O
of BC2GM074994659 IN O
the BC2GM074994659 DT O
human BC2GM074994659 JJ O
cytochrome BC2GM074994659 NN O
P450IIE1 BC2GM074994659 NNP O
gene BC2GM074994659 NN O
. BC2GM074994659 . O
. . O O

Effect BC2GM051181003 NN O
of BC2GM051181003 IN O
a BC2GM051181003 DT O
new BC2GM051181003 JJ O
positive BC2GM051181003 JJ O
inotropic BC2GM051181003 NN O
agent BC2GM051181003 NN O
( BC2GM051181003 ( O
OPC-8212 BC2GM051181003 NNP O
) BC2GM051181003 ) O
on BC2GM051181003 IN O
intracellular BC2GM051181003 JJ O
potential BC2GM051181003 NN O
of BC2GM051181003 IN O
isolated BC2GM051181003 JJ O
canine BC2GM051181003 NN O
ventricular BC2GM051181003 JJ O
papillary BC2GM051181003 JJ O
muscle BC2GM051181003 NN O
. BC2GM051181003 . O
. . O O

Mouse BC2GM011323900 NNP O
macrophage BC2GM011323900 NN O
beta BC2GM011323900 NN O
subunit BC2GM011323900 NN O
( BC2GM011323900 ( O
CD11b BC2GM011323900 NNP O
) BC2GM011323900 ) O
cDNA BC2GM011323900 NN O
for BC2GM011323900 IN O
the BC2GM011323900 DT O
CR3 BC2GM011323900 NNP O
complement BC2GM011323900 NN O
receptor BC2GM011323900 NN O
/ BC2GM011323900 VBD O
Mac-1 BC2GM011323900 NNP O
antigen BC2GM011323900 NN O
. BC2GM011323900 . O
. . O O

There BC2GM041090140 EX O
was BC2GM041090140 VBD O
91 BC2GM041090140 CD O
% BC2GM041090140 NN O
concordance BC2GM041090140 NN O
between BC2GM041090140 IN O
ST-RD BC2GM041090140 NNP O
/ BC2GM041090140 NNP O
RI BC2GM041090140 NNP O
/ BC2GM041090140 NNP O
LRD BC2GM041090140 NNP O
201Tl BC2GM041090140 CD O
and BC2GM041090140 CC O
R-ST BC2GM041090140 NNP O
/ BC2GM041090140 NNP O
N BC2GM041090140 NNP O
+ BC2GM041090140 NNP O
Inf BC2GM041090140 NNP O
99Tcm-tetrofosmin BC2GM041090140 CD O
imaging BC2GM041090140 VBG O
regarding BC2GM041090140 VBG O
reversibility BC2GM041090140 NN O
. BC2GM041090140 . O
. . O O

7-Nitroindazole BC2GM055589568 JJ O
( BC2GM055589568 ( O
7NI BC2GM055589568 CD O
) BC2GM055589568 ) O
, BC2GM055589568 , O
a BC2GM055589568 DT O
relatively BC2GM055589568 RB O
selective BC2GM055589568 JJ O
neuronal BC2GM055589568 JJ O
nitric BC2GM055589568 JJ O
oxide BC2GM055589568 NN O
synthase BC2GM055589568 NN O
( BC2GM055589568 ( O
nNOS BC2GM055589568 JJ O
) BC2GM055589568 ) O
inhibitor BC2GM055589568 NN O
. BC2GM055589568 . O
was BC2GM055589568 VBD O
intraperitoneally BC2GM055589568 RB O
administered BC2GM055589568 VBN O
to BC2GM055589568 TO O
the BC2GM055589568 DT O
guinea BC2GM055589568 NN O
pigs BC2GM055589568 NNS O
30 BC2GM055589568 CD O
minutes BC2GM055589568 NNS O
before BC2GM055589568 IN O
the BC2GM055589568 DT O
onset BC2GM055589568 NN O
of BC2GM055589568 IN O
local BC2GM055589568 JJ O
anoxia BC2GM055589568 NN O
. BC2GM055589568 . O
. . O O

The BC2GM052866692 DT O
free BC2GM052866692 JJ O
fraction BC2GM052866692 NN O
of BC2GM052866692 IN O
amitriptyline BC2GM052866692 NN O
( BC2GM052866692 ( O
AT BC2GM052866692 NNP O
) BC2GM052866692 ) O
, BC2GM052866692 , O
measured BC2GM052866692 VBN O
by BC2GM052866692 IN O
equilibrium BC2GM052866692 JJ O
dialysis BC2GM052866692 NN O
in BC2GM052866692 IN O
plasma BC2GM052866692 NN O
from BC2GM052866692 IN O
29 BC2GM052866692 CD O
AT-treated BC2GM052866692 JJ O
depressed BC2GM052866692 JJ O
patients BC2GM052866692 NNS O
, BC2GM052866692 , O
was BC2GM052866692 VBD O
5.4-9.8 BC2GM052866692 JJ O
% BC2GM052866692 NN O
( BC2GM052866692 ( O
mean BC2GM052866692 JJ O
7.7 BC2GM052866692 CD O
% BC2GM052866692 NN O
) BC2GM052866692 ) O
, BC2GM052866692 , O
which BC2GM052866692 WDT O
was BC2GM052866692 VBD O
the BC2GM052866692 DT O
same BC2GM052866692 JJ O
as BC2GM052866692 IN O
the BC2GM052866692 DT O
values BC2GM052866692 NNS O
in BC2GM052866692 IN O
26 BC2GM052866692 CD O
healthy BC2GM052866692 JJ O
controls BC2GM052866692 NNS O
( BC2GM052866692 ( O
4.9-9.6 BC2GM052866692 CD O
% BC2GM052866692 NN O
, BC2GM052866692 , O
mean BC2GM052866692 JJ O
7.6 BC2GM052866692 CD O
% BC2GM052866692 NN O
) BC2GM052866692 ) O
. BC2GM052866692 . O
. . O O

A BC2GM033123409 DT O
characteristic BC2GM033123409 JJ O
feature BC2GM033123409 NN O
is BC2GM033123409 VBZ O
their BC2GM033123409 PRP$ O
tendency BC2GM033123409 NN O
to BC2GM033123409 TO O
form BC2GM033123409 VB O
homo- BC2GM033123409 JJ O
and BC2GM033123409 CC O
/ BC2GM033123409 JJ O
or BC2GM033123409 CC O
heterodimeric BC2GM033123409 JJ O
complexes BC2GM033123409 NNS O
. BC2GM033123409 . O
. . O O

Electron BC2GM073294653 NNP O
microscopy BC2GM073294653 NN O
of BC2GM073294653 IN O
pH BC2GM073294653 JJ O
7.5-treated BC2GM073294653 JJ O
TMV BC2GM073294653 NNP O
particles BC2GM073294653 NNS O
incubated BC2GM073294653 VBN O
in BC2GM073294653 IN O
SPN-treated BC2GM073294653 JJ O
wheatgerm BC2GM073294653 JJ O
extract BC2GM073294653 NN O
or BC2GM073294653 CC O
rabbit BC2GM073294653 NN O
reticulocyte BC2GM073294653 JJ O
lysate BC2GM073294653 NN O
, BC2GM073294653 , O
showed BC2GM073294653 VBD O
that BC2GM073294653 IN O
approximately BC2GM073294653 RB O
10 BC2GM073294653 CD O
% BC2GM073294653 NN O
of BC2GM073294653 IN O
virions BC2GM073294653 NNS O
complexed BC2GM073294653 VBN O
with BC2GM073294653 IN O
one BC2GM073294653 CD O
ribosome BC2GM073294653 NN O
and BC2GM073294653 CC O
approximately BC2GM073294653 RB O
10 BC2GM073294653 CD O
% BC2GM073294653 NN O
with BC2GM073294653 IN O
two BC2GM073294653 CD O
bound BC2GM073294653 NN O
ribosomes BC2GM073294653 NNS O
, BC2GM073294653 , O
confirming BC2GM073294653 VBG O
that BC2GM073294653 IN O
omega BC2GM073294653 NN O
at BC2GM073294653 IN O
least BC2GM073294653 JJS O
had BC2GM073294653 VBD O
been BC2GM073294653 VBN O
uncoated BC2GM073294653 VBN O
. BC2GM073294653 . O
. . O O

To BC2GM002932224 TO O
assess BC2GM002932224 VB O
the BC2GM002932224 DT O
safety BC2GM002932224 NN O
of BC2GM002932224 IN O
the BC2GM002932224 DT O
angiotensin BC2GM002932224 NN O
converting BC2GM002932224 VBG O
enzyme BC2GM002932224 JJ O
inhibitor BC2GM002932224 NN O
enalapril BC2GM002932224 VBD O
a BC2GM002932224 DT O
multicenter BC2GM002932224 NN O
, BC2GM002932224 , O
open BC2GM002932224 JJ O
, BC2GM002932224 , O
randomized BC2GM002932224 VBN O
, BC2GM002932224 , O
prazosin-controlled BC2GM002932224 JJ O
trial BC2GM002932224 NN O
was BC2GM002932224 VBD O
designed BC2GM002932224 VBN O
comparing BC2GM002932224 VBG O
the BC2GM002932224 DT O
incidence BC2GM002932224 NN O
and BC2GM002932224 CC O
severity BC2GM002932224 NN O
of BC2GM002932224 IN O
symptomatic BC2GM002932224 JJ O
hypotension BC2GM002932224 NN O
on BC2GM002932224 IN O
the BC2GM002932224 DT O
first BC2GM002932224 JJ O
day BC2GM002932224 NN O
of BC2GM002932224 IN O
treatment BC2GM002932224 NN O
. BC2GM002932224 . O
. . O O

Intrathecal BC2GM065119340 JJ O
injections BC2GM065119340 NNS O
of BC2GM065119340 IN O
small BC2GM065119340 JJ O
volumes BC2GM065119340 NNS O
of BC2GM065119340 IN O
the BC2GM065119340 DT O
alpha BC2GM065119340 JJ O
2-adrenoceptor BC2GM065119340 JJ O
agonists BC2GM065119340 NNS O
, BC2GM065119340 , O
xylazine BC2GM065119340 NN O
and BC2GM065119340 CC O
clonidine BC2GM065119340 NN O
, BC2GM065119340 , O
into BC2GM065119340 IN O
the BC2GM065119340 DT O
cervical BC2GM065119340 JJ O
region BC2GM065119340 NN O
of BC2GM065119340 IN O
the BC2GM065119340 DT O
spinal BC2GM065119340 JJ O
cord BC2GM065119340 NN O
of BC2GM065119340 IN O
conscious BC2GM065119340 JJ O
unrestrained BC2GM065119340 JJ O
sheep BC2GM065119340 NN O
produced BC2GM065119340 VBD O
a BC2GM065119340 DT O
dose-dependent BC2GM065119340 JJ O
analgesia BC2GM065119340 NN O
of BC2GM065119340 IN O
the BC2GM065119340 DT O
forelimbs BC2GM065119340 NN O
as BC2GM065119340 IN O
measured BC2GM065119340 VBN O
using BC2GM065119340 VBG O
a BC2GM065119340 DT O
mechanical BC2GM065119340 JJ O
pressure BC2GM065119340 NN O
device BC2GM065119340 NN O
. BC2GM065119340 . O
. . O O

Moreover BC2GM005540562 RB O
, BC2GM005540562 , O
such BC2GM005540562 JJ O
mutations BC2GM005540562 NNS O
lead BC2GM005540562 VBP O
to BC2GM005540562 TO O
a BC2GM005540562 DT O
dramatic BC2GM005540562 JJ O
transition BC2GM005540562 NN O
in BC2GM005540562 IN O
chromatin BC2GM005540562 NN O
structure BC2GM005540562 NN O
: BC2GM005540562 : O
the BC2GM005540562 DT O
DNase BC2GM005540562 NNP O
I BC2GM005540562 PRP O
hypersensitive BC2GM005540562 JJ O
region BC2GM005540562 NN O
is BC2GM005540562 VBZ O
replaced BC2GM005540562 VBN O
by BC2GM005540562 IN O
two BC2GM005540562 CD O
stable BC2GM005540562 JJ O
, BC2GM005540562 , O
sequence-positioned BC2GM005540562 JJ O
nucleosomes BC2GM005540562 NNS O
. BC2GM005540562 . O
. . O O

These BC2GM078278195 DT O
data BC2GM078278195 NNS O
, BC2GM078278195 , O
taken BC2GM078278195 VBN O
together BC2GM078278195 RB O
, BC2GM078278195 , O
suggest BC2GM078278195 VBP O
that BC2GM078278195 IN O
CRF BC2GM078278195 NNP O
produces BC2GM078278195 VBZ O
its BC2GM078278195 PRP$ O
behavioral BC2GM078278195 JJ O
activating BC2GM078278195 NN O
and BC2GM078278195 CC O
anxiogenic BC2GM078278195 JJ O
effects BC2GM078278195 NNS O
, BC2GM078278195 , O
at BC2GM078278195 IN O
least BC2GM078278195 JJS O
in BC2GM078278195 IN O
part BC2GM078278195 NN O
, BC2GM078278195 , O
by BC2GM078278195 IN O
increasing BC2GM078278195 VBG O
the BC2GM078278195 DT O
activity BC2GM078278195 NN O
of BC2GM078278195 IN O
LC BC2GM078278195 NNP O
noradrenergic BC2GM078278195 JJ O
neurons BC2GM078278195 NNS O
. BC2GM078278195 . O
. . O O

3 BC2GM025369087 LS O
) BC2GM025369087 ) O
The BC2GM025369087 DT O
progress BC2GM025369087 NN O
of BC2GM025369087 IN O
fibrinolysis BC2GM025369087 NN O
was BC2GM025369087 VBD O
observed BC2GM025369087 VBN O
by BC2GM025369087 IN O
serial BC2GM025369087 JJ O
collection BC2GM025369087 NN O
of BC2GM025369087 IN O
middle BC2GM025369087 JJ O
ear BC2GM025369087 JJ O
fluid BC2GM025369087 NN O
in BC2GM025369087 IN O
the BC2GM025369087 DT O
same BC2GM025369087 JJ O
side BC2GM025369087 NN O
ear BC2GM025369087 NN O
of BC2GM025369087 IN O
5 BC2GM025369087 CD O
cases BC2GM025369087 NNS O
out BC2GM025369087 IN O
of BC2GM025369087 IN O
17 BC2GM025369087 CD O
cases BC2GM025369087 NNS O
having BC2GM025369087 VBG O
much BC2GM025369087 JJ O
activity BC2GM025369087 NN O
for BC2GM025369087 IN O
fibrin BC2GM025369087 JJ O
degradation BC2GM025369087 NN O
, BC2GM025369087 , O
and BC2GM025369087 CC O
lowering BC2GM025369087 NN O
of BC2GM025369087 IN O
fibrinolytic BC2GM025369087 JJ O
activity BC2GM025369087 NN O
was BC2GM025369087 VBD O
revealed BC2GM025369087 VBN O
in BC2GM025369087 IN O
4 BC2GM025369087 CD O
out BC2GM025369087 IN O
of BC2GM025369087 IN O
these BC2GM025369087 DT O
5 BC2GM025369087 CD O
cases BC2GM025369087 NNS O
as BC2GM025369087 IN O
the BC2GM025369087 DT O
result BC2GM025369087 NN O
. BC2GM025369087 . O
. . O O

Ionic BC2GM049472280 JJ O
composition BC2GM049472280 NN O
( BC2GM049472280 ( O
Na+ BC2GM049472280 NNP O
, BC2GM049472280 , O
K+ BC2GM049472280 NNP O
, BC2GM049472280 , O
Ca+2 BC2GM049472280 NNP O
, BC2GM049472280 , O
and BC2GM049472280 CC O
Mg2+ BC2GM049472280 NNP O
) BC2GM049472280 ) O
of BC2GM049472280 IN O
cerebrospinal BC2GM049472280 JJ O
fluid BC2GM049472280 NN O
and BC2GM049472280 CC O
feeding BC2GM049472280 VBG O
behavior BC2GM049472280 NN O
in BC2GM049472280 IN O
sheep BC2GM049472280 NN O
. BC2GM049472280 . O
. . O O

Results BC2GM040951364 NNS O
: BC2GM040951364 : O
hepatic BC2GM040951364 JJ O
hydatidosis BC2GM040951364 NN O
: BC2GM040951364 : O
177 BC2GM040951364 CD O
patients BC2GM040951364 NNS O
. BC2GM040951364 . O
. . O O

Epithelial BC2GM043526079 JJ O
cells BC2GM043526079 NNS O
had BC2GM043526079 VBD O
abnormal BC2GM043526079 JJ O
and BC2GM043526079 CC O
accelerated BC2GM043526079 JJ O
exfoliation BC2GM043526079 NN O
which BC2GM043526079 WDT O
resulted BC2GM043526079 VBD O
in BC2GM043526079 IN O
multifocal BC2GM043526079 JJ O
epithelial BC2GM043526079 JJ O
defects BC2GM043526079 NNS O
. BC2GM043526079 . O
. . O O

LCCH1 BC2GM070558287 NNP O
was BC2GM070558287 VBD O
identical BC2GM070558287 JJ O
to BC2GM070558287 TO O
the BC2GM070558287 DT O
Rdl BC2GM070558287 NNP O
gene BC2GM070558287 NN O
, BC2GM070558287 , O
a BC2GM070558287 DT O
known BC2GM070558287 VBN O
GABA BC2GM070558287 NNP O
receptor BC2GM070558287 NN O
subunit BC2GM070558287 NN O
gene BC2GM070558287 NN O
from BC2GM070558287 IN O
D. BC2GM070558287 NNP O
melanogaster BC2GM070558287 NN O
, BC2GM070558287 , O
whereas BC2GM070558287 JJ O
LCCH2 BC2GM070558287 NNP O
and BC2GM070558287 CC O
LCCH3 BC2GM070558287 NNP O
were BC2GM070558287 VBD O
novel BC2GM070558287 JJ O
D. BC2GM070558287 NNP O
melanogaster BC2GM070558287 NN O
sequences BC2GM070558287 NNS O
that BC2GM070558287 WDT O
exhibited BC2GM070558287 VBD O
structural BC2GM070558287 JJ O
similarity BC2GM070558287 NN O
to BC2GM070558287 TO O
other BC2GM070558287 JJ O
members BC2GM070558287 NNS O
of BC2GM070558287 IN O
the BC2GM070558287 DT O
ligand-gated BC2GM070558287 JJ O
chloride BC2GM070558287 NN O
channel BC2GM070558287 NN O
gene BC2GM070558287 NN O
family BC2GM070558287 NN O
. BC2GM070558287 . O
. . O O

Rad18 BC2GM005391893 NNP O
is BC2GM005391893 VBZ O
required BC2GM005391893 VBN O
for BC2GM005391893 IN O
DNA BC2GM005391893 NNP O
repair BC2GM005391893 NN O
and BC2GM005391893 CC O
checkpoint BC2GM005391893 NN O
responses BC2GM005391893 NNS O
in BC2GM005391893 IN O
fission BC2GM005391893 NN O
yeast BC2GM005391893 NN O
. BC2GM005391893 . O
. . O O

In BC2GM040122571 IN O
the BC2GM040122571 DT O
case BC2GM040122571 NN O
of BC2GM040122571 IN O
the BC2GM040122571 DT O
pT181 BC2GM040122571 NN O
plasmid BC2GM040122571 NN O
, BC2GM040122571 , O
inactivation BC2GM040122571 NN O
of BC2GM040122571 IN O
the BC2GM040122571 DT O
initiator BC2GM040122571 NN O
RepC BC2GM040122571 NNP O
protein BC2GM040122571 NN O
occurs BC2GM040122571 VBZ O
by BC2GM040122571 IN O
the BC2GM040122571 DT O
attachment BC2GM040122571 NN O
of BC2GM040122571 IN O
an BC2GM040122571 DT O
oligonucleotide BC2GM040122571 NN O
to BC2GM040122571 TO O
its BC2GM040122571 PRP$ O
active BC2GM040122571 JJ O
tyrosine BC2GM040122571 NN O
residue BC2GM040122571 NN O
. BC2GM040122571 . O
. . O O

Retinoic BC2GM039354270 NNP O
acid BC2GM039354270 NN O
, BC2GM039354270 , O
which BC2GM039354270 WDT O
inhibits BC2GM039354270 VBZ O
the BC2GM039354270 DT O
progression BC2GM039354270 NN O
of BC2GM039354270 IN O
certain BC2GM039354270 JJ O
cancers BC2GM039354270 NNS O
, BC2GM039354270 , O
repressed BC2GM039354270 VBD O
v-src-induced BC2GM039354270 JJ O
MMP-1 BC2GM039354270 NNP O
transcription BC2GM039354270 NN O
. BC2GM039354270 . O
. . O O

The BC2GM018630607 DT O
protein BC2GM018630607 NN O
was BC2GM018630607 VBD O
overexpressed BC2GM018630607 VBN O
in BC2GM018630607 IN O
Escherichia BC2GM018630607 NNP O
coli BC2GM018630607 NN O
and BC2GM018630607 CC O
purified BC2GM018630607 VBD O
to BC2GM018630607 TO O
homogeneity BC2GM018630607 NN O
. BC2GM018630607 . O
. . O O

RESULTS BC2GM035614224 NN O
: BC2GM035614224 : O
At BC2GM035614224 IN O
short BC2GM035614224 JJ O
dwell BC2GM035614224 NN O
times BC2GM035614224 NNS O
, BC2GM035614224 , O
uncorrected BC2GM035614224 JJ O
( BC2GM035614224 ( O
whole BC2GM035614224 JJ O
plasma BC2GM035614224 NN O
) BC2GM035614224 ) O
D BC2GM035614224 NNP O
/ BC2GM035614224 NNP O
P BC2GM035614224 NNP O
and BC2GM035614224 CC O
Cp BC2GM035614224 NNP O
of BC2GM035614224 IN O
urea BC2GM035614224 JJ O
values BC2GM035614224 NNS O
were BC2GM035614224 VBD O
higher BC2GM035614224 JJR O
than BC2GM035614224 IN O
the BC2GM035614224 DT O
corrected BC2GM035614224 VBN O
( BC2GM035614224 ( O
plasma BC2GM035614224 JJ O
water BC2GM035614224 NN O
) BC2GM035614224 ) O
values BC2GM035614224 NNS O
by BC2GM035614224 IN O
5.7 BC2GM035614224 CD O
% BC2GM035614224 NN O
-5.9 BC2GM035614224 CD O
% BC2GM035614224 NN O
. BC2GM035614224 . O
. . O O

A BC2GM091683569 DT O
Meis1 BC2GM091683569 NNP O
cDNA BC2GM091683569 NN O
clone BC2GM091683569 NN O
that BC2GM091683569 WDT O
encoded BC2GM091683569 VBD O
a BC2GM091683569 DT O
novel BC2GM091683569 JJ O
member BC2GM091683569 NN O
of BC2GM091683569 IN O
the BC2GM091683569 DT O
homeobox BC2GM091683569 NN O
gene BC2GM091683569 NN O
family BC2GM091683569 NN O
was BC2GM091683569 VBD O
identified BC2GM091683569 VBN O
. BC2GM091683569 . O
. . O O

Insulin-stimulated BC2GM022578153 JJ O
autophosphorylation BC2GM022578153 NN O
at BC2GM022578153 IN O
specific BC2GM022578153 JJ O
sites BC2GM022578153 NNS O
in BC2GM022578153 IN O
the BC2GM022578153 DT O
tyrosine BC2GM022578153 NN O
kinase BC2GM022578153 NN O
domain BC2GM022578153 NN O
of BC2GM022578153 IN O
the BC2GM022578153 DT O
receptor BC2GM022578153 NN O
's BC2GM022578153 POS O
beta-subunit BC2GM022578153 NN O
is BC2GM022578153 VBZ O
correlated BC2GM022578153 VBN O
kinetically BC2GM022578153 RB O
with BC2GM022578153 IN O
activation BC2GM022578153 NN O
of BC2GM022578153 IN O
kinase-catalyzed BC2GM022578153 JJ O
phosphorylation BC2GM022578153 NN O
of BC2GM022578153 IN O
a BC2GM022578153 DT O
model BC2GM022578153 NN O
substrate BC2GM022578153 NN O
( BC2GM022578153 ( O
reduced BC2GM022578153 VBN O
and BC2GM022578153 CC O
carboxyamidomethylated BC2GM022578153 VBN O
lysozyme BC2GM022578153 NN O
; BC2GM022578153 : O
RCAM-lysozyme BC2GM022578153 NNP O
) BC2GM022578153 ) O
. BC2GM022578153 . O
. . O O

DESIGN BC2GM023743832 NNP O
, BC2GM023743832 , O
SETTING BC2GM023743832 NNP O
AND BC2GM023743832 CC O
SUBJECTS BC2GM023743832 NNP O
: BC2GM023743832 : O
The BC2GM023743832 DT O
analysis BC2GM023743832 NN O
is BC2GM023743832 VBZ O
based BC2GM023743832 VBN O
on BC2GM023743832 IN O
data BC2GM023743832 NNS O
collected BC2GM023743832 VBN O
in BC2GM023743832 IN O
the BC2GM023743832 DT O
first BC2GM023743832 JJ O
two BC2GM023743832 CD O
rounds BC2GM023743832 NNS O
of BC2GM023743832 IN O
the BC2GM023743832 DT O
nationally BC2GM023743832 RB O
representative BC2GM023743832 JJ O
Ghana BC2GM023743832 NNP O
Living BC2GM023743832 NNP O
Standards BC2GM023743832 NNP O
Survey BC2GM023743832 NNP O
, BC2GM023743832 , O
held BC2GM023743832 VBD O
in BC2GM023743832 IN O
1987 BC2GM023743832 CD O
/ BC2GM023743832 NN O
88 BC2GM023743832 CD O
( BC2GM023743832 ( O
GLSS-I BC2GM023743832 NNP O
) BC2GM023743832 ) O
and BC2GM023743832 CC O
1988 BC2GM023743832 CD O
/ BC2GM023743832 NN O
89 BC2GM023743832 CD O
( BC2GM023743832 ( O
GLSS-II BC2GM023743832 NNP O
) BC2GM023743832 ) O
, BC2GM023743832 , O
with BC2GM023743832 IN O
both BC2GM023743832 DT O
surveys BC2GM023743832 NNS O
covering BC2GM023743832 VBG O
approximately BC2GM023743832 RB O
3000 BC2GM023743832 CD O
households BC2GM023743832 NNS O
. BC2GM023743832 . O
. . O O

Siglec-9 BC2GM070673792 NNP O
is BC2GM070673792 VBZ O
predicted BC2GM070673792 VBN O
to BC2GM070673792 TO O
contain BC2GM070673792 VB O
three BC2GM070673792 CD O
extracellular BC2GM070673792 JJ O
immunoglobulin-like BC2GM070673792 JJ O
domains BC2GM070673792 NNS O
that BC2GM070673792 WDT O
comprise BC2GM070673792 VBP O
an BC2GM070673792 DT O
N-terminal BC2GM070673792 JJ O
V-set BC2GM070673792 NNP O
domain BC2GM070673792 NN O
and BC2GM070673792 CC O
two BC2GM070673792 CD O
C2-set BC2GM070673792 JJ O
domains BC2GM070673792 NNS O
, BC2GM070673792 , O
a BC2GM070673792 DT O
transmembrane BC2GM070673792 JJ O
region BC2GM070673792 NN O
and BC2GM070673792 CC O
a BC2GM070673792 DT O
cytoplasmic BC2GM070673792 JJ O
tail BC2GM070673792 NN O
containing BC2GM070673792 VBG O
two BC2GM070673792 CD O
putative BC2GM070673792 JJ O
tyrosine-based BC2GM070673792 JJ O
signaling BC2GM070673792 VBG O
motifs BC2GM070673792 NNS O
. BC2GM070673792 . O
. . O O

Analysis BC2GM081586375 NN O
of BC2GM081586375 IN O
domain BC2GM081586375 NN O
deletion BC2GM081586375 NN O
mutants BC2GM081586375 NNS O
demonstrated BC2GM081586375 VBD O
strong BC2GM081586375 JJ O
synergy BC2GM081586375 NN O
between BC2GM081586375 IN O
the BC2GM081586375 DT O
RRM BC2GM081586375 NNP O
and BC2GM081586375 CC O
a BC2GM081586375 DT O
central BC2GM081586375 JJ O
degenerate BC2GM081586375 NN O
RRM BC2GM081586375 NNP O
repeat BC2GM081586375 NN O
in BC2GM081586375 IN O
binding BC2GM081586375 VBG O
to BC2GM081586375 TO O
RNA BC2GM081586375 NNP O
. BC2GM081586375 . O
. . O O

Reduced BC2GM079045353 NNP O
glutathione BC2GM079045353 NN O
in BC2GM079045353 IN O
whole BC2GM079045353 JJ O
blood BC2GM079045353 NN O
decreases BC2GM079045353 NNS O
within BC2GM079045353 IN O
a BC2GM079045353 DT O
blood BC2GM079045353 NN O
Se BC2GM079045353 NNP O
range BC2GM079045353 NN O
of BC2GM079045353 IN O
1.01 BC2GM079045353 CD O
to BC2GM079045353 TO O
2.28 BC2GM079045353 CD O
micrograms BC2GM079045353 NNS O
in BC2GM079045353 IN O
the BC2GM079045353 DT O
high BC2GM079045353 JJ O
Se BC2GM079045353 NNP O
area BC2GM079045353 NN O
. BC2GM079045353 . O
. . O O

This BC2GM043550701 DT O
demonstrates BC2GM043550701 VBZ O
a BC2GM043550701 DT O
relative BC2GM043550701 JJ O
independence BC2GM043550701 NN O
of BC2GM043550701 IN O
the BC2GM043550701 DT O
given BC2GM043550701 VBN O
synchronizer BC2GM043550701 NN O
of BC2GM043550701 IN O
rhythmicity BC2GM043550701 NN O
at BC2GM043550701 IN O
a BC2GM043550701 DT O
tissue BC2GM043550701 NN O
level BC2GM043550701 NN O
from BC2GM043550701 IN O
any BC2GM043550701 DT O
influence BC2GM043550701 NN O
of BC2GM043550701 IN O
the BC2GM043550701 DT O
higher BC2GM043550701 JJR O
regulatory BC2GM043550701 JJ O
center BC2GM043550701 NN O
. BC2GM043550701 . O
. . O O

Candidate BC2GM070372119 NNP O
factors BC2GM070372119 NNS O
have BC2GM070372119 VBP O
been BC2GM070372119 VBN O
identified BC2GM070372119 VBN O
by BC2GM070372119 IN O
the BC2GM070372119 DT O
observation BC2GM070372119 NN O
that BC2GM070372119 WDT O
changes BC2GM070372119 VBZ O
in BC2GM070372119 IN O
glucocorticoid BC2GM070372119 JJ O
induction BC2GM070372119 NN O
parameters BC2GM070372119 NNS O
in BC2GM070372119 IN O
CV-1 BC2GM070372119 NNP O
cells BC2GM070372119 NNS O
could BC2GM070372119 MD O
be BC2GM070372119 VB O
reproduced BC2GM070372119 VBN O
by BC2GM070372119 IN O
varying BC2GM070372119 VBG O
the BC2GM070372119 DT O
cellular BC2GM070372119 JJ O
levels BC2GM070372119 NNS O
of BC2GM070372119 IN O
coactivators BC2GM070372119 NNS O
[ BC2GM070372119 VBP O
transcriptional BC2GM070372119 JJ O
intermediary BC2GM070372119 JJ O
factor BC2GM070372119 NN O
2 BC2GM070372119 CD O
( BC2GM070372119 ( O
TIF2 BC2GM070372119 NNP O
) BC2GM070372119 ) O
, BC2GM070372119 , O
steroid BC2GM070372119 JJ O
receptor BC2GM070372119 NN O
coactivator BC2GM070372119 NN O
1 BC2GM070372119 CD O
( BC2GM070372119 ( O
SRC-1 BC2GM070372119 NNP O
) BC2GM070372119 ) O
, BC2GM070372119 , O
and BC2GM070372119 CC O
amplified BC2GM070372119 VBD O
in BC2GM070372119 IN O
breast BC2GM070372119 NN O
cancer BC2GM070372119 NN O
1 BC2GM070372119 CD O
( BC2GM070372119 ( O
AIB1 BC2GM070372119 NNP O
) BC2GM070372119 ) O
] BC2GM070372119 NN O
, BC2GM070372119 , O
comodulator BC2GM070372119 NN O
[ BC2GM070372119 VBD O
CREB-binding BC2GM070372119 NNP O
protein BC2GM070372119 NN O
( BC2GM070372119 ( O
CBP BC2GM070372119 NNP O
) BC2GM070372119 ) O
] BC2GM070372119 NN O
, BC2GM070372119 , O
or BC2GM070372119 CC O
corepressor BC2GM070372119 NN O
[ BC2GM070372119 CD O
silencing BC2GM070372119 VBG O
mediator BC2GM070372119 NN O
for BC2GM070372119 IN O
retinoid BC2GM070372119 NN O
and BC2GM070372119 CC O
thyroid-hormone BC2GM070372119 NN O
receptors BC2GM070372119 NNS O
( BC2GM070372119 ( O
SMRT BC2GM070372119 NNP O
) BC2GM070372119 ) O
] BC2GM070372119 NN O
without BC2GM070372119 IN O
concomitant BC2GM070372119 NN O
increases BC2GM070372119 NNS O
in BC2GM070372119 IN O
GR BC2GM070372119 NNP O
. BC2GM070372119 . O
. . O O

In BC2GM028392901 IN O
contrast BC2GM028392901 NN O
, BC2GM028392901 , O
a BC2GM028392901 DT O
similar BC2GM028392901 JJ O
fusion BC2GM028392901 NN O
protein BC2GM028392901 NN O
( BC2GM028392901 ( O
hGH-LDLR-DAF17 BC2GM028392901 JJ O
, BC2GM028392901 , O
abbreviated BC2GM028392901 JJ O
HLD BC2GM028392901 NNP O
) BC2GM028392901 ) O
containing BC2GM028392901 VBG O
a BC2GM028392901 DT O
fragment BC2GM028392901 NN O
of BC2GM028392901 IN O
the BC2GM028392901 DT O
serine BC2GM028392901 JJ O
/ BC2GM028392901 NNP O
threonine-rich BC2GM028392901 JJ O
domain BC2GM028392901 NN O
of BC2GM028392901 IN O
the BC2GM028392901 DT O
LDL BC2GM028392901 NNP O
receptor BC2GM028392901 NN O
( BC2GM028392901 ( O
LDLR BC2GM028392901 NNP O
) BC2GM028392901 ) O
in BC2GM028392901 IN O
place BC2GM028392901 NN O
of BC2GM028392901 IN O
the BC2GM028392901 DT O
DAF-derived BC2GM028392901 NNP O
serine BC2GM028392901 NN O
/ BC2GM028392901 NNP O
threonine-rich BC2GM028392901 JJ O
sequences BC2GM028392901 NNS O
, BC2GM028392901 , O
does BC2GM028392901 VBZ O
not BC2GM028392901 RB O
become BC2GM028392901 VB O
GPI BC2GM028392901 NNP O
anchored BC2GM028392901 JJ O
. BC2GM028392901 . O
. . O O

Here BC2GM057451821 RB O
we BC2GM057451821 PRP O
report BC2GM057451821 VBP O
the BC2GM057451821 DT O
cloning BC2GM057451821 NN O
of BC2GM057451821 IN O
the BC2GM057451821 DT O
hemF BC2GM057451821 NN O
gene BC2GM057451821 NN O
, BC2GM057451821 , O
encoding BC2GM057451821 VBG O
the BC2GM057451821 DT O
aerobic BC2GM057451821 JJ O
coproporphyrinogen BC2GM057451821 NN O
III BC2GM057451821 NNP O
oxidase BC2GM057451821 NN O
from BC2GM057451821 IN O
Escherichia BC2GM057451821 NNP O
coli BC2GM057451821 NNS O
, BC2GM057451821 , O
by BC2GM057451821 IN O
functional BC2GM057451821 JJ O
complementation BC2GM057451821 NN O
of BC2GM057451821 IN O
a BC2GM057451821 DT O
Saccharomyces BC2GM057451821 NNP O
cerevisiae BC2GM057451821 NN O
HEM13 BC2GM057451821 NNP O
mutant BC2GM057451821 NN O
. BC2GM057451821 . O
. . O O

This BC2GM026620474 DT O
sequence BC2GM026620474 NN O
was BC2GM026620474 VBD O
sufficient BC2GM026620474 JJ O
to BC2GM026620474 TO O
confer BC2GM026620474 VB O
p53-dependent BC2GM026620474 JJ O
activation BC2GM026620474 NN O
to BC2GM026620474 TO O
a BC2GM026620474 DT O
heterologous BC2GM026620474 JJ O
promoter BC2GM026620474 NN O
and BC2GM026620474 CC O
p53 BC2GM026620474 NN O
was BC2GM026620474 VBD O
capable BC2GM026620474 JJ O
of BC2GM026620474 IN O
binding BC2GM026620474 VBG O
to BC2GM026620474 TO O
this BC2GM026620474 DT O
sequence BC2GM026620474 NN O
as BC2GM026620474 IN O
assessed BC2GM026620474 VBN O
by BC2GM026620474 IN O
gel BC2GM026620474 NN O
shift BC2GM026620474 NN O
analysis BC2GM026620474 NN O
. BC2GM026620474 . O
. . O O

We BC2GM037059835 PRP O
report BC2GM037059835 VBP O
the BC2GM037059835 DT O
complete BC2GM037059835 JJ O
nucleotide BC2GM037059835 JJ O
sequence BC2GM037059835 NN O
of BC2GM037059835 IN O
the BC2GM037059835 DT O
camC BC2GM037059835 JJ O
gene BC2GM037059835 NN O
along BC2GM037059835 IN O
with BC2GM037059835 IN O
155 BC2GM037059835 CD O
base BC2GM037059835 NN O
pairs BC2GM037059835 NN O
of BC2GM037059835 IN O
5 BC2GM037059835 CD O
' BC2GM037059835 POS O
and BC2GM037059835 CC O
175 BC2GM037059835 CD O
base BC2GM037059835 NN O
pairs BC2GM037059835 NN O
of BC2GM037059835 IN O
3 BC2GM037059835 CD O
' BC2GM037059835 POS O
flanking BC2GM037059835 JJ O
sequence BC2GM037059835 NN O
. BC2GM037059835 . O
. . O O

Three BC2GM038169511 CD O
distinct BC2GM038169511 JJ O
human BC2GM038169511 JJ O
HDACs BC2GM038169511 NNP O
are BC2GM038169511 VBP O
homologous BC2GM038169511 JJ O
to BC2GM038169511 TO O
RPD3 BC2GM038169511 NNP O
, BC2GM038169511 , O
a BC2GM038169511 DT O
yeast BC2GM038169511 JJ O
transcriptional BC2GM038169511 JJ O
regulator BC2GM038169511 NN O
. BC2GM038169511 . O
. . O O

Aspirin BC2GM042419868 NNP O
therapy BC2GM042419868 NN O
in BC2GM042419868 IN O
the BC2GM042419868 DT O
rheumatic BC2GM042419868 JJ O
diseases BC2GM042419868 NNS O
. BC2GM042419868 . O
. . O O

The BC2GM069681293 DT O
highly BC2GM069681293 RB O
conserved BC2GM069681293 JJ O
region BC2GM069681293 NN O
of BC2GM069681293 IN O
U6 BC2GM069681293 NNP O
snRNA BC2GM069681293 NN O
has BC2GM069681293 VBZ O
a BC2GM069681293 DT O
structural BC2GM069681293 JJ O
similarity BC2GM069681293 NN O
with BC2GM069681293 IN O
the BC2GM069681293 DT O
catalytic BC2GM069681293 JJ O
domain BC2GM069681293 NN O
of BC2GM069681293 IN O
the BC2GM069681293 DT O
negative BC2GM069681293 JJ O
strand BC2GM069681293 NN O
of BC2GM069681293 IN O
the BC2GM069681293 DT O
satellite BC2GM069681293 NN O
RNA BC2GM069681293 NNP O
of BC2GM069681293 IN O
tobacco BC2GM069681293 NN O
ring BC2GM069681293 VBG O
spot BC2GM069681293 NN O
virus BC2GM069681293 NN O
[ BC2GM069681293 NNP O
( BC2GM069681293 ( O
- BC2GM069681293 : O
) BC2GM069681293 ) O
sTRSV BC2GM069681293 NN O
] BC2GM069681293 NN O
, BC2GM069681293 , O
suggesting BC2GM069681293 VBG O
that BC2GM069681293 IN O
the BC2GM069681293 DT O
highly BC2GM069681293 RB O
conserved BC2GM069681293 JJ O
region BC2GM069681293 NN O
of BC2GM069681293 IN O
U6 BC2GM069681293 NNP O
snRNA BC2GM069681293 NN O
forms BC2GM069681293 VBZ O
the BC2GM069681293 DT O
catalytic BC2GM069681293 JJ O
center BC2GM069681293 NN O
. BC2GM069681293 . O
. . O O

SH3A BC2GM043498135 NNP O
competes BC2GM043498135 VBZ O
with BC2GM043498135 IN O
the BC2GM043498135 DT O
SH3 BC2GM043498135 NNP O
domains BC2GM043498135 NNS O
of BC2GM043498135 IN O
Grb2 BC2GM043498135 NNP O
in BC2GM043498135 IN O
binding BC2GM043498135 VBG O
to BC2GM043498135 TO O
mSos1 BC2GM043498135 VB O
, BC2GM043498135 , O
and BC2GM043498135 CC O
the BC2GM043498135 DT O
intersectin-mSos1 BC2GM043498135 JJ O
complex BC2GM043498135 NN O
can BC2GM043498135 MD O
be BC2GM043498135 VB O
separated BC2GM043498135 VBN O
from BC2GM043498135 IN O
Grb2 BC2GM043498135 NNP O
by BC2GM043498135 IN O
sucrose BC2GM043498135 JJ O
gradient BC2GM043498135 JJ O
centrifugation BC2GM043498135 NN O
. BC2GM043498135 . O
. . O O

Results BC2GM031182945 NNS O
of BC2GM031182945 IN O
the BC2GM031182945 DT O
study BC2GM031182945 NN O
suggest BC2GM031182945 VBP O
that BC2GM031182945 IN O
Chinese BC2GM031182945 JJ O
medicine BC2GM031182945 NN O
use BC2GM031182945 NN O
among BC2GM031182945 IN O
this BC2GM031182945 DT O
population BC2GM031182945 NN O
depends BC2GM031182945 VBZ O
on BC2GM031182945 IN O
health BC2GM031182945 NN O
conditions BC2GM031182945 NNS O
, BC2GM031182945 , O
and BC2GM031182945 CC O
that BC2GM031182945 IN O
having BC2GM031182945 VBG O
a BC2GM031182945 DT O
regular BC2GM031182945 JJ O
source BC2GM031182945 NN O
of BC2GM031182945 IN O
care BC2GM031182945 NN O
for BC2GM031182945 IN O
Chinese BC2GM031182945 JJ O
medicine BC2GM031182945 NN O
as BC2GM031182945 RB O
well BC2GM031182945 RB O
as BC2GM031182945 IN O
a BC2GM031182945 DT O
preference BC2GM031182945 NN O
for BC2GM031182945 IN O
Chinese BC2GM031182945 JJ O
medicine BC2GM031182945 NN O
are BC2GM031182945 VBP O
two BC2GM031182945 CD O
predictors BC2GM031182945 NNS O
for BC2GM031182945 IN O
its BC2GM031182945 PRP$ O
use BC2GM031182945 NN O
. BC2GM031182945 . O
. . O O

Negative BC2GM094941573 JJ O
modulation BC2GM094941573 NN O
of BC2GM094941573 IN O
alpha1 BC2GM094941573 NN O
( BC2GM094941573 ( O
I BC2GM094941573 PRP O
) BC2GM094941573 ) O
procollagen BC2GM094941573 NN O
gene BC2GM094941573 NN O
expression BC2GM094941573 NN O
in BC2GM094941573 IN O
human BC2GM094941573 JJ O
skin BC2GM094941573 NN O
fibroblasts BC2GM094941573 NNS O
: BC2GM094941573 : O
transcriptional BC2GM094941573 JJ O
inhibition BC2GM094941573 NN O
by BC2GM094941573 IN O
interferon-gamma BC2GM094941573 NN O
. BC2GM094941573 . O
. . O O

Early BC2GM097718440 JJ O
detection BC2GM097718440 NN O
and BC2GM097718440 CC O
signs BC2GM097718440 NNS O
of BC2GM097718440 IN O
hepatoangiosarcoma BC2GM097718440 NN O
among BC2GM097718440 IN O
vinyl BC2GM097718440 JJ O
chloride BC2GM097718440 JJ O
workers BC2GM097718440 NNS O
. BC2GM097718440 . O
. . O O

Alternative BC2GM053977202 JJ O
splicing BC2GM053977202 NN O
of BC2GM053977202 IN O
the BC2GM053977202 DT O
human BC2GM053977202 JJ O
serotonin BC2GM053977202 NN O
transporter BC2GM053977202 NN O
gene BC2GM053977202 NN O
. BC2GM053977202 . O
. . O O

We BC2GM081686289 PRP O
used BC2GM081686289 VBD O
an BC2GM081686289 DT O
immobilized BC2GM081686289 JJ O
template-based BC2GM081686289 JJ O
assay BC2GM081686289 NN O
to BC2GM081686289 TO O
examine BC2GM081686289 VB O
transcription BC2GM081686289 NN O
termination BC2GM081686289 NN O
by BC2GM081686289 IN O
VA1 BC2GM081686289 NNP O
, BC2GM081686289 , O
7SL BC2GM081686289 CD O
, BC2GM081686289 , O
and BC2GM081686289 CC O
Alu BC2GM081686289 NNP O
class BC2GM081686289 NN O
III BC2GM081686289 NNP O
templates BC2GM081686289 NNS O
and BC2GM081686289 CC O
the BC2GM081686289 DT O
role BC2GM081686289 NN O
of BC2GM081686289 IN O
transcript BC2GM081686289 NN O
release BC2GM081686289 NN O
in BC2GM081686289 IN O
the BC2GM081686289 DT O
pol BC2GM081686289 NN O
III BC2GM081686289 NNP O
terminator-dependent BC2GM081686289 JJ O
inhibition BC2GM081686289 NN O
of BC2GM081686289 IN O
processing BC2GM081686289 NN O
of BC2GM081686289 IN O
B1-Alu BC2GM081686289 NNP O
transcripts BC2GM081686289 NNS O
. BC2GM081686289 . O
. . O O

From BC2GM016575957 IN O
the BC2GM016575957 DT O
Centers BC2GM016575957 NNPS O
for BC2GM016575957 IN O
Disease BC2GM016575957 NNP O
Control BC2GM016575957 NNP O
and BC2GM016575957 CC O
Prevention BC2GM016575957 NNP O
. BC2GM016575957 . O
. . O O

The BC2GM088368088 DT O
Synechococcus BC2GM088368088 NNP O
gene BC2GM088368088 NN O
rps1 BC2GM088368088 NN O
encoding BC2GM088368088 VBG O
S1 BC2GM088368088 NNP O
is BC2GM088368088 VBZ O
located BC2GM088368088 VBN O
1.1 BC2GM088368088 CD O
kb BC2GM088368088 JJ O
downstream BC2GM088368088 NN O
from BC2GM088368088 IN O
psbB BC2GM088368088 NN O
, BC2GM088368088 , O
which BC2GM088368088 WDT O
encodes BC2GM088368088 VBZ O
the BC2GM088368088 DT O
photosystem BC2GM088368088 NN O
II BC2GM088368088 NNP O
P680 BC2GM088368088 NNP O
chlorophyll BC2GM088368088 VBD O
a BC2GM088368088 DT O
apoprotein BC2GM088368088 NN O
. BC2GM088368088 . O
. . O O

Although BC2GM081453931 IN O
the BC2GM081453931 DT O
Gly252Arg BC2GM081453931 NNP O
substitution BC2GM081453931 NN O
observed BC2GM081453931 VBD O
in BC2GM081453931 IN O
UM BC2GM081453931 NNP O
: BC2GM081453931 : O
JG5 BC2GM081453931 NNP O
is BC2GM081453931 VBZ O
non-conservative BC2GM081453931 JJ O
, BC2GM081453931 , O
it BC2GM081453931 PRP O
was BC2GM081453931 VBD O
not BC2GM081453931 RB O
possible BC2GM081453931 JJ O
to BC2GM081453931 TO O
distinguish BC2GM081453931 VB O
whether BC2GM081453931 IN O
it BC2GM081453931 PRP O
is BC2GM081453931 VBZ O
a BC2GM081453931 DT O
mutation BC2GM081453931 NN O
or BC2GM081453931 CC O
a BC2GM081453931 DT O
polymorphism BC2GM081453931 NN O
. BC2GM081453931 . O
. . O O

A BC2GM023484942 DT O
child BC2GM023484942 NN O
presumed BC2GM023484942 VBN O
to BC2GM023484942 TO O
have BC2GM023484942 VB O
the BC2GM023484942 DT O
21-hydroxylase BC2GM023484942 JJ O
deficiency BC2GM023484942 NN O
form BC2GM023484942 NN O
of BC2GM023484942 IN O
congenital BC2GM023484942 JJ O
adrenal BC2GM023484942 JJ O
hyperplasia BC2GM023484942 NN O
was BC2GM023484942 VBD O
studied BC2GM023484942 VBN O
extensively BC2GM023484942 RB O
as BC2GM023484942 IN O
an BC2GM023484942 DT O
infant BC2GM023484942 NN O
. BC2GM023484942 . O
. . O O

Forty-eight BC2GM097108682 JJ O
pregnant BC2GM097108682 JJ O
adult BC2GM097108682 NN O
and BC2GM097108682 CC O
122 BC2GM097108682 CD O
fetal BC2GM097108682 JJ O
guinea BC2GM097108682 NN O
pigs BC2GM097108682 NNS O
were BC2GM097108682 VBD O
sacrificed BC2GM097108682 VBN O
at BC2GM097108682 IN O
intervals BC2GM097108682 NNS O
throughout BC2GM097108682 IN O
gestation BC2GM097108682 NN O
and BC2GM097108682 CC O
the BC2GM097108682 DT O
carcasses BC2GM097108682 NNS O
analyzed BC2GM097108682 VBN O
for BC2GM097108682 IN O
a BC2GM097108682 DT O
variety BC2GM097108682 NN O
of BC2GM097108682 IN O
growth BC2GM097108682 NN O
parameters BC2GM097108682 NNS O
. BC2GM097108682 . O
. . O O

The BC2GM011018907 DT O
myeloid BC2GM011018907 NN O
zinc BC2GM011018907 NN O
finger BC2GM011018907 NN O
gene BC2GM011018907 NN O
1 BC2GM011018907 CD O
( BC2GM011018907 ( O
MZF1 BC2GM011018907 NNP O
) BC2GM011018907 ) O
encodes BC2GM011018907 VBZ O
a BC2GM011018907 DT O
C BC2GM011018907 NNP O
( BC2GM011018907 ( O
2 BC2GM011018907 CD O
) BC2GM011018907 ) O
H BC2GM011018907 NNP O
( BC2GM011018907 ( O
2 BC2GM011018907 CD O
) BC2GM011018907 ) O
zinc BC2GM011018907 NN O
finger BC2GM011018907 NN O
transcription BC2GM011018907 NN O
factor BC2GM011018907 NN O
that BC2GM011018907 WDT O
regulates BC2GM011018907 VBZ O
granulopoiesis BC2GM011018907 NN O
and BC2GM011018907 CC O
may BC2GM011018907 MD O
have BC2GM011018907 VB O
a BC2GM011018907 DT O
regulatory BC2GM011018907 JJ O
role BC2GM011018907 NN O
in BC2GM011018907 IN O
cellular BC2GM011018907 JJ O
proliferation BC2GM011018907 NN O
and BC2GM011018907 CC O
oncogenesis BC2GM011018907 NN O
. BC2GM011018907 . O
. . O O

Pituitary BC2GM039057912 NNP O
thyrotropic BC2GM039057912 NN O
adenoma BC2GM039057912 NN O
associated BC2GM039057912 VBN O
with BC2GM039057912 IN O
congenital BC2GM039057912 JJ O
hypothyroidism BC2GM039057912 NN O
. BC2GM039057912 . O
. . O O

Heart BC2GM028814476 NNP O
disease BC2GM028814476 NN O
. BC2GM028814476 . O
. . O O

Mammalian BC2GM046724705 JJ O
homologues BC2GM046724705 NNS O
of BC2GM046724705 IN O
the BC2GM046724705 DT O
Polycomb-group BC2GM046724705 NNP O
gene BC2GM046724705 NN O
Enhancer BC2GM046724705 NNP O
of BC2GM046724705 IN O
zeste BC2GM046724705 NN O
mediate BC2GM046724705 NN O
gene BC2GM046724705 NN O
silencing BC2GM046724705 VBG O
in BC2GM046724705 IN O
Drosophila BC2GM046724705 NNP O
heterochromatin BC2GM046724705 NN O
and BC2GM046724705 CC O
at BC2GM046724705 IN O
S. BC2GM046724705 NNP O
cerevisiae BC2GM046724705 NN O
telomeres BC2GM046724705 NNS O
. BC2GM046724705 . O
. . O O

Relation BC2GM039680603 NN O
between BC2GM039680603 IN O
circulating BC2GM039680603 VBG O
immune BC2GM039680603 NN O
complexes BC2GM039680603 NNS O
and BC2GM039680603 CC O
serum BC2GM039680603 NN O
ferritin BC2GM039680603 NN O
in BC2GM039680603 IN O
hemosiderosis BC2GM039680603 NN O
of BC2GM039680603 IN O
different BC2GM039680603 JJ O
etiologies BC2GM039680603 NNS O
. BC2GM039680603 . O
. . O O

The BC2GM004715465 DT O
structure BC2GM004715465 NN O
and BC2GM004715465 CC O
expression BC2GM004715465 NN O
of BC2GM004715465 IN O
the BC2GM004715465 DT O
murine BC2GM004715465 NN O
gene BC2GM004715465 NN O
encoding BC2GM004715465 VBG O
granulocyte-macrophage BC2GM004715465 JJ O
colony BC2GM004715465 NN O
stimulating BC2GM004715465 VBG O
factor BC2GM004715465 NN O
: BC2GM004715465 : O
evidence BC2GM004715465 NN O
for BC2GM004715465 IN O
utilisation BC2GM004715465 NN O
of BC2GM004715465 IN O
alternative BC2GM004715465 JJ O
promoters BC2GM004715465 NNS O
. BC2GM004715465 . O
. . O O

We BC2GM093642275 PRP O
report BC2GM093642275 VBP O
on BC2GM093642275 IN O
a BC2GM093642275 DT O
case BC2GM093642275 NN O
of BC2GM093642275 IN O
a BC2GM093642275 DT O
43-old-male BC2GM093642275 JJ O
with BC2GM093642275 IN O
a BC2GM093642275 DT O
bronchogenic BC2GM093642275 JJ O
cyst BC2GM093642275 NN O
in BC2GM093642275 IN O
the BC2GM093642275 DT O
distal BC2GM093642275 JJ O
esophagus BC2GM093642275 NN O
, BC2GM093642275 , O
which BC2GM093642275 WDT O
was BC2GM093642275 VBD O
misdiagnosed BC2GM093642275 VBN O
as BC2GM093642275 IN O
a BC2GM093642275 DT O
malignant BC2GM093642275 JJ O
esophageal BC2GM093642275 NN O
tumor BC2GM093642275 NN O
based BC2GM093642275 VBN O
on BC2GM093642275 IN O
preoperative BC2GM093642275 JJ O
imaging BC2GM093642275 NN O
and BC2GM093642275 CC O
high BC2GM093642275 JJ O
levels BC2GM093642275 NNS O
of BC2GM093642275 IN O
the BC2GM093642275 DT O
tumor BC2GM093642275 NN O
markers BC2GM093642275 NNS O
CA BC2GM093642275 NNP O
19-9 BC2GM093642275 CD O
and BC2GM093642275 CC O
CA BC2GM093642275 NNP O
125 BC2GM093642275 CD O
. BC2GM093642275 . O
. . O O

It BC2GM047671701 PRP O
is BC2GM047671701 VBZ O
concluded BC2GM047671701 VBN O
that BC2GM047671701 IN O
the BC2GM047671701 DT O
drinking BC2GM047671701 NN O
ampules BC2GM047671701 NNS O
of BC2GM047671701 IN O
VP-16-213 BC2GM047671701 NNP O
can BC2GM047671701 MD O
be BC2GM047671701 VB O
replaced BC2GM047671701 VBN O
with BC2GM047671701 IN O
the BC2GM047671701 DT O
new BC2GM047671701 JJ O
oral BC2GM047671701 JJ O
capsules BC2GM047671701 NNS O
with BC2GM047671701 IN O
a BC2GM047671701 DT O
recommended BC2GM047671701 JJ O
initial BC2GM047671701 JJ O
dose BC2GM047671701 NN O
of BC2GM047671701 IN O
100-130 BC2GM047671701 JJ O
mg BC2GM047671701 NN O
/ BC2GM047671701 NNP O
m2 BC2GM047671701 NN O
given BC2GM047671701 VBN O
in BC2GM047671701 IN O
5-day BC2GM047671701 JJ O
courses BC2GM047671701 NNS O
every BC2GM047671701 DT O
21-28 BC2GM047671701 JJ O
days BC2GM047671701 NNS O
. BC2GM047671701 . O
. . O O

Nuclear BC2GM068306112 JJ O
localization BC2GM068306112 NN O
of BC2GM068306112 IN O
this BC2GM068306112 DT O
SNF2-like BC2GM068306112 JJ O
putative BC2GM068306112 JJ O
helicase BC2GM068306112 NN O
is BC2GM068306112 VBZ O
dependent BC2GM068306112 JJ O
on BC2GM068306112 IN O
a BC2GM068306112 DT O
nuclear BC2GM068306112 JJ O
localization BC2GM068306112 NN O
sequence BC2GM068306112 NN O
located BC2GM068306112 VBN O
in BC2GM068306112 IN O
the BC2GM068306112 DT O
NH2-terminal BC2GM068306112 JJ O
region BC2GM068306112 NN O
. BC2GM068306112 . O
. . O O

The BC2GM010221833 DT O
other BC2GM010221833 JJ O
regions BC2GM010221833 NNS O
include BC2GM010221833 VBP O
potential BC2GM010221833 JJ O
binding BC2GM010221833 NN O
sites BC2GM010221833 NNS O
for BC2GM010221833 IN O
transcription BC2GM010221833 NN O
factors BC2GM010221833 NNS O
ATF BC2GM010221833 NNP O
, BC2GM010221833 , O
NF1 BC2GM010221833 NNP O
, BC2GM010221833 , O
and BC2GM010221833 CC O
a BC2GM010221833 DT O
CCAAT-binding BC2GM010221833 JJ O
protein BC2GM010221833 NN O
. BC2GM010221833 . O
. . O O

Computer BC2GM064373015 NNP O
system BC2GM064373015 NN O
trains BC2GM064373015 NNS O
employees BC2GM064373015 NNS O
to BC2GM064373015 TO O
meet BC2GM064373015 VB O
JCAHO BC2GM064373015 NNP O
safety BC2GM064373015 NN O
ED BC2GM064373015 NNP O
requirements BC2GM064373015 NNS O
. BC2GM064373015 . O
. . O O

Psoriasis BC2GM056771328 NN O
on BC2GM056771328 IN O
tumor BC2GM056771328 NN O
. BC2GM056771328 . O
. . O O

The BC2GM069558891 DT O
more BC2GM069558891 RBR O
severe BC2GM069558891 JJ O
the BC2GM069558891 DT O
CRF BC2GM069558891 NNP O
, BC2GM069558891 , O
the BC2GM069558891 DT O
more BC2GM069558891 RBR O
likely BC2GM069558891 JJ O
that BC2GM069558891 IN O
total BC2GM069558891 JJ O
HDL BC2GM069558891 NNP O
and BC2GM069558891 CC O
HDL2 BC2GM069558891 NNP O
cholesterol BC2GM069558891 NN O
will BC2GM069558891 MD O
be BC2GM069558891 VB O
low BC2GM069558891 JJ O
. BC2GM069558891 . O
. . O O

The BC2GM080121917 DT O
two BC2GM080121917 CD O
SH3 BC2GM080121917 NNP O
domains BC2GM080121917 NNS O
are BC2GM080121917 VBP O
separated BC2GM080121917 VBN O
by BC2GM080121917 IN O
a BC2GM080121917 DT O
54 BC2GM080121917 CD O
amino BC2GM080121917 NN O
acid BC2GM080121917 NN O
linker BC2GM080121917 NN O
region BC2GM080121917 NN O
, BC2GM080121917 , O
whose BC2GM080121917 WP$ O
length BC2GM080121917 NN O
is BC2GM080121917 VBZ O
highly BC2GM080121917 RB O
conserved BC2GM080121917 VBN O
in BC2GM080121917 IN O
xenopus BC2GM080121917 NN O
, BC2GM080121917 , O
chicken BC2GM080121917 NN O
, BC2GM080121917 , O
and BC2GM080121917 CC O
mamalian BC2GM080121917 JJ O
Crk BC2GM080121917 NNP O
II BC2GM080121917 NNP O
proteins BC2GM080121917 VBZ O
. BC2GM080121917 . O
. . O O

In BC2GM066131450 IN O
the BC2GM066131450 DT O
spontaneous BC2GM066131450 JJ O
abortion BC2GM066131450 NN O
group BC2GM066131450 NN O
, BC2GM066131450 , O
the BC2GM066131450 DT O
levels BC2GM066131450 NNS O
of BC2GM066131450 IN O
PAPP-A BC2GM066131450 NNP O
were BC2GM066131450 VBD O
significantly BC2GM066131450 RB O
lower BC2GM066131450 JJR O
than BC2GM066131450 IN O
in BC2GM066131450 IN O
normal BC2GM066131450 JJ O
pregnancy BC2GM066131450 NN O
but BC2GM066131450 CC O
higher BC2GM066131450 JJR O
than BC2GM066131450 IN O
in BC2GM066131450 IN O
non-pregnant BC2GM066131450 JJ O
controls BC2GM066131450 NNS O
. BC2GM066131450 . O
. . O O

We BC2GM037320701 PRP O
report BC2GM037320701 VBP O
the BC2GM037320701 DT O
cloning BC2GM037320701 NN O
of BC2GM037320701 IN O
the BC2GM037320701 DT O
ade1 BC2GM037320701 JJ O
gene BC2GM037320701 NN O
on BC2GM037320701 IN O
a BC2GM037320701 DT O
4.4 BC2GM037320701 CD O
kb BC2GM037320701 NN O
Sau3A BC2GM037320701 NNP O
insert BC2GM037320701 NN O
in BC2GM037320701 IN O
the BC2GM037320701 DT O
yeast BC2GM037320701 NN O
shuttle BC2GM037320701 JJ O
vector BC2GM037320701 NN O
pWH5 BC2GM037320701 NN O
. BC2GM037320701 . O
. . O O

During BC2GM071825291 IN O
4 BC2GM071825291 CD O
% BC2GM071825291 NN O
O2 BC2GM071825291 NNP O
ventilation BC2GM071825291 NN O
, BC2GM071825291 , O
baseline BC2GM071825291 JJ O
pulmonary BC2GM071825291 JJ O
vascular BC2GM071825291 NN O
resistance BC2GM071825291 NN O
( BC2GM071825291 ( O
PVR BC2GM071825291 NNP O
) BC2GM071825291 ) O
and BC2GM071825291 CC O
the BC2GM071825291 DT O
dilator BC2GM071825291 NN O
response BC2GM071825291 NN O
to BC2GM071825291 TO O
both BC2GM071825291 DT O
ACh BC2GM071825291 NNP O
and BC2GM071825291 CC O
SNP BC2GM071825291 NNP O
were BC2GM071825291 VBD O
greater BC2GM071825291 JJR O
in BC2GM071825291 IN O
2D BC2GM071825291 CD O
lungs BC2GM071825291 NNS O
. BC2GM071825291 . O
. . O O

NBSII BC2GM005501477 NNP O
is BC2GM005501477 VBZ O
essential BC2GM005501477 JJ O
for BC2GM005501477 IN O
ribosome-stimulated BC2GM005501477 JJ O
activity BC2GM005501477 NN O
. BC2GM005501477 . O
. . O O

However BC2GM052215077 RB O
, BC2GM052215077 , O
no BC2GM052215077 DT O
consensus BC2GM052215077 NN O
on BC2GM052215077 IN O
indications BC2GM052215077 NNS O
exists BC2GM052215077 NNS O
and BC2GM052215077 CC O
, BC2GM052215077 , O
according BC2GM052215077 VBG O
to BC2GM052215077 TO O
the BC2GM052215077 DT O
literature BC2GM052215077 NN O
, BC2GM052215077 , O
results BC2GM052215077 NNS O
are BC2GM052215077 VBP O
contradictory BC2GM052215077 JJ O
. BC2GM052215077 . O
. . O O

The BC2GM020401171 DT O
encoded BC2GM020401171 JJ O
260-amino-acid BC2GM020401171 JJ O
( BC2GM020401171 ( O
aa BC2GM020401171 NN O
) BC2GM020401171 ) O
( BC2GM020401171 ( O
H1-I BC2GM020401171 NNP O
) BC2GM020401171 ) O
and BC2GM020401171 CC O
240-aa BC2GM020401171 JJ O
( BC2GM020401171 ( O
H1-II BC2GM020401171 NNP O
) BC2GM020401171 ) O
polypeptides BC2GM020401171 VBZ O
possess BC2GM020401171 IN O
the BC2GM020401171 DT O
typical BC2GM020401171 JJ O
tripartite BC2GM020401171 JJ O
organization BC2GM020401171 NN O
of BC2GM020401171 IN O
animal BC2GM020401171 JJ O
H1 BC2GM020401171 NNP O
histones BC2GM020401171 NNS O
, BC2GM020401171 , O
with BC2GM020401171 IN O
variable BC2GM020401171 JJ O
N- BC2GM020401171 JJ O
and BC2GM020401171 CC O
C-terminal BC2GM020401171 JJ O
domains BC2GM020401171 NNS O
flanking BC2GM020401171 VBG O
a BC2GM020401171 DT O
conserved BC2GM020401171 JJ O
'globular BC2GM020401171 JJ O
' BC2GM020401171 POS O
DNA-binding BC2GM020401171 JJ O
domain BC2GM020401171 NN O
. BC2GM020401171 . O
. . O O

Electromobility BC2GM091780091 NNP O
shift BC2GM091780091 NN O
analysis BC2GM091780091 NN O
using BC2GM091780091 VBG O
oligonucleotides BC2GM091780091 NNS O
encompassing BC2GM091780091 VBG O
the BC2GM091780091 DT O
proximal BC2GM091780091 NN O
, BC2GM091780091 , O
distal BC2GM091780091 NN O
, BC2GM091780091 , O
and BC2GM091780091 CC O
BED BC2GM091780091 NNP O
/ BC2GM091780091 NNP O
AP-1-binding BC2GM091780091 NNP O
regions BC2GM091780091 NNS O
failed BC2GM091780091 VBD O
to BC2GM091780091 TO O
demonstrate BC2GM091780091 VB O
selective BC2GM091780091 JJ O
transactivation BC2GM091780091 NN O
after BC2GM091780091 IN O
CD2 BC2GM091780091 NNP O
signaling BC2GM091780091 NN O
of BC2GM091780091 IN O
LPMC BC2GM091780091 NNP O
. BC2GM091780091 . O
. . O O

Laser BC2GM091521562 NNP O
soldering BC2GM091521562 VBG O
with BC2GM091521562 IN O
exogenous BC2GM091521562 JJ O
fibrinogen BC2GM091521562 NN O
is BC2GM091521562 VBZ O
feasible BC2GM091521562 JJ O
without BC2GM091521562 IN O
topical BC2GM091521562 JJ O
administration BC2GM091521562 NN O
of BC2GM091521562 IN O
additional BC2GM091521562 JJ O
clotting BC2GM091521562 NN O
agents BC2GM091521562 NNS O
, BC2GM091521562 , O
significantly BC2GM091521562 RB O
improves BC2GM091521562 VBZ O
the BC2GM091521562 DT O
bursting BC2GM091521562 JJ O
strength BC2GM091521562 NN O
of BC2GM091521562 IN O
primary BC2GM091521562 JJ O
laser BC2GM091521562 NN O
welded BC2GM091521562 VBD O
anastomoses BC2GM091521562 NNS O
, BC2GM091521562 , O
and BC2GM091521562 CC O
appears BC2GM091521562 VBZ O
to BC2GM091521562 TO O
result BC2GM091521562 VB O
from BC2GM091521562 IN O
urokinase-resistant BC2GM091521562 JJ O
fibrinogen BC2GM091521562 NN O
cross-linking BC2GM091521562 NN O
. BC2GM091521562 . O
. . O O

13:961-969 BC2GM046384493 CD O
, BC2GM046384493 , O
1993 BC2GM046384493 CD O
) BC2GM046384493 ) O
suggested BC2GM046384493 VBD O
that BC2GM046384493 IN O
T BC2GM046384493 NNP O
antigen BC2GM046384493 NN O
could BC2GM046384493 MD O
mediate BC2GM046384493 VB O
transcriptional BC2GM046384493 JJ O
activation BC2GM046384493 NN O
through BC2GM046384493 IN O
interaction BC2GM046384493 NN O
with BC2GM046384493 IN O
the BC2GM046384493 DT O
TATA-binding BC2GM046384493 NNP O
protein BC2GM046384493 NN O
, BC2GM046384493 , O
as BC2GM046384493 RB O
well BC2GM046384493 RB O
as BC2GM046384493 IN O
upstream BC2GM046384493 JJ O
bound BC2GM046384493 IN O
transcription BC2GM046384493 NN O
factors BC2GM046384493 NNS O
. BC2GM046384493 . O
. . O O

NASA BC2GM050682340 NNP O
CR-1223 BC2GM050682340 NNP O
. BC2GM050682340 . O
. . O O

Serum BC2GM003985442 NNP O
IgM BC2GM003985442 NNP O
levels BC2GM003985442 NNS O
showed BC2GM003985442 VBD O
a BC2GM003985442 DT O
highly BC2GM003985442 RB O
significant BC2GM003985442 JJ O
increase BC2GM003985442 NN O
in BC2GM003985442 IN O
all BC2GM003985442 DT O
types BC2GM003985442 NNS O
of BC2GM003985442 IN O
brain BC2GM003985442 NN O
tumour BC2GM003985442 NN O
when BC2GM003985442 WRB O
compared BC2GM003985442 VBN O
to BC2GM003985442 TO O
controls BC2GM003985442 NNS O
. BC2GM003985442 . O
. . O O

Gene BC2GM077216151 NNP O
GPR BC2GM077216151 NNP O
51 BC2GM077216151 CD O
was BC2GM077216151 VBD O
localized BC2GM077216151 VBN O
by BC2GM077216151 IN O
radiation BC2GM077216151 NN O
hybrid BC2GM077216151 NN O
mapping BC2GM077216151 NN O
to BC2GM077216151 TO O
chromosome BC2GM077216151 VB O
9 BC2GM077216151 CD O
, BC2GM077216151 , O
4.81 BC2GM077216151 CD O
cR BC2GM077216151 NN O
from BC2GM077216151 IN O
the BC2GM077216151 DT O
WI-8684 BC2GM077216151 NNP O
marker BC2GM077216151 NN O
, BC2GM077216151 , O
and BC2GM077216151 CC O
proximal BC2GM077216151 NN O
to BC2GM077216151 TO O
the BC2GM077216151 DT O
hereditary BC2GM077216151 JJ O
sensory BC2GM077216151 NN O
neuropathy BC2GM077216151 JJ O
type BC2GM077216151 NN O
1 BC2GM077216151 CD O
locus BC2GM077216151 NN O
. BC2GM077216151 . O
. . O O

This BC2GM040336555 DT O
mutation BC2GM040336555 NN O
was BC2GM040336555 VBD O
associated BC2GM040336555 VBN O
with BC2GM040336555 IN O
reduced BC2GM040336555 JJ O
or BC2GM040336555 CC O
absent BC2GM040336555 JJ O
expression BC2GM040336555 NN O
of BC2GM040336555 IN O
TGF-beta BC2GM040336555 NNP O
RI BC2GM040336555 NNP O
protein BC2GM040336555 NN O
and BC2GM040336555 CC O
p53 BC2GM040336555 NN O
protein BC2GM040336555 NN O
in BC2GM040336555 IN O
tumor BC2GM040336555 NN O
tissues BC2GM040336555 NNS O
. BC2GM040336555 . O
. . O O

Effect BC2GM065453807 NN O
of BC2GM065453807 IN O
gentamycin BC2GM065453807 NN O
on BC2GM065453807 IN O
the BC2GM065453807 DT O
kidney BC2GM065453807 NN O
functional BC2GM065453807 JJ O
state BC2GM065453807 NN O
in BC2GM065453807 IN O
experimental BC2GM065453807 JJ O
pyelonephritis BC2GM065453807 NN O
. BC2GM065453807 . O
. . O O

Central BC2GM032656820 NNP O
( BC2GM032656820 ( O
heart BC2GM032656820 NN O
rate BC2GM032656820 NN O
, BC2GM032656820 , O
VE BC2GM032656820 NNP O
, BC2GM032656820 , O
VO2 BC2GM032656820 NNP O
) BC2GM032656820 ) O
or BC2GM032656820 CC O
local BC2GM032656820 JJ O
( BC2GM032656820 ( O
muscle BC2GM032656820 NN O
and BC2GM032656820 CC O
blood BC2GM032656820 NN O
lactate BC2GM032656820 NN O
, BC2GM032656820 , O
adenosine BC2GM032656820 JJ O
triphosphate BC2GM032656820 NN O
, BC2GM032656820 , O
creatine BC2GM032656820 JJ O
phosphokinase BC2GM032656820 NN O
, BC2GM032656820 , O
glycogen BC2GM032656820 NN O
) BC2GM032656820 ) O
cues BC2GM032656820 NNS O
highlighted BC2GM032656820 VBN O
in BC2GM032656820 IN O
these BC2GM032656820 DT O
studies BC2GM032656820 NNS O
demonstrate BC2GM032656820 VBP O
both BC2GM032656820 DT O
the BC2GM032656820 DT O
complexity BC2GM032656820 NN O
of BC2GM032656820 IN O
effort BC2GM032656820 NN O
perception BC2GM032656820 NN O
, BC2GM032656820 , O
and BC2GM032656820 CC O
the BC2GM032656820 DT O
need BC2GM032656820 NN O
for BC2GM032656820 IN O
better BC2GM032656820 JJR O
understanding BC2GM032656820 NN O
of BC2GM032656820 IN O
the BC2GM032656820 DT O
physiological BC2GM032656820 JJ O
components BC2GM032656820 NNS O
upon BC2GM032656820 IN O
which BC2GM032656820 WDT O
it BC2GM032656820 PRP O
is BC2GM032656820 VBZ O
based BC2GM032656820 VBN O
. BC2GM032656820 . O
. . O O

Several BC2GM083269522 JJ O
reports BC2GM083269522 NNS O
assert BC2GM083269522 VBP O
that BC2GM083269522 IN O
prolactin BC2GM083269522 NN O
affects BC2GM083269522 VBZ O
the BC2GM083269522 DT O
delta BC2GM083269522 NN O
5 BC2GM083269522 CD O
and BC2GM083269522 CC O
delta BC2GM083269522 JJ O
4 BC2GM083269522 CD O
pathways BC2GM083269522 NNS O
through BC2GM083269522 IN O
its BC2GM083269522 PRP$ O
effect BC2GM083269522 NN O
on BC2GM083269522 IN O
the BC2GM083269522 DT O
activity BC2GM083269522 NN O
of BC2GM083269522 IN O
3beta-hydroxysteroid BC2GM083269522 JJ O
dehydrogenase BC2GM083269522 NN O
( BC2GM083269522 ( O
3beta-OHSD BC2GM083269522 JJ O
) BC2GM083269522 ) O
. BC2GM083269522 . O
. . O O

( BC2GM032790692 ( O
4 BC2GM032790692 CD O
) BC2GM032790692 ) O
Expression BC2GM032790692 NN O
in BC2GM032790692 IN O
different BC2GM032790692 JJ O
sites BC2GM032790692 NNS O
in BC2GM032790692 IN O
the BC2GM032790692 DT O
central BC2GM032790692 JJ O
nervous BC2GM032790692 JJ O
system BC2GM032790692 NN O
is BC2GM032790692 VBZ O
driven BC2GM032790692 VBN O
by BC2GM032790692 IN O
separable BC2GM032790692 JJ O
elements BC2GM032790692 NNS O
widely BC2GM032790692 RB O
dispersed BC2GM032790692 VBN O
throughout BC2GM032790692 IN O
8 BC2GM032790692 CD O
kb BC2GM032790692 NNS O
3 BC2GM032790692 CD O
' BC2GM032790692 '' O
of BC2GM032790692 IN O
the BC2GM032790692 DT O
gene BC2GM032790692 NN O
. BC2GM032790692 . O
. . O O

Recombinant BC2GM057856601 NNP O
vaccinia BC2GM057856601 NN O
viruses BC2GM057856601 NNS O
that BC2GM057856601 WDT O
express BC2GM057856601 VBP O
the BC2GM057856601 DT O
bacteriophage BC2GM057856601 NN O
T3 BC2GM057856601 NNP O
RNA BC2GM057856601 NNP O
polymerase BC2GM057856601 NN O
( BC2GM057856601 ( O
VV-T3pol BC2GM057856601 NNP O
) BC2GM057856601 ) O
or BC2GM057856601 CC O
the BC2GM057856601 DT O
Escherichia BC2GM057856601 NNP O
coli BC2GM057856601 NN O
lac BC2GM057856601 NN O
repressor BC2GM057856601 NN O
( BC2GM057856601 ( O
VV-lacI BC2GM057856601 NNP O
) BC2GM057856601 ) O
under BC2GM057856601 IN O
control BC2GM057856601 NN O
of BC2GM057856601 IN O
the BC2GM057856601 DT O
early-late BC2GM057856601 JJ O
vaccinia BC2GM057856601 NN O
promoter BC2GM057856601 NN O
P7.5 BC2GM057856601 NNP O
were BC2GM057856601 VBD O
constructed BC2GM057856601 VBN O
. BC2GM057856601 . O
. . O O

We BC2GM044399791 PRP O
have BC2GM044399791 VBP O
previously BC2GM044399791 RB O
shown BC2GM044399791 VBN O
that BC2GM044399791 IN O
UNC-4 BC2GM044399791 NNP O
expression BC2GM044399791 NN O
in BC2GM044399791 IN O
the BC2GM044399791 DT O
VA BC2GM044399791 NNP O
motor BC2GM044399791 NN O
neurons BC2GM044399791 NNS O
specifies BC2GM044399791 VBZ O
the BC2GM044399791 DT O
wild-type BC2GM044399791 JJ O
pattern BC2GM044399791 NN O
of BC2GM044399791 IN O
presynaptic BC2GM044399791 JJ O
input BC2GM044399791 NN O
. BC2GM044399791 . O
. . O O

Consistent BC2GM032259254 JJ O
with BC2GM032259254 IN O
an BC2GM032259254 DT O
effect BC2GM032259254 NN O
on BC2GM032259254 IN O
transcription BC2GM032259254 NN O
, BC2GM032259254 , O
p21 BC2GM032259254 NN O
was BC2GM032259254 VBD O
localized BC2GM032259254 VBN O
in BC2GM032259254 IN O
nuclei BC2GM032259254 NN O
of BC2GM032259254 IN O
transfected BC2GM032259254 JJ O
cells BC2GM032259254 NNS O
. BC2GM032259254 . O
. . O O

Serum BC2GM070067040 NNP O
creatinine BC2GM070067040 JJ O
kinase BC2GM070067040 NN O
activity BC2GM070067040 NN O
was BC2GM070067040 VBD O
7,800-17,500 BC2GM070067040 JJ O
U BC2GM070067040 NNP O
/ BC2GM070067040 NNP O
l BC2GM070067040 NN O
, BC2GM070067040 , O
making BC2GM070067040 VBG O
acute BC2GM070067040 JJ O
muscle BC2GM070067040 NN O
damage BC2GM070067040 NN O
likely BC2GM070067040 RB O
, BC2GM070067040 , O
probably BC2GM070067040 RB O
rhabdomyolysis BC2GM070067040 NN O
. BC2GM070067040 . O
. . O O

We BC2GM004672850 PRP O
have BC2GM004672850 VBP O
found BC2GM004672850 VBN O
that BC2GM004672850 IN O
pro-IGF-2 BC2GM004672850 NN O
can BC2GM004672850 MD O
initially BC2GM004672850 RB O
form BC2GM004672850 VB O
two BC2GM004672850 CD O
disulfide BC2GM004672850 JJ O
isomers BC2GM004672850 NNS O
that BC2GM004672850 WDT O
undergo BC2GM004672850 VBP O
rearrangement BC2GM004672850 NN O
to BC2GM004672850 TO O
a BC2GM004672850 DT O
single BC2GM004672850 JJ O
conformation BC2GM004672850 NN O
in BC2GM004672850 IN O
vivo BC2GM004672850 NN O
. BC2GM004672850 . O
. . O O

The BC2GM006599822 DT O
results BC2GM006599822 NNS O
suggest BC2GM006599822 VBP O
that BC2GM006599822 IN O
both BC2GM006599822 DT O
superficial BC2GM006599822 JJ O
and BC2GM006599822 CC O
deep BC2GM006599822 JJ O
cortical BC2GM006599822 JJ O
venous BC2GM006599822 JJ O
drainage BC2GM006599822 NN O
of BC2GM006599822 IN O
the BC2GM006599822 DT O
cat BC2GM006599822 NN O
kidney BC2GM006599822 NN O
should BC2GM006599822 MD O
be BC2GM006599822 VB O
considered BC2GM006599822 VBN O
when BC2GM006599822 WRB O
measuring BC2GM006599822 VBG O
renal BC2GM006599822 JJ O
renin BC2GM006599822 NN O
release BC2GM006599822 NN O
. BC2GM006599822 . O
. . O O

The BC2GM028908281 DT O
determination BC2GM028908281 NN O
of BC2GM028908281 IN O
antithrombin BC2GM028908281 JJ O
III BC2GM028908281 NNP O
( BC2GM028908281 ( O
AT BC2GM028908281 NNP O
III BC2GM028908281 NNP O
) BC2GM028908281 ) O
and BC2GM028908281 CC O
its BC2GM028908281 PRP$ O
clinical BC2GM028908281 JJ O
significance BC2GM028908281 NN O
. BC2GM028908281 . O
. . O O

We BC2GM070051606 PRP O
examined BC2GM070051606 VBD O
the BC2GM070051606 DT O
contribution BC2GM070051606 NN O
of BC2GM070051606 IN O
the BC2GM070051606 DT O
M-MuLV BC2GM070051606 NNP O
enhancers BC2GM070051606 NNS O
to BC2GM070051606 TO O
the BC2GM070051606 DT O
transcriptional BC2GM070051606 JJ O
activity BC2GM070051606 NN O
and BC2GM070051606 CC O
pathogenesis BC2GM070051606 NN O
of BC2GM070051606 IN O
M-MuLV BC2GM070051606 NNP O
by BC2GM070051606 IN O
constructing BC2GM070051606 VBG O
LTRs BC2GM070051606 NNP O
containing BC2GM070051606 VBG O
heterologous BC2GM070051606 JJ O
enhancer BC2GM070051606 NN O
elements BC2GM070051606 NNS O
. BC2GM070051606 . O
. . O O

The BC2GM088003576 DT O
activity BC2GM088003576 NN O
of BC2GM088003576 IN O
platelet BC2GM088003576 NN O
factor BC2GM088003576 NN O
4 BC2GM088003576 CD O
in BC2GM088003576 IN O
plasma BC2GM088003576 NN O
of BC2GM088003576 IN O
healthy BC2GM088003576 JJ O
and BC2GM088003576 CC O
high BC2GM088003576 JJ O
risk BC2GM088003576 NN O
newborns BC2GM088003576 NNS O
. BC2GM088003576 . O
. . O O

Values BC2GM084539216 NNS O
of BC2GM084539216 IN O
K1 BC2GM084539216 NNP O
and BC2GM084539216 CC O
Vd BC2GM084539216 NNP O
were BC2GM084539216 VBD O
significantly BC2GM084539216 RB O
increased BC2GM084539216 VBN O
in BC2GM084539216 IN O
the BC2GM084539216 DT O
tumour BC2GM084539216 JJ O
tissue BC2GM084539216 NN O
. BC2GM084539216 . O
. . O O

As BC2GM084311645 IN O
a BC2GM084311645 DT O
test BC2GM084311645 NN O
of BC2GM084311645 IN O
this BC2GM084311645 DT O
hypothesis BC2GM084311645 NN O
, BC2GM084311645 , O
we BC2GM084311645 PRP O
predicted BC2GM084311645 VBD O
that BC2GM084311645 IN O
mice BC2GM084311645 NN O
which BC2GM084311645 WDT O
have BC2GM084311645 VBP O
altered BC2GM084311645 VBN O
expression BC2GM084311645 NN O
of BC2GM084311645 IN O
class BC2GM084311645 NN O
I BC2GM084311645 PRP O
gene BC2GM084311645 NN O
products BC2GM084311645 NNS O
, BC2GM084311645 , O
the BC2GM084311645 DT O
beta2-microglobulin BC2GM084311645 NN O
knockout BC2GM084311645 NN O
mice BC2GM084311645 NN O
, BC2GM084311645 , O
[ BC2GM084311645 NNP O
beta2m BC2GM084311645 NN O
( BC2GM084311645 ( O
- BC2GM084311645 : O
/ BC2GM084311645 SYM O
- BC2GM084311645 : O
) BC2GM084311645 ) O
] BC2GM084311645 NN O
, BC2GM084311645 , O
would BC2GM084311645 MD O
develop BC2GM084311645 VB O
Fe BC2GM084311645 NNP O
overload BC2GM084311645 NN O
. BC2GM084311645 . O
. . O O

The BC2GM019727288 DT O
role BC2GM019727288 NN O
of BC2GM019727288 IN O
NUT1 BC2GM019727288 NNP O
and BC2GM019727288 CC O
regulation BC2GM019727288 NN O
of BC2GM019727288 IN O
nitrogen BC2GM019727288 JJ O
metabolism BC2GM019727288 NN O
in BC2GM019727288 IN O
the BC2GM019727288 DT O
disease BC2GM019727288 NN O
process BC2GM019727288 NN O
was BC2GM019727288 VBD O
evaluated BC2GM019727288 VBN O
by BC2GM019727288 IN O
pathogenicity BC2GM019727288 NN O
assays BC2GM019727288 NNS O
. BC2GM019727288 . O
. . O O

On BC2GM048416316 IN O
the BC2GM048416316 DT O
basis BC2GM048416316 NN O
of BC2GM048416316 IN O
this BC2GM048416316 DT O
homology BC2GM048416316 NN O
, BC2GM048416316 , O
we BC2GM048416316 PRP O
examined BC2GM048416316 VBD O
the BC2GM048416316 DT O
potential BC2GM048416316 JJ O
role BC2GM048416316 NN O
of BC2GM048416316 IN O
c-Rel BC2GM048416316 NN O
in BC2GM048416316 IN O
controlling BC2GM048416316 VBG O
IL-2R BC2GM048416316 NNP O
alpha BC2GM048416316 JJ O
transcription BC2GM048416316 NN O
. BC2GM048416316 . O
. . O O

Hip BC2GM099591467 NNP O
fracture BC2GM099591467 NN O
mortality BC2GM099591467 NN O
and BC2GM099591467 CC O
prospective BC2GM099591467 JJ O
payment BC2GM099591467 NN O
system BC2GM099591467 NN O
. BC2GM099591467 . O
. . O O

A BC2GM074827794 DT O
minimal BC2GM074827794 JJ O
region BC2GM074827794 NN O
which BC2GM074827794 WDT O
stimulates BC2GM074827794 VBZ O
origin BC2GM074827794 IN O
function BC2GM074827794 NN O
mapped BC2GM074827794 VBD O
to BC2GM074827794 TO O
50 BC2GM074827794 CD O
amino BC2GM074827794 NN O
acids BC2GM074827794 NNS O
within BC2GM074827794 IN O
the BC2GM074827794 DT O
C-terminus BC2GM074827794 NNP O
of BC2GM074827794 IN O
Abf1p BC2GM074827794 NNP O
. BC2GM074827794 . O
. . O O

A BC2GM044117466 DT O
Buddhist BC2GM044117466 NNP O
view BC2GM044117466 NN O
of BC2GM044117466 IN O
abortion BC2GM044117466 NN O
. BC2GM044117466 . O
. . O O

Wild BC2GM082714483 NNP O
type BC2GM082714483 NN O
MEKK1 BC2GM082714483 NNP O
enhances BC2GM082714483 VBZ O
promoter BC2GM082714483 NN O
activity BC2GM082714483 NN O
and BC2GM082714483 CC O
the BC2GM082714483 DT O
activity BC2GM082714483 NN O
can BC2GM082714483 MD O
be BC2GM082714483 VB O
inhibited BC2GM082714483 VBN O
by BC2GM082714483 IN O
dominant BC2GM082714483 JJ O
negative BC2GM082714483 JJ O
MEKK1 BC2GM082714483 NNP O
, BC2GM082714483 , O
MEK1 BC2GM082714483 NNP O
, BC2GM082714483 , O
MEK7 BC2GM082714483 NNP O
, BC2GM082714483 , O
MEK3 BC2GM082714483 NNP O
, BC2GM082714483 , O
p38 BC2GM082714483 NN O
/ BC2GM082714483 NNP O
RK BC2GM082714483 NNP O
, BC2GM082714483 , O
and BC2GM082714483 CC O
c-Jun BC2GM082714483 NN O
. BC2GM082714483 . O
. . O O

Prevention BC2GM039408846 NN O
of BC2GM039408846 IN O
gravid BC2GM039408846 JJ O
Rhesus BC2GM039408846 NNP O
isoimmunization BC2GM039408846 NN O
. BC2GM039408846 . O
. . O O

These BC2GM060909713 DT O
effects BC2GM060909713 NNS O
were BC2GM060909713 VBD O
antagonized BC2GM060909713 VBN O
by BC2GM060909713 IN O
prior BC2GM060909713 JJ O
administration BC2GM060909713 NN O
of BC2GM060909713 IN O
1- BC2GM060909713 JJ O
( BC2GM060909713 ( O
2-methoxyphenyl BC2GM060909713 JJ O
) BC2GM060909713 ) O
-4- BC2GM060909713 FW O
[ BC2GM060909713 SYM O
- BC2GM060909713 : O
( BC2GM060909713 ( O
2-phthalimido BC2GM060909713 JJ O
) BC2GM060909713 ) O
butyl BC2GM060909713 NN O
] BC2GM060909713 NNP O
piperazine BC2GM060909713 NN O
) BC2GM060909713 ) O
( BC2GM060909713 ( O
0.5 BC2GM060909713 CD O
mg BC2GM060909713 NN O
/ BC2GM060909713 NNP O
kg BC2GM060909713 NN O
, BC2GM060909713 , O
i.p BC2GM060909713 NN O
. BC2GM060909713 . O
) BC2GM060909713 ) O
. BC2GM060909713 . O
. . O O

The BC2GM072512934 DT O
N-terminal BC2GM072512934 JJ O
sequence BC2GM072512934 NN O
of BC2GM072512934 IN O
the BC2GM072512934 DT O
extracellular BC2GM072512934 JJ O
MEP20 BC2GM072512934 NNP O
, BC2GM072512934 , O
TKVAS BC2GM072512934 NNP O
, BC2GM072512934 , O
was BC2GM072512934 VBD O
found BC2GM072512934 VBN O
at BC2GM072512934 IN O
aa BC2GM072512934 JJ O
194-198 BC2GM072512934 CD O
within BC2GM072512934 IN O
the BC2GM072512934 DT O
ORF BC2GM072512934 NNP O
. BC2GM072512934 . O
. . O O

The BC2GM098880938 DT O
major BC2GM098880938 JJ O
promoter BC2GM098880938 NN O
element BC2GM098880938 NN O
of BC2GM098880938 IN O
the BC2GM098880938 DT O
Xenopus BC2GM098880938 NNP O
laevis BC2GM098880938 VBZ O
5S BC2GM098880938 CD O
RNA BC2GM098880938 NNP O
gene BC2GM098880938 NN O
is BC2GM098880938 VBZ O
located BC2GM098880938 VBN O
within BC2GM098880938 IN O
the BC2GM098880938 DT O
transcribed BC2GM098880938 JJ O
region BC2GM098880938 NN O
of BC2GM098880938 IN O
the BC2GM098880938 DT O
gene BC2GM098880938 NN O
and BC2GM098880938 CC O
forms BC2GM098880938 VBZ O
the BC2GM098880938 DT O
binding BC2GM098880938 NN O
site BC2GM098880938 NN O
for BC2GM098880938 IN O
the BC2GM098880938 DT O
transcription BC2GM098880938 NN O
initiation BC2GM098880938 NN O
factor BC2GM098880938 NN O
TFIIIA BC2GM098880938 NNP O
. BC2GM098880938 . O
. . O O

Cell-free BC2GM028602474 JJ O
extracts BC2GM028602474 NNS O
of BC2GM028602474 IN O
E. BC2GM028602474 NNP O
coli BC2GM028602474 NNS O
( BC2GM028602474 ( O
fpg BC2GM028602474 JJ O
mutY BC2GM028602474 NN O
) BC2GM028602474 ) O
harboring BC2GM028602474 VBG O
pYSB10 BC2GM028602474 NN O
possess BC2GM028602474 NN O
an BC2GM028602474 DT O
enzymatic BC2GM028602474 JJ O
activity BC2GM028602474 NN O
that BC2GM028602474 WDT O
cleaves BC2GM028602474 VBZ O
a BC2GM028602474 DT O
34-mer BC2GM028602474 JJ O
oligonucleotide BC2GM028602474 NN O
containing BC2GM028602474 VBG O
a BC2GM028602474 DT O
single BC2GM028602474 JJ O
8-oxoG BC2GM028602474 JJ O
opposite BC2GM028602474 NN O
a BC2GM028602474 DT O
cytosine BC2GM028602474 NN O
( BC2GM028602474 ( O
8-OxoG BC2GM028602474 JJ O
/ BC2GM028602474 NNP O
C BC2GM028602474 NNP O
) BC2GM028602474 ) O
. BC2GM028602474 . O
. . O O

These BC2GM048166276 DT O
studies BC2GM048166276 NNS O
reveal BC2GM048166276 VBP O
that BC2GM048166276 IN O
CREM BC2GM048166276 NNP O
, BC2GM048166276 , O
a BC2GM048166276 DT O
tissue-specific BC2GM048166276 JJ O
factor BC2GM048166276 NN O
, BC2GM048166276 , O
is BC2GM048166276 VBZ O
expressed BC2GM048166276 VBN O
and BC2GM048166276 CC O
regulated BC2GM048166276 VBN O
by BC2GM048166276 IN O
gonadotropins BC2GM048166276 NNS O
in BC2GM048166276 IN O
the BC2GM048166276 DT O
ovary BC2GM048166276 JJ O
, BC2GM048166276 , O
that BC2GM048166276 IN O
the BC2GM048166276 DT O
predominant BC2GM048166276 JJ O
CREM BC2GM048166276 NNP O
transcripts BC2GM048166276 NNS O
encode BC2GM048166276 VBP O
the BC2GM048166276 DT O
repressor BC2GM048166276 NN O
protein BC2GM048166276 NN O
ICER BC2GM048166276 NNP O
, BC2GM048166276 , O
and BC2GM048166276 CC O
that BC2GM048166276 DT O
ICER BC2GM048166276 NNP O
is BC2GM048166276 VBZ O
capable BC2GM048166276 JJ O
of BC2GM048166276 IN O
inhibiting BC2GM048166276 VBG O
cAMP-induced BC2GM048166276 JJ O
expression BC2GM048166276 NN O
of BC2GM048166276 IN O
the BC2GM048166276 DT O
inhibin BC2GM048166276 JJ O
alpha-subunit BC2GM048166276 JJ O
gene BC2GM048166276 NN O
. BC2GM048166276 . O
. . O O

Analysis BC2GM019751316 NN O
of BC2GM019751316 IN O
tobacco BC2GM019751316 NN O
mRNA BC2GM019751316 NN O
using BC2GM019751316 VBG O
the BC2GM019751316 DT O
ACBF BC2GM019751316 NNP O
cDNA BC2GM019751316 NN O
as BC2GM019751316 IN O
probe BC2GM019751316 NN O
showed BC2GM019751316 VBD O
that BC2GM019751316 IN O
while BC2GM019751316 IN O
ACBF BC2GM019751316 NNP O
mRNA BC2GM019751316 NN O
was BC2GM019751316 VBD O
present BC2GM019751316 JJ O
in BC2GM019751316 IN O
all BC2GM019751316 DT O
tissues BC2GM019751316 NNS O
examined BC2GM019751316 VBN O
, BC2GM019751316 , O
the BC2GM019751316 DT O
highest BC2GM019751316 JJS O
transcript BC2GM019751316 NN O
accumulation BC2GM019751316 NN O
occurred BC2GM019751316 VBD O
in BC2GM019751316 IN O
stem BC2GM019751316 NN O
tissues BC2GM019751316 NNS O
. BC2GM019751316 . O
. . O O

BACKGROUND BC2GM087769438 NN O
: BC2GM087769438 : O
Allergic BC2GM087769438 NNP O
rhinoconjunctivitis BC2GM087769438 NN O
is BC2GM087769438 VBZ O
a BC2GM087769438 DT O
common BC2GM087769438 JJ O
disorder BC2GM087769438 NN O
, BC2GM087769438 , O
affecting BC2GM087769438 VBG O
> BC2GM087769438 JJ O
20 BC2GM087769438 CD O
% BC2GM087769438 NN O
of BC2GM087769438 IN O
people BC2GM087769438 NNS O
of BC2GM087769438 IN O
all BC2GM087769438 DT O
socioeconomic BC2GM087769438 JJ O
strata BC2GM087769438 NN O
. BC2GM087769438 . O
. . O O

Coronary BC2GM081297373 JJ O
arteriographies BC2GM081297373 NNS O
and BC2GM081297373 CC O
ventriculographies BC2GM081297373 NNS O
corresponding BC2GM081297373 VBG O
to BC2GM081297373 TO O
274 BC2GM081297373 CD O
consecutive BC2GM081297373 JJ O
patients BC2GM081297373 NNS O
( BC2GM081297373 ( O
January BC2GM081297373 NNP O
, BC2GM081297373 , O
1975-October BC2GM081297373 CD O
, BC2GM081297373 , O
1978 BC2GM081297373 CD O
) BC2GM081297373 ) O
with BC2GM081297373 IN O
significant BC2GM081297373 JJ O
coronary BC2GM081297373 JJ O
lesions BC2GM081297373 NNS O
are BC2GM081297373 VBP O
reviewed BC2GM081297373 VBN O
. BC2GM081297373 . O
. . O O

Moreover BC2GM084991496 RB O
, BC2GM084991496 , O
antibody BC2GM084991496 NN O
binding BC2GM084991496 VBG O
to BC2GM084991496 TO O
the BC2GM084991496 DT O
same BC2GM084991496 JJ O
two BC2GM084991496 CD O
determinants BC2GM084991496 NNS O
was BC2GM084991496 VBD O
also BC2GM084991496 RB O
inhibited BC2GM084991496 VBN O
when BC2GM084991496 WRB O
ZAP-70 BC2GM084991496 NNP O
or BC2GM084991496 CC O
the BC2GM084991496 DT O
SH2 BC2GM084991496 NNP O
domains BC2GM084991496 VBZ O
bound BC2GM084991496 VBN O
to BC2GM084991496 TO O
the BC2GM084991496 DT O
zeta BC2GM084991496 NN O
chain BC2GM084991496 NN O
or BC2GM084991496 CC O
to BC2GM084991496 TO O
a BC2GM084991496 DT O
2pY-ITAM BC2GM084991496 JJ O
. BC2GM084991496 . O
. . O O

Synthesis BC2GM021400038 NN O
of BC2GM021400038 IN O
22-oxavitamin BC2GM021400038 JJ O
D3 BC2GM021400038 NNP O
analogues BC2GM021400038 NNS O
. BC2GM021400038 . O
. . O O

However BC2GM032522078 RB O
, BC2GM032522078 , O
using BC2GM032522078 VBG O
wet BC2GM032522078 JJ O
weight BC2GM032522078 JJ O
/ BC2GM032522078 NN O
dry BC2GM032522078 JJ O
weight BC2GM032522078 NN O
methodology BC2GM032522078 NN O
, BC2GM032522078 , O
we BC2GM032522078 PRP O
found BC2GM032522078 VBD O
that BC2GM032522078 IN O
administration BC2GM032522078 NN O
of BC2GM032522078 IN O
U74006F BC2GM032522078 NNP O
significantly BC2GM032522078 RB O
reduced BC2GM032522078 VBD O
water BC2GM032522078 NN O
content BC2GM032522078 NN O
in BC2GM032522078 IN O
the BC2GM032522078 DT O
right BC2GM032522078 JJ O
hippocampus BC2GM032522078 NN O
( BC2GM032522078 ( O
contralateral BC2GM032522078 JJ O
to BC2GM032522078 TO O
the BC2GM032522078 DT O
site BC2GM032522078 NN O
of BC2GM032522078 IN O
injury BC2GM032522078 NN O
) BC2GM032522078 ) O
compared BC2GM032522078 VBN O
to BC2GM032522078 TO O
saline-treated BC2GM032522078 JJ O
animals BC2GM032522078 NNS O
( BC2GM032522078 ( O
p BC2GM032522078 NN O
less BC2GM032522078 JJR O
than BC2GM032522078 IN O
0.05 BC2GM032522078 CD O
) BC2GM032522078 ) O
. BC2GM032522078 . O
. . O O

Ganglia BC2GM056914428 NNP O
are BC2GM056914428 VBP O
cysts BC2GM056914428 NNS O
which BC2GM056914428 WDT O
frequently BC2GM056914428 RB O
occur BC2GM056914428 VBP O
in BC2GM056914428 IN O
the BC2GM056914428 DT O
proximity BC2GM056914428 NN O
of BC2GM056914428 IN O
joints BC2GM056914428 NNS O
. BC2GM056914428 . O
. . O O

On BC2GM093769700 IN O
days BC2GM093769700 NNS O
7 BC2GM093769700 CD O
, BC2GM093769700 , O
21 BC2GM093769700 CD O
, BC2GM093769700 , O
and BC2GM093769700 CC O
35 BC2GM093769700 CD O
postinoculation BC2GM093769700 NN O
( BC2GM093769700 ( O
PI BC2GM093769700 NNP O
) BC2GM093769700 ) O
, BC2GM093769700 , O
all BC2GM093769700 DT O
birds BC2GM093769700 NNS O
received BC2GM093769700 VBN O
sheep BC2GM093769700 JJ O
erythrocytes BC2GM093769700 NNS O
intravenously BC2GM093769700 RB O
. BC2GM093769700 . O
. . O O

Hyperlipemia BC2GM041150256 NNP O
has BC2GM041150256 VBZ O
been BC2GM041150256 VBN O
recently BC2GM041150256 RB O
described BC2GM041150256 VBN O
in BC2GM041150256 IN O
children BC2GM041150256 NNS O
with BC2GM041150256 IN O
migraine BC2GM041150256 NN O
, BC2GM041150256 , O
being BC2GM041150256 VBG O
suggested BC2GM041150256 VBN O
that BC2GM041150256 IN O
this BC2GM041150256 DT O
alteration BC2GM041150256 NN O
is BC2GM041150256 VBZ O
in BC2GM041150256 IN O
the BC2GM041150256 DT O
base BC2GM041150256 NN O
of BC2GM041150256 IN O
the BC2GM041150256 DT O
disease BC2GM041150256 NN O
. BC2GM041150256 . O
. . O O

The BC2GM038225935 DT O
vaccine BC2GM038225935 NN O
was BC2GM038225935 VBD O
at BC2GM038225935 IN O
least BC2GM038225935 JJS O
80 BC2GM038225935 CD O
% BC2GM038225935 NN O
efficacious BC2GM038225935 JJ O
against BC2GM038225935 IN O
Chlamydia BC2GM038225935 NNP O
and BC2GM038225935 CC O
Campylobacter BC2GM038225935 NNP O
spp BC2GM038225935 NN O
and BC2GM038225935 CC O
appeared BC2GM038225935 VBD O
to BC2GM038225935 TO O
be BC2GM038225935 VB O
protective BC2GM038225935 JJ O
. BC2GM038225935 . O
. . O O

We BC2GM037134844 PRP O
anticipated BC2GM037134844 VBD O
SNS BC2GM037134844 NNP O
function BC2GM037134844 NN O
after BC2GM037134844 IN O
CVA BC2GM037134844 NNP O
to BC2GM037134844 TO O
be BC2GM037134844 VB O
asymmetric BC2GM037134844 JJ O
and BC2GM037134844 CC O
selected BC2GM037134844 VBN O
null BC2GM037134844 JJ O
hypotheses BC2GM037134844 NNS O
of BC2GM037134844 IN O
bilaterally BC2GM037134844 RB O
symmetric BC2GM037134844 JJ O
SSR BC2GM037134844 NNP O
latencies BC2GM037134844 NNS O
and BC2GM037134844 CC O
amplitudes BC2GM037134844 NNS O
irrespective BC2GM037134844 JJ O
of BC2GM037134844 IN O
side BC2GM037134844 NN O
of BC2GM037134844 IN O
stimulation BC2GM037134844 NN O
and BC2GM037134844 CC O
/ BC2GM037134844 NN O
or BC2GM037134844 CC O
recording BC2GM037134844 NN O
. BC2GM037134844 . O
. . O O

The BC2GM036247814 DT O
MAP BC2GM036247814 NNP O
kinase BC2GM036247814 NN O
kinase BC2GM036247814 NN O
kinase BC2GM036247814 VB O
MLK2 BC2GM036247814 NNP O
co-localizes BC2GM036247814 JJ O
with BC2GM036247814 IN O
activated BC2GM036247814 JJ O
JNK BC2GM036247814 NNP O
along BC2GM036247814 IN O
microtubules BC2GM036247814 NNS O
and BC2GM036247814 CC O
associates BC2GM036247814 NNS O
with BC2GM036247814 IN O
kinesin BC2GM036247814 JJ O
superfamily BC2GM036247814 RB O
motor BC2GM036247814 NN O
KIF3 BC2GM036247814 NNP O
. BC2GM036247814 . O
. . O O

As BC2GM044014286 IN O
part BC2GM044014286 NN O
of BC2GM044014286 IN O
a BC2GM044014286 DT O
large BC2GM044014286 JJ O
Dutch BC2GM044014286 NNP O
prospective BC2GM044014286 NN O
multicenter BC2GM044014286 NN O
study BC2GM044014286 NN O
( BC2GM044014286 ( O
Netherlands BC2GM044014286 NNP O
Cooperative BC2GM044014286 NNP O
Study BC2GM044014286 NNP O
on BC2GM044014286 IN O
the BC2GM044014286 DT O
Adequacy BC2GM044014286 NNP O
of BC2GM044014286 IN O
Dialysis-2 BC2GM044014286 NNP O
) BC2GM044014286 ) O
, BC2GM044014286 , O
we BC2GM044014286 PRP O
consecutively BC2GM044014286 RB O
included BC2GM044014286 VBD O
all BC2GM044014286 DT O
new BC2GM044014286 JJ O
patients BC2GM044014286 NNS O
with BC2GM044014286 IN O
end-stage BC2GM044014286 JJ O
renal BC2GM044014286 JJ O
disease BC2GM044014286 NN O
for BC2GM044014286 IN O
whom BC2GM044014286 WP O
residual BC2GM044014286 JJ O
renal BC2GM044014286 JJ O
function BC2GM044014286 NN O
could BC2GM044014286 MD O
be BC2GM044014286 VB O
obtained BC2GM044014286 VBN O
0 BC2GM044014286 CD O
to BC2GM044014286 TO O
4 BC2GM044014286 CD O
weeks BC2GM044014286 NNS O
before BC2GM044014286 IN O
the BC2GM044014286 DT O
start BC2GM044014286 NN O
of BC2GM044014286 IN O
dialysis BC2GM044014286 NN O
therapy BC2GM044014286 NN O
. BC2GM044014286 . O
. . O O

12 BC2GM068674132 CD O
per BC2GM068674132 IN O
cent BC2GM068674132 NN O
was BC2GM068674132 VBD O
observed BC2GM068674132 VBN O
with BC2GM068674132 IN O
the BC2GM068674132 DT O
use BC2GM068674132 NN O
of BC2GM068674132 IN O
tetracycline BC2GM068674132 NN O
and BC2GM068674132 CC O
4-epianhydrotetracycline BC2GM068674132 JJ O
in BC2GM068674132 IN O
doses BC2GM068674132 NNS O
of BC2GM068674132 IN O
1000 BC2GM068674132 CD O
and BC2GM068674132 CC O
100gamma BC2GM068674132 CD O
per BC2GM068674132 IN O
embryo BC2GM068674132 NN O
respectively BC2GM068674132 RB O
. BC2GM068674132 . O
. . O O

Chemical BC2GM017562219 NNP O
structure BC2GM017562219 NN O
of BC2GM017562219 IN O
antibiotic BC2GM017562219 JJ O
SF-837 BC2GM017562219 NNP O
. BC2GM017562219 . O
. . O O

Nimodipine BC2GM044619064 NNP O
( BC2GM044619064 ( O
5 BC2GM044619064 CD O
micrograms BC2GM044619064 NNS O
/ BC2GM044619064 NNP O
kg BC2GM044619064 NN O
) BC2GM044619064 ) O
followed BC2GM044619064 VBN O
by BC2GM044619064 IN O
infusion BC2GM044619064 NN O
of BC2GM044619064 IN O
0.75 BC2GM044619064 CD O
microgram BC2GM044619064 NNS O
/ BC2GM044619064 JJ O
kg BC2GM044619064 FW O
/ BC2GM044619064 FW O
min BC2GM044619064 NN O
lowered BC2GM044619064 VBD O
the BC2GM044619064 DT O
blood BC2GM044619064 NN O
pressure BC2GM044619064 NN O
by BC2GM044619064 IN O
10 BC2GM044619064 CD O
% BC2GM044619064 NN O
in BC2GM044619064 IN O
both BC2GM044619064 DT O
normotensive BC2GM044619064 JJ O
and BC2GM044619064 CC O
hypertensive BC2GM044619064 JJ O
rats BC2GM044619064 NNS O
; BC2GM044619064 : O
the BC2GM044619064 DT O
same BC2GM044619064 JJ O
dose BC2GM044619064 JJ O
schedule BC2GM044619064 NN O
of BC2GM044619064 IN O
nifedipine BC2GM044619064 NN O
did BC2GM044619064 VBD O
not BC2GM044619064 RB O
lower BC2GM044619064 JJR O
MAP BC2GM044619064 NNP O
. BC2GM044619064 . O
. . O O

174 BC2GM009600842 CD O
, BC2GM009600842 , O
233-247 BC2GM009600842 JJ O
) BC2GM009600842 ) O
and BC2GM009600842 CC O
Serrate BC2GM009600842 NNP O
( BC2GM009600842 ( O
Serrate1 BC2GM009600842 NNP O
and BC2GM009600842 CC O
2 BC2GM009600842 CD O
; BC2GM009600842 : O
Myat BC2GM009600842 NNP O
, BC2GM009600842 , O
A. BC2GM009600842 NNP O
, BC2GM009600842 , O
Henrique BC2GM009600842 NNP O
, BC2GM009600842 , O
D. BC2GM009600842 NNP O
, BC2GM009600842 , O
Ish-Horowicz BC2GM009600842 NNP O
, BC2GM009600842 , O
D. BC2GM009600842 NNP O
and BC2GM009600842 CC O
Lewis BC2GM009600842 NNP O
, BC2GM009600842 , O
J. BC2GM009600842 NNP O
, BC2GM009600842 , O
1996 BC2GM009600842 CD O
. BC2GM009600842 . O
. . O O

Increased BC2GM026591982 VBN O
gliadin BC2GM026591982 NN O
antibody BC2GM026591982 NN O
levels BC2GM026591982 NNS O
were BC2GM026591982 VBD O
found BC2GM026591982 VBN O
more BC2GM026591982 RBR O
frequently BC2GM026591982 RB O
in BC2GM026591982 IN O
patients BC2GM026591982 NNS O
with BC2GM026591982 IN O
subtotal BC2GM026591982 JJ O
villous BC2GM026591982 JJ O
atrophy BC2GM026591982 NN O
( BC2GM026591982 ( O
9 BC2GM026591982 CD O
out BC2GM026591982 IN O
of BC2GM026591982 IN O
17 BC2GM026591982 CD O
patients BC2GM026591982 NNS O
, BC2GM026591982 , O
or BC2GM026591982 CC O
53 BC2GM026591982 CD O
% BC2GM026591982 NN O
; BC2GM026591982 : O
p BC2GM026591982 CC O
less BC2GM026591982 JJR O
than BC2GM026591982 IN O
0.05 BC2GM026591982 CD O
) BC2GM026591982 ) O
than BC2GM026591982 IN O
in BC2GM026591982 IN O
patients BC2GM026591982 NNS O
with BC2GM026591982 IN O
partial BC2GM026591982 JJ O
villous BC2GM026591982 JJ O
atrophy BC2GM026591982 NN O
( BC2GM026591982 ( O
2 BC2GM026591982 CD O
out BC2GM026591982 IN O
of BC2GM026591982 IN O
13 BC2GM026591982 CD O
patients BC2GM026591982 NNS O
, BC2GM026591982 , O
or BC2GM026591982 CC O
15 BC2GM026591982 CD O
% BC2GM026591982 NN O
) BC2GM026591982 ) O
or BC2GM026591982 CC O
normal BC2GM026591982 JJ O
villous BC2GM026591982 JJ O
appearance BC2GM026591982 NN O
( BC2GM026591982 ( O
2 BC2GM026591982 CD O
out BC2GM026591982 IN O
of BC2GM026591982 IN O
10 BC2GM026591982 CD O
patients BC2GM026591982 NNS O
, BC2GM026591982 , O
or BC2GM026591982 CC O
20 BC2GM026591982 CD O
% BC2GM026591982 NN O
) BC2GM026591982 ) O
. BC2GM026591982 . O
. . O O

The BC2GM069445885 DT O
reconstituted BC2GM069445885 JJ O
RNA BC2GM069445885 NNP O
polymerases BC2GM069445885 VBZ O
containing BC2GM069445885 VBG O
the BC2GM069445885 DT O
mutant BC2GM069445885 JJ O
alpha BC2GM069445885 NN O
subunits BC2GM069445885 NNS O
were BC2GM069445885 VBD O
examined BC2GM069445885 VBN O
for BC2GM069445885 IN O
their BC2GM069445885 PRP$ O
response BC2GM069445885 NN O
to BC2GM069445885 TO O
transcription BC2GM069445885 NN O
activation BC2GM069445885 NN O
by BC2GM069445885 IN O
cAMP-CRP BC2GM069445885 NN O
and BC2GM069445885 CC O
the BC2GM069445885 DT O
rrnBP1 BC2GM069445885 NN O
UP BC2GM069445885 NNP O
element BC2GM069445885 NN O
. BC2GM069445885 . O
. . O O

G6620 BC2GM035007740 NNP O
is BC2GM035007740 VBZ O
the BC2GM035007740 DT O
3 BC2GM035007740 CD O
' BC2GM035007740 POS O
end BC2GM035007740 NN O
of BC2GM035007740 IN O
the BC2GM035007740 DT O
MOL1 BC2GM035007740 NNP O
gene BC2GM035007740 NN O
coding BC2GM035007740 VBG O
for BC2GM035007740 IN O
a BC2GM035007740 DT O
polypeptide BC2GM035007740 NN O
similar BC2GM035007740 JJ O
to BC2GM035007740 TO O
stress-inducible BC2GM035007740 JJ O
proteins BC2GM035007740 NNS O
from BC2GM035007740 IN O
Fusarium BC2GM035007740 NNP O
; BC2GM035007740 : O
G6630 BC2GM035007740 NNP O
is BC2GM035007740 VBZ O
the BC2GM035007740 DT O
NAT2 BC2GM035007740 NNP O
gene BC2GM035007740 NN O
which BC2GM035007740 WDT O
encodes BC2GM035007740 VBZ O
a BC2GM035007740 DT O
methionine BC2GM035007740 JJ O
N-acetyltransferase BC2GM035007740 NNP O
; BC2GM035007740 : O
G6635 BC2GM035007740 NNP O
is BC2GM035007740 VBZ O
the BC2GM035007740 DT O
RPL30B BC2GM035007740 NNP O
gene BC2GM035007740 NN O
coding BC2GM035007740 VBG O
for BC2GM035007740 IN O
the BC2GM035007740 DT O
ribosomal BC2GM035007740 JJ O
protein BC2GM035007740 NN O
L30 BC2GM035007740 NNP O
; BC2GM035007740 : O
G6658 BC2GM035007740 NNP O
is BC2GM035007740 VBZ O
RSR1 BC2GM035007740 NNP O
encoding BC2GM035007740 VBG O
a BC2GM035007740 DT O
ras-related BC2GM035007740 JJ O
protein BC2GM035007740 NN O
; BC2GM035007740 : O
G6667 BC2GM035007740 NNP O
is BC2GM035007740 VBZ O
CYS4 BC2GM035007740 NNP O
, BC2GM035007740 , O
the BC2GM035007740 DT O
gene BC2GM035007740 NN O
for BC2GM035007740 IN O
cystathionine BC2GM035007740 JJ O
beta-synthase BC2GM035007740 NN O
; BC2GM035007740 : O
G6670 BC2GM035007740 NNP O
is BC2GM035007740 VBZ O
identical BC2GM035007740 JJ O
to BC2GM035007740 TO O
ORF2 BC2GM035007740 NNP O
located BC2GM035007740 VBN O
close BC2GM035007740 RB O
to BC2GM035007740 TO O
CYS4 BC2GM035007740 NNP O
; BC2GM035007740 : O
G6673 BC2GM035007740 NNP O
is BC2GM035007740 VBZ O
PEM1 BC2GM035007740 NNP O
/ BC2GM035007740 NNP O
CHO2 BC2GM035007740 NNP O
encoding BC2GM035007740 VBG O
a BC2GM035007740 DT O
phosphatidylethanolamine BC2GM035007740 JJ O
methyltransferase BC2GM035007740 NN O
; BC2GM035007740 : O
G7001 BC2GM035007740 NNP O
is BC2GM035007740 VBZ O
the BC2GM035007740 DT O
NSR1 BC2GM035007740 NNP O
gene BC2GM035007740 NN O
coding BC2GM035007740 VBG O
for BC2GM035007740 IN O
a BC2GM035007740 DT O
nuclear BC2GM035007740 JJ O
signal BC2GM035007740 JJ O
recognition BC2GM035007740 NN O
protein BC2GM035007740 NN O
. BC2GM035007740 . O
. . O O

Earlier BC2GM068467868 RBR O
published BC2GM068467868 VBN O
data BC2GM068467868 NNS O
, BC2GM068467868 , O
indicating BC2GM068467868 VBG O
Sp1 BC2GM068467868 NNP O
binding BC2GM068467868 NN O
to BC2GM068467868 TO O
the BC2GM068467868 DT O
R1 BC2GM068467868 NNP O
alpha BC2GM068467868 NN O
/ BC2GM068467868 NNP O
beta BC2GM068467868 NN O
regions BC2GM068467868 NNS O
, BC2GM068467868 , O
could BC2GM068467868 MD O
not BC2GM068467868 RB O
be BC2GM068467868 VB O
confirmed BC2GM068467868 VBN O
, BC2GM068467868 , O
suggesting BC2GM068467868 VBG O
that BC2GM068467868 IN O
the BC2GM068467868 DT O
R1 BC2GM068467868 NNP O
initiator BC2GM068467868 NN O
element BC2GM068467868 NN O
may BC2GM068467868 MD O
function BC2GM068467868 VB O
independent BC2GM068467868 JJ O
of BC2GM068467868 IN O
Sp1 BC2GM068467868 NNP O
. BC2GM068467868 . O
. . O O

Serum BC2GM061130955 NNP O
amyloid BC2GM061130955 VBZ O
A BC2GM061130955 NNP O
( BC2GM061130955 ( O
SAA BC2GM061130955 NNP O
) BC2GM061130955 ) O
is BC2GM061130955 VBZ O
a BC2GM061130955 DT O
plasma BC2GM061130955 NN O
protein BC2GM061130955 NN O
which BC2GM061130955 WDT O
has BC2GM061130955 VBZ O
been BC2GM061130955 VBN O
associated BC2GM061130955 VBN O
with BC2GM061130955 IN O
several BC2GM061130955 JJ O
diseases BC2GM061130955 NNS O
, BC2GM061130955 , O
including BC2GM061130955 VBG O
amyloidosis BC2GM061130955 NN O
, BC2GM061130955 , O
arthritis BC2GM061130955 NN O
, BC2GM061130955 , O
and BC2GM061130955 CC O
atherosclerosis BC2GM061130955 NN O
, BC2GM061130955 , O
and BC2GM061130955 CC O
its BC2GM061130955 PRP$ O
abnormal BC2GM061130955 JJ O
expression BC2GM061130955 NN O
, BC2GM061130955 , O
particularly BC2GM061130955 RB O
in BC2GM061130955 IN O
nonhepatic BC2GM061130955 JJ O
cells BC2GM061130955 NNS O
, BC2GM061130955 , O
is BC2GM061130955 VBZ O
implicated BC2GM061130955 VBN O
in BC2GM061130955 IN O
the BC2GM061130955 DT O
pathogenesis BC2GM061130955 NN O
of BC2GM061130955 IN O
these BC2GM061130955 DT O
diseases BC2GM061130955 NNS O
. BC2GM061130955 . O
. . O O

Of BC2GM065297737 IN O
these BC2GM065297737 DT O
, BC2GM065297737 , O
23 BC2GM065297737 CD O
( BC2GM065297737 ( O
13.6 BC2GM065297737 CD O
% BC2GM065297737 NN O
) BC2GM065297737 ) O
were BC2GM065297737 VBD O
due BC2GM065297737 JJ O
to BC2GM065297737 TO O
GIB BC2GM065297737 NNP O
( BC2GM065297737 ( O
Upper BC2GM065297737 NNP O
GIB BC2GM065297737 NNP O
= BC2GM065297737 NNP O
19 BC2GM065297737 CD O
, BC2GM065297737 , O
Lower BC2GM065297737 JJR O
GIB BC2GM065297737 NNP O
= BC2GM065297737 NNP O
4 BC2GM065297737 CD O
) BC2GM065297737 ) O
. BC2GM065297737 . O
. . O O

Suppression BC2GM079025954 NN O
of BC2GM079025954 IN O
the BC2GM079025954 DT O
cka1 BC2GM079025954 NN O
delta BC2GM079025954 JJ O
cka2-8 BC2GM079025954 JJ O
mutant BC2GM079025954 NN O
phenotype BC2GM079025954 NN O
occurs BC2GM079025954 VBZ O
by BC2GM079025954 IN O
interaction BC2GM079025954 NN O
of BC2GM079025954 IN O
CKB1 BC2GM079025954 NNP O
with BC2GM079025954 IN O
the BC2GM079025954 DT O
defective BC2GM079025954 JJ O
, BC2GM079025954 , O
cka2-8-encoded BC2GM079025954 JJ O
, BC2GM079025954 , O
catalytic BC2GM079025954 JJ O
subunit BC2GM079025954 NN O
. BC2GM079025954 . O
. . O O

Effects BC2GM018437479 NNS O
of BC2GM018437479 IN O
timepidium BC2GM018437479 NN O
bromide BC2GM018437479 NN O
( BC2GM018437479 ( O
TB BC2GM018437479 NNP O
; BC2GM018437479 : O
anticholinergic BC2GM018437479 JJ O
agent BC2GM018437479 NN O
) BC2GM018437479 ) O
, BC2GM018437479 , O
acetylcholine BC2GM018437479 NN O
( BC2GM018437479 ( O
ACh BC2GM018437479 NNP O
) BC2GM018437479 ) O
and BC2GM018437479 CC O
neostigmine BC2GM018437479 JJ O
( BC2GM018437479 ( O
Neost BC2GM018437479 NNP O
) BC2GM018437479 ) O
on BC2GM018437479 IN O
gastric BC2GM018437479 NN O
and BC2GM018437479 CC O
duodenal BC2GM018437479 JJ O
blood BC2GM018437479 NN O
flow BC2GM018437479 NN O
distribution BC2GM018437479 NN O
were BC2GM018437479 VBD O
studied BC2GM018437479 VBN O
by BC2GM018437479 IN O
the BC2GM018437479 DT O
use BC2GM018437479 NN O
of BC2GM018437479 IN O
131I-labeled BC2GM018437479 JJ O
macroaggregated BC2GM018437479 JJ O
human BC2GM018437479 JJ O
serum BC2GM018437479 NN O
albumin BC2GM018437479 NN O
( BC2GM018437479 ( O
MAA BC2GM018437479 NNP O
) BC2GM018437479 ) O
in BC2GM018437479 IN O
rabbits BC2GM018437479 NNS O
. BC2GM018437479 . O
. . O O

Drug BC2GM040451160 NNP O
therapy BC2GM040451160 NN O
of BC2GM040451160 IN O
AAPMC BC2GM040451160 NNP O
is BC2GM040451160 VBZ O
directed BC2GM040451160 VBN O
at BC2GM040451160 IN O
reducing BC2GM040451160 VBG O
the BC2GM040451160 DT O
amount BC2GM040451160 NN O
of BC2GM040451160 IN O
Cl BC2GM040451160 NNP O
. BC2GM040451160 . O
difficile BC2GM040451160 NN O
in BC2GM040451160 IN O
the BC2GM040451160 DT O
colon BC2GM040451160 NN O
and BC2GM040451160 CC O
promoting BC2GM040451160 VBG O
normalization BC2GM040451160 NN O
of BC2GM040451160 IN O
intestinal BC2GM040451160 JJ O
flora BC2GM040451160 NNS O
. BC2GM040451160 . O
. . O O

METHOD BC2GM068155086 NN O
: BC2GM068155086 : O
After BC2GM068155086 IN O
eligibility BC2GM068155086 NN O
, BC2GM068155086 , O
patients BC2GM068155086 NNS O
were BC2GM068155086 VBD O
randomly BC2GM068155086 RB O
allocated BC2GM068155086 VBN O
in BC2GM068155086 IN O
one BC2GM068155086 CD O
of BC2GM068155086 IN O
the BC2GM068155086 DT O
following BC2GM068155086 JJ O
groups BC2GM068155086 NNS O
: BC2GM068155086 : O
M BC2GM068155086 NNP O
= BC2GM068155086 NNP O
methylprednisolone BC2GM068155086 VBD O
30 BC2GM068155086 CD O
mg.kg-1 BC2GM068155086 NN O
over BC2GM068155086 IN O
1 BC2GM068155086 CD O
hour BC2GM068155086 NN O
, BC2GM068155086 , O
followed BC2GM068155086 VBN O
by BC2GM068155086 IN O
5.4 BC2GM068155086 CD O
mg.kg-1.h-1 BC2GM068155086 NN O
for BC2GM068155086 IN O
23 BC2GM068155086 CD O
hours BC2GM068155086 NNS O
, BC2GM068155086 , O
N BC2GM068155086 NNP O
= BC2GM068155086 NNP O
nimodipine BC2GM068155086 JJ O
0.015 BC2GM068155086 CD O
mg.kg-1.h-1 BC2GM068155086 NN O
over BC2GM068155086 IN O
2 BC2GM068155086 CD O
hours BC2GM068155086 NNS O
followed BC2GM068155086 VBN O
by BC2GM068155086 IN O
0.03 BC2GM068155086 CD O
mg.kg-1.h-1 BC2GM068155086 NN O
for BC2GM068155086 IN O
7 BC2GM068155086 CD O
days BC2GM068155086 NNS O
, BC2GM068155086 , O
MN BC2GM068155086 NNP O
or BC2GM068155086 CC O
P BC2GM068155086 NNP O
. BC2GM068155086 . O
. . O O

These BC2GM019494722 DT O
results BC2GM019494722 NNS O
were BC2GM019494722 VBD O
not BC2GM019494722 RB O
obtained BC2GM019494722 VBN O
using BC2GM019494722 VBG O
either BC2GM019494722 CC O
preimmune BC2GM019494722 JJ O
sera BC2GM019494722 NN O
or BC2GM019494722 CC O
antiserum BC2GM019494722 NN O
specific BC2GM019494722 NN O
for BC2GM019494722 IN O
the BC2GM019494722 DT O
luminal BC2GM019494722 JJ O
portion BC2GM019494722 NN O
of BC2GM019494722 IN O
the BC2GM019494722 DT O
glycoprotein BC2GM019494722 NN O
precursor BC2GM019494722 NN O
. BC2GM019494722 . O
. . O O

Recognition BC2GM005933281 NN O
of BC2GM005933281 IN O
DNA BC2GM005933281 NN O
by BC2GM005933281 IN O
single-chain BC2GM005933281 JJ O
derivatives BC2GM005933281 NNS O
of BC2GM005933281 IN O
the BC2GM005933281 DT O
phage BC2GM005933281 NN O
434 BC2GM005933281 CD O
repressor BC2GM005933281 NN O
: BC2GM005933281 : O
high BC2GM005933281 JJ O
affinity BC2GM005933281 NN O
binding BC2GM005933281 VBG O
depends BC2GM005933281 NNS O
on BC2GM005933281 IN O
both BC2GM005933281 DT O
the BC2GM005933281 DT O
contacted BC2GM005933281 VBN O
and BC2GM005933281 CC O
non-contacted BC2GM005933281 JJ O
base BC2GM005933281 NN O
pairs BC2GM005933281 NNS O
. BC2GM005933281 . O
. . O O

Southern BC2GM097982255 NNP O
blot BC2GM097982255 NN O
analysis BC2GM097982255 NN O
following BC2GM097982255 VBG O
reverse BC2GM097982255 JJ O
transcription BC2GM097982255 NN O
and BC2GM097982255 CC O
PCR BC2GM097982255 NNP O
showed BC2GM097982255 VBD O
that BC2GM097982255 IN O
B2R BC2GM097982255 NNP O
is BC2GM097982255 VBZ O
expressed BC2GM097982255 VBN O
in BC2GM097982255 IN O
most BC2GM097982255 JJS O
mouse BC2GM097982255 NN O
tissues BC2GM097982255 NNS O
, BC2GM097982255 , O
except BC2GM097982255 IN O
the BC2GM097982255 DT O
liver BC2GM097982255 NN O
and BC2GM097982255 CC O
spleen BC2GM097982255 NN O
, BC2GM097982255 , O
which BC2GM097982255 WDT O
is BC2GM097982255 VBZ O
consistent BC2GM097982255 JJ O
with BC2GM097982255 IN O
the BC2GM097982255 DT O
wide BC2GM097982255 JJ O
distribution BC2GM097982255 NN O
of BC2GM097982255 IN O
B2R BC2GM097982255 NNP O
activity BC2GM097982255 NN O
as BC2GM097982255 IN O
deduced BC2GM097982255 VBN O
from BC2GM097982255 IN O
pharmacological BC2GM097982255 JJ O
studies BC2GM097982255 NNS O
. BC2GM097982255 . O
. . O O

The BC2GM057633611 DT O
ZAG1 BC2GM057633611 NNP O
protein BC2GM057633611 NN O
from BC2GM057633611 IN O
in BC2GM057633611 IN O
vitro BC2GM057633611 JJ O
translations BC2GM057633611 NNS O
binds BC2GM057633611 VBZ O
to BC2GM057633611 TO O
a BC2GM057633611 DT O
consensus BC2GM057633611 NN O
target BC2GM057633611 NN O
site BC2GM057633611 NN O
that BC2GM057633611 WDT O
is BC2GM057633611 VBZ O
recognized BC2GM057633611 VBN O
by BC2GM057633611 IN O
the BC2GM057633611 DT O
AG BC2GM057633611 NNP O
protein BC2GM057633611 NN O
. BC2GM057633611 . O
. . O O

The BC2GM023811799 DT O
mouse BC2GM023811799 NN O
tapasin BC2GM023811799 NN O
gene BC2GM023811799 NN O
was BC2GM023811799 VBD O
mapped BC2GM023811799 VBN O
about BC2GM023811799 IN O
70 BC2GM023811799 CD O
kilobases BC2GM023811799 NNS O
from BC2GM023811799 IN O
H2-K BC2GM023811799 NNP O
at BC2GM023811799 IN O
the BC2GM023811799 DT O
centromeric BC2GM023811799 JJ O
end BC2GM023811799 NN O
of BC2GM023811799 IN O
the BC2GM023811799 DT O
mouse BC2GM023811799 NN O
MHC BC2GM023811799 NNP O
. BC2GM023811799 . O
. . O O

In BC2GM035122268 IN O
the BC2GM035122268 DT O
predicted BC2GM035122268 JJ O
amino BC2GM035122268 NN O
acid BC2GM035122268 JJ O
sequence BC2GM035122268 NN O
of BC2GM035122268 IN O
NPS1 BC2GM035122268 NNP O
, BC2GM035122268 , O
sequences BC2GM035122268 VBZ O
homologous BC2GM035122268 JJ O
to BC2GM035122268 TO O
the BC2GM035122268 DT O
catalytic BC2GM035122268 JJ O
domain BC2GM035122268 NN O
of BC2GM035122268 IN O
protein BC2GM035122268 NN O
kinases BC2GM035122268 NNS O
were BC2GM035122268 VBD O
found BC2GM035122268 VBN O
. BC2GM035122268 . O
. . O O

Immunoblotting BC2GM002401623 VBG O
using BC2GM002401623 VBG O
a BC2GM002401623 DT O
phosphospecific BC2GM002401623 JJ O
anti-Src BC2GM002401623 NN O
( BC2GM002401623 ( O
416Y BC2GM002401623 CD O
) BC2GM002401623 ) O
antibody BC2GM002401623 NN O
showed BC2GM002401623 VBD O
a BC2GM002401623 DT O
ceramide-induced BC2GM002401623 JJ O
increase BC2GM002401623 NN O
in BC2GM002401623 IN O
pp60 BC2GM002401623 NN O
( BC2GM002401623 ( O
src BC2GM002401623 NN O
) BC2GM002401623 ) O
tyrosine BC2GM002401623 NN O
phosphorylation BC2GM002401623 NN O
. BC2GM002401623 . O
. . O O

All BC2GM064382331 DT O
of BC2GM064382331 IN O
this BC2GM064382331 DT O
region BC2GM064382331 NN O
is BC2GM064382331 VBZ O
part BC2GM064382331 NN O
of BC2GM064382331 IN O
a BC2GM064382331 DT O
prominent BC2GM064382331 JJ O
CpG BC2GM064382331 NNP O
island BC2GM064382331 NN O
that BC2GM064382331 WDT O
may BC2GM064382331 MD O
be BC2GM064382331 VB O
acting BC2GM064382331 VBG O
as BC2GM064382331 IN O
an BC2GM064382331 DT O
extended BC2GM064382331 JJ O
, BC2GM064382331 , O
enhancer-independent BC2GM064382331 JJ O
promoter BC2GM064382331 NN O
. BC2GM064382331 . O
. . O O

Effect BC2GM065785628 NN O
of BC2GM065785628 IN O
a BC2GM065785628 DT O
constant BC2GM065785628 JJ O
magnetic BC2GM065785628 JJ O
field BC2GM065785628 NN O
on BC2GM065785628 IN O
different BC2GM065785628 JJ O
models BC2GM065785628 NNS O
of BC2GM065785628 IN O
carcinogenesis BC2GM065785628 NN O
. BC2GM065785628 . O
. . O O

The BC2GM038447358 DT O
yield BC2GM038447358 NN O
of BC2GM038447358 IN O
endocervical BC2GM038447358 JJ O
cells BC2GM038447358 NNS O
and BC2GM038447358 CC O
the BC2GM038447358 DT O
incidence BC2GM038447358 NN O
of BC2GM038447358 IN O
dysplasia BC2GM038447358 NN O
was BC2GM038447358 VBD O
determined BC2GM038447358 VBN O
for BC2GM038447358 IN O
both BC2GM038447358 DT O
the BC2GM038447358 DT O
prenatal BC2GM038447358 NN O
and BC2GM038447358 CC O
the BC2GM038447358 DT O
postpartum BC2GM038447358 NN O
Pap BC2GM038447358 NNP O
smears BC2GM038447358 VBZ O
performed BC2GM038447358 VBN O
for BC2GM038447358 IN O
this BC2GM038447358 DT O
group BC2GM038447358 NN O
of BC2GM038447358 IN O
patients BC2GM038447358 NNS O
. BC2GM038447358 . O
. . O O

Endotoxemia BC2GM088684177 NNP O
and BC2GM088684177 CC O
bacteremia BC2GM088684177 NN O
in BC2GM088684177 IN O
patients BC2GM088684177 NNS O
with BC2GM088684177 IN O
sepsis BC2GM088684177 JJ O
syndrome BC2GM088684177 NN O
in BC2GM088684177 IN O
the BC2GM088684177 DT O
intensive BC2GM088684177 JJ O
care BC2GM088684177 NN O
unit BC2GM088684177 NN O
. BC2GM088684177 . O
. . O O

WBC BC2GM015562296 NNP O
differential BC2GM015562296 NN O
( BC2GM015562296 ( O
SEG BC2GM015562296 NNP O
, BC2GM015562296 , O
BAND BC2GM015562296 NNP O
, BC2GM015562296 , O
LYMPH BC2GM015562296 NNP O
, BC2GM015562296 , O
MONO BC2GM015562296 NNP O
, BC2GM015562296 , O
EOSINO BC2GM015562296 NNP O
, BC2GM015562296 , O
BASO BC2GM015562296 NNP O
) BC2GM015562296 ) O
usually BC2GM015562296 RB O
showed BC2GM015562296 VBD O
log-normal BC2GM015562296 JJ O
distribution BC2GM015562296 NN O
. BC2GM015562296 . O
. . O O

E1 BC2GM044230142 NNP O
recognition BC2GM044230142 NN O
sequences BC2GM044230142 NNS O
in BC2GM044230142 IN O
the BC2GM044230142 DT O
bovine BC2GM044230142 NN O
papillomavirus BC2GM044230142 NN O
type BC2GM044230142 NN O
1 BC2GM044230142 CD O
origin BC2GM044230142 NN O
of BC2GM044230142 IN O
DNA BC2GM044230142 NNP O
replication BC2GM044230142 NN O
: BC2GM044230142 : O
interaction BC2GM044230142 NN O
between BC2GM044230142 IN O
half BC2GM044230142 NN O
sites BC2GM044230142 NNS O
of BC2GM044230142 IN O
the BC2GM044230142 DT O
inverted BC2GM044230142 JJ O
repeats BC2GM044230142 NNS O
. BC2GM044230142 . O
. . O O

Kudzu BC2GM018952146 NNP O
extract BC2GM018952146 NN O
shows BC2GM018952146 VBZ O
potential BC2GM018952146 JJ O
for BC2GM018952146 IN O
moderating BC2GM018952146 VBG O
alcohol BC2GM018952146 NN O
abuse BC2GM018952146 NN O
. BC2GM018952146 . O
. . O O

Protein BC2GM006899273 NNP O
kinase BC2GM006899273 VBD O
C BC2GM006899273 NNP O
transiently BC2GM006899273 RB O
activated BC2GM006899273 VBD O
heteromeric BC2GM006899273 JJ O
N-methyl-D-aspartate BC2GM006899273 NNP O
receptor BC2GM006899273 NN O
channels BC2GM006899273 NNS O
independent BC2GM006899273 JJ O
of BC2GM006899273 IN O
the BC2GM006899273 DT O
phosphorylatable BC2GM006899273 JJ O
C-terminal BC2GM006899273 JJ O
splice BC2GM006899273 NN O
domain BC2GM006899273 NN O
and BC2GM006899273 CC O
of BC2GM006899273 IN O
consensus BC2GM006899273 NN O
phosphorylation BC2GM006899273 NN O
sites BC2GM006899273 NNS O
. BC2GM006899273 . O
. . O O

EMG-based BC2GM019360660 JJ O
measures BC2GM019360660 NNS O
of BC2GM019360660 IN O
fatigue BC2GM019360660 NN O
during BC2GM019360660 IN O
a BC2GM019360660 DT O
repetitive BC2GM019360660 JJ O
squat BC2GM019360660 NN O
exercise BC2GM019360660 NN O
. BC2GM019360660 . O
. . O O

Historically BC2GM079042018 RB O
, BC2GM079042018 , O
Cyps BC2GM079042018 NNP O
were BC2GM079042018 VBD O
first BC2GM079042018 RB O
identified BC2GM079042018 VBN O
by BC2GM079042018 IN O
their BC2GM079042018 PRP$ O
ability BC2GM079042018 NN O
to BC2GM079042018 TO O
bind BC2GM079042018 VB O
the BC2GM079042018 DT O
immunosuppressive BC2GM079042018 JJ O
agent BC2GM079042018 NN O
cyclosporin BC2GM079042018 NN O
A BC2GM079042018 NNP O
( BC2GM079042018 ( O
CsA BC2GM079042018 NNP O
) BC2GM079042018 ) O
with BC2GM079042018 IN O
high BC2GM079042018 JJ O
affinity BC2GM079042018 NN O
; BC2GM079042018 : O
they BC2GM079042018 PRP O
later BC2GM079042018 VBP O
were BC2GM079042018 VBD O
found BC2GM079042018 VBN O
to BC2GM079042018 TO O
have BC2GM079042018 VB O
peptidyl-prolyl BC2GM079042018 JJ O
cis-trans BC2GM079042018 NNS O
isomerase BC2GM079042018 NN O
( BC2GM079042018 ( O
PPIase BC2GM079042018 NNP O
) BC2GM079042018 ) O
activity BC2GM079042018 NN O
, BC2GM079042018 , O
which BC2GM079042018 WDT O
catalyzes BC2GM079042018 VBZ O
the BC2GM079042018 DT O
folding BC2GM079042018 NN O
of BC2GM079042018 IN O
oligopeptides BC2GM079042018 NNS O
at BC2GM079042018 IN O
proline-peptide BC2GM079042018 JJ O
bonds BC2GM079042018 NNS O
in BC2GM079042018 IN O
vitro BC2GM079042018 NN O
and BC2GM079042018 CC O
may BC2GM079042018 MD O
be BC2GM079042018 VB O
important BC2GM079042018 JJ O
for BC2GM079042018 IN O
protein BC2GM079042018 NN O
folding BC2GM079042018 NN O
in BC2GM079042018 IN O
vivo BC2GM079042018 NN O
. BC2GM079042018 . O
. . O O

Eleven BC2GM015899967 NNP O
of BC2GM015899967 IN O
the BC2GM015899967 DT O
12 BC2GM015899967 CD O
exons BC2GM015899967 NNS O
have BC2GM015899967 VBP O
complete BC2GM015899967 JJ O
sequence BC2GM015899967 NN O
homology BC2GM015899967 NN O
with BC2GM015899967 IN O
the BC2GM015899967 DT O
RBM-1 BC2GM015899967 JJ O
sequence BC2GM015899967 NN O
. BC2GM015899967 . O
. . O O

Phenotypic BC2GM039630251 NNP O
and BC2GM039630251 CC O
molecular BC2GM039630251 JJ O
analyses BC2GM039630251 NNS O
of BC2GM039630251 IN O
patients BC2GM039630251 NNS O
with BC2GM039630251 IN O
partial BC2GM039630251 JJ O
chromosome BC2GM039630251 NN O
21 BC2GM039630251 CD O
monosomy BC2GM039630251 NN O
enabled BC2GM039630251 VBD O
us BC2GM039630251 PRP O
to BC2GM039630251 TO O
define BC2GM039630251 VB O
a BC2GM039630251 DT O
region BC2GM039630251 NN O
, BC2GM039630251 , O
spanning BC2GM039630251 VBG O
2.4 BC2GM039630251 CD O
Mb BC2GM039630251 NNP O
between BC2GM039630251 IN O
D21S190 BC2GM039630251 NNP O
and BC2GM039630251 CC O
D21S226 BC2GM039630251 NNP O
, BC2GM039630251 , O
associated BC2GM039630251 VBN O
with BC2GM039630251 IN O
arthrogryposis BC2GM039630251 NN O
, BC2GM039630251 , O
mental BC2GM039630251 JJ O
retardation BC2GM039630251 NN O
, BC2GM039630251 , O
hypertonia BC2GM039630251 NN O
, BC2GM039630251 , O
and BC2GM039630251 CC O
several BC2GM039630251 JJ O
facial BC2GM039630251 JJ O
anomalies BC2GM039630251 NNS O
. BC2GM039630251 . O
. . O O

The BC2GM027266609 DT O
right BC2GM027266609 JJ O
cornea BC2GM027266609 NN O
of BC2GM027266609 IN O
rats BC2GM027266609 NNS O
was BC2GM027266609 VBD O
cauterized BC2GM027266609 VBN O
by BC2GM027266609 IN O
drops BC2GM027266609 NNS O
of BC2GM027266609 IN O
1.5 BC2GM027266609 CD O
N BC2GM027266609 NNP O
HC1 BC2GM027266609 NNP O
over BC2GM027266609 IN O
30 BC2GM027266609 CD O
s BC2GM027266609 NNS O
; BC2GM027266609 : O
the BC2GM027266609 DT O
left BC2GM027266609 NN O
one BC2GM027266609 CD O
served BC2GM027266609 VBD O
as BC2GM027266609 IN O
a BC2GM027266609 DT O
control BC2GM027266609 NN O
. BC2GM027266609 . O
. . O O

On BC2GM008162838 IN O
the BC2GM008162838 DT O
basis BC2GM008162838 NN O
of BC2GM008162838 IN O
8 BC2GM008162838 CD O
cases BC2GM008162838 NNS O
, BC2GM008162838 , O
the BC2GM008162838 DT O
authors BC2GM008162838 NNS O
report BC2GM008162838 VBP O
different BC2GM008162838 JJ O
clinical BC2GM008162838 JJ O
pictures BC2GM008162838 NNS O
all BC2GM008162838 DT O
caused BC2GM008162838 VBN O
by BC2GM008162838 IN O
cardiac BC2GM008162838 JJ O
toxicity BC2GM008162838 NN O
of BC2GM008162838 IN O
5FU BC2GM008162838 CD O
. BC2GM008162838 . O
. . O O

Immunoblotting BC2GM087839527 VBG O
showed BC2GM087839527 VBD O
that BC2GM087839527 IN O
both BC2GM087839527 DT O
the BC2GM087839527 DT O
( BC2GM087839527 ( O
1-404 BC2GM087839527 JJ O
) BC2GM087839527 ) O
-peptide BC2GM087839527 NN O
and BC2GM087839527 CC O
( BC2GM087839527 ( O
1-506 BC2GM087839527 JJ O
) BC2GM087839527 ) O
-peptide BC2GM087839527 NN O
are BC2GM087839527 VBP O
recognized BC2GM087839527 VBN O
by BC2GM087839527 IN O
95J10 BC2GM087839527 CD O
, BC2GM087839527 , O
a BC2GM087839527 DT O
monoclonal BC2GM087839527 JJ O
antibody BC2GM087839527 NN O
that BC2GM087839527 WDT O
was BC2GM087839527 VBD O
previously BC2GM087839527 RB O
raised BC2GM087839527 VBN O
against BC2GM087839527 IN O
perlecan- BC2GM087839527 NN O
( BC2GM087839527 ( O
24-404 BC2GM087839527 JJ O
) BC2GM087839527 ) O
-peptide BC2GM087839527 NN O
expressed BC2GM087839527 VBN O
in BC2GM087839527 IN O
Escherichia BC2GM087839527 NNP O
coli BC2GM087839527 NN O
. BC2GM087839527 . O
. . O O

These BC2GM035995772 DT O
findings BC2GM035995772 NNS O
suggest BC2GM035995772 VBP O
that BC2GM035995772 IN O
PGE1 BC2GM035995772 NNP O
is BC2GM035995772 VBZ O
effective BC2GM035995772 JJ O
in BC2GM035995772 IN O
increasing BC2GM035995772 VBG O
PVF BC2GM035995772 NNP O
in BC2GM035995772 IN O
the BC2GM035995772 DT O
liver BC2GM035995772 NN O
transplanted BC2GM035995772 VBD O
condition BC2GM035995772 NN O
; BC2GM035995772 : O
however BC2GM035995772 RB O
, BC2GM035995772 , O
the BC2GM035995772 DT O
hepatic BC2GM035995772 JJ O
circulatory BC2GM035995772 NN O
improvement BC2GM035995772 NN O
attributed BC2GM035995772 VBD O
to BC2GM035995772 TO O
this BC2GM035995772 DT O
agent BC2GM035995772 NN O
would BC2GM035995772 MD O
be BC2GM035995772 VB O
limited BC2GM035995772 VBN O
to BC2GM035995772 TO O
the BC2GM035995772 DT O
first BC2GM035995772 JJ O
few BC2GM035995772 JJ O
days BC2GM035995772 NNS O
following BC2GM035995772 VBG O
transplantation BC2GM035995772 NN O
. BC2GM035995772 . O
. . O O

DRAP27 BC2GM033668177 NNP O
is BC2GM033668177 VBZ O
recognized BC2GM033668177 VBN O
by BC2GM033668177 IN O
CD9 BC2GM033668177 NNP O
antibodies BC2GM033668177 NNS O
. BC2GM033668177 . O
. . O O

Measurements BC2GM019437752 NNS O
in BC2GM019437752 IN O
rats BC2GM019437752 NNS O
given BC2GM019437752 VBN O
a BC2GM019437752 DT O
dose BC2GM019437752 NN O
of BC2GM019437752 IN O
propranolol BC2GM019437752 NN O
that BC2GM019437752 WDT O
partially BC2GM019437752 RB O
inhibited BC2GM019437752 VBD O
the BC2GM019437752 DT O
NA-induced BC2GM019437752 JJ O
increase BC2GM019437752 NN O
in BC2GM019437752 IN O
Q BC2GM019437752 NNP O
to BC2GM019437752 TO O
IBAT BC2GM019437752 NNP O
indicated BC2GM019437752 VBD O
that BC2GM019437752 IN O
the BC2GM019437752 DT O
decline BC2GM019437752 NN O
in BC2GM019437752 IN O
ENAIBAT BC2GM019437752 NNP O
was BC2GM019437752 VBD O
attributable BC2GM019437752 JJ O
primarily BC2GM019437752 RB O
to BC2GM019437752 TO O
the BC2GM019437752 DT O
increase BC2GM019437752 NN O
in BC2GM019437752 IN O
Q BC2GM019437752 NNP O
rather BC2GM019437752 RB O
than BC2GM019437752 IN O
to BC2GM019437752 TO O
increasing BC2GM019437752 VBG O
saturation BC2GM019437752 NN O
of BC2GM019437752 IN O
uptake BC2GM019437752 JJ O
mechanisms BC2GM019437752 NNS O
. BC2GM019437752 . O
. . O O

The BC2GM095945527 DT O
sensitivity BC2GM095945527 NN O
of BC2GM095945527 IN O
99mTc-IgG BC2GM095945527 JJ O
scintigraphy BC2GM095945527 NN O
ranged BC2GM095945527 VBD O
between BC2GM095945527 IN O
71 BC2GM095945527 CD O
% BC2GM095945527 NN O
and BC2GM095945527 CC O
100 BC2GM095945527 CD O
% BC2GM095945527 NN O
. BC2GM095945527 . O
. . O O

A BC2GM005244368 DT O
case BC2GM005244368 NN O
of BC2GM005244368 IN O
functioning BC2GM005244368 VBG O
parathyroid BC2GM005244368 JJ O
carcinoma BC2GM005244368 NN O
with BC2GM005244368 IN O
hypereninemic BC2GM005244368 JJ O
hypertension BC2GM005244368 NN O
. BC2GM005244368 . O
. . O O

Genetic BC2GM033301301 JJ O
mutation BC2GM033301301 NN O
or BC2GM033301301 CC O
loss BC2GM033301301 NN O
of BC2GM033301301 IN O
activin BC2GM033301301 JJ O
/ BC2GM033301301 NN O
transforming BC2GM033301301 VBG O
growth BC2GM033301301 NN O
factor-beta BC2GM033301301 NN O
( BC2GM033301301 ( O
TGFbeta BC2GM033301301 NNP O
) BC2GM033301301 ) O
receptor BC2GM033301301 NN O
function BC2GM033301301 NN O
has BC2GM033301301 VBZ O
been BC2GM033301301 VBN O
shown BC2GM033301301 VBN O
in BC2GM033301301 IN O
human BC2GM033301301 JJ O
lymphoid BC2GM033301301 NN O
, BC2GM033301301 , O
breast BC2GM033301301 NN O
, BC2GM033301301 , O
and BC2GM033301301 CC O
colorectal BC2GM033301301 JJ O
tumors BC2GM033301301 NNS O
as BC2GM033301301 RB O
well BC2GM033301301 RB O
as BC2GM033301301 IN O
Hep2B BC2GM033301301 NNP O
and BC2GM033301301 CC O
Mv1Lu BC2GM033301301 NNP O
cell BC2GM033301301 NN O
lines BC2GM033301301 NNS O
. BC2GM033301301 . O
. . O O

Seven BC2GM063968223 NNP O
Zebu BC2GM063968223 NNP O
cattle BC2GM063968223 NNS O
were BC2GM063968223 VBD O
also BC2GM063968223 RB O
exposed BC2GM063968223 VBN O
to BC2GM063968223 TO O
challenge BC2GM063968223 VB O
at BC2GM063968223 IN O
the BC2GM063968223 DT O
same BC2GM063968223 JJ O
time BC2GM063968223 NN O
. BC2GM063968223 . O
. . O O

Most BC2GM078039869 JJS O
significantly BC2GM078039869 RB O
, BC2GM078039869 , O
the BC2GM078039869 DT O
cyclin BC2GM078039869 JJ O
E-Cdk2 BC2GM078039869 NNP O
complex BC2GM078039869 NN O
is BC2GM078039869 VBZ O
maximally BC2GM078039869 RB O
active BC2GM078039869 JJ O
at BC2GM078039869 IN O
the BC2GM078039869 DT O
G1 BC2GM078039869 NNP O
/ BC2GM078039869 NNP O
S BC2GM078039869 NNP O
transition BC2GM078039869 NN O
, BC2GM078039869 , O
and BC2GM078039869 CC O
overexpression BC2GM078039869 NN O
of BC2GM078039869 IN O
cyclin BC2GM078039869 NN O
E BC2GM078039869 NNP O
decreases BC2GM078039869 VBZ O
the BC2GM078039869 DT O
time BC2GM078039869 NN O
it BC2GM078039869 PRP O
takes BC2GM078039869 VBZ O
the BC2GM078039869 DT O
cell BC2GM078039869 NN O
to BC2GM078039869 TO O
complete BC2GM078039869 VB O
G1 BC2GM078039869 NNP O
and BC2GM078039869 CC O
enter BC2GM078039869 NN O
S BC2GM078039869 NNP O
phase BC2GM078039869 NN O
. BC2GM078039869 . O
. . O O

Production BC2GM043026651 NN O
of BC2GM043026651 IN O
VT BC2GM043026651 NNP O
was BC2GM043026651 VBD O
also BC2GM043026651 RB O
examined BC2GM043026651 VBN O
retrospectively BC2GM043026651 RB O
in BC2GM043026651 IN O
32 BC2GM043026651 CD O
E. BC2GM043026651 NNP O
coli BC2GM043026651 NNS O
strains BC2GM043026651 NNS O
of BC2GM043026651 IN O
serotype BC2GM043026651 JJ O
O26 BC2GM043026651 NNP O
: BC2GM043026651 : O
H11 BC2GM043026651 NNP O
isolated BC2GM043026651 VBD O
from BC2GM043026651 IN O
children BC2GM043026651 NNS O
with BC2GM043026651 IN O
diarrhoea BC2GM043026651 NN O
; BC2GM043026651 : O
eight BC2GM043026651 CD O
( BC2GM043026651 ( O
25 BC2GM043026651 CD O
% BC2GM043026651 NN O
) BC2GM043026651 ) O
of BC2GM043026651 IN O
them BC2GM043026651 PRP O
produced BC2GM043026651 VBD O
moderate BC2GM043026651 JJ O
to BC2GM043026651 TO O
high BC2GM043026651 JJ O
levels BC2GM043026651 NNS O
of BC2GM043026651 IN O
verotoxin BC2GM043026651 NN O
1 BC2GM043026651 CD O
despite BC2GM043026651 IN O
several BC2GM043026651 JJ O
years BC2GM043026651 NNS O
storage BC2GM043026651 NN O
in BC2GM043026651 IN O
vitro BC2GM043026651 NN O
. BC2GM043026651 . O
. . O O

Like BC2GM005600450 IN O
Mdm2 BC2GM005600450 NNP O
, BC2GM005600450 , O
MdmX BC2GM005600450 NNP O
is BC2GM005600450 VBZ O
able BC2GM005600450 JJ O
to BC2GM005600450 TO O
bind BC2GM005600450 VB O
p53 BC2GM005600450 NN O
and BC2GM005600450 CC O
inhibit BC2GM005600450 NN O
p53 BC2GM005600450 NN O
transactivation BC2GM005600450 NN O
; BC2GM005600450 : O
however BC2GM005600450 RB O
, BC2GM005600450 , O
the BC2GM005600450 DT O
ability BC2GM005600450 NN O
of BC2GM005600450 IN O
MdmX BC2GM005600450 NNP O
to BC2GM005600450 TO O
degrade BC2GM005600450 VB O
p53 BC2GM005600450 NN O
has BC2GM005600450 VBZ O
yet BC2GM005600450 RB O
to BC2GM005600450 TO O
be BC2GM005600450 VB O
examined BC2GM005600450 VBN O
. BC2GM005600450 . O
. . O O

Here BC2GM011301969 RB O
we BC2GM011301969 PRP O
report BC2GM011301969 VBP O
the BC2GM011301969 DT O
cloning BC2GM011301969 NN O
, BC2GM011301969 , O
by BC2GM011301969 IN O
either BC2GM011301969 DT O
peptide BC2GM011301969 JJ O
sequencing BC2GM011301969 NN O
or BC2GM011301969 CC O
by BC2GM011301969 IN O
sequence BC2GM011301969 NN O
similarity BC2GM011301969 NN O
to BC2GM011301969 TO O
the BC2GM011301969 DT O
human BC2GM011301969 JJ O
cDNAs BC2GM011301969 NN O
, BC2GM011301969 , O
of BC2GM011301969 IN O
the BC2GM011301969 DT O
S. BC2GM011301969 NNP O
cerevisiae BC2GM011301969 NN O
genes BC2GM011301969 NNS O
RFC1 BC2GM011301969 NNP O
, BC2GM011301969 , O
RFC2 BC2GM011301969 NNP O
, BC2GM011301969 , O
RFC3 BC2GM011301969 NNP O
, BC2GM011301969 , O
RFC4 BC2GM011301969 NNP O
, BC2GM011301969 , O
and BC2GM011301969 CC O
RFC5 BC2GM011301969 NNP O
. BC2GM011301969 . O
. . O O

Azoospermia BC2GM027526688 NNP O
was BC2GM027526688 VBD O
graded BC2GM027526688 VBN O
in BC2GM027526688 IN O
the BC2GM027526688 DT O
following BC2GM027526688 JJ O
way BC2GM027526688 NN O
: BC2GM027526688 : O
adequate BC2GM027526688 JJ O
spermatozoa BC2GM027526688 NN O
( BC2GM027526688 ( O
A1 BC2GM027526688 NNP O
) BC2GM027526688 ) O
, BC2GM027526688 , O
low BC2GM027526688 JJ O
, BC2GM027526688 , O
scanty BC2GM027526688 NN O
or BC2GM027526688 CC O
rare BC2GM027526688 JJ O
spermatozoa BC2GM027526688 NN O
( BC2GM027526688 ( O
A2 BC2GM027526688 NNP O
) BC2GM027526688 ) O
, BC2GM027526688 , O
spermatid BC2GM027526688 JJ O
arrest BC2GM027526688 NN O
( BC2GM027526688 ( O
B1 BC2GM027526688 NNP O
) BC2GM027526688 ) O
, BC2GM027526688 , O
spermatocyte BC2GM027526688 JJ O
arrest BC2GM027526688 NN O
( BC2GM027526688 ( O
B2 BC2GM027526688 NNP O
) BC2GM027526688 ) O
, BC2GM027526688 , O
Sertoli BC2GM027526688 NNP O
cell-only BC2GM027526688 JJ O
pattern BC2GM027526688 NN O
( BC2GM027526688 ( O
C BC2GM027526688 NNP O
) BC2GM027526688 ) O
and BC2GM027526688 CC O
sclerosis BC2GM027526688 NN O
( BC2GM027526688 ( O
D BC2GM027526688 NNP O
) BC2GM027526688 ) O
. BC2GM027526688 . O
. . O O

The BC2GM090707363 DT O
author BC2GM090707363 NN O
describes BC2GM090707363 VBZ O
the BC2GM090707363 DT O
technique BC2GM090707363 NN O
in BC2GM090707363 IN O
detail BC2GM090707363 NN O
and BC2GM090707363 CC O
presents BC2GM090707363 VBZ O
the BC2GM090707363 DT O
findings BC2GM090707363 NNS O
for BC2GM090707363 IN O
25 BC2GM090707363 CD O
patients BC2GM090707363 NNS O
( BC2GM090707363 ( O
10 BC2GM090707363 CD O
men BC2GM090707363 NNS O
and BC2GM090707363 CC O
15 BC2GM090707363 CD O
women BC2GM090707363 NNS O
) BC2GM090707363 ) O
examined BC2GM090707363 VBD O
for BC2GM090707363 IN O
suspected BC2GM090707363 JJ O
ileostomy BC2GM090707363 JJ O
dysfunction BC2GM090707363 NN O
, BC2GM090707363 , O
recurrent BC2GM090707363 NN O
Crohn BC2GM090707363 NNP O
's BC2GM090707363 POS O
disease BC2GM090707363 NN O
or BC2GM090707363 CC O
ileal BC2GM090707363 JJ O
obstruction BC2GM090707363 NN O
remote BC2GM090707363 NN O
from BC2GM090707363 IN O
the BC2GM090707363 DT O
stoma BC2GM090707363 NN O
. BC2GM090707363 . O
. . O O

The BC2GM005435651 DT O
longest BC2GM005435651 JJS O
S1-S2 BC2GM005435651 JJ O
interval BC2GM005435651 NN O
at BC2GM005435651 IN O
which BC2GM005435651 WDT O
S2 BC2GM005435651 NNP O
failed BC2GM005435651 VBD O
to BC2GM005435651 TO O
capture BC2GM005435651 VB O
( BC2GM005435651 ( O
effective BC2GM005435651 JJ O
refractory BC2GM005435651 NN O
period BC2GM005435651 NN O
) BC2GM005435651 ) O
was BC2GM005435651 VBD O
longer BC2GM005435651 VBN O
by BC2GM005435651 IN O
5.5 BC2GM005435651 CD O
+ BC2GM005435651 NNS O
/ BC2GM005435651 SYM O
- BC2GM005435651 : O
8.2 BC2GM005435651 CD O
msec BC2GM005435651 NN O
at BC2GM005435651 IN O
twice BC2GM005435651 RB O
threshold BC2GM005435651 NN O
( BC2GM005435651 ( O
0.05 BC2GM005435651 CD O
less BC2GM005435651 JJR O
than BC2GM005435651 IN O
p BC2GM005435651 NN O
less BC2GM005435651 JJR O
than BC2GM005435651 IN O
0.10 BC2GM005435651 CD O
) BC2GM005435651 ) O
and BC2GM005435651 CC O
5.5 BC2GM005435651 CD O
+ BC2GM005435651 NN O
/ BC2GM005435651 NNP O
- BC2GM005435651 : O
3.5 BC2GM005435651 CD O
msec BC2GM005435651 NN O
at BC2GM005435651 IN O
5 BC2GM005435651 CD O
times BC2GM005435651 NNS O
threshold BC2GM005435651 JJ O
stimulation BC2GM005435651 NN O
( BC2GM005435651 ( O
p BC2GM005435651 NN O
less BC2GM005435651 JJR O
than BC2GM005435651 IN O
0.01 BC2GM005435651 CD O
) BC2GM005435651 ) O
when BC2GM005435651 WRB O
the BC2GM005435651 DT O
basic BC2GM005435651 JJ O
drive BC2GM005435651 NN O
and BC2GM005435651 CC O
extrastimuli BC2GM005435651 NN O
were BC2GM005435651 VBD O
delivered BC2GM005435651 VBN O
to BC2GM005435651 TO O
separate BC2GM005435651 VB O
sites BC2GM005435651 NNS O
. BC2GM005435651 . O
. . O O

From BC2GM022142685 IN O
1981 BC2GM022142685 CD O
to BC2GM022142685 TO O
1989 BC2GM022142685 CD O
, BC2GM022142685 , O
a BC2GM022142685 DT O
total BC2GM022142685 NN O
of BC2GM022142685 IN O
26 BC2GM022142685 CD O
women BC2GM022142685 NNS O
with BC2GM022142685 IN O
locally BC2GM022142685 RB O
or BC2GM022142685 CC O
regionally BC2GM022142685 RB O
advanced BC2GM022142685 JJ O
carcinoma BC2GM022142685 NN O
of BC2GM022142685 IN O
the BC2GM022142685 DT O
uterine BC2GM022142685 JJ O
cervix BC2GM022142685 NN O
were BC2GM022142685 VBD O
treated BC2GM022142685 VBN O
with BC2GM022142685 IN O
radiotherapy BC2GM022142685 NN O
( BC2GM022142685 ( O
RT BC2GM022142685 NNP O
) BC2GM022142685 ) O
and BC2GM022142685 CC O
pelvic BC2GM022142685 JJ O
regional BC2GM022142685 JJ O
hyperthermia BC2GM022142685 NN O
( BC2GM022142685 ( O
HT BC2GM022142685 NNP O
) BC2GM022142685 ) O
, BC2GM022142685 , O
in BC2GM022142685 IN O
the BC2GM022142685 DT O
Divisions BC2GM022142685 NNP O
of BC2GM022142685 IN O
Radiation BC2GM022142685 NNP O
Oncology BC2GM022142685 NNP O
at BC2GM022142685 IN O
the BC2GM022142685 DT O
University BC2GM022142685 NNP O
of BC2GM022142685 IN O
Utah BC2GM022142685 NNP O
Medical BC2GM022142685 NNP O
Center BC2GM022142685 NNP O
( BC2GM022142685 ( O
UU BC2GM022142685 NNP O
) BC2GM022142685 ) O
and BC2GM022142685 CC O
the BC2GM022142685 DT O
Kenneth BC2GM022142685 NNP O
Norris BC2GM022142685 NNP O
Jr BC2GM022142685 NNP O
Cancer BC2GM022142685 NNP O
Hospital BC2GM022142685 NNP O
of BC2GM022142685 IN O
the BC2GM022142685 DT O
University BC2GM022142685 NNP O
of BC2GM022142685 IN O
Southern BC2GM022142685 NNP O
California BC2GM022142685 NNP O
( BC2GM022142685 ( O
USC BC2GM022142685 NNP O
) BC2GM022142685 ) O
. BC2GM022142685 . O
. . O O

The BC2GM046571166 DT O
AtNMT1 BC2GM046571166 NNP O
expression BC2GM046571166 NN O
profile BC2GM046571166 NN O
indicated BC2GM046571166 VBN O
ubiquity BC2GM046571166 NN O
in BC2GM046571166 IN O
roots BC2GM046571166 NNS O
, BC2GM046571166 , O
stem BC2GM046571166 NN O
, BC2GM046571166 , O
leaves BC2GM046571166 VBZ O
, BC2GM046571166 , O
flowers BC2GM046571166 NNS O
, BC2GM046571166 , O
and BC2GM046571166 CC O
siliques BC2GM046571166 NNS O
( BC2GM046571166 ( O
approximately BC2GM046571166 RB O
1.7 BC2GM046571166 CD O
kb BC2GM046571166 NNS O
transcript BC2GM046571166 NN O
and BC2GM046571166 CC O
approximately BC2GM046571166 RB O
50 BC2GM046571166 CD O
kDa BC2GM046571166 NNS O
immunoreactive BC2GM046571166 JJ O
polypeptide BC2GM046571166 NN O
) BC2GM046571166 ) O
but BC2GM046571166 CC O
a BC2GM046571166 DT O
greater BC2GM046571166 JJR O
level BC2GM046571166 NN O
in BC2GM046571166 IN O
the BC2GM046571166 DT O
younger BC2GM046571166 JJR O
tissue BC2GM046571166 NN O
, BC2GM046571166 , O
which BC2GM046571166 WDT O
are BC2GM046571166 VBP O
developmentally BC2GM046571166 RB O
very BC2GM046571166 RB O
active BC2GM046571166 JJ O
. BC2GM046571166 . O
. . O O

In BC2GM097056879 IN O
addition BC2GM097056879 NN O
, BC2GM097056879 , O
while BC2GM097056879 IN O
GCN1 BC2GM097056879 NNP O
is BC2GM097056879 VBZ O
required BC2GM097056879 VBN O
in BC2GM097056879 IN O
vivo BC2GM097056879 NN O
for BC2GM097056879 IN O
phosphorylation BC2GM097056879 NN O
of BC2GM097056879 IN O
eIF-2 BC2GM097056879 JJ O
alpha BC2GM097056879 NN O
by BC2GM097056879 IN O
GCN2 BC2GM097056879 NNP O
, BC2GM097056879 , O
cell BC2GM097056879 NN O
extracts BC2GM097056879 NNS O
from BC2GM097056879 IN O
gcn1 BC2GM097056879 NN O
delta BC2GM097056879 NN O
strains BC2GM097056879 NNS O
contained BC2GM097056879 VBN O
wild-type BC2GM097056879 JJ O
levels BC2GM097056879 NNS O
of BC2GM097056879 IN O
GCN2 BC2GM097056879 NNP O
eIF-2 BC2GM097056879 JJ O
alpha-kinase BC2GM097056879 JJ O
activity BC2GM097056879 NN O
. BC2GM097056879 . O
. . O O

PC12 BC2GM040204368 NNP O
cultures BC2GM040204368 VBZ O
that BC2GM040204368 WDT O
had BC2GM040204368 VBD O
been BC2GM040204368 VBN O
`` BC2GM040204368 `` O
primed BC2GM040204368 JJ O
'' BC2GM040204368 '' O
in BC2GM040204368 IN O
this BC2GM040204368 DT O
way BC2GM040204368 NN O
showed BC2GM040204368 VBD O
an BC2GM040204368 DT O
accelerated BC2GM040204368 JJ O
and BC2GM040204368 CC O
augmented BC2GM040204368 JJ O
differentiation BC2GM040204368 NN O
response BC2GM040204368 NN O
to BC2GM040204368 TO O
nerve BC2GM040204368 VB O
growth BC2GM040204368 NN O
factor BC2GM040204368 NN O
. BC2GM040204368 . O
. . O O

A BC2GM074130635 DT O
distinct BC2GM074130635 JJ O
5'-sequence BC2GM074130635 NN O
in BC2GM074130635 IN O
clone BC2GM074130635 NN O
hMIWC2 BC2GM074130635 NN O
suggested BC2GM074130635 VBD O
an BC2GM074130635 DT O
alternative BC2GM074130635 JJ O
upstream BC2GM074130635 JJ O
transcription BC2GM074130635 NN O
initiation BC2GM074130635 NN O
site BC2GM074130635 NN O
. BC2GM074130635 . O
. . O O

In BC2GM068073142 IN O
vitro BC2GM068073142 JJ O
DNA BC2GM068073142 NNP O
binding BC2GM068073142 NN O
assays BC2GM068073142 NNS O
indicate BC2GM068073142 VBP O
that BC2GM068073142 IN O
the BC2GM068073142 DT O
elements BC2GM068073142 NNS O
identified BC2GM068073142 VBN O
can BC2GM068073142 MD O
specifically BC2GM068073142 RB O
interact BC2GM068073142 VB O
with BC2GM068073142 IN O
c-Ets-1 BC2GM068073142 JJ O
protein BC2GM068073142 NN O
. BC2GM068073142 . O
. . O O

Homodimers BC2GM083759997 NNS O
of BC2GM083759997 IN O
RIP60 BC2GM083759997 NNP O
( BC2GM083759997 ( O
replication BC2GM083759997 NN O
initiation-region BC2GM083759997 NN O
protein BC2GM083759997 NN O
60 BC2GM083759997 CD O
kDA BC2GM083759997 NN O
) BC2GM083759997 ) O
purified BC2GM083759997 VBD O
from BC2GM083759997 IN O
nuclear BC2GM083759997 JJ O
extract BC2GM083759997 JJ O
bind BC2GM083759997 IN O
two BC2GM083759997 CD O
ATT-rich BC2GM083759997 JJ O
sites BC2GM083759997 NNS O
in BC2GM083759997 IN O
oribeta BC2GM083759997 NN O
and BC2GM083759997 CC O
foster BC2GM083759997 VB O
the BC2GM083759997 DT O
formation BC2GM083759997 NN O
of BC2GM083759997 IN O
a BC2GM083759997 DT O
twisted BC2GM083759997 JJ O
720 BC2GM083759997 CD O
bp BC2GM083759997 NN O
DNA BC2GM083759997 NNP O
loop BC2GM083759997 NN O
in BC2GM083759997 IN O
vitro BC2GM083759997 NN O
. BC2GM083759997 . O
. . O O

In BC2GM062031104 IN O
K562 BC2GM062031104 NNP O
cells BC2GM062031104 NNS O
, BC2GM062031104 , O
using BC2GM062031104 VBG O
the BC2GM062031104 DT O
bicistronic BC2GM062031104 JJ O
vector BC2GM062031104 NN O
, BC2GM062031104 , O
selection BC2GM062031104 NN O
with BC2GM062031104 IN O
colchicine BC2GM062031104 NN O
led BC2GM062031104 VBN O
to BC2GM062031104 TO O
at BC2GM062031104 IN O
least BC2GM062031104 JJS O
20-fold BC2GM062031104 JJ O
higher BC2GM062031104 JJR O
expression BC2GM062031104 NN O
of BC2GM062031104 IN O
the BC2GM062031104 DT O
MDR1 BC2GM062031104 NNP O
gene BC2GM062031104 NN O
product BC2GM062031104 NN O
than BC2GM062031104 IN O
did BC2GM062031104 VBD O
selection BC2GM062031104 NN O
with BC2GM062031104 IN O
G418 BC2GM062031104 NNP O
, BC2GM062031104 , O
suggesting BC2GM062031104 VBG O
that BC2GM062031104 IN O
the BC2GM062031104 DT O
stringent BC2GM062031104 JJ O
MDR1 BC2GM062031104 NNP O
selection BC2GM062031104 NN O
system BC2GM062031104 NN O
is BC2GM062031104 VBZ O
very BC2GM062031104 RB O
efficient BC2GM062031104 JJ O
for BC2GM062031104 IN O
obtaining BC2GM062031104 VBG O
overexpression BC2GM062031104 NN O
of BC2GM062031104 IN O
foreign BC2GM062031104 JJ O
genes BC2GM062031104 NNS O
. BC2GM062031104 . O
. . O O

PTP1-lacZ BC2GM051430553 JJ O
studies BC2GM051430553 NNS O
indicate BC2GM051430553 VBP O
that BC2GM051430553 IN O
PTP1 BC2GM051430553 NNP O
is BC2GM051430553 VBZ O
spatially BC2GM051430553 RB O
localized BC2GM051430553 VBN O
to BC2GM051430553 TO O
prestalk BC2GM051430553 VB O
and BC2GM051430553 CC O
anterior-like BC2GM051430553 VB O
cell BC2GM051430553 NN O
types BC2GM051430553 NNS O
. BC2GM051430553 . O
. . O O

Unlike BC2GM099816783 IN O
these BC2GM099816783 DT O
contaminant-responsive BC2GM099816783 JJ O
T BC2GM099816783 NNP O
cells BC2GM099816783 NNS O
, BC2GM099816783 , O
those BC2GM099816783 DT O
that BC2GM099816783 WDT O
are BC2GM099816783 VBP O
truly BC2GM099816783 RB O
specific BC2GM099816783 JJ O
for BC2GM099816783 IN O
natural BC2GM099816783 JJ O
AChR BC2GM099816783 NNP O
epitopes BC2GM099816783 VBZ O
appear BC2GM099816783 VBP O
less BC2GM099816783 RBR O
heterogeneous BC2GM099816783 JJ O
and BC2GM099816783 CC O
therefore BC2GM099816783 RB O
more BC2GM099816783 RBR O
suitable BC2GM099816783 JJ O
targets BC2GM099816783 NNS O
for BC2GM099816783 IN O
selective BC2GM099816783 JJ O
immunotherapy BC2GM099816783 NN O
. BC2GM099816783 . O
. . O O

Upstream BC2GM039068445 NN O
of BC2GM039068445 IN O
the BC2GM039068445 DT O
afa-3 BC2GM039068445 JJ O
gene BC2GM039068445 NN O
cluster BC2GM039068445 NN O
, BC2GM039068445 , O
a BC2GM039068445 DT O
1.2-kb BC2GM039068445 JJ O
region BC2GM039068445 NN O
was BC2GM039068445 VBD O
found BC2GM039068445 VBN O
to BC2GM039068445 TO O
be BC2GM039068445 VB O
96 BC2GM039068445 CD O
% BC2GM039068445 NN O
identical BC2GM039068445 JJ O
to BC2GM039068445 TO O
the BC2GM039068445 DT O
RepFIB BC2GM039068445 NNP O
sequence BC2GM039068445 NN O
of BC2GM039068445 IN O
one BC2GM039068445 CD O
of BC2GM039068445 IN O
the BC2GM039068445 DT O
enterotoxigenic BC2GM039068445 JJ O
E. BC2GM039068445 NNP O
coli BC2GM039068445 NNS O
plasmids BC2GM039068445 NNS O
( BC2GM039068445 ( O
P307 BC2GM039068445 NNP O
) BC2GM039068445 ) O
, BC2GM039068445 , O
suggesting BC2GM039068445 VBG O
a BC2GM039068445 DT O
common BC2GM039068445 JJ O
ancestor BC2GM039068445 NN O
plasmid BC2GM039068445 NN O
. BC2GM039068445 . O
. . O O

In BC2GM072200502 IN O
analogy BC2GM072200502 NN O
to BC2GM072200502 TO O
human BC2GM072200502 JJ O
CD70 BC2GM072200502 NNP O
, BC2GM072200502 , O
mCD70 BC2GM072200502 FW O
transcript BC2GM072200502 NN O
levels BC2GM072200502 NNS O
are BC2GM072200502 VBP O
strongly BC2GM072200502 RB O
but BC2GM072200502 CC O
transiently BC2GM072200502 RB O
up-regulated BC2GM072200502 JJ O
during BC2GM072200502 IN O
lymphocyte BC2GM072200502 JJ O
activation BC2GM072200502 NN O
, BC2GM072200502 , O
which BC2GM072200502 WDT O
is BC2GM072200502 VBZ O
in BC2GM072200502 IN O
line BC2GM072200502 NN O
with BC2GM072200502 IN O
a BC2GM072200502 DT O
role BC2GM072200502 NN O
for BC2GM072200502 IN O
the BC2GM072200502 DT O
CD27-CD70 BC2GM072200502 NNP O
receptor BC2GM072200502 NN O
pair BC2GM072200502 NN O
early BC2GM072200502 RB O
in BC2GM072200502 IN O
the BC2GM072200502 DT O
immune BC2GM072200502 JJ O
response BC2GM072200502 NN O
. BC2GM072200502 . O
. . O O

GH BC2GM030329937 NNP O
signals BC2GM030329937 NNS O
by BC2GM030329937 IN O
interacting BC2GM030329937 VBG O
with BC2GM030329937 IN O
GH BC2GM030329937 NNP O
receptor BC2GM030329937 NN O
( BC2GM030329937 ( O
GHR BC2GM030329937 NNP O
) BC2GM030329937 ) O
. BC2GM030329937 . O
. . O O

In BC2GM050984092 IN O
cases BC2GM050984092 NNS O
in BC2GM050984092 IN O
which BC2GM050984092 WDT O
it BC2GM050984092 PRP O
was BC2GM050984092 VBD O
identified BC2GM050984092 VBN O
, BC2GM050984092 , O
insulitis BC2GM050984092 NN O
affected BC2GM050984092 VBD O
23 BC2GM050984092 CD O
% BC2GM050984092 NN O
of BC2GM050984092 IN O
islets BC2GM050984092 NNS O
containing BC2GM050984092 VBG O
insulin BC2GM050984092 NN O
, BC2GM050984092 , O
but BC2GM050984092 CC O
affected BC2GM050984092 VBD O
only BC2GM050984092 RB O
1 BC2GM050984092 CD O
% BC2GM050984092 NN O
of BC2GM050984092 IN O
islets BC2GM050984092 NNS O
which BC2GM050984092 WDT O
were BC2GM050984092 VBD O
insulin BC2GM050984092 JJ O
deficient BC2GM050984092 NN O
, BC2GM050984092 , O
thus BC2GM050984092 RB O
supporting BC2GM050984092 VBG O
the BC2GM050984092 DT O
concept BC2GM050984092 NN O
that BC2GM050984092 WDT O
insulitis BC2GM050984092 NN O
represents BC2GM050984092 VBZ O
an BC2GM050984092 DT O
immunologically BC2GM050984092 RB O
mediated BC2GM050984092 VBN O
destruction BC2GM050984092 NN O
of BC2GM050984092 IN O
insulin BC2GM050984092 NN O
secreting BC2GM050984092 VBG O
B BC2GM050984092 NNP O
cells BC2GM050984092 NNS O
. BC2GM050984092 . O
. . O O

Although BC2GM037564004 IN O
cDNA BC2GM037564004 NN O
encoding BC2GM037564004 VBG O
a BC2GM037564004 DT O
human BC2GM037564004 JJ O
phagocyte BC2GM037564004 NN O
formyl BC2GM037564004 NN O
peptide-binding BC2GM037564004 NN O
protein BC2GM037564004 NN O
has BC2GM037564004 VBZ O
been BC2GM037564004 VBN O
reported BC2GM037564004 VBN O
recently BC2GM037564004 RB O
( BC2GM037564004 ( O
Boulay BC2GM037564004 NNP O
, BC2GM037564004 , O
F. BC2GM037564004 NNP O
, BC2GM037564004 , O
Tardif BC2GM037564004 NNP O
, BC2GM037564004 , O
M. BC2GM037564004 NNP O
, BC2GM037564004 , O
Brouchon BC2GM037564004 NNP O
, BC2GM037564004 , O
L. BC2GM037564004 NNP O
, BC2GM037564004 , O
and BC2GM037564004 CC O
Vignais BC2GM037564004 NNP O
, BC2GM037564004 , O
P BC2GM037564004 NNP O
. BC2GM037564004 . O
. . O O

The BC2GM006151148 DT O
data BC2GM006151148 NN O
from BC2GM006151148 IN O
animal BC2GM006151148 JJ O
experiments BC2GM006151148 NNS O
indicate BC2GM006151148 VBP O
that BC2GM006151148 IN O
the BC2GM006151148 DT O
incidence BC2GM006151148 NN O
of BC2GM006151148 IN O
solid BC2GM006151148 JJ O
tumors BC2GM006151148 NNS O
in BC2GM006151148 IN O
marrow BC2GM006151148 NN O
transplant BC2GM006151148 NN O
patients BC2GM006151148 NNS O
may BC2GM006151148 MD O
still BC2GM006151148 RB O
rise BC2GM006151148 VB O
in BC2GM006151148 IN O
the BC2GM006151148 DT O
coming BC2GM006151148 VBG O
decades BC2GM006151148 NNS O
. BC2GM006151148 . O
. . O O

Hypocalcemia BC2GM042620717 NNP O
is BC2GM042620717 VBZ O
usually BC2GM042620717 RB O
due BC2GM042620717 JJ O
to BC2GM042620717 TO O
either BC2GM042620717 VB O
a BC2GM042620717 DT O
disturbance BC2GM042620717 NN O
in BC2GM042620717 IN O
the BC2GM042620717 DT O
parathyroid BC2GM042620717 JJ O
hormone-adenylate BC2GM042620717 JJ O
cyclase BC2GM042620717 NN O
system BC2GM042620717 NN O
or BC2GM042620717 CC O
a BC2GM042620717 DT O
disturbance BC2GM042620717 NN O
in BC2GM042620717 IN O
vitamin BC2GM042620717 NN O
D BC2GM042620717 NNP O
metabolism BC2GM042620717 NN O
. BC2GM042620717 . O
. . O O

The BC2GM040473941 DT O
results BC2GM040473941 NNS O
of BC2GM040473941 IN O
this BC2GM040473941 DT O
study BC2GM040473941 NN O
demonstrate BC2GM040473941 NN O
that BC2GM040473941 IN O
release BC2GM040473941 NN O
of BC2GM040473941 IN O
a BC2GM040473941 DT O
single BC2GM040473941 JJ O
pulley BC2GM040473941 NN O
after BC2GM040473941 IN O
repair BC2GM040473941 NN O
of BC2GM040473941 IN O
the BC2GM040473941 DT O
tendons BC2GM040473941 NNS O
in BC2GM040473941 IN O
this BC2GM040473941 DT O
area BC2GM040473941 NN O
improved BC2GM040473941 VBD O
gliding BC2GM040473941 JJ O
excursions BC2GM040473941 NNS O
of BC2GM040473941 IN O
the BC2GM040473941 DT O
tendons BC2GM040473941 NNS O
and BC2GM040473941 CC O
reduced BC2GM040473941 JJ O
resistance BC2GM040473941 NN O
to BC2GM040473941 TO O
motion BC2GM040473941 NN O
of BC2GM040473941 IN O
the BC2GM040473941 DT O
repaired BC2GM040473941 JJ O
tendons BC2GM040473941 NNS O
, BC2GM040473941 , O
and BC2GM040473941 CC O
provide BC2GM040473941 VB O
support BC2GM040473941 NN O
for BC2GM040473941 IN O
partial BC2GM040473941 JJ O
A2 BC2GM040473941 NNP O
pulley BC2GM040473941 NN O
incision BC2GM040473941 NN O
after BC2GM040473941 IN O
repair BC2GM040473941 NN O
of BC2GM040473941 IN O
the BC2GM040473941 DT O
tendons BC2GM040473941 NNS O
in BC2GM040473941 IN O
the BC2GM040473941 DT O
area BC2GM040473941 NN O
of BC2GM040473941 IN O
the BC2GM040473941 DT O
pulley BC2GM040473941 NN O
. BC2GM040473941 . O
. . O O

Late BC2GM081970159 JJ O
results BC2GM081970159 NNS O
in BC2GM081970159 IN O
the BC2GM081970159 DT O
treatment BC2GM081970159 NN O
of BC2GM081970159 IN O
urotuberculosis BC2GM081970159 NN O
. BC2GM081970159 . O
. . O O

Female BC2GM058204459 NNP O
Wistar BC2GM058204459 NNP O
rats BC2GM058204459 VBZ O
receiving BC2GM058204459 VBG O
alcohol BC2GM058204459 NN O
( BC2GM058204459 ( O
5 BC2GM058204459 CD O
% BC2GM058204459 NN O
) BC2GM058204459 ) O
in BC2GM058204459 IN O
drinking BC2GM058204459 NN O
water BC2GM058204459 NN O
during BC2GM058204459 IN O
lactation BC2GM058204459 NN O
( BC2GM058204459 ( O
N BC2GM058204459 NNP O
= BC2GM058204459 NNP O
7 BC2GM058204459 CD O
) BC2GM058204459 ) O
were BC2GM058204459 VBD O
compared BC2GM058204459 VBN O
to BC2GM058204459 TO O
normal BC2GM058204459 JJ O
controls BC2GM058204459 NNS O
fed BC2GM058204459 VBP O
ad BC2GM058204459 NN O
libitum BC2GM058204459 NN O
( BC2GM058204459 ( O
N BC2GM058204459 NNP O
= BC2GM058204459 NNP O
6 BC2GM058204459 CD O
) BC2GM058204459 ) O
. BC2GM058204459 . O
. . O O

SM BC2GM018078380 NNP O
binds BC2GM018078380 VBZ O
RNA BC2GM018078380 NNP O
in BC2GM018078380 IN O
vitro BC2GM018078380 NN O
, BC2GM018078380 , O
suggesting BC2GM018078380 VBG O
that BC2GM018078380 IN O
sequence- BC2GM018078380 JJ O
or BC2GM018078380 CC O
structure-specific BC2GM018078380 JJ O
mRNA BC2GM018078380 NN O
interactions BC2GM018078380 NNS O
might BC2GM018078380 MD O
mediate BC2GM018078380 VB O
SM BC2GM018078380 NNP O
specificity BC2GM018078380 NN O
. BC2GM018078380 . O
. . O O

Structure BC2GM017589231 NN O
and BC2GM017589231 CC O
regulation BC2GM017589231 NN O
of BC2GM017589231 IN O
the BC2GM017589231 DT O
luteinizing BC2GM017589231 VBG O
hormone BC2GM017589231 NN O
receptor BC2GM017589231 NN O
gene BC2GM017589231 NN O
. BC2GM017589231 . O
. . O O

The BC2GM015350935 DT O
PK BC2GM015350935 NNP O
domain BC2GM015350935 NN O
showed BC2GM015350935 VBD O
pairwise BC2GM015350935 NN O
in BC2GM015350935 IN O
vitro BC2GM015350935 NN O
binding BC2GM015350935 NN O
interactions BC2GM015350935 NNS O
with BC2GM015350935 IN O
the BC2GM015350935 DT O
pseudokinase BC2GM015350935 NN O
, BC2GM015350935 , O
HisRS BC2GM015350935 NNP O
, BC2GM015350935 , O
and BC2GM015350935 CC O
C-term BC2GM015350935 NNP O
domains BC2GM015350935 NNS O
; BC2GM015350935 : O
additionally BC2GM015350935 RB O
, BC2GM015350935 , O
the BC2GM015350935 DT O
HisRS BC2GM015350935 NNP O
domain BC2GM015350935 NN O
interacted BC2GM015350935 VBD O
with BC2GM015350935 IN O
the BC2GM015350935 DT O
C-term BC2GM015350935 JJ O
region BC2GM015350935 NN O
. BC2GM015350935 . O
. . O O

However BC2GM003670421 RB O
, BC2GM003670421 , O
both BC2GM003670421 DT O
peptides BC2GM003670421 NNS O
1-49 BC2GM003670421 CD O
and BC2GM003670421 CC O
63-87 BC2GM003670421 JJ O
bound BC2GM003670421 NN O
to BC2GM003670421 TO O
PDE BC2GM003670421 NNP O
alpha BC2GM003670421 NN O
/ BC2GM003670421 NNP O
beta BC2GM003670421 NN O
in BC2GM003670421 IN O
a BC2GM003670421 DT O
solid-phase BC2GM003670421 JJ O
binding BC2GM003670421 NN O
assay BC2GM003670421 NN O
. BC2GM003670421 . O
. . O O

We BC2GM019584475 PRP O
carried BC2GM019584475 VBD O
out BC2GM019584475 RP O
two BC2GM019584475 CD O
experiments BC2GM019584475 NNS O
to BC2GM019584475 TO O
investigate BC2GM019584475 VB O
this BC2GM019584475 DT O
problem BC2GM019584475 NN O
. BC2GM019584475 . O
. . O O

Pretoria BC2GM089517365 NNP O
Pasteurisation BC2GM089517365 NNP O
is BC2GM089517365 VBZ O
feasible BC2GM089517365 JJ O
and BC2GM089517365 CC O
reliable BC2GM089517365 JJ O
under BC2GM089517365 IN O
a BC2GM089517365 DT O
range BC2GM089517365 NN O
of BC2GM089517365 IN O
conditions BC2GM089517365 NNS O
. BC2GM089517365 . O
. . O O

Elective BC2GM011344570 JJ O
replacement BC2GM011344570 NN O
of BC2GM011344570 IN O
the BC2GM011344570 DT O
aortic BC2GM011344570 JJ O
root BC2GM011344570 NN O
in BC2GM011344570 IN O
Marfan BC2GM011344570 NNP O
's BC2GM011344570 POS O
syndrome BC2GM011344570 NN O
. BC2GM011344570 . O
. . O O

Gas BC2GM036514946 NNP O
chromatographic BC2GM036514946 JJ O
analysis BC2GM036514946 NN O
of BC2GM036514946 IN O
headspace BC2GM036514946 NN O
samples BC2GM036514946 NNS O
of BC2GM036514946 IN O
alkalinized BC2GM036514946 JJ O
vaginal BC2GM036514946 JJ O
discharges BC2GM036514946 NNS O
indicated BC2GM036514946 VBD O
the BC2GM036514946 DT O
presence BC2GM036514946 NN O
of BC2GM036514946 IN O
trimethylamine BC2GM036514946 NN O
in BC2GM036514946 IN O
all BC2GM036514946 DT O
11 BC2GM036514946 CD O
samples BC2GM036514946 NNS O
with BC2GM036514946 IN O
the BC2GM036514946 DT O
fishy BC2GM036514946 JJ O
odor BC2GM036514946 NN O
but BC2GM036514946 CC O
not BC2GM036514946 RB O
in BC2GM036514946 IN O
the BC2GM036514946 DT O
other BC2GM036514946 JJ O
samples BC2GM036514946 NNS O
. BC2GM036514946 . O
. . O O

Particle BC2GM010895648 NNP O
bombardment BC2GM010895648 NN O
of BC2GM010895648 IN O
barley BC2GM010895648 NN O
aleurone BC2GM010895648 NN O
with BC2GM010895648 IN O
a BC2GM010895648 DT O
B22EL8 BC2GM010895648 NNP O
promoter-GUS BC2GM010895648 NN O
( BC2GM010895648 ( O
beta-glucuronidase BC2GM010895648 NN O
) BC2GM010895648 ) O
construct BC2GM010895648 NN O
demonstrates BC2GM010895648 VBZ O
that BC2GM010895648 IN O
the BC2GM010895648 DT O
promoter BC2GM010895648 NN O
( BC2GM010895648 ( O
3 BC2GM010895648 CD O
kb BC2GM010895648 NN O
) BC2GM010895648 ) O
is BC2GM010895648 VBZ O
active BC2GM010895648 JJ O
in BC2GM010895648 IN O
developing BC2GM010895648 VBG O
barley BC2GM010895648 NN O
grains BC2GM010895648 NNS O
. BC2GM010895648 . O
. . O O

A BC2GM013813111 DT O
survey BC2GM013813111 NN O
of BC2GM013813111 IN O
children BC2GM013813111 NNS O
with BC2GM013813111 IN O
HBsAg BC2GM013813111 NNP O
markers BC2GM013813111 NNS O
related BC2GM013813111 VBN O
to BC2GM013813111 TO O
their BC2GM013813111 PRP$ O
parents BC2GM013813111 NNS O
HBV BC2GM013813111 NNP O
markers BC2GM013813111 NNS O
. BC2GM013813111 . O
. . O O

We BC2GM044606080 PRP O
evaluated BC2GM044606080 VBD O
99mTc-ECD BC2GM044606080 CD O
SPECT BC2GM044606080 NNP O
comparing BC2GM044606080 VBG O
with BC2GM044606080 IN O
rCBF BC2GM044606080 NN O
images BC2GM044606080 NNS O
obtained BC2GM044606080 VBN O
by BC2GM044606080 IN O
PET BC2GM044606080 NNP O
in BC2GM044606080 IN O
12 BC2GM044606080 CD O
patients BC2GM044606080 NNS O
with BC2GM044606080 IN O
spinocerebellar BC2GM044606080 JJ O
degeneration BC2GM044606080 NN O
( BC2GM044606080 ( O
SCD BC2GM044606080 NNP O
) BC2GM044606080 ) O
. BC2GM044606080 . O
. . O O

In BC2GM078051387 IN O
this BC2GM078051387 DT O
report BC2GM078051387 NN O
, BC2GM078051387 , O
we BC2GM078051387 PRP O
demonstrate BC2GM078051387 VBP O
that BC2GM078051387 IN O
FRS2 BC2GM078051387 NNP O
forms BC2GM078051387 VBZ O
a BC2GM078051387 DT O
complex BC2GM078051387 JJ O
with BC2GM078051387 IN O
the BC2GM078051387 DT O
N-terminal BC2GM078051387 JJ O
SH2 BC2GM078051387 NNP O
domain BC2GM078051387 NN O
of BC2GM078051387 IN O
the BC2GM078051387 DT O
protein BC2GM078051387 NN O
tyrosine BC2GM078051387 JJ O
phosphatase BC2GM078051387 NN O
Shp2 BC2GM078051387 NNP O
in BC2GM078051387 IN O
response BC2GM078051387 NN O
to BC2GM078051387 TO O
FGF BC2GM078051387 NNP O
stimulation BC2GM078051387 NN O
. BC2GM078051387 . O
. . O O

The BC2GM002241638 DT O
cdc42W97R BC2GM002241638 JJ O
temperature-sensitive BC2GM002241638 JJ O
allele BC2GM002241638 NN O
in BC2GM002241638 IN O
S. BC2GM002241638 NNP O
cerevisiae BC2GM002241638 NN O
displayed BC2GM002241638 VBD O
the BC2GM002241638 DT O
same BC2GM002241638 JJ O
cell-division-cycle BC2GM002241638 NN O
arrest BC2GM002241638 NN O
phenotype BC2GM002241638 NN O
( BC2GM002241638 ( O
large BC2GM002241638 JJ O
, BC2GM002241638 , O
round BC2GM002241638 NN O
unbudded BC2GM002241638 VBD O
cells BC2GM002241638 NNS O
) BC2GM002241638 ) O
as BC2GM002241638 IN O
the BC2GM002241638 DT O
cdc42-1ts BC2GM002241638 JJ O
mutant BC2GM002241638 NN O
. BC2GM002241638 . O
. . O O

Most BC2GM066627539 JJS O
interestingly BC2GM066627539 RB O
, BC2GM066627539 , O
although BC2GM066627539 IN O
the BC2GM066627539 DT O
effector BC2GM066627539 NN O
plasmid BC2GM066627539 NN O
containing BC2GM066627539 VBG O
the BC2GM066627539 DT O
ICP27 BC2GM066627539 NNP O
gene BC2GM066627539 NN O
had BC2GM066627539 VBD O
little BC2GM066627539 JJ O
effect BC2GM066627539 NN O
on BC2GM066627539 IN O
its BC2GM066627539 PRP$ O
own BC2GM066627539 JJ O
, BC2GM066627539 , O
two BC2GM066627539 CD O
different BC2GM066627539 JJ O
and BC2GM066627539 CC O
marked BC2GM066627539 JJ O
effects BC2GM066627539 NNS O
depending BC2GM066627539 VBG O
on BC2GM066627539 IN O
the BC2GM066627539 DT O
target BC2GM066627539 NN O
were BC2GM066627539 VBD O
observed BC2GM066627539 VBN O
when BC2GM066627539 WRB O
ICP27 BC2GM066627539 NNP O
was BC2GM066627539 VBD O
combined BC2GM066627539 VBN O
with BC2GM066627539 IN O
ICP4 BC2GM066627539 NNP O
or BC2GM066627539 CC O
ICP0 BC2GM066627539 NNP O
or BC2GM066627539 CC O
both BC2GM066627539 DT O
. BC2GM066627539 . O
. . O O

Others BC2GM038464760 NNS O
as BC2GM038464760 IN O
for BC2GM038464760 IN O
example BC2GM038464760 NN O
C-11 BC2GM038464760 NNP O
labeled BC2GM038464760 VBD O
short BC2GM038464760 JJ O
chain BC2GM038464760 NN O
fatty BC2GM038464760 JJ O
acids BC2GM038464760 NNS O
are BC2GM038464760 VBP O
on BC2GM038464760 IN O
the BC2GM038464760 DT O
horizon BC2GM038464760 NN O
. BC2GM038464760 . O
. . O O

These BC2GM089213701 DT O
findings BC2GM089213701 NNS O
suggest BC2GM089213701 VBP O
that BC2GM089213701 IN O
low-power BC2GM089213701 JJR O
laser BC2GM089213701 NN O
irradiation BC2GM089213701 NN O
can BC2GM089213701 MD O
be BC2GM089213701 VB O
used BC2GM089213701 VBN O
for BC2GM089213701 IN O
promotion BC2GM089213701 NN O
of BC2GM089213701 IN O
vascularization BC2GM089213701 NN O
and BC2GM089213701 CC O
take BC2GM089213701 VB O
of BC2GM089213701 IN O
tissue BC2GM089213701 NN O
transplants BC2GM089213701 NNS O
. BC2GM089213701 . O
. . O O

These BC2GM076572185 DT O
results BC2GM076572185 NNS O
point BC2GM076572185 VBP O
towards BC2GM076572185 NNS O
post-translational BC2GM076572185 JJ O
steric BC2GM076572185 JJ O
and BC2GM076572185 CC O
/ BC2GM076572185 JJ O
or BC2GM076572185 CC O
allosteric BC2GM076572185 JJ O
control BC2GM076572185 NN O
of BC2GM076572185 IN O
EKLF BC2GM076572185 NNP O
function BC2GM076572185 NN O
that BC2GM076572185 WDT O
may BC2GM076572185 MD O
be BC2GM076572185 VB O
important BC2GM076572185 JJ O
not BC2GM076572185 RB O
just BC2GM076572185 RB O
for BC2GM076572185 IN O
its BC2GM076572185 PRP$ O
DNA BC2GM076572185 NNP O
binding BC2GM076572185 NN O
ability BC2GM076572185 NN O
, BC2GM076572185 , O
but BC2GM076572185 CC O
also BC2GM076572185 RB O
for BC2GM076572185 IN O
its BC2GM076572185 PRP$ O
potential BC2GM076572185 JJ O
to BC2GM076572185 TO O
interact BC2GM076572185 VB O
with BC2GM076572185 IN O
other BC2GM076572185 JJ O
proteins BC2GM076572185 NNS O
that BC2GM076572185 WDT O
fully BC2GM076572185 RB O
establish BC2GM076572185 VB O
the BC2GM076572185 DT O
correct BC2GM076572185 JJ O
stereospecific BC2GM076572185 JJ O
array BC2GM076572185 NN O
leading BC2GM076572185 VBG O
to BC2GM076572185 TO O
efficient BC2GM076572185 JJ O
switching BC2GM076572185 NN O
of BC2GM076572185 IN O
beta-globin BC2GM076572185 JJ O
transcription BC2GM076572185 NN O
during BC2GM076572185 IN O
development BC2GM076572185 NN O
. BC2GM076572185 . O
. . O O

Comparison BC2GM012515903 NNP O
of BC2GM012515903 IN O
this BC2GM012515903 DT O
gene BC2GM012515903 NN O
with BC2GM012515903 IN O
the BC2GM012515903 DT O
available BC2GM012515903 JJ O
databases BC2GM012515903 NNS O
reveals BC2GM012515903 NNS O
very BC2GM012515903 RB O
significant BC2GM012515903 JJ O
homology BC2GM012515903 NN O
to BC2GM012515903 TO O
the BC2GM012515903 DT O
ETS BC2GM012515903 NNP O
factor BC2GM012515903 NN O
PE-1 BC2GM012515903 NNP O
and BC2GM012515903 CC O
probable BC2GM012515903 JJ O
near-identity BC2GM012515903 NN O
with BC2GM012515903 IN O
the BC2GM012515903 DT O
recently BC2GM012515903 RB O
cloned BC2GM012515903 VBN O
factor BC2GM012515903 NN O
ERF BC2GM012515903 NNP O
. BC2GM012515903 . O
. . O O

The BC2GM028429714 DT O
RAG-2 BC2GM028429714 NNP O
gene BC2GM028429714 NN O
encodes BC2GM028429714 VBZ O
a BC2GM028429714 DT O
component BC2GM028429714 NN O
of BC2GM028429714 IN O
the BC2GM028429714 DT O
V BC2GM028429714 NNP O
( BC2GM028429714 ( O
D BC2GM028429714 NNP O
) BC2GM028429714 ) O
J BC2GM028429714 NNP O
recombinase BC2GM028429714 NN O
which BC2GM028429714 WDT O
is BC2GM028429714 VBZ O
essential BC2GM028429714 JJ O
for BC2GM028429714 IN O
the BC2GM028429714 DT O
assembly BC2GM028429714 NN O
of BC2GM028429714 IN O
antigen BC2GM028429714 NN O
receptor BC2GM028429714 NN O
genes BC2GM028429714 NNS O
in BC2GM028429714 IN O
B BC2GM028429714 NNP O
and BC2GM028429714 CC O
T BC2GM028429714 NNP O
lymphocytes BC2GM028429714 NNS O
. BC2GM028429714 . O
. . O O

Univariate BC2GM082165105 NNP O
and BC2GM082165105 CC O
multivariate BC2GM082165105 JJ O
analysis BC2GM082165105 NN O
was BC2GM082165105 VBD O
used BC2GM082165105 VBN O
to BC2GM082165105 TO O
calculate BC2GM082165105 VB O
the BC2GM082165105 DT O
5-year BC2GM082165105 JJ O
survival BC2GM082165105 NN O
probabilities BC2GM082165105 NNS O
with BC2GM082165105 IN O
respect BC2GM082165105 NN O
to BC2GM082165105 TO O
the BC2GM082165105 DT O
following BC2GM082165105 JJ O
variables BC2GM082165105 NNS O
: BC2GM082165105 : O
age BC2GM082165105 NN O
( BC2GM082165105 ( O
< BC2GM082165105 CD O
or BC2GM082165105 CC O
= BC2GM082165105 VB O
65 BC2GM082165105 CD O
, BC2GM082165105 , O
> BC2GM082165105 RB O
65 BC2GM082165105 CD O
) BC2GM082165105 ) O
, BC2GM082165105 , O
sex BC2GM082165105 NN O
, BC2GM082165105 , O
depth BC2GM082165105 NN O
of BC2GM082165105 IN O
invasion BC2GM082165105 NN O
( BC2GM082165105 ( O
mucosal BC2GM082165105 NN O
, BC2GM082165105 , O
submucosal BC2GM082165105 NN O
) BC2GM082165105 ) O
tumor BC2GM082165105 NN O
location BC2GM082165105 NN O
( BC2GM082165105 ( O
upper BC2GM082165105 JJ O
, BC2GM082165105 , O
middle BC2GM082165105 JJ O
and BC2GM082165105 CC O
lower BC2GM082165105 JJR O
third BC2GM082165105 NN O
) BC2GM082165105 ) O
, BC2GM082165105 , O
gross BC2GM082165105 JJ O
appearance BC2GM082165105 NN O
( BC2GM082165105 ( O
type BC2GM082165105 NN O
I BC2GM082165105 PRP O
, BC2GM082165105 , O
type BC2GM082165105 NN O
II BC2GM082165105 NNP O
and BC2GM082165105 CC O
type BC2GM082165105 VB O
III BC2GM082165105 NNP O
) BC2GM082165105 ) O
, BC2GM082165105 , O
size BC2GM082165105 NN O
( BC2GM082165105 ( O
< BC2GM082165105 CD O
or BC2GM082165105 CC O
= BC2GM082165105 VB O
1.5 BC2GM082165105 CD O
cm BC2GM082165105 NN O
, BC2GM082165105 , O
> BC2GM082165105 VBZ O
1.5 BC2GM082165105 CD O
cm BC2GM082165105 NN O
) BC2GM082165105 ) O
, BC2GM082165105 , O
presence BC2GM082165105 NN O
or BC2GM082165105 CC O
absence BC2GM082165105 NN O
of BC2GM082165105 IN O
lymph BC2GM082165105 JJ O
node BC2GM082165105 JJ O
metastasis BC2GM082165105 NN O
, BC2GM082165105 , O
histological BC2GM082165105 JJ O
type BC2GM082165105 NN O
( BC2GM082165105 ( O
intestinal BC2GM082165105 JJ O
, BC2GM082165105 , O
diffuse BC2GM082165105 NN O
) BC2GM082165105 ) O
, BC2GM082165105 , O
extent BC2GM082165105 NN O
of BC2GM082165105 IN O
lymphadenectomy BC2GM082165105 NN O
( BC2GM082165105 ( O
limited BC2GM082165105 JJ O
or BC2GM082165105 CC O
extended BC2GM082165105 VBN O
) BC2GM082165105 ) O
, BC2GM082165105 , O
and BC2GM082165105 CC O
type BC2GM082165105 NN O
of BC2GM082165105 IN O
gastrectomy BC2GM082165105 NN O
( BC2GM082165105 ( O
total BC2GM082165105 JJ O
or BC2GM082165105 CC O
distal BC2GM082165105 JJ O
subtotal BC2GM082165105 NN O
) BC2GM082165105 ) O
. BC2GM082165105 . O
. . O O

BPN BC2GM024171427 NNP O
can BC2GM024171427 MD O
be BC2GM024171427 VB O
experimentally BC2GM024171427 RB O
produced BC2GM024171427 VBN O
by BC2GM024171427 IN O
intratracheal BC2GM024171427 JJ O
inoculation BC2GM024171427 NN O
of BC2GM024171427 IN O
microorganisms BC2GM024171427 NNS O
in BC2GM024171427 IN O
high BC2GM024171427 JJ O
concentrations BC2GM024171427 NNS O
and BC2GM024171427 CC O
ventilator-associated BC2GM024171427 JJ O
BPN BC2GM024171427 NNP O
by BC2GM024171427 IN O
ventilating BC2GM024171427 VBG O
baboons BC2GM024171427 NNS O
with BC2GM024171427 IN O
oleic-acid BC2GM024171427 JJ O
lung BC2GM024171427 NN O
injury BC2GM024171427 NN O
. BC2GM024171427 . O
. . O O

Studies BC2GM058606403 NNS O
on BC2GM058606403 IN O
nitrogen-containing BC2GM058606403 JJ O
heterocyclic BC2GM058606403 JJ O
compounds BC2GM058606403 NNS O
. BC2GM058606403 . O
. . O O

Its BC2GM069784959 PRP$ O
phosphorylation BC2GM069784959 NN O
strongly BC2GM069784959 RB O
potentiates BC2GM069784959 VBZ O
its BC2GM069784959 PRP$ O
ability BC2GM069784959 NN O
to BC2GM069784959 TO O
activate BC2GM069784959 VB O
transcription BC2GM069784959 NN O
of BC2GM069784959 IN O
the BC2GM069784959 DT O
c-fos BC2GM069784959 JJ O
promoter BC2GM069784959 NN O
through BC2GM069784959 IN O
a BC2GM069784959 DT O
ternary BC2GM069784959 JJ O
complex BC2GM069784959 NN O
assembled BC2GM069784959 VBD O
on BC2GM069784959 IN O
the BC2GM069784959 DT O
c-fos BC2GM069784959 JJ O
serum BC2GM069784959 NN O
response BC2GM069784959 NN O
element BC2GM069784959 NN O
. BC2GM069784959 . O
. . O O

The BC2GM037686534 DT O
Valpha BC2GM037686534 NNP O
and BC2GM037686534 CC O
Vbeta BC2GM037686534 NNP O
domains BC2GM037686534 NNS O
have BC2GM037686534 VBP O
the BC2GM037686534 DT O
canonical BC2GM037686534 JJ O
features BC2GM037686534 NNS O
of BC2GM037686534 IN O
known BC2GM037686534 VBN O
teleost BC2GM037686534 NN O
and BC2GM037686534 CC O
mammalian BC2GM037686534 JJ O
TCR BC2GM037686534 NNP O
V BC2GM037686534 NNP O
domains BC2GM037686534 NNS O
, BC2GM037686534 , O
including BC2GM037686534 VBG O
conserved BC2GM037686534 VBN O
residues BC2GM037686534 NNS O
in BC2GM037686534 IN O
the BC2GM037686534 DT O
beginning BC2GM037686534 NN O
of BC2GM037686534 IN O
FR2 BC2GM037686534 NNP O
and BC2GM037686534 CC O
at BC2GM037686534 IN O
the BC2GM037686534 DT O
end BC2GM037686534 NN O
of BC2GM037686534 IN O
FR3 BC2GM037686534 NNP O
. BC2GM037686534 . O
. . O O

These BC2GM069852295 DT O
conditions BC2GM069852295 NNS O
may BC2GM069852295 MD O
determine BC2GM069852295 VB O
an BC2GM069852295 DT O
increase BC2GM069852295 NN O
in BC2GM069852295 IN O
the BC2GM069852295 DT O
level BC2GM069852295 NN O
of BC2GM069852295 IN O
indoor BC2GM069852295 JJ O
pollutants BC2GM069852295 NNS O
( BC2GM069852295 ( O
tobacco BC2GM069852295 NN O
smoke BC2GM069852295 NN O
, BC2GM069852295 , O
gases BC2GM069852295 NNS O
produced BC2GM069852295 VBN O
by BC2GM069852295 IN O
cooling BC2GM069852295 VBG O
processes BC2GM069852295 NNS O
etc BC2GM069852295 FW O
. BC2GM069852295 . O
) BC2GM069852295 ) O
and BC2GM069852295 CC O
of BC2GM069852295 IN O
allergens BC2GM069852295 NNS O
derived BC2GM069852295 VBN O
from BC2GM069852295 IN O
mites BC2GM069852295 NNS O
, BC2GM069852295 , O
domestic BC2GM069852295 JJ O
animals BC2GM069852295 NNS O
and BC2GM069852295 CC O
cockroaches BC2GM069852295 NNS O
. BC2GM069852295 . O
. . O O

Impact BC2GM055613257 NN O
of BC2GM055613257 IN O
cytokine BC2GM055613257 JJ O
gene BC2GM055613257 NN O
polymorphisms BC2GM055613257 NNS O
on BC2GM055613257 IN O
outcomes BC2GM055613257 NNS O
of BC2GM055613257 IN O
coronary BC2GM055613257 JJ O
artery BC2GM055613257 NN O
bypass BC2GM055613257 NN O
graft BC2GM055613257 NN O
surgery BC2GM055613257 NN O
. BC2GM055613257 . O
. . O O

However BC2GM048469729 RB O
, BC2GM048469729 , O
LXRalpha BC2GM048469729 NNP O
inhibited BC2GM048469729 VBD O
binding BC2GM048469729 NN O
of BC2GM048469729 IN O
PPARalpha BC2GM048469729 NNP O
/ BC2GM048469729 NNP O
RXRalpha BC2GM048469729 NNP O
heterodimers BC2GM048469729 NNS O
to BC2GM048469729 TO O
PPREs BC2GM048469729 NNP O
, BC2GM048469729 , O
and BC2GM048469729 CC O
coexpression BC2GM048469729 NN O
of BC2GM048469729 IN O
LXRalpha BC2GM048469729 NNP O
in BC2GM048469729 IN O
mammalian BC2GM048469729 JJ O
cells BC2GM048469729 NNS O
antagonized BC2GM048469729 VBN O
peroxisome BC2GM048469729 JJ O
proliferator BC2GM048469729 NN O
signaling BC2GM048469729 VBG O
mediated BC2GM048469729 VBN O
by BC2GM048469729 IN O
PPARalpha BC2GM048469729 NNP O
/ BC2GM048469729 NNP O
RXRalpha BC2GM048469729 NNP O
in BC2GM048469729 IN O
vivo BC2GM048469729 NN O
. BC2GM048469729 . O
. . O O

The BC2GM094712703 DT O
LT-beta BC2GM094712703 NNP O
gene BC2GM094712703 NN O
is BC2GM094712703 VBZ O
expressed BC2GM094712703 VBN O
in BC2GM094712703 IN O
lymphoid BC2GM094712703 JJ O
cells BC2GM094712703 NNS O
and BC2GM094712703 CC O
organs BC2GM094712703 NNS O
, BC2GM094712703 , O
but BC2GM094712703 CC O
little BC2GM094712703 JJ O
is BC2GM094712703 VBZ O
known BC2GM094712703 VBN O
about BC2GM094712703 IN O
its BC2GM094712703 PRP$ O
inducible BC2GM094712703 JJ O
regulation BC2GM094712703 NN O
. BC2GM094712703 . O
. . O O

Chest BC2GM067111314 NNP O
X-P BC2GM067111314 NN O
revealed BC2GM067111314 VBD O
an BC2GM067111314 DT O
abnormal BC2GM067111314 JJ O
shadow BC2GM067111314 NN O
in BC2GM067111314 IN O
the BC2GM067111314 DT O
left BC2GM067111314 JJ O
upper BC2GM067111314 JJ O
lobe BC2GM067111314 NN O
. BC2GM067111314 . O
. . O O

Escherichia BC2GM064857683 NNP O
coli BC2GM064857683 NN O
cells BC2GM064857683 NNS O
expressing BC2GM064857683 VBG O
a BC2GM064857683 DT O
mutant BC2GM064857683 JJ O
glyV BC2GM064857683 NN O
( BC2GM064857683 ( O
glycine BC2GM064857683 JJ O
tRNA BC2GM064857683 NN O
) BC2GM064857683 ) O
gene BC2GM064857683 NN O
have BC2GM064857683 VBP O
a BC2GM064857683 DT O
UVM-constitutive BC2GM064857683 JJ O
phenotype BC2GM064857683 NN O
: BC2GM064857683 : O
implications BC2GM064857683 NNS O
for BC2GM064857683 IN O
mechanisms BC2GM064857683 NNS O
underlying BC2GM064857683 VBG O
the BC2GM064857683 DT O
mutA BC2GM064857683 NN O
or BC2GM064857683 CC O
mutC BC2GM064857683 NN O
mutator BC2GM064857683 NN O
effect BC2GM064857683 NN O
. BC2GM064857683 . O
. . O O

In BC2GM021539597 IN O
stage BC2GM021539597 NN O
I BC2GM021539597 PRP O
, BC2GM021539597 , O
histochemistry BC2GM021539597 NN O
for BC2GM021539597 IN O
copper BC2GM021539597 NN O
was BC2GM021539597 VBD O
positive BC2GM021539597 JJ O
in BC2GM021539597 IN O
11 BC2GM021539597 CD O
out BC2GM021539597 IN O
of BC2GM021539597 IN O
21 BC2GM021539597 CD O
cases BC2GM021539597 NNS O
: BC2GM021539597 : O
6 BC2GM021539597 CD O
cases BC2GM021539597 NNS O
were BC2GM021539597 VBD O
T+ BC2GM021539597 NNP O
; BC2GM021539597 : O
1 BC2GM021539597 CD O
case BC2GM021539597 NN O
R+ BC2GM021539597 NNP O
and BC2GM021539597 CC O
2 BC2GM021539597 CD O
cases BC2GM021539597 NNS O
O+ BC2GM021539597 NNP O
; BC2GM021539597 : O
2 BC2GM021539597 CD O
cases BC2GM021539597 NNS O
were BC2GM021539597 VBD O
T+ BC2GM021539597 NNP O
, BC2GM021539597 , O
R+ BC2GM021539597 NNP O
, BC2GM021539597 , O
O+ BC2GM021539597 NNP O
. BC2GM021539597 . O
. . O O

( BC2GM070888113 ( O
1982 BC2GM070888113 CD O
) BC2GM070888113 ) O
. BC2GM070888113 . O
. . O O

The BC2GM042091404 DT O
effects BC2GM042091404 NNS O
of BC2GM042091404 IN O
tilmicosin BC2GM042091404 JJ O
administration BC2GM042091404 NN O
in BC2GM042091404 IN O
the BC2GM042091404 DT O
feed BC2GM042091404 NN O
at BC2GM042091404 IN O
400 BC2GM042091404 CD O
mg BC2GM042091404 NN O
/ BC2GM042091404 NNP O
kg BC2GM042091404 NN O
and BC2GM042091404 CC O
an BC2GM042091404 DT O
injection BC2GM042091404 NN O
therapy BC2GM042091404 NN O
of BC2GM042091404 IN O
clinically BC2GM042091404 RB O
diseased BC2GM042091404 VBN O
pigs BC2GM042091404 NNS O
with BC2GM042091404 IN O
long-acting BC2GM042091404 JJ O
oxytetracycline BC2GM042091404 NN O
( BC2GM042091404 ( O
Terramycine BC2GM042091404 NNP O
LA BC2GM042091404 NNP O
) BC2GM042091404 ) O
at BC2GM042091404 IN O
20 BC2GM042091404 CD O
mg BC2GM042091404 NN O
/ BC2GM042091404 NNP O
kg BC2GM042091404 NN O
bodyweight BC2GM042091404 NN O
were BC2GM042091404 VBD O
compared BC2GM042091404 VBN O
. BC2GM042091404 . O
. . O O

These BC2GM011862984 DT O
results BC2GM011862984 NNS O
suggest BC2GM011862984 VBP O
that BC2GM011862984 IN O
E6010 BC2GM011862984 NNP O
may BC2GM011862984 MD O
be BC2GM011862984 VB O
of BC2GM011862984 IN O
clinical BC2GM011862984 JJ O
value BC2GM011862984 NN O
in BC2GM011862984 IN O
the BC2GM011862984 DT O
treatment BC2GM011862984 NN O
of BC2GM011862984 IN O
coronary BC2GM011862984 JJ O
occlusion BC2GM011862984 NN O
. BC2GM011862984 . O
. . O O

Two BC2GM066898247 CD O
patients BC2GM066898247 NNS O
with BC2GM066898247 IN O
Ewing BC2GM066898247 NNP O
's BC2GM066898247 POS O
sarcoma BC2GM066898247 NN O
relapsed BC2GM066898247 VBD O
( BC2GM066898247 ( O
1 BC2GM066898247 CD O
patient BC2GM066898247 NN O
with BC2GM066898247 IN O
both BC2GM066898247 DT O
local BC2GM066898247 JJ O
and BC2GM066898247 CC O
distant BC2GM066898247 JJ O
failure BC2GM066898247 NN O
) BC2GM066898247 ) O
at BC2GM066898247 IN O
26 BC2GM066898247 CD O
and BC2GM066898247 CC O
58 BC2GM066898247 CD O
months BC2GM066898247 NNS O
and BC2GM066898247 CC O
were BC2GM066898247 VBD O
again BC2GM066898247 RB O
rendered BC2GM066898247 VBN O
disease-free BC2GM066898247 JJ O
with BC2GM066898247 IN O
surgery BC2GM066898247 NN O
, BC2GM066898247 , O
total BC2GM066898247 JJ O
body BC2GM066898247 NN O
irradiation BC2GM066898247 NN O
and BC2GM066898247 CC O
further BC2GM066898247 JJ O
chemotherapy BC2GM066898247 NN O
. BC2GM066898247 . O
. . O O

In BC2GM034699530 IN O
gel BC2GM034699530 JJ O
mobility BC2GM034699530 NN O
shift BC2GM034699530 NN O
assays BC2GM034699530 NNS O
, BC2GM034699530 , O
high BC2GM034699530 JJ O
binding BC2GM034699530 NN O
activities BC2GM034699530 NNS O
of BC2GM034699530 IN O
ATPC-2 BC2GM034699530 NNP O
and BC2GM034699530 CC O
low BC2GM034699530 JJ O
binding BC2GM034699530 NN O
activities BC2GM034699530 NNS O
of BC2GM034699530 IN O
CBF BC2GM034699530 NNP O
were BC2GM034699530 VBD O
observed BC2GM034699530 VBN O
with BC2GM034699530 IN O
nuclear BC2GM034699530 JJ O
extracts BC2GM034699530 NNS O
from BC2GM034699530 IN O
tissue BC2GM034699530 NN O
with BC2GM034699530 IN O
low BC2GM034699530 JJ O
AtpC BC2GM034699530 NNP O
expression BC2GM034699530 NN O
levels BC2GM034699530 NNS O
, BC2GM034699530 , O
and BC2GM034699530 CC O
the BC2GM034699530 DT O
opposite BC2GM034699530 NN O
was BC2GM034699530 VBD O
observed BC2GM034699530 VBN O
with BC2GM034699530 IN O
extracts BC2GM034699530 NNS O
from BC2GM034699530 IN O
tissues BC2GM034699530 NNS O
with BC2GM034699530 IN O
high BC2GM034699530 JJ O
AtpC BC2GM034699530 NNP O
expression BC2GM034699530 NN O
levels BC2GM034699530 NNS O
. BC2GM034699530 . O
. . O O

Two BC2GM005568941 CD O
measures BC2GM005568941 NNS O
of BC2GM005568941 IN O
sensory BC2GM005568941 JJ O
inhibition BC2GM005568941 NN O
were BC2GM005568941 VBD O
employed BC2GM005568941 VBN O
, BC2GM005568941 , O
S2 BC2GM005568941 NNP O
/ BC2GM005568941 NNP O
S1 BC2GM005568941 NNP O
x BC2GM005568941 VBD O
100 BC2GM005568941 CD O
amplitude BC2GM005568941 NN O
ratio BC2GM005568941 NN O
and BC2GM005568941 CC O
S1-S2 BC2GM005568941 NNP O
amplitude BC2GM005568941 NN O
difference BC2GM005568941 NN O
. BC2GM005568941 . O
. . O O

6 BC2GM063549189 CD O
h BC2GM063549189 NN O
after BC2GM063549189 IN O
ingestion BC2GM063549189 NN O
of BC2GM063549189 IN O
aspirin BC2GM063549189 NN O
on BC2GM063549189 IN O
day BC2GM063549189 NN O
1 BC2GM063549189 CD O
to BC2GM063549189 TO O
day BC2GM063549189 NN O
14 BC2GM063549189 CD O
, BC2GM063549189 , O
both BC2GM063549189 DT O
TX BC2GM063549189 NNP O
and BC2GM063549189 CC O
PGI2 BC2GM063549189 NNP O
levels BC2GM063549189 NNS O
also BC2GM063549189 RB O
significantly BC2GM063549189 RB O
decreased BC2GM063549189 VBN O
( BC2GM063549189 ( O
p BC2GM063549189 JJ O
< BC2GM063549189 NNP O
0.0001 BC2GM063549189 CD O
) BC2GM063549189 ) O
. BC2GM063549189 . O
. . O O

All BC2GM049796840 PDT O
the BC2GM049796840 DT O
previously BC2GM049796840 RB O
mapped BC2GM049796840 VBN O
structural BC2GM049796840 JJ O
protein-encoding BC2GM049796840 JJ O
genes BC2GM049796840 NNS O
of BC2GM049796840 IN O
phage BC2GM049796840 NN O
LL-H BC2GM049796840 NNP O
were BC2GM049796840 VBD O
included BC2GM049796840 VBN O
in BC2GM049796840 IN O
the BC2GM049796840 DT O
sequence BC2GM049796840 NN O
. BC2GM049796840 . O
. . O O

Fosinopril BC2GM053665808 NNP O
decreased BC2GM053665808 VBD O
blood BC2GM053665808 NN O
pressure BC2GM053665808 NN O
from BC2GM053665808 IN O
174 BC2GM053665808 CD O
/ BC2GM053665808 $ O
101 BC2GM053665808 CD O
mm BC2GM053665808 NN O
Hg BC2GM053665808 NNP O
to BC2GM053665808 TO O
149 BC2GM053665808 CD O
/ BC2GM053665808 NNS O
88 BC2GM053665808 CD O
mm BC2GM053665808 NNS O
Hg BC2GM053665808 NNP O
in BC2GM053665808 IN O
patients BC2GM053665808 NNS O
with BC2GM053665808 IN O
diastolic BC2GM053665808 JJ O
hypertension BC2GM053665808 NN O
and BC2GM053665808 CC O
from BC2GM053665808 IN O
182 BC2GM053665808 CD O
/ BC2GM053665808 $ O
86 BC2GM053665808 CD O
mm BC2GM053665808 NN O
Hg BC2GM053665808 NNP O
to BC2GM053665808 TO O
151 BC2GM053665808 CD O
/ BC2GM053665808 NNS O
80 BC2GM053665808 CD O
mm BC2GM053665808 NNS O
Hg BC2GM053665808 NNP O
in BC2GM053665808 IN O
patients BC2GM053665808 NNS O
with BC2GM053665808 IN O
ISH BC2GM053665808 NNP O
. BC2GM053665808 . O
. . O O

These BC2GM005317665 DT O
results BC2GM005317665 NNS O
demonstrate BC2GM005317665 VBP O
the BC2GM005317665 DT O
preferential BC2GM005317665 JJ O
endometrial BC2GM005317665 JJ O
cell-type BC2GM005317665 JJ O
expression BC2GM005317665 NN O
of BC2GM005317665 IN O
BTEB BC2GM005317665 NNP O
and BC2GM005317665 CC O
suggest BC2GM005317665 JJS O
its BC2GM005317665 PRP$ O
regulatory BC2GM005317665 JJ O
role BC2GM005317665 NN O
in BC2GM005317665 IN O
pregnancy-associated BC2GM005317665 JJ O
endometrial BC2GM005317665 JJ O
epithelial BC2GM005317665 JJ O
gene BC2GM005317665 NN O
expression BC2GM005317665 NN O
. BC2GM005317665 . O
. . O O

The BC2GM056410850 DT O
side BC2GM056410850 NN O
effect BC2GM056410850 NN O
of BC2GM056410850 IN O
pulmonary BC2GM056410850 JJ O
fibrosis BC2GM056410850 NN O
occurs BC2GM056410850 VBZ O
in BC2GM056410850 IN O
20 BC2GM056410850 CD O
to BC2GM056410850 TO O
30 BC2GM056410850 CD O
percent BC2GM056410850 NN O
of BC2GM056410850 IN O
patients BC2GM056410850 NNS O
receiving BC2GM056410850 VBG O
this BC2GM056410850 DT O
drug BC2GM056410850 NN O
. BC2GM056410850 . O
. . O O

CERIP BC2GM039293973 NNP O
interaction BC2GM039293973 NN O
. BC2GM039293973 . O
. . O O

They BC2GM010930693 PRP O
elicit BC2GM010930693 VBP O
similar BC2GM010930693 JJ O
regional BC2GM010930693 JJ O
cerebral BC2GM010930693 JJ O
blood BC2GM010930693 NN O
flow BC2GM010930693 NN O
( BC2GM010930693 ( O
rCBF BC2GM010930693 NN O
) BC2GM010930693 ) O
patterns BC2GM010930693 VBZ O
, BC2GM010930693 , O
even BC2GM010930693 RB O
though BC2GM010930693 IN O
sign BC2GM010930693 JJ O
language BC2GM010930693 NN O
is BC2GM010930693 VBZ O
dependent BC2GM010930693 JJ O
on BC2GM010930693 IN O
spatial BC2GM010930693 JJ O
information BC2GM010930693 NN O
. BC2GM010930693 . O
. . O O

During BC2GM022819615 IN O
chronic BC2GM022819615 JJ O
treatment BC2GM022819615 NN O
with BC2GM022819615 IN O
salmon BC2GM022819615 JJ O
calcitonin BC2GM022819615 NN O
, BC2GM022819615 , O
alkaline BC2GM022819615 JJ O
phosphatase BC2GM022819615 NN O
activity BC2GM022819615 NN O
and BC2GM022819615 CC O
urinary BC2GM022819615 JJ O
hydroxyproline BC2GM022819615 NN O
excretion BC2GM022819615 NN O
decrease BC2GM022819615 NN O
on BC2GM022819615 IN O
an BC2GM022819615 DT O
average BC2GM022819615 NN O
of BC2GM022819615 IN O
50 BC2GM022819615 CD O
% BC2GM022819615 NN O
in BC2GM022819615 IN O
patients BC2GM022819615 NNS O
with BC2GM022819615 IN O
Paget BC2GM022819615 NNP O
's BC2GM022819615 POS O
disease BC2GM022819615 NN O
. BC2GM022819615 . O
. . O O

Effect BC2GM051429391 NN O
of BC2GM051429391 IN O
food BC2GM051429391 NN O
on BC2GM051429391 IN O
hemodynamics BC2GM051429391 NNS O
. BC2GM051429391 . O
. . O O

The BC2GM029932858 DT O
absolute BC2GM029932858 NN O
CD4 BC2GM029932858 NNP O
count BC2GM029932858 NN O
of BC2GM029932858 IN O
patients BC2GM029932858 NNS O
with BC2GM029932858 IN O
de BC2GM029932858 FW O
novo BC2GM029932858 FW O
IBD BC2GM029932858 NNP O
was BC2GM029932858 VBD O
210-700 BC2GM029932858 JJ O
cells BC2GM029932858 NNS O
/ BC2GM029932858 JJ O
ml BC2GM029932858 NN O
at BC2GM029932858 IN O
the BC2GM029932858 DT O
time BC2GM029932858 NN O
of BC2GM029932858 IN O
IBD BC2GM029932858 NNP O
. BC2GM029932858 . O
. . O O

A BC2GM072257563 DT O
total BC2GM072257563 NN O
of BC2GM072257563 IN O
114 BC2GM072257563 CD O
animals BC2GM072257563 NNS O
were BC2GM072257563 VBD O
infected BC2GM072257563 VBN O
by BC2GM072257563 IN O
E. BC2GM072257563 NNP O
coli BC2GM072257563 NNS O
O2 BC2GM072257563 NNP O
: BC2GM072257563 : O
K1 BC2GM072257563 NN O
: BC2GM072257563 : O
H4 BC2GM072257563 NN O
by BC2GM072257563 IN O
the BC2GM072257563 DT O
hematogenic BC2GM072257563 JJ O
route BC2GM072257563 NN O
. BC2GM072257563 . O
. . O O

In BC2GM042469418 IN O
cotransfection BC2GM042469418 NN O
assays BC2GM042469418 NNS O
, BC2GM042469418 , O
a BC2GM042469418 DT O
small BC2GM042469418 JJ O
fragment BC2GM042469418 NN O
of BC2GM042469418 IN O
Sin BC2GM042469418 NNP O
retaining BC2GM042469418 VBG O
the BC2GM042469418 DT O
Src-SH3-binding BC2GM042469418 JJ O
site BC2GM042469418 NN O
and BC2GM042469418 CC O
one BC2GM042469418 CD O
tyrosine-containing BC2GM042469418 NN O
motif BC2GM042469418 NN O
induced BC2GM042469418 VBD O
c-Src BC2GM042469418 JJ O
activation BC2GM042469418 NN O
as BC2GM042469418 IN O
measured BC2GM042469418 VBN O
by BC2GM042469418 IN O
a BC2GM042469418 DT O
transcriptional BC2GM042469418 JJ O
reporter BC2GM042469418 NN O
. BC2GM042469418 . O
. . O O

The BC2GM043513819 DT O
major BC2GM043513819 JJ O
transcription BC2GM043513819 NN O
start BC2GM043513819 NN O
site BC2GM043513819 NN O
, BC2GM043513819 , O
designated BC2GM043513819 VBN O
as BC2GM043513819 IN O
+1 BC2GM043513819 NN O
, BC2GM043513819 , O
was BC2GM043513819 VBD O
determined BC2GM043513819 VBN O
by BC2GM043513819 IN O
RACE BC2GM043513819 NNP O
( BC2GM043513819 ( O
rapid BC2GM043513819 JJ O
amplification BC2GM043513819 NN O
of BC2GM043513819 IN O
cDNA BC2GM043513819 NN O
ends BC2GM043513819 NNS O
) BC2GM043513819 ) O
analysis BC2GM043513819 NN O
of BC2GM043513819 IN O
human BC2GM043513819 JJ O
liver BC2GM043513819 NN O
cDNA BC2GM043513819 NN O
and BC2GM043513819 CC O
was BC2GM043513819 VBD O
found BC2GM043513819 VBN O
to BC2GM043513819 TO O
be BC2GM043513819 VB O
located BC2GM043513819 VBN O
50 BC2GM043513819 CD O
bp BC2GM043513819 JJ O
upstream BC2GM043513819 NN O
from BC2GM043513819 IN O
the BC2GM043513819 DT O
translation BC2GM043513819 NN O
start BC2GM043513819 NN O
site BC2GM043513819 NN O
. BC2GM043513819 . O
. . O O

Considering BC2GM018608003 VBG O
these BC2GM018608003 DT O
two BC2GM018608003 CD O
facts BC2GM018608003 NNS O
together BC2GM018608003 RB O
, BC2GM018608003 , O
we BC2GM018608003 PRP O
propose BC2GM018608003 VBP O
that BC2GM018608003 IN O
vasectomy BC2GM018608003 NN O
may BC2GM018608003 MD O
lead BC2GM018608003 VB O
to BC2GM018608003 TO O
decrease BC2GM018608003 VB O
in BC2GM018608003 IN O
the BC2GM018608003 DT O
incidence BC2GM018608003 NN O
of BC2GM018608003 IN O
prostatic BC2GM018608003 JJ O
tumors BC2GM018608003 NNS O
- BC2GM018608003 : O
a BC2GM018608003 DT O
disease BC2GM018608003 NN O
that BC2GM018608003 WDT O
claims BC2GM018608003 VBZ O
nearly BC2GM018608003 RB O
22,000 BC2GM018608003 CD O
lives BC2GM018608003 NNS O
each BC2GM018608003 DT O
year BC2GM018608003 NN O
in BC2GM018608003 IN O
the BC2GM018608003 DT O
United BC2GM018608003 NNP O
States BC2GM018608003 NNPS O
alone BC2GM018608003 RB O
. BC2GM018608003 . O
. . O O

Radiation BC2GM076181563 NN O
was BC2GM076181563 VBD O
delivered BC2GM076181563 VBN O
in BC2GM076181563 IN O
a BC2GM076181563 DT O
single BC2GM076181563 JJ O
4-mJ BC2GM076181563 JJ O
pulse BC2GM076181563 NN O
of BC2GM076181563 IN O
200 BC2GM076181563 CD O
microseconds BC2GM076181563 NNS O
duration BC2GM076181563 NN O
by BC2GM076181563 IN O
means BC2GM076181563 NNS O
of BC2GM076181563 IN O
an BC2GM076181563 DT O
articulated BC2GM076181563 JJ O
zirconium BC2GM076181563 NN O
fluoride BC2GM076181563 RB O
optical BC2GM076181563 JJ O
fibre BC2GM076181563 NN O
and BC2GM076181563 CC O
a BC2GM076181563 DT O
320-microns BC2GM076181563 JJ O
quartz-fibre BC2GM076181563 JJ O
tip BC2GM076181563 NN O
. BC2GM076181563 . O
. . O O

Additionally BC2GM046785161 RB O
, BC2GM046785161 , O
VAHS BC2GM046785161 NNP O
is BC2GM046785161 VBZ O
often BC2GM046785161 RB O
associated BC2GM046785161 VBN O
with BC2GM046785161 IN O
fatal BC2GM046785161 JJ O
infectious BC2GM046785161 JJ O
mononucleosis BC2GM046785161 NN O
( BC2GM046785161 ( O
IM BC2GM046785161 NNP O
) BC2GM046785161 ) O
. BC2GM046785161 . O
. . O O

A BC2GM091875448 DT O
selectable BC2GM091875448 JJ O
marker BC2GM091875448 NN O
for BC2GM091875448 IN O
transformation BC2GM091875448 NN O
was BC2GM091875448 VBD O
constructed BC2GM091875448 VBN O
by BC2GM091875448 IN O
transcriptional BC2GM091875448 JJ O
fusion BC2GM091875448 NN O
of BC2GM091875448 IN O
a BC2GM091875448 DT O
Ustilago BC2GM091875448 NNP O
maydis BC2GM091875448 NN O
heat BC2GM091875448 NN O
shock BC2GM091875448 NN O
gene BC2GM091875448 NN O
promoter BC2GM091875448 NN O
with BC2GM091875448 IN O
the BC2GM091875448 DT O
hygromycin BC2GM091875448 NN O
B BC2GM091875448 NNP O
phosphotransferase BC2GM091875448 NN O
gene BC2GM091875448 NN O
of BC2GM091875448 IN O
Escherichia BC2GM091875448 NNP O
coli BC2GM091875448 NN O
. BC2GM091875448 . O
. . O O

Tbx6 BC2GM066378322 NNP O
maps BC2GM066378322 NNS O
to BC2GM066378322 TO O
chromosome BC2GM066378322 VB O
7 BC2GM066378322 CD O
and BC2GM066378322 CC O
does BC2GM066378322 VBZ O
not BC2GM066378322 RB O
appear BC2GM066378322 VB O
to BC2GM066378322 TO O
be BC2GM066378322 VB O
linked BC2GM066378322 VBN O
to BC2GM066378322 TO O
any BC2GM066378322 DT O
known BC2GM066378322 VBN O
mutation BC2GM066378322 NN O
. BC2GM066378322 . O
. . O O

The BC2GM026188221 DT O
sequence BC2GM026188221 NN O
of BC2GM026188221 IN O
three BC2GM026188221 CD O
of BC2GM026188221 IN O
them BC2GM026188221 PRP O
revealed BC2GM026188221 VBD O
pure BC2GM026188221 NN O
CAG BC2GM026188221 NNP O
stretches BC2GM026188221 NNS O
. BC2GM026188221 . O
. . O O

This BC2GM006001053 DT O
gene BC2GM006001053 NN O
is BC2GM006001053 VBZ O
named BC2GM006001053 VBN O
PKNOX1 BC2GM006001053 NNP O
by BC2GM006001053 IN O
the BC2GM006001053 DT O
Human BC2GM006001053 NNP O
Nomenclature BC2GM006001053 NNP O
Committee BC2GM006001053 NNP O
. BC2GM006001053 . O
. . O O

The BC2GM068686527 DT O
duration BC2GM068686527 NN O
of BC2GM068686527 IN O
PGE2 BC2GM068686527 NNP O
and BC2GM068686527 CC O
PGF2 BC2GM068686527 NNP O
alpha BC2GM068686527 VBP O
elevations BC2GM068686527 NNS O
as BC2GM068686527 RB O
well BC2GM068686527 RB O
as BC2GM068686527 IN O
the BC2GM068686527 DT O
peak BC2GM068686527 NN O
values BC2GM068686527 NNS O
were BC2GM068686527 VBD O
influenced BC2GM068686527 VBN O
by BC2GM068686527 IN O
day BC2GM068686527 NN O
of BC2GM068686527 IN O
the BC2GM068686527 DT O
cycle BC2GM068686527 NN O
. BC2GM068686527 . O
. . O O

It BC2GM025977756 PRP O
differed BC2GM025977756 VBD O
from BC2GM025977756 IN O
cued BC2GM025977756 VBN O
recall BC2GM025977756 NN O
only BC2GM025977756 RB O
in BC2GM025977756 IN O
the BC2GM025977756 DT O
instructions BC2GM025977756 NNS O
, BC2GM025977756 , O
which BC2GM025977756 WDT O
directed BC2GM025977756 VBD O
subjects BC2GM025977756 NNS O
away BC2GM025977756 RB O
from BC2GM025977756 IN O
the BC2GM025977756 DT O
memory BC2GM025977756 NN O
aspects BC2GM025977756 NNS O
of BC2GM025977756 IN O
the BC2GM025977756 DT O
test BC2GM025977756 NN O
and BC2GM025977756 CC O
asked BC2GM025977756 VBD O
them BC2GM025977756 PRP O
to BC2GM025977756 TO O
complete BC2GM025977756 VB O
each BC2GM025977756 DT O
three-letter BC2GM025977756 NN O
cue BC2GM025977756 NN O
with BC2GM025977756 IN O
the BC2GM025977756 DT O
first BC2GM025977756 JJ O
word BC2GM025977756 NN O
that BC2GM025977756 WDT O
came BC2GM025977756 VBD O
to BC2GM025977756 TO O
mind BC2GM025977756 VB O
. BC2GM025977756 . O
. . O O

Based BC2GM070791643 VBN O
on BC2GM070791643 IN O
PCR BC2GM070791643 NNP O
strategies BC2GM070791643 NNS O
and BC2GM070791643 CC O
expression BC2GM070791643 NN O
studies BC2GM070791643 NNS O
, BC2GM070791643 , O
we BC2GM070791643 PRP O
define BC2GM070791643 VBP O
the BC2GM070791643 DT O
genomic BC2GM070791643 JJ O
organization BC2GM070791643 NN O
of BC2GM070791643 IN O
the BC2GM070791643 DT O
FUT8b BC2GM070791643 NNP O
gene BC2GM070791643 NN O
. BC2GM070791643 . O
. . O O

The BC2GM062801890 DT O
quantification BC2GM062801890 NN O
limit BC2GM062801890 NN O
was BC2GM062801890 VBD O
50 BC2GM062801890 CD O
ng BC2GM062801890 JJ O
/ BC2GM062801890 NNP O
ml BC2GM062801890 NN O
for BC2GM062801890 IN O
each BC2GM062801890 DT O
of BC2GM062801890 IN O
PHT BC2GM062801890 NNP O
, BC2GM062801890 , O
m-HPPH BC2GM062801890 JJ O
and BC2GM062801890 CC O
p-HPPH BC2GM062801890 JJ O
. BC2GM062801890 . O
. . O O

Uptake BC2GM077847565 NN O
of BC2GM077847565 IN O
colicins BC2GM077847565 NNS O
required BC2GM077847565 VBN O
different BC2GM077847565 JJ O
domains BC2GM077847565 NNS O
in BC2GM077847565 IN O
TonB BC2GM077847565 NNP O
, BC2GM077847565 , O
for BC2GM077847565 IN O
colicin BC2GM077847565 NN O
B BC2GM077847565 NNP O
and BC2GM077847565 CC O
M BC2GM077847565 NNP O
around BC2GM077847565 IN O
residue BC2GM077847565 JJ O
160 BC2GM077847565 CD O
and BC2GM077847565 CC O
for BC2GM077847565 IN O
colicin BC2GM077847565 NN O
Ia BC2GM077847565 NNP O
, BC2GM077847565 , O
a BC2GM077847565 DT O
domain BC2GM077847565 NN O
closer BC2GM077847565 NN O
to BC2GM077847565 TO O
the BC2GM077847565 DT O
C-terminal BC2GM077847565 JJ O
end BC2GM077847565 NN O
. BC2GM077847565 . O
. . O O

We BC2GM060814876 PRP O
have BC2GM060814876 VBP O
previously BC2GM060814876 RB O
identified BC2GM060814876 VBN O
LIT1 BC2GM060814876 NNP O
, BC2GM060814876 , O
a BC2GM060814876 DT O
paternally BC2GM060814876 RB O
expressed BC2GM060814876 VBN O
antisense BC2GM060814876 NN O
RNA BC2GM060814876 NNP O
within BC2GM060814876 IN O
the BC2GM060814876 DT O
KvLQT1 BC2GM060814876 NNP O
locus BC2GM060814876 NN O
through BC2GM060814876 IN O
a BC2GM060814876 DT O
positional BC2GM060814876 JJ O
screening BC2GM060814876 NN O
approach BC2GM060814876 NN O
using BC2GM060814876 VBG O
human BC2GM060814876 JJ O
monochromosomal BC2GM060814876 JJ O
hybrids BC2GM060814876 NNS O
. BC2GM060814876 . O
. . O O

In BC2GM096261608 IN O
this BC2GM096261608 DT O
respect BC2GM096261608 NN O
, BC2GM096261608 , O
the BC2GM096261608 DT O
promoter BC2GM096261608 NN O
structure BC2GM096261608 NN O
of BC2GM096261608 IN O
COX BC2GM096261608 NNP O
genes BC2GM096261608 NNS O
resemble BC2GM096261608 VBP O
those BC2GM096261608 DT O
of BC2GM096261608 IN O
many BC2GM096261608 JJ O
house-keeping BC2GM096261608 JJ O
genes BC2GM096261608 NNS O
. BC2GM096261608 . O
. . O O

Eight BC2GM012522981 CD O
of BC2GM012522981 IN O
these BC2GM012522981 DT O
suppressors BC2GM012522981 NNS O
for BC2GM012522981 IN O
into BC2GM012522981 IN O
two BC2GM012522981 CD O
complementation BC2GM012522981 NN O
groups BC2GM012522981 NNS O
, BC2GM012522981 , O
designated BC2GM012522981 VBN O
KCS1 BC2GM012522981 NNP O
and BC2GM012522981 CC O
KCS2 BC2GM012522981 NNP O
. BC2GM012522981 . O
. . O O

ES BC2GM022628668 NNP O
cells BC2GM022628668 NNS O
in BC2GM022628668 IN O
which BC2GM022628668 WDT O
the BC2GM022628668 DT O
gene BC2GM022628668 NN O
for BC2GM022628668 IN O
the BC2GM022628668 DT O
erythroid BC2GM022628668 JJ O
transcription BC2GM022628668 NN O
factor BC2GM022628668 NN O
GATA-1 BC2GM022628668 NNP O
has BC2GM022628668 VBZ O
been BC2GM022628668 VBN O
disrupted BC2GM022628668 VBN O
fail BC2GM022628668 NN O
to BC2GM022628668 TO O
produce BC2GM022628668 VB O
mature BC2GM022628668 JJ O
erythroid BC2GM022628668 NN O
cells BC2GM022628668 NNS O
either BC2GM022628668 CC O
in BC2GM022628668 IN O
vivo BC2GM022628668 NN O
or BC2GM022628668 CC O
in BC2GM022628668 IN O
vitro BC2GM022628668 NN O
. BC2GM022628668 . O
. . O O

Patients BC2GM093300665 NNS O
received BC2GM093300665 VBD O
BPB BC2GM093300665 NNP O
using BC2GM093300665 VBG O
bupivacaine BC2GM093300665 JJ O
2 BC2GM093300665 CD O
mg BC2GM093300665 JJ O
kg-1 BC2GM093300665 NN O
with BC2GM093300665 IN O
adrenaline BC2GM093300665 JJ O
1 BC2GM093300665 CD O
in BC2GM093300665 IN O
200,000 BC2GM093300665 CD O
, BC2GM093300665 , O
either BC2GM093300665 RB O
with BC2GM093300665 IN O
or BC2GM093300665 CC O
without BC2GM093300665 IN O
hyaluronidase BC2GM093300665 JJ O
3000 BC2GM093300665 CD O
iu BC2GM093300665 NN O
, BC2GM093300665 , O
in BC2GM093300665 IN O
a BC2GM093300665 DT O
volume BC2GM093300665 NN O
of BC2GM093300665 IN O
0.5 BC2GM093300665 CD O
ml BC2GM093300665 NNS O
per BC2GM093300665 IN O
2.54 BC2GM093300665 CD O
cm BC2GM093300665 NN O
of BC2GM093300665 IN O
the BC2GM093300665 DT O
patient BC2GM093300665 NN O
's BC2GM093300665 POS O
height BC2GM093300665 NN O
. BC2GM093300665 . O
. . O O

CONCLUSIONS BC2GM009398467 NN O
: BC2GM009398467 : O
The BC2GM009398467 DT O
MC BC2GM009398467 NNP O
/ BC2GM009398467 NNP O
UA BC2GM009398467 NNP O
ratio BC2GM009398467 NN O
improves BC2GM009398467 VBZ O
the BC2GM009398467 DT O
sensitivity BC2GM009398467 NN O
for BC2GM009398467 IN O
the BC2GM009398467 DT O
prediction BC2GM009398467 NN O
of BC2GM009398467 IN O
poor BC2GM009398467 JJ O
perinatal BC2GM009398467 JJ O
outcome BC2GM009398467 NN O
when BC2GM009398467 WRB O
it BC2GM009398467 PRP O
is BC2GM009398467 VBZ O
combined BC2GM009398467 VBN O
with BC2GM009398467 IN O
the BC2GM009398467 DT O
NST BC2GM009398467 NNP O
. BC2GM009398467 . O
. . O O

After BC2GM034228721 IN O
1 BC2GM034228721 CD O
day BC2GM034228721 NN O
, BC2GM034228721 , O
none BC2GM034228721 NN O
of BC2GM034228721 IN O
the BC2GM034228721 DT O
labeled BC2GM034228721 VBN O
erythrocytes BC2GM034228721 NNS O
were BC2GM034228721 VBD O
detected BC2GM034228721 VBN O
. BC2GM034228721 . O
. . O O

14.9 BC2GM015841458 CD O
x BC2GM015841458 JJ O
109 BC2GM015841458 CD O
L-1 BC2GM015841458 JJ O
) BC2GM015841458 ) O
was BC2GM015841458 VBD O
equal BC2GM015841458 JJ O
for BC2GM015841458 IN O
both BC2GM015841458 DT O
groups BC2GM015841458 NNS O
, BC2GM015841458 , O
but BC2GM015841458 CC O
CCI BC2GM015841458 NNP O
values BC2GM015841458 NNS O
were BC2GM015841458 VBD O
significantly BC2GM015841458 RB O
higher BC2GM015841458 JJR O
for BC2GM015841458 IN O
the BC2GM015841458 DT O
bedside BC2GM015841458 NN O
filtered BC2GM015841458 VBD O
PC BC2GM015841458 NNP O
( BC2GM015841458 ( O
14.1 BC2GM015841458 CD O
+ BC2GM015841458 NN O
/ BC2GM015841458 NNP O
- BC2GM015841458 : O
9.5 BC2GM015841458 CD O
vs BC2GM015841458 NN O
. BC2GM015841458 . O
. . O O

No BC2GM033317667 DT O
cleavage BC2GM033317667 NN O
of BC2GM033317667 IN O
gp BC2GM033317667 NN O
130 BC2GM033317667 CD O
was BC2GM033317667 VBD O
observed BC2GM033317667 VBN O
in BC2GM033317667 IN O
analogous BC2GM033317667 JJ O
pulse-chase BC2GM033317667 JJ O
radiolabelling BC2GM033317667 NN O
of BC2GM033317667 IN O
Ad-gB-infected BC2GM033317667 NNP O
human BC2GM033317667 JJ O
fibroblasts BC2GM033317667 NNS O
, BC2GM033317667 , O
even BC2GM033317667 RB O
though BC2GM033317667 IN O
these BC2GM033317667 DT O
cells BC2GM033317667 NNS O
are BC2GM033317667 VBP O
permissive BC2GM033317667 JJ O
for BC2GM033317667 IN O
HCMV BC2GM033317667 NNP O
replication BC2GM033317667 NN O
and BC2GM033317667 CC O
can BC2GM033317667 MD O
process BC2GM033317667 VB O
the BC2GM033317667 DT O
native BC2GM033317667 JJ O
gB BC2GM033317667 NN O
molecule BC2GM033317667 NN O
. BC2GM033317667 . O
. . O O

To BC2GM066012770 TO O
further BC2GM066012770 RBR O
investigate BC2GM066012770 VB O
the BC2GM066012770 DT O
role BC2GM066012770 NN O
of BC2GM066012770 IN O
PKR BC2GM066012770 NNP O
in BC2GM066012770 IN O
transcriptional BC2GM066012770 JJ O
signaling BC2GM066012770 NN O
, BC2GM066012770 , O
we BC2GM066012770 PRP O
expressed BC2GM066012770 VBD O
the BC2GM066012770 DT O
wild BC2GM066012770 JJ O
type BC2GM066012770 NN O
human BC2GM066012770 JJ O
PKR BC2GM066012770 NNP O
and BC2GM066012770 CC O
a BC2GM066012770 DT O
catalytically BC2GM066012770 RB O
inactive BC2GM066012770 JJ O
dominant BC2GM066012770 JJ O
negative BC2GM066012770 JJ O
PKR BC2GM066012770 NNP O
mutant BC2GM066012770 NN O
in BC2GM066012770 IN O
the BC2GM066012770 DT O
murine BC2GM066012770 JJ O
pre-B BC2GM066012770 JJ O
lymphoma BC2GM066012770 NN O
70Z BC2GM066012770 CD O
/ BC2GM066012770 NN O
3 BC2GM066012770 CD O
cells BC2GM066012770 NNS O
. BC2GM066012770 . O
. . O O

Regulation BC2GM034945904 NN O
of BC2GM034945904 IN O
activating BC2GM034945904 VBG O
transcription BC2GM034945904 NN O
factor-1 BC2GM034945904 NN O
and BC2GM034945904 CC O
the BC2GM034945904 DT O
cAMP BC2GM034945904 JJ O
response BC2GM034945904 NN O
element-binding BC2GM034945904 JJ O
protein BC2GM034945904 NN O
by BC2GM034945904 IN O
Ca2+ BC2GM034945904 NNP O
/ BC2GM034945904 NNP O
calmodulin-dependent BC2GM034945904 JJ O
protein BC2GM034945904 NN O
kinases BC2GM034945904 VBZ O
type BC2GM034945904 NN O
I BC2GM034945904 PRP O
, BC2GM034945904 , O
II BC2GM034945904 NNP O
, BC2GM034945904 , O
and BC2GM034945904 CC O
IV BC2GM034945904 NNP O
. BC2GM034945904 . O
. . O O

We BC2GM004396231 PRP O
report BC2GM004396231 VBP O
on BC2GM004396231 IN O
a BC2GM004396231 DT O
case BC2GM004396231 NN O
discovered BC2GM004396231 VBN O
in BC2GM004396231 IN O
a BC2GM004396231 DT O
13 BC2GM004396231 CD O
year-old BC2GM004396231 JJ O
girl BC2GM004396231 NN O
presenting BC2GM004396231 VBG O
with BC2GM004396231 IN O
anaemia BC2GM004396231 NN O
. BC2GM004396231 . O
. . O O

The BC2GM017308812 DT O
two BC2GM017308812 CD O
yeast BC2GM017308812 NN O
pheromone BC2GM017308812 NN O
receptors BC2GM017308812 NNS O
, BC2GM017308812 , O
the BC2GM017308812 DT O
a BC2GM017308812 DT O
and BC2GM017308812 CC O
alpha-factor BC2GM017308812 JJ O
receptors BC2GM017308812 NNS O
, BC2GM017308812 , O
share BC2GM017308812 NN O
many BC2GM017308812 JJ O
functional BC2GM017308812 JJ O
similarities BC2GM017308812 NNS O
: BC2GM017308812 : O
both BC2GM017308812 DT O
G BC2GM017308812 NNP O
protein-coupled BC2GM017308812 JJ O
receptors BC2GM017308812 NNS O
couple BC2GM017308812 NN O
to BC2GM017308812 TO O
the BC2GM017308812 DT O
same BC2GM017308812 JJ O
downstream BC2GM017308812 NN O
signal BC2GM017308812 NN O
transduction BC2GM017308812 NN O
pathway BC2GM017308812 NN O
, BC2GM017308812 , O
and BC2GM017308812 CC O
both BC2GM017308812 DT O
receptors BC2GM017308812 NNS O
undergo BC2GM017308812 VBP O
feedback BC2GM017308812 JJ O
regulation BC2GM017308812 NN O
involving BC2GM017308812 VBG O
increased BC2GM017308812 VBN O
phosphorylation BC2GM017308812 NN O
on BC2GM017308812 IN O
their BC2GM017308812 PRP$ O
C-terminal BC2GM017308812 JJ O
domains BC2GM017308812 NNS O
in BC2GM017308812 IN O
response BC2GM017308812 NN O
to BC2GM017308812 TO O
ligand BC2GM017308812 VB O
challenge BC2GM017308812 NN O
. BC2GM017308812 . O
. . O O

Tight-binding BC2GM077538777 JJ O
band BC2GM077538777 NN O
structure BC2GM077538777 NN O
calculations BC2GM077538777 NNS O
for BC2GM077538777 IN O
beta-MNX BC2GM077538777 NN O
( BC2GM077538777 ( O
M BC2GM077538777 NNP O
= BC2GM077538777 NNP O
Zr BC2GM077538777 NNP O
, BC2GM077538777 , O
X BC2GM077538777 NNP O
= BC2GM077538777 NNP O
Cl BC2GM077538777 NNP O
, BC2GM077538777 , O
Br BC2GM077538777 NNP O
; BC2GM077538777 : O
M BC2GM077538777 NNP O
= BC2GM077538777 NNP O
Hf BC2GM077538777 NNP O
, BC2GM077538777 , O
X BC2GM077538777 NNP O
= BC2GM077538777 NNP O
Cl BC2GM077538777 NNP O
) BC2GM077538777 ) O
, BC2GM077538777 , O
ZrCl BC2GM077538777 NNP O
, BC2GM077538777 , O
and BC2GM077538777 CC O
Y BC2GM077538777 NNP O
( BC2GM077538777 ( O
2 BC2GM077538777 CD O
) BC2GM077538777 ) O
C BC2GM077538777 NNP O
( BC2GM077538777 ( O
2 BC2GM077538777 CD O
) BC2GM077538777 ) O
Br BC2GM077538777 NNP O
( BC2GM077538777 ( O
2 BC2GM077538777 CD O
) BC2GM077538777 ) O
are BC2GM077538777 VBP O
reported BC2GM077538777 VBN O
. BC2GM077538777 . O
. . O O

Possible BC2GM041669085 JJ O
or BC2GM041669085 CC O
definite BC2GM041669085 JJ O
neglect BC2GM041669085 NN O
or BC2GM041669085 CC O
abuse BC2GM041669085 NN O
before BC2GM041669085 IN O
36 BC2GM041669085 CD O
months BC2GM041669085 NNS O
of BC2GM041669085 IN O
age BC2GM041669085 NN O
was BC2GM041669085 VBD O
correlated BC2GM041669085 VBN O
with BC2GM041669085 IN O
low BC2GM041669085 JJ O
DBH BC2GM041669085 NNP O
activity BC2GM041669085 NN O
. BC2GM041669085 . O
. . O O

Serum BC2GM087933545 NNP O
alpha-amylase BC2GM087933545 NN O
, BC2GM087933545 , O
trypsin BC2GM087933545 NN O
, BC2GM087933545 , O
trypsin BC2GM087933545 NN O
inhibitor BC2GM087933545 NN O
, BC2GM087933545 , O
lipase BC2GM087933545 NN O
and BC2GM087933545 CC O
total BC2GM087933545 JJ O
protease BC2GM087933545 NN O
activity BC2GM087933545 NN O
in BC2GM087933545 IN O
the BC2GM087933545 DT O
pancreatic BC2GM087933545 JJ O
tissue BC2GM087933545 NN O
was BC2GM087933545 VBD O
studied BC2GM087933545 VBN O
as BC2GM087933545 IN O
indicator BC2GM087933545 NN O
of BC2GM087933545 IN O
the BC2GM087933545 DT O
treatment BC2GM087933545 NN O
efficacy BC2GM087933545 NN O
with BC2GM087933545 IN O
5-fluorouracil BC2GM087933545 JJ O
electro-cumulation BC2GM087933545 NN O
. BC2GM087933545 . O
. . O O

Gore BC2GM068522547 NNP O
& BC2GM068522547 CC O
Associates BC2GM068522547 NNP O
, BC2GM068522547 , O
Inc. BC2GM068522547 NNP O
) BC2GM068522547 ) O
standard BC2GM068522547 VBP O
wall BC2GM068522547 NN O
graft BC2GM068522547 NN O
segments BC2GM068522547 NNS O
varying BC2GM068522547 VBG O
in BC2GM068522547 IN O
length BC2GM068522547 NN O
from BC2GM068522547 IN O
4 BC2GM068522547 CD O
to BC2GM068522547 TO O
12 BC2GM068522547 CD O
cm BC2GM068522547 NN O
. BC2GM068522547 . O
. . O O

Critical BC2GM079908417 NNP O
review BC2GM079908417 NN O
of BC2GM079908417 IN O
tests BC2GM079908417 NNS O
for BC2GM079908417 IN O
the BC2GM079908417 DT O
HBs BC2GM079908417 NNP O
antigen BC2GM079908417 NN O
in BC2GM079908417 IN O
the BC2GM079908417 DT O
detection BC2GM079908417 NN O
of BC2GM079908417 IN O
infectious BC2GM079908417 JJ O
blood BC2GM079908417 NN O
. BC2GM079908417 . O
. . O O

Biol BC2GM075291885 NNP O
. BC2GM075291885 . O
. . O O

The BC2GM047630047 DT O
results BC2GM047630047 NNS O
show BC2GM047630047 VBP O
that BC2GM047630047 IN O
in BC2GM047630047 IN O
uninfected BC2GM047630047 JJ O
NIH-3T3 BC2GM047630047 NNP O
cells BC2GM047630047 NNS O
Avarol BC2GM047630047 NNP O
( BC2GM047630047 ( O
i BC2GM047630047 NN O
) BC2GM047630047 ) O
causes BC2GM047630047 VBZ O
a BC2GM047630047 DT O
50 BC2GM047630047 CD O
% BC2GM047630047 NN O
reduction BC2GM047630047 NN O
of BC2GM047630047 IN O
the BC2GM047630047 DT O
growth BC2GM047630047 NN O
rate BC2GM047630047 NN O
only BC2GM047630047 RB O
at BC2GM047630047 IN O
the BC2GM047630047 DT O
high BC2GM047630047 JJ O
concentration BC2GM047630047 NN O
of BC2GM047630047 IN O
29.6 BC2GM047630047 CD O
microM BC2GM047630047 NNS O
and BC2GM047630047 CC O
( BC2GM047630047 ( O
ii BC2GM047630047 NN O
) BC2GM047630047 ) O
is BC2GM047630047 VBZ O
accumulated BC2GM047630047 VBN O
in BC2GM047630047 IN O
the BC2GM047630047 DT O
cytoplasm BC2GM047630047 NN O
close BC2GM047630047 RB O
to BC2GM047630047 TO O
the BC2GM047630047 DT O
nucleus BC2GM047630047 NN O
. BC2GM047630047 . O
. . O O

Non-dialyzable BC2GM057069955 JJ O
transfer BC2GM057069955 NN O
factor BC2GM057069955 NN O
. BC2GM057069955 . O
. . O O

Treatment BC2GM079567049 NN O
of BC2GM079567049 IN O
excessive BC2GM079567049 JJ O
bleeding BC2GM079567049 NN O
after BC2GM079567049 IN O
cardiopulmonary BC2GM079567049 JJ O
bypass BC2GM079567049 NN O
was BC2GM079567049 VBD O
based BC2GM079567049 VBN O
on BC2GM079567049 IN O
an BC2GM079567049 DT O
algorithm BC2GM079567049 JJ O
using BC2GM079567049 VBG O
point-of-care BC2GM079567049 JJ O
testing BC2GM079567049 VBG O
with BC2GM079567049 IN O
whole BC2GM079567049 JJ O
blood BC2GM079567049 NN O
prothrombin BC2GM079567049 NN O
time BC2GM079567049 NN O
, BC2GM079567049 , O
activated BC2GM079567049 VBN O
partial BC2GM079567049 JJ O
thromboplastin BC2GM079567049 NN O
time BC2GM079567049 NN O
, BC2GM079567049 , O
heparinase BC2GM079567049 NN O
activated BC2GM079567049 VBD O
clotting BC2GM079567049 JJ O
time BC2GM079567049 NN O
, BC2GM079567049 , O
and BC2GM079567049 CC O
platelet BC2GM079567049 NN O
count BC2GM079567049 NN O
. BC2GM079567049 . O
. . O O

Although BC2GM024364656 IN O
IL-6 BC2GM024364656 NNP O
can BC2GM024364656 MD O
activate BC2GM024364656 VB O
ERK-1 BC2GM024364656 NNP O
in BC2GM024364656 IN O
HepG2 BC2GM024364656 NNP O
cells BC2GM024364656 NNS O
, BC2GM024364656 , O
STAT3 BC2GM024364656 NNP O
transactivation BC2GM024364656 NN O
and BC2GM024364656 CC O
Ser BC2GM024364656 NNP O
( BC2GM024364656 ( O
727 BC2GM024364656 CD O
) BC2GM024364656 ) O
phosphorylation BC2GM024364656 NN O
were BC2GM024364656 VBD O
not BC2GM024364656 RB O
reduced BC2GM024364656 VBN O
by BC2GM024364656 IN O
using BC2GM024364656 VBG O
the BC2GM024364656 DT O
MAP BC2GM024364656 NNP O
kinase BC2GM024364656 NN O
/ BC2GM024364656 NNP O
ERK BC2GM024364656 NNP O
kinase BC2GM024364656 NN O
( BC2GM024364656 ( O
MEK BC2GM024364656 NNP O
) BC2GM024364656 ) O
inhibitor BC2GM024364656 NN O
PD98059 BC2GM024364656 NNP O
or BC2GM024364656 CC O
by BC2GM024364656 IN O
overexpression BC2GM024364656 NN O
of BC2GM024364656 IN O
dominant-negative BC2GM024364656 JJ O
Raf BC2GM024364656 NNP O
. BC2GM024364656 . O
. . O O

The BC2GM009893203 DT O
aim BC2GM009893203 NN O
of BC2GM009893203 IN O
this BC2GM009893203 DT O
study BC2GM009893203 NN O
was BC2GM009893203 VBD O
to BC2GM009893203 TO O
determine BC2GM009893203 VB O
the BC2GM009893203 DT O
response BC2GM009893203 NN O
properties BC2GM009893203 NNS O
of BC2GM009893203 IN O
the BC2GM009893203 DT O
human BC2GM009893203 JJ O
visual BC2GM009893203 JJ O
cortex BC2GM009893203 NN O
to BC2GM009893203 TO O
chromatic BC2GM009893203 JJ O
stimuli BC2GM009893203 NNS O
using BC2GM009893203 VBG O
magnetoencephalography BC2GM009893203 NN O
( BC2GM009893203 ( O
MEG BC2GM009893203 NNP O
) BC2GM009893203 ) O
. BC2GM009893203 . O
. . O O

The BC2GM060833693 DT O
women BC2GM060833693 NNS O
in BC2GM060833693 IN O
the BC2GM060833693 DT O
intermediate BC2GM060833693 JJ O
calcium BC2GM060833693 NN O
group BC2GM060833693 NN O
had BC2GM060833693 VBD O
approximately BC2GM060833693 RB O
the BC2GM060833693 DT O
same BC2GM060833693 JJ O
mean BC2GM060833693 JJ O
BMD BC2GM060833693 NNP O
values BC2GM060833693 NNS O
as BC2GM060833693 IN O
those BC2GM060833693 DT O
in BC2GM060833693 IN O
the BC2GM060833693 DT O
low BC2GM060833693 JJ O
calcium BC2GM060833693 NN O
group BC2GM060833693 NN O
. BC2GM060833693 . O
. . O O

Biochemical BC2GM033925563 JJ O
experiments BC2GM033925563 NNS O
and BC2GM033925563 CC O
genome BC2GM033925563 JJ O
sequencing BC2GM033925563 NN O
have BC2GM033925563 VBP O
shown BC2GM033925563 VBN O
that BC2GM033925563 IN O
, BC2GM033925563 , O
despite BC2GM033925563 IN O
the BC2GM033925563 DT O
prokaryotic BC2GM033925563 JJ O
cell BC2GM033925563 NN O
and BC2GM033925563 CC O
genome BC2GM033925563 JJ O
organization BC2GM033925563 NN O
, BC2GM033925563 , O
basal BC2GM033925563 JJ O
transcriptional BC2GM033925563 JJ O
elements BC2GM033925563 NNS O
of BC2GM033925563 IN O
members BC2GM033925563 NNS O
of BC2GM033925563 IN O
the BC2GM033925563 DT O
domain BC2GM033925563 NN O
Archaea BC2GM033925563 NNP O
( BC2GM033925563 ( O
i.e. BC2GM033925563 FW O
, BC2GM033925563 , O
TATA BC2GM033925563 NNP O
box-like BC2GM033925563 NN O
sequences BC2GM033925563 NNS O
, BC2GM033925563 , O
RNA BC2GM033925563 NNP O
polymerase BC2GM033925563 NN O
, BC2GM033925563 , O
and BC2GM033925563 CC O
transcription BC2GM033925563 NN O
factors BC2GM033925563 NNS O
TBP BC2GM033925563 NNP O
, BC2GM033925563 , O
TFIIB BC2GM033925563 NNP O
, BC2GM033925563 , O
and BC2GM033925563 CC O
TFIIS BC2GM033925563 NNP O
) BC2GM033925563 ) O
are BC2GM033925563 VBP O
of BC2GM033925563 IN O
the BC2GM033925563 DT O
eukaryotic BC2GM033925563 JJ O
type BC2GM033925563 NN O
. BC2GM033925563 . O
. . O O

We BC2GM047747635 PRP O
found BC2GM047747635 VBD O
both BC2GM047747635 DT O
the BC2GM047747635 DT O
v-Ras- BC2GM047747635 JJ O
and BC2GM047747635 CC O
PC-PLC-transformed BC2GM047747635 JJ O
cells BC2GM047747635 NNS O
to BC2GM047747635 TO O
be BC2GM047747635 VB O
insensitive BC2GM047747635 JJ O
to BC2GM047747635 TO O
stimulation BC2GM047747635 VB O
with BC2GM047747635 IN O
platelet-derived BC2GM047747635 JJ O
growth BC2GM047747635 NN O
factor BC2GM047747635 NN O
( BC2GM047747635 ( O
PDGF BC2GM047747635 NNP O
) BC2GM047747635 ) O
. BC2GM047747635 . O
. . O O

Dipetalonema BC2GM064656341 NNP O
( BC2GM064656341 ( O
Acanthocheilonema BC2GM064656341 NNP O
) BC2GM064656341 ) O
didelphis BC2GM064656341 NN O
sp BC2GM064656341 NN O
. BC2GM064656341 . O
n BC2GM064656341 NN O
. BC2GM064656341 . O
. . O O

Number BC2GM003906024 NNP O
of BC2GM003906024 IN O
warm-units BC2GM003906024 NNS O
with BC2GM003906024 IN O
higher BC2GM003906024 JJR O
rates BC2GM003906024 NNS O
of BC2GM003906024 IN O
firing BC2GM003906024 NN O
and BC2GM003906024 CC O
greater BC2GM003906024 JJR O
thermal BC2GM003906024 JJ O
coefficients BC2GM003906024 NNS O
, BC2GM003906024 , O
comparable BC2GM003906024 JJ O
to BC2GM003906024 TO O
those BC2GM003906024 DT O
of BC2GM003906024 IN O
warm-units BC2GM003906024 NNS O
in BC2GM003906024 IN O
the BC2GM003906024 DT O
adult BC2GM003906024 NN O
, BC2GM003906024 , O
gradually BC2GM003906024 RB O
increased BC2GM003906024 VBN O
with BC2GM003906024 IN O
growth BC2GM003906024 NN O
. BC2GM003906024 . O
. . O O

Other BC2GM063827916 JJ O
toxicities BC2GM063827916 NNS O
attributed BC2GM063827916 VBN O
to BC2GM063827916 TO O
CPT-11 BC2GM063827916 NNP O
included BC2GM063827916 JJ O
dehydration BC2GM063827916 NN O
, BC2GM063827916 , O
nausea BC2GM063827916 NN O
, BC2GM063827916 , O
vomiting BC2GM063827916 NN O
, BC2GM063827916 , O
and BC2GM063827916 CC O
asthenia BC2GM063827916 NN O
. BC2GM063827916 . O
. . O O

An BC2GM094703184 DT O
in BC2GM094703184 IN O
vitro BC2GM094703184 JJ O
Raf-1 BC2GM094703184 JJ O
kinase BC2GM094703184 NN O
assay BC2GM094703184 NN O
, BC2GM094703184 , O
however BC2GM094703184 RB O
, BC2GM094703184 , O
failed BC2GM094703184 VBD O
to BC2GM094703184 TO O
detect BC2GM094703184 VB O
LPS-induced BC2GM094703184 NNP O
Raf-1 BC2GM094703184 NNP O
kinase BC2GM094703184 NN O
activity BC2GM094703184 NN O
in BC2GM094703184 IN O
RAW BC2GM094703184 NNP O
264.7 BC2GM094703184 CD O
cells BC2GM094703184 NNS O
, BC2GM094703184 , O
suggesting BC2GM094703184 VBG O
that BC2GM094703184 IN O
in BC2GM094703184 IN O
RAW BC2GM094703184 NNP O
264.7 BC2GM094703184 CD O
cells BC2GM094703184 NNS O
, BC2GM094703184 , O
Raf-1 BC2GM094703184 JJ O
kinase BC2GM094703184 NN O
is BC2GM094703184 VBZ O
not BC2GM094703184 RB O
an BC2GM094703184 DT O
activating BC2GM094703184 VBG O
component BC2GM094703184 NN O
of BC2GM094703184 IN O
the BC2GM094703184 DT O
LPS BC2GM094703184 NNP O
signaling BC2GM094703184 VBG O
pathway BC2GM094703184 RB O
regulating BC2GM094703184 VBG O
MAPK BC2GM094703184 NNP O
activity BC2GM094703184 NN O
or BC2GM094703184 CC O
sIL-1Ra BC2GM094703184 JJ O
promoter BC2GM094703184 NN O
activity BC2GM094703184 NN O
. BC2GM094703184 . O
. . O O

These BC2GM094569593 DT O
motions BC2GM094569593 NNS O
were BC2GM094569593 VBD O
found BC2GM094569593 VBN O
in BC2GM094569593 IN O
the BC2GM094569593 DT O
N- BC2GM094569593 NNP O
and BC2GM094569593 CC O
C- BC2GM094569593 NNP O
terminal BC2GM094569593 NN O
tails BC2GM094569593 NNS O
, BC2GM094569593 , O
in BC2GM094569593 IN O
segment BC2GM094569593 NN O
33-35 BC2GM094569593 CD O
which BC2GM094569593 WDT O
forms BC2GM094569593 VBZ O
the BC2GM094569593 DT O
turn BC2GM094569593 NN O
between BC2GM094569593 IN O
beta-strands BC2GM094569593 NNS O
S1 BC2GM094569593 NNP O
and BC2GM094569593 CC O
S2 BC2GM094569593 NNP O
, BC2GM094569593 , O
and BC2GM094569593 CC O
residues BC2GM094569593 VBZ O
47-52 BC2GM094569593 JJ O
located BC2GM094569593 VBN O
in BC2GM094569593 IN O
a BC2GM094569593 DT O
long BC2GM094569593 JJ O
loop BC2GM094569593 NN O
preceding BC2GM094569593 VBG O
strand BC2GM094569593 NN O
S3 BC2GM094569593 NNP O
. BC2GM094569593 . O
. . O O

Encapsulation BC2GM008085134 NN O
of BC2GM008085134 IN O
sodium BC2GM008085134 NN O
fluorescein BC2GM008085134 NN O
for BC2GM008085134 IN O
dye BC2GM008085134 NN O
release BC2GM008085134 NN O
studies BC2GM008085134 NNS O
. BC2GM008085134 . O
. . O O

The BC2GM038397641 DT O
Zn-15 BC2GM038397641 NNP O
DNA-binding BC2GM038397641 NNP O
domain BC2GM038397641 NN O
comprises BC2GM038397641 NNS O
three BC2GM038397641 CD O
zinc BC2GM038397641 NN O
fingers BC2GM038397641 NNS O
separated BC2GM038397641 VBN O
by BC2GM038397641 IN O
unusually BC2GM038397641 RB O
long BC2GM038397641 JJ O
linker BC2GM038397641 NN O
sequences BC2GM038397641 NNS O
that BC2GM038397641 WDT O
would BC2GM038397641 MD O
be BC2GM038397641 VB O
expected BC2GM038397641 VBN O
to BC2GM038397641 TO O
interrupt BC2GM038397641 VB O
specific BC2GM038397641 JJ O
DNA BC2GM038397641 NNP O
site BC2GM038397641 NN O
recognition BC2GM038397641 NN O
. BC2GM038397641 . O
. . O O

Some BC2GM053931795 DT O
cells BC2GM053931795 NNS O
were BC2GM053931795 VBD O
excited BC2GM053931795 VBN O
, BC2GM053931795 , O
others BC2GM053931795 NNS O
inhibited BC2GM053931795 VBN O
by BC2GM053931795 IN O
, BC2GM053931795 , O
and BC2GM053931795 CC O
only BC2GM053931795 RB O
some BC2GM053931795 DT O
were BC2GM053931795 VBD O
directionally BC2GM053931795 RB O
sensitive BC2GM053931795 JJ O
to BC2GM053931795 TO O
the BC2GM053931795 DT O
optomotor BC2GM053931795 NN O
stimulus BC2GM053931795 NN O
. BC2GM053931795 . O
. . O O

This BC2GM018048012 DT O
region BC2GM018048012 NN O
was BC2GM018048012 VBD O
unfavourable BC2GM018048012 JJ O
, BC2GM018048012 , O
due BC2GM018048012 JJ O
to BC2GM018048012 TO O
malaria BC2GM018048012 VB O
in BC2GM018048012 IN O
the BC2GM018048012 DT O
past BC2GM018048012 NN O
. BC2GM018048012 . O
. . O O

These BC2GM007864175 DT O
results BC2GM007864175 NNS O
establish BC2GM007864175 VB O
that BC2GM007864175 IN O
the BC2GM007864175 DT O
DNA BC2GM007864175 NNP O
fragment BC2GM007864175 NN O
we BC2GM007864175 PRP O
have BC2GM007864175 VBP O
isolated BC2GM007864175 VBN O
contains BC2GM007864175 VBZ O
the BC2GM007864175 DT O
human BC2GM007864175 JJ O
gp130 BC2GM007864175 NN O
promoter BC2GM007864175 NN O
and BC2GM007864175 CC O
that BC2GM007864175 IN O
interleukin-6 BC2GM007864175 JJ O
type BC2GM007864175 NN O
cytokines BC2GM007864175 NNS O
may BC2GM007864175 MD O
influence BC2GM007864175 VB O
the BC2GM007864175 DT O
activity BC2GM007864175 NN O
of BC2GM007864175 IN O
this BC2GM007864175 DT O
promoter BC2GM007864175 NN O
via BC2GM007864175 IN O
activated BC2GM007864175 JJ O
STATs BC2GM007864175 NNP O
. BC2GM007864175 . O
. . O O

Structural BC2GM040930805 JJ O
organization BC2GM040930805 NN O
of BC2GM040930805 IN O
the BC2GM040930805 DT O
human BC2GM040930805 JJ O
Elk1 BC2GM040930805 NNP O
gene BC2GM040930805 NN O
and BC2GM040930805 CC O
its BC2GM040930805 PRP$ O
processed BC2GM040930805 JJ O
pseudogene BC2GM040930805 NN O
Elk2 BC2GM040930805 NNP O
. BC2GM040930805 . O
. . O O

Coexpression BC2GM033482973 NN O
of BC2GM033482973 IN O
CREB-binding BC2GM033482973 NNP O
protein BC2GM033482973 NN O
( BC2GM033482973 ( O
CBP BC2GM033482973 NNP O
) BC2GM033482973 ) O
/ BC2GM033482973 VBD O
p300 BC2GM033482973 JJ O
with BC2GM033482973 IN O
TReP-132 BC2GM033482973 NNP O
has BC2GM033482973 VBZ O
an BC2GM033482973 DT O
additive BC2GM033482973 JJ O
effect BC2GM033482973 NN O
on BC2GM033482973 IN O
promoter BC2GM033482973 NN O
activity BC2GM033482973 NN O
, BC2GM033482973 , O
and BC2GM033482973 CC O
the BC2GM033482973 DT O
proteins BC2GM033482973 NNS O
were BC2GM033482973 VBD O
demonstrated BC2GM033482973 VBN O
to BC2GM033482973 TO O
interact BC2GM033482973 VB O
physically BC2GM033482973 RB O
. BC2GM033482973 . O
. . O O

The BC2GM082082186 DT O
human BC2GM082082186 JJ O
p18 BC2GM082082186 NN O
gene BC2GM082082186 NN O
spans BC2GM082082186 NNS O
at BC2GM082082186 IN O
least BC2GM082082186 JJS O
7.5 BC2GM082082186 CD O
kb BC2GM082082186 NN O
and BC2GM082082186 CC O
is BC2GM082082186 VBZ O
composed BC2GM082082186 VBN O
of BC2GM082082186 IN O
three BC2GM082082186 CD O
exons BC2GM082082186 NNS O
, BC2GM082082186 , O
two BC2GM082082186 CD O
of BC2GM082082186 IN O
which BC2GM082082186 WDT O
encode BC2GM082082186 VBP O
the BC2GM082082186 DT O
p18 BC2GM082082186 NN O
protein BC2GM082082186 NN O
. BC2GM082082186 . O
. . O O

This BC2GM047438255 DT O
latter BC2GM047438255 JJ O
complex BC2GM047438255 JJ O
reacts BC2GM047438255 NNS O
with BC2GM047438255 IN O
an BC2GM047438255 DT O
antibody BC2GM047438255 NN O
to BC2GM047438255 TO O
serum BC2GM047438255 VB O
response BC2GM047438255 NN O
factor BC2GM047438255 NN O
( BC2GM047438255 ( O
SRF BC2GM047438255 NNP O
) BC2GM047438255 ) O
and BC2GM047438255 CC O
exhibits BC2GM047438255 VBZ O
the BC2GM047438255 DT O
same BC2GM047438255 JJ O
binding BC2GM047438255 NN O
characteristics BC2GM047438255 NNS O
as BC2GM047438255 IN O
purified BC2GM047438255 JJ O
SRF BC2GM047438255 NNP O
. BC2GM047438255 . O
. . O O

Moreover BC2GM049116336 RB O
, BC2GM049116336 , O
site-specific BC2GM049116336 JJ O
integration BC2GM049116336 NN O
of BC2GM049116336 IN O
the BC2GM049116336 DT O
ITR-flanked BC2GM049116336 JJ O
DNA BC2GM049116336 NN O
was BC2GM049116336 VBD O
also BC2GM049116336 RB O
detected BC2GM049116336 VBN O
by BC2GM049116336 IN O
PCR BC2GM049116336 NNP O
amplification BC2GM049116336 NN O
of BC2GM049116336 IN O
the BC2GM049116336 DT O
ITR-aavs1 BC2GM049116336 NNP O
junction BC2GM049116336 NN O
in BC2GM049116336 IN O
transduced BC2GM049116336 JJ O
human BC2GM049116336 JJ O
fibroblasts BC2GM049116336 NNS O
. BC2GM049116336 . O
. . O O

The BC2GM070607110 DT O
oxalate BC2GM070607110 JJ O
oxidase BC2GM070607110 NN O
method BC2GM070607110 NN O
results BC2GM070607110 NNS O
in BC2GM070607110 IN O
a BC2GM070607110 DT O
mean BC2GM070607110 NN O
and BC2GM070607110 CC O
reference BC2GM070607110 NN O
interval BC2GM070607110 NN O
for BC2GM070607110 IN O
oxalate BC2GM070607110 JJ O
excretion BC2GM070607110 NN O
that BC2GM070607110 WDT O
are BC2GM070607110 VBP O
comparable BC2GM070607110 JJ O
with BC2GM070607110 IN O
those BC2GM070607110 DT O
by BC2GM070607110 IN O
isotope BC2GM070607110 JJ O
dilution BC2GM070607110 NN O
, BC2GM070607110 , O
gas-chromatographic BC2GM070607110 JJ O
, BC2GM070607110 , O
colorimetric BC2GM070607110 JJ O
, BC2GM070607110 , O
and BC2GM070607110 CC O
other BC2GM070607110 JJ O
enzymic BC2GM070607110 JJ O
procedures BC2GM070607110 NNS O
. BC2GM070607110 . O
. . O O

Guanylyl BC2GM049485558 NNP O
cyclase BC2GM049485558 NN O
C BC2GM049485558 NNP O
, BC2GM049485558 , O
the BC2GM049485558 DT O
apparent BC2GM049485558 JJ O
guanylin BC2GM049485558 NN O
receptor BC2GM049485558 NN O
, BC2GM049485558 , O
was BC2GM049485558 VBD O
found BC2GM049485558 VBN O
in BC2GM049485558 IN O
abundant BC2GM049485558 JJ O
amounts BC2GM049485558 NNS O
in BC2GM049485558 IN O
the BC2GM049485558 DT O
intestine BC2GM049485558 NN O
by BC2GM049485558 IN O
Northern BC2GM049485558 NNP O
analysis BC2GM049485558 NN O
, BC2GM049485558 , O
and BC2GM049485558 CC O
by BC2GM049485558 IN O
the BC2GM049485558 DT O
polymerase BC2GM049485558 NN O
chain BC2GM049485558 NN O
reaction BC2GM049485558 NN O
or BC2GM049485558 CC O
cDNA BC2GM049485558 NN O
cloning BC2GM049485558 VBG O
it BC2GM049485558 PRP O
was BC2GM049485558 VBD O
also BC2GM049485558 RB O
found BC2GM049485558 VBN O
in BC2GM049485558 IN O
adrenal BC2GM049485558 JJ O
gland BC2GM049485558 NN O
, BC2GM049485558 , O
airway BC2GM049485558 RB O
epithelial BC2GM049485558 JJ O
cells BC2GM049485558 NNS O
, BC2GM049485558 , O
brain BC2GM049485558 NN O
, BC2GM049485558 , O
and BC2GM049485558 CC O
olfactory BC2GM049485558 NN O
and BC2GM049485558 CC O
tracheal BC2GM049485558 JJ O
mucosa BC2GM049485558 NN O
. BC2GM049485558 . O
. . O O

The BC2GM091144220 DT O
Sty1 BC2GM091144220 NNP O
kinase BC2GM091144220 NN O
is BC2GM091144220 VBZ O
stimulated BC2GM091144220 VBN O
by BC2GM091144220 IN O
a BC2GM091144220 DT O
variety BC2GM091144220 NN O
of BC2GM091144220 IN O
different BC2GM091144220 JJ O
stress BC2GM091144220 NN O
conditions BC2GM091144220 NNS O
including BC2GM091144220 VBG O
osmotic BC2GM091144220 JJ O
and BC2GM091144220 CC O
oxidative BC2GM091144220 JJ O
stress BC2GM091144220 NN O
and BC2GM091144220 CC O
heat BC2GM091144220 NN O
shock BC2GM091144220 NN O
. BC2GM091144220 . O
. . O O

No BC2GM006558727 DT O
interaction BC2GM006558727 NN O
with BC2GM006558727 IN O
epidural BC2GM006558727 JJ O
anesthesia BC2GM006558727 NN O
was BC2GM006558727 VBD O
observed BC2GM006558727 VBN O
. BC2GM006558727 . O
. . O O

The BC2GM097917359 DT O
purified BC2GM097917359 JJ O
RAG1 BC2GM097917359 NNP O
protein BC2GM097917359 NN O
overexpressed BC2GM097917359 VBD O
in BC2GM097917359 IN O
E.coli BC2GM097917359 NNP O
exhibited BC2GM097917359 VBD O
the BC2GM097917359 DT O
expected BC2GM097917359 JJ O
cleavage BC2GM097917359 NN O
activity BC2GM097917359 NN O
when BC2GM097917359 WRB O
combined BC2GM097917359 VBN O
with BC2GM097917359 IN O
RAG2 BC2GM097917359 NNP O
purified BC2GM097917359 VBD O
from BC2GM097917359 IN O
transfected BC2GM097917359 VBN O
293T BC2GM097917359 CD O
cells BC2GM097917359 NNS O
. BC2GM097917359 . O
. . O O

Lumbar BC2GM054122511 NNP O
spine BC2GM054122511 NN O
bone BC2GM054122511 NN O
mineral BC2GM054122511 JJ O
density BC2GM054122511 NN O
( BC2GM054122511 ( O
BMD BC2GM054122511 NNP O
) BC2GM054122511 ) O
by BC2GM054122511 IN O
dual-energy BC2GM054122511 JJ O
X-ray BC2GM054122511 JJ O
absorptiometry BC2GM054122511 NN O
( BC2GM054122511 ( O
DXA BC2GM054122511 NNP O
) BC2GM054122511 ) O
increased BC2GM054122511 VBN O
by BC2GM054122511 IN O
0.6 BC2GM054122511 CD O
% BC2GM054122511 NN O
, BC2GM054122511 , O
3.6 BC2GM054122511 CD O
% BC2GM054122511 NN O
and BC2GM054122511 CC O
8.1 BC2GM054122511 CD O
% BC2GM054122511 NN O
after BC2GM054122511 IN O
48 BC2GM054122511 CD O
weeks BC2GM054122511 NNS O
in BC2GM054122511 IN O
groups BC2GM054122511 NNS O
L BC2GM054122511 NNP O
, BC2GM054122511 , O
M BC2GM054122511 NNP O
and BC2GM054122511 CC O
H BC2GM054122511 NNP O
respectively BC2GM054122511 RB O
, BC2GM054122511 , O
responses BC2GM054122511 NNS O
in BC2GM054122511 IN O
groups BC2GM054122511 NNS O
M BC2GM054122511 NNP O
and BC2GM054122511 CC O
H BC2GM054122511 NNP O
being BC2GM054122511 VBG O
significantly BC2GM054122511 RB O
higher BC2GM054122511 JJR O
than BC2GM054122511 IN O
in BC2GM054122511 IN O
L BC2GM054122511 NNP O
( BC2GM054122511 ( O
p BC2GM054122511 JJ O
< BC2GM054122511 NN O
0.05 BC2GM054122511 CD O
, BC2GM054122511 , O
Mann-Whitney BC2GM054122511 NNP O
U-test BC2GM054122511 NNP O
) BC2GM054122511 ) O
. BC2GM054122511 . O
. . O O

A BC2GM003230260 DT O
31-year-old BC2GM003230260 JJ O
man BC2GM003230260 NN O
with BC2GM003230260 IN O
primary BC2GM003230260 JJ O
myelofibrosis BC2GM003230260 NN O
initially BC2GM003230260 RB O
received BC2GM003230260 VBD O
low BC2GM003230260 JJ O
dose BC2GM003230260 NN O
Ara BC2GM003230260 NNP O
C BC2GM003230260 NNP O
. BC2GM003230260 . O
. . O O

The BC2GM054072257 DT O
product BC2GM054072257 NN O
of BC2GM054072257 IN O
one BC2GM054072257 CD O
gene BC2GM054072257 NN O
, BC2GM054072257 , O
Bv80 BC2GM054072257 NNP O
, BC2GM054072257 , O
has BC2GM054072257 VBZ O
a BC2GM054072257 DT O
single BC2GM054072257 JJ O
divergent BC2GM054072257 NN O
copy BC2GM054072257 NN O
of BC2GM054072257 IN O
a BC2GM054072257 DT O
sequence BC2GM054072257 NN O
of BC2GM054072257 IN O
149 BC2GM054072257 CD O
amino BC2GM054072257 JJ O
acids BC2GM054072257 NNS O
( BC2GM054072257 ( O
approx BC2GM054072257 NN O
. BC2GM054072257 . O
. . O O

Joint BC2GM097577617 JJ O
ultrasonography BC2GM097577617 NN O
demonstrating BC2GM097577617 VBG O
thickening BC2GM097577617 NN O
of BC2GM097577617 IN O
synoviae BC2GM097577617 NN O
and BC2GM097577617 CC O
tendons BC2GM097577617 NNS O
has BC2GM097577617 VBZ O
become BC2GM097577617 VBN O
a BC2GM097577617 DT O
useful BC2GM097577617 JJ O
non-invasive BC2GM097577617 JJ O
diagnostic BC2GM097577617 JJ O
tool BC2GM097577617 NN O
, BC2GM097577617 , O
although BC2GM097577617 IN O
it BC2GM097577617 PRP O
is BC2GM097577617 VBZ O
not BC2GM097577617 RB O
specific BC2GM097577617 JJ O
for BC2GM097577617 IN O
beta BC2GM097577617 JJ O
2-M BC2GM097577617 JJ O
amyloidosis BC2GM097577617 NN O
, BC2GM097577617 , O
and BC2GM097577617 CC O
results BC2GM097577617 NNS O
depend BC2GM097577617 VBP O
on BC2GM097577617 IN O
observer BC2GM097577617 NN O
experience BC2GM097577617 NN O
. BC2GM097577617 . O
. . O O

Reconstruction BC2GM071151906 NN O
time BC2GM071151906 NN O
for BC2GM071151906 IN O
a BC2GM071151906 DT O
64 BC2GM071151906 CD O
x BC2GM071151906 NN O
64 BC2GM071151906 CD O
matrix BC2GM071151906 NN O
is BC2GM071151906 VBZ O
approximately BC2GM071151906 RB O
45 BC2GM071151906 CD O
s BC2GM071151906 JJ O
/ BC2GM071151906 NNP O
transaxial BC2GM071151906 JJ O
slice BC2GM071151906 NN O
. BC2GM071151906 . O
. . O O

In BC2GM048333023 IN O
another BC2GM048333023 DT O
patient BC2GM048333023 NN O
, BC2GM048333023 , O
IRPF BC2GM048333023 NNP O
recurred BC2GM048333023 VBD O
in BC2GM048333023 IN O
the BC2GM048333023 DT O
ureter BC2GM048333023 NN O
of BC2GM048333023 IN O
a BC2GM048333023 DT O
living BC2GM048333023 NN O
related BC2GM048333023 JJ O
renal BC2GM048333023 JJ O
graft BC2GM048333023 NN O
6 BC2GM048333023 CD O
months BC2GM048333023 NNS O
after BC2GM048333023 IN O
transplantation BC2GM048333023 NN O
. BC2GM048333023 . O
. . O O

A BC2GM078276040 DT O
simple BC2GM078276040 JJ O
technique BC2GM078276040 NN O
for BC2GM078276040 IN O
obtaining BC2GM078276040 VBG O
ultra-thin BC2GM078276040 JJ O
sections BC2GM078276040 NNS O
of BC2GM078276040 IN O
coccidian BC2GM078276040 JJ O
oocysts BC2GM078276040 NNS O
is BC2GM078276040 VBZ O
reported BC2GM078276040 VBN O
. BC2GM078276040 . O
. . O O

Omitting BC2GM031288971 VBG O
part BC2GM031288971 NN O
of BC2GM031288971 IN O
the BC2GM031288971 DT O
experimental BC2GM031288971 JJ O
NOE-derived BC2GM031288971 JJ O
distances BC2GM031288971 NNS O
results BC2GM031288971 NNS O
in BC2GM031288971 IN O
reduced BC2GM031288971 JJ O
restraint BC2GM031288971 NN O
violations BC2GM031288971 NNS O
and BC2GM031288971 CC O
lower BC2GM031288971 JJR O
R BC2GM031288971 NNP O
factors BC2GM031288971 NNS O
but BC2GM031288971 CC O
impairs BC2GM031288971 JJ O
structural BC2GM031288971 JJ O
convergence BC2GM031288971 NN O
in BC2GM031288971 IN O
the BC2GM031288971 DT O
rMD BC2GM031288971 NN O
refinement BC2GM031288971 NN O
. BC2GM031288971 . O
. . O O

Treatment BC2GM088996203 NN O
of BC2GM088996203 IN O
diabetes BC2GM088996203 NNS O
and BC2GM088996203 CC O
retinal BC2GM088996203 JJ O
complications BC2GM088996203 NNS O
. BC2GM088996203 . O
. . O O

Nicotinic BC2GM066800893 NNP O
receptor BC2GM066800893 NN O
antagonists BC2GM066800893 NNS O
mecamylamine BC2GM066800893 VBP O
( BC2GM066800893 ( O
0.5 BC2GM066800893 CD O
and BC2GM066800893 CC O
1 BC2GM066800893 CD O
mg BC2GM066800893 NN O
/ BC2GM066800893 NNP O
kg BC2GM066800893 NN O
) BC2GM066800893 ) O
and BC2GM066800893 CC O
hexamethonium BC2GM066800893 NN O
( BC2GM066800893 ( O
5 BC2GM066800893 CD O
and BC2GM066800893 CC O
10 BC2GM066800893 CD O
mg BC2GM066800893 NN O
/ BC2GM066800893 NNP O
kg BC2GM066800893 NN O
) BC2GM066800893 ) O
reduced BC2GM066800893 VBD O
the BC2GM066800893 DT O
response BC2GM066800893 NN O
induced BC2GM066800893 VBN O
by BC2GM066800893 IN O
nicotine BC2GM066800893 NN O
( BC2GM066800893 ( O
0.25 BC2GM066800893 CD O
mg BC2GM066800893 NN O
/ BC2GM066800893 NNP O
kg BC2GM066800893 NN O
) BC2GM066800893 ) O
. BC2GM066800893 . O
. . O O

Smooth BC2GM015437343 NNP O
pursuit BC2GM015437343 NN O
gain BC2GM015437343 NN O
and BC2GM015437343 CC O
the BC2GM015437343 DT O
percentage BC2GM015437343 NN O
of BC2GM015437343 IN O
total BC2GM015437343 JJ O
eye BC2GM015437343 NN O
movement BC2GM015437343 NN O
due BC2GM015437343 JJ O
to BC2GM015437343 TO O
various BC2GM015437343 JJ O
saccadic BC2GM015437343 JJ O
subtypes BC2GM015437343 NNS O
were BC2GM015437343 VBD O
computed BC2GM015437343 VBN O
using BC2GM015437343 VBG O
infrared BC2GM015437343 JJ O
oculography BC2GM015437343 NN O
and BC2GM015437343 CC O
computerized BC2GM015437343 JJ O
pattern BC2GM015437343 NN O
recognition BC2GM015437343 NN O
software BC2GM015437343 NN O
. BC2GM015437343 . O
. . O O

The BC2GM053826454 DT O
papers BC2GM053826454 NNS O
provide BC2GM053826454 VBP O
a BC2GM053826454 DT O
broad BC2GM053826454 JJ O
perspective BC2GM053826454 NN O
of BC2GM053826454 IN O
MPAs BC2GM053826454 NNP O
and BC2GM053826454 CC O
include BC2GM053826454 VBP O
social BC2GM053826454 JJ O
, BC2GM053826454 , O
economic BC2GM053826454 JJ O
, BC2GM053826454 , O
cultural BC2GM053826454 JJ O
, BC2GM053826454 , O
biological BC2GM053826454 JJ O
and BC2GM053826454 CC O
statistical BC2GM053826454 JJ O
components BC2GM053826454 NNS O
. BC2GM053826454 . O
. . O O

In BC2GM090513544 IN O
the BC2GM090513544 DT O
second BC2GM090513544 JJ O
group BC2GM090513544 NN O
, BC2GM090513544 , O
which BC2GM090513544 WDT O
consisted BC2GM090513544 VBD O
of BC2GM090513544 IN O
babies BC2GM090513544 NNS O
of BC2GM090513544 IN O
33 BC2GM090513544 CD O
to BC2GM090513544 TO O
36 BC2GM090513544 CD O
weeks BC2GM090513544 NNS O
of BC2GM090513544 IN O
gestational BC2GM090513544 JJ O
age BC2GM090513544 NN O
, BC2GM090513544 , O
haptoglobin BC2GM090513544 NN O
was BC2GM090513544 VBD O
detected BC2GM090513544 VBN O
in BC2GM090513544 IN O
6 BC2GM090513544 CD O
infants BC2GM090513544 NNS O
, BC2GM090513544 , O
with BC2GM090513544 IN O
levels BC2GM090513544 NNS O
less BC2GM090513544 JJR O
than BC2GM090513544 IN O
25 BC2GM090513544 CD O
mg BC2GM090513544 JJ O
/ BC2GM090513544 NNP O
dl BC2GM090513544 NN O
in BC2GM090513544 IN O
3 BC2GM090513544 CD O
. BC2GM090513544 . O
. . O O

Clinical BC2GM079563549 JJ O
experience BC2GM079563549 NN O
gained BC2GM079563549 VBN O
from BC2GM079563549 IN O
a BC2GM079563549 DT O
combined BC2GM079563549 VBN O
study BC2GM079563549 NN O
of BC2GM079563549 IN O
252Cf BC2GM079563549 CD O
brachytherapy BC2GM079563549 NN O
by BC2GM079563549 IN O
the BC2GM079563549 DT O
staff-members BC2GM079563549 NNS O
of BC2GM079563549 IN O
the BC2GM079563549 DT O
Research BC2GM079563549 NNP O
Institute BC2GM079563549 NNP O
of BC2GM079563549 IN O
Medical BC2GM079563549 NNP O
Radiology BC2GM079563549 NNP O
, BC2GM079563549 , O
USSR BC2GM079563549 NNP O
AMS BC2GM079563549 NNP O
, BC2GM079563549 , O
was BC2GM079563549 VBD O
generalized BC2GM079563549 VBN O
. BC2GM079563549 . O
. . O O

Eph BC2GM058248998 NNP O
receptors BC2GM058248998 NNS O
and BC2GM058248998 CC O
their BC2GM058248998 PRP$ O
membrane-associated BC2GM058248998 JJ O
ephrin BC2GM058248998 NN O
ligands BC2GM058248998 VBZ O
regulate BC2GM058248998 JJ O
cell-cell BC2GM058248998 JJ O
interactions BC2GM058248998 NNS O
during BC2GM058248998 IN O
development BC2GM058248998 NN O
. BC2GM058248998 . O
. . O O

The BC2GM067923861 DT O
genomic BC2GM067923861 JJ O
organization BC2GM067923861 NN O
in BC2GM067923861 IN O
this BC2GM067923861 DT O
region BC2GM067923861 NN O
is BC2GM067923861 VBZ O
similar BC2GM067923861 JJ O
to BC2GM067923861 TO O
the BC2GM067923861 DT O
neural-restricted BC2GM067923861 JJ O
family BC2GM067923861 NN O
members BC2GM067923861 NNS O
, BC2GM067923861 , O
Hel-N1 BC2GM067923861 NNP O
( BC2GM067923861 ( O
ELAVL2 BC2GM067923861 NNP O
) BC2GM067923861 ) O
and BC2GM067923861 CC O
mHuD BC2GM067923861 $ O
( BC2GM067923861 ( O
Elavl4 BC2GM067923861 NNP O
) BC2GM067923861 ) O
. BC2GM067923861 . O
. . O O

Studies BC2GM088008417 NNS O
of BC2GM088008417 IN O
HS2-gamma BC2GM088008417 NNP O
gene BC2GM088008417 NN O
reporter BC2GM088008417 NN O
constructs BC2GM088008417 NNS O
carrying BC2GM088008417 VBG O
CACCC BC2GM088008417 NNP O
box BC2GM088008417 NN O
deletions BC2GM088008417 NNS O
revealed BC2GM088008417 VBD O
that BC2GM088008417 IN O
the BC2GM088008417 DT O
CACCC BC2GM088008417 NNP O
box BC2GM088008417 NN O
sequence BC2GM088008417 NN O
of BC2GM088008417 IN O
the BC2GM088008417 DT O
gamma BC2GM088008417 NN O
gene BC2GM088008417 NN O
promoter BC2GM088008417 NN O
mediates BC2GM088008417 VBZ O
the BC2GM088008417 DT O
activation BC2GM088008417 NN O
of BC2GM088008417 IN O
the BC2GM088008417 DT O
gamma BC2GM088008417 NN O
gene BC2GM088008417 NN O
by BC2GM088008417 IN O
FKLF BC2GM088008417 NNP O
. BC2GM088008417 . O
. . O O

Computer BC2GM036761066 NNP O
analysis BC2GM036761066 NN O
, BC2GM036761066 , O
simple BC2GM036761066 JJ O
correlation BC2GM036761066 NN O
hypothesis BC2GM036761066 NN O
, BC2GM036761066 , O
and BC2GM036761066 CC O
distribution BC2GM036761066 NN O
method BC2GM036761066 NN O
with BC2GM036761066 IN O
1 BC2GM036761066 CD O
degree BC2GM036761066 NN O
of BC2GM036761066 IN O
freedom BC2GM036761066 NN O
revealed BC2GM036761066 VBD O
significant BC2GM036761066 JJ O
correlation BC2GM036761066 NN O
between BC2GM036761066 IN O
vertical BC2GM036761066 JJ O
root BC2GM036761066 NN O
fracture BC2GM036761066 NN O
and BC2GM036761066 CC O
the BC2GM036761066 DT O
technique BC2GM036761066 NN O
of BC2GM036761066 IN O
instrumentation BC2GM036761066 NN O
and BC2GM036761066 CC O
obturation BC2GM036761066 NN O
of BC2GM036761066 IN O
the BC2GM036761066 DT O
canal BC2GM036761066 NN O
( BC2GM036761066 ( O
p BC2GM036761066 JJ O
= BC2GM036761066 NNP O
0.025 BC2GM036761066 CD O
) BC2GM036761066 ) O
, BC2GM036761066 , O
the BC2GM036761066 DT O
length BC2GM036761066 NN O
of BC2GM036761066 IN O
the BC2GM036761066 DT O
post BC2GM036761066 NN O
( BC2GM036761066 ( O
p BC2GM036761066 JJ O
= BC2GM036761066 NNP O
0.05 BC2GM036761066 CD O
) BC2GM036761066 ) O
, BC2GM036761066 , O
and BC2GM036761066 CC O
the BC2GM036761066 DT O
existence BC2GM036761066 NN O
of BC2GM036761066 IN O
the BC2GM036761066 DT O
post BC2GM036761066 NN O
( BC2GM036761066 ( O
p BC2GM036761066 JJ O
= BC2GM036761066 NNP O
0.05 BC2GM036761066 CD O
) BC2GM036761066 ) O
. BC2GM036761066 . O
. . O O

A BC2GM002647660 DT O
retrospective BC2GM002647660 JJ O
analysis BC2GM002647660 NN O
of BC2GM002647660 IN O
data BC2GM002647660 NNS O
accumulated BC2GM002647660 VBN O
over BC2GM002647660 IN O
a BC2GM002647660 DT O
21-month BC2GM002647660 JJ O
period BC2GM002647660 NN O
, BC2GM002647660 , O
from BC2GM002647660 IN O
December BC2GM002647660 NNP O
1989 BC2GM002647660 CD O
to BC2GM002647660 TO O
September BC2GM002647660 NNP O
1991 BC2GM002647660 CD O
, BC2GM002647660 , O
regarding BC2GM002647660 VBG O
investigational BC2GM002647660 JJ O
use BC2GM002647660 NN O
of BC2GM002647660 IN O
a BC2GM002647660 DT O
308 BC2GM002647660 CD O
nanometer BC2GM002647660 NN O
Xenon BC2GM002647660 NNP O
Chloride BC2GM002647660 NNP O
Excimer BC2GM002647660 NNP O
Laser BC2GM002647660 NNP O
Coronary BC2GM002647660 NNP O
Angioplasty BC2GM002647660 NNP O
( BC2GM002647660 ( O
ELCA BC2GM002647660 NNP O
) BC2GM002647660 ) O
system BC2GM002647660 NN O
( BC2GM002647660 ( O
Advanced BC2GM002647660 NNP O
Interventional BC2GM002647660 NNP O
Systems BC2GM002647660 NNPS O
, BC2GM002647660 , O
Inc. BC2GM002647660 NNP O
, BC2GM002647660 , O
Irvine BC2GM002647660 NNP O
, BC2GM002647660 , O
CA BC2GM002647660 NNP O
) BC2GM002647660 ) O
was BC2GM002647660 VBD O
performed BC2GM002647660 VBN O
. BC2GM002647660 . O
. . O O

This BC2GM090401322 DT O
interaction BC2GM090401322 NN O
is BC2GM090401322 VBZ O
functional BC2GM090401322 JJ O
as BC2GM090401322 IN O
it BC2GM090401322 PRP O
leads BC2GM090401322 VBZ O
to BC2GM090401322 TO O
retargeting BC2GM090401322 VBG O
of BC2GM090401322 IN O
NF-kappa BC2GM090401322 NNP O
B BC2GM090401322 NNP O
p50 BC2GM090401322 NN O
from BC2GM090401322 IN O
the BC2GM090401322 DT O
nucleus BC2GM090401322 NN O
to BC2GM090401322 TO O
the BC2GM090401322 DT O
cytoplasm BC2GM090401322 NN O
. BC2GM090401322 . O
. . O O

These BC2GM013674517 DT O
characteristics BC2GM013674517 NNS O
add BC2GM013674517 VBP O
to BC2GM013674517 TO O
the BC2GM013674517 DT O
suitability BC2GM013674517 NN O
of BC2GM013674517 IN O
NM441 BC2GM013674517 NNP O
as BC2GM013674517 IN O
an BC2GM013674517 DT O
effective BC2GM013674517 JJ O
prodrug BC2GM013674517 NN O
of BC2GM013674517 IN O
NM394 BC2GM013674517 NNP O
. BC2GM013674517 . O
. . O O

Consistent BC2GM040624059 JJ O
with BC2GM040624059 IN O
our BC2GM040624059 PRP$ O
observation BC2GM040624059 NN O
that BC2GM040624059 IN O
AP-1 BC2GM040624059 NNP O
binding BC2GM040624059 NN O
does BC2GM040624059 VBZ O
not BC2GM040624059 RB O
contribute BC2GM040624059 VB O
to BC2GM040624059 TO O
c-Jun BC2GM040624059 JJ O
coactivation BC2GM040624059 NN O
is BC2GM040624059 VBZ O
the BC2GM040624059 DT O
observation BC2GM040624059 NN O
that BC2GM040624059 IN O
the BC2GM040624059 DT O
activation BC2GM040624059 NN O
of BC2GM040624059 IN O
PU.1 BC2GM040624059 NNP O
by BC2GM040624059 IN O
c-Jun BC2GM040624059 NN O
is BC2GM040624059 VBZ O
blocked BC2GM040624059 VBN O
by BC2GM040624059 IN O
overexpression BC2GM040624059 NN O
of BC2GM040624059 IN O
c-Fos BC2GM040624059 NN O
. BC2GM040624059 . O
. . O O

The BC2GM092320331 DT O
BRSV BC2GM092320331 NNP O
L BC2GM092320331 NNP O
gene BC2GM092320331 NN O
is BC2GM092320331 VBZ O
6573 BC2GM092320331 CD O
nt BC2GM092320331 NN O
in BC2GM092320331 IN O
length BC2GM092320331 NN O
and BC2GM092320331 CC O
the BC2GM092320331 DT O
derived BC2GM092320331 VBN O
polypeptide BC2GM092320331 NN O
has BC2GM092320331 VBZ O
2162 BC2GM092320331 CD O
aa BC2GM092320331 NN O
. BC2GM092320331 . O
. . O O

The BC2GM071576712 DT O
results BC2GM071576712 NNS O
in BC2GM071576712 IN O
the BC2GM071576712 DT O
untreated BC2GM071576712 JJ O
patients BC2GM071576712 NNS O
demonstrate BC2GM071576712 VBP O
the BC2GM071576712 DT O
primary BC2GM071576712 JJ O
importance BC2GM071576712 NN O
of BC2GM071576712 IN O
bulk BC2GM071576712 NN O
reduction BC2GM071576712 NN O
at BC2GM071576712 IN O
initial BC2GM071576712 JJ O
laparotomy BC2GM071576712 NN O
. BC2GM071576712 . O
. . O O

By BC2GM018313543 IN O
deletion BC2GM018313543 NN O
analysis BC2GM018313543 NN O
, BC2GM018313543 , O
we BC2GM018313543 PRP O
identified BC2GM018313543 VBD O
the BC2GM018313543 DT O
regions BC2GM018313543 NNS O
of BC2GM018313543 IN O
c-Jun BC2GM018313543 JJ O
encoding BC2GM018313543 VBG O
transformation BC2GM018313543 NN O
and BC2GM018313543 CC O
transactivation BC2GM018313543 NN O
functions BC2GM018313543 NNS O
. BC2GM018313543 . O
. . O O

Probiotics BC2GM096019104 NNS O
, BC2GM096019104 , O
prebiotics BC2GM096019104 NNS O
, BC2GM096019104 , O
vaccination BC2GM096019104 NN O
, BC2GM096019104 , O
and BC2GM096019104 CC O
acidification BC2GM096019104 NN O
of BC2GM096019104 IN O
drinking BC2GM096019104 NN O
water BC2GM096019104 NN O
were BC2GM096019104 VBD O
assessed BC2GM096019104 VBN O
as BC2GM096019104 IN O
means BC2GM096019104 NNS O
of BC2GM096019104 IN O
reducing BC2GM096019104 VBG O
Salmonella BC2GM096019104 NNP O
. BC2GM096019104 . O
. . O O

Nevertheless BC2GM076746345 RB O
, BC2GM076746345 , O
PEG BC2GM076746345 NNP O
influenced BC2GM076746345 VBD O
in BC2GM076746345 IN O
vitro BC2GM076746345 JJ O
drug BC2GM076746345 NN O
availability BC2GM076746345 NN O
considerably BC2GM076746345 RB O
, BC2GM076746345 , O
by BC2GM076746345 IN O
increasing BC2GM076746345 VBG O
both BC2GM076746345 DT O
drug BC2GM076746345 NN O
solubility BC2GM076746345 NN O
and BC2GM076746345 CC O
dissolution BC2GM076746345 NN O
rate BC2GM076746345 NN O
. BC2GM076746345 . O
. . O O

The BC2GM087975149 DT O
possible BC2GM087975149 JJ O
equivalency BC2GM087975149 NN O
of BC2GM087975149 IN O
a BC2GM087975149 DT O
short BC2GM087975149 JJ O
form BC2GM087975149 NN O
and BC2GM087975149 CC O
the BC2GM087975149 DT O
long BC2GM087975149 JJ O
form BC2GM087975149 NN O
of BC2GM087975149 IN O
the BC2GM087975149 DT O
Multiple BC2GM087975149 NNP O
Affect BC2GM087975149 NNP O
Adjective BC2GM087975149 NNP O
Check BC2GM087975149 NNP O
List-Revised BC2GM087975149 JJ O
( BC2GM087975149 ( O
MAACL-R BC2GM087975149 NNP O
; BC2GM087975149 : O
Zuckerman BC2GM087975149 NNP O
& BC2GM087975149 CC O
Lubin,1985 BC2GM087975149 NNP O
) BC2GM087975149 ) O
was BC2GM087975149 VBD O
studied BC2GM087975149 VBN O
by BC2GM087975149 IN O
correlating BC2GM087975149 VBG O
both BC2GM087975149 DT O
forms BC2GM087975149 NNS O
of BC2GM087975149 IN O
the BC2GM087975149 DT O
MAACL-R BC2GM087975149 NNP O
with BC2GM087975149 IN O
the BC2GM087975149 DT O
State BC2GM087975149 NNP O
Trait BC2GM087975149 NNP O
Personality BC2GM087975149 NNP O
Inventory BC2GM087975149 NNP O
( BC2GM087975149 ( O
Spielberger,1995 BC2GM087975149 NNP O
) BC2GM087975149 ) O
; BC2GM087975149 : O
the BC2GM087975149 DT O
Affect BC2GM087975149 NNP O
Balance BC2GM087975149 NNP O
Scale BC2GM087975149 NNP O
( BC2GM087975149 ( O
Bradburn,1969 BC2GM087975149 NNP O
) BC2GM087975149 ) O
; BC2GM087975149 : O
and BC2GM087975149 CC O
the BC2GM087975149 DT O
Sensation BC2GM087975149 NNP O
Seeking BC2GM087975149 NNP O
Scale BC2GM087975149 NNP O
( BC2GM087975149 ( O
Zuckerman,1978 BC2GM087975149 NNP O
) BC2GM087975149 ) O
. BC2GM087975149 . O
. . O O

There BC2GM010999620 EX O
was BC2GM010999620 VBD O
a BC2GM010999620 DT O
direct BC2GM010999620 JJ O
proportional BC2GM010999620 NN O
relationship BC2GM010999620 NN O
between BC2GM010999620 IN O
the BC2GM010999620 DT O
spiral BC2GM010999620 JJ O
artery BC2GM010999620 NN O
flow BC2GM010999620 NN O
and BC2GM010999620 CC O
the BC2GM010999620 DT O
pressure BC2GM010999620 NN O
difference BC2GM010999620 NN O
between BC2GM010999620 IN O
the BC2GM010999620 DT O
spiral BC2GM010999620 JJ O
artery BC2GM010999620 NN O
and BC2GM010999620 CC O
the BC2GM010999620 DT O
amniotic BC2GM010999620 JJ O
fluid BC2GM010999620 NN O
; BC2GM010999620 : O
the BC2GM010999620 DT O
pressure BC2GM010999620 NN O
difference BC2GM010999620 NN O
per BC2GM010999620 IN O
flow BC2GM010999620 NN O
( BC2GM010999620 ( O
the BC2GM010999620 DT O
resistance BC2GM010999620 NN O
of BC2GM010999620 IN O
the BC2GM010999620 DT O
cotyledonary BC2GM010999620 JJ O
unit BC2GM010999620 NN O
) BC2GM010999620 ) O
was BC2GM010999620 VBD O
found BC2GM010999620 VBN O
to BC2GM010999620 TO O
be BC2GM010999620 VB O
1 BC2GM010999620 CD O
-- BC2GM010999620 : O
3 BC2GM010999620 CD O
mm BC2GM010999620 NN O
Hg BC2GM010999620 NNP O
. BC2GM010999620 . O
ml-1 BC2GM010999620 NN O
. BC2GM010999620 . O
min BC2GM010999620 NN O
( BC2GM010999620 ( O
8 BC2GM010999620 CD O
-- BC2GM010999620 : O
24kPa BC2GM010999620 CD O
. BC2GM010999620 . O
ml-1 BC2GM010999620 NN O
. BC2GM010999620 . O
s BC2GM010999620 NN O
) BC2GM010999620 ) O
. BC2GM010999620 . O
. . O O

A BC2GM076347404 DT O
series BC2GM076347404 NN O
of BC2GM076347404 IN O
mutations BC2GM076347404 NNS O
were BC2GM076347404 VBD O
constructed BC2GM076347404 VBN O
within BC2GM076347404 IN O
the BC2GM076347404 DT O
E2 BC2GM076347404 NNP O
open BC2GM076347404 JJ O
reading BC2GM076347404 NN O
frame BC2GM076347404 NN O
which BC2GM076347404 WDT O
delete BC2GM076347404 VBP O
various BC2GM076347404 JJ O
regions BC2GM076347404 NNS O
of BC2GM076347404 IN O
the BC2GM076347404 DT O
conserved BC2GM076347404 JJ O
DNA BC2GM076347404 NNP O
binding BC2GM076347404 NN O
and BC2GM076347404 CC O
transactivation BC2GM076347404 NN O
domains BC2GM076347404 NNS O
as BC2GM076347404 RB O
well BC2GM076347404 RB O
as BC2GM076347404 IN O
the BC2GM076347404 DT O
internal BC2GM076347404 JJ O
hinge BC2GM076347404 NN O
region BC2GM076347404 NN O
. BC2GM076347404 . O
. . O O

We BC2GM024566497 PRP O
found BC2GM024566497 VBD O
that BC2GM024566497 IN O
RXR BC2GM024566497 NNP O
and BC2GM024566497 CC O
VDR BC2GM024566497 NNP O
transactivated BC2GM024566497 VBD O
selectively BC2GM024566497 RB O
from BC2GM024566497 IN O
VDRE-linked BC2GM024566497 NNP O
templates BC2GM024566497 NNS O
exclusively BC2GM024566497 RB O
as BC2GM024566497 IN O
a BC2GM024566497 DT O
heterodimeric BC2GM024566497 NN O
complex BC2GM024566497 NN O
, BC2GM024566497 , O
since BC2GM024566497 IN O
neither BC2GM024566497 DT O
receptor BC2GM024566497 NN O
alone BC2GM024566497 RB O
enhanced BC2GM024566497 JJ O
transcription BC2GM024566497 NN O
in BC2GM024566497 IN O
vitro BC2GM024566497 NN O
. BC2GM024566497 . O
. . O O

CLINICAL BC2GM016704905 JJ O
FEATURES BC2GM016704905 NNP O
: BC2GM016704905 : O
This BC2GM016704905 DT O
30-yr-old BC2GM016704905 JJ O
gravida BC2GM016704905 NN O
V BC2GM016704905 NNP O
para BC2GM016704905 VBZ O
0 BC2GM016704905 CD O
woman BC2GM016704905 NN O
presented BC2GM016704905 VBN O
to BC2GM016704905 TO O
the BC2GM016704905 DT O
anaesthesia BC2GM016704905 JJ O
consultation BC2GM016704905 NN O
clinic BC2GM016704905 NN O
at BC2GM016704905 IN O
37-wk BC2GM016704905 JJ O
gestation BC2GM016704905 NN O
to BC2GM016704905 TO O
discuss BC2GM016704905 VB O
pain BC2GM016704905 NN O
relief BC2GM016704905 NN O
options BC2GM016704905 NNS O
for BC2GM016704905 IN O
labour BC2GM016704905 NN O
and BC2GM016704905 CC O
delivery BC2GM016704905 NN O
. BC2GM016704905 . O
. . O O

VP4 BC2GM056776703 NNP O
differentially BC2GM056776703 RB O
regulates BC2GM056776703 VBZ O
TRAF2 BC2GM056776703 NNP O
signaling BC2GM056776703 NN O
, BC2GM056776703 , O
disengaging BC2GM056776703 VBG O
JNK BC2GM056776703 NNP O
activation BC2GM056776703 NN O
while BC2GM056776703 IN O
directing BC2GM056776703 VBG O
NF-kappa BC2GM056776703 NNP O
B BC2GM056776703 NNP O
to BC2GM056776703 TO O
effect BC2GM056776703 NN O
rotavirus-specific BC2GM056776703 JJ O
cellular BC2GM056776703 JJ O
responses BC2GM056776703 NNS O
. BC2GM056776703 . O
. . O O

The BC2GM035405200 DT O
LS BC2GM035405200 NNP O
gene BC2GM035405200 NN O
promoter BC2GM035405200 NN O
sequence BC2GM035405200 NN O
has BC2GM035405200 VBZ O
homology BC2GM035405200 VBN O
with BC2GM035405200 IN O
Escherichia BC2GM035405200 NNP O
coli BC2GM035405200 VBP O
promoter BC2GM035405200 NN O
sequences BC2GM035405200 NNS O
; BC2GM035405200 : O
its BC2GM035405200 PRP$ O
terminator BC2GM035405200 NN O
sequence BC2GM035405200 NN O
is BC2GM035405200 VBZ O
capable BC2GM035405200 JJ O
of BC2GM035405200 IN O
forming BC2GM035405200 VBG O
a BC2GM035405200 DT O
stem-and-loop BC2GM035405200 JJ O
structure BC2GM035405200 NN O
. BC2GM035405200 . O
. . O O

If BC2GM005891745 IN O
vascular BC2GM005891745 JJ O
induction BC2GM005891745 NN O
between BC2GM005891745 IN O
a BC2GM005891745 DT O
vascular BC2GM005891745 JJ O
carrier BC2GM005891745 NN O
and BC2GM005891745 CC O
the BC2GM005891745 DT O
selected BC2GM005891745 VBN O
jejunal BC2GM005891745 NN O
segment BC2GM005891745 NN O
is BC2GM005891745 VBZ O
done BC2GM005891745 VBN O
as BC2GM005891745 IN O
a BC2GM005891745 DT O
kind BC2GM005891745 NN O
of BC2GM005891745 IN O
flap BC2GM005891745 JJ O
prefabrication BC2GM005891745 NN O
, BC2GM005891745 , O
the BC2GM005891745 DT O
jejunal BC2GM005891745 JJ O
interposition BC2GM005891745 NN O
flap BC2GM005891745 NN O
can BC2GM005891745 MD O
be BC2GM005891745 VB O
used BC2GM005891745 VBN O
without BC2GM005891745 IN O
the BC2GM005891745 DT O
need BC2GM005891745 NN O
for BC2GM005891745 IN O
complex BC2GM005891745 JJ O
microsurgery BC2GM005891745 NN O
. BC2GM005891745 . O
. . O O

Based BC2GM029565037 VBN O
on BC2GM029565037 IN O
these BC2GM029565037 DT O
results BC2GM029565037 NNS O
, BC2GM029565037 , O
it BC2GM029565037 PRP O
has BC2GM029565037 VBZ O
been BC2GM029565037 VBN O
concluded BC2GM029565037 VBN O
that BC2GM029565037 IN O
an BC2GM029565037 DT O
IPFSA BC2GM029565037 NNP O
can BC2GM029565037 MD O
promote BC2GM029565037 VB O
the BC2GM029565037 DT O
healing BC2GM029565037 NN O
process BC2GM029565037 NN O
in BC2GM029565037 IN O
the BC2GM029565037 DT O
avascular BC2GM029565037 JJ O
zone BC2GM029565037 NN O
of BC2GM029565037 IN O
a BC2GM029565037 DT O
torn BC2GM029565037 JJ O
meniscus BC2GM029565037 NN O
in BC2GM029565037 IN O
rabbits BC2GM029565037 NNS O
and BC2GM029565037 CC O
that BC2GM029565037 DT O
systemic BC2GM029565037 JJ O
vascularity BC2GM029565037 NN O
to BC2GM029565037 TO O
the BC2GM029565037 DT O
synovium BC2GM029565037 NN O
or BC2GM029565037 CC O
the BC2GM029565037 DT O
meniscus BC2GM029565037 NN O
is BC2GM029565037 VBZ O
not BC2GM029565037 RB O
essential BC2GM029565037 JJ O
for BC2GM029565037 IN O
healing BC2GM029565037 VBG O
to BC2GM029565037 TO O
occur BC2GM029565037 VB O
. BC2GM029565037 . O
. . O O

Heterotrimeric BC2GM013076333 JJ O
guanine BC2GM013076333 NN O
nucleotide-binding BC2GM013076333 JJ O
proteins BC2GM013076333 NNS O
( BC2GM013076333 ( O
G-proteins BC2GM013076333 NNP O
) BC2GM013076333 ) O
function BC2GM013076333 NN O
as BC2GM013076333 IN O
signal BC2GM013076333 JJ O
transducers BC2GM013076333 NNS O
for BC2GM013076333 IN O
a BC2GM013076333 DT O
variety BC2GM013076333 NN O
of BC2GM013076333 IN O
hormone-coupled BC2GM013076333 JJ O
enzyme BC2GM013076333 NN O
and BC2GM013076333 CC O
ion BC2GM013076333 NN O
transport BC2GM013076333 NN O
systems BC2GM013076333 NNS O
in BC2GM013076333 IN O
eukaryotic BC2GM013076333 JJ O
cells BC2GM013076333 NNS O
. BC2GM013076333 . O
. . O O

No BC2GM092638353 DT O
promoter BC2GM092638353 NN O
activity BC2GM092638353 NN O
could BC2GM092638353 MD O
be BC2GM092638353 VB O
detected BC2GM092638353 VBN O
with BC2GM092638353 IN O
various BC2GM092638353 JJ O
mouse BC2GM092638353 IN O
Fli-1 BC2GM092638353 JJ O
promoter-CAT BC2GM092638353 JJ O
constructs BC2GM092638353 NNS O
containing BC2GM092638353 VBG O
600 BC2GM092638353 CD O
bp BC2GM092638353 NN O
of BC2GM092638353 IN O
the BC2GM092638353 DT O
5 BC2GM092638353 CD O
' BC2GM092638353 POS O
flanking BC2GM092638353 JJ O
region BC2GM092638353 NN O
, BC2GM092638353 , O
the BC2GM092638353 DT O
complete BC2GM092638353 JJ O
exon BC2GM092638353 NN O
1 BC2GM092638353 CD O
, BC2GM092638353 , O
the BC2GM092638353 DT O
5 BC2GM092638353 CD O
' BC2GM092638353 POS O
end BC2GM092638353 NN O
of BC2GM092638353 IN O
intron BC2GM092638353 NN O
1 BC2GM092638353 CD O
and BC2GM092638353 CC O
/ BC2GM092638353 NNP O
or BC2GM092638353 CC O
retroviral BC2GM092638353 JJ O
LTR BC2GM092638353 NNP O
sequence BC2GM092638353 NN O
. BC2GM092638353 . O
. . O O

Coexpression BC2GM038872278 NN O
of BC2GM038872278 IN O
C BC2GM038872278 NNP O
/ BC2GM038872278 NNP O
EBP BC2GM038872278 NNP O
alpha BC2GM038872278 NN O
altered BC2GM038872278 VBD O
the BC2GM038872278 DT O
cell BC2GM038872278 NN O
specificity BC2GM038872278 NN O
. BC2GM038872278 . O
. . O O

Doxazosin BC2GM076461759 NNP O
produced BC2GM076461759 VBD O
increases BC2GM076461759 NNS O
in BC2GM076461759 IN O
both BC2GM076461759 DT O
mean BC2GM076461759 JJ O
and BC2GM076461759 CC O
maximum BC2GM076461759 JJ O
urinary BC2GM076461759 JJ O
flow BC2GM076461759 NN O
rates BC2GM076461759 NNS O
of BC2GM076461759 IN O
1.01 BC2GM076461759 CD O
ml BC2GM076461759 NNS O
/ BC2GM076461759 JJ O
s BC2GM076461759 NN O
and BC2GM076461759 CC O
3.2 BC2GM076461759 CD O
ml BC2GM076461759 NN O
/ BC2GM076461759 NNP O
s BC2GM076461759 NN O
respectively BC2GM076461759 RB O
, BC2GM076461759 , O
compared BC2GM076461759 VBN O
with BC2GM076461759 IN O
0.21 BC2GM076461759 CD O
ml BC2GM076461759 NNS O
/ BC2GM076461759 JJ O
s BC2GM076461759 NN O
and BC2GM076461759 CC O
2.2 BC2GM076461759 CD O
ml BC2GM076461759 NN O
/ BC2GM076461759 NNP O
s BC2GM076461759 NN O
on BC2GM076461759 IN O
placebo BC2GM076461759 NN O
. BC2GM076461759 . O
. . O O

Analysis BC2GM046414753 NN O
of BC2GM046414753 IN O
1 BC2GM046414753 CD O
Mb BC2GM046414753 NNP O
of BC2GM046414753 IN O
published BC2GM046414753 VBN O
sequence BC2GM046414753 NN O
from BC2GM046414753 IN O
the BC2GM046414753 DT O
region BC2GM046414753 NN O
of BC2GM046414753 IN O
conserved BC2GM046414753 VBN O
synteny BC2GM046414753 NN O
on BC2GM046414753 IN O
human BC2GM046414753 JJ O
chromosome BC2GM046414753 NN O
5q31-q33 BC2GM046414753 JJ O
identified BC2GM046414753 VBD O
45 BC2GM046414753 CD O
gene BC2GM046414753 NN O
candidates BC2GM046414753 NNS O
, BC2GM046414753 , O
including BC2GM046414753 VBG O
35 BC2GM046414753 CD O
expressed BC2GM046414753 JJ O
genes BC2GM046414753 NNS O
in BC2GM046414753 IN O
the BC2GM046414753 DT O
human BC2GM046414753 JJ O
IL-4 BC2GM046414753 NNP O
cytokine BC2GM046414753 NN O
gene BC2GM046414753 NN O
cluster BC2GM046414753 NN O
. BC2GM046414753 . O
. . O O

Nucleotide BC2GM018447830 NNP O
sequence BC2GM018447830 NN O
of BC2GM018447830 IN O
the BC2GM018447830 DT O
gag BC2GM018447830 JJ O
gene BC2GM018447830 NN O
and BC2GM018447830 CC O
gag-pol BC2GM018447830 JJ O
junction BC2GM018447830 NN O
of BC2GM018447830 IN O
feline BC2GM018447830 JJ O
leukemia BC2GM018447830 NN O
virus BC2GM018447830 NN O
. BC2GM018447830 . O
. . O O

The BC2GM096363851 DT O
subjects BC2GM096363851 NNS O
were BC2GM096363851 VBD O
started BC2GM096363851 VBN O
on BC2GM096363851 IN O
indomethacin BC2GM096363851 NN O
25 BC2GM096363851 CD O
mg BC2GM096363851 JJ O
thrice BC2GM096363851 JJ O
daily BC2GM096363851 RB O
. BC2GM096363851 . O
. . O O

The BC2GM076178142 DT O
effects BC2GM076178142 NNS O
of BC2GM076178142 IN O
pretreatment BC2GM076178142 NN O
with BC2GM076178142 IN O
the BC2GM076178142 DT O
non-competitive BC2GM076178142 JJ O
NMDA BC2GM076178142 NNP O
antagonist BC2GM076178142 NN O
( BC2GM076178142 ( O
+ BC2GM076178142 JJ O
) BC2GM076178142 ) O
MK-801 BC2GM076178142 NN O
on BC2GM076178142 IN O
the BC2GM076178142 DT O
behavioral BC2GM076178142 JJ O
alterations BC2GM076178142 NNS O
induced BC2GM076178142 VBN O
by BC2GM076178142 IN O
repeated BC2GM076178142 VBN O
restraint BC2GM076178142 NN O
stress BC2GM076178142 NN O
were BC2GM076178142 VBD O
investigated BC2GM076178142 VBN O
. BC2GM076178142 . O
. . O O

The BC2GM028886679 DT O
formation BC2GM028886679 NN O
of BC2GM028886679 IN O
tumorlike BC2GM028886679 JJ O
lesions BC2GM028886679 NNS O
in BC2GM028886679 IN O
the BC2GM028886679 DT O
cockroach BC2GM028886679 NN O
leucophaea BC2GM028886679 NN O
maderae BC2GM028886679 NN O
after BC2GM028886679 IN O
anal BC2GM028886679 JJ O
blockage BC2GM028886679 NN O
. BC2GM028886679 . O
. . O O

Also BC2GM082066284 RB O
, BC2GM082066284 , O
PTx BC2GM082066284 NNP O
had BC2GM082066284 VBD O
no BC2GM082066284 DT O
effect BC2GM082066284 NN O
on BC2GM082066284 IN O
shear-dependent BC2GM082066284 JJ O
activation BC2GM082066284 NN O
of BC2GM082066284 IN O
JNK BC2GM082066284 NNP O
. BC2GM082066284 . O
. . O O

HIV-2 BC2GM092581148 NNP O
in BC2GM092581148 IN O
Spain BC2GM092581148 NNP O
. BC2GM092581148 . O
. . O O

Site-directed BC2GM054844326 JJ O
mutagenesis BC2GM054844326 NN O
of BC2GM054844326 IN O
the BC2GM054844326 DT O
T4 BC2GM054844326 NNP O
endonuclease BC2GM054844326 NN O
V BC2GM054844326 NNP O
gene BC2GM054844326 NN O
: BC2GM054844326 : O
role BC2GM054844326 NN O
of BC2GM054844326 IN O
lysine-130 BC2GM054844326 NN O
. BC2GM054844326 . O
. . O O

The BC2GM059462976 DT O
composition BC2GM059462976 NN O
of BC2GM059462976 IN O
renal BC2GM059462976 JJ O
stones BC2GM059462976 NNS O
analysed BC2GM059462976 VBN O
by BC2GM059462976 IN O
infrared BC2GM059462976 JJ O
spectroscopy BC2GM059462976 NN O
. BC2GM059462976 . O
. . O O

The BC2GM068931709 DT O
unc-101 BC2GM068931709 JJ O
, BC2GM068931709 , O
sli-1 BC2GM068931709 JJ O
, BC2GM068931709 , O
and BC2GM068931709 CC O
rok-1 BC2GM068931709 JJ O
genes BC2GM068931709 NNS O
encode BC2GM068931709 VBD O
a BC2GM068931709 DT O
distinct BC2GM068931709 JJ O
set BC2GM068931709 NN O
of BC2GM068931709 IN O
negative BC2GM068931709 JJ O
regulators BC2GM068931709 NNS O
of BC2GM068931709 IN O
vulval BC2GM068931709 JJ O
differentiation BC2GM068931709 NN O
. BC2GM068931709 . O
. . O O

The BC2GM059504332 DT O
novel BC2GM059504332 JJ O
gene BC2GM059504332 NN O
spans BC2GM059504332 NNS O
16.7 BC2GM059504332 CD O
kb BC2GM059504332 NN O
of BC2GM059504332 IN O
genomic BC2GM059504332 JJ O
sequence BC2GM059504332 NN O
and BC2GM059504332 CC O
it BC2GM059504332 PRP O
is BC2GM059504332 VBZ O
formed BC2GM059504332 VBN O
of BC2GM059504332 IN O
11 BC2GM059504332 CD O
exons BC2GM059504332 NNS O
and BC2GM059504332 CC O
10 BC2GM059504332 CD O
intervening BC2GM059504332 NN O
introns BC2GM059504332 NNS O
. BC2GM059504332 . O
. . O O

In BC2GM090842010 IN O
the BC2GM090842010 DT O
present BC2GM090842010 JJ O
study BC2GM090842010 NN O
we BC2GM090842010 PRP O
have BC2GM090842010 VBP O
used BC2GM090842010 VBN O
Southern BC2GM090842010 NNP O
blot BC2GM090842010 NN O
analysis BC2GM090842010 NN O
to BC2GM090842010 TO O
demonstrate BC2GM090842010 VB O
that BC2GM090842010 DT O
TSG6 BC2GM090842010 NNP O
is BC2GM090842010 VBZ O
a BC2GM090842010 DT O
single-copy BC2GM090842010 JJ O
gene BC2GM090842010 NN O
in BC2GM090842010 IN O
the BC2GM090842010 DT O
human BC2GM090842010 JJ O
and BC2GM090842010 CC O
murine BC2GM090842010 JJ O
species BC2GM090842010 NNS O
. BC2GM090842010 . O
. . O O

Fetal BC2GM015790797 NNP O
PaO2 BC2GM015790797 NNP O
fell BC2GM015790797 VBD O
somewhat BC2GM015790797 RB O
during BC2GM015790797 IN O
the BC2GM015790797 DT O
recovery BC2GM015790797 NN O
stages BC2GM015790797 NNS O
in BC2GM015790797 IN O
both BC2GM015790797 DT O
NIT BC2GM015790797 NNP O
and BC2GM015790797 CC O
control BC2GM015790797 NN O
groups BC2GM015790797 NNS O
. BC2GM015790797 . O
. . O O

Patients BC2GM067787787 NNS O
in BC2GM067787787 IN O
the BC2GM067787787 DT O
mucinous BC2GM067787787 JJ O
cyst BC2GM067787787 NN O
group BC2GM067787787 NN O
had BC2GM067787787 VBD O
significantly BC2GM067787787 RB O
lower BC2GM067787787 JJR O
CA BC2GM067787787 NNP O
125 BC2GM067787787 CD O
cystic BC2GM067787787 JJ O
fluid BC2GM067787787 NN O
levels BC2GM067787787 NNS O
compared BC2GM067787787 VBN O
with BC2GM067787787 IN O
women BC2GM067787787 NNS O
with BC2GM067787787 IN O
endometriomas BC2GM067787787 NN O
and BC2GM067787787 CC O
dermoids BC2GM067787787 NNS O
( BC2GM067787787 ( O
P BC2GM067787787 NNP O
& BC2GM067787787 CC O
lt BC2GM067787787 NN O
; BC2GM067787787 : O
0.05 BC2GM067787787 CD O
) BC2GM067787787 ) O
. BC2GM067787787 . O
. . O O

A BC2GM074348497 DT O
400-bp BC2GM074348497 JJ O
fragment BC2GM074348497 NN O
( BC2GM074348497 ( O
bp BC2GM074348497 JJ O
-339 BC2GM074348497 NNP O
through BC2GM074348497 IN O
+71 BC2GM074348497 NNP O
) BC2GM074348497 ) O
of BC2GM074348497 IN O
the BC2GM074348497 DT O
CD22 BC2GM074348497 NNP O
promoter BC2GM074348497 NN O
region BC2GM074348497 NN O
was BC2GM074348497 VBD O
subcloned BC2GM074348497 VBN O
into BC2GM074348497 IN O
a BC2GM074348497 DT O
pGEM-chloramphenicol BC2GM074348497 JJ O
acetyltransferase BC2GM074348497 NN O
vector BC2GM074348497 NN O
and BC2GM074348497 CC O
after BC2GM074348497 IN O
transfection BC2GM074348497 NN O
into BC2GM074348497 IN O
B BC2GM074348497 NNP O
and BC2GM074348497 CC O
T BC2GM074348497 NNP O
cells BC2GM074348497 NNS O
was BC2GM074348497 VBD O
found BC2GM074348497 VBN O
to BC2GM074348497 TO O
be BC2GM074348497 VB O
active BC2GM074348497 JJ O
in BC2GM074348497 IN O
both BC2GM074348497 DT O
B BC2GM074348497 NNP O
and BC2GM074348497 CC O
T BC2GM074348497 NNP O
cells BC2GM074348497 NNS O
. BC2GM074348497 . O
. . O O

To BC2GM094642532 TO O
elucidate BC2GM094642532 VB O
the BC2GM094642532 DT O
mechanism BC2GM094642532 NN O
of BC2GM094642532 IN O
these BC2GM094642532 DT O
hormonal BC2GM094642532 JJ O
effects BC2GM094642532 NNS O
, BC2GM094642532 , O
we BC2GM094642532 PRP O
have BC2GM094642532 VBP O
studied BC2GM094642532 VBN O
the BC2GM094642532 DT O
regulatory BC2GM094642532 JJ O
regions BC2GM094642532 NNS O
of BC2GM094642532 IN O
the BC2GM094642532 DT O
PFK-2 BC2GM094642532 NNP O
gene BC2GM094642532 NN O
in BC2GM094642532 IN O
transfection BC2GM094642532 NN O
experiments BC2GM094642532 NNS O
. BC2GM094642532 . O
. . O O

Four BC2GM013203108 CD O
of BC2GM013203108 IN O
12 BC2GM013203108 CD O
patients BC2GM013203108 NNS O
( BC2GM013203108 ( O
33 BC2GM013203108 CD O
% BC2GM013203108 NN O
) BC2GM013203108 ) O
were BC2GM013203108 VBD O
initially BC2GM013203108 RB O
diagnosed BC2GM013203108 VBN O
as BC2GM013203108 IN O
having BC2GM013203108 VBG O
a BC2GM013203108 DT O
benign BC2GM013203108 JJ O
disease BC2GM013203108 NN O
( BC2GM013203108 ( O
false-negatives BC2GM013203108 NNS O
) BC2GM013203108 ) O
. BC2GM013203108 . O
. . O O

Recently BC2GM058126747 RB O
, BC2GM058126747 , O
we BC2GM058126747 PRP O
have BC2GM058126747 VBP O
demonstrated BC2GM058126747 VBN O
that BC2GM058126747 IN O
mouse BC2GM058126747 NN O
microglial BC2GM058126747 JJ O
cells BC2GM058126747 NNS O
, BC2GM058126747 , O
the BC2GM058126747 DT O
brain BC2GM058126747 NN O
macrophages BC2GM058126747 NNS O
, BC2GM058126747 , O
express BC2GM058126747 VB O
both BC2GM058126747 DT O
IL-15 BC2GM058126747 NNP O
and BC2GM058126747 CC O
IL-15 BC2GM058126747 NNP O
/ BC2GM058126747 NNP O
IL-2 BC2GM058126747 NNP O
receptors BC2GM058126747 NNS O
. BC2GM058126747 . O
. . O O

One BC2GM052567540 CD O
child BC2GM052567540 NN O
, BC2GM052567540 , O
recently BC2GM052567540 RB O
fed BC2GM052567540 VBN O
, BC2GM052567540 , O
vomited BC2GM052567540 VBD O
a BC2GM052567540 DT O
small BC2GM052567540 JJ O
amount BC2GM052567540 NN O
of BC2GM052567540 IN O
breast BC2GM052567540 NN O
milk BC2GM052567540 NN O
after BC2GM052567540 IN O
a BC2GM052567540 DT O
short BC2GM052567540 JJ O
period BC2GM052567540 NN O
of BC2GM052567540 IN O
crying BC2GM052567540 VBG O
and BC2GM052567540 CC O
apparently BC2GM052567540 RB O
had BC2GM052567540 VBD O
a BC2GM052567540 DT O
laryngospasm BC2GM052567540 NN O
, BC2GM052567540 , O
shown BC2GM052567540 VBN O
by BC2GM052567540 IN O
a BC2GM052567540 DT O
sudden BC2GM052567540 JJ O
drop BC2GM052567540 NN O
in BC2GM052567540 IN O
the BC2GM052567540 DT O
PtcO2 BC2GM052567540 NNP O
level BC2GM052567540 NN O
without BC2GM052567540 IN O
any BC2GM052567540 DT O
other BC2GM052567540 JJ O
signs BC2GM052567540 NNS O
of BC2GM052567540 IN O
discomfort BC2GM052567540 NN O
. BC2GM052567540 . O
. . O O

Finally BC2GM010201696 RB O
, BC2GM010201696 , O
in BC2GM010201696 IN O
samples BC2GM010201696 NNS O
obtained BC2GM010201696 VBN O
from BC2GM010201696 IN O
two BC2GM010201696 CD O
patients BC2GM010201696 NNS O
with BC2GM010201696 IN O
drug BC2GM010201696 NN O
refractory BC2GM010201696 NN O
ALL BC2GM010201696 NNP O
, BC2GM010201696 , O
BAC-derived BC2GM010201696 NNP O
probes BC2GM010201696 NNS O
applied BC2GM010201696 VBD O
to BC2GM010201696 TO O
archived BC2GM010201696 VB O
marrow BC2GM010201696 NN O
cells BC2GM010201696 NNS O
demonstrated BC2GM010201696 VBD O
that BC2GM010201696 IN O
a BC2GM010201696 DT O
breakpoint BC2GM010201696 NN O
occurred BC2GM010201696 VBD O
between BC2GM010201696 IN O
MDR1 BC2GM010201696 NNP O
and BC2GM010201696 CC O
sequences BC2GM010201696 NNS O
500-1000 BC2GM010201696 CD O
KB BC2GM010201696 NNP O
telomeric BC2GM010201696 NN O
to BC2GM010201696 TO O
MDR1 BC2GM010201696 NNP O
, BC2GM010201696 , O
consistent BC2GM010201696 NN O
with BC2GM010201696 IN O
a BC2GM010201696 DT O
random BC2GM010201696 NN O
chromosomal BC2GM010201696 JJ O
rearrangement BC2GM010201696 NN O
. BC2GM010201696 . O
. . O O

YACs BC2GM033682713 RB O
selected BC2GM033682713 VBN O
from BC2GM033682713 IN O
our BC2GM033682713 PRP$ O
contig BC2GM033682713 NN O
will BC2GM033682713 MD O
be BC2GM033682713 VB O
the BC2GM033682713 DT O
starting BC2GM033682713 JJ O
point BC2GM033682713 NN O
for BC2GM033682713 IN O
the BC2GM033682713 DT O
cloning BC2GM033682713 NN O
of BC2GM033682713 IN O
the BC2GM033682713 DT O
LGMD2B BC2GM033682713 NNP O
gene BC2GM033682713 NN O
and BC2GM033682713 CC O
thereby BC2GM033682713 RB O
establish BC2GM033682713 VB O
the BC2GM033682713 DT O
biological BC2GM033682713 JJ O
basis BC2GM033682713 NN O
for BC2GM033682713 IN O
this BC2GM033682713 DT O
form BC2GM033682713 NN O
of BC2GM033682713 IN O
muscular BC2GM033682713 JJ O
dystrophy BC2GM033682713 NN O
and BC2GM033682713 CC O
its BC2GM033682713 PRP$ O
relationship BC2GM033682713 NN O
with BC2GM033682713 IN O
the BC2GM033682713 DT O
other BC2GM033682713 JJ O
limb-girdle BC2GM033682713 JJ O
muscular BC2GM033682713 JJ O
dystrophies BC2GM033682713 NNS O
. BC2GM033682713 . O
. . O O

The BC2GM027315963 DT O
sequences BC2GM027315963 NNS O
of BC2GM027315963 IN O
two BC2GM027315963 CD O
previously BC2GM027315963 RB O
known BC2GM027315963 VBN O
tail BC2GM027315963 NN O
genes BC2GM027315963 NNS O
, BC2GM027315963 , O
R BC2GM027315963 NNP O
and BC2GM027315963 CC O
S BC2GM027315963 NNP O
, BC2GM027315963 , O
of BC2GM027315963 IN O
the BC2GM027315963 DT O
temperate BC2GM027315963 NN O
bacteriophage BC2GM027315963 NN O
P2 BC2GM027315963 NNP O
and BC2GM027315963 CC O
the BC2GM027315963 DT O
sequence BC2GM027315963 NN O
of BC2GM027315963 IN O
an BC2GM027315963 DT O
additional BC2GM027315963 JJ O
open BC2GM027315963 JJ O
reading BC2GM027315963 NN O
frame BC2GM027315963 NN O
( BC2GM027315963 ( O
orf-30 BC2GM027315963 JJ O
) BC2GM027315963 ) O
located BC2GM027315963 VBN O
between BC2GM027315963 IN O
S BC2GM027315963 NNP O
and BC2GM027315963 CC O
V BC2GM027315963 NNP O
, BC2GM027315963 , O
were BC2GM027315963 VBD O
determined BC2GM027315963 VBN O
. BC2GM027315963 . O
. . O O

In BC2GM014801779 IN O
this BC2GM014801779 DT O
cross-over BC2GM014801779 NN O
controlled BC2GM014801779 VBD O
study BC2GM014801779 NN O
, BC2GM014801779 , O
five BC2GM014801779 CD O
male BC2GM014801779 NN O
volunteers BC2GM014801779 NNS O
donated BC2GM014801779 VBD O
one BC2GM014801779 CD O
unit BC2GM014801779 NN O
of BC2GM014801779 IN O
red BC2GM014801779 JJ O
cells BC2GM014801779 NNS O
by BC2GM014801779 IN O
MCS BC2GM014801779 NNP O
and BC2GM014801779 CC O
one BC2GM014801779 CD O
unit BC2GM014801779 NN O
of BC2GM014801779 IN O
whole BC2GM014801779 JJ O
blood BC2GM014801779 NN O
by BC2GM014801779 IN O
the BC2GM014801779 DT O
conventional BC2GM014801779 JJ O
manual BC2GM014801779 JJ O
method BC2GM014801779 NN O
, BC2GM014801779 , O
3 BC2GM014801779 CD O
months BC2GM014801779 NNS O
apart BC2GM014801779 RB O
. BC2GM014801779 . O
. . O O

Sequence BC2GM097589583 NN O
analyses BC2GM097589583 NNS O
revealed BC2GM097589583 VBD O
a BC2GM097589583 DT O
partial BC2GM097589583 JJ O
941 BC2GM097589583 CD O
bp BC2GM097589583 NN O
cDNA BC2GM097589583 NN O
that BC2GM097589583 WDT O
encoded BC2GM097589583 VBD O
a BC2GM097589583 DT O
313-amino-acid BC2GM097589583 JJ O
polypeptide BC2GM097589583 NN O
. BC2GM097589583 . O
. . O O

Mutational BC2GM086602241 JJ O
analysis BC2GM086602241 NN O
of BC2GM086602241 IN O
the BC2GM086602241 DT O
putative BC2GM086602241 JJ O
effector BC2GM086602241 NN O
domain BC2GM086602241 NN O
of BC2GM086602241 IN O
the BC2GM086602241 DT O
GTP-binding BC2GM086602241 NNP O
Ypt1 BC2GM086602241 NNP O
protein BC2GM086602241 NN O
in BC2GM086602241 IN O
yeast BC2GM086602241 NN O
suggests BC2GM086602241 NNS O
specific BC2GM086602241 JJ O
regulation BC2GM086602241 NN O
by BC2GM086602241 IN O
a BC2GM086602241 DT O
novel BC2GM086602241 JJ O
GAP BC2GM086602241 NNP O
activity BC2GM086602241 NN O
. BC2GM086602241 . O
. . O O

Using BC2GM023306376 VBG O
lacZ-inducible BC2GM023306376 JJ O
T BC2GM023306376 NNP O
cells BC2GM023306376 NNS O
as BC2GM023306376 IN O
a BC2GM023306376 DT O
probe BC2GM023306376 NN O
, BC2GM023306376 , O
we BC2GM023306376 PRP O
screened BC2GM023306376 VBD O
a BC2GM023306376 DT O
splenic BC2GM023306376 JJ O
cDNA BC2GM023306376 NN O
library BC2GM023306376 NN O
in BC2GM023306376 IN O
transiently BC2GM023306376 RB O
transfected BC2GM023306376 VBN O
antigen-presenting BC2GM023306376 JJ O
cells BC2GM023306376 NNS O
( BC2GM023306376 ( O
APCs BC2GM023306376 NNP O
) BC2GM023306376 ) O
and BC2GM023306376 CC O
isolated BC2GM023306376 VBD O
a BC2GM023306376 DT O
cDNA BC2GM023306376 NN O
clone BC2GM023306376 NN O
that BC2GM023306376 WDT O
allowed BC2GM023306376 VBD O
expression BC2GM023306376 NN O
of BC2GM023306376 IN O
the BC2GM023306376 DT O
appropriate BC2GM023306376 JJ O
peptide BC2GM023306376 NN O
/ BC2GM023306376 NNP O
Kb BC2GM023306376 NNP O
MHC BC2GM023306376 NNP O
complex BC2GM023306376 NN O
in BC2GM023306376 IN O
APC BC2GM023306376 NNP O
. BC2GM023306376 . O
. . O O

This BC2GM068132374 DT O
residue BC2GM068132374 JJ O
, BC2GM068132374 , O
although BC2GM068132374 IN O
located BC2GM068132374 VBN O
55 BC2GM068132374 CD O
rather BC2GM068132374 RB O
than BC2GM068132374 IN O
35 BC2GM068132374 CD O
residues BC2GM068132374 NNS O
NH2-terminal BC2GM068132374 NNP O
of BC2GM068132374 IN O
the BC2GM068132374 DT O
essential BC2GM068132374 JJ O
glutamate BC2GM068132374 NN O
, BC2GM068132374 , O
is BC2GM068132374 VBZ O
undoubtedly BC2GM068132374 RB O
the BC2GM068132374 DT O
analog BC2GM068132374 NN O
of BC2GM068132374 IN O
the BC2GM068132374 DT O
second BC2GM068132374 JJ O
aspartate BC2GM068132374 NN O
of BC2GM068132374 IN O
the BC2GM068132374 DT O
Asp-Asp-35-Glu BC2GM068132374 NNP O
motif BC2GM068132374 NN O
found BC2GM068132374 VBN O
in BC2GM068132374 IN O
other BC2GM068132374 JJ O
family BC2GM068132374 NN O
members BC2GM068132374 NNS O
. BC2GM068132374 . O
. . O O

Previously BC2GM036373124 RB O
, BC2GM036373124 , O
a BC2GM036373124 DT O
cDNA BC2GM036373124 NN O
( BC2GM036373124 ( O
GT2 BC2GM036373124 NNP O
) BC2GM036373124 ) O
encoding BC2GM036373124 VBG O
this BC2GM036373124 DT O
protein BC2GM036373124 NN O
was BC2GM036373124 VBD O
isolated BC2GM036373124 VBN O
from BC2GM036373124 IN O
a BC2GM036373124 DT O
mouse BC2GM036373124 NN O
3T3-L1 BC2GM036373124 JJ O
adipocyte BC2GM036373124 NN O
library BC2GM036373124 NN O
and BC2GM036373124 CC O
was BC2GM036373124 VBD O
sequenced BC2GM036373124 VBN O
. BC2GM036373124 . O
. . O O

A BC2GM035382344 DT O
visibly BC2GM035382344 RB O
distinct BC2GM035382344 JJ O
muscular BC2GM035382344 JJ O
hypertrophy BC2GM035382344 NN O
( BC2GM035382344 ( O
mh BC2GM035382344 NN O
) BC2GM035382344 ) O
, BC2GM035382344 , O
commonly BC2GM035382344 RB O
known BC2GM035382344 VBN O
as BC2GM035382344 IN O
double BC2GM035382344 JJ O
muscling BC2GM035382344 NN O
, BC2GM035382344 , O
occurs BC2GM035382344 VBZ O
with BC2GM035382344 IN O
high BC2GM035382344 JJ O
frequency BC2GM035382344 NN O
in BC2GM035382344 IN O
the BC2GM035382344 DT O
Belgian BC2GM035382344 JJ O
Blue BC2GM035382344 NNP O
and BC2GM035382344 CC O
Piedmontese BC2GM035382344 NNP O
cattle BC2GM035382344 NNS O
breeds BC2GM035382344 NNS O
. BC2GM035382344 . O
. . O O

Transmission BC2GM052190930 NN O
of BC2GM052190930 IN O
mutans BC2GM052190930 NNS O
streptococci BC2GM052190930 VBP O
to BC2GM052190930 TO O
infants BC2GM052190930 NNS O
following BC2GM052190930 VBG O
short BC2GM052190930 JJ O
term BC2GM052190930 NN O
application BC2GM052190930 NN O
of BC2GM052190930 IN O
an BC2GM052190930 DT O
iodine-NaF BC2GM052190930 JJ O
solution BC2GM052190930 NN O
to BC2GM052190930 TO O
mothers BC2GM052190930 NNS O
' BC2GM052190930 POS O
dentition BC2GM052190930 NN O
. BC2GM052190930 . O
. . O O

The BC2GM040436094 DT O
specificity BC2GM040436094 NN O
and BC2GM040436094 CC O
sensitivity BC2GM040436094 NN O
of BC2GM040436094 IN O
this BC2GM040436094 DT O
method BC2GM040436094 NN O
( BC2GM040436094 ( O
limit BC2GM040436094 NN O
of BC2GM040436094 IN O
detection BC2GM040436094 NN O
in BC2GM040436094 IN O
plasma BC2GM040436094 NN O
0.025 BC2GM040436094 CD O
micrograms BC2GM040436094 NNS O
/ BC2GM040436094 VBP O
mL BC2GM040436094 NN O
and BC2GM040436094 CC O
< BC2GM040436094 NN O
or BC2GM040436094 CC O
= BC2GM040436094 $ O
0.0125 BC2GM040436094 CD O
micrograms BC2GM040436094 NNS O
/ BC2GM040436094 VBP O
mL BC2GM040436094 NN O
for BC2GM040436094 IN O
febantel BC2GM040436094 NN O
and BC2GM040436094 CC O
its BC2GM040436094 PRP$ O
metabolites BC2GM040436094 NNS O
, BC2GM040436094 , O
respectively BC2GM040436094 RB O
) BC2GM040436094 ) O
were BC2GM040436094 VBD O
sufficiently BC2GM040436094 RB O
high BC2GM040436094 JJ O
to BC2GM040436094 TO O
enable BC2GM040436094 VB O
us BC2GM040436094 PRP O
to BC2GM040436094 TO O
characterize BC2GM040436094 VB O
the BC2GM040436094 DT O
time BC2GM040436094 NN O
course BC2GM040436094 NN O
of BC2GM040436094 IN O
the BC2GM040436094 DT O
drug BC2GM040436094 NN O
in BC2GM040436094 IN O
the BC2GM040436094 DT O
plasma BC2GM040436094 NN O
after BC2GM040436094 IN O
oral BC2GM040436094 JJ O
administration BC2GM040436094 NN O
of BC2GM040436094 IN O
therapeutic BC2GM040436094 JJ O
doses BC2GM040436094 NNS O
to BC2GM040436094 TO O
sheep BC2GM040436094 VB O
. BC2GM040436094 . O
. . O O

Schottky-barrier BC2GM086450359 NNP O
heights BC2GM086450359 NNS O
of BC2GM086450359 IN O
Ti BC2GM086450359 NNP O
and BC2GM086450359 CC O
TiSi2 BC2GM086450359 NNP O
on BC2GM086450359 IN O
n-type BC2GM086450359 JJ O
and BC2GM086450359 CC O
p-type BC2GM086450359 JJ O
Si BC2GM086450359 NNP O
( BC2GM086450359 ( O
100 BC2GM086450359 CD O
) BC2GM086450359 ) O
. BC2GM086450359 . O
. . O O

Overexpression BC2GM059522936 NN O
of BC2GM059522936 IN O
a BC2GM059522936 DT O
HIF-1alpha BC2GM059522936 JJ O
construct BC2GM059522936 NN O
with BC2GM059522936 IN O
deletions BC2GM059522936 NNS O
of BC2GM059522936 IN O
the BC2GM059522936 DT O
basic BC2GM059522936 JJ O
domain BC2GM059522936 NN O
and BC2GM059522936 CC O
carboxy BC2GM059522936 JJ O
terminus BC2GM059522936 NN O
blocked BC2GM059522936 VBD O
reporter BC2GM059522936 JJ O
gene BC2GM059522936 NN O
activation BC2GM059522936 NN O
by BC2GM059522936 IN O
endogenous BC2GM059522936 JJ O
HIF-1 BC2GM059522936 NNP O
in BC2GM059522936 IN O
hypoxic BC2GM059522936 NN O
cells BC2GM059522936 NNS O
. BC2GM059522936 . O
. . O O

Biol BC2GM008918951 NNP O
. BC2GM008918951 . O
. . O O

RESULTS BC2GM075900069 NN O
: BC2GM075900069 : O
After BC2GM075900069 IN O
3 BC2GM075900069 CD O
weeks BC2GM075900069 NNS O
of BC2GM075900069 IN O
therapy BC2GM075900069 NN O
, BC2GM075900069 , O
the BC2GM075900069 DT O
patient BC2GM075900069 NN O
had BC2GM075900069 VBD O
an BC2GM075900069 DT O
increase BC2GM075900069 NN O
in BC2GM075900069 IN O
platelet BC2GM075900069 NN O
count BC2GM075900069 NN O
from BC2GM075900069 IN O
a BC2GM075900069 DT O
baseline BC2GM075900069 NN O
of BC2GM075900069 IN O
5,000 BC2GM075900069 CD O
to BC2GM075900069 TO O
8,000 BC2GM075900069 CD O
/ BC2GM075900069 NNS O
microliter BC2GM075900069 NN O
to BC2GM075900069 TO O
a BC2GM075900069 DT O
maximal BC2GM075900069 JJ O
level BC2GM075900069 NN O
of BC2GM075900069 IN O
33,000 BC2GM075900069 CD O
/ BC2GM075900069 JJ O
microliter BC2GM075900069 NN O
. BC2GM075900069 . O
. . O O

In BC2GM033055956 IN O
this BC2GM033055956 DT O
report BC2GM033055956 NN O
we BC2GM033055956 PRP O
describe BC2GM033055956 VBP O
the BC2GM033055956 DT O
structure BC2GM033055956 NN O
and BC2GM033055956 CC O
DNA BC2GM033055956 NNP O
sequence BC2GM033055956 NN O
of BC2GM033055956 IN O
transcriptional BC2GM033055956 JJ O
control BC2GM033055956 NN O
regions BC2GM033055956 NNS O
from BC2GM033055956 IN O
both BC2GM033055956 DT O
human BC2GM033055956 JJ O
and BC2GM033055956 CC O
Wistar-rat BC2GM033055956 NNP O
single BC2GM033055956 JJ O
copy BC2GM033055956 NN O
EGF BC2GM033055956 NNP O
genes BC2GM033055956 NNS O
and BC2GM033055956 CC O
their BC2GM033055956 PRP$ O
functional BC2GM033055956 JJ O
analysis BC2GM033055956 NN O
in BC2GM033055956 IN O
epithelial BC2GM033055956 JJ O
cell BC2GM033055956 NN O
cultures BC2GM033055956 NNS O
. BC2GM033055956 . O
. . O O

The BC2GM004899991 DT O
three BC2GM004899991 CD O
proteins BC2GM004899991 NNS O
copurified BC2GM004899991 VBN O
through BC2GM004899991 IN O
several BC2GM004899991 JJ O
biochemical BC2GM004899991 JJ O
fractionation BC2GM004899991 NN O
steps BC2GM004899991 NNS O
and BC2GM004899991 CC O
could BC2GM004899991 MD O
be BC2GM004899991 VB O
coimmunoprecipitated BC2GM004899991 VBN O
by BC2GM004899991 IN O
using BC2GM004899991 VBG O
antibodies BC2GM004899991 NNS O
against BC2GM004899991 IN O
GCD1 BC2GM004899991 NNP O
or BC2GM004899991 CC O
GCD2 BC2GM004899991 NNP O
. BC2GM004899991 . O
. . O O

Relation BC2GM030055087 NN O
between BC2GM030055087 IN O
clinical BC2GM030055087 JJ O
and BC2GM030055087 CC O
roentgenological BC2GM030055087 JJ O
scores BC2GM030055087 NNS O
and BC2GM030055087 CC O
measures BC2GM030055087 NNS O
of BC2GM030055087 IN O
lung BC2GM030055087 NN O
function BC2GM030055087 NN O
in BC2GM030055087 IN O
cystic BC2GM030055087 JJ O
fibrosis BC2GM030055087 NN O
, BC2GM030055087 , O
with BC2GM030055087 IN O
special BC2GM030055087 JJ O
reference BC2GM030055087 NN O
to BC2GM030055087 TO O
pulmonary BC2GM030055087 JJ O
Xenon133 BC2GM030055087 NNP O
elimination BC2GM030055087 NN O
. BC2GM030055087 . O
. . O O

These BC2GM099053917 DT O
results BC2GM099053917 NNS O
suggest BC2GM099053917 VBP O
that BC2GM099053917 IN O
1a BC2GM099053917 CD O
, BC2GM099053917 , O
which BC2GM099053917 WDT O
also BC2GM099053917 RB O
interacts BC2GM099053917 VBZ O
independently BC2GM099053917 RB O
with BC2GM099053917 IN O
the BC2GM099053917 DT O
ER BC2GM099053917 NNP O
and BC2GM099053917 CC O
viral BC2GM099053917 JJ O
RNA BC2GM099053917 NNP O
, BC2GM099053917 , O
is BC2GM099053917 VBZ O
a BC2GM099053917 DT O
key BC2GM099053917 JJ O
organizer BC2GM099053917 NN O
of BC2GM099053917 IN O
RNA BC2GM099053917 NNP O
replication BC2GM099053917 NN O
complex BC2GM099053917 NN O
assembly BC2GM099053917 NN O
. BC2GM099053917 . O
. . O O

Efficacy BC2GM045332665 NN O
was BC2GM045332665 VBD O
evaluated BC2GM045332665 VBN O
in BC2GM045332665 IN O
24 BC2GM045332665 CD O
patients BC2GM045332665 NNS O
, BC2GM045332665 , O
of BC2GM045332665 IN O
whom BC2GM045332665 WP O
eight BC2GM045332665 CD O
received BC2GM045332665 VBN O
RD BC2GM045332665 NNP O
and BC2GM045332665 CC O
16 BC2GM045332665 CD O
SD BC2GM045332665 NNP O
. BC2GM045332665 . O
. . O O

Short-term BC2GM045351753 JJ O
growth BC2GM045351753 NN O
: BC2GM045351753 : O
rhythms BC2GM045351753 NN O
, BC2GM045351753 , O
chaos BC2GM045351753 NN O
, BC2GM045351753 , O
or BC2GM045351753 CC O
noise BC2GM045351753 RB O
? BC2GM045351753 . O
. BC2GM045351753 . O
. . O O

We BC2GM029915444 PRP O
report BC2GM029915444 VBP O
nine BC2GM029915444 CD O
consecutive BC2GM029915444 JJ O
cases BC2GM029915444 NNS O
of BC2GM029915444 IN O
ACB BC2GM029915444 NNP O
, BC2GM029915444 , O
which BC2GM029915444 WDT O
occurred BC2GM029915444 VBD O
in BC2GM029915444 IN O
five BC2GM029915444 CD O
males BC2GM029915444 NNS O
and BC2GM029915444 CC O
four BC2GM029915444 CD O
females BC2GM029915444 NNS O
and BC2GM029915444 CC O
were BC2GM029915444 VBD O
detected BC2GM029915444 VBN O
in BC2GM029915444 IN O
11,159 BC2GM029915444 CD O
routine BC2GM029915444 JJ O
spiral BC2GM029915444 NN O
CT BC2GM029915444 NNP O
examinations BC2GM029915444 NNS O
of BC2GM029915444 IN O
the BC2GM029915444 DT O
chest BC2GM029915444 NN O
, BC2GM029915444 , O
performed BC2GM029915444 VBD O
between BC2GM029915444 IN O
1994 BC2GM029915444 CD O
and BC2GM029915444 CC O
1998 BC2GM029915444 CD O
. BC2GM029915444 . O
. . O O

Effects BC2GM089807452 NNS O
of BC2GM089807452 IN O
dexamethasone BC2GM089807452 NN O
on BC2GM089807452 IN O
the BC2GM089807452 DT O
development BC2GM089807452 NN O
of BC2GM089807452 IN O
radiation BC2GM089807452 NN O
nephropathy BC2GM089807452 NN O
in BC2GM089807452 IN O
the BC2GM089807452 DT O
rat BC2GM089807452 NN O
. BC2GM089807452 . O
. . O O

The BC2GM050726449 DT O
classic BC2GM050726449 JJ O
sterol BC2GM050726449 NN O
regulatory BC2GM050726449 JJ O
cis BC2GM050726449 NN O
element BC2GM050726449 NN O
( BC2GM050726449 ( O
sre-1 BC2GM050726449 JJ O
) BC2GM050726449 ) O
in BC2GM050726449 IN O
the BC2GM050726449 DT O
LDL BC2GM050726449 NNP O
receptor BC2GM050726449 NN O
promoter BC2GM050726449 NN O
mediates BC2GM050726449 NNS O
sterol BC2GM050726449 VBP O
regulatory BC2GM050726449 JJ O
element BC2GM050726449 NN O
binding BC2GM050726449 VBG O
protein BC2GM050726449 NN O
( BC2GM050726449 ( O
SREBP BC2GM050726449 NNP O
) BC2GM050726449 ) O
-binding BC2GM050726449 NN O
and BC2GM050726449 CC O
the BC2GM050726449 DT O
effects BC2GM050726449 NNS O
of BC2GM050726449 IN O
insulin BC2GM050726449 NN O
and BC2GM050726449 CC O
platelet BC2GM050726449 NN O
derived BC2GM050726449 VBD O
growth BC2GM050726449 NN O
factor BC2GM050726449 NN O
( BC2GM050726449 ( O
PDGF BC2GM050726449 NNP O
) BC2GM050726449 ) O
. BC2GM050726449 . O
. . O O

Biopsy BC2GM021905510 NNP O
of BC2GM021905510 IN O
the BC2GM021905510 DT O
lesion BC2GM021905510 NN O
revealed BC2GM021905510 VBD O
granulomatous BC2GM021905510 JJ O
inflammation BC2GM021905510 NN O
and BC2GM021905510 CC O
numerous BC2GM021905510 JJ O
septate BC2GM021905510 NN O
hyphae BC2GM021905510 NN O
. BC2GM021905510 . O
. . O O

Making BC2GM038333674 VBG O
sense BC2GM038333674 NN O
out BC2GM038333674 IN O
of BC2GM038333674 IN O
oxygen BC2GM038333674 NN O
sensor BC2GM038333674 NN O
. BC2GM038333674 . O
. . O O

A BC2GM048180696 DT O
small BC2GM048180696 JJ O
molecule BC2GM048180696 NN O
ILK BC2GM048180696 NNP O
inhibitor BC2GM048180696 NN O
suppresses BC2GM048180696 VBZ O
the BC2GM048180696 DT O
phosphorylation BC2GM048180696 NN O
of BC2GM048180696 IN O
PKB BC2GM048180696 NNP O
at BC2GM048180696 IN O
the BC2GM048180696 DT O
Ser-473 BC2GM048180696 NNP O
but BC2GM048180696 CC O
not BC2GM048180696 RB O
the BC2GM048180696 DT O
Thr-308 BC2GM048180696 NNP O
site BC2GM048180696 NN O
in BC2GM048180696 IN O
the BC2GM048180696 DT O
PTEN BC2GM048180696 NNP O
mutant BC2GM048180696 JJ O
cells BC2GM048180696 NNS O
. BC2GM048180696 . O
. . O O

After BC2GM032297274 IN O
a BC2GM032297274 DT O
1-h BC2GM032297274 JJ O
rest BC2GM032297274 NN O
( BC2GM032297274 ( O
for BC2GM032297274 IN O
T2 BC2GM032297274 NNP O
return BC2GM032297274 NN O
to BC2GM032297274 TO O
baseline BC2GM032297274 VB O
) BC2GM032297274 ) O
, BC2GM032297274 , O
subjects BC2GM032297274 NNS O
repeated BC2GM032297274 VBD O
the BC2GM032297274 DT O
5-min BC2GM032297274 JJ O
protocol BC2GM032297274 NN O
, BC2GM032297274 , O
followed BC2GM032297274 VBN O
by BC2GM032297274 IN O
a BC2GM032297274 DT O
final BC2GM032297274 JJ O
MRI BC2GM032297274 NNP O
/ BC2GM032297274 NNP O
MRS BC2GM032297274 NNP O
. BC2GM032297274 . O
. . O O

Patients BC2GM007462529 NNS O
with BC2GM007462529 IN O
the BC2GM007462529 DT O
chronic BC2GM007462529 JJ O
photosensitivity BC2GM007462529 NN O
dermatitis BC2GM007462529 NN O
with BC2GM007462529 IN O
actinic BC2GM007462529 JJ O
reticuloid BC2GM007462529 NN O
syndrome BC2GM007462529 NN O
have BC2GM007462529 VBP O
high BC2GM007462529 JJ O
total BC2GM007462529 JJ O
serum BC2GM007462529 NN O
IgE BC2GM007462529 NNP O
concentrations BC2GM007462529 NNS O
. BC2GM007462529 . O
. . O O

Human BC2GM077096663 NNP O
plastin BC2GM077096663 NN O
genes BC2GM077096663 NNS O
. BC2GM077096663 . O
. . O O

C BC2GM089563862 NNP O
/ BC2GM089563862 NNP O
EBP BC2GM089563862 NNP O
delta BC2GM089563862 NN O
( BC2GM089563862 ( O
NFIL-6 BC2GM089563862 NNP O
beta BC2GM089563862 NN O
) BC2GM089563862 ) O
was BC2GM089563862 VBD O
not BC2GM089563862 RB O
detected BC2GM089563862 VBN O
in BC2GM089563862 IN O
complexes BC2GM089563862 NNS O
utilizing BC2GM089563862 VBG O
extracts BC2GM089563862 NNS O
from BC2GM089563862 IN O
the BC2GM089563862 DT O
IL-1 BC2GM089563862 NNP O
nonproducing BC2GM089563862 NN O
T BC2GM089563862 NNP O
cell BC2GM089563862 NN O
line BC2GM089563862 NN O
. BC2GM089563862 . O
. . O O

Fentanyl BC2GM041870029 NNP O
citrate BC2GM041870029 NN O
( BC2GM041870029 ( O
0.1 BC2GM041870029 CD O
mL BC2GM041870029 NN O
) BC2GM041870029 ) O
and BC2GM041870029 CC O
2H5-fentanyl BC2GM041870029 JJ O
( BC2GM041870029 ( O
internal BC2GM041870029 JJ O
standard BC2GM041870029 NN O
, BC2GM041870029 , O
0.05 BC2GM041870029 CD O
mL BC2GM041870029 NN O
, BC2GM041870029 , O
100 BC2GM041870029 CD O
mg BC2GM041870029 NN O
/ BC2GM041870029 NNP O
L BC2GM041870029 NNP O
) BC2GM041870029 ) O
were BC2GM041870029 VBD O
extracted BC2GM041870029 VBN O
with BC2GM041870029 IN O
Toxi-A BC2GM041870029 NNP O
tubes BC2GM041870029 NNS O
( BC2GM041870029 ( O
Toxi-Lab BC2GM041870029 NNP O
, BC2GM041870029 , O
Irvine BC2GM041870029 NNP O
, BC2GM041870029 , O
CA BC2GM041870029 NNP O
) BC2GM041870029 ) O
and BC2GM041870029 CC O
analyzed BC2GM041870029 VBN O
by BC2GM041870029 IN O
gas BC2GM041870029 NN O
chromatography-mass BC2GM041870029 NN O
spectrometry BC2GM041870029 NN O
. BC2GM041870029 . O
. . O O

Cardiovascular BC2GM015327471 JJ O
drug BC2GM015327471 NN O
use BC2GM015327471 NN O
and BC2GM015327471 CC O
hospitalizations BC2GM015327471 NNS O
attributable BC2GM015327471 JJ O
to BC2GM015327471 TO O
type BC2GM015327471 VB O
2 BC2GM015327471 CD O
diabetes BC2GM015327471 NNS O
. BC2GM015327471 . O
. . O O

We BC2GM084139818 PRP O
have BC2GM084139818 VBP O
utilized BC2GM084139818 VBN O
transient BC2GM084139818 JJ O
transfections BC2GM084139818 NNS O
, BC2GM084139818 , O
mutation BC2GM084139818 NN O
analysis BC2GM084139818 NN O
, BC2GM084139818 , O
electromobility BC2GM084139818 NN O
gel-shifts BC2GM084139818 NNS O
, BC2GM084139818 , O
and BC2GM084139818 CC O
immunoblot BC2GM084139818 NN O
analysis BC2GM084139818 NN O
to BC2GM084139818 TO O
test BC2GM084139818 VB O
the BC2GM084139818 DT O
hypothesis BC2GM084139818 NN O
that BC2GM084139818 IN O
expression BC2GM084139818 NN O
of BC2GM084139818 IN O
the BC2GM084139818 DT O
CTalpha BC2GM084139818 NNP O
gene BC2GM084139818 NN O
is BC2GM084139818 VBZ O
controlled BC2GM084139818 VBN O
in BC2GM084139818 IN O
part BC2GM084139818 NN O
by BC2GM084139818 IN O
the BC2GM084139818 DT O
binding BC2GM084139818 NN O
of BC2GM084139818 IN O
three BC2GM084139818 CD O
trans-acting BC2GM084139818 JJ O
nuclear BC2GM084139818 JJ O
factors BC2GM084139818 NNS O
, BC2GM084139818 , O
Sp1 BC2GM084139818 NNP O
, BC2GM084139818 , O
Sp2 BC2GM084139818 NNP O
, BC2GM084139818 , O
and BC2GM084139818 CC O
Sp3 BC2GM084139818 NNP O
. BC2GM084139818 . O
. . O O

Cox BC2GM035842115 NNP O
proportional BC2GM035842115 JJ O
hazard BC2GM035842115 NN O
analysis BC2GM035842115 NN O
identified BC2GM035842115 VBN O
dialysis BC2GM035842115 NN O
modality BC2GM035842115 NN O
and BC2GM035842115 CC O
pre-dialysis BC2GM035842115 NN O
UV BC2GM035842115 NNP O
of BC2GM035842115 IN O
less BC2GM035842115 JJR O
than BC2GM035842115 IN O
1,000 BC2GM035842115 CD O
ml BC2GM035842115 JJ O
/ BC2GM035842115 NNP O
m2 BC2GM035842115 NN O
per BC2GM035842115 IN O
24 BC2GM035842115 CD O
h BC2GM035842115 NN O
as BC2GM035842115 IN O
the BC2GM035842115 DT O
only BC2GM035842115 JJ O
significant BC2GM035842115 JJ O
risk BC2GM035842115 NN O
factors BC2GM035842115 NNS O
for BC2GM035842115 IN O
UV BC2GM035842115 NNP O
survival BC2GM035842115 NN O
. BC2GM035842115 . O
. . O O

New BC2GM010682095 NNP O
TB BC2GM010682095 NNP O
respirator BC2GM010682095 NN O
standards BC2GM010682095 NNS O
mean BC2GM010682095 VBP O
more BC2GM010682095 JJR O
choices BC2GM010682095 NNS O
at BC2GM010682095 IN O
less BC2GM010682095 JJR O
cost BC2GM010682095 NN O
. BC2GM010682095 . O
. . O O

In BC2GM092245108 IN O
this BC2GM092245108 DT O
study BC2GM092245108 NN O
, BC2GM092245108 , O
we BC2GM092245108 PRP O
show BC2GM092245108 VBP O
that BC2GM092245108 IN O
the BC2GM092245108 DT O
activating BC2GM092245108 VBG O
effect BC2GM092245108 NN O
of BC2GM092245108 IN O
this BC2GM092245108 DT O
mutation BC2GM092245108 NN O
is BC2GM092245108 VBZ O
not BC2GM092245108 RB O
the BC2GM092245108 DT O
result BC2GM092245108 NN O
of BC2GM092245108 IN O
creating BC2GM092245108 VBG O
an BC2GM092245108 DT O
exonic BC2GM092245108 JJ O
splicing BC2GM092245108 NN O
enhancer BC2GM092245108 NN O
( BC2GM092245108 ( O
ESE BC2GM092245108 NNP O
) BC2GM092245108 ) O
or BC2GM092245108 CC O
disrupting BC2GM092245108 VBG O
a BC2GM092245108 DT O
putative BC2GM092245108 JJ O
secondary BC2GM092245108 JJ O
structure BC2GM092245108 NN O
. BC2GM092245108 . O
. . O O

Using BC2GM095257968 VBG O
beta BC2GM095257968 JJ O
1-AR-luciferase BC2GM095257968 JJ O
reporter BC2GM095257968 NN O
recombinants BC2GM095257968 NNS O
, BC2GM095257968 , O
we BC2GM095257968 PRP O
have BC2GM095257968 VBP O
previously BC2GM095257968 RB O
determined BC2GM095257968 VBN O
that BC2GM095257968 IN O
important BC2GM095257968 JJ O
beta BC2GM095257968 NN O
1-AR BC2GM095257968 JJ O
genetic BC2GM095257968 JJ O
elements BC2GM095257968 NNS O
controlling BC2GM095257968 VBG O
expression BC2GM095257968 NN O
within BC2GM095257968 IN O
the BC2GM095257968 DT O
C6 BC2GM095257968 NNP O
glioma BC2GM095257968 NN O
cell BC2GM095257968 NN O
line BC2GM095257968 NN O
are BC2GM095257968 VBP O
contained BC2GM095257968 VBN O
within BC2GM095257968 IN O
the BC2GM095257968 DT O
region BC2GM095257968 NN O
-396 BC2GM095257968 NN O
to BC2GM095257968 TO O
-299 BC2GM095257968 VB O
, BC2GM095257968 , O
relative BC2GM095257968 VB O
to BC2GM095257968 TO O
the BC2GM095257968 DT O
translational BC2GM095257968 JJ O
start BC2GM095257968 NN O
site BC2GM095257968 NN O
. BC2GM095257968 . O
. . O O

Similar BC2GM059417476 JJ O
to BC2GM059417476 TO O
what BC2GM059417476 WP O
was BC2GM059417476 VBD O
observed BC2GM059417476 VBN O
for BC2GM059417476 IN O
P. BC2GM059417476 NNP O
putida BC2GM059417476 NN O
, BC2GM059417476 , O
a BC2GM059417476 DT O
psrA BC2GM059417476 NN O
null BC2GM059417476 JJ O
mutant BC2GM059417476 NN O
of BC2GM059417476 IN O
P. BC2GM059417476 NNP O
aeruginosa BC2GM059417476 NN O
also BC2GM059417476 RB O
showed BC2GM059417476 VBD O
a BC2GM059417476 DT O
90 BC2GM059417476 CD O
% BC2GM059417476 NN O
reduction BC2GM059417476 NN O
in BC2GM059417476 IN O
rpoS BC2GM059417476 JJ O
promoter BC2GM059417476 NN O
activity BC2GM059417476 NN O
; BC2GM059417476 : O
both BC2GM059417476 DT O
mutants BC2GM059417476 NNS O
could BC2GM059417476 MD O
be BC2GM059417476 VB O
complemented BC2GM059417476 VBN O
for BC2GM059417476 IN O
rpoS BC2GM059417476 JJ O
promoter BC2GM059417476 NN O
activity BC2GM059417476 NN O
when BC2GM059417476 WRB O
the BC2GM059417476 DT O
psrA BC2GM059417476 NN O
gene BC2GM059417476 NN O
was BC2GM059417476 VBD O
provided BC2GM059417476 VBN O
in BC2GM059417476 IN O
trans BC2GM059417476 NNS O
. BC2GM059417476 . O
psrA BC2GM059417476 JJ O
mutants BC2GM059417476 NNS O
of BC2GM059417476 IN O
both BC2GM059417476 DT O
Pseudomonas BC2GM059417476 NNP O
species BC2GM059417476 NNS O
lost BC2GM059417476 VBD O
the BC2GM059417476 DT O
ability BC2GM059417476 NN O
to BC2GM059417476 TO O
induce BC2GM059417476 VB O
rpoS BC2GM059417476 JJ O
expression BC2GM059417476 NN O
at BC2GM059417476 IN O
stationary BC2GM059417476 JJ O
phase BC2GM059417476 NN O
, BC2GM059417476 , O
but BC2GM059417476 CC O
they BC2GM059417476 PRP O
retained BC2GM059417476 VBD O
the BC2GM059417476 DT O
ability BC2GM059417476 NN O
to BC2GM059417476 TO O
produce BC2GM059417476 VB O
quorum-sensing BC2GM059417476 JJ O
autoinducer BC2GM059417476 NN O
molecules BC2GM059417476 NNS O
. BC2GM059417476 . O
. . O O

Characterization BC2GM081655876 NN O
of BC2GM081655876 IN O
regions BC2GM081655876 NNS O
of BC2GM081655876 IN O
fibronectin BC2GM081655876 NN O
besides BC2GM081655876 IN O
the BC2GM081655876 DT O
arginine-glycine-aspartic BC2GM081655876 JJ O
acid BC2GM081655876 JJ O
sequence BC2GM081655876 NN O
required BC2GM081655876 VBN O
for BC2GM081655876 IN O
adhesive BC2GM081655876 JJ O
function BC2GM081655876 NN O
of BC2GM081655876 IN O
the BC2GM081655876 DT O
cell-binding BC2GM081655876 JJ O
domain BC2GM081655876 NN O
using BC2GM081655876 VBG O
site-directed BC2GM081655876 JJ O
mutagenesis BC2GM081655876 NN O
. BC2GM081655876 . O
. . O O

Eight BC2GM021026668 CD O
of BC2GM021026668 IN O
the BC2GM021026668 DT O
17 BC2GM021026668 CD O
seropositive BC2GM021026668 JJ O
patients BC2GM021026668 NNS O
failed BC2GM021026668 VBD O
to BC2GM021026668 TO O
develop BC2GM021026668 VB O
detectable BC2GM021026668 JJ O
hepatitis BC2GM021026668 NN O
B BC2GM021026668 NNP O
surface BC2GM021026668 NN O
antibody BC2GM021026668 NN O
within BC2GM021026668 IN O
three BC2GM021026668 CD O
months BC2GM021026668 NNS O
of BC2GM021026668 IN O
the BC2GM021026668 DT O
third BC2GM021026668 JJ O
injection BC2GM021026668 NN O
compared BC2GM021026668 VBN O
with BC2GM021026668 IN O
only BC2GM021026668 RB O
one BC2GM021026668 CD O
of BC2GM021026668 IN O
the BC2GM021026668 DT O
18 BC2GM021026668 CD O
seronegative BC2GM021026668 JJ O
patients BC2GM021026668 NNS O
( BC2GM021026668 ( O
p BC2GM021026668 NN O
less BC2GM021026668 JJR O
than BC2GM021026668 IN O
0.01 BC2GM021026668 CD O
) BC2GM021026668 ) O
. BC2GM021026668 . O
. . O O

The BC2GM038580862 DT O
exon BC2GM038580862 NN O
sequences BC2GM038580862 NNS O
determined BC2GM038580862 VBD O
from BC2GM038580862 IN O
genomic BC2GM038580862 JJ O
DNA BC2GM038580862 NN O
sequencing BC2GM038580862 NN O
showed BC2GM038580862 VBD O
some BC2GM038580862 DT O
differences BC2GM038580862 NNS O
when BC2GM038580862 WRB O
compared BC2GM038580862 VBN O
to BC2GM038580862 TO O
the BC2GM038580862 DT O
published BC2GM038580862 VBN O
rat BC2GM038580862 NN O
GLUT2 BC2GM038580862 NNP O
cDNA BC2GM038580862 NN O
. BC2GM038580862 . O
. . O O

These BC2GM045860738 DT O
operons BC2GM045860738 NNS O
encode BC2GM045860738 VBP O
subunits BC2GM045860738 NNS O
of BC2GM045860738 IN O
photosystems BC2GM045860738 NNS O
I BC2GM045860738 PRP O
( BC2GM045860738 ( O
psa BC2GM045860738 NN O
) BC2GM045860738 ) O
and BC2GM045860738 CC O
II BC2GM045860738 NNP O
( BC2GM045860738 ( O
psb BC2GM045860738 NN O
) BC2GM045860738 ) O
, BC2GM045860738 , O
the BC2GM045860738 DT O
cytochrome BC2GM045860738 JJ O
bGf BC2GM045860738 NN O
complex BC2GM045860738 NN O
( BC2GM045860738 ( O
pet BC2GM045860738 NN O
) BC2GM045860738 ) O
, BC2GM045860738 , O
the BC2GM045860738 DT O
plastid BC2GM045860738 NN O
NAD BC2GM045860738 NNP O
( BC2GM045860738 ( O
P BC2GM045860738 NNP O
) BC2GM045860738 ) O
H BC2GM045860738 NNP O
dehydrogenase BC2GM045860738 NN O
( BC2GM045860738 ( O
ndh BC2GM045860738 JJ O
) BC2GM045860738 ) O
, BC2GM045860738 , O
and BC2GM045860738 CC O
the BC2GM045860738 DT O
unidentified BC2GM045860738 JJ O
open BC2GM045860738 JJ O
reading BC2GM045860738 NN O
frame BC2GM045860738 NN O
ycf9 BC2GM045860738 NN O
. BC2GM045860738 . O
. . O O

Six BC2GM014301582 NNP O
cDNAs BC2GM014301582 NN O
represent BC2GM014301582 NN O
human BC2GM014301582 JJ O
homologs BC2GM014301582 NNS O
of BC2GM014301582 IN O
genes BC2GM014301582 NNS O
known BC2GM014301582 VBN O
in BC2GM014301582 IN O
other BC2GM014301582 JJ O
species BC2GM014301582 NNS O
, BC2GM014301582 , O
namely BC2GM014301582 RB O
, BC2GM014301582 , O
mouse BC2GM014301582 NN O
HSPE71 BC2GM014301582 NNP O
, BC2GM014301582 , O
Rat BC2GM014301582 NNP O
RhoGAP BC2GM014301582 NNP O
protein BC2GM014301582 NN O
, BC2GM014301582 , O
S BC2GM014301582 NNP O
cerevisiae BC2GM014301582 NN O
leucyl BC2GM014301582 NN O
tRNA BC2GM014301582 NN O
synthetase BC2GM014301582 NN O
and BC2GM014301582 CC O
S BC2GM014301582 NNP O
cerevisiae BC2GM014301582 VBP O
chromosome BC2GM014301582 NN O
II BC2GM014301582 NNP O
ORF BC2GM014301582 NNP O
YBLO44W BC2GM014301582 NNP O
. BC2GM014301582 . O
. . O O

However BC2GM059750371 RB O
, BC2GM059750371 , O
it BC2GM059750371 PRP O
was BC2GM059750371 VBD O
observed BC2GM059750371 VBN O
that BC2GM059750371 IN O
storage BC2GM059750371 NN O
time BC2GM059750371 NN O
affected BC2GM059750371 VBD O
significantly BC2GM059750371 RB O
the BC2GM059750371 DT O
biochemical BC2GM059750371 JJ O
changes BC2GM059750371 NNS O
occurring BC2GM059750371 VBG O
in BC2GM059750371 IN O
the BC2GM059750371 DT O
constituents BC2GM059750371 NNS O
of BC2GM059750371 IN O
carrots BC2GM059750371 NNS O
exposed BC2GM059750371 VBN O
to BC2GM059750371 TO O
gamma-irradiation BC2GM059750371 NN O
. BC2GM059750371 . O
. . O O

Cytogenetic BC2GM020915741 JJ O
structures BC2GM020915741 NNS O
showed BC2GM020915741 VBD O
a BC2GM020915741 DT O
mixte BC2GM020915741 JJ O
karyotype BC2GM020915741 NN O
: BC2GM020915741 : O
mosaicim BC2GM020915741 NN O
46 BC2GM020915741 CD O
XX BC2GM020915741 NNP O
/ BC2GM020915741 VBD O
46 BC2GM020915741 CD O
XY BC2GM020915741 NN O
with BC2GM020915741 IN O
a BC2GM020915741 DT O
ratio BC2GM020915741 NN O
of BC2GM020915741 IN O
a BC2GM020915741 DT O
80 BC2GM020915741 CD O
/ BC2GM020915741 NN O
20 BC2GM020915741 CD O
. BC2GM020915741 . O
. . O O

Disorganization BC2GM098640095 NNP O
scores BC2GM098640095 NNS O
of BC2GM098640095 IN O
the BC2GM098640095 DT O
hypertrophy BC2GM098640095 NN O
zone BC2GM098640095 NN O
and BC2GM098640095 CC O
trabecular BC2GM098640095 JJ O
bone BC2GM098640095 NN O
were BC2GM098640095 VBD O
low BC2GM098640095 JJ O
, BC2GM098640095 , O
approaching BC2GM098640095 VBG O
normal BC2GM098640095 JJ O
( BC2GM098640095 ( O
P BC2GM098640095 NNP O
< BC2GM098640095 NNP O
0.05 BC2GM098640095 CD O
) BC2GM098640095 ) O
, BC2GM098640095 , O
for BC2GM098640095 IN O
turkey BC2GM098640095 NN O
poults BC2GM098640095 NNS O
fed BC2GM098640095 VBN O
on BC2GM098640095 IN O
diets BC2GM098640095 NNS O
with BC2GM098640095 IN O
phytase BC2GM098640095 NN O
supplementation BC2GM098640095 NN O
, BC2GM098640095 , O
and BC2GM098640095 CC O
tibial BC2GM098640095 JJ O
abnormality BC2GM098640095 NN O
scores BC2GM098640095 NNS O
were BC2GM098640095 VBD O
linearly BC2GM098640095 RB O
decreased BC2GM098640095 VBN O
( BC2GM098640095 ( O
P BC2GM098640095 NNP O
< BC2GM098640095 NNP O
0.001 BC2GM098640095 CD O
) BC2GM098640095 ) O
as BC2GM098640095 IN O
nP BC2GM098640095 JJ O
levels BC2GM098640095 NNS O
increased BC2GM098640095 VBN O
( BC2GM098640095 ( O
zero BC2GM098640095 CD O
score BC2GM098640095 NN O
is BC2GM098640095 VBZ O
considered BC2GM098640095 VBN O
normal BC2GM098640095 JJ O
) BC2GM098640095 ) O
. BC2GM098640095 . O
. . O O

The BC2GM075735017 DT O
presence BC2GM075735017 NN O
of BC2GM075735017 IN O
a BC2GM075735017 DT O
short BC2GM075735017 JJ O
( BC2GM075735017 ( O
70 BC2GM075735017 CD O
bp BC2GM075735017 NN O
) BC2GM075735017 ) O
intron BC2GM075735017 NN O
near BC2GM075735017 IN O
the BC2GM075735017 DT O
N-terminus BC2GM075735017 NNP O
of BC2GM075735017 IN O
the BC2GM075735017 DT O
atX BC2GM075735017 JJ O
gene BC2GM075735017 NN O
was BC2GM075735017 VBD O
predicted BC2GM075735017 VBN O
that BC2GM075735017 IN O
contains BC2GM075735017 VBZ O
the BC2GM075735017 DT O
canonical BC2GM075735017 JJ O
GT BC2GM075735017 NNP O
and BC2GM075735017 CC O
AG BC2GM075735017 NNP O
dinucleotides BC2GM075735017 NNS O
at BC2GM075735017 IN O
its BC2GM075735017 PRP$ O
5'- BC2GM075735017 JJ O
and BC2GM075735017 CC O
3'-splicing BC2GM075735017 JJ O
junctions BC2GM075735017 NNS O
. BC2GM075735017 . O
. . O O

In BC2GM081756425 IN O
vitro BC2GM081756425 JJ O
death BC2GM081756425 NN O
assays BC2GM081756425 NNS O
with BC2GM081756425 IN O
transient BC2GM081756425 JJ O
overexpression BC2GM081756425 NN O
of BC2GM081756425 IN O
deletion BC2GM081756425 NN O
constructs BC2GM081756425 NNS O
of BC2GM081756425 IN O
both BC2GM081756425 DT O
isoforms BC2GM081756425 NNS O
using BC2GM081756425 VBG O
beta-galactosidase BC2GM081756425 NN O
as BC2GM081756425 IN O
a BC2GM081756425 DT O
reporter BC2GM081756425 NN O
gene BC2GM081756425 NN O
in BC2GM081756425 IN O
MCF7 BC2GM081756425 NNP O
cells BC2GM081756425 NNS O
suggest BC2GM081756425 VBP O
the BC2GM081756425 DT O
following BC2GM081756425 NN O
: BC2GM081756425 : O
1 BC2GM081756425 CD O
) BC2GM081756425 ) O
the BC2GM081756425 DT O
nucleotide BC2GM081756425 JJ O
binding BC2GM081756425 NN O
domain BC2GM081756425 NN O
may BC2GM081756425 MD O
act BC2GM081756425 VB O
as BC2GM081756425 IN O
a BC2GM081756425 DT O
negative BC2GM081756425 JJ O
regulator BC2GM081756425 NN O
of BC2GM081756425 IN O
the BC2GM081756425 DT O
killing BC2GM081756425 VBG O
activity BC2GM081756425 NN O
of BC2GM081756425 IN O
DEFCAP BC2GM081756425 NNP O
; BC2GM081756425 : O
2 BC2GM081756425 CD O
) BC2GM081756425 ) O
the BC2GM081756425 DT O
LRR BC2GM081756425 NNP O
/ BC2GM081756425 NNP O
CARD BC2GM081756425 NNP O
represents BC2GM081756425 VBZ O
a BC2GM081756425 DT O
putative BC2GM081756425 JJ O
constitutively BC2GM081756425 RB O
active BC2GM081756425 JJ O
inducer BC2GM081756425 NN O
of BC2GM081756425 IN O
apoptosis BC2GM081756425 NN O
; BC2GM081756425 : O
3 BC2GM081756425 CD O
) BC2GM081756425 ) O
the BC2GM081756425 DT O
killing BC2GM081756425 VBG O
activity BC2GM081756425 NN O
of BC2GM081756425 IN O
LRR BC2GM081756425 NNP O
/ BC2GM081756425 NNP O
CARD BC2GM081756425 NNP O
is BC2GM081756425 VBZ O
inhibitable BC2GM081756425 JJ O
by BC2GM081756425 IN O
benzyloxycarbonyl-Val-Ala-Asp BC2GM081756425 NN O
( BC2GM081756425 ( O
OMe BC2GM081756425 NNP O
) BC2GM081756425 ) O
-fluoromethyl BC2GM081756425 VBP O
ketone BC2GM081756425 NN O
and BC2GM081756425 CC O
to BC2GM081756425 TO O
a BC2GM081756425 DT O
lesser BC2GM081756425 JJR O
extent BC2GM081756425 NN O
by BC2GM081756425 IN O
Asp-Glu-Val-Asp BC2GM081756425 NNP O
( BC2GM081756425 ( O
OMe BC2GM081756425 NNP O
) BC2GM081756425 ) O
-fluoromethyl BC2GM081756425 VBP O
ketone BC2GM081756425 NN O
; BC2GM081756425 : O
and BC2GM081756425 CC O
4 BC2GM081756425 CD O
) BC2GM081756425 ) O
the BC2GM081756425 DT O
CARD BC2GM081756425 NNP O
is BC2GM081756425 VBZ O
critical BC2GM081756425 JJ O
for BC2GM081756425 IN O
killing BC2GM081756425 VBG O
activity BC2GM081756425 NN O
of BC2GM081756425 IN O
DEFCAP BC2GM081756425 NNP O
. BC2GM081756425 . O
. . O O

However BC2GM061354086 RB O
, BC2GM061354086 , O
the BC2GM061354086 DT O
optimum BC2GM061354086 JJ O
compressive BC2GM061354086 JJ O
strength BC2GM061354086 NN O
reached BC2GM061354086 VBD O
values BC2GM061354086 NNS O
up BC2GM061354086 IN O
to BC2GM061354086 TO O
40 BC2GM061354086 CD O
% BC2GM061354086 NN O
higher BC2GM061354086 JJR O
than BC2GM061354086 IN O
CC-free BC2GM061354086 JJ O
samples BC2GM061354086 NNS O
. BC2GM061354086 . O
. . O O

Here BC2GM023722122 RB O
we BC2GM023722122 PRP O
demonstrate BC2GM023722122 VBP O
that BC2GM023722122 IN O
CD40 BC2GM023722122 NNP O
or BC2GM023722122 CC O
IgM BC2GM023722122 NNP O
receptor BC2GM023722122 NN O
stimulation BC2GM023722122 NN O
of BC2GM023722122 IN O
primary BC2GM023722122 JJ O
B BC2GM023722122 NNP O
cells BC2GM023722122 NNS O
results BC2GM023722122 NNS O
in BC2GM023722122 IN O
transactivation BC2GM023722122 NN O
of BC2GM023722122 IN O
this BC2GM023722122 DT O
enhancer BC2GM023722122 NN O
. BC2GM023722122 . O
. . O O

One BC2GM011727188 CD O
ORF BC2GM011727188 NNP O
extends BC2GM011727188 VBZ O
from BC2GM011727188 IN O
nucleotides BC2GM011727188 NNS O
415 BC2GM011727188 CD O
to BC2GM011727188 TO O
1620 BC2GM011727188 CD O
, BC2GM011727188 , O
encodes BC2GM011727188 VBZ O
402 BC2GM011727188 CD O
amino BC2GM011727188 NN O
acids BC2GM011727188 NNS O
, BC2GM011727188 , O
and BC2GM011727188 CC O
is BC2GM011727188 VBZ O
preceded BC2GM011727188 VBN O
by BC2GM011727188 IN O
a BC2GM011727188 DT O
ribosome-binding BC2GM011727188 JJ O
site BC2GM011727188 NN O
. BC2GM011727188 . O
. . O O

Forty-five BC2GM050954712 JJ O
per BC2GM050954712 IN O
cent BC2GM050954712 NN O
of BC2GM050954712 IN O
the BC2GM050954712 DT O
dose BC2GM050954712 NN O
was BC2GM050954712 VBD O
excreted BC2GM050954712 VBN O
as BC2GM050954712 RB O
methyldopa BC2GM050954712 NN O
as BC2GM050954712 IN O
opposed BC2GM050954712 VBN O
to BC2GM050954712 TO O
18 BC2GM050954712 CD O
% BC2GM050954712 NN O
normally BC2GM050954712 RB O
seen BC2GM050954712 VBN O
after BC2GM050954712 IN O
oral BC2GM050954712 JJ O
methyldopa BC2GM050954712 NN O
dosages BC2GM050954712 NNS O
. BC2GM050954712 . O
. . O O

High-affinity BC2GM019111306 NNP O
binding BC2GM019111306 NN O
was BC2GM019111306 VBD O
also BC2GM019111306 RB O
observed BC2GM019111306 VBN O
with BC2GM019111306 IN O
recombinant BC2GM019111306 JJ O
SH2 BC2GM019111306 NNP O
domains BC2GM019111306 NNS O
from BC2GM019111306 IN O
v-src BC2GM019111306 JJ O
and BC2GM019111306 CC O
v-fps BC2GM019111306 JJ O
, BC2GM019111306 , O
raising BC2GM019111306 VBG O
the BC2GM019111306 DT O
possibility BC2GM019111306 NN O
of BC2GM019111306 IN O
protein-protein BC2GM019111306 JJ O
interactions BC2GM019111306 NNS O
between BC2GM019111306 IN O
various BC2GM019111306 JJ O
members BC2GM019111306 NNS O
of BC2GM019111306 IN O
the BC2GM019111306 DT O
cytoplasmic BC2GM019111306 JJ O
PTK BC2GM019111306 NNP O
family BC2GM019111306 NN O
. BC2GM019111306 . O
. . O O

The BC2GM053210179 DT O
aim BC2GM053210179 NN O
of BC2GM053210179 IN O
our BC2GM053210179 PRP$ O
study BC2GM053210179 NN O
was BC2GM053210179 VBD O
to BC2GM053210179 TO O
determine BC2GM053210179 VB O
whether BC2GM053210179 IN O
exercise BC2GM053210179 NN O
training BC2GM053210179 NN O
can BC2GM053210179 MD O
augment BC2GM053210179 VB O
left BC2GM053210179 JJ O
ventricular BC2GM053210179 JJ O
diastolic BC2GM053210179 NN O
filling BC2GM053210179 NN O
at BC2GM053210179 IN O
rest BC2GM053210179 NN O
and BC2GM053210179 CC O
during BC2GM053210179 IN O
exercise BC2GM053210179 NN O
in BC2GM053210179 IN O
patients BC2GM053210179 NNS O
with BC2GM053210179 IN O
ischemic BC2GM053210179 JJ O
cardiomyopathy BC2GM053210179 NN O
and BC2GM053210179 CC O
whether BC2GM053210179 IN O
any BC2GM053210179 DT O
correlation BC2GM053210179 NN O
exists BC2GM053210179 VBZ O
between BC2GM053210179 IN O
changes BC2GM053210179 NNS O
in BC2GM053210179 IN O
diastolic BC2GM053210179 JJ O
filling BC2GM053210179 NN O
and BC2GM053210179 CC O
changes BC2GM053210179 NNS O
in BC2GM053210179 IN O
exercise BC2GM053210179 NN O
tolerance BC2GM053210179 NN O
. BC2GM053210179 . O
. . O O

Western BC2GM059008483 JJ O
blot BC2GM059008483 NN O
analyses BC2GM059008483 NNS O
reveals BC2GM059008483 VBP O
that BC2GM059008483 IN O
cJun BC2GM059008483 NN O
and BC2GM059008483 CC O
the BC2GM059008483 DT O
C BC2GM059008483 NNP O
/ BC2GM059008483 NNP O
EBP BC2GM059008483 NNP O
family BC2GM059008483 NN O
member BC2GM059008483 NN O
C BC2GM059008483 NNP O
/ BC2GM059008483 NNP O
EBP-beta BC2GM059008483 NNP O
are BC2GM059008483 VBP O
physiologically BC2GM059008483 RB O
relevant BC2GM059008483 JJ O
transcription BC2GM059008483 NN O
factors BC2GM059008483 NNS O
whose BC2GM059008483 WP$ O
expression BC2GM059008483 NN O
corresponds BC2GM059008483 VBZ O
with BC2GM059008483 IN O
mda-7 BC2GM059008483 JJ O
mRNA BC2GM059008483 NN O
expression BC2GM059008483 NN O
. BC2GM059008483 . O
. . O O

The BC2GM082618608 DT O
rate BC2GM082618608 NN O
of BC2GM082618608 IN O
decrease BC2GM082618608 NN O
of BC2GM082618608 IN O
PRA BC2GM082618608 NNP O
after BC2GM082618608 IN O
REM BC2GM082618608 NNP O
onset BC2GM082618608 VBD O
closely BC2GM082618608 RB O
approximates BC2GM082618608 VBZ O
the BC2GM082618608 DT O
most BC2GM082618608 RBS O
recent BC2GM082618608 JJ O
estimations BC2GM082618608 NNS O
of BC2GM082618608 IN O
PRA BC2GM082618608 NNP O
half-life BC2GM082618608 NN O
, BC2GM082618608 , O
which BC2GM082618608 WDT O
suggests BC2GM082618608 VBZ O
that BC2GM082618608 IN O
REM BC2GM082618608 NNP O
onset BC2GM082618608 NN O
is BC2GM082618608 VBZ O
associated BC2GM082618608 VBN O
with BC2GM082618608 IN O
a BC2GM082618608 DT O
virtual BC2GM082618608 JJ O
cessation BC2GM082618608 NN O
in BC2GM082618608 IN O
renin BC2GM082618608 NN O
production BC2GM082618608 NN O
. BC2GM082618608 . O
. . O O

Interaction BC2GM076681368 NN O
of BC2GM076681368 IN O
the BC2GM076681368 DT O
v-rel BC2GM076681368 JJ O
protein BC2GM076681368 NN O
with BC2GM076681368 IN O
an BC2GM076681368 DT O
NF-kappa BC2GM076681368 JJ O
B BC2GM076681368 NNP O
DNA BC2GM076681368 NNP O
binding BC2GM076681368 VBG O
site BC2GM076681368 NN O
. BC2GM076681368 . O
. . O O

Incubation BC2GM008093196 NN O
of BC2GM008093196 IN O
HeLa BC2GM008093196 NNP O
cell BC2GM008093196 NN O
cytoplasmic BC2GM008093196 JJ O
extracts BC2GM008093196 NNS O
with BC2GM008093196 IN O
a BC2GM008093196 DT O
purified BC2GM008093196 JJ O
recombinant BC2GM008093196 JJ O
glutathione BC2GM008093196 NN O
S-transferase-raf BC2GM008093196 NNP O
fusion BC2GM008093196 NN O
protein BC2GM008093196 NN O
in BC2GM008093196 IN O
the BC2GM008093196 DT O
presence BC2GM008093196 NN O
of BC2GM008093196 IN O
ATP BC2GM008093196 NNP O
released BC2GM008093196 VBD O
active BC2GM008093196 JJ O
NF-kappa BC2GM008093196 NNP O
B BC2GM008093196 NNP O
that BC2GM008093196 WDT O
could BC2GM008093196 MD O
be BC2GM008093196 VB O
detected BC2GM008093196 VBN O
by BC2GM008093196 IN O
electrophoretic BC2GM008093196 JJ O
gel BC2GM008093196 NN O
mobility BC2GM008093196 NN O
shift BC2GM008093196 NN O
assay BC2GM008093196 NN O
. BC2GM008093196 . O
. . O O

A BC2GM008296773 DT O
poly BC2GM008296773 NN O
( BC2GM008296773 ( O
ortho BC2GM008296773 JJ O
ester BC2GM008296773 NN O
) BC2GM008296773 ) O
designed BC2GM008296773 VBN O
for BC2GM008296773 IN O
combined BC2GM008296773 JJ O
ocular BC2GM008296773 JJ O
delivery BC2GM008296773 NN O
of BC2GM008296773 IN O
dexamethasone BC2GM008296773 NN O
sodium BC2GM008296773 NN O
phosphate BC2GM008296773 NN O
and BC2GM008296773 CC O
5-fluorouracil BC2GM008296773 JJ O
: BC2GM008296773 : O
subconjunctival BC2GM008296773 JJ O
tolerance BC2GM008296773 NN O
and BC2GM008296773 CC O
in BC2GM008296773 IN O
vitro BC2GM008296773 JJ O
release BC2GM008296773 NN O
. BC2GM008296773 . O
. . O O

The BC2GM087385719 DT O
best BC2GM087385719 JJS O
sequences BC2GM087385719 NNS O
for BC2GM087385719 IN O
pelvic BC2GM087385719 NN O
study BC2GM087385719 NN O
are BC2GM087385719 VBP O
, BC2GM087385719 , O
in BC2GM087385719 IN O
our BC2GM087385719 PRP$ O
experience BC2GM087385719 NN O
, BC2GM087385719 , O
IR BC2GM087385719 NNP O
or BC2GM087385719 CC O
short BC2GM087385719 JJ O
TR BC2GM087385719 NNP O
spin-echo BC2GM087385719 NN O
for BC2GM087385719 IN O
T1-weighted BC2GM087385719 JJ O
images BC2GM087385719 NNS O
, BC2GM087385719 , O
and BC2GM087385719 CC O
spin-echo BC2GM087385719 NN O
with BC2GM087385719 IN O
1200 BC2GM087385719 CD O
TR BC2GM087385719 NNP O
for BC2GM087385719 IN O
T2 BC2GM087385719 NNP O
images BC2GM087385719 NNS O
. BC2GM087385719 . O
. . O O

The BC2GM060341382 DT O
pregnancies BC2GM060341382 NNS O
were BC2GM060341382 VBD O
terminated BC2GM060341382 VBN O
at BC2GM060341382 IN O
19 BC2GM060341382 CD O
and BC2GM060341382 CC O
12 BC2GM060341382 CD O
weeks BC2GM060341382 NNS O
of BC2GM060341382 IN O
gestation BC2GM060341382 NN O
, BC2GM060341382 , O
respectively BC2GM060341382 RB O
. BC2GM060341382 . O
. . O O

PMA BC2GM001234519 NNP O
produced BC2GM001234519 VBD O
similar BC2GM001234519 JJ O
results BC2GM001234519 NNS O
, BC2GM001234519 , O
but BC2GM001234519 CC O
the BC2GM001234519 DT O
induction BC2GM001234519 NN O
of BC2GM001234519 IN O
the BC2GM001234519 DT O
WT BC2GM001234519 NNP O
AP1 BC2GM001234519 NNP O
c-jun BC2GM001234519 JJ O
promoter-CAT BC2GM001234519 NN O
plasmid BC2GM001234519 NN O
was BC2GM001234519 VBD O
smaller BC2GM001234519 JJR O
. BC2GM001234519 . O
. . O O

Expression BC2GM001605780 NN O
of BC2GM001605780 IN O
the BC2GM001605780 DT O
E2 BC2GM001605780 NNP O
protein BC2GM001605780 NN O
resulted BC2GM001605780 VBD O
in BC2GM001605780 IN O
rapid BC2GM001605780 JJ O
repression BC2GM001605780 NN O
of BC2GM001605780 IN O
HPV BC2GM001605780 NNP O
E6 BC2GM001605780 NNP O
and BC2GM001605780 CC O
E7 BC2GM001605780 NNP O
expression BC2GM001605780 NN O
, BC2GM001605780 , O
followed BC2GM001605780 VBD O
approximately BC2GM001605780 RB O
12 BC2GM001605780 CD O
h BC2GM001605780 NNS O
later BC2GM001605780 RB O
by BC2GM001605780 IN O
profound BC2GM001605780 JJ O
inhibition BC2GM001605780 NN O
of BC2GM001605780 IN O
cellular BC2GM001605780 JJ O
DNA BC2GM001605780 NNP O
synthesis BC2GM001605780 NN O
. BC2GM001605780 . O
. . O O

Reversal BC2GM092587242 NNP O
of BC2GM092587242 IN O
mefloquine BC2GM092587242 NN O
resistance BC2GM092587242 NN O
in BC2GM092587242 IN O
rodent BC2GM092587242 JJ O
Plasmodium BC2GM092587242 NN O
. BC2GM092587242 . O
. . O O

In BC2GM069080186 IN O
the BC2GM069080186 DT O
virus-infected BC2GM069080186 JJ O
cells BC2GM069080186 NNS O
, BC2GM069080186 , O
translation BC2GM069080186 NN O
of BC2GM069080186 IN O
the BC2GM069080186 DT O
M1 BC2GM069080186 NNP O
protein BC2GM069080186 NN O
was BC2GM069080186 VBD O
reduced BC2GM069080186 VBN O
to BC2GM069080186 TO O
10 BC2GM069080186 CD O
to BC2GM069080186 TO O
20 BC2GM069080186 CD O
% BC2GM069080186 NN O
of BC2GM069080186 IN O
that BC2GM069080186 DT O
of BC2GM069080186 IN O
the BC2GM069080186 DT O
wild-type BC2GM069080186 JJ O
virus BC2GM069080186 NN O
; BC2GM069080186 : O
however BC2GM069080186 RB O
, BC2GM069080186 , O
the BC2GM069080186 DT O
translation BC2GM069080186 NN O
of BC2GM069080186 IN O
neither BC2GM069080186 CC O
the BC2GM069080186 DT O
nucleoprotein BC2GM069080186 JJ O
nor BC2GM069080186 CC O
NS1 BC2GM069080186 NNP O
was BC2GM069080186 VBD O
significantly BC2GM069080186 RB O
interfered BC2GM069080186 VBN O
with BC2GM069080186 IN O
, BC2GM069080186 , O
indicating BC2GM069080186 VBG O
the BC2GM069080186 DT O
important BC2GM069080186 JJ O
role BC2GM069080186 NN O
of BC2GM069080186 IN O
NS1 BC2GM069080186 NNP O
in BC2GM069080186 IN O
translational BC2GM069080186 JJ O
stimulation BC2GM069080186 NN O
of BC2GM069080186 IN O
the BC2GM069080186 DT O
M1 BC2GM069080186 NNP O
protein BC2GM069080186 NN O
. BC2GM069080186 . O
. . O O

Transfection BC2GM008334952 NN O
of BC2GM008334952 IN O
both BC2GM008334952 DT O
Calu-6 BC2GM008334952 NNP O
and BC2GM008334952 CC O
JEG-3 BC2GM008334952 NNP O
cells BC2GM008334952 NNS O
with BC2GM008334952 IN O
a BC2GM008334952 DT O
PKA BC2GM008334952 NNP O
expression BC2GM008334952 NN O
vector BC2GM008334952 NN O
resulted BC2GM008334952 VBD O
in BC2GM008334952 IN O
a BC2GM008334952 DT O
10-fold BC2GM008334952 JJ O
induction BC2GM008334952 NN O
of BC2GM008334952 IN O
human BC2GM008334952 JJ O
renin BC2GM008334952 JJ O
transcriptional BC2GM008334952 JJ O
activity BC2GM008334952 NN O
in BC2GM008334952 IN O
constructs BC2GM008334952 NNS O
containing BC2GM008334952 VBG O
the BC2GM008334952 DT O
native BC2GM008334952 NN O
or BC2GM008334952 CC O
consensus BC2GM008334952 NN O
CRE BC2GM008334952 NNPS O
and BC2GM008334952 CC O
5-fold BC2GM008334952 JJ O
activation BC2GM008334952 NN O
in BC2GM008334952 IN O
a BC2GM008334952 DT O
construct BC2GM008334952 NN O
containing BC2GM008334952 VBG O
a BC2GM008334952 DT O
nonfunctional BC2GM008334952 JJ O
CRE BC2GM008334952 NNP O
. BC2GM008334952 . O
. . O O

Cough-CPR BC2GM084436440 NNP O
, BC2GM084436440 , O
a BC2GM084436440 DT O
deep BC2GM084436440 JJ O
rhythmic BC2GM084436440 NN O
forceful BC2GM084436440 JJ O
cough BC2GM084436440 NN O
repeated BC2GM084436440 VBD O
30-60 BC2GM084436440 JJ O
times BC2GM084436440 NNS O
per BC2GM084436440 IN O
minute BC2GM084436440 NN O
, BC2GM084436440 , O
can BC2GM084436440 MD O
be BC2GM084436440 VB O
an BC2GM084436440 DT O
effective BC2GM084436440 JJ O
resuscitative BC2GM084436440 NN O
technique BC2GM084436440 NN O
during BC2GM084436440 IN O
emergencies BC2GM084436440 NNS O
occurring BC2GM084436440 VBG O
in BC2GM084436440 IN O
the BC2GM084436440 DT O
cardiac BC2GM084436440 JJ O
catheterization BC2GM084436440 NN O
laboratory BC2GM084436440 NN O
. BC2GM084436440 . O
. . O O

The BC2GM001533580 DT O
thalamic BC2GM001533580 JJ O
SD BC2GM001533580 NNP O
was BC2GM001533580 VBD O
regularly BC2GM001533580 RB O
triggered BC2GM001533580 VBN O
by BC2GM001533580 IN O
short BC2GM001533580 JJ O
( BC2GM001533580 ( O
0.02-0.05 BC2GM001533580 JJ O
s BC2GM001533580 NN O
) BC2GM001533580 ) O
high-frequency BC2GM001533580 NN O
( BC2GM001533580 ( O
200-500 BC2GM001533580 JJ O
Hz BC2GM001533580 NNP O
) BC2GM001533580 ) O
ES BC2GM001533580 NNP O
of BC2GM001533580 IN O
the BC2GM001533580 DT O
parietal BC2GM001533580 JJ O
cortical BC2GM001533580 JJ O
surface BC2GM001533580 NN O
. BC2GM001533580 . O
. . O O

Here BC2GM054468941 RB O
we BC2GM054468941 PRP O
show BC2GM054468941 VBP O
that BC2GM054468941 DT O
inhibition BC2GM054468941 NN O
occurs BC2GM054468941 VBZ O
with BC2GM054468941 IN O
a BC2GM054468941 DT O
NS1-Rev BC2GM054468941 JJ O
chimera BC2GM054468941 NN O
in BC2GM054468941 IN O
which BC2GM054468941 WDT O
the BC2GM054468941 DT O
78 BC2GM054468941 CD O
amino-terminal BC2GM054468941 JJ O
amino BC2GM054468941 NN O
acids BC2GM054468941 NNS O
of BC2GM054468941 IN O
the BC2GM054468941 DT O
NS1A BC2GM054468941 NNP O
protein BC2GM054468941 NN O
comprising BC2GM054468941 VBG O
its BC2GM054468941 PRP$ O
entire BC2GM054468941 JJ O
RNA-binding BC2GM054468941 JJ O
domain BC2GM054468941 NN O
is BC2GM054468941 VBZ O
deleted BC2GM054468941 VBN O
, BC2GM054468941 , O
thereby BC2GM054468941 RB O
establishing BC2GM054468941 VBG O
that BC2GM054468941 IN O
this BC2GM054468941 DT O
carboxyl BC2GM054468941 JJ O
portion BC2GM054468941 NN O
of BC2GM054468941 IN O
the BC2GM054468941 DT O
NS1A BC2GM054468941 NNP O
protein BC2GM054468941 NN O
can BC2GM054468941 MD O
function BC2GM054468941 VB O
as BC2GM054468941 IN O
an BC2GM054468941 DT O
independent BC2GM054468941 JJ O
effector BC2GM054468941 NN O
domain BC2GM054468941 NN O
. BC2GM054468941 . O
. . O O

Mean BC2GM069583481 NNP O
CD4 BC2GM069583481 NNP O
percentages BC2GM069583481 NNS O
were BC2GM069583481 VBD O
lower BC2GM069583481 JJR O
postpartum BC2GM069583481 NN O
( BC2GM069583481 ( O
21.9 BC2GM069583481 CD O
+ BC2GM069583481 NN O
/ BC2GM069583481 NNP O
- BC2GM069583481 : O
3.4 BC2GM069583481 CD O
) BC2GM069583481 ) O
than BC2GM069583481 IN O
prepartum BC2GM069583481 NN O
( BC2GM069583481 ( O
45.1 BC2GM069583481 CD O
+ BC2GM069583481 NN O
/ BC2GM069583481 NNP O
- BC2GM069583481 : O
6.7 BC2GM069583481 CD O
) BC2GM069583481 ) O
in BC2GM069583481 IN O
all BC2GM069583481 DT O
five BC2GM069583481 CD O
patients BC2GM069583481 NNS O
studied BC2GM069583481 VBN O
, BC2GM069583481 , O
although BC2GM069583481 IN O
proliferative BC2GM069583481 JJ O
responses BC2GM069583481 NNS O
to BC2GM069583481 TO O
the BC2GM069583481 DT O
mitogens BC2GM069583481 NNS O
phytohemagglutinin BC2GM069583481 NN O
and BC2GM069583481 CC O
pokeweed BC2GM069583481 NN O
were BC2GM069583481 VBD O
unchanged BC2GM069583481 JJ O
during BC2GM069583481 IN O
the BC2GM069583481 DT O
study BC2GM069583481 NN O
period BC2GM069583481 NN O
. BC2GM069583481 . O
. . O O

Kaposi BC2GM001825459 NNP O
's BC2GM001825459 POS O
eruptive BC2GM001825459 JJ O
disease BC2GM001825459 NN O
. BC2GM001825459 . O
. . O O

We BC2GM038488756 PRP O
tested BC2GM038488756 VBD O
the BC2GM038488756 DT O
hypothesis BC2GM038488756 NN O
that BC2GM038488756 IN O
PEH BC2GM038488756 NNP O
is BC2GM038488756 VBZ O
associated BC2GM038488756 VBN O
with BC2GM038488756 IN O
reductions BC2GM038488756 NNS O
in BC2GM038488756 IN O
TPR BC2GM038488756 NNP O
and BC2GM038488756 CC O
sympathetic BC2GM038488756 JJ O
nerve BC2GM038488756 NN O
activity BC2GM038488756 NN O
( BC2GM038488756 ( O
SNA BC2GM038488756 NNP O
) BC2GM038488756 ) O
. BC2GM038488756 . O
. . O O

Administration BC2GM085395991 NN O
of BC2GM085395991 IN O
FR BC2GM085395991 NNP O
34235 BC2GM085395991 CD O
reduced BC2GM085395991 VBD O
aortic BC2GM085395991 JJ O
blood BC2GM085395991 NN O
pressure BC2GM085395991 NN O
and BC2GM085395991 CC O
increased BC2GM085395991 VBD O
cardiac BC2GM085395991 JJ O
output BC2GM085395991 NN O
in BC2GM085395991 IN O
anesthetized BC2GM085395991 JJ O
dogs BC2GM085395991 NNS O
with BC2GM085395991 IN O
an BC2GM085395991 DT O
ameroid-induced BC2GM085395991 JJ O
coronary BC2GM085395991 JJ O
artery BC2GM085395991 NN O
occlusion BC2GM085395991 NN O
. BC2GM085395991 . O
. . O O

Pyknotic BC2GM018365165 JJ O
osteocytes BC2GM018365165 NNS O
increased BC2GM018365165 VBD O
at BC2GM018365165 IN O
12 BC2GM018365165 CD O
h BC2GM018365165 NN O
( BC2GM018365165 ( O
p BC2GM018365165 NN O
less BC2GM018365165 JJR O
than BC2GM018365165 IN O
0.01 BC2GM018365165 CD O
) BC2GM018365165 ) O
and BC2GM018365165 CC O
2 BC2GM018365165 CD O
days BC2GM018365165 NNS O
( BC2GM018365165 ( O
p BC2GM018365165 NN O
less BC2GM018365165 JJR O
than BC2GM018365165 IN O
0.001 BC2GM018365165 CD O
) BC2GM018365165 ) O
of BC2GM018365165 IN O
ischemia BC2GM018365165 NN O
. BC2GM018365165 . O
. . O O

Vav BC2GM069862303 NNP O
and BC2GM069862303 CC O
Dbl BC2GM069862303 NNP O
are BC2GM069862303 VBP O
members BC2GM069862303 NNS O
of BC2GM069862303 IN O
a BC2GM069862303 DT O
novel BC2GM069862303 JJ O
class BC2GM069862303 NN O
of BC2GM069862303 IN O
oncogene BC2GM069862303 JJ O
proteins BC2GM069862303 NNS O
that BC2GM069862303 WDT O
share BC2GM069862303 NN O
significant BC2GM069862303 JJ O
sequence BC2GM069862303 NN O
identity BC2GM069862303 NN O
in BC2GM069862303 IN O
a BC2GM069862303 DT O
approximately BC2GM069862303 RB O
250-amino-acid BC2GM069862303 JJ O
domain BC2GM069862303 NN O
, BC2GM069862303 , O
designated BC2GM069862303 VBD O
the BC2GM069862303 DT O
Dbl BC2GM069862303 NNP O
homology BC2GM069862303 NN O
domain BC2GM069862303 NN O
. BC2GM069862303 . O
. . O O

The BC2GM058597920 DT O
inactive BC2GM058597920 JJ O
X BC2GM058597920 NNP O
allele BC2GM058597920 NN O
, BC2GM058597920 , O
however BC2GM058597920 RB O
, BC2GM058597920 , O
is BC2GM058597920 VBZ O
hypermethylated BC2GM058597920 VBN O
in BC2GM058597920 IN O
leukocytes BC2GM058597920 NNS O
, BC2GM058597920 , O
presumably BC2GM058597920 RB O
reflecting BC2GM058597920 VBG O
early BC2GM058597920 JJ O
X BC2GM058597920 JJ O
inactivation BC2GM058597920 NN O
events BC2GM058597920 NNS O
that BC2GM058597920 WDT O
become BC2GM058597920 VBP O
important BC2GM058597920 JJ O
for BC2GM058597920 IN O
gene BC2GM058597920 NN O
dosage BC2GM058597920 NN O
in BC2GM058597920 IN O
expressing BC2GM058597920 VBG O
lineages BC2GM058597920 NNS O
. BC2GM058597920 . O
. . O O

These BC2GM004527593 DT O
results BC2GM004527593 NNS O
are BC2GM004527593 VBP O
discussed BC2GM004527593 VBN O
in BC2GM004527593 IN O
relation BC2GM004527593 NN O
to BC2GM004527593 TO O
predicted BC2GM004527593 VBN O
isoform BC2GM004527593 NN O
L BC2GM004527593 NNP O
diversity BC2GM004527593 NN O
across BC2GM004527593 IN O
human BC2GM004527593 JJ O
tissues BC2GM004527593 NNS O
and BC2GM004527593 CC O
cells BC2GM004527593 NNS O
. BC2GM004527593 . O
. . O O

To BC2GM084663535 TO O
be BC2GM084663535 VB O
a BC2GM084663535 DT O
nurse BC2GM084663535 NN O
. BC2GM084663535 . O
. . O O

In BC2GM040176899 IN O
conclusion BC2GM040176899 NN O
, BC2GM040176899 , O
ORCA3 BC2GM040176899 NNP O
regulates BC2GM040176899 VBZ O
jasmonate-responsive BC2GM040176899 JJ O
expression BC2GM040176899 NN O
of BC2GM040176899 IN O
the BC2GM040176899 DT O
Str BC2GM040176899 NNP O
gene BC2GM040176899 NN O
via BC2GM040176899 IN O
direct BC2GM040176899 JJ O
interaction BC2GM040176899 NN O
with BC2GM040176899 IN O
the BC2GM040176899 DT O
JERE BC2GM040176899 NNP O
. BC2GM040176899 . O
. . O O

Insulin BC2GM028177619 NNP O
binding BC2GM028177619 NN O
to BC2GM028177619 TO O
the BC2GM028177619 DT O
alpha-subunit BC2GM028177619 NN O
of BC2GM028177619 IN O
its BC2GM028177619 PRP$ O
receptor BC2GM028177619 NN O
stimulates BC2GM028177619 VBZ O
the BC2GM028177619 DT O
receptor BC2GM028177619 NN O
tyrosine BC2GM028177619 NN O
kinase BC2GM028177619 NN O
to BC2GM028177619 TO O
phosphorylate BC2GM028177619 VB O
the BC2GM028177619 DT O
beta-subunit BC2GM028177619 NN O
and BC2GM028177619 CC O
several BC2GM028177619 JJ O
endogenous BC2GM028177619 JJ O
protein BC2GM028177619 NN O
substrates BC2GM028177619 NNS O
, BC2GM028177619 , O
including BC2GM028177619 VBG O
pp120 BC2GM028177619 NN O
/ BC2GM028177619 NNP O
HA4 BC2GM028177619 NNP O
, BC2GM028177619 , O
a BC2GM028177619 DT O
liver-specific BC2GM028177619 JJ O
plasma BC2GM028177619 NN O
membrane BC2GM028177619 NN O
glycoprotein BC2GM028177619 NN O
of BC2GM028177619 IN O
M BC2GM028177619 NNP O
( BC2GM028177619 ( O
r BC2GM028177619 NN O
) BC2GM028177619 ) O
20,000 BC2GM028177619 CD O
. BC2GM028177619 . O
. . O O

After BC2GM027443624 IN O
a BC2GM027443624 DT O
shift BC2GM027443624 NN O
to BC2GM027443624 TO O
37 BC2GM027443624 CD O
degrees BC2GM027443624 NNS O
C BC2GM027443624 NNP O
, BC2GM027443624 , O
the BC2GM027443624 DT O
mutant BC2GM027443624 JJ O
Rat7-1p BC2GM027443624 JJ O
/ BC2GM027443624 JJ O
Nup159-1p BC2GM027443624 NNP O
is BC2GM027443624 VBZ O
lost BC2GM027443624 VBN O
from BC2GM027443624 IN O
the BC2GM027443624 DT O
nuclear BC2GM027443624 JJ O
rim BC2GM027443624 NN O
of BC2GM027443624 IN O
rat7-1 BC2GM027443624 JJ O
cells BC2GM027443624 NNS O
and BC2GM027443624 CC O
NPCs BC2GM027443624 NNP O
, BC2GM027443624 , O
which BC2GM027443624 WDT O
are BC2GM027443624 VBP O
clustered BC2GM027443624 VBN O
together BC2GM027443624 RB O
in BC2GM027443624 IN O
these BC2GM027443624 DT O
cells BC2GM027443624 NNS O
grown BC2GM027443624 VBN O
under BC2GM027443624 IN O
permissive BC2GM027443624 JJ O
conditions BC2GM027443624 NNS O
become BC2GM027443624 VBP O
substantially BC2GM027443624 RB O
less BC2GM027443624 JJR O
clustered BC2GM027443624 VBN O
. BC2GM027443624 . O
. . O O

With BC2GM007416400 IN O
repetitive BC2GM007416400 JJ O
intermittent BC2GM007416400 NN O
exercise BC2GM007416400 NN O
, BC2GM007416400 , O
gradual BC2GM007416400 JJ O
increases BC2GM007416400 NNS O
in BC2GM007416400 IN O
blood BC2GM007416400 NN O
lactate BC2GM007416400 NN O
concentration BC2GM007416400 NN O
[ BC2GM007416400 NNP O
( BC2GM007416400 ( O
LA BC2GM007416400 NNP O
] BC2GM007416400 NNP O
b BC2GM007416400 NN O
) BC2GM007416400 ) O
occurred BC2GM007416400 VBD O
, BC2GM007416400 , O
whereas BC2GM007416400 IN O
its BC2GM007416400 PRP$ O
rate BC2GM007416400 NN O
of BC2GM007416400 IN O
accumulation BC2GM007416400 NN O
( BC2GM007416400 ( O
delta BC2GM007416400 JJ O
[ BC2GM007416400 NNP O
LA BC2GM007416400 NNP O
] BC2GM007416400 NNP O
b BC2GM007416400 NN O
) BC2GM007416400 ) O
decreased BC2GM007416400 VBD O
. BC2GM007416400 . O
. . O O

FACS BC2GM065796546 NNP O
analysis BC2GM065796546 NN O
demonstrated BC2GM065796546 VBD O
that BC2GM065796546 IN O
MCs BC2GM065796546 NNP O
had BC2GM065796546 VBD O
reached BC2GM065796546 VBN O
middle BC2GM065796546 RB O
to BC2GM065796546 TO O
late BC2GM065796546 VB O
G1 BC2GM065796546 NNP O
phase BC2GM065796546 NN O
of BC2GM065796546 IN O
cell BC2GM065796546 NN O
cycle BC2GM065796546 NN O
progression BC2GM065796546 NN O
at BC2GM065796546 IN O
this BC2GM065796546 DT O
timepoint BC2GM065796546 NN O
. BC2GM065796546 . O
. . O O

The BC2GM022760333 DT O
DW BC2GM022760333 NNP O
directions BC2GM022760333 NNS O
uniformly BC2GM022760333 RB O
sampled BC2GM022760333 VBD O
the BC2GM022760333 DT O
diffusion BC2GM022760333 NN O
ellipsoid BC2GM022760333 JJ O
surface BC2GM022760333 NN O
. BC2GM022760333 . O
. . O O

When BC2GM038061455 WRB O
stratifying BC2GM038061455 VBG O
FLM BC2GM038061455 NNP O
values BC2GM038061455 NNS O
< BC2GM038061455 VBP O
34 BC2GM038061455 CD O
and BC2GM038061455 CC O
> BC2GM038061455 $ O
34 BC2GM038061455 CD O
wks BC2GM038061455 NN O
' BC2GM038061455 '' O
gestation BC2GM038061455 NN O
, BC2GM038061455 , O
again BC2GM038061455 RB O
no BC2GM038061455 DT O
difference BC2GM038061455 NN O
was BC2GM038061455 VBD O
found BC2GM038061455 VBN O
in BC2GM038061455 IN O
mean BC2GM038061455 JJ O
difference BC2GM038061455 NN O
of BC2GM038061455 IN O
L BC2GM038061455 NNP O
/ BC2GM038061455 NNP O
S BC2GM038061455 NNP O
and BC2GM038061455 CC O
LB BC2GM038061455 NNP O
before BC2GM038061455 IN O
and BC2GM038061455 CC O
after BC2GM038061455 IN O
34 BC2GM038061455 CD O
wks BC2GM038061455 NN O
. BC2GM038061455 . O
. . O O

BACKGROUND BC2GM041156819 NN O
: BC2GM041156819 : O
A BC2GM041156819 DT O
thorough BC2GM041156819 JJ O
understanding BC2GM041156819 NN O
of BC2GM041156819 IN O
malignant BC2GM041156819 JJ O
fibrous BC2GM041156819 JJ O
histiocytoma BC2GM041156819 NN O
( BC2GM041156819 ( O
MFH BC2GM041156819 NNP O
) BC2GM041156819 ) O
, BC2GM041156819 , O
the BC2GM041156819 DT O
most BC2GM041156819 RBS O
common BC2GM041156819 JJ O
subtype BC2GM041156819 NN O
of BC2GM041156819 IN O
soft BC2GM041156819 JJ O
tissue BC2GM041156819 NN O
sarcoma BC2GM041156819 NN O
, BC2GM041156819 , O
will BC2GM041156819 MD O
lead BC2GM041156819 VB O
to BC2GM041156819 TO O
improved BC2GM041156819 VBN O
histologic-specific BC2GM041156819 JJ O
protocols BC2GM041156819 NNS O
. BC2GM041156819 . O
. . O O

Spontaneous BC2GM039284976 JJ O
fracture BC2GM039284976 NN O
of BC2GM039284976 IN O
the BC2GM039284976 DT O
tarsal BC2GM039284976 NN O
bone BC2GM039284976 NN O
in BC2GM039284976 IN O
2 BC2GM039284976 CD O
cases BC2GM039284976 NNS O
of BC2GM039284976 IN O
leprosy BC2GM039284976 NN O
. BC2GM039284976 . O
. . O O

Sequences BC2GM097617253 NNS O
within BC2GM097617253 IN O
the BC2GM097617253 DT O
UAS2 BC2GM097617253 NNP O
element BC2GM097617253 NN O
of BC2GM097617253 IN O
the BC2GM097617253 DT O
ENO2 BC2GM097617253 NNP O
gene BC2GM097617253 NN O
bound BC2GM097617253 VBD O
a BC2GM097617253 DT O
second BC2GM097617253 JJ O
protein BC2GM097617253 NN O
which BC2GM097617253 WDT O
corresponded BC2GM097617253 VBD O
to BC2GM097617253 TO O
the BC2GM097617253 DT O
ABFI BC2GM097617253 NNP O
( BC2GM097617253 ( O
autonomously BC2GM097617253 RB O
replicating BC2GM097617253 VBG O
sequence-binding BC2GM097617253 JJ O
factor BC2GM097617253 NN O
) BC2GM097617253 ) O
protein BC2GM097617253 NN O
. BC2GM097617253 . O
. . O O

Thus BC2GM021219162 RB O
, BC2GM021219162 , O
over BC2GM021219162 IN O
a BC2GM021219162 DT O
wide BC2GM021219162 JJ O
range BC2GM021219162 NN O
of BC2GM021219162 IN O
arterial BC2GM021219162 JJ O
dimensions BC2GM021219162 NNS O
, BC2GM021219162 , O
results BC2GM021219162 NNS O
obtained BC2GM021219162 VBD O
with BC2GM021219162 IN O
caliper BC2GM021219162 JJ O
estimates BC2GM021219162 NNS O
of BC2GM021219162 IN O
luminal BC2GM021219162 JJ O
area BC2GM021219162 NN O
and BC2GM021219162 CC O
diameter BC2GM021219162 NN O
are BC2GM021219162 VBP O
comparable BC2GM021219162 JJ O
to BC2GM021219162 TO O
those BC2GM021219162 DT O
obtained BC2GM021219162 VBN O
with BC2GM021219162 IN O
videodensitometry BC2GM021219162 NN O
using BC2GM021219162 VBG O
the BC2GM021219162 DT O
XR-70 BC2GM021219162 JJ O
system BC2GM021219162 NN O
. BC2GM021219162 . O
. . O O

Only BC2GM045993010 RB O
the BC2GM045993010 DT O
27-kDa BC2GM045993010 JJ O
protein BC2GM045993010 NN O
was BC2GM045993010 VBD O
detected BC2GM045993010 VBN O
after BC2GM045993010 IN O
N-glycosidase BC2GM045993010 NNP O
treatment BC2GM045993010 NN O
, BC2GM045993010 , O
indicating BC2GM045993010 VBG O
that BC2GM045993010 IN O
PLP-H BC2GM045993010 NNP O
is BC2GM045993010 VBZ O
a BC2GM045993010 DT O
glycoprotein BC2GM045993010 NN O
. BC2GM045993010 . O
. . O O

Patients BC2GM096497535 NNS O
with BC2GM096497535 IN O
binocular BC2GM096497535 JJ O
pregeniculate BC2GM096497535 NN O
visual BC2GM096497535 JJ O
loss BC2GM096497535 NN O
, BC2GM096497535 , O
patients BC2GM096497535 NNS O
with BC2GM096497535 IN O
balanced BC2GM096497535 JJ O
binocular BC2GM096497535 JJ O
pregeniculate BC2GM096497535 NN O
loss BC2GM096497535 NN O
without BC2GM096497535 IN O
RAPD BC2GM096497535 NNP O
, BC2GM096497535 , O
and BC2GM096497535 CC O
patients BC2GM096497535 NNS O
with BC2GM096497535 IN O
monocular BC2GM096497535 JJ O
pregeniculate BC2GM096497535 NN O
visual BC2GM096497535 JJ O
loss BC2GM096497535 NN O
had BC2GM096497535 VBD O
significantly BC2GM096497535 RB O
larger BC2GM096497535 JJR O
pupils BC2GM096497535 NNS O
than BC2GM096497535 IN O
age-matched BC2GM096497535 JJ O
controls BC2GM096497535 NNS O
. BC2GM096497535 . O
. . O O

Extracellular BC2GM059590650 JJ O
protein BC2GM059590650 NN O
kinase BC2GM059590650 VB O
A BC2GM059590650 NNP O
as BC2GM059590650 IN O
a BC2GM059590650 DT O
cancer BC2GM059590650 NN O
biomarker BC2GM059590650 NN O
: BC2GM059590650 : O
its BC2GM059590650 PRP$ O
expression BC2GM059590650 NN O
by BC2GM059590650 IN O
tumor BC2GM059590650 NN O
cells BC2GM059590650 NNS O
and BC2GM059590650 CC O
reversal BC2GM059590650 NN O
by BC2GM059590650 IN O
a BC2GM059590650 DT O
myristate-lacking BC2GM059590650 JJ O
Calpha BC2GM059590650 NNP O
and BC2GM059590650 CC O
RIIbeta BC2GM059590650 NNP O
subunit BC2GM059590650 NN O
overexpression BC2GM059590650 NN O
. BC2GM059590650 . O
. . O O

Four BC2GM011711443 CD O
of BC2GM011711443 IN O
15 BC2GM011711443 CD O
patients BC2GM011711443 NNS O
with BC2GM011711443 IN O
R2 BC2GM011711443 NNP O
had BC2GM011711443 VBD O
rheumatoid BC2GM011711443 VBN O
arthritis BC2GM011711443 NN O
and BC2GM011711443 CC O
in BC2GM011711443 IN O
two BC2GM011711443 CD O
of BC2GM011711443 IN O
these BC2GM011711443 DT O
four BC2GM011711443 CD O
cases BC2GM011711443 NNS O
the BC2GM011711443 DT O
antibody BC2GM011711443 NN O
was BC2GM011711443 VBD O
of BC2GM011711443 IN O
the BC2GM011711443 DT O
IgA BC2GM011711443 NNP O
class BC2GM011711443 NN O
. BC2GM011711443 . O
. . O O

Recombinant BC2GM025052466 JJ O
MsERK1 BC2GM025052466 NNP O
( BC2GM025052466 ( O
rMsERK1 BC2GM025052466 NN O
) BC2GM025052466 ) O
, BC2GM025052466 , O
when BC2GM025052466 WRB O
overexpressed BC2GM025052466 VBN O
in BC2GM025052466 IN O
Escherichia BC2GM025052466 NNP O
coli BC2GM025052466 NN O
, BC2GM025052466 , O
is BC2GM025052466 VBZ O
recognized BC2GM025052466 VBN O
by BC2GM025052466 IN O
antibodies BC2GM025052466 NNS O
raised BC2GM025052466 VBN O
against BC2GM025052466 IN O
MAP BC2GM025052466 NNP O
kinases BC2GM025052466 NNS O
from BC2GM025052466 IN O
rat BC2GM025052466 NN O
, BC2GM025052466 , O
Xenopus BC2GM025052466 NNP O
, BC2GM025052466 , O
and BC2GM025052466 CC O
sea BC2GM025052466 NN O
star BC2GM025052466 NN O
and BC2GM025052466 CC O
by BC2GM025052466 IN O
anti-phosphotyrosine BC2GM025052466 JJ O
antibodies BC2GM025052466 NNS O
. BC2GM025052466 . O
. . O O

Maternal BC2GM018411684 NNP O
behavior BC2GM018411684 NN O
was BC2GM018411684 VBD O
assessed BC2GM018411684 VBN O
using BC2GM018411684 VBG O
observational BC2GM018411684 JJ O
techniques BC2GM018411684 NNS O
. BC2GM018411684 . O
. . O O

Five BC2GM085576147 CD O
girls BC2GM085576147 NNS O
with BC2GM085576147 IN O
Turner BC2GM085576147 NNP O
's BC2GM085576147 POS O
syndrome BC2GM085576147 NN O
aged BC2GM085576147 VBD O
12 BC2GM085576147 CD O
to BC2GM085576147 TO O
17 BC2GM085576147 CD O
years BC2GM085576147 NNS O
showed BC2GM085576147 VBD O
LH BC2GM085576147 NNP O
values BC2GM085576147 NNS O
( BC2GM085576147 ( O
5.0-14.5 BC2GM085576147 JJ O
IU BC2GM085576147 NNP O
/ BC2GM085576147 NNP O
12 BC2GM085576147 CD O
h BC2GM085576147 NN O
) BC2GM085576147 ) O
at BC2GM085576147 IN O
the BC2GM085576147 DT O
upper BC2GM085576147 JJ O
end BC2GM085576147 NN O
of BC2GM085576147 IN O
or BC2GM085576147 CC O
slightly BC2GM085576147 RB O
above BC2GM085576147 IN O
the BC2GM085576147 DT O
normal BC2GM085576147 JJ O
range BC2GM085576147 NN O
and BC2GM085576147 CC O
pathologically BC2GM085576147 RB O
high BC2GM085576147 JJ O
values BC2GM085576147 NNS O
( BC2GM085576147 ( O
22.2-43.5 BC2GM085576147 JJ O
IU BC2GM085576147 NNP O
/ BC2GM085576147 NNP O
12 BC2GM085576147 CD O
h BC2GM085576147 NN O
) BC2GM085576147 ) O
for BC2GM085576147 IN O
FSH BC2GM085576147 NNP O
. BC2GM085576147 . O
. . O O

Confocal BC2GM061416577 JJ O
fluorescent BC2GM061416577 NN O
microscopy BC2GM061416577 NN O
analysis BC2GM061416577 NN O
demonstrated BC2GM061416577 VBD O
that BC2GM061416577 IN O
WT BC2GM061416577 NNP O
, BC2GM061416577 , O
VaI BC2GM061416577 NNP O
, BC2GM061416577 , O
and BC2GM061416577 CC O
VaII BC2GM061416577 NNP O
all BC2GM061416577 DT O
distribute BC2GM061416577 VBP O
equally BC2GM061416577 RB O
to BC2GM061416577 TO O
the BC2GM061416577 DT O
cell BC2GM061416577 NN O
surface BC2GM061416577 NN O
while BC2GM061416577 NN O
, BC2GM061416577 , O
as BC2GM061416577 IN O
expected BC2GM061416577 VBN O
, BC2GM061416577 , O
a BC2GM061416577 DT O
WT BC2GM061416577 NNP O
mutant BC2GM061416577 NN O
lacking BC2GM061416577 VBG O
the BC2GM061416577 DT O
two BC2GM061416577 CD O
C-terminal BC2GM061416577 JJ O
valine BC2GM061416577 NN O
residues BC2GM061416577 NNS O
does BC2GM061416577 VBZ O
not BC2GM061416577 RB O
. BC2GM061416577 . O
. . O O

No BC2GM022006150 DT O
viral BC2GM022006150 JJ O
RNA BC2GM022006150 NNP O
replication BC2GM022006150 NN O
could BC2GM022006150 MD O
be BC2GM022006150 VB O
detected BC2GM022006150 VBN O
in BC2GM022006150 IN O
cells BC2GM022006150 NNS O
transfected BC2GM022006150 VBN O
with BC2GM022006150 IN O
mutant BC2GM022006150 JJ O
RNAs BC2GM022006150 NNP O
. BC2GM022006150 . O
. . O O

In BC2GM001695842 IN O
ten BC2GM001695842 CD O
other BC2GM001695842 JJ O
endotoxin-albumin-treated BC2GM001695842 JJ O
pigs BC2GM001695842 NNS O
PGE1 BC2GM001695842 NNP O
infusion BC2GM001695842 NN O
( BC2GM001695842 ( O
0.25 BC2GM001695842 CD O
micrograms BC2GM001695842 NNS O
X BC2GM001695842 VBP O
kg-1 BC2GM001695842 JJ O
X BC2GM001695842 NNP O
min-1 BC2GM001695842 NN O
) BC2GM001695842 ) O
was BC2GM001695842 VBD O
begun BC2GM001695842 VBN O
after BC2GM001695842 IN O
established BC2GM001695842 VBN O
pulmonary BC2GM001695842 JJ O
and BC2GM001695842 CC O
cardiovascular BC2GM001695842 JJ O
dysfunction BC2GM001695842 NN O
, BC2GM001695842 , O
for BC2GM001695842 IN O
closer BC2GM001695842 JJR O
mimicking BC2GM001695842 NN O
of BC2GM001695842 IN O
clinical BC2GM001695842 JJ O
use BC2GM001695842 NN O
. BC2GM001695842 . O
. . O O

There BC2GM069379364 EX O
has BC2GM069379364 VBZ O
been BC2GM069379364 VBN O
no BC2GM069379364 DT O
significant BC2GM069379364 JJ O
toxicity BC2GM069379364 NN O
associated BC2GM069379364 VBN O
with BC2GM069379364 IN O
repeated BC2GM069379364 VBN O
5-FU BC2GM069379364 JJ O
instillation BC2GM069379364 NN O
into BC2GM069379364 IN O
the BC2GM069379364 DT O
airway BC2GM069379364 NN O
. BC2GM069379364 . O
. . O O

From BC2GM086705446 IN O
the BC2GM086705446 DT O
present BC2GM086705446 JJ O
results BC2GM086705446 NNS O
a BC2GM086705446 DT O
concept BC2GM086705446 NN O
of BC2GM086705446 IN O
hormone-dependent BC2GM086705446 JJ O
AR BC2GM086705446 NNP O
activation BC2GM086705446 NN O
is BC2GM086705446 VBZ O
proposed BC2GM086705446 VBN O
, BC2GM086705446 , O
which BC2GM086705446 WDT O
requires BC2GM086705446 VBZ O
a BC2GM086705446 DT O
functional BC2GM086705446 JJ O
, BC2GM086705446 , O
direct BC2GM086705446 JJ O
or BC2GM086705446 CC O
indirect BC2GM086705446 JJ O
intramolecular BC2GM086705446 JJ O
interaction BC2GM086705446 NN O
between BC2GM086705446 IN O
the BC2GM086705446 DT O
TAD BC2GM086705446 NNP O
and BC2GM086705446 CC O
the BC2GM086705446 DT O
LBD BC2GM086705446 NNP O
. BC2GM086705446 . O
. . O O

Modern BC2GM098689605 JJ O
aspects BC2GM098689605 NNS O
of BC2GM098689605 IN O
shock-treatment BC2GM098689605 NN O
in BC2GM098689605 IN O
extensive BC2GM098689605 JJ O
burns BC2GM098689605 NNS O
( BC2GM098689605 ( O
author BC2GM098689605 NN O
's BC2GM098689605 POS O
transl BC2GM098689605 NN O
) BC2GM098689605 ) O
. BC2GM098689605 . O
. . O O

We BC2GM084526121 PRP O
propose BC2GM084526121 VBP O
that BC2GM084526121 IN O
the BC2GM084526121 DT O
cDNA BC2GM084526121 NN O
encodes BC2GM084526121 VBZ O
an BC2GM084526121 DT O
apical BC2GM084526121 JJ O
plasma BC2GM084526121 NN O
membrane BC2GM084526121 NN O
protein BC2GM084526121 NN O
that BC2GM084526121 WDT O
plays BC2GM084526121 VBZ O
a BC2GM084526121 DT O
role BC2GM084526121 NN O
in BC2GM084526121 IN O
the BC2GM084526121 DT O
functional BC2GM084526121 JJ O
expression BC2GM084526121 NN O
of BC2GM084526121 IN O
the BC2GM084526121 DT O
amiloride-sensitive BC2GM084526121 JJ O
epithelial BC2GM084526121 JJ O
sodium BC2GM084526121 NN O
channel BC2GM084526121 NN O
. BC2GM084526121 . O
. . O O

In BC2GM035313252 IN O
group BC2GM035313252 NN O
1 BC2GM035313252 CD O
, BC2GM035313252 , O
mean BC2GM035313252 JJ O
z-score BC2GM035313252 NN O
for BC2GM035313252 IN O
GFR BC2GM035313252 NNP O
was BC2GM035313252 VBD O
-0.27 BC2GM035313252 NNP O
( BC2GM035313252 ( O
94.6 BC2GM035313252 CD O
% BC2GM035313252 NN O
of BC2GM035313252 IN O
normal BC2GM035313252 JJ O
) BC2GM035313252 ) O
and BC2GM035313252 CC O
in BC2GM035313252 IN O
group BC2GM035313252 NN O
2 BC2GM035313252 CD O
mean BC2GM035313252 JJ O
z-score BC2GM035313252 NN O
was BC2GM035313252 VBD O
-1.51 BC2GM035313252 NNP O
( BC2GM035313252 ( O
72.7 BC2GM035313252 CD O
% BC2GM035313252 NN O
of BC2GM035313252 IN O
normal BC2GM035313252 JJ O
for BC2GM035313252 IN O
two BC2GM035313252 CD O
kidneys BC2GM035313252 NNS O
) BC2GM035313252 ) O
( BC2GM035313252 ( O
P BC2GM035313252 NNP O
= BC2GM035313252 NNP O
0.022 BC2GM035313252 CD O
, BC2GM035313252 , O
Mann-Whitney BC2GM035313252 NNP O
U-test BC2GM035313252 NNP O
) BC2GM035313252 ) O
. BC2GM035313252 . O
. . O O

G-box BC2GM015182129 JJ O
binding BC2GM015182129 NN O
factors BC2GM015182129 NNS O
( BC2GM015182129 ( O
GBFs BC2GM015182129 NNP O
) BC2GM015182129 ) O
constitute BC2GM015182129 VBP O
a BC2GM015182129 DT O
family BC2GM015182129 NN O
of BC2GM015182129 IN O
plant BC2GM015182129 NN O
DNA-binding BC2GM015182129 NNP O
proteins BC2GM015182129 VBZ O
that BC2GM015182129 IN O
bind BC2GM015182129 NN O
to BC2GM015182129 TO O
the BC2GM015182129 DT O
G-box BC2GM015182129 NNP O
motif BC2GM015182129 NN O
, BC2GM015182129 , O
a BC2GM015182129 DT O
regulatory BC2GM015182129 JJ O
cis BC2GM015182129 NN O
element BC2GM015182129 NN O
present BC2GM015182129 NN O
in BC2GM015182129 IN O
many BC2GM015182129 JJ O
plant BC2GM015182129 NN O
genes BC2GM015182129 NNS O
with BC2GM015182129 IN O
a BC2GM015182129 DT O
palindromic BC2GM015182129 JJ O
DNA BC2GM015182129 NNP O
motif BC2GM015182129 NN O
of BC2GM015182129 IN O
CACGTG BC2GM015182129 NNP O
. BC2GM015182129 . O
. . O O

Human BC2GM051315195 NNP O
epidermal BC2GM051315195 JJ O
growth BC2GM051315195 NN O
factor BC2GM051315195 NN O
( BC2GM051315195 ( O
EGF BC2GM051315195 NNP O
) BC2GM051315195 ) O
, BC2GM051315195 , O
a BC2GM051315195 DT O
naturally BC2GM051315195 RB O
occurring BC2GM051315195 VBG O
protein BC2GM051315195 NN O
, BC2GM051315195 , O
has BC2GM051315195 VBZ O
been BC2GM051315195 VBN O
implicated BC2GM051315195 VBN O
in BC2GM051315195 IN O
the BC2GM051315195 DT O
protection BC2GM051315195 NN O
of BC2GM051315195 IN O
gastrointestinal BC2GM051315195 JJ O
mucosal BC2GM051315195 NN O
integrity BC2GM051315195 NN O
. BC2GM051315195 . O
. . O O

We BC2GM077712374 PRP O
conclude BC2GM077712374 VBP O
from BC2GM077712374 IN O
these BC2GM077712374 DT O
observations BC2GM077712374 NNS O
that BC2GM077712374 IN O
the BC2GM077712374 DT O
cTnC BC2GM077712374 NN O
3'Ile BC2GM077712374 CD O
element BC2GM077712374 NN O
is BC2GM077712374 VBZ O
a BC2GM077712374 DT O
composite BC2GM077712374 JJ O
enhancer BC2GM077712374 NN O
that BC2GM077712374 WDT O
functions BC2GM077712374 NNS O
through BC2GM077712374 IN O
the BC2GM077712374 DT O
combined BC2GM077712374 JJ O
interactions BC2GM077712374 NNS O
of BC2GM077712374 IN O
at BC2GM077712374 IN O
least BC2GM077712374 JJS O
five BC2GM077712374 CD O
regulatory BC2GM077712374 JJ O
elements BC2GM077712374 NNS O
and BC2GM077712374 CC O
their BC2GM077712374 PRP$ O
cognate BC2GM077712374 NN O
binding BC2GM077712374 NN O
factors BC2GM077712374 NNS O
: BC2GM077712374 : O
three BC2GM077712374 CD O
or BC2GM077712374 CC O
four BC2GM077712374 CD O
E-boxes BC2GM077712374 NNS O
, BC2GM077712374 , O
a BC2GM077712374 DT O
MEF-2 BC2GM077712374 NNP O
site BC2GM077712374 NN O
, BC2GM077712374 , O
and BC2GM077712374 CC O
a BC2GM077712374 DT O
MEF-3 BC2GM077712374 JJ O
site BC2GM077712374 NN O
. BC2GM077712374 . O
. . O O

It BC2GM014236204 PRP O
is BC2GM014236204 VBZ O
required BC2GM014236204 VBN O
for BC2GM014236204 IN O
correct BC2GM014236204 JJ O
expression BC2GM014236204 NN O
of BC2GM014236204 IN O
both BC2GM014236204 DT O
genes BC2GM014236204 NNS O
. BC2GM014236204 . O
. . O O

When BC2GM087746443 WRB O
targeted BC2GM087746443 VBN O
to BC2GM087746443 TO O
the BC2GM087746443 DT O
GAL1 BC2GM087746443 NNP O
promoter BC2GM087746443 NN O
by BC2GM087746443 IN O
fusing BC2GM087746443 VBG O
with BC2GM087746443 IN O
the BC2GM087746443 DT O
Gal4p BC2GM087746443 NNP O
DNA-binding BC2GM087746443 NNP O
domain BC2GM087746443 NN O
, BC2GM087746443 , O
Sko1p BC2GM087746443 NNP O
acts BC2GM087746443 VBZ O
as BC2GM087746443 IN O
an BC2GM087746443 DT O
Ssn6 BC2GM087746443 NNP O
/ BC2GM087746443 NNP O
Tup1p-dependent BC2GM087746443 NNP O
repressor BC2GM087746443 NN O
regulated BC2GM087746443 VBN O
by BC2GM087746443 IN O
osmotic BC2GM087746443 JJ O
stress BC2GM087746443 NN O
. BC2GM087746443 . O
. . O O

A BC2GM060554389 DT O
case BC2GM060554389 NN O
of BC2GM060554389 IN O
heterotopic BC2GM060554389 NN O
gastric BC2GM060554389 JJ O
mucosa BC2GM060554389 NN O
( BC2GM060554389 ( O
pyloric BC2GM060554389 JJ O
gland BC2GM060554389 NN O
) BC2GM060554389 ) O
in BC2GM060554389 IN O
the BC2GM060554389 DT O
wall BC2GM060554389 NN O
of BC2GM060554389 IN O
the BC2GM060554389 DT O
gallbladder BC2GM060554389 NN O
was BC2GM060554389 VBD O
reported BC2GM060554389 VBN O
. BC2GM060554389 . O
. . O O

However BC2GM083214428 RB O
, BC2GM083214428 , O
patients BC2GM083214428 NNS O
with BC2GM083214428 IN O
DPX BC2GM083214428 NNP O
should BC2GM083214428 MD O
be BC2GM083214428 VB O
observed BC2GM083214428 VBN O
for BC2GM083214428 IN O
the BC2GM083214428 DT O
potential BC2GM083214428 JJ O
occurrence BC2GM083214428 NN O
of BC2GM083214428 IN O
an BC2GM083214428 DT O
associated BC2GM083214428 JJ O
condition BC2GM083214428 NN O
. BC2GM083214428 . O
. . O O

Unfractionated BC2GM062788125 VBN O
heparin BC2GM062788125 NN O
( BC2GM062788125 ( O
UFH BC2GM062788125 NNP O
) BC2GM062788125 ) O
given BC2GM062788125 VBN O
at BC2GM062788125 IN O
a BC2GM062788125 DT O
dose BC2GM062788125 NN O
of BC2GM062788125 IN O
0.3 BC2GM062788125 CD O
mg BC2GM062788125 NNS O
x BC2GM062788125 JJ O
kg-1 BC2GM062788125 JJ O
bolus BC2GM062788125 NN O
+ BC2GM062788125 $ O
0.3 BC2GM062788125 CD O
mg BC2GM062788125 JJ O
x BC2GM062788125 JJ O
kg-1 BC2GM062788125 JJ O
x BC2GM062788125 JJ O
h-1 BC2GM062788125 JJ O
infusion BC2GM062788125 NN O
did BC2GM062788125 VBD O
not BC2GM062788125 RB O
improve BC2GM062788125 VB O
the BC2GM062788125 DT O
incidence BC2GM062788125 NN O
of BC2GM062788125 IN O
reperfusion BC2GM062788125 NN O
or BC2GM062788125 CC O
lower BC2GM062788125 JJR O
the BC2GM062788125 DT O
incidence BC2GM062788125 NN O
of BC2GM062788125 IN O
reocclusion BC2GM062788125 NN O
. BC2GM062788125 . O
. . O O

Treatment BC2GM070860352 NN O
with BC2GM070860352 IN O
H7 BC2GM070860352 NNP O
did BC2GM070860352 VBD O
not BC2GM070860352 RB O
affect BC2GM070860352 VB O
IL-4R-mediated BC2GM070860352 NNP O
immediate BC2GM070860352 JJ O
signaling BC2GM070860352 VBG O
events BC2GM070860352 NNS O
such BC2GM070860352 JJ O
as BC2GM070860352 IN O
tyrosine BC2GM070860352 JJ O
phosphorylation BC2GM070860352 NN O
of BC2GM070860352 IN O
Jak1 BC2GM070860352 NNP O
, BC2GM070860352 , O
Jak3 BC2GM070860352 NNP O
, BC2GM070860352 , O
insulin BC2GM070860352 NN O
receptor BC2GM070860352 NN O
substrate BC2GM070860352 NN O
( BC2GM070860352 ( O
IRS BC2GM070860352 NNP O
) BC2GM070860352 ) O
-1 BC2GM070860352 NN O
and BC2GM070860352 CC O
IRS-2 BC2GM070860352 NNP O
, BC2GM070860352 , O
or BC2GM070860352 CC O
tyrosine BC2GM070860352 JJ O
phosphorylation BC2GM070860352 NN O
and BC2GM070860352 CC O
DNA BC2GM070860352 NNP O
binding BC2GM070860352 NN O
of BC2GM070860352 IN O
Stat6 BC2GM070860352 NNP O
. BC2GM070860352 . O
. . O O

With BC2GM064850672 IN O
six BC2GM064850672 CD O
reports BC2GM064850672 NNS O
in BC2GM064850672 IN O
the BC2GM064850672 DT O
literature BC2GM064850672 NN O
that BC2GM064850672 WDT O
show BC2GM064850672 VBP O
there BC2GM064850672 EX O
is BC2GM064850672 VBZ O
an BC2GM064850672 DT O
order BC2GM064850672 NN O
to BC2GM064850672 TO O
melanoma BC2GM064850672 VB O
nodal BC2GM064850672 JJ O
metastases BC2GM064850672 NNS O
and BC2GM064850672 CC O
that BC2GM064850672 IN O
the BC2GM064850672 DT O
SLN BC2GM064850672 NNP O
histology BC2GM064850672 NN O
is BC2GM064850672 VBZ O
reflective BC2GM064850672 JJ O
of BC2GM064850672 IN O
the BC2GM064850672 DT O
histology BC2GM064850672 NN O
of BC2GM064850672 IN O
the BC2GM064850672 DT O
remainder BC2GM064850672 NN O
of BC2GM064850672 IN O
the BC2GM064850672 DT O
nodal BC2GM064850672 JJ O
basin BC2GM064850672 NN O
, BC2GM064850672 , O
the BC2GM064850672 DT O
more BC2GM064850672 RBR O
conservative BC2GM064850672 JJ O
SLN BC2GM064850672 NNP O
biopsy BC2GM064850672 NN O
can BC2GM064850672 MD O
be BC2GM064850672 VB O
performed BC2GM064850672 VBN O
to BC2GM064850672 TO O
adequately BC2GM064850672 RB O
stage BC2GM064850672 VB O
nodally BC2GM064850672 RB O
the BC2GM064850672 DT O
patient BC2GM064850672 NN O
with BC2GM064850672 IN O
melanoma BC2GM064850672 NN O
. BC2GM064850672 . O
. . O O

2,4- BC2GM053739384 JJ O
and BC2GM053739384 CC O
2,6-toluenediamine BC2GM053739384 JJ O
in BC2GM053739384 IN O
hydrolysed BC2GM053739384 JJ O
plasma BC2GM053739384 NN O
and BC2GM053739384 CC O
urine BC2GM053739384 NN O
after BC2GM053739384 IN O
test-chamber BC2GM053739384 JJ O
exposure BC2GM053739384 NN O
of BC2GM053739384 IN O
humans BC2GM053739384 NNS O
to BC2GM053739384 TO O
2,4- BC2GM053739384 JJ O
and BC2GM053739384 CC O
2,6-toluene BC2GM053739384 JJ O
diisocyanate BC2GM053739384 NN O
. BC2GM053739384 . O
. . O O

No BC2GM094300739 DT O
transactivation BC2GM094300739 NN O
of BC2GM094300739 IN O
the BC2GM094300739 DT O
ovalbumin BC2GM094300739 NN O
promoter BC2GM094300739 NN O
( BC2GM094300739 ( O
pLovTATA BC2GM094300739 NN O
) BC2GM094300739 ) O
template BC2GM094300739 NN O
control BC2GM094300739 NN O
was BC2GM094300739 VBD O
observed BC2GM094300739 VBN O
. BC2GM094300739 . O
. . O O

In BC2GM060862443 IN O
both BC2GM060862443 DT O
cell BC2GM060862443 NN O
types BC2GM060862443 NNS O
, BC2GM060862443 , O
insulin BC2GM060862443 NN O
led BC2GM060862443 VBD O
to BC2GM060862443 TO O
a BC2GM060862443 DT O
dose-dependent BC2GM060862443 JJ O
increase BC2GM060862443 NN O
in BC2GM060862443 IN O
the BC2GM060862443 DT O
association BC2GM060862443 NN O
of BC2GM060862443 IN O
tyrosine BC2GM060862443 NN O
phosphorylated BC2GM060862443 VBN O
IRS-1 BC2GM060862443 NNP O
with BC2GM060862443 IN O
the BC2GM060862443 DT O
SH2 BC2GM060862443 NNP O
domain BC2GM060862443 NN O
of BC2GM060862443 IN O
the BC2GM060862443 DT O
p85 BC2GM060862443 NN O
regulatory BC2GM060862443 JJ O
subunit BC2GM060862443 NN O
of BC2GM060862443 IN O
PI-3 BC2GM060862443 NNP O
kinase BC2GM060862443 NN O
, BC2GM060862443 , O
and BC2GM060862443 CC O
also BC2GM060862443 RB O
increased BC2GM060862443 VBD O
the BC2GM060862443 DT O
amount BC2GM060862443 NN O
of BC2GM060862443 IN O
PI BC2GM060862443 NNP O
kinase BC2GM060862443 NN O
activity BC2GM060862443 NN O
detected BC2GM060862443 VBN O
in BC2GM060862443 IN O
anti-IRS-1 BC2GM060862443 JJ O
immunoprecipitates BC2GM060862443 NNS O
. BC2GM060862443 . O
. . O O

It BC2GM045105148 PRP O
spans BC2GM045105148 VBZ O
20 BC2GM045105148 CD O
kilobases BC2GM045105148 NNS O
, BC2GM045105148 , O
consists BC2GM045105148 NNS O
of BC2GM045105148 IN O
7 BC2GM045105148 CD O
exons BC2GM045105148 NNS O
and BC2GM045105148 CC O
6 BC2GM045105148 CD O
introns BC2GM045105148 NNS O
, BC2GM045105148 , O
and BC2GM045105148 CC O
contains BC2GM045105148 VBZ O
a BC2GM045105148 DT O
TATA BC2GM045105148 NNP O
motif BC2GM045105148 NN O
24 BC2GM045105148 CD O
nucleotides BC2GM045105148 NNS O
upstream BC2GM045105148 NN O
of BC2GM045105148 IN O
the BC2GM045105148 DT O
transcriptional BC2GM045105148 JJ O
start BC2GM045105148 NN O
site BC2GM045105148 NN O
. BC2GM045105148 . O
. . O O

The BC2GM048760172 DT O
screen BC2GM048760172 NN O
identifies BC2GM048760172 VBZ O
mutants BC2GM048760172 NNS O
whose BC2GM048760172 WP$ O
growth BC2GM048760172 NN O
depends BC2GM048760172 VBZ O
on BC2GM048760172 IN O
high BC2GM048760172 JJ O
levels BC2GM048760172 NNS O
of BC2GM048760172 IN O
expression BC2GM048760172 NN O
of BC2GM048760172 IN O
that BC2GM048760172 DT O
gene BC2GM048760172 NN O
. BC2GM048760172 . O
. . O O

Ciprofloxacin BC2GM003645917 NNP O
levels BC2GM003645917 NNS O
in BC2GM003645917 IN O
serum BC2GM003645917 NN O
and BC2GM003645917 CC O
blister BC2GM003645917 NN O
fluid BC2GM003645917 NN O
at BC2GM003645917 IN O
the BC2GM003645917 DT O
end BC2GM003645917 NN O
of BC2GM003645917 IN O
the BC2GM003645917 DT O
dosing BC2GM003645917 NN O
interval BC2GM003645917 NN O
( BC2GM003645917 ( O
8 BC2GM003645917 CD O
h BC2GM003645917 NN O
) BC2GM003645917 ) O
were BC2GM003645917 VBD O
superior BC2GM003645917 JJ O
or BC2GM003645917 CC O
almost BC2GM003645917 RB O
superior BC2GM003645917 JJ O
to BC2GM003645917 TO O
MICs BC2GM003645917 NNP O
for BC2GM003645917 IN O
sensitive BC2GM003645917 JJ O
organisms BC2GM003645917 NNS O
including BC2GM003645917 VBG O
Pseudomonas BC2GM003645917 NNP O
aeruginosa BC2GM003645917 NN O
. BC2GM003645917 . O
. . O O

In BC2GM076247276 IN O
isolated BC2GM076247276 JJ O
olfactory BC2GM076247276 NN O
cilia BC2GM076247276 NNS O
certain BC2GM076247276 JJ O
odorants BC2GM076247276 NNS O
elicit BC2GM076247276 VBP O
a BC2GM076247276 DT O
rapid BC2GM076247276 JJ O
and BC2GM076247276 CC O
transient BC2GM076247276 JJ O
cAMP BC2GM076247276 NN O
response BC2GM076247276 NN O
, BC2GM076247276 , O
terminated BC2GM076247276 VBN O
by BC2GM076247276 IN O
a BC2GM076247276 DT O
concerted BC2GM076247276 JJ O
process BC2GM076247276 NN O
which BC2GM076247276 WDT O
requires BC2GM076247276 VBZ O
the BC2GM076247276 DT O
action BC2GM076247276 NN O
of BC2GM076247276 IN O
two BC2GM076247276 CD O
protein BC2GM076247276 NN O
kinases BC2GM076247276 NNS O
, BC2GM076247276 , O
protein BC2GM076247276 NN O
kinase BC2GM076247276 VBD O
A BC2GM076247276 NNP O
( BC2GM076247276 ( O
PKA BC2GM076247276 NNP O
) BC2GM076247276 ) O
and BC2GM076247276 CC O
a BC2GM076247276 DT O
receptor-specific BC2GM076247276 JJ O
kinase BC2GM076247276 NN O
( BC2GM076247276 ( O
GRK3 BC2GM076247276 NNP O
) BC2GM076247276 ) O
( BC2GM076247276 ( O
Schleicher BC2GM076247276 NNP O
, BC2GM076247276 , O
S. BC2GM076247276 NNP O
, BC2GM076247276 , O
Boekhoff BC2GM076247276 NNP O
, BC2GM076247276 , O
I BC2GM076247276 PRP O
. BC2GM076247276 . O
. . O O

To BC2GM089678817 TO O
study BC2GM089678817 VB O
adaptive BC2GM089678817 JJ O
processes BC2GM089678817 NNS O
following BC2GM089678817 VBG O
spinal BC2GM089678817 JJ O
cord BC2GM089678817 JJ O
injury BC2GM089678817 NN O
, BC2GM089678817 , O
unstructured BC2GM089678817 JJ O
audiotaped BC2GM089678817 VBD O
interviews BC2GM089678817 NNS O
were BC2GM089678817 VBD O
conducted BC2GM089678817 VBN O
on BC2GM089678817 IN O
an BC2GM089678817 DT O
almost BC2GM089678817 RB O
daily BC2GM089678817 JJ O
basis BC2GM089678817 NN O
with BC2GM089678817 IN O
a BC2GM089678817 DT O
30-year-old BC2GM089678817 JJ O
divorced BC2GM089678817 JJ O
male BC2GM089678817 NN O
during BC2GM089678817 IN O
the BC2GM089678817 DT O
first BC2GM089678817 JJ O
3 BC2GM089678817 CD O
months BC2GM089678817 NNS O
of BC2GM089678817 IN O
his BC2GM089678817 PRP$ O
initial BC2GM089678817 JJ O
comprehensive BC2GM089678817 JJ O
inpatient BC2GM089678817 NN O
rehabilitation BC2GM089678817 NN O
. BC2GM089678817 . O
. . O O

Buchstein BC2GM021762963 NNP O
, BC2GM021762963 , O
L.-L BC2GM021762963 NNP O
. BC2GM021762963 . O
. . O O

The BC2GM093786389 DT O
higher BC2GM093786389 JJR O
level BC2GM093786389 NN O
of BC2GM093786389 IN O
calories BC2GM093786389 NNS O
was BC2GM093786389 VBD O
attained BC2GM093786389 VBN O
by BC2GM093786389 IN O
an BC2GM093786389 DT O
increased BC2GM093786389 JJ O
intake BC2GM093786389 NN O
of BC2GM093786389 IN O
carbohydrates BC2GM093786389 NNS O
. BC2GM093786389 . O
. . O O

In BC2GM069598999 IN O
Experiment BC2GM069598999 NNP O
2 BC2GM069598999 CD O
, BC2GM069598999 , O
levels BC2GM069598999 NNS O
were BC2GM069598999 VBD O
: BC2GM069598999 : O
amprolium BC2GM069598999 NN O
and BC2GM069598999 CC O
ethopabate BC2GM069598999 NN O
, BC2GM069598999 , O
.02 BC2GM069598999 CD O
% BC2GM069598999 NN O
; BC2GM069598999 : O
salinomycin BC2GM069598999 NN O
, BC2GM069598999 , O
55 BC2GM069598999 CD O
mg BC2GM069598999 NN O
/ BC2GM069598999 NNP O
kg BC2GM069598999 NN O
; BC2GM069598999 : O
monensin BC2GM069598999 NN O
, BC2GM069598999 , O
99 BC2GM069598999 CD O
mg BC2GM069598999 NN O
/ BC2GM069598999 NNP O
kg BC2GM069598999 NN O
; BC2GM069598999 : O
and BC2GM069598999 CC O
lasalocid BC2GM069598999 VB O
, BC2GM069598999 , O
110 BC2GM069598999 CD O
mg BC2GM069598999 NN O
/ BC2GM069598999 NNP O
kg BC2GM069598999 NN O
. BC2GM069598999 . O
. . O O

Correlation BC2GM004210078 NN O
of BC2GM004210078 IN O
nitrogen BC2GM004210078 NN O
, BC2GM004210078 , O
carbohydrate BC2GM004210078 NN O
and BC2GM004210078 CC O
lipid BC2GM004210078 JJ O
metabolic BC2GM004210078 JJ O
indices BC2GM004210078 NNS O
in BC2GM004210078 IN O
rats BC2GM004210078 NNS O
cooled BC2GM004210078 VBN O
under BC2GM004210078 IN O
conditions BC2GM004210078 NNS O
of BC2GM004210078 IN O
an BC2GM004210078 DT O
altered BC2GM004210078 JJ O
gaseous BC2GM004210078 JJ O
environment BC2GM004210078 NN O
. BC2GM004210078 . O
. . O O

A BC2GM080439811 DT O
single BC2GM080439811 JJ O
clone BC2GM080439811 NN O
, BC2GM080439811 , O
which BC2GM080439811 WDT O
was BC2GM080439811 VBD O
conserved BC2GM080439811 VBN O
and BC2GM080439811 CC O
had BC2GM080439811 VBD O
near-perfect BC2GM080439811 JJ O
homology BC2GM080439811 NN O
to BC2GM080439811 TO O
eight BC2GM080439811 CD O
human BC2GM080439811 NNS O
/ BC2GM080439811 NNP O
rodent BC2GM080439811 NN O
expressed BC2GM080439811 VBD O
sequence BC2GM080439811 NN O
tags BC2GM080439811 NNS O
, BC2GM080439811 , O
was BC2GM080439811 VBD O
used BC2GM080439811 VBN O
as BC2GM080439811 IN O
template BC2GM080439811 NN O
for BC2GM080439811 IN O
5 BC2GM080439811 CD O
' BC2GM080439811 POS O
and BC2GM080439811 CC O
3 BC2GM080439811 CD O
' BC2GM080439811 '' O
rapid BC2GM080439811 JJ O
amplification BC2GM080439811 NN O
of BC2GM080439811 IN O
cDNA BC2GM080439811 NN O
ends BC2GM080439811 NNS O
and BC2GM080439811 CC O
SPICE BC2GM080439811 NNP O
( BC2GM080439811 ( O
system BC2GM080439811 NN O
for BC2GM080439811 IN O
polymerase BC2GM080439811 NN O
chain BC2GM080439811 NN O
reaction BC2GM080439811 NN O
amplification BC2GM080439811 NN O
of BC2GM080439811 IN O
cDNA BC2GM080439811 NN O
ends BC2GM080439811 NNS O
) BC2GM080439811 ) O
reactions BC2GM080439811 NNS O
to BC2GM080439811 TO O
obtain BC2GM080439811 VB O
the BC2GM080439811 DT O
3.6-kb BC2GM080439811 JJ O
cDNA BC2GM080439811 NN O
, BC2GM080439811 , O
LGL2 BC2GM080439811 NNP O
( BC2GM080439811 ( O
Genbank BC2GM080439811 NNP O
, BC2GM080439811 , O
AF BC2GM080439811 NNP O
110195 BC2GM080439811 CD O
) BC2GM080439811 ) O
encoding BC2GM080439811 VBG O
a BC2GM080439811 DT O
deduced BC2GM080439811 JJ O
polypeptide BC2GM080439811 NN O
( BC2GM080439811 ( O
lgl2 BC2GM080439811 JJ O
) BC2GM080439811 ) O
of BC2GM080439811 IN O
963 BC2GM080439811 CD O
amino BC2GM080439811 JJ O
acids BC2GM080439811 NNS O
. BC2GM080439811 . O
. . O O

These BC2GM079551353 DT O
results BC2GM079551353 NNS O
indicate BC2GM079551353 VBP O
that BC2GM079551353 IN O
the BC2GM079551353 DT O
2127-bp BC2GM079551353 JJ O
cDNA BC2GM079551353 NN O
encodes BC2GM079551353 VBZ O
a BC2GM079551353 DT O
functional BC2GM079551353 JJ O
feline BC2GM079551353 NN O
L BC2GM079551353 NNP O
/ BC2GM079551353 NNP O
B BC2GM079551353 NNP O
/ BC2GM079551353 NNP O
K-type BC2GM079551353 NNP O
ALP BC2GM079551353 NNP O
expressed BC2GM079551353 VBD O
on BC2GM079551353 IN O
cell BC2GM079551353 NN O
surfaces BC2GM079551353 NNS O
via BC2GM079551353 IN O
phosphatidylinositol-glycan BC2GM079551353 JJ O
linkage BC2GM079551353 NN O
. BC2GM079551353 . O
. . O O

These BC2GM057810743 DT O
patients BC2GM057810743 NNS O
developed BC2GM057810743 VBD O
severe BC2GM057810743 JJ O
diabetic BC2GM057810743 JJ O
symptoms BC2GM057810743 NNS O
including BC2GM057810743 VBG O
glucose BC2GM057810743 JJ O
intolerance BC2GM057810743 NN O
, BC2GM057810743 , O
weight BC2GM057810743 JJ O
loss BC2GM057810743 NN O
, BC2GM057810743 , O
impaired BC2GM057810743 JJ O
energy BC2GM057810743 NN O
utilization BC2GM057810743 NN O
, BC2GM057810743 , O
and BC2GM057810743 CC O
nerve BC2GM057810743 NN O
and BC2GM057810743 CC O
brain BC2GM057810743 NN O
disorders BC2GM057810743 NNS O
that BC2GM057810743 WDT O
were BC2GM057810743 VBD O
refractory BC2GM057810743 JJ O
to BC2GM057810743 TO O
insulin BC2GM057810743 VB O
. BC2GM057810743 . O
. . O O

However BC2GM089615963 RB O
, BC2GM089615963 , O
mutations BC2GM089615963 NNS O
of BC2GM089615963 IN O
the BC2GM089615963 DT O
C-rich BC2GM089615963 NNP O
element BC2GM089615963 NN O
that BC2GM089615963 WDT O
disrupted BC2GM089615963 VBD O
a BC2GM089615963 DT O
GC BC2GM089615963 NNP O
box BC2GM089615963 NN O
located BC2GM089615963 VBN O
on BC2GM089615963 IN O
the BC2GM089615963 DT O
inverse BC2GM089615963 NN O
strand BC2GM089615963 NN O
eliminated BC2GM089615963 VBD O
PMA BC2GM089615963 NNP O
responsiveness BC2GM089615963 NN O
and BC2GM089615963 CC O
, BC2GM089615963 , O
in BC2GM089615963 IN O
gel BC2GM089615963 JJ O
mobility BC2GM089615963 NN O
shift BC2GM089615963 NN O
assays BC2GM089615963 NNS O
, BC2GM089615963 , O
eliminated BC2GM089615963 VBD O
binding BC2GM089615963 NN O
of BC2GM089615963 IN O
Sp1 BC2GM089615963 NNP O
. BC2GM089615963 . O
. . O O

These BC2GM070645862 DT O
data BC2GM070645862 NNS O
are BC2GM070645862 VBP O
discussed BC2GM070645862 VBN O
in BC2GM070645862 IN O
the BC2GM070645862 DT O
context BC2GM070645862 NN O
of BC2GM070645862 IN O
the BC2GM070645862 DT O
pathogenesis BC2GM070645862 NN O
and BC2GM070645862 CC O
differential BC2GM070645862 JJ O
diagnosis BC2GM070645862 NN O
of BC2GM070645862 IN O
EEC BC2GM070645862 NNP O
. BC2GM070645862 . O
. . O O

Transesophageal BC2GM044423776 NNP O
echocardiography BC2GM044423776 NN O
risk BC2GM044423776 NN O
factors BC2GM044423776 NNS O
for BC2GM044423776 IN O
stroke BC2GM044423776 NN O
in BC2GM044423776 IN O
nonvalvular BC2GM044423776 JJ O
atrial BC2GM044423776 JJ O
fibrillation BC2GM044423776 NN O
. BC2GM044423776 . O
. . O O

On BC2GM052316852 IN O
the BC2GM052316852 DT O
basis BC2GM052316852 NN O
of BC2GM052316852 IN O
experiments BC2GM052316852 NNS O
with BC2GM052316852 IN O
mutant BC2GM052316852 JJ O
virus BC2GM052316852 NN O
and BC2GM052316852 CC O
transfection BC2GM052316852 NN O
with BC2GM052316852 IN O
isolated BC2GM052316852 JJ O
genes BC2GM052316852 NNS O
, BC2GM052316852 , O
the BC2GM052316852 DT O
herpes BC2GM052316852 NNS O
simplex BC2GM052316852 JJ O
virus BC2GM052316852 IN O
immediate-early BC2GM052316852 JJ O
gene BC2GM052316852 NN O
product BC2GM052316852 NN O
ICP4 BC2GM052316852 NNP O
is BC2GM052316852 VBZ O
known BC2GM052316852 VBN O
to BC2GM052316852 TO O
positively BC2GM052316852 RB O
regulate BC2GM052316852 VB O
the BC2GM052316852 DT O
transcription BC2GM052316852 NN O
of BC2GM052316852 IN O
viral BC2GM052316852 JJ O
early BC2GM052316852 JJ O
and BC2GM052316852 CC O
late BC2GM052316852 JJ O
genes BC2GM052316852 NNS O
and BC2GM052316852 CC O
negatively BC2GM052316852 RB O
regulate BC2GM052316852 JJ O
expression BC2GM052316852 NN O
from BC2GM052316852 IN O
its BC2GM052316852 PRP$ O
own BC2GM052316852 JJ O
promoter BC2GM052316852 NN O
. BC2GM052316852 . O
. . O O

Cervical BC2GM036204067 JJ O
CT BC2GM036204067 NNP O
revealed BC2GM036204067 VBD O
an BC2GM036204067 DT O
irregular BC2GM036204067 JJ O
low BC2GM036204067 JJ O
density BC2GM036204067 NN O
at BC2GM036204067 IN O
the BC2GM036204067 DT O
periphery BC2GM036204067 NN O
of BC2GM036204067 IN O
the BC2GM036204067 DT O
cervical BC2GM036204067 JJ O
vertebra BC2GM036204067 NN O
from BC2GM036204067 IN O
the BC2GM036204067 DT O
C2 BC2GM036204067 NNP O
to BC2GM036204067 TO O
C4 BC2GM036204067 NNP O
level BC2GM036204067 NN O
. BC2GM036204067 . O
. . O O

Electrophysiology BC2GM055057838 NN O
and BC2GM055057838 CC O
pharmacology BC2GM055057838 NN O
of BC2GM055057838 IN O
epicardial BC2GM055057838 JJ O
, BC2GM055057838 , O
endocardial BC2GM055057838 JJ O
, BC2GM055057838 , O
and BC2GM055057838 CC O
M BC2GM055057838 NNP O
cells BC2GM055057838 NNS O
. BC2GM055057838 . O
. . O O

The BC2GM050389722 DT O
PEP4 BC2GM050389722 NNP O
gene BC2GM050389722 NN O
was BC2GM050389722 VBD O
isolated BC2GM050389722 VBN O
from BC2GM050389722 IN O
a BC2GM050389722 DT O
genomic BC2GM050389722 JJ O
DNA BC2GM050389722 NNP O
library BC2GM050389722 NN O
by BC2GM050389722 IN O
complementation BC2GM050389722 NN O
of BC2GM050389722 IN O
the BC2GM050389722 DT O
pep4-3 BC2GM050389722 JJ O
mutation BC2GM050389722 NN O
. BC2GM050389722 . O
. . O O

We BC2GM072933790 PRP O
found BC2GM072933790 VBD O
4 BC2GM072933790 CD O
highly BC2GM072933790 RB O
conserved BC2GM072933790 JJ O
regions BC2GM072933790 NNS O
to BC2GM072933790 TO O
vertebrate BC2GM072933790 VB O
Hsp90 BC2GM072933790 NNP O
exclusively BC2GM072933790 RB O
and BC2GM072933790 CC O
27 BC2GM072933790 CD O
amino BC2GM072933790 NN O
acids BC2GM072933790 NNS O
conserved BC2GM072933790 VBD O
among BC2GM072933790 IN O
but BC2GM072933790 CC O
differing BC2GM072933790 VBG O
between BC2GM072933790 IN O
Hsp90 BC2GM072933790 NNP O
alpha BC2GM072933790 NN O
and BC2GM072933790 CC O
Hsp90 BC2GM072933790 NNP O
beta BC2GM072933790 NN O
sequences BC2GM072933790 NNS O
. BC2GM072933790 . O
. . O O

These BC2GM037614071 DT O
results BC2GM037614071 NNS O
suggest BC2GM037614071 VBP O
that BC2GM037614071 IN O
the BC2GM037614071 DT O
PVB BC2GM037614071 NNP O
therapy BC2GM037614071 NN O
is BC2GM037614071 VBZ O
not BC2GM037614071 RB O
sufficient BC2GM037614071 JJ O
to BC2GM037614071 TO O
cure BC2GM037614071 VB O
the BC2GM037614071 DT O
cases BC2GM037614071 NNS O
with BC2GM037614071 IN O
choriocarcinoma BC2GM037614071 JJ O
element BC2GM037614071 NN O
or BC2GM037614071 CC O
bulky BC2GM037614071 JJ O
metastasis BC2GM037614071 NN O
. BC2GM037614071 . O
. . O O

We BC2GM084137425 PRP O
have BC2GM084137425 VBP O
been BC2GM084137425 VBN O
developing BC2GM084137425 VBG O
a BC2GM084137425 DT O
digital BC2GM084137425 JJ O
fluoroscopic BC2GM084137425 NN O
imaging BC2GM084137425 VBG O
system BC2GM084137425 NN O
to BC2GM084137425 TO O
replace BC2GM084137425 VB O
the BC2GM084137425 DT O
portal BC2GM084137425 JJ O
films BC2GM084137425 NNS O
that BC2GM084137425 WDT O
are BC2GM084137425 VBP O
currently BC2GM084137425 RB O
used BC2GM084137425 VBN O
to BC2GM084137425 TO O
verify BC2GM084137425 VB O
patient BC2GM084137425 JJ O
positioning BC2GM084137425 VBG O
during BC2GM084137425 IN O
radiotherapy BC2GM084137425 NN O
treatments BC2GM084137425 NNS O
. BC2GM084137425 . O
. . O O

The BC2GM094180317 DT O
in BC2GM094180317 IN O
vivo BC2GM094180317 JJ O
response BC2GM094180317 NN O
of BC2GM094180317 IN O
the BC2GM094180317 DT O
PacC-like BC2GM094180317 JJ O
decamers BC2GM094180317 NNS O
to BC2GM094180317 TO O
external BC2GM094180317 JJ O
pH BC2GM094180317 NN O
was BC2GM094180317 VBD O
dependent BC2GM094180317 JJ O
on BC2GM094180317 IN O
the BC2GM094180317 DT O
status BC2GM094180317 NN O
of BC2GM094180317 IN O
the BC2GM094180317 DT O
pH-regulated BC2GM094180317 JJ O
activator BC2GM094180317 NN O
YlRim101p BC2GM094180317 NNP O
, BC2GM094180317 , O
which BC2GM094180317 WDT O
is BC2GM094180317 VBZ O
homologous BC2GM094180317 JJ O
to BC2GM094180317 TO O
the BC2GM094180317 DT O
A. BC2GM094180317 NN O
nidulans BC2GM094180317 VBZ O
PacC BC2GM094180317 NNP O
regulator BC2GM094180317 NN O
. BC2GM094180317 . O
. . O O

It BC2GM047020001 PRP O
was BC2GM047020001 VBD O
previously BC2GM047020001 RB O
shown BC2GM047020001 VBN O
that BC2GM047020001 IN O
Vi BC2GM047020001 NNP O
antigen BC2GM047020001 NN O
expression BC2GM047020001 NN O
was BC2GM047020001 VBD O
regulated BC2GM047020001 VBN O
by BC2GM047020001 IN O
a BC2GM047020001 DT O
system BC2GM047020001 NN O
similar BC2GM047020001 JJ O
to BC2GM047020001 TO O
the BC2GM047020001 DT O
rcs BC2GM047020001 NN O
regulatory BC2GM047020001 JJ O
system BC2GM047020001 NN O
involved BC2GM047020001 VBN O
in BC2GM047020001 IN O
colanic BC2GM047020001 JJ O
acid BC2GM047020001 NN O
synthesis BC2GM047020001 NN O
in BC2GM047020001 IN O
Escherichia BC2GM047020001 NNP O
coli BC2GM047020001 NN O
. BC2GM047020001 . O
. . O O

A BC2GM006948843 DT O
TAAATA BC2GM006948843 NNP O
sequence BC2GM006948843 NN O
is BC2GM006948843 VBZ O
present BC2GM006948843 JJ O
26 BC2GM006948843 CD O
nt BC2GM006948843 JJ O
upstream BC2GM006948843 NN O
from BC2GM006948843 IN O
the BC2GM006948843 DT O
major BC2GM006948843 JJ O
CAP BC2GM006948843 NNP O
site BC2GM006948843 NN O
, BC2GM006948843 , O
and BC2GM006948843 CC O
within BC2GM006948843 IN O
the BC2GM006948843 DT O
5'-flanking BC2GM006948843 JJ O
region BC2GM006948843 NN O
there BC2GM006948843 EX O
are BC2GM006948843 VBP O
several BC2GM006948843 JJ O
putative BC2GM006948843 JJ O
transcription BC2GM006948843 NN O
factor BC2GM006948843 NN O
binding BC2GM006948843 VBG O
sites BC2GM006948843 NNS O
. BC2GM006948843 . O
. . O O

Nuclear BC2GM065802628 JJ O
export BC2GM065802628 NN O
of BC2GM065802628 IN O
proteins BC2GM065802628 NNS O
in BC2GM065802628 IN O
plants BC2GM065802628 NNS O
: BC2GM065802628 : O
AtXPO1 BC2GM065802628 NNP O
is BC2GM065802628 VBZ O
the BC2GM065802628 DT O
export BC2GM065802628 NN O
receptor BC2GM065802628 NN O
for BC2GM065802628 IN O
leucine-rich BC2GM065802628 JJ O
nuclear BC2GM065802628 JJ O
export BC2GM065802628 NN O
signals BC2GM065802628 NNS O
in BC2GM065802628 IN O
Arabidopsis BC2GM065802628 NNP O
thaliana BC2GM065802628 NN O
. BC2GM065802628 . O
. . O O

Evolution BC2GM009448248 NN O
of BC2GM009448248 IN O
cytomegalovirus BC2GM009448248 NN O
antibodies BC2GM009448248 NNS O
of BC2GM009448248 IN O
maternal BC2GM009448248 JJ O
origin BC2GM009448248 NN O
and BC2GM009448248 CC O
acquired BC2GM009448248 VBD O
, BC2GM009448248 , O
throughout BC2GM009448248 IN O
the BC2GM009448248 DT O
first BC2GM009448248 JJ O
year BC2GM009448248 NN O
of BC2GM009448248 IN O
life BC2GM009448248 NN O
. BC2GM009448248 . O
. . O O

Genealogical BC2GM032887840 JJ O
analysis BC2GM032887840 NN O
suggested BC2GM032887840 VBD O
mainly BC2GM032887840 RB O
a BC2GM032887840 DT O
mother-to-offspring BC2GM032887840 JJ O
transmission BC2GM032887840 NN O
of BC2GM032887840 IN O
this BC2GM032887840 DT O
STLV-1 BC2GM032887840 NNP O
. BC2GM032887840 . O
. . O O

Cytochrome BC2GM068580780 NNP O
bd BC2GM068580780 NN O
biosynthesis BC2GM068580780 NN O
in BC2GM068580780 IN O
Escherichia BC2GM068580780 NNP O
coli BC2GM068580780 NN O
: BC2GM068580780 : O
the BC2GM068580780 DT O
sequences BC2GM068580780 NNS O
of BC2GM068580780 IN O
the BC2GM068580780 DT O
cydC BC2GM068580780 NN O
and BC2GM068580780 CC O
cydD BC2GM068580780 NN O
genes BC2GM068580780 NNS O
suggest BC2GM068580780 VBP O
that BC2GM068580780 IN O
they BC2GM068580780 PRP O
encode BC2GM068580780 VBP O
the BC2GM068580780 DT O
components BC2GM068580780 NNS O
of BC2GM068580780 IN O
an BC2GM068580780 DT O
ABC BC2GM068580780 NNP O
membrane BC2GM068580780 NN O
transporter BC2GM068580780 NN O
. BC2GM068580780 . O
. . O O

The BC2GM065743412 DT O
nramp2 BC2GM065743412 JJ O
gene BC2GM065743412 NN O
is BC2GM065743412 VBZ O
comprised BC2GM065743412 VBN O
of BC2GM065743412 IN O
17 BC2GM065743412 CD O
exons BC2GM065743412 NNS O
and BC2GM065743412 CC O
spans BC2GM065743412 VBZ O
more BC2GM065743412 JJR O
than BC2GM065743412 IN O
36 BC2GM065743412 CD O
kb BC2GM065743412 NN O
. BC2GM065743412 . O
. . O O

In BC2GM080063852 IN O
two BC2GM080063852 CD O
of BC2GM080063852 IN O
these BC2GM080063852 DT O
nine BC2GM080063852 CD O
patients BC2GM080063852 NNS O
, BC2GM080063852 , O
a BC2GM080063852 DT O
decrease BC2GM080063852 NN O
in BC2GM080063852 IN O
dyskinesia BC2GM080063852 NN O
score BC2GM080063852 NN O
was BC2GM080063852 VBD O
observed BC2GM080063852 VBN O
without BC2GM080063852 IN O
a BC2GM080063852 DT O
concomitant BC2GM080063852 JJ O
worsening BC2GM080063852 NN O
of BC2GM080063852 IN O
parkinsonian BC2GM080063852 JJ O
symptoms BC2GM080063852 NNS O
, BC2GM080063852 , O
whereas BC2GM080063852 NNS O
in BC2GM080063852 IN O
the BC2GM080063852 DT O
remaining BC2GM080063852 VBG O
seven BC2GM080063852 CD O
, BC2GM080063852 , O
full BC2GM080063852 JJ O
parkinsonian BC2GM080063852 NN O
akinesia BC2GM080063852 NN O
followed BC2GM080063852 VBD O
THDL BC2GM080063852 NNP O
administration BC2GM080063852 NN O
. BC2GM080063852 . O
. . O O

Ocular BC2GM028406999 JJ O
injuries BC2GM028406999 NNS O
during BC2GM028406999 IN O
general BC2GM028406999 JJ O
anesthesia BC2GM028406999 NN O
. BC2GM028406999 . O
. . O O

Here BC2GM088125306 RB O
we BC2GM088125306 PRP O
investigate BC2GM088125306 VBP O
the BC2GM088125306 DT O
mechanism BC2GM088125306 NN O
of BC2GM088125306 IN O
TPA BC2GM088125306 NNP O
induction BC2GM088125306 NN O
of BC2GM088125306 IN O
FGF-BP BC2GM088125306 NNP O
gene BC2GM088125306 NN O
expression BC2GM088125306 NN O
in BC2GM088125306 IN O
the BC2GM088125306 DT O
human BC2GM088125306 JJ O
ME-180 BC2GM088125306 NNP O
SCC BC2GM088125306 NNP O
cell BC2GM088125306 NN O
line BC2GM088125306 NN O
. BC2GM088125306 . O
. . O O

A BC2GM072704944 DT O
. BC2GM072704944 . O
. . O O

Identification BC2GM002830287 NN O
of BC2GM002830287 IN O
a BC2GM002830287 DT O
68-kilodalton BC2GM002830287 JJ O
nuclear BC2GM002830287 JJ O
ATP-binding BC2GM002830287 JJ O
phosphoprotein BC2GM002830287 NN O
encoded BC2GM002830287 VBN O
by BC2GM002830287 IN O
bovine BC2GM002830287 NN O
papillomavirus BC2GM002830287 NN O
type BC2GM002830287 NN O
1 BC2GM002830287 CD O
. BC2GM002830287 . O
. . O O

Our BC2GM082766404 PRP$ O
current BC2GM082766404 JJ O
study BC2GM082766404 NN O
aims BC2GM082766404 NNS O
at BC2GM082766404 IN O
clarifying BC2GM082766404 VBG O
the BC2GM082766404 DT O
role BC2GM082766404 NN O
of BC2GM082766404 IN O
myristoylation BC2GM082766404 NN O
in BC2GM082766404 IN O
caveolar BC2GM082766404 JJ O
targeting BC2GM082766404 VBG O
using BC2GM082766404 VBG O
well-characterized BC2GM082766404 JJ O
acylation BC2GM082766404 NN O
mutants BC2GM082766404 NNS O
of BC2GM082766404 IN O
two BC2GM082766404 CD O
model BC2GM082766404 NN O
proteins BC2GM082766404 NNS O
, BC2GM082766404 , O
namely BC2GM082766404 RB O
Gi1 BC2GM082766404 NNP O
alpha BC2GM082766404 NN O
and BC2GM082766404 CC O
c-Src BC2GM082766404 NN O
. BC2GM082766404 . O
. . O O

Km BC2GM065946297 NNP O
values BC2GM065946297 NNS O
of BC2GM065946297 IN O
the BC2GM065946297 DT O
uncoupled BC2GM065946297 JJ O
enzymes BC2GM065946297 NNS O
IIGlc BC2GM065946297 NNP O
for BC2GM065946297 IN O
glucose BC2GM065946297 RB O
ranged BC2GM065946297 VBN O
from BC2GM065946297 IN O
0.5 BC2GM065946297 CD O
to BC2GM065946297 TO O
2.5 BC2GM065946297 CD O
mM BC2GM065946297 NNS O
, BC2GM065946297 , O
2 BC2GM065946297 CD O
orders BC2GM065946297 NNS O
of BC2GM065946297 IN O
magnitude BC2GM065946297 NN O
higher BC2GM065946297 JJR O
than BC2GM065946297 IN O
the BC2GM065946297 DT O
value BC2GM065946297 NN O
of BC2GM065946297 IN O
normal BC2GM065946297 JJ O
IIGlc BC2GM065946297 NNP O
. BC2GM065946297 . O
. . O O

The BC2GM003261420 DT O
c-raf-1 BC2GM003261420 JJ O
proto-oncogene BC2GM003261420 NN O
is BC2GM003261420 VBZ O
the BC2GM003261420 DT O
cellular BC2GM003261420 JJ O
homologue BC2GM003261420 NN O
of BC2GM003261420 IN O
v-raf BC2GM003261420 NN O
, BC2GM003261420 , O
the BC2GM003261420 DT O
oncogene BC2GM003261420 NN O
of BC2GM003261420 IN O
the BC2GM003261420 DT O
acutely BC2GM003261420 RB O
transforming BC2GM003261420 VBG O
retrovirus BC2GM003261420 JJ O
3611-MSV BC2GM003261420 JJ O
. BC2GM003261420 . O
. . O O

Magnetic BC2GM092424481 JJ O
field BC2GM092424481 NN O
influence BC2GM092424481 NN O
on BC2GM092424481 IN O
central BC2GM092424481 JJ O
nervous BC2GM092424481 JJ O
system BC2GM092424481 NN O
function BC2GM092424481 NN O
. BC2GM092424481 . O
. . O O

UICC BC2GM042797974 NNP O
criteria BC2GM042797974 NNS O
) BC2GM042797974 ) O
for BC2GM042797974 IN O
VM BC2GM042797974 NNP O
and BC2GM042797974 CC O
35 BC2GM042797974 CD O
% BC2GM042797974 NN O
for BC2GM042797974 IN O
VE BC2GM042797974 NNP O
( BC2GM042797974 ( O
not BC2GM042797974 RB O
significant BC2GM042797974 JJ O
) BC2GM042797974 ) O
. BC2GM042797974 . O
. . O O

Furthermore BC2GM004196044 RB O
, BC2GM004196044 , O
Grap BC2GM004196044 NNP O
is BC2GM004196044 VBZ O
associated BC2GM004196044 VBN O
with BC2GM004196044 IN O
a BC2GM004196044 DT O
Ras BC2GM004196044 NNP O
guanine BC2GM004196044 NN O
nucleotide BC2GM004196044 RB O
exchange BC2GM004196044 NN O
factor BC2GM004196044 NN O
mSos1 BC2GM004196044 NN O
, BC2GM004196044 , O
primarily BC2GM004196044 RB O
through BC2GM004196044 IN O
its BC2GM004196044 PRP$ O
N-terminal BC2GM004196044 JJ O
SH3 BC2GM004196044 NNP O
domain BC2GM004196044 NN O
. BC2GM004196044 . O
. . O O

Assays BC2GM024592460 NNS O
of BC2GM024592460 IN O
APRE-luciferase BC2GM024592460 NNP O
reporter BC2GM024592460 NN O
plasmids BC2GM024592460 NNS O
transfected BC2GM024592460 VBD O
into BC2GM024592460 IN O
HepG2 BC2GM024592460 NNP O
cells BC2GM024592460 NNS O
show BC2GM024592460 VBP O
that BC2GM024592460 IN O
a BC2GM024592460 DT O
mutated BC2GM024592460 JJ O
APRE BC2GM024592460 NNP O
that BC2GM024592460 IN O
binds BC2GM024592460 VBZ O
only BC2GM024592460 RB O
BPi BC2GM024592460 NNP O
functions BC2GM024592460 NNS O
as BC2GM024592460 IN O
an BC2GM024592460 DT O
IL-1 BC2GM024592460 JJ O
alpha BC2GM024592460 NN O
inducible BC2GM024592460 JJ O
enhancer BC2GM024592460 NN O
, BC2GM024592460 , O
whereas BC2GM024592460 IN O
a BC2GM024592460 DT O
mutated BC2GM024592460 JJ O
APRE BC2GM024592460 NNP O
that BC2GM024592460 IN O
binds BC2GM024592460 VBZ O
only BC2GM024592460 RB O
BPc BC2GM024592460 NNP O
does BC2GM024592460 VBZ O
not BC2GM024592460 RB O
. BC2GM024592460 . O
. . O O

We BC2GM020300405 PRP O
propose BC2GM020300405 VBP O
that BC2GM020300405 IN O
unc-37 BC2GM020300405 JJ O
may BC2GM020300405 MD O
be BC2GM020300405 VB O
regulated BC2GM020300405 VBN O
by BC2GM020300405 IN O
unc-4 BC2GM020300405 JJ O
. BC2GM020300405 . O
. . O O

The BC2GM017195618 DT O
studies BC2GM017195618 NNS O
permit BC2GM017195618 VBP O
considering BC2GM017195618 VBG O
the BC2GM017195618 DT O
detected BC2GM017195618 JJ O
shifts BC2GM017195618 NNS O
in BC2GM017195618 IN O
the BC2GM017195618 DT O
immunity BC2GM017195618 NN O
system BC2GM017195618 NN O
an BC2GM017195618 DT O
important BC2GM017195618 JJ O
component BC2GM017195618 NN O
of BC2GM017195618 IN O
the BC2GM017195618 DT O
pathogenesis BC2GM017195618 NN O
of BC2GM017195618 IN O
chronic BC2GM017195618 JJ O
nontumorous BC2GM017195618 JJ O
diseases BC2GM017195618 NNS O
of BC2GM017195618 IN O
the BC2GM017195618 DT O
parotid BC2GM017195618 NN O
glands BC2GM017195618 NNS O
. BC2GM017195618 . O
. . O O

These BC2GM082960134 DT O
back BC2GM082960134 JJ O
mutations BC2GM082960134 NNS O
led BC2GM082960134 VBD O
to BC2GM082960134 TO O
a BC2GM082960134 DT O
modest BC2GM082960134 JJ O
decrease BC2GM082960134 NN O
in BC2GM082960134 IN O
kinase BC2GM082960134 NN O
activity BC2GM082960134 NN O
, BC2GM082960134 , O
decreased BC2GM082960134 VBN O
tumorigenic BC2GM082960134 JJ O
potential BC2GM082960134 NN O
in BC2GM082960134 IN O
chickens BC2GM082960134 NNS O
, BC2GM082960134 , O
and BC2GM082960134 CC O
an BC2GM082960134 DT O
unexpected BC2GM082960134 JJ O
increase BC2GM082960134 NN O
in BC2GM082960134 IN O
transforming BC2GM082960134 VBG O
activity BC2GM082960134 NN O
in BC2GM082960134 IN O
rat BC2GM082960134 NN O
cells BC2GM082960134 NNS O
. BC2GM082960134 . O
. . O O

The BC2GM070175350 DT O
results BC2GM070175350 NNS O
suggest BC2GM070175350 VBP O
that BC2GM070175350 IN O
the BC2GM070175350 DT O
posterior BC2GM070175350 NN O
wall BC2GM070175350 NN O
is BC2GM070175350 VBZ O
more BC2GM070175350 RBR O
compliant BC2GM070175350 JJ O
than BC2GM070175350 IN O
the BC2GM070175350 DT O
anterior BC2GM070175350 JJ O
wall BC2GM070175350 NN O
( BC2GM070175350 ( O
that BC2GM070175350 WDT O
is BC2GM070175350 VBZ O
, BC2GM070175350 , O
for BC2GM070175350 IN O
a BC2GM070175350 DT O
given BC2GM070175350 VBN O
difference BC2GM070175350 NN O
in BC2GM070175350 IN O
transmural BC2GM070175350 JJ O
pressure BC2GM070175350 NN O
, BC2GM070175350 , O
the BC2GM070175350 DT O
local BC2GM070175350 JJ O
segment BC2GM070175350 NN O
length BC2GM070175350 NN O
change BC2GM070175350 NN O
of BC2GM070175350 IN O
the BC2GM070175350 DT O
posterior BC2GM070175350 NN O
wall BC2GM070175350 NN O
was BC2GM070175350 VBD O
greater BC2GM070175350 JJR O
) BC2GM070175350 ) O
. BC2GM070175350 . O
. . O O

Comparison BC2GM053725258 NNP O
of BC2GM053725258 IN O
Healon BC2GM053725258 NNP O
and BC2GM053725258 CC O
Amvisc BC2GM053725258 NNP O
. BC2GM053725258 . O
. . O O

The BC2GM011075999 DT O
rate BC2GM011075999 NN O
of BC2GM011075999 IN O
collagen BC2GM011075999 NN O
synthesis BC2GM011075999 NN O
in BC2GM011075999 IN O
normal BC2GM011075999 JJ O
scar BC2GM011075999 NN O
was BC2GM011075999 VBD O
approximately BC2GM011075999 RB O
constant BC2GM011075999 JJ O
between BC2GM011075999 IN O
6 BC2GM011075999 CD O
months BC2GM011075999 NNS O
and BC2GM011075999 CC O
20 BC2GM011075999 CD O
years BC2GM011075999 NNS O
after BC2GM011075999 IN O
the BC2GM011075999 DT O
initial BC2GM011075999 JJ O
wounding BC2GM011075999 NN O
, BC2GM011075999 , O
but BC2GM011075999 CC O
in BC2GM011075999 IN O
both BC2GM011075999 DT O
hypertrophic BC2GM011075999 JJ O
scar BC2GM011075999 NN O
and BC2GM011075999 CC O
keloid BC2GM011075999 VB O
the BC2GM011075999 DT O
rate BC2GM011075999 NN O
was BC2GM011075999 VBD O
initially BC2GM011075999 RB O
approximately BC2GM011075999 RB O
twice BC2GM011075999 JJ O
that BC2GM011075999 IN O
in BC2GM011075999 IN O
normal BC2GM011075999 JJ O
scar BC2GM011075999 NN O
, BC2GM011075999 , O
and BC2GM011075999 CC O
2-3 BC2GM011075999 CD O
years BC2GM011075999 NNS O
after BC2GM011075999 IN O
wounding BC2GM011075999 VBG O
it BC2GM011075999 PRP O
fell BC2GM011075999 VBD O
to BC2GM011075999 TO O
approximately BC2GM011075999 RB O
the BC2GM011075999 DT O
same BC2GM011075999 JJ O
level BC2GM011075999 NN O
as BC2GM011075999 IN O
in BC2GM011075999 IN O
normal BC2GM011075999 JJ O
scar BC2GM011075999 NN O
. BC2GM011075999 . O
. . O O

Virgin BC2GM018871936 NNP O
, BC2GM018871936 , O
P BC2GM018871936 NNP O
. BC2GM018871936 . O
. . O O

The BC2GM057418939 DT O
induction BC2GM057418939 NN O
of BC2GM057418939 IN O
the BC2GM057418939 DT O
composite BC2GM057418939 JJ O
H-PK BC2GM057418939 NNP O
/ BC2GM057418939 NNP O
Tag BC2GM057418939 NNP O
and BC2GM057418939 CC O
SV-PK BC2GM057418939 NNP O
/ BC2GM057418939 NNP O
Tag BC2GM057418939 NNP O
transgenes BC2GM057418939 NNS O
by BC2GM057418939 IN O
a BC2GM057418939 DT O
carbohydrate-rich BC2GM057418939 JJ O
diet BC2GM057418939 NN O
in BC2GM057418939 IN O
the BC2GM057418939 DT O
liver BC2GM057418939 NN O
was BC2GM057418939 VBD O
similar BC2GM057418939 JJ O
to BC2GM057418939 TO O
that BC2GM057418939 DT O
of BC2GM057418939 IN O
the BC2GM057418939 DT O
endogenous BC2GM057418939 JJ O
L-PK BC2GM057418939 JJ O
gene BC2GM057418939 NN O
. BC2GM057418939 . O
. . O O

Our BC2GM055784735 PRP$ O
data BC2GM055784735 NNS O
indicate BC2GM055784735 VBP O
that BC2GM055784735 IN O
the BC2GM055784735 DT O
various BC2GM055784735 JJ O
subunits BC2GM055784735 NNS O
of BC2GM055784735 IN O
the BC2GM055784735 DT O
human BC2GM055784735 JJ O
P-TEFb BC2GM055784735 NNP O
complex BC2GM055784735 NN O
may BC2GM055784735 MD O
play BC2GM055784735 VB O
distinct BC2GM055784735 JJ O
roles BC2GM055784735 NNS O
at BC2GM055784735 IN O
multiple BC2GM055784735 JJ O
stages BC2GM055784735 NNS O
to BC2GM055784735 TO O
mediate BC2GM055784735 VB O
Tat BC2GM055784735 NNP O
activation BC2GM055784735 NN O
of BC2GM055784735 IN O
HIV-1 BC2GM055784735 NNP O
transcription BC2GM055784735 NN O
elongation BC2GM055784735 NN O
. BC2GM055784735 . O
. . O O

We BC2GM092640548 PRP O
now BC2GM092640548 RB O
show BC2GM092640548 VBP O
that BC2GM092640548 IN O
the BC2GM092640548 DT O
FRAP BC2GM092640548 NNP O
Ser2035 BC2GM092640548 NNP O
-- BC2GM092640548 : O
> BC2GM092640548 JJ O
Ala BC2GM092640548 NNP O
mutant BC2GM092640548 NN O
displays BC2GM092640548 NNS O
similar BC2GM092640548 JJ O
binding BC2GM092640548 VBG O
affinity BC2GM092640548 NN O
when BC2GM092640548 WRB O
compared BC2GM092640548 VBN O
with BC2GM092640548 IN O
the BC2GM092640548 DT O
wild-type BC2GM092640548 JJ O
protein BC2GM092640548 NN O
, BC2GM092640548 , O
whereas BC2GM092640548 IN O
all BC2GM092640548 DT O
other BC2GM092640548 JJ O
mutations BC2GM092640548 NNS O
at BC2GM092640548 IN O
this BC2GM092640548 DT O
site BC2GM092640548 NN O
, BC2GM092640548 , O
including BC2GM092640548 VBG O
mimics BC2GM092640548 NNS O
of BC2GM092640548 IN O
phosphoserine BC2GM092640548 NN O
, BC2GM092640548 , O
abolish BC2GM092640548 JJ O
binding BC2GM092640548 NN O
, BC2GM092640548 , O
presumably BC2GM092640548 RB O
due BC2GM092640548 JJ O
to BC2GM092640548 TO O
either BC2GM092640548 DT O
unfavorable BC2GM092640548 JJ O
steric BC2GM092640548 JJ O
interactions BC2GM092640548 NNS O
or BC2GM092640548 CC O
induced BC2GM092640548 VBN O
conformational BC2GM092640548 JJ O
changes BC2GM092640548 NNS O
. BC2GM092640548 . O
. . O O

Rabbit BC2GM058761763 NNP O
KCC1 BC2GM058761763 NNP O
( BC2GM058761763 ( O
rbKCC1 BC2GM058761763 NN O
) BC2GM058761763 ) O
and BC2GM058761763 CC O
rat BC2GM058761763 $ O
KCC1 BC2GM058761763 NNP O
( BC2GM058761763 ( O
rtKCC1 BC2GM058761763 NN O
) BC2GM058761763 ) O
were BC2GM058761763 VBD O
cloned BC2GM058761763 VBN O
by BC2GM058761763 IN O
screening BC2GM058761763 VBG O
rabbit BC2GM058761763 NN O
kidney BC2GM058761763 NN O
and BC2GM058761763 CC O
rat BC2GM058761763 NN O
brain BC2GM058761763 NN O
cDNA BC2GM058761763 NN O
libraries BC2GM058761763 NNS O
using BC2GM058761763 VBG O
homologous BC2GM058761763 JJ O
cDNA BC2GM058761763 NN O
probes BC2GM058761763 NNS O
. BC2GM058761763 . O
. . O O

We BC2GM076511044 PRP O
determined BC2GM076511044 VBD O
the BC2GM076511044 DT O
complete BC2GM076511044 JJ O
nucleotide BC2GM076511044 JJ O
sequence BC2GM076511044 NN O
of BC2GM076511044 IN O
the BC2GM076511044 DT O
gypsy BC2GM076511044 NN O
element BC2GM076511044 NN O
present BC2GM076511044 NN O
at BC2GM076511044 IN O
the BC2GM076511044 DT O
forked BC2GM076511044 JJ O
locus BC2GM076511044 NN O
of BC2GM076511044 IN O
Drosophila BC2GM076511044 NNP O
melanogaster BC2GM076511044 NN O
in BC2GM076511044 IN O
the BC2GM076511044 DT O
f1 BC2GM076511044 NN O
allele BC2GM076511044 NN O
. BC2GM076511044 . O
. . O O

Effect BC2GM061897910 NN O
of BC2GM061897910 IN O
bromocriptine BC2GM061897910 NN O
and BC2GM061897910 CC O
metoclopramide BC2GM061897910 NN O
on BC2GM061897910 IN O
serum BC2GM061897910 NN O
prolactin BC2GM061897910 NN O
levels BC2GM061897910 NNS O
in BC2GM061897910 IN O
patients BC2GM061897910 NNS O
with BC2GM061897910 IN O
amyotrophic BC2GM061897910 JJ O
lateral BC2GM061897910 JJ O
sclerosis BC2GM061897910 NN O
. BC2GM061897910 . O
. . O O

When BC2GM048672886 WRB O
furA BC2GM048672886 NN O
alone BC2GM048672886 RB O
was BC2GM048672886 VBD O
introduced BC2GM048672886 VBN O
into BC2GM048672886 IN O
the BC2GM048672886 DT O
Delta BC2GM048672886 NNP O
( BC2GM048672886 ( O
furA-katG BC2GM048672886 JJ O
) BC2GM048672886 ) O
mutant BC2GM048672886 NN O
, BC2GM048672886 , O
survival BC2GM048672886 NN O
in BC2GM048672886 IN O
mouse BC2GM048672886 NN O
lungs BC2GM048672886 NNS O
was BC2GM048672886 VBD O
moderately BC2GM048672886 RB O
increased BC2GM048672886 VBN O
, BC2GM048672886 , O
suggesting BC2GM048672886 VBG O
that BC2GM048672886 IN O
FurA BC2GM048672886 NNP O
could BC2GM048672886 MD O
regulate BC2GM048672886 VB O
genes BC2GM048672886 NNS O
, BC2GM048672886 , O
other BC2GM048672886 JJ O
than BC2GM048672886 IN O
katG BC2GM048672886 NNS O
, BC2GM048672886 , O
that BC2GM048672886 WDT O
are BC2GM048672886 VBP O
involved BC2GM048672886 VBN O
in BC2GM048672886 IN O
pathogenesis BC2GM048672886 NN O
. BC2GM048672886 . O
. . O O

Transient-expression BC2GM081673758 NN O
assay BC2GM081673758 NN O
analysis BC2GM081673758 NN O
of BC2GM081673758 IN O
subclones BC2GM081673758 NNS O
of BC2GM081673758 IN O
pPstI-G BC2GM081673758 JJ O
localized BC2GM081673758 VBN O
the BC2GM081673758 DT O
trans-active BC2GM081673758 JJ O
factor BC2GM081673758 NN O
to BC2GM081673758 TO O
a BC2GM081673758 DT O
3.0-kilobase BC2GM081673758 JJ O
XbaI BC2GM081673758 NNP O
fragment BC2GM081673758 NN O
. BC2GM081673758 . O
. . O O

Adenovirus BC2GM070545500 NNP O
infection BC2GM070545500 NN O
of BC2GM070545500 IN O
hepatoma BC2GM070545500 NN O
cells BC2GM070545500 NNS O
inhibited BC2GM070545500 JJ O
transcription BC2GM070545500 NN O
of BC2GM070545500 IN O
the BC2GM070545500 DT O
phosphoenolpyruvate BC2GM070545500 NN O
carboxykinase BC2GM070545500 NN O
( BC2GM070545500 ( O
GTP BC2GM070545500 NNP O
) BC2GM070545500 ) O
( BC2GM070545500 ( O
EC BC2GM070545500 NNP O
4.1.1.32 BC2GM070545500 CD O
) BC2GM070545500 ) O
( BC2GM070545500 ( O
PEPCK BC2GM070545500 NNP O
) BC2GM070545500 ) O
gene BC2GM070545500 NN O
and BC2GM070545500 CC O
virtually BC2GM070545500 RB O
eliminated BC2GM070545500 JJ O
transcription BC2GM070545500 NN O
of BC2GM070545500 IN O
a BC2GM070545500 DT O
chimeric BC2GM070545500 JJ O
gene BC2GM070545500 NN O
which BC2GM070545500 WDT O
contained BC2GM070545500 VBD O
the BC2GM070545500 DT O
PEPCK BC2GM070545500 NNP O
promoter BC2GM070545500 NN O
linked BC2GM070545500 VBD O
to BC2GM070545500 TO O
the BC2GM070545500 DT O
structural BC2GM070545500 JJ O
gene BC2GM070545500 NN O
for BC2GM070545500 IN O
chloramphenicol BC2GM070545500 JJ O
acetyltransferase BC2GM070545500 NN O
( BC2GM070545500 ( O
CAT BC2GM070545500 NNP O
) BC2GM070545500 ) O
. BC2GM070545500 . O
. . O O

Correlation BC2GM090460954 NN O
coefficients BC2GM090460954 NNS O
between BC2GM090460954 IN O
SF BC2GM090460954 NNP O
thickness BC2GM090460954 NN O
and BC2GM090460954 CC O
NIR BC2GM090460954 NNP O
optical BC2GM090460954 JJ O
density BC2GM090460954 NN O
readings BC2GM090460954 NNS O
at BC2GM090460954 IN O
940 BC2GM090460954 CD O
nm BC2GM090460954 NN O
( BC2GM090460954 ( O
OD1 BC2GM090460954 NNP O
) BC2GM090460954 ) O
and BC2GM090460954 CC O
950 BC2GM090460954 CD O
nm BC2GM090460954 NN O
( BC2GM090460954 ( O
OD2 BC2GM090460954 NNP O
) BC2GM090460954 ) O
wavelengths BC2GM090460954 NNS O
ranged BC2GM090460954 VBN O
from BC2GM090460954 IN O
r BC2GM090460954 NN O
= BC2GM090460954 NN O
-0.30 BC2GM090460954 NNP O
( BC2GM090460954 ( O
subscapula BC2GM090460954 NN O
) BC2GM090460954 ) O
to BC2GM090460954 TO O
r BC2GM090460954 VB O
= BC2GM090460954 NNP O
-0.67 BC2GM090460954 NNP O
( BC2GM090460954 ( O
biceps BC2GM090460954 NNS O
) BC2GM090460954 ) O
for BC2GM090460954 IN O
OD1 BC2GM090460954 NNP O
and BC2GM090460954 CC O
r BC2GM090460954 NN O
= BC2GM090460954 NN O
-0.39 BC2GM090460954 NNP O
( BC2GM090460954 ( O
axilla BC2GM090460954 NN O
) BC2GM090460954 ) O
to BC2GM090460954 TO O
r BC2GM090460954 VB O
= BC2GM090460954 NNP O
-0.68 BC2GM090460954 NNP O
( BC2GM090460954 ( O
biceps BC2GM090460954 NNS O
) BC2GM090460954 ) O
for BC2GM090460954 IN O
OD2 BC2GM090460954 NNP O
. BC2GM090460954 . O
. . O O

Our BC2GM021489980 PRP$ O
results BC2GM021489980 NNS O
suggest BC2GM021489980 VBP O
that BC2GM021489980 IN O
at BC2GM021489980 IN O
least BC2GM021489980 JJS O
some BC2GM021489980 DT O
chloroplast-like BC2GM021489980 JJ O
tRNA BC2GM021489980 NN O
genes BC2GM021489980 NNS O
in BC2GM021489980 IN O
wheat BC2GM021489980 NN O
mtDNA BC2GM021489980 NN O
are BC2GM021489980 VBP O
transcribed BC2GM021489980 VBN O
, BC2GM021489980 , O
with BC2GM021489980 IN O
transcripts BC2GM021489980 NNS O
undergoing BC2GM021489980 VBG O
processing BC2GM021489980 NN O
, BC2GM021489980 , O
post-transcriptional BC2GM021489980 JJ O
modification BC2GM021489980 NN O
and BC2GM021489980 CC O
3'-CCA BC2GM021489980 JJ O
addition BC2GM021489980 NN O
, BC2GM021489980 , O
to BC2GM021489980 TO O
produce BC2GM021489980 VB O
mature BC2GM021489980 NN O
tRNAs BC2GM021489980 IN O
that BC2GM021489980 DT O
may BC2GM021489980 MD O
participate BC2GM021489980 VB O
in BC2GM021489980 IN O
mitochondrial BC2GM021489980 JJ O
protein BC2GM021489980 NN O
synthesis BC2GM021489980 NN O
. BC2GM021489980 . O
. . O O

The BC2GM085613208 DT O
sequence BC2GM085613208 NN O
of BC2GM085613208 IN O
Vac1p BC2GM085613208 NNP O
contains BC2GM085613208 VBZ O
two BC2GM085613208 CD O
putative BC2GM085613208 JJ O
zinc-binding BC2GM085613208 NN O
RING BC2GM085613208 NNP O
motifs BC2GM085613208 NN O
, BC2GM085613208 , O
a BC2GM085613208 DT O
zinc BC2GM085613208 NN O
finger BC2GM085613208 NN O
motif BC2GM085613208 NN O
, BC2GM085613208 , O
and BC2GM085613208 CC O
a BC2GM085613208 DT O
coiled-coil BC2GM085613208 JJ O
motif BC2GM085613208 NN O
. BC2GM085613208 . O
. . O O

We BC2GM091988881 PRP O
studied BC2GM091988881 VBD O
18 BC2GM091988881 CD O
dogs BC2GM091988881 NNS O
, BC2GM091988881 , O
anaesthetised BC2GM091988881 VBN O
and BC2GM091988881 CC O
spontaneously BC2GM091988881 RB O
breathing BC2GM091988881 VBG O
both BC2GM091988881 DT O
room BC2GM091988881 NN O
air BC2GM091988881 NN O
and BC2GM091988881 CC O
after BC2GM091988881 IN O
the BC2GM091988881 DT O
inhalation BC2GM091988881 NN O
of BC2GM091988881 IN O
a BC2GM091988881 DT O
gas BC2GM091988881 NN O
mixture BC2GM091988881 NN O
containing BC2GM091988881 VBG O
10 BC2GM091988881 CD O
% BC2GM091988881 NN O
CO2 BC2GM091988881 NNP O
, BC2GM091988881 , O
20.9 BC2GM091988881 CD O
% BC2GM091988881 NN O
O2 BC2GM091988881 NNP O
, BC2GM091988881 , O
and BC2GM091988881 CC O
69.1 BC2GM091988881 CD O
% BC2GM091988881 NN O
N2 BC2GM091988881 NNP O
, BC2GM091988881 , O
to BC2GM091988881 TO O
determine BC2GM091988881 VB O
the BC2GM091988881 DT O
role BC2GM091988881 NN O
of BC2GM091988881 IN O
histamine BC2GM091988881 NN O
, BC2GM091988881 , O
serotonin BC2GM091988881 NN O
, BC2GM091988881 , O
and BC2GM091988881 CC O
acidaemia BC2GM091988881 NN O
in BC2GM091988881 IN O
pulmonary BC2GM091988881 JJ O
hypertension BC2GM091988881 NN O
produced BC2GM091988881 VBN O
by BC2GM091988881 IN O
hypercapnia BC2GM091988881 NN O
. BC2GM091988881 . O
. . O O

The BC2GM098355088 DT O
average BC2GM098355088 JJ O
mean BC2GM098355088 JJ O
difference BC2GM098355088 NN O
compared BC2GM098355088 VBN O
with BC2GM098355088 IN O
the BC2GM098355088 DT O
low BC2GM098355088 JJ O
and BC2GM098355088 CC O
the BC2GM098355088 DT O
intermediate BC2GM098355088 JJ O
calcium BC2GM098355088 NN O
group BC2GM098355088 NN O
was BC2GM098355088 VBD O
11 BC2GM098355088 CD O
% BC2GM098355088 NN O
for BC2GM098355088 IN O
the BC2GM098355088 DT O
femoral BC2GM098355088 JJ O
neck BC2GM098355088 NN O
, BC2GM098355088 , O
8-11 BC2GM098355088 CD O
% BC2GM098355088 NN O
for BC2GM098355088 IN O
the BC2GM098355088 DT O
lumbar BC2GM098355088 NN O
spine BC2GM098355088 NN O
and BC2GM098355088 CC O
5-6 BC2GM098355088 JJ O
% BC2GM098355088 NN O
for BC2GM098355088 IN O
total BC2GM098355088 JJ O
body BC2GM098355088 NN O
BMDs BC2GM098355088 NNP O
. BC2GM098355088 . O
. . O O

Evaluation BC2GM055466114 NN O
of BC2GM055466114 IN O
gamma-glutamyl BC2GM055466114 JJ O
transpeptidase BC2GM055466114 NN O
in BC2GM055466114 IN O
myocardial BC2GM055466114 JJ O
infarction BC2GM055466114 NN O
. BC2GM055466114 . O
. . O O

First BC2GM077505350 RB O
, BC2GM077505350 , O
mutations BC2GM077505350 NNS O
in BC2GM077505350 IN O
the BC2GM077505350 DT O
IFNgamma-activated BC2GM077505350 JJ O
sequence BC2GM077505350 NN O
( BC2GM077505350 ( O
GAS BC2GM077505350 NNP O
) BC2GM077505350 ) O
, BC2GM077505350 , O
either BC2GM077505350 RB O
multimerized BC2GM077505350 VBD O
or BC2GM077505350 CC O
in BC2GM077505350 IN O
the BC2GM077505350 DT O
context BC2GM077505350 NN O
of BC2GM077505350 IN O
the BC2GM077505350 DT O
1.7-kb BC2GM077505350 JJ O
IRF-1 BC2GM077505350 NNP O
promoter BC2GM077505350 NN O
, BC2GM077505350 , O
failed BC2GM077505350 VBD O
to BC2GM077505350 TO O
mediate BC2GM077505350 VB O
a BC2GM077505350 DT O
PRL BC2GM077505350 NNP O
response BC2GM077505350 NN O
, BC2GM077505350 , O
showing BC2GM077505350 VBG O
that BC2GM077505350 IN O
the BC2GM077505350 DT O
IRF-1 BC2GM077505350 NNP O
GAS BC2GM077505350 NNP O
is BC2GM077505350 VBZ O
a BC2GM077505350 DT O
target BC2GM077505350 NN O
of BC2GM077505350 IN O
PRL BC2GM077505350 NNP O
signaling BC2GM077505350 VBG O
. BC2GM077505350 . O
. . O O

In BC2GM015956258 IN O
each BC2GM015956258 DT O
patient BC2GM015956258 NN O
, BC2GM015956258 , O
MBF BC2GM015956258 NNP O
was BC2GM015956258 VBD O
quantified BC2GM015956258 VBN O
in BC2GM015956258 IN O
the BC2GM015956258 DT O
three BC2GM015956258 CD O
major BC2GM015956258 JJ O
vascular BC2GM015956258 JJ O
territories BC2GM015956258 NNS O
: BC2GM015956258 : O
the BC2GM015956258 DT O
left BC2GM015956258 NN O
anterior BC2GM015956258 JJ O
descending BC2GM015956258 NN O
and BC2GM015956258 CC O
left BC2GM015956258 VBD O
circumflex BC2GM015956258 JJ O
coronary BC2GM015956258 JJ O
artery BC2GM015956258 NN O
territories BC2GM015956258 NNS O
and BC2GM015956258 CC O
the BC2GM015956258 DT O
right BC2GM015956258 JJ O
coronary BC2GM015956258 JJ O
artery BC2GM015956258 NN O
( BC2GM015956258 ( O
control BC2GM015956258 JJ O
region BC2GM015956258 NN O
) BC2GM015956258 ) O
territory BC2GM015956258 NN O
. BC2GM015956258 . O
. . O O

At BC2GM092052838 IN O
promoters BC2GM092052838 NNS O
that BC2GM092052838 WDT O
initiate BC2GM092052838 VBP O
with BC2GM092052838 IN O
+1 BC2GM092052838 NNP O
GGG BC2GM092052838 NNP O
, BC2GM092052838 , O
T7 BC2GM092052838 NNP O
RNAP BC2GM092052838 NNP O
synthesizes BC2GM092052838 VBZ O
a BC2GM092052838 DT O
ladder BC2GM092052838 NN O
of BC2GM092052838 IN O
poly BC2GM092052838 NN O
( BC2GM092052838 ( O
G BC2GM092052838 NNP O
) BC2GM092052838 ) O
products BC2GM092052838 NNS O
as BC2GM092052838 IN O
a BC2GM092052838 DT O
result BC2GM092052838 NN O
of BC2GM092052838 IN O
slippage BC2GM092052838 NN O
of BC2GM092052838 IN O
the BC2GM092052838 DT O
transcript BC2GM092052838 NN O
on BC2GM092052838 IN O
the BC2GM092052838 DT O
three BC2GM092052838 CD O
C BC2GM092052838 NNP O
residues BC2GM092052838 NNS O
in BC2GM092052838 IN O
the BC2GM092052838 DT O
template BC2GM092052838 NN O
strand BC2GM092052838 NN O
from BC2GM092052838 IN O
+1 BC2GM092052838 NN O
to BC2GM092052838 TO O
+3 BC2GM092052838 VB O
. BC2GM092052838 . O
. . O O

Pros BC2GM080507984 NNS O
and BC2GM080507984 CC O
cons BC2GM080507984 NNS O
of BC2GM080507984 IN O
selective BC2GM080507984 JJ O
inhibition BC2GM080507984 NN O
of BC2GM080507984 IN O
cyclooxygenase-2 BC2GM080507984 JJ O
versus BC2GM080507984 NN O
dual BC2GM080507984 JJ O
lipoxygenase BC2GM080507984 NN O
/ BC2GM080507984 NNP O
cyclooxygenase BC2GM080507984 NN O
inhibition BC2GM080507984 NN O
: BC2GM080507984 : O
is BC2GM080507984 VBZ O
two BC2GM080507984 CD O
better BC2GM080507984 JJR O
than BC2GM080507984 IN O
one BC2GM080507984 CD O
? BC2GM080507984 . O
. BC2GM080507984 . O
. . O O

METHODS BC2GM049622274 NNP O
AND BC2GM049622274 CC O
RESULTS BC2GM049622274 NNP O
: BC2GM049622274 : O
With BC2GM049622274 IN O
an BC2GM049622274 DT O
array BC2GM049622274 NN O
of BC2GM049622274 IN O
112 BC2GM049622274 CD O
unipole BC2GM049622274 JJ O
, BC2GM049622274 , O
epicardial BC2GM049622274 JJ O
maps BC2GM049622274 NNS O
of BC2GM049622274 IN O
electrically BC2GM049622274 RB O
induced BC2GM049622274 VBN O
AF BC2GM049622274 NNP O
in BC2GM049622274 IN O
6 BC2GM049622274 CD O
dogs BC2GM049622274 NNS O
( BC2GM049622274 ( O
acute BC2GM049622274 JJ O
group BC2GM049622274 NN O
) BC2GM049622274 ) O
, BC2GM049622274 , O
self-sustained BC2GM049622274 JJ O
AF BC2GM049622274 NNP O
in BC2GM049622274 IN O
6 BC2GM049622274 CD O
dogs BC2GM049622274 NNS O
( BC2GM049622274 ( O
chronic BC2GM049622274 JJ O
group BC2GM049622274 NN O
) BC2GM049622274 ) O
, BC2GM049622274 , O
and BC2GM049622274 CC O
sinus BC2GM049622274 NN O
rhythm BC2GM049622274 NN O
and BC2GM049622274 CC O
atrial BC2GM049622274 JJ O
pacing BC2GM049622274 NN O
in BC2GM049622274 IN O
3 BC2GM049622274 CD O
dogs BC2GM049622274 NNS O
( BC2GM049622274 ( O
control BC2GM049622274 VB O
group BC2GM049622274 NN O
) BC2GM049622274 ) O
were BC2GM049622274 VBD O
analyzed BC2GM049622274 VBN O
before BC2GM049622274 IN O
and BC2GM049622274 CC O
after BC2GM049622274 IN O
creating BC2GM049622274 VBG O
linear BC2GM049622274 JJ O
radiofrequency BC2GM049622274 NN O
ablation BC2GM049622274 NN O
lesions BC2GM049622274 NNS O
in BC2GM049622274 IN O
both BC2GM049622274 DT O
atria BC2GM049622274 NNS O
that BC2GM049622274 WDT O
eliminated BC2GM049622274 VBD O
the BC2GM049622274 DT O
AF BC2GM049622274 NNP O
. BC2GM049622274 . O
. . O O

Monosulfates BC2GM089489545 NNS O
of BC2GM089489545 IN O
16-oxygenated BC2GM089489545 JJ O
ketonic BC2GM089489545 JJ O
C19 BC2GM089489545 NNP O
steroids BC2GM089489545 NNS O
in BC2GM089489545 IN O
adult BC2GM089489545 NN O
human BC2GM089489545 JJ O
urine BC2GM089489545 NN O
. BC2GM089489545 . O
. . O O

We BC2GM091158051 PRP O
prospectively BC2GM091158051 RB O
studied BC2GM091158051 VBD O
serum BC2GM091158051 JJ O
prolactin BC2GM091158051 NN O
( BC2GM091158051 ( O
PRL BC2GM091158051 NNP O
) BC2GM091158051 ) O
elevation BC2GM091158051 NN O
after BC2GM091158051 IN O
different BC2GM091158051 JJ O
types BC2GM091158051 NNS O
of BC2GM091158051 IN O
documented BC2GM091158051 JJ O
seizures BC2GM091158051 NNS O
in BC2GM091158051 IN O
17 BC2GM091158051 CD O
patients BC2GM091158051 NNS O
. BC2GM091158051 . O
. . O O

Morphologically BC2GM051993138 RB O
, BC2GM051993138 , O
corrugation BC2GM051993138 NN O
of BC2GM051993138 IN O
the BC2GM051993138 DT O
internal BC2GM051993138 JJ O
elastic BC2GM051993138 JJ O
lamina BC2GM051993138 NN O
of BC2GM051993138 IN O
vessels BC2GM051993138 NNS O
was BC2GM051993138 VBD O
often BC2GM051993138 RB O
observed BC2GM051993138 VBN O
in BC2GM051993138 IN O
the BC2GM051993138 DT O
vehicle-treated BC2GM051993138 JJ O
group BC2GM051993138 NN O
, BC2GM051993138 , O
but BC2GM051993138 CC O
was BC2GM051993138 VBD O
not BC2GM051993138 RB O
prominent BC2GM051993138 JJ O
in BC2GM051993138 IN O
the BC2GM051993138 DT O
GLNVA-treated BC2GM051993138 JJ O
groups BC2GM051993138 NNS O
or BC2GM051993138 CC O
healthy BC2GM051993138 JJ O
controls BC2GM051993138 NNS O
. BC2GM051993138 . O
. . O O

The BC2GM093618725 DT O
objectives BC2GM093618725 NNS O
of BC2GM093618725 IN O
this BC2GM093618725 DT O
study BC2GM093618725 NN O
were BC2GM093618725 VBD O
1 BC2GM093618725 CD O
) BC2GM093618725 ) O
to BC2GM093618725 TO O
quantify BC2GM093618725 VB O
the BC2GM093618725 DT O
comparative BC2GM093618725 JJ O
structural BC2GM093618725 JJ O
static BC2GM093618725 JJ O
and BC2GM093618725 CC O
fatigue BC2GM093618725 JJ O
properties BC2GM093618725 NNS O
of BC2GM093618725 IN O
the BC2GM093618725 DT O
pointe BC2GM093618725 NN O
shoe BC2GM093618725 NN O
toe BC2GM093618725 NN O
box BC2GM093618725 NN O
, BC2GM093618725 , O
and BC2GM093618725 CC O
2 BC2GM093618725 CD O
) BC2GM093618725 ) O
to BC2GM093618725 TO O
evaluate BC2GM093618725 VB O
the BC2GM093618725 DT O
preferred BC2GM093618725 JJ O
shoe BC2GM093618725 NN O
characteristics BC2GM093618725 NNS O
as BC2GM093618725 IN O
determined BC2GM093618725 VBN O
by BC2GM093618725 IN O
a BC2GM093618725 DT O
survey BC2GM093618725 NN O
of BC2GM093618725 IN O
local BC2GM093618725 JJ O
dancers BC2GM093618725 NNS O
. BC2GM093618725 . O
. . O O

The BC2GM082328834 DT O
NF-kappaB BC2GM082328834 NNP O
/ BC2GM082328834 NNP O
Rel BC2GM082328834 NNP O
transcription BC2GM082328834 NN O
factors BC2GM082328834 NNS O
participate BC2GM082328834 VBP O
in BC2GM082328834 IN O
the BC2GM082328834 DT O
activation BC2GM082328834 NN O
of BC2GM082328834 IN O
immune BC2GM082328834 JJ O
system BC2GM082328834 NN O
regulatory BC2GM082328834 JJ O
genes BC2GM082328834 NNS O
and BC2GM082328834 CC O
viral BC2GM082328834 JJ O
early BC2GM082328834 JJ O
genes BC2GM082328834 NNS O
including BC2GM082328834 VBG O
the BC2GM082328834 DT O
human BC2GM082328834 JJ O
immunodeficiency BC2GM082328834 NN O
virus BC2GM082328834 NN O
type BC2GM082328834 VBD O
1 BC2GM082328834 CD O
long BC2GM082328834 JJ O
terminal BC2GM082328834 JJ O
repeat BC2GM082328834 NN O
. BC2GM082328834 . O
. . O O

Mutations BC2GM033866755 NNS O
of BC2GM033866755 IN O
the BC2GM033866755 DT O
human BC2GM033866755 JJ O
PTEN BC2GM033866755 NNP O
gene BC2GM033866755 NN O
. BC2GM033866755 . O
. . O O

If BC2GM049290595 IN O
failure BC2GM049290595 NN O
to BC2GM049290595 TO O
solve BC2GM049290595 VB O
invisible BC2GM049290595 JJ O
displacements BC2GM049290595 NNS O
was BC2GM049290595 VBD O
due BC2GM049290595 JJ O
to BC2GM049290595 TO O
increased BC2GM049290595 JJ O
memory BC2GM049290595 NN O
requirements BC2GM049290595 NNS O
, BC2GM049290595 , O
then BC2GM049290595 RB O
the BC2GM049290595 DT O
primates BC2GM049290595 NNS O
should BC2GM049290595 MD O
perform BC2GM049290595 VB O
at BC2GM049290595 IN O
chance BC2GM049290595 NN O
level BC2GM049290595 NN O
on BC2GM049290595 IN O
all BC2GM049290595 DT O
3 BC2GM049290595 CD O
problems BC2GM049290595 NNS O
. BC2GM049290595 . O
. . O O

The BC2GM027280090 DT O
purpose BC2GM027280090 NN O
of BC2GM027280090 IN O
this BC2GM027280090 DT O
presentation BC2GM027280090 NN O
is BC2GM027280090 VBZ O
to BC2GM027280090 TO O
review BC2GM027280090 VB O
the BC2GM027280090 DT O
current BC2GM027280090 JJ O
state BC2GM027280090 NN O
of BC2GM027280090 IN O
knowledge BC2GM027280090 NN O
regarding BC2GM027280090 VBG O
5,8,11,14-eicosatetraynoic BC2GM027280090 JJ O
acid BC2GM027280090 NN O
( BC2GM027280090 ( O
ETYA BC2GM027280090 NNP O
, BC2GM027280090 , O
Ro BC2GM027280090 NNP O
3-1428 BC2GM027280090 NNP O
) BC2GM027280090 ) O
and BC2GM027280090 CC O
its BC2GM027280090 PRP$ O
effects BC2GM027280090 NNS O
on BC2GM027280090 IN O
lipid BC2GM027280090 JJ O
metabolism BC2GM027280090 NN O
. BC2GM027280090 . O
. . O O

SETTING BC2GM003679439 NN O
: BC2GM003679439 : O
A BC2GM003679439 DT O
private BC2GM003679439 JJ O
office-based BC2GM003679439 JJ O
fertility BC2GM003679439 NN O
program BC2GM003679439 NN O
. BC2GM003679439 . O
. . O O

The BC2GM015848639 DT O
median BC2GM015848639 JJ O
cumulative BC2GM015848639 JJ O
incidence BC2GM015848639 NN O
rates BC2GM015848639 NNS O
were BC2GM015848639 VBD O
found BC2GM015848639 VBN O
to BC2GM015848639 TO O
be BC2GM015848639 VB O
341 BC2GM015848639 CD O
per BC2GM015848639 IN O
million BC2GM015848639 CD O
for BC2GM015848639 IN O
males BC2GM015848639 NNS O
and BC2GM015848639 CC O
296 BC2GM015848639 CD O
per BC2GM015848639 IN O
million BC2GM015848639 CD O
for BC2GM015848639 IN O
females BC2GM015848639 NNS O
. BC2GM015848639 . O
. . O O

DP-1 BC2GM024331581 JJ O
and BC2GM024331581 CC O
DP-2 BC2GM024331581 JJ O
encode BC2GM024331581 NN O
maternally BC2GM024331581 RB O
stored BC2GM024331581 VBD O
transcripts BC2GM024331581 NNS O
that BC2GM024331581 WDT O
are BC2GM024331581 VBP O
expressed BC2GM024331581 VBN O
during BC2GM024331581 IN O
early BC2GM024331581 JJ O
development BC2GM024331581 NN O
. BC2GM024331581 . O
. . O O

Enhanced BC2GM064815808 NNP O
phospholipid BC2GM064815808 JJ O
hydrolysis BC2GM064815808 NN O
with BC2GM064815808 IN O
free BC2GM064815808 JJ O
fatty BC2GM064815808 JJ O
acid BC2GM064815808 NN O
and BC2GM064815808 CC O
thromboxane BC2GM064815808 NN O
accumulation BC2GM064815808 NN O
, BC2GM064815808 , O
increased BC2GM064815808 VBD O
release BC2GM064815808 NN O
of BC2GM064815808 IN O
excitatory BC2GM064815808 NN O
amino BC2GM064815808 NN O
acids BC2GM064815808 NNS O
, BC2GM064815808 , O
and BC2GM064815808 CC O
decreased BC2GM064815808 VBD O
tissue BC2GM064815808 NN O
magnesium BC2GM064815808 NN O
levels BC2GM064815808 NNS O
may BC2GM064815808 MD O
each BC2GM064815808 DT O
serve BC2GM064815808 VB O
to BC2GM064815808 TO O
worsen BC2GM064815808 VB O
secondary BC2GM064815808 JJ O
tissue BC2GM064815808 NN O
damage BC2GM064815808 NN O
and BC2GM064815808 CC O
diminish BC2GM064815808 JJ O
neurologic BC2GM064815808 JJ O
recovery BC2GM064815808 NN O
after BC2GM064815808 IN O
spinal BC2GM064815808 JJ O
cord BC2GM064815808 NN O
injury BC2GM064815808 NN O
associated BC2GM064815808 VBN O
with BC2GM064815808 IN O
acute BC2GM064815808 JJ O
alcohol BC2GM064815808 NN O
intoxication BC2GM064815808 NN O
. BC2GM064815808 . O
. . O O

The BC2GM037708472 DT O
atpA BC2GM037708472 NN O
reading BC2GM037708472 NN O
frame BC2GM037708472 NN O
ends BC2GM037708472 VBZ O
with BC2GM037708472 IN O
four BC2GM037708472 CD O
tandem BC2GM037708472 NN O
UGA BC2GM037708472 NNP O
codons BC2GM037708472 NNS O
which BC2GM037708472 WDT O
overlap BC2GM037708472 VBP O
four BC2GM037708472 CD O
tandem BC2GM037708472 NN O
AUG BC2GM037708472 NNP O
codons BC2GM037708472 NNS O
initiating BC2GM037708472 VBG O
an BC2GM037708472 DT O
unidentified BC2GM037708472 JJ O
reading BC2GM037708472 NN O
frame BC2GM037708472 NN O
, BC2GM037708472 , O
orf214 BC2GM037708472 NN O
. BC2GM037708472 . O
. . O O

Our BC2GM058510012 PRP$ O
results BC2GM058510012 NNS O
strongly BC2GM058510012 RB O
suggest BC2GM058510012 VBP O
that BC2GM058510012 IN O
activation BC2GM058510012 NN O
of BC2GM058510012 IN O
the BC2GM058510012 DT O
beta BC2GM058510012 NN O
origin BC2GM058510012 NN O
by BC2GM058510012 IN O
a BC2GM058510012 DT O
distant BC2GM058510012 JJ O
replication BC2GM058510012 NN O
enhancer BC2GM058510012 NN O
element BC2GM058510012 NN O
requires BC2GM058510012 VBZ O
a BC2GM058510012 DT O
small BC2GM058510012 JJ O
target BC2GM058510012 NN O
sequence BC2GM058510012 NN O
essential BC2GM058510012 JJ O
for BC2GM058510012 IN O
initiator BC2GM058510012 NN O
protein-mediated BC2GM058510012 JJ O
DNA BC2GM058510012 NNP O
looping BC2GM058510012 NN O
. BC2GM058510012 . O
. . O O

In BC2GM090325124 IN O
addition BC2GM090325124 NN O
to BC2GM090325124 TO O
TAK1 BC2GM090325124 NNP O
, BC2GM090325124 , O
TGF-beta BC2GM090325124 NNP O
also BC2GM090325124 RB O
stimulated BC2GM090325124 VBD O
JNK BC2GM090325124 NNP O
activity BC2GM090325124 NN O
. BC2GM090325124 . O
. . O O

Morphologic BC2GM051466655 NNP O
evidence BC2GM051466655 NN O
that BC2GM051466655 IN O
rhe BC2GM051466655 VBZ O
renal BC2GM051466655 JJ O
calyx BC2GM051466655 NN O
and BC2GM051466655 CC O
pelvis BC2GM051466655 VB O
control BC2GM051466655 NN O
ureteric BC2GM051466655 JJ O
activity BC2GM051466655 NN O
in BC2GM051466655 IN O
the BC2GM051466655 DT O
rabbit BC2GM051466655 NN O
. BC2GM051466655 . O
. . O O

This BC2GM089171248 DT O
is BC2GM089171248 VBZ O
the BC2GM089171248 DT O
first BC2GM089171248 JJ O
report BC2GM089171248 NN O
that BC2GM089171248 IN O
the BC2GM089171248 DT O
PH BC2GM089171248 NNP O
domain BC2GM089171248 NN O
of BC2GM089171248 IN O
an BC2GM089171248 DT O
IRS BC2GM089171248 NNP O
protein BC2GM089171248 NN O
can BC2GM089171248 MD O
function BC2GM089171248 VB O
in BC2GM089171248 IN O
a BC2GM089171248 DT O
dominant BC2GM089171248 JJ O
negative BC2GM089171248 JJ O
manner BC2GM089171248 NN O
to BC2GM089171248 TO O
inhibit BC2GM089171248 VB O
insulin BC2GM089171248 JJ O
signaling BC2GM089171248 NN O
. BC2GM089171248 . O
. . O O

Benzyl BC2GM023937291 NNP O
alcohol BC2GM023937291 NN O
administration BC2GM023937291 NN O
in BC2GM023937291 IN O
neonates BC2GM023937291 NNS O
. BC2GM023937291 . O
. . O O

The BC2GM035632930 DT O
AmyI BC2GM035632930 NNP O
specific BC2GM035632930 JJ O
3'-UTR BC2GM035632930 CD O
is BC2GM035632930 VBZ O
characterized BC2GM035632930 VBN O
by BC2GM035632930 IN O
the BC2GM035632930 DT O
absence BC2GM035632930 NN O
of BC2GM035632930 IN O
IR BC2GM035632930 NNP O
sequences BC2GM035632930 NNS O
and BC2GM035632930 CC O
the BC2GM035632930 DT O
presence BC2GM035632930 NN O
of BC2GM035632930 IN O
a BC2GM035632930 DT O
putative BC2GM035632930 JJ O
'AATAAA BC2GM035632930 NN O
' BC2GM035632930 POS O
polyadenylation BC2GM035632930 NN O
signal BC2GM035632930 NN O
. BC2GM035632930 . O
. . O O

Under BC2GM052914680 IN O
anaerobic BC2GM052914680 JJ O
conditions BC2GM052914680 NNS O
( BC2GM052914680 ( O
a BC2GM052914680 DT O
50-day BC2GM052914680 JJ O
experiment BC2GM052914680 NN O
) BC2GM052914680 ) O
these BC2GM052914680 DT O
organisms BC2GM052914680 NNS O
degraded BC2GM052914680 VBD O
15-18 BC2GM052914680 CD O
% BC2GM052914680 NN O
of BC2GM052914680 IN O
the BC2GM052914680 DT O
TEM BC2GM052914680 NNP O
, BC2GM052914680 , O
20-25 BC2GM052914680 JJ O
% BC2GM052914680 NN O
of BC2GM052914680 IN O
some BC2GM052914680 DT O
alkanes BC2GM052914680 NNS O
, BC2GM052914680 , O
and BC2GM052914680 CC O
15-18 BC2GM052914680 CD O
% BC2GM052914680 NN O
of BC2GM052914680 IN O
selected BC2GM052914680 VBN O
polycyclic BC2GM052914680 JJ O
aromatic BC2GM052914680 JJ O
hydrocarbons BC2GM052914680 NNS O
. BC2GM052914680 . O
. . O O

Analytical BC2GM009718351 JJ O
scanning BC2GM009718351 VBG O
isoelectrofocusing BC2GM009718351 NN O
. BC2GM009718351 . O
. . O O

We BC2GM043147756 PRP O
have BC2GM043147756 VBP O
now BC2GM043147756 RB O
completed BC2GM043147756 VBN O
the BC2GM043147756 DT O
primary BC2GM043147756 JJ O
structure BC2GM043147756 NN O
of BC2GM043147756 IN O
fibrillin BC2GM043147756 NN O
, BC2GM043147756 , O
elucidated BC2GM043147756 VBD O
the BC2GM043147756 DT O
exon BC2GM043147756 NN O
/ BC2GM043147756 NNP O
intron BC2GM043147756 NN O
organization BC2GM043147756 NN O
of BC2GM043147756 IN O
the BC2GM043147756 DT O
gene BC2GM043147756 NN O
and BC2GM043147756 CC O
derived BC2GM043147756 VBD O
a BC2GM043147756 DT O
physical BC2GM043147756 JJ O
map BC2GM043147756 NN O
of BC2GM043147756 IN O
the BC2GM043147756 DT O
genetic BC2GM043147756 JJ O
locus BC2GM043147756 NN O
. BC2GM043147756 . O
. . O O

Thus BC2GM026487710 RB O
, BC2GM026487710 , O
the BC2GM026487710 DT O
rates BC2GM026487710 NNS O
of BC2GM026487710 IN O
a-factor BC2GM026487710 JJ O
receptor BC2GM026487710 NN O
endocytosis BC2GM026487710 NN O
and BC2GM026487710 CC O
consequent BC2GM026487710 JJ O
vacuolar BC2GM026487710 NN O
turnover BC2GM026487710 NN O
depend BC2GM026487710 VBP O
on BC2GM026487710 IN O
the BC2GM026487710 DT O
available BC2GM026487710 JJ O
level BC2GM026487710 NN O
of BC2GM026487710 IN O
ubiquitin BC2GM026487710 NN O
in BC2GM026487710 IN O
the BC2GM026487710 DT O
cell BC2GM026487710 NN O
. BC2GM026487710 . O
. . O O

Evidence BC2GM031470999 NN O
for BC2GM031470999 IN O
involvement BC2GM031470999 NN O
of BC2GM031470999 IN O
proteins BC2GM031470999 NNS O
HU BC2GM031470999 NNP O
and BC2GM031470999 CC O
RpoS BC2GM031470999 NNP O
in BC2GM031470999 IN O
transcription BC2GM031470999 NN O
of BC2GM031470999 IN O
the BC2GM031470999 DT O
osmoresponsive BC2GM031470999 JJ O
proU BC2GM031470999 NN O
operon BC2GM031470999 NN O
in BC2GM031470999 IN O
Escherichia BC2GM031470999 NNP O
coli BC2GM031470999 NN O
. BC2GM031470999 . O
. . O O

Judge BC2GM016713440 NNP O
Christian BC2GM016713440 NNP O
Byk BC2GM016713440 NNP O
renders BC2GM016713440 NNS O
service BC2GM016713440 NN O
to BC2GM016713440 TO O
the BC2GM016713440 DT O
Steering BC2GM016713440 NNP O
Committee BC2GM016713440 NNP O
on BC2GM016713440 IN O
Bioethics BC2GM016713440 NNP O
of BC2GM016713440 IN O
the BC2GM016713440 DT O
Council BC2GM016713440 NNP O
of BC2GM016713440 IN O
Europe BC2GM016713440 NNP O
( BC2GM016713440 ( O
CDBI BC2GM016713440 NNP O
) BC2GM016713440 ) O
by BC2GM016713440 IN O
proposing BC2GM016713440 VBG O
a BC2GM016713440 DT O
draft BC2GM016713440 NN O
of BC2GM016713440 IN O
the BC2GM016713440 DT O
protocol BC2GM016713440 NN O
destined BC2GM016713440 VBD O
to BC2GM016713440 TO O
fill BC2GM016713440 VB O
in BC2GM016713440 IN O
a BC2GM016713440 DT O
gap BC2GM016713440 NN O
in BC2GM016713440 IN O
international BC2GM016713440 JJ O
law BC2GM016713440 NN O
on BC2GM016713440 IN O
the BC2GM016713440 DT O
status BC2GM016713440 NN O
of BC2GM016713440 IN O
the BC2GM016713440 DT O
human BC2GM016713440 JJ O
embryo BC2GM016713440 NN O
. BC2GM016713440 . O
. . O O

To BC2GM043956840 TO O
prevent BC2GM043956840 VB O
section BC2GM043956840 NN O
wrinkles BC2GM043956840 NNS O
usually BC2GM043956840 RB O
encountered BC2GM043956840 VBN O
with BC2GM043956840 IN O
the BC2GM043956840 DT O
use BC2GM043956840 NN O
of BC2GM043956840 IN O
coated BC2GM043956840 JJ O
single-hole BC2GM043956840 JJ O
grids BC2GM043956840 NNS O
, BC2GM043956840 , O
a BC2GM043956840 DT O
simple BC2GM043956840 JJ O
method BC2GM043956840 NN O
was BC2GM043956840 VBD O
developed BC2GM043956840 VBN O
. BC2GM043956840 . O
. . O O

Nature BC2GM037381460 NN O
of BC2GM037381460 IN O
the BC2GM037381460 DT O
thermopower BC2GM037381460 NN O
in BC2GM037381460 IN O
bipolar BC2GM037381460 JJ O
semiconductors BC2GM037381460 NNS O
. BC2GM037381460 . O
. . O O

Moreover BC2GM006926838 RB O
, BC2GM006926838 , O
we BC2GM006926838 PRP O
show BC2GM006926838 VBP O
that BC2GM006926838 IN O
ectopic BC2GM006926838 JJ O
expression BC2GM006926838 NN O
of BC2GM006926838 IN O
the BC2GM006926838 DT O
E2A BC2GM006926838 NNP O
protein BC2GM006926838 NN O
E12 BC2GM006926838 NNP O
in BC2GM006926838 IN O
this BC2GM006926838 DT O
macrophage BC2GM006926838 NN O
line BC2GM006926838 NN O
results BC2GM006926838 NNS O
in BC2GM006926838 IN O
the BC2GM006926838 DT O
induction BC2GM006926838 NN O
of BC2GM006926838 IN O
many BC2GM006926838 JJ O
B BC2GM006926838 NNP O
lineage BC2GM006926838 NN O
genes BC2GM006926838 NNS O
, BC2GM006926838 , O
including BC2GM006926838 VBG O
EBF BC2GM006926838 NNP O
, BC2GM006926838 , O
IL7Ralpha BC2GM006926838 NNP O
, BC2GM006926838 , O
lambda5 BC2GM006926838 NN O
, BC2GM006926838 , O
and BC2GM006926838 CC O
Rag-1 BC2GM006926838 NNP O
, BC2GM006926838 , O
and BC2GM006926838 CC O
the BC2GM006926838 DT O
ability BC2GM006926838 NN O
to BC2GM006926838 TO O
induce BC2GM006926838 VB O
kappa BC2GM006926838 JJ O
light BC2GM006926838 NN O
chain BC2GM006926838 NN O
in BC2GM006926838 IN O
response BC2GM006926838 NN O
to BC2GM006926838 TO O
mitogen BC2GM006926838 NN O
. BC2GM006926838 . O
. . O O

Yet BC2GM094951467 CC O
IL-2 BC2GM094951467 NNP O
and BC2GM094951467 CC O
IFN-gamma BC2GM094951467 NNP O
production BC2GM094951467 NN O
are BC2GM094951467 VBP O
independently BC2GM094951467 RB O
regulated BC2GM094951467 VBN O
, BC2GM094951467 , O
as BC2GM094951467 IN O
demonstrated BC2GM094951467 VBN O
by BC2GM094951467 IN O
their BC2GM094951467 PRP$ O
differential BC2GM094951467 JJ O
expression BC2GM094951467 NN O
in BC2GM094951467 IN O
certain BC2GM094951467 JJ O
T BC2GM094951467 NNP O
cell BC2GM094951467 NN O
subsets BC2GM094951467 NNS O
, BC2GM094951467 , O
suggesting BC2GM094951467 VBG O
that BC2GM094951467 IN O
the BC2GM094951467 DT O
regulatory BC2GM094951467 JJ O
elements BC2GM094951467 NNS O
in BC2GM094951467 IN O
these BC2GM094951467 DT O
two BC2GM094951467 CD O
genes BC2GM094951467 NNS O
must BC2GM094951467 MD O
differ BC2GM094951467 VB O
. BC2GM094951467 . O
. . O O

Theoretical BC2GM023767363 JJ O
mechanisms BC2GM023767363 NNS O
of BC2GM023767363 IN O
hyperuricemia BC2GM023767363 NN O
. BC2GM023767363 . O
. . O O

The BC2GM005052505 DT O
evolutionary BC2GM005052505 JJ O
significance BC2GM005052505 NN O
of BC2GM005052505 IN O
the BC2GM005052505 DT O
similarities BC2GM005052505 NNS O
of BC2GM005052505 IN O
intron BC2GM005052505 NN O
secondary BC2GM005052505 JJ O
structures BC2GM005052505 NNS O
and BC2GM005052505 CC O
open BC2GM005052505 JJ O
reading BC2GM005052505 NN O
frames BC2GM005052505 NNS O
of BC2GM005052505 IN O
the BC2GM005052505 DT O
ND3 BC2GM005052505 NNP O
, BC2GM005052505 , O
4 BC2GM005052505 CD O
and BC2GM005052505 CC O
ATPase BC2GM005052505 NNP O
6 BC2GM005052505 CD O
genes BC2GM005052505 NNS O
is BC2GM005052505 VBZ O
discussed BC2GM005052505 VBN O
, BC2GM005052505 , O
including BC2GM005052505 VBG O
the BC2GM005052505 DT O
possible BC2GM005052505 JJ O
separate BC2GM005052505 JJ O
evolution BC2GM005052505 NN O
of BC2GM005052505 IN O
structural BC2GM005052505 JJ O
and BC2GM005052505 CC O
coding BC2GM005052505 JJ O
sequences BC2GM005052505 NNS O
. BC2GM005052505 . O
. . O O

Selective BC2GM092881858 JJ O
upper BC2GM092881858 JJ O
abdominal BC2GM092881858 JJ O
sympathectomy BC2GM092881858 NN O
increased BC2GM092881858 VBD O
basal BC2GM092881858 JJ O
acid BC2GM092881858 NN O
output BC2GM092881858 NN O
in BC2GM092881858 IN O
rats BC2GM092881858 NNS O
but BC2GM092881858 CC O
was BC2GM092881858 VBD O
without BC2GM092881858 IN O
effect BC2GM092881858 NN O
on BC2GM092881858 IN O
stimulated BC2GM092881858 JJ O
acid BC2GM092881858 NN O
output BC2GM092881858 NN O
, BC2GM092881858 , O
serum BC2GM092881858 JJ O
gastrin BC2GM092881858 NN O
concentration BC2GM092881858 NN O
, BC2GM092881858 , O
and BC2GM092881858 CC O
gastric BC2GM092881858 JJ O
mucosal BC2GM092881858 NN O
histidine BC2GM092881858 JJ O
decarboxylase BC2GM092881858 NN O
activity BC2GM092881858 NN O
. BC2GM092881858 . O
. . O O

The BC2GM086764035 DT O
cells BC2GM086764035 NNS O
were BC2GM086764035 VBD O
densely BC2GM086764035 RB O
ciliated BC2GM086764035 VBN O
, BC2GM086764035 , O
each BC2GM086764035 DT O
cilium BC2GM086764035 NN O
showing BC2GM086764035 VBG O
a BC2GM086764035 DT O
typical BC2GM086764035 JJ O
9+2 BC2GM086764035 CD O
fibrilar BC2GM086764035 JJ O
pattern BC2GM086764035 NN O
. BC2GM086764035 . O
. . O O

These BC2GM059254999 DT O
alterations BC2GM059254999 NNS O
occurred BC2GM059254999 VBD O
at BC2GM059254999 IN O
both BC2GM059254999 DT O
the BC2GM059254999 DT O
mRNA BC2GM059254999 NN O
and BC2GM059254999 CC O
protein BC2GM059254999 NN O
levels BC2GM059254999 NNS O
but BC2GM059254999 CC O
did BC2GM059254999 VBD O
not BC2GM059254999 RB O
significantly BC2GM059254999 RB O
affect BC2GM059254999 VBP O
the BC2GM059254999 DT O
subcellular BC2GM059254999 JJ O
distribution BC2GM059254999 NN O
of BC2GM059254999 IN O
any BC2GM059254999 DT O
of BC2GM059254999 IN O
the BC2GM059254999 DT O
four BC2GM059254999 CD O
isoforms BC2GM059254999 NNS O
. BC2GM059254999 . O
. . O O

Mutations BC2GM030904098 NNS O
abolishing BC2GM030904098 VBG O
MalK BC2GM030904098 NNP O
function BC2GM030904098 NN O
not BC2GM030904098 RB O
only BC2GM030904098 RB O
result BC2GM030904098 NN O
in BC2GM030904098 IN O
inability BC2GM030904098 NN O
to BC2GM030904098 TO O
transport BC2GM030904098 VB O
maltose BC2GM030904098 NN O
but BC2GM030904098 CC O
also BC2GM030904098 RB O
cause BC2GM030904098 VBP O
constitutive BC2GM030904098 JJ O
expression BC2GM030904098 NN O
of BC2GM030904098 IN O
the BC2GM030904098 DT O
maltose BC2GM030904098 JJ O
regulon BC2GM030904098 NN O
. BC2GM030904098 . O
. . O O

The BC2GM050762362 DT O
D443N BC2GM050762362 NNP O
substitution BC2GM050762362 NN O
is BC2GM050762362 VBZ O
an BC2GM050762362 DT O
activating BC2GM050762362 VBG O
mutation BC2GM050762362 NN O
that BC2GM050762362 WDT O
increases BC2GM050762362 VBZ O
the BC2GM050762362 DT O
activity BC2GM050762362 NN O
of BC2GM050762362 IN O
SCAP BC2GM050762362 NNP O
and BC2GM050762362 CC O
renders BC2GM050762362 NNS O
it BC2GM050762362 PRP O
resistant BC2GM050762362 VBP O
to BC2GM050762362 TO O
inhibition BC2GM050762362 NN O
by BC2GM050762362 IN O
25-hydroxycholesterol BC2GM050762362 JJ O
. BC2GM050762362 . O
. . O O

Zta BC2GM009473053 NNP O
stimulated BC2GM009473053 VBD O
the BC2GM009473053 DT O
HAT BC2GM009473053 NNP O
activity BC2GM009473053 NN O
of BC2GM009473053 IN O
CBP BC2GM009473053 NNP O
that BC2GM009473053 WDT O
had BC2GM009473053 VBD O
been BC2GM009473053 VBN O
partially BC2GM009473053 RB O
purified BC2GM009473053 VBN O
or BC2GM009473053 CC O
immunoprecipitated BC2GM009473053 VBN O
from BC2GM009473053 IN O
mammalian BC2GM009473053 JJ O
cells BC2GM009473053 NNS O
as BC2GM009473053 RB O
well BC2GM009473053 RB O
as BC2GM009473053 IN O
from BC2GM009473053 IN O
affinity-purified BC2GM009473053 JJ O
, BC2GM009473053 , O
baculovirus BC2GM009473053 NN O
expressed BC2GM009473053 VBD O
CBP BC2GM009473053 NNP O
. BC2GM009473053 . O
. . O O

We BC2GM051338650 PRP O
constructed BC2GM051338650 VBD O
a BC2GM051338650 DT O
series BC2GM051338650 NN O
of BC2GM051338650 IN O
chimeric BC2GM051338650 JJ O
genes BC2GM051338650 NNS O
containing BC2GM051338650 VBG O
part BC2GM051338650 NN O
of BC2GM051338650 IN O
the BC2GM051338650 DT O
first BC2GM051338650 JJ O
exon BC2GM051338650 NN O
and BC2GM051338650 CC O
increasingly BC2GM051338650 RB O
longer BC2GM051338650 RB O
5 BC2GM051338650 CD O
' BC2GM051338650 '' O
flanking BC2GM051338650 VBG O
sequences BC2GM051338650 NNS O
of BC2GM051338650 IN O
the BC2GM051338650 DT O
ODC BC2GM051338650 NNP O
gene BC2GM051338650 NN O
fused BC2GM051338650 VBD O
to BC2GM051338650 TO O
either BC2GM051338650 DT O
bacterial BC2GM051338650 JJ O
chloramphenicol BC2GM051338650 NN O
acetyltransferase BC2GM051338650 NN O
( BC2GM051338650 ( O
CAT BC2GM051338650 NNP O
) BC2GM051338650 ) O
or BC2GM051338650 CC O
luciferase BC2GM051338650 JJ O
reporter BC2GM051338650 NN O
genes BC2GM051338650 NNS O
. BC2GM051338650 . O
. . O O

Menstrual BC2GM048186198 JJ O
and BC2GM048186198 CC O
lunar BC2GM048186198 JJ O
cycles BC2GM048186198 NNS O
. BC2GM048186198 . O
. . O O

Acute BC2GM057017444 NNP O
morphine BC2GM057017444 NN O
treatment BC2GM057017444 NN O
did BC2GM057017444 VBD O
not BC2GM057017444 RB O
increase BC2GM057017444 VB O
the BC2GM057017444 DT O
locomotor BC2GM057017444 NN O
activity BC2GM057017444 NN O
of BC2GM057017444 IN O
mice BC2GM057017444 NNS O
withdrawn BC2GM057017444 VBN O
for BC2GM057017444 IN O
1 BC2GM057017444 CD O
day BC2GM057017444 NN O
, BC2GM057017444 , O
after BC2GM057017444 IN O
withdrawal BC2GM057017444 NN O
for BC2GM057017444 IN O
3 BC2GM057017444 CD O
days BC2GM057017444 NNS O
the BC2GM057017444 DT O
increase BC2GM057017444 NN O
was BC2GM057017444 VBD O
similar BC2GM057017444 JJ O
to BC2GM057017444 TO O
that BC2GM057017444 DT O
in BC2GM057017444 IN O
controls BC2GM057017444 NNS O
, BC2GM057017444 , O
and BC2GM057017444 CC O
after BC2GM057017444 IN O
5 BC2GM057017444 CD O
days BC2GM057017444 NNS O
the BC2GM057017444 DT O
increase BC2GM057017444 NN O
was BC2GM057017444 VBD O
clearly BC2GM057017444 RB O
larger BC2GM057017444 JJR O
than BC2GM057017444 IN O
in BC2GM057017444 IN O
controls BC2GM057017444 NNS O
. BC2GM057017444 . O
. . O O

A BC2GM030395765 DT O
pharmacokinetic BC2GM030395765 JJ O
interaction BC2GM030395765 NN O
between BC2GM030395765 IN O
LY354740 BC2GM030395765 NNP O
and BC2GM030395765 CC O
diazepam BC2GM030395765 NN O
, BC2GM030395765 , O
leading BC2GM030395765 VBG O
to BC2GM030395765 TO O
the BC2GM030395765 DT O
lowering BC2GM030395765 NN O
of BC2GM030395765 IN O
the BC2GM030395765 DT O
plasma BC2GM030395765 JJ O
level BC2GM030395765 NN O
of BC2GM030395765 IN O
free BC2GM030395765 JJ O
diazepam BC2GM030395765 NN O
, BC2GM030395765 , O
was BC2GM030395765 VBD O
also BC2GM030395765 RB O
demonstrated BC2GM030395765 VBN O
. BC2GM030395765 . O
. . O O

These BC2GM030209063 DT O
cells BC2GM030209063 NNS O
also BC2GM030209063 RB O
showed BC2GM030209063 VBD O
an BC2GM030209063 DT O
increase BC2GM030209063 NN O
in BC2GM030209063 IN O
cyclin BC2GM030209063 NN O
A BC2GM030209063 NNP O
and BC2GM030209063 CC O
cyclin BC2GM030209063 JJ O
A- BC2GM030209063 NNP O
and BC2GM030209063 CC O
E-associated BC2GM030209063 JJ O
kinase BC2GM030209063 NN O
activities BC2GM030209063 NNS O
characteristic BC2GM030209063 NN O
of BC2GM030209063 IN O
S BC2GM030209063 NNP O
phase BC2GM030209063 NN O
induction BC2GM030209063 NN O
. BC2GM030209063 . O
. . O O

Molecular BC2GM070947450 JJ O
analysis BC2GM070947450 NN O
of BC2GM070947450 IN O
the BC2GM070947450 DT O
mannitol BC2GM070947450 NN O
operon BC2GM070947450 NN O
of BC2GM070947450 IN O
Clostridium BC2GM070947450 NNP O
acetobutylicum BC2GM070947450 NN O
encoding BC2GM070947450 VBG O
a BC2GM070947450 DT O
phosphotransferase BC2GM070947450 NN O
system BC2GM070947450 NN O
and BC2GM070947450 CC O
a BC2GM070947450 DT O
putative BC2GM070947450 JJ O
PTS-modulated BC2GM070947450 JJ O
regulator BC2GM070947450 NN O
. BC2GM070947450 . O
. . O O

These BC2GM033424223 DT O
results BC2GM033424223 NNS O
extend BC2GM033424223 VBP O
our BC2GM033424223 PRP$ O
knowledge BC2GM033424223 NN O
of BC2GM033424223 IN O
this BC2GM033424223 DT O
SNF2-like BC2GM033424223 JJ O
family BC2GM033424223 NN O
member BC2GM033424223 NN O
and BC2GM033424223 CC O
suggest BC2GM033424223 VBP O
a BC2GM033424223 DT O
role BC2GM033424223 NN O
for BC2GM033424223 IN O
PASG BC2GM033424223 NNP O
in BC2GM033424223 IN O
leukemogenesis BC2GM033424223 NN O
. BC2GM033424223 . O
. . O O

Desensitization BC2GM053199516 NN O
of BC2GM053199516 IN O
the BC2GM053199516 DT O
growth BC2GM053199516 NN O
hormone-induced BC2GM053199516 JJ O
Janus BC2GM053199516 NNP O
kinase BC2GM053199516 NN O
2 BC2GM053199516 CD O
( BC2GM053199516 ( O
Jak BC2GM053199516 NNP O
2 BC2GM053199516 CD O
) BC2GM053199516 ) O
/ BC2GM053199516 FW O
signal BC2GM053199516 JJ O
transducer BC2GM053199516 NN O
and BC2GM053199516 CC O
activator BC2GM053199516 NN O
of BC2GM053199516 IN O
transcription BC2GM053199516 NN O
5 BC2GM053199516 CD O
( BC2GM053199516 ( O
Stat5 BC2GM053199516 NNP O
) BC2GM053199516 ) O
-signaling BC2GM053199516 VBG O
pathway BC2GM053199516 NN O
requires BC2GM053199516 VBZ O
protein BC2GM053199516 JJ O
synthesis BC2GM053199516 NN O
and BC2GM053199516 CC O
phospholipase BC2GM053199516 NN O
C BC2GM053199516 NNP O
. BC2GM053199516 . O
. . O O

By BC2GM084839351 IN O
24 BC2GM084839351 CD O
h BC2GM084839351 NN O
, BC2GM084839351 , O
there BC2GM084839351 EX O
was BC2GM084839351 VBD O
no BC2GM084839351 DT O
significant BC2GM084839351 JJ O
difference BC2GM084839351 NN O
in BC2GM084839351 IN O
FFA BC2GM084839351 NNP O
levels BC2GM084839351 NNS O
from BC2GM084839351 IN O
shams BC2GM084839351 NN O
. BC2GM084839351 . O
. . O O

In BC2GM008340188 IN O
renal BC2GM008340188 JJ O
vein BC2GM008340188 NN O
thrombosis BC2GM008340188 NN O
, BC2GM008340188 , O
similar BC2GM008340188 JJ O
pattern BC2GM008340188 NN O
to BC2GM008340188 TO O
acute BC2GM008340188 VB O
tubular BC2GM008340188 JJ O
necrosis BC2GM008340188 NN O
was BC2GM008340188 VBD O
found BC2GM008340188 VBN O
but BC2GM008340188 CC O
RI BC2GM008340188 NNP O
venography BC2GM008340188 NN O
was BC2GM008340188 VBD O
helpful BC2GM008340188 JJ O
. BC2GM008340188 . O
. . O O

The BC2GM069666252 DT O
level BC2GM069666252 NN O
of BC2GM069666252 IN O
transcription BC2GM069666252 NN O
generated BC2GM069666252 VBN O
by BC2GM069666252 IN O
all BC2GM069666252 DT O
of BC2GM069666252 IN O
these BC2GM069666252 DT O
activators BC2GM069666252 NNS O
is BC2GM069666252 VBZ O
greater BC2GM069666252 JJR O
than BC2GM069666252 IN O
the BC2GM069666252 DT O
sum BC2GM069666252 NN O
of BC2GM069666252 IN O
the BC2GM069666252 DT O
levels BC2GM069666252 NNS O
generated BC2GM069666252 VBN O
by BC2GM069666252 IN O
individual BC2GM069666252 JJ O
factors BC2GM069666252 NNS O
, BC2GM069666252 , O
a BC2GM069666252 DT O
phenomenon BC2GM069666252 NN O
designated BC2GM069666252 VBN O
transcriptional BC2GM069666252 JJ O
synergy BC2GM069666252 NN O
. BC2GM069666252 . O
. . O O

Our BC2GM086116473 PRP$ O
data BC2GM086116473 NNS O
are BC2GM086116473 VBP O
in BC2GM086116473 IN O
line BC2GM086116473 NN O
with BC2GM086116473 IN O
the BC2GM086116473 DT O
hypothesis BC2GM086116473 NN O
that BC2GM086116473 WDT O
E2F BC2GM086116473 NNP O
functions BC2GM086116473 NNS O
as BC2GM086116473 IN O
a BC2GM086116473 DT O
growth- BC2GM086116473 JJ O
and BC2GM086116473 CC O
cell BC2GM086116473 JJ O
cycle BC2GM086116473 NN O
regulated BC2GM086116473 VBD O
tethering BC2GM086116473 VBG O
factor BC2GM086116473 NN O
between BC2GM086116473 IN O
Sp1 BC2GM086116473 NNP O
and BC2GM086116473 CC O
the BC2GM086116473 DT O
basic BC2GM086116473 JJ O
transcription BC2GM086116473 NN O
machinery BC2GM086116473 NN O
. BC2GM086116473 . O
. . O O

Comparison BC2GM066695661 NNP O
of BC2GM066695661 IN O
the BC2GM066695661 DT O
predicted BC2GM066695661 VBN O
amino BC2GM066695661 NN O
acid BC2GM066695661 JJ O
sequence BC2GM066695661 NN O
with BC2GM066695661 IN O
that BC2GM066695661 DT O
of BC2GM066695661 IN O
the BC2GM066695661 DT O
Drosophila BC2GM066695661 NNP O
virilis BC2GM066695661 NN O
gene BC2GM066695661 NN O
shows BC2GM066695661 VBZ O
that BC2GM066695661 IN O
several BC2GM066695661 JJ O
blocks BC2GM066695661 NNS O
of BC2GM066695661 IN O
amino BC2GM066695661 NN O
acid BC2GM066695661 NN O
sequence BC2GM066695661 NN O
have BC2GM066695661 VBP O
been BC2GM066695661 VBN O
very BC2GM066695661 RB O
highly BC2GM066695661 RB O
conserved BC2GM066695661 VBN O
. BC2GM066695661 . O
. . O O

Binding BC2GM087011590 NN O
of BC2GM087011590 IN O
the BC2GM087011590 DT O
TorR BC2GM087011590 NNP O
regulator BC2GM087011590 NN O
to BC2GM087011590 TO O
cis-acting BC2GM087011590 JJ O
direct BC2GM087011590 JJ O
repeats BC2GM087011590 NNS O
activates BC2GM087011590 VBZ O
tor BC2GM087011590 NN O
operon BC2GM087011590 NN O
expression BC2GM087011590 NN O
. BC2GM087011590 . O
. . O O

Interestingly BC2GM056432965 RB O
, BC2GM056432965 , O
these BC2GM056432965 DT O
`` BC2GM056432965 `` O
activation-defective BC2GM056432965 JJ O
'' BC2GM056432965 '' O
mutants BC2GM056432965 NNS O
segregated BC2GM056432965 VBD O
into BC2GM056432965 IN O
two BC2GM056432965 CD O
classes BC2GM056432965 NNS O
: BC2GM056432965 : O
1 BC2GM056432965 CD O
) BC2GM056432965 ) O
those BC2GM056432965 DT O
that BC2GM056432965 WDT O
were BC2GM056432965 VBD O
unable BC2GM056432965 JJ O
to BC2GM056432965 TO O
form BC2GM056432965 VB O
dimers BC2GM056432965 NNS O
but BC2GM056432965 CC O
that BC2GM056432965 DT O
could BC2GM056432965 MD O
still BC2GM056432965 RB O
form BC2GM056432965 VB O
higher BC2GM056432965 JJR O
order BC2GM056432965 NN O
oligomers BC2GM056432965 NNS O
and BC2GM056432965 CC O
transform BC2GM056432965 NN O
cells BC2GM056432965 NNS O
, BC2GM056432965 , O
and BC2GM056432965 CC O
2 BC2GM056432965 CD O
) BC2GM056432965 ) O
those BC2GM056432965 DT O
that BC2GM056432965 WDT O
were BC2GM056432965 VBD O
defective BC2GM056432965 JJ O
for BC2GM056432965 IN O
PDGF-R BC2GM056432965 NNP O
binding BC2GM056432965 NN O
and BC2GM056432965 CC O
were BC2GM056432965 VBD O
transformation-incompetent BC2GM056432965 JJ O
. BC2GM056432965 . O
. . O O

Patients BC2GM021742629 NNS O
adopt BC2GM021742629 VBP O
new BC2GM021742629 JJ O
sets BC2GM021742629 NNS O
based BC2GM021742629 VBN O
partly BC2GM021742629 RB O
on BC2GM021742629 IN O
the BC2GM021742629 DT O
original BC2GM021742629 JJ O
topic BC2GM021742629 NN O
and BC2GM021742629 CC O
partly BC2GM021742629 RB O
on BC2GM021742629 IN O
their BC2GM021742629 PRP$ O
own BC2GM021742629 JJ O
personal BC2GM021742629 JJ O
idiosyncratic BC2GM021742629 JJ O
concerns BC2GM021742629 NNS O
. BC2GM021742629 . O
. . O O

Although BC2GM087282034 IN O
IRS-1 BC2GM087282034 NNP O
, BC2GM087282034 , O
-2 BC2GM087282034 NNP O
, BC2GM087282034 , O
and BC2GM087282034 CC O
-4 BC2GM087282034 NNS O
are BC2GM087282034 VBP O
similar BC2GM087282034 JJ O
in BC2GM087282034 IN O
overall BC2GM087282034 JJ O
structure BC2GM087282034 NN O
, BC2GM087282034 , O
IRS-3 BC2GM087282034 NNP O
is BC2GM087282034 VBZ O
approximately BC2GM087282034 RB O
50 BC2GM087282034 CD O
% BC2GM087282034 NN O
shorter BC2GM087282034 JJR O
and BC2GM087282034 CC O
differs BC2GM087282034 NNS O
with BC2GM087282034 IN O
respect BC2GM087282034 NN O
to BC2GM087282034 TO O
sites BC2GM087282034 NNS O
of BC2GM087282034 IN O
tyrosine BC2GM087282034 JJ O
phosphorylation BC2GM087282034 NN O
. BC2GM087282034 . O
. . O O

We BC2GM017071077 PRP O
conclude BC2GM017071077 VBP O
that BC2GM017071077 IN O
a BC2GM017071077 DT O
0.25 BC2GM017071077 CD O
mg BC2GM017071077 NN O
dose BC2GM017071077 NN O
of BC2GM017071077 IN O
triazolam BC2GM017071077 NN O
does BC2GM017071077 VBZ O
not BC2GM017071077 RB O
effectively BC2GM017071077 RB O
counteract BC2GM017071077 VB O
a BC2GM017071077 DT O
posture-induced BC2GM017071077 JJ O
sleep BC2GM017071077 NN O
disturbance BC2GM017071077 NN O
, BC2GM017071077 , O
but BC2GM017071077 CC O
induces BC2GM017071077 NNS O
changes BC2GM017071077 NNS O
in BC2GM017071077 IN O
the BC2GM017071077 DT O
EEG BC2GM017071077 NNP O
spectra BC2GM017071077 NN O
which BC2GM017071077 WDT O
are BC2GM017071077 VBP O
typical BC2GM017071077 JJ O
for BC2GM017071077 IN O
benzodiazepine BC2GM017071077 NN O
receptor BC2GM017071077 NN O
agonists BC2GM017071077 NNS O
. BC2GM017071077 . O
. . O O

A BC2GM087049151 DT O
mean BC2GM087049151 JJ O
value BC2GM087049151 NN O
for BC2GM087049151 IN O
HbA1 BC2GM087049151 NNP O
greater BC2GM087049151 JJR O
than BC2GM087049151 IN O
10 BC2GM087049151 CD O
% BC2GM087049151 NN O
was BC2GM087049151 VBD O
associated BC2GM087049151 VBN O
with BC2GM087049151 IN O
an BC2GM087049151 DT O
increased BC2GM087049151 VBN O
risk BC2GM087049151 NN O
of BC2GM087049151 IN O
progression BC2GM087049151 NN O
of BC2GM087049151 IN O
retinopathy BC2GM087049151 NN O
and BC2GM087049151 CC O
a BC2GM087049151 DT O
mean BC2GM087049151 JJ O
value BC2GM087049151 NN O
less BC2GM087049151 JJR O
than BC2GM087049151 IN O
8.7 BC2GM087049151 CD O
% BC2GM087049151 NN O
was BC2GM087049151 VBD O
associated BC2GM087049151 VBN O
with BC2GM087049151 IN O
a BC2GM087049151 DT O
diminished BC2GM087049151 JJ O
risk BC2GM087049151 NN O
. BC2GM087049151 . O
. . O O

However BC2GM064134481 RB O
, BC2GM064134481 , O
it BC2GM064134481 PRP O
is BC2GM064134481 VBZ O
not BC2GM064134481 RB O
easy BC2GM064134481 JJ O
to BC2GM064134481 TO O
establish BC2GM064134481 VB O
the BC2GM064134481 DT O
diagnosis BC2GM064134481 NN O
of BC2GM064134481 IN O
thoracic BC2GM064134481 NN O
MFH BC2GM064134481 NNP O
. BC2GM064134481 . O
. . O O

Serum BC2GM026154054 NNP O
prolactin BC2GM026154054 NN O
and BC2GM026154054 CC O
oestradiol BC2GM026154054 NN O
levels BC2GM026154054 NNS O
at BC2GM026154054 IN O
different BC2GM026154054 JJ O
stages BC2GM026154054 NNS O
of BC2GM026154054 IN O
puberty BC2GM026154054 NN O
. BC2GM026154054 . O
. . O O

Its BC2GM008564407 PRP$ O
prognostic BC2GM008564407 JJ O
impact BC2GM008564407 NN O
is BC2GM008564407 VBZ O
superior BC2GM008564407 JJ O
to BC2GM008564407 TO O
the BC2GM008564407 DT O
T1 BC2GM008564407 NNP O
/ BC2GM008564407 VBD O
2 BC2GM008564407 CD O
one BC2GM008564407 CD O
( BC2GM008564407 ( O
RR BC2GM008564407 NNP O
= BC2GM008564407 NNP O
2.9 BC2GM008564407 CD O
; BC2GM008564407 : O
p BC2GM008564407 NN O
= BC2GM008564407 VBZ O
0.0010 BC2GM008564407 CD O
) BC2GM008564407 ) O
. BC2GM008564407 . O
. . O O

Contrast BC2GM076852913 NNP O
radiography BC2GM076852913 NN O
appears BC2GM076852913 VBZ O
to BC2GM076852913 TO O
be BC2GM076852913 VB O
an BC2GM076852913 DT O
especially BC2GM076852913 RB O
inaccurate BC2GM076852913 JJ O
method BC2GM076852913 NN O
to BC2GM076852913 TO O
document BC2GM076852913 VB O
PUD BC2GM076852913 NNP O
in BC2GM076852913 IN O
CF BC2GM076852913 NNP O
because BC2GM076852913 IN O
the BC2GM076852913 DT O
duodenal BC2GM076852913 JJ O
mucosa BC2GM076852913 NN O
typically BC2GM076852913 RB O
appears BC2GM076852913 VBZ O
nodular BC2GM076852913 JJ O
and BC2GM076852913 CC O
distorted BC2GM076852913 VBN O
with BC2GM076852913 IN O
poor BC2GM076852913 JJ O
definition BC2GM076852913 NN O
of BC2GM076852913 IN O
the BC2GM076852913 DT O
mucosal BC2GM076852913 NN O
folds BC2GM076852913 NNS O
. BC2GM076852913 . O
. . O O

Interestingly BC2GM077588119 RB O
, BC2GM077588119 , O
the BC2GM077588119 DT O
expression BC2GM077588119 NN O
of BC2GM077588119 IN O
Id4 BC2GM077588119 NNP O
in BC2GM077588119 IN O
Sertoli BC2GM077588119 NNP O
cells BC2GM077588119 NNS O
is BC2GM077588119 VBZ O
only BC2GM077588119 RB O
detectable BC2GM077588119 JJ O
after BC2GM077588119 IN O
stimulation BC2GM077588119 NN O
with BC2GM077588119 IN O
FSH BC2GM077588119 NNP O
or BC2GM077588119 CC O
cAMP BC2GM077588119 NN O
. BC2GM077588119 . O
. . O O

We BC2GM009127817 PRP O
tested BC2GM009127817 VBD O
the BC2GM009127817 DT O
effects BC2GM009127817 NNS O
of BC2GM009127817 IN O
antifungal BC2GM009127817 JJ O
drugs BC2GM009127817 NNS O
on BC2GM009127817 IN O
adherence BC2GM009127817 NN O
of BC2GM009127817 IN O
Candida BC2GM009127817 NNP O
albicans BC2GM009127817 NNS O
in BC2GM009127817 IN O
vitro BC2GM009127817 NN O
. BC2GM009127817 . O
. . O O

The BC2GM084871019 DT O
odds BC2GM084871019 NNS O
of BC2GM084871019 IN O
atopy BC2GM084871019 NN O
( BC2GM084871019 ( O
defined BC2GM084871019 VBN O
as BC2GM084871019 IN O
a BC2GM084871019 DT O
positive BC2GM084871019 JJ O
test BC2GM084871019 NN O
for BC2GM084871019 IN O
at BC2GM084871019 IN O
least BC2GM084871019 JJS O
one BC2GM084871019 CD O
of BC2GM084871019 IN O
the BC2GM084871019 DT O
antigens BC2GM084871019 NNS O
) BC2GM084871019 ) O
were BC2GM084871019 VBD O
5 BC2GM084871019 CD O
times BC2GM084871019 NNS O
higher BC2GM084871019 RBR O
( BC2GM084871019 ( O
odds BC2GM084871019 NNS O
ratio BC2GM084871019 VBP O
= BC2GM084871019 JJ O
7.0 BC2GM084871019 CD O
; BC2GM084871019 : O
95 BC2GM084871019 CD O
% BC2GM084871019 NN O
confidence BC2GM084871019 NN O
interval BC2GM084871019 JJ O
= BC2GM084871019 JJ O
1.6-31.1 BC2GM084871019 JJ O
% BC2GM084871019 NN O
; BC2GM084871019 : O
p BC2GM084871019 CC O
= BC2GM084871019 VB O
0.01 BC2GM084871019 CD O
) BC2GM084871019 ) O
in BC2GM084871019 IN O
the BC2GM084871019 DT O
uninfected BC2GM084871019 JJ O
group BC2GM084871019 NN O
, BC2GM084871019 , O
after BC2GM084871019 IN O
taking BC2GM084871019 VBG O
into BC2GM084871019 IN O
account BC2GM084871019 NN O
the BC2GM084871019 DT O
potential BC2GM084871019 JJ O
influence BC2GM084871019 NN O
of BC2GM084871019 IN O
gender BC2GM084871019 NN O
and BC2GM084871019 CC O
age BC2GM084871019 NN O
. BC2GM084871019 . O
. . O O

The BC2GM012464195 DT O
`` BC2GM012464195 `` O
Ulm BC2GM012464195 NNP O
Zucker BC2GM012464195 NNP O
Uhr BC2GM012464195 NNP O
System BC2GM012464195 NNP O
'' BC2GM012464195 '' O
comprises BC2GM012464195 VBZ O
a BC2GM012464195 DT O
microdialysis BC2GM012464195 NN O
probe BC2GM012464195 NN O
, BC2GM012464195 , O
a BC2GM012464195 DT O
biosensor BC2GM012464195 NN O
( BC2GM012464195 ( O
Glucosensor BC2GM012464195 NNP O
Unitec BC2GM012464195 NNP O
Ulm BC2GM012464195 NNP O
s.c. BC2GM012464195 NN O
) BC2GM012464195 ) O
, BC2GM012464195 , O
a BC2GM012464195 DT O
sender BC2GM012464195 NN O
transferring BC2GM012464195 VBG O
telemetrically BC2GM012464195 RB O
the BC2GM012464195 DT O
glucose BC2GM012464195 JJ O
concentrations BC2GM012464195 NNS O
, BC2GM012464195 , O
and BC2GM012464195 CC O
a BC2GM012464195 DT O
receiving BC2GM012464195 JJ O
indicator BC2GM012464195 NN O
. BC2GM012464195 . O
. . O O

Lack BC2GM018207544 NN O
of BC2GM018207544 IN O
changes BC2GM018207544 NNS O
in BC2GM018207544 IN O
milk BC2GM018207544 NN O
production BC2GM018207544 NN O
and BC2GM018207544 CC O
milk BC2GM018207544 NN O
composition BC2GM018207544 NN O
suggest BC2GM018207544 VBP O
that BC2GM018207544 IN O
acute BC2GM018207544 NN O
increases BC2GM018207544 NNS O
in BC2GM018207544 IN O
somatotropin BC2GM018207544 NN O
with BC2GM018207544 IN O
concomitant BC2GM018207544 JJ O
increases BC2GM018207544 NNS O
in BC2GM018207544 IN O
insulin BC2GM018207544 NN O
are BC2GM018207544 VBP O
not BC2GM018207544 RB O
sufficient BC2GM018207544 JJ O
to BC2GM018207544 TO O
stimulate BC2GM018207544 VB O
synthesis BC2GM018207544 NN O
of BC2GM018207544 IN O
milk BC2GM018207544 NN O
and BC2GM018207544 CC O
milk BC2GM018207544 NN O
components BC2GM018207544 NNS O
by BC2GM018207544 IN O
cows BC2GM018207544 NNS O
during BC2GM018207544 IN O
established BC2GM018207544 VBN O
lactation BC2GM018207544 NN O
. BC2GM018207544 . O
. . O O

These BC2GM032149031 DT O
data BC2GM032149031 NNS O
show BC2GM032149031 NN O
that BC2GM032149031 IN O
both BC2GM032149031 DT O
Sp1 BC2GM032149031 NNP O
and BC2GM032149031 CC O
Sp3 BC2GM032149031 NNP O
transcription BC2GM032149031 NN O
factors BC2GM032149031 NNS O
upregulate BC2GM032149031 VBP O
HGF BC2GM032149031 NNP O
promoter BC2GM032149031 NN O
activity BC2GM032149031 NN O
by BC2GM032149031 IN O
binding BC2GM032149031 VBG O
to BC2GM032149031 TO O
the BC2GM032149031 DT O
Sp1 BC2GM032149031 NNP O
binding BC2GM032149031 NN O
site BC2GM032149031 NN O
at BC2GM032149031 IN O
position BC2GM032149031 NN O
-318 BC2GM032149031 NN O
to BC2GM032149031 TO O
-303 BC2GM032149031 VB O
bp BC2GM032149031 NN O
in BC2GM032149031 IN O
the BC2GM032149031 DT O
HGF BC2GM032149031 NNP O
gene BC2GM032149031 NN O
promoter BC2GM032149031 NN O
. BC2GM032149031 . O
. . O O

Recent BC2GM008130653 JJ O
geological BC2GM008130653 JJ O
studies BC2GM008130653 NNS O
focusing BC2GM008130653 VBG O
on BC2GM008130653 IN O
the BC2GM008130653 DT O
Davie BC2GM008130653 NNP O
Fracture BC2GM008130653 NNP O
Zone BC2GM008130653 NNP O
of BC2GM008130653 IN O
the BC2GM008130653 DT O
Mozambique BC2GM008130653 NNP O
Channel BC2GM008130653 NNP O
offer BC2GM008130653 NN O
a BC2GM008130653 DT O
resolution BC2GM008130653 NN O
to BC2GM008130653 TO O
this BC2GM008130653 DT O
situation BC2GM008130653 NN O
, BC2GM008130653 , O
by BC2GM008130653 IN O
suggesting BC2GM008130653 VBG O
the BC2GM008130653 DT O
presence BC2GM008130653 NN O
of BC2GM008130653 IN O
a BC2GM008130653 DT O
land-bridge BC2GM008130653 NN O
from BC2GM008130653 IN O
the BC2GM008130653 DT O
mid-Eocene BC2GM008130653 NN O
to BC2GM008130653 TO O
the BC2GM008130653 DT O
early BC2GM008130653 JJ O
Miocene BC2GM008130653 NNP O
, BC2GM008130653 , O
an BC2GM008130653 DT O
interval BC2GM008130653 NN O
that BC2GM008130653 WDT O
matches BC2GM008130653 VBZ O
the BC2GM008130653 DT O
ages BC2GM008130653 NNS O
of BC2GM008130653 IN O
Madagascar BC2GM008130653 NNP O
's BC2GM008130653 POS O
mammalian BC2GM008130653 JJ O
groups BC2GM008130653 NNS O
. BC2GM008130653 . O
. . O O

The BC2GM029325311 DT O
anaesthetic BC2GM029325311 JJ O
management BC2GM029325311 NN O
of BC2GM029325311 IN O
41 BC2GM029325311 CD O
patients BC2GM029325311 NNS O
who BC2GM029325311 WP O
underwent BC2GM029325311 VBP O
cardiac BC2GM029325311 JJ O
transplantation BC2GM029325311 NN O
during BC2GM029325311 IN O
a BC2GM029325311 DT O
40 BC2GM029325311 CD O
month BC2GM029325311 NN O
period BC2GM029325311 NN O
at BC2GM029325311 IN O
Clinica BC2GM029325311 NNP O
Puerta BC2GM029325311 NNP O
de BC2GM029325311 IN O
Hierro BC2GM029325311 NNP O
is BC2GM029325311 VBZ O
reviewed BC2GM029325311 VBN O
. BC2GM029325311 . O
. . O O

Three BC2GM077944631 CD O
putative BC2GM077944631 JJ O
ORFs BC2GM077944631 NNP O
have BC2GM077944631 VBP O
significant BC2GM077944631 JJ O
homology BC2GM077944631 NN O
with BC2GM077944631 IN O
known BC2GM077944631 JJ O
proteins BC2GM077944631 NNS O
: BC2GM077944631 : O
L0968 BC2GM077944631 NNP O
is BC2GM077944631 VBZ O
a BC2GM077944631 DT O
new BC2GM077944631 JJ O
member BC2GM077944631 NN O
of BC2GM077944631 IN O
the BC2GM077944631 DT O
very BC2GM077944631 RB O
large BC2GM077944631 JJ O
'seripauperins BC2GM077944631 NNS O
' BC2GM077944631 POS O
family BC2GM077944631 NN O
, BC2GM077944631 , O
comprising BC2GM077944631 VBG O
at BC2GM077944631 IN O
least BC2GM077944631 JJS O
20 BC2GM077944631 CD O
yeast BC2GM077944631 JJ O
members BC2GM077944631 NNS O
; BC2GM077944631 : O
L1313 BC2GM077944631 NNP O
is BC2GM077944631 VBZ O
a BC2GM077944631 DT O
new BC2GM077944631 JJ O
ABC BC2GM077944631 NNP O
transporter BC2GM077944631 NN O
highly BC2GM077944631 RB O
homologous BC2GM077944631 JJ O
to BC2GM077944631 TO O
the BC2GM077944631 DT O
yeast BC2GM077944631 NN O
cadmium BC2GM077944631 NN O
resistance BC2GM077944631 NN O
protein BC2GM077944631 NN O
Ycf1p BC2GM077944631 NNP O
and BC2GM077944631 CC O
to BC2GM077944631 TO O
the BC2GM077944631 DT O
human BC2GM077944631 JJ O
multidrug BC2GM077944631 NN O
resistance BC2GM077944631 NN O
protein BC2GM077944631 NN O
hMRP1 BC2GM077944631 NN O
; BC2GM077944631 : O
the BC2GM077944631 DT O
C-terminal BC2GM077944631 JJ O
part BC2GM077944631 NN O
of BC2GM077944631 IN O
L1325 BC2GM077944631 NNP O
present BC2GM077944631 NN O
in BC2GM077944631 IN O
our BC2GM077944631 PRP$ O
sequence BC2GM077944631 NN O
is BC2GM077944631 VBZ O
very BC2GM077944631 RB O
homologous BC2GM077944631 JJ O
to BC2GM077944631 TO O
the BC2GM077944631 DT O
fruit BC2GM077944631 NN O
fly BC2GM077944631 VBP O
abdominal BC2GM077944631 JJ O
segment BC2GM077944631 NN O
formation BC2GM077944631 NN O
protein BC2GM077944631 NN O
Pumilio BC2GM077944631 NNP O
. BC2GM077944631 . O
. . O O

Peptide BC2GM047129964 NNP O
competition BC2GM047129964 NN O
studies BC2GM047129964 NNS O
have BC2GM047129964 VBP O
localized BC2GM047129964 VBN O
a BC2GM047129964 DT O
cyclin BC2GM047129964 NN O
A BC2GM047129964 DT O
interaction BC2GM047129964 NN O
site BC2GM047129964 NN O
to BC2GM047129964 TO O
a BC2GM047129964 DT O
Lys381Lys382Leu383Met384Phe385 BC2GM047129964 NNP O
sequence BC2GM047129964 NN O
within BC2GM047129964 IN O
C-terminal BC2GM047129964 NNP O
negative BC2GM047129964 JJ O
regulatory BC2GM047129964 JJ O
domain BC2GM047129964 NN O
of BC2GM047129964 IN O
human BC2GM047129964 JJ O
p53 BC2GM047129964 NN O
. BC2GM047129964 . O
. . O O

Results BC2GM068305355 NNS O
on BC2GM068305355 IN O
the BC2GM068305355 DT O
use BC2GM068305355 NN O
of BC2GM068305355 IN O
amiodarone BC2GM068305355 NN O
in BC2GM068305355 IN O
the BC2GM068305355 DT O
prevention BC2GM068305355 NN O
of BC2GM068305355 IN O
paroxysmal BC2GM068305355 JJ O
AF BC2GM068305355 NNP O
have BC2GM068305355 VBP O
been BC2GM068305355 VBN O
equivocal BC2GM068305355 JJ O
; BC2GM068305355 : O
this BC2GM068305355 DT O
may BC2GM068305355 MD O
be BC2GM068305355 VB O
attributed BC2GM068305355 VBN O
to BC2GM068305355 TO O
differences BC2GM068305355 NNS O
in BC2GM068305355 IN O
defining BC2GM068305355 VBG O
paroxysmal BC2GM068305355 JJ O
AF BC2GM068305355 NNP O
. BC2GM068305355 . O
. . O O

It BC2GM041137121 PRP O
is BC2GM041137121 VBZ O
suggested BC2GM041137121 VBN O
that BC2GM041137121 IN O
biliary BC2GM041137121 JJ O
secretion BC2GM041137121 NN O
of BC2GM041137121 IN O
both BC2GM041137121 DT O
TBZ BC2GM041137121 NNP O
and BC2GM041137121 CC O
FBZ BC2GM041137121 NNP O
and BC2GM041137121 CC O
their BC2GM041137121 PRP$ O
metabolites BC2GM041137121 NNS O
may BC2GM041137121 MD O
contribute BC2GM041137121 VB O
to BC2GM041137121 TO O
this BC2GM041137121 DT O
recycling BC2GM041137121 NN O
. BC2GM041137121 . O
. . O O

Roller BC2GM055712987 NNP O
pumps BC2GM055712987 NNS O
, BC2GM055712987 , O
coronary BC2GM055712987 JJ O
suction BC2GM055712987 NN O
and BC2GM055712987 CC O
an BC2GM055712987 DT O
open BC2GM055712987 JJ O
cardiotomy BC2GM055712987 NN O
reservoir BC2GM055712987 NN O
were BC2GM055712987 VBD O
used BC2GM055712987 VBN O
. BC2GM055712987 . O
. . O O

The BC2GM045969390 DT O
immunoreactive BC2GM045969390 JJ O
antithrombin BC2GM045969390 NN O
III BC2GM045969390 NNP O
increased BC2GM045969390 VBD O
significantly BC2GM045969390 RB O
while BC2GM045969390 IN O
the BC2GM045969390 DT O
increase BC2GM045969390 NN O
in BC2GM045969390 IN O
antithrombin BC2GM045969390 JJ O
III BC2GM045969390 NNP O
activity BC2GM045969390 NN O
was BC2GM045969390 VBD O
insignificant BC2GM045969390 JJ O
in BC2GM045969390 IN O
20 BC2GM045969390 CD O
male BC2GM045969390 JJ O
Caucasian BC2GM045969390 JJ O
Danes BC2GM045969390 NNP O
upon BC2GM045969390 IN O
3 BC2GM045969390 CD O
weeks BC2GM045969390 NNS O
supplementation BC2GM045969390 NN O
of BC2GM045969390 IN O
the BC2GM045969390 DT O
diet BC2GM045969390 JJ O
with BC2GM045969390 IN O
10 BC2GM045969390 CD O
ml BC2GM045969390 JJ O
daily BC2GM045969390 RB O
of BC2GM045969390 IN O
a BC2GM045969390 DT O
cod BC2GM045969390 NN O
liver BC2GM045969390 NN O
oil BC2GM045969390 NN O
concentrate BC2GM045969390 NN O
. BC2GM045969390 . O
. . O O

On BC2GM066529343 IN O
transfer BC2GM066529343 NN O
from BC2GM066529343 IN O
glucose BC2GM066529343 NN O
, BC2GM066529343 , O
succinate BC2GM066529343 NN O
, BC2GM066529343 , O
malate BC2GM066529343 NN O
, BC2GM066529343 , O
or BC2GM066529343 CC O
glycerol BC2GM066529343 VB O
medium BC2GM066529343 NN O
to BC2GM066529343 TO O
citrate BC2GM066529343 VB O
medium BC2GM066529343 NN O
, BC2GM066529343 , O
the BC2GM066529343 DT O
Cit+ BC2GM066529343 NNP O
Escherichia BC2GM066529343 NNP O
coli BC2GM066529343 NN O
strains BC2GM066529343 NNS O
showed BC2GM066529343 VBD O
a BC2GM066529343 DT O
delay BC2GM066529343 NN O
of BC2GM066529343 IN O
36 BC2GM066529343 CD O
to BC2GM066529343 TO O
48 BC2GM066529343 CD O
h BC2GM066529343 NN O
before BC2GM066529343 IN O
growth BC2GM066529343 NN O
. BC2GM066529343 . O
. . O O

The BC2GM076143207 DT O
relationship BC2GM076143207 NN O
between BC2GM076143207 IN O
donor BC2GM076143207 NN O
status BC2GM076143207 NN O
for BC2GM076143207 IN O
antibody BC2GM076143207 NN O
to BC2GM076143207 TO O
hepatitis BC2GM076143207 VB O
B BC2GM076143207 NNP O
core BC2GM076143207 NN O
antigen BC2GM076143207 NN O
and BC2GM076143207 CC O
the BC2GM076143207 DT O
occurrence BC2GM076143207 NN O
of BC2GM076143207 IN O
non-A BC2GM076143207 JJ O
, BC2GM076143207 , O
non-B BC2GM076143207 JJ O
posttransfusion BC2GM076143207 NN O
hepatitis BC2GM076143207 NN O
in BC2GM076143207 IN O
the BC2GM076143207 DT O
recipient BC2GM076143207 NN O
was BC2GM076143207 VBD O
prospectively BC2GM076143207 RB O
studied BC2GM076143207 VBN O
in BC2GM076143207 IN O
112 BC2GM076143207 CD O
patients BC2GM076143207 NNS O
undergoing BC2GM076143207 JJ O
open-heart BC2GM076143207 JJ O
surgery BC2GM076143207 NN O
who BC2GM076143207 WP O
were BC2GM076143207 VBD O
followed BC2GM076143207 VBN O
for BC2GM076143207 IN O
6.5 BC2GM076143207 CD O
months BC2GM076143207 NNS O
after BC2GM076143207 IN O
surgery BC2GM076143207 NN O
. BC2GM076143207 . O
. . O O

The BC2GM088652504 DT O
phosphatidylglycerol BC2GM088652504 NN O
/ BC2GM088652504 NNP O
phosphatidylinositol BC2GM088652504 NN O
transfer BC2GM088652504 NN O
protein BC2GM088652504 NN O
( BC2GM088652504 ( O
PG BC2GM088652504 NNP O
/ BC2GM088652504 NNP O
PI-TP BC2GM088652504 NNP O
) BC2GM088652504 ) O
is BC2GM088652504 VBZ O
a BC2GM088652504 DT O
new BC2GM088652504 JJ O
and BC2GM088652504 CC O
original BC2GM088652504 JJ O
phospholipid BC2GM088652504 NN O
transfer BC2GM088652504 NN O
protein BC2GM088652504 NN O
( BC2GM088652504 ( O
PLTP BC2GM088652504 NNP O
) BC2GM088652504 ) O
isolated BC2GM088652504 VBD O
from BC2GM088652504 IN O
the BC2GM088652504 DT O
Deuteromycete BC2GM088652504 NNP O
, BC2GM088652504 , O
Aspergillus BC2GM088652504 NNP O
oryzae BC2GM088652504 NN O
. BC2GM088652504 . O
. . O O

Thus BC2GM074489263 RB O
, BC2GM074489263 , O
the BC2GM074489263 DT O
cognitive BC2GM074489263 JJ O
performance BC2GM074489263 NN O
of BC2GM074489263 IN O
elderly BC2GM074489263 JJ O
subjects BC2GM074489263 NNS O
could BC2GM074489263 MD O
be BC2GM074489263 VB O
trained BC2GM074489263 VBN O
to BC2GM074489263 TO O
a BC2GM074489263 DT O
large BC2GM074489263 JJ O
extent BC2GM074489263 NN O
. BC2GM074489263 . O
. . O O

To BC2GM079983245 TO O
confirm BC2GM079983245 VB O
the BC2GM079983245 DT O
data BC2GM079983245 NNS O
obtained BC2GM079983245 VBD O
using BC2GM079983245 VBG O
the BC2GM079983245 DT O
HPLC-ESI-MS BC2GM079983245 JJ O
procedure BC2GM079983245 NN O
, BC2GM079983245 , O
fractions BC2GM079983245 NNS O
of BC2GM079983245 IN O
the BC2GM079983245 DT O
glycosides BC2GM079983245 NNS O
from BC2GM079983245 IN O
four BC2GM079983245 CD O
berries BC2GM079983245 NNS O
were BC2GM079983245 VBD O
separated BC2GM079983245 VBN O
, BC2GM079983245 , O
hydrolyzed BC2GM079983245 VBN O
, BC2GM079983245 , O
silylated BC2GM079983245 VBN O
and BC2GM079983245 CC O
the BC2GM079983245 DT O
sugars BC2GM079983245 NNS O
were BC2GM079983245 VBD O
analyzed BC2GM079983245 VBN O
using BC2GM079983245 VBG O
gas BC2GM079983245 NN O
chromatography-mass BC2GM079983245 NN O
spectrometry BC2GM079983245 NN O
. BC2GM079983245 . O
. . O O

Substitutions BC2GM091139291 NNS O
of BC2GM091139291 IN O
Asp11 BC2GM091139291 NNP O
led BC2GM091139291 VBD O
to BC2GM091139291 TO O
dominant BC2GM091139291 JJ O
lethality BC2GM091139291 NN O
. BC2GM091139291 . O
. . O O

In BC2GM089371905 IN O
cells BC2GM089371905 NNS O
infected BC2GM089371905 VBN O
with BC2GM089371905 IN O
a BC2GM089371905 DT O
recombinant BC2GM089371905 JJ O
vaccinia BC2GM089371905 NN O
virus BC2GM089371905 NN O
expressing BC2GM089371905 VBG O
HCV BC2GM089371905 NNP O
structural BC2GM089371905 JJ O
proteins BC2GM089371905 NNS O
( BC2GM089371905 ( O
core BC2GM089371905 NN O
, BC2GM089371905 , O
E1 BC2GM089371905 NNP O
, BC2GM089371905 , O
and BC2GM089371905 CC O
E2 BC2GM089371905 NNP O
) BC2GM089371905 ) O
, BC2GM089371905 , O
DDX3 BC2GM089371905 NNP O
and BC2GM089371905 CC O
core BC2GM089371905 NN O
colocalized BC2GM089371905 VBN O
in BC2GM089371905 IN O
distinct BC2GM089371905 JJ O
spots BC2GM089371905 NNS O
in BC2GM089371905 IN O
the BC2GM089371905 DT O
perinuclear BC2GM089371905 JJ O
region BC2GM089371905 NN O
of BC2GM089371905 IN O
the BC2GM089371905 DT O
cytoplasm BC2GM089371905 NN O
. BC2GM089371905 . O
. . O O

This BC2GM051225435 DT O
is BC2GM051225435 VBZ O
the BC2GM051225435 DT O
first BC2GM051225435 JJ O
report BC2GM051225435 NN O
demonstrating BC2GM051225435 VBG O
specificity BC2GM051225435 NN O
at BC2GM051225435 IN O
the BC2GM051225435 DT O
level BC2GM051225435 NN O
of BC2GM051225435 IN O
the BC2GM051225435 DT O
energy BC2GM051225435 NN O
coupling BC2GM051225435 VBG O
proteins BC2GM051225435 NNS O
of BC2GM051225435 IN O
the BC2GM051225435 DT O
PTS BC2GM051225435 NNP O
. BC2GM051225435 . O
. . O O

By BC2GM095308818 IN O
screening BC2GM095308818 VBG O
a BC2GM095308818 DT O
human BC2GM095308818 JJ O
testis BC2GM095308818 NN O
cDNA BC2GM095308818 NN O
library BC2GM095308818 NN O
with BC2GM095308818 IN O
a BC2GM095308818 DT O
probe BC2GM095308818 NN O
containing BC2GM095308818 VBG O
the BC2GM095308818 DT O
mouse BC2GM095308818 NN O
PEA3 BC2GM095308818 NNP O
ETS BC2GM095308818 NNP O
domain BC2GM095308818 NN O
, BC2GM095308818 , O
we BC2GM095308818 PRP O
isolated BC2GM095308818 VBD O
a BC2GM095308818 DT O
2.2 BC2GM095308818 CD O
kb BC2GM095308818 NN O
clone BC2GM095308818 NN O
containing BC2GM095308818 VBG O
a BC2GM095308818 DT O
510 BC2GM095308818 CD O
AA BC2GM095308818 NNP O
open BC2GM095308818 JJ O
reading BC2GM095308818 NN O
frame BC2GM095308818 NN O
. BC2GM095308818 . O
. . O O

The BC2GM006903423 DT O
incidence BC2GM006903423 NN O
of BC2GM006903423 IN O
the BC2GM006903423 DT O
variability BC2GM006903423 NN O
of BC2GM006903423 IN O
the BC2GM006903423 DT O
free BC2GM006903423 JJ O
PSA BC2GM006903423 NNP O
/ BC2GM006903423 NNP O
total BC2GM006903423 JJ O
PSA BC2GM006903423 NNP O
ratio BC2GM006903423 NN O
on BC2GM006903423 IN O
the BC2GM006903423 DT O
early BC2GM006903423 JJ O
diagnosis BC2GM006903423 NN O
of BC2GM006903423 IN O
prostate BC2GM006903423 NN O
cancer BC2GM006903423 NN O
. BC2GM006903423 . O
. . O O

They BC2GM053004410 PRP O
are BC2GM053004410 VBP O
found BC2GM053004410 VBN O
to BC2GM053004410 TO O
have BC2GM053004410 VB O
several BC2GM053004410 JJ O
advantages BC2GM053004410 NNS O
over BC2GM053004410 IN O
the BC2GM053004410 DT O
conventional BC2GM053004410 JJ O
indices BC2GM053004410 NNS O
of BC2GM053004410 IN O
skewness BC2GM053004410 NN O
and BC2GM053004410 CC O
kurtosis BC2GM053004410 NN O
( BC2GM053004410 ( O
square BC2GM053004410 JJ O
root BC2GM053004410 NN O
of BC2GM053004410 IN O
b1 BC2GM053004410 NN O
and BC2GM053004410 CC O
b2 BC2GM053004410 NN O
) BC2GM053004410 ) O
and BC2GM053004410 CC O
no BC2GM053004410 DT O
serious BC2GM053004410 JJ O
drawbacks BC2GM053004410 NNS O
. BC2GM053004410 . O
. . O O

The BC2GM097964351 DT O
use BC2GM097964351 NN O
of BC2GM097964351 IN O
medication BC2GM097964351 NN O
is BC2GM097964351 VBZ O
of BC2GM097964351 IN O
minor BC2GM097964351 JJ O
importance BC2GM097964351 NN O
in BC2GM097964351 IN O
the BC2GM097964351 DT O
treatment BC2GM097964351 NN O
of BC2GM097964351 IN O
flight BC2GM097964351 NN O
phobia BC2GM097964351 NN O
. BC2GM097964351 . O
. . O O

Concerning BC2GM048995612 VBG O
the BC2GM048995612 DT O
practical BC2GM048995612 JJ O
approach BC2GM048995612 NN O
in BC2GM048995612 IN O
a BC2GM048995612 DT O
clinical BC2GM048995612 JJ O
setting BC2GM048995612 NN O
, BC2GM048995612 , O
it BC2GM048995612 PRP O
has BC2GM048995612 VBZ O
to BC2GM048995612 TO O
be BC2GM048995612 VB O
pointed BC2GM048995612 VBN O
out BC2GM048995612 RP O
that BC2GM048995612 IN O
with BC2GM048995612 IN O
these BC2GM048995612 DT O
diseases BC2GM048995612 NNS O
a BC2GM048995612 DT O
hepatitis BC2GM048995612 NN O
C BC2GM048995612 NNP O
infection BC2GM048995612 NN O
has BC2GM048995612 VBZ O
to BC2GM048995612 TO O
be BC2GM048995612 VB O
considered BC2GM048995612 VBN O
and BC2GM048995612 CC O
testing BC2GM048995612 VBG O
for BC2GM048995612 IN O
hepatitis BC2GM048995612 NN O
C BC2GM048995612 NNP O
antibodies BC2GM048995612 NNS O
and BC2GM048995612 CC O
, BC2GM048995612 , O
if BC2GM048995612 IN O
positive BC2GM048995612 JJ O
, BC2GM048995612 , O
hepatitis BC2GM048995612 JJ O
C-RNA BC2GM048995612 NNP O
is BC2GM048995612 VBZ O
indicated BC2GM048995612 VBN O
. BC2GM048995612 . O
. . O O

Expression BC2GM003883590 NN O
of BC2GM003883590 IN O
the BC2GM003883590 DT O
gene BC2GM003883590 NN O
encoding BC2GM003883590 VBG O
transcription BC2GM003883590 NN O
factor BC2GM003883590 NN O
cyclic BC2GM003883590 JJ O
adenosine BC2GM003883590 JJ O
3',5'-monophosphate BC2GM003883590 JJ O
( BC2GM003883590 ( O
cAMP BC2GM003883590 NN O
) BC2GM003883590 ) O
response BC2GM003883590 NN O
element-binding BC2GM003883590 JJ O
protein BC2GM003883590 NN O
( BC2GM003883590 ( O
CREB BC2GM003883590 NNP O
) BC2GM003883590 ) O
: BC2GM003883590 : O
regulation BC2GM003883590 NN O
by BC2GM003883590 IN O
follicle-stimulating BC2GM003883590 JJ O
hormone-induced BC2GM003883590 JJ O
cAMP BC2GM003883590 NN O
signaling BC2GM003883590 VBG O
in BC2GM003883590 IN O
primary BC2GM003883590 JJ O
rat BC2GM003883590 NN O
Sertoli BC2GM003883590 NNP O
cells BC2GM003883590 NNS O
. BC2GM003883590 . O
. . O O

Asthma BC2GM037692816 NNP O
diagnoses BC2GM037692816 NNS O
were BC2GM037692816 VBD O
made BC2GM037692816 VBN O
according BC2GM037692816 VBG O
to BC2GM037692816 TO O
recommended BC2GM037692816 VBN O
National BC2GM037692816 NNP O
Asthma BC2GM037692816 NNP O
Expert BC2GM037692816 NNP O
Panel BC2GM037692816 NNP O
Guidelines BC2GM037692816 NNP O
. BC2GM037692816 . O
. . O O

The BC2GM014735675 DT O
PHO5 BC2GM014735675 NNP O
gene BC2GM014735675 NN O
is BC2GM014735675 VBZ O
activated BC2GM014735675 VBN O
by BC2GM014735675 IN O
the BC2GM014735675 DT O
Pho4p BC2GM014735675 NNP O
transcription BC2GM014735675 NN O
factor BC2GM014735675 NN O
, BC2GM014735675 , O
which BC2GM014735675 WDT O
itself BC2GM014735675 PRP O
is BC2GM014735675 VBZ O
negatively BC2GM014735675 RB O
regulated BC2GM014735675 VBN O
through BC2GM014735675 IN O
phosphorylation BC2GM014735675 NN O
by BC2GM014735675 IN O
the BC2GM014735675 DT O
products BC2GM014735675 NNS O
of BC2GM014735675 IN O
PHO80 BC2GM014735675 NNP O
and BC2GM014735675 CC O
PHO85 BC2GM014735675 NNP O
. BC2GM014735675 . O
. . O O

The BC2GM008190369 DT O
immunoprofile BC2GM008190369 NN O
of BC2GM008190369 IN O
60 BC2GM008190369 CD O
adult BC2GM008190369 NN O
patients BC2GM008190369 NNS O
of BC2GM008190369 IN O
pulmonary BC2GM008190369 JJ O
tuberculosis BC2GM008190369 NN O
was BC2GM008190369 VBD O
studied BC2GM008190369 VBN O
and BC2GM008190369 CC O
compared BC2GM008190369 VBN O
with BC2GM008190369 IN O
22 BC2GM008190369 CD O
normal BC2GM008190369 JJ O
controls BC2GM008190369 NNS O
. BC2GM008190369 . O
. . O O

Rectal BC2GM074194450 JJ O
temperatures BC2GM074194450 NNS O
after BC2GM074194450 IN O
the BC2GM074194450 DT O
walk BC2GM074194450 NN O
were BC2GM074194450 VBD O
greater BC2GM074194450 JJR O
( BC2GM074194450 ( O
P BC2GM074194450 NNP O
< BC2GM074194450 NNP O
.001 BC2GM074194450 NNP O
) BC2GM074194450 ) O
in BC2GM074194450 IN O
native BC2GM074194450 JJ O
Simmental BC2GM074194450 NNP O
( BC2GM074194450 ( O
39.87 BC2GM074194450 CD O
+ BC2GM074194450 NN O
/ BC2GM074194450 NNP O
- BC2GM074194450 : O
.05 BC2GM074194450 NN O
degrees BC2GM074194450 NNS O
C BC2GM074194450 NNP O
) BC2GM074194450 ) O
than BC2GM074194450 IN O
in BC2GM074194450 IN O
Bos BC2GM074194450 NNP O
indicus BC2GM074194450 NN O
( BC2GM074194450 ( O
39.46 BC2GM074194450 CD O
+ BC2GM074194450 NN O
/ BC2GM074194450 NNP O
- BC2GM074194450 : O
.05 BC2GM074194450 NN O
degrees BC2GM074194450 NNS O
C BC2GM074194450 NNP O
) BC2GM074194450 ) O
. BC2GM074194450 . O
. . O O

In BC2GM098872814 IN O
treatments BC2GM098872814 NNS O
R1 BC2GM098872814 NNP O
and BC2GM098872814 CC O
R2 BC2GM098872814 NNP O
, BC2GM098872814 , O
feed BC2GM098872814 VBP O
quality BC2GM098872814 NN O
was BC2GM098872814 VBD O
restricted BC2GM098872814 VBN O
by BC2GM098872814 IN O
withholding BC2GM098872814 VBG O
concentrates BC2GM098872814 NNS O
for BC2GM098872814 IN O
3 BC2GM098872814 CD O
and BC2GM098872814 CC O
4.5 BC2GM098872814 CD O
mo BC2GM098872814 NN O
, BC2GM098872814 , O
respectively BC2GM098872814 RB O
. BC2GM098872814 . O
. . O O

In BC2GM064548155 IN O
patients BC2GM064548155 NNS O
autografted BC2GM064548155 VBN O
in BC2GM064548155 IN O
CR1 BC2GM064548155 NNP O
, BC2GM064548155 , O
the BC2GM064548155 DT O
transplant-related BC2GM064548155 JJ O
mortality BC2GM064548155 NN O
( BC2GM064548155 ( O
TRM BC2GM064548155 NNP O
) BC2GM064548155 ) O
was BC2GM064548155 VBD O
15 BC2GM064548155 CD O
+ BC2GM064548155 JJ O
/ BC2GM064548155 NNP O
- BC2GM064548155 : O
4 BC2GM064548155 CD O
% BC2GM064548155 NN O
, BC2GM064548155 , O
the BC2GM064548155 DT O
relapse BC2GM064548155 NN O
incidence BC2GM064548155 NN O
( BC2GM064548155 ( O
RI BC2GM064548155 NNP O
) BC2GM064548155 ) O
was BC2GM064548155 VBD O
58 BC2GM064548155 CD O
+ BC2GM064548155 JJ O
/ BC2GM064548155 NNP O
- BC2GM064548155 : O
5 BC2GM064548155 CD O
% BC2GM064548155 NN O
, BC2GM064548155 , O
the BC2GM064548155 DT O
leukaemia-free BC2GM064548155 JJ O
survival BC2GM064548155 NN O
( BC2GM064548155 ( O
LFS BC2GM064548155 NNP O
) BC2GM064548155 ) O
was BC2GM064548155 VBD O
36 BC2GM064548155 CD O
+ BC2GM064548155 JJ O
/ BC2GM064548155 NNP O
- BC2GM064548155 : O
5 BC2GM064548155 CD O
% BC2GM064548155 NN O
and BC2GM064548155 CC O
the BC2GM064548155 DT O
overall BC2GM064548155 JJ O
survival BC2GM064548155 NN O
was BC2GM064548155 VBD O
47 BC2GM064548155 CD O
+ BC2GM064548155 JJ O
/ BC2GM064548155 NNP O
- BC2GM064548155 : O
5 BC2GM064548155 CD O
% BC2GM064548155 NN O
at BC2GM064548155 IN O
3 BC2GM064548155 CD O
years BC2GM064548155 NNS O
. BC2GM064548155 . O
. . O O

Chemiluminescence BC2GM041430420 NN O
induced BC2GM041430420 VBN O
by BC2GM041430420 IN O
opsonized BC2GM041430420 JJ O
zymosan BC2GM041430420 NN O
increased BC2GM041430420 VBD O
significantly BC2GM041430420 RB O
( BC2GM041430420 ( O
P BC2GM041430420 NNP O
less BC2GM041430420 JJR O
than BC2GM041430420 IN O
0.05 BC2GM041430420 CD O
) BC2GM041430420 ) O
after BC2GM041430420 IN O
treatment BC2GM041430420 NN O
with BC2GM041430420 IN O
bacterial BC2GM041430420 JJ O
extracts BC2GM041430420 NNS O
, BC2GM041430420 , O
whereas BC2GM041430420 IN O
no BC2GM041430420 DT O
significant BC2GM041430420 JJ O
changes BC2GM041430420 NNS O
were BC2GM041430420 VBD O
observed BC2GM041430420 VBN O
in BC2GM041430420 IN O
the BC2GM041430420 DT O
fMLP-stimulated BC2GM041430420 JJ O
PMNs BC2GM041430420 NNP O
. BC2GM041430420 . O
. . O O

Functional BC2GM031056055 JJ O
uncoupling BC2GM031056055 NN O
of BC2GM031056055 IN O
the BC2GM031056055 DT O
Janus BC2GM031056055 NNP O
kinase BC2GM031056055 VBD O
3-Stat5 BC2GM031056055 JJ O
pathway BC2GM031056055 NN O
in BC2GM031056055 IN O
malignant BC2GM031056055 JJ O
growth BC2GM031056055 NN O
of BC2GM031056055 IN O
human BC2GM031056055 JJ O
T BC2GM031056055 NNP O
cell BC2GM031056055 NN O
leukemia BC2GM031056055 NN O
virus BC2GM031056055 NN O
type BC2GM031056055 JJ O
1-transformed BC2GM031056055 JJ O
human BC2GM031056055 JJ O
T BC2GM031056055 NNP O
cells BC2GM031056055 NNS O
. BC2GM031056055 . O
. . O O

Reexamination BC2GM017582406 NN O
of BC2GM017582406 IN O
the BC2GM017582406 DT O
cdc4-1 BC2GM017582406 JJ O
mutant BC2GM017582406 NN O
revealed BC2GM017582406 VBD O
that BC2GM017582406 IN O
, BC2GM017582406 , O
in BC2GM017582406 IN O
addition BC2GM017582406 NN O
to BC2GM017582406 TO O
being BC2GM017582406 VBG O
defective BC2GM017582406 JJ O
in BC2GM017582406 IN O
the BC2GM017582406 DT O
onset BC2GM017582406 NN O
of BC2GM017582406 IN O
S BC2GM017582406 NNP O
phase BC2GM017582406 NN O
, BC2GM017582406 , O
it BC2GM017582406 PRP O
is BC2GM017582406 VBZ O
also BC2GM017582406 RB O
defective BC2GM017582406 JJ O
in BC2GM017582406 IN O
G BC2GM017582406 NNP O
( BC2GM017582406 ( O
2 BC2GM017582406 CD O
) BC2GM017582406 ) O
/ BC2GM017582406 FW O
M BC2GM017582406 NNP O
transition BC2GM017582406 NN O
when BC2GM017582406 WRB O
released BC2GM017582406 VBN O
from BC2GM017582406 IN O
hydroxyurea-induced BC2GM017582406 JJ O
S-phase BC2GM017582406 NNP O
arrest BC2GM017582406 NN O
. BC2GM017582406 . O
. . O O

Whereas BC2GM063812072 NNP O
mutant BC2GM063812072 VBP O
6C4 BC2GM063812072 CD O
specified BC2GM063812072 VBD O
a BC2GM063812072 DT O
wild-type-size BC2GM063812072 JJ O
Pol BC2GM063812072 NNP O
protein BC2GM063812072 NN O
, BC2GM063812072 , O
we BC2GM063812072 PRP O
detected BC2GM063812072 VBD O
no BC2GM063812072 DT O
full-length BC2GM063812072 JJ O
Pol BC2GM063812072 NNP O
protein BC2GM063812072 NN O
in BC2GM063812072 IN O
7E4-infected BC2GM063812072 JJ O
cell BC2GM063812072 NN O
extracts BC2GM063812072 NNS O
. BC2GM063812072 . O
. . O O

The BC2GM026702973 DT O
pra2 BC2GM026702973 NN O
gene BC2GM026702973 NN O
encodes BC2GM026702973 VBZ O
a BC2GM026702973 DT O
pea BC2GM026702973 NN O
( BC2GM026702973 ( O
Pisum BC2GM026702973 NNP O
sativum BC2GM026702973 NN O
) BC2GM026702973 ) O
small BC2GM026702973 JJ O
GTPase BC2GM026702973 NNP O
belonging BC2GM026702973 NN O
to BC2GM026702973 TO O
the BC2GM026702973 DT O
YPT BC2GM026702973 NNP O
/ BC2GM026702973 NNP O
rab BC2GM026702973 VBD O
family BC2GM026702973 NN O
, BC2GM026702973 , O
and BC2GM026702973 CC O
its BC2GM026702973 PRP$ O
expression BC2GM026702973 NN O
is BC2GM026702973 VBZ O
down-regulated BC2GM026702973 JJ O
by BC2GM026702973 IN O
light BC2GM026702973 NN O
, BC2GM026702973 , O
mediated BC2GM026702973 VBN O
by BC2GM026702973 IN O
phytochrome BC2GM026702973 NN O
. BC2GM026702973 . O
. . O O

The BC2GM082618683 DT O
second BC2GM082618683 JJ O
( BC2GM082618683 ( O
control BC2GM082618683 NN O
) BC2GM082618683 ) O
group BC2GM082618683 NN O
was BC2GM082618683 VBD O
represented BC2GM082618683 VBN O
by BC2GM082618683 IN O
cases BC2GM082618683 NNS O
diagnosed BC2GM082618683 VBN O
as BC2GM082618683 IN O
HSIL BC2GM082618683 NNP O
by BC2GM082618683 IN O
cytology BC2GM082618683 NN O
. BC2GM082618683 . O
. . O O

Expression BC2GM085437815 NN O
of BC2GM085437815 IN O
putative BC2GM085437815 JJ O
constitutively BC2GM085437815 RB O
active BC2GM085437815 JJ O
forms BC2GM085437815 NNS O
of BC2GM085437815 IN O
DdMEK1 BC2GM085437815 NNP O
in BC2GM085437815 IN O
a BC2GM085437815 DT O
ddmek1 BC2GM085437815 JJ O
null BC2GM085437815 NN O
background BC2GM085437815 NN O
is BC2GM085437815 VBZ O
capable BC2GM085437815 JJ O
, BC2GM085437815 , O
at BC2GM085437815 IN O
least BC2GM085437815 JJS O
partially BC2GM085437815 RB O
, BC2GM085437815 , O
of BC2GM085437815 IN O
complementing BC2GM085437815 VBG O
the BC2GM085437815 DT O
small BC2GM085437815 JJ O
aggregate BC2GM085437815 NN O
size BC2GM085437815 NN O
defect BC2GM085437815 NN O
and BC2GM085437815 CC O
the BC2GM085437815 DT O
ability BC2GM085437815 NN O
to BC2GM085437815 TO O
activate BC2GM085437815 VB O
guanylyl BC2GM085437815 JJ O
cyclase BC2GM085437815 NN O
. BC2GM085437815 . O
. . O O

Mating BC2GM022119208 VBG O
response BC2GM022119208 NN O
, BC2GM022119208 , O
ovulation BC2GM022119208 NN O
rate BC2GM022119208 NN O
, BC2GM022119208 , O
follicle BC2GM022119208 NN O
and BC2GM022119208 CC O
corpus BC2GM022119208 NN O
luteum BC2GM022119208 NN O
size BC2GM022119208 NN O
, BC2GM022119208 , O
gestation BC2GM022119208 NN O
length BC2GM022119208 NN O
, BC2GM022119208 , O
pregnancy BC2GM022119208 NN O
rate BC2GM022119208 NN O
, BC2GM022119208 , O
lambing BC2GM022119208 VBG O
rate BC2GM022119208 NN O
, BC2GM022119208 , O
and BC2GM022119208 CC O
lamb BC2GM022119208 JJ O
birth BC2GM022119208 NN O
weight BC2GM022119208 NN O
were BC2GM022119208 VBD O
recorded BC2GM022119208 VBN O
. BC2GM022119208 . O
. . O O

Vibrio BC2GM059483475 NNP O
cholerae BC2GM059483475 NN O
iron BC2GM059483475 NN O
transport BC2GM059483475 NN O
: BC2GM059483475 : O
haem BC2GM059483475 NN O
transport BC2GM059483475 NN O
genes BC2GM059483475 NNS O
are BC2GM059483475 VBP O
linked BC2GM059483475 VBN O
to BC2GM059483475 TO O
one BC2GM059483475 CD O
of BC2GM059483475 IN O
two BC2GM059483475 CD O
sets BC2GM059483475 NNS O
of BC2GM059483475 IN O
tonB BC2GM059483475 NN O
, BC2GM059483475 , O
exbB BC2GM059483475 NN O
, BC2GM059483475 , O
exbD BC2GM059483475 JJ O
genes BC2GM059483475 NNS O
. BC2GM059483475 . O
. . O O

The BC2GM084966023 DT O
phosphatase BC2GM084966023 NN O
active BC2GM084966023 JJ O
site BC2GM084966023 NN O
is BC2GM084966023 VBZ O
located BC2GM084966023 VBN O
within BC2GM084966023 IN O
residues BC2GM084966023 NNS O
367-374 BC2GM084966023 CD O
. BC2GM084966023 . O
. . O O

Other BC2GM059696646 JJ O
clinicopathological BC2GM059696646 JJ O
features BC2GM059696646 NNS O
have BC2GM059696646 VBP O
no BC2GM059696646 DT O
definite BC2GM059696646 JJ O
influence BC2GM059696646 NN O
in BC2GM059696646 IN O
survival BC2GM059696646 NN O
expectancy BC2GM059696646 NN O
. BC2GM059696646 . O
. . O O

Comparison BC2GM041800456 NNP O
of BC2GM041800456 IN O
the BC2GM041800456 DT O
derived BC2GM041800456 VBN O
amino BC2GM041800456 NN O
acid BC2GM041800456 NN O
sequence BC2GM041800456 NN O
with BC2GM041800456 IN O
that BC2GM041800456 DT O
of BC2GM041800456 IN O
the BC2GM041800456 DT O
HCMV BC2GM041800456 NNP O
UL99 BC2GM041800456 NNP O
gene BC2GM041800456 NN O
product BC2GM041800456 NN O
reveals BC2GM041800456 VBZ O
34.8 BC2GM041800456 CD O
% BC2GM041800456 NN O
identity BC2GM041800456 NN O
in BC2GM041800456 IN O
an BC2GM041800456 DT O
overlap BC2GM041800456 NN O
of BC2GM041800456 IN O
66 BC2GM041800456 CD O
amino BC2GM041800456 JJ O
acids BC2GM041800456 NNS O
. BC2GM041800456 . O
. . O O

The BC2GM084544513 DT O
binding BC2GM084544513 NN O
of BC2GM084544513 IN O
PTB BC2GM084544513 NNP O
was BC2GM084544513 VBD O
antagonistic BC2GM084544513 JJ O
to BC2GM084544513 TO O
the BC2GM084544513 DT O
binding BC2GM084544513 NN O
of BC2GM084544513 IN O
U2AF BC2GM084544513 NNP O
to BC2GM084544513 TO O
the BC2GM084544513 DT O
enhancer-located BC2GM084544513 JJ O
pyrimidine BC2GM084544513 NN O
tract BC2GM084544513 NN O
. BC2GM084544513 . O
. . O O

( BC2GM004363438 ( O
1993 BC2GM004363438 CD O
) BC2GM004363438 ) O
8 BC2GM004363438 CD O
, BC2GM004363438 , O
94-99 BC2GM004363438 CD O
) BC2GM004363438 ) O
. BC2GM004363438 . O
. . O O

Although BC2GM098358600 IN O
the BC2GM098358600 DT O
number BC2GM098358600 NN O
of BC2GM098358600 IN O
kits BC2GM098358600 NNS O
has BC2GM098358600 VBZ O
increased BC2GM098358600 VBN O
, BC2GM098358600 , O
the BC2GM098358600 DT O
precision BC2GM098358600 NN O
has BC2GM098358600 VBZ O
improved BC2GM098358600 VBN O
, BC2GM098358600 , O
showing BC2GM098358600 VBG O
that BC2GM098358600 IN O
more BC2GM098358600 JJR O
robust BC2GM098358600 JJ O
methods BC2GM098358600 NNS O
are BC2GM098358600 VBP O
now BC2GM098358600 RB O
employed BC2GM098358600 VBN O
. BC2GM098358600 . O
. . O O

The BC2GM008233762 DT O
corresponding BC2GM008233762 JJ O
tetrapeptide BC2GM008233762 NN O
sequences BC2GM008233762 NNS O
SSPD BC2GM008233762 NNP O
and BC2GM008233762 CC O
SATD BC2GM008233762 NNP O
for BC2GM008233762 IN O
human BC2GM008233762 JJ O
and BC2GM008233762 CC O
mouse BC2GM008233762 VB O
PKC-epsilon BC2GM008233762 NNP O
, BC2GM008233762 , O
respectively BC2GM008233762 RB O
, BC2GM008233762 , O
are BC2GM008233762 VBP O
unusual BC2GM008233762 JJ O
for BC2GM008233762 IN O
caspase-3 BC2GM008233762 NN O
. BC2GM008233762 . O
. . O O

Here BC2GM058404635 RB O
we BC2GM058404635 PRP O
show BC2GM058404635 VBP O
that BC2GM058404635 DT O
expression BC2GM058404635 NN O
of BC2GM058404635 IN O
KRAB BC2GM058404635 NNP O
domain BC2GM058404635 NN O
suppresses BC2GM058404635 NNS O
in BC2GM058404635 IN O
vivo BC2GM058404635 NN O
the BC2GM058404635 DT O
activating BC2GM058404635 VBG O
function BC2GM058404635 NN O
of BC2GM058404635 IN O
various BC2GM058404635 JJ O
defined BC2GM058404635 JJ O
activating BC2GM058404635 VBG O
transcription BC2GM058404635 NN O
factors BC2GM058404635 NNS O
, BC2GM058404635 , O
and BC2GM058404635 CC O
we BC2GM058404635 PRP O
demonstrate BC2GM058404635 VBP O
that BC2GM058404635 IN O
the BC2GM058404635 DT O
KRAB BC2GM058404635 NNP O
domain BC2GM058404635 NN O
specifically BC2GM058404635 RB O
silences BC2GM058404635 VBZ O
the BC2GM058404635 DT O
activity BC2GM058404635 NN O
of BC2GM058404635 IN O
promoters BC2GM058404635 NNS O
whose BC2GM058404635 WP$ O
initiation BC2GM058404635 NN O
is BC2GM058404635 VBZ O
dependent BC2GM058404635 JJ O
on BC2GM058404635 IN O
the BC2GM058404635 DT O
presence BC2GM058404635 NN O
of BC2GM058404635 IN O
a BC2GM058404635 DT O
TATA BC2GM058404635 NNP O
box BC2GM058404635 NN O
. BC2GM058404635 . O
. . O O

Strains BC2GM065804496 NNS O
carrying BC2GM065804496 VBG O
a BC2GM065804496 DT O
snf1 BC2GM065804496 JJ O
mutation BC2GM065804496 NN O
are BC2GM065804496 VBP O
unable BC2GM065804496 JJ O
to BC2GM065804496 TO O
grow BC2GM065804496 VB O
on BC2GM065804496 IN O
sucrose BC2GM065804496 NN O
, BC2GM065804496 , O
galactose BC2GM065804496 NN O
, BC2GM065804496 , O
maltose BC2GM065804496 RB O
, BC2GM065804496 , O
melibiose BC2GM065804496 VB O
, BC2GM065804496 , O
or BC2GM065804496 CC O
nonfermentable BC2GM065804496 JJ O
carbon BC2GM065804496 NN O
sources BC2GM065804496 NNS O
; BC2GM065804496 : O
utilization BC2GM065804496 NN O
of BC2GM065804496 IN O
these BC2GM065804496 DT O
carbon BC2GM065804496 NN O
sources BC2GM065804496 NNS O
is BC2GM065804496 VBZ O
regulated BC2GM065804496 VBN O
by BC2GM065804496 IN O
glucose BC2GM065804496 JJ O
repression BC2GM065804496 NN O
. BC2GM065804496 . O
. . O O

No BC2GM004455813 DT O
IORT BC2GM004455813 NNP O
related BC2GM004455813 VBN O
mortality BC2GM004455813 NN O
has BC2GM004455813 VBZ O
been BC2GM004455813 VBN O
observed BC2GM004455813 VBN O
. BC2GM004455813 . O
. . O O

A BC2GM028852576 DT O
definitive BC2GM028852576 JJ O
answer BC2GM028852576 NN O
to BC2GM028852576 TO O
the BC2GM028852576 DT O
question BC2GM028852576 NN O
must BC2GM028852576 MD O
come BC2GM028852576 VB O
from BC2GM028852576 IN O
large BC2GM028852576 JJ O
scale BC2GM028852576 JJ O
mortality BC2GM028852576 NN O
studies BC2GM028852576 NNS O
of BC2GM028852576 IN O
patients BC2GM028852576 NNS O
in BC2GM028852576 IN O
whom BC2GM028852576 WP O
the BC2GM028852576 DT O
risk BC2GM028852576 NN O
/ BC2GM028852576 NNP O
benefit BC2GM028852576 NN O
ratio BC2GM028852576 NN O
of BC2GM028852576 IN O
thrombolysis BC2GM028852576 NN O
is BC2GM028852576 VBZ O
not BC2GM028852576 RB O
unacceptably BC2GM028852576 RB O
high BC2GM028852576 JJ O
, BC2GM028852576 , O
in BC2GM028852576 IN O
whom BC2GM028852576 WP O
electrocardiographic BC2GM028852576 JJ O
criteria BC2GM028852576 NNS O
of BC2GM028852576 IN O
infarction BC2GM028852576 NN O
are BC2GM028852576 VBP O
unequivocal BC2GM028852576 JJ O
, BC2GM028852576 , O
and BC2GM028852576 CC O
in BC2GM028852576 IN O
whom BC2GM028852576 WP O
treatment BC2GM028852576 NN O
can BC2GM028852576 MD O
be BC2GM028852576 VB O
initiated BC2GM028852576 VBN O
early BC2GM028852576 RB O
after BC2GM028852576 IN O
the BC2GM028852576 DT O
onset BC2GM028852576 NN O
of BC2GM028852576 IN O
symptoms BC2GM028852576 NNS O
with BC2GM028852576 IN O
regimens BC2GM028852576 NNS O
that BC2GM028852576 WDT O
will BC2GM028852576 MD O
induce BC2GM028852576 VB O
not BC2GM028852576 RB O
only BC2GM028852576 RB O
early BC2GM028852576 JJ O
recanalization BC2GM028852576 NN O
, BC2GM028852576 , O
but BC2GM028852576 CC O
also BC2GM028852576 RB O
sustained BC2GM028852576 VBD O
patency BC2GM028852576 NN O
in BC2GM028852576 IN O
infarct-related BC2GM028852576 JJ O
arteries BC2GM028852576 NNS O
. BC2GM028852576 . O
. . O O

We BC2GM084799105 PRP O
have BC2GM084799105 VBP O
introduced BC2GM084799105 VBN O
the BC2GM084799105 DT O
same BC2GM084799105 JJ O
change BC2GM084799105 NN O
in BC2GM084799105 IN O
a BC2GM084799105 DT O
yeast BC2GM084799105 NN O
tRNA BC2GM084799105 NN O
( BC2GM084799105 ( O
Trp BC2GM084799105 NNP O
) BC2GM084799105 ) O
gene BC2GM084799105 NN O
and BC2GM084799105 CC O
demonstrated BC2GM084799105 VBD O
that BC2GM084799105 IN O
the BC2GM084799105 DT O
tRNA BC2GM084799105 JJ O
acts BC2GM084799105 NNS O
as BC2GM084799105 IN O
an BC2GM084799105 DT O
efficient BC2GM084799105 JJ O
amber BC2GM084799105 NN O
suppressor BC2GM084799105 NN O
in BC2GM084799105 IN O
vivo BC2GM084799105 NN O
. BC2GM084799105 . O
. . O O

Blockade BC2GM048403963 NN O
of BC2GM048403963 IN O
T BC2GM048403963 NNP O
cell BC2GM048403963 NN O
activation BC2GM048403963 NN O
using BC2GM048403963 VBG O
a BC2GM048403963 DT O
surface-linked BC2GM048403963 JJ O
single-chain BC2GM048403963 NN O
antibody BC2GM048403963 NN O
to BC2GM048403963 TO O
CTLA-4 BC2GM048403963 NNP O
( BC2GM048403963 ( O
CD152 BC2GM048403963 NNP O
) BC2GM048403963 ) O
. BC2GM048403963 . O
. . O O

The BC2GM011323524 DT O
isomerization BC2GM011323524 NN O
of BC2GM011323524 IN O
the BC2GM011323524 DT O
pre-existing BC2GM011323524 NN O
closed BC2GM011323524 VBD O
complex BC2GM011323524 NN O
to BC2GM011323524 TO O
an BC2GM011323524 DT O
open BC2GM011323524 JJ O
promoter BC2GM011323524 NN O
form BC2GM011323524 NN O
, BC2GM011323524 , O
as BC2GM011323524 IN O
judged BC2GM011323524 VBN O
by BC2GM011323524 IN O
the BC2GM011323524 DT O
local BC2GM011323524 JJ O
denaturation BC2GM011323524 NN O
of BC2GM011323524 IN O
promoter BC2GM011323524 NN O
DNA BC2GM011323524 NNP O
which BC2GM011323524 WDT O
rendered BC2GM011323524 VBD O
sequences BC2GM011323524 NNS O
from BC2GM011323524 IN O
+5 BC2GM011323524 NN O
to BC2GM011323524 TO O
-10 BC2GM011323524 VB O
reactive BC2GM011323524 JJ O
towards BC2GM011323524 NNS O
KMnO4 BC2GM011323524 NNP O
, BC2GM011323524 , O
was BC2GM011323524 VBD O
shown BC2GM011323524 VBN O
to BC2GM011323524 TO O
be BC2GM011323524 VB O
fully BC2GM011323524 RB O
dependent BC2GM011323524 JJ O
on BC2GM011323524 IN O
NifA BC2GM011323524 NNP O
. BC2GM011323524 . O
. . O O

The BC2GM018805771 DT O
biological BC2GM018805771 JJ O
basis BC2GM018805771 NN O
for BC2GM018805771 IN O
the BC2GM018805771 DT O
changes BC2GM018805771 NNS O
in BC2GM018805771 IN O
CNAPs BC2GM018805771 NNP O
produced BC2GM018805771 VBN O
by BC2GM018805771 IN O
CS2 BC2GM018805771 NNP O
is BC2GM018805771 VBZ O
under BC2GM018805771 IN O
investigation BC2GM018805771 NN O
. BC2GM018805771 . O
. . O O

The BC2GM096262172 DT O
predicted BC2GM096262172 VBN O
amino BC2GM096262172 NN O
acid BC2GM096262172 JJ O
sequence BC2GM096262172 NN O
of BC2GM096262172 IN O
the BC2GM096262172 DT O
FlaB2 BC2GM096262172 NNP O
polypeptide BC2GM096262172 NN O
was BC2GM096262172 VBD O
92 BC2GM096262172 CD O
% BC2GM096262172 NN O
identical BC2GM096262172 JJ O
to BC2GM096262172 TO O
that BC2GM096262172 DT O
of BC2GM096262172 IN O
T. BC2GM096262172 NNP O
pallidum BC2GM096262172 NN O
FlaB2 BC2GM096262172 NNP O
, BC2GM096262172 , O
with BC2GM096262172 IN O
a BC2GM096262172 DT O
76 BC2GM096262172 CD O
% BC2GM096262172 NN O
identity BC2GM096262172 NN O
at BC2GM096262172 IN O
the BC2GM096262172 DT O
nucleotide BC2GM096262172 JJ O
level BC2GM096262172 NN O
. BC2GM096262172 . O
. . O O

However BC2GM088202512 RB O
, BC2GM088202512 , O
FosB-L BC2GM088202512 NNP O
and BC2GM088202512 CC O
FosB-S BC2GM088202512 NNP O
do BC2GM088202512 VBP O
not BC2GM088202512 RB O
differ BC2GM088202512 VB O
in BC2GM088202512 IN O
all BC2GM088202512 DT O
trans-regulatory BC2GM088202512 JJ O
properties BC2GM088202512 NNS O
: BC2GM088202512 : O
Trans-activation BC2GM088202512 NN O
of BC2GM088202512 IN O
a BC2GM088202512 DT O
5x BC2GM088202512 CD O
TRE-CAT BC2GM088202512 JJ O
reporter BC2GM088202512 NN O
construct BC2GM088202512 NN O
in BC2GM088202512 IN O
HeLa BC2GM088202512 NNP O
and BC2GM088202512 CC O
NIH-3T3 BC2GM088202512 NNP O
cells BC2GM088202512 NNS O
was BC2GM088202512 VBD O
found BC2GM088202512 VBN O
with BC2GM088202512 IN O
both BC2GM088202512 DT O
FosB BC2GM088202512 NNP O
forms BC2GM088202512 NNS O
. BC2GM088202512 . O
. . O O

The BC2GM060653717 DT O
model BC2GM060653717 NN O
therefore BC2GM060653717 NN O
predicts BC2GM060653717 VBZ O
that BC2GM060653717 IN O
1 BC2GM060653717 CD O
) BC2GM060653717 ) O
on-line BC2GM060653717 JJ O
calculation BC2GM060653717 NN O
of BC2GM060653717 IN O
airway BC2GM060653717 RB O
dead BC2GM060653717 JJ O
space BC2GM060653717 NN O
and BC2GM060653717 CC O
end-expired BC2GM060653717 JJ O
lung BC2GM060653717 NN O
volume BC2GM060653717 NN O
can BC2GM060653717 MD O
be BC2GM060653717 VB O
made BC2GM060653717 VBN O
by BC2GM060653717 IN O
the BC2GM060653717 DT O
addition BC2GM060653717 NN O
of BC2GM060653717 IN O
an BC2GM060653717 DT O
oxygen BC2GM060653717 NN O
sine-wave BC2GM060653717 JJ O
perturbation BC2GM060653717 NN O
component BC2GM060653717 NN O
to BC2GM060653717 TO O
the BC2GM060653717 DT O
mean BC2GM060653717 JJ O
FIO2 BC2GM060653717 NNP O
; BC2GM060653717 : O
and BC2GM060653717 CC O
( BC2GM060653717 ( O
2 BC2GM060653717 CD O
) BC2GM060653717 ) O
QS BC2GM060653717 NNP O
/ BC2GM060653717 NNP O
QT BC2GM060653717 NNP O
can BC2GM060653717 MD O
be BC2GM060653717 VB O
measured BC2GM060653717 VBN O
from BC2GM060653717 IN O
the BC2GM060653717 DT O
resultant BC2GM060653717 JJ O
oxygen BC2GM060653717 NN O
perturbation BC2GM060653717 NN O
sine-wave BC2GM060653717 JJ O
amplitudes BC2GM060653717 NNS O
in BC2GM060653717 IN O
the BC2GM060653717 DT O
expired BC2GM060653717 JJ O
gas BC2GM060653717 NN O
and BC2GM060653717 CC O
in BC2GM060653717 IN O
arterial BC2GM060653717 JJ O
and BC2GM060653717 CC O
mixed-venous BC2GM060653717 JJ O
blood BC2GM060653717 NN O
and BC2GM060653717 CC O
is BC2GM060653717 VBZ O
independent BC2GM060653717 JJ O
of BC2GM060653717 IN O
the BC2GM060653717 DT O
mean BC2GM060653717 JJ O
blood BC2GM060653717 NN O
oxygen BC2GM060653717 NN O
partial BC2GM060653717 JJ O
pressure BC2GM060653717 NN O
and BC2GM060653717 CC O
oxyhemoglobin BC2GM060653717 JJ O
saturation BC2GM060653717 NN O
values BC2GM060653717 NNS O
. BC2GM060653717 . O
. . O O

By BC2GM081727936 IN O
using BC2GM081727936 VBG O
methanol-0.15 BC2GM081727936 JJ O
M BC2GM081727936 NNP O
borate BC2GM081727936 NN O
buffer BC2GM081727936 NN O
of BC2GM081727936 IN O
pH BC2GM081727936 NN O
8.0 BC2GM081727936 CD O
, BC2GM081727936 , O
cate-chol-O-methyltransferase BC2GM081727936 JJ O
activity BC2GM081727936 NN O
might BC2GM081727936 MD O
be BC2GM081727936 VB O
assayed BC2GM081727936 VBN O
. BC2GM081727936 . O
. . O O

Malformations BC2GM084635327 NNS O
of BC2GM084635327 IN O
the BC2GM084635327 DT O
regenerating BC2GM084635327 VBG O
optic BC2GM084635327 JJ O
tectum BC2GM084635327 NN O
of BC2GM084635327 IN O
larvae BC2GM084635327 NN O
of BC2GM084635327 IN O
the BC2GM084635327 DT O
Egyptian BC2GM084635327 JJ O
toad BC2GM084635327 NN O
, BC2GM084635327 , O
Bufo BC2GM084635327 NNP O
regularis BC2GM084635327 VBZ O
Reuss BC2GM084635327 NNP O
. BC2GM084635327 . O
. . O O

Outlook BC2GM044764990 NN O
in BC2GM044764990 IN O
oral BC2GM044764990 JJ O
and BC2GM044764990 CC O
cutaneous BC2GM044764990 JJ O
Kaposi BC2GM044764990 NNP O
's BC2GM044764990 POS O
sarcoma BC2GM044764990 NN O
. BC2GM044764990 . O
. . O O

A BC2GM037544012 DT O
higher BC2GM037544012 JJR O
median BC2GM037544012 JJ O
proportion BC2GM037544012 NN O
of BC2GM037544012 IN O
spirochaetes BC2GM037544012 NNS O
was BC2GM037544012 VBD O
observed BC2GM037544012 VBN O
in BC2GM037544012 IN O
sites BC2GM037544012 NNS O
after BC2GM037544012 IN O
diagnosis BC2GM037544012 NN O
of BC2GM037544012 IN O
loss BC2GM037544012 NN O
of BC2GM037544012 IN O
attachment BC2GM037544012 NN O
. BC2GM037544012 . O
. . O O

In BC2GM005308134 IN O
contrast BC2GM005308134 NN O
, BC2GM005308134 , O
the BC2GM005308134 DT O
holo-dTFIIA BC2GM005308134 NN O
( BC2GM005308134 ( O
L BC2GM005308134 NNP O
/ BC2GM005308134 NNP O
S BC2GM005308134 NNP O
) BC2GM005308134 ) O
binds BC2GM005308134 VBZ O
TBP BC2GM005308134 NNP O
with BC2GM005308134 IN O
high BC2GM005308134 JJ O
affinity BC2GM005308134 NN O
. BC2GM005308134 . O
. . O O

Acad BC2GM095955751 NNP O
. BC2GM095955751 . O
. . O O

In BC2GM045825131 IN O
both BC2GM045825131 DT O
immortalized BC2GM045825131 JJ O
and BC2GM045825131 CC O
normal BC2GM045825131 JJ O
diploid BC2GM045825131 JJ O
human BC2GM045825131 JJ O
cells BC2GM045825131 NNS O
, BC2GM045825131 , O
wt BC2GM045825131 VBP O
AAV BC2GM045825131 NNP O
targeted BC2GM045825131 VBD O
integration BC2GM045825131 NN O
to BC2GM045825131 TO O
ch-19 BC2GM045825131 NN O
. BC2GM045825131 . O
. . O O

However BC2GM087552846 RB O
, BC2GM087552846 , O
a BC2GM087552846 DT O
lesser BC2GM087552846 JJR O
extent BC2GM087552846 NN O
effect BC2GM087552846 NN O
was BC2GM087552846 VBD O
noticed BC2GM087552846 VBN O
in BC2GM087552846 IN O
nonpregnant BC2GM087552846 NN O
than BC2GM087552846 IN O
seen BC2GM087552846 VBN O
in BC2GM087552846 IN O
pregnant BC2GM087552846 JJ O
rats BC2GM087552846 NNS O
. BC2GM087552846 . O
. . O O

Endocarditis BC2GM079579959 NN O
remains BC2GM079579959 VBZ O
a BC2GM079579959 DT O
life-threatening BC2GM079579959 JJ O
disease BC2GM079579959 NN O
with BC2GM079579959 IN O
substantial BC2GM079579959 JJ O
morbidity BC2GM079579959 NN O
and BC2GM079579959 CC O
mortality BC2GM079579959 NN O
. BC2GM079579959 . O
. . O O

Previously BC2GM030584049 RB O
, BC2GM030584049 , O
we BC2GM030584049 PRP O
had BC2GM030584049 VBD O
shown BC2GM030584049 VBN O
that BC2GM030584049 IN O
interleukin BC2GM030584049 JJ O
8 BC2GM030584049 CD O
( BC2GM030584049 ( O
IL-8 BC2GM030584049 NNP O
) BC2GM030584049 ) O
is BC2GM030584049 VBZ O
constitutively BC2GM030584049 RB O
expressed BC2GM030584049 VBN O
in BC2GM030584049 IN O
HTLV-I-infected BC2GM030584049 NNP O
cells BC2GM030584049 NNS O
and BC2GM030584049 CC O
in BC2GM030584049 IN O
cells BC2GM030584049 NNS O
transiently BC2GM030584049 RB O
expressing BC2GM030584049 VBG O
Tax BC2GM030584049 NNP O
. BC2GM030584049 . O
. . O O

Transient BC2GM056636695 JJ O
cotransfection BC2GM056636695 NN O
analyses BC2GM056636695 NNS O
indicate BC2GM056636695 VBP O
that BC2GM056636695 IN O
the BC2GM056636695 DT O
cooperative BC2GM056636695 JJ O
association BC2GM056636695 NN O
of BC2GM056636695 IN O
NF-IL-6 BC2GM056636695 NNP O
and BC2GM056636695 CC O
RelA BC2GM056636695 NNP O
with BC2GM056636695 IN O
the BC2GM056636695 DT O
IL-8 BC2GM056636695 NNP O
promoter BC2GM056636695 NN O
results BC2GM056636695 NNS O
in BC2GM056636695 IN O
synergistic BC2GM056636695 JJ O
transcriptional BC2GM056636695 JJ O
activation BC2GM056636695 NN O
. BC2GM056636695 . O
. . O O

D BC2GM014851186 NNP O
. BC2GM014851186 . O
. . O O

The BC2GM053163697 DT O
proliferative BC2GM053163697 JJ O
potential BC2GM053163697 NN O
of BC2GM053163697 IN O
the BC2GM053163697 DT O
pilocytic BC2GM053163697 JJ O
astrocytoma BC2GM053163697 NN O
: BC2GM053163697 : O
the BC2GM053163697 DT O
relation BC2GM053163697 NN O
between BC2GM053163697 IN O
MIB-1 BC2GM053163697 NNP O
labeling BC2GM053163697 NN O
and BC2GM053163697 CC O
clinical BC2GM053163697 JJ O
and BC2GM053163697 CC O
neuro-radiological BC2GM053163697 JJ O
follow-up BC2GM053163697 NN O
. BC2GM053163697 . O
. . O O

22-Veneto BC2GM040702474 JJ O
Region BC2GM040702474 NNP O
) BC2GM040702474 ) O
. BC2GM040702474 . O
. . O O

The BC2GM036029614 DT O
WEB2 BC2GM036029614 NNP O
gene BC2GM036029614 NN O
encodes BC2GM036029614 VBZ O
a BC2GM036029614 DT O
1,522-amino-acid BC2GM036029614 JJ O
protein BC2GM036029614 NN O
with BC2GM036029614 IN O
homology BC2GM036029614 NN O
to BC2GM036029614 TO O
nucleic BC2GM036029614 VB O
acid-dependent BC2GM036029614 JJ O
ATPases BC2GM036029614 NNS O
. BC2GM036029614 . O
. . O O

Taken BC2GM098793518 VBN O
together BC2GM098793518 RB O
, BC2GM098793518 , O
these BC2GM098793518 DT O
data BC2GM098793518 NNS O
suggest BC2GM098793518 VBP O
that BC2GM098793518 IN O
the BC2GM098793518 DT O
Smad3 BC2GM098793518 NNP O
/ BC2GM098793518 NNP O
Smad4 BC2GM098793518 NNP O
complex BC2GM098793518 NN O
has BC2GM098793518 VBZ O
at BC2GM098793518 IN O
least BC2GM098793518 JJS O
two BC2GM098793518 CD O
separable BC2GM098793518 JJ O
nuclear BC2GM098793518 JJ O
functions BC2GM098793518 NNS O
: BC2GM098793518 : O
it BC2GM098793518 PRP O
forms BC2GM098793518 VBZ O
a BC2GM098793518 DT O
rapid BC2GM098793518 JJ O
, BC2GM098793518 , O
yet BC2GM098793518 RB O
transient BC2GM098793518 JJ O
sequence-specific BC2GM098793518 JJ O
DNA BC2GM098793518 NNP O
binding BC2GM098793518 NN O
complex BC2GM098793518 NN O
, BC2GM098793518 , O
and BC2GM098793518 CC O
it BC2GM098793518 PRP O
potentiates BC2GM098793518 VBZ O
AP1-dependent BC2GM098793518 JJ O
transcriptional BC2GM098793518 JJ O
activation BC2GM098793518 NN O
. BC2GM098793518 . O
. . O O

Neither BC2GM052708788 DT O
raw BC2GM052708788 JJ O
nor BC2GM052708788 CC O
retrograded BC2GM052708788 JJ O
resistant BC2GM052708788 NN O
starch BC2GM052708788 NN O
lowers BC2GM052708788 NNS O
fasting BC2GM052708788 VBG O
serum BC2GM052708788 NN O
cholesterol BC2GM052708788 NN O
concentrations BC2GM052708788 NNS O
in BC2GM052708788 IN O
healthy BC2GM052708788 JJ O
normolipidemic BC2GM052708788 JJ O
subjects BC2GM052708788 NNS O
. BC2GM052708788 . O
. . O O

The BC2GM015098322 DT O
results BC2GM015098322 NNS O
obtained BC2GM015098322 VBD O
with BC2GM015098322 IN O
[ BC2GM015098322 NNP O
F304 BC2GM015098322 NNP O
] BC2GM015098322 NNP O
R2 BC2GM015098322 NNP O
indicate BC2GM015098322 VBP O
that BC2GM015098322 IN O
structural BC2GM015098322 JJ O
changes BC2GM015098322 NNS O
in BC2GM015098322 IN O
E. BC2GM015098322 NNP O
coli BC2GM015098322 NNS O
R2 BC2GM015098322 NNP O
in BC2GM015098322 IN O
the BC2GM015098322 DT O
vicinity BC2GM015098322 NN O
of BC2GM015098322 IN O
this BC2GM015098322 DT O
helix BC2GM015098322 NN O
distortion BC2GM015098322 NN O
can BC2GM015098322 MD O
influence BC2GM015098322 VB O
the BC2GM015098322 DT O
catalytic BC2GM015098322 JJ O
activity BC2GM015098322 NN O
of BC2GM015098322 IN O
the BC2GM015098322 DT O
holoenzyme BC2GM015098322 NN O
. BC2GM015098322 . O
. . O O

Each BC2GM093817406 DT O
receptor BC2GM093817406 NN O
must BC2GM093817406 MD O
therefore BC2GM093817406 VB O
engage BC2GM093817406 VB O
a BC2GM093817406 DT O
unique BC2GM093817406 JJ O
subset BC2GM093817406 NN O
of BC2GM093817406 IN O
the BC2GM093817406 DT O
available BC2GM093817406 JJ O
signaling BC2GM093817406 JJ O
elements BC2GM093817406 NNS O
-- BC2GM093817406 : O
at BC2GM093817406 IN O
least BC2GM093817406 JJS O
partly BC2GM093817406 RB O
through BC2GM093817406 IN O
the BC2GM093817406 DT O
selection BC2GM093817406 NN O
of BC2GM093817406 IN O
proteins BC2GM093817406 NNS O
with BC2GM093817406 IN O
src-homology BC2GM093817406 JJ O
2 BC2GM093817406 CD O
domains BC2GM093817406 NNS O
( BC2GM093817406 ( O
SH2 BC2GM093817406 NNP O
proteins BC2GM093817406 VBZ O
) BC2GM093817406 ) O
. BC2GM093817406 . O
. . O O

An BC2GM020044790 DT O
ICU BC2GM020044790 NNP O
length BC2GM020044790 NN O
of BC2GM020044790 IN O
stay BC2GM020044790 NN O
shorter BC2GM020044790 JJR O
than BC2GM020044790 IN O
24 BC2GM020044790 CD O
h BC2GM020044790 NN O
was BC2GM020044790 VBD O
not BC2GM020044790 RB O
related BC2GM020044790 VBN O
to BC2GM020044790 TO O
the BC2GM020044790 DT O
frequency BC2GM020044790 NN O
of BC2GM020044790 IN O
group BC2GM020044790 NN O
C BC2GM020044790 NNP O
errors BC2GM020044790 NNS O
. BC2GM020044790 . O
. . O O

The BC2GM098824982 DT O
donors BC2GM098824982 NNS O
of BC2GM098824982 IN O
10 BC2GM098824982 CD O
patients BC2GM098824982 NNS O
were BC2GM098824982 VBD O
ABO-incompatible BC2GM098824982 JJ O
, BC2GM098824982 , O
and BC2GM098824982 CC O
for BC2GM098824982 IN O
five BC2GM098824982 CD O
pairs BC2GM098824982 NNS O
the BC2GM098824982 DT O
ABO BC2GM098824982 NNP O
incompatibility BC2GM098824982 NN O
was BC2GM098824982 VBD O
major BC2GM098824982 JJ O
. BC2GM098824982 . O
. . O O

The BC2GM032835553 DT O
software BC2GM032835553 NN O
is BC2GM032835553 VBZ O
in BC2GM032835553 IN O
BASIC BC2GM032835553 NNP O
adapted BC2GM032835553 VBD O
for BC2GM032835553 IN O
the BC2GM032835553 DT O
Hewlett-Packard BC2GM032835553 NNP O
calculators BC2GM032835553 NNS O
HP-9845B BC2GM032835553 NNP O
and BC2GM032835553 CC O
HP-85A BC2GM032835553 NNP O
. BC2GM032835553 . O
. . O O

Almost BC2GM021589926 RB O
every BC2GM021589926 DT O
image BC2GM021589926 NN O
that BC2GM021589926 WDT O
appears BC2GM021589926 VBZ O
during BC2GM021589926 IN O
a BC2GM021589926 DT O
therapy BC2GM021589926 NN O
session BC2GM021589926 NN O
reveals BC2GM021589926 VBZ O
a BC2GM021589926 DT O
symbolic BC2GM021589926 JJ O
nature BC2GM021589926 NN O
, BC2GM021589926 , O
but BC2GM021589926 CC O
the BC2GM021589926 DT O
very BC2GM021589926 RB O
concept BC2GM021589926 NN O
of BC2GM021589926 IN O
symbol BC2GM021589926 NN O
is BC2GM021589926 VBZ O
not BC2GM021589926 RB O
free BC2GM021589926 JJ O
from BC2GM021589926 IN O
ambiguity BC2GM021589926 NN O
some BC2GM021589926 DT O
positions BC2GM021589926 NNS O
originated BC2GM021589926 VBN O
in BC2GM021589926 IN O
different BC2GM021589926 JJ O
areas BC2GM021589926 NNS O
of BC2GM021589926 IN O
investigation BC2GM021589926 NN O
are BC2GM021589926 VBP O
mentioned BC2GM021589926 VBN O
, BC2GM021589926 , O
ending BC2GM021589926 VBG O
with BC2GM021589926 IN O
a BC2GM021589926 DT O
description BC2GM021589926 NN O
of BC2GM021589926 IN O
the BC2GM021589926 DT O
traits BC2GM021589926 NNS O
that BC2GM021589926 IN O
, BC2GM021589926 , O
according BC2GM021589926 VBG O
to BC2GM021589926 TO O
the BC2GM021589926 DT O
writer BC2GM021589926 NN O
, BC2GM021589926 , O
bestow BC2GM021589926 VB O
a BC2GM021589926 DT O
symbolic BC2GM021589926 JJ O
character BC2GM021589926 NN O
to BC2GM021589926 TO O
images BC2GM021589926 NNS O
. BC2GM021589926 . O
. . O O

NO2 BC2GM036738213 NNP O
pollution BC2GM036738213 NN O
on BC2GM036738213 IN O
major BC2GM036738213 JJ O
trunk BC2GM036738213 NN O
roads BC2GM036738213 NNS O
frequently BC2GM036738213 RB O
exceeded BC2GM036738213 VBD O
British BC2GM036738213 JJ O
and BC2GM036738213 CC O
European BC2GM036738213 NNP O
Union BC2GM036738213 NNP O
air BC2GM036738213 NN O
quality BC2GM036738213 NN O
standards BC2GM036738213 NNS O
, BC2GM036738213 , O
while BC2GM036738213 IN O
particle BC2GM036738213 NN O
pollution BC2GM036738213 NN O
was BC2GM036738213 VBD O
lower BC2GM036738213 JJR O
. BC2GM036738213 . O
. . O O

The BC2GM018332132 DT O
response BC2GM018332132 NN O
to BC2GM018332132 TO O
nitroglycerin BC2GM018332132 VB O
, BC2GM018332132 , O
however BC2GM018332132 RB O
, BC2GM018332132 , O
remained BC2GM018332132 VBD O
intact BC2GM018332132 JJ O
regardless BC2GM018332132 NN O
of BC2GM018332132 IN O
initial BC2GM018332132 JJ O
reperfusion BC2GM018332132 NN O
pressure BC2GM018332132 NN O
. BC2GM018332132 . O
. . O O

The BC2GM070838857 DT O
effect BC2GM070838857 NN O
of BC2GM070838857 IN O
the BC2GM070838857 DT O
NMDA-receptor BC2GM070838857 NNP O
antagonist BC2GM070838857 NN O
( BC2GM070838857 ( O
+ BC2GM070838857 JJ O
/ BC2GM070838857 NNP O
- BC2GM070838857 : O
) BC2GM070838857 ) O
-CPP BC2GM070838857 NN O
on BC2GM070838857 IN O
the BC2GM070838857 DT O
conditioned-reflex BC2GM070838857 JJ O
activation BC2GM070838857 NN O
of BC2GM070838857 IN O
an BC2GM070838857 DT O
operant BC2GM070838857 JJ O
reaction BC2GM070838857 NN O
in BC2GM070838857 IN O
the BC2GM070838857 DT O
brain BC2GM070838857 NN O
electrical BC2GM070838857 JJ O
self-stimulation BC2GM070838857 JJ O
test BC2GM070838857 NN O
in BC2GM070838857 IN O
rats BC2GM070838857 NNS O
. BC2GM070838857 . O
. . O O

This BC2GM015438826 DT O
is BC2GM015438826 VBZ O
similar BC2GM015438826 JJ O
to BC2GM015438826 TO O
previous BC2GM015438826 JJ O
reports BC2GM015438826 NNS O
of BC2GM015438826 IN O
muscle BC2GM015438826 NN O
creatine BC2GM015438826 NN O
phosphokinase BC2GM015438826 NN O
release BC2GM015438826 NN O
in BC2GM015438826 IN O
psychiatric BC2GM015438826 JJ O
patients BC2GM015438826 NNS O
. BC2GM015438826 . O
. . O O

The BC2GM089291687 DT O
scores BC2GM089291687 NNS O
for BC2GM089291687 IN O
these BC2GM089291687 DT O
three BC2GM089291687 CD O
factors BC2GM089291687 NNS O
, BC2GM089291687 , O
which BC2GM089291687 WDT O
corresponded BC2GM089291687 VBD O
to BC2GM089291687 TO O
recognizable BC2GM089291687 JJ O
dimensions BC2GM089291687 NNS O
of BC2GM089291687 IN O
depressive BC2GM089291687 JJ O
illness BC2GM089291687 NN O
, BC2GM089291687 , O
were BC2GM089291687 VBD O
then BC2GM089291687 RB O
correlated BC2GM089291687 VBN O
with BC2GM089291687 IN O
rCBF BC2GM089291687 NN O
. BC2GM089291687 . O
. . O O

The BC2GM034033075 DT O
magnesium BC2GM034033075 NN O
content BC2GM034033075 NN O
in BC2GM034033075 IN O
leukocytes BC2GM034033075 NNS O
could BC2GM034033075 MD O
not BC2GM034033075 RB O
be BC2GM034033075 VB O
estimated BC2GM034033075 VBN O
because BC2GM034033075 IN O
of BC2GM034033075 IN O
interaction BC2GM034033075 NN O
between BC2GM034033075 IN O
the BC2GM034033075 DT O
ion BC2GM034033075 NN O
and BC2GM034033075 CC O
the BC2GM034033075 DT O
Percoll BC2GM034033075 NNP O
( BC2GM034033075 ( O
R BC2GM034033075 NNP O
) BC2GM034033075 ) O
media BC2GM034033075 NNS O
. BC2GM034033075 . O
. . O O

Here BC2GM071545303 RB O
, BC2GM071545303 , O
we BC2GM071545303 PRP O
report BC2GM071545303 VBP O
the BC2GM071545303 DT O
isolation BC2GM071545303 NN O
of BC2GM071545303 IN O
a BC2GM071545303 DT O
new BC2GM071545303 JJ O
spindle BC2GM071545303 JJ O
checkpoint BC2GM071545303 NN O
gene BC2GM071545303 NN O
, BC2GM071545303 , O
mph1 BC2GM071545303 FW O
( BC2GM071545303 ( O
Mps1p-like BC2GM071545303 NNP O
pombe BC2GM071545303 NNP O
homolog BC2GM071545303 NN O
) BC2GM071545303 ) O
, BC2GM071545303 , O
in BC2GM071545303 IN O
the BC2GM071545303 DT O
fission BC2GM071545303 NN O
yeast BC2GM071545303 NN O
Schizosaccharomyces BC2GM071545303 NNP O
pombe BC2GM071545303 NN O
, BC2GM071545303 , O
that BC2GM071545303 WDT O
is BC2GM071545303 VBZ O
required BC2GM071545303 VBN O
for BC2GM071545303 IN O
checkpoint BC2GM071545303 NN O
activation BC2GM071545303 NN O
in BC2GM071545303 IN O
response BC2GM071545303 NN O
to BC2GM071545303 TO O
spindle BC2GM071545303 VB O
defects BC2GM071545303 NNS O
. BC2GM071545303 . O
mph1 BC2GM071545303 NN O
functions BC2GM071545303 NNS O
upstream BC2GM071545303 NN O
of BC2GM071545303 IN O
mad2 BC2GM071545303 NN O
, BC2GM071545303 , O
a BC2GM071545303 DT O
previously BC2GM071545303 RB O
characterized BC2GM071545303 VBN O
component BC2GM071545303 NN O
of BC2GM071545303 IN O
the BC2GM071545303 DT O
spindle BC2GM071545303 JJ O
checkpoint BC2GM071545303 NN O
. BC2GM071545303 . O
. . O O

PRP20 BC2GM073386715 NNP O
is BC2GM073386715 VBZ O
related BC2GM073386715 VBN O
, BC2GM073386715 , O
both BC2GM073386715 DT O
in BC2GM073386715 IN O
structure BC2GM073386715 NN O
and BC2GM073386715 CC O
function BC2GM073386715 NN O
, BC2GM073386715 , O
to BC2GM073386715 TO O
the BC2GM073386715 DT O
RCC1 BC2GM073386715 NNP O
gene BC2GM073386715 NN O
of BC2GM073386715 IN O
mammals BC2GM073386715 NNS O
and BC2GM073386715 CC O
the BC2GM073386715 DT O
PIM1 BC2GM073386715 NNP O
gene BC2GM073386715 NN O
of BC2GM073386715 IN O
Schizosaccharomyces BC2GM073386715 NNP O
pombe BC2GM073386715 NN O
, BC2GM073386715 , O
both BC2GM073386715 DT O
of BC2GM073386715 IN O
which BC2GM073386715 WDT O
appear BC2GM073386715 VBP O
to BC2GM073386715 TO O
regulate BC2GM073386715 VB O
entry BC2GM073386715 NN O
into BC2GM073386715 IN O
mitosis BC2GM073386715 NN O
and BC2GM073386715 CC O
chromosome BC2GM073386715 NN O
condensation BC2GM073386715 NN O
. BC2GM073386715 . O
. . O O

Although BC2GM013735127 IN O
the BC2GM013735127 DT O
energy-based BC2GM013735127 JJ O
DFT BC2GM013735127 NNP O
was BC2GM013735127 VBD O
not BC2GM013735127 RB O
affected BC2GM013735127 VBN O
by BC2GM013735127 IN O
isoproterenol BC2GM013735127 NN O
( BC2GM013735127 ( O
from BC2GM013735127 IN O
6.1 BC2GM013735127 CD O
+ BC2GM013735127 NNS O
/ BC2GM013735127 SYM O
- BC2GM013735127 : O
1.5 BC2GM013735127 CD O
to BC2GM013735127 TO O
6.0 BC2GM013735127 CD O
+ BC2GM013735127 NNS O
/ BC2GM013735127 SYM O
- BC2GM013735127 : O
1.7 BC2GM013735127 CD O
J BC2GM013735127 NNP O
) BC2GM013735127 ) O
, BC2GM013735127 , O
it BC2GM013735127 PRP O
was BC2GM013735127 VBD O
decreased BC2GM013735127 VBN O
to BC2GM013735127 TO O
3.7 BC2GM013735127 CD O
+ BC2GM013735127 NNS O
/ BC2GM013735127 SYM O
- BC2GM013735127 : O
1.6 BC2GM013735127 CD O
J BC2GM013735127 NNP O
in BC2GM013735127 IN O
the BC2GM013735127 DT O
third BC2GM013735127 JJ O
stage BC2GM013735127 NN O
by BC2GM013735127 IN O
infusion BC2GM013735127 NN O
of BC2GM013735127 IN O
E4031 BC2GM013735127 NNP O
and BC2GM013735127 CC O
isoproterenol BC2GM013735127 NN O
( BC2GM013735127 ( O
p BC2GM013735127 JJ O
< BC2GM013735127 $ O
0.01 BC2GM013735127 CD O
vs. BC2GM013735127 FW O
baseline BC2GM013735127 NN O
and BC2GM013735127 CC O
vs. BC2GM013735127 FW O
isoproterenol BC2GM013735127 NN O
) BC2GM013735127 ) O
. BC2GM013735127 . O
. . O O

The BC2GM012934099 DT O
4-nt BC2GM012934099 JJ O
sequence BC2GM012934099 NN O
of BC2GM012934099 IN O
the BC2GM012934099 DT O
rotavirus BC2GM012934099 NN O
3 BC2GM012934099 CD O
' BC2GM012934099 '' O
TE BC2GM012934099 NNP O
represents BC2GM012934099 VBZ O
by BC2GM012934099 IN O
far BC2GM012934099 RB O
the BC2GM012934099 DT O
shortest BC2GM012934099 JJS O
of BC2GM012934099 IN O
any BC2GM012934099 DT O
of BC2GM012934099 IN O
the BC2GM012934099 DT O
sequence BC2GM012934099 NN O
enhancers BC2GM012934099 NNS O
known BC2GM012934099 VBN O
to BC2GM012934099 TO O
stimulate BC2GM012934099 VB O
translation BC2GM012934099 NN O
. BC2GM012934099 . O
. . O O

CONCLUSION BC2GM088118556 NNP O
/ BC2GM088118556 NNP O
INTERPRETATION BC2GM088118556 NNP O
: BC2GM088118556 : O
We BC2GM088118556 PRP O
found BC2GM088118556 VBD O
an BC2GM088118556 DT O
increased BC2GM088118556 VBN O
risk BC2GM088118556 NN O
of BC2GM088118556 IN O
hip BC2GM088118556 NN O
fracture BC2GM088118556 NN O
in BC2GM088118556 IN O
women BC2GM088118556 NNS O
younger BC2GM088118556 JJR O
than BC2GM088118556 IN O
75 BC2GM088118556 CD O
years BC2GM088118556 NNS O
with BC2GM088118556 IN O
Type BC2GM088118556 NNP O
I BC2GM088118556 PRP O
diabetes BC2GM088118556 VBZ O
or BC2GM088118556 CC O
with BC2GM088118556 IN O
Type BC2GM088118556 NNP O
II BC2GM088118556 NNP O
diabetes BC2GM088118556 NNS O
of BC2GM088118556 IN O
long BC2GM088118556 JJ O
duration BC2GM088118556 NN O
. BC2GM088118556 . O
. . O O

The BC2GM081816003 DT O
terminal BC2GM081816003 NN O
a BC2GM081816003 DT O
sequence BC2GM081816003 NN O
of BC2GM081816003 IN O
the BC2GM081816003 DT O
herpes BC2GM081816003 NNS O
simplex BC2GM081816003 JJ O
virus BC2GM081816003 NN O
genome BC2GM081816003 NN O
contains BC2GM081816003 VBZ O
the BC2GM081816003 DT O
promoter BC2GM081816003 NN O
of BC2GM081816003 IN O
a BC2GM081816003 DT O
gene BC2GM081816003 NN O
located BC2GM081816003 VBN O
in BC2GM081816003 IN O
the BC2GM081816003 DT O
repeat BC2GM081816003 NN O
sequences BC2GM081816003 NNS O
of BC2GM081816003 IN O
the BC2GM081816003 DT O
L BC2GM081816003 NNP O
component BC2GM081816003 NN O
. BC2GM081816003 . O
. . O O

IgE-binding BC2GM009597017 JJ O
proteins BC2GM009597017 NNS O
of BC2GM009597017 IN O
Psocoptera BC2GM009597017 NNP O
were BC2GM009597017 VBD O
determined BC2GM009597017 VBN O
by BC2GM009597017 IN O
immunoblotting BC2GM009597017 VBG O
experiments BC2GM009597017 NNS O
. BC2GM009597017 . O
. . O O

Sub-inhibitory BC2GM041094338 JJ O
and BC2GM041094338 CC O
post-antibiotic BC2GM041094338 JJ O
effects BC2GM041094338 NNS O
of BC2GM041094338 IN O
spiramycin BC2GM041094338 NN O
and BC2GM041094338 CC O
erythromycin BC2GM041094338 NN O
on BC2GM041094338 IN O
Staphylococcus BC2GM041094338 NNP O
aureus BC2GM041094338 NN O
. BC2GM041094338 . O
. . O O

The BC2GM056273356 DT O
A3B3 BC2GM056273356 NNP O
domain BC2GM056273356 NN O
had BC2GM056273356 VBD O
a BC2GM056273356 DT O
mass BC2GM056273356 NN O
of BC2GM056273356 IN O
34,462 BC2GM056273356 CD O
, BC2GM056273356 , O
with BC2GM056273356 IN O
a BC2GM056273356 DT O
glycosylation BC2GM056273356 NN O
mass BC2GM056273356 NN O
of BC2GM056273356 IN O
14,900 BC2GM056273356 CD O
, BC2GM056273356 , O
in BC2GM056273356 IN O
good BC2GM056273356 JJ O
agreement BC2GM056273356 NN O
with BC2GM056273356 IN O
seven BC2GM056273356 CD O
N-linked BC2GM056273356 JJ O
glycosylation BC2GM056273356 NN O
sites BC2GM056273356 NNS O
of BC2GM056273356 IN O
average BC2GM056273356 JJ O
mass BC2GM056273356 NN O
2100 BC2GM056273356 CD O
. BC2GM056273356 . O
. . O O

Epstein-Barr BC2GM024610990 JJ O
virus BC2GM024610990 NN O
nuclear BC2GM024610990 JJ O
antigen BC2GM024610990 NN O
2 BC2GM024610990 CD O
exerts BC2GM024610990 VBZ O
its BC2GM024610990 PRP$ O
transactivating BC2GM024610990 NN O
function BC2GM024610990 NN O
through BC2GM024610990 IN O
interaction BC2GM024610990 NN O
with BC2GM024610990 IN O
recombination BC2GM024610990 NN O
signal BC2GM024610990 NN O
binding BC2GM024610990 VBG O
protein BC2GM024610990 JJ O
RBP-J BC2GM024610990 JJ O
kappa BC2GM024610990 NN O
, BC2GM024610990 , O
the BC2GM024610990 DT O
homologue BC2GM024610990 NN O
of BC2GM024610990 IN O
Drosophila BC2GM024610990 NNP O
Suppressor BC2GM024610990 NNP O
of BC2GM024610990 IN O
Hairless BC2GM024610990 NNP O
. BC2GM024610990 . O
. . O O

The BC2GM054393816 DT O
adeno-associated BC2GM054393816 JJ O
virus BC2GM054393816 NN O
type BC2GM054393816 NN O
2 BC2GM054393816 CD O
( BC2GM054393816 ( O
AAV-2 BC2GM054393816 NNP O
) BC2GM054393816 ) O
Rep78 BC2GM054393816 NNP O
/ BC2GM054393816 NNP O
Rep68 BC2GM054393816 NNP O
regulatory BC2GM054393816 JJ O
proteins BC2GM054393816 NNS O
are BC2GM054393816 VBP O
pleiotropic BC2GM054393816 JJ O
effectors BC2GM054393816 NNS O
of BC2GM054393816 IN O
viral BC2GM054393816 JJ O
and BC2GM054393816 CC O
cellular BC2GM054393816 JJ O
DNA BC2GM054393816 NNP O
replication BC2GM054393816 NN O
, BC2GM054393816 , O
of BC2GM054393816 IN O
cellular BC2GM054393816 JJ O
transformation BC2GM054393816 NN O
by BC2GM054393816 IN O
viral BC2GM054393816 JJ O
and BC2GM054393816 CC O
cellular BC2GM054393816 JJ O
oncogenes BC2GM054393816 NNS O
, BC2GM054393816 , O
and BC2GM054393816 CC O
of BC2GM054393816 IN O
homologous BC2GM054393816 JJ O
and BC2GM054393816 CC O
heterologous BC2GM054393816 JJ O
gene BC2GM054393816 NN O
expression BC2GM054393816 NN O
. BC2GM054393816 . O
. . O O

Repression BC2GM080831833 NN O
was BC2GM080831833 VBD O
strictly BC2GM080831833 RB O
dependent BC2GM080831833 JJ O
on BC2GM080831833 IN O
the BC2GM080831833 DT O
presence BC2GM080831833 NN O
of BC2GM080831833 IN O
upstream BC2GM080831833 JJ O
Oshox1 BC2GM080831833 NNP O
binding BC2GM080831833 NN O
sites BC2GM080831833 NNS O
in BC2GM080831833 IN O
the BC2GM080831833 DT O
reporter BC2GM080831833 NN O
gene BC2GM080831833 NN O
constructs BC2GM080831833 NNS O
and BC2GM080831833 CC O
a BC2GM080831833 DT O
function BC2GM080831833 NN O
of BC2GM080831833 IN O
the BC2GM080831833 DT O
N-terminal BC2GM080831833 JJ O
region BC2GM080831833 NN O
of BC2GM080831833 IN O
Oshox1 BC2GM080831833 NNP O
, BC2GM080831833 , O
preceding BC2GM080831833 VBG O
the BC2GM080831833 DT O
homeodomain BC2GM080831833 NN O
. BC2GM080831833 . O
. . O O

Here BC2GM085827097 RB O
we BC2GM085827097 PRP O
demonstrate BC2GM085827097 VBP O
that BC2GM085827097 IN O
the BC2GM085827097 DT O
T BC2GM085827097 NNP O
cell BC2GM085827097 NN O
antigen BC2GM085827097 NN O
receptor BC2GM085827097 NN O
zeta-chain-associated BC2GM085827097 JJ O
ZAP-70 BC2GM085827097 JJ O
kinase BC2GM085827097 NN O
and BC2GM085827097 CC O
T BC2GM085827097 NNP O
cell BC2GM085827097 VBP O
antigen BC2GM085827097 JJ O
receptor BC2GM085827097 NN O
zeta-chain BC2GM085827097 JJ O
immunoreceptor BC2GM085827097 NN O
tyrosine-based BC2GM085827097 JJ O
activation BC2GM085827097 NN O
motifs BC2GM085827097 NNS O
are BC2GM085827097 VBP O
essential BC2GM085827097 JJ O
for BC2GM085827097 IN O
the BC2GM085827097 DT O
membrane BC2GM085827097 NN O
recruitment BC2GM085827097 NN O
of BC2GM085827097 IN O
SOS BC2GM085827097 NNP O
and BC2GM085827097 CC O
Vav BC2GM085827097 NNP O
. BC2GM085827097 . O
. . O O

Unlike BC2GM073109990 IN O
CSK BC2GM073109990 NNP O
, BC2GM073109990 , O
the BC2GM073109990 DT O
SH3 BC2GM073109990 NNP O
domain BC2GM073109990 NN O
of BC2GM073109990 IN O
HYL BC2GM073109990 NNP O
was BC2GM073109990 VBD O
unique BC2GM073109990 JJ O
since BC2GM073109990 IN O
the BC2GM073109990 DT O
ALYDY BC2GM073109990 NNP O
motif BC2GM073109990 NN O
was BC2GM073109990 VBD O
absent BC2GM073109990 JJ O
. BC2GM073109990 . O
. . O O

Expression BC2GM073223559 NN O
of BC2GM073223559 IN O
Helios BC2GM073223559 NNP O
was BC2GM073223559 VBD O
detected BC2GM073223559 VBN O
in BC2GM073223559 IN O
the BC2GM073223559 DT O
earliest BC2GM073223559 JJS O
hematopoietic BC2GM073223559 JJ O
sites BC2GM073223559 NNS O
of BC2GM073223559 IN O
the BC2GM073223559 DT O
embryo BC2GM073223559 NN O
, BC2GM073223559 , O
in BC2GM073223559 IN O
hematopoietic BC2GM073223559 JJ O
stem BC2GM073223559 NN O
cells BC2GM073223559 NNS O
in BC2GM073223559 IN O
the BC2GM073223559 DT O
adult BC2GM073223559 NN O
and BC2GM073223559 CC O
was BC2GM073223559 VBD O
subsequently BC2GM073223559 RB O
restricted BC2GM073223559 VBN O
to BC2GM073223559 TO O
a BC2GM073223559 DT O
subset BC2GM073223559 NN O
of BC2GM073223559 IN O
cells BC2GM073223559 NNS O
in BC2GM073223559 IN O
the BC2GM073223559 DT O
T BC2GM073223559 NNP O
cell BC2GM073223559 NN O
lineage BC2GM073223559 NN O
. BC2GM073223559 . O
. . O O

A BC2GM007721864 DT O
total BC2GM007721864 NN O
of BC2GM007721864 IN O
10,763 BC2GM007721864 CD O
men BC2GM007721864 NNS O
and BC2GM007721864 CC O
3,118 BC2GM007721864 CD O
women BC2GM007721864 NNS O
has BC2GM007721864 VBZ O
been BC2GM007721864 VBN O
studied BC2GM007721864 VBN O
, BC2GM007721864 , O
of BC2GM007721864 IN O
whom BC2GM007721864 WP O
97 BC2GM007721864 CD O
% BC2GM007721864 NN O
and BC2GM007721864 CC O
89 BC2GM007721864 CD O
% BC2GM007721864 NN O
, BC2GM007721864 , O
respectively BC2GM007721864 RB O
, BC2GM007721864 , O
have BC2GM007721864 VBP O
been BC2GM007721864 VBN O
traced BC2GM007721864 VBN O
and BC2GM007721864 CC O
36 BC2GM007721864 CD O
% BC2GM007721864 NN O
and BC2GM007721864 CC O
16 BC2GM007721864 CD O
% BC2GM007721864 NN O
have BC2GM007721864 VBP O
died BC2GM007721864 VBN O
. BC2GM007721864 . O
. . O O

A BC2GM066303688 DT O
GT-rich BC2GM066303688 JJ O
sequence BC2GM066303688 NN O
binding BC2GM066303688 VBG O
the BC2GM066303688 DT O
transcription BC2GM066303688 NN O
factor BC2GM066303688 NN O
Sp1 BC2GM066303688 NNP O
is BC2GM066303688 VBZ O
crucial BC2GM066303688 JJ O
for BC2GM066303688 IN O
high BC2GM066303688 JJ O
expression BC2GM066303688 NN O
of BC2GM066303688 IN O
the BC2GM066303688 DT O
human BC2GM066303688 JJ O
type BC2GM066303688 NN O
VII BC2GM066303688 NNP O
collagen BC2GM066303688 NN O
gene BC2GM066303688 NN O
( BC2GM066303688 ( O
COL7A1 BC2GM066303688 NNP O
) BC2GM066303688 ) O
in BC2GM066303688 IN O
fibroblasts BC2GM066303688 NNS O
and BC2GM066303688 CC O
keratinocytes BC2GM066303688 NNS O
. BC2GM066303688 . O
. . O O

Further BC2GM029530491 JJ O
studies BC2GM029530491 NNS O
are BC2GM029530491 VBP O
warranted BC2GM029530491 VBN O
to BC2GM029530491 TO O
determine BC2GM029530491 VB O
whether BC2GM029530491 IN O
these BC2GM029530491 DT O
findings BC2GM029530491 NNS O
are BC2GM029530491 VBP O
idiosyncratic BC2GM029530491 JJ O
, BC2GM029530491 , O
coincidental BC2GM029530491 JJ O
, BC2GM029530491 , O
or BC2GM029530491 CC O
a BC2GM029530491 DT O
more BC2GM029530491 RBR O
general BC2GM029530491 JJ O
phenomenon BC2GM029530491 NN O
. BC2GM029530491 . O
. . O O

In BC2GM020542705 IN O
contrast BC2GM020542705 NN O
, BC2GM020542705 , O
inactivation BC2GM020542705 NN O
of BC2GM020542705 IN O
the BC2GM020542705 DT O
Sir4p-interacting BC2GM020542705 NNP O
protein BC2GM020542705 NN O
Rap1p BC2GM020542705 NNP O
reduces BC2GM020542705 VBZ O
partitioning BC2GM020542705 NN O
by BC2GM020542705 IN O
a BC2GM020542705 DT O
LexA-Sir4p BC2GM020542705 JJ O
fusion BC2GM020542705 NN O
. BC2GM020542705 . O
. . O O

Human BC2GM093692420 NNP O
and BC2GM093692420 CC O
murine BC2GM093692420 VB O
cytotoxic BC2GM093692420 NN O
T BC2GM093692420 NNP O
lymphocyte BC2GM093692420 VBZ O
serine BC2GM093692420 JJ O
proteases BC2GM093692420 NNS O
: BC2GM093692420 : O
subsite BC2GM093692420 JJ O
mapping BC2GM093692420 NN O
with BC2GM093692420 IN O
peptide BC2GM093692420 JJ O
thioester BC2GM093692420 NN O
substrates BC2GM093692420 NNS O
and BC2GM093692420 CC O
inhibition BC2GM093692420 NN O
of BC2GM093692420 IN O
enzyme BC2GM093692420 JJ O
activity BC2GM093692420 NN O
and BC2GM093692420 CC O
cytolysis BC2GM093692420 NN O
by BC2GM093692420 IN O
isocoumarins BC2GM093692420 NNS O
. BC2GM093692420 . O
. . O O

The BC2GM094871087 DT O
pepI BC2GM094871087 NN O
gene BC2GM094871087 NN O
was BC2GM094871087 VBD O
overexpressed BC2GM094871087 VBN O
in BC2GM094871087 IN O
Escherichia BC2GM094871087 NNP O
coli BC2GM094871087 NN O
. BC2GM094871087 . O
. . O O

Comparison BC2GM065617223 NNP O
of BC2GM065617223 IN O
dose BC2GM065617223 JJ O
volume BC2GM065617223 NN O
histograms BC2GM065617223 NNS O
revealed BC2GM065617223 VBD O
that BC2GM065617223 IN O
the BC2GM065617223 DT O
6-field BC2GM065617223 JJ O
plan BC2GM065617223 NN O
spared BC2GM065617223 VBD O
relatively BC2GM065617223 RB O
more BC2GM065617223 RBR O
heart BC2GM065617223 NN O
whereas BC2GM065617223 IN O
the BC2GM065617223 DT O
8-field BC2GM065617223 JJ O
plan BC2GM065617223 NN O
spared BC2GM065617223 VBD O
relatively BC2GM065617223 RB O
more BC2GM065617223 RBR O
lung BC2GM065617223 NN O
. BC2GM065617223 . O
. . O O

Thus BC2GM088340339 RB O
, BC2GM088340339 , O
22 BC2GM088340339 CD O
% BC2GM088340339 NN O
of BC2GM088340339 IN O
MDS BC2GM088340339 NNP O
responded BC2GM088340339 VBD O
to BC2GM088340339 TO O
oral BC2GM088340339 JJ O
PLAC BC2GM088340339 NNP O
. BC2GM088340339 . O
. . O O

Diabetic BC2GM027030914 NNP O
osteopenia BC2GM027030914 NN O
, BC2GM027030914 , O
a BC2GM027030914 DT O
known BC2GM027030914 VBN O
chronic BC2GM027030914 JJ O
complication BC2GM027030914 NN O
of BC2GM027030914 IN O
diabetes BC2GM027030914 NNS O
, BC2GM027030914 , O
has BC2GM027030914 VBZ O
been BC2GM027030914 VBN O
demonstrated BC2GM027030914 VBN O
with BC2GM027030914 IN O
alterations BC2GM027030914 NNS O
in BC2GM027030914 IN O
the BC2GM027030914 DT O
calcium-vitamin BC2GM027030914 JJ O
D BC2GM027030914 NNP O
endocrine BC2GM027030914 NN O
system BC2GM027030914 NN O
. BC2GM027030914 . O
. . O O

A BC2GM067301071 DT O
Premenstrual BC2GM067301071 JJ O
Syndrome BC2GM067301071 NNP O
, BC2GM067301071 , O
the BC2GM067301071 DT O
late BC2GM067301071 JJ O
luteal BC2GM067301071 NN O
phase BC2GM067301071 NN O
disorder BC2GM067301071 NN O
of BC2GM067301071 IN O
DSM-IIIR BC2GM067301071 NNP O
criteria BC2GM067301071 NNS O
, BC2GM067301071 , O
was BC2GM067301071 VBD O
identified BC2GM067301071 VBN O
in BC2GM067301071 IN O
6 BC2GM067301071 CD O
% BC2GM067301071 NN O
of BC2GM067301071 IN O
the BC2GM067301071 DT O
women BC2GM067301071 NNS O
. BC2GM067301071 . O
. . O O

In BC2GM097306913 IN O
contrast BC2GM097306913 NN O
, BC2GM097306913 , O
vRel BC2GM097306913 NN O
lacks BC2GM097306913 VBZ O
a BC2GM097306913 DT O
strong BC2GM097306913 JJ O
C-terminal BC2GM097306913 JJ O
gene BC2GM097306913 NN O
activation BC2GM097306913 NN O
function BC2GM097306913 NN O
, BC2GM097306913 , O
since BC2GM097306913 IN O
a BC2GM097306913 DT O
LexA BC2GM097306913 NNP O
fusion BC2GM097306913 NN O
protein BC2GM097306913 NN O
containing BC2GM097306913 VBG O
C-terminal BC2GM097306913 JJ O
vRel BC2GM097306913 NN O
sequences BC2GM097306913 NNS O
alone BC2GM097306913 RB O
only BC2GM097306913 RB O
weakly BC2GM097306913 RB O
activated BC2GM097306913 VBN O
transcription BC2GM097306913 NN O
. BC2GM097306913 . O
. . O O

Ondansetron BC2GM042376349 NNP O
is BC2GM042376349 VBZ O
thus BC2GM042376349 RB O
an BC2GM042376349 DT O
effective BC2GM042376349 JJ O
first-line BC2GM042376349 JJ O
antiemetic BC2GM042376349 NN O
in BC2GM042376349 IN O
children BC2GM042376349 NNS O
undergoing BC2GM042376349 VBG O
chemotherapy BC2GM042376349 NN O
, BC2GM042376349 , O
radiotherapy BC2GM042376349 NN O
and BC2GM042376349 CC O
surgery BC2GM042376349 NN O
. BC2GM042376349 . O
. . O O

Transient BC2GM053451054 JJ O
thyrotoxicosis BC2GM053451054 NN O
in BC2GM053451054 IN O
primary BC2GM053451054 JJ O
anti-phospholipid BC2GM053451054 JJ O
syndrome BC2GM053451054 NN O
. BC2GM053451054 . O
. . O O

Northern BC2GM033997623 NNP O
blot BC2GM033997623 NN O
analysis BC2GM033997623 NN O
of BC2GM033997623 IN O
enoyl-ACP BC2GM033997623 JJ O
reductase BC2GM033997623 NN O
mRNA BC2GM033997623 VBD O
steady-state BC2GM033997623 JJ O
levels BC2GM033997623 NNS O
during BC2GM033997623 IN O
seed BC2GM033997623 NN O
development BC2GM033997623 NN O
suggests BC2GM033997623 VBZ O
that BC2GM033997623 IN O
the BC2GM033997623 DT O
increase BC2GM033997623 NN O
in BC2GM033997623 IN O
enzyme BC2GM033997623 JJ O
activity BC2GM033997623 NN O
during BC2GM033997623 IN O
the BC2GM033997623 DT O
phase BC2GM033997623 NN O
of BC2GM033997623 IN O
storage BC2GM033997623 NN O
lipid BC2GM033997623 JJ O
accumulation BC2GM033997623 NN O
is BC2GM033997623 VBZ O
regulated BC2GM033997623 VBN O
at BC2GM033997623 IN O
the BC2GM033997623 DT O
level BC2GM033997623 NN O
of BC2GM033997623 IN O
gene BC2GM033997623 NN O
expression BC2GM033997623 NN O
. BC2GM033997623 . O
. . O O

The BC2GM093469461 DT O
BHV-1 BC2GM093469461 NNP O
UL24 BC2GM093469461 NNP O
, BC2GM093469461 , O
UL25 BC2GM093469461 NNP O
, BC2GM093469461 , O
UL26 BC2GM093469461 NNP O
and BC2GM093469461 CC O
UL26.5 BC2GM093469461 NNP O
transcripts BC2GM093469461 VBP O
all BC2GM093469461 DT O
terminated BC2GM093469461 VBN O
at BC2GM093469461 IN O
a BC2GM093469461 DT O
common BC2GM093469461 JJ O
3'-polyadenylation BC2GM093469461 JJ O
site BC2GM093469461 NN O
and BC2GM093469461 CC O
varied BC2GM093469461 VBD O
significantly BC2GM093469461 RB O
in BC2GM093469461 IN O
their BC2GM093469461 PRP$ O
relative BC2GM093469461 JJ O
abundance BC2GM093469461 NN O
. BC2GM093469461 . O
. . O O

Cellular BC2GM091685564 JJ O
lysates BC2GM091685564 NNS O
were BC2GM091685564 VBD O
analyzed BC2GM091685564 VBN O
for BC2GM091685564 IN O
luciferase BC2GM091685564 NN O
and BC2GM091685564 CC O
beta-galactosidase BC2GM091685564 NN O
activities BC2GM091685564 NNS O
. BC2GM091685564 . O
. . O O

To BC2GM040397014 TO O
initiate BC2GM040397014 VB O
our BC2GM040397014 PRP$ O
analysis BC2GM040397014 NN O
of BC2GM040397014 IN O
factors BC2GM040397014 NNS O
required BC2GM040397014 VBN O
for BC2GM040397014 IN O
eIF-2 BC2GM040397014 JJ O
alpha BC2GM040397014 JJ O
expression BC2GM040397014 NN O
, BC2GM040397014 , O
selected BC2GM040397014 VBD O
a BC2GM040397014 DT O
CAP-proximal BC2GM040397014 JJ O
element BC2GM040397014 NN O
shown BC2GM040397014 VBN O
by BC2GM040397014 IN O
in BC2GM040397014 IN O
vivo BC2GM040397014 JJ O
methylation BC2GM040397014 NN O
protection BC2GM040397014 NN O
analysis BC2GM040397014 NN O
to BC2GM040397014 TO O
bind BC2GM040397014 VB O
a BC2GM040397014 DT O
potential BC2GM040397014 JJ O
regulatory BC2GM040397014 JJ O
factor BC2GM040397014 NN O
. BC2GM040397014 . O
. . O O

The BC2GM081193454 DT O
goals BC2GM081193454 NNS O
of BC2GM081193454 IN O
these BC2GM081193454 DT O
experiments BC2GM081193454 NNS O
were BC2GM081193454 VBD O
to BC2GM081193454 TO O
determine BC2GM081193454 VB O
whether BC2GM081193454 IN O
lactational BC2GM081193454 JJ O
anestrus BC2GM081193454 NN O
would BC2GM081193454 MD O
be BC2GM081193454 VB O
prolonged BC2GM081193454 VBN O
by BC2GM081193454 IN O
a BC2GM081193454 DT O
48-h BC2GM081193454 JJ O
fast BC2GM081193454 NN O
at BC2GM081193454 IN O
days BC2GM081193454 NNS O
13 BC2GM081193454 CD O
and BC2GM081193454 CC O
14 BC2GM081193454 CD O
postpartum BC2GM081193454 NN O
( BC2GM081193454 ( O
pp BC2GM081193454 NN O
) BC2GM081193454 ) O
and BC2GM081193454 CC O
, BC2GM081193454 , O
if BC2GM081193454 IN O
so BC2GM081193454 RB O
, BC2GM081193454 , O
to BC2GM081193454 TO O
determine BC2GM081193454 VB O
whether BC2GM081193454 IN O
this BC2GM081193454 DT O
effect BC2GM081193454 NN O
could BC2GM081193454 MD O
be BC2GM081193454 VB O
reversed BC2GM081193454 VBN O
by BC2GM081193454 IN O
treatment BC2GM081193454 NN O
with BC2GM081193454 IN O
the BC2GM081193454 DT O
Ob BC2GM081193454 NNP O
protein BC2GM081193454 NN O
leptin BC2GM081193454 NN O
. BC2GM081193454 . O
. . O O

We BC2GM076054604 PRP O
now BC2GM076054604 RB O
show BC2GM076054604 VBP O
that BC2GM076054604 IN O
purified BC2GM076054604 VBD O
recombinant BC2GM076054604 JJ O
c-sis BC2GM076054604 NN O
/ BC2GM076054604 NN O
PDGF BC2GM076054604 NNP O
can BC2GM076054604 MD O
induce BC2GM076054604 VB O
this BC2GM076054604 DT O
binding BC2GM076054604 NN O
activity BC2GM076054604 NN O
which BC2GM076054604 WDT O
we BC2GM076054604 PRP O
have BC2GM076054604 VBP O
termed BC2GM076054604 VBN O
SIF BC2GM076054604 NNP O
, BC2GM076054604 , O
for BC2GM076054604 IN O
sis-inducible BC2GM076054604 JJ O
factor BC2GM076054604 NN O
. BC2GM076054604 . O
. . O O

It BC2GM032470094 PRP O
is BC2GM032470094 VBZ O
concluded BC2GM032470094 VBN O
that BC2GM032470094 IN O
the BC2GM032470094 DT O
predominant BC2GM032470094 JJ O
action BC2GM032470094 NN O
of BC2GM032470094 IN O
LSD BC2GM032470094 NNP O
on BC2GM032470094 IN O
the BC2GM032470094 DT O
female BC2GM032470094 JJ O
copulatory BC2GM032470094 NN O
response BC2GM032470094 NN O
is BC2GM032470094 VBZ O
not BC2GM032470094 RB O
mediated BC2GM032470094 VBN O
by BC2GM032470094 IN O
increased BC2GM032470094 JJ O
dopamine BC2GM032470094 NN O
receptor BC2GM032470094 NN O
activity BC2GM032470094 NN O
but BC2GM032470094 CC O
that BC2GM032470094 IN O
the BC2GM032470094 DT O
LSD BC2GM032470094 NNP O
effect BC2GM032470094 NN O
might BC2GM032470094 MD O
be BC2GM032470094 VB O
modulated BC2GM032470094 VBN O
by BC2GM032470094 IN O
decreased BC2GM032470094 JJ O
dopaminergic BC2GM032470094 NN O
activity BC2GM032470094 NN O
. BC2GM032470094 . O
. . O O

The BC2GM098647724 DT O
collicular BC2GM098647724 NN O
labels BC2GM098647724 NNS O
found BC2GM098647724 VBN O
after BC2GM098647724 IN O
injections BC2GM098647724 NNS O
within BC2GM098647724 IN O
the BC2GM098647724 DT O
MST BC2GM098647724 NNP O
area BC2GM098647724 NN O
exhibited BC2GM098647724 VBD O
their BC2GM098647724 PRP$ O
distribution BC2GM098647724 NN O
over BC2GM098647724 IN O
the BC2GM098647724 DT O
deep BC2GM098647724 JJ O
SC BC2GM098647724 NNP O
subdivision BC2GM098647724 NN O
, BC2GM098647724 , O
whereas BC2GM098647724 IN O
they BC2GM098647724 PRP O
spared BC2GM098647724 VBD O
all BC2GM098647724 PDT O
the BC2GM098647724 DT O
superficial BC2GM098647724 JJ O
layers BC2GM098647724 NNS O
but BC2GM098647724 CC O
the BC2GM098647724 DT O
deep BC2GM098647724 JJ O
part BC2GM098647724 NN O
of BC2GM098647724 IN O
the BC2GM098647724 DT O
SO BC2GM098647724 NNP O
. BC2GM098647724 . O
. . O O

We BC2GM070276124 PRP O
have BC2GM070276124 VBP O
previously BC2GM070276124 RB O
reported BC2GM070276124 VBN O
the BC2GM070276124 DT O
first BC2GM070276124 JJ O
isolation BC2GM070276124 NN O
of BC2GM070276124 IN O
a BC2GM070276124 DT O
c-myc-null BC2GM070276124 JJ O
cell BC2GM070276124 NN O
line BC2GM070276124 NN O
. BC2GM070276124 . O
. . O O

Four BC2GM029942800 CD O
of BC2GM029942800 IN O
these BC2GM029942800 DT O
fibroblast BC2GM029942800 JJ O
clones BC2GM029942800 NNS O
were BC2GM029942800 VBD O
infected BC2GM029942800 VBN O
with BC2GM029942800 IN O
a BC2GM029942800 DT O
retrovirus BC2GM029942800 NN O
containing BC2GM029942800 VBG O
the BC2GM029942800 DT O
cDNA BC2GM029942800 NN O
encoding BC2GM029942800 VBG O
myoD BC2GM029942800 NN O
and BC2GM029942800 CC O
a BC2GM029942800 DT O
puromycin BC2GM029942800 JJ O
selection BC2GM029942800 NN O
marker BC2GM029942800 NN O
. BC2GM029942800 . O
. . O O

Creatinine BC2GM013413021 NNP O
and BC2GM013413021 CC O
creatine BC2GM013413021 JJ O
phosphokinase BC2GM013413021 NN O
( BC2GM013413021 ( O
CPK BC2GM013413021 NNP O
) BC2GM013413021 ) O
. BC2GM013413021 . O
. . O O

The BC2GM038777318 DT O
column BC2GM038777318 NN O
densities BC2GM038777318 NNS O
of BC2GM038777318 IN O
frozen BC2GM038777318 JJ O
molecular BC2GM038777318 JJ O
hydrogen BC2GM038777318 NN O
and BC2GM038777318 CC O
methanol BC2GM038777318 NN O
are BC2GM038777318 VBP O
inferred BC2GM038777318 VBN O
to BC2GM038777318 TO O
be BC2GM038777318 VB O
about BC2GM038777318 IN O
2.5 BC2GM038777318 CD O
x BC2GM038777318 NNS O
10 BC2GM038777318 CD O
( BC2GM038777318 ( O
18 BC2GM038777318 CD O
) BC2GM038777318 ) O
and BC2GM038777318 CC O
3.0 BC2GM038777318 CD O
x BC2GM038777318 NNS O
10 BC2GM038777318 CD O
( BC2GM038777318 ( O
19 BC2GM038777318 CD O
) BC2GM038777318 ) O
, BC2GM038777318 , O
respectively BC2GM038777318 RB O
. BC2GM038777318 . O
. . O O

The BC2GM003829554 DT O
prosomal BC2GM003829554 JJ O
RNA-binding BC2GM003829554 NNP O
protein BC2GM003829554 NN O
p27K BC2GM003829554 NN O
is BC2GM003829554 VBZ O
a BC2GM003829554 DT O
member BC2GM003829554 NN O
of BC2GM003829554 IN O
the BC2GM003829554 DT O
alpha-type BC2GM003829554 JJ O
human BC2GM003829554 JJ O
prosomal BC2GM003829554 JJ O
gene BC2GM003829554 NN O
family BC2GM003829554 NN O
. BC2GM003829554 . O
. . O O

Gastrin BC2GM040848172 NNP O
stimulates BC2GM040848172 VBZ O
transcription BC2GM040848172 NN O
of BC2GM040848172 IN O
the BC2GM040848172 DT O
human BC2GM040848172 JJ O
histidine BC2GM040848172 NN O
decarboxylase BC2GM040848172 NN O
( BC2GM040848172 ( O
HDC BC2GM040848172 NNP O
) BC2GM040848172 ) O
gene BC2GM040848172 NN O
through BC2GM040848172 IN O
binding BC2GM040848172 VBG O
to BC2GM040848172 TO O
the BC2GM040848172 DT O
G-protein-coupled BC2GM040848172 JJ O
cholecystokinin-B BC2GM040848172 JJ O
/ BC2GM040848172 NN O
gastrin BC2GM040848172 NN O
receptor BC2GM040848172 NN O
. BC2GM040848172 . O
. . O O

Similarly BC2GM097555294 RB O
, BC2GM097555294 , O
interfering BC2GM097555294 VBG O
with BC2GM097555294 IN O
MEKK BC2GM097555294 NNP O
, BC2GM097555294 , O
which BC2GM097555294 WDT O
lies BC2GM097555294 VBZ O
upstream BC2GM097555294 NN O
of BC2GM097555294 IN O
JNK1 BC2GM097555294 NNP O
, BC2GM097555294 , O
using BC2GM097555294 VBG O
a BC2GM097555294 DT O
dominant BC2GM097555294 JJ O
negative BC2GM097555294 JJ O
expression BC2GM097555294 NN O
vector BC2GM097555294 NN O
reduced BC2GM097555294 VBD O
MMP-9 BC2GM097555294 NNP O
promoter BC2GM097555294 NN O
activity BC2GM097555294 NN O
over BC2GM097555294 IN O
the BC2GM097555294 DT O
same BC2GM097555294 JJ O
concentration BC2GM097555294 NN O
range BC2GM097555294 NN O
which BC2GM097555294 WDT O
repressed BC2GM097555294 VBD O
the BC2GM097555294 DT O
AP-1-thymidine BC2GM097555294 JJ O
kinase BC2GM097555294 NN O
CAT BC2GM097555294 NNP O
reporter BC2GM097555294 NN O
construct BC2GM097555294 NN O
. BC2GM097555294 . O
. . O O

Pollinosis BC2GM014045933 NN O
in BC2GM014045933 IN O
the BC2GM014045933 DT O
U.A.R BC2GM014045933 NNP O
. BC2GM014045933 . O
. . O O

Paradoxically BC2GM063663214 RB O
there BC2GM063663214 EX O
is BC2GM063663214 VBZ O
a BC2GM063663214 DT O
decrease BC2GM063663214 NN O
in BC2GM063663214 IN O
the BC2GM063663214 DT O
level BC2GM063663214 NN O
of BC2GM063663214 IN O
soluble BC2GM063663214 JJ O
A BC2GM063663214 NNP O
beta BC2GM063663214 NN O
secreted BC2GM063663214 VBN O
from BC2GM063663214 IN O
the BC2GM063663214 DT O
cells BC2GM063663214 NNS O
. BC2GM063663214 . O
. . O O

Prevalence BC2GM079994389 NN O
of BC2GM079994389 IN O
use BC2GM079994389 NN O
, BC2GM079994389 , O
claims BC2GM079994389 NNS O
volume BC2GM079994389 NN O
, BC2GM079994389 , O
and BC2GM079994389 CC O
expenditures BC2GM079994389 NNS O
were BC2GM079994389 VBD O
compared BC2GM079994389 VBN O
for BC2GM079994389 IN O
cisapride BC2GM079994389 NN O
, BC2GM079994389 , O
proton BC2GM079994389 NN O
pump BC2GM079994389 NN O
inhibitors BC2GM079994389 NNS O
, BC2GM079994389 , O
histamine-2 BC2GM079994389 JJ O
receptor BC2GM079994389 NN O
antagonists BC2GM079994389 NNS O
, BC2GM079994389 , O
and BC2GM079994389 CC O
the BC2GM079994389 DT O
prokinetic BC2GM079994389 JJ O
agent BC2GM079994389 NN O
metoclopramide BC2GM079994389 NN O
during BC2GM079994389 IN O
these BC2GM079994389 DT O
periods BC2GM079994389 NNS O
. BC2GM079994389 . O
. . O O

At BC2GM066374194 IN O
onset BC2GM066374194 NN O
of BC2GM066374194 IN O
first BC2GM066374194 JJ O
post-weaning BC2GM066374194 JJ O
estrus BC2GM066374194 NN O
, BC2GM066374194 , O
sows BC2GM066374194 VBZ O
received BC2GM066374194 VBN O
either BC2GM066374194 DT O
an BC2GM066374194 DT O
intravulval BC2GM066374194 JJ O
injection BC2GM066374194 NN O
of BC2GM066374194 IN O
3.75 BC2GM066374194 CD O
mg BC2GM066374194 NN O
of BC2GM066374194 IN O
prostaglandin BC2GM066374194 NN O
analogue BC2GM066374194 NN O
( BC2GM066374194 ( O
PGF BC2GM066374194 NNP O
) BC2GM066374194 ) O
or BC2GM066374194 CC O
, BC2GM066374194 , O
served BC2GM066374194 VBD O
as BC2GM066374194 IN O
a BC2GM066374194 DT O
non-injected BC2GM066374194 JJ O
control BC2GM066374194 NN O
( BC2GM066374194 ( O
CON BC2GM066374194 NNP O
) BC2GM066374194 ) O
. BC2GM066374194 . O
. . O O

Transcriptional BC2GM014113607 JJ O
activation BC2GM014113607 NN O
of BC2GM014113607 IN O
the BC2GM014113607 DT O
proopiomelanocortin BC2GM014113607 NN O
gene BC2GM014113607 NN O
by BC2GM014113607 IN O
cyclic BC2GM014113607 JJ O
AMP-responsive BC2GM014113607 JJ O
element BC2GM014113607 NN O
binding BC2GM014113607 VBG O
protein BC2GM014113607 NN O
. BC2GM014113607 . O
. . O O

STUDY BC2GM043394225 NNP O
SELECTION BC2GM043394225 NNP O
: BC2GM043394225 : O
Not BC2GM043394225 RB O
applicable BC2GM043394225 JJ O
. BC2GM043394225 . O
. . O O

The BC2GM032810661 DT O
virus BC2GM032810661 NN O
must BC2GM032810661 MD O
progress BC2GM032810661 VB O
past BC2GM032810661 IN O
the BC2GM032810661 DT O
immediate-early BC2GM032810661 JJ O
phase BC2GM032810661 NN O
and BC2GM032810661 CC O
express BC2GM032810661 VB O
an BC2GM032810661 DT O
early BC2GM032810661 JJ O
gene BC2GM032810661 NN O
product BC2GM032810661 NN O
( BC2GM032810661 ( O
s BC2GM032810661 JJ O
) BC2GM032810661 ) O
for BC2GM032810661 IN O
activation BC2GM032810661 NN O
of BC2GM032810661 IN O
cyclin BC2GM032810661 NN O
E BC2GM032810661 NNP O
expression BC2GM032810661 NN O
. BC2GM032810661 . O
. . O O

Two BC2GM036910658 CD O
courses BC2GM036910658 NNS O
of BC2GM036910658 IN O
chemotherapy BC2GM036910658 NN O
( BC2GM036910658 ( O
CBCDA BC2GM036910658 NNP O
+ BC2GM036910658 NNP O
VDS BC2GM036910658 NNP O
) BC2GM036910658 ) O
failed BC2GM036910658 VBD O
to BC2GM036910658 TO O
gain BC2GM036910658 VB O
any BC2GM036910658 DT O
improvement BC2GM036910658 NN O
, BC2GM036910658 , O
and BC2GM036910658 CC O
the BC2GM036910658 DT O
pain BC2GM036910658 NN O
resulting BC2GM036910658 VBG O
from BC2GM036910658 IN O
recurrent BC2GM036910658 NN O
bone BC2GM036910658 NN O
metastases BC2GM036910658 NNS O
was BC2GM036910658 VBD O
managed BC2GM036910658 VBN O
mainly BC2GM036910658 RB O
by BC2GM036910658 IN O
the BC2GM036910658 DT O
administration BC2GM036910658 NN O
of BC2GM036910658 IN O
the BC2GM036910658 DT O
best BC2GM036910658 JJS O
supportive BC2GM036910658 JJ O
care BC2GM036910658 NN O
. BC2GM036910658 . O
. . O O

When BC2GM011080889 WRB O
phentermine BC2GM011080889 NN O
was BC2GM011080889 VBD O
mixed BC2GM011080889 JJ O
with BC2GM011080889 IN O
other BC2GM011080889 JJ O
unlabeled BC2GM011080889 JJ O
reversible BC2GM011080889 JJ O
MAO BC2GM011080889 NNP O
inhibitors BC2GM011080889 NNS O
( BC2GM011080889 ( O
e.g BC2GM011080889 NN O
. BC2GM011080889 . O
pseudoephedrine BC2GM011080889 NN O
, BC2GM011080889 , O
ephedrine BC2GM011080889 NN O
, BC2GM011080889 , O
norephedrine BC2GM011080889 NN O
; BC2GM011080889 : O
estradiol BC2GM011080889 CC O
benzoate BC2GM011080889 NN O
) BC2GM011080889 ) O
, BC2GM011080889 , O
the BC2GM011080889 DT O
degree BC2GM011080889 NN O
of BC2GM011080889 IN O
MAO BC2GM011080889 NNP O
inhibition BC2GM011080889 NN O
was BC2GM011080889 VBD O
additive BC2GM011080889 JJ O
. BC2GM011080889 . O
. . O O

The BC2GM011190047 DT O
RTI40 BC2GM011190047 NNP O
gene BC2GM011190047 NN O
spans BC2GM011190047 NNS O
35 BC2GM011190047 CD O
kilobase BC2GM011190047 NN O
pairs BC2GM011190047 NNS O
; BC2GM011190047 : O
it BC2GM011190047 PRP O
contains BC2GM011190047 VBZ O
6 BC2GM011190047 CD O
exons BC2GM011190047 NNS O
and BC2GM011190047 CC O
at BC2GM011190047 IN O
least BC2GM011190047 JJS O
6 BC2GM011190047 CD O
rat BC2GM011190047 NN O
Identifier BC2GM011190047 NNP O
repetitive BC2GM011190047 JJ O
elements BC2GM011190047 NNS O
. BC2GM011190047 . O
. . O O

Teratospermia BC2GM074968808 NN O
is BC2GM074968808 VBZ O
therefore BC2GM074968808 RB O
an BC2GM074968808 DT O
important BC2GM074968808 JJ O
factor BC2GM074968808 NN O
in BC2GM074968808 IN O
evaluating BC2GM074968808 VBG O
fertilization BC2GM074968808 NN O
capacity BC2GM074968808 NN O
. BC2GM074968808 . O
. . O O

SHBG BC2GM017257591 NNP O
concentrations BC2GM017257591 NNS O
in BC2GM017257591 IN O
women BC2GM017257591 NNS O
were BC2GM017257591 VBD O
also BC2GM017257591 RB O
significantly BC2GM017257591 RB O
higher BC2GM017257591 JJR O
at BC2GM017257591 IN O
T-2 BC2GM017257591 NNP O
and BC2GM017257591 CC O
T-3 BC2GM017257591 NNP O
when BC2GM017257591 WRB O
compared BC2GM017257591 VBN O
to BC2GM017257591 TO O
T-1 BC2GM017257591 NNP O
values BC2GM017257591 NNS O
. BC2GM017257591 . O
. . O O

Although BC2GM071898501 IN O
FKH2 BC2GM071898501 NNP O
is BC2GM071898501 VBZ O
redundant BC2GM071898501 JJ O
with BC2GM071898501 IN O
FKH1 BC2GM071898501 NNP O
in BC2GM071898501 IN O
controlling BC2GM071898501 VBG O
pseudohyphal BC2GM071898501 JJ O
growth BC2GM071898501 NN O
, BC2GM071898501 , O
the BC2GM071898501 DT O
two BC2GM071898501 CD O
genes BC2GM071898501 NNS O
have BC2GM071898501 VBP O
different BC2GM071898501 JJ O
functions BC2GM071898501 NNS O
in BC2GM071898501 IN O
silencing BC2GM071898501 VBG O
HMRa BC2GM071898501 NNP O
. BC2GM071898501 . O
. . O O

Asymptomatic BC2GM017449722 JJ O
ischaemia BC2GM017449722 NN O
during BC2GM017449722 IN O
daily BC2GM017449722 JJ O
life BC2GM017449722 NN O
in BC2GM017449722 IN O
stable BC2GM017449722 JJ O
coronary BC2GM017449722 JJ O
artery BC2GM017449722 NN O
disease BC2GM017449722 NN O
: BC2GM017449722 : O
relevant BC2GM017449722 NN O
or BC2GM017449722 CC O
redundant BC2GM017449722 NN O
? BC2GM017449722 . O
. BC2GM017449722 . O
. . O O

METHOD BC2GM056384922 NN O
: BC2GM056384922 : O
Six BC2GM056384922 CD O
instruments BC2GM056384922 NNS O
were BC2GM056384922 VBD O
reviewed BC2GM056384922 VBN O
: BC2GM056384922 : O
the BC2GM056384922 DT O
Berg BC2GM056384922 NNP O
Balance BC2GM056384922 NNP O
Scale BC2GM056384922 NNP O
( BC2GM056384922 ( O
Berg BC2GM056384922 NNP O
) BC2GM056384922 ) O
, BC2GM056384922 , O
the BC2GM056384922 DT O
Clinical BC2GM056384922 JJ O
Test BC2GM056384922 NNP O
of BC2GM056384922 IN O
Sensory BC2GM056384922 NNP O
Interaction BC2GM056384922 NNP O
and BC2GM056384922 CC O
Balance BC2GM056384922 NNP O
( BC2GM056384922 ( O
CTSIB BC2GM056384922 NNP O
) BC2GM056384922 ) O
, BC2GM056384922 , O
the BC2GM056384922 DT O
Functional BC2GM056384922 NNP O
Reach BC2GM056384922 NNP O
Test BC2GM056384922 NNP O
, BC2GM056384922 , O
the BC2GM056384922 DT O
Tinetti BC2GM056384922 NNP O
Balance BC2GM056384922 NNP O
Test BC2GM056384922 NNP O
of BC2GM056384922 IN O
the BC2GM056384922 DT O
Performance-Oriented BC2GM056384922 JJ O
Assessment BC2GM056384922 NNP O
of BC2GM056384922 IN O
Mobility BC2GM056384922 NNP O
Problems BC2GM056384922 NNP O
( BC2GM056384922 ( O
Tinetti BC2GM056384922 NNP O
) BC2GM056384922 ) O
, BC2GM056384922 , O
the BC2GM056384922 DT O
Timed BC2GM056384922 NNP O
`` BC2GM056384922 `` O
Up BC2GM056384922 NNP O
and BC2GM056384922 CC O
Go BC2GM056384922 NNP O
'' BC2GM056384922 '' O
Test BC2GM056384922 NNP O
( BC2GM056384922 ( O
TU BC2GM056384922 NNP O
& BC2GM056384922 CC O
GT BC2GM056384922 NNP O
) BC2GM056384922 ) O
, BC2GM056384922 , O
and BC2GM056384922 CC O
the BC2GM056384922 DT O
Physical BC2GM056384922 JJ O
Performance BC2GM056384922 NNP O
Test BC2GM056384922 NNP O
( BC2GM056384922 ( O
PPT BC2GM056384922 NNP O
) BC2GM056384922 ) O
. BC2GM056384922 . O
. . O O

The BC2GM016312848 DT O
major BC2GM016312848 JJ O
open BC2GM016312848 JJ O
reading BC2GM016312848 VBG O
frame BC2GM016312848 NN O
of BC2GM016312848 IN O
the BC2GM016312848 DT O
cDNA BC2GM016312848 NN O
predicts BC2GM016312848 VBZ O
a BC2GM016312848 DT O
protein BC2GM016312848 NN O
of BC2GM016312848 IN O
59 BC2GM016312848 CD O
kD BC2GM016312848 NNS O
, BC2GM016312848 , O
with BC2GM016312848 IN O
a BC2GM016312848 DT O
leucine BC2GM016312848 JJ O
zipper BC2GM016312848 NN O
situated BC2GM016312848 VBD O
adjacent BC2GM016312848 JJ O
to BC2GM016312848 TO O
an BC2GM016312848 DT O
myc-related BC2GM016312848 JJ O
motif BC2GM016312848 NN O
that BC2GM016312848 WDT O
has BC2GM016312848 VBZ O
been BC2GM016312848 VBN O
proposed BC2GM016312848 VBN O
to BC2GM016312848 TO O
assume BC2GM016312848 VB O
a BC2GM016312848 DT O
helix-loop-helix BC2GM016312848 JJ O
structure BC2GM016312848 NN O
. BC2GM016312848 . O
. . O O

An BC2GM058292678 DT O
analysis BC2GM058292678 NN O
of BC2GM058292678 IN O
the BC2GM058292678 DT O
c-kit BC2GM058292678 JJ O
5 BC2GM058292678 CD O
' BC2GM058292678 POS O
flanking BC2GM058292678 JJ O
region BC2GM058292678 NN O
using BC2GM058292678 VBG O
the BC2GM058292678 DT O
bacterial BC2GM058292678 JJ O
chloramphenicol BC2GM058292678 NN O
acetyltransferase BC2GM058292678 NN O
gene BC2GM058292678 NN O
( BC2GM058292678 ( O
CAT BC2GM058292678 NNP O
assay BC2GM058292678 VBP O
) BC2GM058292678 ) O
in BC2GM058292678 IN O
human BC2GM058292678 JJ O
erythroleukemia BC2GM058292678 NN O
HEL BC2GM058292678 NNP O
cells BC2GM058292678 NNS O
, BC2GM058292678 , O
which BC2GM058292678 WDT O
express BC2GM058292678 VBP O
the BC2GM058292678 DT O
endogenous BC2GM058292678 JJ O
c-kit BC2GM058292678 JJ O
mRNA BC2GM058292678 NN O
at BC2GM058292678 IN O
high BC2GM058292678 JJ O
levels BC2GM058292678 NNS O
, BC2GM058292678 , O
showed BC2GM058292678 VBD O
that BC2GM058292678 IN O
a BC2GM058292678 DT O
region BC2GM058292678 NN O
from BC2GM058292678 IN O
-180 BC2GM058292678 NN O
to BC2GM058292678 TO O
-22 BC2GM058292678 NNP O
is BC2GM058292678 VBZ O
important BC2GM058292678 JJ O
for BC2GM058292678 IN O
the BC2GM058292678 DT O
expression BC2GM058292678 NN O
of BC2GM058292678 IN O
the BC2GM058292678 DT O
c-kit BC2GM058292678 JJ O
gene BC2GM058292678 NN O
. BC2GM058292678 . O
. . O O

This BC2GM074262831 DT O
result BC2GM074262831 NN O
suggests BC2GM074262831 VBZ O
that BC2GM074262831 IN O
the BC2GM074262831 DT O
target BC2GM074262831 NN O
protein BC2GM074262831 JJ O
specificity BC2GM074262831 NN O
of BC2GM074262831 IN O
E2s BC2GM074262831 NNP O
can BC2GM074262831 MD O
be BC2GM074262831 VB O
altered BC2GM074262831 VBN O
by BC2GM074262831 IN O
the BC2GM074262831 DT O
addition BC2GM074262831 NN O
of BC2GM074262831 IN O
appropriate BC2GM074262831 JJ O
C-terminal BC2GM074262831 JJ O
extensions BC2GM074262831 NNS O
, BC2GM074262831 , O
thus BC2GM074262831 RB O
providing BC2GM074262831 VBG O
a BC2GM074262831 DT O
way BC2GM074262831 NN O
to BC2GM074262831 TO O
modify BC2GM074262831 VB O
the BC2GM074262831 DT O
selectivity BC2GM074262831 NN O
of BC2GM074262831 IN O
the BC2GM074262831 DT O
ubiquitin BC2GM074262831 JJ O
system BC2GM074262831 NN O
. BC2GM074262831 . O
. . O O

Treatment BC2GM091775961 NN O
with BC2GM091775961 IN O
KP-45 BC2GM091775961 NNP O
preparation BC2GM091775961 NN O
usually BC2GM091775961 RB O
resulted BC2GM091775961 VBD O
in BC2GM091775961 IN O
partial BC2GM091775961 JJ O
regression BC2GM091775961 NN O
of BC2GM091775961 IN O
tumor BC2GM091775961 NN O
growth BC2GM091775961 NN O
, BC2GM091775961 , O
accompanied BC2GM091775961 VBN O
by BC2GM091775961 IN O
improvement BC2GM091775961 NN O
of BC2GM091775961 IN O
the BC2GM091775961 DT O
clinical BC2GM091775961 JJ O
state BC2GM091775961 NN O
of BC2GM091775961 IN O
these BC2GM091775961 DT O
patients BC2GM091775961 NNS O
, BC2GM091775961 , O
as BC2GM091775961 RB O
well BC2GM091775961 RB O
as BC2GM091775961 IN O
reappearance BC2GM091775961 NN O
of BC2GM091775961 IN O
normal BC2GM091775961 JJ O
values BC2GM091775961 NNS O
of BC2GM091775961 IN O
blood BC2GM091775961 NN O
picture BC2GM091775961 NN O
and BC2GM091775961 CC O
biochemical BC2GM091775961 JJ O
parameters BC2GM091775961 NNS O
. BC2GM091775961 . O
. . O O

The BC2GM018214365 DT O
initial BC2GM018214365 JJ O
oral BC2GM018214365 JJ O
administration BC2GM018214365 NN O
of BC2GM018214365 IN O
the BC2GM018214365 DT O
1 BC2GM018214365 CD O
and BC2GM018214365 CC O
2 BC2GM018214365 CD O
mg BC2GM018214365 NN O
/ BC2GM018214365 NNP O
kg BC2GM018214365 NN O
doses BC2GM018214365 NNS O
of BC2GM018214365 IN O
enoximone BC2GM018214365 NN O
improved BC2GM018214365 JJ O
central BC2GM018214365 JJ O
hemodynamic BC2GM018214365 JJ O
parameters BC2GM018214365 NNS O
with BC2GM018214365 IN O
apparent BC2GM018214365 JJ O
preferential BC2GM018214365 JJ O
reduction BC2GM018214365 NN O
of BC2GM018214365 IN O
limb BC2GM018214365 NN O
vascular BC2GM018214365 JJ O
resistance BC2GM018214365 NN O
and BC2GM018214365 CC O
augmentation BC2GM018214365 NN O
of BC2GM018214365 IN O
blood BC2GM018214365 NN O
flow BC2GM018214365 NN O
to BC2GM018214365 TO O
the BC2GM018214365 DT O
limb BC2GM018214365 NN O
region BC2GM018214365 NN O
( BC2GM018214365 ( O
peripheral BC2GM018214365 JJ O
musculoskeletal BC2GM018214365 NN O
system BC2GM018214365 NN O
) BC2GM018214365 ) O
. BC2GM018214365 . O
. . O O

Taken BC2GM058781724 VBN O
together BC2GM058781724 RB O
, BC2GM058781724 , O
these BC2GM058781724 DT O
findings BC2GM058781724 NNS O
demonstrate BC2GM058781724 VBP O
that BC2GM058781724 IN O
ZNF76 BC2GM058781724 NNP O
and BC2GM058781724 CC O
ZNF143 BC2GM058781724 NNP O
are BC2GM058781724 VBP O
two BC2GM058781724 CD O
members BC2GM058781724 NNS O
of BC2GM058781724 IN O
a BC2GM058781724 DT O
same BC2GM058781724 JJ O
family BC2GM058781724 NN O
of BC2GM058781724 IN O
transactivator BC2GM058781724 NN O
proteins BC2GM058781724 NNS O
. BC2GM058781724 . O
. . O O

RESULTS BC2GM012328015 NN O
: BC2GM012328015 : O
Twenty-two BC2GM012328015 JJ O
patients BC2GM012328015 NNS O
( BC2GM012328015 ( O
30 BC2GM012328015 CD O
% BC2GM012328015 NN O
) BC2GM012328015 ) O
showed BC2GM012328015 VBD O
ST-segment BC2GM012328015 JJ O
depression BC2GM012328015 NN O
during BC2GM012328015 IN O
AEM BC2GM012328015 NNP O
and BC2GM012328015 CC O
34 BC2GM012328015 CD O
( BC2GM012328015 ( O
49 BC2GM012328015 CD O
% BC2GM012328015 NN O
) BC2GM012328015 ) O
on BC2GM012328015 IN O
ExT BC2GM012328015 NNP O
. BC2GM012328015 . O
. . O O

The BC2GM066509312 DT O
extent BC2GM066509312 NN O
of BC2GM066509312 IN O
the BC2GM066509312 DT O
odontoblast BC2GM066509312 JJ O
process BC2GM066509312 NN O
in BC2GM066509312 IN O
human BC2GM066509312 JJ O
dentin BC2GM066509312 NN O
. BC2GM066509312 . O
. . O O

Like BC2GM078763746 IN O
the BC2GM078763746 DT O
DMA BC2GM078763746 NNP O
, BC2GM078763746 , O
but BC2GM078763746 CC O
unlike BC2GM078763746 IN O
all BC2GM078763746 DT O
other BC2GM078763746 JJ O
mammalian BC2GM078763746 JJ O
class BC2GM078763746 NN O
II BC2GM078763746 NNP O
A BC2GM078763746 NNP O
genes BC2GM078763746 NNS O
, BC2GM078763746 , O
the BC2GM078763746 DT O
zebrafish BC2GM078763746 JJ O
gene BC2GM078763746 NN O
codes BC2GM078763746 NNS O
for BC2GM078763746 IN O
two BC2GM078763746 CD O
cysteine BC2GM078763746 NN O
residues BC2GM078763746 NNS O
which BC2GM078763746 WDT O
might BC2GM078763746 MD O
potentially BC2GM078763746 RB O
be BC2GM078763746 VB O
involved BC2GM078763746 VBN O
in BC2GM078763746 IN O
the BC2GM078763746 DT O
formation BC2GM078763746 NN O
of BC2GM078763746 IN O
a BC2GM078763746 DT O
disulfide BC2GM078763746 JJ O
bond BC2GM078763746 NN O
in BC2GM078763746 IN O
the BC2GM078763746 DT O
alpha BC2GM078763746 NN O
1 BC2GM078763746 CD O
domain BC2GM078763746 NN O
. BC2GM078763746 . O
. . O O

Toward BC2GM097629610 IN O
this BC2GM097629610 DT O
end BC2GM097629610 NN O
, BC2GM097629610 , O
we BC2GM097629610 PRP O
used BC2GM097629610 VBD O
two BC2GM097629610 CD O
cultured BC2GM097629610 JJ O
colon BC2GM097629610 NN O
cancer BC2GM097629610 NN O
cell BC2GM097629610 NN O
lines BC2GM097629610 NNS O
; BC2GM097629610 : O
one BC2GM097629610 CD O
( BC2GM097629610 ( O
RKO BC2GM097629610 NNP O
) BC2GM097629610 ) O
has BC2GM097629610 VBZ O
a BC2GM097629610 DT O
transcriptionally BC2GM097629610 RB O
activated BC2GM097629610 VBN O
u-PAR BC2GM097629610 JJ O
gene BC2GM097629610 NN O
, BC2GM097629610 , O
and BC2GM097629610 CC O
the BC2GM097629610 DT O
other BC2GM097629610 JJ O
( BC2GM097629610 ( O
GEO BC2GM097629610 NNP O
) BC2GM097629610 ) O
overexpresses BC2GM097629610 VBZ O
the BC2GM097629610 DT O
receptor BC2GM097629610 NN O
only BC2GM097629610 RB O
after BC2GM097629610 IN O
phorbol BC2GM097629610 NN O
ester BC2GM097629610 NN O
treatment BC2GM097629610 NN O
. BC2GM097629610 . O
. . O O

Effectively BC2GM065939725 RB O
, BC2GM065939725 , O
the BC2GM065939725 DT O
upstream BC2GM065939725 JJ O
, BC2GM065939725 , O
housekeeping-type BC2GM065939725 JJ O
promoter BC2GM065939725 NN O
responds BC2GM065939725 NNS O
to BC2GM065939725 TO O
FIXK BC2GM065939725 NNP O
and BC2GM065939725 CC O
positively BC2GM065939725 RB O
regulates BC2GM065939725 VBZ O
the BC2GM065939725 DT O
downstream BC2GM065939725 NN O
, BC2GM065939725 , O
sigma BC2GM065939725 JJ O
54-type BC2GM065939725 JJ O
promoter BC2GM065939725 NN O
. BC2GM065939725 . O
. . O O

Herewith BC2GM034072679 NNP O
C. BC2GM034072679 NNP O
psittaci BC2GM034072679 NN O
could BC2GM034072679 MD O
be BC2GM034072679 VB O
diagnosed BC2GM034072679 VBN O
in BC2GM034072679 IN O
all BC2GM034072679 DT O
positive BC2GM034072679 JJ O
samples BC2GM034072679 NNS O
. BC2GM034072679 . O
. . O O

The BC2GM092277877 DT O
architecture BC2GM092277877 NN O
of BC2GM092277877 IN O
the BC2GM092277877 DT O
hRap1 BC2GM092277877 NN O
Myb BC2GM092277877 NNP O
domain BC2GM092277877 NN O
is BC2GM092277877 VBZ O
very BC2GM092277877 RB O
close BC2GM092277877 RB O
to BC2GM092277877 TO O
that BC2GM092277877 DT O
of BC2GM092277877 IN O
each BC2GM092277877 DT O
of BC2GM092277877 IN O
the BC2GM092277877 DT O
Myb BC2GM092277877 NNP O
domains BC2GM092277877 NNS O
from BC2GM092277877 IN O
TRF1 BC2GM092277877 NNP O
, BC2GM092277877 , O
scRap1p BC2GM092277877 NN O
and BC2GM092277877 CC O
c-Myb BC2GM092277877 NN O
. BC2GM092277877 . O
. . O O

Being BC2GM081412271 VBG O
implicated BC2GM081412271 VBN O
in BC2GM081412271 IN O
insulin BC2GM081412271 NN O
and BC2GM081412271 CC O
GK BC2GM081412271 NNP O
gene BC2GM081412271 NN O
regulations BC2GM081412271 NNS O
as BC2GM081412271 IN O
a BC2GM081412271 DT O
common BC2GM081412271 JJ O
transcription BC2GM081412271 NN O
factor BC2GM081412271 NN O
, BC2GM081412271 , O
IPF1 BC2GM081412271 NNP O
/ BC2GM081412271 NNP O
STF-1 BC2GM081412271 NNP O
/ BC2GM081412271 NNP O
PDX-1 BC2GM081412271 NNP O
is BC2GM081412271 VBZ O
likely BC2GM081412271 JJ O
to BC2GM081412271 TO O
play BC2GM081412271 VB O
an BC2GM081412271 DT O
essential BC2GM081412271 JJ O
role BC2GM081412271 NN O
in BC2GM081412271 IN O
maintaining BC2GM081412271 VBG O
normal BC2GM081412271 JJ O
beta-cell BC2GM081412271 JJ O
functions BC2GM081412271 NNS O
. BC2GM081412271 . O
. . O O

Using BC2GM013271145 VBG O
reporter BC2GM013271145 NN O
gene BC2GM013271145 NN O
constructs BC2GM013271145 NNS O
driven BC2GM013271145 VBN O
by BC2GM013271145 IN O
the BC2GM013271145 DT O
CD4 BC2GM013271145 NNP O
promoter BC2GM013271145 NN O
, BC2GM013271145 , O
we BC2GM013271145 PRP O
report BC2GM013271145 VBP O
that BC2GM013271145 IN O
HHV-6 BC2GM013271145 NNP O
can BC2GM013271145 MD O
efficiently BC2GM013271145 RB O
transactivate BC2GM013271145 VB O
such BC2GM013271145 JJ O
genetic BC2GM013271145 JJ O
elements BC2GM013271145 NNS O
. BC2GM013271145 . O
. . O O

Studies BC2GM016763749 NNS O
in BC2GM016763749 IN O
B. BC2GM016763749 NNP O
glabrata BC2GM016763749 NN O
, BC2GM016763749 , O
B. BC2GM016763749 NNP O
straminea BC2GM016763749 NN O
and BC2GM016763749 CC O
B. BC2GM016763749 NNP O
tenagophila BC2GM016763749 NN O
under BC2GM016763749 IN O
outdoor BC2GM016763749 JJ O
conditions BC2GM016763749 NNS O
. BC2GM016763749 . O
. . O O

We BC2GM087148691 PRP O
have BC2GM087148691 VBP O
measured BC2GM087148691 VBN O
percentage BC2GM087148691 NN O
O3 BC2GM087148691 NNP O
uptake BC2GM087148691 NN O
in BC2GM087148691 IN O
30 BC2GM087148691 CD O
adult BC2GM087148691 NN O
Sprague-Dawley BC2GM087148691 NNP O
rats BC2GM087148691 NNS O
exposed BC2GM087148691 VBD O
, BC2GM087148691 , O
nose BC2GM087148691 JJ O
only BC2GM087148691 RB O
, BC2GM087148691 , O
for BC2GM087148691 IN O
1 BC2GM087148691 CD O
hr BC2GM087148691 NN O
to BC2GM087148691 TO O
0.3 BC2GM087148691 CD O
, BC2GM087148691 , O
0.6 BC2GM087148691 CD O
, BC2GM087148691 , O
or BC2GM087148691 CC O
1.0 BC2GM087148691 CD O
ppm BC2GM087148691 JJ O
O3 BC2GM087148691 NNP O
. BC2GM087148691 . O
. . O O

Enzymatic BC2GM022592779 JJ O
and BC2GM022592779 CC O
chemical BC2GM022592779 JJ O
structure BC2GM022592779 NN O
probing BC2GM022592779 VBG O
revealed BC2GM022592779 VBN O
mainly BC2GM022592779 RB O
the BC2GM022592779 DT O
conserved BC2GM022592779 VBN O
terminal BC2GM022592779 JJ O
part BC2GM022592779 NN O
( BC2GM022592779 ( O
termed BC2GM022592779 JJ O
3'C BC2GM022592779 CD O
) BC2GM022592779 ) O
of BC2GM022592779 IN O
the BC2GM022592779 DT O
DI9c BC2GM022592779 NNP O
3 BC2GM022592779 CD O
' BC2GM022592779 '' O
UTR BC2GM022592779 NNP O
containing BC2GM022592779 VBG O
distinctive BC2GM022592779 JJ O
RNA BC2GM022592779 NNP O
motifs BC2GM022592779 NN O
, BC2GM022592779 , O
i.e. BC2GM022592779 FW O
, BC2GM022592779 , O
a BC2GM022592779 DT O
stable BC2GM022592779 JJ O
stem-loop BC2GM022592779 NN O
, BC2GM022592779 , O
SL BC2GM022592779 NNP O
I BC2GM022592779 PRP O
, BC2GM022592779 , O
near BC2GM022592779 IN O
the BC2GM022592779 DT O
RNA BC2GM022592779 NNP O
3 BC2GM022592779 CD O
' BC2GM022592779 '' O
terminus BC2GM022592779 NN O
and BC2GM022592779 CC O
a BC2GM022592779 DT O
considerably BC2GM022592779 RB O
less BC2GM022592779 RBR O
stable BC2GM022592779 JJ O
stem-loop BC2GM022592779 NN O
, BC2GM022592779 , O
SL BC2GM022592779 NNP O
II BC2GM022592779 NNP O
, BC2GM022592779 , O
that BC2GM022592779 WDT O
forms BC2GM022592779 VBZ O
the BC2GM022592779 DT O
5 BC2GM022592779 CD O
' BC2GM022592779 POS O
portion BC2GM022592779 NN O
of BC2GM022592779 IN O
3'C BC2GM022592779 CD O
. BC2GM022592779 . O
. . O O

Our BC2GM013625410 PRP$ O
previous BC2GM013625410 JJ O
studies BC2GM013625410 NNS O
demonstrated BC2GM013625410 VBD O
that BC2GM013625410 IN O
the BC2GM013625410 DT O
promyelocytic BC2GM013625410 JJ O
leukemia BC2GM013625410 NN O
gene BC2GM013625410 NN O
, BC2GM013625410 , O
PML BC2GM013625410 NNP O
which BC2GM013625410 WDT O
involved BC2GM013625410 VBD O
in BC2GM013625410 IN O
the BC2GM013625410 DT O
15 BC2GM013625410 CD O
; BC2GM013625410 : O
17 BC2GM013625410 CD O
translocation BC2GM013625410 NN O
in BC2GM013625410 IN O
acute BC2GM013625410 JJ O
promyelocytic BC2GM013625410 JJ O
leukemia BC2GM013625410 NN O
( BC2GM013625410 ( O
APL BC2GM013625410 NNP O
) BC2GM013625410 ) O
is BC2GM013625410 VBZ O
a BC2GM013625410 DT O
growth BC2GM013625410 NN O
and BC2GM013625410 CC O
transformation BC2GM013625410 NN O
suppressor BC2GM013625410 NN O
. BC2GM013625410 . O
. . O O

Recent BC2GM022818569 JJ O
, BC2GM022818569 , O
highly BC2GM022818569 RB O
visible BC2GM022818569 JJ O
reviews BC2GM022818569 NNS O
on BC2GM022818569 IN O
the BC2GM022818569 DT O
subject BC2GM022818569 NN O
have BC2GM022818569 VBP O
clearly BC2GM022818569 RB O
pointed BC2GM022818569 VBN O
out BC2GM022818569 RP O
that BC2GM022818569 DT O
little BC2GM022818569 JJ O
is BC2GM022818569 VBZ O
known BC2GM022818569 VBN O
about BC2GM022818569 IN O
the BC2GM022818569 DT O
cellular BC2GM022818569 JJ O
mechanisms BC2GM022818569 NNS O
through BC2GM022818569 IN O
which BC2GM022818569 WDT O
inhaled BC2GM022818569 VBD O
asbestos BC2GM022818569 NN O
fibers BC2GM022818569 NNS O
cause BC2GM022818569 VBP O
the BC2GM022818569 DT O
well BC2GM022818569 NN O
known BC2GM022818569 VBN O
, BC2GM022818569 , O
debilitating BC2GM022818569 VBG O
lung BC2GM022818569 NN O
disease BC2GM022818569 NN O
- BC2GM022818569 : O
asbestosis BC2GM022818569 NN O
( BC2GM022818569 ( O
i.e BC2GM022818569 NN O
. BC2GM022818569 . O
interstitial BC2GM022818569 JJ O
pulmonary BC2GM022818569 JJ O
fibrosis BC2GM022818569 NN O
) BC2GM022818569 ) O
. BC2GM022818569 . O
. . O O

In BC2GM005711983 IN O
bell BC2GM005711983 NN O
pepper BC2GM005711983 NN O
, BC2GM005711983 , O
a BC2GM005711983 DT O
gene BC2GM005711983 NN O
encoding BC2GM005711983 VBG O
a BC2GM005711983 DT O
major BC2GM005711983 JJ O
plastid-lipid BC2GM005711983 JJ O
associated BC2GM005711983 VBN O
protein BC2GM005711983 NN O
is BC2GM005711983 VBZ O
expressed BC2GM005711983 VBN O
as BC2GM005711983 IN O
both BC2GM005711983 DT O
partially BC2GM005711983 RB O
and BC2GM005711983 CC O
totally BC2GM005711983 RB O
spliced BC2GM005711983 JJ O
transcripts BC2GM005711983 NNS O
( BC2GM005711983 ( O
respectively BC2GM005711983 RB O
PAP2 BC2GM005711983 NNP O
and BC2GM005711983 CC O
PAP1 BC2GM005711983 NNP O
) BC2GM005711983 ) O
. BC2GM005711983 . O
. . O O

Heterodimerization BC2GM010669638 NNP O
mutant BC2GM010669638 JJ O
RXR BC2GM010669638 NNP O
failed BC2GM010669638 VBD O
to BC2GM010669638 TO O
alter BC2GM010669638 VB O
GFP-VDR BC2GM010669638 NNP O
and BC2GM010669638 CC O
nlsGFP-VDR BC2GM010669638 JJ O
distribution BC2GM010669638 NN O
or BC2GM010669638 CC O
activity BC2GM010669638 NN O
. BC2GM010669638 . O
. . O O

The BC2GM099940943 DT O
goal BC2GM099940943 NN O
of BC2GM099940943 IN O
our BC2GM099940943 PRP$ O
work BC2GM099940943 NN O
was BC2GM099940943 VBD O
to BC2GM099940943 TO O
determine BC2GM099940943 VB O
hearing BC2GM099940943 VBG O
thresholds BC2GM099940943 NNS O
in BC2GM099940943 IN O
patients BC2GM099940943 NNS O
with BC2GM099940943 IN O
hearing BC2GM099940943 JJ O
impairment BC2GM099940943 NN O
due BC2GM099940943 JJ O
to BC2GM099940943 TO O
hereditary BC2GM099940943 JJ O
motor BC2GM099940943 NN O
and BC2GM099940943 CC O
sensory BC2GM099940943 JJ O
neuropathy BC2GM099940943 NN O
( BC2GM099940943 ( O
HMSN BC2GM099940943 NNP O
I BC2GM099940943 PRP O
) BC2GM099940943 ) O
. BC2GM099940943 . O
. . O O

In BC2GM083405439 IN O
spite BC2GM083405439 NN O
of BC2GM083405439 IN O
the BC2GM083405439 DT O
presence BC2GM083405439 NN O
of BC2GM083405439 IN O
a BC2GM083405439 DT O
physician BC2GM083405439 NN O
, BC2GM083405439 , O
the BC2GM083405439 DT O
real BC2GM083405439 JJ O
pathology BC2GM083405439 NN O
of BC2GM083405439 IN O
an BC2GM083405439 DT O
indian BC2GM083405439 JJ O
population BC2GM083405439 NN O
of BC2GM083405439 IN O
Colombie BC2GM083405439 NNP O
is BC2GM083405439 VBZ O
not BC2GM083405439 RB O
very BC2GM083405439 RB O
well BC2GM083405439 RB O
known BC2GM083405439 VBN O
. BC2GM083405439 . O
. . O O

Additional BC2GM051379224 JJ O
simulations BC2GM051379224 NNS O
account BC2GM051379224 VBP O
for BC2GM051379224 IN O
interactions BC2GM051379224 NNS O
of BC2GM051379224 IN O
spatial BC2GM051379224 JJ O
frequency BC2GM051379224 NN O
with BC2GM051379224 IN O
stimulus BC2GM051379224 JJ O
duration BC2GM051379224 NN O
, BC2GM051379224 , O
effects BC2GM051379224 NNS O
of BC2GM051379224 IN O
adaptation BC2GM051379224 NN O
, BC2GM051379224 , O
and BC2GM051379224 CC O
properties BC2GM051379224 NNS O
of BC2GM051379224 IN O
residual BC2GM051379224 JJ O
traces BC2GM051379224 NNS O
, BC2GM051379224 , O
as BC2GM051379224 IN O
opposed BC2GM051379224 VBN O
to BC2GM051379224 TO O
visual BC2GM051379224 JJ O
persistence BC2GM051379224 NN O
. BC2GM051379224 . O
. . O O

Since BC2GM043598116 IN O
nearly BC2GM043598116 RB O
all BC2GM043598116 DT O
transformants BC2GM043598116 NNS O
involving BC2GM043598116 VBG O
homeologous BC2GM043598116 JJ O
DNAs BC2GM043598116 NNP O
carried BC2GM043598116 VBD O
a BC2GM043598116 DT O
single BC2GM043598116 JJ O
recombinant BC2GM043598116 NN O
plasmid BC2GM043598116 NN O
in BC2GM043598116 IN O
both BC2GM043598116 DT O
Pms+ BC2GM043598116 NNP O
and BC2GM043598116 CC O
Pms- BC2GM043598116 NNP O
strains BC2GM043598116 NNS O
, BC2GM043598116 , O
stable BC2GM043598116 JJ O
heteroduplex BC2GM043598116 NN O
DNA BC2GM043598116 NNP O
appears BC2GM043598116 VBZ O
less BC2GM043598116 RBR O
likely BC2GM043598116 JJ O
than BC2GM043598116 IN O
for BC2GM043598116 IN O
homologous BC2GM043598116 JJ O
DNAs BC2GM043598116 NNP O
. BC2GM043598116 . O
. . O O

Mutational BC2GM045048834 JJ O
analysis BC2GM045048834 NN O
of BC2GM045048834 IN O
yeast BC2GM045048834 NN O
CEG1 BC2GM045048834 NNP O
demonstrated BC2GM045048834 VBD O
that BC2GM045048834 IN O
four BC2GM045048834 CD O
of BC2GM045048834 IN O
the BC2GM045048834 DT O
five BC2GM045048834 CD O
conserved BC2GM045048834 VBN O
motifs BC2GM045048834 NNS O
are BC2GM045048834 VBP O
essential BC2GM045048834 JJ O
for BC2GM045048834 IN O
capping BC2GM045048834 VBG O
enzyme BC2GM045048834 JJ O
function BC2GM045048834 NN O
in BC2GM045048834 IN O
vivo BC2GM045048834 NN O
. BC2GM045048834 . O
. . O O

Our BC2GM005593098 PRP$ O
results BC2GM005593098 NNS O
suggest BC2GM005593098 VBP O
a BC2GM005593098 DT O
biological BC2GM005593098 JJ O
role BC2GM005593098 NN O
for BC2GM005593098 IN O
Elf-1 BC2GM005593098 NNP O
in BC2GM005593098 IN O
the BC2GM005593098 DT O
regulation BC2GM005593098 NN O
of BC2GM005593098 IN O
IgH BC2GM005593098 NNP O
gene BC2GM005593098 NN O
expression BC2GM005593098 NN O
, BC2GM005593098 , O
attribute BC2GM005593098 VB O
a BC2GM005593098 DT O
functional BC2GM005593098 JJ O
role BC2GM005593098 NN O
for BC2GM005593098 IN O
receptor-induced BC2GM005593098 JJ O
AP-1 BC2GM005593098 JJ O
proteins BC2GM005593098 NNS O
in BC2GM005593098 IN O
B BC2GM005593098 NNP O
lymphocytes BC2GM005593098 NNS O
and BC2GM005593098 CC O
provide BC2GM005593098 VB O
evidence BC2GM005593098 NN O
for BC2GM005593098 IN O
a BC2GM005593098 DT O
direct BC2GM005593098 JJ O
link BC2GM005593098 NN O
between BC2GM005593098 IN O
IgM BC2GM005593098 NNP O
receptor-mediated BC2GM005593098 JJ O
signalling BC2GM005593098 NN O
and BC2GM005593098 CC O
3 BC2GM005593098 CD O
' BC2GM005593098 '' O
enhancer BC2GM005593098 NN O
activation BC2GM005593098 NN O
. BC2GM005593098 . O
. . O O

The BC2GM079896671 DT O
entire BC2GM079896671 JJ O
coding BC2GM079896671 NN O
region BC2GM079896671 NN O
of BC2GM079896671 IN O
an BC2GM079896671 DT O
ovine BC2GM079896671 JJ O
endometrial BC2GM079896671 JJ O
oxytocin BC2GM079896671 NN O
receptor BC2GM079896671 NN O
( BC2GM079896671 ( O
OTR BC2GM079896671 NNP O
) BC2GM079896671 ) O
cDNA BC2GM079896671 NN O
was BC2GM079896671 VBD O
generated BC2GM079896671 VBN O
by BC2GM079896671 IN O
PCR BC2GM079896671 NNP O
, BC2GM079896671 , O
subcloned BC2GM079896671 VBD O
into BC2GM079896671 IN O
the BC2GM079896671 DT O
SV40 BC2GM079896671 NNP O
major BC2GM079896671 JJ O
late BC2GM079896671 RB O
promoter BC2GM079896671 NN O
expression BC2GM079896671 NN O
vector BC2GM079896671 NN O
pSVLJ BC2GM079896671 NN O
and BC2GM079896671 CC O
transiently BC2GM079896671 RB O
expressed BC2GM079896671 VBN O
in BC2GM079896671 IN O
Cos-7 BC2GM079896671 NNP O
cells BC2GM079896671 NNS O
. BC2GM079896671 . O
. . O O

Identification BC2GM046385397 NN O
of BC2GM046385397 IN O
a BC2GM046385397 DT O
putative BC2GM046385397 JJ O
infC-rpmI-rplT BC2GM046385397 JJ O
operon BC2GM046385397 NN O
flanked BC2GM046385397 VBN O
by BC2GM046385397 IN O
long BC2GM046385397 RB O
inverted BC2GM046385397 JJ O
repeats BC2GM046385397 NNS O
in BC2GM046385397 IN O
Mycoplasma BC2GM046385397 NNP O
fermentans BC2GM046385397 NNS O
( BC2GM046385397 ( O
incognitus BC2GM046385397 VB O
strain BC2GM046385397 NN O
) BC2GM046385397 ) O
. BC2GM046385397 . O
. . O O

When BC2GM030304217 WRB O
incubated BC2GM030304217 VBN O
with BC2GM030304217 IN O
infective BC2GM030304217 JJ O
larvae BC2GM030304217 NN O
which BC2GM030304217 WDT O
had BC2GM030304217 VBD O
penetrated BC2GM030304217 VBN O
mouse BC2GM030304217 NN O
skin BC2GM030304217 NN O
, BC2GM030304217 , O
both BC2GM030304217 DT O
normal BC2GM030304217 JJ O
and BC2GM030304217 CC O
immune BC2GM030304217 JJ O
cells BC2GM030304217 NNS O
attached BC2GM030304217 VBN O
to BC2GM030304217 TO O
larvae BC2GM030304217 VB O
in BC2GM030304217 IN O
the BC2GM030304217 DT O
absence BC2GM030304217 NN O
of BC2GM030304217 IN O
serum BC2GM030304217 NN O
. BC2GM030304217 . O
. . O O

The BC2GM039797757 DT O
deviation BC2GM039797757 NN O
site BC2GM039797757 NN O
is BC2GM039797757 VBZ O
equivalent BC2GM039797757 JJ O
to BC2GM039797757 TO O
the BC2GM039797757 DT O
exon BC2GM039797757 NN O
1 BC2GM039797757 CD O
/ BC2GM039797757 NNP O
exon BC2GM039797757 VBD O
2 BC2GM039797757 CD O
splice BC2GM039797757 NN O
site BC2GM039797757 NN O
of BC2GM039797757 IN O
the BC2GM039797757 DT O
mouse BC2GM039797757 NN O
C-subunit BC2GM039797757 NNP O
. BC2GM039797757 . O
. . O O

Southern BC2GM033846356 JJ O
hybridization BC2GM033846356 NN O
of BC2GM033846356 IN O
genomic BC2GM033846356 JJ O
DNA BC2GM033846356 NN O
from BC2GM033846356 IN O
WT BC2GM033846356 NNP O
and BC2GM033846356 CC O
Lp BC2GM033846356 NNP O
/ BC2GM033846356 NNP O
Lp BC2GM033846356 NNP O
embryos BC2GM033846356 NN O
failed BC2GM033846356 VBD O
to BC2GM033846356 TO O
identify BC2GM033846356 VB O
specific BC2GM033846356 JJ O
rearrangements BC2GM033846356 NNS O
at BC2GM033846356 IN O
or BC2GM033846356 CC O
near BC2GM033846356 IN O
the BC2GM033846356 DT O
Nhlh1 BC2GM033846356 NNP O
locus BC2GM033846356 NN O
, BC2GM033846356 , O
and BC2GM033846356 CC O
Northern BC2GM033846356 NNP O
RNA BC2GM033846356 NNP O
blotting BC2GM033846356 NN O
and BC2GM033846356 CC O
RT-PCR BC2GM033846356 JJ O
evaluation BC2GM033846356 NN O
of BC2GM033846356 IN O
Nhlh1 BC2GM033846356 NNP O
mRNA BC2GM033846356 NNP O
expression BC2GM033846356 NN O
indicated BC2GM033846356 VBD O
that BC2GM033846356 IN O
both BC2GM033846356 DT O
the BC2GM033846356 DT O
levels BC2GM033846356 NNS O
and BC2GM033846356 CC O
types BC2GM033846356 NNS O
of BC2GM033846356 IN O
Nhlh1 BC2GM033846356 NNP O
mRNAs BC2GM033846356 NN O
produced BC2GM033846356 VBN O
in BC2GM033846356 IN O
WT BC2GM033846356 NNP O
and BC2GM033846356 CC O
Lp BC2GM033846356 NNP O
/ BC2GM033846356 NNP O
Lp BC2GM033846356 NNP O
embryos BC2GM033846356 NN O
were BC2GM033846356 VBD O
indistinguishable BC2GM033846356 JJ O
. BC2GM033846356 . O
. . O O

Likewise BC2GM022584300 RB O
, BC2GM022584300 , O
the BC2GM022584300 DT O
consensus BC2GM022584300 NN O
signal BC2GM022584300 NN O
believed BC2GM022584300 VBN O
to BC2GM022584300 TO O
be BC2GM022584300 VB O
involved BC2GM022584300 VBN O
in BC2GM022584300 IN O
terminating BC2GM022584300 VBG O
VV BC2GM022584300 NNP O
early BC2GM022584300 JJ O
gene BC2GM022584300 NN O
transcription BC2GM022584300 NN O
, BC2GM022584300 , O
TTTTTNT BC2GM022584300 NNP O
, BC2GM022584300 , O
was BC2GM022584300 VBD O
evident BC2GM022584300 JJ O
at BC2GM022584300 IN O
the BC2GM022584300 DT O
3'-boundary BC2GM022584300 JJ O
of BC2GM022584300 IN O
both BC2GM022584300 DT O
the BC2GM022584300 DT O
N2 BC2GM022584300 NNP O
and BC2GM022584300 CC O
M1 BC2GM022584300 NNP O
ORFs BC2GM022584300 NNP O
suggesting BC2GM022584300 VBG O
that BC2GM022584300 IN O
these BC2GM022584300 DT O
genes BC2GM022584300 NNS O
may BC2GM022584300 MD O
be BC2GM022584300 VB O
VV BC2GM022584300 NNP O
early BC2GM022584300 JJ O
genes BC2GM022584300 NNS O
. BC2GM022584300 . O
. . O O

Iris BC2GM006980122 NNP O
binding BC2GM006980122 NN O
and BC2GM006980122 CC O
bioavailability BC2GM006980122 NN O
. BC2GM006980122 . O
. . O O

The BC2GM050874939 DT O
fecal BC2GM050874939 JJ O
excretion BC2GM050874939 NN O
is BC2GM050874939 VBZ O
found BC2GM050874939 VBN O
to BC2GM050874939 TO O
be BC2GM050874939 VB O
only BC2GM050874939 RB O
one BC2GM050874939 CD O
third BC2GM050874939 NN O
of BC2GM050874939 IN O
that BC2GM050874939 DT O
measured BC2GM050874939 VBN O
in BC2GM050874939 IN O
urine BC2GM050874939 NN O
. BC2GM050874939 . O
. . O O

Soluble BC2GM065349890 JJ O
fibrin BC2GM065349890 JJ O
monomer BC2GM065349890 NN O
complexes BC2GM065349890 NNS O
in BC2GM065349890 IN O
thromboembolism BC2GM065349890 NN O
. BC2GM065349890 . O
. . O O

Anisotropy BC2GM030261099 NNP O
of BC2GM030261099 IN O
Hc2 BC2GM030261099 NNP O
and BC2GM030261099 CC O
the BC2GM030261099 DT O
breadth BC2GM030261099 NN O
of BC2GM030261099 IN O
the BC2GM030261099 DT O
resistive BC2GM030261099 JJ O
transition BC2GM030261099 NN O
of BC2GM030261099 IN O
polycrystalline BC2GM030261099 NN O
YBa2Cu BC2GM030261099 NNP O
. BC2GM030261099 . O
. . O O

Leukocytoclasic BC2GM006571611 JJ O
vasculitis BC2GM006571611 NN O
during BC2GM006571611 IN O
treatment BC2GM006571611 NN O
with BC2GM006571611 IN O
low-dose BC2GM006571611 JJ O
captopril BC2GM006571611 NN O
. BC2GM006571611 . O
. . O O

The BC2GM071199911 DT O
hyperpigmentation BC2GM071199911 NN O
is BC2GM071199911 VBZ O
linked BC2GM071199911 VBN O
to BC2GM071199911 TO O
the BC2GM071199911 DT O
presence BC2GM071199911 NN O
of BC2GM071199911 IN O
numerous BC2GM071199911 JJ O
single BC2GM071199911 JJ O
melanosomes BC2GM071199911 NNS O
and BC2GM071199911 CC O
polymelanosomes BC2GM071199911 NNS O
in BC2GM071199911 IN O
keratinocytes BC2GM071199911 NNS O
at BC2GM071199911 IN O
all BC2GM071199911 DT O
levels BC2GM071199911 NNS O
of BC2GM071199911 IN O
the BC2GM071199911 DT O
epidermis BC2GM071199911 NN O
, BC2GM071199911 , O
and BC2GM071199911 CC O
in BC2GM071199911 IN O
dermal BC2GM071199911 JJ O
Factor BC2GM071199911 NNP O
XIIIa-positive BC2GM071199911 JJ O
dendrocytes BC2GM071199911 NNS O
. BC2GM071199911 . O
. . O O

PATIENT BC2GM098476170 NNP O
( BC2GM098476170 ( O
S BC2GM098476170 NNP O
) BC2GM098476170 ) O
: BC2GM098476170 : O
Two BC2GM098476170 CD O
hundred BC2GM098476170 VBD O
thirty-eight BC2GM098476170 JJ O
patients BC2GM098476170 NNS O
with BC2GM098476170 IN O
RPLs BC2GM098476170 NNP O
, BC2GM098476170 , O
48 BC2GM098476170 CD O
patients BC2GM098476170 NNS O
with BC2GM098476170 IN O
recurrent BC2GM098476170 JJ O
IVF-ET BC2GM098476170 JJ O
failure BC2GM098476170 NN O
and BC2GM098476170 CC O
179 BC2GM098476170 CD O
nonpregnant BC2GM098476170 NN O
and BC2GM098476170 CC O
120 BC2GM098476170 CD O
pregnant BC2GM098476170 JJ O
control BC2GM098476170 NN O
group BC2GM098476170 NN O
women BC2GM098476170 NNS O
. BC2GM098476170 . O
. . O O

Levels BC2GM068389238 NNS O
of BC2GM068389238 IN O
p53 BC2GM068389238 NN O
were BC2GM068389238 VBD O
substantially BC2GM068389238 RB O
increased BC2GM068389238 VBN O
by BC2GM068389238 IN O
E1A BC2GM068389238 NNP O
expression BC2GM068389238 NN O
during BC2GM068389238 IN O
adenovirus BC2GM068389238 JJ O
infection BC2GM068389238 NN O
. BC2GM068389238 . O
. . O O

We BC2GM054437021 PRP O
conclude BC2GM054437021 VBP O
that BC2GM054437021 IN O
the BC2GM054437021 DT O
outcome BC2GM054437021 NN O
of BC2GM054437021 IN O
patients BC2GM054437021 NNS O
with BC2GM054437021 IN O
uterine BC2GM054437021 JJ O
MMMT BC2GM054437021 NNP O
is BC2GM054437021 VBZ O
mainly BC2GM054437021 RB O
influenced BC2GM054437021 VBN O
by BC2GM054437021 IN O
the BC2GM054437021 DT O
initial BC2GM054437021 JJ O
stage BC2GM054437021 NN O
and BC2GM054437021 CC O
the BC2GM054437021 DT O
type BC2GM054437021 NN O
of BC2GM054437021 IN O
epithelial BC2GM054437021 JJ O
component BC2GM054437021 NN O
. BC2GM054437021 . O
. . O O

Of BC2GM041916498 IN O
all BC2GM041916498 DT O
YASR BC2GM041916498 NNP O
syndromes BC2GM041916498 NNS O
, BC2GM041916498 , O
the BC2GM041916498 DT O
highest BC2GM041916498 JJS O
stability BC2GM041916498 NN O
was BC2GM041916498 VBD O
for BC2GM041916498 IN O
the BC2GM041916498 DT O
Anxious BC2GM041916498 NNP O
/ BC2GM041916498 NNP O
Depressed BC2GM041916498 VBD O
scale BC2GM041916498 NN O
. BC2GM041916498 . O
. . O O

The BC2GM041364730 DT O
newly BC2GM041364730 RB O
identified BC2GM041364730 VBN O
NF BC2GM041364730 NNP O
kappa BC2GM041364730 NN O
B BC2GM041364730 NNP O
enhancer BC2GM041364730 NN O
( BC2GM041364730 ( O
TGGAAATTCC BC2GM041364730 NNP O
) BC2GM041364730 ) O
is BC2GM041364730 VBZ O
bound BC2GM041364730 VBN O
by BC2GM041364730 IN O
a BC2GM041364730 DT O
TNF BC2GM041364730 NNP O
alpha-induced BC2GM041364730 JJ O
nuclear BC2GM041364730 JJ O
protein BC2GM041364730 NN O
and BC2GM041364730 CC O
appears BC2GM041364730 VBZ O
to BC2GM041364730 TO O
be BC2GM041364730 VB O
the BC2GM041364730 DT O
key BC2GM041364730 JJ O
element BC2GM041364730 NN O
in BC2GM041364730 IN O
rapid BC2GM041364730 JJ O
transcription BC2GM041364730 NN O
induction BC2GM041364730 NN O
by BC2GM041364730 IN O
TNF BC2GM041364730 NNP O
alpha BC2GM041364730 NN O
( BC2GM041364730 ( O
and BC2GM041364730 CC O
TPA BC2GM041364730 NNP O
) BC2GM041364730 ) O
, BC2GM041364730 , O
while BC2GM041364730 IN O
transactivation BC2GM041364730 NN O
of BC2GM041364730 IN O
this BC2GM041364730 DT O
element BC2GM041364730 NN O
is BC2GM041364730 VBZ O
repressed BC2GM041364730 VBN O
by BC2GM041364730 IN O
the BC2GM041364730 DT O
ligand-bound BC2GM041364730 JJ O
glucocorticoid BC2GM041364730 NN O
receptor BC2GM041364730 NN O
. BC2GM041364730 . O
. . O O

Genetic BC2GM015590289 JJ O
analyses BC2GM015590289 NNS O
indicate BC2GM015590289 VBP O
that BC2GM015590289 IN O
most BC2GM015590289 JJS O
of BC2GM015590289 IN O
the BC2GM015590289 DT O
dominant BC2GM015590289 JJ O
mutants BC2GM015590289 NNS O
are BC2GM015590289 VBP O
cis-acting BC2GM015590289 JJ O
and BC2GM015590289 CC O
that BC2GM015590289 IN O
the BC2GM015590289 DT O
recessive BC2GM015590289 JJ O
mutants BC2GM015590289 NNS O
define BC2GM015590289 VB O
a BC2GM015590289 DT O
minimum BC2GM015590289 NN O
of BC2GM015590289 IN O
three BC2GM015590289 CD O
complementation BC2GM015590289 NN O
groups BC2GM015590289 NNS O
, BC2GM015590289 , O
indicating BC2GM015590289 VBG O
that BC2GM015590289 DT O
defects BC2GM015590289 VBZ O
in BC2GM015590289 IN O
several BC2GM015590289 JJ O
different BC2GM015590289 JJ O
genes BC2GM015590289 NNS O
can BC2GM015590289 MD O
restore BC2GM015590289 VB O
higher BC2GM015590289 JJR O
levels BC2GM015590289 NNS O
of BC2GM015590289 IN O
HIS4C BC2GM015590289 NNP O
expression BC2GM015590289 NN O
. BC2GM015590289 . O
. . O O

CONCLUSIONS BC2GM029733938 NN O
: BC2GM029733938 : O
Neurodevelopmental BC2GM029733938 JJ O
assessment BC2GM029733938 NN O
at BC2GM029733938 IN O
1 BC2GM029733938 CD O
year BC2GM029733938 NN O
is BC2GM029733938 VBZ O
predictive BC2GM029733938 JJ O
of BC2GM029733938 IN O
school BC2GM029733938 NN O
performance BC2GM029733938 NN O
and BC2GM029733938 CC O
outcome BC2GM029733938 NN O
in BC2GM029733938 IN O
the BC2GM029733938 DT O
adolescent BC2GM029733938 JJ O
period BC2GM029733938 NN O
. BC2GM029733938 . O
. . O O

The BC2GM011948412 DT O
critical BC2GM011948412 JJ O
obstacle BC2GM011948412 NN O
in BC2GM011948412 IN O
modeling BC2GM011948412 VBG O
psychiatric BC2GM011948412 JJ O
disorders BC2GM011948412 NNS O
has BC2GM011948412 VBZ O
been BC2GM011948412 VBN O
limited BC2GM011948412 VBN O
information BC2GM011948412 NN O
about BC2GM011948412 IN O
their BC2GM011948412 PRP$ O
origin BC2GM011948412 NN O
and BC2GM011948412 CC O
underlying BC2GM011948412 JJ O
neural BC2GM011948412 JJ O
mechanisms BC2GM011948412 NNS O
. BC2GM011948412 . O
. . O O

A BC2GM062117187 DT O
model BC2GM062117187 NN O
for BC2GM062117187 IN O
the BC2GM062117187 DT O
SMase-sphingomyelin BC2GM062117187 NNP O
complex BC2GM062117187 JJ O
structure BC2GM062117187 NN O
was BC2GM062117187 VBD O
built BC2GM062117187 VBN O
to BC2GM062117187 TO O
investigate BC2GM062117187 VB O
how BC2GM062117187 WRB O
the BC2GM062117187 DT O
SMase BC2GM062117187 NNP O
specifically BC2GM062117187 RB O
recognizes BC2GM062117187 VBZ O
its BC2GM062117187 PRP$ O
substrate BC2GM062117187 NN O
. BC2GM062117187 . O
. . O O

Deletion BC2GM079948235 NN O
analysis BC2GM079948235 NN O
defines BC2GM079948235 NNS O
distinct BC2GM079948235 JJ O
functional BC2GM079948235 JJ O
domains BC2GM079948235 NNS O
for BC2GM079948235 IN O
protein-protein BC2GM079948235 NN O
and BC2GM079948235 CC O
nucleic BC2GM079948235 JJ O
acid BC2GM079948235 NN O
interactions BC2GM079948235 NNS O
in BC2GM079948235 IN O
the BC2GM079948235 DT O
ORF1 BC2GM079948235 NNP O
protein BC2GM079948235 NN O
of BC2GM079948235 IN O
mouse BC2GM079948235 NN O
LINE-1 BC2GM079948235 NNP O
. BC2GM079948235 . O
. . O O

The BC2GM009988175 DT O
root-mean-square BC2GM009988175 JJ O
deviation BC2GM009988175 NN O
of BC2GM009988175 IN O
bond BC2GM009988175 NN O
lengths BC2GM009988175 NNS O
from BC2GM009988175 IN O
the BC2GM009988175 DT O
ideal BC2GM009988175 NN O
values BC2GM009988175 NNS O
is BC2GM009988175 VBZ O
0.02 BC2GM009988175 CD O
A BC2GM009988175 NNP O
. BC2GM009988175 . O
. . O O

Bandwidth BC2GM060173727 NNP O
of BC2GM060173727 IN O
auditory BC2GM060173727 JJ O
units BC2GM060173727 NNS O
in BC2GM060173727 IN O
the BC2GM060173727 DT O
chick BC2GM060173727 NN O
forebrain BC2GM060173727 NN O
( BC2GM060173727 ( O
field BC2GM060173727 NN O
L BC2GM060173727 NNP O
/ BC2GM060173727 NNP O
Hv BC2GM060173727 NNP O
complex BC2GM060173727 NN O
) BC2GM060173727 ) O
was BC2GM060173727 VBD O
measured BC2GM060173727 VBN O
with BC2GM060173727 IN O
isointensity BC2GM060173727 NN O
tone BC2GM060173727 NN O
stimuli BC2GM060173727 NN O
. BC2GM060173727 . O
. . O O

J. BC2GM024081433 NNP O
, BC2GM024081433 , O
& BC2GM024081433 CC O
Olefsky BC2GM024081433 NNP O
, BC2GM024081433 , O
J BC2GM024081433 NNP O
. BC2GM024081433 . O
. . O O

Highly BC2GM093919585 NNP O
significant BC2GM093919585 JJ O
similarities BC2GM093919585 NNS O
were BC2GM093919585 VBD O
detected BC2GM093919585 VBN O
between BC2GM093919585 IN O
the BC2GM093919585 DT O
N-terminal BC2GM093919585 JJ O
region BC2GM093919585 NN O
of BC2GM093919585 IN O
P30 BC2GM093919585 NNP O
and BC2GM093919585 CC O
those BC2GM093919585 DT O
of BC2GM093919585 IN O
GENA BC2GM093919585 NNP O
[ BC2GM093919585 NNP O
the BC2GM093919585 DT O
product BC2GM093919585 NN O
of BC2GM093919585 IN O
another BC2GM093919585 DT O
unidentified BC2GM093919585 JJ O
gene BC2GM093919585 NN O
( BC2GM093919585 ( O
geneA BC2GM093919585 NN O
) BC2GM093919585 ) O
located BC2GM093919585 VBD O
upstream BC2GM093919585 NN O
of BC2GM093919585 IN O
the BC2GM093919585 DT O
aceEF-lpd BC2GM093919585 JJ O
operon BC2GM093919585 NN O
] BC2GM093919585 NN O
, BC2GM093919585 , O
and BC2GM093919585 CC O
GNTR BC2GM093919585 NNP O
( BC2GM093919585 ( O
a BC2GM093919585 DT O
putative BC2GM093919585 JJ O
transcriptional BC2GM093919585 JJ O
repressor BC2GM093919585 NN O
of BC2GM093919585 IN O
the BC2GM093919585 DT O
gluconate BC2GM093919585 NN O
operon BC2GM093919585 NN O
of BC2GM093919585 IN O
Bacillus BC2GM093919585 NNP O
subtilis BC2GM093919585 NNS O
) BC2GM093919585 ) O
. BC2GM093919585 . O
. . O O

Akt-dependent BC2GM055737184 JJ O
antiapoptotic BC2GM055737184 JJ O
action BC2GM055737184 NN O
of BC2GM055737184 IN O
insulin BC2GM055737184 NN O
is BC2GM055737184 VBZ O
sensitive BC2GM055737184 JJ O
to BC2GM055737184 TO O
farnesyltransferase BC2GM055737184 VB O
inhibitor BC2GM055737184 NN O
. BC2GM055737184 . O
. . O O

The BC2GM080095863 DT O
expression BC2GM080095863 NN O
of BC2GM080095863 IN O
the BC2GM080095863 DT O
leukocyte BC2GM080095863 JJ O
EL-246 BC2GM080095863 NNP O
antigen BC2GM080095863 NN O
was BC2GM080095863 VBD O
regulated BC2GM080095863 VBN O
in BC2GM080095863 IN O
the BC2GM080095863 DT O
same BC2GM080095863 JJ O
manner BC2GM080095863 NN O
as BC2GM080095863 IN O
L-selectin BC2GM080095863 NNP O
and BC2GM080095863 CC O
EL-246 BC2GM080095863 NNP O
recognized BC2GM080095863 VBD O
anti-L-selectin BC2GM080095863 JJ O
mAb BC2GM080095863 NN O
affinity-purified BC2GM080095863 JJ O
antigen BC2GM080095863 NN O
in BC2GM080095863 IN O
SDS BC2GM080095863 NNP O
/ BC2GM080095863 NNP O
PAGE BC2GM080095863 NNP O
Western BC2GM080095863 NNP O
blot BC2GM080095863 NN O
analysis BC2GM080095863 NN O
. BC2GM080095863 . O
. . O O

In BC2GM012836491 IN O
the BC2GM012836491 DT O
present BC2GM012836491 JJ O
study BC2GM012836491 NN O
we BC2GM012836491 PRP O
found BC2GM012836491 VBD O
that BC2GM012836491 IN O
CD34 BC2GM012836491 NNP O
downregulation BC2GM012836491 NN O
during BC2GM012836491 IN O
hematopoiesis BC2GM012836491 NN O
occured BC2GM012836491 VBN O
at BC2GM012836491 IN O
the BC2GM012836491 DT O
level BC2GM012836491 NN O
of BC2GM012836491 IN O
transcriptional BC2GM012836491 JJ O
initiation BC2GM012836491 NN O
. BC2GM012836491 . O
. . O O

The BC2GM069268475 DT O
GST-CBL-LZIP BC2GM069268475 NNP O
fusion BC2GM069268475 NN O
protein BC2GM069268475 NN O
contains BC2GM069268475 VBZ O
a BC2GM069268475 DT O
binding BC2GM069268475 NN O
site BC2GM069268475 NN O
for BC2GM069268475 IN O
the BC2GM069268475 DT O
SH2 BC2GM069268475 NNP O
domain BC2GM069268475 NN O
of BC2GM069268475 IN O
the BC2GM069268475 DT O
p85 BC2GM069268475 JJ O
subunit BC2GM069268475 NN O
of BC2GM069268475 IN O
phosphatidylinositol BC2GM069268475 JJ O
3-kinase BC2GM069268475 CD O
, BC2GM069268475 , O
which BC2GM069268475 WDT O
mapped BC2GM069268475 VBD O
to BC2GM069268475 TO O
Tyr731 BC2GM069268475 NNP O
, BC2GM069268475 , O
which BC2GM069268475 WDT O
is BC2GM069268475 VBZ O
present BC2GM069268475 JJ O
in BC2GM069268475 IN O
the BC2GM069268475 DT O
sequence BC2GM069268475 NN O
YEAM BC2GM069268475 NNP O
. BC2GM069268475 . O
. . O O

Neuronal BC2GM014203936 JJ O
activity BC2GM014203936 NN O
of BC2GM014203936 IN O
58 BC2GM014203936 CD O
dopaminergic BC2GM014203936 NN O
( BC2GM014203936 ( O
DA BC2GM014203936 NNP O
) BC2GM014203936 ) O
and BC2GM014203936 CC O
200 BC2GM014203936 CD O
non-dopaminergic BC2GM014203936 JJ O
( BC2GM014203936 ( O
non-DA BC2GM014203936 JJ O
) BC2GM014203936 ) O
neurons BC2GM014203936 NNS O
in BC2GM014203936 IN O
the BC2GM014203936 DT O
ventral BC2GM014203936 JJ O
tegmental BC2GM014203936 JJ O
area BC2GM014203936 NN O
( BC2GM014203936 ( O
VTA BC2GM014203936 NNP O
) BC2GM014203936 ) O
of BC2GM014203936 IN O
female BC2GM014203936 JJ O
monkeys BC2GM014203936 NN O
was BC2GM014203936 VBD O
recorded BC2GM014203936 VBN O
, BC2GM014203936 , O
and BC2GM014203936 CC O
correlation BC2GM014203936 NN O
to BC2GM014203936 TO O
bar BC2GM014203936 VB O
press BC2GM014203936 NN O
feeding BC2GM014203936 NN O
, BC2GM014203936 , O
sensory BC2GM014203936 JJ O
stimulation BC2GM014203936 NN O
and BC2GM014203936 CC O
change BC2GM014203936 NN O
in BC2GM014203936 IN O
motivation BC2GM014203936 NN O
was BC2GM014203936 VBD O
investigated BC2GM014203936 VBN O
. BC2GM014203936 . O
. . O O

The BC2GM047053837 DT O
library BC2GM047053837 NN O
will BC2GM047053837 MD O
thus BC2GM047053837 RB O
be BC2GM047053837 VB O
useful BC2GM047053837 JJ O
for BC2GM047053837 IN O
the BC2GM047053837 DT O
selection BC2GM047053837 NN O
of BC2GM047053837 IN O
cosmid BC2GM047053837 NN O
clones BC2GM047053837 NNS O
which BC2GM047053837 WDT O
carry BC2GM047053837 VBP O
CDC BC2GM047053837 NNP O
genes BC2GM047053837 NNS O
from BC2GM047053837 IN O
yeast BC2GM047053837 NN O
by BC2GM047053837 IN O
complementing BC2GM047053837 VBG O
first BC2GM047053837 RB O
, BC2GM047053837 , O
with BC2GM047053837 IN O
the BC2GM047053837 DT O
vectorial BC2GM047053837 JJ O
yeast BC2GM047053837 NN O
gene BC2GM047053837 NN O
URA1 BC2GM047053837 NNP O
, BC2GM047053837 , O
the BC2GM047053837 DT O
pyrimidine BC2GM047053837 NN O
auxotrophy BC2GM047053837 NN O
of BC2GM047053837 IN O
most BC2GM047053837 JJS O
cdc-strains BC2GM047053837 NNS O
and BC2GM047053837 CC O
then BC2GM047053837 RB O
, BC2GM047053837 , O
with BC2GM047053837 IN O
the BC2GM047053837 DT O
respective BC2GM047053837 JJ O
CDC BC2GM047053837 NNP O
wild-type BC2GM047053837 NN O
genes BC2GM047053837 NNS O
, BC2GM047053837 , O
of BC2GM047053837 IN O
the BC2GM047053837 DT O
temperature-sensitive BC2GM047053837 JJ O
mutant BC2GM047053837 NN O
alleles BC2GM047053837 NNS O
. BC2GM047053837 . O
. . O O

This BC2GM059240976 DT O
review BC2GM059240976 NN O
chronicles BC2GM059240976 VBZ O
the BC2GM059240976 DT O
characteristics BC2GM059240976 NNS O
of BC2GM059240976 IN O
deliberate BC2GM059240976 NN O
and BC2GM059240976 CC O
accidental BC2GM059240976 JJ O
mass BC2GM059240976 NN O
poisonings BC2GM059240976 NNS O
that BC2GM059240976 WDT O
occurred BC2GM059240976 VBD O
in BC2GM059240976 IN O
World BC2GM059240976 NNP O
Wars BC2GM059240976 NNP O
I BC2GM059240976 PRP O
and BC2GM059240976 CC O
II BC2GM059240976 NNP O
, BC2GM059240976 , O
in BC2GM059240976 IN O
Bhopal BC2GM059240976 NNP O
, BC2GM059240976 , O
and BC2GM059240976 CC O
in BC2GM059240976 IN O
other BC2GM059240976 JJ O
historical BC2GM059240976 JJ O
cases BC2GM059240976 NNS O
up BC2GM059240976 RB O
to BC2GM059240976 TO O
and BC2GM059240976 CC O
including BC2GM059240976 VBG O
modern BC2GM059240976 JJ O
wars BC2GM059240976 NNS O
. BC2GM059240976 . O
. . O O

Jornvall BC2GM084039328 NNP O
, BC2GM084039328 , O
B BC2GM084039328 NNP O
. BC2GM084039328 . O
. . O O

W. BC2GM011104369 NNP O
, BC2GM011104369 , O
and BC2GM011104369 CC O
Touster BC2GM011104369 NNP O
, BC2GM011104369 , O
O BC2GM011104369 NNP O
. BC2GM011104369 . O
. . O O

This BC2GM090921453 DT O
study BC2GM090921453 NN O
includes BC2GM090921453 VBZ O
200 BC2GM090921453 CD O
patients BC2GM090921453 NNS O
treated BC2GM090921453 VBN O
from BC2GM090921453 IN O
1964 BC2GM090921453 CD O
to BC2GM090921453 TO O
1978 BC2GM090921453 CD O
, BC2GM090921453 , O
with BC2GM090921453 IN O
an BC2GM090921453 DT O
age BC2GM090921453 NN O
range BC2GM090921453 NN O
from BC2GM090921453 IN O
15 BC2GM090921453 CD O
to BC2GM090921453 TO O
102 BC2GM090921453 CD O
years BC2GM090921453 NNS O
, BC2GM090921453 , O
who BC2GM090921453 WP O
required BC2GM090921453 VBD O
329 BC2GM090921453 CD O
generators BC2GM090921453 NNS O
. BC2GM090921453 . O
. . O O

Determination BC2GM045006907 NN O
of BC2GM045006907 IN O
the BC2GM045006907 DT O
LD BC2GM045006907 NNP O
50 BC2GM045006907 CD O
( BC2GM045006907 ( O
30 BC2GM045006907 CD O
) BC2GM045006907 ) O
during BC2GM045006907 IN O
infant BC2GM045006907 JJ O
period BC2GM045006907 NN O
and BC2GM045006907 CC O
growth BC2GM045006907 NN O
period BC2GM045006907 NN O
. BC2GM045006907 . O
. . O O

The BC2GM074067305 DT O
law BC2GM074067305 NN O
and BC2GM074067305 CC O
the BC2GM074067305 DT O
chiropractor BC2GM074067305 NN O
. BC2GM074067305 . O
. . O O

In BC2GM066933865 IN O
this BC2GM066933865 DT O
study BC2GM066933865 NN O
, BC2GM066933865 , O
the BC2GM066933865 DT O
subcellular BC2GM066933865 JJ O
location BC2GM066933865 NN O
, BC2GM066933865 , O
domain BC2GM066933865 NN O
structure BC2GM066933865 NN O
, BC2GM066933865 , O
and BC2GM066933865 CC O
biochemical BC2GM066933865 JJ O
function BC2GM066933865 NN O
of BC2GM066933865 IN O
metaxin BC2GM066933865 NN O
were BC2GM066933865 VBD O
investigated BC2GM066933865 VBN O
. BC2GM066933865 . O
. . O O

Following BC2GM022540559 VBG O
EGF BC2GM022540559 NNP O
or BC2GM022540559 CC O
NGF BC2GM022540559 NNP O
stimulation BC2GM022540559 NN O
of BC2GM022540559 IN O
the BC2GM022540559 DT O
v-CrkPC12 BC2GM022540559 JJ O
cells BC2GM022540559 NNS O
, BC2GM022540559 , O
the BC2GM022540559 DT O
v-Crk BC2GM022540559 NN O
protein BC2GM022540559 NN O
itself BC2GM022540559 PRP O
became BC2GM022540559 VBD O
tyrosine BC2GM022540559 RB O
phosphorylated BC2GM022540559 VBN O
within BC2GM022540559 IN O
1 BC2GM022540559 CD O
min BC2GM022540559 NNS O
. BC2GM022540559 . O
. . O O

The BC2GM017027776 DT O
BDU BC2GM017027776 NNP O
neurons BC2GM017027776 NNS O
and BC2GM017027776 CC O
the BC2GM017027776 DT O
ALM BC2GM017027776 NNP O
touch BC2GM017027776 JJ O
neurons BC2GM017027776 NNS O
are BC2GM017027776 VBP O
lineal BC2GM017027776 JJ O
sister BC2GM017027776 JJ O
cells BC2GM017027776 NNS O
in BC2GM017027776 IN O
the BC2GM017027776 DT O
AB.a BC2GM017027776 NNP O
lineage BC2GM017027776 NN O
and BC2GM017027776 CC O
the BC2GM017027776 DT O
VA BC2GM017027776 NNP O
and BC2GM017027776 CC O
VB BC2GM017027776 NNP O
motor BC2GM017027776 NN O
neurons BC2GM017027776 NNS O
are BC2GM017027776 VBP O
lineal BC2GM017027776 JJ O
sister BC2GM017027776 JJ O
cells BC2GM017027776 NNS O
in BC2GM017027776 IN O
the BC2GM017027776 DT O
AB.p BC2GM017027776 NNP O
lineage BC2GM017027776 NN O
. BC2GM017027776 . O
. . O O

The BC2GM030625500 DT O
lowest BC2GM030625500 JJS O
PaCO2 BC2GM030625500 NN O
values BC2GM030625500 NNS O
were BC2GM030625500 VBD O
significantly BC2GM030625500 RB O
lower BC2GM030625500 JJR O
in BC2GM030625500 IN O
MCE BC2GM030625500 NNP O
than BC2GM030625500 IN O
in BC2GM030625500 IN O
the BC2GM030625500 DT O
F BC2GM030625500 NNP O
, BC2GM030625500 , O
W BC2GM030625500 NNP O
, BC2GM030625500 , O
and BC2GM030625500 CC O
D BC2GM030625500 NNP O
( BC2GM030625500 ( O
F BC2GM030625500 NNP O
+ BC2GM030625500 NNP O
W BC2GM030625500 NNP O
+ BC2GM030625500 NNP O
D BC2GM030625500 NNP O
) BC2GM030625500 ) O
group BC2GM030625500 NN O
or BC2GM030625500 CC O
controls BC2GM030625500 NNS O
. BC2GM030625500 . O
. . O O

50-fold BC2GM091616739 JJ O
increase BC2GM091616739 NN O
in BC2GM091616739 IN O
foreign BC2GM091616739 JJ O
protein BC2GM091616739 JJ O
production BC2GM091616739 NN O
. BC2GM091616739 . O
. . O O

Of BC2GM056423678 IN O
the BC2GM056423678 DT O
47 BC2GM056423678 CD O
women BC2GM056423678 NNS O
with BC2GM056423678 IN O
AGCUS BC2GM056423678 NNP O
, BC2GM056423678 , O
16 BC2GM056423678 CD O
had BC2GM056423678 VBD O
intraepithelial BC2GM056423678 JJ O
or BC2GM056423678 CC O
invasive BC2GM056423678 JJ O
neoplasms BC2GM056423678 NNS O
( BC2GM056423678 ( O
34 BC2GM056423678 CD O
% BC2GM056423678 NN O
; BC2GM056423678 : O
95 BC2GM056423678 CD O
% BC2GM056423678 NN O
confidence BC2GM056423678 NN O
interval BC2GM056423678 NN O
, BC2GM056423678 , O
21-49 BC2GM056423678 CD O
% BC2GM056423678 NN O
) BC2GM056423678 ) O
, BC2GM056423678 , O
including BC2GM056423678 VBG O
9 BC2GM056423678 CD O
low BC2GM056423678 JJ O
or BC2GM056423678 CC O
high BC2GM056423678 JJ O
grade BC2GM056423678 NN O
squamous BC2GM056423678 JJ O
intraepithelial BC2GM056423678 JJ O
lesions BC2GM056423678 NNS O
, BC2GM056423678 , O
1 BC2GM056423678 CD O
adenocarcinoma BC2GM056423678 NN O
in BC2GM056423678 IN O
situ BC2GM056423678 NN O
of BC2GM056423678 IN O
the BC2GM056423678 DT O
cervix BC2GM056423678 NN O
, BC2GM056423678 , O
3 BC2GM056423678 CD O
adenocarcinomas BC2GM056423678 NN O
of BC2GM056423678 IN O
the BC2GM056423678 DT O
cervix BC2GM056423678 NN O
, BC2GM056423678 , O
2 BC2GM056423678 CD O
adenocarcinomas BC2GM056423678 NN O
of BC2GM056423678 IN O
the BC2GM056423678 DT O
endometrium BC2GM056423678 NN O
and BC2GM056423678 CC O
1 BC2GM056423678 CD O
adenoid BC2GM056423678 JJ O
basal BC2GM056423678 NN O
cell BC2GM056423678 NN O
carcinoma BC2GM056423678 NN O
of BC2GM056423678 IN O
the BC2GM056423678 DT O
cervix BC2GM056423678 NN O
. BC2GM056423678 . O
. . O O

Four BC2GM098934435 CD O
experiments BC2GM098934435 NNS O
examined BC2GM098934435 VBD O
the BC2GM098934435 DT O
role BC2GM098934435 NN O
of BC2GM098934435 IN O
the BC2GM098934435 DT O
cholinergic BC2GM098934435 JJ O
projections BC2GM098934435 NNS O
from BC2GM098934435 IN O
the BC2GM098934435 DT O
septum BC2GM098934435 NN O
and BC2GM098934435 CC O
vertical BC2GM098934435 JJ O
limb BC2GM098934435 NN O
nucleus BC2GM098934435 NN O
of BC2GM098934435 IN O
the BC2GM098934435 DT O
diagonal BC2GM098934435 JJ O
band BC2GM098934435 NN O
of BC2GM098934435 IN O
Broca BC2GM098934435 NNP O
( BC2GM098934435 ( O
VDB BC2GM098934435 NNP O
) BC2GM098934435 ) O
in BC2GM098934435 IN O
acquisition BC2GM098934435 NN O
and BC2GM098934435 CC O
performance BC2GM098934435 NN O
of BC2GM098934435 IN O
a BC2GM098934435 DT O
conditional BC2GM098934435 JJ O
visual BC2GM098934435 JJ O
discrimination BC2GM098934435 NN O
. BC2GM098934435 . O
. . O O

Previous BC2GM012470081 JJ O
work BC2GM012470081 NN O
has BC2GM012470081 VBZ O
shown BC2GM012470081 VBN O
that BC2GM012470081 IN O
glucose BC2GM012470081 JJ O
repression BC2GM012470081 NN O
of BC2GM012470081 IN O
PRB1 BC2GM012470081 NNP O
transcription BC2GM012470081 NN O
is BC2GM012470081 VBZ O
not BC2GM012470081 RB O
mediated BC2GM012470081 VBN O
by BC2GM012470081 IN O
HXK2 BC2GM012470081 NNP O
or BC2GM012470081 CC O
by BC2GM012470081 IN O
the BC2GM012470081 DT O
SNF1 BC2GM012470081 NNP O
, BC2GM012470081 , O
SNF4 BC2GM012470081 NNP O
, BC2GM012470081 , O
and BC2GM012470081 CC O
SNF6 BC2GM012470081 NNP O
genes BC2GM012470081 NNS O
( BC2GM012470081 ( O
C BC2GM012470081 NNP O
. BC2GM012470081 . O
. . O O

The BC2GM098004575 DT O
effect BC2GM098004575 NN O
of BC2GM098004575 IN O
the BC2GM098004575 DT O
negative BC2GM098004575 JJ O
regulatory BC2GM098004575 JJ O
element BC2GM098004575 NN O
is BC2GM098004575 VBZ O
negated BC2GM098004575 VBN O
by BC2GM098004575 IN O
the BC2GM098004575 DT O
viral BC2GM098004575 JJ O
IE2 BC2GM098004575 NNP O
protein BC2GM098004575 NN O
( BC2GM098004575 ( O
L BC2GM098004575 NNP O
. BC2GM098004575 . O
. . O O

Fibrosis BC2GM071774854 NN O
of BC2GM071774854 IN O
the BC2GM071774854 DT O
adjacent BC2GM071774854 JJ O
myocardium BC2GM071774854 NN O
was BC2GM071774854 VBD O
seen BC2GM071774854 VBN O
in BC2GM071774854 IN O
five BC2GM071774854 CD O
cases BC2GM071774854 NNS O
. BC2GM071774854 . O
. . O O

To BC2GM041206962 TO O
investigate BC2GM041206962 VB O
the BC2GM041206962 DT O
role BC2GM041206962 NN O
of BC2GM041206962 IN O
this BC2GM041206962 DT O
domain BC2GM041206962 NN O
in BC2GM041206962 IN O
the BC2GM041206962 DT O
incorporation BC2GM041206962 NN O
of BC2GM041206962 IN O
the BC2GM041206962 DT O
SIV BC2GM041206962 NNP O
Env BC2GM041206962 NNP O
into BC2GM041206962 IN O
virions BC2GM041206962 NNS O
, BC2GM041206962 , O
we BC2GM041206962 PRP O
generated BC2GM041206962 VBD O
a BC2GM041206962 DT O
series BC2GM041206962 NN O
of BC2GM041206962 IN O
SIV BC2GM041206962 NNP O
Env BC2GM041206962 NNP O
mutants BC2GM041206962 NNS O
carrying BC2GM041206962 VBG O
small BC2GM041206962 JJ O
in-frame BC2GM041206962 JJ O
deletions BC2GM041206962 NNS O
within BC2GM041206962 IN O
the BC2GM041206962 DT O
cytoplasmic BC2GM041206962 JJ O
domain BC2GM041206962 NN O
. BC2GM041206962 . O
. . O O

Cross-sectional BC2GM034977775 JJ O
studies BC2GM034977775 NNS O
continue BC2GM034977775 VBP O
to BC2GM034977775 TO O
dominate BC2GM034977775 VB O
. BC2GM034977775 . O
. . O O

Management BC2GM032114855 NN O
of BC2GM032114855 IN O
patients BC2GM032114855 NNS O
with BC2GM032114855 IN O
Ewing BC2GM032114855 NNP O
's BC2GM032114855 POS O
sarcoma BC2GM032114855 NN O
has BC2GM032114855 VBZ O
been BC2GM032114855 VBN O
discussed BC2GM032114855 VBN O
with BC2GM032114855 IN O
reference BC2GM032114855 NN O
to BC2GM032114855 TO O
the BC2GM032114855 DT O
need BC2GM032114855 NN O
to BC2GM032114855 TO O
achieve BC2GM032114855 VB O
an BC2GM032114855 DT O
excellent BC2GM032114855 JJ O
local BC2GM032114855 JJ O
result BC2GM032114855 NN O
from BC2GM032114855 IN O
radiation BC2GM032114855 NN O
therapy BC2GM032114855 NN O
now BC2GM032114855 RB O
that BC2GM032114855 IN O
patients BC2GM032114855 NNS O
are BC2GM032114855 VBP O
experiencing BC2GM032114855 VBG O
long-term BC2GM032114855 JJ O
survival BC2GM032114855 NN O
. BC2GM032114855 . O
. . O O

The BC2GM016105671 DT O
exact BC2GM016105671 JJ O
function BC2GM016105671 NN O
of BC2GM016105671 IN O
IP-30 BC2GM016105671 NNP O
is BC2GM016105671 VBZ O
not BC2GM016105671 RB O
yet BC2GM016105671 RB O
known BC2GM016105671 VBN O
, BC2GM016105671 , O
but BC2GM016105671 CC O
it BC2GM016105671 PRP O
may BC2GM016105671 MD O
play BC2GM016105671 VB O
a BC2GM016105671 DT O
role BC2GM016105671 NN O
in BC2GM016105671 IN O
gamma-interferon BC2GM016105671 NN O
mediated BC2GM016105671 VBN O
immune BC2GM016105671 JJ O
reactions BC2GM016105671 NNS O
. BC2GM016105671 . O
. . O O

The BC2GM062537661 DT O
antimicrobial BC2GM062537661 NN O
of BC2GM062537661 IN O
choice BC2GM062537661 NN O
for BC2GM062537661 IN O
initial BC2GM062537661 JJ O
prophylactic BC2GM062537661 JJ O
therapy BC2GM062537661 NN O
among BC2GM062537661 IN O
asymptomatic BC2GM062537661 JJ O
pregnant BC2GM062537661 JJ O
women BC2GM062537661 NNS O
exposed BC2GM062537661 VBD O
to BC2GM062537661 TO O
Bacillus BC2GM062537661 NNP O
anthracis BC2GM062537661 NN O
is BC2GM062537661 VBZ O
ciprofloxacin BC2GM062537661 JJ O
, BC2GM062537661 , O
500 BC2GM062537661 CD O
mg BC2GM062537661 NN O
twice BC2GM062537661 RB O
a BC2GM062537661 DT O
day BC2GM062537661 NN O
for BC2GM062537661 IN O
60 BC2GM062537661 CD O
days BC2GM062537661 NNS O
. BC2GM062537661 . O
. . O O

Collectively BC2GM025598452 RB O
, BC2GM025598452 , O
these BC2GM025598452 DT O
studies BC2GM025598452 NNS O
suggest BC2GM025598452 VBP O
that BC2GM025598452 IN O
the BC2GM025598452 DT O
major BC2GM025598452 JJ O
EGF-stimulated BC2GM025598452 JJ O
mitotic BC2GM025598452 JJ O
growth BC2GM025598452 NN O
pathways BC2GM025598452 NNS O
may BC2GM025598452 MD O
not BC2GM025598452 RB O
be BC2GM025598452 VB O
absolutely BC2GM025598452 RB O
linked BC2GM025598452 VBN O
to BC2GM025598452 TO O
the BC2GM025598452 DT O
stat91 BC2GM025598452 NN O
signaling BC2GM025598452 VBG O
pathways BC2GM025598452 NNS O
and BC2GM025598452 CC O
that BC2GM025598452 DT O
such BC2GM025598452 JJ O
transcription BC2GM025598452 NN O
complexes BC2GM025598452 NNS O
are BC2GM025598452 VBP O
more BC2GM025598452 RBR O
complex BC2GM025598452 JJ O
than BC2GM025598452 IN O
previously BC2GM025598452 RB O
reported BC2GM025598452 VBN O
. BC2GM025598452 . O
. . O O

This BC2GM026908014 DT O
complex BC2GM026908014 NN O
was BC2GM026908014 VBD O
eliminated BC2GM026908014 VBN O
by BC2GM026908014 IN O
mutation BC2GM026908014 NN O
of BC2GM026908014 IN O
either BC2GM026908014 DT O
half-site BC2GM026908014 JJ O
, BC2GM026908014 , O
and BC2GM026908014 CC O
it BC2GM026908014 PRP O
was BC2GM026908014 VBD O
supershifted BC2GM026908014 VBN O
by BC2GM026908014 IN O
antibodies BC2GM026908014 NNS O
against BC2GM026908014 IN O
chicken BC2GM026908014 NN O
ovalbumin BC2GM026908014 JJ O
upstream BC2GM026908014 JJ O
promoter-transcription BC2GM026908014 NN O
factor BC2GM026908014 NN O
( BC2GM026908014 ( O
COUP-TF BC2GM026908014 NNP O
) BC2GM026908014 ) O
. BC2GM026908014 . O
. . O O

Although BC2GM044291180 IN O
polyubiquitin BC2GM044291180 NN O
chains BC2GM044291180 NNS O
linked BC2GM044291180 VBN O
through BC2GM044291180 IN O
Lys BC2GM044291180 NNP O
( BC2GM044291180 ( O
29 BC2GM044291180 CD O
) BC2GM044291180 ) O
of BC2GM044291180 IN O
ubiquitin BC2GM044291180 NN O
have BC2GM044291180 VBP O
been BC2GM044291180 VBN O
implicated BC2GM044291180 VBN O
in BC2GM044291180 IN O
the BC2GM044291180 DT O
targeting BC2GM044291180 NN O
of BC2GM044291180 IN O
certain BC2GM044291180 JJ O
substrates BC2GM044291180 NNS O
to BC2GM044291180 TO O
proteasomes BC2GM044291180 NNS O
, BC2GM044291180 , O
the BC2GM044291180 DT O
signaling BC2GM044291180 VBG O
properties BC2GM044291180 NNS O
of BC2GM044291180 IN O
these BC2GM044291180 DT O
chains BC2GM044291180 NNS O
are BC2GM044291180 VBP O
poorly BC2GM044291180 RB O
understood BC2GM044291180 JJ O
. BC2GM044291180 . O
. . O O

A BC2GM058884519 DT O
model BC2GM058884519 NN O
for BC2GM058884519 IN O
oligomerization-dependent BC2GM058884519 JJ O
subunit BC2GM058884519 NN O
folding BC2GM058884519 NN O
. BC2GM058884519 . O
. . O O

Serum BC2GM019020336 NNP O
IgG BC2GM019020336 NNP O
and BC2GM019020336 CC O
IgA BC2GM019020336 NNP O
level BC2GM019020336 NN O
were BC2GM019020336 VBD O
decreased BC2GM019020336 VBN O
. BC2GM019020336 . O
. . O O

Changes BC2GM069498013 NNS O
in BC2GM069498013 IN O
the BC2GM069498013 DT O
greater BC2GM069498013 JJR O
omentum BC2GM069498013 NN O
of BC2GM069498013 IN O
mice BC2GM069498013 NN O
of BC2GM069498013 IN O
different BC2GM069498013 JJ O
strains BC2GM069498013 NNS O
after BC2GM069498013 IN O
intraperitoneal BC2GM069498013 JJ O
immunization BC2GM069498013 NN O
with BC2GM069498013 IN O
sheep BC2GM069498013 JJ O
erythrocytes BC2GM069498013 NNS O
. BC2GM069498013 . O
. . O O

Replication BC2GM065607488 NN O
regions BC2GM065607488 NNS O
from BC2GM065607488 IN O
plant-pathogenic BC2GM065607488 JJ O
Pseudomonas BC2GM065607488 NNP O
syringae BC2GM065607488 NN O
plasmids BC2GM065607488 NNS O
are BC2GM065607488 VBP O
similar BC2GM065607488 JJ O
to BC2GM065607488 TO O
ColE2-related BC2GM065607488 JJ O
replicons BC2GM065607488 NNS O
. BC2GM065607488 . O
. . O O

In BC2GM028930096 IN O
each BC2GM028930096 DT O
of BC2GM028930096 IN O
the BC2GM028930096 DT O
studied BC2GM028930096 JJ O
HPV BC2GM028930096 NNP O
types BC2GM028930096 NNS O
, BC2GM028930096 , O
the BC2GM028930096 DT O
two BC2GM028930096 CD O
CDP BC2GM028930096 NNP O
/ BC2GM028930096 FW O
Cut BC2GM028930096 NNP O
binding BC2GM028930096 VBG O
sites BC2GM028930096 NNS O
of BC2GM028930096 IN O
PSM BC2GM028930096 NNP O
overlap BC2GM028930096 NN O
with BC2GM028930096 IN O
the BC2GM028930096 DT O
known BC2GM028930096 NN O
or BC2GM028930096 CC O
presumed BC2GM028930096 VBN O
binding BC2GM028930096 VBG O
sites BC2GM028930096 NNS O
of BC2GM028930096 IN O
the BC2GM028930096 DT O
replication BC2GM028930096 NN O
initiator BC2GM028930096 NN O
protein BC2GM028930096 NN O
E1 BC2GM028930096 NNP O
. BC2GM028930096 . O
. . O O

In BC2GM048779386 IN O
a BC2GM048779386 DT O
study BC2GM048779386 NN O
in BC2GM048779386 IN O
Singapore BC2GM048779386 NNP O
, BC2GM048779386 , O
Chinese BC2GM048779386 NNP O
, BC2GM048779386 , O
Malay BC2GM048779386 NNP O
and BC2GM048779386 CC O
Indian BC2GM048779386 JJ O
patients BC2GM048779386 NNS O
with BC2GM048779386 IN O
pulmonary BC2GM048779386 JJ O
tuberculosis BC2GM048779386 NN O
received BC2GM048779386 VBD O
2 BC2GM048779386 CD O
months BC2GM048779386 NNS O
of BC2GM048779386 IN O
daily BC2GM048779386 JJ O
treatment BC2GM048779386 NN O
with BC2GM048779386 IN O
streptomycin BC2GM048779386 NN O
, BC2GM048779386 , O
isoniazid BC2GM048779386 NN O
, BC2GM048779386 , O
rifampicin BC2GM048779386 NN O
, BC2GM048779386 , O
and BC2GM048779386 CC O
pyrazinamide BC2GM048779386 NN O
followed BC2GM048779386 VBN O
by BC2GM048779386 IN O
daily BC2GM048779386 JJ O
isoniazid BC2GM048779386 NN O
, BC2GM048779386 , O
and BC2GM048779386 CC O
rifampicin BC2GM048779386 VB O
either BC2GM048779386 RB O
with BC2GM048779386 IN O
pyrazinamide BC2GM048779386 NN O
( BC2GM048779386 ( O
SHRZ BC2GM048779386 NNP O
/ BC2GM048779386 NNP O
HRZ BC2GM048779386 NNP O
) BC2GM048779386 ) O
or BC2GM048779386 CC O
without BC2GM048779386 IN O
it BC2GM048779386 PRP O
( BC2GM048779386 ( O
SHRZ BC2GM048779386 NNP O
/ BC2GM048779386 NNP O
HR BC2GM048779386 NNP O
) BC2GM048779386 ) O
, BC2GM048779386 , O
allocated BC2GM048779386 VBN O
at BC2GM048779386 IN O
random BC2GM048779386 NN O
. BC2GM048779386 . O
. . O O

Availability BC2GM083864266 NN O
of BC2GM083864266 IN O
a BC2GM083864266 DT O
less BC2GM083864266 RBR O
palatable BC2GM083864266 JJ O
diet BC2GM083864266 NN O
( BC2GM083864266 ( O
chow BC2GM083864266 NN O
) BC2GM083864266 ) O
following BC2GM083864266 VBG O
presentation BC2GM083864266 NN O
of BC2GM083864266 IN O
palatable BC2GM083864266 JJ O
diets BC2GM083864266 NNS O
will BC2GM083864266 MD O
not BC2GM083864266 RB O
result BC2GM083864266 VB O
in BC2GM083864266 IN O
diminished BC2GM083864266 JJ O
caloric BC2GM083864266 JJ O
intake BC2GM083864266 NN O
, BC2GM083864266 , O
body BC2GM083864266 NN O
weight BC2GM083864266 NN O
, BC2GM083864266 , O
obesity BC2GM083864266 NN O
and BC2GM083864266 CC O
hyperinsulinemia BC2GM083864266 NN O
. BC2GM083864266 . O
. . O O

In BC2GM053477208 IN O
this BC2GM053477208 DT O
study BC2GM053477208 NN O
, BC2GM053477208 , O
to BC2GM053477208 TO O
elucidate BC2GM053477208 VB O
the BC2GM053477208 DT O
possible BC2GM053477208 JJ O
mechanism BC2GM053477208 NN O
of BC2GM053477208 IN O
action BC2GM053477208 NN O
of BC2GM053477208 IN O
EM BC2GM053477208 NNP O
, BC2GM053477208 , O
we BC2GM053477208 PRP O
examined BC2GM053477208 VBD O
the BC2GM053477208 DT O
effect BC2GM053477208 NN O
of BC2GM053477208 IN O
the BC2GM053477208 DT O
drug BC2GM053477208 NN O
on BC2GM053477208 IN O
the BC2GM053477208 DT O
expression BC2GM053477208 NN O
of BC2GM053477208 IN O
neutrophil BC2GM053477208 JJ O
adhesion BC2GM053477208 NN O
molecules BC2GM053477208 NNS O
such BC2GM053477208 JJ O
as BC2GM053477208 IN O
L-selectin BC2GM053477208 NNP O
and BC2GM053477208 CC O
Mac-1 BC2GM053477208 NNP O
. BC2GM053477208 . O
. . O O

In BC2GM025371189 IN O
lyzozyme BC2GM025371189 JJ O
activity BC2GM025371189 NN O
there BC2GM025371189 EX O
was BC2GM025371189 VBD O
periodicity BC2GM025371189 NN O
in BC2GM025371189 IN O
three BC2GM025371189 CD O
groups BC2GM025371189 NNS O
but BC2GM025371189 CC O
not BC2GM025371189 RB O
in BC2GM025371189 IN O
the BC2GM025371189 DT O
youngest BC2GM025371189 JJS O
foals BC2GM025371189 NNS O
. BC2GM025371189 . O
. . O O

LV BC2GM008918503 NNP O
compliance BC2GM008918503 NN O
was BC2GM008918503 VBD O
determined BC2GM008918503 VBN O
from BC2GM008918503 IN O
the BC2GM008918503 DT O
slope BC2GM008918503 NN O
of BC2GM008918503 IN O
the BC2GM008918503 DT O
LV BC2GM008918503 NNP O
end-diastolic BC2GM008918503 JJ O
pressure BC2GM008918503 NN O
( BC2GM008918503 ( O
LVEDP BC2GM008918503 NNP O
) BC2GM008918503 ) O
vs BC2GM008918503 NN O
. BC2GM008918503 . O
. . O O

Attenuated BC2GM047204097 VBN O
serum BC2GM047204097 NN O
cortisol BC2GM047204097 NN O
responses BC2GM047204097 NNS O
were BC2GM047204097 VBD O
found BC2GM047204097 VBN O
in BC2GM047204097 IN O
six BC2GM047204097 CD O
of BC2GM047204097 IN O
the BC2GM047204097 DT O
patients BC2GM047204097 NNS O
despite BC2GM047204097 IN O
a BC2GM047204097 DT O
normal BC2GM047204097 JJ O
ACTH BC2GM047204097 NNP O
test BC2GM047204097 NN O
. BC2GM047204097 . O
. . O O

Subjects BC2GM094704292 NNS O
were BC2GM094704292 VBD O
73 BC2GM094704292 CD O
male BC2GM094704292 NN O
and BC2GM094704292 CC O
female BC2GM094704292 JJ O
employees BC2GM094704292 NNS O
of BC2GM094704292 IN O
the BC2GM094704292 DT O
Xerox BC2GM094704292 NNP O
Corporation BC2GM094704292 NNP O
joining BC2GM094704292 VBG O
a BC2GM094704292 DT O
newly BC2GM094704292 RB O
developed BC2GM094704292 VBN O
health BC2GM094704292 NN O
fitness BC2GM094704292 NN O
program BC2GM094704292 NN O
. BC2GM094704292 . O
. . O O

We BC2GM000293986 PRP O
present BC2GM000293986 VBP O
here BC2GM000293986 RB O
the BC2GM000293986 DT O
complete BC2GM000293986 JJ O
primary BC2GM000293986 JJ O
structure BC2GM000293986 NN O
of BC2GM000293986 IN O
human BC2GM000293986 JJ O
gp330 BC2GM000293986 NN O
, BC2GM000293986 , O
the BC2GM000293986 DT O
human BC2GM000293986 JJ O
variant BC2GM000293986 NN O
of BC2GM000293986 IN O
the BC2GM000293986 DT O
principal BC2GM000293986 JJ O
kidney BC2GM000293986 NN O
autoantigen BC2GM000293986 NN O
causing BC2GM000293986 VBG O
Heymann BC2GM000293986 NNP O
membranous BC2GM000293986 JJ O
glomerulonephritis BC2GM000293986 NN O
in BC2GM000293986 IN O
rats BC2GM000293986 NNS O
. BC2GM000293986 . O
. . O O

The BC2GM016890014 DT O
80 BC2GM016890014 CD O
kb BC2GM016890014 NN O
preceding BC2GM016890014 VBG O
the BC2GM016890014 DT O
expression BC2GM016890014 NN O
site BC2GM016890014 NN O
has BC2GM016890014 VBZ O
few BC2GM016890014 JJ O
, BC2GM016890014 , O
if BC2GM016890014 IN O
any BC2GM016890014 DT O
, BC2GM016890014 , O
functional BC2GM016890014 JJ O
ORFs BC2GM016890014 NNP O
, BC2GM016890014 , O
but BC2GM016890014 CC O
contains BC2GM016890014 VBZ O
50 BC2GM016890014 CD O
bp BC2GM016890014 NN O
repeats BC2GM016890014 NNS O
, BC2GM016890014 , O
INGI BC2GM016890014 NNP O
retrotransposon-like BC2GM016890014 JJ O
elements BC2GM016890014 NNS O
, BC2GM016890014 , O
and BC2GM016890014 CC O
novel BC2GM016890014 JJ O
4-12 BC2GM016890014 JJ O
kb BC2GM016890014 NN O
repeats BC2GM016890014 NNS O
found BC2GM016890014 VBD O
near BC2GM016890014 IN O
other BC2GM016890014 JJ O
telomeres BC2GM016890014 NNS O
. BC2GM016890014 . O
. . O O

Estrogen BC2GM017190400 NNP O
pretreated BC2GM017190400 VBD O
castrated BC2GM017190400 JJ O
males BC2GM017190400 NNS O
also BC2GM017190400 RB O
showed BC2GM017190400 VBD O
no BC2GM017190400 DT O
change BC2GM017190400 NN O
in BC2GM017190400 IN O
myocardial BC2GM017190400 JJ O
blood BC2GM017190400 NN O
flow BC2GM017190400 NN O
after BC2GM017190400 IN O
17 BC2GM017190400 CD O
beta-estradiol BC2GM017190400 JJ O
, BC2GM017190400 , O
but BC2GM017190400 CC O
coronary BC2GM017190400 JJ O
flow BC2GM017190400 NN O
velocity BC2GM017190400 NN O
decreased BC2GM017190400 VBN O
( BC2GM017190400 ( O
P BC2GM017190400 NNP O
< BC2GM017190400 NNP O
0.05 BC2GM017190400 CD O
) BC2GM017190400 ) O
compared BC2GM017190400 VBN O
with BC2GM017190400 IN O
baseline BC2GM017190400 NN O
1 BC2GM017190400 CD O
h BC2GM017190400 NN O
after BC2GM017190400 IN O
the BC2GM017190400 DT O
200 BC2GM017190400 CD O
ng BC2GM017190400 JJ O
/ BC2GM017190400 NNP O
kg BC2GM017190400 NN O
dose BC2GM017190400 NN O
( BC2GM017190400 ( O
from BC2GM017190400 IN O
1.69 BC2GM017190400 CD O
+ BC2GM017190400 NNS O
/ BC2GM017190400 SYM O
- BC2GM017190400 : O
0.61 BC2GM017190400 CD O
to BC2GM017190400 TO O
1.41 BC2GM017190400 CD O
+ BC2GM017190400 NNS O
/ BC2GM017190400 SYM O
- BC2GM017190400 : O
0.42 BC2GM017190400 CD O
kHz BC2GM017190400 NN O
) BC2GM017190400 ) O
and BC2GM017190400 CC O
diastolic BC2GM017190400 JJ O
coronary BC2GM017190400 JJ O
resistance BC2GM017190400 NN O
increased BC2GM017190400 VBD O
significantly BC2GM017190400 RB O
( BC2GM017190400 ( O
P BC2GM017190400 NNP O
< BC2GM017190400 NNP O
0.01 BC2GM017190400 CD O
) BC2GM017190400 ) O
compared BC2GM017190400 VBN O
with BC2GM017190400 IN O
control BC2GM017190400 NN O
at BC2GM017190400 IN O
this BC2GM017190400 DT O
time BC2GM017190400 NN O
( BC2GM017190400 ( O
51 BC2GM017190400 CD O
+ BC2GM017190400 NN O
/ BC2GM017190400 NNP O
- BC2GM017190400 : O
15 BC2GM017190400 CD O
compared BC2GM017190400 VBN O
with BC2GM017190400 IN O
39 BC2GM017190400 CD O
+ BC2GM017190400 NNS O
/ BC2GM017190400 SYM O
- BC2GM017190400 : O
14 BC2GM017190400 CD O
mmHg BC2GM017190400 NN O
/ BC2GM017190400 NNP O
mkHz BC2GM017190400 NN O
) BC2GM017190400 ) O
. BC2GM017190400 . O
. . O O

We BC2GM003040896 PRP O
propose BC2GM003040896 VBP O
that BC2GM003040896 IN O
GCD7 BC2GM003040896 NNP O
and BC2GM003040896 CC O
GCD2 BC2GM003040896 NNP O
play BC2GM003040896 VBP O
important BC2GM003040896 JJ O
roles BC2GM003040896 NNS O
in BC2GM003040896 IN O
the BC2GM003040896 DT O
regulatory BC2GM003040896 JJ O
interaction BC2GM003040896 NN O
between BC2GM003040896 IN O
eIF-2 BC2GM003040896 JJ O
and BC2GM003040896 CC O
eIF-2B BC2GM003040896 JJ O
and BC2GM003040896 CC O
that BC2GM003040896 IN O
the BC2GM003040896 DT O
suppressor BC2GM003040896 NN O
mutations BC2GM003040896 NNS O
we BC2GM003040896 PRP O
isolated BC2GM003040896 VBD O
in BC2GM003040896 IN O
these BC2GM003040896 DT O
genes BC2GM003040896 NNS O
decrease BC2GM003040896 VBD O
the BC2GM003040896 DT O
susceptibility BC2GM003040896 NN O
of BC2GM003040896 IN O
eIF-2B BC2GM003040896 NN O
to BC2GM003040896 TO O
the BC2GM003040896 DT O
inhibitory BC2GM003040896 JJ O
effects BC2GM003040896 NNS O
of BC2GM003040896 IN O
phosphorylated BC2GM003040896 JJ O
eIF-2 BC2GM003040896 NN O
without BC2GM003040896 IN O
impairing BC2GM003040896 VBG O
the BC2GM003040896 DT O
essential BC2GM003040896 JJ O
catalytic BC2GM003040896 JJ O
function BC2GM003040896 NN O
of BC2GM003040896 IN O
eIF-2B BC2GM003040896 NN O
in BC2GM003040896 IN O
translation BC2GM003040896 NN O
initiation BC2GM003040896 NN O
. BC2GM003040896 . O
. . O O

The BC2GM083193914 DT O
single BC2GM083193914 JJ O
copy BC2GM083193914 NN O
flotillin-1 BC2GM083193914 JJ O
gene BC2GM083193914 NN O
is BC2GM083193914 VBZ O
located BC2GM083193914 VBN O
at BC2GM083193914 IN O
6p21.3 BC2GM083193914 CD O
in BC2GM083193914 IN O
the BC2GM083193914 DT O
MHC BC2GM083193914 NNP O
class BC2GM083193914 NN O
I BC2GM083193914 PRP O
region BC2GM083193914 NN O
and BC2GM083193914 CC O
consists BC2GM083193914 VBZ O
of BC2GM083193914 IN O
13 BC2GM083193914 CD O
exons BC2GM083193914 NNS O
over BC2GM083193914 IN O
15 BC2GM083193914 CD O
kb BC2GM083193914 NNS O
. BC2GM083193914 . O
. . O O

Ultrasound-guided BC2GM048358040 JJ O
fine-needle BC2GM048358040 JJ O
aspiration BC2GM048358040 NN O
biopsy BC2GM048358040 NN O
( BC2GM048358040 ( O
US-FNAB BC2GM048358040 NNP O
) BC2GM048358040 ) O
revealed BC2GM048358040 VBD O
normal-looking BC2GM048358040 JJ O
squamous BC2GM048358040 JJ O
cells BC2GM048358040 NNS O
. BC2GM048358040 . O
. . O O

Also BC2GM030428855 RB O
, BC2GM030428855 , O
in BC2GM030428855 IN O
patients BC2GM030428855 NNS O
with BC2GM030428855 IN O
MYD BC2GM030428855 NNP O
, BC2GM030428855 , O
there BC2GM030428855 EX O
was BC2GM030428855 VBD O
a BC2GM030428855 DT O
significant BC2GM030428855 JJ O
decrease BC2GM030428855 NN O
in BC2GM030428855 IN O
arterial BC2GM030428855 JJ O
PO2 BC2GM030428855 NNP O
from BC2GM030428855 IN O
the BC2GM030428855 DT O
seated BC2GM030428855 JJ O
posture BC2GM030428855 NN O
to BC2GM030428855 TO O
the BC2GM030428855 DT O
supine BC2GM030428855 NN O
posture BC2GM030428855 NN O
, BC2GM030428855 , O
without BC2GM030428855 IN O
a BC2GM030428855 DT O
significant BC2GM030428855 JJ O
change BC2GM030428855 NN O
in BC2GM030428855 IN O
the BC2GM030428855 DT O
arterial BC2GM030428855 JJ O
PCO2 BC2GM030428855 NNP O
. BC2GM030428855 . O
. . O O

Thus BC2GM013419270 RB O
, BC2GM013419270 , O
cross-resistance BC2GM013419270 NN O
between BC2GM013419270 IN O
fluoroquinolones BC2GM013419270 NNS O
was BC2GM013419270 VBD O
shown BC2GM013419270 VBN O
for BC2GM013419270 IN O
both BC2GM013419270 DT O
enterococci BC2GM013419270 NN O
and BC2GM013419270 CC O
MRSA BC2GM013419270 NNP O
. BC2GM013419270 . O
. . O O

SF1 BC2GM094133140 NNP O
/ BC2GM094133140 NNP O
mBBP BC2GM094133140 NN O
utilizes BC2GM094133140 VBZ O
a BC2GM094133140 DT O
`` BC2GM094133140 `` O
maxi-K BC2GM094133140 JJ O
homology BC2GM094133140 NN O
'' BC2GM094133140 '' O
( BC2GM094133140 ( O
maxi-KH BC2GM094133140 NN O
) BC2GM094133140 ) O
domain BC2GM094133140 NN O
for BC2GM094133140 IN O
recognition BC2GM094133140 NN O
of BC2GM094133140 IN O
the BC2GM094133140 DT O
single-stranded BC2GM094133140 JJ O
BPS BC2GM094133140 NNP O
and BC2GM094133140 CC O
requires BC2GM094133140 VBZ O
a BC2GM094133140 DT O
cooperative BC2GM094133140 JJ O
interaction BC2GM094133140 NN O
with BC2GM094133140 IN O
splicing BC2GM094133140 VBG O
factor BC2GM094133140 NN O
U2AF65 BC2GM094133140 NNP O
bound BC2GM094133140 NN O
to BC2GM094133140 TO O
an BC2GM094133140 DT O
adjacent BC2GM094133140 JJ O
polypyrimidine BC2GM094133140 NN O
tract BC2GM094133140 NN O
( BC2GM094133140 ( O
PPT BC2GM094133140 NNP O
) BC2GM094133140 ) O
for BC2GM094133140 IN O
high-affinity BC2GM094133140 NN O
binding BC2GM094133140 NN O
. BC2GM094133140 . O
. . O O

Over BC2GM014061737 IN O
a BC2GM014061737 DT O
period BC2GM014061737 NN O
of BC2GM014061737 IN O
five BC2GM014061737 CD O
training BC2GM014061737 NN O
sessions BC2GM014061737 NNS O
( BC2GM014061737 ( O
2.5 BC2GM014061737 CD O
days BC2GM014061737 NNS O
) BC2GM014061737 ) O
, BC2GM014061737 , O
the BC2GM014061737 DT O
animals BC2GM014061737 NNS O
learned BC2GM014061737 VBD O
not BC2GM014061737 RB O
to BC2GM014061737 TO O
breathe BC2GM014061737 VB O
, BC2GM014061737 , O
and BC2GM014061737 CC O
the BC2GM014061737 DT O
number BC2GM014061737 NN O
of BC2GM014061737 IN O
stimuli BC2GM014061737 NNS O
received BC2GM014061737 VBN O
in BC2GM014061737 IN O
the BC2GM014061737 DT O
fifth BC2GM014061737 JJ O
session BC2GM014061737 NN O
was BC2GM014061737 VBD O
significantly BC2GM014061737 RB O
lower BC2GM014061737 JJR O
than BC2GM014061737 IN O
in BC2GM014061737 IN O
the BC2GM014061737 DT O
first BC2GM014061737 JJ O
session BC2GM014061737 NN O
. BC2GM014061737 . O
. . O O

Fusion BC2GM022693469 NN O
proteins BC2GM022693469 NNS O
were BC2GM022693469 VBD O
isolated BC2GM022693469 VBN O
by BC2GM022693469 IN O
affinity BC2GM022693469 NN O
chromatography BC2GM022693469 NN O
on BC2GM022693469 IN O
APTG-Sepharose BC2GM022693469 NNP O
. BC2GM022693469 . O
. . O O

Similar BC2GM048352135 JJ O
to BC2GM048352135 TO O
the BC2GM048352135 DT O
D BC2GM048352135 NNP O
, BC2GM048352135 , O
B BC2GM048352135 NNP O
/ BC2GM048352135 NNP O
B BC2GM048352135 NNP O
' BC2GM048352135 POS O
and BC2GM048352135 CC O
E BC2GM048352135 NNP O
proteins BC2GM048352135 NNS O
, BC2GM048352135 , O
the BC2GM048352135 DT O
F BC2GM048352135 NNP O
and BC2GM048352135 CC O
G BC2GM048352135 NNP O
proteins BC2GM048352135 NNS O
do BC2GM048352135 VBP O
not BC2GM048352135 RB O
possess BC2GM048352135 VB O
any BC2GM048352135 DT O
of BC2GM048352135 IN O
the BC2GM048352135 DT O
known BC2GM048352135 VBN O
RNA BC2GM048352135 NNP O
binding BC2GM048352135 VBG O
motifs BC2GM048352135 NNS O
, BC2GM048352135 , O
suggesting BC2GM048352135 VBG O
that BC2GM048352135 IN O
other BC2GM048352135 JJ O
types BC2GM048352135 NNS O
of BC2GM048352135 IN O
RNA-protein BC2GM048352135 NNP O
interactions BC2GM048352135 NNS O
occur BC2GM048352135 VBP O
in BC2GM048352135 IN O
the BC2GM048352135 DT O
snRNP BC2GM048352135 NN O
core BC2GM048352135 NN O
. BC2GM048352135 . O
. . O O

Residues BC2GM083865368 NNS O
of BC2GM083865368 IN O
Stauffer BC2GM083865368 NNP O
R-3828 BC2GM083865368 NNP O
and BC2GM083865368 CC O
its BC2GM083865368 PRP$ O
oxygen BC2GM083865368 NN O
analogue BC2GM083865368 NN O
in BC2GM083865368 IN O
the BC2GM083865368 DT O
body BC2GM083865368 NN O
tissues BC2GM083865368 NNS O
of BC2GM083865368 IN O
cattle BC2GM083865368 NNS O
fed BC2GM083865368 VBN O
R-3828 BC2GM083865368 NNP O
in BC2GM083865368 IN O
the BC2GM083865368 DT O
diet BC2GM083865368 NN O
. BC2GM083865368 . O
. . O O

Penicillamine-induced BC2GM078652752 NNP O
myasthenia BC2GM078652752 NN O
gravis BC2GM078652752 NN O
associated BC2GM078652752 VBN O
with BC2GM078652752 IN O
antibodies BC2GM078652752 NNS O
to BC2GM078652752 TO O
acetylcholine BC2GM078652752 VB O
receptor BC2GM078652752 NN O
. BC2GM078652752 . O
. . O O

UV BC2GM078674905 NNP O
cross-linking BC2GM078674905 NN O
and BC2GM078674905 CC O
Southwestern BC2GM078674905 NNP O
analysis BC2GM078674905 NN O
suggested BC2GM078674905 VBD O
that BC2GM078674905 IN O
KTP1 BC2GM078674905 NNP O
is BC2GM078674905 VBZ O
a BC2GM078674905 DT O
DNA-binding BC2GM078674905 JJ O
protein BC2GM078674905 NN O
clearly BC2GM078674905 RB O
distinct BC2GM078674905 JJ O
from BC2GM078674905 IN O
AP2 BC2GM078674905 NNP O
, BC2GM078674905 , O
and BC2GM078674905 CC O
this BC2GM078674905 DT O
protein BC2GM078674905 NN O
may BC2GM078674905 MD O
be BC2GM078674905 VB O
responsible BC2GM078674905 JJ O
for BC2GM078674905 IN O
the BC2GM078674905 DT O
basal BC2GM078674905 NN O
keratinocyte-specific BC2GM078674905 JJ O
expression BC2GM078674905 NN O
of BC2GM078674905 IN O
the BC2GM078674905 DT O
BPAG1 BC2GM078674905 NNP O
gene BC2GM078674905 NN O
. BC2GM078674905 . O
. . O O

For BC2GM010655694 IN O
the BC2GM010655694 DT O
first BC2GM010655694 JJ O
, BC2GM010655694 , O
short-term BC2GM010655694 JJ O
( BC2GM010655694 ( O
concurrent BC2GM010655694 NN O
) BC2GM010655694 ) O
TAL BC2GM010655694 NNP O
, BC2GM010655694 , O
two BC2GM010655694 CD O
different-flavored BC2GM010655694 JJ O
stimuli BC2GM010655694 NNS O
were BC2GM010655694 VBD O
presented BC2GM010655694 VBN O
at BC2GM010655694 IN O
the BC2GM010655694 DT O
same BC2GM010655694 JJ O
time BC2GM010655694 NN O
, BC2GM010655694 , O
one BC2GM010655694 CD O
associated BC2GM010655694 VBN O
with BC2GM010655694 IN O
simultaneous BC2GM010655694 JJ O
intragastric BC2GM010655694 JJ O
administration BC2GM010655694 NN O
of BC2GM010655694 IN O
an BC2GM010655694 DT O
aversive BC2GM010655694 JJ O
product BC2GM010655694 NN O
, BC2GM010655694 , O
hypertonic BC2GM010655694 JJ O
NaCl BC2GM010655694 NNP O
, BC2GM010655694 , O
and BC2GM010655694 CC O
the BC2GM010655694 DT O
other BC2GM010655694 JJ O
with BC2GM010655694 IN O
saline BC2GM010655694 NN O
. BC2GM010655694 . O
. . O O

Copyright BC2GM091665948 JJ O
1999 BC2GM091665948 CD O
Academic BC2GM091665948 NNP O
Press BC2GM091665948 NNP O
. BC2GM091665948 . O
. . O O

Subsequent BC2GM061773962 JJ O
analysis BC2GM061773962 NN O
revealed BC2GM061773962 VBD O
that BC2GM061773962 IN O
MyD88 BC2GM061773962 NNP O
possesses BC2GM061773962 VBZ O
a BC2GM061773962 DT O
unique BC2GM061773962 JJ O
modular BC2GM061773962 JJ O
structure BC2GM061773962 NN O
, BC2GM061773962 , O
which BC2GM061773962 WDT O
consists BC2GM061773962 VBZ O
of BC2GM061773962 IN O
an BC2GM061773962 DT O
N-terminal BC2GM061773962 JJ O
`` BC2GM061773962 `` O
death BC2GM061773962 NN O
domain BC2GM061773962 NN O
, BC2GM061773962 , O
'' BC2GM061773962 '' O
similar BC2GM061773962 JJ O
to BC2GM061773962 TO O
the BC2GM061773962 DT O
intracellular BC2GM061773962 JJ O
segments BC2GM061773962 NNS O
of BC2GM061773962 IN O
TNF BC2GM061773962 NNP O
receptor BC2GM061773962 NN O
1 BC2GM061773962 CD O
and BC2GM061773962 CC O
Fas BC2GM061773962 NNP O
, BC2GM061773962 , O
and BC2GM061773962 CC O
a BC2GM061773962 DT O
C-terminal BC2GM061773962 JJ O
region BC2GM061773962 NN O
related BC2GM061773962 VBN O
to BC2GM061773962 TO O
the BC2GM061773962 DT O
cytoplasmic BC2GM061773962 JJ O
domains BC2GM061773962 NNS O
of BC2GM061773962 IN O
the BC2GM061773962 DT O
Drosophila BC2GM061773962 NNP O
morphogen BC2GM061773962 NN O
Toll BC2GM061773962 NNP O
and BC2GM061773962 CC O
vertebrate BC2GM061773962 VB O
interleukin-1 BC2GM061773962 JJ O
receptors BC2GM061773962 NNS O
. BC2GM061773962 . O
. . O O

Using BC2GM081722350 VBG O
a BC2GM081722350 DT O
GTP-dependent BC2GM081722350 JJ O
, BC2GM081722350 , O
brefeldin BC2GM081722350 JJ O
A-sensitive BC2GM081722350 JJ O
in BC2GM081722350 IN O
vitro BC2GM081722350 JJ O
AP-1 BC2GM081722350 NNP O
binding BC2GM081722350 NN O
assay BC2GM081722350 NN O
, BC2GM081722350 , O
we BC2GM081722350 PRP O
have BC2GM081722350 VBP O
determined BC2GM081722350 VBN O
here BC2GM081722350 RB O
the BC2GM081722350 DT O
parameters BC2GM081722350 NNS O
of BC2GM081722350 IN O
the BC2GM081722350 DT O
AP-1 BC2GM081722350 NNP O
binding BC2GM081722350 NN O
reaction BC2GM081722350 NN O
. BC2GM081722350 . O
. . O O

As BC2GM022332450 IN O
in BC2GM022332450 IN O
the BC2GM022332450 DT O
case BC2GM022332450 NN O
of BC2GM022332450 IN O
the BC2GM022332450 DT O
chicken BC2GM022332450 NN O
homologue BC2GM022332450 NN O
, BC2GM022332450 , O
there BC2GM022332450 EX O
are BC2GM022332450 VBP O
two BC2GM022332450 CD O
hPR BC2GM022332450 JJ O
forms BC2GM022332450 NNS O
, BC2GM022332450 , O
A BC2GM022332450 NNP O
and BC2GM022332450 CC O
B BC2GM022332450 NNP O
, BC2GM022332450 , O
which BC2GM022332450 WDT O
originate BC2GM022332450 VBP O
from BC2GM022332450 IN O
translational BC2GM022332450 JJ O
initiation BC2GM022332450 NN O
at BC2GM022332450 IN O
AUG2 BC2GM022332450 NNP O
( BC2GM022332450 ( O
codon BC2GM022332450 VB O
165 BC2GM022332450 CD O
) BC2GM022332450 ) O
and BC2GM022332450 CC O
AUG1 BC2GM022332450 NNP O
, BC2GM022332450 , O
respectively BC2GM022332450 RB O
. BC2GM022332450 . O
. . O O

Furthermore BC2GM091220407 RB O
, BC2GM091220407 , O
the BC2GM091220407 DT O
secondary BC2GM091220407 JJ O
stress BC2GM091220407 NN O
responses BC2GM091220407 NNS O
were BC2GM091220407 VBD O
more BC2GM091220407 RBR O
pronounced BC2GM091220407 JJ O
and BC2GM091220407 CC O
the BC2GM091220407 DT O
ability BC2GM091220407 NN O
to BC2GM091220407 TO O
recover BC2GM091220407 VB O
from BC2GM091220407 IN O
them BC2GM091220407 PRP O
seemed BC2GM091220407 VBD O
to BC2GM091220407 TO O
be BC2GM091220407 VB O
impaired BC2GM091220407 VBN O
in BC2GM091220407 IN O
exposed BC2GM091220407 JJ O
fish BC2GM091220407 NN O
as BC2GM091220407 IN O
compared BC2GM091220407 VBN O
to BC2GM091220407 TO O
unexposed BC2GM091220407 JJ O
fish BC2GM091220407 NN O
. BC2GM091220407 . O
. . O O

The BC2GM084554864 DT O
results BC2GM084554864 NNS O
obtained BC2GM084554864 VBD O
show BC2GM084554864 NN O
that BC2GM084554864 IN O
expression BC2GM084554864 NN O
of BC2GM084554864 IN O
the BC2GM084554864 DT O
gene BC2GM084554864 NN O
is BC2GM084554864 VBZ O
low BC2GM084554864 JJ O
at BC2GM084554864 IN O
23 BC2GM084554864 CD O
degrees BC2GM084554864 NNS O
C BC2GM084554864 NNP O
and BC2GM084554864 CC O
is BC2GM084554864 VBZ O
induced BC2GM084554864 VBN O
rapidly BC2GM084554864 RB O
at BC2GM084554864 IN O
37 BC2GM084554864 CD O
degrees BC2GM084554864 NNS O
C BC2GM084554864 NNP O
. BC2GM084554864 . O
. . O O

The BC2GM024256148 DT O
plants BC2GM024256148 NNS O
were BC2GM024256148 VBD O
then BC2GM024256148 RB O
brought BC2GM024256148 VBN O
to BC2GM024256148 TO O
our BC2GM024256148 PRP$ O
Houston BC2GM024256148 NNP O
laboratory BC2GM024256148 NN O
where BC2GM024256148 WRB O
they BC2GM024256148 PRP O
were BC2GM024256148 VBD O
measured BC2GM024256148 VBN O
and BC2GM024256148 CC O
analyzed BC2GM024256148 VBN O
for BC2GM024256148 IN O
lignin BC2GM024256148 NN O
and BC2GM024256148 CC O
protein BC2GM024256148 NN O
content BC2GM024256148 NN O
and BC2GM024256148 CC O
for BC2GM024256148 IN O
phenylalanine BC2GM024256148 JJ O
ammonia-lyase BC2GM024256148 NN O
( BC2GM024256148 ( O
PAL BC2GM024256148 NNP O
) BC2GM024256148 ) O
and BC2GM024256148 CC O
peroxidase BC2GM024256148 JJ O
activities BC2GM024256148 NNS O
. BC2GM024256148 . O
. . O O

However BC2GM005335832 RB O
, BC2GM005335832 , O
the BC2GM005335832 DT O
sequence BC2GM005335832 NN O
of BC2GM005335832 IN O
mRAR-beta BC2GM005335832 JJ O
3 BC2GM005335832 CD O
region BC2GM005335832 NN O
A BC2GM005335832 DT O
differs BC2GM005335832 NNS O
from BC2GM005335832 IN O
that BC2GM005335832 DT O
of BC2GM005335832 IN O
mRAR-beta BC2GM005335832 JJ O
1 BC2GM005335832 CD O
by BC2GM005335832 IN O
an BC2GM005335832 DT O
additional BC2GM005335832 JJ O
27 BC2GM005335832 CD O
C-terminal BC2GM005335832 JJ O
amino BC2GM005335832 NN O
acids BC2GM005335832 NNS O
encoded BC2GM005335832 VBD O
in BC2GM005335832 IN O
an BC2GM005335832 DT O
81 BC2GM005335832 CD O
nucleotide-long BC2GM005335832 JJ O
putative BC2GM005335832 NN O
exon BC2GM005335832 NN O
which BC2GM005335832 WDT O
is BC2GM005335832 VBZ O
spliced BC2GM005335832 VBN O
in BC2GM005335832 IN O
between BC2GM005335832 IN O
the BC2GM005335832 DT O
exons BC2GM005335832 NNS O
encoding BC2GM005335832 VBG O
the BC2GM005335832 DT O
A BC2GM005335832 NNP O
and BC2GM005335832 CC O
B BC2GM005335832 NNP O
regions BC2GM005335832 NNS O
of BC2GM005335832 IN O
mRAR-beta BC2GM005335832 JJ O
1 BC2GM005335832 CD O
. BC2GM005335832 . O
. . O O

While BC2GM096155639 IN O
differential BC2GM096155639 JJ O
expression BC2GM096155639 NN O
of BC2GM096155639 IN O
the BC2GM096155639 DT O
two BC2GM096155639 CD O
transcripts BC2GM096155639 NNS O
was BC2GM096155639 VBD O
not BC2GM096155639 RB O
found BC2GM096155639 VBN O
, BC2GM096155639 , O
the BC2GM096155639 DT O
promoter BC2GM096155639 NN O
controlling BC2GM096155639 VBG O
LT1 BC2GM096155639 NNP O
/ BC2GM096155639 NNP O
LT2 BC2GM096155639 NNP O
transcription BC2GM096155639 NN O
is BC2GM096155639 VBZ O
regulated BC2GM096155639 VBN O
in BC2GM096155639 IN O
a BC2GM096155639 DT O
cell BC2GM096155639 NN O
cycle-dependent BC2GM096155639 JJ O
manner BC2GM096155639 NN O
. BC2GM096155639 . O
. . O O

S16 BC2GM065355579 NNP O
, BC2GM065355579 , O
16.8 BC2GM065355579 CD O
% BC2GM065355579 NN O
, BC2GM065355579 , O
P BC2GM065355579 NNP O
= BC2GM065355579 NNP O
0.001 BC2GM065355579 CD O
) BC2GM065355579 ) O
. BC2GM065355579 . O
. . O O

1H BC2GM043315404 CD O
and BC2GM043315404 CC O
15N BC2GM043315404 CD O
magnetic BC2GM043315404 JJ O
resonance BC2GM043315404 NN O
assignments BC2GM043315404 NNS O
, BC2GM043315404 , O
secondary BC2GM043315404 JJ O
structure BC2GM043315404 NN O
, BC2GM043315404 , O
and BC2GM043315404 CC O
tertiary BC2GM043315404 JJ O
fold BC2GM043315404 NN O
of BC2GM043315404 IN O
Escherichia BC2GM043315404 NNP O
coli BC2GM043315404 NNS O
DnaJ BC2GM043315404 NNP O
( BC2GM043315404 ( O
1-78 BC2GM043315404 JJ O
) BC2GM043315404 ) O
. BC2GM043315404 . O
. . O O

Here BC2GM088538156 RB O
, BC2GM088538156 , O
we BC2GM088538156 PRP O
describe BC2GM088538156 VBP O
the BC2GM088538156 DT O
nucleotide BC2GM088538156 NN O
( BC2GM088538156 ( O
nt BC2GM088538156 JJ O
) BC2GM088538156 ) O
sequence BC2GM088538156 NN O
and BC2GM088538156 CC O
genomic BC2GM088538156 JJ O
organization BC2GM088538156 NN O
of BC2GM088538156 IN O
ipiB BC2GM088538156 NN O
and BC2GM088538156 CC O
ipiO BC2GM088538156 NN O
. BC2GM088538156 . O
. . O O

A BC2GM073035412 DT O
cDNA BC2GM073035412 NN O
for BC2GM073035412 IN O
human BC2GM073035412 JJ O
microfibril-associated BC2GM073035412 JJ O
glycoprotein-2 BC2GM073035412 NN O
( BC2GM073035412 ( O
MAGP-2 BC2GM073035412 NNP O
) BC2GM073035412 ) O
was BC2GM073035412 VBD O
used BC2GM073035412 VBN O
to BC2GM073035412 TO O
screen BC2GM073035412 VB O
a BC2GM073035412 DT O
human BC2GM073035412 JJ O
leukocyte BC2GM073035412 NN O
genomic BC2GM073035412 JJ O
DNA BC2GM073035412 NNP O
library BC2GM073035412 NN O
in BC2GM073035412 IN O
EMBL-3 BC2GM073035412 NNP O
vector BC2GM073035412 NN O
. BC2GM073035412 . O
. . O O

Developmental BC2GM060829915 NNP O
slot BC2GM060829915 NN O
blots BC2GM060829915 NNS O
demonstrate BC2GM060829915 VBP O
that BC2GM060829915 IN O
mRNAs BC2GM060829915 NN O
corresponding BC2GM060829915 VBG O
to BC2GM060829915 TO O
the BC2GM060829915 DT O
three BC2GM060829915 CD O
LHM BC2GM060829915 NNP O
cDNAs BC2GM060829915 NN O
are BC2GM060829915 VBP O
transcribed BC2GM060829915 VBN O
from BC2GM060829915 IN O
prophase BC2GM060829915 NN O
of BC2GM060829915 IN O
meiosis BC2GM060829915 NN O
I BC2GM060829915 PRP O
to BC2GM060829915 TO O
the BC2GM060829915 DT O
uninucleate BC2GM060829915 JJ O
microspore BC2GM060829915 NN O
stage BC2GM060829915 NN O
, BC2GM060829915 , O
while BC2GM060829915 IN O
Northern BC2GM060829915 NNP O
analysis BC2GM060829915 NN O
reveals BC2GM060829915 NNS O
these BC2GM060829915 DT O
tapetally BC2GM060829915 RB O
expressed BC2GM060829915 VBN O
cDNAs BC2GM060829915 NN O
to BC2GM060829915 TO O
correspond BC2GM060829915 VB O
with BC2GM060829915 IN O
transcripts BC2GM060829915 NNS O
of BC2GM060829915 IN O
some BC2GM060829915 DT O
500 BC2GM060829915 CD O
bp BC2GM060829915 NNS O
. BC2GM060829915 . O
. . O O

Screening BC2GM032241035 VBG O
of BC2GM032241035 IN O
human BC2GM032241035 JJ O
cDNA BC2GM032241035 NN O
libraries BC2GM032241035 NNS O
has BC2GM032241035 VBZ O
identified BC2GM032241035 VBN O
two BC2GM032241035 CD O
different BC2GM032241035 JJ O
5'-termini BC2GM032241035 NNS O
and BC2GM032241035 CC O
alternatively BC2GM032241035 RB O
spliced BC2GM032241035 VBD O
forms BC2GM032241035 NNS O
of BC2GM032241035 IN O
the BC2GM032241035 DT O
human BC2GM032241035 JJ O
Fli-1 BC2GM032241035 NNP O
gene BC2GM032241035 NN O
( BC2GM032241035 ( O
Fli-1b BC2GM032241035 NNP O
) BC2GM032241035 ) O
, BC2GM032241035 , O
suggesting BC2GM032241035 VBG O
the BC2GM032241035 DT O
possible BC2GM032241035 JJ O
existence BC2GM032241035 NN O
of BC2GM032241035 IN O
two BC2GM032241035 CD O
independent BC2GM032241035 JJ O
promoters BC2GM032241035 NNS O
. BC2GM032241035 . O
. . O O

RESULTS BC2GM032337812 NN O
: BC2GM032337812 : O
Here BC2GM032337812 RB O
, BC2GM032337812 , O
we BC2GM032337812 PRP O
report BC2GM032337812 VBP O
the BC2GM032337812 DT O
identification BC2GM032337812 NN O
of BC2GM032337812 IN O
two BC2GM032337812 CD O
major BC2GM032337812 JJ O
and BC2GM032337812 CC O
novel BC2GM032337812 JJ O
Shc BC2GM032337812 NNP O
tyrosine BC2GM032337812 NN O
phosphorylation BC2GM032337812 NN O
sites BC2GM032337812 NNS O
, BC2GM032337812 , O
Y239 BC2GM032337812 NNP O
and BC2GM032337812 CC O
Y240 BC2GM032337812 NNP O
. BC2GM032337812 . O
. . O O

Lag BC2GM081353874 NN O
phases BC2GM081353874 NNS O
were BC2GM081353874 VBD O
14.89 BC2GM081353874 CD O
hours BC2GM081353874 NNS O
+ BC2GM081353874 JJ O
/ BC2GM081353874 NNP O
- BC2GM081353874 : O
0.77 BC2GM081353874 CD O
, BC2GM081353874 , O
13.33 BC2GM081353874 CD O
hours BC2GM081353874 NNS O
+ BC2GM081353874 JJ O
/ BC2GM081353874 NNP O
- BC2GM081353874 : O
0.50 BC2GM081353874 CD O
, BC2GM081353874 , O
20.22 BC2GM081353874 CD O
hours BC2GM081353874 NNS O
+ BC2GM081353874 JJ O
/ BC2GM081353874 NNP O
- BC2GM081353874 : O
0.76 BC2GM081353874 CD O
, BC2GM081353874 , O
and BC2GM081353874 CC O
20.00 BC2GM081353874 CD O
hours BC2GM081353874 NNS O
+ BC2GM081353874 JJ O
/ BC2GM081353874 NNP O
- BC2GM081353874 : O
0.79 BC2GM081353874 CD O
, BC2GM081353874 , O
respectively BC2GM081353874 RB O
, BC2GM081353874 , O
for BC2GM081353874 IN O
endothelial BC2GM081353874 JJ O
cell-induced BC2GM081353874 JJ O
LDL BC2GM081353874 NNP O
oxidation BC2GM081353874 NN O
. BC2GM081353874 . O
. . O O

3 BC2GM011031439 CD O
. BC2GM011031439 . O
. . O O

Highly BC2GM027073602 RB O
conserved BC2GM027073602 VBN O
regions BC2GM027073602 NNS O
called BC2GM027073602 VBD O
src BC2GM027073602 JJ O
homology BC2GM027073602 NN O
2 BC2GM027073602 CD O
and BC2GM027073602 CC O
3 BC2GM027073602 CD O
( BC2GM027073602 ( O
SH2 BC2GM027073602 NNP O
and BC2GM027073602 CC O
SH3 BC2GM027073602 NNP O
) BC2GM027073602 ) O
, BC2GM027073602 , O
comprising BC2GM027073602 VBG O
amino BC2GM027073602 NN O
acid BC2GM027073602 NN O
residues BC2GM027073602 VBZ O
88 BC2GM027073602 CD O
to BC2GM027073602 TO O
250 BC2GM027073602 CD O
, BC2GM027073602 , O
are BC2GM027073602 VBP O
believed BC2GM027073602 VBN O
to BC2GM027073602 TO O
modulate BC2GM027073602 VB O
the BC2GM027073602 DT O
protein-tyrosine BC2GM027073602 JJ O
kinase BC2GM027073602 NN O
activity BC2GM027073602 NN O
present BC2GM027073602 NN O
in BC2GM027073602 IN O
the BC2GM027073602 DT O
carboxy-terminal BC2GM027073602 JJ O
halves BC2GM027073602 NNS O
of BC2GM027073602 IN O
the BC2GM027073602 DT O
src BC2GM027073602 NN O
proteins BC2GM027073602 NNS O
. BC2GM027073602 . O
. . O O

Both BC2GM049997228 DT O
genes BC2GM049997228 NNS O
ARO3 BC2GM049997228 NNP O
and BC2GM049997228 CC O
ARO4 BC2GM049997228 NNP O
are BC2GM049997228 VBP O
strongly BC2GM049997228 RB O
regulated BC2GM049997228 VBN O
under BC2GM049997228 IN O
the BC2GM049997228 DT O
general BC2GM049997228 JJ O
control BC2GM049997228 NN O
regulatory BC2GM049997228 JJ O
system BC2GM049997228 NN O
. BC2GM049997228 . O
. . O O

We BC2GM057515981 PRP O
analyzed BC2GM057515981 VBD O
the BC2GM057515981 DT O
contribution BC2GM057515981 NN O
of BC2GM057515981 IN O
the BC2GM057515981 DT O
three BC2GM057515981 CD O
different BC2GM057515981 JJ O
types BC2GM057515981 NNS O
of BC2GM057515981 IN O
UV-inducible BC2GM057515981 JJ O
mitogen-activated BC2GM057515981 JJ O
protein BC2GM057515981 NN O
( BC2GM057515981 ( O
MAP BC2GM057515981 NNP O
) BC2GM057515981 ) O
kinases BC2GM057515981 VBZ O
( BC2GM057515981 ( O
ERK BC2GM057515981 NNP O
, BC2GM057515981 , O
JNK BC2GM057515981 NNP O
/ BC2GM057515981 NNP O
SAPK BC2GM057515981 NNP O
, BC2GM057515981 , O
and BC2GM057515981 CC O
p38 BC2GM057515981 NN O
) BC2GM057515981 ) O
to BC2GM057515981 TO O
the BC2GM057515981 DT O
activation BC2GM057515981 NN O
of BC2GM057515981 IN O
the BC2GM057515981 DT O
murine BC2GM057515981 NN O
uPA BC2GM057515981 JJ O
promoter BC2GM057515981 NN O
by BC2GM057515981 IN O
UV BC2GM057515981 NNP O
. BC2GM057515981 . O
. . O O

This BC2GM070035080 DT O
regulation BC2GM070035080 NN O
is BC2GM070035080 VBZ O
mediated BC2GM070035080 VBN O
by BC2GM070035080 IN O
several BC2GM070035080 JJ O
kinases BC2GM070035080 NNS O
that BC2GM070035080 WDT O
phosphorylate BC2GM070035080 VBP O
specific BC2GM070035080 JJ O
residues BC2GM070035080 NNS O
in BC2GM070035080 IN O
the BC2GM070035080 DT O
different BC2GM070035080 JJ O
functional BC2GM070035080 JJ O
domains BC2GM070035080 NNS O
of BC2GM070035080 IN O
the BC2GM070035080 DT O
p53 BC2GM070035080 NN O
molecule BC2GM070035080 NN O
. BC2GM070035080 . O
. . O O

In BC2GM005475872 IN O
addition BC2GM005475872 NN O
, BC2GM005475872 , O
six BC2GM005475872 CD O
other BC2GM005475872 JJ O
landmarks BC2GM005475872 NNS O
favored BC2GM005475872 VBD O
the BC2GM005475872 DT O
xeroradiograph BC2GM005475872 NN O
but BC2GM005475872 CC O
not BC2GM005475872 RB O
to BC2GM005475872 TO O
the BC2GM005475872 DT O
degree BC2GM005475872 NN O
of BC2GM005475872 IN O
statistical BC2GM005475872 JJ O
significance BC2GM005475872 NN O
. BC2GM005475872 . O
. . O O

In BC2GM042560945 IN O
addition BC2GM042560945 NN O
, BC2GM042560945 , O
269 BC2GM042560945 CD O
mice BC2GM042560945 NN O
from BC2GM042560945 IN O
a BC2GM042560945 DT O
( BC2GM042560945 ( O
Mus BC2GM042560945 NNP O
spretus BC2GM042560945 NN O
x BC2GM042560945 NNP O
C57BL BC2GM042560945 NNP O
/ BC2GM042560945 NNP O
6J BC2GM042560945 CD O
) BC2GM042560945 ) O
F1 BC2GM042560945 NNP O
x BC2GM042560945 NNP O
C57BL BC2GM042560945 NNP O
/ BC2GM042560945 VBD O
6J BC2GM042560945 CD O
interspecific BC2GM042560945 JJ O
backcross BC2GM042560945 NN O
were BC2GM042560945 VBD O
also BC2GM042560945 RB O
used BC2GM042560945 VBN O
to BC2GM042560945 TO O
order BC2GM042560945 NN O
marker BC2GM042560945 NN O
loci BC2GM042560945 NN O
and BC2GM042560945 CC O
calculate BC2GM042560945 VB O
intergene BC2GM042560945 NN O
distances BC2GM042560945 NNS O
for BC2GM042560945 IN O
this BC2GM042560945 DT O
region BC2GM042560945 NN O
. BC2GM042560945 . O
. . O O

These BC2GM082129693 DT O
cDNAs BC2GM082129693 NNS O
were BC2GM082129693 VBD O
found BC2GM082129693 VBN O
to BC2GM082129693 TO O
be BC2GM082129693 VB O
derived BC2GM082129693 VBN O
from BC2GM082129693 IN O
the BC2GM082129693 DT O
3 BC2GM082129693 CD O
'' BC2GM082129693 '' O
-untranslated BC2GM082129693 VBN O
region BC2GM082129693 NN O
( BC2GM082129693 ( O
3 BC2GM082129693 CD O
'' BC2GM082129693 '' O
-UTR BC2GM082129693 NN O
) BC2GM082129693 ) O
of BC2GM082129693 IN O
the BC2GM082129693 DT O
methyl-CpG-binding BC2GM082129693 JJ O
protein BC2GM082129693 NN O
2 BC2GM082129693 CD O
gene BC2GM082129693 NN O
( BC2GM082129693 ( O
MeCP2 BC2GM082129693 NNP O
) BC2GM082129693 ) O
. BC2GM082129693 . O
. . O O

Instead BC2GM027824972 RB O
, BC2GM027824972 , O
HBx BC2GM027824972 NNP O
is BC2GM027824972 VBZ O
shown BC2GM027824972 VBN O
to BC2GM027824972 TO O
activate BC2GM027824972 VB O
the BC2GM027824972 DT O
cyclin BC2GM027824972 NN O
A BC2GM027824972 NNP O
promoter BC2GM027824972 NN O
, BC2GM027824972 , O
induce BC2GM027824972 VB O
cyclin BC2GM027824972 JJ O
A-cyclin-dependent BC2GM027824972 JJ O
kinase BC2GM027824972 NN O
2 BC2GM027824972 CD O
complexes BC2GM027824972 NNS O
, BC2GM027824972 , O
and BC2GM027824972 CC O
promote BC2GM027824972 VBP O
cycling BC2GM027824972 NN O
of BC2GM027824972 IN O
growth-arrested BC2GM027824972 JJ O
cells BC2GM027824972 NNS O
into BC2GM027824972 IN O
G1 BC2GM027824972 NNP O
through BC2GM027824972 IN O
a BC2GM027824972 DT O
pathway BC2GM027824972 NN O
involving BC2GM027824972 VBG O
activation BC2GM027824972 NN O
of BC2GM027824972 IN O
Src BC2GM027824972 NNP O
tyrosine BC2GM027824972 NN O
kinases BC2GM027824972 NNS O
. BC2GM027824972 . O
. . O O

Further BC2GM023518208 RB O
, BC2GM023518208 , O
more BC2GM023518208 RBR O
recent BC2GM023518208 JJ O
communications BC2GM023518208 NNS O
suggest BC2GM023518208 VBP O
that BC2GM023518208 IN O
liver BC2GM023518208 NN O
disease BC2GM023518208 NN O
led BC2GM023518208 VBD O
to BC2GM023518208 TO O
a BC2GM023518208 DT O
differential BC2GM023518208 JJ O
alteration BC2GM023518208 NN O
of BC2GM023518208 IN O
the BC2GM023518208 DT O
cytochrome BC2GM023518208 JJ O
P-450s BC2GM023518208 NNP O
with BC2GM023518208 IN O
regard BC2GM023518208 NN O
to BC2GM023518208 TO O
protein BC2GM023518208 VB O
content BC2GM023518208 JJ O
and BC2GM023518208 CC O
activity BC2GM023518208 NN O
. BC2GM023518208 . O
. . O O

AIMS BC2GM072307565 NNS O
: BC2GM072307565 : O
The BC2GM072307565 DT O
aim BC2GM072307565 NN O
of BC2GM072307565 IN O
this BC2GM072307565 DT O
study BC2GM072307565 NN O
was BC2GM072307565 VBD O
to BC2GM072307565 TO O
assess BC2GM072307565 VB O
static BC2GM072307565 JJ O
and BC2GM072307565 CC O
dynamic BC2GM072307565 JJ O
bone BC2GM072307565 NN O
changes BC2GM072307565 NNS O
in BC2GM072307565 IN O
patients BC2GM072307565 NNS O
suffering BC2GM072307565 VBG O
from BC2GM072307565 IN O
rickets BC2GM072307565 NNS O
. BC2GM072307565 . O
. . O O

Methylprednisolone BC2GM074690721 NN O
and BC2GM074690721 CC O
U-74006F BC2GM074690721 NNP O
were BC2GM074690721 VBD O
equally BC2GM074690721 RB O
effective BC2GM074690721 JJ O
at BC2GM074690721 IN O
preventing BC2GM074690721 VBG O
neurological BC2GM074690721 JJ O
dysfunction BC2GM074690721 NN O
compared BC2GM074690721 VBN O
to BC2GM074690721 TO O
the BC2GM074690721 DT O
control BC2GM074690721 NN O
group BC2GM074690721 NN O
( BC2GM074690721 ( O
p BC2GM074690721 VBZ O
less BC2GM074690721 JJR O
than BC2GM074690721 IN O
0.01 BC2GM074690721 CD O
) BC2GM074690721 ) O
; BC2GM074690721 : O
U-78517F BC2GM074690721 NNP O
was BC2GM074690721 VBD O
slightly BC2GM074690721 RB O
less BC2GM074690721 RBR O
effective BC2GM074690721 JJ O
than BC2GM074690721 IN O
U-74006F BC2GM074690721 NNP O
and BC2GM074690721 CC O
methylprednisolone BC2GM074690721 NN O
but BC2GM074690721 CC O
was BC2GM074690721 VBD O
significantly BC2GM074690721 RB O
better BC2GM074690721 JJR O
than BC2GM074690721 IN O
vehicle BC2GM074690721 NN O
in BC2GM074690721 IN O
preventing BC2GM074690721 VBG O
neurological BC2GM074690721 JJ O
dysfunction BC2GM074690721 NN O
. BC2GM074690721 . O
. . O O

Anovulatory BC2GM015287152 JJ O
cycles BC2GM015287152 NNS O
with BC2GM015287152 IN O
an BC2GM015287152 DT O
apparently BC2GM015287152 RB O
normal BC2GM015287152 JJ O
level BC2GM015287152 NN O
of BC2GM015287152 IN O
blood BC2GM015287152 NN O
prolactin BC2GM015287152 NN O
. BC2GM015287152 . O
. . O O

HPV-16 BC2GM070953330 JJ O
MARs BC2GM070953330 NNP O
are BC2GM070953330 VBP O
context BC2GM070953330 JJ O
dependent BC2GM070953330 JJ O
transcriptional BC2GM070953330 JJ O
enhancers BC2GM070953330 NNS O
, BC2GM070953330 , O
and BC2GM070953330 CC O
activated BC2GM070953330 VBD O
expression BC2GM070953330 NN O
of BC2GM070953330 IN O
HPV-16 BC2GM070953330 NNP O
oncogenes BC2GM070953330 NNS O
dependent BC2GM070953330 NN O
on BC2GM070953330 IN O
chromosomal BC2GM070953330 JJ O
integration BC2GM070953330 NN O
may BC2GM070953330 MD O
positively BC2GM070953330 RB O
select BC2GM070953330 VB O
tumorigenic BC2GM070953330 JJ O
cells BC2GM070953330 NNS O
during BC2GM070953330 IN O
the BC2GM070953330 DT O
multistep BC2GM070953330 NN O
etiology BC2GM070953330 NN O
of BC2GM070953330 IN O
cervical BC2GM070953330 JJ O
cancer BC2GM070953330 NN O
. BC2GM070953330 . O
. . O O

It BC2GM094013655 PRP O
is BC2GM094013655 VBZ O
postulated BC2GM094013655 VBN O
that BC2GM094013655 IN O
the BC2GM094013655 DT O
synthesis BC2GM094013655 NN O
of BC2GM094013655 IN O
the BC2GM094013655 DT O
peptidoglycan BC2GM094013655 JJ O
layer BC2GM094013655 NN O
was BC2GM094013655 VBD O
affected BC2GM094013655 VBN O
by BC2GM094013655 IN O
the BC2GM094013655 DT O
antimetabolites BC2GM094013655 NNS O
since BC2GM094013655 IN O
the BC2GM094013655 DT O
morphological BC2GM094013655 JJ O
effects BC2GM094013655 NNS O
were BC2GM094013655 VBD O
strikingly BC2GM094013655 RB O
similar BC2GM094013655 JJ O
to BC2GM094013655 TO O
those BC2GM094013655 DT O
caused BC2GM094013655 VBN O
by BC2GM094013655 IN O
treatment BC2GM094013655 NN O
of BC2GM094013655 IN O
E. BC2GM094013655 NNP O
cloacae BC2GM094013655 NN O
with BC2GM094013655 IN O
disodium BC2GM094013655 NN O
edetate BC2GM094013655 NN O
plus BC2GM094013655 CC O
lysozyme BC2GM094013655 NN O
. BC2GM094013655 . O
. . O O

The BC2GM081350038 DT O
data BC2GM081350038 NN O
show BC2GM081350038 NN O
that BC2GM081350038 IN O
processing BC2GM081350038 VBG O
time BC2GM081350038 NN O
as BC2GM081350038 IN O
a BC2GM081350038 DT O
function BC2GM081350038 NN O
of BC2GM081350038 IN O
intensity BC2GM081350038 NN O
is BC2GM081350038 VBZ O
modified BC2GM081350038 VBN O
not BC2GM081350038 RB O
only BC2GM081350038 RB O
at BC2GM081350038 IN O
the BC2GM081350038 DT O
retina BC2GM081350038 NN O
but BC2GM081350038 CC O
also BC2GM081350038 RB O
at BC2GM081350038 IN O
later BC2GM081350038 RB O
processing BC2GM081350038 VBG O
sites BC2GM081350038 NNS O
. BC2GM081350038 . O
. . O O

It BC2GM073487820 PRP O
is BC2GM073487820 VBZ O
noteworthy BC2GM073487820 JJ O
that BC2GM073487820 IN O
under BC2GM073487820 IN O
more BC2GM073487820 JJR O
physiological BC2GM073487820 JJ O
conditions BC2GM073487820 NNS O
mimicking BC2GM073487820 VBG O
the BC2GM073487820 DT O
cellular BC2GM073487820 JJ O
GDP BC2GM073487820 NNP O
/ BC2GM073487820 NNP O
GTP BC2GM073487820 NNP O
ratio BC2GM073487820 NN O
, BC2GM073487820 , O
Raf BC2GM073487820 NNP O
enhances BC2GM073487820 VBZ O
the BC2GM073487820 DT O
GEF-stimulated BC2GM073487820 JJ O
GDP BC2GM073487820 NNP O
/ BC2GM073487820 NNP O
GTP BC2GM073487820 NNP O
exchange BC2GM073487820 NN O
on BC2GM073487820 IN O
Ha-Ras BC2GM073487820 NNP O
, BC2GM073487820 , O
in BC2GM073487820 IN O
agreement BC2GM073487820 NN O
with BC2GM073487820 IN O
the BC2GM073487820 DT O
sequestration BC2GM073487820 NN O
of BC2GM073487820 IN O
Ras.GTP BC2GM073487820 NNP O
by BC2GM073487820 IN O
Raf BC2GM073487820 NNP O
. BC2GM073487820 . O
. . O O

Combined BC2GM085389685 VBN O
chemotherapy BC2GM085389685 NN O
with BC2GM085389685 IN O
VM BC2GM085389685 NNP O
26 BC2GM085389685 CD O
and BC2GM085389685 CC O
BCNU BC2GM085389685 NNP O
for BC2GM085389685 IN O
recurrent BC2GM085389685 NN O
malignant BC2GM085389685 NN O
gliomas BC2GM085389685 NN O
after BC2GM085389685 IN O
operation BC2GM085389685 NN O
and BC2GM085389685 CC O
irradiation BC2GM085389685 NN O
. BC2GM085389685 . O
. . O O

Therefore BC2GM051957137 RB O
, BC2GM051957137 , O
we BC2GM051957137 PRP O
have BC2GM051957137 VBP O
reevaluated BC2GM051957137 VBN O
the BC2GM051957137 DT O
age-related BC2GM051957137 JJ O
changes BC2GM051957137 NNS O
in BC2GM051957137 IN O
serum BC2GM051957137 NN O
leptin BC2GM051957137 NN O
levels BC2GM051957137 NNS O
and BC2GM051957137 CC O
their BC2GM051957137 PRP$ O
relationship BC2GM051957137 NN O
with BC2GM051957137 IN O
adiposity BC2GM051957137 NN O
and BC2GM051957137 CC O
androgen BC2GM051957137 NN O
levels BC2GM051957137 NNS O
in BC2GM051957137 IN O
a BC2GM051957137 DT O
large BC2GM051957137 JJ O
group BC2GM051957137 NN O
of BC2GM051957137 IN O
community BC2GM051957137 NN O
dwelling BC2GM051957137 VBG O
men BC2GM051957137 NNS O
. BC2GM051957137 . O
. . O O

Phenacetin BC2GM048198274 NNP O
nephritis BC2GM048198274 NN O
. BC2GM048198274 . O
. . O O

Post-CPB BC2GM093522380 NNP O
cardiac BC2GM093522380 JJ O
index BC2GM093522380 NN O
was BC2GM093522380 VBD O
superior BC2GM093522380 JJ O
in BC2GM093522380 IN O
group BC2GM093522380 NN O
B BC2GM093522380 NNP O
( BC2GM093522380 ( O
3.9+ BC2GM093522380 CD O
/ BC2GM093522380 NNP O
-0.3 BC2GM093522380 NNP O
vs BC2GM093522380 NN O
. BC2GM093522380 . O
. . O O

Changes BC2GM069431845 NNS O
in BC2GM069431845 IN O
testicular BC2GM069431845 JJ O
testosterone BC2GM069431845 NN O
and BC2GM069431845 CC O
acid BC2GM069431845 NN O
and BC2GM069431845 CC O
alkaline BC2GM069431845 JJ O
phosphatase BC2GM069431845 NN O
activity BC2GM069431845 NN O
in BC2GM069431845 IN O
testis BC2GM069431845 NN O
and BC2GM069431845 CC O
accessory BC2GM069431845 JJ O
sex BC2GM069431845 NN O
organs BC2GM069431845 NNS O
after BC2GM069431845 IN O
induction BC2GM069431845 NN O
of BC2GM069431845 IN O
varicocele BC2GM069431845 NN O
in BC2GM069431845 IN O
Noble BC2GM069431845 JJ O
rats BC2GM069431845 NNS O
. BC2GM069431845 . O
. . O O

When BC2GM076004917 WRB O
the BC2GM076004917 DT O
opioid BC2GM076004917 JJ O
antagonist BC2GM076004917 NN O
was BC2GM076004917 VBD O
administered BC2GM076004917 VBN O
to BC2GM076004917 TO O
animals BC2GM076004917 NNS O
24 BC2GM076004917 CD O
hr BC2GM076004917 NN O
after BC2GM076004917 IN O
termination BC2GM076004917 NN O
of BC2GM076004917 IN O
single BC2GM076004917 JJ O
or BC2GM076004917 CC O
multiple BC2GM076004917 JJ O
exposures BC2GM076004917 NNS O
to BC2GM076004917 TO O
restraint BC2GM076004917 VB O
, BC2GM076004917 , O
NALT-induced BC2GM076004917 JJ O
increases BC2GM076004917 NNS O
in BC2GM076004917 IN O
basal BC2GM076004917 NN O
plasma BC2GM076004917 NN O
LH BC2GM076004917 NNP O
were BC2GM076004917 VBD O
significantly BC2GM076004917 RB O
attenuated BC2GM076004917 VBN O
in BC2GM076004917 IN O
the BC2GM076004917 DT O
chronically BC2GM076004917 RB O
stressed BC2GM076004917 JJ O
rats BC2GM076004917 NNS O
compared BC2GM076004917 VBN O
to BC2GM076004917 TO O
animals BC2GM076004917 NNS O
subjected BC2GM076004917 VBN O
to BC2GM076004917 TO O
stress BC2GM076004917 VB O
only BC2GM076004917 RB O
once BC2GM076004917 RB O
or BC2GM076004917 CC O
not BC2GM076004917 RB O
at BC2GM076004917 IN O
all BC2GM076004917 DT O
. BC2GM076004917 . O
( BC2GM076004917 ( O
ABSTRACT BC2GM076004917 NNP O
TRUNCATED BC2GM076004917 NNP O
AT BC2GM076004917 NNP O
250 BC2GM076004917 CD O
WORDS BC2GM076004917 NNP O
) BC2GM076004917 ) O
. BC2GM076004917 . O
. . O O

YLL031c BC2GM087141217 NNP O
is BC2GM087141217 VBZ O
an BC2GM087141217 DT O
essential BC2GM087141217 JJ O
gene BC2GM087141217 NN O
. BC2GM087141217 . O
. . O O

A BC2GM000360337 DT O
series BC2GM000360337 NN O
of BC2GM000360337 IN O
deletion BC2GM000360337 NN O
mutants BC2GM000360337 NNS O
was BC2GM000360337 VBD O
expressed BC2GM000360337 VBN O
transiently BC2GM000360337 RB O
in BC2GM000360337 IN O
two BC2GM000360337 CD O
human BC2GM000360337 JJ O
hepatocytes BC2GM000360337 NNS O
, BC2GM000360337 , O
HepG2 BC2GM000360337 NNP O
and BC2GM000360337 CC O
PLC BC2GM000360337 NNP O
. BC2GM000360337 . O
. . O O

Characterization BC2GM061728098 NN O
of BC2GM061728098 IN O
Chlamydomonas BC2GM061728098 NNP O
reinhardtii BC2GM061728098 VBP O
zygote-specific BC2GM061728098 JJ O
cDNAs BC2GM061728098 NN O
that BC2GM061728098 WDT O
encode BC2GM061728098 VBZ O
novel BC2GM061728098 JJ O
proteins BC2GM061728098 NNS O
containing BC2GM061728098 VBG O
ankyrin BC2GM061728098 JJ O
repeats BC2GM061728098 NNS O
and BC2GM061728098 CC O
WW BC2GM061728098 NNP O
domains BC2GM061728098 NNS O
. BC2GM061728098 . O
. . O O

A BC2GM000687386 DT O
comparison BC2GM000687386 NN O
of BC2GM000687386 IN O
the BC2GM000687386 DT O
rate BC2GM000687386 NN O
of BC2GM000687386 IN O
recovery BC2GM000687386 NN O
and BC2GM000687386 CC O
time BC2GM000687386 NN O
for BC2GM000687386 IN O
detection BC2GM000687386 NN O
of BC2GM000687386 IN O
mycobacteria BC2GM000687386 NN O
from BC2GM000687386 IN O
clinical BC2GM000687386 JJ O
specimens BC2GM000687386 NNS O
of BC2GM000687386 IN O
the BC2GM000687386 DT O
newly BC2GM000687386 RB O
developed BC2GM000687386 VBN O
Mycobacteria BC2GM000687386 NNP O
Growth BC2GM000687386 NNP O
Indicator BC2GM000687386 NNP O
Tube BC2GM000687386 NNP O
( BC2GM000687386 ( O
MGIT BC2GM000687386 NNP O
) BC2GM000687386 ) O
, BC2GM000687386 , O
the BC2GM000687386 DT O
biphasic BC2GM000687386 JJ O
Septi-Chek BC2GM000687386 NNP O
, BC2GM000687386 , O
and BC2GM000687386 CC O
the BC2GM000687386 DT O
egg-based BC2GM000687386 JJ O
Ogawa BC2GM000687386 NNP O
medium BC2GM000687386 NN O
was BC2GM000687386 VBD O
made BC2GM000687386 VBN O
. BC2GM000687386 . O
. . O O

The BC2GM034787245 DT O
p58 BC2GM034787245 NN O
( BC2GM034787245 ( O
PITSLRE BC2GM034787245 NNP O
beta BC2GM034787245 RB O
1 BC2GM034787245 CD O
) BC2GM034787245 ) O
protein BC2GM034787245 NN O
kinase BC2GM034787245 NN O
( BC2GM034787245 ( O
PK BC2GM034787245 NNP O
) BC2GM034787245 ) O
is BC2GM034787245 VBZ O
a BC2GM034787245 DT O
member BC2GM034787245 NN O
of BC2GM034787245 IN O
a BC2GM034787245 DT O
large BC2GM034787245 JJ O
supergene BC2GM034787245 JJ O
family BC2GM034787245 NN O
related BC2GM034787245 VBN O
to BC2GM034787245 TO O
the BC2GM034787245 DT O
master BC2GM034787245 NN O
mitotic BC2GM034787245 JJ O
protein BC2GM034787245 NN O
kinase BC2GM034787245 NN O
, BC2GM034787245 , O
p34cdc2 BC2GM034787245 NN O
. BC2GM034787245 . O
. . O O

The BC2GM009237641 DT O
ARE BC2GM009237641 NNP O
is BC2GM009237641 VBZ O
loosely BC2GM009237641 RB O
defined BC2GM009237641 VBN O
as BC2GM009237641 IN O
the BC2GM009237641 DT O
five-nucleotide BC2GM009237641 JJ O
sequence BC2GM009237641 NN O
AUUUA BC2GM009237641 NNP O
embedded BC2GM009237641 VBD O
in BC2GM009237641 IN O
a BC2GM009237641 DT O
uracil-rich BC2GM009237641 JJ O
region BC2GM009237641 NN O
. BC2GM009237641 . O
. . O O

The BC2GM039116924 DT O
contribution BC2GM039116924 NN O
of BC2GM039116924 IN O
reviewers BC2GM039116924 NNS O
and BC2GM039116924 CC O
editors BC2GM039116924 NNS O
to BC2GM039116924 TO O
the BC2GM039116924 DT O
scientific BC2GM039116924 JJ O
work BC2GM039116924 NN O
of BC2GM039116924 IN O
the BC2GM039116924 DT O
authors BC2GM039116924 NNS O
. BC2GM039116924 . O
. . O O

Mitoxantrone BC2GM015535578 NNP O
plus BC2GM015535578 CC O
ara-C BC2GM015535578 NN O
is BC2GM015535578 VBZ O
an BC2GM015535578 DT O
active BC2GM015535578 JJ O
combination BC2GM015535578 NN O
with BC2GM015535578 IN O
great BC2GM015535578 JJ O
promise BC2GM015535578 NN O
for BC2GM015535578 IN O
the BC2GM015535578 DT O
therapy BC2GM015535578 NN O
of BC2GM015535578 IN O
previously BC2GM015535578 RB O
untreated BC2GM015535578 JJ O
patients BC2GM015535578 NNS O
with BC2GM015535578 IN O
AML BC2GM015535578 NNP O
. BC2GM015535578 . O
. . O O

DSIP BC2GM036805670 NNP O
was BC2GM036805670 VBD O
found BC2GM036805670 VBN O
to BC2GM036805670 TO O
significantly BC2GM036805670 RB O
increase BC2GM036805670 VB O
slow-waves BC2GM036805670 NNS O
( BC2GM036805670 ( O
delta BC2GM036805670 JJ O
sleep BC2GM036805670 NN O
) BC2GM036805670 ) O
in BC2GM036805670 IN O
the BC2GM036805670 DT O
sleep BC2GM036805670 JJ O
EEG BC2GM036805670 NNP O
. BC2GM036805670 . O
. . O O

Residues BC2GM074024777 NNS O
that BC2GM074024777 WDT O
affect BC2GM074024777 VBP O
PLCbeta BC2GM074024777 NNP O
and BC2GM074024777 CC O
adenylyl BC2GM074024777 JJ O
cyclase BC2GM074024777 NN O
II BC2GM074024777 NNP O
activity BC2GM074024777 NN O
are BC2GM074024777 VBP O
found BC2GM074024777 VBN O
on BC2GM074024777 IN O
opposite BC2GM074024777 JJ O
sides BC2GM074024777 NNS O
of BC2GM074024777 IN O
the BC2GM074024777 DT O
central BC2GM074024777 JJ O
tunnel BC2GM074024777 NN O
, BC2GM074024777 , O
suggesting BC2GM074024777 VBG O
that BC2GM074024777 IN O
PLC BC2GM074024777 NNP O
and BC2GM074024777 CC O
adenylyl BC2GM074024777 JJ O
cyclase BC2GM074024777 NN O
, BC2GM074024777 , O
like BC2GM074024777 IN O
the BC2GM074024777 DT O
alpha BC2GM074024777 NN O
subunit BC2GM074024777 NN O
, BC2GM074024777 , O
make BC2GM074024777 VBP O
many BC2GM074024777 JJ O
contacts BC2GM074024777 NNS O
on BC2GM074024777 IN O
the BC2GM074024777 DT O
top BC2GM074024777 JJ O
surface BC2GM074024777 NN O
. BC2GM074024777 . O
. . O O

It BC2GM075459951 PRP O
is BC2GM075459951 VBZ O
considered BC2GM075459951 VBN O
important BC2GM075459951 JJ O
, BC2GM075459951 , O
therefore BC2GM075459951 RB O
, BC2GM075459951 , O
when BC2GM075459951 WRB O
treating BC2GM075459951 VBG O
diabetic BC2GM075459951 JJ O
patients BC2GM075459951 NNS O
with BC2GM075459951 IN O
peripheral BC2GM075459951 JJ O
neuropathy BC2GM075459951 NNS O
not BC2GM075459951 RB O
to BC2GM075459951 TO O
assume BC2GM075459951 VB O
that BC2GM075459951 IN O
the BC2GM075459951 DT O
diabetes BC2GM075459951 NNS O
itself BC2GM075459951 PRP O
is BC2GM075459951 VBZ O
the BC2GM075459951 DT O
cause BC2GM075459951 NN O
in BC2GM075459951 IN O
all BC2GM075459951 DT O
cases BC2GM075459951 NNS O
. BC2GM075459951 . O
. . O O

Choline BC2GM097835170 NNP O
acetyltransferase BC2GM097835170 NN O
immunohistochemistry BC2GM097835170 NN O
combined BC2GM097835170 VBN O
with BC2GM097835170 IN O
the BC2GM097835170 DT O
retrograde BC2GM097835170 NN O
transport BC2GM097835170 NN O
of BC2GM097835170 IN O
horseradish BC2GM097835170 JJ O
peroxidase BC2GM097835170 NN O
showed BC2GM097835170 VBD O
that BC2GM097835170 IN O
the BC2GM097835170 DT O
reticular BC2GM097835170 NN O
and BC2GM097835170 CC O
mediodorsal BC2GM097835170 NN O
thalamic BC2GM097835170 JJ O
nuclei BC2GM097835170 NN O
of BC2GM097835170 IN O
the BC2GM097835170 DT O
cat BC2GM097835170 NN O
receive BC2GM097835170 VBP O
an BC2GM097835170 DT O
important BC2GM097835170 JJ O
input BC2GM097835170 NN O
from BC2GM097835170 IN O
cholinergic BC2GM097835170 JJ O
and BC2GM097835170 CC O
non-cholinergic BC2GM097835170 JJ O
neurons BC2GM097835170 NNS O
of BC2GM097835170 IN O
substantia BC2GM097835170 NN O
innominata BC2GM097835170 NN O
and BC2GM097835170 CC O
adjacent BC2GM097835170 JJ O
structures BC2GM097835170 NNS O
in BC2GM097835170 IN O
the BC2GM097835170 DT O
basal BC2GM097835170 NN O
forebrain BC2GM097835170 NN O
. BC2GM097835170 . O
. . O O

RESULTS BC2GM040893145 NNP O
-- BC2GM040893145 : O
The BC2GM040893145 DT O
maximal BC2GM040893145 JJ O
early BC2GM040893145 JJ O
asthmatic BC2GM040893145 JJ O
response BC2GM040893145 NN O
after BC2GM040893145 IN O
allergen BC2GM040893145 NN O
with BC2GM040893145 IN O
placebo BC2GM040893145 NN O
treatment BC2GM040893145 NN O
was BC2GM040893145 VBD O
18.4 BC2GM040893145 CD O
% BC2GM040893145 NN O
( BC2GM040893145 ( O
SE BC2GM040893145 NNP O
4.4 BC2GM040893145 CD O
% BC2GM040893145 NN O
) BC2GM040893145 ) O
and BC2GM040893145 CC O
with BC2GM040893145 IN O
WEB BC2GM040893145 NNP O
2086 BC2GM040893145 CD O
18.9 BC2GM040893145 CD O
% BC2GM040893145 NN O
( BC2GM040893145 ( O
4.4 BC2GM040893145 CD O
% BC2GM040893145 NN O
) BC2GM040893145 ) O
. BC2GM040893145 . O
. . O O

Airborne BC2GM092609683 JJ O
rabies BC2GM092609683 NNS O
encephalitis BC2GM092609683 NN O
: BC2GM092609683 : O
demonstration BC2GM092609683 NN O
of BC2GM092609683 IN O
rabies BC2GM092609683 NNS O
virus BC2GM092609683 VBP O
in BC2GM092609683 IN O
the BC2GM092609683 DT O
human BC2GM092609683 JJ O
central BC2GM092609683 JJ O
nervous BC2GM092609683 JJ O
system BC2GM092609683 NN O
. BC2GM092609683 . O
. . O O

Maximal BC2GM011254040 NNP O
exercise BC2GM011254040 NN O
duration BC2GM011254040 NN O
and BC2GM011254040 CC O
peak BC2GM011254040 NN O
oxygen BC2GM011254040 NN O
consumption BC2GM011254040 NN O
were BC2GM011254040 VBD O
not BC2GM011254040 RB O
changed BC2GM011254040 VBN O
. BC2GM011254040 . O
. . O O

It BC2GM023488977 PRP O
was BC2GM023488977 VBD O
found BC2GM023488977 VBN O
that BC2GM023488977 IN O
Nopp140 BC2GM023488977 NNP O
binds BC2GM023488977 VBZ O
primarily BC2GM023488977 RB O
to BC2GM023488977 TO O
the BC2GM023488977 DT O
CK2 BC2GM023488977 NNP O
regulatory BC2GM023488977 JJ O
subunit BC2GM023488977 NN O
, BC2GM023488977 , O
beta BC2GM023488977 NN O
. BC2GM023488977 . O
. . O O

This BC2GM050151466 DT O
interesting BC2GM050151466 JJ O
exon BC2GM050151466 NN O
junction BC2GM050151466 NN O
resulted BC2GM050151466 VBD O
in BC2GM050151466 IN O
novel BC2GM050151466 NN O
deduced BC2GM050151466 VBN O
amino BC2GM050151466 IN O
terminal BC2GM050151466 JJ O
open BC2GM050151466 JJ O
reading BC2GM050151466 NN O
frames BC2GM050151466 NNS O
, BC2GM050151466 , O
which BC2GM050151466 WDT O
are BC2GM050151466 VBP O
completely BC2GM050151466 RB O
in-frame BC2GM050151466 JJ O
with BC2GM050151466 IN O
sequences BC2GM050151466 NNS O
located BC2GM050151466 VBN O
further BC2GM050151466 JJ O
downstream BC2GM050151466 NN O
. BC2GM050151466 . O
. . O O

Although BC2GM095698085 IN O
no BC2GM095698085 DT O
detectable BC2GM095698085 JJ O
phenotypes BC2GM095698085 NNS O
are BC2GM095698085 VBP O
associated BC2GM095698085 VBN O
with BC2GM095698085 IN O
a BC2GM095698085 DT O
disruption BC2GM095698085 NN O
allele BC2GM095698085 NN O
of BC2GM095698085 IN O
ABP1 BC2GM095698085 NNP O
, BC2GM095698085 , O
mutations BC2GM095698085 NNS O
that BC2GM095698085 WDT O
create BC2GM095698085 VBP O
a BC2GM095698085 DT O
requirement BC2GM095698085 NN O
for BC2GM095698085 IN O
this BC2GM095698085 DT O
protein BC2GM095698085 NN O
have BC2GM095698085 VBP O
now BC2GM095698085 RB O
been BC2GM095698085 VBN O
isolated BC2GM095698085 VBN O
in BC2GM095698085 IN O
the BC2GM095698085 DT O
previously BC2GM095698085 RB O
identified BC2GM095698085 VBN O
gene BC2GM095698085 NN O
SAC6 BC2GM095698085 NNP O
and BC2GM095698085 CC O
in BC2GM095698085 IN O
two BC2GM095698085 CD O
new BC2GM095698085 JJ O
genes BC2GM095698085 NNS O
, BC2GM095698085 , O
SLA1 BC2GM095698085 NNP O
and BC2GM095698085 CC O
SLA2 BC2GM095698085 NNP O
. BC2GM095698085 . O
. . O O

Southern BC2GM019377317 NNP O
blot BC2GM019377317 NN O
analysis BC2GM019377317 NN O
revealed BC2GM019377317 VBD O
that BC2GM019377317 IN O
CCaMK BC2GM019377317 NNP O
is BC2GM019377317 VBZ O
encoded BC2GM019377317 VBN O
by BC2GM019377317 IN O
a BC2GM019377317 DT O
single BC2GM019377317 JJ O
gene BC2GM019377317 NN O
. BC2GM019377317 . O
. . O O

The BC2GM031611293 DT O
species BC2GM031611293 NNS O
composition BC2GM031611293 NN O
and BC2GM031611293 CC O
abundance BC2GM031611293 NN O
upon BC2GM031611293 IN O
treatment BC2GM031611293 NN O
of BC2GM031611293 IN O
manure BC2GM031611293 NN O
with BC2GM031611293 IN O
polyethylene BC2GM031611293 NN O
, BC2GM031611293 , O
polystyrene BC2GM031611293 NN O
and BC2GM031611293 CC O
glass BC2GM031611293 NN O
particles BC2GM031611293 NNS O
was BC2GM031611293 VBD O
similar BC2GM031611293 JJ O
to BC2GM031611293 TO O
that BC2GM031611293 DT O
of BC2GM031611293 IN O
the BC2GM031611293 DT O
treatment BC2GM031611293 NN O
control BC2GM031611293 NN O
, BC2GM031611293 , O
i.e BC2GM031611293 NN O
. BC2GM031611293 . O
natural BC2GM031611293 JJ O
and BC2GM031611293 CC O
inert BC2GM031611293 JJ O
sand BC2GM031611293 NN O
. BC2GM031611293 . O
. . O O

CONCLUSIONS BC2GM052999467 NNP O
-- BC2GM052999467 : O
Postlumbar BC2GM052999467 NNP O
puncture BC2GM052999467 NN O
headache BC2GM052999467 NN O
may BC2GM052999467 MD O
be BC2GM052999467 VB O
mediated BC2GM052999467 VBN O
by BC2GM052999467 IN O
the BC2GM052999467 DT O
release BC2GM052999467 NN O
of BC2GM052999467 IN O
substance BC2GM052999467 NN O
P BC2GM052999467 NNP O
triggered BC2GM052999467 VBN O
by BC2GM052999467 IN O
lumbar BC2GM052999467 NN O
puncture BC2GM052999467 NN O
, BC2GM052999467 , O
in BC2GM052999467 IN O
patients BC2GM052999467 NNS O
predisposed BC2GM052999467 VBN O
to BC2GM052999467 TO O
headache BC2GM052999467 VB O
by BC2GM052999467 IN O
a BC2GM052999467 DT O
hypersensitivity BC2GM052999467 NN O
to BC2GM052999467 TO O
substance BC2GM052999467 VB O
P BC2GM052999467 NNP O
. BC2GM052999467 . O
. . O O

The BC2GM034391394 DT O
CHED BC2GM034391394 NNP O
protein BC2GM034391394 NN O
includes BC2GM034391394 VBZ O
the BC2GM034391394 DT O
consensus BC2GM034391394 NN O
ATP BC2GM034391394 NNP O
binding BC2GM034391394 NN O
and BC2GM034391394 CC O
phosphorylation BC2GM034391394 NN O
domains BC2GM034391394 NNS O
characteristic BC2GM034391394 JJ O
of BC2GM034391394 IN O
kinases BC2GM034391394 NNS O
, BC2GM034391394 , O
displays BC2GM034391394 NNS O
34-42 BC2GM034391394 CD O
% BC2GM034391394 NN O
identically BC2GM034391394 RB O
aligned BC2GM034391394 VBN O
amino BC2GM034391394 NN O
acid BC2GM034391394 NN O
residues BC2GM034391394 NNS O
with BC2GM034391394 IN O
other BC2GM034391394 JJ O
cdc2-related BC2GM034391394 JJ O
kinases BC2GM034391394 NNS O
, BC2GM034391394 , O
and BC2GM034391394 CC O
is BC2GM034391394 VBZ O
considerably BC2GM034391394 RB O
longer BC2GM034391394 RBR O
at BC2GM034391394 IN O
its BC2GM034391394 PRP$ O
amino BC2GM034391394 NN O
and BC2GM034391394 CC O
carboxyl BC2GM034391394 NN O
termini BC2GM034391394 NN O
. BC2GM034391394 . O
. . O O

Sesame BC2GM047234366 NNP O
seed BC2GM047234366 NN O
should BC2GM047234366 MD O
also BC2GM047234366 RB O
be BC2GM047234366 VB O
considered BC2GM047234366 VBN O
a BC2GM047234366 DT O
cause BC2GM047234366 NN O
of BC2GM047234366 IN O
allergic BC2GM047234366 JJ O
reactions BC2GM047234366 NNS O
to BC2GM047234366 TO O
drug BC2GM047234366 NN O
products BC2GM047234366 NNS O
and BC2GM047234366 CC O
cosmetics BC2GM047234366 NNS O
. BC2GM047234366 . O
. . O O

Cerebral BC2GM022830780 JJ O
blood BC2GM022830780 NN O
flow BC2GM022830780 NN O
was BC2GM022830780 VBD O
measured BC2GM022830780 VBN O
using BC2GM022830780 VBG O
the BC2GM022830780 DT O
iv BC2GM022830780 JJ O
method BC2GM022830780 NN O
of BC2GM022830780 IN O
133-Xe BC2GM022830780 JJ O
CBF BC2GM022830780 NNP O
determination BC2GM022830780 NN O
and BC2GM022830780 CC O
AVDO2 BC2GM022830780 NNP O
was BC2GM022830780 VBD O
measured BC2GM022830780 VBN O
using BC2GM022830780 VBG O
systemic BC2GM022830780 JJ O
arterial-jugular BC2GM022830780 JJ O
venous BC2GM022830780 JJ O
oxygen BC2GM022830780 NN O
content BC2GM022830780 NN O
differences BC2GM022830780 NNS O
. BC2GM022830780 . O
. . O O

RNA BC2GM071933956 JJ O
determinants BC2GM071933956 NNS O
required BC2GM071933956 VBN O
for BC2GM071933956 IN O
L4-mediated BC2GM071933956 JJ O
attenuation BC2GM071933956 NN O
control BC2GM071933956 NN O
of BC2GM071933956 IN O
the BC2GM071933956 DT O
S10 BC2GM071933956 NNP O
r-protein BC2GM071933956 JJ O
operon BC2GM071933956 NN O
of BC2GM071933956 IN O
Escherichia BC2GM071933956 NNP O
coli BC2GM071933956 NN O
. BC2GM071933956 . O
. . O O

Decreased BC2GM005627247 VBN O
plasma BC2GM005627247 JJ O
level BC2GM005627247 NN O
of BC2GM005627247 IN O
antithrombin BC2GM005627247 JJ O
III BC2GM005627247 NNP O
was BC2GM005627247 VBD O
assumed BC2GM005627247 VBN O
to BC2GM005627247 TO O
be BC2GM005627247 VB O
one BC2GM005627247 CD O
of BC2GM005627247 IN O
the BC2GM005627247 DT O
major BC2GM005627247 JJ O
factors BC2GM005627247 NNS O
underlying BC2GM005627247 VBG O
hypercoagulable BC2GM005627247 JJ O
state BC2GM005627247 NN O
in BC2GM005627247 IN O
nephrotic BC2GM005627247 JJ O
syndrome BC2GM005627247 NN O
. BC2GM005627247 . O
. . O O

Differentiation BC2GM094584922 NN O
of BC2GM094584922 IN O
porcine BC2GM094584922 NN O
mycoplasma BC2GM094584922 NN O
strains BC2GM094584922 NNS O
by BC2GM094584922 IN O
means BC2GM094584922 NNS O
of BC2GM094584922 IN O
a BC2GM094584922 DT O
simple BC2GM094584922 JJ O
paper BC2GM094584922 NN O
chromatography BC2GM094584922 NN O
test BC2GM094584922 NN O
. BC2GM094584922 . O
. . O O

CAT BC2GM026662709 NNP O
assays BC2GM026662709 NNS O
demonstrated BC2GM026662709 VBD O
that BC2GM026662709 IN O
overexpression BC2GM026662709 NN O
of BC2GM026662709 IN O
RXRalpha BC2GM026662709 NNP O
conferred BC2GM026662709 VBD O
the BC2GM026662709 DT O
best BC2GM026662709 JJS O
RA BC2GM026662709 NNP O
response BC2GM026662709 NN O
, BC2GM026662709 , O
consistent BC2GM026662709 NN O
with BC2GM026662709 IN O
our BC2GM026662709 PRP$ O
previous BC2GM026662709 JJ O
observation BC2GM026662709 NN O
that BC2GM026662709 IN O
9-cis-RA BC2GM026662709 CD O
is BC2GM026662709 VBZ O
more BC2GM026662709 RBR O
potent BC2GM026662709 JJ O
than BC2GM026662709 IN O
all-trans-RA BC2GM026662709 JJ O
for BC2GM026662709 IN O
inducing BC2GM026662709 VBG O
the BC2GM026662709 DT O
expression BC2GM026662709 NN O
of BC2GM026662709 IN O
the BC2GM026662709 DT O
AFP BC2GM026662709 NNP O
gene BC2GM026662709 NN O
. BC2GM026662709 . O
. . O O

Previous BC2GM025661360 JJ O
studies BC2GM025661360 NNS O
showed BC2GM025661360 VBD O
that BC2GM025661360 IN O
a BC2GM025661360 DT O
palindromic BC2GM025661360 JJ O
sequence BC2GM025661360 NN O
located BC2GM025661360 VBN O
at BC2GM025661360 IN O
-159 BC2GM025661360 JJ O
base BC2GM025661360 NN O
pairs BC2GM025661360 NN O
is BC2GM025661360 VBZ O
essential BC2GM025661360 JJ O
for BC2GM025661360 IN O
induction BC2GM025661360 NN O
of BC2GM025661360 IN O
cutinase BC2GM025661360 NN O
gene BC2GM025661360 NN O
in BC2GM025661360 IN O
Fusarium BC2GM025661360 NNP O
solani BC2GM025661360 NN O
f. BC2GM025661360 NN O
sp BC2GM025661360 NN O
. BC2GM025661360 . O
pisi BC2GM025661360 NN O
( BC2GM025661360 ( O
Nectria BC2GM025661360 NNP O
haematococca BC2GM025661360 VBZ O
mating BC2GM025661360 VBG O
type BC2GM025661360 JJ O
VI BC2GM025661360 NNP O
) BC2GM025661360 ) O
by BC2GM025661360 IN O
the BC2GM025661360 DT O
hydroxy BC2GM025661360 JJ O
fatty BC2GM025661360 JJ O
acids BC2GM025661360 NNS O
from BC2GM025661360 IN O
plant BC2GM025661360 NN O
cutin BC2GM025661360 NN O
and BC2GM025661360 CC O
that BC2GM025661360 IN O
a BC2GM025661360 DT O
50-kDa BC2GM025661360 JJ O
nuclear BC2GM025661360 JJ O
protein BC2GM025661360 NN O
binds BC2GM025661360 VBZ O
to BC2GM025661360 TO O
a BC2GM025661360 DT O
promoter BC2GM025661360 NN O
that BC2GM025661360 WDT O
contains BC2GM025661360 VBZ O
this BC2GM025661360 DT O
element BC2GM025661360 NN O
. BC2GM025661360 . O
. . O O

Similarly BC2GM034834811 RB O
, BC2GM034834811 , O
antisense BC2GM034834811 JJ O
TGF-beta BC2GM034834811 NNP O
type BC2GM034834811 NN O
II BC2GM034834811 NNP O
receptor BC2GM034834811 NN O
oligodeoxynucleotides BC2GM034834811 NNS O
( BC2GM034834811 ( O
40 BC2GM034834811 CD O
microM BC2GM034834811 NN O
) BC2GM034834811 ) O
resulted BC2GM034834811 VBD O
in BC2GM034834811 IN O
a BC2GM034834811 DT O
58 BC2GM034834811 CD O
% BC2GM034834811 NN O
increase BC2GM034834811 NN O
in BC2GM034834811 IN O
branching BC2GM034834811 VBG O
, BC2GM034834811 , O
compared BC2GM034834811 VBN O
to BC2GM034834811 TO O
scrambled BC2GM034834811 VB O
and BC2GM034834811 CC O
mismatched BC2GM034834811 VB O
sequence BC2GM034834811 NN O
controls BC2GM034834811 NNS O
, BC2GM034834811 , O
while BC2GM034834811 IN O
TGF-beta BC2GM034834811 NNP O
, BC2GM034834811 , O
type BC2GM034834811 NN O
II BC2GM034834811 NNP O
receptor BC2GM034834811 NN O
mRNA BC2GM034834811 NN O
and BC2GM034834811 CC O
its BC2GM034834811 PRP$ O
protein BC2GM034834811 NN O
expression BC2GM034834811 NN O
levels BC2GM034834811 NNS O
were BC2GM034834811 VBD O
suppressed BC2GM034834811 VBN O
by BC2GM034834811 IN O
95 BC2GM034834811 CD O
and BC2GM034834811 CC O
84 BC2GM034834811 CD O
% BC2GM034834811 NN O
, BC2GM034834811 , O
respectively BC2GM034834811 RB O
. BC2GM034834811 . O
. . O O

Northern BC2GM023807131 NNP O
blot BC2GM023807131 NN O
analyses BC2GM023807131 NNS O
were BC2GM023807131 VBD O
used BC2GM023807131 VBN O
to BC2GM023807131 TO O
examine BC2GM023807131 VB O
the BC2GM023807131 DT O
regulated BC2GM023807131 JJ O
expression BC2GM023807131 NN O
of BC2GM023807131 IN O
the BC2GM023807131 DT O
cys-14+ BC2GM023807131 JJ O
gene BC2GM023807131 NN O
. BC2GM023807131 . O
. . O O

Excellent BC2GM086563474 JJ O
results BC2GM086563474 NNS O
were BC2GM086563474 VBD O
recorded BC2GM086563474 VBN O
in BC2GM086563474 IN O
390 BC2GM086563474 CD O
( BC2GM086563474 ( O
83.69 BC2GM086563474 CD O
% BC2GM086563474 NN O
) BC2GM086563474 ) O
of BC2GM086563474 IN O
the BC2GM086563474 DT O
patients BC2GM086563474 NNS O
, BC2GM086563474 , O
improvement BC2GM086563474 NN O
in BC2GM086563474 IN O
46 BC2GM086563474 CD O
( BC2GM086563474 ( O
9.87 BC2GM086563474 CD O
% BC2GM086563474 NN O
) BC2GM086563474 ) O
where BC2GM086563474 WRB O
in BC2GM086563474 IN O
the BC2GM086563474 DT O
majority BC2GM086563474 NN O
a BC2GM086563474 DT O
varicose BC2GM086563474 NN O
complex BC2GM086563474 NN O
was BC2GM086563474 VBD O
involved BC2GM086563474 VBN O
. BC2GM086563474 . O
. . O O

However BC2GM080041758 RB O
, BC2GM080041758 , O
the BC2GM080041758 DT O
quasiparticle BC2GM080041758 NN O
scattering BC2GM080041758 VBG O
rate BC2GM080041758 NN O
tau BC2GM080041758 NN O
( BC2GM080041758 ( O
-1 BC2GM080041758 NNP O
) BC2GM080041758 ) O
is BC2GM080041758 VBZ O
such BC2GM080041758 JJ O
that BC2GM080041758 IN O
Planck BC2GM080041758 NNP O
's BC2GM080041758 POS O
over BC2GM080041758 IN O
2pi BC2GM080041758 CD O
/ BC2GM080041758 JJ O
tau BC2GM080041758 NN O
approximately BC2GM080041758 RB O
6t BC2GM080041758 CD O
( BC2GM080041758 ( O
perpendicular BC2GM080041758 NN O
) BC2GM080041758 ) O
, BC2GM080041758 , O
implying BC2GM080041758 VBG O
that BC2GM080041758 IN O
kappa BC2GM080041758 FW O
- BC2GM080041758 : O
( BC2GM080041758 ( O
BEDT-TTF BC2GM080041758 NNP O
) BC2GM080041758 ) O
2Cu BC2GM080041758 CD O
( BC2GM080041758 ( O
NCS BC2GM080041758 NNP O
) BC2GM080041758 ) O
( BC2GM080041758 ( O
2 BC2GM080041758 CD O
) BC2GM080041758 ) O
meets BC2GM080041758 VBZ O
the BC2GM080041758 DT O
criterion BC2GM080041758 NN O
used BC2GM080041758 VBN O
to BC2GM080041758 TO O
identify BC2GM080041758 VB O
interlayer BC2GM080041758 JJ O
incoherence BC2GM080041758 NN O
. BC2GM080041758 . O
. . O O

The BC2GM062023800 DT O
AP-1 BC2GM062023800 NNP O
recruited BC2GM062023800 VBN O
by BC2GM062023800 IN O
ARF1.GTP BC2GM062023800 NNP O
is BC2GM062023800 VBZ O
released BC2GM062023800 VBN O
from BC2GM062023800 IN O
the BC2GM062023800 DT O
Golgi BC2GM062023800 NNP O
membrane BC2GM062023800 NN O
by BC2GM062023800 IN O
treatment BC2GM062023800 NN O
with BC2GM062023800 IN O
1 BC2GM062023800 CD O
M BC2GM062023800 NNP O
Tris-HCl BC2GM062023800 NNP O
( BC2GM062023800 ( O
pH BC2GM062023800 VB O
7 BC2GM062023800 CD O
) BC2GM062023800 ) O
or BC2GM062023800 CC O
upon BC2GM062023800 JJ O
reincubation BC2GM062023800 NN O
at BC2GM062023800 IN O
37 BC2GM062023800 CD O
degreesC BC2GM062023800 NN O
, BC2GM062023800 , O
whereas BC2GM062023800 IN O
AP-1 BC2GM062023800 NNP O
recruited BC2GM062023800 VBD O
with BC2GM062023800 IN O
GTPgammaS BC2GM062023800 NNP O
or BC2GM062023800 CC O
by BC2GM062023800 IN O
a BC2GM062023800 DT O
constitutively BC2GM062023800 RB O
active BC2GM062023800 JJ O
point BC2GM062023800 NN O
mutant BC2GM062023800 NN O
, BC2GM062023800 , O
ARF1 BC2GM062023800 NNP O
( BC2GM062023800 ( O
Q71L BC2GM062023800 NNP O
) BC2GM062023800 ) O
, BC2GM062023800 , O
remains BC2GM062023800 VBZ O
membrane BC2GM062023800 JJ O
bound BC2GM062023800 NN O
after BC2GM062023800 IN O
either BC2GM062023800 DT O
treatment BC2GM062023800 NN O
. BC2GM062023800 . O
. . O O

These BC2GM087325432 DT O
results BC2GM087325432 NNS O
demonstrate BC2GM087325432 VBP O
a BC2GM087325432 DT O
specific BC2GM087325432 JJ O
association BC2GM087325432 NN O
of BC2GM087325432 IN O
SIV BC2GM087325432 NNP O
and BC2GM087325432 CC O
HIV-2 BC2GM087325432 NNP O
nef BC2GM087325432 NN O
, BC2GM087325432 , O
but BC2GM087325432 CC O
not BC2GM087325432 RB O
HIV-1 BC2GM087325432 NNP O
nef BC2GM087325432 NN O
, BC2GM087325432 , O
with BC2GM087325432 IN O
TCRzeta BC2GM087325432 NNP O
. BC2GM087325432 . O
. . O O

Detailed BC2GM070253288 JJ O
analysis BC2GM070253288 NN O
of BC2GM070253288 IN O
the BC2GM070253288 DT O
predicted BC2GM070253288 VBN O
amino BC2GM070253288 NN O
acid BC2GM070253288 JJ O
sequence BC2GM070253288 NN O
revealed BC2GM070253288 VBD O
sequence BC2GM070253288 NN O
elements BC2GM070253288 NNS O
which BC2GM070253288 WDT O
are BC2GM070253288 VBP O
conserved BC2GM070253288 VBN O
in BC2GM070253288 IN O
many BC2GM070253288 JJ O
DNA BC2GM070253288 NNP O
and BC2GM070253288 CC O
RNA BC2GM070253288 NNP O
polymerases BC2GM070253288 NNS O
. BC2GM070253288 . O
. . O O

METHODS BC2GM009844506 NN O
: BC2GM009844506 : O
A BC2GM009844506 DT O
discriminant BC2GM009844506 JJ O
function BC2GM009844506 NN O
predicting BC2GM009844506 VBG O
surgery BC2GM009844506 JJ O
outcome BC2GM009844506 NN O
( BC2GM009844506 ( O
seizure-free BC2GM009844506 JJ O
vs. BC2GM009844506 IN O
non-seizure-free BC2GM009844506 JJ O
) BC2GM009844506 ) O
was BC2GM009844506 VBD O
computed BC2GM009844506 VBN O
separately BC2GM009844506 RB O
for BC2GM009844506 IN O
samples BC2GM009844506 NNS O
of BC2GM009844506 IN O
patients BC2GM009844506 NNS O
with BC2GM009844506 IN O
left BC2GM009844506 JJ O
( BC2GM009844506 ( O
n BC2GM009844506 JJ O
= BC2GM009844506 NNP O
79 BC2GM009844506 CD O
) BC2GM009844506 ) O
and BC2GM009844506 CC O
right BC2GM009844506 JJ O
( BC2GM009844506 ( O
n BC2GM009844506 JJ O
= BC2GM009844506 NNP O
62 BC2GM009844506 CD O
) BC2GM009844506 ) O
temporal BC2GM009844506 JJ O
lobectomy BC2GM009844506 NN O
( BC2GM009844506 ( O
LATL BC2GM009844506 NNP O
, BC2GM009844506 , O
RATL BC2GM009844506 NNP O
) BC2GM009844506 ) O
. BC2GM009844506 . O
. . O O

Optical BC2GM012221483 JJ O
rotation BC2GM012221483 NN O
of BC2GM012221483 IN O
the BC2GM012221483 DT O
second BC2GM012221483 JJ O
harmonic BC2GM012221483 JJ O
radiation BC2GM012221483 NN O
from BC2GM012221483 IN O
retinal BC2GM012221483 JJ O
in BC2GM012221483 IN O
bacteriorhodopsin BC2GM012221483 NN O
monomers BC2GM012221483 NNS O
in BC2GM012221483 IN O
Langmuir-Blodgett BC2GM012221483 NNP O
film BC2GM012221483 NN O
: BC2GM012221483 : O
evidence BC2GM012221483 NN O
for BC2GM012221483 IN O
nonplanar BC2GM012221483 JJ O
retinal BC2GM012221483 JJ O
structure BC2GM012221483 NN O
. BC2GM012221483 . O
. . O O

Back-ground BC2GM051407853 NNP O
factors BC2GM051407853 NNS O
which BC2GM051407853 WDT O
affect BC2GM051407853 VBP O
the BC2GM051407853 DT O
outcome BC2GM051407853 NN O
of BC2GM051407853 IN O
steroid BC2GM051407853 JJ O
withdrawal BC2GM051407853 NN O
therapy BC2GM051407853 NN O
in BC2GM051407853 IN O
patients BC2GM051407853 NNS O
with BC2GM051407853 IN O
chronic BC2GM051407853 JJ O
type BC2GM051407853 NN O
B BC2GM051407853 NNP O
hepatitis BC2GM051407853 NN O
-- BC2GM051407853 : O
statistical BC2GM051407853 JJ O
evaluation BC2GM051407853 NN O
of BC2GM051407853 IN O
the BC2GM051407853 DT O
importance BC2GM051407853 NN O
of BC2GM051407853 IN O
the BC2GM051407853 DT O
mode BC2GM051407853 NN O
of BC2GM051407853 IN O
HBV BC2GM051407853 NNP O
transmission BC2GM051407853 NN O
. BC2GM051407853 . O
. . O O

CONCLUSIONS BC2GM063051307 NN O
: BC2GM063051307 : O
The BC2GM063051307 DT O
RRM BC2GM063051307 NNP O
is BC2GM063051307 VBZ O
one BC2GM063051307 CD O
of BC2GM063051307 IN O
the BC2GM063051307 DT O
most BC2GM063051307 RBS O
common BC2GM063051307 JJ O
and BC2GM063051307 CC O
best BC2GM063051307 JJS O
characterized BC2GM063051307 VBN O
RNA-binding BC2GM063051307 JJ O
motifs BC2GM063051307 NNS O
. BC2GM063051307 . O
. . O O

This BC2GM070173071 DT O
is BC2GM070173071 VBZ O
mediated BC2GM070173071 VBN O
by BC2GM070173071 IN O
vascular BC2GM070173071 JJ O
remodeling BC2GM070173071 NN O
, BC2GM070173071 , O
an BC2GM070173071 DT O
active BC2GM070173071 JJ O
process BC2GM070173071 NN O
that BC2GM070173071 WDT O
results BC2GM070173071 NNS O
in BC2GM070173071 IN O
a BC2GM070173071 DT O
change BC2GM070173071 NN O
in BC2GM070173071 IN O
the BC2GM070173071 DT O
geometry BC2GM070173071 NN O
of BC2GM070173071 IN O
the BC2GM070173071 DT O
blood BC2GM070173071 NN O
vessel BC2GM070173071 NN O
. BC2GM070173071 . O
. . O O

Platelet BC2GM087473233 NNP O
factor BC2GM087473233 NN O
4 BC2GM087473233 CD O
levels BC2GM087473233 NNS O
in BC2GM087473233 IN O
patients BC2GM087473233 NNS O
with BC2GM087473233 IN O
coronary BC2GM087473233 JJ O
artery BC2GM087473233 NN O
disease BC2GM087473233 NN O
. BC2GM087473233 . O
. . O O

Tissue BC2GM063318762 NN O
expansion BC2GM063318762 NN O
was BC2GM063318762 VBD O
used BC2GM063318762 VBN O
successfully BC2GM063318762 RB O
to BC2GM063318762 TO O
prepare BC2GM063318762 VB O
adequate BC2GM063318762 JJ O
soft BC2GM063318762 JJ O
tissue BC2GM063318762 NN O
for BC2GM063318762 IN O
closure BC2GM063318762 NN O
following BC2GM063318762 VBG O
a BC2GM063318762 DT O
difficult BC2GM063318762 JJ O
clubfoot BC2GM063318762 NN O
correction BC2GM063318762 NN O
. BC2GM063318762 . O
. . O O

From BC2GM004900930 IN O
1998 BC2GM004900930 CD O
to BC2GM004900930 TO O
1999 BC2GM004900930 CD O
, BC2GM004900930 , O
a BC2GM004900930 DT O
large BC2GM004900930 JJ O
number BC2GM004900930 NN O
of BC2GM004900930 IN O
community-acquired BC2GM004900930 JJ O
respiratory BC2GM004900930 NN O
tract BC2GM004900930 NN O
isolates BC2GM004900930 NNS O
of BC2GM004900930 IN O
Streptococcus BC2GM004900930 NNP O
pneumoniae BC2GM004900930 NN O
( BC2GM004900930 ( O
n=566 BC2GM004900930 JJ O
) BC2GM004900930 ) O
, BC2GM004900930 , O
Haemophilus BC2GM004900930 NNP O
influenzae BC2GM004900930 NN O
( BC2GM004900930 ( O
n=513 BC2GM004900930 JJ O
) BC2GM004900930 ) O
and BC2GM004900930 CC O
Moraxella BC2GM004900930 NNP O
catarrhalis BC2GM004900930 NN O
( BC2GM004900930 ( O
n=228 BC2GM004900930 JJ O
) BC2GM004900930 ) O
were BC2GM004900930 VBD O
collected BC2GM004900930 VBN O
from BC2GM004900930 IN O
15 BC2GM004900930 CD O
centres BC2GM004900930 NNS O
in BC2GM004900930 IN O
Australia BC2GM004900930 NNP O
, BC2GM004900930 , O
Hong BC2GM004900930 NNP O
Kong BC2GM004900930 NNP O
, BC2GM004900930 , O
Japan BC2GM004900930 NNP O
, BC2GM004900930 , O
China BC2GM004900930 NNP O
, BC2GM004900930 , O
the BC2GM004900930 DT O
Philippines BC2GM004900930 NNPS O
, BC2GM004900930 , O
Singapore BC2GM004900930 NNP O
, BC2GM004900930 , O
South BC2GM004900930 NNP O
Africa BC2GM004900930 NNP O
and BC2GM004900930 CC O
Taiwan BC2GM004900930 NNP O
through BC2GM004900930 IN O
the BC2GM004900930 DT O
SENTRY BC2GM004900930 NNP O
Antimicrobial BC2GM004900930 NNP O
Surveillance BC2GM004900930 NNP O
Program BC2GM004900930 NNP O
. BC2GM004900930 . O
. . O O

The BC2GM088537216 DT O
amino BC2GM088537216 NN O
acid BC2GM088537216 NN O
residues BC2GM088537216 NNS O
and BC2GM088537216 CC O
subdomains BC2GM088537216 NNS O
important BC2GM088537216 JJ O
for BC2GM088537216 IN O
DNA BC2GM088537216 NNP O
binding BC2GM088537216 NN O
, BC2GM088537216 , O
hormone BC2GM088537216 NN O
binding BC2GM088537216 NN O
, BC2GM088537216 , O
dimerization BC2GM088537216 NN O
, BC2GM088537216 , O
and BC2GM088537216 CC O
transactivation BC2GM088537216 NN O
are BC2GM088537216 VBP O
mostly BC2GM088537216 RB O
conserved BC2GM088537216 VBN O
among BC2GM088537216 IN O
all BC2GM088537216 DT O
VDR BC2GM088537216 NNP O
species BC2GM088537216 NNS O
. BC2GM088537216 . O
. . O O

In BC2GM014433955 IN O
resume BC2GM014433955 JJ O
response BC2GM014433955 NN O
to BC2GM014433955 TO O
treatment BC2GM014433955 NN O
with BC2GM014433955 IN O
usual BC2GM014433955 JJ O
regimens BC2GM014433955 NNS O
, BC2GM014433955 , O
doxycycline BC2GM014433955 JJ O
plus BC2GM014433955 CC O
streptomycin BC2GM014433955 NN O
of BC2GM014433955 IN O
doxycycline BC2GM014433955 NN O
rifampicin BC2GM014433955 NN O
is BC2GM014433955 VBZ O
good BC2GM014433955 JJ O
, BC2GM014433955 , O
being BC2GM014433955 VBG O
however BC2GM014433955 RB O
time BC2GM014433955 NN O
elapsed BC2GM014433955 VBN O
until BC2GM014433955 IN O
pain BC2GM014433955 JJ O
ceases BC2GM014433955 NNS O
of BC2GM014433955 IN O
mean BC2GM014433955 JJ O
length BC2GM014433955 NN O
in BC2GM014433955 IN O
hospital BC2GM014433955 NN O
stay BC2GM014433955 NN O
shorter BC2GM014433955 RB O
in BC2GM014433955 IN O
the BC2GM014433955 DT O
group BC2GM014433955 NN O
receiving BC2GM014433955 VBG O
doxycycline BC2GM014433955 NN O
plus BC2GM014433955 CC O
streptomycin BC2GM014433955 NN O
. BC2GM014433955 . O
. . O O

We BC2GM022069821 PRP O
have BC2GM022069821 VBP O
now BC2GM022069821 RB O
isolated BC2GM022069821 VBN O
cDNA BC2GM022069821 NN O
for BC2GM022069821 IN O
an BC2GM022069821 DT O
invertebrate BC2GM022069821 JJ O
Pax-6 BC2GM022069821 JJ O
protein BC2GM022069821 NN O
from BC2GM022069821 IN O
sea BC2GM022069821 NN O
urchin BC2GM022069821 JJ O
embryos BC2GM022069821 NN O
. BC2GM022069821 . O
. . O O

Methylation BC2GM082011055 NNP O
interference BC2GM082011055 NN O
analysis BC2GM082011055 NN O
established BC2GM082011055 VBN O
at BC2GM082011055 IN O
single BC2GM082011055 JJ O
nucleotide BC2GM082011055 JJ O
resolution BC2GM082011055 NN O
that BC2GM082011055 WDT O
purified BC2GM082011055 VBD O
recombinant BC2GM082011055 JJ O
Fos BC2GM082011055 NNP O
and BC2GM082011055 CC O
Jun BC2GM082011055 NNP O
proteins BC2GM082011055 VBZ O
bind BC2GM082011055 VB O
in BC2GM082011055 IN O
a BC2GM082011055 DT O
sequence-specific BC2GM082011055 JJ O
manner BC2GM082011055 NN O
to BC2GM082011055 TO O
the BC2GM082011055 DT O
AP-1 BC2GM082011055 NNP O
sites BC2GM082011055 NNS O
within BC2GM082011055 IN O
the BC2GM082011055 DT O
VDRE BC2GM082011055 NNP O
and BC2GM082011055 CC O
OC BC2GM082011055 NNP O
box BC2GM082011055 NN O
. BC2GM082011055 . O
. . O O

Upon BC2GM002649706 IN O
increasing BC2GM002649706 VBG O
the BC2GM002649706 DT O
Marangoni BC2GM002649706 NNP O
number BC2GM002649706 NN O
beyond BC2GM002649706 IN O
this BC2GM002649706 DT O
threshold BC2GM002649706 NN O
, BC2GM002649706 , O
the BC2GM002649706 DT O
initially BC2GM002649706 RB O
stationary BC2GM002649706 JJ O
flow BC2GM002649706 NN O
becomes BC2GM002649706 NNS O
quickly BC2GM002649706 RB O
time BC2GM002649706 NN O
dependent BC2GM002649706 JJ O
. BC2GM002649706 . O
. . O O

Amplitude BC2GM017641405 NNP O
of BC2GM017641405 IN O
late BC2GM017641405 JJ O
surface BC2GM017641405 NN O
( BC2GM017641405 ( O
P2 BC2GM017641405 NNP O
and BC2GM017641405 CC O
N2 BC2GM017641405 NNP O
) BC2GM017641405 ) O
and BC2GM017641405 CC O
depth BC2GM017641405 NN O
( BC2GM017641405 ( O
B BC2GM017641405 NNP O
and BC2GM017641405 CC O
C BC2GM017641405 NNP O
) BC2GM017641405 ) O
components BC2GM017641405 NNS O
significantly BC2GM017641405 RB O
decreased BC2GM017641405 VBD O
when BC2GM017641405 WRB O
patients BC2GM017641405 NNS O
shifted BC2GM017641405 VBD O
from BC2GM017641405 IN O
SWS BC2GM017641405 NNP O
IV BC2GM017641405 NNP O
to BC2GM017641405 TO O
PS BC2GM017641405 NNP O
and BC2GM017641405 CC O
increased BC2GM017641405 VBN O
from BC2GM017641405 IN O
PS BC2GM017641405 NNP O
to BC2GM017641405 TO O
W2 BC2GM017641405 NNP O
. BC2GM017641405 . O
. . O O

Analysis BC2GM011499496 NN O
of BC2GM011499496 IN O
rat BC2GM011499496 NN O
brain BC2GM011499496 NN O
, BC2GM011499496 , O
heart BC2GM011499496 NN O
, BC2GM011499496 , O
lung BC2GM011499496 NN O
, BC2GM011499496 , O
liver BC2GM011499496 NN O
, BC2GM011499496 , O
kidney BC2GM011499496 NN O
and BC2GM011499496 CC O
skeletal BC2GM011499496 JJ O
muscle BC2GM011499496 NN O
revealed BC2GM011499496 VBD O
psi BC2GM011499496 JJ O
PKC BC2GM011499496 NNP O
zeta BC2GM011499496 NN O
mRNA BC2GM011499496 NN O
only BC2GM011499496 RB O
in BC2GM011499496 IN O
brain BC2GM011499496 NN O
. BC2GM011499496 . O
. . O O

Consistent BC2GM019838730 JJ O
with BC2GM019838730 IN O
this BC2GM019838730 DT O
, BC2GM019838730 , O
rh5 BC2GM019838730 JJ O
expression BC2GM019838730 NN O
in BC2GM019838730 IN O
R8 BC2GM019838730 NNP O
disappears BC2GM019838730 NNS O
when BC2GM019838730 WRB O
R7 BC2GM019838730 NNP O
cells BC2GM019838730 NNS O
are BC2GM019838730 VBP O
absent BC2GM019838730 JJ O
( BC2GM019838730 ( O
in BC2GM019838730 IN O
sevenless BC2GM019838730 NN O
mutant BC2GM019838730 NN O
) BC2GM019838730 ) O
. BC2GM019838730 . O
. . O O

The BC2GM056032445 DT O
detection BC2GM056032445 NN O
limits BC2GM056032445 NNS O
obtained BC2GM056032445 VBN O
by BC2GM056032445 IN O
using BC2GM056032445 VBG O
the BC2GM056032445 DT O
mixed BC2GM056032445 JJ O
eluent BC2GM056032445 NN O
were BC2GM056032445 VBD O
0.05-0.13 BC2GM056032445 JJ O
mg BC2GM056032445 NN O
/ BC2GM056032445 NNP O
L BC2GM056032445 NNP O
, BC2GM056032445 , O
several BC2GM056032445 JJ O
times BC2GM056032445 NNS O
lower BC2GM056032445 JJR O
than BC2GM056032445 IN O
those BC2GM056032445 DT O
obtained BC2GM056032445 VBN O
by BC2GM056032445 IN O
using BC2GM056032445 VBG O
single BC2GM056032445 JJ O
KHPh BC2GM056032445 NNP O
eluent BC2GM056032445 NN O
. BC2GM056032445 . O
. . O O

Reading BC2GM078904500 VBG O
disability BC2GM078904500 NN O
in BC2GM078904500 IN O
twins BC2GM078904500 NNS O
. BC2GM078904500 . O
. . O O

Bovine BC2GM031508417 JJ O
anaplasmosis BC2GM031508417 NN O
: BC2GM031508417 : O
susceptibility BC2GM031508417 NN O
of BC2GM031508417 IN O
seronegative BC2GM031508417 JJ O
cows BC2GM031508417 NNS O
from BC2GM031508417 IN O
an BC2GM031508417 DT O
infected BC2GM031508417 JJ O
herd BC2GM031508417 NN O
to BC2GM031508417 TO O
experimental BC2GM031508417 JJ O
infection BC2GM031508417 NN O
with BC2GM031508417 IN O
Anaplasma BC2GM031508417 NNP O
marginale BC2GM031508417 NN O
. BC2GM031508417 . O
. . O O

YACs BC2GM063998013 NN O
, BC2GM063998013 , O
BACs BC2GM063998013 NNP O
, BC2GM063998013 , O
cosmids BC2GM063998013 NNS O
, BC2GM063998013 , O
and BC2GM063998013 CC O
STSs BC2GM063998013 NNP O
are BC2GM063998013 VBP O
defined BC2GM063998013 VBN O
to BC2GM063998013 TO O
aid BC2GM063998013 VB O
in BC2GM063998013 IN O
further BC2GM063998013 JJ O
study BC2GM063998013 NN O
of BC2GM063998013 IN O
this BC2GM063998013 DT O
gene BC2GM063998013 NN O
. BC2GM063998013 . O
. . O O

In BC2GM036721419 IN O
contrast BC2GM036721419 NN O
, BC2GM036721419 , O
postmitotic BC2GM036721419 JJ O
neurons BC2GM036721419 NNS O
possessed BC2GM036721419 VBD O
extremely BC2GM036721419 RB O
low BC2GM036721419 JJ O
levels BC2GM036721419 NNS O
of BC2GM036721419 IN O
E2F1 BC2GM036721419 NNP O
protein BC2GM036721419 NN O
as BC2GM036721419 IN O
assessed BC2GM036721419 VBN O
by BC2GM036721419 IN O
the BC2GM036721419 DT O
electrophoretic BC2GM036721419 JJ O
mobility BC2GM036721419 NN O
shift BC2GM036721419 NN O
assay BC2GM036721419 NN O
and BC2GM036721419 CC O
Western BC2GM036721419 JJ O
blotting BC2GM036721419 NN O
. BC2GM036721419 . O
. . O O

METHODS BC2GM045193318 NN O
: BC2GM045193318 : O
Precision BC2GM045193318 NN O
and BC2GM045193318 CC O
accuracy BC2GM045193318 NN O
were BC2GM045193318 VBD O
measured BC2GM045193318 VBN O
using BC2GM045193318 VBG O
controls BC2GM045193318 NNS O
and BC2GM045193318 CC O
method BC2GM045193318 NN O
comparison BC2GM045193318 NN O
studies BC2GM045193318 NNS O
. BC2GM045193318 . O
. . O O

An BC2GM002706624 DT O
identical BC2GM002706624 JJ O
polypeptide BC2GM002706624 NN O
was BC2GM002706624 VBD O
detected BC2GM002706624 VBN O
by BC2GM002706624 IN O
Western BC2GM002706624 JJ O
blot BC2GM002706624 NN O
analysis BC2GM002706624 NN O
of BC2GM002706624 IN O
K1F BC2GM002706624 NNP O
virions BC2GM002706624 NNS O
. BC2GM002706624 . O
. . O O

We BC2GM006418171 PRP O
have BC2GM006418171 VBP O
previously BC2GM006418171 RB O
shown BC2GM006418171 VBN O
that BC2GM006418171 IN O
the BC2GM006418171 DT O
transcriptional BC2GM006418171 JJ O
activator BC2GM006418171 NN O
CREM BC2GM006418171 NNP O
is BC2GM006418171 VBZ O
highly BC2GM006418171 RB O
expressed BC2GM006418171 VBN O
in BC2GM006418171 IN O
postmeiotic BC2GM006418171 JJ O
cells BC2GM006418171 NNS O
. BC2GM006418171 . O
. . O O

Vorozole BC2GM091667751 NNP O
( BC2GM091667751 ( O
Rivizor BC2GM091667751 NNP O
) BC2GM091667751 ) O
is BC2GM091667751 VBZ O
a BC2GM091667751 DT O
potent BC2GM091667751 NN O
and BC2GM091667751 CC O
stereospecific BC2GM091667751 JJ O
inhibitor BC2GM091667751 NN O
of BC2GM091667751 IN O
aromatase BC2GM091667751 NN O
having BC2GM091667751 VBG O
shown BC2GM091667751 VBN O
promising BC2GM091667751 JJ O
endocrine BC2GM091667751 NN O
effects BC2GM091667751 NNS O
in BC2GM091667751 IN O
phase BC2GM091667751 NN O
I BC2GM091667751 PRP O
studies BC2GM091667751 NNS O
. BC2GM091667751 . O
. . O O

P53 BC2GM009500252 NNP O
mutations BC2GM009500252 NNS O
also BC2GM009500252 RB O
offer BC2GM009500252 VBP O
new BC2GM009500252 JJ O
approaches BC2GM009500252 NNS O
to BC2GM009500252 TO O
the BC2GM009500252 DT O
study BC2GM009500252 NN O
of BC2GM009500252 IN O
the BC2GM009500252 DT O
origins BC2GM009500252 NNS O
of BC2GM009500252 IN O
mutations BC2GM009500252 NNS O
in BC2GM009500252 IN O
human BC2GM009500252 JJ O
cancer BC2GM009500252 NN O
. BC2GM009500252 . O
. . O O

Several BC2GM078938959 JJ O
of BC2GM078938959 IN O
the BC2GM078938959 DT O
drugs BC2GM078938959 NNS O
used BC2GM078938959 VBN O
in BC2GM078938959 IN O
the BC2GM078938959 DT O
management BC2GM078938959 NN O
of BC2GM078938959 IN O
MAC BC2GM078938959 NNP O
have BC2GM078938959 VBP O
been BC2GM078938959 VBN O
associated BC2GM078938959 VBN O
with BC2GM078938959 IN O
significant BC2GM078938959 JJ O
drug BC2GM078938959 NN O
interactions BC2GM078938959 NNS O
involving BC2GM078938959 VBG O
the BC2GM078938959 DT O
cytochrome BC2GM078938959 NN O
P450 BC2GM078938959 NNP O
( BC2GM078938959 ( O
CYP BC2GM078938959 NNP O
) BC2GM078938959 ) O
enzyme BC2GM078938959 NN O
system BC2GM078938959 NN O
. BC2GM078938959 . O
. . O O

The BC2GM081961422 DT O
human BC2GM081961422 JJ O
IFI16 BC2GM081961422 NNP O
gene BC2GM081961422 NN O
is BC2GM081961422 VBZ O
a BC2GM081961422 DT O
member BC2GM081961422 NN O
of BC2GM081961422 IN O
an BC2GM081961422 DT O
interferon-inducible BC2GM081961422 JJ O
family BC2GM081961422 NN O
of BC2GM081961422 IN O
mouse BC2GM081961422 NN O
and BC2GM081961422 CC O
human BC2GM081961422 JJ O
genes BC2GM081961422 NNS O
closely BC2GM081961422 RB O
linked BC2GM081961422 VBN O
on BC2GM081961422 IN O
syntenic BC2GM081961422 JJ O
regions BC2GM081961422 NNS O
of BC2GM081961422 IN O
chromosome BC2GM081961422 NN O
1 BC2GM081961422 CD O
. BC2GM081961422 . O
. . O O

However BC2GM000132505 RB O
the BC2GM000132505 DT O
precise BC2GM000132505 JJ O
function BC2GM000132505 NN O
of BC2GM000132505 IN O
DNA-PK BC2GM000132505 NNP O
in BC2GM000132505 IN O
DNA BC2GM000132505 NNP O
double-strand BC2GM000132505 JJ O
break BC2GM000132505 NN O
repair BC2GM000132505 NN O
is BC2GM000132505 VBZ O
not BC2GM000132505 RB O
known BC2GM000132505 VBN O
. BC2GM000132505 . O
. . O O

Activation BC2GM070526429 NN O
of BC2GM070526429 IN O
the BC2GM070526429 DT O
receptor BC2GM070526429 NN O
induces BC2GM070526429 VBZ O
Ret BC2GM070526429 NNP O
phosphorylation BC2GM070526429 NN O
that BC2GM070526429 WDT O
leads BC2GM070526429 VBZ O
the BC2GM070526429 DT O
survival-promoting BC2GM070526429 JJ O
effects BC2GM070526429 NNS O
. BC2GM070526429 . O
. . O O

On BC2GM060736050 IN O
the BC2GM060736050 DT O
contrary BC2GM060736050 JJ O
i.v BC2GM060736050 NN O
. BC2GM060736050 . O
administration BC2GM060736050 NN O
of BC2GM060736050 IN O
calcitonin BC2GM060736050 NN O
increased BC2GM060736050 VBN O
intrapyloric BC2GM060736050 JJ O
pressure BC2GM060736050 NN O
via BC2GM060736050 IN O
vagal BC2GM060736050 JJ O
nerves BC2GM060736050 NNS O
in BC2GM060736050 IN O
atropinized BC2GM060736050 JJ O
or BC2GM060736050 CC O
gallaminized BC2GM060736050 JJ O
animals BC2GM060736050 NNS O
. BC2GM060736050 . O
. . O O

Like BC2GM022317313 IN O
other BC2GM022317313 JJ O
IAPs BC2GM022317313 NNP O
, BC2GM022317313 , O
ch-IAP1 BC2GM022317313 NN O
contains BC2GM022317313 VBZ O
the BC2GM022317313 DT O
N-terminal BC2GM022317313 JJ O
baculovirus BC2GM022317313 NN O
IAP BC2GM022317313 NNP O
repeats BC2GM022317313 NNS O
and BC2GM022317313 CC O
C-terminal BC2GM022317313 JJ O
RING BC2GM022317313 NNP O
finger BC2GM022317313 NN O
motifs BC2GM022317313 NNS O
. BC2GM022317313 . O
. . O O

Heliox BC2GM055178229 NNP O
improves BC2GM055178229 VBZ O
pulsus BC2GM055178229 NN O
paradoxus BC2GM055178229 NN O
and BC2GM055178229 CC O
peak BC2GM055178229 JJ O
expiratory BC2GM055178229 NN O
flow BC2GM055178229 NN O
in BC2GM055178229 IN O
nonintubated BC2GM055178229 JJ O
patients BC2GM055178229 NNS O
with BC2GM055178229 IN O
severe BC2GM055178229 JJ O
asthma BC2GM055178229 NN O
. BC2GM055178229 . O
. . O O

This BC2GM093691513 DT O
substrate BC2GM093691513 NN O
was BC2GM093691513 VBD O
cleaved BC2GM093691513 VBN O
efficiently BC2GM093691513 RB O
in BC2GM093691513 IN O
trans BC2GM093691513 NNS O
by BC2GM093691513 IN O
protease BC2GM093691513 NN O
3C BC2GM093691513 CD O
derived BC2GM093691513 VBN O
from BC2GM093691513 IN O
another BC2GM093691513 DT O
recombinant BC2GM093691513 NN O
vaccinia BC2GM093691513 NN O
virus BC2GM093691513 NN O
expressing BC2GM093691513 VBG O
a BC2GM093691513 DT O
3C BC2GM093691513 CD O
precursor BC2GM093691513 NN O
protein BC2GM093691513 NN O
. BC2GM093691513 . O
. . O O

Non-specific BC2GM033304611 JJ O
immunological BC2GM033304611 JJ O
abnormalities BC2GM033304611 NNS O
were BC2GM033304611 VBD O
detected BC2GM033304611 VBN O
in BC2GM033304611 IN O
8 BC2GM033304611 CD O
of BC2GM033304611 IN O
the BC2GM033304611 DT O
13 BC2GM033304611 CD O
patients BC2GM033304611 NNS O
in BC2GM033304611 IN O
whom BC2GM033304611 WP O
they BC2GM033304611 PRP O
were BC2GM033304611 VBD O
looked BC2GM033304611 VBN O
for BC2GM033304611 IN O
. BC2GM033304611 . O
. . O O

This BC2GM086696613 DT O
ligand-independent BC2GM086696613 JJ O
pathway BC2GM086696613 NN O
can BC2GM086696613 MD O
function BC2GM086696613 VB O
through BC2GM086696613 IN O
another BC2GM086696613 DT O
androgen-regulated BC2GM086696613 JJ O
promoter BC2GM086696613 NN O
as BC2GM086696613 IN O
shown BC2GM086696613 VBN O
by BC2GM086696613 IN O
the BC2GM086696613 DT O
use BC2GM086696613 NN O
of BC2GM086696613 IN O
the BC2GM086696613 DT O
mouse BC2GM086696613 NN O
mammary BC2GM086696613 JJ O
tumor BC2GM086696613 NN O
virus BC2GM086696613 NN O
MMTV-CAT BC2GM086696613 NNP O
reporter BC2GM086696613 NN O
. BC2GM086696613 . O
. . O O

Rac2 BC2GM087367998 NNP O
, BC2GM087367998 , O
a BC2GM087367998 DT O
member BC2GM087367998 NN O
of BC2GM087367998 IN O
the BC2GM087367998 DT O
Rho BC2GM087367998 NNP O
family BC2GM087367998 NN O
of BC2GM087367998 IN O
GTPases BC2GM087367998 NNP O
, BC2GM087367998 , O
is BC2GM087367998 VBZ O
highly BC2GM087367998 RB O
expressed BC2GM087367998 VBN O
in BC2GM087367998 IN O
myeloid BC2GM087367998 NN O
cells BC2GM087367998 NNS O
and BC2GM087367998 CC O
is BC2GM087367998 VBZ O
a BC2GM087367998 DT O
regulator BC2GM087367998 NN O
of BC2GM087367998 IN O
the BC2GM087367998 DT O
NADPH-oxidase BC2GM087367998 NNP O
complex BC2GM087367998 NN O
. BC2GM087367998 . O
. . O O

The BC2GM025882502 DT O
NF-kappa BC2GM025882502 NNP O
B BC2GM025882502 NNP O
precursor BC2GM025882502 NN O
p100 BC2GM025882502 NN O
( BC2GM025882502 ( O
lyt-10 BC2GM025882502 JJ O
, BC2GM025882502 , O
p97 BC2GM025882502 NN O
, BC2GM025882502 , O
p98 BC2GM025882502 NN O
) BC2GM025882502 ) O
generates BC2GM025882502 VBZ O
after BC2GM025882502 IN O
proteolytic BC2GM025882502 JJ O
processing BC2GM025882502 VBG O
a BC2GM025882502 DT O
52 BC2GM025882502 CD O
kDa BC2GM025882502 NN O
subunit BC2GM025882502 NN O
, BC2GM025882502 , O
which BC2GM025882502 WDT O
can BC2GM025882502 MD O
bind BC2GM025882502 VB O
to BC2GM025882502 TO O
kappa BC2GM025882502 VB O
B-motifs BC2GM025882502 NNP O
. BC2GM025882502 . O
. . O O

The BC2GM087357752 DT O
distinct BC2GM087357752 JJ O
spatial BC2GM087357752 JJ O
pattern BC2GM087357752 NN O
of BC2GM087357752 IN O
expression BC2GM087357752 NN O
, BC2GM087357752 , O
and BC2GM087357752 CC O
unusual BC2GM087357752 JJ O
amino BC2GM087357752 NN O
acid BC2GM087357752 NN O
sequence BC2GM087357752 NN O
in BC2GM087357752 IN O
its BC2GM087357752 PRP$ O
DNA BC2GM087357752 NNP O
binding BC2GM087357752 NN O
domain BC2GM087357752 NN O
, BC2GM087357752 , O
may BC2GM087357752 MD O
indicate BC2GM087357752 VB O
a BC2GM087357752 DT O
particular BC2GM087357752 JJ O
role BC2GM087357752 NN O
for BC2GM087357752 IN O
DTEF-1 BC2GM087357752 NNP O
in BC2GM087357752 IN O
cell-specific BC2GM087357752 JJ O
gene BC2GM087357752 NN O
regulation BC2GM087357752 NN O
. BC2GM087357752 . O
. . O O

We BC2GM002489529 PRP O
have BC2GM002489529 VBP O
produced BC2GM002489529 VBN O
the BC2GM002489529 DT O
Ure2 BC2GM002489529 NNP O
protein BC2GM002489529 NN O
to BC2GM002489529 TO O
high BC2GM002489529 JJ O
yield BC2GM002489529 NN O
in BC2GM002489529 IN O
Escherichia BC2GM002489529 NNP O
coli BC2GM002489529 NN O
from BC2GM002489529 IN O
a BC2GM002489529 DT O
synthetic BC2GM002489529 JJ O
gene BC2GM002489529 NN O
. BC2GM002489529 . O
. . O O

Central BC2GM004737779 JJ O
treatment BC2GM004737779 NN O
unit BC2GM004737779 NN O
saves BC2GM004737779 VBZ O
nurses BC2GM004737779 NNS O
, BC2GM004737779 , O
adds BC2GM004737779 VBZ O
income BC2GM004737779 NN O
, BC2GM004737779 , O
improves BC2GM004737779 VBZ O
care BC2GM004737779 NN O
. BC2GM004737779 . O
. . O O

However BC2GM014160134 RB O
, BC2GM014160134 , O
their BC2GM014160134 PRP$ O
stability BC2GM014160134 NN O
was BC2GM014160134 VBD O
low BC2GM014160134 JJ O
as BC2GM014160134 IN O
already BC2GM014160134 RB O
reported BC2GM014160134 VBN O
for BC2GM014160134 IN O
the BC2GM014160134 DT O
ARS BC2GM014160134 NNP O
in BC2GM014160134 IN O
S. BC2GM014160134 NNP O
occidentalis BC2GM014160134 NN O
. BC2GM014160134 . O
. . O O

A BC2GM092358374 DT O
novel BC2GM092358374 JJ O
Cdc42Hs BC2GM092358374 NNP O
mutant BC2GM092358374 NN O
induces BC2GM092358374 NNS O
cellular BC2GM092358374 JJ O
transformation BC2GM092358374 NN O
. BC2GM092358374 . O
. . O O

Dominant-negative BC2GM038900690 JJ O
mutations BC2GM038900690 NNS O
in BC2GM038900690 IN O
the BC2GM038900690 DT O
G-protein-coupled BC2GM038900690 JJ O
alpha-factor BC2GM038900690 NN O
receptor BC2GM038900690 NN O
map BC2GM038900690 NN O
to BC2GM038900690 TO O
the BC2GM038900690 DT O
extracellular BC2GM038900690 JJ O
ends BC2GM038900690 NNS O
of BC2GM038900690 IN O
the BC2GM038900690 DT O
transmembrane BC2GM038900690 NN O
segments BC2GM038900690 NNS O
. BC2GM038900690 . O
. . O O

Visualization BC2GM068660777 NN O
of BC2GM068660777 IN O
the BC2GM068660777 DT O
cells BC2GM068660777 NNS O
by BC2GM068660777 IN O
phase BC2GM068660777 NN O
contrast BC2GM068660777 NN O
microscopy BC2GM068660777 NN O
indicated BC2GM068660777 VBD O
that BC2GM068660777 IN O
murine BC2GM068660777 NN O
PKCepsilon BC2GM068660777 NNP O
expression BC2GM068660777 NN O
in BC2GM068660777 IN O
the BC2GM068660777 DT O
presence BC2GM068660777 NN O
of BC2GM068660777 IN O
glycerol BC2GM068660777 NN O
resulted BC2GM068660777 VBN O
in BC2GM068660777 IN O
a BC2GM068660777 DT O
significant BC2GM068660777 JJ O
increase BC2GM068660777 NN O
in BC2GM068660777 IN O
the BC2GM068660777 DT O
number BC2GM068660777 NN O
of BC2GM068660777 IN O
yeast BC2GM068660777 JJ O
cells BC2GM068660777 NNS O
exhibiting BC2GM068660777 VBG O
very BC2GM068660777 RB O
small BC2GM068660777 JJ O
buds BC2GM068660777 NNS O
. BC2GM068660777 . O
. . O O

Kondo BC2GM078490707 NNP O
effect BC2GM078490707 NN O
in BC2GM078490707 IN O
Cu BC2GM078490707 NNP O
( BC2GM078490707 ( O
Fe BC2GM078490707 NNP O
) BC2GM078490707 ) O
films BC2GM078490707 NNS O
. BC2GM078490707 . O
. . O O

Fourteen BC2GM049868543 JJ O
Centers BC2GM049868543 NNPS O
participated BC2GM049868543 VBD O
in BC2GM049868543 IN O
this BC2GM049868543 DT O
trial BC2GM049868543 NN O
. BC2GM049868543 . O
. . O O

Failure BC2GM017168033 NN O
to BC2GM017168033 TO O
demonstrate BC2GM017168033 VB O
a BC2GM017168033 DT O
major BC2GM017168033 JJ O
anti-inflammatory BC2GM017168033 JJ O
effect BC2GM017168033 NN O
with BC2GM017168033 IN O
alpha BC2GM017168033 JJ O
tocopherol BC2GM017168033 NN O
supplementation BC2GM017168033 NN O
( BC2GM017168033 ( O
400 BC2GM017168033 CD O
IU BC2GM017168033 NNP O
/ BC2GM017168033 NNP O
day BC2GM017168033 NN O
) BC2GM017168033 ) O
in BC2GM017168033 IN O
normal BC2GM017168033 JJ O
subjects BC2GM017168033 NNS O
. BC2GM017168033 . O
. . O O

TNF-alpha BC2GM042846376 JJ O
effect BC2GM042846376 NN O
was BC2GM042846376 VBD O
eliminated BC2GM042846376 VBN O
by BC2GM042846376 IN O
a BC2GM042846376 DT O
2-bp BC2GM042846376 JJ O
substitution BC2GM042846376 NN O
mutation BC2GM042846376 NN O
in BC2GM042846376 IN O
the BC2GM042846376 DT O
NF-kappa BC2GM042846376 NNP O
B1 BC2GM042846376 NNP O
binding BC2GM042846376 VBG O
half BC2GM042846376 JJ O
site BC2GM042846376 NN O
of BC2GM042846376 IN O
the BC2GM042846376 DT O
NF-kappa BC2GM042846376 NNP O
B BC2GM042846376 NNP O
cis BC2GM042846376 NN O
element BC2GM042846376 NN O
. BC2GM042846376 . O
. . O O

Genetic BC2GM063800112 JJ O
diagnosis BC2GM063800112 NN O
of BC2GM063800112 IN O
respiratory BC2GM063800112 NN O
diseases BC2GM063800112 NNS O
. BC2GM063800112 . O
. . O O

The BC2GM035173306 DT O
results BC2GM035173306 NNS O
showed BC2GM035173306 VBD O
differential BC2GM035173306 JJ O
activation BC2GM035173306 NN O
of BC2GM035173306 IN O
each BC2GM035173306 DT O
parahippocampal BC2GM035173306 JJ O
region BC2GM035173306 NN O
during BC2GM035173306 IN O
verbal BC2GM035173306 JJ O
memory BC2GM035173306 NN O
tasks BC2GM035173306 NNS O
in BC2GM035173306 IN O
which BC2GM035173306 WDT O
the BC2GM035173306 DT O
side BC2GM035173306 NN O
activated BC2GM035173306 VBD O
shifted BC2GM035173306 JJ O
depending BC2GM035173306 VBG O
on BC2GM035173306 IN O
the BC2GM035173306 DT O
nature BC2GM035173306 NN O
of BC2GM035173306 IN O
the BC2GM035173306 DT O
task BC2GM035173306 NN O
employed BC2GM035173306 VBD O
; BC2GM035173306 : O
an BC2GM035173306 DT O
increase BC2GM035173306 NN O
in BC2GM035173306 IN O
rCBF BC2GM035173306 NN O
in BC2GM035173306 IN O
the BC2GM035173306 DT O
left BC2GM035173306 NN O
parahippocampal BC2GM035173306 JJ O
gyrus BC2GM035173306 NN O
was BC2GM035173306 VBD O
associated BC2GM035173306 VBN O
with BC2GM035173306 IN O
retrieval BC2GM035173306 JJ O
strategy BC2GM035173306 NN O
of BC2GM035173306 IN O
non-matching BC2GM035173306 JJ O
, BC2GM035173306 , O
and BC2GM035173306 CC O
an BC2GM035173306 DT O
increase BC2GM035173306 NN O
in BC2GM035173306 IN O
rCBF BC2GM035173306 NN O
in BC2GM035173306 IN O
the BC2GM035173306 DT O
right BC2GM035173306 JJ O
parahippocampal BC2GM035173306 NN O
gyrus BC2GM035173306 NN O
was BC2GM035173306 VBD O
associated BC2GM035173306 VBN O
with BC2GM035173306 IN O
retrieval BC2GM035173306 JJ O
strategy BC2GM035173306 NN O
of BC2GM035173306 IN O
matching BC2GM035173306 NN O
. BC2GM035173306 . O
. . O O

Cbl BC2GM006557709 NNP O
is BC2GM006557709 VBZ O
a BC2GM006557709 DT O
signaling BC2GM006557709 VBG O
molecule BC2GM006557709 NN O
with BC2GM006557709 IN O
multiple BC2GM006557709 JJ O
functional BC2GM006557709 JJ O
domains BC2GM006557709 NNS O
: BC2GM006557709 : O
an BC2GM006557709 DT O
SH2 BC2GM006557709 NNP O
domain BC2GM006557709 NN O
which BC2GM006557709 WDT O
binds BC2GM006557709 VBZ O
phosphotyrosine BC2GM006557709 NN O
residues BC2GM006557709 NNS O
, BC2GM006557709 , O
a BC2GM006557709 DT O
RING BC2GM006557709 NNP O
finger BC2GM006557709 NN O
domain BC2GM006557709 NN O
which BC2GM006557709 WDT O
acts BC2GM006557709 VBZ O
as BC2GM006557709 IN O
a BC2GM006557709 DT O
ubiquitin BC2GM006557709 JJ O
ligase BC2GM006557709 NN O
, BC2GM006557709 , O
a BC2GM006557709 DT O
proline-rich BC2GM006557709 JJ O
region BC2GM006557709 NN O
which BC2GM006557709 WDT O
serves BC2GM006557709 VBZ O
as BC2GM006557709 IN O
a BC2GM006557709 DT O
docking BC2GM006557709 NN O
site BC2GM006557709 NN O
for BC2GM006557709 IN O
SH3-containing BC2GM006557709 JJ O
proteins BC2GM006557709 NNS O
, BC2GM006557709 , O
phosphotyrosine BC2GM006557709 NN O
residues BC2GM006557709 NNS O
which BC2GM006557709 WDT O
serve BC2GM006557709 VBP O
as BC2GM006557709 IN O
docking BC2GM006557709 NN O
sites BC2GM006557709 NNS O
for BC2GM006557709 IN O
SH2-containing BC2GM006557709 JJ O
proteins BC2GM006557709 NNS O
such BC2GM006557709 JJ O
a BC2GM006557709 DT O
CrkL BC2GM006557709 NNP O
and BC2GM006557709 CC O
the BC2GM006557709 DT O
p85 BC2GM006557709 JJ O
subunit BC2GM006557709 NN O
of BC2GM006557709 IN O
PI BC2GM006557709 NNP O
3-kinase BC2GM006557709 NNP O
, BC2GM006557709 , O
and BC2GM006557709 CC O
a BC2GM006557709 DT O
nuclear BC2GM006557709 JJ O
localization BC2GM006557709 NN O
signal BC2GM006557709 NN O
. BC2GM006557709 . O
. . O O

To BC2GM055252448 TO O
examine BC2GM055252448 VB O
the BC2GM055252448 DT O
effect BC2GM055252448 NN O
of BC2GM055252448 IN O
the BC2GM055252448 DT O
cAMP BC2GM055252448 JJ O
signal BC2GM055252448 JJ O
transduction BC2GM055252448 NN O
pathway BC2GM055252448 NN O
on BC2GM055252448 IN O
transcription BC2GM055252448 NN O
of BC2GM055252448 IN O
the BC2GM055252448 DT O
gene BC2GM055252448 NN O
encoding BC2GM055252448 VBG O
the BC2GM055252448 DT O
catalytic BC2GM055252448 JJ O
subunit BC2GM055252448 NN O
of BC2GM055252448 IN O
glucose-6-phosphatase BC2GM055252448 NN O
( BC2GM055252448 ( O
G6Pase BC2GM055252448 NNP O
) BC2GM055252448 ) O
, BC2GM055252448 , O
G6Pase-chloramphenicol BC2GM055252448 JJ O
acetyltransferase BC2GM055252448 NN O
( BC2GM055252448 ( O
CAT BC2GM055252448 NNP O
) BC2GM055252448 ) O
fusion BC2GM055252448 NN O
genes BC2GM055252448 NNS O
were BC2GM055252448 VBD O
transiently BC2GM055252448 RB O
transfected BC2GM055252448 VBN O
into BC2GM055252448 IN O
either BC2GM055252448 CC O
the BC2GM055252448 DT O
liver-derived BC2GM055252448 JJ O
HepG2 BC2GM055252448 NNP O
or BC2GM055252448 CC O
kidney-derived BC2GM055252448 JJ O
LLC-PK BC2GM055252448 NNP O
cell BC2GM055252448 NN O
line BC2GM055252448 NN O
. BC2GM055252448 . O
. . O O

A BC2GM033367187 DT O
case BC2GM033367187 NN O
comparison BC2GM033367187 NN O
of BC2GM033367187 IN O
acquired BC2GM033367187 VBN O
immune BC2GM033367187 JJ O
deficiency BC2GM033367187 NN O
syndrome BC2GM033367187 NN O
( BC2GM033367187 ( O
AIDS BC2GM033367187 NNP O
) BC2GM033367187 ) O
in BC2GM033367187 IN O
homosexual BC2GM033367187 JJ O
males BC2GM033367187 NNS O
with BC2GM033367187 IN O
spindle-endothelial BC2GM033367187 JJ O
cell BC2GM033367187 NN O
abnormalities BC2GM033367187 NNS O
and BC2GM033367187 CC O
with BC2GM033367187 IN O
recrudescent BC2GM033367187 JJ O
melioidosis BC2GM033367187 NN O
. BC2GM033367187 . O
. . O O

Here BC2GM099206103 RB O
we BC2GM099206103 PRP O
examine BC2GM099206103 VBP O
the BC2GM099206103 DT O
population BC2GM099206103 NN O
of BC2GM099206103 IN O
gammaS BC2GM099206103 NN O
transcripts BC2GM099206103 NNS O
in BC2GM099206103 IN O
adult BC2GM099206103 NN O
human BC2GM099206103 JJ O
lens BC2GM099206103 NNS O
and BC2GM099206103 CC O
the BC2GM099206103 DT O
structure BC2GM099206103 NN O
of BC2GM099206103 IN O
the BC2GM099206103 DT O
human BC2GM099206103 JJ O
CRYGS BC2GM099206103 NNP O
genes BC2GM099206103 NNS O
. BC2GM099206103 . O
. . O O

All BC2GM075271187 DT O
testosterone BC2GM075271187 NN O
treatments BC2GM075271187 NNS O
raised BC2GM075271187 VBD O
plasma BC2GM075271187 JJ O
testosterone BC2GM075271187 NN O
concentrations BC2GM075271187 NNS O
above BC2GM075271187 IN O
control BC2GM075271187 NN O
and BC2GM075271187 CC O
pretreatment BC2GM075271187 NN O
levels BC2GM075271187 NNS O
( BC2GM075271187 ( O
testosterone BC2GM075271187 NN O
and BC2GM075271187 CC O
synovex BC2GM075271187 NN O
+ BC2GM075271187 NNP O
testosterone BC2GM075271187 NN O
> BC2GM075271187 NNP O
synovex BC2GM075271187 VBZ O
> BC2GM075271187 NNP O
control BC2GM075271187 NN O
; BC2GM075271187 : O
all BC2GM075271187 DT O
P BC2GM075271187 NNP O
< BC2GM075271187 NNP O
0.05 BC2GM075271187 CD O
) BC2GM075271187 ) O
. BC2GM075271187 . O
. . O O

Thomas BC2GM096419837 NNP O
, BC2GM096419837 , O
S.S BC2GM096419837 NNP O
. BC2GM096419837 . O
. . O O

Now BC2GM046716836 RB O
: BC2GM046716836 : O
pleasure BC2GM046716836 NN O
in BC2GM046716836 IN O
work BC2GM046716836 NN O
. BC2GM046716836 . O
. . O O

METHODS BC2GM087329770 NNS O
: BC2GM087329770 : O
We BC2GM087329770 PRP O
retrospectively BC2GM087329770 RB O
analyzed BC2GM087329770 VBD O
the BC2GM087329770 DT O
data BC2GM087329770 NNS O
of BC2GM087329770 IN O
20 BC2GM087329770 CD O
patients BC2GM087329770 NNS O
who BC2GM087329770 WP O
underwent BC2GM087329770 VBP O
both BC2GM087329770 DT O
gated BC2GM087329770 JJ O
fluorine BC2GM087329770 NN O
18 BC2GM087329770 CD O
deoxyglucose BC2GM087329770 NN O
( BC2GM087329770 ( O
FDG BC2GM087329770 NNP O
) BC2GM087329770 ) O
-PET BC2GM087329770 NN O
and BC2GM087329770 CC O
equilibrium BC2GM087329770 NN O
radionuclide BC2GM087329770 NN O
angiography BC2GM087329770 NN O
( BC2GM087329770 ( O
ERNA BC2GM087329770 NNP O
) BC2GM087329770 ) O
. BC2GM087329770 . O
. . O O

The BC2GM003073174 DT O
antiserum BC2GM003073174 NN O
used BC2GM003073174 VBN O
for BC2GM003073174 IN O
immunoblotting BC2GM003073174 VBG O
specifically BC2GM003073174 RB O
supershifts BC2GM003073174 JJ O
uteroglobin BC2GM003073174 JJ O
promoter-protein BC2GM003073174 NN O
complexes BC2GM003073174 NNS O
in BC2GM003073174 IN O
gel BC2GM003073174 JJ O
shift BC2GM003073174 NN O
experiments BC2GM003073174 NNS O
. BC2GM003073174 . O
. . O O

Polyoma BC2GM015901462 NNP O
virus BC2GM015901462 NN O
in BC2GM015901462 IN O
urine BC2GM015901462 JJ O
during BC2GM015901462 IN O
pregnancy BC2GM015901462 NN O
. BC2GM015901462 . O
. . O O

Footprints BC2GM082123096 NNS O
on BC2GM082123096 IN O
the BC2GM082123096 DT O
HPV BC2GM082123096 NNP O
18 BC2GM082123096 CD O
enhancer BC2GM082123096 NN O
show BC2GM082123096 NN O
five BC2GM082123096 CD O
protected BC2GM082123096 VBN O
regions BC2GM082123096 NNS O
with BC2GM082123096 IN O
homologies BC2GM082123096 NNS O
to BC2GM082123096 TO O
NF1 BC2GM082123096 NNP O
, BC2GM082123096 , O
AP1 BC2GM082123096 NNP O
and BC2GM082123096 CC O
EFII BC2GM082123096 NNP O
transcription BC2GM082123096 NN O
factor BC2GM082123096 NN O
binding BC2GM082123096 VBG O
motifs BC2GM082123096 NNS O
. BC2GM082123096 . O
. . O O

We BC2GM007915861 PRP O
also BC2GM007915861 RB O
show BC2GM007915861 VBP O
that BC2GM007915861 IN O
an BC2GM007915861 DT O
internal BC2GM007915861 JJ O
fragment BC2GM007915861 NN O
of BC2GM007915861 IN O
U24 BC2GM007915861 NNP O
methylation BC2GM007915861 NN O
guide BC2GM007915861 NN O
snoRNA BC2GM007915861 NN O
, BC2GM007915861 , O
encompassing BC2GM007915861 VBG O
the BC2GM007915861 DT O
upstream BC2GM007915861 JJ O
antisense BC2GM007915861 NN O
element BC2GM007915861 NN O
and BC2GM007915861 CC O
the BC2GM007915861 DT O
D BC2GM007915861 NNP O
' BC2GM007915861 POS O
and BC2GM007915861 CC O
C BC2GM007915861 NNP O
' BC2GM007915861 POS O
box BC2GM007915861 NN O
motifs BC2GM007915861 NNS O
, BC2GM007915861 , O
can BC2GM007915861 MD O
support BC2GM007915861 VB O
the BC2GM007915861 DT O
site-specific BC2GM007915861 JJ O
methylation BC2GM007915861 NN O
of BC2GM007915861 IN O
rRNA BC2GM007915861 NN O
. BC2GM007915861 . O
. . O O

Those BC2GM034605250 DT O
diagnosed BC2GM034605250 VBN O
as BC2GM034605250 IN O
having BC2GM034605250 VBG O
affective BC2GM034605250 JJ O
disorder BC2GM034605250 NN O
( BC2GM034605250 ( O
n BC2GM034605250 JJ O
= BC2GM034605250 NNP O
96 BC2GM034605250 CD O
) BC2GM034605250 ) O
, BC2GM034605250 , O
according BC2GM034605250 VBG O
to BC2GM034605250 TO O
DSM-IIIR BC2GM034605250 NNP O
criteria BC2GM034605250 NNS O
, BC2GM034605250 , O
were BC2GM034605250 VBD O
compared BC2GM034605250 VBN O
with BC2GM034605250 IN O
the BC2GM034605250 DT O
other BC2GM034605250 JJ O
non-affective BC2GM034605250 JJ O
suicide BC2GM034605250 NN O
attempters BC2GM034605250 NNS O
( BC2GM034605250 ( O
n BC2GM034605250 JJ O
= BC2GM034605250 NNP O
161 BC2GM034605250 CD O
) BC2GM034605250 ) O
. BC2GM034605250 . O
. . O O

Sequences BC2GM045403692 NNS O
homologous BC2GM045403692 JJ O
to BC2GM045403692 TO O
the BC2GM045403692 DT O
consensus BC2GM045403692 NN O
TUF-binding BC2GM045403692 NNP O
UAS BC2GM045403692 NNP O
boxes BC2GM045403692 NNS O
are BC2GM045403692 VBP O
present BC2GM045403692 JJ O
in BC2GM045403692 IN O
the BC2GM045403692 DT O
5 BC2GM045403692 CD O
' BC2GM045403692 POS O
flanking BC2GM045403692 JJ O
regions BC2GM045403692 NNS O
of BC2GM045403692 IN O
both BC2GM045403692 DT O
genes BC2GM045403692 NNS O
. BC2GM045403692 . O
. . O O

Cord BC2GM070795322 NNP O
formation BC2GM070795322 NN O
in BC2GM070795322 IN O
BACTEC BC2GM070795322 NNP O
7H12 BC2GM070795322 CD O
medium BC2GM070795322 NN O
for BC2GM070795322 IN O
rapid BC2GM070795322 JJ O
, BC2GM070795322 , O
presumptive BC2GM070795322 JJ O
identification BC2GM070795322 NN O
of BC2GM070795322 IN O
Mycobacterium BC2GM070795322 NNP O
tuberculosis BC2GM070795322 NN O
complex BC2GM070795322 NN O
. BC2GM070795322 . O
. . O O

Promoter BC2GM010561492 NNP O
activity BC2GM010561492 NN O
of BC2GM010561492 IN O
the BC2GM010561492 DT O
proliferating-cell BC2GM010561492 JJ O
nuclear BC2GM010561492 JJ O
antigen BC2GM010561492 NN O
gene BC2GM010561492 NN O
is BC2GM010561492 VBZ O
associated BC2GM010561492 VBN O
with BC2GM010561492 IN O
inducible BC2GM010561492 JJ O
CRE-binding BC2GM010561492 JJ O
proteins BC2GM010561492 NNS O
in BC2GM010561492 IN O
interleukin BC2GM010561492 JJ O
2-stimulated BC2GM010561492 JJ O
T BC2GM010561492 NNP O
lymphocytes BC2GM010561492 NNS O
. BC2GM010561492 . O
. . O O

Two BC2GM043104937 CD O
of BC2GM043104937 IN O
the BC2GM043104937 DT O
three BC2GM043104937 CD O
groups BC2GM043104937 NNS O
were BC2GM043104937 VBD O
submitted BC2GM043104937 VBN O
to BC2GM043104937 TO O
two BC2GM043104937 CD O
different BC2GM043104937 JJ O
levels BC2GM043104937 NNS O
of BC2GM043104937 IN O
hypoxia BC2GM043104937 NN O
( BC2GM043104937 ( O
FiO2 BC2GM043104937 NNP O
= BC2GM043104937 NNP O
0.05 BC2GM043104937 CD O
, BC2GM043104937 , O
group BC2GM043104937 NN O
F5 BC2GM043104937 NNP O
and BC2GM043104937 CC O
FiO2 BC2GM043104937 NNP O
= BC2GM043104937 NNP O
0.1 BC2GM043104937 CD O
, BC2GM043104937 , O
group BC2GM043104937 NN O
F10 BC2GM043104937 NNP O
) BC2GM043104937 ) O
and BC2GM043104937 CC O
the BC2GM043104937 DT O
third BC2GM043104937 JJ O
to BC2GM043104937 TO O
normoxia BC2GM043104937 VB O
( BC2GM043104937 ( O
FiO2 BC2GM043104937 NNP O
= BC2GM043104937 NNP O
0.21 BC2GM043104937 CD O
, BC2GM043104937 , O
group BC2GM043104937 NN O
F21 BC2GM043104937 NNP O
) BC2GM043104937 ) O
in BC2GM043104937 IN O
a BC2GM043104937 DT O
thermoneutral BC2GM043104937 JJ O
and BC2GM043104937 CC O
controlled BC2GM043104937 JJ O
environment BC2GM043104937 NN O
. BC2GM043104937 . O
. . O O

Serum BC2GM093048431 NNP O
zinc BC2GM093048431 NN O
and BC2GM093048431 CC O
copper BC2GM093048431 NN O
levels BC2GM093048431 NNS O
and BC2GM093048431 CC O
urine BC2GM093048431 JJ O
copper BC2GM093048431 NN O
concentrations BC2GM093048431 NNS O
in BC2GM093048431 IN O
men BC2GM093048431 NNS O
were BC2GM093048431 VBD O
significantly BC2GM093048431 RB O
lower BC2GM093048431 JJR O
than BC2GM093048431 IN O
in BC2GM093048431 IN O
women BC2GM093048431 NNS O
, BC2GM093048431 , O
while BC2GM093048431 IN O
there BC2GM093048431 EX O
were BC2GM093048431 VBD O
no BC2GM093048431 DT O
differences BC2GM093048431 NNS O
in BC2GM093048431 IN O
serum BC2GM093048431 NN O
or BC2GM093048431 CC O
urinary BC2GM093048431 JJ O
zinc BC2GM093048431 NN O
and BC2GM093048431 CC O
copper BC2GM093048431 NN O
levels BC2GM093048431 NNS O
with BC2GM093048431 IN O
age BC2GM093048431 NN O
. BC2GM093048431 . O
. . O O

Phase BC2GM072220423 NN O
I BC2GM072220423 PRP O
clinical BC2GM072220423 JJ O
trial BC2GM072220423 NN O
with BC2GM072220423 IN O
a BC2GM072220423 DT O
combination BC2GM072220423 NN O
of BC2GM072220423 IN O
methotrexate BC2GM072220423 NN O
and BC2GM072220423 CC O
mitomycin BC2GM072220423 NN O
C BC2GM072220423 NNP O
. BC2GM072220423 . O
. . O O

The BC2GM053837168 DT O
great BC2GM053837168 JJ O
cardiac BC2GM053837168 JJ O
vein BC2GM053837168 NN O
flow BC2GM053837168 NN O
became BC2GM053837168 VBD O
zero BC2GM053837168 CD O
due BC2GM053837168 JJ O
to BC2GM053837168 TO O
the BC2GM053837168 DT O
cardiac BC2GM053837168 JJ O
arrest BC2GM053837168 NN O
and BC2GM053837168 CC O
remained BC2GM053837168 VBD O
at BC2GM053837168 IN O
zero BC2GM053837168 NN O
for BC2GM053837168 IN O
a BC2GM053837168 DT O
moment BC2GM053837168 NN O
( BC2GM053837168 ( O
dead BC2GM053837168 JJ O
time BC2GM053837168 NN O
) BC2GM053837168 ) O
after BC2GM053837168 IN O
the BC2GM053837168 DT O
initiation BC2GM053837168 NN O
of BC2GM053837168 IN O
reperfusion BC2GM053837168 NN O
. BC2GM053837168 . O
. . O O

Restricted BC2GM008418248 VBN O
expression BC2GM008418248 NN O
of BC2GM008418248 IN O
a BC2GM008418248 DT O
novel BC2GM008418248 JJ O
murine BC2GM008418248 NN O
atonal-related BC2GM008418248 JJ O
bHLH BC2GM008418248 NN O
protein BC2GM008418248 NN O
in BC2GM008418248 IN O
undifferentiated BC2GM008418248 JJ O
neural BC2GM008418248 JJ O
precursors BC2GM008418248 NNS O
. BC2GM008418248 . O
. . O O

The BC2GM043720007 DT O
extraordinary BC2GM043720007 JJ O
high BC2GM043720007 JJ O
substrate BC2GM043720007 NN O
specificity BC2GM043720007 NN O
of BC2GM043720007 IN O
rPulA BC2GM043720007 NN O
together BC2GM043720007 RB O
with BC2GM043720007 IN O
its BC2GM043720007 PRP$ O
thermal BC2GM043720007 JJ O
stability BC2GM043720007 NN O
makes BC2GM043720007 VBZ O
this BC2GM043720007 DT O
enzyme BC2GM043720007 VBZ O
a BC2GM043720007 DT O
good BC2GM043720007 JJ O
candidate BC2GM043720007 NN O
for BC2GM043720007 IN O
biotechnological BC2GM043720007 JJ O
applications BC2GM043720007 NNS O
in BC2GM043720007 IN O
the BC2GM043720007 DT O
starch-processing BC2GM043720007 JJ O
industry BC2GM043720007 NN O
. BC2GM043720007 . O
. . O O

The BC2GM031759031 DT O
originally BC2GM031759031 RB O
embryonic BC2GM031759031 JJ O
gamma-globin BC2GM031759031 JJ O
locus BC2GM031759031 NN O
duplicated BC2GM031759031 VBN O
and BC2GM031759031 CC O
acquired BC2GM031759031 VBD O
a BC2GM031759031 DT O
novel BC2GM031759031 NN O
( BC2GM031759031 ( O
fetal BC2GM031759031 JJ O
) BC2GM031759031 ) O
pattern BC2GM031759031 NN O
of BC2GM031759031 IN O
expression BC2GM031759031 NN O
in BC2GM031759031 IN O
a BC2GM031759031 DT O
defined BC2GM031759031 JJ O
time BC2GM031759031 NN O
period BC2GM031759031 NN O
( BC2GM031759031 ( O
55-40 BC2GM031759031 JJ O
million BC2GM031759031 CD O
years BC2GM031759031 NNS O
ago BC2GM031759031 RB O
) BC2GM031759031 ) O
during BC2GM031759031 IN O
primate BC2GM031759031 NN O
phylogeny BC2GM031759031 NN O
. BC2GM031759031 . O
. . O O

Human BC2GM051472026 NNP O
alcohol BC2GM051472026 NN O
dehydrogenase BC2GM051472026 NN O
( BC2GM051472026 ( O
ADH BC2GM051472026 NNP O
) BC2GM051472026 ) O
exists BC2GM051472026 VBZ O
as BC2GM051472026 IN O
a BC2GM051472026 DT O
heterogeneous BC2GM051472026 JJ O
group BC2GM051472026 NN O
of BC2GM051472026 IN O
isozymes BC2GM051472026 NNS O
capable BC2GM051472026 JJ O
of BC2GM051472026 IN O
oxidizing BC2GM051472026 VBG O
a BC2GM051472026 DT O
wide BC2GM051472026 JJ O
variety BC2GM051472026 NN O
of BC2GM051472026 IN O
aliphatic BC2GM051472026 JJ O
and BC2GM051472026 CC O
aromatic BC2GM051472026 JJ O
alcohols BC2GM051472026 NNS O
. BC2GM051472026 . O
. . O O

Bile BC2GM022908464 NNP O
salts BC2GM022908464 NNS O
, BC2GM022908464 , O
hormonal BC2GM022908464 JJ O
control BC2GM022908464 NN O
, BC2GM022908464 , O
and BC2GM022908464 CC O
the BC2GM022908464 DT O
male BC2GM022908464 JJ O
disadvantage BC2GM022908464 NN O
. BC2GM022908464 . O
. . O O

The BC2GM046112338 DT O
analysis BC2GM046112338 NN O
consisted BC2GM046112338 VBD O
of BC2GM046112338 IN O
1 BC2GM046112338 CD O
) BC2GM046112338 ) O
fitting BC2GM046112338 VBG O
first- BC2GM046112338 JJ O
and BC2GM046112338 CC O
second-order BC2GM046112338 JJ O
autoregressive BC2GM046112338 JJ O
models BC2GM046112338 NNS O
( BC2GM046112338 ( O
AR1 BC2GM046112338 NNP O
and BC2GM046112338 CC O
AR2 BC2GM046112338 NNP O
) BC2GM046112338 ) O
and BC2GM046112338 CC O
2 BC2GM046112338 CD O
) BC2GM046112338 ) O
obtaining BC2GM046112338 VBG O
the BC2GM046112338 DT O
power BC2GM046112338 NN O
spectra BC2GM046112338 NN O
of BC2GM046112338 IN O
the BC2GM046112338 DT O
data BC2GM046112338 NNS O
by BC2GM046112338 IN O
fast-Fourier BC2GM046112338 JJ O
transform BC2GM046112338 NN O
. BC2GM046112338 . O
. . O O

Synergistic BC2GM046530898 JJ O
induction BC2GM046530898 NN O
of BC2GM046530898 IN O
apoptosis BC2GM046530898 NN O
in BC2GM046530898 IN O
human BC2GM046530898 JJ O
leukemia BC2GM046530898 NN O
cells BC2GM046530898 NNS O
( BC2GM046530898 ( O
U937 BC2GM046530898 NNP O
) BC2GM046530898 ) O
exposed BC2GM046530898 VBD O
to BC2GM046530898 TO O
bryostatin BC2GM046530898 VB O
1 BC2GM046530898 CD O
and BC2GM046530898 CC O
the BC2GM046530898 DT O
proteasome BC2GM046530898 JJ O
inhibitor BC2GM046530898 NN O
lactacystin BC2GM046530898 NN O
involves BC2GM046530898 VBZ O
dysregulation BC2GM046530898 NN O
of BC2GM046530898 IN O
the BC2GM046530898 DT O
PKC BC2GM046530898 NNP O
/ BC2GM046530898 NNP O
MAPK BC2GM046530898 NNP O
cascade BC2GM046530898 NN O
. BC2GM046530898 . O
. . O O

The BC2GM056723131 DT O
shear BC2GM056723131 JJ O
bond BC2GM056723131 NN O
strength BC2GM056723131 NN O
recorded BC2GM056723131 VBD O
for BC2GM056723131 IN O
the BC2GM056723131 DT O
Novabond BC2GM056723131 NNP O
system BC2GM056723131 NN O
was BC2GM056723131 VBD O
significantly BC2GM056723131 RB O
lower BC2GM056723131 JJR O
( BC2GM056723131 ( O
17 BC2GM056723131 CD O
MPa BC2GM056723131 NNP O
) BC2GM056723131 ) O
. BC2GM056723131 . O
. . O O

The BC2GM012807345 DT O
ventricular BC2GM012807345 JJ O
demand BC2GM012807345 NN O
pacemaker BC2GM012807345 NN O
( BC2GM012807345 ( O
VVI BC2GM012807345 NNP O
) BC2GM012807345 ) O
was BC2GM012807345 VBD O
implanted BC2GM012807345 VBN O
three BC2GM012807345 CD O
years BC2GM012807345 NNS O
ago BC2GM012807345 RB O
and BC2GM012807345 CC O
because BC2GM012807345 IN O
of BC2GM012807345 IN O
further BC2GM012807345 JJ O
impairment BC2GM012807345 NN O
of BC2GM012807345 IN O
cardiac BC2GM012807345 JJ O
performance BC2GM012807345 NN O
an BC2GM012807345 DT O
av-sequential BC2GM012807345 JJ O
pacemaker BC2GM012807345 NN O
( BC2GM012807345 ( O
DDD BC2GM012807345 NNP O
) BC2GM012807345 ) O
was BC2GM012807345 VBD O
used BC2GM012807345 VBN O
to BC2GM012807345 TO O
restore BC2GM012807345 VB O
atrio-ventricular BC2GM012807345 JJ O
synchronisation BC2GM012807345 NN O
. BC2GM012807345 . O
. . O O

In BC2GM076684671 IN O
the BC2GM076684671 DT O
Saccharomyces BC2GM076684671 NNP O
cerevisiae BC2GM076684671 NN O
actin BC2GM076684671 NN O
intron BC2GM076684671 VBZ O
a BC2GM076684671 DT O
silent BC2GM076684671 JJ O
branch BC2GM076684671 NN O
point-like BC2GM076684671 JJ O
sequence BC2GM076684671 NN O
( BC2GM076684671 ( O
UACUAAG BC2GM076684671 NNP O
) BC2GM076684671 ) O
is BC2GM076684671 VBZ O
located BC2GM076684671 VBN O
7 BC2GM076684671 CD O
nt BC2GM076684671 JJ O
upstream BC2GM076684671 NN O
of BC2GM076684671 IN O
the BC2GM076684671 DT O
canonical BC2GM076684671 JJ O
sequence BC2GM076684671 NN O
. BC2GM076684671 . O
. . O O

Four BC2GM072949997 CD O
newborns BC2GM072949997 NNS O
in BC2GM072949997 IN O
this BC2GM072949997 DT O
group BC2GM072949997 NN O
became BC2GM072949997 VBD O
HBsAg BC2GM072949997 NNP O
carriers BC2GM072949997 NNS O
. BC2GM072949997 . O
. . O O

For BC2GM070142081 IN O
the BC2GM070142081 DT O
most BC2GM070142081 JJS O
part BC2GM070142081 NN O
, BC2GM070142081 , O
only BC2GM070142081 RB O
aerobic BC2GM070142081 JJ O
microbial BC2GM070142081 JJ O
degradation BC2GM070142081 NN O
systems BC2GM070142081 NNS O
have BC2GM070142081 VBP O
been BC2GM070142081 VBN O
reported BC2GM070142081 VBN O
so BC2GM070142081 RB O
far BC2GM070142081 RB O
. BC2GM070142081 . O
. . O O

Thus BC2GM080904323 RB O
G17 BC2GM080904323 NNP O
targets BC2GM080904323 VBZ O
the BC2GM080904323 DT O
c-fos BC2GM080904323 JJ O
promoter BC2GM080904323 NN O
CArG BC2GM080904323 NNP O
sequence BC2GM080904323 NN O
via BC2GM080904323 IN O
Rho BC2GM080904323 NNP O
A-dependent BC2GM080904323 NNP O
pathways BC2GM080904323 NNS O
, BC2GM080904323 , O
and BC2GM080904323 CC O
Rho BC2GM080904323 NNP O
A BC2GM080904323 NNP O
appears BC2GM080904323 VBZ O
to BC2GM080904323 TO O
play BC2GM080904323 VB O
an BC2GM080904323 DT O
important BC2GM080904323 JJ O
role BC2GM080904323 NN O
in BC2GM080904323 IN O
the BC2GM080904323 DT O
regulation BC2GM080904323 NN O
of BC2GM080904323 IN O
the BC2GM080904323 DT O
trophic BC2GM080904323 JJ O
action BC2GM080904323 NN O
of BC2GM080904323 IN O
G17 BC2GM080904323 NNP O
. BC2GM080904323 . O
. . O O

This BC2GM074265935 DT O
pattern BC2GM074265935 NN O
of BC2GM074265935 IN O
expression BC2GM074265935 NN O
and BC2GM074265935 CC O
differential BC2GM074265935 JJ O
processing BC2GM074265935 NN O
suggests BC2GM074265935 VBZ O
a BC2GM074265935 DT O
role BC2GM074265935 NN O
for BC2GM074265935 IN O
inrpk1 BC2GM074265935 NN O
in BC2GM074265935 IN O
some BC2GM074265935 DT O
aspect BC2GM074265935 NN O
of BC2GM074265935 IN O
SD BC2GM074265935 NNP O
photoperiodic-induced BC2GM074265935 JJ O
flowering BC2GM074265935 NN O
in BC2GM074265935 IN O
morning BC2GM074265935 NN O
glory BC2GM074265935 NN O
. BC2GM074265935 . O
. . O O

However BC2GM052383687 RB O
, BC2GM052383687 , O
studies BC2GM052383687 NNS O
using BC2GM052383687 VBG O
the BC2GM052383687 DT O
A20 BC2GM052383687 NNP O
promoter BC2GM052383687 NN O
demonstrated BC2GM052383687 VBD O
that BC2GM052383687 IN O
LMP1 BC2GM052383687 NNP O
transcriptionally BC2GM052383687 RB O
activates BC2GM052383687 VBZ O
the BC2GM052383687 DT O
A20 BC2GM052383687 NNP O
gene BC2GM052383687 NN O
through BC2GM052383687 IN O
cis-acting BC2GM052383687 JJ O
kappa BC2GM052383687 NN O
B BC2GM052383687 NNP O
sites BC2GM052383687 VBZ O
. BC2GM052383687 . O
. . O O

These BC2GM076157697 DT O
data BC2GM076157697 NNS O
suggested BC2GM076157697 VBD O
that BC2GM076157697 IN O
mutant BC2GM076157697 JJ O
PS1 BC2GM076157697 NNP O
may BC2GM076157697 MD O
cause BC2GM076157697 VB O
disease BC2GM076157697 NN O
as BC2GM076157697 IN O
a BC2GM076157697 DT O
result BC2GM076157697 NN O
of BC2GM076157697 IN O
reduction BC2GM076157697 NN O
in BC2GM076157697 IN O
PS1 BC2GM076157697 NNP O
function BC2GM076157697 NN O
. BC2GM076157697 . O
. . O O

Zoonotic BC2GM050974186 JJ O
areas BC2GM050974186 NNS O
in BC2GM050974186 IN O
which BC2GM050974186 WDT O
HIV BC2GM050974186 NNP O
co-infection BC2GM050974186 NN O
is BC2GM050974186 VBZ O
common BC2GM050974186 JJ O
could BC2GM050974186 MD O
also BC2GM050974186 RB O
be BC2GM050974186 VB O
at BC2GM050974186 IN O
risk BC2GM050974186 NN O
as BC2GM050974186 IN O
sandflies BC2GM050974186 NNS O
can BC2GM050974186 MD O
become BC2GM050974186 VB O
infected BC2GM050974186 JJ O
from BC2GM050974186 IN O
co-infected BC2GM050974186 JJ O
individuals BC2GM050974186 NNS O
. BC2GM050974186 . O
. . O O

Although BC2GM007746647 IN O
the BC2GM007746647 DT O
elevated BC2GM007746647 JJ O
signalling BC2GM007746647 NN O
is BC2GM007746647 VBZ O
eliminated BC2GM007746647 VBN O
by BC2GM007746647 IN O
deletion BC2GM007746647 NN O
of BC2GM007746647 IN O
Ste20p BC2GM007746647 NNP O
( BC2GM007746647 ( O
or BC2GM007746647 CC O
components BC2GM007746647 NNS O
downstream BC2GM007746647 NN O
of BC2GM007746647 IN O
Ste20p BC2GM007746647 NNP O
) BC2GM007746647 ) O
, BC2GM007746647 , O
the BC2GM007746647 DT O
growth BC2GM007746647 NN O
and BC2GM007746647 CC O
morphological BC2GM007746647 JJ O
abnormalities BC2GM007746647 NNS O
of BC2GM007746647 IN O
cells BC2GM007746647 NNS O
lacking BC2GM007746647 VBG O
Akr1p BC2GM007746647 NNP O
are BC2GM007746647 VBP O
not BC2GM007746647 RB O
rescued BC2GM007746647 VBN O
by BC2GM007746647 IN O
deletion BC2GM007746647 NN O
of BC2GM007746647 IN O
any BC2GM007746647 DT O
of BC2GM007746647 IN O
the BC2GM007746647 DT O
known BC2GM007746647 VBN O
pheromone BC2GM007746647 NN O
response BC2GM007746647 NN O
pathway BC2GM007746647 NN O
components BC2GM007746647 NNS O
. BC2GM007746647 . O
. . O O

In BC2GM096544601 IN O
serum-starved BC2GM096544601 JJ O
NIH BC2GM096544601 NNP O
3T3 BC2GM096544601 CD O
cells BC2GM096544601 NNS O
, BC2GM096544601 , O
v-raf BC2GM096544601 NN O
increased BC2GM096544601 VBD O
mdr1 BC2GM096544601 JJ O
promoter BC2GM096544601 NN O
activity BC2GM096544601 NN O
approximately BC2GM096544601 RB O
10-fold BC2GM096544601 JJ O
compared BC2GM096544601 VBN O
to BC2GM096544601 TO O
a BC2GM096544601 DT O
v-raf BC2GM096544601 JJ O
frame-shift BC2GM096544601 NN O
control BC2GM096544601 NN O
. BC2GM096544601 . O
. . O O

Here BC2GM087506083 RB O
, BC2GM087506083 , O
we BC2GM087506083 PRP O
describe BC2GM087506083 VBP O
the BC2GM087506083 DT O
crystal BC2GM087506083 JJ O
structure BC2GM087506083 NN O
at BC2GM087506083 IN O
2.5 BC2GM087506083 CD O
A BC2GM087506083 DT O
resolution BC2GM087506083 NN O
of BC2GM087506083 IN O
a BC2GM087506083 DT O
fragment BC2GM087506083 NN O
of BC2GM087506083 IN O
the BC2GM087506083 DT O
integrase BC2GM087506083 NN O
of BC2GM087506083 IN O
Rous BC2GM087506083 NNP O
sarcoma BC2GM087506083 NN O
virus BC2GM087506083 NN O
( BC2GM087506083 ( O
residues BC2GM087506083 VB O
49-286 BC2GM087506083 NNP O
) BC2GM087506083 ) O
containing BC2GM087506083 VBG O
both BC2GM087506083 CC O
the BC2GM087506083 DT O
conserved BC2GM087506083 VBN O
catalytic BC2GM087506083 JJ O
domain BC2GM087506083 NN O
and BC2GM087506083 CC O
a BC2GM087506083 DT O
modulatory BC2GM087506083 JJ O
DNA-binding BC2GM087506083 JJ O
domain BC2GM087506083 NN O
( BC2GM087506083 ( O
C BC2GM087506083 NNP O
domain BC2GM087506083 NN O
) BC2GM087506083 ) O
. BC2GM087506083 . O
. . O O

Our BC2GM070280766 PRP$ O
study BC2GM070280766 NN O
investigated BC2GM070280766 VBD O
the BC2GM070280766 DT O
hypothesis BC2GM070280766 NN O
that BC2GM070280766 IN O
the BC2GM070280766 DT O
combination BC2GM070280766 NN O
of BC2GM070280766 IN O
a BC2GM070280766 DT O
high BC2GM070280766 JJ O
NaCl BC2GM070280766 NNP O
diet BC2GM070280766 NN O
and BC2GM070280766 CC O
social BC2GM070280766 JJ O
isolation BC2GM070280766 NN O
stress BC2GM070280766 NN O
would BC2GM070280766 MD O
increase BC2GM070280766 VB O
systolic BC2GM070280766 JJ O
blood BC2GM070280766 NN O
pressure BC2GM070280766 NN O
( BC2GM070280766 ( O
SBP BC2GM070280766 NNP O
) BC2GM070280766 ) O
and BC2GM070280766 CC O
endogenous BC2GM070280766 JJ O
sodium BC2GM070280766 NN O
pump BC2GM070280766 NN O
ligands BC2GM070280766 NNS O
( BC2GM070280766 ( O
SPL BC2GM070280766 NNP O
) BC2GM070280766 ) O
, BC2GM070280766 , O
ouabainlike BC2GM070280766 JJ O
compound BC2GM070280766 NN O
( BC2GM070280766 ( O
OLC BC2GM070280766 NNP O
) BC2GM070280766 ) O
, BC2GM070280766 , O
and BC2GM070280766 CC O
marinobufagenin BC2GM070280766 NN O
( BC2GM070280766 ( O
MBG BC2GM070280766 NNP O
) BC2GM070280766 ) O
. BC2GM070280766 . O
. . O O

We BC2GM056805115 PRP O
found BC2GM056805115 VBD O
a BC2GM056805115 DT O
prevalence BC2GM056805115 NN O
of BC2GM056805115 IN O
eating BC2GM056805115 VBG O
disorders BC2GM056805115 NNS O
of BC2GM056805115 IN O
5.9 BC2GM056805115 CD O
% BC2GM056805115 NN O
( BC2GM056805115 ( O
lifetime BC2GM056805115 JJ O
prevalence BC2GM056805115 NN O
of BC2GM056805115 IN O
10 BC2GM056805115 CD O
% BC2GM056805115 NN O
) BC2GM056805115 ) O
, BC2GM056805115 , O
irrespective BC2GM056805115 JJ O
of BC2GM056805115 IN O
gender BC2GM056805115 NN O
and BC2GM056805115 CC O
type BC2GM056805115 NN O
of BC2GM056805115 IN O
diabetes BC2GM056805115 NNS O
; BC2GM056805115 : O
4.1 BC2GM056805115 CD O
% BC2GM056805115 NN O
of BC2GM056805115 IN O
the BC2GM056805115 DT O
whole BC2GM056805115 JJ O
sample BC2GM056805115 NN O
reported BC2GM056805115 VBD O
intentional BC2GM056805115 JJ O
insulin BC2GM056805115 NN O
undertreatment BC2GM056805115 NN O
or BC2GM056805115 CC O
omission BC2GM056805115 NN O
. BC2GM056805115 . O
. . O O

The BC2GM098204946 DT O
role BC2GM098204946 NN O
of BC2GM098204946 IN O
the BC2GM098204946 DT O
putative BC2GM098204946 JJ O
C2 BC2GM098204946 NNP O
domain BC2GM098204946 NN O
of BC2GM098204946 IN O
Nedd4 BC2GM098204946 NNP O
has BC2GM098204946 VBZ O
not BC2GM098204946 RB O
been BC2GM098204946 VBN O
elucidated BC2GM098204946 VBN O
. BC2GM098204946 . O
. . O O

Uncertainty BC2GM011154838 NN O
exists BC2GM011154838 VBZ O
about BC2GM011154838 IN O
the BC2GM011154838 DT O
function BC2GM011154838 NN O
of BC2GM011154838 IN O
these BC2GM011154838 DT O
potential BC2GM011154838 JJ O
isoforms BC2GM011154838 NNS O
of BC2GM011154838 IN O
the BC2GM011154838 DT O
Cbfa1 BC2GM011154838 NNP O
gene BC2GM011154838 NN O
. BC2GM011154838 . O
. . O O

( BC2GM074912352 ( O
1991 BC2GM074912352 CD O
) BC2GM074912352 ) O
EMBO BC2GM074912352 NNP O
J BC2GM074912352 NNP O
. BC2GM074912352 . O
. . O O

In BC2GM052716394 IN O
6 BC2GM052716394 CD O
patients BC2GM052716394 NNS O
( BC2GM052716394 ( O
9 BC2GM052716394 CD O
kidneys BC2GM052716394 NNS O
) BC2GM052716394 ) O
irrigation BC2GM052716394 NN O
with BC2GM052716394 IN O
Solution BC2GM052716394 NNP O
G BC2GM052716394 NNP O
in BC2GM052716394 IN O
the BC2GM052716394 DT O
renal BC2GM052716394 JJ O
pelvis BC2GM052716394 NN O
was BC2GM052716394 VBD O
performed BC2GM052716394 VBN O
for BC2GM052716394 IN O
the BC2GM052716394 DT O
dissolution BC2GM052716394 NN O
of BC2GM052716394 IN O
their BC2GM052716394 PRP$ O
infectious BC2GM052716394 JJ O
stones BC2GM052716394 NNS O
. BC2GM052716394 . O
. . O O

The BC2GM034609463 DT O
p63 BC2GM034609463 NN O
sequence BC2GM034609463 NN O
also BC2GM034609463 RB O
features BC2GM034609463 VBZ O
an BC2GM034609463 DT O
acidic BC2GM034609463 JJ O
domain BC2GM034609463 NN O
characteristic BC2GM034609463 NN O
of BC2GM034609463 IN O
transcriptional BC2GM034609463 JJ O
activation BC2GM034609463 NN O
factors BC2GM034609463 NNS O
, BC2GM034609463 , O
as BC2GM034609463 RB O
well BC2GM034609463 RB O
as BC2GM034609463 IN O
sequence BC2GM034609463 NN O
blocks BC2GM034609463 NNS O
displaying BC2GM034609463 VBG O
limited BC2GM034609463 JJ O
similarity BC2GM034609463 NN O
to BC2GM034609463 TO O
positionally BC2GM034609463 RB O
equivalent BC2GM034609463 JJ O
regions BC2GM034609463 NNS O
in BC2GM034609463 IN O
sigma BC2GM034609463 JJ O
factors BC2GM034609463 NNS O
from BC2GM034609463 IN O
eubacteria BC2GM034609463 RB O
related BC2GM034609463 VBN O
to BC2GM034609463 TO O
mitochondria BC2GM034609463 NNS O
. BC2GM034609463 . O
. . O O

A BC2GM024780744 DT O
third BC2GM024780744 JJ O
group BC2GM024780744 NN O
( BC2GM024780744 ( O
n BC2GM024780744 JJ O
= BC2GM024780744 NNP O
10 BC2GM024780744 CD O
) BC2GM024780744 ) O
was BC2GM024780744 VBD O
assigned BC2GM024780744 VBN O
to BC2GM024780744 TO O
receive BC2GM024780744 VB O
the BC2GM024780744 DT O
canalith BC2GM024780744 NN O
repositioning BC2GM024780744 VBG O
maneuver BC2GM024780744 NN O
without BC2GM024780744 IN O
mastoid BC2GM024780744 JJ O
vibration BC2GM024780744 NN O
. BC2GM024780744 . O
. . O O

Finally BC2GM052496419 RB O
, BC2GM052496419 , O
we BC2GM052496419 PRP O
tested BC2GM052496419 VBD O
whether BC2GM052496419 IN O
activation BC2GM052496419 NN O
by BC2GM052496419 IN O
either BC2GM052496419 DT O
of BC2GM052496419 IN O
these BC2GM052496419 DT O
factors BC2GM052496419 NNS O
is BC2GM052496419 VBZ O
dependent BC2GM052496419 JJ O
on BC2GM052496419 IN O
components BC2GM052496419 NNS O
of BC2GM052496419 IN O
the BC2GM052496419 DT O
SAGA BC2GM052496419 NNP O
complex BC2GM052496419 NN O
. BC2GM052496419 . O
. . O O

Experimental BC2GM075404725 JJ O
exposure BC2GM075404725 NN O
of BC2GM075404725 IN O
poults BC2GM075404725 NNS O
with BC2GM075404725 IN O
each BC2GM075404725 DT O
of BC2GM075404725 IN O
two BC2GM075404725 CD O
strains BC2GM075404725 NNS O
representing BC2GM075404725 VBG O
the BC2GM075404725 DT O
rarely BC2GM075404725 RB O
reported BC2GM075404725 JJ O
capsular BC2GM075404725 JJ O
group BC2GM075404725 NN O
B BC2GM075404725 NNP O
indicated BC2GM075404725 VBD O
that BC2GM075404725 IN O
both BC2GM075404725 DT O
were BC2GM075404725 VBD O
virulent BC2GM075404725 NN O
. BC2GM075404725 . O
. . O O

Many BC2GM065484905 JJ O
human BC2GM065484905 JJ O
malignant BC2GM065484905 JJ O
cells BC2GM065484905 NNS O
lack BC2GM065484905 VBP O
methylthioadenosine BC2GM065484905 JJ O
phosphorylase BC2GM065484905 NN O
( BC2GM065484905 ( O
MTAP BC2GM065484905 NNP O
) BC2GM065484905 ) O
enzyme BC2GM065484905 NN O
activity BC2GM065484905 NN O
. BC2GM065484905 . O
. . O O

We BC2GM000026289 PRP O
measured BC2GM000026289 VBD O
electromyograms BC2GM000026289 NNS O
( BC2GM000026289 ( O
EMG BC2GM000026289 NNP O
) BC2GM000026289 ) O
of BC2GM000026289 IN O
the BC2GM000026289 DT O
alae BC2GM000026289 NN O
nasi BC2GM000026289 NN O
to BC2GM000026289 TO O
determine BC2GM000026289 VB O
the BC2GM000026289 DT O
relationship BC2GM000026289 NN O
between BC2GM000026289 IN O
their BC2GM000026289 PRP$ O
activity BC2GM000026289 NN O
and BC2GM000026289 CC O
timing BC2GM000026289 NN O
to BC2GM000026289 TO O
contraction BC2GM000026289 NN O
of BC2GM000026289 IN O
the BC2GM000026289 DT O
rib BC2GM000026289 NN O
cage BC2GM000026289 NN O
muscles BC2GM000026289 NNS O
and BC2GM000026289 CC O
diaphragm BC2GM000026289 NN O
during BC2GM000026289 IN O
obstructive BC2GM000026289 JJ O
apnea BC2GM000026289 NN O
in BC2GM000026289 IN O
nine BC2GM000026289 CD O
patients BC2GM000026289 NNS O
. BC2GM000026289 . O
. . O O

Western BC2GM093098525 JJ O
immunoblot BC2GM093098525 NN O
analysis BC2GM093098525 NN O
detected BC2GM093098525 VBN O
p55gag BC2GM093098525 NN O
and BC2GM093098525 CC O
its BC2GM093098525 PRP$ O
cleavage BC2GM093098525 NN O
products BC2GM093098525 NNS O
p39 BC2GM093098525 NN O
and BC2GM093098525 CC O
p27 BC2GM093098525 NN O
in BC2GM093098525 IN O
purified BC2GM093098525 JJ O
particles BC2GM093098525 NNS O
derived BC2GM093098525 VBN O
by BC2GM093098525 IN O
expression BC2GM093098525 NN O
of BC2GM093098525 IN O
gag BC2GM093098525 NN O
and BC2GM093098525 CC O
gag-pol BC2GM093098525 NN O
, BC2GM093098525 , O
respectively BC2GM093098525 RB O
. BC2GM093098525 . O
. . O O

We BC2GM052977122 PRP O
then BC2GM052977122 RB O
isolated BC2GM052977122 VBD O
the BC2GM052977122 DT O
full-length BC2GM052977122 JJ O
coding BC2GM052977122 JJ O
region BC2GM052977122 NN O
of BC2GM052977122 IN O
the BC2GM052977122 DT O
human BC2GM052977122 JJ O
BACH1 BC2GM052977122 NNP O
gene BC2GM052977122 NN O
using BC2GM052977122 VBG O
expressed BC2GM052977122 VBN O
sequence BC2GM052977122 NN O
tags BC2GM052977122 NN O
, BC2GM052977122 , O
reverse BC2GM052977122 VB O
transcription-polymerase BC2GM052977122 NN O
chain BC2GM052977122 NN O
reaction BC2GM052977122 NN O
and BC2GM052977122 CC O
rapid BC2GM052977122 JJ O
amplification BC2GM052977122 NN O
of BC2GM052977122 IN O
cDNA BC2GM052977122 NN O
ends BC2GM052977122 NNS O
. BC2GM052977122 . O
. . O O

This BC2GM084419683 DT O
dose BC2GM084419683 NN O
of BC2GM084419683 IN O
Na3 BC2GM084419683 NNP O
citrate BC2GM084419683 NN O
produced BC2GM084419683 VBD O
no BC2GM084419683 DT O
clinical BC2GM084419683 JJ O
symptoms BC2GM084419683 NNS O
suggestive BC2GM084419683 NN O
of BC2GM084419683 IN O
hypocalcaemia BC2GM084419683 NN O
in BC2GM084419683 IN O
these BC2GM084419683 DT O
subjects BC2GM084419683 NNS O
, BC2GM084419683 , O
even BC2GM084419683 RB O
though BC2GM084419683 IN O
the BC2GM084419683 DT O
use BC2GM084419683 NN O
of BC2GM084419683 IN O
acid-citrate-dextrose BC2GM084419683 JJ O
, BC2GM084419683 , O
NIH BC2GM084419683 NNP O
formula BC2GM084419683 VBP O
A BC2GM084419683 NNP O
( BC2GM084419683 ( O
ACD-A BC2GM084419683 NNP O
) BC2GM084419683 ) O
under BC2GM084419683 IN O
identical BC2GM084419683 JJ O
conditions BC2GM084419683 NNS O
has BC2GM084419683 VBZ O
been BC2GM084419683 VBN O
reported BC2GM084419683 VBN O
to BC2GM084419683 TO O
reduce BC2GM084419683 VB O
significantly BC2GM084419683 RB O
the BC2GM084419683 DT O
level BC2GM084419683 NN O
of BC2GM084419683 IN O
total BC2GM084419683 JJ O
calcium BC2GM084419683 NN O
in BC2GM084419683 IN O
serum BC2GM084419683 NN O
, BC2GM084419683 , O
and BC2GM084419683 CC O
concomitantly BC2GM084419683 RB O
increase BC2GM084419683 VB O
the BC2GM084419683 DT O
number BC2GM084419683 NN O
or BC2GM084419683 CC O
reactions BC2GM084419683 NNS O
occurring BC2GM084419683 VBG O
in BC2GM084419683 IN O
donors BC2GM084419683 NNS O
. BC2GM084419683 . O
. . O O

The BC2GM030482607 DT O
animals BC2GM030482607 NNS O
were BC2GM030482607 VBD O
followed BC2GM030482607 VBN O
over BC2GM030482607 IN O
a BC2GM030482607 DT O
1- BC2GM030482607 JJ O
to BC2GM030482607 TO O
6-h BC2GM030482607 JJ O
posttraumatic BC2GM030482607 JJ O
course BC2GM030482607 NN O
, BC2GM030482607 , O
and BC2GM030482607 CC O
processed BC2GM030482607 VBD O
for BC2GM030482607 IN O
the BC2GM030482607 DT O
LM BC2GM030482607 NNP O
and BC2GM030482607 CC O
TEM BC2GM030482607 NNP O
visualization BC2GM030482607 NN O
of BC2GM030482607 IN O
HRP BC2GM030482607 NNP O
. BC2GM030482607 . O
. . O O

Acute BC2GM091155868 NNP O
toxicity BC2GM091155868 NN O
tests BC2GM091155868 NNS O
were BC2GM091155868 VBD O
conducted BC2GM091155868 VBN O
to BC2GM091155868 TO O
measure BC2GM091155868 VB O
the BC2GM091155868 DT O
response BC2GM091155868 NN O
of BC2GM091155868 IN O
first BC2GM091155868 JJ O
instar BC2GM091155868 NN O
Toxorhynchites BC2GM091155868 NNP O
splendens BC2GM091155868 VBZ O
to BC2GM091155868 TO O
commonly BC2GM091155868 VB O
used BC2GM091155868 VBN O
mosquito BC2GM091155868 JJ O
adulticides BC2GM091155868 NNS O
: BC2GM091155868 : O
malathion BC2GM091155868 NN O
, BC2GM091155868 , O
naled BC2GM091155868 VBN O
and BC2GM091155868 CC O
resmethrin BC2GM091155868 NN O
. BC2GM091155868 . O
. . O O

We BC2GM088490970 PRP O
report BC2GM088490970 VBP O
that BC2GM088490970 DT O
Gcn5 BC2GM088490970 NNP O
, BC2GM088490970 , O
a BC2GM088490970 DT O
histone BC2GM088490970 NN O
H3 BC2GM088490970 NNP O
acetylase BC2GM088490970 NN O
, BC2GM088490970 , O
plays BC2GM088490970 VBZ O
a BC2GM088490970 DT O
central BC2GM088490970 JJ O
role BC2GM088490970 NN O
in BC2GM088490970 IN O
initiation BC2GM088490970 NN O
of BC2GM088490970 IN O
meiosis BC2GM088490970 NN O
via BC2GM088490970 IN O
effects BC2GM088490970 NNS O
on BC2GM088490970 IN O
IME2 BC2GM088490970 NNP O
expression BC2GM088490970 NN O
. BC2GM088490970 . O
. . O O

Ultra-energy BC2GM004099886 NNP O
( BC2GM004099886 ( O
UHE BC2GM004099886 NNP O
) BC2GM004099886 ) O
imaging BC2GM004099886 NN O
is BC2GM004099886 VBZ O
usually BC2GM004099886 RB O
performed BC2GM004099886 VBN O
in BC2GM004099886 IN O
simultaneous BC2GM004099886 JJ O
F-18 BC2GM004099886 NNP O
FDG BC2GM004099886 NNP O
/ BC2GM004099886 NNP O
Tc-99m BC2GM004099886 NNP O
MIBI BC2GM004099886 NNP O
studies BC2GM004099886 NNS O
. BC2GM004099886 . O
. . O O

Mutant BC2GM047557108 JJ O
beta2-adrenergic BC2GM047557108 JJ O
receptors BC2GM047557108 NNS O
with BC2GM047557108 IN O
a BC2GM047557108 DT O
Tyr-to-Phe BC2GM047557108 JJ O
substitution BC2GM047557108 NN O
at BC2GM047557108 IN O
Tyr-350 BC2GM047557108 NNP O
do BC2GM047557108 VBP O
not BC2GM047557108 RB O
display BC2GM047557108 VB O
agonist-induced BC2GM047557108 JJ O
desensitization BC2GM047557108 NN O
, BC2GM047557108 , O
Src BC2GM047557108 NNP O
recruitment BC2GM047557108 NN O
, BC2GM047557108 , O
or BC2GM047557108 CC O
Src BC2GM047557108 NNP O
activation BC2GM047557108 NN O
. BC2GM047557108 . O
. . O O

Ischaemia BC2GM021995713 NNP O
and BC2GM021995713 CC O
reperfusion BC2GM021995713 NN O
injury BC2GM021995713 NN O
in BC2GM021995713 IN O
the BC2GM021995713 DT O
kidney BC2GM021995713 NN O
: BC2GM021995713 : O
current BC2GM021995713 JJ O
status BC2GM021995713 NN O
and BC2GM021995713 CC O
future BC2GM021995713 JJ O
direction BC2GM021995713 NN O
. BC2GM021995713 . O
. . O O

Effect BC2GM084096579 NN O
of BC2GM084096579 IN O
prostaglandin BC2GM084096579 NN O
E2 BC2GM084096579 NNP O
on BC2GM084096579 IN O
experimental BC2GM084096579 JJ O
atherosclerosis BC2GM084096579 NN O
. BC2GM084096579 . O
. . O O

Furthermore BC2GM076012440 RB O
, BC2GM076012440 , O
CBP BC2GM076012440 NNP O
/ BC2GM076012440 NNP O
p300 BC2GM076012440 NN O
stimulated BC2GM076012440 VBD O
both BC2GM076012440 DT O
TGF-beta- BC2GM076012440 NNP O
and BC2GM076012440 CC O
Smad-induced BC2GM076012440 NNP O
transcription BC2GM076012440 NN O
in BC2GM076012440 IN O
a BC2GM076012440 DT O
Smad4 BC2GM076012440 NNP O
/ BC2GM076012440 NNP O
DPC4-dependent BC2GM076012440 JJ O
fashion BC2GM076012440 NN O
. BC2GM076012440 . O
. . O O

One BC2GM023238812 CD O
of BC2GM023238812 IN O
the BC2GM023238812 DT O
repeating BC2GM023238812 NN O
domains BC2GM023238812 NNS O
( BC2GM023238812 ( O
Yheb1 BC2GM023238812 NNP O
) BC2GM023238812 ) O
, BC2GM023238812 , O
consisting BC2GM023238812 VBG O
of BC2GM023238812 IN O
67 BC2GM023238812 CD O
amino BC2GM023238812 NN O
acids BC2GM023238812 NNS O
, BC2GM023238812 , O
was BC2GM023238812 VBD O
cloned BC2GM023238812 VBN O
from BC2GM023238812 IN O
the BC2GM023238812 DT O
E. BC2GM023238812 NNP O
coli BC2GM023238812 NNS O
chromosome BC2GM023238812 NN O
and BC2GM023238812 CC O
purified BC2GM023238812 VBN O
by BC2GM023238812 IN O
metal BC2GM023238812 NN O
chelating BC2GM023238812 VBG O
chromatography BC2GM023238812 NN O
. BC2GM023238812 . O
. . O O

Amniotic BC2GM067854100 JJ O
fluid BC2GM067854100 NN O
ionic BC2GM067854100 JJ O
concentration BC2GM067854100 NN O
in BC2GM067854100 IN O
response BC2GM067854100 NN O
to BC2GM067854100 TO O
chronic BC2GM067854100 JJ O
fetal BC2GM067854100 JJ O
vasopressin BC2GM067854100 NN O
infusion BC2GM067854100 NN O
. BC2GM067854100 . O
. . O O

Two BC2GM007792943 CD O
authors BC2GM007792943 NNS O
, BC2GM007792943 , O
two BC2GM007792943 CD O
journal BC2GM007792943 NN O
titles BC2GM007792943 NNS O
, BC2GM007792943 , O
two BC2GM007792943 CD O
drug BC2GM007792943 NN O
names BC2GM007792943 NNS O
, BC2GM007792943 , O
and BC2GM007792943 CC O
two BC2GM007792943 CD O
topics BC2GM007792943 NNS O
of BC2GM007792943 IN O
a BC2GM007792943 DT O
general BC2GM007792943 JJ O
medical BC2GM007792943 JJ O
nature BC2GM007792943 NN O
were BC2GM007792943 VBD O
retrieved BC2GM007792943 VBN O
under BC2GM007792943 IN O
identical BC2GM007792943 JJ O
circumstances BC2GM007792943 NNS O
and BC2GM007792943 CC O
conditions BC2GM007792943 NNS O
on BC2GM007792943 IN O
the BC2GM007792943 DT O
hosts BC2GM007792943 NNS O
DATA-STAR BC2GM007792943 NNP O
, BC2GM007792943 , O
DIALOG BC2GM007792943 NNP O
, BC2GM007792943 , O
DIMDI BC2GM007792943 NNP O
, BC2GM007792943 , O
and BC2GM007792943 CC O
STN BC2GM007792943 NNP O
. BC2GM007792943 . O
. . O O

This BC2GM061631132 DT O
growth-inhibitory BC2GM061631132 JJ O
effect BC2GM061631132 NN O
was BC2GM061631132 VBD O
suppressed BC2GM061631132 VBN O
by BC2GM061631132 IN O
the BC2GM061631132 DT O
mpk1 BC2GM061631132 NN O
delta BC2GM061631132 NN O
mutation BC2GM061631132 NN O
, BC2GM061631132 , O
suggesting BC2GM061631132 VBG O
that BC2GM061631132 IN O
hyperactivation BC2GM061631132 NN O
of BC2GM061631132 IN O
the BC2GM061631132 DT O
Mpk1 BC2GM061631132 NNP O
pathway BC2GM061631132 NN O
is BC2GM061631132 VBZ O
toxic BC2GM061631132 JJ O
to BC2GM061631132 TO O
cells BC2GM061631132 NNS O
. BC2GM061631132 . O
. . O O

Since BC2GM012136507 IN O
blood BC2GM012136507 NN O
serotonin BC2GM012136507 NN O
is BC2GM012136507 VBZ O
primarily BC2GM012136507 RB O
produced BC2GM012136507 VBN O
peripherally BC2GM012136507 RB O
, BC2GM012136507 , O
these BC2GM012136507 DT O
results BC2GM012136507 NNS O
suggest BC2GM012136507 VBP O
that BC2GM012136507 IN O
some BC2GM012136507 DT O
aspect BC2GM012136507 NN O
of BC2GM012136507 IN O
peripheral BC2GM012136507 JJ O
serotonin BC2GM012136507 NN O
metabolism BC2GM012136507 NN O
is BC2GM012136507 VBZ O
abnormal BC2GM012136507 JJ O
in BC2GM012136507 IN O
major BC2GM012136507 JJ O
depression BC2GM012136507 NN O
. BC2GM012136507 . O
. . O O

In BC2GM085223521 IN O
rats BC2GM085223521 NNS O
exposed BC2GM085223521 VBN O
to BC2GM085223521 TO O
Cd BC2GM085223521 NNP O
for BC2GM085223521 IN O
30 BC2GM085223521 CD O
d BC2GM085223521 NN O
, BC2GM085223521 , O
the BC2GM085223521 DT O
levels BC2GM085223521 NNS O
of BC2GM085223521 IN O
urinary BC2GM085223521 JJ O
excretion BC2GM085223521 NN O
of BC2GM085223521 IN O
cAMP BC2GM085223521 NN O
after BC2GM085223521 IN O
treatment BC2GM085223521 NN O
with BC2GM085223521 IN O
parathyroid BC2GM085223521 JJ O
hormone BC2GM085223521 NN O
( BC2GM085223521 ( O
PTH BC2GM085223521 NNP O
) BC2GM085223521 ) O
, BC2GM085223521 , O
parathyroidectomy BC2GM085223521 FW O
( BC2GM085223521 ( O
PTX BC2GM085223521 NNP O
) BC2GM085223521 ) O
, BC2GM085223521 , O
or BC2GM085223521 CC O
1 BC2GM085223521 CD O
alpha-hydroxycholecalciferol BC2GM085223521 NN O
( BC2GM085223521 ( O
1 BC2GM085223521 CD O
alpha-OH-D3 BC2GM085223521 NN O
) BC2GM085223521 ) O
showed BC2GM085223521 VBD O
almost BC2GM085223521 RB O
the BC2GM085223521 DT O
same BC2GM085223521 JJ O
patterns BC2GM085223521 NNS O
as BC2GM085223521 IN O
those BC2GM085223521 DT O
of BC2GM085223521 IN O
control BC2GM085223521 NN O
rats BC2GM085223521 NNS O
: BC2GM085223521 : O
the BC2GM085223521 DT O
response BC2GM085223521 NN O
of BC2GM085223521 IN O
urinary BC2GM085223521 JJ O
cAMP BC2GM085223521 NN O
to BC2GM085223521 TO O
treatment BC2GM085223521 NN O
with BC2GM085223521 IN O
PTH BC2GM085223521 NNP O
was BC2GM085223521 VBD O
not BC2GM085223521 RB O
influenced BC2GM085223521 VBN O
by BC2GM085223521 IN O
continuous BC2GM085223521 JJ O
oral BC2GM085223521 JJ O
administration BC2GM085223521 NN O
of BC2GM085223521 IN O
Cd BC2GM085223521 NNP O
. BC2GM085223521 . O
. . O O

Mutant BC2GM029595476 NNP O
p53 BC2GM029595476 NN O
DNA BC2GM029595476 NNP O
clones BC2GM029595476 NNS O
from BC2GM029595476 IN O
human BC2GM029595476 JJ O
colon BC2GM029595476 NN O
carcinomas BC2GM029595476 NN O
cooperate BC2GM029595476 NN O
with BC2GM029595476 IN O
ras BC2GM029595476 NNS O
in BC2GM029595476 IN O
transforming BC2GM029595476 VBG O
primary BC2GM029595476 JJ O
rat BC2GM029595476 NN O
cells BC2GM029595476 NNS O
: BC2GM029595476 : O
a BC2GM029595476 DT O
comparison BC2GM029595476 NN O
of BC2GM029595476 IN O
the BC2GM029595476 DT O
`` BC2GM029595476 `` O
hot BC2GM029595476 JJ O
spot BC2GM029595476 NN O
'' BC2GM029595476 '' O
mutant BC2GM029595476 JJ O
phenotypes BC2GM029595476 NNS O
. BC2GM029595476 . O
. . O O

CTP BC2GM064675128 NNP O
, BC2GM064675128 , O
GDP BC2GM064675128 NNP O
, BC2GM064675128 , O
GTP BC2GM064675128 NNP O
, BC2GM064675128 , O
ITP BC2GM064675128 NNP O
) BC2GM064675128 ) O
did BC2GM064675128 VBD O
not BC2GM064675128 RB O
affect BC2GM064675128 VB O
the BC2GM064675128 DT O
response BC2GM064675128 NN O
. BC2GM064675128 . O
. . O O

These BC2GM049936595 DT O
include BC2GM049936595 VBP O
not BC2GM049936595 RB O
only BC2GM049936595 RB O
antioxidants BC2GM049936595 NNS O
, BC2GM049936595 , O
N-methyl-D-aspartate BC2GM049936595 NNP O
receptor BC2GM049936595 NN O
antagonists BC2GM049936595 NNS O
, BC2GM049936595 , O
inhibitors BC2GM049936595 NNS O
of BC2GM049936595 IN O
glutamate BC2GM049936595 NN O
release BC2GM049936595 NN O
, BC2GM049936595 , O
calcium BC2GM049936595 NN O
channel BC2GM049936595 NN O
blockers BC2GM049936595 NNS O
, BC2GM049936595 , O
polyamine BC2GM049936595 NN O
antagonists BC2GM049936595 NNS O
, BC2GM049936595 , O
and BC2GM049936595 CC O
nitric BC2GM049936595 JJ O
oxide BC2GM049936595 NN O
synthase BC2GM049936595 NN O
inhibitors BC2GM049936595 NNS O
, BC2GM049936595 , O
but BC2GM049936595 CC O
cannabinoids BC2GM049936595 NNS O
, BC2GM049936595 , O
aspirin BC2GM049936595 NN O
, BC2GM049936595 , O
melatonin BC2GM049936595 NN O
, BC2GM049936595 , O
and BC2GM049936595 CC O
vitamin BC2GM049936595 JJ O
B-12 BC2GM049936595 NNP O
. BC2GM049936595 . O
. . O O

A BC2GM090086707 DT O
1.5-month-old BC2GM090086707 JJ O
boy BC2GM090086707 NN O
with BC2GM090086707 IN O
Sandifer BC2GM090086707 NNP O
's BC2GM090086707 POS O
syndrome BC2GM090086707 NN O
is BC2GM090086707 VBZ O
described BC2GM090086707 VBN O
. BC2GM090086707 . O
. . O O

Nuclear BC2GM027361300 JJ O
transcription BC2GM027361300 NN O
assays BC2GM027361300 NNS O
confirmed BC2GM027361300 VBD O
that BC2GM027361300 IN O
cys-3+ BC2GM027361300 NN O
was BC2GM027361300 VBD O
under BC2GM027361300 IN O
sulfur-regulated BC2GM027361300 JJ O
transcriptional BC2GM027361300 JJ O
control BC2GM027361300 NN O
and BC2GM027361300 CC O
that BC2GM027361300 IN O
cys-3+ BC2GM027361300 JJ O
transcription BC2GM027361300 NN O
was BC2GM027361300 VBD O
constitutive BC2GM027361300 JJ O
in BC2GM027361300 IN O
sulfur BC2GM027361300 JJ O
controller BC2GM027361300 NN O
( BC2GM027361300 ( O
scon BC2GM027361300 NN O
) BC2GM027361300 ) O
-negative BC2GM027361300 JJ O
regulator BC2GM027361300 NN O
mutants BC2GM027361300 NNS O
. BC2GM027361300 . O
. . O O

To BC2GM056577777 TO O
determine BC2GM056577777 VB O
whether BC2GM056577777 IN O
transcription BC2GM056577777 NN O
of BC2GM056577777 IN O
orfX BC2GM056577777 NN O
and BC2GM056577777 CC O
vfr BC2GM056577777 NN O
are BC2GM056577777 VBP O
controlled BC2GM056577777 VBN O
by BC2GM056577777 IN O
the BC2GM056577777 DT O
same BC2GM056577777 JJ O
mechanisms BC2GM056577777 NN O
that BC2GM056577777 WDT O
control BC2GM056577777 VBP O
transcription BC2GM056577777 NN O
of BC2GM056577777 IN O
the BC2GM056577777 DT O
region BC2GM056577777 NN O
of BC2GM056577777 IN O
the BC2GM056577777 DT O
divergent BC2GM056577777 NN O
ORF BC2GM056577777 NNP O
( BC2GM056577777 ( O
dorf BC2GM056577777 NN O
) BC2GM056577777 ) O
and BC2GM056577777 CC O
of BC2GM056577777 IN O
crp BC2GM056577777 NN O
, BC2GM056577777 , O
we BC2GM056577777 PRP O
compared BC2GM056577777 VBN O
the BC2GM056577777 DT O
vfr-orfX BC2GM056577777 JJ O
and BC2GM056577777 CC O
crp-dorf BC2GM056577777 JJ O
intergenic BC2GM056577777 JJ O
regions BC2GM056577777 NNS O
. BC2GM056577777 . O
. . O O

Mannich BC2GM003445386 NNP O
bases BC2GM003445386 NNS O
of BC2GM003445386 IN O
vanillin BC2GM003445386 NN O
oxime BC2GM003445386 NN O
. BC2GM003445386 . O
. . O O

Moreover BC2GM028241887 RB O
, BC2GM028241887 , O
our BC2GM028241887 PRP$ O
recent BC2GM028241887 JJ O
findings BC2GM028241887 NNS O
on BC2GM028241887 IN O
the BC2GM028241887 DT O
Tc52 BC2GM028241887 NNP O
encoding BC2GM028241887 VBG O
gene BC2GM028241887 NN O
underline BC2GM028241887 VBP O
the BC2GM028241887 DT O
interest BC2GM028241887 NN O
of BC2GM028241887 IN O
genetic BC2GM028241887 JJ O
manipulation BC2GM028241887 NN O
of BC2GM028241887 IN O
T. BC2GM028241887 NNP O
cruzi BC2GM028241887 NN O
, BC2GM028241887 , O
not BC2GM028241887 RB O
only BC2GM028241887 RB O
making BC2GM028241887 VBG O
it BC2GM028241887 PRP O
possible BC2GM028241887 JJ O
to BC2GM028241887 TO O
use BC2GM028241887 VB O
more BC2GM028241887 RBR O
closely BC2GM028241887 RB O
an BC2GM028241887 DT O
in BC2GM028241887 IN O
vitro BC2GM028241887 NN O
approach BC2GM028241887 NN O
to BC2GM028241887 TO O
find BC2GM028241887 VB O
out BC2GM028241887 RP O
how BC2GM028241887 WRB O
genes BC2GM028241887 NNS O
function BC2GM028241887 VBP O
, BC2GM028241887 , O
but BC2GM028241887 CC O
also BC2GM028241887 RB O
to BC2GM028241887 TO O
obtain BC2GM028241887 VB O
'attenuated BC2GM028241887 JJ O
' BC2GM028241887 POS O
strains BC2GM028241887 NNS O
that BC2GM028241887 WDT O
could BC2GM028241887 MD O
be BC2GM028241887 VB O
used BC2GM028241887 VBN O
in BC2GM028241887 IN O
the BC2GM028241887 DT O
development BC2GM028241887 NN O
of BC2GM028241887 IN O
vaccinal BC2GM028241887 JJ O
strategies BC2GM028241887 NNS O
. BC2GM028241887 . O
. . O O

This BC2GM095560139 DT O
is BC2GM095560139 VBZ O
the BC2GM095560139 DT O
first BC2GM095560139 JJ O
clinical BC2GM095560139 JJ O
case BC2GM095560139 NN O
report BC2GM095560139 NN O
of BC2GM095560139 IN O
NIHF BC2GM095560139 NNP O
due BC2GM095560139 JJ O
to BC2GM095560139 TO O
fetal BC2GM095560139 JJ O
Kasabach-Merritt BC2GM095560139 NNP O
syndrome BC2GM095560139 NN O
that BC2GM095560139 WDT O
was BC2GM095560139 VBD O
prenatally BC2GM095560139 RB O
diagnosed BC2GM095560139 VBN O
by BC2GM095560139 IN O
sonography BC2GM095560139 NN O
, BC2GM095560139 , O
computerized BC2GM095560139 JJ O
tomography BC2GM095560139 NN O
, BC2GM095560139 , O
and BC2GM095560139 CC O
percutaneous BC2GM095560139 JJ O
umbilical BC2GM095560139 JJ O
blood BC2GM095560139 NN O
sampling BC2GM095560139 NN O
. BC2GM095560139 . O
. . O O

Tissue-specific BC2GM074932175 JJ O
gene BC2GM074932175 NN O
regulation BC2GM074932175 NN O
of BC2GM074932175 IN O
eukaryotic BC2GM074932175 JJ O
organisms BC2GM074932175 NNS O
is BC2GM074932175 VBZ O
to BC2GM074932175 TO O
a BC2GM074932175 DT O
large BC2GM074932175 JJ O
extent BC2GM074932175 NN O
mediated BC2GM074932175 VBN O
by BC2GM074932175 IN O
transcription BC2GM074932175 NN O
factors BC2GM074932175 NNS O
that BC2GM074932175 IN O
interact BC2GM074932175 NN O
with BC2GM074932175 IN O
genomic BC2GM074932175 JJ O
DNA BC2GM074932175 NN O
sequences BC2GM074932175 NNS O
in BC2GM074932175 IN O
a BC2GM074932175 DT O
sequence-specific BC2GM074932175 JJ O
manner BC2GM074932175 NN O
. BC2GM074932175 . O
. . O O

Karyo- BC2GM090002876 NNP O
and BC2GM090002876 CC O
cytometric BC2GM090002876 JJ O
investigations BC2GM090002876 NNS O
of BC2GM090002876 IN O
cortical BC2GM090002876 JJ O
layer BC2GM090002876 NN O
V BC2GM090002876 NNP O
pyramidal BC2GM090002876 JJ O
neurons BC2GM090002876 NNS O
of BC2GM090002876 IN O
albino BC2GM090002876 NN O
rat BC2GM090002876 NN O
after BC2GM090002876 IN O
three BC2GM090002876 CD O
various BC2GM090002876 JJ O
fixations BC2GM090002876 NNS O
. BC2GM090002876 . O
. . O O

Disaster BC2GM091989431 NN O
medicine BC2GM091989431 NN O
. BC2GM091989431 . O
. . O O

The BC2GM051143447 DT O
vicinity BC2GM051143447 NN O
of BC2GM051143447 IN O
large BC2GM051143447 JJ O
industrial BC2GM051143447 JJ O
emissions BC2GM051143447 NNS O
of BC2GM051143447 IN O
lead BC2GM051143447 NN O
, BC2GM051143447 , O
where BC2GM051143447 WRB O
mean BC2GM051143447 JJ O
Pb-B BC2GM051143447 JJ O
concentrations BC2GM051143447 NNS O
were BC2GM051143447 VBD O
usually BC2GM051143447 RB O
twice BC2GM051143447 RB O
as BC2GM051143447 RB O
high BC2GM051143447 JJ O
as BC2GM051143447 IN O
in BC2GM051143447 IN O
rural BC2GM051143447 JJ O
areas BC2GM051143447 NNS O
of BC2GM051143447 IN O
the BC2GM051143447 DT O
Katowice BC2GM051143447 NNP O
voivodship BC2GM051143447 NN O
. BC2GM051143447 . O
. . O O

HDE BC2GM080763421 NNP O
was BC2GM080763421 VBD O
found BC2GM080763421 VBN O
to BC2GM080763421 TO O
be BC2GM080763421 VB O
exclusively BC2GM080763421 RB O
targeted BC2GM080763421 VBN O
to BC2GM080763421 TO O
and BC2GM080763421 CC O
imported BC2GM080763421 VBN O
into BC2GM080763421 IN O
peroxisomes BC2GM080763421 NNS O
in BC2GM080763421 IN O
both BC2GM080763421 DT O
heterologous BC2GM080763421 JJ O
expression BC2GM080763421 NN O
systems BC2GM080763421 NNS O
. BC2GM080763421 . O
. . O O

The BC2GM087511042 DT O
effect BC2GM087511042 NN O
on BC2GM087511042 IN O
kidney BC2GM087511042 NN O
length BC2GM087511042 NN O
was BC2GM087511042 VBD O
considerably BC2GM087511042 RB O
prolonged BC2GM087511042 VBN O
compared BC2GM087511042 VBN O
with BC2GM087511042 IN O
the BC2GM087511042 DT O
vascular BC2GM087511042 JJ O
effect BC2GM087511042 NN O
. BC2GM087511042 . O
. . O O

The BC2GM036866383 DT O
oral BC2GM036866383 JJ O
movements BC2GM036866383 NNS O
which BC2GM036866383 WDT O
did BC2GM036866383 VBD O
occur BC2GM036866383 VB O
in BC2GM036866383 IN O
the BC2GM036866383 DT O
HAL-treated BC2GM036866383 JJ O
rats BC2GM036866383 NNS O
were BC2GM036866383 VBD O
slower BC2GM036866383 JJR O
than BC2GM036866383 IN O
normal BC2GM036866383 JJ O
. BC2GM036866383 . O
. . O O

Threefold BC2GM087160593 JJ O
risks BC2GM087160593 NNS O
were BC2GM087160593 VBD O
observed BC2GM087160593 VBN O
for BC2GM087160593 IN O
men BC2GM087160593 NNS O
with BC2GM087160593 IN O
the BC2GM087160593 DT O
highest BC2GM087160593 JJS O
level BC2GM087160593 NN O
of BC2GM087160593 IN O
intensity BC2GM087160593 NN O
and BC2GM087160593 CC O
for BC2GM087160593 IN O
those BC2GM087160593 DT O
with BC2GM087160593 IN O
the BC2GM087160593 DT O
highest BC2GM087160593 JJS O
probability BC2GM087160593 NN O
of BC2GM087160593 IN O
EMF BC2GM087160593 NNP O
exposure BC2GM087160593 NN O
, BC2GM087160593 , O
although BC2GM087160593 IN O
women BC2GM087160593 NNS O
with BC2GM087160593 IN O
heavy BC2GM087160593 JJ O
EMF BC2GM087160593 NNP O
exposure BC2GM087160593 NN O
did BC2GM087160593 VBD O
not BC2GM087160593 RB O
experience BC2GM087160593 VB O
increased BC2GM087160593 VBN O
risk BC2GM087160593 NN O
. BC2GM087160593 . O
. . O O

A BC2GM091632436 DT O
rare BC2GM091632436 JJ O
tRNA-Arg BC2GM091632436 NN O
( BC2GM091632436 ( O
CCU BC2GM091632436 NNP O
) BC2GM091632436 ) O
that BC2GM091632436 WDT O
regulates BC2GM091632436 VBZ O
Ty1 BC2GM091632436 NNP O
element BC2GM091632436 NN O
ribosomal BC2GM091632436 NN O
frameshifting BC2GM091632436 NN O
is BC2GM091632436 VBZ O
essential BC2GM091632436 JJ O
for BC2GM091632436 IN O
Ty1 BC2GM091632436 NNP O
retrotransposition BC2GM091632436 NN O
in BC2GM091632436 IN O
Saccharomyces BC2GM091632436 NNP O
cerevisiae BC2GM091632436 NN O
. BC2GM091632436 . O
. . O O

They BC2GM032584152 PRP O
showed BC2GM032584152 VBD O
moderate BC2GM032584152 JJ O
in BC2GM032584152 IN O
vitro BC2GM032584152 JJ O
antifungal BC2GM032584152 JJ O
activity BC2GM032584152 NN O
against BC2GM032584152 IN O
a BC2GM032584152 DT O
wide BC2GM032584152 JJ O
variety BC2GM032584152 NN O
of BC2GM032584152 IN O
fungi BC2GM032584152 NNS O
and BC2GM032584152 CC O
yeasts BC2GM032584152 NNS O
including BC2GM032584152 VBG O
clinically BC2GM032584152 RB O
important BC2GM032584152 JJ O
pathogens BC2GM032584152 NNS O
, BC2GM032584152 , O
and BC2GM032584152 CC O
were BC2GM032584152 VBD O
highly BC2GM032584152 RB O
effective BC2GM032584152 JJ O
in BC2GM032584152 IN O
systemic BC2GM032584152 JJ O
infection BC2GM032584152 NN O
with BC2GM032584152 IN O
Candida BC2GM032584152 NNP O
albicans BC2GM032584152 NNS O
in BC2GM032584152 IN O
mice BC2GM032584152 NN O
after BC2GM032584152 IN O
iv BC2GM032584152 NN O
and BC2GM032584152 CC O
im BC2GM032584152 JJ O
administrations BC2GM032584152 NNS O
. BC2GM032584152 . O
. . O O

The BC2GM065459831 DT O
time-dependent BC2GM065459831 JJ O
changes BC2GM065459831 NNS O
in BC2GM065459831 IN O
measured BC2GM065459831 JJ O
facility BC2GM065459831 NN O
of BC2GM065459831 IN O
outflow BC2GM065459831 NN O
or BC2GM065459831 CC O
`` BC2GM065459831 `` O
washout BC2GM065459831 IN O
phenomenon BC2GM065459831 NN O
'' BC2GM065459831 '' O
appeared BC2GM065459831 VBD O
to BC2GM065459831 TO O
result BC2GM065459831 VB O
from BC2GM065459831 IN O
the BC2GM065459831 DT O
gradual BC2GM065459831 JJ O
dissolution BC2GM065459831 NN O
of BC2GM065459831 IN O
the BC2GM065459831 DT O
hyaluronidase-sensitive BC2GM065459831 JJ O
component BC2GM065459831 NN O
of BC2GM065459831 IN O
the BC2GM065459831 DT O
barriers BC2GM065459831 NNS O
to BC2GM065459831 TO O
aqueous BC2GM065459831 JJ O
outflow BC2GM065459831 NN O
in BC2GM065459831 IN O
the BC2GM065459831 DT O
canine BC2GM065459831 NN O
eye BC2GM065459831 NN O
. BC2GM065459831 . O
. . O O

Overall BC2GM000577306 JJ O
graft BC2GM000577306 NN O
and BC2GM000577306 CC O
patient BC2GM000577306 JJ O
survival BC2GM000577306 NN O
after BC2GM000577306 IN O
HAT BC2GM000577306 NNP O
were BC2GM000577306 VBD O
33.3 BC2GM000577306 CD O
% BC2GM000577306 NN O
and BC2GM000577306 CC O
75 BC2GM000577306 CD O
% BC2GM000577306 NN O
, BC2GM000577306 , O
respectively BC2GM000577306 RB O
. BC2GM000577306 . O
. . O O

We BC2GM011637972 PRP O
compared BC2GM011637972 VBN O
the BC2GM011637972 DT O
quantities BC2GM011637972 NNS O
collected BC2GM011637972 VBN O
with BC2GM011637972 IN O
both BC2GM011637972 DT O
pollen BC2GM011637972 JJ O
traps BC2GM011637972 NNS O
during BC2GM011637972 IN O
February BC2GM011637972 NNP O
, BC2GM011637972 , O
March BC2GM011637972 NNP O
and BC2GM011637972 CC O
April BC2GM011637972 NNP O
1988 BC2GM011637972 CD O
and BC2GM011637972 CC O
1989 BC2GM011637972 CD O
. BC2GM011637972 . O
. . O O

The BC2GM034035554 DT O
need BC2GM034035554 NN O
for BC2GM034035554 IN O
such BC2GM034035554 JJ O
guidelines BC2GM034035554 NNS O
is BC2GM034035554 VBZ O
clear BC2GM034035554 JJ O
on BC2GM034035554 IN O
both BC2GM034035554 DT O
clinical BC2GM034035554 JJ O
and BC2GM034035554 CC O
scientific BC2GM034035554 JJ O
grounds BC2GM034035554 NNS O
. BC2GM034035554 . O
. . O O

The BC2GM044150575 DT O
T BC2GM044150575 NNP O
( BC2GM044150575 ( O
CCO2 BC2GM044150575 NNP O
) BC2GM044150575 ) O
was BC2GM044150575 VBD O
related BC2GM044150575 VBN O
to BC2GM044150575 TO O
the BC2GM044150575 DT O
PCO2 BC2GM044150575 NNP O
by BC2GM044150575 IN O
a BC2GM044150575 DT O
Pearson BC2GM044150575 NNP O
product BC2GM044150575 NN O
coefficient BC2GM044150575 NN O
of BC2GM044150575 IN O
0.79 BC2GM044150575 CD O
( BC2GM044150575 ( O
p BC2GM044150575 JJ O
< BC2GM044150575 NNP O
.0005 BC2GM044150575 NNP O
) BC2GM044150575 ) O
, BC2GM044150575 , O
with BC2GM044150575 IN O
a BC2GM044150575 DT O
mean BC2GM044150575 JJ O
difference BC2GM044150575 NN O
of BC2GM044150575 IN O
1.94 BC2GM044150575 CD O
( BC2GM044150575 ( O
T BC2GM044150575 NNP O
( BC2GM044150575 ( O
CCO2 BC2GM044150575 NNP O
) BC2GM044150575 ) O
> BC2GM044150575 VBP O
P BC2GM044150575 NNP O
( BC2GM044150575 ( O
CO2 BC2GM044150575 NNP O
) BC2GM044150575 ) O
and BC2GM044150575 CC O
95 BC2GM044150575 CD O
% BC2GM044150575 NN O
confidence BC2GM044150575 NN O
interval BC2GM044150575 NN O
of BC2GM044150575 IN O
-0.12 BC2GM044150575 NN O
to BC2GM044150575 TO O
4.07 BC2GM044150575 CD O
. BC2GM044150575 . O
. . O O

The BC2GM023962152 DT O
characterization BC2GM023962152 NN O
of BC2GM023962152 IN O
fly BC2GM023962152 JJ O
receptors BC2GM023962152 NNS O
with BC2GM023962152 IN O
features BC2GM023962152 NNS O
similar BC2GM023962152 JJ O
to BC2GM023962152 TO O
mammalian BC2GM023962152 JJ O
glycoprotein BC2GM023962152 NN O
hormone BC2GM023962152 NN O
receptors BC2GM023962152 NNS O
allows BC2GM023962152 VBZ O
a BC2GM023962152 DT O
better BC2GM023962152 JJR O
understanding BC2GM023962152 NN O
of BC2GM023962152 IN O
the BC2GM023962152 DT O
evolution BC2GM023962152 NN O
of BC2GM023962152 IN O
this BC2GM023962152 DT O
unique BC2GM023962152 JJ O
group BC2GM023962152 NN O
of BC2GM023962152 IN O
GPCRs BC2GM023962152 NNP O
and BC2GM023962152 CC O
future BC2GM023962152 JJ O
elucidation BC2GM023962152 NN O
of BC2GM023962152 IN O
their BC2GM023962152 PRP$ O
ligand BC2GM023962152 NN O
signaling BC2GM023962152 VBG O
mechanisms BC2GM023962152 NNS O
. BC2GM023962152 . O
. . O O

Cetn1 BC2GM091136434 NNP O
possesses BC2GM091136434 VBZ O
the BC2GM091136434 DT O
sequence BC2GM091136434 NN O
features BC2GM091136434 NNS O
of BC2GM091136434 IN O
an BC2GM091136434 DT O
expressed BC2GM091136434 JJ O
retroposon BC2GM091136434 NN O
: BC2GM091136434 : O
the BC2GM091136434 DT O
gene BC2GM091136434 NN O
lacks BC2GM091136434 VBZ O
introns BC2GM091136434 NNS O
, BC2GM091136434 , O
the BC2GM091136434 DT O
open BC2GM091136434 JJ O
reading BC2GM091136434 NN O
frame BC2GM091136434 NN O
is BC2GM091136434 VBZ O
not BC2GM091136434 RB O
interrupted BC2GM091136434 VBN O
by BC2GM091136434 IN O
stop BC2GM091136434 JJ O
codons BC2GM091136434 NNS O
, BC2GM091136434 , O
and BC2GM091136434 CC O
the BC2GM091136434 DT O
coding BC2GM091136434 JJ O
region BC2GM091136434 NN O
is BC2GM091136434 VBZ O
flanked BC2GM091136434 VBN O
by BC2GM091136434 IN O
a BC2GM091136434 DT O
pair BC2GM091136434 NN O
of BC2GM091136434 IN O
direct BC2GM091136434 JJ O
repeats BC2GM091136434 NNS O
. BC2GM091136434 . O
. . O O

Expression BC2GM051665080 NN O
in BC2GM051665080 IN O
all BC2GM051665080 DT O
lines BC2GM051665080 NNS O
was BC2GM051665080 VBD O
decreased BC2GM051665080 VBN O
by BC2GM051665080 IN O
the BC2GM051665080 DT O
inclusion BC2GM051665080 NN O
of BC2GM051665080 IN O
regions BC2GM051665080 NNS O
further BC2GM051665080 RBR O
upstream BC2GM051665080 RB O
, BC2GM051665080 , O
and BC2GM051665080 CC O
extinguished BC2GM051665080 VBN O
by BC2GM051665080 IN O
the BC2GM051665080 DT O
inclusion BC2GM051665080 NN O
of BC2GM051665080 IN O
the BC2GM051665080 DT O
first BC2GM051665080 JJ O
intron BC2GM051665080 NN O
. BC2GM051665080 . O
. . O O

In BC2GM047245566 IN O
absence BC2GM047245566 NN O
of BC2GM047245566 IN O
i.m BC2GM047245566 NN O
. BC2GM047245566 . O
medication BC2GM047245566 NN O
, BC2GM047245566 , O
levels BC2GM047245566 NNS O
over BC2GM047245566 IN O
1,000 BC2GM047245566 CD O
U BC2GM047245566 NNS O
must BC2GM047245566 MD O
be BC2GM047245566 VB O
carefully BC2GM047245566 RB O
screened BC2GM047245566 VBN O
in BC2GM047245566 IN O
order BC2GM047245566 NN O
to BC2GM047245566 TO O
rule BC2GM047245566 VB O
out BC2GM047245566 RP O
SNM BC2GM047245566 NNP O
or BC2GM047245566 CC O
organic BC2GM047245566 JJ O
pathology BC2GM047245566 NN O
associated BC2GM047245566 VBN O
. BC2GM047245566 . O
. . O O

All BC2GM057809152 DT O
relapses BC2GM057809152 NNS O
occurred BC2GM057809152 VBD O
within BC2GM057809152 IN O
the BC2GM057809152 DT O
first BC2GM057809152 JJ O
year BC2GM057809152 NN O
and BC2GM057809152 CC O
were BC2GM057809152 VBD O
confined BC2GM057809152 VBN O
to BC2GM057809152 TO O
patients BC2GM057809152 NNS O
with BC2GM057809152 IN O
PS BC2GM057809152 NNP O
II BC2GM057809152 NNP O
disease BC2GM057809152 NN O
and BC2GM057809152 CC O
four BC2GM057809152 CD O
or BC2GM057809152 CC O
more BC2GM057809152 JJR O
sites BC2GM057809152 NNS O
of BC2GM057809152 IN O
involvement BC2GM057809152 NN O
. BC2GM057809152 . O
. . O O

Estimating BC2GM097598269 VBG O
the BC2GM097598269 DT O
health BC2GM097598269 NN O
care BC2GM097598269 NN O
costs BC2GM097598269 NNS O
of BC2GM097598269 IN O
smokers BC2GM097598269 NNS O
. BC2GM097598269 . O
. . O O

All BC2GM005667784 DT O
patients BC2GM005667784 NNS O
received BC2GM005667784 VBN O
marrow BC2GM005667784 JJ O
from BC2GM005667784 IN O
HLA-identical BC2GM005667784 JJ O
sibling BC2GM005667784 VBG O
donors BC2GM005667784 NNS O
, BC2GM005667784 , O
underwent BC2GM005667784 JJ O
similar BC2GM005667784 JJ O
myeloablative BC2GM005667784 NN O
regimens BC2GM005667784 NNS O
, BC2GM005667784 , O
and BC2GM005667784 CC O
had BC2GM005667784 VBD O
similar BC2GM005667784 JJ O
pretreatment BC2GM005667784 NN O
characteristics BC2GM005667784 NNS O
. BC2GM005667784 . O
. . O O

ANL-7535 BC2GM025704157 NNP O
. BC2GM025704157 . O
. . O O

These BC2GM018717750 DT O
results BC2GM018717750 NNS O
support BC2GM018717750 VBP O
an BC2GM018717750 DT O
in BC2GM018717750 IN O
vivo BC2GM018717750 NN O
interaction BC2GM018717750 NN O
between BC2GM018717750 IN O
Nck BC2GM018717750 NNP O
and BC2GM018717750 CC O
CKI-gamma2 BC2GM018717750 NNP O
and BC2GM018717750 CC O
suggest BC2GM018717750 VBP O
that BC2GM018717750 IN O
CKI-gamma2 BC2GM018717750 NNP O
could BC2GM018717750 MD O
be BC2GM018717750 VB O
involved BC2GM018717750 VBN O
in BC2GM018717750 IN O
signaling BC2GM018717750 VBG O
pathways BC2GM018717750 JJ O
downstream BC2GM018717750 NN O
of BC2GM018717750 IN O
RTKs BC2GM018717750 NNP O
. BC2GM018717750 . O
. . O O

The BC2GM034493633 DT O
encoded BC2GM034493633 JJ O
protein BC2GM034493633 NN O
contains BC2GM034493633 VBZ O
an BC2GM034493633 DT O
amino BC2GM034493633 JJ O
terminal BC2GM034493633 JJ O
PDZ BC2GM034493633 NNP O
domain BC2GM034493633 NN O
, BC2GM034493633 , O
followed BC2GM034493633 VBN O
by BC2GM034493633 IN O
a BC2GM034493633 DT O
predicted BC2GM034493633 JJ O
coiled-coil BC2GM034493633 NN O
region BC2GM034493633 NN O
, BC2GM034493633 , O
a BC2GM034493633 DT O
PEST BC2GM034493633 NNP O
domain BC2GM034493633 NN O
, BC2GM034493633 , O
and BC2GM034493633 CC O
a BC2GM034493633 DT O
carboxy-terminal BC2GM034493633 JJ O
SAM BC2GM034493633 NNP O
domain BC2GM034493633 NN O
. BC2GM034493633 . O
. . O O

We BC2GM053556516 PRP O
also BC2GM053556516 RB O
show BC2GM053556516 VBP O
that BC2GM053556516 IN O
the BC2GM053556516 DT O
products BC2GM053556516 NNS O
of BC2GM053556516 IN O
both BC2GM053556516 DT O
the BC2GM053556516 DT O
GIY-YIG BC2GM053556516 NNP O
ORF BC2GM053556516 NNP O
and BC2GM053556516 CC O
the BC2GM053556516 DT O
non-canonical BC2GM053556516 JJ O
LAGLI-DADG-GIY-YIG BC2GM053556516 NNP O
ORF BC2GM053556516 NNP O
, BC2GM053556516 , O
which BC2GM053556516 WDT O
is BC2GM053556516 VBZ O
generated BC2GM053556516 VBN O
by BC2GM053556516 IN O
its BC2GM053556516 PRP$ O
integration BC2GM053556516 NN O
, BC2GM053556516 , O
have BC2GM053556516 VBP O
endonuclease BC2GM053556516 NN O
activities BC2GM053556516 NNS O
which BC2GM053556516 WDT O
recognize BC2GM053556516 VBP O
and BC2GM053556516 CC O
cut BC2GM053556516 VBD O
the BC2GM053556516 DT O
insertion BC2GM053556516 NN O
site BC2GM053556516 NN O
of BC2GM053556516 IN O
the BC2GM053556516 DT O
optional BC2GM053556516 JJ O
sequence BC2GM053556516 NN O
. BC2GM053556516 . O
. . O O

The BC2GM004512108 DT O
antihypertensive BC2GM004512108 JJ O
action BC2GM004512108 NN O
corresponds BC2GM004512108 NNS O
to BC2GM004512108 TO O
those BC2GM004512108 DT O
of BC2GM004512108 IN O
established BC2GM004512108 VBN O
diuretics BC2GM004512108 NNS O
. BC2GM004512108 . O
. . O O

Sugar BC2GM009991407 NNP O
analysis BC2GM009991407 NN O
was BC2GM009991407 VBD O
performed BC2GM009991407 VBN O
on BC2GM009991407 IN O
alpha-TM BC2GM009991407 NN O
to BC2GM009991407 TO O
investigate BC2GM009991407 VB O
a BC2GM009991407 DT O
possible BC2GM009991407 JJ O
biosynthetic BC2GM009991407 JJ O
mechanism BC2GM009991407 NN O
for BC2GM009991407 IN O
part-time BC2GM009991407 JJ O
PGs BC2GM009991407 NNP O
. BC2GM009991407 . O
. . O O

Transcription BC2GM017792516 NN O
of BC2GM017792516 IN O
the BC2GM017792516 DT O
inserted BC2GM017792516 JJ O
gene BC2GM017792516 NN O
into BC2GM017792516 IN O
the BC2GM017792516 DT O
predicted BC2GM017792516 JJ O
subgenomic BC2GM017792516 NN O
polyadenylated BC2GM017792516 VBD O
mRNA BC2GM017792516 NN O
was BC2GM017792516 VBD O
demonstrated BC2GM017792516 VBN O
by BC2GM017792516 IN O
Northern BC2GM017792516 NNP O
( BC2GM017792516 ( O
RNA BC2GM017792516 NNP O
) BC2GM017792516 ) O
blot BC2GM017792516 NN O
hybridization BC2GM017792516 NN O
analysis BC2GM017792516 NN O
, BC2GM017792516 , O
and BC2GM017792516 CC O
the BC2GM017792516 DT O
encoded BC2GM017792516 JJ O
protein BC2GM017792516 NN O
was BC2GM017792516 VBD O
detected BC2GM017792516 VBN O
by BC2GM017792516 IN O
enzyme BC2GM017792516 NNS O
assay BC2GM017792516 NNS O
and BC2GM017792516 CC O
by BC2GM017792516 IN O
radioimmunoprecipitation BC2GM017792516 NN O
. BC2GM017792516 . O
. . O O

The BC2GM044672439 DT O
family BC2GM044672439 NN O
histories BC2GM044672439 NNS O
were BC2GM044672439 VBD O
obtained BC2GM044672439 VBN O
from BC2GM044672439 IN O
the BC2GM044672439 DT O
parents BC2GM044672439 NNS O
. BC2GM044672439 . O
. . O O

The BC2GM056550890 DT O
facilitation BC2GM056550890 NN O
started BC2GM056550890 VBD O
preceding BC2GM056550890 VBG O
the BC2GM056550890 DT O
onset BC2GM056550890 NN O
of BC2GM056550890 IN O
electromyographic BC2GM056550890 JJ O
activity BC2GM056550890 NN O
of BC2GM056550890 IN O
the BC2GM056550890 DT O
masseter BC2GM056550890 NN O
muscle BC2GM056550890 NN O
. BC2GM056550890 . O
. . O O

Despite BC2GM024681168 IN O
this BC2GM024681168 DT O
dependency BC2GM024681168 NN O
, BC2GM024681168 , O
however BC2GM024681168 RB O
, BC2GM024681168 , O
a BC2GM024681168 DT O
B. BC2GM024681168 NNP O
japonicum BC2GM024681168 NN O
fixK BC2GM024681168 NN O
mutant BC2GM024681168 NN O
did BC2GM024681168 VBD O
not BC2GM024681168 RB O
have BC2GM024681168 VB O
the BC2GM024681168 DT O
phenotypic BC2GM024681168 NN O
characteristics BC2GM024681168 NNS O
of BC2GM024681168 IN O
B. BC2GM024681168 NNP O
japonicum BC2GM024681168 NN O
fixL BC2GM024681168 NN O
and BC2GM024681168 CC O
fixJ BC2GM024681168 JJ O
mutants BC2GM024681168 NNS O
: BC2GM024681168 : O
the BC2GM024681168 DT O
fixK BC2GM024681168 NN O
mutant BC2GM024681168 NN O
was BC2GM024681168 VBD O
neither BC2GM024681168 DT O
Fix- BC2GM024681168 NNP O
in BC2GM024681168 IN O
symbiosis BC2GM024681168 NN O
with BC2GM024681168 IN O
soybean BC2GM024681168 NN O
plants BC2GM024681168 NNS O
nor BC2GM024681168 CC O
defective BC2GM024681168 JJ O
in BC2GM024681168 IN O
anaerobic BC2GM024681168 JJ O
respiration BC2GM024681168 NN O
with BC2GM024681168 IN O
nitrate BC2GM024681168 NN O
as BC2GM024681168 IN O
the BC2GM024681168 DT O
terminal BC2GM024681168 JJ O
electron BC2GM024681168 NN O
acceptor BC2GM024681168 NN O
. BC2GM024681168 . O
. . O O

We BC2GM019952339 PRP O
have BC2GM019952339 VBP O
recently BC2GM019952339 RB O
shown BC2GM019952339 VBN O
that BC2GM019952339 IN O
induced BC2GM019952339 JJ O
expression BC2GM019952339 NN O
of BC2GM019952339 IN O
a BC2GM019952339 DT O
CDK BC2GM019952339 NNP O
target BC2GM019952339 NN O
site-deficient BC2GM019952339 JJ O
mutant BC2GM019952339 NN O
, BC2GM019952339 , O
Op18-S25A BC2GM019952339 NNP O
, BC2GM019952339 , O
S38A BC2GM019952339 NNP O
, BC2GM019952339 , O
blocks BC2GM019952339 VBZ O
human BC2GM019952339 JJ O
cell BC2GM019952339 NN O
lines BC2GM019952339 NNS O
during BC2GM019952339 IN O
G2 BC2GM019952339 NNP O
/ BC2GM019952339 NNP O
M BC2GM019952339 NNP O
transition BC2GM019952339 NN O
. BC2GM019952339 . O
. . O O

RESULTS BC2GM029691403 NN O
: BC2GM029691403 : O
In BC2GM029691403 IN O
men BC2GM029691403 NNS O
, BC2GM029691403 , O
weight BC2GM029691403 VBD O
/ BC2GM029691403 NNP O
height2 BC2GM029691403 NN O
met BC2GM029691403 VBD O
the BC2GM029691403 DT O
criteria BC2GM029691403 NNS O
for BC2GM029691403 IN O
a BC2GM029691403 DT O
satisfactory BC2GM029691403 JJ O
index BC2GM029691403 NN O
in BC2GM029691403 IN O
that BC2GM029691403 DT O
there BC2GM029691403 EX O
was BC2GM029691403 VBD O
a BC2GM029691403 DT O
very BC2GM029691403 RB O
strong BC2GM029691403 JJ O
correlation BC2GM029691403 NN O
with BC2GM029691403 IN O
triceps BC2GM029691403 NNS O
skinfold BC2GM029691403 VBN O
, BC2GM029691403 , O
and BC2GM029691403 CC O
a BC2GM029691403 DT O
negligible BC2GM029691403 JJ O
correlation BC2GM029691403 NN O
with BC2GM029691403 IN O
height BC2GM029691403 NN O
. BC2GM029691403 . O
. . O O

The BC2GM070003542 DT O
greatest BC2GM070003542 JJS O
risk BC2GM070003542 NN O
of BC2GM070003542 IN O
preterm BC2GM070003542 JJ O
prelabour BC2GM070003542 JJ O
rupture BC2GM070003542 NN O
of BC2GM070003542 IN O
membranes BC2GM070003542 NNS O
( BC2GM070003542 ( O
PPROM BC2GM070003542 NNP O
) BC2GM070003542 ) O
is BC2GM070003542 VBZ O
preterm BC2GM070003542 JJ O
delivery BC2GM070003542 NN O
. BC2GM070003542 . O
. . O O

The BC2GM070776704 DT O
DNA BC2GM070776704 NN O
element BC2GM070776704 NN O
through BC2GM070776704 IN O
which BC2GM070776704 WDT O
EBNA-3C BC2GM070776704 NNP O
activates BC2GM070776704 VBZ O
the BC2GM070776704 DT O
LMP-1 BC2GM070776704 JJ O
promoter BC2GM070776704 NN O
includes BC2GM070776704 VBZ O
a BC2GM070776704 DT O
Spi-1 BC2GM070776704 JJ O
/ BC2GM070776704 JJ O
Spi-B BC2GM070776704 NNP O
binding BC2GM070776704 NN O
site BC2GM070776704 NN O
, BC2GM070776704 , O
previously BC2GM070776704 RB O
characterized BC2GM070776704 VBN O
as BC2GM070776704 IN O
an BC2GM070776704 DT O
important BC2GM070776704 JJ O
EBNA-2 BC2GM070776704 JJ O
response BC2GM070776704 NN O
element BC2GM070776704 NN O
. BC2GM070776704 . O
. . O O

Overall BC2GM012382882 JJ O
, BC2GM012382882 , O
it BC2GM012382882 PRP O
appears BC2GM012382882 VBZ O
that BC2GM012382882 IN O
prenatal BC2GM012382882 JJ O
exposure BC2GM012382882 NN O
to BC2GM012382882 TO O
androgen-based BC2GM012382882 JJ O
synthetic BC2GM012382882 JJ O
progestin BC2GM012382882 NN O
exerted BC2GM012382882 VBD O
a BC2GM012382882 DT O
masculinizing BC2GM012382882 NN O
and BC2GM012382882 CC O
/ BC2GM012382882 NN O
or BC2GM012382882 CC O
defeminizing BC2GM012382882 VBG O
influence BC2GM012382882 NN O
on BC2GM012382882 IN O
human BC2GM012382882 JJ O
behavioral BC2GM012382882 JJ O
development BC2GM012382882 NN O
, BC2GM012382882 , O
whereas BC2GM012382882 IN O
prenatal BC2GM012382882 JJ O
exposure BC2GM012382882 NN O
to BC2GM012382882 TO O
natural BC2GM012382882 JJ O
progesterone BC2GM012382882 NN O
and BC2GM012382882 CC O
progesterone-based BC2GM012382882 JJ O
synthetic BC2GM012382882 JJ O
progestin BC2GM012382882 NN O
had BC2GM012382882 VBD O
a BC2GM012382882 DT O
feminizing BC2GM012382882 NN O
and BC2GM012382882 CC O
/ BC2GM012382882 NN O
or BC2GM012382882 CC O
demasculinizing BC2GM012382882 VBG O
influence BC2GM012382882 NN O
, BC2GM012382882 , O
particularly BC2GM012382882 RB O
among BC2GM012382882 IN O
female BC2GM012382882 JJ O
subjects BC2GM012382882 NNS O
. BC2GM012382882 . O
. . O O

In BC2GM002567582 IN O
contrast BC2GM002567582 NN O
to BC2GM002567582 TO O
the BC2GM002567582 DT O
p16-mediated BC2GM002567582 JJ O
G1 BC2GM002567582 NNP O
block BC2GM002567582 NN O
, BC2GM002567582 , O
G1 BC2GM002567582 NNP O
arrest BC2GM002567582 RB O
mediated BC2GM002567582 VBN O
by BC2GM002567582 IN O
the BC2GM002567582 DT O
cdk BC2GM002567582 NN O
inhibitors BC2GM002567582 NNS O
p21Cip1 BC2GM002567582 VBP O
or BC2GM002567582 CC O
p27Kip1 BC2GM002567582 VBP O
can BC2GM002567582 MD O
not BC2GM002567582 RB O
be BC2GM002567582 VB O
bypassed BC2GM002567582 VBN O
either BC2GM002567582 RB O
by BC2GM002567582 IN O
inactivation BC2GM002567582 NN O
of BC2GM002567582 IN O
pRb BC2GM002567582 NN O
or BC2GM002567582 CC O
overexpression BC2GM002567582 NN O
of BC2GM002567582 IN O
E2F BC2GM002567582 NNP O
family BC2GM002567582 NN O
members BC2GM002567582 NNS O
. BC2GM002567582 . O
. . O O

Using BC2GM034715588 VBG O
green BC2GM034715588 JJ O
fluorescent BC2GM034715588 NN O
protein BC2GM034715588 NN O
fusions BC2GM034715588 NNS O
we BC2GM034715588 PRP O
demonstrate BC2GM034715588 VBP O
that BC2GM034715588 IN O
the BC2GM034715588 DT O
SYT BC2GM034715588 NNP O
, BC2GM034715588 , O
SSX BC2GM034715588 NNP O
and BC2GM034715588 CC O
the BC2GM034715588 DT O
SYT-SSX BC2GM034715588 JJ O
proteins BC2GM034715588 NNS O
are BC2GM034715588 VBP O
nuclear BC2GM034715588 JJ O
proteins BC2GM034715588 NNS O
. BC2GM034715588 . O
. . O O

The BC2GM064479626 DT O
XPR2 BC2GM064479626 NNP O
gene BC2GM064479626 NN O
from BC2GM064479626 IN O
Yarrowia BC2GM064479626 NNP O
lipolytica BC2GM064479626 NNP O
encodes BC2GM064479626 VBZ O
an BC2GM064479626 DT O
inducible BC2GM064479626 JJ O
alkaline BC2GM064479626 NN O
extracellular BC2GM064479626 JJ O
protease BC2GM064479626 NN O
. BC2GM064479626 . O
. . O O

The BC2GM046577623 DT O
majority BC2GM046577623 NN O
of BC2GM046577623 IN O
putative BC2GM046577623 JJ O
TSC2 BC2GM046577623 NNP O
mutations BC2GM046577623 NNS O
were BC2GM046577623 VBD O
found BC2GM046577623 VBN O
in BC2GM046577623 IN O
sporadic BC2GM046577623 JJ O
rather BC2GM046577623 RB O
than BC2GM046577623 IN O
TSC2-linked BC2GM046577623 JJ O
families BC2GM046577623 NNS O
. BC2GM046577623 . O
. . O O

It BC2GM064262659 PRP O
is BC2GM064262659 VBZ O
also BC2GM064262659 RB O
conceivable BC2GM064262659 JJ O
that BC2GM064262659 IN O
elevated BC2GM064262659 VBD O
insulin BC2GM064262659 NN O
levels BC2GM064262659 NNS O
may BC2GM064262659 MD O
cause BC2GM064262659 VB O
hypertriglyceridaemia BC2GM064262659 NN O
and BC2GM064262659 CC O
possibly BC2GM064262659 RB O
other BC2GM064262659 JJ O
abnormalities BC2GM064262659 NNS O
of BC2GM064262659 IN O
lipid BC2GM064262659 JJ O
metabolism BC2GM064262659 NN O
. BC2GM064262659 . O
. . O O

Normal BC2GM023957927 JJ O
dogs BC2GM023957927 NNS O
were BC2GM023957927 VBD O
exposed BC2GM023957927 VBN O
to BC2GM023957927 TO O
either BC2GM023957927 DT O
10 BC2GM023957927 CD O
, BC2GM023957927 , O
15 BC2GM023957927 CD O
, BC2GM023957927 , O
or BC2GM023957927 CC O
30 BC2GM023957927 CD O
Gy BC2GM023957927 NNP O
of BC2GM023957927 IN O
X BC2GM023957927 NNP O
rays BC2GM023957927 NNS O
to BC2GM023957927 TO O
a BC2GM023957927 DT O
single BC2GM023957927 JJ O
hemisphere BC2GM023957927 NN O
and BC2GM023957927 CC O
the BC2GM023957927 DT O
gross BC2GM023957927 JJ O
and BC2GM023957927 CC O
histopathologic BC2GM023957927 JJ O
changes BC2GM023957927 NNS O
were BC2GM023957927 VBD O
evaluated BC2GM023957927 VBN O
qualitatively BC2GM023957927 RB O
. BC2GM023957927 . O
. . O O

A BC2GM091736061 DT O
cephalothoracophagus BC2GM091736061 NN O
disymmetros BC2GM091736061 NN O
buffalo BC2GM091736061 NN O
calf BC2GM091736061 NN O
. BC2GM091736061 . O
. . O O

The BC2GM002436660 DT O
Htf9-a BC2GM002436660 NNP O
gene BC2GM002436660 NN O
encodes BC2GM002436660 VBZ O
the BC2GM002436660 DT O
RanBP1 BC2GM002436660 NNP O
protein BC2GM002436660 NN O
, BC2GM002436660 , O
a BC2GM002436660 DT O
major BC2GM002436660 JJ O
partner BC2GM002436660 NN O
of BC2GM002436660 IN O
the BC2GM002436660 DT O
Ran BC2GM002436660 NNP O
GTPase BC2GM002436660 NNP O
. BC2GM002436660 . O
. . O O

Genomic BC2GM018246985 NNP O
clones BC2GM018246985 NNS O
containing BC2GM018246985 VBG O
the BC2GM018246985 DT O
C. BC2GM018246985 NNP O
briggsae BC2GM018246985 NN O
gene BC2GM018246985 NN O
are BC2GM018246985 VBP O
able BC2GM018246985 JJ O
to BC2GM018246985 TO O
completely BC2GM018246985 RB O
rescue BC2GM018246985 VB O
the BC2GM018246985 DT O
unc-119 BC2GM018246985 JJ O
phenotype BC2GM018246985 NN O
in BC2GM018246985 IN O
transgenic BC2GM018246985 JJ O
C. BC2GM018246985 NNP O
elegans BC2GM018246985 VBZ O
mutants BC2GM018246985 NNS O
. BC2GM018246985 . O
. . O O

Copyright BC2GM043332798 JJ O
1998 BC2GM043332798 CD O
Academic BC2GM043332798 NNP O
Press BC2GM043332798 NNP O
. BC2GM043332798 . O
. . O O

A BC2GM049751751 DT O
role BC2GM049751751 NN O
for BC2GM049751751 IN O
phosphatidylinositol BC2GM049751751 JJ O
3-kinase BC2GM049751751 CD O
in BC2GM049751751 IN O
the BC2GM049751751 DT O
regulation BC2GM049751751 NN O
of BC2GM049751751 IN O
beta BC2GM049751751 NN O
1 BC2GM049751751 CD O
integrin BC2GM049751751 NN O
activity BC2GM049751751 NN O
by BC2GM049751751 IN O
the BC2GM049751751 DT O
CD2 BC2GM049751751 NNP O
antigen BC2GM049751751 NN O
. BC2GM049751751 . O
. . O O

Recurrence BC2GM065562233 NN O
of BC2GM065562233 IN O
the BC2GM065562233 DT O
hepatic BC2GM065562233 JJ O
cyst BC2GM065562233 NN O
after BC2GM065562233 IN O
partial BC2GM065562233 JJ O
excision BC2GM065562233 NN O
and BC2GM065562233 CC O
drainage BC2GM065562233 NN O
was BC2GM065562233 VBD O
complicated BC2GM065562233 VBN O
by BC2GM065562233 IN O
fistula BC2GM065562233 JJ O
formation BC2GM065562233 NN O
between BC2GM065562233 IN O
the BC2GM065562233 DT O
cyst BC2GM065562233 NN O
and BC2GM065562233 CC O
the BC2GM065562233 DT O
duodenum BC2GM065562233 NN O
. BC2GM065562233 . O
. . O O

Possibility BC2GM038900990 NN O
of BC2GM038900990 IN O
using BC2GM038900990 VBG O
gynecologic BC2GM038900990 JJ O
nurses BC2GM038900990 NNS O
in BC2GM038900990 IN O
the BC2GM038900990 DT O
independently BC2GM038900990 RB O
administered BC2GM038900990 VBN O
health BC2GM038900990 NN O
centers BC2GM038900990 NNS O
. BC2GM038900990 . O
. . O O

Effect BC2GM092745333 NN O
of BC2GM092745333 IN O
tetracycline BC2GM092745333 NN O
on BC2GM092745333 IN O
the BC2GM092745333 DT O
glycogen-producing BC2GM092745333 JJ O
function BC2GM092745333 NN O
of BC2GM092745333 IN O
the BC2GM092745333 DT O
liver BC2GM092745333 NN O
and BC2GM092745333 CC O
intestinal BC2GM092745333 JJ O
microflora BC2GM092745333 NN O
in BC2GM092745333 IN O
white BC2GM092745333 JJ O
mice BC2GM092745333 NN O
. BC2GM092745333 . O
. . O O

Vertebrate BC2GM071659744 NNP O
U6 BC2GM071659744 NNP O
small BC2GM071659744 JJ O
nuclear BC2GM071659744 JJ O
RNA BC2GM071659744 NNP O
( BC2GM071659744 ( O
snRNA BC2GM071659744 NN O
) BC2GM071659744 ) O
loci BC2GM071659744 VBZ O
exemplify BC2GM071659744 VB O
a BC2GM071659744 DT O
novel BC2GM071659744 JJ O
class BC2GM071659744 NN O
of BC2GM071659744 IN O
polymerase BC2GM071659744 JJ O
III-transcribed BC2GM071659744 NNP O
genes BC2GM071659744 NNS O
that BC2GM071659744 WDT O
lack BC2GM071659744 VBP O
an BC2GM071659744 DT O
intragenic BC2GM071659744 JJ O
control BC2GM071659744 NN O
region BC2GM071659744 NN O
( BC2GM071659744 ( O
ICR BC2GM071659744 NNP O
) BC2GM071659744 ) O
. BC2GM071659744 . O
. . O O

The BC2GM089976750 DT O
temporal BC2GM089976750 JJ O
changes BC2GM089976750 NNS O
in BC2GM089976750 IN O
the BC2GM089976750 DT O
plasma BC2GM089976750 JJ O
concentration BC2GM089976750 NN O
of BC2GM089976750 IN O
immunoreactive BC2GM089976750 JJ O
atrial BC2GM089976750 JJ O
natriuretic BC2GM089976750 JJ O
factor BC2GM089976750 NN O
( BC2GM089976750 ( O
iANF BC2GM089976750 NN O
) BC2GM089976750 ) O
were BC2GM089976750 VBD O
studied BC2GM089976750 VBN O
in BC2GM089976750 IN O
six BC2GM089976750 CD O
conscious BC2GM089976750 JJ O
dogs BC2GM089976750 NNS O
with BC2GM089976750 IN O
an BC2GM089976750 DT O
arteriovenous BC2GM089976750 JJ O
( BC2GM089976750 ( O
AV BC2GM089976750 NNP O
) BC2GM089976750 ) O
fistula BC2GM089976750 NN O
, BC2GM089976750 , O
a BC2GM089976750 DT O
model BC2GM089976750 NN O
of BC2GM089976750 IN O
chronic BC2GM089976750 JJ O
high-output BC2GM089976750 JJ O
heart BC2GM089976750 NN O
failure BC2GM089976750 NN O
. BC2GM089976750 . O
. . O O

A BC2GM058267325 DT O
group BC2GM058267325 NN O
of BC2GM058267325 IN O
factors BC2GM058267325 NNS O
known BC2GM058267325 VBN O
as BC2GM058267325 IN O
activating BC2GM058267325 VBG O
transcription BC2GM058267325 NN O
factors BC2GM058267325 NNS O
( BC2GM058267325 ( O
ATF BC2GM058267325 NNP O
) BC2GM058267325 ) O
have BC2GM058267325 VBP O
been BC2GM058267325 VBN O
found BC2GM058267325 VBN O
to BC2GM058267325 TO O
bind BC2GM058267325 VB O
to BC2GM058267325 TO O
the BC2GM058267325 DT O
latter BC2GM058267325 NN O
and BC2GM058267325 CC O
related BC2GM058267325 JJ O
sequences BC2GM058267325 NNS O
found BC2GM058267325 VBD O
upstream BC2GM058267325 NN O
of BC2GM058267325 IN O
early BC2GM058267325 JJ O
adenovirus BC2GM058267325 NN O
promoters BC2GM058267325 NNS O
induced BC2GM058267325 VBN O
by BC2GM058267325 IN O
E1A BC2GM058267325 NNP O
, BC2GM058267325 , O
and BC2GM058267325 CC O
these BC2GM058267325 DT O
factors BC2GM058267325 NNS O
are BC2GM058267325 VBP O
highly BC2GM058267325 RB O
homologous BC2GM058267325 JJ O
to BC2GM058267325 TO O
the BC2GM058267325 DT O
CREB BC2GM058267325 NNP O
protein BC2GM058267325 NN O
. BC2GM058267325 . O
. . O O

The BC2GM036723867 DT O
high BC2GM036723867 JJ O
degree BC2GM036723867 NN O
of BC2GM036723867 IN O
sequence BC2GM036723867 NN O
conservation BC2GM036723867 NN O
together BC2GM036723867 RB O
with BC2GM036723867 IN O
the BC2GM036723867 DT O
ability BC2GM036723867 NN O
to BC2GM036723867 TO O
direct BC2GM036723867 VB O
nucleolar BC2GM036723867 JJ O
protein BC2GM036723867 NN O
transport BC2GM036723867 NN O
supports BC2GM036723867 VBZ O
the BC2GM036723867 DT O
hypothesis BC2GM036723867 NN O
that BC2GM036723867 WDT O
MAK16 BC2GM036723867 NNP O
proteins BC2GM036723867 VBZ O
play BC2GM036723867 VB O
a BC2GM036723867 DT O
key BC2GM036723867 JJ O
role BC2GM036723867 NN O
in BC2GM036723867 IN O
the BC2GM036723867 DT O
biogenesis BC2GM036723867 NN O
of BC2GM036723867 IN O
60S BC2GM036723867 CD O
subunits BC2GM036723867 NNS O
. BC2GM036723867 . O
. . O O

Between BC2GM014569562 IN O
the BC2GM014569562 DT O
RNA BC2GM014569562 NNP O
initiation BC2GM014569562 NN O
site BC2GM014569562 NN O
and BC2GM014569562 CC O
the BC2GM014569562 DT O
coding BC2GM014569562 JJ O
region BC2GM014569562 NN O
is BC2GM014569562 VBZ O
a BC2GM014569562 DT O
GC-rich BC2GM014569562 JJ O
hairpin BC2GM014569562 NN O
structure BC2GM014569562 NN O
followed BC2GM014569562 VBN O
by BC2GM014569562 IN O
8 BC2GM014569562 CD O
T BC2GM014569562 NNP O
residues BC2GM014569562 NNS O
that BC2GM014569562 WDT O
looks BC2GM014569562 VBZ O
like BC2GM014569562 IN O
a BC2GM014569562 DT O
rho-independent BC2GM014569562 JJ O
transcription BC2GM014569562 NN O
terminator BC2GM014569562 NN O
. BC2GM014569562 . O
. . O O

Two BC2GM015726029 CD O
adjacent BC2GM015726029 JJ O
, BC2GM015726029 , O
highly BC2GM015726029 RB O
homologous BC2GM015726029 JJ O
endoglucanase BC2GM015726029 NN O
genes BC2GM015726029 NNS O
, BC2GM015726029 , O
celD BC2GM015726029 NN O
and BC2GM015726029 CC O
celE BC2GM015726029 NN O
from BC2GM015726029 IN O
Fibrobacter BC2GM015726029 NNP O
succinogenes BC2GM015726029 NNS O
S85 BC2GM015726029 NNP O
, BC2GM015726029 , O
which BC2GM015726029 WDT O
were BC2GM015726029 VBD O
separated BC2GM015726029 VBN O
by BC2GM015726029 IN O
an BC2GM015726029 DT O
AT-rich BC2GM015726029 JJ O
223-nucleotide BC2GM015726029 JJ O
intergenic BC2GM015726029 JJ O
region BC2GM015726029 NN O
were BC2GM015726029 VBD O
characterized BC2GM015726029 VBN O
. BC2GM015726029 . O
. . O O

The BC2GM046491009 DT O
rec8 BC2GM046491009 NN O
( BC2GM046491009 ( O
+ BC2GM046491009 NNP O
) BC2GM046491009 ) O
, BC2GM046491009 , O
rec10 BC2GM046491009 FW O
( BC2GM046491009 ( O
+ BC2GM046491009 NN O
) BC2GM046491009 ) O
, BC2GM046491009 , O
and BC2GM046491009 CC O
rec11 BC2GM046491009 NN O
( BC2GM046491009 ( O
+ BC2GM046491009 NNP O
) BC2GM046491009 ) O
genes BC2GM046491009 NNS O
of BC2GM046491009 IN O
the BC2GM046491009 DT O
fission BC2GM046491009 NN O
yeast BC2GM046491009 NN O
Schizosaccharomyces BC2GM046491009 NNP O
pombe BC2GM046491009 NN O
exhibit BC2GM046491009 NN O
similar BC2GM046491009 JJ O
specificities BC2GM046491009 NNS O
for BC2GM046491009 IN O
meiotic BC2GM046491009 JJ O
recombination BC2GM046491009 NN O
and BC2GM046491009 CC O
rec8 BC2GM046491009 NN O
( BC2GM046491009 ( O
+ BC2GM046491009 NNP O
) BC2GM046491009 ) O
is BC2GM046491009 VBZ O
required BC2GM046491009 VBN O
for BC2GM046491009 IN O
sister BC2GM046491009 NN O
chromatid BC2GM046491009 NN O
cohesion BC2GM046491009 NN O
and BC2GM046491009 CC O
homolog BC2GM046491009 NN O
pairing BC2GM046491009 NN O
. BC2GM046491009 . O
. . O O

We BC2GM077180939 PRP O
have BC2GM077180939 VBP O
characterized BC2GM077180939 VBN O
a BC2GM077180939 DT O
new BC2GM077180939 JJ O
cDNA BC2GM077180939 NN O
, BC2GM077180939 , O
33k-6 BC2GM077180939 JJ O
, BC2GM077180939 , O
potentially BC2GM077180939 RB O
encoding BC2GM077180939 VBG O
a BC2GM077180939 DT O
tobacco BC2GM077180939 NN O
33 BC2GM077180939 CD O
kDa BC2GM077180939 NN O
chloroplast BC2GM077180939 NN O
RNP BC2GM077180939 NNP O
( BC2GM077180939 ( O
cp33 BC2GM077180939 NN O
) BC2GM077180939 ) O
homologue BC2GM077180939 NN O
. BC2GM077180939 . O
. . O O

CTDK1 BC2GM049324176 NNP O
and BC2GM049324176 CC O
CTDK2 BC2GM049324176 NNP O
also BC2GM049324176 RB O
differ BC2GM049324176 VBP O
in BC2GM049324176 IN O
their BC2GM049324176 PRP$ O
protein BC2GM049324176 NN O
substrate BC2GM049324176 NN O
specificity BC2GM049324176 NN O
. BC2GM049324176 . O
. . O O

In BC2GM050874395 IN O
those BC2GM050874395 DT O
patients BC2GM050874395 NNS O
who BC2GM050874395 WP O
before BC2GM050874395 IN O
transplantation BC2GM050874395 NN O
were BC2GM050874395 VBD O
serological BC2GM050874395 JJ O
negative BC2GM050874395 JJ O
for BC2GM050874395 IN O
CMV BC2GM050874395 NNP O
but BC2GM050874395 CC O
had BC2GM050874395 VBD O
received BC2GM050874395 VBN O
organs BC2GM050874395 NNS O
from BC2GM050874395 IN O
CMV-IgG BC2GM050874395 NNP O
positive BC2GM050874395 JJ O
donors BC2GM050874395 NNS O
, BC2GM050874395 , O
the BC2GM050874395 DT O
incidence BC2GM050874395 NN O
of BC2GM050874395 IN O
the BC2GM050874395 DT O
disease BC2GM050874395 NN O
was BC2GM050874395 VBD O
highest BC2GM050874395 JJS O
. BC2GM050874395 . O
. . O O

Red BC2GM002778880 JJ O
blood BC2GM002778880 NN O
cell BC2GM002778880 NN O
binding BC2GM002778880 NN O
of BC2GM002778880 IN O
99mTc-EC BC2GM002778880 CD O
and BC2GM002778880 CC O
131I-OIH BC2GM002778880 CD O
was BC2GM002778880 VBD O
6.1 BC2GM002778880 CD O
% BC2GM002778880 NN O
and BC2GM002778880 CC O
20 BC2GM002778880 CD O
% BC2GM002778880 NN O
, BC2GM002778880 , O
respectively BC2GM002778880 RB O
. BC2GM002778880 . O
. . O O

Vk8 BC2GM058284658 NNP O
/ BC2GM058284658 NNP O
Jk2 BC2GM058284658 NNP O
and BC2GM058284658 CC O
Vk1 BC2GM058284658 NNP O
/ BC2GM058284658 NNP O
Jk5 BC2GM058284658 NNP O
rearrangements BC2GM058284658 NNS O
encoded BC2GM058284658 VBD O
the BC2GM058284658 DT O
respective BC2GM058284658 JJ O
L BC2GM058284658 NNP O
chain BC2GM058284658 NN O
V-regions BC2GM058284658 NNS O
. BC2GM058284658 . O
. . O O

However BC2GM029296962 RB O
, BC2GM029296962 , O
elimination BC2GM029296962 NN O
of BC2GM029296962 IN O
the BC2GM029296962 DT O
kinase BC2GM029296962 NN O
activity BC2GM029296962 NN O
of BC2GM029296962 IN O
DCAMKL1 BC2GM029296962 NNP O
has BC2GM029296962 VBZ O
no BC2GM029296962 DT O
detectable BC2GM029296962 JJ O
effect BC2GM029296962 NN O
on BC2GM029296962 IN O
its BC2GM029296962 PRP$ O
microtubule BC2GM029296962 NN O
polymerization BC2GM029296962 NN O
activity BC2GM029296962 NN O
. BC2GM029296962 . O
. . O O

Changes BC2GM026812413 NNS O
in BC2GM026812413 IN O
water BC2GM026812413 NN O
and BC2GM026812413 CC O
electrolyte BC2GM026812413 JJ O
content BC2GM026812413 NN O
of BC2GM026812413 IN O
the BC2GM026812413 DT O
brain BC2GM026812413 NN O
and BC2GM026812413 CC O
edema BC2GM026812413 NN O
formation BC2GM026812413 NN O
after BC2GM026812413 IN O
acute BC2GM026812413 NN O
, BC2GM026812413 , O
drug-induced BC2GM026812413 JJ O
hypertension BC2GM026812413 NN O
were BC2GM026812413 VBD O
studied BC2GM026812413 VBN O
in BC2GM026812413 IN O
albino BC2GM026812413 NN O
rabbits BC2GM026812413 NNS O
. BC2GM026812413 . O
. . O O

The BC2GM035122816 DT O
cDNA BC2GM035122816 NN O
contains BC2GM035122816 VBZ O
a BC2GM035122816 DT O
reading BC2GM035122816 NN O
frame BC2GM035122816 NN O
for BC2GM035122816 IN O
a BC2GM035122816 DT O
145-amino-acid BC2GM035122816 JJ O
protein BC2GM035122816 NN O
and BC2GM035122816 CC O
it BC2GM035122816 PRP O
lacks BC2GM035122816 VBZ O
the BC2GM035122816 DT O
UGA BC2GM035122816 NNP O
codons BC2GM035122816 NNS O
, BC2GM035122816 , O
which BC2GM035122816 WDT O
have BC2GM035122816 VBP O
been BC2GM035122816 VBN O
found BC2GM035122816 VBN O
in BC2GM035122816 IN O
the BC2GM035122816 DT O
reading BC2GM035122816 NN O
frame BC2GM035122816 NN O
of BC2GM035122816 IN O
the BC2GM035122816 DT O
mouse BC2GM035122816 NN O
MCS BC2GM035122816 NNP O
cDNA BC2GM035122816 NN O
and BC2GM035122816 CC O
have BC2GM035122816 VBP O
been BC2GM035122816 VBN O
presumed BC2GM035122816 VBN O
to BC2GM035122816 TO O
encode BC2GM035122816 VB O
the BC2GM035122816 DT O
selenocysteine BC2GM035122816 NN O
in BC2GM035122816 IN O
the BC2GM035122816 DT O
amino BC2GM035122816 JJ O
terminal BC2GM035122816 NN O
of BC2GM035122816 IN O
the BC2GM035122816 DT O
deduced BC2GM035122816 JJ O
mouse BC2GM035122816 NN O
amino BC2GM035122816 NN O
acid BC2GM035122816 JJ O
sequence BC2GM035122816 NN O
. BC2GM035122816 . O
. . O O

This BC2GM086974168 DT O
incompatibility BC2GM086974168 NN O
phenotype BC2GM086974168 NN O
requires BC2GM086974168 VBZ O
the BC2GM086974168 DT O
global BC2GM086974168 JJ O
transcriptional BC2GM086974168 NN O
repressor BC2GM086974168 NN O
, BC2GM086974168 , O
KorB BC2GM086974168 NNP O
, BC2GM086974168 , O
and BC2GM086974168 CC O
the BC2GM086974168 DT O
target BC2GM086974168 NN O
for BC2GM086974168 IN O
incC-mediated BC2GM086974168 JJ O
incompatibility BC2GM086974168 NN O
is BC2GM086974168 VBZ O
a BC2GM086974168 DT O
KorB-binding BC2GM086974168 JJ O
site BC2GM086974168 NN O
( BC2GM086974168 ( O
O BC2GM086974168 NNP O
( BC2GM086974168 ( O
B BC2GM086974168 NNP O
) BC2GM086974168 ) O
) BC2GM086974168 ) O
. BC2GM086974168 . O
. . O O

The BC2GM052697029 DT O
results BC2GM052697029 NNS O
of BC2GM052697029 IN O
these BC2GM052697029 DT O
experiments BC2GM052697029 NNS O
indicated BC2GM052697029 VBD O
that BC2GM052697029 IN O
charcoal BC2GM052697029 NN O
, BC2GM052697029 , O
imbiber BC2GM052697029 VB O
beads BC2GM052697029 NNS O
, BC2GM052697029 , O
and BC2GM052697029 CC O
the BC2GM052697029 DT O
anion BC2GM052697029 NN O
exchanges BC2GM052697029 NNS O
resins BC2GM052697029 NNS O
, BC2GM052697029 , O
Dowex BC2GM052697029 NNP O
XFS-4022 BC2GM052697029 NNP O
and BC2GM052697029 CC O
Dowex BC2GM052697029 NNP O
SBR-C1 BC2GM052697029 NNP O
, BC2GM052697029 , O
would BC2GM052697029 MD O
not BC2GM052697029 RB O
be BC2GM052697029 VB O
useful BC2GM052697029 JJ O
agents BC2GM052697029 NNS O
for BC2GM052697029 IN O
increasing BC2GM052697029 VBG O
the BC2GM052697029 DT O
amount BC2GM052697029 NN O
of BC2GM052697029 IN O
dieldrin BC2GM052697029 NN O
eliminated BC2GM052697029 VBN O
via BC2GM052697029 IN O
feces BC2GM052697029 NNS O
( BC2GM052697029 ( O
droppings BC2GM052697029 NNS O
) BC2GM052697029 ) O
of BC2GM052697029 IN O
chickens BC2GM052697029 NNS O
. BC2GM052697029 . O
. . O O

Initial BC2GM045303279 NNP O
computer BC2GM045303279 NN O
based BC2GM045303279 VBN O
similarity BC2GM045303279 NN O
searches BC2GM045303279 NNS O
identified BC2GM045303279 VBN O
human BC2GM045303279 JJ O
retinoblastoma BC2GM045303279 NN O
binding BC2GM045303279 VBG O
protein BC2GM045303279 NN O
1 BC2GM045303279 CD O
( BC2GM045303279 ( O
RBP-1 BC2GM045303279 NNP O
) BC2GM045303279 ) O
, BC2GM045303279 , O
Drosophila BC2GM045303279 NNP O
melanogaster BC2GM045303279 NN O
male BC2GM045303279 NN O
specific BC2GM045303279 JJ O
lethal-3 BC2GM045303279 JJ O
( BC2GM045303279 ( O
Msl-3 BC2GM045303279 NNP O
) BC2GM045303279 ) O
, BC2GM045303279 , O
S. BC2GM045303279 NNP O
pombe BC2GM045303279 NN O
altered BC2GM045303279 VBD O
polarity-13 BC2GM045303279 NN O
( BC2GM045303279 ( O
Alp13 BC2GM045303279 NNP O
) BC2GM045303279 ) O
and BC2GM045303279 CC O
S. BC2GM045303279 NNP O
cerevisiae BC2GM045303279 VBP O
Eaf3p BC2GM045303279 NNP O
, BC2GM045303279 , O
a BC2GM045303279 DT O
component BC2GM045303279 NN O
of BC2GM045303279 IN O
the BC2GM045303279 DT O
yeast BC2GM045303279 NN O
NuA4 BC2GM045303279 NNP O
HAT BC2GM045303279 NNP O
complex BC2GM045303279 NN O
( BC2GM045303279 ( O
Galarneau BC2GM045303279 NNP O
et BC2GM045303279 RB O
al. BC2GM045303279 RB O
, BC2GM045303279 , O
2000 BC2GM045303279 CD O
. BC2GM045303279 . O
. . O O

Other BC2GM016356336 JJ O
Fischer-344 BC2GM016356336 JJ O
rats BC2GM016356336 NNS O
were BC2GM016356336 VBD O
also BC2GM016356336 RB O
exposed BC2GM016356336 VBN O
for BC2GM016356336 IN O
1 BC2GM016356336 CD O
hr BC2GM016356336 NN O
to BC2GM016356336 TO O
0.0 BC2GM016356336 CD O
or BC2GM016356336 CC O
to BC2GM016356336 TO O
0.6 BC2GM016356336 CD O
ppm BC2GM016356336 NN O
O3 BC2GM016356336 NNP O
. BC2GM016356336 . O
. . O O

Genomic BC2GM074970735 NNP O
DNA BC2GM074970735 NNP O
blot BC2GM074970735 NN O
analysis BC2GM074970735 NN O
indicates BC2GM074970735 VBZ O
that BC2GM074970735 IN O
the BC2GM074970735 DT O
trout BC2GM074970735 NN O
L2 BC2GM074970735 NNP O
locus BC2GM074970735 NN O
has BC2GM074970735 VBZ O
a BC2GM074970735 DT O
cluster-like BC2GM074970735 JJ O
organization BC2GM074970735 NN O
similar BC2GM074970735 JJ O
to BC2GM074970735 TO O
the BC2GM074970735 DT O
trout BC2GM074970735 NN O
L1 BC2GM074970735 NNP O
locus BC2GM074970735 NN O
and BC2GM074970735 CC O
the BC2GM074970735 DT O
IgL BC2GM074970735 NNP O
locus BC2GM074970735 NN O
of BC2GM074970735 IN O
several BC2GM074970735 JJ O
teleost BC2GM074970735 JJ O
fish BC2GM074970735 NN O
. BC2GM074970735 . O
. . O O

The BC2GM017938095 DT O
detergent-solubilized BC2GM017938095 JJ O
complex BC2GM017938095 JJ O
oxidizes BC2GM017938095 NNS O
caldariella BC2GM017938095 NN O
quinol BC2GM017938095 NN O
at BC2GM017938095 IN O
high BC2GM017938095 JJ O
rates BC2GM017938095 NNS O
and BC2GM017938095 CC O
is BC2GM017938095 VBZ O
completely BC2GM017938095 RB O
inhibited BC2GM017938095 VBN O
by BC2GM017938095 IN O
cyanide BC2GM017938095 NN O
and BC2GM017938095 CC O
by BC2GM017938095 IN O
quinolone BC2GM017938095 NN O
analogs BC2GM017938095 NNS O
, BC2GM017938095 , O
potent BC2GM017938095 JJ O
inhibitors BC2GM017938095 NNS O
of BC2GM017938095 IN O
quinol BC2GM017938095 NN O
oxidases BC2GM017938095 NNS O
. BC2GM017938095 . O
. . O O

The BC2GM082852129 DT O
encoded BC2GM082852129 JJ O
Arabidopsis BC2GM082852129 NNP O
U3 BC2GM082852129 NNP O
snRNAs BC2GM082852129 NN O
can BC2GM082852129 MD O
be BC2GM082852129 VB O
folded BC2GM082852129 VBN O
into BC2GM082852129 IN O
a BC2GM082852129 DT O
secondary BC2GM082852129 JJ O
structure BC2GM082852129 NN O
which BC2GM082852129 WDT O
is BC2GM082852129 VBZ O
more BC2GM082852129 JJR O
similar BC2GM082852129 JJ O
to BC2GM082852129 TO O
that BC2GM082852129 DT O
of BC2GM082852129 IN O
U3 BC2GM082852129 NNP O
RNAs BC2GM082852129 NNP O
from BC2GM082852129 IN O
lower BC2GM082852129 JJR O
eukaryotes BC2GM082852129 NNS O
rather BC2GM082852129 RB O
than BC2GM082852129 IN O
from BC2GM082852129 IN O
metazoa BC2GM082852129 NN O
. BC2GM082852129 . O
. . O O

The BC2GM058610750 DT O
psychosocial BC2GM058610750 JJ O
features BC2GM058610750 NNS O
of BC2GM058610750 IN O
people BC2GM058610750 NNS O
using BC2GM058610750 VBG O
self-ignition BC2GM058610750 NN O
as BC2GM058610750 IN O
a BC2GM058610750 DT O
method BC2GM058610750 NN O
of BC2GM058610750 IN O
suicide BC2GM058610750 NN O
are BC2GM058610750 VBP O
consistent BC2GM058610750 JJ O
with BC2GM058610750 IN O
those BC2GM058610750 DT O
of BC2GM058610750 IN O
suicide BC2GM058610750 NN O
in BC2GM058610750 IN O
general BC2GM058610750 JJ O
. BC2GM058610750 . O
. . O O

Adenomas BC2GM086808769 NNP O
in BC2GM086808769 IN O
the BC2GM086808769 DT O
upper BC2GM086808769 JJ O
gastrointestinal BC2GM086808769 JJ O
tract BC2GM086808769 NN O
were BC2GM086808769 VBD O
found BC2GM086808769 VBN O
in BC2GM086808769 IN O
all BC2GM086808769 DT O
of BC2GM086808769 IN O
the BC2GM086808769 DT O
patients BC2GM086808769 NNS O
: BC2GM086808769 : O
Vater BC2GM086808769 NNP O
's BC2GM086808769 POS O
papilla BC2GM086808769 NN O
-- BC2GM086808769 : O
12 BC2GM086808769 CD O
, BC2GM086808769 , O
duodenum BC2GM086808769 NN O
-- BC2GM086808769 : O
nine BC2GM086808769 CD O
, BC2GM086808769 , O
and BC2GM086808769 CC O
gastric BC2GM086808769 JJ O
antrum BC2GM086808769 NN O
-- BC2GM086808769 : O
seven BC2GM086808769 CD O
. BC2GM086808769 . O
. . O O

Lesions BC2GM002383342 NNS O
of BC2GM002383342 IN O
this BC2GM002383342 DT O
kind BC2GM002383342 NN O
resemble BC2GM002383342 JJ O
those BC2GM002383342 DT O
in BC2GM002383342 IN O
vitamin BC2GM002383342 JJ O
A-deficient BC2GM002383342 JJ O
chickens BC2GM002383342 NNS O
and BC2GM002383342 CC O
are BC2GM002383342 VBP O
the BC2GM002383342 DT O
first BC2GM002383342 JJ O
to BC2GM002383342 TO O
be BC2GM002383342 VB O
induced BC2GM002383342 VBN O
by BC2GM002383342 IN O
excess BC2GM002383342 JJ O
vitamin BC2GM002383342 NN O
E BC2GM002383342 NNP O
. BC2GM002383342 . O
. . O O

An BC2GM051884914 DT O
scrR BC2GM051884914 JJ O
promoter BC2GM051884914 NN O
fragment BC2GM051884914 NN O
, BC2GM051884914 , O
which BC2GM051884914 WDT O
dose BC2GM051884914 VBZ O
not BC2GM051884914 RB O
contain BC2GM051884914 VB O
a BC2GM051884914 DT O
sequence BC2GM051884914 NN O
resembling BC2GM051884914 VBG O
OB BC2GM051884914 NNP O
, BC2GM051884914 , O
was BC2GM051884914 VBD O
not BC2GM051884914 RB O
shifted BC2GM051884914 VBN O
by BC2GM051884914 IN O
the BC2GM051884914 DT O
fusion BC2GM051884914 NN O
protein BC2GM051884914 NN O
. BC2GM051884914 . O
. . O O

In BC2GM043181941 IN O
contrast BC2GM043181941 NN O
, BC2GM043181941 , O
stem-loop BC2GM043181941 JJ O
structures BC2GM043181941 NNS O
2 BC2GM043181941 CD O
, BC2GM043181941 , O
3 BC2GM043181941 CD O
, BC2GM043181941 , O
and BC2GM043181941 CC O
4 BC2GM043181941 CD O
of BC2GM043181941 IN O
the BC2GM043181941 DT O
3 BC2GM043181941 CD O
' BC2GM043181941 POS O
domain BC2GM043181941 NN O
showed BC2GM043181941 VBD O
great BC2GM043181941 JJ O
variations BC2GM043181941 NNS O
in BC2GM043181941 IN O
size BC2GM043181941 NN O
, BC2GM043181941 , O
sequence BC2GM043181941 NN O
, BC2GM043181941 , O
and BC2GM043181941 CC O
structure BC2GM043181941 NN O
. BC2GM043181941 . O
. . O O

When BC2GM063564891 WRB O
transfected BC2GM063564891 VBN O
into BC2GM063564891 IN O
HepG2 BC2GM063564891 NNP O
cells BC2GM063564891 NNS O
, BC2GM063564891 , O
which BC2GM063564891 WDT O
lack BC2GM063564891 VBP O
C BC2GM063564891 NNP O
/ BC2GM063564891 NNP O
EBP BC2GM063564891 NNP O
alpha BC2GM063564891 NN O
, BC2GM063564891 , O
the BC2GM063564891 DT O
mouse BC2GM063564891 NN O
ob BC2GM063564891 NN O
promoter BC2GM063564891 NN O
was BC2GM063564891 VBD O
only BC2GM063564891 RB O
weakly BC2GM063564891 RB O
active BC2GM063564891 JJ O
. BC2GM063564891 . O
. . O O

Point BC2GM090403592 NNP O
mutations BC2GM090403592 NNS O
of BC2GM090403592 IN O
Stat3 BC2GM090403592 NNP O
within BC2GM090403592 IN O
the BC2GM090403592 DT O
interacting BC2GM090403592 NN O
domains BC2GM090403592 VBZ O
blocked BC2GM090403592 VBN O
both BC2GM090403592 DT O
physical BC2GM090403592 JJ O
interaction BC2GM090403592 NN O
of BC2GM090403592 IN O
Stat3 BC2GM090403592 NNP O
with BC2GM090403592 IN O
c-Jun BC2GM090403592 NN O
and BC2GM090403592 CC O
their BC2GM090403592 PRP$ O
cooperation BC2GM090403592 NN O
in BC2GM090403592 IN O
IL-6-induced BC2GM090403592 NNP O
transcription BC2GM090403592 NN O
directed BC2GM090403592 VBN O
by BC2GM090403592 IN O
the BC2GM090403592 DT O
alpha BC2GM090403592 NN O
( BC2GM090403592 ( O
2 BC2GM090403592 CD O
) BC2GM090403592 ) O
-macroglobulin BC2GM090403592 NN O
enhancer BC2GM090403592 NN O
. BC2GM090403592 . O
. . O O

Toxicity BC2GM015782693 NN O
of BC2GM015782693 IN O
benzoyl BC2GM015782693 JJ O
chloride BC2GM015782693 NN O
( BC2GM015782693 ( O
2,4,6-trichlorophenyl BC2GM015782693 JJ O
) BC2GM015782693 ) O
hydrazone BC2GM015782693 NN O
( BC2GM015782693 ( O
Banamite BC2GM015782693 NNP O
) BC2GM015782693 ) O
and BC2GM015782693 CC O
potential BC2GM015782693 JJ O
metabolites BC2GM015782693 NNS O
to BC2GM015782693 TO O
twospotted BC2GM015782693 VB O
spider BC2GM015782693 NN O
mites BC2GM015782693 NNS O
and BC2GM015782693 CC O
potency BC2GM015782693 NN O
as BC2GM015782693 IN O
inhibitors BC2GM015782693 NNS O
of BC2GM015782693 IN O
rat BC2GM015782693 NN O
liver BC2GM015782693 FW O
monoamine BC2GM015782693 NN O
oxidase BC2GM015782693 NN O
. BC2GM015782693 . O
. . O O

The BC2GM071536994 DT O
glucose BC2GM071536994 JJ O
effect BC2GM071536994 NN O
on BC2GM071536994 IN O
the BC2GM071536994 DT O
pyruvate BC2GM071536994 NN O
kinase BC2GM071536994 NN O
gene BC2GM071536994 NN O
is BC2GM071536994 VBZ O
reversibly BC2GM071536994 RB O
antagonized BC2GM071536994 VBN O
by BC2GM071536994 IN O
agents BC2GM071536994 NNS O
increasing BC2GM071536994 VBG O
intracellular BC2GM071536994 JJ O
cAMP BC2GM071536994 NN O
. BC2GM071536994 . O
. . O O

However BC2GM013941232 RB O
, BC2GM013941232 , O
and BC2GM013941232 CC O
in BC2GM013941232 IN O
contrast BC2GM013941232 NN O
to BC2GM013941232 TO O
other BC2GM013941232 JJ O
MMP BC2GM013941232 NNP O
genes BC2GM013941232 NNS O
, BC2GM013941232 , O
no BC2GM013941232 DT O
significative BC2GM013941232 JJ O
synergistic BC2GM013941232 JJ O
effect BC2GM013941232 NN O
on BC2GM013941232 IN O
CAT BC2GM013941232 NNP O
activity BC2GM013941232 NN O
between BC2GM013941232 IN O
the BC2GM013941232 DT O
AP-1 BC2GM013941232 NNP O
and BC2GM013941232 CC O
PEA-3 BC2GM013941232 NNP O
elements BC2GM013941232 NNS O
found BC2GM013941232 VBN O
in BC2GM013941232 IN O
the BC2GM013941232 DT O
collagenase-3 BC2GM013941232 JJ O
gene BC2GM013941232 NN O
promoter BC2GM013941232 NN O
was BC2GM013941232 VBD O
found BC2GM013941232 VBN O
. BC2GM013941232 . O
. . O O

Small BC2GM098933066 NNP O
cell BC2GM098933066 NN O
tumors BC2GM098933066 NNS O
in BC2GM098933066 IN O
children BC2GM098933066 NNS O
: BC2GM098933066 : O
contribution BC2GM098933066 NN O
to BC2GM098933066 TO O
the BC2GM098933066 DT O
solution BC2GM098933066 NN O
of BC2GM098933066 IN O
the BC2GM098933066 DT O
problem BC2GM098933066 NN O
of BC2GM098933066 IN O
differential BC2GM098933066 JJ O
diagnosis BC2GM098933066 NN O
with BC2GM098933066 IN O
immunohistochemistry BC2GM098933066 NN O
and BC2GM098933066 CC O
electron BC2GM098933066 NN O
microscopy BC2GM098933066 NN O
. BC2GM098933066 . O
. . O O

Interestingly BC2GM084160257 RB O
, BC2GM084160257 , O
unlike BC2GM084160257 IN O
PAK65 BC2GM084160257 NNP O
, BC2GM084160257 , O
HPK1 BC2GM084160257 NNP O
does BC2GM084160257 VBZ O
not BC2GM084160257 RB O
contain BC2GM084160257 VB O
the BC2GM084160257 DT O
small BC2GM084160257 JJ O
GTPase BC2GM084160257 NNP O
Rac1 BC2GM084160257 NNP O
/ BC2GM084160257 NNP O
Cdc42-binding BC2GM084160257 NNP O
domain BC2GM084160257 NN O
and BC2GM084160257 CC O
does BC2GM084160257 VBZ O
not BC2GM084160257 RB O
bind BC2GM084160257 VB O
to BC2GM084160257 TO O
either BC2GM084160257 DT O
Rac1 BC2GM084160257 NNP O
or BC2GM084160257 CC O
Cdc42 BC2GM084160257 NNP O
, BC2GM084160257 , O
suggesting BC2GM084160257 VBG O
that BC2GM084160257 IN O
HPK1 BC2GM084160257 NNP O
. BC2GM084160257 . O
activation BC2GM084160257 NN O
is BC2GM084160257 VBZ O
Rac1 BC2GM084160257 NNP O
/ BC2GM084160257 NNP O
Cdc42-independent BC2GM084160257 NNP O
. BC2GM084160257 . O
. . O O

The BC2GM098365261 DT O
predicted BC2GM098365261 VBN O
amino BC2GM098365261 NN O
acid BC2GM098365261 JJ O
sequence BC2GM098365261 NN O
contained BC2GM098365261 VBD O
all BC2GM098365261 DT O
consensus BC2GM098365261 NN O
regions BC2GM098365261 NNS O
for BC2GM098365261 IN O
S-adenosyl BC2GM098365261 NNP O
methionine BC2GM098365261 NN O
methyltransferases BC2GM098365261 NNS O
and BC2GM098365261 CC O
presented BC2GM098365261 VBD O
26 BC2GM098365261 CD O
% BC2GM098365261 NN O
identity BC2GM098365261 NN O
with BC2GM098365261 IN O
Saccharomyces BC2GM098365261 NNP O
cerevisiae BC2GM098365261 VBP O
DHHB-methyltransferase BC2GM098365261 NNP O
and BC2GM098365261 CC O
38 BC2GM098365261 CD O
% BC2GM098365261 NN O
identity BC2GM098365261 NN O
with BC2GM098365261 IN O
the BC2GM098365261 DT O
rat BC2GM098365261 NN O
protein BC2GM098365261 NN O
, BC2GM098365261 , O
as BC2GM098365261 RB O
well BC2GM098365261 RB O
as BC2GM098365261 IN O
with BC2GM098365261 IN O
a BC2GM098365261 DT O
bacterial BC2GM098365261 JJ O
( BC2GM098365261 ( O
Escherichia BC2GM098365261 NNP O
coli BC2GM098365261 NNS O
and BC2GM098365261 CC O
Salmonella BC2GM098365261 NNP O
typhimurium BC2GM098365261 NN O
) BC2GM098365261 ) O
methyltransferase BC2GM098365261 NN O
encoded BC2GM098365261 VBN O
by BC2GM098365261 IN O
the BC2GM098365261 DT O
UBIG BC2GM098365261 NNP O
gene BC2GM098365261 NN O
. BC2GM098365261 . O
. . O O

To BC2GM057610190 TO O
facilitate BC2GM057610190 VB O
the BC2GM057610190 DT O
characterization BC2GM057610190 NN O
of BC2GM057610190 IN O
NF-E2 BC2GM057610190 NNP O
functions BC2GM057610190 NNS O
in BC2GM057610190 IN O
human BC2GM057610190 JJ O
cells BC2GM057610190 NNS O
, BC2GM057610190 , O
we BC2GM057610190 PRP O
isolated BC2GM057610190 VBD O
cDNAs BC2GM057610190 JJ O
encoding BC2GM057610190 VBG O
two BC2GM057610190 CD O
members BC2GM057610190 NNS O
of BC2GM057610190 IN O
the BC2GM057610190 DT O
small BC2GM057610190 JJ O
Maf BC2GM057610190 NNP O
family BC2GM057610190 NN O
, BC2GM057610190 , O
MafK BC2GM057610190 NNP O
and BC2GM057610190 CC O
MafG BC2GM057610190 NNP O
. BC2GM057610190 . O
. . O O

Thus BC2GM064716554 RB O
, BC2GM064716554 , O
it BC2GM064716554 PRP O
appears BC2GM064716554 VBZ O
that BC2GM064716554 IN O
moxalactam BC2GM064716554 NN O
is BC2GM064716554 VBZ O
a BC2GM064716554 DT O
reliable BC2GM064716554 JJ O
and BC2GM064716554 CC O
useful BC2GM064716554 JJ O
antibiotic BC2GM064716554 NN O
for BC2GM064716554 IN O
the BC2GM064716554 DT O
treatment BC2GM064716554 NN O
of BC2GM064716554 IN O
complicated BC2GM064716554 JJ O
urinary BC2GM064716554 JJ O
tract BC2GM064716554 NN O
infections BC2GM064716554 NNS O
. BC2GM064716554 . O
. . O O

Inspection BC2GM029654898 NN O
of BC2GM029654898 IN O
X. BC2GM029654898 NNP O
tropicalis BC2GM029654898 NN O
, BC2GM029654898 , O
mouse BC2GM029654898 NN O
and BC2GM029654898 CC O
human BC2GM029654898 JJ O
U6 BC2GM029654898 NNP O
DNA BC2GM029654898 NNP O
upstream BC2GM029654898 JJ O
sequences BC2GM029654898 NNS O
revealed BC2GM029654898 VBD O
the BC2GM029654898 DT O
presence BC2GM029654898 NN O
of BC2GM029654898 IN O
a BC2GM029654898 DT O
TATA BC2GM029654898 NNP O
box BC2GM029654898 NN O
as BC2GM029654898 RB O
well BC2GM029654898 RB O
as BC2GM029654898 IN O
of BC2GM029654898 IN O
the BC2GM029654898 DT O
proximal BC2GM029654898 NN O
and BC2GM029654898 CC O
enhancer BC2GM029654898 NN O
( BC2GM029654898 ( O
octamer BC2GM029654898 JJ O
motif BC2GM029654898 NN O
) BC2GM029654898 ) O
elements BC2GM029654898 NNS O
contained BC2GM029654898 VBN O
in BC2GM029654898 IN O
snRNA BC2GM029654898 JJ O
genes BC2GM029654898 NNS O
transcribed BC2GM029654898 VBN O
by BC2GM029654898 IN O
RNA BC2GM029654898 NNP O
polymerase BC2GM029654898 NN O
II BC2GM029654898 NNP O
. BC2GM029654898 . O
. . O O

Partial BC2GM012197912 JJ O
albinism BC2GM012197912 NN O
and BC2GM012197912 CC O
immunodeficiency BC2GM012197912 NN O
: BC2GM012197912 : O
ultrastructural BC2GM012197912 JJ O
study BC2GM012197912 NN O
of BC2GM012197912 IN O
haemophagocytosis BC2GM012197912 NN O
and BC2GM012197912 CC O
bone BC2GM012197912 NN O
marrow BC2GM012197912 NN O
erythroblasts BC2GM012197912 VBZ O
in BC2GM012197912 IN O
one BC2GM012197912 CD O
case BC2GM012197912 NN O
. BC2GM012197912 . O
. . O O

The BC2GM066811191 DT O
present BC2GM066811191 JJ O
work BC2GM066811191 NN O
represents BC2GM066811191 VBZ O
an BC2GM066811191 DT O
attempt BC2GM066811191 NN O
to BC2GM066811191 TO O
develop BC2GM066811191 VB O
a BC2GM066811191 DT O
method BC2GM066811191 NN O
for BC2GM066811191 IN O
measuring BC2GM066811191 VBG O
relative BC2GM066811191 JJ O
blood BC2GM066811191 NN O
flow BC2GM066811191 NN O
in BC2GM066811191 IN O
intestinal BC2GM066811191 JJ O
capillaries BC2GM066811191 NNS O
, BC2GM066811191 , O
by BC2GM066811191 IN O
the BC2GM066811191 DT O
use BC2GM066811191 NN O
of BC2GM066811191 IN O
sodium BC2GM066811191 NN O
fluorescein BC2GM066811191 NN O
( BC2GM066811191 ( O
Na-F BC2GM066811191 NNP O
) BC2GM066811191 ) O
as BC2GM066811191 IN O
an BC2GM066811191 DT O
indicator BC2GM066811191 NN O
substance BC2GM066811191 NN O
. BC2GM066811191 . O
. . O O

In BC2GM076159056 IN O
response BC2GM076159056 NN O
to BC2GM076159056 TO O
phosphorus BC2GM076159056 VB O
limitation BC2GM076159056 NN O
, BC2GM076159056 , O
the BC2GM076159056 DT O
fungus BC2GM076159056 NN O
Neurospora BC2GM076159056 NNP O
crassa BC2GM076159056 NN O
synthesizes BC2GM076159056 VBZ O
a BC2GM076159056 DT O
number BC2GM076159056 NN O
of BC2GM076159056 IN O
enzymes BC2GM076159056 NNS O
that BC2GM076159056 WDT O
function BC2GM076159056 VBP O
to BC2GM076159056 TO O
bring BC2GM076159056 VB O
more BC2GM076159056 JJR O
phosphate BC2GM076159056 NN O
into BC2GM076159056 IN O
the BC2GM076159056 DT O
cell BC2GM076159056 NN O
. BC2GM076159056 . O
. . O O

A BC2GM077229462 DT O
) BC2GM077229462 ) O
During BC2GM077229462 IN O
O2-ischemia BC2GM077229462 NNP O
both BC2GM077229462 DT O
extracellular BC2GM077229462 JJ O
[ BC2GM077229462 NN O
K+ BC2GM077229462 NNP O
] BC2GM077229462 NNP O
and BC2GM077229462 CC O
change BC2GM077229462 NN O
of BC2GM077229462 IN O
pH BC2GM077229462 NN O
in BC2GM077229462 IN O
the BC2GM077229462 DT O
subepicardium BC2GM077229462 NN O
are BC2GM077229462 VBP O
significantly BC2GM077229462 RB O
less BC2GM077229462 JJR O
than BC2GM077229462 IN O
in BC2GM077229462 IN O
the BC2GM077229462 DT O
midmyocardium BC2GM077229462 NN O
. BC2GM077229462 . O
. . O O

Antiserum BC2GM078078201 NNP O
raised BC2GM078078201 VBD O
against BC2GM078078201 IN O
rat BC2GM078078201 NN O
liver BC2GM078078201 NN O
S6 BC2GM078078201 NNP O
kinase BC2GM078078201 NNP O
specifically BC2GM078078201 RB O
immunoprecipitates BC2GM078078201 VBZ O
the BC2GM078078201 DT O
purified BC2GM078078201 JJ O
32P-labeled BC2GM078078201 JJ O
H4 BC2GM078078201 NNP O
hepatoma BC2GM078078201 NN O
insulin-stimulated BC2GM078078201 JJ O
S6 BC2GM078078201 NNP O
kinase BC2GM078078201 NN O
. BC2GM078078201 . O
. . O O

Kohtz BC2GM070643698 NNP O
, BC2GM070643698 , O
J BC2GM070643698 NNP O
. BC2GM070643698 . O
. . O O

A BC2GM090355952 DT O
case BC2GM090355952 NN O
report BC2GM090355952 NN O
. BC2GM090355952 . O
. . O O

Different BC2GM054786865 NNP O
clinical BC2GM054786865 JJ O
variants BC2GM054786865 NNS O
of BC2GM054786865 IN O
the BC2GM054786865 DT O
empty BC2GM054786865 JJ O
sella BC2GM054786865 NN O
turcica BC2GM054786865 NN O
syndrome BC2GM054786865 NN O
are BC2GM054786865 VBP O
demonstrated BC2GM054786865 VBN O
, BC2GM054786865 , O
including BC2GM054786865 VBG O
variants BC2GM054786865 NNS O
resultant BC2GM054786865 NN O
from BC2GM054786865 IN O
substitution BC2GM054786865 NN O
therapy BC2GM054786865 NN O
of BC2GM054786865 IN O
thyroid BC2GM054786865 JJ O
hypofunction BC2GM054786865 NN O
, BC2GM054786865 , O
from BC2GM054786865 IN O
dopamine BC2GM054786865 JJ O
agonist BC2GM054786865 NN O
therapy BC2GM054786865 NN O
for BC2GM054786865 IN O
hyperprolactinemic BC2GM054786865 JJ O
hypogonadism BC2GM054786865 NN O
, BC2GM054786865 , O
from BC2GM054786865 IN O
radiotherapy BC2GM054786865 NN O
of BC2GM054786865 IN O
hypophyseal BC2GM054786865 JJ O
adenoma BC2GM054786865 NN O
. BC2GM054786865 . O
. . O O

We BC2GM034421651 PRP O
challenge BC2GM034421651 VBP O
each BC2GM034421651 DT O
of BC2GM034421651 IN O
55 BC2GM034421651 CD O
consecutive BC2GM034421651 JJ O
ragweed BC2GM034421651 NN O
( BC2GM034421651 ( O
RW BC2GM034421651 NNP O
) BC2GM034421651 ) O
-allergic BC2GM034421651 VBD O
patients BC2GM034421651 NNS O
with BC2GM034421651 IN O
hay BC2GM034421651 JJ O
fever BC2GM034421651 NN O
and BC2GM034421651 CC O
with BC2GM034421651 IN O
graded BC2GM034421651 JJ O
increasing BC2GM034421651 VBG O
doses BC2GM034421651 NNS O
of BC2GM034421651 IN O
ragweed BC2GM034421651 NN O
extract BC2GM034421651 NN O
to BC2GM034421651 TO O
investigate BC2GM034421651 VB O
the BC2GM034421651 DT O
frequency BC2GM034421651 NN O
and BC2GM034421651 CC O
relationship BC2GM034421651 NN O
between BC2GM034421651 IN O
the BC2GM034421651 DT O
early BC2GM034421651 JJ O
( BC2GM034421651 ( O
ER BC2GM034421651 NNP O
) BC2GM034421651 ) O
, BC2GM034421651 , O
late BC2GM034421651 RB O
( BC2GM034421651 ( O
LPR BC2GM034421651 NNP O
) BC2GM034421651 ) O
, BC2GM034421651 , O
and BC2GM034421651 CC O
rechallenge BC2GM034421651 NN O
reactions BC2GM034421651 NNS O
( BC2GM034421651 ( O
RCRs BC2GM034421651 NNP O
) BC2GM034421651 ) O
to BC2GM034421651 TO O
nasal BC2GM034421651 JJ O
challenge BC2GM034421651 NN O
. BC2GM034421651 . O
. . O O

The BC2GM004628180 DT O
metalloproteinase BC2GM004628180 NN O
mediating BC2GM004628180 VBG O
Met BC2GM004628180 NNP O
cleavage BC2GM004628180 NN O
was BC2GM004628180 VBD O
specifically BC2GM004628180 RB O
inhibited BC2GM004628180 VBN O
by BC2GM004628180 IN O
the BC2GM004628180 DT O
tissue BC2GM004628180 NN O
inhibitor BC2GM004628180 NN O
of BC2GM004628180 IN O
metalloproteinases BC2GM004628180 NNS O
( BC2GM004628180 ( O
TIMP BC2GM004628180 NNP O
) BC2GM004628180 ) O
-3 BC2GM004628180 NN O
, BC2GM004628180 , O
but BC2GM004628180 CC O
not BC2GM004628180 RB O
by BC2GM004628180 IN O
TIMP-1 BC2GM004628180 NNP O
or BC2GM004628180 CC O
TIMP-2 BC2GM004628180 NNP O
. BC2GM004628180 . O
. . O O

Brome BC2GM030881541 NNP O
mosaic BC2GM030881541 PRP O
virus BC2GM030881541 VBD O
polymerase-like BC2GM030881541 JJ O
protein BC2GM030881541 NN O
2a BC2GM030881541 CD O
is BC2GM030881541 VBZ O
directed BC2GM030881541 VBN O
to BC2GM030881541 TO O
the BC2GM030881541 DT O
endoplasmic BC2GM030881541 JJ O
reticulum BC2GM030881541 NN O
by BC2GM030881541 IN O
helicase-like BC2GM030881541 JJ O
viral BC2GM030881541 JJ O
protein BC2GM030881541 NN O
1a BC2GM030881541 CD O
. BC2GM030881541 . O
. . O O

Transcriptional BC2GM050802693 JJ O
modulation BC2GM050802693 NN O
of BC2GM050802693 IN O
the BC2GM050802693 DT O
anti-apoptotic BC2GM050802693 JJ O
protein BC2GM050802693 NN O
BCL-XL BC2GM050802693 NNP O
by BC2GM050802693 IN O
the BC2GM050802693 DT O
paired BC2GM050802693 JJ O
box BC2GM050802693 NN O
transcription BC2GM050802693 NN O
factors BC2GM050802693 NNS O
PAX3 BC2GM050802693 NNP O
and BC2GM050802693 CC O
PAX3 BC2GM050802693 NNP O
/ BC2GM050802693 NNP O
FKHR BC2GM050802693 NNP O
. BC2GM050802693 . O
. . O O

We BC2GM027382651 PRP O
conclude BC2GM027382651 VBP O
, BC2GM027382651 , O
therefore BC2GM027382651 RB O
, BC2GM027382651 , O
that BC2GM027382651 IN O
in BC2GM027382651 IN O
the BC2GM027382651 DT O
absence BC2GM027382651 NN O
of BC2GM027382651 IN O
E1A BC2GM027382651 NNP O
, BC2GM027382651 , O
E4orf4 BC2GM027382651 NNP O
is BC2GM027382651 VBZ O
sufficient BC2GM027382651 JJ O
by BC2GM027382651 IN O
itself BC2GM027382651 PRP O
to BC2GM027382651 TO O
trigger BC2GM027382651 VB O
a BC2GM027382651 DT O
p53-independent BC2GM027382651 JJ O
apoptosis BC2GM027382651 NN O
pathway BC2GM027382651 NN O
that BC2GM027382651 WDT O
may BC2GM027382651 MD O
operate BC2GM027382651 VB O
independently BC2GM027382651 RB O
of BC2GM027382651 IN O
the BC2GM027382651 DT O
known BC2GM027382651 VBN O
zVAD-inhibitable BC2GM027382651 JJ O
caspases BC2GM027382651 NNS O
, BC2GM027382651 , O
and BC2GM027382651 CC O
that BC2GM027382651 DT O
may BC2GM027382651 MD O
involve BC2GM027382651 VB O
an BC2GM027382651 DT O
as BC2GM027382651 IN O
yet BC2GM027382651 RB O
uncharacterized BC2GM027382651 JJ O
mechanism BC2GM027382651 NN O
. BC2GM027382651 . O
. . O O

All BC2GM066297688 DT O
possessed BC2GM066297688 VBD O
cutaneous BC2GM066297688 JJ O
receptive BC2GM066297688 JJ O
fields BC2GM066297688 NNS O
on BC2GM066297688 IN O
the BC2GM066297688 DT O
distal BC2GM066297688 JJ O
segments BC2GM066297688 NNS O
of BC2GM066297688 IN O
digits BC2GM066297688 NNS O
2 BC2GM066297688 CD O
, BC2GM066297688 , O
3 BC2GM066297688 CD O
, BC2GM066297688 , O
or BC2GM066297688 CC O
4 BC2GM066297688 CD O
. BC2GM066297688 . O
. . O O

D BC2GM018583333 NNP O
. BC2GM018583333 . O
. . O O

The BC2GM053475151 DT O
BUR BC2GM053475151 NNP O
was BC2GM053475151 VBD O
set BC2GM053475151 VBN O
at BC2GM053475151 IN O
20 BC2GM053475151 CD O
/ BC2GM053475151 JJ O
min BC2GM053475151 NN O
and BC2GM053475151 CC O
the BC2GM053475151 DT O
IT BC2GM053475151 NNP O
at BC2GM053475151 IN O
.5 BC2GM053475151 NNP O
seconds BC2GM053475151 NNS O
. BC2GM053475151 . O
. . O O

However BC2GM086205722 RB O
, BC2GM086205722 , O
to BC2GM086205722 TO O
encourage BC2GM086205722 VB O
good BC2GM086205722 JJ O
contact BC2GM086205722 NN O
between BC2GM086205722 IN O
the BC2GM086205722 DT O
farmers BC2GM086205722 NNS O
and BC2GM086205722 CC O
the BC2GM086205722 DT O
inseminating BC2GM086205722 NN O
personnel BC2GM086205722 NNS O
, BC2GM086205722 , O
it BC2GM086205722 PRP O
is BC2GM086205722 VBZ O
beneficial BC2GM086205722 JJ O
that BC2GM086205722 IN O
herdsmen BC2GM086205722 NNS O
are BC2GM086205722 VBP O
present BC2GM086205722 JJ O
when BC2GM086205722 WRB O
cows BC2GM086205722 NNS O
are BC2GM086205722 VBP O
inseminated BC2GM086205722 VBN O
. BC2GM086205722 . O
. . O O

These BC2GM073729839 DT O
results BC2GM073729839 NNS O
suggest BC2GM073729839 VBP O
that BC2GM073729839 IN O
the BC2GM073729839 DT O
Reg1-Glc7 BC2GM073729839 NNP O
phosphatase BC2GM073729839 NN O
is BC2GM073729839 VBZ O
a BC2GM073729839 DT O
cytoplasmic BC2GM073729839 JJ O
component BC2GM073729839 NN O
of BC2GM073729839 IN O
the BC2GM073729839 DT O
machinery BC2GM073729839 NN O
responsible BC2GM073729839 JJ O
for BC2GM073729839 IN O
returning BC2GM073729839 VBG O
Snf1 BC2GM073729839 NNP O
kinase BC2GM073729839 NN O
activity BC2GM073729839 NN O
to BC2GM073729839 TO O
its BC2GM073729839 PRP$ O
basal BC2GM073729839 NN O
level BC2GM073729839 NN O
and BC2GM073729839 CC O
reestablishing BC2GM073729839 VBG O
glucose BC2GM073729839 JJ O
repression BC2GM073729839 NN O
. BC2GM073729839 . O
. . O O

This BC2GM026543710 DT O
approach BC2GM026543710 NN O
allowed BC2GM026543710 VBD O
examination BC2GM026543710 NN O
of BC2GM026543710 IN O
baseline BC2GM026543710 JJ O
factors BC2GM026543710 NNS O
as BC2GM026543710 RB O
well BC2GM026543710 RB O
as BC2GM026543710 IN O
the BC2GM026543710 DT O
effect BC2GM026543710 NN O
of BC2GM026543710 IN O
change BC2GM026543710 NN O
in BC2GM026543710 IN O
mileage BC2GM026543710 NN O
, BC2GM026543710 , O
the BC2GM026543710 DT O
occurrence BC2GM026543710 NN O
of BC2GM026543710 IN O
a BC2GM026543710 DT O
musculoskeletal BC2GM026543710 NN O
problem BC2GM026543710 NN O
, BC2GM026543710 , O
or BC2GM026543710 CC O
the BC2GM026543710 DT O
occurrence BC2GM026543710 NN O
of BC2GM026543710 IN O
another BC2GM026543710 DT O
health BC2GM026543710 NN O
problem BC2GM026543710 NN O
on BC2GM026543710 IN O
the BC2GM026543710 DT O
rate BC2GM026543710 NN O
of BC2GM026543710 IN O
dropout BC2GM026543710 NN O
. BC2GM026543710 . O
. . O O

On BC2GM056690514 IN O
average BC2GM056690514 NN O
, BC2GM056690514 , O
rCMRglc BC2GM056690514 NN O
values BC2GM056690514 NNS O
were BC2GM056690514 VBD O
23 BC2GM056690514 CD O
% BC2GM056690514 NN O
below BC2GM056690514 IN O
control BC2GM056690514 NN O
values BC2GM056690514 NNS O
for BC2GM056690514 IN O
all BC2GM056690514 DT O
regions BC2GM056690514 NNS O
studied BC2GM056690514 VBN O
, BC2GM056690514 , O
with BC2GM056690514 IN O
the BC2GM056690514 DT O
greatest BC2GM056690514 JJS O
differences BC2GM056690514 NNS O
in BC2GM056690514 IN O
posterior BC2GM056690514 JJ O
brain BC2GM056690514 NN O
regions BC2GM056690514 NNS O
( BC2GM056690514 ( O
visual BC2GM056690514 JJ O
association BC2GM056690514 NN O
cortex BC2GM056690514 NN O
, BC2GM056690514 , O
primary BC2GM056690514 JJ O
visual BC2GM056690514 JJ O
cortex BC2GM056690514 NN O
, BC2GM056690514 , O
and BC2GM056690514 CC O
parietal BC2GM056690514 JJ O
cortex BC2GM056690514 NN O
) BC2GM056690514 ) O
and BC2GM056690514 CC O
thalamus BC2GM056690514 NN O
. BC2GM056690514 . O
. . O O

The BC2GM011718637 DT O
PDSS BC2GM011718637 NNP O
identified BC2GM011718637 VBD O
17 BC2GM011718637 CD O
( BC2GM011718637 ( O
94 BC2GM011718637 CD O
% BC2GM011718637 NN O
) BC2GM011718637 ) O
of BC2GM011718637 IN O
the BC2GM011718637 DT O
women BC2GM011718637 NNS O
diagnosed BC2GM011718637 VBD O
with BC2GM011718637 IN O
major BC2GM011718637 JJ O
postpartum BC2GM011718637 NN O
depression BC2GM011718637 NN O
, BC2GM011718637 , O
the BC2GM011718637 DT O
EPDS BC2GM011718637 NNP O
identified BC2GM011718637 VBD O
14 BC2GM011718637 CD O
of BC2GM011718637 IN O
these BC2GM011718637 DT O
women BC2GM011718637 NNS O
( BC2GM011718637 ( O
78 BC2GM011718637 CD O
% BC2GM011718637 NN O
) BC2GM011718637 ) O
, BC2GM011718637 , O
and BC2GM011718637 CC O
the BC2GM011718637 DT O
BDI-II BC2GM011718637 NNP O
identified BC2GM011718637 VBD O
10 BC2GM011718637 CD O
of BC2GM011718637 IN O
the BC2GM011718637 DT O
18 BC2GM011718637 CD O
women BC2GM011718637 NNS O
( BC2GM011718637 ( O
56 BC2GM011718637 CD O
% BC2GM011718637 NN O
) BC2GM011718637 ) O
. BC2GM011718637 . O
. . O O

The BC2GM010924622 DT O
cloning BC2GM010924622 NN O
of BC2GM010924622 IN O
CWH43 BC2GM010924622 NNP O
showed BC2GM010924622 VBD O
that BC2GM010924622 IN O
it BC2GM010924622 PRP O
corresponds BC2GM010924622 VBZ O
to BC2GM010924622 TO O
YCR017c BC2GM010924622 VB O
and BC2GM010924622 CC O
encodes BC2GM010924622 VB O
a BC2GM010924622 DT O
protein BC2GM010924622 NN O
with BC2GM010924622 IN O
14-16 BC2GM010924622 JJ O
transmembrane BC2GM010924622 NN O
segments BC2GM010924622 NNS O
containing BC2GM010924622 VBG O
several BC2GM010924622 JJ O
putative BC2GM010924622 JJ O
phosphorylation BC2GM010924622 NN O
and BC2GM010924622 CC O
glycosylation BC2GM010924622 NN O
sites BC2GM010924622 NNS O
. BC2GM010924622 . O
. . O O

The BC2GM098491104 DT O
effects BC2GM098491104 NNS O
of BC2GM098491104 IN O
oxalate-containing BC2GM098491104 JJ O
products BC2GM098491104 NNS O
on BC2GM098491104 IN O
the BC2GM098491104 DT O
exposed BC2GM098491104 VBN O
dentine BC2GM098491104 NN O
surface BC2GM098491104 NN O
: BC2GM098491104 : O
an BC2GM098491104 DT O
SEM BC2GM098491104 NNP O
investigation BC2GM098491104 NN O
. BC2GM098491104 . O
. . O O

We BC2GM002757226 PRP O
have BC2GM002757226 VBP O
shown BC2GM002757226 VBN O
that BC2GM002757226 IN O
the BC2GM002757226 DT O
human BC2GM002757226 JJ O
cell BC2GM002757226 NN O
MRC BC2GM002757226 NNP O
closely BC2GM002757226 RB O
resembles BC2GM002757226 VBZ O
the BC2GM002757226 DT O
murine BC2GM002757226 NN O
cell BC2GM002757226 NN O
MRC BC2GM002757226 NNP O
, BC2GM002757226 , O
in BC2GM002757226 IN O
both BC2GM002757226 DT O
its BC2GM002757226 PRP$ O
protein BC2GM002757226 NN O
composition BC2GM002757226 NN O
and BC2GM002757226 CC O
its BC2GM002757226 PRP$ O
fractionation BC2GM002757226 NN O
and BC2GM002757226 CC O
chromatographic BC2GM002757226 JJ O
profile BC2GM002757226 NN O
. BC2GM002757226 . O
. . O O

The BC2GM032479556 DT O
frequency BC2GM032479556 NN O
of BC2GM032479556 IN O
severe BC2GM032479556 JJ O
congestive BC2GM032479556 JJ O
heart BC2GM032479556 NN O
failure BC2GM032479556 NN O
( BC2GM032479556 ( O
Killip BC2GM032479556 NNP O
class BC2GM032479556 NN O
III BC2GM032479556 NNP O
or BC2GM032479556 CC O
IV BC2GM032479556 NNP O
) BC2GM032479556 ) O
at BC2GM032479556 IN O
admission BC2GM032479556 NN O
was BC2GM032479556 VBD O
significantly BC2GM032479556 RB O
higher BC2GM032479556 JJR O
in BC2GM032479556 IN O
patients BC2GM032479556 NNS O
with BC2GM032479556 IN O
early BC2GM032479556 JJ O
presentation BC2GM032479556 NN O
, BC2GM032479556 , O
than BC2GM032479556 IN O
with BC2GM032479556 IN O
late BC2GM032479556 JJ O
presentation BC2GM032479556 NN O
( BC2GM032479556 ( O
30.7 BC2GM032479556 CD O
% BC2GM032479556 NN O
vs BC2GM032479556 JJ O
7.6 BC2GM032479556 CD O
% BC2GM032479556 NN O
, BC2GM032479556 , O
p BC2GM032479556 NN O
less BC2GM032479556 JJR O
than BC2GM032479556 IN O
0.05 BC2GM032479556 CD O
) BC2GM032479556 ) O
. BC2GM032479556 . O
. . O O

Left BC2GM068857149 NNP O
ventricular BC2GM068857149 JJ O
responses BC2GM068857149 NNS O
to BC2GM068857149 TO O
dopamine BC2GM068857149 VB O
in BC2GM068857149 IN O
dilated BC2GM068857149 JJ O
cardiomyopathy BC2GM068857149 NN O
as BC2GM068857149 IN O
assessed BC2GM068857149 VBN O
by BC2GM068857149 IN O
two-dimensional BC2GM068857149 JJ O
echocardiography BC2GM068857149 NN O
and BC2GM068857149 CC O
compared BC2GM068857149 VBN O
with BC2GM068857149 IN O
findings BC2GM068857149 NNS O
of BC2GM068857149 IN O
thallium-201 BC2GM068857149 JJ O
scintigraphy BC2GM068857149 NN O
. BC2GM068857149 . O
. . O O

Maximum BC2GM044994896 JJ O
overexpression BC2GM044994896 NN O
of BC2GM044994896 IN O
holoenzyme BC2GM044994896 NN O
activity BC2GM044994896 NN O
was BC2GM044994896 VBD O
achieved BC2GM044994896 VBN O
by BC2GM044994896 IN O
the BC2GM044994896 DT O
inclusion BC2GM044994896 NN O
in BC2GM044994896 IN O
such BC2GM044994896 JJ O
plasmids BC2GM044994896 NNS O
of BC2GM044994896 IN O
Salmonella BC2GM044994896 NNP O
typhimurium BC2GM044994896 NN O
cysG BC2GM044994896 NN O
, BC2GM044994896 , O
which BC2GM044994896 WDT O
encodes BC2GM044994896 VBZ O
a BC2GM044994896 DT O
uroporphyrinogen BC2GM044994896 JJ O
III BC2GM044994896 NNP O
methyltransferase BC2GM044994896 NN O
required BC2GM044994896 VBN O
for BC2GM044994896 IN O
the BC2GM044994896 DT O
synthesis BC2GM044994896 NN O
of BC2GM044994896 IN O
siroheme BC2GM044994896 NN O
, BC2GM044994896 , O
a BC2GM044994896 DT O
cofactor BC2GM044994896 NN O
for BC2GM044994896 IN O
the BC2GM044994896 DT O
hemoprotein BC2GM044994896 NN O
. BC2GM044994896 . O
. . O O

One BC2GM007988676 CD O
of BC2GM007988676 IN O
them BC2GM007988676 PRP O
is BC2GM007988676 VBZ O
its BC2GM007988676 PRP$ O
limited BC2GM007988676 JJ O
sensitivity BC2GM007988676 NN O
to BC2GM007988676 TO O
weak BC2GM007988676 JJ O
interactions BC2GM007988676 NNS O
, BC2GM007988676 , O
which BC2GM007988676 WDT O
are BC2GM007988676 VBP O
common BC2GM007988676 JJ O
in BC2GM007988676 IN O
the BC2GM007988676 DT O
mammalian BC2GM007988676 JJ O
cerebral BC2GM007988676 JJ O
cortex BC2GM007988676 NN O
. BC2GM007988676 . O
. . O O

Although BC2GM066709301 IN O
RAD17 BC2GM066709301 NNP O
, BC2GM066709301 , O
RAD24 BC2GM066709301 NNP O
and BC2GM066709301 CC O
MEC3 BC2GM066709301 NNP O
are BC2GM066709301 VBP O
not BC2GM066709301 RB O
required BC2GM066709301 VBN O
for BC2GM066709301 IN O
cell BC2GM066709301 NN O
cycle BC2GM066709301 NN O
arrest BC2GM066709301 NN O
when BC2GM066709301 WRB O
S BC2GM066709301 NNP O
phase BC2GM066709301 NN O
is BC2GM066709301 VBZ O
inhibited BC2GM066709301 VBN O
by BC2GM066709301 IN O
hydroxyurea BC2GM066709301 NN O
( BC2GM066709301 ( O
HU BC2GM066709301 NNP O
) BC2GM066709301 ) O
, BC2GM066709301 , O
they BC2GM066709301 PRP O
do BC2GM066709301 VBP O
contribute BC2GM066709301 VB O
to BC2GM066709301 TO O
the BC2GM066709301 DT O
viability BC2GM066709301 NN O
of BC2GM066709301 IN O
yeast BC2GM066709301 NN O
cells BC2GM066709301 NNS O
grown BC2GM066709301 VBN O
in BC2GM066709301 IN O
the BC2GM066709301 DT O
presence BC2GM066709301 NN O
of BC2GM066709301 IN O
HU BC2GM066709301 NNP O
, BC2GM066709301 , O
possibly BC2GM066709301 RB O
because BC2GM066709301 IN O
they BC2GM066709301 PRP O
are BC2GM066709301 VBP O
required BC2GM066709301 VBN O
for BC2GM066709301 IN O
the BC2GM066709301 DT O
repair BC2GM066709301 NN O
of BC2GM066709301 IN O
HU-induced BC2GM066709301 NNP O
DNA BC2GM066709301 NNP O
damage BC2GM066709301 NN O
. BC2GM066709301 . O
. . O O

Uterine BC2GM004982621 NNP O
contractions BC2GM004982621 NNS O
began BC2GM004982621 VBD O
with BC2GM004982621 IN O
a BC2GM004982621 DT O
mean BC2GM004982621 JJ O
latency BC2GM004982621 NN O
of BC2GM004982621 IN O
62 BC2GM004982621 CD O
min BC2GM004982621 NN O
in BC2GM004982621 IN O
the BC2GM004982621 DT O
PGF2 BC2GM004982621 NNP O
alpha BC2GM004982621 NN O
infused BC2GM004982621 VBD O
women BC2GM004982621 NNS O
, BC2GM004982621 , O
in BC2GM004982621 IN O
controls BC2GM004982621 NNS O
uterine BC2GM004982621 JJ O
activity BC2GM004982621 NN O
remained BC2GM004982621 VBD O
unchanged BC2GM004982621 JJ O
. BC2GM004982621 . O
. . O O

These BC2GM031237575 DT O
observations BC2GM031237575 NNS O
suggest BC2GM031237575 VBP O
that BC2GM031237575 IN O
clr4+ BC2GM031237575 NN O
and BC2GM031237575 CC O
rik1+ BC2GM031237575 NN O
must BC2GM031237575 MD O
play BC2GM031237575 VB O
a BC2GM031237575 DT O
role BC2GM031237575 NN O
in BC2GM031237575 IN O
the BC2GM031237575 DT O
assembly BC2GM031237575 NN O
of BC2GM031237575 IN O
Swi6p BC2GM031237575 NNP O
into BC2GM031237575 IN O
a BC2GM031237575 DT O
transcriptionally BC2GM031237575 RB O
silent BC2GM031237575 JJ O
, BC2GM031237575 , O
inaccessible BC2GM031237575 JJ O
chromatin BC2GM031237575 NN O
structure BC2GM031237575 NN O
at BC2GM031237575 IN O
fission BC2GM031237575 NN O
yeast BC2GM031237575 NN O
centromeres BC2GM031237575 NNS O
which BC2GM031237575 WDT O
is BC2GM031237575 VBZ O
required BC2GM031237575 VBN O
to BC2GM031237575 TO O
facilitate BC2GM031237575 VB O
interactions BC2GM031237575 NNS O
with BC2GM031237575 IN O
spindle BC2GM031237575 JJ O
microtubules BC2GM031237575 NNS O
and BC2GM031237575 CC O
to BC2GM031237575 TO O
ensure BC2GM031237575 VB O
normal BC2GM031237575 JJ O
chromosome BC2GM031237575 NN O
segregation BC2GM031237575 NN O
. BC2GM031237575 . O
. . O O

The BC2GM063796611 DT O
genes BC2GM063796611 NNS O
encoding BC2GM063796611 VBG O
these BC2GM063796611 DT O
carotenoids BC2GM063796611 NNS O
in BC2GM063796611 IN O
E. BC2GM063796611 NNP O
herbicola BC2GM063796611 NN O
Eho13 BC2GM063796611 NNP O
are BC2GM063796611 VBP O
clustered BC2GM063796611 VBN O
in BC2GM063796611 IN O
a BC2GM063796611 DT O
7 BC2GM063796611 CD O
kb BC2GM063796611 NN O
DNA BC2GM063796611 NNP O
fragment BC2GM063796611 NN O
. BC2GM063796611 . O
. . O O

Because BC2GM033321471 IN O
levels BC2GM033321471 NNS O
of BC2GM033321471 IN O
Vo2DIR BC2GM033321471 NNP O
and BC2GM033321471 CC O
Vo2INDIR BC2GM033321471 NNP O
were BC2GM033321471 VBD O
similar BC2GM033321471 JJ O
in BC2GM033321471 IN O
both BC2GM033321471 DT O
groups BC2GM033321471 NNS O
, BC2GM033321471 , O
we BC2GM033321471 PRP O
pooled BC2GM033321471 VBD O
data BC2GM033321471 NNS O
from BC2GM033321471 IN O
septic BC2GM033321471 JJ O
and BC2GM033321471 CC O
control BC2GM033321471 NN O
animals BC2GM033321471 NNS O
. BC2GM033321471 . O
. . O O

Like BC2GM087746529 IN O
Rev-Erb BC2GM087746529 NNP O
, BC2GM087746529 , O
BD73 BC2GM087746529 NNP O
binds BC2GM087746529 VBZ O
as BC2GM087746529 IN O
a BC2GM087746529 DT O
monomer BC2GM087746529 NN O
to BC2GM087746529 TO O
a BC2GM087746529 DT O
DNA BC2GM087746529 NN O
sequence BC2GM087746529 NN O
which BC2GM087746529 WDT O
consists BC2GM087746529 VBZ O
of BC2GM087746529 IN O
a BC2GM087746529 DT O
specific BC2GM087746529 NN O
A BC2GM087746529 DT O
/ BC2GM087746529 JJ O
T-rich BC2GM087746529 JJ O
sequence BC2GM087746529 NN O
upstream BC2GM087746529 NN O
of BC2GM087746529 IN O
the BC2GM087746529 DT O
consensus BC2GM087746529 NN O
hexameric BC2GM087746529 JJ O
half-site BC2GM087746529 JJ O
specified BC2GM087746529 VBN O
by BC2GM087746529 IN O
the BC2GM087746529 DT O
P BC2GM087746529 NNP O
box BC2GM087746529 NN O
of BC2GM087746529 IN O
the BC2GM087746529 DT O
DNA-binding BC2GM087746529 NNP O
domain BC2GM087746529 NN O
. BC2GM087746529 . O
. . O O

The BC2GM027086451 DT O
addition BC2GM027086451 NN O
of BC2GM027086451 IN O
novel BC2GM027086451 NN O
techniques BC2GM027086451 NNS O
, BC2GM027086451 , O
such BC2GM027086451 JJ O
as BC2GM027086451 IN O
histopathologic BC2GM027086451 JJ O
ultrastaging BC2GM027086451 NN O
, BC2GM027086451 , O
immunohistochemistry BC2GM027086451 NN O
staining BC2GM027086451 NN O
, BC2GM027086451 , O
and BC2GM027086451 CC O
reverse BC2GM027086451 VB O
transcriptase BC2GM027086451 NN O
polymerase BC2GM027086451 NN O
chain BC2GM027086451 NN O
reaction BC2GM027086451 NN O
assays BC2GM027086451 NNS O
, BC2GM027086451 , O
will BC2GM027086451 MD O
help BC2GM027086451 VB O
increase BC2GM027086451 VB O
the BC2GM027086451 DT O
accuracy BC2GM027086451 NN O
and BC2GM027086451 CC O
rate BC2GM027086451 NN O
of BC2GM027086451 IN O
detection BC2GM027086451 NN O
of BC2GM027086451 IN O
disease BC2GM027086451 NN O
. BC2GM027086451 . O
. . O O

The BC2GM010457655 DT O
blood BC2GM010457655 NN O
pressures BC2GM010457655 NNS O
in BC2GM010457655 IN O
43 BC2GM010457655 CD O
subjects BC2GM010457655 NNS O
were BC2GM010457655 VBD O
compared BC2GM010457655 VBN O
during BC2GM010457655 IN O
rapid BC2GM010457655 JJ O
weight BC2GM010457655 JJ O
loss BC2GM010457655 NN O
and BC2GM010457655 CC O
at BC2GM010457655 IN O
identical BC2GM010457655 JJ O
weights BC2GM010457655 NNS O
during BC2GM010457655 IN O
post-fast BC2GM010457655 JJ O
weight BC2GM010457655 NN O
gain BC2GM010457655 NN O
( BC2GM010457655 ( O
Study BC2GM010457655 NNP O
A BC2GM010457655 NNP O
) BC2GM010457655 ) O
. BC2GM010457655 . O
. . O O

The BC2GM052484918 DT O
reduced BC2GM052484918 JJ O
expression BC2GM052484918 NN O
caused BC2GM052484918 VBN O
by BC2GM052484918 IN O
multimerization BC2GM052484918 NN O
of BC2GM052484918 IN O
UAS2 BC2GM052484918 NNP O
in BC2GM052484918 IN O
the BC2GM052484918 DT O
native BC2GM052484918 JJ O
promoter BC2GM052484918 NN O
was BC2GM052484918 VBD O
observed BC2GM052484918 VBN O
only BC2GM052484918 RB O
in BC2GM052484918 IN O
the BC2GM052484918 DT O
presence BC2GM052484918 NN O
of BC2GM052484918 IN O
ADR1 BC2GM052484918 NNP O
. BC2GM052484918 . O
. . O O

Consistent BC2GM057852138 JJ O
with BC2GM057852138 IN O
this BC2GM057852138 DT O
observation BC2GM057852138 NN O
, BC2GM057852138 , O
introduction BC2GM057852138 NN O
of BC2GM057852138 IN O
Smad BC2GM057852138 NNP O
sites BC2GM057852138 VBZ O
into BC2GM057852138 IN O
a BC2GM057852138 DT O
TGFbeta-insensitive BC2GM057852138 JJ O
LEF1 BC2GM057852138 NNP O
/ BC2GM057852138 NNP O
TCF BC2GM057852138 NNP O
target BC2GM057852138 NN O
gene BC2GM057852138 NN O
confers BC2GM057852138 NNS O
cooperative BC2GM057852138 VBP O
TGFbeta BC2GM057852138 NNP O
and BC2GM057852138 CC O
Wnt BC2GM057852138 NNP O
responsiveness BC2GM057852138 NN O
to BC2GM057852138 TO O
the BC2GM057852138 DT O
promoter BC2GM057852138 NN O
. BC2GM057852138 . O
. . O O

Our BC2GM077069782 PRP$ O
results BC2GM077069782 NNS O
indicate BC2GM077069782 VBP O
that BC2GM077069782 IN O
GCN4 BC2GM077069782 NNP O
contains BC2GM077069782 VBZ O
two BC2GM077069782 CD O
activation BC2GM077069782 NN O
domains BC2GM077069782 NNS O
of BC2GM077069782 IN O
similar BC2GM077069782 JJ O
potency BC2GM077069782 NN O
that BC2GM077069782 WDT O
can BC2GM077069782 MD O
function BC2GM077069782 VB O
independently BC2GM077069782 RB O
to BC2GM077069782 TO O
promote BC2GM077069782 VB O
high-level BC2GM077069782 JJ O
transcription BC2GM077069782 NN O
of BC2GM077069782 IN O
the BC2GM077069782 DT O
target BC2GM077069782 NN O
genes BC2GM077069782 NNS O
HIS3 BC2GM077069782 NNP O
and BC2GM077069782 CC O
HIS4 BC2GM077069782 NNP O
. BC2GM077069782 . O
. . O O

Laparoscopic BC2GM005500521 NNP O
examination BC2GM005500521 NN O
1 BC2GM005500521 CD O
year BC2GM005500521 NN O
after BC2GM005500521 IN O
surgery BC2GM005500521 NN O
revealed BC2GM005500521 VBD O
an BC2GM005500521 DT O
enlarged BC2GM005500521 JJ O
, BC2GM005500521 , O
thin-walled BC2GM005500521 JJ O
, BC2GM005500521 , O
and BC2GM005500521 CC O
fluid-filled BC2GM005500521 JJ O
uterine BC2GM005500521 JJ O
segment BC2GM005500521 NN O
cranial BC2GM005500521 NN O
to BC2GM005500521 TO O
the BC2GM005500521 DT O
midcornus BC2GM005500521 NN O
occlusion BC2GM005500521 NN O
sites BC2GM005500521 NNS O
in BC2GM005500521 IN O
all BC2GM005500521 DT O
animals BC2GM005500521 NNS O
. BC2GM005500521 . O
. . O O

Three BC2GM022663710 CD O
of BC2GM022663710 IN O
these BC2GM022663710 DT O
positions BC2GM022663710 NNS O
are BC2GM022663710 VBP O
novel BC2GM022663710 JJ O
in BC2GM022663710 IN O
that BC2GM022663710 DT O
they BC2GM022663710 PRP O
had BC2GM022663710 VBD O
not BC2GM022663710 RB O
been BC2GM022663710 VBN O
identified BC2GM022663710 VBN O
to BC2GM022663710 TO O
be BC2GM022663710 VB O
important BC2GM022663710 JJ O
for BC2GM022663710 IN O
binding BC2GM022663710 VBG O
PC BC2GM022663710 NN O
by BC2GM022663710 IN O
previous BC2GM022663710 JJ O
crystallographic BC2GM022663710 JJ O
analysis BC2GM022663710 NN O
. BC2GM022663710 . O
. . O O

Whereas BC2GM012346343 IN O
the BC2GM012346343 DT O
sequence BC2GM012346343 NN O
of BC2GM012346343 IN O
alpha-actinin BC2GM012346343 NN O
( BC2GM012346343 ( O
Noegel BC2GM012346343 NNP O
, BC2GM012346343 , O
A. BC2GM012346343 NNP O
, BC2GM012346343 , O
W BC2GM012346343 NNP O
. BC2GM012346343 . O
. . O O

Two BC2GM076278508 CD O
hundred BC2GM076278508 CD O
and BC2GM076278508 CC O
eighty-three BC2GM076278508 JJ O
patients BC2GM076278508 NNS O
, BC2GM076278508 , O
217 BC2GM076278508 CD O
females BC2GM076278508 NNS O
( BC2GM076278508 ( O
median BC2GM076278508 JJ O
age BC2GM076278508 NN O
24 BC2GM076278508 CD O
years BC2GM076278508 NNS O
, BC2GM076278508 , O
range BC2GM076278508 VB O
0.5-73 BC2GM076278508 NNP O
) BC2GM076278508 ) O
and BC2GM076278508 CC O
66 BC2GM076278508 CD O
males BC2GM076278508 NNS O
( BC2GM076278508 ( O
median BC2GM076278508 JJ O
age BC2GM076278508 NN O
20 BC2GM076278508 CD O
years BC2GM076278508 NNS O
, BC2GM076278508 , O
range BC2GM076278508 VB O
0.75-72 BC2GM076278508 NNP O
) BC2GM076278508 ) O
, BC2GM076278508 , O
were BC2GM076278508 VBD O
examined BC2GM076278508 VBN O
. BC2GM076278508 . O
. . O O

PDGF BC2GM034695488 NNP O
stimulated BC2GM034695488 VBD O
CDK2 BC2GM034695488 NNP O
activity BC2GM034695488 NN O
in BC2GM034695488 IN O
mesangial BC2GM034695488 JJ O
cells BC2GM034695488 NNS O
and BC2GM034695488 CC O
decreased BC2GM034695488 VBD O
the BC2GM034695488 DT O
level BC2GM034695488 NN O
of BC2GM034695488 IN O
p27 BC2GM034695488 NN O
( BC2GM034695488 ( O
kip1 BC2GM034695488 NN O
) BC2GM034695488 ) O
cyclin BC2GM034695488 NN O
kinase BC2GM034695488 NN O
inhibitor BC2GM034695488 NN O
protein BC2GM034695488 NN O
. BC2GM034695488 . O
. . O O

The BC2GM035226570 DT O
rapid BC2GM035226570 JJ O
decrease BC2GM035226570 NN O
of BC2GM035226570 IN O
plasma BC2GM035226570 JJ O
potassium BC2GM035226570 NN O
during BC2GM035226570 IN O
the BC2GM035226570 DT O
first BC2GM035226570 JJ O
two BC2GM035226570 CD O
hours BC2GM035226570 NNS O
of BC2GM035226570 IN O
standard BC2GM035226570 JJ O
HD BC2GM035226570 NNP O
causes BC2GM035226570 VBZ O
a BC2GM035226570 DT O
membrane BC2GM035226570 JJ O
hyperpolarization BC2GM035226570 NN O
. BC2GM035226570 . O
. . O O

Thirty-seven BC2GM085583133 JJ O
patients BC2GM085583133 NNS O
with BC2GM085583133 IN O
severe BC2GM085583133 JJ O
temporal BC2GM085583133 JJ O
lobe BC2GM085583133 NN O
epilepsy BC2GM085583133 NN O
were BC2GM085583133 VBD O
studied BC2GM085583133 VBN O
interictally BC2GM085583133 RB O
with BC2GM085583133 IN O
[ BC2GM085583133 JJ O
18F BC2GM085583133 CD O
] BC2GM085583133 JJ O
fluorodeoxyglucose-PET BC2GM085583133 NN O
in BC2GM085583133 IN O
each BC2GM085583133 DT O
of BC2GM085583133 IN O
three BC2GM085583133 CD O
conditions BC2GM085583133 NNS O
: BC2GM085583133 : O
resting BC2GM085583133 NN O
, BC2GM085583133 , O
during BC2GM085583133 IN O
emotional BC2GM085583133 JJ O
speech BC2GM085583133 NN O
, BC2GM085583133 , O
and BC2GM085583133 CC O
while BC2GM085583133 IN O
performing BC2GM085583133 VBG O
a BC2GM085583133 DT O
visual BC2GM085583133 JJ O
recognition BC2GM085583133 NN O
task BC2GM085583133 NN O
. BC2GM085583133 . O
. . O O

To BC2GM096383167 TO O
further BC2GM096383167 RBR O
study BC2GM096383167 VB O
the BC2GM096383167 DT O
role BC2GM096383167 NN O
of BC2GM096383167 IN O
tTG BC2GM096383167 NN O
in BC2GM096383167 IN O
liver BC2GM096383167 JJ O
disease BC2GM096383167 NN O
, BC2GM096383167 , O
we BC2GM096383167 PRP O
initiated BC2GM096383167 VBD O
investigations BC2GM096383167 NNS O
into BC2GM096383167 IN O
the BC2GM096383167 DT O
effect BC2GM096383167 NN O
of BC2GM096383167 IN O
a BC2GM096383167 DT O
proinflammatory BC2GM096383167 NN O
mediator BC2GM096383167 NN O
, BC2GM096383167 , O
tumor BC2GM096383167 NN O
necrosis BC2GM096383167 NN O
factor BC2GM096383167 NN O
( BC2GM096383167 ( O
TNF BC2GM096383167 NNP O
) BC2GM096383167 ) O
-alpha BC2GM096383167 NN O
, BC2GM096383167 , O
on BC2GM096383167 IN O
tTG BC2GM096383167 NN O
activity BC2GM096383167 NN O
in BC2GM096383167 IN O
cultured BC2GM096383167 VBN O
liver BC2GM096383167 NN O
cells BC2GM096383167 NNS O
. BC2GM096383167 . O
. . O O

The BC2GM074447065 DT O
comparisons BC2GM074447065 NNS O
of BC2GM074447065 IN O
swimming BC2GM074447065 VBG O
performance BC2GM074447065 NN O
before BC2GM074447065 IN O
and BC2GM074447065 CC O
after BC2GM074447065 IN O
treatments BC2GM074447065 NNS O
with BC2GM074447065 IN O
deltamethrin BC2GM074447065 NNS O
have BC2GM074447065 VBP O
shown BC2GM074447065 VBN O
a BC2GM074447065 DT O
significant BC2GM074447065 JJ O
effect BC2GM074447065 NN O
on BC2GM074447065 IN O
locomotory BC2GM074447065 JJ O
ability BC2GM074447065 NN O
of BC2GM074447065 IN O
rainbow BC2GM074447065 NN O
trout BC2GM074447065 NN O
which BC2GM074447065 WDT O
at BC2GM074447065 IN O
the BC2GM074447065 DT O
end BC2GM074447065 NN O
of BC2GM074447065 IN O
strong BC2GM074447065 JJ O
exposure BC2GM074447065 NN O
( BC2GM074447065 ( O
e.g BC2GM074447065 NN O
. BC2GM074447065 . O
. . O O

Latex BC2GM034256968 NNP O
products BC2GM034256968 NNS O
( BC2GM034256968 ( O
gloves BC2GM034256968 NNS O
, BC2GM034256968 , O
balloons BC2GM034256968 NNS O
, BC2GM034256968 , O
and BC2GM034256968 CC O
condoms BC2GM034256968 NNS O
) BC2GM034256968 ) O
directly BC2GM034256968 RB O
bound BC2GM034256968 VBN O
IgE BC2GM034256968 NNP O
from BC2GM034256968 IN O
all BC2GM034256968 DT O
four BC2GM034256968 CD O
patients BC2GM034256968 NNS O
. BC2GM034256968 . O
. . O O

When BC2GM077013458 WRB O
labeled BC2GM077013458 VBN O
by BC2GM077013458 IN O
the BC2GM077013458 DT O
described BC2GM077013458 JJ O
method BC2GM077013458 NN O
, BC2GM077013458 , O
99mTc BC2GM077013458 CD O
on BC2GM077013458 IN O
DTPA BC2GM077013458 NNP O
coupled BC2GM077013458 VBD O
antibodies BC2GM077013458 NNS O
shows BC2GM077013458 VBZ O
instability BC2GM077013458 NN O
in BC2GM077013458 IN O
serum BC2GM077013458 NN O
but BC2GM077013458 CC O
superior BC2GM077013458 JJ O
stability BC2GM077013458 NN O
than BC2GM077013458 IN O
99mTc BC2GM077013458 CD O
on BC2GM077013458 IN O
antibodies BC2GM077013458 NNS O
without BC2GM077013458 IN O
the BC2GM077013458 DT O
attached BC2GM077013458 JJ O
DTPA BC2GM077013458 NNP O
. BC2GM077013458 . O
. . O O

Rather BC2GM016976027 RB O
than BC2GM016976027 IN O
seeking BC2GM016976027 VBG O
a BC2GM016976027 DT O
blanket BC2GM016976027 NN O
characterization BC2GM016976027 NN O
of BC2GM016976027 IN O
an BC2GM016976027 DT O
essentially BC2GM016976027 RB O
heterogeneous BC2GM016976027 JJ O
group BC2GM016976027 NN O
, BC2GM016976027 , O
it BC2GM016976027 PRP O
may BC2GM016976027 MD O
be BC2GM016976027 VB O
more BC2GM016976027 JJR O
useful BC2GM016976027 JJ O
to BC2GM016976027 TO O
consider BC2GM016976027 VB O
idiom BC2GM016976027 JJ O
comprehension BC2GM016976027 NN O
a BC2GM016976027 DT O
secondary BC2GM016976027 JJ O
manifestation BC2GM016976027 NN O
of BC2GM016976027 IN O
semantic BC2GM016976027 JJ O
and BC2GM016976027 CC O
/ BC2GM016976027 JJ O
or BC2GM016976027 CC O
pragmatic BC2GM016976027 JJ O
difficulties BC2GM016976027 NNS O
. BC2GM016976027 . O
. . O O

In BC2GM056277482 IN O
the BC2GM056277482 DT O
present BC2GM056277482 JJ O
study BC2GM056277482 NN O
we BC2GM056277482 PRP O
prospectively BC2GM056277482 RB O
compared BC2GM056277482 VBN O
side BC2GM056277482 NN O
effects BC2GM056277482 NNS O
occurring BC2GM056277482 VBG O
in BC2GM056277482 IN O
12 BC2GM056277482 CD O
patients BC2GM056277482 NNS O
after BC2GM056277482 IN O
the BC2GM056277482 DT O
first BC2GM056277482 JJ O
administration BC2GM056277482 NN O
of BC2GM056277482 IN O
low-dose BC2GM056277482 JJ O
OKT3 BC2GM056277482 NNP O
( BC2GM056277482 ( O
0.5 BC2GM056277482 CD O
mg BC2GM056277482 NN O
twice BC2GM056277482 RB O
daily BC2GM056277482 RB O
) BC2GM056277482 ) O
induction BC2GM056277482 NN O
therapy BC2GM056277482 NN O
with BC2GM056277482 IN O
those BC2GM056277482 DT O
in BC2GM056277482 IN O
10 BC2GM056277482 CD O
patients BC2GM056277482 NNS O
who BC2GM056277482 WP O
were BC2GM056277482 VBD O
treated BC2GM056277482 VBN O
with BC2GM056277482 IN O
a BC2GM056277482 DT O
conventional BC2GM056277482 JJ O
dose BC2GM056277482 NN O
of BC2GM056277482 IN O
OKT3 BC2GM056277482 NNP O
( BC2GM056277482 ( O
5 BC2GM056277482 CD O
mg BC2GM056277482 NNS O
daily BC2GM056277482 RB O
) BC2GM056277482 ) O
for BC2GM056277482 IN O
acute BC2GM056277482 JJ O
rejection BC2GM056277482 NN O
. BC2GM056277482 . O
. . O O

Concentrations BC2GM081703119 NNS O
of BC2GM081703119 IN O
platelet BC2GM081703119 NN O
nitrite BC2GM081703119 NN O
and BC2GM081703119 CC O
total BC2GM081703119 JJ O
nitrate BC2GM081703119 NN O
/ BC2GM081703119 NNP O
nitrite BC2GM081703119 NN O
were BC2GM081703119 VBD O
determined BC2GM081703119 VBN O
using BC2GM081703119 VBG O
simple BC2GM081703119 JJ O
and BC2GM081703119 CC O
sensitive BC2GM081703119 JJ O
nitrate BC2GM081703119 NN O
/ BC2GM081703119 NNP O
nitrite BC2GM081703119 RB O
fluorometric BC2GM081703119 JJ O
assay BC2GM081703119 NN O
techniques BC2GM081703119 NNS O
. BC2GM081703119 . O
. . O O

When BC2GM018593064 WRB O
a BC2GM018593064 DT O
longer BC2GM018593064 RBR O
-714 BC2GM018593064 NN O
to BC2GM018593064 TO O
+78 BC2GM018593064 VB O
fragment BC2GM018593064 NN O
of BC2GM018593064 IN O
the BC2GM018593064 DT O
PBGD BC2GM018593064 NNP O
promoter BC2GM018593064 NN O
is BC2GM018593064 VBZ O
used BC2GM018593064 VBN O
, BC2GM018593064 , O
the BC2GM018593064 DT O
-70 BC2GM018593064 NNP O
GATA BC2GM018593064 NNP O
mutant BC2GM018593064 NN O
still BC2GM018593064 RB O
displays BC2GM018593064 VBZ O
erythroid-specific BC2GM018593064 JJ O
activity BC2GM018593064 NN O
and BC2GM018593064 CC O
is BC2GM018593064 VBZ O
cis-activated BC2GM018593064 VBN O
by BC2GM018593064 IN O
the BC2GM018593064 DT O
5'HS-2 BC2GM018593064 JJ O
enhancer BC2GM018593064 NN O
, BC2GM018593064 , O
while BC2GM018593064 IN O
the BC2GM018593064 DT O
-100 BC2GM018593064 NNP O
CCACC BC2GM018593064 NNP O
mutant BC2GM018593064 NN O
is BC2GM018593064 VBZ O
completely BC2GM018593064 RB O
inactive BC2GM018593064 JJ O
in BC2GM018593064 IN O
the BC2GM018593064 DT O
absence BC2GM018593064 NN O
or BC2GM018593064 CC O
in BC2GM018593064 IN O
the BC2GM018593064 DT O
presence BC2GM018593064 NN O
of BC2GM018593064 IN O
the BC2GM018593064 DT O
5'HS-2 BC2GM018593064 JJ O
enhancer BC2GM018593064 NN O
. BC2GM018593064 . O
. . O O

We BC2GM024572595 PRP O
found BC2GM024572595 VBD O
a BC2GM024572595 DT O
significant BC2GM024572595 JJ O
increase BC2GM024572595 NN O
of BC2GM024572595 IN O
thromboxane BC2GM024572595 NN O
as BC2GM024572595 IN O
evidenced BC2GM024572595 VBN O
by BC2GM024572595 IN O
the BC2GM024572595 DT O
major BC2GM024572595 JJ O
urinary BC2GM024572595 JJ O
metabolite BC2GM024572595 NN O
2,3-dinorthromboxane BC2GM024572595 JJ O
B2 BC2GM024572595 NNP O
in BC2GM024572595 IN O
the BC2GM024572595 DT O
oestrogen BC2GM024572595 NN O
group BC2GM024572595 NN O
as BC2GM024572595 IN O
compared BC2GM024572595 VBN O
to BC2GM024572595 TO O
the BC2GM024572595 DT O
orchidectomy BC2GM024572595 NN O
group BC2GM024572595 NN O
. BC2GM024572595 . O
. . O O

The BC2GM073564937 DT O
local BC2GM073564937 JJ O
median BC2GM073564937 NN O
scores BC2GM073564937 NNS O
( BC2GM073564937 ( O
ranges BC2GM073564937 NNS O
) BC2GM073564937 ) O
of BC2GM073564937 IN O
the BC2GM073564937 DT O
above BC2GM073564937 JJ O
tests BC2GM073564937 NNS O
were BC2GM073564937 VBD O
as BC2GM073564937 IN O
follows-AMT BC2GM073564937 JJ O
: BC2GM073564937 : O
9 BC2GM073564937 CD O
( BC2GM073564937 ( O
6-10 BC2GM073564937 JJ O
) BC2GM073564937 ) O
; BC2GM073564937 : O
CMMS BC2GM073564937 NNP O
: BC2GM073564937 : O
25 BC2GM073564937 CD O
( BC2GM073564937 ( O
16-28 BC2GM073564937 JJ O
) BC2GM073564937 ) O
; BC2GM073564937 : O
SBT BC2GM073564937 NNP O
: BC2GM073564937 : O
2 BC2GM073564937 CD O
( BC2GM073564937 ( O
0-10 BC2GM073564937 JJ O
) BC2GM073564937 ) O
; BC2GM073564937 : O
WL-i BC2GM073564937 JJ O
: BC2GM073564937 : O
17 BC2GM073564937 CD O
( BC2GM073564937 ( O
8-27 BC2GM073564937 CD O
) BC2GM073564937 ) O
; BC2GM073564937 : O
WL-d BC2GM073564937 JJ O
: BC2GM073564937 : O
5 BC2GM073564937 CD O
( BC2GM073564937 ( O
0-10 BC2GM073564937 JJ O
) BC2GM073564937 ) O
; BC2GM073564937 : O
WL-r BC2GM073564937 JJ O
: BC2GM073564937 : O
9 BC2GM073564937 CD O
( BC2GM073564937 ( O
1-10 BC2GM073564937 JJ O
) BC2GM073564937 ) O
; BC2GM073564937 : O
ST BC2GM073564937 NNP O
: BC2GM073564937 : O
13 BC2GM073564937 CD O
( BC2GM073564937 ( O
6-25 BC2GM073564937 JJ O
) BC2GM073564937 ) O
; BC2GM073564937 : O
BNT BC2GM073564937 NNP O
: BC2GM073564937 : O
14 BC2GM073564937 CD O
( BC2GM073564937 ( O
10-15 BC2GM073564937 CD O
) BC2GM073564937 ) O
; BC2GM073564937 : O
CPT BC2GM073564937 NNP O
: BC2GM073564937 : O
1 BC2GM073564937 CD O
( BC2GM073564937 ( O
0-3 BC2GM073564937 JJ O
) BC2GM073564937 ) O
; BC2GM073564937 : O
BDT BC2GM073564937 NNP O
: BC2GM073564937 : O
19 BC2GM073564937 CD O
( BC2GM073564937 ( O
0-42 BC2GM073564937 JJ O
) BC2GM073564937 ) O
; BC2GM073564937 : O
OAT BC2GM073564937 NNP O
: BC2GM073564937 : O
20 BC2GM073564937 CD O
( BC2GM073564937 ( O
3-33 BC2GM073564937 JJ O
) BC2GM073564937 ) O
. BC2GM073564937 . O
. . O O

This BC2GM004233255 DT O
regimen BC2GM004233255 NN O
may BC2GM004233255 MD O
be BC2GM004233255 VB O
considered BC2GM004233255 VBN O
front-line BC2GM004233255 JJ O
therapy BC2GM004233255 NN O
when BC2GM004233255 WRB O
autologous BC2GM004233255 JJ O
stem BC2GM004233255 NN O
cell BC2GM004233255 NN O
transplantation BC2GM004233255 NN O
is BC2GM004233255 VBZ O
not BC2GM004233255 RB O
feasible BC2GM004233255 JJ O
and BC2GM004233255 CC O
when BC2GM004233255 WRB O
a BC2GM004233255 DT O
rapid BC2GM004233255 JJ O
response BC2GM004233255 NN O
is BC2GM004233255 VBZ O
particularly BC2GM004233255 RB O
important BC2GM004233255 JJ O
. BC2GM004233255 . O
. . O O

This BC2GM038625120 DT O
integration BC2GM038625120 NN O
results BC2GM038625120 NNS O
in BC2GM038625120 IN O
the BC2GM038625120 DT O
production BC2GM038625120 NN O
of BC2GM038625120 IN O
MMTV BC2GM038625120 NNP O
/ BC2GM038625120 NNP O
mdr3 BC2GM038625120 POS O
fusion BC2GM038625120 NN O
transcripts BC2GM038625120 NNS O
that BC2GM038625120 WDT O
originate BC2GM038625120 VBP O
from BC2GM038625120 IN O
the BC2GM038625120 DT O
antisense BC2GM038625120 JJ O
5'LTR BC2GM038625120 CD O
of BC2GM038625120 IN O
the BC2GM038625120 DT O
provirus BC2GM038625120 NN O
. BC2GM038625120 . O
. . O O

In BC2GM044336863 IN O
this BC2GM044336863 DT O
study BC2GM044336863 NN O
, BC2GM044336863 , O
we BC2GM044336863 PRP O
verified BC2GM044336863 VBD O
that BC2GM044336863 IN O
PI BC2GM044336863 NNP O
3-kinase BC2GM044336863 JJ O
associates BC2GM044336863 NNS O
with BC2GM044336863 IN O
the BC2GM044336863 DT O
CD4 BC2GM044336863 NNP O
: BC2GM044336863 : O
p56lck BC2GM044336863 NN O
complex BC2GM044336863 NN O
as BC2GM044336863 IN O
judged BC2GM044336863 VBN O
by BC2GM044336863 IN O
the BC2GM044336863 DT O
presence BC2GM044336863 NN O
of BC2GM044336863 IN O
PI BC2GM044336863 NNP O
3-phosphate BC2GM044336863 JJ O
generated BC2GM044336863 VBD O
from BC2GM044336863 IN O
anti-CD4 BC2GM044336863 JJ O
immunoprecipitates BC2GM044336863 NNS O
and BC2GM044336863 CC O
detected BC2GM044336863 VBN O
by BC2GM044336863 IN O
high-pressure BC2GM044336863 NN O
liquid BC2GM044336863 NN O
chromatographic BC2GM044336863 JJ O
analysis BC2GM044336863 NN O
. BC2GM044336863 . O
. . O O

During BC2GM030320745 IN O
each BC2GM030320745 DT O
step BC2GM030320745 NN O
of BC2GM030320745 IN O
the BC2GM030320745 DT O
pulse BC2GM030320745 JJ O
infusion BC2GM030320745 NN O
the BC2GM030320745 DT O
osteocalcin BC2GM030320745 NN O
responses BC2GM030320745 VBZ O
to BC2GM030320745 TO O
changes BC2GM030320745 NNS O
in BC2GM030320745 IN O
CaI BC2GM030320745 NNP O
in BC2GM030320745 IN O
general BC2GM030320745 JJ O
were BC2GM030320745 VBD O
parallel BC2GM030320745 JJ O
to BC2GM030320745 TO O
the BC2GM030320745 DT O
changes BC2GM030320745 NNS O
in BC2GM030320745 IN O
PTH BC2GM030320745 NNP O
( BC2GM030320745 ( O
r BC2GM030320745 VB O
= BC2GM030320745 RB O
0.462 BC2GM030320745 CD O
; BC2GM030320745 : O
P BC2GM030320745 NNP O
= BC2GM030320745 NNP O
0.02 BC2GM030320745 CD O
) BC2GM030320745 ) O
and BC2GM030320745 CC O
were BC2GM030320745 VBD O
inversely BC2GM030320745 RB O
correlated BC2GM030320745 VBN O
to BC2GM030320745 TO O
CaI BC2GM030320745 NNP O
( BC2GM030320745 ( O
r BC2GM030320745 NN O
= BC2GM030320745 NNP O
-0.562 BC2GM030320745 NNP O
; BC2GM030320745 : O
P BC2GM030320745 NNP O
= BC2GM030320745 NNP O
0.003 BC2GM030320745 CD O
) BC2GM030320745 ) O
. BC2GM030320745 . O
. . O O

Significantly BC2GM092754644 RB O
higher BC2GM092754644 JJR O
levels BC2GM092754644 NNS O
of BC2GM092754644 IN O
vitamin BC2GM092754644 NN O
C BC2GM092754644 NNP O
and BC2GM092754644 CC O
catalase BC2GM092754644 NN O
activity BC2GM092754644 NN O
were BC2GM092754644 VBD O
found BC2GM092754644 VBN O
in BC2GM092754644 IN O
vegetarians BC2GM092754644 NNS O
( BC2GM092754644 ( O
C-63.6 BC2GM092754644 NNP O
and BC2GM092754644 CC O
86.5 BC2GM092754644 CD O
mumol BC2GM092754644 NN O
/ BC2GM092754644 NNP O
l BC2GM092754644 NN O
; BC2GM092754644 : O
CAT-1497 BC2GM092754644 NNP O
and BC2GM092754644 CC O
1313 BC2GM092754644 CD O
U BC2GM092754644 NNP O
/ BC2GM092754644 NNP O
ml BC2GM092754644 NN O
for BC2GM092754644 IN O
males BC2GM092754644 NNS O
and BC2GM092754644 CC O
females BC2GM092754644 NNS O
, BC2GM092754644 , O
respectively BC2GM092754644 RB O
) BC2GM092754644 ) O
when BC2GM092754644 WRB O
compared BC2GM092754644 VBN O
to BC2GM092754644 TO O
nonvegetarians BC2GM092754644 NNS O
( BC2GM092754644 ( O
C-41.3 BC2GM092754644 NNP O
and BC2GM092754644 CC O
54.4 BC2GM092754644 CD O
mumol BC2GM092754644 NN O
/ BC2GM092754644 NNP O
l BC2GM092754644 NN O
; BC2GM092754644 : O
CAT-1192 BC2GM092754644 NNP O
and BC2GM092754644 CC O
1086 BC2GM092754644 CD O
U BC2GM092754644 NNP O
/ BC2GM092754644 NNP O
ml BC2GM092754644 NN O
) BC2GM092754644 ) O
. BC2GM092754644 . O
. . O O

Student BC2GM001302183 NN O
health BC2GM001302183 NN O
. BC2GM001302183 . O
. . O O

Exhaled BC2GM067195317 VBD O
NO BC2GM067195317 DT O
was BC2GM067195317 VBD O
assessed BC2GM067195317 VBN O
by BC2GM067195317 IN O
controlled-flow BC2GM067195317 JJ O
chemoluminescence BC2GM067195317 NN O
after BC2GM067195317 IN O
adjusting BC2GM067195317 VBG O
for BC2GM067195317 IN O
trapped BC2GM067195317 VBN O
air BC2GM067195317 NN O
and BC2GM067195317 CC O
after BC2GM067195317 IN O
generating BC2GM067195317 VBG O
pressure BC2GM067195317 NN O
in BC2GM067195317 IN O
the BC2GM067195317 DT O
oral BC2GM067195317 JJ O
cavity BC2GM067195317 NN O
that BC2GM067195317 WDT O
was BC2GM067195317 VBD O
sufficient BC2GM067195317 JJ O
to BC2GM067195317 TO O
close BC2GM067195317 VB O
the BC2GM067195317 DT O
soft BC2GM067195317 JJ O
palate BC2GM067195317 NN O
( BC2GM067195317 ( O
Eco BC2GM067195317 NNP O
Physics BC2GM067195317 NNP O
CLD BC2GM067195317 NNP O
77 BC2GM067195317 CD O
AM BC2GM067195317 NNP O
analyzer BC2GM067195317 NN O
) BC2GM067195317 ) O
. BC2GM067195317 . O
. . O O

The BC2GM052397745 DT O
first BC2GM052397745 JJ O
270 BC2GM052397745 CD O
bp BC2GM052397745 NN O
of BC2GM052397745 IN O
the BC2GM052397745 DT O
promoter BC2GM052397745 NN O
region BC2GM052397745 NN O
were BC2GM052397745 VBD O
sequenced BC2GM052397745 VBN O
and BC2GM052397745 CC O
found BC2GM052397745 VBN O
to BC2GM052397745 TO O
contain BC2GM052397745 VB O
a BC2GM052397745 DT O
CATAA BC2GM052397745 NNP O
box BC2GM052397745 NN O
rather BC2GM052397745 RB O
than BC2GM052397745 IN O
a BC2GM052397745 DT O
TATAA BC2GM052397745 NNP O
box BC2GM052397745 NN O
and BC2GM052397745 CC O
several BC2GM052397745 JJ O
DNA BC2GM052397745 NNP O
motifs BC2GM052397745 NNS O
found BC2GM052397745 VBD O
in BC2GM052397745 IN O
activation BC2GM052397745 NN O
genes BC2GM052397745 NNS O
. BC2GM052397745 . O
. . O O

GH BC2GM075378170 NNP O
induced BC2GM075378170 VBD O
rapid BC2GM075378170 JJ O
tyrosine BC2GM075378170 JJ O
phosphorylation BC2GM075378170 NN O
of BC2GM075378170 IN O
a BC2GM075378170 DT O
protein BC2GM075378170 NN O
at BC2GM075378170 IN O
approximately BC2GM075378170 RB O
93 BC2GM075378170 CD O
kDa BC2GM075378170 NNS O
in BC2GM075378170 IN O
normal BC2GM075378170 JJ O
fibroblasts BC2GM075378170 NNS O
, BC2GM075378170 , O
and BC2GM075378170 CC O
Western BC2GM075378170 JJ O
blotting BC2GM075378170 VBG O
with BC2GM075378170 IN O
STAT-specific BC2GM075378170 NNP O
antibodies BC2GM075378170 NNS O
revealed BC2GM075378170 VBD O
STAT5 BC2GM075378170 NNP O
activation BC2GM075378170 NN O
( BC2GM075378170 ( O
phosphorylation BC2GM075378170 NN O
) BC2GM075378170 ) O
by BC2GM075378170 IN O
GH BC2GM075378170 NNP O
. BC2GM075378170 . O
. . O O

In BC2GM099614397 IN O
human BC2GM099614397 JJ O
myxoid BC2GM099614397 NN O
liposarcoma BC2GM099614397 NN O
, BC2GM099614397 , O
a BC2GM099614397 DT O
chromosomal BC2GM099614397 JJ O
rearrangement BC2GM099614397 NN O
leads BC2GM099614397 VBZ O
to BC2GM099614397 TO O
fusion BC2GM099614397 NN O
of BC2GM099614397 IN O
the BC2GM099614397 DT O
growth-arresting BC2GM099614397 JJ O
and BC2GM099614397 CC O
DNA-damage-inducible BC2GM099614397 JJ O
transcription BC2GM099614397 NN O
factor BC2GM099614397 NN O
CHOP BC2GM099614397 NNP O
( BC2GM099614397 ( O
GADD153 BC2GM099614397 NNP O
) BC2GM099614397 ) O
to BC2GM099614397 TO O
a BC2GM099614397 DT O
peptide BC2GM099614397 JJ O
fragment BC2GM099614397 NN O
encoded BC2GM099614397 VBN O
by BC2GM099614397 IN O
the BC2GM099614397 DT O
TLS BC2GM099614397 NNP O
gene BC2GM099614397 NN O
. BC2GM099614397 . O
. . O O

The BC2GM005608882 DT O
structure BC2GM005608882 NN O
of BC2GM005608882 IN O
the BC2GM005608882 DT O
mAR BC2GM005608882 NN O
ORF BC2GM005608882 NNP O
was BC2GM005608882 VBD O
confirmed BC2GM005608882 VBN O
by BC2GM005608882 IN O
sequence BC2GM005608882 NN O
analysis BC2GM005608882 NN O
of BC2GM005608882 IN O
mAR BC2GM005608882 NN O
cDNA BC2GM005608882 NN O
fragments BC2GM005608882 NNS O
, BC2GM005608882 , O
which BC2GM005608882 WDT O
were BC2GM005608882 VBD O
obtained BC2GM005608882 VBN O
by BC2GM005608882 IN O
PCR BC2GM005608882 NNP O
amplification BC2GM005608882 NN O
of BC2GM005608882 IN O
mouse BC2GM005608882 NN O
testis BC2GM005608882 NN O
cDNA BC2GM005608882 NN O
, BC2GM005608882 , O
using BC2GM005608882 VBG O
mAR BC2GM005608882 NN O
specific BC2GM005608882 JJ O
primers BC2GM005608882 NNS O
. BC2GM005608882 . O
. . O O

Therapeutic BC2GM047781166 JJ O
iodine BC2GM047781166 NN O
125 BC2GM047781166 CD O
for BC2GM047781166 IN O
hyperthyroidism BC2GM047781166 NN O
: BC2GM047781166 : O
evidence BC2GM047781166 NN O
for BC2GM047781166 IN O
a BC2GM047781166 DT O
special BC2GM047781166 JJ O
radiobiological BC2GM047781166 JJ O
effect BC2GM047781166 NN O
on BC2GM047781166 IN O
the BC2GM047781166 DT O
follicular BC2GM047781166 JJ O
cell BC2GM047781166 NN O
. BC2GM047781166 . O
. . O O

Three BC2GM042907506 CD O
RasV12 BC2GM042907506 NNP O
mutants BC2GM042907506 NNS O
( BC2GM042907506 ( O
S35 BC2GM042907506 NNP O
, BC2GM042907506 , O
G37 BC2GM042907506 NNP O
, BC2GM042907506 , O
and BC2GM042907506 CC O
C40 BC2GM042907506 NNP O
) BC2GM042907506 ) O
which BC2GM042907506 WDT O
differ BC2GM042907506 VBP O
by BC2GM042907506 IN O
their BC2GM042907506 PRP$ O
ability BC2GM042907506 NN O
to BC2GM042907506 TO O
bind BC2GM042907506 VB O
to BC2GM042907506 TO O
Ras BC2GM042907506 NNP O
effectors BC2GM042907506 NNS O
( BC2GM042907506 ( O
Raf BC2GM042907506 NNP O
, BC2GM042907506 , O
Ral-GEFs BC2GM042907506 NNP O
, BC2GM042907506 , O
and BC2GM042907506 CC O
the BC2GM042907506 DT O
p110 BC2GM042907506 JJ O
subunit BC2GM042907506 NN O
of BC2GM042907506 IN O
PI BC2GM042907506 NNP O
3-kinase BC2GM042907506 NNP O
, BC2GM042907506 , O
respectively BC2GM042907506 RB O
) BC2GM042907506 ) O
were BC2GM042907506 VBD O
able BC2GM042907506 JJ O
to BC2GM042907506 TO O
induce BC2GM042907506 VB O
sustained BC2GM042907506 JJ O
NR BC2GM042907506 NNP O
cell BC2GM042907506 NN O
proliferation BC2GM042907506 NN O
, BC2GM042907506 , O
although BC2GM042907506 IN O
none BC2GM042907506 NN O
of BC2GM042907506 IN O
these BC2GM042907506 DT O
mutants BC2GM042907506 NNS O
was BC2GM042907506 VBD O
reported BC2GM042907506 VBN O
to BC2GM042907506 TO O
transform BC2GM042907506 VB O
NIH BC2GM042907506 NNP O
3T3 BC2GM042907506 CD O
cells BC2GM042907506 NNS O
. BC2GM042907506 . O
. . O O

The BC2GM024845152 DT O
S. BC2GM024845152 NNP O
typhimurium BC2GM024845152 NN O
aspartyl BC2GM024845152 NN O
/ BC2GM024845152 NNP O
asparaginyl BC2GM024845152 VBZ O
beta-hydroxylase BC2GM024845152 NN O
homologue BC2GM024845152 NN O
( BC2GM024845152 ( O
designated BC2GM024845152 VBN O
lpxO BC2GM024845152 NN O
) BC2GM024845152 ) O
was BC2GM024845152 VBD O
cloned BC2GM024845152 VBN O
into BC2GM024845152 IN O
pBluescriptSK BC2GM024845152 NN O
and BC2GM024845152 CC O
expressed BC2GM024845152 VBN O
in BC2GM024845152 IN O
Escherichia BC2GM024845152 NNP O
coli BC2GM024845152 JJ O
K-12 BC2GM024845152 NNP O
, BC2GM024845152 , O
which BC2GM024845152 WDT O
does BC2GM024845152 VBZ O
not BC2GM024845152 RB O
contain BC2GM024845152 VB O
lpxO BC2GM024845152 NN O
. BC2GM024845152 . O
. . O O

The BC2GM040090407 DT O
other BC2GM040090407 JJ O
end BC2GM040090407 NN O
of BC2GM040090407 IN O
this BC2GM040090407 DT O
cluster BC2GM040090407 NN O
contained BC2GM040090407 VBD O
the BC2GM040090407 DT O
human BC2GM040090407 JJ O
type BC2GM040090407 NN O
I BC2GM040090407 PRP O
cytokeratin BC2GM040090407 VBP O
K20 BC2GM040090407 NNP O
and BC2GM040090407 CC O
K12 BC2GM040090407 NNP O
gene BC2GM040090407 NN O
loci BC2GM040090407 NN O
. BC2GM040090407 . O
. . O O

Sodium BC2GM010869565 NN O
dodecylsulfate BC2GM010869565 NN O
polyacrylamide BC2GM010869565 NN O
gel BC2GM010869565 NN O
electrophoresis BC2GM010869565 NN O
( BC2GM010869565 ( O
SDS-PAGE BC2GM010869565 NNP O
) BC2GM010869565 ) O
showed BC2GM010869565 VBD O
two BC2GM010869565 CD O
bands BC2GM010869565 NNS O
of BC2GM010869565 IN O
about BC2GM010869565 IN O
the BC2GM010869565 DT O
same BC2GM010869565 JJ O
intensity BC2GM010869565 NN O
with BC2GM010869565 IN O
apparent BC2GM010869565 JJ O
molecular BC2GM010869565 JJ O
masses BC2GM010869565 NNS O
of BC2GM010869565 IN O
24.5 BC2GM010869565 CD O
and BC2GM010869565 CC O
22.5 BC2GM010869565 CD O
kDa BC2GM010869565 NN O
. BC2GM010869565 . O
. . O O

Multiple BC2GM054625415 JJ O
attempts BC2GM054625415 NNS O
aimed BC2GM054625415 VBN O
at BC2GM054625415 IN O
disruption BC2GM054625415 NN O
of BC2GM054625415 IN O
the BC2GM054625415 DT O
chromosomal BC2GM054625415 JJ O
fabG BC2GM054625415 JJ O
gene BC2GM054625415 NN O
were BC2GM054625415 VBD O
unsuccessful BC2GM054625415 JJ O
. BC2GM054625415 . O
. . O O

A BC2GM049920668 DT O
gene BC2GM049920668 NN O
( BC2GM049920668 ( O
FMR-1 BC2GM049920668 NNP O
) BC2GM049920668 ) O
was BC2GM049920668 VBD O
identified BC2GM049920668 VBN O
within BC2GM049920668 IN O
a BC2GM049920668 DT O
four BC2GM049920668 CD O
cosmid BC2GM049920668 NN O
contig BC2GM049920668 NN O
of BC2GM049920668 IN O
YAC BC2GM049920668 NNP O
DNA BC2GM049920668 NNP O
that BC2GM049920668 WDT O
expresses BC2GM049920668 VBZ O
a BC2GM049920668 DT O
4.8 BC2GM049920668 CD O
kb BC2GM049920668 NN O
message BC2GM049920668 NN O
in BC2GM049920668 IN O
human BC2GM049920668 JJ O
brain BC2GM049920668 NN O
. BC2GM049920668 . O
. . O O

The BC2GM038764825 DT O
NS-2 BC2GM038764825 JJ O
isoforms BC2GM038764825 NNS O
were BC2GM038764825 VBD O
resolved BC2GM038764825 VBN O
at BC2GM038764825 IN O
a BC2GM038764825 DT O
pI BC2GM038764825 NN O
value BC2GM038764825 NN O
close BC2GM038764825 RB O
to BC2GM038764825 TO O
5.5 BC2GM038764825 CD O
as BC2GM038764825 IN O
three BC2GM038764825 CD O
groups BC2GM038764825 NNS O
of BC2GM038764825 IN O
unevenly BC2GM038764825 RB O
phosphorylated BC2GM038764825 VBN O
polypeptides BC2GM038764825 NNS O
, BC2GM038764825 , O
each BC2GM038764825 DT O
composed BC2GM038764825 VBN O
of BC2GM038764825 IN O
at BC2GM038764825 IN O
least BC2GM038764825 JJS O
two BC2GM038764825 CD O
protein BC2GM038764825 JJ O
species BC2GM038764825 NNS O
. BC2GM038764825 . O
. . O O

CONCLUSIONS BC2GM078755837 NN O
: BC2GM078755837 : O
Elevation BC2GM078755837 NN O
of BC2GM078755837 IN O
TBARS BC2GM078755837 NNP O
and BC2GM078755837 CC O
decrease BC2GM078755837 NN O
of BC2GM078755837 IN O
GSH BC2GM078755837 NNP O
show BC2GM078755837 VBP O
the BC2GM078755837 DT O
presence BC2GM078755837 NN O
of BC2GM078755837 IN O
oxidative BC2GM078755837 JJ O
stress BC2GM078755837 NN O
during BC2GM078755837 IN O
the BC2GM078755837 DT O
PFD BC2GM078755837 NNP O
treatment BC2GM078755837 NN O
with BC2GM078755837 IN O
hemodiafilter BC2GM078755837 NN O
SG3 BC2GM078755837 NNP O
. BC2GM078755837 . O
. . O O

The BC2GM040414983 DT O
effect BC2GM040414983 NN O
of BC2GM040414983 IN O
monaural BC2GM040414983 JJ O
middle BC2GM040414983 JJ O
ear BC2GM040414983 JJ O
destruction BC2GM040414983 NN O
on BC2GM040414983 IN O
postnatal BC2GM040414983 JJ O
development BC2GM040414983 NN O
of BC2GM040414983 IN O
mouse BC2GM040414983 NN O
inferior BC2GM040414983 JJ O
colliculus BC2GM040414983 NN O
. BC2GM040414983 . O
. . O O

The BC2GM040414744 DT O
isoproterenol BC2GM040414744 JJ O
infusion BC2GM040414744 NN O
was BC2GM040414744 VBD O
adjusted BC2GM040414744 VBN O
so BC2GM040414744 RB O
that BC2GM040414744 IN O
heart BC2GM040414744 NN O
rate BC2GM040414744 NN O
( BC2GM040414744 ( O
HR BC2GM040414744 NNP O
) BC2GM040414744 ) O
was BC2GM040414744 VBD O
at BC2GM040414744 IN O
least BC2GM040414744 JJS O
30 BC2GM040414744 CD O
beats BC2GM040414744 NNS O
/ BC2GM040414744 VBP O
min BC2GM040414744 RB O
greater BC2GM040414744 JJR O
than BC2GM040414744 IN O
baseline BC2GM040414744 NN O
. BC2GM040414744 . O
. . O O

A BC2GM071079182 DT O
comparison BC2GM071079182 NN O
between BC2GM071079182 IN O
attenuation-corrected BC2GM071079182 JJ O
and BC2GM071079182 CC O
-uncorrected BC2GM071079182 JJ O
transmission-emission BC2GM071079182 NN O
SPECT BC2GM071079182 NNP O
images BC2GM071079182 NNS O
obtained BC2GM071079182 VBN O
with BC2GM071079182 IN O
Tl-201 BC2GM071079182 NNP O
in BC2GM071079182 IN O
CAD BC2GM071079182 NNP O
patients BC2GM071079182 NNS O
. BC2GM071079182 . O
. . O O

METHODS BC2GM094635943 NN O
: BC2GM094635943 : O
The BC2GM094635943 DT O
prevalence BC2GM094635943 NN O
of BC2GM094635943 IN O
haemagglutination BC2GM094635943 NN O
inhibiting BC2GM094635943 NN O
( BC2GM094635943 ( O
HI BC2GM094635943 NNP O
) BC2GM094635943 ) O
antibodies BC2GM094635943 VBZ O
to BC2GM094635943 TO O
JE BC2GM094635943 NNP O
virus BC2GM094635943 NN O
( BC2GM094635943 ( O
JEV BC2GM094635943 NNP O
) BC2GM094635943 ) O
, BC2GM094635943 , O
West BC2GM094635943 NNP O
Nile BC2GM094635943 NNP O
virus BC2GM094635943 NN O
( BC2GM094635943 ( O
WNV BC2GM094635943 NNP O
) BC2GM094635943 ) O
and BC2GM094635943 CC O
dengue-2 BC2GM094635943 JJ O
virus BC2GM094635943 NN O
( BC2GM094635943 ( O
DEN-2 BC2GM094635943 NNP O
) BC2GM094635943 ) O
was BC2GM094635943 VBD O
detected BC2GM094635943 VBN O
by BC2GM094635943 IN O
HI BC2GM094635943 NNP O
test BC2GM094635943 NN O
and BC2GM094635943 CC O
IgM BC2GM094635943 NNP O
antibody BC2GM094635943 NN O
capture BC2GM094635943 NN O
ELISA BC2GM094635943 NNP O
( BC2GM094635943 ( O
MAC BC2GM094635943 NNP O
ELISA BC2GM094635943 NNP O
) BC2GM094635943 ) O
was BC2GM094635943 VBD O
performed BC2GM094635943 VBN O
to BC2GM094635943 TO O
determine BC2GM094635943 VB O
recent BC2GM094635943 JJ O
infections BC2GM094635943 NNS O
with BC2GM094635943 IN O
JE BC2GM094635943 NNP O
virus BC2GM094635943 NN O
. BC2GM094635943 . O
. . O O

Left BC2GM030782524 NNP O
ventricle BC2GM030782524 NN O
to BC2GM030782524 TO O
coronary BC2GM030782524 JJ O
sinus BC2GM030782524 NN O
fistula BC2GM030782524 NN O
. BC2GM030782524 . O
. . O O

As BC2GM081450728 IN O
an BC2GM081450728 DT O
approach BC2GM081450728 NN O
to BC2GM081450728 TO O
the BC2GM081450728 DT O
determination BC2GM081450728 NN O
of BC2GM081450728 IN O
structure-function BC2GM081450728 JJ O
relationships BC2GM081450728 NNS O
in BC2GM081450728 IN O
the BC2GM081450728 DT O
PRP4 BC2GM081450728 NNP O
protein BC2GM081450728 NN O
, BC2GM081450728 , O
we BC2GM081450728 PRP O
have BC2GM081450728 VBP O
isolated BC2GM081450728 VBN O
more BC2GM081450728 JJR O
than BC2GM081450728 IN O
fifty BC2GM081450728 JJ O
new BC2GM081450728 JJ O
alleles BC2GM081450728 NNS O
of BC2GM081450728 IN O
the BC2GM081450728 DT O
PRP4 BC2GM081450728 NNP O
gene BC2GM081450728 NN O
through BC2GM081450728 IN O
random BC2GM081450728 NN O
and BC2GM081450728 CC O
site-directed BC2GM081450728 JJ O
mutagenesis BC2GM081450728 NN O
, BC2GM081450728 , O
and BC2GM081450728 CC O
have BC2GM081450728 VBP O
analyzed BC2GM081450728 VBN O
the BC2GM081450728 DT O
phenotypes BC2GM081450728 NNS O
of BC2GM081450728 IN O
many BC2GM081450728 JJ O
of BC2GM081450728 IN O
them BC2GM081450728 PRP O
. BC2GM081450728 . O
. . O O

The BC2GM021740420 DT O
role BC2GM021740420 NN O
of BC2GM021740420 IN O
haptoglobin BC2GM021740420 NN O
in BC2GM021740420 IN O
asphyxia BC2GM021740420 NN O
mechanism BC2GM021740420 NN O
( BC2GM021740420 ( O
II BC2GM021740420 NNP O
) BC2GM021740420 ) O
-- BC2GM021740420 : O
Acute BC2GM021740420 JJ O
drowning BC2GM021740420 NN O
and BC2GM021740420 CC O
hanging BC2GM021740420 NN O
. BC2GM021740420 . O
. . O O

One BC2GM095014015 CD O
had BC2GM095014015 VBD O
a BC2GM095014015 DT O
48-hour BC2GM095014015 JJ O
cycle BC2GM095014015 NN O
and BC2GM095014015 CC O
the BC2GM095014015 DT O
other BC2GM095014015 JJ O
a BC2GM095014015 DT O
24-hour BC2GM095014015 JJ O
cycle BC2GM095014015 NN O
. BC2GM095014015 . O
. . O O

By BC2GM080887068 IN O
cloning BC2GM080887068 VBG O
genes BC2GM080887068 NNS O
encoding BC2GM080887068 VBG O
benzene-degradative BC2GM080887068 JJ O
enzymes BC2GM080887068 NNS O
, BC2GM080887068 , O
we BC2GM080887068 PRP O
found BC2GM080887068 VBD O
that BC2GM080887068 IN O
strain BC2GM080887068 NN O
JS150 BC2GM080887068 NNP O
also BC2GM080887068 RB O
carries BC2GM080887068 VBZ O
genes BC2GM080887068 NNS O
for BC2GM080887068 IN O
a BC2GM080887068 DT O
toluene BC2GM080887068 JJ O
/ BC2GM080887068 JJ O
benzene-2-monooxygenase BC2GM080887068 NN O
. BC2GM080887068 . O
. . O O

Plasma BC2GM031585190 NNP O
prolactin BC2GM031585190 NN O
concentrations BC2GM031585190 NNS O
in BC2GM031585190 IN O
pinealectomized BC2GM031585190 JJ O
ewes BC2GM031585190 NN O
receiving BC2GM031585190 VBG O
melatonin BC2GM031585190 NN O
treatment BC2GM031585190 NN O
and BC2GM031585190 CC O
in BC2GM031585190 IN O
pineal BC2GM031585190 JJ O
intact BC2GM031585190 JJ O
ewes BC2GM031585190 NN O
maintained BC2GM031585190 VBN O
under BC2GM031585190 IN O
a BC2GM031585190 DT O
non-24-hour BC2GM031585190 JJ O
photoperiod BC2GM031585190 NN O
. BC2GM031585190 . O
. . O O

However BC2GM035996110 RB O
, BC2GM035996110 , O
in BC2GM035996110 IN O
a BC2GM035996110 DT O
variation BC2GM035996110 NN O
of BC2GM035996110 IN O
this BC2GM035996110 DT O
assay BC2GM035996110 NN O
in BC2GM035996110 IN O
which BC2GM035996110 WDT O
the BC2GM035996110 DT O
protease BC2GM035996110 NN O
is BC2GM035996110 VBZ O
omitted BC2GM035996110 VBN O
, BC2GM035996110 , O
the BC2GM035996110 DT O
mutant BC2GM035996110 JJ O
enzymes BC2GM035996110 NNS O
exhibited BC2GM035996110 VBN O
substantial BC2GM035996110 JJ O
levels BC2GM035996110 NNS O
of BC2GM035996110 IN O
prolyl BC2GM035996110 JJ O
isomerase BC2GM035996110 NN O
activity BC2GM035996110 NN O
( BC2GM035996110 ( O
5-20 BC2GM035996110 CD O
% BC2GM035996110 NN O
of BC2GM035996110 IN O
wild-type BC2GM035996110 NN O
) BC2GM035996110 ) O
, BC2GM035996110 , O
revealing BC2GM035996110 VBG O
that BC2GM035996110 IN O
these BC2GM035996110 DT O
mutations BC2GM035996110 NNS O
confer BC2GM035996110 VBP O
sensitivity BC2GM035996110 NN O
to BC2GM035996110 TO O
protease BC2GM035996110 VB O
digestion BC2GM035996110 NN O
and BC2GM035996110 CC O
that BC2GM035996110 IN O
the BC2GM035996110 DT O
classic BC2GM035996110 JJ O
in BC2GM035996110 IN O
vitro BC2GM035996110 JJ O
assay BC2GM035996110 NN O
for BC2GM035996110 IN O
prolyl BC2GM035996110 JJ O
isomerase BC2GM035996110 NN O
activity BC2GM035996110 NN O
may BC2GM035996110 MD O
be BC2GM035996110 VB O
misleading BC2GM035996110 VBG O
. BC2GM035996110 . O
. . O O

CONCLUSIONS BC2GM050815443 NN O
: BC2GM050815443 : O
This BC2GM050815443 DT O
study BC2GM050815443 NN O
shows BC2GM050815443 VBZ O
that BC2GM050815443 IN O
the BC2GM050815443 DT O
annual BC2GM050815443 JJ O
rate BC2GM050815443 NN O
of BC2GM050815443 IN O
de BC2GM050815443 FW O
novo BC2GM050815443 FW O
aneurysm BC2GM050815443 JJ O
formation BC2GM050815443 NN O
is BC2GM050815443 VBZ O
relatively BC2GM050815443 RB O
high BC2GM050815443 JJ O
( BC2GM050815443 ( O
0.89 BC2GM050815443 CD O
% BC2GM050815443 NN O
) BC2GM050815443 ) O
and BC2GM050815443 CC O
that BC2GM050815443 IN O
the BC2GM050815443 DT O
cumulative BC2GM050815443 JJ O
risk BC2GM050815443 NN O
becomes BC2GM050815443 NNS O
significant BC2GM050815443 JJ O
after BC2GM050815443 IN O
9 BC2GM050815443 CD O
years BC2GM050815443 NNS O
. BC2GM050815443 . O
. . O O

The BC2GM015500367 DT O
TaqI BC2GM015500367 NNP O
and BC2GM015500367 CC O
HaeIII BC2GM015500367 NNP O
RFLPs BC2GM015500367 NNP O
will BC2GM015500367 MD O
provide BC2GM015500367 VB O
tools BC2GM015500367 NNS O
for BC2GM015500367 IN O
the BC2GM015500367 DT O
genetic BC2GM015500367 JJ O
analysis BC2GM015500367 NN O
of BC2GM015500367 IN O
CR2 BC2GM015500367 NNP O
. BC2GM015500367 . O
. . O O

It BC2GM040553763 PRP O
is BC2GM040553763 VBZ O
targeted BC2GM040553763 VBN O
to BC2GM040553763 TO O
peroxisomes BC2GM040553763 NNS O
when BC2GM040553763 WRB O
expressed BC2GM040553763 VBN O
in BC2GM040553763 IN O
mammalian BC2GM040553763 JJ O
cells BC2GM040553763 NNS O
and BC2GM040553763 CC O
yeast BC2GM040553763 NN O
. BC2GM040553763 . O
. . O O

Smectic-A BC2GM010728052 JJ O
ordering BC2GM010728052 NN O
at BC2GM010728052 IN O
a BC2GM010728052 DT O
liquid-vapor BC2GM010728052 JJ O
interface BC2GM010728052 NN O
. BC2GM010728052 . O
. . O O

APL BC2GM084502835 NNP O
patients BC2GM084502835 NNS O
showed BC2GM084502835 VBD O
a BC2GM084502835 DT O
low BC2GM084502835 JJ O
, BC2GM084502835 , O
yet BC2GM084502835 RB O
variable BC2GM084502835 JJ O
, BC2GM084502835 , O
level BC2GM084502835 NN O
of BC2GM084502835 IN O
JEM-1 BC2GM084502835 NNP O
mRNA BC2GM084502835 NN O
in BC2GM084502835 IN O
bone BC2GM084502835 NN O
marrow BC2GM084502835 NN O
. BC2GM084502835 . O
. . O O

Is BC2GM034139781 VBZ O
it BC2GM034139781 PRP O
time BC2GM034139781 NN O
for BC2GM034139781 IN O
a BC2GM034139781 DT O
wine BC2GM034139781 JJ O
trial BC2GM034139781 NN O
? BC2GM034139781 . O
. BC2GM034139781 . O
. . O O

Rv BC2GM013836575 NNP O
was BC2GM013836575 VBD O
7.7 BC2GM013836575 CD O
+ BC2GM013836575 JJ O
/ BC2GM013836575 NNP O
- BC2GM013836575 : O
1.4 BC2GM013836575 CD O
mmHg.ml-1.min.100 BC2GM013836575 JJ O
g-1 BC2GM013836575 NN O
and BC2GM013836575 CC O
Cv BC2GM013836575 NNP O
was BC2GM013836575 VBD O
0.59 BC2GM013836575 CD O
+ BC2GM013836575 JJ O
/ BC2GM013836575 NNP O
- BC2GM013836575 : O
0.25 BC2GM013836575 CD O
ml BC2GM013836575 NN O
/ BC2GM013836575 NNP O
mmHg BC2GM013836575 NN O
, BC2GM013836575 , O
tau BC2GM013836575 JJ O
v BC2GM013836575 NN O
calculated BC2GM013836575 VBN O
from BC2GM013836575 IN O
the BC2GM013836575 DT O
product BC2GM013836575 NN O
of BC2GM013836575 IN O
Rv BC2GM013836575 NNP O
and BC2GM013836575 CC O
Cv BC2GM013836575 NNP O
was BC2GM013836575 VBD O
4.20 BC2GM013836575 CD O
+ BC2GM013836575 JJ O
/ BC2GM013836575 NNP O
- BC2GM013836575 : O
1.58 BC2GM013836575 CD O
s BC2GM013836575 NN O
and BC2GM013836575 CC O
from BC2GM013836575 IN O
the BC2GM013836575 DT O
ratio BC2GM013836575 NN O
of BC2GM013836575 IN O
delta BC2GM013836575 NN O
V BC2GM013836575 NNP O
to BC2GM013836575 TO O
delta BC2GM013836575 VB O
Q BC2GM013836575 NNP O
was BC2GM013836575 VBD O
4.95 BC2GM013836575 CD O
+ BC2GM013836575 JJ O
/ BC2GM013836575 NNP O
- BC2GM013836575 : O
1.53 BC2GM013836575 CD O
s BC2GM013836575 NN O
( BC2GM013836575 ( O
P BC2GM013836575 NNP O
= BC2GM013836575 NNP O
NS BC2GM013836575 NNP O
) BC2GM013836575 ) O
at BC2GM013836575 IN O
a BC2GM013836575 DT O
mean BC2GM013836575 JJ O
Pel BC2GM013836575 NNP O
of BC2GM013836575 IN O
17.6 BC2GM013836575 CD O
+ BC2GM013836575 NNS O
/ BC2GM013836575 SYM O
- BC2GM013836575 : O
3.7 BC2GM013836575 CD O
mmHg BC2GM013836575 NN O
. BC2GM013836575 . O
delta BC2GM013836575 NN O
V BC2GM013836575 NNP O
was BC2GM013836575 VBD O
also BC2GM013836575 RB O
produced BC2GM013836575 VBN O
by BC2GM013836575 IN O
changing BC2GM013836575 VBG O
Pv BC2GM013836575 NNP O
; BC2GM013836575 : O
the BC2GM013836575 DT O
average BC2GM013836575 JJ O
tau BC2GM013836575 JJ O
v BC2GM013836575 NN O
( BC2GM013836575 ( O
1.95 BC2GM013836575 CD O
+ BC2GM013836575 NN O
/ BC2GM013836575 NNP O
- BC2GM013836575 : O
0.37 BC2GM013836575 CD O
s BC2GM013836575 NN O
) BC2GM013836575 ) O
, BC2GM013836575 , O
was BC2GM013836575 VBD O
shorter BC2GM013836575 JJR O
than BC2GM013836575 IN O
that BC2GM013836575 DT O
with BC2GM013836575 IN O
changes BC2GM013836575 NNS O
in BC2GM013836575 IN O
flow BC2GM013836575 NN O
. BC2GM013836575 . O
. . O O

trans-activation BC2GM034214374 NN O
of BC2GM034214374 IN O
the BC2GM034214374 DT O
HIV-1 BC2GM034214374 NNP O
LTR BC2GM034214374 NNP O
by BC2GM034214374 IN O
the BC2GM034214374 DT O
HIV-1 BC2GM034214374 NNP O
Tat BC2GM034214374 NNP O
and BC2GM034214374 CC O
HTLV-I BC2GM034214374 NNP O
Tax BC2GM034214374 NNP O
proteins BC2GM034214374 VBZ O
is BC2GM034214374 VBZ O
mediated BC2GM034214374 VBN O
by BC2GM034214374 IN O
different BC2GM034214374 JJ O
cis-acting BC2GM034214374 JJ O
sequences BC2GM034214374 NNS O
. BC2GM034214374 . O
. . O O

The BC2GM009256073 DT O
essential BC2GM009256073 JJ O
oil BC2GM009256073 NN O
composition BC2GM009256073 NN O
of BC2GM009256073 IN O
three BC2GM009256073 CD O
Zingiberaceae BC2GM009256073 NNP O
widely BC2GM009256073 RB O
used BC2GM009256073 VBD O
as BC2GM009256073 IN O
medicinal BC2GM009256073 JJ O
aromatic BC2GM009256073 JJ O
plants BC2GM009256073 NNS O
from BC2GM009256073 IN O
S BC2GM009256073 NNP O
. BC2GM009256073 . O
. . O O

Therefore BC2GM081384324 RB O
, BC2GM081384324 , O
the BC2GM081384324 DT O
Ogg1 BC2GM081384324 NNP O
protein BC2GM081384324 NN O
is BC2GM081384324 VBZ O
a BC2GM081384324 DT O
eukaryotic BC2GM081384324 JJ O
DNA BC2GM081384324 NNP O
glycosylase BC2GM081384324 NN O
/ BC2GM081384324 NNP O
AP BC2GM081384324 NNP O
lyase BC2GM081384324 NN O
. BC2GM081384324 . O
. . O O

3 BC2GM064361080 CD O
patients BC2GM064361080 NNS O
with BC2GM064361080 IN O
acute BC2GM064361080 JJ O
leukaemia BC2GM064361080 NN O
, BC2GM064361080 , O
HLA BC2GM064361080 NNP O
antibodies BC2GM064361080 NNS O
and BC2GM064361080 CC O
thrombocytopenia BC2GM064361080 JJ O
refractory BC2GM064361080 NN O
to BC2GM064361080 TO O
random BC2GM064361080 VB O
donor BC2GM064361080 JJ O
platelet BC2GM064361080 NN O
transfusions BC2GM064361080 NNS O
were BC2GM064361080 VBD O
treated BC2GM064361080 VBN O
with BC2GM064361080 IN O
high-dose BC2GM064361080 JJ O
i.v BC2GM064361080 NN O
. BC2GM064361080 . O
immunoglobulin BC2GM064361080 NN O
. BC2GM064361080 . O
. . O O

Nucleotide BC2GM057520621 RB O
sequencing BC2GM057520621 VBG O
revealed BC2GM057520621 VBD O
a BC2GM057520621 DT O
2076-base BC2GM057520621 JJ O
pair BC2GM057520621 NN O
open BC2GM057520621 JJ O
reading BC2GM057520621 NN O
frame BC2GM057520621 NN O
encoding BC2GM057520621 VBG O
a BC2GM057520621 DT O
692-amino BC2GM057520621 JJ O
acid BC2GM057520621 NN O
protein BC2GM057520621 NN O
. BC2GM057520621 . O
. . O O

However BC2GM061836675 RB O
, BC2GM061836675 , O
the BC2GM061836675 DT O
recovery BC2GM061836675 NN O
curve BC2GM061836675 NN O
of BC2GM061836675 IN O
the BC2GM061836675 DT O
R2 BC2GM061836675 NNP O
component BC2GM061836675 NN O
of BC2GM061836675 IN O
the BC2GM061836675 DT O
blink BC2GM061836675 NN O
reflex BC2GM061836675 NN O
diminished BC2GM061836675 VBN O
in BC2GM061836675 IN O
patients BC2GM061836675 NNS O
with BC2GM061836675 IN O
tension-type BC2GM061836675 JJ O
headache BC2GM061836675 NN O
compared BC2GM061836675 VBN O
with BC2GM061836675 IN O
the BC2GM061836675 DT O
other BC2GM061836675 JJ O
groups BC2GM061836675 NNS O
. BC2GM061836675 . O
. . O O

ALT BC2GM018406143 NNP O
( BC2GM018406143 ( O
alanine BC2GM018406143 JJ O
aminotransferase BC2GM018406143 NN O
) BC2GM018406143 ) O
and BC2GM018406143 CC O
Hb BC2GM018406143 NNP O
( BC2GM018406143 ( O
hemoglobin BC2GM018406143 NN O
) BC2GM018406143 ) O
appeared BC2GM018406143 VBD O
to BC2GM018406143 TO O
be BC2GM018406143 VB O
predictive BC2GM018406143 JJ O
for BC2GM018406143 IN O
efficacy BC2GM018406143 NN O
. BC2GM018406143 . O
. . O O

Coronatine BC2GM052077853 NNP O
( BC2GM052077853 ( O
COR BC2GM052077853 NNP O
) BC2GM052077853 ) O
is BC2GM052077853 VBZ O
a BC2GM052077853 DT O
plasmid-encoded BC2GM052077853 JJ O
phytotoxin BC2GM052077853 NN O
synthesized BC2GM052077853 VBN O
by BC2GM052077853 IN O
several BC2GM052077853 JJ O
pathovars BC2GM052077853 NNS O
of BC2GM052077853 IN O
phytopathogenic BC2GM052077853 JJ O
Pseudomonas BC2GM052077853 NNP O
syringae BC2GM052077853 NN O
. BC2GM052077853 . O
. . O O

SCAN BC2GM012120254 NNP O
boxes BC2GM012120254 NNS O
are BC2GM012120254 VBP O
found BC2GM012120254 VBN O
in BC2GM012120254 IN O
eight BC2GM012120254 CD O
other BC2GM012120254 JJ O
genes BC2GM012120254 NNS O
in BC2GM012120254 IN O
the BC2GM012120254 DT O
GenBank BC2GM012120254 NNP O
database BC2GM012120254 NN O
, BC2GM012120254 , O
five BC2GM012120254 CD O
of BC2GM012120254 IN O
which BC2GM012120254 WDT O
are BC2GM012120254 VBP O
also BC2GM012120254 RB O
in BC2GM012120254 IN O
the BC2GM012120254 DT O
Kruppel BC2GM012120254 NNP O
family BC2GM012120254 NN O
of BC2GM012120254 IN O
zinc BC2GM012120254 NN O
finger BC2GM012120254 NN O
proteins BC2GM012120254 VBZ O
lacking BC2GM012120254 VBG O
KRAB BC2GM012120254 NNP O
A BC2GM012120254 NNP O
and BC2GM012120254 CC O
B BC2GM012120254 NNP O
domains BC2GM012120254 NNS O
and BC2GM012120254 CC O
thereby BC2GM012120254 RB O
define BC2GM012120254 VB O
a BC2GM012120254 DT O
new BC2GM012120254 JJ O
subclass BC2GM012120254 NN O
of BC2GM012120254 IN O
zinc BC2GM012120254 NN O
finger BC2GM012120254 NN O
proteins BC2GM012120254 NNS O
. BC2GM012120254 . O
. . O O

Sucrose BC2GM086837323 NNP O
produced BC2GM086837323 VBD O
in BC2GM086837323 IN O
source BC2GM086837323 NN O
leaves BC2GM086837323 NNS O
is BC2GM086837323 VBZ O
the BC2GM086837323 DT O
predominant BC2GM086837323 JJ O
carbon BC2GM086837323 NN O
source BC2GM086837323 NN O
for BC2GM086837323 IN O
developing BC2GM086837323 VBG O
sink BC2GM086837323 NN O
tissues BC2GM086837323 NNS O
in BC2GM086837323 IN O
most BC2GM086837323 JJS O
higher BC2GM086837323 JJR O
plants BC2GM086837323 NNS O
. BC2GM086837323 . O
. . O O

These BC2GM093351969 DT O
findings BC2GM093351969 NNS O
suggest BC2GM093351969 VBP O
that BC2GM093351969 IN O
the BC2GM093351969 DT O
proteolipids BC2GM093351969 NNS O
of BC2GM093351969 IN O
the BC2GM093351969 DT O
vacuolar BC2GM093351969 JJ O
H+-ATPases BC2GM093351969 NNS O
were BC2GM093351969 VBD O
evolved BC2GM093351969 VBN O
in BC2GM093351969 IN O
parallel BC2GM093351969 NN O
with BC2GM093351969 IN O
the BC2GM093351969 DT O
eubacterial BC2GM093351969 JJ O
proteolipid BC2GM093351969 NN O
, BC2GM093351969 , O
from BC2GM093351969 IN O
a BC2GM093351969 DT O
common BC2GM093351969 JJ O
ancestral BC2GM093351969 JJ O
gene BC2GM093351969 NN O
that BC2GM093351969 WDT O
underwent BC2GM093351969 JJ O
gene BC2GM093351969 NN O
duplication BC2GM093351969 NN O
. BC2GM093351969 . O
. . O O

TFIIIB BC2GM061879889 NNP O
assembles BC2GM061879889 VBZ O
autonomously BC2GM061879889 RB O
on BC2GM061879889 IN O
the BC2GM061879889 DT O
upstream BC2GM061879889 JJ O
promoter BC2GM061879889 NN O
of BC2GM061879889 IN O
the BC2GM061879889 DT O
yeast BC2GM061879889 NN O
U6 BC2GM061879889 NNP O
snRNA BC2GM061879889 NN O
( BC2GM061879889 ( O
SNR6 BC2GM061879889 NNP O
) BC2GM061879889 ) O
gene BC2GM061879889 NN O
in BC2GM061879889 IN O
vitro BC2GM061879889 NN O
, BC2GM061879889 , O
through BC2GM061879889 IN O
the BC2GM061879889 DT O
interaction BC2GM061879889 NN O
of BC2GM061879889 IN O
its BC2GM061879889 PRP$ O
TBP BC2GM061879889 NNP O
subunit BC2GM061879889 NN O
with BC2GM061879889 IN O
a BC2GM061879889 DT O
consensus BC2GM061879889 NN O
TATA BC2GM061879889 NNP O
box BC2GM061879889 NN O
located BC2GM061879889 VBN O
at BC2GM061879889 IN O
base BC2GM061879889 NN O
pair BC2GM061879889 NN O
-30 BC2GM061879889 NN O
. BC2GM061879889 . O
. . O O

This BC2GM047650925 DT O
B-box BC2GM047650925 NNP O
is BC2GM047650925 VBZ O
not BC2GM047650925 RB O
present BC2GM047650925 JJ O
in BC2GM047650925 IN O
ETS1 BC2GM047650925 NNP O
, BC2GM047650925 , O
ETS2 BC2GM047650925 NNP O
, BC2GM047650925 , O
PEA3 BC2GM047650925 NNP O
or BC2GM047650925 CC O
PU.1 BC2GM047650925 NNP O
and BC2GM047650925 CC O
these BC2GM047650925 DT O
proteins BC2GM047650925 NNS O
were BC2GM047650925 VBD O
unable BC2GM047650925 JJ O
to BC2GM047650925 TO O
form BC2GM047650925 VB O
ternary BC2GM047650925 JJ O
complexes BC2GM047650925 NNS O
with BC2GM047650925 IN O
SRF BC2GM047650925 NNP O
and BC2GM047650925 CC O
Egrl-SREs BC2GM047650925 NNP O
or BC2GM047650925 CC O
c-fos BC2GM047650925 JJ O
SRE BC2GM047650925 NNP O
. BC2GM047650925 . O
. . O O

Indigenous BC2GM064320390 JJ O
microbial BC2GM064320390 JJ O
flora BC2GM064320390 NN O
and BC2GM064320390 CC O
the BC2GM064320390 DT O
large BC2GM064320390 JJ O
intestine BC2GM064320390 NN O
in BC2GM064320390 IN O
tadpoles BC2GM064320390 NNS O
. BC2GM064320390 . O
. . O O

A BC2GM085015084 DT O
representative BC2GM085015084 JJ O
group BC2GM085015084 NN O
of BC2GM085015084 IN O
patients BC2GM085015084 NNS O
undergoing BC2GM085015084 VBG O
open BC2GM085015084 JJ O
radical BC2GM085015084 JJ O
nephrectomy BC2GM085015084 NN O
for BC2GM085015084 IN O
clinical BC2GM085015084 JJ O
T1 BC2GM085015084 NNP O
, BC2GM085015084 , O
T2 BC2GM085015084 NNP O
lesions BC2GM085015084 NNS O
was BC2GM085015084 VBD O
also BC2GM085015084 RB O
identified BC2GM085015084 VBN O
. BC2GM085015084 . O
. . O O

For BC2GM096844246 IN O
the BC2GM096844246 DT O
second BC2GM096844246 JJ O
phase BC2GM096844246 NN O
, BC2GM096844246 , O
it BC2GM096844246 PRP O
was BC2GM096844246 VBD O
12.5 BC2GM096844246 CD O
wk BC2GM096844246 NN O
for BC2GM096844246 IN O
RIR BC2GM096844246 NNP O
and BC2GM096844246 CC O
10 BC2GM096844246 CD O
for BC2GM096844246 IN O
WL BC2GM096844246 NNP O
males BC2GM096844246 NNS O
, BC2GM096844246 , O
whereas BC2GM096844246 IN O
it BC2GM096844246 PRP O
was BC2GM096844246 VBD O
5 BC2GM096844246 CD O
wk BC2GM096844246 NN O
for BC2GM096844246 IN O
RIR BC2GM096844246 NNP O
and BC2GM096844246 CC O
6 BC2GM096844246 CD O
for BC2GM096844246 IN O
WL BC2GM096844246 NNP O
females BC2GM096844246 NNS O
. BC2GM096844246 . O
. . O O

It BC2GM072060480 PRP O
is BC2GM072060480 VBZ O
not BC2GM072060480 RB O
tested BC2GM072060480 VBN O
yet BC2GM072060480 RB O
, BC2GM072060480 , O
whether BC2GM072060480 IN O
the BC2GM072060480 DT O
extent BC2GM072060480 NN O
of BC2GM072060480 IN O
glaucoma BC2GM072060480 NN O
damage BC2GM072060480 NN O
should BC2GM072060480 MD O
be BC2GM072060480 VB O
better BC2GM072060480 JJR O
quantified BC2GM072060480 VBN O
using BC2GM072060480 VBG O
reference BC2GM072060480 NN O
plane BC2GM072060480 NN O
1 BC2GM072060480 CD O
or BC2GM072060480 CC O
2 BC2GM072060480 CD O
. BC2GM072060480 . O
. . O O

The BC2GM097088873 DT O
phP1 BC2GM097088873 NN O
mutation BC2GM097088873 NN O
was BC2GM097088873 VBD O
induced BC2GM097088873 VBN O
by BC2GM097088873 IN O
insertion BC2GM097088873 NN O
of BC2GM097088873 IN O
a BC2GM097088873 DT O
1.2-kb BC2GM097088873 JJ O
P BC2GM097088873 NNP O
element BC2GM097088873 NN O
into BC2GM097088873 IN O
the BC2GM097088873 DT O
5 BC2GM097088873 CD O
' BC2GM097088873 POS O
transcribed BC2GM097088873 NN O
nontranslated BC2GM097088873 JJ O
region BC2GM097088873 NN O
of BC2GM097088873 IN O
the BC2GM097088873 DT O
proximal BC2GM097088873 JJ O
polyhomeotic BC2GM097088873 JJ O
gene BC2GM097088873 NN O
. BC2GM097088873 . O
. . O O

We BC2GM074751014 PRP O
report BC2GM074751014 VBP O
five BC2GM074751014 CD O
of BC2GM074751014 IN O
13 BC2GM074751014 CD O
evaluable BC2GM074751014 JJ O
patients BC2GM074751014 NNS O
undergoing BC2GM074751014 VBG O
allogeneic BC2GM074751014 JJ O
sibling BC2GM074751014 VBG O
BM BC2GM074751014 NNP O
or BC2GM074751014 CC O
PBSC BC2GM074751014 NNP O
transplantation BC2GM074751014 NN O
for BC2GM074751014 IN O
MM BC2GM074751014 NNP O
between BC2GM074751014 IN O
1990 BC2GM074751014 CD O
and BC2GM074751014 CC O
1997 BC2GM074751014 CD O
who BC2GM074751014 WP O
met BC2GM074751014 VBD O
the BC2GM074751014 DT O
criteria BC2GM074751014 NNS O
for BC2GM074751014 IN O
adjuvant BC2GM074751014 JJ O
alpha-IFN BC2GM074751014 JJ O
therapy BC2GM074751014 NN O
. BC2GM074751014 . O
. . O O

These BC2GM027366629 DT O
results BC2GM027366629 NNS O
suggest BC2GM027366629 VBP O
that BC2GM027366629 IN O
UvrA BC2GM027366629 NNP O
is BC2GM027366629 VBZ O
involved BC2GM027366629 VBN O
in BC2GM027366629 IN O
triplet BC2GM027366629 NN O
repeat BC2GM027366629 NN O
instability BC2GM027366629 NN O
in BC2GM027366629 IN O
cells BC2GM027366629 NNS O
. BC2GM027366629 . O
. . O O

Vasodilation BC2GM070901707 NN O
in BC2GM070901707 IN O
congestive BC2GM070901707 JJ O
heart BC2GM070901707 NN O
failure BC2GM070901707 NN O
is BC2GM070901707 VBZ O
an BC2GM070901707 DT O
established BC2GM070901707 VBN O
therapeutic BC2GM070901707 JJ O
principal BC2GM070901707 NN O
. BC2GM070901707 . O
. . O O

Depending BC2GM089298534 VBG O
on BC2GM089298534 IN O
the BC2GM089298534 DT O
patient BC2GM089298534 NN O
's BC2GM089298534 POS O
body BC2GM089298534 NN O
position BC2GM089298534 NN O
telemetrically BC2GM089298534 RB O
measured BC2GM089298534 VBD O
CSF-pressures BC2GM089298534 NNS O
varied BC2GM089298534 VBD O
between BC2GM089298534 IN O
-20 BC2GM089298534 NNP O
cmH2O BC2GM089298534 NN O
in BC2GM089298534 IN O
erect BC2GM089298534 NN O
and BC2GM089298534 CC O
15 BC2GM089298534 CD O
cmH2O BC2GM089298534 NN O
in BC2GM089298534 IN O
supine BC2GM089298534 JJ O
position BC2GM089298534 NN O
. BC2GM089298534 . O
. . O O

Sixteen BC2GM071420231 JJ O
patients BC2GM071420231 NNS O
( BC2GM071420231 ( O
25.4 BC2GM071420231 CD O
% BC2GM071420231 NN O
) BC2GM071420231 ) O
encountered BC2GM071420231 VBD O
rejection BC2GM071420231 NN O
while BC2GM071420231 IN O
weaning BC2GM071420231 VBG O
at BC2GM071420231 IN O
median BC2GM071420231 JJ O
period BC2GM071420231 NN O
of BC2GM071420231 IN O
9.5 BC2GM071420231 CD O
months BC2GM071420231 NNS O
( BC2GM071420231 ( O
range BC2GM071420231 NN O
, BC2GM071420231 , O
1-63 BC2GM071420231 JJ O
months BC2GM071420231 NNS O
) BC2GM071420231 ) O
from BC2GM071420231 IN O
the BC2GM071420231 DT O
start BC2GM071420231 NN O
of BC2GM071420231 IN O
weaning BC2GM071420231 NN O
. BC2GM071420231 . O
. . O O

In BC2GM060450171 IN O
the BC2GM060450171 DT O
fungus BC2GM060450171 NN O
Neurospora BC2GM060450171 NNP O
crassa BC2GM060450171 NN O
, BC2GM060450171 , O
nit-2 BC2GM060450171 JJ O
, BC2GM060450171 , O
the BC2GM060450171 DT O
major BC2GM060450171 JJ O
nitrogen BC2GM060450171 NN O
regulatory BC2GM060450171 JJ O
gene BC2GM060450171 NN O
, BC2GM060450171 , O
activates BC2GM060450171 VBZ O
the BC2GM060450171 DT O
expression BC2GM060450171 NN O
of BC2GM060450171 IN O
unlinked BC2GM060450171 JJ O
structural BC2GM060450171 JJ O
genes BC2GM060450171 NNS O
that BC2GM060450171 WDT O
specify BC2GM060450171 VBP O
nitrogen-catabolic BC2GM060450171 JJ O
enzymes BC2GM060450171 NNS O
during BC2GM060450171 IN O
conditions BC2GM060450171 NNS O
of BC2GM060450171 IN O
nitrogen BC2GM060450171 NN O
limitation BC2GM060450171 NN O
. BC2GM060450171 . O
. . O O

Early BC2GM087236793 JJ O
complement BC2GM087236793 NN O
components BC2GM087236793 NNS O
, BC2GM087236793 , O
C1q BC2GM087236793 NNP O
and BC2GM087236793 CC O
C4 BC2GM087236793 NNP O
, BC2GM087236793 , O
and BC2GM087236793 CC O
IgA BC2GM087236793 NNP O
secretory BC2GM087236793 JJ O
piece BC2GM087236793 NN O
were BC2GM087236793 VBD O
absent BC2GM087236793 JJ O
. BC2GM087236793 . O
. . O O

Moreover BC2GM042227725 RB O
, BC2GM042227725 , O
the BC2GM042227725 DT O
noncoordinate BC2GM042227725 JJ O
effects BC2GM042227725 NNS O
of BC2GM042227725 IN O
FSK BC2GM042227725 NNP O
on BC2GM042227725 IN O
PMA-stimulated BC2GM042227725 NNP O
MKK BC2GM042227725 NNP O
and BC2GM042227725 CC O
MAPK BC2GM042227725 NNP O
activities BC2GM042227725 NNS O
indicates BC2GM042227725 VBZ O
the BC2GM042227725 DT O
presence BC2GM042227725 NN O
of BC2GM042227725 IN O
a BC2GM042227725 DT O
additional BC2GM042227725 JJ O
distal BC2GM042227725 JJ O
cAMP-dependent BC2GM042227725 JJ O
inhibitory BC2GM042227725 NN O
mechanisms BC2GM042227725 NNS O
. BC2GM042227725 . O
. . O O

Autophosphorylation BC2GM043951008 NN O
on BC2GM043951008 IN O
the BC2GM043951008 DT O
major BC2GM043951008 JJ O
phosphorylation BC2GM043951008 NN O
site BC2GM043951008 NN O
Y1235 BC2GM043951008 NNP O
upregulates BC2GM043951008 VBZ O
the BC2GM043951008 DT O
kinase BC2GM043951008 NN O
activity BC2GM043951008 NN O
of BC2GM043951008 IN O
the BC2GM043951008 DT O
receptor BC2GM043951008 NN O
, BC2GM043951008 , O
increasing BC2GM043951008 VBG O
the BC2GM043951008 DT O
Vmax BC2GM043951008 NNP O
of BC2GM043951008 IN O
the BC2GM043951008 DT O
phosphotransfer BC2GM043951008 NN O
reaction BC2GM043951008 NN O
. BC2GM043951008 . O
. . O O

MATERIAL BC2GM081421874 NNP O
AND BC2GM081421874 CC O
METHODS BC2GM081421874 NNP O
: BC2GM081421874 : O
. BC2GM081421874 . O
. . O O

Low BC2GM083212050 JJ O
plasma BC2GM083212050 NN O
glucose BC2GM083212050 NN O
concentrations BC2GM083212050 NNS O
that BC2GM083212050 WDT O
may BC2GM083212050 MD O
or BC2GM083212050 CC O
may BC2GM083212050 MD O
not BC2GM083212050 RB O
be BC2GM083212050 VB O
sufficiently BC2GM083212050 RB O
low BC2GM083212050 JJ O
to BC2GM083212050 TO O
result BC2GM083212050 VB O
in BC2GM083212050 IN O
symptoms BC2GM083212050 NNS O
can BC2GM083212050 MD O
be BC2GM083212050 VB O
observed BC2GM083212050 VBN O
as BC2GM083212050 IN O
a BC2GM083212050 DT O
concomitant BC2GM083212050 NN O
of BC2GM083212050 IN O
several BC2GM083212050 JJ O
diverse BC2GM083212050 JJ O
diseases BC2GM083212050 NNS O
. BC2GM083212050 . O
. . O O

H BC2GM023194685 NNP O
. BC2GM023194685 . O
. . O O

K562 BC2GM067585100 NNP O
erythroleukemia BC2GM067585100 NN O
cells BC2GM067585100 NNS O
stably BC2GM067585100 RB O
transfected BC2GM067585100 VBD O
with BC2GM067585100 IN O
constructs BC2GM067585100 NNS O
containing BC2GM067585100 VBG O
the BC2GM067585100 DT O
human BC2GM067585100 JJ O
Agamma-globin BC2GM067585100 NNP O
promoter BC2GM067585100 NN O
linked BC2GM067585100 VBD O
to BC2GM067585100 TO O
an BC2GM067585100 DT O
enhanced BC2GM067585100 VBN O
green BC2GM067585100 JJ O
fluorescent BC2GM067585100 NN O
protein BC2GM067585100 NN O
( BC2GM067585100 ( O
EGFP BC2GM067585100 NNP O
) BC2GM067585100 ) O
reporter BC2GM067585100 NN O
, BC2GM067585100 , O
with BC2GM067585100 IN O
or BC2GM067585100 CC O
without BC2GM067585100 IN O
HS2 BC2GM067585100 NNP O
, BC2GM067585100 , O
were BC2GM067585100 VBD O
analyzed BC2GM067585100 VBN O
for BC2GM067585100 IN O
EGFP BC2GM067585100 NNP O
expression BC2GM067585100 NN O
by BC2GM067585100 IN O
flow BC2GM067585100 JJ O
cytometry BC2GM067585100 NN O
. BC2GM067585100 . O
. . O O

We BC2GM090258989 PRP O
then BC2GM090258989 RB O
developed BC2GM090258989 VBD O
a BC2GM090258989 DT O
yeast BC2GM090258989 JJ O
artificial BC2GM090258989 JJ O
chromosome BC2GM090258989 NN O
( BC2GM090258989 ( O
YAC BC2GM090258989 NNP O
) BC2GM090258989 ) O
contig BC2GM090258989 NN O
for BC2GM090258989 IN O
this BC2GM090258989 DT O
region BC2GM090258989 NN O
. BC2GM090258989 . O
. . O O

Bilirubin BC2GM037286587 NNP O
and BC2GM037286587 CC O
red BC2GM037286587 JJ O
cell BC2GM037286587 NN O
metabolism BC2GM037286587 NN O
in BC2GM037286587 IN O
relation BC2GM037286587 NN O
to BC2GM037286587 TO O
neonatal BC2GM037286587 JJ O
jaundice BC2GM037286587 NN O
. BC2GM037286587 . O
. . O O

In BC2GM014952112 IN O
conclusion BC2GM014952112 NN O
, BC2GM014952112 , O
in BC2GM014952112 IN O
coronary BC2GM014952112 JJ O
artery BC2GM014952112 NN O
disease BC2GM014952112 NN O
patients BC2GM014952112 NNS O
, BC2GM014952112 , O
exercise-redistribution BC2GM014952112 JJ O
201Thallium BC2GM014952112 CD O
cardiac BC2GM014952112 JJ O
imaging BC2GM014952112 VBG O
with BC2GM014952112 IN O
reinjection BC2GM014952112 NN O
at BC2GM014952112 IN O
rest BC2GM014952112 NN O
can BC2GM014952112 MD O
identify BC2GM014952112 VB O
severely BC2GM014952112 RB O
ischemic BC2GM014952112 JJ O
but BC2GM014952112 CC O
still BC2GM014952112 RB O
viable BC2GM014952112 JJ O
myocardium BC2GM014952112 NN O
and BC2GM014952112 CC O
may BC2GM014952112 MD O
be BC2GM014952112 VB O
particularly BC2GM014952112 RB O
useful BC2GM014952112 JJ O
in BC2GM014952112 IN O
the BC2GM014952112 DT O
prognosis BC2GM014952112 NN O
of BC2GM014952112 IN O
such BC2GM014952112 JJ O
patients BC2GM014952112 NNS O
. BC2GM014952112 . O
. . O O

Production BC2GM011836972 NN O
of BC2GM011836972 IN O
a BC2GM011836972 DT O
chicken BC2GM011836972 JJ O
meat BC2GM011836972 NN O
infusion BC2GM011836972 NN O
broth BC2GM011836972 DT O
suitable BC2GM011836972 JJ O
for BC2GM011836972 IN O
the BC2GM011836972 DT O
mass BC2GM011836972 NN O
production BC2GM011836972 NN O
of BC2GM011836972 IN O
a BC2GM011836972 DT O
Haemophilus BC2GM011836972 NNP O
gallinarum BC2GM011836972 NN O
bacterin BC2GM011836972 NN O
. BC2GM011836972 . O
. . O O

This BC2GM021857972 DT O
is BC2GM021857972 VBZ O
probably BC2GM021857972 RB O
because BC2GM021857972 IN O
, BC2GM021857972 , O
in BC2GM021857972 IN O
vivo BC2GM021857972 NN O
, BC2GM021857972 , O
some BC2GM021857972 DT O
bacteria BC2GM021857972 NNS O
( BC2GM021857972 ( O
perhaps BC2GM021857972 RB O
dormant BC2GM021857972 VB O
forms BC2GM021857972 NNS O
) BC2GM021857972 ) O
are BC2GM021857972 VBP O
not BC2GM021857972 RB O
entirely BC2GM021857972 RB O
dependent BC2GM021857972 JJ O
upon BC2GM021857972 IN O
urease BC2GM021857972 NN O
for BC2GM021857972 IN O
survival BC2GM021857972 NN O
. BC2GM021857972 . O
. . O O

The BC2GM032903217 DT O
deduced BC2GM032903217 JJ O
amino-acid BC2GM032903217 JJ O
sequence BC2GM032903217 NN O
of BC2GM032903217 IN O
the BC2GM032903217 DT O
mature BC2GM032903217 NN O
enzyme BC2GM032903217 NN O
showed BC2GM032903217 VBD O
very BC2GM032903217 RB O
low BC2GM032903217 JJ O
homology BC2GM032903217 NN O
( BC2GM032903217 ( O
< BC2GM032903217 JJ O
20.4 BC2GM032903217 CD O
% BC2GM032903217 NN O
identity BC2GM032903217 NN O
) BC2GM032903217 ) O
to BC2GM032903217 TO O
those BC2GM032903217 DT O
of BC2GM032903217 IN O
known BC2GM032903217 VBN O
pectinolytic BC2GM032903217 JJ O
enzymes BC2GM032903217 NNS O
in BC2GM032903217 IN O
the BC2GM032903217 DT O
large BC2GM032903217 JJ O
pectate BC2GM032903217 NN O
lyase BC2GM032903217 NN O
superfamily BC2GM032903217 RB O
( BC2GM032903217 ( O
the BC2GM032903217 DT O
polysaccharide BC2GM032903217 NN O
lyase BC2GM032903217 VBD O
family BC2GM032903217 NN O
1 BC2GM032903217 CD O
) BC2GM032903217 ) O
. BC2GM032903217 . O
. . O O

The BC2GM095387001 DT O
sensitivity BC2GM095387001 NN O
of BC2GM095387001 IN O
central BC2GM095387001 JJ O
dopamine BC2GM095387001 NN O
receptors BC2GM095387001 NNS O
was BC2GM095387001 VBD O
assessed BC2GM095387001 VBN O
with BC2GM095387001 IN O
the BC2GM095387001 DT O
growth BC2GM095387001 NN O
hormone BC2GM095387001 NN O
response BC2GM095387001 NN O
to BC2GM095387001 TO O
apomorphine BC2GM095387001 VB O
application BC2GM095387001 NN O
. BC2GM095387001 . O
. . O O

OBJECTIVES BC2GM006956250 NN O
: BC2GM006956250 : O
The BC2GM006956250 DT O
present BC2GM006956250 JJ O
study BC2GM006956250 NN O
tested BC2GM006956250 VBD O
the BC2GM006956250 DT O
hypothesis BC2GM006956250 NN O
that BC2GM006956250 WDT O
stimulating BC2GM006956250 VBG O
the BC2GM006956250 DT O
central BC2GM006956250 JJ O
noradrenergic BC2GM006956250 JJ O
system BC2GM006956250 NN O
using BC2GM006956250 VBG O
the BC2GM006956250 DT O
new BC2GM006956250 JJ O
noradrenaline BC2GM006956250 JJ O
re-uptake BC2GM006956250 JJ O
inhibitor BC2GM006956250 NN O
reboxetine BC2GM006956250 NN O
would BC2GM006956250 MD O
result BC2GM006956250 VB O
in BC2GM006956250 IN O
a BC2GM006956250 DT O
dose-dependent BC2GM006956250 JJ O
enhancement BC2GM006956250 NN O
of BC2GM006956250 IN O
memory BC2GM006956250 NN O
for BC2GM006956250 IN O
emotional BC2GM006956250 JJ O
material BC2GM006956250 NN O
in BC2GM006956250 IN O
man BC2GM006956250 NN O
. BC2GM006956250 . O
. . O O

Loss BC2GM053683599 NNP O
of BC2GM053683599 IN O
pRb BC2GM053683599 NN O
or BC2GM053683599 CC O
p107 BC2GM053683599 NN O
binding BC2GM053683599 NN O
results BC2GM053683599 NNS O
in BC2GM053683599 IN O
the BC2GM053683599 DT O
loss BC2GM053683599 NN O
of BC2GM053683599 IN O
transforming BC2GM053683599 VBG O
activity BC2GM053683599 NN O
. BC2GM053683599 . O
. . O O

All BC2GM049034176 PDT O
the BC2GM049034176 DT O
cognate BC2GM049034176 NN O
gene BC2GM049034176 NN O
clones BC2GM049034176 NNS O
were BC2GM049034176 VBD O
constructed BC2GM049034176 VBN O
, BC2GM049034176 , O
using BC2GM049034176 VBG O
either BC2GM049034176 CC O
PCR BC2GM049034176 NNP O
products BC2GM049034176 NNS O
amplified BC2GM049034176 VBN O
from BC2GM049034176 IN O
genomic BC2GM049034176 JJ O
DNA BC2GM049034176 NNP O
, BC2GM049034176 , O
or BC2GM049034176 CC O
gap-repair BC2GM049034176 NN O
. BC2GM049034176 . O
. . O O

We BC2GM035651086 PRP O
examined BC2GM035651086 VBD O
the BC2GM035651086 DT O
mechanisms BC2GM035651086 NNS O
by BC2GM035651086 IN O
which BC2GM035651086 WDT O
two BC2GM035651086 CD O
different BC2GM035651086 JJ O
types BC2GM035651086 NNS O
of BC2GM035651086 IN O
photonic BC2GM035651086 JJ O
radiation BC2GM035651086 NN O
, BC2GM035651086 , O
short BC2GM035651086 JJ O
wavelength BC2GM035651086 NN O
UV BC2GM035651086 NNP O
( BC2GM035651086 ( O
UV-C BC2GM035651086 NNP O
) BC2GM035651086 ) O
and BC2GM035651086 CC O
gamma BC2GM035651086 JJ O
radiation BC2GM035651086 NN O
, BC2GM035651086 , O
activate BC2GM035651086 JJ O
transcription BC2GM035651086 NN O
factor BC2GM035651086 NN O
NF-kappaB BC2GM035651086 NNP O
. BC2GM035651086 . O
. . O O

We BC2GM037509935 PRP O
have BC2GM037509935 VBP O
determined BC2GM037509935 VBN O
the BC2GM037509935 DT O
complete BC2GM037509935 JJ O
cDNA BC2GM037509935 NN O
sequence BC2GM037509935 NN O
of BC2GM037509935 IN O
rat BC2GM037509935 NN O
plectin BC2GM037509935 NN O
from BC2GM037509935 IN O
a BC2GM037509935 DT O
number BC2GM037509935 NN O
of BC2GM037509935 IN O
well-characterized BC2GM037509935 JJ O
overlapping BC2GM037509935 VBG O
lambda BC2GM037509935 JJ O
gt11 BC2GM037509935 NN O
clones BC2GM037509935 NNS O
. BC2GM037509935 . O
. . O O

Genomic BC2GM094853535 NNP O
organization BC2GM094853535 NN O
of BC2GM094853535 IN O
the BC2GM094853535 DT O
human BC2GM094853535 JJ O
multidrug BC2GM094853535 NN O
resistance BC2GM094853535 NN O
( BC2GM094853535 ( O
MDR1 BC2GM094853535 NNP O
) BC2GM094853535 ) O
gene BC2GM094853535 NN O
and BC2GM094853535 CC O
origin BC2GM094853535 NN O
of BC2GM094853535 IN O
P-glycoproteins BC2GM094853535 NNP O
. BC2GM094853535 . O
. . O O

Reality BC2GM044349472 NN O
and BC2GM044349472 CC O
clinical BC2GM044349472 JJ O
application BC2GM044349472 NN O
of BC2GM044349472 IN O
immunoglobulin BC2GM044349472 JJ O
preparations BC2GM044349472 NNS O
. BC2GM044349472 . O
. . O O

The BC2GM022402970 DT O
activity BC2GM022402970 NN O
of BC2GM022402970 IN O
gamma-glutamyl BC2GM022402970 JJ O
transpeptidase BC2GM022402970 NN O
in BC2GM022402970 IN O
the BC2GM022402970 DT O
serum BC2GM022402970 NN O
of BC2GM022402970 IN O
problem BC2GM022402970 NN O
drinkers BC2GM022402970 NNS O
. BC2GM022402970 . O
. . O O

The BC2GM089723467 DT O
broad BC2GM089723467 JJ O
range BC2GM089723467 NN O
protein BC2GM089723467 NN O
tyrosine BC2GM089723467 JJ O
kinase BC2GM089723467 NN O
inhibitor BC2GM089723467 NN O
genistein BC2GM089723467 NN O
and BC2GM089723467 CC O
the BC2GM089723467 DT O
phosphatidylinositol BC2GM089723467 JJ O
3-kinase BC2GM089723467 JJ O
inhibitors BC2GM089723467 NNS O
wortmannin BC2GM089723467 NN O
and BC2GM089723467 CC O
LY BC2GM089723467 NNP O
294002 BC2GM089723467 CD O
( BC2GM089723467 ( O
2- BC2GM089723467 JJ O
( BC2GM089723467 ( O
4-morpholinyl BC2GM089723467 JJ O
) BC2GM089723467 ) O
-8-phenyl-4H-1-benzopyran-4-one BC2GM089723467 NN O
) BC2GM089723467 ) O
also BC2GM089723467 RB O
blocked BC2GM089723467 VBD O
adenosine BC2GM089723467 JJ O
A3 BC2GM089723467 NNP O
receptor BC2GM089723467 NN O
stimulation BC2GM089723467 NN O
of BC2GM089723467 IN O
p42 BC2GM089723467 NN O
/ BC2GM089723467 NNP O
p44 BC2GM089723467 NN O
MAPK BC2GM089723467 NNP O
. BC2GM089723467 . O
. . O O

Hemorrheological BC2GM053041146 JJ O
evaluation BC2GM053041146 NN O
and BC2GM053041146 CC O
proposed BC2GM053041146 VBD O
pharmacological BC2GM053041146 JJ O
uses BC2GM053041146 NNS O
. BC2GM053041146 . O
. . O O

The BC2GM068280141 DT O
traW BC2GM068280141 JJ O
gene BC2GM068280141 NN O
of BC2GM068280141 IN O
the BC2GM068280141 DT O
Escherichia BC2GM068280141 NNP O
coli BC2GM068280141 VBD O
K-12 BC2GM068280141 NNP O
sex BC2GM068280141 NN O
factor BC2GM068280141 NN O
, BC2GM068280141 , O
F BC2GM068280141 NNP O
, BC2GM068280141 , O
encodes BC2GM068280141 VBZ O
one BC2GM068280141 CD O
of BC2GM068280141 IN O
the BC2GM068280141 DT O
numerous BC2GM068280141 JJ O
proteins BC2GM068280141 NNS O
required BC2GM068280141 VBN O
for BC2GM068280141 IN O
conjugative BC2GM068280141 JJ O
transfer BC2GM068280141 NN O
of BC2GM068280141 IN O
this BC2GM068280141 DT O
plasmid BC2GM068280141 NN O
. BC2GM068280141 . O
. . O O

In BC2GM064734705 IN O
the BC2GM064734705 DT O
second BC2GM064734705 JJ O
, BC2GM064734705 , O
37 BC2GM064734705 CD O
students BC2GM064734705 NNS O
were BC2GM064734705 VBD O
given BC2GM064734705 VBN O
trimethoprim BC2GM064734705 JJ O
/ BC2GM064734705 JJ O
sulphamethoxazole BC2GM064734705 NN O
( BC2GM064734705 ( O
160 BC2GM064734705 CD O
mg BC2GM064734705 RB O
TMP-SMX BC2GM064734705 NNP O
800 BC2GM064734705 CD O
mg BC2GM064734705 NN O
) BC2GM064734705 ) O
, BC2GM064734705 , O
38 BC2GM064734705 CD O
TMP BC2GM064734705 NNP O
( BC2GM064734705 ( O
200 BC2GM064734705 CD O
mg BC2GM064734705 NN O
) BC2GM064734705 ) O
, BC2GM064734705 , O
and BC2GM064734705 CC O
in BC2GM064734705 IN O
35 BC2GM064734705 CD O
a BC2GM064734705 DT O
placebo BC2GM064734705 NN O
was BC2GM064734705 VBD O
given BC2GM064734705 VBN O
b.i.d BC2GM064734705 NN O
. BC2GM064734705 . O
for BC2GM064734705 IN O
five BC2GM064734705 CD O
days BC2GM064734705 NNS O
. BC2GM064734705 . O
. . O O

The BC2GM034827451 DT O
expression BC2GM034827451 NN O
pattern BC2GM034827451 NN O
of BC2GM034827451 IN O
LjEmx BC2GM034827451 NNP O
changed BC2GM034827451 VBD O
dramatically BC2GM034827451 RB O
during BC2GM034827451 IN O
embryogenesis BC2GM034827451 NN O
; BC2GM034827451 : O
expression BC2GM034827451 NN O
was BC2GM034827451 VBD O
seen BC2GM034827451 VBN O
initially BC2GM034827451 RB O
in BC2GM034827451 IN O
the BC2GM034827451 DT O
entire BC2GM034827451 JJ O
neural BC2GM034827451 JJ O
tube BC2GM034827451 NN O
and BC2GM034827451 CC O
mesoderm BC2GM034827451 NN O
, BC2GM034827451 , O
which BC2GM034827451 WDT O
were BC2GM034827451 VBD O
secondarily BC2GM034827451 RB O
downregulated BC2GM034827451 VBN O
, BC2GM034827451 , O
and BC2GM034827451 CC O
secondarily BC2GM034827451 RB O
in BC2GM034827451 IN O
cranial BC2GM034827451 JJ O
nerve BC2GM034827451 NN O
ganglia BC2GM034827451 NN O
and BC2GM034827451 CC O
in BC2GM034827451 IN O
the BC2GM034827451 DT O
craniofacial BC2GM034827451 JJ O
mesenchyme BC2GM034827451 NN O
. BC2GM034827451 . O
. . O O

Mapping BC2GM091675853 VBG O
the BC2GM091675853 DT O
5 BC2GM091675853 CD O
' BC2GM091675853 POS O
and BC2GM091675853 CC O
3 BC2GM091675853 CD O
' BC2GM091675853 '' O
termini BC2GM091675853 NN O
of BC2GM091675853 IN O
TED BC2GM091675853 NNP O
RNAs BC2GM091675853 NNP O
indicated BC2GM091675853 VBD O
that BC2GM091675853 IN O
the BC2GM091675853 DT O
LTRs BC2GM091675853 NNP O
have BC2GM091675853 VBP O
a BC2GM091675853 DT O
retroviral BC2GM091675853 JJ O
U3-R-U5 BC2GM091675853 JJ O
structural BC2GM091675853 JJ O
organization BC2GM091675853 NN O
that BC2GM091675853 WDT O
is BC2GM091675853 VBZ O
capable BC2GM091675853 JJ O
of BC2GM091675853 IN O
directing BC2GM091675853 VBG O
the BC2GM091675853 DT O
synthesis BC2GM091675853 NN O
of BC2GM091675853 IN O
transcripts BC2GM091675853 NNS O
that BC2GM091675853 WDT O
represent BC2GM091675853 VBP O
potential BC2GM091675853 JJ O
substrates BC2GM091675853 NNS O
for BC2GM091675853 IN O
reverse BC2GM091675853 JJ O
transcription BC2GM091675853 NN O
and BC2GM091675853 CC O
intermediates BC2GM091675853 NNS O
in BC2GM091675853 IN O
transposition BC2GM091675853 NN O
. BC2GM091675853 . O
. . O O

In BC2GM019331308 IN O
seven BC2GM019331308 CD O
patients BC2GM019331308 NNS O
( BC2GM019331308 ( O
7.8 BC2GM019331308 CD O
% BC2GM019331308 NN O
) BC2GM019331308 ) O
with BC2GM019331308 IN O
new BC2GM019331308 JJ O
Q-waves BC2GM019331308 NNS O
and BC2GM019331308 CC O
a BC2GM019331308 DT O
pathologic BC2GM019331308 JJ O
CK-MB BC2GM019331308 NNP O
profile BC2GM019331308 NN O
( BC2GM019331308 ( O
group BC2GM019331308 NN O
II BC2GM019331308 NNP O
) BC2GM019331308 ) O
troponin BC2GM019331308 NN O
T BC2GM019331308 NNP O
reached BC2GM019331308 VBD O
median BC2GM019331308 JJ O
levels BC2GM019331308 NNS O
of BC2GM019331308 IN O
10.47 BC2GM019331308 CD O
micrograms BC2GM019331308 NNS O
/ BC2GM019331308 JJ O
l BC2GM019331308 NN O
( BC2GM019331308 ( O
quartile BC2GM019331308 JJ O
6.34-12.50 BC2GM019331308 JJ O
micrograms BC2GM019331308 NNS O
/ BC2GM019331308 VBP O
l BC2GM019331308 NN O
) BC2GM019331308 ) O
( BC2GM019331308 ( O
P BC2GM019331308 NNP O
< BC2GM019331308 VBZ O
0.001 BC2GM019331308 CD O
I BC2GM019331308 PRP O
vs BC2GM019331308 VBP O
II BC2GM019331308 NNP O
) BC2GM019331308 ) O
. BC2GM019331308 . O
. . O O

Importantly BC2GM042108030 RB O
, BC2GM042108030 , O
a BC2GM042108030 DT O
single BC2GM042108030 JJ O
base BC2GM042108030 NN O
change BC2GM042108030 NN O
in BC2GM042108030 IN O
the BC2GM042108030 DT O
fifth BC2GM042108030 JJ O
position BC2GM042108030 NN O
of BC2GM042108030 IN O
the BC2GM042108030 DT O
c-fos BC2GM042108030 JJ O
sequence BC2GM042108030 NN O
( BC2GM042108030 ( O
GGTCTnnnAGACC BC2GM042108030 NNP O
to BC2GM042108030 TO O
GGTCA BC2GM042108030 NNP O
/ BC2GM042108030 NNP O
GnnnAGACC BC2GM042108030 NNP O
) BC2GM042108030 ) O
produced BC2GM042108030 VBD O
an BC2GM042108030 DT O
element BC2GM042108030 NN O
that BC2GM042108030 WDT O
bound BC2GM042108030 VBD O
the BC2GM042108030 DT O
estrogen BC2GM042108030 NN O
receptor BC2GM042108030 NN O
and BC2GM042108030 CC O
conferred BC2GM042108030 VBD O
estrogen-dependent BC2GM042108030 JJ O
transcriptional BC2GM042108030 JJ O
activation BC2GM042108030 NN O
of BC2GM042108030 IN O
a BC2GM042108030 DT O
reporter BC2GM042108030 NN O
gene BC2GM042108030 NN O
. BC2GM042108030 . O
. . O O

Mutating BC2GM057387777 VBG O
this BC2GM057387777 DT O
sequence BC2GM057387777 NN O
eliminated BC2GM057387777 VBD O
complex BC2GM057387777 JJ O
formation BC2GM057387777 NN O
and BC2GM057387777 CC O
markedly BC2GM057387777 RB O
reduced BC2GM057387777 VBD O
basal BC2GM057387777 NN O
and BC2GM057387777 CC O
cAMP-dependent BC2GM057387777 JJ O
promoter BC2GM057387777 NN O
activity BC2GM057387777 NN O
of BC2GM057387777 IN O
transfected BC2GM057387777 JJ O
reporter BC2GM057387777 NN O
genes BC2GM057387777 NNS O
. BC2GM057387777 . O
. . O O

We BC2GM090587249 PRP O
hypothesize BC2GM090587249 VBP O
that BC2GM090587249 IN O
the BC2GM090587249 DT O
ability BC2GM090587249 NN O
of BC2GM090587249 IN O
these BC2GM090587249 DT O
acidic BC2GM090587249 JJ O
activators BC2GM090587249 NNS O
to BC2GM090587249 TO O
specifically BC2GM090587249 RB O
interact BC2GM090587249 VB O
with BC2GM090587249 IN O
multiple BC2GM090587249 JJ O
components BC2GM090587249 NNS O
of BC2GM090587249 IN O
the BC2GM090587249 DT O
transcription BC2GM090587249 NN O
initiation BC2GM090587249 NN O
complex BC2GM090587249 NN O
likely BC2GM090587249 JJ O
underlies BC2GM090587249 VBZ O
the BC2GM090587249 DT O
dramatic BC2GM090587249 JJ O
functional BC2GM090587249 JJ O
synergy BC2GM090587249 NN O
exhibited BC2GM090587249 VBN O
by BC2GM090587249 IN O
this BC2GM090587249 DT O
class BC2GM090587249 NN O
of BC2GM090587249 IN O
activation BC2GM090587249 NN O
domains BC2GM090587249 NNS O
in BC2GM090587249 IN O
vivo BC2GM090587249 NN O
. BC2GM090587249 . O
. . O O

Morphological-functional BC2GM020995115 JJ O
status BC2GM020995115 NN O
of BC2GM020995115 IN O
the BC2GM020995115 DT O
edentulous BC2GM020995115 JJ O
mandible BC2GM020995115 JJ O
and BC2GM020995115 CC O
selection BC2GM020995115 NN O
of BC2GM020995115 IN O
the BC2GM020995115 DT O
most BC2GM020995115 RBS O
effective BC2GM020995115 JJ O
method BC2GM020995115 NN O
for BC2GM020995115 IN O
functional BC2GM020995115 JJ O
impression-taking BC2GM020995115 NN O
. BC2GM020995115 . O
. . O O

Characterization BC2GM029519664 NN O
and BC2GM029519664 CC O
targeted BC2GM029519664 JJ O
disruption BC2GM029519664 NN O
of BC2GM029519664 IN O
murine BC2GM029519664 NN O
Nup50 BC2GM029519664 NNP O
, BC2GM029519664 , O
a BC2GM029519664 DT O
p27 BC2GM029519664 NN O
( BC2GM029519664 ( O
Kip1 BC2GM029519664 NNP O
) BC2GM029519664 ) O
-interacting BC2GM029519664 VBG O
component BC2GM029519664 NN O
of BC2GM029519664 IN O
the BC2GM029519664 DT O
nuclear BC2GM029519664 JJ O
pore BC2GM029519664 NN O
complex BC2GM029519664 NN O
. BC2GM029519664 . O
p27 BC2GM029519664 NN O
( BC2GM029519664 ( O
Kip1 BC2GM029519664 NNP O
) BC2GM029519664 ) O
is BC2GM029519664 VBZ O
a BC2GM029519664 DT O
member BC2GM029519664 NN O
of BC2GM029519664 IN O
the BC2GM029519664 DT O
Cip-Kip BC2GM029519664 NNP O
family BC2GM029519664 NN O
of BC2GM029519664 IN O
cyclin-dependent BC2GM029519664 JJ O
kinase BC2GM029519664 NN O
( BC2GM029519664 ( O
Cdk BC2GM029519664 NNP O
) BC2GM029519664 ) O
inhibitors BC2GM029519664 NNS O
that BC2GM029519664 WDT O
binds BC2GM029519664 VBZ O
to BC2GM029519664 TO O
cyclin-Cdk BC2GM029519664 VB O
complexes BC2GM029519664 NNS O
and BC2GM029519664 CC O
inhibits BC2GM029519664 NNS O
their BC2GM029519664 PRP$ O
catalytic BC2GM029519664 JJ O
activity BC2GM029519664 NN O
in BC2GM029519664 IN O
response BC2GM029519664 NN O
to BC2GM029519664 TO O
antiproliferative BC2GM029519664 JJ O
stimuli BC2GM029519664 NNS O
. BC2GM029519664 . O
p27 BC2GM029519664 NN O
( BC2GM029519664 ( O
Kip1 BC2GM029519664 NNP O
) BC2GM029519664 ) O
is BC2GM029519664 VBZ O
regulated BC2GM029519664 VBN O
by BC2GM029519664 IN O
several BC2GM029519664 JJ O
posttranscriptional BC2GM029519664 JJ O
mechanisms BC2GM029519664 NNS O
, BC2GM029519664 , O
including BC2GM029519664 VBG O
subcellular BC2GM029519664 JJ O
localization BC2GM029519664 NN O
. BC2GM029519664 . O
. . O O

Cytomegalovirus BC2GM094806221 NNP O
infection BC2GM094806221 NN O
-- BC2GM094806221 : O
modern BC2GM094806221 JJ O
diagnosis BC2GM094806221 NN O
. BC2GM094806221 . O
. . O O

Inability BC2GM047223393 NN O
of BC2GM047223393 IN O
niacin BC2GM047223393 NN O
to BC2GM047223393 TO O
protect BC2GM047223393 VB O
from BC2GM047223393 IN O
in BC2GM047223393 IN O
vivo BC2GM047223393 NN O
hyperoxia BC2GM047223393 NN O
or BC2GM047223393 CC O
in BC2GM047223393 IN O
vitro BC2GM047223393 JJ O
microsomal BC2GM047223393 JJ O
lipid BC2GM047223393 JJ O
peroxidation BC2GM047223393 NN O
. BC2GM047223393 . O
. . O O

The BC2GM036507029 DT O
chromosomal BC2GM036507029 JJ O
location BC2GM036507029 NN O
of BC2GM036507029 IN O
these BC2GM036507029 DT O
YACs BC2GM036507029 NNP O
was BC2GM036507029 VBD O
verified BC2GM036507029 VBN O
using BC2GM036507029 VBG O
FISH BC2GM036507029 NNP O
, BC2GM036507029 , O
which BC2GM036507029 WDT O
also BC2GM036507029 RB O
demonstrated BC2GM036507029 VBD O
their BC2GM036507029 PRP$ O
nonchimeric BC2GM036507029 JJ O
nature BC2GM036507029 NN O
. BC2GM036507029 . O
. . O O

FEurea BC2GM000169441 NNP O
was BC2GM000169441 VBD O
also BC2GM000169441 RB O
measured BC2GM000169441 VBN O
during BC2GM000169441 IN O
stable BC2GM000169441 JJ O
graft BC2GM000169441 NN O
function BC2GM000169441 NN O
, BC2GM000169441 , O
7-14 BC2GM000169441 JJ O
days BC2GM000169441 NNS O
prior BC2GM000169441 RB O
to BC2GM000169441 TO O
allograft BC2GM000169441 VB O
dysfunction BC2GM000169441 NN O
. BC2GM000169441 . O
. . O O

Immunoblot BC2GM043953870 NNP O
analysis BC2GM043953870 NN O
of BC2GM043953870 IN O
purified BC2GM043953870 JJ O
and BC2GM043953870 CC O
protease-digested BC2GM043953870 JJ O
intracellular BC2GM043953870 JJ O
mature BC2GM043953870 NN O
virus BC2GM043953870 NN O
( BC2GM043953870 ( O
IMV BC2GM043953870 NNP O
) BC2GM043953870 ) O
and BC2GM043953870 CC O
extracellular BC2GM043953870 JJ O
enveloped BC2GM043953870 VBD O
virus BC2GM043953870 NN O
( BC2GM043953870 ( O
EEV BC2GM043953870 NNP O
) BC2GM043953870 ) O
showed BC2GM043953870 VBD O
that BC2GM043953870 IN O
the BC2GM043953870 DT O
A36R BC2GM043953870 NNP O
proteins BC2GM043953870 NNS O
were BC2GM043953870 VBD O
present BC2GM043953870 JJ O
on BC2GM043953870 IN O
the BC2GM043953870 DT O
surface BC2GM043953870 NN O
of BC2GM043953870 IN O
EEV BC2GM043953870 NNP O
with BC2GM043953870 IN O
type BC2GM043953870 NN O
II BC2GM043953870 NNP O
membrane BC2GM043953870 NN O
topology BC2GM043953870 NN O
, BC2GM043953870 , O
but BC2GM043953870 CC O
were BC2GM043953870 VBD O
absent BC2GM043953870 JJ O
from BC2GM043953870 IN O
IMV BC2GM043953870 NNP O
. BC2GM043953870 . O
. . O O

In BC2GM041546990 IN O
our BC2GM041546990 PRP$ O
initial BC2GM041546990 JJ O
studies BC2GM041546990 NNS O
, BC2GM041546990 , O
we BC2GM041546990 PRP O
treated BC2GM041546990 VBD O
MCF-7 BC2GM041546990 NNP O
cells BC2GM041546990 NNS O
with BC2GM041546990 IN O
paclitaxel BC2GM041546990 NN O
, BC2GM041546990 , O
which BC2GM041546990 WDT O
results BC2GM041546990 NNS O
in BC2GM041546990 IN O
the BC2GM041546990 DT O
arrest BC2GM041546990 NN O
of BC2GM041546990 IN O
cells BC2GM041546990 NNS O
in BC2GM041546990 IN O
G1 BC2GM041546990 NNP O
with BC2GM041546990 IN O
4n BC2GM041546990 CD O
DNA BC2GM041546990 NN O
content BC2GM041546990 NN O
( BC2GM041546990 ( O
pseudo BC2GM041546990 JJ O
G1 BC2GM041546990 NNP O
) BC2GM041546990 ) O
. BC2GM041546990 . O
. . O O

First BC2GM037682924 RB O
, BC2GM037682924 , O
ste12Delta BC2GM037682924 JJ O
cells BC2GM037682924 NNS O
differ BC2GM037682924 VBP O
from BC2GM037682924 IN O
cells BC2GM037682924 NNS O
with BC2GM037682924 IN O
disruptions BC2GM037682924 NNS O
of BC2GM037682924 IN O
the BC2GM037682924 DT O
upstream BC2GM037682924 JJ O
signaling BC2GM037682924 NN O
elements BC2GM037682924 NNS O
( BC2GM037682924 ( O
e.g. BC2GM037682924 NN O
, BC2GM037682924 , O
ste4Delta BC2GM037682924 NN O
, BC2GM037682924 , O
ste20Delta BC2GM037682924 NN O
, BC2GM037682924 , O
ste5Delta BC2GM037682924 NN O
, BC2GM037682924 , O
ste11Delta BC2GM037682924 NN O
, BC2GM037682924 , O
ste7Delta BC2GM037682924 NN O
, BC2GM037682924 , O
or BC2GM037682924 CC O
fus3Delta BC2GM037682924 JJ O
kss1Delta BC2GM037682924 NN O
cells BC2GM037682924 NNS O
) BC2GM037682924 ) O
in BC2GM037682924 IN O
that BC2GM037682924 DT O
they BC2GM037682924 PRP O
clearly BC2GM037682924 RB O
retain BC2GM037682924 VBP O
some BC2GM037682924 DT O
capacity BC2GM037682924 NN O
for BC2GM037682924 IN O
inducing BC2GM037682924 VBG O
Ste3p BC2GM037682924 NNP O
phosphorylation BC2GM037682924 NN O
. BC2GM037682924 . O
. . O O

The BC2GM097463042 DT O
amino BC2GM097463042 NN O
acid BC2GM097463042 JJ O
sequence BC2GM097463042 NN O
of BC2GM097463042 IN O
the BC2GM097463042 DT O
protein BC2GM097463042 NN O
encoded BC2GM097463042 VBN O
by BC2GM097463042 IN O
MSK1 BC2GM097463042 NNP O
is BC2GM097463042 VBZ O
homologous BC2GM097463042 JJ O
to BC2GM097463042 TO O
yeast BC2GM097463042 VB O
cytoplasmic BC2GM097463042 JJ O
lysyl-tRNA BC2GM097463042 JJ O
synthetase BC2GM097463042 NN O
and BC2GM097463042 CC O
to BC2GM097463042 TO O
the BC2GM097463042 DT O
product BC2GM097463042 NN O
of BC2GM097463042 IN O
the BC2GM097463042 DT O
herC BC2GM097463042 NN O
gene BC2GM097463042 NN O
, BC2GM097463042 , O
which BC2GM097463042 WDT O
has BC2GM097463042 VBZ O
recently BC2GM097463042 RB O
been BC2GM097463042 VBN O
suggested BC2GM097463042 VBN O
to BC2GM097463042 TO O
code BC2GM097463042 VB O
for BC2GM097463042 IN O
the BC2GM097463042 DT O
Escherichia BC2GM097463042 NNP O
coli BC2GM097463042 NN O
enzyme BC2GM097463042 NN O
. BC2GM097463042 . O
. . O O

Insertion BC2GM006294233 NN O
of BC2GM006294233 IN O
alternatively BC2GM006294233 RB O
spliced BC2GM006294233 VBN O
exon BC2GM006294233 JJ O
W BC2GM006294233 NNP O
into BC2GM006294233 IN O
CREB BC2GM006294233 NNP O
mRNA BC2GM006294233 NN O
during BC2GM006294233 IN O
spermatogenesis BC2GM006294233 NN O
results BC2GM006294233 NNS O
in BC2GM006294233 IN O
a BC2GM006294233 DT O
polycistronic BC2GM006294233 JJ O
RNA BC2GM006294233 NNP O
that BC2GM006294233 WDT O
encodes BC2GM006294233 VBZ O
two BC2GM006294233 CD O
novel BC2GM006294233 NN O
internally BC2GM006294233 RB O
translated BC2GM006294233 VBN O
CREB BC2GM006294233 NNP O
repressor BC2GM006294233 NN O
isoforms BC2GM006294233 NNS O
called BC2GM006294233 VBD O
I-CREBs BC2GM006294233 NNP O
, BC2GM006294233 , O
consisting BC2GM006294233 VBG O
of BC2GM006294233 IN O
the BC2GM006294233 DT O
carboxy-terminal BC2GM006294233 JJ O
DNA-binding BC2GM006294233 NNP O
domain BC2GM006294233 NN O
devoid BC2GM006294233 NN O
of BC2GM006294233 IN O
the BC2GM006294233 DT O
transactivation BC2GM006294233 NN O
domains BC2GM006294233 VBZ O
. BC2GM006294233 . O
. . O O

In BC2GM009829131 IN O
the BC2GM009829131 DT O
future BC2GM009829131 NN O
, BC2GM009829131 , O
transoesophageal BC2GM009829131 JJ O
echocardiography BC2GM009829131 NN O
may BC2GM009829131 MD O
be BC2GM009829131 VB O
used BC2GM009829131 VBN O
to BC2GM009829131 TO O
measure BC2GM009829131 VB O
variations BC2GM009829131 NNS O
in BC2GM009829131 IN O
wall BC2GM009829131 NN O
thickness BC2GM009829131 NN O
which BC2GM009829131 WDT O
change BC2GM009829131 VBP O
the BC2GM009829131 DT O
global BC2GM009829131 JJ O
loading BC2GM009829131 NN O
conditions BC2GM009829131 NNS O
in BC2GM009829131 IN O
the BC2GM009829131 DT O
basal BC2GM009829131 NN O
midwall BC2GM009829131 JJ O
compartments BC2GM009829131 NNS O
of BC2GM009829131 IN O
the BC2GM009829131 DT O
left BC2GM009829131 JJ O
ventricle BC2GM009829131 NN O
. BC2GM009829131 . O
. . O O

The BC2GM077245988 DT O
1.6-kb BC2GM077245988 JJ O
cDNA BC2GM077245988 NN O
( BC2GM077245988 ( O
CBF-A BC2GM077245988 NNP O
) BC2GM077245988 ) O
encoding BC2GM077245988 VBG O
285 BC2GM077245988 CD O
amino BC2GM077245988 JJ O
acids BC2GM077245988 NNS O
( BC2GM077245988 ( O
aa BC2GM077245988 NN O
) BC2GM077245988 ) O
was BC2GM077245988 VBD O
obtained BC2GM077245988 VBN O
, BC2GM077245988 , O
and BC2GM077245988 CC O
a BC2GM077245988 DT O
beta-galactosidase BC2GM077245988 JJ O
fusion BC2GM077245988 NN O
protein BC2GM077245988 NN O
, BC2GM077245988 , O
bacterially BC2GM077245988 RB O
produced BC2GM077245988 VBN O
from BC2GM077245988 IN O
the BC2GM077245988 DT O
cDNA BC2GM077245988 NN O
, BC2GM077245988 , O
bound BC2GM077245988 NN O
to BC2GM077245988 TO O
DNA BC2GM077245988 NNP O
fragments BC2GM077245988 NNS O
containing BC2GM077245988 VBG O
several BC2GM077245988 JJ O
CArG BC2GM077245988 NNP O
boxes BC2GM077245988 NNS O
. BC2GM077245988 . O
. . O O

There BC2GM062484182 EX O
is BC2GM062484182 VBZ O
a BC2GM062484182 DT O
good BC2GM062484182 JJ O
correlation BC2GM062484182 NN O
between BC2GM062484182 IN O
the BC2GM062484182 DT O
occurrence BC2GM062484182 NN O
in BC2GM062484182 IN O
any BC2GM062484182 DT O
particular BC2GM062484182 JJ O
vascular BC2GM062484182 JJ O
segment BC2GM062484182 NN O
of BC2GM062484182 IN O
the BC2GM062484182 DT O
transient BC2GM062484182 NN O
contractile BC2GM062484182 NN O
response BC2GM062484182 NN O
and BC2GM062484182 CC O
intrinsic BC2GM062484182 JJ O
tone BC2GM062484182 NN O
as BC2GM062484182 IN O
assessed BC2GM062484182 VBN O
by BC2GM062484182 IN O
relaxation BC2GM062484182 NN O
to BC2GM062484182 TO O
papaverine BC2GM062484182 VB O
( BC2GM062484182 ( O
10 BC2GM062484182 CD O
( BC2GM062484182 ( O
-6 BC2GM062484182 NN O
) BC2GM062484182 ) O
M BC2GM062484182 NNP O
) BC2GM062484182 ) O
. BC2GM062484182 . O
. . O O

Stress-induced BC2GM018080572 JJ O
suppression BC2GM018080572 NN O
of BC2GM018080572 IN O
the BC2GM018080572 DT O
prolactin BC2GM018080572 NN O
afternoon BC2GM018080572 NN O
surge BC2GM018080572 NN O
in BC2GM018080572 IN O
ovariectomized BC2GM018080572 JJ O
, BC2GM018080572 , O
estrogen-treated BC2GM018080572 JJ O
rats BC2GM018080572 NNS O
and BC2GM018080572 CC O
the BC2GM018080572 DT O
nocturnal BC2GM018080572 JJ O
surge BC2GM018080572 NN O
in BC2GM018080572 IN O
pseudopregnant BC2GM018080572 JJ O
rats BC2GM018080572 NNS O
are BC2GM018080572 VBP O
accompanied BC2GM018080572 VBN O
by BC2GM018080572 IN O
an BC2GM018080572 DT O
increase BC2GM018080572 NN O
in BC2GM018080572 IN O
median BC2GM018080572 JJ O
eminence BC2GM018080572 NN O
dihydroxyphenylacetic BC2GM018080572 JJ O
acid BC2GM018080572 NN O
concentrations BC2GM018080572 NNS O
. BC2GM018080572 . O
. . O O

A BC2GM084258366 DT O
99m BC2GM084258366 CD O
Tc BC2GM084258366 NNP O
bone BC2GM084258366 NN O
scan BC2GM084258366 NN O
showed BC2GM084258366 VBD O
a BC2GM084258366 DT O
focal BC2GM084258366 JJ O
area BC2GM084258366 NN O
of BC2GM084258366 IN O
an BC2GM084258366 DT O
increased BC2GM084258366 JJ O
uptake BC2GM084258366 NN O
at BC2GM084258366 IN O
the BC2GM084258366 DT O
site BC2GM084258366 NN O
of BC2GM084258366 IN O
the BC2GM084258366 DT O
mass BC2GM084258366 NN O
below BC2GM084258366 IN O
the BC2GM084258366 DT O
calcaneus BC2GM084258366 NN O
. BC2GM084258366 . O
. . O O

An BC2GM070522560 DT O
additional BC2GM070522560 JJ O
dose BC2GM070522560 NN O
of BC2GM070522560 IN O
20-25 BC2GM070522560 JJ O
Gy BC2GM070522560 NNP O
was BC2GM070522560 VBD O
delivered BC2GM070522560 VBN O
to BC2GM070522560 TO O
the BC2GM070522560 DT O
site BC2GM070522560 NN O
of BC2GM070522560 IN O
original BC2GM070522560 JJ O
involvement BC2GM070522560 NN O
using BC2GM070522560 VBG O
an BC2GM070522560 DT O
implant BC2GM070522560 NN O
when BC2GM070522560 WRB O
feasible BC2GM070522560 NN O
. BC2GM070522560 . O
. . O O

C. BC2GM033082377 NNP O
glabrata BC2GM033082377 NN O
cells BC2GM033082377 NNS O
containing BC2GM033082377 VBG O
the BC2GM033082377 DT O
CBF1 BC2GM033082377 NNP O
gene BC2GM033082377 NN O
under BC2GM033082377 IN O
the BC2GM033082377 DT O
influence BC2GM033082377 NN O
of BC2GM033082377 IN O
a BC2GM033082377 DT O
shutdown BC2GM033082377 JJ O
promoter BC2GM033082377 NN O
( BC2GM033082377 ( O
tetO-ScHOP BC2GM033082377 JJ O
) BC2GM033082377 ) O
arrested BC2GM033082377 VBD O
their BC2GM033082377 PRP$ O
growth BC2GM033082377 NN O
after BC2GM033082377 IN O
5 BC2GM033082377 CD O
h BC2GM033082377 NN O
of BC2GM033082377 IN O
cultivation BC2GM033082377 NN O
in BC2GM033082377 IN O
the BC2GM033082377 DT O
presence BC2GM033082377 NN O
of BC2GM033082377 IN O
the BC2GM033082377 DT O
reactive BC2GM033082377 JJ O
drug BC2GM033082377 NN O
doxycycline BC2GM033082377 NN O
. BC2GM033082377 . O
. . O O

Five BC2GM074423927 CD O
RNA BC2GM074423927 NNP O
transcripts BC2GM074423927 NNS O
of BC2GM074423927 IN O
about BC2GM074423927 RB O
1.2 BC2GM074423927 CD O
to BC2GM074423927 TO O
1.7 BC2GM074423927 CD O
kilobases BC2GM074423927 NNS O
were BC2GM074423927 VBD O
mapped BC2GM074423927 VBN O
to BC2GM074423927 TO O
a BC2GM074423927 DT O
part BC2GM074423927 NN O
of BC2GM074423927 IN O
the BC2GM074423927 DT O
genome BC2GM074423927 NN O
of BC2GM074423927 IN O
insect BC2GM074423927 JJ O
iridescent BC2GM074423927 NN O
virus BC2GM074423927 NN O
type BC2GM074423927 NN O
6 BC2GM074423927 CD O
( BC2GM074423927 ( O
Chilo BC2GM074423927 NNP O
iridescent BC2GM074423927 NN O
virus BC2GM074423927 NN O
; BC2GM074423927 : O
CIV BC2GM074423927 NNP O
) BC2GM074423927 ) O
between BC2GM074423927 IN O
genome BC2GM074423927 NN O
coordinates BC2GM074423927 NNS O
0.832 BC2GM074423927 CD O
and BC2GM074423927 CC O
0.856 BC2GM074423927 CD O
within BC2GM074423927 IN O
the BC2GM074423927 DT O
EcoRI BC2GM074423927 NNP O
DNA BC2GM074423927 NNP O
fragment BC2GM074423927 NN O
F BC2GM074423927 NNP O
. BC2GM074423927 . O
. . O O

A BC2GM090142421 DT O
silica-based BC2GM090142421 JJ O
, BC2GM090142421 , O
fluoride-free BC2GM090142421 JJ O
placebo BC2GM090142421 NN O
containing BC2GM090142421 VBG O
NaTPP BC2GM090142421 NNP O
, BC2GM090142421 , O
and BC2GM090142421 CC O
a BC2GM090142421 DT O
NaF-containing BC2GM090142421 JJ O
silica-based BC2GM090142421 JJ O
USP BC2GM090142421 NNP O
reference BC2GM090142421 NN O
standard BC2GM090142421 NN O
toothpaste BC2GM090142421 NN O
were BC2GM090142421 VBD O
used BC2GM090142421 VBN O
as BC2GM090142421 IN O
negative BC2GM090142421 JJ O
and BC2GM090142421 CC O
positive BC2GM090142421 JJ O
control BC2GM090142421 NN O
toothpastes BC2GM090142421 VBZ O
, BC2GM090142421 , O
respectively BC2GM090142421 RB O
. BC2GM090142421 . O
. . O O

Since BC2GM049209935 IN O
RIP140 BC2GM049209935 NNP O
generally BC2GM049209935 RB O
down-regulates BC2GM049209935 VBZ O
receptor BC2GM049209935 NN O
activity BC2GM049209935 NN O
in BC2GM049209935 IN O
mammalian BC2GM049209935 JJ O
cells BC2GM049209935 NNS O
and BC2GM049209935 CC O
specifically BC2GM049209935 RB O
down-regulates BC2GM049209935 NNS O
coactivation BC2GM049209935 NN O
mediated BC2GM049209935 VBN O
by BC2GM049209935 IN O
SRC-1 BC2GM049209935 NNP O
, BC2GM049209935 , O
we BC2GM049209935 PRP O
propose BC2GM049209935 VBP O
a BC2GM049209935 DT O
model BC2GM049209935 NN O
in BC2GM049209935 IN O
which BC2GM049209935 WDT O
RIP140 BC2GM049209935 NNP O
indirectly BC2GM049209935 RB O
regulates BC2GM049209935 VBZ O
nuclear BC2GM049209935 JJ O
receptor BC2GM049209935 NN O
AF-2 BC2GM049209935 NNP O
activity BC2GM049209935 NN O
by BC2GM049209935 IN O
competition BC2GM049209935 NN O
for BC2GM049209935 IN O
coactivators BC2GM049209935 NNS O
such BC2GM049209935 JJ O
as BC2GM049209935 IN O
SRC-1 BC2GM049209935 NNP O
. BC2GM049209935 . O
. . O O

Preventing BC2GM082234251 VBG O
the BC2GM082234251 DT O
heterosexual BC2GM082234251 JJ O
spread BC2GM082234251 NN O
of BC2GM082234251 IN O
HIV BC2GM082234251 NNP O
into BC2GM082234251 IN O
this BC2GM082234251 DT O
vulnerable BC2GM082234251 JJ O
population BC2GM082234251 NN O
is BC2GM082234251 VBZ O
a BC2GM082234251 DT O
formidable BC2GM082234251 JJ O
public BC2GM082234251 JJ O
health BC2GM082234251 NN O
challenge BC2GM082234251 NN O
. BC2GM082234251 . O
. . O O

CrkII BC2GM036783364 NNP O
and BC2GM036783364 CC O
CrkL BC2GM036783364 NNP O
constitutively BC2GM036783364 RB O
formed BC2GM036783364 VBD O
complex BC2GM036783364 JJ O
with BC2GM036783364 IN O
the BC2GM036783364 DT O
guanine BC2GM036783364 NN O
nucleotide BC2GM036783364 IN O
exchange BC2GM036783364 NN O
factor BC2GM036783364 NN O
C3G BC2GM036783364 NNP O
, BC2GM036783364 , O
in BC2GM036783364 IN O
unstimulated BC2GM036783364 JJ O
as BC2GM036783364 RB O
well BC2GM036783364 RB O
as BC2GM036783364 IN O
PDGF-stimulated BC2GM036783364 NNP O
cells BC2GM036783364 NNS O
. BC2GM036783364 . O
. . O O

The BC2GM055081476 DT O
data BC2GM055081476 NN O
suggest BC2GM055081476 NN O
that BC2GM055081476 IN O
compromised BC2GM055081476 VBD O
fibrinolytic BC2GM055081476 JJ O
capacity BC2GM055081476 NN O
may BC2GM055081476 MD O
be BC2GM055081476 VB O
a BC2GM055081476 DT O
contributing BC2GM055081476 JJ O
factor BC2GM055081476 NN O
in BC2GM055081476 IN O
the BC2GM055081476 DT O
development BC2GM055081476 NN O
of BC2GM055081476 IN O
thrombosis BC2GM055081476 NN O
in BC2GM055081476 IN O
patients BC2GM055081476 NNS O
with BC2GM055081476 IN O
the BC2GM055081476 DT O
lupus BC2GM055081476 NN O
anticoagulant BC2GM055081476 NN O
. BC2GM055081476 . O
. . O O

To BC2GM076930779 TO O
clarify BC2GM076930779 VB O
the BC2GM076930779 DT O
mechanisms BC2GM076930779 NNS O
that BC2GM076930779 WDT O
regulate BC2GM076930779 VBP O
transcription BC2GM076930779 NN O
of BC2GM076930779 IN O
the BC2GM076930779 DT O
GTP BC2GM076930779 NNP O
cyclohydrolase BC2GM076930779 NN O
I BC2GM076930779 PRP O
gene BC2GM076930779 NN O
and BC2GM076930779 CC O
to BC2GM076930779 TO O
generate BC2GM076930779 VB O
multiple BC2GM076930779 JJ O
species BC2GM076930779 NNS O
of BC2GM076930779 IN O
mRNA BC2GM076930779 NN O
, BC2GM076930779 , O
we BC2GM076930779 PRP O
isolated BC2GM076930779 VBD O
genomic BC2GM076930779 JJ O
DNA BC2GM076930779 NNP O
clones BC2GM076930779 NNS O
for BC2GM076930779 IN O
the BC2GM076930779 DT O
human BC2GM076930779 JJ O
and BC2GM076930779 CC O
mouse BC2GM076930779 NN O
GTP BC2GM076930779 NNP O
cyclohydrolase BC2GM076930779 NN O
I BC2GM076930779 PRP O
genes BC2GM076930779 NNS O
. BC2GM076930779 . O
. . O O

Moreover BC2GM082796346 RB O
, BC2GM082796346 , O
the BC2GM082796346 DT O
formation BC2GM082796346 NN O
of BC2GM082796346 IN O
the BC2GM082796346 DT O
complex BC2GM082796346 NN O
between BC2GM082796346 IN O
IclR BC2GM082796346 NNP O
and BC2GM082796346 CC O
the BC2GM082796346 DT O
operator BC2GM082796346 NN O
/ BC2GM082796346 NNP O
promoter BC2GM082796346 NN O
region BC2GM082796346 NN O
has BC2GM082796346 VBZ O
been BC2GM082796346 VBN O
found BC2GM082796346 VBN O
to BC2GM082796346 TO O
be BC2GM082796346 VB O
impaired BC2GM082796346 VBN O
by BC2GM082796346 IN O
phosphoenol BC2GM082796346 JJ O
pyruvate BC2GM082796346 NN O
but BC2GM082796346 CC O
insensitive BC2GM082796346 JJ O
to BC2GM082796346 TO O
acetate BC2GM082796346 VB O
, BC2GM082796346 , O
acetyl-CoA BC2GM082796346 JJ O
, BC2GM082796346 , O
pyruvate BC2GM082796346 NN O
, BC2GM082796346 , O
and BC2GM082796346 CC O
oxaloacetate BC2GM082796346 NN O
. BC2GM082796346 . O
. . O O

In BC2GM000748612 IN O
transient BC2GM000748612 JJ O
transfections BC2GM000748612 NNS O
using BC2GM000748612 VBG O
luciferase BC2GM000748612 JJ O
reporter BC2GM000748612 NN O
genes BC2GM000748612 NNS O
driven BC2GM000748612 VBN O
by BC2GM000748612 IN O
1 BC2GM000748612 CD O
kb BC2GM000748612 NNS O
of BC2GM000748612 IN O
the BC2GM000748612 DT O
5 BC2GM000748612 CD O
' BC2GM000748612 POS O
flanking BC2GM000748612 VBG O
DNA BC2GM000748612 NN O
of BC2GM000748612 IN O
the BC2GM000748612 DT O
three BC2GM000748612 CD O
CALM BC2GM000748612 NNP O
genes BC2GM000748612 NNS O
, BC2GM000748612 , O
the BC2GM000748612 DT O
promoter BC2GM000748612 NN O
activity BC2GM000748612 NN O
correlated BC2GM000748612 VBN O
with BC2GM000748612 IN O
the BC2GM000748612 DT O
endogenous BC2GM000748612 JJ O
CALM BC2GM000748612 NNP O
transcriptional BC2GM000748612 JJ O
activity BC2GM000748612 NN O
, BC2GM000748612 , O
but BC2GM000748612 CC O
only BC2GM000748612 RB O
when BC2GM000748612 WRB O
the BC2GM000748612 DT O
5 BC2GM000748612 CD O
' BC2GM000748612 POS O
untranslated BC2GM000748612 JJ O
regions BC2GM000748612 NNS O
were BC2GM000748612 VBD O
included BC2GM000748612 VBN O
in BC2GM000748612 IN O
the BC2GM000748612 DT O
constructs BC2GM000748612 NNS O
. BC2GM000748612 . O
. . O O

Mean BC2GM055489778 JJ O
latency BC2GM055489778 NN O
periods BC2GM055489778 NNS O
were BC2GM055489778 VBD O
29.6 BC2GM055489778 CD O
among BC2GM055489778 IN O
insulators BC2GM055489778 NNS O
, BC2GM055489778 , O
35.4 BC2GM055489778 CD O
among BC2GM055489778 IN O
dock BC2GM055489778 JJ O
workers BC2GM055489778 NNS O
, BC2GM055489778 , O
43.7 BC2GM055489778 CD O
in BC2GM055489778 IN O
a BC2GM055489778 DT O
heterogeneous BC2GM055489778 JJ O
group BC2GM055489778 NN O
defined BC2GM055489778 VBD O
as BC2GM055489778 IN O
various BC2GM055489778 JJ O
, BC2GM055489778 , O
46.4 BC2GM055489778 CD O
in BC2GM055489778 IN O
non-shipbuilding BC2GM055489778 JJ O
industry BC2GM055489778 NN O
workers BC2GM055489778 NNS O
, BC2GM055489778 , O
49.4 BC2GM055489778 CD O
in BC2GM055489778 IN O
shipyard BC2GM055489778 NN O
workers BC2GM055489778 NNS O
, BC2GM055489778 , O
51.7 BC2GM055489778 CD O
among BC2GM055489778 IN O
women BC2GM055489778 NNS O
with BC2GM055489778 IN O
a BC2GM055489778 DT O
history BC2GM055489778 NN O
of BC2GM055489778 IN O
domestic BC2GM055489778 JJ O
exposure BC2GM055489778 NN O
to BC2GM055489778 TO O
asbestos BC2GM055489778 NN O
, BC2GM055489778 , O
and BC2GM055489778 CC O
56.2 BC2GM055489778 CD O
in BC2GM055489778 IN O
people BC2GM055489778 NNS O
employed BC2GM055489778 VBN O
in BC2GM055489778 IN O
maritime BC2GM055489778 NN O
trades BC2GM055489778 NNS O
. BC2GM055489778 . O
. . O O

These BC2GM060589467 DT O
segments BC2GM060589467 NNS O
may BC2GM060589467 MD O
represent BC2GM060589467 VB O
pseudogenes BC2GM060589467 NNS O
. BC2GM060589467 . O
. . O O

The BC2GM027886760 DT O
vertebrate BC2GM027886760 JJ O
transcription BC2GM027886760 NN O
factors BC2GM027886760 NNS O
TCF BC2GM027886760 NNP O
( BC2GM027886760 ( O
T BC2GM027886760 NNP O
cell BC2GM027886760 NNP O
factor BC2GM027886760 NN O
) BC2GM027886760 ) O
and BC2GM027886760 CC O
LEF BC2GM027886760 NNP O
( BC2GM027886760 ( O
lymphocyte BC2GM027886760 JJ O
enhancer BC2GM027886760 NN O
binding BC2GM027886760 VBG O
factor BC2GM027886760 NN O
) BC2GM027886760 ) O
interact BC2GM027886760 NN O
with BC2GM027886760 IN O
beta-catenin BC2GM027886760 NN O
and BC2GM027886760 CC O
are BC2GM027886760 VBP O
hypothesized BC2GM027886760 VBN O
to BC2GM027886760 TO O
mediate BC2GM027886760 VB O
Wingless BC2GM027886760 NNP O
/ BC2GM027886760 NNP O
Wnt BC2GM027886760 NNP O
signaling BC2GM027886760 NN O
. BC2GM027886760 . O
. . O O

SETTING BC2GM059332523 NN O
: BC2GM059332523 : O
Participants BC2GM059332523 NNS O
in BC2GM059332523 IN O
the BC2GM059332523 DT O
Physicians BC2GM059332523 NNPS O
' BC2GM059332523 POS O
Health BC2GM059332523 NNP O
Study BC2GM059332523 NNP O
, BC2GM059332523 , O
a BC2GM059332523 DT O
randomized BC2GM059332523 JJ O
trial BC2GM059332523 NN O
of BC2GM059332523 IN O
aspirin BC2GM059332523 NN O
and BC2GM059332523 CC O
beta-carotene BC2GM059332523 NN O
among BC2GM059332523 IN O
U.S. BC2GM059332523 NNP O
male BC2GM059332523 JJ O
physicians BC2GM059332523 NNS O
. BC2GM059332523 . O
. . O O

This BC2GM020803257 DT O
domain BC2GM020803257 NN O
encompasses BC2GM020803257 VBZ O
the BC2GM020803257 DT O
region BC2GM020803257 NN O
of BC2GM020803257 IN O
ARP-1 BC2GM020803257 NNP O
/ BC2GM020803257 NNP O
COUP-TFII BC2GM020803257 NNP O
corresponding BC2GM020803257 VBG O
to BC2GM020803257 TO O
helices BC2GM020803257 NNS O
3 BC2GM020803257 CD O
to BC2GM020803257 TO O
12 BC2GM020803257 CD O
in BC2GM020803257 IN O
the BC2GM020803257 DT O
recently BC2GM020803257 RB O
published BC2GM020803257 VBN O
crystal BC2GM020803257 JJ O
structure BC2GM020803257 NN O
of BC2GM020803257 IN O
other BC2GM020803257 JJ O
members BC2GM020803257 NNS O
of BC2GM020803257 IN O
the BC2GM020803257 DT O
nuclear BC2GM020803257 JJ O
receptor BC2GM020803257 NN O
superfamily BC2GM020803257 RB O
. BC2GM020803257 . O
. . O O

The BC2GM042134341 DT O
existence BC2GM042134341 NN O
of BC2GM042134341 IN O
a BC2GM042134341 DT O
TFIIIB BC2GM042134341 NNP O
assembly BC2GM042134341 NN O
pathway BC2GM042134341 RB O
leading BC2GM042134341 VBG O
to BC2GM042134341 TO O
the BC2GM042134341 DT O
faithful BC2GM042134341 JJ O
transcription BC2GM042134341 NN O
of BC2GM042134341 IN O
natural BC2GM042134341 JJ O
eukaryotic BC2GM042134341 JJ O
tRNA BC2GM042134341 NN O
genes BC2GM042134341 NNS O
in BC2GM042134341 IN O
the BC2GM042134341 DT O
absence BC2GM042134341 NN O
of BC2GM042134341 IN O
TFIIIC BC2GM042134341 NNP O
provides BC2GM042134341 VBZ O
novel BC2GM042134341 JJ O
insights BC2GM042134341 NNS O
into BC2GM042134341 IN O
the BC2GM042134341 DT O
functional BC2GM042134341 JJ O
flexibility BC2GM042134341 NN O
of BC2GM042134341 IN O
the BC2GM042134341 DT O
eukaryotic BC2GM042134341 JJ O
tRNA BC2GM042134341 NN O
gene BC2GM042134341 NN O
transcription BC2GM042134341 NN O
machinery BC2GM042134341 NN O
and BC2GM042134341 CC O
on BC2GM042134341 IN O
its BC2GM042134341 PRP$ O
evolution BC2GM042134341 NN O
from BC2GM042134341 IN O
an BC2GM042134341 DT O
ancestral BC2GM042134341 JJ O
RNA BC2GM042134341 NNP O
polymerase BC2GM042134341 NN O
III BC2GM042134341 NNP O
system BC2GM042134341 NN O
relying BC2GM042134341 VBG O
on BC2GM042134341 IN O
upstream BC2GM042134341 NN O
, BC2GM042134341 , O
TATA- BC2GM042134341 NNP O
centered BC2GM042134341 VBD O
control BC2GM042134341 NN O
elements BC2GM042134341 NNS O
. BC2GM042134341 . O
. . O O

Maduromycosis BC2GM091114680 NN O
in BC2GM091114680 IN O
Italy BC2GM091114680 NNP O
. BC2GM091114680 . O
. . O O

Cloning BC2GM076520533 VBG O
and BC2GM076520533 CC O
nucleotide BC2GM076520533 JJ O
sequence BC2GM076520533 NN O
analysis BC2GM076520533 NN O
reveals BC2GM076520533 NNS O
that BC2GM076520533 WDT O
BUR6 BC2GM076520533 NNP O
encodes BC2GM076520533 VBZ O
a BC2GM076520533 DT O
homolog BC2GM076520533 NN O
of BC2GM076520533 IN O
DRAP1 BC2GM076520533 NNP O
( BC2GM076520533 ( O
also BC2GM076520533 RB O
called BC2GM076520533 VBN O
NC2alpha BC2GM076520533 NNP O
) BC2GM076520533 ) O
, BC2GM076520533 , O
a BC2GM076520533 DT O
mammalian BC2GM076520533 JJ O
repressor BC2GM076520533 NN O
of BC2GM076520533 IN O
basal BC2GM076520533 JJ O
transcription BC2GM076520533 NN O
. BC2GM076520533 . O
. . O O

The BC2GM059456391 DT O
increments BC2GM059456391 NNS O
in BC2GM059456391 IN O
median BC2GM059456391 JJ O
plasma BC2GM059456391 NN O
secretin BC2GM059456391 NN O
concentration BC2GM059456391 NN O
were BC2GM059456391 VBD O
1.6 BC2GM059456391 CD O
, BC2GM059456391 , O
3.0 BC2GM059456391 CD O
, BC2GM059456391 , O
and BC2GM059456391 CC O
6.4 BC2GM059456391 CD O
pmol BC2GM059456391 NN O
x BC2GM059456391 NN O
1 BC2GM059456391 CD O
( BC2GM059456391 ( O
-1 BC2GM059456391 NN O
) BC2GM059456391 ) O
after BC2GM059456391 IN O
secretin BC2GM059456391 NN O
, BC2GM059456391 , O
125 BC2GM059456391 CD O
, BC2GM059456391 , O
250 BC2GM059456391 CD O
and BC2GM059456391 CC O
500 BC2GM059456391 CD O
fmol BC2GM059456391 JJ O
x BC2GM059456391 JJ O
kg-1 BC2GM059456391 NN O
, BC2GM059456391 , O
and BC2GM059456391 CC O
the BC2GM059456391 DT O
corresponding BC2GM059456391 JJ O
15-min BC2GM059456391 JJ O
bicarbonate BC2GM059456391 NN O
output BC2GM059456391 NN O
283 BC2GM059456391 CD O
, BC2GM059456391 , O
442 BC2GM059456391 CD O
, BC2GM059456391 , O
and BC2GM059456391 CC O
1435 BC2GM059456391 CD O
micromol BC2GM059456391 NN O
, BC2GM059456391 , O
respectively BC2GM059456391 RB O
. BC2GM059456391 . O
. . O O

The BC2GM094778247 DT O
difference BC2GM094778247 NN O
between BC2GM094778247 IN O
the BC2GM094778247 DT O
results BC2GM094778247 NNS O
in BC2GM094778247 IN O
the BC2GM094778247 DT O
high BC2GM094778247 JJ O
dose BC2GM094778247 NN O
AHLG BC2GM094778247 NNP O
and BC2GM094778247 CC O
in BC2GM094778247 IN O
the BC2GM094778247 DT O
control BC2GM094778247 NN O
group BC2GM094778247 NN O
was BC2GM094778247 VBD O
significant BC2GM094778247 JJ O
( BC2GM094778247 ( O
p BC2GM094778247 NN O
less BC2GM094778247 JJR O
than BC2GM094778247 IN O
0.05 BC2GM094778247 CD O
) BC2GM094778247 ) O
. BC2GM094778247 . O
. . O O

Isolation BC2GM011525777 NN O
and BC2GM011525777 CC O
characterization BC2GM011525777 NN O
of BC2GM011525777 IN O
human BC2GM011525777 JJ O
orthologs BC2GM011525777 NNS O
of BC2GM011525777 IN O
yeast BC2GM011525777 JJ O
CCR4-NOT BC2GM011525777 NNP O
complex BC2GM011525777 JJ O
subunits BC2GM011525777 NNS O
. BC2GM011525777 . O
. . O O

Thus BC2GM059243006 RB O
, BC2GM059243006 , O
an BC2GM059243006 DT O
unmodified BC2GM059243006 JJ O
threonine BC2GM059243006 NN O
at BC2GM059243006 IN O
position BC2GM059243006 NN O
169 BC2GM059243006 CD O
in BC2GM059243006 IN O
Cdc28 BC2GM059243006 NNP O
is BC2GM059243006 VBZ O
important BC2GM059243006 JJ O
for BC2GM059243006 IN O
interaction BC2GM059243006 NN O
with BC2GM059243006 IN O
G1 BC2GM059243006 NNP O
cyclins BC2GM059243006 NNS O
. BC2GM059243006 . O
. . O O

To BC2GM003912165 TO O
investigate BC2GM003912165 VB O
the BC2GM003912165 DT O
effect BC2GM003912165 NN O
of BC2GM003912165 IN O
hyperthyroidism BC2GM003912165 NN O
on BC2GM003912165 IN O
the BC2GM003912165 DT O
pattern BC2GM003912165 NN O
and BC2GM003912165 CC O
time BC2GM003912165 NN O
course BC2GM003912165 NN O
of BC2GM003912165 IN O
O2 BC2GM003912165 NNP O
uptake BC2GM003912165 NN O
( BC2GM003912165 ( O
VO2 BC2GM003912165 NNP O
) BC2GM003912165 ) O
following BC2GM003912165 VBG O
the BC2GM003912165 DT O
transition BC2GM003912165 NN O
from BC2GM003912165 IN O
rest BC2GM003912165 NN O
to BC2GM003912165 TO O
exercise BC2GM003912165 VB O
, BC2GM003912165 , O
six BC2GM003912165 CD O
patients BC2GM003912165 NNS O
and BC2GM003912165 CC O
six BC2GM003912165 CD O
healthy BC2GM003912165 JJ O
subjects BC2GM003912165 NNS O
performed BC2GM003912165 VBN O
cycle BC2GM003912165 NN O
exercise BC2GM003912165 NN O
at BC2GM003912165 IN O
an BC2GM003912165 DT O
average BC2GM003912165 JJ O
work BC2GM003912165 NN O
rate BC2GM003912165 NN O
( BC2GM003912165 ( O
WR BC2GM003912165 NNP O
) BC2GM003912165 ) O
of BC2GM003912165 IN O
18 BC2GM003912165 CD O
and BC2GM003912165 CC O
20 BC2GM003912165 CD O
W BC2GM003912165 NNP O
respectively BC2GM003912165 RB O
. BC2GM003912165 . O
. . O O

Thus BC2GM020598843 RB O
, BC2GM020598843 , O
the BC2GM020598843 DT O
end BC2GM020598843 NN O
of BC2GM020598843 IN O
a BC2GM020598843 DT O
linearized BC2GM020598843 JJ O
DNA BC2GM020598843 NN O
fragment BC2GM020598843 NN O
can BC2GM020598843 MD O
initiate BC2GM020598843 VB O
new BC2GM020598843 JJ O
DNA BC2GM020598843 NNP O
synthesis BC2GM020598843 NN O
by BC2GM020598843 IN O
BIR BC2GM020598843 NNP O
in BC2GM020598843 IN O
which BC2GM020598843 WDT O
the BC2GM020598843 DT O
newly BC2GM020598843 RB O
synthesized BC2GM020598843 VBN O
DNA BC2GM020598843 NN O
is BC2GM020598843 VBZ O
displaced BC2GM020598843 VBN O
and BC2GM020598843 CC O
subsequently BC2GM020598843 RB O
forms BC2GM020598843 NNS O
circles BC2GM020598843 NNS O
by BC2GM020598843 IN O
NHEJ BC2GM020598843 NNP O
. BC2GM020598843 . O
. . O O

Indications BC2GM024357509 NNS O
for BC2GM024357509 IN O
therapy BC2GM024357509 NN O
using BC2GM024357509 VBG O
MAO BC2GM024357509 NNP O
inhibitors BC2GM024357509 NNS O
. BC2GM024357509 . O
. . O O

In BC2GM061606382 IN O
this BC2GM061606382 DT O
report BC2GM061606382 NN O
, BC2GM061606382 , O
we BC2GM061606382 PRP O
establish BC2GM061606382 VB O
that BC2GM061606382 IN O
the BC2GM061606382 DT O
heteromeric BC2GM061606382 JJ O
CCAAT-binding BC2GM061606382 NNP O
factor BC2GM061606382 NN O
CBF BC2GM061606382 NNP O
is BC2GM061606382 VBZ O
the BC2GM061606382 DT O
major BC2GM061606382 JJ O
component BC2GM061606382 NN O
of BC2GM061606382 IN O
the BC2GM061606382 DT O
C1-binding BC2GM061606382 NNP O
factor BC2GM061606382 NN O
( BC2GM061606382 ( O
C1F BC2GM061606382 NNP O
) BC2GM061606382 ) O
in BC2GM061606382 IN O
human BC2GM061606382 JJ O
cells BC2GM061606382 NNS O
. BC2GM061606382 . O
. . O O

The BC2GM011910286 DT O
determination BC2GM011910286 NN O
of BC2GM011910286 IN O
diacetyl BC2GM011910286 NN O
, BC2GM011910286 , O
2,3-pentanedione BC2GM011910286 CD O
and BC2GM011910286 CC O
acetoin BC2GM011910286 NN O
was BC2GM011910286 VBD O
performed BC2GM011910286 VBN O
in BC2GM011910286 IN O
two BC2GM011910286 CD O
steps BC2GM011910286 NNS O
. BC2GM011910286 . O
. . O O

Manual BC2GM088957012 JJ O
sample BC2GM088957012 NN O
clean-up BC2GM088957012 JJ O
procedures BC2GM088957012 NNS O
as BC2GM088957012 RB O
well BC2GM088957012 RB O
as BC2GM088957012 IN O
the BC2GM088957012 DT O
addition BC2GM088957012 NN O
of BC2GM088957012 IN O
an BC2GM088957012 DT O
internal BC2GM088957012 JJ O
standard BC2GM088957012 NN O
are BC2GM088957012 VBP O
not BC2GM088957012 RB O
needed BC2GM088957012 VBN O
. BC2GM088957012 . O
. . O O

Because BC2GM056033881 IN O
of BC2GM056033881 IN O
gut BC2GM056033881 JJ O
fermentation BC2GM056033881 NN O
, BC2GM056033881 , O
a BC2GM056033881 DT O
substantial BC2GM056033881 JJ O
portion BC2GM056033881 NN O
( BC2GM056033881 ( O
16-80 BC2GM056033881 CD O
% BC2GM056033881 NN O
) BC2GM056033881 ) O
of BC2GM056033881 IN O
N BC2GM056033881 NNP O
is BC2GM056033881 VBZ O
absorbed BC2GM056033881 VBN O
as BC2GM056033881 IN O
ammonia BC2GM056033881 NN O
N BC2GM056033881 NNP O
( BC2GM056033881 ( O
NH3N BC2GM056033881 NNP O
) BC2GM056033881 ) O
. BC2GM056033881 . O
. . O O

We BC2GM038474271 PRP O
conclude BC2GM038474271 VBP O
that BC2GM038474271 IN O
the BC2GM038474271 DT O
BR-C BC2GM038474271 NNP O
early BC2GM038474271 JJ O
gene BC2GM038474271 NN O
directly BC2GM038474271 RB O
activates BC2GM038474271 VBZ O
late BC2GM038474271 JJ O
gene BC2GM038474271 NN O
transcription BC2GM038474271 NN O
by BC2GM038474271 IN O
interacting BC2GM038474271 VBG O
with BC2GM038474271 IN O
late BC2GM038474271 JJ O
gene BC2GM038474271 NN O
cis-acting BC2GM038474271 JJ O
regulatory BC2GM038474271 JJ O
elements BC2GM038474271 NNS O
and BC2GM038474271 CC O
that BC2GM038474271 IN O
this BC2GM038474271 DT O
interaction BC2GM038474271 NN O
is BC2GM038474271 VBZ O
responsible BC2GM038474271 JJ O
for BC2GM038474271 IN O
the BC2GM038474271 DT O
temporal BC2GM038474271 JJ O
linkage BC2GM038474271 NN O
of BC2GM038474271 IN O
early BC2GM038474271 JJ O
and BC2GM038474271 CC O
late BC2GM038474271 JJ O
ecdysone-induced BC2GM038474271 JJ O
gene BC2GM038474271 NN O
expression BC2GM038474271 NN O
. BC2GM038474271 . O
. . O O

A BC2GM062392652 DT O
Frank BC2GM062392652 NNP O
vectorcardiogram BC2GM062392652 NN O
was BC2GM062392652 VBD O
recorded BC2GM062392652 VBN O
before BC2GM062392652 RB O
and BC2GM062392652 CC O
every BC2GM062392652 DT O
15-30 BC2GM062392652 JJ O
minutes BC2GM062392652 NNS O
for BC2GM062392652 IN O
10 BC2GM062392652 CD O
hours BC2GM062392652 NNS O
after BC2GM062392652 IN O
the BC2GM062392652 DT O
occlusion BC2GM062392652 NN O
. BC2GM062392652 . O
. . O O

The BC2GM082256131 DT O
first BC2GM082256131 JJ O
decision BC2GM082256131 NN O
in BC2GM082256131 IN O
management BC2GM082256131 NN O
is BC2GM082256131 VBZ O
to BC2GM082256131 TO O
consider BC2GM082256131 VB O
cardioversion BC2GM082256131 NN O
which BC2GM082256131 WDT O
can BC2GM082256131 MD O
be BC2GM082256131 VB O
achieved BC2GM082256131 VBN O
in BC2GM082256131 IN O
suitable BC2GM082256131 JJ O
cases BC2GM082256131 NNS O
electrically BC2GM082256131 RB O
, BC2GM082256131 , O
or BC2GM082256131 CC O
pharmacologically BC2GM082256131 RB O
with BC2GM082256131 IN O
a BC2GM082256131 DT O
class BC2GM082256131 NN O
Ic BC2GM082256131 NNP O
antiarrhythmic BC2GM082256131 JJ O
drug BC2GM082256131 NN O
like BC2GM082256131 IN O
flecainide BC2GM082256131 NN O
or BC2GM082256131 CC O
propafenone BC2GM082256131 NN O
. BC2GM082256131 . O
. . O O

The BC2GM064739272 DT O
infection BC2GM064739272 NN O
of BC2GM064739272 IN O
cells BC2GM064739272 NNS O
with BC2GM064739272 IN O
Moloney BC2GM064739272 NNP O
murine BC2GM064739272 NN O
leukemia BC2GM064739272 NN O
virus BC2GM064739272 NN O
( BC2GM064739272 ( O
M-MuLV BC2GM064739272 NNP O
) BC2GM064739272 ) O
causes BC2GM064739272 VBZ O
an BC2GM064739272 DT O
increase BC2GM064739272 NN O
in BC2GM064739272 IN O
specific BC2GM064739272 JJ O
cellular BC2GM064739272 JJ O
gene BC2GM064739272 NN O
products BC2GM064739272 NNS O
, BC2GM064739272 , O
including BC2GM064739272 VBG O
the BC2GM064739272 DT O
major BC2GM064739272 JJ O
histocompatibility BC2GM064739272 NN O
complex BC2GM064739272 NN O
( BC2GM064739272 ( O
MHC BC2GM064739272 NNP O
) BC2GM064739272 ) O
class BC2GM064739272 NN O
I BC2GM064739272 PRP O
antigens BC2GM064739272 VBP O
. BC2GM064739272 . O
. . O O

One-hour BC2GM025050820 JJ O
O3 BC2GM025050820 NNP O
, BC2GM025050820 , O
NO2 BC2GM025050820 NNP O
, BC2GM025050820 , O
and BC2GM025050820 CC O
SO2 BC2GM025050820 NNP O
personal BC2GM025050820 JJ O
exposures BC2GM025050820 NNS O
were BC2GM025050820 VBD O
measured BC2GM025050820 VBN O
using BC2GM025050820 VBG O
samplers BC2GM025050820 NNS O
developed BC2GM025050820 VBD O
in BC2GM025050820 IN O
our BC2GM025050820 PRP$ O
laboratory BC2GM025050820 NN O
, BC2GM025050820 , O
while BC2GM025050820 IN O
short-term BC2GM025050820 JJ O
PM2.5 BC2GM025050820 NNP O
, BC2GM025050820 , O
CO BC2GM025050820 NNP O
, BC2GM025050820 , O
and BC2GM025050820 CC O
VOCs BC2GM025050820 NNP O
exposures BC2GM025050820 NNS O
were BC2GM025050820 VBD O
measured BC2GM025050820 VBN O
using BC2GM025050820 VBG O
currently BC2GM025050820 RB O
available BC2GM025050820 JJ O
monitors BC2GM025050820 NNS O
. BC2GM025050820 . O
. . O O

The BC2GM005019655 DT O
implication BC2GM005019655 NN O
of BC2GM005019655 IN O
Rac BC2GM005019655 NNP O
and BC2GM005019655 CC O
Cdc42 BC2GM005019655 NNP O
was BC2GM005019655 VBD O
analyzed BC2GM005019655 VBN O
in BC2GM005019655 IN O
transient BC2GM005019655 JJ O
transfection BC2GM005019655 NN O
experiments BC2GM005019655 NNS O
using BC2GM005019655 VBG O
either BC2GM005019655 CC O
constitutively BC2GM005019655 RB O
active BC2GM005019655 JJ O
( BC2GM005019655 ( O
V12 BC2GM005019655 NNP O
) BC2GM005019655 ) O
or BC2GM005019655 CC O
dominant-interfering BC2GM005019655 JJ O
( BC2GM005019655 ( O
N17 BC2GM005019655 NNP O
) BC2GM005019655 ) O
mutants BC2GM005019655 NNS O
. BC2GM005019655 . O
. . O O

Promoter BC2GM029191037 NN O
, BC2GM029191037 , O
spliced BC2GM029191037 VBD O
leader BC2GM029191037 NN O
, BC2GM029191037 , O
and BC2GM029191037 CC O
coding BC2GM029191037 VBG O
sequence BC2GM029191037 NN O
for BC2GM029191037 IN O
BICP4 BC2GM029191037 NNP O
, BC2GM029191037 , O
the BC2GM029191037 DT O
largest BC2GM029191037 JJS O
of BC2GM029191037 IN O
the BC2GM029191037 DT O
immediate-early BC2GM029191037 JJ O
proteins BC2GM029191037 NNS O
of BC2GM029191037 IN O
bovine BC2GM029191037 NN O
herpesvirus BC2GM029191037 NN O
1 BC2GM029191037 CD O
. BC2GM029191037 . O
. . O O

However BC2GM048797879 RB O
, BC2GM048797879 , O
C BC2GM048797879 NNP O
/ BC2GM048797879 NNP O
EBP BC2GM048797879 NNP O
beta BC2GM048797879 NN O
stimulated BC2GM048797879 VBD O
transcription BC2GM048797879 NN O
primarily BC2GM048797879 RB O
through BC2GM048797879 IN O
the BC2GM048797879 DT O
cAMP-responsive BC2GM048797879 JJ O
element BC2GM048797879 NN O
( BC2GM048797879 ( O
CRE BC2GM048797879 NNP O
) BC2GM048797879 ) O
, BC2GM048797879 , O
which BC2GM048797879 WDT O
maps BC2GM048797879 VBP O
between BC2GM048797879 IN O
positions BC2GM048797879 NNS O
-77 BC2GM048797879 VBP O
to BC2GM048797879 TO O
-94 BC2GM048797879 VB O
, BC2GM048797879 , O
but BC2GM048797879 CC O
not BC2GM048797879 RB O
at BC2GM048797879 IN O
the BC2GM048797879 DT O
more BC2GM048797879 JJR O
5'-binding BC2GM048797879 JJ O
sites BC2GM048797879 NNS O
. BC2GM048797879 . O
. . O O

We BC2GM030870274 PRP O
have BC2GM030870274 VBP O
used BC2GM030870274 VBN O
nuclear BC2GM030870274 JJ O
magnetic BC2GM030870274 JJ O
resonance BC2GM030870274 NN O
( BC2GM030870274 ( O
NMR BC2GM030870274 NNP O
) BC2GM030870274 ) O
to BC2GM030870274 TO O
obtain BC2GM030870274 VB O
the BC2GM030870274 DT O
structure BC2GM030870274 NN O
of BC2GM030870274 IN O
an BC2GM030870274 DT O
RNA BC2GM030870274 NNP O
`` BC2GM030870274 `` O
kissing BC2GM030870274 VBG O
'' BC2GM030870274 '' O
hairpin BC2GM030870274 NN O
complex BC2GM030870274 NN O
formed BC2GM030870274 VBD O
between BC2GM030870274 IN O
the BC2GM030870274 DT O
HIV-2 BC2GM030870274 NNP O
TAR BC2GM030870274 NNP O
hairpin BC2GM030870274 NN O
loop BC2GM030870274 NN O
and BC2GM030870274 CC O
a BC2GM030870274 DT O
hairpin BC2GM030870274 NN O
with BC2GM030870274 IN O
a BC2GM030870274 DT O
complementary BC2GM030870274 JJ O
loop BC2GM030870274 NN O
sequence BC2GM030870274 NN O
. BC2GM030870274 . O
. . O O

We BC2GM012170235 PRP O
next BC2GM012170235 VBP O
developed BC2GM012170235 VBD O
a BC2GM012170235 DT O
rapid BC2GM012170235 JJ O
purification BC2GM012170235 NN O
method BC2GM012170235 NN O
for BC2GM012170235 IN O
bacterial BC2GM012170235 JJ O
recombinant BC2GM012170235 JJ O
MyoD-bHLH BC2GM012170235 NNP O
domain BC2GM012170235 NN O
by BC2GM012170235 IN O
affinity BC2GM012170235 NN O
chromatography BC2GM012170235 NN O
using BC2GM012170235 VBG O
a BC2GM012170235 DT O
calmodulin-Sepharose BC2GM012170235 JJ O
column BC2GM012170235 NN O
and BC2GM012170235 CC O
investigated BC2GM012170235 VBD O
the BC2GM012170235 DT O
phosphorylation BC2GM012170235 NN O
of BC2GM012170235 IN O
that BC2GM012170235 DT O
peptide BC2GM012170235 NN O
by BC2GM012170235 IN O
PKC BC2GM012170235 NNP O
and BC2GM012170235 CC O
its BC2GM012170235 PRP$ O
interactions BC2GM012170235 NNS O
with BC2GM012170235 IN O
calmodulin BC2GM012170235 NN O
and BC2GM012170235 CC O
S100a BC2GM012170235 NNP O
. BC2GM012170235 . O
. . O O

When BC2GM060672103 WRB O
patients BC2GM060672103 NNS O
were BC2GM060672103 VBD O
admitted BC2GM060672103 VBN O
within BC2GM060672103 IN O
one BC2GM060672103 CD O
week BC2GM060672103 NN O
of BC2GM060672103 IN O
the BC2GM060672103 DT O
onset BC2GM060672103 NN O
of BC2GM060672103 IN O
dark BC2GM060672103 JJ O
urine BC2GM060672103 NN O
, BC2GM060672103 , O
45 BC2GM060672103 CD O
% BC2GM060672103 NN O
were BC2GM060672103 VBD O
found BC2GM060672103 VBN O
to BC2GM060672103 TO O
be BC2GM060672103 VB O
shedding BC2GM060672103 VBG O
HAV BC2GM060672103 NNP O
, BC2GM060672103 , O
whereas BC2GM060672103 VBZ O
only BC2GM060672103 RB O
11 BC2GM060672103 CD O
% BC2GM060672103 NN O
of BC2GM060672103 IN O
specimens BC2GM060672103 NNS O
obtained BC2GM060672103 VBN O
from BC2GM060672103 IN O
patients BC2GM060672103 NNS O
admitted BC2GM060672103 VBN O
during BC2GM060672103 IN O
the BC2GM060672103 DT O
second BC2GM060672103 JJ O
week BC2GM060672103 NN O
contained BC2GM060672103 VBN O
virus BC2GM060672103 NN O
. BC2GM060672103 . O
. . O O

The BC2GM023485577 DT O
size BC2GM023485577 NN O
and BC2GM023485577 CC O
the BC2GM023485577 DT O
predicted BC2GM023485577 JJ O
N-terminal BC2GM023485577 JJ O
sequence BC2GM023485577 NN O
of BC2GM023485577 IN O
the BC2GM023485577 DT O
mouse BC2GM023485577 NN O
protein BC2GM023485577 NN O
were BC2GM023485577 VBD O
confirmed BC2GM023485577 VBN O
experimentally BC2GM023485577 RB O
. BC2GM023485577 . O
. . O O

However BC2GM098791019 RB O
, BC2GM098791019 , O
whether BC2GM098791019 IN O
this BC2GM098791019 DT O
was BC2GM098791019 VBD O
associated BC2GM098791019 VBN O
with BC2GM098791019 IN O
spleen BC2GM098791019 JJ O
removal BC2GM098791019 NN O
after BC2GM098791019 IN O
adjustment BC2GM098791019 NN O
for BC2GM098791019 IN O
risk BC2GM098791019 NN O
factors BC2GM098791019 NNS O
was BC2GM098791019 VBD O
not BC2GM098791019 RB O
determined BC2GM098791019 VBN O
. BC2GM098791019 . O
. . O O

All BC2GM091911719 DT O
exon BC2GM091911719 VBP O
/ BC2GM091911719 NNP O
intron BC2GM091911719 NN O
splice BC2GM091911719 NN O
junctions BC2GM091911719 NNS O
follow BC2GM091911719 VBP O
the BC2GM091911719 DT O
GT BC2GM091911719 NNP O
/ BC2GM091911719 NNP O
AG BC2GM091911719 NNP O
rule BC2GM091911719 NN O
. BC2GM091911719 . O
. . O O

Cerumen BC2GM046719637 NNP O
management BC2GM046719637 NN O
in BC2GM046719637 IN O
hearing BC2GM046719637 VBG O
conservation BC2GM046719637 NN O
: BC2GM046719637 : O
the BC2GM046719637 DT O
Dallas BC2GM046719637 NNP O
( BC2GM046719637 ( O
Texas BC2GM046719637 NNP O
) BC2GM046719637 ) O
Independent BC2GM046719637 NNP O
School BC2GM046719637 NNP O
District BC2GM046719637 NNP O
program BC2GM046719637 NN O
. BC2GM046719637 . O
. . O O

Subclones BC2GM002025862 NNS O
of BC2GM002025862 IN O
R15 BC2GM002025862 NNP O
which BC2GM002025862 WDT O
reverted BC2GM002025862 VBD O
to BC2GM002025862 TO O
kappa BC2GM002025862 VB O
light BC2GM002025862 JJ O
chain BC2GM002025862 NN O
production BC2GM002025862 NN O
contained BC2GM002025862 VBD O
genomic BC2GM002025862 JJ O
deletions BC2GM002025862 NNS O
of BC2GM002025862 IN O
R15ns BC2GM002025862 NNP O
and BC2GM002025862 CC O
/ BC2GM002025862 NNP O
or BC2GM002025862 CC O
the BC2GM002025862 DT O
surrounding BC2GM002025862 VBG O
intron BC2GM002025862 NN O
. BC2GM002025862 . O
. . O O

Alterations BC2GM053225720 NNS O
in BC2GM053225720 IN O
TCR-MHC BC2GM053225720 NNP O
contacts BC2GM053225720 NNS O
subsequent BC2GM053225720 JJ O
to BC2GM053225720 TO O
cross-recognition BC2GM053225720 NN O
of BC2GM053225720 IN O
class BC2GM053225720 NN O
I BC2GM053225720 PRP O
MHC BC2GM053225720 NNP O
and BC2GM053225720 CC O
singly BC2GM053225720 RB O
substituted BC2GM053225720 VBD O
peptide BC2GM053225720 JJ O
variants BC2GM053225720 NNS O
. BC2GM053225720 . O
. . O O

Plasmodium BC2GM081729599 NNP O
vivax BC2GM081729599 NN O
malaria BC2GM081729599 NN O
. BC2GM081729599 . O
. . O O

TNF-alpha BC2GM085879791 NNP O
stimulated BC2GM085879791 VBD O
these BC2GM085879791 DT O
changes BC2GM085879791 NNS O
in BC2GM085879791 IN O
part BC2GM085879791 NN O
by BC2GM085879791 IN O
increasing BC2GM085879791 VBG O
transcription BC2GM085879791 NN O
and BC2GM085879791 CC O
stabilization BC2GM085879791 NN O
of BC2GM085879791 IN O
RNA BC2GM085879791 NNP O
for BC2GM085879791 IN O
amphiregulin BC2GM085879791 NN O
, BC2GM085879791 , O
an BC2GM085879791 DT O
EGF BC2GM085879791 NNP O
receptor BC2GM085879791 NN O
ligand BC2GM085879791 NN O
, BC2GM085879791 , O
and BC2GM085879791 CC O
amphiregulin BC2GM085879791 RB O
directly BC2GM085879791 RB O
increased BC2GM085879791 VBN O
HPV-16 BC2GM085879791 NNP O
E6 BC2GM085879791 NNP O
/ BC2GM085879791 NNP O
E7 BC2GM085879791 NNP O
and BC2GM085879791 CC O
cyclin BC2GM085879791 VB O
A BC2GM085879791 NNP O
RNAs BC2GM085879791 NNP O
. BC2GM085879791 . O
. . O O

3 BC2GM029039601 CD O
. BC2GM029039601 . O
. . O O

Nine BC2GM020647680 NNP O
months BC2GM020647680 NNS O
after BC2GM020647680 IN O
the BC2GM020647680 DT O
end BC2GM020647680 NN O
of BC2GM020647680 IN O
the BC2GM020647680 DT O
vaccination BC2GM020647680 NN O
anti-HBsAg BC2GM020647680 NN O
levels BC2GM020647680 NNS O
had BC2GM020647680 VBD O
dropped BC2GM020647680 VBN O
to BC2GM020647680 TO O
9 BC2GM020647680 CD O
+ BC2GM020647680 NNS O
/ BC2GM020647680 SYM O
- BC2GM020647680 : O
4 BC2GM020647680 CD O
IU BC2GM020647680 NNP O
/ BC2GM020647680 $ O
1 BC2GM020647680 CD O
( BC2GM020647680 ( O
M BC2GM020647680 NNP O
+ BC2GM020647680 NNP O
/ BC2GM020647680 NNP O
- BC2GM020647680 : O
SE BC2GM020647680 NN O
) BC2GM020647680 ) O
, BC2GM020647680 , O
with BC2GM020647680 IN O
a BC2GM020647680 DT O
geometric BC2GM020647680 JJ O
mean BC2GM020647680 NN O
of BC2GM020647680 IN O
5 BC2GM020647680 CD O
IU BC2GM020647680 NNP O
/ BC2GM020647680 NNP O
1 BC2GM020647680 CD O
, BC2GM020647680 , O
in BC2GM020647680 IN O
the BC2GM020647680 DT O
nine BC2GM020647680 CD O
remaining BC2GM020647680 VBG O
evaluable BC2GM020647680 JJ O
patients BC2GM020647680 NNS O
. BC2GM020647680 . O
. . O O

The BC2GM080383743 DT O
use BC2GM080383743 NN O
of BC2GM080383743 IN O
ALAD BC2GM080383743 NNP O
activity BC2GM080383743 NN O
and BC2GM080383743 CC O
EP BC2GM080383743 NNP O
as BC2GM080383743 IN O
cumulative BC2GM080383743 JJ O
lead BC2GM080383743 NN O
exposure BC2GM080383743 NN O
indicators BC2GM080383743 NNS O
is BC2GM080383743 VBZ O
suggested BC2GM080383743 VBN O
. BC2GM080383743 . O
. . O O

The BC2GM084852812 DT O
clr1 BC2GM084852812 NN O
locus BC2GM084852812 NN O
regulates BC2GM084852812 VBZ O
the BC2GM084852812 DT O
expression BC2GM084852812 NN O
of BC2GM084852812 IN O
the BC2GM084852812 DT O
cryptic BC2GM084852812 JJ O
mating-type BC2GM084852812 JJ O
loci BC2GM084852812 NN O
of BC2GM084852812 IN O
fission BC2GM084852812 NN O
yeast BC2GM084852812 NN O
. BC2GM084852812 . O
. . O O

On BC2GM041284002 IN O
the BC2GM041284002 DT O
3rd BC2GM041284002 CD O
day BC2GM041284002 NN O
after BC2GM041284002 IN O
ischemia BC2GM041284002 NN O
of BC2GM041284002 IN O
the BC2GM041284002 DT O
remained BC2GM041284002 JJ O
kidney BC2GM041284002 NN O
for BC2GM041284002 IN O
30 BC2GM041284002 CD O
min BC2GM041284002 NN O
, BC2GM041284002 , O
structural BC2GM041284002 JJ O
components BC2GM041284002 NNS O
of BC2GM041284002 IN O
the BC2GM041284002 DT O
walls BC2GM041284002 NNS O
of BC2GM041284002 IN O
the BC2GM041284002 DT O
glomerular BC2GM041284002 JJ O
arterioles BC2GM041284002 NNS O
and BC2GM041284002 CC O
those BC2GM041284002 DT O
of BC2GM041284002 IN O
the BC2GM041284002 DT O
filtration-reabsorption BC2GM041284002 NN O
barrier BC2GM041284002 NN O
undergo BC2GM041284002 NN O
certain BC2GM041284002 JJ O
ultrastructural BC2GM041284002 JJ O
changes BC2GM041284002 NNS O
, BC2GM041284002 , O
that BC2GM041284002 IN O
with BC2GM041284002 IN O
time BC2GM041284002 NN O
elapsed BC2GM041284002 VBN O
( BC2GM041284002 ( O
7 BC2GM041284002 CD O
, BC2GM041284002 , O
14 BC2GM041284002 CD O
days BC2GM041284002 NNS O
) BC2GM041284002 ) O
gradually BC2GM041284002 RB O
pass BC2GM041284002 VB O
away BC2GM041284002 RB O
, BC2GM041284002 , O
and BC2GM041284002 CC O
amount BC2GM041284002 NN O
of BC2GM041284002 IN O
cells BC2GM041284002 NNS O
with BC2GM041284002 IN O
hypertrophic BC2GM041284002 JJ O
processes BC2GM041284002 NNS O
increases BC2GM041284002 NNS O
. BC2GM041284002 . O
. . O O

Bedbug BC2GM097784903 NNP O
( BC2GM097784903 ( O
Cimex BC2GM097784903 NNP O
lectularius BC2GM097784903 NN O
) BC2GM097784903 ) O
samples BC2GM097784903 VBZ O
adult BC2GM097784903 NN O
and BC2GM097784903 CC O
nymphs BC2GM097784903 NN O
either BC2GM097784903 RB O
engorged BC2GM097784903 VBD O
or BC2GM097784903 CC O
starved BC2GM097784903 VBN O
from BC2GM097784903 IN O
Central BC2GM097784903 NNP O
Security BC2GM097784903 NNP O
Forces BC2GM097784903 NNP O
sleeping BC2GM097784903 NN O
wards BC2GM097784903 NNS O
, BC2GM097784903 , O
laboratory BC2GM097784903 NN O
animal BC2GM097784903 JJ O
house BC2GM097784903 NN O
and BC2GM097784903 CC O
control BC2GM097784903 NN O
samples BC2GM097784903 NNS O
from BC2GM097784903 IN O
laboratory BC2GM097784903 NN O
reared BC2GM097784903 VBN O
colonies BC2GM097784903 NNS O
were BC2GM097784903 VBD O
ground BC2GM097784903 NN O
and BC2GM097784903 CC O
subjected BC2GM097784903 VBN O
to BC2GM097784903 TO O
ELISA BC2GM097784903 NNP O
test BC2GM097784903 NN O
of BC2GM097784903 IN O
hepatitis BC2GM097784903 NN O
B BC2GM097784903 NNP O
surface BC2GM097784903 NN O
antigen BC2GM097784903 NN O
together BC2GM097784903 RB O
with BC2GM097784903 IN O
276 BC2GM097784903 CD O
serum BC2GM097784903 NN O
samples BC2GM097784903 NNS O
from BC2GM097784903 IN O
the BC2GM097784903 DT O
recruits BC2GM097784903 NNS O
slept BC2GM097784903 VBP O
in BC2GM097784903 IN O
those BC2GM097784903 DT O
wards BC2GM097784903 NNS O
. BC2GM097784903 . O
. . O O

The BC2GM035663099 DT O
atf1+ BC2GM035663099 JJ O
gene BC2GM035663099 NN O
of BC2GM035663099 IN O
Schizosaccharomyces BC2GM035663099 NNP O
pombe BC2GM035663099 NN O
encodes BC2GM035663099 VBZ O
a BC2GM035663099 DT O
bZIP BC2GM035663099 JJ O
transcription BC2GM035663099 NN O
factor BC2GM035663099 NN O
with BC2GM035663099 IN O
strong BC2GM035663099 JJ O
homology BC2GM035663099 NN O
to BC2GM035663099 TO O
the BC2GM035663099 DT O
mammalian BC2GM035663099 JJ O
factor BC2GM035663099 NN O
ATF-2 BC2GM035663099 NNP O
. BC2GM035663099 . O
. . O O

Muscle BC2GM012939166 NN O
and BC2GM012939166 CC O
liver BC2GM012939166 NN O
biopsies BC2GM012939166 NNS O
demonstrated BC2GM012939166 VBD O
the BC2GM012939166 DT O
same BC2GM012939166 JJ O
anomalies BC2GM012939166 NNS O
, BC2GM012939166 , O
again BC2GM012939166 RB O
without BC2GM012939166 IN O
branching BC2GM012939166 VBG O
enzyme BC2GM012939166 JJ O
deficiency BC2GM012939166 NN O
in BC2GM012939166 IN O
the BC2GM012939166 DT O
liver BC2GM012939166 NN O
. BC2GM012939166 . O
. . O O

Ureases BC2GM026246927 NNS O
were BC2GM026246927 VBD O
purified BC2GM026246927 VBN O
from BC2GM026246927 IN O
the BC2GM026246927 DT O
recombinant BC2GM026246927 JJ O
cells BC2GM026246927 NNS O
and BC2GM026246927 CC O
shown BC2GM026246927 VBN O
to BC2GM026246927 TO O
be BC2GM026246927 VB O
identical BC2GM026246927 JJ O
to BC2GM026246927 TO O
control BC2GM026246927 VB O
enzyme BC2GM026246927 NN O
when BC2GM026246927 WRB O
analyzed BC2GM026246927 VBN O
by BC2GM026246927 IN O
gel BC2GM026246927 JJ O
filtration BC2GM026246927 NN O
chromatography BC2GM026246927 NN O
and BC2GM026246927 CC O
sodium BC2GM026246927 NN O
dodecyl BC2GM026246927 NN O
sulfate-polyacrylamide BC2GM026246927 JJ O
gel BC2GM026246927 JJ O
electrophoresis BC2GM026246927 NN O
; BC2GM026246927 : O
however BC2GM026246927 RB O
, BC2GM026246927 , O
in BC2GM026246927 IN O
every BC2GM026246927 DT O
case BC2GM026246927 NN O
the BC2GM026246927 DT O
activity BC2GM026246927 NN O
levels BC2GM026246927 NNS O
correlated BC2GM026246927 VBN O
to BC2GM026246927 TO O
nickel BC2GM026246927 VB O
contents BC2GM026246927 NNS O
as BC2GM026246927 IN O
analyzed BC2GM026246927 VBN O
by BC2GM026246927 IN O
atomic BC2GM026246927 JJ O
absorption BC2GM026246927 NN O
analysis BC2GM026246927 NN O
. BC2GM026246927 . O
. . O O

Dermatophagoides BC2GM070700185 NNP O
farinae-sensitized BC2GM070700185 JJ O
lymphocytes BC2GM070700185 NNS O
in BC2GM070700185 IN O
asthmatic BC2GM070700185 JJ O
children BC2GM070700185 NNS O
as BC2GM070700185 IN O
evaluated BC2GM070700185 VBN O
by BC2GM070700185 IN O
interleukin-2 BC2GM070700185 NN O
( BC2GM070700185 ( O
IL-2 BC2GM070700185 NNP O
) BC2GM070700185 ) O
production BC2GM070700185 NN O
and BC2GM070700185 CC O
acquisition BC2GM070700185 NN O
of BC2GM070700185 IN O
IL-2 BC2GM070700185 NNP O
responsiveness BC2GM070700185 NN O
. BC2GM070700185 . O
. . O O

In BC2GM063547892 IN O
HMEC BC2GM063547892 NNP O
stably BC2GM063547892 RB O
transfected BC2GM063547892 VBD O
with BC2GM063547892 IN O
an BC2GM063547892 DT O
ER BC2GM063547892 NNP O
mutant BC2GM063547892 NN O
containing BC2GM063547892 VBG O
a BC2GM063547892 DT O
deletion BC2GM063547892 NN O
in BC2GM063547892 IN O
the BC2GM063547892 DT O
second BC2GM063547892 JJ O
zinc BC2GM063547892 NN O
finger BC2GM063547892 NN O
of BC2GM063547892 IN O
the BC2GM063547892 DT O
DNA-binding BC2GM063547892 NNP O
domain BC2GM063547892 NN O
, BC2GM063547892 , O
E BC2GM063547892 NNP O
and BC2GM063547892 CC O
HT BC2GM063547892 NNP O
had BC2GM063547892 VBD O
different BC2GM063547892 JJ O
effects BC2GM063547892 NNS O
on BC2GM063547892 IN O
EBBP BC2GM063547892 NNP O
gene BC2GM063547892 NN O
expression BC2GM063547892 NN O
; BC2GM063547892 : O
EBBP BC2GM063547892 NNP O
regulation BC2GM063547892 NN O
by BC2GM063547892 IN O
E BC2GM063547892 NNP O
was BC2GM063547892 VBD O
dramatically BC2GM063547892 RB O
reduced BC2GM063547892 VBN O
while BC2GM063547892 IN O
the BC2GM063547892 DT O
effects BC2GM063547892 NNS O
of BC2GM063547892 IN O
HT BC2GM063547892 NNP O
were BC2GM063547892 VBD O
augmented BC2GM063547892 VBN O
. BC2GM063547892 . O
. . O O

Acoustic-property BC2GM058654225 JJ O
measurements BC2GM058654225 NNS O
of BC2GM058654225 IN O
the BC2GM058654225 DT O
oxide BC2GM058654225 JJ O
superconductor BC2GM058654225 NN O
BaPb1-xBixO3 BC2GM058654225 NNP O
by BC2GM058654225 IN O
the BC2GM058654225 DT O
sphere-resonance BC2GM058654225 NN O
method BC2GM058654225 NN O
. BC2GM058654225 . O
. . O O

Our BC2GM053866508 PRP$ O
data BC2GM053866508 NNS O
suggest BC2GM053866508 VBP O
that BC2GM053866508 IN O
some BC2GM053866508 DT O
defects BC2GM053866508 NNS O
observed BC2GM053866508 VBN O
in BC2GM053866508 IN O
BS BC2GM053866508 NNP O
, BC2GM053866508 , O
WS BC2GM053866508 NNP O
or BC2GM053866508 CC O
RTS BC2GM053866508 NNP O
are BC2GM053866508 VBP O
the BC2GM053866508 DT O
consequence BC2GM053866508 NN O
of BC2GM053866508 IN O
unrestrained BC2GM053866508 JJ O
recombination BC2GM053866508 NN O
. BC2GM053866508 . O
. . O O

These BC2GM006832917 DT O
results BC2GM006832917 NNS O
suggest BC2GM006832917 VBP O
that BC2GM006832917 IN O
dauricine BC2GM006832917 NN O
and BC2GM006832917 CC O
verapamil BC2GM006832917 NN O
have BC2GM006832917 VBP O
a BC2GM006832917 DT O
salutary BC2GM006832917 JJ O
effect BC2GM006832917 NN O
in BC2GM006832917 IN O
extracorporeal BC2GM006832917 JJ O
circulation BC2GM006832917 NN O
. BC2GM006832917 . O
. . O O

Elevated BC2GM041201611 VBN O
total BC2GM041201611 JJ O
serum BC2GM041201611 NN O
calcium BC2GM041201611 NN O
to BC2GM041201611 TO O
a BC2GM041201611 DT O
level BC2GM041201611 NN O
of BC2GM041201611 IN O
11.9 BC2GM041201611 CD O
+ BC2GM041201611 NNS O
/ BC2GM041201611 SYM O
- BC2GM041201611 : O
0.2 BC2GM041201611 CD O
mg BC2GM041201611 NN O
/ BC2GM041201611 NN O
dl BC2GM041201611 NN O
( BC2GM041201611 ( O
p BC2GM041201611 NN O
less BC2GM041201611 JJR O
than BC2GM041201611 IN O
0.001 BC2GM041201611 CD O
compared BC2GM041201611 VBN O
to BC2GM041201611 TO O
control BC2GM041201611 VB O
group BC2GM041201611 NN O
) BC2GM041201611 ) O
developed BC2GM041201611 VBD O
in BC2GM041201611 IN O
the BC2GM041201611 DT O
gentamicin BC2GM041201611 NN O
/ BC2GM041201611 VBZ O
1,25 BC2GM041201611 CD O
( BC2GM041201611 ( O
OH BC2GM041201611 NNP O
) BC2GM041201611 ) O
2 BC2GM041201611 CD O
vitamin BC2GM041201611 JJ O
D3 BC2GM041201611 NNP O
group BC2GM041201611 NN O
on BC2GM041201611 IN O
day BC2GM041201611 NN O
4 BC2GM041201611 CD O
, BC2GM041201611 , O
2 BC2GM041201611 CD O
days BC2GM041201611 NNS O
prior BC2GM041201611 RB O
to BC2GM041201611 TO O
pronounced BC2GM041201611 VB O
structural BC2GM041201611 JJ O
damage BC2GM041201611 NN O
, BC2GM041201611 , O
and BC2GM041201611 CC O
continued BC2GM041201611 VBD O
to BC2GM041201611 TO O
be BC2GM041201611 VB O
elevated BC2GM041201611 VBN O
through BC2GM041201611 IN O
day BC2GM041201611 NN O
7 BC2GM041201611 CD O
. BC2GM041201611 . O
. . O O

The BC2GM067367771 DT O
highest BC2GM067367771 JJS O
concentration BC2GM067367771 NN O
of BC2GM067367771 IN O
respirable BC2GM067367771 JJ O
mineral BC2GM067367771 JJ O
fibres BC2GM067367771 NNS O
was BC2GM067367771 VBD O
found BC2GM067367771 VBN O
during BC2GM067367771 IN O
the BC2GM067367771 DT O
overhaul BC2GM067367771 NN O
of BC2GM067367771 IN O
a BC2GM067367771 DT O
truck BC2GM067367771 NN O
with BC2GM067367771 IN O
asbestos BC2GM067367771 JJ O
insulation BC2GM067367771 NN O
; BC2GM067367771 : O
respirable BC2GM067367771 JJ O
fibre BC2GM067367771 NN O
concentration BC2GM067367771 NN O
reached BC2GM067367771 VBD O
the BC2GM067367771 DT O
value BC2GM067367771 NN O
of BC2GM067367771 IN O
5 BC2GM067367771 CD O
f BC2GM067367771 JJ O
/ BC2GM067367771 NNP O
cm3 BC2GM067367771 NN O
, BC2GM067367771 , O
and BC2GM067367771 CC O
total BC2GM067367771 JJ O
dust BC2GM067367771 NN O
concentration-the BC2GM067367771 JJ O
value BC2GM067367771 NN O
of BC2GM067367771 IN O
about BC2GM067367771 IN O
80 BC2GM067367771 CD O
mg BC2GM067367771 NNS O
/ BC2GM067367771 JJ O
m3 BC2GM067367771 NN O
. BC2GM067367771 . O
. . O O

Biochemical BC2GM009033514 JJ O
studies BC2GM009033514 NNS O
and BC2GM009033514 CC O
studies BC2GM009033514 NNS O
of BC2GM009033514 IN O
cells BC2GM009033514 NNS O
expressing BC2GM009033514 VBG O
mutant BC2GM009033514 JJ O
IL-2 BC2GM009033514 JJ O
receptors BC2GM009033514 NNS O
indicate BC2GM009033514 VBP O
that BC2GM009033514 IN O
IL-2-induced BC2GM009033514 NNP O
tyrosine BC2GM009033514 NN O
kinase BC2GM009033514 NN O
activation BC2GM009033514 NN O
initiates BC2GM009033514 VBZ O
a BC2GM009033514 DT O
complex BC2GM009033514 JJ O
signaling BC2GM009033514 NN O
cascade BC2GM009033514 NN O
. BC2GM009033514 . O
. . O O

An BC2GM059995524 DT O
X-linked BC2GM059995524 JJ O
zinc BC2GM059995524 NN O
finger BC2GM059995524 NN O
gene BC2GM059995524 NN O
mapping BC2GM059995524 VBG O
to BC2GM059995524 TO O
Xq21.1-q21.3 BC2GM059995524 NNP O
closely BC2GM059995524 RB O
related BC2GM059995524 JJ O
to BC2GM059995524 TO O
ZFX BC2GM059995524 NNP O
and BC2GM059995524 CC O
ZFY BC2GM059995524 NNP O
: BC2GM059995524 : O
possible BC2GM059995524 JJ O
origins BC2GM059995524 NNS O
from BC2GM059995524 IN O
a BC2GM059995524 DT O
common BC2GM059995524 JJ O
ancestral BC2GM059995524 JJ O
gene BC2GM059995524 NN O
. BC2GM059995524 . O
. . O O

( BC2GM009260448 ( O
3 BC2GM009260448 CD O
) BC2GM009260448 ) O
With BC2GM009260448 IN O
the BC2GM009260448 DT O
exception BC2GM009260448 NN O
of BC2GM009260448 IN O
the BC2GM009260448 DT O
anteroposterior BC2GM009260448 JJ O
direction BC2GM009260448 NN O
of BC2GM009260448 IN O
layers BC2GM009260448 NNS O
II BC2GM009260448 NNP O
-- BC2GM009260448 : O
III BC2GM009260448 NNP O
and BC2GM009260448 CC O
the BC2GM009260448 DT O
mediolateral BC2GM009260448 JJ O
direction BC2GM009260448 NN O
of BC2GM009260448 IN O
layer BC2GM009260448 NN O
IV BC2GM009260448 NNP O
, BC2GM009260448 , O
the BC2GM009260448 DT O
vertical BC2GM009260448 JJ O
conductivity BC2GM009260448 NN O
of BC2GM009260448 IN O
the BC2GM009260448 DT O
cortex BC2GM009260448 NN O
was BC2GM009260448 VBD O
always BC2GM009260448 RB O
greater BC2GM009260448 JJR O
than BC2GM009260448 IN O
either BC2GM009260448 DT O
of BC2GM009260448 IN O
the BC2GM009260448 DT O
horizontal BC2GM009260448 JJ O
conductivities BC2GM009260448 NNS O
. BC2GM009260448 . O
. . O O

Simvastatin BC2GM042831244 NNP O
decreased BC2GM042831244 VBD O
levels BC2GM042831244 NNS O
of BC2GM042831244 IN O
total BC2GM042831244 JJ O
cholesterol BC2GM042831244 NN O
by BC2GM042831244 IN O
20.8 BC2GM042831244 CD O
% BC2GM042831244 NN O
, BC2GM042831244 , O
LDL BC2GM042831244 NNP O
cholesterol BC2GM042831244 NN O
by BC2GM042831244 IN O
29.7 BC2GM042831244 CD O
% BC2GM042831244 NN O
, BC2GM042831244 , O
triglycerides BC2GM042831244 NNS O
by BC2GM042831244 IN O
13.6 BC2GM042831244 CD O
% BC2GM042831244 NN O
, BC2GM042831244 , O
apolipoprotein BC2GM042831244 NN O
B BC2GM042831244 NNP O
by BC2GM042831244 IN O
22.4 BC2GM042831244 CD O
% BC2GM042831244 NN O
, BC2GM042831244 , O
alpha-tocopherol BC2GM042831244 NN O
by BC2GM042831244 IN O
16.2 BC2GM042831244 CD O
% BC2GM042831244 NN O
, BC2GM042831244 , O
beta-carotene BC2GM042831244 JJ O
by BC2GM042831244 IN O
19.5 BC2GM042831244 CD O
% BC2GM042831244 NN O
, BC2GM042831244 , O
and BC2GM042831244 CC O
ubiquinol-10 BC2GM042831244 JJ O
by BC2GM042831244 IN O
22.0 BC2GM042831244 CD O
% BC2GM042831244 NN O
( BC2GM042831244 ( O
P BC2GM042831244 NNP O
< BC2GM042831244 NNP O
.001 BC2GM042831244 NNP O
for BC2GM042831244 IN O
all BC2GM042831244 DT O
) BC2GM042831244 ) O
and BC2GM042831244 CC O
increased BC2GM042831244 JJ O
levels BC2GM042831244 NNS O
of BC2GM042831244 IN O
HDL BC2GM042831244 NNP O
cholesterol BC2GM042831244 NN O
by BC2GM042831244 IN O
7.0 BC2GM042831244 CD O
% BC2GM042831244 NN O
( BC2GM042831244 ( O
P BC2GM042831244 NNP O
< BC2GM042831244 NNP O
.001 BC2GM042831244 NNP O
) BC2GM042831244 ) O
and BC2GM042831244 CC O
serum BC2GM042831244 JJ O
insulin BC2GM042831244 NN O
by BC2GM042831244 IN O
13.2 BC2GM042831244 CD O
% BC2GM042831244 NN O
( BC2GM042831244 ( O
P BC2GM042831244 NNP O
=.005 BC2GM042831244 NNP O
) BC2GM042831244 ) O
. BC2GM042831244 . O
. . O O

If BC2GM088054752 IN O
the BC2GM088054752 DT O
size BC2GM088054752 NN O
of BC2GM088054752 IN O
the BC2GM088054752 DT O
cystic BC2GM088054752 JJ O
liver-lesions BC2GM088054752 NNS O
excludes BC2GM088054752 VBZ O
a BC2GM088054752 DT O
curative BC2GM088054752 JJ O
operative BC2GM088054752 JJ O
treatment BC2GM088054752 NN O
or BC2GM088054752 CC O
if BC2GM088054752 IN O
the BC2GM088054752 DT O
patient BC2GM088054752 NN O
refuses BC2GM088054752 VBZ O
surgery BC2GM088054752 NN O
, BC2GM088054752 , O
the BC2GM088054752 DT O
indication BC2GM088054752 NN O
for BC2GM088054752 IN O
chemotherapy BC2GM088054752 NN O
with BC2GM088054752 IN O
mebendazole BC2GM088054752 NN O
is BC2GM088054752 VBZ O
given BC2GM088054752 VBN O
. BC2GM088054752 . O
. . O O

When BC2GM063679270 WRB O
translated BC2GM063679270 VBN O
in-frame BC2GM063679270 NN O
with BC2GM063679270 IN O
PKC BC2GM063679270 NNP O
zeta BC2GM063679270 NN O
, BC2GM063679270 , O
a BC2GM063679270 DT O
stop BC2GM063679270 NN O
codon BC2GM063679270 NN O
is BC2GM063679270 VBZ O
located BC2GM063679270 VBN O
28 BC2GM063679270 CD O
amino BC2GM063679270 JJ O
acids BC2GM063679270 NNS O
towards BC2GM063679270 IN O
the BC2GM063679270 DT O
N-terminus BC2GM063679270 NNP O
of BC2GM063679270 IN O
the BC2GM063679270 DT O
divergence BC2GM063679270 NN O
point BC2GM063679270 NN O
and BC2GM063679270 CC O
the BC2GM063679270 DT O
intervening BC2GM063679270 NN O
sequence BC2GM063679270 NN O
lacks BC2GM063679270 VBZ O
an BC2GM063679270 DT O
expected BC2GM063679270 JJ O
initiating BC2GM063679270 NN O
methionine BC2GM063679270 NN O
. BC2GM063679270 . O
psi BC2GM063679270 NN O
PKC BC2GM063679270 NNP O
zeta BC2GM063679270 NN O
is BC2GM063679270 VBZ O
non-functional BC2GM063679270 JJ O
in BC2GM063679270 IN O
terms BC2GM063679270 NNS O
of BC2GM063679270 IN O
protein BC2GM063679270 NN O
synthesis BC2GM063679270 NN O
since BC2GM063679270 IN O
Western BC2GM063679270 JJ O
blotting BC2GM063679270 VBG O
with BC2GM063679270 IN O
an BC2GM063679270 DT O
antibody BC2GM063679270 NN O
directed BC2GM063679270 VBN O
against BC2GM063679270 IN O
the BC2GM063679270 DT O
C-terminus BC2GM063679270 NNP O
of BC2GM063679270 IN O
PKC BC2GM063679270 NNP O
zeta BC2GM063679270 NNP O
failed BC2GM063679270 VBD O
to BC2GM063679270 TO O
reveal BC2GM063679270 VB O
a BC2GM063679270 DT O
protein BC2GM063679270 NN O
smaller BC2GM063679270 JJR O
than BC2GM063679270 IN O
PKC BC2GM063679270 NNP O
zeta BC2GM063679270 NN O
, BC2GM063679270 , O
and BC2GM063679270 CC O
synthetic BC2GM063679270 JJ O
psi BC2GM063679270 NN O
PKC BC2GM063679270 NNP O
zeta BC2GM063679270 NNP O
RNA BC2GM063679270 NNP O
failed BC2GM063679270 VBD O
to BC2GM063679270 TO O
support BC2GM063679270 VB O
protein BC2GM063679270 JJ O
synthesis BC2GM063679270 NN O
in BC2GM063679270 IN O
a BC2GM063679270 DT O
translation BC2GM063679270 NN O
system BC2GM063679270 NN O
in BC2GM063679270 IN O
vitro BC2GM063679270 NN O
. BC2GM063679270 . O
. . O O

The BC2GM053146893 DT O
Id4 BC2GM053146893 NNP O
protein BC2GM053146893 NN O
contains BC2GM053146893 VBZ O
a BC2GM053146893 DT O
HLH BC2GM053146893 NNP O
domain BC2GM053146893 NN O
highly BC2GM053146893 RB O
conserved BC2GM053146893 VBN O
among BC2GM053146893 IN O
the BC2GM053146893 DT O
dnHLH BC2GM053146893 NN O
proteins BC2GM053146893 VBZ O
from BC2GM053146893 IN O
mouse BC2GM053146893 NN O
and BC2GM053146893 CC O
drosophila BC2GM053146893 NN O
. BC2GM053146893 . O
. . O O

Its BC2GM003460926 PRP$ O
activity BC2GM003460926 NN O
was BC2GM003460926 VBD O
twice BC2GM003460926 RB O
that BC2GM003460926 IN O
of BC2GM003460926 IN O
a BC2GM003460926 DT O
construct BC2GM003460926 NN O
where BC2GM003460926 WRB O
the BC2GM003460926 DT O
CAT BC2GM003460926 NNP O
gene BC2GM003460926 NN O
was BC2GM003460926 VBD O
driven BC2GM003460926 VBN O
by BC2GM003460926 IN O
the BC2GM003460926 DT O
H-2Kb BC2GM003460926 NNP O
5 BC2GM003460926 CD O
' BC2GM003460926 '' O
enhancer BC2GM003460926 JJ O
region BC2GM003460926 NN O
( BC2GM003460926 ( O
H2TF1 BC2GM003460926 NNP O
/ BC2GM003460926 NNP O
KBF1 BC2GM003460926 NNP O
site BC2GM003460926 NN O
) BC2GM003460926 ) O
and BC2GM003460926 CC O
comparable BC2GM003460926 JJ O
to BC2GM003460926 TO O
that BC2GM003460926 DT O
of BC2GM003460926 IN O
pRSVCAT BC2GM003460926 NN O
construct BC2GM003460926 NN O
carrying BC2GM003460926 VBG O
the BC2GM003460926 DT O
strong BC2GM003460926 JJ O
Rous BC2GM003460926 NNP O
sarcoma BC2GM003460926 NN O
virus BC2GM003460926 NN O
LTR BC2GM003460926 NNP O
enhancer BC2GM003460926 NN O
. BC2GM003460926 . O
. . O O

The BC2GM088022090 DT O
ossification BC2GM088022090 NN O
was BC2GM088022090 VBD O
located BC2GM088022090 VBN O
on BC2GM088022090 IN O
the BC2GM088022090 DT O
left BC2GM088022090 JJ O
side BC2GM088022090 NN O
of BC2GM088022090 IN O
C3-4 BC2GM088022090 NNP O
. BC2GM088022090 . O
. . O O

Soluble BC2GM003154305 JJ O
recombinant BC2GM003154305 JJ O
RI BC2GM003154305 NNP O
and BC2GM003154305 CC O
soluble BC2GM003154305 JJ O
recombinant BC2GM003154305 JJ O
C BC2GM003154305 NNP O
alpha BC2GM003154305 NN O
can BC2GM003154305 MD O
associate BC2GM003154305 VB O
in BC2GM003154305 IN O
vitro BC2GM003154305 NN O
and BC2GM003154305 CC O
be BC2GM003154305 VB O
activated BC2GM003154305 VBN O
by BC2GM003154305 IN O
cyclic BC2GM003154305 JJ O
AMP BC2GM003154305 NNP O
. BC2GM003154305 . O
. . O O

A BC2GM059747347 DT O
direct BC2GM059747347 JJ O
statistically BC2GM059747347 RB O
reliable BC2GM059747347 JJ O
correction BC2GM059747347 NN O
of BC2GM059747347 IN O
decrease BC2GM059747347 NN O
of BC2GM059747347 IN O
the BC2GM059747347 DT O
enzymes BC2GM059747347 NNS O
with BC2GM059747347 IN O
the BC2GM059747347 DT O
initial BC2GM059747347 JJ O
state BC2GM059747347 NN O
of BC2GM059747347 IN O
the BC2GM059747347 DT O
patients BC2GM059747347 NNS O
has BC2GM059747347 VBZ O
been BC2GM059747347 VBN O
established BC2GM059747347 VBN O
in BC2GM059747347 IN O
an BC2GM059747347 DT O
analysis BC2GM059747347 NN O
of BC2GM059747347 IN O
25 BC2GM059747347 CD O
patients BC2GM059747347 NNS O
aged BC2GM059747347 VBN O
from BC2GM059747347 IN O
18 BC2GM059747347 CD O
to BC2GM059747347 TO O
60 BC2GM059747347 CD O
years BC2GM059747347 NNS O
in BC2GM059747347 IN O
prosthesis BC2GM059747347 NN O
of+ BC2GM059747347 IN O
the BC2GM059747347 DT O
mitral BC2GM059747347 JJ O
valve BC2GM059747347 NN O
( BC2GM059747347 ( O
n-9 BC2GM059747347 JJ O
) BC2GM059747347 ) O
and BC2GM059747347 CC O
closed BC2GM059747347 VBD O
mitral BC2GM059747347 JJ O
commissurotomy BC2GM059747347 NN O
( BC2GM059747347 ( O
n-16 BC2GM059747347 JJ O
) BC2GM059747347 ) O
. BC2GM059747347 . O
. . O O

The BC2GM025900425 DT O
delta BC2GM025900425 JJ O
mean BC2GM025900425 NN O
VAF BC2GM025900425 NNP O
and BC2GM025900425 CC O
delta BC2GM025900425 JJ O
mean BC2GM025900425 NN O
SABP BC2GM025900425 NNP O
indicated BC2GM025900425 VBD O
varied BC2GM025900425 JJ O
mean BC2GM025900425 JJ O
values BC2GM025900425 NNS O
of BC2GM025900425 IN O
VAF BC2GM025900425 NNP O
and BC2GM025900425 CC O
SABP BC2GM025900425 NNP O
, BC2GM025900425 , O
respectively BC2GM025900425 RB O
. BC2GM025900425 . O
. . O O

Seventy-nine BC2GM011712856 JJ O
percent BC2GM011712856 NN O
of BC2GM011712856 IN O
the BC2GM011712856 DT O
children BC2GM011712856 NNS O
screened BC2GM011712856 VBD O
and BC2GM011712856 CC O
91.0 BC2GM011712856 CD O
% BC2GM011712856 NN O
of BC2GM011712856 IN O
the BC2GM011712856 DT O
children BC2GM011712856 NNS O
with BC2GM011712856 IN O
PbB BC2GM011712856 NNP O
at BC2GM011712856 IN O
least BC2GM011712856 JJS O
10 BC2GM011712856 CD O
micrograms BC2GM011712856 NNS O
/ BC2GM011712856 JJ O
dL BC2GM011712856 NNS O
were BC2GM011712856 VBD O
Hispanic BC2GM011712856 NNP O
. BC2GM011712856 . O
. . O O

Background BC2GM072420137 NNP O
reduction BC2GM072420137 NN O
with BC2GM072420137 IN O
various BC2GM072420137 JJ O
agents BC2GM072420137 NNS O
had BC2GM072420137 VBD O
a BC2GM072420137 DT O
prominent BC2GM072420137 JJ O
effect BC2GM072420137 NN O
on BC2GM072420137 IN O
DTIn1 BC2GM072420137 NNP O
as BC2GM072420137 RB O
well BC2GM072420137 RB O
as BC2GM072420137 IN O
99mTc-DTPA BC2GM072420137 JJ O
biodistribution BC2GM072420137 NN O
. BC2GM072420137 . O
. . O O

The BC2GM010227811 DT O
analysis BC2GM010227811 NN O
predicted BC2GM010227811 VBD O
that BC2GM010227811 IN O
progressive BC2GM010227811 JJ O
increases BC2GM010227811 NNS O
in BC2GM010227811 IN O
serum BC2GM010227811 JJ O
creatinine BC2GM010227811 NN O
or BC2GM010227811 CC O
aspartate BC2GM010227811 JJ O
transaminase BC2GM010227811 NN O
activity BC2GM010227811 NN O
will BC2GM010227811 MD O
result BC2GM010227811 VB O
in BC2GM010227811 IN O
only BC2GM010227811 RB O
a BC2GM010227811 DT O
50 BC2GM010227811 CD O
% BC2GM010227811 NN O
reduction BC2GM010227811 NN O
of BC2GM010227811 IN O
clearance BC2GM010227811 NN O
. BC2GM010227811 . O
. . O O

Chronic BC2GM076657224 NNP O
active BC2GM076657224 JJ O
hepatitis BC2GM076657224 NN O
and BC2GM076657224 CC O
cirrhosis BC2GM076657224 NN O
of BC2GM076657224 IN O
the BC2GM076657224 DT O
liver BC2GM076657224 NN O
. BC2GM076657224 . O
. . O O

GH BC2GM057108840 NNP O
stimulated BC2GM057108840 VBD O
the BC2GM057108840 DT O
activity BC2GM057108840 NN O
of BC2GM057108840 IN O
promoter BC2GM057108840 NN O
fragments BC2GM057108840 NNS O
with BC2GM057108840 IN O
5'-ends BC2GM057108840 NNS O
between BC2GM057108840 IN O
nucleotide BC2GM057108840 NN O
( BC2GM057108840 ( O
nt BC2GM057108840 JJ O
) BC2GM057108840 ) O
-2001 BC2GM057108840 NN O
and BC2GM057108840 CC O
nt BC2GM057108840 JJ O
-653 BC2GM057108840 NN O
by BC2GM057108840 IN O
1.9- BC2GM057108840 JJ O
to BC2GM057108840 TO O
2.7-fold BC2GM057108840 JJ O
. BC2GM057108840 . O
. . O O

However BC2GM025063596 RB O
, BC2GM025063596 , O
UV BC2GM025063596 NNP O
resistance BC2GM025063596 NN O
is BC2GM025063596 VBZ O
only BC2GM025063596 RB O
minimally BC2GM025063596 RB O
restored BC2GM025063596 VBN O
, BC2GM025063596 , O
and BC2GM025063596 CC O
mutant BC2GM025063596 JJ O
cells BC2GM025063596 NNS O
remain BC2GM025063596 VBP O
sensitive BC2GM025063596 JJ O
to BC2GM025063596 TO O
gamma BC2GM025063596 VB O
radiation BC2GM025063596 NN O
. BC2GM025063596 . O
. . O O

This BC2GM026047963 DT O
element BC2GM026047963 NN O
was BC2GM026047963 VBD O
required BC2GM026047963 VBN O
for BC2GM026047963 IN O
both BC2GM026047963 DT O
basal BC2GM026047963 NN O
and BC2GM026047963 CC O
activated BC2GM026047963 JJ O
expression BC2GM026047963 NN O
and BC2GM026047963 CC O
almost BC2GM026047963 RB O
certainly BC2GM026047963 RB O
functions BC2GM026047963 NNS O
as BC2GM026047963 IN O
a BC2GM026047963 DT O
TATA-binding BC2GM026047963 JJ O
protein BC2GM026047963 NN O
interaction BC2GM026047963 NN O
site BC2GM026047963 NN O
. BC2GM026047963 . O
. . O O

Thermal BC2GM025716724 JJ O
changes BC2GM025716724 NNS O
of BC2GM025716724 IN O
the BC2GM025716724 DT O
bovine BC2GM025716724 NN O
uterus BC2GM025716724 NN O
following BC2GM025716724 VBG O
administration BC2GM025716724 NN O
of BC2GM025716724 IN O
estradiol-17beta BC2GM025716724 NN O
. BC2GM025716724 . O
. . O O

A BC2GM006771200 DT O
review BC2GM006771200 NN O
of BC2GM006771200 IN O
156 BC2GM006771200 CD O
patients BC2GM006771200 NNS O
younger BC2GM006771200 JJR O
than BC2GM006771200 IN O
40 BC2GM006771200 CD O
treated BC2GM006771200 VBD O
at BC2GM006771200 IN O
our BC2GM006771200 PRP$ O
Department BC2GM006771200 NNP O
between BC2GM006771200 IN O
1960 BC2GM006771200 CD O
and BC2GM006771200 CC O
1991 BC2GM006771200 CD O
with BC2GM006771200 IN O
transitional BC2GM006771200 JJ O
cell BC2GM006771200 NN O
carcinoma BC2GM006771200 NN O
of BC2GM006771200 IN O
the BC2GM006771200 DT O
bladder BC2GM006771200 NN O
revealed BC2GM006771200 VBD O
that BC2GM006771200 IN O
89.1 BC2GM006771200 CD O
% BC2GM006771200 NN O
had BC2GM006771200 VBD O
superficial BC2GM006771200 JJ O
( BC2GM006771200 ( O
Ta BC2GM006771200 NNP O
/ BC2GM006771200 NNP O
T1 BC2GM006771200 NNP O
) BC2GM006771200 ) O
disease BC2GM006771200 NN O
and BC2GM006771200 CC O
the BC2GM006771200 DT O
remaining BC2GM006771200 VBG O
10.9 BC2GM006771200 CD O
% BC2GM006771200 NN O
presented BC2GM006771200 VBN O
with BC2GM006771200 IN O
invasive BC2GM006771200 JJ O
disease BC2GM006771200 NN O
. BC2GM006771200 . O
. . O O

Four BC2GM025829397 CD O
antifungal BC2GM025829397 JJ O
agents BC2GM025829397 NNS O
were BC2GM025829397 VBD O
compared BC2GM025829397 VBN O
: BC2GM025829397 : O
amphotericin BC2GM025829397 NN O
B BC2GM025829397 NNP O
, BC2GM025829397 , O
flucytosine BC2GM025829397 NN O
, BC2GM025829397 , O
miconazole BC2GM025829397 NN O
, BC2GM025829397 , O
and BC2GM025829397 CC O
ketoconazole BC2GM025829397 NN O
. BC2GM025829397 . O
. . O O

AST BC2GM036908769 NNP O
activity BC2GM036908769 NN O
in BC2GM036908769 IN O
PMNs BC2GM036908769 NNP O
was BC2GM036908769 VBD O
significantly BC2GM036908769 RB O
low BC2GM036908769 JJ O
, BC2GM036908769 , O
approximately BC2GM036908769 RB O
2 BC2GM036908769 CD O
% BC2GM036908769 NN O
of BC2GM036908769 IN O
that BC2GM036908769 DT O
observed BC2GM036908769 VBD O
in BC2GM036908769 IN O
HPLFs BC2GM036908769 NNP O
. BC2GM036908769 . O
. . O O

Long-term BC2GM066994310 JJ O
renal BC2GM066994310 JJ O
function BC2GM066994310 NN O
in BC2GM066994310 IN O
on-heart-beating BC2GM066994310 JJ O
donor BC2GM066994310 NN O
kidney BC2GM066994310 NN O
transplantation BC2GM066994310 NN O
: BC2GM066994310 : O
a BC2GM066994310 DT O
single-center BC2GM066994310 JJ O
experience BC2GM066994310 NN O
. BC2GM066994310 . O
. . O O

Identification BC2GM007200523 NN O
of BC2GM007200523 IN O
domains BC2GM007200523 NNS O
mediating BC2GM007200523 VBG O
transcription BC2GM007200523 NN O
activation BC2GM007200523 NN O
, BC2GM007200523 , O
repression BC2GM007200523 NN O
, BC2GM007200523 , O
and BC2GM007200523 CC O
inhibition BC2GM007200523 NN O
in BC2GM007200523 IN O
the BC2GM007200523 DT O
paired-related BC2GM007200523 JJ O
homeobox BC2GM007200523 NN O
protein BC2GM007200523 NN O
, BC2GM007200523 , O
Prx2 BC2GM007200523 NNP O
( BC2GM007200523 ( O
S8 BC2GM007200523 NNP O
) BC2GM007200523 ) O
. BC2GM007200523 . O
. . O O

This BC2GM069603149 DT O
duplicated BC2GM069603149 JJ O
genomic BC2GM069603149 JJ O
region BC2GM069603149 NN O
is BC2GM069603149 VBZ O
also BC2GM069603149 RB O
linked BC2GM069603149 VBN O
tightly BC2GM069603149 RB O
to BC2GM069603149 TO O
D1Z2 BC2GM069603149 NNP O
, BC2GM069603149 , O
a BC2GM069603149 DT O
genetic BC2GM069603149 JJ O
marker BC2GM069603149 NN O
containing BC2GM069603149 VBG O
a BC2GM069603149 DT O
highly BC2GM069603149 RB O
polymorphic BC2GM069603149 JJ O
VNTR BC2GM069603149 NNP O
( BC2GM069603149 ( O
variable BC2GM069603149 JJ O
number BC2GM069603149 NN O
tandem BC2GM069603149 JJ O
repeat BC2GM069603149 NN O
) BC2GM069603149 ) O
consisting BC2GM069603149 NN O
of BC2GM069603149 IN O
an BC2GM069603149 DT O
unusual BC2GM069603149 JJ O
40-bp BC2GM069603149 JJ O
reiterated BC2GM069603149 VBN O
sequence BC2GM069603149 NN O
. BC2GM069603149 . O
. . O O

Chronic BC2GM082757224 NNP O
, BC2GM082757224 , O
recurrent BC2GM082757224 JJ O
multifocal BC2GM082757224 JJ O
osteomyelitis BC2GM082757224 NN O
. BC2GM082757224 . O
. . O O

ZNS BC2GM037965797 NNP O
, BC2GM037965797 , O
in BC2GM037965797 IN O
the BC2GM037965797 DT O
mmolar BC2GM037965797 JJ O
range BC2GM037965797 NN O
, BC2GM037965797 , O
scavenged BC2GM037965797 VBD O
hydroxyl BC2GM037965797 NN O
and BC2GM037965797 CC O
nitric BC2GM037965797 JJ O
oxide BC2GM037965797 NN O
radicals BC2GM037965797 NNS O
in BC2GM037965797 IN O
a BC2GM037965797 DT O
dose-dependent BC2GM037965797 JJ O
manner BC2GM037965797 NN O
. BC2GM037965797 . O
. . O O

Increasing BC2GM002325093 VBG O
insulin BC2GM002325093 NN O
sensitivity BC2GM002325093 NN O
in BC2GM002325093 IN O
type BC2GM002325093 NN O
I BC2GM002325093 PRP O
diabetic BC2GM002325093 JJ O
patients BC2GM002325093 NNS O
should BC2GM002325093 MD O
alert BC2GM002325093 VB O
clinicians BC2GM002325093 NNS O
to BC2GM002325093 TO O
the BC2GM002325093 DT O
possibility BC2GM002325093 NN O
of BC2GM002325093 IN O
glucocorticoid BC2GM002325093 JJ O
deficiency BC2GM002325093 NN O
. BC2GM002325093 . O
. . O O

Evidence BC2GM016375910 NN O
from BC2GM016375910 IN O
four BC2GM016375910 CD O
areas BC2GM016375910 NNS O
-- BC2GM016375910 : O
sensory BC2GM016375910 JJ O
deprivation BC2GM016375910 NN O
, BC2GM016375910 , O
enriched BC2GM016375910 VBD O
environments BC2GM016375910 NNS O
, BC2GM016375910 , O
nervous BC2GM016375910 JJ O
system BC2GM016375910 NN O
plasticity BC2GM016375910 NN O
, BC2GM016375910 , O
and BC2GM016375910 CC O
sensitive BC2GM016375910 JJ O
periods BC2GM016375910 NNS O
of BC2GM016375910 IN O
neurodevelopment BC2GM016375910 NN O
-- BC2GM016375910 : O
suggests BC2GM016375910 VBZ O
that BC2GM016375910 IN O
sensory BC2GM016375910 JJ O
stimulation BC2GM016375910 NN O
programs BC2GM016375910 NNS O
are BC2GM016375910 VBP O
potentially BC2GM016375910 RB O
beneficial BC2GM016375910 JJ O
for BC2GM016375910 IN O
STR BC2GM016375910 NNP O
patients BC2GM016375910 NNS O
. BC2GM016375910 . O
. . O O

Jet BC2GM088911039 NNP O
lag BC2GM088911039 NN O
and BC2GM088911039 CC O
melatonin BC2GM088911039 NN O
. BC2GM088911039 . O
. . O O

It BC2GM060403286 PRP O
is BC2GM060403286 VBZ O
concluded BC2GM060403286 VBN O
that BC2GM060403286 IN O
the BC2GM060403286 DT O
new BC2GM060403286 JJ O
class BC2GM060403286 NN O
of BC2GM060403286 IN O
competitive BC2GM060403286 JJ O
NMDA BC2GM060403286 NNP O
receptor BC2GM060403286 NN O
antagonists BC2GM060403286 NNS O
, BC2GM060403286 , O
exemplified BC2GM060403286 VBN O
by BC2GM060403286 IN O
CGP BC2GM060403286 NNP O
37849 BC2GM060403286 CD O
, BC2GM060403286 , O
is BC2GM060403286 VBZ O
the BC2GM060403286 DT O
most BC2GM060403286 RBS O
promising BC2GM060403286 JJ O
candidate BC2GM060403286 NN O
for BC2GM060403286 IN O
clinical BC2GM060403286 JJ O
trials BC2GM060403286 NNS O
in BC2GM060403286 IN O
anxiety BC2GM060403286 NN O
disorders BC2GM060403286 NNS O
. BC2GM060403286 . O
. . O O

Hybridization BC2GM032722941 NN O
was BC2GM032722941 VBD O
detected BC2GM032722941 VBN O
between BC2GM032722941 IN O
polyadenylated BC2GM032722941 VBN O
H BC2GM032722941 NNP O
chain BC2GM032722941 NN O
mRNA BC2GM032722941 NN O
, BC2GM032722941 , O
isolated BC2GM032722941 VBN O
from BC2GM032722941 IN O
the BC2GM032722941 DT O
majority BC2GM032722941 NN O
of BC2GM032722941 IN O
the BC2GM032722941 DT O
hybridomas BC2GM032722941 NN O
, BC2GM032722941 , O
and BC2GM032722941 CC O
the BC2GM032722941 DT O
VH BC2GM032722941 NNP O
probe BC2GM032722941 NN O
. BC2GM032722941 . O
. . O O

In BC2GM006588780 IN O
contrast BC2GM006588780 NN O
to BC2GM006588780 TO O
Phase BC2GM006588780 NNP O
III BC2GM006588780 NNP O
, BC2GM006588780 , O
which BC2GM006588780 WDT O
has BC2GM006588780 VBZ O
a BC2GM006588780 DT O
single BC2GM006588780 JJ O
study BC2GM006588780 NN O
design BC2GM006588780 NN O
-- BC2GM006588780 : O
the BC2GM006588780 DT O
controlled BC2GM006588780 VBN O
, BC2GM006588780 , O
randomized BC2GM006588780 VBN O
, BC2GM006588780 , O
double-blind BC2GM006588780 JJ O
study BC2GM006588780 NN O
-- BC2GM006588780 : O
Phase BC2GM006588780 NNP O
IV BC2GM006588780 NNP O
requires BC2GM006588780 VBZ O
different BC2GM006588780 JJ O
designs BC2GM006588780 NNS O
for BC2GM006588780 IN O
each BC2GM006588780 DT O
of BC2GM006588780 IN O
the BC2GM006588780 DT O
many BC2GM006588780 JJ O
different BC2GM006588780 JJ O
questions BC2GM006588780 NNS O
. BC2GM006588780 . O
. . O O

Spontaneous BC2GM062537861 JJ O
coronary BC2GM062537861 JJ O
artery BC2GM062537861 NN O
spasm BC2GM062537861 NN O
during BC2GM062537861 IN O
coronary BC2GM062537861 JJ O
angiography BC2GM062537861 NN O
in BC2GM062537861 IN O
a BC2GM062537861 DT O
patient BC2GM062537861 NN O
with BC2GM062537861 IN O
exercise-induced BC2GM062537861 JJ O
ST BC2GM062537861 NNP O
segment BC2GM062537861 NN O
elevation BC2GM062537861 NN O
. BC2GM062537861 . O
. . O O

The BC2GM071664936 DT O
well-trained BC2GM071664936 JJ O
group BC2GM071664936 NN O
was BC2GM071664936 VBD O
measured BC2GM071664936 VBN O
once BC2GM071664936 RB O
in BC2GM071664936 IN O
the BC2GM071664936 DT O
respiration BC2GM071664936 NN O
chamber BC2GM071664936 NN O
for BC2GM071664936 IN O
36 BC2GM071664936 CD O
h BC2GM071664936 NN O
according BC2GM071664936 VBG O
to BC2GM071664936 TO O
the BC2GM071664936 DT O
same BC2GM071664936 JJ O
protocol BC2GM071664936 NN O
. BC2GM071664936 . O
. . O O

The BC2GM072477958 DT O
cooperation BC2GM072477958 NN O
between BC2GM072477958 IN O
health BC2GM072477958 NN O
and BC2GM072477958 CC O
hospital BC2GM072477958 NN O
services BC2GM072477958 NNS O
. BC2GM072477958 . O
. . O O

We BC2GM012717933 PRP O
suggest BC2GM012717933 VBP O
that BC2GM012717933 IN O
the BC2GM012717933 DT O
responses BC2GM012717933 NNS O
to BC2GM012717933 TO O
types BC2GM012717933 NNS O
I BC2GM012717933 PRP O
and BC2GM012717933 CC O
II BC2GM012717933 NNP O
collagen BC2GM012717933 NN O
were BC2GM012717933 VBD O
caused BC2GM012717933 VBN O
by BC2GM012717933 IN O
a BC2GM012717933 DT O
cross-reaction BC2GM012717933 NN O
with BC2GM012717933 IN O
type BC2GM012717933 JJ O
III BC2GM012717933 NNP O
collagen BC2GM012717933 NN O
peptides BC2GM012717933 NNS O
. BC2GM012717933 . O
. . O O

An BC2GM096583756 DT O
insertion BC2GM096583756 NN O
sequence BC2GM096583756 NN O
element BC2GM096583756 NN O
( BC2GM096583756 ( O
IS1170 BC2GM096583756 NNP O
) BC2GM096583756 ) O
was BC2GM096583756 VBD O
identified BC2GM096583756 VBN O
upstream BC2GM096583756 NN O
of BC2GM096583756 IN O
the BC2GM096583756 DT O
nimC BC2GM096583756 JJ O
gene BC2GM096583756 NN O
. BC2GM096583756 . O
. . O O

The BC2GM014046465 DT O
use BC2GM014046465 NN O
of BC2GM014046465 IN O
sigma BC2GM014046465 NN O
54 BC2GM014046465 CD O
promoters BC2GM014046465 NNS O
, BC2GM014046465 , O
known BC2GM014046465 VBN O
to BC2GM014046465 TO O
require BC2GM014046465 VB O
cognate BC2GM014046465 NN O
binding BC2GM014046465 NN O
proteins BC2GM014046465 NNS O
, BC2GM014046465 , O
could BC2GM014046465 MD O
allow BC2GM014046465 VB O
the BC2GM014046465 DT O
fine-tuning BC2GM014046465 JJ O
that BC2GM014046465 WDT O
provides BC2GM014046465 VBZ O
the BC2GM014046465 DT O
temporal BC2GM014046465 JJ O
ordering BC2GM014046465 NN O
of BC2GM014046465 IN O
flagellar BC2GM014046465 JJ O
gene BC2GM014046465 NN O
transcription BC2GM014046465 NN O
. BC2GM014046465 . O
. . O O

Competition BC2GM084759712 NN O
and BC2GM084759712 CC O
methylation BC2GM084759712 NN O
interference BC2GM084759712 NN O
assays BC2GM084759712 NNS O
showed BC2GM084759712 VBD O
that BC2GM084759712 IN O
the BC2GM084759712 DT O
binding BC2GM084759712 NN O
site BC2GM084759712 NN O
for BC2GM084759712 IN O
the BC2GM084759712 DT O
novel BC2GM084759712 JJ O
factor BC2GM084759712 NN O
was BC2GM084759712 VBD O
limited BC2GM084759712 VBN O
to BC2GM084759712 TO O
nucleotides BC2GM084759712 NNS O
in BC2GM084759712 IN O
the BC2GM084759712 DT O
3 BC2GM084759712 CD O
' BC2GM084759712 POS O
half BC2GM084759712 NN O
of BC2GM084759712 IN O
the BC2GM084759712 DT O
kappa BC2GM084759712 NN O
B BC2GM084759712 NNP O
site BC2GM084759712 NN O
. BC2GM084759712 . O
. . O O

Using BC2GM041191504 VBG O
yeast BC2GM041191504 JJ O
two-hybrid BC2GM041191504 JJ O
screening BC2GM041191504 NN O
, BC2GM041191504 , O
we BC2GM041191504 PRP O
isolated BC2GM041191504 VBD O
histone BC2GM041191504 RB O
H3 BC2GM041191504 NNP O
as BC2GM041191504 IN O
an BC2GM041191504 DT O
interacting BC2GM041191504 JJ O
factor BC2GM041191504 NN O
of BC2GM041191504 IN O
CIA BC2GM041191504 NNP O
. BC2GM041191504 . O
. . O O

For BC2GM089290440 IN O
the BC2GM089290440 DT O
albino BC2GM089290440 NN O
, BC2GM089290440 , O
both BC2GM089290440 CC O
the BC2GM089290440 DT O
ST1 BC2GM089290440 NNP O
and BC2GM089290440 CC O
ST2 BC2GM089290440 NNP O
spatial BC2GM089290440 JJ O
responses BC2GM089290440 NNS O
peak BC2GM089290440 VBP O
at BC2GM089290440 IN O
around BC2GM089290440 IN O
0.3 BC2GM089290440 CD O
cycles BC2GM089290440 NNS O
deg-1 BC2GM089290440 JJ O
, BC2GM089290440 , O
and BC2GM089290440 CC O
both BC2GM089290440 DT O
curves BC2GM089290440 NNS O
are BC2GM089290440 VBP O
displaced BC2GM089290440 VBN O
considerably BC2GM089290440 RB O
to BC2GM089290440 TO O
the BC2GM089290440 DT O
low BC2GM089290440 JJ O
spatial BC2GM089290440 JJ O
frequency BC2GM089290440 NN O
side BC2GM089290440 NN O
of BC2GM089290440 IN O
the BC2GM089290440 DT O
normal BC2GM089290440 JJ O
ST2 BC2GM089290440 NNP O
spatial BC2GM089290440 JJ O
response BC2GM089290440 NN O
. BC2GM089290440 . O
. . O O

Carcinogenic BC2GM018123689 JJ O
action BC2GM018123689 NN O
of BC2GM018123689 IN O
groundnut BC2GM018123689 NN O
meal BC2GM018123689 NN O
containing BC2GM018123689 VBG O
aflatoxin BC2GM018123689 NN O
in BC2GM018123689 IN O
rats BC2GM018123689 NNS O
. BC2GM018123689 . O
. . O O

To BC2GM083705867 TO O
date BC2GM083705867 NN O
, BC2GM083705867 , O
6 BC2GM083705867 CD O
mammalian BC2GM083705867 JJ O
GRKs BC2GM083705867 NNP O
have BC2GM083705867 VBP O
been BC2GM083705867 VBN O
identified BC2GM083705867 VBN O
by BC2GM083705867 IN O
molecular BC2GM083705867 JJ O
cloning BC2GM083705867 NN O
. BC2GM083705867 . O
. . O O

Human BC2GM014145288 NNP O
forearm BC2GM014145288 NN O
was BC2GM014145288 VBD O
used BC2GM014145288 VBN O
as BC2GM014145288 IN O
a BC2GM014145288 DT O
dummy BC2GM014145288 JJ O
ear BC2GM014145288 NN O
and BC2GM014145288 CC O
the BC2GM014145288 DT O
electrode BC2GM014145288 JJ O
HN-5 BC2GM014145288 NNP O
was BC2GM014145288 VBD O
fixed BC2GM014145288 VBN O
thereon BC2GM014145288 NN O
, BC2GM014145288 , O
and BC2GM014145288 CC O
a BC2GM014145288 DT O
sound BC2GM014145288 JJ O
stimulus BC2GM014145288 NN O
of BC2GM014145288 IN O
90dBnHL BC2GM014145288 CD O
was BC2GM014145288 VBD O
delivered BC2GM014145288 VBN O
by BC2GM014145288 IN O
the BC2GM014145288 DT O
earphone BC2GM014145288 NN O
( BC2GM014145288 ( O
NC-3 BC2GM014145288 NNP O
) BC2GM014145288 ) O
. BC2GM014145288 . O
. . O O

These BC2GM029863453 DT O
findings BC2GM029863453 NNS O
suggest BC2GM029863453 VBP O
that BC2GM029863453 IN O
IL-1-stimulated BC2GM029863453 NNP O
, BC2GM029863453 , O
Rho-dependent BC2GM029863453 NNP O
cytoskeletal BC2GM029863453 NN O
reorganization BC2GM029863453 NN O
may BC2GM029863453 MD O
cluster BC2GM029863453 VB O
signaling BC2GM029863453 VBG O
molecules BC2GM029863453 NNS O
in BC2GM029863453 IN O
specific BC2GM029863453 JJ O
architectures BC2GM029863453 NNS O
that BC2GM029863453 WDT O
are BC2GM029863453 VBP O
necessary BC2GM029863453 JJ O
for BC2GM029863453 IN O
persistent BC2GM029863453 JJ O
cell BC2GM029863453 NN O
activation BC2GM029863453 NN O
in BC2GM029863453 IN O
chronic BC2GM029863453 JJ O
inflammatory BC2GM029863453 JJ O
disease BC2GM029863453 NN O
. BC2GM029863453 . O
. . O O

Both BC2GM055197158 DT O
DMP2 BC2GM055197158 NNP O
and BC2GM055197158 CC O
DMP3 BC2GM055197158 NNP O
are BC2GM055197158 VBP O
closely BC2GM055197158 RB O
localized BC2GM055197158 VBN O
on BC2GM055197158 IN O
mouse BC2GM055197158 NN O
chromosome BC2GM055197158 NN O
5q21 BC2GM055197158 CD O
, BC2GM055197158 , O
corresponding BC2GM055197158 VBG O
to BC2GM055197158 TO O
human BC2GM055197158 JJ O
chromosome BC2GM055197158 NN O
4q21 BC2GM055197158 CD O
. BC2GM055197158 . O
. . O O

Together BC2GM054968924 RB O
, BC2GM054968924 , O
these BC2GM054968924 DT O
results BC2GM054968924 NNS O
implicate BC2GM054968924 VBP O
Fal1p BC2GM054968924 NNP O
in BC2GM054968924 IN O
the BC2GM054968924 DT O
18S BC2GM054968924 CD O
rRNA BC2GM054968924 NN O
maturation BC2GM054968924 NN O
pathway BC2GM054968924 RB O
rather BC2GM054968924 RB O
than BC2GM054968924 IN O
in BC2GM054968924 IN O
translation BC2GM054968924 NN O
initiation BC2GM054968924 NN O
. BC2GM054968924 . O
. . O O

Nonsuicidal BC2GM003556533 NNP O
mortality BC2GM003556533 NN O
in BC2GM003556533 IN O
late-life BC2GM003556533 JJ O
depression BC2GM003556533 NN O
. BC2GM003556533 . O
. . O O

The BC2GM005826415 DT O
electron BC2GM005826415 NN O
spin BC2GM005826415 NN O
resonance BC2GM005826415 NN O
study BC2GM005826415 NN O
also BC2GM005826415 RB O
demonstrated BC2GM005826415 VBD O
that BC2GM005826415 IN O
the BC2GM005826415 DT O
formation BC2GM005826415 NN O
of BC2GM005826415 IN O
superoxide-DMPO BC2GM005826415 JJ O
spin BC2GM005826415 NN O
adduct BC2GM005826415 NN O
was BC2GM005826415 VBD O
strongly BC2GM005826415 RB O
inhibited BC2GM005826415 VBN O
by BC2GM005826415 IN O
a BC2GM005826415 DT O
selective BC2GM005826415 JJ O
cyclooxygenase-2 BC2GM005826415 JJ O
inhibitor BC2GM005826415 NN O
, BC2GM005826415 , O
etodolac BC2GM005826415 NN O
, BC2GM005826415 , O
in BC2GM005826415 IN O
a BC2GM005826415 DT O
concentration-dependent BC2GM005826415 JJ O
manner BC2GM005826415 NN O
. BC2GM005826415 . O
. . O O

Immunofluorescence BC2GM080424073 NN O
obtained BC2GM080424073 VBD O
using BC2GM080424073 VBG O
antibodies BC2GM080424073 NNS O
against BC2GM080424073 IN O
alphaI BC2GM080424073 JJ O
SigmaI BC2GM080424073 NNP O
/ BC2GM080424073 NNP O
++betaI BC2GM080424073 NNP O
SigmaI BC2GM080424073 NNP O
spectrin BC2GM080424073 NN O
and BC2GM080424073 CC O
Abl BC2GM080424073 NNP O
tyrosine BC2GM080424073 JJ O
kinase BC2GM080424073 NN O
but BC2GM080424073 CC O
not BC2GM080424073 RB O
against BC2GM080424073 IN O
alphaII BC2GM080424073 JJ O
/ BC2GM080424073 JJ O
betaII BC2GM080424073 NN O
spectrin BC2GM080424073 NN O
colocalized BC2GM080424073 VBN O
with BC2GM080424073 IN O
the BC2GM080424073 DT O
overexpressed BC2GM080424073 JJ O
green BC2GM080424073 JJ O
fluorescent BC2GM080424073 NN O
protein-SH3-binding BC2GM080424073 NN O
protein BC2GM080424073 NN O
. BC2GM080424073 . O
. . O O

Conversion BC2GM097783604 NN O
of BC2GM097783604 IN O
an BC2GM097783604 DT O
NF-kappaB BC2GM097783604 NNP O
into BC2GM097783604 IN O
a BC2GM097783604 DT O
GABP BC2GM097783604 NNP O
binding BC2GM097783604 NN O
site BC2GM097783604 NN O
is BC2GM097783604 VBZ O
likely BC2GM097783604 JJ O
to BC2GM097783604 TO O
have BC2GM097783604 VB O
occurred BC2GM097783604 VBN O
also BC2GM097783604 RB O
during BC2GM097783604 IN O
the BC2GM097783604 DT O
worldwide BC2GM097783604 JJ O
spread BC2GM097783604 NN O
of BC2GM097783604 IN O
HIV-1 BC2GM097783604 NNP O
, BC2GM097783604 , O
as BC2GM097783604 IN O
we BC2GM097783604 PRP O
noticed BC2GM097783604 VBD O
the BC2GM097783604 DT O
same BC2GM097783604 JJ O
LTR BC2GM097783604 NNP O
modification BC2GM097783604 NN O
in BC2GM097783604 IN O
subtype BC2GM097783604 JJ O
E BC2GM097783604 NN O
isolates BC2GM097783604 NNS O
from BC2GM097783604 IN O
Thailand BC2GM097783604 NNP O
. BC2GM097783604 . O
. . O O

Although BC2GM005086687 IN O
there BC2GM005086687 EX O
is BC2GM005086687 VBZ O
evidence BC2GM005086687 NN O
that BC2GM005086687 IN O
cone BC2GM005086687 NN O
ratios BC2GM005086687 NNS O
do BC2GM005086687 VBP O
determine BC2GM005086687 VB O
colour BC2GM005086687 VB O
appearance BC2GM005086687 NN O
under BC2GM005086687 IN O
many BC2GM005086687 JJ O
conditions BC2GM005086687 NNS O
, BC2GM005086687 , O
the BC2GM005086687 DT O
site BC2GM005086687 NN O
or BC2GM005086687 CC O
sites BC2GM005086687 NNS O
of BC2GM005086687 IN O
their BC2GM005086687 PRP$ O
computation BC2GM005086687 NN O
is BC2GM005086687 VBZ O
unknown BC2GM005086687 JJ O
. BC2GM005086687 . O
. . O O

These BC2GM046451066 DT O
p21-E2F BC2GM046451066 JJ O
complexes BC2GM046451066 NNS O
, BC2GM046451066 , O
while BC2GM046451066 IN O
present BC2GM046451066 JJ O
in BC2GM046451066 IN O
young BC2GM046451066 JJ O
G1 BC2GM046451066 NNP O
cells BC2GM046451066 NNS O
at BC2GM046451066 IN O
very BC2GM046451066 RB O
low BC2GM046451066 JJ O
levels BC2GM046451066 NNS O
, BC2GM046451066 , O
were BC2GM046451066 VBD O
elevated BC2GM046451066 VBN O
in BC2GM046451066 IN O
senescent BC2GM046451066 JJ O
cells BC2GM046451066 NNS O
. BC2GM046451066 . O
. . O O

This BC2GM009468247 DT O
paper BC2GM009468247 NN O
reports BC2GM009468247 VBZ O
estimates BC2GM009468247 NNS O
of BC2GM009468247 IN O
the BC2GM009468247 DT O
prevalence BC2GM009468247 NN O
of BC2GM009468247 IN O
mental BC2GM009468247 JJ O
retardation BC2GM009468247 NN O
and BC2GM009468247 CC O
associated BC2GM009468247 VBN O
factors BC2GM009468247 NNS O
based BC2GM009468247 VBN O
on BC2GM009468247 IN O
a BC2GM009468247 DT O
population BC2GM009468247 NN O
survey BC2GM009468247 NN O
of BC2GM009468247 IN O
2- BC2GM009468247 JJ O
to BC2GM009468247 TO O
9-year-old BC2GM009468247 JJ O
children BC2GM009468247 NNS O
in BC2GM009468247 IN O
Greater BC2GM009468247 NNP O
Karachi BC2GM009468247 NNP O
, BC2GM009468247 , O
Pakistan BC2GM009468247 NNP O
. BC2GM009468247 . O
. . O O

On BC2GM068082913 IN O
the BC2GM068082913 DT O
optic BC2GM068082913 JJ O
tentacle-gonadal BC2GM068082913 JJ O
axis BC2GM068082913 NN O
in BC2GM068082913 IN O
the BC2GM068082913 DT O
control BC2GM068082913 NN O
of BC2GM068082913 IN O
the BC2GM068082913 DT O
male-phase BC2GM068082913 JJ O
ovotestis BC2GM068082913 NN O
in BC2GM068082913 IN O
the BC2GM068082913 DT O
slug BC2GM068082913 NN O
( BC2GM068082913 ( O
Ariolimax BC2GM068082913 NNP O
californicus BC2GM068082913 NN O
) BC2GM068082913 ) O
. BC2GM068082913 . O
. . O O

Furthermore BC2GM015309588 RB O
, BC2GM015309588 , O
CL100 BC2GM015309588 NNP O
suppresses BC2GM015309588 VBZ O
the BC2GM015309588 DT O
[ BC2GM015309588 NNP O
val12 BC2GM015309588 NN O
] BC2GM015309588 NNP O
ras-induced BC2GM015309588 JJ O
activation BC2GM015309588 NN O
of BC2GM015309588 IN O
MAP BC2GM015309588 NNP O
kinase BC2GM015309588 NN O
in BC2GM015309588 IN O
a BC2GM015309588 DT O
cell-free BC2GM015309588 JJ O
system BC2GM015309588 NN O
from BC2GM015309588 IN O
Xenopus BC2GM015309588 NNP O
oocytes BC2GM015309588 NNS O
. BC2GM015309588 . O
. . O O

Increased BC2GM054451965 VBN O
susceptibility BC2GM054451965 NN O
of BC2GM054451965 IN O
aphasics BC2GM054451965 NNS O
to BC2GM054451965 TO O
a BC2GM054451965 DT O
distractor BC2GM054451965 NN O
task BC2GM054451965 NN O
in BC2GM054451965 IN O
the BC2GM054451965 DT O
recall BC2GM054451965 NN O
of BC2GM054451965 IN O
verbal BC2GM054451965 JJ O
commands BC2GM054451965 NNS O
. BC2GM054451965 . O
. . O O

Cells BC2GM002081221 NNS O
were BC2GM002081221 VBD O
cotransfected BC2GM002081221 VBN O
with BC2GM002081221 IN O
this BC2GM002081221 DT O
plasmid BC2GM002081221 NN O
, BC2GM002081221 , O
and BC2GM002081221 CC O
the BC2GM002081221 DT O
appropriate BC2GM002081221 JJ O
responder BC2GM002081221 NN O
plasmids BC2GM002081221 NNS O
and BC2GM002081221 CC O
clonies BC2GM002081221 NNS O
were BC2GM002081221 VBD O
selected BC2GM002081221 VBN O
on BC2GM002081221 IN O
the BC2GM002081221 DT O
basis BC2GM002081221 NN O
of BC2GM002081221 IN O
their BC2GM002081221 PRP$ O
resistance BC2GM002081221 NN O
to BC2GM002081221 TO O
Geneticin BC2GM002081221 NNP O
( BC2GM002081221 ( O
via BC2GM002081221 IN O
the BC2GM002081221 DT O
neomycin BC2GM002081221 JJ O
aminoglycoside BC2GM002081221 JJ O
phosphotransferase BC2GM002081221 NN O
gene BC2GM002081221 NN O
) BC2GM002081221 ) O
. BC2GM002081221 . O
. . O O

Procedures BC2GM005098468 NNS O
with BC2GM005098468 IN O
perfected BC2GM005098468 JJ O
method BC2GM005098468 NN O
. BC2GM005098468 . O
. . O O

Histological BC2GM016146952 JJ O
examination BC2GM016146952 NN O
revealed BC2GM016146952 VBD O
variable BC2GM016146952 JJ O
loss BC2GM016146952 NN O
of BC2GM016146952 IN O
motor BC2GM016146952 NN O
neurons BC2GM016146952 NNS O
limited BC2GM016146952 VBD O
to BC2GM016146952 TO O
the BC2GM016146952 DT O
injection BC2GM016146952 NN O
site BC2GM016146952 NN O
. BC2GM016146952 . O
. . O O

Demonstration BC2GM089782491 NN O
of BC2GM089782491 IN O
changes BC2GM089782491 NNS O
in BC2GM089782491 IN O
fetal BC2GM089782491 JJ O
liver BC2GM089782491 NN O
erythropoiesis BC2GM089782491 NN O
using BC2GM089782491 VBG O
echo-planar BC2GM089782491 JJ O
magnetic BC2GM089782491 JJ O
resonance BC2GM089782491 NN O
imaging BC2GM089782491 NN O
. BC2GM089782491 . O
. . O O

ORF3 BC2GM049346947 NNP O
appears BC2GM049346947 VBZ O
to BC2GM049346947 TO O
encode BC2GM049346947 VB O
the BC2GM049346947 DT O
homologue BC2GM049346947 NN O
of BC2GM049346947 IN O
the BC2GM049346947 DT O
well-conserved BC2GM049346947 JJ O
proteasomal BC2GM049346947 JJ O
26S BC2GM049346947 CD O
regulatory BC2GM049346947 JJ O
subunit BC2GM049346947 NN O
. BC2GM049346947 . O
. . O O

Located BC2GM028948784 VBN O
between BC2GM028948784 IN O
the BC2GM028948784 DT O
3 BC2GM028948784 CD O
' BC2GM028948784 POS O
trans-spliced BC2GM028948784 JJ O
leader BC2GM028948784 NN O
acceptor BC2GM028948784 NN O
site BC2GM028948784 NN O
and BC2GM028948784 CC O
the BC2GM028948784 DT O
translational BC2GM028948784 JJ O
initiation BC2GM028948784 NN O
codon BC2GM028948784 NN O
of BC2GM028948784 IN O
the BC2GM028948784 DT O
GP63 BC2GM028948784 NNP O
gene BC2GM028948784 NN O
is BC2GM028948784 VBZ O
an BC2GM028948784 DT O
area BC2GM028948784 NN O
of BC2GM028948784 IN O
conserved BC2GM028948784 JJ O
hexanucleotide BC2GM028948784 NN O
direct BC2GM028948784 JJ O
repeats BC2GM028948784 NNS O
( BC2GM028948784 ( O
CTCGCC BC2GM028948784 NNP O
) BC2GM028948784 ) O
which BC2GM028948784 WDT O
vary BC2GM028948784 VBP O
in BC2GM028948784 IN O
number BC2GM028948784 NN O
according BC2GM028948784 VBG O
to BC2GM028948784 TO O
species BC2GM028948784 NNS O
. BC2GM028948784 . O
. . O O

Toxicological BC2GM057796202 JJ O
effects BC2GM057796202 NNS O
of BC2GM057796202 IN O
dietary BC2GM057796202 JJ O
Maillard BC2GM057796202 NNP O
reaction BC2GM057796202 NN O
products BC2GM057796202 NNS O
in BC2GM057796202 IN O
the BC2GM057796202 DT O
rat BC2GM057796202 NN O
. BC2GM057796202 . O
. . O O

Accumulation BC2GM086842152 NN O
of BC2GM086842152 IN O
amines BC2GM086842152 NNS O
in BC2GM086842152 IN O
the BC2GM086842152 DT O
isolated BC2GM086842152 JJ O
perfused BC2GM086842152 JJ O
rabbit BC2GM086842152 NN O
lung BC2GM086842152 NN O
. BC2GM086842152 . O
. . O O

Furthermore BC2GM065096427 RB O
, BC2GM065096427 , O
addition BC2GM065096427 NN O
of BC2GM065096427 IN O
the BC2GM065096427 DT O
recombinant BC2GM065096427 JJ O
NF-YA BC2GM065096427 NNP O
subunit BC2GM065096427 NN O
restores BC2GM065096427 VBZ O
NF-Y BC2GM065096427 NNP O
binding BC2GM065096427 NN O
. BC2GM065096427 . O
. . O O

Diagnostic BC2GM025162060 JJ O
importance BC2GM025162060 NN O
of BC2GM025162060 IN O
determining BC2GM025162060 VBG O
leucine BC2GM025162060 JJ O
aminotransferase BC2GM025162060 NN O
activity BC2GM025162060 NN O
in BC2GM025162060 IN O
acute BC2GM025162060 JJ O
pancreatitis BC2GM025162060 NN O
. BC2GM025162060 . O
. . O O

The BC2GM034355012 DT O
transcriptional BC2GM034355012 JJ O
activity BC2GM034355012 NN O
of BC2GM034355012 IN O
P-450 BC2GM034355012 NNP O
( BC2GM034355012 ( O
11 BC2GM034355012 CD O
beta BC2GM034355012 NN O
) BC2GM034355012 ) O
gene BC2GM034355012 NN O
was BC2GM034355012 VBD O
studied BC2GM034355012 VBN O
with BC2GM034355012 IN O
an BC2GM034355012 DT O
in BC2GM034355012 IN O
vitro BC2GM034355012 NN O
transcription BC2GM034355012 NN O
system BC2GM034355012 NN O
using BC2GM034355012 VBG O
nuclear BC2GM034355012 JJ O
extracts BC2GM034355012 NNS O
prepared BC2GM034355012 VBN O
from BC2GM034355012 IN O
bovine BC2GM034355012 JJ O
adrenal BC2GM034355012 JJ O
cortex BC2GM034355012 NN O
. BC2GM034355012 . O
. . O O

Positive BC2GM060681176 JJ O
effects BC2GM060681176 NNS O
of BC2GM060681176 IN O
radioactive BC2GM060681176 JJ O
therapy BC2GM060681176 NN O
in BC2GM060681176 IN O
Guarapari BC2GM060681176 NNP O
. BC2GM060681176 . O
. . O O

Identification BC2GM037344526 NN O
and BC2GM037344526 CC O
characterization BC2GM037344526 NN O
of BC2GM037344526 IN O
a BC2GM037344526 DT O
yeast BC2GM037344526 JJ O
gene BC2GM037344526 NN O
encoding BC2GM037344526 VBG O
the BC2GM037344526 DT O
U2 BC2GM037344526 NNP O
small BC2GM037344526 JJ O
nuclear BC2GM037344526 JJ O
ribonucleoprotein BC2GM037344526 NN O
particle BC2GM037344526 NN O
B BC2GM037344526 NNP O
'' BC2GM037344526 '' O
protein BC2GM037344526 NN O
. BC2GM037344526 . O
. . O O

Mammalian BC2GM070953023 JJ O
chromosome BC2GM070953023 NN O
ends BC2GM070953023 NNS O
contain BC2GM070953023 VBP O
long BC2GM070953023 JJ O
arrays BC2GM070953023 NNS O
of BC2GM070953023 IN O
TTAGGG BC2GM070953023 NNP O
repeats BC2GM070953023 NNS O
that BC2GM070953023 WDT O
are BC2GM070953023 VBP O
complexed BC2GM070953023 VBN O
to BC2GM070953023 TO O
a BC2GM070953023 DT O
telomere BC2GM070953023 JJ O
specific BC2GM070953023 JJ O
protein BC2GM070953023 NN O
, BC2GM070953023 , O
the BC2GM070953023 DT O
TTAGGG BC2GM070953023 NNP O
repeat BC2GM070953023 NN O
binding BC2GM070953023 VBG O
factor BC2GM070953023 NN O
, BC2GM070953023 , O
TRF1 BC2GM070953023 NNP O
. BC2GM070953023 . O
. . O O

Basal BC2GM075049436 NNP O
JNK BC2GM075049436 NNP O
MAPK BC2GM075049436 NNP O
kinase BC2GM075049436 NN O
activity BC2GM075049436 NN O
was BC2GM075049436 VBD O
also BC2GM075049436 RB O
specifically BC2GM075049436 RB O
induced BC2GM075049436 VBN O
by BC2GM075049436 IN O
deltaEGFR BC2GM075049436 NN O
, BC2GM075049436 , O
which BC2GM075049436 WDT O
correlated BC2GM075049436 VBD O
with BC2GM075049436 IN O
increased BC2GM075049436 JJ O
phosphorylation BC2GM075049436 NN O
of BC2GM075049436 IN O
a BC2GM075049436 DT O
54-kDa BC2GM075049436 JJ O
JNK2 BC2GM075049436 NNP O
protein BC2GM075049436 NN O
observed BC2GM075049436 VBD O
in BC2GM075049436 IN O
deltaEGFR-containing BC2GM075049436 JJ O
cells BC2GM075049436 NNS O
. BC2GM075049436 . O
. . O O

The BC2GM084353628 DT O
synthesis BC2GM084353628 NN O
of BC2GM084353628 IN O
endo-adduct BC2GM084353628 NN O
[ BC2GM084353628 NN O
4aS,5S,8R,8aR BC2GM084353628 CD O
, BC2GM084353628 , O
SS BC2GM084353628 NNP O
] BC2GM084353628 NNP O
-9d BC2GM084353628 NNP O
resulting BC2GM084353628 VBG O
from BC2GM084353628 IN O
cycloaddition BC2GM084353628 NN O
on BC2GM084353628 IN O
the BC2GM084353628 DT O
substituted BC2GM084353628 VBN O
C BC2GM084353628 NNP O
( BC2GM084353628 ( O
2 BC2GM084353628 CD O
) BC2GM084353628 ) O
-C BC2GM084353628 NN O
( BC2GM084353628 ( O
3 BC2GM084353628 CD O
) BC2GM084353628 ) O
double BC2GM084353628 JJ O
bond BC2GM084353628 NN O
was BC2GM084353628 VBD O
achieved BC2GM084353628 VBN O
in BC2GM084353628 IN O
a BC2GM084353628 DT O
chemo- BC2GM084353628 JJ O
and BC2GM084353628 CC O
diastereoselective BC2GM084353628 JJ O
way BC2GM084353628 NN O
from BC2GM084353628 IN O
quinone BC2GM084353628 NN O
1d BC2GM084353628 CD O
in BC2GM084353628 IN O
the BC2GM084353628 DT O
presence BC2GM084353628 NN O
of BC2GM084353628 IN O
ZnBr BC2GM084353628 NNP O
( BC2GM084353628 ( O
2 BC2GM084353628 CD O
) BC2GM084353628 ) O
. BC2GM084353628 . O
. . O O

The BC2GM049085863 DT O
transcriptional BC2GM049085863 JJ O
transactivator BC2GM049085863 NN O
( BC2GM049085863 ( O
Tas BC2GM049085863 NNP O
) BC2GM049085863 ) O
of BC2GM049085863 IN O
simian BC2GM049085863 JJ O
foamy BC2GM049085863 NN O
virus BC2GM049085863 NN O
type BC2GM049085863 NN O
1 BC2GM049085863 CD O
strongly BC2GM049085863 RB O
augments BC2GM049085863 NNS O
gene BC2GM049085863 NN O
expression BC2GM049085863 NN O
directed BC2GM049085863 VBN O
by BC2GM049085863 IN O
both BC2GM049085863 DT O
the BC2GM049085863 DT O
promoter BC2GM049085863 NN O
in BC2GM049085863 IN O
the BC2GM049085863 DT O
viral BC2GM049085863 JJ O
long BC2GM049085863 JJ O
terminal BC2GM049085863 JJ O
repeat BC2GM049085863 NN O
and BC2GM049085863 CC O
the BC2GM049085863 DT O
newly BC2GM049085863 RB O
discovered BC2GM049085863 VBN O
internal BC2GM049085863 JJ O
promoter BC2GM049085863 NN O
located BC2GM049085863 VBN O
within BC2GM049085863 IN O
the BC2GM049085863 DT O
env BC2GM049085863 JJ O
gene BC2GM049085863 NN O
. BC2GM049085863 . O
. . O O

The BC2GM014548790 DT O
most BC2GM014548790 RBS O
common BC2GM014548790 JJ O
hosts BC2GM014548790 NNS O
were BC2GM014548790 VBD O
equines BC2GM014548790 NNS O
( BC2GM014548790 ( O
31 BC2GM014548790 CD O
% BC2GM014548790 NN O
) BC2GM014548790 ) O
, BC2GM014548790 , O
bovines BC2GM014548790 NNS O
( BC2GM014548790 ( O
25 BC2GM014548790 CD O
% BC2GM014548790 NN O
) BC2GM014548790 ) O
and BC2GM014548790 CC O
raccoons BC2GM014548790 NNS O
( BC2GM014548790 ( O
19 BC2GM014548790 CD O
% BC2GM014548790 NN O
) BC2GM014548790 ) O
. BC2GM014548790 . O
. . O O

It BC2GM048773311 PRP O
is BC2GM048773311 VBZ O
suggested BC2GM048773311 VBN O
that BC2GM048773311 IN O
the BC2GM048773311 DT O
mechanism BC2GM048773311 NN O
of BC2GM048773311 IN O
intestinal BC2GM048773311 JJ O
absorption BC2GM048773311 NN O
of BC2GM048773311 IN O
vitamin BC2GM048773311 NN O
D BC2GM048773311 NNP O
and BC2GM048773311 CC O
25-hydroxy-vitamin BC2GM048773311 JJ O
D BC2GM048773311 NNP O
may BC2GM048773311 MD O
differ BC2GM048773311 VB O
in BC2GM048773311 IN O
man BC2GM048773311 NN O
, BC2GM048773311 , O
the BC2GM048773311 DT O
absorption BC2GM048773311 NN O
of BC2GM048773311 IN O
25-hydroxy-vitamin BC2GM048773311 JJ O
D BC2GM048773311 NNP O
possibly BC2GM048773311 RB O
being BC2GM048773311 VBG O
less BC2GM048773311 RBR O
dependent BC2GM048773311 JJ O
on BC2GM048773311 IN O
bile BC2GM048773311 JJ O
acids BC2GM048773311 NNS O
. BC2GM048773311 . O
. . O O

Several BC2GM075861735 JJ O
DNA BC2GM075861735 NNP O
clones BC2GM075861735 NNS O
were BC2GM075861735 VBD O
obtained BC2GM075861735 VBN O
by BC2GM075861735 IN O
this BC2GM075861735 DT O
procedure BC2GM075861735 NN O
, BC2GM075861735 , O
one BC2GM075861735 CD O
of BC2GM075861735 IN O
which BC2GM075861735 WDT O
, BC2GM075861735 , O
clone BC2GM075861735 NN O
18 BC2GM075861735 CD O
, BC2GM075861735 , O
is BC2GM075861735 VBZ O
reported BC2GM075861735 VBN O
and BC2GM075861735 CC O
characterized BC2GM075861735 VBN O
here BC2GM075861735 RB O
. BC2GM075861735 . O
. . O O

ESR BC2GM079434119 NNP O
spectra BC2GM079434119 NN O
of BC2GM079434119 IN O
Er3+ BC2GM079434119 NNP O
in BC2GM079434119 IN O
SmB6 BC2GM079434119 NNP O
single BC2GM079434119 JJ O
crystals BC2GM079434119 NNS O
: BC2GM079434119 : O
Dynamic BC2GM079434119 NNP O
Jahn-Teller BC2GM079434119 NNP O
effect BC2GM079434119 NN O
in BC2GM079434119 IN O
a BC2GM079434119 DT O
mixed-valence BC2GM079434119 NN O
compound BC2GM079434119 NN O
. BC2GM079434119 . O
. . O O

In BC2GM075742629 IN O
accordance BC2GM075742629 NN O
with BC2GM075742629 IN O
Ann BC2GM075742629 NNP O
Arbor BC2GM075742629 NNP O
classification BC2GM075742629 NN O
, BC2GM075742629 , O
we BC2GM075742629 PRP O
observed BC2GM075742629 VBD O
12 BC2GM075742629 CD O
CS BC2GM075742629 NNP O
IA BC2GM075742629 NNP O
( BC2GM075742629 ( O
21.3 BC2GM075742629 CD O
% BC2GM075742629 NN O
) BC2GM075742629 ) O
, BC2GM075742629 , O
2 BC2GM075742629 CD O
CS BC2GM075742629 NNP O
IB BC2GM075742629 NNP O
( BC2GM075742629 ( O
3.5 BC2GM075742629 CD O
% BC2GM075742629 NN O
) BC2GM075742629 ) O
, BC2GM075742629 , O
14 BC2GM075742629 CD O
CS BC2GM075742629 NNP O
IIA BC2GM075742629 NNP O
( BC2GM075742629 ( O
25.4 BC2GM075742629 CD O
% BC2GM075742629 NN O
) BC2GM075742629 ) O
and BC2GM075742629 CC O
27 BC2GM075742629 CD O
CS BC2GM075742629 NNP O
IIB BC2GM075742629 NNP O
( BC2GM075742629 ( O
49.7 BC2GM075742629 CD O
% BC2GM075742629 NN O
) BC2GM075742629 ) O
. BC2GM075742629 . O
. . O O

Using BC2GM041444754 VBG O
the BC2GM041444754 DT O
two-hybrid BC2GM041444754 JJ O
screening BC2GM041444754 NN O
method BC2GM041444754 NN O
, BC2GM041444754 , O
we BC2GM041444754 PRP O
have BC2GM041444754 VBP O
identified BC2GM041444754 VBN O
an BC2GM041444754 DT O
additional BC2GM041444754 JJ O
component BC2GM041444754 NN O
of BC2GM041444754 IN O
the BC2GM041444754 DT O
CCAAT-binding BC2GM041444754 NNP O
factor BC2GM041444754 NN O
. BC2GM041444754 . O
. . O O

The BC2GM034110005 DT O
gene BC2GM034110005 NN O
responsible BC2GM034110005 JJ O
for BC2GM034110005 IN O
multiple BC2GM034110005 JJ O
endocrine BC2GM034110005 NN O
neoplasia BC2GM034110005 NN O
type BC2GM034110005 NN O
1 BC2GM034110005 CD O
( BC2GM034110005 ( O
MEN1 BC2GM034110005 NNP O
) BC2GM034110005 ) O
, BC2GM034110005 , O
a BC2GM034110005 DT O
heritable BC2GM034110005 JJ O
predisposition BC2GM034110005 NN O
to BC2GM034110005 TO O
endocrine BC2GM034110005 VB O
tumours BC2GM034110005 NNS O
in BC2GM034110005 IN O
man BC2GM034110005 NN O
, BC2GM034110005 , O
has BC2GM034110005 VBZ O
recently BC2GM034110005 RB O
been BC2GM034110005 VBN O
identified BC2GM034110005 VBN O
. BC2GM034110005 . O
. . O O

Methodological BC2GM033188821 JJ O
considerations BC2GM033188821 NNS O
limiting BC2GM033188821 VBG O
causal BC2GM033188821 NN O
assertions BC2GM033188821 NNS O
permissible BC2GM033188821 JJ O
with BC2GM033188821 IN O
nonexperimental BC2GM033188821 JJ O
data BC2GM033188821 NNS O
are BC2GM033188821 VBP O
discussed BC2GM033188821 VBN O
. BC2GM033188821 . O
. . O O

Mol BC2GM010461186 NNP O
. BC2GM010461186 . O
. . O O

CONCLUSIONS BC2GM054248395 NN O
: BC2GM054248395 : O
Systemic BC2GM054248395 JJ O
factors BC2GM054248395 NNS O
that BC2GM054248395 IN O
increase BC2GM054248395 NN O
bone BC2GM054248395 NN O
mineral BC2GM054248395 JJ O
density BC2GM054248395 NN O
appear BC2GM054248395 VBP O
to BC2GM054248395 TO O
be BC2GM054248395 VB O
involved BC2GM054248395 VBN O
in BC2GM054248395 IN O
the BC2GM054248395 DT O
pathogenesis BC2GM054248395 NN O
of BC2GM054248395 IN O
ossification BC2GM054248395 NN O
of BC2GM054248395 IN O
the BC2GM054248395 DT O
posterior BC2GM054248395 JJ O
longitudinal BC2GM054248395 JJ O
ligament BC2GM054248395 NN O
, BC2GM054248395 , O
and BC2GM054248395 CC O
these BC2GM054248395 DT O
factors BC2GM054248395 NNS O
may BC2GM054248395 MD O
be BC2GM054248395 VB O
activated BC2GM054248395 VBN O
after BC2GM054248395 IN O
middle BC2GM054248395 JJ O
age BC2GM054248395 NN O
. BC2GM054248395 . O
. . O O

Thus BC2GM051860407 RB O
, BC2GM051860407 , O
in BC2GM051860407 IN O
V. BC2GM051860407 NNP O
furnissii BC2GM051860407 NN O
, BC2GM051860407 , O
the BC2GM051860407 DT O
E. BC2GM051860407 NNP O
coli BC2GM051860407 NNS O
manX BC2GM051860407 VBP O
equivalent BC2GM051860407 JJ O
comprises BC2GM051860407 NNS O
two BC2GM051860407 CD O
genes BC2GM051860407 NNS O
, BC2GM051860407 , O
which BC2GM051860407 WDT O
are BC2GM051860407 VBP O
separated BC2GM051860407 VBN O
in BC2GM051860407 IN O
the BC2GM051860407 DT O
genome BC2GM051860407 NN O
by BC2GM051860407 IN O
two BC2GM051860407 CD O
other BC2GM051860407 JJ O
genes BC2GM051860407 NNS O
of BC2GM051860407 IN O
the BC2GM051860407 DT O
ptsM BC2GM051860407 NN O
complex BC2GM051860407 NN O
. BC2GM051860407 . O
. . O O

A BC2GM096620128 DT O
minimal BC2GM096620128 JJ O
pheromone BC2GM096620128 NN O
induction BC2GM096620128 NN O
domain BC2GM096620128 NN O
, BC2GM096620128 , O
delineated BC2GM096620128 VBN O
as BC2GM096620128 IN O
residues BC2GM096620128 NNS O
301 BC2GM096620128 CD O
to BC2GM096620128 TO O
335 BC2GM096620128 CD O
of BC2GM096620128 IN O
Ste12p BC2GM096620128 NNP O
, BC2GM096620128 , O
is BC2GM096620128 VBZ O
dependent BC2GM096620128 JJ O
on BC2GM096620128 IN O
the BC2GM096620128 DT O
pheromone BC2GM096620128 NN O
mitogen-activated BC2GM096620128 JJ O
protein BC2GM096620128 NN O
( BC2GM096620128 ( O
MAP BC2GM096620128 NNP O
) BC2GM096620128 ) O
kinase BC2GM096620128 VBD O
pathway BC2GM096620128 NN O
for BC2GM096620128 IN O
induction BC2GM096620128 NN O
activity BC2GM096620128 NN O
. BC2GM096620128 . O
. . O O

Rev BC2GM087589281 NNP O
. BC2GM087589281 . O
. . O O

Mibefradil BC2GM013088114 NNP O
( BC2GM013088114 ( O
Ro BC2GM013088114 NNP O
40-5967 BC2GM013088114 CD O
) BC2GM013088114 ) O
is BC2GM013088114 VBZ O
a BC2GM013088114 DT O
novel BC2GM013088114 JJ O
nondihydropyridine BC2GM013088114 JJ O
calcium BC2GM013088114 NN O
antagonist BC2GM013088114 NN O
. BC2GM013088114 . O
. . O O

Regulation BC2GM093724132 NN O
of BC2GM093724132 IN O
the BC2GM093724132 DT O
human BC2GM093724132 JJ O
stress BC2GM093724132 NN O
response BC2GM093724132 NN O
gene BC2GM093724132 NN O
GADD153 BC2GM093724132 NNP O
expression BC2GM093724132 NN O
: BC2GM093724132 : O
role BC2GM093724132 NN O
of BC2GM093724132 IN O
ETS1 BC2GM093724132 NNP O
and BC2GM093724132 CC O
FLI-1 BC2GM093724132 NNP O
gene BC2GM093724132 NN O
products BC2GM093724132 NNS O
. BC2GM093724132 . O
. . O O

The BC2GM004561125 DT O
aromatic BC2GM004561125 JJ O
hydrocarbon BC2GM004561125 NN O
receptor BC2GM004561125 NN O
( BC2GM004561125 ( O
AHR BC2GM004561125 NNP O
) BC2GM004561125 ) O
is BC2GM004561125 VBZ O
a BC2GM004561125 DT O
ligand-activated BC2GM004561125 JJ O
transcription BC2GM004561125 NN O
factor BC2GM004561125 NN O
that BC2GM004561125 WDT O
regulates BC2GM004561125 VBZ O
the BC2GM004561125 DT O
expression BC2GM004561125 NN O
of BC2GM004561125 IN O
several BC2GM004561125 JJ O
drug-metabolizing BC2GM004561125 JJ O
enzymes BC2GM004561125 NNS O
and BC2GM004561125 CC O
has BC2GM004561125 VBZ O
been BC2GM004561125 VBN O
implicated BC2GM004561125 VBN O
in BC2GM004561125 IN O
immunosuppression BC2GM004561125 NN O
, BC2GM004561125 , O
teratogenesis BC2GM004561125 NN O
, BC2GM004561125 , O
cell-specific BC2GM004561125 JJ O
hyperplasia BC2GM004561125 NN O
, BC2GM004561125 , O
and BC2GM004561125 CC O
certain BC2GM004561125 JJ O
types BC2GM004561125 NNS O
of BC2GM004561125 IN O
malignancies BC2GM004561125 NNS O
and BC2GM004561125 CC O
toxicities BC2GM004561125 NNS O
. BC2GM004561125 . O
. . O O

Fetal BC2GM070100199 JJ O
arterial BC2GM070100199 JJ O
and BC2GM070100199 CC O
sagittal BC2GM070100199 JJ O
sinus BC2GM070100199 NN O
pH BC2GM070100199 NN O
, BC2GM070100199 , O
base BC2GM070100199 NN O
excess BC2GM070100199 NN O
, BC2GM070100199 , O
po2 BC2GM070100199 NN O
, BC2GM070100199 , O
and BC2GM070100199 CC O
oxygen BC2GM070100199 NN O
saturation BC2GM070100199 NN O
decreased BC2GM070100199 VBN O
, BC2GM070100199 , O
and BC2GM070100199 CC O
hydrogen BC2GM070100199 NN O
ion BC2GM070100199 NN O
concentrations BC2GM070100199 NNS O
and BC2GM070100199 CC O
pco2 BC2GM070100199 NN O
increased BC2GM070100199 VBD O
during BC2GM070100199 IN O
asphyxia BC2GM070100199 JJ O
alone BC2GM070100199 RB O
and BC2GM070100199 CC O
asphyxia BC2GM070100199 JJ O
plus BC2GM070100199 CC O
isoflurane-oxygen BC2GM070100199 JJ O
. BC2GM070100199 . O
. . O O

We BC2GM068470337 PRP O
sought BC2GM068470337 VBD O
to BC2GM068470337 TO O
test BC2GM068470337 VB O
whether BC2GM068470337 IN O
a BC2GM068470337 DT O
prolonged BC2GM068470337 JJ O
infusion BC2GM068470337 NN O
of BC2GM068470337 IN O
magnesium BC2GM068470337 NN O
sulfate BC2GM068470337 NN O
( BC2GM068470337 ( O
MgSO BC2GM068470337 NNP O
( BC2GM068470337 ( O
4 BC2GM068470337 CD O
) BC2GM068470337 ) O
; BC2GM068470337 : O
40 BC2GM068470337 CD O
mmol BC2GM068470337 NN O
/ BC2GM068470337 VBD O
24 BC2GM068470337 CD O
hours BC2GM068470337 NNS O
) BC2GM068470337 ) O
would BC2GM068470337 MD O
normalize BC2GM068470337 VB O
QT BC2GM068470337 NNP O
interval BC2GM068470337 JJ O
variability BC2GM068470337 NN O
in BC2GM068470337 IN O
patients BC2GM068470337 NNS O
with BC2GM068470337 IN O
compensated BC2GM068470337 JJ O
heart BC2GM068470337 NN O
failure BC2GM068470337 NN O
. BC2GM068470337 . O
. . O O

A BC2GM066127781 DT O
relationship BC2GM066127781 NN O
between BC2GM066127781 IN O
the BC2GM066127781 DT O
immunological BC2GM066127781 JJ O
changes BC2GM066127781 NNS O
and BC2GM066127781 CC O
the BC2GM066127781 DT O
disease BC2GM066127781 NN O
stage BC2GM066127781 NN O
was BC2GM066127781 VBD O
discovered BC2GM066127781 VBN O
: BC2GM066127781 : O
the BC2GM066127781 DT O
index BC2GM066127781 NN O
of BC2GM066127781 IN O
the BC2GM066127781 DT O
3H-thymidine BC2GM066127781 JJ O
incorporation BC2GM066127781 NN O
was BC2GM066127781 VBD O
found BC2GM066127781 VBN O
to BC2GM066127781 TO O
be BC2GM066127781 VB O
67.9 BC2GM066127781 CD O
at BC2GM066127781 IN O
the BC2GM066127781 DT O
stage BC2GM066127781 NN O
of BC2GM066127781 IN O
disease BC2GM066127781 NN O
exacerbation BC2GM066127781 NN O
, BC2GM066127781 , O
and BC2GM066127781 CC O
208.8 BC2GM066127781 CD O
at BC2GM066127781 IN O
the BC2GM066127781 DT O
stage BC2GM066127781 NN O
of BC2GM066127781 IN O
remission BC2GM066127781 NN O
; BC2GM066127781 : O
the BC2GM066127781 DT O
complement BC2GM066127781 NN O
titre BC2GM066127781 NN O
reached BC2GM066127781 VBD O
, BC2GM066127781 , O
respectively BC2GM066127781 RB O
, BC2GM066127781 , O
46.64 BC2GM066127781 CD O
+ BC2GM066127781 NN O
/ BC2GM066127781 NNP O
- BC2GM066127781 : O
5.28 BC2GM066127781 CD O
and BC2GM066127781 CC O
112.0 BC2GM066127781 CD O
+ BC2GM066127781 NN O
/ BC2GM066127781 NNP O
- BC2GM066127781 : O
6.0 BC2GM066127781 CD O
units BC2GM066127781 NNS O
per BC2GM066127781 IN O
ml BC2GM066127781 NN O
. BC2GM066127781 . O
. . O O

Our BC2GM062846639 PRP$ O
aim BC2GM062846639 NN O
was BC2GM062846639 VBD O
to BC2GM062846639 TO O
check BC2GM062846639 VB O
whether BC2GM062846639 IN O
, BC2GM062846639 , O
during BC2GM062846639 IN O
PG-DS BC2GM062846639 NNP O
administration BC2GM062846639 NN O
, BC2GM062846639 , O
serum BC2GM062846639 JJ O
lipase BC2GM062846639 NN O
activity BC2GM062846639 NN O
changes BC2GM062846639 VBZ O
simultaneously BC2GM062846639 RB O
with BC2GM062846639 IN O
serum BC2GM062846639 JJ O
amylase BC2GM062846639 NN O
activity BC2GM062846639 NN O
, BC2GM062846639 , O
and BC2GM062846639 CC O
, BC2GM062846639 , O
if BC2GM062846639 IN O
so BC2GM062846639 RB O
, BC2GM062846639 , O
what BC2GM062846639 WP O
the BC2GM062846639 DT O
reason BC2GM062846639 NN O
is BC2GM062846639 VBZ O
for BC2GM062846639 IN O
the BC2GM062846639 DT O
detected BC2GM062846639 JJ O
change BC2GM062846639 NN O
. BC2GM062846639 . O
. . O O

In BC2GM094275796 IN O
contrast BC2GM094275796 NN O
, BC2GM094275796 , O
the BC2GM094275796 DT O
sequences BC2GM094275796 NNS O
essential BC2GM094275796 JJ O
for BC2GM094275796 IN O
the BC2GM094275796 DT O
transcription BC2GM094275796 NN O
of BC2GM094275796 IN O
EFT1 BC2GM094275796 NNP O
were BC2GM094275796 VBD O
localized BC2GM094275796 VBN O
to BC2GM094275796 TO O
the BC2GM094275796 DT O
region BC2GM094275796 NN O
between BC2GM094275796 IN O
the BC2GM094275796 DT O
start BC2GM094275796 NN O
ATG BC2GM094275796 NNP O
and BC2GM094275796 CC O
the BC2GM094275796 DT O
stop BC2GM094275796 JJ O
codon BC2GM094275796 NN O
of BC2GM094275796 IN O
the BC2GM094275796 DT O
VPS17 BC2GM094275796 NNP O
gene BC2GM094275796 NN O
that BC2GM094275796 WDT O
terminates BC2GM094275796 VBZ O
267 BC2GM094275796 CD O
nt BC2GM094275796 JJ O
upstream BC2GM094275796 NN O
on BC2GM094275796 IN O
the BC2GM094275796 DT O
same BC2GM094275796 JJ O
strand BC2GM094275796 NN O
. BC2GM094275796 . O
. . O O

Antibodies BC2GM069540508 NNS O
against BC2GM069540508 IN O
REAP-1 BC2GM069540508 NNP O
inhibit BC2GM069540508 NN O
in BC2GM069540508 IN O
vitro BC2GM069540508 JJ O
RNA BC2GM069540508 NNP O
editing BC2GM069540508 VBG O
reactions BC2GM069540508 NNS O
confirming BC2GM069540508 VBG O
its BC2GM069540508 PRP$ O
role BC2GM069540508 NN O
in BC2GM069540508 IN O
RNA BC2GM069540508 NNP O
editing BC2GM069540508 NN O
. BC2GM069540508 . O
. . O O

Six BC2GM071251330 CD O
patients BC2GM071251330 NNS O
underwent BC2GM071251330 JJ O
an BC2GM071251330 DT O
electrophysiologic BC2GM071251330 JJ O
study BC2GM071251330 NN O
. BC2GM071251330 . O
. . O O

In BC2GM013299082 IN O
fifty BC2GM013299082 JJ O
non BC2GM013299082 NN O
selected BC2GM013299082 VBN O
ductal BC2GM013299082 JJ O
carcinomas BC2GM013299082 NN O
of BC2GM013299082 IN O
the BC2GM013299082 DT O
breast BC2GM013299082 NN O
we BC2GM013299082 PRP O
found BC2GM013299082 VBD O
that BC2GM013299082 IN O
a BC2GM013299082 DT O
marked BC2GM013299082 JJ O
tumoral BC2GM013299082 JJ O
inflammatory BC2GM013299082 NN O
infiltrate BC2GM013299082 NN O
( BC2GM013299082 ( O
P BC2GM013299082 NNP O
less BC2GM013299082 JJR O
than BC2GM013299082 IN O
0.025 BC2GM013299082 CD O
) BC2GM013299082 ) O
, BC2GM013299082 , O
perinodal BC2GM013299082 JJ O
tumoral BC2GM013299082 JJ O
infiltrate BC2GM013299082 NN O
( BC2GM013299082 ( O
P BC2GM013299082 NNP O
less BC2GM013299082 JJR O
than BC2GM013299082 IN O
0.01 BC2GM013299082 CD O
) BC2GM013299082 ) O
, BC2GM013299082 , O
sinus BC2GM013299082 JJ O
catarrh BC2GM013299082 NN O
( BC2GM013299082 ( O
P BC2GM013299082 NNP O
less BC2GM013299082 JJR O
than BC2GM013299082 IN O
0.05 BC2GM013299082 CD O
) BC2GM013299082 ) O
, BC2GM013299082 , O
follicular BC2GM013299082 JJ O
hyperplasia BC2GM013299082 NN O
( BC2GM013299082 ( O
P BC2GM013299082 NNP O
less BC2GM013299082 JJR O
than BC2GM013299082 IN O
0.025 BC2GM013299082 CD O
) BC2GM013299082 ) O
, BC2GM013299082 , O
mixed BC2GM013299082 JJ O
pattern BC2GM013299082 NN O
in BC2GM013299082 IN O
lymph BC2GM013299082 NN O
nodes BC2GM013299082 NNS O
( BC2GM013299082 ( O
P BC2GM013299082 NNP O
less BC2GM013299082 JJR O
than BC2GM013299082 IN O
0.01 BC2GM013299082 CD O
) BC2GM013299082 ) O
and BC2GM013299082 CC O
with BC2GM013299082 IN O
54 BC2GM013299082 CD O
years BC2GM013299082 NNS O
of BC2GM013299082 IN O
age BC2GM013299082 NN O
or BC2GM013299082 CC O
younger BC2GM013299082 JJR O
( BC2GM013299082 ( O
P BC2GM013299082 NNP O
less BC2GM013299082 JJR O
than BC2GM013299082 IN O
0.01 BC2GM013299082 CD O
) BC2GM013299082 ) O
correlated BC2GM013299082 VBN O
significantly BC2GM013299082 RB O
with BC2GM013299082 IN O
lymph BC2GM013299082 JJ O
node BC2GM013299082 NN O
metastases BC2GM013299082 NNS O
and BC2GM013299082 CC O
/ BC2GM013299082 NNP O
or BC2GM013299082 CC O
high BC2GM013299082 JJ O
histologic BC2GM013299082 NN O
grade BC2GM013299082 NN O
. BC2GM013299082 . O
. . O O

Our BC2GM048607810 PRP$ O
results BC2GM048607810 NNS O
suggest BC2GM048607810 VBP O
that BC2GM048607810 IN O
Bry1 BC2GM048607810 NNP O
/ BC2GM048607810 NNP O
Skn7 BC2GM048607810 NNP O
can BC2GM048607810 MD O
influence BC2GM048607810 VB O
the BC2GM048607810 DT O
expression BC2GM048607810 NN O
of BC2GM048607810 IN O
MCB- BC2GM048607810 NNP O
and BC2GM048607810 CC O
SCB-driven BC2GM048607810 NNP O
gene BC2GM048607810 NN O
expression BC2GM048607810 NN O
in BC2GM048607810 IN O
budding BC2GM048607810 VBG O
yeast BC2GM048607810 NN O
, BC2GM048607810 , O
perhaps BC2GM048607810 RB O
including BC2GM048607810 VBG O
genes BC2GM048607810 NNS O
involved BC2GM048607810 VBN O
in BC2GM048607810 IN O
cell BC2GM048607810 NN O
wall BC2GM048607810 NN O
metabolism BC2GM048607810 NN O
, BC2GM048607810 , O
via BC2GM048607810 IN O
a BC2GM048607810 DT O
two-component BC2GM048607810 JJ O
signal BC2GM048607810 JJ O
transduction BC2GM048607810 NN O
pathway BC2GM048607810 NN O
which BC2GM048607810 WDT O
activates BC2GM048607810 VBZ O
Bry1 BC2GM048607810 NNP O
/ BC2GM048607810 NNP O
Skn7 BC2GM048607810 NNP O
in BC2GM048607810 IN O
response BC2GM048607810 NN O
to BC2GM048607810 TO O
an BC2GM048607810 DT O
unidentified BC2GM048607810 JJ O
signal BC2GM048607810 NN O
. BC2GM048607810 . O
. . O O

Effects BC2GM015964287 NNS O
of BC2GM015964287 IN O
shosaikoto BC2GM015964287 NN O
, BC2GM015964287 , O
an BC2GM015964287 DT O
oriental BC2GM015964287 JJ O
herbal BC2GM015964287 JJ O
medicinal BC2GM015964287 JJ O
mixture BC2GM015964287 NN O
, BC2GM015964287 , O
on BC2GM015964287 IN O
restraint-stressed BC2GM015964287 JJ O
mice BC2GM015964287 NN O
. BC2GM015964287 . O
. . O O

V-ErbB-mediated BC2GM036041110 JJ O
complex BC2GM036041110 JJ O
formation BC2GM036041110 NN O
and BC2GM036041110 CC O
transformation BC2GM036041110 NN O
have BC2GM036041110 VBP O
been BC2GM036041110 VBN O
shown BC2GM036041110 VBN O
to BC2GM036041110 TO O
occur BC2GM036041110 VB O
independently BC2GM036041110 RB O
of BC2GM036041110 IN O
Ras BC2GM036041110 NNP O
activation BC2GM036041110 NN O
. BC2GM036041110 . O
. . O O

On BC2GM013283171 IN O
a BC2GM013283171 DT O
variety BC2GM013283171 NN O
of BC2GM013283171 IN O
fronts BC2GM013283171 NNS O
, BC2GM013283171 , O
chronic BC2GM013283171 JJ O
bacterial BC2GM013283171 JJ O
infection BC2GM013283171 NN O
is BC2GM013283171 VBZ O
being BC2GM013283171 VBG O
found BC2GM013283171 VBN O
to BC2GM013283171 TO O
be BC2GM013283171 VB O
significantly BC2GM013283171 RB O
associated BC2GM013283171 VBN O
with BC2GM013283171 IN O
the BC2GM013283171 DT O
development BC2GM013283171 NN O
of BC2GM013283171 IN O
atherosclerosis BC2GM013283171 NN O
and BC2GM013283171 CC O
the BC2GM013283171 DT O
clinical BC2GM013283171 JJ O
complications BC2GM013283171 NNS O
of BC2GM013283171 IN O
unstable BC2GM013283171 JJ O
angina BC2GM013283171 NN O
, BC2GM013283171 , O
myocardial BC2GM013283171 JJ O
infarction BC2GM013283171 NN O
, BC2GM013283171 , O
and BC2GM013283171 CC O
stroke BC2GM013283171 NN O
. BC2GM013283171 . O
. . O O

One BC2GM025934950 CD O
of BC2GM025934950 IN O
the BC2GM025934950 DT O
ORFs BC2GM025934950 NNP O
in BC2GM025934950 IN O
the BC2GM025934950 DT O
Methanococcus BC2GM025934950 NNP O
jannaschii BC2GM025934950 NN O
genome BC2GM025934950 NN O
possesses BC2GM025934950 NNS O
high BC2GM025934950 JJ O
similarity BC2GM025934950 NN O
to BC2GM025934950 TO O
the BC2GM025934950 DT O
M. BC2GM025934950 NNP O
aeolicus BC2GM025934950 NN O
ilvB BC2GM025934950 NN O
, BC2GM025934950 , O
indicating BC2GM025934950 VBG O
that BC2GM025934950 IN O
it BC2GM025934950 PRP O
is BC2GM025934950 VBZ O
an BC2GM025934950 DT O
authentic BC2GM025934950 JJ O
AHAS BC2GM025934950 NNP O
. BC2GM025934950 . O
. . O O

Electrophoretic BC2GM048761602 JJ O
mobility BC2GM048761602 NN O
shift BC2GM048761602 NN O
analysis BC2GM048761602 NN O
of BC2GM048761602 IN O
protein-DNA BC2GM048761602 NN O
complexes BC2GM048761602 NNS O
formed BC2GM048761602 VBN O
with BC2GM048761602 IN O
nuclear BC2GM048761602 JJ O
proteins BC2GM048761602 NNS O
isolated BC2GM048761602 VBN O
from BC2GM048761602 IN O
I3C-treated BC2GM048761602 JJ O
and BC2GM048761602 CC O
-untreated BC2GM048761602 JJ O
cells BC2GM048761602 NNS O
, BC2GM048761602 , O
in BC2GM048761602 IN O
combination BC2GM048761602 NN O
with BC2GM048761602 IN O
supershift BC2GM048761602 NN O
assays BC2GM048761602 NNS O
using BC2GM048761602 VBG O
Sp1 BC2GM048761602 NNP O
antibodies BC2GM048761602 NNS O
, BC2GM048761602 , O
demonstrated BC2GM048761602 VBD O
that BC2GM048761602 IN O
the BC2GM048761602 DT O
Sp1-binding BC2GM048761602 NNP O
site BC2GM048761602 NN O
in BC2GM048761602 IN O
the BC2GM048761602 DT O
CDK6 BC2GM048761602 NNP O
promoter BC2GM048761602 NN O
forms BC2GM048761602 VBZ O
a BC2GM048761602 DT O
specific BC2GM048761602 JJ O
I3C-responsive BC2GM048761602 JJ O
DNA-protein BC2GM048761602 NNP O
complex BC2GM048761602 NN O
that BC2GM048761602 WDT O
contains BC2GM048761602 VBZ O
the BC2GM048761602 DT O
Sp1 BC2GM048761602 NNP O
transcription BC2GM048761602 NN O
factor BC2GM048761602 NN O
. BC2GM048761602 . O
. . O O

Furthermore BC2GM055154765 RB O
, BC2GM055154765 , O
agonist BC2GM055154765 JJ O
action BC2GM055154765 NN O
at BC2GM055154765 IN O
a BC2GM055154765 DT O
5-HT1 BC2GM055154765 JJ O
receptor BC2GM055154765 NN O
and BC2GM055154765 CC O
antagonist BC2GM055154765 JJ O
action BC2GM055154765 NN O
at BC2GM055154765 IN O
5-HT2 BC2GM055154765 JJ O
receptors BC2GM055154765 NNS O
both BC2GM055154765 DT O
appear BC2GM055154765 VBP O
to BC2GM055154765 TO O
contribute BC2GM055154765 VB O
to BC2GM055154765 TO O
antidepressant-like BC2GM055154765 JJ O
activity BC2GM055154765 NN O
on BC2GM055154765 IN O
the BC2GM055154765 DT O
DRL BC2GM055154765 NNP O
72-s BC2GM055154765 JJ O
schedule BC2GM055154765 NN O
. BC2GM055154765 . O
. . O O

We BC2GM050909815 PRP O
report BC2GM050909815 VBP O
the BC2GM050909815 DT O
sequence BC2GM050909815 NN O
of BC2GM050909815 IN O
a BC2GM050909815 DT O
7941 BC2GM050909815 CD O
bp BC2GM050909815 NN O
DNA BC2GM050909815 NNP O
fragment BC2GM050909815 NN O
from BC2GM050909815 IN O
the BC2GM050909815 DT O
left BC2GM050909815 JJ O
arm BC2GM050909815 NN O
of BC2GM050909815 IN O
chromosome BC2GM050909815 NN O
VII BC2GM050909815 NNP O
of BC2GM050909815 IN O
Saccharomyces BC2GM050909815 NNP O
cerevisiae BC2GM050909815 NN O
which BC2GM050909815 WDT O
contains BC2GM050909815 VBZ O
four BC2GM050909815 CD O
open BC2GM050909815 JJ O
reading BC2GM050909815 VBG O
frames BC2GM050909815 NNS O
( BC2GM050909815 ( O
ORFs BC2GM050909815 NNP O
) BC2GM050909815 ) O
of BC2GM050909815 IN O
greater BC2GM050909815 JJR O
than BC2GM050909815 IN O
100 BC2GM050909815 CD O
amino BC2GM050909815 JJ O
acid BC2GM050909815 NN O
residues BC2GM050909815 NNS O
. BC2GM050909815 . O
. . O O

The BC2GM084522196 DT O
cDNA BC2GM084522196 NN O
clones BC2GM084522196 NNS O
encode BC2GM084522196 VBD O
a BC2GM084522196 DT O
polypeptide BC2GM084522196 NN O
of BC2GM084522196 IN O
657 BC2GM084522196 CD O
amino BC2GM084522196 JJ O
acids BC2GM084522196 NNS O
with BC2GM084522196 IN O
a BC2GM084522196 DT O
bHLH BC2GM084522196 NN O
( BC2GM084522196 ( O
basic-helix-loop-helix BC2GM084522196 NN O
) BC2GM084522196 ) O
domain BC2GM084522196 NN O
, BC2GM084522196 , O
characteristic BC2GM084522196 NN O
of BC2GM084522196 IN O
a BC2GM084522196 DT O
large BC2GM084522196 JJ O
family BC2GM084522196 NN O
of BC2GM084522196 IN O
transcription BC2GM084522196 NN O
factors BC2GM084522196 NNS O
, BC2GM084522196 , O
and BC2GM084522196 CC O
a BC2GM084522196 DT O
PAS BC2GM084522196 NNP O
( BC2GM084522196 ( O
Per-Arnt-Sim BC2GM084522196 NNP O
) BC2GM084522196 ) O
domain BC2GM084522196 NN O
in BC2GM084522196 IN O
the BC2GM084522196 DT O
amino-terminal BC2GM084522196 JJ O
half BC2GM084522196 NN O
region BC2GM084522196 NN O
. BC2GM084522196 . O
. . O O

However BC2GM093787356 RB O
, BC2GM093787356 , O
it BC2GM093787356 PRP O
is BC2GM093787356 VBZ O
now BC2GM093787356 RB O
suggested BC2GM093787356 VBN O
that BC2GM093787356 IN O
the BC2GM093787356 DT O
use BC2GM093787356 NN O
of BC2GM093787356 IN O
more BC2GM093787356 RBR O
slowly BC2GM093787356 RB O
digested BC2GM093787356 VBN O
starchy BC2GM093787356 JJ O
foods BC2GM093787356 NNS O
may BC2GM093787356 MD O
have BC2GM093787356 VB O
positive BC2GM093787356 JJ O
health BC2GM093787356 NN O
benefits BC2GM093787356 NNS O
. BC2GM093787356 . O
. . O O

In BC2GM045876412 IN O
contrast BC2GM045876412 NN O
, BC2GM045876412 , O
dominant BC2GM045876412 JJ O
negative BC2GM045876412 JJ O
Rac BC2GM045876412 NNP O
( BC2GM045876412 ( O
N17Rac1 BC2GM045876412 NNP O
) BC2GM045876412 ) O
inhibited BC2GM045876412 VBD O
JNK BC2GM045876412 NNP O
activation BC2GM045876412 NN O
by BC2GM045876412 IN O
Galpha12 BC2GM045876412 NNP O
in BC2GM045876412 IN O
HEK293 BC2GM045876412 NNP O
cells BC2GM045876412 NNS O
as BC2GM045876412 RB O
well BC2GM045876412 RB O
as BC2GM045876412 IN O
three BC2GM045876412 CD O
other BC2GM045876412 JJ O
cell BC2GM045876412 NN O
lines BC2GM045876412 NNS O
. BC2GM045876412 . O
. . O O

As BC2GM075043873 IN O
exogenously BC2GM075043873 RB O
expressed BC2GM075043873 VBN O
PKR BC2GM075043873 NNP O
can BC2GM075043873 MD O
form BC2GM075043873 VB O
heterodimers BC2GM075043873 NNS O
with BC2GM075043873 IN O
endogenous BC2GM075043873 JJ O
PKR BC2GM075043873 NNP O
, BC2GM075043873 , O
the BC2GM075043873 DT O
results BC2GM075043873 NNS O
obtained BC2GM075043873 VBD O
on BC2GM075043873 IN O
the BC2GM075043873 DT O
functional BC2GM075043873 JJ O
characterization BC2GM075043873 NN O
of BC2GM075043873 IN O
mutant BC2GM075043873 JJ O
forms BC2GM075043873 NNS O
of BC2GM075043873 IN O
PKR BC2GM075043873 NNP O
have BC2GM075043873 VBP O
been BC2GM075043873 VBN O
taken BC2GM075043873 VBN O
with BC2GM075043873 IN O
caution BC2GM075043873 NN O
. BC2GM075043873 . O
. . O O

The BC2GM040034463 DT O
IB2 BC2GM040034463 NNP O
gene BC2GM040034463 NN O
( BC2GM040034463 ( O
HGMW-approved BC2GM040034463 JJ O
symbol BC2GM040034463 NN O
MAPK8IP2 BC2GM040034463 NNP O
) BC2GM040034463 ) O
maps BC2GM040034463 VBZ O
to BC2GM040034463 TO O
human BC2GM040034463 JJ O
chromosome BC2GM040034463 NN O
22q13 BC2GM040034463 CD O
and BC2GM040034463 CC O
contains BC2GM040034463 VBZ O
10 BC2GM040034463 CD O
coding BC2GM040034463 NN O
exons BC2GM040034463 NNS O
. BC2GM040034463 . O
. . O O

Specifically BC2GM024346106 RB O
, BC2GM024346106 , O
we BC2GM024346106 PRP O
engineered BC2GM024346106 VBD O
two BC2GM024346106 CD O
chimeras BC2GM024346106 NNS O
in BC2GM024346106 IN O
which BC2GM024346106 WDT O
the BC2GM024346106 DT O
N-terminal BC2GM024346106 NNP O
lobe BC2GM024346106 NN O
of BC2GM024346106 IN O
the BC2GM024346106 DT O
SH1 BC2GM024346106 NNP O
domain BC2GM024346106 NN O
of BC2GM024346106 IN O
c-Abl BC2GM024346106 NN O
was BC2GM024346106 VBD O
swapped BC2GM024346106 VBN O
with BC2GM024346106 IN O
that BC2GM024346106 DT O
of BC2GM024346106 IN O
v-Src BC2GM024346106 NN O
. BC2GM024346106 . O
. . O O

The BC2GM026304956 DT O
perforated BC2GM026304956 JJ O
splint BC2GM026304956 NN O
gives BC2GM026304956 VBZ O
superior BC2GM026304956 JJ O
results BC2GM026304956 NNS O
by BC2GM026304956 IN O
virtue BC2GM026304956 NN O
of BC2GM026304956 IN O
the BC2GM026304956 DT O
fact BC2GM026304956 NN O
that BC2GM026304956 IN O
it BC2GM026304956 PRP O
does BC2GM026304956 VBZ O
not BC2GM026304956 RB O
require BC2GM026304956 VB O
to BC2GM026304956 TO O
be BC2GM026304956 VB O
removed BC2GM026304956 VBN O
for BC2GM026304956 IN O
purposes BC2GM026304956 NNS O
of BC2GM026304956 IN O
hygiene BC2GM026304956 NN O
and BC2GM026304956 CC O
can BC2GM026304956 MD O
thus BC2GM026304956 RB O
produce BC2GM026304956 VB O
a BC2GM026304956 DT O
satisfactory BC2GM026304956 JJ O
result BC2GM026304956 NN O
even BC2GM026304956 RB O
in BC2GM026304956 IN O
those BC2GM026304956 DT O
patients BC2GM026304956 NNS O
who BC2GM026304956 WP O
fail BC2GM026304956 VBP O
to BC2GM026304956 TO O
grasp BC2GM026304956 VB O
the BC2GM026304956 DT O
technique BC2GM026304956 NN O
of BC2GM026304956 IN O
removal BC2GM026304956 NN O
and BC2GM026304956 CC O
replacement BC2GM026304956 NN O
of BC2GM026304956 IN O
the BC2GM026304956 DT O
splint BC2GM026304956 NN O
. BC2GM026304956 . O
. . O O

Structure BC2GM085794657 NN O
and BC2GM085794657 CC O
regulation BC2GM085794657 NN O
of BC2GM085794657 IN O
KGD2 BC2GM085794657 NNP O
, BC2GM085794657 , O
the BC2GM085794657 DT O
structural BC2GM085794657 JJ O
gene BC2GM085794657 NN O
for BC2GM085794657 IN O
yeast BC2GM085794657 JJ O
dihydrolipoyl BC2GM085794657 JJ O
transsuccinylase BC2GM085794657 NN O
. BC2GM085794657 . O
. . O O

Translation BC2GM025017192 NN O
of BC2GM025017192 IN O
mok BC2GM025017192 NN O
is BC2GM025017192 VBZ O
tightly BC2GM025017192 RB O
regulated BC2GM025017192 VBN O
by BC2GM025017192 IN O
Sok BC2GM025017192 NNP O
RNA BC2GM025017192 NNP O
, BC2GM025017192 , O
and BC2GM025017192 CC O
Sok BC2GM025017192 NNP O
RNA BC2GM025017192 NNP O
thus BC2GM025017192 RB O
regulates BC2GM025017192 VBZ O
hok BC2GM025017192 JJ O
translation BC2GM025017192 NN O
indirectly BC2GM025017192 RB O
through BC2GM025017192 IN O
mok BC2GM025017192 NN O
. BC2GM025017192 . O
. . O O

We BC2GM076134275 PRP O
report BC2GM076134275 VBP O
here BC2GM076134275 RB O
that BC2GM076134275 IN O
AChE BC2GM076134275 NNP O
activity BC2GM076134275 NN O
tends BC2GM076134275 VBZ O
to BC2GM076134275 TO O
decrease BC2GM076134275 VB O
in BC2GM076134275 IN O
individuals BC2GM076134275 NNS O
sampled BC2GM076134275 VBN O
in BC2GM076134275 IN O
tanks BC2GM076134275 NNS O
at BC2GM076134275 IN O
a BC2GM076134275 DT O
salinity BC2GM076134275 NN O
of BC2GM076134275 IN O
30 BC2GM076134275 CD O
per BC2GM076134275 JJ O
thousand BC2GM076134275 NN O
as BC2GM076134275 IN O
temperature BC2GM076134275 NN O
increases BC2GM076134275 NNS O
. BC2GM076134275 . O
. . O O

Cutaneous BC2GM026873451 JJ O
melanoma BC2GM026873451 NN O
and BC2GM026873451 CC O
bilateral BC2GM026873451 JJ O
retinoblastoma BC2GM026873451 NN O
. BC2GM026873451 . O
. . O O

Also BC2GM056359594 RB O
, BC2GM056359594 , O
residues BC2GM056359594 VBZ O
273 BC2GM056359594 CD O
to BC2GM056359594 TO O
287 BC2GM056359594 CD O
, BC2GM056359594 , O
which BC2GM056359594 WDT O
are BC2GM056359594 VBP O
identical BC2GM056359594 JJ O
in BC2GM056359594 IN O
sequence BC2GM056359594 NN O
to BC2GM056359594 TO O
a BC2GM056359594 DT O
15-amino-acid BC2GM056359594 JJ O
segment BC2GM056359594 NN O
near BC2GM056359594 IN O
the BC2GM056359594 DT O
carboxy BC2GM056359594 JJ O
terminus BC2GM056359594 NN O
of BC2GM056359594 IN O
the BC2GM056359594 DT O
simian BC2GM056359594 JJ O
foamy BC2GM056359594 NN O
virus BC2GM056359594 NN O
transcriptional BC2GM056359594 JJ O
activator BC2GM056359594 NN O
Taf BC2GM056359594 NNP O
, BC2GM056359594 , O
can BC2GM056359594 MD O
independently BC2GM056359594 RB O
enhance BC2GM056359594 VB O
the BC2GM056359594 DT O
activity BC2GM056359594 NN O
of BC2GM056359594 IN O
the BC2GM056359594 DT O
minimal BC2GM056359594 JJ O
activator BC2GM056359594 NN O
region BC2GM056359594 NN O
. BC2GM056359594 . O
. . O O

We BC2GM053940831 PRP O
have BC2GM053940831 VBP O
cloned BC2GM053940831 VBN O
the BC2GM053940831 DT O
cDNA BC2GM053940831 NN O
for BC2GM053940831 IN O
the BC2GM053940831 DT O
SLBP BC2GM053940831 NNP O
from BC2GM053940831 IN O
humans BC2GM053940831 NNS O
, BC2GM053940831 , O
mice BC2GM053940831 NN O
, BC2GM053940831 , O
and BC2GM053940831 CC O
frogs BC2GM053940831 NNS O
, BC2GM053940831 , O
using BC2GM053940831 VBG O
the BC2GM053940831 DT O
recently BC2GM053940831 RB O
developed BC2GM053940831 VBN O
yeast BC2GM053940831 RB O
three-hybrid BC2GM053940831 JJ O
system BC2GM053940831 NN O
. BC2GM053940831 . O
. . O O

Promoter BC2GM086432214 NNP O
region BC2GM086432214 NN O
of BC2GM086432214 IN O
the BC2GM086432214 DT O
human BC2GM086432214 JJ O
alpha BC2GM086432214 NN O
2A BC2GM086432214 CD O
adrenergic BC2GM086432214 JJ O
receptor BC2GM086432214 NN O
gene BC2GM086432214 NN O
. BC2GM086432214 . O
. . O O

On BC2GM011797834 IN O
a BC2GM011797834 DT O
national BC2GM011797834 JJ O
level BC2GM011797834 NN O
, BC2GM011797834 , O
undiscounted BC2GM011797834 JJ O
costs BC2GM011797834 NNS O
are BC2GM011797834 VBP O
expected BC2GM011797834 VBN O
to BC2GM011797834 TO O
increase BC2GM011797834 VB O
up BC2GM011797834 RP O
to BC2GM011797834 TO O
approximately BC2GM011797834 RB O
DF1 BC2GM011797834 VB O
42 BC2GM011797834 CD O
million BC2GM011797834 CD O
annually BC2GM011797834 RB O
during BC2GM011797834 IN O
the BC2GM011797834 DT O
first BC2GM011797834 JJ O
40 BC2GM011797834 CD O
years BC2GM011797834 NNS O
after BC2GM011797834 IN O
introduction BC2GM011797834 NN O
of BC2GM011797834 IN O
the BC2GM011797834 DT O
preventative BC2GM011797834 JJ O
strategy BC2GM011797834 NN O
. BC2GM011797834 . O
. . O O

Manifestation BC2GM003241979 NN O
of BC2GM003241979 IN O
superfluidity BC2GM003241979 NN O
in BC2GM003241979 IN O
an BC2GM003241979 DT O
evolving BC2GM003241979 VBG O
bose-einstein BC2GM003241979 NN O
condensed BC2GM003241979 VBD O
Gas BC2GM003241979 NNP O
We BC2GM003241979 PRP O
study BC2GM003241979 VBP O
the BC2GM003241979 DT O
generation BC2GM003241979 NN O
of BC2GM003241979 IN O
excitations BC2GM003241979 NNS O
due BC2GM003241979 JJ O
to BC2GM003241979 TO O
an BC2GM003241979 DT O
`` BC2GM003241979 `` O
impurity BC2GM003241979 NN O
'' BC2GM003241979 '' O
( BC2GM003241979 ( O
static BC2GM003241979 JJ O
perturbation BC2GM003241979 NN O
) BC2GM003241979 ) O
placed BC2GM003241979 VBD O
into BC2GM003241979 IN O
an BC2GM003241979 DT O
oscillating BC2GM003241979 VBG O
Bose-Einstein BC2GM003241979 NNP O
condensed BC2GM003241979 VBD O
gas BC2GM003241979 NN O
in BC2GM003241979 IN O
the BC2GM003241979 DT O
time-dependent BC2GM003241979 JJ O
trapping BC2GM003241979 NN O
field BC2GM003241979 NN O
. BC2GM003241979 . O
. . O O

The BC2GM032379937 DT O
results BC2GM032379937 NNS O
obtained BC2GM032379937 VBD O
demonstrate BC2GM032379937 RP O
the BC2GM032379937 DT O
applicability BC2GM032379937 NN O
of BC2GM032379937 IN O
countercurrent BC2GM032379937 NN O
chromatography BC2GM032379937 NN O
to BC2GM032379937 TO O
the BC2GM032379937 DT O
determination BC2GM032379937 NN O
of BC2GM032379937 IN O
ultratrace BC2GM032379937 JJ O
elements BC2GM032379937 NNS O
. BC2GM032379937 . O
. . O O

These BC2GM055437471 DT O
results BC2GM055437471 NNS O
suggest BC2GM055437471 VBP O
that BC2GM055437471 IN O
the BC2GM055437471 DT O
PVB BC2GM055437471 NNP O
therapy BC2GM055437471 NN O
is BC2GM055437471 VBZ O
not BC2GM055437471 RB O
sufficient BC2GM055437471 JJ O
to BC2GM055437471 TO O
cure BC2GM055437471 VB O
the BC2GM055437471 DT O
cases BC2GM055437471 NNS O
with BC2GM055437471 IN O
choriocarcinoma BC2GM055437471 JJ O
element BC2GM055437471 NN O
or BC2GM055437471 CC O
bulky BC2GM055437471 JJ O
metastasis BC2GM055437471 NN O
. BC2GM055437471 . O
. . O O

Phosphorylation BC2GM005335689 NN O
at BC2GM005335689 IN O
Ser BC2GM005335689 NNP O
( BC2GM005335689 ( O
670 BC2GM005335689 CD O
) BC2GM005335689 ) O
impairs BC2GM005335689 VBZ O
the BC2GM005335689 DT O
ability BC2GM005335689 NN O
of BC2GM005335689 IN O
GRK2 BC2GM005335689 NNP O
to BC2GM005335689 TO O
phosphorylate BC2GM005335689 VB O
both BC2GM005335689 DT O
soluble BC2GM005335689 JJ O
and BC2GM005335689 CC O
membrane-incorporated BC2GM005335689 JJ O
receptor BC2GM005335689 NN O
substrates BC2GM005335689 NNS O
and BC2GM005335689 CC O
dramatically BC2GM005335689 RB O
attenuates BC2GM005335689 VBZ O
Gbetagamma-mediated BC2GM005335689 JJ O
activation BC2GM005335689 NN O
of BC2GM005335689 IN O
this BC2GM005335689 DT O
enzyme BC2GM005335689 NN O
. BC2GM005335689 . O
. . O O

The BC2GM075671967 DT O
interleukin-2 BC2GM075671967 JJ O
receptor BC2GM075671967 NN O
alpha BC2GM075671967 NN O
( BC2GM075671967 ( O
IL-2R BC2GM075671967 NNP O
alpha BC2GM075671967 NN O
) BC2GM075671967 ) O
chain BC2GM075671967 NN O
gene BC2GM075671967 NN O
contains BC2GM075671967 VBZ O
a BC2GM075671967 DT O
sequence BC2GM075671967 NN O
similar BC2GM075671967 JJ O
to BC2GM075671967 TO O
the BC2GM075671967 DT O
immunoglobulin BC2GM075671967 NN O
( BC2GM075671967 ( O
Ig BC2GM075671967 NNP O
) BC2GM075671967 ) O
kappa BC2GM075671967 NN O
( BC2GM075671967 ( O
kappa BC2GM075671967 NN O
) BC2GM075671967 ) O
enhancer BC2GM075671967 VBZ O
NF-kappa BC2GM075671967 JJ O
B BC2GM075671967 NNP O
binding BC2GM075671967 NN O
site BC2GM075671967 NN O
. BC2GM075671967 . O
. . O O

However BC2GM017403809 RB O
, BC2GM017403809 , O
in BC2GM017403809 IN O
7 BC2GM017403809 CD O
patients BC2GM017403809 NNS O
with BC2GM017403809 IN O
normal BC2GM017403809 JJ O
CT BC2GM017403809 NNP O
results BC2GM017403809 NNS O
the BC2GM017403809 DT O
latter BC2GM017403809 JJ O
method BC2GM017403809 NN O
showed BC2GM017403809 VBD O
areas BC2GM017403809 NNS O
of BC2GM017403809 IN O
cerebral BC2GM017403809 JJ O
activity BC2GM017403809 NN O
anatomically BC2GM017403809 RB O
correlated BC2GM017403809 VBN O
with BC2GM017403809 IN O
neurological BC2GM017403809 JJ O
signs BC2GM017403809 NNS O
or BC2GM017403809 CC O
vascular BC2GM017403809 JJ O
lesions BC2GM017403809 NNS O
. BC2GM017403809 . O
. . O O

A BC2GM050016393 DT O
homologue BC2GM050016393 NN O
of BC2GM050016393 IN O
the BC2GM050016393 DT O
MAP BC2GM050016393 NNP O
/ BC2GM050016393 NNP O
ERK BC2GM050016393 NNP O
family BC2GM050016393 NN O
of BC2GM050016393 IN O
protein BC2GM050016393 JJ O
kinase BC2GM050016393 NN O
genes BC2GM050016393 NNS O
is BC2GM050016393 VBZ O
expressed BC2GM050016393 VBN O
in BC2GM050016393 IN O
vegetative BC2GM050016393 NN O
and BC2GM050016393 CC O
in BC2GM050016393 IN O
female BC2GM050016393 JJ O
reproductive BC2GM050016393 JJ O
organs BC2GM050016393 NNS O
of BC2GM050016393 IN O
Petunia BC2GM050016393 NNP O
hybrida BC2GM050016393 NN O
. BC2GM050016393 . O
. . O O

The BC2GM019218967 DT O
MI BC2GM019218967 NNP O
site BC2GM019218967 NN O
is BC2GM019218967 VBZ O
predictive BC2GM019218967 JJ O
of BC2GM019218967 IN O
hemodynamic BC2GM019218967 JJ O
left BC2GM019218967 VBD O
ventricular BC2GM019218967 JJ O
dysfunction BC2GM019218967 NN O
both BC2GM019218967 DT O
at BC2GM019218967 IN O
rest BC2GM019218967 NN O
and BC2GM019218967 CC O
during BC2GM019218967 IN O
exercise BC2GM019218967 NN O
: BC2GM019218967 : O
anterior BC2GM019218967 JJ O
MIs BC2GM019218967 NNP O
are BC2GM019218967 VBP O
more BC2GM019218967 RBR O
impaired BC2GM019218967 JJ O
than BC2GM019218967 IN O
inferior BC2GM019218967 JJ O
MIs BC2GM019218967 NNP O
. BC2GM019218967 . O
. . O O

Physical BC2GM064092498 JJ O
map BC2GM064092498 NN O
of BC2GM064092498 IN O
the BC2GM064092498 DT O
genome BC2GM064092498 NN O
of BC2GM064092498 IN O
sonchus BC2GM064092498 JJ O
yellow BC2GM064092498 JJ O
net BC2GM064092498 NN O
virus BC2GM064092498 NN O
, BC2GM064092498 , O
a BC2GM064092498 DT O
plant BC2GM064092498 NN O
rhabdovirus BC2GM064092498 NN O
with BC2GM064092498 IN O
six BC2GM064092498 CD O
genes BC2GM064092498 NNS O
and BC2GM064092498 CC O
conserved BC2GM064092498 VBD O
gene BC2GM064092498 NN O
junction BC2GM064092498 NN O
sequences BC2GM064092498 NNS O
. BC2GM064092498 . O
. . O O

This BC2GM095754088 DT O
result BC2GM095754088 NN O
, BC2GM095754088 , O
together BC2GM095754088 RB O
with BC2GM095754088 IN O
the BC2GM095754088 DT O
fact BC2GM095754088 NN O
that BC2GM095754088 IN O
unrearranged BC2GM095754088 VBD O
V BC2GM095754088 NNP O
kappa BC2GM095754088 NNP O
genes BC2GM095754088 NNS O
are BC2GM095754088 VBP O
transcriptionally BC2GM095754088 RB O
silent BC2GM095754088 JJ O
, BC2GM095754088 , O
suggests BC2GM095754088 VBZ O
that BC2GM095754088 IN O
structural BC2GM095754088 JJ O
features BC2GM095754088 NNS O
of BC2GM095754088 IN O
both BC2GM095754088 DT O
the BC2GM095754088 DT O
V BC2GM095754088 NNP O
kappa BC2GM095754088 NN O
and BC2GM095754088 CC O
C BC2GM095754088 NNP O
kappa BC2GM095754088 NNP O
loci BC2GM095754088 VBZ O
contribute BC2GM095754088 NN O
to BC2GM095754088 TO O
the BC2GM095754088 DT O
overall BC2GM095754088 JJ O
transcriptional BC2GM095754088 JJ O
efficiency BC2GM095754088 NN O
of BC2GM095754088 IN O
a BC2GM095754088 DT O
rearranged BC2GM095754088 JJ O
V BC2GM095754088 NNP O
kappa-C BC2GM095754088 NN O
kappa BC2GM095754088 NN O
gene BC2GM095754088 NN O
. BC2GM095754088 . O
. . O O

However BC2GM004118493 RB O
, BC2GM004118493 , O
electron BC2GM004118493 VBP O
microscopy BC2GM004118493 NN O
revealed BC2GM004118493 VBD O
that BC2GM004118493 IN O
while BC2GM004118493 IN O
sec4 BC2GM004118493 NN O
mutant BC2GM004118493 JJ O
cells BC2GM004118493 NNS O
accumulate BC2GM004118493 JJ O
secretory BC2GM004118493 NN O
vesicles BC2GM004118493 NNS O
, BC2GM004118493 , O
ypt31 BC2GM004118493 EX O
/ BC2GM004118493 $ O
32 BC2GM004118493 CD O
mutant BC2GM004118493 JJ O
cells BC2GM004118493 NNS O
accumulate BC2GM004118493 VBP O
aberrant BC2GM004118493 JJ O
Golgi BC2GM004118493 NNP O
structures BC2GM004118493 NNS O
. BC2GM004118493 . O
. . O O

While BC2GM097376485 IN O
there BC2GM097376485 EX O
is BC2GM097376485 VBZ O
growing BC2GM097376485 VBG O
evidence BC2GM097376485 NN O
that BC2GM097376485 IN O
perception BC2GM097376485 NN O
and BC2GM097376485 CC O
imagery BC2GM097376485 NN O
share BC2GM097376485 NN O
common BC2GM097376485 JJ O
neural BC2GM097376485 JJ O
substrates BC2GM097376485 NNS O
, BC2GM097376485 , O
the BC2GM097376485 DT O
fact BC2GM097376485 NN O
that BC2GM097376485 IN O
D.F BC2GM097376485 NNP O
. BC2GM097376485 . O
shows BC2GM097376485 NNS O
intact BC2GM097376485 JJ O
visual BC2GM097376485 JJ O
imagery BC2GM097376485 NN O
in BC2GM097376485 IN O
the BC2GM097376485 DT O
face BC2GM097376485 NN O
of BC2GM097376485 IN O
a BC2GM097376485 DT O
massive BC2GM097376485 JJ O
perceptual BC2GM097376485 JJ O
deficit BC2GM097376485 NN O
in BC2GM097376485 IN O
form BC2GM097376485 JJ O
vision BC2GM097376485 NN O
challenges BC2GM097376485 NNS O
recent BC2GM097376485 JJ O
suggestions BC2GM097376485 NNS O
that BC2GM097376485 IN O
these BC2GM097376485 DT O
two BC2GM097376485 CD O
psychological BC2GM097376485 JJ O
processes BC2GM097376485 NNS O
share BC2GM097376485 NN O
common BC2GM097376485 JJ O
input BC2GM097376485 NN O
pathways BC2GM097376485 NNS O
in BC2GM097376485 IN O
early BC2GM097376485 JJ O
vision BC2GM097376485 NN O
. BC2GM097376485 . O
. . O O

Only BC2GM031270698 RB O
the BC2GM031270698 DT O
native BC2GM031270698 JJ O
structure BC2GM031270698 NN O
of BC2GM031270698 IN O
phosphorylated BC2GM031270698 JJ O
ERK BC2GM031270698 NNP O
was BC2GM031270698 VBD O
recognized BC2GM031270698 VBN O
by BC2GM031270698 IN O
VHR BC2GM031270698 NNP O
and BC2GM031270698 CC O
was BC2GM031270698 VBD O
inactivated BC2GM031270698 VBN O
with BC2GM031270698 IN O
a BC2GM031270698 DT O
second-order BC2GM031270698 JJ O
rate BC2GM031270698 NN O
constant BC2GM031270698 NN O
of BC2GM031270698 IN O
40,000 BC2GM031270698 CD O
M-1 BC2GM031270698 JJ O
s-1 BC2GM031270698 NN O
. BC2GM031270698 . O
. . O O

NER BC2GM056813896 NNP O
was BC2GM056813896 VBD O
also BC2GM056813896 RB O
measured BC2GM056813896 VBN O
by BC2GM056813896 IN O
a BC2GM056813896 DT O
plasmid BC2GM056813896 NN O
host BC2GM056813896 NN O
cell BC2GM056813896 NN O
re-activation BC2GM056813896 NN O
assay BC2GM056813896 VBP O
using BC2GM056813896 VBG O
a BC2GM056813896 DT O
vector BC2GM056813896 NN O
containing BC2GM056813896 VBG O
a BC2GM056813896 DT O
luciferase BC2GM056813896 NN O
reporter BC2GM056813896 NN O
gene BC2GM056813896 NN O
. BC2GM056813896 . O
. . O O

The BC2GM028126771 DT O
in BC2GM028126771 IN O
vitro BC2GM028126771 JJ O
activity BC2GM028126771 NN O
of BC2GM028126771 IN O
KP-103 BC2GM028126771 NNP O
, BC2GM028126771 , O
a BC2GM028126771 DT O
novel BC2GM028126771 JJ O
triazole BC2GM028126771 NN O
derivative BC2GM028126771 NN O
, BC2GM028126771 , O
against BC2GM028126771 IN O
pathogenic BC2GM028126771 JJ O
fungi BC2GM028126771 NNS O
that BC2GM028126771 WDT O
cause BC2GM028126771 VBP O
dermatomycoses BC2GM028126771 NNS O
and BC2GM028126771 CC O
its BC2GM028126771 PRP$ O
therapeutic BC2GM028126771 JJ O
efficacy BC2GM028126771 NN O
against BC2GM028126771 IN O
plantar BC2GM028126771 NN O
tinea BC2GM028126771 NN O
pedis BC2GM028126771 NN O
and BC2GM028126771 CC O
cutaneous BC2GM028126771 JJ O
candidiasis BC2GM028126771 NN O
in BC2GM028126771 IN O
guinea BC2GM028126771 NN O
pigs BC2GM028126771 NNS O
were BC2GM028126771 VBD O
investigated BC2GM028126771 VBN O
. BC2GM028126771 . O
. . O O

This BC2GM015111811 DT O
result BC2GM015111811 NN O
is BC2GM015111811 VBZ O
consistent BC2GM015111811 JJ O
with BC2GM015111811 IN O
the BC2GM015111811 DT O
previous BC2GM015111811 JJ O
observation BC2GM015111811 NN O
that BC2GM015111811 IN O
expression BC2GM015111811 NN O
of BC2GM015111811 IN O
the BC2GM015111811 DT O
hsp70 BC2GM015111811 NN O
genes BC2GM015111811 NNS O
in BC2GM015111811 IN O
T. BC2GM015111811 NNP O
brucei BC2GM015111811 NN O
is BC2GM015111811 VBZ O
mainly BC2GM015111811 RB O
controlled BC2GM015111811 VBN O
at BC2GM015111811 IN O
the BC2GM015111811 DT O
posttranscriptional BC2GM015111811 JJ O
level BC2GM015111811 NN O
. BC2GM015111811 . O
. . O O

Some BC2GM067853242 DT O
may BC2GM067853242 MD O
affect BC2GM067853242 VB O
the BC2GM067853242 DT O
folding BC2GM067853242 JJ O
pathway BC2GM067853242 NN O
or BC2GM067853242 CC O
the BC2GM067853242 DT O
affinity BC2GM067853242 NN O
for BC2GM067853242 IN O
chaperonins BC2GM067853242 NNS O
. BC2GM067853242 . O
. . O O

Transfection BC2GM074709603 NN O
assays BC2GM074709603 NNS O
using BC2GM074709603 VBG O
the BC2GM074709603 DT O
first BC2GM074709603 JJ O
600 BC2GM074709603 CD O
bp BC2GM074709603 NN O
of BC2GM074709603 IN O
the BC2GM074709603 DT O
upstream BC2GM074709603 JJ O
nucleotide BC2GM074709603 NN O
sequences BC2GM074709603 NNS O
indicated BC2GM074709603 VBD O
that BC2GM074709603 IN O
a BC2GM074709603 DT O
region BC2GM074709603 NN O
from BC2GM074709603 IN O
-75 BC2GM074709603 NN O
to BC2GM074709603 TO O
-120 BC2GM074709603 VB O
was BC2GM074709603 VBD O
necessary BC2GM074709603 JJ O
for BC2GM074709603 IN O
the BC2GM074709603 DT O
ALDH2 BC2GM074709603 NNP O
gene BC2GM074709603 NN O
expression BC2GM074709603 NN O
, BC2GM074709603 , O
and BC2GM074709603 CC O
especially BC2GM074709603 RB O
NF-Y BC2GM074709603 NNP O
/ BC2GM074709603 NNP O
CP1 BC2GM074709603 NNP O
binding BC2GM074709603 VBG O
site BC2GM074709603 NN O
from BC2GM074709603 IN O
-92 BC2GM074709603 NN O
to BC2GM074709603 TO O
-96 BC2GM074709603 NNP O
( BC2GM074709603 ( O
CCAAT BC2GM074709603 NNP O
box BC2GM074709603 NN O
) BC2GM074709603 ) O
is BC2GM074709603 VBZ O
important BC2GM074709603 JJ O
in BC2GM074709603 IN O
the BC2GM074709603 DT O
expression BC2GM074709603 NN O
of BC2GM074709603 IN O
the BC2GM074709603 DT O
gene BC2GM074709603 NN O
. BC2GM074709603 . O
. . O O

Determinants BC2GM084151426 NNS O
of BC2GM084151426 IN O
recurrent BC2GM084151426 NN O
ischaemia BC2GM084151426 NN O
and BC2GM084151426 CC O
revascularisation BC2GM084151426 NN O
procedures BC2GM084151426 NNS O
after BC2GM084151426 IN O
thrombolysis BC2GM084151426 NN O
with BC2GM084151426 IN O
recombinant BC2GM084151426 JJ O
tissue BC2GM084151426 NN O
plasminogen BC2GM084151426 NN O
activator BC2GM084151426 NN O
in BC2GM084151426 IN O
primary BC2GM084151426 JJ O
coronary BC2GM084151426 JJ O
occlusion BC2GM084151426 NN O
. BC2GM084151426 . O
. . O O

Sociological BC2GM092988479 JJ O
analysis BC2GM092988479 NN O
of BC2GM092988479 IN O
the BC2GM092988479 DT O
family BC2GM092988479 NN O
. BC2GM092988479 . O
. . O O

Prematurely BC2GM040960284 RB O
inactivating BC2GM040960284 VBG O
p42 BC2GM040960284 NN O
MAPK BC2GM040960284 NNP O
in BC2GM040960284 IN O
egg BC2GM040960284 NN O
extracts BC2GM040960284 NNS O
resulted BC2GM040960284 VBD O
in BC2GM040960284 IN O
a BC2GM040960284 DT O
corresponding BC2GM040960284 JJ O
hastening BC2GM040960284 NN O
of BC2GM040960284 IN O
the BC2GM040960284 DT O
first BC2GM040960284 JJ O
mitosis BC2GM040960284 NN O
. BC2GM040960284 . O
. . O O

The BC2GM040902360 DT O
3 BC2GM040902360 CD O
' BC2GM040902360 POS O
region BC2GM040902360 NN O
of BC2GM040902360 IN O
the BC2GM040902360 DT O
transcript BC2GM040902360 NN O
contained BC2GM040902360 VBD O
a BC2GM040902360 DT O
fully BC2GM040902360 RB O
conserved BC2GM040902360 VBN O
, BC2GM040902360 , O
correctly BC2GM040902360 RB O
spliced BC2GM040902360 VBD O
TCR BC2GM040902360 NNP O
alpha BC2GM040902360 JJ O
C BC2GM040902360 NNP O
region BC2GM040902360 NN O
which BC2GM040902360 WDT O
was BC2GM040902360 VBD O
polyadenylated BC2GM040902360 VBN O
at BC2GM040902360 IN O
the BC2GM040902360 DT O
3 BC2GM040902360 CD O
' BC2GM040902360 POS O
end BC2GM040902360 NN O
. BC2GM040902360 . O
. . O O

Ion-Bernstein-wave BC2GM096331297 JJ O
heating BC2GM096331297 NN O
and BC2GM096331297 CC O
improved BC2GM096331297 JJ O
confinement BC2GM096331297 NN O
in BC2GM096331297 IN O
the BC2GM096331297 DT O
Alcator BC2GM096331297 NNP O
C BC2GM096331297 NNP O
tokamak BC2GM096331297 NN O
. BC2GM096331297 . O
. . O O

Mutation BC2GM096030020 NN O
of BC2GM096030020 IN O
this BC2GM096030020 DT O
threonine BC2GM096030020 NN O
to BC2GM096030020 TO O
isoleucine BC2GM096030020 VB O
had BC2GM096030020 VBN O
no BC2GM096030020 DT O
observable BC2GM096030020 JJ O
effect BC2GM096030020 NN O
on BC2GM096030020 IN O
either BC2GM096030020 CC O
nuclear BC2GM096030020 JJ O
localization BC2GM096030020 NN O
of BC2GM096030020 IN O
E1 BC2GM096030020 NNP O
or BC2GM096030020 CC O
DNA BC2GM096030020 NNP O
replication BC2GM096030020 NN O
of BC2GM096030020 IN O
the BC2GM096030020 DT O
intact BC2GM096030020 JJ O
viral BC2GM096030020 JJ O
genome BC2GM096030020 NN O
. BC2GM096030020 . O
. . O O

Experience BC2GM061933593 NN O
in BC2GM061933593 IN O
using BC2GM061933593 VBG O
the BC2GM061933593 DT O
Romashka-1 BC2GM061933593 NNP O
laser BC2GM061933593 NN O
surgical BC2GM061933593 JJ O
unit BC2GM061933593 NN O
in BC2GM061933593 IN O
treating BC2GM061933593 VBG O
suppurative BC2GM061933593 JJ O
wounds BC2GM061933593 NNS O
. BC2GM061933593 . O
. . O O

The BC2GM036938050 DT O
H5 BC2GM036938050 NNP O
mutants BC2GM036938050 NNS O
were BC2GM036938050 VBD O
: BC2GM036938050 : O
DH5 BC2GM036938050 NNP O
( BC2GM036938050 ( O
all BC2GM036938050 DT O
amino BC2GM036938050 NN O
acids BC2GM036938050 NNS O
in BC2GM036938050 IN O
D BC2GM036938050 NNP O
configuration BC2GM036938050 NN O
) BC2GM036938050 ) O
and BC2GM036938050 CC O
H5F BC2GM036938050 NNP O
( BC2GM036938050 ( O
where BC2GM036938050 WRB O
all BC2GM036938050 DT O
His BC2GM036938050 PRP$ O
are BC2GM036938050 VBP O
replaced BC2GM036938050 VBN O
by BC2GM036938050 IN O
Phe BC2GM036938050 NNP O
at BC2GM036938050 IN O
positions BC2GM036938050 NNS O
3 BC2GM036938050 CD O
, BC2GM036938050 , O
7 BC2GM036938050 CD O
, BC2GM036938050 , O
8 BC2GM036938050 CD O
, BC2GM036938050 , O
15 BC2GM036938050 CD O
, BC2GM036938050 , O
18 BC2GM036938050 CD O
, BC2GM036938050 , O
19 BC2GM036938050 CD O
, BC2GM036938050 , O
21 BC2GM036938050 CD O
) BC2GM036938050 ) O
. BC2GM036938050 . O
. . O O

This BC2GM057945888 DT O
study BC2GM057945888 NN O
examines BC2GM057945888 VBZ O
LEIBNIZ BC2GM057945888 NNP O
' BC2GM057945888 POS O
idea BC2GM057945888 NN O
of BC2GM057945888 IN O
Veterinary BC2GM057945888 NNP O
medicine BC2GM057945888 NN O
in BC2GM057945888 IN O
a BC2GM057945888 DT O
biographical BC2GM057945888 JJ O
context BC2GM057945888 NN O
. BC2GM057945888 . O
. . O O

Experience BC2GM079722932 NN O
in BC2GM079722932 IN O
a BC2GM079722932 DT O
Kenya BC2GM079722932 NNP O
district BC2GM079722932 NN O
hospital BC2GM079722932 NN O
. BC2GM079722932 . O
. . O O

The BC2GM090670157 DT O
Prompt BC2GM090670157 NNP O
and BC2GM090670157 CC O
Praise BC2GM090670157 NNP O
condition BC2GM090670157 NN O
was BC2GM090670157 VBD O
superior BC2GM090670157 JJ O
to BC2GM090670157 TO O
the BC2GM090670157 DT O
other BC2GM090670157 JJ O
two BC2GM090670157 CD O
conditions BC2GM090670157 NNS O
in BC2GM090670157 IN O
encouraging BC2GM090670157 VBG O
participation BC2GM090670157 NN O
in BC2GM090670157 IN O
low-interest BC2GM090670157 JJ O
recreational BC2GM090670157 JJ O
activities BC2GM090670157 NNS O
. BC2GM090670157 . O
. . O O

To BC2GM017323042 TO O
determine BC2GM017323042 VB O
the BC2GM017323042 DT O
transactivation BC2GM017323042 NN O
potential BC2GM017323042 NN O
of BC2GM017323042 IN O
each BC2GM017323042 DT O
of BC2GM017323042 IN O
the BC2GM017323042 DT O
four BC2GM017323042 CD O
Ahr BC2GM017323042 NNP O
Sp1 BC2GM017323042 NNP O
sites BC2GM017323042 NNS O
, BC2GM017323042 , O
we BC2GM017323042 PRP O
fused BC2GM017323042 VBD O
the BC2GM017323042 DT O
Ahr BC2GM017323042 NNP O
promoter BC2GM017323042 NN O
to BC2GM017323042 TO O
a BC2GM017323042 DT O
luciferase BC2GM017323042 NN O
( BC2GM017323042 ( O
LUC BC2GM017323042 NNP O
) BC2GM017323042 ) O
reporter BC2GM017323042 NN O
gene BC2GM017323042 NN O
and BC2GM017323042 CC O
transfected BC2GM017323042 VBD O
the BC2GM017323042 DT O
construct BC2GM017323042 NN O
into BC2GM017323042 IN O
the BC2GM017323042 DT O
Drosophila BC2GM017323042 NNP O
cell BC2GM017323042 NN O
line BC2GM017323042 NN O
Schneider-2 BC2GM017323042 NNP O
, BC2GM017323042 , O
which BC2GM017323042 WDT O
contains BC2GM017323042 VBZ O
no BC2GM017323042 DT O
Sp1 BC2GM017323042 NNP O
or BC2GM017323042 CC O
Sp1-like BC2GM017323042 JJ O
factors BC2GM017323042 NNS O
. BC2GM017323042 . O
. . O O

Deletion BC2GM098953976 NN O
of BC2GM098953976 IN O
this BC2GM098953976 DT O
consensus BC2GM098953976 NN O
element BC2GM098953976 NN O
from BC2GM098953976 IN O
the BC2GM098953976 DT O
spo6 BC2GM098953976 JJ O
promoter BC2GM098953976 NN O
abolished BC2GM098953976 VBD O
the BC2GM098953976 DT O
transcription BC2GM098953976 NN O
of BC2GM098953976 IN O
spo6+ BC2GM098953976 NN O
and BC2GM098953976 CC O
resulted BC2GM098953976 VBD O
in BC2GM098953976 IN O
a BC2GM098953976 DT O
sporulation BC2GM098953976 NN O
deficiency BC2GM098953976 NN O
. BC2GM098953976 . O
. . O O

The BC2GM084448237 DT O
gene BC2GM084448237 NN O
encoding BC2GM084448237 VBG O
the BC2GM084448237 DT O
Neisseria BC2GM084448237 NNP O
lactamica BC2GM084448237 NN O
III BC2GM084448237 NNP O
DNA BC2GM084448237 NNP O
methyltransferase BC2GM084448237 NN O
( BC2GM084448237 ( O
M.NlaIII BC2GM084448237 NNP O
) BC2GM084448237 ) O
which BC2GM084448237 WDT O
recognizes BC2GM084448237 VBZ O
the BC2GM084448237 DT O
sequence BC2GM084448237 NN O
CATG BC2GM084448237 NNP O
has BC2GM084448237 VBZ O
been BC2GM084448237 VBN O
cloned BC2GM084448237 VBN O
and BC2GM084448237 CC O
expressed BC2GM084448237 VBN O
in BC2GM084448237 IN O
Escherichia BC2GM084448237 NNP O
coli BC2GM084448237 NN O
. BC2GM084448237 . O
. . O O

A BC2GM041191299 DT O
total BC2GM041191299 NN O
of BC2GM041191299 IN O
64 BC2GM041191299 CD O
uncomplicated BC2GM041191299 JJ O
Type-2 BC2GM041191299 NNP O
diabetic BC2GM041191299 JJ O
individuals BC2GM041191299 NNS O
of BC2GM041191299 IN O
higher BC2GM041191299 JJR O
middle BC2GM041191299 JJ O
class BC2GM041191299 NN O
to BC2GM041191299 TO O
rich BC2GM041191299 VB O
socio-economic BC2GM041191299 JJ O
status BC2GM041191299 NN O
were BC2GM041191299 VBD O
studied BC2GM041191299 VBN O
. BC2GM041191299 . O
. . O O

Through BC2GM024460635 IN O
effective BC2GM024460635 JJ O
use BC2GM024460635 NN O
of BC2GM024460635 IN O
laboratory BC2GM024460635 NN O
testing BC2GM024460635 VBG O
database BC2GM024460635 NN O
, BC2GM024460635 , O
it BC2GM024460635 PRP O
will BC2GM024460635 MD O
be BC2GM024460635 VB O
possible BC2GM024460635 JJ O
to BC2GM024460635 TO O
shift BC2GM024460635 VB O
away BC2GM024460635 RB O
our BC2GM024460635 PRP$ O
vague BC2GM024460635 JJ O
management BC2GM024460635 NN O
of BC2GM024460635 IN O
pre-analytic BC2GM024460635 JJ O
phase BC2GM024460635 NN O
of BC2GM024460635 IN O
quality BC2GM024460635 NN O
control BC2GM024460635 NN O
so BC2GM024460635 RB O
far BC2GM024460635 RB O
to BC2GM024460635 TO O
its BC2GM024460635 PRP$ O
established BC2GM024460635 VBN O
system BC2GM024460635 NN O
based BC2GM024460635 VBN O
on BC2GM024460635 IN O
objective BC2GM024460635 JJ O
evaluation BC2GM024460635 NN O
. BC2GM024460635 . O
. . O O

Peak BC2GM033034194 NNP O
plasma BC2GM033034194 NN O
ACTH BC2GM033034194 NNP O
responses BC2GM033034194 NNS O
were BC2GM033034194 VBD O
not BC2GM033034194 RB O
significantly BC2GM033034194 RB O
different BC2GM033034194 JJ O
between BC2GM033034194 IN O
control BC2GM033034194 NN O
and BC2GM033034194 CC O
patient BC2GM033034194 JJ O
groups BC2GM033034194 NNS O
. BC2GM033034194 . O
. . O O

Finally BC2GM015421655 RB O
, BC2GM015421655 , O
antisense BC2GM015421655 NN O
mediated BC2GM015421655 VBD O
reduction BC2GM015421655 NN O
of BC2GM015421655 IN O
Elk-1 BC2GM015421655 NNP O
in BC2GM015421655 IN O
GH4 BC2GM015421655 NNP O
cells BC2GM015421655 NNS O
decreased BC2GM015421655 VBD O
insulin-increased BC2GM015421655 JJ O
prolactin BC2GM015421655 NN O
gene BC2GM015421655 NN O
expression BC2GM015421655 NN O
and BC2GM015421655 CC O
confirmed BC2GM015421655 VBD O
the BC2GM015421655 DT O
requirement BC2GM015421655 NN O
for BC2GM015421655 IN O
Elk-1 BC2GM015421655 NNP O
for BC2GM015421655 IN O
insulin-increased BC2GM015421655 JJ O
prolactin BC2GM015421655 NN O
gene BC2GM015421655 NN O
expression BC2GM015421655 NN O
. BC2GM015421655 . O
. . O O

These BC2GM011957341 DT O
results BC2GM011957341 NNS O
suggest BC2GM011957341 VBP O
that BC2GM011957341 IN O
both BC2GM011957341 DT O
the BC2GM011957341 DT O
distinct BC2GM011957341 JJ O
DNA BC2GM011957341 NNP O
binding BC2GM011957341 NN O
properties BC2GM011957341 NNS O
of BC2GM011957341 IN O
PMLRAR BC2GM011957341 NNP O
homodimers BC2GM011957341 NNS O
and BC2GM011957341 CC O
the BC2GM011957341 DT O
sequestration BC2GM011957341 NN O
of BC2GM011957341 IN O
RXR BC2GM011957341 NNP O
by BC2GM011957341 IN O
PMLRARs BC2GM011957341 NNP O
may BC2GM011957341 MD O
contribute BC2GM011957341 VB O
to BC2GM011957341 TO O
the BC2GM011957341 DT O
molecular BC2GM011957341 JJ O
mechanisms BC2GM011957341 NN O
which BC2GM011957341 WDT O
underlie BC2GM011957341 VBZ O
the BC2GM011957341 DT O
pathogenesis BC2GM011957341 NN O
of BC2GM011957341 IN O
APL BC2GM011957341 NNP O
. BC2GM011957341 . O
. . O O

Seven BC2GM097074870 CD O
patients BC2GM097074870 NNS O
were BC2GM097074870 VBD O
without BC2GM097074870 IN O
a BC2GM097074870 DT O
syndromic BC2GM097074870 JJ O
diagnosis BC2GM097074870 NN O
. BC2GM097074870 . O
. . O O

STUDY BC2GM094973350 NNP O
DESIGN BC2GM094973350 NNP O
: BC2GM094973350 : O
Retrospective BC2GM094973350 JJ O
review BC2GM094973350 NN O
. BC2GM094973350 . O
. . O O

This BC2GM051391908 DT O
cell BC2GM051391908 NN O
line BC2GM051391908 NN O
expresses BC2GM051391908 VBZ O
productively BC2GM051391908 RB O
rearranged BC2GM051391908 VBN O
immunoglobulin BC2GM051391908 NN O
genes BC2GM051391908 NNS O
as BC2GM051391908 RB O
well BC2GM051391908 RB O
as BC2GM051391908 IN O
the BC2GM051391908 DT O
Oct-2 BC2GM051391908 NNP O
gene BC2GM051391908 NN O
at BC2GM051391908 IN O
high BC2GM051391908 JJ O
levels BC2GM051391908 NNS O
which BC2GM051391908 WDT O
are BC2GM051391908 VBP O
comparable BC2GM051391908 JJ O
to BC2GM051391908 TO O
those BC2GM051391908 DT O
observed BC2GM051391908 VBN O
in BC2GM051391908 IN O
activated BC2GM051391908 JJ O
murine BC2GM051391908 NN O
splenic BC2GM051391908 NN O
B BC2GM051391908 NNP O
cells BC2GM051391908 NNS O
. BC2GM051391908 . O
. . O O

Plasma BC2GM064369940 NNP O
renin BC2GM064369940 NN O
activity BC2GM064369940 NN O
in BC2GM064369940 IN O
end-stage BC2GM064369940 JJ O
kidney BC2GM064369940 NN O
disease BC2GM064369940 NN O
. BC2GM064369940 . O
. . O O

Cognitive BC2GM093591586 JJ O
measures BC2GM093591586 NNS O
of BC2GM093591586 IN O
attention BC2GM093591586 NN O
included BC2GM093591586 VBD O
the BC2GM093591586 DT O
Stroop BC2GM093591586 NNP O
and BC2GM093591586 CC O
Controlled BC2GM093591586 NNP O
Oral BC2GM093591586 NNP O
Word BC2GM093591586 NNP O
Association BC2GM093591586 NNP O
Test BC2GM093591586 NNP O
using BC2GM093591586 VBG O
the BC2GM093591586 DT O
letters BC2GM093591586 NNS O
`` BC2GM093591586 `` O
C BC2GM093591586 NNP O
, BC2GM093591586 , O
'' BC2GM093591586 '' O
`` BC2GM093591586 `` O
F BC2GM093591586 NNP O
, BC2GM093591586 , O
'' BC2GM093591586 '' O
and BC2GM093591586 CC O
`` BC2GM093591586 `` O
L BC2GM093591586 NNP O
'' BC2GM093591586 '' O
( BC2GM093591586 ( O
COWAT BC2GM093591586 NNP O
, BC2GM093591586 , O
CFL BC2GM093591586 NNP O
version BC2GM093591586 NN O
) BC2GM093591586 ) O
. BC2GM093591586 . O
. . O O

SETTING BC2GM041273228 NN O
: BC2GM041273228 : O
University BC2GM041273228 NNP O
research BC2GM041273228 NN O
laboratory BC2GM041273228 NN O
. BC2GM041273228 . O
. . O O

The BC2GM011914168 DT O
same BC2GM011914168 JJ O
pattern BC2GM011914168 NN O
of BC2GM011914168 IN O
firing BC2GM011914168 NN O
was BC2GM011914168 VBD O
seen BC2GM011914168 VBN O
with BC2GM011914168 IN O
saccades BC2GM011914168 NNS O
in BC2GM011914168 IN O
light BC2GM011914168 NN O
and BC2GM011914168 CC O
in BC2GM011914168 IN O
complete BC2GM011914168 JJ O
darkness BC2GM011914168 NN O
. BC2GM011914168 . O
. . O O

They BC2GM073086948 PRP O
are BC2GM073086948 VBP O
transduced BC2GM073086948 VBN O
through BC2GM073086948 IN O
TM BC2GM073086948 NNP O
to BC2GM073086948 TO O
the BC2GM073086948 DT O
cytoplasmic BC2GM073086948 JJ O
portion BC2GM073086948 NN O
( BC2GM073086948 ( O
cytoloops BC2GM073086948 NNS O
and BC2GM073086948 CC O
the BC2GM073086948 DT O
C-terminal BC2GM073086948 NNP O
tail BC2GM073086948 NN O
) BC2GM073086948 ) O
of BC2GM073086948 IN O
the BC2GM073086948 DT O
receptor BC2GM073086948 NN O
and BC2GM073086948 CC O
then BC2GM073086948 RB O
, BC2GM073086948 , O
transferred BC2GM073086948 VBD O
to BC2GM073086948 TO O
cytoplasmic BC2GM073086948 VB O
signaling BC2GM073086948 VBG O
molecules BC2GM073086948 NNS O
, BC2GM073086948 , O
such BC2GM073086948 JJ O
as BC2GM073086948 IN O
G BC2GM073086948 NNP O
protein BC2GM073086948 NN O
. BC2GM073086948 . O
. . O O

RNA BC2GM026348883 NNP O
unwinding BC2GM026348883 NN O
in BC2GM026348883 IN O
U4 BC2GM026348883 NNP O
/ BC2GM026348883 NNP O
U6 BC2GM026348883 NNP O
snRNPs BC2GM026348883 NN O
requires BC2GM026348883 VBZ O
ATP BC2GM026348883 NNP O
hydrolysis BC2GM026348883 NN O
and BC2GM026348883 CC O
the BC2GM026348883 DT O
DEIH-box BC2GM026348883 NNP O
splicing BC2GM026348883 NN O
factor BC2GM026348883 NN O
Brr2 BC2GM026348883 NNP O
. BC2GM026348883 . O
. . O O

The BC2GM015853606 DT O
unexpected BC2GM015853606 JJ O
prevalence BC2GM015853606 NN O
of BC2GM015853606 IN O
c-myc BC2GM015853606 JJ O
and BC2GM015853606 CC O
alpha-tubulin BC2GM015853606 JJ O
in BC2GM015853606 IN O
the BC2GM015853606 DT O
S-phase BC2GM015853606 NNP O
library BC2GM015853606 NN O
is BC2GM015853606 VBZ O
supported BC2GM015853606 VBN O
by BC2GM015853606 IN O
Northern BC2GM015853606 NNP O
analysis BC2GM015853606 NN O
of BC2GM015853606 IN O
RNA BC2GM015853606 NNP O
from BC2GM015853606 IN O
phase-synchronous BC2GM015853606 JJ O
cells BC2GM015853606 NNS O
. BC2GM015853606 . O
. . O O

The BC2GM078881982 DT O
percentage BC2GM078881982 NN O
distribution BC2GM078881982 NN O
of BC2GM078881982 IN O
types BC2GM078881982 NNS O
of BC2GM078881982 IN O
fixation BC2GM078881982 NN O
disparity BC2GM078881982 NN O
curves BC2GM078881982 NNS O
was BC2GM078881982 VBD O
found BC2GM078881982 VBN O
to BC2GM078881982 TO O
be BC2GM078881982 VB O
similar BC2GM078881982 JJ O
to BC2GM078881982 TO O
some BC2GM078881982 DT O
previous BC2GM078881982 JJ O
studies BC2GM078881982 NNS O
, BC2GM078881982 , O
with BC2GM078881982 IN O
a BC2GM078881982 DT O
higher BC2GM078881982 JJR O
prevalence BC2GM078881982 NN O
of BC2GM078881982 IN O
Type BC2GM078881982 NNP O
I BC2GM078881982 PRP O
curve BC2GM078881982 VBP O
( BC2GM078881982 ( O
64.3 BC2GM078881982 CD O
% BC2GM078881982 NN O
) BC2GM078881982 ) O
, BC2GM078881982 , O
followed BC2GM078881982 VBN O
by BC2GM078881982 IN O
Type BC2GM078881982 NNP O
II BC2GM078881982 NNP O
( BC2GM078881982 ( O
28.6 BC2GM078881982 CD O
% BC2GM078881982 NN O
) BC2GM078881982 ) O
and BC2GM078881982 CC O
Type BC2GM078881982 NNP O
III BC2GM078881982 NNP O
( BC2GM078881982 ( O
7.1 BC2GM078881982 CD O
% BC2GM078881982 NN O
) BC2GM078881982 ) O
curves BC2GM078881982 VBZ O
. BC2GM078881982 . O
. . O O

Comparison BC2GM046685387 NNP O
of BC2GM046685387 IN O
the BC2GM046685387 DT O
genes BC2GM046685387 NNS O
coding BC2GM046685387 VBG O
for BC2GM046685387 IN O
mouse BC2GM046685387 NN O
and BC2GM046685387 CC O
human BC2GM046685387 JJ O
p36 BC2GM046685387 NN O
( BC2GM046685387 ( O
annexin BC2GM046685387 JJ O
II BC2GM046685387 NNP O
) BC2GM046685387 ) O
and BC2GM046685387 CC O
mouse BC2GM046685387 NN O
, BC2GM046685387 , O
rat BC2GM046685387 NN O
and BC2GM046685387 CC O
human BC2GM046685387 JJ O
p35 BC2GM046685387 NN O
( BC2GM046685387 ( O
annexin BC2GM046685387 IN O
I BC2GM046685387 PRP O
) BC2GM046685387 ) O
and BC2GM046685387 CC O
pigeon BC2GM046685387 JJ O
cp35 BC2GM046685387 NN O
( BC2GM046685387 ( O
an BC2GM046685387 DT O
annexin BC2GM046685387 NN O
I-related BC2GM046685387 NNP O
protein BC2GM046685387 NN O
) BC2GM046685387 ) O
shows BC2GM046685387 VBZ O
strong BC2GM046685387 JJ O
genomic BC2GM046685387 JJ O
structural BC2GM046685387 JJ O
conservation BC2GM046685387 NN O
supporting BC2GM046685387 VBG O
the BC2GM046685387 DT O
hypothesis BC2GM046685387 NN O
that BC2GM046685387 IN O
these BC2GM046685387 DT O
genes BC2GM046685387 NNS O
had BC2GM046685387 VBD O
a BC2GM046685387 DT O
common BC2GM046685387 JJ O
ancestor BC2GM046685387 NN O
. BC2GM046685387 . O
. . O O

Accordingly BC2GM036949597 RB O
, BC2GM036949597 , O
infection BC2GM036949597 NN O
of BC2GM036949597 IN O
IFN-pretreated BC2GM036949597 NNP O
HeLa BC2GM036949597 NNP O
S3 BC2GM036949597 NNP O
cells BC2GM036949597 NNS O
with BC2GM036949597 IN O
an BC2GM036949597 DT O
E3L-deficient BC2GM036949597 JJ O
VV BC2GM036949597 NNP O
( BC2GM036949597 ( O
VVDeltaE3L BC2GM036949597 NNP O
) BC2GM036949597 ) O
resulted BC2GM036949597 VBD O
in BC2GM036949597 IN O
increased BC2GM036949597 JJ O
phosphorylation BC2GM036949597 NN O
levels BC2GM036949597 NNS O
of BC2GM036949597 IN O
both BC2GM036949597 DT O
PKR BC2GM036949597 NNP O
and BC2GM036949597 CC O
eIF2alpha BC2GM036949597 NN O
. BC2GM036949597 . O
. . O O

I BC2GM003525859 PRP O
. BC2GM003525859 . O
. . O O

In BC2GM084901055 IN O
mouse BC2GM084901055 NN O
, BC2GM084901055 , O
two BC2GM084901055 CD O
high-affinity BC2GM084901055 NN O
binding BC2GM084901055 NN O
sites BC2GM084901055 NNS O
with BC2GM084901055 IN O
an BC2GM084901055 DT O
apparent BC2GM084901055 JJ O
dissociation BC2GM084901055 NN O
constant BC2GM084901055 NN O
( BC2GM084901055 ( O
Kd BC2GM084901055 NNP O
) BC2GM084901055 ) O
of BC2GM084901055 IN O
50 BC2GM084901055 CD O
to BC2GM084901055 TO O
100 BC2GM084901055 CD O
nM BC2GM084901055 NNS O
have BC2GM084901055 VBP O
been BC2GM084901055 VBN O
mapped BC2GM084901055 VBN O
in BC2GM084901055 IN O
the BC2GM084901055 DT O
5 BC2GM084901055 CD O
' BC2GM084901055 POS O
ETS BC2GM084901055 NNP O
upstream BC2GM084901055 NN O
from BC2GM084901055 IN O
the BC2GM084901055 DT O
early BC2GM084901055 JJ O
pre-rRNA BC2GM084901055 NN O
processing BC2GM084901055 NN O
site BC2GM084901055 NN O
. BC2GM084901055 . O
. . O O

Like BC2GM055710514 IN O
troponin BC2GM055710514 NN O
Cs BC2GM055710514 NNP O
and BC2GM055710514 CC O
calmodulins BC2GM055710514 NNS O
, BC2GM055710514 , O
PfCPK BC2GM055710514 NNP O
also BC2GM055710514 RB O
contains BC2GM055710514 VBZ O
four BC2GM055710514 CD O
EF BC2GM055710514 NNP O
hand BC2GM055710514 NN O
calcium-binding BC2GM055710514 NN O
motifs BC2GM055710514 NNS O
. BC2GM055710514 . O
. . O O

A. BC2GM024641386 NN O
thaliana BC2GM024641386 NNS O
cystathionine BC2GM024641386 VBP O
beta-lyase BC2GM024641386 JJ O
exhibits BC2GM024641386 NNS O
22 BC2GM024641386 CD O
% BC2GM024641386 NN O
sequence BC2GM024641386 NN O
identity BC2GM024641386 NN O
with BC2GM024641386 IN O
the BC2GM024641386 DT O
E. BC2GM024641386 NNP O
coli BC2GM024641386 NNS O
corresponding BC2GM024641386 VBG O
enzyme BC2GM024641386 NN O
and BC2GM024641386 CC O
contains BC2GM024641386 VBZ O
a BC2GM024641386 DT O
70 BC2GM024641386 CD O
amino BC2GM024641386 NN O
acid BC2GM024641386 JJ O
N-terminal BC2GM024641386 JJ O
additional BC2GM024641386 JJ O
sequence BC2GM024641386 NN O
compared BC2GM024641386 VBN O
with BC2GM024641386 IN O
the BC2GM024641386 DT O
bacterial BC2GM024641386 JJ O
protein BC2GM024641386 NN O
. BC2GM024641386 . O
. . O O

The BC2GM077359774 DT O
pattern BC2GM077359774 NN O
of BC2GM077359774 IN O
expression BC2GM077359774 NN O
of BC2GM077359774 IN O
this BC2GM077359774 DT O
and BC2GM077359774 CC O
other BC2GM077359774 JJ O
Chi26 BC2GM077359774 NNP O
/ BC2GM077359774 NNP O
Chi33 BC2GM077359774 NNP O
chimeric BC2GM077359774 JJ O
promoters BC2GM077359774 NNS O
suggest BC2GM077359774 VBP O
that BC2GM077359774 IN O
the BC2GM077359774 DT O
E-region BC2GM077359774 NNP O
contains BC2GM077359774 VBZ O
cis-acting BC2GM077359774 NN O
sequences BC2GM077359774 NNS O
which BC2GM077359774 WDT O
activate BC2GM077359774 VBP O
transcription BC2GM077359774 NN O
in BC2GM077359774 IN O
aleurone BC2GM077359774 NN O
and BC2GM077359774 CC O
silence BC2GM077359774 NN O
transcription BC2GM077359774 NN O
in BC2GM077359774 IN O
leaves BC2GM077359774 NNS O
. BC2GM077359774 . O
. . O O

We BC2GM030618899 PRP O
undertook BC2GM030618899 VBP O
this BC2GM030618899 DT O
study BC2GM030618899 NN O
to BC2GM030618899 TO O
examine BC2GM030618899 VB O
the BC2GM030618899 DT O
relationship BC2GM030618899 NN O
between BC2GM030618899 IN O
systemic BC2GM030618899 JJ O
oxygen BC2GM030618899 NN O
delivery BC2GM030618899 NN O
( BC2GM030618899 ( O
DO2 BC2GM030618899 NNP O
) BC2GM030618899 ) O
and BC2GM030618899 CC O
tissue BC2GM030618899 NN O
oxygen BC2GM030618899 NN O
tension BC2GM030618899 NN O
( BC2GM030618899 ( O
TPO2 BC2GM030618899 NNP O
) BC2GM030618899 ) O
in BC2GM030618899 IN O
hypovolemic BC2GM030618899 JJ O
shock BC2GM030618899 NN O
. BC2GM030618899 . O
. . O O

Reproduction BC2GM028481632 NN O
and BC2GM028481632 CC O
maternal BC2GM028481632 JJ O
response BC2GM028481632 NN O
of BC2GM028481632 IN O
the BC2GM028481632 DT O
rat BC2GM028481632 NN O
when BC2GM028481632 WRB O
thiamine BC2GM028481632 NN O
intake BC2GM028481632 NN O
is BC2GM028481632 VBZ O
limited BC2GM028481632 VBN O
. BC2GM028481632 . O
. . O O

Copyright BC2GM064638906 NN O
1998 BC2GM064638906 CD O
The BC2GM064638906 DT O
Association BC2GM064638906 NNP O
for BC2GM064638906 IN O
the BC2GM064638906 DT O
Study BC2GM064638906 NNP O
of BC2GM064638906 IN O
Animal BC2GM064638906 NNP O
Behaviour BC2GM064638906 NNP O
. BC2GM064638906 . O
. . O O

The BC2GM039715012 DT O
determination BC2GM039715012 NN O
of BC2GM039715012 IN O
antithrombin BC2GM039715012 JJ O
III BC2GM039715012 NNP O
( BC2GM039715012 ( O
AT BC2GM039715012 NNP O
III BC2GM039715012 NNP O
) BC2GM039715012 ) O
and BC2GM039715012 CC O
its BC2GM039715012 PRP$ O
clinical BC2GM039715012 JJ O
significance BC2GM039715012 NN O
. BC2GM039715012 . O
. . O O

Site-directed BC2GM097406919 JJ O
mutagenesis BC2GM097406919 NN O
of BC2GM097406919 IN O
the BC2GM097406919 DT O
conserved BC2GM097406919 JJ O
cysteine BC2GM097406919 NN O
residue BC2GM097406919 NN O
( BC2GM097406919 ( O
tom1C3235A BC2GM097406919 NN O
) BC2GM097406919 ) O
in BC2GM097406919 IN O
the BC2GM097406919 DT O
hect-domain BC2GM097406919 NN O
, BC2GM097406919 , O
supposed BC2GM097406919 VBN O
to BC2GM097406919 TO O
be BC2GM097406919 VB O
necessary BC2GM097406919 JJ O
for BC2GM097406919 IN O
thioester-bond BC2GM097406919 JJ O
formation BC2GM097406919 NN O
with BC2GM097406919 IN O
ubiquitin BC2GM097406919 JJ O
, BC2GM097406919 , O
abolished BC2GM097406919 VBD O
the BC2GM097406919 DT O
gene BC2GM097406919 NN O
function BC2GM097406919 NN O
. BC2GM097406919 . O
. . O O

METHODS BC2GM062323081 NNP O
AND BC2GM062323081 CC O
RESULTS BC2GM062323081 NNP O
: BC2GM062323081 : O
The BC2GM062323081 DT O
QTd BC2GM062323081 NNP O
and BC2GM062323081 CC O
JTd BC2GM062323081 NNP O
intervals BC2GM062323081 NNS O
in BC2GM062323081 IN O
39 BC2GM062323081 CD O
children BC2GM062323081 NNS O
with BC2GM062323081 IN O
long BC2GM062323081 JJ O
QT BC2GM062323081 NNP O
syndrome BC2GM062323081 NN O
were BC2GM062323081 VBD O
compared BC2GM062323081 VBN O
to BC2GM062323081 TO O
those BC2GM062323081 DT O
of BC2GM062323081 IN O
50 BC2GM062323081 CD O
normal BC2GM062323081 JJ O
age-matched BC2GM062323081 JJ O
children BC2GM062323081 NNS O
. BC2GM062323081 . O
. . O O

Biol BC2GM000365921 NNP O
. BC2GM000365921 . O
. . O O

In BC2GM068752767 IN O
contrast BC2GM068752767 NN O
, BC2GM068752767 , O
group BC2GM068752767 NN O
II BC2GM068752767 NNP O
showed BC2GM068752767 VBD O
a BC2GM068752767 DT O
significant BC2GM068752767 JJ O
improvement BC2GM068752767 NN O
in BC2GM068752767 IN O
peak BC2GM068752767 NN O
VO2 BC2GM068752767 NNP O
with BC2GM068752767 IN O
rate BC2GM068752767 NN O
adaptive BC2GM068752767 JJ O
AV BC2GM068752767 NNP O
delay BC2GM068752767 NN O
compared BC2GM068752767 VBN O
to BC2GM068752767 TO O
fixed BC2GM068752767 VBN O
AV BC2GM068752767 NNP O
delay BC2GM068752767 NN O
programming BC2GM068752767 NN O
( BC2GM068752767 ( O
P BC2GM068752767 NNP O
less BC2GM068752767 JJR O
than BC2GM068752767 IN O
0.05 BC2GM068752767 CD O
) BC2GM068752767 ) O
. BC2GM068752767 . O
. . O O

Thus BC2GM054621405 RB O
integration BC2GM054621405 NN O
host BC2GM054621405 NN O
factor BC2GM054621405 NN O
is BC2GM054621405 VBZ O
required BC2GM054621405 VBN O
for BC2GM054621405 IN O
normal BC2GM054621405 JJ O
type BC2GM054621405 NN O
1 BC2GM054621405 CD O
fimbriae BC2GM054621405 JJ O
phase BC2GM054621405 NN O
variation BC2GM054621405 NN O
in BC2GM054621405 IN O
E. BC2GM054621405 NNP O
coli BC2GM054621405 NNS O
. BC2GM054621405 . O
. . O O

Viral BC2GM043460200 NNP O
protein BC2GM043460200 NN O
U BC2GM043460200 NNP O
( BC2GM043460200 ( O
Vpu BC2GM043460200 NNP O
) BC2GM043460200 ) O
is BC2GM043460200 VBZ O
a BC2GM043460200 DT O
protein BC2GM043460200 NN O
encoded BC2GM043460200 VBN O
by BC2GM043460200 IN O
human BC2GM043460200 JJ O
immunodeficiency BC2GM043460200 NN O
virus BC2GM043460200 NN O
type BC2GM043460200 NN O
1 BC2GM043460200 CD O
( BC2GM043460200 ( O
HIV-1 BC2GM043460200 NNP O
) BC2GM043460200 ) O
that BC2GM043460200 WDT O
promotes BC2GM043460200 VBZ O
the BC2GM043460200 DT O
degradation BC2GM043460200 NN O
of BC2GM043460200 IN O
the BC2GM043460200 DT O
virus BC2GM043460200 NN O
receptor BC2GM043460200 NN O
, BC2GM043460200 , O
CD4 BC2GM043460200 NNP O
, BC2GM043460200 , O
and BC2GM043460200 CC O
enhances BC2GM043460200 VBZ O
the BC2GM043460200 DT O
release BC2GM043460200 NN O
of BC2GM043460200 IN O
virus BC2GM043460200 NN O
particles BC2GM043460200 NNS O
from BC2GM043460200 IN O
cells BC2GM043460200 NNS O
. BC2GM043460200 . O
. . O O

We BC2GM063432144 PRP O
show BC2GM063432144 VBP O
that BC2GM063432144 IN O
GCNF BC2GM063432144 NNP O
binds BC2GM063432144 VBZ O
to BC2GM063432144 TO O
one BC2GM063432144 CD O
of BC2GM063432144 IN O
the BC2GM063432144 DT O
two BC2GM063432144 CD O
DRO BC2GM063432144 NNP O
sequences BC2GM063432144 NNS O
in BC2GM063432144 IN O
the BC2GM063432144 DT O
Prm1 BC2GM063432144 NNP O
promoter BC2GM063432144 NN O
, BC2GM063432144 , O
and BC2GM063432144 CC O
to BC2GM063432144 TO O
the BC2GM063432144 DT O
DRO BC2GM063432144 NNP O
sequence BC2GM063432144 NN O
in BC2GM063432144 IN O
the BC2GM063432144 DT O
Prm2 BC2GM063432144 NNP O
promoter BC2GM063432144 NN O
in BC2GM063432144 IN O
a BC2GM063432144 DT O
specific BC2GM063432144 JJ O
manner BC2GM063432144 NN O
. BC2GM063432144 . O
. . O O

The BC2GM033838267 DT O
5-HT3 BC2GM033838267 JJ O
antagonist BC2GM033838267 NN O
ondansetron BC2GM033838267 NN O
reduced BC2GM033838267 VBD O
alcohol BC2GM033838267 JJ O
intake BC2GM033838267 NN O
in BC2GM033838267 IN O
both BC2GM033838267 CC O
the BC2GM033838267 DT O
medium BC2GM033838267 NN O
and BC2GM033838267 CC O
high BC2GM033838267 JJ O
alcohol BC2GM033838267 NN O
preferring BC2GM033838267 VBG O
rats BC2GM033838267 NNS O
at BC2GM033838267 IN O
doses BC2GM033838267 NNS O
between BC2GM033838267 IN O
0.01 BC2GM033838267 CD O
and BC2GM033838267 CC O
0.16 BC2GM033838267 CD O
mg BC2GM033838267 NN O
/ BC2GM033838267 NNP O
kg BC2GM033838267 NN O
. BC2GM033838267 . O
. . O O

Without BC2GM037181461 IN O
a BC2GM037181461 DT O
team BC2GM037181461 NN O
, BC2GM037181461 , O
there BC2GM037181461 EX O
is BC2GM037181461 VBZ O
little BC2GM037181461 JJ O
hope BC2GM037181461 NN O
for BC2GM037181461 IN O
fetal BC2GM037181461 JJ O
survival BC2GM037181461 NN O
; BC2GM037181461 : O
mortality BC2GM037181461 NN O
will BC2GM037181461 MD O
be BC2GM037181461 VB O
80-100 BC2GM037181461 JJ O
% BC2GM037181461 NN O
. BC2GM037181461 . O
. . O O

The BC2GM006080494 DT O
carboxyl-terminal BC2GM006080494 JJ O
75 BC2GM006080494 CD O
amino BC2GM006080494 JJ O
acids BC2GM006080494 NNS O
of BC2GM006080494 IN O
the BC2GM006080494 DT O
two BC2GM006080494 CD O
proteins BC2GM006080494 NNS O
contain BC2GM006080494 VBP O
the BC2GM006080494 DT O
bHLH BC2GM006080494 NN O
motif BC2GM006080494 NN O
and BC2GM006080494 CC O
differ BC2GM006080494 NN O
from BC2GM006080494 IN O
each BC2GM006080494 DT O
other BC2GM006080494 JJ O
by BC2GM006080494 IN O
only BC2GM006080494 JJ O
three BC2GM006080494 CD O
conservative BC2GM006080494 JJ O
amino BC2GM006080494 NN O
acid BC2GM006080494 NN O
changes BC2GM006080494 NNS O
, BC2GM006080494 , O
while BC2GM006080494 IN O
the BC2GM006080494 DT O
amino-terminal BC2GM006080494 JJ O
portions BC2GM006080494 NNS O
are BC2GM006080494 VBP O
markedly BC2GM006080494 RB O
divergent BC2GM006080494 JJ O
from BC2GM006080494 IN O
each BC2GM006080494 DT O
other BC2GM006080494 JJ O
. BC2GM006080494 . O
. . O O

We BC2GM045792980 PRP O
found BC2GM045792980 VBD O
that BC2GM045792980 IN O
in BC2GM045792980 IN O
premature BC2GM045792980 NN O
infants BC2GM045792980 NNS O
plasminogen BC2GM045792980 NN O
levels BC2GM045792980 NNS O
are BC2GM045792980 VBP O
low BC2GM045792980 JJ O
; BC2GM045792980 : O
thus BC2GM045792980 RB O
, BC2GM045792980 , O
defense BC2GM045792980 NN O
against BC2GM045792980 IN O
intra-alveolar BC2GM045792980 JJ O
fibrin BC2GM045792980 JJ O
deposition BC2GM045792980 NN O
during BC2GM045792980 IN O
birth BC2GM045792980 NN O
trauma BC2GM045792980 NN O
is BC2GM045792980 VBZ O
reduced BC2GM045792980 VBN O
. BC2GM045792980 . O
. . O O

( BC2GM075721646 ( O
1996 BC2GM075721646 CD O
) BC2GM075721646 ) O
J BC2GM075721646 NNP O
. BC2GM075721646 . O
. . O O

In BC2GM027793192 IN O
particular BC2GM027793192 JJ O
, BC2GM027793192 , O
lacZ BC2GM027793192 JJ O
transcripts BC2GM027793192 NNS O
synthesised BC2GM027793192 VBD O
this BC2GM027793192 DT O
way BC2GM027793192 NN O
are BC2GM027793192 VBP O
highly BC2GM027793192 RB O
unstable BC2GM027793192 JJ O
and BC2GM027793192 CC O
yield BC2GM027793192 JJ O
little BC2GM027793192 JJ O
beta-galactosidase BC2GM027793192 NN O
. BC2GM027793192 . O
. . O O

These BC2GM095342382 DT O
results BC2GM095342382 NNS O
indicate BC2GM095342382 VBP O
that BC2GM095342382 IN O
H-2RIIBP BC2GM095342382 NNP O
( BC2GM095342382 ( O
i BC2GM095342382 NN O
) BC2GM095342382 ) O
is BC2GM095342382 VBZ O
a BC2GM095342382 DT O
member BC2GM095342382 NN O
of BC2GM095342382 IN O
the BC2GM095342382 DT O
superfamily BC2GM095342382 NN O
of BC2GM095342382 IN O
nuclear BC2GM095342382 JJ O
hormone BC2GM095342382 NN O
receptors BC2GM095342382 NNS O
and BC2GM095342382 CC O
( BC2GM095342382 ( O
ii BC2GM095342382 NN O
) BC2GM095342382 ) O
may BC2GM095342382 MD O
regulate BC2GM095342382 VB O
not BC2GM095342382 RB O
only BC2GM095342382 RB O
MHC BC2GM095342382 NNP O
class BC2GM095342382 NN O
I BC2GM095342382 PRP O
genes BC2GM095342382 NNS O
but BC2GM095342382 CC O
also BC2GM095342382 RB O
genes BC2GM095342382 NNS O
containing BC2GM095342382 VBG O
the BC2GM095342382 DT O
ERE BC2GM095342382 NNP O
and BC2GM095342382 CC O
related BC2GM095342382 JJ O
sequences BC2GM095342382 NNS O
. BC2GM095342382 . O
. . O O

The BC2GM025499244 DT O
median BC2GM025499244 JJ O
levels BC2GM025499244 NNS O
of BC2GM025499244 IN O
t-PA BC2GM025499244 JJ O
Ag BC2GM025499244 NNP O
and BC2GM025499244 CC O
PAI BC2GM025499244 NNP O
in BC2GM025499244 IN O
plasma BC2GM025499244 NN O
were BC2GM025499244 VBD O
respectively BC2GM025499244 RB O
10.7 BC2GM025499244 CD O
ng BC2GM025499244 JJ O
/ BC2GM025499244 NN O
ml BC2GM025499244 NN O
( BC2GM025499244 ( O
interquartile BC2GM025499244 JJ O
range BC2GM025499244 NN O
8.6 BC2GM025499244 CD O
ng BC2GM025499244 JJ O
/ BC2GM025499244 NNP O
ml BC2GM025499244 NN O
) BC2GM025499244 ) O
and BC2GM025499244 CC O
15.7 BC2GM025499244 CD O
IU BC2GM025499244 NNP O
/ BC2GM025499244 NNP O
ml BC2GM025499244 NN O
( BC2GM025499244 ( O
interquartile BC2GM025499244 JJ O
range BC2GM025499244 NN O
12.2 BC2GM025499244 CD O
IU BC2GM025499244 NNP O
/ BC2GM025499244 NNP O
ml BC2GM025499244 NN O
) BC2GM025499244 ) O
. BC2GM025499244 . O
. . O O

In BC2GM089906052 IN O
addition BC2GM089906052 NN O
, BC2GM089906052 , O
these BC2GM089906052 DT O
results BC2GM089906052 NNS O
suggest BC2GM089906052 VBP O
that BC2GM089906052 IN O
the BC2GM089906052 DT O
interactions BC2GM089906052 NNS O
, BC2GM089906052 , O
and BC2GM089906052 CC O
consequently BC2GM089906052 RB O
the BC2GM089906052 DT O
mechanisms BC2GM089906052 NN O
, BC2GM089906052 , O
governing BC2GM089906052 VBG O
transcriptional BC2GM089906052 JJ O
activation BC2GM089906052 NN O
by BC2GM089906052 IN O
CTF BC2GM089906052 NNP O
are BC2GM089906052 VBP O
distinct BC2GM089906052 JJ O
from BC2GM089906052 IN O
those BC2GM089906052 DT O
mediating BC2GM089906052 VBG O
DNA BC2GM089906052 NNP O
replication BC2GM089906052 NN O
. BC2GM089906052 . O
. . O O

The BC2GM076892506 DT O
relation BC2GM076892506 NN O
between BC2GM076892506 IN O
the BC2GM076892506 DT O
changes BC2GM076892506 NNS O
of BC2GM076892506 IN O
bone BC2GM076892506 NN O
density BC2GM076892506 NN O
and BC2GM076892506 CC O
the BC2GM076892506 DT O
level BC2GM076892506 NN O
of BC2GM076892506 IN O
blood BC2GM076892506 NN O
calcium BC2GM076892506 NN O
, BC2GM076892506 , O
blood BC2GM076892506 NN O
phosphorus BC2GM076892506 NN O
and BC2GM076892506 CC O
alkaline BC2GM076892506 JJ O
phosphatase BC2GM076892506 NN O
( BC2GM076892506 ( O
AKP BC2GM076892506 NNP O
) BC2GM076892506 ) O
as BC2GM076892506 RB O
well BC2GM076892506 RB O
as BC2GM076892506 IN O
the BC2GM076892506 DT O
metabolism BC2GM076892506 NN O
of BC2GM076892506 IN O
vitamin BC2GM076892506 NN O
D BC2GM076892506 NNP O
was BC2GM076892506 VBD O
studied BC2GM076892506 VBN O
. BC2GM076892506 . O
. . O O

This BC2GM019284772 DT O
transformation BC2GM019284772 NN O
suppression BC2GM019284772 NN O
by BC2GM019284772 IN O
Rb BC2GM019284772 NNP O
was BC2GM019284772 VBD O
further BC2GM019284772 RBR O
shown BC2GM019284772 VBN O
to BC2GM019284772 TO O
be BC2GM019284772 VB O
due BC2GM019284772 JJ O
to BC2GM019284772 TO O
transcriptional BC2GM019284772 JJ O
repression BC2GM019284772 NN O
of BC2GM019284772 IN O
neu BC2GM019284772 JJ O
using BC2GM019284772 VBG O
Rb BC2GM019284772 NNP O
expressing BC2GM019284772 VBG O
effector BC2GM019284772 NN O
plasmid BC2GM019284772 NN O
and BC2GM019284772 CC O
neu BC2GM019284772 JJ O
promoter-chloramphenicol BC2GM019284772 JJ O
acetyltransferase BC2GM019284772 NN O
reporter BC2GM019284772 NN O
gene BC2GM019284772 NN O
. BC2GM019284772 . O
. . O O

This BC2GM064017613 DT O
chimera BC2GM064017613 NN O
transduced BC2GM064017613 VBD O
IL-4-specific BC2GM064017613 JJ O
signals BC2GM064017613 NNS O
in BC2GM064017613 IN O
response BC2GM064017613 NN O
to BC2GM064017613 TO O
IL-2 BC2GM064017613 NNP O
binding BC2GM064017613 NN O
and BC2GM064017613 CC O
dramatically BC2GM064017613 RB O
enhanced BC2GM064017613 VBD O
type BC2GM064017613 JJ O
2 BC2GM064017613 CD O
responses BC2GM064017613 NNS O
( BC2GM064017613 ( O
IL-4 BC2GM064017613 NNP O
, BC2GM064017613 , O
IL-5 BC2GM064017613 NNP O
, BC2GM064017613 , O
and BC2GM064017613 CC O
immunoglobulin BC2GM064017613 JJ O
E BC2GM064017613 NNP O
production BC2GM064017613 NN O
) BC2GM064017613 ) O
upon BC2GM064017613 IN O
in BC2GM064017613 IN O
vitro BC2GM064017613 NN O
TCR BC2GM064017613 NNP O
stimulation BC2GM064017613 NN O
or BC2GM064017613 CC O
in BC2GM064017613 IN O
vivo BC2GM064017613 JJ O
antigen BC2GM064017613 NN O
challenge BC2GM064017613 NN O
. BC2GM064017613 . O
. . O O

Androgen BC2GM026086766 NNP O
ablation BC2GM026086766 NN O
-- BC2GM026086766 : O
50 BC2GM026086766 CD O
years BC2GM026086766 NNS O
later BC2GM026086766 RB O
. BC2GM026086766 . O
. . O O

The BC2GM019432575 DT O
N1-P2 BC2GM019432575 NNP O
amplitudes BC2GM019432575 NNS O
of BC2GM019432575 IN O
the BC2GM019432575 DT O
AEP BC2GM019432575 NNP O
decreased BC2GM019432575 VBD O
with BC2GM019432575 IN O
increasing BC2GM019432575 VBG O
strength BC2GM019432575 NN O
of BC2GM019432575 IN O
muscular BC2GM019432575 JJ O
innervation BC2GM019432575 NN O
. BC2GM019432575 . O
. . O O

Thus BC2GM031800406 RB O
, BC2GM031800406 , O
the BC2GM031800406 DT O
i-leader BC2GM031800406 JJ O
protein BC2GM031800406 NN O
is BC2GM031800406 VBZ O
a BC2GM031800406 DT O
viral BC2GM031800406 JJ O
gene BC2GM031800406 NN O
product BC2GM031800406 NN O
of BC2GM031800406 IN O
unknown BC2GM031800406 JJ O
function BC2GM031800406 NN O
and BC2GM031800406 CC O
high BC2GM031800406 JJ O
stability BC2GM031800406 NN O
that BC2GM031800406 WDT O
is BC2GM031800406 VBZ O
made BC2GM031800406 VBN O
in BC2GM031800406 IN O
large BC2GM031800406 JJ O
quantities BC2GM031800406 NNS O
at BC2GM031800406 IN O
intermediate BC2GM031800406 JJ O
times BC2GM031800406 NNS O
of BC2GM031800406 IN O
productive BC2GM031800406 JJ O
infection BC2GM031800406 NN O
. BC2GM031800406 . O
( BC2GM031800406 ( O
ABSTRACT BC2GM031800406 NNP O
TRUNCATED BC2GM031800406 NNP O
AT BC2GM031800406 NNP O
400 BC2GM031800406 CD O
WORDS BC2GM031800406 NNP O
) BC2GM031800406 ) O
. BC2GM031800406 . O
. . O O

Protein BC2GM071692892 NNP O
sequencing BC2GM071692892 NN O
, BC2GM071692892 , O
electrophoretic BC2GM071692892 JJ O
mobility BC2GM071692892 NN O
shift BC2GM071692892 NN O
assay BC2GM071692892 NN O
, BC2GM071692892 , O
and BC2GM071692892 CC O
immunoblot BC2GM071692892 NN O
analyses BC2GM071692892 NNS O
identify BC2GM071692892 VBP O
p54 BC2GM071692892 NN O
and BC2GM071692892 CC O
p47 BC2GM071692892 NN O
/ BC2GM071692892 RB O
48 BC2GM071692892 CD O
as BC2GM071692892 IN O
members BC2GM071692892 NNS O
of BC2GM071692892 IN O
the BC2GM071692892 DT O
hepatocyte BC2GM071692892 NN O
nuclear BC2GM071692892 JJ O
factor BC2GM071692892 NN O
3 BC2GM071692892 CD O
( BC2GM071692892 ( O
HNF3 BC2GM071692892 NNP O
[ BC2GM071692892 NNP O
forkhead BC2GM071692892 VBP O
] BC2GM071692892 NNP O
) BC2GM071692892 ) O
family BC2GM071692892 NN O
of BC2GM071692892 IN O
transcription BC2GM071692892 NN O
factors BC2GM071692892 NNS O
. BC2GM071692892 . O
p54 BC2GM071692892 JJ O
belongs BC2GM071692892 NNS O
to BC2GM071692892 TO O
the BC2GM071692892 DT O
subfamily BC2GM071692892 NN O
of BC2GM071692892 IN O
HNF3 BC2GM071692892 NNP O
beta BC2GM071692892 NN O
proteins BC2GM071692892 NNS O
, BC2GM071692892 , O
while BC2GM071692892 IN O
p47 BC2GM071692892 JJ O
/ BC2GM071692892 $ O
48 BC2GM071692892 CD O
binding BC2GM071692892 NN O
activity BC2GM071692892 NN O
includes BC2GM071692892 VBZ O
HNF3 BC2GM071692892 NNP O
gamma BC2GM071692892 NN O
. BC2GM071692892 . O
. . O O

CONCLUSIONS BC2GM073017347 NN O
: BC2GM073017347 : O
In BC2GM073017347 IN O
the BC2GM073017347 DT O
majority BC2GM073017347 NN O
of BC2GM073017347 IN O
patients BC2GM073017347 NNS O
with BC2GM073017347 IN O
severe BC2GM073017347 JJ O
ulcerative BC2GM073017347 JJ O
colitis BC2GM073017347 NN O
, BC2GM073017347 , O
circulating BC2GM073017347 VBG O
concentrations BC2GM073017347 NNS O
of BC2GM073017347 IN O
NOX BC2GM073017347 NNP O
are BC2GM073017347 VBP O
increased BC2GM073017347 VBN O
at BC2GM073017347 IN O
presentation BC2GM073017347 NN O
and BC2GM073017347 CC O
fall BC2GM073017347 NN O
promptly BC2GM073017347 RB O
during BC2GM073017347 IN O
parenteral BC2GM073017347 JJ O
steroid BC2GM073017347 JJ O
therapy BC2GM073017347 NN O
, BC2GM073017347 , O
irrespective BC2GM073017347 NN O
of BC2GM073017347 IN O
clinical BC2GM073017347 JJ O
outcome BC2GM073017347 NN O
. BC2GM073017347 . O
. . O O

The BC2GM013853953 DT O
meaning BC2GM013853953 NN O
of BC2GM013853953 IN O
hope BC2GM013853953 NN O
in BC2GM013853953 IN O
health BC2GM013853953 NN O
and BC2GM013853953 CC O
illness BC2GM013853953 NN O
. BC2GM013853953 . O
. . O O

We BC2GM032251939 PRP O
were BC2GM032251939 VBD O
unable BC2GM032251939 JJ O
to BC2GM032251939 TO O
construct BC2GM032251939 VB O
chvI BC2GM032251939 NN O
or BC2GM032251939 CC O
chvG BC2GM032251939 NN O
insertion BC2GM032251939 NN O
mutants BC2GM032251939 NNS O
of BC2GM032251939 IN O
R. BC2GM032251939 NNP O
meliloti BC2GM032251939 NN O
, BC2GM032251939 , O
whereas BC2GM032251939 JJ O
mutants BC2GM032251939 NNS O
carrying BC2GM032251939 VBG O
insertions BC2GM032251939 NNS O
outside BC2GM032251939 IN O
of BC2GM032251939 IN O
these BC2GM032251939 DT O
genes BC2GM032251939 NNS O
were BC2GM032251939 VBD O
readily BC2GM032251939 RB O
obtained BC2GM032251939 VBN O
. BC2GM032251939 . O
. . O O

The BC2GM044742819 DT O
structure BC2GM044742819 NN O
of BC2GM044742819 IN O
the BC2GM044742819 DT O
murine BC2GM044742819 NN O
Dtk BC2GM044742819 NNP O
gene BC2GM044742819 NN O
has BC2GM044742819 VBZ O
been BC2GM044742819 VBN O
determined BC2GM044742819 VBN O
. BC2GM044742819 . O
. . O O

Compared BC2GM024601560 VBN O
with BC2GM024601560 IN O
controls BC2GM024601560 NNS O
, BC2GM024601560 , O
patients BC2GM024601560 NNS O
in BC2GM024601560 IN O
the BC2GM024601560 DT O
unmedicated BC2GM024601560 JJ O
state BC2GM024601560 NN O
had BC2GM024601560 VBD O
low BC2GM024601560 JJ O
smooth BC2GM024601560 JJ O
pursuit BC2GM024601560 NN O
gain BC2GM024601560 NN O
, BC2GM024601560 , O
had BC2GM024601560 VBD O
a BC2GM024601560 DT O
higher BC2GM024601560 JJR O
rate BC2GM024601560 NN O
of BC2GM024601560 IN O
corrective BC2GM024601560 JJ O
catch-up BC2GM024601560 JJ O
saccades BC2GM024601560 NNS O
, BC2GM024601560 , O
and BC2GM024601560 CC O
tended BC2GM024601560 VBD O
to BC2GM024601560 TO O
spend BC2GM024601560 VB O
less BC2GM024601560 JJR O
time BC2GM024601560 NN O
engaged BC2GM024601560 VBN O
in BC2GM024601560 IN O
the BC2GM024601560 DT O
tracking BC2GM024601560 NN O
task BC2GM024601560 NN O
. BC2GM024601560 . O
. . O O

Sequence BC2GM026261296 NNP O
analysis BC2GM026261296 NN O
of BC2GM026261296 IN O
the BC2GM026261296 DT O
catfish BC2GM026261296 JJ O
JH-CH BC2GM026261296 NNP O
intron BC2GM026261296 NN O
suggests BC2GM026261296 VBZ O
that BC2GM026261296 IN O
several BC2GM026261296 JJ O
sequences BC2GM026261296 NNS O
are BC2GM026261296 VBP O
present BC2GM026261296 JJ O
which BC2GM026261296 WDT O
appear BC2GM026261296 VBP O
similar BC2GM026261296 JJ O
to BC2GM026261296 TO O
important BC2GM026261296 JJ O
transcriptional BC2GM026261296 JJ O
regulatory BC2GM026261296 JJ O
elements BC2GM026261296 NNS O
found BC2GM026261296 VBD O
within BC2GM026261296 IN O
JH-CH BC2GM026261296 NNP O
introns BC2GM026261296 NNS O
of BC2GM026261296 IN O
higher BC2GM026261296 JJR O
vertebrates BC2GM026261296 NNS O
. BC2GM026261296 . O
. . O O

Serum BC2GM097944036 NNP O
triglycerides BC2GM097944036 NNS O
also BC2GM097944036 RB O
showed BC2GM097944036 VBD O
an BC2GM097944036 DT O
increase BC2GM097944036 NN O
from BC2GM097944036 IN O
birth BC2GM097944036 NN O
to BC2GM097944036 TO O
6 BC2GM097944036 CD O
months BC2GM097944036 NNS O
of BC2GM097944036 IN O
age BC2GM097944036 NN O
, BC2GM097944036 , O
but BC2GM097944036 CC O
a BC2GM097944036 DT O
decrease BC2GM097944036 NN O
from BC2GM097944036 IN O
6 BC2GM097944036 CD O
months BC2GM097944036 NNS O
to BC2GM097944036 TO O
1 BC2GM097944036 CD O
years BC2GM097944036 NNS O
of BC2GM097944036 IN O
age BC2GM097944036 NN O
. BC2GM097944036 . O
. . O O

Increase BC2GM031456280 NN O
in BC2GM031456280 IN O
[ BC2GM031456280 JJ O
Ca++ BC2GM031456280 NNP O
] BC2GM031456280 NNP O
counteracted BC2GM031456280 VBD O
the BC2GM031456280 DT O
effects BC2GM031456280 NNS O
of BC2GM031456280 IN O
verapamil BC2GM031456280 NN O
on BC2GM031456280 IN O
RAD BC2GM031456280 NNP O
. BC2GM031456280 . O
. . O O

This BC2GM081513417 DT O
resulted BC2GM081513417 VBD O
in BC2GM081513417 IN O
a BC2GM081513417 DT O
shift BC2GM081513417 NN O
of BC2GM081513417 IN O
C1 BC2GM081513417 NNP O
/ BC2GM081513417 NNP O
C2 BC2GM081513417 NNP O
, BC2GM081513417 , O
so BC2GM081513417 IN O
that BC2GM081513417 IN O
the BC2GM081513417 DT O
effect BC2GM081513417 NN O
of BC2GM081513417 IN O
collagen BC2GM081513417 NN O
was BC2GM081513417 VBD O
more BC2GM081513417 RBR O
pronounced BC2GM081513417 JJ O
( BC2GM081513417 ( O
maximal BC2GM081513417 JJ O
increase BC2GM081513417 NN O
of BC2GM081513417 IN O
C1 BC2GM081513417 NNP O
/ BC2GM081513417 NNP O
C2 BC2GM081513417 NNP O
= BC2GM081513417 VBD O
134 BC2GM081513417 CD O
% BC2GM081513417 NN O
) BC2GM081513417 ) O
than BC2GM081513417 IN O
ADP BC2GM081513417 NNP O
( BC2GM081513417 ( O
maximal BC2GM081513417 JJ O
increase BC2GM081513417 NN O
of BC2GM081513417 IN O
C1 BC2GM081513417 NNP O
/ BC2GM081513417 NNP O
C2 BC2GM081513417 NNP O
= BC2GM081513417 VBD O
79 BC2GM081513417 CD O
% BC2GM081513417 NN O
) BC2GM081513417 ) O
. BC2GM081513417 . O
. . O O

Pediatric BC2GM037814296 JJ O
patients BC2GM037814296 NNS O
-- BC2GM037814296 : O
handle BC2GM037814296 VB O
with BC2GM037814296 IN O
care BC2GM037814296 NN O
. BC2GM037814296 . O
. . O O

No BC2GM018887080 DT O
universally BC2GM018887080 RB O
accepted BC2GM018887080 VBN O
standardized BC2GM018887080 VBN O
classification BC2GM018887080 NN O
system BC2GM018887080 NN O
for BC2GM018887080 IN O
acne BC2GM018887080 JJ O
vulgaris BC2GM018887080 NN O
exists BC2GM018887080 NNS O
, BC2GM018887080 , O
although BC2GM018887080 IN O
there BC2GM018887080 EX O
is BC2GM018887080 VBZ O
a BC2GM018887080 DT O
strong BC2GM018887080 JJ O
need BC2GM018887080 NN O
for BC2GM018887080 IN O
it BC2GM018887080 PRP O
. BC2GM018887080 . O
. . O O

By BC2GM034824731 IN O
a BC2GM034824731 DT O
combination BC2GM034824731 NN O
of BC2GM034824731 IN O
alternative BC2GM034824731 JJ O
promoter BC2GM034824731 NN O
usage BC2GM034824731 NN O
and BC2GM034824731 CC O
exon BC2GM034824731 NN O
splicing BC2GM034824731 NN O
, BC2GM034824731 , O
each BC2GM034824731 DT O
ROR BC2GM034824731 NNP O
gene BC2GM034824731 NN O
generates BC2GM034824731 VBZ O
several BC2GM034824731 JJ O
isoforms BC2GM034824731 NNS O
that BC2GM034824731 WDT O
differ BC2GM034824731 VBP O
only BC2GM034824731 RB O
in BC2GM034824731 IN O
their BC2GM034824731 PRP$ O
amino BC2GM034824731 NN O
terminus BC2GM034824731 NN O
. BC2GM034824731 . O
. . O O

Custom-made BC2GM067535519 JJ O
orthoses BC2GM067535519 NNS O
play BC2GM067535519 VBP O
an BC2GM067535519 DT O
invaluable BC2GM067535519 JJ O
role BC2GM067535519 NN O
in BC2GM067535519 IN O
achieving BC2GM067535519 VBG O
a BC2GM067535519 DT O
wide BC2GM067535519 JJ O
range BC2GM067535519 NN O
of BC2GM067535519 IN O
therapeutic BC2GM067535519 JJ O
goals BC2GM067535519 NNS O
: BC2GM067535519 : O
improving BC2GM067535519 VBG O
function BC2GM067535519 NN O
and BC2GM067535519 CC O
pinch BC2GM067535519 NN O
, BC2GM067535519 , O
stabilizing BC2GM067535519 VBG O
individual BC2GM067535519 JJ O
joints BC2GM067535519 NNS O
, BC2GM067535519 , O
preventing BC2GM067535519 VBG O
positional BC2GM067535519 JJ O
contractures BC2GM067535519 NNS O
, BC2GM067535519 , O
protecting BC2GM067535519 VBG O
joints BC2GM067535519 NNS O
from BC2GM067535519 IN O
trauma BC2GM067535519 NN O
, BC2GM067535519 , O
stretching BC2GM067535519 VBG O
the BC2GM067535519 DT O
intrinsic BC2GM067535519 JJ O
muscles BC2GM067535519 NNS O
, BC2GM067535519 , O
correcting BC2GM067535519 VBG O
joint- BC2GM067535519 NN O
and BC2GM067535519 CC O
soft-tissue BC2GM067535519 NN O
contractures BC2GM067535519 NNS O
, BC2GM067535519 , O
and BC2GM067535519 CC O
controlling BC2GM067535519 VBG O
inflammation BC2GM067535519 NN O
. BC2GM067535519 . O
. . O O

Electrophoretic BC2GM003302721 JJ O
mobility-shift BC2GM003302721 NN O
assays BC2GM003302721 NNS O
between BC2GM003302721 IN O
viral BC2GM003302721 JJ O
RNA BC2GM003302721 NNP O
and BC2GM003302721 CC O
BMV BC2GM003302721 NNP O
CP BC2GM003302721 NNP O
peptides BC2GM003302721 VBZ O
with BC2GM003302721 IN O
either BC2GM003302721 DT O
proline BC2GM003302721 NN O
or BC2GM003302721 CC O
alanine BC2GM003302721 JJ O
substitutions BC2GM003302721 NNS O
revealed BC2GM003302721 VBD O
that BC2GM003302721 IN O
the BC2GM003302721 DT O
interaction BC2GM003302721 NN O
is BC2GM003302721 VBZ O
nonspecific BC2GM003302721 JJ O
. BC2GM003302721 . O
. . O O

Thus BC2GM092925197 RB O
, BC2GM092925197 , O
in BC2GM092925197 IN O
addition BC2GM092925197 NN O
to BC2GM092925197 TO O
the BC2GM092925197 DT O
previously BC2GM092925197 RB O
characterized BC2GM092925197 VBN O
FAS-binding BC2GM092925197 NNP O
factor BC2GM092925197 NN O
1 BC2GM092925197 CD O
interacting BC2GM092925197 NN O
with BC2GM092925197 IN O
the BC2GM092925197 DT O
inositol BC2GM092925197 JJ O
/ BC2GM092925197 JJ O
choline-responsive-element BC2GM092925197 JJ O
motif BC2GM092925197 NN O
, BC2GM092925197 , O
a BC2GM092925197 DT O
second BC2GM092925197 JJ O
motif BC2GM092925197 NN O
common BC2GM092925197 JJ O
to BC2GM092925197 TO O
the BC2GM092925197 DT O
promoter BC2GM092925197 NN O
regions BC2GM092925197 NNS O
of BC2GM092925197 IN O
both BC2GM092925197 DT O
FAS BC2GM092925197 NNP O
genes BC2GM092925197 NNS O
could BC2GM092925197 MD O
be BC2GM092925197 VB O
identified BC2GM092925197 VBN O
. BC2GM092925197 . O
. . O O

The BC2GM088793769 DT O
MEF-2 BC2GM088793769 JJ O
proteins BC2GM088793769 NNS O
are BC2GM088793769 VBP O
a BC2GM088793769 DT O
family BC2GM088793769 NN O
of BC2GM088793769 IN O
transcriptional BC2GM088793769 JJ O
activators BC2GM088793769 NNS O
that BC2GM088793769 WDT O
have BC2GM088793769 VBP O
been BC2GM088793769 VBN O
detected BC2GM088793769 VBN O
in BC2GM088793769 IN O
a BC2GM088793769 DT O
wide BC2GM088793769 JJ O
variety BC2GM088793769 NN O
of BC2GM088793769 IN O
cell BC2GM088793769 NN O
types BC2GM088793769 NNS O
. BC2GM088793769 . O
. . O O

Chromosome-specific BC2GM017291390 JJ O
STSs BC2GM017291390 NNP O
for BC2GM017291390 IN O
27 BC2GM017291390 CD O
telomeres BC2GM017291390 NNS O
were BC2GM017291390 VBD O
identified BC2GM017291390 VBN O
from BC2GM017291390 IN O
the BC2GM017291390 DT O
196 BC2GM017291390 CD O
TYACs BC2GM017291390 NNP O
. BC2GM017291390 . O
. . O O

The BC2GM012757246 DT O
nucleotide BC2GM012757246 JJ O
sequence BC2GM012757246 NN O
of BC2GM012757246 IN O
the BC2GM012757246 DT O
estrogen BC2GM012757246 NN O
receptor BC2GM012757246 NN O
gene BC2GM012757246 NN O
of BC2GM012757246 IN O
Oreochromis BC2GM012757246 NNP O
aureus BC2GM012757246 NN O
( BC2GM012757246 ( O
OaER BC2GM012757246 NNP O
) BC2GM012757246 ) O
indicates BC2GM012757246 VBZ O
that BC2GM012757246 IN O
the BC2GM012757246 DT O
hormone-binding BC2GM012757246 JJ O
E BC2GM012757246 NNP O
domain BC2GM012757246 NN O
is BC2GM012757246 VBZ O
composed BC2GM012757246 VBN O
of BC2GM012757246 IN O
4 BC2GM012757246 CD O
exons BC2GM012757246 NNS O
interspersed BC2GM012757246 VBN O
by BC2GM012757246 IN O
short BC2GM012757246 JJ O
introns BC2GM012757246 NNS O
of BC2GM012757246 IN O
only BC2GM012757246 RB O
0.18-1.3 BC2GM012757246 JJ O
kb BC2GM012757246 NNS O
each BC2GM012757246 DT O
. BC2GM012757246 . O
. . O O

2 BC2GM007772947 CD O
) BC2GM007772947 ) O
Depending BC2GM007772947 VBG O
on BC2GM007772947 IN O
the BC2GM007772947 DT O
structure BC2GM007772947 NN O
, BC2GM007772947 , O
certain BC2GM007772947 JJ O
compounds BC2GM007772947 NNS O
are BC2GM007772947 VBP O
sequestered BC2GM007772947 VBN O
in BC2GM007772947 IN O
the BC2GM007772947 DT O
cornea BC2GM007772947 NN O
( BC2GM007772947 ( O
presumably BC2GM007772947 RB O
the BC2GM007772947 DT O
stroma BC2GM007772947 NN O
) BC2GM007772947 ) O
and BC2GM007772947 CC O
form BC2GM007772947 VB O
a BC2GM007772947 DT O
release BC2GM007772947 NN O
system BC2GM007772947 NN O
into BC2GM007772947 IN O
the BC2GM007772947 DT O
anterior BC2GM007772947 JJ O
aqueous BC2GM007772947 JJ O
. BC2GM007772947 . O
. . O O

Juvenile BC2GM021696117 NNP O
angiofibromas BC2GM021696117 NN O
. BC2GM021696117 . O
. . O O

The BC2GM052040080 DT O
phenomena BC2GM052040080 NN O
of BC2GM052040080 IN O
nursing BC2GM052040080 NN O
are BC2GM052040080 VBP O
deeply BC2GM052040080 RB O
rooted BC2GM052040080 VBN O
in BC2GM052040080 IN O
the BC2GM052040080 DT O
human BC2GM052040080 JJ O
condition BC2GM052040080 NN O
. BC2GM052040080 . O
. . O O

The BC2GM007702287 DT O
following BC2GM007702287 JJ O
parameters BC2GM007702287 NNS O
were BC2GM007702287 VBD O
measured BC2GM007702287 VBN O
: BC2GM007702287 : O
onset BC2GM007702287 JJ O
time BC2GM007702287 NN O
( BC2GM007702287 ( O
time BC2GM007702287 NN O
interval BC2GM007702287 NN O
from BC2GM007702287 IN O
injection BC2GM007702287 NN O
to BC2GM007702287 TO O
maximal BC2GM007702287 VB O
or BC2GM007702287 CC O
total BC2GM007702287 JJ O
block BC2GM007702287 NN O
) BC2GM007702287 ) O
, BC2GM007702287 , O
T125 BC2GM007702287 NNP O
/ BC2GM007702287 VBZ O
75 BC2GM007702287 CD O
( BC2GM007702287 ( O
time BC2GM007702287 NN O
for BC2GM007702287 IN O
T1 BC2GM007702287 NNP O
to BC2GM007702287 TO O
reach BC2GM007702287 VB O
25 BC2GM007702287 CD O
% BC2GM007702287 NN O
or BC2GM007702287 CC O
75 BC2GM007702287 CD O
% BC2GM007702287 NN O
of BC2GM007702287 IN O
control BC2GM007702287 NN O
) BC2GM007702287 ) O
, BC2GM007702287 , O
TOF70 BC2GM007702287 NNP O
( BC2GM007702287 ( O
time BC2GM007702287 NN O
for BC2GM007702287 IN O
TOF BC2GM007702287 NNP O
ratio BC2GM007702287 NN O
to BC2GM007702287 TO O
reach BC2GM007702287 VB O
70 BC2GM007702287 CD O
% BC2GM007702287 NN O
of BC2GM007702287 IN O
control BC2GM007702287 NN O
) BC2GM007702287 ) O
, BC2GM007702287 , O
heart BC2GM007702287 NN O
rate BC2GM007702287 NN O
and BC2GM007702287 CC O
blood BC2GM007702287 NN O
pressure BC2GM007702287 NN O
. BC2GM007702287 . O
. . O O

The BC2GM084985682 DT O
central BC2GM084985682 JJ O
region BC2GM084985682 NN O
of BC2GM084985682 IN O
the BC2GM084985682 DT O
sarcomere BC2GM084985682 NN O
, BC2GM084985682 , O
coincident BC2GM084985682 NN O
with BC2GM084985682 IN O
the BC2GM084985682 DT O
M BC2GM084985682 NNP O
line BC2GM084985682 NN O
, BC2GM084985682 , O
was BC2GM084985682 VBD O
selectively BC2GM084985682 RB O
labeled BC2GM084985682 VBN O
with BC2GM084985682 IN O
antibodies BC2GM084985682 NNS O
to BC2GM084985682 TO O
the BC2GM084985682 DT O
short BC2GM084985682 JJ O
C-terminal BC2GM084985682 JJ O
form BC2GM084985682 NN O
. BC2GM084985682 . O
. . O O

BACKGROUND BC2GM093024251 NN O
: BC2GM093024251 : O
Murine BC2GM093024251 NNP O
Nramp BC2GM093024251 NNP O
is BC2GM093024251 VBZ O
a BC2GM093024251 DT O
candidate BC2GM093024251 NN O
for BC2GM093024251 IN O
the BC2GM093024251 DT O
macrophage BC2GM093024251 NN O
resistance BC2GM093024251 NN O
gene BC2GM093024251 NN O
Ity BC2GM093024251 NNP O
/ BC2GM093024251 NNP O
Lsh BC2GM093024251 NNP O
/ BC2GM093024251 NNP O
Bcg BC2GM093024251 NNP O
. BC2GM093024251 . O
. . O O

Genetic BC2GM023754004 NNP O
and BC2GM023754004 CC O
physiological BC2GM023754004 JJ O
experiments BC2GM023754004 NNS O
suggest BC2GM023754004 VBP O
a BC2GM023754004 DT O
close BC2GM023754004 JJ O
relationship BC2GM023754004 NN O
between BC2GM023754004 IN O
cdc27+ BC2GM023754004 NN O
and BC2GM023754004 CC O
the BC2GM023754004 DT O
cdc2+ BC2GM023754004 NN O
gene BC2GM023754004 NN O
, BC2GM023754004 , O
a BC2GM023754004 DT O
key BC2GM023754004 JJ O
regulator BC2GM023754004 NN O
of BC2GM023754004 IN O
mitosis BC2GM023754004 NN O
in BC2GM023754004 IN O
yeast BC2GM023754004 NN O
and BC2GM023754004 CC O
also BC2GM023754004 RB O
in BC2GM023754004 IN O
higher BC2GM023754004 JJR O
eukaryotic BC2GM023754004 JJ O
cells BC2GM023754004 NNS O
. BC2GM023754004 . O
. . O O

The BC2GM010615307 DT O
influence BC2GM010615307 NN O
of BC2GM010615307 IN O
a BC2GM010615307 DT O
high BC2GM010615307 JJ O
n-3 BC2GM010615307 JJ O
PUFA BC2GM010615307 NNP O
intake BC2GM010615307 NN O
on BC2GM010615307 IN O
measures BC2GM010615307 NNS O
of BC2GM010615307 IN O
lipid BC2GM010615307 JJ O
peroxidation BC2GM010615307 NN O
has BC2GM010615307 VBZ O
been BC2GM010615307 VBN O
equivocal BC2GM010615307 JJ O
. BC2GM010615307 . O
. . O O

Are BC2GM038107026 NNP O
there BC2GM038107026 EX O
any BC2GM038107026 DT O
lessons BC2GM038107026 NNS O
to BC2GM038107026 TO O
be BC2GM038107026 VB O
learnt BC2GM038107026 VBN O
? BC2GM038107026 . O
. BC2GM038107026 . O
. . O O

Recombinant BC2GM035479139 JJ O
mouse BC2GM035479139 NN O
GSTT1-1 BC2GM035479139 NNP O
was BC2GM035479139 VBD O
catalytically BC2GM035479139 RB O
active BC2GM035479139 JJ O
towards BC2GM035479139 NNS O
1 BC2GM035479139 CD O
, BC2GM035479139 , O
2-epoxy-3- BC2GM035479139 JJ O
( BC2GM035479139 ( O
p-nitrophenoxy BC2GM035479139 JJ O
) BC2GM035479139 ) O
propane BC2GM035479139 NN O
, BC2GM035479139 , O
4-nitrobenzyl BC2GM035479139 JJ O
chloride BC2GM035479139 NN O
and BC2GM035479139 CC O
dichloromethane BC2GM035479139 NN O
. BC2GM035479139 . O
. . O O

Expression BC2GM084033136 NN O
, BC2GM084033136 , O
characterization BC2GM084033136 NN O
, BC2GM084033136 , O
and BC2GM084033136 CC O
genomic BC2GM084033136 JJ O
structure BC2GM084033136 NN O
of BC2GM084033136 IN O
carp BC2GM084033136 NN O
JAK1 BC2GM084033136 NNP O
kinase BC2GM084033136 NN O
gene BC2GM084033136 NN O
. BC2GM084033136 . O
. . O O

A BC2GM009855865 DT O
porcine BC2GM009855865 JJ O
model BC2GM009855865 NN O
of BC2GM009855865 IN O
diffuse BC2GM009855865 NN O
axonal BC2GM009855865 JJ O
injury BC2GM009855865 NN O
, BC2GM009855865 , O
developed BC2GM009855865 VBN O
with BC2GM009855865 IN O
information BC2GM009855865 NN O
from BC2GM009855865 IN O
these BC2GM009855865 DT O
physical BC2GM009855865 JJ O
models BC2GM009855865 NNS O
and BC2GM009855865 CC O
earlier BC2GM009855865 RBR O
in BC2GM009855865 IN O
vitro BC2GM009855865 JJ O
tissue BC2GM009855865 NN O
modeling BC2GM009855865 VBG O
studies BC2GM009855865 NNS O
, BC2GM009855865 , O
is BC2GM009855865 VBZ O
used BC2GM009855865 VBN O
to BC2GM009855865 TO O
correlate BC2GM009855865 VB O
histologic BC2GM009855865 NN O
and BC2GM009855865 CC O
radiologic BC2GM009855865 JJ O
evidence BC2GM009855865 NN O
of BC2GM009855865 IN O
axonal BC2GM009855865 JJ O
injury BC2GM009855865 NN O
to BC2GM009855865 TO O
predicted BC2GM009855865 VBN O
regions BC2GM009855865 NNS O
of BC2GM009855865 IN O
injury BC2GM009855865 NN O
from BC2GM009855865 IN O
the BC2GM009855865 DT O
experimental BC2GM009855865 JJ O
and BC2GM009855865 CC O
theoretical BC2GM009855865 JJ O
analysis BC2GM009855865 NN O
. BC2GM009855865 . O
. . O O

It BC2GM086255271 PRP O
is BC2GM086255271 VBZ O
recommended BC2GM086255271 VBN O
that BC2GM086255271 IN O
area BC2GM086255271 NN O
correction BC2GM086255271 NN O
be BC2GM086255271 VB O
attempted BC2GM086255271 VBN O
in BC2GM086255271 IN O
bioequivalence BC2GM086255271 NN O
studies BC2GM086255271 NNS O
of BC2GM086255271 IN O
drugs BC2GM086255271 NNS O
where BC2GM086255271 WRB O
high BC2GM086255271 JJ O
intrasubject BC2GM086255271 JJ O
variability BC2GM086255271 NN O
in BC2GM086255271 IN O
clearance BC2GM086255271 NN O
is BC2GM086255271 VBZ O
known BC2GM086255271 VBN O
or BC2GM086255271 CC O
suspected BC2GM086255271 VBN O
. BC2GM086255271 . O
. . O O

The BC2GM043491752 DT O
overall BC2GM043491752 JJ O
objective BC2GM043491752 JJ O
response BC2GM043491752 NN O
rate BC2GM043491752 NN O
( BC2GM043491752 ( O
RR BC2GM043491752 NNP O
) BC2GM043491752 ) O
was BC2GM043491752 VBD O
50 BC2GM043491752 CD O
% BC2GM043491752 NN O
[ BC2GM043491752 JJ O
95 BC2GM043491752 CD O
% BC2GM043491752 NN O
confidence BC2GM043491752 NN O
interval BC2GM043491752 NN O
( BC2GM043491752 ( O
CI BC2GM043491752 NNP O
) BC2GM043491752 ) O
= BC2GM043491752 VBD O
29-71 BC2GM043491752 CD O
% BC2GM043491752 NN O
] BC2GM043491752 CC O
including BC2GM043491752 VBG O
four BC2GM043491752 CD O
complete BC2GM043491752 JJ O
responses BC2GM043491752 NNS O
and BC2GM043491752 CC O
eight BC2GM043491752 CD O
partial BC2GM043491752 JJ O
responses BC2GM043491752 NNS O
. BC2GM043491752 . O
. . O O

Several BC2GM088697037 JJ O
35-mm BC2GM088697037 CD O
slides BC2GM088697037 NNS O
of BC2GM088697037 IN O
dystrophin- BC2GM088697037 JJ O
, BC2GM088697037 , O
laminin- BC2GM088697037 JJ O
, BC2GM088697037 , O
and BC2GM088697037 CC O
concanavalin BC2GM088697037 VB O
A BC2GM088697037 NNP O
( BC2GM088697037 ( O
ConA BC2GM088697037 NNP O
) BC2GM088697037 ) O
-stained BC2GM088697037 VBD O
muscle BC2GM088697037 NN O
sections BC2GM088697037 NNS O
were BC2GM088697037 VBD O
used BC2GM088697037 VBN O
to BC2GM088697037 TO O
calculate BC2GM088697037 VB O
myofiber BC2GM088697037 NNP O
cross-sectional BC2GM088697037 JJ O
areas BC2GM088697037 NNS O
and BC2GM088697037 CC O
to BC2GM088697037 TO O
compare BC2GM088697037 VB O
different BC2GM088697037 JJ O
techniques BC2GM088697037 NNS O
and BC2GM088697037 CC O
settings BC2GM088697037 NNS O
of BC2GM088697037 IN O
an BC2GM088697037 DT O
image BC2GM088697037 NN O
capture BC2GM088697037 NN O
system BC2GM088697037 NN O
. BC2GM088697037 . O
. . O O

The BC2GM041957406 DT O
introduction BC2GM041957406 NN O
gives BC2GM041957406 VBZ O
also BC2GM041957406 RB O
the BC2GM041957406 DT O
history BC2GM041957406 NN O
of BC2GM041957406 IN O
Research BC2GM041957406 NNP O
Programme BC2GM041957406 NNP O
MZ-XVII BC2GM041957406 NNP O
and BC2GM041957406 CC O
its BC2GM041957406 PRP$ O
implementation BC2GM041957406 NN O
in BC2GM041957406 IN O
several BC2GM041957406 JJ O
regions BC2GM041957406 NNS O
of BC2GM041957406 IN O
Poland BC2GM041957406 NNP O
. BC2GM041957406 . O
. . O O

Our BC2GM062155957 PRP$ O
results BC2GM062155957 NNS O
show BC2GM062155957 VBP O
that BC2GM062155957 IN O
a BC2GM062155957 DT O
combination BC2GM062155957 NN O
of BC2GM062155957 IN O
Pfu BC2GM062155957 NNP O
exo BC2GM062155957 NN O
( BC2GM062155957 ( O
- BC2GM062155957 : O
) BC2GM062155957 ) O
at BC2GM062155957 IN O
the BC2GM062155957 DT O
primer BC2GM062155957 NN O
extension BC2GM062155957 NN O
step BC2GM062155957 NN O
and BC2GM062155957 CC O
Taq BC2GM062155957 NNP O
at BC2GM062155957 IN O
the BC2GM062155957 DT O
PCR BC2GM062155957 NNP O
amplification BC2GM062155957 NN O
step BC2GM062155957 NN O
is BC2GM062155957 VBZ O
ideal BC2GM062155957 JJ O
for BC2GM062155957 IN O
in BC2GM062155957 IN O
vivo BC2GM062155957 NN O
DNA BC2GM062155957 NNP O
analysis BC2GM062155957 NN O
and BC2GM062155957 CC O
DNA BC2GM062155957 NNP O
damage BC2GM062155957 NN O
mapping BC2GM062155957 VBG O
using BC2GM062155957 VBG O
LMPCR BC2GM062155957 NNP O
. BC2GM062155957 . O
. . O O

The BC2GM035406397 DT O
apparent BC2GM035406397 JJ O
binding BC2GM035406397 NN O
constant BC2GM035406397 NN O
of BC2GM035406397 IN O
6 BC2GM035406397 CD O
to BC2GM035406397 TO O
calf BC2GM035406397 VB O
thymus BC2GM035406397 JJ O
DNA BC2GM035406397 NNP O
is BC2GM035406397 VBZ O
1.68 BC2GM035406397 CD O
X BC2GM035406397 NN O
10 BC2GM035406397 CD O
( BC2GM035406397 ( O
5 BC2GM035406397 CD O
) BC2GM035406397 ) O
M-1 BC2GM035406397 NNP O
whereas BC2GM035406397 IN O
netropsin BC2GM035406397 NN O
under BC2GM035406397 IN O
similar BC2GM035406397 JJ O
conditions BC2GM035406397 NNS O
gives BC2GM035406397 VBZ O
a BC2GM035406397 DT O
value BC2GM035406397 NN O
of BC2GM035406397 IN O
1.85 BC2GM035406397 CD O
X BC2GM035406397 NNS O
10 BC2GM035406397 CD O
( BC2GM035406397 ( O
7 BC2GM035406397 CD O
) BC2GM035406397 ) O
M-1 BC2GM035406397 NN O
. BC2GM035406397 . O
. . O O

A BC2GM041578046 DT O
GTP BC2GM041578046 NNP O
/ BC2GM041578046 NNP O
GDP BC2GM041578046 NNP O
exchange BC2GM041578046 NN O
assay BC2GM041578046 NN O
was BC2GM041578046 VBD O
used BC2GM041578046 VBN O
to BC2GM041578046 TO O
assess BC2GM041578046 VB O
the BC2GM041578046 DT O
potential BC2GM041578046 JJ O
role BC2GM041578046 NN O
of BC2GM041578046 IN O
Ras BC2GM041578046 NNP O
in BC2GM041578046 IN O
the BC2GM041578046 DT O
pathway BC2GM041578046 NN O
leading BC2GM041578046 VBG O
to BC2GM041578046 TO O
ERK BC2GM041578046 NNP O
phosphorylation BC2GM041578046 NN O
; BC2GM041578046 : O
DADLE BC2GM041578046 NNP O
failed BC2GM041578046 VBD O
to BC2GM041578046 TO O
stimulate BC2GM041578046 VB O
GTP BC2GM041578046 NNP O
/ BC2GM041578046 NNP O
GDP BC2GM041578046 NNP O
exchange BC2GM041578046 NN O
in BC2GM041578046 IN O
comparison BC2GM041578046 NN O
to BC2GM041578046 TO O
PMA BC2GM041578046 NNP O
. BC2GM041578046 . O
. . O O

Mutant BC2GM025315374 NNP O
M BC2GM025315374 NNP O
proteins BC2GM025315374 NNS O
were BC2GM025315374 VBD O
tested BC2GM025315374 VBN O
for BC2GM025315374 IN O
their BC2GM025315374 PRP$ O
ability BC2GM025315374 NN O
to BC2GM025315374 TO O
complement BC2GM025315374 VB O
growth BC2GM025315374 NN O
of BC2GM025315374 IN O
the BC2GM025315374 DT O
temperature-sensitive BC2GM025315374 JJ O
M BC2GM025315374 NNP O
protein BC2GM025315374 NN O
mutant BC2GM025315374 NN O
virus BC2GM025315374 NN O
tsO23 BC2GM025315374 NN O
at BC2GM025315374 IN O
the BC2GM025315374 DT O
nonpermissive BC2GM025315374 JJ O
temperature BC2GM025315374 NN O
. BC2GM025315374 . O
. . O O

This BC2GM035302816 DT O
set BC2GM035302816 NN O
of BC2GM035302816 IN O
genetic BC2GM035302816 JJ O
and BC2GM035302816 CC O
physical BC2GM035302816 JJ O
interactions BC2GM035302816 NNS O
suggests BC2GM035302816 VBZ O
a BC2GM035302816 DT O
role BC2GM035302816 NN O
for BC2GM035302816 IN O
yeast BC2GM035302816 JJ O
RNA-binding BC2GM035302816 JJ O
proteins BC2GM035302816 NNS O
in BC2GM035302816 IN O
transcriptional BC2GM035302816 JJ O
regulation BC2GM035302816 NN O
. BC2GM035302816 . O
. . O O

FTF BC2GM095213644 NNP O
( BC2GM095213644 ( O
Joint BC2GM095213644 NNP O
Council BC2GM095213644 NNP O
of BC2GM095213644 IN O
Civil BC2GM095213644 NNP O
Servants BC2GM095213644 NNP O
and BC2GM095213644 CC O
Functionaries BC2GM095213644 NNPS O
) BC2GM095213644 ) O
: BC2GM095213644 : O
clarification BC2GM095213644 NN O
about BC2GM095213644 IN O
membership BC2GM095213644 NN O
in BC2GM095213644 IN O
the BC2GM095213644 DT O
main BC2GM095213644 JJ O
organizations BC2GM095213644 NNS O
. BC2GM095213644 . O
. . O O

Both BC2GM093016277 DT O
algorithms BC2GM093016277 NNS O
have BC2GM093016277 VBP O
been BC2GM093016277 VBN O
implemented BC2GM093016277 VBN O
and BC2GM093016277 CC O
applied BC2GM093016277 VBN O
to BC2GM093016277 TO O
data BC2GM093016277 NNS O
simulated BC2GM093016277 VBN O
for BC2GM093016277 IN O
a BC2GM093016277 DT O
scanner BC2GM093016277 NN O
with BC2GM093016277 IN O
a BC2GM093016277 DT O
large BC2GM093016277 JJ O
axial BC2GM093016277 JJ O
aperture BC2GM093016277 NN O
( BC2GM093016277 ( O
30 BC2GM093016277 CD O
degrees BC2GM093016277 NNS O
) BC2GM093016277 ) O
, BC2GM093016277 , O
and BC2GM093016277 CC O
also BC2GM093016277 RB O
to BC2GM093016277 TO O
data BC2GM093016277 NNS O
acquired BC2GM093016277 VBN O
with BC2GM093016277 IN O
the BC2GM093016277 DT O
ECAT BC2GM093016277 NNP O
HR BC2GM093016277 NNP O
and BC2GM093016277 CC O
the BC2GM093016277 DT O
ECAT BC2GM093016277 NNP O
HR+ BC2GM093016277 NNP O
scanners BC2GM093016277 NNS O
. BC2GM093016277 . O
. . O O

The BC2GM079167914 DT O
relationship BC2GM079167914 NN O
between BC2GM079167914 IN O
CSF BC2GM079167914 NNP O
somatostatin BC2GM079167914 NN O
and BC2GM079167914 CC O
peripheral BC2GM079167914 JJ O
thyroid BC2GM079167914 NN O
hormones BC2GM079167914 NNS O
was BC2GM079167914 VBD O
assessed BC2GM079167914 VBN O
in BC2GM079167914 IN O
11 BC2GM079167914 CD O
affectively BC2GM079167914 RB O
ill BC2GM079167914 JJ O
patients BC2GM079167914 NNS O
before BC2GM079167914 IN O
and BC2GM079167914 CC O
during BC2GM079167914 IN O
carbamazepine BC2GM079167914 JJ O
treatment BC2GM079167914 NN O
. BC2GM079167914 . O
. . O O

The BC2GM090038156 DT O
cloning BC2GM090038156 NN O
of BC2GM090038156 IN O
human BC2GM090038156 JJ O
apo BC2GM090038156 NN O
B-100 BC2GM090038156 NNP O
has BC2GM090038156 VBZ O
provided BC2GM090038156 VBN O
new BC2GM090038156 JJ O
insights BC2GM090038156 NNS O
into BC2GM090038156 IN O
the BC2GM090038156 DT O
structure BC2GM090038156 NN O
and BC2GM090038156 CC O
physicochemical BC2GM090038156 JJ O
properties BC2GM090038156 NNS O
of BC2GM090038156 IN O
apo BC2GM090038156 JJ O
B-100 BC2GM090038156 NNP O
and BC2GM090038156 CC O
will BC2GM090038156 MD O
facilitate BC2GM090038156 VB O
studies BC2GM090038156 NNS O
on BC2GM090038156 IN O
the BC2GM090038156 DT O
factors BC2GM090038156 NNS O
modulating BC2GM090038156 VBG O
apo BC2GM090038156 JJ O
B-100 BC2GM090038156 JJ O
biosynthesis BC2GM090038156 NN O
and BC2GM090038156 CC O
the BC2GM090038156 DT O
expression BC2GM090038156 NN O
of BC2GM090038156 IN O
the BC2GM090038156 DT O
apo BC2GM090038156 JJ O
B-100 BC2GM090038156 NNP O
gene BC2GM090038156 NN O
in BC2GM090038156 IN O
patients BC2GM090038156 NNS O
with BC2GM090038156 IN O
dyslipoproteinemias BC2GM090038156 NNS O
. BC2GM090038156 . O
. . O O

MTX BC2GM094246030 NNP O
therapy BC2GM094246030 NN O
decreased BC2GM094246030 VBD O
Ga-67 BC2GM094246030 NNP O
uptake BC2GM094246030 NN O
in BC2GM094246030 IN O
liver BC2GM094246030 NN O
, BC2GM094246030 , O
tumor BC2GM094246030 NN O
, BC2GM094246030 , O
and BC2GM094246030 CC O
muscle BC2GM094246030 NN O
. BC2GM094246030 . O
. . O O

Histopathologically BC2GM053427855 RB O
, BC2GM053427855 , O
( BC2GM053427855 ( O
mice BC2GM053427855 NN O
killed BC2GM053427855 VBN O
with BC2GM053427855 IN O
high BC2GM053427855 JJ O
doses BC2GM053427855 NNS O
of BC2GM053427855 IN O
GMC-II BC2GM053427855 NNP O
, BC2GM053427855 , O
given BC2GM053427855 VBN O
orally BC2GM053427855 RB O
) BC2GM053427855 ) O
there BC2GM053427855 EX O
were BC2GM053427855 VBD O
diffuse BC2GM053427855 NN O
hyperemia BC2GM053427855 NN O
of BC2GM053427855 IN O
the BC2GM053427855 DT O
liver BC2GM053427855 NN O
, BC2GM053427855 , O
parenchymal BC2GM053427855 JJ O
degeneration BC2GM053427855 NN O
of BC2GM053427855 IN O
the BC2GM053427855 DT O
kidney BC2GM053427855 NN O
tubuli BC2GM053427855 NN O
epithelium BC2GM053427855 NN O
, BC2GM053427855 , O
and BC2GM053427855 CC O
edema BC2GM053427855 NN O
and BC2GM053427855 CC O
emphysema BC2GM053427855 NN O
of BC2GM053427855 IN O
the BC2GM053427855 DT O
lungs BC2GM053427855 NNS O
. BC2GM053427855 . O
. . O O

In BC2GM092393835 IN O
general BC2GM092393835 JJ O
, BC2GM092393835 , O
the BC2GM092393835 DT O
scallop BC2GM092393835 NN O
extract BC2GM092393835 NN O
potentiated BC2GM092393835 VBN O
phototactic BC2GM092393835 JJ O
suppression BC2GM092393835 NN O
. BC2GM092393835 . O
. . O O

A BC2GM084450992 DT O
multivariant BC2GM084450992 JJ O
study BC2GM084450992 NN O
of BC2GM084450992 IN O
pituitary BC2GM084450992 JJ O
adenoma BC2GM084450992 NN O
, BC2GM084450992 , O
obtainment BC2GM084450992 NN O
of BC2GM084450992 IN O
two BC2GM084450992 CD O
logistic BC2GM084450992 JJ O
regression BC2GM084450992 NN O
equations BC2GM084450992 NNS O
as BC2GM084450992 IN O
an BC2GM084450992 DT O
auxiliary BC2GM084450992 JJ O
support BC2GM084450992 NN O
in BC2GM084450992 IN O
the BC2GM084450992 DT O
diagnosis BC2GM084450992 NN O
of BC2GM084450992 IN O
these BC2GM084450992 DT O
tumors BC2GM084450992 NNS O
. BC2GM084450992 . O
. . O O

Characterization BC2GM038704123 NN O
of BC2GM038704123 IN O
a BC2GM038704123 DT O
DEAD BC2GM038704123 NNP O
box BC2GM038704123 NN O
ATPase BC2GM038704123 NNP O
/ BC2GM038704123 NNP O
RNA BC2GM038704123 NNP O
helicase BC2GM038704123 NN O
protein BC2GM038704123 NN O
of BC2GM038704123 IN O
Arabidopsis BC2GM038704123 NNP O
thaliana BC2GM038704123 NN O
. BC2GM038704123 . O
. . O O

Furthermore BC2GM024075956 RB O
, BC2GM024075956 , O
deletion BC2GM024075956 NN O
of BC2GM024075956 IN O
two BC2GM024075956 CD O
potential BC2GM024075956 JJ O
Ste11 BC2GM024075956 NNP O
recognition BC2GM024075956 NN O
sites BC2GM024075956 NNS O
in BC2GM024075956 IN O
the BC2GM024075956 DT O
fus1 BC2GM024075956 NN O
promoter BC2GM024075956 NN O
region BC2GM024075956 NN O
abolished BC2GM024075956 VBD O
transcription BC2GM024075956 NN O
, BC2GM024075956 , O
and BC2GM024075956 CC O
expression BC2GM024075956 NN O
could BC2GM024075956 MD O
be BC2GM024075956 VB O
restored BC2GM024075956 VBN O
when BC2GM024075956 WRB O
we BC2GM024075956 PRP O
inserted BC2GM024075956 VBD O
a BC2GM024075956 DT O
different BC2GM024075956 JJ O
Ste11 BC2GM024075956 NNP O
site BC2GM024075956 NN O
from BC2GM024075956 IN O
the BC2GM024075956 DT O
mat1-P BC2GM024075956 JJ O
promoter BC2GM024075956 NN O
. BC2GM024075956 . O
. . O O

Cotransfection BC2GM056590088 NN O
with BC2GM056590088 IN O
C BC2GM056590088 NNP O
/ BC2GM056590088 NNP O
EBPbeta BC2GM056590088 NNP O
and BC2GM056590088 CC O
GATA-1 BC2GM056590088 NNP O
expression BC2GM056590088 NN O
vectors BC2GM056590088 NNS O
produced BC2GM056590088 VBD O
a BC2GM056590088 DT O
5-fold BC2GM056590088 JJ O
increase BC2GM056590088 NN O
compared BC2GM056590088 VBN O
with BC2GM056590088 IN O
cotransfection BC2GM056590088 NN O
with BC2GM056590088 IN O
the BC2GM056590088 DT O
C BC2GM056590088 NNP O
/ BC2GM056590088 NNP O
EBPbeta BC2GM056590088 NNP O
or BC2GM056590088 CC O
GATA-1 BC2GM056590088 NNP O
expression BC2GM056590088 NN O
vectors BC2GM056590088 NNS O
individually BC2GM056590088 RB O
. BC2GM056590088 . O
. . O O

Developmentally-regulated BC2GM040737294 JJ O
interaction BC2GM040737294 NN O
of BC2GM040737294 IN O
a BC2GM040737294 DT O
transcription BC2GM040737294 NN O
factor BC2GM040737294 NN O
complex BC2GM040737294 JJ O
containing BC2GM040737294 VBG O
CDP BC2GM040737294 NNP O
/ BC2GM040737294 NNP O
cut BC2GM040737294 NN O
with BC2GM040737294 IN O
the BC2GM040737294 DT O
early BC2GM040737294 JJ O
histone BC2GM040737294 NN O
H3 BC2GM040737294 NNP O
gene BC2GM040737294 NN O
promoter BC2GM040737294 NN O
of BC2GM040737294 IN O
the BC2GM040737294 DT O
sea BC2GM040737294 NN O
urchin BC2GM040737294 JJ O
Tetrapygus BC2GM040737294 NNP O
niger BC2GM040737294 NN O
is BC2GM040737294 VBZ O
associated BC2GM040737294 VBN O
with BC2GM040737294 IN O
changes BC2GM040737294 NNS O
in BC2GM040737294 IN O
chromatin BC2GM040737294 NN O
structure BC2GM040737294 NN O
and BC2GM040737294 CC O
gene BC2GM040737294 NN O
expression BC2GM040737294 NN O
. BC2GM040737294 . O
. . O O

Phylogenetic BC2GM016210640 JJ O
analysis BC2GM016210640 NN O
using BC2GM016210640 VBG O
a BC2GM016210640 DT O
neighbor-joining BC2GM016210640 JJ O
algorithm BC2GM016210640 NN O
showed BC2GM016210640 VBD O
closest BC2GM016210640 JJS O
similarity BC2GM016210640 NN O
of BC2GM016210640 IN O
the BC2GM016210640 DT O
horse BC2GM016210640 NN O
mu BC2GM016210640 NN O
chain-encoding BC2GM016210640 JJ O
constant BC2GM016210640 JJ O
region BC2GM016210640 NN O
gene BC2GM016210640 NN O
to BC2GM016210640 TO O
human BC2GM016210640 JJ O
and BC2GM016210640 CC O
dog BC2GM016210640 JJ O
sequences BC2GM016210640 NNS O
. BC2GM016210640 . O
. . O O

The BC2GM083696051 DT O
prevalence BC2GM083696051 NN O
of BC2GM083696051 IN O
antibodies BC2GM083696051 NNS O
to BC2GM083696051 TO O
HRES-1 BC2GM083696051 NNP O
peptides BC2GM083696051 NNS O
pep14-24 BC2GM083696051 JJ O
and BC2GM083696051 CC O
pep117-127 BC2GM083696051 NN O
was BC2GM083696051 VBD O
determined BC2GM083696051 VBN O
in BC2GM083696051 IN O
65 BC2GM083696051 CD O
normal BC2GM083696051 JJ O
blood BC2GM083696051 NN O
donors BC2GM083696051 NNS O
and BC2GM083696051 CC O
146 BC2GM083696051 CD O
patients BC2GM083696051 NNS O
with BC2GM083696051 IN O
immunological BC2GM083696051 JJ O
disorders BC2GM083696051 NNS O
. BC2GM083696051 . O
. . O O

This BC2GM085276860 DT O
cDNA BC2GM085276860 NN O
corresponded BC2GM085276860 VBD O
to BC2GM085276860 TO O
FGF-binding BC2GM085276860 NNP O
protein BC2GM085276860 NN O
( BC2GM085276860 ( O
FGF-BP BC2GM085276860 NNP O
) BC2GM085276860 ) O
, BC2GM085276860 , O
a BC2GM085276860 DT O
secreted BC2GM085276860 JJ O
protein BC2GM085276860 NN O
previously BC2GM085276860 RB O
shown BC2GM085276860 VBN O
to BC2GM085276860 TO O
bind BC2GM085276860 VB O
acidic BC2GM085276860 JJ O
and BC2GM085276860 CC O
basic BC2GM085276860 JJ O
FGF BC2GM085276860 NNP O
and BC2GM085276860 CC O
to BC2GM085276860 TO O
modulate BC2GM085276860 VB O
their BC2GM085276860 PRP$ O
activities BC2GM085276860 NNS O
. BC2GM085276860 . O
. . O O

To BC2GM097216118 TO O
investigate BC2GM097216118 VB O
the BC2GM097216118 DT O
in BC2GM097216118 IN O
vivo BC2GM097216118 JJ O
role BC2GM097216118 NN O
of BC2GM097216118 IN O
this BC2GM097216118 DT O
chimeric BC2GM097216118 JJ O
bZIP BC2GM097216118 NN O
protein BC2GM097216118 NN O
in BC2GM097216118 IN O
oncogenic BC2GM097216118 JJ O
transformation BC2GM097216118 NN O
, BC2GM097216118 , O
its BC2GM097216118 PRP$ O
expression BC2GM097216118 NN O
was BC2GM097216118 VBD O
directed BC2GM097216118 VBN O
to BC2GM097216118 TO O
the BC2GM097216118 DT O
lymphoid BC2GM097216118 JJ O
compartments BC2GM097216118 NNS O
of BC2GM097216118 IN O
transgenic BC2GM097216118 JJ O
mice BC2GM097216118 NN O
. BC2GM097216118 . O
. . O O

Thirty-three BC2GM067091384 JJ O
percent BC2GM067091384 NN O
had BC2GM067091384 VBD O
elevated BC2GM067091384 VBN O
titers BC2GM067091384 NNS O
( BC2GM067091384 ( O
above BC2GM067091384 IN O
1:20 BC2GM067091384 CD O
dilution BC2GM067091384 NN O
) BC2GM067091384 ) O
. BC2GM067091384 . O
. . O O

Two BC2GM030583614 CD O
human BC2GM030583614 JJ O
beta-1,6-N-acetylglucosaminyltransferases BC2GM030583614 NNS O
forming BC2GM030583614 VBG O
the BC2GM030583614 DT O
core BC2GM030583614 NN O
2 BC2GM030583614 CD O
O-glycan BC2GM030583614 JJ O
branch BC2GM030583614 NN O
, BC2GM030583614 , O
C2GnT BC2GM030583614 NNP O
and BC2GM030583614 CC O
the BC2GM030583614 DT O
I BC2GM030583614 PRP O
antigen BC2GM030583614 VBP O
, BC2GM030583614 , O
IGnT BC2GM030583614 NNP O
, BC2GM030583614 , O
are BC2GM030583614 VBP O
homologous BC2GM030583614 JJ O
to BC2GM030583614 TO O
each BC2GM030583614 DT O
other BC2GM030583614 JJ O
in BC2GM030583614 IN O
three BC2GM030583614 CD O
regions BC2GM030583614 NNS O
of BC2GM030583614 IN O
the BC2GM030583614 DT O
catalytic BC2GM030583614 JJ O
domain BC2GM030583614 NN O
( BC2GM030583614 ( O
A BC2GM030583614 NNP O
, BC2GM030583614 , O
B BC2GM030583614 NNP O
, BC2GM030583614 , O
C BC2GM030583614 NNP O
) BC2GM030583614 ) O
and BC2GM030583614 CC O
their BC2GM030583614 PRP$ O
genes BC2GM030583614 NNS O
reside BC2GM030583614 RB O
at BC2GM030583614 IN O
the BC2GM030583614 DT O
same BC2GM030583614 JJ O
locus BC2GM030583614 NN O
, BC2GM030583614 , O
chromosome BC2GM030583614 NN O
9 BC2GM030583614 CD O
, BC2GM030583614 , O
band BC2GM030583614 NN O
q21 BC2GM030583614 NN O
( BC2GM030583614 ( O
Bierhuizen BC2GM030583614 NNP O
, BC2GM030583614 , O
M.F.A. BC2GM030583614 NNP O
, BC2GM030583614 , O
Mattei BC2GM030583614 NNP O
, BC2GM030583614 , O
M.-G. BC2GM030583614 NNP O
and BC2GM030583614 CC O
Fukuda BC2GM030583614 NNP O
, BC2GM030583614 , O
M. BC2GM030583614 NNP O
, BC2GM030583614 , O
Genes BC2GM030583614 NNP O
Dev. BC2GM030583614 NNP O
, BC2GM030583614 , O
7 BC2GM030583614 CD O
, BC2GM030583614 , O
468-478 BC2GM030583614 CD O
, BC2GM030583614 , O
1993 BC2GM030583614 CD O
) BC2GM030583614 ) O
. BC2GM030583614 . O
. . O O

We BC2GM031982996 PRP O
analyzed BC2GM031982996 VBD O
right BC2GM031982996 JJ O
ventricular BC2GM031982996 NN O
size BC2GM031982996 NN O
and BC2GM031982996 CC O
function BC2GM031982996 NN O
and BC2GM031982996 CC O
201Tl BC2GM031982996 CD O
uptake BC2GM031982996 NN O
to BC2GM031982996 TO O
determine BC2GM031982996 VB O
if BC2GM031982996 IN O
there BC2GM031982996 EX O
was BC2GM031982996 VBD O
a BC2GM031982996 DT O
relationship BC2GM031982996 NN O
between BC2GM031982996 IN O
201Tl BC2GM031982996 CD O
uptake BC2GM031982996 NN O
and BC2GM031982996 CC O
systolic BC2GM031982996 JJ O
function BC2GM031982996 NN O
in BC2GM031982996 IN O
19 BC2GM031982996 CD O
patients BC2GM031982996 NNS O
with BC2GM031982996 IN O
pulmonary BC2GM031982996 JJ O
artery BC2GM031982996 NN O
hypertension BC2GM031982996 NN O
who BC2GM031982996 WP O
were BC2GM031982996 VBD O
being BC2GM031982996 VBG O
evaluated BC2GM031982996 VBN O
for BC2GM031982996 IN O
heart-lung BC2GM031982996 JJ O
transplantation BC2GM031982996 NN O
. BC2GM031982996 . O
. . O O

Some BC2GM065082565 DT O
CHOP-C BC2GM065082565 NNP O
/ BC2GM065082565 NNP O
EBP BC2GM065082565 NNP O
heterodimers BC2GM065082565 NNS O
apparently BC2GM065082565 RB O
bind BC2GM065082565 IN O
to BC2GM065082565 TO O
alternative BC2GM065082565 VB O
DNA BC2GM065082565 NNP O
sequence BC2GM065082565 NN O
and BC2GM065082565 CC O
thereby BC2GM065082565 RB O
regulate BC2GM065082565 VB O
the BC2GM065082565 DT O
transcription BC2GM065082565 NN O
of BC2GM065082565 IN O
other BC2GM065082565 JJ O
genes BC2GM065082565 NNS O
. BC2GM065082565 . O
. . O O

Surprisingly BC2GM049698710 RB O
, BC2GM049698710 , O
apo-iso-1-cytochrome BC2GM049698710 JJ O
c BC2GM049698710 NN O
is BC2GM049698710 VBZ O
absent BC2GM049698710 JJ O
in BC2GM049698710 IN O
cyc3- BC2GM049698710 JJ O
strains BC2GM049698710 NNS O
, BC2GM049698710 , O
although BC2GM049698710 IN O
apo-iso-2-cytochrome BC2GM049698710 JJ O
c BC2GM049698710 NN O
is BC2GM049698710 VBZ O
present BC2GM049698710 JJ O
at BC2GM049698710 IN O
approximately BC2GM049698710 RB O
the BC2GM049698710 DT O
same BC2GM049698710 JJ O
level BC2GM049698710 NN O
at BC2GM049698710 IN O
which BC2GM049698710 WDT O
holo-iso-2-cytochrome BC2GM049698710 JJ O
c BC2GM049698710 NN O
is BC2GM049698710 VBZ O
found BC2GM049698710 VBN O
in BC2GM049698710 IN O
CYC3+ BC2GM049698710 NNP O
strains BC2GM049698710 NNS O
. BC2GM049698710 . O
. . O O

Therefore BC2GM032017565 RB O
the BC2GM032017565 DT O
effect BC2GM032017565 NN O
of BC2GM032017565 IN O
GAL11 BC2GM032017565 NNP O
on BC2GM032017565 IN O
PGK BC2GM032017565 NNP O
transcription BC2GM032017565 NN O
must BC2GM032017565 MD O
be BC2GM032017565 VB O
mediated BC2GM032017565 VBN O
at BC2GM032017565 IN O
the BC2GM032017565 DT O
PGK BC2GM032017565 NNP O
UAS BC2GM032017565 NNP O
, BC2GM032017565 , O
presumably BC2GM032017565 RB O
as BC2GM032017565 IN O
part BC2GM032017565 NN O
of BC2GM032017565 IN O
the BC2GM032017565 DT O
activation BC2GM032017565 NN O
complex BC2GM032017565 NN O
. BC2GM032017565 . O
. . O O

Under BC2GM053532690 IN O
control BC2GM053532690 NN O
conditions BC2GM053532690 NNS O
, BC2GM053532690 , O
pretreatment BC2GM053532690 NN O
with BC2GM053532690 IN O
lithium BC2GM053532690 NN O
during BC2GM053532690 IN O
7 BC2GM053532690 CD O
days BC2GM053532690 NNS O
did BC2GM053532690 VBD O
not BC2GM053532690 RB O
modify BC2GM053532690 VB O
the BC2GM053532690 DT O
hyperlocomotion BC2GM053532690 NN O
produced BC2GM053532690 VBN O
by BC2GM053532690 IN O
d-amphetamine BC2GM053532690 NN O
. BC2GM053532690 . O
. . O O

Phenotypic BC2GM059055199 NNP O
screening BC2GM059055199 NN O
of BC2GM059055199 IN O
mutations BC2GM059055199 NNS O
in BC2GM059055199 IN O
Pmr1 BC2GM059055199 NNP O
, BC2GM059055199 , O
the BC2GM059055199 DT O
yeast BC2GM059055199 NN O
secretory BC2GM059055199 JJ O
pathway BC2GM059055199 NN O
Ca2+ BC2GM059055199 NNP O
/ BC2GM059055199 NNP O
Mn2+-ATPase BC2GM059055199 NNP O
, BC2GM059055199 , O
reveals BC2GM059055199 VBZ O
residues BC2GM059055199 NNS O
critical BC2GM059055199 JJ O
for BC2GM059055199 IN O
ion BC2GM059055199 NN O
selectivity BC2GM059055199 NN O
and BC2GM059055199 CC O
transport BC2GM059055199 NN O
. BC2GM059055199 . O
. . O O

Little BC2GM033388156 JJ O
honoured BC2GM033388156 VBD O
in BC2GM033388156 IN O
his BC2GM033388156 PRP$ O
own BC2GM033388156 JJ O
country BC2GM033388156 NN O
: BC2GM033388156 : O
statues BC2GM033388156 NNS O
in BC2GM033388156 IN O
recognition BC2GM033388156 NN O
of BC2GM033388156 IN O
Edward BC2GM033388156 NNP O
Jenner BC2GM033388156 NNP O
MD BC2GM033388156 NNP O
FRS BC2GM033388156 NNP O
. BC2GM033388156 . O
. . O O

The BC2GM057123623 DT O
6.5-kb BC2GM057123623 JJ O
genomic BC2GM057123623 JJ O
fragment BC2GM057123623 NN O
contains BC2GM057123623 VBZ O
the BC2GM057123623 DT O
complete BC2GM057123623 JJ O
coding BC2GM057123623 VBG O
region BC2GM057123623 NN O
of BC2GM057123623 IN O
MyoD BC2GM057123623 NNP O
, BC2GM057123623 , O
distributed BC2GM057123623 VBD O
over BC2GM057123623 IN O
three BC2GM057123623 CD O
exons BC2GM057123623 NNS O
, BC2GM057123623 , O
plus BC2GM057123623 CC O
2.3 BC2GM057123623 CD O
kb BC2GM057123623 NN O
of BC2GM057123623 IN O
5'-noncoding BC2GM057123623 JJ O
sequence BC2GM057123623 NN O
and BC2GM057123623 CC O
1.4 BC2GM057123623 CD O
kb BC2GM057123623 NN O
of BC2GM057123623 IN O
3'-noncoding BC2GM057123623 JJ O
sequence BC2GM057123623 NN O
. BC2GM057123623 . O
. . O O

The BC2GM080455463 DT O
GIS BC2GM080455463 NNP O
software BC2GM080455463 NN O
program BC2GM080455463 NN O
, BC2GM080455463 , O
ArcView BC2GM080455463 NNP O
, BC2GM080455463 , O
was BC2GM080455463 VBD O
used BC2GM080455463 VBN O
for BC2GM080455463 IN O
spatial BC2GM080455463 JJ O
analysis BC2GM080455463 NN O
and BC2GM080455463 CC O
distance BC2GM080455463 NN O
calculations BC2GM080455463 NNS O
. BC2GM080455463 . O
chi2 BC2GM080455463 NN O
Tests BC2GM080455463 NNS O
were BC2GM080455463 VBD O
used BC2GM080455463 VBN O
to BC2GM080455463 TO O
compare BC2GM080455463 VB O
the BC2GM080455463 DT O
distribution BC2GM080455463 NN O
of BC2GM080455463 IN O
the BC2GM080455463 DT O
characteristics BC2GM080455463 NNS O
between BC2GM080455463 IN O
intersection BC2GM080455463 NN O
and BC2GM080455463 CC O
midblock BC2GM080455463 NN O
collisions BC2GM080455463 NNS O
. BC2GM080455463 . O
. . O O

It BC2GM020223301 PRP O
encodes BC2GM020223301 VBZ O
a BC2GM020223301 DT O
sequence-specific BC2GM020223301 JJ O
transcription BC2GM020223301 NN O
factor BC2GM020223301 NN O
that BC2GM020223301 WDT O
controls BC2GM020223301 VBZ O
, BC2GM020223301 , O
in BC2GM020223301 IN O
concert BC2GM020223301 NN O
with BC2GM020223301 IN O
other BC2GM020223301 JJ O
gene BC2GM020223301 NN O
products BC2GM020223301 NNS O
, BC2GM020223301 , O
differentiative BC2GM020223301 JJ O
pathways BC2GM020223301 NNS O
of BC2GM020223301 IN O
tissues BC2GM020223301 NNS O
in BC2GM020223301 IN O
which BC2GM020223301 WDT O
Scr BC2GM020223301 NNP O
is BC2GM020223301 VBZ O
expressed BC2GM020223301 VBN O
. BC2GM020223301 . O
. . O O

Comparison BC2GM004277618 NNP O
to BC2GM004277618 TO O
the BC2GM004277618 DT O
murine BC2GM004277618 NN O
homologues BC2GM004277618 NNS O
of BC2GM004277618 IN O
these BC2GM004277618 DT O
molecules BC2GM004277618 NNS O
reveals BC2GM004277618 VBZ O
a BC2GM004277618 DT O
high BC2GM004277618 JJ O
degree BC2GM004277618 NN O
of BC2GM004277618 IN O
conservation BC2GM004277618 NN O
between BC2GM004277618 IN O
the BC2GM004277618 DT O
products BC2GM004277618 NNS O
of BC2GM004277618 IN O
one BC2GM004277618 CD O
of BC2GM004277618 IN O
these BC2GM004277618 DT O
genes BC2GM004277618 NNS O
, BC2GM004277618 , O
Fc BC2GM004277618 NNP O
gamma BC2GM004277618 NN O
RIIb BC2GM004277618 NNP O
, BC2GM004277618 , O
and BC2GM004277618 CC O
the BC2GM004277618 DT O
murine BC2GM004277618 NN O
beta BC2GM004277618 NN O
gene BC2GM004277618 NN O
in BC2GM004277618 IN O
primary BC2GM004277618 JJ O
sequence BC2GM004277618 NN O
, BC2GM004277618 , O
splicing BC2GM004277618 VBG O
pattern BC2GM004277618 NN O
, BC2GM004277618 , O
and BC2GM004277618 CC O
tissue BC2GM004277618 NN O
distribution BC2GM004277618 NN O
. BC2GM004277618 . O
. . O O

MUS81 BC2GM066241550 NNP O
encodes BC2GM066241550 VBZ O
a BC2GM066241550 DT O
novel BC2GM066241550 JJ O
helix-hairpin-helix BC2GM066241550 JJ O
protein BC2GM066241550 NN O
involved BC2GM066241550 VBN O
in BC2GM066241550 IN O
the BC2GM066241550 DT O
response BC2GM066241550 NN O
to BC2GM066241550 TO O
UV- BC2GM066241550 NNP O
and BC2GM066241550 CC O
methylation-induced BC2GM066241550 JJ O
DNA BC2GM066241550 NNP O
damage BC2GM066241550 NN O
in BC2GM066241550 IN O
Saccharomyces BC2GM066241550 NNP O
cerevisiae BC2GM066241550 NN O
. BC2GM066241550 . O
. . O O

Phenylalanine BC2GM029716691 NNP O
and BC2GM029716691 CC O
tyrosine BC2GM029716691 NN O
levels BC2GM029716691 NNS O
were BC2GM029716691 VBD O
higher BC2GM029716691 RBR O
in BC2GM029716691 IN O
those BC2GM029716691 DT O
who BC2GM029716691 WP O
received BC2GM029716691 VBD O
Vamin BC2GM029716691 NNP O
9 BC2GM029716691 CD O
glucose BC2GM029716691 NN O
but BC2GM029716691 CC O
55 BC2GM029716691 CD O
% BC2GM029716691 NN O
of BC2GM029716691 IN O
infants BC2GM029716691 NNS O
given BC2GM029716691 VBN O
Vamin BC2GM029716691 NNP O
Infant BC2GM029716691 NNP O
had BC2GM029716691 VBD O
tyrosine BC2GM029716691 NN O
levels BC2GM029716691 NNS O
below BC2GM029716691 IN O
the BC2GM029716691 DT O
lower BC2GM029716691 JJR O
limit BC2GM029716691 NN O
of BC2GM029716691 IN O
the BC2GM029716691 DT O
target BC2GM029716691 NN O
range BC2GM029716691 NN O
. BC2GM029716691 . O
. . O O

Combination BC2GM071557168 NNP O
chemotherapy BC2GM071557168 NN O
in BC2GM071557168 IN O
advanced BC2GM071557168 JJ O
ovarian BC2GM071557168 JJ O
cancer BC2GM071557168 NN O
. BC2GM071557168 . O
. . O O

The BC2GM052791430 DT O
influence BC2GM052791430 NN O
of BC2GM052791430 IN O
different BC2GM052791430 JJ O
temperatures BC2GM052791430 NNS O
between BC2GM052791430 IN O
13 BC2GM052791430 CD O
degrees BC2GM052791430 NNS O
C BC2GM052791430 NNP O
and BC2GM052791430 CC O
45 BC2GM052791430 CD O
degrees BC2GM052791430 NNS O
C BC2GM052791430 NNP O
on BC2GM052791430 IN O
coagulation BC2GM052791430 NN O
factors BC2GM052791430 NNS O
in BC2GM052791430 IN O
vitro BC2GM052791430 NN O
was BC2GM052791430 VBD O
studied BC2GM052791430 VBN O
by BC2GM052791430 IN O
measuring BC2GM052791430 VBG O
clotting BC2GM052791430 VBG O
time BC2GM052791430 NN O
with BC2GM052791430 IN O
the BC2GM052791430 DT O
recalcification BC2GM052791430 NN O
time BC2GM052791430 NN O
, BC2GM052791430 , O
partial BC2GM052791430 JJ O
thromboplastin BC2GM052791430 NN O
time BC2GM052791430 NN O
( BC2GM052791430 ( O
PTT BC2GM052791430 NNP O
) BC2GM052791430 ) O
, BC2GM052791430 , O
and BC2GM052791430 CC O
thromboplastin BC2GM052791430 JJ O
time BC2GM052791430 NN O
test BC2GM052791430 NN O
. BC2GM052791430 . O
. . O O

E. BC2GM083059835 NNP O
granulosus BC2GM083059835 NN O
infection BC2GM083059835 NN O
has BC2GM083059835 VBZ O
been BC2GM083059835 VBN O
confirmed BC2GM083059835 VBN O
in BC2GM083059835 IN O
25 BC2GM083059835 CD O
patients BC2GM083059835 NNS O
( BC2GM083059835 ( O
20.6 BC2GM083059835 CD O
% BC2GM083059835 NN O
) BC2GM083059835 ) O
, BC2GM083059835 , O
in BC2GM083059835 IN O
16 BC2GM083059835 CD O
cases BC2GM083059835 NNS O
by BC2GM083059835 IN O
finding BC2GM083059835 VBG O
parasite BC2GM083059835 JJ O
protoscoleces BC2GM083059835 NNS O
or BC2GM083059835 CC O
hooks BC2GM083059835 NNS O
and BC2GM083059835 CC O
in BC2GM083059835 IN O
nine BC2GM083059835 CD O
cases BC2GM083059835 NNS O
by BC2GM083059835 IN O
detection BC2GM083059835 NN O
of BC2GM083059835 IN O
an BC2GM083059835 DT O
antigen BC2GM083059835 NN O
specific BC2GM083059835 NN O
for BC2GM083059835 IN O
E. BC2GM083059835 NNP O
granulosus BC2GM083059835 NN O
, BC2GM083059835 , O
antigen BC2GM083059835 NN O
5 BC2GM083059835 CD O
( BC2GM083059835 ( O
Ag5 BC2GM083059835 NNP O
) BC2GM083059835 ) O
. BC2GM083059835 . O
. . O O

Coexpression BC2GM093377314 NN O
of BC2GM093377314 IN O
c-Rel BC2GM093377314 NN O
in BC2GM093377314 IN O
combination BC2GM093377314 NN O
with BC2GM093377314 IN O
ATF-1 BC2GM093377314 NNP O
, BC2GM093377314 , O
CREB2 BC2GM093377314 NNP O
, BC2GM093377314 , O
or BC2GM093377314 CC O
ATF-1 BC2GM093377314 NNP O
/ BC2GM093377314 NNP O
CREB2 BC2GM093377314 NNP O
leads BC2GM093377314 VBZ O
to BC2GM093377314 TO O
synergistic BC2GM093377314 JJ O
transactivation BC2GM093377314 NN O
of BC2GM093377314 IN O
a BC2GM093377314 DT O
CD28RE-TRE BC2GM093377314 JJ O
reporter BC2GM093377314 NN O
plasmid BC2GM093377314 NN O
in BC2GM093377314 IN O
quiescent BC2GM093377314 JJ O
Jurkat BC2GM093377314 NNP O
T-cells BC2GM093377314 NNP O
. BC2GM093377314 . O
. . O O

Gene BC2GM001006298 NNP O
expression BC2GM001006298 NN O
is BC2GM001006298 VBZ O
in BC2GM001006298 IN O
part BC2GM001006298 NN O
controlled BC2GM001006298 VBN O
by BC2GM001006298 IN O
chromatin BC2GM001006298 NN O
remodeling BC2GM001006298 VBG O
factors BC2GM001006298 NNS O
and BC2GM001006298 CC O
the BC2GM001006298 DT O
acetylation BC2GM001006298 NN O
state BC2GM001006298 NN O
of BC2GM001006298 IN O
nucleosomal BC2GM001006298 JJ O
histones BC2GM001006298 NNS O
. BC2GM001006298 . O
. . O O

It BC2GM045854489 PRP O
was BC2GM045854489 VBD O
found BC2GM045854489 VBN O
that BC2GM045854489 IN O
both BC2GM045854489 DT O
versions BC2GM045854489 NNS O
of BC2GM045854489 IN O
the BC2GM045854489 DT O
brief BC2GM045854489 JJ O
SL BC2GM045854489 NNP O
& BC2GM045854489 CC O
amp BC2GM045854489 NN O
; BC2GM045854489 : O
shy BC2GM045854489 CC O
; BC2GM045854489 : O
ASIA BC2GM045854489 NNP O
had BC2GM045854489 VBD O
similar BC2GM045854489 JJ O
correlations BC2GM045854489 NNS O
to BC2GM045854489 TO O
the BC2GM045854489 DT O
target BC2GM045854489 NN O
variables BC2GM045854489 NNS O
as BC2GM045854489 IN O
the BC2GM045854489 DT O
full BC2GM045854489 JJ O
scale BC2GM045854489 NN O
SL BC2GM045854489 NNP O
& BC2GM045854489 CC O
amp BC2GM045854489 NN O
; BC2GM045854489 : O
shy BC2GM045854489 CC O
; BC2GM045854489 : O
ASIA BC2GM045854489 NNP O
. BC2GM045854489 . O
. . O O

We BC2GM073202656 PRP O
suggest BC2GM073202656 VBP O
that BC2GM073202656 IN O
this BC2GM073202656 DT O
relatively BC2GM073202656 RB O
small BC2GM073202656 JJ O
deletion BC2GM073202656 NN O
affects BC2GM073202656 VBZ O
a BC2GM073202656 DT O
segment BC2GM073202656 NN O
containing BC2GM073202656 VBG O
3 BC2GM073202656 CD O
' BC2GM073202656 '' O
VH BC2GM073202656 NNP O
genes BC2GM073202656 NNS O
with BC2GM073202656 IN O
important BC2GM073202656 JJ O
regulatory BC2GM073202656 JJ O
functions BC2GM073202656 NNS O
, BC2GM073202656 , O
the BC2GM073202656 DT O
loss BC2GM073202656 NN O
of BC2GM073202656 IN O
which BC2GM073202656 WDT O
leads BC2GM073202656 VBZ O
to BC2GM073202656 TO O
the BC2GM073202656 DT O
ali BC2GM073202656 NN O
phenotype BC2GM073202656 NN O
. BC2GM073202656 . O
. . O O

The BC2GM033281770 DT O
primary BC2GM033281770 JJ O
conditions BC2GM033281770 NNS O
for BC2GM033281770 IN O
acceptable BC2GM033281770 JJ O
hospital BC2GM033281770 NN O
use BC2GM033281770 NN O
were BC2GM033281770 VBD O
that BC2GM033281770 IN O
exhaled-volume BC2GM033281770 JJ O
monitoring BC2GM033281770 NN O
be BC2GM033281770 VB O
performed BC2GM033281770 VBN O
for BC2GM033281770 IN O
all BC2GM033281770 DT O
patients BC2GM033281770 NNS O
and BC2GM033281770 CC O
that BC2GM033281770 DT O
O2 BC2GM033281770 NNP O
monitoring BC2GM033281770 NN O
be BC2GM033281770 VB O
performed BC2GM033281770 VBN O
both BC2GM033281770 DT O
when BC2GM033281770 WRB O
setting BC2GM033281770 VBG O
FIO2 BC2GM033281770 NNP O
and BC2GM033281770 CC O
continuously BC2GM033281770 RB O
when BC2GM033281770 WRB O
FIO2 BC2GM033281770 NNP O
levels BC2GM033281770 NNS O
are BC2GM033281770 VBP O
critical BC2GM033281770 JJ O
. BC2GM033281770 . O
. . O O

The BC2GM064778776 DT O
orthologs BC2GM064778776 NNS O
of BC2GM064778776 IN O
the BC2GM064778776 DT O
Y BC2GM064778776 NNP O
( BC2GM064778776 ( O
1 BC2GM064778776 CD O
) BC2GM064778776 ) O
and BC2GM064778776 CC O
Y BC2GM064778776 NNP O
( BC2GM064778776 ( O
2 BC2GM064778776 CD O
) BC2GM064778776 ) O
subtypes BC2GM064778776 NNS O
display BC2GM064778776 VBP O
high BC2GM064778776 JJ O
amino BC2GM064778776 NN O
acid BC2GM064778776 NN O
sequence BC2GM064778776 NN O
identities BC2GM064778776 NNS O
between BC2GM064778776 IN O
pig BC2GM064778776 NN O
, BC2GM064778776 , O
human BC2GM064778776 JJ O
, BC2GM064778776 , O
and BC2GM064778776 CC O
mouse BC2GM064778776 NN O
( BC2GM064778776 ( O
92 BC2GM064778776 CD O
% BC2GM064778776 NN O
-94 BC2GM064778776 CD O
% BC2GM064778776 NN O
) BC2GM064778776 ) O
, BC2GM064778776 , O
whereas BC2GM064778776 IN O
the BC2GM064778776 DT O
Y BC2GM064778776 NNP O
( BC2GM064778776 ( O
4 BC2GM064778776 CD O
) BC2GM064778776 ) O
, BC2GM064778776 , O
Y BC2GM064778776 NNP O
( BC2GM064778776 ( O
5 BC2GM064778776 CD O
) BC2GM064778776 ) O
, BC2GM064778776 , O
and BC2GM064778776 CC O
y BC2GM064778776 NN O
( BC2GM064778776 ( O
6 BC2GM064778776 CD O
) BC2GM064778776 ) O
subtypes BC2GM064778776 NNS O
display BC2GM064778776 VBP O
lower BC2GM064778776 JJR O
identities BC2GM064778776 NNS O
( BC2GM064778776 ( O
76 BC2GM064778776 CD O
% BC2GM064778776 NN O
-87 BC2GM064778776 NNP O
% BC2GM064778776 NN O
) BC2GM064778776 ) O
. BC2GM064778776 . O
. . O O

Patients BC2GM041796235 NNS O
with BC2GM041796235 IN O
Eales BC2GM041796235 NNP O
' BC2GM041796235 POS O
disease BC2GM041796235 NN O
, BC2GM041796235 , O
chorioretinitis BC2GM041796235 NN O
, BC2GM041796235 , O
central BC2GM041796235 JJ O
serous BC2GM041796235 JJ O
retinopathy BC2GM041796235 NN O
, BC2GM041796235 , O
or BC2GM041796235 CC O
malignant BC2GM041796235 JJ O
choroidal BC2GM041796235 JJ O
melanoma BC2GM041796235 NN O
were BC2GM041796235 VBD O
tested BC2GM041796235 VBN O
for BC2GM041796235 IN O
HLA BC2GM041796235 NNP O
antigen BC2GM041796235 NN O
deviation BC2GM041796235 NN O
. BC2GM041796235 . O
. . O O

These BC2GM046023789 DT O
sequence BC2GM046023789 NN O
differences BC2GM046023789 NNS O
are BC2GM046023789 VBP O
reflected BC2GM046023789 VBN O
in BC2GM046023789 IN O
differences BC2GM046023789 NNS O
in BC2GM046023789 IN O
gene BC2GM046023789 NN O
expression BC2GM046023789 NN O
in BC2GM046023789 IN O
three BC2GM046023789 CD O
cell BC2GM046023789 NN O
lines BC2GM046023789 NNS O
. BC2GM046023789 . O
. . O O

Three BC2GM022687280 CD O
transcriptional BC2GM022687280 JJ O
control BC2GM022687280 NN O
elements BC2GM022687280 NNS O
within BC2GM022687280 IN O
300 BC2GM022687280 CD O
base BC2GM022687280 NN O
pairs BC2GM022687280 NN O
of BC2GM022687280 IN O
the BC2GM022687280 DT O
5'-flanking BC2GM022687280 JJ O
region BC2GM022687280 NN O
of BC2GM022687280 IN O
the BC2GM022687280 DT O
rat BC2GM022687280 NN O
glucagon BC2GM022687280 NN O
gene BC2GM022687280 NN O
interact BC2GM022687280 NN O
with BC2GM022687280 IN O
regulatory BC2GM022687280 JJ O
cellular BC2GM022687280 JJ O
proteins BC2GM022687280 NNS O
and BC2GM022687280 CC O
direct BC2GM022687280 JJ O
transcription BC2GM022687280 NN O
only BC2GM022687280 RB O
in BC2GM022687280 IN O
glucagon-producing BC2GM022687280 JJ O
islet BC2GM022687280 NN O
cells BC2GM022687280 NNS O
. BC2GM022687280 . O
. . O O

Multiple BC2GM010446827 JJ O
copies BC2GM010446827 NNS O
of BC2GM010446827 IN O
this BC2GM010446827 DT O
binding BC2GM010446827 NN O
site BC2GM010446827 NN O
are BC2GM010446827 VBP O
found BC2GM010446827 VBN O
in BC2GM010446827 IN O
the BC2GM010446827 DT O
viral BC2GM010446827 JJ O
genomes BC2GM010446827 NNS O
. BC2GM010446827 . O
. . O O

We BC2GM068206225 PRP O
have BC2GM068206225 VBP O
shown BC2GM068206225 VBN O
previously BC2GM068206225 RB O
that BC2GM068206225 IN O
EGF BC2GM068206225 NNP O
receptor BC2GM068206225 NN O
activation BC2GM068206225 NN O
stimulates BC2GM068206225 VBZ O
gastrin BC2GM068206225 JJ O
gene BC2GM068206225 NN O
expression BC2GM068206225 NN O
through BC2GM068206225 IN O
a BC2GM068206225 DT O
GC-rich BC2GM068206225 JJ O
element BC2GM068206225 NN O
called BC2GM068206225 VBN O
gERE BC2GM068206225 NN O
. BC2GM068206225 . O
. . O O

The BC2GM040683768 DT O
levels BC2GM040683768 NNS O
of BC2GM040683768 IN O
products BC2GM040683768 NNS O
expressed BC2GM040683768 VBN O
from BC2GM040683768 IN O
these BC2GM040683768 DT O
chimeric BC2GM040683768 JJ O
cDNAs BC2GM040683768 NN O
in BC2GM040683768 IN O
COS BC2GM040683768 NNP O
cells BC2GM040683768 NNS O
were BC2GM040683768 VBD O
assessed BC2GM040683768 VBN O
by BC2GM040683768 IN O
activity BC2GM040683768 NN O
assay BC2GM040683768 NN O
and BC2GM040683768 CC O
by BC2GM040683768 IN O
metabolic BC2GM040683768 JJ O
labeling BC2GM040683768 NN O
of BC2GM040683768 IN O
the BC2GM040683768 DT O
proteins BC2GM040683768 NNS O
followed BC2GM040683768 VBN O
by BC2GM040683768 IN O
immunoprecipitation BC2GM040683768 NN O
and BC2GM040683768 CC O
SDS-PAGE BC2GM040683768 NN O
. BC2GM040683768 . O
. . O O

As BC2GM001534399 IN O
in BC2GM001534399 IN O
IncP BC2GM001534399 NNP O
alpha BC2GM001534399 NN O
plasmids BC2GM001534399 NNS O
, BC2GM001534399 , O
these BC2GM001534399 DT O
operons BC2GM001534399 NNS O
are BC2GM001534399 VBP O
transcribed BC2GM001534399 VBN O
from BC2GM001534399 IN O
a BC2GM001534399 DT O
bidirectional BC2GM001534399 JJ O
promoter BC2GM001534399 NN O
region BC2GM001534399 NN O
consisting BC2GM001534399 VBG O
of BC2GM001534399 IN O
trfAp BC2GM001534399 NN O
for BC2GM001534399 IN O
the BC2GM001534399 DT O
trfA BC2GM001534399 NN O
operon BC2GM001534399 NN O
and BC2GM001534399 CC O
trbAp BC2GM001534399 NN O
and BC2GM001534399 CC O
trbBp BC2GM001534399 NN O
for BC2GM001534399 IN O
the BC2GM001534399 DT O
trb BC2GM001534399 NN O
operon BC2GM001534399 NN O
. BC2GM001534399 . O
. . O O

Postcontrast BC2GM081733082 NN O
images BC2GM081733082 NNS O
were BC2GM081733082 VBD O
also BC2GM081733082 RB O
acquired BC2GM081733082 VBN O
in BC2GM081733082 IN O
the BC2GM081733082 DT O
sagittal BC2GM081733082 NN O
( BC2GM081733082 ( O
six BC2GM081733082 CD O
patients BC2GM081733082 NNS O
) BC2GM081733082 ) O
and BC2GM081733082 CC O
coronal BC2GM081733082 JJ O
( BC2GM081733082 ( O
three BC2GM081733082 CD O
patients BC2GM081733082 NNS O
) BC2GM081733082 ) O
planes BC2GM081733082 NNS O
. BC2GM081733082 . O
. . O O

After BC2GM010707671 IN O
first BC2GM010707671 JJ O
strand BC2GM010707671 NN O
cDNA BC2GM010707671 NN O
synthesis BC2GM010707671 NN O
from BC2GM010707671 IN O
fetal BC2GM010707671 JJ O
brain BC2GM010707671 NN O
mRNAs BC2GM010707671 NN O
, BC2GM010707671 , O
short BC2GM010707671 JJ O
fragment BC2GM010707671 NN O
cDNAs BC2GM010707671 NN O
( BC2GM010707671 ( O
sf-cDNAs BC2GM010707671 JJ O
) BC2GM010707671 ) O
were BC2GM010707671 VBD O
synthesized BC2GM010707671 VBN O
with BC2GM010707671 IN O
a BC2GM010707671 DT O
two-step BC2GM010707671 JJ O
amplification BC2GM010707671 NN O
system BC2GM010707671 NN O
by BC2GM010707671 IN O
use BC2GM010707671 NN O
of BC2GM010707671 IN O
our BC2GM010707671 PRP$ O
modified BC2GM010707671 JJ O
Degenerate BC2GM010707671 NNP O
Oligonucleotide BC2GM010707671 NNP O
Primed BC2GM010707671 NNP O
Shuttle BC2GM010707671 NNP O
Polymerase BC2GM010707671 NNP O
Chain BC2GM010707671 NNP O
Reaction BC2GM010707671 NNP O
( BC2GM010707671 ( O
DOP-Shuttle-PCR BC2GM010707671 NNP O
) BC2GM010707671 ) O
method BC2GM010707671 NN O
. BC2GM010707671 . O
. . O O

Sucrose-specific BC2GM021811332 JJ O
signalling BC2GM021811332 NN O
represses BC2GM021811332 NNS O
translation BC2GM021811332 NN O
of BC2GM021811332 IN O
the BC2GM021811332 DT O
Arabidopsis BC2GM021811332 NNP O
ATB2 BC2GM021811332 NNP O
bZIP BC2GM021811332 NN O
transcription BC2GM021811332 NN O
factor BC2GM021811332 NN O
gene BC2GM021811332 NN O
. BC2GM021811332 . O
. . O O

Both BC2GM074751408 DT O
the BC2GM074751408 DT O
5 BC2GM074751408 CD O
' BC2GM074751408 POS O
and BC2GM074751408 CC O
3 BC2GM074751408 CD O
' BC2GM074751408 '' O
untranslated BC2GM074751408 JJ O
regions BC2GM074751408 NNS O
also BC2GM074751408 RB O
show BC2GM074751408 VBP O
significant BC2GM074751408 JJ O
similarity BC2GM074751408 NN O
to BC2GM074751408 TO O
the BC2GM074751408 DT O
murine BC2GM074751408 NN O
gene BC2GM074751408 NN O
, BC2GM074751408 , O
with BC2GM074751408 IN O
79 BC2GM074751408 CD O
and BC2GM074751408 CC O
70 BC2GM074751408 CD O
% BC2GM074751408 NN O
sequence BC2GM074751408 NN O
identity BC2GM074751408 NN O
, BC2GM074751408 , O
respectively BC2GM074751408 RB O
. BC2GM074751408 . O
. . O O

We BC2GM003162436 PRP O
have BC2GM003162436 VBP O
isolated BC2GM003162436 VBN O
and BC2GM003162436 CC O
structurally BC2GM003162436 RB O
characterized BC2GM003162436 JJ O
genomic BC2GM003162436 JJ O
DNA BC2GM003162436 NN O
and BC2GM003162436 CC O
cDNA BC2GM003162436 NN O
sequences BC2GM003162436 NNS O
encoding BC2GM003162436 VBG O
ribulose-1,5-bisphosphate BC2GM003162436 JJ O
carboxylase BC2GM003162436 NN O
/ BC2GM003162436 NNP O
oxygenase BC2GM003162436 NN O
( BC2GM003162436 ( O
Rbu-P2 BC2GM003162436 NNP O
carboxylase BC2GM003162436 NN O
) BC2GM003162436 ) O
activase BC2GM003162436 NN O
from BC2GM003162436 IN O
barley BC2GM003162436 NN O
( BC2GM003162436 ( O
Hordeum BC2GM003162436 NNP O
vulgare BC2GM003162436 NNP O
L. BC2GM003162436 NNP O
) BC2GM003162436 ) O
. BC2GM003162436 . O
. . O O

The BC2GM040688881 DT O
leucine BC2GM040688881 JJ O
zipper BC2GM040688881 NNP O
region BC2GM040688881 NN O
of BC2GM040688881 IN O
ATF BC2GM040688881 NNP O
proteins BC2GM040688881 NNS O
is BC2GM040688881 VBZ O
also BC2GM040688881 RB O
similar BC2GM040688881 JJ O
to BC2GM040688881 TO O
that BC2GM040688881 DT O
of BC2GM040688881 IN O
the BC2GM040688881 DT O
AP-1 BC2GM040688881 NNP O
/ BC2GM040688881 NNP O
c-jun BC2GM040688881 JJ O
family BC2GM040688881 NN O
of BC2GM040688881 IN O
transcription BC2GM040688881 NN O
factors BC2GM040688881 NNS O
, BC2GM040688881 , O
whose BC2GM040688881 WP$ O
DNA-binding BC2GM040688881 JJ O
site BC2GM040688881 NN O
differs BC2GM040688881 NNS O
from BC2GM040688881 IN O
the BC2GM040688881 DT O
ATF-binding BC2GM040688881 NNP O
site BC2GM040688881 NN O
at BC2GM040688881 IN O
a BC2GM040688881 DT O
single BC2GM040688881 JJ O
position BC2GM040688881 NN O
. BC2GM040688881 . O
. . O O

RESULTS BC2GM060444035 NN O
: BC2GM060444035 : O
Sixty-one BC2GM060444035 JJ O
percent BC2GM060444035 NN O
of BC2GM060444035 IN O
the BC2GM060444035 DT O
patients BC2GM060444035 NNS O
had BC2GM060444035 VBD O
damage BC2GM060444035 NN O
within BC2GM060444035 IN O
7 BC2GM060444035 CD O
years BC2GM060444035 NNS O
of BC2GM060444035 IN O
onset BC2GM060444035 NN O
( BC2GM060444035 ( O
mean BC2GM060444035 JJ O
3.8 BC2GM060444035 CD O
yrs BC2GM060444035 NN O
) BC2GM060444035 ) O
. BC2GM060444035 . O
. . O O

RESULTS BC2GM004666921 NNP O
-- BC2GM004666921 : O
261 BC2GM004666921 CD O
patients BC2GM004666921 NNS O
were BC2GM004666921 VBD O
enrolled BC2GM004666921 VBN O
into BC2GM004666921 IN O
this BC2GM004666921 DT O
study BC2GM004666921 NN O
; BC2GM004666921 : O
of BC2GM004666921 IN O
these BC2GM004666921 DT O
, BC2GM004666921 , O
138 BC2GM004666921 CD O
( BC2GM004666921 ( O
53 BC2GM004666921 CD O
% BC2GM004666921 NN O
) BC2GM004666921 ) O
patients BC2GM004666921 NNS O
attended BC2GM004666921 VBD O
for BC2GM004666921 IN O
repeat BC2GM004666921 NN O
colposcopy BC2GM004666921 NN O
and BC2GM004666921 CC O
cytology BC2GM004666921 NN O
at BC2GM004666921 IN O
one BC2GM004666921 CD O
year BC2GM004666921 NN O
. BC2GM004666921 . O
. . O O

The BC2GM018283736 DT O
role BC2GM018283736 NN O
of BC2GM018283736 IN O
phosphorylation BC2GM018283736 NN O
on BC2GM018283736 IN O
receptor BC2GM018283736 NN O
desensitization BC2GM018283736 NN O
was BC2GM018283736 VBD O
assessed BC2GM018283736 VBN O
using BC2GM018283736 VBG O
receptor BC2GM018283736 NN O
mutants BC2GM018283736 NNS O
expressed BC2GM018283736 VBN O
in BC2GM018283736 IN O
COS BC2GM018283736 NNP O
cells BC2GM018283736 NNS O
or BC2GM018283736 CC O
Chinese BC2GM018283736 JJ O
hamster BC2GM018283736 NN O
lung BC2GM018283736 NN O
fibroblasts BC2GM018283736 NNS O
. BC2GM018283736 . O
. . O O

The BC2GM060294420 DT O
promoter BC2GM060294420 NN O
of BC2GM060294420 IN O
this BC2GM060294420 DT O
methyltransferase BC2GM060294420 NN O
gene BC2GM060294420 NN O
lacks BC2GM060294420 VBZ O
an BC2GM060294420 DT O
identifiable BC2GM060294420 JJ O
TATA BC2GM060294420 NNP O
box BC2GM060294420 NN O
but BC2GM060294420 CC O
is BC2GM060294420 VBZ O
characterized BC2GM060294420 VBN O
by BC2GM060294420 IN O
a BC2GM060294420 DT O
CpG BC2GM060294420 NNP O
island BC2GM060294420 NN O
which BC2GM060294420 WDT O
begins BC2GM060294420 VBZ O
approximately BC2GM060294420 RB O
723 BC2GM060294420 CD O
nucleotides BC2GM060294420 NNS O
upstream BC2GM060294420 NN O
of BC2GM060294420 IN O
the BC2GM060294420 DT O
major BC2GM060294420 JJ O
transcriptional BC2GM060294420 JJ O
start BC2GM060294420 NN O
site BC2GM060294420 NN O
and BC2GM060294420 CC O
extends BC2GM060294420 VBZ O
through BC2GM060294420 IN O
exon BC2GM060294420 NN O
1 BC2GM060294420 CD O
and BC2GM060294420 CC O
into BC2GM060294420 IN O
the BC2GM060294420 DT O
first BC2GM060294420 JJ O
intron BC2GM060294420 NN O
. BC2GM060294420 . O
. . O O

The BC2GM058928163 DT O
reporter BC2GM058928163 NN O
gene BC2GM058928163 NN O
with BC2GM058928163 IN O
two BC2GM058928163 CD O
copies BC2GM058928163 NNS O
of BC2GM058928163 IN O
the BC2GM058928163 DT O
wild-type BC2GM058928163 JJ O
Repeat BC2GM058928163 NNP O
2 BC2GM058928163 CD O
+ BC2GM058928163 VBD O
3 BC2GM058928163 CD O
sequence BC2GM058928163 NN O
was BC2GM058928163 VBD O
transcribed BC2GM058928163 VBN O
actively BC2GM058928163 RB O
in BC2GM058928163 IN O
sterol-deprived BC2GM058928163 JJ O
cells BC2GM058928163 NNS O
and BC2GM058928163 CC O
was BC2GM058928163 VBD O
repressed BC2GM058928163 VBN O
by BC2GM058928163 IN O
more BC2GM058928163 JJR O
than BC2GM058928163 IN O
80 BC2GM058928163 CD O
% BC2GM058928163 NN O
when BC2GM058928163 WRB O
sterols BC2GM058928163 NNS O
were BC2GM058928163 VBD O
present BC2GM058928163 JJ O
. BC2GM058928163 . O
. . O O

The BC2GM062680443 DT O
gene BC2GM062680443 NN O
, BC2GM062680443 , O
from BC2GM062680443 IN O
the BC2GM062680443 DT O
initiator BC2GM062680443 NN O
methionine BC2GM062680443 NN O
to BC2GM062680443 TO O
the BC2GM062680443 DT O
polyadenylation BC2GM062680443 NN O
site BC2GM062680443 NN O
, BC2GM062680443 , O
is BC2GM062680443 VBZ O
contained BC2GM062680443 VBN O
within BC2GM062680443 IN O
13 BC2GM062680443 CD O
244 BC2GM062680443 CD O
basepairs BC2GM062680443 NNS O
and BC2GM062680443 CC O
contains BC2GM062680443 VBZ O
19 BC2GM062680443 CD O
exons BC2GM062680443 NNS O
. BC2GM062680443 . O
. . O O

Interestingly BC2GM036335955 RB O
, BC2GM036335955 , O
the BC2GM036335955 DT O
NES BC2GM036335955 NNP O
mutant BC2GM036335955 JJ O
proteins BC2GM036335955 NNS O
appeared BC2GM036335955 VBD O
to BC2GM036335955 TO O
have BC2GM036335955 VB O
altered BC2GM036335955 VBN O
interactions BC2GM036335955 NNS O
with BC2GM036335955 IN O
the BC2GM036335955 DT O
splicing BC2GM036335955 NN O
complex BC2GM036335955 NN O
, BC2GM036335955 , O
binding BC2GM036335955 VBG O
more BC2GM036335955 RBR O
tightly BC2GM036335955 RB O
to BC2GM036335955 TO O
SC35 BC2GM036335955 NNP O
in BC2GM036335955 IN O
co-immunoprecipitation BC2GM036335955 NN O
assays BC2GM036335955 NNS O
. BC2GM036335955 . O
. . O O

Sample BC2GM074709129 NNP O
size BC2GM074709129 NN O
requirement BC2GM074709129 NN O
for BC2GM074709129 IN O
repeated BC2GM074709129 JJ O
measurements BC2GM074709129 NNS O
in BC2GM074709129 IN O
continuous BC2GM074709129 JJ O
data BC2GM074709129 NNS O
. BC2GM074709129 . O
. . O O

Evaluation BC2GM006291661 NN O
of BC2GM006291661 IN O
the BC2GM006291661 DT O
effects BC2GM006291661 NNS O
of BC2GM006291661 IN O
chelation BC2GM006291661 NN O
therapy BC2GM006291661 NN O
with BC2GM006291661 IN O
time BC2GM006291661 NN O
following BC2GM006291661 VBG O
strontium BC2GM006291661 NN O
exposure BC2GM006291661 NN O
to BC2GM006291661 TO O
mice BC2GM006291661 VB O
. BC2GM006291661 . O
. . O O

From BC2GM020630421 IN O
the BC2GM020630421 DT O
deduced BC2GM020630421 VBN O
amino BC2GM020630421 NN O
acid BC2GM020630421 NN O
sequence BC2GM020630421 NN O
, BC2GM020630421 , O
a BC2GM020630421 DT O
molecular BC2GM020630421 JJ O
weight BC2GM020630421 NN O
of BC2GM020630421 IN O
38,549 BC2GM020630421 CD O
was BC2GM020630421 VBD O
calculated BC2GM020630421 VBN O
for BC2GM020630421 IN O
the BC2GM020630421 DT O
ADH BC2GM020630421 NNP O
subunit BC2GM020630421 NN O
. BC2GM020630421 . O
. . O O

Structure BC2GM081653847 NN O
of BC2GM081653847 IN O
the BC2GM081653847 DT O
connective BC2GM081653847 JJ O
stroma BC2GM081653847 NN O
of BC2GM081653847 IN O
the BC2GM081653847 DT O
epididymis BC2GM081653847 NN O
in BC2GM081653847 IN O
the BC2GM081653847 DT O
zebu BC2GM081653847 NN O
. BC2GM081653847 . O
. . O O

Promoter BC2GM079046783 NN O
elements BC2GM079046783 NNS O
and BC2GM079046783 CC O
transcriptional BC2GM079046783 JJ O
control BC2GM079046783 NN O
of BC2GM079046783 IN O
the BC2GM079046783 DT O
mouse BC2GM079046783 NN O
acetylcholinesterase BC2GM079046783 NN O
gene BC2GM079046783 NN O
. BC2GM079046783 . O
. . O O

Principal BC2GM083794730 JJ O
component BC2GM083794730 NN O
analysis BC2GM083794730 NN O
using BC2GM083794730 VBG O
psychosocial BC2GM083794730 JJ O
factors BC2GM083794730 NNS O
in BC2GM083794730 IN O
women BC2GM083794730 NNS O
showed BC2GM083794730 VBD O
two BC2GM083794730 CD O
psychosocial BC2GM083794730 JJ O
structures BC2GM083794730 NNS O
, BC2GM083794730 , O
i.e BC2GM083794730 NN O
. BC2GM083794730 . O
the BC2GM083794730 DT O
second BC2GM083794730 JJ O
principal BC2GM083794730 NN O
( BC2GM083794730 ( O
high BC2GM083794730 JJ O
SOC BC2GM083794730 NNP O
, BC2GM083794730 , O
high BC2GM083794730 JJ O
lifestyle BC2GM083794730 NN O
, BC2GM083794730 , O
and BC2GM083794730 CC O
low BC2GM083794730 JJ O
stress BC2GM083794730 NN O
) BC2GM083794730 ) O
and BC2GM083794730 CC O
the BC2GM083794730 DT O
4th BC2GM083794730 CD O
principal BC2GM083794730 JJ O
components BC2GM083794730 NNS O
( BC2GM083794730 ( O
high BC2GM083794730 JJ O
supernatural BC2GM083794730 NN O
HLC BC2GM083794730 NNP O
, BC2GM083794730 , O
and BC2GM083794730 CC O
high BC2GM083794730 JJ O
PHLC BC2GM083794730 NNP O
) BC2GM083794730 ) O
. BC2GM083794730 . O
. . O O

This BC2GM064837210 DT O
suggests BC2GM064837210 VBZ O
that BC2GM064837210 IN O
the BC2GM064837210 DT O
ratio BC2GM064837210 NN O
of BC2GM064837210 IN O
IL-6 BC2GM064837210 NNP O
to BC2GM064837210 TO O
IL-10 BC2GM064837210 NNP O
may BC2GM064837210 MD O
be BC2GM064837210 VB O
used BC2GM064837210 VBN O
to BC2GM064837210 TO O
predict BC2GM064837210 VB O
the BC2GM064837210 DT O
injury BC2GM064837210 NN O
severity BC2GM064837210 NN O
after BC2GM064837210 IN O
trauma BC2GM064837210 NN O
. BC2GM064837210 . O
. . O O

Xnr3 BC2GM030870711 NN O
is BC2GM030870711 VBZ O
transcriptionally BC2GM030870711 RB O
activated BC2GM030870711 VBN O
by BC2GM030870711 IN O
wnt BC2GM030870711 JJ O
signaling BC2GM030870711 VBG O
during BC2GM030870711 IN O
gastrulation BC2GM030870711 NN O
in BC2GM030870711 IN O
the BC2GM030870711 DT O
Xenopus BC2GM030870711 NNP O
embryo BC2GM030870711 NN O
. BC2GM030870711 . O
. . O O

Our BC2GM003734508 PRP$ O
results BC2GM003734508 NNS O
showed BC2GM003734508 VBD O
that BC2GM003734508 IN O
direct BC2GM003734508 JJ O
enantiomeric BC2GM003734508 JJ O
separation BC2GM003734508 NN O
of BC2GM003734508 IN O
mephenytoin BC2GM003734508 NN O
was BC2GM003734508 VBD O
obtained BC2GM003734508 VBN O
by BC2GM003734508 IN O
using BC2GM003734508 VBG O
a BC2GM003734508 DT O
chiral BC2GM003734508 JJ O
capillary BC2GM003734508 JJ O
column BC2GM003734508 NN O
, BC2GM003734508 , O
the BC2GM003734508 DT O
retention BC2GM003734508 NN O
times BC2GM003734508 NNS O
for BC2GM003734508 IN O
S- BC2GM003734508 NNP O
and BC2GM003734508 CC O
R-mephenytoin BC2GM003734508 NNP O
were BC2GM003734508 VBD O
25.5 BC2GM003734508 CD O
and BC2GM003734508 CC O
26.2 BC2GM003734508 CD O
min BC2GM003734508 NN O
respectively BC2GM003734508 RB O
, BC2GM003734508 , O
with BC2GM003734508 IN O
a BC2GM003734508 DT O
detection BC2GM003734508 NN O
limit BC2GM003734508 NN O
less BC2GM003734508 JJR O
than BC2GM003734508 IN O
50 BC2GM003734508 CD O
ng BC2GM003734508 JJ O
/ BC2GM003734508 NNP O
ml BC2GM003734508 NN O
of BC2GM003734508 IN O
mephenytoin BC2GM003734508 NN O
. BC2GM003734508 . O
. . O O

During BC2GM038038322 IN O
the BC2GM038038322 DT O
1st BC2GM038038322 CD O
week BC2GM038038322 NN O
of BC2GM038038322 IN O
treatment BC2GM038038322 NN O
all BC2GM038038322 DT O
subjects BC2GM038038322 VBZ O
received BC2GM038038322 VBN O
either BC2GM038038322 RB O
mianserin BC2GM038038322 JJ O
30 BC2GM038038322 CD O
mg BC2GM038038322 NN O
or BC2GM038038322 CC O
clomipramine BC2GM038038322 VB O
75 BC2GM038038322 CD O
mg BC2GM038038322 NNS O
once BC2GM038038322 RB O
daily BC2GM038038322 RB O
. BC2GM038038322 . O
. . O O

To BC2GM033468681 TO O
elucidate BC2GM033468681 VB O
the BC2GM033468681 DT O
molecular BC2GM033468681 JJ O
mechanism BC2GM033468681 NN O
by BC2GM033468681 IN O
which BC2GM033468681 WDT O
the BC2GM033468681 DT O
Ras BC2GM033468681 NNP O
signaling BC2GM033468681 VBG O
pathway BC2GM033468681 RB O
activates BC2GM033468681 VBZ O
a BC2GM033468681 DT O
cell-type-specific BC2GM033468681 JJ O
gene BC2GM033468681 NN O
, BC2GM033468681 , O
we BC2GM033468681 PRP O
have BC2GM033468681 VBP O
used BC2GM033468681 VBN O
the BC2GM033468681 DT O
pituitary-specific BC2GM033468681 JJ O
rat BC2GM033468681 NN O
prolactin BC2GM033468681 NN O
( BC2GM033468681 ( O
rPRL BC2GM033468681 NN O
) BC2GM033468681 ) O
promoter BC2GM033468681 NN O
as BC2GM033468681 IN O
a BC2GM033468681 DT O
target BC2GM033468681 NN O
of BC2GM033468681 IN O
oncogenic BC2GM033468681 JJ O
Ras BC2GM033468681 NNP O
and BC2GM033468681 CC O
Raf BC2GM033468681 NNP O
in BC2GM033468681 IN O
GH4 BC2GM033468681 NNP O
rat BC2GM033468681 NN O
pituitary BC2GM033468681 JJ O
cells BC2GM033468681 NNS O
. BC2GM033468681 . O
. . O O

A BC2GM068605843 DT O
brief BC2GM068605843 JJ O
discussion BC2GM068605843 NN O
for BC2GM068605843 IN O
the BC2GM068605843 DT O
relationship BC2GM068605843 NN O
among BC2GM068605843 IN O
these BC2GM068605843 DT O
formulas BC2GM068605843 NNS O
is BC2GM068605843 VBZ O
given BC2GM068605843 VBN O
. BC2GM068605843 . O
. . O O

RESULTS BC2GM021744548 NN O
: BC2GM021744548 : O
PET BC2GM021744548 NNP O
revealed BC2GM021744548 VBD O
wide BC2GM021744548 JJ O
variations BC2GM021744548 NNS O
in BC2GM021744548 IN O
CBF BC2GM021744548 NNP O
between BC2GM021744548 IN O
regions BC2GM021744548 NNS O
during BC2GM021744548 IN O
isoflurane BC2GM021744548 NN O
anaesthesia BC2GM021744548 NNS O
, BC2GM021744548 , O
particularly BC2GM021744548 RB O
in BC2GM021744548 IN O
comparison BC2GM021744548 NN O
with BC2GM021744548 IN O
propofol BC2GM021744548 JJ O
anaesthesia BC2GM021744548 NNS O
, BC2GM021744548 , O
while BC2GM021744548 IN O
rCMRO2 BC2GM021744548 NNS O
decreased BC2GM021744548 VBN O
globally BC2GM021744548 RB O
in BC2GM021744548 IN O
a BC2GM021744548 DT O
dose-dependent BC2GM021744548 JJ O
manner BC2GM021744548 NN O
during BC2GM021744548 IN O
both BC2GM021744548 DT O
isoflurane BC2GM021744548 NN O
and BC2GM021744548 CC O
propofol BC2GM021744548 NN O
anaesthesia BC2GM021744548 NN O
. BC2GM021744548 . O
. . O O

Early BC2GM026532994 JJ O
diagnosis BC2GM026532994 NN O
and BC2GM026532994 CC O
early BC2GM026532994 JJ O
surgical BC2GM026532994 JJ O
division BC2GM026532994 NN O
of BC2GM026532994 IN O
the BC2GM026532994 DT O
biliary BC2GM026532994 JJ O
tract BC2GM026532994 NN O
and BC2GM026532994 CC O
pancreatic BC2GM026532994 JJ O
duct BC2GM026532994 NN O
is BC2GM026532994 VBZ O
recommended BC2GM026532994 VBN O
for BC2GM026532994 IN O
children BC2GM026532994 NNS O
with BC2GM026532994 IN O
AAPBD BC2GM026532994 NNP O
. BC2GM026532994 . O
. . O O

The BC2GM061863069 DT O
GvpE BC2GM061863069 NNP O
protein BC2GM061863069 NN O
involved BC2GM061863069 VBN O
in BC2GM061863069 IN O
the BC2GM061863069 DT O
regulation BC2GM061863069 NN O
of BC2GM061863069 IN O
gas BC2GM061863069 NN O
vesicles BC2GM061863069 NNS O
synthesis BC2GM061863069 NN O
in BC2GM061863069 IN O
halophilic BC2GM061863069 JJ O
archaea BC2GM061863069 NN O
has BC2GM061863069 VBZ O
been BC2GM061863069 VBN O
identified BC2GM061863069 VBN O
as BC2GM061863069 IN O
the BC2GM061863069 DT O
transcriptional BC2GM061863069 JJ O
activator BC2GM061863069 NN O
for BC2GM061863069 IN O
the BC2GM061863069 DT O
promoter BC2GM061863069 NN O
located BC2GM061863069 VBN O
upstream BC2GM061863069 NN O
of BC2GM061863069 IN O
the BC2GM061863069 DT O
gvpA BC2GM061863069 JJ O
gene BC2GM061863069 NN O
encoding BC2GM061863069 VBG O
the BC2GM061863069 DT O
major BC2GM061863069 JJ O
gas BC2GM061863069 NN O
vesicle BC2GM061863069 NN O
structural BC2GM061863069 JJ O
protein BC2GM061863069 NN O
GvpA BC2GM061863069 NNP O
. BC2GM061863069 . O
. . O O

We BC2GM023883518 PRP O
propose BC2GM023883518 VBP O
that BC2GM023883518 IN O
, BC2GM023883518 , O
while BC2GM023883518 IN O
Y. BC2GM023883518 NNP O
lipolytica BC2GM023883518 VBP O
CEN BC2GM023883518 NNP O
DNA BC2GM023883518 NNP O
is BC2GM023883518 VBZ O
essential BC2GM023883518 JJ O
for BC2GM023883518 IN O
plasmid BC2GM023883518 JJ O
maintenance BC2GM023883518 NN O
, BC2GM023883518 , O
this BC2GM023883518 DT O
function BC2GM023883518 NN O
can BC2GM023883518 MD O
be BC2GM023883518 VB O
supplied BC2GM023883518 VBN O
by BC2GM023883518 IN O
several BC2GM023883518 JJ O
sub-fragments BC2GM023883518 NNS O
which BC2GM023883518 WDT O
, BC2GM023883518 , O
together BC2GM023883518 RB O
, BC2GM023883518 , O
form BC2GM023883518 VB O
the BC2GM023883518 DT O
active BC2GM023883518 JJ O
chromosomal BC2GM023883518 NN O
centromere BC2GM023883518 NN O
. BC2GM023883518 . O
. . O O

To BC2GM051369049 TO O
explore BC2GM051369049 VB O
the BC2GM051369049 DT O
mechanism BC2GM051369049 NN O
of BC2GM051369049 IN O
insulin BC2GM051369049 NN O
receptor BC2GM051369049 NN O
phosphorylation BC2GM051369049 NN O
we BC2GM051369049 PRP O
have BC2GM051369049 VBP O
used BC2GM051369049 VBN O
NIH3T3 BC2GM051369049 NNP O
cells BC2GM051369049 NNS O
transfected BC2GM051369049 VBN O
with BC2GM051369049 IN O
two BC2GM051369049 CD O
receptor BC2GM051369049 NN O
constructs BC2GM051369049 NNS O
: BC2GM051369049 : O
one BC2GM051369049 CD O
encoding BC2GM051369049 VBG O
a BC2GM051369049 DT O
chimeric BC2GM051369049 JJ O
receptor BC2GM051369049 NN O
composed BC2GM051369049 VBD O
of BC2GM051369049 IN O
the BC2GM051369049 DT O
extracellular BC2GM051369049 JJ O
domain BC2GM051369049 NN O
of BC2GM051369049 IN O
the BC2GM051369049 DT O
human BC2GM051369049 JJ O
EGF BC2GM051369049 NNP O
receptor BC2GM051369049 NN O
and BC2GM051369049 CC O
the BC2GM051369049 DT O
cytosolic BC2GM051369049 JJ O
domain BC2GM051369049 NN O
of BC2GM051369049 IN O
the BC2GM051369049 DT O
human BC2GM051369049 JJ O
insulin BC2GM051369049 NN O
receptor BC2GM051369049 NN O
beta-subunit BC2GM051369049 NN O
, BC2GM051369049 , O
and BC2GM051369049 CC O
a BC2GM051369049 DT O
second BC2GM051369049 JJ O
construct BC2GM051369049 NN O
encoding BC2GM051369049 VBG O
a BC2GM051369049 DT O
kinase-defiecient BC2GM051369049 JJ O
human BC2GM051369049 JJ O
insulin BC2GM051369049 NN O
receptor BC2GM051369049 NN O
. BC2GM051369049 . O
. . O O

The BC2GM053959497 DT O
molecular BC2GM053959497 JJ O
event BC2GM053959497 NN O
( BC2GM053959497 ( O
s BC2GM053959497 PRP O
) BC2GM053959497 ) O
underlying BC2GM053959497 VBG O
the BC2GM053959497 DT O
functional BC2GM053959497 JJ O
specificities BC2GM053959497 NNS O
of BC2GM053959497 IN O
these BC2GM053959497 DT O
receptors BC2GM053959497 NNS O
( BC2GM053959497 ( O
in BC2GM053959497 IN O
regulating BC2GM053959497 VBG O
the BC2GM053959497 DT O
expression BC2GM053959497 NN O
of BC2GM053959497 IN O
their BC2GM053959497 PRP$ O
native BC2GM053959497 JJ O
target BC2GM053959497 NN O
genes BC2GM053959497 NNS O
) BC2GM053959497 ) O
is BC2GM053959497 VBZ O
a BC2GM053959497 DT O
very BC2GM053959497 RB O
important BC2GM053959497 JJ O
issue BC2GM053959497 NN O
that BC2GM053959497 WDT O
remains BC2GM053959497 VBZ O
poorly BC2GM053959497 RB O
understood BC2GM053959497 JJ O
. BC2GM053959497 . O
. . O O

Left BC2GM091592742 NNP O
ventricular BC2GM091592742 JJ O
insufficiency BC2GM091592742 NN O
requires BC2GM091592742 VBZ O
two BC2GM091592742 CD O
SP BC2GM091592742 NNP O
/ BC2GM091592742 NNP O
patient BC2GM091592742 NN O
, BC2GM091592742 , O
with BC2GM091592742 IN O
good BC2GM091592742 JJ O
results BC2GM091592742 NNS O
in BC2GM091592742 IN O
approximately BC2GM091592742 RB O
81 BC2GM091592742 CD O
p. BC2GM091592742 JJ O
cent BC2GM091592742 NN O
. BC2GM091592742 . O
. . O O

The BC2GM014829301 DT O
derepressed BC2GM014829301 JJ O
expression BC2GM014829301 NN O
of BC2GM014829301 IN O
fixN BC2GM014829301 NN O
was BC2GM014829301 VBD O
not BC2GM014829301 RB O
observed BC2GM014829301 VBN O
in BC2GM014829301 IN O
a BC2GM014829301 DT O
purH BC2GM014829301 NN O
mutant BC2GM014829301 NN O
. BC2GM014829301 . O
. . O O

Biochemical BC2GM090747273 JJ O
studies BC2GM090747273 NNS O
have BC2GM090747273 VBP O
identified BC2GM090747273 VBN O
a BC2GM090747273 DT O
cellular BC2GM090747273 JJ O
non-P BC2GM090747273 JJ O
element-encoded BC2GM090747273 JJ O
DNA BC2GM090747273 NNP O
binding BC2GM090747273 NN O
protein BC2GM090747273 NN O
, BC2GM090747273 , O
termed BC2GM090747273 VBD O
the BC2GM090747273 DT O
inverted BC2GM090747273 JJ O
repeat BC2GM090747273 NN O
binding BC2GM090747273 VBG O
protein BC2GM090747273 NN O
( BC2GM090747273 ( O
IRBP BC2GM090747273 NNP O
) BC2GM090747273 ) O
, BC2GM090747273 , O
that BC2GM090747273 WDT O
specifically BC2GM090747273 RB O
interacts BC2GM090747273 VBZ O
with BC2GM090747273 IN O
the BC2GM090747273 DT O
outer BC2GM090747273 JJ O
half BC2GM090747273 NN O
of BC2GM090747273 IN O
the BC2GM090747273 DT O
31-bp BC2GM090747273 JJ O
terminal BC2GM090747273 NN O
inverted BC2GM090747273 JJ O
repeats BC2GM090747273 NNS O
. BC2GM090747273 . O
. . O O

Regulation BC2GM023376128 NN O
of BC2GM023376128 IN O
the BC2GM023376128 DT O
p21-activated BC2GM023376128 JJ O
kinase BC2GM023376128 NN O
( BC2GM023376128 ( O
PAK BC2GM023376128 NNP O
) BC2GM023376128 ) O
by BC2GM023376128 IN O
a BC2GM023376128 DT O
human BC2GM023376128 JJ O
Gbeta BC2GM023376128 NNP O
-like BC2GM023376128 IN O
WD-repeat BC2GM023376128 NNP O
protein BC2GM023376128 NN O
, BC2GM023376128 , O
hPIP1 BC2GM023376128 NN O
. BC2GM023376128 . O
. . O O

Foamy BC2GM007199944 NNP O
viruses BC2GM007199944 NNS O
( BC2GM007199944 ( O
FVs BC2GM007199944 NNP O
) BC2GM007199944 ) O
express BC2GM007199944 VBP O
the BC2GM007199944 DT O
Gag BC2GM007199944 NNP O
protein BC2GM007199944 NN O
as BC2GM007199944 IN O
a BC2GM007199944 DT O
precursor BC2GM007199944 NN O
with BC2GM007199944 IN O
a BC2GM007199944 DT O
molecular BC2GM007199944 JJ O
mass BC2GM007199944 NN O
of BC2GM007199944 IN O
74 BC2GM007199944 CD O
kDa BC2GM007199944 NNS O
( BC2GM007199944 ( O
pr74 BC2GM007199944 NN O
) BC2GM007199944 ) O
from BC2GM007199944 IN O
which BC2GM007199944 WDT O
a BC2GM007199944 DT O
70-kDa BC2GM007199944 JJ O
protein BC2GM007199944 NN O
( BC2GM007199944 ( O
p70 BC2GM007199944 NN O
) BC2GM007199944 ) O
is BC2GM007199944 VBZ O
cleaved BC2GM007199944 VBN O
by BC2GM007199944 IN O
the BC2GM007199944 DT O
viral BC2GM007199944 JJ O
protease BC2GM007199944 NN O
. BC2GM007199944 . O
. . O O

Of BC2GM096331447 IN O
3841 BC2GM096331447 CD O
serum BC2GM096331447 NN O
samples BC2GM096331447 NNS O
from BC2GM096331447 IN O
sows BC2GM096331447 NNS O
received BC2GM096331447 VBN O
from BC2GM096331447 IN O
the BC2GM096331447 DT O
Tennessee BC2GM096331447 NNP O
State BC2GM096331447 NNP O
Diagnostic BC2GM096331447 NNP O
Laboratory BC2GM096331447 NNP O
in BC2GM096331447 IN O
1991-1992 BC2GM096331447 CD O
, BC2GM096331447 , O
1130 BC2GM096331447 CD O
were BC2GM096331447 VBD O
positive BC2GM096331447 JJ O
for BC2GM096331447 IN O
Toxoplasma BC2GM096331447 NNP O
gondii BC2GM096331447 NN O
antibody BC2GM096331447 NN O
. BC2GM096331447 . O
. . O O

The BC2GM089297892 DT O
etiology BC2GM089297892 NN O
was BC2GM089297892 VBD O
established BC2GM089297892 VBN O
in BC2GM089297892 IN O
73 BC2GM089297892 CD O
( BC2GM089297892 ( O
76.8 BC2GM089297892 CD O
% BC2GM089297892 NN O
) BC2GM089297892 ) O
out BC2GM089297892 IN O
of BC2GM089297892 IN O
95 BC2GM089297892 CD O
cases BC2GM089297892 NNS O
. BC2GM089297892 . O
. . O O

Role BC2GM019659042 NNP O
of BC2GM019659042 IN O
distinct BC2GM019659042 JJ O
mitogen-activated BC2GM019659042 JJ O
protein BC2GM019659042 NN O
kinase BC2GM019659042 NN O
pathways BC2GM019659042 NNS O
and BC2GM019659042 CC O
cooperation BC2GM019659042 NN O
between BC2GM019659042 IN O
Ets-2 BC2GM019659042 NNP O
, BC2GM019659042 , O
ATF-2 BC2GM019659042 NNP O
, BC2GM019659042 , O
and BC2GM019659042 CC O
Jun BC2GM019659042 NNP O
family BC2GM019659042 NN O
members BC2GM019659042 NNS O
in BC2GM019659042 IN O
human BC2GM019659042 JJ O
urokinase-type BC2GM019659042 JJ O
plasminogen BC2GM019659042 NN O
activator BC2GM019659042 NN O
gene BC2GM019659042 NN O
induction BC2GM019659042 NN O
by BC2GM019659042 IN O
interleukin-1 BC2GM019659042 JJ O
and BC2GM019659042 CC O
tetradecanoyl BC2GM019659042 JJ O
phorbol BC2GM019659042 NN O
acetate BC2GM019659042 NN O
. BC2GM019659042 . O
. . O O

Were BC2GM050603433 WRB O
this BC2GM050603433 DT O
hypothesis BC2GM050603433 NN O
correct BC2GM050603433 NN O
, BC2GM050603433 , O
the BC2GM050603433 DT O
requirement BC2GM050603433 NN O
for BC2GM050603433 IN O
elF4A BC2GM050603433 NN O
should BC2GM050603433 MD O
correlate BC2GM050603433 VB O
with BC2GM050603433 IN O
the BC2GM050603433 DT O
degree BC2GM050603433 NN O
of BC2GM050603433 IN O
mRNA BC2GM050603433 NN O
secondary BC2GM050603433 JJ O
structure BC2GM050603433 NN O
. BC2GM050603433 . O
. . O O

Where BC2GM007239314 WRB O
the BC2GM007239314 DT O
resonator BC2GM007239314 NN O
has BC2GM007239314 VBZ O
two BC2GM007239314 CD O
holes BC2GM007239314 NNS O
, BC2GM007239314 , O
these BC2GM007239314 DT O
terms BC2GM007239314 NNS O
should BC2GM007239314 MD O
be BC2GM007239314 VB O
somewhat BC2GM007239314 RB O
modified BC2GM007239314 JJ O
: BC2GM007239314 : O
A BC2GM007239314 DT O
is BC2GM007239314 VBZ O
the BC2GM007239314 DT O
combined BC2GM007239314 JJ O
area BC2GM007239314 NN O
of BC2GM007239314 IN O
the BC2GM007239314 DT O
two BC2GM007239314 CD O
holes BC2GM007239314 NNS O
, BC2GM007239314 , O
L BC2GM007239314 NNP O
is BC2GM007239314 VBZ O
16 BC2GM007239314 CD O
/ BC2GM007239314 NN O
3pi BC2GM007239314 CD O
r BC2GM007239314 NN O
( BC2GM007239314 ( O
~1.7r BC2GM007239314 NNP O
) BC2GM007239314 ) O
for BC2GM007239314 IN O
a BC2GM007239314 DT O
simple BC2GM007239314 JJ O
hole BC2GM007239314 NN O
in BC2GM007239314 IN O
a BC2GM007239314 DT O
thin-walled BC2GM007239314 JJ O
vessel BC2GM007239314 NN O
and BC2GM007239314 CC O
r BC2GM007239314 NN O
is BC2GM007239314 VBZ O
the BC2GM007239314 DT O
radius BC2GM007239314 NN O
of BC2GM007239314 IN O
one BC2GM007239314 CD O
hole BC2GM007239314 NN O
( BC2GM007239314 ( O
Seto BC2GM007239314 NNP O
, BC2GM007239314 , O
1971 BC2GM007239314 CD O
) BC2GM007239314 ) O
. BC2GM007239314 . O
. . O O

However BC2GM066438188 RB O
, BC2GM066438188 , O
additional BC2GM066438188 JJ O
studies BC2GM066438188 NNS O
on BC2GM066438188 IN O
cell BC2GM066438188 NN O
lines BC2GM066438188 NNS O
and BC2GM066438188 CC O
whole BC2GM066438188 JJ O
animals BC2GM066438188 NNS O
are BC2GM066438188 VBP O
required BC2GM066438188 VBN O
to BC2GM066438188 TO O
understand BC2GM066438188 VB O
GnRH BC2GM066438188 NNP O
signaling BC2GM066438188 VBG O
in BC2GM066438188 IN O
the BC2GM066438188 DT O
context BC2GM066438188 NN O
of BC2GM066438188 IN O
other BC2GM066438188 JJ O
hormones BC2GM066438188 NNS O
during BC2GM066438188 IN O
the BC2GM066438188 DT O
reproductive BC2GM066438188 JJ O
cycle BC2GM066438188 NN O
of BC2GM066438188 IN O
mouse BC2GM066438188 NN O
and BC2GM066438188 CC O
human BC2GM066438188 NN O
. BC2GM066438188 . O
. . O O

The BC2GM087025767 DT O
subjects BC2GM087025767 NNS O
were BC2GM087025767 VBD O
17 BC2GM087025767 CD O
patients BC2GM087025767 NNS O
with BC2GM087025767 IN O
android BC2GM087025767 JJ O
obesity BC2GM087025767 NN O
( BC2GM087025767 ( O
four BC2GM087025767 CD O
men BC2GM087025767 NNS O
and BC2GM087025767 CC O
13 BC2GM087025767 CD O
women BC2GM087025767 NNS O
) BC2GM087025767 ) O
aged BC2GM087025767 VBD O
21 BC2GM087025767 CD O
to BC2GM087025767 TO O
58 BC2GM087025767 CD O
years BC2GM087025767 NNS O
with BC2GM087025767 IN O
a BC2GM087025767 DT O
body BC2GM087025767 NN O
mass BC2GM087025767 NN O
index BC2GM087025767 NN O
( BC2GM087025767 ( O
BMI BC2GM087025767 NNP O
) BC2GM087025767 ) O
ranging BC2GM087025767 VBG O
from BC2GM087025767 IN O
32.0 BC2GM087025767 CD O
to BC2GM087025767 TO O
52.2 BC2GM087025767 CD O
kg BC2GM087025767 NNS O
/ BC2GM087025767 JJ O
m2 BC2GM087025767 NN O
and BC2GM087025767 CC O
an BC2GM087025767 DT O
abdominal-gluteal BC2GM087025767 JJ O
ratio BC2GM087025767 NN O
greater BC2GM087025767 JJR O
than BC2GM087025767 IN O
1.0 BC2GM087025767 CD O
. BC2GM087025767 . O
. . O O

Identification BC2GM090412824 NN O
of BC2GM090412824 IN O
masked BC2GM090412824 JJ O
toxins BC2GM090412824 NNS O
in BC2GM090412824 IN O
the BC2GM090412824 DT O
exotoxin BC2GM090412824 NN O
complex BC2GM090412824 NN O
of BC2GM090412824 IN O
Staphylococcus BC2GM090412824 NNP O
pyogenes BC2GM090412824 NNS O
und BC2GM090412824 IN O
Cl BC2GM090412824 NNP O
. BC2GM090412824 . O
perfringens BC2GM090412824 NNS O
; BC2GM090412824 : O
significance BC2GM090412824 NN O
of BC2GM090412824 IN O
their BC2GM090412824 PRP$ O
existence BC2GM090412824 NN O
for BC2GM090412824 IN O
clarifying BC2GM090412824 NN O
of BC2GM090412824 IN O
the BC2GM090412824 DT O
masking BC2GM090412824 NN O
mechanism BC2GM090412824 NN O
. BC2GM090412824 . O
. . O O

Treatment BC2GM078543585 NN O
of BC2GM078543585 IN O
JEA2 BC2GM078543585 NNP O
cells BC2GM078543585 NNS O
with BC2GM078543585 IN O
interleukin BC2GM078543585 NN O
( BC2GM078543585 ( O
IL BC2GM078543585 NNP O
) BC2GM078543585 ) O
-7 BC2GM078543585 NN O
induces BC2GM078543585 NNS O
CBLB BC2GM078543585 NNP O
phosphorylation BC2GM078543585 NN O
as BC2GM078543585 RB O
well BC2GM078543585 RB O
. BC2GM078543585 . O
. . O O

RESULTS BC2GM088454426 NN O
: BC2GM088454426 : O
Analysis BC2GM088454426 NN O
by BC2GM088454426 IN O
Pearson BC2GM088454426 NNP O
's BC2GM088454426 POS O
correlation BC2GM088454426 NN O
showed BC2GM088454426 VBD O
that BC2GM088454426 IN O
the BC2GM088454426 DT O
subjects BC2GM088454426 NNS O
who BC2GM088454426 WP O
had BC2GM088454426 VBD O
higher BC2GM088454426 JJR O
scores BC2GM088454426 NNS O
of BC2GM088454426 IN O
SSMS BC2GM088454426 NNP O
during BC2GM088454426 IN O
the BC2GM088454426 DT O
drum BC2GM088454426 JJ O
rotation BC2GM088454426 NN O
generated BC2GM088454426 VBD O
the BC2GM088454426 DT O
following BC2GM088454426 JJ O
: BC2GM088454426 : O
a BC2GM088454426 DT O
) BC2GM088454426 ) O
a BC2GM088454426 DT O
higher BC2GM088454426 JJR O
rating BC2GM088454426 NN O
of BC2GM088454426 IN O
over-all BC2GM088454426 JJ O
sickness BC2GM088454426 NN O
( BC2GM088454426 ( O
r BC2GM088454426 JJ O
= BC2GM088454426 NNP O
0.76 BC2GM088454426 CD O
) BC2GM088454426 ) O
; BC2GM088454426 : O
b BC2GM088454426 NN O
) BC2GM088454426 ) O
a BC2GM088454426 DT O
higher BC2GM088454426 JJR O
ratio BC2GM088454426 NN O
of BC2GM088454426 IN O
spectral BC2GM088454426 JJ O
power BC2GM088454426 NN O
of BC2GM088454426 IN O
EGG BC2GM088454426 NNP O
at BC2GM088454426 IN O
4-9 BC2GM088454426 JJ O
cycles BC2GM088454426 NNS O
per BC2GM088454426 IN O
minute BC2GM088454426 NN O
( BC2GM088454426 ( O
cpm BC2GM088454426 NN O
) BC2GM088454426 ) O
between BC2GM088454426 IN O
drum BC2GM088454426 NN O
rotation BC2GM088454426 NN O
and BC2GM088454426 CC O
baseline BC2GM088454426 NN O
periods BC2GM088454426 NNS O
( BC2GM088454426 ( O
r BC2GM088454426 VB O
= BC2GM088454426 RB O
0.63 BC2GM088454426 CD O
) BC2GM088454426 ) O
; BC2GM088454426 : O
c BC2GM088454426 VBN O
) BC2GM088454426 ) O
a BC2GM088454426 DT O
higher BC2GM088454426 JJR O
net BC2GM088454426 JJ O
percent BC2GM088454426 NN O
increase BC2GM088454426 NN O
of BC2GM088454426 IN O
spectral BC2GM088454426 JJ O
power BC2GM088454426 NN O
in BC2GM088454426 IN O
the BC2GM088454426 DT O
EEG BC2GM088454426 NNP O
frequency BC2GM088454426 NN O
band BC2GM088454426 NN O
0.5-4 BC2GM088454426 JJ O
Hz BC2GM088454426 NNP O
between BC2GM088454426 IN O
drum BC2GM088454426 NN O
rotation BC2GM088454426 NN O
and BC2GM088454426 CC O
baseline BC2GM088454426 NN O
periods BC2GM088454426 NNS O
on BC2GM088454426 IN O
C3 BC2GM088454426 NNP O
( BC2GM088454426 ( O
r BC2GM088454426 VB O
= BC2GM088454426 RB O
0.29 BC2GM088454426 CD O
) BC2GM088454426 ) O
and BC2GM088454426 CC O
C4 BC2GM088454426 NNP O
( BC2GM088454426 ( O
r BC2GM088454426 VB O
= BC2GM088454426 RB O
0.31 BC2GM088454426 CD O
) BC2GM088454426 ) O
; BC2GM088454426 : O
d BC2GM088454426 NN O
) BC2GM088454426 ) O
a BC2GM088454426 DT O
higher BC2GM088454426 JJR O
ratio BC2GM088454426 NN O
of BC2GM088454426 IN O
spectral BC2GM088454426 JJ O
power BC2GM088454426 NN O
of BC2GM088454426 IN O
EEG BC2GM088454426 NNP O
frequency BC2GM088454426 NN O
band BC2GM088454426 NN O
0.5-4 BC2GM088454426 JJ O
Hz BC2GM088454426 NNP O
between BC2GM088454426 IN O
drum BC2GM088454426 NN O
rotation BC2GM088454426 NN O
and BC2GM088454426 CC O
baseline BC2GM088454426 NN O
periods BC2GM088454426 NNS O
on BC2GM088454426 IN O
C3 BC2GM088454426 NNP O
( BC2GM088454426 ( O
r BC2GM088454426 VB O
= BC2GM088454426 RB O
0.31 BC2GM088454426 CD O
) BC2GM088454426 ) O
; BC2GM088454426 : O
and BC2GM088454426 CC O
e BC2GM088454426 VB O
) BC2GM088454426 ) O
a BC2GM088454426 DT O
higher BC2GM088454426 JJR O
level BC2GM088454426 NN O
of BC2GM088454426 IN O
net BC2GM088454426 JJ O
increase BC2GM088454426 NN O
in BC2GM088454426 IN O
skin BC2GM088454426 JJ O
conductance BC2GM088454426 NN O
from BC2GM088454426 IN O
baseline BC2GM088454426 NN O
to BC2GM088454426 TO O
drum BC2GM088454426 VB O
rotation BC2GM088454426 NN O
( BC2GM088454426 ( O
r BC2GM088454426 JJ O
= BC2GM088454426 NNP O
0.30 BC2GM088454426 CD O
) BC2GM088454426 ) O
. BC2GM088454426 . O
. . O O

CONCLUSION BC2GM093097670 NN O
: BC2GM093097670 : O
In BC2GM093097670 IN O
these BC2GM093097670 DT O
patients BC2GM093097670 NNS O
control BC2GM093097670 NN O
of BC2GM093097670 IN O
ventricular BC2GM093097670 JJ O
response BC2GM093097670 NN O
rate BC2GM093097670 NN O
with BC2GM093097670 IN O
either BC2GM093097670 DT O
HBA BC2GM093097670 NNP O
+ BC2GM093097670 NNP O
VVIR BC2GM093097670 NNP O
pacemaker BC2GM093097670 NN O
or BC2GM093097670 CC O
atrioventricular BC2GM093097670 JJ O
modifying BC2GM093097670 NN O
drugs BC2GM093097670 NNS O
+ BC2GM093097670 VBP O
VVI BC2GM093097670 NNP O
pacemaker BC2GM093097670 NN O
will BC2GM093097670 MD O
lead BC2GM093097670 VB O
to BC2GM093097670 TO O
a BC2GM093097670 DT O
significant BC2GM093097670 JJ O
improvement BC2GM093097670 NN O
in BC2GM093097670 IN O
exercise BC2GM093097670 NN O
duration BC2GM093097670 NN O
and BC2GM093097670 CC O
quality BC2GM093097670 NN O
of BC2GM093097670 IN O
life BC2GM093097670 NN O
. BC2GM093097670 . O
. . O O

Expression BC2GM039440214 NN O
of BC2GM039440214 IN O
medical BC2GM039440214 JJ O
efficiency BC2GM039440214 NN O
by BC2GM039440214 IN O
integration BC2GM039440214 NN O
indicators BC2GM039440214 NNS O
with BC2GM039440214 IN O
the BC2GM039440214 DT O
rational BC2GM039440214 JJ O
utilization BC2GM039440214 NN O
of BC2GM039440214 IN O
budgeted BC2GM039440214 JJ O
funds BC2GM039440214 NNS O
. BC2GM039440214 . O
. . O O

Skytthe BC2GM033197644 NNP O
, BC2GM033197644 , O
and BC2GM033197644 CC O
K BC2GM033197644 NNP O
. BC2GM033197644 . O
. . O O

Extracellular BC2GM060649336 JJ O
regulated BC2GM060649336 VBN O
kinases BC2GM060649336 NNS O
( BC2GM060649336 ( O
ERK BC2GM060649336 NNP O
) BC2GM060649336 ) O
1 BC2GM060649336 CD O
and BC2GM060649336 CC O
ERK2 BC2GM060649336 NNP O
are BC2GM060649336 VBP O
authentic BC2GM060649336 JJ O
substrates BC2GM060649336 NNS O
for BC2GM060649336 IN O
the BC2GM060649336 DT O
dual-specificity BC2GM060649336 JJ O
protein-tyrosine BC2GM060649336 JJ O
phosphatase BC2GM060649336 NN O
VHR BC2GM060649336 NNP O
. BC2GM060649336 . O
. . O O

Tumor BC2GM087902003 NN O
necrosis BC2GM087902003 NN O
factor BC2GM087902003 NN O
levels BC2GM087902003 NNS O
were BC2GM087902003 VBD O
measured BC2GM087902003 VBN O
by BC2GM087902003 IN O
enzyme-linked BC2GM087902003 JJ O
immunoabsorbent BC2GM087902003 NN O
assay BC2GM087902003 NN O
in BC2GM087902003 IN O
plasma BC2GM087902003 NN O
samples BC2GM087902003 NNS O
obtained BC2GM087902003 VBN O
from BC2GM087902003 IN O
the BC2GM087902003 DT O
hyperthermic BC2GM087902003 JJ O
isolated BC2GM087902003 JJ O
limb BC2GM087902003 NN O
perfusion BC2GM087902003 NN O
circuit BC2GM087902003 NN O
and BC2GM087902003 CC O
systemic BC2GM087902003 JJ O
circulation BC2GM087902003 NN O
. BC2GM087902003 . O
. . O O

A BC2GM061678141 DT O
close BC2GM061678141 JJ O
homologue BC2GM061678141 NN O
of BC2GM061678141 IN O
the BC2GM061678141 DT O
APK2a BC2GM061678141 NNP O
gene BC2GM061678141 NN O
, BC2GM061678141 , O
named BC2GM061678141 VBN O
APK2b BC2GM061678141 NNP O
, BC2GM061678141 , O
was BC2GM061678141 VBD O
also BC2GM061678141 RB O
isolated BC2GM061678141 VBN O
from BC2GM061678141 IN O
the BC2GM061678141 DT O
Arabidopsis BC2GM061678141 NNP O
cDNA BC2GM061678141 NN O
library BC2GM061678141 NN O
. BC2GM061678141 . O
. . O O

Transcription BC2GM025278730 NNP O
factor BC2GM025278730 NN O
IIIC BC2GM025278730 NNP O
( BC2GM025278730 ( O
TFIIIC BC2GM025278730 NNP O
) BC2GM025278730 ) O
is BC2GM025278730 VBZ O
required BC2GM025278730 VBN O
for BC2GM025278730 IN O
the BC2GM025278730 DT O
assembly BC2GM025278730 NN O
of BC2GM025278730 IN O
a BC2GM025278730 DT O
preinitiation BC2GM025278730 NN O
complex BC2GM025278730 NN O
on BC2GM025278730 IN O
5S BC2GM025278730 CD O
RNA BC2GM025278730 NNP O
, BC2GM025278730 , O
tRNA BC2GM025278730 NN O
, BC2GM025278730 , O
and BC2GM025278730 CC O
adenovirus BC2GM025278730 RB O
VA BC2GM025278730 NNP O
RNA BC2GM025278730 NNP O
genes BC2GM025278730 NNS O
and BC2GM025278730 CC O
contains BC2GM025278730 NNS O
two BC2GM025278730 CD O
separable BC2GM025278730 JJ O
components BC2GM025278730 NNS O
, BC2GM025278730 , O
TFIIIC1 BC2GM025278730 NNP O
and BC2GM025278730 CC O
TFIIIC2 BC2GM025278730 NNP O
. BC2GM025278730 . O
. . O O

A BC2GM054126156 DT O
genomic BC2GM054126156 JJ O
clone BC2GM054126156 NN O
representing BC2GM054126156 VBG O
the BC2GM054126156 DT O
5 BC2GM054126156 CD O
' BC2GM054126156 POS O
part BC2GM054126156 NN O
of BC2GM054126156 IN O
the BC2GM054126156 DT O
message BC2GM054126156 NN O
was BC2GM054126156 VBD O
also BC2GM054126156 RB O
isolated BC2GM054126156 VBN O
. BC2GM054126156 . O
. . O O

CONCLUSIONS BC2GM008294222 NN O
: BC2GM008294222 : O
In BC2GM008294222 IN O
the BC2GM008294222 DT O
results BC2GM008294222 NNS O
of BC2GM008294222 IN O
this BC2GM008294222 DT O
study BC2GM008294222 NN O
, BC2GM008294222 , O
SDB BC2GM008294222 NNP O
, BC2GM008294222 , O
even BC2GM008294222 RB O
snoring BC2GM008294222 VBG O
, BC2GM008294222 , O
was BC2GM008294222 VBD O
independently BC2GM008294222 RB O
associated BC2GM008294222 VBN O
with BC2GM008294222 IN O
hypertension BC2GM008294222 NN O
in BC2GM008294222 IN O
both BC2GM008294222 DT O
men BC2GM008294222 NNS O
and BC2GM008294222 CC O
women BC2GM008294222 NNS O
. BC2GM008294222 . O
. . O O

In BC2GM052999233 IN O
addition BC2GM052999233 NN O
, BC2GM052999233 , O
wild-type BC2GM052999233 JJ O
and BC2GM052999233 CC O
mutated BC2GM052999233 JJ O
DNA BC2GM052999233 NN O
templates BC2GM052999233 NNS O
were BC2GM052999233 VBD O
used BC2GM052999233 VBN O
as BC2GM052999233 IN O
probes BC2GM052999233 NNS O
in BC2GM052999233 IN O
DNase BC2GM052999233 NNP O
I BC2GM052999233 PRP O
protection BC2GM052999233 NN O
experiments BC2GM052999233 NNS O
to BC2GM052999233 TO O
determine BC2GM052999233 VB O
sites BC2GM052999233 NNS O
of BC2GM052999233 IN O
protein-DNA BC2GM052999233 JJ O
interaction BC2GM052999233 NN O
. BC2GM052999233 . O
. . O O

The BC2GM021758062 DT O
results BC2GM021758062 NNS O
of BC2GM021758062 IN O
this BC2GM021758062 DT O
study BC2GM021758062 NN O
indicate BC2GM021758062 VBP O
that BC2GM021758062 IN O
the BC2GM021758062 DT O
Improved BC2GM021758062 NNP O
Crest BC2GM021758062 NNP O
Complete BC2GM021758062 NNP O
with BC2GM021758062 IN O
longer BC2GM021758062 JJR O
rippled BC2GM021758062 VBN O
outer BC2GM021758062 NN O
bristles BC2GM021758062 NNS O
provided BC2GM021758062 VBD O
significantly BC2GM021758062 RB O
superior BC2GM021758062 JJ O
( BC2GM021758062 ( O
p BC2GM021758062 JJ O
< BC2GM021758062 NNP O
0.05 BC2GM021758062 CD O
) BC2GM021758062 ) O
interproximal BC2GM021758062 JJ O
penetration BC2GM021758062 NN O
overall BC2GM021758062 JJ O
and BC2GM021758062 CC O
at BC2GM021758062 IN O
the BC2GM021758062 DT O
gumline BC2GM021758062 NN O
than BC2GM021758062 IN O
the BC2GM021758062 DT O
Colgate BC2GM021758062 NNP O
Total BC2GM021758062 NNP O
and BC2GM021758062 CC O
Oral-B BC2GM021758062 NNP O
Advantage BC2GM021758062 NNP O
brushes BC2GM021758062 NNS O
. BC2GM021758062 . O
. . O O

These BC2GM020102507 DT O
results BC2GM020102507 NNS O
provide BC2GM020102507 VBP O
strong BC2GM020102507 JJ O
evidence BC2GM020102507 NN O
that BC2GM020102507 IN O
conserved BC2GM020102507 VBD O
interhelical BC2GM020102507 JJ O
packing BC2GM020102507 NN O
interactions BC2GM020102507 NNS O
in BC2GM020102507 IN O
the BC2GM020102507 DT O
gp41 BC2GM020102507 NN O
core BC2GM020102507 NN O
are BC2GM020102507 VBP O
important BC2GM020102507 JJ O
determinants BC2GM020102507 NNS O
of BC2GM020102507 IN O
HIV-1 BC2GM020102507 NNP O
entry BC2GM020102507 NN O
and BC2GM020102507 CC O
its BC2GM020102507 PRP$ O
inhibition BC2GM020102507 NN O
. BC2GM020102507 . O
. . O O

In BC2GM089015386 IN O
contrast BC2GM089015386 NN O
, BC2GM089015386 , O
an BC2GM089015386 DT O
N-terminal BC2GM089015386 JJ O
RNAP BC2GM089015386 NNP O
mutant BC2GM089015386 NN O
that BC2GM089015386 WDT O
has BC2GM089015386 VBZ O
a BC2GM089015386 DT O
decreased BC2GM089015386 VBN O
capacity BC2GM089015386 NN O
to BC2GM089015386 TO O
bind BC2GM089015386 VB O
single-stranded BC2GM089015386 JJ O
RNA BC2GM089015386 NNP O
forms BC2GM089015386 NNS O
halted BC2GM089015386 VBD O
complexes BC2GM089015386 NNS O
with BC2GM089015386 IN O
much BC2GM089015386 JJ O
lower BC2GM089015386 JJR O
levels BC2GM089015386 NNS O
of BC2GM089015386 IN O
stability BC2GM089015386 NN O
than BC2GM089015386 IN O
the BC2GM089015386 DT O
WT BC2GM089015386 NNP O
enzyme BC2GM089015386 NN O
, BC2GM089015386 , O
and BC2GM089015386 CC O
these BC2GM089015386 DT O
complexes BC2GM089015386 NNS O
are BC2GM089015386 VBP O
not BC2GM089015386 RB O
stabilized BC2GM089015386 VBN O
by BC2GM089015386 IN O
the BC2GM089015386 DT O
presence BC2GM089015386 NN O
of BC2GM089015386 IN O
the BC2GM089015386 DT O
NT BC2GM089015386 NNP O
strand BC2GM089015386 NN O
. BC2GM089015386 . O
. . O O

Two BC2GM075340756 CD O
estimates BC2GM075340756 NNS O
of BC2GM075340756 IN O
the BC2GM075340756 DT O
fractal BC2GM075340756 JJ O
exponent BC2GM075340756 NN O
are BC2GM075340756 VBP O
considered BC2GM075340756 VBN O
which BC2GM075340756 WDT O
do BC2GM075340756 VBP O
not BC2GM075340756 RB O
suffer BC2GM075340756 VB O
from BC2GM075340756 IN O
this BC2GM075340756 DT O
limit BC2GM075340756 NN O
: BC2GM075340756 : O
one BC2GM075340756 CD O
derived BC2GM075340756 VBN O
from BC2GM075340756 IN O
the BC2GM075340756 DT O
Allan BC2GM075340756 NNP O
variance BC2GM075340756 NN O
, BC2GM075340756 , O
which BC2GM075340756 WDT O
was BC2GM075340756 VBD O
developed BC2GM075340756 VBN O
by BC2GM075340756 IN O
the BC2GM075340756 DT O
authors BC2GM075340756 NNS O
, BC2GM075340756 , O
and BC2GM075340756 CC O
one BC2GM075340756 CD O
based BC2GM075340756 VBN O
on BC2GM075340756 IN O
the BC2GM075340756 DT O
periodogram BC2GM075340756 NN O
. BC2GM075340756 . O
. . O O

A BC2GM081530471 DT O
significant BC2GM081530471 JJ O
increase BC2GM081530471 NN O
of BC2GM081530471 IN O
gastric BC2GM081530471 JJ O
mucosal BC2GM081530471 NN O
permeability BC2GM081530471 NN O
was BC2GM081530471 VBD O
observed BC2GM081530471 VBN O
in BC2GM081530471 IN O
six BC2GM081530471 CD O
normal BC2GM081530471 JJ O
human BC2GM081530471 JJ O
subjects BC2GM081530471 NNS O
after BC2GM081530471 IN O
instillation BC2GM081530471 NN O
of BC2GM081530471 IN O
ethanol BC2GM081530471 NN O
( BC2GM081530471 ( O
20 BC2GM081530471 CD O
percent BC2GM081530471 NN O
v BC2GM081530471 NN O
/ BC2GM081530471 NNP O
v BC2GM081530471 NN O
) BC2GM081530471 ) O
. BC2GM081530471 . O
. . O O

Diff-Quik BC2GM079928665 NNP O
stain BC2GM079928665 NN O
for BC2GM079928665 IN O
Tzanck BC2GM079928665 NNP O
smears BC2GM079928665 NNS O
. BC2GM079928665 . O
. . O O

Homology BC2GM020497918 NNP O
is BC2GM020497918 VBZ O
much BC2GM020497918 RB O
higher BC2GM020497918 JJR O
( BC2GM020497918 ( O
64 BC2GM020497918 CD O
% BC2GM020497918 NN O
) BC2GM020497918 ) O
between BC2GM020497918 IN O
the BC2GM020497918 DT O
28-kDa BC2GM020497918 JJ O
protein BC2GM020497918 NN O
and BC2GM020497918 CC O
regions BC2GM020497918 NNS O
that BC2GM020497918 WDT O
are BC2GM020497918 VBP O
strongly BC2GM020497918 RB O
conserved BC2GM020497918 VBN O
among BC2GM020497918 IN O
the BC2GM020497918 DT O
members BC2GM020497918 NNS O
of BC2GM020497918 IN O
the BC2GM020497918 DT O
serine BC2GM020497918 JJ O
protease BC2GM020497918 NN O
family BC2GM020497918 NN O
. BC2GM020497918 . O
. . O O

Copyright BC2GM000462914 JJ O
2000 BC2GM000462914 CD O
Academic BC2GM000462914 NNP O
Press BC2GM000462914 NNP O
. BC2GM000462914 . O
. . O O

Following BC2GM012849815 VBG O
replicate BC2GM012849815 NN O
control BC2GM012849815 NN O
measurements BC2GM012849815 NNS O
, BC2GM012849815 , O
test BC2GM012849815 NN O
ramps BC2GM012849815 NNS O
were BC2GM012849815 VBD O
repeated BC2GM012849815 VBN O
in BC2GM012849815 IN O
the BC2GM012849815 DT O
presence BC2GM012849815 NN O
of BC2GM012849815 IN O
sodium BC2GM012849815 NN O
nitroprusside BC2GM012849815 NN O
( BC2GM012849815 ( O
1 BC2GM012849815 CD O
microM BC2GM012849815 NN O
) BC2GM012849815 ) O
and BC2GM012849815 CC O
phentolamine BC2GM012849815 NN O
( BC2GM012849815 ( O
1 BC2GM012849815 CD O
microM BC2GM012849815 NN O
) BC2GM012849815 ) O
to BC2GM012849815 TO O
eliminate BC2GM012849815 VB O
potential BC2GM012849815 JJ O
smooth BC2GM012849815 JJ O
muscle BC2GM012849815 NN O
and BC2GM012849815 CC O
alpha BC2GM012849815 JJ O
1-adrenoceptor BC2GM012849815 JJ O
effects BC2GM012849815 NNS O
, BC2GM012849815 , O
respectively BC2GM012849815 RB O
. BC2GM012849815 . O
. . O O

Significantly BC2GM017992906 RB O
, BC2GM017992906 , O
the BC2GM017992906 DT O
murine BC2GM017992906 NN O
P-selectin BC2GM017992906 NNP O
gene BC2GM017992906 NN O
had BC2GM017992906 VBD O
several BC2GM017992906 JJ O
features BC2GM017992906 NNS O
not BC2GM017992906 RB O
found BC2GM017992906 VBN O
in BC2GM017992906 IN O
the BC2GM017992906 DT O
human BC2GM017992906 JJ O
gene BC2GM017992906 NN O
. BC2GM017992906 . O
. . O O

Torsion BC2GM063086995 NN O
of BC2GM063086995 IN O
the BC2GM063086995 DT O
contralateral BC2GM063086995 JJ O
testis BC2GM063086995 NN O
5 BC2GM063086995 CD O
years BC2GM063086995 NNS O
after BC2GM063086995 IN O
orchiopexy BC2GM063086995 NN O
. BC2GM063086995 . O
. . O O

This BC2GM072711375 DT O
case BC2GM072711375 NN O
report BC2GM072711375 NN O
describes BC2GM072711375 VBZ O
the BC2GM072711375 DT O
treatment BC2GM072711375 NN O
of BC2GM072711375 IN O
a BC2GM072711375 DT O
patient BC2GM072711375 NN O
with BC2GM072711375 IN O
periodontosis BC2GM072711375 NN O
. BC2GM072711375 . O
. . O O

All BC2GM096229187 DT O
three BC2GM096229187 CD O
SSV-transformed BC2GM096229187 NNP O
cells BC2GM096229187 NNS O
secreted BC2GM096229187 VBD O
v-sis BC2GM096229187 JJ O
gene BC2GM096229187 NN O
product BC2GM096229187 NN O
( BC2GM096229187 ( O
p44 BC2GM096229187 JJ O
) BC2GM096229187 ) O
. BC2GM096229187 . O
p44 BC2GM096229187 NN O
was BC2GM096229187 VBD O
secreted BC2GM096229187 VBN O
but BC2GM096229187 CC O
remained BC2GM096229187 VBN O
tightly BC2GM096229187 RB O
associated BC2GM096229187 VBN O
with BC2GM096229187 IN O
the BC2GM096229187 DT O
cell BC2GM096229187 NN O
surface BC2GM096229187 NN O
. BC2GM096229187 . O
. . O O

Validity BC2GM011270186 NN O
of BC2GM011270186 IN O
the BC2GM011270186 DT O
short-form BC2GM011270186 JJ O
QIF BC2GM011270186 NNP O
was BC2GM011270186 VBD O
assessed BC2GM011270186 VBN O
by BC2GM011270186 IN O
correlation BC2GM011270186 NN O
with BC2GM011270186 IN O
motor BC2GM011270186 NN O
scores BC2GM011270186 NNS O
and BC2GM011270186 CC O
using BC2GM011270186 VBG O
analysis BC2GM011270186 NN O
of BC2GM011270186 IN O
variance BC2GM011270186 NN O
by BC2GM011270186 IN O
motor BC2GM011270186 NN O
levels BC2GM011270186 NNS O
and BC2GM011270186 CC O
motor BC2GM011270186 NN O
score BC2GM011270186 NN O
groupings BC2GM011270186 NNS O
. BC2GM011270186 . O
. . O O

Expression BC2GM068318843 NN O
of BC2GM068318843 IN O
these BC2GM068318843 DT O
chemokines BC2GM068318843 NNS O
is BC2GM068318843 VBZ O
similar BC2GM068318843 JJ O
in BC2GM068318843 IN O
that BC2GM068318843 DT O
both BC2GM068318843 DT O
require BC2GM068318843 VBP O
the BC2GM068318843 DT O
NF-kappa BC2GM068318843 NNP O
B BC2GM068318843 NNP O
element BC2GM068318843 NN O
and BC2GM068318843 CC O
additional BC2GM068318843 JJ O
regions BC2GM068318843 NNS O
such BC2GM068318843 JJ O
as BC2GM068318843 IN O
the BC2GM068318843 DT O
CAAT BC2GM068318843 NNP O
/ BC2GM068318843 NNP O
enhancer BC2GM068318843 NN O
binding BC2GM068318843 VBG O
protein BC2GM068318843 NN O
( BC2GM068318843 ( O
C BC2GM068318843 NNP O
/ BC2GM068318843 NNP O
EBP BC2GM068318843 NNP O
) BC2GM068318843 ) O
element BC2GM068318843 NN O
of BC2GM068318843 IN O
the BC2GM068318843 DT O
IL-8 BC2GM068318843 NNP O
promoter BC2GM068318843 NN O
. BC2GM068318843 . O
. . O O

Since BC2GM057130541 IN O
1985 BC2GM057130541 CD O
the BC2GM057130541 DT O
combination BC2GM057130541 NN O
of BC2GM057130541 IN O
chlorambucil BC2GM057130541 NN O
( BC2GM057130541 ( O
10 BC2GM057130541 CD O
mg BC2GM057130541 NNS O
daily BC2GM057130541 RB O
, BC2GM057130541 , O
initially BC2GM057130541 RB O
for BC2GM057130541 IN O
six BC2GM057130541 CD O
weeks BC2GM057130541 NNS O
, BC2GM057130541 , O
then BC2GM057130541 RB O
alternating BC2GM057130541 VBG O
fortnights BC2GM057130541 NNS O
for BC2GM057130541 IN O
12 BC2GM057130541 CD O
weeks BC2GM057130541 NNS O
) BC2GM057130541 ) O
and BC2GM057130541 CC O
interferon-alpha BC2GM057130541 JJ O
2b BC2GM057130541 CD O
( BC2GM057130541 ( O
Schering-Plough BC2GM057130541 NNP O
; BC2GM057130541 : O
2 BC2GM057130541 CD O
x BC2GM057130541 $ O
10 BC2GM057130541 CD O
( BC2GM057130541 ( O
6 BC2GM057130541 CD O
) BC2GM057130541 ) O
U BC2GM057130541 NNP O
/ BC2GM057130541 NNP O
m2 BC2GM057130541 VBD O
three BC2GM057130541 CD O
times BC2GM057130541 NNS O
weekly BC2GM057130541 JJ O
by BC2GM057130541 IN O
subcutaneous BC2GM057130541 JJ O
injection BC2GM057130541 NN O
for BC2GM057130541 IN O
18 BC2GM057130541 CD O
weeks BC2GM057130541 NNS O
) BC2GM057130541 ) O
has BC2GM057130541 VBZ O
been BC2GM057130541 VBN O
compared BC2GM057130541 VBN O
in BC2GM057130541 IN O
a BC2GM057130541 DT O
randomised BC2GM057130541 JJ O
trial BC2GM057130541 NN O
with BC2GM057130541 IN O
chlorambucil BC2GM057130541 NN O
alone BC2GM057130541 RB O
in BC2GM057130541 IN O
previously BC2GM057130541 RB O
untreated BC2GM057130541 JJ O
patients BC2GM057130541 NNS O
with BC2GM057130541 IN O
stage BC2GM057130541 NN O
III BC2GM057130541 NNP O
or BC2GM057130541 CC O
IV BC2GM057130541 NNP O
follicular BC2GM057130541 JJ O
lymphoma BC2GM057130541 NN O
. BC2GM057130541 . O
. . O O

METHODS BC2GM037647258 NN O
: BC2GM037647258 : O
A BC2GM037647258 DT O
spatial BC2GM037647258 JJ O
counting BC2GM037647258 NN O
approach BC2GM037647258 NN O
in BC2GM037647258 IN O
which BC2GM037647258 WDT O
the BC2GM037647258 DT O
location BC2GM037647258 NN O
of BC2GM037647258 IN O
each BC2GM037647258 DT O
and BC2GM037647258 CC O
every BC2GM037647258 DT O
PN BC2GM037647258 NNP O
and BC2GM037647258 CC O
NP BC2GM037647258 NNP O
in BC2GM037647258 IN O
the BC2GM037647258 DT O
stratum BC2GM037647258 JJ O
pyramidale BC2GM037647258 NN O
of BC2GM037647258 IN O
sectors BC2GM037647258 NNS O
CA1-4 BC2GM037647258 NNP O
was BC2GM037647258 VBD O
applied BC2GM037647258 VBN O
to BC2GM037647258 TO O
11 BC2GM037647258 CD O
normal BC2GM037647258 JJ O
control BC2GM037647258 NN O
( BC2GM037647258 ( O
CONs BC2GM037647258 NNP O
) BC2GM037647258 ) O
and BC2GM037647258 CC O
10 BC2GM037647258 CD O
SZs BC2GM037647258 NNP O
matched BC2GM037647258 VBD O
for BC2GM037647258 IN O
age BC2GM037647258 NN O
and BC2GM037647258 CC O
postmortem BC2GM037647258 NN O
interval BC2GM037647258 NN O
, BC2GM037647258 , O
as BC2GM037647258 RB O
well BC2GM037647258 RB O
as BC2GM037647258 IN O
4 BC2GM037647258 CD O
manic BC2GM037647258 JJ O
depressive BC2GM037647258 NN O
( BC2GM037647258 ( O
MD BC2GM037647258 NNP O
) BC2GM037647258 ) O
subjects BC2GM037647258 VBZ O
matched BC2GM037647258 VBN O
for BC2GM037647258 IN O
age BC2GM037647258 NN O
. BC2GM037647258 . O
. . O O

Adaptability BC2GM023469972 NN O
of BC2GM023469972 IN O
Nippostrongylus BC2GM023469972 NNP O
brasiliensis BC2GM023469972 NN O
( BC2GM023469972 ( O
Travassos BC2GM023469972 NNP O
, BC2GM023469972 , O
1914 BC2GM023469972 CD O
) BC2GM023469972 ) O
to BC2GM023469972 TO O
lead BC2GM023469972 VB O
contamination BC2GM023469972 NN O
. BC2GM023469972 . O
. . O O

Based BC2GM023118027 VBN O
on BC2GM023118027 IN O
29 BC2GM023118027 CD O
determinations BC2GM023118027 NNS O
of BC2GM023118027 IN O
the BC2GM023118027 DT O
glucose BC2GM023118027 NN O
from BC2GM023118027 IN O
sinigrin BC2GM023118027 NN O
, BC2GM023118027 , O
analyzed BC2GM023118027 VBN O
under BC2GM023118027 IN O
different BC2GM023118027 JJ O
conditions BC2GM023118027 NNS O
, BC2GM023118027 , O
accuracy BC2GM023118027 NN O
of BC2GM023118027 IN O
the BC2GM023118027 DT O
total BC2GM023118027 JJ O
glucosinolate BC2GM023118027 NN O
determination BC2GM023118027 NN O
was BC2GM023118027 VBD O
94.8 BC2GM023118027 CD O
+ BC2GM023118027 JJ O
/ BC2GM023118027 NNP O
- BC2GM023118027 : O
7.3 BC2GM023118027 CD O
% BC2GM023118027 NN O
. BC2GM023118027 . O
. . O O

Liver BC2GM083638339 NNP O
disease BC2GM083638339 NN O
and BC2GM083638339 CC O
HCV BC2GM083638339 NNP O
infection BC2GM083638339 NN O
after BC2GM083638339 IN O
transplantation BC2GM083638339 NN O
of BC2GM083638339 IN O
organs BC2GM083638339 NNS O
from BC2GM083638339 IN O
hepatitis BC2GM083638339 NN O
C BC2GM083638339 NNP O
antibody BC2GM083638339 NN O
positive BC2GM083638339 JJ O
donors BC2GM083638339 NNS O
. BC2GM083638339 . O
. . O O

To BC2GM036637526 TO O
investigate BC2GM036637526 VB O
the BC2GM036637526 DT O
step BC2GM036637526 NN O
of BC2GM036637526 IN O
spliceosome BC2GM036637526 NN O
assembly BC2GM036637526 NN O
at BC2GM036637526 IN O
which BC2GM036637526 WDT O
Snu17p BC2GM036637526 NNP O
acts BC2GM036637526 VBZ O
, BC2GM036637526 , O
we BC2GM036637526 PRP O
have BC2GM036637526 VBP O
used BC2GM036637526 VBN O
nondenaturing BC2GM036637526 JJ O
gel BC2GM036637526 JJ O
electrophoresis BC2GM036637526 NN O
. BC2GM036637526 . O
. . O O

This BC2GM050904596 DT O
ERD BC2GM050904596 NNP O
is BC2GM050904596 VBZ O
recorded BC2GM050904596 VBN O
over BC2GM050904596 IN O
the BC2GM050904596 DT O
contralateral BC2GM050904596 JJ O
central BC2GM050904596 JJ O
region BC2GM050904596 NN O
. BC2GM050904596 . O
. . O O

The BC2GM003230275 DT O
factors BC2GM003230275 NNS O
defective BC2GM003230275 VBP O
in BC2GM003230275 IN O
groups BC2GM003230275 NNS O
A BC2GM003230275 NNP O
( BC2GM003230275 ( O
CIITA BC2GM003230275 NNP O
) BC2GM003230275 ) O
, BC2GM003230275 , O
C BC2GM003230275 NNP O
( BC2GM003230275 ( O
RFX5 BC2GM003230275 NNP O
) BC2GM003230275 ) O
and BC2GM003230275 CC O
D BC2GM003230275 NNP O
( BC2GM003230275 ( O
RFXAP BC2GM003230275 NNP O
) BC2GM003230275 ) O
have BC2GM003230275 VBP O
been BC2GM003230275 VBN O
identified BC2GM003230275 VBN O
. BC2GM003230275 . O
. . O O

In BC2GM031364553 IN O
marked BC2GM031364553 VBN O
contrast BC2GM031364553 NN O
to BC2GM031364553 TO O
the BC2GM031364553 DT O
previously BC2GM031364553 RB O
published BC2GM031364553 VBN O
human BC2GM031364553 JJ O
CD6 BC2GM031364553 NNP O
sequence BC2GM031364553 NN O
, BC2GM031364553 , O
the BC2GM031364553 DT O
mouse BC2GM031364553 NN O
sequence BC2GM031364553 NN O
predicts BC2GM031364553 VBZ O
a BC2GM031364553 DT O
long BC2GM031364553 JJ O
cytoplasmic BC2GM031364553 JJ O
tail BC2GM031364553 NN O
that BC2GM031364553 WDT O
is BC2GM031364553 VBZ O
not BC2GM031364553 RB O
closely BC2GM031364553 RB O
related BC2GM031364553 VBN O
to BC2GM031364553 TO O
other BC2GM031364553 JJ O
proteins BC2GM031364553 NNS O
and BC2GM031364553 CC O
possesses BC2GM031364553 NNS O
two BC2GM031364553 CD O
proline-rich BC2GM031364553 JJ O
motifs BC2GM031364553 NNS O
containing BC2GM031364553 VBG O
the BC2GM031364553 DT O
SH3-domain BC2GM031364553 JJ O
binding BC2GM031364553 NN O
consensus BC2GM031364553 NN O
sequence BC2GM031364553 NN O
, BC2GM031364553 , O
three BC2GM031364553 CD O
protein BC2GM031364553 NN O
kinase BC2GM031364553 VBD O
C BC2GM031364553 NNP O
phosphorylation BC2GM031364553 NN O
site BC2GM031364553 NN O
motifs BC2GM031364553 NNS O
, BC2GM031364553 , O
nine BC2GM031364553 CD O
casein BC2GM031364553 NN O
kinase-2 BC2GM031364553 JJ O
phosphorylation BC2GM031364553 NN O
site BC2GM031364553 NN O
motifs BC2GM031364553 NNS O
, BC2GM031364553 , O
and BC2GM031364553 CC O
a BC2GM031364553 DT O
serine-threonine-rich BC2GM031364553 JJ O
motif BC2GM031364553 NN O
repeated BC2GM031364553 VBD O
three BC2GM031364553 CD O
times BC2GM031364553 NNS O
. BC2GM031364553 . O
. . O O

Rising BC2GM089767540 VBG O
antibody BC2GM089767540 NN O
titres BC2GM089767540 NNS O
to BC2GM089767540 TO O
the BC2GM089767540 DT O
astrovirus BC2GM089767540 NN O
particles BC2GM089767540 NNS O
were BC2GM089767540 VBD O
demonstrated BC2GM089767540 VBN O
in BC2GM089767540 IN O
one BC2GM089767540 CD O
child BC2GM089767540 NN O
, BC2GM089767540 , O
and BC2GM089767540 CC O
IgM BC2GM089767540 NNP O
was BC2GM089767540 VBD O
also BC2GM089767540 RB O
demonstrated BC2GM089767540 VBN O
in BC2GM089767540 IN O
this BC2GM089767540 DT O
patient BC2GM089767540 NN O
's BC2GM089767540 POS O
serum BC2GM089767540 NN O
. BC2GM089767540 . O
. . O O

Samarium-153 BC2GM026014073 NNP O
for BC2GM026014073 IN O
intravascular BC2GM026014073 JJ O
irradiation BC2GM026014073 NN O
therapy BC2GM026014073 NN O
with BC2GM026014073 IN O
liquid-filled BC2GM026014073 JJ O
balloons BC2GM026014073 NNS O
to BC2GM026014073 TO O
prevent BC2GM026014073 VB O
restenosis BC2GM026014073 NN O
: BC2GM026014073 : O
acute BC2GM026014073 NN O
and BC2GM026014073 CC O
long-term BC2GM026014073 JJ O
results BC2GM026014073 NNS O
in BC2GM026014073 IN O
a BC2GM026014073 DT O
hypercholesterolemic BC2GM026014073 JJ O
rabbit BC2GM026014073 NN O
restenosis BC2GM026014073 NN O
model BC2GM026014073 NN O
. BC2GM026014073 . O
. . O O

We BC2GM054410700 PRP O
show BC2GM054410700 VBP O
here BC2GM054410700 RB O
that BC2GM054410700 IN O
Spb1p BC2GM054410700 NNP O
is BC2GM054410700 VBZ O
able BC2GM054410700 JJ O
to BC2GM054410700 TO O
bind BC2GM054410700 VB O
[ BC2GM054410700 NNP O
( BC2GM054410700 ( O
3 BC2GM054410700 CD O
) BC2GM054410700 ) O
H BC2GM054410700 NNP O
] BC2GM054410700 NNP O
AdoMet BC2GM054410700 NNP O
in BC2GM054410700 IN O
vitro BC2GM054410700 NN O
, BC2GM054410700 , O
suggesting BC2GM054410700 VBG O
that BC2GM054410700 IN O
it BC2GM054410700 PRP O
is BC2GM054410700 VBZ O
a BC2GM054410700 DT O
novel BC2GM054410700 JJ O
methylase BC2GM054410700 NN O
, BC2GM054410700 , O
whose BC2GM054410700 WP$ O
possible BC2GM054410700 JJ O
substrates BC2GM054410700 NNS O
will BC2GM054410700 MD O
be BC2GM054410700 VB O
discussed BC2GM054410700 VBN O
. BC2GM054410700 . O
. . O O

In BC2GM025168893 IN O
contrast BC2GM025168893 NN O
, BC2GM025168893 , O
T229E-p70s6k BC2GM025168893 NNP O
migrated BC2GM025168893 VBD O
more BC2GM025168893 RBR O
slowly BC2GM025168893 RB O
in BC2GM025168893 IN O
SDS-polyacrylamide BC2GM025168893 NNP O
gels BC2GM025168893 NNS O
, BC2GM025168893 , O
but BC2GM025168893 CC O
demonstrated BC2GM025168893 VBD O
partial BC2GM025168893 JJ O
kinase BC2GM025168893 NN O
activity BC2GM025168893 NN O
( BC2GM025168893 ( O
approximately BC2GM025168893 RB O
20 BC2GM025168893 CD O
% BC2GM025168893 NN O
compared BC2GM025168893 VBN O
with BC2GM025168893 IN O
the BC2GM025168893 DT O
wild BC2GM025168893 JJ O
type BC2GM025168893 NN O
) BC2GM025168893 ) O
. BC2GM025168893 . O
. . O O

Acad BC2GM009274132 NNP O
. BC2GM009274132 . O
. . O O

However BC2GM053331936 RB O
, BC2GM053331936 , O
the BC2GM053331936 DT O
malaria BC2GM053331936 NN O
vectors BC2GM053331936 NNS O
Anopheles BC2GM053331936 NNP O
funestus BC2GM053331936 NN O
and BC2GM053331936 CC O
An BC2GM053331936 DT O
. BC2GM053331936 . O
gambiae BC2GM053331936 NN O
have BC2GM053331936 VBP O
both BC2GM053331936 DT O
become BC2GM053331936 VBN O
more BC2GM053331936 RBR O
abundant BC2GM053331936 JJ O
during BC2GM053331936 IN O
the BC2GM053331936 DT O
1970s BC2GM053331936 CD O
and BC2GM053331936 CC O
1980s BC2GM053331936 CD O
and BC2GM053331936 CC O
sporozoite-positive BC2GM053331936 JJ O
specimens BC2GM053331936 NNS O
of BC2GM053331936 IN O
both BC2GM053331936 DT O
have BC2GM053331936 VBP O
been BC2GM053331936 VBN O
found BC2GM053331936 VBN O
. BC2GM053331936 . O
. . O O

The BC2GM018877680 DT O
present BC2GM018877680 JJ O
report BC2GM018877680 NN O
shows BC2GM018877680 VBZ O
that BC2GM018877680 IN O
a BC2GM018877680 DT O
cis-acting BC2GM018877680 JJ O
element BC2GM018877680 NN O
between BC2GM018877680 IN O
-189 BC2GM018877680 NNP O
and BC2GM018877680 CC O
-175 BC2GM018877680 NNP O
bp BC2GM018877680 NN O
, BC2GM018877680 , O
which BC2GM018877680 WDT O
binds BC2GM018877680 VBZ O
thyroid BC2GM018877680 JJ O
transcription BC2GM018877680 NN O
factor-1 BC2GM018877680 NN O
( BC2GM018877680 ( O
TTF-1 BC2GM018877680 NNP O
) BC2GM018877680 ) O
, BC2GM018877680 , O
is BC2GM018877680 VBZ O
involved BC2GM018877680 VBN O
in BC2GM018877680 IN O
both BC2GM018877680 DT O
activities BC2GM018877680 NNS O
. BC2GM018877680 . O
. . O O

Effect BC2GM083779200 NN O
of BC2GM083779200 IN O
age BC2GM083779200 NN O
on BC2GM083779200 IN O
glucose BC2GM083779200 NN O
, BC2GM083779200 , O
reducing BC2GM083779200 VBG O
sugars BC2GM083779200 NNS O
and BC2GM083779200 CC O
plasma BC2GM083779200 JJ O
insulin BC2GM083779200 NN O
in BC2GM083779200 IN O
blood BC2GM083779200 NN O
of BC2GM083779200 IN O
milk-fed BC2GM083779200 JJ O
calves BC2GM083779200 NNS O
. BC2GM083779200 . O
. . O O

Samples BC2GM035901068 NNP O
( BC2GM035901068 ( O
1 BC2GM035901068 CD O
g BC2GM035901068 NN O
) BC2GM035901068 ) O
were BC2GM035901068 VBD O
extracted BC2GM035901068 VBN O
with BC2GM035901068 IN O
0.5 BC2GM035901068 CD O
% BC2GM035901068 NN O
potassium BC2GM035901068 NN O
chloride BC2GM035901068 NN O
( BC2GM035901068 ( O
KCl BC2GM035901068 NNP O
) BC2GM035901068 ) O
in BC2GM035901068 IN O
70 BC2GM035901068 CD O
% BC2GM035901068 NN O
methanol BC2GM035901068 NN O
( BC2GM035901068 ( O
5 BC2GM035901068 CD O
ml BC2GM035901068 NN O
) BC2GM035901068 ) O
and BC2GM035901068 CC O
diluted BC2GM035901068 VBN O
subsequently BC2GM035901068 RB O
to BC2GM035901068 TO O
give BC2GM035901068 VB O
two-fold BC2GM035901068 JJ O
to BC2GM035901068 TO O
ten-fold BC2GM035901068 JJ O
step-wise BC2GM035901068 JJ O
dilutions BC2GM035901068 NNS O
in BC2GM035901068 IN O
phosphate-buffered BC2GM035901068 JJ O
saline BC2GM035901068 NN O
containing BC2GM035901068 VBG O
0.05 BC2GM035901068 CD O
% BC2GM035901068 NN O
Tween BC2GM035901068 NNP O
20 BC2GM035901068 CD O
and BC2GM035901068 CC O
0.2 BC2GM035901068 CD O
% BC2GM035901068 NN O
bovine BC2GM035901068 NN O
serum BC2GM035901068 NN O
albumin BC2GM035901068 NN O
( BC2GM035901068 ( O
PBS-T BC2GM035901068 NNP O
BSA BC2GM035901068 NNP O
) BC2GM035901068 ) O
. BC2GM035901068 . O
. . O O

4 BC2GM066650758 CD O
) BC2GM066650758 ) O
Mutation BC2GM066650758 NN O
of BC2GM066650758 IN O
the BC2GM066650758 DT O
three BC2GM066650758 CD O
extracellular BC2GM066650758 JJ O
cysteine BC2GM066650758 NN O
residues BC2GM066650758 NNS O
of BC2GM066650758 IN O
GFKAR BC2GM066650758 NNP O
beta BC2GM066650758 NN O
indicated BC2GM066650758 VBD O
that BC2GM066650758 IN O
the BC2GM066650758 DT O
two BC2GM066650758 CD O
conserved BC2GM066650758 VBD O
cysteine BC2GM066650758 NN O
residues BC2GM066650758 NNS O
( BC2GM066650758 ( O
C305 BC2GM066650758 NNP O
and BC2GM066650758 CC O
C385 BC2GM066650758 NNP O
) BC2GM066650758 ) O
, BC2GM066650758 , O
located BC2GM066650758 VBN O
between BC2GM066650758 IN O
two BC2GM066650758 CD O
transmembrane BC2GM066650758 NN O
segments BC2GM066650758 NNS O
, BC2GM066650758 , O
form BC2GM066650758 VB O
a BC2GM066650758 DT O
solvent-accessible BC2GM066650758 JJ O
disulfide BC2GM066650758 NN O
bond BC2GM066650758 NN O
. BC2GM066650758 . O
. . O O

It BC2GM066038185 PRP O
is BC2GM066038185 VBZ O
envisaged BC2GM066038185 VBN O
that BC2GM066038185 IN O
the BC2GM066038185 DT O
WHOQOL-BREF BC2GM066038185 NNP O
will BC2GM066038185 MD O
be BC2GM066038185 VB O
most BC2GM066038185 RBS O
useful BC2GM066038185 JJ O
in BC2GM066038185 IN O
studies BC2GM066038185 NNS O
that BC2GM066038185 WDT O
require BC2GM066038185 VBP O
a BC2GM066038185 DT O
brief BC2GM066038185 JJ O
assessment BC2GM066038185 NN O
of BC2GM066038185 IN O
quality BC2GM066038185 NN O
of BC2GM066038185 IN O
life BC2GM066038185 NN O
, BC2GM066038185 , O
for BC2GM066038185 IN O
example BC2GM066038185 NN O
, BC2GM066038185 , O
in BC2GM066038185 IN O
large BC2GM066038185 JJ O
epidemiological BC2GM066038185 JJ O
studies BC2GM066038185 NNS O
and BC2GM066038185 CC O
clinical BC2GM066038185 JJ O
trials BC2GM066038185 NNS O
where BC2GM066038185 WRB O
quality BC2GM066038185 NN O
of BC2GM066038185 IN O
life BC2GM066038185 NN O
is BC2GM066038185 VBZ O
of BC2GM066038185 IN O
interest BC2GM066038185 NN O
. BC2GM066038185 . O
. . O O

Inhibition BC2GM079565746 NN O
of BC2GM079565746 IN O
endogenous BC2GM079565746 JJ O
Cdk2 BC2GM079565746 NNP O
by BC2GM079565746 IN O
dominant BC2GM079565746 JJ O
negative BC2GM079565746 JJ O
Cdk2 BC2GM079565746 NNP O
attenuated BC2GM079565746 VBD O
phosphorylation BC2GM079565746 NN O
of BC2GM079565746 IN O
Thr447 BC2GM079565746 NNP O
, BC2GM079565746 , O
Thr490 BC2GM079565746 NNP O
and BC2GM079565746 CC O
Thr497 BC2GM079565746 NNP O
, BC2GM079565746 , O
but BC2GM079565746 CC O
had BC2GM079565746 VBD O
no BC2GM079565746 DT O
effect BC2GM079565746 NN O
upon BC2GM079565746 IN O
Ser581 BC2GM079565746 NNP O
modification BC2GM079565746 NN O
. BC2GM079565746 . O
. . O O

TRAF2 BC2GM055024591 NNP O
has BC2GM055024591 VBZ O
previously BC2GM055024591 RB O
been BC2GM055024591 VBN O
demonstrated BC2GM055024591 VBN O
to BC2GM055024591 TO O
activate BC2GM055024591 VB O
both BC2GM055024591 DT O
transcription BC2GM055024591 NN O
factor BC2GM055024591 NN O
nuclear BC2GM055024591 JJ O
factor BC2GM055024591 NN O
kappaB BC2GM055024591 NN O
( BC2GM055024591 ( O
NFkappaB BC2GM055024591 NNP O
) BC2GM055024591 ) O
and BC2GM055024591 CC O
the BC2GM055024591 DT O
c-Jun BC2GM055024591 JJ O
N-terminal BC2GM055024591 JJ O
kinase BC2GM055024591 NN O
/ BC2GM055024591 NNP O
stress-activated BC2GM055024591 JJ O
protein BC2GM055024591 NN O
kinase BC2GM055024591 NN O
( BC2GM055024591 ( O
JNK BC2GM055024591 NNP O
/ BC2GM055024591 NNP O
SAPK BC2GM055024591 NNP O
) BC2GM055024591 ) O
pathway BC2GM055024591 NN O
, BC2GM055024591 , O
which BC2GM055024591 WDT O
in BC2GM055024591 IN O
turn BC2GM055024591 NN O
stimulates BC2GM055024591 NNS O
transcription BC2GM055024591 VBP O
factor BC2GM055024591 NN O
activating BC2GM055024591 VBG O
protein BC2GM055024591 NN O
1 BC2GM055024591 CD O
( BC2GM055024591 ( O
AP1 BC2GM055024591 NNP O
) BC2GM055024591 ) O
mainly BC2GM055024591 RB O
via BC2GM055024591 IN O
phosphorylation BC2GM055024591 NN O
of BC2GM055024591 IN O
the BC2GM055024591 DT O
c-Jun BC2GM055024591 JJ O
component BC2GM055024591 NN O
. BC2GM055024591 . O
. . O O

RESULTS BC2GM096903917 NN O
: BC2GM096903917 : O
Three BC2GM096903917 CD O
patients BC2GM096903917 NNS O
did BC2GM096903917 VBD O
not BC2GM096903917 RB O
tolerate BC2GM096903917 VB O
PPI BC2GM096903917 NNP O
medication BC2GM096903917 NN O
and BC2GM096903917 CC O
were BC2GM096903917 VBD O
managed BC2GM096903917 VBN O
by BC2GM096903917 IN O
treatment BC2GM096903917 NN O
with BC2GM096903917 IN O
type BC2GM096903917 JJ O
2 BC2GM096903917 CD O
histamine BC2GM096903917 NN O
( BC2GM096903917 ( O
H2 BC2GM096903917 NNP O
) BC2GM096903917 ) O
blockers BC2GM096903917 NNS O
. BC2GM096903917 . O
. . O O

The BC2GM007741669 DT O
association BC2GM007741669 NN O
of BC2GM007741669 IN O
I-92 BC2GM007741669 NNP O
with BC2GM007741669 IN O
p92 BC2GM007741669 NN O
, BC2GM007741669 , O
p84 BC2GM007741669 NN O
, BC2GM007741669 , O
p75 BC2GM007741669 NN O
, BC2GM007741669 , O
p73 BC2GM007741669 NN O
, BC2GM007741669 , O
p69 BC2GM007741669 NN O
, BC2GM007741669 , O
and BC2GM007741669 CC O
p57 BC2GM007741669 NN O
was BC2GM007741669 VBD O
completely BC2GM007741669 RB O
reversible BC2GM007741669 JJ O
after BC2GM007741669 IN O
treatment BC2GM007741669 NN O
with BC2GM007741669 IN O
the BC2GM007741669 DT O
detergent BC2GM007741669 NN O
deoxycholate BC2GM007741669 NN O
( BC2GM007741669 ( O
DOC BC2GM007741669 NNP O
) BC2GM007741669 ) O
. BC2GM007741669 . O
. . O O

To BC2GM092921833 TO O
isolate BC2GM092921833 VB O
genes BC2GM092921833 NNS O
that BC2GM092921833 WDT O
contain BC2GM092921833 VBP O
zinc BC2GM092921833 JJ O
finger BC2GM092921833 NN O
motifs BC2GM092921833 NNS O
, BC2GM092921833 , O
a BC2GM092921833 DT O
human BC2GM092921833 JJ O
brain BC2GM092921833 NN O
cDNA BC2GM092921833 NN O
library BC2GM092921833 NN O
was BC2GM092921833 VBD O
screened BC2GM092921833 VBN O
with BC2GM092921833 IN O
an BC2GM092921833 DT O
oligonucleotide BC2GM092921833 JJ O
complementary BC2GM092921833 NN O
to BC2GM092921833 TO O
the BC2GM092921833 DT O
conserved BC2GM092921833 VBN O
`` BC2GM092921833 `` O
linker BC2GM092921833 NN O
'' BC2GM092921833 '' O
sequence BC2GM092921833 NN O
between BC2GM092921833 IN O
adjacent BC2GM092921833 JJ O
zinc BC2GM092921833 NN O
fingers BC2GM092921833 NNS O
. BC2GM092921833 . O
. . O O

Plasma BC2GM000667374 NNP O
prolactin BC2GM000667374 NN O
in BC2GM000667374 IN O
patients BC2GM000667374 NNS O
with BC2GM000667374 IN O
colorectal BC2GM000667374 JJ O
cancer BC2GM000667374 NN O
. BC2GM000667374 . O
. . O O

A BC2GM056219276 DT O
continuous-flow BC2GM056219276 JJ O
BIPAP BC2GM056219276 NNP O
system BC2GM056219276 NN O
consists BC2GM056219276 VBZ O
of BC2GM056219276 IN O
a BC2GM056219276 DT O
high-flow BC2GM056219276 JJ O
CPAP BC2GM056219276 NNP O
system BC2GM056219276 NN O
, BC2GM056219276 , O
a BC2GM056219276 DT O
reservoir BC2GM056219276 NN O
bag BC2GM056219276 NN O
, BC2GM056219276 , O
and BC2GM056219276 CC O
a BC2GM056219276 DT O
pneumatically BC2GM056219276 RB O
controlled BC2GM056219276 VBN O
membrane BC2GM056219276 NN O
valve BC2GM056219276 NN O
in BC2GM056219276 IN O
the BC2GM056219276 DT O
expiratory BC2GM056219276 NN O
limb BC2GM056219276 NN O
. BC2GM056219276 . O
. . O O

However BC2GM042983371 RB O
, BC2GM042983371 , O
depending BC2GM042983371 VBG O
upon BC2GM042983371 IN O
the BC2GM042983371 DT O
promoter BC2GM042983371 NN O
context BC2GM042983371 NN O
, BC2GM042983371 , O
we BC2GM042983371 PRP O
observed BC2GM042983371 VBD O
cooperative BC2GM042983371 JJ O
interactions BC2GM042983371 NNS O
between BC2GM042983371 IN O
the BC2GM042983371 DT O
two BC2GM042983371 CD O
domains BC2GM042983371 NNS O
to BC2GM042983371 TO O
confer BC2GM042983371 VB O
high BC2GM042983371 JJ O
DNA-binding BC2GM042983371 NNP O
affinity BC2GM042983371 NN O
and BC2GM042983371 CC O
specificity BC2GM042983371 NN O
. BC2GM042983371 . O
. . O O

In BC2GM071264087 IN O
agreement BC2GM071264087 NN O
with BC2GM071264087 IN O
this BC2GM071264087 DT O
, BC2GM071264087 , O
archaea BC2GM071264087 RB O
appear BC2GM071264087 VBP O
to BC2GM071264087 TO O
lack BC2GM071264087 VB O
eIF5 BC2GM071264087 NN O
, BC2GM071264087 , O
eIF2B BC2GM071264087 NN O
and BC2GM071264087 CC O
the BC2GM071264087 DT O
lysine-rich BC2GM071264087 JJ O
binding BC2GM071264087 NN O
domain BC2GM071264087 NN O
for BC2GM071264087 IN O
these BC2GM071264087 DT O
factors BC2GM071264087 NNS O
in BC2GM071264087 IN O
their BC2GM071264087 PRP$ O
eIF2beta BC2GM071264087 NN O
homolog BC2GM071264087 NN O
. BC2GM071264087 . O
. . O O

Protein BC2GM049393382 NNP O
binding BC2GM049393382 VBG O
to BC2GM049393382 TO O
UAS1MLS1 BC2GM049393382 NNP O
was BC2GM049393382 VBD O
observed BC2GM049393382 VBN O
with BC2GM049393382 IN O
extracts BC2GM049393382 NNS O
from BC2GM049393382 IN O
derepressed BC2GM049393382 VBN O
but BC2GM049393382 CC O
not BC2GM049393382 RB O
from BC2GM049393382 IN O
repressed BC2GM049393382 VBN O
cells BC2GM049393382 NNS O
, BC2GM049393382 , O
and BC2GM049393382 CC O
could BC2GM049393382 MD O
be BC2GM049393382 VB O
competed BC2GM049393382 VBN O
for BC2GM049393382 IN O
by BC2GM049393382 IN O
an BC2GM049393382 DT O
excess BC2GM049393382 NN O
of BC2GM049393382 IN O
the BC2GM049393382 DT O
unlabelled BC2GM049393382 JJ O
CSRE BC2GM049393382 NNP O
( BC2GM049393382 ( O
ICL1 BC2GM049393382 NNP O
) BC2GM049393382 ) O
sequence BC2GM049393382 NN O
. BC2GM049393382 . O
. . O O

These BC2GM030336153 DT O
data BC2GM030336153 NNS O
suggest BC2GM030336153 VBP O
that BC2GM030336153 IN O
overexpression BC2GM030336153 NN O
of BC2GM030336153 IN O
MT BC2GM030336153 NNP O
potentiates BC2GM030336153 VBZ O
the BC2GM030336153 DT O
growth BC2GM030336153 NN O
of BC2GM030336153 IN O
MCF7 BC2GM030336153 NNP O
cells BC2GM030336153 NNS O
, BC2GM030336153 , O
whereas BC2GM030336153 JJ O
downregulation BC2GM030336153 NN O
of BC2GM030336153 IN O
MT BC2GM030336153 NNP O
elicits BC2GM030336153 NNS O
antiproliferative BC2GM030336153 JJ O
effects BC2GM030336153 NNS O
. BC2GM030336153 . O
. . O O

Most BC2GM082814800 RBS O
important BC2GM082814800 JJ O
, BC2GM082814800 , O
after BC2GM082814800 IN O
all BC2GM082814800 DT O
, BC2GM082814800 , O
is BC2GM082814800 VBZ O
not BC2GM082814800 RB O
the BC2GM082814800 DT O
ionization BC2GM082814800 NN O
technique BC2GM082814800 NN O
but BC2GM082814800 CC O
the BC2GM082814800 DT O
stage BC2GM082814800 NN O
with BC2GM082814800 IN O
a BC2GM082814800 DT O
47.1 BC2GM082814800 CD O
% BC2GM082814800 NN O
five-year BC2GM082814800 JJ O
survival BC2GM082814800 NN O
rate BC2GM082814800 NN O
in BC2GM082814800 IN O
T1N0 BC2GM082814800 NNP O
as BC2GM082814800 IN O
compared BC2GM082814800 VBN O
to BC2GM082814800 TO O
T2N0 BC2GM082814800 NNP O
with BC2GM082814800 IN O
28.6 BC2GM082814800 CD O
% BC2GM082814800 NN O
and BC2GM082814800 CC O
T1N1 BC2GM082814800 NNP O
with BC2GM082814800 IN O
19.4 BC2GM082814800 CD O
% BC2GM082814800 NN O
. BC2GM082814800 . O
. . O O

The BC2GM089085833 DT O
mouse BC2GM089085833 NN O
lactoferrin BC2GM089085833 JJ O
gene BC2GM089085833 NN O
promoter BC2GM089085833 NN O
was BC2GM089085833 VBD O
active BC2GM089085833 JJ O
in BC2GM089085833 IN O
human BC2GM089085833 JJ O
endometrium BC2GM089085833 NN O
carcinoma BC2GM089085833 NN O
RL BC2GM089085833 NNP O
95-2 BC2GM089085833 CD O
cells BC2GM089085833 NNS O
and BC2GM089085833 CC O
in BC2GM089085833 IN O
rat BC2GM089085833 NN O
glioma BC2GM089085833 NN O
C6 BC2GM089085833 NNP O
cells BC2GM089085833 NNS O
. BC2GM089085833 . O
. . O O

The BC2GM092679978 DT O
fru BC2GM092679978 NN O
gene BC2GM092679978 NN O
has BC2GM092679978 VBZ O
seven BC2GM092679978 CD O
exons BC2GM092679978 NNS O
spanning BC2GM092679978 VBG O
15-kb BC2GM092679978 JJ O
encoding BC2GM092679978 VBG O
two BC2GM092679978 CD O
transcripts BC2GM092679978 NNS O
with BC2GM092679978 IN O
ORFs BC2GM092679978 NNP O
of BC2GM092679978 IN O
841 BC2GM092679978 CD O
and BC2GM092679978 CC O
695 BC2GM092679978 CD O
amino BC2GM092679978 NN O
acids BC2GM092679978 NNS O
. BC2GM092679978 . O
. . O O

Previous BC2GM002038023 JJ O
data BC2GM002038023 NNS O
suggested BC2GM002038023 VBD O
a BC2GM002038023 DT O
subtle BC2GM002038023 JJ O
increase BC2GM002038023 NN O
in BC2GM002038023 IN O
serum BC2GM002038023 JJ O
P BC2GM002038023 NNP O
at BC2GM002038023 IN O
the BC2GM002038023 DT O
time BC2GM002038023 NN O
of BC2GM002038023 IN O
hCG BC2GM002038023 JJ O
injection BC2GM002038023 NN O
without BC2GM002038023 IN O
LH BC2GM002038023 NNP O
surge BC2GM002038023 NN O
reduces BC2GM002038023 VBZ O
the BC2GM002038023 DT O
PR BC2GM002038023 NNP O
of BC2GM002038023 IN O
women BC2GM002038023 NNS O
having BC2GM002038023 VBG O
oocyte BC2GM002038023 JJ O
retrievals BC2GM002038023 NNS O
for BC2GM002038023 IN O
IVF BC2GM002038023 NNP O
; BC2GM002038023 : O
this BC2GM002038023 DT O
study BC2GM002038023 NN O
compared BC2GM002038023 VBN O
PRs BC2GM002038023 NNP O
of BC2GM002038023 IN O
recipients BC2GM002038023 NNS O
in BC2GM002038023 IN O
a BC2GM002038023 DT O
shared BC2GM002038023 JJ O
oocyte BC2GM002038023 NN O
program BC2GM002038023 NN O
according BC2GM002038023 VBG O
to BC2GM002038023 TO O
the BC2GM002038023 DT O
donors BC2GM002038023 NNS O
' BC2GM002038023 POS O
pre-hCG BC2GM002038023 JJ O
P BC2GM002038023 NNP O
level BC2GM002038023 NN O
. BC2GM002038023 . O
. . O O

Nonetheless BC2GM057164114 RB O
, BC2GM057164114 , O
the BC2GM057164114 DT O
majority BC2GM057164114 NN O
were BC2GM057164114 VBD O
located BC2GM057164114 VBN O
within BC2GM057164114 IN O
three BC2GM057164114 CD O
short BC2GM057164114 JJ O
sequences BC2GM057164114 NNS O
at BC2GM057164114 IN O
the BC2GM057164114 DT O
N BC2GM057164114 NNP O
terminus BC2GM057164114 NN O
, BC2GM057164114 , O
middle BC2GM057164114 NN O
, BC2GM057164114 , O
and BC2GM057164114 CC O
C BC2GM057164114 NNP O
terminus BC2GM057164114 NN O
that BC2GM057164114 WDT O
are BC2GM057164114 VBP O
phylogenetically BC2GM057164114 RB O
conserved BC2GM057164114 VBN O
among BC2GM057164114 IN O
all BC2GM057164114 DT O
known BC2GM057164114 VBN O
eubacterial BC2GM057164114 JJ O
and BC2GM057164114 CC O
chloroplast BC2GM057164114 JJ O
versions BC2GM057164114 NNS O
of BC2GM057164114 IN O
this BC2GM057164114 DT O
protein BC2GM057164114 NN O
. BC2GM057164114 . O
. . O O

An BC2GM092481573 DT O
OD BC2GM092481573 NNP O
650 BC2GM092481573 CD O
greater BC2GM092481573 JJR O
than BC2GM092481573 IN O
0.15 BC2GM092481573 CD O
appears BC2GM092481573 VBZ O
to BC2GM092481573 TO O
be BC2GM092481573 VB O
a BC2GM092481573 DT O
rapid BC2GM092481573 JJ O
, BC2GM092481573 , O
reliable BC2GM092481573 JJ O
indicator BC2GM092481573 NN O
of BC2GM092481573 IN O
fetal BC2GM092481573 JJ O
lung BC2GM092481573 NN O
maturity BC2GM092481573 NN O
. BC2GM092481573 . O
. . O O

Sequence BC2GM010596597 NN O
analysis BC2GM010596597 NN O
revealed BC2GM010596597 VBD O
100 BC2GM010596597 CD O
% BC2GM010596597 NN O
homology BC2GM010596597 NN O
of BC2GM010596597 IN O
all BC2GM010596597 DT O
RA-derived BC2GM010596597 NNP O
PTEN BC2GM010596597 NNP O
fragments BC2GM010596597 NNS O
to BC2GM010596597 TO O
those BC2GM010596597 DT O
from BC2GM010596597 IN O
normal BC2GM010596597 JJ O
SF BC2GM010596597 NNP O
as BC2GM010596597 RB O
well BC2GM010596597 RB O
as BC2GM010596597 IN O
to BC2GM010596597 TO O
the BC2GM010596597 DT O
published BC2GM010596597 VBN O
GenBank BC2GM010596597 NNP O
sequence BC2GM010596597 NN O
( BC2GM010596597 ( O
accession BC2GM010596597 JJ O
number BC2GM010596597 NN O
U93051 BC2GM010596597 NNP O
) BC2GM010596597 ) O
. BC2GM010596597 . O
. . O O

Carcinoma-related BC2GM094469292 JJ O
protein BC2GM094469292 NN O
production BC2GM094469292 NN O
may BC2GM094469292 MD O
have BC2GM094469292 VB O
played BC2GM094469292 VBN O
a BC2GM094469292 DT O
role BC2GM094469292 NN O
in BC2GM094469292 IN O
the BC2GM094469292 DT O
development BC2GM094469292 NN O
of BC2GM094469292 IN O
the BC2GM094469292 DT O
observed BC2GM094469292 JJ O
renal BC2GM094469292 JJ O
lesions BC2GM094469292 NNS O
. BC2GM094469292 . O
. . O O

Hepatocyte BC2GM074834235 NNP O
growth BC2GM074834235 NN O
factor BC2GM074834235 NN O
( BC2GM074834235 ( O
HGF BC2GM074834235 NNP O
) BC2GM074834235 ) O
is BC2GM074834235 VBZ O
an BC2GM074834235 DT O
inducible BC2GM074834235 JJ O
cytokine BC2GM074834235 NN O
that BC2GM074834235 WDT O
is BC2GM074834235 VBZ O
essential BC2GM074834235 JJ O
for BC2GM074834235 IN O
the BC2GM074834235 DT O
normal BC2GM074834235 JJ O
growth BC2GM074834235 NN O
and BC2GM074834235 CC O
development BC2GM074834235 NN O
of BC2GM074834235 IN O
various BC2GM074834235 JJ O
tissues BC2GM074834235 NNS O
, BC2GM074834235 , O
such BC2GM074834235 JJ O
as BC2GM074834235 IN O
the BC2GM074834235 DT O
liver BC2GM074834235 NN O
. BC2GM074834235 . O
. . O O

In BC2GM083277547 IN O
each BC2GM083277547 DT O
study BC2GM083277547 NN O
group BC2GM083277547 NN O
, BC2GM083277547 , O
elevated BC2GM083277547 VBD O
levels BC2GM083277547 NNS O
of BC2GM083277547 IN O
serum BC2GM083277547 NN O
I BC2GM083277547 PRP O
were BC2GM083277547 VBD O
observed BC2GM083277547 VBN O
. BC2GM083277547 . O
. . O O

Right-sided BC2GM069899033 JJ O
hemiplegia BC2GM069899033 NN O
of BC2GM069899033 IN O
5 BC2GM069899033 CD O
years BC2GM069899033 NNS O
duration BC2GM069899033 NN O
occurred BC2GM069899033 VBD O
in BC2GM069899033 IN O
the BC2GM069899033 DT O
remaining BC2GM069899033 VBG O
case BC2GM069899033 NN O
. BC2GM069899033 . O
. . O O

Excretion BC2GM047662900 NN O
of BC2GM047662900 IN O
radiopharmaceuticals BC2GM047662900 NNS O
into BC2GM047662900 IN O
breast BC2GM047662900 NN O
milk BC2GM047662900 NN O
. BC2GM047662900 . O
. . O O

The BC2GM075119828 DT O
effective BC2GM075119828 JJ O
use BC2GM075119828 NN O
of BC2GM075119828 IN O
superoxide BC2GM075119828 JJ O
dismutase BC2GM075119828 NN O
from BC2GM075119828 IN O
human BC2GM075119828 JJ O
erythrocytes BC2GM075119828 NNS O
in BC2GM075119828 IN O
the BC2GM075119828 DT O
late BC2GM075119828 JJ O
stages BC2GM075119828 NNS O
of BC2GM075119828 IN O
experimental BC2GM075119828 JJ O
influenza BC2GM075119828 JJ O
infection BC2GM075119828 NN O
. BC2GM075119828 . O
. . O O

Northern BC2GM050069224 NNP O
blot BC2GM050069224 NN O
analysis BC2GM050069224 NN O
confirmed BC2GM050069224 VBD O
that BC2GM050069224 IN O
ADAMTS-1 BC2GM050069224 NNP O
was BC2GM050069224 VBD O
up-regulated BC2GM050069224 JJ O
in BC2GM050069224 IN O
both BC2GM050069224 DT O
metaphyseal BC2GM050069224 NN O
( BC2GM050069224 ( O
14- BC2GM050069224 JJ O
to BC2GM050069224 TO O
35-fold BC2GM050069224 JJ O
) BC2GM050069224 ) O
and BC2GM050069224 CC O
diaphyseal BC2GM050069224 JJ O
( BC2GM050069224 ( O
4.2-fold BC2GM050069224 JJ O
) BC2GM050069224 ) O
bone BC2GM050069224 NN O
1 BC2GM050069224 CD O
h BC2GM050069224 NN O
after BC2GM050069224 IN O
PTH- BC2GM050069224 NNP O
( BC2GM050069224 ( O
1-38 BC2GM050069224 CD O
) BC2GM050069224 ) O
injection BC2GM050069224 NN O
and BC2GM050069224 CC O
returned BC2GM050069224 VBN O
to BC2GM050069224 TO O
control BC2GM050069224 NN O
levels BC2GM050069224 NNS O
by BC2GM050069224 IN O
24 BC2GM050069224 CD O
h BC2GM050069224 NN O
. BC2GM050069224 . O
. . O O

Signal BC2GM017429831 JJ O
transduction BC2GM017429831 NN O
in BC2GM017429831 IN O
fibroblasts BC2GM017429831 NNS O
stably BC2GM017429831 RB O
transformed BC2GM017429831 VBN O
by BC2GM017429831 IN O
[ BC2GM017429831 NNP O
Val12 BC2GM017429831 NNP O
] BC2GM017429831 NNP O
Ras BC2GM017429831 NNP O
-- BC2GM017429831 : O
the BC2GM017429831 DT O
activities BC2GM017429831 NNS O
of BC2GM017429831 IN O
extracellular-signal-regulated BC2GM017429831 JJ O
kinase BC2GM017429831 NN O
and BC2GM017429831 CC O
Jun BC2GM017429831 NNP O
N-terminal BC2GM017429831 JJ O
kinase BC2GM017429831 NN O
are BC2GM017429831 VBP O
only BC2GM017429831 RB O
moderately BC2GM017429831 RB O
increased BC2GM017429831 VBN O
, BC2GM017429831 , O
and BC2GM017429831 CC O
the BC2GM017429831 DT O
activity BC2GM017429831 NN O
of BC2GM017429831 IN O
the BC2GM017429831 DT O
delta-inhibitor BC2GM017429831 NN O
of BC2GM017429831 IN O
c-Jun BC2GM017429831 NN O
is BC2GM017429831 VBZ O
not BC2GM017429831 RB O
alleviated BC2GM017429831 VBN O
. BC2GM017429831 . O
. . O O

The BC2GM019152487 DT O
steady-state BC2GM019152487 JJ O
levels BC2GM019152487 NNS O
of BC2GM019152487 IN O
Cdk2 BC2GM019152487 NNP O
, BC2GM019152487 , O
Cdk4 BC2GM019152487 NNP O
and BC2GM019152487 CC O
Cyclin BC2GM019152487 NNP O
A BC2GM019152487 NNP O
proteins BC2GM019152487 NNS O
were BC2GM019152487 VBD O
unaffected BC2GM019152487 VBN O
by BC2GM019152487 IN O
HPR BC2GM019152487 NNP O
, BC2GM019152487 , O
while BC2GM019152487 IN O
those BC2GM019152487 DT O
of BC2GM019152487 IN O
Cyclin BC2GM019152487 NNP O
D1 BC2GM019152487 NNP O
were BC2GM019152487 VBD O
significantly BC2GM019152487 RB O
reduced BC2GM019152487 VBN O
in BC2GM019152487 IN O
all BC2GM019152487 DT O
three BC2GM019152487 CD O
cell BC2GM019152487 NN O
lines BC2GM019152487 NNS O
. BC2GM019152487 . O
. . O O

Mutations BC2GM009570936 NNS O
in BC2GM009570936 IN O
glnB BC2GM009570936 NN O
, BC2GM009570936 , O
nifR1 BC2GM009570936 FW O
( BC2GM009570936 ( O
ntrC BC2GM009570936 NN O
) BC2GM009570936 ) O
, BC2GM009570936 , O
and BC2GM009570936 CC O
NifR4 BC2GM009570936 NNP O
( BC2GM009570936 ( O
ntrA BC2GM009570936 JJ O
encoding BC2GM009570936 VBG O
sigma BC2GM009570936 NN O
54 BC2GM009570936 CD O
) BC2GM009570936 ) O
had BC2GM009570936 VBD O
no BC2GM009570936 DT O
influence BC2GM009570936 NN O
on BC2GM009570936 IN O
put BC2GM009570936 NN O
gene BC2GM009570936 NN O
expression BC2GM009570936 NN O
. BC2GM009570936 . O
. . O O

A BC2GM047251992 DT O
yeast BC2GM047251992 JJ O
mitochondrial BC2GM047251992 JJ O
translation BC2GM047251992 NN O
initiation BC2GM047251992 NN O
codon BC2GM047251992 NN O
mutation BC2GM047251992 NN O
affecting BC2GM047251992 VBG O
the BC2GM047251992 DT O
gene BC2GM047251992 NN O
for BC2GM047251992 IN O
cytochrome BC2GM047251992 JJ O
oxidase BC2GM047251992 NN O
subunit BC2GM047251992 NN O
III BC2GM047251992 NNP O
( BC2GM047251992 ( O
COX3 BC2GM047251992 NNP O
) BC2GM047251992 ) O
was BC2GM047251992 VBD O
partially BC2GM047251992 RB O
suppressed BC2GM047251992 VBN O
by BC2GM047251992 IN O
a BC2GM047251992 DT O
spontaneous BC2GM047251992 JJ O
nuclear BC2GM047251992 JJ O
mutation BC2GM047251992 NN O
. BC2GM047251992 . O
. . O O

The BC2GM030960650 DT O
D. BC2GM030960650 NNP O
discoideum BC2GM030960650 NN O
proteins BC2GM030960650 NNS O
were BC2GM030960650 VBD O
entirely BC2GM030960650 RB O
conserved BC2GM030960650 VBN O
over BC2GM030960650 IN O
the BC2GM030960650 DT O
four BC2GM030960650 CD O
regions BC2GM030960650 NNS O
known BC2GM030960650 VBN O
to BC2GM030960650 TO O
be BC2GM030960650 VB O
important BC2GM030960650 JJ O
for BC2GM030960650 IN O
GTP BC2GM030960650 NNP O
binding BC2GM030960650 NN O
and BC2GM030960650 CC O
all BC2GM030960650 DT O
contained BC2GM030960650 VBD O
the BC2GM030960650 DT O
C-terminal BC2GM030960650 JJ O
CAAX BC2GM030960650 NNP O
aa BC2GM030960650 NN O
motifs BC2GM030960650 NNS O
shared BC2GM030960650 VBN O
by BC2GM030960650 IN O
other BC2GM030960650 JJ O
Rho BC2GM030960650 NNP O
proteins BC2GM030960650 NNS O
. BC2GM030960650 . O
. . O O

Patients BC2GM047324484 NNS O
with BC2GM047324484 IN O
endocarditis BC2GM047324484 NN O
or BC2GM047324484 CC O
vascular BC2GM047324484 JJ O
infection BC2GM047324484 NN O
were BC2GM047324484 VBD O
more BC2GM047324484 RBR O
frequently BC2GM047324484 RB O
immunocompromised BC2GM047324484 VBN O
and BC2GM047324484 CC O
older BC2GM047324484 JJR O
than BC2GM047324484 IN O
those BC2GM047324484 DT O
with BC2GM047324484 IN O
acute BC2GM047324484 JJ O
Q BC2GM047324484 NNP O
fever BC2GM047324484 NN O
. BC2GM047324484 . O
. . O O

In BC2GM037303937 IN O
this BC2GM037303937 DT O
report BC2GM037303937 NN O
, BC2GM037303937 , O
we BC2GM037303937 PRP O
describe BC2GM037303937 VBP O
a BC2GM037303937 DT O
patient BC2GM037303937 NN O
with BC2GM037303937 IN O
renal BC2GM037303937 JJ O
cell BC2GM037303937 NN O
carcinoma BC2GM037303937 NN O
who BC2GM037303937 WP O
experienced BC2GM037303937 VBD O
ventricular BC2GM037303937 JJ O
tachycardia BC2GM037303937 NN O
while BC2GM037303937 IN O
undergoing BC2GM037303937 VBG O
treatment BC2GM037303937 NN O
with BC2GM037303937 IN O
high-dose BC2GM037303937 JJ O
bolus BC2GM037303937 JJ O
IL-2 BC2GM037303937 NNP O
. BC2GM037303937 . O
. . O O

The BC2GM046461652 DT O
delta BC2GM046461652 NN O
Mo BC2GM046461652 NNP O
+ BC2GM046461652 NNP O
SV BC2GM046461652 NNP O
tumor BC2GM046461652 NN O
DNAs BC2GM046461652 NNP O
from BC2GM046461652 IN O
B-lineage BC2GM046461652 NNP O
tumors BC2GM046461652 NNS O
were BC2GM046461652 VBD O
typically BC2GM046461652 RB O
rearranged BC2GM046461652 VBN O
at BC2GM046461652 IN O
the BC2GM046461652 DT O
immunoglobulin BC2GM046461652 NN O
gene BC2GM046461652 NN O
loci BC2GM046461652 NN O
and BC2GM046461652 CC O
contained BC2GM046461652 VBD O
germ BC2GM046461652 NNS O
line BC2GM046461652 NN O
configurations BC2GM046461652 NNS O
of BC2GM046461652 IN O
the BC2GM046461652 DT O
T-cell BC2GM046461652 NNP O
receptor BC2GM046461652 NN O
beta BC2GM046461652 NN O
gene BC2GM046461652 NN O
. BC2GM046461652 . O
. . O O

Ftz BC2GM072980050 NNP O
, BC2GM072980050 , O
on BC2GM072980050 IN O
the BC2GM072980050 DT O
other BC2GM072980050 JJ O
hand BC2GM072980050 NN O
, BC2GM072980050 , O
influences BC2GM072980050 VBZ O
Ftz-F1 BC2GM072980050 NNP O
activity BC2GM072980050 NN O
by BC2GM072980050 IN O
interacting BC2GM072980050 VBG O
with BC2GM072980050 IN O
its BC2GM072980050 PRP$ O
AF-2 BC2GM072980050 NNP O
domain BC2GM072980050 NN O
in BC2GM072980050 IN O
a BC2GM072980050 DT O
manner BC2GM072980050 NN O
that BC2GM072980050 IN O
mimics BC2GM072980050 VBZ O
a BC2GM072980050 DT O
nuclear BC2GM072980050 JJ O
receptor BC2GM072980050 NN O
coactivator BC2GM072980050 NN O
. BC2GM072980050 . O
. . O O

An BC2GM031127519 DT O
environmental BC2GM031127519 JJ O
investigation BC2GM031127519 NN O
found BC2GM031127519 VBD O
evidence BC2GM031127519 NN O
of BC2GM031127519 IN O
suboptimal BC2GM031127519 JJ O
food BC2GM031127519 NN O
storage BC2GM031127519 NN O
and BC2GM031127519 CC O
cooking BC2GM031127519 NN O
temperatures BC2GM031127519 NNS O
at BC2GM031127519 IN O
Restaurant BC2GM031127519 NNP O
A BC2GM031127519 NNP O
; BC2GM031127519 : O
cross BC2GM031127519 JJ O
contamination BC2GM031127519 NN O
of BC2GM031127519 IN O
foods BC2GM031127519 NNS O
may BC2GM031127519 MD O
have BC2GM031127519 VB O
contributed BC2GM031127519 VBN O
to BC2GM031127519 TO O
the BC2GM031127519 DT O
low BC2GM031127519 JJ O
attributable BC2GM031127519 JJ O
risk BC2GM031127519 NN O
identified BC2GM031127519 VBN O
for BC2GM031127519 IN O
chile BC2GM031127519 JJ O
rellenos BC2GM031127519 NNS O
. BC2GM031127519 . O
. . O O

Treatments BC2GM039739428 NNS O
were BC2GM039739428 VBD O
two BC2GM039739428 CD O
adrenocorticotrophin BC2GM039739428 NN O
( BC2GM039739428 ( O
ACTH BC2GM039739428 NNP O
) BC2GM039739428 ) O
preparations BC2GM039739428 NNS O
given BC2GM039739428 VBN O
intramuscularly BC2GM039739428 RB O
at BC2GM039739428 IN O
2.2 BC2GM039739428 CD O
U BC2GM039739428 NNP O
/ BC2GM039739428 NNP O
kg BC2GM039739428 NN O
, BC2GM039739428 , O
one BC2GM039739428 CD O
of BC2GM039739428 IN O
the BC2GM039739428 DT O
ACTH BC2GM039739428 NNP O
preparations BC2GM039739428 NNS O
given BC2GM039739428 VBN O
intramuscularly BC2GM039739428 RB O
at BC2GM039739428 IN O
1 BC2GM039739428 CD O
U BC2GM039739428 NNP O
/ BC2GM039739428 NNP O
kg BC2GM039739428 NN O
and BC2GM039739428 CC O
a BC2GM039739428 DT O
synthetic BC2GM039739428 JJ O
polypeptide BC2GM039739428 NN O
with BC2GM039739428 IN O
ACTH-like BC2GM039739428 JJ O
activity BC2GM039739428 NN O
( BC2GM039739428 ( O
tetracosactrin BC2GM039739428 NN O
, BC2GM039739428 , O
cosyntropin BC2GM039739428 NN O
) BC2GM039739428 ) O
given BC2GM039739428 VBN O
intravenously BC2GM039739428 RB O
at BC2GM039739428 IN O
5 BC2GM039739428 CD O
micrograms BC2GM039739428 NNS O
/ BC2GM039739428 JJ O
kg BC2GM039739428 NN O
. BC2GM039739428 . O
. . O O

Microalbuminuria BC2GM066604493 NNS O
: BC2GM066604493 : O
a BC2GM066604493 DT O
marker BC2GM066604493 NN O
of BC2GM066604493 IN O
systemic BC2GM066604493 JJ O
disease BC2GM066604493 NN O
. BC2GM066604493 . O
. . O O

However BC2GM044414750 RB O
, BC2GM044414750 , O
technical BC2GM044414750 JJ O
advances BC2GM044414750 NNS O
have BC2GM044414750 VBP O
shown BC2GM044414750 VBN O
the BC2GM044414750 DT O
limitations BC2GM044414750 NNS O
of BC2GM044414750 IN O
these BC2GM044414750 DT O
tests BC2GM044414750 NNS O
as BC2GM044414750 IN O
tests BC2GM044414750 NNS O
for BC2GM044414750 IN O
IgM BC2GM044414750 NNP O
can BC2GM044414750 MD O
be BC2GM044414750 VB O
positive BC2GM044414750 JJ O
because BC2GM044414750 IN O
of BC2GM044414750 IN O
residual BC2GM044414750 JJ O
specific BC2GM044414750 JJ O
IgM BC2GM044414750 NNP O
or BC2GM044414750 CC O
even BC2GM044414750 RB O
in BC2GM044414750 IN O
subjects BC2GM044414750 NNS O
free BC2GM044414750 JJ O
of BC2GM044414750 IN O
acute BC2GM044414750 JJ O
infection BC2GM044414750 NN O
due BC2GM044414750 JJ O
to BC2GM044414750 TO O
the BC2GM044414750 DT O
existence BC2GM044414750 NN O
of BC2GM044414750 IN O
natural BC2GM044414750 JJ O
interfering BC2GM044414750 VBG O
IgM BC2GM044414750 NNP O
. BC2GM044414750 . O
. . O O

The BC2GM077706962 DT O
related BC2GM077706962 JJ O
tumor BC2GM077706962 NN O
suppressor BC2GM077706962 NN O
, BC2GM077706962 , O
p130 BC2GM077706962 NN O
, BC2GM077706962 , O
also BC2GM077706962 RB O
effects BC2GM077706962 NNS O
this BC2GM077706962 DT O
function BC2GM077706962 NN O
. BC2GM077706962 . O
p107 BC2GM077706962 NN O
levels BC2GM077706962 NNS O
increase BC2GM077706962 VB O
substantially BC2GM077706962 RB O
as BC2GM077706962 IN O
cells BC2GM077706962 NNS O
progress BC2GM077706962 IN O
through BC2GM077706962 IN O
S BC2GM077706962 NNP O
phase BC2GM077706962 NN O
. BC2GM077706962 . O
p107 BC2GM077706962 JJ O
induction BC2GM077706962 NN O
of BC2GM077706962 IN O
E2F BC2GM077706962 NNP O
DNA BC2GM077706962 NNP O
binding BC2GM077706962 NN O
was BC2GM077706962 VBD O
observed BC2GM077706962 VBN O
primarily BC2GM077706962 RB O
in BC2GM077706962 IN O
S BC2GM077706962 NNP O
phase BC2GM077706962 NN O
cells BC2GM077706962 NNS O
coincident BC2GM077706962 NN O
with BC2GM077706962 IN O
the BC2GM077706962 DT O
increase BC2GM077706962 NN O
in BC2GM077706962 IN O
p107 BC2GM077706962 JJ O
protein BC2GM077706962 NN O
levels BC2GM077706962 NNS O
. BC2GM077706962 . O
. . O O

Kettin BC2GM079199097 NNP O
is BC2GM079199097 VBZ O
a BC2GM079199097 DT O
large BC2GM079199097 JJ O
modular BC2GM079199097 JJ O
protein BC2GM079199097 NN O
associated BC2GM079199097 VBN O
with BC2GM079199097 IN O
thin BC2GM079199097 JJ O
filaments BC2GM079199097 NNS O
in BC2GM079199097 IN O
the BC2GM079199097 DT O
Z-disc BC2GM079199097 JJ O
region BC2GM079199097 NN O
of BC2GM079199097 IN O
insect BC2GM079199097 JJ O
muscles BC2GM079199097 NNS O
. BC2GM079199097 . O
. . O O

According BC2GM027946341 VBG O
to BC2GM027946341 TO O
the BC2GM027946341 DT O
penetration BC2GM027946341 NN O
of BC2GM027946341 IN O
Ca-45 BC2GM027946341 NNP O
, BC2GM027946341 , O
the BC2GM027946341 DT O
microleakage BC2GM027946341 NN O
level BC2GM027946341 NN O
was BC2GM027946341 VBD O
scored BC2GM027946341 VBN O
for BC2GM027946341 IN O
each BC2GM027946341 DT O
section BC2GM027946341 NN O
. BC2GM027946341 . O
. . O O

A BC2GM040272991 DT O
computerized BC2GM040272991 JJ O
database BC2GM040272991 NN O
of BC2GM040272991 IN O
veterans BC2GM040272991 NNS O
discharged BC2GM040272991 VBN O
from BC2GM040272991 IN O
the BC2GM040272991 DT O
military BC2GM040272991 NN O
after BC2GM040272991 IN O
1967 BC2GM040272991 CD O
was BC2GM040272991 VBD O
selected BC2GM040272991 VBN O
as BC2GM040272991 IN O
the BC2GM040272991 DT O
source BC2GM040272991 NN O
because BC2GM040272991 IN O
it BC2GM040272991 PRP O
contains BC2GM040272991 VBZ O
about BC2GM040272991 IN O
50 BC2GM040272991 CD O
% BC2GM040272991 NN O
of BC2GM040272991 IN O
the BC2GM040272991 DT O
total BC2GM040272991 JJ O
Vietnam BC2GM040272991 NNP O
era BC2GM040272991 NN O
veteran BC2GM040272991 NN O
population BC2GM040272991 NN O
, BC2GM040272991 , O
is BC2GM040272991 VBZ O
reasonably BC2GM040272991 RB O
unbiased BC2GM040272991 JJ O
, BC2GM040272991 , O
and BC2GM040272991 CC O
provides BC2GM040272991 VBZ O
a BC2GM040272991 DT O
feasible BC2GM040272991 JJ O
method BC2GM040272991 NN O
for BC2GM040272991 IN O
identifying BC2GM040272991 VBG O
twins BC2GM040272991 NNS O
. BC2GM040272991 . O
. . O O

Characterization BC2GM095870614 NN O
of BC2GM095870614 IN O
trinucleotide- BC2GM095870614 NN O
and BC2GM095870614 CC O
tandem BC2GM095870614 JJ O
repeat-containing BC2GM095870614 JJ O
transcripts BC2GM095870614 NNS O
obtained BC2GM095870614 VBN O
from BC2GM095870614 IN O
human BC2GM095870614 JJ O
spinal BC2GM095870614 JJ O
cord BC2GM095870614 NN O
cDNA BC2GM095870614 NN O
library BC2GM095870614 JJ O
by BC2GM095870614 IN O
high-density BC2GM095870614 NN O
filter BC2GM095870614 NN O
hybridization BC2GM095870614 NN O
. BC2GM095870614 . O
. . O O

We BC2GM085800935 PRP O
identified BC2GM085800935 VBD O
two BC2GM085800935 CD O
potential BC2GM085800935 JJ O
phosphorylation BC2GM085800935 NN O
sites BC2GM085800935 NNS O
at BC2GM085800935 IN O
serine49 BC2GM085800935 NN O
and BC2GM085800935 CC O
serine133 BC2GM085800935 NN O
, BC2GM085800935 , O
both BC2GM085800935 DT O
of BC2GM085800935 IN O
which BC2GM085800935 WDT O
seem BC2GM085800935 VBP O
to BC2GM085800935 TO O
be BC2GM085800935 VB O
necessary BC2GM085800935 JJ O
for BC2GM085800935 IN O
Myf-5 BC2GM085800935 NNP O
activity BC2GM085800935 NN O
. BC2GM085800935 . O
. . O O

Thus BC2GM010412536 RB O
, BC2GM010412536 , O
d-delta3-carene BC2GM010412536 NN O
was BC2GM010412536 VBD O
about BC2GM010412536 IN O
four BC2GM010412536 CD O
times BC2GM010412536 NNS O
more BC2GM010412536 RBR O
potent BC2GM010412536 JJ O
as BC2GM010412536 IN O
a BC2GM010412536 DT O
sensory BC2GM010412536 NN O
irritant BC2GM010412536 NN O
than BC2GM010412536 IN O
I-beta-pinene BC2GM010412536 NNP O
, BC2GM010412536 , O
whereas BC2GM010412536 IN O
the BC2GM010412536 DT O
difference BC2GM010412536 NN O
with BC2GM010412536 IN O
I-alpha-pinene BC2GM010412536 NNP O
was BC2GM010412536 VBD O
more BC2GM010412536 RBR O
marked BC2GM010412536 JJ O
; BC2GM010412536 : O
as BC2GM010412536 IN O
a BC2GM010412536 DT O
sensory BC2GM010412536 JJ O
irritant BC2GM010412536 NN O
, BC2GM010412536 , O
I-alpha-pinene BC2GM010412536 NNP O
is BC2GM010412536 VBZ O
almost BC2GM010412536 RB O
inactive BC2GM010412536 JJ O
. BC2GM010412536 . O
. . O O

Analysis BC2GM079844918 NN O
of BC2GM079844918 IN O
larger BC2GM079844918 JJR O
cDNA BC2GM079844918 NN O
clones BC2GM079844918 NNS O
demonstrates BC2GM079844918 VBZ O
that BC2GM079844918 IN O
there BC2GM079844918 EX O
are BC2GM079844918 VBP O
at BC2GM079844918 IN O
least BC2GM079844918 JJS O
two BC2GM079844918 CD O
isoforms BC2GM079844918 NNS O
of BC2GM079844918 IN O
RIP14 BC2GM079844918 NNP O
that BC2GM079844918 WDT O
differ BC2GM079844918 VBP O
in BC2GM079844918 IN O
the BC2GM079844918 DT O
N-terminal BC2GM079844918 NNP O
( BC2GM079844918 ( O
A BC2GM079844918 NNP O
and BC2GM079844918 CC O
B BC2GM079844918 NNP O
) BC2GM079844918 ) O
and BC2GM079844918 CC O
hinge BC2GM079844918 NN O
( BC2GM079844918 ( O
D BC2GM079844918 NNP O
) BC2GM079844918 ) O
domains BC2GM079844918 VBZ O
. BC2GM079844918 . O
. . O O

4 BC2GM010073598 CD O
. BC2GM010073598 . O
. . O O

Acute BC2GM070056586 NNP O
respiratory BC2GM070056586 NN O
distress BC2GM070056586 NN O
syndrome BC2GM070056586 NN O
. BC2GM070056586 . O
. . O O

Retroviral BC2GM095220597 JJ O
vector BC2GM095220597 NN O
producer BC2GM095220597 NN O
cell BC2GM095220597 NN O
populations BC2GM095220597 NNS O
and BC2GM095220597 CC O
cell BC2GM095220597 NN O
clones BC2GM095220597 NNS O
were BC2GM095220597 VBD O
established BC2GM095220597 VBN O
for BC2GM095220597 IN O
each BC2GM095220597 DT O
chLTR BC2GM095220597 NN O
vector BC2GM095220597 NN O
, BC2GM095220597 , O
and BC2GM095220597 CC O
all BC2GM095220597 DT O
were BC2GM095220597 VBD O
capable BC2GM095220597 JJ O
of BC2GM095220597 IN O
yielding BC2GM095220597 VBG O
high BC2GM095220597 JJ O
vector BC2GM095220597 NN O
titers BC2GM095220597 NNS O
( BC2GM095220597 ( O
> BC2GM095220597 $ O
10 BC2GM095220597 CD O
( BC2GM095220597 ( O
5 BC2GM095220597 CD O
) BC2GM095220597 ) O
G418R BC2GM095220597 NNP O
cfu BC2GM095220597 NN O
/ BC2GM095220597 NNP O
ml BC2GM095220597 NN O
on BC2GM095220597 IN O
NIH-3T3 BC2GM095220597 NNP O
) BC2GM095220597 ) O
. BC2GM095220597 . O
. . O O

Transforming BC2GM092923041 VBG O
growth BC2GM092923041 NN O
factor BC2GM092923041 NN O
beta BC2GM092923041 NN O
activates BC2GM092923041 VBZ O
the BC2GM092923041 DT O
promoter BC2GM092923041 NN O
of BC2GM092923041 IN O
cyclin-dependent BC2GM092923041 JJ O
kinase BC2GM092923041 NN O
inhibitor BC2GM092923041 NN O
p15INK4B BC2GM092923041 NN O
through BC2GM092923041 IN O
an BC2GM092923041 DT O
Sp1 BC2GM092923041 NNP O
consensus BC2GM092923041 NN O
site BC2GM092923041 NN O
. BC2GM092923041 . O
. . O O

No BC2GM030793511 DT O
other BC2GM030793511 JJ O
transcripts BC2GM030793511 NNS O
of BC2GM030793511 IN O
different BC2GM030793511 JJ O
length BC2GM030793511 NN O
could BC2GM030793511 MD O
be BC2GM030793511 VB O
detected BC2GM030793511 VBN O
after BC2GM030793511 IN O
prolonged BC2GM030793511 JJ O
exposure BC2GM030793511 NN O
. BC2GM030793511 . O
. . O O

In BC2GM073785891 IN O
F9 BC2GM073785891 NNP O
, BC2GM073785891 , O
which BC2GM073785891 WDT O
is BC2GM073785891 VBZ O
a BC2GM073785891 DT O
prototype BC2GM073785891 NN O
of BC2GM073785891 IN O
embryonal BC2GM073785891 JJ O
carcinoma BC2GM073785891 NN O
cells BC2GM073785891 NNS O
expressing BC2GM073785891 VBG O
hst BC2GM073785891 NN O
, BC2GM073785891 , O
the BC2GM073785891 DT O
expression BC2GM073785891 NN O
of BC2GM073785891 IN O
hst BC2GM073785891 JJ O
gene BC2GM073785891 NN O
is BC2GM073785891 VBZ O
positively BC2GM073785891 RB O
regulated BC2GM073785891 VBN O
by BC2GM073785891 IN O
a BC2GM073785891 DT O
downstream BC2GM073785891 NN O
octamer BC2GM073785891 NN O
motif BC2GM073785891 NN O
that BC2GM073785891 WDT O
functions BC2GM073785891 NNS O
as BC2GM073785891 IN O
an BC2GM073785891 DT O
enhancer BC2GM073785891 NN O
. BC2GM073785891 . O
. . O O

Binding BC2GM000796681 NNP O
of BC2GM000796681 IN O
ZAP-70 BC2GM000796681 NNP O
to BC2GM000796681 TO O
phospho-TAMs BC2GM000796681 NN O
is BC2GM000796681 VBZ O
notable BC2GM000796681 JJ O
for BC2GM000796681 IN O
the BC2GM000796681 DT O
high BC2GM000796681 JJ O
level BC2GM000796681 NN O
of BC2GM000796681 IN O
cooperativity BC2GM000796681 NN O
between BC2GM000796681 IN O
the BC2GM000796681 DT O
two BC2GM000796681 CD O
SH2 BC2GM000796681 NNP O
domains BC2GM000796681 NNS O
, BC2GM000796681 , O
which BC2GM000796681 WDT O
individually BC2GM000796681 RB O
demonstrate BC2GM000796681 VBP O
low BC2GM000796681 JJ O
affinity BC2GM000796681 NN O
interaction BC2GM000796681 NN O
with BC2GM000796681 IN O
the BC2GM000796681 DT O
ligand BC2GM000796681 NN O
. BC2GM000796681 . O
. . O O

In BC2GM021360319 IN O
agreement BC2GM021360319 NN O
with BC2GM021360319 IN O
other BC2GM021360319 JJ O
authors BC2GM021360319 NNS O
, BC2GM021360319 , O
we BC2GM021360319 PRP O
recommend BC2GM021360319 VBP O
the BC2GM021360319 DT O
procedure BC2GM021360319 NN O
as BC2GM021360319 IN O
a BC2GM021360319 DT O
safe BC2GM021360319 JJ O
one BC2GM021360319 CD O
, BC2GM021360319 , O
providing BC2GM021360319 VBG O
satisfactory BC2GM021360319 JJ O
results BC2GM021360319 NNS O
. BC2GM021360319 . O
. . O O

The BC2GM071999397 DT O
psh3 BC2GM071999397 NN O
( BC2GM071999397 ( O
+ BC2GM071999397 NNP O
) BC2GM071999397 ) O
gene BC2GM071999397 NN O
encodes BC2GM071999397 VBZ O
a BC2GM071999397 DT O
protein BC2GM071999397 NN O
of BC2GM071999397 IN O
215 BC2GM071999397 CD O
amino BC2GM071999397 NN O
acids BC2GM071999397 NNS O
, BC2GM071999397 , O
which BC2GM071999397 WDT O
shares BC2GM071999397 NNS O
a BC2GM071999397 DT O
high BC2GM071999397 JJ O
degree BC2GM071999397 NN O
of BC2GM071999397 IN O
structural BC2GM071999397 JJ O
and BC2GM071999397 CC O
functional BC2GM071999397 JJ O
similarity BC2GM071999397 NN O
with BC2GM071999397 IN O
Shr3p BC2GM071999397 NNP O
. BC2GM071999397 . O
. . O O

Previous BC2GM080374905 JJ O
work BC2GM080374905 NN O
established BC2GM080374905 VBD O
that BC2GM080374905 IN O
the BC2GM080374905 DT O
TAL1 BC2GM080374905 NNP O
proteins BC2GM080374905 NNS O
are BC2GM080374905 VBP O
phosphorylated BC2GM080374905 VBN O
exclusively BC2GM080374905 RB O
on BC2GM080374905 IN O
serine BC2GM080374905 NN O
and BC2GM080374905 CC O
identified BC2GM080374905 JJ O
Ser122 BC2GM080374905 NNP O
as BC2GM080374905 IN O
a BC2GM080374905 DT O
substrate BC2GM080374905 NN O
for BC2GM080374905 IN O
the BC2GM080374905 DT O
mitogen-activated BC2GM080374905 JJ O
protein BC2GM080374905 NN O
kinase BC2GM080374905 VBD O
ERK-1 BC2GM080374905 NNP O
. BC2GM080374905 . O
. . O O

Three BC2GM007910996 CD O
simple BC2GM007910996 JJ O
methods BC2GM007910996 NNS O
of BC2GM007910996 IN O
detecting BC2GM007910996 VBG O
malnutrition BC2GM007910996 NN O
on BC2GM007910996 IN O
medical BC2GM007910996 JJ O
wards BC2GM007910996 NNS O
. BC2GM007910996 . O
. . O O

Clinical BC2GM082621888 JJ O
trial BC2GM082621888 NN O
endpoints BC2GM082621888 NNS O
based BC2GM082621888 VBN O
on BC2GM082621888 IN O
magnitude BC2GM082621888 NN O
of BC2GM082621888 IN O
reduction BC2GM082621888 NN O
in BC2GM082621888 IN O
HIV-1 BC2GM082621888 NNP O
RNA BC2GM082621888 NNP O
levels BC2GM082621888 NNS O
provide BC2GM082621888 VBP O
an BC2GM082621888 DT O
important BC2GM082621888 JJ O
complement BC2GM082621888 NN O
to BC2GM082621888 TO O
endpoints BC2GM082621888 NNS O
based BC2GM082621888 VBN O
on BC2GM082621888 IN O
percentage BC2GM082621888 NN O
of BC2GM082621888 IN O
patients BC2GM082621888 NNS O
achieving BC2GM082621888 VBG O
complete BC2GM082621888 JJ O
virologic BC2GM082621888 JJ O
suppression BC2GM082621888 NN O
. BC2GM082621888 . O
. . O O

Cotransfection BC2GM004721098 NN O
of BC2GM004721098 IN O
pINV-2473 BC2GM004721098 NN O
, BC2GM004721098 , O
a BC2GM004721098 DT O
construct BC2GM004721098 NN O
containing BC2GM004721098 NN O
2473 BC2GM004721098 CD O
base BC2GM004721098 NN O
pairs BC2GM004721098 NN O
of BC2GM004721098 IN O
hINV BC2GM004721098 JJ O
upstream BC2GM004721098 JJ O
sequence BC2GM004721098 NN O
linked BC2GM004721098 VBD O
to BC2GM004721098 TO O
luciferase BC2GM004721098 VB O
, BC2GM004721098 , O
with BC2GM004721098 IN O
POU BC2GM004721098 NNP O
homeodomain BC2GM004721098 VBP O
transcription BC2GM004721098 NN O
factors BC2GM004721098 NNS O
Oct1 BC2GM004721098 NNP O
, BC2GM004721098 , O
Oct2 BC2GM004721098 NNP O
, BC2GM004721098 , O
Brn4 BC2GM004721098 NNP O
, BC2GM004721098 , O
SCIP BC2GM004721098 NNP O
, BC2GM004721098 , O
Skn1a BC2GM004721098 NNP O
or BC2GM004721098 CC O
Skn1i BC2GM004721098 NNP O
, BC2GM004721098 , O
results BC2GM004721098 NNS O
in BC2GM004721098 IN O
a BC2GM004721098 DT O
strong BC2GM004721098 JJ O
suppression BC2GM004721098 NN O
of BC2GM004721098 IN O
basal BC2GM004721098 JJ O
promoter BC2GM004721098 NN O
activity BC2GM004721098 NN O
. BC2GM004721098 . O
. . O O

While BC2GM051967353 IN O
reviewing BC2GM051967353 VBG O
gastric BC2GM051967353 JJ O
specimens BC2GM051967353 NNS O
from BC2GM051967353 IN O
215 BC2GM051967353 CD O
baboons BC2GM051967353 NNS O
, BC2GM051967353 , O
we BC2GM051967353 PRP O
found BC2GM051967353 VBD O
diffuse BC2GM051967353 RB O
giant BC2GM051967353 JJ O
mucosal BC2GM051967353 NN O
folds BC2GM051967353 NNS O
in BC2GM051967353 IN O
2 BC2GM051967353 CD O
specimens BC2GM051967353 NNS O
and BC2GM051967353 CC O
multiple BC2GM051967353 JJ O
giant BC2GM051967353 JJ O
mucosal BC2GM051967353 NN O
nodules BC2GM051967353 NNS O
in BC2GM051967353 IN O
another BC2GM051967353 DT O
3 BC2GM051967353 CD O
. BC2GM051967353 . O
. . O O

These BC2GM068744925 DT O
data BC2GM068744925 NNS O
indicate BC2GM068744925 VBP O
that BC2GM068744925 IN O
SB BC2GM068744925 NNP O
203580 BC2GM068744925 CD O
sensitive BC2GM068744925 JJ O
p38 BC2GM068744925 NN O
MAP BC2GM068744925 NNP O
kinases BC2GM068744925 NNS O
are BC2GM068744925 VBP O
not BC2GM068744925 RB O
involved BC2GM068744925 VBN O
in BC2GM068744925 IN O
okadaic BC2GM068744925 JJ O
acid BC2GM068744925 NN O
mediated BC2GM068744925 VBD O
increases BC2GM068744925 NNS O
in BC2GM068744925 IN O
TRE BC2GM068744925 NNP O
DNA BC2GM068744925 NNP O
binding BC2GM068744925 NN O
and BC2GM068744925 CC O
transactivation BC2GM068744925 NN O
. BC2GM068744925 . O
. . O O

Materials BC2GM036499922 NNS O
are BC2GM036499922 VBP O
presented BC2GM036499922 VBN O
of BC2GM036499922 IN O
a BC2GM036499922 DT O
comparative BC2GM036499922 JJ O
study BC2GM036499922 NN O
of BC2GM036499922 IN O
morphological BC2GM036499922 JJ O
and BC2GM036499922 CC O
cultural BC2GM036499922 JJ O
properties BC2GM036499922 NNS O
and BC2GM036499922 CC O
virulence BC2GM036499922 NN O
of BC2GM036499922 IN O
liophylized BC2GM036499922 JJ O
cultures BC2GM036499922 NNS O
of BC2GM036499922 IN O
Leishmania BC2GM036499922 NNP O
tropica BC2GM036499922 NN O
major BC2GM036499922 JJ O
after BC2GM036499922 IN O
their BC2GM036499922 PRP$ O
rehydration BC2GM036499922 NN O
or BC2GM036499922 CC O
after BC2GM036499922 IN O
a BC2GM036499922 DT O
long BC2GM036499922 JJ O
passage BC2GM036499922 NN O
on BC2GM036499922 IN O
the BC2GM036499922 DT O
NNN BC2GM036499922 NNP O
medium BC2GM036499922 NN O
. BC2GM036499922 . O
. . O O

The BC2GM075767585 DT O
level BC2GM075767585 NN O
of BC2GM075767585 IN O
expression BC2GM075767585 NN O
of BC2GM075767585 IN O
the BC2GM075767585 DT O
PDE BC2GM075767585 NNP O
protein BC2GM075767585 NN O
was BC2GM075767585 VBD O
monitored BC2GM075767585 VBN O
by BC2GM075767585 IN O
immunoblot BC2GM075767585 NN O
analysis BC2GM075767585 NN O
using BC2GM075767585 VBG O
two BC2GM075767585 CD O
specific BC2GM075767585 JJ O
cAMP-PDE BC2GM075767585 JJ O
polyclonal BC2GM075767585 JJ O
antibodies BC2GM075767585 NNS O
and BC2GM075767585 CC O
by BC2GM075767585 IN O
measuring BC2GM075767585 VBG O
the BC2GM075767585 DT O
PDE BC2GM075767585 NNP O
activity BC2GM075767585 NN O
. BC2GM075767585 . O
. . O O

Using BC2GM046544917 VBG O
a BC2GM046544917 DT O
set BC2GM046544917 NN O
of BC2GM046544917 IN O
sera BC2GM046544917 NN O
for BC2GM046544917 IN O
which BC2GM046544917 WDT O
full BC2GM046544917 JJ O
chlamydial BC2GM046544917 JJ O
micro-immunofluorescence BC2GM046544917 NN O
results BC2GM046544917 NNS O
suggested BC2GM046544917 VBD O
a BC2GM046544917 DT O
clear BC2GM046544917 JJ O
diagnosis BC2GM046544917 NN O
, BC2GM046544917 , O
we BC2GM046544917 PRP O
have BC2GM046544917 VBP O
evaluated BC2GM046544917 VBN O
the BC2GM046544917 DT O
Chlamydia BC2GM046544917 NNP O
Spot-IF BC2GM046544917 NNP O
test BC2GM046544917 NN O
( BC2GM046544917 ( O
bioMerieux BC2GM046544917 NN O
) BC2GM046544917 ) O
, BC2GM046544917 , O
which BC2GM046544917 WDT O
allows BC2GM046544917 VBZ O
a BC2GM046544917 DT O
comparison BC2GM046544917 NN O
of BC2GM046544917 IN O
titres BC2GM046544917 NNS O
to BC2GM046544917 TO O
Chlamydia BC2GM046544917 NNP O
trachomatis BC2GM046544917 NN O
and BC2GM046544917 CC O
C. BC2GM046544917 NNP O
psittaci BC2GM046544917 NN O
antigens BC2GM046544917 NNS O
. BC2GM046544917 . O
. . O O

The BC2GM014834356 DT O
lipopolysaccharide-binding BC2GM014834356 JJ O
protein BC2GM014834356 NN O
is BC2GM014834356 VBZ O
a BC2GM014834356 DT O
secretory BC2GM014834356 JJ O
class BC2GM014834356 NN O
1 BC2GM014834356 CD O
acute-phase BC2GM014834356 JJ O
protein BC2GM014834356 NN O
whose BC2GM014834356 WP$ O
gene BC2GM014834356 NN O
is BC2GM014834356 VBZ O
transcriptionally BC2GM014834356 RB O
activated BC2GM014834356 VBN O
by BC2GM014834356 IN O
APRF BC2GM014834356 NNP O
/ BC2GM014834356 NNP O
STAT BC2GM014834356 NNP O
/ BC2GM014834356 NNP O
3 BC2GM014834356 CD O
and BC2GM014834356 CC O
other BC2GM014834356 JJ O
cytokine-inducible BC2GM014834356 JJ O
nuclear BC2GM014834356 JJ O
proteins BC2GM014834356 NNS O
. BC2GM014834356 . O
. . O O

Twenty BC2GM031697099 NNP O
male BC2GM031697099 NN O
volunteers BC2GM031697099 NNS O
were BC2GM031697099 VBD O
studied BC2GM031697099 VBN O
during BC2GM031697099 IN O
almokalant BC2GM031697099 JJ O
infusion BC2GM031697099 NN O
aiming BC2GM031697099 VBG O
at BC2GM031697099 IN O
plasma BC2GM031697099 JJ O
concentrations BC2GM031697099 NNS O
( BC2GM031697099 ( O
Cpl BC2GM031697099 NNP O
) BC2GM031697099 ) O
of BC2GM031697099 IN O
20 BC2GM031697099 CD O
, BC2GM031697099 , O
50 BC2GM031697099 CD O
, BC2GM031697099 , O
100 BC2GM031697099 CD O
, BC2GM031697099 , O
and BC2GM031697099 CC O
150 BC2GM031697099 CD O
nmol BC2GM031697099 JJ O
/ BC2GM031697099 NNP O
l BC2GM031697099 NN O
. BC2GM031697099 . O
. . O O

6,320 BC2GM080220626 CD O
cells BC2GM080220626 NNS O
/ BC2GM080220626 JJ O
mm3 BC2GM080220626 NN O
, BC2GM080220626 , O
respectively BC2GM080220626 RB O
; BC2GM080220626 : O
P BC2GM080220626 NNP O
less BC2GM080220626 JJR O
than BC2GM080220626 IN O
.005 BC2GM080220626 NN O
) BC2GM080220626 ) O
; BC2GM080220626 : O
twelve BC2GM080220626 NN O
( BC2GM080220626 ( O
86 BC2GM080220626 CD O
% BC2GM080220626 NN O
) BC2GM080220626 ) O
of BC2GM080220626 IN O
the BC2GM080220626 DT O
14 BC2GM080220626 CD O
inmates BC2GM080220626 NNS O
who BC2GM080220626 WP O
developed BC2GM080220626 VBD O
AIDS BC2GM080220626 NNP O
had BC2GM080220626 VBD O
counts BC2GM080220626 NNS O
of BC2GM080220626 IN O
less BC2GM080220626 JJR O
than BC2GM080220626 IN O
5,000 BC2GM080220626 CD O
cells BC2GM080220626 NNS O
/ BC2GM080220626 JJ O
mm3 BC2GM080220626 NN O
, BC2GM080220626 , O
compared BC2GM080220626 VBN O
with BC2GM080220626 IN O
only BC2GM080220626 RB O
six BC2GM080220626 CD O
( BC2GM080220626 ( O
14 BC2GM080220626 CD O
% BC2GM080220626 NN O
) BC2GM080220626 ) O
of BC2GM080220626 IN O
the BC2GM080220626 DT O
42 BC2GM080220626 CD O
controls BC2GM080220626 NNS O
( BC2GM080220626 ( O
P BC2GM080220626 NNP O
less BC2GM080220626 JJR O
than BC2GM080220626 IN O
.00001 BC2GM080220626 NN O
) BC2GM080220626 ) O
. BC2GM080220626 . O
. . O O

Internal BC2GM011480207 NNP O
controls BC2GM011480207 VBZ O
over BC2GM011480207 IN O
the BC2GM011480207 DT O
volume BC2GM011480207 NN O
of BC2GM011480207 IN O
milk BC2GM011480207 NN O
suckled BC2GM011480207 VBN O
do BC2GM011480207 VBP O
not BC2GM011480207 RB O
appear BC2GM011480207 VB O
until BC2GM011480207 IN O
infant BC2GM011480207 JJ O
rats BC2GM011480207 NNS O
are BC2GM011480207 VBP O
about BC2GM011480207 IN O
2 BC2GM011480207 CD O
weeks BC2GM011480207 NNS O
of BC2GM011480207 IN O
age BC2GM011480207 NN O
at BC2GM011480207 IN O
which BC2GM011480207 WDT O
time BC2GM011480207 NN O
gastric BC2GM011480207 JJ O
distension BC2GM011480207 NN O
, BC2GM011480207 , O
milk BC2GM011480207 NN O
, BC2GM011480207 , O
systemic BC2GM011480207 JJ O
dehydration BC2GM011480207 NN O
, BC2GM011480207 , O
and BC2GM011480207 CC O
intestinal BC2GM011480207 JJ O
hormone BC2GM011480207 NN O
cholecystokinin BC2GM011480207 NN O
suppress BC2GM011480207 NN O
milk BC2GM011480207 NN O
intake BC2GM011480207 NN O
derived BC2GM011480207 VBD O
through BC2GM011480207 IN O
suckling BC2GM011480207 NN O
. BC2GM011480207 . O
. . O O

We BC2GM030828493 PRP O
have BC2GM030828493 VBP O
isolated BC2GM030828493 VBN O
and BC2GM030828493 CC O
sequenced BC2GM030828493 VBN O
cDNA BC2GM030828493 NN O
sequences BC2GM030828493 NNS O
corresponding BC2GM030828493 VBG O
to BC2GM030828493 TO O
two BC2GM030828493 CD O
novel BC2GM030828493 NN O
genes BC2GM030828493 NNS O
that BC2GM030828493 WDT O
map BC2GM030828493 VBP O
to BC2GM030828493 TO O
Xq28 BC2GM030828493 NNP O
. BC2GM030828493 . O
. . O O

Despite BC2GM041365584 IN O
the BC2GM041365584 DT O
fact BC2GM041365584 NN O
that BC2GM041365584 IN O
biochemical BC2GM041365584 JJ O
estimates BC2GM041365584 NNS O
of BC2GM041365584 IN O
bone BC2GM041365584 NN O
turnover BC2GM041365584 NN O
indicate BC2GM041365584 VBP O
that BC2GM041365584 IN O
( BC2GM041365584 ( O
short-term BC2GM041365584 JJ O
) BC2GM041365584 ) O
administration BC2GM041365584 NN O
of BC2GM041365584 IN O
rhGH BC2GM041365584 NN O
and BC2GM041365584 CC O
IGF-I BC2GM041365584 NNP O
stimulates BC2GM041365584 VBZ O
bone BC2GM041365584 CD O
metabolism BC2GM041365584 NN O
in BC2GM041365584 IN O
non-osteoporotic BC2GM041365584 JJ O
older BC2GM041365584 NN O
people BC2GM041365584 NNS O
, BC2GM041365584 , O
no BC2GM041365584 DT O
significant BC2GM041365584 JJ O
changes BC2GM041365584 NNS O
have BC2GM041365584 VBP O
been BC2GM041365584 VBN O
observed BC2GM041365584 VBN O
in BC2GM041365584 IN O
bone BC2GM041365584 JJ O
mineral BC2GM041365584 JJ O
density BC2GM041365584 NN O
at BC2GM041365584 IN O
the BC2GM041365584 DT O
proximal BC2GM041365584 JJ O
femur BC2GM041365584 NN O
. BC2GM041365584 . O
. . O O

In BC2GM058476475 IN O
response BC2GM058476475 NN O
to BC2GM058476475 TO O
the BC2GM058476475 DT O
need BC2GM058476475 NN O
for BC2GM058476475 IN O
better BC2GM058476475 JJR O
quantitative BC2GM058476475 JJ O
estimates BC2GM058476475 NNS O
of BC2GM058476475 IN O
the BC2GM058476475 DT O
regional BC2GM058476475 JJ O
distribution BC2GM058476475 NN O
of BC2GM058476475 IN O
the BC2GM058476475 DT O
active BC2GM058476475 JJ O
bone BC2GM058476475 NN O
marrow BC2GM058476475 NN O
organ BC2GM058476475 NN O
in BC2GM058476475 IN O
infants BC2GM058476475 NNS O
and BC2GM058476475 CC O
children BC2GM058476475 NNS O
, BC2GM058476475 , O
a BC2GM058476475 DT O
method BC2GM058476475 NN O
using BC2GM058476475 VBG O
various BC2GM058476475 JJ O
anatomical BC2GM058476475 JJ O
data BC2GM058476475 NN O
has BC2GM058476475 VBZ O
been BC2GM058476475 VBN O
developed BC2GM058476475 VBN O
. BC2GM058476475 . O
. . O O

Dmyd BC2GM057671926 NNP O
clone BC2GM057671926 NN O
encodes BC2GM057671926 VBZ O
a BC2GM057671926 DT O
polypeptide BC2GM057671926 NN O
of BC2GM057671926 IN O
332 BC2GM057671926 CD O
amino BC2GM057671926 JJ O
acids BC2GM057671926 NNS O
with BC2GM057671926 IN O
82 BC2GM057671926 CD O
% BC2GM057671926 NN O
identity BC2GM057671926 NN O
to BC2GM057671926 TO O
MyoD BC2GM057671926 NNP O
in BC2GM057671926 IN O
the BC2GM057671926 DT O
41 BC2GM057671926 CD O
amino BC2GM057671926 JJ O
acids BC2GM057671926 NNS O
of BC2GM057671926 IN O
the BC2GM057671926 DT O
putative BC2GM057671926 JJ O
helix-loop-helix BC2GM057671926 JJ O
region BC2GM057671926 NN O
and BC2GM057671926 CC O
100 BC2GM057671926 CD O
% BC2GM057671926 NN O
identity BC2GM057671926 NN O
in BC2GM057671926 IN O
the BC2GM057671926 DT O
13 BC2GM057671926 CD O
amino BC2GM057671926 JJ O
acids BC2GM057671926 NNS O
of BC2GM057671926 IN O
the BC2GM057671926 DT O
basic BC2GM057671926 JJ O
domain BC2GM057671926 NN O
proposed BC2GM057671926 VBD O
to BC2GM057671926 TO O
contain BC2GM057671926 VB O
the BC2GM057671926 DT O
essential BC2GM057671926 JJ O
recognition BC2GM057671926 NN O
code BC2GM057671926 NN O
for BC2GM057671926 IN O
muscle-specific BC2GM057671926 JJ O
gene BC2GM057671926 NN O
activation BC2GM057671926 NN O
. BC2GM057671926 . O
. . O O

Helenalin BC2GM048811705 NNP O
triggers BC2GM048811705 VBZ O
a BC2GM048811705 DT O
CD95 BC2GM048811705 NNP O
death BC2GM048811705 NN O
receptor-independent BC2GM048811705 NN O
apoptosis BC2GM048811705 NN O
that BC2GM048811705 WDT O
is BC2GM048811705 VBZ O
not BC2GM048811705 RB O
affected BC2GM048811705 VBN O
by BC2GM048811705 IN O
overexpression BC2GM048811705 NN O
of BC2GM048811705 IN O
Bcl-x BC2GM048811705 NNP O
( BC2GM048811705 ( O
L BC2GM048811705 NNP O
) BC2GM048811705 ) O
or BC2GM048811705 CC O
Bcl-2 BC2GM048811705 NNP O
. BC2GM048811705 . O
. . O O

Previous BC2GM031712129 JJ O
studies BC2GM031712129 NNS O
have BC2GM031712129 VBP O
shown BC2GM031712129 VBN O
that BC2GM031712129 IN O
TGFbeta1 BC2GM031712129 NNP O
expression BC2GM031712129 NN O
is BC2GM031712129 VBZ O
upregulated BC2GM031712129 VBN O
in BC2GM031712129 IN O
mouse BC2GM031712129 NN O
keratinocytes BC2GM031712129 NNS O
infected BC2GM031712129 VBN O
with BC2GM031712129 IN O
a BC2GM031712129 DT O
v-rasHa BC2GM031712129 JJ O
retrovirus BC2GM031712129 NN O
, BC2GM031712129 , O
although BC2GM031712129 IN O
the BC2GM031712129 DT O
functional BC2GM031712129 JJ O
significance BC2GM031712129 NN O
of BC2GM031712129 IN O
this BC2GM031712129 DT O
has BC2GM031712129 VBZ O
not BC2GM031712129 RB O
been BC2GM031712129 VBN O
clear BC2GM031712129 JJ O
. BC2GM031712129 . O
. . O O

BACKGROUND BC2GM020863784 NNP O
. BC2GM020863784 . O
. . O O

Effect BC2GM080452134 NN O
of BC2GM080452134 IN O
dimethyl BC2GM080452134 NN O
sulfoxide BC2GM080452134 NN O
on BC2GM080452134 IN O
cooling BC2GM080452134 VBG O
rates BC2GM080452134 NNS O
of BC2GM080452134 IN O
unrestrained BC2GM080452134 JJ O
rats BC2GM080452134 NNS O
. BC2GM080452134 . O
. . O O

Lifestyle BC2GM070595219 JJ O
characteristics BC2GM070595219 NNS O
were BC2GM070595219 VBD O
ascertained BC2GM070595219 VBN O
by BC2GM070595219 IN O
a BC2GM070595219 DT O
self-administered BC2GM070595219 JJ O
questionnaire BC2GM070595219 NN O
. BC2GM070595219 . O
. . O O

This BC2GM054158346 DT O
unusual BC2GM054158346 JJ O
behaviour BC2GM054158346 NN O
may BC2GM054158346 MD O
be BC2GM054158346 VB O
explained BC2GM054158346 VBN O
by BC2GM054158346 IN O
the BC2GM054158346 DT O
18 BC2GM054158346 CD O
amino BC2GM054158346 JJ O
acid-long BC2GM054158346 JJ O
CDR-H3 BC2GM054158346 NNP O
and BC2GM054158346 CC O
could BC2GM054158346 MD O
be BC2GM054158346 VB O
of BC2GM054158346 IN O
value BC2GM054158346 NN O
in BC2GM054158346 IN O
the BC2GM054158346 DT O
design BC2GM054158346 NN O
of BC2GM054158346 IN O
'single BC2GM054158346 NNP O
domain BC2GM054158346 NN O
' BC2GM054158346 POS O
antibodies BC2GM054158346 NNS O
. BC2GM054158346 . O
. . O O

We BC2GM004666359 PRP O
have BC2GM004666359 VBP O
demonstrated BC2GM004666359 VBN O
that BC2GM004666359 IN O
a BC2GM004666359 DT O
putative BC2GM004666359 JJ O
HOX BC2GM004666359 NNP O
cofactor BC2GM004666359 NN O
, BC2GM004666359 , O
PBX1A BC2GM004666359 NNP O
, BC2GM004666359 , O
participates BC2GM004666359 VBZ O
in BC2GM004666359 IN O
cooperative BC2GM004666359 JJ O
DNA BC2GM004666359 NNP O
binding BC2GM004666359 VBG O
with BC2GM004666359 IN O
HOXA-1 BC2GM004666359 NNP O
and BC2GM004666359 CC O
the BC2GM004666359 DT O
Deformed BC2GM004666359 NNP O
group BC2GM004666359 NN O
protein BC2GM004666359 VBD O
HOXD-4 BC2GM004666359 NNP O
. BC2GM004666359 . O
. . O O

Patients BC2GM010522848 NNS O
with BC2GM010522848 IN O
advanced BC2GM010522848 JJ O
ovarian BC2GM010522848 JJ O
carcinoma BC2GM010522848 NN O
, BC2GM010522848 , O
Stage BC2GM010522848 NNP O
III BC2GM010522848 NNP O
or BC2GM010522848 CC O
IV BC2GM010522848 NNP O
( BC2GM010522848 ( O
International BC2GM010522848 NNP O
Federation BC2GM010522848 NNP O
of BC2GM010522848 IN O
Gynaecology BC2GM010522848 NNP O
and BC2GM010522848 CC O
Obstetrics BC2GM010522848 NNP O
) BC2GM010522848 ) O
, BC2GM010522848 , O
were BC2GM010522848 VBD O
randomized BC2GM010522848 VBN O
to BC2GM010522848 TO O
primary BC2GM010522848 JJ O
chemotherapy BC2GM010522848 NN O
with BC2GM010522848 IN O
doxorubicin BC2GM010522848 NN O
( BC2GM010522848 ( O
Adriamycin BC2GM010522848 NNP O
) BC2GM010522848 ) O
and BC2GM010522848 CC O
cisplatin BC2GM010522848 JJ O
plus BC2GM010522848 CC O
or BC2GM010522848 CC O
minus BC2GM010522848 CC O
hexamethylmelamine BC2GM010522848 NN O
, BC2GM010522848 , O
and BC2GM010522848 CC O
cyclophosphamide BC2GM010522848 NN O
( BC2GM010522848 ( O
CHAP BC2GM010522848 NNP O
) BC2GM010522848 ) O
. BC2GM010522848 . O
. . O O

In BC2GM084277240 IN O
addition BC2GM084277240 NN O
, BC2GM084277240 , O
FOP-FGFR1-expressing BC2GM084277240 NNP O
cells BC2GM084277240 NNS O
show BC2GM084277240 VBP O
constitutive BC2GM084277240 JJ O
phosphorylation BC2GM084277240 NN O
of BC2GM084277240 IN O
the BC2GM084277240 DT O
positive BC2GM084277240 JJ O
regulator BC2GM084277240 NN O
of BC2GM084277240 IN O
translation BC2GM084277240 NN O
p70S6 BC2GM084277240 NN O
kinase BC2GM084277240 NN O
; BC2GM084277240 : O
this BC2GM084277240 DT O
phosphorylation BC2GM084277240 NN O
is BC2GM084277240 VBZ O
inhibited BC2GM084277240 VBN O
by BC2GM084277240 IN O
PI3-kinase BC2GM084277240 NNP O
and BC2GM084277240 CC O
mTOR BC2GM084277240 NN O
( BC2GM084277240 ( O
mammalian BC2GM084277240 JJ O
target BC2GM084277240 NN O
of BC2GM084277240 IN O
rapamycin BC2GM084277240 NN O
) BC2GM084277240 ) O
inhibitors BC2GM084277240 NNS O
. BC2GM084277240 . O
. . O O

Gingival BC2GM097462810 NNP O
retraction BC2GM097462810 NN O
for BC2GM097462810 IN O
class BC2GM097462810 NN O
V BC2GM097462810 NNP O
restorations BC2GM097462810 NNS O
. BC2GM097462810 . O
. . O O

The BC2GM036044830 DT O
three BC2GM036044830 CD O
OAS BC2GM036044830 NNP O
genes BC2GM036044830 NNS O
are BC2GM036044830 VBP O
flanked BC2GM036044830 VBN O
by BC2GM036044830 IN O
markers BC2GM036044830 NNS O
WI-10614 BC2GM036044830 NNP O
( BC2GM036044830 ( O
cen BC2GM036044830 NN O
) BC2GM036044830 ) O
and BC2GM036044830 CC O
D12S2293 BC2GM036044830 NNP O
( BC2GM036044830 ( O
tel BC2GM036044830 NN O
) BC2GM036044830 ) O
and BC2GM036044830 CC O
are BC2GM036044830 VBP O
contained BC2GM036044830 VBN O
within BC2GM036044830 IN O
three BC2GM036044830 CD O
sets BC2GM036044830 NNS O
of BC2GM036044830 IN O
overlapping BC2GM036044830 VBG O
cosmid BC2GM036044830 JJ O
clones BC2GM036044830 NNS O
. BC2GM036044830 . O
. . O O

The BC2GM019879007 DT O
human BC2GM019879007 JJ O
RIL BC2GM019879007 NNP O
gene BC2GM019879007 NN O
: BC2GM019879007 : O
mapping BC2GM019879007 NN O
to BC2GM019879007 TO O
human BC2GM019879007 JJ O
chromosome BC2GM019879007 NN O
5q31.1 BC2GM019879007 CD O
, BC2GM019879007 , O
genomic BC2GM019879007 JJ O
organization BC2GM019879007 NN O
and BC2GM019879007 CC O
alternative BC2GM019879007 JJ O
transcripts BC2GM019879007 NNS O
. BC2GM019879007 . O
. . O O

Here BC2GM048576585 RB O
we BC2GM048576585 PRP O
show BC2GM048576585 VBP O
that BC2GM048576585 IN O
one BC2GM048576585 CD O
nudF BC2GM048576585 NN O
suppressor BC2GM048576585 NN O
also BC2GM048576585 RB O
suppresses BC2GM048576585 VBZ O
hs- BC2GM048576585 JJ O
mutations BC2GM048576585 NNS O
in BC2GM048576585 IN O
nudA BC2GM048576585 NN O
, BC2GM048576585 , O
nudC BC2GM048576585 NN O
, BC2GM048576585 , O
and BC2GM048576585 CC O
nudG BC2GM048576585 RB O
and BC2GM048576585 CC O
deletions BC2GM048576585 NNS O
in BC2GM048576585 IN O
nudA BC2GM048576585 NN O
and BC2GM048576585 CC O
nudF BC2GM048576585 NN O
. BC2GM048576585 . O
. . O O

Transmural BC2GM083596704 NNP O
metabolic BC2GM083596704 JJ O
heterogeneity BC2GM083596704 NN O
at BC2GM083596704 IN O
high BC2GM083596704 JJ O
cardiac BC2GM083596704 JJ O
work BC2GM083596704 NN O
states BC2GM083596704 NNS O
. BC2GM083596704 . O
. . O O

The BC2GM028146318 DT O
effects BC2GM028146318 NNS O
of BC2GM028146318 IN O
4 BC2GM028146318 CD O
weeks BC2GM028146318 NNS O
of BC2GM028146318 IN O
cyclosporin BC2GM028146318 NN O
A BC2GM028146318 NNP O
( BC2GM028146318 ( O
7 BC2GM028146318 CD O
mg BC2GM028146318 NN O
/ BC2GM028146318 NNP O
kg BC2GM028146318 FW O
per BC2GM028146318 IN O
day BC2GM028146318 NN O
) BC2GM028146318 ) O
( BC2GM028146318 ( O
CyA BC2GM028146318 NNP O
) BC2GM028146318 ) O
on BC2GM028146318 IN O
the BC2GM028146318 DT O
survival BC2GM028146318 NN O
of BC2GM028146318 IN O
vascularized BC2GM028146318 JJ O
osteochondral BC2GM028146318 JJ O
grafts BC2GM028146318 NNS O
between BC2GM028146318 IN O
rat BC2GM028146318 NN O
strains BC2GM028146318 NNS O
[ BC2GM028146318 VBP O
DA BC2GM028146318 NNP O
( BC2GM028146318 ( O
donor BC2GM028146318 NN O
) BC2GM028146318 ) O
and BC2GM028146318 CC O
Lewis BC2GM028146318 NNP O
( BC2GM028146318 ( O
recipient BC2GM028146318 NN O
) BC2GM028146318 ) O
] BC2GM028146318 NN O
and BC2GM028146318 CC O
the BC2GM028146318 DT O
presence BC2GM028146318 NN O
and BC2GM028146318 CC O
significance BC2GM028146318 NN O
of BC2GM028146318 IN O
host BC2GM028146318 NN O
immune BC2GM028146318 JJ O
tolerance BC2GM028146318 NN O
and BC2GM028146318 CC O
graft BC2GM028146318 NN O
antigen BC2GM028146318 NN O
modulation BC2GM028146318 NN O
after BC2GM028146318 IN O
cessation BC2GM028146318 NN O
of BC2GM028146318 IN O
immunosuppression BC2GM028146318 NN O
have BC2GM028146318 VBP O
been BC2GM028146318 VBN O
examined BC2GM028146318 VBN O
. BC2GM028146318 . O
. . O O

Neonatal BC2GM035523240 JJ O
masculinization BC2GM035523240 NN O
affects BC2GM035523240 VBZ O
maternal BC2GM035523240 JJ O
behavior BC2GM035523240 NN O
sensitivity BC2GM035523240 NN O
in BC2GM035523240 IN O
female BC2GM035523240 JJ O
rats BC2GM035523240 NNS O
. BC2GM035523240 . O
. . O O

One BC2GM056600805 CD O
of BC2GM056600805 IN O
these BC2GM056600805 DT O
clones BC2GM056600805 NNS O
encodes BC2GM056600805 NNS O
Xenopus BC2GM056600805 VBP O
N-ras BC2GM056600805 NNP O
. BC2GM056600805 . O
. . O O

Exogenous BC2GM038486910 JJ O
heart BC2GM038486910 NN O
stress BC2GM038486910 NN O
raised BC2GM038486910 VBD O
log BC2GM038486910 NN O
circulating BC2GM038486910 VBG O
NE BC2GM038486910 NNP O
concentration BC2GM038486910 NN O
in BC2GM038486910 IN O
proportion BC2GM038486910 NN O
to BC2GM038486910 TO O
the BC2GM038486910 DT O
rise BC2GM038486910 NN O
in BC2GM038486910 IN O
heart BC2GM038486910 NN O
rate BC2GM038486910 NN O
at BC2GM038486910 IN O
a BC2GM038486910 DT O
given BC2GM038486910 VBN O
work BC2GM038486910 NN O
load BC2GM038486910 NN O
so BC2GM038486910 IN O
that BC2GM038486910 IN O
the BC2GM038486910 DT O
usual BC2GM038486910 JJ O
relationship BC2GM038486910 NN O
between BC2GM038486910 IN O
these BC2GM038486910 DT O
variables BC2GM038486910 NNS O
, BC2GM038486910 , O
previously BC2GM038486910 RB O
observed BC2GM038486910 VBN O
during BC2GM038486910 IN O
other BC2GM038486910 JJ O
stresses BC2GM038486910 NNS O
, BC2GM038486910 , O
was BC2GM038486910 VBD O
preserved BC2GM038486910 VBN O
. BC2GM038486910 . O
. . O O

Histopathologic BC2GM003392848 NNP O
studies BC2GM003392848 NNS O
displaying BC2GM003392848 VBG O
spongiform BC2GM003392848 NN O
changes BC2GM003392848 NNS O
in BC2GM003392848 IN O
the BC2GM003392848 DT O
gray BC2GM003392848 JJ O
matter BC2GM003392848 NN O
, BC2GM003392848 , O
neuronal BC2GM003392848 JJ O
loss BC2GM003392848 NN O
, BC2GM003392848 , O
and BC2GM003392848 CC O
atrogliosis BC2GM003392848 NN O
confirmed BC2GM003392848 VBD O
the BC2GM003392848 DT O
clinical BC2GM003392848 JJ O
diagnosis BC2GM003392848 NN O
of BC2GM003392848 IN O
Creutzfeldt-Jakob BC2GM003392848 NNP O
disease BC2GM003392848 NN O
. BC2GM003392848 . O
. . O O

In BC2GM017509191 IN O
contrast BC2GM017509191 NN O
, BC2GM017509191 , O
polypropylene BC2GM017509191 NN O
glycol BC2GM017509191 NN O
, BC2GM017509191 , O
PG-C BC2GM017509191 NNP O
, BC2GM017509191 , O
and BC2GM017509191 CC O
corn BC2GM017509191 NN O
oil BC2GM017509191 NN O
all BC2GM017509191 DT O
removed BC2GM017509191 VBD O
68-86 BC2GM017509191 CD O
% BC2GM017509191 NN O
of BC2GM017509191 IN O
the BC2GM017509191 DT O
MDI BC2GM017509191 NNP O
in BC2GM017509191 IN O
the BC2GM017509191 DT O
first BC2GM017509191 JJ O
h BC2GM017509191 NN O
, BC2GM017509191 , O
74-79 BC2GM017509191 JJ O
% BC2GM017509191 NN O
at BC2GM017509191 IN O
4 BC2GM017509191 CD O
h BC2GM017509191 NN O
, BC2GM017509191 , O
and BC2GM017509191 CC O
72-86 BC2GM017509191 CD O
% BC2GM017509191 NN O
at BC2GM017509191 IN O
8 BC2GM017509191 CD O
h BC2GM017509191 NN O
. BC2GM017509191 . O
. . O O

Using BC2GM028349983 VBG O
the BC2GM028349983 DT O
same BC2GM028349983 JJ O
electrical BC2GM028349983 JJ O
analog BC2GM028349983 NN O
, BC2GM028349983 , O
we BC2GM028349983 PRP O
present BC2GM028349983 VBP O
an BC2GM028349983 DT O
analysis BC2GM028349983 NN O
that BC2GM028349983 WDT O
allows BC2GM028349983 VBZ O
calculation BC2GM028349983 NN O
of BC2GM028349983 IN O
these BC2GM028349983 DT O
parameters BC2GM028349983 NNS O
, BC2GM028349983 , O
as BC2GM028349983 RB O
well BC2GM028349983 RB O
as BC2GM028349983 IN O
the BC2GM028349983 DT O
corner BC2GM028349983 NN O
frequency BC2GM028349983 NN O
of BC2GM028349983 IN O
the BC2GM028349983 DT O
network BC2GM028349983 NN O
( BC2GM028349983 ( O
f1 BC2GM028349983 NN O
) BC2GM028349983 ) O
, BC2GM028349983 , O
without BC2GM028349983 IN O
need BC2GM028349983 NN O
for BC2GM028349983 IN O
similar BC2GM028349983 JJ O
assumptions BC2GM028349983 NNS O
. BC2GM028349983 . O
. . O O

With BC2GM024789471 IN O
the BC2GM024789471 DT O
help BC2GM024789471 NN O
of BC2GM024789471 IN O
partially BC2GM024789471 RB O
overlapping BC2GM024789471 VBG O
parenchymatous BC2GM024789471 JJ O
sutures BC2GM024789471 NNS O
, BC2GM024789471 , O
different BC2GM024789471 JJ O
renal BC2GM024789471 JJ O
segments BC2GM024789471 NNS O
were BC2GM024789471 VBD O
devitalized BC2GM024789471 VBN O
. BC2GM024789471 . O
. . O O

Analysis BC2GM064988521 NN O
of BC2GM064988521 IN O
a BC2GM064988521 DT O
Het- BC2GM064988521 JJ O
mutation BC2GM064988521 NN O
in BC2GM064988521 IN O
Anabaena BC2GM064988521 NNP O
sp BC2GM064988521 NN O
. BC2GM064988521 . O
strain BC2GM064988521 NN O
PCC BC2GM064988521 NNP O
7120 BC2GM064988521 CD O
implicates BC2GM064988521 VBZ O
a BC2GM064988521 DT O
secondary BC2GM064988521 JJ O
metabolite BC2GM064988521 NN O
in BC2GM064988521 IN O
the BC2GM064988521 DT O
regulation BC2GM064988521 NN O
of BC2GM064988521 IN O
heterocyst BC2GM064988521 NN O
spacing BC2GM064988521 NN O
. BC2GM064988521 . O
. . O O

Comparative BC2GM019718038 JJ O
volumetric BC2GM019718038 JJ O
analysis BC2GM019718038 NN O
is BC2GM019718038 VBZ O
defined BC2GM019718038 VBN O
as BC2GM019718038 IN O
the BC2GM019718038 DT O
difference BC2GM019718038 NN O
between BC2GM019718038 IN O
mean BC2GM019718038 JJ O
corpuscular BC2GM019718038 JJ O
erythrocyte BC2GM019718038 NN O
volume BC2GM019718038 NN O
in BC2GM019718038 IN O
peripheral BC2GM019718038 JJ O
blood BC2GM019718038 NN O
( BC2GM019718038 ( O
MCVB BC2GM019718038 NNP O
) BC2GM019718038 ) O
diluted BC2GM019718038 VBD O
in BC2GM019718038 IN O
urine BC2GM019718038 JJ O
supernatant BC2GM019718038 NN O
after BC2GM019718038 IN O
centrifugation BC2GM019718038 NN O
and BC2GM019718038 CC O
mean BC2GM019718038 JJ O
corpuscular BC2GM019718038 JJ O
volume BC2GM019718038 NN O
of BC2GM019718038 IN O
urinary BC2GM019718038 JJ O
erythrocytes BC2GM019718038 NNS O
( BC2GM019718038 ( O
MCVU BC2GM019718038 NNP O
) BC2GM019718038 ) O
. BC2GM019718038 . O
. . O O

Upon BC2GM016668855 IN O
incubation BC2GM016668855 NN O
of BC2GM016668855 IN O
the BC2GM016668855 DT O
most BC2GM016668855 RBS O
highly BC2GM016668855 RB O
purified BC2GM016668855 JJ O
fractions BC2GM016668855 NNS O
with BC2GM016668855 IN O
Mn-ATP BC2GM016668855 NNP O
or BC2GM016668855 CC O
Mg-ATP BC2GM016668855 NNP O
, BC2GM016668855 , O
p40 BC2GM016668855 NN O
was BC2GM016668855 VBD O
the BC2GM016668855 DT O
only BC2GM016668855 JJ O
protein BC2GM016668855 NN O
phosphorylated BC2GM016668855 VBD O
on BC2GM016668855 IN O
tyrosine BC2GM016668855 NN O
. BC2GM016668855 . O
. . O O

These BC2GM054420057 DT O
data BC2GM054420057 NNS O
suggest BC2GM054420057 VBP O
that BC2GM054420057 IN O
weight BC2GM054420057 JJ O
gain BC2GM054420057 NN O
or BC2GM054420057 CC O
increased BC2GM054420057 VBN O
caloric BC2GM054420057 JJ O
intake BC2GM054420057 NN O
, BC2GM054420057 , O
in BC2GM054420057 IN O
contrast BC2GM054420057 NN O
to BC2GM054420057 TO O
its BC2GM054420057 PRP$ O
large BC2GM054420057 JJ O
effect BC2GM054420057 NN O
on BC2GM054420057 IN O
peripheral BC2GM054420057 JJ O
thyroid BC2GM054420057 NN O
function BC2GM054420057 NN O
, BC2GM054420057 , O
has BC2GM054420057 VBZ O
relatively BC2GM054420057 RB O
little BC2GM054420057 JJ O
effect BC2GM054420057 NN O
on BC2GM054420057 IN O
CNS BC2GM054420057 NNP O
TRH BC2GM054420057 NNP O
activity BC2GM054420057 NN O
. BC2GM054420057 . O
. . O O

These BC2GM077718596 DT O
data BC2GM077718596 NNS O
suggest BC2GM077718596 VBP O
that BC2GM077718596 IN O
the BC2GM077718596 DT O
secreted BC2GM077718596 VBN O
, BC2GM077718596 , O
truncated BC2GM077718596 VBD O
receptor BC2GM077718596 NN O
encoded BC2GM077718596 VBN O
by BC2GM077718596 IN O
the BC2GM077718596 DT O
2.6-kb BC2GM077718596 JJ O
c-erbB BC2GM077718596 JJ O
transcript BC2GM077718596 NN O
can BC2GM077718596 MD O
bind BC2GM077718596 VB O
to BC2GM077718596 TO O
TGF BC2GM077718596 NNP O
alpha BC2GM077718596 NN O
and BC2GM077718596 CC O
may BC2GM077718596 MD O
play BC2GM077718596 VB O
an BC2GM077718596 DT O
important BC2GM077718596 JJ O
growth-regulatory BC2GM077718596 JJ O
function BC2GM077718596 NN O
in BC2GM077718596 IN O
vitro BC2GM077718596 NN O
. BC2GM077718596 . O
. . O O

Serum BC2GM068703036 NNP O
angiogenin BC2GM068703036 NN O
concentrations BC2GM068703036 NNS O
in BC2GM068703036 IN O
young BC2GM068703036 JJ O
patients BC2GM068703036 NNS O
with BC2GM068703036 IN O
diabetes BC2GM068703036 NNS O
mellitus BC2GM068703036 NNS O
. BC2GM068703036 . O
. . O O

Repeated BC2GM054816469 VBN O
time BC2GM054816469 NN O
course BC2GM054816469 NN O
studies BC2GM054816469 NNS O
in BC2GM054816469 IN O
the BC2GM054816469 DT O
same BC2GM054816469 JJ O
patient BC2GM054816469 NN O
were BC2GM054816469 VBD O
reproducible BC2GM054816469 JJ O
although BC2GM054816469 IN O
the BC2GM054816469 DT O
absolute BC2GM054816469 JJ O
concentrations BC2GM054816469 NNS O
showed BC2GM054816469 VBD O
some BC2GM054816469 DT O
variation BC2GM054816469 NN O
. BC2GM054816469 . O
. . O O

Primer BC2GM013174234 NNP O
extension BC2GM013174234 NN O
experiments BC2GM013174234 NNS O
using BC2GM013174234 VBG O
dbcAMP-differentiated BC2GM013174234 JJ O
U937 BC2GM013174234 NNP O
RNA BC2GM013174234 NNP O
indicated BC2GM013174234 VBD O
a BC2GM013174234 DT O
single BC2GM013174234 JJ O
transcriptional BC2GM013174234 JJ O
initiation BC2GM013174234 NN O
site BC2GM013174234 NN O
. BC2GM013174234 . O
. . O O

This BC2GM009739613 DT O
novel BC2GM009739613 JJ O
TRPC7 BC2GM009739613 NNP O
gene BC2GM009739613 NN O
could BC2GM009739613 MD O
be BC2GM009739613 VB O
a BC2GM009739613 DT O
candidate BC2GM009739613 JJ O
gene BC2GM009739613 NN O
for BC2GM009739613 IN O
genetic BC2GM009739613 JJ O
disorders BC2GM009739613 NNS O
such BC2GM009739613 JJ O
as BC2GM009739613 IN O
bipolar BC2GM009739613 JJ O
affective BC2GM009739613 JJ O
disorder BC2GM009739613 NN O
, BC2GM009739613 , O
nonsyndromic BC2GM009739613 JJ O
hereditary BC2GM009739613 JJ O
deafness BC2GM009739613 NN O
, BC2GM009739613 , O
Knobloch BC2GM009739613 NNP O
syndrome BC2GM009739613 NN O
, BC2GM009739613 , O
and BC2GM009739613 CC O
holoprosencephaly BC2GM009739613 NN O
, BC2GM009739613 , O
which BC2GM009739613 WDT O
were BC2GM009739613 VBD O
mapped BC2GM009739613 VBN O
to BC2GM009739613 TO O
this BC2GM009739613 DT O
region BC2GM009739613 NN O
. BC2GM009739613 . O
. . O O

Analysis BC2GM078923542 NN O
of BC2GM078923542 IN O
the BC2GM078923542 DT O
5 BC2GM078923542 CD O
' BC2GM078923542 POS O
and BC2GM078923542 CC O
3 BC2GM078923542 CD O
' BC2GM078923542 '' O
termini BC2GM078923542 NN O
of BC2GM078923542 IN O
the BC2GM078923542 DT O
transcripts BC2GM078923542 NNS O
produced BC2GM078923542 VBN O
in BC2GM078923542 IN O
vivo BC2GM078923542 NN O
from BC2GM078923542 IN O
the BC2GM078923542 DT O
puf BC2GM078923542 NN O
operon BC2GM078923542 NN O
of BC2GM078923542 IN O
R. BC2GM078923542 NNP O
sphaeroides BC2GM078923542 NNS O
PUF BC2GM078923542 NNP O
delta BC2GM078923542 NN O
348-420 BC2GM078923542 NNP O
( BC2GM078923542 ( O
three BC2GM078923542 CD O
transcripts BC2GM078923542 NNS O
; BC2GM078923542 : O
0.59 BC2GM078923542 CD O
, BC2GM078923542 , O
0.64 BC2GM078923542 CD O
, BC2GM078923542 , O
and BC2GM078923542 CC O
2.63 BC2GM078923542 CD O
kilobases BC2GM078923542 NNS O
) BC2GM078923542 ) O
lacking BC2GM078923542 VBG O
the BC2GM078923542 DT O
puf-intercistronic BC2GM078923542 JJ O
terminator BC2GM078923542 NN O
structure BC2GM078923542 NN O
were BC2GM078923542 VBD O
identical BC2GM078923542 JJ O
to BC2GM078923542 TO O
those BC2GM078923542 DT O
of BC2GM078923542 IN O
the BC2GM078923542 DT O
corresponding BC2GM078923542 JJ O
puf BC2GM078923542 NN O
transcripts BC2GM078923542 NNS O
derived BC2GM078923542 VBN O
from BC2GM078923542 IN O
wild-type BC2GM078923542 JJ O
R. BC2GM078923542 NNP O
sphaeroides BC2GM078923542 VBZ O
2.4.1 BC2GM078923542 CD O
( BC2GM078923542 ( O
four BC2GM078923542 CD O
transcripts BC2GM078923542 NNS O
; BC2GM078923542 : O
0.50 BC2GM078923542 CD O
, BC2GM078923542 , O
0.66 BC2GM078923542 CD O
, BC2GM078923542 , O
0.71 BC2GM078923542 CD O
, BC2GM078923542 , O
and BC2GM078923542 CC O
2.7 BC2GM078923542 CD O
kilobases BC2GM078923542 NNS O
) BC2GM078923542 ) O
showing BC2GM078923542 VBG O
that BC2GM078923542 IN O
the BC2GM078923542 DT O
transcripts BC2GM078923542 NNS O
begin BC2GM078923542 VBP O
and BC2GM078923542 CC O
end BC2GM078923542 VBP O
at BC2GM078923542 IN O
the BC2GM078923542 DT O
same BC2GM078923542 JJ O
sites BC2GM078923542 NNS O
. BC2GM078923542 . O
. . O O

A BC2GM022729580 DT O
less BC2GM022729580 RBR O
common BC2GM022729580 JJ O
and BC2GM022729580 CC O
much BC2GM022729580 RB O
more BC2GM022729580 RBR O
perplexing BC2GM022729580 JJ O
circumstance BC2GM022729580 NN O
occurs BC2GM022729580 VBZ O
when BC2GM022729580 WRB O
evaluating BC2GM022729580 VBG O
patients BC2GM022729580 NNS O
with BC2GM022729580 IN O
sarcoidosis BC2GM022729580 NN O
established BC2GM022729580 VBN O
for BC2GM022729580 IN O
several BC2GM022729580 JJ O
years BC2GM022729580 NNS O
present BC2GM022729580 JJ O
with BC2GM022729580 IN O
evidence BC2GM022729580 NN O
of BC2GM022729580 IN O
progressive BC2GM022729580 JJ O
or BC2GM022729580 CC O
chronic BC2GM022729580 JJ O
pulmonary BC2GM022729580 JJ O
involvement BC2GM022729580 NN O
and BC2GM022729580 CC O
dyspnea BC2GM022729580 NN O
. BC2GM022729580 . O
. . O O

Activation BC2GM090889601 NN O
of BC2GM090889601 IN O
HIV BC2GM090889601 NNP O
gene BC2GM090889601 NN O
expression BC2GM090889601 NN O
by BC2GM090889601 IN O
UV BC2GM090889601 NNP O
must BC2GM090889601 MD O
therefore BC2GM090889601 RB O
involve BC2GM090889601 VB O
additional BC2GM090889601 JJ O
cellular BC2GM090889601 JJ O
processes BC2GM090889601 NNS O
, BC2GM090889601 , O
such BC2GM090889601 JJ O
as BC2GM090889601 IN O
those BC2GM090889601 DT O
triggered BC2GM090889601 VBN O
by BC2GM090889601 IN O
DNA BC2GM090889601 NNP O
damage BC2GM090889601 NN O
, BC2GM090889601 , O
for BC2GM090889601 IN O
generation BC2GM090889601 NN O
of BC2GM090889601 IN O
a BC2GM090889601 DT O
full BC2GM090889601 JJ O
gene BC2GM090889601 NN O
expression BC2GM090889601 NN O
response BC2GM090889601 NN O
. BC2GM090889601 . O
. . O O

The BC2GM017296599 DT O
patient BC2GM017296599 NN O
groups BC2GM017296599 NNS O
consisted BC2GM017296599 VBD O
of BC2GM017296599 IN O
31 BC2GM017296599 CD O
with BC2GM017296599 IN O
dilated BC2GM017296599 VBN O
cardiomyopathy BC2GM017296599 NN O
, BC2GM017296599 , O
22 BC2GM017296599 CD O
with BC2GM017296599 IN O
hypertrophic BC2GM017296599 JJ O
cardiomyopathy BC2GM017296599 NN O
, BC2GM017296599 , O
38 BC2GM017296599 CD O
with BC2GM017296599 IN O
myocardial BC2GM017296599 JJ O
infarction BC2GM017296599 NN O
, BC2GM017296599 , O
15 BC2GM017296599 CD O
with BC2GM017296599 IN O
angina BC2GM017296599 JJ O
pectoris BC2GM017296599 NN O
and BC2GM017296599 CC O
26 BC2GM017296599 CD O
with BC2GM017296599 IN O
rheumatic BC2GM017296599 JJ O
valvular BC2GM017296599 JJ O
disease BC2GM017296599 NN O
. BC2GM017296599 . O
. . O O

Ultrasonography BC2GM042842840 NN O
is BC2GM042842840 VBZ O
a BC2GM042842840 DT O
diagnostic BC2GM042842840 JJ O
alternative BC2GM042842840 NN O
which BC2GM042842840 WDT O
may BC2GM042842840 MD O
replace BC2GM042842840 VB O
arthrography BC2GM042842840 NN O
. BC2GM042842840 . O
. . O O

Both BC2GM075167563 DT O
purH BC2GM075167563 NN O
and BC2GM075167563 CC O
purD BC2GM075167563 NN O
genes BC2GM075167563 NNS O
constitute BC2GM075167563 VBP O
a BC2GM075167563 DT O
single BC2GM075167563 JJ O
operon BC2GM075167563 NN O
and BC2GM075167563 CC O
are BC2GM075167563 VBP O
coregulated BC2GM075167563 VBN O
in BC2GM075167563 IN O
expression BC2GM075167563 NN O
by BC2GM075167563 IN O
purines BC2GM075167563 NNS O
as BC2GM075167563 IN O
other BC2GM075167563 JJ O
purine BC2GM075167563 NN O
genes BC2GM075167563 NNS O
are BC2GM075167563 VBP O
. BC2GM075167563 . O
. . O O

The BC2GM081897643 DT O
first BC2GM081897643 JJ O
operon BC2GM081897643 NN O
, BC2GM081897643 , O
orf1-tolQRA BC2GM081897643 JJ O
, BC2GM081897643 , O
is BC2GM081897643 VBZ O
iron BC2GM081897643 NN O
regulated BC2GM081897643 VBN O
throughout BC2GM081897643 IN O
growth BC2GM081897643 NN O
, BC2GM081897643 , O
but BC2GM081897643 CC O
iron-regulated BC2GM081897643 JJ O
expression BC2GM081897643 NN O
of BC2GM081897643 IN O
tolB BC2GM081897643 NN O
and BC2GM081897643 CC O
oprL BC2GM081897643 JJ O
fusions BC2GM081897643 NNS O
occurs BC2GM081897643 VBZ O
only BC2GM081897643 RB O
in BC2GM081897643 IN O
late BC2GM081897643 JJ O
log BC2GM081897643 NN O
phase BC2GM081897643 NN O
. BC2GM081897643 . O
. . O O

Cotransfection BC2GM043707576 NN O
of BC2GM043707576 IN O
a BC2GM043707576 DT O
junB BC2GM043707576 NN O
stimulated BC2GM043707576 VBD O
the BC2GM043707576 DT O
basal BC2GM043707576 NN O
activity BC2GM043707576 NN O
of BC2GM043707576 IN O
the BC2GM043707576 DT O
alpha BC2GM043707576 NN O
2 BC2GM043707576 CD O
( BC2GM043707576 ( O
I BC2GM043707576 PRP O
) BC2GM043707576 ) O
collagen BC2GM043707576 NN O
promoter BC2GM043707576 NN O
93-fold BC2GM043707576 CD O
, BC2GM043707576 , O
respectively BC2GM043707576 RB O
. BC2GM043707576 . O
. . O O

This BC2GM058805467 DT O
model BC2GM058805467 NN O
system BC2GM058805467 NN O
exploits BC2GM058805467 VBZ O
the BC2GM058805467 DT O
polyomavirus BC2GM058805467 NN O
late BC2GM058805467 JJ O
transcription BC2GM058805467 NN O
termination BC2GM058805467 NN O
and BC2GM058805467 CC O
polyadenylation BC2GM058805467 NN O
signals BC2GM058805467 NNS O
, BC2GM058805467 , O
which BC2GM058805467 WDT O
are BC2GM058805467 VBP O
sufficiently BC2GM058805467 RB O
weak BC2GM058805467 JJ O
to BC2GM058805467 TO O
allow BC2GM058805467 VB O
the BC2GM058805467 DT O
production BC2GM058805467 NN O
of BC2GM058805467 IN O
many BC2GM058805467 JJ O
multigenome-length BC2GM058805467 JJ O
primary BC2GM058805467 JJ O
transcripts BC2GM058805467 NNS O
with BC2GM058805467 IN O
repeating BC2GM058805467 VBG O
introns BC2GM058805467 NNS O
, BC2GM058805467 , O
exons BC2GM058805467 NNS O
, BC2GM058805467 , O
and BC2GM058805467 CC O
poly BC2GM058805467 NN O
( BC2GM058805467 ( O
A BC2GM058805467 DT O
) BC2GM058805467 ) O
sites BC2GM058805467 VBZ O
. BC2GM058805467 . O
. . O O

It BC2GM016838790 PRP O
also BC2GM016838790 RB O
appears BC2GM016838790 VBZ O
that BC2GM016838790 IN O
in BC2GM016838790 IN O
patients BC2GM016838790 NNS O
with BC2GM016838790 IN O
laboratory BC2GM016838790 JJ O
diagnosis BC2GM016838790 NN O
of BC2GM016838790 IN O
prerenal BC2GM016838790 JJ O
acute BC2GM016838790 JJ O
renal BC2GM016838790 JJ O
failure BC2GM016838790 NN O
( BC2GM016838790 ( O
i.e. BC2GM016838790 FW O
, BC2GM016838790 , O
a BC2GM016838790 DT O
RFT BC2GM016838790 NNP O
less BC2GM016838790 JJR O
than BC2GM016838790 IN O
1.0 BC2GM016838790 CD O
) BC2GM016838790 ) O
, BC2GM016838790 , O
the BC2GM016838790 DT O
response BC2GM016838790 NN O
to BC2GM016838790 TO O
treatment BC2GM016838790 NN O
is BC2GM016838790 VBZ O
unpredictable BC2GM016838790 JJ O
and BC2GM016838790 CC O
in BC2GM016838790 IN O
fact BC2GM016838790 NN O
may BC2GM016838790 MD O
have BC2GM016838790 VB O
a BC2GM016838790 DT O
worse BC2GM016838790 JJR O
prognosis BC2GM016838790 NN O
than BC2GM016838790 IN O
in BC2GM016838790 IN O
those BC2GM016838790 DT O
with BC2GM016838790 IN O
a BC2GM016838790 DT O
RFI BC2GM016838790 NNP O
greater BC2GM016838790 JJR O
than BC2GM016838790 IN O
1.0 BC2GM016838790 CD O
( BC2GM016838790 ( O
5 BC2GM016838790 CD O
/ BC2GM016838790 RB O
7 BC2GM016838790 CD O
deaths BC2GM016838790 NNS O
vs BC2GM016838790 RB O
10 BC2GM016838790 CD O
/ BC2GM016838790 JJ O
48 BC2GM016838790 CD O
deaths BC2GM016838790 NNS O
) BC2GM016838790 ) O
. BC2GM016838790 . O
. . O O

The BC2GM048059334 DT O
coding BC2GM048059334 VBG O
region BC2GM048059334 NN O
of BC2GM048059334 IN O
nifA BC2GM048059334 NN O
was BC2GM048059334 VBD O
determined BC2GM048059334 VBN O
using BC2GM048059334 VBG O
a BC2GM048059334 DT O
translational BC2GM048059334 JJ O
lacZ BC2GM048059334 NN O
fusion BC2GM048059334 NN O
and BC2GM048059334 CC O
by BC2GM048059334 IN O
site-directed BC2GM048059334 JJ O
mutagenesis BC2GM048059334 NN O
to BC2GM048059334 TO O
identify BC2GM048059334 VB O
which BC2GM048059334 WDT O
of BC2GM048059334 IN O
four BC2GM048059334 CD O
in BC2GM048059334 IN O
frame BC2GM048059334 NN O
AUG BC2GM048059334 NNP O
codons BC2GM048059334 NNS O
was BC2GM048059334 VBD O
used BC2GM048059334 VBN O
. BC2GM048059334 . O
. . O O

Protein BC2GM031729179 NNP O
kinase BC2GM031729179 VBD O
C BC2GM031729179 NNP O
( BC2GM031729179 ( O
PKC BC2GM031729179 NNP O
) BC2GM031729179 ) O
activation BC2GM031729179 NN O
after BC2GM031729179 IN O
treatment BC2GM031729179 NN O
of BC2GM031729179 IN O
human BC2GM031729179 JJ O
neuroblastoma BC2GM031729179 JJ O
SK-N-BE BC2GM031729179 NNP O
( BC2GM031729179 ( O
2 BC2GM031729179 CD O
) BC2GM031729179 ) O
C BC2GM031729179 NNP O
cells BC2GM031729179 NNS O
with BC2GM031729179 IN O
phorbol BC2GM031729179 JJ O
12-myristate BC2GM031729179 JJ O
13-acetate BC2GM031729179 JJ O
( BC2GM031729179 ( O
PMA BC2GM031729179 NNP O
) BC2GM031729179 ) O
was BC2GM031729179 VBD O
found BC2GM031729179 VBN O
to BC2GM031729179 TO O
enhance BC2GM031729179 VB O
transcription BC2GM031729179 NN O
of BC2GM031729179 IN O
the BC2GM031729179 DT O
human BC2GM031729179 JJ O
dopamine BC2GM031729179 NN O
beta-hydroxylase BC2GM031729179 NN O
( BC2GM031729179 ( O
DBH BC2GM031729179 NNP O
) BC2GM031729179 ) O
in BC2GM031729179 IN O
those BC2GM031729179 DT O
cells BC2GM031729179 NNS O
. BC2GM031729179 . O
. . O O

The BC2GM028226886 DT O
second BC2GM028226886 JJ O
intron BC2GM028226886 NN O
is BC2GM028226886 VBZ O
the BC2GM028226886 DT O
smallest BC2GM028226886 JJS O
of BC2GM028226886 IN O
all BC2GM028226886 PDT O
the BC2GM028226886 DT O
introns BC2GM028226886 NNS O
( BC2GM028226886 ( O
116 BC2GM028226886 CD O
bp BC2GM028226886 NN O
) BC2GM028226886 ) O
. BC2GM028226886 . O
. . O O

Case BC2GM075427191 NNP O
of BC2GM075427191 IN O
nephrotic BC2GM075427191 JJ O
syndrome BC2GM075427191 NN O
caused BC2GM075427191 VBN O
by BC2GM075427191 IN O
gold BC2GM075427191 JJ O
preparations BC2GM075427191 NNS O
. BC2GM075427191 . O
. . O O

We BC2GM055940358 PRP O
identify BC2GM055940358 VBP O
YY1 BC2GM055940358 JJ O
recognition BC2GM055940358 NN O
sequences BC2GM055940358 NNS O
within BC2GM055940358 IN O
the BC2GM055940358 DT O
vitamin BC2GM055940358 NN O
D BC2GM055940358 NNP O
response BC2GM055940358 NN O
element BC2GM055940358 NN O
( BC2GM055940358 ( O
VDRE BC2GM055940358 NNP O
) BC2GM055940358 ) O
of BC2GM055940358 IN O
the BC2GM055940358 DT O
osteocalcin BC2GM055940358 JJ O
gene BC2GM055940358 NN O
that BC2GM055940358 WDT O
are BC2GM055940358 VBP O
critical BC2GM055940358 JJ O
for BC2GM055940358 IN O
YY1-dependent BC2GM055940358 JJ O
repression BC2GM055940358 NN O
of BC2GM055940358 IN O
vitamin BC2GM055940358 JJ O
D-enhanced BC2GM055940358 NNP O
promoter BC2GM055940358 NN O
activity BC2GM055940358 NN O
. BC2GM055940358 . O
. . O O

Significant BC2GM042018281 JJ O
differences BC2GM042018281 NNS O
were BC2GM042018281 VBD O
observed BC2GM042018281 VBN O
in BC2GM042018281 IN O
the BC2GM042018281 DT O
composition BC2GM042018281 NN O
of BC2GM042018281 IN O
nuclear BC2GM042018281 JJ O
transcription BC2GM042018281 NN O
factors BC2GM042018281 NNS O
bound BC2GM042018281 IN O
to BC2GM042018281 TO O
cis-elements BC2GM042018281 NNS O
within BC2GM042018281 IN O
the BC2GM042018281 DT O
LDH BC2GM042018281 NNP O
/ BC2GM042018281 NNP O
C BC2GM042018281 NNP O
proximal BC2GM042018281 JJ O
promoter BC2GM042018281 NN O
region BC2GM042018281 NN O
in BC2GM042018281 IN O
somatic BC2GM042018281 JJ O
versus BC2GM042018281 NN O
germ BC2GM042018281 NN O
cells BC2GM042018281 NNS O
. BC2GM042018281 . O
. . O O

Pretreatment BC2GM088402436 NN O
with BC2GM088402436 IN O
lipid BC2GM088402436 JJ O
X BC2GM088402436 NNP O
was BC2GM088402436 VBD O
not BC2GM088402436 RB O
necessary BC2GM088402436 JJ O
to BC2GM088402436 TO O
improve BC2GM088402436 VB O
survival BC2GM088402436 NN O
: BC2GM088402436 : O
16 BC2GM088402436 CD O
of BC2GM088402436 IN O
17 BC2GM088402436 CD O
( BC2GM088402436 ( O
94 BC2GM088402436 CD O
% BC2GM088402436 NN O
) BC2GM088402436 ) O
infected BC2GM088402436 VBN O
and BC2GM088402436 CC O
visibly BC2GM088402436 RB O
ill BC2GM088402436 JJ O
animals BC2GM088402436 NNS O
that BC2GM088402436 WDT O
received BC2GM088402436 VBD O
lipid BC2GM088402436 JJ O
X BC2GM088402436 NNP O
and BC2GM088402436 CC O
ticarcillin BC2GM088402436 $ O
6 BC2GM088402436 CD O
h BC2GM088402436 NN O
after BC2GM088402436 IN O
thigh BC2GM088402436 JJ O
inoculation BC2GM088402436 NN O
survived BC2GM088402436 VBD O
versus BC2GM088402436 JJ O
30 BC2GM088402436 CD O
of BC2GM088402436 IN O
44 BC2GM088402436 CD O
( BC2GM088402436 ( O
68 BC2GM088402436 CD O
% BC2GM088402436 NN O
) BC2GM088402436 ) O
control BC2GM088402436 NN O
animals BC2GM088402436 NNS O
treated BC2GM088402436 VBN O
with BC2GM088402436 IN O
ticarcillin BC2GM088402436 NN O
alone BC2GM088402436 RB O
( BC2GM088402436 ( O
P BC2GM088402436 NNP O
less BC2GM088402436 JJR O
than BC2GM088402436 IN O
0.0001 BC2GM088402436 CD O
) BC2GM088402436 ) O
. BC2GM088402436 . O
. . O O

Association BC2GM093309915 NNP O
between BC2GM093309915 IN O
hyperhomocysteinemia BC2GM093309915 NN O
and BC2GM093309915 CC O
ischemic BC2GM093309915 JJ O
heart BC2GM093309915 NN O
disease BC2GM093309915 NN O
in BC2GM093309915 IN O
Sri BC2GM093309915 NNP O
Lankans BC2GM093309915 NNPS O
. BC2GM093309915 . O
. . O O

The BC2GM026838513 DT O
subjects BC2GM026838513 NNS O
' BC2GM026838513 POS O
lungs BC2GM026838513 NNS O
were BC2GM026838513 VBD O
ventilated BC2GM026838513 VBN O
with BC2GM026838513 IN O
N2O BC2GM026838513 NNP O
in BC2GM026838513 IN O
O2 BC2GM026838513 NNP O
( BC2GM026838513 ( O
FIO2 BC2GM026838513 NNP O
0.3 BC2GM026838513 CD O
) BC2GM026838513 ) O
to BC2GM026838513 TO O
the BC2GM026838513 DT O
end-tidal BC2GM026838513 JJ O
CO2 BC2GM026838513 NNP O
present BC2GM026838513 NN O
before BC2GM026838513 IN O
anesthesia BC2GM026838513 NN O
, BC2GM026838513 , O
and BC2GM026838513 CC O
then BC2GM026838513 RB O
CBF BC2GM026838513 NNP O
was BC2GM026838513 VBD O
measured BC2GM026838513 VBN O
using BC2GM026838513 VBG O
intravenous BC2GM026838513 JJ O
133Xe BC2GM026838513 CD O
and BC2GM026838513 CC O
ten BC2GM026838513 JJ O
scintillation BC2GM026838513 NN O
counters BC2GM026838513 NNS O
, BC2GM026838513 , O
five BC2GM026838513 CD O
over BC2GM026838513 IN O
each BC2GM026838513 DT O
cerebral BC2GM026838513 NN O
hemisphere BC2GM026838513 RB O
. BC2GM026838513 . O
. . O O

Monoclonal BC2GM001213287 JJ O
antibodies BC2GM001213287 NNS O
to BC2GM001213287 TO O
the BC2GM001213287 DT O
hapten BC2GM001213287 NN O
phenyloxazolone BC2GM001213287 NN O
were BC2GM001213287 VBD O
raised BC2GM001213287 VBN O
7 BC2GM001213287 CD O
days BC2GM001213287 NNS O
after BC2GM001213287 IN O
immunization BC2GM001213287 NN O
in BC2GM001213287 IN O
mice BC2GM001213287 NN O
of BC2GM001213287 IN O
six BC2GM001213287 CD O
strains BC2GM001213287 NNS O
( BC2GM001213287 ( O
BALB BC2GM001213287 NNP O
/ BC2GM001213287 NNP O
c BC2GM001213287 NN O
, BC2GM001213287 , O
C57BL-Igha BC2GM001213287 NNP O
, BC2GM001213287 , O
DBA2 BC2GM001213287 NNP O
, BC2GM001213287 , O
RF BC2GM001213287 NNP O
, BC2GM001213287 , O
A BC2GM001213287 NNP O
/ BC2GM001213287 NNP O
J BC2GM001213287 NNP O
, BC2GM001213287 , O
and BC2GM001213287 CC O
CE BC2GM001213287 NNP O
) BC2GM001213287 ) O
. BC2GM001213287 . O
. . O O

The BC2GM068399734 DT O
toxicity BC2GM068399734 NN O
of BC2GM068399734 IN O
copper BC2GM068399734 NN O
to BC2GM068399734 TO O
the BC2GM068399734 DT O
collembolan BC2GM068399734 NN O
Folsomia BC2GM068399734 NNP O
fimetaria BC2GM068399734 NN O
L. BC2GM068399734 NNP O
was BC2GM068399734 VBD O
studied BC2GM068399734 VBN O
in BC2GM068399734 IN O
soil BC2GM068399734 NN O
incubated BC2GM068399734 VBN O
with BC2GM068399734 IN O
copper BC2GM068399734 NN O
sulfate BC2GM068399734 NN O
for BC2GM068399734 IN O
different BC2GM068399734 JJ O
periods BC2GM068399734 NNS O
before BC2GM068399734 IN O
the BC2GM068399734 DT O
introduction BC2GM068399734 NN O
of BC2GM068399734 IN O
collembolans BC2GM068399734 NNS O
, BC2GM068399734 , O
to BC2GM068399734 TO O
assess BC2GM068399734 VB O
the BC2GM068399734 DT O
effect BC2GM068399734 NN O
of BC2GM068399734 IN O
aging BC2GM068399734 VBG O
of BC2GM068399734 IN O
contamination BC2GM068399734 NN O
on BC2GM068399734 IN O
the BC2GM068399734 DT O
toxicity BC2GM068399734 NN O
of BC2GM068399734 IN O
copper BC2GM068399734 NN O
. BC2GM068399734 . O
. . O O

Proceedings BC2GM010137266 NNS O
: BC2GM010137266 : O
Influence BC2GM010137266 NN O
of BC2GM010137266 IN O
halothane BC2GM010137266 NN O
on BC2GM010137266 IN O
mortality BC2GM010137266 NN O
from BC2GM010137266 IN O
murine BC2GM010137266 NN O
hepatitis BC2GM010137266 NN O
virus BC2GM010137266 NN O
( BC2GM010137266 ( O
MHV3 BC2GM010137266 NNP O
) BC2GM010137266 ) O
. BC2GM010137266 . O
. . O O

Maximal BC2GM084376040 NNP O
Expiratory BC2GM084376040 NNP O
Flow BC2GM084376040 NNP O
Rates BC2GM084376040 NNS O
such BC2GM084376040 JJ O
as BC2GM084376040 IN O
Peak BC2GM084376040 NNP O
Expiratory BC2GM084376040 NNP O
Flow BC2GM084376040 NNP O
Rate BC2GM084376040 NNP O
( BC2GM084376040 ( O
PEFR BC2GM084376040 NNP O
) BC2GM084376040 ) O
, BC2GM084376040 , O
rates BC2GM084376040 NNS O
at BC2GM084376040 IN O
25 BC2GM084376040 CD O
% BC2GM084376040 NN O
, BC2GM084376040 , O
50 BC2GM084376040 CD O
% BC2GM084376040 NN O
and BC2GM084376040 CC O
75 BC2GM084376040 CD O
% BC2GM084376040 NN O
of BC2GM084376040 IN O
forced BC2GM084376040 JJ O
vital BC2GM084376040 JJ O
capacity BC2GM084376040 NN O
( BC2GM084376040 ( O
V BC2GM084376040 NNP O
max BC2GM084376040 RB O
25 BC2GM084376040 CD O
% BC2GM084376040 NN O
, BC2GM084376040 , O
V BC2GM084376040 NNP O
max BC2GM084376040 VBD O
50 BC2GM084376040 CD O
% BC2GM084376040 NN O
and BC2GM084376040 CC O
V BC2GM084376040 NNP O
max BC2GM084376040 VBP O
75 BC2GM084376040 CD O
% BC2GM084376040 NN O
) BC2GM084376040 ) O
and BC2GM084376040 CC O
forced BC2GM084376040 JJ O
expiratory BC2GM084376040 NN O
flow BC2GM084376040 NN O
during BC2GM084376040 IN O
the BC2GM084376040 DT O
middle BC2GM084376040 JJ O
half BC2GM084376040 NN O
of BC2GM084376040 IN O
forced BC2GM084376040 JJ O
vital BC2GM084376040 JJ O
capacity BC2GM084376040 NN O
( BC2GM084376040 ( O
FEF BC2GM084376040 NNP O
25-75 BC2GM084376040 CD O
% BC2GM084376040 NN O
) BC2GM084376040 ) O
were BC2GM084376040 VBD O
measured BC2GM084376040 VBN O
in BC2GM084376040 IN O
273 BC2GM084376040 CD O
healthy BC2GM084376040 JJ O
non-smoking BC2GM084376040 JJ O
adults BC2GM084376040 NNS O
( BC2GM084376040 ( O
144 BC2GM084376040 CD O
males BC2GM084376040 NNS O
, BC2GM084376040 , O
129 BC2GM084376040 CD O
females BC2GM084376040 NNS O
) BC2GM084376040 ) O
aged BC2GM084376040 VBN O
15-63 BC2GM084376040 CD O
years BC2GM084376040 NNS O
living BC2GM084376040 VBG O
in BC2GM084376040 IN O
Madras BC2GM084376040 NNP O
. BC2GM084376040 . O
. . O O

High-level BC2GM042434185 JJ O
expression BC2GM042434185 NN O
of BC2GM042434185 IN O
sccypB BC2GM042434185 NN O
as BC2GM042434185 RB O
well BC2GM042434185 RB O
as BC2GM042434185 IN O
of BC2GM042434185 IN O
sccypA BC2GM042434185 NN O
cloned BC2GM042434185 VBN O
into BC2GM042434185 IN O
the BC2GM042434185 DT O
expression BC2GM042434185 NN O
vector BC2GM042434185 NN O
pIJ702 BC2GM042434185 NN O
did BC2GM042434185 VBD O
not BC2GM042434185 RB O
produce BC2GM042434185 VB O
detectable BC2GM042434185 JJ O
changes BC2GM042434185 NNS O
in BC2GM042434185 IN O
growth BC2GM042434185 NN O
and BC2GM042434185 CC O
morphology BC2GM042434185 NN O
of BC2GM042434185 IN O
S. BC2GM042434185 NNP O
chrysomallus BC2GM042434185 NN O
and BC2GM042434185 CC O
S. BC2GM042434185 NNP O
lividans BC2GM042434185 NNS O
. BC2GM042434185 . O
. . O O

We BC2GM052141177 PRP O
conclude BC2GM052141177 VBP O
that BC2GM052141177 IN O
the BC2GM052141177 DT O
MMF BC2GM052141177 NNP O
lesion BC2GM052141177 NN O
is BC2GM052141177 VBZ O
secondary BC2GM052141177 JJ O
to BC2GM052141177 TO O
intramuscular BC2GM052141177 JJ O
injection BC2GM052141177 NN O
of BC2GM052141177 IN O
aluminium BC2GM052141177 JJ O
hydroxide-containing BC2GM052141177 JJ O
vaccines BC2GM052141177 NNS O
, BC2GM052141177 , O
shows BC2GM052141177 VBZ O
both BC2GM052141177 DT O
long-term BC2GM052141177 JJ O
persistence BC2GM052141177 NN O
of BC2GM052141177 IN O
aluminium BC2GM052141177 NN O
hydroxide BC2GM052141177 NN O
and BC2GM052141177 CC O
an BC2GM052141177 DT O
ongoing BC2GM052141177 JJ O
local BC2GM052141177 JJ O
immune BC2GM052141177 NN O
reaction BC2GM052141177 NN O
, BC2GM052141177 , O
and BC2GM052141177 CC O
is BC2GM052141177 VBZ O
detected BC2GM052141177 VBN O
in BC2GM052141177 IN O
patients BC2GM052141177 NNS O
with BC2GM052141177 IN O
systemic BC2GM052141177 JJ O
symptoms BC2GM052141177 NNS O
which BC2GM052141177 WDT O
appeared BC2GM052141177 VBD O
subsequently BC2GM052141177 RB O
to BC2GM052141177 TO O
vaccination BC2GM052141177 NN O
. BC2GM052141177 . O
. . O O

Uncoupling BC2GM011126259 VBG O
gene BC2GM011126259 NN O
activity BC2GM011126259 NN O
from BC2GM011126259 IN O
chromatin BC2GM011126259 NN O
structure BC2GM011126259 NN O
: BC2GM011126259 : O
promoter BC2GM011126259 NN O
mutations BC2GM011126259 NNS O
can BC2GM011126259 MD O
inactivate BC2GM011126259 VB O
transcription BC2GM011126259 NN O
of BC2GM011126259 IN O
the BC2GM011126259 DT O
yeast BC2GM011126259 NN O
HSP82 BC2GM011126259 NNP O
gene BC2GM011126259 NN O
without BC2GM011126259 IN O
eliminating BC2GM011126259 VBG O
nucleosome-free BC2GM011126259 JJ O
regions BC2GM011126259 NNS O
. BC2GM011126259 . O
. . O O

RMR BC2GM074512746 NNP O
was BC2GM074512746 VBD O
positively BC2GM074512746 RB O
correlated BC2GM074512746 VBN O
with BC2GM074512746 IN O
TEF BC2GM074512746 NNP O
( BC2GM074512746 ( O
r BC2GM074512746 VB O
= BC2GM074512746 RB O
0.613 BC2GM074512746 CD O
, BC2GM074512746 , O
p BC2GM074512746 NN O
< BC2GM074512746 NNP O
0.01 BC2GM074512746 CD O
) BC2GM074512746 ) O
and BC2GM074512746 CC O
net BC2GM074512746 JJ O
TEF BC2GM074512746 NNP O
( BC2GM074512746 ( O
r BC2GM074512746 VB O
= BC2GM074512746 RB O
0.648 BC2GM074512746 CD O
, BC2GM074512746 , O
p BC2GM074512746 NN O
< BC2GM074512746 NNP O
0.005 BC2GM074512746 CD O
) BC2GM074512746 ) O
in BC2GM074512746 IN O
the BC2GM074512746 DT O
luteal BC2GM074512746 NN O
but BC2GM074512746 CC O
not BC2GM074512746 RB O
the BC2GM074512746 DT O
follicular BC2GM074512746 JJ O
phase BC2GM074512746 NN O
. BC2GM074512746 . O
. . O O

It BC2GM015826249 PRP O
also BC2GM015826249 RB O
showed BC2GM015826249 VBD O
which BC2GM015826249 WDT O
amino BC2GM015826249 NN O
acid BC2GM015826249 NN O
residues BC2GM015826249 NNS O
would BC2GM015826249 MD O
contact BC2GM015826249 VB O
an BC2GM015826249 DT O
extended BC2GM015826249 JJ O
TATA BC2GM015826249 NNP O
box BC2GM015826249 NN O
with BC2GM015826249 IN O
a BC2GM015826249 DT O
B BC2GM015826249 NNP O
recognition BC2GM015826249 NN O
element BC2GM015826249 NN O
, BC2GM015826249 , O
and BC2GM015826249 CC O
evolutionary BC2GM015826249 JJ O
conservation BC2GM015826249 NN O
of BC2GM015826249 IN O
the BC2GM015826249 DT O
TBP-TFB-DNA BC2GM015826249 NNP O
complex BC2GM015826249 JJ O
orientation BC2GM015826249 NN O
between BC2GM015826249 IN O
two BC2GM015826249 CD O
archaeal BC2GM015826249 JJ O
organisms BC2GM015826249 NNS O
with BC2GM015826249 IN O
widely BC2GM015826249 RB O
different BC2GM015826249 JJ O
optimal BC2GM015826249 JJ O
temperature BC2GM015826249 NN O
for BC2GM015826249 IN O
growth BC2GM015826249 NN O
( BC2GM015826249 ( O
37 BC2GM015826249 CD O
and BC2GM015826249 CC O
100 BC2GM015826249 CD O
degrees BC2GM015826249 NNS O
C BC2GM015826249 NNP O
) BC2GM015826249 ) O
. BC2GM015826249 . O
. . O O

A BC2GM009334391 DT O
regulatory BC2GM009334391 JJ O
element BC2GM009334391 NN O
of BC2GM009334391 IN O
the BC2GM009334391 DT O
empty BC2GM009334391 JJ O
spiracles BC2GM009334391 NNS O
homeobox BC2GM009334391 PRP$ O
gene BC2GM009334391 NN O
is BC2GM009334391 VBZ O
composed BC2GM009334391 VBN O
of BC2GM009334391 IN O
three BC2GM009334391 CD O
distinct BC2GM009334391 NNS O
conserved BC2GM009334391 VBD O
regions BC2GM009334391 NNS O
that BC2GM009334391 IN O
bind BC2GM009334391 VBP O
regulatory BC2GM009334391 JJ O
proteins BC2GM009334391 NNS O
. BC2GM009334391 . O
. . O O

RET BC2GM068921814 NNP O
/ BC2GM068921814 NNP O
PTC BC2GM068921814 NNP O
oncogenes BC2GM068921814 NNS O
, BC2GM068921814 , O
generated BC2GM068921814 VBN O
by BC2GM068921814 IN O
chromosomal BC2GM068921814 JJ O
rearrangements BC2GM068921814 NNS O
in BC2GM068921814 IN O
papillary BC2GM068921814 JJ O
thyroid BC2GM068921814 NN O
carcinomas BC2GM068921814 NN O
, BC2GM068921814 , O
are BC2GM068921814 VBP O
constitutively BC2GM068921814 RB O
activated BC2GM068921814 JJ O
versions BC2GM068921814 NNS O
of BC2GM068921814 IN O
proto-RET BC2GM068921814 NN O
, BC2GM068921814 , O
a BC2GM068921814 DT O
gene BC2GM068921814 NN O
coding BC2GM068921814 VBG O
for BC2GM068921814 IN O
a BC2GM068921814 DT O
receptor-type BC2GM068921814 JJ O
tyrosine BC2GM068921814 NN O
kinase BC2GM068921814 NN O
( BC2GM068921814 ( O
TK BC2GM068921814 NNP O
) BC2GM068921814 ) O
whose BC2GM068921814 WP$ O
ligand BC2GM068921814 NN O
is BC2GM068921814 VBZ O
still BC2GM068921814 RB O
unknown BC2GM068921814 JJ O
. BC2GM068921814 . O
. . O O

The BC2GM038144373 DT O
other BC2GM038144373 JJ O
five BC2GM038144373 CD O
from BC2GM038144373 IN O
within BC2GM038144373 IN O
the BC2GM038144373 DT O
SRO BC2GM038144373 NNP O
may BC2GM038144373 MD O
provide BC2GM038144373 VB O
an BC2GM038144373 DT O
entrance BC2GM038144373 NN O
point BC2GM038144373 NN O
for BC2GM038144373 IN O
the BC2GM038144373 DT O
cloning BC2GM038144373 NN O
of BC2GM038144373 IN O
candidate BC2GM038144373 NN O
genes BC2GM038144373 NNS O
for BC2GM038144373 IN O
neuroblastoma BC2GM038144373 NN O
. BC2GM038144373 . O
. . O O

Comparison BC2GM084727485 NNP O
of BC2GM084727485 IN O
the BC2GM084727485 DT O
5 BC2GM084727485 CD O
' BC2GM084727485 POS O
flanking BC2GM084727485 JJ O
regions BC2GM084727485 NNS O
of BC2GM084727485 IN O
the BC2GM084727485 DT O
mouse BC2GM084727485 NN O
J BC2GM084727485 NNP O
kappa BC2GM084727485 NN O
elements BC2GM084727485 NNS O
, BC2GM084727485 , O
including BC2GM084727485 VBG O
the BC2GM084727485 DT O
conserved BC2GM084727485 JJ O
putative BC2GM084727485 JJ O
recombination BC2GM084727485 NN O
target BC2GM084727485 NN O
sequences BC2GM084727485 NNS O
, BC2GM084727485 , O
shows BC2GM084727485 VBZ O
no BC2GM084727485 DT O
obvious BC2GM084727485 JJ O
differences BC2GM084727485 NNS O
consistent BC2GM084727485 JJ O
with BC2GM084727485 IN O
the BC2GM084727485 DT O
variation BC2GM084727485 NN O
in BC2GM084727485 IN O
recombinational BC2GM084727485 JJ O
efficiency BC2GM084727485 NN O
, BC2GM084727485 , O
so BC2GM084727485 IN O
we BC2GM084727485 PRP O
conclude BC2GM084727485 VBP O
that BC2GM084727485 IN O
, BC2GM084727485 , O
although BC2GM084727485 IN O
the BC2GM084727485 DT O
consensus BC2GM084727485 NN O
heptamer BC2GM084727485 NN O
and BC2GM084727485 CC O
nonamer BC2GM084727485 JJ O
signals BC2GM084727485 NNS O
may BC2GM084727485 MD O
be BC2GM084727485 VB O
sufficient BC2GM084727485 JJ O
to BC2GM084727485 TO O
identify BC2GM084727485 VB O
a BC2GM084727485 DT O
recombination BC2GM084727485 NN O
site BC2GM084727485 NN O
, BC2GM084727485 , O
the BC2GM084727485 DT O
probability BC2GM084727485 NN O
that BC2GM084727485 IN O
that BC2GM084727485 DT O
site BC2GM084727485 NN O
will BC2GM084727485 MD O
be BC2GM084727485 VB O
used BC2GM084727485 VBN O
depends BC2GM084727485 NNS O
also BC2GM084727485 RB O
on BC2GM084727485 IN O
other BC2GM084727485 JJ O
determinants BC2GM084727485 NNS O
. BC2GM084727485 . O
. . O O

The BC2GM003186870 DT O
cases BC2GM003186870 NNS O
with BC2GM003186870 IN O
terminal BC2GM003186870 JJ O
forces BC2GM003186870 NNS O
of BC2GM003186870 IN O
left BC2GM003186870 JJ O
ventricular BC2GM003186870 JJ O
activation BC2GM003186870 NN O
in BC2GM003186870 IN O
the BC2GM003186870 DT O
same BC2GM003186870 JJ O
direction BC2GM003186870 NN O
as BC2GM003186870 IN O
the BC2GM003186870 DT O
delta BC2GM003186870 NN O
wave BC2GM003186870 NN O
, BC2GM003186870 , O
superiorly BC2GM003186870 RB O
and BC2GM003186870 CC O
to BC2GM003186870 TO O
the BC2GM003186870 DT O
left BC2GM003186870 NN O
at BC2GM003186870 IN O
-60 BC2GM003186870 JJ O
degrees BC2GM003186870 NNS O
or BC2GM003186870 CC O
inferiorly BC2GM003186870 RB O
and BC2GM003186870 CC O
to BC2GM003186870 TO O
the BC2GM003186870 DT O
right BC2GM003186870 NN O
at BC2GM003186870 IN O
+120 BC2GM003186870 NNP O
degrees BC2GM003186870 NNS O
, BC2GM003186870 , O
forming BC2GM003186870 VBG O
a BC2GM003186870 DT O
single BC2GM003186870 JJ O
deflection BC2GM003186870 NN O
of BC2GM003186870 IN O
over BC2GM003186870 IN O
0,12 BC2GM003186870 CD O
seconds BC2GM003186870 NNS O
' BC2GM003186870 POS O
duration BC2GM003186870 NN O
, BC2GM003186870 , O
are BC2GM003186870 VBP O
the BC2GM003186870 DT O
result BC2GM003186870 NN O
of BC2GM003186870 IN O
delayed BC2GM003186870 JJ O
activation BC2GM003186870 NN O
of BC2GM003186870 IN O
the BC2GM003186870 DT O
anterior BC2GM003186870 NN O
or BC2GM003186870 CC O
posterior BC2GM003186870 JJ O
fascicle BC2GM003186870 NN O
of BC2GM003186870 IN O
the BC2GM003186870 DT O
left BC2GM003186870 NN O
bundle BC2GM003186870 NN O
after BC2GM003186870 IN O
a BC2GM003186870 DT O
long BC2GM003186870 JJ O
delay BC2GM003186870 NN O
. BC2GM003186870 . O
. . O O

Ultimobranchial BC2GM002546611 JJ O
body BC2GM002546611 NN O
and BC2GM002546611 CC O
parathyroid BC2GM002546611 JJ O
glands BC2GM002546611 NNS O
of BC2GM002546611 IN O
the BC2GM002546611 DT O
freshwater BC2GM002546611 NN O
snake BC2GM002546611 VBP O
Natrix BC2GM002546611 NNP O
piscator BC2GM002546611 NN O
in BC2GM002546611 IN O
response BC2GM002546611 NN O
to BC2GM002546611 TO O
vitamin BC2GM002546611 VB O
D3 BC2GM002546611 NNP O
administration BC2GM002546611 NN O
. BC2GM002546611 . O
. . O O

Posterior BC2GM008866104 JJ O
osteophytes BC2GM008866104 NNS O
around BC2GM008866104 IN O
the BC2GM008866104 DT O
posterior BC2GM008866104 JJ O
edges BC2GM008866104 NNS O
of BC2GM008866104 IN O
vertebral BC2GM008866104 JJ O
body BC2GM008866104 NN O
resulted BC2GM008866104 VBD O
in BC2GM008866104 IN O
intervertebral BC2GM008866104 JJ O
insufficiency BC2GM008866104 NN O
, BC2GM008866104 , O
and BC2GM008866104 CC O
corresponded BC2GM008866104 VBD O
to BC2GM008866104 TO O
hypertrophic BC2GM008866104 VB O
spur BC2GM008866104 NN O
in BC2GM008866104 IN O
osteochondrosis BC2GM008866104 NN O
. BC2GM008866104 . O
. . O O

Characterization BC2GM093377717 NN O
of BC2GM093377717 IN O
a BC2GM093377717 DT O
cDNA BC2GM093377717 NN O
encoding BC2GM093377717 VBG O
CNN BC2GM093377717 NNP O
predicts BC2GM093377717 VBZ O
a BC2GM093377717 DT O
novel BC2GM093377717 JJ O
structural BC2GM093377717 JJ O
protein BC2GM093377717 NN O
with BC2GM093377717 IN O
three BC2GM093377717 CD O
leucine BC2GM093377717 JJ O
zipper BC2GM093377717 NN O
motifs BC2GM093377717 NNS O
and BC2GM093377717 CC O
several BC2GM093377717 JJ O
coiled-coil BC2GM093377717 NN O
domains BC2GM093377717 NNS O
exhibiting BC2GM093377717 VBG O
limited BC2GM093377717 JJ O
homology BC2GM093377717 NN O
to BC2GM093377717 TO O
the BC2GM093377717 DT O
rod BC2GM093377717 JJ O
portion BC2GM093377717 NN O
of BC2GM093377717 IN O
myosin BC2GM093377717 NN O
. BC2GM093377717 . O
. . O O

The BC2GM053590893 DT O
pharmacokinetics BC2GM053590893 NNS O
were BC2GM053590893 VBD O
best BC2GM053590893 RBS O
described BC2GM053590893 VBN O
by BC2GM053590893 IN O
a BC2GM053590893 DT O
two-compartment BC2GM053590893 JJ O
open BC2GM053590893 JJ O
model BC2GM053590893 NN O
giving BC2GM053590893 VBG O
distribution BC2GM053590893 NN O
half-lives BC2GM053590893 NNS O
of BC2GM053590893 IN O
0.31 BC2GM053590893 CD O
h BC2GM053590893 NN O
and BC2GM053590893 CC O
1.53 BC2GM053590893 CD O
h BC2GM053590893 NN O
, BC2GM053590893 , O
and BC2GM053590893 CC O
elimination BC2GM053590893 NN O
half-lives BC2GM053590893 NNS O
of BC2GM053590893 IN O
69.7 BC2GM053590893 CD O
h BC2GM053590893 NN O
and BC2GM053590893 CC O
60.3 BC2GM053590893 CD O
h BC2GM053590893 NN O
for BC2GM053590893 IN O
oxolinic BC2GM053590893 JJ O
acid BC2GM053590893 NN O
and BC2GM053590893 CC O
oxytetracycline BC2GM053590893 NN O
, BC2GM053590893 , O
respectively BC2GM053590893 RB O
. BC2GM053590893 . O
. . O O

The BC2GM048694992 DT O
resulting BC2GM048694992 VBG O
threshold BC2GM048694992 JJ O
elevation BC2GM048694992 NN O
curves BC2GM048694992 NNS O
fell BC2GM048694992 VBD O
into BC2GM048694992 IN O
a BC2GM048694992 DT O
small BC2GM048694992 JJ O
number BC2GM048694992 NN O
of BC2GM048694992 IN O
distinct BC2GM048694992 JJ O
groups BC2GM048694992 NNS O
, BC2GM048694992 , O
suggesting BC2GM048694992 VBG O
the BC2GM048694992 DT O
existence BC2GM048694992 NN O
of BC2GM048694992 IN O
discrete BC2GM048694992 JJ O
spatial BC2GM048694992 JJ O
frequency BC2GM048694992 NN O
mechanisms BC2GM048694992 NNS O
in BC2GM048694992 IN O
human BC2GM048694992 JJ O
central BC2GM048694992 JJ O
vision BC2GM048694992 NN O
. BC2GM048694992 . O
. . O O

Peak BC2GM001606938 NNP O
reactive BC2GM001606938 JJ O
hyperemia BC2GM001606938 NN O
( BC2GM001606938 ( O
mL.min-1.100 BC2GM001606938 JJ O
mL-1 BC2GM001606938 NN O
) BC2GM001606938 ) O
was BC2GM001606938 VBD O
determined BC2GM001606938 VBN O
in BC2GM001606938 IN O
the BC2GM001606938 DT O
calf BC2GM001606938 NN O
and BC2GM001606938 CC O
forearm BC2GM001606938 NN O
immediately BC2GM001606938 RB O
before BC2GM001606938 IN O
and BC2GM001606938 CC O
after BC2GM001606938 IN O
12 BC2GM001606938 CD O
weeks BC2GM001606938 NNS O
of BC2GM001606938 IN O
training BC2GM001606938 NN O
. BC2GM001606938 . O
. . O O

Circulating BC2GM070556783 VBG O
immune BC2GM070556783 NN O
complexes BC2GM070556783 NNS O
were BC2GM070556783 VBD O
determined BC2GM070556783 VBN O
by BC2GM070556783 IN O
the BC2GM070556783 DT O
method BC2GM070556783 NN O
of BC2GM070556783 IN O
phagocytosis BC2GM070556783 NN O
and BC2GM070556783 CC O
immunofluorescence BC2GM070556783 NN O
. BC2GM070556783 . O
. . O O

Additions BC2GM088377969 NNS O
of BC2GM088377969 IN O
NH4+ BC2GM088377969 NNP O
up BC2GM088377969 RB O
to BC2GM088377969 TO O
200 BC2GM088377969 CD O
micrograms BC2GM088377969 NNS O
1 BC2GM088377969 CD O
( BC2GM088377969 ( O
-1 BC2GM088377969 NN O
) BC2GM088377969 ) O
were BC2GM088377969 VBD O
not BC2GM088377969 RB O
stimulatory BC2GM088377969 JJ O
, BC2GM088377969 , O
whereas BC2GM088377969 NNS O
at BC2GM088377969 IN O
1.0 BC2GM088377969 CD O
mg BC2GM088377969 NN O
1 BC2GM088377969 CD O
( BC2GM088377969 ( O
-1 BC2GM088377969 NN O
) BC2GM088377969 ) O
levels BC2GM088377969 NNS O
, BC2GM088377969 , O
Ke BC2GM088377969 NNP O
was BC2GM088377969 VBD O
50 BC2GM088377969 CD O
% BC2GM088377969 NN O
greater BC2GM088377969 JJR O
than BC2GM088377969 IN O
for BC2GM088377969 IN O
NO3- BC2GM088377969 NNP O
enriched BC2GM088377969 VBD O
medium BC2GM088377969 NN O
. BC2GM088377969 . O
. . O O

Carotid BC2GM082240751 NNP O
body BC2GM082240751 NN O
chemoreceptor BC2GM082240751 NN O
activity BC2GM082240751 NN O
as BC2GM082240751 IN O
recorded BC2GM082240751 VBN O
from BC2GM082240751 IN O
the BC2GM082240751 DT O
petrosal BC2GM082240751 NN O
ganglion BC2GM082240751 NN O
in BC2GM082240751 IN O
cats BC2GM082240751 NNS O
. BC2GM082240751 . O
. . O O

In BC2GM097830096 IN O
two BC2GM097830096 CD O
patients BC2GM097830096 NNS O
, BC2GM097830096 , O
a BC2GM097830096 DT O
male BC2GM097830096 JJ O
homosexual BC2GM097830096 JJ O
and BC2GM097830096 CC O
an BC2GM097830096 DT O
hemophiliac BC2GM097830096 NN O
, BC2GM097830096 , O
thrombocytopenia BC2GM097830096 NN O
was BC2GM097830096 VBD O
associated BC2GM097830096 VBN O
with BC2GM097830096 IN O
AIDS-related BC2GM097830096 NNP O
complex BC2GM097830096 NN O
. BC2GM097830096 . O
. . O O

Thus BC2GM034750890 RB O
, BC2GM034750890 , O
the BC2GM034750890 DT O
mutants BC2GM034750890 NNS O
are BC2GM034750890 VBP O
deficient BC2GM034750890 JJ O
in BC2GM034750890 IN O
production BC2GM034750890 NN O
of BC2GM034750890 IN O
the BC2GM034750890 DT O
O-antigen BC2GM034750890 NNP O
polymerase BC2GM034750890 NN O
and BC2GM034750890 CC O
were BC2GM034750890 VBD O
termed BC2GM034750890 VBN O
rfc BC2GM034750890 JJ O
mutants BC2GM034750890 NNS O
. BC2GM034750890 . O
. . O O

To BC2GM011520579 TO O
identify BC2GM011520579 VB O
and BC2GM011520579 CC O
determine BC2GM011520579 VB O
the BC2GM011520579 DT O
function BC2GM011520579 NN O
of BC2GM011520579 IN O
Ino2p BC2GM011520579 NNP O
in BC2GM011520579 IN O
yeast BC2GM011520579 NNP O
cells BC2GM011520579 NNS O
, BC2GM011520579 , O
we BC2GM011520579 PRP O
raised BC2GM011520579 VBD O
antibodies BC2GM011520579 NNS O
to BC2GM011520579 TO O
a BC2GM011520579 DT O
beta-galactosidase BC2GM011520579 JJ O
/ BC2GM011520579 NN O
Ino2 BC2GM011520579 NNP O
fusion BC2GM011520579 NN O
protein BC2GM011520579 NN O
. BC2GM011520579 . O
. . O O

Receptor-type BC2GM085260486 JJ O
serine BC2GM085260486 NN O
/ BC2GM085260486 NNP O
threonine BC2GM085260486 NN O
kinases BC2GM085260486 NNS O
( BC2GM085260486 ( O
RSKs BC2GM085260486 NNP O
) BC2GM085260486 ) O
have BC2GM085260486 VBP O
been BC2GM085260486 VBN O
organized BC2GM085260486 VBN O
into BC2GM085260486 IN O
two BC2GM085260486 CD O
distinct BC2GM085260486 JJ O
classes BC2GM085260486 NNS O
known BC2GM085260486 VBN O
as BC2GM085260486 IN O
types BC2GM085260486 NNS O
I BC2GM085260486 PRP O
and BC2GM085260486 CC O
II BC2GM085260486 NNP O
on BC2GM085260486 IN O
the BC2GM085260486 DT O
basis BC2GM085260486 NN O
of BC2GM085260486 IN O
sequence BC2GM085260486 NN O
similarity BC2GM085260486 NN O
. BC2GM085260486 . O
. . O O

Effect BC2GM085416989 NN O
of BC2GM085416989 IN O
a BC2GM085416989 DT O
high BC2GM085416989 JJ O
sugar BC2GM085416989 NN O
intake BC2GM085416989 NN O
on BC2GM085416989 IN O
some BC2GM085416989 DT O
metabolic BC2GM085416989 NN O
and BC2GM085416989 CC O
regulatory BC2GM085416989 JJ O
indicators BC2GM085416989 NNS O
in BC2GM085416989 IN O
young BC2GM085416989 JJ O
men BC2GM085416989 NNS O
. BC2GM085416989 . O
. . O O

In BC2GM094952768 IN O
summary BC2GM094952768 JJ O
, BC2GM094952768 , O
FGFR3 BC2GM094952768 NNP O
signaling BC2GM094952768 VBG O
pathway BC2GM094952768 RB O
utilizes BC2GM094952768 JJ O
two BC2GM094952768 CD O
GRB2-containing BC2GM094952768 JJ O
complexes BC2GM094952768 NNS O
; BC2GM094952768 : O
Shc.GRB2.Sos BC2GM094952768 NNP O
and BC2GM094952768 CC O
80K-H.pp66.GRB2.Sos BC2GM094952768 JJ O
; BC2GM094952768 : O
these BC2GM094952768 DT O
two BC2GM094952768 CD O
complexes BC2GM094952768 NNS O
may BC2GM094952768 MD O
alternatively BC2GM094952768 RB O
link BC2GM094952768 VB O
FGFG3 BC2GM094952768 NNP O
to BC2GM094952768 TO O
mitogen-activated BC2GM094952768 JJ O
protein BC2GM094952768 NN O
kinase BC2GM094952768 NN O
. BC2GM094952768 . O
. . O O

Administration BC2GM091799459 NN O
of BC2GM091799459 IN O
SnCl2 BC2GM091799459 NNP O
and BC2GM091799459 CC O
ZnSO4 BC2GM091799459 NNP O
( BC2GM091799459 ( O
group BC2GM091799459 NN O
V BC2GM091799459 NNP O
) BC2GM091799459 ) O
resulted BC2GM091799459 VBD O
in BC2GM091799459 IN O
a BC2GM091799459 DT O
decrease BC2GM091799459 NN O
of BC2GM091799459 IN O
ALA-D BC2GM091799459 NNP O
activity BC2GM091799459 NN O
and BC2GM091799459 CC O
in BC2GM091799459 IN O
an BC2GM091799459 DT O
increase BC2GM091799459 NN O
in BC2GM091799459 IN O
CP-U BC2GM091799459 NNP O
. BC2GM091799459 . O
. . O O

In BC2GM063579260 IN O
murine BC2GM063579260 NN O
cells BC2GM063579260 NNS O
, BC2GM063579260 , O
FPGS BC2GM063579260 NNP O
expression BC2GM063579260 NN O
is BC2GM063579260 VBZ O
controlled BC2GM063579260 VBN O
by BC2GM063579260 IN O
two BC2GM063579260 CD O
promoters BC2GM063579260 NNS O
that BC2GM063579260 RB O
, BC2GM063579260 , O
as BC2GM063579260 IN O
we BC2GM063579260 PRP O
show BC2GM063579260 VBP O
here BC2GM063579260 RB O
, BC2GM063579260 , O
vary BC2GM063579260 JJ O
substantially BC2GM063579260 RB O
in BC2GM063579260 IN O
their BC2GM063579260 PRP$ O
efficiency BC2GM063579260 NN O
, BC2GM063579260 , O
at BC2GM063579260 IN O
least BC2GM063579260 JJS O
in BC2GM063579260 IN O
the BC2GM063579260 DT O
context BC2GM063579260 NN O
of BC2GM063579260 IN O
a BC2GM063579260 DT O
reporter BC2GM063579260 NN O
gene BC2GM063579260 NN O
assay BC2GM063579260 VBP O
. BC2GM063579260 . O
. . O O

Furthermore BC2GM014171853 RB O
, BC2GM014171853 , O
the BC2GM014171853 DT O
GC-rich BC2GM014171853 NNP O
sequences BC2GM014171853 NNS O
could BC2GM014171853 MD O
confer BC2GM014171853 VB O
Sp1-dependent BC2GM014171853 JJ O
transactivation BC2GM014171853 NN O
to BC2GM014171853 TO O
a BC2GM014171853 DT O
heterologous BC2GM014171853 JJ O
prolactin BC2GM014171853 NN O
minimal BC2GM014171853 JJ O
promoter BC2GM014171853 NN O
. BC2GM014171853 . O
. . O O

In BC2GM043493383 IN O
spite BC2GM043493383 NN O
of BC2GM043493383 IN O
the BC2GM043493383 DT O
variability BC2GM043493383 NN O
of BC2GM043493383 IN O
DD95 BC2GM043493383 NNP O
with BC2GM043493383 IN O
regard BC2GM043493383 NN O
to BC2GM043493383 TO O
body BC2GM043493383 NN O
weight BC2GM043493383 NN O
, BC2GM043493383 , O
the BC2GM043493383 DT O
recovery BC2GM043493383 NN O
of BC2GM043493383 IN O
neuromuscular BC2GM043493383 JJ O
transmission BC2GM043493383 NN O
in BC2GM043493383 IN O
the BC2GM043493383 DT O
patients BC2GM043493383 NNS O
of BC2GM043493383 IN O
the BC2GM043493383 DT O
three BC2GM043493383 CD O
groups BC2GM043493383 NNS O
is BC2GM043493383 VBZ O
comparable BC2GM043493383 JJ O
. BC2GM043493383 . O
. . O O

Transformation BC2GM086019506 NN O
of BC2GM086019506 IN O
chicken BC2GM086019506 NN O
embryo BC2GM086019506 NN O
fibroblasts BC2GM086019506 NNS O
( BC2GM086019506 ( O
CEF BC2GM086019506 NNP O
) BC2GM086019506 ) O
with BC2GM086019506 IN O
the BC2GM086019506 DT O
Gag-Crk BC2GM086019506 NNP O
fusion BC2GM086019506 NN O
protein BC2GM086019506 NN O
results BC2GM086019506 NNS O
in BC2GM086019506 IN O
the BC2GM086019506 DT O
elevation BC2GM086019506 NN O
of BC2GM086019506 IN O
tyrosine BC2GM086019506 JJ O
phosphorylation BC2GM086019506 NN O
on BC2GM086019506 IN O
specific BC2GM086019506 JJ O
cellular BC2GM086019506 JJ O
proteins BC2GM086019506 NNS O
with BC2GM086019506 IN O
molecular BC2GM086019506 JJ O
weights BC2GM086019506 NNS O
of BC2GM086019506 IN O
130,000 BC2GM086019506 CD O
, BC2GM086019506 , O
110,000 BC2GM086019506 CD O
, BC2GM086019506 , O
and BC2GM086019506 CC O
70,000 BC2GM086019506 CD O
( BC2GM086019506 ( O
p130 BC2GM086019506 NN O
, BC2GM086019506 , O
p110 BC2GM086019506 NN O
, BC2GM086019506 , O
and BC2GM086019506 CC O
p70 BC2GM086019506 NN O
, BC2GM086019506 , O
respectively BC2GM086019506 RB O
) BC2GM086019506 ) O
, BC2GM086019506 , O
an BC2GM086019506 DT O
event BC2GM086019506 NN O
which BC2GM086019506 WDT O
has BC2GM086019506 VBZ O
been BC2GM086019506 VBN O
correlated BC2GM086019506 VBN O
with BC2GM086019506 IN O
cell BC2GM086019506 NN O
transformation BC2GM086019506 NN O
. BC2GM086019506 . O
. . O O

Letter BC2GM061508124 NN O
: BC2GM061508124 : O
Ballistocardiography BC2GM061508124 NN O
. BC2GM061508124 . O
. . O O

The BC2GM078500347 DT O
S3 BC2GM078500347 NNP O
protein BC2GM078500347 NN O
also BC2GM078500347 RB O
contains BC2GM078500347 VBZ O
a BC2GM078500347 DT O
DNA BC2GM078500347 NNP O
repair BC2GM078500347 NN O
activity BC2GM078500347 NN O
, BC2GM078500347 , O
efficiently BC2GM078500347 RB O
processing BC2GM078500347 VBG O
8-oxoguanine BC2GM078500347 JJ O
residues BC2GM078500347 NNS O
in BC2GM078500347 IN O
DNA BC2GM078500347 NNP O
via BC2GM078500347 IN O
an BC2GM078500347 DT O
N-glycosylase BC2GM078500347 JJ O
/ BC2GM078500347 NN O
apurinic-apyrimidinic BC2GM078500347 JJ O
( BC2GM078500347 ( O
AP BC2GM078500347 NNP O
) BC2GM078500347 ) O
lyase BC2GM078500347 NN O
activity BC2GM078500347 NN O
. BC2GM078500347 . O
. . O O

Characterization BC2GM004475360 NN O
of BC2GM004475360 IN O
a BC2GM004475360 DT O
unique BC2GM004475360 JJ O
protein BC2GM004475360 JJ O
component BC2GM004475360 NN O
of BC2GM004475360 IN O
yeast BC2GM004475360 JJ O
RNase BC2GM004475360 NNP O
MRP BC2GM004475360 NNP O
: BC2GM004475360 : O
an BC2GM004475360 DT O
RNA-binding BC2GM004475360 JJ O
protein BC2GM004475360 NN O
with BC2GM004475360 IN O
a BC2GM004475360 DT O
zinc-cluster BC2GM004475360 NN O
domain BC2GM004475360 NN O
. BC2GM004475360 . O
. . O O

A BC2GM048329227 DT O
positive BC2GM048329227 JJ O
correlation BC2GM048329227 NN O
was BC2GM048329227 VBD O
also BC2GM048329227 RB O
established BC2GM048329227 VBN O
between BC2GM048329227 IN O
the BC2GM048329227 DT O
level BC2GM048329227 NN O
of BC2GM048329227 IN O
FP9C BC2GM048329227 NNP O
binding BC2GM048329227 NN O
and BC2GM048329227 CC O
the BC2GM048329227 DT O
degree BC2GM048329227 NN O
of BC2GM048329227 IN O
cell BC2GM048329227 NN O
differentiation BC2GM048329227 NN O
in BC2GM048329227 IN O
vitro BC2GM048329227 NN O
. BC2GM048329227 . O
. . O O

cDNA BC2GM016530751 NN O
cloning BC2GM016530751 VBG O
reveals BC2GM016530751 NNS O
two BC2GM016530751 CD O
mouse BC2GM016530751 NN O
beta5 BC2GM016530751 NN O
integrin BC2GM016530751 NN O
transcripts BC2GM016530751 NNS O
distinct BC2GM016530751 VBP O
in BC2GM016530751 IN O
cytoplasmic BC2GM016530751 JJ O
domains BC2GM016530751 NNS O
as BC2GM016530751 IN O
a BC2GM016530751 DT O
result BC2GM016530751 NN O
of BC2GM016530751 IN O
alternative BC2GM016530751 JJ O
splicing BC2GM016530751 NN O
. BC2GM016530751 . O
. . O O

There BC2GM067096168 EX O
is BC2GM067096168 VBZ O
, BC2GM067096168 , O
however BC2GM067096168 RB O
, BC2GM067096168 , O
uncertainty BC2GM067096168 NN O
as BC2GM067096168 IN O
to BC2GM067096168 TO O
how BC2GM067096168 WRB O
results BC2GM067096168 NNS O
obtained BC2GM067096168 VBD O
in BC2GM067096168 IN O
recent BC2GM067096168 JJ O
experiments BC2GM067096168 NNS O
scale BC2GM067096168 VBZ O
up BC2GM067096168 IN O
to BC2GM067096168 TO O
landscape BC2GM067096168 VB O
and BC2GM067096168 CC O
regional BC2GM067096168 JJ O
levels BC2GM067096168 NNS O
and BC2GM067096168 CC O
generalize BC2GM067096168 VB O
across BC2GM067096168 IN O
ecosystem BC2GM067096168 NN O
types BC2GM067096168 NNS O
and BC2GM067096168 CC O
processes BC2GM067096168 NNS O
. BC2GM067096168 . O
. . O O

Fifty-seven BC2GM027879674 JJ O
per BC2GM027879674 IN O
cent BC2GM027879674 NN O
of BC2GM027879674 IN O
the BC2GM027879674 DT O
primary BC2GM027879674 JJ O
patients BC2GM027879674 NNS O
reporting BC2GM027879674 VBG O
mild BC2GM027879674 NN O
symptoms BC2GM027879674 NNS O
had BC2GM027879674 VBD O
abnormal BC2GM027879674 JJ O
levels BC2GM027879674 NNS O
of BC2GM027879674 IN O
leucocytes BC2GM027879674 NNS O
in BC2GM027879674 IN O
their BC2GM027879674 PRP$ O
CSF BC2GM027879674 NNP O
. BC2GM027879674 . O
. . O O

Subtype- BC2GM001207192 NNP O
and BC2GM001207192 CC O
response BC2GM001207192 NN O
element-dependent BC2GM001207192 JJ O
differences BC2GM001207192 NNS O
in BC2GM001207192 IN O
transactivation BC2GM001207192 NN O
by BC2GM001207192 IN O
peroxisome BC2GM001207192 JJ O
proliferator-activated BC2GM001207192 JJ O
receptors BC2GM001207192 NNS O
alpha BC2GM001207192 VBP O
and BC2GM001207192 CC O
gamma BC2GM001207192 VBP O
. BC2GM001207192 . O
. . O O

Acanthamoeba BC2GM027092021 NNP O
myosin BC2GM027092021 NN O
I BC2GM027092021 PRP O
heavy BC2GM027092021 VBP O
chain BC2GM027092021 NN O
kinase BC2GM027092021 NN O
( BC2GM027092021 ( O
MIHCK BC2GM027092021 NNP O
) BC2GM027092021 ) O
phosphorylates BC2GM027092021 VBZ O
the BC2GM027092021 DT O
heavy BC2GM027092021 JJ O
chains BC2GM027092021 NNS O
of BC2GM027092021 IN O
amoeba BC2GM027092021 NN O
myosins BC2GM027092021 NNS O
I BC2GM027092021 PRP O
, BC2GM027092021 , O
increasing BC2GM027092021 VBG O
their BC2GM027092021 PRP$ O
actin-activated BC2GM027092021 JJ O
ATPase BC2GM027092021 NNP O
activities BC2GM027092021 NNS O
. BC2GM027092021 . O
. . O O

It BC2GM085712382 PRP O
was BC2GM085712382 VBD O
predicted BC2GM085712382 VBN O
that BC2GM085712382 IN O
the BC2GM085712382 DT O
Stroop BC2GM085712382 NNP O
task BC2GM085712382 NN O
would BC2GM085712382 MD O
trigger BC2GM085712382 VB O
greater BC2GM085712382 JJR O
consumption BC2GM085712382 NN O
of BC2GM085712382 IN O
ice BC2GM085712382 NN O
cream BC2GM085712382 NN O
than BC2GM085712382 IN O
a BC2GM085712382 DT O
fearful BC2GM085712382 JJ O
film BC2GM085712382 NN O
, BC2GM085712382 , O
and BC2GM085712382 CC O
that BC2GM085712382 IN O
this BC2GM085712382 DT O
effect BC2GM085712382 NN O
would BC2GM085712382 MD O
be BC2GM085712382 VB O
more BC2GM085712382 RBR O
pronounced BC2GM085712382 JJ O
for BC2GM085712382 IN O
binge-eaters BC2GM085712382 NNS O
than BC2GM085712382 IN O
non-binge-eaters BC2GM085712382 NNS O
. BC2GM085712382 . O
. . O O

When BC2GM030100060 WRB O
recombinant BC2GM030100060 JJ O
gE BC2GM030100060 NN O
produced BC2GM030100060 VBN O
in BC2GM030100060 IN O
HeLa BC2GM030100060 NNP O
cells BC2GM030100060 NNS O
was BC2GM030100060 VBD O
probed BC2GM030100060 VBN O
with BC2GM030100060 IN O
the BC2GM030100060 DT O
same BC2GM030100060 JJ O
antiphosphotyrosine BC2GM030100060 NN O
antibody BC2GM030100060 NN O
, BC2GM030100060 , O
a BC2GM030100060 DT O
dimeric BC2GM030100060 JJ O
gE BC2GM030100060 NN O
form BC2GM030100060 NN O
at BC2GM030100060 IN O
130 BC2GM030100060 CD O
kDa BC2GM030100060 NN O
was BC2GM030100060 VBD O
detected BC2GM030100060 VBN O
on BC2GM030100060 IN O
the BC2GM030100060 DT O
cell BC2GM030100060 NN O
surface BC2GM030100060 NN O
. BC2GM030100060 . O
. . O O

The BC2GM083218556 DT O
effects BC2GM083218556 NNS O
of BC2GM083218556 IN O
castor BC2GM083218556 NN O
oil BC2GM083218556 NN O
, BC2GM083218556 , O
alone BC2GM083218556 RB O
, BC2GM083218556 , O
as BC2GM083218556 RB O
well BC2GM083218556 RB O
as BC2GM083218556 IN O
in BC2GM083218556 IN O
combination BC2GM083218556 NN O
with BC2GM083218556 IN O
PGI2 BC2GM083218556 NNP O
and BC2GM083218556 CC O
indomethacin BC2GM083218556 VB O
on BC2GM083218556 IN O
gastrointestinal BC2GM083218556 JJ O
functions BC2GM083218556 NNS O
have BC2GM083218556 VBP O
been BC2GM083218556 VBN O
examined BC2GM083218556 VBN O
in BC2GM083218556 IN O
rats BC2GM083218556 NNS O
. BC2GM083218556 . O
. . O O

Genetic BC2GM084023430 JJ O
linkage BC2GM084023430 NN O
mapping BC2GM084023430 NN O
of BC2GM084023430 IN O
the BC2GM084023430 DT O
CYP11A1 BC2GM084023430 NNP O
gene BC2GM084023430 NN O
encoding BC2GM084023430 VBG O
the BC2GM084023430 DT O
cholesterol BC2GM084023430 NN O
side-chain BC2GM084023430 JJ O
cleavage BC2GM084023430 NN O
P450scc BC2GM084023430 NNP O
close BC2GM084023430 NN O
to BC2GM084023430 TO O
the BC2GM084023430 DT O
CYP1A1 BC2GM084023430 NNP O
gene BC2GM084023430 NN O
and BC2GM084023430 CC O
D15S204 BC2GM084023430 NNP O
in BC2GM084023430 IN O
the BC2GM084023430 DT O
chromosome BC2GM084023430 NN O
15q22.33-q23 BC2GM084023430 JJ O
region BC2GM084023430 NN O
. BC2GM084023430 . O
. . O O

Therefore BC2GM044494195 RB O
, BC2GM044494195 , O
in BC2GM044494195 IN O
VDR-mediated BC2GM044494195 NNP O
transcriptional BC2GM044494195 JJ O
activation BC2GM044494195 NN O
, BC2GM044494195 , O
1,25 BC2GM044494195 CD O
( BC2GM044494195 ( O
OH BC2GM044494195 NNP O
) BC2GM044494195 ) O
2D3 BC2GM044494195 CD O
binding BC2GM044494195 VBG O
to BC2GM044494195 TO O
VDR BC2GM044494195 NNP O
alters BC2GM044494195 VBZ O
the BC2GM044494195 DT O
conformation BC2GM044494195 NN O
of BC2GM044494195 IN O
the BC2GM044494195 DT O
ligand BC2GM044494195 NN O
binding BC2GM044494195 VBG O
domain BC2GM044494195 NN O
such BC2GM044494195 JJ O
that BC2GM044494195 IN O
it BC2GM044494195 PRP O
: BC2GM044494195 : O
( BC2GM044494195 ( O
i BC2GM044494195 NN O
) BC2GM044494195 ) O
engages BC2GM044494195 VBZ O
in BC2GM044494195 IN O
strong BC2GM044494195 JJ O
heterodimerization BC2GM044494195 NN O
with BC2GM044494195 IN O
RXR BC2GM044494195 NNP O
to BC2GM044494195 TO O
facilitate BC2GM044494195 VB O
VDRE BC2GM044494195 NNP O
binding BC2GM044494195 NN O
, BC2GM044494195 , O
( BC2GM044494195 ( O
ii BC2GM044494195 NN O
) BC2GM044494195 ) O
influences BC2GM044494195 VBZ O
the BC2GM044494195 DT O
RXR BC2GM044494195 NNP O
ligand BC2GM044494195 NN O
binding BC2GM044494195 VBG O
domain BC2GM044494195 NN O
such BC2GM044494195 JJ O
that BC2GM044494195 IN O
it BC2GM044494195 PRP O
is BC2GM044494195 VBZ O
resistant BC2GM044494195 JJ O
to BC2GM044494195 TO O
the BC2GM044494195 DT O
binding BC2GM044494195 NN O
of BC2GM044494195 IN O
9-cis BC2GM044494195 JJ O
RA BC2GM044494195 NNP O
but BC2GM044494195 CC O
active BC2GM044494195 JJ O
in BC2GM044494195 IN O
recruiting BC2GM044494195 VBG O
coactivator BC2GM044494195 NN O
to BC2GM044494195 TO O
its BC2GM044494195 PRP$ O
AF-2 BC2GM044494195 NNP O
and BC2GM044494195 CC O
( BC2GM044494195 ( O
iii BC2GM044494195 NN O
) BC2GM044494195 ) O
presents BC2GM044494195 VBZ O
the BC2GM044494195 DT O
AF-2 BC2GM044494195 JJ O
region BC2GM044494195 NN O
in BC2GM044494195 IN O
VDR BC2GM044494195 NNP O
for BC2GM044494195 IN O
coactivator BC2GM044494195 NN O
association BC2GM044494195 NN O
. BC2GM044494195 . O
. . O O

Sexual BC2GM029944945 JJ O
adventurism BC2GM029944945 NN O
, BC2GM029944945 , O
high-risk BC2GM029944945 JJ O
behavior BC2GM029944945 NN O
, BC2GM029944945 , O
and BC2GM029944945 CC O
human BC2GM029944945 JJ O
immunodeficiency BC2GM029944945 NN O
virus-1 BC2GM029944945 JJ O
seroconversion BC2GM029944945 NN O
among BC2GM029944945 IN O
the BC2GM029944945 DT O
Chicago BC2GM029944945 NNP O
MACS-CCS BC2GM029944945 NNP O
cohort BC2GM029944945 NN O
, BC2GM029944945 , O
1984 BC2GM029944945 CD O
to BC2GM029944945 TO O
1992 BC2GM029944945 CD O
. BC2GM029944945 . O
. . O O

This BC2GM043347947 DT O
dynamic BC2GM043347947 JJ O
nature BC2GM043347947 NN O
may BC2GM043347947 MD O
be BC2GM043347947 VB O
relevant BC2GM043347947 JJ O
to BC2GM043347947 TO O
the BC2GM043347947 DT O
ability BC2GM043347947 NN O
of BC2GM043347947 IN O
E47 BC2GM043347947 NNP O
both BC2GM043347947 DT O
to BC2GM043347947 TO O
homodimerize BC2GM043347947 VB O
and BC2GM043347947 CC O
to BC2GM043347947 TO O
heterodimerize BC2GM043347947 VB O
with BC2GM043347947 IN O
MyoD BC2GM043347947 NNP O
, BC2GM043347947 , O
Id BC2GM043347947 NNP O
, BC2GM043347947 , O
and BC2GM043347947 CC O
Tal1 BC2GM043347947 NNP O
. BC2GM043347947 . O
. . O O

Gene BC2GM010380443 NNP O
structure BC2GM010380443 NN O
and BC2GM010380443 CC O
precursor BC2GM010380443 NN O
processing BC2GM010380443 NN O
. BC2GM010380443 . O
. . O O

A BC2GM019414766 DT O
fine-structure BC2GM019414766 JJ O
radiation BC2GM019414766 NN O
hybrid BC2GM019414766 NN O
map BC2GM019414766 NN O
for BC2GM019414766 IN O
the BC2GM019414766 DT O
region BC2GM019414766 NN O
that BC2GM019414766 WDT O
extends BC2GM019414766 VBZ O
from BC2GM019414766 IN O
D8S520 BC2GM019414766 NNP O
( BC2GM019414766 ( O
distal BC2GM019414766 NN O
) BC2GM019414766 ) O
to BC2GM019414766 TO O
D8S1759 BC2GM019414766 NNP O
( BC2GM019414766 ( O
proximal BC2GM019414766 JJ O
) BC2GM019414766 ) O
was BC2GM019414766 VBD O
prepared BC2GM019414766 VBN O
, BC2GM019414766 , O
followed BC2GM019414766 VBN O
by BC2GM019414766 IN O
construction BC2GM019414766 NN O
of BC2GM019414766 IN O
a BC2GM019414766 DT O
single BC2GM019414766 JJ O
, BC2GM019414766 , O
integrated BC2GM019414766 JJ O
YAC BC2GM019414766 NNP O
/ BC2GM019414766 NNP O
BAC BC2GM019414766 NNP O
contig BC2GM019414766 NN O
for BC2GM019414766 IN O
the BC2GM019414766 DT O
interval BC2GM019414766 NN O
. BC2GM019414766 . O
. . O O

BRAP2 BC2GM092320908 NNP O
also BC2GM092320908 RB O
shares BC2GM092320908 NNS O
significant BC2GM092320908 JJ O
homology BC2GM092320908 NN O
with BC2GM092320908 IN O
a BC2GM092320908 DT O
hypothetical BC2GM092320908 JJ O
protein BC2GM092320908 NN O
from BC2GM092320908 IN O
yeast BC2GM092320908 JJ O
Saccharomyces BC2GM092320908 NNP O
cerevisiae BC2GM092320908 NN O
, BC2GM092320908 , O
especially BC2GM092320908 RB O
in BC2GM092320908 IN O
the BC2GM092320908 DT O
zinc BC2GM092320908 NN O
finger BC2GM092320908 NN O
region BC2GM092320908 NN O
. BC2GM092320908 . O
. . O O

The BC2GM003517703 DT O
dipper BC2GM003517703 NN O
( BC2GM003517703 ( O
RONF BC2GM003517703 NNP O
of BC2GM003517703 IN O
BP BC2GM003517703 NNP O
( BC2GM003517703 ( O
or BC2GM003517703 CC O
HR BC2GM003517703 NNP O
) BC2GM003517703 ) O
> BC2GM003517703 VBD O
or BC2GM003517703 CC O
= BC2GM003517703 VB O
10 BC2GM003517703 CD O
% BC2GM003517703 NN O
2 BC2GM003517703 CD O
. BC2GM003517703 . O
. . O O

Our BC2GM020828058 PRP$ O
data BC2GM020828058 NNS O
suggest BC2GM020828058 VBP O
that BC2GM020828058 IN O
the BC2GM020828058 DT O
ZF-HD BC2GM020828058 NNP O
class BC2GM020828058 NN O
of BC2GM020828058 IN O
homeodomain BC2GM020828058 NN O
proteins BC2GM020828058 NNS O
may BC2GM020828058 MD O
be BC2GM020828058 VB O
involved BC2GM020828058 VBN O
in BC2GM020828058 IN O
the BC2GM020828058 DT O
establishment BC2GM020828058 NN O
of BC2GM020828058 IN O
the BC2GM020828058 DT O
characteristic BC2GM020828058 JJ O
expression BC2GM020828058 NN O
pattern BC2GM020828058 NN O
of BC2GM020828058 IN O
the BC2GM020828058 DT O
C4 BC2GM020828058 NNP O
PEPCase BC2GM020828058 NNP O
gene BC2GM020828058 NN O
. BC2GM020828058 . O
. . O O

Effect BC2GM032120704 NN O
of BC2GM032120704 IN O
hyperaemia BC2GM032120704 NN O
on BC2GM032120704 IN O
thallium-201 BC2GM032120704 JJ O
redistribution BC2GM032120704 NN O
in BC2GM032120704 IN O
normal BC2GM032120704 JJ O
canine BC2GM032120704 JJ O
myocardium BC2GM032120704 NN O
. BC2GM032120704 . O
. . O O

It BC2GM067657042 PRP O
has BC2GM067657042 VBZ O
also BC2GM067657042 RB O
been BC2GM067657042 VBN O
previously BC2GM067657042 RB O
demonstrated BC2GM067657042 VBN O
that BC2GM067657042 IN O
LPS BC2GM067657042 NNP O
treatment BC2GM067657042 NN O
of BC2GM067657042 IN O
splenic BC2GM067657042 JJ O
B BC2GM067657042 NNP O
cells BC2GM067657042 NNS O
from BC2GM067657042 IN O
athymic BC2GM067657042 JJ O
mice BC2GM067657042 NN O
results BC2GM067657042 NNS O
in BC2GM067657042 IN O
a BC2GM067657042 DT O
decrease BC2GM067657042 NN O
in BC2GM067657042 IN O
steady BC2GM067657042 JJ O
state BC2GM067657042 NN O
mRNA BC2GM067657042 NN O
encoding BC2GM067657042 VBG O
the BC2GM067657042 DT O
A BC2GM067657042 NNP O
alpha BC2GM067657042 NN O
class BC2GM067657042 NN O
II BC2GM067657042 NNP O
protein BC2GM067657042 NN O
. BC2GM067657042 . O
. . O O

Specifically BC2GM088550314 RB O
, BC2GM088550314 , O
we BC2GM088550314 PRP O
demonstrate BC2GM088550314 VBP O
that BC2GM088550314 IN O
this BC2GM088550314 DT O
25-base BC2GM088550314 JJ O
pair BC2GM088550314 NN O
region BC2GM088550314 NN O
mediates BC2GM088550314 VBZ O
the BC2GM088550314 DT O
up-regulatory BC2GM088550314 JJ O
effect BC2GM088550314 NN O
of BC2GM088550314 IN O
TGF-beta BC2GM088550314 NNP O
on BC2GM088550314 IN O
COL1A2 BC2GM088550314 NNP O
promoter BC2GM088550314 NN O
activity BC2GM088550314 NN O
and BC2GM088550314 CC O
allows BC2GM088550314 VBZ O
antagonistic BC2GM088550314 JJ O
activity BC2GM088550314 NN O
of BC2GM088550314 IN O
TNF-alpha BC2GM088550314 NNP O
on BC2GM088550314 IN O
the BC2GM088550314 DT O
TGF-beta BC2GM088550314 JJ O
effect BC2GM088550314 NN O
. BC2GM088550314 . O
. . O O

Here BC2GM092355993 RB O
, BC2GM092355993 , O
we BC2GM092355993 PRP O
describe BC2GM092355993 VBP O
the BC2GM092355993 DT O
results BC2GM092355993 NNS O
of BC2GM092355993 IN O
a BC2GM092355993 DT O
detailed BC2GM092355993 JJ O
study BC2GM092355993 NN O
aimed BC2GM092355993 VBN O
at BC2GM092355993 IN O
identifying BC2GM092355993 VBG O
the BC2GM092355993 DT O
gene BC2GM092355993 NN O
or BC2GM092355993 CC O
genes BC2GM092355993 NNS O
responsible BC2GM092355993 JJ O
for BC2GM092355993 IN O
the BC2GM092355993 DT O
rapid BC2GM092355993 JJ O
growth-arrest BC2GM092355993 JJ O
response BC2GM092355993 NN O
obtained BC2GM092355993 VBN O
with BC2GM092355993 IN O
human BC2GM092355993 JJ O
chromosome-9 BC2GM092355993 NN O
. BC2GM092355993 . O
. . O O

Neonatal BC2GM014151852 JJ O
hyperthyroidism BC2GM014151852 NN O
. BC2GM014151852 . O
. . O O

By BC2GM009914955 IN O
subtractive BC2GM009914955 JJ O
and BC2GM009914955 CC O
differential BC2GM009914955 JJ O
screening BC2GM009914955 NN O
, BC2GM009914955 , O
we BC2GM009914955 PRP O
have BC2GM009914955 VBP O
cloned BC2GM009914955 VBN O
12 BC2GM009914955 CD O
of BC2GM009914955 IN O
these BC2GM009914955 DT O
sequences BC2GM009914955 NNS O
, BC2GM009914955 , O
2 BC2GM009914955 CD O
of BC2GM009914955 IN O
which BC2GM009914955 WDT O
were BC2GM009914955 VBD O
c-fos BC2GM009914955 JJ O
and BC2GM009914955 CC O
krox-24 BC2GM009914955 JJ O
. BC2GM009914955 . O
. . O O

The BC2GM088152859 DT O
influence BC2GM088152859 NN O
of BC2GM088152859 IN O
gas BC2GM088152859 NN O
composition BC2GM088152859 NN O
in BC2GM088152859 IN O
the BC2GM088152859 DT O
air BC2GM088152859 NN O
cell BC2GM088152859 NN O
on BC2GM088152859 IN O
pipping BC2GM088152859 NN O
and BC2GM088152859 CC O
liver BC2GM088152859 NN O
metabolism BC2GM088152859 NN O
in BC2GM088152859 IN O
embryonic BC2GM088152859 JJ O
chicks BC2GM088152859 NNS O
. BC2GM088152859 . O
. . O O

IgE BC2GM046405419 NNP O
antibody BC2GM046405419 NN O
to BC2GM046405419 TO O
twelve BC2GM046405419 VB O
common BC2GM046405419 JJ O
food BC2GM046405419 NN O
and BC2GM046405419 CC O
inhalant BC2GM046405419 NN O
allergens BC2GM046405419 NNS O
was BC2GM046405419 VBD O
measured BC2GM046405419 VBN O
by BC2GM046405419 IN O
enzyme-linked BC2GM046405419 JJ O
immunosorbent BC2GM046405419 NN O
assay BC2GM046405419 NN O
( BC2GM046405419 ( O
ELISA BC2GM046405419 NNP O
) BC2GM046405419 ) O
in BC2GM046405419 IN O
the BC2GM046405419 DT O
sera BC2GM046405419 NN O
of BC2GM046405419 IN O
thirteen BC2GM046405419 JJ O
atopic BC2GM046405419 NN O
patients BC2GM046405419 NNS O
with BC2GM046405419 IN O
one BC2GM046405419 CD O
or BC2GM046405419 CC O
more BC2GM046405419 JJR O
allergic BC2GM046405419 JJ O
disorders BC2GM046405419 NNS O
( BC2GM046405419 ( O
asthma BC2GM046405419 JJ O
occurring BC2GM046405419 VBG O
in BC2GM046405419 IN O
eleven BC2GM046405419 RB O
; BC2GM046405419 : O
rhinitis BC2GM046405419 NN O
in BC2GM046405419 IN O
ten BC2GM046405419 NN O
; BC2GM046405419 : O
eczema BC2GM046405419 CC O
in BC2GM046405419 IN O
six BC2GM046405419 CD O
; BC2GM046405419 : O
urticaria BC2GM046405419 NNS O
in BC2GM046405419 IN O
four BC2GM046405419 CD O
; BC2GM046405419 : O
mouth BC2GM046405419 NN O
and BC2GM046405419 CC O
gastro-intestinal BC2GM046405419 JJ O
symptoms BC2GM046405419 NNS O
in BC2GM046405419 IN O
six BC2GM046405419 CD O
) BC2GM046405419 ) O
, BC2GM046405419 , O
of BC2GM046405419 IN O
twelve BC2GM046405419 JJ O
non-atopic BC2GM046405419 JJ O
patients BC2GM046405419 NNS O
with BC2GM046405419 IN O
various BC2GM046405419 JJ O
clinical BC2GM046405419 JJ O
symptoms BC2GM046405419 NNS O
( BC2GM046405419 ( O
asthma BC2GM046405419 VB O
in BC2GM046405419 IN O
four BC2GM046405419 CD O
; BC2GM046405419 : O
rhinitis BC2GM046405419 NN O
in BC2GM046405419 IN O
four BC2GM046405419 CD O
; BC2GM046405419 : O
eczema BC2GM046405419 NN O
in BC2GM046405419 IN O
one BC2GM046405419 CD O
; BC2GM046405419 : O
urticaria BC2GM046405419 NNS O
in BC2GM046405419 IN O
two BC2GM046405419 CD O
; BC2GM046405419 : O
mouth BC2GM046405419 NNS O
and BC2GM046405419 CC O
gastro-intestinal BC2GM046405419 JJ O
symptoms BC2GM046405419 NNS O
in BC2GM046405419 IN O
four BC2GM046405419 CD O
) BC2GM046405419 ) O
and BC2GM046405419 CC O
sixteen BC2GM046405419 JJ O
cord BC2GM046405419 NN O
blood BC2GM046405419 NN O
sera BC2GM046405419 NN O
. BC2GM046405419 . O
. . O O

These BC2GM097957533 DT O
mutant BC2GM097957533 JJ O
rps7 BC2GM097957533 NN O
leaders BC2GM097957533 NNS O
were BC2GM097957533 VBD O
ligated BC2GM097957533 VBN O
into BC2GM097957533 IN O
an BC2GM097957533 DT O
aadA BC2GM097957533 JJ O
expression BC2GM097957533 NN O
cassette BC2GM097957533 NN O
and BC2GM097957533 CC O
transformed BC2GM097957533 VBD O
into BC2GM097957533 IN O
the BC2GM097957533 DT O
chloroplast BC2GM097957533 NN O
of BC2GM097957533 IN O
C. BC2GM097957533 NNP O
reinhardtii BC2GM097957533 NN O
and BC2GM097957533 CC O
into BC2GM097957533 IN O
E. BC2GM097957533 NNP O
coli BC2GM097957533 NNS O
. BC2GM097957533 . O
. . O O

Focal BC2GM027254558 NNP O
or BC2GM027254558 CC O
regional BC2GM027254558 JJ O
8- BC2GM027254558 JJ O
to BC2GM027254558 TO O
20-Hz BC2GM027254558 JJ O
low-voltage BC2GM027254558 JJ O
epileptiform BC2GM027254558 NN O
paroxysms BC2GM027254558 NN O
in BC2GM027254558 IN O
either BC2GM027254558 DT O
hippocampus BC2GM027254558 NN O
( BC2GM027254558 ( O
10 BC2GM027254558 CD O
patients BC2GM027254558 NNS O
) BC2GM027254558 ) O
, BC2GM027254558 , O
amygdala BC2GM027254558 RB O
( BC2GM027254558 ( O
1 BC2GM027254558 CD O
patient BC2GM027254558 NN O
) BC2GM027254558 ) O
, BC2GM027254558 , O
or BC2GM027254558 CC O
both BC2GM027254558 DT O
( BC2GM027254558 ( O
1 BC2GM027254558 CD O
patient BC2GM027254558 NN O
) BC2GM027254558 ) O
preceded BC2GM027254558 VBD O
initial BC2GM027254558 JJ O
motionless BC2GM027254558 NN O
staring BC2GM027254558 NN O
. BC2GM027254558 . O
. . O O

Reduced BC2GM042721293 VBN O
concentrations BC2GM042721293 NNS O
of BC2GM042721293 IN O
antithrombin BC2GM042721293 NN O
III BC2GM042721293 NNP O
, BC2GM042721293 , O
plasminogen BC2GM042721293 NN O
, BC2GM042721293 , O
( BC2GM042721293 ( O
free BC2GM042721293 JJ O
) BC2GM042721293 ) O
protein BC2GM042721293 NN O
S BC2GM042721293 NNP O
, BC2GM042721293 , O
and BC2GM042721293 CC O
protein BC2GM042721293 RB O
C BC2GM042721293 NNP O
were BC2GM042721293 VBD O
found BC2GM042721293 VBN O
in BC2GM042721293 IN O
some BC2GM042721293 DT O
patients BC2GM042721293 NNS O
but BC2GM042721293 CC O
were BC2GM042721293 VBD O
not BC2GM042721293 RB O
associated BC2GM042721293 VBN O
with BC2GM042721293 IN O
either BC2GM042721293 DT O
thrombosis BC2GM042721293 NN O
or BC2GM042721293 CC O
lupus BC2GM042721293 NN O
anticoagulant BC2GM042721293 NN O
. BC2GM042721293 . O
. . O O

JCAHO BC2GM094415622 NNP O
to BC2GM094415622 TO O
use BC2GM094415622 VB O
ORYX BC2GM094415622 NNP O
data BC2GM094415622 NNS O
to BC2GM094415622 TO O
detect BC2GM094415622 VB O
sentinel BC2GM094415622 JJ O
events BC2GM094415622 NNS O
. BC2GM094415622 . O
. . O O

Long-term BC2GM013162443 JJ O
results BC2GM013162443 NNS O
and BC2GM013162443 CC O
curative BC2GM013162443 JJ O
mechanisms BC2GM013162443 NNS O
of BC2GM013162443 IN O
vesicoureteral BC2GM013162443 JJ O
reflux BC2GM013162443 NN O
by BC2GM013162443 IN O
endoscopic BC2GM013162443 JJ O
injection BC2GM013162443 NN O
of BC2GM013162443 IN O
blood BC2GM013162443 NN O
. BC2GM013162443 . O
. . O O

Furthermore BC2GM098314451 RB O
, BC2GM098314451 , O
we BC2GM098314451 PRP O
show BC2GM098314451 VBP O
that BC2GM098314451 IN O
Nck-2 BC2GM098314451 NNP O
is BC2GM098314451 VBZ O
capable BC2GM098314451 JJ O
of BC2GM098314451 IN O
recognizing BC2GM098314451 VBG O
several BC2GM098314451 JJ O
key BC2GM098314451 JJ O
components BC2GM098314451 NNS O
of BC2GM098314451 IN O
growth BC2GM098314451 NN O
factor BC2GM098314451 NN O
receptor BC2GM098314451 NN O
kinase-signaling BC2GM098314451 JJ O
pathways BC2GM098314451 NNS O
including BC2GM098314451 VBG O
EGF BC2GM098314451 NNP O
receptors BC2GM098314451 NNS O
, BC2GM098314451 , O
PDGF BC2GM098314451 NNP O
receptor-beta BC2GM098314451 NN O
, BC2GM098314451 , O
and BC2GM098314451 CC O
IRS-1 BC2GM098314451 NNP O
. BC2GM098314451 . O
. . O O

There BC2GM090935032 EX O
is BC2GM090935032 VBZ O
little BC2GM090935032 JJ O
similarity BC2GM090935032 NN O
among BC2GM090935032 IN O
the BC2GM090935032 DT O
sequences BC2GM090935032 NNS O
upstream BC2GM090935032 RB O
from BC2GM090935032 IN O
the BC2GM090935032 DT O
CAP BC2GM090935032 NNP O
site BC2GM090935032 NN O
of BC2GM090935032 IN O
the BC2GM090935032 DT O
Spec2 BC2GM090935032 NNP O
genes BC2GM090935032 NNS O
except BC2GM090935032 IN O
the BC2GM090935032 DT O
TATA BC2GM090935032 NNP O
consensus BC2GM090935032 NN O
sequence BC2GM090935032 NN O
and BC2GM090935032 CC O
a BC2GM090935032 DT O
repeating BC2GM090935032 JJ O
trinucleotide BC2GM090935032 NN O
, BC2GM090935032 , O
AAC BC2GM090935032 NNP O
. BC2GM090935032 . O
. . O O

Studies BC2GM046628798 NNS O
in BC2GM046628798 IN O
26 BC2GM046628798 CD O
patients BC2GM046628798 NNS O
. BC2GM046628798 . O
. . O O

They BC2GM076616336 PRP O
are BC2GM076616336 VBP O
growth-inhibited BC2GM076616336 JJ O
by BC2GM076616336 IN O
TGF-beta1 BC2GM076616336 NNP O
. BC2GM076616336 . O
. . O O

Serum BC2GM011526436 NNP O
AFP BC2GM011526436 NNP O
is BC2GM011526436 VBZ O
a BC2GM011526436 DT O
useful BC2GM011526436 JJ O
tumor BC2GM011526436 NN O
marker BC2GM011526436 NN O
for BC2GM011526436 IN O
monitoring BC2GM011526436 VBG O
the BC2GM011526436 DT O
results BC2GM011526436 NNS O
of BC2GM011526436 IN O
therapy BC2GM011526436 NN O
. BC2GM011526436 . O
. . O O

To BC2GM010069099 TO O
our BC2GM010069099 PRP$ O
knowledge BC2GM010069099 NN O
no BC2GM010069099 DT O
transcription BC2GM010069099 NN O
factors BC2GM010069099 NNS O
have BC2GM010069099 VBP O
previously BC2GM010069099 RB O
been BC2GM010069099 VBN O
identified BC2GM010069099 VBN O
that BC2GM010069099 IN O
exhibit BC2GM010069099 NN O
androgen-dependent BC2GM010069099 JJ O
expression BC2GM010069099 NN O
in BC2GM010069099 IN O
the BC2GM010069099 DT O
epididymis BC2GM010069099 NN O
. BC2GM010069099 . O
. . O O

Partial BC2GM082122625 JJ O
characterization BC2GM082122625 NN O
of BC2GM082122625 IN O
the BC2GM082122625 DT O
CCAAT BC2GM082122625 NNP O
box BC2GM082122625 NN O
in BC2GM082122625 IN O
the BC2GM082122625 DT O
promoter BC2GM082122625 NN O
of BC2GM082122625 IN O
the BC2GM082122625 DT O
hLGFBP-1 BC2GM082122625 JJ O
gene BC2GM082122625 NN O
: BC2GM082122625 : O
interaction BC2GM082122625 NN O
with BC2GM082122625 IN O
negatively BC2GM082122625 RB O
acting BC2GM082122625 VBG O
transcription BC2GM082122625 NN O
factors BC2GM082122625 NNS O
in BC2GM082122625 IN O
decidualized BC2GM082122625 JJ O
human BC2GM082122625 JJ O
endometrial BC2GM082122625 JJ O
stromal BC2GM082122625 NN O
cells BC2GM082122625 NNS O
. BC2GM082122625 . O
. . O O

Pathogenesis BC2GM095399332 NN O
of BC2GM095399332 IN O
fever BC2GM095399332 NN O
. BC2GM095399332 . O
. . O O

Two BC2GM064518776 CD O
closely BC2GM064518776 RB O
related BC2GM064518776 JJ O
groups BC2GM064518776 NNS O
of BC2GM064518776 IN O
transcripts BC2GM064518776 NNS O
, BC2GM064518776 , O
Sagrp1 BC2GM064518776 NNP O
and BC2GM064518776 CC O
Sagrp2 BC2GM064518776 NNP O
, BC2GM064518776 , O
controlled BC2GM064518776 VBN O
by BC2GM064518776 IN O
a BC2GM064518776 DT O
circadian BC2GM064518776 JJ O
rhythm BC2GM064518776 NN O
have BC2GM064518776 VBP O
been BC2GM064518776 VBN O
isolated BC2GM064518776 VBN O
. BC2GM064518776 . O
. . O O

In BC2GM026679979 IN O
addition BC2GM026679979 NN O
, BC2GM026679979 , O
the BC2GM026679979 DT O
results BC2GM026679979 NNS O
suggest BC2GM026679979 VBP O
that BC2GM026679979 IN O
N BC2GM026679979 NNP O
region BC2GM026679979 NN O
diversity BC2GM026679979 NN O
at BC2GM026679979 IN O
V BC2GM026679979 NNP O
( BC2GM026679979 ( O
D BC2GM026679979 NNP O
) BC2GM026679979 ) O
J BC2GM026679979 NNP O
junctions BC2GM026679979 NNS O
within BC2GM026679979 IN O
rearranged BC2GM026679979 VBN O
immunoglobulin BC2GM026679979 NN O
and BC2GM026679979 CC O
T BC2GM026679979 NNP O
cell BC2GM026679979 NN O
receptor BC2GM026679979 NN O
gene BC2GM026679979 NN O
loci BC2GM026679979 NN O
can BC2GM026679979 MD O
only BC2GM026679979 RB O
be BC2GM026679979 VB O
introduced BC2GM026679979 VBN O
after BC2GM026679979 IN O
the BC2GM026679979 DT O
generation BC2GM026679979 NN O
of BC2GM026679979 IN O
RAG-catalyzed BC2GM026679979 JJ O
DNA BC2GM026679979 NNP O
double-strand BC2GM026679979 NN O
breaks BC2GM026679979 NNS O
, BC2GM026679979 , O
i.e BC2GM026679979 NN O
. BC2GM026679979 . O
during BC2GM026679979 IN O
the BC2GM026679979 DT O
DNA BC2GM026679979 NNP O
end BC2GM026679979 NN O
joining BC2GM026679979 VBG O
phase BC2GM026679979 NN O
of BC2GM026679979 IN O
the BC2GM026679979 DT O
V BC2GM026679979 NNP O
( BC2GM026679979 ( O
D BC2GM026679979 NNP O
) BC2GM026679979 ) O
J BC2GM026679979 NNP O
recombination BC2GM026679979 NN O
reaction BC2GM026679979 NN O
. BC2GM026679979 . O
. . O O

OBJECTIVE BC2GM083915598 NN O
: BC2GM083915598 : O
Respiratory-related BC2GM083915598 JJ O
electromyographic BC2GM083915598 NN O
( BC2GM083915598 ( O
EMG BC2GM083915598 NNP O
) BC2GM083915598 ) O
activity BC2GM083915598 NN O
of BC2GM083915598 IN O
the BC2GM083915598 DT O
superior BC2GM083915598 JJ O
pharyngeal BC2GM083915598 NN O
constrictor BC2GM083915598 NN O
( BC2GM083915598 ( O
SPC BC2GM083915598 NNP O
) BC2GM083915598 ) O
muscle BC2GM083915598 NN O
was BC2GM083915598 VBD O
analyzed BC2GM083915598 VBN O
during BC2GM083915598 IN O
the BC2GM083915598 DT O
early BC2GM083915598 JJ O
stage BC2GM083915598 NN O
of BC2GM083915598 IN O
forced BC2GM083915598 JJ O
breathing BC2GM083915598 NN O
. BC2GM083915598 . O
. . O O

The BC2GM038812570 DT O
carboxyl BC2GM038812570 NN O
globular BC2GM038812570 NN O
domain BC2GM038812570 NN O
was BC2GM038812570 VBD O
found BC2GM038812570 VBN O
to BC2GM038812570 TO O
be BC2GM038812570 VB O
encoded BC2GM038812570 VBN O
by BC2GM038812570 IN O
six BC2GM038812570 CD O
exons BC2GM038812570 NNS O
which BC2GM038812570 WDT O
appear BC2GM038812570 VBP O
to BC2GM038812570 TO O
delineate BC2GM038812570 VB O
its BC2GM038812570 PRP$ O
structural BC2GM038812570 JJ O
subdomains BC2GM038812570 NNS O
. BC2GM038812570 . O
. . O O

UPR BC2GM033552450 JJ O
elements BC2GM033552450 NNS O
present BC2GM033552450 JJ O
in BC2GM033552450 IN O
other BC2GM033552450 JJ O
ER BC2GM033552450 NNP O
chaperone BC2GM033552450 NN O
genes BC2GM033552450 NNS O
, BC2GM033552450 , O
such BC2GM033552450 JJ O
as BC2GM033552450 IN O
yeast BC2GM033552450 NN O
KAR2 BC2GM033552450 NNP O
( BC2GM033552450 ( O
BiP BC2GM033552450 NNP O
) BC2GM033552450 ) O
, BC2GM033552450 , O
mammalian BC2GM033552450 JJ O
GRP78 BC2GM033552450 NNP O
( BC2GM033552450 ( O
BiP BC2GM033552450 NNP O
) BC2GM033552450 ) O
, BC2GM033552450 , O
and BC2GM033552450 CC O
GRP94 BC2GM033552450 NNP O
, BC2GM033552450 , O
function BC2GM033552450 NN O
in BC2GM033552450 IN O
an BC2GM033552450 DT O
analogous BC2GM033552450 JJ O
manner BC2GM033552450 NN O
to BC2GM033552450 TO O
that BC2GM033552450 DT O
in BC2GM033552450 IN O
FKB2 BC2GM033552450 NNP O
. BC2GM033552450 . O
. . O O

Recent BC2GM027811998 JJ O
research BC2GM027811998 NN O
on BC2GM027811998 IN O
lipolysis BC2GM027811998 NN O
. BC2GM027811998 . O
. . O O

Importin BC2GM023971804 NNP O
beta BC2GM023971804 NN O
mediates BC2GM023971804 NNS O
nuclear BC2GM023971804 JJ O
translocation BC2GM023971804 NN O
of BC2GM023971804 IN O
Smad BC2GM023971804 NNP O
3 BC2GM023971804 CD O
. BC2GM023971804 . O
. . O O

Here BC2GM003994836 RB O
we BC2GM003994836 PRP O
describe BC2GM003994836 VBP O
the BC2GM003994836 DT O
characterization BC2GM003994836 NN O
of BC2GM003994836 IN O
cDNAs BC2GM003994836 JJ O
encoding BC2GM003994836 VBG O
two BC2GM003994836 CD O
unusual BC2GM003994836 JJ O
E2Fs BC2GM003994836 NNP O
, BC2GM003994836 , O
E2F-4 BC2GM003994836 NNP O
and BC2GM003994836 CC O
E2F-5 BC2GM003994836 NNP O
, BC2GM003994836 , O
each BC2GM003994836 DT O
identified BC2GM003994836 VBN O
by BC2GM003994836 IN O
the BC2GM003994836 DT O
ability BC2GM003994836 NN O
of BC2GM003994836 IN O
their BC2GM003994836 PRP$ O
gene BC2GM003994836 NN O
product BC2GM003994836 NN O
to BC2GM003994836 TO O
interact BC2GM003994836 VB O
with BC2GM003994836 IN O
p130 BC2GM003994836 NN O
in BC2GM003994836 IN O
a BC2GM003994836 DT O
yeast BC2GM003994836 JJ O
two-hybrid BC2GM003994836 JJ O
system BC2GM003994836 NN O
. BC2GM003994836 . O
. . O O

Under BC2GM069671775 IN O
control BC2GM069671775 NN O
conditions BC2GM069671775 NNS O
and BC2GM069671775 CC O
in BC2GM069671775 IN O
the BC2GM069671775 DT O
presence BC2GM069671775 NN O
of BC2GM069671775 IN O
3 BC2GM069671775 CD O
micromol BC2GM069671775 NNS O
/ BC2GM069671775 JJ O
kg BC2GM069671775 NN O
MIB BC2GM069671775 NNP O
and BC2GM069671775 CC O
VER BC2GM069671775 NNP O
the BC2GM069671775 DT O
maximal BC2GM069671775 JJ O
effect BC2GM069671775 NN O
of BC2GM069671775 IN O
noradrenaline BC2GM069671775 NN O
was BC2GM069671775 VBD O
reached BC2GM069671775 VBN O
at BC2GM069671775 IN O
0.1 BC2GM069671775 CD O
micromol BC2GM069671775 NN O
/ BC2GM069671775 NNP O
kg BC2GM069671775 NNP O
whereas BC2GM069671775 NNS O
in BC2GM069671775 IN O
the BC2GM069671775 DT O
presence BC2GM069671775 NN O
of BC2GM069671775 IN O
10 BC2GM069671775 CD O
micromol BC2GM069671775 NNS O
/ BC2GM069671775 JJ O
kg BC2GM069671775 NN O
MIB BC2GM069671775 NNP O
and BC2GM069671775 CC O
VER BC2GM069671775 NNP O
it BC2GM069671775 PRP O
was BC2GM069671775 VBD O
reached BC2GM069671775 VBN O
at BC2GM069671775 IN O
a BC2GM069671775 DT O
dose BC2GM069671775 NN O
of BC2GM069671775 IN O
1 BC2GM069671775 CD O
micromol BC2GM069671775 NNS O
/ BC2GM069671775 JJ O
kg BC2GM069671775 NN O
. BC2GM069671775 . O
. . O O

SCOF-1 BC2GM083699993 JJ O
localized BC2GM083699993 VBN O
to BC2GM083699993 TO O
the BC2GM083699993 DT O
nucleus BC2GM083699993 NN O
but BC2GM083699993 CC O
did BC2GM083699993 VBD O
not BC2GM083699993 RB O
bind BC2GM083699993 VB O
directly BC2GM083699993 RB O
to BC2GM083699993 TO O
either BC2GM083699993 DT O
C-repeat BC2GM083699993 NNP O
/ BC2GM083699993 NNP O
dehydration BC2GM083699993 NN O
( BC2GM083699993 ( O
CRT BC2GM083699993 NNP O
/ BC2GM083699993 NNP O
DRE BC2GM083699993 NNP O
) BC2GM083699993 ) O
or BC2GM083699993 CC O
ABA BC2GM083699993 NNP O
responsive BC2GM083699993 JJ O
element BC2GM083699993 NN O
( BC2GM083699993 ( O
ABRE BC2GM083699993 NNP O
) BC2GM083699993 ) O
, BC2GM083699993 , O
cis-acting BC2GM083699993 JJ O
DNA BC2GM083699993 NNP O
regulatory BC2GM083699993 JJ O
elements BC2GM083699993 NNS O
present BC2GM083699993 JJ O
in BC2GM083699993 IN O
COR BC2GM083699993 NNP O
gene BC2GM083699993 NN O
promoters BC2GM083699993 NNS O
. BC2GM083699993 . O
. . O O

There BC2GM043473136 EX O
also BC2GM043473136 RB O
may BC2GM043473136 MD O
be BC2GM043473136 VB O
osmotic BC2GM043473136 JJ O
challenges BC2GM043473136 NNS O
to BC2GM043473136 TO O
mucosal BC2GM043473136 VB O
cell BC2GM043473136 NN O
function BC2GM043473136 NN O
as BC2GM043473136 IN O
evidenced BC2GM043473136 VBN O
by BC2GM043473136 IN O
the BC2GM043473136 DT O
different BC2GM043473136 JJ O
reaction BC2GM043473136 NN O
rates BC2GM043473136 NNS O
with BC2GM043473136 IN O
hyper- BC2GM043473136 JJ O
and BC2GM043473136 CC O
hypotonic BC2GM043473136 JJ O
saline BC2GM043473136 NN O
. BC2GM043473136 . O
. . O O

Quantitative BC2GM085517047 JJ O
Tl-201 BC2GM085517047 NNP O
analysis BC2GM085517047 NN O
after BC2GM085517047 IN O
stress BC2GM085517047 NN O
has BC2GM085517047 VBZ O
also BC2GM085517047 RB O
shown BC2GM085517047 VBN O
viable BC2GM085517047 JJ O
myocardium BC2GM085517047 NN O
in BC2GM085517047 IN O
most BC2GM085517047 JJS O
mild BC2GM085517047 JJ O
to BC2GM085517047 TO O
moderate BC2GM085517047 VB O
( BC2GM085517047 ( O
51 BC2GM085517047 CD O
% BC2GM085517047 NN O
to BC2GM085517047 TO O
85 BC2GM085517047 CD O
% BC2GM085517047 NN O
of BC2GM085517047 IN O
normal BC2GM085517047 JJ O
uptake BC2GM085517047 NN O
) BC2GM085517047 ) O
irreversible BC2GM085517047 JJ O
Tl-201 BC2GM085517047 JJ O
defects BC2GM085517047 NNS O
. BC2GM085517047 . O
. . O O

It BC2GM033054784 PRP O
is BC2GM033054784 VBZ O
likely BC2GM033054784 JJ O
that BC2GM033054784 IN O
these BC2GM033054784 DT O
recordings BC2GM033054784 NNS O
are BC2GM033054784 VBP O
incomplete BC2GM033054784 JJ O
; BC2GM033054784 : O
the BC2GM033054784 DT O
actual BC2GM033054784 JJ O
number BC2GM033054784 NN O
of BC2GM033054784 IN O
activated BC2GM033054784 JJ O
neurons BC2GM033054784 NNS O
is BC2GM033054784 VBZ O
estimated BC2GM033054784 VBN O
to BC2GM033054784 TO O
be BC2GM033054784 VB O
about BC2GM033054784 RB O
300 BC2GM033054784 CD O
in BC2GM033054784 IN O
the BC2GM033054784 DT O
acutely BC2GM033054784 RB O
sensitized BC2GM033054784 JJ O
preparation BC2GM033054784 NN O
. BC2GM033054784 . O
. . O O

By BC2GM059603247 IN O
incorporating BC2GM059603247 VBG O
a BC2GM059603247 DT O
stent BC2GM059603247 NN O
with BC2GM059603247 IN O
posts BC2GM059603247 NNS O
that BC2GM059603247 WDT O
pivot BC2GM059603247 VBP O
about BC2GM059603247 IN O
their BC2GM059603247 PRP$ O
base BC2GM059603247 NN O
, BC2GM059603247 , O
such BC2GM059603247 JJ O
that BC2GM059603247 IN O
a BC2GM059603247 DT O
10 BC2GM059603247 CD O
% BC2GM059603247 NN O
expansion BC2GM059603247 NN O
at BC2GM059603247 IN O
the BC2GM059603247 DT O
commissures BC2GM059603247 NNS O
is BC2GM059603247 VBZ O
realized BC2GM059603247 VBN O
, BC2GM059603247 , O
we BC2GM059603247 PRP O
were BC2GM059603247 VBD O
able BC2GM059603247 JJ O
to BC2GM059603247 TO O
reduce BC2GM059603247 VB O
the BC2GM059603247 DT O
compressive BC2GM059603247 JJ O
commissural BC2GM059603247 JJ O
stressing BC2GM059603247 VBG O
from BC2GM059603247 IN O
250 BC2GM059603247 CD O
to BC2GM059603247 TO O
150 BC2GM059603247 CD O
kPa BC2GM059603247 NNS O
. BC2GM059603247 . O
. . O O

On BC2GM049036740 IN O
Western BC2GM049036740 JJ O
blots BC2GM049036740 NNS O
, BC2GM049036740 , O
the BC2GM049036740 DT O
same BC2GM049036740 JJ O
antibodies BC2GM049036740 NNS O
recognized BC2GM049036740 VBD O
the BC2GM049036740 DT O
recombinant BC2GM049036740 NN O
protein BC2GM049036740 NN O
migrating BC2GM049036740 VBG O
slightly BC2GM049036740 RB O
slower BC2GM049036740 JJR O
on BC2GM049036740 IN O
SDS BC2GM049036740 NNP O
/ BC2GM049036740 NNP O
PAGE BC2GM049036740 NNP O
than BC2GM049036740 IN O
chicken BC2GM049036740 VBN O
axonin-1 BC2GM049036740 NN O
. BC2GM049036740 . O
. . O O

Northern BC2GM054235351 NNP O
blot BC2GM054235351 NN O
analysis BC2GM054235351 NN O
demonstrated BC2GM054235351 VBD O
that BC2GM054235351 IN O
the BC2GM054235351 DT O
genes BC2GM054235351 NNS O
are BC2GM054235351 VBP O
transcribed BC2GM054235351 VBN O
separately BC2GM054235351 RB O
. BC2GM054235351 . O
. . O O

Structure BC2GM050351916 NN O
and BC2GM050351916 CC O
chromosomal BC2GM050351916 JJ O
localization BC2GM050351916 NN O
of BC2GM050351916 IN O
the BC2GM050351916 DT O
human BC2GM050351916 JJ O
gene BC2GM050351916 NN O
of BC2GM050351916 IN O
the BC2GM050351916 DT O
phosphotyrosyl BC2GM050351916 NN O
phosphatase BC2GM050351916 NN O
activator BC2GM050351916 NN O
( BC2GM050351916 ( O
PTPA BC2GM050351916 NNP O
) BC2GM050351916 ) O
of BC2GM050351916 IN O
protein BC2GM050351916 NN O
phosphatase BC2GM050351916 NN O
2A BC2GM050351916 CD O
. BC2GM050351916 . O
. . O O

Growth BC2GM070141070 NNP O
hormone BC2GM070141070 NN O
exerts BC2GM070141070 VBZ O
its BC2GM070141070 PRP$ O
effects BC2GM070141070 NNS O
on BC2GM070141070 IN O
the BC2GM070141070 DT O
ovarian BC2GM070141070 JJ O
follicular BC2GM070141070 JJ O
cycle BC2GM070141070 NN O
directly BC2GM070141070 RB O
or BC2GM070141070 CC O
by BC2GM070141070 IN O
local BC2GM070141070 JJ O
production BC2GM070141070 NN O
of BC2GM070141070 IN O
insulin-like BC2GM070141070 JJ O
growth BC2GM070141070 NN O
factor BC2GM070141070 NN O
1 BC2GM070141070 CD O
( BC2GM070141070 ( O
IGF-1 BC2GM070141070 NNP O
) BC2GM070141070 ) O
. BC2GM070141070 . O
. . O O

The BC2GM033441009 DT O
interaction BC2GM033441009 NN O
obtained BC2GM033441009 VBN O
with BC2GM033441009 IN O
DBM BC2GM033441009 NNP O
scores BC2GM033441009 NNS O
was BC2GM033441009 VBD O
further BC2GM033441009 RB O
qualified BC2GM033441009 VBN O
by BC2GM033441009 IN O
a BC2GM033441009 DT O
three-way BC2GM033441009 JJ O
interaction BC2GM033441009 NN O
that BC2GM033441009 WDT O
limited BC2GM033441009 VBD O
this BC2GM033441009 DT O
pattern BC2GM033441009 NN O
to BC2GM033441009 TO O
participants BC2GM033441009 NNS O
scoring BC2GM033441009 VBG O
higher BC2GM033441009 JJR O
on BC2GM033441009 IN O
self-deception BC2GM033441009 NN O
. BC2GM033441009 . O
. . O O

Providing BC2GM059988355 VBG O
appropriate BC2GM059988355 JJ O
care BC2GM059988355 NN O
to BC2GM059988355 TO O
both BC2GM059988355 DT O
sexes BC2GM059988355 NNS O
. BC2GM059988355 . O
. . O O

Id-1H BC2GM023938146 JJ O
and BC2GM023938146 CC O
Id-2H BC2GM023938146 JJ O
seem BC2GM023938146 NN O
to BC2GM023938146 TO O
be BC2GM023938146 VB O
human BC2GM023938146 JJ O
homologues BC2GM023938146 NNS O
of BC2GM023938146 IN O
mouse BC2GM023938146 NN O
Id-1 BC2GM023938146 NNP O
and BC2GM023938146 CC O
Id-2 BC2GM023938146 NNP O
, BC2GM023938146 , O
respectively BC2GM023938146 RB O
, BC2GM023938146 , O
and BC2GM023938146 CC O
have BC2GM023938146 VBP O
potential BC2GM023938146 VBN O
to BC2GM023938146 TO O
encode BC2GM023938146 VB O
154 BC2GM023938146 CD O
and BC2GM023938146 CC O
135 BC2GM023938146 CD O
amino BC2GM023938146 NN O
acid BC2GM023938146 NN O
proteins BC2GM023938146 NNS O
. BC2GM023938146 . O
. . O O

Progressive BC2GM016213373 JJ O
immunodeficiency BC2GM016213373 NN O
in BC2GM016213373 IN O
a BC2GM016213373 DT O
patient BC2GM016213373 NN O
with BC2GM016213373 IN O
IgA BC2GM016213373 NNP O
deficiency BC2GM016213373 NN O
. BC2GM016213373 . O
. . O O

From BC2GM063458894 IN O
1977 BC2GM063458894 CD O
to BC2GM063458894 TO O
1985 BC2GM063458894 CD O
, BC2GM063458894 , O
42 BC2GM063458894 CD O
patients BC2GM063458894 NNS O
with BC2GM063458894 IN O
squamous BC2GM063458894 JJ O
cell BC2GM063458894 NN O
carcinoma BC2GM063458894 NN O
of BC2GM063458894 IN O
the BC2GM063458894 DT O
anal BC2GM063458894 JJ O
canal BC2GM063458894 NN O
were BC2GM063458894 VBD O
treated BC2GM063458894 VBN O
with BC2GM063458894 IN O
mitomycin BC2GM063458894 JJ O
C BC2GM063458894 NNP O
( BC2GM063458894 ( O
15 BC2GM063458894 CD O
mg BC2GM063458894 NN O
/ BC2GM063458894 NNP O
m2 BC2GM063458894 NN O
) BC2GM063458894 ) O
and BC2GM063458894 CC O
5-fluorouracil BC2GM063458894 JJ O
( BC2GM063458894 ( O
750 BC2GM063458894 CD O
mg BC2GM063458894 NN O
/ BC2GM063458894 NNP O
m2 BC2GM063458894 NN O
) BC2GM063458894 ) O
on BC2GM063458894 IN O
day BC2GM063458894 NN O
1 BC2GM063458894 CD O
, BC2GM063458894 , O
5-FU BC2GM063458894 JJ O
( BC2GM063458894 ( O
750 BC2GM063458894 CD O
mg BC2GM063458894 NN O
/ BC2GM063458894 NNP O
m2 BC2GM063458894 NN O
/ BC2GM063458894 NNP O
d BC2GM063458894 NN O
) BC2GM063458894 ) O
alone BC2GM063458894 RB O
on BC2GM063458894 IN O
days BC2GM063458894 NNS O
2 BC2GM063458894 CD O
to BC2GM063458894 TO O
5 BC2GM063458894 CD O
, BC2GM063458894 , O
and BC2GM063458894 CC O
radiation BC2GM063458894 NN O
therapy BC2GM063458894 NN O
( BC2GM063458894 ( O
3000 BC2GM063458894 CD O
cGy BC2GM063458894 NN O
) BC2GM063458894 ) O
on BC2GM063458894 IN O
days BC2GM063458894 NNS O
7 BC2GM063458894 CD O
to BC2GM063458894 TO O
28 BC2GM063458894 CD O
. BC2GM063458894 . O
. . O O

Changes BC2GM007167261 NNS O
in BC2GM007167261 IN O
BHR BC2GM007167261 NNP O
were BC2GM007167261 VBD O
found BC2GM007167261 VBN O
to BC2GM007167261 TO O
correlate BC2GM007167261 VB O
significantly BC2GM007167261 RB O
with BC2GM007167261 IN O
changes BC2GM007167261 NNS O
in BC2GM007167261 IN O
the BC2GM007167261 DT O
levels BC2GM007167261 NNS O
of BC2GM007167261 IN O
24 BC2GM007167261 CD O
h BC2GM007167261 JJ O
mean BC2GM007167261 JJ O
SO2 BC2GM007167261 NNP O
, BC2GM007167261 , O
NO2 BC2GM007167261 NNP O
and BC2GM007167261 CC O
smoke BC2GM007167261 VBD O
; BC2GM007167261 : O
48 BC2GM007167261 CD O
h BC2GM007167261 NN O
mean BC2GM007167261 JJ O
NO2 BC2GM007167261 NNP O
and BC2GM007167261 CC O
smoke BC2GM007167261 VBD O
; BC2GM007167261 : O
24 BC2GM007167261 CD O
h BC2GM007167261 NN O
lag BC2GM007167261 NN O
NO2 BC2GM007167261 NNP O
; BC2GM007167261 : O
although BC2GM007167261 IN O
the BC2GM007167261 DT O
effect BC2GM007167261 NN O
was BC2GM007167261 VBD O
only BC2GM007167261 RB O
small BC2GM007167261 JJ O
, BC2GM007167261 , O
accounting BC2GM007167261 VBG O
for BC2GM007167261 IN O
approximately BC2GM007167261 RB O
10 BC2GM007167261 CD O
% BC2GM007167261 NN O
of BC2GM007167261 IN O
the BC2GM007167261 DT O
variability BC2GM007167261 NN O
in BC2GM007167261 IN O
within-subject BC2GM007167261 JJ O
BHR BC2GM007167261 NNP O
between BC2GM007167261 IN O
visits BC2GM007167261 NNS O
. BC2GM007167261 . O
. . O O

Central BC2GM005581370 JJ O
projections BC2GM005581370 NNS O
of BC2GM005581370 IN O
gastric BC2GM005581370 JJ O
afferent BC2GM005581370 JJ O
vagal BC2GM005581370 NN O
inputs BC2GM005581370 NNS O
. BC2GM005581370 . O
. . O O

NSAIDS BC2GM093870796 NNP O
and BC2GM093870796 CC O
the BC2GM093870796 DT O
microcirculation BC2GM093870796 NN O
of BC2GM093870796 IN O
the BC2GM093870796 DT O
stomach BC2GM093870796 NN O
. BC2GM093870796 . O
. . O O

In BC2GM046011623 IN O
three BC2GM046011623 CD O
other BC2GM046011623 JJ O
patients BC2GM046011623 NNS O
the BC2GM046011623 DT O
electrophysiologic BC2GM046011623 JJ O
characteristics BC2GM046011623 NNS O
of BC2GM046011623 IN O
atrioventricular BC2GM046011623 JJ O
conduction BC2GM046011623 NN O
prevented BC2GM046011623 VBD O
a BC2GM046011623 DT O
demonstration BC2GM046011623 NN O
of BC2GM046011623 IN O
these BC2GM046011623 DT O
differences BC2GM046011623 NNS O
. BC2GM046011623 . O
. . O O

The BC2GM015147115 DT O
cloned BC2GM015147115 JJ O
rRNA BC2GM015147115 NN O
operon BC2GM015147115 NN O
was BC2GM015147115 VBD O
transcribed BC2GM015147115 VBN O
in BC2GM015147115 IN O
vitro BC2GM015147115 NN O
by BC2GM015147115 IN O
using BC2GM015147115 VBG O
purified BC2GM015147115 JJ O
RNA BC2GM015147115 NNP O
polymerase BC2GM015147115 NN O
of BC2GM015147115 IN O
Escherichia BC2GM015147115 NNP O
coli BC2GM015147115 NN O
. BC2GM015147115 . O
. . O O

K BC2GM037830517 NNP O
. BC2GM037830517 . O
. . O O

The BC2GM002743419 DT O
concentration BC2GM002743419 NN O
of BC2GM002743419 IN O
vitamin BC2GM002743419 NN O
B1 BC2GM002743419 NNP O
, BC2GM002743419 , O
B2 BC2GM002743419 NNP O
and BC2GM002743419 CC O
B6 BC2GM002743419 NNP O
are BC2GM002743419 VBP O
found BC2GM002743419 VBN O
to BC2GM002743419 TO O
be BC2GM002743419 VB O
9.96 BC2GM002743419 CD O
, BC2GM002743419 , O
9.92 BC2GM002743419 CD O
and BC2GM002743419 CC O
3.01 BC2GM002743419 CD O
mg BC2GM002743419 NN O
, BC2GM002743419 , O
respectively BC2GM002743419 RB O
in BC2GM002743419 IN O
240 BC2GM002743419 CD O
mg BC2GM002743419 NN O
of BC2GM002743419 IN O
capsule BC2GM002743419 NN O
powder BC2GM002743419 NN O
of BC2GM002743419 IN O
a BC2GM002743419 DT O
standard BC2GM002743419 JJ O
company BC2GM002743419 NN O
( BC2GM002743419 ( O
name BC2GM002743419 NN O
has BC2GM002743419 VBZ O
not BC2GM002743419 RB O
been BC2GM002743419 VBN O
disclosed BC2GM002743419 VBN O
due BC2GM002743419 JJ O
to BC2GM002743419 TO O
secrecy BC2GM002743419 VB O
purpose BC2GM002743419 NN O
) BC2GM002743419 ) O
. BC2GM002743419 . O
. . O O

Rhinovirus BC2GM023199646 NNP O
2A BC2GM023199646 CD O
protease BC2GM023199646 NN O
and BC2GM023199646 CC O
foot-and-mouth-disease BC2GM023199646 JJ O
virus BC2GM023199646 NN O
L BC2GM023199646 NNP O
protease BC2GM023199646 NN O
were BC2GM023199646 VBD O
used BC2GM023199646 VBN O
to BC2GM023199646 TO O
analyze BC2GM023199646 VB O
the BC2GM023199646 DT O
association BC2GM023199646 NN O
of BC2GM023199646 IN O
eIF4G BC2GM023199646 NN O
with BC2GM023199646 IN O
eIF4A BC2GM023199646 NN O
, BC2GM023199646 , O
eIF4E BC2GM023199646 NN O
, BC2GM023199646 , O
and BC2GM023199646 CC O
eIF3 BC2GM023199646 NN O
. BC2GM023199646 . O
. . O O

MAPKK BC2GM090642348 NNP O
kinase BC2GM090642348 NN O
/ BC2GM090642348 NNP O
MEKK BC2GM090642348 NNP O
phosphorylates BC2GM090642348 NNS O
and BC2GM090642348 CC O
activates BC2GM090642348 VBZ O
its BC2GM090642348 PRP$ O
downstream BC2GM090642348 NN O
protein BC2GM090642348 NN O
kinase BC2GM090642348 NN O
, BC2GM090642348 , O
MAPK BC2GM090642348 NNP O
kinase BC2GM090642348 NNP O
/ BC2GM090642348 NNP O
MEK BC2GM090642348 NNP O
, BC2GM090642348 , O
which BC2GM090642348 WDT O
in BC2GM090642348 IN O
turn BC2GM090642348 NN O
activates BC2GM090642348 NNS O
MAPK BC2GM090642348 NNP O
. BC2GM090642348 . O
. . O O

These BC2GM020095584 DT O
results BC2GM020095584 NNS O
demonstrate BC2GM020095584 VBP O
that BC2GM020095584 IN O
GGTase-I BC2GM020095584 NNP O
inhibitors BC2GM020095584 NNS O
arrest BC2GM020095584 VBP O
cells BC2GM020095584 NNS O
in BC2GM020095584 IN O
G0 BC2GM020095584 NNP O
/ BC2GM020095584 NNP O
G1 BC2GM020095584 NNP O
and BC2GM020095584 CC O
induce BC2GM020095584 VB O
accumulation BC2GM020095584 NN O
of BC2GM020095584 IN O
p21WAF BC2GM020095584 NN O
in BC2GM020095584 IN O
a BC2GM020095584 DT O
p53-independent BC2GM020095584 JJ O
manner BC2GM020095584 NN O
and BC2GM020095584 CC O
that BC2GM020095584 IN O
FTase BC2GM020095584 NNP O
inhibitors BC2GM020095584 NNS O
can BC2GM020095584 MD O
interfere BC2GM020095584 VB O
with BC2GM020095584 IN O
cell BC2GM020095584 NN O
cycle BC2GM020095584 NN O
events BC2GM020095584 NNS O
by BC2GM020095584 IN O
a BC2GM020095584 DT O
mechanism BC2GM020095584 NN O
that BC2GM020095584 WDT O
involves BC2GM020095584 VBZ O
neither BC2GM020095584 DT O
p21WAF BC2GM020095584 NN O
nor BC2GM020095584 CC O
p27KIP BC2GM020095584 NN O
. BC2GM020095584 . O
. . O O

The BC2GM032669155 DT O
method BC2GM032669155 NN O
was BC2GM032669155 VBD O
tested BC2GM032669155 VBN O
on BC2GM032669155 IN O
7 BC2GM032669155 CD O
rats BC2GM032669155 NNS O
with BC2GM032669155 IN O
48-hr-old BC2GM032669155 JJ O
myocardial BC2GM032669155 JJ O
infarction BC2GM032669155 NN O
and BC2GM032669155 CC O
4 BC2GM032669155 CD O
sham-operated BC2GM032669155 JJ O
controls BC2GM032669155 NNS O
. BC2GM032669155 . O
. . O O

( BC2GM056026890 ( O
i BC2GM056026890 NN O
) BC2GM056026890 ) O
Several BC2GM056026890 NNP O
ribosomal BC2GM056026890 JJ O
proteins BC2GM056026890 NNS O
were BC2GM056026890 VBD O
synthesized BC2GM056026890 VBN O
in BC2GM056026890 IN O
substantial BC2GM056026890 JJ O
excess BC2GM056026890 NN O
. BC2GM056026890 . O
. . O O

New BC2GM049617857 NNP O
strategies BC2GM049617857 NNS O
are BC2GM049617857 VBP O
needed BC2GM049617857 VBN O
to BC2GM049617857 TO O
prevent BC2GM049617857 VB O
coronary BC2GM049617857 JJ O
rethrombosis BC2GM049617857 NN O
in BC2GM049617857 IN O
patients BC2GM049617857 NNS O
with BC2GM049617857 IN O
minimal BC2GM049617857 JJ O
atherosclerosis BC2GM049617857 NN O
after BC2GM049617857 IN O
thrombolytic BC2GM049617857 JJ O
therapy BC2GM049617857 NN O
for BC2GM049617857 IN O
acute BC2GM049617857 JJ O
myocardial BC2GM049617857 JJ O
infarction BC2GM049617857 NN O
. BC2GM049617857 . O
. . O O

Six BC2GM026991147 CD O
patients BC2GM026991147 NNS O
( BC2GM026991147 ( O
24 BC2GM026991147 CD O
% BC2GM026991147 NN O
) BC2GM026991147 ) O
developed BC2GM026991147 VBD O
sepsis BC2GM026991147 NN O
and BC2GM026991147 CC O
only BC2GM026991147 RB O
one BC2GM026991147 CD O
survived BC2GM026991147 VBD O
. BC2GM026991147 . O
. . O O

The BC2GM078878267 DT O
aetiology BC2GM078878267 NN O
and BC2GM078878267 CC O
management BC2GM078878267 NN O
of BC2GM078878267 IN O
diabetic BC2GM078878267 JJ O
impotence BC2GM078878267 NN O
is BC2GM078878267 VBZ O
well-documented BC2GM078878267 JJ O
; BC2GM078878267 : O
the BC2GM078878267 DT O
effects BC2GM078878267 NNS O
of BC2GM078878267 IN O
diabetes BC2GM078878267 NNS O
on BC2GM078878267 IN O
female BC2GM078878267 JJ O
sexuality BC2GM078878267 NN O
are BC2GM078878267 VBP O
not BC2GM078878267 RB O
so BC2GM078878267 RB O
clear BC2GM078878267 JJ O
. BC2GM078878267 . O
. . O O

3 BC2GM009964186 CD O
. BC2GM009964186 . O
. . O O

A BC2GM085924161 DT O
mouth BC2GM085924161 NN O
asymmetry BC2GM085924161 NN O
study BC2GM085924161 NN O
. BC2GM085924161 . O
. . O O

Mean BC2GM019595321 JJ O
concentration BC2GM019595321 NN O
of BC2GM019595321 IN O
insulin BC2GM019595321 NN O
in BC2GM019595321 IN O
maternal BC2GM019595321 JJ O
plasma BC2GM019595321 NN O
across BC2GM019595321 IN O
all BC2GM019595321 DT O
sampling BC2GM019595321 VBG O
times BC2GM019595321 NNS O
was BC2GM019595321 VBD O
higher BC2GM019595321 RBR O
in BC2GM019595321 IN O
ethanol BC2GM019595321 RB O
treated BC2GM019595321 VBN O
animals BC2GM019595321 NNS O
. BC2GM019595321 . O
. . O O

The BC2GM031563114 DT O
related BC2GM031563114 JJ O
adhesion BC2GM031563114 NN O
focal BC2GM031563114 JJ O
tyrosine BC2GM031563114 NN O
kinase BC2GM031563114 NN O
is BC2GM031563114 VBZ O
tyrosine-phosphorylated BC2GM031563114 JJ O
after BC2GM031563114 IN O
beta1-integrin BC2GM031563114 JJ O
stimulation BC2GM031563114 NN O
in BC2GM031563114 IN O
B BC2GM031563114 NNP O
cells BC2GM031563114 NNS O
and BC2GM031563114 CC O
binds BC2GM031563114 NNS O
to BC2GM031563114 TO O
p130cas BC2GM031563114 VB O
. BC2GM031563114 . O
. . O O

Here BC2GM071527942 RB O
we BC2GM071527942 PRP O
report BC2GM071527942 VBP O
that BC2GM071527942 DT O
point BC2GM071527942 NN O
mutations BC2GM071527942 NNS O
of BC2GM071527942 IN O
the BC2GM071527942 DT O
Abd-B BC2GM071527942 NNP O
gene BC2GM071527942 NN O
in BC2GM071527942 IN O
trans BC2GM071527942 NNS O
suppress BC2GM071527942 VBP O
the BC2GM071527942 DT O
Fab-7 BC2GM071527942 NNP O
phenotype BC2GM071527942 NN O
in BC2GM071527942 IN O
a BC2GM071527942 DT O
pairing-dependent BC2GM071527942 JJ O
manner BC2GM071527942 NN O
and BC2GM071527942 CC O
thus BC2GM071527942 RB O
represent BC2GM071527942 VB O
a BC2GM071527942 DT O
type BC2GM071527942 NN O
of BC2GM071527942 IN O
transvection BC2GM071527942 NN O
. BC2GM071527942 . O
. . O O

Development BC2GM058599775 NNP O
of BC2GM058599775 IN O
neural BC2GM058599775 JJ O
control BC2GM058599775 NN O
of BC2GM058599775 IN O
alimentary BC2GM058599775 JJ O
motor BC2GM058599775 NN O
function BC2GM058599775 NN O
in BC2GM058599775 IN O
the BC2GM058599775 DT O
vertebrates BC2GM058599775 NNS O
. BC2GM058599775 . O
. . O O

We BC2GM044080615 PRP O
suggest BC2GM044080615 VBP O
that BC2GM044080615 IN O
the BC2GM044080615 DT O
induction BC2GM044080615 NN O
of BC2GM044080615 IN O
IFNA BC2GM044080615 NNP O
promoter BC2GM044080615 NN O
region BC2GM044080615 NN O
requires BC2GM044080615 VBZ O
cooperation BC2GM044080615 NN O
between BC2GM044080615 IN O
alpha BC2GM044080615 JJ O
F1 BC2GM044080615 NNP O
binding BC2GM044080615 NN O
proteins BC2GM044080615 NNS O
and BC2GM044080615 CC O
IRF-1 BC2GM044080615 NNP O
. BC2GM044080615 . O
. . O O

S1 BC2GM037899934 NNP O
nuclease BC2GM037899934 JJ O
analysis BC2GM037899934 NN O
of BC2GM037899934 IN O
the BC2GM037899934 DT O
RNA BC2GM037899934 NNP O
from BC2GM037899934 IN O
a BC2GM037899934 DT O
number BC2GM037899934 NN O
of BC2GM037899934 IN O
QT6-LD BC2GM037899934 NNP O
clones BC2GM037899934 NNS O
gave BC2GM037899934 VBD O
similar BC2GM037899934 JJ O
results BC2GM037899934 NNS O
, BC2GM037899934 , O
indicating BC2GM037899934 VBG O
that BC2GM037899934 IN O
the BC2GM037899934 DT O
LD BC2GM037899934 NNP O
population BC2GM037899934 NN O
was BC2GM037899934 VBD O
composed BC2GM037899934 VBN O
of BC2GM037899934 IN O
viruses BC2GM037899934 NNS O
with BC2GM037899934 IN O
similar BC2GM037899934 JJ O
but BC2GM037899934 CC O
not BC2GM037899934 RB O
identical BC2GM037899934 JJ O
deletion BC2GM037899934 NN O
endpoints BC2GM037899934 NNS O
. BC2GM037899934 . O
. . O O

The BC2GM026606071 DT O
effects BC2GM026606071 NNS O
of BC2GM026606071 IN O
cefazolin BC2GM026606071 NN O
, BC2GM026606071 , O
given BC2GM026606071 VBN O
into BC2GM026606071 IN O
the BC2GM026606071 DT O
III BC2GM026606071 NNP O
cerebral BC2GM026606071 JJ O
ventricle BC2GM026606071 NN O
at BC2GM026606071 IN O
different BC2GM026606071 JJ O
doses BC2GM026606071 NNS O
were BC2GM026606071 VBD O
studied BC2GM026606071 VBN O
on BC2GM026606071 IN O
GABA BC2GM026606071 NNP O
content BC2GM026606071 NN O
, BC2GM026606071 , O
GAD BC2GM026606071 NNP O
and BC2GM026606071 CC O
GABA-T BC2GM026606071 NNP O
in BC2GM026606071 IN O
the BC2GM026606071 DT O
brain-stem BC2GM026606071 NN O
of BC2GM026606071 IN O
young BC2GM026606071 JJ O
chickens BC2GM026606071 NNS O
( BC2GM026606071 ( O
Gallus BC2GM026606071 NNP O
domesticus BC2GM026606071 NN O
) BC2GM026606071 ) O
. BC2GM026606071 . O
. . O O

In BC2GM004916804 IN O
order BC2GM004916804 NN O
to BC2GM004916804 TO O
search BC2GM004916804 VB O
for BC2GM004916804 IN O
mutations BC2GM004916804 NNS O
in BC2GM004916804 IN O
the BC2GM004916804 DT O
multicopy BC2GM004916804 NN O
RBM BC2GM004916804 NNP O
genes BC2GM004916804 NNS O
that BC2GM004916804 WDT O
might BC2GM004916804 MD O
be BC2GM004916804 VB O
associated BC2GM004916804 VBN O
with BC2GM004916804 IN O
male BC2GM004916804 JJ O
infertility BC2GM004916804 NN O
, BC2GM004916804 , O
we BC2GM004916804 PRP O
have BC2GM004916804 VBP O
used BC2GM004916804 VBN O
sequence BC2GM004916804 NN O
data BC2GM004916804 NNS O
from BC2GM004916804 IN O
the BC2GM004916804 DT O
reported BC2GM004916804 VBN O
cDNA BC2GM004916804 NN O
clone BC2GM004916804 NN O
to BC2GM004916804 TO O
determine BC2GM004916804 VB O
the BC2GM004916804 DT O
intron BC2GM004916804 NN O
exon BC2GM004916804 NN O
boundaries BC2GM004916804 NNS O
of BC2GM004916804 IN O
the BC2GM004916804 DT O
YRRM BC2GM004916804 NNP O
1 BC2GM004916804 CD O
gene BC2GM004916804 NN O
. BC2GM004916804 . O
. . O O

A BC2GM000816003 DT O
clinical BC2GM000816003 JJ O
study BC2GM000816003 NN O
. BC2GM000816003 . O
. . O O

Cloning BC2GM014250094 VBG O
the BC2GM014250094 DT O
cDNA BC2GM014250094 NN O
for BC2GM014250094 IN O
a BC2GM014250094 DT O
new BC2GM014250094 JJ O
human BC2GM014250094 JJ O
zinc BC2GM014250094 NN O
finger BC2GM014250094 NN O
protein BC2GM014250094 NN O
defines BC2GM014250094 VBZ O
a BC2GM014250094 DT O
group BC2GM014250094 NN O
of BC2GM014250094 IN O
closely BC2GM014250094 RB O
related BC2GM014250094 JJ O
Kruppel-like BC2GM014250094 JJ O
transcription BC2GM014250094 NN O
factors BC2GM014250094 NNS O
. BC2GM014250094 . O
. . O O

Relaxant BC2GM095367875 JJ O
effect BC2GM095367875 NN O
of BC2GM095367875 IN O
prostaglandin BC2GM095367875 NN O
E1 BC2GM095367875 NNP O
( BC2GM095367875 ( O
PGE1 BC2GM095367875 NNP O
) BC2GM095367875 ) O
and BC2GM095367875 CC O
papaverine BC2GM095367875 NN O
( BC2GM095367875 ( O
PAP BC2GM095367875 NNP O
) BC2GM095367875 ) O
were BC2GM095367875 VBD O
measured BC2GM095367875 VBN O
in BC2GM095367875 IN O
strips BC2GM095367875 NNS O
of BC2GM095367875 IN O
corpus BC2GM095367875 NN O
cavernosum BC2GM095367875 NN O
smooth BC2GM095367875 JJ O
muscle BC2GM095367875 NN O
taken BC2GM095367875 VBN O
from BC2GM095367875 IN O
a BC2GM095367875 DT O
healthy BC2GM095367875 JJ O
control BC2GM095367875 NN O
group BC2GM095367875 NN O
of BC2GM095367875 IN O
men BC2GM095367875 NNS O
( BC2GM095367875 ( O
A BC2GM095367875 DT O
; BC2GM095367875 : O
n BC2GM095367875 CC O
= BC2GM095367875 VB O
5 BC2GM095367875 CD O
) BC2GM095367875 ) O
, BC2GM095367875 , O
from BC2GM095367875 IN O
arteriogenically BC2GM095367875 RB O
impotent BC2GM095367875 JJ O
men BC2GM095367875 NNS O
( BC2GM095367875 ( O
B BC2GM095367875 NNP O
; BC2GM095367875 : O
n BC2GM095367875 CC O
= BC2GM095367875 VB O
6 BC2GM095367875 CD O
) BC2GM095367875 ) O
and BC2GM095367875 CC O
from BC2GM095367875 IN O
additionally BC2GM095367875 RB O
diabetic BC2GM095367875 JJ O
impotent BC2GM095367875 NN O
men BC2GM095367875 NNS O
( BC2GM095367875 ( O
C BC2GM095367875 NNP O
; BC2GM095367875 : O
n BC2GM095367875 CC O
= BC2GM095367875 VB O
5 BC2GM095367875 CD O
) BC2GM095367875 ) O
with BC2GM095367875 IN O
venous BC2GM095367875 JJ O
leakage BC2GM095367875 NN O
. BC2GM095367875 . O
. . O O

Hpr1 BC2GM080331933 NNP O
forms BC2GM080331933 NNS O
, BC2GM080331933 , O
together BC2GM080331933 RB O
with BC2GM080331933 IN O
Tho2 BC2GM080331933 NNP O
, BC2GM080331933 , O
Mft1 BC2GM080331933 NNP O
, BC2GM080331933 , O
and BC2GM080331933 CC O
Thp2 BC2GM080331933 NNP O
, BC2GM080331933 , O
the BC2GM080331933 DT O
THO BC2GM080331933 NNP O
complex BC2GM080331933 NN O
, BC2GM080331933 , O
which BC2GM080331933 WDT O
controls BC2GM080331933 VBZ O
transcription BC2GM080331933 NN O
elongation BC2GM080331933 NN O
and BC2GM080331933 CC O
genome BC2GM080331933 JJ O
stability BC2GM080331933 NN O
in BC2GM080331933 IN O
Saccharomyces BC2GM080331933 NNP O
cerevisiae BC2GM080331933 NN O
. BC2GM080331933 . O
. . O O

Serum BC2GM022393515 NNP O
alkaline BC2GM022393515 JJ O
phosphatase BC2GM022393515 NN O
and BC2GM022393515 CC O
creatine BC2GM022393515 JJ O
kinase BC2GM022393515 NN O
activities BC2GM022393515 NNS O
were BC2GM022393515 VBD O
significantly BC2GM022393515 RB O
increased BC2GM022393515 VBN O
in BC2GM022393515 IN O
the BC2GM022393515 DT O
A BC2GM022393515 NNP O
praelongus-fed BC2GM022393515 JJ O
pigs BC2GM022393515 NNS O
and BC2GM022393515 CC O
significantly BC2GM022393515 RB O
decreased BC2GM022393515 VBN O
in BC2GM022393515 IN O
Na2SeO4-fed BC2GM022393515 NNP O
pigs BC2GM022393515 NNS O
. BC2GM022393515 . O
. . O O

This BC2GM015232187 DT O
was BC2GM015232187 VBD O
further BC2GM015232187 RBR O
suggested BC2GM015232187 VBN O
by BC2GM015232187 IN O
transactivation BC2GM015232187 NN O
assays BC2GM015232187 NNS O
in BC2GM015232187 IN O
which BC2GM015232187 WDT O
mouse BC2GM015232187 NN O
fibroblasts BC2GM015232187 NNS O
were BC2GM015232187 VBD O
transiently BC2GM015232187 RB O
transfected BC2GM015232187 VBN O
with BC2GM015232187 IN O
a BC2GM015232187 DT O
human BC2GM015232187 JJ O
beta-globin BC2GM015232187 JJ O
reporter BC2GM015232187 NN O
gene BC2GM015232187 NN O
in BC2GM015232187 IN O
the BC2GM015232187 DT O
absence BC2GM015232187 NN O
and BC2GM015232187 CC O
presence BC2GM015232187 NN O
of BC2GM015232187 IN O
an BC2GM015232187 DT O
LKLF BC2GM015232187 NNP O
cDNA BC2GM015232187 NN O
construct BC2GM015232187 NN O
. BC2GM015232187 . O
. . O O

METHODS BC2GM004656785 NNP O
AND BC2GM004656785 CC O
RESULTS BC2GM004656785 NNP O
: BC2GM004656785 : O
The BC2GM004656785 DT O
effect BC2GM004656785 NN O
of BC2GM004656785 IN O
prolonged BC2GM004656785 JJ O
nitrate BC2GM004656785 JJ O
therapy BC2GM004656785 NN O
between BC2GM004656785 IN O
2 BC2GM004656785 CD O
days BC2GM004656785 NNS O
and BC2GM004656785 CC O
6 BC2GM004656785 CD O
weeks BC2GM004656785 NNS O
during BC2GM004656785 IN O
healing BC2GM004656785 VBG O
after BC2GM004656785 IN O
infarction BC2GM004656785 NN O
on BC2GM004656785 IN O
serial BC2GM004656785 JJ O
parameters BC2GM004656785 NNS O
of BC2GM004656785 IN O
ventricular BC2GM004656785 JJ O
remodeling BC2GM004656785 NN O
( BC2GM004656785 ( O
scar BC2GM004656785 JJ O
expansion BC2GM004656785 NN O
, BC2GM004656785 , O
scar BC2GM004656785 NN O
thinning BC2GM004656785 NN O
, BC2GM004656785 , O
ventricular BC2GM004656785 JJ O
dilation BC2GM004656785 NN O
, BC2GM004656785 , O
and BC2GM004656785 CC O
hypertrophy BC2GM004656785 NN O
) BC2GM004656785 ) O
and BC2GM004656785 CC O
function BC2GM004656785 NN O
( BC2GM004656785 ( O
asynergy BC2GM004656785 JJ O
or BC2GM004656785 CC O
akinesis BC2GM004656785 JJ O
plus BC2GM004656785 CC O
dyskinesis BC2GM004656785 NN O
and BC2GM004656785 CC O
ejection BC2GM004656785 NN O
fraction BC2GM004656785 NN O
) BC2GM004656785 ) O
by BC2GM004656785 IN O
serial BC2GM004656785 JJ O
two-dimensional BC2GM004656785 JJ O
echocardiography BC2GM004656785 NN O
, BC2GM004656785 , O
hemodynamics BC2GM004656785 NNS O
, BC2GM004656785 , O
postmortem BC2GM004656785 NN O
topography BC2GM004656785 NN O
( BC2GM004656785 ( O
computerized BC2GM004656785 JJ O
planimetry BC2GM004656785 NN O
, BC2GM004656785 , O
geometric BC2GM004656785 JJ O
maps BC2GM004656785 NNS O
, BC2GM004656785 , O
and BC2GM004656785 CC O
radiographs BC2GM004656785 NN O
) BC2GM004656785 ) O
, BC2GM004656785 , O
and BC2GM004656785 CC O
collagen BC2GM004656785 NN O
content BC2GM004656785 NN O
( BC2GM004656785 ( O
hydroxyproline BC2GM004656785 NN O
) BC2GM004656785 ) O
was BC2GM004656785 VBD O
studied BC2GM004656785 VBN O
in BC2GM004656785 IN O
64 BC2GM004656785 CD O
instrumented BC2GM004656785 JJ O
dogs BC2GM004656785 NNS O
randomized BC2GM004656785 VBD O
2 BC2GM004656785 CD O
days BC2GM004656785 NNS O
after BC2GM004656785 IN O
left BC2GM004656785 JJ O
anterior BC2GM004656785 JJ O
descending BC2GM004656785 VBG O
coronary BC2GM004656785 JJ O
artery BC2GM004656785 NN O
ligation BC2GM004656785 NN O
to BC2GM004656785 TO O
various BC2GM004656785 JJ O
nitrate BC2GM004656785 JJ O
regimens BC2GM004656785 NNS O
( BC2GM004656785 ( O
n BC2GM004656785 JJ O
= BC2GM004656785 NNP O
32 BC2GM004656785 CD O
) BC2GM004656785 ) O
over BC2GM004656785 IN O
the BC2GM004656785 DT O
first BC2GM004656785 JJ O
2 BC2GM004656785 CD O
weeks BC2GM004656785 NNS O
( BC2GM004656785 ( O
subgroup BC2GM004656785 JJ O
1 BC2GM004656785 CD O
: BC2GM004656785 : O
2 BC2GM004656785 CD O
% BC2GM004656785 NN O
transdermal BC2GM004656785 JJ O
nitroglycerin BC2GM004656785 NN O
at BC2GM004656785 IN O
8 BC2GM004656785 CD O
AM BC2GM004656785 NNP O
and BC2GM004656785 CC O
4 BC2GM004656785 CD O
PM BC2GM004656785 NNP O
, BC2GM004656785 , O
n BC2GM004656785 JJ O
= BC2GM004656785 VBP O
6 BC2GM004656785 CD O
; BC2GM004656785 : O
subgroup BC2GM004656785 CC O
2 BC2GM004656785 CD O
: BC2GM004656785 : O
2 BC2GM004656785 CD O
% BC2GM004656785 NN O
transdermal BC2GM004656785 JJ O
nitroglycerin BC2GM004656785 JJ O
plus BC2GM004656785 CC O
2.6 BC2GM004656785 CD O
mg BC2GM004656785 NN O
of BC2GM004656785 IN O
sustained-release BC2GM004656785 JJ O
oral BC2GM004656785 JJ O
nitroglycerin BC2GM004656785 NN O
at BC2GM004656785 IN O
8 BC2GM004656785 CD O
AM BC2GM004656785 NNP O
, BC2GM004656785 , O
3 BC2GM004656785 CD O
PM BC2GM004656785 NNP O
, BC2GM004656785 , O
and BC2GM004656785 CC O
10 BC2GM004656785 CD O
PM BC2GM004656785 NNP O
, BC2GM004656785 , O
n BC2GM004656785 JJ O
= BC2GM004656785 VBP O
5 BC2GM004656785 CD O
; BC2GM004656785 : O
subgroup BC2GM004656785 CC O
3 BC2GM004656785 CD O
: BC2GM004656785 : O
oral BC2GM004656785 JJ O
isosorbide BC2GM004656785 NN O
dinitrate BC2GM004656785 NN O
, BC2GM004656785 , O
30 BC2GM004656785 CD O
mg BC2GM004656785 NN O
at BC2GM004656785 IN O
8 BC2GM004656785 CD O
AM BC2GM004656785 NNP O
and BC2GM004656785 CC O
4 BC2GM004656785 CD O
PM BC2GM004656785 NNP O
, BC2GM004656785 , O
n BC2GM004656785 JJ O
= BC2GM004656785 NNP O
11 BC2GM004656785 CD O
) BC2GM004656785 ) O
or BC2GM004656785 CC O
6 BC2GM004656785 CD O
weeks BC2GM004656785 NNS O
( BC2GM004656785 ( O
subgroup BC2GM004656785 JJ O
4 BC2GM004656785 CD O
: BC2GM004656785 : O
isosorbide BC2GM004656785 NN O
dinitrate BC2GM004656785 NN O
, BC2GM004656785 , O
n BC2GM004656785 JJ O
= BC2GM004656785 NNP O
10 BC2GM004656785 CD O
) BC2GM004656785 ) O
and BC2GM004656785 CC O
in BC2GM004656785 IN O
matching BC2GM004656785 VBG O
controls BC2GM004656785 NNS O
( BC2GM004656785 ( O
n BC2GM004656785 JJ O
= BC2GM004656785 NNP O
32 BC2GM004656785 CD O
) BC2GM004656785 ) O
. BC2GM004656785 . O
. . O O

Similar BC2GM085081988 JJ O
immunological BC2GM085081988 JJ O
disturbances BC2GM085081988 NNS O
were BC2GM085081988 VBD O
observed BC2GM085081988 VBN O
in BC2GM085081988 IN O
SCI BC2GM085081988 NNP O
but BC2GM085081988 CC O
not BC2GM085081988 RB O
in BC2GM085081988 IN O
the BC2GM085081988 DT O
PC2 BC2GM085081988 NNP O
subgroup BC2GM085081988 NN O
, BC2GM085081988 , O
i.e BC2GM085081988 NN O
. BC2GM085081988 . O
patients BC2GM085081988 NNS O
examined BC2GM085081988 VBD O
later BC2GM085081988 RB O
than BC2GM085081988 IN O
6 BC2GM085081988 CD O
months BC2GM085081988 NNS O
after BC2GM085081988 IN O
injury BC2GM085081988 NN O
. BC2GM085081988 . O
. . O O

METHODS BC2GM092790663 NNP O
. BC2GM092790663 . O
. . O O

Nramp2 BC2GM018506059 NNP O
contains BC2GM018506059 VBZ O
a BC2GM018506059 DT O
classical BC2GM018506059 JJ O
iron BC2GM018506059 NN O
responsive BC2GM018506059 JJ O
element BC2GM018506059 NN O
in BC2GM018506059 IN O
the BC2GM018506059 DT O
3 BC2GM018506059 CD O
' BC2GM018506059 POS O
untranslated BC2GM018506059 JJ O
region BC2GM018506059 NN O
that BC2GM018506059 IN O
confers BC2GM018506059 NNS O
iron BC2GM018506059 VBP O
dependent BC2GM018506059 JJ O
mRNA BC2GM018506059 NN O
stabilization BC2GM018506059 NN O
. BC2GM018506059 . O
. . O O

Ptx1 BC2GM021306881 NNP O
belongs BC2GM021306881 VBZ O
to BC2GM021306881 TO O
an BC2GM021306881 DT O
expanding BC2GM021306881 VBG O
family BC2GM021306881 NN O
of BC2GM021306881 IN O
bicoid-related BC2GM021306881 JJ O
vertebrate BC2GM021306881 NN O
homeobox BC2GM021306881 NN O
genes BC2GM021306881 NNS O
. BC2GM021306881 . O
. . O O

Activity BC2GM056965108 NN O
was BC2GM056965108 VBD O
reconstituted BC2GM056965108 VBN O
, BC2GM056965108 , O
however BC2GM056965108 RB O
, BC2GM056965108 , O
by BC2GM056965108 IN O
combining BC2GM056965108 VBG O
fractions BC2GM056965108 NNS O
that BC2GM056965108 WDT O
were BC2GM056965108 VBD O
enriched BC2GM056965108 VBN O
in BC2GM056965108 IN O
the BC2GM056965108 DT O
two BC2GM056965108 CD O
components BC2GM056965108 NNS O
. BC2GM056965108 . O
. . O O

Xa4 BC2GM032212038 NN O
is BC2GM032212038 VBZ O
a BC2GM032212038 DT O
dominantly BC2GM032212038 RB O
inherited BC2GM032212038 VBN O
rice BC2GM032212038 NN O
gene BC2GM032212038 NN O
that BC2GM032212038 IN O
confers BC2GM032212038 NNS O
resistance BC2GM032212038 VBP O
to BC2GM032212038 TO O
Philippine BC2GM032212038 VB O
race BC2GM032212038 NN O
1 BC2GM032212038 CD O
of BC2GM032212038 IN O
the BC2GM032212038 DT O
bacterial BC2GM032212038 JJ O
blight BC2GM032212038 NN O
pathogen BC2GM032212038 NN O
Xanthomonas BC2GM032212038 NNP O
oryzae BC2GM032212038 NN O
pv BC2GM032212038 NN O
. BC2GM032212038 . O
oryzae BC2GM032212038 NN O
in BC2GM032212038 IN O
rice BC2GM032212038 NN O
. BC2GM032212038 . O
. . O O

Cardiac BC2GM042327107 JJ O
lesion BC2GM042327107 NN O
in BC2GM042327107 IN O
exotoxic BC2GM042327107 NN O
shock BC2GM042327107 NN O
. BC2GM042327107 . O
. . O O

Youssoufian BC2GM019139361 JJ O
, BC2GM019139361 , O
A BC2GM019139361 NNP O
. BC2GM019139361 . O
. . O O

Thus BC2GM032797223 RB O
, BC2GM032797223 , O
an BC2GM032797223 DT O
increase BC2GM032797223 NN O
in BC2GM032797223 IN O
lactate BC2GM032797223 JJ O
concentration BC2GM032797223 NN O
of BC2GM032797223 IN O
the BC2GM032797223 DT O
magnitude BC2GM032797223 NN O
observed BC2GM032797223 VBD O
during BC2GM032797223 IN O
alkali BC2GM032797223 JJ O
therapy BC2GM032797223 NN O
need BC2GM032797223 MD O
not BC2GM032797223 RB O
indicate BC2GM032797223 VB O
a BC2GM032797223 DT O
worsening BC2GM032797223 NN O
of BC2GM032797223 IN O
the BC2GM032797223 DT O
metabolic BC2GM032797223 JJ O
picture BC2GM032797223 NN O
in BC2GM032797223 IN O
lactic BC2GM032797223 JJ O
acidosis BC2GM032797223 NN O
. BC2GM032797223 . O
. . O O

It BC2GM052103407 PRP O
has BC2GM052103407 VBZ O
become BC2GM052103407 VBN O
clear BC2GM052103407 JJ O
that BC2GM052103407 IN O
there BC2GM052103407 EX O
is BC2GM052103407 VBZ O
not BC2GM052103407 RB O
one BC2GM052103407 CD O
mediator BC2GM052103407 NN O
responsible BC2GM052103407 JJ O
for BC2GM052103407 IN O
ALI BC2GM052103407 NNP O
, BC2GM052103407 , O
but BC2GM052103407 CC O
rather BC2GM052103407 RB O
a BC2GM052103407 DT O
complex BC2GM052103407 JJ O
interplay BC2GM052103407 NN O
exists BC2GM052103407 VBZ O
between BC2GM052103407 IN O
diverse BC2GM052103407 JJ O
proinflammatory BC2GM052103407 NN O
( BC2GM052103407 ( O
e.g. BC2GM052103407 JJ O
, BC2GM052103407 , O
lipopolysaccharide BC2GM052103407 RB O
, BC2GM052103407 , O
complement BC2GM052103407 NN O
products BC2GM052103407 NNS O
, BC2GM052103407 , O
cytocains BC2GM052103407 NNS O
, BC2GM052103407 , O
chemocains BC2GM052103407 NNS O
, BC2GM052103407 , O
reactive BC2GM052103407 JJ O
oxygen BC2GM052103407 NN O
species BC2GM052103407 NNS O
and BC2GM052103407 CC O
arachidonic BC2GM052103407 JJ O
acid BC2GM052103407 NN O
products BC2GM052103407 NNS O
) BC2GM052103407 ) O
and BC2GM052103407 CC O
anti-inflammatory BC2GM052103407 JJ O
( BC2GM052103407 ( O
IL-10 BC2GM052103407 NNP O
, BC2GM052103407 , O
IL-1-RA BC2GM052103407 NNP O
, BC2GM052103407 , O
PGI2 BC2GM052103407 NNP O
) BC2GM052103407 ) O
mediators BC2GM052103407 NNS O
. BC2GM052103407 . O
. . O O

Neither BC2GM007000776 DT O
symptoms BC2GM007000776 NNS O
, BC2GM007000776 , O
virions BC2GM007000776 NNS O
, BC2GM007000776 , O
nor BC2GM007000776 CC O
viral BC2GM007000776 JJ O
RNA BC2GM007000776 NNP O
was BC2GM007000776 VBD O
detectable BC2GM007000776 JJ O
in BC2GM007000776 IN O
plants BC2GM007000776 NNS O
inoculated BC2GM007000776 VBN O
with BC2GM007000776 IN O
this BC2GM007000776 DT O
mutant BC2GM007000776 NN O
or BC2GM007000776 CC O
a BC2GM007000776 DT O
mutant BC2GM007000776 JJ O
with BC2GM007000776 IN O
a BC2GM007000776 DT O
frameshift BC2GM007000776 NN O
mutation BC2GM007000776 NN O
in BC2GM007000776 IN O
the BC2GM007000776 DT O
coat BC2GM007000776 NN O
gene BC2GM007000776 NN O
. BC2GM007000776 . O
. . O O

The BC2GM050074470 DT O
findings BC2GM050074470 NNS O
in BC2GM050074470 IN O
the BC2GM050074470 DT O
human BC2GM050074470 JJ O
multiple BC2GM050074470 JJ O
myeloma BC2GM050074470 NN O
cell BC2GM050074470 NN O
lines BC2GM050074470 NNS O
represent BC2GM050074470 VBP O
the BC2GM050074470 DT O
first BC2GM050074470 JJ O
examples BC2GM050074470 NNS O
of BC2GM050074470 IN O
B BC2GM050074470 NNP O
cells BC2GM050074470 NNS O
with BC2GM050074470 IN O
downregulated BC2GM050074470 JJ O
PU.1 BC2GM050074470 NNP O
expression BC2GM050074470 NN O
and BC2GM050074470 CC O
apparently BC2GM050074470 RB O
contradict BC2GM050074470 JJ O
observations BC2GM050074470 NNS O
in BC2GM050074470 IN O
the BC2GM050074470 DT O
murine BC2GM050074470 NN O
system BC2GM050074470 NN O
in BC2GM050074470 IN O
which BC2GM050074470 WDT O
PU.1 BC2GM050074470 NNP O
is BC2GM050074470 VBZ O
expressed BC2GM050074470 VBN O
and BC2GM050074470 CC O
active BC2GM050074470 JJ O
in BC2GM050074470 IN O
plasmacytoma BC2GM050074470 NN O
cell BC2GM050074470 NN O
lines BC2GM050074470 NNS O
. BC2GM050074470 . O
. . O O

To BC2GM091199615 TO O
further BC2GM091199615 RBR O
identify BC2GM091199615 VB O
the BC2GM091199615 DT O
residues BC2GM091199615 NNS O
responsible BC2GM091199615 JJ O
for BC2GM091199615 IN O
the BC2GM091199615 DT O
activity BC2GM091199615 NN O
, BC2GM091199615 , O
we BC2GM091199615 PRP O
isolated BC2GM091199615 VBD O
the BC2GM091199615 DT O
mutant BC2GM091199615 JJ O
viruses BC2GM091199615 NNS O
that BC2GM091199615 WDT O
were BC2GM091199615 VBD O
not BC2GM091199615 RB O
neutralized BC2GM091199615 VBN O
with BC2GM091199615 IN O
the BC2GM091199615 DT O
soluble BC2GM091199615 JJ O
form BC2GM091199615 NN O
of BC2GM091199615 IN O
MHV BC2GM091199615 NNP O
receptor BC2GM091199615 NN O
proteins BC2GM091199615 NNS O
, BC2GM091199615 , O
since BC2GM091199615 IN O
such BC2GM091199615 JJ O
mutants BC2GM091199615 NNS O
were BC2GM091199615 VBD O
expected BC2GM091199615 VBN O
to BC2GM091199615 TO O
have BC2GM091199615 VB O
mutations BC2GM091199615 NNS O
in BC2GM091199615 IN O
amino BC2GM091199615 JJ O
acids BC2GM091199615 NNS O
responsible BC2GM091199615 JJ O
for BC2GM091199615 IN O
receptor-binding BC2GM091199615 JJ O
activity BC2GM091199615 NN O
. BC2GM091199615 . O
. . O O

Based BC2GM017399394 VBN O
on BC2GM017399394 IN O
the BC2GM017399394 DT O
results BC2GM017399394 NNS O
of BC2GM017399394 IN O
this BC2GM017399394 DT O
analysis BC2GM017399394 NN O
, BC2GM017399394 , O
we BC2GM017399394 PRP O
also BC2GM017399394 RB O
predict BC2GM017399394 VBP O
that BC2GM017399394 IN O
the BC2GM017399394 DT O
budding BC2GM017399394 NN O
yeast BC2GM017399394 NN O
arsenate BC2GM017399394 NN O
resistance BC2GM017399394 NN O
protein BC2GM017399394 NN O
Acr2 BC2GM017399394 NNP O
and BC2GM017399394 CC O
the BC2GM017399394 DT O
ORF BC2GM017399394 NNP O
Ygr203w BC2GM017399394 NNP O
encode BC2GM017399394 NN O
protein BC2GM017399394 NN O
phosphatases BC2GM017399394 VBZ O
with BC2GM017399394 IN O
catalytic BC2GM017399394 JJ O
properties BC2GM017399394 NNS O
similar BC2GM017399394 JJ O
to BC2GM017399394 TO O
that BC2GM017399394 DT O
of BC2GM017399394 IN O
the BC2GM017399394 DT O
Cdc25 BC2GM017399394 NNP O
family BC2GM017399394 NN O
. BC2GM017399394 . O
. . O O

The BC2GM088087323 DT O
contribution BC2GM088087323 NN O
of BC2GM088087323 IN O
residues BC2GM088087323 NNS O
outside BC2GM088087323 IN O
the BC2GM088087323 DT O
Ras BC2GM088087323 NNP O
binding BC2GM088087323 VBG O
domain BC2GM088087323 NN O
of BC2GM088087323 IN O
Raf BC2GM088087323 NNP O
( BC2GM088087323 ( O
RafRBD BC2GM088087323 NNP O
) BC2GM088087323 ) O
to BC2GM088087323 TO O
Ras-Raf BC2GM088087323 JJ O
interaction BC2GM088087323 NN O
and BC2GM088087323 CC O
Ras-dependent BC2GM088087323 JJ O
Raf BC2GM088087323 NNP O
activation BC2GM088087323 NN O
has BC2GM088087323 VBZ O
remained BC2GM088087323 VBN O
unresolved BC2GM088087323 JJ O
. BC2GM088087323 . O
. . O O

Morphometry BC2GM096342624 NN O
of BC2GM096342624 IN O
the BC2GM096342624 DT O
intestine BC2GM096342624 NN O
of BC2GM096342624 IN O
the BC2GM096342624 DT O
pig BC2GM096342624 NN O
. BC2GM096342624 . O
. . O O

Primer BC2GM009734777 NNP O
extension BC2GM009734777 NN O
analysis BC2GM009734777 NN O
and BC2GM009734777 CC O
subcloning BC2GM009734777 NN O
of BC2GM009734777 IN O
the BC2GM009734777 DT O
virJ-phoA BC2GM009734777 JJ O
fusion BC2GM009734777 NN O
indicate BC2GM009734777 NN O
that BC2GM009734777 IN O
the BC2GM009734777 DT O
acetosyringone-inducible BC2GM009734777 JJ O
promoter BC2GM009734777 NN O
lies BC2GM009734777 VBZ O
directly BC2GM009734777 RB O
upstream BC2GM009734777 JJ O
of BC2GM009734777 IN O
the BC2GM009734777 DT O
virJ BC2GM009734777 JJ O
structural BC2GM009734777 JJ O
gene BC2GM009734777 NN O
. BC2GM009734777 . O
. . O O

This BC2GM053499725 DT O
nuclear BC2GM053499725 JJ O
/ BC2GM053499725 NN O
organellar BC2GM053499725 JJ O
gene BC2GM053499725 NN O
transfer BC2GM053499725 NN O
event BC2GM053499725 NN O
is BC2GM053499725 VBZ O
strikingly BC2GM053499725 RB O
similar BC2GM053499725 JJ O
to BC2GM053499725 TO O
the BC2GM053499725 DT O
experimentally BC2GM053499725 RB O
accessible BC2GM053499725 JJ O
process BC2GM053499725 NN O
of BC2GM053499725 IN O
nuclear BC2GM053499725 JJ O
integration BC2GM053499725 NN O
of BC2GM053499725 IN O
introduced BC2GM053499725 VBN O
heterologous BC2GM053499725 JJ O
DNA BC2GM053499725 NN O
. BC2GM053499725 . O
. . O O

This BC2GM092705100 DT O
sequence BC2GM092705100 NN O
can BC2GM092705100 MD O
interact BC2GM092705100 VB O
with BC2GM092705100 IN O
at BC2GM092705100 IN O
least BC2GM092705100 JJS O
two BC2GM092705100 CD O
proteins BC2GM092705100 NNS O
in BC2GM092705100 IN O
a BC2GM092705100 DT O
fibroblast BC2GM092705100 JJ O
nuclear BC2GM092705100 JJ O
extract BC2GM092705100 NN O
that BC2GM092705100 WDT O
have BC2GM092705100 VBP O
binding BC2GM092705100 VBG O
characteristics BC2GM092705100 NNS O
of BC2GM092705100 IN O
an BC2GM092705100 DT O
Ets BC2GM092705100 NNP O
family BC2GM092705100 NN O
protein BC2GM092705100 NN O
and BC2GM092705100 CC O
a BC2GM092705100 DT O
serum BC2GM092705100 JJ O
response BC2GM092705100 NN O
factor-like BC2GM092705100 JJ O
protein BC2GM092705100 NN O
. BC2GM092705100 . O
. . O O

In BC2GM052291844 IN O
contrast BC2GM052291844 NN O
, BC2GM052291844 , O
no BC2GM052291844 DT O
change BC2GM052291844 NN O
in BC2GM052291844 IN O
the BC2GM052291844 DT O
level BC2GM052291844 NN O
of BC2GM052291844 IN O
either BC2GM052291844 DT O
p53 BC2GM052291844 NN O
or BC2GM052291844 CC O
activation BC2GM052291844 NN O
of BC2GM052291844 IN O
mdm2 BC2GM052291844 NN O
protein BC2GM052291844 NN O
by BC2GM052291844 IN O
p53 BC2GM052291844 NN O
was BC2GM052291844 VBD O
observed BC2GM052291844 VBN O
in BC2GM052291844 IN O
hamster BC2GM052291844 NN O
UV61 BC2GM052291844 NNP O
cells BC2GM052291844 NNS O
after BC2GM052291844 IN O
UV BC2GM052291844 NNP O
exposure BC2GM052291844 NN O
. BC2GM052291844 . O
. . O O

Nuclear BC2GM008972334 JJ O
extracts BC2GM008972334 NNS O
from BC2GM008972334 IN O
Sertoli BC2GM008972334 NNP O
cells BC2GM008972334 NNS O
were BC2GM008972334 VBD O
found BC2GM008972334 VBN O
to BC2GM008972334 TO O
cause BC2GM008972334 VB O
an BC2GM008972334 DT O
E-box BC2GM008972334 JJ O
gel BC2GM008972334 NN O
shift BC2GM008972334 NN O
when BC2GM008972334 WRB O
the BC2GM008972334 DT O
cells BC2GM008972334 NNS O
were BC2GM008972334 VBD O
stimulated BC2GM008972334 VBN O
to BC2GM008972334 TO O
differentiate BC2GM008972334 VB O
in BC2GM008972334 IN O
culture BC2GM008972334 NN O
, BC2GM008972334 , O
but BC2GM008972334 CC O
not BC2GM008972334 RB O
under BC2GM008972334 IN O
basal BC2GM008972334 NN O
conditions BC2GM008972334 NNS O
. BC2GM008972334 . O
. . O O

In BC2GM091971820 IN O
this BC2GM091971820 DT O
study BC2GM091971820 NN O
, BC2GM091971820 , O
we BC2GM091971820 PRP O
investigated BC2GM091971820 VBD O
the BC2GM091971820 DT O
mechanism BC2GM091971820 NN O
by BC2GM091971820 IN O
which BC2GM091971820 WDT O
Tax BC2GM091971820 NNP O
activates BC2GM091971820 VBZ O
gene BC2GM091971820 NN O
expression BC2GM091971820 NN O
in BC2GM091971820 IN O
conjunction BC2GM091971820 NN O
with BC2GM091971820 IN O
members BC2GM091971820 NNS O
of BC2GM091971820 IN O
the BC2GM091971820 DT O
ATF BC2GM091971820 NNP O
/ BC2GM091971820 NNP O
CREB BC2GM091971820 NNP O
family BC2GM091971820 NN O
. BC2GM091971820 . O
. . O O

In BC2GM080153743 IN O
patients BC2GM080153743 NNS O
with BC2GM080153743 IN O
active BC2GM080153743 JJ O
TB BC2GM080153743 NNP O
, BC2GM080153743 , O
cytokines BC2GM080153743 NNS O
that BC2GM080153743 WDT O
were BC2GM080153743 VBD O
elevated BC2GM080153743 VBN O
in BC2GM080153743 IN O
serum BC2GM080153743 NN O
were BC2GM080153743 VBD O
IFN-gamma BC2GM080153743 NNP O
, BC2GM080153743 , O
IL-6 BC2GM080153743 NNP O
and BC2GM080153743 CC O
IL-10 BC2GM080153743 NNP O
. BC2GM080153743 . O
. . O O

The BC2GM012984521 DT O
1031-bp BC2GM012984521 JJ O
wild-type BC2GM012984521 JJ O
HIT1 BC2GM012984521 NNP O
DNA BC2GM012984521 NNP O
which BC2GM012984521 WDT O
contained BC2GM012984521 VBD O
an BC2GM012984521 DT O
open BC2GM012984521 JJ O
reading BC2GM012984521 NN O
frame BC2GM012984521 NN O
encoding BC2GM012984521 VBG O
a BC2GM012984521 DT O
protein BC2GM012984521 NN O
of BC2GM012984521 IN O
164 BC2GM012984521 CD O
amino BC2GM012984521 JJ O
acids BC2GM012984521 NNS O
and BC2GM012984521 CC O
the BC2GM012984521 DT O
AGG BC2GM012984521 NNP O
arginine BC2GM012984521 NN O
tRNA BC2GM012984521 NN O
gene BC2GM012984521 NN O
complemented BC2GM012984521 VBD O
all BC2GM012984521 DT O
hit1-1 BC2GM012984521 JJ O
mutant BC2GM012984521 JJ O
phenotypes BC2GM012984521 NNS O
, BC2GM012984521 , O
indicating BC2GM012984521 VBG O
that BC2GM012984521 IN O
the BC2GM012984521 DT O
mutant BC2GM012984521 JJ O
phenotypes BC2GM012984521 NNS O
were BC2GM012984521 VBD O
caused BC2GM012984521 VBN O
by BC2GM012984521 IN O
the BC2GM012984521 DT O
deletion BC2GM012984521 NN O
of BC2GM012984521 IN O
these BC2GM012984521 DT O
genes BC2GM012984521 NNS O
. BC2GM012984521 . O
. . O O

Adenovirus-mediated BC2GM002300410 JJ O
gene BC2GM002300410 NN O
transfer BC2GM002300410 NN O
of BC2GM002300410 IN O
MMAC1 BC2GM002300410 NNP O
/ BC2GM002300410 NNP O
PTEN BC2GM002300410 NNP O
to BC2GM002300410 TO O
glioblastoma BC2GM002300410 VB O
cells BC2GM002300410 NNS O
inhibits BC2GM002300410 VBZ O
S BC2GM002300410 NNP O
phase BC2GM002300410 NN O
entry BC2GM002300410 NN O
by BC2GM002300410 IN O
the BC2GM002300410 DT O
recruitment BC2GM002300410 NN O
of BC2GM002300410 IN O
p27Kip1 BC2GM002300410 NN O
into BC2GM002300410 IN O
cyclin BC2GM002300410 NN O
E BC2GM002300410 NNP O
/ BC2GM002300410 NNP O
CDK2 BC2GM002300410 NNP O
complexes BC2GM002300410 NNS O
. BC2GM002300410 . O
. . O O

Furthermore BC2GM039407902 RB O
, BC2GM039407902 , O
it BC2GM039407902 PRP O
is BC2GM039407902 VBZ O
also BC2GM039407902 RB O
established BC2GM039407902 VBN O
that BC2GM039407902 IN O
serine BC2GM039407902 JJ O
phosphorylation BC2GM039407902 NN O
of BC2GM039407902 IN O
STAT5a BC2GM039407902 NNP O
transactivation BC2GM039407902 NN O
domain BC2GM039407902 NN O
, BC2GM039407902 , O
via BC2GM039407902 IN O
the BC2GM039407902 DT O
MAPK BC2GM039407902 NNP O
pathway BC2GM039407902 NN O
, BC2GM039407902 , O
is BC2GM039407902 VBZ O
a BC2GM039407902 DT O
means BC2GM039407902 NN O
of BC2GM039407902 IN O
modifying BC2GM039407902 VBG O
GH-induced BC2GM039407902 NNP O
transcriptional BC2GM039407902 JJ O
activation BC2GM039407902 NN O
. BC2GM039407902 . O
. . O O

TFIIB BC2GM042537375 NNP O
and BC2GM042537375 CC O
VDR BC2GM042537375 NNP O
can BC2GM042537375 MD O
also BC2GM042537375 RB O
interact BC2GM042537375 VB O
directly BC2GM042537375 RB O
, BC2GM042537375 , O
and BC2GM042537375 CC O
these BC2GM042537375 DT O
factors BC2GM042537375 NNS O
synergize BC2GM042537375 VBP O
to BC2GM042537375 TO O
mediate BC2GM042537375 VB O
transactivation BC2GM042537375 NN O
. BC2GM042537375 . O
. . O O

Result BC2GM015846745 NN O
were BC2GM015846745 VBD O
as BC2GM015846745 IN O
followed BC2GM015846745 VBN O
: BC2GM015846745 : O
1 BC2GM015846745 CD O
) BC2GM015846745 ) O
Early BC2GM015846745 RB O
cancer-like BC2GM015846745 NN O
advanced BC2GM015846745 JJ O
cancers BC2GM015846745 NNS O
were BC2GM015846745 VBD O
consisted BC2GM015846745 VBN O
of BC2GM015846745 IN O
133 BC2GM015846745 CD O
lesions BC2GM015846745 NNS O
, BC2GM015846745 , O
of BC2GM015846745 IN O
which BC2GM015846745 WDT O
128 BC2GM015846745 CD O
lesions BC2GM015846745 NNS O
( BC2GM015846745 ( O
96.2 BC2GM015846745 CD O
% BC2GM015846745 NN O
) BC2GM015846745 ) O
had BC2GM015846745 VBD O
peptic BC2GM015846745 JJ O
ulcer BC2GM015846745 NN O
in BC2GM015846745 IN O
cancerous BC2GM015846745 JJ O
lesion BC2GM015846745 NN O
( BC2GM015846745 ( O
73 BC2GM015846745 CD O
lesions BC2GM015846745 NNS O
were BC2GM015846745 VBD O
active BC2GM015846745 JJ O
stage BC2GM015846745 NN O
and BC2GM015846745 CC O
55 BC2GM015846745 CD O
lesions BC2GM015846745 NNS O
were BC2GM015846745 VBD O
scarring BC2GM015846745 VBG O
stage BC2GM015846745 NN O
) BC2GM015846745 ) O
. BC2GM015846745 . O
. . O O

To BC2GM051341452 TO O
investigate BC2GM051341452 VB O
this BC2GM051341452 DT O
possibility BC2GM051341452 NN O
, BC2GM051341452 , O
we BC2GM051341452 PRP O
conducted BC2GM051341452 VBD O
split-visual-field BC2GM051341452 JJ O
studies BC2GM051341452 NNS O
in BC2GM051341452 IN O
which BC2GM051341452 WDT O
we BC2GM051341452 PRP O
manipulated BC2GM051341452 VBD O
stimulus BC2GM051341452 JJ O
sets BC2GM051341452 NNS O
, BC2GM051341452 , O
recognition BC2GM051341452 NN O
task BC2GM051341452 NN O
, BC2GM051341452 , O
and BC2GM051341452 CC O
exposure BC2GM051341452 NN O
duration BC2GM051341452 NN O
. BC2GM051341452 . O
. . O O

A BC2GM025608940 DT O
procaryotic BC2GM025608940 JJ O
regulatory BC2GM025608940 JJ O
factor BC2GM025608940 NN O
with BC2GM025608940 IN O
a BC2GM025608940 DT O
histone BC2GM025608940 JJ O
H1-like BC2GM025608940 JJ O
carboxy-terminal BC2GM025608940 JJ O
domain BC2GM025608940 NN O
: BC2GM025608940 : O
clonal BC2GM025608940 JJ O
variation BC2GM025608940 NN O
of BC2GM025608940 IN O
repeats BC2GM025608940 NNS O
within BC2GM025608940 IN O
algP BC2GM025608940 NN O
, BC2GM025608940 , O
a BC2GM025608940 DT O
gene BC2GM025608940 NN O
involved BC2GM025608940 VBN O
in BC2GM025608940 IN O
regulation BC2GM025608940 NN O
of BC2GM025608940 IN O
mucoidy BC2GM025608940 NN O
in BC2GM025608940 IN O
Pseudomonas BC2GM025608940 NNP O
aeruginosa BC2GM025608940 NN O
. BC2GM025608940 . O
. . O O

The BC2GM034787231 DT O
program BC2GM034787231 NN O
for BC2GM034787231 IN O
myogenic BC2GM034787231 JJ O
differentiation BC2GM034787231 NN O
is BC2GM034787231 VBZ O
subject BC2GM034787231 JJ O
to BC2GM034787231 TO O
negative BC2GM034787231 JJ O
control BC2GM034787231 NN O
by BC2GM034787231 IN O
several BC2GM034787231 JJ O
peptide BC2GM034787231 JJ O
growth BC2GM034787231 NN O
factors BC2GM034787231 NNS O
and BC2GM034787231 CC O
by BC2GM034787231 IN O
the BC2GM034787231 DT O
products BC2GM034787231 NNS O
of BC2GM034787231 IN O
mutationally BC2GM034787231 RB O
activated BC2GM034787231 VBN O
ras BC2GM034787231 NN O
oncogenes BC2GM034787231 NNS O
, BC2GM034787231 , O
which BC2GM034787231 WDT O
persistently BC2GM034787231 RB O
activate BC2GM034787231 VBP O
intracellular BC2GM034787231 JJ O
cascades BC2GM034787231 NNS O
normally BC2GM034787231 RB O
triggered BC2GM034787231 VBN O
by BC2GM034787231 IN O
specific BC2GM034787231 JJ O
growth BC2GM034787231 NN O
factors BC2GM034787231 NNS O
. BC2GM034787231 . O
. . O O

These BC2GM065577575 DT O
data BC2GM065577575 NNS O
show BC2GM065577575 VBP O
that BC2GM065577575 IN O
tyrosine BC2GM065577575 JJ O
phosphorylation BC2GM065577575 NN O
by BC2GM065577575 IN O
FES BC2GM065577575 NNP O
affects BC2GM065577575 VBZ O
the BC2GM065577575 DT O
interaction BC2GM065577575 NN O
of BC2GM065577575 IN O
BCR BC2GM065577575 NNP O
with BC2GM065577575 IN O
multiple BC2GM065577575 JJ O
signaling BC2GM065577575 VBG O
partners BC2GM065577575 NNS O
and BC2GM065577575 CC O
suggest BC2GM065577575 VBP O
a BC2GM065577575 DT O
general BC2GM065577575 JJ O
role BC2GM065577575 NN O
for BC2GM065577575 IN O
BCR BC2GM065577575 NNP O
in BC2GM065577575 IN O
non-receptor BC2GM065577575 JJ O
protein-tyrosine BC2GM065577575 JJ O
kinase BC2GM065577575 NN O
regulation BC2GM065577575 NN O
and BC2GM065577575 CC O
signal BC2GM065577575 JJ O
transduction BC2GM065577575 NN O
. BC2GM065577575 . O
. . O O

One BC2GM085352639 CD O
day BC2GM085352639 NN O
after BC2GM085352639 IN O
injection BC2GM085352639 NN O
48 BC2GM085352639 CD O
% BC2GM085352639 NN O
of BC2GM085352639 IN O
the BC2GM085352639 DT O
injected BC2GM085352639 JJ O
activity BC2GM085352639 NN O
was BC2GM085352639 VBD O
in BC2GM085352639 IN O
the BC2GM085352639 DT O
skeleton BC2GM085352639 NN O
, BC2GM085352639 , O
9.3 BC2GM085352639 CD O
% BC2GM085352639 NN O
in BC2GM085352639 IN O
the BC2GM085352639 DT O
liver BC2GM085352639 NN O
, BC2GM085352639 , O
3 BC2GM085352639 CD O
% BC2GM085352639 NN O
in BC2GM085352639 IN O
the BC2GM085352639 DT O
kidneys BC2GM085352639 NNS O
and BC2GM085352639 CC O
4.4 BC2GM085352639 CD O
% BC2GM085352639 NN O
in BC2GM085352639 IN O
the BC2GM085352639 DT O
rest BC2GM085352639 NN O
of BC2GM085352639 IN O
the BC2GM085352639 DT O
organs BC2GM085352639 NNS O
. BC2GM085352639 . O
. . O O

For BC2GM007804673 IN O
example BC2GM007804673 NN O
, BC2GM007804673 , O
the BC2GM007804673 DT O
presence BC2GM007804673 NN O
of BC2GM007804673 IN O
two BC2GM007804673 CD O
related BC2GM007804673 JJ O
genes BC2GM007804673 NNS O
, BC2GM007804673 , O
b BC2GM007804673 NN O
and BC2GM007804673 CC O
b BC2GM007804673 NN O
' BC2GM007804673 '' O
, BC2GM007804673 , O
in BC2GM007804673 IN O
the BC2GM007804673 DT O
cyanobacterium BC2GM007804673 NN O
suggests BC2GM007804673 VBZ O
that BC2GM007804673 IN O
its BC2GM007804673 PRP$ O
ATP BC2GM007804673 NNP O
synthase BC2GM007804673 NN O
is BC2GM007804673 VBZ O
a BC2GM007804673 DT O
complex BC2GM007804673 NN O
of BC2GM007804673 IN O
nine BC2GM007804673 CD O
polypeptides BC2GM007804673 NNS O
, BC2GM007804673 , O
and BC2GM007804673 CC O
that BC2GM007804673 IN O
it BC2GM007804673 PRP O
may BC2GM007804673 MD O
have BC2GM007804673 VB O
single BC2GM007804673 JJ O
copies BC2GM007804673 NNS O
of BC2GM007804673 IN O
related BC2GM007804673 JJ O
b BC2GM007804673 NN O
and BC2GM007804673 CC O
b BC2GM007804673 NN O
' BC2GM007804673 '' O
proteins BC2GM007804673 NNS O
rather BC2GM007804673 RB O
than BC2GM007804673 IN O
two BC2GM007804673 CD O
copies BC2GM007804673 NNS O
of BC2GM007804673 IN O
identical BC2GM007804673 JJ O
b BC2GM007804673 NN O
subunits BC2GM007804673 NNS O
as BC2GM007804673 IN O
found BC2GM007804673 VBN O
in BC2GM007804673 IN O
the BC2GM007804673 DT O
E. BC2GM007804673 NNP O
coli BC2GM007804673 NNS O
enzyme.4+off BC2GM007804673 NN O
. BC2GM007804673 . O
. . O O

The BC2GM000136143 DT O
COR BC2GM000136143 NNP O
biosynthetic BC2GM000136143 JJ O
gene BC2GM000136143 NN O
cluster BC2GM000136143 NN O
in BC2GM000136143 IN O
P. BC2GM000136143 NNP O
syringae BC2GM000136143 NN O
pv BC2GM000136143 NN O
. BC2GM000136143 . O
glycinea BC2GM000136143 NN O
PG4180 BC2GM000136143 NNP O
is BC2GM000136143 VBZ O
encoded BC2GM000136143 VBN O
by BC2GM000136143 IN O
a BC2GM000136143 DT O
32-kb BC2GM000136143 JJ O
region BC2GM000136143 NN O
which BC2GM000136143 WDT O
contains BC2GM000136143 VBZ O
both BC2GM000136143 CC O
the BC2GM000136143 DT O
structural BC2GM000136143 JJ O
and BC2GM000136143 CC O
regulatory BC2GM000136143 JJ O
genes BC2GM000136143 NNS O
needed BC2GM000136143 VBN O
for BC2GM000136143 IN O
COR BC2GM000136143 NNP O
synthesis BC2GM000136143 NN O
. BC2GM000136143 . O
. . O O

Column BC2GM089468953 NNP O
chromatographic BC2GM089468953 JJ O
determination BC2GM089468953 NN O
of BC2GM089468953 IN O
polymyxin BC2GM089468953 NN O
B BC2GM089468953 NNP O
sulfate BC2GM089468953 NN O
. BC2GM089468953 . O
. . O O

Gas BC2GM018705374 NNP O
exchange BC2GM018705374 NN O
was BC2GM018705374 VBD O
measured BC2GM018705374 VBN O
breath BC2GM018705374 NN O
by BC2GM018705374 IN O
breath BC2GM018705374 NN O
. BC2GM018705374 . O
. . O O

Reactive BC2GM021307129 JJ O
mesothelial BC2GM021307129 NN O
cells BC2GM021307129 NNS O
, BC2GM021307129 , O
usually BC2GM021307129 RB O
seen BC2GM021307129 VBN O
as BC2GM021307129 IN O
exfoliated BC2GM021307129 JJ O
cells BC2GM021307129 NNS O
, BC2GM021307129 , O
were BC2GM021307129 VBD O
consistently BC2GM021307129 RB O
strongly BC2GM021307129 RB O
positive BC2GM021307129 JJ O
for BC2GM021307129 IN O
alpha BC2GM021307129 JJ O
1-antichymotrypsin BC2GM021307129 CD O
and BC2GM021307129 CC O
more BC2GM021307129 JJR O
variably BC2GM021307129 RB O
for BC2GM021307129 IN O
alpha BC2GM021307129 JJ O
1-antitrypsin BC2GM021307129 CD O
and BC2GM021307129 CC O
lysozyme BC2GM021307129 NN O
. BC2GM021307129 . O
. . O O

As BC2GM023793226 IN O
a BC2GM023793226 DT O
result BC2GM023793226 NN O
, BC2GM023793226 , O
relative BC2GM023793226 JJ O
biological BC2GM023793226 JJ O
effects BC2GM023793226 NNS O
( BC2GM023793226 ( O
RBE BC2GM023793226 NNP O
) BC2GM023793226 ) O
of BC2GM023793226 IN O
2.3-2.7 BC2GM023793226 JJ O
was BC2GM023793226 VBD O
obtained BC2GM023793226 VBN O
from BC2GM023793226 IN O
the BC2GM023793226 DT O
straight BC2GM023793226 JJ O
line BC2GM023793226 NN O
that BC2GM023793226 WDT O
was BC2GM023793226 VBD O
given BC2GM023793226 VBN O
by BC2GM023793226 IN O
modifying BC2GM023793226 VBG O
by BC2GM023793226 IN O
the BC2GM023793226 DT O
method BC2GM023793226 NN O
of BC2GM023793226 IN O
least BC2GM023793226 JJS O
squares BC2GM023793226 NNS O
the BC2GM023793226 DT O
curves BC2GM023793226 NNS O
of BC2GM023793226 IN O
the BC2GM023793226 DT O
frequency BC2GM023793226 NN O
of BC2GM023793226 IN O
anomalous BC2GM023793226 JJ O
fetuses BC2GM023793226 NNS O
in BC2GM023793226 IN O
total BC2GM023793226 JJ O
implants BC2GM023793226 NNS O
and BC2GM023793226 CC O
survived BC2GM023793226 VBD O
embryos BC2GM023793226 RB O
irradiated BC2GM023793226 VBN O
from BC2GM023793226 IN O
20 BC2GM023793226 CD O
to BC2GM023793226 TO O
120 BC2GM023793226 CD O
rad BC2GM023793226 NNS O
by BC2GM023793226 IN O
Cf-252 BC2GM023793226 NNP O
and BC2GM023793226 CC O
from BC2GM023793226 IN O
80 BC2GM023793226 CD O
to BC2GM023793226 TO O
220 BC2GM023793226 CD O
rad BC2GM023793226 NNS O
by BC2GM023793226 IN O
Co-60 BC2GM023793226 NNP O
on BC2GM023793226 IN O
day BC2GM023793226 NN O
8 BC2GM023793226 CD O
of BC2GM023793226 IN O
pregnancy BC2GM023793226 NN O
. BC2GM023793226 . O
. . O O

Spodoptera BC2GM076876749 NNP O
frugiperda BC2GM076876749 NN O
( BC2GM076876749 ( O
Sf9 BC2GM076876749 NNP O
) BC2GM076876749 ) O
cells BC2GM076876749 NNS O
have BC2GM076876749 VBP O
proved BC2GM076876749 VBN O
a BC2GM076876749 DT O
suitable BC2GM076876749 JJ O
cell BC2GM076876749 NN O
system BC2GM076876749 NN O
in BC2GM076876749 IN O
which BC2GM076876749 WDT O
to BC2GM076876749 TO O
study BC2GM076876749 VB O
this BC2GM076876749 DT O
association BC2GM076876749 NN O
and BC2GM076876749 CC O
to BC2GM076876749 TO O
produce BC2GM076876749 VB O
recombinant BC2GM076876749 JJ O
CR3 BC2GM076876749 NNP O
, BC2GM076876749 , O
and BC2GM076876749 CC O
we BC2GM076876749 PRP O
show BC2GM076876749 VBP O
here BC2GM076876749 RB O
that BC2GM076876749 IN O
another BC2GM076876749 DT O
lepidopteran BC2GM076876749 NN O
cell BC2GM076876749 NN O
line BC2GM076876749 NN O
, BC2GM076876749 , O
Trichoplusia BC2GM076876749 NNP O
niTN-5B1-4 BC2GM076876749 JJ O
( BC2GM076876749 ( O
High-Five BC2GM076876749 JJ O
) BC2GM076876749 ) O
cells BC2GM076876749 NNS O
, BC2GM076876749 , O
allows BC2GM076876749 VBZ O
the BC2GM076876749 DT O
recovery BC2GM076876749 NN O
of BC2GM076876749 IN O
large BC2GM076876749 JJ O
amounts BC2GM076876749 NNS O
of BC2GM076876749 IN O
functional BC2GM076876749 JJ O
recombinant BC2GM076876749 JJ O
CR3 BC2GM076876749 NNP O
. BC2GM076876749 . O
. . O O

This BC2GM010367775 DT O
50-kDa BC2GM010367775 JJ O
protein BC2GM010367775 NN O
contains BC2GM010367775 VBZ O
two BC2GM010367775 CD O
SH2 BC2GM010367775 NNP O
domains BC2GM010367775 NNS O
and BC2GM010367775 CC O
an BC2GM010367775 DT O
inter-SH2 BC2GM010367775 JJ O
domain BC2GM010367775 NN O
of BC2GM010367775 IN O
p85alpha BC2GM010367775 NN O
, BC2GM010367775 , O
but BC2GM010367775 CC O
the BC2GM010367775 DT O
SH3 BC2GM010367775 NNP O
and BC2GM010367775 CC O
bcr BC2GM010367775 JJ O
homology BC2GM010367775 NN O
domains BC2GM010367775 NNS O
of BC2GM010367775 IN O
p85alpha BC2GM010367775 NN O
were BC2GM010367775 VBD O
replaced BC2GM010367775 VBN O
by BC2GM010367775 IN O
a BC2GM010367775 DT O
unique BC2GM010367775 JJ O
6-amino BC2GM010367775 JJ O
acid BC2GM010367775 NN O
sequence BC2GM010367775 NN O
. BC2GM010367775 . O
. . O O

By BC2GM079234722 IN O
means BC2GM079234722 NNS O
of BC2GM079234722 IN O
early BC2GM079234722 JJ O
detection BC2GM079234722 NN O
and BC2GM079234722 CC O
correction BC2GM079234722 NN O
of BC2GM079234722 IN O
the BC2GM079234722 DT O
possible BC2GM079234722 JJ O
causes BC2GM079234722 NNS O
, BC2GM079234722 , O
the BC2GM079234722 DT O
goal BC2GM079234722 NN O
of BC2GM079234722 IN O
increasing BC2GM079234722 VBG O
therapeutic BC2GM079234722 JJ O
efficacy BC2GM079234722 NN O
can BC2GM079234722 MD O
be BC2GM079234722 VB O
achieved BC2GM079234722 VBN O
. BC2GM079234722 . O
. . O O

Multiple BC2GM061319895 NNP O
aortic BC2GM061319895 JJ O
thrombi BC2GM061319895 NN O
associated BC2GM061319895 VBN O
with BC2GM061319895 IN O
protein BC2GM061319895 NN O
C BC2GM061319895 NNP O
and BC2GM061319895 CC O
S BC2GM061319895 NNP O
deficiency BC2GM061319895 NN O
. BC2GM061319895 . O
. . O O

The BC2GM039939591 DT O
( BC2GM039939591 ( O
0 BC2GM039939591 CD O
0 BC2GM039939591 CD O
2 BC2GM039939591 CD O
) BC2GM039939591 ) O
diffraction BC2GM039939591 NN O
of BC2GM039939591 IN O
the BC2GM039939591 DT O
synthesized BC2GM039939591 JJ O
HAp BC2GM039939591 NNP O
crystals BC2GM039939591 NNS O
on BC2GM039939591 IN O
a BC2GM039939591 DT O
Col BC2GM039939591 NNP O
fiber BC2GM039939591 NN O
showed BC2GM039939591 VBD O
an BC2GM039939591 DT O
around BC2GM039939591 IN O
60 BC2GM039939591 CD O
arching BC2GM039939591 VBG O
angle BC2GM039939591 NN O
, BC2GM039939591 , O
while BC2GM039939591 IN O
that BC2GM039939591 DT O
on BC2GM039939591 IN O
a BC2GM039939591 DT O
ChS BC2GM039939591 NNP O
fiber BC2GM039939591 NN O
showed BC2GM039939591 VBD O
just BC2GM039939591 RB O
around BC2GM039939591 RB O
10 BC2GM039939591 CD O
degrees BC2GM039939591 NNS O
. BC2GM039939591 . O
. . O O

Above BC2GM085843951 IN O
this BC2GM085843951 DT O
transition BC2GM085843951 NN O
temperature BC2GM085843951 NN O
the BC2GM085843951 DT O
calcium BC2GM085843951 NN O
antagonist BC2GM085843951 NN O
lowers BC2GM085843951 NNS O
fm BC2GM085843951 VBP O
more BC2GM085843951 JJR O
pronouncedly BC2GM085843951 RB O
than BC2GM085843951 IN O
below BC2GM085843951 IN O
. BC2GM085843951 . O
. . O O

Although BC2GM097805959 IN O
they BC2GM097805959 PRP O
are BC2GM097805959 VBP O
similar BC2GM097805959 JJ O
to BC2GM097805959 TO O
the BC2GM097805959 DT O
IL9R BC2GM097805959 NNP O
gene BC2GM097805959 NN O
( BC2GM097805959 ( O
approximately BC2GM097805959 RB O
90 BC2GM097805959 CD O
% BC2GM097805959 NN O
identity BC2GM097805959 NN O
) BC2GM097805959 ) O
, BC2GM097805959 , O
none BC2GM097805959 NN O
of BC2GM097805959 IN O
these BC2GM097805959 DT O
copies BC2GM097805959 NNS O
encodes BC2GM097805959 VBP O
a BC2GM097805959 DT O
functional BC2GM097805959 JJ O
receptor BC2GM097805959 NN O
: BC2GM097805959 : O
none BC2GM097805959 NN O
of BC2GM097805959 IN O
them BC2GM097805959 PRP O
contains BC2GM097805959 VBZ O
sequences BC2GM097805959 NNS O
homologous BC2GM097805959 JJ O
to BC2GM097805959 TO O
the BC2GM097805959 DT O
5 BC2GM097805959 CD O
' BC2GM097805959 POS O
flanking BC2GM097805959 JJ O
region BC2GM097805959 NN O
or BC2GM097805959 CC O
exon BC2GM097805959 VB O
1 BC2GM097805959 CD O
of BC2GM097805959 IN O
the BC2GM097805959 DT O
IL9R BC2GM097805959 NNP O
gene BC2GM097805959 NN O
, BC2GM097805959 , O
and BC2GM097805959 CC O
the BC2GM097805959 DT O
remaining BC2GM097805959 VBG O
ORFs BC2GM097805959 NNP O
have BC2GM097805959 VBP O
been BC2GM097805959 VBN O
inactivated BC2GM097805959 VBN O
by BC2GM097805959 IN O
various BC2GM097805959 JJ O
point BC2GM097805959 NN O
mutations BC2GM097805959 NNS O
and BC2GM097805959 CC O
deletions BC2GM097805959 NNS O
. BC2GM097805959 . O
. . O O

White BC2GM041801302 NNP O
female BC2GM041801302 JJ O
cases BC2GM041801302 NNS O
were BC2GM041801302 VBD O
more BC2GM041801302 RBR O
likely BC2GM041801302 JJ O
to BC2GM041801302 TO O
have BC2GM041801302 VB O
worked BC2GM041801302 VBN O
as BC2GM041801302 IN O
registered BC2GM041801302 JJ O
nurses BC2GM041801302 NNS O
than BC2GM041801302 IN O
were BC2GM041801302 VBD O
the BC2GM041801302 DT O
controls BC2GM041801302 NNS O
( BC2GM041801302 ( O
OR BC2GM041801302 NNP O
= BC2GM041801302 VBZ O
1.9 BC2GM041801302 CD O
, BC2GM041801302 , O
95 BC2GM041801302 CD O
% BC2GM041801302 NN O
CI BC2GM041801302 NNP O
= BC2GM041801302 NNP O
1.0-3.5 BC2GM041801302 JJ O
) BC2GM041801302 ) O
. BC2GM041801302 . O
. . O O

Polymorphisms BC2GM026914728 NNS O
in BC2GM026914728 IN O
the BC2GM026914728 DT O
CCR5 BC2GM026914728 NNP O
genes BC2GM026914728 NNS O
of BC2GM026914728 IN O
African BC2GM026914728 NNP O
green BC2GM026914728 JJ O
monkeys BC2GM026914728 NNS O
and BC2GM026914728 CC O
mice BC2GM026914728 NN O
implicate BC2GM026914728 NN O
specific BC2GM026914728 JJ O
amino BC2GM026914728 NN O
acids BC2GM026914728 NNS O
in BC2GM026914728 IN O
infections BC2GM026914728 NNS O
by BC2GM026914728 IN O
simian BC2GM026914728 JJ O
and BC2GM026914728 CC O
human BC2GM026914728 JJ O
immunodeficiency BC2GM026914728 NN O
viruses BC2GM026914728 NNS O
. BC2GM026914728 . O
. . O O

ADR1 BC2GM032512561 NNP O
in BC2GM032512561 IN O
extracts BC2GM032512561 NNS O
made BC2GM032512561 VBN O
from BC2GM032512561 IN O
glucose-repressed BC2GM032512561 JJ O
and BC2GM032512561 CC O
-derepressed BC2GM032512561 JJ O
cells BC2GM032512561 NNS O
bound BC2GM032512561 IN O
UAS1 BC2GM032512561 NNP O
DNA BC2GM032512561 NNP O
with BC2GM032512561 IN O
similar BC2GM032512561 JJ O
affinities BC2GM032512561 NNS O
despite BC2GM032512561 IN O
having BC2GM032512561 VBG O
greatly BC2GM032512561 RB O
different BC2GM032512561 JJ O
abilities BC2GM032512561 NNS O
to BC2GM032512561 TO O
activate BC2GM032512561 VB O
ADH2 BC2GM032512561 NNP O
gene BC2GM032512561 NN O
expression BC2GM032512561 NN O
in BC2GM032512561 IN O
vivo BC2GM032512561 NN O
. BC2GM032512561 . O
. . O O

The BC2GM015573126 DT O
majority BC2GM015573126 NN O
of BC2GM015573126 IN O
the BC2GM015573126 DT O
respondents BC2GM015573126 NNS O
( BC2GM015573126 ( O
83.4 BC2GM015573126 CD O
% BC2GM015573126 NN O
) BC2GM015573126 ) O
considered BC2GM015573126 VBD O
that BC2GM015573126 IN O
coitus BC2GM015573126 NN O
should BC2GM015573126 MD O
not BC2GM015573126 RB O
be BC2GM015573126 VB O
stopped BC2GM015573126 VBN O
during BC2GM015573126 IN O
pregnancy BC2GM015573126 NN O
. BC2GM015573126 . O
. . O O

To BC2GM096761437 TO O
assess BC2GM096761437 VB O
the BC2GM096761437 DT O
effect BC2GM096761437 NN O
on BC2GM096761437 IN O
thrombus BC2GM096761437 NN O
growth BC2GM096761437 NN O
, BC2GM096761437 , O
we BC2GM096761437 PRP O
determined BC2GM096761437 VBD O
the BC2GM096761437 DT O
accretion BC2GM096761437 NN O
of BC2GM096761437 IN O
125I-labeled BC2GM096761437 JJ O
fibrinogen BC2GM096761437 NN O
onto BC2GM096761437 IN O
autologous BC2GM096761437 JJ O
non-radioactive BC2GM096761437 JJ O
thrombi BC2GM096761437 NN O
preformed BC2GM096761437 VBN O
in BC2GM096761437 IN O
the BC2GM096761437 DT O
jugular BC2GM096761437 JJ O
veins BC2GM096761437 NNS O
of BC2GM096761437 IN O
rabbits BC2GM096761437 NNS O
. BC2GM096761437 . O
. . O O

Buserelin BC2GM057834406 NNP O
offers BC2GM057834406 VBZ O
an BC2GM057834406 DT O
effective BC2GM057834406 JJ O
alternative BC2GM057834406 JJ O
medical BC2GM057834406 JJ O
treatment BC2GM057834406 NN O
of BC2GM057834406 IN O
carcinoma BC2GM057834406 NN O
of BC2GM057834406 IN O
the BC2GM057834406 DT O
prostate BC2GM057834406 NN O
and BC2GM057834406 CC O
, BC2GM057834406 , O
apart BC2GM057834406 RB O
from BC2GM057834406 IN O
impotence BC2GM057834406 NN O
, BC2GM057834406 , O
does BC2GM057834406 VBZ O
not BC2GM057834406 RB O
have BC2GM057834406 VB O
the BC2GM057834406 DT O
side BC2GM057834406 NN O
effects BC2GM057834406 NNS O
of BC2GM057834406 IN O
oestrogens BC2GM057834406 NNS O
. BC2GM057834406 . O
. . O O

The BC2GM069019076 DT O
effects BC2GM069019076 NNS O
of BC2GM069019076 IN O
space BC2GM069019076 NN O
radiation BC2GM069019076 NN O
are BC2GM069019076 VBP O
partially BC2GM069019076 RB O
known BC2GM069019076 VBN O
on BC2GM069019076 IN O
astronauts BC2GM069019076 NNS O
, BC2GM069019076 , O
but BC2GM069019076 CC O
much BC2GM069019076 RB O
remains BC2GM069019076 VBZ O
to BC2GM069019076 TO O
be BC2GM069019076 VB O
discovered BC2GM069019076 VBN O
. BC2GM069019076 . O
. . O O

When BC2GM019777256 WRB O
PCR BC2GM019777256 NNP O
was BC2GM019777256 VBD O
used BC2GM019777256 VBN O
to BC2GM019777256 TO O
amplify BC2GM019777256 VB O
agar BC2GM019777256 NN O
cultures BC2GM019777256 NNS O
which BC2GM019777256 WDT O
do BC2GM019777256 VBP O
not BC2GM019777256 RB O
express BC2GM019777256 VB O
the BC2GM019777256 DT O
fimbriae BC2GM019777256 NN O
, BC2GM019777256 , O
the BC2GM019777256 DT O
switch BC2GM019777256 NN O
region BC2GM019777256 NN O
was BC2GM019777256 VBD O
OFF BC2GM019777256 NNP O
only BC2GM019777256 RB O
. BC2GM019777256 . O
. . O O

Single BC2GM094515271 NNP O
amino BC2GM094515271 NN O
acid BC2GM094515271 NN O
substitutions BC2GM094515271 NNS O
were BC2GM094515271 VBD O
shown BC2GM094515271 VBN O
to BC2GM094515271 TO O
result BC2GM094515271 VB O
from BC2GM094515271 IN O
the BC2GM094515271 DT O
mutations BC2GM094515271 NNS O
pdr1-2 BC2GM094515271 NN O
( BC2GM094515271 ( O
M308I BC2GM094515271 NNP O
) BC2GM094515271 ) O
, BC2GM094515271 , O
pdr1-3 BC2GM094515271 JJ O
( BC2GM094515271 ( O
F815S BC2GM094515271 NNP O
) BC2GM094515271 ) O
, BC2GM094515271 , O
pdr1-6 BC2GM094515271 JJ O
( BC2GM094515271 ( O
K302Q BC2GM094515271 NNP O
) BC2GM094515271 ) O
, BC2GM094515271 , O
pdr1-7 BC2GM094515271 JJ O
( BC2GM094515271 ( O
P298A BC2GM094515271 NNP O
) BC2GM094515271 ) O
and BC2GM094515271 CC O
pdr1-8 BC2GM094515271 JJ O
( BC2GM094515271 ( O
L1036 BC2GM094515271 NNP O
W BC2GM094515271 NNP O
) BC2GM094515271 ) O
, BC2GM094515271 , O
whereas BC2GM094515271 IN O
the BC2GM094515271 DT O
intragenic BC2GM094515271 JJ O
suppressor BC2GM094515271 NN O
mutant BC2GM094515271 JJ O
pdr1-100 BC2GM094515271 NN O
is BC2GM094515271 VBZ O
deleted BC2GM094515271 VBN O
for BC2GM094515271 IN O
the BC2GM094515271 DT O
two BC2GM094515271 CD O
amino BC2GM094515271 NN O
acids BC2GM094515271 NNS O
L537 BC2GM094515271 NNP O
and BC2GM094515271 CC O
A538 BC2GM094515271 NNP O
. BC2GM094515271 . O
. . O O

The BC2GM056745249 DT O
IR4 BC2GM056745249 NNP O
ORF BC2GM056745249 NNP O
exhibits BC2GM056745249 VBZ O
significant BC2GM056745249 JJ O
homology BC2GM056745249 NN O
to BC2GM056745249 TO O
the BC2GM056745249 DT O
immediate-early BC2GM056745249 JJ O
gene BC2GM056745249 NN O
US1 BC2GM056745249 NNP O
( BC2GM056745249 ( O
ICP22 BC2GM056745249 NNP O
) BC2GM056745249 ) O
of BC2GM056745249 IN O
herpes BC2GM056745249 NNS O
simplex BC2GM056745249 JJ O
virus BC2GM056745249 NN O
type BC2GM056745249 NN O
1 BC2GM056745249 CD O
and BC2GM056745249 CC O
to BC2GM056745249 TO O
the BC2GM056745249 DT O
ICP22 BC2GM056745249 NNP O
homologs BC2GM056745249 NNS O
of BC2GM056745249 IN O
varicella-zoster BC2GM056745249 JJ O
virus BC2GM056745249 NN O
( BC2GM056745249 ( O
ORF63 BC2GM056745249 NNP O
) BC2GM056745249 ) O
, BC2GM056745249 , O
pseudorabies BC2GM056745249 NNS O
virus BC2GM056745249 VBP O
( BC2GM056745249 ( O
RSp40 BC2GM056745249 NNP O
) BC2GM056745249 ) O
, BC2GM056745249 , O
and BC2GM056745249 CC O
equine BC2GM056745249 VB O
herpesvirus BC2GM056745249 NN O
4 BC2GM056745249 CD O
( BC2GM056745249 ( O
ORF4 BC2GM056745249 NNP O
) BC2GM056745249 ) O
. BC2GM056745249 . O
. . O O

The BC2GM041774560 DT O
dynamics BC2GM041774560 NNS O
of BC2GM041774560 IN O
protozoa BC2GM041774560 NN O
were BC2GM041774560 VBD O
studied BC2GM041774560 VBN O
in BC2GM041774560 IN O
two BC2GM041774560 CD O
groups BC2GM041774560 NNS O
of BC2GM041774560 IN O
rumen-fistulated BC2GM041774560 JJ O
cattle BC2GM041774560 NNS O
fed BC2GM041774560 VBN O
on BC2GM041774560 IN O
a BC2GM041774560 DT O
basal BC2GM041774560 NN O
diet BC2GM041774560 NN O
of BC2GM041774560 IN O
molasses BC2GM041774560 NNS O
ad BC2GM041774560 NN O
lib. BC2GM041774560 NN O
, BC2GM041774560 , O
with BC2GM041774560 IN O
oaten BC2GM041774560 JJ O
chaff BC2GM041774560 NN O
given BC2GM041774560 VBN O
at BC2GM041774560 IN O
6 BC2GM041774560 CD O
or BC2GM041774560 CC O
18 BC2GM041774560 CD O
g BC2GM041774560 NNS O
/ BC2GM041774560 JJ O
kg BC2GM041774560 VBP O
live BC2GM041774560 JJ O
weight BC2GM041774560 NN O
. BC2GM041774560 . O
. . O O

Surprisingly BC2GM092872868 RB O
, BC2GM092872868 , O
although BC2GM092872868 IN O
Mist1 BC2GM092872868 NNP O
binds BC2GM092872868 VBZ O
to BC2GM092872868 TO O
E-boxes BC2GM092872868 NNP O
in BC2GM092872868 IN O
vivo BC2GM092872868 NN O
, BC2GM092872868 , O
the BC2GM092872868 DT O
Mist1 BC2GM092872868 NNP O
protein BC2GM092872868 NN O
lacks BC2GM092872868 VBZ O
a BC2GM092872868 DT O
functional BC2GM092872868 JJ O
transcription BC2GM092872868 NN O
activation BC2GM092872868 NN O
domain BC2GM092872868 NN O
. BC2GM092872868 . O
. . O O

RESULTS BC2GM073138597 NN O
: BC2GM073138597 : O
Although BC2GM073138597 IN O
low BC2GM073138597 JJ O
levels BC2GM073138597 NNS O
of BC2GM073138597 IN O
vIRF-2 BC2GM073138597 JJ O
mRNAs BC2GM073138597 NN O
can BC2GM073138597 MD O
be BC2GM073138597 VB O
detected BC2GM073138597 VBN O
in BC2GM073138597 IN O
the BC2GM073138597 DT O
HHV-8-positive BC2GM073138597 JJ O
BCBL-1 BC2GM073138597 NNP O
tumor BC2GM073138597 NN O
cell BC2GM073138597 NN O
line BC2GM073138597 NN O
, BC2GM073138597 , O
12-0-tetradecanoylphorbol-13-acetate BC2GM073138597 JJ O
( BC2GM073138597 ( O
TPA BC2GM073138597 NNP O
) BC2GM073138597 ) O
treatment BC2GM073138597 NN O
does BC2GM073138597 VBZ O
not BC2GM073138597 RB O
stimulate BC2GM073138597 VB O
expression BC2GM073138597 NN O
of BC2GM073138597 IN O
vIRF-2 BC2GM073138597 JJ O
gene BC2GM073138597 NN O
together BC2GM073138597 RB O
with BC2GM073138597 IN O
primary BC2GM073138597 JJ O
lytic BC2GM073138597 JJ O
cycle BC2GM073138597 NN O
genes BC2GM073138597 NNS O
. BC2GM073138597 . O
. . O O

Angiographic BC2GM079355460 JJ O
follow-up BC2GM079355460 NN O
was BC2GM079355460 VBD O
obtained BC2GM079355460 VBN O
in BC2GM079355460 IN O
92 BC2GM079355460 CD O
% BC2GM079355460 NN O
of BC2GM079355460 IN O
patients BC2GM079355460 NNS O
with BC2GM079355460 IN O
a BC2GM079355460 DT O
primary BC2GM079355460 JJ O
success BC2GM079355460 NN O
of BC2GM079355460 IN O
angioplasty BC2GM079355460 NN O
. BC2GM079355460 . O
. . O O

A BC2GM023340483 DT O
previously BC2GM023340483 RB O
developed BC2GM023340483 VBN O
kinetic BC2GM023340483 JJ O
model BC2GM023340483 NN O
was BC2GM023340483 VBD O
used BC2GM023340483 VBN O
to BC2GM023340483 TO O
identify BC2GM023340483 VB O
major BC2GM023340483 JJ O
chemical BC2GM023340483 JJ O
reaction BC2GM023340483 NN O
pathways BC2GM023340483 VBZ O
involving BC2GM023340483 VBG O
PAH BC2GM023340483 NNP O
in BC2GM023340483 IN O
the BC2GM023340483 DT O
afterburner BC2GM023340483 NN O
. BC2GM023340483 . O
. . O O

We BC2GM013088712 PRP O
have BC2GM013088712 VBP O
used BC2GM013088712 VBN O
the BC2GM013088712 DT O
chloramphenicol BC2GM013088712 NN O
acetyltransferase BC2GM013088712 NN O
( BC2GM013088712 ( O
CAT BC2GM013088712 NNP O
) BC2GM013088712 ) O
reporter BC2GM013088712 NN O
gene BC2GM013088712 NN O
system BC2GM013088712 NN O
to BC2GM013088712 TO O
study BC2GM013088712 VB O
the BC2GM013088712 DT O
effect BC2GM013088712 NN O
of BC2GM013088712 IN O
T BC2GM013088712 NNP O
on BC2GM013088712 IN O
the BC2GM013088712 DT O
long BC2GM013088712 JJ O
terminal BC2GM013088712 JJ O
repeats BC2GM013088712 NNS O
( BC2GM013088712 ( O
LTRs BC2GM013088712 NNP O
) BC2GM013088712 ) O
of BC2GM013088712 IN O
a BC2GM013088712 DT O
large BC2GM013088712 JJ O
family BC2GM013088712 NN O
of BC2GM013088712 IN O
human BC2GM013088712 JJ O
endogenous BC2GM013088712 JJ O
retrovirus-like BC2GM013088712 NN O
sequences BC2GM013088712 NNS O
, BC2GM013088712 , O
RTVL-H BC2GM013088712 NNP O
. BC2GM013088712 . O
. . O O

Consistent BC2GM062202050 JJ O
with BC2GM062202050 IN O
this BC2GM062202050 DT O
hypothesis BC2GM062202050 NN O
, BC2GM062202050 , O
alpha1-PDX BC2GM062202050 JJ O
prevents BC2GM062202050 NNS O
cleavage BC2GM062202050 NN O
of BC2GM062202050 IN O
BMP-4 BC2GM062202050 NNP O
in BC2GM062202050 IN O
an BC2GM062202050 DT O
oocyte BC2GM062202050 JJ O
translation BC2GM062202050 NN O
assay BC2GM062202050 NN O
. BC2GM062202050 . O
. . O O

Most BC2GM072697080 JJS O
other BC2GM072697080 JJ O
differences BC2GM072697080 NNS O
between BC2GM072697080 IN O
these BC2GM072697080 DT O
two BC2GM072697080 CD O
Leporipoxviruses BC2GM072697080 NNS O
are BC2GM072697080 VBP O
located BC2GM072697080 VBN O
in BC2GM072697080 IN O
the BC2GM072697080 DT O
telomeres BC2GM072697080 NNS O
. BC2GM072697080 . O
. . O O

The BC2GM035066986 DT O
tau BC2GM035066986 NN O
v BC2GM035066986 NN O
at BC2GM035066986 IN O
rest BC2GM035066986 NN O
was BC2GM035066986 VBD O
4.06 BC2GM035066986 CD O
+ BC2GM035066986 JJ O
/ BC2GM035066986 NNP O
- BC2GM035066986 : O
2.16 BC2GM035066986 CD O
s BC2GM035066986 NN O
and BC2GM035066986 CC O
decreased BC2GM035066986 VBD O
to BC2GM035066986 TO O
2.44 BC2GM035066986 CD O
+ BC2GM035066986 NNS O
/ BC2GM035066986 SYM O
- BC2GM035066986 : O
1.07 BC2GM035066986 CD O
s BC2GM035066986 NN O
( BC2GM035066986 ( O
P BC2GM035066986 NNP O
< BC2GM035066986 NNP O
0.05 BC2GM035066986 CD O
) BC2GM035066986 ) O
at BC2GM035066986 IN O
1 BC2GM035066986 CD O
Hz BC2GM035066986 NNP O
and BC2GM035066986 CC O
to BC2GM035066986 TO O
1.81 BC2GM035066986 CD O
+ BC2GM035066986 NNS O
/ BC2GM035066986 SYM O
- BC2GM035066986 : O
0.4 BC2GM035066986 CD O
s BC2GM035066986 NN O
at BC2GM035066986 IN O
5 BC2GM035066986 CD O
Hz BC2GM035066986 NNP O
. BC2GM035066986 . O
. . O O

The BC2GM046036818 DT O
cumulative BC2GM046036818 JJ O
dose BC2GM046036818 NN O
to BC2GM046036818 TO O
nursing BC2GM046036818 JJ O
staff BC2GM046036818 NN O
for BC2GM046036818 IN O
the BC2GM046036818 DT O
week BC2GM046036818 NN O
after BC2GM046036818 IN O
treatment BC2GM046036818 NN O
was BC2GM046036818 VBD O
dependent BC2GM046036818 JJ O
on BC2GM046036818 IN O
patient BC2GM046036818 JJ O
mobility BC2GM046036818 NN O
and BC2GM046036818 CC O
was BC2GM046036818 VBD O
estimated BC2GM046036818 VBN O
at BC2GM046036818 IN O
0.08 BC2GM046036818 CD O
mSv BC2GM046036818 NN O
for BC2GM046036818 IN O
a BC2GM046036818 DT O
self-caring BC2GM046036818 JJ O
patient BC2GM046036818 NN O
to BC2GM046036818 TO O
6.3 BC2GM046036818 CD O
mSv BC2GM046036818 NN O
for BC2GM046036818 IN O
a BC2GM046036818 DT O
totally BC2GM046036818 RB O
helpless BC2GM046036818 JJ O
patient BC2GM046036818 NN O
( BC2GM046036818 ( O
1840 BC2GM046036818 CD O
MBq BC2GM046036818 NNP O
/ BC2GM046036818 NNP O
group BC2GM046036818 NN O
A BC2GM046036818 NNP O
) BC2GM046036818 ) O
. BC2GM046036818 . O
. . O O

However BC2GM035615525 RB O
, BC2GM035615525 , O
there BC2GM035615525 EX O
are BC2GM035615525 VBP O
some BC2GM035615525 DT O
cows BC2GM035615525 NNS O
that BC2GM035615525 WDT O
fail BC2GM035615525 VBP O
to BC2GM035615525 TO O
produce BC2GM035615525 VB O
adequate BC2GM035615525 JJ O
1,25-dihydroxyvitamin BC2GM035615525 JJ O
D BC2GM035615525 NNP O
at BC2GM035615525 IN O
the BC2GM035615525 DT O
onset BC2GM035615525 NN O
of BC2GM035615525 IN O
lactation BC2GM035615525 NN O
. BC2GM035615525 . O
. . O O

Statistical BC2GM029508007 JJ O
conservation BC2GM029508007 NN O
laws BC2GM029508007 NNS O
in BC2GM029508007 IN O
turbulent BC2GM029508007 JJ O
transport BC2GM029508007 NN O
. BC2GM029508007 . O
. . O O

Based BC2GM023454935 VBN O
on BC2GM023454935 IN O
the BC2GM023454935 DT O
ratios BC2GM023454935 NNS O
of BC2GM023454935 IN O
the BC2GM023454935 DT O
areas BC2GM023454935 NNS O
under BC2GM023454935 IN O
the BC2GM023454935 DT O
concentration-time BC2GM023454935 JJ O
curves BC2GM023454935 NNS O
in BC2GM023454935 IN O
CSF BC2GM023454935 NNP O
and BC2GM023454935 CC O
serum BC2GM023454935 NN O
, BC2GM023454935 , O
the BC2GM023454935 DT O
overall BC2GM023454935 JJ O
penetration BC2GM023454935 NN O
of BC2GM023454935 IN O
rifampicin BC2GM023454935 NN O
into BC2GM023454935 IN O
CSF BC2GM023454935 NNP O
was BC2GM023454935 VBD O
0.13-0.42 BC2GM023454935 JJ O
( BC2GM023454935 ( O
median BC2GM023454935 JJ O
= BC2GM023454935 NNP O
0.22 BC2GM023454935 CD O
) BC2GM023454935 ) O
. BC2GM023454935 . O
. . O O

Nuclear BC2GM057222507 NNP O
runoff BC2GM057222507 NN O
assays BC2GM057222507 VBZ O
show BC2GM057222507 VBP O
that BC2GM057222507 IN O
complementation BC2GM057222507 NN O
by BC2GM057222507 IN O
HPV16 BC2GM057222507 NNP O
E7 BC2GM057222507 NNP O
restores BC2GM057222507 VBZ O
the BC2GM057222507 DT O
ability BC2GM057222507 NN O
of BC2GM057222507 IN O
the BC2GM057222507 DT O
E1A BC2GM057222507 NNP O
mutants BC2GM057222507 NNS O
to BC2GM057222507 TO O
stimulate BC2GM057222507 VB O
early BC2GM057222507 JJ O
gene BC2GM057222507 NN O
expression BC2GM057222507 NN O
at BC2GM057222507 IN O
the BC2GM057222507 DT O
level BC2GM057222507 NN O
of BC2GM057222507 IN O
transcription BC2GM057222507 NN O
. BC2GM057222507 . O
. . O O

Immunoprecipitation BC2GM075862192 NN O
of BC2GM075862192 IN O
cell BC2GM075862192 NN O
lysates BC2GM075862192 NNS O
with BC2GM075862192 IN O
anti-phosphotyrosine BC2GM075862192 JJ O
and BC2GM075862192 CC O
immunoblotting BC2GM075862192 VBG O
showed BC2GM075862192 VBD O
phosphorylated BC2GM075862192 JJ O
forms BC2GM075862192 NNS O
of BC2GM075862192 IN O
the BC2GM075862192 DT O
mitogenic BC2GM075862192 JJ O
pathway BC2GM075862192 NN O
proteins BC2GM075862192 NNS O
Shc BC2GM075862192 NNP O
and BC2GM075862192 CC O
MAPK BC2GM075862192 NNP O
in BC2GM075862192 IN O
addition BC2GM075862192 NN O
to BC2GM075862192 TO O
p185 BC2GM075862192 VB O
( BC2GM075862192 ( O
neu BC2GM075862192 NN O
) BC2GM075862192 ) O
, BC2GM075862192 , O
suggesting BC2GM075862192 VBG O
that BC2GM075862192 IN O
the BC2GM075862192 DT O
Ras BC2GM075862192 NNP O
to BC2GM075862192 TO O
MAPK BC2GM075862192 NNP O
mitogenic BC2GM075862192 JJ O
pathway BC2GM075862192 NN O
is BC2GM075862192 VBZ O
activated BC2GM075862192 VBN O
. BC2GM075862192 . O
. . O O

We BC2GM092362540 PRP O
identified BC2GM092362540 VBD O
Tyr BC2GM092362540 NNP O
( BC2GM092362540 ( O
112 BC2GM092362540 CD O
) BC2GM092362540 ) O
and BC2GM092362540 CC O
Leu BC2GM092362540 NNP O
( BC2GM092362540 ( O
175 BC2GM092362540 CD O
) BC2GM092362540 ) O
within BC2GM092362540 IN O
the BC2GM092362540 DT O
RNA-binding BC2GM092362540 JJ O
domain BC2GM092362540 NN O
of BC2GM092362540 IN O
the BC2GM092362540 DT O
U1 BC2GM092362540 NNP O
70K BC2GM092362540 CD O
protein BC2GM092362540 NN O
to BC2GM092362540 TO O
be BC2GM092362540 VB O
cross-linked BC2GM092362540 JJ O
to BC2GM092362540 TO O
G BC2GM092362540 NNP O
( BC2GM092362540 ( O
28 BC2GM092362540 CD O
) BC2GM092362540 ) O
and BC2GM092362540 CC O
U BC2GM092362540 NNP O
( BC2GM092362540 ( O
30 BC2GM092362540 CD O
) BC2GM092362540 ) O
in BC2GM092362540 IN O
stem-loop BC2GM092362540 NN O
I BC2GM092362540 PRP O
, BC2GM092362540 , O
respectively BC2GM092362540 RB O
. BC2GM092362540 . O
. . O O

The BC2GM066547944 DT O
index BC2GM066547944 NN O
patient BC2GM066547944 NN O
, BC2GM066547944 , O
a BC2GM066547944 DT O
10-year-old BC2GM066547944 JJ O
boy BC2GM066547944 NN O
, BC2GM066547944 , O
presents BC2GM066547944 VBZ O
typical BC2GM066547944 JJ O
symptoms BC2GM066547944 NNS O
of BC2GM066547944 IN O
OPD BC2GM066547944 NNP O
type BC2GM066547944 NN O
I BC2GM066547944 PRP O
together BC2GM066547944 RB O
with BC2GM066547944 IN O
bowing BC2GM066547944 NN O
of BC2GM066547944 IN O
the BC2GM066547944 DT O
long BC2GM066547944 JJ O
bones BC2GM066547944 NNS O
and BC2GM066547944 CC O
abnormalities BC2GM066547944 NNS O
of BC2GM066547944 IN O
the BC2GM066547944 DT O
thorax BC2GM066547944 NN O
and BC2GM066547944 CC O
spinal BC2GM066547944 JJ O
column BC2GM066547944 NN O
. BC2GM066547944 . O
. . O O

The BC2GM061649078 DT O
use BC2GM061649078 NN O
of BC2GM061649078 IN O
specific BC2GM061649078 JJ O
somatic BC2GM061649078 JJ O
cell BC2GM061649078 NN O
hybrids BC2GM061649078 NNS O
have BC2GM061649078 VBP O
allowed BC2GM061649078 VBN O
us BC2GM061649078 PRP O
to BC2GM061649078 TO O
locate BC2GM061649078 VB O
the BC2GM061649078 DT O
YAC BC2GM061649078 NNP O
contig BC2GM061649078 NN O
telomeric BC2GM061649078 NN O
to BC2GM061649078 TO O
the BC2GM061649078 DT O
D3F15S2 BC2GM061649078 NNP O
locus BC2GM061649078 NN O
, BC2GM061649078 , O
in BC2GM061649078 IN O
a BC2GM061649078 DT O
region BC2GM061649078 NN O
which BC2GM061649078 WDT O
is BC2GM061649078 VBZ O
frequently BC2GM061649078 RB O
deleted BC2GM061649078 VBN O
in BC2GM061649078 IN O
lung BC2GM061649078 NN O
carcinomas BC2GM061649078 NN O
. BC2GM061649078 . O
. . O O

In BC2GM070037858 IN O
group BC2GM070037858 NN O
I BC2GM070037858 PRP O
during BC2GM070037858 IN O
the BC2GM070037858 DT O
pain BC2GM070037858 NN O
free BC2GM070037858 JJ O
period BC2GM070037858 NN O
26 BC2GM070037858 CD O
of BC2GM070037858 IN O
81 BC2GM070037858 CD O
patients BC2GM070037858 NNS O
had BC2GM070037858 VBD O
positive BC2GM070037858 JJ O
thallium-201 BC2GM070037858 JJ O
scans BC2GM070037858 NNS O
, BC2GM070037858 , O
whereas BC2GM070037858 NNS O
20 BC2GM070037858 CD O
patients BC2GM070037858 NNS O
had BC2GM070037858 VBD O
an BC2GM070037858 DT O
abnormal BC2GM070037858 JJ O
ECG BC2GM070037858 NN O
at BC2GM070037858 IN O
that BC2GM070037858 DT O
time BC2GM070037858 NN O
; BC2GM070037858 : O
during BC2GM070037858 IN O
angina BC2GM070037858 $ O
18 BC2GM070037858 CD O
patients BC2GM070037858 NNS O
had BC2GM070037858 VBD O
transient BC2GM070037858 JJ O
ECG BC2GM070037858 NNP O
changes BC2GM070037858 NNS O
. BC2GM070037858 . O
. . O O

The BC2GM017023323 DT O
two BC2GM017023323 CD O
redox BC2GM017023323 NN O
centers BC2GM017023323 NNS O
in BC2GM017023323 IN O
the BC2GM017023323 DT O
protein BC2GM017023323 NN O
, BC2GM017023323 , O
FAD BC2GM017023323 NNP O
and BC2GM017023323 CC O
a BC2GM017023323 DT O
[ BC2GM017023323 JJ O
4Fe4S BC2GM017023323 CD O
] BC2GM017023323 JJ O
+2 BC2GM017023323 NN O
, BC2GM017023323 , O
+1 BC2GM017023323 NNP O
cluster BC2GM017023323 NN O
, BC2GM017023323 , O
are BC2GM017023323 VBP O
present BC2GM017023323 JJ O
in BC2GM017023323 IN O
a BC2GM017023323 DT O
64-kDa BC2GM017023323 JJ O
monomer BC2GM017023323 NN O
. BC2GM017023323 . O
. . O O

[ BC2GM062639747 NN O
( BC2GM062639747 ( O
OP BC2GM062639747 NNP O
) BC2GM062639747 ) O
2Cu BC2GM062639747 CD O
] BC2GM062639747 NN O
+ BC2GM062639747 NNP O
also BC2GM062639747 RB O
detected BC2GM062639747 VBD O
protections BC2GM062639747 NNS O
in BC2GM062639747 IN O
the BC2GM062639747 DT O
C BC2GM062639747 NNP O
alpha-helix BC2GM062639747 NN O
, BC2GM062639747 , O
the BC2GM062639747 DT O
interdomain BC2GM062639747 NN O
hinge BC2GM062639747 NN O
, BC2GM062639747 , O
and BC2GM062639747 CC O
beta-strands BC2GM062639747 NNS O
2-7 BC2GM062639747 JJ O
. BC2GM062639747 . O
. . O O

Total BC2GM026200487 JJ O
body BC2GM026200487 NN O
BMD BC2GM026200487 NNP O
( BC2GM026200487 ( O
r BC2GM026200487 VB O
= BC2GM026200487 RB O
0.30 BC2GM026200487 CD O
; BC2GM026200487 : O
P BC2GM026200487 NNP O
= BC2GM026200487 NNP O
0.02 BC2GM026200487 CD O
) BC2GM026200487 ) O
and BC2GM026200487 CC O
femoral BC2GM026200487 JJ O
neck BC2GM026200487 NN O
BMD BC2GM026200487 NNP O
( BC2GM026200487 ( O
r BC2GM026200487 VB O
= BC2GM026200487 RB O
0.39 BC2GM026200487 CD O
; BC2GM026200487 : O
P BC2GM026200487 NNP O
= BC2GM026200487 NNP O
0.002 BC2GM026200487 CD O
) BC2GM026200487 ) O
were BC2GM026200487 VBD O
positively BC2GM026200487 RB O
correlated BC2GM026200487 VBN O
with BC2GM026200487 IN O
weight-bearing BC2GM026200487 JJ O
activity BC2GM026200487 NN O
but BC2GM026200487 CC O
not BC2GM026200487 RB O
with BC2GM026200487 IN O
non-weight-bearing BC2GM026200487 JJ O
activity BC2GM026200487 NN O
. BC2GM026200487 . O
. . O O

A BC2GM045159719 DT O
survey BC2GM045159719 NN O
of BC2GM045159719 IN O
274 BC2GM045159719 CD O
late BC2GM045159719 JJ O
detected BC2GM045159719 VBN O
cases BC2GM045159719 NNS O
of BC2GM045159719 IN O
CDH BC2GM045159719 NNP O
born BC2GM045159719 NN O
in BC2GM045159719 IN O
the BC2GM045159719 DT O
years BC2GM045159719 NNS O
1970 BC2GM045159719 CD O
-- BC2GM045159719 : O
74 BC2GM045159719 CD O
is BC2GM045159719 VBZ O
presented BC2GM045159719 VBN O
. BC2GM045159719 . O
. . O O

This BC2GM043897639 DT O
group BC2GM043897639 NN O
showed BC2GM043897639 VBD O
the BC2GM043897639 DT O
presence BC2GM043897639 NN O
of BC2GM043897639 IN O
bacteria BC2GM043897639 NNS O
infiltrated BC2GM043897639 VBN O
at BC2GM043897639 IN O
the BC2GM043897639 DT O
dentinal BC2GM043897639 JJ O
tubules BC2GM043897639 NNS O
coronally BC2GM043897639 RB O
and BC2GM043897639 CC O
into BC2GM043897639 IN O
the BC2GM043897639 DT O
root BC2GM043897639 NN O
canals BC2GM043897639 NNS O
. BC2GM043897639 . O
. . O O

The BC2GM071764861 DT O
TCR BC2GM071764861 NNP O
beta BC2GM071764861 NN O
enhancer BC2GM071764861 NN O
was BC2GM071764861 VBD O
active BC2GM071764861 JJ O
on BC2GM071764861 IN O
both BC2GM071764861 DT O
the BC2GM071764861 DT O
minimal BC2GM071764861 JJ O
simian BC2GM071764861 JJ O
virus BC2GM071764861 NN O
40 BC2GM071764861 CD O
promoter BC2GM071764861 NN O
and BC2GM071764861 CC O
a BC2GM071764861 DT O
TCR BC2GM071764861 NNP O
beta BC2GM071764861 NN O
variable BC2GM071764861 JJ O
gene BC2GM071764861 NN O
promoter BC2GM071764861 NN O
in BC2GM071764861 IN O
both BC2GM071764861 DT O
TCR BC2GM071764861 NNP O
alpha BC2GM071764861 NN O
/ BC2GM071764861 NNP O
beta BC2GM071764861 NN O
+ BC2GM071764861 NN O
and BC2GM071764861 CC O
TCR BC2GM071764861 NNP O
gamma BC2GM071764861 VBP O
/ BC2GM071764861 NNP O
delta BC2GM071764861 NN O
+ BC2GM071764861 NNP O
T BC2GM071764861 NNP O
cells BC2GM071764861 NNS O
. BC2GM071764861 . O
. . O O

Nature BC2GM049820346 NN O
and BC2GM049820346 CC O
incidence BC2GM049820346 NN O
of BC2GM049820346 IN O
conditioned BC2GM049820346 JJ O
responses BC2GM049820346 NNS O
in BC2GM049820346 IN O
a BC2GM049820346 DT O
methadone BC2GM049820346 NN O
population BC2GM049820346 NN O
: BC2GM049820346 : O
a BC2GM049820346 DT O
comparison BC2GM049820346 NN O
of BC2GM049820346 IN O
laboratory BC2GM049820346 NN O
, BC2GM049820346 , O
clinic BC2GM049820346 NN O
, BC2GM049820346 , O
and BC2GM049820346 CC O
naturalistic BC2GM049820346 JJ O
settings BC2GM049820346 NNS O
. BC2GM049820346 . O
. . O O

At BC2GM037435242 IN O
the BC2GM037435242 DT O
start BC2GM037435242 NN O
of BC2GM037435242 IN O
the BC2GM037435242 DT O
performance BC2GM037435242 NN O
ride BC2GM037435242 NN O
, BC2GM037435242 , O
plasma BC2GM037435242 NN O
glucose BC2GM037435242 VBD O
averaged BC2GM037435242 VBD O
4.2 BC2GM037435242 CD O
+ BC2GM037435242 NNP O
/ BC2GM037435242 NNP O
- BC2GM037435242 : O
0.2 BC2GM037435242 CD O
, BC2GM037435242 , O
5.2 BC2GM037435242 CD O
+ BC2GM037435242 NN O
/ BC2GM037435242 NNP O
- BC2GM037435242 : O
0.1 BC2GM037435242 CD O
, BC2GM037435242 , O
and BC2GM037435242 CC O
5.7 BC2GM037435242 CD O
+ BC2GM037435242 NN O
/ BC2GM037435242 NNP O
- BC2GM037435242 : O
0.2 BC2GM037435242 CD O
mmol.l-1 BC2GM037435242 NN O
in BC2GM037435242 IN O
CON BC2GM037435242 NNP O
, BC2GM037435242 , O
CHO-7 BC2GM037435242 NNP O
, BC2GM037435242 , O
and BC2GM037435242 CC O
CHO-0 BC2GM037435242 NNP O
/ BC2GM037435242 NNP O
21 BC2GM037435242 CD O
, BC2GM037435242 , O
respectively BC2GM037435242 RB O
( BC2GM037435242 ( O
all BC2GM037435242 DT O
different BC2GM037435242 JJ O
, BC2GM037435242 , O
P BC2GM037435242 NNP O
< BC2GM037435242 NNP O
0.05 BC2GM037435242 CD O
) BC2GM037435242 ) O
. BC2GM037435242 . O
. . O O

Sera BC2GM016410750 NN O
collected BC2GM016410750 VBN O
in BC2GM016410750 IN O
1973-1975 BC2GM016410750 CD O
from BC2GM016410750 IN O
3053 BC2GM016410750 CD O
residents BC2GM016410750 NNS O
of BC2GM016410750 IN O
12 BC2GM016410750 CD O
selected BC2GM016410750 VBN O
Alaskan BC2GM016410750 NNP O
Eskimo BC2GM016410750 NNP O
villages BC2GM016410750 NNS O
were BC2GM016410750 VBD O
tested BC2GM016410750 VBN O
for BC2GM016410750 IN O
evidence BC2GM016410750 NN O
of BC2GM016410750 IN O
hepatitis BC2GM016410750 NN O
B BC2GM016410750 NNP O
virus BC2GM016410750 NN O
infection BC2GM016410750 NN O
. BC2GM016410750 . O
. . O O

Satisfactory BC2GM015891432 JJ O
correlation BC2GM015891432 NN O
was BC2GM015891432 VBD O
also BC2GM015891432 RB O
obtained BC2GM015891432 VBN O
between BC2GM015891432 IN O
the BC2GM015891432 DT O
in BC2GM015891432 IN O
vivo BC2GM015891432 NN O
and BC2GM015891432 CC O
the BC2GM015891432 DT O
in BC2GM015891432 IN O
vitro BC2GM015891432 JJ O
results BC2GM015891432 NNS O
. BC2GM015891432 . O
. . O O

A BC2GM072003693 DT O
very BC2GM072003693 RB O
large BC2GM072003693 JJ O
PC BC2GM072003693 NN O
LAN BC2GM072003693 NNP O
as BC2GM072003693 IN O
the BC2GM072003693 DT O
basis BC2GM072003693 NN O
for BC2GM072003693 IN O
a BC2GM072003693 DT O
hospital BC2GM072003693 NN O
information BC2GM072003693 NN O
system BC2GM072003693 NN O
. BC2GM072003693 . O
. . O O

Patients BC2GM085716701 NNS O
with BC2GM085716701 IN O
PLM BC2GM085716701 NNP O
show BC2GM085716701 VBP O
excessive BC2GM085716701 JJ O
daytime BC2GM085716701 JJ O
sleepiness BC2GM085716701 NN O
or BC2GM085716701 CC O
insomnia BC2GM085716701 NN O
. BC2GM085716701 . O
. . O O

Comparative BC2GM063705940 JJ O
ultrafiltration BC2GM063705940 NN O
( BC2GM063705940 ( O
UF BC2GM063705940 NNP O
) BC2GM063705940 ) O
studies BC2GM063705940 NNS O
with BC2GM063705940 IN O
BiGG BC2GM063705940 NNP O
and BC2GM063705940 CC O
standard BC2GM063705940 JJ O
lactate BC2GM063705940 NN O
( BC2GM063705940 ( O
La BC2GM063705940 NNP O
) BC2GM063705940 ) O
solutions BC2GM063705940 NNS O
in BC2GM063705940 IN O
rabbits BC2GM063705940 NNS O
showed BC2GM063705940 VBD O
that BC2GM063705940 IN O
net BC2GM063705940 JJ O
UF BC2GM063705940 NNP O
with BC2GM063705940 IN O
La BC2GM063705940 NNP O
solution BC2GM063705940 NN O
peaked BC2GM063705940 VBD O
at BC2GM063705940 IN O
2 BC2GM063705940 CD O
h BC2GM063705940 NN O
and BC2GM063705940 CC O
decreased BC2GM063705940 VBN O
significantly BC2GM063705940 RB O
at BC2GM063705940 IN O
4 BC2GM063705940 CD O
h BC2GM063705940 NN O
and BC2GM063705940 CC O
6 BC2GM063705940 CD O
h BC2GM063705940 NN O
. BC2GM063705940 . O
. . O O

We BC2GM088286294 PRP O
found BC2GM088286294 VBD O
that BC2GM088286294 IN O
48 BC2GM088286294 CD O
% BC2GM088286294 NN O
of BC2GM088286294 IN O
the BC2GM088286294 DT O
patients BC2GM088286294 NNS O
had BC2GM088286294 VBD O
their BC2GM088286294 PRP$ O
thoracolumbar BC2GM088286294 NN O
blood BC2GM088286294 NN O
supply BC2GM088286294 NN O
based BC2GM088286294 VBN O
on BC2GM088286294 IN O
two BC2GM088286294 CD O
anterior BC2GM088286294 JJ O
radiculospinal BC2GM088286294 JJ O
arteries BC2GM088286294 NNS O
the BC2GM088286294 DT O
lowest BC2GM088286294 JJS O
of BC2GM088286294 IN O
which BC2GM088286294 WDT O
was BC2GM088286294 VBD O
located BC2GM088286294 VBN O
at BC2GM088286294 IN O
, BC2GM088286294 , O
or BC2GM088286294 CC O
lower BC2GM088286294 JJR O
than BC2GM088286294 IN O
, BC2GM088286294 , O
T12 BC2GM088286294 NNP O
, BC2GM088286294 , O
and BC2GM088286294 CC O
the BC2GM088286294 DT O
second BC2GM088286294 JJ O
and BC2GM088286294 CC O
higher BC2GM088286294 JJR O
one BC2GM088286294 CD O
between BC2GM088286294 IN O
T6 BC2GM088286294 NNP O
and BC2GM088286294 CC O
T10 BC2GM088286294 NNP O
. BC2GM088286294 . O
. . O O

The BC2GM011752487 DT O
Ras BC2GM011752487 NNP O
GTPase-activating-protein-related BC2GM011752487 NNP O
human BC2GM011752487 JJ O
protein BC2GM011752487 NN O
IQGAP2 BC2GM011752487 NNP O
harbors BC2GM011752487 VBZ O
a BC2GM011752487 DT O
potential BC2GM011752487 JJ O
actin BC2GM011752487 NN O
binding BC2GM011752487 VBG O
domain BC2GM011752487 NN O
and BC2GM011752487 CC O
interacts BC2GM011752487 NNS O
with BC2GM011752487 IN O
calmodulin BC2GM011752487 NN O
and BC2GM011752487 CC O
Rho BC2GM011752487 NNP O
family BC2GM011752487 NN O
GTPases BC2GM011752487 NNP O
. BC2GM011752487 . O
. . O O

To BC2GM026767504 TO O
directly BC2GM026767504 RB O
address BC2GM026767504 VB O
this BC2GM026767504 DT O
issue BC2GM026767504 NN O
, BC2GM026767504 , O
we BC2GM026767504 PRP O
used BC2GM026767504 VBD O
a BC2GM026767504 DT O
tetracycline-regulated BC2GM026767504 JJ O
system BC2GM026767504 NN O
in BC2GM026767504 IN O
human BC2GM026767504 JJ O
U2OS BC2GM026767504 NNP O
osteosarcoma BC2GM026767504 NN O
cells BC2GM026767504 NNS O
and BC2GM026767504 CC O
thus BC2GM026767504 RB O
found BC2GM026767504 VBD O
that BC2GM026767504 IN O
BCL6 BC2GM026767504 NNP O
mediates BC2GM026767504 VBZ O
growth BC2GM026767504 NN O
suppression BC2GM026767504 NN O
associated BC2GM026767504 VBN O
with BC2GM026767504 IN O
impaired BC2GM026767504 JJ O
S BC2GM026767504 NNP O
phase BC2GM026767504 NN O
progression BC2GM026767504 NN O
and BC2GM026767504 CC O
apoptosis BC2GM026767504 NN O
. BC2GM026767504 . O
. . O O

A BC2GM063546497 DT O
sharp BC2GM063546497 JJ O
transition BC2GM063546497 NN O
from BC2GM063546497 IN O
a BC2GM063546497 DT O
random BC2GM063546497 JJ O
chaotic BC2GM063546497 JJ O
state BC2GM063546497 NN O
to BC2GM063546497 TO O
a BC2GM063546497 DT O
correlated BC2GM063546497 VBN O
turbulent BC2GM063546497 NN O
state BC2GM063546497 NN O
of BC2GM063546497 IN O
finite BC2GM063546497 JJ O
coherence BC2GM063546497 NN O
time BC2GM063546497 NN O
is BC2GM063546497 VBZ O
found BC2GM063546497 VBN O
when BC2GM063546497 WRB O
the BC2GM063546497 DT O
Rayleigh BC2GM063546497 NNP O
number BC2GM063546497 NN O
becomes BC2GM063546497 VBZ O
larger BC2GM063546497 JJR O
than BC2GM063546497 IN O
a BC2GM063546497 DT O
critical BC2GM063546497 JJ O
value BC2GM063546497 NN O
Ra BC2GM063546497 NNP O
( BC2GM063546497 ( O
c BC2GM063546497 NN O
) BC2GM063546497 ) O
approximately BC2GM063546497 RB O
equal BC2GM063546497 JJ O
to BC2GM063546497 TO O
5 BC2GM063546497 CD O
x BC2GM063546497 NNS O
10 BC2GM063546497 CD O
( BC2GM063546497 ( O
7 BC2GM063546497 CD O
) BC2GM063546497 ) O
. BC2GM063546497 . O
. . O O

Seminal BC2GM045721161 NNP O
prolactin BC2GM045721161 NN O
levels BC2GM045721161 NNS O
were BC2GM045721161 VBD O
significantly BC2GM045721161 RB O
elevated BC2GM045721161 VBN O
in BC2GM045721161 IN O
all BC2GM045721161 DT O
infertile BC2GM045721161 JJ O
males BC2GM045721161 NNS O
. BC2GM045721161 . O
. . O O

While BC2GM075482500 IN O
working BC2GM075482500 VBG O
on BC2GM075482500 IN O
the BC2GM075482500 DT O
toxicity BC2GM075482500 NN O
of BC2GM075482500 IN O
war BC2GM075482500 NN O
gases BC2GM075482500 NNS O
. BC2GM075482500 . O
he BC2GM075482500 PRP O
formulated BC2GM075482500 VBD O
'Haber BC2GM075482500 NNP O
's BC2GM075482500 POS O
rule BC2GM075482500 NN O
' BC2GM075482500 '' O
, BC2GM075482500 , O
also BC2GM075482500 RB O
known BC2GM075482500 VBN O
as BC2GM075482500 IN O
C BC2GM075482500 NNP O
x BC2GM075482500 NNP O
T= BC2GM075482500 NNP O
constant BC2GM075482500 NN O
in BC2GM075482500 IN O
order BC2GM075482500 NN O
to BC2GM075482500 TO O
characterize BC2GM075482500 VB O
the BC2GM075482500 DT O
toxicity BC2GM075482500 NN O
of BC2GM075482500 IN O
an BC2GM075482500 DT O
inhalant BC2GM075482500 NN O
. BC2GM075482500 . O
. . O O

Xanthoepocin BC2GM046754199 NN O
, BC2GM046754199 , O
a BC2GM046754199 DT O
new BC2GM046754199 JJ O
antibiotic BC2GM046754199 JJ O
from BC2GM046754199 IN O
Penicillium BC2GM046754199 NNP O
simplicissimum BC2GM046754199 JJ O
IFO5762 BC2GM046754199 NNP O
. BC2GM046754199 . O
. . O O

Bleeding BC2GM054191583 NNP O
was BC2GM054191583 VBD O
successfully BC2GM054191583 RB O
prevented BC2GM054191583 VBN O
in BC2GM054191583 IN O
28 BC2GM054191583 CD O
patients BC2GM054191583 NNS O
with BC2GM054191583 IN O
the BC2GM054191583 DT O
use BC2GM054191583 NN O
of BC2GM054191583 IN O
a BC2GM054191583 DT O
combined BC2GM054191583 JJ O
treatment BC2GM054191583 NN O
incorporating BC2GM054191583 VBG O
IV BC2GM054191583 NNP O
desmopressin BC2GM054191583 NN O
, BC2GM054191583 , O
an BC2GM054191583 DT O
antifibrinolytic BC2GM054191583 JJ O
agent BC2GM054191583 NN O
( BC2GM054191583 ( O
tranexamic BC2GM054191583 JJ O
acid BC2GM054191583 NN O
) BC2GM054191583 ) O
, BC2GM054191583 , O
and BC2GM054191583 CC O
local BC2GM054191583 JJ O
methods BC2GM054191583 NNS O
( BC2GM054191583 ( O
surgical BC2GM054191583 JJ O
glue BC2GM054191583 NN O
and BC2GM054191583 CC O
compression BC2GM054191583 NN O
techniques BC2GM054191583 NNS O
) BC2GM054191583 ) O
. BC2GM054191583 . O
. . O O

The BC2GM096040259 DT O
inhibition BC2GM096040259 NN O
of BC2GM096040259 IN O
monoamine BC2GM096040259 JJ O
oxidase BC2GM096040259 NN O
( BC2GM096040259 ( O
MAO BC2GM096040259 NNP O
) BC2GM096040259 ) O
by BC2GM096040259 IN O
tranylcypromine BC2GM096040259 NN O
was BC2GM096040259 VBD O
studied BC2GM096040259 VBN O
in BC2GM096040259 IN O
6 BC2GM096040259 CD O
healthy BC2GM096040259 JJ O
volunteers BC2GM096040259 NNS O
given BC2GM096040259 VBN O
increasing BC2GM096040259 VBG O
doses BC2GM096040259 NNS O
of BC2GM096040259 IN O
10 BC2GM096040259 CD O
, BC2GM096040259 , O
15 BC2GM096040259 CD O
, BC2GM096040259 , O
20 BC2GM096040259 CD O
and BC2GM096040259 CC O
25 BC2GM096040259 CD O
mg BC2GM096040259 NNS O
/ BC2GM096040259 JJ O
day BC2GM096040259 NN O
over BC2GM096040259 IN O
a BC2GM096040259 DT O
4-week BC2GM096040259 JJ O
period BC2GM096040259 NN O
. BC2GM096040259 . O
. . O O

Differences BC2GM019813491 NNS O
were BC2GM019813491 VBD O
not BC2GM019813491 RB O
found BC2GM019813491 VBN O
in BC2GM019813491 IN O
colons BC2GM019813491 NNS O
by BC2GM019813491 IN O
SEM BC2GM019813491 NNP O
. BC2GM019813491 . O
. . O O

Long-term BC2GM066607362 JJ O
ambulatory BC2GM066607362 JJ O
measurement BC2GM066607362 NN O
of BC2GM066607362 IN O
transcutaneous BC2GM066607362 JJ O
arterial BC2GM066607362 JJ O
CO2 BC2GM066607362 NNP O
pressure BC2GM066607362 NN O
( BC2GM066607362 ( O
PCO2 BC2GM066607362 NNP O
) BC2GM066607362 ) O
offers BC2GM066607362 VBZ O
an BC2GM066607362 DT O
opportunity BC2GM066607362 NN O
to BC2GM066607362 TO O
test BC2GM066607362 VB O
directly BC2GM066607362 RB O
the BC2GM066607362 DT O
co-occurrence BC2GM066607362 NN O
of BC2GM066607362 IN O
panic BC2GM066607362 NN O
and BC2GM066607362 CC O
hyperventilation BC2GM066607362 NN O
under BC2GM066607362 IN O
natural BC2GM066607362 JJ O
conditions BC2GM066607362 NNS O
. BC2GM066607362 . O
. . O O

The BC2GM080799996 DT O
main BC2GM080799996 JJ O
side-effects BC2GM080799996 NNS O
were BC2GM080799996 VBD O
myelosuppression BC2GM080799996 NN O
, BC2GM080799996 , O
mucositis BC2GM080799996 NN O
and BC2GM080799996 CC O
peripheral BC2GM080799996 JJ O
neuropathy BC2GM080799996 NN O
, BC2GM080799996 , O
which BC2GM080799996 WDT O
were BC2GM080799996 VBD O
all BC2GM080799996 DT O
common BC2GM080799996 JJ O
and BC2GM080799996 CC O
often BC2GM080799996 RB O
severe BC2GM080799996 JJ O
. BC2GM080799996 . O
. . O O

The BC2GM051932313 DT O
mouse BC2GM051932313 NN O
alpha BC2GM051932313 VBZ O
A-CRYBP1 BC2GM051932313 NNP O
gene BC2GM051932313 NN O
specifies BC2GM051932313 VBZ O
a BC2GM051932313 DT O
2,688-amino BC2GM051932313 JJ O
acid BC2GM051932313 NN O
protein BC2GM051932313 NN O
with BC2GM051932313 IN O
72 BC2GM051932313 CD O
% BC2GM051932313 NN O
amino BC2GM051932313 NN O
acid BC2GM051932313 NN O
identity BC2GM051932313 NN O
to BC2GM051932313 TO O
its BC2GM051932313 PRP$ O
human BC2GM051932313 JJ O
homologue BC2GM051932313 NN O
, BC2GM051932313 , O
PRDII-BF1 BC2GM051932313 NNP O
. BC2GM051932313 . O
. . O O

MDA-MB-468 BC2GM028962502 JJ O
cells BC2GM028962502 NNS O
were BC2GM028962502 VBD O
stably BC2GM028962502 RB O
transfected BC2GM028962502 VBN O
with BC2GM028962502 IN O
either BC2GM028962502 CC O
a BC2GM028962502 DT O
plasmid BC2GM028962502 NN O
having BC2GM028962502 VBG O
a BC2GM028962502 DT O
CMV BC2GM028962502 NNP O
promoter-driven BC2GM028962502 JJ O
rabbit BC2GM028962502 NN O
beta-globin BC2GM028962502 JJ O
gene BC2GM028962502 NN O
or BC2GM028962502 CC O
plasmids BC2GM028962502 NNS O
having BC2GM028962502 VBG O
a BC2GM028962502 DT O
CMV BC2GM028962502 NNP O
promoter-driven BC2GM028962502 JJ O
chimeric BC2GM028962502 NN O
gadd45 BC2GM028962502 NN O
5 BC2GM028962502 CD O
'' BC2GM028962502 '' O
-UTR-rabbit BC2GM028962502 NN O
beta-globin BC2GM028962502 JJ O
gene BC2GM028962502 NN O
, BC2GM028962502 , O
where BC2GM028962502 WRB O
the BC2GM028962502 DT O
entire BC2GM028962502 JJ O
gadd45 BC2GM028962502 NN O
5 BC2GM028962502 CD O
'' BC2GM028962502 '' O
-UTR BC2GM028962502 NN O
( BC2GM028962502 ( O
from BC2GM028962502 IN O
+1 BC2GM028962502 NN O
to BC2GM028962502 TO O
+298 BC2GM028962502 VB O
) BC2GM028962502 ) O
or BC2GM028962502 CC O
a BC2GM028962502 DT O
45 BC2GM028962502 CD O
bp BC2GM028962502 JJ O
subfragment BC2GM028962502 NN O
of BC2GM028962502 IN O
the BC2GM028962502 DT O
gadd45 BC2GM028962502 NN O
5 BC2GM028962502 CD O
'' BC2GM028962502 '' O
-UTR BC2GM028962502 NN O
( BC2GM028962502 ( O
from BC2GM028962502 IN O
+10 BC2GM028962502 NN O
to BC2GM028962502 TO O
+55 BC2GM028962502 VB O
) BC2GM028962502 ) O
was BC2GM028962502 VBD O
positioned BC2GM028962502 VBN O
at BC2GM028962502 IN O
the BC2GM028962502 DT O
5 BC2GM028962502 CD O
'' BC2GM028962502 '' O
-end BC2GM028962502 NN O
of BC2GM028962502 IN O
the BC2GM028962502 DT O
rabbit BC2GM028962502 NN O
beta-globin BC2GM028962502 JJ O
gene BC2GM028962502 NN O
. BC2GM028962502 . O
. . O O

Despite BC2GM087578129 IN O
their BC2GM087578129 PRP$ O
high BC2GM087578129 JJ O
degree BC2GM087578129 NN O
of BC2GM087578129 IN O
sequence BC2GM087578129 NN O
similarity BC2GM087578129 NN O
, BC2GM087578129 , O
all BC2GM087578129 DT O
five BC2GM087578129 CD O
RFC BC2GM087578129 NNP O
genes BC2GM087578129 NNS O
are BC2GM087578129 VBP O
essential BC2GM087578129 JJ O
for BC2GM087578129 IN O
cell BC2GM087578129 NN O
proliferation BC2GM087578129 NN O
in BC2GM087578129 IN O
S. BC2GM087578129 NNP O
cerevisiae BC2GM087578129 NN O
. BC2GM087578129 . O
. . O O

Evidence BC2GM027460732 NN O
for BC2GM027460732 IN O
Gcr1p BC2GM027460732 NNP O
/ BC2GM027460732 NNP O
Gcr2p BC2GM027460732 NNP O
interaction BC2GM027460732 NN O
has BC2GM027460732 VBZ O
been BC2GM027460732 VBN O
presented BC2GM027460732 VBN O
earlier BC2GM027460732 RBR O
and BC2GM027460732 CC O
is BC2GM027460732 VBZ O
now BC2GM027460732 RB O
supported BC2GM027460732 VBN O
by BC2GM027460732 IN O
the BC2GM027460732 DT O
isolation BC2GM027460732 NN O
of BC2GM027460732 IN O
mutations BC2GM027460732 NNS O
in BC2GM027460732 IN O
Gcr1p BC2GM027460732 NNP O
suppressing BC2GM027460732 VBG O
gcr2 BC2GM027460732 NN O
, BC2GM027460732 , O
as BC2GM027460732 IN O
assessed BC2GM027460732 VBN O
by BC2GM027460732 IN O
growth BC2GM027460732 NN O
and BC2GM027460732 CC O
enzyme BC2GM027460732 VB O
assay BC2GM027460732 NN O
. BC2GM027460732 . O
. . O O

48.35 BC2GM038586241 CD O
+ BC2GM038586241 JJ O
/ BC2GM038586241 NNP O
- BC2GM038586241 : O
5.07 BC2GM038586241 CD O
mg BC2GM038586241 NN O
/ BC2GM038586241 NNP O
l BC2GM038586241 NN O
in BC2GM038586241 IN O
R3 BC2GM038586241 NNP O
; BC2GM038586241 : O
p BC2GM038586241 VBZ O
< BC2GM038586241 $ O
0.05 BC2GM038586241 CD O
) BC2GM038586241 ) O
and BC2GM038586241 CC O
in BC2GM038586241 IN O
the BC2GM038586241 DT O
AUC BC2GM038586241 NNP O
( BC2GM038586241 ( O
0.50 BC2GM038586241 CD O
h BC2GM038586241 NN O
) BC2GM038586241 ) O
( BC2GM038586241 ( O
1429.92 BC2GM038586241 CD O
+ BC2GM038586241 NN O
/ BC2GM038586241 NNP O
- BC2GM038586241 : O
284.23 BC2GM038586241 CD O
in BC2GM038586241 IN O
PR BC2GM038586241 NNP O
vs BC2GM038586241 NN O
. BC2GM038586241 . O
. . O O

Each BC2GM094263980 DT O
of BC2GM094263980 IN O
these BC2GM094263980 DT O
materials BC2GM094263980 NNS O
were BC2GM094263980 VBD O
placed BC2GM094263980 VBN O
by BC2GM094263980 IN O
means BC2GM094263980 NNS O
of BC2GM094263980 IN O
three BC2GM094263980 CD O
different BC2GM094263980 JJ O
placement BC2GM094263980 NN O
techniques BC2GM094263980 NNS O
( BC2GM094263980 ( O
Bulk BC2GM094263980 NNP O
pack BC2GM094263980 NN O
, BC2GM094263980 , O
Horizontal BC2GM094263980 NNP O
layering BC2GM094263980 NN O
and BC2GM094263980 CC O
Vertical BC2GM094263980 NNP O
layering BC2GM094263980 NN O
) BC2GM094263980 ) O
into BC2GM094263980 IN O
class BC2GM094263980 NN O
II BC2GM094263980 NNP O
cavities BC2GM094263980 NNS O
in BC2GM094263980 IN O
extracted BC2GM094263980 JJ O
human BC2GM094263980 JJ O
molars BC2GM094263980 NNS O
. BC2GM094263980 . O
. . O O

We BC2GM029532307 PRP O
have BC2GM029532307 VBP O
identified BC2GM029532307 VBN O
the BC2GM029532307 DT O
gene BC2GM029532307 NN O
encoding BC2GM029532307 VBG O
sigma BC2GM029532307 JJ O
E BC2GM029532307 NNP O
using BC2GM029532307 VBG O
a BC2GM029532307 DT O
genetic BC2GM029532307 JJ O
screen BC2GM029532307 NN O
designed BC2GM029532307 VBN O
to BC2GM029532307 TO O
isolate BC2GM029532307 VB O
trans-acting BC2GM029532307 JJ O
mutations BC2GM029532307 NNS O
that BC2GM029532307 IN O
abolish BC2GM029532307 JJ O
expression BC2GM029532307 NN O
from BC2GM029532307 IN O
either BC2GM029532307 CC O
htrA BC2GM029532307 NN O
or BC2GM029532307 CC O
rpoHP3 BC2GM029532307 NN O
, BC2GM029532307 , O
two BC2GM029532307 CD O
promoters BC2GM029532307 NNS O
recognized BC2GM029532307 VBN O
uniquely BC2GM029532307 RB O
by BC2GM029532307 IN O
sigma BC2GM029532307 JJ O
E-containing BC2GM029532307 JJ O
RNA BC2GM029532307 NNP O
polymerase BC2GM029532307 NN O
. BC2GM029532307 . O
. . O O

The BC2GM021160807 DT O
performances BC2GM021160807 NNS O
of BC2GM021160807 IN O
two BC2GM021160807 CD O
tests BC2GM021160807 NNS O
, BC2GM021160807 , O
the BC2GM021160807 DT O
ProstAsure BC2GM021160807 NNP O
index BC2GM021160807 NN O
and BC2GM021160807 CC O
the BC2GM021160807 DT O
percent BC2GM021160807 NN O
free BC2GM021160807 JJ O
PSA BC2GM021160807 NNP O
test BC2GM021160807 NN O
, BC2GM021160807 , O
were BC2GM021160807 VBD O
evaluated BC2GM021160807 VBN O
in BC2GM021160807 IN O
detecting BC2GM021160807 VBG O
cancer BC2GM021160807 NN O
. BC2GM021160807 . O
. . O O

Two BC2GM085413059 CD O
sibs BC2GM085413059 NN O
with BC2GM085413059 IN O
identical BC2GM085413059 JJ O
features BC2GM085413059 NNS O
of BC2GM085413059 IN O
short-limbed BC2GM085413059 JJ O
dwarfism BC2GM085413059 NN O
, BC2GM085413059 , O
a BC2GM085413059 DT O
normal BC2GM085413059 JJ O
skull BC2GM085413059 NN O
and BC2GM085413059 CC O
face BC2GM085413059 NN O
and BC2GM085413059 CC O
normal BC2GM085413059 JJ O
intelligence BC2GM085413059 NN O
are BC2GM085413059 VBP O
described BC2GM085413059 VBN O
. BC2GM085413059 . O
. . O O

These BC2GM007849960 DT O
events BC2GM007849960 NNS O
were BC2GM007849960 VBD O
only BC2GM007849960 RB O
weakly BC2GM007849960 RB O
stimulated BC2GM007849960 VBN O
by BC2GM007849960 IN O
the BC2GM007849960 DT O
activated BC2GM007849960 JJ O
PDGF BC2GM007849960 NNP O
alpha-receptor BC2GM007849960 NN O
. BC2GM007849960 . O
. . O O

It BC2GM095315156 PRP O
is BC2GM095315156 VBZ O
also BC2GM095315156 RB O
affected BC2GM095315156 VBN O
by BC2GM095315156 IN O
the BC2GM095315156 DT O
HAP2 BC2GM095315156 NNP O
/ BC2GM095315156 NNP O
3 BC2GM095315156 CD O
/ BC2GM095315156 VBD O
4 BC2GM095315156 CD O
transcription BC2GM095315156 NN O
factor BC2GM095315156 NN O
complex BC2GM095315156 NN O
and BC2GM095315156 CC O
by BC2GM095315156 IN O
SNF1 BC2GM095315156 NNP O
and BC2GM095315156 CC O
SSN6 BC2GM095315156 NNP O
. BC2GM095315156 . O
. . O O

Several BC2GM018326303 JJ O
waveforms BC2GM018326303 NNS O
of BC2GM018326303 IN O
both BC2GM018326303 DT O
the BC2GM018326303 DT O
somatosensory BC2GM018326303 NN O
( BC2GM018326303 ( O
N20 BC2GM018326303 NNP O
, BC2GM018326303 , O
P BC2GM018326303 NNP O
/ BC2GM018326303 NNP O
N BC2GM018326303 NNP O
30 BC2GM018326303 CD O
, BC2GM018326303 , O
and BC2GM018326303 CC O
P200 BC2GM018326303 NNP O
) BC2GM018326303 ) O
and BC2GM018326303 CC O
the BC2GM018326303 DT O
brainstem BC2GM018326303 NN O
auditory-evoked BC2GM018326303 JJ O
response BC2GM018326303 NN O
( BC2GM018326303 ( O
I BC2GM018326303 PRP O
, BC2GM018326303 , O
III BC2GM018326303 NNP O
, BC2GM018326303 , O
IV BC2GM018326303 NNP O
, BC2GM018326303 , O
and BC2GM018326303 CC O
V BC2GM018326303 NNP O
) BC2GM018326303 ) O
demonstrated BC2GM018326303 VBD O
shorter BC2GM018326303 JJR O
( BC2GM018326303 ( O
p BC2GM018326303 NN O
less BC2GM018326303 JJR O
than BC2GM018326303 IN O
0.05 BC2GM018326303 CD O
) BC2GM018326303 ) O
latencies BC2GM018326303 NNS O
in BC2GM018326303 IN O
growth-retarded BC2GM018326303 JJ O
fetuses BC2GM018326303 NNS O
relative BC2GM018326303 VBP O
to BC2GM018326303 TO O
normal-sized BC2GM018326303 JJ O
fetuses BC2GM018326303 NNS O
. BC2GM018326303 . O
. . O O

273 BC2GM046830258 CD O
, BC2GM046830258 , O
27420-27429 BC2GM046830258 JJ O
) BC2GM046830258 ) O
a BC2GM046830258 DT O
putative BC2GM046830258 JJ O
peroxisome BC2GM046830258 NN O
proliferator-activated BC2GM046830258 JJ O
receptor BC2GM046830258 NN O
response BC2GM046830258 NN O
element BC2GM046830258 NN O
( BC2GM046830258 ( O
PPRE BC2GM046830258 NNP O
) BC2GM046830258 ) O
is BC2GM046830258 VBZ O
present BC2GM046830258 JJ O
from BC2GM046830258 IN O
-458 BC2GM046830258 NN O
to BC2GM046830258 TO O
-474 BC2GM046830258 VB O
. BC2GM046830258 . O
. . O O

Patients BC2GM089330500 NNS O
received BC2GM089330500 VBD O
either BC2GM089330500 RB O
sodium BC2GM089330500 JJ O
cephalothin BC2GM089330500 NN O
or BC2GM089330500 CC O
placebo BC2GM089330500 NN O
intravenously BC2GM089330500 RB O
before BC2GM089330500 IN O
the BC2GM089330500 DT O
procedure BC2GM089330500 NN O
and BC2GM089330500 CC O
for BC2GM089330500 IN O
up BC2GM089330500 RB O
to BC2GM089330500 TO O
8 BC2GM089330500 CD O
additional BC2GM089330500 JJ O
doses BC2GM089330500 NNS O
. BC2GM089330500 . O
. . O O

Copyright BC2GM033128498 JJ O
1999 BC2GM033128498 CD O
Academic BC2GM033128498 NNP O
Press BC2GM033128498 NNP O
. BC2GM033128498 . O
. . O O

A BC2GM088666537 DT O
5789-nucleotide-long BC2GM088666537 JJ O
EcoRI BC2GM088666537 NNP O
fragment BC2GM088666537 NN O
from BC2GM088666537 IN O
the BC2GM088666537 DT O
genome BC2GM088666537 NN O
of BC2GM088666537 IN O
Thermotoga BC2GM088666537 NNP O
maritima BC2GM088666537 NNP O
, BC2GM088666537 , O
identified BC2GM088666537 VBN O
by BC2GM088666537 IN O
cross-hybridization BC2GM088666537 NN O
to BC2GM088666537 TO O
L11 BC2GM088666537 NNP O
, BC2GM088666537 , O
L1 BC2GM088666537 NNP O
, BC2GM088666537 , O
L10 BC2GM088666537 NNP O
, BC2GM088666537 , O
and BC2GM088666537 CC O
L12 BC2GM088666537 NNP O
ribosomal BC2GM088666537 VBP O
protein BC2GM088666537 JJ O
gene BC2GM088666537 NN O
sequences BC2GM088666537 NNS O
from BC2GM088666537 IN O
Escherichia BC2GM088666537 NNP O
coli BC2GM088666537 NN O
, BC2GM088666537 , O
was BC2GM088666537 VBD O
cloned BC2GM088666537 VBN O
and BC2GM088666537 CC O
sequenced BC2GM088666537 VBN O
. BC2GM088666537 . O
. . O O

Sin4 BC2GM019801606 NNP O
and BC2GM019801606 CC O
Srb10 BC2GM019801606 NNP O
, BC2GM019801606 , O
components BC2GM019801606 NNS O
of BC2GM019801606 IN O
specific BC2GM019801606 JJ O
RNA BC2GM019801606 NNP O
polymerase BC2GM019801606 NN O
II BC2GM019801606 NNP O
sub-complexes BC2GM019801606 NN O
that BC2GM019801606 WDT O
are BC2GM019801606 VBP O
required BC2GM019801606 VBN O
for BC2GM019801606 IN O
Ssn6-Tup1 BC2GM019801606 JJ O
repression BC2GM019801606 NN O
activity BC2GM019801606 NN O
, BC2GM019801606 , O
are BC2GM019801606 VBP O
found BC2GM019801606 VBN O
to BC2GM019801606 TO O
be BC2GM019801606 VB O
required BC2GM019801606 VBN O
for BC2GM019801606 IN O
Sfl1 BC2GM019801606 NNP O
repression BC2GM019801606 NN O
function BC2GM019801606 NN O
. BC2GM019801606 . O
. . O O

Reversible BC2GM069537069 JJ O
pressure-induced BC2GM069537069 JJ O
amorphization BC2GM069537069 NN O
in BC2GM069537069 IN O
solid BC2GM069537069 JJ O
C70 BC2GM069537069 NN O
: BC2GM069537069 : O
Raman BC2GM069537069 NNP O
and BC2GM069537069 CC O
photoluminescence BC2GM069537069 NN O
study BC2GM069537069 NN O
. BC2GM069537069 . O
. . O O

1 BC2GM095042999 CD O
The BC2GM095042999 DT O
effects BC2GM095042999 NNS O
of BC2GM095042999 IN O
high BC2GM095042999 JJ O
doses BC2GM095042999 NNS O
of BC2GM095042999 IN O
piretanide BC2GM095042999 NN O
, BC2GM095042999 , O
a BC2GM095042999 DT O
new BC2GM095042999 JJ O
diuretic BC2GM095042999 JJ O
agent BC2GM095042999 NN O
chemically BC2GM095042999 RB O
related BC2GM095042999 VBN O
to BC2GM095042999 TO O
frusemide BC2GM095042999 VB O
and BC2GM095042999 CC O
bumetanide BC2GM095042999 VB O
were BC2GM095042999 VBD O
evaluated BC2GM095042999 VBN O
in BC2GM095042999 IN O
twelve BC2GM095042999 NN O
patients BC2GM095042999 NNS O
with BC2GM095042999 IN O
severe BC2GM095042999 JJ O
chronic BC2GM095042999 JJ O
renal BC2GM095042999 JJ O
insufficiency BC2GM095042999 NN O
( BC2GM095042999 ( O
creatinine BC2GM095042999 JJ O
clearance BC2GM095042999 NN O
below BC2GM095042999 IN O
25 BC2GM095042999 CD O
ml BC2GM095042999 NNS O
/ BC2GM095042999 NNP O
min BC2GM095042999 NN O
) BC2GM095042999 ) O
. BC2GM095042999 . O
. . O O

Both BC2GM050148188 DT O
sequence BC2GM050148188 NN O
analysis BC2GM050148188 NN O
and BC2GM050148188 CC O
restriction BC2GM050148188 NN O
fragment BC2GM050148188 NN O
length BC2GM050148188 NN O
polymorphism BC2GM050148188 NN O
analysis BC2GM050148188 NN O
revealed BC2GM050148188 VBD O
a BC2GM050148188 DT O
high BC2GM050148188 JJ O
degree BC2GM050148188 NN O
of BC2GM050148188 IN O
sequence BC2GM050148188 NN O
( BC2GM050148188 ( O
97 BC2GM050148188 CD O
% BC2GM050148188 NN O
homology BC2GM050148188 NN O
) BC2GM050148188 ) O
and BC2GM050148188 CC O
structural BC2GM050148188 JJ O
similarity BC2GM050148188 NN O
among BC2GM050148188 IN O
members BC2GM050148188 NNS O
of BC2GM050148188 IN O
the BC2GM050148188 DT O
ART-CH BC2GM050148188 NNP O
family BC2GM050148188 NN O
, BC2GM050148188 , O
indicating BC2GM050148188 VBG O
their BC2GM050148188 PRP$ O
common BC2GM050148188 JJ O
origin BC2GM050148188 NN O
and BC2GM050148188 CC O
recent BC2GM050148188 JJ O
penetration BC2GM050148188 NN O
into BC2GM050148188 IN O
chicken BC2GM050148188 NN O
DNA BC2GM050148188 NN O
. BC2GM050148188 . O
. . O O

Transformations BC2GM084163116 NNS O
with BC2GM084163116 IN O
circular BC2GM084163116 JJ O
plasmids BC2GM084163116 NNS O
yielded BC2GM084163116 VBD O
slowly BC2GM084163116 RB O
and BC2GM084163116 CC O
irregularly BC2GM084163116 RB O
growing BC2GM084163116 VBG O
geneticin-resistant BC2GM084163116 JJ O
mycelia BC2GM084163116 NN O
in BC2GM084163116 IN O
which BC2GM084163116 WDT O
1 BC2GM084163116 CD O
% BC2GM084163116 NN O
of BC2GM084163116 IN O
nuclei BC2GM084163116 NN O
contained BC2GM084163116 VBN O
plasmid BC2GM084163116 JJ O
sequences BC2GM084163116 NNS O
. BC2GM084163116 . O
. . O O

We BC2GM068734803 PRP O
studied BC2GM068734803 VBD O
about BC2GM068734803 IN O
the BC2GM068734803 DT O
histological BC2GM068734803 JJ O
findings BC2GM068734803 NNS O
of BC2GM068734803 IN O
the BC2GM068734803 DT O
kidneys BC2GM068734803 NNS O
including BC2GM068734803 VBG O
of BC2GM068734803 IN O
the BC2GM068734803 DT O
infiltrated BC2GM068734803 JJ O
macrophages BC2GM068734803 NNS O
in BC2GM068734803 IN O
one BC2GM068734803 CD O
hour BC2GM068734803 NN O
post-transplantation BC2GM068734803 NN O
kidney BC2GM068734803 NN O
biopsies BC2GM068734803 NNS O
( BC2GM068734803 ( O
one BC2GM068734803 CD O
hour BC2GM068734803 NN O
biopsies BC2GM068734803 NNS O
) BC2GM068734803 ) O
and BC2GM068734803 CC O
re-biopsies BC2GM068734803 NNS O
on BC2GM068734803 IN O
11 BC2GM068734803 CD O
patients BC2GM068734803 NNS O
. BC2GM068734803 . O
. . O O

5.3 BC2GM050804040 CD O
+ BC2GM050804040 JJ O
/ BC2GM050804040 NNP O
- BC2GM050804040 : O
6.6 BC2GM050804040 CD O
for BC2GM050804040 IN O
risperidone BC2GM050804040 NN O
( BC2GM050804040 ( O
P BC2GM050804040 NNP O
= BC2GM050804040 NNP O
0.09 BC2GM050804040 CD O
) BC2GM050804040 ) O
. BC2GM050804040 . O
. . O O

Juvenile BC2GM006679416 NNP O
idiopathic BC2GM006679416 JJ O
inflammatory BC2GM006679416 JJ O
myopathies BC2GM006679416 NNS O
: BC2GM006679416 : O
the BC2GM006679416 DT O
value BC2GM006679416 NN O
of BC2GM006679416 IN O
magnetic BC2GM006679416 JJ O
resonance BC2GM006679416 NN O
imaging BC2GM006679416 NN O
in BC2GM006679416 IN O
the BC2GM006679416 DT O
detection BC2GM006679416 NN O
of BC2GM006679416 IN O
muscle BC2GM006679416 NN O
involvement BC2GM006679416 NN O
. BC2GM006679416 . O
. . O O

The BC2GM009017382 DT O
combination BC2GM009017382 NN O
of BC2GM009017382 IN O
ICP47 BC2GM009017382 NNP O
and BC2GM009017382 CC O
US11 BC2GM009017382 NNP O
rendered BC2GM009017382 VBD O
fibroblasts BC2GM009017382 NNS O
negative BC2GM009017382 JJ O
for BC2GM009017382 IN O
surface BC2GM009017382 NN O
class BC2GM009017382 NN O
I BC2GM009017382 PRP O
MHC BC2GM009017382 NNP O
and BC2GM009017382 CC O
allowed BC2GM009017382 VBD O
a BC2GM009017382 DT O
class BC2GM009017382 NN O
I BC2GM009017382 PRP O
MHC-low BC2GM009017382 JJ O
population BC2GM009017382 NN O
of BC2GM009017382 IN O
T BC2GM009017382 NNP O
cells BC2GM009017382 NNS O
to BC2GM009017382 TO O
be BC2GM009017382 VB O
sorted BC2GM009017382 VBN O
by BC2GM009017382 IN O
flow BC2GM009017382 JJ O
cytometry BC2GM009017382 NN O
. BC2GM009017382 . O
. . O O

This BC2GM034042990 DT O
activity BC2GM034042990 NN O
creates BC2GM034042990 VBZ O
a BC2GM034042990 DT O
4-bp BC2GM034042990 JJ O
staggered BC2GM034042990 JJ O
cut BC2GM034042990 NN O
with BC2GM034042990 IN O
3 BC2GM034042990 CD O
' BC2GM034042990 POS O
OH BC2GM034042990 NNP O
overhangs BC2GM034042990 NNS O
within BC2GM034042990 IN O
a BC2GM034042990 DT O
specific BC2GM034042990 JJ O
sequence BC2GM034042990 NN O
of BC2GM034042990 IN O
the BC2GM034042990 DT O
21S BC2GM034042990 CD O
rRNA BC2GM034042990 JJ O
gene BC2GM034042990 NN O
of BC2GM034042990 IN O
omega- BC2GM034042990 JJ O
strains BC2GM034042990 NNS O
. BC2GM034042990 . O
. . O O

Istanbul BC2GM096120426 NNP O
, BC2GM096120426 , O
Turkey BC2GM096120426 NNP O
. BC2GM096120426 . O
. . O O

This BC2GM092286757 DT O
was BC2GM092286757 VBD O
tragically BC2GM092286757 RB O
highlighted BC2GM092286757 VBN O
by BC2GM092286757 IN O
the BC2GM092286757 DT O
death BC2GM092286757 NN O
of BC2GM092286757 IN O
a BC2GM092286757 DT O
17 BC2GM092286757 CD O
year BC2GM092286757 NN O
old BC2GM092286757 JJ O
dental BC2GM092286757 NN O
nurse BC2GM092286757 NN O
after BC2GM092286757 IN O
taking BC2GM092286757 VBG O
a BC2GM092286757 DT O
single BC2GM092286757 JJ O
1 BC2GM092286757 CD O
g BC2GM092286757 JJ O
tablet BC2GM092286757 NN O
of BC2GM092286757 IN O
sodium BC2GM092286757 NN O
nitrite BC2GM092286757 NN O
. BC2GM092286757 . O
. . O O

We BC2GM026076995 PRP O
determined BC2GM026076995 VBD O
that BC2GM026076995 IN O
Hop BC2GM026076995 NNP O
( BC2GM026076995 ( O
T42 BC2GM026076995 NNP O
) BC2GM026076995 ) O
contains BC2GM026076995 VBZ O
a BC2GM026076995 DT O
glutamic BC2GM026076995 JJ O
acid-to-lysine BC2GM026076995 JJ O
substitution BC2GM026076995 NN O
at BC2GM026076995 IN O
amino BC2GM026076995 NN O
acid BC2GM026076995 NN O
residue BC2GM026076995 JJ O
695 BC2GM026076995 CD O
( BC2GM026076995 ( O
E695K BC2GM026076995 NNP O
) BC2GM026076995 ) O
. BC2GM026076995 . O
. . O O

In BC2GM000099421 IN O
the BC2GM000099421 DT O
absence BC2GM000099421 NN O
of BC2GM000099421 IN O
shock BC2GM000099421 NN O
, BC2GM000099421 , O
sepsis BC2GM000099421 NN O
, BC2GM000099421 , O
or BC2GM000099421 CC O
other BC2GM000099421 JJ O
identifiable BC2GM000099421 JJ O
causes BC2GM000099421 NNS O
of BC2GM000099421 IN O
lactic BC2GM000099421 JJ O
acidosis BC2GM000099421 NN O
, BC2GM000099421 , O
the BC2GM000099421 DT O
severe BC2GM000099421 JJ O
anemia BC2GM000099421 NN O
( BC2GM000099421 ( O
hemoglobin BC2GM000099421 JJ O
1.2 BC2GM000099421 CD O
g BC2GM000099421 NN O
/ BC2GM000099421 NNP O
dl BC2GM000099421 NN O
) BC2GM000099421 ) O
appeared BC2GM000099421 VBD O
to BC2GM000099421 TO O
be BC2GM000099421 VB O
the BC2GM000099421 DT O
primary BC2GM000099421 JJ O
etiologic BC2GM000099421 JJ O
factor BC2GM000099421 NN O
. BC2GM000099421 . O
. . O O

The BC2GM066800010 DT O
arterial BC2GM066800010 JJ O
blood BC2GM066800010 NN O
pressure BC2GM066800010 NN O
was BC2GM066800010 VBD O
measured BC2GM066800010 VBN O
by BC2GM066800010 IN O
using BC2GM066800010 VBG O
bloody BC2GM066800010 JJ O
method BC2GM066800010 NN O
in BC2GM066800010 IN O
anesthizied BC2GM066800010 JJ O
animals BC2GM066800010 NNS O
. BC2GM066800010 . O
. . O O

The BC2GM091790699 DT O
use BC2GM091790699 NN O
of BC2GM091790699 IN O
aluminum BC2GM091790699 NN O
hydroxide BC2GM091790699 NN O
was BC2GM091790699 VBD O
associated BC2GM091790699 VBN O
with BC2GM091790699 IN O
an BC2GM091790699 DT O
increase BC2GM091790699 NN O
in BC2GM091790699 IN O
fecal BC2GM091790699 JJ O
fluoride BC2GM091790699 NN O
excretion BC2GM091790699 NN O
and BC2GM091790699 CC O
a BC2GM091790699 DT O
decrease BC2GM091790699 NN O
in BC2GM091790699 IN O
net BC2GM091790699 JJ O
absorption BC2GM091790699 NN O
of BC2GM091790699 IN O
fluoride BC2GM091790699 JJ O
regardless BC2GM091790699 NN O
of BC2GM091790699 IN O
the BC2GM091790699 DT O
intake BC2GM091790699 NN O
fluoride BC2GM091790699 NN O
, BC2GM091790699 , O
calcium BC2GM091790699 NN O
, BC2GM091790699 , O
phosphorus BC2GM091790699 NN O
, BC2GM091790699 , O
or BC2GM091790699 CC O
magnesium BC2GM091790699 NN O
. BC2GM091790699 . O
. . O O

SETTING BC2GM056576430 NN O
-- BC2GM056576430 : O
Hospital BC2GM056576430 JJ O
laboratories BC2GM056576430 NNS O
in BC2GM056576430 IN O
the BC2GM056576430 DT O
United BC2GM056576430 NNP O
States BC2GM056576430 NNPS O
submitting BC2GM056576430 VBG O
pneumococcal BC2GM056576430 JJ O
isolates BC2GM056576430 NNS O
to BC2GM056576430 TO O
the BC2GM056576430 DT O
CDC BC2GM056576430 NNP O
between BC2GM056576430 IN O
October BC2GM056576430 NNP O
1 BC2GM056576430 CD O
, BC2GM056576430 , O
1991 BC2GM056576430 CD O
, BC2GM056576430 , O
and BC2GM056576430 CC O
September BC2GM056576430 NNP O
30 BC2GM056576430 CD O
, BC2GM056576430 , O
1992 BC2GM056576430 CD O
. BC2GM056576430 . O
. . O O

Furthermore BC2GM003056399 RB O
, BC2GM003056399 , O
we BC2GM003056399 PRP O
demonstrate BC2GM003056399 VBP O
that BC2GM003056399 IN O
in BC2GM003056399 IN O
myeloid BC2GM003056399 NN O
and BC2GM003056399 CC O
B BC2GM003056399 NNP O
cell BC2GM003056399 NN O
extracts BC2GM003056399 NNS O
, BC2GM003056399 , O
PU.1 BC2GM003056399 NNP O
forms BC2GM003056399 VBZ O
a BC2GM003056399 DT O
novel BC2GM003056399 NN O
, BC2GM003056399 , O
specific BC2GM003056399 JJ O
, BC2GM003056399 , O
more BC2GM003056399 RBR O
slowly BC2GM003056399 RB O
migrating BC2GM003056399 VBG O
complex BC2GM003056399 JJ O
( BC2GM003056399 ( O
PU-SF BC2GM003056399 NNP O
) BC2GM003056399 ) O
when BC2GM003056399 WRB O
binding BC2GM003056399 VBG O
the BC2GM003056399 DT O
GM-CSF BC2GM003056399 NNP O
receptor BC2GM003056399 NN O
alpha BC2GM003056399 NN O
promoter BC2GM003056399 NN O
PU.1 BC2GM003056399 NNP O
site BC2GM003056399 NN O
. BC2GM003056399 . O
. . O O

In BC2GM097468485 IN O
contrast BC2GM097468485 NN O
to BC2GM097468485 TO O
p62 BC2GM097468485 VB O
( BC2GM097468485 ( O
dok BC2GM097468485 NN O
) BC2GM097468485 ) O
, BC2GM097468485 , O
DOKL BC2GM097468485 NNP O
lacks BC2GM097468485 VBZ O
YxxP BC2GM097468485 NNP O
motifs BC2GM097468485 NN O
in BC2GM097468485 IN O
the BC2GM097468485 DT O
C BC2GM097468485 NNP O
terminus BC2GM097468485 NN O
and BC2GM097468485 CC O
does BC2GM097468485 VBZ O
not BC2GM097468485 RB O
bind BC2GM097468485 VB O
to BC2GM097468485 TO O
Ras BC2GM097468485 NNP O
GTPase-activating BC2GM097468485 NNP O
protein BC2GM097468485 NN O
( BC2GM097468485 ( O
RasGAP BC2GM097468485 NNP O
) BC2GM097468485 ) O
upon BC2GM097468485 IN O
phosphorylation BC2GM097468485 NN O
. BC2GM097468485 . O
. . O O

Nuclear BC2GM054001196 JJ O
proteins BC2GM054001196 VBZ O
bound BC2GM054001196 IN O
the BC2GM054001196 DT O
cad BC2GM054001196 NN O
+55 BC2GM054001196 NNP O
/ BC2GM054001196 NNP O
+75 BC2GM054001196 NNP O
element BC2GM054001196 NN O
in BC2GM054001196 IN O
a BC2GM054001196 DT O
cell BC2GM054001196 NN O
cycle-dependent BC2GM054001196 JJ O
manner BC2GM054001196 NN O
in BC2GM054001196 IN O
electromobility BC2GM054001196 NN O
shift BC2GM054001196 NN O
assays BC2GM054001196 NNS O
; BC2GM054001196 : O
antibodies BC2GM054001196 NNS O
specific BC2GM054001196 VBP O
to BC2GM054001196 TO O
USF BC2GM054001196 NNP O
and BC2GM054001196 CC O
Max BC2GM054001196 NNP O
blocked BC2GM054001196 VBD O
the BC2GM054001196 DT O
DNA-binding BC2GM054001196 JJ O
activity BC2GM054001196 NN O
of BC2GM054001196 IN O
different BC2GM054001196 JJ O
growth-regulated BC2GM054001196 JJ O
protein-DNA BC2GM054001196 NN O
complexes BC2GM054001196 NNS O
. BC2GM054001196 . O
. . O O

An BC2GM037763094 DT O
ERp60-like BC2GM037763094 JJ O
protein BC2GM037763094 NN O
from BC2GM037763094 IN O
the BC2GM037763094 DT O
filarial BC2GM037763094 JJ O
parasite BC2GM037763094 NN O
Dirofilaria BC2GM037763094 NNP O
immitis BC2GM037763094 NN O
has BC2GM037763094 VBZ O
both BC2GM037763094 DT O
transglutaminase BC2GM037763094 NN O
and BC2GM037763094 CC O
protein BC2GM037763094 NN O
disulfide BC2GM037763094 JJ O
isomerase BC2GM037763094 NN O
activity BC2GM037763094 NN O
. BC2GM037763094 . O
. . O O

Fulminant BC2GM010723108 NNP O
hepatic BC2GM010723108 JJ O
failure BC2GM010723108 NN O
in BC2GM010723108 IN O
these BC2GM010723108 DT O
cases BC2GM010723108 NNS O
could BC2GM010723108 MD O
be BC2GM010723108 VB O
characterized BC2GM010723108 VBN O
by BC2GM010723108 IN O
: BC2GM010723108 : O
( BC2GM010723108 ( O
1 BC2GM010723108 CD O
) BC2GM010723108 ) O
rapid BC2GM010723108 JJ O
decrease BC2GM010723108 NN O
in BC2GM010723108 IN O
serum BC2GM010723108 JJ O
alanine BC2GM010723108 JJ O
transaminase BC2GM010723108 NN O
( BC2GM010723108 ( O
ALT BC2GM010723108 NNP O
) BC2GM010723108 ) O
level BC2GM010723108 NN O
after BC2GM010723108 IN O
discontinuation BC2GM010723108 NN O
of BC2GM010723108 IN O
ecarazine BC2GM010723108 NN O
, BC2GM010723108 , O
( BC2GM010723108 ( O
2 BC2GM010723108 CD O
) BC2GM010723108 ) O
prolonged BC2GM010723108 VBD O
jaundice BC2GM010723108 NN O
despite BC2GM010723108 IN O
discontinuation BC2GM010723108 NN O
of BC2GM010723108 IN O
ecarazine BC2GM010723108 NN O
, BC2GM010723108 , O
( BC2GM010723108 ( O
3 BC2GM010723108 CD O
) BC2GM010723108 ) O
high BC2GM010723108 JJ O
incidence BC2GM010723108 NN O
of BC2GM010723108 IN O
anti-nuclear BC2GM010723108 JJ O
antibody BC2GM010723108 NN O
( BC2GM010723108 ( O
ANA BC2GM010723108 NNP O
) BC2GM010723108 ) O
( BC2GM010723108 ( O
57 BC2GM010723108 CD O
% BC2GM010723108 NN O
) BC2GM010723108 ) O
, BC2GM010723108 , O
and BC2GM010723108 CC O
( BC2GM010723108 ( O
4 BC2GM010723108 CD O
) BC2GM010723108 ) O
histological BC2GM010723108 JJ O
findings BC2GM010723108 NNS O
of BC2GM010723108 IN O
extensive BC2GM010723108 JJ O
hepatocellular BC2GM010723108 JJ O
necrosis BC2GM010723108 NN O
ranging BC2GM010723108 VBG O
from BC2GM010723108 IN O
bridging BC2GM010723108 VBG O
necrosis BC2GM010723108 NN O
to BC2GM010723108 TO O
massive BC2GM010723108 JJ O
necrosis BC2GM010723108 NN O
. BC2GM010723108 . O
. . O O

Recent BC2GM097038641 JJ O
studies BC2GM097038641 NNS O
have BC2GM097038641 VBP O
concentrated BC2GM097038641 VBN O
on BC2GM097038641 IN O
the BC2GM097038641 DT O
methods BC2GM097038641 NNS O
of BC2GM097038641 IN O
preparation BC2GM097038641 NN O
of BC2GM097038641 IN O
coffee BC2GM097038641 NN O
, BC2GM097038641 , O
which BC2GM097038641 WDT O
vary BC2GM097038641 VBP O
from BC2GM097038641 IN O
country BC2GM097038641 NN O
to BC2GM097038641 TO O
country BC2GM097038641 NN O
. BC2GM097038641 . O
. . O O

Scleraxis BC2GM002038787 NNP O
overexpression BC2GM002038787 NN O
enhanced BC2GM002038787 VBD O
expression BC2GM002038787 NN O
of BC2GM002038787 IN O
the BC2GM002038787 DT O
aggrecan BC2GM002038787 JJ O
gene BC2GM002038787 NN O
, BC2GM002038787 , O
which BC2GM002038787 WDT O
is BC2GM002038787 VBZ O
not BC2GM002038787 RB O
normally BC2GM002038787 RB O
expressed BC2GM002038787 VBN O
at BC2GM002038787 IN O
high BC2GM002038787 JJ O
levels BC2GM002038787 NNS O
in BC2GM002038787 IN O
these BC2GM002038787 DT O
osteoblastic BC2GM002038787 JJ O
cells BC2GM002038787 NNS O
. BC2GM002038787 . O
. . O O

The BC2GM089028538 DT O
densities BC2GM089028538 NNS O
ranged BC2GM089028538 VBD O
between BC2GM089028538 IN O
2 BC2GM089028538 CD O
and BC2GM089028538 CC O
3976 BC2GM089028538 CD O
neurites BC2GM089028538 NNS O
/ BC2GM089028538 VBP O
mm2 BC2GM089028538 JJ O
skin BC2GM089028538 NN O
surface BC2GM089028538 NN O
, BC2GM089028538 , O
but BC2GM089028538 CC O
the BC2GM089028538 DT O
overlap BC2GM089028538 NN O
between BC2GM089028538 IN O
subjects BC2GM089028538 NNS O
and BC2GM089028538 CC O
without BC2GM089028538 IN O
PHN BC2GM089028538 NNP O
was BC2GM089028538 VBD O
small BC2GM089028538 JJ O
. BC2GM089028538 . O
. . O O

We BC2GM069327394 PRP O
have BC2GM069327394 VBP O
generated BC2GM069327394 VBN O
transgenic BC2GM069327394 JJ O
fly BC2GM069327394 NN O
strains BC2GM069327394 NNS O
with BC2GM069327394 IN O
mutations BC2GM069327394 NNS O
affecting BC2GM069327394 VBG O
specific BC2GM069327394 JJ O
TRA-2 BC2GM069327394 JJ O
isoforms BC2GM069327394 NNS O
to BC2GM069327394 TO O
investigate BC2GM069327394 VB O
their BC2GM069327394 PRP$ O
individual BC2GM069327394 JJ O
roles BC2GM069327394 NNS O
in BC2GM069327394 IN O
regulating BC2GM069327394 VBG O
the BC2GM069327394 DT O
alternative BC2GM069327394 JJ O
processing BC2GM069327394 NN O
of BC2GM069327394 IN O
doublesex BC2GM069327394 NN O
, BC2GM069327394 , O
exuperantia BC2GM069327394 NN O
and BC2GM069327394 CC O
tra-2 BC2GM069327394 JJ O
pre-mRNA BC2GM069327394 NN O
. BC2GM069327394 . O
. . O O

Inhibitory BC2GM053719721 JJ O
receptors BC2GM053719721 NNS O
are BC2GM053719721 VBP O
characterized BC2GM053719721 VBN O
by BC2GM053719721 IN O
the BC2GM053719721 DT O
presence BC2GM053719721 NN O
of BC2GM053719721 IN O
a BC2GM053719721 DT O
characteristic BC2GM053719721 JJ O
sequence BC2GM053719721 NN O
known BC2GM053719721 VBN O
as BC2GM053719721 IN O
an BC2GM053719721 DT O
immunoreceptor BC2GM053719721 NN O
tyrosine-based BC2GM053719721 JJ O
inhibitory BC2GM053719721 NN O
motif BC2GM053719721 NN O
( BC2GM053719721 ( O
ITIM BC2GM053719721 NNP O
) BC2GM053719721 ) O
in BC2GM053719721 IN O
their BC2GM053719721 PRP$ O
cytoplasmic BC2GM053719721 JJ O
tail BC2GM053719721 NN O
. BC2GM053719721 . O
. . O O

The BC2GM043040465 DT O
tam BC2GM043040465 NN O
A BC2GM043040465 NNP O
gene BC2GM043040465 NN O
of BC2GM043040465 IN O
Aspergillus BC2GM043040465 NNP O
nidulans BC2GM043040465 NNS O
encodes BC2GM043040465 VBZ O
a BC2GM043040465 DT O
739-amino BC2GM043040465 JJ O
acid BC2GM043040465 NN O
protein BC2GM043040465 NN O
with BC2GM043040465 IN O
similarity BC2GM043040465 NN O
to BC2GM043040465 TO O
Uga35p BC2GM043040465 NNP O
/ BC2GM043040465 NNP O
Dal81p BC2GM043040465 NNP O
/ BC2GM043040465 NNP O
DurLp BC2GM043040465 NNP O
of BC2GM043040465 IN O
Saccharomyces BC2GM043040465 NNP O
cerevisiae BC2GM043040465 NN O
. BC2GM043040465 . O
. . O O

A BC2GM025160880 DT O
simple BC2GM025160880 JJ O
procedure BC2GM025160880 NN O
for BC2GM025160880 IN O
accurate BC2GM025160880 JJ O
quantitation BC2GM025160880 NN O
of BC2GM025160880 IN O
factor BC2GM025160880 NN O
VIII BC2GM025160880 NNP O
inhibitors BC2GM025160880 NNS O
. BC2GM025160880 . O
. . O O

The BC2GM036149639 DT O
main BC2GM036149639 JJ O
new BC2GM036149639 JJ O
features BC2GM036149639 NNS O
of BC2GM036149639 IN O
this BC2GM036149639 DT O
version BC2GM036149639 NN O
are BC2GM036149639 VBP O
that BC2GM036149639 IN O
end-tidal BC2GM036149639 JJ O
PO2 BC2GM036149639 NNP O
instead BC2GM036149639 RB O
of BC2GM036149639 IN O
inspiratory BC2GM036149639 JJ O
PO2 BC2GM036149639 NNP O
can BC2GM036149639 MD O
be BC2GM036149639 VB O
kept BC2GM036149639 VBN O
constant BC2GM036149639 JJ O
, BC2GM036149639 , O
and BC2GM036149639 CC O
that BC2GM036149639 IN O
the BC2GM036149639 DT O
correcting BC2GM036149639 NN O
activity BC2GM036149639 NN O
of BC2GM036149639 IN O
both BC2GM036149639 DT O
controllers BC2GM036149639 NNS O
( BC2GM036149639 ( O
capnostat BC2GM036149639 NN O
and BC2GM036149639 CC O
oxystat BC2GM036149639 NN O
) BC2GM036149639 ) O
is BC2GM036149639 VBZ O
proportional BC2GM036149639 JJ O
to BC2GM036149639 TO O
the BC2GM036149639 DT O
magnitude BC2GM036149639 NN O
of BC2GM036149639 IN O
the BC2GM036149639 DT O
difference BC2GM036149639 NN O
between BC2GM036149639 IN O
the BC2GM036149639 DT O
actual BC2GM036149639 JJ O
and BC2GM036149639 CC O
the BC2GM036149639 DT O
adjusted BC2GM036149639 VBN O
end-tidal BC2GM036149639 JJ O
PCO2 BC2GM036149639 NNP O
or BC2GM036149639 CC O
PO2 BC2GM036149639 NNP O
. BC2GM036149639 . O
. . O O

The BC2GM060831893 DT O
curse BC2GM060831893 NN O
of BC2GM060831893 IN O
the BC2GM060831893 DT O
Pharaohs BC2GM060831893 NNP O
. BC2GM060831893 . O
. . O O

Adjusting BC2GM095153900 VBG O
a BC2GM095153900 DT O
steady-state BC2GM095153900 JJ O
warfarin BC2GM095153900 NN O
dose BC2GM095153900 NN O
depends BC2GM095153900 VBZ O
on BC2GM095153900 IN O
the BC2GM095153900 DT O
measured BC2GM095153900 VBN O
INR BC2GM095153900 NNP O
values BC2GM095153900 NNS O
and BC2GM095153900 CC O
clinical BC2GM095153900 JJ O
factors BC2GM095153900 NNS O
: BC2GM095153900 : O
the BC2GM095153900 DT O
dose BC2GM095153900 NN O
does BC2GM095153900 VBZ O
not BC2GM095153900 RB O
need BC2GM095153900 VB O
to BC2GM095153900 TO O
be BC2GM095153900 VB O
adjusted BC2GM095153900 VBN O
for BC2GM095153900 IN O
a BC2GM095153900 DT O
single BC2GM095153900 JJ O
INR BC2GM095153900 NNP O
that BC2GM095153900 WDT O
is BC2GM095153900 VBZ O
slightly BC2GM095153900 RB O
out BC2GM095153900 IN O
of BC2GM095153900 IN O
range BC2GM095153900 NN O
, BC2GM095153900 , O
and BC2GM095153900 CC O
most BC2GM095153900 JJS O
changes BC2GM095153900 NNS O
should BC2GM095153900 MD O
alter BC2GM095153900 VB O
the BC2GM095153900 DT O
total BC2GM095153900 JJ O
weekly BC2GM095153900 JJ O
dose BC2GM095153900 NN O
by BC2GM095153900 IN O
5 BC2GM095153900 CD O
% BC2GM095153900 NN O
to BC2GM095153900 TO O
20 BC2GM095153900 CD O
% BC2GM095153900 NN O
. BC2GM095153900 . O
. . O O

A BC2GM066121491 DT O
360-bp BC2GM066121491 JJ O
DNA BC2GM066121491 NNP O
fragment BC2GM066121491 NN O
located BC2GM066121491 VBN O
over BC2GM066121491 IN O
500 BC2GM066121491 CD O
bp BC2GM066121491 JJ O
upstream BC2GM066121491 NN O
from BC2GM066121491 IN O
the BC2GM066121491 DT O
cfl BC2GM066121491 JJ O
transcriptional BC2GM066121491 JJ O
start BC2GM066121491 NN O
site BC2GM066121491 NN O
was BC2GM066121491 VBD O
used BC2GM066121491 VBN O
in BC2GM066121491 IN O
DNase BC2GM066121491 NNP O
I BC2GM066121491 PRP O
protection BC2GM066121491 NN O
assays BC2GM066121491 NNS O
to BC2GM066121491 TO O
define BC2GM066121491 VB O
the BC2GM066121491 DT O
specific BC2GM066121491 JJ O
bases BC2GM066121491 NNS O
bound BC2GM066121491 VBN O
by BC2GM066121491 IN O
CorR BC2GM066121491 NNP O
. BC2GM066121491 . O
. . O O

025 BC2GM013433125 CD O
) BC2GM013433125 ) O
. BC2GM013433125 . O
. . O O

Thus BC2GM037195225 RB O
, BC2GM037195225 , O
the BC2GM037195225 DT O
search BC2GM037195225 NN O
for BC2GM037195225 IN O
genetic BC2GM037195225 JJ O
and BC2GM037195225 CC O
acquired BC2GM037195225 VBN O
susceptibility BC2GM037195225 NN O
to BC2GM037195225 TO O
nontuberculous BC2GM037195225 JJ O
mycobacteria BC2GM037195225 NN O
is BC2GM037195225 VBZ O
also BC2GM037195225 RB O
a BC2GM037195225 DT O
search BC2GM037195225 NN O
for BC2GM037195225 IN O
susceptibility BC2GM037195225 NN O
factors BC2GM037195225 NNS O
for BC2GM037195225 IN O
MTB BC2GM037195225 NNP O
as BC2GM037195225 RB O
well BC2GM037195225 RB O
as BC2GM037195225 IN O
an BC2GM037195225 DT O
opportunity BC2GM037195225 NN O
to BC2GM037195225 TO O
recognize BC2GM037195225 VB O
endogenous BC2GM037195225 JJ O
pathways BC2GM037195225 NNS O
that BC2GM037195225 WDT O
can BC2GM037195225 MD O
be BC2GM037195225 VB O
exploited BC2GM037195225 VBN O
therapeutically BC2GM037195225 RB O
. BC2GM037195225 . O
. . O O

From BC2GM056788126 IN O
the BC2GM056788126 DT O
autopsy BC2GM056788126 NN O
findings BC2GM056788126 NNS O
, BC2GM056788126 , O
in BC2GM056788126 IN O
5 BC2GM056788126 CD O
out BC2GM056788126 IN O
of BC2GM056788126 IN O
the BC2GM056788126 DT O
remaining BC2GM056788126 VBG O
23 BC2GM056788126 CD O
expired BC2GM056788126 JJ O
patients BC2GM056788126 NNS O
, BC2GM056788126 , O
Legionella BC2GM056788126 NNP O
pneumonia BC2GM056788126 NN O
seemed BC2GM056788126 VBD O
to BC2GM056788126 TO O
be BC2GM056788126 VB O
successfully BC2GM056788126 RB O
treated BC2GM056788126 VBN O
, BC2GM056788126 , O
but BC2GM056788126 CC O
other BC2GM056788126 JJ O
disease BC2GM056788126 NN O
or BC2GM056788126 CC O
other BC2GM056788126 JJ O
bacterial BC2GM056788126 JJ O
pneumonia BC2GM056788126 NN O
put BC2GM056788126 VBD O
an BC2GM056788126 DT O
end BC2GM056788126 NN O
to BC2GM056788126 TO O
the BC2GM056788126 DT O
patients BC2GM056788126 NNS O
. BC2GM056788126 . O
. . O O

( BC2GM058378997 ( O
LH BC2GM058378997 NNP O
P BC2GM058378997 NNP O
< BC2GM058378997 NNP O
0.05 BC2GM058378997 CD O
, BC2GM058378997 , O
LH BC2GM058378997 NNP O
/ BC2GM058378997 NNP O
FSH BC2GM058378997 NNP O
P BC2GM058378997 NNP O
< BC2GM058378997 NNP O
0.01 BC2GM058378997 CD O
) BC2GM058378997 ) O
. BC2GM058378997 . O
. . O O

( BC2GM062859122 ( O
i BC2GM062859122 NN O
) BC2GM062859122 ) O
The BC2GM062859122 DT O
chimeric BC2GM062859122 JJ O
gene BC2GM062859122 NN O
consisting BC2GM062859122 VBG O
of BC2GM062859122 IN O
the BC2GM062859122 DT O
coding BC2GM062859122 NN O
and BC2GM062859122 CC O
5 BC2GM062859122 CD O
' BC2GM062859122 '' O
nontranslated BC2GM062859122 JJ O
leader BC2GM062859122 NN O
regions BC2GM062859122 NNS O
of BC2GM062859122 IN O
the BC2GM062859122 DT O
TK BC2GM062859122 NNP O
gene BC2GM062859122 NN O
fused BC2GM062859122 VBD O
to BC2GM062859122 TO O
portions BC2GM062859122 NNS O
of BC2GM062859122 IN O
the BC2GM062859122 DT O
domain BC2GM062859122 NN O
of BC2GM062859122 IN O
alpha BC2GM062859122 JJ O
gene BC2GM062859122 NN O
0 BC2GM062859122 CD O
extending BC2GM062859122 VBG O
largely BC2GM062859122 RB O
upstream BC2GM062859122 JJ O
from BC2GM062859122 IN O
the BC2GM062859122 DT O
site BC2GM062859122 NN O
of BC2GM062859122 IN O
initiation BC2GM062859122 NN O
of BC2GM062859122 IN O
transcription BC2GM062859122 NN O
of BC2GM062859122 IN O
alpha BC2GM062859122 JJ O
gene BC2GM062859122 NN O
0 BC2GM062859122 CD O
was BC2GM062859122 VBD O
regulated BC2GM062859122 VBN O
in BC2GM062859122 IN O
the BC2GM062859122 DT O
same BC2GM062859122 JJ O
fashion BC2GM062859122 NN O
as BC2GM062859122 IN O
the BC2GM062859122 DT O
alpha BC2GM062859122 JJ O
4- BC2GM062859122 JJ O
and BC2GM062859122 CC O
alpha BC2GM062859122 JJ O
27-TK BC2GM062859122 JJ O
chimeras BC2GM062859122 NNS O
. BC2GM062859122 . O
. . O O

The BC2GM006670958 DT O
deduced BC2GM006670958 JJ O
amino BC2GM006670958 NN O
acid BC2GM006670958 NN O
sequence BC2GM006670958 NN O
exhibits BC2GM006670958 VBZ O
95.3 BC2GM006670958 CD O
and BC2GM006670958 CC O
76.1 BC2GM006670958 CD O
% BC2GM006670958 NN O
identity BC2GM006670958 NN O
with BC2GM006670958 IN O
the BC2GM006670958 DT O
CAD BC2GM006670958 NNP O
sequences BC2GM006670958 NNS O
of BC2GM006670958 IN O
hamster BC2GM006670958 NN O
and BC2GM006670958 CC O
Squalus BC2GM006670958 NNP O
acanthias BC2GM006670958 NNS O
. BC2GM006670958 . O
. . O O

Previous BC2GM008631262 JJ O
studies BC2GM008631262 NNS O
have BC2GM008631262 VBP O
demonstrated BC2GM008631262 VBN O
that BC2GM008631262 IN O
the BC2GM008631262 DT O
21- BC2GM008631262 JJ O
or BC2GM008631262 CC O
the BC2GM008631262 DT O
72-bp BC2GM008631262 JJ O
repeat BC2GM008631262 NN O
transcriptional BC2GM008631262 JJ O
control BC2GM008631262 NN O
elements BC2GM008631262 NNS O
enhance BC2GM008631262 VB O
the BC2GM008631262 DT O
efficiency BC2GM008631262 NN O
of BC2GM008631262 IN O
SV40 BC2GM008631262 NNP O
DNA BC2GM008631262 NNP O
replication BC2GM008631262 NN O
in BC2GM008631262 IN O
vivo BC2GM008631262 NN O
, BC2GM008631262 , O
provided BC2GM008631262 VBD O
either BC2GM008631262 CC O
of BC2GM008631262 IN O
these BC2GM008631262 DT O
repeats BC2GM008631262 NNS O
is BC2GM008631262 VBZ O
located BC2GM008631262 VBN O
near BC2GM008631262 IN O
the BC2GM008631262 DT O
end BC2GM008631262 NN O
of BC2GM008631262 IN O
the BC2GM008631262 DT O
core BC2GM008631262 NN O
replication BC2GM008631262 NN O
origin BC2GM008631262 IN O
containing BC2GM008631262 VBG O
the BC2GM008631262 DT O
17-bp BC2GM008631262 CD O
A BC2GM008631262 NNP O
+ BC2GM008631262 JJ O
T-containing BC2GM008631262 JJ O
sequence BC2GM008631262 NN O
. BC2GM008631262 . O
. . O O

Some BC2GM044079043 DT O
of BC2GM044079043 IN O
these BC2GM044079043 DT O
DNA BC2GM044079043 NN O
: BC2GM044079043 : O
protein BC2GM044079043 NN O
complexes BC2GM044079043 NNS O
were BC2GM044079043 VBD O
also BC2GM044079043 RB O
present BC2GM044079043 JJ O
, BC2GM044079043 , O
but BC2GM044079043 CC O
at BC2GM044079043 IN O
lower BC2GM044079043 JJR O
levels BC2GM044079043 NNS O
, BC2GM044079043 , O
in BC2GM044079043 IN O
nuclear BC2GM044079043 JJ O
extracts BC2GM044079043 NNS O
from BC2GM044079043 IN O
untransformed BC2GM044079043 JJ O
rat BC2GM044079043 NN O
cells BC2GM044079043 NNS O
suggesting BC2GM044079043 VBG O
the BC2GM044079043 DT O
possible BC2GM044079043 JJ O
involvement BC2GM044079043 NN O
of BC2GM044079043 IN O
cellular BC2GM044079043 JJ O
factors BC2GM044079043 NNS O
in BC2GM044079043 IN O
the BC2GM044079043 DT O
mechanism BC2GM044079043 NN O
of BC2GM044079043 IN O
down-regulation BC2GM044079043 NN O
mediated BC2GM044079043 VBN O
by BC2GM044079043 IN O
Ad12 BC2GM044079043 NNP O
E1A BC2GM044079043 NNP O
. BC2GM044079043 . O
. . O O

Mineralized BC2GM088220160 NNP O
bone BC2GM088220160 NN O
nodule BC2GM088220160 NN O
formation BC2GM088220160 NN O
in BC2GM088220160 IN O
vitro BC2GM088220160 NN O
by BC2GM088220160 IN O
cell BC2GM088220160 NN O
populations BC2GM088220160 NNS O
from BC2GM088220160 IN O
young BC2GM088220160 JJ O
adult BC2GM088220160 NN O
rabbit BC2GM088220160 NN O
alveolar BC2GM088220160 JJ O
bone BC2GM088220160 NN O
. BC2GM088220160 . O
. . O O

The BC2GM064583998 DT O
effectiveness BC2GM064583998 NN O
and BC2GM064583998 CC O
pathogenetic BC2GM064583998 JJ O
expediency BC2GM064583998 NN O
of BC2GM064583998 IN O
correcting BC2GM064583998 VBG O
disorders BC2GM064583998 NNS O
of BC2GM064583998 IN O
lipid BC2GM064583998 JJ O
metabolism BC2GM064583998 NN O
in BC2GM064583998 IN O
atherosclerosis BC2GM064583998 NN O
with BC2GM064583998 IN O
enterosorbents BC2GM064583998 NNS O
is BC2GM064583998 VBZ O
substantiated BC2GM064583998 VBN O
. BC2GM064583998 . O
. . O O

The BC2GM033472267 DT O
results BC2GM033472267 NNS O
indicate BC2GM033472267 VBP O
that BC2GM033472267 DT O
expression BC2GM033472267 NN O
of BC2GM033472267 IN O
proU BC2GM033472267 NN O
in BC2GM033472267 IN O
E. BC2GM033472267 NNP O
coli BC2GM033472267 NNS O
is BC2GM033472267 VBZ O
directed BC2GM033472267 VBN O
from BC2GM033472267 IN O
two BC2GM033472267 CD O
promoters BC2GM033472267 NNS O
, BC2GM033472267 , O
one BC2GM033472267 CD O
( BC2GM033472267 ( O
P2 BC2GM033472267 NNP O
) BC2GM033472267 ) O
characterized BC2GM033472267 VBN O
earlier BC2GM033472267 RB O
by BC2GM033472267 IN O
other BC2GM033472267 JJ O
workers BC2GM033472267 NNS O
with BC2GM033472267 IN O
the BC2GM033472267 DT O
start BC2GM033472267 NN O
site BC2GM033472267 NN O
of BC2GM033472267 IN O
transcription BC2GM033472267 NN O
60 BC2GM033472267 CD O
nucleotides BC2GM033472267 NNS O
upstream BC2GM033472267 NN O
of BC2GM033472267 IN O
the BC2GM033472267 DT O
initiation BC2GM033472267 NN O
codon BC2GM033472267 NN O
of BC2GM033472267 IN O
the BC2GM033472267 DT O
first BC2GM033472267 JJ O
structural BC2GM033472267 JJ O
gene BC2GM033472267 NN O
( BC2GM033472267 ( O
proV BC2GM033472267 NN O
) BC2GM033472267 ) O
, BC2GM033472267 , O
and BC2GM033472267 CC O
the BC2GM033472267 DT O
other BC2GM033472267 JJ O
( BC2GM033472267 ( O
P1 BC2GM033472267 NNP O
) BC2GM033472267 ) O
situated BC2GM033472267 VBD O
250 BC2GM033472267 CD O
nucleotides BC2GM033472267 NNS O
upstream BC2GM033472267 NN O
of BC2GM033472267 IN O
proV BC2GM033472267 NN O
. BC2GM033472267 . O
. . O O

From BC2GM027051573 IN O
the BC2GM027051573 DT O
comparison BC2GM027051573 NN O
of BC2GM027051573 IN O
the BC2GM027051573 DT O
nod BC2GM027051573 NN O
box BC2GM027051573 NN O
sequences BC2GM027051573 NNS O
of BC2GM027051573 IN O
( BC2GM027051573 ( O
brady BC2GM027051573 JJ O
) BC2GM027051573 ) O
rhizobia BC2GM027051573 NN O
with BC2GM027051573 IN O
a BC2GM027051573 DT O
more BC2GM027051573 RBR O
divergent BC2GM027051573 JJ O
nod BC2GM027051573 NN O
box BC2GM027051573 NN O
from BC2GM027051573 IN O
Azorhizobium BC2GM027051573 NNP O
caulinodans BC2GM027051573 NNS O
, BC2GM027051573 , O
we BC2GM027051573 PRP O
now BC2GM027051573 RB O
propose BC2GM027051573 VBP O
a BC2GM027051573 DT O
modular BC2GM027051573 JJ O
build-up BC2GM027051573 NN O
of BC2GM027051573 IN O
the BC2GM027051573 DT O
nod BC2GM027051573 NN O
box BC2GM027051573 NN O
with BC2GM027051573 IN O
the BC2GM027051573 DT O
sequence BC2GM027051573 NN O
A-T-C-N9-G-A-T BC2GM027051573 NNP O
as BC2GM027051573 IN O
the BC2GM027051573 DT O
binding BC2GM027051573 VBG O
target BC2GM027051573 NN O
of BC2GM027051573 IN O
the BC2GM027051573 DT O
NodD BC2GM027051573 NNP O
protein BC2GM027051573 NN O
( BC2GM027051573 ( O
the BC2GM027051573 DT O
NodD BC2GM027051573 NNP O
box BC2GM027051573 NN O
) BC2GM027051573 ) O
. BC2GM027051573 . O
. . O O

Similarly BC2GM080587518 RB O
, BC2GM080587518 , O
an BC2GM080587518 DT O
increase BC2GM080587518 NN O
in BC2GM080587518 IN O
CAT BC2GM080587518 NNP O
expression BC2GM080587518 NN O
from BC2GM080587518 IN O
the BC2GM080587518 DT O
same BC2GM080587518 JJ O
construct BC2GM080587518 NN O
( BC2GM080587518 ( O
pBLCAT-ENDOA BC2GM080587518 JJ O
) BC2GM080587518 ) O
was BC2GM080587518 VBD O
also BC2GM080587518 RB O
observed BC2GM080587518 VBN O
in BC2GM080587518 IN O
7AQS2.1 BC2GM080587518 CD O
cells BC2GM080587518 NNS O
. BC2GM080587518 . O
. . O O

Kaposi BC2GM084714947 NNP O
's BC2GM084714947 POS O
sarcoma-associated BC2GM084714947 JJ O
herpesvirus BC2GM084714947 NN O
/ BC2GM084714947 NNP O
human BC2GM084714947 JJ O
herpesvirus-8 BC2GM084714947 JJ O
ORF50 BC2GM084714947 NNP O
gene BC2GM084714947 NN O
product BC2GM084714947 NN O
contains BC2GM084714947 VBZ O
a BC2GM084714947 DT O
potent BC2GM084714947 JJ O
C-terminal BC2GM084714947 JJ O
activation BC2GM084714947 NN O
domain BC2GM084714947 NN O
which BC2GM084714947 WDT O
activates BC2GM084714947 VBZ O
gene BC2GM084714947 NN O
expression BC2GM084714947 NN O
via BC2GM084714947 IN O
a BC2GM084714947 DT O
specific BC2GM084714947 JJ O
target BC2GM084714947 NN O
sequence BC2GM084714947 NN O
. BC2GM084714947 . O
. . O O

Further BC2GM003776641 RB O
, BC2GM003776641 , O
we BC2GM003776641 PRP O
find BC2GM003776641 VBP O
that BC2GM003776641 IN O
the BC2GM003776641 DT O
BMI1 BC2GM003776641 NNP O
protein BC2GM003776641 NN O
can BC2GM003776641 MD O
also BC2GM003776641 RB O
interact BC2GM003776641 VB O
with BC2GM003776641 IN O
itself BC2GM003776641 PRP O
. BC2GM003776641 . O
. . O O

Plasma BC2GM088354300 NNP O
beta-thromboglobulin BC2GM088354300 NN O
( BC2GM088354300 ( O
beta-TG BC2GM088354300 NN O
) BC2GM088354300 ) O
, BC2GM088354300 , O
a BC2GM088354300 DT O
platelet-specific BC2GM088354300 JJ O
protein BC2GM088354300 NN O
, BC2GM088354300 , O
is BC2GM088354300 VBZ O
a BC2GM088354300 DT O
marker BC2GM088354300 NN O
of BC2GM088354300 IN O
intravascular BC2GM088354300 JJ O
platelet BC2GM088354300 NN O
degranulation BC2GM088354300 NN O
. BC2GM088354300 . O
. . O O

We BC2GM096245457 PRP O
also BC2GM096245457 RB O
identified BC2GM096245457 VBD O
a BC2GM096245457 DT O
DNA BC2GM096245457 NNP O
fragment BC2GM096245457 NN O
, BC2GM096245457 , O
10.7 BC2GM096245457 CD O
kbp BC2GM096245457 NN O
upstream BC2GM096245457 NN O
from BC2GM096245457 IN O
the BC2GM096245457 DT O
first BC2GM096245457 JJ O
coding BC2GM096245457 VBG O
exon BC2GM096245457 NN O
of BC2GM096245457 IN O
human BC2GM096245457 JJ O
aFGF BC2GM096245457 NN O
, BC2GM096245457 , O
whose BC2GM096245457 WP$ O
sequence BC2GM096245457 NN O
is BC2GM096245457 VBZ O
conserved BC2GM096245457 VBN O
in BC2GM096245457 IN O
both BC2GM096245457 DT O
the BC2GM096245457 DT O
primate BC2GM096245457 NN O
and BC2GM096245457 CC O
rodent BC2GM096245457 NN O
genomes BC2GM096245457 NNS O
. BC2GM096245457 . O
. . O O

Using BC2GM076888648 VBG O
the BC2GM076888648 DT O
standard BC2GM076888648 NN O
scoring BC2GM076888648 NN O
, BC2GM076888648 , O
children BC2GM076888648 NNS O
with BC2GM076888648 IN O
full BC2GM076888648 JJ O
scale BC2GM076888648 NN O
IQ BC2GM076888648 NNP O
< BC2GM076888648 NNP O
or BC2GM076888648 CC O
= BC2GM076888648 $ O
84 BC2GM076888648 CD O
on BC2GM076888648 IN O
the BC2GM076888648 DT O
Wechsler BC2GM076888648 NNP O
Preschool BC2GM076888648 NNP O
and BC2GM076888648 CC O
Primary BC2GM076888648 NNP O
Scale BC2GM076888648 NNP O
of BC2GM076888648 IN O
Intelligence BC2GM076888648 NNP O
at BC2GM076888648 IN O
age BC2GM076888648 NN O
4-5 BC2GM076888648 CD O
years BC2GM076888648 NNS O
were BC2GM076888648 VBD O
poorly BC2GM076888648 RB O
identified BC2GM076888648 VBN O
( BC2GM076888648 ( O
sensitivity BC2GM076888648 JJ O
54 BC2GM076888648 CD O
% BC2GM076888648 NN O
) BC2GM076888648 ) O
from BC2GM076888648 IN O
the BC2GM076888648 DT O
composite BC2GM076888648 JJ O
S-B BC2GM076888648 NNP O
IV BC2GM076888648 NNP O
score BC2GM076888648 NN O
at BC2GM076888648 IN O
age BC2GM076888648 NN O
3 BC2GM076888648 CD O
. BC2GM076888648 . O
. . O O

We BC2GM088102124 PRP O
suggest BC2GM088102124 VBP O
that BC2GM088102124 DT O
electrical BC2GM088102124 JJ O
stimulation BC2GM088102124 NN O
of BC2GM088102124 IN O
the BC2GM088102124 DT O
NTS BC2GM088102124 NNP O
in BC2GM088102124 IN O
rats BC2GM088102124 NNS O
undergoing BC2GM088102124 VBG O
such BC2GM088102124 JJ O
surgical BC2GM088102124 JJ O
preparation BC2GM088102124 NN O
to BC2GM088102124 TO O
observe BC2GM088102124 VB O
the BC2GM088102124 DT O
pressor BC2GM088102124 NN O
response BC2GM088102124 NN O
and BC2GM088102124 CC O
/ BC2GM088102124 NN O
or BC2GM088102124 CC O
increase BC2GM088102124 VB O
in BC2GM088102124 IN O
pVP BC2GM088102124 NN O
, BC2GM088102124 , O
represents BC2GM088102124 VBZ O
a BC2GM088102124 DT O
rapid BC2GM088102124 JJ O
approach BC2GM088102124 NN O
for BC2GM088102124 IN O
screening BC2GM088102124 VBG O
the BC2GM088102124 DT O
neurosecretory BC2GM088102124 JJ O
function BC2GM088102124 NN O
of BC2GM088102124 IN O
the BC2GM088102124 DT O
central BC2GM088102124 JJ O
neural BC2GM088102124 JJ O
integration BC2GM088102124 NN O
to BC2GM088102124 TO O
release BC2GM088102124 VB O
vasopressin BC2GM088102124 NN O
. BC2GM088102124 . O
. . O O

Genomic BC2GM056468201 NNP O
Southern BC2GM056468201 NNP O
blot BC2GM056468201 NN O
analysis BC2GM056468201 NN O
suggests BC2GM056468201 VBZ O
that BC2GM056468201 IN O
the BC2GM056468201 DT O
human BC2GM056468201 JJ O
haploid BC2GM056468201 NN O
genome BC2GM056468201 NN O
contains BC2GM056468201 VBZ O
a BC2GM056468201 DT O
single BC2GM056468201 JJ O
Gs BC2GM056468201 NNP O
alpha BC2GM056468201 NN O
gene BC2GM056468201 NN O
. BC2GM056468201 . O
. . O O

There BC2GM062580234 EX O
was BC2GM062580234 VBD O
no BC2GM062580234 DT O
correlation BC2GM062580234 NN O
between BC2GM062580234 IN O
starting BC2GM062580234 VBG O
platelet-associated BC2GM062580234 JJ O
IgG BC2GM062580234 NNP O
levels BC2GM062580234 NNS O
or BC2GM062580234 CC O
changes BC2GM062580234 NNS O
in BC2GM062580234 IN O
platelet-associated BC2GM062580234 JJ O
IgG BC2GM062580234 NNP O
levels BC2GM062580234 NNS O
with BC2GM062580234 IN O
therapy BC2GM062580234 NN O
and BC2GM062580234 CC O
the BC2GM062580234 DT O
increment BC2GM062580234 NN O
in BC2GM062580234 IN O
the BC2GM062580234 DT O
patient BC2GM062580234 NN O
's BC2GM062580234 POS O
platelet BC2GM062580234 NN O
count BC2GM062580234 NN O
. BC2GM062580234 . O
. . O O

Complementary BC2GM048519833 JJ O
DNA BC2GM048519833 NNP O
libraries BC2GM048519833 NNS O
from BC2GM048519833 IN O
liver BC2GM048519833 NN O
and BC2GM048519833 CC O
ovary BC2GM048519833 NN O
of BC2GM048519833 IN O
an BC2GM048519833 DT O
immature BC2GM048519833 NN O
female BC2GM048519833 JJ O
channel BC2GM048519833 NNS O
catfish BC2GM048519833 JJ O
were BC2GM048519833 VBD O
screened BC2GM048519833 VBN O
with BC2GM048519833 IN O
a BC2GM048519833 DT O
homologous BC2GM048519833 JJ O
ERalpha BC2GM048519833 NNP O
cDNA BC2GM048519833 NN O
probe BC2GM048519833 NN O
. BC2GM048519833 . O
. . O O

Clinical BC2GM024410649 JJ O
trials BC2GM024410649 NNS O
bring BC2GM024410649 VBP O
informations BC2GM024410649 NNS O
for BC2GM024410649 IN O
pharmacology BC2GM024410649 NN O
and BC2GM024410649 CC O
epidemiology BC2GM024410649 NN O
. BC2GM024410649 . O
. . O O

Psychopathological BC2GM049579036 NNP O
, BC2GM049579036 , O
vegetative BC2GM049579036 NN O
, BC2GM049579036 , O
and BC2GM049579036 CC O
vital BC2GM049579036 JJ O
parameters BC2GM049579036 NNS O
were BC2GM049579036 VBD O
assessed BC2GM049579036 VBN O
every BC2GM049579036 DT O
hour BC2GM049579036 NN O
. BC2GM049579036 . O
. . O O

4.7 BC2GM068897228 CD O
+ BC2GM068897228 JJ O
/ BC2GM068897228 NNP O
- BC2GM068897228 : O
0.6 BC2GM068897228 CD O
micromol BC2GM068897228 NN O
. BC2GM068897228 . O
kg-1 BC2GM068897228 NN O
. BC2GM068897228 . O
min-1 BC2GM068897228 NN O
) BC2GM068897228 ) O
but BC2GM068897228 CC O
was BC2GM068897228 VBD O
not BC2GM068897228 RB O
changed BC2GM068897228 VBN O
by BC2GM068897228 IN O
training BC2GM068897228 NN O
. BC2GM068897228 . O
. . O O

Previous BC2GM020911940 JJ O
studies BC2GM020911940 NNS O
have BC2GM020911940 VBP O
shown BC2GM020911940 VBN O
that BC2GM020911940 IN O
the BC2GM020911940 DT O
IME1 BC2GM020911940 NNP O
gene BC2GM020911940 NN O
is BC2GM020911940 VBZ O
required BC2GM020911940 VBN O
for BC2GM020911940 IN O
sporulation BC2GM020911940 NN O
and BC2GM020911940 CC O
the BC2GM020911940 DT O
expression BC2GM020911940 NN O
of BC2GM020911940 IN O
meiosis BC2GM020911940 NN O
specific BC2GM020911940 JJ O
genes BC2GM020911940 NNS O
in BC2GM020911940 IN O
Saccharomyces BC2GM020911940 NNP O
cerevisiae BC2GM020911940 NN O
. BC2GM020911940 . O
. . O O

Overall BC2GM060809395 JJ O
, BC2GM060809395 , O
free-chlorine BC2GM060809395 JJ O
treatments BC2GM060809395 NNS O
( BC2GM060809395 ( O
0.3 BC2GM060809395 CD O
or BC2GM060809395 CC O
1.0 BC2GM060809395 CD O
mg BC2GM060809395 NNS O
/ BC2GM060809395 NNP O
L BC2GM060809395 NNP O
) BC2GM060809395 ) O
showed BC2GM060809395 VBD O
significantly BC2GM060809395 RB O
lower BC2GM060809395 JJR O
heterotrophic BC2GM060809395 JJ O
plate BC2GM060809395 NN O
numbers BC2GM060809395 NNS O
than BC2GM060809395 IN O
those BC2GM060809395 DT O
without BC2GM060809395 IN O
free BC2GM060809395 JJ O
chlorine BC2GM060809395 NN O
. BC2GM060809395 . O
. . O O

GeneCalling BC2GM007283823 VBG O
analysis BC2GM007283823 NN O
was BC2GM007283823 VBD O
successful BC2GM007283823 JJ O
in BC2GM007283823 IN O
detecting BC2GM007283823 VBG O
members BC2GM007283823 NNS O
of BC2GM007283823 IN O
complex BC2GM007283823 JJ O
metabolic BC2GM007283823 NN O
pathways BC2GM007283823 NNS O
and BC2GM007283823 CC O
uncovering BC2GM007283823 VBG O
novel BC2GM007283823 JJ O
genes BC2GM007283823 NNS O
that BC2GM007283823 WDT O
were BC2GM007283823 VBD O
either BC2GM007283823 DT O
coincidentally BC2GM007283823 RB O
regulated BC2GM007283823 VBN O
or BC2GM007283823 CC O
directly BC2GM007283823 RB O
involved BC2GM007283823 VBN O
in BC2GM007283823 IN O
such BC2GM007283823 JJ O
pathways BC2GM007283823 NNS O
. BC2GM007283823 . O
. . O O

To BC2GM012758546 TO O
test BC2GM012758546 VB O
for BC2GM012758546 IN O
progesterone BC2GM012758546 NN O
receptor-mediated BC2GM012758546 JJ O
activation BC2GM012758546 NN O
of BC2GM012758546 IN O
transcription BC2GM012758546 NN O
in BC2GM012758546 IN O
yeast BC2GM012758546 NN O
, BC2GM012758546 , O
reporter BC2GM012758546 NN O
plasmids BC2GM012758546 NNS O
were BC2GM012758546 VBD O
constructed BC2GM012758546 VBN O
to BC2GM012758546 TO O
transform BC2GM012758546 VB O
yeast BC2GM012758546 NN O
cells BC2GM012758546 NNS O
expressing BC2GM012758546 VBG O
PRB BC2GM012758546 NNP O
or BC2GM012758546 CC O
C1C2 BC2GM012758546 NNP O
receptors BC2GM012758546 NNS O
. BC2GM012758546 . O
. . O O

Long-range BC2GM037412150 JJ O
mapping BC2GM037412150 NN O
by BC2GM037412150 IN O
pulse-field BC2GM037412150 JJ O
gel BC2GM037412150 JJ O
electrophoresis BC2GM037412150 NN O
indicated BC2GM037412150 VBD O
that BC2GM037412150 IN O
the BC2GM037412150 DT O
three BC2GM037412150 CD O
mdr BC2GM037412150 NN O
genes BC2GM037412150 NNS O
are BC2GM037412150 VBP O
closely BC2GM037412150 RB O
linked BC2GM037412150 VBN O
on BC2GM037412150 IN O
a BC2GM037412150 DT O
genomic BC2GM037412150 JJ O
DNA BC2GM037412150 NNP O
segment BC2GM037412150 NN O
of BC2GM037412150 IN O
approximately BC2GM037412150 RB O
625 BC2GM037412150 CD O
kilobases BC2GM037412150 NNS O
. BC2GM037412150 . O
. . O O

High BC2GM090610024 JJ O
and BC2GM090610024 CC O
pathological BC2GM090610024 JJ O
PAI-1 BC2GM090610024 NNP O
levels BC2GM090610024 NNS O
before BC2GM090610024 IN O
and BC2GM090610024 CC O
after BC2GM090610024 IN O
the BC2GM090610024 DT O
VO BC2GM090610024 NNP O
test BC2GM090610024 NN O
were BC2GM090610024 VBD O
consistent BC2GM090610024 JJ O
with BC2GM090610024 IN O
a BC2GM090610024 DT O
defective BC2GM090610024 JJ O
fibrinolytic BC2GM090610024 JJ O
potential BC2GM090610024 NN O
due BC2GM090610024 JJ O
to BC2GM090610024 TO O
the BC2GM090610024 DT O
inhibitory BC2GM090610024 JJ O
effect BC2GM090610024 NN O
of BC2GM090610024 IN O
PAI-1 BC2GM090610024 NNP O
on BC2GM090610024 IN O
plasminogen BC2GM090610024 NN O
activation BC2GM090610024 NN O
. BC2GM090610024 . O
. . O O

The BC2GM020659515 DT O
point BC2GM020659515 NN O
mutation BC2GM020659515 NN O
Asp-316 BC2GM020659515 NNP O
-- BC2GM020659515 : O
> BC2GM020659515 JJ O
Asn BC2GM020659515 NNP O
in BC2GM020659515 IN O
the BC2GM020659515 DT O
C-terminus BC2GM020659515 NNP O
of BC2GM020659515 IN O
p38 BC2GM020659515 NN O
, BC2GM020659515 , O
analogous BC2GM020659515 JJ O
to BC2GM020659515 TO O
the BC2GM020659515 DT O
ERK2 BC2GM020659515 NNP O
( BC2GM020659515 ( O
extracellular-signal-regulated BC2GM020659515 JJ O
kinase BC2GM020659515 NN O
2 BC2GM020659515 CD O
) BC2GM020659515 ) O
sevenmaker BC2GM020659515 NN O
mutation BC2GM020659515 NN O
, BC2GM020659515 , O
dramatically BC2GM020659515 RB O
decreases BC2GM020659515 VBZ O
its BC2GM020659515 PRP$ O
binding BC2GM020659515 NN O
to BC2GM020659515 TO O
MKP-1 BC2GM020659515 NNP O
and BC2GM020659515 CC O
substantially BC2GM020659515 RB O
compromises BC2GM020659515 VBZ O
its BC2GM020659515 PRP$ O
stimulatory BC2GM020659515 JJ O
effect BC2GM020659515 NN O
on BC2GM020659515 IN O
the BC2GM020659515 DT O
catalytic BC2GM020659515 JJ O
activity BC2GM020659515 NN O
of BC2GM020659515 IN O
this BC2GM020659515 DT O
phosphatase BC2GM020659515 NN O
. BC2GM020659515 . O
. . O O

Quinethazone BC2GM031373959 NN O
. BC2GM031373959 . O
. . O O

The BC2GM065027203 DT O
kinetics BC2GM065027203 NNS O
of BC2GM065027203 IN O
erythromycin BC2GM065027203 NN O
( BC2GM065027203 ( O
E. BC2GM065027203 NNP O
) BC2GM065027203 ) O
was BC2GM065027203 VBD O
studied BC2GM065027203 VBN O
in BC2GM065027203 IN O
16 BC2GM065027203 CD O
patients BC2GM065027203 NNS O
with BC2GM065027203 IN O
different BC2GM065027203 JJ O
degrees BC2GM065027203 NNS O
of BC2GM065027203 IN O
impairment BC2GM065027203 NN O
of BC2GM065027203 IN O
renal BC2GM065027203 JJ O
function BC2GM065027203 NN O
after BC2GM065027203 IN O
a BC2GM065027203 DT O
single BC2GM065027203 JJ O
intravenous BC2GM065027203 JJ O
dose BC2GM065027203 NN O
. BC2GM065027203 . O
. . O O

Transfer BC2GM004225569 NN O
of BC2GM004225569 IN O
F-like BC2GM004225569 NNP O
plasmids BC2GM004225569 NNS O
is BC2GM004225569 VBZ O
regulated BC2GM004225569 VBN O
by BC2GM004225569 IN O
the BC2GM004225569 DT O
FinOP BC2GM004225569 NNP O
system BC2GM004225569 NN O
, BC2GM004225569 , O
which BC2GM004225569 WDT O
controls BC2GM004225569 VBZ O
the BC2GM004225569 DT O
expression BC2GM004225569 NN O
of BC2GM004225569 IN O
traJ BC2GM004225569 NN O
, BC2GM004225569 , O
a BC2GM004225569 DT O
positive BC2GM004225569 JJ O
regulator BC2GM004225569 NN O
of BC2GM004225569 IN O
the BC2GM004225569 DT O
transfer BC2GM004225569 NN O
operon BC2GM004225569 NN O
. BC2GM004225569 . O
. . O O

Patients BC2GM046344700 NNS O
randomized BC2GM046344700 VBN O
into BC2GM046344700 IN O
the BC2GM046344700 DT O
active BC2GM046344700 JJ O
treatment BC2GM046344700 NN O
groups BC2GM046344700 NNS O
A30 BC2GM046344700 NNP O
( BC2GM046344700 ( O
n BC2GM046344700 JJ O
= BC2GM046344700 NNP O
49 BC2GM046344700 CD O
) BC2GM046344700 ) O
and BC2GM046344700 CC O
A60 BC2GM046344700 NNP O
( BC2GM046344700 ( O
n BC2GM046344700 JJ O
= BC2GM046344700 NNP O
48 BC2GM046344700 CD O
) BC2GM046344700 ) O
received BC2GM046344700 VBD O
topical BC2GM046344700 JJ O
treatment BC2GM046344700 NN O
with BC2GM046344700 IN O
3.0 BC2GM046344700 CD O
% BC2GM046344700 NN O
diclofenac BC2GM046344700 NN O
in BC2GM046344700 IN O
2.5 BC2GM046344700 CD O
% BC2GM046344700 NN O
hyaluronan BC2GM046344700 NN O
gel BC2GM046344700 NN O
0.5 BC2GM046344700 CD O
g BC2GM046344700 NN O
twice BC2GM046344700 RB O
daily BC2GM046344700 RB O
for BC2GM046344700 IN O
30 BC2GM046344700 CD O
or BC2GM046344700 CC O
60 BC2GM046344700 CD O
days BC2GM046344700 NNS O
, BC2GM046344700 , O
respectively BC2GM046344700 RB O
. BC2GM046344700 . O
. . O O

In BC2GM027260839 IN O
addition BC2GM027260839 NN O
, BC2GM027260839 , O
the BC2GM027260839 DT O
authors BC2GM027260839 NNS O
found BC2GM027260839 VBD O
one BC2GM027260839 CD O
an3 BC2GM027260839 NN O
allele BC2GM027260839 NN O
( BC2GM027260839 ( O
an3-W138A BC2GM027260839 JJ O
) BC2GM027260839 ) O
in BC2GM027260839 IN O
which BC2GM027260839 WDT O
a BC2GM027260839 DT O
dTph1 BC2GM027260839 NN O
element BC2GM027260839 NN O
had BC2GM027260839 VBD O
inserted BC2GM027260839 VBN O
30 BC2GM027260839 CD O
bp BC2GM027260839 NN O
upstream BC2GM027260839 IN O
the BC2GM027260839 DT O
translation BC2GM027260839 NN O
start BC2GM027260839 NN O
, BC2GM027260839 , O
without BC2GM027260839 IN O
inactivating BC2GM027260839 VBG O
the BC2GM027260839 DT O
gene BC2GM027260839 NN O
. BC2GM027260839 . O
. . O O

The BC2GM037915116 DT O
prevalence BC2GM037915116 NN O
of BC2GM037915116 IN O
ocular BC2GM037915116 JJ O
/ BC2GM037915116 NNP O
adnexal BC2GM037915116 NN O
SCC BC2GM037915116 NNP O
was BC2GM037915116 VBD O
significantly BC2GM037915116 RB O
greater BC2GM037915116 JJR O
for BC2GM037915116 IN O
all BC2GM037915116 DT O
hair BC2GM037915116 NN O
colors BC2GM037915116 NNS O
when BC2GM037915116 WRB O
compared BC2GM037915116 VBN O
with BC2GM037915116 IN O
bay BC2GM037915116 NN O
, BC2GM037915116 , O
brown BC2GM037915116 NN O
, BC2GM037915116 , O
or BC2GM037915116 CC O
black BC2GM037915116 JJ O
( BC2GM037915116 ( O
P BC2GM037915116 NNP O
less BC2GM037915116 JJR O
than BC2GM037915116 IN O
0.01 BC2GM037915116 CD O
) BC2GM037915116 ) O
. BC2GM037915116 . O
. . O O

Partial BC2GM059902297 JJ O
proteolysis BC2GM059902297 NN O
of BC2GM059902297 IN O
cell BC2GM059902297 NN O
surface-iodinated BC2GM059902297 JJ O
B-G BC2GM059902297 NNP O
molecules BC2GM059902297 NNS O
generates BC2GM059902297 VBZ O
extremely BC2GM059902297 RB O
similar BC2GM059902297 JJ O
patterns BC2GM059902297 NNS O
of BC2GM059902297 IN O
spots BC2GM059902297 NNS O
, BC2GM059902297 , O
both BC2GM059902297 DT O
within BC2GM059902297 IN O
and BC2GM059902297 CC O
between BC2GM059902297 IN O
haplotypes BC2GM059902297 NNS O
. BC2GM059902297 . O
. . O O

Pax-6 BC2GM075443045 JJ O
constructs BC2GM075443045 NNS O
lacking BC2GM075443045 VBG O
the BC2GM075443045 DT O
C-terminal BC2GM075443045 JJ O
activation BC2GM075443045 NN O
domain BC2GM075443045 NN O
repressed BC2GM075443045 VBD O
betaB1-crystallin BC2GM075443045 JJ O
promoter BC2GM075443045 NN O
activity BC2GM075443045 NN O
as BC2GM075443045 RB O
effectively BC2GM075443045 RB O
as BC2GM075443045 IN O
the BC2GM075443045 DT O
full-length BC2GM075443045 JJ O
protein BC2GM075443045 NN O
, BC2GM075443045 , O
but BC2GM075443045 CC O
the BC2GM075443045 DT O
PD BC2GM075443045 NNP O
alone BC2GM075443045 RB O
or BC2GM075443045 CC O
Pax-6 BC2GM075443045 NNP O
( BC2GM075443045 ( O
5a BC2GM075443045 CD O
) BC2GM075443045 ) O
, BC2GM075443045 , O
a BC2GM075443045 DT O
splice BC2GM075443045 NN O
variant BC2GM075443045 NN O
with BC2GM075443045 IN O
an BC2GM075443045 DT O
altered BC2GM075443045 JJ O
PD BC2GM075443045 NNP O
affecting BC2GM075443045 VBG O
its BC2GM075443045 PRP$ O
DNA BC2GM075443045 NN O
binding BC2GM075443045 NN O
specificity BC2GM075443045 NN O
, BC2GM075443045 , O
did BC2GM075443045 VBD O
not BC2GM075443045 RB O
. BC2GM075443045 . O
. . O O

Ligand BC2GM093512186 NNP O
binding BC2GM093512186 NN O
of BC2GM093512186 IN O
multi-chain BC2GM093512186 JJ O
antigen BC2GM093512186 NN O
receptors BC2GM093512186 NNS O
and BC2GM093512186 CC O
hematopoietin BC2GM093512186 NN O
/ BC2GM093512186 JJ O
cytokine BC2GM093512186 NN O
receptors BC2GM093512186 NNS O
results BC2GM093512186 NNS O
in BC2GM093512186 IN O
rapid BC2GM093512186 JJ O
activation BC2GM093512186 NN O
of BC2GM093512186 IN O
protein BC2GM093512186 JJ O
tyrosine BC2GM093512186 JJ O
kinase BC2GM093512186 NN O
( BC2GM093512186 ( O
PTK BC2GM093512186 NNP O
) BC2GM093512186 ) O
-dependent BC2GM093512186 NN O
signalling BC2GM093512186 VBG O
molecules BC2GM093512186 NNS O
such BC2GM093512186 JJ O
as BC2GM093512186 IN O
phosphatidylinositol BC2GM093512186 JJ O
3-kinase BC2GM093512186 JJ O
( BC2GM093512186 ( O
PI BC2GM093512186 NNP O
3-kinase BC2GM093512186 NNP O
) BC2GM093512186 ) O
. BC2GM093512186 . O
. . O O

For BC2GM037678814 IN O
large BC2GM037678814 JJ O
breasts BC2GM037678814 NNS O
( BC2GM037678814 ( O
> BC2GM037678814 $ O
70 BC2GM037678814 CD O
mm BC2GM037678814 NN O
) BC2GM037678814 ) O
the BC2GM037678814 DT O
use BC2GM037678814 NN O
of BC2GM037678814 IN O
X-ray BC2GM037678814 JJ O
sets BC2GM037678814 NNS O
such BC2GM037678814 JJ O
as BC2GM037678814 IN O
the BC2GM037678814 DT O
IGE BC2GM037678814 NNP O
DMR BC2GM037678814 NNP O
, BC2GM037678814 , O
which BC2GM037678814 WDT O
automatically BC2GM037678814 RB O
select BC2GM037678814 VBP O
the BC2GM037678814 DT O
beam BC2GM037678814 NN O
quality BC2GM037678814 NN O
for BC2GM037678814 IN O
each BC2GM037678814 DT O
breast BC2GM037678814 NN O
, BC2GM037678814 , O
resulted BC2GM037678814 VBD O
in BC2GM037678814 IN O
lower BC2GM037678814 JJR O
doses BC2GM037678814 NNS O
compared BC2GM037678814 VBN O
with BC2GM037678814 IN O
sets BC2GM037678814 NNS O
using BC2GM037678814 VBG O
manual BC2GM037678814 JJ O
tube BC2GM037678814 NN O
potential BC2GM037678814 JJ O
selection BC2GM037678814 NN O
. BC2GM037678814 . O
. . O O

Chem BC2GM034088457 NNP O
. BC2GM034088457 . O
. . O O

The BC2GM073340870 DT O
absorbance BC2GM073340870 NN O
of BC2GM073340870 IN O
the BC2GM073340870 DT O
eluent BC2GM073340870 NN O
was BC2GM073340870 VBD O
monitored BC2GM073340870 VBN O
at BC2GM073340870 IN O
254 BC2GM073340870 CD O
nm BC2GM073340870 NNS O
. BC2GM073340870 . O
. . O O

We BC2GM087423181 PRP O
now BC2GM087423181 RB O
describe BC2GM087423181 VBZ O
a BC2GM087423181 DT O
HepG2 BC2GM087423181 NNP O
cell BC2GM087423181 NN O
casein BC2GM087423181 NN O
kinase BC2GM087423181 NN O
II BC2GM087423181 NNP O
beta BC2GM087423181 NN O
subunit BC2GM087423181 NN O
cDNA BC2GM087423181 NN O
of BC2GM087423181 IN O
2.57 BC2GM087423181 CD O
kb BC2GM087423181 NNS O
containing BC2GM087423181 VBG O
96 BC2GM087423181 CD O
bases BC2GM087423181 NNS O
of BC2GM087423181 IN O
5 BC2GM087423181 CD O
' BC2GM087423181 POS O
untranslated BC2GM087423181 JJ O
sequence BC2GM087423181 NN O
, BC2GM087423181 , O
645 BC2GM087423181 CD O
bases BC2GM087423181 NNS O
of BC2GM087423181 IN O
open BC2GM087423181 JJ O
reading BC2GM087423181 NN O
frame BC2GM087423181 NN O
, BC2GM087423181 , O
and BC2GM087423181 CC O
1832 BC2GM087423181 CD O
bases BC2GM087423181 NNS O
of BC2GM087423181 IN O
3 BC2GM087423181 CD O
' BC2GM087423181 POS O
untranslated BC2GM087423181 JJ O
sequence BC2GM087423181 NN O
with BC2GM087423181 IN O
two BC2GM087423181 CD O
polyadenylation BC2GM087423181 NN O
consensus BC2GM087423181 NN O
signal BC2GM087423181 JJ O
sequences BC2GM087423181 NNS O
and BC2GM087423181 CC O
two BC2GM087423181 CD O
poly BC2GM087423181 NN O
( BC2GM087423181 ( O
A BC2GM087423181 DT O
) BC2GM087423181 ) O
stretches BC2GM087423181 NNS O
. BC2GM087423181 . O
. . O O

They BC2GM022663100 PRP O
encode BC2GM022663100 VBP O
proteins BC2GM022663100 NNS O
whose BC2GM022663100 WP$ O
core BC2GM022663100 NN O
regions BC2GM022663100 NNS O
display BC2GM022663100 VBP O
great BC2GM022663100 JJ O
similarity BC2GM022663100 NN O
to BC2GM022663100 TO O
Aspergillus BC2GM022663100 NNP O
HAPB BC2GM022663100 NNP O
, BC2GM022663100 , O
HAPC BC2GM022663100 NNP O
and BC2GM022663100 CC O
HAPE BC2GM022663100 NNP O
and BC2GM022663100 CC O
to BC2GM022663100 TO O
known BC2GM022663100 VB O
HAP BC2GM022663100 NNP O
homologs BC2GM022663100 NNS O
from BC2GM022663100 IN O
other BC2GM022663100 JJ O
organisms BC2GM022663100 NNS O
. BC2GM022663100 . O
. . O O

We BC2GM034162528 PRP O
previously BC2GM034162528 RB O
identified BC2GM034162528 VBD O
a BC2GM034162528 DT O
highly BC2GM034162528 RB O
conserved BC2GM034162528 VBN O
L-X-X-L-F BC2GM034162528 JJ O
sequence BC2GM034162528 NN O
near BC2GM034162528 IN O
the BC2GM034162528 DT O
C BC2GM034162528 NNP O
terminus BC2GM034162528 NN O
of BC2GM034162528 IN O
the BC2GM034162528 DT O
p6 BC2GM034162528 NN O
domain BC2GM034162528 NN O
of BC2GM034162528 IN O
the BC2GM034162528 DT O
Gag BC2GM034162528 NNP O
precursor BC2GM034162528 NN O
as BC2GM034162528 IN O
the BC2GM034162528 DT O
major BC2GM034162528 JJ O
virion BC2GM034162528 NN O
association BC2GM034162528 NN O
motif BC2GM034162528 NN O
for BC2GM034162528 IN O
HIV-1 BC2GM034162528 NNP O
Vpr BC2GM034162528 NNP O
. BC2GM034162528 . O
. . O O

We BC2GM016009074 PRP O
conclude BC2GM016009074 VBP O
that BC2GM016009074 DT O
99mTc-HL91 BC2GM016009074 CD O
is BC2GM016009074 VBZ O
a BC2GM016009074 DT O
potent BC2GM016009074 JJ O
marker BC2GM016009074 NN O
of BC2GM016009074 IN O
myocardial BC2GM016009074 JJ O
viability BC2GM016009074 NN O
when BC2GM016009074 WRB O
used BC2GM016009074 VBN O
during BC2GM016009074 IN O
the BC2GM016009074 DT O
early BC2GM016009074 JJ O
acute BC2GM016009074 NN O
phase BC2GM016009074 NN O
after BC2GM016009074 IN O
reperfusion BC2GM016009074 NN O
. BC2GM016009074 . O
. . O O

Nedocromil BC2GM084536918 NNP O
sodium BC2GM084536918 NN O
shifted BC2GM084536918 VBD O
the BC2GM084536918 DT O
severity BC2GM084536918 NN O
of BC2GM084536918 IN O
the BC2GM084536918 DT O
early BC2GM084536918 JJ O
allergic BC2GM084536918 JJ O
reaction BC2GM084536918 NN O
( BC2GM084536918 ( O
EAR BC2GM084536918 NNP O
) BC2GM084536918 ) O
from BC2GM084536918 IN O
mean BC2GM084536918 JJ O
-34.8 BC2GM084536918 CD O
% BC2GM084536918 NN O
to BC2GM084536918 TO O
-6.9 BC2GM084536918 VB O
% BC2GM084536918 NN O
and BC2GM084536918 CC O
inhibited BC2GM084536918 VBN O
the BC2GM084536918 DT O
later BC2GM084536918 RBR O
allergic BC2GM084536918 JJ O
reaction BC2GM084536918 NN O
( BC2GM084536918 ( O
LAR BC2GM084536918 NNP O
) BC2GM084536918 ) O
from BC2GM084536918 IN O
-30.5 BC2GM084536918 $ O
% BC2GM084536918 NN O
to BC2GM084536918 TO O
+0.4 BC2GM084536918 CD O
% BC2GM084536918 NN O
( BC2GM084536918 ( O
p BC2GM084536918 NN O
less BC2GM084536918 JJR O
than BC2GM084536918 IN O
0.005 BC2GM084536918 CD O
) BC2GM084536918 ) O
. BC2GM084536918 . O
. . O O

S1 BC2GM095049284 NNP O
nuclease BC2GM095049284 NN O
protection BC2GM095049284 NN O
mapping BC2GM095049284 NN O
and BC2GM095049284 CC O
primer BC2GM095049284 JJ O
extension BC2GM095049284 NN O
analysis BC2GM095049284 NN O
allowed BC2GM095049284 VBD O
us BC2GM095049284 PRP O
to BC2GM095049284 TO O
propose BC2GM095049284 VB O
that BC2GM095049284 IN O
the BC2GM095049284 DT O
A BC2GM095049284 NNP O
residue BC2GM095049284 NN O
located BC2GM095049284 VBN O
19 BC2GM095049284 CD O
bp BC2GM095049284 JJ O
upstream BC2GM095049284 NN O
from BC2GM095049284 IN O
the BC2GM095049284 DT O
translation BC2GM095049284 NN O
initiation BC2GM095049284 NN O
codon BC2GM095049284 NN O
is BC2GM095049284 VBZ O
the BC2GM095049284 DT O
site BC2GM095049284 NN O
of BC2GM095049284 IN O
transcription BC2GM095049284 NN O
initiation BC2GM095049284 NN O
. BC2GM095049284 . O
. . O O

Moreover BC2GM005295111 RB O
, BC2GM005295111 , O
since BC2GM005295111 IN O
the BC2GM005295111 DT O
integrated BC2GM005295111 VBN O
transforming BC2GM005295111 NN O
DNA BC2GM005295111 NN O
was BC2GM005295111 VBD O
not BC2GM005295111 RB O
altered BC2GM005295111 VBN O
or BC2GM005295111 CC O
lost BC2GM005295111 VBN O
expression BC2GM005295111 NN O
of BC2GM005295111 IN O
the BC2GM005295111 DT O
RbcS2 BC2GM005295111 NNP O
: BC2GM005295111 : O
:aadA BC2GM005295111 NN O
: BC2GM005295111 : O
:RbcS2 BC2GM005295111 JJ O
gene BC2GM005295111 NN O
( BC2GM005295111 ( O
s BC2GM005295111 PRP O
) BC2GM005295111 ) O
appears BC2GM005295111 VBZ O
to BC2GM005295111 TO O
be BC2GM005295111 VB O
repressed BC2GM005295111 VBN O
. BC2GM005295111 . O
. . O O

The BC2GM055477804 DT O
yjr041c BC2GM055477804 NN O
delta BC2GM055477804 NN O
haploid BC2GM055477804 NN O
cells BC2GM055477804 NNS O
gave BC2GM055477804 VBD O
rise BC2GM055477804 NN O
to BC2GM055477804 TO O
microcolonies BC2GM055477804 NNS O
comprising BC2GM055477804 VBG O
about BC2GM055477804 RB O
20 BC2GM055477804 CD O
to BC2GM055477804 TO O
50 BC2GM055477804 CD O
cells BC2GM055477804 NNS O
. BC2GM055477804 . O
. . O O

Defective BC2GM089738543 JJ O
concanavalin BC2GM089738543 NN O
A-induced BC2GM089738543 NNP O
suppression BC2GM089738543 NN O
in BC2GM089738543 IN O
bancroftian BC2GM089738543 JJ O
filariasis BC2GM089738543 NN O
. BC2GM089738543 . O
. . O O

VBP BC2GM067886213 NNP O
and BC2GM067886213 CC O
a1 BC2GM067886213 JJ O
/ BC2GM067886213 NNP O
EBP BC2GM067886213 NNP O
could BC2GM067886213 MD O
mediate BC2GM067886213 VB O
the BC2GM067886213 DT O
high BC2GM067886213 JJ O
rates BC2GM067886213 NNS O
of BC2GM067886213 IN O
ALV BC2GM067886213 NNP O
and BC2GM067886213 CC O
RSV BC2GM067886213 NNP O
LTR-enhanced BC2GM067886213 NNP O
transcription BC2GM067886213 NN O
in BC2GM067886213 IN O
bursal BC2GM067886213 NN O
lymphoma BC2GM067886213 NN O
cells BC2GM067886213 NNS O
and BC2GM067886213 CC O
many BC2GM067886213 JJ O
other BC2GM067886213 JJ O
cell BC2GM067886213 NN O
types BC2GM067886213 NNS O
. BC2GM067886213 . O
. . O O

CONCLUSION BC2GM095888580 NN O
: BC2GM095888580 : O
Urbanisation BC2GM095888580 NN O
is BC2GM095888580 VBZ O
associated BC2GM095888580 VBN O
with BC2GM095888580 IN O
an BC2GM095888580 DT O
increase BC2GM095888580 NN O
in BC2GM095888580 IN O
the BC2GM095888580 DT O
prevalence BC2GM095888580 NN O
rates BC2GM095888580 NNS O
of BC2GM095888580 IN O
some BC2GM095888580 DT O
risk BC2GM095888580 NN O
behaviours BC2GM095888580 NNS O
. BC2GM095888580 . O
. . O O

The BC2GM062362815 DT O
prgX BC2GM062362815 NN O
gene BC2GM062362815 NN O
is BC2GM062362815 VBZ O
adjacent BC2GM062362815 JJ O
to BC2GM062362815 TO O
prgQ BC2GM062362815 VB O
which BC2GM062362815 WDT O
provides BC2GM062362815 VBZ O
the BC2GM062362815 DT O
promoter BC2GM062362815 NN O
for BC2GM062362815 IN O
prgB BC2GM062362815 JJ O
expression BC2GM062362815 NN O
. BC2GM062362815 . O
. . O O

Next BC2GM081105938 RB O
, BC2GM081105938 , O
to BC2GM081105938 TO O
examine BC2GM081105938 VB O
the BC2GM081105938 DT O
regulation BC2GM081105938 NN O
mechanism BC2GM081105938 NN O
of BC2GM081105938 IN O
CD44 BC2GM081105938 NNP O
/ BC2GM081105938 NNP O
ERM BC2GM081105938 NNP O
interaction BC2GM081105938 NN O
in BC2GM081105938 IN O
vivo BC2GM081105938 NN O
, BC2GM081105938 , O
we BC2GM081105938 PRP O
reexamined BC2GM081105938 VBD O
the BC2GM081105938 DT O
immunoprecipitated BC2GM081105938 JJ O
CD44 BC2GM081105938 NNP O
/ BC2GM081105938 NNP O
ERM BC2GM081105938 NNP O
complex BC2GM081105938 NN O
from BC2GM081105938 IN O
BHK BC2GM081105938 NNP O
cells BC2GM081105938 NNS O
and BC2GM081105938 CC O
found BC2GM081105938 VBD O
that BC2GM081105938 IN O
it BC2GM081105938 PRP O
contains BC2GM081105938 VBZ O
Rho-GDP BC2GM081105938 JJ O
dissociation BC2GM081105938 NN O
inhibitor BC2GM081105938 NN O
( BC2GM081105938 ( O
GDI BC2GM081105938 NNP O
) BC2GM081105938 ) O
, BC2GM081105938 , O
a BC2GM081105938 DT O
regulator BC2GM081105938 NN O
of BC2GM081105938 IN O
Rho BC2GM081105938 NNP O
GTPase BC2GM081105938 NNP O
. BC2GM081105938 . O
. . O O

The BC2GM053409406 DT O
salt BC2GM053409406 JJ O
sensitivity BC2GM053409406 NN O
of BC2GM053409406 IN O
the BC2GM053409406 DT O
interaction BC2GM053409406 NN O
indicated BC2GM053409406 VBD O
that BC2GM053409406 IN O
two BC2GM053409406 CD O
ion BC2GM053409406 NN O
pairs BC2GM053409406 NNS O
are BC2GM053409406 VBP O
involved BC2GM053409406 VBN O
in BC2GM053409406 IN O
the BC2GM053409406 DT O
association BC2GM053409406 NN O
of BC2GM053409406 IN O
Zn2+ BC2GM053409406 NNP O
( BC2GM053409406 ( O
NC-F1 BC2GM053409406 NNP O
) BC2GM053409406 ) O
with BC2GM053409406 IN O
polynucleotide BC2GM053409406 NN O
, BC2GM053409406 , O
whereas BC2GM053409406 IN O
one BC2GM053409406 CD O
ion BC2GM053409406 NN O
pair BC2GM053409406 NN O
is BC2GM053409406 VBZ O
found BC2GM053409406 VBN O
in BC2GM053409406 IN O
the BC2GM053409406 DT O
metal-free BC2GM053409406 JJ O
peptide-nucleic BC2GM053409406 JJ O
acid BC2GM053409406 NN O
complex BC2GM053409406 NN O
. BC2GM053409406 . O
. . O O

Biochemical BC2GM053097733 JJ O
status BC2GM053097733 NN O
was BC2GM053097733 VBD O
examined BC2GM053097733 VBN O
using BC2GM053097733 VBG O
erythrocyte BC2GM053097733 JJ O
enzyme BC2GM053097733 NN O
function BC2GM053097733 NN O
and BC2GM053097733 CC O
blood BC2GM053097733 NN O
vitamin BC2GM053097733 NN O
levels BC2GM053097733 NNS O
. BC2GM053097733 . O
. . O O

Attention BC2GM022597499 NN O
is BC2GM022597499 VBZ O
devoted BC2GM022597499 VBN O
in BC2GM022597499 IN O
particular BC2GM022597499 JJ O
to BC2GM022597499 TO O
the BC2GM022597499 DT O
action BC2GM022597499 NN O
of BC2GM022597499 IN O
thermoregulating BC2GM022597499 VBG O
nervous BC2GM022597499 JJ O
and BC2GM022597499 CC O
hormonal BC2GM022597499 JJ O
mechanisms BC2GM022597499 NNS O
. BC2GM022597499 . O
. . O O

The BC2GM028463998 DT O
LAB BC2GM028463998 NNP O
in BC2GM028463998 IN O
the BC2GM028463998 DT O
cecum BC2GM028463998 NN O
( BC2GM028463998 ( O
mean BC2GM028463998 JJ O
9.4 BC2GM028463998 CD O
log BC2GM028463998 NN O
CFU BC2GM028463998 NNP O
/ BC2GM028463998 NNP O
g BC2GM028463998 NN O
) BC2GM028463998 ) O
increased BC2GM028463998 VBD O
slightly BC2GM028463998 RB O
with BC2GM028463998 IN O
increasing BC2GM028463998 VBG O
abattoir BC2GM028463998 RP O
holding BC2GM028463998 VBG O
time BC2GM028463998 NN O
. BC2GM028463998 . O
. . O O

RESULT BC2GM079274366 NNP O
( BC2GM079274366 ( O
S BC2GM079274366 NNP O
) BC2GM079274366 ) O
: BC2GM079274366 : O
A BC2GM079274366 DT O
prospective BC2GM079274366 JJ O
study BC2GM079274366 NN O
was BC2GM079274366 VBD O
conducted BC2GM079274366 VBN O
with BC2GM079274366 IN O
44 BC2GM079274366 CD O
cycles BC2GM079274366 NNS O
for BC2GM079274366 IN O
34 BC2GM079274366 CD O
couples BC2GM079274366 NNS O
with BC2GM079274366 IN O
nafarelin BC2GM079274366 JJ O
acetate BC2GM079274366 NN O
( BC2GM079274366 ( O
group BC2GM079274366 NN O
1 BC2GM079274366 CD O
) BC2GM079274366 ) O
and BC2GM079274366 CC O
47 BC2GM079274366 CD O
cycles BC2GM079274366 NNS O
for BC2GM079274366 IN O
40 BC2GM079274366 CD O
couples BC2GM079274366 NNS O
with BC2GM079274366 IN O
buserelin BC2GM079274366 NN O
acetate BC2GM079274366 NN O
( BC2GM079274366 ( O
group BC2GM079274366 NN O
2 BC2GM079274366 CD O
) BC2GM079274366 ) O
with BC2GM079274366 IN O
a BC2GM079274366 DT O
long BC2GM079274366 JJ O
IVF BC2GM079274366 NNP O
protocol BC2GM079274366 NN O
; BC2GM079274366 : O
68 BC2GM079274366 CD O
cycles BC2GM079274366 NNS O
for BC2GM079274366 IN O
46 BC2GM079274366 CD O
couples BC2GM079274366 NNS O
with BC2GM079274366 IN O
nafarelin BC2GM079274366 JJ O
acetate BC2GM079274366 NN O
( BC2GM079274366 ( O
group BC2GM079274366 NN O
3 BC2GM079274366 CD O
) BC2GM079274366 ) O
and BC2GM079274366 CC O
56 BC2GM079274366 CD O
cycles BC2GM079274366 NNS O
for BC2GM079274366 IN O
39 BC2GM079274366 CD O
couples BC2GM079274366 NNS O
with BC2GM079274366 IN O
buserelin BC2GM079274366 NN O
acetate BC2GM079274366 NN O
( BC2GM079274366 ( O
group BC2GM079274366 NN O
4 BC2GM079274366 CD O
) BC2GM079274366 ) O
with BC2GM079274366 IN O
a BC2GM079274366 DT O
short BC2GM079274366 JJ O
IVF BC2GM079274366 NNP O
protocol BC2GM079274366 NN O
; BC2GM079274366 : O
39 BC2GM079274366 CD O
cycles BC2GM079274366 NNS O
for BC2GM079274366 IN O
32 BC2GM079274366 CD O
couples BC2GM079274366 NNS O
with BC2GM079274366 IN O
nafarelin BC2GM079274366 JJ O
acetate BC2GM079274366 NN O
( BC2GM079274366 ( O
group BC2GM079274366 NN O
5 BC2GM079274366 CD O
) BC2GM079274366 ) O
and BC2GM079274366 CC O
50 BC2GM079274366 CD O
cycles BC2GM079274366 NNS O
for BC2GM079274366 IN O
30 BC2GM079274366 CD O
couples BC2GM079274366 NNS O
with BC2GM079274366 IN O
buserelin BC2GM079274366 NN O
acetate BC2GM079274366 NN O
( BC2GM079274366 ( O
group BC2GM079274366 NN O
6 BC2GM079274366 CD O
) BC2GM079274366 ) O
with BC2GM079274366 IN O
a BC2GM079274366 DT O
long BC2GM079274366 JJ O
ICSI BC2GM079274366 NNP O
protocol BC2GM079274366 NN O
; BC2GM079274366 : O
and BC2GM079274366 CC O
87 BC2GM079274366 CD O
cycles BC2GM079274366 NNS O
for BC2GM079274366 IN O
60 BC2GM079274366 CD O
couples BC2GM079274366 NNS O
with BC2GM079274366 IN O
nafarelin BC2GM079274366 JJ O
acetate BC2GM079274366 NN O
( BC2GM079274366 ( O
group BC2GM079274366 NN O
7 BC2GM079274366 CD O
) BC2GM079274366 ) O
and BC2GM079274366 CC O
81 BC2GM079274366 CD O
cycles BC2GM079274366 NNS O
for BC2GM079274366 IN O
61 BC2GM079274366 CD O
couples BC2GM079274366 NNS O
with BC2GM079274366 IN O
buserelin BC2GM079274366 NN O
acetate BC2GM079274366 NN O
( BC2GM079274366 ( O
group BC2GM079274366 NN O
8 BC2GM079274366 CD O
) BC2GM079274366 ) O
with BC2GM079274366 IN O
a BC2GM079274366 DT O
short BC2GM079274366 JJ O
ICSI BC2GM079274366 NNP O
protocol BC2GM079274366 NN O
. BC2GM079274366 . O
. . O O

The BC2GM035857523 DT O
sequence BC2GM035857523 NN O
of BC2GM035857523 IN O
the BC2GM035857523 DT O
25-kDa BC2GM035857523 JJ O
chain BC2GM035857523 NN O
of BC2GM035857523 IN O
the BC2GM035857523 DT O
alpha BC2GM035857523 NN O
subunit BC2GM035857523 NN O
was BC2GM035857523 VBD O
found BC2GM035857523 VBN O
in BC2GM035857523 IN O
a BC2GM035857523 DT O
cDNA BC2GM035857523 NN O
clone BC2GM035857523 NN O
, BC2GM035857523 , O
and BC2GM035857523 CC O
the BC2GM035857523 DT O
amino BC2GM035857523 NN O
acid BC2GM035857523 JJ O
sequence BC2GM035857523 NN O
deduced BC2GM035857523 VBD O
from BC2GM035857523 IN O
the BC2GM035857523 DT O
cDNA BC2GM035857523 NN O
establishes BC2GM035857523 VBZ O
the BC2GM035857523 DT O
complete BC2GM035857523 JJ O
amino BC2GM035857523 NN O
acid BC2GM035857523 JJ O
sequence BC2GM035857523 NN O
of BC2GM035857523 IN O
the BC2GM035857523 DT O
25-kDa BC2GM035857523 JJ O
chain BC2GM035857523 NN O
. BC2GM035857523 . O
. . O O

Anesthesia BC2GM043725941 NNP O
was BC2GM043725941 VBD O
induced BC2GM043725941 VBN O
by BC2GM043725941 IN O
droperidol BC2GM043725941 JJ O
0.2 BC2GM043725941 CD O
mg.kg-1 BC2GM043725941 NN O
, BC2GM043725941 , O
fentanyl BC2GM043725941 VBZ O
50 BC2GM043725941 CD O
micrograms BC2GM043725941 NNS O
, BC2GM043725941 , O
thiamylal BC2GM043725941 JJ O
150-250 BC2GM043725941 JJ O
mg BC2GM043725941 NN O
, BC2GM043725941 , O
and BC2GM043725941 CC O
succinylcholine BC2GM043725941 VB O
1 BC2GM043725941 CD O
mg.kg-1 BC2GM043725941 NN O
, BC2GM043725941 , O
and BC2GM043725941 CC O
maintained BC2GM043725941 VBD O
with BC2GM043725941 IN O
nitrous BC2GM043725941 JJ O
oxide BC2GM043725941 NN O
and BC2GM043725941 CC O
O2 BC2GM043725941 NNP O
( BC2GM043725941 ( O
67:33 BC2GM043725941 CD O
) BC2GM043725941 ) O
supplemented BC2GM043725941 VBN O
with BC2GM043725941 IN O
repeated BC2GM043725941 JJ O
i.v BC2GM043725941 NN O
. BC2GM043725941 . O
doses BC2GM043725941 NNS O
of BC2GM043725941 IN O
fentanyl BC2GM043725941 NN O
( BC2GM043725941 ( O
within BC2GM043725941 IN O
15 BC2GM043725941 CD O
micrograms.kg-1 BC2GM043725941 NN O
) BC2GM043725941 ) O
. BC2GM043725941 . O
. . O O

Antibiotic BC2GM014430266 JJ O
prophylaxis BC2GM014430266 NN O
in BC2GM014430266 IN O
a BC2GM014430266 DT O
surgical BC2GM014430266 JJ O
setting BC2GM014430266 NN O
. BC2GM014430266 . O
. . O O

U BC2GM051717947 NNP O
. BC2GM051717947 . O
. . O O

The BC2GM090178909 DT O
present BC2GM090178909 JJ O
study BC2GM090178909 NN O
tries BC2GM090178909 NNS O
to BC2GM090178909 TO O
associate BC2GM090178909 VB O
some BC2GM090178909 DT O
of BC2GM090178909 IN O
the BC2GM090178909 DT O
causes BC2GM090178909 NNS O
of BC2GM090178909 IN O
hot BC2GM090178909 JJ O
ischaemia BC2GM090178909 NN O
during BC2GM090178909 IN O
the BC2GM090178909 DT O
agony BC2GM090178909 NN O
of BC2GM090178909 IN O
the BC2GM090178909 DT O
corpse BC2GM090178909 NN O
donor BC2GM090178909 NN O
and BC2GM090178909 CC O
to BC2GM090178909 TO O
evaluate BC2GM090178909 VB O
those BC2GM090178909 DT O
that BC2GM090178909 WDT O
may BC2GM090178909 MD O
be BC2GM090178909 VB O
caused BC2GM090178909 VBN O
by BC2GM090178909 IN O
sympathetic BC2GM090178909 JJ O
efference BC2GM090178909 NN O
during BC2GM090178909 IN O
removal BC2GM090178909 NN O
. BC2GM090178909 . O
. . O O

Categorisation BC2GM099647804 NN O
of BC2GM099647804 IN O
the BC2GM099647804 DT O
different BC2GM099647804 JJ O
substructures BC2GM099647804 NNS O
within BC2GM099647804 IN O
the BC2GM099647804 DT O
sections BC2GM099647804 NNS O
allows BC2GM099647804 VBZ O
them BC2GM099647804 PRP O
to BC2GM099647804 TO O
be BC2GM099647804 VB O
analysed BC2GM099647804 VBN O
and BC2GM099647804 CC O
displayed BC2GM099647804 VBN O
separately BC2GM099647804 RB O
. BC2GM099647804 . O
. . O O

Therapy BC2GM078941863 NN O
and BC2GM078941863 CC O
prevention BC2GM078941863 NN O
of BC2GM078941863 IN O
irreversible BC2GM078941863 JJ O
shock BC2GM078941863 NN O
with BC2GM078941863 IN O
pharmacological BC2GM078941863 JJ O
doses BC2GM078941863 NNS O
of BC2GM078941863 IN O
some BC2GM078941863 DT O
corticosteroids BC2GM078941863 NNS O
. BC2GM078941863 . O
. . O O

Interferon-alpha BC2GM039075173 JJ O
inducibility BC2GM039075173 NN O
of BC2GM039075173 IN O
IFI16 BC2GM039075173 NNP O
may BC2GM039075173 MD O
be BC2GM039075173 VB O
regulated BC2GM039075173 VBN O
by BC2GM039075173 IN O
an BC2GM039075173 DT O
interferon-alpha BC2GM039075173 JJ O
/ BC2GM039075173 JJ O
beta-stimulated BC2GM039075173 JJ O
response BC2GM039075173 NN O
consensus BC2GM039075173 NN O
element BC2GM039075173 NN O
in BC2GM039075173 IN O
the BC2GM039075173 DT O
5 BC2GM039075173 CD O
' BC2GM039075173 POS O
UT BC2GM039075173 NNP O
exon BC2GM039075173 NN O
, BC2GM039075173 , O
as BC2GM039075173 IN O
a BC2GM039075173 DT O
similar BC2GM039075173 JJ O
motif BC2GM039075173 NN O
is BC2GM039075173 VBZ O
conserved BC2GM039075173 VBN O
in BC2GM039075173 IN O
the BC2GM039075173 DT O
corresponding BC2GM039075173 JJ O
position BC2GM039075173 NN O
in BC2GM039075173 IN O
the BC2GM039075173 DT O
related BC2GM039075173 JJ O
myeloid BC2GM039075173 NN O
cell BC2GM039075173 NN O
nuclear BC2GM039075173 JJ O
differentiation BC2GM039075173 NN O
antigen BC2GM039075173 NN O
gene BC2GM039075173 NN O
. BC2GM039075173 . O
( BC2GM039075173 ( O
ABSTRACT BC2GM039075173 NNP O
TRUNCATED BC2GM039075173 NNP O
AT BC2GM039075173 NNP O
400 BC2GM039075173 CD O
WORDS BC2GM039075173 NNP O
) BC2GM039075173 ) O
. BC2GM039075173 . O
. . O O

( BC2GM035688360 ( O
5 BC2GM035688360 CD O
) BC2GM035688360 ) O
. BC2GM035688360 . O
. . O O

There BC2GM094732618 EX O
were BC2GM094732618 VBD O
no BC2GM094732618 DT O
differences BC2GM094732618 NNS O
in BC2GM094732618 IN O
the BC2GM094732618 DT O
incidence BC2GM094732618 NN O
of BC2GM094732618 IN O
fractured BC2GM094732618 JJ O
zonas BC2GM094732618 NNS O
. BC2GM094732618 . O
. . O O

Only BC2GM007906275 RB O
53 BC2GM007906275 CD O
% BC2GM007906275 NN O
of BC2GM007906275 IN O
all BC2GM007906275 DT O
injuries BC2GM007906275 NNS O
and BC2GM007906275 CC O
12.5 BC2GM007906275 CD O
% BC2GM007906275 NN O
of BC2GM007906275 IN O
serious BC2GM007906275 JJ O
injuries BC2GM007906275 NNS O
involved BC2GM007906275 VBN O
children BC2GM007906275 NNS O
, BC2GM007906275 , O
and BC2GM007906275 CC O
in BC2GM007906275 IN O
contrast BC2GM007906275 NN O
to BC2GM007906275 TO O
the BC2GM007906275 DT O
1950s BC2GM007906275 CD O
and BC2GM007906275 CC O
early BC2GM007906275 RB O
1960s BC2GM007906275 CD O
, BC2GM007906275 , O
young BC2GM007906275 JJ O
adults BC2GM007906275 NNS O
appear BC2GM007906275 VBP O
at BC2GM007906275 IN O
greatest BC2GM007906275 JJS O
risk BC2GM007906275 NN O
in BC2GM007906275 IN O
the BC2GM007906275 DT O
1980s BC2GM007906275 CD O
. BC2GM007906275 . O
. . O O

Also BC2GM072766443 RB O
, BC2GM072766443 , O
the BC2GM072766443 DT O
placebo BC2GM072766443 NN O
nondepressed BC2GM072766443 VBD O
patients BC2GM072766443 NNS O
had BC2GM072766443 VBD O
significantly BC2GM072766443 RB O
better BC2GM072766443 RBR O
treatment BC2GM072766443 NN O
outcome BC2GM072766443 NN O
compared BC2GM072766443 VBN O
with BC2GM072766443 IN O
the BC2GM072766443 DT O
placebo BC2GM072766443 NN O
depressed BC2GM072766443 VBD O
patients BC2GM072766443 NNS O
. BC2GM072766443 . O
. . O O

The BC2GM071742493 DT O
psbA BC2GM071742493 NN O
gene BC2GM071742493 NN O
encodes BC2GM071742493 VBZ O
the BC2GM071742493 DT O
D1 BC2GM071742493 NNP O
protein BC2GM071742493 NN O
of BC2GM071742493 IN O
photosystem BC2GM071742493 NN O
II BC2GM071742493 NNP O
, BC2GM071742493 , O
which BC2GM071742493 WDT O
is BC2GM071742493 VBZ O
synthesized BC2GM071742493 VBN O
at BC2GM071742493 IN O
very BC2GM071742493 RB O
high BC2GM071742493 JJ O
rates BC2GM071742493 NNS O
in BC2GM071742493 IN O
the BC2GM071742493 DT O
light BC2GM071742493 NN O
in BC2GM071742493 IN O
order BC2GM071742493 NN O
to BC2GM071742493 TO O
replace BC2GM071742493 VB O
photodamaged BC2GM071742493 JJ O
protein BC2GM071742493 NN O
. BC2GM071742493 . O
. . O O

The BC2GM021354805 DT O
wet BC2GM021354805 NN O
and BC2GM021354805 CC O
dry BC2GM021354805 JJ O
methods BC2GM021354805 NNS O
of BC2GM021354805 IN O
the BC2GM021354805 DT O
HA BC2GM021354805 NNP O
synthesis BC2GM021354805 NN O
are BC2GM021354805 VBP O
considered BC2GM021354805 VBN O
. BC2GM021354805 . O
. . O O

All BC2GM040611661 DT O
except BC2GM040611661 IN O
the BC2GM040611661 DT O
last BC2GM040611661 JJ O
two BC2GM040611661 CD O
interventions BC2GM040611661 NNS O
are BC2GM040611661 VBP O
physical BC2GM040611661 JJ O
treatments BC2GM040611661 NNS O
that BC2GM040611661 WDT O
create BC2GM040611661 VBP O
a BC2GM040611661 DT O
wound-tissue BC2GM040611661 JJ O
environment BC2GM040611661 NN O
conducive BC2GM040611661 NN O
to BC2GM040611661 TO O
healing BC2GM040611661 NN O
. BC2GM040611661 . O
. . O O

Phosphate BC2GM004383808 NNP O
compounds BC2GM004383808 NNS O
in BC2GM004383808 IN O
isolated BC2GM004383808 JJ O
, BC2GM004383808 , O
perfused BC2GM004383808 JJ O
hearts BC2GM004383808 NNS O
during BC2GM004383808 IN O
pH BC2GM004383808 JJ O
variation BC2GM004383808 NN O
due BC2GM004383808 JJ O
to BC2GM004383808 TO O
changes BC2GM004383808 NNS O
in BC2GM004383808 IN O
extracellular BC2GM004383808 JJ O
PCO2 BC2GM004383808 NNP O
and BC2GM004383808 CC O
bicarbonate BC2GM004383808 NN O
. BC2GM004383808 . O
. . O O

Total BC2GM042959881 JJ O
cross BC2GM042959881 NN O
sections BC2GM042959881 NNS O
for BC2GM042959881 IN O
electron BC2GM042959881 NN O
scattering BC2GM042959881 NN O
by BC2GM042959881 IN O
CO2 BC2GM042959881 NNP O
molecules BC2GM042959881 NNS O
in BC2GM042959881 IN O
the BC2GM042959881 DT O
energy BC2GM042959881 NN O
range BC2GM042959881 NN O
400-5000 BC2GM042959881 CD O
eV BC2GM042959881 NN O
. BC2GM042959881 . O
. . O O

An BC2GM024474184 DT O
in BC2GM024474184 IN O
vitro BC2GM024474184 JJ O
'glass BC2GM024474184 POS O
stomach BC2GM024474184 NN O
' BC2GM024474184 '' O
( BC2GM024474184 ( O
containing BC2GM024474184 VBG O
various BC2GM024474184 JJ O
volumes BC2GM024474184 NNS O
of BC2GM024474184 IN O
hydrochloric BC2GM024474184 JJ O
acid BC2GM024474184 NN O
[ BC2GM024474184 NNP O
HCl BC2GM024474184 NNP O
] BC2GM024474184 NNP O
and BC2GM024474184 CC O
ammonium BC2GM024474184 NN O
chloride BC2GM024474184 NN O
[ BC2GM024474184 NNP O
NH4Cl BC2GM024474184 NNP O
] BC2GM024474184 NNP O
) BC2GM024474184 ) O
was BC2GM024474184 VBD O
used BC2GM024474184 VBN O
to BC2GM024474184 TO O
evaluate BC2GM024474184 VB O
the BC2GM024474184 DT O
means BC2GM024474184 NNS O
of BC2GM024474184 IN O
increasing BC2GM024474184 VBG O
'gastric BC2GM024474184 NNP O
' BC2GM024474184 POS O
pH BC2GM024474184 NN O
to BC2GM024474184 TO O
that BC2GM024474184 DT O
of BC2GM024474184 IN O
the BC2GM024474184 DT O
NH4+ BC2GM024474184 NNP O
-- BC2GM024474184 : O
> BC2GM024474184 JJ O
NH3 BC2GM024474184 NNP O
transition BC2GM024474184 NN O
that BC2GM024474184 WDT O
occurs BC2GM024474184 VBZ O
significantly BC2GM024474184 RB O
at BC2GM024474184 IN O
pH BC2GM024474184 JJ O
9.24 BC2GM024474184 CD O
. BC2GM024474184 . O
. . O O

Triethylene BC2GM002497068 NNP O
glycol BC2GM002497068 NN O
. BC2GM002497068 . O
. . O O

However BC2GM078178539 RB O
, BC2GM078178539 , O
they BC2GM078178539 PRP O
had BC2GM078178539 VBD O
no BC2GM078178539 DT O
cross-resistance BC2GM078178539 NN O
to BC2GM078178539 TO O
quinolone BC2GM078178539 VB O
, BC2GM078178539 , O
josamycin BC2GM078178539 NN O
and BC2GM078178539 CC O
tylosin BC2GM078178539 NN O
. BC2GM078178539 . O
. . O O

Acetyl-CoA BC2GM005929354 JJ O
carboxylase BC2GM005929354 NN O
from BC2GM005929354 IN O
yeast BC2GM005929354 NN O
is BC2GM005929354 VBZ O
an BC2GM005929354 DT O
essential BC2GM005929354 JJ O
enzyme BC2GM005929354 NN O
and BC2GM005929354 CC O
is BC2GM005929354 VBZ O
regulated BC2GM005929354 VBN O
by BC2GM005929354 IN O
factors BC2GM005929354 NNS O
that BC2GM005929354 WDT O
control BC2GM005929354 VBP O
phospholipid BC2GM005929354 JJ O
metabolism BC2GM005929354 NN O
. BC2GM005929354 . O
. . O O

Immunological BC2GM084639431 JJ O
studies BC2GM084639431 NNS O
also BC2GM084639431 RB O
failed BC2GM084639431 VBD O
to BC2GM084639431 TO O
demonstrate BC2GM084639431 VB O
any BC2GM084639431 DT O
significant BC2GM084639431 JJ O
change BC2GM084639431 NN O
except BC2GM084639431 IN O
for BC2GM084639431 IN O
a BC2GM084639431 DT O
significant BC2GM084639431 JJ O
increase BC2GM084639431 NN O
of BC2GM084639431 IN O
natural BC2GM084639431 JJ O
killer BC2GM084639431 NN O
( BC2GM084639431 ( O
NK BC2GM084639431 NNP O
) BC2GM084639431 ) O
cell BC2GM084639431 NN O
activity BC2GM084639431 NN O
after BC2GM084639431 IN O
IFN-gamma BC2GM084639431 NNP O
infusion BC2GM084639431 NN O
. BC2GM084639431 . O
. . O O

PATIENTS BC2GM036409328 NNS O
: BC2GM036409328 : O
33 BC2GM036409328 CD O
HIV-infected BC2GM036409328 JJ O
, BC2GM036409328 , O
zidovudine-experienced BC2GM036409328 JJ O
patients BC2GM036409328 NNS O
with BC2GM036409328 IN O
serum BC2GM036409328 JJ O
HIV BC2GM036409328 NNP O
RNA BC2GM036409328 NNP O
levels BC2GM036409328 NNS O
of BC2GM036409328 IN O
at BC2GM036409328 IN O
least BC2GM036409328 JJS O
20,000 BC2GM036409328 CD O
copies BC2GM036409328 NNS O
/ BC2GM036409328 VBP O
mL BC2GM036409328 NN O
and BC2GM036409328 CC O
CD4 BC2GM036409328 NNP O
counts BC2GM036409328 VBZ O
ranging BC2GM036409328 VBG O
from BC2GM036409328 IN O
50 BC2GM036409328 CD O
to BC2GM036409328 TO O
400 BC2GM036409328 CD O
cells BC2GM036409328 NNS O
/ BC2GM036409328 JJ O
mm3 BC2GM036409328 NN O
. BC2GM036409328 . O
. . O O

The BC2GM031239616 DT O
gene BC2GM031239616 NN O
sequence BC2GM031239616 NN O
predicts BC2GM031239616 VBZ O
a BC2GM031239616 DT O
150,825 BC2GM031239616 CD O
mol BC2GM031239616 NN O
wt BC2GM031239616 NN O
apoprotein BC2GM031239616 NN O
of BC2GM031239616 IN O
1363 BC2GM031239616 CD O
amino BC2GM031239616 NN O
acids BC2GM031239616 NNS O
having BC2GM031239616 VBG O
an BC2GM031239616 DT O
N-terminal BC2GM031239616 JJ O
hydrophobic BC2GM031239616 JJ O
signal BC2GM031239616 JJ O
sequence BC2GM031239616 NN O
of BC2GM031239616 IN O
17 BC2GM031239616 CD O
amino BC2GM031239616 NN O
acids BC2GM031239616 NNS O
, BC2GM031239616 , O
19 BC2GM031239616 CD O
potential BC2GM031239616 JJ O
N-linked BC2GM031239616 JJ O
glycosylation BC2GM031239616 NN O
sites BC2GM031239616 NNS O
, BC2GM031239616 , O
a BC2GM031239616 DT O
hydrophobic BC2GM031239616 JJ O
anchor BC2GM031239616 NN O
sequence BC2GM031239616 NN O
of BC2GM031239616 IN O
approximately BC2GM031239616 RB O
17 BC2GM031239616 CD O
amino BC2GM031239616 JJ O
acids BC2GM031239616 NNS O
near BC2GM031239616 IN O
the BC2GM031239616 DT O
C BC2GM031239616 NNP O
terminus BC2GM031239616 NN O
, BC2GM031239616 , O
and BC2GM031239616 CC O
a BC2GM031239616 DT O
hydrophilic BC2GM031239616 JJ O
cysteine-rich BC2GM031239616 JJ O
C BC2GM031239616 NNP O
terminus BC2GM031239616 NN O
of BC2GM031239616 IN O
35 BC2GM031239616 CD O
amino BC2GM031239616 JJ O
acids BC2GM031239616 NNS O
. BC2GM031239616 . O
. . O O

As BC2GM070226026 IN O
a BC2GM070226026 DT O
quantitative BC2GM070226026 JJ O
index BC2GM070226026 NN O
of BC2GM070226026 IN O
cochlear BC2GM070226026 JJ O
function BC2GM070226026 NN O
, BC2GM070226026 , O
2f1-f2 BC2GM070226026 JJ O
distortion-product BC2GM070226026 NN O
otoacoustic BC2GM070226026 JJ O
emissions BC2GM070226026 NNS O
( BC2GM070226026 ( O
DPOAEs BC2GM070226026 NNP O
) BC2GM070226026 ) O
were BC2GM070226026 VBD O
monitored BC2GM070226026 VBN O
systematically BC2GM070226026 RB O
over BC2GM070226026 IN O
time BC2GM070226026 NN O
in BC2GM070226026 IN O
three BC2GM070226026 CD O
groups BC2GM070226026 NNS O
of BC2GM070226026 IN O
rabbits BC2GM070226026 NNS O
, BC2GM070226026 , O
with BC2GM070226026 IN O
each BC2GM070226026 DT O
group BC2GM070226026 NN O
experiencing BC2GM070226026 VBG O
a BC2GM070226026 DT O
unique BC2GM070226026 JJ O
paradigm BC2GM070226026 NN O
that BC2GM070226026 WDT O
incorporated BC2GM070226026 VBD O
repeated BC2GM070226026 JJ O
exposure BC2GM070226026 NN O
to BC2GM070226026 TO O
the BC2GM070226026 DT O
low-frequency BC2GM070226026 NN O
tone BC2GM070226026 NN O
. BC2GM070226026 . O
. . O O

Decidual BC2GM074465218 JJ O
/ BC2GM074465218 NNP O
trophoblast BC2GM074465218 NN O
prolactin-related BC2GM074465218 JJ O
protein BC2GM074465218 NN O
: BC2GM074465218 : O
characterization BC2GM074465218 NN O
of BC2GM074465218 IN O
gene BC2GM074465218 NN O
structure BC2GM074465218 NN O
and BC2GM074465218 CC O
cell-specific BC2GM074465218 JJ O
expression BC2GM074465218 NN O
. BC2GM074465218 . O
. . O O

A BC2GM048156343 DT O
derived BC2GM048156343 JJ O
RA-resistant BC2GM048156343 JJ O
line BC2GM048156343 NN O
, BC2GM048156343 , O
NT2 BC2GM048156343 NNP O
/ BC2GM048156343 NNP O
D1-R1 BC2GM048156343 NNP O
, BC2GM048156343 , O
is BC2GM048156343 VBZ O
deficient BC2GM048156343 JJ O
in BC2GM048156343 IN O
this BC2GM048156343 DT O
activity BC2GM048156343 NN O
and BC2GM048156343 CC O
is BC2GM048156343 VBZ O
co-resistant BC2GM048156343 JJ O
to BC2GM048156343 TO O
cisplatin BC2GM048156343 VB O
. BC2GM048156343 . O
. . O O

The BC2GM017612777 DT O
procedure BC2GM017612777 NN O
was BC2GM017612777 VBD O
technically BC2GM017612777 RB O
successful BC2GM017612777 JJ O
in BC2GM017612777 IN O
12 BC2GM017612777 CD O
of BC2GM017612777 IN O
14 BC2GM017612777 CD O
( BC2GM017612777 ( O
86 BC2GM017612777 CD O
% BC2GM017612777 NN O
) BC2GM017612777 ) O
stenoses BC2GM017612777 VBZ O
in BC2GM017612777 IN O
the BC2GM017612777 DT O
fibromuscular BC2GM017612777 JJ O
dysplasia BC2GM017612777 NN O
subgroup BC2GM017612777 NN O
but BC2GM017612777 CC O
in BC2GM017612777 IN O
only BC2GM017612777 RB O
one BC2GM017612777 CD O
of BC2GM017612777 IN O
five BC2GM017612777 CD O
( BC2GM017612777 ( O
20 BC2GM017612777 CD O
% BC2GM017612777 NN O
) BC2GM017612777 ) O
lesions BC2GM017612777 NNS O
in BC2GM017612777 IN O
the BC2GM017612777 DT O
neurofibromatosis BC2GM017612777 NN O
subgroup BC2GM017612777 NN O
. BC2GM017612777 . O
. . O O

Human BC2GM046382854 NNP O
PDNP3 BC2GM046382854 NNP O
is BC2GM046382854 VBZ O
expressed BC2GM046382854 VBN O
in BC2GM046382854 IN O
glioma BC2GM046382854 NN O
cells BC2GM046382854 NNS O
, BC2GM046382854 , O
prostate BC2GM046382854 NN O
, BC2GM046382854 , O
and BC2GM046382854 CC O
uterus BC2GM046382854 JJ O
, BC2GM046382854 , O
but BC2GM046382854 CC O
not BC2GM046382854 RB O
in BC2GM046382854 IN O
the BC2GM046382854 DT O
alimentary BC2GM046382854 JJ O
tract BC2GM046382854 NN O
. BC2GM046382854 . O
. . O O

Activation BC2GM069202593 NN O
of BC2GM069202593 IN O
the BC2GM069202593 DT O
mitogen-activated BC2GM069202593 JJ O
protein BC2GM069202593 NN O
kinase BC2GM069202593 NN O
( BC2GM069202593 ( O
MAPK BC2GM069202593 NNP O
) BC2GM069202593 ) O
pathway BC2GM069202593 NN O
enhances BC2GM069202593 VBZ O
long-range BC2GM069202593 JJ O
transactivation BC2GM069202593 NN O
by BC2GM069202593 IN O
the BC2GM069202593 DT O
beta-globin BC2GM069202593 JJ O
locus BC2GM069202593 NN O
control BC2GM069202593 NN O
region BC2GM069202593 NN O
( BC2GM069202593 ( O
LCR BC2GM069202593 NNP O
) BC2GM069202593 ) O
( BC2GM069202593 ( O
W BC2GM069202593 NNP O
. BC2GM069202593 . O
. . O O

Effects BC2GM039571849 NNS O
of BC2GM039571849 IN O
negative BC2GM039571849 JJ O
pi BC2GM039571849 NN O
mesons BC2GM039571849 NNS O
on BC2GM039571849 IN O
mouse BC2GM039571849 NN O
bone BC2GM039571849 NN O
marrow BC2GM039571849 NN O
cells BC2GM039571849 NNS O
. BC2GM039571849 . O
. . O O

METHODS BC2GM094472638 NN O
: BC2GM094472638 : O
The BC2GM094472638 DT O
study BC2GM094472638 NN O
population BC2GM094472638 NN O
included BC2GM094472638 VBD O
70 BC2GM094472638 CD O
patients BC2GM094472638 NNS O
with BC2GM094472638 IN O
acute BC2GM094472638 JJ O
coronary BC2GM094472638 JJ O
syndromes BC2GM094472638 NNS O
( BC2GM094472638 ( O
14 BC2GM094472638 CD O
with BC2GM094472638 IN O
recent BC2GM094472638 JJ O
acute BC2GM094472638 JJ O
myocardial BC2GM094472638 JJ O
infarction BC2GM094472638 NN O
and BC2GM094472638 CC O
56 BC2GM094472638 CD O
with BC2GM094472638 IN O
unstable BC2GM094472638 JJ O
angina BC2GM094472638 NNS O
pectoris BC2GM094472638 NN O
) BC2GM094472638 ) O
, BC2GM094472638 , O
105 BC2GM094472638 CD O
patients BC2GM094472638 NNS O
with BC2GM094472638 IN O
stable BC2GM094472638 JJ O
angina BC2GM094472638 NNS O
pectoris BC2GM094472638 NN O
, BC2GM094472638 , O
and BC2GM094472638 CC O
75 BC2GM094472638 CD O
control BC2GM094472638 NN O
subjects BC2GM094472638 NNS O
. BC2GM094472638 . O
. . O O

Our BC2GM003435732 PRP$ O
results BC2GM003435732 NNS O
are BC2GM003435732 VBP O
consistent BC2GM003435732 JJ O
with BC2GM003435732 IN O
TCOF1 BC2GM003435732 NNP O
mutations BC2GM003435732 NNS O
leading BC2GM003435732 VBG O
to BC2GM003435732 TO O
the BC2GM003435732 DT O
Treacher BC2GM003435732 NNP O
Collins BC2GM003435732 NNP O
syndrome BC2GM003435732 JJ O
phenotype BC2GM003435732 NN O
. BC2GM003435732 . O
. . O O

The BC2GM089850642 DT O
present BC2GM089850642 JJ O
study BC2GM089850642 NN O
also BC2GM089850642 RB O
emphasizes BC2GM089850642 VBZ O
the BC2GM089850642 DT O
need BC2GM089850642 NN O
of BC2GM089850642 IN O
establishing BC2GM089850642 VBG O
dose-response BC2GM089850642 JJ O
curves BC2GM089850642 NNS O
to BC2GM089850642 TO O
correctly BC2GM089850642 RB O
assess BC2GM089850642 VB O
the BC2GM089850642 DT O
relative BC2GM089850642 JJ O
contribution BC2GM089850642 NN O
of BC2GM089850642 IN O
the BC2GM089850642 DT O
different BC2GM089850642 JJ O
regions BC2GM089850642 NNS O
of BC2GM089850642 IN O
steroid BC2GM089850642 JJ O
hormone BC2GM089850642 NN O
receptors BC2GM089850642 NNS O
in BC2GM089850642 IN O
activation BC2GM089850642 NN O
of BC2GM089850642 IN O
transcription BC2GM089850642 NN O
. BC2GM089850642 . O
. . O O

RT-PCR BC2GM009533483 JJ O
analysis BC2GM009533483 NN O
of BC2GM009533483 IN O
FGFR-3 BC2GM009533483 NNP O
mRNA BC2GM009533483 NN O
showed BC2GM009533483 VBD O
the BC2GM009533483 DT O
presence BC2GM009533483 NN O
of BC2GM009533483 IN O
a BC2GM009533483 DT O
splice BC2GM009533483 NN O
variant BC2GM009533483 NN O
in BC2GM009533483 IN O
which BC2GM009533483 WDT O
exons BC2GM009533483 NNS O
7 BC2GM009533483 CD O
and BC2GM009533483 CC O
8 BC2GM009533483 CD O
are BC2GM009533483 VBP O
deleted BC2GM009533483 VBN O
. BC2GM009533483 . O
. . O O

Promoter BC2GM060051589 NN O
activity BC2GM060051589 NN O
was BC2GM060051589 VBD O
assayed BC2GM060051589 VBN O
by BC2GM060051589 IN O
transient BC2GM060051589 JJ O
transfection BC2GM060051589 NN O
of BC2GM060051589 IN O
luciferase BC2GM060051589 NN O
reporter BC2GM060051589 NN O
constructs BC2GM060051589 NNS O
containing BC2GM060051589 VBG O
nested BC2GM060051589 JJ O
deletions BC2GM060051589 NNS O
of BC2GM060051589 IN O
the BC2GM060051589 DT O
upstream BC2GM060051589 JJ O
sequence BC2GM060051589 NN O
in BC2GM060051589 IN O
the BC2GM060051589 DT O
human BC2GM060051589 JJ O
RPE BC2GM060051589 NNP O
cell BC2GM060051589 NN O
lines BC2GM060051589 NNS O
ARPE19 BC2GM060051589 NNP O
and BC2GM060051589 CC O
D407 BC2GM060051589 NNP O
, BC2GM060051589 , O
as BC2GM060051589 RB O
well BC2GM060051589 RB O
as BC2GM060051589 IN O
in BC2GM060051589 IN O
the BC2GM060051589 DT O
SK-Mel-28 BC2GM060051589 NNP O
and BC2GM060051589 CC O
HeLa BC2GM060051589 NNP O
cell BC2GM060051589 NN O
lines BC2GM060051589 NNS O
. BC2GM060051589 . O
. . O O

Parental BC2GM041377318 JJ O
and BC2GM041377318 CC O
vector-transfected BC2GM041377318 JJ O
MCF7 BC2GM041377318 NNP O
cells BC2GM041377318 NNS O
, BC2GM041377318 , O
which BC2GM041377318 WDT O
were BC2GM041377318 VBD O
sensitive BC2GM041377318 JJ O
to BC2GM041377318 TO O
the BC2GM041377318 DT O
growth-inhibitory BC2GM041377318 JJ O
effects BC2GM041377318 NNS O
of BC2GM041377318 IN O
atRA BC2GM041377318 NN O
, BC2GM041377318 , O
exhibited BC2GM041377318 VBD O
atRA-dependent BC2GM041377318 JJ O
retinoic BC2GM041377318 NN O
acid BC2GM041377318 NN O
receptor BC2GM041377318 NN O
( BC2GM041377318 ( O
RAR BC2GM041377318 NNP O
) BC2GM041377318 ) O
transactivation BC2GM041377318 NN O
and BC2GM041377318 CC O
transrepression BC2GM041377318 NN O
of BC2GM041377318 IN O
12-O-tetradecanoylphorbol-13-acetate-induced BC2GM041377318 JJ O
AP-1 BC2GM041377318 JJ O
activity BC2GM041377318 NN O
. BC2GM041377318 . O
. . O O

BACKGROUND BC2GM082790827 NN O
: BC2GM082790827 : O
The BC2GM082790827 DT O
extract BC2GM082790827 NN O
of BC2GM082790827 IN O
medicinal BC2GM082790827 JJ O
plants BC2GM082790827 NNS O
containing BC2GM082790827 VBG O
curcumin BC2GM082790827 NN O
is BC2GM082790827 VBZ O
traditionally BC2GM082790827 RB O
believed BC2GM082790827 VBN O
to BC2GM082790827 TO O
have BC2GM082790827 VB O
a BC2GM082790827 DT O
positive BC2GM082790827 JJ O
contraction BC2GM082790827 NN O
effect BC2GM082790827 NN O
on BC2GM082790827 IN O
the BC2GM082790827 DT O
human BC2GM082790827 JJ O
gall-bladder BC2GM082790827 NN O
. BC2GM082790827 . O
. . O O

Spinal BC2GM013367918 JJ O
injuries BC2GM013367918 NNS O
in BC2GM013367918 IN O
a BC2GM013367918 DT O
multiple BC2GM013367918 JJ O
trauma BC2GM013367918 NN O
patient BC2GM013367918 NN O
. BC2GM013367918 . O
. . O O

Acute BC2GM003538479 NNP O
spontaneous BC2GM003538479 JJ O
subdural BC2GM003538479 JJ O
haematoma BC2GM003538479 NN O
. BC2GM003538479 . O
. . O O

Patients BC2GM032976661 NNS O
commonly BC2GM032976661 RB O
considered BC2GM032976661 VBD O
the BC2GM032976661 DT O
external BC2GM032976661 JJ O
frame BC2GM032976661 NN O
cumbersome BC2GM032976661 NN O
. BC2GM032976661 . O
. . O O

He BC2GM065009088 PRP O
presented BC2GM065009088 VBD O
with BC2GM065009088 IN O
left BC2GM065009088 JJ O
lower BC2GM065009088 JJR O
abdominal BC2GM065009088 JJ O
pain BC2GM065009088 NN O
and BC2GM065009088 CC O
hematoma BC2GM065009088 NN O
after BC2GM065009088 IN O
a BC2GM065009088 DT O
fall BC2GM065009088 NN O
. BC2GM065009088 . O
. . O O

To BC2GM049191503 TO O
gain BC2GM049191503 VB O
additional BC2GM049191503 JJ O
insights BC2GM049191503 NNS O
into BC2GM049191503 IN O
this BC2GM049191503 DT O
novel BC2GM049191503 JJ O
apoptotic BC2GM049191503 JJ O
checkpoint BC2GM049191503 NN O
, BC2GM049191503 , O
we BC2GM049191503 PRP O
have BC2GM049191503 VBP O
now BC2GM049191503 RB O
characterized BC2GM049191503 VBN O
the BC2GM049191503 DT O
mouse BC2GM049191503 NN O
survivin BC2GM049191503 NN O
locus BC2GM049191503 NN O
. BC2GM049191503 . O
. . O O

Patients BC2GM078540680 NNS O
were BC2GM078540680 VBD O
treated BC2GM078540680 VBN O
with BC2GM078540680 IN O
either BC2GM078540680 DT O
4.8 BC2GM078540680 CD O
million BC2GM078540680 CD O
units BC2GM078540680 NNS O
of BC2GM078540680 IN O
procaine BC2GM078540680 JJ O
penicillin BC2GM078540680 NN O
with BC2GM078540680 IN O
1 BC2GM078540680 CD O
g BC2GM078540680 NNS O
probenecid BC2GM078540680 NN O
, BC2GM078540680 , O
3.5 BC2GM078540680 CD O
or BC2GM078540680 CC O
4.5 BC2GM078540680 CD O
g BC2GM078540680 NN O
of BC2GM078540680 IN O
ampicillin BC2GM078540680 NN O
with BC2GM078540680 IN O
1 BC2GM078540680 CD O
g BC2GM078540680 NNS O
probenecid BC2GM078540680 NN O
, BC2GM078540680 , O
or BC2GM078540680 CC O
9.5 BC2GM078540680 CD O
g BC2GM078540680 NN O
of BC2GM078540680 IN O
tetracycline BC2GM078540680 NN O
given BC2GM078540680 VBN O
over BC2GM078540680 IN O
4 BC2GM078540680 CD O
days BC2GM078540680 NNS O
. BC2GM078540680 . O
. . O O

A BC2GM067512942 DT O
deletion BC2GM067512942 NN O
analysis BC2GM067512942 NN O
of BC2GM067512942 IN O
the BC2GM067512942 DT O
FAS1 BC2GM067512942 NNP O
promoter BC2GM067512942 NN O
lacking BC2GM067512942 VBG O
the BC2GM067512942 DT O
previously BC2GM067512942 RB O
characterized BC2GM067512942 VBN O
inositol BC2GM067512942 JJ O
/ BC2GM067512942 JJ O
choline-responsive-element BC2GM067512942 JJ O
motif BC2GM067512942 NN O
defined BC2GM067512942 VBD O
a BC2GM067512942 DT O
region BC2GM067512942 NN O
( BC2GM067512942 ( O
nucleotides BC2GM067512942 JJ O
-760 BC2GM067512942 NN O
to BC2GM067512942 TO O
-850 BC2GM067512942 VB O
) BC2GM067512942 ) O
responsible BC2GM067512942 JJ O
for BC2GM067512942 IN O
most BC2GM067512942 JJS O
of BC2GM067512942 IN O
the BC2GM067512942 DT O
remaining BC2GM067512942 VBG O
activation BC2GM067512942 NN O
potency BC2GM067512942 NN O
. BC2GM067512942 . O
. . O O

T. BC2GM079526142 NNP O
infestans BC2GM079526142 NNS O
, BC2GM079526142 , O
T. BC2GM079526142 NNP O
delpontei BC2GM079526142 NN O
, BC2GM079526142 , O
T. BC2GM079526142 NNP O
rubrovaria BC2GM079526142 NN O
, BC2GM079526142 , O
T. BC2GM079526142 NNP O
sordida BC2GM079526142 NN O
, BC2GM079526142 , O
T. BC2GM079526142 NNP O
guasayana BC2GM079526142 NN O
and BC2GM079526142 CC O
T. BC2GM079526142 NNP O
vitticeps BC2GM079526142 NNS O
from BC2GM079526142 IN O
infestans BC2GM079526142 NNS O
subgroup BC2GM079526142 VBN O
and BC2GM079526142 CC O
T. BC2GM079526142 NNP O
pallidipennis BC2GM079526142 NN O
from BC2GM079526142 IN O
rubrofasciata BC2GM079526142 NN O
, BC2GM079526142 , O
were BC2GM079526142 VBD O
studied BC2GM079526142 VBN O
. BC2GM079526142 . O
. . O O

In BC2GM054680908 IN O
our BC2GM054680908 PRP$ O
case BC2GM054680908 NN O
the BC2GM054680908 DT O
development BC2GM054680908 NN O
of BC2GM054680908 IN O
the BC2GM054680908 DT O
tumor BC2GM054680908 NN O
at BC2GM054680908 IN O
the BC2GM054680908 DT O
posterior BC2GM054680908 JJ O
side BC2GM054680908 NN O
of BC2GM054680908 IN O
the BC2GM054680908 DT O
prostate BC2GM054680908 NN O
, BC2GM054680908 , O
the BC2GM054680908 DT O
lack BC2GM054680908 NN O
of BC2GM054680908 IN O
PSA BC2GM054680908 NNP O
immunoreactivity BC2GM054680908 NN O
and BC2GM054680908 CC O
the BC2GM054680908 DT O
presence BC2GM054680908 NN O
of BC2GM054680908 IN O
mucinous BC2GM054680908 JJ O
glands BC2GM054680908 NNS O
, BC2GM054680908 , O
sometimes BC2GM054680908 RB O
`` BC2GM054680908 `` O
endocervical-like BC2GM054680908 JJ O
'' BC2GM054680908 '' O
, BC2GM054680908 , O
could BC2GM054680908 MD O
suggest BC2GM054680908 VB O
an BC2GM054680908 DT O
origin BC2GM054680908 NN O
from BC2GM054680908 IN O
embryonic BC2GM054680908 JJ O
mullerian BC2GM054680908 JJ O
remnants BC2GM054680908 NNS O
in BC2GM054680908 IN O
the BC2GM054680908 DT O
prostatic BC2GM054680908 JJ O
utricle BC2GM054680908 NN O
rather BC2GM054680908 RB O
than BC2GM054680908 IN O
urogenital BC2GM054680908 JJ O
sinus BC2GM054680908 NN O
. BC2GM054680908 . O
. . O O

Northern BC2GM050121577 NNP O
blot BC2GM050121577 NN O
analysis BC2GM050121577 NN O
identified BC2GM050121577 VBN O
retina-specific BC2GM050121577 JJ O
transcripts BC2GM050121577 NNS O
of BC2GM050121577 IN O
3.0 BC2GM050121577 CD O
kb BC2GM050121577 NN O
for BC2GM050121577 IN O
rod BC2GM050121577 NN O
G BC2GM050121577 NNP O
alpha BC2GM050121577 NN O
t BC2GM050121577 NN O
and BC2GM050121577 CC O
2.6 BC2GM050121577 CD O
kb BC2GM050121577 NN O
for BC2GM050121577 IN O
cone BC2GM050121577 NN O
G BC2GM050121577 NNP O
alpha BC2GM050121577 NN O
t BC2GM050121577 NN O
. BC2GM050121577 . O
. . O O

One BC2GM064390333 CD O
function BC2GM064390333 NN O
of BC2GM064390333 IN O
p53 BC2GM064390333 NN O
is BC2GM064390333 VBZ O
in BC2GM064390333 IN O
regulating BC2GM064390333 VBG O
cell BC2GM064390333 NN O
cycle BC2GM064390333 NN O
check-point BC2GM064390333 NN O
control BC2GM064390333 NN O
after BC2GM064390333 IN O
DNA BC2GM064390333 NNP O
damage BC2GM064390333 NN O
. BC2GM064390333 . O
. . O O

The BC2GM049762234 DT O
cluster BC2GM049762234 NN O
was BC2GM049762234 VBD O
mapped BC2GM049762234 VBN O
to BC2GM049762234 TO O
nucleotides BC2GM049762234 NNS O
-464 BC2GM049762234 FW O
to BC2GM049762234 TO O
-434 BC2GM049762234 VB O
( BC2GM049762234 ( O
relative BC2GM049762234 JJ O
to BC2GM049762234 TO O
nucleotide BC2GM049762234 VB O
A BC2GM049762234 NNP O
in BC2GM049762234 IN O
the BC2GM049762234 DT O
initiation BC2GM049762234 NN O
codon BC2GM049762234 NN O
) BC2GM049762234 ) O
in BC2GM049762234 IN O
genomic BC2GM049762234 JJ O
DNA BC2GM049762234 NN O
. BC2GM049762234 . O
. . O O

Sequencing BC2GM029314014 VBG O
and BC2GM029314014 CC O
restriction BC2GM029314014 NN O
enzyme BC2GM029314014 NN O
analysis BC2GM029314014 NN O
demonstrated BC2GM029314014 VBD O
that BC2GM029314014 IN O
this BC2GM029314014 DT O
single-copy BC2GM029314014 JJ O
gene BC2GM029314014 NN O
contains BC2GM029314014 VBZ O
11 BC2GM029314014 CD O
exons BC2GM029314014 NNS O
and BC2GM029314014 CC O
spans BC2GM029314014 NNS O
9596 BC2GM029314014 CD O
base BC2GM029314014 NN O
pairs BC2GM029314014 NN O
. BC2GM029314014 . O
. . O O

Tilisolol BC2GM086028884 NNP O
and BC2GM086028884 CC O
carboxymethylcellulose BC2GM086028884 JJ O
sodium BC2GM086028884 NN O
salt BC2GM086028884 NN O
( BC2GM086028884 ( O
CMC BC2GM086028884 NNP O
) BC2GM086028884 ) O
were BC2GM086028884 VBD O
used BC2GM086028884 VBN O
as BC2GM086028884 IN O
the BC2GM086028884 DT O
model BC2GM086028884 NN O
ophthalmic BC2GM086028884 JJ O
drug BC2GM086028884 NN O
and BC2GM086028884 CC O
viscous BC2GM086028884 JJ O
polymer BC2GM086028884 NN O
, BC2GM086028884 , O
respectively BC2GM086028884 RB O
. BC2GM086028884 . O
. . O O

Based BC2GM072127832 VBN O
on BC2GM072127832 IN O
the BC2GM072127832 DT O
deduced BC2GM072127832 JJ O
amino BC2GM072127832 NN O
acid BC2GM072127832 NN O
sequence BC2GM072127832 NN O
identity BC2GM072127832 NN O
we BC2GM072127832 PRP O
designated BC2GM072127832 VBD O
GAPC1 BC2GM072127832 NNP O
and BC2GM072127832 CC O
GAPC2 BC2GM072127832 NNP O
as BC2GM072127832 IN O
group BC2GM072127832 NN O
I BC2GM072127832 PRP O
( BC2GM072127832 ( O
97 BC2GM072127832 CD O
% BC2GM072127832 NN O
identical BC2GM072127832 JJ O
) BC2GM072127832 ) O
and BC2GM072127832 CC O
GAPC3 BC2GM072127832 NNP O
and BC2GM072127832 CC O
GAPC4 BC2GM072127832 NNP O
as BC2GM072127832 IN O
group BC2GM072127832 NN O
II BC2GM072127832 NNP O
( BC2GM072127832 ( O
99.4 BC2GM072127832 CD O
% BC2GM072127832 NN O
identical BC2GM072127832 JJ O
) BC2GM072127832 ) O
. BC2GM072127832 . O
. . O O

In BC2GM048518411 IN O
clinical BC2GM048518411 JJ O
stroke BC2GM048518411 NN O
cardiovascular BC2GM048518411 JJ O
abnormalities BC2GM048518411 NNS O
are BC2GM048518411 VBP O
frequently BC2GM048518411 RB O
neglected BC2GM048518411 VBN O
although BC2GM048518411 IN O
they BC2GM048518411 PRP O
occur BC2GM048518411 VBP O
more BC2GM048518411 RBR O
often BC2GM048518411 RB O
than BC2GM048518411 IN O
it BC2GM048518411 PRP O
is BC2GM048518411 VBZ O
generally BC2GM048518411 RB O
assumed BC2GM048518411 VBN O
. BC2GM048518411 . O
. . O O

Deletion BC2GM044293029 NNP O
analysis BC2GM044293029 NN O
of BC2GM044293029 IN O
the BC2GM044293029 DT O
7.3-kb BC2GM044293029 JJ O
GATA-2 BC2GM044293029 NNP O
promoter BC2GM044293029 NN O
region BC2GM044293029 NN O
revealed BC2GM044293029 VBD O
that BC2GM044293029 IN O
a BC2GM044293029 DT O
1.1-kb BC2GM044293029 JJ O
DNA BC2GM044293029 NN O
sequence BC2GM044293029 NN O
is BC2GM044293029 VBZ O
critical BC2GM044293029 JJ O
for BC2GM044293029 IN O
expression BC2GM044293029 NN O
of BC2GM044293029 IN O
GATA-2 BC2GM044293029 NNP O
in BC2GM044293029 IN O
neurons BC2GM044293029 NNS O
. BC2GM044293029 . O
. . O O

In BC2GM011525523 IN O
addition BC2GM011525523 NN O
, BC2GM011525523 , O
WR-3689 BC2GM011525523 NNP O
, BC2GM011525523 , O
WR-109342 BC2GM011525523 NNP O
, BC2GM011525523 , O
and BC2GM011525523 CC O
WR-168643 BC2GM011525523 NNP O
were BC2GM011525523 VBD O
used BC2GM011525523 VBN O
with BC2GM011525523 IN O
per BC2GM011525523 IN O
os BC2GM011525523 NN O
administration BC2GM011525523 NN O
to BC2GM011525523 TO O
determine BC2GM011525523 VB O
hematopoietic BC2GM011525523 JJ O
lethality BC2GM011525523 NN O
. BC2GM011525523 . O
. . O O

The BC2GM017879501 DT O
reading BC2GM017879501 NN O
achievement BC2GM017879501 NN O
of BC2GM017879501 IN O
students BC2GM017879501 NNS O
with BC2GM017879501 IN O
learning BC2GM017879501 VBG O
disabilities BC2GM017879501 NNS O
who BC2GM017879501 WP O
received BC2GM017879501 VBD O
reading BC2GM017879501 NN O
instruction BC2GM017879501 NN O
through BC2GM017879501 IN O
the BC2GM017879501 DT O
DISTAR BC2GM017879501 NNP O
program BC2GM017879501 NN O
was BC2GM017879501 VBD O
compared BC2GM017879501 VBN O
to BC2GM017879501 TO O
that BC2GM017879501 DT O
of BC2GM017879501 IN O
similar BC2GM017879501 JJ O
students BC2GM017879501 NNS O
using BC2GM017879501 VBG O
basal BC2GM017879501 JJ O
reader BC2GM017879501 NN O
materials BC2GM017879501 NNS O
. BC2GM017879501 . O
. . O O

22.6 BC2GM048987709 CD O
% BC2GM048987709 NN O
of BC2GM048987709 IN O
patients BC2GM048987709 NNS O
were BC2GM048987709 VBD O
found BC2GM048987709 VBN O
to BC2GM048987709 TO O
be BC2GM048987709 VB O
positive BC2GM048987709 JJ O
at BC2GM048987709 IN O
histology BC2GM048987709 NN O
in BC2GM048987709 IN O
the BC2GM048987709 DT O
corpus BC2GM048987709 NN O
mucosa BC2GM048987709 NN O
; BC2GM048987709 : O
all BC2GM048987709 DT O
but BC2GM048987709 CC O
one BC2GM048987709 CD O
of BC2GM048987709 IN O
these BC2GM048987709 DT O
patients BC2GM048987709 NNS O
had BC2GM048987709 VBD O
elevated BC2GM048987709 VBN O
circulating BC2GM048987709 VBG O
IgG BC2GM048987709 NNP O
to BC2GM048987709 TO O
H. BC2GM048987709 NNP O
pylori BC2GM048987709 NNP O
( BC2GM048987709 ( O
Group BC2GM048987709 NNP O
C BC2GM048987709 NNP O
) BC2GM048987709 ) O
. BC2GM048987709 . O
. . O O

By BC2GM086570767 IN O
differential BC2GM086570767 JJ O
screening BC2GM086570767 NN O
of BC2GM086570767 IN O
a BC2GM086570767 DT O
Xenopus BC2GM086570767 NNP O
laevis BC2GM086570767 NN O
egg BC2GM086570767 NN O
cDNA BC2GM086570767 NN O
library BC2GM086570767 NN O
, BC2GM086570767 , O
we BC2GM086570767 PRP O
have BC2GM086570767 VBP O
isolated BC2GM086570767 VBN O
a BC2GM086570767 DT O
2,111 BC2GM086570767 CD O
bp BC2GM086570767 NN O
cDNA BC2GM086570767 NN O
which BC2GM086570767 WDT O
corresponds BC2GM086570767 VBZ O
to BC2GM086570767 TO O
a BC2GM086570767 DT O
maternal BC2GM086570767 JJ O
mRNA BC2GM086570767 NN O
specifically BC2GM086570767 RB O
deadenylated BC2GM086570767 VBN O
after BC2GM086570767 IN O
fertilisation BC2GM086570767 NN O
. BC2GM086570767 . O
. . O O

The BC2GM026443605 DT O
present BC2GM026443605 JJ O
study BC2GM026443605 NN O
indicates BC2GM026443605 VBZ O
that BC2GM026443605 IN O
the BC2GM026443605 DT O
high-dose BC2GM026443605 JJ O
5-fluorouracil BC2GM026443605 JJ O
regimen BC2GM026443605 NN O
shows BC2GM026443605 VBZ O
weak BC2GM026443605 JJ O
activity BC2GM026443605 NN O
in BC2GM026443605 IN O
advanced BC2GM026443605 JJ O
pancreatic BC2GM026443605 JJ O
cancer BC2GM026443605 NN O
which BC2GM026443605 WDT O
seems BC2GM026443605 VBZ O
comparable BC2GM026443605 JJ O
to BC2GM026443605 TO O
gemcitabine BC2GM026443605 VB O
. BC2GM026443605 . O
. . O O

Insulin BC2GM067919498 NNP O
therapy BC2GM067919498 NN O
has BC2GM067919498 VBZ O
been BC2GM067919498 VBN O
expanded BC2GM067919498 VBN O
by BC2GM067919498 IN O
development BC2GM067919498 NN O
of BC2GM067919498 IN O
human BC2GM067919498 JJ O
insulin BC2GM067919498 NN O
and BC2GM067919498 CC O
new BC2GM067919498 JJ O
modes BC2GM067919498 NNS O
of BC2GM067919498 IN O
injection BC2GM067919498 NN O
, BC2GM067919498 , O
including BC2GM067919498 VBG O
insulin BC2GM067919498 NN O
pumps BC2GM067919498 NNS O
. BC2GM067919498 . O
. . O O

IRIS BC2GM038301816 NNP O
/ BC2GM038301816 NNP O
GAS BC2GM038301816 NNP O
DNA BC2GM038301816 NNP O
also BC2GM038301816 RB O
formed BC2GM038301816 VBD O
a BC2GM038301816 DT O
number BC2GM038301816 NN O
of BC2GM038301816 IN O
specific BC2GM038301816 JJ O
complexes BC2GM038301816 NNS O
with BC2GM038301816 IN O
constitutively BC2GM038301816 RB O
expressed BC2GM038301816 VBN O
factors BC2GM038301816 NNS O
, BC2GM038301816 , O
none BC2GM038301816 NN O
of BC2GM038301816 IN O
which BC2GM038301816 WDT O
were BC2GM038301816 VBD O
affected BC2GM038301816 VBN O
by BC2GM038301816 IN O
the BC2GM038301816 DT O
above BC2GM038301816 JJ O
Abs BC2GM038301816 NNP O
. BC2GM038301816 . O
. . O O

Most BC2GM086588725 JJS O
of BC2GM086588725 IN O
these BC2GM086588725 DT O
elements BC2GM086588725 NNS O
are BC2GM086588725 VBP O
adjacent BC2GM086588725 JJ O
to BC2GM086588725 TO O
type BC2GM086588725 VB O
X BC2GM086588725 NNP O
telomeric BC2GM086588725 JJ O
repeats BC2GM086588725 NNS O
, BC2GM086588725 , O
and BC2GM086588725 CC O
regions BC2GM086588725 NNS O
flanking BC2GM086588725 VBG O
four BC2GM086588725 CD O
of BC2GM086588725 IN O
five BC2GM086588725 CD O
characterized BC2GM086588725 NNS O
S. BC2GM086588725 NNP O
paradoxus BC2GM086588725 NN O
insertions BC2GM086588725 NNS O
carry BC2GM086588725 VBP O
autonomously BC2GM086588725 RB O
replicating BC2GM086588725 VBG O
sequences BC2GM086588725 NNS O
. BC2GM086588725 . O
. . O O

In BC2GM029344954 IN O
the BC2GM029344954 DT O
unit BC2GM029344954 NN O
housing BC2GM029344954 NN O
of BC2GM029344954 IN O
a BC2GM029344954 DT O
compact BC2GM029344954 JJ O
cyclotron BC2GM029344954 NN O
and BC2GM029344954 CC O
positron BC2GM029344954 NN O
emission BC2GM029344954 NN O
CT BC2GM029344954 NNP O
( BC2GM029344954 ( O
PET BC2GM029344954 NNP O
) BC2GM029344954 ) O
, BC2GM029344954 , O
positron BC2GM029344954 VBP O
emitting BC2GM029344954 VBG O
gas BC2GM029344954 NN O
such BC2GM029344954 JJ O
as BC2GM029344954 IN O
15O BC2GM029344954 CD O
, BC2GM029344954 , O
11C BC2GM029344954 CD O
, BC2GM029344954 , O
C15O2 BC2GM029344954 NNP O
, BC2GM029344954 , O
C15O BC2GM029344954 NNP O
etc BC2GM029344954 FW O
. BC2GM029344954 . O
is BC2GM029344954 VBZ O
supplied BC2GM029344954 VBN O
from BC2GM029344954 IN O
a BC2GM029344954 DT O
cyclotron BC2GM029344954 NN O
to BC2GM029344954 TO O
a BC2GM029344954 DT O
PET BC2GM029344954 NNP O
room BC2GM029344954 NN O
through BC2GM029344954 IN O
a BC2GM029344954 DT O
transportation BC2GM029344954 NN O
pipe BC2GM029344954 NN O
with BC2GM029344954 IN O
an BC2GM029344954 DT O
appropriate BC2GM029344954 JJ O
shield BC2GM029344954 NN O
to BC2GM029344954 TO O
reduce BC2GM029344954 VB O
positron BC2GM029344954 NN O
annihilation BC2GM029344954 NN O
radiation BC2GM029344954 NN O
. BC2GM029344954 . O
. . O O

Over BC2GM022531495 IN O
9 BC2GM022531495 CD O
kb BC2GM022531495 NNS O
of BC2GM022531495 IN O
DNA BC2GM022531495 NNP O
sequence BC2GM022531495 NN O
was BC2GM022531495 VBD O
obtained BC2GM022531495 VBN O
for BC2GM022531495 IN O
one BC2GM022531495 CD O
clone BC2GM022531495 NN O
( BC2GM022531495 ( O
A1 BC2GM022531495 NNP O
) BC2GM022531495 ) O
with BC2GM022531495 IN O
a BC2GM022531495 DT O
total BC2GM022531495 JJ O
IGS BC2GM022531495 NNP O
length BC2GM022531495 NN O
of BC2GM022531495 IN O
approximately BC2GM022531495 RB O
12.4 BC2GM022531495 CD O
kb BC2GM022531495 NNS O
. BC2GM022531495 . O
. . O O

The BC2GM031044079 DT O
lack BC2GM031044079 NN O
of BC2GM031044079 IN O
chronically BC2GM031044079 RB O
depressed BC2GM031044079 VBN O
LCBF BC2GM031044079 NNP O
( BC2GM031044079 ( O
after BC2GM031044079 IN O
1 BC2GM031044079 CD O
day BC2GM031044079 NN O
) BC2GM031044079 ) O
may BC2GM031044079 MD O
be BC2GM031044079 VB O
related BC2GM031044079 VBN O
to BC2GM031044079 TO O
the BC2GM031044079 DT O
quick BC2GM031044079 JJ O
structural BC2GM031044079 JJ O
repair BC2GM031044079 NN O
of BC2GM031044079 IN O
endothelium BC2GM031044079 NN O
. BC2GM031044079 . O
. . O O

Usefulness BC2GM079993649 NN O
of BC2GM079993649 IN O
computerized BC2GM079993649 JJ O
tomography BC2GM079993649 NN O
in BC2GM079993649 IN O
hemodialysis BC2GM079993649 NN O
patients BC2GM079993649 NNS O
. BC2GM079993649 . O
. . O O

Barium BC2GM050337073 NNP O
mucosal BC2GM050337073 NN O
coating BC2GM050337073 NN O
was BC2GM050337073 VBD O
judged BC2GM050337073 VBN O
to BC2GM050337073 TO O
be BC2GM050337073 VB O
better BC2GM050337073 RB O
in BC2GM050337073 IN O
the BC2GM050337073 DT O
members BC2GM050337073 NNS O
to BC2GM050337073 TO O
whom BC2GM050337073 WP O
magnesium BC2GM050337073 NN O
sulphate BC2GM050337073 NN O
was BC2GM050337073 VBD O
administered BC2GM050337073 VBN O
( BC2GM050337073 ( O
p BC2GM050337073 JJ O
= BC2GM050337073 NNP O
0.0007 BC2GM050337073 CD O
) BC2GM050337073 ) O
. BC2GM050337073 . O
. . O O

However BC2GM083483260 RB O
, BC2GM083483260 , O
coligation BC2GM083483260 NN O
of BC2GM083483260 IN O
Fc BC2GM083483260 NNP O
gamma BC2GM083483260 NN O
RIIB1 BC2GM083483260 NNP O
with BC2GM083483260 IN O
B BC2GM083483260 NNP O
cell BC2GM083483260 NN O
Ag BC2GM083483260 NNP O
receptors BC2GM083483260 NNS O
( BC2GM083483260 ( O
BCR BC2GM083483260 NNP O
) BC2GM083483260 ) O
inhibits BC2GM083483260 VBZ O
BCR-mediated BC2GM083483260 JJ O
signaling BC2GM083483260 NN O
by BC2GM083483260 IN O
a BC2GM083483260 DT O
mechanism BC2GM083483260 NN O
that BC2GM083483260 WDT O
may BC2GM083483260 MD O
involve BC2GM083483260 VB O
recruitment BC2GM083483260 NN O
of BC2GM083483260 IN O
phosphatases BC2GM083483260 NNS O
SHP-1 BC2GM083483260 NNP O
, BC2GM083483260 , O
SHP-2 BC2GM083483260 NNP O
, BC2GM083483260 , O
and BC2GM083483260 CC O
the BC2GM083483260 DT O
SH2 BC2GM083483260 NNP O
containing BC2GM083483260 VBG O
inositol BC2GM083483260 JJ O
5'phosphatase BC2GM083483260 CD O
( BC2GM083483260 ( O
SHIP BC2GM083483260 NNP O
) BC2GM083483260 ) O
to BC2GM083483260 TO O
the BC2GM083483260 DT O
phosphorylated BC2GM083483260 VBN O
Fc BC2GM083483260 NNP O
gamma BC2GM083483260 NN O
RIIB1 BC2GM083483260 NNP O
immunoreceptor BC2GM083483260 NN O
tyrosine-based BC2GM083483260 JJ O
inhibitory BC2GM083483260 NN O
motif BC2GM083483260 NN O
. BC2GM083483260 . O
. . O O

Moreover BC2GM024519999 RB O
, BC2GM024519999 , O
a BC2GM024519999 DT O
hybrid BC2GM024519999 JJ O
protein BC2GM024519999 NN O
composed BC2GM024519999 VBD O
of BC2GM024519999 IN O
a BC2GM024519999 DT O
PvALF BC2GM024519999 NNP O
activation BC2GM024519999 NN O
domain BC2GM024519999 NN O
and BC2GM024519999 CC O
the BC2GM024519999 DT O
DNA BC2GM024519999 NNP O
binding BC2GM024519999 NN O
and BC2GM024519999 CC O
dimerization BC2GM024519999 NN O
domain BC2GM024519999 NN O
of BC2GM024519999 IN O
ROM2 BC2GM024519999 NNP O
activated BC2GM024519999 VBD O
gene BC2GM024519999 NN O
expression BC2GM024519999 NN O
, BC2GM024519999 , O
indicating BC2GM024519999 VBG O
that BC2GM024519999 IN O
ROM2 BC2GM024519999 NNP O
recognizes BC2GM024519999 VBZ O
the BC2GM024519999 DT O
DLEC2 BC2GM024519999 NNP O
enhancer BC2GM024519999 NN O
in BC2GM024519999 IN O
vivo BC2GM024519999 NN O
; BC2GM024519999 : O
consequently BC2GM024519999 RB O
, BC2GM024519999 , O
ROM2 BC2GM024519999 NNP O
functions BC2GM024519999 NNS O
as BC2GM024519999 IN O
a BC2GM024519999 DT O
DNA BC2GM024519999 NN O
binding BC2GM024519999 VBG O
site-dependent BC2GM024519999 JJ O
repressor BC2GM024519999 NN O
. BC2GM024519999 . O
. . O O

Drosophila BC2GM069806610 NNP O
melanogaster BC2GM069806610 NN O
casein BC2GM069806610 NN O
kinase BC2GM069806610 NN O
II BC2GM069806610 NNP O
( BC2GM069806610 ( O
DmCKII BC2GM069806610 NNP O
) BC2GM069806610 ) O
is BC2GM069806610 VBZ O
composed BC2GM069806610 VBN O
of BC2GM069806610 IN O
catalytic BC2GM069806610 JJ O
( BC2GM069806610 ( O
alpha BC2GM069806610 NN O
) BC2GM069806610 ) O
and BC2GM069806610 CC O
regulatory BC2GM069806610 JJ O
( BC2GM069806610 ( O
beta BC2GM069806610 NN O
) BC2GM069806610 ) O
subunits BC2GM069806610 VBZ O
associated BC2GM069806610 VBN O
as BC2GM069806610 IN O
an BC2GM069806610 DT O
alpha2beta2 BC2GM069806610 JJ O
heterotetramer BC2GM069806610 NN O
. BC2GM069806610 . O
. . O O

Our BC2GM021860677 PRP$ O
aim BC2GM021860677 NN O
was BC2GM021860677 VBD O
to BC2GM021860677 TO O
evaluate BC2GM021860677 VB O
this BC2GM021860677 DT O
technique BC2GM021860677 NN O
by BC2GM021860677 IN O
cross-calibrating BC2GM021860677 VBG O
the BC2GM021860677 DT O
DXA BC2GM021860677 NNP O
method BC2GM021860677 NN O
with BC2GM021860677 IN O
the BC2GM021860677 DT O
carcass BC2GM021860677 NN O
chemical BC2GM021860677 NN O
analysis BC2GM021860677 NN O
in BC2GM021860677 IN O
a BC2GM021860677 DT O
heterogeneous BC2GM021860677 JJ O
population BC2GM021860677 NN O
of BC2GM021860677 IN O
nondiabetic BC2GM021860677 JJ O
Wistar BC2GM021860677 NNP O
and BC2GM021860677 CC O
diabetic BC2GM021860677 JJ O
GK BC2GM021860677 NNP O
rats BC2GM021860677 NNS O
( BC2GM021860677 ( O
21 BC2GM021860677 CD O
animals BC2GM021860677 NNS O
were BC2GM021860677 VBD O
used BC2GM021860677 VBN O
for BC2GM021860677 IN O
precision BC2GM021860677 NN O
error BC2GM021860677 NN O
and BC2GM021860677 CC O
reproducibility BC2GM021860677 NN O
determinations BC2GM021860677 NNS O
and BC2GM021860677 CC O
26 BC2GM021860677 CD O
were BC2GM021860677 VBD O
used BC2GM021860677 VBN O
for BC2GM021860677 IN O
accuracy BC2GM021860677 NN O
studies BC2GM021860677 NNS O
) BC2GM021860677 ) O
. BC2GM021860677 . O
. . O O

Although BC2GM096609252 IN O
the BC2GM096609252 DT O
cDNAs BC2GM096609252 NN O
of BC2GM096609252 IN O
HMG-14 BC2GM096609252 NNP O
and BC2GM096609252 CC O
HMG-17 BC2GM096609252 NNP O
do BC2GM096609252 VBP O
not BC2GM096609252 RB O
cross-hybridize BC2GM096609252 VB O
, BC2GM096609252 , O
they BC2GM096609252 PRP O
have BC2GM096609252 VBP O
several BC2GM096609252 JJ O
similar BC2GM096609252 JJ O
structural BC2GM096609252 JJ O
features BC2GM096609252 NNS O
: BC2GM096609252 : O
the BC2GM096609252 DT O
open BC2GM096609252 JJ O
reading BC2GM096609252 NN O
frame BC2GM096609252 NN O
comprises BC2GM096609252 VBZ O
only BC2GM096609252 RB O
23 BC2GM096609252 CD O
% BC2GM096609252 NN O
of BC2GM096609252 IN O
the BC2GM096609252 DT O
transcripts BC2GM096609252 NNS O
, BC2GM096609252 , O
the BC2GM096609252 DT O
5'-untranslated BC2GM096609252 JJ O
region BC2GM096609252 NN O
is BC2GM096609252 VBZ O
extremely BC2GM096609252 RB O
GC BC2GM096609252 NNP O
rich BC2GM096609252 JJ O
whereas BC2GM096609252 VBD O
the BC2GM096609252 DT O
3'-untranslated BC2GM096609252 JJ O
region BC2GM096609252 NN O
is BC2GM096609252 VBZ O
unusually BC2GM096609252 RB O
long BC2GM096609252 JJ O
and BC2GM096609252 CC O
AT BC2GM096609252 NNP O
rich BC2GM096609252 NN O
. BC2GM096609252 . O
. . O O

This BC2GM004649890 DT O
constant BC2GM004649890 JJ O
expression BC2GM004649890 NN O
profile BC2GM004649890 NN O
, BC2GM004649890 , O
coupled BC2GM004649890 VBN O
with BC2GM004649890 IN O
the BC2GM004649890 DT O
observation BC2GM004649890 NN O
that BC2GM004649890 IN O
over-expression BC2GM004649890 NN O
of BC2GM004649890 IN O
mSin3A BC2GM004649890 NN O
does BC2GM004649890 VBZ O
not BC2GM004649890 RB O
augment BC2GM004649890 VB O
the BC2GM004649890 DT O
anti-Myc BC2GM004649890 JJ O
activity BC2GM004649890 NN O
of BC2GM004649890 IN O
Mxi1-SR BC2GM004649890 NNP O
in BC2GM004649890 IN O
the BC2GM004649890 DT O
rat BC2GM004649890 NN O
embryo BC2GM004649890 NN O
fibroblast BC2GM004649890 NN O
( BC2GM004649890 ( O
REF BC2GM004649890 NNP O
) BC2GM004649890 ) O
transformation BC2GM004649890 NN O
assay BC2GM004649890 NN O
, BC2GM004649890 , O
suggests BC2GM004649890 VBZ O
that BC2GM004649890 IN O
mSin3A BC2GM004649890 NN O
is BC2GM004649890 VBZ O
not BC2GM004649890 RB O
a BC2GM004649890 DT O
limiting BC2GM004649890 JJ O
factor BC2GM004649890 NN O
in BC2GM004649890 IN O
the BC2GM004649890 DT O
regulation BC2GM004649890 NN O
of BC2GM004649890 IN O
Myc BC2GM004649890 NNP O
superfamily BC2GM004649890 JJ O
function BC2GM004649890 NN O
. BC2GM004649890 . O
. . O O

An BC2GM009210929 DT O
analogue BC2GM009210929 NN O
of BC2GM009210929 IN O
calcium BC2GM009210929 NN O
, BC2GM009210929 , O
strontium BC2GM009210929 NN O
chloride BC2GM009210929 NN O
Sr BC2GM009210929 NNP O
89 BC2GM009210929 CD O
is BC2GM009210929 VBZ O
rapidly BC2GM009210929 RB O
cleared BC2GM009210929 VBN O
from BC2GM009210929 IN O
the BC2GM009210929 DT O
blood BC2GM009210929 NN O
after BC2GM009210929 IN O
i.v BC2GM009210929 NN O
. BC2GM009210929 . O
injection BC2GM009210929 NN O
. BC2GM009210929 . O
. . O O

In BC2GM050861861 IN O
this BC2GM050861861 DT O
case BC2GM050861861 NN O
myogenic BC2GM050861861 JJ O
factors BC2GM050861861 NNS O
are BC2GM050861861 VBP O
not BC2GM050861861 RB O
initially BC2GM050861861 RB O
expressed BC2GM050861861 VBN O
and BC2GM050861861 CC O
these BC2GM050861861 DT O
migratory BC2GM050861861 JJ O
cells BC2GM050861861 NNS O
are BC2GM050861861 VBP O
characterized BC2GM050861861 VBN O
by BC2GM050861861 IN O
the BC2GM050861861 DT O
expression BC2GM050861861 NN O
of BC2GM050861861 IN O
the BC2GM050861861 DT O
paired-box BC2GM050861861 JJ O
gene BC2GM050861861 NN O
Pax3 BC2GM050861861 NNP O
. BC2GM050861861 . O
. . O O

On BC2GM015257023 IN O
average BC2GM015257023 JJ O
these BC2GM015257023 DT O
maximum BC2GM015257023 JJ O
potency BC2GM015257023 NN O
estimates BC2GM015257023 NNS O
were BC2GM015257023 VBD O
within BC2GM015257023 IN O
one BC2GM015257023 CD O
order BC2GM015257023 NN O
of BC2GM015257023 IN O
magnitude BC2GM015257023 NN O
of BC2GM015257023 IN O
the BC2GM015257023 DT O
inverse BC2GM015257023 JJ O
maximum BC2GM015257023 NN O
dose BC2GM015257023 NN O
tested BC2GM015257023 VBN O
. BC2GM015257023 . O
. . O O

Routine BC2GM036174332 JJ O
imaging BC2GM036174332 NN O
modalities BC2GM036174332 NNS O
revealed BC2GM036174332 VBD O
a BC2GM036174332 DT O
total BC2GM036174332 NN O
of BC2GM036174332 IN O
79 BC2GM036174332 CD O
metastases BC2GM036174332 NNS O
. BC2GM036174332 . O
. . O O

The BC2GM003959017 DT O
total BC2GM003959017 JJ O
area BC2GM003959017 NN O
under BC2GM003959017 IN O
the BC2GM003959017 DT O
blood BC2GM003959017 NN O
glucose BC2GM003959017 JJ O
curve BC2GM003959017 NN O
over BC2GM003959017 IN O
the BC2GM003959017 DT O
initial BC2GM003959017 JJ O
value BC2GM003959017 NN O
was BC2GM003959017 VBD O
not BC2GM003959017 RB O
altered BC2GM003959017 JJ O
2 BC2GM003959017 CD O
h BC2GM003959017 NN O
after BC2GM003959017 IN O
treatment BC2GM003959017 NN O
with BC2GM003959017 IN O
SH BC2GM003959017 NNP O
B BC2GM003959017 NNP O
209 BC2GM003959017 CD O
AB BC2GM003959017 NNP O
or BC2GM003959017 CC O
Neogynon BC2GM003959017 NNP O
. BC2GM003959017 . O
. . O O

As BC2GM029952373 IN O
already BC2GM029952373 RB O
available BC2GM029952373 JJ O
for BC2GM029952373 IN O
the BC2GM029952373 DT O
other BC2GM029952373 JJ O
known BC2GM029952373 JJ O
mammalian BC2GM029952373 JJ O
members BC2GM029952373 NNS O
of BC2GM029952373 IN O
this BC2GM029952373 DT O
enzyme BC2GM029952373 JJ O
family BC2GM029952373 NN O
, BC2GM029952373 , O
we BC2GM029952373 PRP O
here BC2GM029952373 RB O
define BC2GM029952373 VBP O
structural BC2GM029952373 JJ O
and BC2GM029952373 CC O
functional BC2GM029952373 JJ O
features BC2GM029952373 NNS O
of BC2GM029952373 IN O
human BC2GM029952373 JJ O
lymphoma BC2GM029952373 NN O
proprotein BC2GM029952373 NN O
convertase BC2GM029952373 NN O
( BC2GM029952373 ( O
LPC BC2GM029952373 NNP O
) BC2GM029952373 ) O
. BC2GM029952373 . O
. . O O

One BC2GM090911628 CD O
promoter BC2GM090911628 NN O
, BC2GM090911628 , O
p53P1 BC2GM090911628 NN O
, BC2GM090911628 , O
is BC2GM090911628 VBZ O
located BC2GM090911628 VBN O
100-250 BC2GM090911628 JJ O
bp BC2GM090911628 NN O
upstream BC2GM090911628 NN O
of BC2GM090911628 IN O
the BC2GM090911628 DT O
218-bp BC2GM090911628 JJ O
noncoding BC2GM090911628 NN O
first BC2GM090911628 JJ O
exon BC2GM090911628 NN O
; BC2GM090911628 : O
a BC2GM090911628 DT O
second BC2GM090911628 JJ O
, BC2GM090911628 , O
stronger BC2GM090911628 JJR O
promoter BC2GM090911628 NN O
, BC2GM090911628 , O
p53P2 BC2GM090911628 NN O
, BC2GM090911628 , O
maps BC2GM090911628 NNS O
within BC2GM090911628 IN O
the BC2GM090911628 DT O
first BC2GM090911628 JJ O
intron BC2GM090911628 NN O
. BC2GM090911628 . O
. . O O

Our BC2GM078534924 PRP$ O
results BC2GM078534924 NNS O
show BC2GM078534924 VBP O
that BC2GM078534924 IN O
unlike BC2GM078534924 IN O
the BC2GM078534924 DT O
case BC2GM078534924 NN O
for BC2GM078534924 IN O
sos1 BC2GM078534924 NN O
, BC2GM078534924 , O
sos2 BC2GM078534924 JJ O
gene BC2GM078534924 NN O
function BC2GM078534924 NN O
is BC2GM078534924 VBZ O
dispensable BC2GM078534924 JJ O
for BC2GM078534924 IN O
normal BC2GM078534924 JJ O
mouse BC2GM078534924 NN O
development BC2GM078534924 NN O
, BC2GM078534924 , O
growth BC2GM078534924 NN O
, BC2GM078534924 , O
and BC2GM078534924 CC O
fertility BC2GM078534924 NN O
. BC2GM078534924 . O
. . O O

We BC2GM016475600 PRP O
have BC2GM016475600 VBP O
studied BC2GM016475600 VBN O
some BC2GM016475600 DT O
of BC2GM016475600 IN O
the BC2GM016475600 DT O
parameters BC2GM016475600 NNS O
governing BC2GM016475600 VBG O
the BC2GM016475600 DT O
expression BC2GM016475600 NN O
of BC2GM016475600 IN O
a BC2GM016475600 DT O
foreign BC2GM016475600 JJ O
promoter-reporter BC2GM016475600 JJ O
gene BC2GM016475600 NN O
construct BC2GM016475600 NN O
incorporated BC2GM016475600 VBN O
into BC2GM016475600 IN O
herpes BC2GM016475600 NNS O
simplex BC2GM016475600 JJ O
virus BC2GM016475600 NN O
( BC2GM016475600 ( O
HSV BC2GM016475600 NNP O
) BC2GM016475600 ) O
type BC2GM016475600 VBD O
1 BC2GM016475600 CD O
. BC2GM016475600 . O
. . O O

Tritium BC2GM066838338 NN O
concentrations BC2GM066838338 NNS O
in BC2GM066838338 IN O
environmental BC2GM066838338 JJ O
water BC2GM066838338 NN O
samples BC2GM066838338 NNS O
were BC2GM066838338 VBD O
found BC2GM066838338 VBN O
to BC2GM066838338 TO O
be BC2GM066838338 VB O
determined BC2GM066838338 VBN O
within BC2GM066838338 IN O
an BC2GM066838338 DT O
accuracy BC2GM066838338 NN O
of BC2GM066838338 IN O
10 BC2GM066838338 CD O
% BC2GM066838338 NN O
by BC2GM066838338 IN O
this BC2GM066838338 DT O
method BC2GM066838338 NN O
when BC2GM066838338 WRB O
Vi BC2GM066838338 NNP O
/ BC2GM066838338 NNP O
Vf BC2GM066838338 NNP O
was BC2GM066838338 VBD O
14-25 BC2GM066838338 JJ O
. BC2GM066838338 . O
. . O O

Transient BC2GM001910152 JJ O
transfection BC2GM001910152 NN O
assays BC2GM001910152 NNS O
indicated BC2GM001910152 VBD O
that BC2GM001910152 IN O
the BC2GM001910152 DT O
( BC2GM001910152 ( O
-4551 BC2GM001910152 NN O
) BC2GM001910152 ) O
UCP1-CAT BC2GM001910152 NNP O
construct BC2GM001910152 NN O
, BC2GM001910152 , O
containing BC2GM001910152 VBG O
the BC2GM001910152 DT O
5'-regulatory BC2GM001910152 JJ O
region BC2GM001910152 NN O
of BC2GM001910152 IN O
the BC2GM001910152 DT O
rat BC2GM001910152 NN O
ucp-1 BC2GM001910152 JJ O
gene BC2GM001910152 NN O
, BC2GM001910152 , O
was BC2GM001910152 VBD O
activated BC2GM001910152 VBN O
by BC2GM001910152 IN O
PPARalpha BC2GM001910152 NNP O
co-transfection BC2GM001910152 NN O
in BC2GM001910152 IN O
a BC2GM001910152 DT O
dose-dependent BC2GM001910152 JJ O
manner BC2GM001910152 NN O
and BC2GM001910152 CC O
this BC2GM001910152 DT O
activation BC2GM001910152 NN O
was BC2GM001910152 VBD O
potentiated BC2GM001910152 VBN O
by BC2GM001910152 IN O
Wy BC2GM001910152 NNP O
14,643 BC2GM001910152 CD O
and BC2GM001910152 CC O
retinoid BC2GM001910152 VB O
X BC2GM001910152 NNP O
receptor BC2GM001910152 NN O
alpha BC2GM001910152 NN O
. BC2GM001910152 . O
. . O O

Acidosis BC2GM083274778 NN O
provoked BC2GM083274778 VBN O
by BC2GM083274778 IN O
30 BC2GM083274778 CD O
% BC2GM083274778 NN O
CO2 BC2GM083274778 NNP O
irreversibly BC2GM083274778 RB O
increased BC2GM083274778 VBD O
the BC2GM083274778 DT O
BDRT BC2GM083274778 NNP O
, BC2GM083274778 , O
however BC2GM083274778 RB O
the BC2GM083274778 DT O
TRT BC2GM083274778 NNP O
were BC2GM083274778 VBD O
not BC2GM083274778 RB O
changed BC2GM083274778 VBN O
. BC2GM083274778 . O
. . O O

By BC2GM056080482 IN O
contrast BC2GM056080482 NN O
, BC2GM056080482 , O
CIS BC2GM056080482 NNP O
failed BC2GM056080482 VBD O
to BC2GM056080482 TO O
affect BC2GM056080482 VB O
the BC2GM056080482 DT O
IL-9 BC2GM056080482 NNP O
response BC2GM056080482 NN O
. BC2GM056080482 . O
. . O O

Here BC2GM056033085 RB O
we BC2GM056033085 PRP O
report BC2GM056033085 VBP O
the BC2GM056033085 DT O
fabrication BC2GM056033085 NN O
of BC2GM056033085 IN O
single-molecule BC2GM056033085 JJ O
transistors BC2GM056033085 NNS O
based BC2GM056033085 VBN O
on BC2GM056033085 IN O
individual BC2GM056033085 JJ O
C60 BC2GM056033085 NNP O
molecules BC2GM056033085 NNS O
connected BC2GM056033085 VBN O
to BC2GM056033085 TO O
gold BC2GM056033085 VB O
electrodes BC2GM056033085 NNS O
. BC2GM056033085 . O
. . O O

Differential BC2GM040715083 JJ O
transcription BC2GM040715083 NN O
of BC2GM040715083 IN O
plastome-encoded BC2GM040715083 JJ O
genes BC2GM040715083 NNS O
in BC2GM040715083 IN O
the BC2GM040715083 DT O
mesophyll BC2GM040715083 NN O
and BC2GM040715083 CC O
bundle-sheath BC2GM040715083 JJ O
chloroplasts BC2GM040715083 NNS O
of BC2GM040715083 IN O
the BC2GM040715083 DT O
monocotyledonous BC2GM040715083 JJ O
NADP-malic BC2GM040715083 JJ O
enzyme-type BC2GM040715083 JJ O
C4 BC2GM040715083 NN O
plants BC2GM040715083 NNS O
maize BC2GM040715083 VB O
and BC2GM040715083 CC O
Sorghum BC2GM040715083 NNP O
. BC2GM040715083 . O
. . O O

On BC2GM038829305 IN O
both BC2GM038829305 DT O
indocyanine BC2GM038829305 JJ O
green BC2GM038829305 JJ O
video BC2GM038829305 NN O
and BC2GM038829305 CC O
fluorescein BC2GM038829305 NN O
angiography BC2GM038829305 NN O
, BC2GM038829305 , O
hypofluorescent BC2GM038829305 JJ O
lesions BC2GM038829305 NNS O
were BC2GM038829305 VBD O
almost BC2GM038829305 RB O
the BC2GM038829305 DT O
same BC2GM038829305 JJ O
size BC2GM038829305 NN O
as BC2GM038829305 IN O
the BC2GM038829305 DT O
light BC2GM038829305 JJ O
yellow BC2GM038829305 JJ O
area BC2GM038829305 NN O
and BC2GM038829305 CC O
the BC2GM038829305 DT O
dark BC2GM038829305 JJ O
yellow BC2GM038829305 JJ O
center BC2GM038829305 NN O
of BC2GM038829305 IN O
a BC2GM038829305 DT O
placoid BC2GM038829305 JJ O
lesion BC2GM038829305 NN O
. BC2GM038829305 . O
. . O O

Deletion BC2GM002155163 NNP O
analysis BC2GM002155163 NN O
of BC2GM002155163 IN O
the BC2GM002155163 DT O
3.5kb BC2GM002155163 CD O
DNA BC2GM002155163 NNP O
fragment BC2GM002155163 NN O
revealed BC2GM002155163 VBD O
that BC2GM002155163 IN O
the BC2GM002155163 DT O
region BC2GM002155163 NN O
between BC2GM002155163 IN O
-125 BC2GM002155163 NN O
to BC2GM002155163 TO O
+1 BC2GM002155163 VB O
, BC2GM002155163 , O
containing BC2GM002155163 VBG O
a BC2GM002155163 DT O
single BC2GM002155163 JJ O
Sp1 BC2GM002155163 NNP O
binding BC2GM002155163 NN O
site BC2GM002155163 NN O
, BC2GM002155163 , O
is BC2GM002155163 VBZ O
essential BC2GM002155163 JJ O
for BC2GM002155163 IN O
transcription BC2GM002155163 NN O
of BC2GM002155163 IN O
the BC2GM002155163 DT O
embigin BC2GM002155163 NN O
gene BC2GM002155163 NN O
. BC2GM002155163 . O
. . O O

Identification BC2GM041058675 NN O
of BC2GM041058675 IN O
a BC2GM041058675 DT O
putative BC2GM041058675 JJ O
chromosomal BC2GM041058675 JJ O
replication BC2GM041058675 NN O
origin BC2GM041058675 NN O
from BC2GM041058675 IN O
Helicobacter BC2GM041058675 NNP O
pylori BC2GM041058675 NN O
and BC2GM041058675 CC O
its BC2GM041058675 PRP$ O
interaction BC2GM041058675 NN O
with BC2GM041058675 IN O
the BC2GM041058675 DT O
initiator BC2GM041058675 NN O
protein BC2GM041058675 NN O
DnaA BC2GM041058675 NNP O
. BC2GM041058675 . O
. . O O

Functional BC2GM019804740 NNP O
PET BC2GM019804740 NNP O
scanning BC2GM019804740 VBG O
in BC2GM019804740 IN O
the BC2GM019804740 DT O
preoperative BC2GM019804740 JJ O
assessment BC2GM019804740 NN O
of BC2GM019804740 IN O
cerebral BC2GM019804740 JJ O
arteriovenous BC2GM019804740 JJ O
malformations BC2GM019804740 NNS O
. BC2GM019804740 . O
. . O O

The BC2GM025926172 DT O
rice BC2GM025926172 NN O
gene BC2GM025926172 NN O
consists BC2GM025926172 VBZ O
of BC2GM025926172 IN O
four BC2GM025926172 CD O
exons BC2GM025926172 NNS O
. BC2GM025926172 . O
. . O O

The BC2GM096432502 DT O
patient BC2GM096432502 NN O
demographics BC2GM096432502 NNS O
( BC2GM096432502 ( O
means BC2GM096432502 VBZ O
+ BC2GM096432502 VBP O
/ BC2GM096432502 SYM O
- BC2GM096432502 : O
standard BC2GM096432502 JJ O
deviations BC2GM096432502 NNS O
) BC2GM096432502 ) O
were BC2GM096432502 VBD O
as BC2GM096432502 IN O
follows BC2GM096432502 VBZ O
: BC2GM096432502 : O
age BC2GM096432502 NN O
, BC2GM096432502 , O
57 BC2GM096432502 CD O
+ BC2GM096432502 NN O
/ BC2GM096432502 NNP O
- BC2GM096432502 : O
12 BC2GM096432502 CD O
years BC2GM096432502 NNS O
; BC2GM096432502 : O
sex BC2GM096432502 NN O
, BC2GM096432502 , O
nine BC2GM096432502 CD O
males BC2GM096432502 NNS O
and BC2GM096432502 CC O
three BC2GM096432502 CD O
females BC2GM096432502 NNS O
; BC2GM096432502 : O
APACHE BC2GM096432502 NNP O
II BC2GM096432502 NNP O
score BC2GM096432502 NN O
, BC2GM096432502 , O
15 BC2GM096432502 CD O
+ BC2GM096432502 NN O
/ BC2GM096432502 NNP O
- BC2GM096432502 : O
3 BC2GM096432502 CD O
; BC2GM096432502 : O
diagnosis BC2GM096432502 NN O
, BC2GM096432502 , O
9 BC2GM096432502 CD O
of BC2GM096432502 IN O
12 BC2GM096432502 CD O
patients BC2GM096432502 NNS O
with BC2GM096432502 IN O
pneumonia BC2GM096432502 NN O
. BC2GM096432502 . O
. . O O

This BC2GM019793109 DT O
study BC2GM019793109 NN O
tests BC2GM019793109 VBZ O
the BC2GM019793109 DT O
hypothesis BC2GM019793109 NN O
that BC2GM019793109 IN O
O2 BC2GM019793109 NNP O
is BC2GM019793109 VBZ O
a BC2GM019793109 DT O
critical BC2GM019793109 JJ O
component BC2GM019793109 NN O
in BC2GM019793109 IN O
myocardial BC2GM019793109 JJ O
protection BC2GM019793109 NN O
afforded BC2GM019793109 VBN O
by BC2GM019793109 IN O
BCP BC2GM019793109 NNP O
. BC2GM019793109 . O
. . O O

It BC2GM060307457 PRP O
also BC2GM060307457 RB O
describes BC2GM060307457 VBZ O
the BC2GM060307457 DT O
preliminary BC2GM060307457 JJ O
results BC2GM060307457 NNS O
of BC2GM060307457 IN O
a BC2GM060307457 DT O
Phase BC2GM060307457 NNP O
II BC2GM060307457 NNP O
trial BC2GM060307457 NN O
going BC2GM060307457 VBG O
on BC2GM060307457 IN O
at BC2GM060307457 IN O
the BC2GM060307457 DT O
Central BC2GM060307457 NNP O
Institute BC2GM060307457 NNP O
for BC2GM060307457 IN O
Tumors BC2GM060307457 NNPS O
in BC2GM060307457 IN O
Zagreb BC2GM060307457 NNP O
, BC2GM060307457 , O
using BC2GM060307457 VBG O
a BC2GM060307457 DT O
combination BC2GM060307457 NN O
of BC2GM060307457 IN O
cis-DDP BC2GM060307457 JJ O
, BC2GM060307457 , O
5-fluorouracil BC2GM060307457 JJ O
and BC2GM060307457 CC O
vincristine BC2GM060307457 NN O
. BC2GM060307457 . O
. . O O

The BC2GM083471063 DT O
most BC2GM083471063 RBS O
valid BC2GM083471063 JJ O
method BC2GM083471063 NN O
was BC2GM083471063 VBD O
the BC2GM083471063 DT O
AXB BC2GM083471063 NNP O
bearing BC2GM083471063 NN O
with BC2GM083471063 IN O
the BC2GM083471063 DT O
cephalometric BC2GM083471063 JJ O
clinical BC2GM083471063 JJ O
diagnosis BC2GM083471063 NN O
a BC2GM083471063 DT O
90.91 BC2GM083471063 CD O
% BC2GM083471063 NN O
concordance BC2GM083471063 NN O
. BC2GM083471063 . O
. . O O

To BC2GM077439334 TO O
determine BC2GM077439334 VB O
the BC2GM077439334 DT O
role BC2GM077439334 NN O
of BC2GM077439334 IN O
the BC2GM077439334 DT O
transmembrane BC2GM077439334 JJ O
region BC2GM077439334 NN O
of BC2GM077439334 IN O
HN BC2GM077439334 NNP O
on BC2GM077439334 IN O
fusion-promoting BC2GM077439334 JJ O
activity BC2GM077439334 NN O
, BC2GM077439334 , O
mutant BC2GM077439334 JJ O
HN BC2GM077439334 NNP O
proteins BC2GM077439334 NNS O
were BC2GM077439334 VBD O
expressed BC2GM077439334 VBN O
and BC2GM077439334 CC O
their BC2GM077439334 PRP$ O
biological BC2GM077439334 JJ O
activities BC2GM077439334 NNS O
examined BC2GM077439334 VBD O
. BC2GM077439334 . O
. . O O

The BC2GM031297991 DT O
region BC2GM031297991 NN O
immediately BC2GM031297991 RB O
following BC2GM031297991 VBG O
the BC2GM031297991 DT O
promoter BC2GM031297991 NN O
and BC2GM031297991 CC O
5 BC2GM031297991 CD O
' BC2GM031297991 '' O
to BC2GM031297991 TO O
ORF1 BC2GM031297991 NNP O
has BC2GM031297991 VBZ O
a BC2GM031297991 DT O
potential BC2GM031297991 JJ O
transcription BC2GM031297991 NN O
terminator BC2GM031297991 NN O
sequence BC2GM031297991 NN O
. BC2GM031297991 . O
. . O O

However BC2GM092290359 RB O
, BC2GM092290359 , O
this BC2GM092290359 DT O
posttranslational BC2GM092290359 JJ O
modification BC2GM092290359 NN O
of BC2GM092290359 IN O
the BC2GM092290359 DT O
gar2 BC2GM092290359 NN O
protein BC2GM092290359 NN O
does BC2GM092290359 VBZ O
not BC2GM092290359 RB O
appear BC2GM092290359 VB O
to BC2GM092290359 TO O
be BC2GM092290359 VB O
essential BC2GM092290359 JJ O
for BC2GM092290359 IN O
normal BC2GM092290359 JJ O
production BC2GM092290359 NN O
of BC2GM092290359 IN O
18S BC2GM092290359 CD O
rRNA BC2GM092290359 NN O
. BC2GM092290359 . O
. . O O

Unestablished BC2GM067166518 VBN O
quail BC2GM067166518 JJ O
myoblasts BC2GM067166518 NNS O
were BC2GM067166518 VBD O
infected BC2GM067166518 VBN O
with BC2GM067166518 IN O
a BC2GM067166518 DT O
retroviral BC2GM067166518 JJ O
vector BC2GM067166518 NN O
encoding BC2GM067166518 VBG O
the BC2GM067166518 DT O
oncogenic BC2GM067166518 JJ O
form BC2GM067166518 NN O
of BC2GM067166518 IN O
H-Ras BC2GM067166518 NNP O
in BC2GM067166518 IN O
order BC2GM067166518 NN O
to BC2GM067166518 TO O
investigate BC2GM067166518 VB O
the BC2GM067166518 DT O
mechanism BC2GM067166518 NN O
by BC2GM067166518 IN O
which BC2GM067166518 WDT O
this BC2GM067166518 DT O
oncoprotein BC2GM067166518 NN O
interferes BC2GM067166518 VBZ O
with BC2GM067166518 IN O
terminal BC2GM067166518 JJ O
differentiation BC2GM067166518 NN O
. BC2GM067166518 . O
. . O O

We BC2GM006490341 PRP O
therefore BC2GM006490341 VBP O
propose BC2GM006490341 JJ O
that BC2GM006490341 IN O
PRR2 BC2GM006490341 NNP O
, BC2GM006490341 , O
and BC2GM006490341 CC O
not BC2GM006490341 RB O
PVR BC2GM006490341 NNP O
, BC2GM006490341 , O
is BC2GM006490341 VBZ O
the BC2GM006490341 DT O
true BC2GM006490341 JJ O
human BC2GM006490341 JJ O
homolog BC2GM006490341 NN O
of BC2GM006490341 IN O
MPH BC2GM006490341 NNP O
. BC2GM006490341 . O
. . O O

The BC2GM029605480 DT O
RHO1 BC2GM029605480 NNP O
gene BC2GM029605480 NN O
encodes BC2GM029605480 VBZ O
a BC2GM029605480 DT O
homolog BC2GM029605480 NN O
of BC2GM029605480 IN O
the BC2GM029605480 DT O
mammalian BC2GM029605480 JJ O
RhoA BC2GM029605480 NNP O
small BC2GM029605480 JJ O
GTP-binding BC2GM029605480 NNP O
protein BC2GM029605480 NN O
in BC2GM029605480 IN O
the BC2GM029605480 DT O
yeast BC2GM029605480 NN O
Saccharomyces BC2GM029605480 NNP O
cerevisiae BC2GM029605480 NN O
. BC2GM029605480 . O
. . O O

Gastric BC2GM067397943 NNP O
secretory BC2GM067397943 NN O
inhibition BC2GM067397943 NN O
induced BC2GM067397943 VBN O
by BC2GM067397943 IN O
three BC2GM067397943 CD O
methyl BC2GM067397943 NNS O
analogs BC2GM067397943 NNS O
of BC2GM067397943 IN O
prostaglandin BC2GM067397943 NN O
E2 BC2GM067397943 NNP O
administered BC2GM067397943 VBD O
intragastrically BC2GM067397943 RB O
to BC2GM067397943 TO O
man BC2GM067397943 NN O
. BC2GM067397943 . O
. . O O

Stimulation BC2GM053054541 NN O
of BC2GM053054541 IN O
the BC2GM053054541 DT O
endosteal BC2GM053054541 NN O
bone BC2GM053054541 NN O
formation BC2GM053054541 NN O
rate BC2GM053054541 NN O
was BC2GM053054541 VBD O
mainly BC2GM053054541 RB O
impaired BC2GM053054541 VBN O
in BC2GM053054541 IN O
D-depleted BC2GM053054541 NNP O
rats BC2GM053054541 NNS O
, BC2GM053054541 , O
resulting BC2GM053054541 VBG O
in BC2GM053054541 IN O
trabecular BC2GM053054541 JJ O
bone BC2GM053054541 NN O
loss BC2GM053054541 NN O
, BC2GM053054541 , O
which BC2GM053054541 WDT O
, BC2GM053054541 , O
in BC2GM053054541 IN O
-D BC2GM053054541 NNP O
mother BC2GM053054541 NN O
rats BC2GM053054541 NNS O
, BC2GM053054541 , O
was BC2GM053054541 VBD O
associated BC2GM053054541 VBN O
with BC2GM053054541 IN O
decreased BC2GM053054541 JJ O
bone BC2GM053054541 NN O
ash BC2GM053054541 NN O
and BC2GM053054541 CC O
total BC2GM053054541 JJ O
bone BC2GM053054541 NN O
calcium BC2GM053054541 NN O
. BC2GM053054541 . O
. . O O

A BC2GM015870833 DT O
spectrophotometric BC2GM015870833 JJ O
method BC2GM015870833 NN O
for BC2GM015870833 IN O
the BC2GM015870833 DT O
microdetermination BC2GM015870833 NN O
of BC2GM015870833 IN O
periodate BC2GM015870833 NN O
. BC2GM015870833 . O
. . O O

The BC2GM061017656 DT O
human BC2GM061017656 JJ O
parvalbumin BC2GM061017656 NN O
mRNA BC2GM061017656 NN O
contains BC2GM061017656 VBZ O
the BC2GM061017656 DT O
putative BC2GM061017656 JJ O
polyadenylation BC2GM061017656 NN O
signal BC2GM061017656 NN O
AATAAA BC2GM061017656 NNP O
13 BC2GM061017656 CD O
nucleotides BC2GM061017656 NNS O
upstream BC2GM061017656 RB O
from BC2GM061017656 IN O
the BC2GM061017656 DT O
polyadenylation BC2GM061017656 NN O
site BC2GM061017656 NN O
. BC2GM061017656 . O
. . O O

YDL003w BC2GM036865431 NNP O
( BC2GM036865431 ( O
also BC2GM036865431 RB O
termed BC2GM036865431 VBN O
MCD1 BC2GM036865431 NNP O
) BC2GM036865431 ) O
is BC2GM036865431 VBZ O
a BC2GM036865431 DT O
homologue BC2GM036865431 NN O
of BC2GM036865431 IN O
Schizosaccharomyces BC2GM036865431 NNP O
pombe BC2GM036865431 NN O
rad21 BC2GM036865431 NN O
, BC2GM036865431 , O
an BC2GM036865431 DT O
essential BC2GM036865431 JJ O
gene BC2GM036865431 NN O
implicated BC2GM036865431 VBN O
in BC2GM036865431 IN O
DNA BC2GM036865431 NNP O
double-strand BC2GM036865431 JJ O
break BC2GM036865431 NN O
repair BC2GM036865431 NN O
and BC2GM036865431 CC O
nuclear BC2GM036865431 JJ O
organization BC2GM036865431 NN O
in BC2GM036865431 IN O
fission BC2GM036865431 NN O
yeast BC2GM036865431 NN O
. BC2GM036865431 . O
. . O O

I BC2GM014357227 PRP O
. BC2GM014357227 . O
. . O O

In BC2GM051724994 IN O
the BC2GM051724994 DT O
case BC2GM051724994 NN O
of BC2GM051724994 IN O
a BC2GM051724994 DT O
moderate BC2GM051724994 JJ O
buccal BC2GM051724994 JJ O
Class BC2GM051724994 NNP O
II BC2GM051724994 NNP O
tendency BC2GM051724994 NN O
, BC2GM051724994 , O
55 BC2GM051724994 CD O
% BC2GM051724994 NN O
of BC2GM051724994 IN O
the BC2GM051724994 DT O
molars BC2GM051724994 NNS O
were BC2GM051724994 VBD O
in BC2GM051724994 IN O
a BC2GM051724994 DT O
Class BC2GM051724994 NN O
I BC2GM051724994 PRP O
relationship BC2GM051724994 NN O
when BC2GM051724994 WRB O
evaluated BC2GM051724994 VBN O
from BC2GM051724994 IN O
the BC2GM051724994 DT O
lingual BC2GM051724994 JJ O
side BC2GM051724994 NN O
, BC2GM051724994 , O
whereas BC2GM051724994 RB O
45 BC2GM051724994 CD O
% BC2GM051724994 NN O
belonged BC2GM051724994 VBN O
to BC2GM051724994 TO O
mild BC2GM051724994 VB O
( BC2GM051724994 ( O
1st BC2GM051724994 CD O
degrees BC2GM051724994 NNS O
) BC2GM051724994 ) O
Class BC2GM051724994 NNP O
II BC2GM051724994 NNP O
with BC2GM051724994 IN O
molar BC2GM051724994 JJ O
rotations BC2GM051724994 NNS O
present BC2GM051724994 VBP O
in BC2GM051724994 IN O
81 BC2GM051724994 CD O
% BC2GM051724994 NN O
of BC2GM051724994 IN O
the BC2GM051724994 DT O
cases BC2GM051724994 NNS O
. BC2GM051724994 . O
. . O O

Epithelial BC2GM035302143 JJ O
cell-specific BC2GM035302143 JJ O
activation BC2GM035302143 NN O
is BC2GM035302143 VBZ O
achieved BC2GM035302143 VBN O
by BC2GM035302143 IN O
the BC2GM035302143 DT O
cooperative BC2GM035302143 JJ O
interaction BC2GM035302143 NN O
of BC2GM035302143 IN O
apparently BC2GM035302143 RB O
ubiquitous BC2GM035302143 JJ O
transcriptional BC2GM035302143 JJ O
factors BC2GM035302143 NNS O
. BC2GM035302143 . O
. . O O

We BC2GM025350751 PRP O
conclude BC2GM025350751 VBP O
that BC2GM025350751 DT O
LGCS BC2GM025350751 NNP O
is BC2GM025350751 VBZ O
successful BC2GM025350751 JJ O
in BC2GM025350751 IN O
treating BC2GM025350751 VBG O
esophageal BC2GM025350751 JJ O
varices BC2GM025350751 NNS O
in BC2GM025350751 IN O
the BC2GM025350751 DT O
setting BC2GM025350751 NN O
of BC2GM025350751 IN O
hyperdynamic BC2GM025350751 JJ O
portal BC2GM025350751 JJ O
circulation BC2GM025350751 NN O
with BC2GM025350751 IN O
acceptable BC2GM025350751 JJ O
liver BC2GM025350751 NN O
function BC2GM025350751 NN O
. BC2GM025350751 . O
. . O O

In BC2GM095421849 IN O
many BC2GM095421849 JJ O
other BC2GM095421849 JJ O
contractile BC2GM095421849 NN O
protein BC2GM095421849 NNS O
gene BC2GM095421849 NN O
families BC2GM095421849 NNS O
, BC2GM095421849 , O
genes BC2GM095421849 NNS O
encoding BC2GM095421849 VBG O
cardiac BC2GM095421849 JJ O
isoforms BC2GM095421849 NNS O
are BC2GM095421849 VBP O
expressed BC2GM095421849 VBN O
early BC2GM095421849 RB O
in BC2GM095421849 IN O
skeletal BC2GM095421849 JJ O
muscle BC2GM095421849 NN O
development BC2GM095421849 NN O
and BC2GM095421849 CC O
are BC2GM095421849 VBP O
later BC2GM095421849 RB O
repressed BC2GM095421849 VBN O
. BC2GM095421849 . O
. . O O

The BC2GM027002069 DT O
material BC2GM027002069 NN O
then BC2GM027002069 RB O
was BC2GM027002069 VBD O
cut BC2GM027002069 VBN O
with BC2GM027002069 IN O
a BC2GM027002069 DT O
diamond BC2GM027002069 NN O
saw BC2GM027002069 NN O
into BC2GM027002069 IN O
sheets BC2GM027002069 NNS O
of BC2GM027002069 IN O
8 BC2GM027002069 CD O
x BC2GM027002069 JJ O
10 BC2GM027002069 CD O
x BC2GM027002069 JJ O
3 BC2GM027002069 CD O
mm BC2GM027002069 NN O
, BC2GM027002069 , O
and BC2GM027002069 CC O
the BC2GM027002069 DT O
upper BC2GM027002069 JJ O
surface BC2GM027002069 NN O
was BC2GM027002069 VBD O
polished BC2GM027002069 VBN O
by BC2GM027002069 IN O
colloidal BC2GM027002069 JJ O
SiO2 BC2GM027002069 NNP O
and BC2GM027002069 CC O
/ BC2GM027002069 NNP O
or BC2GM027002069 CC O
covered BC2GM027002069 VBN O
with BC2GM027002069 IN O
a BC2GM027002069 DT O
carbon-titanium BC2GM027002069 NN O
( BC2GM027002069 ( O
C BC2GM027002069 NNP O
: BC2GM027002069 : O
Ti BC2GM027002069 NNP O
) BC2GM027002069 ) O
layer BC2GM027002069 NN O
( BC2GM027002069 ( O
3.3 BC2GM027002069 CD O
microm BC2GM027002069 NN O
) BC2GM027002069 ) O
using BC2GM027002069 VBG O
the BC2GM027002069 DT O
plasma-enhanced BC2GM027002069 JJ O
physical BC2GM027002069 JJ O
vapor BC2GM027002069 NN O
deposition BC2GM027002069 NN O
method BC2GM027002069 NN O
. BC2GM027002069 . O
. . O O

Investigation BC2GM002651672 NN O
on BC2GM002651672 IN O
the BC2GM002651672 DT O
asymmetrical BC2GM002651672 JJ O
induced BC2GM002651672 JJ O
yields BC2GM002651672 NNS O
in BC2GM002651672 IN O
90Sr- BC2GM002651672 JJ O
90Y-beta-irradiated BC2GM002651672 JJ O
D- BC2GM002651672 NNP O
and BC2GM002651672 CC O
L-alanines BC2GM002651672 NNP O
. BC2GM002651672 . O
. . O O

The BC2GM095436717 DT O
NH2-terminal BC2GM095436717 JJ O
fragments BC2GM095436717 NNS O
were BC2GM095436717 VBD O
tested BC2GM095436717 VBN O
for BC2GM095436717 IN O
susceptibility BC2GM095436717 NN O
to BC2GM095436717 TO O
modification BC2GM095436717 NN O
with BC2GM095436717 IN O
Nalpha- BC2GM095436717 NNP O
( BC2GM095436717 ( O
3-maleimidylpropionyl BC2GM095436717 CD O
) BC2GM095436717 ) O
biocytin BC2GM095436717 NN O
, BC2GM095436717 , O
which BC2GM095436717 WDT O
attaches BC2GM095436717 VBZ O
a BC2GM095436717 DT O
biotin BC2GM095436717 NN O
group BC2GM095436717 NN O
to BC2GM095436717 TO O
cysteine BC2GM095436717 VB O
sulfhydryls BC2GM095436717 NN O
. BC2GM095436717 . O
. . O O

IL-6 BC2GM076163727 NNP O
was BC2GM076163727 VBD O
detected BC2GM076163727 VBN O
in BC2GM076163727 IN O
the BC2GM076163727 DT O
urine BC2GM076163727 NN O
of BC2GM076163727 IN O
52 BC2GM076163727 CD O
% BC2GM076163727 NN O
of BC2GM076163727 IN O
children BC2GM076163727 NNS O
with BC2GM076163727 IN O
pyelonephritis BC2GM076163727 NN O
compared BC2GM076163727 VBN O
with BC2GM076163727 IN O
15 BC2GM076163727 CD O
% BC2GM076163727 NN O
of BC2GM076163727 IN O
other BC2GM076163727 JJ O
children BC2GM076163727 NNS O
( BC2GM076163727 ( O
P BC2GM076163727 NNP O
< BC2GM076163727 NNP O
0.001 BC2GM076163727 CD O
) BC2GM076163727 ) O
. BC2GM076163727 . O
. . O O

Prenatal BC2GM035693756 JJ O
diagnosis BC2GM035693756 NN O
of BC2GM035693756 IN O
genetic BC2GM035693756 JJ O
diseases BC2GM035693756 NNS O
. BC2GM035693756 . O
. . O O

Atrial BC2GM066025610 JJ O
dissociation BC2GM066025610 NN O
. BC2GM066025610 . O
. . O O

However BC2GM039216973 RB O
, BC2GM039216973 , O
the BC2GM039216973 DT O
in BC2GM039216973 IN O
vivo BC2GM039216973 JJ O
attachment BC2GM039216973 JJ O
strength BC2GM039216973 NN O
of BC2GM039216973 IN O
the BC2GM039216973 DT O
CSTi-2 BC2GM039216973 NNP O
coating BC2GM039216973 NN O
was BC2GM039216973 VBD O
comparable BC2GM039216973 JJ O
both BC2GM039216973 DT O
to BC2GM039216973 TO O
CSTi-1 BC2GM039216973 NNP O
and BC2GM039216973 CC O
to BC2GM039216973 TO O
an BC2GM039216973 DT O
HA-coated BC2GM039216973 JJ O
control BC2GM039216973 NN O
after BC2GM039216973 IN O
8 BC2GM039216973 CD O
weeks BC2GM039216973 NNS O
. BC2GM039216973 . O
. . O O

These BC2GM068116027 DT O
morphological BC2GM068116027 JJ O
changes BC2GM068116027 NNS O
are BC2GM068116027 VBP O
associated BC2GM068116027 VBN O
with BC2GM068116027 IN O
a BC2GM068116027 DT O
marked BC2GM068116027 JJ O
induction BC2GM068116027 NN O
of BC2GM068116027 IN O
P450arom BC2GM068116027 NNP O
gene BC2GM068116027 NN O
expression BC2GM068116027 NN O
. BC2GM068116027 . O
. . O O

Increasing BC2GM036058953 VBG O
the BC2GM036058953 DT O
height BC2GM036058953 NN O
of BC2GM036058953 IN O
the BC2GM036058953 DT O
agar BC2GM036058953 JJ O
column BC2GM036058953 NN O
overlying BC2GM036058953 VBG O
the BC2GM036058953 DT O
SN BC2GM036058953 NNP O
fabric BC2GM036058953 NN O
diminished BC2GM036058953 VBD O
the BC2GM036058953 DT O
inhibitory BC2GM036058953 JJ O
effect BC2GM036058953 NN O
of BC2GM036058953 IN O
SN BC2GM036058953 NNP O
on BC2GM036058953 IN O
microbial BC2GM036058953 JJ O
growth BC2GM036058953 NN O
. BC2GM036058953 . O
. . O O

This BC2GM010408815 DT O
effect BC2GM010408815 NN O
is BC2GM010408815 VBZ O
independent BC2GM010408815 JJ O
of BC2GM010408815 IN O
the BC2GM010408815 DT O
Gal4 BC2GM010408815 NNP O
protein BC2GM010408815 NN O
, BC2GM010408815 , O
as BC2GM010408815 IN O
it BC2GM010408815 PRP O
operates BC2GM010408815 VBZ O
in BC2GM010408815 IN O
a BC2GM010408815 DT O
gal4 BC2GM010408815 NN O
mutant BC2GM010408815 NN O
background BC2GM010408815 NN O
as BC2GM010408815 RB O
well BC2GM010408815 RB O
. BC2GM010408815 . O
. . O O

The BC2GM030124031 DT O
levels BC2GM030124031 NNS O
of BC2GM030124031 IN O
soluble BC2GM030124031 JJ O
L-selectin BC2GM030124031 JJ O
and BC2GM030124031 CC O
ICAM-1 BC2GM030124031 NNP O
in BC2GM030124031 IN O
the BC2GM030124031 DT O
serum BC2GM030124031 NN O
were BC2GM030124031 VBD O
determined BC2GM030124031 VBN O
by BC2GM030124031 IN O
the BC2GM030124031 DT O
ELISA BC2GM030124031 NNP O
method BC2GM030124031 NN O
. BC2GM030124031 . O
. . O O

An BC2GM087067391 DT O
emended BC2GM087067391 JJ O
diagnosis BC2GM087067391 NN O
of BC2GM087067391 IN O
Tylocephalum BC2GM087067391 NNP O
is BC2GM087067391 VBZ O
proposed BC2GM087067391 VBN O
excluding BC2GM087067391 VBG O
this BC2GM087067391 DT O
feature BC2GM087067391 NN O
, BC2GM087067391 , O
along BC2GM087067391 IN O
with BC2GM087067391 IN O
distribution BC2GM087067391 NN O
of BC2GM087067391 IN O
the BC2GM087067391 DT O
testes BC2GM087067391 NNS O
in BC2GM087067391 IN O
the BC2GM087067391 DT O
preovarian BC2GM087067391 JJ O
field BC2GM087067391 NN O
and BC2GM087067391 CC O
circummedullary BC2GM087067391 JJ O
distribution BC2GM087067391 NN O
of BC2GM087067391 IN O
vitelline BC2GM087067391 NN O
follicles BC2GM087067391 NNS O
. BC2GM087067391 . O
. . O O

One BC2GM068691299 CD O
hundred BC2GM068691299 VBN O
men BC2GM068691299 NNS O
who BC2GM068691299 WP O
received BC2GM068691299 VBD O
alpha-tocopherol BC2GM068691299 NN O
were BC2GM068691299 VBD O
matched BC2GM068691299 VBN O
on BC2GM068691299 IN O
age BC2GM068691299 NN O
, BC2GM068691299 , O
study BC2GM068691299 NN O
center BC2GM068691299 NN O
, BC2GM068691299 , O
and BC2GM068691299 CC O
length BC2GM068691299 NN O
of BC2GM068691299 IN O
time BC2GM068691299 NN O
between BC2GM068691299 IN O
blood BC2GM068691299 NN O
draws BC2GM068691299 NNS O
to BC2GM068691299 TO O
100 BC2GM068691299 CD O
men BC2GM068691299 NNS O
who BC2GM068691299 WP O
received BC2GM068691299 VBD O
a BC2GM068691299 DT O
placebo BC2GM068691299 NN O
. BC2GM068691299 . O
. . O O

Copyright BC2GM018263888 JJ O
1999 BC2GM018263888 CD O
Academic BC2GM018263888 NNP O
Press BC2GM018263888 NNP O
. BC2GM018263888 . O
. . O O

CONCLUSION BC2GM005777371 NN O
: BC2GM005777371 : O
DaunoXome BC2GM005777371 NNP O
has BC2GM005777371 VBZ O
an BC2GM005777371 DT O
improved BC2GM005777371 VBN O
pharmacokinetic BC2GM005777371 JJ O
profile BC2GM005777371 NN O
compared BC2GM005777371 VBN O
with BC2GM005777371 IN O
free BC2GM005777371 JJ O
daunorubicin BC2GM005777371 NN O
, BC2GM005777371 , O
and BC2GM005777371 CC O
is BC2GM005777371 VBZ O
well BC2GM005777371 RB O
tolerated BC2GM005777371 VBN O
. BC2GM005777371 . O
. . O O

Mutations BC2GM060037556 NNS O
that BC2GM060037556 WDT O
extend BC2GM060037556 VBP O
the BC2GM060037556 DT O
specificity BC2GM060037556 NN O
of BC2GM060037556 IN O
the BC2GM060037556 DT O
endonuclease BC2GM060037556 NN O
activity BC2GM060037556 NN O
of BC2GM060037556 IN O
lambda BC2GM060037556 JJ O
terminase BC2GM060037556 NN O
. BC2GM060037556 . O
. . O O

Based BC2GM032387601 VBN O
on BC2GM032387601 IN O
our BC2GM032387601 PRP$ O
sequence BC2GM032387601 NN O
data BC2GM032387601 NNS O
, BC2GM032387601 , O
ORF2 BC2GM032387601 NNP O
from BC2GM032387601 IN O
most BC2GM032387601 JJS O
isolates BC2GM032387601 NNS O
excluding BC2GM032387601 VBG O
G1 BC2GM032387601 NNP O
encode BC2GM032387601 NN O
truncated BC2GM032387601 VBD O
49 BC2GM032387601 CD O
aa BC2GM032387601 NN O
( BC2GM032387601 ( O
pORF2a BC2GM032387601 NN O
) BC2GM032387601 ) O
because BC2GM032387601 IN O
of BC2GM032387601 IN O
an BC2GM032387601 DT O
in-frame BC2GM032387601 JJ O
stop BC2GM032387601 NN O
codon BC2GM032387601 NN O
, BC2GM032387601 , O
although BC2GM032387601 IN O
ORF2s BC2GM032387601 NNP O
from BC2GM032387601 IN O
most BC2GM032387601 JJS O
G1 BC2GM032387601 NNP O
isolates BC2GM032387601 VBZ O
encode BC2GM032387601 RB O
202 BC2GM032387601 CD O
aa BC2GM032387601 NN O
( BC2GM032387601 ( O
pORF2ab BC2GM032387601 NN O
) BC2GM032387601 ) O
. BC2GM032387601 . O
. . O O

Rottlerin BC2GM075844356 NNP O
also BC2GM075844356 RB O
inhibited BC2GM075844356 VBD O
the BC2GM075844356 DT O
activation BC2GM075844356 NN O
of BC2GM075844356 IN O
MAP BC2GM075844356 NNP O
kinase BC2GM075844356 NN O
kinase BC2GM075844356 NN O
( BC2GM075844356 ( O
MEK BC2GM075844356 NNP O
) BC2GM075844356 ) O
in BC2GM075844356 IN O
response BC2GM075844356 NN O
to BC2GM075844356 TO O
activated BC2GM075844356 VBN O
Raf BC2GM075844356 NNP O
, BC2GM075844356 , O
but BC2GM075844356 CC O
had BC2GM075844356 VBD O
no BC2GM075844356 DT O
effect BC2GM075844356 NN O
upon BC2GM075844356 IN O
c-Raf BC2GM075844356 JJ O
activity BC2GM075844356 NN O
or BC2GM075844356 CC O
ERK BC2GM075844356 NNP O
activation BC2GM075844356 NN O
by BC2GM075844356 IN O
activated BC2GM075844356 JJ O
MEK BC2GM075844356 NNP O
. BC2GM075844356 . O
. . O O

Wolf-Hirschhorn BC2GM002263739 JJ O
syndrome BC2GM002263739 NN O
( BC2GM002263739 ( O
WHS BC2GM002263739 NNP O
) BC2GM002263739 ) O
is BC2GM002263739 VBZ O
a BC2GM002263739 DT O
malformation BC2GM002263739 NN O
syndrome BC2GM002263739 NN O
associated BC2GM002263739 VBN O
with BC2GM002263739 IN O
a BC2GM002263739 DT O
hemizygous BC2GM002263739 JJ O
deletion BC2GM002263739 NN O
of BC2GM002263739 IN O
the BC2GM002263739 DT O
distal BC2GM002263739 JJ O
short BC2GM002263739 JJ O
arm BC2GM002263739 NN O
of BC2GM002263739 IN O
chromosome BC2GM002263739 NN O
4 BC2GM002263739 CD O
( BC2GM002263739 ( O
4p16.3 BC2GM002263739 CD O
) BC2GM002263739 ) O
. BC2GM002263739 . O
. . O O

Fusions BC2GM032391800 NNS O
between BC2GM032391800 IN O
the BC2GM032391800 DT O
GAL BC2GM032391800 NNP O
DNA BC2GM032391800 NNP O
binding BC2GM032391800 VBG O
domain BC2GM032391800 NN O
and BC2GM032391800 CC O
full-length BC2GM032391800 JJ O
mSin3 BC2GM032391800 NN O
were BC2GM032391800 VBD O
also BC2GM032391800 RB O
capable BC2GM032391800 JJ O
of BC2GM032391800 IN O
repression BC2GM032391800 NN O
. BC2GM032391800 . O
. . O O

Radioimmunoassay BC2GM063257384 NNP O
of BC2GM063257384 IN O
plasma BC2GM063257384 NN O
gonadotropins BC2GM063257384 NNS O
; BC2GM063257384 : O
problems BC2GM063257384 NNS O
of BC2GM063257384 IN O
specificity BC2GM063257384 NN O
. BC2GM063257384 . O
. . O O

Pretreatment BC2GM028280868 NN O
of BC2GM028280868 IN O
rats BC2GM028280868 NNS O
with BC2GM028280868 IN O
different BC2GM028280868 JJ O
dose BC2GM028280868 JJ O
levels BC2GM028280868 NNS O
of BC2GM028280868 IN O
CCl4 BC2GM028280868 NNP O
resulted BC2GM028280868 VBD O
in BC2GM028280868 IN O
a BC2GM028280868 DT O
prolongation BC2GM028280868 NN O
of BC2GM028280868 IN O
TMO BC2GM028280868 NNP O
half-life BC2GM028280868 NN O
, BC2GM028280868 , O
and BC2GM028280868 CC O
increase BC2GM028280868 NN O
of BC2GM028280868 IN O
the BC2GM028280868 DT O
area BC2GM028280868 NN O
under BC2GM028280868 IN O
the BC2GM028280868 DT O
curve BC2GM028280868 NN O
( BC2GM028280868 ( O
AUC BC2GM028280868 NNP O
) BC2GM028280868 ) O
, BC2GM028280868 , O
and BC2GM028280868 CC O
a BC2GM028280868 DT O
decrease BC2GM028280868 NN O
of BC2GM028280868 IN O
clearance BC2GM028280868 NN O
, BC2GM028280868 , O
but BC2GM028280868 CC O
the BC2GM028280868 DT O
apparent BC2GM028280868 JJ O
volume BC2GM028280868 NN O
of BC2GM028280868 IN O
distribution BC2GM028280868 NN O
( BC2GM028280868 ( O
Vd BC2GM028280868 NNP O
) BC2GM028280868 ) O
was BC2GM028280868 VBD O
not BC2GM028280868 RB O
significantly BC2GM028280868 RB O
decreased BC2GM028280868 VBN O
. BC2GM028280868 . O
. . O O

The BC2GM051136020 DT O
differences BC2GM051136020 NNS O
of BC2GM051136020 IN O
percentages BC2GM051136020 NNS O
for BC2GM051136020 IN O
HIV-1 BC2GM051136020 NNP O
infection BC2GM051136020 NN O
in BC2GM051136020 IN O
intravenous BC2GM051136020 JJ O
drug BC2GM051136020 NN O
users BC2GM051136020 NNS O
( BC2GM051136020 ( O
IVDU BC2GM051136020 NNP O
) BC2GM051136020 ) O
were BC2GM051136020 VBD O
67.7 BC2GM051136020 CD O
% BC2GM051136020 NN O
and BC2GM051136020 CC O
in BC2GM051136020 IN O
non BC2GM051136020 JJ O
IVDU BC2GM051136020 NNP O
were BC2GM051136020 VBD O
3.8 BC2GM051136020 CD O
% BC2GM051136020 NN O
with BC2GM051136020 IN O
a BC2GM051136020 DT O
significant BC2GM051136020 JJ O
statistical BC2GM051136020 JJ O
difference BC2GM051136020 NN O
( BC2GM051136020 ( O
chi BC2GM051136020 JJ O
2 BC2GM051136020 CD O
= BC2GM051136020 JJ O
557.5 BC2GM051136020 CD O
; BC2GM051136020 : O
p BC2GM051136020 NN O
< BC2GM051136020 VBZ O
0.0001 BC2GM051136020 CD O
) BC2GM051136020 ) O
. BC2GM051136020 . O
. . O O

Western BC2GM048998172 JJ O
blot BC2GM048998172 NN O
experiments BC2GM048998172 NNS O
detected BC2GM048998172 VBD O
SMBP BC2GM048998172 NNP O
as BC2GM048998172 IN O
a BC2GM048998172 DT O
70 BC2GM048998172 CD O
kDa BC2GM048998172 NN O
protein BC2GM048998172 NN O
that BC2GM048998172 WDT O
may BC2GM048998172 MD O
be BC2GM048998172 VB O
further BC2GM048998172 JJ O
cleaved BC2GM048998172 VBN O
into BC2GM048998172 IN O
an BC2GM048998172 DT O
active BC2GM048998172 JJ O
34 BC2GM048998172 CD O
kDa BC2GM048998172 JJ O
N-terminal BC2GM048998172 JJ O
polypeptide BC2GM048998172 NN O
. BC2GM048998172 . O
. . O O

The BC2GM045455828 DT O
gene BC2GM045455828 NN O
atp6 BC2GM045455828 NN O
, BC2GM045455828 , O
encoding BC2GM045455828 VBG O
subunit BC2GM045455828 JJ O
6 BC2GM045455828 CD O
of BC2GM045455828 IN O
the BC2GM045455828 DT O
mitochondrial BC2GM045455828 JJ O
F0-ATPase BC2GM045455828 NNP O
complex BC2GM045455828 NN O
, BC2GM045455828 , O
has BC2GM045455828 VBZ O
been BC2GM045455828 VBN O
characterized BC2GM045455828 VBN O
from BC2GM045455828 IN O
both BC2GM045455828 CC O
the BC2GM045455828 DT O
normal BC2GM045455828 JJ O
( BC2GM045455828 ( O
fertile BC2GM045455828 JJ O
) BC2GM045455828 ) O
and BC2GM045455828 CC O
Ogura BC2GM045455828 NNP O
( BC2GM045455828 ( O
male-sterile BC2GM045455828 JJ O
) BC2GM045455828 ) O
radish BC2GM045455828 JJ O
cytoplasms BC2GM045455828 NN O
in BC2GM045455828 IN O
order BC2GM045455828 NN O
to BC2GM045455828 TO O
determine BC2GM045455828 VB O
if BC2GM045455828 IN O
previously BC2GM045455828 RB O
identified BC2GM045455828 VBN O
atp6 BC2GM045455828 JJ O
transcriptional BC2GM045455828 JJ O
differences BC2GM045455828 NNS O
could BC2GM045455828 MD O
play BC2GM045455828 VB O
a BC2GM045455828 DT O
role BC2GM045455828 NN O
in BC2GM045455828 IN O
cytoplasmic BC2GM045455828 JJ O
male BC2GM045455828 JJ O
sterility BC2GM045455828 NN O
. BC2GM045455828 . O
. . O O

A BC2GM001730189 DT O
single BC2GM001730189 JJ O
HD BC2GM001730189 NNP O
session BC2GM001730189 NN O
using BC2GM001730189 VBG O
cellulose BC2GM001730189 JJ O
triacetate BC2GM001730189 NN O
or BC2GM001730189 CC O
polysulfone BC2GM001730189 NN O
membrane BC2GM001730189 NN O
significantly BC2GM001730189 RB O
increased BC2GM001730189 VBD O
water BC2GM001730189 NN O
content BC2GM001730189 NN O
both BC2GM001730189 DT O
at BC2GM001730189 IN O
forearm BC2GM001730189 NN O
and BC2GM001730189 CC O
lower BC2GM001730189 JJR O
leg BC2GM001730189 NN O
( BC2GM001730189 ( O
p BC2GM001730189 JJ O
< BC2GM001730189 NNP O
0.05 BC2GM001730189 CD O
) BC2GM001730189 ) O
. BC2GM001730189 . O
. . O O

These BC2GM070651049 DT O
data BC2GM070651049 NNS O
suggest BC2GM070651049 VBP O
that BC2GM070651049 IN O
the BC2GM070651049 DT O
fibrinogen BC2GM070651049 NN O
gamma BC2GM070651049 NN O
chain BC2GM070651049 NN O
region BC2GM070651049 NN O
Gly190-Val202 BC2GM070651049 NNP O
functions BC2GM070651049 NNS O
as BC2GM070651049 IN O
a BC2GM070651049 DT O
minimal BC2GM070651049 JJ O
recognition BC2GM070651049 NN O
sequence BC2GM070651049 NN O
for BC2GM070651049 IN O
the BC2GM070651049 DT O
leukocyte BC2GM070651049 NN O
integrin BC2GM070651049 NN O
CD11b BC2GM070651049 NNP O
/ BC2GM070651049 NNP O
CD18 BC2GM070651049 NNP O
. BC2GM070651049 . O
. . O O

For BC2GM008563458 IN O
capsules BC2GM008563458 NNS O
containing BC2GM008563458 VBG O
only BC2GM008563458 RB O
the BC2GM008563458 DT O
drug BC2GM008563458 NN O
, BC2GM008563458 , O
the BC2GM008563458 DT O
value BC2GM008563458 NN O
of BC2GM008563458 IN O
T50 BC2GM008563458 NNP O
increased BC2GM008563458 VBD O
as BC2GM008563458 IN O
the BC2GM008563458 DT O
particle BC2GM008563458 NN O
size BC2GM008563458 NN O
of BC2GM008563458 IN O
the BC2GM008563458 DT O
drug BC2GM008563458 NN O
decreased BC2GM008563458 VBN O
. BC2GM008563458 . O
. . O O

Significant BC2GM085078611 JJ O
reductions BC2GM085078611 NNS O
were BC2GM085078611 VBD O
noted BC2GM085078611 VBN O
in BC2GM085078611 IN O
vertical BC2GM085078611 JJ O
GRFs BC2GM085078611 NNP O
per BC2GM085078611 IN O
newton BC2GM085078611 NN O
of BC2GM085078611 IN O
body BC2GM085078611 NN O
weight BC2GM085078611 NN O
exerted BC2GM085078611 VBD O
at BC2GM085078611 IN O
10 BC2GM085078611 CD O
% BC2GM085078611 NN O
( BC2GM085078611 ( O
P BC2GM085078611 NNP O
= BC2GM085078611 NNP O
0.0009 BC2GM085078611 CD O
) BC2GM085078611 ) O
and BC2GM085078611 CC O
20 BC2GM085078611 CD O
% BC2GM085078611 NN O
( BC2GM085078611 ( O
P BC2GM085078611 NNP O
= BC2GM085078611 NNP O
0.0383 BC2GM085078611 CD O
) BC2GM085078611 ) O
of BC2GM085078611 IN O
stance BC2GM085078611 NN O
phase BC2GM085078611 NN O
and BC2GM085078611 CC O
in BC2GM085078611 IN O
anteroposterior BC2GM085078611 JJ O
GRFs BC2GM085078611 NNP O
exerted BC2GM085078611 VBD O
at BC2GM085078611 IN O
10 BC2GM085078611 CD O
% BC2GM085078611 NN O
( BC2GM085078611 ( O
P BC2GM085078611 NNP O
= BC2GM085078611 NNP O
0.0009 BC2GM085078611 CD O
) BC2GM085078611 ) O
and BC2GM085078611 CC O
50 BC2GM085078611 CD O
% BC2GM085078611 NN O
( BC2GM085078611 ( O
P BC2GM085078611 NNP O
= BC2GM085078611 NNP O
0.0033 BC2GM085078611 CD O
) BC2GM085078611 ) O
of BC2GM085078611 IN O
stance BC2GM085078611 NN O
phase BC2GM085078611 NN O
when BC2GM085078611 WRB O
ambulation BC2GM085078611 NN O
was BC2GM085078611 VBD O
compared BC2GM085078611 VBN O
with BC2GM085078611 IN O
and BC2GM085078611 CC O
without BC2GM085078611 IN O
the BC2GM085078611 DT O
orthotic BC2GM085078611 JJ O
device BC2GM085078611 NN O
. BC2GM085078611 . O
. . O O

Disruption BC2GM063598630 NN O
of BC2GM063598630 IN O
INP53 BC2GM063598630 NNP O
, BC2GM063598630 , O
but BC2GM063598630 CC O
not BC2GM063598630 RB O
the BC2GM063598630 DT O
related BC2GM063598630 JJ O
INP51 BC2GM063598630 NNP O
and BC2GM063598630 CC O
INP52 BC2GM063598630 NNP O
genes BC2GM063598630 NNS O
, BC2GM063598630 , O
resulted BC2GM063598630 VBD O
in BC2GM063598630 IN O
alpha-factor BC2GM063598630 JJ O
maturation BC2GM063598630 NN O
defects BC2GM063598630 NNS O
and BC2GM063598630 CC O
exacerbated BC2GM063598630 VBD O
alpha-factor BC2GM063598630 NN O
maturation BC2GM063598630 NN O
defects BC2GM063598630 NNS O
when BC2GM063598630 WRB O
combined BC2GM063598630 VBN O
with BC2GM063598630 IN O
chc1-521 BC2GM063598630 NN O
. BC2GM063598630 . O
. . O O

Although BC2GM001245991 IN O
the BC2GM001245991 DT O
QT BC2GM001245991 NNP O
duration BC2GM001245991 NN O
was BC2GM001245991 VBD O
higher BC2GM001245991 JJR O
( BC2GM001245991 ( O
p BC2GM001245991 JJ O
= BC2GM001245991 NNP O
0.0001 BC2GM001245991 CD O
) BC2GM001245991 ) O
at BC2GM001245991 IN O
night BC2GM001245991 NN O
, BC2GM001245991 , O
the BC2GM001245991 DT O
beat-to-beat BC2GM001245991 JJ O
variability BC2GM001245991 NN O
of BC2GM001245991 IN O
this BC2GM001245991 DT O
interval BC2GM001245991 NN O
was BC2GM001245991 VBD O
lower BC2GM001245991 JJR O
: BC2GM001245991 : O
in BC2GM001245991 IN O
the BC2GM001245991 DT O
time BC2GM001245991 NN O
domain BC2GM001245991 NN O
( BC2GM001245991 ( O
decreased BC2GM001245991 JJ O
standard BC2GM001245991 NN O
deviation BC2GM001245991 NN O
, BC2GM001245991 , O
p BC2GM001245991 NN O
= BC2GM001245991 NNP O
0.0005 BC2GM001245991 CD O
) BC2GM001245991 ) O
, BC2GM001245991 , O
in BC2GM001245991 IN O
the BC2GM001245991 DT O
frequency BC2GM001245991 NN O
domain BC2GM001245991 NN O
( BC2GM001245991 ( O
decreased BC2GM001245991 VBN O
low-frequency BC2GM001245991 NN O
power BC2GM001245991 NN O
of BC2GM001245991 IN O
the BC2GM001245991 DT O
spectra BC2GM001245991 NN O
, BC2GM001245991 , O
p BC2GM001245991 NN O
= BC2GM001245991 NNP O
0.004 BC2GM001245991 CD O
) BC2GM001245991 ) O
, BC2GM001245991 , O
and BC2GM001245991 CC O
the BC2GM001245991 DT O
chaotic BC2GM001245991 JJ O
domain BC2GM001245991 NN O
( BC2GM001245991 ( O
tighter BC2GM001245991 JJ O
clustering BC2GM001245991 NN O
of BC2GM001245991 IN O
the BC2GM001245991 DT O
points BC2GM001245991 NNS O
in BC2GM001245991 IN O
the BC2GM001245991 DT O
Poincare BC2GM001245991 NNP O
plots BC2GM001245991 NNS O
) BC2GM001245991 ) O
. BC2GM001245991 . O
. . O O

The BC2GM019234582 DT O
median BC2GM019234582 JJ O
survival BC2GM019234582 NN O
time BC2GM019234582 NN O
was BC2GM019234582 VBD O
18 BC2GM019234582 CD O
months BC2GM019234582 NNS O
. BC2GM019234582 . O
. . O O

Recent BC2GM059024558 JJ O
developments BC2GM059024558 NNS O
in BC2GM059024558 IN O
the BC2GM059024558 DT O
study BC2GM059024558 NN O
of BC2GM059024558 IN O
growth BC2GM059024558 NN O
factors BC2GM059024558 NNS O
: BC2GM059024558 : O
GRF BC2GM059024558 NNP O
and BC2GM059024558 CC O
somatomedins BC2GM059024558 NNS O
. BC2GM059024558 . O
. . O O

Additionally BC2GM098250324 RB O
, BC2GM098250324 , O
these BC2GM098250324 DT O
findings BC2GM098250324 NNS O
have BC2GM098250324 VBP O
important BC2GM098250324 JJ O
implications BC2GM098250324 NNS O
for BC2GM098250324 IN O
the BC2GM098250324 DT O
understanding BC2GM098250324 NN O
of BC2GM098250324 IN O
the BC2GM098250324 DT O
mechanisms BC2GM098250324 NNS O
of BC2GM098250324 IN O
HIV-1 BC2GM098250324 NNP O
latency BC2GM098250324 NN O
and BC2GM098250324 CC O
reactivation BC2GM098250324 NN O
. BC2GM098250324 . O
. . O O

The BC2GM043027311 DT O
present BC2GM043027311 JJ O
study BC2GM043027311 NN O
deals BC2GM043027311 NNS O
with BC2GM043027311 IN O
the BC2GM043027311 DT O
screening BC2GM043027311 NN O
of BC2GM043027311 IN O
11 BC2GM043027311 CD O
of BC2GM043027311 IN O
these BC2GM043027311 DT O
plants BC2GM043027311 NNS O
against BC2GM043027311 IN O
the BC2GM043027311 DT O
opportunistic BC2GM043027311 JJ O
pathogen BC2GM043027311 NN O
fungus BC2GM043027311 NN O
Candida BC2GM043027311 NNP O
albicans BC2GM043027311 NNS O
. BC2GM043027311 . O
. . O O

A BC2GM000030196 DT O
case BC2GM000030196 NN O
control BC2GM000030196 NN O
study BC2GM000030196 NN O
( BC2GM000030196 ( O
1:2 BC2GM000030196 CD O
) BC2GM000030196 ) O
of BC2GM000030196 IN O
182 BC2GM000030196 CD O
pairs BC2GM000030196 NNS O
of BC2GM000030196 IN O
Hepatitis BC2GM000030196 NNP O
A BC2GM000030196 NNP O
was BC2GM000030196 VBD O
carried BC2GM000030196 VBN O
out BC2GM000030196 RP O
in BC2GM000030196 IN O
Weng-ling BC2GM000030196 JJ O
Zhe-jiang BC2GM000030196 NNP O
during BC2GM000030196 IN O
April BC2GM000030196 NNP O
1988 BC2GM000030196 CD O
. BC2GM000030196 . O
. . O O

In BC2GM072444628 IN O
human BC2GM072444628 JJ O
WI38 BC2GM072444628 NNP O
cells BC2GM072444628 NNS O
, BC2GM072444628 , O
the BC2GM072444628 DT O
E1B BC2GM072444628 NNP O
19K BC2GM072444628 CD O
gene BC2GM072444628 NN O
mutant BC2GM072444628 JJ O
viruses BC2GM072444628 NNS O
had BC2GM072444628 VBD O
a BC2GM072444628 DT O
substantial BC2GM072444628 JJ O
growth BC2GM072444628 NN O
advantage BC2GM072444628 NN O
over BC2GM072444628 IN O
the BC2GM072444628 DT O
wild-type BC2GM072444628 JJ O
virus BC2GM072444628 NN O
, BC2GM072444628 , O
yielding BC2GM072444628 VBG O
500-fold-higher BC2GM072444628 JJ O
titers BC2GM072444628 NNS O
. BC2GM072444628 . O
. . O O

Mapping BC2GM098787807 NN O
of BC2GM098787807 IN O
the BC2GM098787807 DT O
region BC2GM098787807 NN O
in BC2GM098787807 IN O
KAP-1 BC2GM098787807 NNP O
required BC2GM098787807 VBD O
for BC2GM098787807 IN O
HP1 BC2GM098787807 NNP O
interaction BC2GM098787807 NN O
showed BC2GM098787807 VBD O
that BC2GM098787807 IN O
amino BC2GM098787807 NN O
acid BC2GM098787807 NN O
substitutions BC2GM098787807 NNS O
which BC2GM098787807 WDT O
abolish BC2GM098787807 VBP O
HP1 BC2GM098787807 NNP O
binding BC2GM098787807 NN O
in BC2GM098787807 IN O
vitro BC2GM098787807 JJ O
reduce BC2GM098787807 VB O
KAP-1 BC2GM098787807 NNP O
mediated BC2GM098787807 JJ O
repression BC2GM098787807 NN O
in BC2GM098787807 IN O
vivo BC2GM098787807 NN O
. BC2GM098787807 . O
. . O O

Two BC2GM055588958 CD O
plasmids BC2GM055588958 NNS O
, BC2GM055588958 , O
one BC2GM055588958 CD O
containing BC2GM055588958 VBG O
the BC2GM055588958 DT O
amino BC2GM055588958 NN O
terminus BC2GM055588958 NN O
of BC2GM055588958 IN O
P BC2GM055588958 NNP O
fused BC2GM055588958 VBD O
to BC2GM055588958 TO O
the BC2GM055588958 DT O
DNA-binding BC2GM055588958 NNP O
domain BC2GM055588958 NN O
of BC2GM055588958 IN O
the BC2GM055588958 DT O
yeast BC2GM055588958 NN O
transactivator BC2GM055588958 NN O
, BC2GM055588958 , O
GAL4 BC2GM055588958 NNP O
, BC2GM055588958 , O
and BC2GM055588958 CC O
the BC2GM055588958 DT O
other BC2GM055588958 JJ O
containing BC2GM055588958 VBG O
the BC2GM055588958 DT O
amino BC2GM055588958 NN O
terminus BC2GM055588958 NN O
of BC2GM055588958 IN O
NP BC2GM055588958 NNP O
fused BC2GM055588958 VBD O
to BC2GM055588958 TO O
the BC2GM055588958 DT O
herpesvirus BC2GM055588958 NN O
transactivator BC2GM055588958 NN O
, BC2GM055588958 , O
VP16 BC2GM055588958 NNP O
, BC2GM055588958 , O
were BC2GM055588958 VBD O
transfected BC2GM055588958 VBN O
in BC2GM055588958 IN O
COS-1 BC2GM055588958 NNP O
cells BC2GM055588958 NNS O
along BC2GM055588958 IN O
with BC2GM055588958 IN O
a BC2GM055588958 DT O
chloramphenicol BC2GM055588958 NN O
acetyltransferase BC2GM055588958 NN O
( BC2GM055588958 ( O
CAT BC2GM055588958 NNP O
) BC2GM055588958 ) O
reporter BC2GM055588958 NN O
plasmid BC2GM055588958 NN O
containing BC2GM055588958 VBG O
GAL4 BC2GM055588958 NNP O
DNA-binding BC2GM055588958 NNP O
sites BC2GM055588958 NNS O
. BC2GM055588958 . O
. . O O

No BC2GM070224595 DT O
consensus BC2GM070224595 NN O
binding BC2GM070224595 VBG O
sequence BC2GM070224595 NN O
could BC2GM070224595 MD O
be BC2GM070224595 VB O
discerned BC2GM070224595 VBN O
in BC2GM070224595 IN O
these BC2GM070224595 DT O
fragments BC2GM070224595 NNS O
and BC2GM070224595 CC O
bound BC2GM070224595 NN O
factor BC2GM070224595 NN O
is BC2GM070224595 VBZ O
in BC2GM070224595 IN O
rapid BC2GM070224595 JJ O
equilibrium BC2GM070224595 NN O
with BC2GM070224595 IN O
unbound BC2GM070224595 NN O
. BC2GM070224595 . O
. . O O

In BC2GM035589605 IN O
the BC2GM035589605 DT O
univariate BC2GM035589605 JJ O
models BC2GM035589605 NNS O
of BC2GM035589605 IN O
either BC2GM035589605 DT O
fixed BC2GM035589605 VBN O
or BC2GM035589605 CC O
time BC2GM035589605 NN O
dependent BC2GM035589605 JJ O
covariates BC2GM035589605 NNS O
, BC2GM035589605 , O
many BC2GM035589605 JJ O
variables BC2GM035589605 NNS O
were BC2GM035589605 VBD O
significantly BC2GM035589605 RB O
associated BC2GM035589605 VBN O
with BC2GM035589605 IN O
risk BC2GM035589605 NN O
of BC2GM035589605 IN O
progression BC2GM035589605 NN O
to BC2GM035589605 TO O
AIDS BC2GM035589605 NNP O
( BC2GM035589605 ( O
T4 BC2GM035589605 NNP O
cell BC2GM035589605 NN O
count BC2GM035589605 NN O
, BC2GM035589605 , O
T4 BC2GM035589605 NNP O
/ BC2GM035589605 NNP O
T8 BC2GM035589605 NNP O
ratio BC2GM035589605 NN O
, BC2GM035589605 , O
blastogenic BC2GM035589605 JJ O
responses BC2GM035589605 NNS O
to BC2GM035589605 TO O
phytohemagglutinin BC2GM035589605 VB O
, BC2GM035589605 , O
concanavalin BC2GM035589605 VB O
A BC2GM035589605 NNP O
, BC2GM035589605 , O
and BC2GM035589605 CC O
pokeweed BC2GM035589605 NN O
mitogen BC2GM035589605 NN O
, BC2GM035589605 , O
serum BC2GM035589605 NN O
IgA BC2GM035589605 NNP O
, BC2GM035589605 , O
appearance BC2GM035589605 NN O
of BC2GM035589605 IN O
p24 BC2GM035589605 NN O
antigen BC2GM035589605 NN O
, BC2GM035589605 , O
and BC2GM035589605 CC O
the BC2GM035589605 DT O
development BC2GM035589605 NN O
of BC2GM035589605 IN O
oral BC2GM035589605 JJ O
hairy BC2GM035589605 NN O
leukoplakia BC2GM035589605 NN O
, BC2GM035589605 , O
thrush BC2GM035589605 NN O
, BC2GM035589605 , O
or BC2GM035589605 CC O
herpes BC2GM035589605 NNS O
zoster BC2GM035589605 NN O
) BC2GM035589605 ) O
. BC2GM035589605 . O
. . O O

Deletion BC2GM037741487 NNP O
mutagenesis BC2GM037741487 NN O
of BC2GM037741487 IN O
the BC2GM037741487 DT O
promoter BC2GM037741487 NN O
indicated BC2GM037741487 VBD O
that BC2GM037741487 IN O
a BC2GM037741487 DT O
positive BC2GM037741487 JJ O
regulatory BC2GM037741487 JJ O
element BC2GM037741487 NN O
( BC2GM037741487 ( O
PRE BC2GM037741487 NNP O
) BC2GM037741487 ) O
was BC2GM037741487 VBD O
likely BC2GM037741487 JJ O
to BC2GM037741487 TO O
exist BC2GM037741487 VB O
downstream BC2GM037741487 NN O
of BC2GM037741487 IN O
the BC2GM037741487 DT O
UL94 BC2GM037741487 NNP O
mRNA BC2GM037741487 NNP O
start BC2GM037741487 NN O
site BC2GM037741487 NN O
, BC2GM037741487 , O
while BC2GM037741487 IN O
a BC2GM037741487 DT O
negative BC2GM037741487 JJ O
regulatory BC2GM037741487 JJ O
element BC2GM037741487 NN O
( BC2GM037741487 ( O
NRE BC2GM037741487 NNP O
) BC2GM037741487 ) O
was BC2GM037741487 VBD O
present BC2GM037741487 JJ O
upstream BC2GM037741487 NN O
of BC2GM037741487 IN O
the BC2GM037741487 DT O
TATA BC2GM037741487 NNP O
box BC2GM037741487 NN O
. BC2GM037741487 . O
. . O O

This BC2GM060812049 DT O
evaluation BC2GM060812049 NN O
examines BC2GM060812049 VBZ O
several BC2GM060812049 JJ O
analytical BC2GM060812049 JJ O
and BC2GM060812049 CC O
cost BC2GM060812049 NN O
parameters BC2GM060812049 NNS O
for BC2GM060812049 IN O
five BC2GM060812049 CD O
representative BC2GM060812049 JJ O
assays BC2GM060812049 NNS O
: BC2GM060812049 : O
IgG BC2GM060812049 NNP O
, BC2GM060812049 , O
IgA BC2GM060812049 NNP O
, BC2GM060812049 , O
IgM BC2GM060812049 NNP O
, BC2GM060812049 , O
phenytoin BC2GM060812049 NN O
, BC2GM060812049 , O
and BC2GM060812049 CC O
phenobarbital BC2GM060812049 NN O
. BC2GM060812049 . O
. . O O

Further BC2GM087199820 RB O
, BC2GM087199820 , O
cells BC2GM087199820 NNS O
cotransfected BC2GM087199820 VBN O
with BC2GM087199820 IN O
a BC2GM087199820 DT O
UF BC2GM087199820 NNP O
promoter-luciferase BC2GM087199820 NN O
( BC2GM087199820 ( O
-1935UF-Luc BC2GM087199820 NNP O
) BC2GM087199820 ) O
reporter BC2GM087199820 NN O
gene BC2GM087199820 NN O
and BC2GM087199820 CC O
the BC2GM087199820 DT O
BTEB BC2GM087199820 NNP O
expression BC2GM087199820 NN O
vector BC2GM087199820 NN O
had BC2GM087199820 VBD O
2-fold BC2GM087199820 JJ O
higher BC2GM087199820 JJR O
Luc BC2GM087199820 NNP O
activity BC2GM087199820 NN O
than BC2GM087199820 IN O
those BC2GM087199820 DT O
cotransfected BC2GM087199820 VBN O
with BC2GM087199820 IN O
reporter BC2GM087199820 NN O
gene BC2GM087199820 NN O
and BC2GM087199820 CC O
pcDNA-3 BC2GM087199820 NN O
. BC2GM087199820 . O
. . O O

The BC2GM006738398 DT O
signal-to-noise BC2GM006738398 JJ O
ratio BC2GM006738398 NN O
( BC2GM006738398 ( O
SNR BC2GM006738398 NNP O
) BC2GM006738398 ) O
was BC2GM006738398 VBD O
calculated BC2GM006738398 VBN O
in BC2GM006738398 IN O
the BC2GM006738398 DT O
T2-weighted BC2GM006738398 JJ O
sequence BC2GM006738398 NN O
. BC2GM006738398 . O
. . O O

This BC2GM009595830 DT O
bud BC2GM009595830 NN O
morphology BC2GM009595830 NN O
results BC2GM009595830 NNS O
at BC2GM009595830 IN O
least BC2GM009595830 JJS O
in BC2GM009595830 IN O
part BC2GM009595830 NN O
from BC2GM009595830 IN O
a BC2GM009595830 DT O
cell BC2GM009595830 NN O
cycle BC2GM009595830 NN O
delay BC2GM009595830 NN O
imposed BC2GM009595830 VBN O
by BC2GM009595830 IN O
the BC2GM009595830 DT O
Cdc28p-inhibitory BC2GM009595830 JJ O
kinase BC2GM009595830 NN O
Swe1p BC2GM009595830 NNP O
. BC2GM009595830 . O
. . O O

Aggregation BC2GM005714480 NN O
in BC2GM005714480 IN O
washed BC2GM005714480 JJ O
platelets BC2GM005714480 NNS O
from BC2GM005714480 IN O
rats BC2GM005714480 NNS O
with BC2GM005714480 IN O
diabetes BC2GM005714480 NNS O
was BC2GM005714480 VBD O
enhanced BC2GM005714480 VBN O
. BC2GM005714480 . O
. . O O

While BC2GM013622004 IN O
these BC2GM013622004 DT O
could BC2GM013622004 MD O
be BC2GM013622004 VB O
unusual BC2GM013622004 JJ O
cases BC2GM013622004 NNS O
of BC2GM013622004 IN O
chronic BC2GM013622004 JJ O
non-A BC2GM013622004 JJ O
, BC2GM013622004 , O
non-B BC2GM013622004 JJ O
hepatitis BC2GM013622004 NN O
, BC2GM013622004 , O
this BC2GM013622004 DT O
can BC2GM013622004 MD O
be BC2GM013622004 VB O
only BC2GM013622004 JJ O
speculation BC2GM013622004 NN O
until BC2GM013622004 IN O
a BC2GM013622004 DT O
serologic BC2GM013622004 JJ O
test BC2GM013622004 NN O
for BC2GM013622004 IN O
non-A BC2GM013622004 JJ O
, BC2GM013622004 , O
non-B BC2GM013622004 JJ O
hepatitis BC2GM013622004 NN O
becomes BC2GM013622004 VBZ O
available BC2GM013622004 JJ O
. BC2GM013622004 . O
. . O O

Further BC2GM018615629 JJ O
studies BC2GM018615629 NNS O
aim BC2GM018615629 VBP O
at BC2GM018615629 IN O
characterizing BC2GM018615629 VBG O
the BC2GM018615629 DT O
trans-acting BC2GM018615629 JJ O
factors BC2GM018615629 NNS O
that BC2GM018615629 WDT O
mediate BC2GM018615629 VBP O
the BC2GM018615629 DT O
spatial BC2GM018615629 JJ O
and BC2GM018615629 CC O
temporal BC2GM018615629 JJ O
expression BC2GM018615629 NN O
of BC2GM018615629 IN O
Hox BC2GM018615629 NNP O
genes BC2GM018615629 NNS O
in BC2GM018615629 IN O
the BC2GM018615629 DT O
developing BC2GM018615629 JJ O
embryo BC2GM018615629 NN O
. BC2GM018615629 . O
. . O O

Given BC2GM002670368 VBN O
a BC2GM002670368 DT O
rapid BC2GM002670368 JJ O
induction BC2GM002670368 NN O
of BC2GM002670368 IN O
Egr-1 BC2GM002670368 NNP O
on BC2GM002670368 IN O
stimulation BC2GM002670368 NN O
with BC2GM002670368 IN O
growth BC2GM002670368 NN O
factors BC2GM002670368 NNS O
or BC2GM002670368 CC O
injury BC2GM002670368 NN O
, BC2GM002670368 , O
these BC2GM002670368 DT O
findings BC2GM002670368 NNS O
may BC2GM002670368 MD O
represent BC2GM002670368 VB O
at BC2GM002670368 IN O
least BC2GM002670368 JJS O
one BC2GM002670368 CD O
of BC2GM002670368 IN O
the BC2GM002670368 DT O
molecular BC2GM002670368 JJ O
mechanisms BC2GM002670368 NNS O
underlying BC2GM002670368 VBG O
phenotypic BC2GM002670368 JJ O
modulation BC2GM002670368 NN O
of BC2GM002670368 IN O
smooth BC2GM002670368 JJ O
muscles BC2GM002670368 NNS O
after BC2GM002670368 IN O
vascular BC2GM002670368 JJ O
injury BC2GM002670368 NN O
. BC2GM002670368 . O
. . O O

The BC2GM047782308 DT O
biological BC2GM047782308 JJ O
activity BC2GM047782308 NN O
of BC2GM047782308 IN O
these BC2GM047782308 DT O
mutants BC2GM047782308 NNS O
was BC2GM047782308 VBD O
tested BC2GM047782308 VBN O
by BC2GM047782308 IN O
determining BC2GM047782308 VBG O
their BC2GM047782308 PRP$ O
capacity BC2GM047782308 NN O
to BC2GM047782308 TO O
( BC2GM047782308 ( O
i BC2GM047782308 NN O
) BC2GM047782308 ) O
reconstitute BC2GM047782308 NN O
RNA BC2GM047782308 NNP O
polymerase BC2GM047782308 NN O
activity BC2GM047782308 NN O
in BC2GM047782308 IN O
vivo BC2GM047782308 NN O
by BC2GM047782308 IN O
cotransfection BC2GM047782308 NN O
with BC2GM047782308 IN O
proteins BC2GM047782308 NNS O
NP BC2GM047782308 NNP O
, BC2GM047782308 , O
PB1 BC2GM047782308 NNP O
, BC2GM047782308 , O
and BC2GM047782308 CC O
PA BC2GM047782308 NNP O
and BC2GM047782308 CC O
a BC2GM047782308 DT O
virion-like BC2GM047782308 JJ O
RNA BC2GM047782308 NNP O
encoding BC2GM047782308 VBG O
the BC2GM047782308 DT O
cat BC2GM047782308 NN O
gene BC2GM047782308 NN O
into BC2GM047782308 IN O
vaccinia BC2GM047782308 JJ O
virus BC2GM047782308 JJ O
T7-infected BC2GM047782308 JJ O
COS-1 BC2GM047782308 NNP O
cells BC2GM047782308 NNS O
and BC2GM047782308 CC O
( BC2GM047782308 ( O
ii BC2GM047782308 NN O
) BC2GM047782308 ) O
complete BC2GM047782308 NN O
with BC2GM047782308 IN O
the BC2GM047782308 DT O
wild-type BC2GM047782308 JJ O
PB2 BC2GM047782308 NNP O
activity BC2GM047782308 NN O
. BC2GM047782308 . O
. . O O

Type BC2GM072992671 NNP O
C BC2GM072992671 NNP O
units BC2GM072992671 NNS O
summate BC2GM072992671 VBP O
the BC2GM072992671 DT O
responses BC2GM072992671 NNS O
to BC2GM072992671 TO O
the BC2GM072992671 DT O
two-tone BC2GM072992671 JJ O
stimulus BC2GM072992671 NN O
, BC2GM072992671 , O
and BC2GM072992671 CC O
show BC2GM072992671 VB O
little BC2GM072992671 JJ O
or BC2GM072992671 CC O
no BC2GM072992671 DT O
inhibitory BC2GM072992671 JJ O
influences BC2GM072992671 NNS O
. BC2GM072992671 . O
. . O O

These BC2GM051669825 DT O
results BC2GM051669825 NNS O
indicate BC2GM051669825 VBP O
that BC2GM051669825 IN O
the BC2GM051669825 DT O
changes BC2GM051669825 NNS O
in BC2GM051669825 IN O
the BC2GM051669825 DT O
patient BC2GM051669825 NN O
's BC2GM051669825 POS O
thyroid BC2GM051669825 JJ O
scan BC2GM051669825 JJ O
and BC2GM051669825 CC O
RAIU BC2GM051669825 NNP O
were BC2GM051669825 VBD O
attributable BC2GM051669825 JJ O
to BC2GM051669825 TO O
the BC2GM051669825 DT O
presence BC2GM051669825 NN O
of BC2GM051669825 IN O
TSAb BC2GM051669825 NNP O
. BC2GM051669825 . O
. . O O

The BC2GM006986011 DT O
dopamine BC2GM006986011 NN O
D1 BC2GM006986011 NNP O
dopamine BC2GM006986011 NN O
receptor BC2GM006986011 NN O
antagonist BC2GM006986011 NN O
SCH BC2GM006986011 NNP O
23390 BC2GM006986011 CD O
dose BC2GM006986011 NN O
dependently BC2GM006986011 RB O
( BC2GM006986011 ( O
7.5-30 BC2GM006986011 JJ O
micrograms BC2GM006986011 NNS O
/ BC2GM006986011 VBP O
kg BC2GM006986011 VB O
s.c. BC2GM006986011 NN O
) BC2GM006986011 ) O
antagonized BC2GM006986011 VBD O
the BC2GM006986011 DT O
stimulant BC2GM006986011 NN O
locomotor BC2GM006986011 NN O
effect BC2GM006986011 NN O
on BC2GM006986011 IN O
both BC2GM006986011 DT O
drugs BC2GM006986011 NNS O
but BC2GM006986011 CC O
did BC2GM006986011 VBD O
not BC2GM006986011 RB O
prevent BC2GM006986011 VB O
their BC2GM006986011 PRP$ O
antiimmobility BC2GM006986011 NN O
effect BC2GM006986011 NN O
on BC2GM006986011 IN O
the BC2GM006986011 DT O
behavioral BC2GM006986011 JJ O
despair BC2GM006986011 NN O
test BC2GM006986011 NN O
. BC2GM006986011 . O
. . O O

The BC2GM025094273 DT O
activated BC2GM025094273 JJ O
glucocorticoid BC2GM025094273 NN O
receptor BC2GM025094273 NN O
forms BC2GM025094273 VBZ O
a BC2GM025094273 DT O
complex BC2GM025094273 JJ O
with BC2GM025094273 IN O
Stat5 BC2GM025094273 NNP O
and BC2GM025094273 CC O
enhances BC2GM025094273 VBZ O
Stat5-mediated BC2GM025094273 JJ O
transcriptional BC2GM025094273 JJ O
induction BC2GM025094273 NN O
. BC2GM025094273 . O
. . O O

( BC2GM022697096 ( O
99m BC2GM022697096 CD O
) BC2GM022697096 ) O
Tc BC2GM022697096 NNP O
Ethyl BC2GM022697096 NNP O
Cysteinate BC2GM022697096 NNP O
Dimer BC2GM022697096 NNP O
stable BC2GM022697096 JJ O
during BC2GM022697096 IN O
6h BC2GM022697096 CD O
has BC2GM022697096 VBZ O
contributed BC2GM022697096 VBN O
to BC2GM022697096 TO O
develop BC2GM022697096 VB O
ictal BC2GM022697096 JJ O
studies BC2GM022697096 NNS O
to BC2GM022697096 TO O
evaluate BC2GM022697096 VB O
the BC2GM022697096 DT O
location BC2GM022697096 NN O
of BC2GM022697096 IN O
partial BC2GM022697096 JJ O
seizure BC2GM022697096 NN O
. BC2GM022697096 . O
. . O O

The BC2GM058528014 DT O
UL3 BC2GM058528014 NNP O
ORF BC2GM058528014 NNP O
of BC2GM058528014 IN O
204 BC2GM058528014 CD O
amino BC2GM058528014 NN O
acids BC2GM058528014 NNS O
shows BC2GM058528014 VBZ O
significant BC2GM058528014 JJ O
homology BC2GM058528014 NN O
to BC2GM058528014 TO O
UL3 BC2GM058528014 NNP O
( BC2GM058528014 ( O
nuclear BC2GM058528014 JJ O
phosphoprotein BC2GM058528014 NN O
) BC2GM058528014 ) O
of BC2GM058528014 IN O
HSV-1 BC2GM058528014 NNP O
( BC2GM058528014 ( O
62 BC2GM058528014 CD O
% BC2GM058528014 NN O
) BC2GM058528014 ) O
and BC2GM058528014 CC O
PRV BC2GM058528014 NNP O
( BC2GM058528014 ( O
53 BC2GM058528014 CD O
% BC2GM058528014 NN O
) BC2GM058528014 ) O
. BC2GM058528014 . O
. . O O

This BC2GM046996485 DT O
is BC2GM046996485 VBZ O
consistent BC2GM046996485 JJ O
with BC2GM046996485 IN O
the BC2GM046996485 DT O
need BC2GM046996485 NN O
for BC2GM046996485 IN O
a BC2GM046996485 DT O
nuclear BC2GM046996485 JJ O
retinoid BC2GM046996485 NN O
receptor BC2GM046996485 NN O
function BC2GM046996485 NN O
in BC2GM046996485 IN O
RA-induced BC2GM046996485 NNP O
ERK2 BC2GM046996485 NNP O
activation BC2GM046996485 NN O
. BC2GM046996485 . O
. . O O

The BC2GM061043119 DT O
effects BC2GM061043119 NNS O
of BC2GM061043119 IN O
dopamine BC2GM061043119 NN O
and BC2GM061043119 CC O
of BC2GM061043119 IN O
dopamine BC2GM061043119 JJ O
D2 BC2GM061043119 NNP O
receptor BC2GM061043119 NN O
blocker BC2GM061043119 NN O
haloperidol BC2GM061043119 NN O
on BC2GM061043119 IN O
the BC2GM061043119 DT O
activity BC2GM061043119 NN O
of BC2GM061043119 IN O
carotid BC2GM061043119 NN O
chemoreceptors BC2GM061043119 NNS O
were BC2GM061043119 VBD O
studied BC2GM061043119 VBN O
in BC2GM061043119 IN O
24 BC2GM061043119 CD O
anesthetized BC2GM061043119 JJ O
, BC2GM061043119 , O
paralyzed BC2GM061043119 JJ O
and BC2GM061043119 CC O
artificially BC2GM061043119 RB O
ventilated BC2GM061043119 VBD O
newborn BC2GM061043119 JJ O
kittens BC2GM061043119 NNS O
aged BC2GM061043119 VBN O
0-17 BC2GM061043119 JJ O
days BC2GM061043119 NNS O
. BC2GM061043119 . O
. . O O

Morphine BC2GM044104855 NNP O
administration BC2GM044104855 NN O
acutely BC2GM044104855 RB O
reduced BC2GM044104855 VBD O
plasma BC2GM044104855 JJ O
clearance BC2GM044104855 NN O
of BC2GM044104855 IN O
sulfobromophthalein BC2GM044104855 NN O
( BC2GM044104855 ( O
BSP BC2GM044104855 NNP O
) BC2GM044104855 ) O
in BC2GM044104855 IN O
mice BC2GM044104855 NN O
and BC2GM044104855 CC O
increased BC2GM044104855 VBD O
hepatic BC2GM044104855 JJ O
retention BC2GM044104855 NN O
of BC2GM044104855 IN O
this BC2GM044104855 DT O
dye BC2GM044104855 NN O
. BC2GM044104855 . O
. . O O

In BC2GM069147712 IN O
contrast BC2GM069147712 NN O
translocation BC2GM069147712 NN O
of BC2GM069147712 IN O
G1 BC2GM069147712 NNP O
to BC2GM069147712 TO O
the BC2GM069147712 DT O
Golgi BC2GM069147712 NNP O
was BC2GM069147712 VBD O
not BC2GM069147712 RB O
observed BC2GM069147712 VBN O
when BC2GM069147712 WRB O
G1 BC2GM069147712 NNP O
was BC2GM069147712 VBD O
coexpressed BC2GM069147712 VBN O
with BC2GM069147712 IN O
NSm BC2GM069147712 NNP O
, BC2GM069147712 , O
although BC2GM069147712 IN O
NSm BC2GM069147712 NNP O
itself BC2GM069147712 PRP O
was BC2GM069147712 VBD O
still BC2GM069147712 RB O
detected BC2GM069147712 VBN O
in BC2GM069147712 IN O
the BC2GM069147712 DT O
Golgi BC2GM069147712 NNP O
. BC2GM069147712 . O
. . O O

BCR-ABL BC2GM049036959 JJ O
elicits BC2GM049036959 NNS O
transformation BC2GM049036959 NN O
of BC2GM049036959 IN O
both BC2GM049036959 DT O
fibroblast BC2GM049036959 NN O
and BC2GM049036959 CC O
hematopoietic BC2GM049036959 JJ O
cells BC2GM049036959 NNS O
and BC2GM049036959 CC O
blocks BC2GM049036959 NNS O
apoptosis BC2GM049036959 VBP O
following BC2GM049036959 VBG O
cytokine BC2GM049036959 NN O
deprivation BC2GM049036959 NN O
in BC2GM049036959 IN O
various BC2GM049036959 JJ O
factor-dependent BC2GM049036959 JJ O
cells BC2GM049036959 NNS O
. BC2GM049036959 . O
. . O O

To BC2GM079202513 TO O
probe BC2GM079202513 VB O
the BC2GM079202513 DT O
inter-relationship BC2GM079202513 NN O
between BC2GM079202513 IN O
the BC2GM079202513 DT O
virion-anchoring BC2GM079202513 JJ O
function BC2GM079202513 NN O
and BC2GM079202513 CC O
the BC2GM079202513 DT O
oligomerization BC2GM079202513 NN O
function BC2GM079202513 NN O
, BC2GM079202513 , O
we BC2GM079202513 PRP O
constructed BC2GM079202513 VBD O
two BC2GM079202513 CD O
serotype BC2GM079202513 NN O
3 BC2GM079202513 CD O
( BC2GM079202513 ( O
T3 BC2GM079202513 NNP O
) BC2GM079202513 ) O
sigma BC2GM079202513 VBD O
1 BC2GM079202513 CD O
deletion BC2GM079202513 NN O
mutants BC2GM079202513 NNS O
in BC2GM079202513 IN O
SV40 BC2GM079202513 NNP O
expression BC2GM079202513 NN O
vectors BC2GM079202513 NNS O
, BC2GM079202513 , O
one BC2GM079202513 CD O
lacking BC2GM079202513 VBG O
the BC2GM079202513 DT O
hydrophobic BC2GM079202513 JJ O
tail BC2GM079202513 NN O
and BC2GM079202513 CC O
the BC2GM079202513 DT O
hinge BC2GM079202513 NN O
, BC2GM079202513 , O
and BC2GM079202513 CC O
the BC2GM079202513 DT O
other BC2GM079202513 JJ O
lacking BC2GM079202513 VBG O
an BC2GM079202513 DT O
adjacent BC2GM079202513 JJ O
region BC2GM079202513 NN O
which BC2GM079202513 WDT O
constituted BC2GM079202513 VBD O
part BC2GM079202513 NN O
of BC2GM079202513 IN O
the BC2GM079202513 DT O
coiled-coil BC2GM079202513 NN O
. BC2GM079202513 . O
. . O O

Numerous BC2GM088211733 JJ O
genes BC2GM088211733 NNS O
of BC2GM088211733 IN O
this BC2GM088211733 DT O
family BC2GM088211733 NN O
have BC2GM088211733 VBP O
been BC2GM088211733 VBN O
identified BC2GM088211733 VBN O
in BC2GM088211733 IN O
animals BC2GM088211733 NNS O
, BC2GM088211733 , O
with BC2GM088211733 IN O
the BC2GM088211733 DT O
largest BC2GM088211733 JJS O
number BC2GM088211733 NN O
found BC2GM088211733 VBN O
in BC2GM088211733 IN O
vertebrates BC2GM088211733 NNS O
. BC2GM088211733 . O
. . O O

Transcripts BC2GM051997462 NNS O
initiating BC2GM051997462 VBG O
at BC2GM051997462 IN O
the BC2GM051997462 DT O
CAGT BC2GM051997462 NNP O
motif BC2GM051997462 NN O
( BC2GM051997462 ( O
proximal BC2GM051997462 JJ O
transcripts BC2GM051997462 NNS O
) BC2GM051997462 ) O
were BC2GM051997462 VBD O
abolished BC2GM051997462 VBN O
by BC2GM051997462 IN O
deletion BC2GM051997462 NN O
of BC2GM051997462 IN O
the BC2GM051997462 DT O
proximal BC2GM051997462 JJ O
TATA BC2GM051997462 NNP O
box BC2GM051997462 NN O
located BC2GM051997462 VBN O
at BC2GM051997462 IN O
-29 BC2GM051997462 NNP O
relative BC2GM051997462 VBP O
to BC2GM051997462 TO O
CAGT BC2GM051997462 NNP O
. BC2GM051997462 . O
. . O O

Co-expression BC2GM024652235 NN O
of BC2GM024652235 IN O
PLD1 BC2GM024652235 NNP O
in BC2GM024652235 IN O
COS-7 BC2GM024652235 NNP O
cells BC2GM024652235 NNS O
with BC2GM024652235 IN O
the BC2GM024652235 DT O
two BC2GM024652235 CD O
recombinant BC2GM024652235 JJ O
CK2 BC2GM024652235 NNP O
subunits BC2GM024652235 NNS O
, BC2GM024652235 , O
alpha BC2GM024652235 NN O
or BC2GM024652235 CC O
beta BC2GM024652235 NN O
, BC2GM024652235 , O
suggests BC2GM024652235 VBZ O
that BC2GM024652235 IN O
the BC2GM024652235 DT O
association BC2GM024652235 NN O
of BC2GM024652235 IN O
PLD1 BC2GM024652235 NNP O
with BC2GM024652235 IN O
the BC2GM024652235 DT O
kinase BC2GM024652235 NN O
is BC2GM024652235 VBZ O
through BC2GM024652235 IN O
the BC2GM024652235 DT O
beta BC2GM024652235 NN O
subunit BC2GM024652235 NN O
. BC2GM024652235 . O
. . O O

Metapsychiatry BC2GM080820769 NN O
is BC2GM080820769 VBZ O
a BC2GM080820769 DT O
term BC2GM080820769 NN O
born BC2GM080820769 NN O
of BC2GM080820769 IN O
necessity BC2GM080820769 NN O
to BC2GM080820769 TO O
designate BC2GM080820769 VB O
the BC2GM080820769 DT O
important BC2GM080820769 JJ O
but BC2GM080820769 CC O
hitherto BC2GM080820769 JJ O
unclassified BC2GM080820769 JJ O
interface BC2GM080820769 NN O
between BC2GM080820769 IN O
psychiatry BC2GM080820769 NN O
and BC2GM080820769 CC O
mysticism BC2GM080820769 NN O
. BC2GM080820769 . O
. . O O

The BC2GM034539107 DT O
5 BC2GM034539107 CD O
' BC2GM034539107 POS O
ends BC2GM034539107 NNS O
of BC2GM034539107 IN O
the BC2GM034539107 DT O
P BC2GM034539107 NNP O
and BC2GM034539107 CC O
O BC2GM034539107 NNP O
gene BC2GM034539107 NN O
mRNAs BC2GM034539107 NNS O
are BC2GM034539107 VBP O
separated BC2GM034539107 VBN O
by BC2GM034539107 IN O
109 BC2GM034539107 CD O
nucleotide BC2GM034539107 JJ O
pairs BC2GM034539107 NNS O
in BC2GM034539107 IN O
the BC2GM034539107 DT O
DNA BC2GM034539107 NN O
template BC2GM034539107 NN O
. BC2GM034539107 . O
. . O O

Fetal BC2GM086175633 JJ O
transplants BC2GM086175633 NNS O
rescue BC2GM086175633 VBP O
axial BC2GM086175633 JJ O
muscle BC2GM086175633 NN O
representations BC2GM086175633 NNS O
in BC2GM086175633 IN O
M1 BC2GM086175633 NNP O
cortex BC2GM086175633 NN O
of BC2GM086175633 IN O
neonatally BC2GM086175633 RB O
transected BC2GM086175633 VBN O
rats BC2GM086175633 NNS O
that BC2GM086175633 IN O
develop BC2GM086175633 VBP O
weight BC2GM086175633 JJ O
support BC2GM086175633 NN O
. BC2GM086175633 . O
. . O O

Increased BC2GM084495640 VBN O
TRE BC2GM084495640 NNP O
DNA BC2GM084495640 NNP O
binding BC2GM084495640 VBG O
failed BC2GM084495640 VBD O
to BC2GM084495640 TO O
lead BC2GM084495640 VB O
to BC2GM084495640 TO O
increased BC2GM084495640 VBN O
transactivation BC2GM084495640 NN O
correlating BC2GM084495640 VBG O
with BC2GM084495640 IN O
the BC2GM084495640 DT O
inability BC2GM084495640 NN O
of BC2GM084495640 IN O
SB BC2GM084495640 NNP O
203580 BC2GM084495640 CD O
to BC2GM084495640 TO O
increase BC2GM084495640 VB O
phosphorylation BC2GM084495640 NN O
of BC2GM084495640 IN O
these BC2GM084495640 DT O
AP-1 BC2GM084495640 NNP O
proteins BC2GM084495640 NNS O
. BC2GM084495640 . O
. . O O

Cell BC2GM031305543 NNP O
cycle BC2GM031305543 NN O
regulatory BC2GM031305543 JJ O
components BC2GM031305543 NNS O
have BC2GM031305543 VBP O
been BC2GM031305543 VBN O
largely BC2GM031305543 RB O
conserved BC2GM031305543 VBN O
in BC2GM031305543 IN O
eukaryotes BC2GM031305543 NNS O
; BC2GM031305543 : O
however BC2GM031305543 RB O
, BC2GM031305543 , O
orthologs BC2GM031305543 NNS O
of BC2GM031305543 IN O
neither BC2GM031305543 DT O
CAK1 BC2GM031305543 NNP O
nor BC2GM031305543 CC O
csk1 BC2GM031305543 NNS O
have BC2GM031305543 VBP O
been BC2GM031305543 VBN O
identified BC2GM031305543 VBN O
in BC2GM031305543 IN O
other BC2GM031305543 JJ O
species BC2GM031305543 NNS O
to BC2GM031305543 TO O
date BC2GM031305543 NN O
. BC2GM031305543 . O
. . O O

The BC2GM073475138 DT O
electrocardiogram BC2GM073475138 NN O
in BC2GM073475138 IN O
tachycardia BC2GM073475138 NN O
. BC2GM073475138 . O
. . O O

In BC2GM091752131 IN O
32 BC2GM091752131 CD O
of BC2GM091752131 IN O
them BC2GM091752131 PRP O
the BC2GM091752131 DT O
results BC2GM091752131 NNS O
of BC2GM091752131 IN O
an BC2GM091752131 DT O
exercise BC2GM091752131 NN O
performance BC2GM091752131 NN O
test BC2GM091752131 NN O
based BC2GM091752131 VBN O
on BC2GM091752131 IN O
heart BC2GM091752131 NN O
rate BC2GM091752131 NN O
response BC2GM091752131 NN O
to BC2GM091752131 TO O
submaximal BC2GM091752131 VB O
exercise BC2GM091752131 NN O
( BC2GM091752131 ( O
VO2 BC2GM091752131 NNP O
, BC2GM091752131 , O
170 BC2GM091752131 CD O
[ BC2GM091752131 NN O
bpm BC2GM091752131 NN O
] BC2GM091752131 NN O
) BC2GM091752131 ) O
was BC2GM091752131 VBD O
compared BC2GM091752131 VBN O
with BC2GM091752131 IN O
another BC2GM091752131 DT O
index BC2GM091752131 NN O
of BC2GM091752131 IN O
physical BC2GM091752131 JJ O
performance BC2GM091752131 NN O
capacity BC2GM091752131 NN O
, BC2GM091752131 , O
which BC2GM091752131 WDT O
is BC2GM091752131 VBZ O
independent BC2GM091752131 JJ O
from BC2GM091752131 IN O
heart BC2GM091752131 NN O
rate BC2GM091752131 NN O
: BC2GM091752131 : O
the BC2GM091752131 DT O
ventilatory BC2GM091752131 NN O
threshold BC2GM091752131 NN O
. BC2GM091752131 . O
. . O O

Many BC2GM097779504 JJ O
retroviruses BC2GM097779504 NNS O
, BC2GM097779504 , O
including BC2GM097779504 VBG O
the BC2GM097779504 DT O
human BC2GM097779504 JJ O
and BC2GM097779504 CC O
simian BC2GM097779504 JJ O
immunodeficiency BC2GM097779504 NN O
viruses BC2GM097779504 NNS O
, BC2GM097779504 , O
contain BC2GM097779504 VBP O
a BC2GM097779504 DT O
leucine BC2GM097779504 JJ O
zipper-like BC2GM097779504 JJ O
repeat BC2GM097779504 NN O
in BC2GM097779504 IN O
a BC2GM097779504 DT O
highly BC2GM097779504 RB O
conserved BC2GM097779504 JJ O
region BC2GM097779504 NN O
of BC2GM097779504 IN O
the BC2GM097779504 DT O
external BC2GM097779504 JJ O
domain BC2GM097779504 NN O
of BC2GM097779504 IN O
the BC2GM097779504 DT O
transmembrane BC2GM097779504 NN O
( BC2GM097779504 ( O
TM BC2GM097779504 NNP O
) BC2GM097779504 ) O
glycoprotein BC2GM097779504 NN O
. BC2GM097779504 . O
. . O O

Intramolecular BC2GM064970806 JJ O
interaction BC2GM064970806 NN O
is BC2GM064970806 VBZ O
believed BC2GM064970806 VBN O
to BC2GM064970806 TO O
result BC2GM064970806 VB O
in BC2GM064970806 IN O
the BC2GM064970806 DT O
formation BC2GM064970806 NN O
of BC2GM064970806 IN O
MxA BC2GM064970806 NNP O
monomers BC2GM064970806 NNS O
, BC2GM064970806 , O
whereas BC2GM064970806 IN O
intermolecular BC2GM064970806 JJ O
interaction BC2GM064970806 NN O
may BC2GM064970806 MD O
induce BC2GM064970806 VB O
the BC2GM064970806 DT O
formation BC2GM064970806 NN O
of BC2GM064970806 IN O
large BC2GM064970806 JJ O
MxA BC2GM064970806 NNP O
oligomers BC2GM064970806 NNS O
. BC2GM064970806 . O
. . O O

In BC2GM058412492 IN O
the BC2GM058412492 DT O
renal BC2GM058412492 JJ O
cortex BC2GM058412492 NN O
, BC2GM058412492 , O
spleen BC2GM058412492 NN O
, BC2GM058412492 , O
distal BC2GM058412492 JJ O
colon BC2GM058412492 NN O
, BC2GM058412492 , O
ileum BC2GM058412492 NN O
, BC2GM058412492 , O
gallbladder BC2GM058412492 NN O
, BC2GM058412492 , O
and BC2GM058412492 CC O
stomach BC2GM058412492 NN O
body BC2GM058412492 NN O
, BC2GM058412492 , O
regional BC2GM058412492 JJ O
O2 BC2GM058412492 NNP O
delivery BC2GM058412492 NN O
was BC2GM058412492 VBD O
significantly BC2GM058412492 RB O
decreased BC2GM058412492 VBN O
with BC2GM058412492 IN O
hemodilution BC2GM058412492 NN O
to BC2GM058412492 TO O
20 BC2GM058412492 CD O
% BC2GM058412492 NN O
in BC2GM058412492 IN O
both BC2GM058412492 DT O
groups BC2GM058412492 NNS O
. BC2GM058412492 . O
. . O O

CONCLUSIONS BC2GM010665846 NN O
: BC2GM010665846 : O
LHB BC2GM010665846 NNP O
is BC2GM010665846 VBZ O
simple BC2GM010665846 JJ O
, BC2GM010665846 , O
easy BC2GM010665846 JJ O
and BC2GM010665846 CC O
safe BC2GM010665846 JJ O
to BC2GM010665846 TO O
implement BC2GM010665846 VB O
, BC2GM010665846 , O
and BC2GM010665846 CC O
is BC2GM010665846 VBZ O
the BC2GM010665846 DT O
only BC2GM010665846 JJ O
technique BC2GM010665846 NN O
capable BC2GM010665846 JJ O
of BC2GM010665846 IN O
maintaining BC2GM010665846 VBG O
independent BC2GM010665846 JJ O
upper BC2GM010665846 JJ O
and BC2GM010665846 CC O
lower BC2GM010665846 JJR O
body BC2GM010665846 NN O
perfusion BC2GM010665846 NN O
pressure BC2GM010665846 NN O
. BC2GM010665846 . O
. . O O

Power BC2GM053319803 NNP O
deposition BC2GM053319803 NN O
by BC2GM053319803 IN O
inverse-bremsstrahlung BC2GM053319803 NN O
is BC2GM053319803 VBZ O
modeled BC2GM053319803 VBN O
with BC2GM053319803 IN O
a BC2GM053319803 DT O
scheme BC2GM053319803 NN O
based BC2GM053319803 VBN O
on BC2GM053319803 IN O
Gaussian BC2GM053319803 JJ O
quadrature BC2GM053319803 NN O
to BC2GM053319803 TO O
accommodate BC2GM053319803 VB O
a BC2GM053319803 DT O
deposition BC2GM053319803 NN O
rate BC2GM053319803 NN O
whose BC2GM053319803 WP$ O
spatial BC2GM053319803 JJ O
variation BC2GM053319803 NN O
is BC2GM053319803 VBZ O
highly BC2GM053319803 RB O
nonuniform BC2GM053319803 JJ O
. BC2GM053319803 . O
. . O O

Although BC2GM029787145 IN O
hSSTR5 BC2GM029787145 NN O
displays BC2GM029787145 NNS O
approximately BC2GM029787145 RB O
75 BC2GM029787145 CD O
% BC2GM029787145 NN O
sequence BC2GM029787145 NN O
identity BC2GM029787145 NN O
with BC2GM029787145 IN O
rat BC2GM029787145 NN O
SSTR5 BC2GM029787145 NNP O
, BC2GM029787145 , O
the BC2GM029787145 DT O
two BC2GM029787145 CD O
receptors BC2GM029787145 NNS O
display BC2GM029787145 VBP O
significantly BC2GM029787145 RB O
different BC2GM029787145 JJ O
pharmacological BC2GM029787145 JJ O
profiles BC2GM029787145 NNS O
, BC2GM029787145 , O
especially BC2GM029787145 RB O
with BC2GM029787145 IN O
respect BC2GM029787145 NN O
to BC2GM029787145 TO O
their BC2GM029787145 PRP$ O
binding BC2GM029787145 NN O
affinities BC2GM029787145 NNS O
for BC2GM029787145 IN O
the BC2GM029787145 DT O
SST BC2GM029787145 NNP O
analogue BC2GM029787145 NN O
SMS BC2GM029787145 NNP O
201-995 BC2GM029787145 CD O
. BC2GM029787145 . O
. . O O

Allergic BC2GM044831438 JJ O
field BC2GM044831438 NN O
: BC2GM044831438 : O
how BC2GM044831438 WRB O
to BC2GM044831438 TO O
detect BC2GM044831438 VB O
it BC2GM044831438 PRP O
? BC2GM044831438 . O
. BC2GM044831438 . O
. . O O

They BC2GM086852055 PRP O
also BC2GM086852055 RB O
show BC2GM086852055 VBP O
that BC2GM086852055 IN O
M. BC2GM086852055 NNP O
malmoense BC2GM086852055 NN O
can BC2GM086852055 MD O
be BC2GM086852055 VB O
isolated BC2GM086852055 VBN O
from BC2GM086852055 IN O
the BC2GM086852055 DT O
environment BC2GM086852055 NN O
which BC2GM086852055 WDT O
may BC2GM086852055 MD O
be BC2GM086852055 VB O
the BC2GM086852055 DT O
source BC2GM086852055 NN O
of BC2GM086852055 IN O
the BC2GM086852055 DT O
infection BC2GM086852055 NN O
. BC2GM086852055 . O
. . O O

Further BC2GM012610098 JJ O
analysis BC2GM012610098 NN O
of BC2GM012610098 IN O
the BC2GM012610098 DT O
CAP59 BC2GM012610098 NNP O
locus BC2GM012610098 NN O
of BC2GM012610098 IN O
Cryptococcus BC2GM012610098 NNP O
neoformans BC2GM012610098 NNS O
: BC2GM012610098 : O
structure BC2GM012610098 NN O
defined BC2GM012610098 VBN O
by BC2GM012610098 IN O
forced BC2GM012610098 JJ O
expression BC2GM012610098 NN O
and BC2GM012610098 CC O
description BC2GM012610098 NN O
of BC2GM012610098 IN O
a BC2GM012610098 DT O
new BC2GM012610098 JJ O
ribosomal BC2GM012610098 JJ O
protein-encoding BC2GM012610098 JJ O
gene BC2GM012610098 NN O
. BC2GM012610098 . O
. . O O

Furthermore BC2GM075235574 RB O
, BC2GM075235574 , O
we BC2GM075235574 PRP O
have BC2GM075235574 VBP O
identified BC2GM075235574 VBN O
the BC2GM075235574 DT O
major BC2GM075235574 JJ O
open BC2GM075235574 JJ O
reading BC2GM075235574 NN O
frame BC2GM075235574 NN O
( BC2GM075235574 ( O
RF4 BC2GM075235574 NNP O
; BC2GM075235574 : O
2.3 BC2GM075235574 CD O
kb BC2GM075235574 NN O
) BC2GM075235574 ) O
as BC2GM075235574 IN O
being BC2GM075235574 VBG O
essential BC2GM075235574 JJ O
for BC2GM075235574 IN O
activation BC2GM075235574 NN O
, BC2GM075235574 , O
and BC2GM075235574 CC O
we BC2GM075235574 PRP O
have BC2GM075235574 VBP O
shown BC2GM075235574 VBN O
that BC2GM075235574 IN O
the BC2GM075235574 DT O
NF BC2GM075235574 NNP O
kappa BC2GM075235574 NN O
B BC2GM075235574 NNP O
, BC2GM075235574 , O
SP1 BC2GM075235574 NNP O
, BC2GM075235574 , O
and BC2GM075235574 CC O
TATA BC2GM075235574 NNP O
box BC2GM075235574 NN O
motifs BC2GM075235574 NNS O
in BC2GM075235574 IN O
the BC2GM075235574 DT O
human BC2GM075235574 JJ O
immunodeficiency BC2GM075235574 NN O
virus BC2GM075235574 NN O
LTR BC2GM075235574 NNP O
are BC2GM075235574 VBP O
all BC2GM075235574 DT O
required BC2GM075235574 VBN O
for BC2GM075235574 IN O
full BC2GM075235574 JJ O
induction BC2GM075235574 NN O
of BC2GM075235574 IN O
the BC2GM075235574 DT O
promoter BC2GM075235574 NN O
by BC2GM075235574 IN O
the BC2GM075235574 DT O
HHV-6-encoded BC2GM075235574 JJ O
transactivator BC2GM075235574 NN O
. BC2GM075235574 . O
. . O O

Similarly BC2GM065840723 RB O
, BC2GM065840723 , O
beta BC2GM065840723 NN O
adrenoceptors BC2GM065840723 NNS O
blockade BC2GM065840723 VBD O
has BC2GM065840723 VBZ O
been BC2GM065840723 VBN O
shown BC2GM065840723 VBN O
to BC2GM065840723 TO O
be BC2GM065840723 VB O
of BC2GM065840723 IN O
value BC2GM065840723 NN O
in BC2GM065840723 IN O
achieving BC2GM065840723 VBG O
continence BC2GM065840723 NN O
in BC2GM065840723 IN O
a BC2GM065840723 DT O
small BC2GM065840723 JJ O
group BC2GM065840723 NN O
of BC2GM065840723 IN O
patients BC2GM065840723 NNS O
. BC2GM065840723 . O
. . O O

Heterologous BC2GM052715986 JJ O
hybridization BC2GM052715986 NN O
with BC2GM052715986 IN O
a BC2GM052715986 DT O
rps12 BC2GM052715986 NN O
gene BC2GM052715986 NN O
specific BC2GM052715986 JJ O
probe BC2GM052715986 NN O
from BC2GM052715986 IN O
Euglena BC2GM052715986 NNP O
has BC2GM052715986 VBZ O
revealed BC2GM052715986 VBN O
the BC2GM052715986 DT O
presence BC2GM052715986 NN O
of BC2GM052715986 IN O
rps12 BC2GM052715986 NN O
homologous BC2GM052715986 JJ O
sequences BC2GM052715986 NNS O
within BC2GM052715986 IN O
the BC2GM052715986 DT O
inverted BC2GM052715986 JJ O
repeat BC2GM052715986 NN O
of BC2GM052715986 IN O
Spirodela BC2GM052715986 NNP O
chloroplast BC2GM052715986 NN O
DNA BC2GM052715986 NN O
on BC2GM052715986 IN O
the BC2GM052715986 DT O
fragment BC2GM052715986 JJ O
BamHI-V BC2GM052715986 NNP O
. BC2GM052715986 . O
. . O O

Both BC2GM067269145 DT O
the BC2GM067269145 DT O
inactive BC2GM067269145 JJ O
domain BC2GM067269145 NN O
II BC2GM067269145 NNP O
P68 BC2GM067269145 NNP O
mutant BC2GM067269145 NN O
and BC2GM067269145 CC O
the BC2GM067269145 DT O
deletion BC2GM067269145 NN O
mutant BC2GM067269145 NN O
lacking BC2GM067269145 VBG O
aa BC2GM067269145 JJ O
91-243 BC2GM067269145 CD O
were BC2GM067269145 VBD O
less BC2GM067269145 JJR O
inhibitory BC2GM067269145 JJ O
to BC2GM067269145 TO O
growth BC2GM067269145 NN O
in BC2GM067269145 IN O
yeast BC2GM067269145 NN O
due BC2GM067269145 JJ O
to BC2GM067269145 TO O
the BC2GM067269145 DT O
reduced BC2GM067269145 VBN O
ability BC2GM067269145 NN O
to BC2GM067269145 TO O
phosphorylate BC2GM067269145 VB O
initiation BC2GM067269145 NN O
factor BC2GM067269145 NN O
2 BC2GM067269145 CD O
alpha BC2GM067269145 NN O
in BC2GM067269145 IN O
vivo BC2GM067269145 NN O
. BC2GM067269145 . O
. . O O

25 BC2GM023685054 CD O
patients BC2GM023685054 NNS O
received BC2GM023685054 VBD O
20 BC2GM023685054 CD O
mgs BC2GM023685054 NN O
of BC2GM023685054 IN O
hyoscine BC2GM023685054 JJ O
N-butyl BC2GM023685054 NNP O
bromide BC2GM023685054 NN O
and BC2GM023685054 CC O
the BC2GM023685054 DT O
rest BC2GM023685054 NN O
5 BC2GM023685054 CD O
mgs BC2GM023685054 NN O
propinoxate BC2GM023685054 NN O
, BC2GM023685054 , O
i.v BC2GM023685054 NN O
. BC2GM023685054 . O
plus BC2GM023685054 CC O
diazepam BC2GM023685054 NN O
. BC2GM023685054 . O
. . O O

Issues BC2GM053865645 NNS O
discussed BC2GM053865645 VBN O
include BC2GM053865645 VBP O
the BC2GM053865645 DT O
validity BC2GM053865645 NN O
of BC2GM053865645 IN O
the BC2GM053865645 DT O
MMPI BC2GM053865645 NNP O
Mf BC2GM053865645 NNP O
scale BC2GM053865645 NN O
, BC2GM053865645 , O
questions BC2GM053865645 NNS O
of BC2GM053865645 IN O
sample BC2GM053865645 NN O
representativeness BC2GM053865645 NN O
, BC2GM053865645 , O
whether BC2GM053865645 IN O
`` BC2GM053865645 `` O
straights BC2GM053865645 NNS O
'' BC2GM053865645 '' O
can BC2GM053865645 MD O
do BC2GM053865645 VB O
adequate BC2GM053865645 VB O
research BC2GM053865645 NN O
on BC2GM053865645 IN O
homosexuality BC2GM053865645 NN O
, BC2GM053865645 , O
differences BC2GM053865645 NNS O
in BC2GM053865645 IN O
heterosexual BC2GM053865645 JJ O
and BC2GM053865645 CC O
homosexual BC2GM053865645 JJ O
sexuality BC2GM053865645 NN O
, BC2GM053865645 , O
the BC2GM053865645 DT O
role BC2GM053865645 NN O
of BC2GM053865645 IN O
subculture BC2GM053865645 NN O
acculturation BC2GM053865645 NN O
in BC2GM053865645 IN O
homosexual BC2GM053865645 JJ O
psychological BC2GM053865645 JJ O
adjustment BC2GM053865645 NN O
, BC2GM053865645 , O
and BC2GM053865645 CC O
the BC2GM053865645 DT O
use BC2GM053865645 NN O
of BC2GM053865645 IN O
cluster-analysis BC2GM053865645 NN O
to BC2GM053865645 TO O
generate BC2GM053865645 VB O
typologies BC2GM053865645 NNS O
of BC2GM053865645 IN O
homosexualities BC2GM053865645 NNS O
. BC2GM053865645 . O
. . O O

The BC2GM050193880 DT O
presence BC2GM050193880 NN O
of BC2GM050193880 IN O
highly BC2GM050193880 RB O
correlated BC2GM050193880 JJ O
frequencies BC2GM050193880 NNS O
provided BC2GM050193880 VBN O
strong BC2GM050193880 JJ O
evidence BC2GM050193880 NN O
of BC2GM050193880 IN O
a BC2GM050193880 DT O
medium-frequency BC2GM050193880 NN O
pattern BC2GM050193880 NN O
generator BC2GM050193880 NN O
which BC2GM050193880 WDT O
may BC2GM050193880 MD O
remain BC2GM050193880 VB O
operative BC2GM050193880 JJ O
beyond BC2GM050193880 IN O
the BC2GM050193880 DT O
neonatal BC2GM050193880 JJ O
period BC2GM050193880 NN O
. BC2GM050193880 . O
. . O O

DSS4-1 BC2GM003613157 NNP O
is BC2GM003613157 VBZ O
a BC2GM003613157 DT O
dominant BC2GM003613157 JJ O
suppressor BC2GM003613157 NN O
of BC2GM003613157 IN O
sec4-8 BC2GM003613157 NN O
that BC2GM003613157 WDT O
encodes BC2GM003613157 VBZ O
a BC2GM003613157 DT O
nucleotide BC2GM003613157 JJ O
exchange BC2GM003613157 NN O
protein BC2GM003613157 NN O
that BC2GM003613157 WDT O
aids BC2GM003613157 VBZ O
Sec4p BC2GM003613157 NNP O
function BC2GM003613157 NN O
. BC2GM003613157 . O
. . O O

Elevated BC2GM003946244 VBN O
systolic BC2GM003946244 JJ O
blood BC2GM003946244 NN O
pressure BC2GM003946244 NN O
and BC2GM003946244 CC O
high BC2GM003946244 JJ O
postglucose BC2GM003946244 NN O
serum BC2GM003946244 JJ O
insulin BC2GM003946244 NN O
levels BC2GM003946244 NNS O
showed BC2GM003946244 VBD O
an BC2GM003946244 DT O
independent BC2GM003946244 JJ O
, BC2GM003946244 , O
significant BC2GM003946244 JJ O
association BC2GM003946244 NN O
with BC2GM003946244 IN O
left BC2GM003946244 JJ O
ventricular BC2GM003946244 JJ O
mass BC2GM003946244 NN O
in BC2GM003946244 IN O
female BC2GM003946244 JJ O
diabetic BC2GM003946244 JJ O
subjects BC2GM003946244 NNS O
. BC2GM003946244 . O
. . O O

There BC2GM041921266 EX O
was BC2GM041921266 VBD O
no BC2GM041921266 DT O
difference BC2GM041921266 NN O
in BC2GM041921266 IN O
serum BC2GM041921266 NN O
albumin BC2GM041921266 NN O
and BC2GM041921266 CC O
transferrin BC2GM041921266 NN O
levels BC2GM041921266 NNS O
, BC2GM041921266 , O
but BC2GM041921266 CC O
serum BC2GM041921266 VBP O
prealbumin BC2GM041921266 NN O
levels BC2GM041921266 NNS O
in BC2GM041921266 IN O
the BC2GM041921266 DT O
group BC2GM041921266 NN O
fed BC2GM041921266 VBD O
early BC2GM041921266 JJ O
were BC2GM041921266 VBD O
more BC2GM041921266 RBR O
desirable BC2GM041921266 JJ O
than BC2GM041921266 IN O
those BC2GM041921266 DT O
of BC2GM041921266 IN O
the BC2GM041921266 DT O
control BC2GM041921266 NN O
group BC2GM041921266 NN O
( BC2GM041921266 ( O
from BC2GM041921266 IN O
15.8 BC2GM041921266 CD O
+ BC2GM041921266 NNS O
/ BC2GM041921266 SYM O
- BC2GM041921266 : O
2.5 BC2GM041921266 CD O
mg BC2GM041921266 NN O
/ BC2GM041921266 NN O
dl BC2GM041921266 NN O
to BC2GM041921266 TO O
28.9 BC2GM041921266 CD O
+ BC2GM041921266 NNS O
/ BC2GM041921266 SYM O
- BC2GM041921266 : O
3.8 BC2GM041921266 CD O
mg BC2GM041921266 NN O
/ BC2GM041921266 NNP O
dl BC2GM041921266 NN O
vs BC2GM041921266 NN O
from BC2GM041921266 IN O
18.0 BC2GM041921266 CD O
+ BC2GM041921266 NNS O
/ BC2GM041921266 SYM O
- BC2GM041921266 : O
2.0 BC2GM041921266 CD O
mg BC2GM041921266 NN O
/ BC2GM041921266 NN O
dl BC2GM041921266 NN O
to BC2GM041921266 TO O
25.9 BC2GM041921266 CD O
+ BC2GM041921266 NNS O
/ BC2GM041921266 SYM O
- BC2GM041921266 : O
3.9 BC2GM041921266 CD O
mg BC2GM041921266 NN O
/ BC2GM041921266 NNP O
dl BC2GM041921266 NN O
) BC2GM041921266 ) O
. BC2GM041921266 . O
. . O O

Two BC2GM044089781 CD O
pharmacokinetic BC2GM044089781 JJ O
models BC2GM044089781 NNS O
were BC2GM044089781 VBD O
compared BC2GM044089781 VBN O
. BC2GM044089781 . O
. . O O

Promoting BC2GM093930415 VBG O
fat BC2GM093930415 JJ O
utilisation BC2GM093930415 NN O
by BC2GM093930415 IN O
reducing BC2GM093930415 VBG O
the BC2GM093930415 DT O
carbohydrate-fat BC2GM093930415 JJ O
ratio BC2GM093930415 NN O
of BC2GM093930415 IN O
the BC2GM093930415 DT O
TPN BC2GM093930415 NNP O
reduces BC2GM093930415 NNS O
free BC2GM093930415 JJ O
radical BC2GM093930415 JJ O
activity BC2GM093930415 NN O
to BC2GM093930415 TO O
a BC2GM093930415 DT O
similar BC2GM093930415 JJ O
extent BC2GM093930415 NN O
as BC2GM093930415 IN O
fat BC2GM093930415 JJ O
exclusion BC2GM093930415 NN O
. BC2GM093930415 . O
. . O O

Using BC2GM073396210 VBG O
this BC2GM073396210 DT O
oligonucleotide BC2GM073396210 NN O
as BC2GM073396210 IN O
a BC2GM073396210 DT O
probe BC2GM073396210 NN O
, BC2GM073396210 , O
an BC2GM073396210 DT O
8-kilobase BC2GM073396210 JJ O
HindIII BC2GM073396210 NNP O
fragment BC2GM073396210 NN O
of BC2GM073396210 IN O
genomic BC2GM073396210 JJ O
DNA BC2GM073396210 NNP O
was BC2GM073396210 VBD O
isolated BC2GM073396210 VBN O
and BC2GM073396210 CC O
subjected BC2GM073396210 VBN O
to BC2GM073396210 TO O
Sanger BC2GM073396210 NNP O
dideoxy BC2GM073396210 VB O
DNA BC2GM073396210 NNP O
sequencing BC2GM073396210 NN O
. BC2GM073396210 . O
. . O O

Crystals BC2GM015678949 NNS O
of BC2GM015678949 IN O
the BC2GM015678949 DT O
triple BC2GM015678949 JJ O
mutant BC2GM015678949 JJ O
A42D BC2GM015678949 NNP O
/ BC2GM015678949 NNP O
D47P BC2GM015678949 NNP O
/ BC2GM015678949 NNP O
A63L BC2GM015678949 NNP O
, BC2GM015678949 , O
which BC2GM015678949 WDT O
are BC2GM015678949 VBP O
stable BC2GM015678949 JJ O
for BC2GM015678949 IN O
days BC2GM015678949 NNS O
in BC2GM015678949 IN O
its BC2GM015678949 PRP$ O
oxidized BC2GM015678949 JJ O
form BC2GM015678949 NN O
, BC2GM015678949 , O
were BC2GM015678949 VBD O
grown BC2GM015678949 VBN O
from BC2GM015678949 IN O
ammonium BC2GM015678949 NN O
sulfate BC2GM015678949 NN O
, BC2GM015678949 , O
with BC2GM015678949 IN O
the BC2GM015678949 DT O
cell BC2GM015678949 NN O
constants BC2GM015678949 VBZ O
a BC2GM015678949 DT O
= BC2GM015678949 NN O
b BC2GM015678949 NN O
= BC2GM015678949 $ O
34.3 BC2GM015678949 CD O
A BC2GM015678949 NNP O
and BC2GM015678949 CC O
c BC2GM015678949 JJ O
= BC2GM015678949 NN O
111.8 BC2GM015678949 CD O
A BC2GM015678949 NNP O
belonging BC2GM015678949 NN O
to BC2GM015678949 TO O
space BC2GM015678949 NN O
group BC2GM015678949 NN O
P3 BC2GM015678949 NNP O
( BC2GM015678949 ( O
2 BC2GM015678949 CD O
) BC2GM015678949 ) O
21 BC2GM015678949 CD O
. BC2GM015678949 . O
. . O O

Constant BC2GM018910839 JJ O
slowing BC2GM018910839 NN O
of BC2GM018910839 IN O
median BC2GM018910839 JJ O
MNCV BC2GM018910839 NNP O
and BC2GM018910839 CC O
SNCV BC2GM018910839 NNP O
and BC2GM018910839 CC O
ulnar BC2GM018910839 JJ O
SNCV BC2GM018910839 NNP O
without BC2GM018910839 IN O
changes BC2GM018910839 NNS O
in BC2GM018910839 IN O
morphology BC2GM018910839 NN O
, BC2GM018910839 , O
amplitude BC2GM018910839 NN O
and BC2GM018910839 CC O
duration BC2GM018910839 NN O
of BC2GM018910839 IN O
MAP BC2GM018910839 NNP O
and BC2GM018910839 CC O
SAP BC2GM018910839 NNP O
have BC2GM018910839 VBP O
been BC2GM018910839 VBN O
observed BC2GM018910839 VBN O
in BC2GM018910839 IN O
92 BC2GM018910839 CD O
patients BC2GM018910839 NNS O
, BC2GM018910839 , O
with BC2GM018910839 IN O
persistent BC2GM018910839 JJ O
abnormalities BC2GM018910839 NNS O
in BC2GM018910839 IN O
64 BC2GM018910839 CD O
cases BC2GM018910839 NNS O
after BC2GM018910839 IN O
six BC2GM018910839 CD O
months BC2GM018910839 NNS O
. BC2GM018910839 . O
. . O O

A BC2GM033998537 DT O
new BC2GM033998537 JJ O
myocyte-specific BC2GM033998537 JJ O
enhancer-binding BC2GM033998537 JJ O
factor BC2GM033998537 NN O
that BC2GM033998537 WDT O
recognizes BC2GM033998537 VBZ O
a BC2GM033998537 DT O
conserved BC2GM033998537 JJ O
element BC2GM033998537 NN O
associated BC2GM033998537 VBN O
with BC2GM033998537 IN O
multiple BC2GM033998537 JJ O
muscle-specific BC2GM033998537 JJ O
genes BC2GM033998537 NNS O
. BC2GM033998537 . O
. . O O

Rapid BC2GM060431058 NNP O
, BC2GM060431058 , O
sensitive BC2GM060431058 JJ O
gas BC2GM060431058 NN O
chromatographic BC2GM060431058 JJ O
analysis BC2GM060431058 NN O
of BC2GM060431058 IN O
8-methoxypsoralen BC2GM060431058 JJ O
in BC2GM060431058 IN O
human BC2GM060431058 JJ O
plasma BC2GM060431058 NN O
. BC2GM060431058 . O
. . O O

A BC2GM048911038 DT O
personal BC2GM048911038 JJ O
view BC2GM048911038 NN O
of BC2GM048911038 IN O
future BC2GM048911038 JJ O
trends BC2GM048911038 NNS O
in BC2GM048911038 IN O
the BC2GM048911038 DT O
field BC2GM048911038 NN O
of BC2GM048911038 IN O
immunoassay BC2GM048911038 JJ O
concludes BC2GM048911038 NNS O
this BC2GM048911038 DT O
review BC2GM048911038 NN O
. BC2GM048911038 . O
. . O O

In BC2GM086367761 IN O
the BC2GM086367761 DT O
present BC2GM086367761 JJ O
study BC2GM086367761 NN O
we BC2GM086367761 PRP O
use BC2GM086367761 VBP O
a BC2GM086367761 DT O
tnaC-UGA-'lacZ BC2GM086367761 JJ O
construct BC2GM086367761 NN O
lacking BC2GM086367761 VBG O
the BC2GM086367761 DT O
tnaC-tnaA BC2GM086367761 JJ O
spacer BC2GM086367761 NN O
region BC2GM086367761 NN O
to BC2GM086367761 TO O
analyze BC2GM086367761 VB O
the BC2GM086367761 DT O
effect BC2GM086367761 NN O
of BC2GM086367761 IN O
TnaC BC2GM086367761 NNP O
synthesis BC2GM086367761 NN O
on BC2GM086367761 IN O
the BC2GM086367761 DT O
behavior BC2GM086367761 NN O
of BC2GM086367761 IN O
the BC2GM086367761 DT O
ribosome BC2GM086367761 NN O
that BC2GM086367761 WDT O
translates BC2GM086367761 VBZ O
tnaC BC2GM086367761 NNS O
. BC2GM086367761 . O
. . O O

This BC2GM012913597 DT O
C-terminal BC2GM012913597 JJ O
domain BC2GM012913597 NN O
contains BC2GM012913597 NNS O
several BC2GM012913597 JJ O
YxxI BC2GM012913597 NNP O
/ BC2GM012913597 NNP O
L BC2GM012913597 NNP O
motifs BC2GM012913597 FW O
reminiscent BC2GM012913597 NN O
of BC2GM012913597 IN O
LMP2A BC2GM012913597 NNP O
and BC2GM012913597 CC O
a BC2GM012913597 DT O
putative BC2GM012913597 JJ O
TRAF BC2GM012913597 NNP O
binding BC2GM012913597 VBG O
site BC2GM012913597 NN O
as BC2GM012913597 IN O
in BC2GM012913597 IN O
LMP1 BC2GM012913597 NNP O
. BC2GM012913597 . O
. . O O

Reasons BC2GM003313671 NNS O
are BC2GM003313671 VBP O
given BC2GM003313671 VBN O
for BC2GM003313671 IN O
suggesting BC2GM003313671 VBG O
that BC2GM003313671 DT O
tiapamil BC2GM003313671 NN O
warrants BC2GM003313671 NNS O
further BC2GM003313671 RBR O
clinical BC2GM003313671 JJ O
evaluation BC2GM003313671 NN O
, BC2GM003313671 , O
after BC2GM003313671 IN O
which BC2GM003313671 WDT O
it BC2GM003313671 PRP O
may BC2GM003313671 MD O
join BC2GM003313671 VB O
the BC2GM003313671 DT O
more BC2GM003313671 RBR O
established BC2GM003313671 JJ O
calcium BC2GM003313671 NN O
antagonists BC2GM003313671 NNS O
as BC2GM003313671 IN O
a BC2GM003313671 DT O
valuable BC2GM003313671 JJ O
therapeutic BC2GM003313671 JJ O
agent BC2GM003313671 NN O
. BC2GM003313671 . O
. . O O

Current BC2GM003408029 JJ O
body BC2GM003408029 NN O
size BC2GM003408029 NN O
( BC2GM003408029 ( O
wt BC2GM003408029 JJ O
/ BC2GM003408029 NNP O
ht2 BC2GM003408029 NN O
) BC2GM003408029 ) O
was BC2GM003408029 VBD O
significantly BC2GM003408029 RB O
associated BC2GM003408029 VBN O
with BC2GM003408029 IN O
life-time BC2GM003408029 JJ O
weight BC2GM003408029 NN O
dissatisfaction BC2GM003408029 NN O
in BC2GM003408029 IN O
both BC2GM003408029 DT O
sexes BC2GM003408029 NNS O
( BC2GM003408029 ( O
P BC2GM003408029 NNP O
less BC2GM003408029 JJR O
than BC2GM003408029 IN O
0.0005 BC2GM003408029 CD O
) BC2GM003408029 ) O
. BC2GM003408029 . O
. . O O

SATB1 BC2GM067263204 NNP O
interacted BC2GM067263204 VBD O
with BC2GM067263204 IN O
CDP BC2GM067263204 NNP O
through BC2GM067263204 IN O
its BC2GM067263204 PRP$ O
DNA-binding BC2GM067263204 NNP O
domain BC2GM067263204 NN O
, BC2GM067263204 , O
as BC2GM067263204 IN O
demonstrated BC2GM067263204 VBN O
by BC2GM067263204 IN O
glutathione BC2GM067263204 NN O
S-transferase BC2GM067263204 NNP O
( BC2GM067263204 ( O
GST BC2GM067263204 NNP O
) BC2GM067263204 ) O
pull-down BC2GM067263204 JJ O
assays BC2GM067263204 NNS O
. BC2GM067263204 . O
. . O O

The BC2GM080679474 DT O
two BC2GM080679474 CD O
complexes BC2GM080679474 NNS O
were BC2GM080679474 VBD O
detected BC2GM080679474 VBN O
with BC2GM080679474 IN O
a BC2GM080679474 DT O
similar BC2GM080679474 JJ O
activation BC2GM080679474 NN O
kinetics BC2GM080679474 NNS O
upon BC2GM080679474 IN O
IL-4 BC2GM080679474 NNP O
stimulation BC2GM080679474 NN O
. BC2GM080679474 . O
. . O O

The BC2GM069139164 DT O
protein BC2GM069139164 NN O
encoded BC2GM069139164 VBN O
by BC2GM069139164 IN O
the BC2GM069139164 DT O
NF2 BC2GM069139164 NNP O
gene BC2GM069139164 NN O
has BC2GM069139164 VBZ O
a BC2GM069139164 DT O
similarity BC2GM069139164 NN O
to BC2GM069139164 TO O
ezrin BC2GM069139164 VB O
, BC2GM069139164 , O
radixin BC2GM069139164 NN O
and BC2GM069139164 CC O
moesin BC2GM069139164 NN O
( BC2GM069139164 ( O
ERM BC2GM069139164 NNP O
) BC2GM069139164 ) O
proteins BC2GM069139164 VBZ O
that BC2GM069139164 IN O
link BC2GM069139164 NN O
membrane BC2GM069139164 NN O
proteins BC2GM069139164 NNS O
to BC2GM069139164 TO O
the BC2GM069139164 DT O
cytoskeleton BC2GM069139164 NN O
. BC2GM069139164 . O
. . O O

A BC2GM086259287 DT O
method BC2GM086259287 NN O
for BC2GM086259287 IN O
determining BC2GM086259287 VBG O
the BC2GM086259287 DT O
toxicity BC2GM086259287 NN O
of BC2GM086259287 IN O
neutralizers BC2GM086259287 NNS O
for BC2GM086259287 IN O
antimicrobial BC2GM086259287 JJ O
agents BC2GM086259287 NNS O
to BC2GM086259287 TO O
A. BC2GM086259287 NNP O
castellanii BC2GM086259287 NN O
was BC2GM086259287 VBD O
also BC2GM086259287 RB O
evaluated BC2GM086259287 VBN O
. BC2GM086259287 . O
. . O O

Association BC2GM079614007 NNP O
between BC2GM079614007 IN O
diaphragm BC2GM079614007 NN O
use BC2GM079614007 NN O
and BC2GM079614007 CC O
asymptomatic BC2GM079614007 JJ O
bacteriuria BC2GM079614007 NN O
. BC2GM079614007 . O
. . O O

Furthermore BC2GM047759053 RB O
, BC2GM047759053 , O
it BC2GM047759053 PRP O
was BC2GM047759053 VBD O
found BC2GM047759053 VBN O
that BC2GM047759053 IN O
the BC2GM047759053 DT O
Shb-overexpressing BC2GM047759053 NNP O
cells BC2GM047759053 NNS O
extended BC2GM047759053 VBD O
neurites BC2GM047759053 NNS O
in BC2GM047759053 IN O
response BC2GM047759053 NN O
to BC2GM047759053 TO O
epidermal BC2GM047759053 VB O
growth BC2GM047759053 NN O
factor BC2GM047759053 NN O
. BC2GM047759053 . O
. . O O

The BC2GM055940365 DT O
nine BC2GM055940365 CD O
subjects BC2GM055940365 NNS O
were BC2GM055940365 VBD O
treated BC2GM055940365 VBN O
in BC2GM055940365 IN O
random BC2GM055940365 JJ O
sequence BC2GM055940365 NN O
with BC2GM055940365 IN O
cimetidine BC2GM055940365 JJ O
0-8-1-0 BC2GM055940365 JJ O
g BC2GM055940365 NN O
on BC2GM055940365 IN O
one BC2GM055940365 CD O
day BC2GM055940365 NN O
and BC2GM055940365 CC O
placebo BC2GM055940365 NN O
capsules BC2GM055940365 NNS O
on BC2GM055940365 IN O
the BC2GM055940365 DT O
other BC2GM055940365 JJ O
. BC2GM055940365 . O
. . O O

These BC2GM044796005 DT O
data BC2GM044796005 NNS O
demonstrate BC2GM044796005 NN O
that BC2GM044796005 IN O
oleosin BC2GM044796005 VBZ O
gene BC2GM044796005 NN O
transcription BC2GM044796005 NN O
is BC2GM044796005 VBZ O
regulated BC2GM044796005 VBN O
in BC2GM044796005 IN O
a BC2GM044796005 DT O
tissue-specific BC2GM044796005 JJ O
and BC2GM044796005 CC O
temporally BC2GM044796005 RB O
regulated BC2GM044796005 JJ O
manner BC2GM044796005 NN O
and BC2GM044796005 CC O
clearly BC2GM044796005 RB O
indicate BC2GM044796005 VBP O
that BC2GM044796005 IN O
oleosin BC2GM044796005 NN O
protein BC2GM044796005 NN O
expression BC2GM044796005 NN O
is BC2GM044796005 VBZ O
co-ordinated BC2GM044796005 JJ O
primarily BC2GM044796005 RB O
at BC2GM044796005 IN O
the BC2GM044796005 DT O
transcriptional BC2GM044796005 JJ O
level BC2GM044796005 NN O
. BC2GM044796005 . O
. . O O

Intensive BC2GM095085610 JJ O
therapy BC2GM095085610 NN O
of BC2GM095085610 IN O
viral BC2GM095085610 JJ O
hepatitis BC2GM095085610 NN O
. BC2GM095085610 . O
. . O O

A BC2GM057027725 DT O
significant BC2GM057027725 JJ O
and BC2GM057027725 CC O
specific BC2GM057027725 JJ O
reduction BC2GM057027725 NN O
in BC2GM057027725 IN O
binaural BC2GM057027725 JJ O
peak BC2GM057027725 JJ O
amplitude BC2GM057027725 NN O
and BC2GM057027725 CC O
area BC2GM057027725 NN O
of BC2GM057027725 IN O
the BC2GM057027725 DT O
echo-evoked BC2GM057027725 JJ O
middle-latency BC2GM057027725 NN O
component BC2GM057027725 NN O
Pa BC2GM057027725 NNP O
was BC2GM057027725 VBD O
observed BC2GM057027725 VBN O
. BC2GM057027725 . O
. . O O

Divergent BC2GM031391098 NNP O
regions BC2GM031391098 NNS O
of BC2GM031391098 IN O
the BC2GM031391098 DT O
posterior BC2GM031391098 JJ O
left BC2GM031391098 NN O
hemisphere BC2GM031391098 NN O
used BC2GM031391098 VBN O
for BC2GM031391098 IN O
decoding BC2GM031391098 VBG O
and BC2GM031391098 CC O
storage BC2GM031391098 NN O
of BC2GM031391098 IN O
information BC2GM031391098 NN O
emerged BC2GM031391098 VBN O
in BC2GM031391098 IN O
each BC2GM031391098 DT O
working BC2GM031391098 VBG O
memory BC2GM031391098 NN O
versus BC2GM031391098 NN O
control BC2GM031391098 NN O
task BC2GM031391098 NN O
comparison BC2GM031391098 NN O
. BC2GM031391098 . O
. . O O

Serum BC2GM009072433 NNP O
levels BC2GM009072433 NNS O
of BC2GM009072433 IN O
angiotensin BC2GM009072433 NN O
converting BC2GM009072433 VBG O
enzyme BC2GM009072433 NN O
were BC2GM009072433 VBD O
well BC2GM009072433 RB O
maintained BC2GM009072433 VBN O
. BC2GM009072433 . O
. . O O

Processing BC2GM057189560 VBG O
MES BC2GM057189560 NNP O
data BC2GM057189560 NN O
requires BC2GM057189560 VBZ O
large BC2GM057189560 JJ O
bit BC2GM057189560 NN O
manipulations BC2GM057189560 NNS O
and BC2GM057189560 CC O
heavy BC2GM057189560 JJ O
memory BC2GM057189560 NN O
storage BC2GM057189560 NN O
requirements BC2GM057189560 NNS O
. BC2GM057189560 . O
. . O O

99Tcm-labelled BC2GM032189532 JJ O
albumin BC2GM032189532 NN O
colloid BC2GM032189532 NN O
, BC2GM032189532 , O
albures BC2GM032189532 NNS O
( BC2GM032189532 ( O
radius BC2GM032189532 VB O
250 BC2GM032189532 CD O
nm BC2GM032189532 NN O
) BC2GM032189532 ) O
or BC2GM032189532 CC O
nanocoll BC2GM032189532 NN O
( BC2GM032189532 ( O
radius BC2GM032189532 JJ O
25 BC2GM032189532 CD O
nm BC2GM032189532 NN O
) BC2GM032189532 ) O
, BC2GM032189532 , O
or BC2GM032189532 CC O
both BC2GM032189532 CC O
were BC2GM032189532 VBD O
used BC2GM032189532 VBN O
as BC2GM032189532 IN O
test BC2GM032189532 NN O
substances BC2GM032189532 NNS O
to BC2GM032189532 TO O
study BC2GM032189532 VB O
the BC2GM032189532 DT O
kinetics BC2GM032189532 NNS O
of BC2GM032189532 IN O
vascular BC2GM032189532 JJ O
clearance BC2GM032189532 NN O
after BC2GM032189532 IN O
RES BC2GM032189532 NNP O
stimulation BC2GM032189532 NN O
. BC2GM032189532 . O
. . O O

To BC2GM079052068 TO O
our BC2GM079052068 PRP$ O
knowledge BC2GM079052068 NN O
108 BC2GM079052068 CD O
cases BC2GM079052068 NNS O
of BC2GM079052068 IN O
EAT BC2GM079052068 NNP O
treated BC2GM079052068 VBN O
by BC2GM079052068 IN O
catheter BC2GM079052068 JJR O
ablation BC2GM079052068 NN O
of BC2GM079052068 IN O
the BC2GM079052068 DT O
ectopic BC2GM079052068 NN O
focus BC2GM079052068 NN O
are BC2GM079052068 VBP O
reported BC2GM079052068 VBN O
in BC2GM079052068 IN O
the BC2GM079052068 DT O
literature BC2GM079052068 NN O
with BC2GM079052068 IN O
a BC2GM079052068 DT O
success BC2GM079052068 NN O
rate BC2GM079052068 NN O
superior BC2GM079052068 JJ O
to BC2GM079052068 TO O
90 BC2GM079052068 CD O
% BC2GM079052068 NN O
. BC2GM079052068 . O
. . O O

In BC2GM078861237 IN O
contrast BC2GM078861237 NN O
, BC2GM078861237 , O
overexpression BC2GM078861237 NN O
of BC2GM078861237 IN O
the BC2GM078861237 DT O
DREB2A BC2GM078861237 NNP O
cDNA BC2GM078861237 NN O
induced BC2GM078861237 VBD O
weak BC2GM078861237 JJ O
expression BC2GM078861237 NN O
of BC2GM078861237 IN O
the BC2GM078861237 DT O
target BC2GM078861237 NN O
genes BC2GM078861237 NNS O
under BC2GM078861237 IN O
unstressed BC2GM078861237 JJ O
conditions BC2GM078861237 NNS O
and BC2GM078861237 CC O
caused BC2GM078861237 VBD O
growth BC2GM078861237 NN O
retardation BC2GM078861237 NN O
of BC2GM078861237 IN O
the BC2GM078861237 DT O
transgenic BC2GM078861237 JJ O
plants BC2GM078861237 NNS O
. BC2GM078861237 . O
. . O O

Molecular BC2GM071696836 JJ O
analysis BC2GM071696836 NN O
indicated BC2GM071696836 VBD O
that BC2GM071696836 IN O
inactivation BC2GM071696836 NN O
of BC2GM071696836 IN O
H-2L BC2GM071696836 NNP O
expression BC2GM071696836 NN O
in BC2GM071696836 IN O
nearly BC2GM071696836 RB O
every BC2GM071696836 DT O
null BC2GM071696836 NN O
clone BC2GM071696836 NN O
resulted BC2GM071696836 VBD O
from BC2GM071696836 IN O
an BC2GM071696836 DT O
apparent BC2GM071696836 JJ O
deletion BC2GM071696836 NN O
or BC2GM071696836 CC O
rearrangement BC2GM071696836 NN O
of BC2GM071696836 IN O
5'-flanking BC2GM071696836 JJ O
and BC2GM071696836 CC O
5'-coding BC2GM071696836 JJ O
H-2L BC2GM071696836 NNP O
sequences BC2GM071696836 NNS O
, BC2GM071696836 , O
with BC2GM071696836 IN O
breakpoints BC2GM071696836 NNS O
consistently BC2GM071696836 RB O
mapping BC2GM071696836 VBG O
to BC2GM071696836 TO O
within BC2GM071696836 IN O
a BC2GM071696836 DT O
550 BC2GM071696836 CD O
bp BC2GM071696836 NN O
GC-rich BC2GM071696836 JJ O
region BC2GM071696836 NN O
between BC2GM071696836 IN O
exon BC2GM071696836 $ O
1 BC2GM071696836 CD O
and BC2GM071696836 CC O
the BC2GM071696836 DT O
middle BC2GM071696836 NN O
of BC2GM071696836 IN O
intron BC2GM071696836 NN O
2 BC2GM071696836 CD O
. BC2GM071696836 . O
. . O O

Alveoli-capillary BC2GM077346848 JJ O
diffusion BC2GM077346848 NN O
. BC2GM077346848 . O
. . O O

The BC2GM068101333 DT O
protein BC2GM068101333 NN O
kinase BC2GM068101333 VBD O
C BC2GM068101333 NNP O
inhibitor BC2GM068101333 NN O
GF-109203X BC2GM068101333 NNP O
abolished BC2GM068101333 VBD O
the BC2GM068101333 DT O
activation BC2GM068101333 NN O
by BC2GM068101333 IN O
phorbol BC2GM068101333 NN O
ester BC2GM068101333 NN O
and BC2GM068101333 CC O
inhibited BC2GM068101333 VBD O
the BC2GM068101333 DT O
effect BC2GM068101333 NN O
of BC2GM068101333 IN O
CCK BC2GM068101333 NNP O
by BC2GM068101333 IN O
78 BC2GM068101333 CD O
% BC2GM068101333 NN O
but BC2GM068101333 CC O
had BC2GM068101333 VBD O
no BC2GM068101333 DT O
effect BC2GM068101333 NN O
on BC2GM068101333 IN O
EGF-activated BC2GM068101333 JJ O
MAPK BC2GM068101333 NNP O
activity BC2GM068101333 NN O
. BC2GM068101333 . O
. . O O

Polar BC2GM028713807 JJ O
effects BC2GM028713807 NNS O
of BC2GM028713807 IN O
transposon BC2GM028713807 NN O
insertions BC2GM028713807 NNS O
demonstrated BC2GM028713807 VBD O
that BC2GM028713807 IN O
all BC2GM028713807 DT O
of BC2GM028713807 IN O
these BC2GM028713807 DT O
mRNAs BC2GM028713807 NNS O
arose BC2GM028713807 VBP O
from BC2GM028713807 IN O
a BC2GM028713807 DT O
single BC2GM028713807 JJ O
promoter BC2GM028713807 NN O
region BC2GM028713807 NN O
, BC2GM028713807 , O
where BC2GM028713807 WRB O
transcription BC2GM028713807 NN O
initiated BC2GM028713807 VBD O
80 BC2GM028713807 CD O
bp BC2GM028713807 NN O
5 BC2GM028713807 CD O
' BC2GM028713807 '' O
to BC2GM028713807 TO O
nifH BC2GM028713807 VB O
. BC2GM028713807 . O
. . O O

The BC2GM039707957 DT O
zinc BC2GM039707957 NN O
finger BC2GM039707957 NN O
protein BC2GM039707957 NN O
A20 BC2GM039707957 NNP O
is BC2GM039707957 VBZ O
a BC2GM039707957 DT O
tumor BC2GM039707957 NN O
necrosis BC2GM039707957 NN O
factor BC2GM039707957 NN O
( BC2GM039707957 ( O
TNF BC2GM039707957 NNP O
) BC2GM039707957 ) O
- BC2GM039707957 : O
and BC2GM039707957 CC O
interleukin BC2GM039707957 VB O
1 BC2GM039707957 CD O
( BC2GM039707957 ( O
IL-1 BC2GM039707957 NNP O
) BC2GM039707957 ) O
-inducible BC2GM039707957 JJ O
protein BC2GM039707957 NN O
that BC2GM039707957 WDT O
negatively BC2GM039707957 RB O
regulates BC2GM039707957 VBZ O
nuclear BC2GM039707957 JJ O
factor-kappa BC2GM039707957 JJ O
B BC2GM039707957 NNP O
( BC2GM039707957 ( O
NF-kappaB BC2GM039707957 NNP O
) BC2GM039707957 ) O
-dependent BC2GM039707957 NN O
gene BC2GM039707957 NN O
expression BC2GM039707957 NN O
. BC2GM039707957 . O
. . O O

An BC2GM043975609 DT O
alternative BC2GM043975609 JJ O
approach BC2GM043975609 NN O
to BC2GM043975609 TO O
random BC2GM043975609 VB O
integration BC2GM043975609 NN O
of BC2GM043975609 IN O
large BC2GM043975609 JJ O
DNA BC2GM043975609 NNP O
fragments BC2GM043975609 NNS O
into BC2GM043975609 IN O
plants BC2GM043975609 NNS O
is BC2GM043975609 VBZ O
to BC2GM043975609 TO O
utilize BC2GM043975609 VB O
one BC2GM043975609 CD O
of BC2GM043975609 IN O
several BC2GM043975609 JJ O
site-specific BC2GM043975609 JJ O
recombination BC2GM043975609 NN O
( BC2GM043975609 ( O
SSR BC2GM043975609 NNP O
) BC2GM043975609 ) O
systems BC2GM043975609 NNS O
, BC2GM043975609 , O
such BC2GM043975609 JJ O
as BC2GM043975609 IN O
Cre BC2GM043975609 NNP O
/ BC2GM043975609 NNP O
lox BC2GM043975609 NN O
. BC2GM043975609 . O
. . O O

Hamdija BC2GM046248491 NNP O
Karamehmedovic BC2GM046248491 NNP O
; BC2GM046248491 : O
Ibn BC2GM046248491 NNP O
al-Nefis BC2GM046248491 NN O
, BC2GM046248491 , O
`` BC2GM046248491 `` O
Mudzez BC2GM046248491 NNP O
al-Kanum BC2GM046248491 NN O
'' BC2GM046248491 '' O
, BC2GM046248491 , O
Republicki BC2GM046248491 NNP O
zavod BC2GM046248491 NNP O
za BC2GM046248491 NNP O
zdravstvenu BC2GM046248491 NNP O
zastitu BC2GM046248491 NNP O
Sarajevo BC2GM046248491 NNP O
, BC2GM046248491 , O
1961 BC2GM046248491 CD O
, BC2GM046248491 , O
1-219 BC2GM046248491 CD O
; BC2GM046248491 : O
Mr BC2GM046248491 NNP O
ph BC2GM046248491 VBP O
Samuel BC2GM046248491 NNP O
Elazar BC2GM046248491 NNP O
, BC2GM046248491 , O
Ajnija BC2GM046248491 NNP O
Omanic BC2GM046248491 NNP O
: BC2GM046248491 : O
`` BC2GM046248491 `` O
Bibliografija BC2GM046248491 NNP O
medicinskih BC2GM046248491 NN O
djela BC2GM046248491 NN O
u BC2GM046248491 JJ O
SR BC2GM046248491 NNP O
BiH BC2GM046248491 NNP O
do BC2GM046248491 VBP O
1895 BC2GM046248491 CD O
. BC2GM046248491 . O
'' BC2GM046248491 '' O
Medicinska BC2GM046248491 NNP O
knjiga BC2GM046248491 VBD O
Beograd-Zagreb BC2GM046248491 NNP O
1984 BC2GM046248491 CD O
; BC2GM046248491 : O
Besides BC2GM046248491 NNP O
, BC2GM046248491 , O
the BC2GM046248491 DT O
great BC2GM046248491 JJ O
contribution BC2GM046248491 NN O
in BC2GM046248491 IN O
bibliography BC2GM046248491 NN O
was BC2GM046248491 VBD O
given BC2GM046248491 VBN O
by BC2GM046248491 IN O
dr BC2GM046248491 NN O
Lujo BC2GM046248491 NNP O
Taler BC2GM046248491 NNP O
, BC2GM046248491 , O
prof. BC2GM046248491 NN O
dr BC2GM046248491 NN O
. BC2GM046248491 . O
. . O O

The BC2GM055275814 DT O
structural BC2GM055275814 JJ O
intestinal BC2GM055275814 JJ O
defects BC2GM055275814 NNS O
are BC2GM055275814 VBP O
presumed BC2GM055275814 VBN O
to BC2GM055275814 TO O
be BC2GM055275814 VB O
the BC2GM055275814 DT O
result BC2GM055275814 NN O
of BC2GM055275814 IN O
defective BC2GM055275814 JJ O
collagen BC2GM055275814 NN O
synthesis BC2GM055275814 NN O
in BC2GM055275814 IN O
these BC2GM055275814 DT O
hereditary BC2GM055275814 JJ O
connective BC2GM055275814 NN O
tissue BC2GM055275814 NN O
disorders BC2GM055275814 NNS O
. BC2GM055275814 . O
. . O O

When BC2GM014162917 WRB O
gene BC2GM014162917 NN O
conversion BC2GM014162917 NN O
is BC2GM014162917 VBZ O
initiated BC2GM014162917 VBN O
by BC2GM014162917 IN O
a BC2GM014162917 DT O
double-strand BC2GM014162917 JJ O
break BC2GM014162917 NN O
( BC2GM014162917 ( O
DSB BC2GM014162917 NNP O
) BC2GM014162917 ) O
, BC2GM014162917 , O
any BC2GM014162917 DT O
nonhomologous BC2GM014162917 JJ O
DNA BC2GM014162917 NN O
that BC2GM014162917 WDT O
may BC2GM014162917 MD O
be BC2GM014162917 VB O
present BC2GM014162917 JJ O
at BC2GM014162917 IN O
the BC2GM014162917 DT O
ends BC2GM014162917 NNS O
must BC2GM014162917 MD O
be BC2GM014162917 VB O
removed BC2GM014162917 VBN O
before BC2GM014162917 IN O
new BC2GM014162917 JJ O
DNA BC2GM014162917 NNP O
synthesis BC2GM014162917 NN O
can BC2GM014162917 MD O
be BC2GM014162917 VB O
initiated BC2GM014162917 VBN O
. BC2GM014162917 . O
. . O O

Hard BC2GM011268636 NNP O
methacrylic BC2GM011268636 NN O
polymers BC2GM011268636 NNS O
. BC2GM011268636 . O
. . O O

One BC2GM000854272 CD O
patient BC2GM000854272 NN O
exhibited BC2GM000854272 VBD O
a BC2GM000854272 DT O
non-sense BC2GM000854272 JJ O
mutation BC2GM000854272 NN O
( BC2GM000854272 ( O
codon BC2GM000854272 VB O
388 BC2GM000854272 CD O
) BC2GM000854272 ) O
, BC2GM000854272 , O
which BC2GM000854272 WDT O
changed BC2GM000854272 VBD O
a BC2GM000854272 DT O
glutamine BC2GM000854272 NN O
codon BC2GM000854272 NN O
( BC2GM000854272 ( O
CAG BC2GM000854272 NNP O
) BC2GM000854272 ) O
to BC2GM000854272 TO O
a BC2GM000854272 DT O
stop BC2GM000854272 NN O
codon BC2GM000854272 NN O
( BC2GM000854272 ( O
TAG BC2GM000854272 NNP O
) BC2GM000854272 ) O
. BC2GM000854272 . O
. . O O

Here BC2GM001191968 RB O
we BC2GM001191968 PRP O
demonstrate BC2GM001191968 VBP O
that BC2GM001191968 IN O
several BC2GM001191968 JJ O
genes BC2GM001191968 NNS O
associated BC2GM001191968 VBN O
with BC2GM001191968 IN O
NHEJ BC2GM001191968 NNP O
perform BC2GM001191968 VBP O
essential BC2GM001191968 JJ O
functions BC2GM001191968 NNS O
in BC2GM001191968 IN O
the BC2GM001191968 DT O
repair BC2GM001191968 NN O
of BC2GM001191968 IN O
endonuclease-induced BC2GM001191968 JJ O
DSBs BC2GM001191968 NNP O
in BC2GM001191968 IN O
vivo BC2GM001191968 NN O
. BC2GM001191968 . O
. . O O

The BC2GM079654891 DT O
high BC2GM079654891 JJ O
prevalence BC2GM079654891 NN O
of BC2GM079654891 IN O
atrial BC2GM079654891 JJ O
septal BC2GM079654891 JJ O
defect BC2GM079654891 NN O
in BC2GM079654891 IN O
tetralogy BC2GM079654891 NN O
of BC2GM079654891 IN O
Fallot BC2GM079654891 NNP O
is BC2GM079654891 VBZ O
cited BC2GM079654891 VBN O
as BC2GM079654891 IN O
a BC2GM079654891 DT O
possible BC2GM079654891 JJ O
analogy BC2GM079654891 NN O
because BC2GM079654891 IN O
right BC2GM079654891 JJ O
ventricular BC2GM079654891 JJ O
pressure BC2GM079654891 NN O
is BC2GM079654891 VBZ O
high BC2GM079654891 JJ O
and BC2GM079654891 CC O
right BC2GM079654891 JJ O
ventricular BC2GM079654891 NN O
compliance BC2GM079654891 NN O
is BC2GM079654891 VBZ O
low BC2GM079654891 JJ O
from BC2GM079654891 IN O
birth BC2GM079654891 NN O
. BC2GM079654891 . O
. . O O

The BC2GM057768867 DT O
majority BC2GM057768867 NN O
of BC2GM057768867 IN O
these BC2GM057768867 DT O
cells BC2GM057768867 NNS O
were BC2GM057768867 VBD O
also BC2GM057768867 RB O
OKT4 BC2GM057768867 NNP O
positive BC2GM057768867 JJ O
( BC2GM057768867 ( O
helper BC2GM057768867 JJ O
/ BC2GM057768867 NN O
inducer BC2GM057768867 NN O
T BC2GM057768867 NNP O
lymphocytes BC2GM057768867 VBZ O
) BC2GM057768867 ) O
, BC2GM057768867 , O
while BC2GM057768867 IN O
the BC2GM057768867 DT O
minority BC2GM057768867 NN O
were BC2GM057768867 VBD O
OKT8 BC2GM057768867 NNP O
positive BC2GM057768867 JJ O
( BC2GM057768867 ( O
suppressor BC2GM057768867 JJ O
/ BC2GM057768867 NNP O
cytotoxic BC2GM057768867 NN O
T BC2GM057768867 NNP O
lymphocytes BC2GM057768867 VBZ O
) BC2GM057768867 ) O
. BC2GM057768867 . O
. . O O

Embryonal BC2GM008491090 JJ O
mortality BC2GM008491090 NN O
. BC2GM008491090 . O
. . O O

The BC2GM030739462 DT O
transcriptional BC2GM030739462 JJ O
start BC2GM030739462 NN O
site BC2GM030739462 NN O
( BC2GM030739462 ( O
s BC2GM030739462 JJ O
) BC2GM030739462 ) O
of BC2GM030739462 IN O
the BC2GM030739462 DT O
IA-2 BC2GM030739462 NNP O
gene BC2GM030739462 NN O
was BC2GM030739462 VBD O
mapped BC2GM030739462 VBN O
by BC2GM030739462 IN O
5 BC2GM030739462 CD O
' BC2GM030739462 POS O
rapid BC2GM030739462 JJ O
amplification BC2GM030739462 NN O
of BC2GM030739462 IN O
cDNA BC2GM030739462 NN O
ends BC2GM030739462 NNS O
to BC2GM030739462 TO O
97 BC2GM030739462 CD O
bp BC2GM030739462 NN O
upstream BC2GM030739462 NN O
of BC2GM030739462 IN O
the BC2GM030739462 DT O
translational BC2GM030739462 JJ O
start BC2GM030739462 NN O
site BC2GM030739462 NN O
. BC2GM030739462 . O
. . O O

We BC2GM094617831 PRP O
further BC2GM094617831 VBP O
showed BC2GM094617831 VBD O
a BC2GM094617831 DT O
significant BC2GM094617831 JJ O
repression BC2GM094617831 NN O
of BC2GM094617831 IN O
promoter BC2GM094617831 NN O
activity BC2GM094617831 NN O
( BC2GM094617831 ( O
> BC2GM094617831 $ O
40 BC2GM094617831 CD O
fold BC2GM094617831 NN O
) BC2GM094617831 ) O
by BC2GM094617831 IN O
E2-2 BC2GM094617831 NNP O
( BC2GM094617831 ( O
lacking BC2GM094617831 VBG O
the BC2GM094617831 DT O
amino BC2GM094617831 NN O
acid BC2GM094617831 JJ O
sequence BC2GM094617831 NN O
RSRS BC2GM094617831 NNP O
) BC2GM094617831 ) O
when BC2GM094617831 WRB O
the BC2GM094617831 DT O
E47 BC2GM094617831 NNP O
reporter BC2GM094617831 NN O
construct BC2GM094617831 NN O
, BC2GM094617831 , O
containing BC2GM094617831 VBG O
a BC2GM094617831 DT O
hexameric BC2GM094617831 JJ O
E-box BC2GM094617831 NNP O
site BC2GM094617831 NN O
, BC2GM094617831 , O
was BC2GM094617831 VBD O
used BC2GM094617831 VBN O
. BC2GM094617831 . O
. . O O

The BC2GM000493215 DT O
P-ITIM-compelled BC2GM000493215 JJ O
multi-phosphoprotein BC2GM000493215 NN O
complex BC2GM000493215 JJ O
binds BC2GM000493215 NNS O
to BC2GM000493215 TO O
and BC2GM000493215 CC O
activates BC2GM000493215 VBZ O
SHP-2 BC2GM000493215 NNP O
, BC2GM000493215 , O
which BC2GM000493215 WDT O
in BC2GM000493215 IN O
turn BC2GM000493215 NN O
dephosphorylates BC2GM000493215 NNS O
SHIP BC2GM000493215 NNP O
and BC2GM000493215 CC O
Shc BC2GM000493215 NNP O
and BC2GM000493215 CC O
probably BC2GM000493215 RB O
other BC2GM000493215 JJ O
substrates BC2GM000493215 NNS O
. BC2GM000493215 . O
. . O O

Wingless BC2GM007417930 NNP O
/ BC2GM007417930 NNP O
Wnt BC2GM007417930 NNP O
signaling BC2GM007417930 VBG O
directs BC2GM007417930 NNS O
cell-fate BC2GM007417930 JJ O
choices BC2GM007417930 NNS O
during BC2GM007417930 IN O
embryonic BC2GM007417930 JJ O
development BC2GM007417930 NN O
. BC2GM007417930 . O
. . O O

These BC2GM076369923 DT O
data BC2GM076369923 NNS O
indicate BC2GM076369923 VBP O
that BC2GM076369923 IN O
chromatic BC2GM076369923 JJ O
processing BC2GM076369923 NN O
in BC2GM076369923 IN O
areas BC2GM076369923 NNS O
V1 BC2GM076369923 NNP O
and BC2GM076369923 CC O
V2 BC2GM076369923 NNP O
is BC2GM076369923 VBZ O
normal BC2GM076369923 JJ O
after BC2GM076369923 IN O
V4 BC2GM076369923 NNP O
lesions BC2GM076369923 NNS O
and BC2GM076369923 CC O
, BC2GM076369923 , O
together BC2GM076369923 RB O
with BC2GM076369923 IN O
the BC2GM076369923 DT O
behavioural BC2GM076369923 JJ O
evidence BC2GM076369923 NN O
, BC2GM076369923 , O
that BC2GM076369923 IN O
these BC2GM076369923 DT O
areas BC2GM076369923 NNS O
are BC2GM076369923 VBP O
sufficient BC2GM076369923 JJ O
for BC2GM076369923 IN O
some BC2GM076369923 DT O
basic BC2GM076369923 JJ O
aspects BC2GM076369923 NNS O
of BC2GM076369923 IN O
colour BC2GM076369923 JJ O
perception BC2GM076369923 NN O
. BC2GM076369923 . O
. . O O

Detailed BC2GM053319236 JJ O
comparison BC2GM053319236 NN O
of BC2GM053319236 IN O
the BC2GM053319236 DT O
sequences BC2GM053319236 NNS O
of BC2GM053319236 IN O
cp35 BC2GM053319236 NN O
and BC2GM053319236 CC O
human BC2GM053319236 JJ O
calpactin BC2GM053319236 NN O
II BC2GM053319236 NNP O
shows BC2GM053319236 VBZ O
that BC2GM053319236 IN O
the BC2GM053319236 DT O
only BC2GM053319236 JJ O
substantial BC2GM053319236 JJ O
sequence BC2GM053319236 NN O
dissimilarity BC2GM053319236 NN O
is BC2GM053319236 VBZ O
a BC2GM053319236 DT O
domain BC2GM053319236 NN O
encoding BC2GM053319236 VBG O
amino BC2GM053319236 JJ O
acids BC2GM053319236 NNS O
between BC2GM053319236 IN O
residues BC2GM053319236 NNS O
20 BC2GM053319236 CD O
and BC2GM053319236 CC O
40 BC2GM053319236 CD O
which BC2GM053319236 WDT O
includes BC2GM053319236 VBZ O
a BC2GM053319236 DT O
tyrosine BC2GM053319236 JJ O
phosphorylation BC2GM053319236 NN O
site BC2GM053319236 NN O
in BC2GM053319236 IN O
the BC2GM053319236 DT O
human BC2GM053319236 JJ O
molecule BC2GM053319236 NN O
, BC2GM053319236 , O
along BC2GM053319236 IN O
with BC2GM053319236 IN O
other BC2GM053319236 JJ O
residues BC2GM053319236 NNS O
of BC2GM053319236 IN O
possible BC2GM053319236 JJ O
physiological BC2GM053319236 JJ O
significance BC2GM053319236 NN O
. BC2GM053319236 . O
. . O O

In BC2GM096424310 IN O
addition BC2GM096424310 NN O
to BC2GM096424310 TO O
these BC2GM096424310 DT O
cases BC2GM096424310 NNS O
, BC2GM096424310 , O
patients BC2GM096424310 NNS O
w BC2GM096424310 VBP O
with BC2GM096424310 IN O
high BC2GM096424310 JJ O
Loa BC2GM096424310 NNP O
microfilaremia BC2GM096424310 NN O
also BC2GM096424310 RB O
developed BC2GM096424310 VBD O
milder BC2GM096424310 JJR O
neurologic BC2GM096424310 JJ O
manifestations BC2GM096424310 NNS O
causing BC2GM096424310 VBG O
functional BC2GM096424310 JJ O
impairment BC2GM096424310 NN O
lasting BC2GM096424310 VBG O
for BC2GM096424310 IN O
at BC2GM096424310 IN O
least BC2GM096424310 JJS O
one BC2GM096424310 CD O
week BC2GM096424310 NN O
after BC2GM096424310 IN O
treatment BC2GM096424310 NN O
. BC2GM096424310 . O
. . O O

After BC2GM014143125 IN O
discharge BC2GM014143125 NN O
, BC2GM014143125 , O
he BC2GM014143125 PRP O
was BC2GM014143125 VBD O
finally BC2GM014143125 RB O
given BC2GM014143125 VBN O
a BC2GM014143125 DT O
diagnosis BC2GM014143125 NN O
of BC2GM014143125 IN O
PCH BC2GM014143125 NNP O
because BC2GM014143125 IN O
a BC2GM014143125 DT O
Donath-Landsteiner BC2GM014143125 NNP O
test BC2GM014143125 NN O
was BC2GM014143125 VBD O
positive BC2GM014143125 JJ O
. BC2GM014143125 . O
. . O O

Several BC2GM062247998 JJ O
sequences BC2GM062247998 NNS O
resembling BC2GM062247998 VBG O
binding BC2GM062247998 NN O
sites BC2GM062247998 NNS O
for BC2GM062247998 IN O
liver- BC2GM062247998 JJ O
and BC2GM062247998 CC O
fat BC2GM062247998 JJ O
body-specific BC2GM062247998 JJ O
transcription BC2GM062247998 NN O
factors BC2GM062247998 NNS O
were BC2GM062247998 VBD O
identified BC2GM062247998 VBN O
within BC2GM062247998 IN O
1 BC2GM062247998 CD O
kb BC2GM062247998 NNS O
upstream BC2GM062247998 RB O
and BC2GM062247998 CC O
downstream BC2GM062247998 NN O
of BC2GM062247998 IN O
the BC2GM062247998 DT O
gene BC2GM062247998 NN O
. BC2GM062247998 . O
. . O O

The BC2GM075887001 DT O
development BC2GM075887001 NN O
of BC2GM075887001 IN O
various BC2GM075887001 JJ O
pathological BC2GM075887001 JJ O
lesions BC2GM075887001 NNS O
in BC2GM075887001 IN O
thymus BC2GM075887001 NN O
, BC2GM075887001 , O
spleen BC2GM075887001 NN O
, BC2GM075887001 , O
lymph BC2GM075887001 NN O
nodes BC2GM075887001 NNS O
and BC2GM075887001 CC O
bone-marrow BC2GM075887001 NN O
is BC2GM075887001 VBZ O
frequently BC2GM075887001 RB O
observed BC2GM075887001 VBN O
. BC2GM075887001 . O
. . O O

We BC2GM044661165 PRP O
have BC2GM044661165 VBP O
raised BC2GM044661165 VBN O
antibodies BC2GM044661165 NNS O
against BC2GM044661165 IN O
a BC2GM044661165 DT O
peptide BC2GM044661165 NN O
specific BC2GM044661165 NN O
to BC2GM044661165 TO O
the BC2GM044661165 DT O
predicted BC2GM044661165 VBN O
protein BC2GM044661165 NN O
product BC2GM044661165 NN O
of BC2GM044661165 IN O
this BC2GM044661165 DT O
second BC2GM044661165 JJ O
mRNA BC2GM044661165 NN O
. BC2GM044661165 . O
. . O O

He BC2GM069407837 PRP O
had BC2GM069407837 VBD O
complained BC2GM069407837 VBN O
of BC2GM069407837 IN O
fever BC2GM069407837 NN O
and BC2GM069407837 CC O
right BC2GM069407837 JJ O
hypochondralgia BC2GM069407837 NN O
2 BC2GM069407837 CD O
months BC2GM069407837 NNS O
after BC2GM069407837 IN O
being BC2GM069407837 VBG O
operated BC2GM069407837 VBN O
for BC2GM069407837 IN O
appendicitis BC2GM069407837 NN O
. BC2GM069407837 . O
. . O O

The BC2GM006761039 DT O
MIC90 BC2GM006761039 NNP O
of BC2GM006761039 IN O
ABK BC2GM006761039 NNP O
against BC2GM006761039 IN O
coagulase BC2GM006761039 NN O
type BC2GM006761039 NN O
IV BC2GM006761039 NNP O
strains BC2GM006761039 VBZ O
was BC2GM006761039 VBD O
rather BC2GM006761039 RB O
high BC2GM006761039 JJ O
, BC2GM006761039 , O
12.5 BC2GM006761039 CD O
micrograms BC2GM006761039 NNS O
/ BC2GM006761039 JJ O
ml BC2GM006761039 NN O
. BC2GM006761039 . O
. . O O

The BC2GM049253682 DT O
isolation BC2GM049253682 NN O
of BC2GM049253682 IN O
crt5-262 BC2GM049253682 NN O
, BC2GM049253682 , O
an BC2GM049253682 DT O
additional BC2GM049253682 JJ O
cdc BC2GM049253682 NN O
allele BC2GM049253682 NN O
of BC2GM049253682 IN O
POL1 BC2GM049253682 NNP O
/ BC2GM049253682 NNP O
CDC17 BC2GM049253682 NNP O
, BC2GM049253682 , O
suggests BC2GM049253682 VBZ O
for BC2GM049253682 IN O
the BC2GM049253682 DT O
first BC2GM049253682 JJ O
time BC2GM049253682 NN O
that BC2GM049253682 WDT O
directly BC2GM049253682 RB O
blocking BC2GM049253682 VBG O
DNA BC2GM049253682 NNP O
replication BC2GM049253682 NN O
can BC2GM049253682 MD O
provide BC2GM049253682 VB O
a BC2GM049253682 DT O
signal BC2GM049253682 NN O
to BC2GM049253682 TO O
induce BC2GM049253682 VB O
the BC2GM049253682 DT O
DNA BC2GM049253682 NNP O
damage BC2GM049253682 NN O
response BC2GM049253682 NN O
. BC2GM049253682 . O
crt2 BC2GM049253682 NN O
mutants BC2GM049253682 NNS O
show BC2GM049253682 VBP O
a BC2GM049253682 DT O
defect BC2GM049253682 NN O
in BC2GM049253682 IN O
basal BC2GM049253682 JJ O
level BC2GM049253682 JJ O
expression BC2GM049253682 NN O
of BC2GM049253682 IN O
RNR1-lacZ BC2GM049253682 NNP O
reporter BC2GM049253682 NN O
constructs BC2GM049253682 NNS O
. BC2GM049253682 . O
. . O O

The BC2GM027655679 DT O
activation BC2GM027655679 NN O
of BC2GM027655679 IN O
NF-kappaB-dependent BC2GM027655679 NNP O
reporter BC2GM027655679 NN O
gene BC2GM027655679 NN O
transcription BC2GM027655679 NN O
by BC2GM027655679 IN O
E1A BC2GM027655679 NNP O
was BC2GM027655679 VBD O
potently BC2GM027655679 RB O
suppressed BC2GM027655679 VBN O
upon BC2GM027655679 IN O
coexpression BC2GM027655679 NN O
of BC2GM027655679 IN O
the BC2GM027655679 DT O
E1B BC2GM027655679 NNP O
19-kDa BC2GM027655679 JJ O
protein BC2GM027655679 NN O
( BC2GM027655679 ( O
19K BC2GM027655679 CD O
) BC2GM027655679 ) O
. BC2GM027655679 . O
. . O O

The BC2GM055659274 DT O
human BC2GM055659274 JJ O
protein BC2GM055659274 NN O
binds BC2GM055659274 VBZ O
most BC2GM055659274 RBS O
strongly BC2GM055659274 RB O
to BC2GM055659274 TO O
the BC2GM055659274 DT O
SH3 BC2GM055659274 NNP O
domain BC2GM055659274 NN O
from BC2GM055659274 IN O
the BC2GM055659274 DT O
abl BC2GM055659274 JJ O
proto-oncogene BC2GM055659274 NN O
. BC2GM055659274 . O
. . O O

N0 BC2GM000562167 NNP O
disease BC2GM000562167 NN O
is BC2GM000562167 VBZ O
more BC2GM000562167 RBR O
favorable BC2GM000562167 JJ O
than BC2GM000562167 IN O
N1 BC2GM000562167 NNP O
or BC2GM000562167 CC O
N2 BC2GM000562167 NNP O
disease BC2GM000562167 NN O
. BC2GM000562167 . O
. . O O

However BC2GM074224073 RB O
, BC2GM074224073 , O
the BC2GM074224073 DT O
pre3-2 BC2GM074224073 JJ O
mutation BC2GM074224073 NN O
strengthened BC2GM074224073 VBD O
phenotypes BC2GM074224073 NNS O
induced BC2GM074224073 VBN O
by BC2GM074224073 IN O
other BC2GM074224073 JJ O
20 BC2GM074224073 CD O
S BC2GM074224073 NNP O
proteasomal BC2GM074224073 JJ O
mutations BC2GM074224073 NNS O
, BC2GM074224073 , O
indicating BC2GM074224073 VBG O
that BC2GM074224073 IN O
the BC2GM074224073 DT O
peptidylglutamyl BC2GM074224073 JJ O
peptide-hydrolyzing BC2GM074224073 NN O
activity BC2GM074224073 NN O
has BC2GM074224073 VBZ O
to BC2GM074224073 TO O
fulfill BC2GM074224073 VB O
some BC2GM074224073 DT O
rescue BC2GM074224073 NN O
functions BC2GM074224073 NNS O
. BC2GM074224073 . O
. . O O

As BC2GM081842707 IN O
tat BC2GM081842707 JJ O
itself BC2GM081842707 PRP O
dramatically BC2GM081842707 RB O
increases BC2GM081842707 VBZ O
HIV-1 BC2GM081842707 NNP O
gene BC2GM081842707 NN O
expression BC2GM081842707 NN O
, BC2GM081842707 , O
it BC2GM081842707 PRP O
too BC2GM081842707 RB O
is BC2GM081842707 VBZ O
presumably BC2GM081842707 RB O
regulated BC2GM081842707 VBN O
in BC2GM081842707 IN O
the BC2GM081842707 DT O
latent BC2GM081842707 NN O
state BC2GM081842707 NN O
, BC2GM081842707 , O
and BC2GM081842707 CC O
may BC2GM081842707 MD O
also BC2GM081842707 RB O
be BC2GM081842707 VB O
activated BC2GM081842707 VBN O
by BC2GM081842707 IN O
mitogenic BC2GM081842707 JJ O
stimulation BC2GM081842707 NN O
. BC2GM081842707 . O
. . O O

Through BC2GM048702510 IN O
interactions BC2GM048702510 NNS O
with BC2GM048702510 IN O
the BC2GM048702510 DT O
pre-mRNA BC2GM048702510 NN O
and BC2GM048702510 CC O
the BC2GM048702510 DT O
CTD BC2GM048702510 NNP O
domain BC2GM048702510 NN O
of BC2GM048702510 IN O
the BC2GM048702510 DT O
Polymerase BC2GM048702510 NNP O
II BC2GM048702510 NNP O
, BC2GM048702510 , O
SR BC2GM048702510 NNP O
proteins BC2GM048702510 NNS O
have BC2GM048702510 VBP O
been BC2GM048702510 VBN O
shown BC2GM048702510 VBN O
to BC2GM048702510 TO O
regulate BC2GM048702510 VB O
alternative BC2GM048702510 JJ O
splicing BC2GM048702510 NN O
. BC2GM048702510 . O
. . O O

Using BC2GM005461741 VBG O
in BC2GM005461741 IN O
vivo BC2GM005461741 NN O
screening BC2GM005461741 NN O
, BC2GM005461741 , O
we BC2GM005461741 PRP O
first BC2GM005461741 RB O
identified BC2GM005461741 VBD O
a BC2GM005461741 DT O
gene BC2GM005461741 NN O
that BC2GM005461741 WDT O
appeared BC2GM005461741 VBD O
to BC2GM005461741 TO O
interfere BC2GM005461741 VB O
with BC2GM005461741 IN O
the BC2GM005461741 DT O
His-Asp BC2GM005461741 NNP O
phosphorelay BC2GM005461741 NN O
between BC2GM005461741 IN O
the BC2GM005461741 DT O
HPt BC2GM005461741 NNP O
domain BC2GM005461741 NN O
and BC2GM005461741 CC O
the BC2GM005461741 DT O
receiver BC2GM005461741 NN O
domain BC2GM005461741 NN O
of BC2GM005461741 IN O
OmpR BC2GM005461741 NNP O
, BC2GM005461741 , O
provided BC2GM005461741 VBD O
that BC2GM005461741 IN O
the BC2GM005461741 DT O
gene BC2GM005461741 NN O
product BC2GM005461741 NN O
was BC2GM005461741 VBD O
expressed BC2GM005461741 VBN O
through BC2GM005461741 IN O
a BC2GM005461741 DT O
multicopy BC2GM005461741 NN O
plasmid BC2GM005461741 NN O
. BC2GM005461741 . O
. . O O

It BC2GM033119151 PRP O
was BC2GM033119151 VBD O
observed BC2GM033119151 VBN O
that BC2GM033119151 IN O
muscle BC2GM033119151 NN O
infarction BC2GM033119151 NN O
in BC2GM033119151 IN O
the BC2GM033119151 DT O
IPC BC2GM033119151 NNP O
( BC2GM033119151 ( O
24 BC2GM033119151 CD O
+ BC2GM033119151 NN O
/ BC2GM033119151 NNP O
- BC2GM033119151 : O
2 BC2GM033119151 CD O
% BC2GM033119151 NN O
) BC2GM033119151 ) O
and BC2GM033119151 CC O
preischemic BC2GM033119151 JJ O
LMK BC2GM033119151 NNP O
( BC2GM033119151 ( O
21 BC2GM033119151 CD O
+ BC2GM033119151 NN O
/ BC2GM033119151 NNP O
- BC2GM033119151 : O
2 BC2GM033119151 CD O
% BC2GM033119151 NN O
) BC2GM033119151 ) O
groups BC2GM033119151 NNS O
were BC2GM033119151 VBD O
smaller BC2GM033119151 JJR O
( BC2GM033119151 ( O
P BC2GM033119151 NNP O
< BC2GM033119151 NNP O
0.05 BC2GM033119151 CD O
) BC2GM033119151 ) O
than BC2GM033119151 IN O
that BC2GM033119151 DT O
in BC2GM033119151 IN O
the BC2GM033119151 DT O
control BC2GM033119151 NN O
( BC2GM033119151 ( O
42 BC2GM033119151 CD O
+ BC2GM033119151 NN O
/ BC2GM033119151 NNP O
- BC2GM033119151 : O
2 BC2GM033119151 CD O
% BC2GM033119151 NN O
) BC2GM033119151 ) O
. BC2GM033119151 . O
. . O O

A BC2GM080141188 DT O
clinical BC2GM080141188 JJ O
trial BC2GM080141188 NN O
of BC2GM080141188 IN O
a BC2GM080141188 DT O
new BC2GM080141188 JJ O
mitomycin BC2GM080141188 NN O
C BC2GM080141188 NNP O
derivative BC2GM080141188 JJ O
, BC2GM080141188 , O
KW-2083 BC2GM080141188 NNP O
( BC2GM080141188 ( O
7-N- BC2GM080141188 JJ O
( BC2GM080141188 ( O
p-hydroxyphenyl BC2GM080141188 JJ O
) BC2GM080141188 ) O
-mitomycin BC2GM080141188 FW O
C BC2GM080141188 NNP O
) BC2GM080141188 ) O
. BC2GM080141188 . O
. . O O

Non-finger-coding BC2GM041323158 JJ O
modules BC2GM041323158 NNS O
conserved BC2GM041323158 VBN O
among BC2GM041323158 IN O
members BC2GM041323158 NNS O
of BC2GM041323158 IN O
subfamilies BC2GM041323158 NNS O
of BC2GM041323158 IN O
zinc BC2GM041323158 NN O
finger BC2GM041323158 NN O
genes BC2GM041323158 NNS O
have BC2GM041323158 VBP O
been BC2GM041323158 VBN O
described BC2GM041323158 VBN O
in BC2GM041323158 IN O
the BC2GM041323158 DT O
murine BC2GM041323158 NN O
genome BC2GM041323158 NN O
( BC2GM041323158 ( O
finger-associated BC2GM041323158 JJ O
boxes BC2GM041323158 NNS O
, BC2GM041323158 , O
or BC2GM041323158 CC O
FAX BC2GM041323158 NNP O
domain BC2GM041323158 NN O
) BC2GM041323158 ) O
and BC2GM041323158 CC O
the BC2GM041323158 DT O
human BC2GM041323158 JJ O
genome BC2GM041323158 NN O
( BC2GM041323158 ( O
Kruppel-associated BC2GM041323158 JJ O
boxes BC2GM041323158 NNS O
, BC2GM041323158 , O
or BC2GM041323158 CC O
KRAB BC2GM041323158 NNP O
domain BC2GM041323158 NN O
) BC2GM041323158 ) O
. BC2GM041323158 . O
. . O O

O5257 BC2GM041894560 NN O
shows BC2GM041894560 VBZ O
homology BC2GM041894560 NN O
with BC2GM041894560 IN O
the BC2GM041894560 DT O
SAS2 BC2GM041894560 NNP O
protein BC2GM041894560 NN O
and BC2GM041894560 CC O
another BC2GM041894560 DT O
hypothetical BC2GM041894560 JJ O
protein BC2GM041894560 NN O
from BC2GM041894560 IN O
yeast BC2GM041894560 NN O
. BC2GM041894560 . O
. . O O

She BC2GM012154477 PRP O
had BC2GM012154477 VBD O
been BC2GM012154477 VBN O
diagnosed BC2GM012154477 VBN O
with BC2GM012154477 IN O
severe BC2GM012154477 JJ O
aplastic BC2GM012154477 JJ O
anemia BC2GM012154477 NN O
1 BC2GM012154477 CD O
year BC2GM012154477 NN O
previously BC2GM012154477 RB O
and BC2GM012154477 CC O
, BC2GM012154477 , O
while BC2GM012154477 IN O
hospitalized BC2GM012154477 VBN O
, BC2GM012154477 , O
had BC2GM012154477 VBD O
received BC2GM012154477 VBN O
methyl BC2GM012154477 RB O
prednisolone BC2GM012154477 JJ O
pulse BC2GM012154477 JJ O
therapy BC2GM012154477 NN O
, BC2GM012154477 , O
which BC2GM012154477 WDT O
was BC2GM012154477 VBD O
not BC2GM012154477 RB O
successful BC2GM012154477 JJ O
. BC2GM012154477 . O
. . O O

Blood BC2GM087481968 NNP O
ammonia BC2GM087481968 NN O
concentration BC2GM087481968 NN O
was BC2GM087481968 VBD O
significantly BC2GM087481968 RB O
higher BC2GM087481968 JJR O
in BC2GM087481968 IN O
males BC2GM087481968 NNS O
at BC2GM087481968 IN O
70 BC2GM087481968 CD O
, BC2GM087481968 , O
80 BC2GM087481968 CD O
and BC2GM087481968 CC O
90 BC2GM087481968 CD O
% BC2GM087481968 NN O
of BC2GM087481968 IN O
VO2 BC2GM087481968 NNP O
peak BC2GM087481968 NN O
. BC2GM087481968 . O
. . O O

We BC2GM024417394 PRP O
have BC2GM024417394 VBP O
compared BC2GM024417394 VBN O
the BC2GM024417394 DT O
ability BC2GM024417394 NN O
of BC2GM024417394 IN O
GST-Bem3 BC2GM024417394 NNP O
to BC2GM024417394 TO O
serve BC2GM024417394 VB O
as BC2GM024417394 IN O
a BC2GM024417394 DT O
GAP BC2GM024417394 NNP O
for BC2GM024417394 IN O
Cdc42Hs BC2GM024417394 NNP O
relative BC2GM024417394 VBP O
to BC2GM024417394 TO O
other BC2GM024417394 JJ O
members BC2GM024417394 NNS O
of BC2GM024417394 IN O
the BC2GM024417394 DT O
rho-GAP BC2GM024417394 JJ O
subfamily BC2GM024417394 NN O
and BC2GM024417394 CC O
found BC2GM024417394 VBD O
the BC2GM024417394 DT O
following BC2GM024417394 JJ O
order BC2GM024417394 NN O
of BC2GM024417394 IN O
potency BC2GM024417394 NN O
: BC2GM024417394 : O
human BC2GM024417394 JJ O
platelet BC2GM024417394 NN O
Cdc42Hs BC2GM024417394 NNP O
GAP BC2GM024417394 NNP O
> BC2GM024417394 NNP O
p190 BC2GM024417394 NN O
> BC2GM024417394 NNP O
Bem3 BC2GM024417394 NNP O
> BC2GM024417394 NNP O
break BC2GM024417394 NN O
point BC2GM024417394 NN O
cluster BC2GM024417394 NN O
region BC2GM024417394 NN O
protein BC2GM024417394 NN O
, BC2GM024417394 , O
whereas BC2GM024417394 JJ O
p85 BC2GM024417394 NN O
, BC2GM024417394 , O
like BC2GM024417394 IN O
Bem2 BC2GM024417394 NNP O
, BC2GM024417394 , O
shows BC2GM024417394 VBZ O
no BC2GM024417394 DT O
GAP BC2GM024417394 NNP O
activity BC2GM024417394 NN O
or BC2GM024417394 CC O
any BC2GM024417394 DT O
ability BC2GM024417394 NN O
to BC2GM024417394 TO O
bind BC2GM024417394 VB O
to BC2GM024417394 TO O
the BC2GM024417394 DT O
GTP-bound BC2GM024417394 NNP O
form BC2GM024417394 NN O
of BC2GM024417394 IN O
Cdc42Hs BC2GM024417394 NNP O
. BC2GM024417394 . O
. . O O

In BC2GM026322966 IN O
contrast BC2GM026322966 NN O
, BC2GM026322966 , O
MAPK BC2GM026322966 NNP O
activation BC2GM026322966 NN O
stimulated BC2GM026322966 VBN O
by BC2GM026322966 IN O
the BC2GM026322966 DT O
Gq-coupled BC2GM026322966 JJ O
alpha BC2GM026322966 NN O
1B BC2GM026322966 CD O
AR BC2GM026322966 NNP O
or BC2GM026322966 CC O
M1 BC2GM026322966 NNP O
muscarinic BC2GM026322966 JJ O
cholinergic BC2GM026322966 NN O
receptor BC2GM026322966 NN O
is BC2GM026322966 VBZ O
unaffected BC2GM026322966 VBN O
by BC2GM026322966 IN O
expression BC2GM026322966 NN O
of BC2GM026322966 IN O
beta BC2GM026322966 NN O
ARKct BC2GM026322966 NNP O
or BC2GM026322966 CC O
RasN17 BC2GM026322966 NNP O
expression BC2GM026322966 NN O
or BC2GM026322966 CC O
by BC2GM026322966 IN O
PTK BC2GM026322966 NNP O
inhibitors BC2GM026322966 NNS O
, BC2GM026322966 , O
but BC2GM026322966 CC O
is BC2GM026322966 VBZ O
blocked BC2GM026322966 VBN O
by BC2GM026322966 IN O
expression BC2GM026322966 NN O
of BC2GM026322966 IN O
N BC2GM026322966 NNP O
delta BC2GM026322966 NN O
Raf BC2GM026322966 NNP O
or BC2GM026322966 CC O
by BC2GM026322966 IN O
PKC BC2GM026322966 NNP O
depletion BC2GM026322966 NN O
. BC2GM026322966 . O
. . O O

It BC2GM035126404 PRP O
differed BC2GM035126404 VBD O
significantly BC2GM035126404 RB O
by BC2GM035126404 IN O
country BC2GM035126404 NN O
( BC2GM035126404 ( O
from BC2GM035126404 IN O
2.4 BC2GM035126404 CD O
% BC2GM035126404 NN O
in BC2GM035126404 IN O
the BC2GM035126404 DT O
United BC2GM035126404 NNP O
Kingdom BC2GM035126404 NNP O
to BC2GM035126404 TO O
24.7 BC2GM035126404 CD O
% BC2GM035126404 NN O
in BC2GM035126404 IN O
Portugal BC2GM035126404 NNP O
) BC2GM035126404 ) O
and BC2GM035126404 CC O
by BC2GM035126404 IN O
transmission BC2GM035126404 NN O
category BC2GM035126404 NN O
( BC2GM035126404 ( O
2.7 BC2GM035126404 CD O
% BC2GM035126404 NN O
among BC2GM035126404 IN O
homo BC2GM035126404 JJ O
/ BC2GM035126404 JJ O
bisexuals BC2GM035126404 NNS O
, BC2GM035126404 , O
5.8 BC2GM035126404 CD O
% BC2GM035126404 NN O
among BC2GM035126404 IN O
injecting BC2GM035126404 JJ O
drug BC2GM035126404 NN O
users BC2GM035126404 NNS O
, BC2GM035126404 , O
13.6 BC2GM035126404 CD O
% BC2GM035126404 NN O
among BC2GM035126404 IN O
heterosexual BC2GM035126404 JJ O
subgroup BC2GM035126404 NN O
1 BC2GM035126404 CD O
) BC2GM035126404 ) O
. BC2GM035126404 . O
. . O O

Herein BC2GM084752921 NNP O
, BC2GM084752921 , O
we BC2GM084752921 PRP O
report BC2GM084752921 VBP O
that BC2GM084752921 IN O
CRE-decoy BC2GM084752921 NNP O
oligonucleotide BC2GM084752921 MD O
treatment BC2GM084752921 NN O
results BC2GM084752921 NNS O
in BC2GM084752921 IN O
an BC2GM084752921 DT O
increase BC2GM084752921 NN O
in BC2GM084752921 IN O
the BC2GM084752921 DT O
p53 BC2GM084752921 NN O
protein BC2GM084752921 NN O
level BC2GM084752921 NN O
in BC2GM084752921 IN O
MCF-7 BC2GM084752921 NNP O
human BC2GM084752921 JJ O
breast BC2GM084752921 NN O
cancer BC2GM084752921 NN O
cells BC2GM084752921 NNS O
that BC2GM084752921 WDT O
express BC2GM084752921 VBP O
wild-type BC2GM084752921 JJ O
p53 BC2GM084752921 NN O
. BC2GM084752921 . O
. . O O

The BC2GM033411321 DT O
significance BC2GM033411321 NN O
of BC2GM033411321 IN O
these BC2GM033411321 DT O
changes BC2GM033411321 NNS O
in BC2GM033411321 IN O
relation BC2GM033411321 NN O
to BC2GM033411321 TO O
the BC2GM033411321 DT O
control BC2GM033411321 NN O
of BC2GM033411321 IN O
phosphorus BC2GM033411321 NN O
balance BC2GM033411321 NN O
in BC2GM033411321 IN O
ruminants BC2GM033411321 NNS O
is BC2GM033411321 VBZ O
discussed BC2GM033411321 VBN O
. BC2GM033411321 . O
. . O O

Two BC2GM075265710 CD O
conserved BC2GM075265710 VBD O
motifs BC2GM075265710 NNS O
, BC2GM075265710 , O
W89RKRRY94 BC2GM075265710 NNP O
and BC2GM075265710 CC O
P156KKIKP161 BC2GM075265710 NNP O
, BC2GM075265710 , O
seemed BC2GM075265710 VBD O
to BC2GM075265710 TO O
act BC2GM075265710 VB O
as BC2GM075265710 IN O
nuclear BC2GM075265710 JJ O
addressing BC2GM075265710 NN O
signals BC2GM075265710 NNS O
. BC2GM075265710 . O
. . O O

We BC2GM098970669 PRP O
have BC2GM098970669 VBP O
previously BC2GM098970669 RB O
reported BC2GM098970669 VBN O
that BC2GM098970669 IN O
analgesic BC2GM098970669 JJ O
doses BC2GM098970669 NNS O
of BC2GM098970669 IN O
morphine BC2GM098970669 NN O
accelerate BC2GM098970669 NN O
mortality BC2GM098970669 NN O
of BC2GM098970669 IN O
rats BC2GM098970669 NNS O
exposed BC2GM098970669 VBN O
to BC2GM098970669 TO O
hemorrhage BC2GM098970669 VB O
( BC2GM098970669 ( O
Feuerstein BC2GM098970669 NNP O
and BC2GM098970669 CC O
Siren BC2GM098970669 NNP O
: BC2GM098970669 : O
Circ BC2GM098970669 NNP O
Shock BC2GM098970669 NNP O
19:293-300 BC2GM098970669 CD O
, BC2GM098970669 , O
1986 BC2GM098970669 CD O
) BC2GM098970669 ) O
. BC2GM098970669 . O
. . O O

Older BC2GM049538260 JJR O
females BC2GM049538260 NNS O
had BC2GM049538260 VBD O
lumbar BC2GM049538260 NN O
( BC2GM049538260 ( O
0.6 BC2GM049538260 CD O
+ BC2GM049538260 NN O
/ BC2GM049538260 NNP O
- BC2GM049538260 : O
1.3 BC2GM049538260 CD O
) BC2GM049538260 ) O
and BC2GM049538260 CC O
TB BC2GM049538260 NNP O
( BC2GM049538260 ( O
1.1 BC2GM049538260 CD O
+ BC2GM049538260 NN O
/ BC2GM049538260 NNP O
- BC2GM049538260 : O
1.1 BC2GM049538260 CD O
) BC2GM049538260 ) O
BMD BC2GM049538260 NNP O
Z BC2GM049538260 NNP O
scores BC2GM049538260 VBZ O
greater BC2GM049538260 JJR O
than BC2GM049538260 IN O
0 BC2GM049538260 CD O
( BC2GM049538260 ( O
both BC2GM049538260 DT O
, BC2GM049538260 , O
p BC2GM049538260 NN O
< BC2GM049538260 NNP O
0.001 BC2GM049538260 CD O
) BC2GM049538260 ) O
. BC2GM049538260 . O
. . O O

To BC2GM070120777 TO O
clarify BC2GM070120777 VB O
the BC2GM070120777 DT O
difference BC2GM070120777 NN O
, BC2GM070120777 , O
both BC2GM070120777 CC O
the BC2GM070120777 DT O
Crk BC2GM070120777 NNP O
II BC2GM070120777 NNP O
and BC2GM070120777 CC O
Crk BC2GM070120777 NNP O
II-23 BC2GM070120777 NNP O
, BC2GM070120777 , O
proteins BC2GM070120777 NNS O
were BC2GM070120777 VBD O
expressed BC2GM070120777 VBN O
in BC2GM070120777 IN O
E. BC2GM070120777 NNP O
coli BC2GM070120777 NNS O
and BC2GM070120777 CC O
examined BC2GM070120777 VBD O
their BC2GM070120777 PRP$ O
binding BC2GM070120777 NN O
capacity BC2GM070120777 NN O
in BC2GM070120777 IN O
vitro BC2GM070120777 NN O
. BC2GM070120777 . O
. . O O

These BC2GM050442878 DT O
results BC2GM050442878 NNS O
suggest BC2GM050442878 VBP O
that BC2GM050442878 IN O
panretinal BC2GM050442878 JJ O
photocoagulation BC2GM050442878 NN O
offers BC2GM050442878 VBZ O
a BC2GM050442878 DT O
highly BC2GM050442878 RB O
effective BC2GM050442878 JJ O
means BC2GM050442878 NNS O
of BC2GM050442878 IN O
dealing BC2GM050442878 VBG O
with BC2GM050442878 IN O
early BC2GM050442878 JJ O
and BC2GM050442878 CC O
moderately BC2GM050442878 RB O
advanced BC2GM050442878 JJ O
cases BC2GM050442878 NNS O
of BC2GM050442878 IN O
angle BC2GM050442878 JJ O
neovascularization BC2GM050442878 NN O
. BC2GM050442878 . O
. . O O

A BC2GM049586226 DT O
new BC2GM049586226 JJ O
family BC2GM049586226 NN O
of BC2GM049586226 IN O
rate-adaptive BC2GM049586226 JJ O
pacemakers BC2GM049586226 NNS O
accomplishes BC2GM049586226 VBZ O
this BC2GM049586226 DT O
circadian BC2GM049586226 JJ O
rate BC2GM049586226 NN O
variation BC2GM049586226 NN O
by BC2GM049586226 IN O
modeling BC2GM049586226 VBG O
the BC2GM049586226 DT O
patient BC2GM049586226 NN O
's BC2GM049586226 POS O
sleep-wake BC2GM049586226 JJ O
cycle BC2GM049586226 NN O
using BC2GM049586226 VBG O
a BC2GM049586226 DT O
time-of-day BC2GM049586226 JJ O
clock BC2GM049586226 NN O
inside BC2GM049586226 IN O
the BC2GM049586226 DT O
device BC2GM049586226 NN O
. BC2GM049586226 . O
. . O O

After BC2GM067677787 IN O
birth BC2GM067677787 NN O
, BC2GM067677787 , O
there BC2GM067677787 EX O
was BC2GM067677787 VBD O
a BC2GM067677787 DT O
significantly BC2GM067677787 RB O
higher BC2GM067677787 JJR O
increase BC2GM067677787 NN O
of BC2GM067677787 IN O
IgA BC2GM067677787 NNP O
and BC2GM067677787 CC O
IgM BC2GM067677787 NNP O
anti-M. BC2GM067677787 JJ O
leprae BC2GM067677787 NN O
antibody BC2GM067677787 NN O
activity BC2GM067677787 NN O
in BC2GM067677787 IN O
sera BC2GM067677787 NN O
taken BC2GM067677787 VBN O
3-6 BC2GM067677787 JJ O
months BC2GM067677787 NNS O
after BC2GM067677787 IN O
birth BC2GM067677787 NN O
from BC2GM067677787 IN O
babies BC2GM067677787 NNS O
of BC2GM067677787 IN O
Group BC2GM067677787 NNP O
1 BC2GM067677787 CD O
compared BC2GM067677787 VBN O
to BC2GM067677787 TO O
Group BC2GM067677787 NNP O
2 BC2GM067677787 CD O
, BC2GM067677787 , O
but BC2GM067677787 CC O
the BC2GM067677787 DT O
IgA BC2GM067677787 NNP O
and BC2GM067677787 CC O
IgM BC2GM067677787 NNP O
activity BC2GM067677787 NN O
in BC2GM067677787 IN O
sera BC2GM067677787 NN O
taken BC2GM067677787 VBN O
after BC2GM067677787 IN O
6 BC2GM067677787 CD O
months BC2GM067677787 NNS O
of BC2GM067677787 IN O
age BC2GM067677787 NN O
showed BC2GM067677787 VBD O
the BC2GM067677787 DT O
same BC2GM067677787 JJ O
increase BC2GM067677787 NN O
in BC2GM067677787 IN O
the BC2GM067677787 DT O
two BC2GM067677787 CD O
groups BC2GM067677787 NNS O
. BC2GM067677787 . O
. . O O

5'-Deletion BC2GM036047624 NN O
of BC2GM036047624 IN O
the BC2GM036047624 DT O
Stat-binding BC2GM036047624 NNP O
sites BC2GM036047624 NNS O
abolished BC2GM036047624 VBD O
all BC2GM036047624 DT O
promoter-reporter BC2GM036047624 JJ O
activity BC2GM036047624 NN O
in BC2GM036047624 IN O
response BC2GM036047624 NN O
to BC2GM036047624 TO O
PRL BC2GM036047624 NNP O
. BC2GM036047624 . O
. . O O

Anderson BC2GM029899910 NNP O
Hospital BC2GM029899910 NNP O
and BC2GM029899910 CC O
Tumor BC2GM029899910 NNP O
Institute BC2GM029899910 NNP O
at BC2GM029899910 IN O
Houston BC2GM029899910 NNP O
during BC2GM029899910 IN O
a BC2GM029899910 DT O
30-year BC2GM029899910 JJ O
interval BC2GM029899910 NN O
( BC2GM029899910 ( O
1944 BC2GM029899910 CD O
to BC2GM029899910 TO O
1974 BC2GM029899910 CD O
) BC2GM029899910 ) O
, BC2GM029899910 , O
with BC2GM029899910 IN O
a BC2GM029899910 DT O
minimum BC2GM029899910 NN O
of BC2GM029899910 IN O
ten BC2GM029899910 JJ O
years BC2GM029899910 NNS O
of BC2GM029899910 IN O
follow-up BC2GM029899910 JJ O
, BC2GM029899910 , O
we BC2GM029899910 PRP O
determined BC2GM029899910 VBD O
that BC2GM029899910 IN O
the BC2GM029899910 DT O
major BC2GM029899910 JJ O
prognostic BC2GM029899910 JJ O
factor BC2GM029899910 NN O
of BC2GM029899910 IN O
survival BC2GM029899910 NN O
was BC2GM029899910 VBD O
the BC2GM029899910 DT O
number BC2GM029899910 NN O
of BC2GM029899910 IN O
positive BC2GM029899910 JJ O
nodes BC2GM029899910 NNS O
. BC2GM029899910 . O
. . O O

Hetero-oligomerization BC2GM043891105 NN O
of BC2GM043891105 IN O
Smad4 BC2GM043891105 NNP O
with BC2GM043891105 IN O
the BC2GM043891105 DT O
pathway-restricted BC2GM043891105 JJ O
SMAD BC2GM043891105 NNP O
proteins BC2GM043891105 NNS O
is BC2GM043891105 VBZ O
essential BC2GM043891105 JJ O
for BC2GM043891105 IN O
Smad4-mediated BC2GM043891105 JJ O
transcription BC2GM043891105 NN O
. BC2GM043891105 . O
. . O O

Injections BC2GM097368062 NNS O
of BC2GM097368062 IN O
PD BC2GM097368062 NNP O
solutions BC2GM097368062 NNS O
with BC2GM097368062 IN O
13.6 BC2GM097368062 CD O
, BC2GM097368062 , O
22.7 BC2GM097368062 CD O
, BC2GM097368062 , O
and BC2GM097368062 CC O
38.6 BC2GM097368062 CD O
g BC2GM097368062 NN O
/ BC2GM097368062 NNP O
liter BC2GM097368062 NN O
of BC2GM097368062 IN O
glucose BC2GM097368062 NN O
reduced BC2GM097368062 VBD O
the BC2GM097368062 DT O
ingestion BC2GM097368062 NN O
of BC2GM097368062 IN O
sucrose BC2GM097368062 JJ O
by BC2GM097368062 IN O
12.4 BC2GM097368062 CD O
% BC2GM097368062 NN O
, BC2GM097368062 , O
23.6 BC2GM097368062 CD O
% BC2GM097368062 NN O
and BC2GM097368062 CC O
36.1 BC2GM097368062 CD O
% BC2GM097368062 NN O
, BC2GM097368062 , O
respectively BC2GM097368062 RB O
, BC2GM097368062 , O
but BC2GM097368062 CC O
did BC2GM097368062 VBD O
not BC2GM097368062 RB O
affect BC2GM097368062 VB O
the BC2GM097368062 DT O
ingestion BC2GM097368062 NN O
of BC2GM097368062 IN O
protein BC2GM097368062 NN O
. BC2GM097368062 . O
. . O O

Colonization BC2GM076657562 NN O
increased BC2GM076657562 VBD O
with BC2GM076657562 IN O
level BC2GM076657562 NN O
of BC2GM076657562 IN O
care BC2GM076657562 NN O
: BC2GM076657562 : O
from BC2GM076657562 IN O
9 BC2GM076657562 CD O
per BC2GM076657562 IN O
cent BC2GM076657562 NN O
in BC2GM076657562 IN O
independent BC2GM076657562 JJ O
residents BC2GM076657562 NNS O
of BC2GM076657562 IN O
apartments BC2GM076657562 NNS O
to BC2GM076657562 TO O
60 BC2GM076657562 CD O
per BC2GM076657562 IN O
cent BC2GM076657562 NN O
in BC2GM076657562 IN O
patients BC2GM076657562 NNS O
on BC2GM076657562 IN O
an BC2GM076657562 DT O
acute BC2GM076657562 JJ O
hospital BC2GM076657562 NN O
ward BC2GM076657562 NN O
( BC2GM076657562 ( O
P BC2GM076657562 NNP O
less BC2GM076657562 JJR O
than BC2GM076657562 IN O
0.0001 BC2GM076657562 CD O
) BC2GM076657562 ) O
. BC2GM076657562 . O
. . O O

Central-venous-catheter-related BC2GM006849123 JJ O
infection BC2GM006849123 NN O
is BC2GM006849123 VBZ O
readily BC2GM006849123 RB O
diagnosed BC2GM006849123 VBN O
by BC2GM006849123 IN O
comparing BC2GM006849123 VBG O
simultaneous BC2GM006849123 JJ O
quantitative BC2GM006849123 JJ O
cultures BC2GM006849123 NNS O
of BC2GM006849123 IN O
blood BC2GM006849123 NN O
samples BC2GM006849123 NNS O
obtained BC2GM006849123 VBD O
via BC2GM006849123 IN O
the BC2GM006849123 DT O
catheter BC2GM006849123 NN O
and BC2GM006849123 CC O
a BC2GM006849123 DT O
peripheral BC2GM006849123 JJ O
vein BC2GM006849123 NN O
. BC2GM006849123 . O
. . O O

A BC2GM021612626 DT O
trend BC2GM021612626 NN O
was BC2GM021612626 VBD O
observed BC2GM021612626 VBN O
toward BC2GM021612626 IN O
increased BC2GM021612626 VBN O
graft BC2GM021612626 NN O
half-life BC2GM021612626 NN O
in BC2GM021612626 IN O
era BC2GM021612626 NN O
2 BC2GM021612626 CD O
( BC2GM021612626 ( O
p BC2GM021612626 JJ O
= BC2GM021612626 NNP O
NS BC2GM021612626 NNP O
) BC2GM021612626 ) O
. BC2GM021612626 . O
. . O O

Comparing BC2GM032519240 VBG O
the BC2GM032519240 DT O
outcome BC2GM032519240 NN O
of BC2GM032519240 IN O
the BC2GM032519240 DT O
group BC2GM032519240 NN O
having BC2GM032519240 VBG O
histologically BC2GM032519240 RB O
normal BC2GM032519240 JJ O
biopsies BC2GM032519240 NNS O
with BC2GM032519240 IN O
the BC2GM032519240 DT O
group BC2GM032519240 NN O
having BC2GM032519240 VBG O
nonspecifically BC2GM032519240 RB O
abnormal BC2GM032519240 JJ O
ones BC2GM032519240 NNS O
it BC2GM032519240 PRP O
is BC2GM032519240 VBZ O
concluded BC2GM032519240 VBN O
that BC2GM032519240 IN O
frontal BC2GM032519240 JJ O
biopsy BC2GM032519240 NN O
is BC2GM032519240 VBZ O
not BC2GM032519240 RB O
of BC2GM032519240 IN O
such BC2GM032519240 JJ O
high BC2GM032519240 JJ O
prognostic BC2GM032519240 JJ O
value BC2GM032519240 NN O
as BC2GM032519240 IN O
has BC2GM032519240 VBZ O
been BC2GM032519240 VBN O
claimed BC2GM032519240 VBN O
in BC2GM032519240 IN O
previous BC2GM032519240 JJ O
reports BC2GM032519240 NNS O
. BC2GM032519240 . O
. . O O

Free BC2GM020782530 JJ O
protein BC2GM020782530 NN O
S BC2GM020782530 NNP O
deficiency BC2GM020782530 NN O
in BC2GM020782530 IN O
acute BC2GM020782530 JJ O
ischemic BC2GM020782530 JJ O
stroke BC2GM020782530 NN O
. BC2GM020782530 . O
. . O O

The BC2GM050501523 DT O
E. BC2GM050501523 NNP O
multilocularis BC2GM050501523 NNP O
/ BC2GM050501523 NNP O
Mongolian BC2GM050501523 NNP O
gerbil BC2GM050501523 NN O
system BC2GM050501523 NN O
can BC2GM050501523 MD O
replace BC2GM050501523 VB O
the BC2GM050501523 DT O
natural BC2GM050501523 JJ O
canid BC2GM050501523 NN O
hosts BC2GM050501523 NNS O
as BC2GM050501523 IN O
a BC2GM050501523 DT O
new BC2GM050501523 JJ O
way BC2GM050501523 NN O
to BC2GM050501523 TO O
obtain BC2GM050501523 VB O
infective BC2GM050501523 JJ O
eggs BC2GM050501523 NNS O
and BC2GM050501523 CC O
to BC2GM050501523 TO O
analyze BC2GM050501523 VB O
host-parasite BC2GM050501523 JJ O
interactions BC2GM050501523 NNS O
. BC2GM050501523 . O
. . O O

We BC2GM001474754 PRP O
have BC2GM001474754 VBP O
earlier BC2GM001474754 RBR O
proposed BC2GM001474754 VBN O
that BC2GM001474754 IN O
CG BC2GM001474754 NNP O
rich BC2GM001474754 JJ O
sequences BC2GM001474754 NNS O
resembling BC2GM001474754 VBG O
CpG BC2GM001474754 NNP O
islands BC2GM001474754 NNS O
, BC2GM001474754 , O
which BC2GM001474754 WDT O
are BC2GM001474754 VBP O
associated BC2GM001474754 VBN O
with BC2GM001474754 IN O
many BC2GM001474754 JJ O
imprinted BC2GM001474754 VBN O
genes BC2GM001474754 NNS O
and BC2GM001474754 CC O
often BC2GM001474754 RB O
subject BC2GM001474754 JJ O
to BC2GM001474754 TO O
parental-specific BC2GM001474754 JJ O
methylation BC2GM001474754 NN O
, BC2GM001474754 , O
could BC2GM001474754 MD O
act BC2GM001474754 VB O
as BC2GM001474754 IN O
a BC2GM001474754 DT O
common BC2GM001474754 JJ O
imprinting BC2GM001474754 NN O
element BC2GM001474754 NN O
. BC2GM001474754 . O
. . O O

Tetrazepam BC2GM060485652 NN O
: BC2GM060485652 : O
a BC2GM060485652 DT O
benzodiazepine BC2GM060485652 NN O
which BC2GM060485652 WDT O
dissociates BC2GM060485652 VBZ O
sedation BC2GM060485652 NN O
from BC2GM060485652 IN O
other BC2GM060485652 JJ O
benzodiazepine BC2GM060485652 NN O
activities BC2GM060485652 NNS O
. BC2GM060485652 . O
. . O O

Influence BC2GM053712179 NN O
of BC2GM053712179 IN O
huanglian BC2GM053712179 NN O
used BC2GM053712179 VBN O
in BC2GM053712179 IN O
combination BC2GM053712179 NN O
with BC2GM053712179 IN O
huangqin BC2GM053712179 NN O
and BC2GM053712179 CC O
gancao BC2GM053712179 NN O
on BC2GM053712179 IN O
the BC2GM053712179 DT O
erythrocytic BC2GM053712179 JJ O
osmotic BC2GM053712179 JJ O
fragilitas BC2GM053712179 NNS O
of BC2GM053712179 IN O
experimental BC2GM053712179 JJ O
glucose-6-phosphate BC2GM053712179 JJ O
dehydrogenase BC2GM053712179 NN O
deficiency BC2GM053712179 NN O
in BC2GM053712179 IN O
rats BC2GM053712179 NNS O
] BC2GM053712179 VBP O
OBJECTIVE BC2GM053712179 NN O
: BC2GM053712179 : O
To BC2GM053712179 TO O
study BC2GM053712179 VB O
the BC2GM053712179 DT O
influence BC2GM053712179 NN O
of BC2GM053712179 IN O
common BC2GM053712179 JJ O
combination BC2GM053712179 NN O
of BC2GM053712179 IN O
Huanglian BC2GM053712179 NNP O
( BC2GM053712179 ( O
Coptis BC2GM053712179 NNP O
chinensis BC2GM053712179 NN O
) BC2GM053712179 ) O
on BC2GM053712179 IN O
the BC2GM053712179 DT O
erythrocytic BC2GM053712179 JJ O
osmotic BC2GM053712179 JJ O
fragilitas BC2GM053712179 NNS O
of BC2GM053712179 IN O
glucose-6-phosphate BC2GM053712179 JJ O
dehydrogenase BC2GM053712179 NN O
( BC2GM053712179 ( O
G6PD BC2GM053712179 NNP O
) BC2GM053712179 ) O
deficiency BC2GM053712179 NN O
in BC2GM053712179 IN O
rats BC2GM053712179 NNS O
. BC2GM053712179 . O
. . O O

Base BC2GM054770517 NNP O
substitutions BC2GM054770517 NNS O
within BC2GM054770517 IN O
this BC2GM054770517 DT O
NFIL-6 BC2GM054770517 JJ O
site BC2GM054770517 NN O
resulted BC2GM054770517 VBD O
in BC2GM054770517 IN O
virtual BC2GM054770517 JJ O
elimination BC2GM054770517 NN O
of BC2GM054770517 IN O
LPS-induced BC2GM054770517 NNP O
IL-1 BC2GM054770517 NNP O
beta BC2GM054770517 NN O
gene BC2GM054770517 NN O
transcription BC2GM054770517 NN O
. BC2GM054770517 . O
. . O O

This BC2GM074417017 DT O
suggests BC2GM074417017 VBZ O
that BC2GM074417017 IN O
the BC2GM074417017 DT O
duration BC2GM074417017 NN O
of BC2GM074417017 IN O
varicocele BC2GM074417017 FW O
per BC2GM074417017 IN O
se BC2GM074417017 NN O
could BC2GM074417017 MD O
affect BC2GM074417017 VB O
DHT BC2GM074417017 NNP O
seminal BC2GM074417017 JJ O
plasma BC2GM074417017 NN O
levels BC2GM074417017 NNS O
. BC2GM074417017 . O
. . O O

By BC2GM080933132 IN O
contrast BC2GM080933132 NN O
with BC2GM080933132 IN O
ama-1 BC2GM080933132 JJ O
, BC2GM080933132 , O
rpc-1 BC2GM080933132 NN O
was BC2GM080933132 VBD O
not BC2GM080933132 RB O
deleted BC2GM080933132 VBN O
by BC2GM080933132 IN O
mDf4 BC2GM080933132 NN O
or BC2GM080933132 CC O
larger BC2GM080933132 JJR O
deficiencies BC2GM080933132 NNS O
examined BC2GM080933132 VBD O
, BC2GM080933132 , O
indicating BC2GM080933132 VBG O
that BC2GM080933132 IN O
these BC2GM080933132 DT O
genes BC2GM080933132 NNS O
are BC2GM080933132 VBP O
no BC2GM080933132 DT O
closer BC2GM080933132 JJR O
than BC2GM080933132 IN O
150 BC2GM080933132 CD O
kb BC2GM080933132 NN O
. BC2GM080933132 . O
. . O O

Both BC2GM096057654 DT O
atracurium BC2GM096057654 JJ O
1-100 BC2GM096057654 JJ O
mumol BC2GM096057654 NN O
litre-1 BC2GM096057654 NN O
and BC2GM096057654 CC O
laudanosine BC2GM096057654 JJ O
1-50 BC2GM096057654 JJ O
mumol BC2GM096057654 NN O
litre-1 BC2GM096057654 NN O
enhanced BC2GM096057654 VBD O
the BC2GM096057654 DT O
release BC2GM096057654 NN O
of BC2GM096057654 IN O
3H-NA BC2GM096057654 JJ O
evoked BC2GM096057654 VBN O
by BC2GM096057654 IN O
field BC2GM096057654 NN O
stimulation BC2GM096057654 NN O
( BC2GM096057654 ( O
2 BC2GM096057654 CD O
Hz BC2GM096057654 NNP O
, BC2GM096057654 , O
24 BC2GM096057654 CD O
stimuli BC2GM096057654 NN O
) BC2GM096057654 ) O
, BC2GM096057654 , O
but BC2GM096057654 CC O
did BC2GM096057654 VBD O
not BC2GM096057654 RB O
affect BC2GM096057654 VB O
resting BC2GM096057654 VBG O
release BC2GM096057654 NN O
. BC2GM096057654 . O
. . O O

RESULTS BC2GM028996943 NN O
: BC2GM028996943 : O
BMK-1 BC2GM028996943 JJ O
and BC2GM028996943 CC O
other BC2GM028996943 JJ O
19 BC2GM028996943 CD O
contents BC2GM028996943 NNS O
significantly BC2GM028996943 RB O
decreased BC2GM028996943 VBN O
depolarization BC2GM028996943 NN O
parameters BC2GM028996943 NNS O
Vmax BC2GM028996943 NNP O
, BC2GM028996943 , O
APA BC2GM028996943 NNP O
, BC2GM028996943 , O
OS BC2GM028996943 NNP O
, BC2GM028996943 , O
and BC2GM028996943 CC O
MDP BC2GM028996943 NNP O
, BC2GM028996943 , O
which BC2GM028996943 WDT O
was BC2GM028996943 VBD O
similar BC2GM028996943 JJ O
to BC2GM028996943 TO O
that BC2GM028996943 DT O
of BC2GM028996943 IN O
TTX BC2GM028996943 NNP O
and BC2GM028996943 CC O
different BC2GM028996943 JJ O
from BC2GM028996943 IN O
that BC2GM028996943 DT O
of BC2GM028996943 IN O
Nim BC2GM028996943 NNP O
and BC2GM028996943 CC O
BaCl2 BC2GM028996943 NNP O
. BC2GM028996943 . O
. . O O

It BC2GM025329435 PRP O
competes BC2GM025329435 VBZ O
with BC2GM025329435 IN O
the BC2GM025329435 DT O
calcium BC2GM025329435 NN O
ion BC2GM025329435 NN O
which BC2GM025329435 WDT O
brings BC2GM025329435 VBZ O
about BC2GM025329435 IN O
inhibition BC2GM025329435 NN O
of BC2GM025329435 IN O
myosine BC2GM025329435 JJ O
kinase BC2GM025329435 NN O
, BC2GM025329435 , O
and BC2GM025329435 CC O
therefore BC2GM025329435 RB O
a BC2GM025329435 DT O
drop BC2GM025329435 NN O
in BC2GM025329435 IN O
phosphorylated BC2GM025329435 JJ O
myosine BC2GM025329435 NN O
. BC2GM025329435 . O
. . O O

PtdIns BC2GM071680095 NNP O
( BC2GM071680095 ( O
4,5 BC2GM071680095 CD O
) BC2GM071680095 ) O
P2 BC2GM071680095 NNP O
synthesis BC2GM071680095 NN O
, BC2GM071680095 , O
on BC2GM071680095 IN O
the BC2GM071680095 DT O
other BC2GM071680095 JJ O
hand BC2GM071680095 NN O
, BC2GM071680095 , O
is BC2GM071680095 VBZ O
only BC2GM071680095 RB O
moderately BC2GM071680095 RB O
affected BC2GM071680095 VBD O
even BC2GM071680095 RB O
in BC2GM071680095 IN O
fab1Delta BC2GM071680095 JJ O
mutants BC2GM071680095 NNS O
. BC2GM071680095 . O
. . O O

The BC2GM073635511 DT O
organization BC2GM073635511 NN O
of BC2GM073635511 IN O
the BC2GM073635511 DT O
MBP-A BC2GM073635511 NNP O
gene BC2GM073635511 NN O
is BC2GM073635511 VBZ O
very BC2GM073635511 RB O
similar BC2GM073635511 JJ O
to BC2GM073635511 TO O
the BC2GM073635511 DT O
arrangement BC2GM073635511 NN O
of BC2GM073635511 IN O
the BC2GM073635511 DT O
gene BC2GM073635511 NN O
encoding BC2GM073635511 VBG O
the BC2GM073635511 DT O
highly BC2GM073635511 RB O
homologous BC2GM073635511 JJ O
pulmonary BC2GM073635511 JJ O
surfactant BC2GM073635511 NN O
apoprotein BC2GM073635511 NN O
, BC2GM073635511 , O
although BC2GM073635511 IN O
one BC2GM073635511 CD O
of BC2GM073635511 IN O
the BC2GM073635511 DT O
intron BC2GM073635511 NN O
positions BC2GM073635511 NNS O
is BC2GM073635511 VBZ O
shifted BC2GM073635511 VBN O
by BC2GM073635511 IN O
a BC2GM073635511 DT O
single BC2GM073635511 JJ O
amino BC2GM073635511 NN O
acid BC2GM073635511 NN O
. BC2GM073635511 . O
. . O O

To BC2GM002297931 TO O
address BC2GM002297931 VB O
this BC2GM002297931 DT O
question BC2GM002297931 NN O
with BC2GM002297931 IN O
respect BC2GM002297931 NN O
to BC2GM002297931 TO O
skeletal BC2GM002297931 JJ O
muscle BC2GM002297931 NN O
, BC2GM002297931 , O
we BC2GM002297931 PRP O
have BC2GM002297931 VBP O
examined BC2GM002297931 VBN O
the BC2GM002297931 DT O
effects BC2GM002297931 NNS O
of BC2GM002297931 IN O
the BC2GM002297931 DT O
Providence BC2GM002297931 NNP O
mutation BC2GM002297931 NN O
in BC2GM002297931 IN O
cultured BC2GM002297931 JJ O
muscle BC2GM002297931 NN O
cells BC2GM002297931 NNS O
, BC2GM002297931 , O
after BC2GM002297931 IN O
adoptive BC2GM002297931 JJ O
gene BC2GM002297931 NN O
transfer BC2GM002297931 NN O
to BC2GM002297931 TO O
adult BC2GM002297931 VB O
mice BC2GM002297931 NN O
, BC2GM002297931 , O
and BC2GM002297931 CC O
in BC2GM002297931 IN O
two BC2GM002297931 CD O
infants BC2GM002297931 NNS O
homozygous BC2GM002297931 JJ O
for BC2GM002297931 IN O
spectrin BC2GM002297931 JJ O
Providence BC2GM002297931 NNP O
. BC2GM002297931 . O
. . O O

Complexities BC2GM080157820 NNS O
in BC2GM080157820 IN O
the BC2GM080157820 DT O
host-pathogen BC2GM080157820 JJ O
interactions BC2GM080157820 NNS O
during BC2GM080157820 IN O
actual BC2GM080157820 JJ O
infection BC2GM080157820 NN O
with BC2GM080157820 IN O
Gram-negative BC2GM080157820 JJ O
bacteria BC2GM080157820 NNS O
may BC2GM080157820 MD O
account BC2GM080157820 VB O
for BC2GM080157820 IN O
the BC2GM080157820 DT O
difficulties BC2GM080157820 NNS O
in BC2GM080157820 IN O
demonstrating BC2GM080157820 VBG O
this BC2GM080157820 DT O
phenomena BC2GM080157820 NN O
in BC2GM080157820 IN O
vivo BC2GM080157820 NN O
. BC2GM080157820 . O
. . O O

The BC2GM077458624 DT O
cDNA BC2GM077458624 NN O
is BC2GM077458624 VBZ O
predicted BC2GM077458624 VBN O
to BC2GM077458624 TO O
encode BC2GM077458624 VB O
a BC2GM077458624 DT O
polypeptide BC2GM077458624 NN O
of BC2GM077458624 IN O
298 BC2GM077458624 CD O
amino BC2GM077458624 NN O
acids BC2GM077458624 NNS O
that BC2GM077458624 WDT O
is BC2GM077458624 VBZ O
homologous BC2GM077458624 JJ O
to BC2GM077458624 TO O
the BC2GM077458624 DT O
Y-box BC2GM077458624 NNP O
( BC2GM077458624 ( O
inverted BC2GM077458624 VBN O
CCAAT BC2GM077458624 NNP O
) BC2GM077458624 ) O
family BC2GM077458624 NN O
of BC2GM077458624 IN O
DNA-binding BC2GM077458624 NNP O
transcription BC2GM077458624 NN O
factors BC2GM077458624 NNS O
. BC2GM077458624 . O
. . O O

Site-directed BC2GM042292162 JJ O
mutagenesis BC2GM042292162 NN O
was BC2GM042292162 VBD O
conducted BC2GM042292162 VBN O
to BC2GM042292162 TO O
investigate BC2GM042292162 VB O
the BC2GM042292162 DT O
functional BC2GM042292162 JJ O
significance BC2GM042292162 NN O
of BC2GM042292162 IN O
this BC2GM042292162 DT O
element BC2GM042292162 NN O
and BC2GM042292162 CC O
the BC2GM042292162 DT O
3 BC2GM042292162 CD O
' BC2GM042292162 POS O
minus-strand BC2GM042292162 JJ O
terminal BC2GM042292162 JJ O
sequence BC2GM042292162 NN O
`` BC2GM042292162 `` O
3'-OH-CCCUAU BC2GM042292162 JJ O
, BC2GM042292162 , O
'' BC2GM042292162 '' O
which BC2GM042292162 WDT O
contains BC2GM042292162 VBZ O
the BC2GM042292162 DT O
minus-strand BC2GM042292162 JJ O
3'-end BC2GM042292162 JJ O
sequence BC2GM042292162 NN O
`` BC2GM042292162 `` O
3'-OH-CC BC2GM042292162 JJ O
( BC2GM042292162 ( O
1-2 BC2GM042292162 JJ O
) BC2GM042292162 ) O
( BC2GM042292162 ( O
A BC2GM042292162 DT O
/ BC2GM042292162 NNP O
U BC2GM042292162 NNP O
) BC2GM042292162 ) O
( BC2GM042292162 ( O
A BC2GM042292162 DT O
/ BC2GM042292162 NNP O
U BC2GM042292162 NNP O
) BC2GM042292162 ) O
( BC2GM042292162 ( O
A BC2GM042292162 DT O
/ BC2GM042292162 NNP O
U BC2GM042292162 NNP O
) BC2GM042292162 ) O
'' BC2GM042292162 '' O
found BC2GM042292162 VBN O
in BC2GM042292162 IN O
all BC2GM042292162 DT O
carmovirus BC2GM042292162 NN O
RNAs BC2GM042292162 NNP O
. BC2GM042292162 . O
. . O O

Charcot BC2GM084696826 JJ O
joints BC2GM084696826 NNS O
. BC2GM084696826 . O
. . O O

We BC2GM085703128 PRP O
generated BC2GM085703128 VBD O
`` BC2GM085703128 `` O
signature BC2GM085703128 NN O
'' BC2GM085703128 '' O
oligonucleotides BC2GM085703128 NNS O
from BC2GM085703128 IN O
these BC2GM085703128 DT O
CDR3s BC2GM085703128 NNP O
and BC2GM085703128 CC O
probed BC2GM085703128 VBD O
PCR BC2GM085703128 NNP O
amplified BC2GM085703128 VBD O
V BC2GM085703128 NNP O
kappa BC2GM085703128 NN O
products BC2GM085703128 NNS O
from BC2GM085703128 IN O
the BC2GM085703128 DT O
synovium BC2GM085703128 NN O
and BC2GM085703128 CC O
PBLs BC2GM085703128 NNP O
of BC2GM085703128 IN O
the BC2GM085703128 DT O
same BC2GM085703128 JJ O
patient BC2GM085703128 NN O
, BC2GM085703128 , O
and BC2GM085703128 CC O
from BC2GM085703128 IN O
PBLs BC2GM085703128 NNP O
and BC2GM085703128 CC O
spleen BC2GM085703128 NN O
of BC2GM085703128 IN O
individuals BC2GM085703128 NNS O
without BC2GM085703128 IN O
rheumatic BC2GM085703128 JJ O
disease BC2GM085703128 NN O
. BC2GM085703128 . O
. . O O

These BC2GM056030212 DT O
results BC2GM056030212 NNS O
suggest BC2GM056030212 VBP O
that BC2GM056030212 IN O
camptothecin BC2GM056030212 NN O
resistance BC2GM056030212 NN O
in BC2GM056030212 IN O
CEM BC2GM056030212 NNP O
/ BC2GM056030212 NNP O
DOX BC2GM056030212 NNP O
cells BC2GM056030212 NNS O
is BC2GM056030212 VBZ O
due BC2GM056030212 JJ O
to BC2GM056030212 TO O
different BC2GM056030212 JJ O
mechanism BC2GM056030212 NN O
( BC2GM056030212 ( O
s BC2GM056030212 PRP O
) BC2GM056030212 ) O
than BC2GM056030212 IN O
topoisomerase- BC2GM056030212 JJ O
or BC2GM056030212 CC O
P-glycoprotein-associated BC2GM056030212 JJ O
multidrug BC2GM056030212 NN O
resistance BC2GM056030212 NN O
. BC2GM056030212 . O
. . O O

By BC2GM002235510 IN O
applying BC2GM002235510 VBG O
a BC2GM002235510 DT O
sufficiently BC2GM002235510 RB O
strong BC2GM002235510 JJ O
crusher BC2GM002235510 NN O
gradient BC2GM002235510 NN O
in BC2GM002235510 IN O
the BC2GM002235510 DT O
EPI BC2GM002235510 NNP O
pulse BC2GM002235510 NN O
sequence BC2GM002235510 NN O
, BC2GM002235510 , O
the BC2GM002235510 DT O
temporal BC2GM002235510 JJ O
variation BC2GM002235510 NN O
induced BC2GM002235510 VBN O
by BC2GM002235510 IN O
SSFP BC2GM002235510 NNP O
disturbance BC2GM002235510 NN O
can BC2GM002235510 MD O
be BC2GM002235510 VB O
suppressed BC2GM002235510 VBN O
due BC2GM002235510 JJ O
to BC2GM002235510 TO O
diffusion BC2GM002235510 NN O
. BC2GM002235510 . O
. . O O

Exposure BC2GM085810143 NN O
of BC2GM085810143 IN O
raft BC2GM085810143 NN O
cultures BC2GM085810143 NNS O
to BC2GM085810143 TO O
activators BC2GM085810143 NNS O
of BC2GM085810143 IN O
protein BC2GM085810143 JJ O
kinase BC2GM085810143 NN O
C BC2GM085810143 NNP O
, BC2GM085810143 , O
such BC2GM085810143 JJ O
as BC2GM085810143 IN O
phorbol BC2GM085810143 NN O
esters BC2GM085810143 NNS O
, BC2GM085810143 , O
results BC2GM085810143 NNS O
in BC2GM085810143 IN O
the BC2GM085810143 DT O
further BC2GM085810143 JJ O
induction BC2GM085810143 NN O
of BC2GM085810143 IN O
late BC2GM085810143 JJ O
gene BC2GM085810143 NN O
expression BC2GM085810143 NN O
as BC2GM085810143 RB O
well BC2GM085810143 RB O
as BC2GM085810143 IN O
virion BC2GM085810143 NN O
assembly BC2GM085810143 NN O
. BC2GM085810143 . O
. . O O

The BC2GM098002058 DT O
dynamics BC2GM098002058 NNS O
of BC2GM098002058 IN O
N-interaction BC2GM098002058 NNP O
and BC2GM098002058 CC O
N-retention BC2GM098002058 NNP O
during BC2GM098002058 IN O
3 BC2GM098002058 CD O
hr BC2GM098002058 NNS O
CPB BC2GM098002058 NNP O
was BC2GM098002058 VBD O
quantified BC2GM098002058 VBN O
with BC2GM098002058 IN O
autologous BC2GM098002058 JJ O
In-111 BC2GM098002058 NNP O
labeled BC2GM098002058 VBD O
neutrophils BC2GM098002058 NNS O
( BC2GM098002058 ( O
INN BC2GM098002058 NNP O
) BC2GM098002058 ) O
in BC2GM098002058 IN O
4 BC2GM098002058 CD O
groups BC2GM098002058 NNS O
of BC2GM098002058 IN O
20 BC2GM098002058 CD O
Yorkshire BC2GM098002058 NN O
pigs BC2GM098002058 NNS O
( BC2GM098002058 ( O
28-35 BC2GM098002058 JJ O
kg BC2GM098002058 NN O
, BC2GM098002058 , O
5 BC2GM098002058 CD O
sham BC2GM098002058 NN O
; BC2GM098002058 : O
5 BC2GM098002058 CD O
CPB BC2GM098002058 NNP O
, BC2GM098002058 , O
1 BC2GM098002058 CD O
hr BC2GM098002058 NN O
; BC2GM098002058 : O
5 BC2GM098002058 CD O
CPB BC2GM098002058 NNP O
, BC2GM098002058 , O
3 BC2GM098002058 CD O
hr BC2GM098002058 NN O
and BC2GM098002058 CC O
5 BC2GM098002058 CD O
CPB BC2GM098002058 NNP O
with BC2GM098002058 IN O
heparinized BC2GM098002058 JJ O
circuit BC2GM098002058 NN O
, BC2GM098002058 , O
3 BC2GM098002058 CD O
hr BC2GM098002058 NN O
) BC2GM098002058 ) O
; BC2GM098002058 : O
anesthetized BC2GM098002058 VBN O
pigs BC2GM098002058 NNS O
were BC2GM098002058 VBD O
injected BC2GM098002058 VBN O
with BC2GM098002058 IN O
INN BC2GM098002058 NNP O
( BC2GM098002058 ( O
500-650 BC2GM098002058 JJ O
microCi BC2GM098002058 NN O
) BC2GM098002058 ) O
, BC2GM098002058 , O
30 BC2GM098002058 CD O
min BC2GM098002058 NN O
before BC2GM098002058 IN O
CPB BC2GM098002058 NNP O
and BC2GM098002058 CC O
heparinized BC2GM098002058 VBN O
, BC2GM098002058 , O
and BC2GM098002058 CC O
underwent BC2GM098002058 JJ O
CPB BC2GM098002058 NNP O
with BC2GM098002058 IN O
a BC2GM098002058 DT O
roller BC2GM098002058 NN O
pump BC2GM098002058 NN O
, BC2GM098002058 , O
a BC2GM098002058 DT O
hollow BC2GM098002058 JJ O
fiber BC2GM098002058 NN O
OX BC2GM098002058 NNP O
( BC2GM098002058 ( O
Bentley BC2GM098002058 NNP O
CM BC2GM098002058 NNP O
50 BC2GM098002058 CD O
, BC2GM098002058 , O
5.0 BC2GM098002058 CD O
m2 BC2GM098002058 NN O
) BC2GM098002058 ) O
and BC2GM098002058 CC O
AF BC2GM098002058 NNP O
( BC2GM098002058 ( O
Bentley BC2GM098002058 NNP O
AF BC2GM098002058 NNP O
025 BC2GM098002058 CD O
, BC2GM098002058 , O
0.25 BC2GM098002058 CD O
m2 BC2GM098002058 NN O
) BC2GM098002058 ) O
at BC2GM098002058 IN O
2.5-3.6 BC2GM098002058 JJ O
l BC2GM098002058 NN O
/ BC2GM098002058 NNP O
min BC2GM098002058 NN O
for BC2GM098002058 IN O
3 BC2GM098002058 CD O
hr BC2GM098002058 NN O
. BC2GM098002058 . O
. . O O

Despite BC2GM067117543 IN O
these BC2GM067117543 DT O
high BC2GM067117543 JJ O
initial BC2GM067117543 JJ O
rates BC2GM067117543 NNS O
of BC2GM067117543 IN O
transcription BC2GM067117543 NN O
, BC2GM067117543 , O
of BC2GM067117543 IN O
all BC2GM067117543 PDT O
the BC2GM067117543 DT O
promoter BC2GM067117543 NN O
constructs BC2GM067117543 VBZ O
only BC2GM067117543 RB O
LAT-LTR BC2GM067117543 NNP O
was BC2GM067117543 VBD O
able BC2GM067117543 JJ O
to BC2GM067117543 TO O
remain BC2GM067117543 VB O
transcriptionally BC2GM067117543 RB O
active BC2GM067117543 JJ O
after BC2GM067117543 IN O
the BC2GM067117543 DT O
establishment BC2GM067117543 NN O
of BC2GM067117543 IN O
a BC2GM067117543 DT O
latent BC2GM067117543 JJ O
state BC2GM067117543 NN O
. BC2GM067117543 . O
. . O O

The BC2GM039075708 DT O
secondary BC2GM039075708 JJ O
end BC2GM039075708 NN O
points BC2GM039075708 NNS O
included BC2GM039075708 VBD O
creatine BC2GM039075708 JJ O
kinase BC2GM039075708 NN O
peak BC2GM039075708 NN O
, BC2GM039075708 , O
ventricular BC2GM039075708 JJ O
fibrillation BC2GM039075708 NN O
/ BC2GM039075708 NNP O
tachycardia BC2GM039075708 NN O
within BC2GM039075708 IN O
the BC2GM039075708 DT O
first BC2GM039075708 JJ O
24 BC2GM039075708 CD O
hours BC2GM039075708 NNS O
, BC2GM039075708 , O
death BC2GM039075708 NN O
and BC2GM039075708 CC O
congestive BC2GM039075708 JJ O
heart BC2GM039075708 NN O
failure BC2GM039075708 NN O
within BC2GM039075708 IN O
the BC2GM039075708 DT O
30-day BC2GM039075708 JJ O
follow-up BC2GM039075708 NN O
, BC2GM039075708 , O
and BC2GM039075708 CC O
30-day BC2GM039075708 JJ O
left BC2GM039075708 NN O
ventricular BC2GM039075708 JJ O
ejection BC2GM039075708 NN O
fraction BC2GM039075708 NN O
. BC2GM039075708 . O
. . O O

Possible BC2GM022896971 JJ O
consequences BC2GM022896971 NNS O
of BC2GM022896971 IN O
such BC2GM022896971 JJ O
binder BC2GM022896971 NN O
distribution BC2GM022896971 NN O
through BC2GM022896971 IN O
powder BC2GM022896971 NN O
aggregates BC2GM022896971 NNS O
are BC2GM022896971 VBP O
discussed BC2GM022896971 VBN O
. BC2GM022896971 . O
. . O O

Viral BC2GM048306473 NNP O
complementary BC2GM048306473 JJ O
15 BC2GM048306473 CD O
S BC2GM048306473 NNP O
mRNA BC2GM048306473 NN O
that BC2GM048306473 WDT O
directs BC2GM048306473 VBZ O
the BC2GM048306473 DT O
synthesis BC2GM048306473 NN O
of BC2GM048306473 IN O
N BC2GM048306473 NNP O
protein BC2GM048306473 NN O
and BC2GM048306473 CC O
hybridizes BC2GM048306473 VBZ O
to BC2GM048306473 TO O
the BC2GM048306473 DT O
predicted BC2GM048306473 VBN O
N BC2GM048306473 NNP O
gene BC2GM048306473 NN O
DNA BC2GM048306473 NNP O
has BC2GM048306473 VBZ O
been BC2GM048306473 VBN O
identified BC2GM048306473 VBN O
in BC2GM048306473 IN O
infected BC2GM048306473 JJ O
cell BC2GM048306473 NN O
extracts BC2GM048306473 NNS O
. BC2GM048306473 . O
. . O O

In BC2GM073514147 IN O
Cos BC2GM073514147 NNP O
7 BC2GM073514147 CD O
cells BC2GM073514147 NNS O
transfected BC2GM073514147 VBN O
with BC2GM073514147 IN O
oCRF1var BC2GM073514147 NN O
, BC2GM073514147 , O
cAMP BC2GM073514147 JJ O
accumulation BC2GM073514147 NN O
was BC2GM073514147 VBD O
only BC2GM073514147 RB O
observed BC2GM073514147 VBN O
at BC2GM073514147 IN O
the BC2GM073514147 DT O
highest BC2GM073514147 JJS O
concentration BC2GM073514147 NN O
of BC2GM073514147 IN O
oCRF BC2GM073514147 JJ O
utilized BC2GM073514147 JJ O
( BC2GM073514147 ( O
100 BC2GM073514147 CD O
nM BC2GM073514147 NN O
) BC2GM073514147 ) O
. BC2GM073514147 . O
. . O O

The BC2GM039343812 DT O
expression BC2GM039343812 NN O
of BC2GM039343812 IN O
Scmh1 BC2GM039343812 NNP O
and BC2GM039343812 CC O
rae28 BC2GM039343812 VB O
/ BC2GM039343812 NNP O
mph1 BC2GM039343812 NN O
is BC2GM039343812 VBZ O
well BC2GM039343812 RB O
correlated BC2GM039343812 VBN O
in BC2GM039343812 IN O
most BC2GM039343812 JJS O
tissues BC2GM039343812 NNS O
of BC2GM039343812 IN O
embryos BC2GM039343812 NN O
. BC2GM039343812 . O
. . O O

Effects BC2GM008214727 NNS O
of BC2GM008214727 IN O
long-term BC2GM008214727 JJ O
use BC2GM008214727 NN O
of BC2GM008214727 IN O
raloxifene BC2GM008214727 NN O
, BC2GM008214727 , O
a BC2GM008214727 DT O
selective BC2GM008214727 JJ O
estrogen BC2GM008214727 NN O
receptor BC2GM008214727 NN O
modulator BC2GM008214727 NN O
, BC2GM008214727 , O
on BC2GM008214727 IN O
thyroid BC2GM008214727 JJ O
function BC2GM008214727 NN O
test BC2GM008214727 NN O
profiles BC2GM008214727 NNS O
. BC2GM008214727 . O
. . O O

Ultrastructure BC2GM055762789 NN O
and BC2GM055762789 CC O
toxin BC2GM055762789 NN O
formation BC2GM055762789 NN O
of BC2GM055762789 IN O
Cor BC2GM055762789 NNP O
. BC2GM055762789 . O
diphtheriae BC2GM055762789 JJ O
PW-8 BC2GM055762789 NNP O
cultured BC2GM055762789 VBD O
in BC2GM055762789 IN O
the BC2GM055762789 DT O
presence BC2GM055762789 NN O
of BC2GM055762789 IN O
penicillin BC2GM055762789 NN O
. BC2GM055762789 . O
. . O O

This BC2GM084929620 DT O
article BC2GM084929620 NN O
reviews BC2GM084929620 VBZ O
current BC2GM084929620 JJ O
concepts BC2GM084929620 NNS O
of BC2GM084929620 IN O
pathophysiology BC2GM084929620 NN O
and BC2GM084929620 CC O
summarises BC2GM084929620 VBZ O
clinical BC2GM084929620 JJ O
features BC2GM084929620 NNS O
, BC2GM084929620 , O
natural BC2GM084929620 JJ O
history BC2GM084929620 NN O
and BC2GM084929620 CC O
available BC2GM084929620 JJ O
treatments BC2GM084929620 NNS O
. BC2GM084929620 . O
. . O O

Cloning BC2GM098014583 NN O
of BC2GM098014583 IN O
the BC2GM098014583 DT O
GATA-binding BC2GM098014583 NNP O
protein BC2GM098014583 NN O
that BC2GM098014583 WDT O
regulates BC2GM098014583 VBZ O
endothelin-1 BC2GM098014583 JJ O
gene BC2GM098014583 NN O
expression BC2GM098014583 NN O
in BC2GM098014583 IN O
endothelial BC2GM098014583 JJ O
cells BC2GM098014583 NNS O
. BC2GM098014583 . O
. . O O

Here BC2GM008819696 RB O
, BC2GM008819696 , O
we BC2GM008819696 PRP O
describe BC2GM008819696 VBP O
the BC2GM008819696 DT O
three-dimensional BC2GM008819696 JJ O
structure BC2GM008819696 NN O
of BC2GM008819696 IN O
the BC2GM008819696 DT O
enzyme BC2GM008819696 NN O
from BC2GM008819696 IN O
Escherichia BC2GM008819696 NNP O
colidetermined BC2GM008819696 VBD O
and BC2GM008819696 CC O
refined BC2GM008819696 VBD O
to BC2GM008819696 TO O
2.0 BC2GM008819696 CD O
A BC2GM008819696 DT O
resolution BC2GM008819696 NN O
. BC2GM008819696 . O
. . O O

A BC2GM090138510 DT O
40-fold BC2GM090138510 JJ O
stimulation BC2GM090138510 NN O
of BC2GM090138510 IN O
chloramphenicol BC2GM090138510 JJ O
acetyltransferase BC2GM090138510 NN O
activity BC2GM090138510 NN O
mediated BC2GM090138510 VBN O
by BC2GM090138510 IN O
four BC2GM090138510 CD O
tandem BC2GM090138510 NN O
repeats BC2GM090138510 NNS O
of BC2GM090138510 IN O
the BC2GM090138510 DT O
SNE BC2GM090138510 NNP O
could BC2GM090138510 MD O
be BC2GM090138510 VB O
induced BC2GM090138510 VBN O
within BC2GM090138510 IN O
2 BC2GM090138510 CD O
h BC2GM090138510 NN O
( BC2GM090138510 ( O
and BC2GM090138510 CC O
up BC2GM090138510 RB O
to BC2GM090138510 TO O
250-fold BC2GM090138510 JJ O
within BC2GM090138510 IN O
6 BC2GM090138510 CD O
h BC2GM090138510 NN O
) BC2GM090138510 ) O
after BC2GM090138510 IN O
addition BC2GM090138510 NN O
of BC2GM090138510 IN O
TPA BC2GM090138510 NNP O
in BC2GM090138510 IN O
DNA-transfected BC2GM090138510 NNP O
U-937 BC2GM090138510 NNP O
cells BC2GM090138510 NNS O
, BC2GM090138510 , O
indicating BC2GM090138510 VBG O
that BC2GM090138510 IN O
the BC2GM090138510 DT O
stimulation BC2GM090138510 NN O
appeared BC2GM090138510 VBD O
likely BC2GM090138510 JJ O
to BC2GM090138510 TO O
be BC2GM090138510 VB O
a BC2GM090138510 DT O
true BC2GM090138510 JJ O
protein BC2GM090138510 NN O
kinase BC2GM090138510 VBD O
C-mediated BC2GM090138510 JJ O
signal BC2GM090138510 JJ O
transduction BC2GM090138510 NN O
event BC2GM090138510 NN O
rather BC2GM090138510 RB O
than BC2GM090138510 IN O
a BC2GM090138510 DT O
differentiation BC2GM090138510 NN O
response BC2GM090138510 NN O
. BC2GM090138510 . O
. . O O

Studies BC2GM069902375 NNS O
on BC2GM069902375 IN O
the BC2GM069902375 DT O
excretion BC2GM069902375 NN O
of BC2GM069902375 IN O
selenium BC2GM069902375 NN O
in BC2GM069902375 IN O
urine BC2GM069902375 JJ O
and BC2GM069902375 CC O
feces BC2GM069902375 NNS O
and BC2GM069902375 CC O
distribution BC2GM069902375 NN O
in BC2GM069902375 IN O
the BC2GM069902375 DT O
organs BC2GM069902375 NNS O
of BC2GM069902375 IN O
rats BC2GM069902375 NNS O
by BC2GM069902375 IN O
a BC2GM069902375 DT O
method BC2GM069902375 NN O
of BC2GM069902375 IN O
radioactivity BC2GM069902375 NN O
measurement BC2GM069902375 NN O
. BC2GM069902375 . O
. . O O

The BC2GM001205480 DT O
primary BC2GM001205480 JJ O
structure BC2GM001205480 NN O
of BC2GM001205480 IN O
cholesterol BC2GM001205480 NN O
esterase BC2GM001205480 NN O
displayed BC2GM001205480 VBD O
no BC2GM001205480 DT O
significant BC2GM001205480 JJ O
homology BC2GM001205480 NN O
with BC2GM001205480 IN O
other BC2GM001205480 JJ O
lipases BC2GM001205480 NNS O
, BC2GM001205480 , O
although BC2GM001205480 IN O
the BC2GM001205480 DT O
putative BC2GM001205480 JJ O
lipid BC2GM001205480 JJ O
interfacial BC2GM001205480 JJ O
recognition BC2GM001205480 NN O
site BC2GM001205480 NN O
of BC2GM001205480 IN O
G-X-S-X-G BC2GM001205480 NNP O
is BC2GM001205480 VBZ O
present BC2GM001205480 JJ O
in BC2GM001205480 IN O
the BC2GM001205480 DT O
cholesterol BC2GM001205480 NN O
esterase BC2GM001205480 NN O
sequence BC2GM001205480 NN O
. BC2GM001205480 . O
. . O O

To BC2GM019723956 TO O
assess BC2GM019723956 VB O
whether BC2GM019723956 IN O
thallium-201 BC2GM019723956 JJ O
thallous BC2GM019723956 JJ O
chloride BC2GM019723956 NN O
( BC2GM019723956 ( O
Tl BC2GM019723956 NNP O
) BC2GM019723956 ) O
can BC2GM019723956 MD O
detect BC2GM019723956 VB O
childhood BC2GM019723956 NN O
tumors BC2GM019723956 NNS O
and BC2GM019723956 CC O
whether BC2GM019723956 IN O
diagnostic BC2GM019723956 JJ O
effectiveness BC2GM019723956 NN O
improves BC2GM019723956 VBZ O
with BC2GM019723956 IN O
combined BC2GM019723956 JJ O
blood BC2GM019723956 NN O
flow BC2GM019723956 NN O
imaging BC2GM019723956 NN O
, BC2GM019723956 , O
28 BC2GM019723956 CD O
children BC2GM019723956 NNS O
( BC2GM019723956 ( O
1.0-18.6 BC2GM019723956 CD O
years BC2GM019723956 NNS O
) BC2GM019723956 ) O
were BC2GM019723956 VBD O
studied BC2GM019723956 VBN O
using BC2GM019723956 VBG O
single BC2GM019723956 JJ O
photon BC2GM019723956 NN O
emission BC2GM019723956 NN O
computed BC2GM019723956 VBN O
tomography BC2GM019723956 NN O
( BC2GM019723956 ( O
SPECT BC2GM019723956 NNP O
) BC2GM019723956 ) O
: BC2GM019723956 : O
Tl BC2GM019723956 NN O
( BC2GM019723956 ( O
1.3-1.8 BC2GM019723956 JJ O
mCi BC2GM019723956 NN O
intravenously BC2GM019723956 RB O
) BC2GM019723956 ) O
, BC2GM019723956 , O
followed BC2GM019723956 VBD O
in BC2GM019723956 IN O
13 BC2GM019723956 CD O
of BC2GM019723956 IN O
the BC2GM019723956 DT O
patients BC2GM019723956 NNS O
by BC2GM019723956 IN O
technetium-99m-hexamethylpropyleneamine BC2GM019723956 JJ O
oxime BC2GM019723956 NN O
( BC2GM019723956 ( O
99mTc-HMPAO BC2GM019723956 CD O
; BC2GM019723956 : O
8-18 BC2GM019723956 CD O
mCi BC2GM019723956 NNS O
intravenously BC2GM019723956 RB O
) BC2GM019723956 ) O
. BC2GM019723956 . O
. . O O

BCV BC2GM057843919 NNP O
mRNAs BC2GM057843919 VBD O
5 BC2GM057843919 CD O
and BC2GM057843919 CC O
5-1 BC2GM057843919 JJ O
appear BC2GM057843919 NN O
to BC2GM057843919 TO O
be BC2GM057843919 VB O
used BC2GM057843919 VBN O
for BC2GM057843919 IN O
the BC2GM057843919 DT O
synthesis BC2GM057843919 NN O
of BC2GM057843919 IN O
the BC2GM057843919 DT O
12.7- BC2GM057843919 JJ O
and BC2GM057843919 CC O
9.5-kDa BC2GM057843919 JJ O
proteins BC2GM057843919 NNS O
, BC2GM057843919 , O
respectively BC2GM057843919 RB O
, BC2GM057843919 , O
which BC2GM057843919 WDT O
demonstrates BC2GM057843919 VBZ O
a BC2GM057843919 DT O
pattern BC2GM057843919 NN O
of BC2GM057843919 IN O
expression BC2GM057843919 NN O
strikingly BC2GM057843919 RB O
different BC2GM057843919 JJ O
from BC2GM057843919 IN O
that BC2GM057843919 DT O
utilized BC2GM057843919 VBN O
by BC2GM057843919 IN O
MHV BC2GM057843919 NNP O
. BC2GM057843919 . O
. . O O

Vancomycin BC2GM070993491 NNP O
and BC2GM070993491 CC O
tetracycline BC2GM070993491 NN O
eliminated BC2GM070993491 VBN O
toxin BC2GM070993491 NN O
in BC2GM070993491 IN O
stools BC2GM070993491 NNS O
and BC2GM070993491 CC O
delayed BC2GM070993491 VBN O
death BC2GM070993491 NN O
. BC2GM070993491 . O
. . O O

However BC2GM071282561 RB O
, BC2GM071282561 , O
the BC2GM071282561 DT O
MCMI-III BC2GM071282561 NNP O
group BC2GM071282561 NN O
profile BC2GM071282561 NN O
was BC2GM071282561 VBD O
significantly BC2GM071282561 RB O
lower BC2GM071282561 JJR O
in BC2GM071282561 IN O
magnitude BC2GM071282561 NN O
compared BC2GM071282561 VBN O
with BC2GM071282561 IN O
the BC2GM071282561 DT O
MCMI-II BC2GM071282561 NNP O
. BC2GM071282561 . O
. . O O

Interobserver BC2GM077422273 NNP O
agreement BC2GM077422273 NN O
of BC2GM077422273 IN O
the BC2GM077422273 DT O
Nottingham BC2GM077422273 NNP O
histologic BC2GM077422273 NN O
grading BC2GM077422273 VBG O
scheme BC2GM077422273 NN O
for BC2GM077422273 IN O
infiltrating BC2GM077422273 VBG O
duct BC2GM077422273 NN O
carcinoma BC2GM077422273 NN O
breast BC2GM077422273 NN O
. BC2GM077422273 . O
. . O O

We BC2GM051904662 PRP O
screened BC2GM051904662 VBD O
an BC2GM051904662 DT O
A. BC2GM051904662 NN O
thaliana BC2GM051904662 NN O
cDNA BC2GM051904662 NN O
library BC2GM051904662 NN O
, BC2GM051904662 , O
whose BC2GM051904662 WP$ O
inserts BC2GM051904662 NNS O
are BC2GM051904662 VBP O
under BC2GM051904662 IN O
the BC2GM051904662 DT O
control BC2GM051904662 NN O
of BC2GM051904662 IN O
the BC2GM051904662 DT O
galactose-inducible BC2GM051904662 JJ O
GAL10 BC2GM051904662 NNP O
promoter BC2GM051904662 NN O
, BC2GM051904662 , O
for BC2GM051904662 IN O
cDNAs BC2GM051904662 NN O
which BC2GM051904662 WDT O
enabled BC2GM051904662 VBD O
YDH8 BC2GM051904662 NNP O
cells BC2GM051904662 NNS O
to BC2GM051904662 TO O
grow BC2GM051904662 VB O
at BC2GM051904662 IN O
the BC2GM051904662 DT O
restrictive BC2GM051904662 JJ O
temperature BC2GM051904662 NN O
. BC2GM051904662 . O
. . O O

The BC2GM012661651 DT O
results BC2GM012661651 NNS O
showed BC2GM012661651 VBD O
a BC2GM012661651 DT O
significant BC2GM012661651 JJ O
group BC2GM012661651 NN O
effect BC2GM012661651 NN O
only BC2GM012661651 RB O
on BC2GM012661651 IN O
the BC2GM012661651 DT O
active BC2GM012661651 JJ O
task BC2GM012661651 NN O
. BC2GM012661651 . O
. . O O

The BC2GM087530510 DT O
prevalence BC2GM087530510 NN O
of BC2GM087530510 IN O
microalbuminuria BC2GM087530510 NNS O
, BC2GM087530510 , O
defined BC2GM087530510 VBD O
as BC2GM087530510 IN O
an BC2GM087530510 DT O
UAER BC2GM087530510 NNP O
in BC2GM087530510 IN O
the BC2GM087530510 DT O
range BC2GM087530510 NN O
of BC2GM087530510 IN O
15-150 BC2GM087530510 JJ O
micrograms BC2GM087530510 NNS O
min-1 BC2GM087530510 NNS O
in BC2GM087530510 IN O
an BC2GM087530510 DT O
overnight BC2GM087530510 JJ O
urine BC2GM087530510 NN O
sample BC2GM087530510 NN O
, BC2GM087530510 , O
was BC2GM087530510 VBD O
3 BC2GM087530510 CD O
% BC2GM087530510 NN O
( BC2GM087530510 ( O
95 BC2GM087530510 CD O
% BC2GM087530510 NN O
C.I BC2GM087530510 NNP O
. BC2GM087530510 . O
interval BC2GM087530510 NN O
: BC2GM087530510 : O
1.9-4.0 BC2GM087530510 JJ O
) BC2GM087530510 ) O
. BC2GM087530510 . O
. . O O

Taken BC2GM037150480 VBN O
together BC2GM037150480 RB O
, BC2GM037150480 , O
these BC2GM037150480 DT O
results BC2GM037150480 NNS O
demonstrate BC2GM037150480 VBP O
that BC2GM037150480 IN O
the BC2GM037150480 DT O
BSMV BC2GM037150480 NNP O
coat BC2GM037150480 NN O
protein BC2GM037150480 NN O
is BC2GM037150480 VBZ O
the BC2GM037150480 DT O
sole BC2GM037150480 JJ O
translation BC2GM037150480 NN O
product BC2GM037150480 NN O
of BC2GM037150480 IN O
the BC2GM037150480 DT O
genomic BC2GM037150480 JJ O
RNA BC2GM037150480 NNP O
beta BC2GM037150480 NN O
, BC2GM037150480 , O
whereas BC2GM037150480 WP O
sgRNA BC2GM037150480 VBD O
beta BC2GM037150480 NN O
1 BC2GM037150480 CD O
serves BC2GM037150480 NNS O
as BC2GM037150480 IN O
a BC2GM037150480 DT O
messenger BC2GM037150480 NN O
for BC2GM037150480 IN O
translation BC2GM037150480 NN O
of BC2GM037150480 IN O
the BC2GM037150480 DT O
beta BC2GM037150480 NN O
b BC2GM037150480 NN O
protein BC2GM037150480 NN O
, BC2GM037150480 , O
and BC2GM037150480 CC O
sgRNA BC2GM037150480 VBD O
beta BC2GM037150480 NN O
2 BC2GM037150480 CD O
functions BC2GM037150480 NNS O
as BC2GM037150480 IN O
a BC2GM037150480 DT O
messenger BC2GM037150480 NN O
for BC2GM037150480 IN O
translation BC2GM037150480 NN O
of BC2GM037150480 IN O
beta BC2GM037150480 NN O
c BC2GM037150480 NNS O
and BC2GM037150480 CC O
beta BC2GM037150480 NN O
d BC2GM037150480 NN O
and BC2GM037150480 CC O
the BC2GM037150480 DT O
newly BC2GM037150480 RB O
discovered BC2GM037150480 VBN O
beta BC2GM037150480 NN O
d BC2GM037150480 NN O
' BC2GM037150480 POS O
protein BC2GM037150480 NN O
. BC2GM037150480 . O
. . O O

The BC2GM031886187 DT O
Pi BC2GM031886187 NNP O
signals BC2GM031886187 NNS O
are BC2GM031886187 VBP O
conveyed BC2GM031886187 VBN O
to BC2GM031886187 TO O
PHO8 BC2GM031886187 VB O
by BC2GM031886187 IN O
binding BC2GM031886187 VBG O
of BC2GM031886187 IN O
PHO4 BC2GM031886187 NNP O
protein BC2GM031886187 NN O
, BC2GM031886187 , O
a BC2GM031886187 DT O
positive BC2GM031886187 JJ O
regulatory BC2GM031886187 JJ O
factor BC2GM031886187 NN O
, BC2GM031886187 , O
to BC2GM031886187 TO O
a BC2GM031886187 DT O
promoter BC2GM031886187 NN O
region BC2GM031886187 NN O
of BC2GM031886187 IN O
PHO8 BC2GM031886187 NNP O
( BC2GM031886187 ( O
PHO8p BC2GM031886187 NNP O
) BC2GM031886187 ) O
under BC2GM031886187 IN O
the BC2GM031886187 DT O
influence BC2GM031886187 NN O
of BC2GM031886187 IN O
the BC2GM031886187 DT O
PHO BC2GM031886187 NNP O
regulatory BC2GM031886187 JJ O
circuit BC2GM031886187 NN O
. BC2GM031886187 . O
. . O O

The BC2GM097574601 DT O
7.2 BC2GM097574601 CD O
kb BC2GM097574601 NN O
EcoRI BC2GM097574601 NNP O
fragment BC2GM097574601 NN O
of BC2GM097574601 IN O
AfMNPV BC2GM097574601 NNP O
was BC2GM097574601 VBD O
cloned BC2GM097574601 VBN O
and BC2GM097574601 CC O
the BC2GM097574601 DT O
nucleotide BC2GM097574601 JJ O
sequences BC2GM097574601 NNS O
of BC2GM097574601 IN O
the BC2GM097574601 DT O
polyhedrin BC2GM097574601 NN O
coding BC2GM097574601 VBG O
region BC2GM097574601 NN O
and BC2GM097574601 CC O
its BC2GM097574601 PRP$ O
flanking BC2GM097574601 NN O
regions BC2GM097574601 NNS O
were BC2GM097574601 VBD O
determined BC2GM097574601 VBN O
. BC2GM097574601 . O
. . O O

A BC2GM011606685 DT O
long-term BC2GM011606685 JJ O
follow-up BC2GM011606685 JJ O
study BC2GM011606685 NN O
of BC2GM011606685 IN O
a BC2GM011606685 DT O
children BC2GM011606685 NNS O
's BC2GM011606685 POS O
psychiatric BC2GM011606685 JJ O
day BC2GM011606685 NN O
treatment BC2GM011606685 NN O
center BC2GM011606685 NN O
. BC2GM011606685 . O
. . O O

IV BC2GM067289380 NNP O
. BC2GM067289380 . O
. . O O

Bile BC2GM074597498 NNP O
reflux BC2GM074597498 NN O
demonstrated BC2GM074597498 VBN O
by BC2GM074597498 IN O
99m BC2GM074597498 CD O
Tc BC2GM074597498 NNP O
disofenin BC2GM074597498 NN O
. BC2GM074597498 . O
. . O O

The BC2GM063772047 DT O
authors BC2GM063772047 NNS O
report BC2GM063772047 VBP O
about BC2GM063772047 IN O
the BC2GM063772047 DT O
exeresis BC2GM063772047 NN O
of BC2GM063772047 IN O
a BC2GM063772047 DT O
pyelonephrictic BC2GM063772047 JJ O
left BC2GM063772047 NN O
small BC2GM063772047 JJ O
kidney BC2GM063772047 NN O
with BC2GM063772047 IN O
laparoscopic BC2GM063772047 NN O
surgery BC2GM063772047 NN O
. BC2GM063772047 . O
. . O O

We BC2GM077161229 PRP O
also BC2GM077161229 RB O
demonstrate BC2GM077161229 VBP O
that BC2GM077161229 IN O
a BC2GM077161229 DT O
p110RB1 BC2GM077161229 NN O
mutant BC2GM077161229 NN O
, BC2GM077161229 , O
which BC2GM077161229 WDT O
is BC2GM077161229 VBZ O
refractory BC2GM077161229 NN O
to BC2GM077161229 TO O
cell BC2GM077161229 VB O
cycle BC2GM077161229 NN O
phosphorylation BC2GM077161229 NN O
but BC2GM077161229 CC O
intact BC2GM077161229 JJ O
in BC2GM077161229 IN O
E1a BC2GM077161229 NNP O
/ BC2GM077161229 NNP O
large BC2GM077161229 JJ O
T BC2GM077161229 NNP O
antigen-binding BC2GM077161229 NN O
properties BC2GM077161229 NNS O
, BC2GM077161229 , O
represses BC2GM077161229 NNS O
EIIaE BC2GM077161229 VBP O
with BC2GM077161229 IN O
50- BC2GM077161229 JJ O
to BC2GM077161229 TO O
80-fold BC2GM077161229 JJ O
greater BC2GM077161229 JJR O
efficiency BC2GM077161229 NN O
than BC2GM077161229 IN O
wild-type BC2GM077161229 JJ O
p110RB1 BC2GM077161229 NN O
. BC2GM077161229 . O
. . O O

Twelve BC2GM060909038 NNP O
( BC2GM060909038 ( O
92 BC2GM060909038 CD O
% BC2GM060909038 NN O
) BC2GM060909038 ) O
showed BC2GM060909038 VBD O
cognitive BC2GM060909038 JJ O
dysfunction BC2GM060909038 NN O
including BC2GM060909038 VBG O
impairments BC2GM060909038 NNS O
in BC2GM060909038 IN O
memory BC2GM060909038 NN O
, BC2GM060909038 , O
attention BC2GM060909038 NN O
, BC2GM060909038 , O
and BC2GM060909038 CC O
affective BC2GM060909038 JJ O
disturbances BC2GM060909038 NNS O
( BC2GM060909038 ( O
anxiety BC2GM060909038 NN O
, BC2GM060909038 , O
depression BC2GM060909038 NN O
, BC2GM060909038 , O
irritability BC2GM060909038 NN O
, BC2GM060909038 , O
and BC2GM060909038 CC O
poor BC2GM060909038 JJ O
frustration BC2GM060909038 NN O
tolerance BC2GM060909038 NN O
) BC2GM060909038 ) O
. BC2GM060909038 . O
. . O O

However BC2GM021336202 RB O
, BC2GM021336202 , O
all BC2GM021336202 DT O
pathophysiologic BC2GM021336202 JJ O
assessments BC2GM021336202 NNS O
reported BC2GM021336202 VBN O
to BC2GM021336202 TO O
date BC2GM021336202 NN O
have BC2GM021336202 VB O
been BC2GM021336202 VBN O
carried BC2GM021336202 VBN O
out BC2GM021336202 RP O
during BC2GM021336202 IN O
or BC2GM021336202 CC O
immediately BC2GM021336202 RB O
after BC2GM021336202 IN O
IVOX BC2GM021336202 NNP O
utilization BC2GM021336202 NN O
. BC2GM021336202 . O
. . O O

These BC2GM085074416 DT O
extrachromosomal BC2GM085074416 JJ O
copies BC2GM085074416 NNS O
can BC2GM085074416 MD O
be BC2GM085074416 VB O
isolated BC2GM085074416 VBN O
as BC2GM085074416 IN O
covalently BC2GM085074416 RB O
closed BC2GM085074416 VBD O
molecules BC2GM085074416 NNS O
with BC2GM085074416 IN O
lengths BC2GM085074416 NNS O
around BC2GM085074416 IN O
3mu BC2GM085074416 CD O
. BC2GM085074416 . O
. . O O

RESULTS BC2GM058485418 NN O
: BC2GM058485418 : O
Considering BC2GM058485418 VBG O
an BC2GM058485418 DT O
inulin BC2GM058485418 JJ O
clearance BC2GM058485418 NN O
of BC2GM058485418 IN O
less BC2GM058485418 JJR O
than BC2GM058485418 IN O
80 BC2GM058485418 CD O
ml BC2GM058485418 JJ O
/ BC2GM058485418 NNP O
min BC2GM058485418 NN O
/ BC2GM058485418 VBD O
1.73 BC2GM058485418 CD O
m2 BC2GM058485418 NN O
, BC2GM058485418 , O
the BC2GM058485418 DT O
cut-off BC2GM058485418 NN O
value BC2GM058485418 NN O
for BC2GM058485418 IN O
serum BC2GM058485418 JJ O
creatinine BC2GM058485418 NN O
was BC2GM058485418 VBD O
11.5 BC2GM058485418 CD O
mumol BC2GM058485418 NN O
/ BC2GM058485418 NN O
liter BC2GM058485418 NN O
for BC2GM058485418 IN O
men BC2GM058485418 NNS O
and BC2GM058485418 CC O
90 BC2GM058485418 CD O
mumol BC2GM058485418 NN O
/ BC2GM058485418 NN O
liter BC2GM058485418 NN O
for BC2GM058485418 IN O
women BC2GM058485418 NNS O
. BC2GM058485418 . O
. . O O

In BC2GM088776852 IN O
solution BC2GM088776852 NN O
, BC2GM088776852 , O
[ BC2GM088776852 NNP O
( BC2GM088776852 ( O
125 BC2GM088776852 CD O
) BC2GM088776852 ) O
I BC2GM088776852 PRP O
] BC2GM088776852 VBP O
-labeled BC2GM088776852 JJ O
ankyrin BC2GM088776852 NN O
was BC2GM088776852 VBD O
found BC2GM088776852 VBN O
by BC2GM088776852 IN O
ND-PAGE3 BC2GM088776852 NNP O
to BC2GM088776852 TO O
enhance BC2GM088776852 VB O
the BC2GM088776852 DT O
affinity BC2GM088776852 NN O
of BC2GM088776852 IN O
spectrin BC2GM088776852 JJ O
self-association BC2GM088776852 NN O
by BC2GM088776852 IN O
10-fold BC2GM088776852 JJ O
. BC2GM088776852 . O
. . O O

Identification BC2GM029724458 NN O
of BC2GM029724458 IN O
an BC2GM029724458 DT O
osteocalcin BC2GM029724458 JJ O
gene BC2GM029724458 NN O
promoter BC2GM029724458 NN O
sequence BC2GM029724458 NN O
that BC2GM029724458 WDT O
binds BC2GM029724458 VBZ O
AP1 BC2GM029724458 NNP O
. BC2GM029724458 . O
. . O O

The BC2GM016884667 DT O
human BC2GM016884667 JJ O
protein BC2GM016884667 NN O
is BC2GM016884667 VBZ O
encoded BC2GM016884667 VBN O
by BC2GM016884667 IN O
a BC2GM016884667 DT O
900-base BC2GM016884667 JJ O
pair-long BC2GM016884667 JJ O
mRNA BC2GM016884667 NN O
that BC2GM016884667 WDT O
is BC2GM016884667 VBZ O
expressed BC2GM016884667 VBN O
in BC2GM016884667 IN O
the BC2GM016884667 DT O
glandular BC2GM016884667 JJ O
epithelial BC2GM016884667 JJ O
cells BC2GM016884667 NNS O
of BC2GM016884667 IN O
the BC2GM016884667 DT O
endometrium BC2GM016884667 NN O
in BC2GM016884667 IN O
a BC2GM016884667 DT O
cyclic BC2GM016884667 JJ O
manner BC2GM016884667 NN O
; BC2GM016884667 : O
in BC2GM016884667 IN O
addition BC2GM016884667 NN O
, BC2GM016884667 , O
it BC2GM016884667 PRP O
is BC2GM016884667 VBZ O
found BC2GM016884667 VBN O
in BC2GM016884667 IN O
the BC2GM016884667 DT O
mucosal BC2GM016884667 NN O
epithelial BC2GM016884667 JJ O
cells BC2GM016884667 NNS O
of BC2GM016884667 IN O
the BC2GM016884667 DT O
fallopian BC2GM016884667 JJ O
tubes BC2GM016884667 NN O
. BC2GM016884667 . O
. . O O

Doctors BC2GM020757047 NNS O
given BC2GM020757047 VBN O
intrathecal BC2GM020757047 JJ O
methotrexate BC2GM020757047 NN O
had BC2GM020757047 VBD O
headache BC2GM020757047 NN O
when BC2GM020757047 WRB O
20 BC2GM020757047 CD O
gauge BC2GM020757047 JJ O
standard BC2GM020757047 NN O
needle BC2GM020757047 NN O
was BC2GM020757047 VBD O
used BC2GM020757047 VBN O
. BC2GM020757047 . O
. . O O

Acceptability BC2GM033697921 NNP O
of BC2GM033697921 IN O
home BC2GM033697921 NN O
monitoring BC2GM033697921 NN O
as BC2GM033697921 IN O
an BC2GM033697921 DT O
aid BC2GM033697921 NN O
to BC2GM033697921 TO O
conception BC2GM033697921 NN O
. BC2GM033697921 . O
. . O O

Of BC2GM046169713 IN O
921 BC2GM046169713 CD O
specimens BC2GM046169713 NNS O
, BC2GM046169713 , O
95 BC2GM046169713 CD O
yielded BC2GM046169713 VBD O
non-albicans BC2GM046169713 JJ O
species BC2GM046169713 NNS O
, BC2GM046169713 , O
mainly BC2GM046169713 RB O
from BC2GM046169713 IN O
patients BC2GM046169713 NNS O
with BC2GM046169713 IN O
low BC2GM046169713 JJ O
CD4 BC2GM046169713 NNP O
lymphocyte BC2GM046169713 NN O
counts BC2GM046169713 NNS O
and BC2GM046169713 CC O
extensive BC2GM046169713 JJ O
previous BC2GM046169713 JJ O
azole BC2GM046169713 NN O
exposure BC2GM046169713 NN O
. BC2GM046169713 . O
. . O O

The BC2GM062434933 DT O
treatment BC2GM062434933 NN O
of BC2GM062434933 IN O
Sudeck BC2GM062434933 NNP O
's BC2GM062434933 POS O
atrophy BC2GM062434933 NN O
in BC2GM062434933 IN O
the BC2GM062434933 DT O
upper BC2GM062434933 JJ O
limb BC2GM062434933 NN O
by BC2GM062434933 IN O
sympathetic BC2GM062434933 JJ O
blockade BC2GM062434933 NN O
. BC2GM062434933 . O
. . O O

A BC2GM099912787 DT O
Brassica BC2GM099912787 NNP O
cDNA BC2GM099912787 NN O
clone BC2GM099912787 NN O
encoding BC2GM099912787 VBG O
a BC2GM099912787 DT O
bifunctional BC2GM099912787 JJ O
hydroxymethylpyrimidine BC2GM099912787 NN O
kinase BC2GM099912787 NN O
/ BC2GM099912787 NNP O
thiamin-phosphate BC2GM099912787 JJ O
pyrophosphorylase BC2GM099912787 NN O
involved BC2GM099912787 VBN O
in BC2GM099912787 IN O
thiamin BC2GM099912787 JJ O
biosynthesis BC2GM099912787 NN O
. BC2GM099912787 . O
. . O O

Diabetic BC2GM078238867 NNP O
osteopathy BC2GM078238867 NN O
. BC2GM078238867 . O
. . O O

Indirect BC2GM080639482 JJ O
determination BC2GM080639482 NN O
of BC2GM080639482 IN O
maximal BC2GM080639482 JJ O
O2 BC2GM080639482 NNP O
consumption BC2GM080639482 NN O
in BC2GM080639482 IN O
man BC2GM080639482 NN O
. BC2GM080639482 . O
. . O O

The BC2GM058190767 DT O
deduced BC2GM058190767 JJ O
amino BC2GM058190767 NN O
acid BC2GM058190767 JJ O
sequence BC2GM058190767 NN O
of BC2GM058190767 IN O
this BC2GM058190767 DT O
open BC2GM058190767 JJ O
reading BC2GM058190767 NN O
frame BC2GM058190767 NN O
is BC2GM058190767 VBZ O
significantly BC2GM058190767 RB O
homologous BC2GM058190767 JJ O
to BC2GM058190767 TO O
the BC2GM058190767 DT O
HSV BC2GM058190767 NNP O
1 BC2GM058190767 CD O
UL49.5 BC2GM058190767 NNP O
gene BC2GM058190767 NN O
product BC2GM058190767 NN O
, BC2GM058190767 , O
and BC2GM058190767 CC O
as BC2GM058190767 IN O
with BC2GM058190767 IN O
UL49.5 BC2GM058190767 NNP O
, BC2GM058190767 , O
it BC2GM058190767 PRP O
contains BC2GM058190767 VBZ O
a BC2GM058190767 DT O
potential BC2GM058190767 JJ O
signal BC2GM058190767 NN O
sequence BC2GM058190767 NN O
and BC2GM058190767 CC O
transmembrane BC2GM058190767 NN O
domain BC2GM058190767 VBP O
characteristic BC2GM058190767 JJ O
of BC2GM058190767 IN O
membrane-associated BC2GM058190767 JJ O
proteins BC2GM058190767 NNS O
. BC2GM058190767 . O
. . O O

The BC2GM066832835 DT O
matrix BC2GM066832835 NN O
of BC2GM066832835 IN O
the BC2GM066832835 DT O
CBs BC2GM066832835 NNP O
contains BC2GM066832835 VBZ O
the BC2GM066832835 DT O
diagnostic BC2GM066832835 JJ O
protein BC2GM066832835 NN O
p80-coilin BC2GM066832835 NN O
, BC2GM066832835 , O
which BC2GM066832835 WDT O
is BC2GM066832835 VBZ O
colocalized BC2GM066832835 VBN O
with BC2GM066832835 IN O
the BC2GM066832835 DT O
U7 BC2GM066832835 NNP O
small BC2GM066832835 JJ O
nuclear BC2GM066832835 JJ O
ribonucleoprotein BC2GM066832835 NN O
( BC2GM066832835 ( O
snRNP BC2GM066832835 NN O
) BC2GM066832835 ) O
, BC2GM066832835 , O
whereas BC2GM066832835 IN O
the BC2GM066832835 DT O
attached BC2GM066832835 JJ O
and BC2GM066832835 CC O
embedded BC2GM066832835 VBD O
B-snurposomes BC2GM066832835 NNP O
contain BC2GM066832835 NN O
splicing BC2GM066832835 VBG O
snRNPs BC2GM066832835 NN O
. BC2GM066832835 . O
. . O O

Water BC2GM066639389 NNP O
pair BC2GM066639389 NN O
and BC2GM066639389 CC O
three-body BC2GM066639389 JJ O
potential BC2GM066639389 NN O
of BC2GM066639389 IN O
spectroscopic BC2GM066639389 JJ O
quality BC2GM066639389 NN O
from BC2GM066639389 IN O
Ab BC2GM066639389 NNP O
initio BC2GM066639389 NN O
calculations BC2GM066639389 NNS O
. BC2GM066639389 . O
. . O O

Electron BC2GM079407274 NNP O
microscopic BC2GM079407274 NN O
visualization BC2GM079407274 NN O
of BC2GM079407274 IN O
the BC2GM079407274 DT O
general BC2GM079407274 JJ O
population BC2GM079407274 NN O
of BC2GM079407274 IN O
active BC2GM079407274 JJ O
genes BC2GM079407274 NNS O
in BC2GM079407274 IN O
flies BC2GM079407274 NNS O
overexpressing BC2GM079407274 VBG O
hnRNP BC2GM079407274 NN O
proteins BC2GM079407274 NNS O
also BC2GM079407274 RB O
indicated BC2GM079407274 VBD O
that BC2GM079407274 IN O
the BC2GM079407274 DT O
great BC2GM079407274 JJ O
majority BC2GM079407274 NN O
of BC2GM079407274 IN O
genes BC2GM079407274 NNS O
seemed BC2GM079407274 VBD O
normal BC2GM079407274 JJ O
in BC2GM079407274 IN O
terms BC2GM079407274 NNS O
of BC2GM079407274 IN O
cotranscriptional BC2GM079407274 JJ O
RNA BC2GM079407274 NNP O
processing BC2GM079407274 NN O
events BC2GM079407274 NNS O
, BC2GM079407274 , O
although BC2GM079407274 IN O
there BC2GM079407274 EX O
were BC2GM079407274 VBD O
a BC2GM079407274 DT O
few BC2GM079407274 JJ O
abnormalities BC2GM079407274 NNS O
consistent BC2GM079407274 VBP O
with BC2GM079407274 IN O
rare BC2GM079407274 JJ O
exon-skipping BC2GM079407274 JJ O
events BC2GM079407274 NNS O
. BC2GM079407274 . O
. . O O

Fluorescent BC2GM068997634 NN O
in BC2GM068997634 IN O
situ BC2GM068997634 JJ O
hybridization BC2GM068997634 NN O
( BC2GM068997634 ( O
FISH BC2GM068997634 NNP O
) BC2GM068997634 ) O
analysis BC2GM068997634 NN O
showed BC2GM068997634 VBD O
that BC2GM068997634 IN O
the BC2GM068997634 DT O
novel BC2GM068997634 JJ O
regions BC2GM068997634 NNS O
involved BC2GM068997634 VBN O
in BC2GM068997634 IN O
the BC2GM068997634 DT O
NFKB2 BC2GM068997634 NNP O
rearrangement BC2GM068997634 NN O
originated BC2GM068997634 VBD O
from BC2GM068997634 IN O
chromosome BC2GM068997634 NN O
7q34 BC2GM068997634 CD O
, BC2GM068997634 , O
thus BC2GM068997634 RB O
implying BC2GM068997634 VBG O
the BC2GM068997634 DT O
occurrence BC2GM068997634 NN O
of BC2GM068997634 IN O
a BC2GM068997634 DT O
t BC2GM068997634 NN O
( BC2GM068997634 ( O
7 BC2GM068997634 CD O
; BC2GM068997634 : O
10 BC2GM068997634 CD O
) BC2GM068997634 ) O
( BC2GM068997634 ( O
q34 BC2GM068997634 NN O
; BC2GM068997634 : O
q24 BC2GM068997634 CC O
) BC2GM068997634 ) O
reciprocal BC2GM068997634 JJ O
chromosomal BC2GM068997634 JJ O
translocation BC2GM068997634 NN O
. BC2GM068997634 . O
. . O O

D. BC2GM094592158 NNP O
, BC2GM094592158 , O
Hughes BC2GM094592158 NNP O
, BC2GM094592158 , O
F BC2GM094592158 NNP O
. BC2GM094592158 . O
. . O O

The BC2GM011193274 DT O
characteristics BC2GM011193274 NNS O
of BC2GM011193274 IN O
a BC2GM011193274 DT O
simple BC2GM011193274 JJ O
apparatus BC2GM011193274 NN O
for BC2GM011193274 IN O
clinical BC2GM011193274 JJ O
use BC2GM011193274 NN O
to BC2GM011193274 TO O
measure BC2GM011193274 VB O
DEOAEs BC2GM011193274 NNP O
are BC2GM011193274 VBP O
described BC2GM011193274 VBN O
together BC2GM011193274 RB O
with BC2GM011193274 IN O
typical BC2GM011193274 JJ O
examples BC2GM011193274 NNS O
of BC2GM011193274 IN O
emissions BC2GM011193274 NNS O
. BC2GM011193274 . O
. . O O

Fine BC2GM062962431 NNP O
tangled BC2GM062962431 VBD O
pili BC2GM062962431 NNS O
expressed BC2GM062962431 VBN O
by BC2GM062962431 IN O
Haemophilus BC2GM062962431 NNP O
ducreyi BC2GM062962431 NNS O
are BC2GM062962431 VBP O
a BC2GM062962431 DT O
novel BC2GM062962431 JJ O
class BC2GM062962431 NN O
of BC2GM062962431 IN O
pili BC2GM062962431 NN O
. BC2GM062962431 . O
. . O O

Sequence BC2GM052592239 NN O
comparisons BC2GM052592239 NNS O
reveal BC2GM052592239 VBP O
that BC2GM052592239 IN O
the BC2GM052592239 DT O
P. BC2GM052592239 NNP O
woesei BC2GM052592239 VBD O
GTP-binding BC2GM052592239 NNP O
protein BC2GM052592239 NN O
is BC2GM052592239 VBZ O
strikingly BC2GM052592239 RB O
related BC2GM052592239 VBN O
in BC2GM052592239 IN O
sequence BC2GM052592239 NN O
to BC2GM052592239 TO O
eubacterial BC2GM052592239 JJ O
FtsZ BC2GM052592239 NNP O
and BC2GM052592239 CC O
is BC2GM052592239 VBZ O
marginally BC2GM052592239 RB O
more BC2GM052592239 JJR O
similar BC2GM052592239 JJ O
to BC2GM052592239 TO O
eukaryotic BC2GM052592239 JJ O
tubulins BC2GM052592239 NNS O
than BC2GM052592239 IN O
are BC2GM052592239 VBP O
bacterial BC2GM052592239 JJ O
FtsZ BC2GM052592239 NNP O
proteins BC2GM052592239 NNS O
. BC2GM052592239 . O
. . O O

In BC2GM001304367 IN O
both BC2GM001304367 DT O
study BC2GM001304367 NN O
stages BC2GM001304367 NNS O
. BC2GM001304367 . O
post-exposure BC2GM001304367 NN O
treatment BC2GM001304367 NN O
consisted BC2GM001304367 VBD O
of BC2GM001304367 IN O
five BC2GM001304367 CD O
injections BC2GM001304367 NNS O
of BC2GM001304367 IN O
vaccine BC2GM001304367 NN O
[ BC2GM001304367 NNP O
( BC2GM001304367 ( O
D BC2GM001304367 NNP O
) BC2GM001304367 ) O
ays BC2GM001304367 VBZ O
0 BC2GM001304367 CD O
, BC2GM001304367 , O
3 BC2GM001304367 CD O
, BC2GM001304367 , O
7 BC2GM001304367 CD O
, BC2GM001304367 , O
14 BC2GM001304367 CD O
, BC2GM001304367 , O
28 BC2GM001304367 CD O
] BC2GM001304367 NN O
, BC2GM001304367 , O
together BC2GM001304367 RB O
with BC2GM001304367 IN O
a BC2GM001304367 DT O
dose BC2GM001304367 NN O
of BC2GM001304367 IN O
rabies BC2GM001304367 NNS O
immunoglobulin BC2GM001304367 VBP O
( BC2GM001304367 ( O
RIG BC2GM001304367 NNP O
) BC2GM001304367 ) O
of BC2GM001304367 IN O
equine BC2GM001304367 NN O
or BC2GM001304367 CC O
human BC2GM001304367 JJ O
origin BC2GM001304367 NN O
on BC2GM001304367 IN O
D0 BC2GM001304367 NNP O
. BC2GM001304367 . O
. . O O

Association BC2GM023763281 NNP O
of BC2GM023763281 IN O
Syk BC2GM023763281 NNP O
protein BC2GM023763281 FW O
tyrosine BC2GM023763281 JJ O
kinase BC2GM023763281 NN O
( BC2GM023763281 ( O
PTK BC2GM023763281 NNP O
) BC2GM023763281 ) O
with BC2GM023763281 IN O
LMP2A BC2GM023763281 NNP O
occurs BC2GM023763281 VBZ O
at BC2GM023763281 IN O
the BC2GM023763281 DT O
two BC2GM023763281 CD O
tyrosines BC2GM023763281 NNS O
of BC2GM023763281 IN O
the BC2GM023763281 DT O
LMP2A BC2GM023763281 NNP O
immunoreceptor BC2GM023763281 NN O
tyrosine-based BC2GM023763281 JJ O
activation BC2GM023763281 NN O
motif BC2GM023763281 NN O
, BC2GM023763281 , O
and BC2GM023763281 CC O
it BC2GM023763281 PRP O
is BC2GM023763281 VBZ O
hypothesized BC2GM023763281 VBN O
that BC2GM023763281 IN O
Lyn BC2GM023763281 NNP O
PTK BC2GM023763281 NNP O
associates BC2GM023763281 VBZ O
with BC2GM023763281 IN O
the BC2GM023763281 DT O
YEEA BC2GM023763281 NNP O
amino BC2GM023763281 NN O
acid BC2GM023763281 NN O
motif BC2GM023763281 NN O
at BC2GM023763281 IN O
LMP2A BC2GM023763281 NNP O
tyrosine BC2GM023763281 NN O
112 BC2GM023763281 CD O
( BC2GM023763281 ( O
Y112 BC2GM023763281 NNP O
) BC2GM023763281 ) O
. BC2GM023763281 . O
. . O O

Standing BC2GM050960720 VBG O
values BC2GM050960720 NNS O
: BC2GM050960720 : O
placebo BC2GM050960720 NN O
114 BC2GM050960720 CD O
/ BC2GM050960720 JJ O
79 BC2GM050960720 CD O
; BC2GM050960720 : O
BHT-933 BC2GM050960720 JJ O
92 BC2GM050960720 CD O
/ BC2GM050960720 JJ O
67 BC2GM050960720 CD O
. BC2GM050960720 . O
. . O O

Furthermore BC2GM075504151 RB O
, BC2GM075504151 , O
the BC2GM075504151 DT O
regulation BC2GM075504151 NN O
conferred BC2GM075504151 VBD O
on BC2GM075504151 IN O
a BC2GM075504151 DT O
reporter BC2GM075504151 NN O
gene BC2GM075504151 NN O
in BC2GM075504151 IN O
Drosophila BC2GM075504151 NNP O
by BC2GM075504151 IN O
three BC2GM075504151 CD O
closely BC2GM075504151 RB O
related BC2GM075504151 JJ O
sequences BC2GM075504151 NNS O
demonstrates BC2GM075504151 VBZ O
that BC2GM075504151 IN O
even BC2GM075504151 RB O
subtle BC2GM075504151 JJ O
sequence BC2GM075504151 NN O
changes BC2GM075504151 NNS O
within BC2GM075504151 IN O
an BC2GM075504151 DT O
E BC2GM075504151 NNP O
box BC2GM075504151 NN O
or BC2GM075504151 CC O
flanking BC2GM075504151 NN O
bases BC2GM075504151 NNS O
have BC2GM075504151 VBP O
dramatic BC2GM075504151 JJ O
consequences BC2GM075504151 NNS O
on BC2GM075504151 IN O
the BC2GM075504151 DT O
overall BC2GM075504151 JJ O
repertoire BC2GM075504151 NN O
of BC2GM075504151 IN O
proteins BC2GM075504151 NNS O
that BC2GM075504151 WDT O
can BC2GM075504151 MD O
bind BC2GM075504151 VB O
in BC2GM075504151 IN O
vivo BC2GM075504151 NN O
. BC2GM075504151 . O
. . O O

But BC2GM021163962 CC O
if BC2GM021163962 IN O
one BC2GM021163962 CD O
equalizes BC2GM021163962 VBZ O
the BC2GM021163962 DT O
upper BC2GM021163962 JJ O
limits BC2GM021163962 NNS O
of BC2GM021163962 IN O
normal BC2GM021163962 JJ O
for BC2GM021163962 IN O
both BC2GM021163962 DT O
markers BC2GM021163962 NNS O
to BC2GM021163962 TO O
a BC2GM021163962 DT O
common BC2GM021163962 JJ O
95 BC2GM021163962 CD O
% BC2GM021163962 NN O
specificity BC2GM021163962 NN O
, BC2GM021163962 , O
the BC2GM021163962 DT O
tumour-indicating BC2GM021163962 JJ O
sensitivity BC2GM021163962 NN O
of BC2GM021163962 IN O
CA BC2GM021163962 NNP O
19-9 BC2GM021163962 JJ O
clearly BC2GM021163962 RB O
surpasses BC2GM021163962 VBZ O
that BC2GM021163962 IN O
of BC2GM021163962 IN O
CA BC2GM021163962 NNP O
50 BC2GM021163962 CD O
. BC2GM021163962 . O
. . O O

The BC2GM011563299 DT O
paper BC2GM011563299 NN O
calls BC2GM011563299 VBZ O
for BC2GM011563299 IN O
standardized BC2GM011563299 JJ O
question BC2GM011563299 NN O
formats BC2GM011563299 NNS O
and BC2GM011563299 CC O
a BC2GM011563299 DT O
centralized BC2GM011563299 JJ O
body BC2GM011563299 NN O
to BC2GM011563299 TO O
monitor BC2GM011563299 VB O
changes BC2GM011563299 NNS O
in BC2GM011563299 IN O
these BC2GM011563299 DT O
parameters BC2GM011563299 NNS O
of BC2GM011563299 IN O
sexual BC2GM011563299 JJ O
behaviour BC2GM011563299 NN O
. BC2GM011563299 . O
. . O O

Different BC2GM087106608 JJ O
effects BC2GM087106608 NNS O
of BC2GM087106608 IN O
reoxygenation BC2GM087106608 NN O
on BC2GM087106608 IN O
the BC2GM087106608 DT O
electrical BC2GM087106608 JJ O
activity BC2GM087106608 NN O
of BC2GM087106608 IN O
ventricular BC2GM087106608 JJ O
muscle BC2GM087106608 NN O
. BC2GM087106608 . O
. . O O

The BC2GM046025995 DT O
10 BC2GM046025995 CD O
eyes BC2GM046025995 NNS O
injected BC2GM046025995 VBN O
with BC2GM046025995 IN O
human BC2GM046025995 JJ O
RPE BC2GM046025995 NNP O
cells BC2GM046025995 NNS O
showed BC2GM046025995 VBD O
STAGE BC2GM046025995 NNP O
2 BC2GM046025995 CD O
or BC2GM046025995 CC O
less BC2GM046025995 JJR O
in BC2GM046025995 IN O
4 BC2GM046025995 CD O
weeks BC2GM046025995 NNS O
. BC2GM046025995 . O
. . O O

Recently BC2GM067611275 RB O
, BC2GM067611275 , O
we BC2GM067611275 PRP O
demonstrated BC2GM067611275 VBD O
that BC2GM067611275 IN O
platelet-derived BC2GM067611275 JJ O
growth BC2GM067611275 NN O
factor BC2GM067611275 NN O
( BC2GM067611275 ( O
PDGF BC2GM067611275 NNP O
) BC2GM067611275 ) O
-beta BC2GM067611275 NNP O
receptor BC2GM067611275 NN O
stimulation BC2GM067611275 NN O
, BC2GM067611275 , O
but BC2GM067611275 CC O
not BC2GM067611275 RB O
various BC2GM067611275 JJ O
other BC2GM067611275 JJ O
growth BC2GM067611275 NN O
factors BC2GM067611275 NNS O
, BC2GM067611275 , O
inhibits BC2GM067611275 NNS O
transcription BC2GM067611275 NN O
of BC2GM067611275 IN O
alpha1D- BC2GM067611275 JJ O
, BC2GM067611275 , O
but BC2GM067611275 CC O
not BC2GM067611275 RB O
alpha1A- BC2GM067611275 JJ O
or BC2GM067611275 CC O
alpha1B-ARs BC2GM067611275 JJ O
, BC2GM067611275 , O
resulting BC2GM067611275 VBG O
in BC2GM067611275 IN O
reduced BC2GM067611275 VBN O
norepinephrine-mediated BC2GM067611275 JJ O
SMC BC2GM067611275 NNP O
growth BC2GM067611275 NN O
. BC2GM067611275 . O
. . O O

Electrophoretic BC2GM001477367 JJ O
mobility-shift BC2GM001477367 NN O
assays BC2GM001477367 NNS O
showed BC2GM001477367 VBD O
a BC2GM001477367 DT O
rapid BC2GM001477367 JJ O
induction BC2GM001477367 NN O
of BC2GM001477367 IN O
nuclear BC2GM001477367 JJ O
proteins BC2GM001477367 NNS O
that BC2GM001477367 WDT O
bound BC2GM001477367 VBP O
to BC2GM001477367 TO O
the BC2GM001477367 DT O
consensus BC2GM001477367 NN O
kappa BC2GM001477367 NN O
B BC2GM001477367 NNP O
motif BC2GM001477367 NN O
. BC2GM001477367 . O
. . O O

If BC2GM097549804 IN O
, BC2GM097549804 , O
however BC2GM097549804 RB O
, BC2GM097549804 , O
myocardial BC2GM097549804 JJ O
stunning BC2GM097549804 NN O
is BC2GM097549804 VBZ O
severe BC2GM097549804 JJ O
, BC2GM097549804 , O
and BC2GM097549804 CC O
it BC2GM097549804 PRP O
involves BC2GM097549804 VBZ O
large BC2GM097549804 JJ O
parts BC2GM097549804 NNS O
of BC2GM097549804 IN O
the BC2GM097549804 DT O
LV BC2GM097549804 NNP O
and BC2GM097549804 CC O
thus BC2GM097549804 RB O
impairs BC2GM097549804 NNS O
global BC2GM097549804 JJ O
LV BC2GM097549804 NNP O
function BC2GM097549804 NN O
, BC2GM097549804 , O
it BC2GM097549804 PRP O
can BC2GM097549804 MD O
be BC2GM097549804 VB O
reversed BC2GM097549804 VBN O
with BC2GM097549804 IN O
inotropic BC2GM097549804 NN O
agents BC2GM097549804 NNS O
and BC2GM097549804 CC O
procedures BC2GM097549804 NNS O
. BC2GM097549804 . O
. . O O

We BC2GM039462814 PRP O
infer BC2GM039462814 VBP O
that BC2GM039462814 IN O
RecA-mediated BC2GM039462814 JJ O
cleavage BC2GM039462814 NN O
of BC2GM039462814 IN O
UmuD BC2GM039462814 NNP O
is BC2GM039462814 VBZ O
another BC2GM039462814 DT O
role BC2GM039462814 NN O
for BC2GM039462814 IN O
RecA BC2GM039462814 NNP O
in BC2GM039462814 IN O
SOS BC2GM039462814 NNP O
mutagenesis BC2GM039462814 NN O
, BC2GM039462814 , O
probably BC2GM039462814 RB O
activating BC2GM039462814 VBG O
UmuD BC2GM039462814 NNP O
for BC2GM039462814 IN O
its BC2GM039462814 PRP$ O
mutagenic BC2GM039462814 JJ O
function BC2GM039462814 NN O
. BC2GM039462814 . O
. . O O

Radiative BC2GM099407743 JJ O
corrections BC2GM099407743 NNS O
to BC2GM099407743 TO O
pi BC2GM099407743 VB O
l2 BC2GM099407743 JJ O
decays BC2GM099407743 NNS O
. BC2GM099407743 . O
. . O O

Disease-free BC2GM079935127 JJ O
interval BC2GM079935127 NN O
was BC2GM079935127 VBD O
greater BC2GM079935127 JJR O
in BC2GM079935127 IN O
node-negative BC2GM079935127 JJ O
Lx BC2GM079935127 NNP O
patients BC2GM079935127 NNS O
for BC2GM079935127 IN O
both BC2GM079935127 DT O
T1 BC2GM079935127 NNP O
( BC2GM079935127 ( O
P BC2GM079935127 NNP O
less BC2GM079935127 JJR O
than BC2GM079935127 IN O
0.007 BC2GM079935127 CD O
) BC2GM079935127 ) O
and BC2GM079935127 CC O
T2 BC2GM079935127 NNP O
( BC2GM079935127 ( O
P BC2GM079935127 NNP O
less BC2GM079935127 JJR O
than BC2GM079935127 IN O
0.05 BC2GM079935127 CD O
) BC2GM079935127 ) O
presentations BC2GM079935127 NNS O
. BC2GM079935127 . O
. . O O

In BC2GM000019979 IN O
the BC2GM000019979 DT O
cervical BC2GM000019979 JJ O
enlargement BC2GM000019979 NN O
they BC2GM000019979 PRP O
were BC2GM000019979 VBD O
located BC2GM000019979 VBN O
in BC2GM000019979 IN O
the BC2GM000019979 DT O
middle BC2GM000019979 JJ O
part BC2GM000019979 NN O
of BC2GM000019979 IN O
lamina BC2GM000019979 NN O
VII BC2GM000019979 NNP O
and BC2GM000019979 CC O
in BC2GM000019979 IN O
lamina BC2GM000019979 JJ O
VIII BC2GM000019979 NNP O
, BC2GM000019979 , O
accounting BC2GM000019979 NN O
for BC2GM000019979 IN O
about BC2GM000019979 RB O
25 BC2GM000019979 CD O
% BC2GM000019979 NN O
of BC2GM000019979 IN O
the BC2GM000019979 DT O
total BC2GM000019979 NN O
labeled BC2GM000019979 VBD O
neurons BC2GM000019979 NNS O
. BC2GM000019979 . O
. . O O

HrpE BC2GM057597725 NNP O
is BC2GM057597725 VBZ O
similar BC2GM057597725 JJ O
to BC2GM057597725 TO O
YscL BC2GM057597725 NNP O
of BC2GM057597725 IN O
Yersinia BC2GM057597725 NNP O
spp BC2GM057597725 NN O
. BC2GM057597725 . O
. . O O

This BC2GM052408999 DT O
study BC2GM052408999 NN O
investigated BC2GM052408999 VBD O
if BC2GM052408999 IN O
signal-averaged BC2GM052408999 JJ O
low BC2GM052408999 JJ O
amplitude BC2GM052408999 NN O
atrial BC2GM052408999 JJ O
potentials BC2GM052408999 NNS O
predict BC2GM052408999 VBP O
atrial BC2GM052408999 JJ O
fibrillation BC2GM052408999 NN O
or BC2GM052408999 CC O
flutter BC2GM052408999 NN O
( BC2GM052408999 ( O
AFF BC2GM052408999 NNP O
) BC2GM052408999 ) O
. BC2GM052408999 . O
. . O O

Long-term BC2GM068517982 JJ O
follow-up BC2GM068517982 NN O
of BC2GM068517982 IN O
kidney BC2GM068517982 NN O
donors BC2GM068517982 NNS O
: BC2GM068517982 : O
a BC2GM068517982 DT O
longitudinal BC2GM068517982 JJ O
study BC2GM068517982 NN O
. BC2GM068517982 . O
. . O O

The BC2GM027891273 DT O
PRP4 BC2GM027891273 NNP O
protein BC2GM027891273 NN O
of BC2GM027891273 IN O
Saccharomyces BC2GM027891273 NNP O
cerevisiae BC2GM027891273 NN O
is BC2GM027891273 VBZ O
an BC2GM027891273 DT O
essential BC2GM027891273 JJ O
part BC2GM027891273 NN O
of BC2GM027891273 IN O
the BC2GM027891273 DT O
U4 BC2GM027891273 NNP O
/ BC2GM027891273 NNP O
U6 BC2GM027891273 NNP O
snRNP BC2GM027891273 NN O
, BC2GM027891273 , O
a BC2GM027891273 DT O
component BC2GM027891273 NN O
of BC2GM027891273 IN O
the BC2GM027891273 DT O
mRNA BC2GM027891273 NN O
splicing BC2GM027891273 VBG O
apparatus BC2GM027891273 NN O
. BC2GM027891273 . O
. . O O

Internalization BC2GM057965554 NN O
of BC2GM057965554 IN O
prolactin BC2GM057965554 NN O
receptor BC2GM057965554 NN O
and BC2GM057965554 CC O
prolactin BC2GM057965554 NN O
in BC2GM057965554 IN O
transfected BC2GM057965554 JJ O
cells BC2GM057965554 NNS O
does BC2GM057965554 VBZ O
not BC2GM057965554 RB O
involve BC2GM057965554 VB O
nuclear BC2GM057965554 JJ O
translocation BC2GM057965554 NN O
. BC2GM057965554 . O
. . O O

Fluctuations BC2GM004578175 NNS O
of BC2GM004578175 IN O
the BC2GM004578175 DT O
measured BC2GM004578175 JJ O
ECF BC2GM004578175 NNP O
energy-related BC2GM004578175 JJ O
substances BC2GM004578175 NNS O
corresponded BC2GM004578175 VBD O
to BC2GM004578175 TO O
various BC2GM004578175 JJ O
clinical BC2GM004578175 JJ O
events BC2GM004578175 NNS O
presumably BC2GM004578175 RB O
involving BC2GM004578175 VBG O
hypoxia BC2GM004578175 NN O
/ BC2GM004578175 NNP O
ischemia BC2GM004578175 NN O
. BC2GM004578175 . O
. . O O

Biology BC2GM019247724 NNP O
of BC2GM019247724 IN O
Anopheles BC2GM019247724 NNP O
quadrimaculatus BC2GM019247724 FW O
under BC2GM019247724 IN O
field BC2GM019247724 NN O
conditions BC2GM019247724 NNS O
in BC2GM019247724 IN O
central BC2GM019247724 JJ O
Florida BC2GM019247724 NNP O
. BC2GM019247724 . O
. . O O

So BC2GM097338238 IN O
it BC2GM097338238 PRP O
is BC2GM097338238 VBZ O
sometimes BC2GM097338238 RB O
more BC2GM097338238 RBR O
convenient BC2GM097338238 JJ O
to BC2GM097338238 TO O
use BC2GM097338238 VB O
the BC2GM097338238 DT O
back BC2GM097338238 JJ O
Radon BC2GM097338238 NNP O
transform BC2GM097338238 NN O
R-1 BC2GM097338238 NNP O
and BC2GM097338238 CC O
then BC2GM097338238 RB O
to BC2GM097338238 TO O
correct BC2GM097338238 VB O
the BC2GM097338238 DT O
result BC2GM097338238 NN O
, BC2GM097338238 , O
taking BC2GM097338238 VBG O
into BC2GM097338238 IN O
account BC2GM097338238 NN O
attenuation BC2GM097338238 NN O
. BC2GM097338238 . O
. . O O

M. BC2GM061416403 NNP O
, BC2GM061416403 , O
Adrich BC2GM061416403 NNP O
, BC2GM061416403 , O
Z. BC2GM061416403 NNP O
, BC2GM061416403 , O
Fournet BC2GM061416403 NNP O
, BC2GM061416403 , O
B. BC2GM061416403 NNP O
, BC2GM061416403 , O
Capon BC2GM061416403 NNP O
, BC2GM061416403 , O
C. BC2GM061416403 NNP O
, BC2GM061416403 , O
Bonicel BC2GM061416403 NNP O
, BC2GM061416403 , O
J BC2GM061416403 NNP O
. BC2GM061416403 . O
. . O O

J BC2GM001246752 NNP O
. BC2GM001246752 . O
. . O O

These BC2GM028364416 DT O
results BC2GM028364416 NNS O
suggest BC2GM028364416 VBP O
that BC2GM028364416 IN O
transcription BC2GM028364416 NN O
influences BC2GM028364416 NNS O
aspects BC2GM028364416 NNS O
of BC2GM028364416 IN O
gene BC2GM028364416 NN O
conversion BC2GM028364416 NN O
after BC2GM028364416 IN O
initiation BC2GM028364416 NN O
, BC2GM028364416 , O
such BC2GM028364416 JJ O
as BC2GM028364416 IN O
strand BC2GM028364416 NN O
invasion BC2GM028364416 NN O
and BC2GM028364416 CC O
/ BC2GM028364416 NN O
or BC2GM028364416 CC O
mismatch BC2GM028364416 NN O
repair BC2GM028364416 NN O
( BC2GM028364416 ( O
MMR BC2GM028364416 NNP O
) BC2GM028364416 ) O
. BC2GM028364416 . O
. . O O

Immunofluorescence BC2GM091513023 NN O
tests BC2GM091513023 NNS O
for BC2GM091513023 IN O
Borrelia BC2GM091513023 NNP O
burgdorferi BC2GM091513023 NN O
serum BC2GM091513023 NN O
antibodies BC2GM091513023 NNS O
had BC2GM091513023 VBD O
positive BC2GM091513023 JJ O
results BC2GM091513023 NNS O
, BC2GM091513023 , O
but BC2GM091513023 CC O
G-penicillin BC2GM091513023 NNP O
treatment BC2GM091513023 NN O
was BC2GM091513023 VBD O
ineffective BC2GM091513023 JJ O
. BC2GM091513023 . O
. . O O

Legionella BC2GM063338768 NNP O
antibodies BC2GM063338768 NNS O
in BC2GM063338768 IN O
domestic BC2GM063338768 JJ O
animals BC2GM063338768 NNS O
. BC2GM063338768 . O
. . O O

Nevertheless BC2GM060722870 RB O
, BC2GM060722870 , O
lower BC2GM060722870 JJR O
doses BC2GM060722870 NNS O
which BC2GM060722870 WDT O
alone BC2GM060722870 RB O
were BC2GM060722870 VBD O
lacking BC2GM060722870 VBG O
in BC2GM060722870 IN O
activity BC2GM060722870 NN O
( BC2GM060722870 ( O
100-250 BC2GM060722870 JJ O
mg BC2GM060722870 NN O
/ BC2GM060722870 NNP O
kg BC2GM060722870 NN O
B1 BC2GM060722870 NNP O
and BC2GM060722870 CC O
B6 BC2GM060722870 NNP O
, BC2GM060722870 , O
1-2.5 BC2GM060722870 JJ O
mg BC2GM060722870 NN O
/ BC2GM060722870 NNP O
kg BC2GM060722870 NNP O
B12 BC2GM060722870 NNP O
p.o BC2GM060722870 NN O
. BC2GM060722870 . O
) BC2GM060722870 ) O
dose-dependently BC2GM060722870 RB O
potentiated BC2GM060722870 VBD O
the BC2GM060722870 DT O
antinociceptive BC2GM060722870 NN O
of BC2GM060722870 IN O
diclofenac BC2GM060722870 NN O
. BC2GM060722870 . O
. . O O

These BC2GM032501279 DT O
findings BC2GM032501279 NNS O
also BC2GM032501279 RB O
demonstrate BC2GM032501279 VBP O
that BC2GM032501279 IN O
unless BC2GM032501279 IN O
excluded BC2GM032501279 VBN O
by BC2GM032501279 IN O
other BC2GM032501279 JJ O
factors BC2GM032501279 NNS O
, BC2GM032501279 , O
the BC2GM032501279 DT O
C BC2GM032501279 NNP O
proteins BC2GM032501279 NNS O
are BC2GM032501279 VBP O
likely BC2GM032501279 JJ O
to BC2GM032501279 TO O
be BC2GM032501279 VB O
located BC2GM032501279 VBN O
along BC2GM032501279 IN O
the BC2GM032501279 DT O
length BC2GM032501279 NN O
of BC2GM032501279 IN O
nascent BC2GM032501279 JJ O
transcripts BC2GM032501279 NNS O
. BC2GM032501279 . O
. . O O

The BC2GM014345579 DT O
hepatic BC2GM014345579 JJ O
isoform BC2GM014345579 NN O
of BC2GM014345579 IN O
6-phosphofructo-2-kinase BC2GM014345579 JJ O
/ BC2GM014345579 JJ O
fructose-2,6-bisphosphatase BC2GM014345579 NN O
( BC2GM014345579 ( O
PF2K BC2GM014345579 NNP O
/ BC2GM014345579 NNP O
Fru-2,6-BPase BC2GM014345579 NNP O
) BC2GM014345579 ) O
is BC2GM014345579 VBZ O
transcriptionally BC2GM014345579 RB O
stimulated BC2GM014345579 VBN O
by BC2GM014345579 IN O
glucocorticoids BC2GM014345579 NNS O
, BC2GM014345579 , O
whereas BC2GM014345579 JJ O
insulin BC2GM014345579 NN O
blocks BC2GM014345579 NNS O
this BC2GM014345579 DT O
stimulatory BC2GM014345579 JJ O
effect BC2GM014345579 NN O
. BC2GM014345579 . O
. . O O

SN-38 BC2GM078411814 JJ O
rebound BC2GM078411814 NN O
concentrations BC2GM078411814 NNS O
were BC2GM078411814 VBD O
observed BC2GM078411814 VBN O
in BC2GM078411814 IN O
many BC2GM078411814 JJ O
courses BC2GM078411814 NNS O
at BC2GM078411814 IN O
about BC2GM078411814 RB O
0.5 BC2GM078411814 CD O
to BC2GM078411814 TO O
1 BC2GM078411814 CD O
hour BC2GM078411814 NN O
following BC2GM078411814 VBG O
the BC2GM078411814 DT O
end BC2GM078411814 NN O
of BC2GM078411814 IN O
the BC2GM078411814 DT O
i.v BC2GM078411814 NN O
. BC2GM078411814 . O
infusion BC2GM078411814 NN O
, BC2GM078411814 , O
which BC2GM078411814 WDT O
is BC2GM078411814 VBZ O
suggestive BC2GM078411814 JJ O
of BC2GM078411814 IN O
enterohepatic BC2GM078411814 JJ O
recycling BC2GM078411814 NN O
. BC2GM078411814 . O
. . O O

Whether BC2GM066216653 IN O
this BC2GM066216653 DT O
lack BC2GM066216653 NN O
of BC2GM066216653 IN O
preferential BC2GM066216653 JJ O
repair BC2GM066216653 NN O
has BC2GM066216653 VBZ O
to BC2GM066216653 TO O
be BC2GM066216653 VB O
explained BC2GM066216653 VBN O
by BC2GM066216653 IN O
a BC2GM066216653 DT O
defect BC2GM066216653 NN O
in BC2GM066216653 IN O
repair BC2GM066216653 NN O
or BC2GM066216653 CC O
in BC2GM066216653 IN O
general BC2GM066216653 JJ O
transcription BC2GM066216653 NN O
is BC2GM066216653 VBZ O
unclear BC2GM066216653 JJ O
at BC2GM066216653 IN O
present BC2GM066216653 NN O
. BC2GM066216653 . O
. . O O

DESIGN BC2GM027887044 NN O
: BC2GM027887044 : O
Activating BC2GM027887044 JJ O
protein-1 BC2GM027887044 JJ O
( BC2GM027887044 ( O
AP-1 BC2GM027887044 NNP O
) BC2GM027887044 ) O
and BC2GM027887044 CC O
Tat-induced BC2GM027887044 JJ O
transcription BC2GM027887044 NN O
were BC2GM027887044 VBD O
assessed BC2GM027887044 VBN O
using BC2GM027887044 VBG O
Jun BC2GM027887044 NNP O
and BC2GM027887044 CC O
hybrid BC2GM027887044 JJ O
Tat BC2GM027887044 NNP O
/ BC2GM027887044 NNP O
Jun-expression BC2GM027887044 NNP O
plasmids BC2GM027887044 NNS O
and BC2GM027887044 CC O
reporter BC2GM027887044 NN O
gene BC2GM027887044 NN O
constructs BC2GM027887044 NNS O
which BC2GM027887044 WDT O
contained BC2GM027887044 VBD O
AP-1 BC2GM027887044 NNP O
binding BC2GM027887044 VBG O
sites BC2GM027887044 NNS O
upstream BC2GM027887044 RB O
of BC2GM027887044 IN O
the BC2GM027887044 DT O
rat BC2GM027887044 NN O
prolactin BC2GM027887044 NN O
TATAA BC2GM027887044 NNP O
element BC2GM027887044 NN O
or BC2GM027887044 CC O
an BC2GM027887044 DT O
HIV-1 BC2GM027887044 JJ O
LTR BC2GM027887044 NNP O
construct BC2GM027887044 NN O
in BC2GM027887044 IN O
which BC2GM027887044 WDT O
AP-1 BC2GM027887044 NNP O
binding BC2GM027887044 NN O
sites BC2GM027887044 NNS O
replaced BC2GM027887044 VBD O
the BC2GM027887044 DT O
TAR BC2GM027887044 NNP O
element BC2GM027887044 NN O
. BC2GM027887044 . O
. . O O

Microsporum BC2GM099003482 NNP O
persicolor BC2GM099003482 NN O
, BC2GM099003482 , O
an BC2GM099003482 DT O
easily BC2GM099003482 RB O
misinterpreted BC2GM099003482 VBN O
dermatophyt BC2GM099003482 NN O
. BC2GM099003482 . O
. . O O

Keys BC2GM040338006 NNS O
can BC2GM040338006 MD O
be BC2GM040338006 VB O
used BC2GM040338006 VBN O
for BC2GM040338006 IN O
identifying BC2GM040338006 VBG O
species BC2GM040338006 NNS O
from BC2GM040338006 IN O
the BC2GM040338006 DT O
European BC2GM040338006 NNP O
part BC2GM040338006 NN O
of BC2GM040338006 IN O
the BC2GM040338006 DT O
USSR BC2GM040338006 NNP O
and BC2GM040338006 CC O
north-eastern BC2GM040338006 JJ O
Kazakhstan BC2GM040338006 NNP O
. BC2GM040338006 . O
. . O O

Three BC2GM014331768 CD O
high-amylose BC2GM014331768 JJ O
rice BC2GM014331768 NN O
varieties BC2GM014331768 NNS O
, BC2GM014331768 , O
IR42 BC2GM014331768 NNP O
, BC2GM014331768 , O
IR36 BC2GM014331768 NNP O
, BC2GM014331768 , O
and BC2GM014331768 CC O
IR62 BC2GM014331768 NNP O
, BC2GM014331768 , O
with BC2GM014331768 IN O
similar BC2GM014331768 JJ O
chemical BC2GM014331768 NN O
composition BC2GM014331768 NN O
including BC2GM014331768 VBG O
amylose BC2GM014331768 JJ O
content BC2GM014331768 NN O
( BC2GM014331768 ( O
26.7-27.0 BC2GM014331768 CD O
% BC2GM014331768 NN O
) BC2GM014331768 ) O
, BC2GM014331768 , O
were BC2GM014331768 VBD O
cooked BC2GM014331768 VBN O
under BC2GM014331768 IN O
the BC2GM014331768 DT O
same BC2GM014331768 JJ O
conditions BC2GM014331768 NNS O
and BC2GM014331768 CC O
tested BC2GM014331768 VBN O
for BC2GM014331768 IN O
in BC2GM014331768 IN O
vitro BC2GM014331768 JJ O
digestibility BC2GM014331768 NN O
as BC2GM014331768 RB O
well BC2GM014331768 RB O
as BC2GM014331768 IN O
blood BC2GM014331768 NN O
glucose BC2GM014331768 NN O
and BC2GM014331768 CC O
insulin BC2GM014331768 NN O
responses BC2GM014331768 NNS O
in BC2GM014331768 IN O
healthy BC2GM014331768 JJ O
human BC2GM014331768 JJ O
volunteers BC2GM014331768 NNS O
. BC2GM014331768 . O
. . O O

The BC2GM055948186 DT O
mutant BC2GM055948186 NN O
strain BC2GM055948186 NN O
carries BC2GM055948186 VBZ O
three BC2GM055948186 CD O
tandem BC2GM055948186 NN O
copies BC2GM055948186 NNS O
of BC2GM055948186 IN O
the BC2GM055948186 DT O
18 BC2GM055948186 CD O
bp BC2GM055948186 NN O
sequence BC2GM055948186 NN O
that BC2GM055948186 WDT O
is BC2GM055948186 VBZ O
duplicated BC2GM055948186 VBN O
in BC2GM055948186 IN O
the BC2GM055948186 DT O
amdI66 BC2GM055948186 JJ O
mutation BC2GM055948186 NN O
. BC2GM055948186 . O
. . O O

Consistent BC2GM094372415 JJ O
with BC2GM094372415 IN O
this BC2GM094372415 DT O
hypothesis BC2GM094372415 NN O
, BC2GM094372415 , O
stimulation BC2GM094372415 NN O
of BC2GM094372415 IN O
A BC2GM094372415 NNP O
( BC2GM094372415 ( O
2A BC2GM094372415 CD O
) BC2GM094372415 ) O
-R BC2GM094372415 NN O
or BC2GM094372415 CC O
PKA BC2GM094372415 NNP O
enhanced BC2GM094372415 VBD O
nuclear BC2GM094372415 JJ O
aPKC BC2GM094372415 NN O
activity BC2GM094372415 NN O
. BC2GM094372415 . O
. . O O

This BC2GM084397329 DT O
polypeptide BC2GM084397329 NN O
includes BC2GM084397329 VBZ O
the BC2GM084397329 DT O
first BC2GM084397329 JJ O
three BC2GM084397329 CD O
zinc BC2GM084397329 NN O
fingers BC2GM084397329 NNS O
of BC2GM084397329 IN O
the BC2GM084397329 DT O
TFIIIA BC2GM084397329 NNP O
DNA BC2GM084397329 NNP O
binding BC2GM084397329 VBG O
domain BC2GM084397329 NN O
. BC2GM084397329 . O
. . O O

Corticosteroid BC2GM001125172 NNP O
treatment BC2GM001125172 NN O
before BC2GM001125172 RB O
, BC2GM001125172 , O
during BC2GM001125172 IN O
, BC2GM001125172 , O
or BC2GM001125172 CC O
after BC2GM001125172 IN O
fludarabine BC2GM001125172 JJ O
treatment BC2GM001125172 NN O
in BC2GM001125172 IN O
patients BC2GM001125172 NNS O
with BC2GM001125172 IN O
alkylator-resistant BC2GM001125172 JJ O
, BC2GM001125172 , O
low-grade BC2GM001125172 JJ O
lymphoid BC2GM001125172 JJ O
malignancies BC2GM001125172 NNS O
who BC2GM001125172 WP O
have BC2GM001125172 VBP O
not BC2GM001125172 RB O
received BC2GM001125172 VBN O
PCP BC2GM001125172 NNP O
prophylaxis BC2GM001125172 NN O
is BC2GM001125172 VBZ O
associated BC2GM001125172 VBN O
with BC2GM001125172 IN O
an BC2GM001125172 DT O
increased BC2GM001125172 VBN O
risk BC2GM001125172 NN O
of BC2GM001125172 IN O
opportunistic BC2GM001125172 JJ O
pulmonary BC2GM001125172 JJ O
infections BC2GM001125172 NNS O
. BC2GM001125172 . O
. . O O

FdsR BC2GM054295560 NNP O
purified BC2GM054295560 VBD O
to BC2GM054295560 TO O
homogeneity BC2GM054295560 NN O
after BC2GM054295560 IN O
overexpression BC2GM054295560 NN O
of BC2GM054295560 IN O
fdsR BC2GM054295560 NN O
in BC2GM054295560 IN O
E. BC2GM054295560 NNP O
coli BC2GM054295560 NNS O
is BC2GM054295560 VBZ O
a BC2GM054295560 DT O
130 BC2GM054295560 CD O
kDa BC2GM054295560 NN O
homotetramer BC2GM054295560 NN O
binding BC2GM054295560 NN O
to BC2GM054295560 TO O
the BC2GM054295560 DT O
fds BC2GM054295560 NN O
control BC2GM054295560 NN O
region BC2GM054295560 NN O
located BC2GM054295560 VBN O
between BC2GM054295560 IN O
the BC2GM054295560 DT O
fdsR BC2GM054295560 NN O
and BC2GM054295560 CC O
fdsG BC2GM054295560 JJ O
genes BC2GM054295560 NNS O
. BC2GM054295560 . O
. . O O

NGF BC2GM027354703 NNP O
also BC2GM027354703 RB O
induced BC2GM027354703 VBD O
a BC2GM027354703 DT O
synthetic BC2GM027354703 JJ O
promoter BC2GM027354703 NN O
with BC2GM027354703 IN O
repeated BC2GM027354703 VBN O
Sp1 BC2GM027354703 NNP O
sites BC2GM027354703 NNS O
linked BC2GM027354703 VBD O
to BC2GM027354703 TO O
a BC2GM027354703 DT O
core BC2GM027354703 NN O
promoter BC2GM027354703 NN O
, BC2GM027354703 , O
and BC2GM027354703 CC O
a BC2GM027354703 DT O
plasmid BC2GM027354703 NN O
regulated BC2GM027354703 VBN O
by BC2GM027354703 IN O
a BC2GM027354703 DT O
chimeric BC2GM027354703 JJ O
transactivator BC2GM027354703 NN O
in BC2GM027354703 IN O
which BC2GM027354703 WDT O
the BC2GM027354703 DT O
Gal4 BC2GM027354703 NNP O
DNA BC2GM027354703 NNP O
binding BC2GM027354703 VBG O
domain BC2GM027354703 NN O
is BC2GM027354703 VBZ O
fused BC2GM027354703 VBN O
to BC2GM027354703 TO O
the BC2GM027354703 DT O
Sp1 BC2GM027354703 NNP O
transactivation BC2GM027354703 NN O
domain BC2GM027354703 NN O
, BC2GM027354703 , O
indicating BC2GM027354703 VBG O
that BC2GM027354703 IN O
this BC2GM027354703 DT O
transactivation BC2GM027354703 NN O
domain BC2GM027354703 NN O
is BC2GM027354703 VBZ O
regulated BC2GM027354703 VBN O
by BC2GM027354703 IN O
NGF BC2GM027354703 NNP O
. BC2GM027354703 . O
. . O O

DNA BC2GM067442667 NNP O
sequence BC2GM067442667 NN O
of BC2GM067442667 IN O
the BC2GM067442667 DT O
UL6 BC2GM067442667 NNP O
to BC2GM067442667 TO O
UL20 BC2GM067442667 NNP O
genes BC2GM067442667 NNS O
of BC2GM067442667 IN O
infectious BC2GM067442667 JJ O
laryngotracheitis BC2GM067442667 NN O
virus BC2GM067442667 NN O
and BC2GM067442667 CC O
characterization BC2GM067442667 NN O
of BC2GM067442667 IN O
the BC2GM067442667 DT O
UL10 BC2GM067442667 NNP O
gene BC2GM067442667 NN O
product BC2GM067442667 NN O
as BC2GM067442667 IN O
a BC2GM067442667 DT O
nonglycosylated BC2GM067442667 JJ O
and BC2GM067442667 CC O
nonessential BC2GM067442667 JJ O
virion BC2GM067442667 NN O
protein BC2GM067442667 NN O
. BC2GM067442667 . O
. . O O

The BC2GM093697629 DT O
human BC2GM093697629 JJ O
Fc BC2GM093697629 NNP O
gamma BC2GM093697629 NN O
receptor BC2GM093697629 NN O
gene BC2GM093697629 NN O
Fc BC2GM093697629 NNP O
gamma BC2GM093697629 NN O
RIIA BC2GM093697629 NNP O
is BC2GM093697629 VBZ O
expressed BC2GM093697629 VBN O
in BC2GM093697629 IN O
platelets BC2GM093697629 NNS O
, BC2GM093697629 , O
neutrophils BC2GM093697629 NNS O
, BC2GM093697629 , O
monocytes BC2GM093697629 NNS O
and BC2GM093697629 CC O
macrophages BC2GM093697629 NNS O
. BC2GM093697629 . O
. . O O

The BC2GM080722657 DT O
frequency BC2GM080722657 NN O
of BC2GM080722657 IN O
eating BC2GM080722657 VBG O
dark-meat BC2GM080722657 JJ O
fish BC2GM080722657 NN O
was BC2GM080722657 VBD O
positively BC2GM080722657 RB O
associated BC2GM080722657 VBN O
with BC2GM080722657 IN O
serum BC2GM080722657 NN O
eicosapentaenoic BC2GM080722657 NN O
acid BC2GM080722657 NN O
and BC2GM080722657 CC O
docosahexaenoic BC2GM080722657 NN O
acid BC2GM080722657 NN O
, BC2GM080722657 , O
omega3 BC2GM080722657 JJ O
fatty BC2GM080722657 JJ O
acids BC2GM080722657 NNS O
, BC2GM080722657 , O
and BC2GM080722657 CC O
inversely BC2GM080722657 RB O
associated BC2GM080722657 VBN O
with BC2GM080722657 IN O
serum BC2GM080722657 NN O
stearic BC2GM080722657 JJ O
acid BC2GM080722657 NN O
and BC2GM080722657 CC O
linoleic BC2GM080722657 JJ O
acid BC2GM080722657 NN O
. BC2GM080722657 . O
. . O O

We BC2GM071925716 PRP O
concluded BC2GM071925716 VBD O
that BC2GM071925716 IN O
RXR-gamma BC2GM071925716 NNP O
induced BC2GM071925716 VBD O
terminal BC2GM071925716 JJ O
differentiation BC2GM071925716 NN O
in BC2GM071925716 IN O
SCC BC2GM071925716 NNP O
lines BC2GM071925716 NNS O
, BC2GM071925716 , O
suggesting BC2GM071925716 VBG O
a BC2GM071925716 DT O
potential BC2GM071925716 JJ O
tumor BC2GM071925716 NN O
suppressor BC2GM071925716 NN O
function BC2GM071925716 NN O
for BC2GM071925716 IN O
this BC2GM071925716 DT O
transcription BC2GM071925716 NN O
factor BC2GM071925716 NN O
. BC2GM071925716 . O
. . O O

The BC2GM013080012 DT O
enzyme BC2GM013080012 NN O
ACC BC2GM013080012 NNP O
oxidase BC2GM013080012 NN O
catalyses BC2GM013080012 VBZ O
the BC2GM013080012 DT O
last BC2GM013080012 JJ O
step BC2GM013080012 NN O
of BC2GM013080012 IN O
ethylene BC2GM013080012 JJ O
biosynthesis BC2GM013080012 NN O
in BC2GM013080012 IN O
plants BC2GM013080012 NNS O
, BC2GM013080012 , O
converting BC2GM013080012 VBG O
1-aminocyclopropane-1-carboxylic BC2GM013080012 JJ O
acid BC2GM013080012 NN O
( BC2GM013080012 ( O
ACC BC2GM013080012 NNP O
) BC2GM013080012 ) O
to BC2GM013080012 TO O
ethylene BC2GM013080012 VB O
. BC2GM013080012 . O
. . O O

We BC2GM088326389 PRP O
have BC2GM088326389 VBP O
isolated BC2GM088326389 VBN O
a BC2GM088326389 DT O
unique BC2GM088326389 JJ O
murine BC2GM088326389 NN O
FLT3 BC2GM088326389 NNP O
cDNA BC2GM088326389 NN O
that BC2GM088326389 WDT O
codes BC2GM088326389 VBZ O
for BC2GM088326389 IN O
a BC2GM088326389 DT O
variant BC2GM088326389 JJ O
isoform BC2GM088326389 NN O
of BC2GM088326389 IN O
FLT3 BC2GM088326389 NNP O
, BC2GM088326389 , O
devoid BC2GM088326389 NN O
of BC2GM088326389 IN O
the BC2GM088326389 DT O
fifth BC2GM088326389 JJ O
Ig-like BC2GM088326389 NNP O
domain BC2GM088326389 NN O
, BC2GM088326389 , O
by BC2GM088326389 IN O
comparison BC2GM088326389 NN O
with BC2GM088326389 IN O
the BC2GM088326389 DT O
prototypic BC2GM088326389 NN O
form BC2GM088326389 NN O
. BC2GM088326389 . O
. . O O

Transfection BC2GM046642250 NN O
of BC2GM046642250 IN O
H BC2GM046642250 NNP O
chain BC2GM046642250 NN O
loss BC2GM046642250 NN O
variant BC2GM046642250 JJ O
myeloma BC2GM046642250 NN O
with BC2GM046642250 IN O
the BC2GM046642250 DT O
complete BC2GM046642250 JJ O
12 BC2GM046642250 CD O
kb BC2GM046642250 NN O
construct BC2GM046642250 NN O
, BC2GM046642250 , O
termed BC2GM046642250 VBD O
238H-Cmicro BC2GM046642250 JJ O
, BC2GM046642250 , O
resulted BC2GM046642250 VBD O
in BC2GM046642250 IN O
secretion BC2GM046642250 NN O
of BC2GM046642250 IN O
intact BC2GM046642250 JJ O
Ig BC2GM046642250 NNP O
pairing BC2GM046642250 VBG O
238H-Cmicro BC2GM046642250 JJ O
, BC2GM046642250 , O
with BC2GM046642250 IN O
a BC2GM046642250 DT O
lambda BC2GM046642250 JJ O
L BC2GM046642250 NNP O
chain BC2GM046642250 NN O
; BC2GM046642250 : O
however BC2GM046642250 RB O
, BC2GM046642250 , O
transfectant BC2GM046642250 JJ O
Ig BC2GM046642250 NNP O
lacked BC2GM046642250 VBD O
autoreactivity BC2GM046642250 NN O
and BC2GM046642250 CC O
pathogenicity BC2GM046642250 NN O
. BC2GM046642250 . O
. . O O

Moist BC2GM056870406 NNP O
healing BC2GM056870406 VBG O
versus BC2GM056870406 JJ O
wet-to-dry BC2GM056870406 JJ O
. BC2GM056870406 . O
. . O O

The BC2GM072974603 DT O
destruction BC2GM072974603 NN O
of BC2GM072974603 IN O
the BC2GM072974603 DT O
mesometrium BC2GM072974603 NN O
did BC2GM072974603 VBD O
not BC2GM072974603 RB O
lengthen BC2GM072974603 VB O
the BC2GM072974603 DT O
oestrous BC2GM072974603 JJ O
cycle BC2GM072974603 NN O
. BC2GM072974603 . O
. . O O

Copyright BC2GM084077526 JJ O
1998 BC2GM084077526 CD O
Academic BC2GM084077526 NNP O
Press BC2GM084077526 NNP O
. BC2GM084077526 . O
. . O O

Using BC2GM005451560 VBG O
lasers BC2GM005451560 NNS O
, BC2GM005451560 , O
PRK BC2GM005451560 NNP O
involves BC2GM005451560 VBZ O
reshaping BC2GM005451560 VBG O
the BC2GM005451560 DT O
cornea BC2GM005451560 NN O
so BC2GM005451560 RB O
that BC2GM005451560 IN O
its BC2GM005451560 PRP$ O
refractive BC2GM005451560 JJ O
power BC2GM005451560 NN O
is BC2GM005451560 VBZ O
increased BC2GM005451560 VBN O
. BC2GM005451560 . O
. . O O

The BC2GM051746475 DT O
resulting BC2GM051746475 VBG O
score BC2GM051746475 NN O
, BC2GM051746475 , O
which BC2GM051746475 WDT O
allowed BC2GM051746475 VBD O
the BC2GM051746475 DT O
disease BC2GM051746475 NN O
to BC2GM051746475 TO O
be BC2GM051746475 VB O
expressed BC2GM051746475 VBN O
as BC2GM051746475 IN O
a BC2GM051746475 DT O
continuous BC2GM051746475 JJ O
variable BC2GM051746475 NN O
, BC2GM051746475 , O
was BC2GM051746475 VBD O
effectively BC2GM051746475 RB O
utilized BC2GM051746475 JJ O
to BC2GM051746475 TO O
see BC2GM051746475 VB O
the BC2GM051746475 DT O
correlations BC2GM051746475 NNS O
between BC2GM051746475 IN O
the BC2GM051746475 DT O
severity BC2GM051746475 NN O
of BC2GM051746475 IN O
coronary BC2GM051746475 JJ O
arterial BC2GM051746475 JJ O
disease BC2GM051746475 NN O
( BC2GM051746475 ( O
CAD BC2GM051746475 NNP O
) BC2GM051746475 ) O
and BC2GM051746475 CC O
individual BC2GM051746475 JJ O
risk BC2GM051746475 NN O
factors BC2GM051746475 NNS O
/ BC2GM051746475 VBP O
risk BC2GM051746475 NN O
markers BC2GM051746475 NNS O
. BC2GM051746475 . O
. . O O

88 BC2GM003935200 CD O
, BC2GM003935200 , O
3739-3743 BC2GM003935200 NNP O
) BC2GM003935200 ) O
) BC2GM003935200 ) O
. BC2GM003935200 . O
. . O O

1.23 BC2GM078893266 CD O
) BC2GM078893266 ) O
as BC2GM078893266 IN O
a BC2GM078893266 DT O
PPARalpha-interacting BC2GM078893266 JJ O
protein BC2GM078893266 NN O
. BC2GM078893266 . O
. . O O

This BC2GM013984753 DT O
fragment BC2GM013984753 NN O
contains BC2GM013984753 VBZ O
two BC2GM013984753 CD O
complete BC2GM013984753 JJ O
endo-beta-1,4-glucanase-encoding BC2GM013984753 JJ O
genes BC2GM013984753 NNS O
, BC2GM013984753 , O
designated BC2GM013984753 VBN O
celCCC BC2GM013984753 NN O
and BC2GM013984753 CC O
celCCG BC2GM013984753 NN O
. BC2GM013984753 . O
. . O O

Adaptive BC2GM064612390 JJ O
effects BC2GM064612390 NNS O
of BC2GM064612390 IN O
repeated BC2GM064612390 JJ O
immersion BC2GM064612390 NN O
exposure BC2GM064612390 NN O
on BC2GM064612390 IN O
the BC2GM064612390 DT O
human BC2GM064612390 JJ O
body BC2GM064612390 NN O
. BC2GM064612390 . O
. . O O

Blood BC2GM081973466 NN O
samples BC2GM081973466 NNS O
for BC2GM081973466 IN O
determination BC2GM081973466 NN O
of BC2GM081973466 IN O
fibrinolytic BC2GM081973466 JJ O
activity BC2GM081973466 NN O
and BC2GM081973466 CC O
factor BC2GM081973466 NN O
VIII BC2GM081973466 NNP O
in BC2GM081973466 IN O
plasma BC2GM081973466 NN O
were BC2GM081973466 VBD O
obtained BC2GM081973466 VBN O
before BC2GM081973466 IN O
and BC2GM081973466 CC O
immediately BC2GM081973466 RB O
after BC2GM081973466 IN O
the BC2GM081973466 DT O
end BC2GM081973466 NN O
of BC2GM081973466 IN O
compression BC2GM081973466 NN O
and BC2GM081973466 CC O
application BC2GM081973466 NN O
of BC2GM081973466 IN O
a BC2GM081973466 DT O
stocking BC2GM081973466 NN O
, BC2GM081973466 , O
respectively BC2GM081973466 RB O
. BC2GM081973466 . O
. . O O

Despite BC2GM050673543 IN O
a BC2GM050673543 DT O
lowering BC2GM050673543 NN O
of BC2GM050673543 IN O
her BC2GM050673543 PRP$ O
plasma BC2GM050673543 NN O
ACTH BC2GM050673543 NNP O
concentration BC2GM050673543 NN O
during BC2GM050673543 IN O
therapy BC2GM050673543 NN O
with BC2GM050673543 IN O
valproic BC2GM050673543 JJ O
acid BC2GM050673543 NN O
, BC2GM050673543 , O
the BC2GM050673543 DT O
patient BC2GM050673543 NN O
's BC2GM050673543 POS O
tumour BC2GM050673543 NN O
showed BC2GM050673543 VBD O
no BC2GM050673543 DT O
evidence BC2GM050673543 NN O
of BC2GM050673543 IN O
regression BC2GM050673543 NN O
while BC2GM050673543 IN O
she BC2GM050673543 PRP O
was BC2GM050673543 VBD O
taking BC2GM050673543 VBG O
the BC2GM050673543 DT O
drug BC2GM050673543 NN O
. BC2GM050673543 . O
. . O O

Injection BC2GM020166073 NN O
of BC2GM020166073 IN O
horseradish BC2GM020166073 JJ O
peroxidase BC2GM020166073 NN O
( BC2GM020166073 ( O
HRP BC2GM020166073 NNP O
) BC2GM020166073 ) O
into BC2GM020166073 IN O
the BC2GM020166073 DT O
cerebellar BC2GM020166073 JJ O
flocculus BC2GM020166073 NN O
of BC2GM020166073 IN O
the BC2GM020166073 DT O
rat BC2GM020166073 NN O
was BC2GM020166073 VBD O
employed BC2GM020166073 VBN O
to BC2GM020166073 TO O
identify BC2GM020166073 VB O
neurons BC2GM020166073 NNS O
in BC2GM020166073 IN O
the BC2GM020166073 DT O
abducens BC2GM020166073 NNS O
nucleus BC2GM020166073 VBP O
that BC2GM020166073 IN O
project BC2GM020166073 NN O
to BC2GM020166073 TO O
the BC2GM020166073 DT O
flocculus BC2GM020166073 NN O
. BC2GM020166073 . O
. . O O

The BC2GM002520653 DT O
SM-specific BC2GM002520653 JJ O
selection BC2GM002520653 NN O
of BC2GM002520653 IN O
exon BC2GM002520653 $ O
2 BC2GM002520653 CD O
results BC2GM002520653 NNS O
from BC2GM002520653 IN O
the BC2GM002520653 DT O
inhibition BC2GM002520653 NN O
of BC2GM002520653 IN O
exon BC2GM002520653 $ O
3 BC2GM002520653 CD O
. BC2GM002520653 . O
. . O O

The BC2GM027249093 DT O
polypeptide BC2GM027249093 NN O
encoded BC2GM027249093 VBN O
by BC2GM027249093 IN O
the BC2GM027249093 DT O
cDNA BC2GM027249093 NN O
contained BC2GM027249093 VBD O
450 BC2GM027249093 CD O
amino BC2GM027249093 NN O
acids BC2GM027249093 NNS O
with BC2GM027249093 IN O
a BC2GM027249093 DT O
calculated BC2GM027249093 JJ O
M BC2GM027249093 NNP O
( BC2GM027249093 ( O
r BC2GM027249093 NN O
) BC2GM027249093 ) O
of BC2GM027249093 IN O
52,057 BC2GM027249093 CD O
, BC2GM027249093 , O
and BC2GM027249093 CC O
showed BC2GM027249093 VBD O
significant BC2GM027249093 JJ O
homology BC2GM027249093 NN O
with BC2GM027249093 IN O
human BC2GM027249093 JJ O
and BC2GM027249093 CC O
mouse BC2GM027249093 NN O
CAD BC2GM027249093 NNP O
( BC2GM027249093 ( O
22 BC2GM027249093 CD O
% BC2GM027249093 NN O
identity BC2GM027249093 NN O
) BC2GM027249093 ) O
. BC2GM027249093 . O
. . O O

We BC2GM076808148 PRP O
have BC2GM076808148 VBP O
documented BC2GM076808148 VBN O
previously BC2GM076808148 RB O
that BC2GM076808148 IN O
glucocorticoid BC2GM076808148 JJ O
hormones BC2GM076808148 NNS O
modulate BC2GM076808148 VBP O
the BC2GM076808148 DT O
posttranslational BC2GM076808148 JJ O
localization BC2GM076808148 NN O
of BC2GM076808148 IN O
cell BC2GM076808148 NN O
surface BC2GM076808148 NN O
mouse BC2GM076808148 NN O
mammary BC2GM076808148 JJ O
tumor BC2GM076808148 NN O
virus BC2GM076808148 NN O
( BC2GM076808148 ( O
MMTV BC2GM076808148 NNP O
) BC2GM076808148 ) O
glycoproteins BC2GM076808148 VBZ O
in BC2GM076808148 IN O
the BC2GM076808148 DT O
viral-infected BC2GM076808148 JJ O
M1.54 BC2GM076808148 NNP O
rat BC2GM076808148 NN O
HTC BC2GM076808148 NNP O
hepatoma BC2GM076808148 NN O
cell BC2GM076808148 NN O
line BC2GM076808148 NN O
. BC2GM076808148 . O
. . O O

Cotransfection BC2GM035682880 NN O
experiments BC2GM035682880 NNS O
revealed BC2GM035682880 VBD O
that BC2GM035682880 IN O
both BC2GM035682880 DT O
hGATA-4 BC2GM035682880 JJ O
and BC2GM035682880 CC O
PMA BC2GM035682880 NNP O
/ BC2GM035682880 NNP O
A23187 BC2GM035682880 NNP O
stimulation BC2GM035682880 NN O
are BC2GM035682880 VBP O
necessary BC2GM035682880 JJ O
for BC2GM035682880 IN O
the BC2GM035682880 DT O
IL-5 BC2GM035682880 NNP O
promoter BC2GM035682880 NN O
activation BC2GM035682880 NN O
. BC2GM035682880 . O
. . O O

Transcription BC2GM060988781 NN O
initiation BC2GM060988781 NN O
from BC2GM060988781 IN O
this BC2GM060988781 DT O
region BC2GM060988781 NN O
was BC2GM060988781 VBD O
also BC2GM060988781 RB O
detected BC2GM060988781 VBN O
in BC2GM060988781 IN O
vivo BC2GM060988781 NN O
, BC2GM060988781 , O
when BC2GM060988781 WRB O
the BC2GM060988781 DT O
cloned BC2GM060988781 VBN O
rRNA BC2GM060988781 NN O
gene BC2GM060988781 NN O
cluster BC2GM060988781 NN O
was BC2GM060988781 VBD O
present BC2GM060988781 JJ O
on BC2GM060988781 IN O
a BC2GM060988781 DT O
multi-copy BC2GM060988781 JJ O
plasmid BC2GM060988781 NN O
. BC2GM060988781 . O
. . O O

The BC2GM058293960 DT O
quantitative BC2GM058293960 JJ O
analysis BC2GM058293960 NN O
of BC2GM058293960 IN O
1-alpha-acetylmethadol BC2GM058293960 JJ O
and BC2GM058293960 CC O
its BC2GM058293960 PRP$ O
principal BC2GM058293960 JJ O
metabolites BC2GM058293960 NNS O
in BC2GM058293960 IN O
biological BC2GM058293960 JJ O
specimens BC2GM058293960 NNS O
by BC2GM058293960 IN O
gas BC2GM058293960 NN O
chromatography-chemical BC2GM058293960 JJ O
ionization-multiple BC2GM058293960 JJ O
ion BC2GM058293960 NN O
monitoring BC2GM058293960 VBG O
mass BC2GM058293960 NN O
spectrometry BC2GM058293960 NN O
. BC2GM058293960 . O
. . O O

Serum BC2GM001962189 NNP O
C3 BC2GM001962189 NNP O
was BC2GM001962189 VBD O
measured BC2GM001962189 VBN O
in BC2GM001962189 IN O
1,282 BC2GM001962189 CD O
school BC2GM001962189 NN O
children BC2GM001962189 NNS O
with BC2GM001962189 IN O
abnormal BC2GM001962189 JJ O
urinary BC2GM001962189 JJ O
findings BC2GM001962189 NNS O
between BC2GM001962189 IN O
1980 BC2GM001962189 CD O
and BC2GM001962189 CC O
1997 BC2GM001962189 CD O
. BC2GM001962189 . O
. . O O

Kramer BC2GM011471991 NNP O
Hamburg BC2GM011471991 NNP O
1988 BC2GM011471991 CD O
, BC2GM011471991 , O
ISBN BC2GM011471991 NNP O
: BC2GM011471991 : O
3 BC2GM011471991 CD O
926952 BC2GM011471991 CD O
07 BC2GM011471991 CD O
5 BC2GM011471991 CD O
) BC2GM011471991 ) O
, BC2GM011471991 , O
the BC2GM011471991 DT O
syndromatic BC2GM011471991 JJ O
day-to-day BC2GM011471991 JJ O
shifting BC2GM011471991 NN O
of BC2GM011471991 IN O
the BC2GM011471991 DT O
psychopathological BC2GM011471991 JJ O
features BC2GM011471991 NNS O
with BC2GM011471991 IN O
manic BC2GM011471991 NN O
, BC2GM011471991 , O
depressive BC2GM011471991 JJ O
and BC2GM011471991 CC O
several BC2GM011471991 JJ O
mixed BC2GM011471991 JJ O
states BC2GM011471991 NNS O
has BC2GM011471991 VBZ O
a BC2GM011471991 DT O
well-defined BC2GM011471991 JJ O
time BC2GM011471991 NN O
structure BC2GM011471991 NN O
, BC2GM011471991 , O
as BC2GM011471991 IN O
in BC2GM011471991 IN O
25 BC2GM011471991 CD O
patients BC2GM011471991 NNS O
studied BC2GM011471991 VBN O
and BC2GM011471991 CC O
reported BC2GM011471991 VBN O
on BC2GM011471991 IN O
in BC2GM011471991 IN O
this BC2GM011471991 DT O
paper BC2GM011471991 NN O
. BC2GM011471991 . O
. . O O

Isolation BC2GM075054681 NN O
and BC2GM075054681 CC O
properties BC2GM075054681 NNS O
of BC2GM075054681 IN O
Drosophila BC2GM075054681 NNP O
melanogaster BC2GM075054681 NN O
ferritin BC2GM075054681 NN O
-- BC2GM075054681 : O
molecular BC2GM075054681 JJ O
cloning BC2GM075054681 NN O
of BC2GM075054681 IN O
a BC2GM075054681 DT O
cDNA BC2GM075054681 NN O
that BC2GM075054681 WDT O
encodes BC2GM075054681 VBZ O
one BC2GM075054681 CD O
subunit BC2GM075054681 NN O
, BC2GM075054681 , O
and BC2GM075054681 CC O
localization BC2GM075054681 NN O
of BC2GM075054681 IN O
the BC2GM075054681 DT O
gene BC2GM075054681 NN O
on BC2GM075054681 IN O
the BC2GM075054681 DT O
third BC2GM075054681 JJ O
chromosome BC2GM075054681 NN O
. BC2GM075054681 . O
. . O O

Interleukin-1 BC2GM085006579 NNP O
increased BC2GM085006579 VBD O
the BC2GM085006579 DT O
noradrenaline BC2GM085006579 JJ O
release BC2GM085006579 NN O
. BC2GM085006579 . O
. . O O

Sorting BC2GM093006252 VBG O
information BC2GM093006252 NN O
to BC2GM093006252 TO O
the BC2GM093006252 DT O
chloroplastic BC2GM093006252 JJ O
inner BC2GM093006252 NN O
envelope BC2GM093006252 NN O
is BC2GM093006252 VBZ O
contained BC2GM093006252 VBN O
in BC2GM093006252 IN O
an BC2GM093006252 DT O
NH2-proximal BC2GM093006252 JJ O
part BC2GM093006252 NN O
of BC2GM093006252 IN O
mature BC2GM093006252 NN O
IEP110 BC2GM093006252 NNP O
( BC2GM093006252 ( O
110N BC2GM093006252 CD O
) BC2GM093006252 ) O
. BC2GM093006252 . O
. . O O

The BC2GM001618021 DT O
hematopoietic BC2GM001618021 JJ O
form BC2GM001618021 NN O
of BC2GM001618021 IN O
PTPN6 BC2GM001618021 NNP O
transcript BC2GM001618021 NN O
is BC2GM001618021 VBZ O
initiated BC2GM001618021 VBN O
at BC2GM001618021 IN O
a BC2GM001618021 DT O
downstream BC2GM001618021 NN O
promoter BC2GM001618021 NN O
separated BC2GM001618021 VBN O
by BC2GM001618021 IN O
7 BC2GM001618021 CD O
kb BC2GM001618021 NNS O
from BC2GM001618021 IN O
the BC2GM001618021 DT O
first BC2GM001618021 JJ O
. BC2GM001618021 . O
. . O O

The BC2GM095896930 DT O
authors BC2GM095896930 NNS O
emphasize BC2GM095896930 VBP O
absence BC2GM095896930 NN O
of BC2GM095896930 IN O
specific BC2GM095896930 JJ O
signs BC2GM095896930 NNS O
of BC2GM095896930 IN O
vagal BC2GM095896930 JJ O
involvement BC2GM095896930 NN O
, BC2GM095896930 , O
importance BC2GM095896930 NN O
for BC2GM095896930 IN O
diagnosis BC2GM095896930 NN O
of BC2GM095896930 IN O
surgical BC2GM095896930 JJ O
extirpation BC2GM095896930 NN O
, BC2GM095896930 , O
and BC2GM095896930 CC O
mildness BC2GM095896930 NN O
of BC2GM095896930 IN O
post BC2GM095896930 NN O
operative BC2GM095896930 JJ O
course BC2GM095896930 NN O
. BC2GM095896930 . O
. . O O

Quantitative BC2GM063584171 JJ O
measurement BC2GM063584171 NN O
of BC2GM063584171 IN O
antigamma BC2GM063584171 JJ O
globulin BC2GM063584171 NN O
factors BC2GM063584171 NNS O
( BC2GM063584171 ( O
rheumatoid BC2GM063584171 JJ O
factors BC2GM063584171 NNS O
) BC2GM063584171 ) O
using BC2GM063584171 VBG O
laser-nephelometry BC2GM063584171 NN O
in BC2GM063584171 IN O
comparison BC2GM063584171 NN O
with BC2GM063584171 IN O
the BC2GM063584171 DT O
latex BC2GM063584171 JJ O
agglutination BC2GM063584171 NN O
test BC2GM063584171 NN O
and BC2GM063584171 CC O
the BC2GM063584171 DT O
Waaler-Rose BC2GM063584171 JJ O
test BC2GM063584171 NN O
. BC2GM063584171 . O
. . O O

Covariates BC2GM055697926 NNS O
were BC2GM055697926 VBD O
lower BC2GM055697926 JJR O
extremity BC2GM055697926 NN O
range BC2GM055697926 NN O
of BC2GM055697926 IN O
motion BC2GM055697926 NN O
and BC2GM055697926 CC O
sensory BC2GM055697926 JJ O
status BC2GM055697926 NN O
. BC2GM055697926 . O
. . O O

All BC2GM073366663 DT O
patients BC2GM073366663 NNS O
studied BC2GM073366663 VBN O
were BC2GM073366663 VBD O
pregnant BC2GM073366663 JJ O
women BC2GM073366663 NNS O
and BC2GM073366663 CC O
their BC2GM073366663 PRP$ O
delivered BC2GM073366663 JJ O
children BC2GM073366663 NNS O
. BC2GM073366663 . O
. . O O

Mutation BC2GM049574231 NN O
of BC2GM049574231 IN O
the BC2GM049574231 DT O
distal BC2GM049574231 JJ O
E2F BC2GM049574231 NNP O
binding BC2GM049574231 VBG O
site BC2GM049574231 NN O
in BC2GM049574231 IN O
the BC2GM049574231 DT O
cdc25A BC2GM049574231 NN O
promoter BC2GM049574231 NN O
abolished BC2GM049574231 VBD O
E2-induced BC2GM049574231 NNP O
repression BC2GM049574231 NN O
, BC2GM049574231 , O
whereas BC2GM049574231 JJ O
mutation BC2GM049574231 NN O
of BC2GM049574231 IN O
the BC2GM049574231 DT O
proximal BC2GM049574231 JJ O
E2F BC2GM049574231 NNP O
site BC2GM049574231 NN O
or BC2GM049574231 CC O
the BC2GM049574231 DT O
E2 BC2GM049574231 NNP O
site BC2GM049574231 NN O
had BC2GM049574231 VBD O
no BC2GM049574231 DT O
effect BC2GM049574231 NN O
. BC2GM049574231 . O
. . O O

Serum BC2GM063096861 NNP O
levels BC2GM063096861 NNS O
of BC2GM063096861 IN O
total BC2GM063096861 NN O
and BC2GM063096861 CC O
specific BC2GM063096861 JJ O
immunoglobulin BC2GM063096861 NN O
E BC2GM063096861 NNP O
( BC2GM063096861 ( O
IgE BC2GM063096861 NNP O
) BC2GM063096861 ) O
have BC2GM063096861 VBP O
been BC2GM063096861 VBN O
determined BC2GM063096861 VBN O
by BC2GM063096861 IN O
radioimmunoassays BC2GM063096861 NNS O
in BC2GM063096861 IN O
sixty-nine BC2GM063096861 JJ O
allergic BC2GM063096861 JJ O
subjects BC2GM063096861 NNS O
. BC2GM063096861 . O
. . O O

The BC2GM045293373 DT O
efficiency BC2GM045293373 NN O
of BC2GM045293373 IN O
transfections BC2GM045293373 NNS O
was BC2GM045293373 VBD O
normalized BC2GM045293373 VBN O
relative BC2GM045293373 JJ O
to BC2GM045293373 TO O
the BC2GM045293373 DT O
net BC2GM045293373 JJ O
amount BC2GM045293373 NN O
of BC2GM045293373 IN O
CAT BC2GM045293373 NNP O
plasmid BC2GM045293373 FW O
actually BC2GM045293373 RB O
transfected BC2GM045293373 VBN O
into BC2GM045293373 IN O
recipient BC2GM045293373 NN O
cells BC2GM045293373 NNS O
, BC2GM045293373 , O
determined BC2GM045293373 VBN O
by BC2GM045293373 IN O
a BC2GM045293373 DT O
modified BC2GM045293373 JJ O
Southern BC2GM045293373 JJ O
hybridization BC2GM045293373 NN O
procedure BC2GM045293373 NN O
. BC2GM045293373 . O
. . O O

The BC2GM066166532 DT O
gene BC2GM066166532 NN O
encoding BC2GM066166532 VBG O
rat BC2GM066166532 JJ O
peptidylglycine BC2GM066166532 JJ O
alpha-amidating BC2GM066166532 JJ O
monooxygenase BC2GM066166532 NN O
( BC2GM066166532 ( O
PAM BC2GM066166532 NNP O
) BC2GM066166532 ) O
contains BC2GM066166532 VBZ O
26 BC2GM066166532 CD O
protein-coding BC2GM066166532 JJ O
exons BC2GM066166532 NNS O
. BC2GM066166532 . O
. . O O

A BC2GM003632823 DT O
study BC2GM003632823 NN O
of BC2GM003632823 IN O
characteristics BC2GM003632823 NNS O
in BC2GM003632823 IN O
adult BC2GM003632823 NN O
asthmatics BC2GM003632823 NNS O
who BC2GM003632823 WP O
are BC2GM003632823 VBP O
sensitized BC2GM003632823 VBN O
by BC2GM003632823 IN O
cats BC2GM003632823 NNS O
and BC2GM003632823 CC O
dogs BC2GM003632823 NNS O
allergens BC2GM003632823 NNS O
. BC2GM003632823 . O
. . O O

Healthy BC2GM028289615 JJ O
preterm BC2GM028289615 NN O
infants BC2GM028289615 NNS O
of BC2GM028289615 IN O
gestational BC2GM028289615 JJ O
age BC2GM028289615 NN O
26-29 BC2GM028289615 JJ O
weeks BC2GM028289615 NNS O
showed BC2GM028289615 VBD O
a BC2GM028289615 DT O
'mature BC2GM028289615 NN O
' BC2GM028289615 POS O
pattern BC2GM028289615 NN O
of BC2GM028289615 IN O
permeability BC2GM028289615 NN O
at BC2GM028289615 IN O
birth BC2GM028289615 NN O
, BC2GM028289615 , O
followed BC2GM028289615 VBN O
by BC2GM028289615 IN O
a BC2GM028289615 DT O
temporary BC2GM028289615 JJ O
period BC2GM028289615 NN O
of BC2GM028289615 IN O
enhanced BC2GM028289615 JJ O
permeability BC2GM028289615 NN O
after BC2GM028289615 IN O
3-4 BC2GM028289615 JJ O
weeks BC2GM028289615 NNS O
of BC2GM028289615 IN O
life BC2GM028289615 NN O
. BC2GM028289615 . O
. . O O

The BC2GM064662484 DT O
promyelocytic BC2GM064662484 JJ O
leukemia BC2GM064662484 NN O
protein BC2GM064662484 NN O
interacts BC2GM064662484 VBZ O
with BC2GM064662484 IN O
Sp1 BC2GM064662484 NNP O
and BC2GM064662484 CC O
inhibits BC2GM064662484 VBZ O
its BC2GM064662484 PRP$ O
transactivation BC2GM064662484 NN O
of BC2GM064662484 IN O
the BC2GM064662484 DT O
epidermal BC2GM064662484 JJ O
growth BC2GM064662484 NN O
factor BC2GM064662484 NN O
receptor BC2GM064662484 NN O
promoter BC2GM064662484 NN O
. BC2GM064662484 . O
. . O O

These BC2GM052334866 DT O
data BC2GM052334866 NNS O
suggest BC2GM052334866 VBP O
that BC2GM052334866 IN O
reduction BC2GM052334866 NN O
in BC2GM052334866 IN O
PRA BC2GM052334866 NNP O
may BC2GM052334866 MD O
have BC2GM052334866 VB O
contributed BC2GM052334866 VBN O
to BC2GM052334866 TO O
the BC2GM052334866 DT O
hemodynamic BC2GM052334866 JJ O
effects BC2GM052334866 NNS O
of BC2GM052334866 IN O
this BC2GM052334866 DT O
peak BC2GM052334866 JJ O
III BC2GM052334866 NNP O
PDE BC2GM052334866 NNP O
inhibitor BC2GM052334866 NN O
. BC2GM052334866 . O
. . O O

LT-beta BC2GM055754960 JJ O
transcription BC2GM055754960 NN O
is BC2GM055754960 VBZ O
maximal BC2GM055754960 JJ O
in BC2GM055754960 IN O
the BC2GM055754960 DT O
thymic BC2GM055754960 JJ O
medulla BC2GM055754960 NN O
and BC2GM055754960 CC O
in BC2GM055754960 IN O
splenic BC2GM055754960 JJ O
white BC2GM055754960 JJ O
pulp BC2GM055754960 NN O
. BC2GM055754960 . O
. . O O

KatA BC2GM028011707 NNP O
, BC2GM028011707 , O
AhpCF BC2GM028011707 NNP O
, BC2GM028011707 , O
heme BC2GM028011707 JJ O
biosynthesis BC2GM028011707 NN O
enzymes BC2GM028011707 NNS O
, BC2GM028011707 , O
and BC2GM028011707 CC O
MrgA BC2GM028011707 NNP O
are BC2GM028011707 VBP O
also BC2GM028011707 RB O
induced BC2GM028011707 VBN O
upon BC2GM028011707 IN O
entry BC2GM028011707 NN O
into BC2GM028011707 IN O
stationary BC2GM028011707 JJ O
phase BC2GM028011707 NN O
under BC2GM028011707 IN O
conditions BC2GM028011707 NNS O
of BC2GM028011707 IN O
iron BC2GM028011707 NN O
and BC2GM028011707 CC O
manganese BC2GM028011707 JJ O
limitation BC2GM028011707 NN O
. BC2GM028011707 . O
. . O O

To BC2GM045487899 TO O
determine BC2GM045487899 VB O
whether BC2GM045487899 IN O
the BC2GM045487899 DT O
transcript BC2GM045487899 NN O
encodes BC2GM045487899 VBZ O
an BC2GM045487899 DT O
active BC2GM045487899 JJ O
enzyme BC2GM045487899 NN O
, BC2GM045487899 , O
we BC2GM045487899 PRP O
developed BC2GM045487899 VBD O
a BC2GM045487899 DT O
novel BC2GM045487899 JJ O
transient BC2GM045487899 NN O
embryonic BC2GM045487899 JJ O
excision BC2GM045487899 NN O
assay BC2GM045487899 NN O
in BC2GM045487899 IN O
which BC2GM045487899 WDT O
zebrafish BC2GM045487899 JJ O
fertilized BC2GM045487899 VBN O
eggs BC2GM045487899 NNS O
were BC2GM045487899 VBD O
co-injected BC2GM045487899 JJ O
with BC2GM045487899 IN O
RNA BC2GM045487899 NNP O
transcribed BC2GM045487899 VBD O
in BC2GM045487899 IN O
vitro BC2GM045487899 NN O
using BC2GM045487899 VBG O
the BC2GM045487899 DT O
Tol2 BC2GM045487899 NNP O
cDNA BC2GM045487899 NN O
as BC2GM045487899 IN O
a BC2GM045487899 DT O
template BC2GM045487899 NN O
and BC2GM045487899 CC O
a BC2GM045487899 DT O
plasmid BC2GM045487899 JJ O
DNA BC2GM045487899 NNP O
harboring BC2GM045487899 VBG O
a BC2GM045487899 DT O
nonautonomous BC2GM045487899 JJ O
Tol2 BC2GM045487899 NNP O
element BC2GM045487899 NN O
, BC2GM045487899 , O
which BC2GM045487899 WDT O
has BC2GM045487899 VBZ O
a BC2GM045487899 DT O
deletion BC2GM045487899 NN O
in BC2GM045487899 IN O
the BC2GM045487899 DT O
transposase BC2GM045487899 NN O
coding BC2GM045487899 VBG O
region BC2GM045487899 NN O
. BC2GM045487899 . O
. . O O

In BC2GM088510048 IN O
the BC2GM088510048 DT O
presence BC2GM088510048 NN O
of BC2GM088510048 IN O
high BC2GM088510048 JJ O
concentrations BC2GM088510048 NNS O
( BC2GM088510048 ( O
propofol BC2GM088510048 JJ O
100 BC2GM088510048 CD O
microg BC2GM088510048 JJ O
mL-1 BC2GM088510048 NN O
, BC2GM088510048 , O
thiopental BC2GM088510048 JJ O
50 BC2GM088510048 CD O
microg BC2GM088510048 JJ O
mL-1 BC2GM088510048 NN O
) BC2GM088510048 ) O
marked BC2GM088510048 VBD O
relaxation BC2GM088510048 NN O
was BC2GM088510048 VBD O
observed BC2GM088510048 VBN O
( BC2GM088510048 ( O
propofol BC2GM088510048 JJ O
-32 BC2GM088510048 NN O
% BC2GM088510048 NN O
up BC2GM088510048 IN O
to BC2GM088510048 TO O
-49 BC2GM088510048 VB O
% BC2GM088510048 NN O
, BC2GM088510048 , O
P BC2GM088510048 NNP O
< BC2GM088510048 NNP O
0,05 BC2GM088510048 CD O
; BC2GM088510048 : O
thiopental BC2GM088510048 JJ O
-23 BC2GM088510048 CD O
% BC2GM088510048 NN O
up BC2GM088510048 RB O
to BC2GM088510048 TO O
-67 BC2GM088510048 VB O
% BC2GM088510048 NN O
, BC2GM088510048 , O
P BC2GM088510048 NNP O
< BC2GM088510048 NNP O
0.05 BC2GM088510048 CD O
) BC2GM088510048 ) O
. BC2GM088510048 . O
. . O O

The BC2GM036750141 DT O
human BC2GM036750141 JJ O
RFC-1 BC2GM036750141 NNP O
gene BC2GM036750141 NN O
differs BC2GM036750141 NNS O
from BC2GM036750141 IN O
the BC2GM036750141 DT O
mouse BC2GM036750141 NN O
and BC2GM036750141 CC O
hamster BC2GM036750141 NN O
genes BC2GM036750141 NNS O
both BC2GM036750141 DT O
in BC2GM036750141 IN O
terms BC2GM036750141 NNS O
of BC2GM036750141 IN O
the BC2GM036750141 DT O
total BC2GM036750141 JJ O
number BC2GM036750141 NN O
of BC2GM036750141 IN O
exons BC2GM036750141 NNS O
and BC2GM036750141 CC O
in BC2GM036750141 IN O
regard BC2GM036750141 NN O
to BC2GM036750141 TO O
alternatives BC2GM036750141 NNS O
of BC2GM036750141 IN O
exon BC2GM036750141 NN O
1 BC2GM036750141 CD O
which BC2GM036750141 WDT O
encode BC2GM036750141 VBD O
5 BC2GM036750141 CD O
' BC2GM036750141 '' O
end BC2GM036750141 NN O
heterogeneity BC2GM036750141 NN O
. BC2GM036750141 . O
. . O O

We BC2GM021603045 PRP O
have BC2GM021603045 VBP O
mapped BC2GM021603045 VBN O
the BC2GM021603045 DT O
specific BC2GM021603045 NN O
domains BC2GM021603045 VBZ O
within BC2GM021603045 IN O
each BC2GM021603045 DT O
of BC2GM021603045 IN O
the BC2GM021603045 DT O
proteins BC2GM021603045 NNS O
responsible BC2GM021603045 JJ O
for BC2GM021603045 IN O
this BC2GM021603045 DT O
interaction BC2GM021603045 NN O
. BC2GM021603045 . O
. . O O

A BC2GM042911073 DT O
possible BC2GM042911073 JJ O
correlation BC2GM042911073 NN O
between BC2GM042911073 IN O
mandibular BC2GM042911073 JJ O
growth BC2GM042911073 NN O
retardation BC2GM042911073 NN O
and BC2GM042911073 CC O
palatal BC2GM042911073 JJ O
clefting BC2GM042911073 NN O
is BC2GM042911073 VBZ O
discussed BC2GM042911073 VBN O
. BC2GM042911073 . O
. . O O

S-phase-promoting BC2GM033262537 JJ O
cyclin-dependent BC2GM033262537 JJ O
kinases BC2GM033262537 NNS O
( BC2GM033262537 ( O
Cdks BC2GM033262537 NNP O
) BC2GM033262537 ) O
and BC2GM033262537 CC O
the BC2GM033262537 DT O
kinase BC2GM033262537 NN O
Dbf4-Cdc7 BC2GM033262537 NNP O
then BC2GM033262537 RB O
act BC2GM033262537 VB O
to BC2GM033262537 TO O
initiate BC2GM033262537 VB O
replication BC2GM033262537 NN O
. BC2GM033262537 . O
. . O O

In BC2GM088515251 IN O
further BC2GM088515251 JJ O
support BC2GM088515251 NN O
of BC2GM088515251 IN O
the BC2GM088515251 DT O
biological BC2GM088515251 JJ O
significance BC2GM088515251 NN O
of BC2GM088515251 IN O
these BC2GM088515251 DT O
DNA-protein BC2GM088515251 NNP O
interactions BC2GM088515251 NNS O
, BC2GM088515251 , O
the BC2GM088515251 DT O
IL2RA BC2GM088515251 NNP O
oligonucleotide BC2GM088515251 NN O
from BC2GM088515251 IN O
-291 BC2GM088515251 NN O
to BC2GM088515251 TO O
-245 BC2GM088515251 VB O
proved BC2GM088515251 VBN O
to BC2GM088515251 TO O
be BC2GM088515251 VB O
sufficient BC2GM088515251 JJ O
in BC2GM088515251 IN O
either BC2GM088515251 DT O
orientation BC2GM088515251 NN O
to BC2GM088515251 TO O
confer BC2GM088515251 VB O
PMA BC2GM088515251 NNP O
inducibility BC2GM088515251 NN O
to BC2GM088515251 TO O
the BC2GM088515251 DT O
mitogen-insensitive BC2GM088515251 JJ O
thymidine BC2GM088515251 NN O
kinase BC2GM088515251 NN O
gene BC2GM088515251 NN O
promoter BC2GM088515251 NN O
in BC2GM088515251 IN O
Jurkat BC2GM088515251 NNP O
cells BC2GM088515251 NNS O
. BC2GM088515251 . O
. . O O

Two BC2GM027119323 CD O
different BC2GM027119323 JJ O
genes BC2GM027119323 NNS O
( BC2GM027119323 ( O
polA BC2GM027119323 NN O
and BC2GM027119323 CC O
polB BC2GM027119323 NN O
) BC2GM027119323 ) O
encoding BC2GM027119323 VBG O
family BC2GM027119323 NN O
B BC2GM027119323 NNP O
DNA BC2GM027119323 NNP O
polymerases BC2GM027119323 NNS O
were BC2GM027119323 VBD O
cloned BC2GM027119323 VBN O
from BC2GM027119323 IN O
the BC2GM027119323 DT O
organism BC2GM027119323 NN O
by BC2GM027119323 IN O
PCR BC2GM027119323 NNP O
using BC2GM027119323 VBG O
degenerated BC2GM027119323 VBD O
primers BC2GM027119323 NNS O
based BC2GM027119323 VBN O
on BC2GM027119323 IN O
the BC2GM027119323 DT O
two BC2GM027119323 CD O
conserved BC2GM027119323 VBD O
motifs BC2GM027119323 NNS O
( BC2GM027119323 ( O
motif BC2GM027119323 VB O
A BC2GM027119323 DT O
and BC2GM027119323 CC O
B BC2GM027119323 NNP O
) BC2GM027119323 ) O
. BC2GM027119323 . O
. . O O

100 BC2GM064420857 CD O
. BC2GM064420857 . O
. . O O

A BC2GM082132977 DT O
simple BC2GM082132977 JJ O
algorithm BC2GM082132977 NN O
fitting BC2GM082132977 VBG O
the BC2GM082132977 DT O
data BC2GM082132977 NN O
for BC2GM082132977 IN O
the BC2GM082132977 DT O
moving BC2GM082132977 VBG O
192Ir BC2GM082132977 CD O
source BC2GM082132977 NN O
is BC2GM082132977 VBZ O
proposed BC2GM082132977 VBN O
. BC2GM082132977 . O
. . O O

The BC2GM074622354 DT O
mode BC2GM074622354 NN O
of BC2GM074622354 IN O
action BC2GM074622354 NN O
is BC2GM074622354 VBZ O
often BC2GM074622354 RB O
suggested BC2GM074622354 VBN O
as BC2GM074622354 IN O
an BC2GM074622354 DT O
explanation BC2GM074622354 NN O
for BC2GM074622354 IN O
the BC2GM074622354 DT O
different BC2GM074622354 JJ O
slopes BC2GM074622354 NNS O
of BC2GM074622354 IN O
concentration-effect BC2GM074622354 JJ O
curves BC2GM074622354 NNS O
. BC2GM074622354 . O
. . O O

The BC2GM019520345 DT O
yeast BC2GM019520345 NN O
genome BC2GM019520345 NN O
contains BC2GM019520345 VBZ O
a BC2GM019520345 DT O
single BC2GM019520345 JJ O
ORD1 BC2GM019520345 NNP O
gene BC2GM019520345 NN O
that BC2GM019520345 WDT O
resides BC2GM019520345 VBZ O
on BC2GM019520345 IN O
chromosome BC2GM019520345 NN O
XI BC2GM019520345 NN O
. BC2GM019520345 . O
. . O O

We BC2GM049234843 PRP O
constructed BC2GM049234843 VBD O
a BC2GM049234843 DT O
stable BC2GM049234843 JJ O
, BC2GM049234843 , O
doubly BC2GM049234843 RB O
transfected BC2GM049234843 VBN O
cell BC2GM049234843 NN O
line BC2GM049234843 NN O
( BC2GM049234843 ( O
TIS-10 BC2GM049234843 NNP O
) BC2GM049234843 ) O
carrying BC2GM049234843 VBG O
a BC2GM049234843 DT O
chromosomally BC2GM049234843 RB O
integrated BC2GM049234843 JJ O
ptetO7-CMV-L BC2GM049234843 JJ O
reporter BC2GM049234843 NN O
construct BC2GM049234843 NN O
and BC2GM049234843 CC O
expressing BC2GM049234843 VBG O
the BC2GM049234843 DT O
TetR-KRAB BC2GM049234843 NNP O
protein BC2GM049234843 NN O
. BC2GM049234843 . O
. . O O

The BC2GM049635982 DT O
mitochondrial BC2GM049635982 JJ O
tyrosyl-tRNA BC2GM049635982 JJ O
synthetase BC2GM049635982 NN O
of BC2GM049635982 IN O
Podospora BC2GM049635982 NNP O
anserina BC2GM049635982 NN O
is BC2GM049635982 VBZ O
a BC2GM049635982 DT O
bifunctional BC2GM049635982 JJ O
enzyme BC2GM049635982 NN O
active BC2GM049635982 JJ O
in BC2GM049635982 IN O
protein BC2GM049635982 JJ O
synthesis BC2GM049635982 NN O
and BC2GM049635982 CC O
RNA BC2GM049635982 NNP O
splicing BC2GM049635982 NN O
. BC2GM049635982 . O
. . O O

TOM1 BC2GM095526870 NNP O
encodes BC2GM095526870 VBZ O
a BC2GM095526870 DT O
member BC2GM095526870 NN O
of BC2GM095526870 IN O
the BC2GM095526870 DT O
hect-domain-containing BC2GM095526870 JJ O
E3 BC2GM095526870 NNP O
ubiquitin-protein BC2GM095526870 JJ O
ligase BC2GM095526870 NN O
family BC2GM095526870 NN O
that BC2GM095526870 WDT O
is BC2GM095526870 VBZ O
required BC2GM095526870 VBN O
for BC2GM095526870 IN O
growth BC2GM095526870 NN O
at BC2GM095526870 IN O
elevated BC2GM095526870 JJ O
temperatures BC2GM095526870 NNS O
. BC2GM095526870 . O
. . O O

Alternative BC2GM085408195 JJ O
immune BC2GM085408195 JJ O
globulin BC2GM085408195 NN O
preparation BC2GM085408195 NN O
when BC2GM085408195 WRB O
standard BC2GM085408195 NN O
immune BC2GM085408195 NN O
serum BC2GM085408195 NN O
globulin BC2GM085408195 NN O
is BC2GM085408195 VBZ O
not BC2GM085408195 RB O
available BC2GM085408195 JJ O
. BC2GM085408195 . O
. . O O

CBD BC2GM071733083 NNP O
exploration BC2GM071733083 NN O
was BC2GM071733083 VBD O
avoided BC2GM071733083 VBN O
in BC2GM071733083 IN O
7 BC2GM071733083 CD O
patients BC2GM071733083 NNS O
with BC2GM071733083 IN O
normal BC2GM071733083 JJ O
POC BC2GM071733083 NNP O
. BC2GM071733083 . O
. . O O

The BC2GM081183440 DT O
illuminator BC2GM081183440 NN O
uses BC2GM081183440 VBZ O
a BC2GM081183440 DT O
grain-of-wheat BC2GM081183440 JJ O
light BC2GM081183440 NN O
bulb BC2GM081183440 NN O
and BC2GM081183440 CC O
an BC2GM081183440 DT O
adjustable BC2GM081183440 JJ O
bulb BC2GM081183440 NN O
holder BC2GM081183440 NN O
fashioned BC2GM081183440 VBN O
from BC2GM081183440 IN O
bent BC2GM081183440 JJ O
paper BC2GM081183440 NN O
clips BC2GM081183440 NNS O
. BC2GM081183440 . O
. . O O

A BC2GM004658722 DT O
nationwide BC2GM004658722 JJ O
survey BC2GM004658722 NN O
uncovered BC2GM004658722 VBD O
a BC2GM004658722 DT O
tenfold BC2GM004658722 JJ O
variation BC2GM004658722 NN O
between BC2GM004658722 IN O
counties BC2GM004658722 NNS O
in BC2GM004658722 IN O
the BC2GM004658722 DT O
prescribing BC2GM004658722 NN O
of BC2GM004658722 IN O
IFNB BC2GM004658722 NNP O
. BC2GM004658722 . O
. . O O

In BC2GM098160022 IN O
contrast BC2GM098160022 NN O
SF BC2GM098160022 NNP O
, BC2GM098160022 , O
but BC2GM098160022 CC O
not BC2GM098160022 RB O
GM-CSF BC2GM098160022 NNP O
or BC2GM098160022 CC O
IL-3 BC2GM098160022 NNP O
, BC2GM098160022 , O
induced BC2GM098160022 VBD O
tyrosine BC2GM098160022 JJ O
phosphorylation BC2GM098160022 NN O
of BC2GM098160022 IN O
phospholipase BC2GM098160022 NN O
C-gamma BC2GM098160022 NNP O
( BC2GM098160022 ( O
PLC-gamma BC2GM098160022 NNP O
) BC2GM098160022 ) O
. BC2GM098160022 . O
. . O O

On BC2GM043142143 IN O
the BC2GM043142143 DT O
other BC2GM043142143 JJ O
hand BC2GM043142143 NN O
, BC2GM043142143 , O
NE BC2GM043142143 NNP O
transport BC2GM043142143 NN O
and BC2GM043142143 CC O
antagonist BC2GM043142143 NN O
( BC2GM043142143 ( O
[ BC2GM043142143 JJ O
125I BC2GM043142143 CD O
] BC2GM043142143 JJ O
RTI-55 BC2GM043142143 NNP O
) BC2GM043142143 ) O
binding BC2GM043142143 NN O
assays BC2GM043142143 NNS O
on BC2GM043142143 IN O
whole BC2GM043142143 JJ O
LLC-NET BC2GM043142143 JJ O
cells BC2GM043142143 NNS O
treated BC2GM043142143 VBN O
with BC2GM043142143 IN O
tunicamycin BC2GM043142143 JJ O
reveal BC2GM043142143 NN O
a BC2GM043142143 DT O
pronounced BC2GM043142143 JJ O
reduction BC2GM043142143 NN O
in BC2GM043142143 IN O
NE BC2GM043142143 NNP O
transport BC2GM043142143 NN O
activity BC2GM043142143 NN O
and BC2GM043142143 CC O
hNET BC2GM043142143 NN O
membrane BC2GM043142143 NN O
density BC2GM043142143 NN O
paralleled BC2GM043142143 VBN O
by BC2GM043142143 IN O
an BC2GM043142143 DT O
inability BC2GM043142143 NN O
of BC2GM043142143 IN O
NET BC2GM043142143 JJ O
proteins BC2GM043142143 NNS O
to BC2GM043142143 TO O
replenish BC2GM043142143 VB O
the BC2GM043142143 DT O
higher BC2GM043142143 JJR O
M BC2GM043142143 NNP O
( BC2GM043142143 ( O
r BC2GM043142143 NN O
) BC2GM043142143 ) O
hNET BC2GM043142143 NN O
pool BC2GM043142143 NN O
. BC2GM043142143 . O
. . O O

Anti-Jo-1 BC2GM004690060 JJ O
antibody BC2GM004690060 NN O
was BC2GM004690060 VBD O
not BC2GM004690060 RB O
present BC2GM004690060 JJ O
. BC2GM004690060 . O
. . O O

Phytohemagglutinin BC2GM030060311 NNP O
( BC2GM030060311 ( O
PHA BC2GM030060311 NNP O
) BC2GM030060311 ) O
, BC2GM030060311 , O
the BC2GM030060311 DT O
seed BC2GM030060311 NN O
lectin BC2GM030060311 NN O
of BC2GM030060311 IN O
the BC2GM030060311 DT O
common BC2GM030060311 JJ O
bean BC2GM030060311 NN O
, BC2GM030060311 , O
accumulates BC2GM030060311 VBZ O
in BC2GM030060311 IN O
protein BC2GM030060311 JJ O
storage BC2GM030060311 NN O
vacuoles BC2GM030060311 NNS O
of BC2GM030060311 IN O
storage BC2GM030060311 NN O
parenchyma BC2GM030060311 NN O
cells BC2GM030060311 NNS O
in BC2GM030060311 IN O
cotyledons BC2GM030060311 NNS O
. BC2GM030060311 . O
. . O O

Mammalian BC2GM027522433 JJ O
ribonucleotide BC2GM027522433 NN O
reductase BC2GM027522433 NN O
shows BC2GM027522433 VBZ O
S-phase BC2GM027522433 NNP O
specific BC2GM027522433 JJ O
expression BC2GM027522433 NN O
and BC2GM027522433 CC O
consists BC2GM027522433 NNS O
of BC2GM027522433 IN O
two BC2GM027522433 CD O
non-identical BC2GM027522433 JJ O
subunits BC2GM027522433 NNS O
, BC2GM027522433 , O
proteins BC2GM027522433 NNS O
R1 BC2GM027522433 NNP O
( BC2GM027522433 ( O
large BC2GM027522433 JJ O
subunit BC2GM027522433 NN O
) BC2GM027522433 ) O
and BC2GM027522433 CC O
R2 BC2GM027522433 NNP O
( BC2GM027522433 ( O
small BC2GM027522433 JJ O
subunit BC2GM027522433 NN O
) BC2GM027522433 ) O
. BC2GM027522433 . O
. . O O

The BC2GM020742355 DT O
bioconversion BC2GM020742355 NN O
of BC2GM020742355 IN O
penicillin BC2GM020742355 NN O
G BC2GM020742355 NNP O
, BC2GM020742355 , O
an BC2GM020742355 DT O
inexpensive BC2GM020742355 JJ O
substrate BC2GM020742355 NN O
, BC2GM020742355 , O
to BC2GM020742355 TO O
the BC2GM020742355 DT O
valuable BC2GM020742355 JJ O
intermediate BC2GM020742355 NN O
for BC2GM020742355 IN O
semisynthetic BC2GM020742355 JJ O
cephalosporin BC2GM020742355 NN O
production BC2GM020742355 NN O
, BC2GM020742355 , O
deacetoxycephalosporin BC2GM020742355 NN O
G BC2GM020742355 NNP O
( BC2GM020742355 ( O
DAOG BC2GM020742355 NNP O
) BC2GM020742355 ) O
, BC2GM020742355 , O
had BC2GM020742355 VBD O
been BC2GM020742355 VBN O
recently BC2GM020742355 RB O
shown BC2GM020742355 VBN O
to BC2GM020742355 TO O
be BC2GM020742355 VB O
increased BC2GM020742355 VBN O
by BC2GM020742355 IN O
eliminating BC2GM020742355 VBG O
agitation BC2GM020742355 NN O
and BC2GM020742355 CC O
adding BC2GM020742355 VBG O
decane BC2GM020742355 NN O
. BC2GM020742355 . O
. . O O

Behavioral BC2GM085844125 JJ O
effects BC2GM085844125 NNS O
of BC2GM085844125 IN O
benzodiazepine BC2GM085844125 NN O
ligands BC2GM085844125 NNS O
in BC2GM085844125 IN O
non-dependent BC2GM085844125 JJ O
, BC2GM085844125 , O
diazepam-dependent BC2GM085844125 JJ O
and BC2GM085844125 CC O
diazepam-withdrawn BC2GM085844125 JJ O
baboons BC2GM085844125 NNS O
. BC2GM085844125 . O
. . O O

Electrophoretic BC2GM042193332 JJ O
mobility BC2GM042193332 NN O
shift BC2GM042193332 NN O
assays BC2GM042193332 NNS O
and BC2GM042193332 CC O
DNase BC2GM042193332 NNP O
I BC2GM042193332 PRP O
protection BC2GM042193332 NN O
analyses BC2GM042193332 NNS O
revealed BC2GM042193332 VBD O
that BC2GM042193332 IN O
FP BC2GM042193332 NNP O
I BC2GM042193332 PRP O
was BC2GM042193332 VBD O
bound BC2GM042193332 VBN O
by BC2GM042193332 IN O
the BC2GM042193332 DT O
transcription BC2GM042193332 NN O
factor BC2GM042193332 NN O
PU.1 BC2GM042193332 NNP O
/ BC2GM042193332 NNP O
Spi-1 BC2GM042193332 NNP O
. BC2GM042193332 . O
. . O O

Reactivation BC2GM056569042 NN O
of BC2GM056569042 IN O
hepatitis BC2GM056569042 NN O
B BC2GM056569042 NNP O
virus BC2GM056569042 NN O
replication BC2GM056569042 NN O
is BC2GM056569042 VBZ O
a BC2GM056569042 DT O
rare BC2GM056569042 JJ O
event BC2GM056569042 NN O
during BC2GM056569042 IN O
the BC2GM056569042 DT O
natural BC2GM056569042 JJ O
history BC2GM056569042 NN O
of BC2GM056569042 IN O
chronic BC2GM056569042 JJ O
hepatitis BC2GM056569042 NN O
B BC2GM056569042 NNP O
. BC2GM056569042 . O
. . O O

It BC2GM053494756 PRP O
contains BC2GM053494756 VBZ O
31 BC2GM053494756 CD O
exons BC2GM053494756 NNS O
and BC2GM053494756 CC O
a BC2GM053494756 DT O
high BC2GM053494756 JJ O
proportion BC2GM053494756 NN O
of BC2GM053494756 IN O
class BC2GM053494756 NN O
0 BC2GM053494756 CD O
introns BC2GM053494756 NNS O
, BC2GM053494756 , O
alternative BC2GM053494756 JJ O
splicing BC2GM053494756 NN O
of BC2GM053494756 IN O
which BC2GM053494756 WDT O
results BC2GM053494756 NNS O
in BC2GM053494756 IN O
significant BC2GM053494756 JJ O
levels BC2GM053494756 NNS O
of BC2GM053494756 IN O
variant BC2GM053494756 NN O
transcripts BC2GM053494756 NNS O
that BC2GM053494756 WDT O
maintain BC2GM053494756 VBP O
the BC2GM053494756 DT O
original BC2GM053494756 JJ O
open BC2GM053494756 JJ O
reading BC2GM053494756 NN O
frame BC2GM053494756 NN O
of BC2GM053494756 IN O
MRP BC2GM053494756 NNP O
mRNA BC2GM053494756 NN O
. BC2GM053494756 . O
. . O O

The BC2GM005581340 DT O
clinical BC2GM005581340 JJ O
effects BC2GM005581340 NNS O
of BC2GM005581340 IN O
valproate BC2GM005581340 NN O
and BC2GM005581340 CC O
ethosuximide BC2GM005581340 NN O
can BC2GM005581340 MD O
be BC2GM005581340 VB O
related BC2GM005581340 VBN O
to BC2GM005581340 TO O
this BC2GM005581340 DT O
differential BC2GM005581340 JJ O
modulation BC2GM005581340 NN O
of BC2GM005581340 IN O
thalamocortical BC2GM005581340 JJ O
excitability BC2GM005581340 NN O
. BC2GM005581340 . O
. . O O

Coexistence BC2GM091817900 NN O
of BC2GM091817900 IN O
Turner BC2GM091817900 NNP O
's BC2GM091817900 POS O
syndrome BC2GM091817900 NN O
and BC2GM091817900 CC O
schizophrenia BC2GM091817900 NN O
. BC2GM091817900 . O
. . O O

The BC2GM004874774 DT O
rest BC2GM004874774 NN O
of BC2GM004874774 IN O
the BC2GM004874774 DT O
3 BC2GM004874774 CD O
' BC2GM004874774 POS O
untranslated BC2GM004874774 JJ O
sequences BC2GM004874774 NNS O
were BC2GM004874774 VBD O
common BC2GM004874774 JJ O
to BC2GM004874774 TO O
both BC2GM004874774 DT O
cDNA BC2GM004874774 JJ O
clones BC2GM004874774 NNS O
. BC2GM004874774 . O
. . O O

Furthermore BC2GM005798555 RB O
, BC2GM005798555 , O
the BC2GM005798555 DT O
zincon-loaded BC2GM005798555 JJ O
resin BC2GM005798555 NN O
was BC2GM005798555 VBD O
applied BC2GM005798555 VBN O
to BC2GM005798555 TO O
the BC2GM005798555 DT O
selective BC2GM005798555 JJ O
concentration BC2GM005798555 NN O
of BC2GM005798555 IN O
trace BC2GM005798555 NN O
amounts BC2GM005798555 NNS O
of BC2GM005798555 IN O
chalcophile BC2GM005798555 NN O
elements BC2GM005798555 NNS O
in BC2GM005798555 IN O
natural BC2GM005798555 JJ O
water BC2GM005798555 NN O
samples BC2GM005798555 NNS O
prior BC2GM005798555 RB O
to BC2GM005798555 TO O
neutron BC2GM005798555 VB O
activation BC2GM005798555 NN O
analysis BC2GM005798555 NN O
. BC2GM005798555 . O
. . O O

Healthy BC2GM083937971 JJ O
subjects BC2GM083937971 NNS O
received BC2GM083937971 VBD O
the BC2GM083937971 DT O
following BC2GM083937971 JJ O
regimens BC2GM083937971 NNS O
, BC2GM083937971 , O
dosed BC2GM083937971 VBD O
to BC2GM083937971 TO O
steady BC2GM083937971 JJ O
state BC2GM083937971 NN O
: BC2GM083937971 : O
trovafloxacin BC2GM083937971 NN O
300 BC2GM083937971 CD O
mg BC2GM083937971 NN O
/ BC2GM083937971 VBD O
24 BC2GM083937971 CD O
h BC2GM083937971 NN O
; BC2GM083937971 : O
ciprofloxacin BC2GM083937971 CC O
400 BC2GM083937971 CD O
mg BC2GM083937971 NN O
/ BC2GM083937971 VBD O
12 BC2GM083937971 CD O
h BC2GM083937971 NN O
; BC2GM083937971 : O
trovafloxacin BC2GM083937971 CC O
300 BC2GM083937971 CD O
mg BC2GM083937971 NN O
/ BC2GM083937971 VBD O
24 BC2GM083937971 CD O
h BC2GM083937971 NN O
plus BC2GM083937971 CC O
cefepime BC2GM083937971 JJ O
2 BC2GM083937971 CD O
g BC2GM083937971 NN O
/ BC2GM083937971 VBD O
12 BC2GM083937971 CD O
h BC2GM083937971 NN O
, BC2GM083937971 , O
and BC2GM083937971 CC O
ciprofloxacin BC2GM083937971 VBZ O
400 BC2GM083937971 CD O
mg BC2GM083937971 NN O
/ BC2GM083937971 VBD O
12 BC2GM083937971 CD O
h BC2GM083937971 NN O
plus BC2GM083937971 CC O
cefepime BC2GM083937971 JJ O
2 BC2GM083937971 CD O
g BC2GM083937971 NN O
/ BC2GM083937971 VBD O
12 BC2GM083937971 CD O
h BC2GM083937971 NN O
. BC2GM083937971 . O
. . O O

Together BC2GM009438252 RB O
with BC2GM009438252 IN O
previous BC2GM009438252 JJ O
work BC2GM009438252 NN O
our BC2GM009438252 PRP$ O
results BC2GM009438252 NNS O
suggest BC2GM009438252 VBP O
that BC2GM009438252 IN O
C BC2GM009438252 NNP O
/ BC2GM009438252 NNP O
EBP BC2GM009438252 NNP O
may BC2GM009438252 MD O
be BC2GM009438252 VB O
a BC2GM009438252 DT O
general BC2GM009438252 JJ O
cooperation BC2GM009438252 NN O
partner BC2GM009438252 NN O
for BC2GM009438252 IN O
v-Myb BC2GM009438252 NN O
in BC2GM009438252 IN O
myelomonocytic BC2GM009438252 JJ O
cells BC2GM009438252 NNS O
. BC2GM009438252 . O
. . O O

A BC2GM011571896 DT O
heterologous BC2GM011571896 JJ O
promoter BC2GM011571896 NN O
construct BC2GM011571896 NN O
containing BC2GM011571896 VBG O
three BC2GM011571896 CD O
repeats BC2GM011571896 NNS O
of BC2GM011571896 IN O
a BC2GM011571896 DT O
consensus BC2GM011571896 NN O
Sp1 BC2GM011571896 NNP O
site BC2GM011571896 NN O
, BC2GM011571896 , O
cloned BC2GM011571896 VBD O
upstream BC2GM011571896 NN O
of BC2GM011571896 IN O
a BC2GM011571896 DT O
single BC2GM011571896 JJ O
copy BC2GM011571896 NN O
of BC2GM011571896 IN O
the BC2GM011571896 DT O
ZII BC2GM011571896 NNP O
( BC2GM011571896 ( O
CREB BC2GM011571896 NNP O
/ BC2GM011571896 NNP O
AP1 BC2GM011571896 NNP O
) BC2GM011571896 ) O
element BC2GM011571896 NN O
from BC2GM011571896 IN O
the BC2GM011571896 DT O
BZLF1 BC2GM011571896 NNP O
promoter BC2GM011571896 NN O
linked BC2GM011571896 VBD O
to BC2GM011571896 TO O
the BC2GM011571896 DT O
beta-globin BC2GM011571896 JJ O
TATA BC2GM011571896 NNP O
box BC2GM011571896 NN O
, BC2GM011571896 , O
exhibited BC2GM011571896 VBD O
phorbol BC2GM011571896 NN O
ester BC2GM011571896 NN O
inducibility BC2GM011571896 NN O
. BC2GM011571896 . O
. . O O

Our BC2GM042573806 PRP$ O
findings BC2GM042573806 NNS O
suggest BC2GM042573806 VBP O
that BC2GM042573806 IN O
AIF BC2GM042573806 NNP O
may BC2GM042573806 MD O
be BC2GM042573806 VB O
a BC2GM042573806 DT O
morphologic BC2GM042573806 JJ O
correlate BC2GM042573806 NN O
of BC2GM042573806 IN O
tumor BC2GM042573806 NN O
regression BC2GM042573806 NN O
following BC2GM042573806 VBG O
preoperative BC2GM042573806 JJ O
cytotoxic BC2GM042573806 JJ O
chemotherapy BC2GM042573806 NN O
. BC2GM042573806 . O
. . O O

Genetic BC2GM001605361 JJ O
analysis BC2GM001605361 NN O
places BC2GM001605361 NNS O
CWH43 BC2GM001605361 NNP O
upstream BC2GM001605361 NN O
of BC2GM001605361 IN O
the BC2GM001605361 DT O
BCK2 BC2GM001605361 NNP O
branch BC2GM001605361 NN O
of BC2GM001605361 IN O
the BC2GM001605361 DT O
PKC1 BC2GM001605361 NNP O
signalling BC2GM001605361 VBG O
pathway BC2GM001605361 RB O
, BC2GM001605361 , O
since BC2GM001605361 IN O
cwh43 BC2GM001605361 NN O
mutations BC2GM001605361 NNS O
were BC2GM001605361 VBD O
synthetic BC2GM001605361 JJ O
lethal BC2GM001605361 NN O
with BC2GM001605361 IN O
pkc1 BC2GM001605361 JJ O
deletion BC2GM001605361 NN O
, BC2GM001605361 , O
whereas BC2GM001605361 IN O
the BC2GM001605361 DT O
cwh43 BC2GM001605361 NN O
defects BC2GM001605361 NNS O
could BC2GM001605361 MD O
be BC2GM001605361 VB O
rescued BC2GM001605361 VBN O
by BC2GM001605361 IN O
overexpression BC2GM001605361 NN O
of BC2GM001605361 IN O
BCK2 BC2GM001605361 NNP O
and BC2GM001605361 CC O
not BC2GM001605361 RB O
by BC2GM001605361 IN O
high-copy-number BC2GM001605361 JJ O
expression BC2GM001605361 NN O
of BC2GM001605361 IN O
genes BC2GM001605361 NNS O
encoding BC2GM001605361 VBG O
downstream BC2GM001605361 NN O
proteins BC2GM001605361 NNS O
of BC2GM001605361 IN O
the BC2GM001605361 DT O
PKC1 BC2GM001605361 NNP O
pathway BC2GM001605361 NN O
However BC2GM001605361 RB O
, BC2GM001605361 , O
unlike BC2GM001605361 IN O
BCK2 BC2GM001605361 NNP O
, BC2GM001605361 , O
whose BC2GM001605361 WP$ O
disruption BC2GM001605361 NN O
in BC2GM001605361 IN O
a BC2GM001605361 DT O
cln3 BC2GM001605361 NN O
mutant BC2GM001605361 NN O
resulted BC2GM001605361 VBD O
in BC2GM001605361 IN O
growth BC2GM001605361 NN O
arrest BC2GM001605361 NN O
in BC2GM001605361 IN O
G BC2GM001605361 NNP O
( BC2GM001605361 ( O
1 BC2GM001605361 CD O
) BC2GM001605361 ) O
, BC2GM001605361 , O
no BC2GM001605361 DT O
growth BC2GM001605361 NN O
defect BC2GM001605361 NN O
was BC2GM001605361 VBD O
observed BC2GM001605361 VBN O
in BC2GM001605361 IN O
a BC2GM001605361 DT O
double BC2GM001605361 JJ O
cwh43 BC2GM001605361 NN O
cln3 BC2GM001605361 NN O
mutants BC2GM001605361 NNS O
. BC2GM001605361 . O
. . O O

The BC2GM049307951 DT O
cumulative BC2GM049307951 JJ O
length BC2GM049307951 NN O
of BC2GM049307951 IN O
the BC2GM049307951 DT O
RGSV BC2GM049307951 NNP O
genome BC2GM049307951 NN O
, BC2GM049307951 , O
including BC2GM049307951 VBG O
RNAs BC2GM049307951 NNP O
5 BC2GM049307951 CD O
and BC2GM049307951 CC O
6 BC2GM049307951 CD O
, BC2GM049307951 , O
was BC2GM049307951 VBD O
25142 BC2GM049307951 CD O
nt BC2GM049307951 NN O
. BC2GM049307951 . O
. . O O

After BC2GM067330469 IN O
5-h BC2GM067330469 JJ O
thermal BC2GM067330469 JJ O
induction BC2GM067330469 NN O
of BC2GM067330469 IN O
cells BC2GM067330469 NNS O
carrying BC2GM067330469 VBG O
the BC2GM067330469 DT O
runaway BC2GM067330469 JJ O
recombinant BC2GM067330469 JJ O
pBS1 BC2GM067330469 NN O
, BC2GM067330469 , O
protein BC2GM067330469 NN O
B2 BC2GM067330469 NNP O
constituted BC2GM067330469 VBD O
40 BC2GM067330469 CD O
% BC2GM067330469 NN O
of BC2GM067330469 IN O
the BC2GM067330469 DT O
soluble BC2GM067330469 JJ O
protein BC2GM067330469 JJ O
fraction BC2GM067330469 NN O
of BC2GM067330469 IN O
the BC2GM067330469 DT O
cells BC2GM067330469 NNS O
. BC2GM067330469 . O
. . O O

Letter BC2GM055283849 NN O
: BC2GM055283849 : O
Dehydrated BC2GM055283849 VBN O
test BC2GM055283849 NN O
strip BC2GM055283849 NN O
for BC2GM055283849 IN O
the BC2GM055283849 DT O
detection BC2GM055283849 NN O
of BC2GM055283849 IN O
yeasts BC2GM055283849 NNS O
. BC2GM055283849 . O
. . O O

A BC2GM022364640 DT O
biopsy BC2GM022364640 NN O
specimen BC2GM022364640 NNS O
taken BC2GM022364640 VBN O
from BC2GM022364640 IN O
the BC2GM022364640 DT O
frontal BC2GM022364640 JJ O
branch BC2GM022364640 NN O
of BC2GM022364640 IN O
the BC2GM022364640 DT O
right BC2GM022364640 JJ O
superficial BC2GM022364640 JJ O
artery BC2GM022364640 NN O
revealed BC2GM022364640 VBD O
segmental BC2GM022364640 JJ O
intimal BC2GM022364640 JJ O
thickening BC2GM022364640 VBG O
consistent BC2GM022364640 JJ O
with BC2GM022364640 IN O
intimal BC2GM022364640 JJ O
fibroplasia BC2GM022364640 NN O
type BC2GM022364640 NN O
FMD BC2GM022364640 NNP O
upon BC2GM022364640 IN O
histological BC2GM022364640 JJ O
examination BC2GM022364640 NN O
. BC2GM022364640 . O
. . O O

However BC2GM089393717 RB O
, BC2GM089393717 , O
PC12 BC2GM089393717 NNP O
cell BC2GM089393717 NN O
clones BC2GM089393717 NNS O
which BC2GM089393717 WDT O
expressed BC2GM089393717 VBD O
p33rsu-1 BC2GM089393717 NN O
at BC2GM089393717 IN O
an BC2GM089393717 DT O
increased BC2GM089393717 JJ O
level BC2GM089393717 NN O
in BC2GM089393717 IN O
a BC2GM089393717 DT O
regulatable BC2GM089393717 JJ O
fashion BC2GM089393717 NN O
in BC2GM089393717 IN O
response BC2GM089393717 NN O
to BC2GM089393717 TO O
dexamethasone BC2GM089393717 VB O
were BC2GM089393717 VBD O
isolated BC2GM089393717 VBN O
. BC2GM089393717 . O
. . O O

Transcription BC2GM084411684 NN O
of BC2GM084411684 IN O
eukaryotic BC2GM084411684 JJ O
tRNA BC2GM084411684 NN O
genes BC2GM084411684 NNS O
is BC2GM084411684 VBZ O
dependent BC2GM084411684 JJ O
on BC2GM084411684 IN O
the BC2GM084411684 DT O
A- BC2GM084411684 NNP O
and BC2GM084411684 CC O
B-Box BC2GM084411684 NNP O
internal BC2GM084411684 JJ O
control BC2GM084411684 NN O
regions BC2GM084411684 NNS O
( BC2GM084411684 ( O
ICRs BC2GM084411684 NNP O
) BC2GM084411684 ) O
and BC2GM084411684 CC O
the BC2GM084411684 DT O
upstream BC2GM084411684 JJ O
transcription BC2GM084411684 NN O
modulatory BC2GM084411684 NN O
region BC2GM084411684 NN O
. BC2GM084411684 . O
. . O O

Sox8 BC2GM005882702 NNP O
maps BC2GM005882702 NNS O
to BC2GM005882702 TO O
the BC2GM005882702 DT O
t BC2GM005882702 NN O
complex BC2GM005882702 NN O
on BC2GM005882702 IN O
mouse BC2GM005882702 NN O
chromosome BC2GM005882702 NN O
17 BC2GM005882702 CD O
and BC2GM005882702 CC O
to BC2GM005882702 TO O
human BC2GM005882702 JJ O
chromosome BC2GM005882702 NN O
16p13.3 BC2GM005882702 CD O
, BC2GM005882702 , O
a BC2GM005882702 DT O
region BC2GM005882702 NN O
associated BC2GM005882702 VBN O
with BC2GM005882702 IN O
the BC2GM005882702 DT O
microphthalmia-cataract BC2GM005882702 JJ O
syndrome BC2GM005882702 NN O
CATM BC2GM005882702 NNP O
and BC2GM005882702 CC O
the BC2GM005882702 DT O
alpha-thalassemia BC2GM005882702 JJ O
/ BC2GM005882702 NNP O
mental BC2GM005882702 JJ O
retardation BC2GM005882702 NN O
syndrome BC2GM005882702 VBD O
ATR-16 BC2GM005882702 NNP O
. BC2GM005882702 . O
. . O O

A BC2GM021649255 DT O
24-year-old BC2GM021649255 JJ O
pregnant BC2GM021649255 JJ O
woman BC2GM021649255 NN O
started BC2GM021649255 VBD O
to BC2GM021649255 TO O
have BC2GM021649255 VB O
hyperemesis BC2GM021649255 NN O
gravidarum BC2GM021649255 NN O
6 BC2GM021649255 CD O
weeks BC2GM021649255 NNS O
before BC2GM021649255 IN O
admission BC2GM021649255 NN O
. BC2GM021649255 . O
. . O O

Assessment BC2GM023248039 NN O
of BC2GM023248039 IN O
two BC2GM023248039 CD O
anion-exchange BC2GM023248039 NN O
resins BC2GM023248039 NNS O
for BC2GM023248039 IN O
direct BC2GM023248039 JJ O
use BC2GM023248039 NN O
in BC2GM023248039 IN O
the BC2GM023248039 DT O
screening BC2GM023248039 NN O
method BC2GM023248039 NN O
for BC2GM023248039 IN O
urinary BC2GM023248039 JJ O
porphobilinogen BC2GM023248039 NN O
. BC2GM023248039 . O
. . O O

These BC2GM003814386 DT O
data BC2GM003814386 NNS O
suggest BC2GM003814386 VBP O
that BC2GM003814386 IN O
certain BC2GM003814386 JJ O
of BC2GM003814386 IN O
the BC2GM003814386 DT O
nuclear BC2GM003814386 JJ O
protein BC2GM003814386 NN O
import BC2GM003814386 NN O
functions BC2GM003814386 NNS O
of BC2GM003814386 IN O
NTF2 BC2GM003814386 NNP O
and BC2GM003814386 CC O
Ran BC2GM003814386 NNP O
/ BC2GM003814386 NNP O
TC4 BC2GM003814386 NNP O
are BC2GM003814386 VBP O
closely BC2GM003814386 RB O
linked BC2GM003814386 VBN O
and BC2GM003814386 CC O
that BC2GM003814386 IN O
NTF2 BC2GM003814386 NNP O
may BC2GM003814386 MD O
serve BC2GM003814386 VB O
to BC2GM003814386 TO O
modulate BC2GM003814386 VB O
a BC2GM003814386 DT O
transport BC2GM003814386 JJ O
step BC2GM003814386 NN O
involving BC2GM003814386 VBG O
Ran BC2GM003814386 NNP O
/ BC2GM003814386 NNP O
TC4 BC2GM003814386 NNP O
. BC2GM003814386 . O
. . O O

Alternative BC2GM025395318 JJ O
roles BC2GM025395318 NNS O
of BC2GM025395318 IN O
these BC2GM025395318 DT O
DNA BC2GM025395318 NNP O
motifs BC2GM025395318 NNS O
as BC2GM025395318 IN O
activators BC2GM025395318 NNS O
of BC2GM025395318 IN O
early BC2GM025395318 JJ O
mRNA BC2GM025395318 NN O
transcription BC2GM025395318 NN O
and BC2GM025395318 CC O
as BC2GM025395318 IN O
an BC2GM025395318 DT O
initiator BC2GM025395318 NN O
element BC2GM025395318 NN O
for BC2GM025395318 IN O
late BC2GM025395318 JJ O
mRNA BC2GM025395318 NN O
transcription BC2GM025395318 NN O
help BC2GM025395318 NN O
explain BC2GM025395318 VB O
how BC2GM025395318 WRB O
polyomavirus BC2GM025395318 JJ O
gene BC2GM025395318 NN O
expression BC2GM025395318 NN O
is BC2GM025395318 VBZ O
regulated BC2GM025395318 VBN O
during BC2GM025395318 IN O
lytic BC2GM025395318 JJ O
growth BC2GM025395318 NN O
and BC2GM025395318 CC O
provides BC2GM025395318 VBZ O
a BC2GM025395318 DT O
model BC2GM025395318 NN O
for BC2GM025395318 IN O
cellular BC2GM025395318 JJ O
transcription BC2GM025395318 NN O
during BC2GM025395318 IN O
development BC2GM025395318 NN O
. BC2GM025395318 . O
. . O O

Cortical BC2GM020664774 JJ O
somatosensory BC2GM020664774 NN O
evoked BC2GM020664774 VBD O
potentials BC2GM020664774 NNS O
to BC2GM020664774 TO O
median BC2GM020664774 JJ O
nerve BC2GM020664774 NN O
stimulation BC2GM020664774 NN O
revealed BC2GM020664774 VBD O
significantly BC2GM020664774 RB O
delayed BC2GM020664774 VBN O
peak BC2GM020664774 NN O
latencies BC2GM020664774 NNS O
of BC2GM020664774 IN O
N20 BC2GM020664774 NNP O
, BC2GM020664774 , O
P20 BC2GM020664774 NNP O
, BC2GM020664774 , O
P25 BC2GM020664774 NNP O
, BC2GM020664774 , O
and BC2GM020664774 CC O
N26 BC2GM020664774 NNP O
, BC2GM020664774 , O
although BC2GM020664774 IN O
N16 BC2GM020664774 NNP O
latency BC2GM020664774 NN O
was BC2GM020664774 VBD O
normal BC2GM020664774 JJ O
. BC2GM020664774 . O
. . O O

Here BC2GM096535818 RB O
we BC2GM096535818 PRP O
show BC2GM096535818 VBP O
that BC2GM096535818 IN O
these BC2GM096535818 DT O
sequences BC2GM096535818 NNS O
are BC2GM096535818 VBP O
essential BC2GM096535818 JJ O
for BC2GM096535818 IN O
processing BC2GM096535818 NN O
of BC2GM096535818 IN O
U18 BC2GM096535818 NNP O
and BC2GM096535818 CC O
snR38 BC2GM096535818 VB O
snoRNAs BC2GM096535818 NN O
and BC2GM096535818 CC O
that BC2GM096535818 IN O
they BC2GM096535818 PRP O
compensate BC2GM096535818 VBP O
for BC2GM096535818 IN O
the BC2GM096535818 DT O
lack BC2GM096535818 NN O
of BC2GM096535818 IN O
a BC2GM096535818 DT O
canonical BC2GM096535818 JJ O
terminal BC2GM096535818 JJ O
stem BC2GM096535818 NN O
. BC2GM096535818 . O
. . O O

250 BC2GM079069555 CD O
, BC2GM079069555 , O
302-311 BC2GM079069555 JJ O
] BC2GM079069555 NN O
. BC2GM079069555 . O
. . O O

Recombinant BC2GM052825552 NNP O
propeptides BC2GM052825552 VBZ O
containing BC2GM052825552 VBG O
mutations BC2GM052825552 NNS O
of BC2GM052825552 IN O
one BC2GM052825552 CD O
of BC2GM052825552 IN O
the BC2GM052825552 DT O
three BC2GM052825552 CD O
tryptophan BC2GM052825552 NN O
residues BC2GM052825552 NNS O
were BC2GM052825552 VBD O
three BC2GM052825552 CD O
orders BC2GM052825552 NNS O
of BC2GM052825552 IN O
magnitude BC2GM052825552 NN O
less BC2GM052825552 RBR O
effective BC2GM052825552 JJ O
as BC2GM052825552 IN O
inhibitors BC2GM052825552 NNS O
of BC2GM052825552 IN O
mature BC2GM052825552 NN O
cathepsin BC2GM052825552 NN O
S BC2GM052825552 NNP O
than BC2GM052825552 IN O
the BC2GM052825552 DT O
wild-type BC2GM052825552 JJ O
propeptide BC2GM052825552 NN O
. BC2GM052825552 . O
. . O O

Copyright BC2GM041662908 JJ O
1999 BC2GM041662908 CD O
Academic BC2GM041662908 NNP O
Press BC2GM041662908 NNP O
. BC2GM041662908 . O
. . O O

An BC2GM011015031 DT O
oligomer BC2GM011015031 NN O
synthesized BC2GM011015031 VBN O
to BC2GM011015031 TO O
this BC2GM011015031 DT O
region BC2GM011015031 NN O
of BC2GM011015031 IN O
homology BC2GM011015031 NN O
produced BC2GM011015031 VBN O
two BC2GM011015031 CD O
DNA-protein BC2GM011015031 JJ O
complexes BC2GM011015031 NNS O
with BC2GM011015031 IN O
oviduct BC2GM011015031 NN O
nuclear BC2GM011015031 JJ O
proteins BC2GM011015031 NNS O
. BC2GM011015031 . O
. . O O

Two BC2GM074636309 CD O
full-length BC2GM074636309 JJ O
clones BC2GM074636309 NNS O
( BC2GM074636309 ( O
pBCH1 BC2GM074636309 NN O
and BC2GM074636309 CC O
pBCH2 BC2GM074636309 NN O
) BC2GM074636309 ) O
were BC2GM074636309 VBD O
isolated BC2GM074636309 VBN O
. BC2GM074636309 . O
. . O O

The BC2GM016623296 DT O
analysis BC2GM016623296 NN O
of BC2GM016623296 IN O
the BC2GM016623296 DT O
effects BC2GM016623296 NNS O
of BC2GM016623296 IN O
eight BC2GM016623296 CD O
signaling BC2GM016623296 VBG O
molecules BC2GM016623296 NNS O
in BC2GM016623296 IN O
the BC2GM016623296 DT O
TGFbeta BC2GM016623296 NNP O
, BC2GM016623296 , O
FGF BC2GM016623296 NNP O
, BC2GM016623296 , O
Hh BC2GM016623296 NNP O
, BC2GM016623296 , O
Wnt BC2GM016623296 NNP O
, BC2GM016623296 , O
and BC2GM016623296 CC O
EGF BC2GM016623296 NNP O
families BC2GM016623296 NNS O
in BC2GM016623296 IN O
tooth BC2GM016623296 DT O
explant BC2GM016623296 JJ O
cultures BC2GM016623296 NNS O
revealed BC2GM016623296 VBD O
that BC2GM016623296 IN O
the BC2GM016623296 DT O
expression BC2GM016623296 NN O
of BC2GM016623296 IN O
edar BC2GM016623296 NN O
was BC2GM016623296 VBD O
induced BC2GM016623296 VBN O
by BC2GM016623296 IN O
activinbetaA BC2GM016623296 NN O
, BC2GM016623296 , O
whereas BC2GM016623296 WP O
Wnt6 BC2GM016623296 NNP O
induced BC2GM016623296 VBD O
ectodysplasin BC2GM016623296 DT O
expression BC2GM016623296 NN O
. BC2GM016623296 . O
. . O O

The BC2GM083717359 DT O
1.5-Mb BC2GM083717359 JJ O
region BC2GM083717359 NN O
was BC2GM083717359 VBD O
covered BC2GM083717359 VBN O
by BC2GM083717359 IN O
137 BC2GM083717359 CD O
cosmids BC2GM083717359 NNS O
with BC2GM083717359 IN O
a BC2GM083717359 DT O
minimum BC2GM083717359 JJ O
overlap BC2GM083717359 NN O
set BC2GM083717359 NN O
of BC2GM083717359 IN O
52 BC2GM083717359 CD O
cosmids BC2GM083717359 NNS O
assigned BC2GM083717359 VBD O
to BC2GM083717359 TO O
17 BC2GM083717359 CD O
bins BC2GM083717359 NNS O
and BC2GM083717359 CC O
9 BC2GM083717359 CD O
contigs BC2GM083717359 NNS O
. BC2GM083717359 . O
. . O O

CONCLUSIONS BC2GM019371061 NN O
: BC2GM019371061 : O
The BC2GM019371061 DT O
results BC2GM019371061 NNS O
show BC2GM019371061 VBP O
that BC2GM019371061 IN O
intranasal BC2GM019371061 JJ O
challenge BC2GM019371061 NN O
with BC2GM019371061 IN O
FLU BC2GM019371061 NNP O
induces BC2GM019371061 NNS O
changes BC2GM019371061 NNS O
in BC2GM019371061 IN O
leukocyte BC2GM019371061 NN O
histamine BC2GM019371061 NN O
release BC2GM019371061 NN O
, BC2GM019371061 , O
but BC2GM019371061 CC O
not BC2GM019371061 RB O
other BC2GM019371061 JJ O
systemic BC2GM019371061 JJ O
immune BC2GM019371061 NN O
and BC2GM019371061 CC O
inflammatory BC2GM019371061 JJ O
responses BC2GM019371061 NNS O
. BC2GM019371061 . O
. . O O

Role BC2GM061835883 NNP O
of BC2GM061835883 IN O
zinc-finger BC2GM061835883 JJ O
proteins BC2GM061835883 NNS O
Sp1 BC2GM061835883 NNP O
and BC2GM061835883 CC O
zif268 BC2GM061835883 NNP O
/ BC2GM061835883 NNP O
egr-1 BC2GM061835883 NN O
in BC2GM061835883 IN O
transcriptional BC2GM061835883 JJ O
regulation BC2GM061835883 NN O
of BC2GM061835883 IN O
the BC2GM061835883 DT O
human BC2GM061835883 JJ O
synaptobrevin BC2GM061835883 NN O
II BC2GM061835883 NNP O
gene BC2GM061835883 NN O
. BC2GM061835883 . O
. . O O

Over BC2GM005821288 IN O
half BC2GM005821288 NN O
of BC2GM005821288 IN O
the BC2GM005821288 DT O
children BC2GM005821288 NNS O
initially BC2GM005821288 RB O
unresponsive BC2GM005821288 JJ O
to BC2GM005821288 TO O
H. BC2GM005821288 NNP O
influenzae BC2GM005821288 NN O
type BC2GM005821288 NN O
b BC2GM005821288 NN O
meningitis BC2GM005821288 NN O
subsequently BC2GM005821288 RB O
developed BC2GM005821288 VBD O
specific BC2GM005821288 JJ O
antibodies BC2GM005821288 NNS O
. BC2GM005821288 . O
. . O O

The BC2GM075394719 DT O
team BC2GM075394719 NN O
physician BC2GM075394719 NN O
and BC2GM075394719 CC O
conditioning BC2GM075394719 NN O
of BC2GM075394719 IN O
athletes BC2GM075394719 NNS O
for BC2GM075394719 IN O
sports BC2GM075394719 NNS O
: BC2GM075394719 : O
a BC2GM075394719 DT O
consensus BC2GM075394719 NN O
statement BC2GM075394719 NN O
. BC2GM075394719 . O
. . O O

Biomass BC2GM029590199 NNP O
growth BC2GM029590199 NN O
monitoring BC2GM029590199 VBG O
using BC2GM029590199 VBG O
pressure BC2GM029590199 NN O
drop BC2GM029590199 NN O
in BC2GM029590199 IN O
a BC2GM029590199 DT O
cocurrent BC2GM029590199 NN O
biofilter BC2GM029590199 NN O
. BC2GM029590199 . O
. . O O

Cytokines BC2GM062865451 NNS O
and BC2GM062865451 CC O
steroid BC2GM062865451 JJ O
hormones BC2GM062865451 NNS O
use BC2GM062865451 VBP O
different BC2GM062865451 JJ O
sets BC2GM062865451 NNS O
of BC2GM062865451 IN O
signal BC2GM062865451 JJ O
transduction BC2GM062865451 NN O
pathways BC2GM062865451 NNS O
, BC2GM062865451 , O
which BC2GM062865451 WDT O
seem BC2GM062865451 VBP O
to BC2GM062865451 TO O
be BC2GM062865451 VB O
unrelated BC2GM062865451 JJ O
. BC2GM062865451 . O
. . O O

Results BC2GM039204419 NNS O
of BC2GM039204419 IN O
these BC2GM039204419 DT O
in BC2GM039204419 IN O
vitro BC2GM039204419 NN O
studies BC2GM039204419 NNS O
may BC2GM039204419 MD O
be BC2GM039204419 VB O
relevant BC2GM039204419 JJ O
to BC2GM039204419 TO O
the BC2GM039204419 DT O
pathogenesis BC2GM039204419 NN O
of BC2GM039204419 IN O
alveolitis BC2GM039204419 NN O
in BC2GM039204419 IN O
organic BC2GM039204419 JJ O
dust-induced BC2GM039204419 JJ O
lung BC2GM039204419 NN O
diseases BC2GM039204419 NNS O
. BC2GM039204419 . O
. . O O

From BC2GM033647434 IN O
this BC2GM033647434 DT O
asymmetry BC2GM033647434 NN O
, BC2GM033647434 , O
we BC2GM033647434 PRP O
suggested BC2GM033647434 VBD O
previously BC2GM033647434 RB O
that BC2GM033647434 IN O
GCN4 BC2GM033647434 NNP O
interacts BC2GM033647434 VBZ O
with BC2GM033647434 IN O
nonequivalent BC2GM033647434 NN O
and BC2GM033647434 CC O
possibly BC2GM033647434 RB O
overlapping BC2GM033647434 VBG O
half-sites BC2GM033647434 NNS O
( BC2GM033647434 ( O
ATGAC BC2GM033647434 NNP O
and BC2GM033647434 CC O
ATGAG BC2GM033647434 NNP O
) BC2GM033647434 ) O
that BC2GM033647434 WDT O
have BC2GM033647434 VBP O
different BC2GM033647434 JJ O
affinities BC2GM033647434 NNS O
. BC2GM033647434 . O
. . O O

Cardiac BC2GM024886173 NNP O
NE BC2GM024886173 NNP O
spillover BC2GM024886173 NN O
was BC2GM024886173 VBD O
higher BC2GM024886173 JJR O
( BC2GM024886173 ( O
P BC2GM024886173 NNP O
< BC2GM024886173 NNP O
.05 BC2GM024886173 NNP O
) BC2GM024886173 ) O
at BC2GM024886173 IN O
baseline BC2GM024886173 NN O
in BC2GM024886173 IN O
the BC2GM024886173 DT O
patient BC2GM024886173 NN O
group BC2GM024886173 NN O
than BC2GM024886173 IN O
in BC2GM024886173 IN O
healthy BC2GM024886173 JJ O
subjects BC2GM024886173 NNS O
, BC2GM024886173 , O
whereas BC2GM024886173 JJ O
renal BC2GM024886173 JJ O
and BC2GM024886173 CC O
whole-body BC2GM024886173 JJ O
NE BC2GM024886173 NNP O
spillovers BC2GM024886173 NNS O
were BC2GM024886173 VBD O
similar BC2GM024886173 JJ O
between BC2GM024886173 IN O
the BC2GM024886173 DT O
study BC2GM024886173 NN O
groups BC2GM024886173 NNS O
. BC2GM024886173 . O
. . O O

A BC2GM033154318 DT O
female BC2GM033154318 JJ O
infant BC2GM033154318 NN O
with BC2GM033154318 IN O
isolated BC2GM033154318 JJ O
noncompaction BC2GM033154318 NN O
of BC2GM033154318 IN O
ventricular BC2GM033154318 JJ O
myocardium BC2GM033154318 NN O
who BC2GM033154318 WP O
developed BC2GM033154318 VBD O
ventricular BC2GM033154318 JJ O
tachyarrhythmia BC2GM033154318 NN O
is BC2GM033154318 VBZ O
described BC2GM033154318 VBN O
. BC2GM033154318 . O
. . O O

Interestingly BC2GM056101330 RB O
, BC2GM056101330 , O
PMA- BC2GM056101330 NNP O
, BC2GM056101330 , O
PDGF- BC2GM056101330 NNP O
, BC2GM056101330 , O
and BC2GM056101330 CC O
serum-induced BC2GM056101330 JJ O
GHR BC2GM056101330 NNP O
proteolysis BC2GM056101330 NN O
was BC2GM056101330 VBD O
associated BC2GM056101330 VBN O
with BC2GM056101330 IN O
substantial BC2GM056101330 JJ O
decreases BC2GM056101330 NNS O
in BC2GM056101330 IN O
GH-induced BC2GM056101330 NNP O
activation BC2GM056101330 NN O
of BC2GM056101330 IN O
Janus BC2GM056101330 NNP O
kinase-2 BC2GM056101330 NN O
, BC2GM056101330 , O
which BC2GM056101330 WDT O
were BC2GM056101330 VBD O
also BC2GM056101330 RB O
prevented BC2GM056101330 VBN O
by BC2GM056101330 IN O
IC3 BC2GM056101330 NNP O
. BC2GM056101330 . O
. . O O

In BC2GM029072102 IN O
addition BC2GM029072102 NN O
to BC2GM029072102 TO O
loss BC2GM029072102 NN O
of BC2GM029072102 IN O
digit BC2GM029072102 JJ O
identity BC2GM029072102 NN O
and BC2GM029072102 CC O
varying BC2GM029072102 VBG O
degrees BC2GM029072102 NNS O
of BC2GM029072102 IN O
polydactyly BC2GM029072102 NN O
, BC2GM029072102 , O
proximal BC2GM029072102 JJ O
skeletal BC2GM029072102 JJ O
elements BC2GM029072102 NNS O
are BC2GM029072102 VBP O
severely BC2GM029072102 RB O
shortened BC2GM029072102 VBN O
in BC2GM029072102 IN O
Xt BC2GM029072102 NNP O
; BC2GM029072102 : O
ld BC2GM029072102 CC O
double BC2GM029072102 JJ O
homozygous BC2GM029072102 JJ O
limbs BC2GM029072102 NNS O
. BC2GM029072102 . O
. . O O

A BC2GM089490423 DT O
case BC2GM089490423 NN O
of BC2GM089490423 IN O
2 BC2GM089490423 CD O
cancers BC2GM089490423 NNS O
of BC2GM089490423 IN O
the BC2GM089490423 DT O
colon BC2GM089490423 NN O
. BC2GM089490423 . O
. . O O

For BC2GM006873780 IN O
rotating BC2GM006873780 VBG O
stimuli BC2GM006873780 NNS O
presented BC2GM006873780 VBN O
to BC2GM006873780 TO O
the BC2GM006873780 DT O
dominant BC2GM006873780 JJ O
eye BC2GM006873780 NN O
, BC2GM006873780 , O
this BC2GM006873780 DT O
class BC2GM006873780 NN O
of BC2GM006873780 IN O
neurons BC2GM006873780 NNS O
responded BC2GM006873780 VBD O
best BC2GM006873780 JJS O
to BC2GM006873780 TO O
rotation BC2GM006873780 NN O
of BC2GM006873780 IN O
the BC2GM006873780 DT O
visual BC2GM006873780 JJ O
world BC2GM006873780 NN O
about BC2GM006873780 IN O
an BC2GM006873780 DT O
axis BC2GM006873780 NN O
oriented BC2GM006873780 VBD O
near BC2GM006873780 IN O
the BC2GM006873780 DT O
horizontal BC2GM006873780 JJ O
plane BC2GM006873780 NN O
and BC2GM006873780 CC O
approximately BC2GM006873780 RB O
45 BC2GM006873780 CD O
degrees BC2GM006873780 NNS O
azimuth BC2GM006873780 RB O
. BC2GM006873780 . O
. . O O

The BC2GM034262338 DT O
results BC2GM034262338 NNS O
indicate BC2GM034262338 VBP O
that BC2GM034262338 IN O
the BC2GM034262338 DT O
RNA BC2GM034262338 NNP O
in BC2GM034262338 IN O
T7 BC2GM034262338 NNP O
RNA BC2GM034262338 NNP O
polymerase BC2GM034262338 NN O
is BC2GM034262338 VBZ O
not BC2GM034262338 RB O
free BC2GM034262338 JJ O
of BC2GM034262338 IN O
steric BC2GM034262338 JJ O
interactions BC2GM034262338 NNS O
in BC2GM034262338 IN O
the BC2GM034262338 DT O
ternary BC2GM034262338 JJ O
complex BC2GM034262338 NN O
and BC2GM034262338 CC O
not BC2GM034262338 RB O
available BC2GM034262338 JJ O
for BC2GM034262338 IN O
structure BC2GM034262338 NN O
formation BC2GM034262338 NN O
until BC2GM034262338 IN O
it BC2GM034262338 PRP O
is BC2GM034262338 VBZ O
at BC2GM034262338 IN O
least BC2GM034262338 JJS O
10 BC2GM034262338 CD O
bases BC2GM034262338 NNS O
away BC2GM034262338 RB O
from BC2GM034262338 IN O
the BC2GM034262338 DT O
site BC2GM034262338 NN O
of BC2GM034262338 IN O
polymerization BC2GM034262338 NN O
. BC2GM034262338 . O
. . O O

Using BC2GM068485408 VBG O
probes BC2GM068485408 NNS O
containing BC2GM068485408 VBG O
C BC2GM068485408 NNP O
/ BC2GM068485408 NNP O
EBP-binding BC2GM068485408 NNP O
sites BC2GM068485408 NNS O
from BC2GM068485408 IN O
the BC2GM068485408 DT O
iNOS BC2GM068485408 JJ O
gene BC2GM068485408 NN O
revealed BC2GM068485408 VBD O
further BC2GM068485408 RBR O
binding BC2GM068485408 NN O
of BC2GM068485408 IN O
different BC2GM068485408 JJ O
complexes BC2GM068485408 NNS O
, BC2GM068485408 , O
all BC2GM068485408 DT O
of BC2GM068485408 IN O
which BC2GM068485408 WDT O
were BC2GM068485408 VBD O
strongly BC2GM068485408 RB O
inducible BC2GM068485408 JJ O
by BC2GM068485408 IN O
cAMP BC2GM068485408 NN O
and BC2GM068485408 CC O
to BC2GM068485408 TO O
a BC2GM068485408 DT O
lower BC2GM068485408 JJR O
extent BC2GM068485408 NN O
also BC2GM068485408 RB O
by BC2GM068485408 IN O
IL-1beta BC2GM068485408 NNP O
. BC2GM068485408 . O
. . O O

Mutations BC2GM040023769 NNS O
of BC2GM040023769 IN O
SIN4 BC2GM040023769 NNP O
, BC2GM040023769 , O
ROX3 BC2GM040023769 NNP O
, BC2GM040023769 , O
SRB8 BC2GM040023769 NNP O
, BC2GM040023769 , O
SRB9 BC2GM040023769 NNP O
, BC2GM040023769 , O
SRB10 BC2GM040023769 NNP O
, BC2GM040023769 , O
SRB11 BC2GM040023769 NNP O
, BC2GM040023769 , O
and BC2GM040023769 CC O
two BC2GM040023769 CD O
novel BC2GM040023769 NN O
genes BC2GM040023769 NNS O
, BC2GM040023769 , O
NUT1 BC2GM040023769 NNP O
and BC2GM040023769 CC O
NUT2 BC2GM040023769 NNP O
, BC2GM040023769 , O
relieve BC2GM040023769 VBP O
the BC2GM040023769 DT O
requirement BC2GM040023769 NN O
of BC2GM040023769 IN O
Swi4p BC2GM040023769 NNP O
for BC2GM040023769 IN O
expression BC2GM040023769 NN O
of BC2GM040023769 IN O
this BC2GM040023769 DT O
reporter BC2GM040023769 NN O
. BC2GM040023769 . O
. . O O

Dose-dependent BC2GM094724499 JJ O
pharmacokinetics BC2GM094724499 NNS O
: BC2GM094724499 : O
emphasis BC2GM094724499 NN O
on BC2GM094724499 IN O
phase BC2GM094724499 NN O
I BC2GM094724499 PRP O
metabolism BC2GM094724499 VBP O
. BC2GM094724499 . O
. . O O

Cytochemical BC2GM053432792 JJ O
and BC2GM053432792 CC O
ultrastructural BC2GM053432792 JJ O
observations BC2GM053432792 NNS O
on BC2GM053432792 IN O
the BC2GM053432792 DT O
tegument BC2GM053432792 NN O
of BC2GM053432792 IN O
the BC2GM053432792 DT O
trematode BC2GM053432792 NN O
Megalodiscus BC2GM053432792 NNP O
temperatus BC2GM053432792 NN O
. BC2GM053432792 . O
. . O O

It BC2GM095278451 PRP O
is BC2GM095278451 VBZ O
not BC2GM095278451 RB O
well BC2GM095278451 RB O
known BC2GM095278451 VBN O
that BC2GM095278451 IN O
giant BC2GM095278451 NN O
cell BC2GM095278451 NN O
arteritis BC2GM095278451 NN O
can BC2GM095278451 MD O
cause BC2GM095278451 VB O
fatal BC2GM095278451 JJ O
complications BC2GM095278451 NNS O
due BC2GM095278451 JJ O
to BC2GM095278451 TO O
rupture BC2GM095278451 NN O
of BC2GM095278451 IN O
aortic BC2GM095278451 JJ O
aneurysms BC2GM095278451 NNS O
or BC2GM095278451 CC O
cerebral BC2GM095278451 JJ O
and BC2GM095278451 CC O
myocardial BC2GM095278451 JJ O
infarctions BC2GM095278451 NNS O
. BC2GM095278451 . O
. . O O

When BC2GM039160075 WRB O
proper BC2GM039160075 JJ O
controls BC2GM039160075 NNS O
were BC2GM039160075 VBD O
used BC2GM039160075 VBN O
, BC2GM039160075 , O
the BC2GM039160075 DT O
psychophysical BC2GM039160075 JJ O
data BC2GM039160075 NNS O
and BC2GM039160075 CC O
computer BC2GM039160075 NN O
simulation BC2GM039160075 NN O
gave BC2GM039160075 VBD O
remarkably BC2GM039160075 RB O
comparable BC2GM039160075 JJ O
results BC2GM039160075 NNS O
. BC2GM039160075 . O
. . O O

Clostridium BC2GM062176134 NN O
botulinum BC2GM062176134 NN O
in BC2GM062176134 IN O
marine BC2GM062176134 JJ O
sediment BC2GM062176134 NN O
. BC2GM062176134 . O
. . O O

The BC2GM035550761 DT O
Thrombolysis BC2GM035550761 NN O
in BC2GM035550761 IN O
Myocardial BC2GM035550761 NNP O
Infarction BC2GM035550761 NNP O
( BC2GM035550761 ( O
TIMI BC2GM035550761 NNP O
) BC2GM035550761 ) O
Phase BC2GM035550761 NNP O
II BC2GM035550761 NNP O
Trial BC2GM035550761 NNP O
randomized BC2GM035550761 VBD O
3,339 BC2GM035550761 CD O
patients BC2GM035550761 NNS O
to BC2GM035550761 TO O
either BC2GM035550761 DT O
an BC2GM035550761 DT O
invasive BC2GM035550761 JJ O
( BC2GM035550761 ( O
INV BC2GM035550761 NNP O
, BC2GM035550761 , O
n BC2GM035550761 JJ O
= BC2GM035550761 NNP O
1,681 BC2GM035550761 CD O
) BC2GM035550761 ) O
or BC2GM035550761 CC O
a BC2GM035550761 DT O
conservative BC2GM035550761 JJ O
( BC2GM035550761 ( O
CON BC2GM035550761 NNP O
, BC2GM035550761 , O
n BC2GM035550761 JJ O
= BC2GM035550761 NNP O
1,658 BC2GM035550761 CD O
) BC2GM035550761 ) O
strategy BC2GM035550761 NN O
after BC2GM035550761 IN O
intravenous BC2GM035550761 JJ O
recombinant BC2GM035550761 JJ O
tissue-type BC2GM035550761 JJ O
plasminogen BC2GM035550761 NN O
activator BC2GM035550761 NN O
( BC2GM035550761 ( O
rt-PA BC2GM035550761 JJ O
) BC2GM035550761 ) O
for BC2GM035550761 IN O
acute BC2GM035550761 JJ O
myocardial BC2GM035550761 JJ O
infarction BC2GM035550761 NN O
. BC2GM035550761 . O
. . O O

These BC2GM034402560 DT O
include BC2GM034402560 VBP O
urinalysis BC2GM034402560 NN O
, BC2GM034402560 , O
chest BC2GM034402560 JJ O
X-P BC2GM034402560 NN O
, BC2GM034402560 , O
ECG BC2GM034402560 NNP O
, BC2GM034402560 , O
hematological BC2GM034402560 JJ O
examinations BC2GM034402560 NNS O
( BC2GM034402560 ( O
RBC BC2GM034402560 NNP O
, BC2GM034402560 , O
WBC BC2GM034402560 NNP O
, BC2GM034402560 , O
Ht BC2GM034402560 NNP O
, BC2GM034402560 , O
Hb BC2GM034402560 NNP O
, BC2GM034402560 , O
PLT BC2GM034402560 NNP O
and BC2GM034402560 CC O
ESR BC2GM034402560 NNP O
) BC2GM034402560 ) O
and BC2GM034402560 CC O
biochemical BC2GM034402560 JJ O
tests BC2GM034402560 NNS O
( BC2GM034402560 ( O
AST BC2GM034402560 NNP O
, BC2GM034402560 , O
ALT BC2GM034402560 NNP O
, BC2GM034402560 , O
ALP BC2GM034402560 NNP O
, BC2GM034402560 , O
gamma BC2GM034402560 NN O
GTP BC2GM034402560 NNP O
, BC2GM034402560 , O
LDH BC2GM034402560 NNP O
, BC2GM034402560 , O
CPK BC2GM034402560 NNP O
, BC2GM034402560 , O
Chol BC2GM034402560 NNP O
, BC2GM034402560 , O
T-Bil BC2GM034402560 NNP O
, BC2GM034402560 , O
TP BC2GM034402560 NNP O
, BC2GM034402560 , O
Alb BC2GM034402560 NNP O
, BC2GM034402560 , O
TG BC2GM034402560 NNP O
, BC2GM034402560 , O
BUN BC2GM034402560 NNP O
, BC2GM034402560 , O
Cr BC2GM034402560 NNP O
, BC2GM034402560 , O
Glu BC2GM034402560 NNP O
, BC2GM034402560 , O
Na BC2GM034402560 NNP O
, BC2GM034402560 , O
K BC2GM034402560 NNP O
, BC2GM034402560 , O
Ca BC2GM034402560 NNP O
, BC2GM034402560 , O
P BC2GM034402560 NNP O
and BC2GM034402560 CC O
CRP BC2GM034402560 NNP O
) BC2GM034402560 ) O
. BC2GM034402560 . O
. . O O

The BC2GM018128647 DT O
UASB BC2GM018128647 NNP O
reactors BC2GM018128647 NNS O
treated BC2GM018128647 VBD O
a BC2GM018128647 DT O
VFA BC2GM018128647 NNP O
mixture BC2GM018128647 NN O
( BC2GM018128647 ( O
with BC2GM018128647 IN O
an BC2GM018128647 DT O
acetate BC2GM018128647 NN O
: BC2GM018128647 : O
propionate BC2GM018128647 NN O
: BC2GM018128647 : O
butyrate BC2GM018128647 NN O
ratio BC2GM018128647 NN O
of BC2GM018128647 IN O
5:3:2 BC2GM018128647 CD O
on BC2GM018128647 IN O
COD BC2GM018128647 NNP O
basis BC2GM018128647 NN O
) BC2GM018128647 ) O
or BC2GM018128647 CC O
acetate BC2GM018128647 VB O
as BC2GM018128647 IN O
the BC2GM018128647 DT O
sole BC2GM018128647 JJ O
substrate BC2GM018128647 NN O
at BC2GM018128647 IN O
different BC2GM018128647 JJ O
COD BC2GM018128647 NNP O
: BC2GM018128647 : O
sulfate BC2GM018128647 JJ O
ratios BC2GM018128647 NNS O
. BC2GM018128647 . O
. . O O

The BC2GM004875958 DT O
anesthesiologist BC2GM004875958 NN O
and BC2GM004875958 CC O
the BC2GM004875958 DT O
cardiac BC2GM004875958 JJ O
surgeon BC2GM004875958 NN O
. BC2GM004875958 . O
. . O O

Ectopic BC2GM007719127 NNP O
Xbra BC2GM007719127 NNP O
can BC2GM007719127 MD O
induce BC2GM007719127 VB O
Xegr-1 BC2GM007719127 JJ O
transcription BC2GM007719127 NN O
by BC2GM007719127 IN O
an BC2GM007719127 DT O
indirect BC2GM007719127 JJ O
mechanism BC2GM007719127 NN O
that BC2GM007719127 WDT O
appears BC2GM007719127 VBZ O
to BC2GM007719127 TO O
operate BC2GM007719127 VB O
via BC2GM007719127 IN O
primary BC2GM007719127 JJ O
activation BC2GM007719127 NN O
of BC2GM007719127 IN O
fibroblast BC2GM007719127 JJ O
growth BC2GM007719127 NN O
factor BC2GM007719127 NN O
secretion BC2GM007719127 NN O
. BC2GM007719127 . O
. . O O

The BC2GM095403151 DT O
occurrence BC2GM095403151 NN O
of BC2GM095403151 IN O
the BC2GM095403151 DT O
different BC2GM095403151 JJ O
types BC2GM095403151 NNS O
of BC2GM095403151 IN O
TCRB BC2GM095403151 NNP O
rearrangement BC2GM095403151 NN O
patterns BC2GM095403151 NNS O
has BC2GM095403151 VBZ O
implications BC2GM095403151 NNS O
for BC2GM095403151 IN O
PCR-based BC2GM095403151 JJ O
clonality BC2GM095403151 NN O
assessment BC2GM095403151 NN O
and BC2GM095403151 CC O
for BC2GM095403151 IN O
PCR-based BC2GM095403151 JJ O
detection BC2GM095403151 NN O
of BC2GM095403151 IN O
minimal BC2GM095403151 JJ O
residual BC2GM095403151 JJ O
disease BC2GM095403151 NN O
via BC2GM095403151 IN O
TCRB BC2GM095403151 NNP O
gene BC2GM095403151 NN O
analysis BC2GM095403151 NN O
. BC2GM095403151 . O
. . O O

Acetoacetate BC2GM091917178 NNP O
decarboxylase BC2GM091917178 NN O
( BC2GM091917178 ( O
ADC BC2GM091917178 NNP O
) BC2GM091917178 ) O
( BC2GM091917178 ( O
EC4.1.1.4 BC2GM091917178 NNP O
) BC2GM091917178 ) O
of BC2GM091917178 IN O
Clostridium BC2GM091917178 NNP O
acetobutylicum BC2GM091917178 VBP O
DSM BC2GM091917178 NNP O
792 BC2GM091917178 CD O
was BC2GM091917178 VBD O
purified BC2GM091917178 VBN O
to BC2GM091917178 TO O
homogeneity BC2GM091917178 NN O
, BC2GM091917178 , O
and BC2GM091917178 CC O
its BC2GM091917178 PRP$ O
first BC2GM091917178 JJ O
25 BC2GM091917178 CD O
N-terminal BC2GM091917178 JJ O
amino BC2GM091917178 NN O
acids BC2GM091917178 NNS O
were BC2GM091917178 VBD O
determined BC2GM091917178 VBN O
. BC2GM091917178 . O
. . O O

In BC2GM033913312 IN O
addition BC2GM033913312 NN O
, BC2GM033913312 , O
we BC2GM033913312 PRP O
mapped BC2GM033913312 VBD O
a BC2GM033913312 DT O
putative BC2GM033913312 JJ O
hnRNP BC2GM033913312 NN O
A1 BC2GM033913312 NNP O
binding BC2GM033913312 VBG O
site BC2GM033913312 NN O
in BC2GM033913312 IN O
U5 BC2GM033913312 NNP O
RNA BC2GM033913312 NNP O
and BC2GM033913312 CC O
demonstrated BC2GM033913312 VBD O
that BC2GM033913312 IN O
p40CRS BC2GM033913312 NN O
( BC2GM033913312 ( O
hnRNP BC2GM033913312 JJ O
A1 BC2GM033913312 NNP O
) BC2GM033913312 ) O
binding BC2GM033913312 VBG O
to BC2GM033913312 TO O
that BC2GM033913312 DT O
site BC2GM033913312 NN O
correlates BC2GM033913312 VBZ O
with BC2GM033913312 IN O
CRS BC2GM033913312 NNP O
function BC2GM033913312 NN O
. BC2GM033913312 . O
. . O O

The BC2GM028611908 DT O
authors BC2GM028611908 NNS O
discussed BC2GM028611908 VBD O
their BC2GM028611908 PRP$ O
experience BC2GM028611908 NN O
in BC2GM028611908 IN O
investigating BC2GM028611908 VBG O
20 BC2GM028611908 CD O
patients BC2GM028611908 NNS O
with BC2GM028611908 IN O
maxillary BC2GM028611908 JJ O
malignant BC2GM028611908 JJ O
tumors BC2GM028611908 NNS O
using BC2GM028611908 VBG O
routine BC2GM028611908 JJ O
x-ray BC2GM028611908 JJ O
studies BC2GM028611908 NNS O
and BC2GM028611908 CC O
MR-tomography BC2GM028611908 NNP O
, BC2GM028611908 , O
and BC2GM028611908 CC O
13 BC2GM028611908 CD O
patients BC2GM028611908 NNS O
, BC2GM028611908 , O
investigated BC2GM028611908 VBN O
in BC2GM028611908 IN O
the BC2GM028611908 DT O
same BC2GM028611908 JJ O
way BC2GM028611908 NN O
plus BC2GM028611908 CC O
CT BC2GM028611908 NNP O
. BC2GM028611908 . O
. . O O

In BC2GM078070574 IN O
static BC2GM078070574 JJ O
conditions BC2GM078070574 NNS O
, BC2GM078070574 , O
body BC2GM078070574 NN O
sway BC2GM078070574 NN O
was BC2GM078070574 VBD O
assessed BC2GM078070574 VBN O
using BC2GM078070574 VBG O
a BC2GM078070574 DT O
conventional BC2GM078070574 JJ O
force BC2GM078070574 NN O
platform BC2GM078070574 NN O
with BC2GM078070574 IN O
eyes BC2GM078070574 NNS O
open BC2GM078070574 JJ O
and BC2GM078070574 CC O
with BC2GM078070574 IN O
eyes BC2GM078070574 NNS O
closed BC2GM078070574 VBD O
. BC2GM078070574 . O
. . O O

CONCLUSIONS BC2GM063757924 NN O
: BC2GM063757924 : O
These BC2GM063757924 DT O
principally BC2GM063757924 RB O
structural BC2GM063757924 JJ O
studies BC2GM063757924 NNS O
support BC2GM063757924 VBP O
the BC2GM063757924 DT O
hypothesis BC2GM063757924 NN O
that BC2GM063757924 IN O
the BC2GM063757924 DT O
thrombus BC2GM063757924 NN O
is BC2GM063757924 VBZ O
a BC2GM063757924 DT O
self-sustaining BC2GM063757924 JJ O
entity BC2GM063757924 NN O
that BC2GM063757924 WDT O
may BC2GM063757924 MD O
have BC2GM063757924 VB O
significance BC2GM063757924 NN O
in BC2GM063757924 IN O
the BC2GM063757924 DT O
pathophysiologic BC2GM063757924 JJ O
mechanism BC2GM063757924 NN O
of BC2GM063757924 IN O
abdominal BC2GM063757924 JJ O
aortic BC2GM063757924 JJ O
aneurysms BC2GM063757924 NNS O
. BC2GM063757924 . O
. . O O

The BC2GM005288788 DT O
study BC2GM005288788 NN O
was BC2GM005288788 VBD O
performed BC2GM005288788 VBN O
in BC2GM005288788 IN O
a BC2GM005288788 DT O
class BC2GM005288788 NN O
100 BC2GM005288788 CD O
laminar BC2GM005288788 NN O
flow BC2GM005288788 NN O
clean BC2GM005288788 JJ O
bench BC2GM005288788 NN O
in BC2GM005288788 IN O
order BC2GM005288788 NN O
to BC2GM005288788 TO O
minimize BC2GM005288788 VB O
particulate BC2GM005288788 JJ O
contamination BC2GM005288788 NN O
from BC2GM005288788 IN O
extraneous BC2GM005288788 JJ O
sources BC2GM005288788 NNS O
. BC2GM005288788 . O
. . O O

Births BC2GM059704173 NNS O
, BC2GM059704173 , O
marriages BC2GM059704173 NNS O
, BC2GM059704173 , O
divorces BC2GM059704173 NNS O
, BC2GM059704173 , O
and BC2GM059704173 CC O
deaths BC2GM059704173 NNS O
for BC2GM059704173 IN O
July BC2GM059704173 NNP O
1997 BC2GM059704173 CD O
. BC2GM059704173 . O
. . O O

A BC2GM077904179 DT O
phase BC2GM077904179 NN O
II BC2GM077904179 NNP O
study BC2GM077904179 NN O
of BC2GM077904179 IN O
interferon-alpha BC2GM077904179 JJ O
, BC2GM077904179 , O
interleukin-2 BC2GM077904179 JJ O
and BC2GM077904179 CC O
5-fluorouracil BC2GM077904179 JJ O
in BC2GM077904179 IN O
advanced BC2GM077904179 JJ O
renal BC2GM077904179 JJ O
carcinoma BC2GM077904179 NN O
: BC2GM077904179 : O
clinical BC2GM077904179 JJ O
data BC2GM077904179 NNS O
and BC2GM077904179 CC O
laboratory BC2GM077904179 JJ O
evidence BC2GM077904179 NN O
of BC2GM077904179 IN O
protease BC2GM077904179 NN O
activation BC2GM077904179 NN O
. BC2GM077904179 . O
. . O O

New BC2GM087826956 NNP O
results BC2GM087826956 NNS O
of BC2GM087826956 IN O
importance BC2GM087826956 NN O
for BC2GM087826956 IN O
optimization BC2GM087826956 NN O
of BC2GM087826956 IN O
the BC2GM087826956 DT O
postoperative BC2GM087826956 JJ O
course BC2GM087826956 NN O
] BC2GM087826956 NNP O
Complications BC2GM087826956 NNP O
after BC2GM087826956 IN O
major BC2GM087826956 JJ O
surgery BC2GM087826956 NN O
may BC2GM087826956 MD O
be BC2GM087826956 VB O
related BC2GM087826956 VBN O
to BC2GM087826956 TO O
factors BC2GM087826956 NNS O
in BC2GM087826956 IN O
the BC2GM087826956 DT O
surgical BC2GM087826956 JJ O
stress BC2GM087826956 NN O
response BC2GM087826956 NN O
with BC2GM087826956 IN O
endocrine-metabolic BC2GM087826956 JJ O
and BC2GM087826956 CC O
inflammatory BC2GM087826956 JJ O
changes BC2GM087826956 NNS O
. BC2GM087826956 . O
. . O O

The BC2GM071034942 DT O
duration BC2GM071034942 NN O
of BC2GM071034942 IN O
naloxone BC2GM071034942 NN O
appears BC2GM071034942 VBZ O
to BC2GM071034942 TO O
be BC2GM071034942 VB O
dose-related BC2GM071034942 JJ O
, BC2GM071034942 , O
statistically BC2GM071034942 RB O
significant BC2GM071034942 JJ O
up BC2GM071034942 IN O
to BC2GM071034942 TO O
approximately BC2GM071034942 RB O
1.5 BC2GM071034942 CD O
hr BC2GM071034942 NN O
. BC2GM071034942 . O
. . O O

This BC2GM039524689 DT O
may BC2GM039524689 MD O
be BC2GM039524689 VB O
another BC2GM039524689 DT O
example BC2GM039524689 NN O
of BC2GM039524689 IN O
the BC2GM039524689 DT O
principle BC2GM039524689 NN O
-- BC2GM039524689 : O
less BC2GM039524689 CC O
is BC2GM039524689 VBZ O
more BC2GM039524689 RBR O
. BC2GM039524689 . O
. . O O

However BC2GM098818949 RB O
, BC2GM098818949 , O
one BC2GM098818949 CD O
activity BC2GM098818949 NN O
binds BC2GM098818949 VBZ O
preferentially BC2GM098818949 RB O
to BC2GM098818949 TO O
G+C-rich BC2GM098818949 NNP O
promoters BC2GM098818949 NNS O
, BC2GM098818949 , O
and BC2GM098818949 CC O
another BC2GM098818949 DT O
activity BC2GM098818949 NN O
appears BC2GM098818949 VBZ O
to BC2GM098818949 TO O
bind BC2GM098818949 VB O
preferentially BC2GM098818949 RB O
to BC2GM098818949 TO O
only BC2GM098818949 RB O
two BC2GM098818949 CD O
of BC2GM098818949 IN O
the BC2GM098818949 DT O
promoters BC2GM098818949 NNS O
tested BC2GM098818949 VBD O
. BC2GM098818949 . O
. . O O

The BC2GM028335304 DT O
promoter BC2GM028335304 NN O
for BC2GM028335304 IN O
HMG-CoA BC2GM028335304 NNP O
synthase BC2GM028335304 NN O
contains BC2GM028335304 VBZ O
two BC2GM028335304 CD O
binding BC2GM028335304 NN O
sites BC2GM028335304 NNS O
for BC2GM028335304 IN O
the BC2GM028335304 DT O
sterol BC2GM028335304 NN O
regulatory BC2GM028335304 JJ O
element-binding BC2GM028335304 JJ O
proteins BC2GM028335304 NNS O
( BC2GM028335304 ( O
SREBPs BC2GM028335304 NNP O
) BC2GM028335304 ) O
. BC2GM028335304 . O
. . O O

The BC2GM019564620 DT O
fz-1 BC2GM019564620 JJ O
and BC2GM019564620 CC O
fz-2 BC2GM019564620 JJ O
genes BC2GM019564620 NNS O
are BC2GM019564620 VBP O
widely BC2GM019564620 RB O
expressed BC2GM019564620 VBN O
in BC2GM019564620 IN O
rat BC2GM019564620 NN O
tissues BC2GM019564620 NNS O
with BC2GM019564620 IN O
the BC2GM019564620 DT O
highest BC2GM019564620 JJS O
steady-state BC2GM019564620 JJ O
levels BC2GM019564620 NNS O
of BC2GM019564620 IN O
mRNA BC2GM019564620 NN O
in BC2GM019564620 IN O
kidney BC2GM019564620 NN O
, BC2GM019564620 , O
liver BC2GM019564620 NN O
, BC2GM019564620 , O
heart BC2GM019564620 NN O
, BC2GM019564620 , O
uterus BC2GM019564620 NN O
, BC2GM019564620 , O
and BC2GM019564620 CC O
ovary BC2GM019564620 JJ O
. BC2GM019564620 . O
fz-1 BC2GM019564620 NN O
and BC2GM019564620 CC O
-2 BC2GM019564620 NNP O
mRNA BC2GM019564620 NN O
levels BC2GM019564620 NNS O
were BC2GM019564620 VBD O
greater BC2GM019564620 JJR O
in BC2GM019564620 IN O
neonatal BC2GM019564620 JJ O
than BC2GM019564620 IN O
in BC2GM019564620 IN O
corresponding BC2GM019564620 VBG O
adult BC2GM019564620 NN O
tissues BC2GM019564620 NNS O
. BC2GM019564620 . O
. . O O

The BC2GM013239156 DT O
mean BC2GM013239156 NN O
was BC2GM013239156 VBD O
66 BC2GM013239156 CD O
cells BC2GM013239156 NNS O
/ BC2GM013239156 JJ O
mm2 BC2GM013239156 NN O
in BC2GM013239156 IN O
the BC2GM013239156 DT O
laser BC2GM013239156 NN O
group BC2GM013239156 NN O
and BC2GM013239156 CC O
63.7 BC2GM013239156 CD O
cells BC2GM013239156 NNS O
/ BC2GM013239156 JJ O
mm2 BC2GM013239156 NN O
in BC2GM013239156 IN O
the BC2GM013239156 DT O
control BC2GM013239156 NN O
group BC2GM013239156 NN O
. BC2GM013239156 . O
. . O O

Role BC2GM087087501 NNP O
of BC2GM087087501 IN O
double-stranded BC2GM087087501 JJ O
RNA-dependent BC2GM087087501 JJ O
protein BC2GM087087501 NN O
kinase BC2GM087087501 NN O
in BC2GM087087501 IN O
mediating BC2GM087087501 VBG O
hypersensitivity BC2GM087087501 NN O
of BC2GM087087501 IN O
Fanconi BC2GM087087501 NNP O
anemia BC2GM087087501 NN O
complementation BC2GM087087501 NN O
group BC2GM087087501 NN O
C BC2GM087087501 NNP O
cells BC2GM087087501 NNS O
to BC2GM087087501 TO O
interferon BC2GM087087501 VB O
gamma BC2GM087087501 NN O
, BC2GM087087501 , O
tumor BC2GM087087501 NN O
necrosis BC2GM087087501 NN O
factor-alpha BC2GM087087501 NN O
, BC2GM087087501 , O
and BC2GM087087501 CC O
double-stranded BC2GM087087501 JJ O
RNA BC2GM087087501 NNP O
. BC2GM087087501 . O
. . O O

Gene BC2GM061568897 NNP O
transcripts BC2GM061568897 NNS O
are BC2GM061568897 VBP O
detected BC2GM061568897 VBN O
on BC2GM061568897 IN O
tissues BC2GM061568897 NNS O
such BC2GM061568897 JJ O
as BC2GM061568897 IN O
bovine BC2GM061568897 NN O
liver BC2GM061568897 NN O
, BC2GM061568897 , O
kidney BC2GM061568897 NN O
, BC2GM061568897 , O
lung BC2GM061568897 NN O
, BC2GM061568897 , O
and BC2GM061568897 CC O
brain BC2GM061568897 NN O
. BC2GM061568897 . O
. . O O

The BC2GM022740779 DT O
training BC2GM022740779 NN O
programs BC2GM022740779 NNS O
had BC2GM022740779 VBD O
a BC2GM022740779 DT O
duration BC2GM022740779 NN O
of BC2GM022740779 IN O
30 BC2GM022740779 CD O
days BC2GM022740779 NNS O
, BC2GM022740779 , O
5 BC2GM022740779 CD O
days BC2GM022740779 NNS O
/ BC2GM022740779 JJ O
week BC2GM022740779 NN O
, BC2GM022740779 , O
and BC2GM022740779 CC O
was BC2GM022740779 VBD O
performed BC2GM022740779 VBN O
on BC2GM022740779 IN O
a BC2GM022740779 DT O
motor-driven BC2GM022740779 JJ O
treadmill BC2GM022740779 NN O
. BC2GM022740779 . O
. . O O

PRIP BC2GM024114351 NNP O
contains BC2GM024114351 VBZ O
two BC2GM024114351 CD O
LXXLL BC2GM024114351 NNP O
signature BC2GM024114351 NN O
motifs BC2GM024114351 NNS O
. BC2GM024114351 . O
. . O O

A BC2GM071889141 DT O
third-order BC2GM071889141 JJ O
polynominal BC2GM071889141 JJ O
fit BC2GM071889141 NN O
showed BC2GM071889141 VBD O
a BC2GM071889141 DT O
good BC2GM071889141 JJ O
correlation BC2GM071889141 NN O
for BC2GM071889141 IN O
the BC2GM071889141 DT O
parameter BC2GM071889141 NN O
Q* BC2GM071889141 NNP O
and BC2GM071889141 CC O
MTT BC2GM071889141 NNP O
, BC2GM071889141 , O
whereas BC2GM071889141 JJ O
T BC2GM071889141 NNP O
and BC2GM071889141 CC O
SImax BC2GM071889141 NNP O
were BC2GM071889141 VBD O
found BC2GM071889141 VBN O
to BC2GM071889141 TO O
have BC2GM071889141 VB O
a BC2GM071889141 DT O
poor BC2GM071889141 JJ O
correlation BC2GM071889141 NN O
. BC2GM071889141 . O
. . O O

42nd BC2GM067993736 CD O
annual BC2GM067993736 JJ O
meeting BC2GM067993736 NN O
of BC2GM067993736 IN O
the BC2GM067993736 DT O
American BC2GM067993736 NNP O
Academy BC2GM067993736 NNP O
of BC2GM067993736 IN O
Oral BC2GM067993736 NNP O
Pathology BC2GM067993736 NNP O
. BC2GM067993736 . O
. . O O

There BC2GM011109464 EX O
was BC2GM011109464 VBD O
a BC2GM011109464 DT O
57 BC2GM011109464 CD O
% BC2GM011109464 NN O
reduction BC2GM011109464 NN O
in BC2GM011109464 IN O
IGF BC2GM011109464 NNP O
IR BC2GM011109464 NNP O
mRNA BC2GM011109464 NN O
levels BC2GM011109464 NNS O
in BC2GM011109464 IN O
clone BC2GM011109464 NN O
CA9 BC2GM011109464 NNP O
after BC2GM011109464 IN O
confluence BC2GM011109464 NN O
compared BC2GM011109464 VBN O
with BC2GM011109464 IN O
clone BC2GM011109464 NN O
ME10 BC2GM011109464 NNP O
. BC2GM011109464 . O
. . O O

One BC2GM023083522 CD O
of BC2GM023083522 IN O
these BC2GM023083522 DT O
elements BC2GM023083522 NNS O
resembles BC2GM023083522 VBZ O
the BC2GM023083522 DT O
binding BC2GM023083522 VBG O
site BC2GM023083522 NN O
of BC2GM023083522 IN O
a BC2GM023083522 DT O
previously BC2GM023083522 RB O
identified BC2GM023083522 VBN O
cellular BC2GM023083522 JJ O
`` BC2GM023083522 `` O
transcription BC2GM023083522 NN O
'' BC2GM023083522 '' O
factor BC2GM023083522 NN O
. BC2GM023083522 . O
. . O O

The BC2GM017085693 DT O
biological BC2GM017085693 JJ O
actions BC2GM017085693 NNS O
of BC2GM017085693 IN O
VHR BC2GM017085693 NNP O
in BC2GM017085693 IN O
oocytes BC2GM017085693 NNS O
clearly BC2GM017085693 RB O
distinguish BC2GM017085693 VBP O
it BC2GM017085693 PRP O
from BC2GM017085693 IN O
other BC2GM017085693 JJ O
dual BC2GM017085693 JJ O
specificity BC2GM017085693 NN O
phosphatases BC2GM017085693 NNS O
, BC2GM017085693 , O
which BC2GM017085693 WDT O
have BC2GM017085693 VBP O
shown BC2GM017085693 VBN O
inhibitory BC2GM017085693 JJ O
effects BC2GM017085693 NNS O
when BC2GM017085693 WRB O
tested BC2GM017085693 VBN O
in BC2GM017085693 IN O
oocytes BC2GM017085693 NNS O
. BC2GM017085693 . O
. . O O

Many BC2GM077833737 JJ O
of BC2GM077833737 IN O
the BC2GM077833737 DT O
metabolic BC2GM077833737 JJ O
effects BC2GM077833737 NNS O
induced BC2GM077833737 VBN O
by BC2GM077833737 IN O
thiazide BC2GM077833737 NN O
diuretics BC2GM077833737 NNS O
, BC2GM077833737 , O
however BC2GM077833737 RB O
, BC2GM077833737 , O
can BC2GM077833737 MD O
be BC2GM077833737 VB O
limited BC2GM077833737 VBN O
by BC2GM077833737 IN O
the BC2GM077833737 DT O
use BC2GM077833737 NN O
of BC2GM077833737 IN O
low BC2GM077833737 JJ O
doses BC2GM077833737 NNS O
. BC2GM077833737 . O
. . O O

For BC2GM078789356 IN O
any BC2GM078789356 DT O
given BC2GM078789356 VBN O
age BC2GM078789356 NN O
, BC2GM078789356 , O
high-stressed BC2GM078789356 JJ O
plantaris BC2GM078789356 NN O
tendons BC2GM078789356 NNS O
were BC2GM078789356 VBD O
of BC2GM078789356 IN O
a BC2GM078789356 DT O
higher BC2GM078789356 JJR O
fatigue BC2GM078789356 NN O
quality BC2GM078789356 NN O
than BC2GM078789356 IN O
low-stressed BC2GM078789356 JJ O
extensor BC2GM078789356 NN O
tendons BC2GM078789356 NNS O
. BC2GM078789356 . O
. . O O

A BC2GM033817811 DT O
4.0-kb BC2GM033817811 JJ O
Nlk BC2GM033817811 NNP O
message BC2GM033817811 NN O
is BC2GM033817811 VBZ O
also BC2GM033817811 RB O
present BC2GM033817811 JJ O
during BC2GM033817811 IN O
embryogenesis BC2GM033817811 NN O
, BC2GM033817811 , O
detectable BC2GM033817811 JJ O
at BC2GM033817811 IN O
day BC2GM033817811 NN O
E10 BC2GM033817811 NNP O
. BC2GM033817811 . O
. . O O

The BC2GM058726742 DT O
ends BC2GM058726742 NNS O
of BC2GM058726742 IN O
the BC2GM058726742 DT O
barrel BC2GM058726742 NN O
are BC2GM058726742 VBP O
capped BC2GM058726742 VBN O
by BC2GM058726742 IN O
short BC2GM058726742 JJ O
helices BC2GM058726742 NNS O
. BC2GM058726742 . O
. . O O

( BC2GM022742805 ( O
1992 BC2GM022742805 CD O
) BC2GM022742805 ) O
J BC2GM022742805 NNP O
. BC2GM022742805 . O
. . O O

The BC2GM071213428 DT O
immediate BC2GM071213428 JJ O
and BC2GM071213428 CC O
remote BC2GM071213428 JJ O
results BC2GM071213428 NNS O
of BC2GM071213428 IN O
surgical BC2GM071213428 JJ O
treatment BC2GM071213428 NN O
of BC2GM071213428 IN O
renal BC2GM071213428 JJ O
adenocarcinomas BC2GM071213428 NN O
. BC2GM071213428 . O
. . O O

Computed BC2GM035428099 VBN O
tomographic BC2GM035428099 JJ O
( BC2GM035428099 ( O
CT BC2GM035428099 NNP O
) BC2GM035428099 ) O
findings BC2GM035428099 NNS O
of BC2GM035428099 IN O
pancreatic BC2GM035428099 JJ O
ductal BC2GM035428099 JJ O
adenocarcinoma BC2GM035428099 NN O
were BC2GM035428099 VBD O
studied BC2GM035428099 VBN O
with BC2GM035428099 IN O
the BC2GM035428099 DT O
combined BC2GM035428099 JJ O
method BC2GM035428099 NN O
of BC2GM035428099 IN O
early BC2GM035428099 JJ O
enhancement BC2GM035428099 NN O
CT BC2GM035428099 NNP O
and BC2GM035428099 CC O
high BC2GM035428099 JJ O
dose BC2GM035428099 NN O
enhancement BC2GM035428099 NN O
CT BC2GM035428099 NNP O
in BC2GM035428099 IN O
72 BC2GM035428099 CD O
carcinomas BC2GM035428099 NN O
. BC2GM035428099 . O
. . O O

An BC2GM046472114 DT O
increased BC2GM046472114 JJ O
incidence BC2GM046472114 NN O
of BC2GM046472114 IN O
ATN BC2GM046472114 NNP O
has BC2GM046472114 VBZ O
been BC2GM046472114 VBN O
reported BC2GM046472114 VBN O
since BC2GM046472114 IN O
the BC2GM046472114 DT O
introduction BC2GM046472114 NN O
of BC2GM046472114 IN O
cyclosporin BC2GM046472114 NN O
A BC2GM046472114 NNP O
. BC2GM046472114 . O
. . O O

Serum BC2GM085649644 NNP O
concentrations BC2GM085649644 NNS O
of BC2GM085649644 IN O
hormones BC2GM085649644 NNS O
in BC2GM085649644 IN O
patients BC2GM085649644 NNS O
classified BC2GM085649644 VBN O
as BC2GM085649644 IN O
C BC2GM085649644 NNP O
were BC2GM085649644 VBD O
characteristically BC2GM085649644 RB O
and BC2GM085649644 CC O
inclined BC2GM085649644 VBD O
to BC2GM085649644 TO O
be BC2GM085649644 VB O
hypergonadotropic BC2GM085649644 JJ O
and BC2GM085649644 CC O
hypoestrogenic BC2GM085649644 JJ O
. BC2GM085649644 . O
. . O O

Erdheim-Chester BC2GM088020091 JJ O
disease BC2GM088020091 NN O
: BC2GM088020091 : O
a BC2GM088020091 DT O
distinct BC2GM088020091 JJ O
lipoidosis BC2GM088020091 NN O
or BC2GM088020091 CC O
part BC2GM088020091 NN O
of BC2GM088020091 IN O
the BC2GM088020091 DT O
spectrum BC2GM088020091 NN O
of BC2GM088020091 IN O
histiocytosis BC2GM088020091 NN O
? BC2GM088020091 . O
Erdheim-Chester BC2GM088020091 JJ O
disease BC2GM088020091 NN O
has BC2GM088020091 VBZ O
always BC2GM088020091 RB O
been BC2GM088020091 VBN O
considered BC2GM088020091 VBN O
a BC2GM088020091 DT O
distinct BC2GM088020091 JJ O
lipoidosis BC2GM088020091 NN O
based BC2GM088020091 VBN O
on BC2GM088020091 IN O
clinical BC2GM088020091 JJ O
and BC2GM088020091 CC O
radiographic BC2GM088020091 JJ O
criteria BC2GM088020091 NNS O
. BC2GM088020091 . O
. . O O

The BC2GM009022291 DT O
recovery BC2GM009022291 NN O
of BC2GM009022291 IN O
adults BC2GM009022291 NNS O
schistosomes BC2GM009022291 NNS O
by BC2GM009022291 IN O
extracorporeal BC2GM009022291 JJ O
filtration BC2GM009022291 NN O
. BC2GM009022291 . O
. . O O

Moreover BC2GM091903894 RB O
, BC2GM091903894 , O
FACT BC2GM091903894 NNP O
specifically BC2GM091903894 RB O
interacts BC2GM091903894 VBZ O
with BC2GM091903894 IN O
nucleosomes BC2GM091903894 NNS O
and BC2GM091903894 CC O
histone BC2GM091903894 NN O
H2A BC2GM091903894 NNP O
/ BC2GM091903894 NNP O
H2B BC2GM091903894 NNP O
dimers BC2GM091903894 NNS O
, BC2GM091903894 , O
indicating BC2GM091903894 VBG O
that BC2GM091903894 IN O
it BC2GM091903894 PRP O
may BC2GM091903894 MD O
work BC2GM091903894 VB O
by BC2GM091903894 IN O
promoting BC2GM091903894 VBG O
nucleosome BC2GM091903894 NN O
disassembly BC2GM091903894 RB O
upon BC2GM091903894 IN O
transcription BC2GM091903894 NN O
. BC2GM091903894 . O
. . O O

Therefore BC2GM092558649 RB O
, BC2GM092558649 , O
it BC2GM092558649 PRP O
appears BC2GM092558649 VBZ O
that BC2GM092558649 IN O
GCN2 BC2GM092558649 NNP O
protein BC2GM092558649 VBD O
kinase BC2GM092558649 JJ O
function BC2GM092558649 NN O
is BC2GM092558649 VBZ O
stimulated BC2GM092558649 VBN O
posttranslationally BC2GM092558649 RB O
in BC2GM092558649 IN O
amino BC2GM092558649 JJ O
acid-starved BC2GM092558649 JJ O
cells BC2GM092558649 NNS O
. BC2GM092558649 . O
. . O O

In BC2GM016725379 IN O
agreement BC2GM016725379 NN O
with BC2GM016725379 IN O
this BC2GM016725379 DT O
model BC2GM016725379 NN O
, BC2GM016725379 , O
elimination BC2GM016725379 NN O
of BC2GM016725379 IN O
the BC2GM016725379 DT O
ADAM13 BC2GM016725379 NNP O
cytoplasmic BC2GM016725379 JJ O
domain BC2GM016725379 NN O
increased BC2GM016725379 VBD O
developmental BC2GM016725379 JJ O
alterations BC2GM016725379 NNS O
attributable BC2GM016725379 JJ O
to BC2GM016725379 TO O
ADAM13 BC2GM016725379 NNP O
proteolytic BC2GM016725379 JJ O
activity BC2GM016725379 NN O
. BC2GM016725379 . O
. . O O

The BC2GM075272247 DT O
educational BC2GM075272247 JJ O
program BC2GM075272247 NN O
was BC2GM075272247 VBD O
the BC2GM075272247 DT O
significant BC2GM075272247 JJ O
factor BC2GM075272247 NN O
that BC2GM075272247 WDT O
influenced BC2GM075272247 VBD O
the BC2GM075272247 DT O
change BC2GM075272247 NN O
of BC2GM075272247 IN O
concern BC2GM075272247 NN O
trajectories BC2GM075272247 NNS O
, BC2GM075272247 , O
and BC2GM075272247 CC O
the BC2GM075272247 DT O
recurrent BC2GM075272247 JJ O
/ BC2GM075272247 JJ O
non-recurrent BC2GM075272247 JJ O
factor BC2GM075272247 NN O
influenced BC2GM075272247 VBD O
the BC2GM075272247 DT O
change BC2GM075272247 NN O
of BC2GM075272247 IN O
concern BC2GM075272247 NN O
only BC2GM075272247 RB O
in BC2GM075272247 IN O
pamphlet BC2GM075272247 NN O
group BC2GM075272247 NN O
. BC2GM075272247 . O
. . O O

Clinical BC2GM065187167 JJ O
development BC2GM065187167 NN O
of BC2GM065187167 IN O
interleukin-10 BC2GM065187167 NN O
. BC2GM065187167 . O
. . O O

Restriction BC2GM095568717 NN O
mapping BC2GM095568717 NN O
showed BC2GM095568717 VBD O
that BC2GM095568717 IN O
the BC2GM095568717 DT O
two BC2GM095568717 CD O
recombinant BC2GM095568717 JJ O
plasmids BC2GM095568717 NNS O
shared BC2GM095568717 VBD O
an BC2GM095568717 DT O
EcoRI BC2GM095568717 NNP O
fragment BC2GM095568717 NN O
of BC2GM095568717 IN O
8.9 BC2GM095568717 CD O
kb BC2GM095568717 NNS O
. BC2GM095568717 . O
. . O O

BK-induced BC2GM082522645 JJ O
translocation BC2GM082522645 NN O
and BC2GM082522645 CC O
overexpression BC2GM082522645 NN O
of BC2GM082522645 IN O
PKC BC2GM082522645 NNP O
isoforms BC2GM082522645 NNS O
as BC2GM082522645 RB O
well BC2GM082522645 RB O
as BC2GM082522645 IN O
coexpression BC2GM082522645 NN O
of BC2GM082522645 IN O
inactive BC2GM082522645 JJ O
or BC2GM082522645 CC O
constitutively BC2GM082522645 RB O
active BC2GM082522645 JJ O
mutants BC2GM082522645 NNS O
of BC2GM082522645 IN O
different BC2GM082522645 JJ O
PKC BC2GM082522645 NNP O
isozymes BC2GM082522645 NNS O
provided BC2GM082522645 VBD O
evidence BC2GM082522645 NN O
for BC2GM082522645 IN O
a BC2GM082522645 DT O
role BC2GM082522645 NN O
of BC2GM082522645 IN O
the BC2GM082522645 DT O
diacylglycerol-sensitive BC2GM082522645 JJ O
PKCs BC2GM082522645 NNP O
alpha BC2GM082522645 NN O
and BC2GM082522645 CC O
epsilon BC2GM082522645 NN O
in BC2GM082522645 IN O
BK BC2GM082522645 NNP O
signaling BC2GM082522645 VBG O
toward BC2GM082522645 IN O
MAPK BC2GM082522645 NNP O
. BC2GM082522645 . O
. . O O

These BC2GM091928685 DT O
studies BC2GM091928685 NNS O
suggest BC2GM091928685 VBP O
that BC2GM091928685 IN O
tandem BC2GM091928685 JJ O
alpha-helices BC2GM091928685 NNS O
located BC2GM091928685 VBN O
near BC2GM091928685 IN O
the BC2GM091928685 DT O
C-terminus BC2GM091928685 NNP O
of BC2GM091928685 IN O
PC-TP BC2GM091928685 NNP O
facilitate BC2GM091928685 NN O
membrane BC2GM091928685 NN O
binding BC2GM091928685 NN O
and BC2GM091928685 CC O
extraction BC2GM091928685 NN O
of BC2GM091928685 IN O
phosphatidylcholines BC2GM091928685 NNS O
. BC2GM091928685 . O
. . O O

A BC2GM062047431 DT O
surge BC2GM062047431 NN O
in BC2GM062047431 IN O
the BC2GM062047431 DT O
rate BC2GM062047431 NN O
of BC2GM062047431 IN O
ascorbyl BC2GM062047431 JJ O
radical BC2GM062047431 JJ O
production BC2GM062047431 NN O
, BC2GM062047431 , O
directly BC2GM062047431 RB O
correlated BC2GM062047431 VBN O
with BC2GM062047431 IN O
oxyradical BC2GM062047431 JJ O
stress BC2GM062047431 NN O
and BC2GM062047431 CC O
an BC2GM062047431 DT O
abrupt BC2GM062047431 JJ O
fall BC2GM062047431 NN O
in BC2GM062047431 IN O
superoxide BC2GM062047431 JJ O
dismutase BC2GM062047431 NN O
activity BC2GM062047431 NN O
in BC2GM062047431 IN O
the BC2GM062047431 DT O
granuloma BC2GM062047431 NN O
, BC2GM062047431 , O
indicates BC2GM062047431 VBZ O
'switching BC2GM062047431 VBG O
on BC2GM062047431 IN O
' BC2GM062047431 NNS O
of BC2GM062047431 IN O
a BC2GM062047431 DT O
free BC2GM062047431 JJ O
radical-dependent BC2GM062047431 JJ O
machinery BC2GM062047431 NN O
for BC2GM062047431 IN O
the BC2GM062047431 DT O
formation BC2GM062047431 NN O
of BC2GM062047431 IN O
granuloma BC2GM062047431 NN O
after BC2GM062047431 IN O
vasectomy BC2GM062047431 NN O
. BC2GM062047431 . O
. . O O

Sequence BC2GM013674707 NNP O
analysis BC2GM013674707 NN O
of BC2GM013674707 IN O
cDNA BC2GM013674707 NN O
clones BC2GM013674707 NNS O
encoding BC2GM013674707 VBG O
human BC2GM013674707 JJ O
gamma BC2GM013674707 NN O
revealed BC2GM013674707 VBD O
an BC2GM013674707 DT O
open BC2GM013674707 JJ O
reading BC2GM013674707 NN O
frame BC2GM013674707 NN O
predicting BC2GM013674707 VBG O
a BC2GM013674707 DT O
protein BC2GM013674707 NN O
of BC2GM013674707 IN O
299 BC2GM013674707 CD O
amino BC2GM013674707 JJ O
acids BC2GM013674707 NNS O
( BC2GM013674707 ( O
approximately BC2GM013674707 RB O
32 BC2GM013674707 CD O
kDa BC2GM013674707 NN O
) BC2GM013674707 ) O
, BC2GM013674707 , O
half BC2GM013674707 PDT O
the BC2GM013674707 DT O
size BC2GM013674707 NN O
of BC2GM013674707 IN O
the BC2GM013674707 DT O
bovine BC2GM013674707 NN O
gamma BC2GM013674707 NN O
subunit BC2GM013674707 NN O
. BC2GM013674707 . O
. . O O

Kinase BC2GM085654782 NNP O
renaturation BC2GM085654782 NN O
tests BC2GM085654782 NNS O
designed BC2GM085654782 VBN O
to BC2GM085654782 TO O
detect BC2GM085654782 VB O
reactivated BC2GM085654782 JJ O
protein BC2GM085654782 NN O
kinases BC2GM085654782 NNS O
after BC2GM085654782 IN O
electrophoresis BC2GM085654782 NN O
in BC2GM085654782 IN O
sodium BC2GM085654782 NN O
dodecyl BC2GM085654782 NN O
sulfate-polyacrylamide BC2GM085654782 JJ O
gels BC2GM085654782 NNS O
revealed BC2GM085654782 VBD O
the BC2GM085654782 DT O
presence BC2GM085654782 NN O
of BC2GM085654782 IN O
a BC2GM085654782 DT O
60-kDa BC2GM085654782 JJ O
kinase BC2GM085654782 NN O
in BC2GM085654782 IN O
the BC2GM085654782 DT O
washed BC2GM085654782 JJ O
immunoprecipitate BC2GM085654782 NN O
obtained BC2GM085654782 VBN O
from BC2GM085654782 IN O
liver BC2GM085654782 NN O
cytosol BC2GM085654782 NN O
using BC2GM085654782 VBG O
anti-AHR BC2GM085654782 JJ O
antibody BC2GM085654782 NN O
( BC2GM085654782 ( O
IgG BC2GM085654782 NNP O
) BC2GM085654782 ) O
and BC2GM085654782 CC O
protein BC2GM085654782 VBZ O
A BC2GM085654782 DT O
/ BC2GM085654782 JJ O
G BC2GM085654782 NNP O
/ BC2GM085654782 NNP O
agarose BC2GM085654782 JJ O
beads BC2GM085654782 NNS O
but BC2GM085654782 CC O
not BC2GM085654782 RB O
when BC2GM085654782 WRB O
a BC2GM085654782 DT O
nonspecific BC2GM085654782 JJ O
IgG BC2GM085654782 NNP O
was BC2GM085654782 VBD O
used BC2GM085654782 VBN O
instead BC2GM085654782 RB O
of BC2GM085654782 IN O
anti-AHR BC2GM085654782 JJ O
antibody BC2GM085654782 NN O
. BC2GM085654782 . O
. . O O

Expression BC2GM022846280 NN O
of BC2GM022846280 IN O
FNCAT BC2GM022846280 NNP O
increased BC2GM022846280 VBD O
on BC2GM022846280 IN O
serum BC2GM022846280 NN O
treatment BC2GM022846280 NN O
indicating BC2GM022846280 VBG O
that BC2GM022846280 IN O
the BC2GM022846280 DT O
region BC2GM022846280 NN O
of BC2GM022846280 IN O
the BC2GM022846280 DT O
FN BC2GM022846280 NNP O
gene BC2GM022846280 NN O
between BC2GM022846280 IN O
positions BC2GM022846280 NNS O
+69 BC2GM022846280 NNP O
and BC2GM022846280 CC O
-510 BC2GM022846280 NNP O
bp BC2GM022846280 NN O
mediated BC2GM022846280 VBD O
serum BC2GM022846280 JJ O
responsiveness BC2GM022846280 NN O
. BC2GM022846280 . O
. . O O

HL BC2GM075780214 NNP O
is BC2GM075780214 VBZ O
hypothesized BC2GM075780214 VBN O
to BC2GM075780214 TO O
directly BC2GM075780214 RB O
couple BC2GM075780214 VB O
HDL BC2GM075780214 NNP O
lipid BC2GM075780214 JJ O
metabolism BC2GM075780214 NN O
to BC2GM075780214 TO O
tissue BC2GM075780214 VB O
/ BC2GM075780214 NNP O
cellular BC2GM075780214 JJ O
lipid BC2GM075780214 JJ O
metabolism BC2GM075780214 NN O
. BC2GM075780214 . O
. . O O

Mechanisms BC2GM067383084 NNP O
of BC2GM067383084 IN O
action BC2GM067383084 NN O
of BC2GM067383084 IN O
local BC2GM067383084 JJ O
anaesthetics BC2GM067383084 NNS O
. BC2GM067383084 . O
. . O O

The BC2GM088319331 DT O
leader BC2GM088319331 NN O
peptide BC2GM088319331 NN O
was BC2GM088319331 VBD O
hypothesized BC2GM088319331 VBN O
to BC2GM088319331 TO O
inhibit BC2GM088319331 VB O
ribosome BC2GM088319331 JJ O
release BC2GM088319331 NN O
at BC2GM088319331 IN O
the BC2GM088319331 DT O
tnaC BC2GM088319331 NN O
stop BC2GM088319331 NN O
codon BC2GM088319331 NN O
, BC2GM088319331 , O
thereby BC2GM088319331 RB O
blocking BC2GM088319331 VBG O
Rho BC2GM088319331 NNP O
's BC2GM088319331 POS O
access BC2GM088319331 NN O
to BC2GM088319331 TO O
the BC2GM088319331 DT O
transcript BC2GM088319331 NN O
. BC2GM088319331 . O
. . O O

RNase BC2GM039253941 NNP O
protection BC2GM039253941 NN O
analysis BC2GM039253941 NN O
reveals BC2GM039253941 VBZ O
a BC2GM039253941 DT O
10-fold BC2GM039253941 JJ O
increase BC2GM039253941 NN O
in BC2GM039253941 IN O
the BC2GM039253941 DT O
expression BC2GM039253941 NN O
of BC2GM039253941 IN O
SCD2 BC2GM039253941 NNP O
mRNA BC2GM039253941 NN O
during BC2GM039253941 IN O
3T3-L1 BC2GM039253941 JJ O
preadipocyte BC2GM039253941 JJ O
differentiation BC2GM039253941 NN O
. BC2GM039253941 . O
. . O O

Restriction BC2GM025767093 NNP O
analysis BC2GM025767093 NN O
of BC2GM025767093 IN O
the BC2GM025767093 DT O
isolated BC2GM025767093 JJ O
genomic BC2GM025767093 JJ O
clones BC2GM025767093 NNS O
indicated BC2GM025767093 VBD O
that BC2GM025767093 IN O
the BC2GM025767093 DT O
endogenous BC2GM025767093 JJ O
sequences BC2GM025767093 NNS O
abutting BC2GM025767093 VBG O
the BC2GM025767093 DT O
3 BC2GM025767093 CD O
' BC2GM025767093 POS O
ends BC2GM025767093 NNS O
of BC2GM025767093 IN O
the BC2GM025767093 DT O
94-A BC2GM025767093 JJ O
and BC2GM025767093 CC O
94-K BC2GM025767093 JJ O
transgenes BC2GM025767093 NNS O
are BC2GM025767093 VBP O
separated BC2GM025767093 VBN O
by BC2GM025767093 IN O
less BC2GM025767093 JJR O
than BC2GM025767093 IN O
20 BC2GM025767093 CD O
kb BC2GM025767093 NNS O
, BC2GM025767093 , O
providing BC2GM025767093 VBG O
strong BC2GM025767093 JJ O
support BC2GM025767093 NN O
for BC2GM025767093 IN O
the BC2GM025767093 DT O
single BC2GM025767093 JJ O
integration BC2GM025767093 NN O
model BC2GM025767093 NN O
. BC2GM025767093 . O
. . O O

Salts BC2GM054717309 NNS O
of BC2GM054717309 IN O
these BC2GM054717309 DT O
four BC2GM054717309 CD O
metal BC2GM054717309 NN O
ions BC2GM054717309 NNS O
may BC2GM054717309 MD O
be BC2GM054717309 VB O
added BC2GM054717309 VBN O
to BC2GM054717309 TO O
the BC2GM054717309 DT O
growth BC2GM054717309 NN O
medium BC2GM054717309 NN O
to BC2GM054717309 TO O
facilitate BC2GM054717309 VB O
selective BC2GM054717309 JJ O
isolation BC2GM054717309 NN O
of BC2GM054717309 IN O
Acinetobacter BC2GM054717309 NNP O
. BC2GM054717309 . O
. . O O

Analyses BC2GM005819408 NNS O
focused BC2GM005819408 VBD O
on BC2GM005819408 IN O
two BC2GM005819408 CD O
platyrrhine BC2GM005819408 NN O
( BC2GM005819408 ( O
New BC2GM005819408 NNP O
World BC2GM005819408 NNP O
monkey BC2GM005819408 NN O
) BC2GM005819408 ) O
species BC2GM005819408 NNS O
: BC2GM005819408 : O
the BC2GM005819408 DT O
common BC2GM005819408 JJ O
marmoset BC2GM005819408 NN O
( BC2GM005819408 ( O
Callithrix BC2GM005819408 NNP O
jacchus BC2GM005819408 NN O
) BC2GM005819408 ) O
and BC2GM005819408 CC O
the BC2GM005819408 DT O
brown BC2GM005819408 NN O
capuchin BC2GM005819408 NN O
monkey BC2GM005819408 NN O
( BC2GM005819408 ( O
Cebus BC2GM005819408 NNP O
apella BC2GM005819408 NN O
) BC2GM005819408 ) O
, BC2GM005819408 , O
each BC2GM005819408 DT O
of BC2GM005819408 IN O
which BC2GM005819408 WDT O
has BC2GM005819408 VBZ O
paired BC2GM005819408 VBN O
, BC2GM005819408 , O
non-allelic BC2GM005819408 JJ O
gamma BC2GM005819408 NN O
loci BC2GM005819408 NN O
( BC2GM005819408 ( O
5'-gamma BC2GM005819408 JJ O
1-gamma BC2GM005819408 JJ O
2-3 BC2GM005819408 JJ O
' BC2GM005819408 POS O
) BC2GM005819408 ) O
. BC2GM005819408 . O
. . O O

CONCLUSION BC2GM068009369 NN O
: BC2GM068009369 : O
The BC2GM068009369 DT O
biodistribution BC2GM068009369 NN O
of BC2GM068009369 IN O
111In BC2GM068009369 CD O
IgG BC2GM068009369 NNP O
is BC2GM068009369 VBZ O
similar BC2GM068009369 JJ O
to BC2GM068009369 TO O
that BC2GM068009369 DT O
of BC2GM068009369 IN O
99mTc-HMPAO-labeled BC2GM068009369 JJ O
leukocytes BC2GM068009369 NNS O
. BC2GM068009369 . O
. . O O

Platelet BC2GM038904960 NNP O
count BC2GM038904960 NN O
and BC2GM038904960 CC O
plasma BC2GM038904960 NN O
volume BC2GM038904960 NN O
were BC2GM038904960 VBD O
significantly BC2GM038904960 RB O
higher BC2GM038904960 JJR O
in BC2GM038904960 IN O
group BC2GM038904960 NN O
A BC2GM038904960 NNP O
than BC2GM038904960 IN O
in BC2GM038904960 IN O
group BC2GM038904960 NN O
B BC2GM038904960 NNP O
throughout BC2GM038904960 IN O
pregnancy BC2GM038904960 NN O
. BC2GM038904960 . O
. . O O

These BC2GM069191701 DT O
data BC2GM069191701 NNS O
may BC2GM069191701 MD O
indicate BC2GM069191701 VB O
redundancy BC2GM069191701 NN O
between BC2GM069191701 IN O
members BC2GM069191701 NNS O
of BC2GM069191701 IN O
the BC2GM069191701 DT O
NGFI-B BC2GM069191701 NNP O
/ BC2GM069191701 NNP O
Nurr1 BC2GM069191701 NNP O
/ BC2GM069191701 NNP O
Nor1 BC2GM069191701 NNP O
subfamily BC2GM069191701 RB O
and BC2GM069191701 CC O
could BC2GM069191701 MD O
explain BC2GM069191701 VB O
why BC2GM069191701 WRB O
no BC2GM069191701 DT O
phenotypic BC2GM069191701 NN O
disturbances BC2GM069191701 NNS O
have BC2GM069191701 VBP O
yet BC2GM069191701 RB O
been BC2GM069191701 VBN O
found BC2GM069191701 VBN O
in BC2GM069191701 IN O
mice BC2GM069191701 NN O
in BC2GM069191701 IN O
which BC2GM069191701 WDT O
the BC2GM069191701 DT O
NGFI-B BC2GM069191701 NNP O
gene BC2GM069191701 NN O
has BC2GM069191701 VBZ O
been BC2GM069191701 VBN O
inactivated BC2GM069191701 VBN O
. BC2GM069191701 . O
. . O O

There BC2GM069129077 EX O
was BC2GM069129077 VBD O
a BC2GM069129077 DT O
positive BC2GM069129077 JJ O
correlation BC2GM069129077 NN O
between BC2GM069129077 IN O
change BC2GM069129077 NN O
from BC2GM069129077 IN O
baseline BC2GM069129077 NN O
in BC2GM069129077 IN O
parietal BC2GM069129077 JJ O
lobe BC2GM069129077 NN O
gray-matter BC2GM069129077 JJ O
cytosolic BC2GM069129077 JJ O
choline BC2GM069129077 NN O
, BC2GM069129077 , O
expressed BC2GM069129077 VBN O
in BC2GM069129077 IN O
terms BC2GM069129077 NNS O
of BC2GM069129077 IN O
choline BC2GM069129077 NN O
/ BC2GM069129077 NNP O
creatine BC2GM069129077 NN O
resonance BC2GM069129077 NN O
ratios BC2GM069129077 NNS O
, BC2GM069129077 , O
and BC2GM069129077 CC O
cognitive BC2GM069129077 JJ O
performance BC2GM069129077 NN O
as BC2GM069129077 IN O
measured BC2GM069129077 VBN O
with BC2GM069129077 IN O
the BC2GM069129077 DT O
Alzheimer BC2GM069129077 NNP O
's BC2GM069129077 POS O
Disease BC2GM069129077 NNP O
Assessment BC2GM069129077 NNP O
Scale BC2GM069129077 NNP O
Cognitive BC2GM069129077 NNP O
Subscale BC2GM069129077 NNP O
. BC2GM069129077 . O
. . O O

In BC2GM083801874 IN O
response BC2GM083801874 NN O
to BC2GM083801874 TO O
acoustical BC2GM083801874 JJ O
stimulation BC2GM083801874 NN O
the BC2GM083801874 DT O
properties BC2GM083801874 NNS O
of BC2GM083801874 IN O
response BC2GM083801874 NN O
latency BC2GM083801874 NN O
, BC2GM083801874 , O
discharge BC2GM083801874 NN O
pattern BC2GM083801874 NN O
, BC2GM083801874 , O
frequency BC2GM083801874 NN O
tuning BC2GM083801874 NN O
, BC2GM083801874 , O
binaural BC2GM083801874 JJ O
interaction BC2GM083801874 NN O
, BC2GM083801874 , O
and BC2GM083801874 CC O
habituation BC2GM083801874 NN O
were BC2GM083801874 VBD O
examined BC2GM083801874 VBN O
to BC2GM083801874 TO O
allow BC2GM083801874 VB O
an BC2GM083801874 DT O
appraisal BC2GM083801874 NN O
of BC2GM083801874 IN O
the BC2GM083801874 DT O
differentiation BC2GM083801874 NN O
of BC2GM083801874 IN O
the BC2GM083801874 DT O
MGB BC2GM083801874 NNP O
by BC2GM083801874 IN O
electrophysiological BC2GM083801874 JJ O
means BC2GM083801874 NNS O
. BC2GM083801874 . O
. . O O

Such BC2GM005749359 JJ O
results BC2GM005749359 NNS O
suggest BC2GM005749359 VBP O
that BC2GM005749359 IN O
there BC2GM005749359 EX O
are BC2GM005749359 VBP O
no BC2GM005749359 DT O
differences BC2GM005749359 NNS O
in BC2GM005749359 IN O
the BC2GM005749359 DT O
BMR BC2GM005749359 NNP O
of BC2GM005749359 IN O
age- BC2GM005749359 JJ O
and BC2GM005749359 CC O
weight-matched BC2GM005749359 JJ O
Asian BC2GM005749359 JJ O
Indian BC2GM005749359 JJ O
males BC2GM005749359 NNS O
, BC2GM005749359 , O
other BC2GM005749359 JJ O
tropical BC2GM005749359 JJ O
populations BC2GM005749359 NNS O
and BC2GM005749359 CC O
Americans BC2GM005749359 NNPS O
. BC2GM005749359 . O
. . O O

In BC2GM065739819 IN O
the BC2GM065739819 DT O
normal BC2GM065739819 JJ O
controls BC2GM065739819 VBZ O
the BC2GM065739819 DT O
plasma BC2GM065739819 NN O
FPA BC2GM065739819 NNP O
level BC2GM065739819 NN O
( BC2GM065739819 ( O
mean BC2GM065739819 JJ O
+ BC2GM065739819 NNP O
/ BC2GM065739819 NNP O
- BC2GM065739819 : O
SD BC2GM065739819 NN O
) BC2GM065739819 ) O
was BC2GM065739819 VBD O
1.43 BC2GM065739819 CD O
+ BC2GM065739819 JJ O
/ BC2GM065739819 NNP O
- BC2GM065739819 : O
0.46 BC2GM065739819 CD O
ng BC2GM065739819 JJ O
/ BC2GM065739819 NNP O
ml BC2GM065739819 NN O
. BC2GM065739819 . O
. . O O

Minute BC2GM037522432 NNP O
virus BC2GM037522432 NN O
of BC2GM037522432 IN O
mice BC2GM037522432 NN O
NS1 BC2GM037522432 NNP O
, BC2GM037522432 , O
an BC2GM037522432 DT O
83-kDa BC2GM037522432 JJ O
mainly BC2GM037522432 RB O
nuclear BC2GM037522432 JJ O
phosphoprotein BC2GM037522432 NN O
, BC2GM037522432 , O
is BC2GM037522432 VBZ O
the BC2GM037522432 DT O
only BC2GM037522432 JJ O
viral BC2GM037522432 JJ O
nonstructural BC2GM037522432 JJ O
protein BC2GM037522432 NN O
required BC2GM037522432 VBN O
in BC2GM037522432 IN O
all BC2GM037522432 DT O
cell BC2GM037522432 NN O
types BC2GM037522432 NNS O
and BC2GM037522432 CC O
it BC2GM037522432 PRP O
is BC2GM037522432 VBZ O
involved BC2GM037522432 VBN O
in BC2GM037522432 IN O
multiple BC2GM037522432 JJ O
processes BC2GM037522432 NNS O
necessary BC2GM037522432 JJ O
for BC2GM037522432 IN O
virus BC2GM037522432 JJ O
propagation BC2GM037522432 NN O
. BC2GM037522432 . O
. . O O

HC-toxin BC2GM048362726 NNP O
exerts BC2GM048362726 VBZ O
a BC2GM048362726 DT O
potent BC2GM048362726 JJ O
cytostatic BC2GM048362726 JJ O
effect BC2GM048362726 NN O
on BC2GM048362726 IN O
plant BC2GM048362726 NN O
and BC2GM048362726 CC O
animal BC2GM048362726 NN O
cells BC2GM048362726 NNS O
by BC2GM048362726 IN O
inhibiting BC2GM048362726 VBG O
histone BC2GM048362726 NN O
deacetylase BC2GM048362726 NN O
. BC2GM048362726 . O
. . O O

We BC2GM060551138 PRP O
have BC2GM060551138 VBP O
characterized BC2GM060551138 VBN O
21 BC2GM060551138 CD O
mutations BC2GM060551138 NNS O
in BC2GM060551138 IN O
the BC2GM060551138 DT O
type BC2GM060551138 NN O
VII BC2GM060551138 NNP O
collagen BC2GM060551138 NN O
gene BC2GM060551138 NN O
( BC2GM060551138 ( O
COL7A1 BC2GM060551138 NNP O
) BC2GM060551138 ) O
encoding BC2GM060551138 VBG O
the BC2GM060551138 DT O
anchoring BC2GM060551138 NN O
fibrils BC2GM060551138 NNS O
, BC2GM060551138 , O
18 BC2GM060551138 CD O
of BC2GM060551138 IN O
which BC2GM060551138 WDT O
were BC2GM060551138 VBD O
not BC2GM060551138 RB O
previously BC2GM060551138 RB O
reported BC2GM060551138 VBN O
, BC2GM060551138 , O
in BC2GM060551138 IN O
patients BC2GM060551138 NNS O
from BC2GM060551138 IN O
15 BC2GM060551138 CD O
unrelated BC2GM060551138 JJ O
families BC2GM060551138 NNS O
with BC2GM060551138 IN O
recessive BC2GM060551138 JJ O
dystrophic BC2GM060551138 JJ O
epidermolysis BC2GM060551138 NN O
bullosa BC2GM060551138 NN O
( BC2GM060551138 ( O
RDEB BC2GM060551138 NNP O
) BC2GM060551138 ) O
. BC2GM060551138 . O
. . O O

Patients BC2GM009567777 NNS O
with BC2GM009567777 IN O
risk BC2GM009567777 NN O
factors BC2GM009567777 NNS O
were BC2GM009567777 VBD O
compared BC2GM009567777 VBN O
with BC2GM009567777 IN O
those BC2GM009567777 DT O
without BC2GM009567777 IN O
risk BC2GM009567777 NN O
factors BC2GM009567777 NNS O
. BC2GM009567777 . O
. . O O

The BC2GM093459907 DT O
serum BC2GM093459907 NN O
levels BC2GM093459907 NNS O
of BC2GM093459907 IN O
cortisol BC2GM093459907 NN O
and BC2GM093459907 CC O
prolactin BC2GM093459907 NN O
after BC2GM093459907 IN O
nasal BC2GM093459907 JJ O
instillation BC2GM093459907 NN O
of BC2GM093459907 IN O
a BC2GM093459907 DT O
suspension BC2GM093459907 NN O
of BC2GM093459907 IN O
vaginal BC2GM093459907 JJ O
exudate BC2GM093459907 NN O
showed BC2GM093459907 VBD O
lower BC2GM093459907 JJR O
values BC2GM093459907 NNS O
than BC2GM093459907 IN O
in BC2GM093459907 IN O
control BC2GM093459907 NN O
conditions BC2GM093459907 NNS O
( BC2GM093459907 ( O
nasal BC2GM093459907 JJ O
instillation BC2GM093459907 NN O
of BC2GM093459907 IN O
saline BC2GM093459907 NN O
) BC2GM093459907 ) O
. BC2GM093459907 . O
. . O O

Cytokinetics BC2GM082875858 NNS O
of BC2GM082875858 IN O
the BC2GM082875858 DT O
Krebs BC2GM082875858 NNP O
2 BC2GM082875858 CD O
carcinoma BC2GM082875858 NN O
. BC2GM082875858 . O
. . O O

These BC2GM012664119 DT O
larger BC2GM012664119 JJR O
sizes BC2GM012664119 NNS O
, BC2GM012664119 , O
however BC2GM012664119 RB O
, BC2GM012664119 , O
are BC2GM012664119 VBP O
consistent BC2GM012664119 JJ O
with BC2GM012664119 IN O
predictions BC2GM012664119 NNS O
from BC2GM012664119 IN O
the BC2GM012664119 DT O
DNA BC2GM012664119 NNP O
sequence BC2GM012664119 NN O
of BC2GM012664119 IN O
the BC2GM012664119 DT O
pol BC2GM012664119 JJ O
gene BC2GM012664119 NN O
. BC2GM012664119 . O
. . O O

Tc-99m BC2GM001964645 JJ O
HMPAO BC2GM001964645 NNP O
brain BC2GM001964645 NN O
SPECT BC2GM001964645 NNP O
compared BC2GM001964645 VBN O
to BC2GM001964645 TO O
CT BC2GM001964645 NNP O
and BC2GM001964645 CC O
EEG BC2GM001964645 NNP O
after BC2GM001964645 IN O
seizures BC2GM001964645 NNS O
in BC2GM001964645 IN O
childhood BC2GM001964645 NN O
. BC2GM001964645 . O
. . O O

CONCLUSION BC2GM012402149 NN O
: BC2GM012402149 : O
In BC2GM012402149 IN O
an BC2GM012402149 DT O
acute BC2GM012402149 JJ O
canine BC2GM012402149 NN O
model BC2GM012402149 NN O
of BC2GM012402149 IN O
progressive BC2GM012402149 JJ O
LCX BC2GM012402149 NNP O
coronary BC2GM012402149 JJ O
stenosis BC2GM012402149 NN O
, BC2GM012402149 , O
CFR BC2GM012402149 NNP O
was BC2GM012402149 VBD O
impaired BC2GM012402149 VBN O
in BC2GM012402149 IN O
both BC2GM012402149 DT O
ischemic BC2GM012402149 JJ O
and BC2GM012402149 CC O
remote BC2GM012402149 JJ O
nonischemic BC2GM012402149 JJ O
regions BC2GM012402149 NNS O
in BC2GM012402149 IN O
association BC2GM012402149 NN O
with BC2GM012402149 IN O
mild BC2GM012402149 NN O
to BC2GM012402149 TO O
moderate BC2GM012402149 VB O
ischemic-induced BC2GM012402149 JJ O
regional BC2GM012402149 JJ O
myocardial BC2GM012402149 JJ O
dysfunction BC2GM012402149 NN O
. BC2GM012402149 . O
. . O O

These BC2GM055386745 DT O
Tlr BC2GM055386745 NNP O
family BC2GM055386745 NN O
members BC2GM055386745 NNS O
, BC2GM055386745 , O
unlike BC2GM055386745 IN O
others BC2GM055386745 NNS O
reported BC2GM055386745 VBN O
to BC2GM055386745 TO O
date BC2GM055386745 NN O
, BC2GM055386745 , O
were BC2GM055386745 VBD O
identified BC2GM055386745 VBN O
within BC2GM055386745 IN O
a BC2GM055386745 DT O
genomic BC2GM055386745 JJ O
database BC2GM055386745 NN O
. BC2GM055386745 . O
. . O O

Applying BC2GM067272025 VBG O
the BC2GM067272025 DT O
experience BC2GM067272025 NN O
mentioned BC2GM067272025 VBD O
above BC2GM067272025 IN O
, BC2GM067272025 , O
4-META BC2GM067272025 CD O
was BC2GM067272025 VBD O
used BC2GM067272025 VBN O
to BC2GM067272025 TO O
bond BC2GM067272025 NN O
a BC2GM067272025 DT O
proprietary BC2GM067272025 JJ O
photocuring BC2GM067272025 NN O
microfilled BC2GM067272025 VBD O
composite BC2GM067272025 JJ O
material BC2GM067272025 NN O
to BC2GM067272025 TO O
Class BC2GM067272025 NNP O
V BC2GM067272025 NNP O
cavities BC2GM067272025 NNS O
in BC2GM067272025 IN O
freshly BC2GM067272025 RB O
extracted BC2GM067272025 VBN O
human BC2GM067272025 JJ O
teeth BC2GM067272025 NNS O
. BC2GM067272025 . O
. . O O

This BC2GM053572973 DT O
article BC2GM053572973 NN O
describes BC2GM053572973 VBZ O
a BC2GM053572973 DT O
program BC2GM053572973 NN O
that BC2GM053572973 WDT O
resulted BC2GM053572973 VBD O
in BC2GM053572973 IN O
a BC2GM053572973 DT O
75-percent BC2GM053572973 JJ O
reduction BC2GM053572973 NN O
of BC2GM053572973 IN O
inventory BC2GM053572973 NN O
over BC2GM053572973 IN O
a BC2GM053572973 DT O
five-year BC2GM053572973 JJ O
interval BC2GM053572973 NN O
. BC2GM053572973 . O
. . O O

Accuracy BC2GM056857198 NN O
and BC2GM056857198 CC O
predictive BC2GM056857198 JJ O
value BC2GM056857198 NN O
of BC2GM056857198 IN O
ultrasound BC2GM056857198 NN O
in BC2GM056857198 IN O
acute BC2GM056857198 JJ O
rejection BC2GM056857198 NN O
. BC2GM056857198 . O
. . O O

In BC2GM031481247 IN O
comparison BC2GM031481247 NN O
to BC2GM031481247 TO O
a BC2GM031481247 DT O
silent BC2GM031481247 JJ O
baseline BC2GM031481247 NN O
, BC2GM031481247 , O
CBF BC2GM031481247 NNP O
increases BC2GM031481247 NNS O
were BC2GM031481247 VBD O
observed BC2GM031481247 VBN O
in BC2GM031481247 IN O
auditory BC2GM031481247 JJ O
cortex BC2GM031481247 NN O
bilaterally BC2GM031481247 RB O
and BC2GM031481247 CC O
in BC2GM031481247 IN O
the BC2GM031481247 DT O
right BC2GM031481247 JJ O
superior BC2GM031481247 JJ O
parietal BC2GM031481247 NN O
, BC2GM031481247 , O
right BC2GM031481247 JJ O
dorsolateral BC2GM031481247 JJ O
frontal BC2GM031481247 NN O
, BC2GM031481247 , O
and BC2GM031481247 CC O
right BC2GM031481247 JJ O
premotor BC2GM031481247 NN O
regions BC2GM031481247 NNS O
, BC2GM031481247 , O
with BC2GM031481247 IN O
no BC2GM031481247 DT O
modulation BC2GM031481247 NN O
as BC2GM031481247 IN O
a BC2GM031481247 DT O
function BC2GM031481247 NN O
of BC2GM031481247 IN O
attentional BC2GM031481247 JJ O
condition BC2GM031481247 NN O
. BC2GM031481247 . O
. . O O

Children BC2GM016568777 NNP O
with BC2GM016568777 IN O
repeated BC2GM016568777 VBN O
proteinuria BC2GM016568777 NNS O
during BC2GM016568777 IN O
follow-up BC2GM016568777 JJ O
tend BC2GM016568777 NN O
to BC2GM016568777 TO O
have BC2GM016568777 VB O
a BC2GM016568777 DT O
higher BC2GM016568777 JJR O
incidence BC2GM016568777 NN O
of BC2GM016568777 IN O
pathologic BC2GM016568777 JJ O
findings BC2GM016568777 NNS O
on BC2GM016568777 IN O
the BC2GM016568777 DT O
i.v.-pyelogram BC2GM016568777 NN O
. BC2GM016568777 . O
. . O O

The BC2GM069267647 DT O
gp41 BC2GM069267647 NN O
peptide BC2GM069267647 NN O
( BC2GM069267647 ( O
Glu-Leu-Asp-Lys-Trp-Ala BC2GM069267647 NNP O
) BC2GM069267647 ) O
fused BC2GM069267647 VBD O
to BC2GM069267647 TO O
the BC2GM069267647 DT O
C-terminus BC2GM069267647 NNP O
of BC2GM069267647 IN O
Sj BC2GM069267647 NNP O
GST BC2GM069267647 NNP O
forms BC2GM069267647 VBZ O
a BC2GM069267647 DT O
loop BC2GM069267647 NN O
stabilized BC2GM069267647 VBN O
by BC2GM069267647 IN O
symmetry-related BC2GM069267647 JJ O
GSTs BC2GM069267647 NNP O
. BC2GM069267647 . O
. . O O

Orlistat BC2GM055880563 NNP O
is BC2GM055880563 VBZ O
a BC2GM055880563 DT O
specific BC2GM055880563 JJ O
lipase BC2GM055880563 NN O
inhibitor BC2GM055880563 NN O
that BC2GM055880563 WDT O
impairs BC2GM055880563 VBZ O
fat BC2GM055880563 JJ O
absorption BC2GM055880563 NN O
, BC2GM055880563 , O
thereby BC2GM055880563 RB O
reducing BC2GM055880563 VBG O
fat BC2GM055880563 JJ O
uptake BC2GM055880563 NN O
. BC2GM055880563 . O
. . O O

Suprapubic BC2GM080360635 NNP O
and BC2GM080360635 CC O
intravesical BC2GM080360635 JJ O
methods BC2GM080360635 NNS O
. BC2GM080360635 . O
. . O O

The BC2GM070374572 DT O
pyridostigmine BC2GM070374572 NN O
inhibited BC2GM070374572 VBN O
AChE BC2GM070374572 NNP O
recovered BC2GM070374572 VBD O
only BC2GM070374572 RB O
in BC2GM070374572 IN O
the BC2GM070374572 DT O
100 BC2GM070374572 CD O
mumol BC2GM070374572 JJ O
kg-1 BC2GM070374572 JJ O
kg BC2GM070374572 NN O
oxime BC2GM070374572 NN O
groups BC2GM070374572 NNS O
at BC2GM070374572 IN O
the BC2GM070374572 DT O
end BC2GM070374572 NN O
of BC2GM070374572 IN O
the BC2GM070374572 DT O
experiment BC2GM070374572 NN O
. BC2GM070374572 . O
. . O O

Region BC2GM006559447 NN O
I BC2GM006559447 PRP O
includes BC2GM006559447 VBZ O
the BC2GM006559447 DT O
two BC2GM006559447 CD O
cysteine-cysteine BC2GM006559447 JJ O
zinc BC2GM006559447 NN O
fingers BC2GM006559447 NNS O
that BC2GM006559447 WDT O
comprise BC2GM006559447 VBP O
a BC2GM006559447 DT O
DNA-binding BC2GM006559447 NNP O
domain BC2GM006559447 NN O
which BC2GM006559447 WDT O
typifies BC2GM006559447 VBZ O
all BC2GM006559447 DT O
members BC2GM006559447 NNS O
of BC2GM006559447 IN O
the BC2GM006559447 DT O
superfamily BC2GM006559447 NN O
. BC2GM006559447 . O
. . O O

Gel BC2GM025908037 NNP O
mobility BC2GM025908037 NN O
shift BC2GM025908037 NN O
analyses BC2GM025908037 VBZ O
reveal BC2GM025908037 VBP O
that BC2GM025908037 IN O
FRTL-5 BC2GM025908037 NNP O
thyroid BC2GM025908037 NN O
cell BC2GM025908037 NN O
nuclear BC2GM025908037 JJ O
extracts BC2GM025908037 VBZ O
form BC2GM025908037 NN O
a BC2GM025908037 DT O
specific BC2GM025908037 JJ O
protein BC2GM025908037 NN O
/ BC2GM025908037 JJ O
DNA BC2GM025908037 NNP O
complex BC2GM025908037 NN O
with BC2GM025908037 IN O
this BC2GM025908037 DT O
region BC2GM025908037 NN O
, BC2GM025908037 , O
which BC2GM025908037 WDT O
is BC2GM025908037 VBZ O
prevented BC2GM025908037 VBN O
by BC2GM025908037 IN O
the BC2GM025908037 DT O
TTF-1 BC2GM025908037 NNP O
binding BC2GM025908037 NN O
element BC2GM025908037 NN O
from BC2GM025908037 IN O
the BC2GM025908037 DT O
TG BC2GM025908037 NNP O
promoter BC2GM025908037 NN O
; BC2GM025908037 : O
FRT BC2GM025908037 NNP O
and BC2GM025908037 CC O
BRL BC2GM025908037 NNP O
cell BC2GM025908037 VBP O
nuclear BC2GM025908037 JJ O
extracts BC2GM025908037 NNS O
do BC2GM025908037 VBP O
not BC2GM025908037 RB O
have BC2GM025908037 VB O
TTF-1 BC2GM025908037 NNP O
and BC2GM025908037 CC O
do BC2GM025908037 VB O
not BC2GM025908037 RB O
form BC2GM025908037 VB O
this BC2GM025908037 DT O
complex BC2GM025908037 NN O
. BC2GM025908037 . O
. . O O

The BC2GM036498049 DT O
potential BC2GM036498049 JJ O
biological BC2GM036498049 JJ O
significance BC2GM036498049 NN O
of BC2GM036498049 IN O
the BC2GM036498049 DT O
identified BC2GM036498049 JJ O
structural BC2GM036498049 JJ O
motif BC2GM036498049 NNS O
shared BC2GM036498049 VBN O
by BC2GM036498049 IN O
the BC2GM036498049 DT O
human BC2GM036498049 JJ O
CCR5 BC2GM036498049 NNP O
, BC2GM036498049 , O
CCR3 BC2GM036498049 NNP O
, BC2GM036498049 , O
CCR2B BC2GM036498049 NNP O
and BC2GM036498049 CC O
other BC2GM036498049 JJ O
GPCRs BC2GM036498049 NNP O
is BC2GM036498049 VBZ O
discussed BC2GM036498049 VBN O
. BC2GM036498049 . O
. . O O

Cellular BC2GM000980177 JJ O
fractionation BC2GM000980177 NN O
and BC2GM000980177 CC O
Percoll BC2GM000980177 NNP O
gradient BC2GM000980177 NN O
centrifugation BC2GM000980177 NN O
combined BC2GM000980177 VBN O
with BC2GM000980177 IN O
immunoblotting BC2GM000980177 VBG O
show BC2GM000980177 NN O
that BC2GM000980177 IN O
p67 BC2GM000980177 VBZ O
cofractionates BC2GM000980177 NNS O
with BC2GM000980177 IN O
nuclei BC2GM000980177 NN O
and BC2GM000980177 CC O
is BC2GM000980177 VBZ O
enriched BC2GM000980177 VBN O
in BC2GM000980177 IN O
resistant BC2GM000980177 JJ O
structure BC2GM000980177 NN O
that BC2GM000980177 WDT O
is BC2GM000980177 VBZ O
insoluble BC2GM000980177 JJ O
in BC2GM000980177 IN O
2 BC2GM000980177 CD O
M BC2GM000980177 NNP O
NaCl BC2GM000980177 NNP O
, BC2GM000980177 , O
25 BC2GM000980177 CD O
mM BC2GM000980177 JJ O
lithium BC2GM000980177 NN O
3,5'-diiodosalicylate BC2GM000980177 JJ O
, BC2GM000980177 , O
and BC2GM000980177 CC O
1 BC2GM000980177 CD O
% BC2GM000980177 NN O
Triton BC2GM000980177 NNP O
but BC2GM000980177 CC O
is BC2GM000980177 VBZ O
soluble BC2GM000980177 JJ O
in BC2GM000980177 IN O
8 BC2GM000980177 CD O
M BC2GM000980177 NNP O
urea BC2GM000980177 NN O
. BC2GM000980177 . O
. . O O

Using BC2GM058050857 VBG O
the BC2GM058050857 DT O
conflict BC2GM058050857 NN O
drinking BC2GM058050857 VBG O
test BC2GM058050857 NN O
as BC2GM058050857 IN O
a BC2GM058050857 DT O
model BC2GM058050857 NN O
, BC2GM058050857 , O
we BC2GM058050857 PRP O
studied BC2GM058050857 VBD O
in BC2GM058050857 IN O
rats BC2GM058050857 NNS O
the BC2GM058050857 DT O
effect BC2GM058050857 NN O
of BC2GM058050857 IN O
the BC2GM058050857 DT O
nonselective BC2GM058050857 JJ O
beta-adrenoceptor BC2GM058050857 NN O
blockers BC2GM058050857 NNS O
pindolol BC2GM058050857 VBP O
and BC2GM058050857 CC O
cyanopindolol BC2GM058050857 VBP O
which BC2GM058050857 WDT O
bind BC2GM058050857 VBP O
to BC2GM058050857 TO O
5-HT1A BC2GM058050857 JJ O
and BC2GM058050857 CC O
5-HT1B BC2GM058050857 JJ O
receptors BC2GM058050857 NNS O
, BC2GM058050857 , O
and BC2GM058050857 CC O
of BC2GM058050857 IN O
the BC2GM058050857 DT O
selective BC2GM058050857 JJ O
beta BC2GM058050857 NN O
1- BC2GM058050857 JJ O
and BC2GM058050857 CC O
beta BC2GM058050857 JJ O
2-adrenoceptor BC2GM058050857 JJ O
antagonists BC2GM058050857 NNS O
betaxolol BC2GM058050857 NN O
and BC2GM058050857 CC O
ICI BC2GM058050857 NNP O
118,551 BC2GM058050857 CD O
, BC2GM058050857 , O
respectively BC2GM058050857 RB O
, BC2GM058050857 , O
which BC2GM058050857 WDT O
have BC2GM058050857 VBP O
a BC2GM058050857 DT O
negligible BC2GM058050857 JJ O
affinity BC2GM058050857 NN O
for BC2GM058050857 IN O
5-HT BC2GM058050857 JJ O
receptors BC2GM058050857 NNS O
. BC2GM058050857 . O
. . O O

These BC2GM071734326 DT O
mutations BC2GM071734326 NNS O
prevent BC2GM071734326 VBP O
FKBP12-rapamycin BC2GM071734326 JJ O
binding BC2GM071734326 NN O
to BC2GM071734326 TO O
TOR2 BC2GM071734326 NNP O
, BC2GM071734326 , O
as BC2GM071734326 IN O
assayed BC2GM071734326 VBN O
with BC2GM071734326 IN O
the BC2GM071734326 DT O
two-hybrid BC2GM071734326 JJ O
system BC2GM071734326 NN O
. BC2GM071734326 . O
. . O O

These BC2GM063927738 DT O
transcripts BC2GM063927738 NNS O
directed BC2GM063927738 VBD O
the BC2GM063927738 DT O
synthesis BC2GM063927738 NN O
of BC2GM063927738 IN O
three BC2GM063927738 CD O
proteins BC2GM063927738 NNS O
: BC2GM063927738 : O
the BC2GM063927738 DT O
virus BC2GM063927738 NN O
trans-activator BC2GM063927738 NN O
protein BC2GM063927738 NN O
( BC2GM063927738 ( O
EIAV BC2GM063927738 NNP O
Tat BC2GM063927738 NNP O
) BC2GM063927738 ) O
encoded BC2GM063927738 VBN O
by BC2GM063927738 IN O
ORF BC2GM063927738 NNP O
S1 BC2GM063927738 NNP O
, BC2GM063927738 , O
a BC2GM063927738 DT O
protein BC2GM063927738 NN O
of BC2GM063927738 IN O
unknown BC2GM063927738 JJ O
function BC2GM063927738 NN O
encoded BC2GM063927738 VBN O
by BC2GM063927738 IN O
ORF BC2GM063927738 NNP O
S2 BC2GM063927738 NNP O
, BC2GM063927738 , O
and BC2GM063927738 CC O
the BC2GM063927738 DT O
virus BC2GM063927738 NN O
envelope BC2GM063927738 NN O
glycoprotein BC2GM063927738 NN O
. BC2GM063927738 . O
. . O O

The BC2GM040056717 DT O
RsmA- BC2GM040056717 NNP O
mutant BC2GM040056717 NN O
, BC2GM040056717 , O
like BC2GM040056717 IN O
its BC2GM040056717 PRP$ O
parent BC2GM040056717 NN O
, BC2GM040056717 , O
produces BC2GM040056717 VBZ O
N- BC2GM040056717 NNP O
( BC2GM040056717 ( O
3-oxohexanoyl BC2GM040056717 CD O
) BC2GM040056717 ) O
-L-homoserine BC2GM040056717 VB O
lactone BC2GM040056717 NN O
( BC2GM040056717 ( O
HSL BC2GM040056717 NNP O
) BC2GM040056717 ) O
, BC2GM040056717 , O
a BC2GM040056717 DT O
starvation BC2GM040056717 NN O
/ BC2GM040056717 NN O
cell BC2GM040056717 NN O
density-sensing BC2GM040056717 JJ O
signal BC2GM040056717 NN O
required BC2GM040056717 VBN O
for BC2GM040056717 IN O
extracellular BC2GM040056717 JJ O
enzyme BC2GM040056717 NN O
production BC2GM040056717 NN O
. BC2GM040056717 . O
. . O O

To BC2GM014963504 TO O
this BC2GM014963504 DT O
effect BC2GM014963504 NN O
, BC2GM014963504 , O
the BC2GM014963504 DT O
present BC2GM014963504 JJ O
survey BC2GM014963504 NN O
puts BC2GM014963504 VBZ O
in BC2GM014963504 IN O
evidence BC2GM014963504 NN O
that BC2GM014963504 IN O
the BC2GM014963504 DT O
maximum BC2GM014963504 JJ O
delay BC2GM014963504 NN O
of BC2GM014963504 IN O
stream BC2GM014963504 NN O
that BC2GM014963504 WDT O
guarantees BC2GM014963504 VBZ O
the BC2GM014963504 DT O
good BC2GM014963504 JJ O
dimensional BC2GM014963504 JJ O
stability BC2GM014963504 NN O
of BC2GM014963504 IN O
these BC2GM014963504 DT O
class BC2GM014963504 NN O
A BC2GM014963504 DT O
alginates BC2GM014963504 NNS O
is BC2GM014963504 VBZ O
of BC2GM014963504 IN O
45 BC2GM014963504 CD O
minutes BC2GM014963504 NNS O
in BC2GM014963504 IN O
the BC2GM014963504 DT O
hot BC2GM014963504 JJ O
and BC2GM014963504 CC O
humid BC2GM014963504 JJ O
climatic BC2GM014963504 JJ O
tropical BC2GM014963504 JJ O
country BC2GM014963504 NN O
conditions BC2GM014963504 NNS O
. BC2GM014963504 . O
. . O O

CONCLUSIONS BC2GM024324906 NN O
: BC2GM024324906 : O
Transpulmonary BC2GM024324906 NNP O
stable BC2GM024324906 JJ O
air BC2GM024324906 NN O
microbubbles BC2GM024324906 NNS O
bound BC2GM024324906 VBP O
to BC2GM024324906 TO O
a BC2GM024324906 DT O
galactose BC2GM024324906 NN O
carrier BC2GM024324906 NN O
represent BC2GM024324906 VBP O
a BC2GM024324906 DT O
useful BC2GM024324906 JJ O
and BC2GM024324906 CC O
safe BC2GM024324906 JJ O
contrast BC2GM024324906 NN O
agent BC2GM024324906 NN O
in BC2GM024324906 IN O
case BC2GM024324906 NN O
of BC2GM024324906 IN O
an BC2GM024324906 DT O
insufficient BC2GM024324906 JJ O
native BC2GM024324906 JJ O
signal BC2GM024324906 NN O
in BC2GM024324906 IN O
transcranial BC2GM024324906 JJ O
Doppler BC2GM024324906 NNP O
investigation BC2GM024324906 NN O
. BC2GM024324906 . O
. . O O

Phase BC2GM044241169 NN O
I BC2GM044241169 PRP O
study BC2GM044241169 VBP O
of BC2GM044241169 IN O
5-fluorouracil BC2GM044241169 JJ O
and BC2GM044241169 CC O
leucovorin BC2GM044241169 JJ O
by BC2GM044241169 IN O
a BC2GM044241169 DT O
14-day BC2GM044241169 JJ O
circadian BC2GM044241169 JJ O
infusion BC2GM044241169 NN O
in BC2GM044241169 IN O
metastatic BC2GM044241169 JJ O
adenocarcinoma BC2GM044241169 NN O
patients BC2GM044241169 NNS O
. BC2GM044241169 . O
. . O O

Aspartame BC2GM069669537 NNP O
is BC2GM069669537 VBZ O
a BC2GM069669537 DT O
synthetic BC2GM069669537 JJ O
sweetener BC2GM069669537 NN O
commonly BC2GM069669537 RB O
used BC2GM069669537 VBN O
in BC2GM069669537 IN O
soft BC2GM069669537 JJ O
drinks BC2GM069669537 NNS O
and BC2GM069669537 CC O
many BC2GM069669537 JJ O
foods BC2GM069669537 NNS O
. BC2GM069669537 . O
. . O O

Both BC2GM046917309 DT O
residues BC2GM046917309 NNS O
are BC2GM046917309 VBP O
conserved BC2GM046917309 VBN O
in BC2GM046917309 IN O
the BC2GM046917309 DT O
three BC2GM046917309 CD O
phosphorylated BC2GM046917309 VBD O
paralogs BC2GM046917309 NNS O
but BC2GM046917309 CC O
are BC2GM046917309 VBP O
absent BC2GM046917309 JJ O
in BC2GM046917309 IN O
the BC2GM046917309 DT O
ones BC2GM046917309 NNS O
that BC2GM046917309 WDT O
were BC2GM046917309 VBD O
not BC2GM046917309 RB O
substrates BC2GM046917309 NNS O
of BC2GM046917309 IN O
RsbT BC2GM046917309 NNP O
: BC2GM046917309 : O
YetI BC2GM046917309 NN O
and BC2GM046917309 CC O
YezB BC2GM046917309 NNP O
, BC2GM046917309 , O
each BC2GM046917309 DT O
of BC2GM046917309 IN O
which BC2GM046917309 WDT O
bears BC2GM046917309 VBZ O
only BC2GM046917309 RB O
one BC2GM046917309 CD O
of BC2GM046917309 IN O
the BC2GM046917309 DT O
conserved BC2GM046917309 JJ O
residues BC2GM046917309 NNS O
; BC2GM046917309 : O
and BC2GM046917309 CC O
YtvA BC2GM046917309 NNP O
, BC2GM046917309 , O
which BC2GM046917309 WDT O
lacks BC2GM046917309 VBZ O
both BC2GM046917309 DT O
residues BC2GM046917309 NNS O
and BC2GM046917309 CC O
instead BC2GM046917309 RB O
possesses BC2GM046917309 VBZ O
an BC2GM046917309 DT O
N-terminal BC2GM046917309 JJ O
PAS BC2GM046917309 NNP O
domain BC2GM046917309 NN O
. BC2GM046917309 . O
. . O O

ZF87 BC2GM081600105 NNP O
specifically BC2GM081600105 RB O
binds BC2GM081600105 VBZ O
the BC2GM081600105 DT O
ME1a1 BC2GM081600105 NNP O
element BC2GM081600105 NN O
with BC2GM081600105 IN O
higher BC2GM081600105 JJR O
affinity BC2GM081600105 NN O
than BC2GM081600105 IN O
the BC2GM081600105 DT O
ME1a2 BC2GM081600105 NNP O
element BC2GM081600105 NN O
. BC2GM081600105 . O
. . O O

Application BC2GM075197573 NN O
of BC2GM075197573 IN O
the BC2GM075197573 DT O
method BC2GM075197573 NN O
using BC2GM075197573 VBG O
an BC2GM075197573 DT O
11-year BC2GM075197573 JJ O
microseismicity BC2GM075197573 NN O
record BC2GM075197573 NN O
revealed BC2GM075197573 VBD O
systematic BC2GM075197573 JJ O
spatial BC2GM075197573 NN O
and BC2GM075197573 CC O
temporal BC2GM075197573 JJ O
changes BC2GM075197573 NNS O
in BC2GM075197573 IN O
the BC2GM075197573 DT O
slip BC2GM075197573 NN O
rate BC2GM075197573 NN O
that BC2GM075197573 WDT O
were BC2GM075197573 VBD O
synchronous BC2GM075197573 JJ O
with BC2GM075197573 IN O
earthquake BC2GM075197573 NN O
activity BC2GM075197573 NN O
and BC2GM075197573 CC O
other BC2GM075197573 JJ O
independent BC2GM075197573 JJ O
measures BC2GM075197573 NNS O
of BC2GM075197573 IN O
fault-zone BC2GM075197573 NN O
slip BC2GM075197573 NN O
. BC2GM075197573 . O
. . O O

Nucleocapsid BC2GM065497063 NN O
structure BC2GM065497063 NN O
and BC2GM065497063 CC O
thermostability BC2GM065497063 NN O
of BC2GM065497063 IN O
the BC2GM065497063 DT O
virion BC2GM065497063 NN O
, BC2GM065497063 , O
nucleocapsid BC2GM065497063 NN O
and BC2GM065497063 CC O
polymerase BC2GM065497063 NN O
complex BC2GM065497063 NN O
. BC2GM065497063 . O
. . O O

A BC2GM034622067 DT O
phase BC2GM034622067 NN O
II BC2GM034622067 NNP O
clinical BC2GM034622067 JJ O
trial BC2GM034622067 NN O
on BC2GM034622067 IN O
MDS BC2GM034622067 NNP O
was BC2GM034622067 VBD O
conducted BC2GM034622067 VBN O
in BC2GM034622067 IN O
a BC2GM034622067 DT O
cooperative BC2GM034622067 JJ O
study BC2GM034622067 NN O
with BC2GM034622067 IN O
orally BC2GM034622067 RB O
administrable BC2GM034622067 JJ O
ara-C BC2GM034622067 JJ O
analogue BC2GM034622067 NN O
, BC2GM034622067 , O
PLAC BC2GM034622067 NNP O
, BC2GM034622067 , O
which BC2GM034622067 WDT O
is BC2GM034622067 VBZ O
resistant BC2GM034622067 JJ O
to BC2GM034622067 TO O
cytidine BC2GM034622067 VB O
deaminase BC2GM034622067 NN O
and BC2GM034622067 CC O
had BC2GM034622067 VBD O
shown BC2GM034622067 VBN O
an BC2GM034622067 DT O
anti-tumor BC2GM034622067 JJ O
activity BC2GM034622067 NN O
on BC2GM034622067 IN O
various BC2GM034622067 JJ O
experimental BC2GM034622067 JJ O
tumors BC2GM034622067 NNS O
by BC2GM034622067 IN O
oral BC2GM034622067 JJ O
route BC2GM034622067 NN O
. BC2GM034622067 . O
. . O O

Treatment BC2GM059365097 NN O
of BC2GM059365097 IN O
chronic BC2GM059365097 JJ O
hepatitis BC2GM059365097 NN O
B BC2GM059365097 NNP O
with BC2GM059365097 IN O
interferon BC2GM059365097 NN O
: BC2GM059365097 : O
experience BC2GM059365097 NN O
in BC2GM059365097 IN O
western BC2GM059365097 JJ O
countries BC2GM059365097 NNS O
. BC2GM059365097 . O
. . O O

These BC2GM093130778 DT O
three BC2GM093130778 CD O
phases BC2GM093130778 NNS O
of BC2GM093130778 IN O
cyclin BC2GM093130778 NN O
E BC2GM093130778 NNP O
association BC2GM093130778 NN O
with BC2GM093130778 IN O
chromatin BC2GM093130778 NN O
may BC2GM093130778 MD O
facilitate BC2GM093130778 VB O
the BC2GM093130778 DT O
diverse BC2GM093130778 JJ O
activities BC2GM093130778 NNS O
of BC2GM093130778 IN O
cyclin BC2GM093130778 NN O
E BC2GM093130778 NNP O
-- BC2GM093130778 : O
Cdk2 BC2GM093130778 NNP O
in BC2GM093130778 IN O
initiating BC2GM093130778 VBG O
replication BC2GM093130778 NN O
, BC2GM093130778 , O
blocking BC2GM093130778 VBG O
rereplication BC2GM093130778 NN O
, BC2GM093130778 , O
and BC2GM093130778 CC O
allowing BC2GM093130778 VBG O
resetting BC2GM093130778 NN O
of BC2GM093130778 IN O
origins BC2GM093130778 NNS O
after BC2GM093130778 IN O
mitosis BC2GM093130778 NN O
. BC2GM093130778 . O
. . O O

Transcriptional BC2GM070088556 JJ O
regulation BC2GM070088556 NN O
of BC2GM070088556 IN O
the BC2GM070088556 DT O
murine BC2GM070088556 JJ O
k-fgf BC2GM070088556 JJ O
gene BC2GM070088556 NN O
. BC2GM070088556 . O
. . O O

Sci BC2GM041496183 NNP O
. BC2GM041496183 . O
. . O O

From BC2GM083564005 IN O
this BC2GM083564005 DT O
comparison BC2GM083564005 NN O
of BC2GM083564005 IN O
aa BC2GM083564005 JJ O
sequences BC2GM083564005 NNS O
, BC2GM083564005 , O
the BC2GM083564005 DT O
ATPK7 BC2GM083564005 NNP O
protein BC2GM083564005 NN O
is BC2GM083564005 VBZ O
considered BC2GM083564005 VBN O
to BC2GM083564005 TO O
be BC2GM083564005 VB O
a BC2GM083564005 DT O
member BC2GM083564005 NN O
of BC2GM083564005 IN O
a BC2GM083564005 DT O
novel BC2GM083564005 JJ O
subfamily BC2GM083564005 NN O
of BC2GM083564005 IN O
Ser BC2GM083564005 NNP O
/ BC2GM083564005 NNP O
Thr BC2GM083564005 NNP O
PKs BC2GM083564005 NNP O
in BC2GM083564005 IN O
plants BC2GM083564005 NNS O
. BC2GM083564005 . O
. . O O

In BC2GM089231665 IN O
experiment BC2GM089231665 JJ O
1 BC2GM089231665 CD O
, BC2GM089231665 , O
subjects BC2GM089231665 NNS O
were BC2GM089231665 VBD O
required BC2GM089231665 VBN O
to BC2GM089231665 TO O
discriminate BC2GM089231665 VB O
male BC2GM089231665 NN O
from BC2GM089231665 IN O
female BC2GM089231665 JJ O
faces BC2GM089231665 VBZ O
and BC2GM089231665 CC O
no BC2GM089231665 DT O
hemispheric BC2GM089231665 JJ O
asymmetries BC2GM089231665 NNS O
were BC2GM089231665 VBD O
found BC2GM089231665 VBN O
. BC2GM089231665 . O
. . O O

This BC2GM006641909 DT O
bound BC2GM006641909 NN O
[ BC2GM006641909 VBZ O
3H BC2GM006641909 CD O
] BC2GM006641909 NN O
iloprost BC2GM006641909 NN O
with BC2GM006641909 IN O
high BC2GM006641909 JJ O
affinity BC2GM006641909 NN O
and BC2GM006641909 CC O
stimulated BC2GM006641909 VBD O
cAMP BC2GM006641909 NN O
production BC2GM006641909 NN O
when BC2GM006641909 WRB O
exposed BC2GM006641909 VBN O
to BC2GM006641909 TO O
agonist BC2GM006641909 VB O
. BC2GM006641909 . O
. . O O

Comparison BC2GM049482687 NNP O
of BC2GM049482687 IN O
the BC2GM049482687 DT O
sequences BC2GM049482687 NNS O
of BC2GM049482687 IN O
the BC2GM049482687 DT O
alpha-like BC2GM049482687 JJ O
DNA BC2GM049482687 NNP O
polymerases BC2GM049482687 VBZ O
including BC2GM049482687 VBG O
E. BC2GM049482687 NNP O
coli BC2GM049482687 NNS O
DNA BC2GM049482687 NNP O
polymerase BC2GM049482687 NN O
II BC2GM049482687 NNP O
showed BC2GM049482687 VBD O
that BC2GM049482687 IN O
there BC2GM049482687 EX O
were BC2GM049482687 VBD O
nine BC2GM049482687 CD O
highly BC2GM049482687 RB O
conserved BC2GM049482687 JJ O
regions BC2GM049482687 NNS O
, BC2GM049482687 , O
and BC2GM049482687 CC O
we BC2GM049482687 PRP O
constructed BC2GM049482687 VBD O
an BC2GM049482687 DT O
unrooted BC2GM049482687 JJ O
phylogenetic BC2GM049482687 JJ O
tree BC2GM049482687 NN O
of BC2GM049482687 IN O
the BC2GM049482687 DT O
DNA BC2GM049482687 NNP O
polymerases BC2GM049482687 NNS O
based BC2GM049482687 VBN O
on BC2GM049482687 IN O
the BC2GM049482687 DT O
differences BC2GM049482687 NNS O
in BC2GM049482687 IN O
these BC2GM049482687 DT O
conserved BC2GM049482687 JJ O
regions BC2GM049482687 NNS O
. BC2GM049482687 . O
. . O O

A BC2GM078821043 DT O
mutated BC2GM078821043 JJ O
ABF1 BC2GM078821043 NNP O
site BC2GM078821043 NN O
that BC2GM078821043 WDT O
displays BC2GM078821043 VBZ O
a BC2GM078821043 DT O
very BC2GM078821043 RB O
low BC2GM078821043 JJ O
affinity BC2GM078821043 NN O
for BC2GM078821043 IN O
ABF1 BC2GM078821043 NNP O
does BC2GM078821043 VBZ O
not BC2GM078821043 RB O
functionally BC2GM078821043 RB O
replace BC2GM078821043 VB O
the BC2GM078821043 DT O
ILV1 BC2GM078821043 NNP O
REB1 BC2GM078821043 NNP O
site BC2GM078821043 NN O
. BC2GM078821043 . O
. . O O

Gene BC2GM057071865 NNP O
1 BC2GM057071865 CD O
of BC2GM057071865 IN O
the BC2GM057071865 DT O
murine BC2GM057071865 NN O
coronavirus BC2GM057071865 NN O
, BC2GM057071865 , O
MHV-A59 BC2GM057071865 NNP O
, BC2GM057071865 , O
encodes BC2GM057071865 VBZ O
approximately BC2GM057071865 RB O
800 BC2GM057071865 CD O
kDa BC2GM057071865 NNS O
of BC2GM057071865 IN O
protein BC2GM057071865 NN O
products BC2GM057071865 NNS O
within BC2GM057071865 IN O
two BC2GM057071865 CD O
overlapping BC2GM057071865 VBG O
open BC2GM057071865 JJ O
reading BC2GM057071865 NN O
frames BC2GM057071865 NNS O
( BC2GM057071865 ( O
ORFs BC2GM057071865 NNP O
1a BC2GM057071865 CD O
and BC2GM057071865 CC O
1b BC2GM057071865 CD O
) BC2GM057071865 ) O
. BC2GM057071865 . O
. . O O

Gel BC2GM024043854 NNP O
shift BC2GM024043854 NN O
analysis BC2GM024043854 NN O
of BC2GM024043854 IN O
protein BC2GM024043854 NN O
binding BC2GM024043854 VBG O
from BC2GM024043854 IN O
nuclear BC2GM024043854 JJ O
extracts BC2GM024043854 NNS O
to BC2GM024043854 TO O
these BC2GM024043854 DT O
caveolin BC2GM024043854 NNS O
promoter BC2GM024043854 VBP O
DNA BC2GM024043854 NNP O
sequences BC2GM024043854 NNS O
, BC2GM024043854 , O
together BC2GM024043854 RB O
with BC2GM024043854 IN O
DNase BC2GM024043854 NNP O
I BC2GM024043854 PRP O
footprinting BC2GM024043854 VBP O
, BC2GM024043854 , O
confirmed BC2GM024043854 VBD O
nucleoprotein BC2GM024043854 RB O
binding BC2GM024043854 VBG O
to BC2GM024043854 TO O
the BC2GM024043854 DT O
SRE-like BC2GM024043854 JJ O
elements BC2GM024043854 NNS O
as BC2GM024043854 IN O
part BC2GM024043854 NN O
of BC2GM024043854 IN O
the BC2GM024043854 DT O
transcriptional BC2GM024043854 JJ O
response BC2GM024043854 NN O
to BC2GM024043854 TO O
LDL-FC BC2GM024043854 NNP O
. BC2GM024043854 . O
. . O O

However BC2GM047029029 RB O
, BC2GM047029029 , O
the BC2GM047029029 DT O
molecular BC2GM047029029 JJ O
mechanisms BC2GM047029029 NNS O
by BC2GM047029029 IN O
which BC2GM047029029 WDT O
specific BC2GM047029029 JJ O
cis- BC2GM047029029 NN O
and BC2GM047029029 CC O
trans-acting BC2GM047029029 JJ O
factors BC2GM047029029 NNS O
control BC2GM047029029 VBP O
activity BC2GM047029029 NN O
of BC2GM047029029 IN O
the BC2GM047029029 DT O
prodynorphin BC2GM047029029 JJ O
promoter BC2GM047029029 NN O
are BC2GM047029029 VBP O
not BC2GM047029029 RB O
as BC2GM047029029 IN O
clearly BC2GM047029029 RB O
defined BC2GM047029029 VBN O
. BC2GM047029029 . O
. . O O

The BC2GM056719795 DT O
NF1 BC2GM056719795 NNP O
family BC2GM056719795 NN O
members BC2GM056719795 NNS O
and BC2GM056719795 CC O
HNF4 BC2GM056719795 NNP O
interacted BC2GM056719795 VBD O
with BC2GM056719795 IN O
overlapping BC2GM056719795 VBG O
sequences BC2GM056719795 NNS O
of BC2GM056719795 IN O
the BC2GM056719795 DT O
L-II BC2GM056719795 NNP O
element BC2GM056719795 NN O
, BC2GM056719795 , O
wherein BC2GM056719795 VBD O
the BC2GM056719795 DT O
5 BC2GM056719795 CD O
' BC2GM056719795 POS O
half-site BC2GM056719795 NN O
was BC2GM056719795 VBD O
more BC2GM056719795 RBR O
critical BC2GM056719795 JJ O
for BC2GM056719795 IN O
NF1 BC2GM056719795 NNP O
binding BC2GM056719795 NN O
, BC2GM056719795 , O
and BC2GM056719795 CC O
the BC2GM056719795 DT O
3 BC2GM056719795 CD O
' BC2GM056719795 POS O
site BC2GM056719795 NN O
was BC2GM056719795 VBD O
more BC2GM056719795 RBR O
important BC2GM056719795 JJ O
for BC2GM056719795 IN O
HNF4 BC2GM056719795 NNP O
binding BC2GM056719795 NN O
. BC2GM056719795 . O
. . O O

This BC2GM029984247 DT O
study BC2GM029984247 NN O
demonstrates BC2GM029984247 VBZ O
the BC2GM029984247 DT O
feasibility BC2GM029984247 NN O
and BC2GM029984247 CC O
potential BC2GM029984247 JJ O
usefulness BC2GM029984247 NN O
of BC2GM029984247 IN O
syngeneic BC2GM029984247 JJ O
BM BC2GM029984247 NNP O
Txp BC2GM029984247 NNP O
in BC2GM029984247 IN O
myeloma BC2GM029984247 NN O
. BC2GM029984247 . O
. . O O

Apparent BC2GM064768852 JJ O
Buschke-Loewenstein BC2GM064768852 NNP O
tumour BC2GM064768852 NN O
of BC2GM064768852 IN O
the BC2GM064768852 DT O
penis BC2GM064768852 NN O
. BC2GM064768852 . O
. . O O

The BC2GM097445371 DT O
Seldinger BC2GM097445371 NNP O
technique BC2GM097445371 NN O
for BC2GM097445371 IN O
difficult BC2GM097445371 JJ O
transurethral BC2GM097445371 JJ O
catheterization BC2GM097445371 NN O
: BC2GM097445371 : O
a BC2GM097445371 DT O
gentle BC2GM097445371 JJ O
alternative BC2GM097445371 JJ O
to BC2GM097445371 TO O
suprapubic BC2GM097445371 VB O
puncture BC2GM097445371 NN O
( BC2GM097445371 ( O
Br BC2GM097445371 NNP O
J BC2GM097445371 NNP O
Surg BC2GM097445371 NNP O
2000 BC2GM097445371 CD O
; BC2GM097445371 : O
87 BC2GM097445371 CD O
: BC2GM097445371 : O
1729-30 BC2GM097445371 JJ O
) BC2GM097445371 ) O
. BC2GM097445371 . O
. . O O

In BC2GM063929508 IN O
addition BC2GM063929508 NN O
, BC2GM063929508 , O
because BC2GM063929508 IN O
SB203580 BC2GM063929508 NNP O
had BC2GM063929508 VBD O
no BC2GM063929508 DT O
effect BC2GM063929508 NN O
of BC2GM063929508 IN O
TNF- BC2GM063929508 NNP O
or BC2GM063929508 CC O
ceramide-induced BC2GM063929508 JJ O
apoptosis BC2GM063929508 NN O
, BC2GM063929508 , O
our BC2GM063929508 PRP$ O
results BC2GM063929508 NNS O
strongly BC2GM063929508 RB O
argue BC2GM063929508 VBP O
against BC2GM063929508 IN O
a BC2GM063929508 DT O
role BC2GM063929508 NN O
for BC2GM063929508 IN O
p38 BC2GM063929508 JJ O
MAPK BC2GM063929508 NNP O
in BC2GM063929508 IN O
the BC2GM063929508 DT O
induction BC2GM063929508 NN O
of BC2GM063929508 IN O
TNF BC2GM063929508 NNP O
-- BC2GM063929508 : O
or BC2GM063929508 CC O
ceramide-induced BC2GM063929508 JJ O
apoptosis BC2GM063929508 NN O
. BC2GM063929508 . O
. . O O

METHODS BC2GM092473600 NN O
: BC2GM092473600 : O
The BC2GM092473600 DT O
Die BC2GM092473600 NNP O
Deutsche BC2GM092473600 NNP O
Diabetes BC2GM092473600 NNP O
Dialyse BC2GM092473600 NNP O
Studie BC2GM092473600 NNP O
is BC2GM092473600 VBZ O
a BC2GM092473600 DT O
prospective BC2GM092473600 JJ O
randomized BC2GM092473600 VBN O
placebo-controlled BC2GM092473600 JJ O
trial BC2GM092473600 NN O
that BC2GM092473600 WDT O
tests BC2GM092473600 VBZ O
the BC2GM092473600 DT O
hypothesis BC2GM092473600 NN O
that BC2GM092473600 WDT O
atorvastatin BC2GM092473600 VBZ O
, BC2GM092473600 , O
a BC2GM092473600 DT O
hydroxymethyl-glutaryl BC2GM092473600 JJ O
coenzyme BC2GM092473600 NN O
A BC2GM092473600 NNP O
reductase BC2GM092473600 NN O
inhibitor BC2GM092473600 NN O
, BC2GM092473600 , O
decreases BC2GM092473600 VBZ O
the BC2GM092473600 DT O
rate BC2GM092473600 NN O
of BC2GM092473600 IN O
cardiovascular BC2GM092473600 JJ O
mortality BC2GM092473600 NN O
and BC2GM092473600 CC O
of BC2GM092473600 IN O
nonfatal BC2GM092473600 JJ O
myocardial BC2GM092473600 JJ O
infarction BC2GM092473600 NN O
in BC2GM092473600 IN O
patients BC2GM092473600 NNS O
with BC2GM092473600 IN O
type BC2GM092473600 JJ O
2 BC2GM092473600 CD O
diabetes BC2GM092473600 NNS O
who BC2GM092473600 WP O
have BC2GM092473600 VBP O
been BC2GM092473600 VBN O
on BC2GM092473600 IN O
hemodialysis BC2GM092473600 NN O
treatment BC2GM092473600 NN O
for BC2GM092473600 IN O
no BC2GM092473600 DT O
more BC2GM092473600 JJR O
than BC2GM092473600 IN O
two BC2GM092473600 CD O
years BC2GM092473600 NNS O
. BC2GM092473600 . O
. . O O

Maintenance BC2GM039069187 NN O
metabolizable-energy BC2GM039069187 NN O
( BC2GM039069187 ( O
ME BC2GM039069187 NNP O
) BC2GM039069187 ) O
requirement BC2GM039069187 NN O
averaged BC2GM039069187 VBD O
31.0 BC2GM039069187 CD O
kcal BC2GM039069187 JJ O
/ BC2GM039069187 NNP O
kg BC2GM039069187 NN O
body BC2GM039069187 NN O
wt BC2GM039069187 NN O
. BC2GM039069187 . O
. . O O

We BC2GM045059476 PRP O
conclude BC2GM045059476 VBP O
that BC2GM045059476 IN O
exercise-induced BC2GM045059476 JJ O
ST-segment BC2GM045059476 JJ O
elevation BC2GM045059476 NN O
in BC2GM045059476 IN O
patients BC2GM045059476 NNS O
without BC2GM045059476 IN O
a BC2GM045059476 DT O
history BC2GM045059476 NN O
of BC2GM045059476 IN O
myocardial BC2GM045059476 JJ O
infarction BC2GM045059476 NN O
or BC2GM045059476 CC O
left BC2GM045059476 VBD O
ventricular BC2GM045059476 JJ O
aneurysm BC2GM045059476 NN O
is BC2GM045059476 VBZ O
caused BC2GM045059476 VBN O
by BC2GM045059476 IN O
coronary BC2GM045059476 JJ O
spasm BC2GM045059476 NN O
of BC2GM045059476 IN O
a BC2GM045059476 DT O
major BC2GM045059476 JJ O
coronary BC2GM045059476 JJ O
vessel BC2GM045059476 NN O
. BC2GM045059476 . O
. . O O

S. BC2GM090622796 NNP O
aureus BC2GM090622796 JJ O
leakage BC2GM090622796 NN O
into BC2GM090622796 IN O
the BC2GM090622796 DT O
totally BC2GM090622796 RB O
submerged BC2GM090622796 JJ O
test BC2GM090622796 NN O
specimens BC2GM090622796 NNS O
was BC2GM090622796 VBD O
detected BC2GM090622796 VBN O
in BC2GM090622796 IN O
1 BC2GM090622796 CD O
of BC2GM090622796 IN O
5 BC2GM090622796 CD O
samples BC2GM090622796 NNS O
incubated BC2GM090622796 VBN O
for BC2GM090622796 IN O
4 BC2GM090622796 CD O
weeks BC2GM090622796 NNS O
, BC2GM090622796 , O
while BC2GM090622796 IN O
no BC2GM090622796 DT O
leakage BC2GM090622796 NN O
was BC2GM090622796 VBD O
detected BC2GM090622796 VBN O
in BC2GM090622796 IN O
specimens BC2GM090622796 NNS O
incubated BC2GM090622796 VBN O
for BC2GM090622796 IN O
3 BC2GM090622796 CD O
, BC2GM090622796 , O
5 BC2GM090622796 CD O
, BC2GM090622796 , O
6 BC2GM090622796 CD O
, BC2GM090622796 , O
7 BC2GM090622796 CD O
, BC2GM090622796 , O
and BC2GM090622796 CC O
8 BC2GM090622796 CD O
weeks BC2GM090622796 NNS O
. BC2GM090622796 . O
. . O O

Primary BC2GM099607997 NNP O
care BC2GM099607997 NN O
programs BC2GM099607997 NNS O
for BC2GM099607997 IN O
the BC2GM099607997 DT O
indigent BC2GM099607997 NN O
. BC2GM099607997 . O
. . O O

All BC2GM025777984 PDT O
these BC2GM025777984 DT O
abnormalities BC2GM025777984 NNS O
returned BC2GM025777984 VBD O
to BC2GM025777984 TO O
normal BC2GM025777984 JJ O
after BC2GM025777984 IN O
removal BC2GM025777984 NN O
of BC2GM025777984 IN O
the BC2GM025777984 DT O
tumor BC2GM025777984 NN O
. BC2GM025777984 . O
. . O O

Southern BC2GM035459552 JJ O
hybridization BC2GM035459552 NN O
analysis BC2GM035459552 NN O
of BC2GM035459552 IN O
BenR BC2GM035459552 NNP O
and BC2GM035459552 CC O
BenS BC2GM035459552 NNP O
transformants BC2GM035459552 NNS O
suggested BC2GM035459552 VBD O
that BC2GM035459552 IN O
plasmid BC2GM035459552 JJ O
integration BC2GM035459552 NN O
occurred BC2GM035459552 VBD O
most BC2GM035459552 JJS O
frequently BC2GM035459552 RB O
at BC2GM035459552 IN O
the BC2GM035459552 DT O
chromosomal BC2GM035459552 JJ O
bens BC2GM035459552 NNS O
locus BC2GM035459552 NN O
, BC2GM035459552 , O
however BC2GM035459552 RB O
evidence BC2GM035459552 NN O
for BC2GM035459552 IN O
gene BC2GM035459552 NN O
conversion BC2GM035459552 NN O
and BC2GM035459552 CC O
heterologous BC2GM035459552 JJ O
recombination BC2GM035459552 NN O
was BC2GM035459552 VBD O
also BC2GM035459552 RB O
observed BC2GM035459552 VBN O
. BC2GM035459552 . O
. . O O

Expression BC2GM006783722 NN O
of BC2GM006783722 IN O
the BC2GM006783722 DT O
Asp BC2GM006783722 NNP O
but BC2GM006783722 CC O
not BC2GM006783722 RB O
the BC2GM006783722 DT O
Ala BC2GM006783722 NNP O
gB BC2GM006783722 NN O
mutation BC2GM006783722 NN O
resulted BC2GM006783722 VBD O
in BC2GM006783722 IN O
an BC2GM006783722 DT O
increase BC2GM006783722 NN O
in BC2GM006783722 IN O
the BC2GM006783722 DT O
steady-state BC2GM006783722 JJ O
expression BC2GM006783722 NN O
of BC2GM006783722 IN O
gB BC2GM006783722 NN O
at BC2GM006783722 IN O
the BC2GM006783722 DT O
plasma BC2GM006783722 NN O
membrane BC2GM006783722 NN O
( BC2GM006783722 ( O
PM BC2GM006783722 NNP O
) BC2GM006783722 ) O
in BC2GM006783722 IN O
U373 BC2GM006783722 NNP O
cells BC2GM006783722 NNS O
. BC2GM006783722 . O
. . O O

We BC2GM060582381 PRP O
further BC2GM060582381 RB O
examined BC2GM060582381 VBD O
the BC2GM060582381 DT O
interaction BC2GM060582381 NN O
of BC2GM060582381 IN O
JAK2 BC2GM060582381 NNP O
with BC2GM060582381 IN O
the BC2GM060582381 DT O
GHR BC2GM060582381 NNP O
cytoplasmic BC2GM060582381 JJ O
domain BC2GM060582381 NN O
by BC2GM060582381 IN O
two BC2GM060582381 CD O
lines BC2GM060582381 NNS O
of BC2GM060582381 IN O
investigation BC2GM060582381 NN O
. BC2GM060582381 . O
. . O O

Innervation BC2GM025636824 NN O
of BC2GM025636824 IN O
reticular BC2GM025636824 JJ O
papillae BC2GM025636824 NN O
in BC2GM025636824 IN O
sheep BC2GM025636824 NN O
and BC2GM025636824 CC O
goats BC2GM025636824 NNS O
. BC2GM025636824 . O
. . O O

Although BC2GM030561421 IN O
mutant BC2GM030561421 JJ O
pex5delta BC2GM030561421 NN O
cells BC2GM030561421 NNS O
expressing BC2GM030561421 VBG O
a BC2GM030561421 DT O
yeast BC2GM030561421 NN O
/ BC2GM030561421 NN O
tobacco BC2GM030561421 NN O
Pex5p BC2GM030561421 NNP O
chimaera BC2GM030561421 NN O
failed BC2GM030561421 VBD O
to BC2GM030561421 TO O
import BC2GM030561421 VB O
a BC2GM030561421 DT O
GFP-Eci1p BC2GM030561421 JJ O
reporter BC2GM030561421 NN O
protein BC2GM030561421 NN O
, BC2GM030561421 , O
they BC2GM030561421 PRP O
were BC2GM030561421 VBD O
able BC2GM030561421 JJ O
to BC2GM030561421 TO O
grow BC2GM030561421 VB O
on BC2GM030561421 IN O
oleic BC2GM030561421 JJ O
acid BC2GM030561421 NN O
. BC2GM030561421 . O
. . O O

The BC2GM094104412 DT O
newly BC2GM094104412 RB O
identified BC2GM094104412 VBN O
repressor BC2GM094104412 NN O
element BC2GM094104412 NN O
is BC2GM094104412 VBZ O
a BC2GM094104412 DT O
rare BC2GM094104412 JJ O
example BC2GM094104412 NN O
of BC2GM094104412 IN O
a BC2GM094104412 DT O
naturally BC2GM094104412 RB O
occurring BC2GM094104412 VBG O
perfect BC2GM094104412 JJ O
palindromic BC2GM094104412 JJ O
binding BC2GM094104412 NN O
motif BC2GM094104412 NN O
for BC2GM094104412 IN O
the BC2GM094104412 DT O
NF-kappa BC2GM094104412 NNP O
B BC2GM094104412 NNP O
/ BC2GM094104412 NNP O
Rel BC2GM094104412 NNP O
family BC2GM094104412 NN O
of BC2GM094104412 IN O
transcription BC2GM094104412 NN O
factors BC2GM094104412 NNS O
. BC2GM094104412 . O
. . O O

Four BC2GM091781458 CD O
families BC2GM091781458 NNS O
of BC2GM091781458 IN O
homing BC2GM091781458 VBG O
endonucleases BC2GM091781458 NNS O
have BC2GM091781458 VBP O
been BC2GM091781458 VBN O
identified BC2GM091781458 VBN O
, BC2GM091781458 , O
including BC2GM091781458 VBG O
the BC2GM091781458 DT O
LAGLIDADG BC2GM091781458 NNP O
, BC2GM091781458 , O
the BC2GM091781458 DT O
His-Cys BC2GM091781458 NNP O
box BC2GM091781458 NN O
, BC2GM091781458 , O
the BC2GM091781458 DT O
GIY-YIG BC2GM091781458 NNP O
and BC2GM091781458 CC O
the BC2GM091781458 DT O
H-N-H BC2GM091781458 NNP O
endonucleases BC2GM091781458 NNS O
. BC2GM091781458 . O
. . O O

The BC2GM003763223 DT O
consensus BC2GM003763223 NN O
mammalian BC2GM003763223 JJ O
ER BC2GM003763223 NNP O
stress BC2GM003763223 NN O
response BC2GM003763223 NN O
element BC2GM003763223 NN O
( BC2GM003763223 ( O
ERSE BC2GM003763223 NNP O
) BC2GM003763223 ) O
conserved BC2GM003763223 VBD O
among BC2GM003763223 IN O
grp BC2GM003763223 JJ O
promoters BC2GM003763223 NNS O
consists BC2GM003763223 VBZ O
of BC2GM003763223 IN O
a BC2GM003763223 DT O
tripartite BC2GM003763223 JJ O
structure BC2GM003763223 NN O
CCAAT BC2GM003763223 NNP O
( BC2GM003763223 ( O
N9 BC2GM003763223 NNP O
) BC2GM003763223 ) O
CCACG BC2GM003763223 NNP O
, BC2GM003763223 , O
with BC2GM003763223 IN O
N BC2GM003763223 NNP O
being BC2GM003763223 VBG O
a BC2GM003763223 DT O
strikingly BC2GM003763223 RB O
GC-rich BC2GM003763223 JJ O
region BC2GM003763223 NN O
of BC2GM003763223 IN O
9 BC2GM003763223 CD O
bp BC2GM003763223 NN O
. BC2GM003763223 . O
. . O O

Usefulness BC2GM073528534 NN O
of BC2GM073528534 IN O
glucocorticoids BC2GM073528534 NNS O
in BC2GM073528534 IN O
the BC2GM073528534 DT O
treatment BC2GM073528534 NN O
of BC2GM073528534 IN O
congestive BC2GM073528534 JJ O
heart BC2GM073528534 NN O
failure BC2GM073528534 NN O
. BC2GM073528534 . O
. . O O

The BC2GM038724792 DT O
host BC2GM038724792 NN O
range BC2GM038724792 NN O
( BC2GM038724792 ( O
HR BC2GM038724792 NNP O
) BC2GM038724792 ) O
of BC2GM038724792 IN O
poliovirus BC2GM038724792 NN O
is BC2GM038724792 VBZ O
thought BC2GM038724792 VBN O
to BC2GM038724792 TO O
be BC2GM038724792 VB O
primarily BC2GM038724792 RB O
determined BC2GM038724792 VBN O
by BC2GM038724792 IN O
a BC2GM038724792 DT O
cell BC2GM038724792 NN O
surface BC2GM038724792 NN O
molecule BC2GM038724792 NN O
that BC2GM038724792 WDT O
functions BC2GM038724792 NNS O
as BC2GM038724792 IN O
poliovirus BC2GM038724792 NN O
receptor BC2GM038724792 NN O
( BC2GM038724792 ( O
PVR BC2GM038724792 NNP O
) BC2GM038724792 ) O
, BC2GM038724792 , O
since BC2GM038724792 IN O
it BC2GM038724792 PRP O
has BC2GM038724792 VBZ O
been BC2GM038724792 VBN O
shown BC2GM038724792 VBN O
that BC2GM038724792 IN O
transgenic BC2GM038724792 JJ O
mice BC2GM038724792 NNS O
are BC2GM038724792 VBP O
made BC2GM038724792 VBN O
poliovirus BC2GM038724792 NNS O
sensitive BC2GM038724792 JJ O
by BC2GM038724792 IN O
introducing BC2GM038724792 VBG O
the BC2GM038724792 DT O
human BC2GM038724792 JJ O
PVR BC2GM038724792 NNP O
gene BC2GM038724792 NN O
into BC2GM038724792 IN O
the BC2GM038724792 DT O
genome BC2GM038724792 NN O
. BC2GM038724792 . O
. . O O

In BC2GM034205084 IN O
contrast BC2GM034205084 NN O
to BC2GM034205084 TO O
Torpedo BC2GM034205084 NNP O
, BC2GM034205084 , O
where BC2GM034205084 WRB O
only BC2GM034205084 RB O
a BC2GM034205084 DT O
single BC2GM034205084 JJ O
transcript BC2GM034205084 NN O
is BC2GM034205084 VBZ O
seen BC2GM034205084 VBN O
, BC2GM034205084 , O
the BC2GM034205084 DT O
mouse BC2GM034205084 NN O
expresses BC2GM034205084 VBZ O
several BC2GM034205084 JJ O
mRNAs BC2GM034205084 NNS O
encoding BC2GM034205084 VBG O
different BC2GM034205084 JJ O
isoforms BC2GM034205084 NNS O
. BC2GM034205084 . O
. . O O

Transcription BC2GM032692465 NNP O
start BC2GM032692465 VBP O
sites BC2GM032692465 NNS O
of BC2GM032692465 IN O
sal BC2GM032692465 NN O
and BC2GM032692465 CC O
salR BC2GM032692465 NN O
genes BC2GM032692465 NNS O
were BC2GM032692465 VBD O
determined BC2GM032692465 VBN O
to BC2GM032692465 TO O
lie BC2GM032692465 VB O
30- BC2GM032692465 JJ O
and BC2GM032692465 CC O
24-bp BC2GM032692465 JJ O
upstream BC2GM032692465 NN O
of BC2GM032692465 IN O
the BC2GM032692465 DT O
respective BC2GM032692465 JJ O
initiation BC2GM032692465 NN O
codons BC2GM032692465 NNS O
and BC2GM032692465 CC O
separated BC2GM032692465 VBN O
from BC2GM032692465 IN O
each BC2GM032692465 DT O
other BC2GM032692465 JJ O
by BC2GM032692465 IN O
78 BC2GM032692465 CD O
nucleotides BC2GM032692465 NNS O
. BC2GM032692465 . O
. . O O

The BC2GM023165643 DT O
regions BC2GM023165643 NNS O
encoding BC2GM023165643 VBG O
the BC2GM023165643 DT O
mature BC2GM023165643 NN O
proteinases BC2GM023165643 NNS O
were BC2GM023165643 VBD O
cloned BC2GM023165643 VBN O
into BC2GM023165643 IN O
an BC2GM023165643 DT O
expression BC2GM023165643 NN O
vector BC2GM023165643 NN O
and BC2GM023165643 CC O
recombinant BC2GM023165643 JJ O
protein BC2GM023165643 NN O
produced BC2GM023165643 VBN O
in BC2GM023165643 IN O
Escherichia BC2GM023165643 NNP O
coli BC2GM023165643 NN O
. BC2GM023165643 . O
. . O O

CONCLUSIONS BC2GM090857419 NN O
: BC2GM090857419 : O
Latanoprost BC2GM090857419 NNP O
administered BC2GM090857419 VBD O
once BC2GM090857419 RB O
daily BC2GM090857419 JJ O
was BC2GM090857419 VBD O
significantly BC2GM090857419 RB O
more BC2GM090857419 RBR O
effective BC2GM090857419 JJ O
in BC2GM090857419 IN O
reducing BC2GM090857419 VBG O
IOP BC2GM090857419 NNP O
compared BC2GM090857419 VBN O
with BC2GM090857419 IN O
unoprostone BC2GM090857419 NN O
administered BC2GM090857419 VBN O
twice BC2GM090857419 RB O
daily BC2GM090857419 RB O
in BC2GM090857419 IN O
patients BC2GM090857419 NNS O
with BC2GM090857419 IN O
POAG BC2GM090857419 NNP O
and BC2GM090857419 CC O
OH BC2GM090857419 NNP O
. BC2GM090857419 . O
. . O O

The BC2GM098226809 DT O
effect BC2GM098226809 NN O
on BC2GM098226809 IN O
FIV BC2GM098226809 NNP O
LTR BC2GM098226809 NNP O
promoter BC2GM098226809 NN O
activity BC2GM098226809 NN O
of BC2GM098226809 IN O
progressively BC2GM098226809 RB O
deleting BC2GM098226809 VBG O
these BC2GM098226809 DT O
nuclear BC2GM098226809 JJ O
factor BC2GM098226809 NN O
binding BC2GM098226809 VBG O
sites BC2GM098226809 NNS O
was BC2GM098226809 VBD O
examined BC2GM098226809 VBN O
by BC2GM098226809 IN O
linking BC2GM098226809 VBG O
LTR BC2GM098226809 NNP O
deletion BC2GM098226809 NN O
mutants BC2GM098226809 NNS O
to BC2GM098226809 TO O
the BC2GM098226809 DT O
chloramphenicol BC2GM098226809 NN O
acetyltransferase BC2GM098226809 NN O
( BC2GM098226809 ( O
CAT BC2GM098226809 NNP O
) BC2GM098226809 ) O
gene BC2GM098226809 NN O
. BC2GM098226809 . O
. . O O

A BC2GM093193565 DT O
higher BC2GM093193565 JJR O
percentage BC2GM093193565 NN O
of BC2GM093193565 IN O
children BC2GM093193565 NNS O
with BC2GM093193565 IN O
cerebral BC2GM093193565 JJ O
malaria BC2GM093193565 NNS O
( BC2GM093193565 ( O
40 BC2GM093193565 CD O
per BC2GM093193565 IN O
cent BC2GM093193565 NN O
) BC2GM093193565 ) O
than BC2GM093193565 IN O
with BC2GM093193565 IN O
non-cerebral BC2GM093193565 JJ O
malaria BC2GM093193565 NNS O
( BC2GM093193565 ( O
29 BC2GM093193565 CD O
per BC2GM093193565 IN O
cent BC2GM093193565 NN O
) BC2GM093193565 ) O
or BC2GM093193565 CC O
controls BC2GM093193565 NNS O
( BC2GM093193565 ( O
20 BC2GM093193565 CD O
per BC2GM093193565 IN O
cent BC2GM093193565 NN O
) BC2GM093193565 ) O
also BC2GM093193565 RB O
had BC2GM093193565 VBD O
either BC2GM093193565 CC O
serum BC2GM093193565 JJ O
ferritin BC2GM093193565 NN O
< BC2GM093193565 VBD O
100 BC2GM093193565 CD O
micrograms BC2GM093193565 NNS O
/ BC2GM093193565 VBP O
l BC2GM093193565 NN O
and BC2GM093193565 CC O
inflammation BC2GM093193565 NN O
or BC2GM093193565 CC O
sTfR BC2GM093193565 NN O
> BC2GM093193565 VBP O
7.3 BC2GM093193565 CD O
mg BC2GM093193565 NN O
/ BC2GM093193565 NNP O
l BC2GM093193565 NN O
or BC2GM093193565 CC O
both BC2GM093193565 DT O
. BC2GM093193565 . O
. . O O

The BC2GM080507424 DT O
likelihood BC2GM080507424 NN O
of BC2GM080507424 IN O
death BC2GM080507424 NN O
was BC2GM080507424 VBD O
more BC2GM080507424 JJR O
than BC2GM080507424 IN O
3 BC2GM080507424 CD O
times BC2GM080507424 NNS O
higher BC2GM080507424 RBR O
among BC2GM080507424 IN O
patients BC2GM080507424 NNS O
in BC2GM080507424 IN O
the BC2GM080507424 DT O
ERA-II BC2GM080507424 NNP O
group BC2GM080507424 NN O
( BC2GM080507424 ( O
mortality BC2GM080507424 NN O
risk BC2GM080507424 NN O
ratio BC2GM080507424 VBP O
3.82 BC2GM080507424 CD O
[ BC2GM080507424 JJ O
95 BC2GM080507424 CD O
% BC2GM080507424 NN O
CI BC2GM080507424 NNP O
1.48 BC2GM080507424 CD O
% BC2GM080507424 NN O
to BC2GM080507424 TO O
9.84 BC2GM080507424 CD O
] BC2GM080507424 NNS O
, BC2GM080507424 , O
p BC2GM080507424 VBP O
= BC2GM080507424 RB O
0.006 BC2GM080507424 CD O
) BC2GM080507424 ) O
. BC2GM080507424 . O
. . O O

No BC2GM063388732 DT O
significant BC2GM063388732 JJ O
difference BC2GM063388732 NN O
was BC2GM063388732 VBD O
seen BC2GM063388732 VBN O
found BC2GM063388732 VBN O
between BC2GM063388732 IN O
the BC2GM063388732 DT O
two BC2GM063388732 CD O
groups BC2GM063388732 NNS O
in BC2GM063388732 IN O
the BC2GM063388732 DT O
degree BC2GM063388732 NN O
of BC2GM063388732 IN O
postoperative BC2GM063388732 JJ O
deterioration BC2GM063388732 NN O
in BC2GM063388732 IN O
cardiopulmonary BC2GM063388732 JJ O
function BC2GM063388732 NN O
or BC2GM063388732 CC O
in BC2GM063388732 IN O
interleukin-6 BC2GM063388732 JJ O
levels BC2GM063388732 NNS O
. BC2GM063388732 . O
. . O O

Effects BC2GM043242186 NNS O
of BC2GM043242186 IN O
dietary BC2GM043242186 JJ O
lipids BC2GM043242186 NNS O
on BC2GM043242186 IN O
whole-body BC2GM043242186 JJ O
retention BC2GM043242186 NN O
and BC2GM043242186 CC O
organ BC2GM043242186 JJ O
distribution BC2GM043242186 NN O
of BC2GM043242186 IN O
organic BC2GM043242186 JJ O
and BC2GM043242186 CC O
inorganic BC2GM043242186 JJ O
mercury BC2GM043242186 NN O
in BC2GM043242186 IN O
mice BC2GM043242186 NN O
. BC2GM043242186 . O
. . O O

The BC2GM038217943 DT O
longest BC2GM038217943 JJS O
cDNA BC2GM038217943 NN O
insert BC2GM038217943 NN O
identified BC2GM038217943 VBN O
was BC2GM038217943 VBD O
2.2 BC2GM038217943 CD O
kb BC2GM038217943 NN O
and BC2GM038217943 CC O
encoded BC2GM038217943 VBD O
the BC2GM038217943 DT O
entire BC2GM038217943 JJ O
462-amino BC2GM038217943 JJ O
acid BC2GM038217943 NN O
open BC2GM038217943 JJ O
reading BC2GM038217943 NN O
frame BC2GM038217943 NN O
of BC2GM038217943 IN O
rat BC2GM038217943 NN O
CgA BC2GM038217943 NNP O
including BC2GM038217943 VBG O
an BC2GM038217943 DT O
18-amino BC2GM038217943 JJ O
acid BC2GM038217943 NN O
hydrophobic BC2GM038217943 JJ O
signal BC2GM038217943 JJ O
peptide BC2GM038217943 NN O
. BC2GM038217943 . O
. . O O

To BC2GM073745691 TO O
explore BC2GM073745691 VB O
further BC2GM073745691 JJ O
the BC2GM073745691 DT O
role BC2GM073745691 NN O
of BC2GM073745691 IN O
the BC2GM073745691 DT O
carboxyl-terminal BC2GM073745691 JJ O
domain BC2GM073745691 NN O
in BC2GM073745691 IN O
determining BC2GM073745691 VBG O
the BC2GM073745691 DT O
cell BC2GM073745691 NN O
cycle BC2GM073745691 NN O
function BC2GM073745691 NN O
of BC2GM073745691 IN O
CDC34 BC2GM073745691 NNP O
, BC2GM073745691 , O
we BC2GM073745691 PRP O
constructed BC2GM073745691 VBD O
and BC2GM073745691 CC O
characterized BC2GM073745691 VBD O
genes BC2GM073745691 NNS O
encoding BC2GM073745691 VBG O
chimeric BC2GM073745691 JJ O
E2s BC2GM073745691 NNP O
incorporating BC2GM073745691 VBG O
sequences BC2GM073745691 NNS O
from BC2GM073745691 IN O
CDC34 BC2GM073745691 NNP O
and BC2GM073745691 CC O
the BC2GM073745691 DT O
related BC2GM073745691 JJ O
but BC2GM073745691 CC O
functionally BC2GM073745691 RB O
distinct BC2GM073745691 JJ O
E2 BC2GM073745691 NNP O
RAD6 BC2GM073745691 NNP O
( BC2GM073745691 ( O
UBC2 BC2GM073745691 NNP O
) BC2GM073745691 ) O
. BC2GM073745691 . O
. . O O

This BC2GM023331710 DT O
results BC2GM023331710 NNS O
in BC2GM023331710 IN O
a BC2GM023331710 DT O
decreased BC2GM023331710 JJ O
secretion BC2GM023331710 NN O
of BC2GM023331710 IN O
immunoglobulin BC2GM023331710 NN O
A BC2GM023331710 NNP O
, BC2GM023331710 , O
and BC2GM023331710 CC O
, BC2GM023331710 , O
consequently BC2GM023331710 RB O
, BC2GM023331710 , O
a BC2GM023331710 DT O
decreased BC2GM023331710 JJ O
resistance BC2GM023331710 NN O
against BC2GM023331710 IN O
infections BC2GM023331710 NNS O
. BC2GM023331710 . O
. . O O

( BC2GM067637713 ( O
A BC2GM067637713 DT O
short BC2GM067637713 JJ O
account BC2GM067637713 NN O
of BC2GM067637713 IN O
Karl BC2GM067637713 NNP O
Touton BC2GM067637713 NNP O
's BC2GM067637713 POS O
life BC2GM067637713 NN O
is BC2GM067637713 VBZ O
also BC2GM067637713 RB O
included BC2GM067637713 VBN O
. BC2GM067637713 . O
) BC2GM067637713 ) O
After BC2GM067637713 IN O
reviewing BC2GM067637713 VBG O
the BC2GM067637713 DT O
historical BC2GM067637713 JJ O
development BC2GM067637713 NN O
of BC2GM067637713 IN O
the BC2GM067637713 DT O
concept BC2GM067637713 NN O
of BC2GM067637713 IN O
giant BC2GM067637713 JJ O
cells BC2GM067637713 NNS O
and BC2GM067637713 CC O
current BC2GM067637713 JJ O
interpretations BC2GM067637713 NNS O
of BC2GM067637713 IN O
their BC2GM067637713 PRP$ O
nature BC2GM067637713 NN O
, BC2GM067637713 , O
the BC2GM067637713 DT O
unitarian BC2GM067637713 JJ O
view BC2GM067637713 NN O
of BC2GM067637713 IN O
polykaryons BC2GM067637713 NNS O
now BC2GM067637713 RB O
favored BC2GM067637713 VBN O
by BC2GM067637713 IN O
workers BC2GM067637713 NNS O
in BC2GM067637713 IN O
the BC2GM067637713 DT O
field BC2GM067637713 NN O
is BC2GM067637713 VBZ O
extended BC2GM067637713 VBN O
to BC2GM067637713 TO O
include BC2GM067637713 VB O
also BC2GM067637713 RB O
the BC2GM067637713 DT O
`` BC2GM067637713 `` O
xanthelasmatic BC2GM067637713 JJ O
giant BC2GM067637713 NN O
cell BC2GM067637713 NN O
'' BC2GM067637713 '' O
of BC2GM067637713 IN O
Touton BC2GM067637713 NNP O
, BC2GM067637713 , O
whose BC2GM067637713 WP$ O
characteristic BC2GM067637713 JJ O
appearance BC2GM067637713 NN O
is BC2GM067637713 VBZ O
determined BC2GM067637713 VBN O
merely BC2GM067637713 RB O
by BC2GM067637713 IN O
the BC2GM067637713 DT O
presence BC2GM067637713 NN O
of BC2GM067637713 IN O
demonstrable BC2GM067637713 JJ O
lipid BC2GM067637713 NN O
in BC2GM067637713 IN O
the BC2GM067637713 DT O
cytoplasm BC2GM067637713 NN O
. BC2GM067637713 . O
. . O O

On BC2GM086866960 IN O
the BC2GM086866960 DT O
pharmacology BC2GM086866960 NN O
of BC2GM086866960 IN O
9,10-dihydro-10- BC2GM086866960 JJ O
( BC2GM086866960 ( O
1-methyl-4-piperidylidene BC2GM086866960 JJ O
) BC2GM086866960 ) O
-9-anthrol BC2GM086866960 NN O
( BC2GM086866960 ( O
WA BC2GM086866960 NNP O
335 BC2GM086866960 CD O
) BC2GM086866960 ) O
, BC2GM086866960 , O
a BC2GM086866960 DT O
histamine BC2GM086866960 NN O
and BC2GM086866960 CC O
serotonin BC2GM086866960 JJ O
antagonist BC2GM086866960 NN O
. BC2GM086866960 . O
. . O O

An BC2GM064144639 DT O
11.5-kb BC2GM064144639 JJ O
intron BC2GM064144639 NN O
is BC2GM064144639 VBZ O
found BC2GM064144639 VBN O
at BC2GM064144639 IN O
the BC2GM064144639 DT O
end BC2GM064144639 NN O
of BC2GM064144639 IN O
transmembrane BC2GM064144639 NN O
6 BC2GM064144639 CD O
, BC2GM064144639 , O
and BC2GM064144639 CC O
the BC2GM064144639 DT O
rest BC2GM064144639 NN O
of BC2GM064144639 IN O
the BC2GM064144639 DT O
ORF BC2GM064144639 NNP O
is BC2GM064144639 VBZ O
in BC2GM064144639 IN O
exon BC2GM064144639 JJ O
3 BC2GM064144639 CD O
. BC2GM064144639 . O
. . O O

Three BC2GM034171141 CD O
patients BC2GM034171141 NNS O
treated BC2GM034171141 VBN O
with BC2GM034171141 IN O
amphotericin BC2GM034171141 NN O
B BC2GM034171141 NNP O
, BC2GM034171141 , O
single BC2GM034171141 JJ O
course BC2GM034171141 NN O
as BC2GM034171141 RB O
well BC2GM034171141 RB O
as BC2GM034171141 IN O
multiple BC2GM034171141 JJ O
courses BC2GM034171141 NNS O
, BC2GM034171141 , O
and BC2GM034171141 CC O
other BC2GM034171141 JJ O
antifungal BC2GM034171141 JJ O
agents BC2GM034171141 NNS O
( BC2GM034171141 ( O
hydroxystilbamidine BC2GM034171141 NN O
and BC2GM034171141 CC O
miconazole BC2GM034171141 NN O
) BC2GM034171141 ) O
have BC2GM034171141 VBP O
all BC2GM034171141 DT O
relapsed BC2GM034171141 VBN O
. BC2GM034171141 . O
. . O O

Using BC2GM000870973 VBG O
the BC2GM000870973 DT O
same BC2GM000870973 JJ O
approach BC2GM000870973 NN O
we BC2GM000870973 PRP O
have BC2GM000870973 VBP O
shown BC2GM000870973 VBN O
that BC2GM000870973 IN O
hFIRE BC2GM000870973 NN O
binds BC2GM000870973 VBZ O
the BC2GM000870973 DT O
stimulatory BC2GM000870973 NN O
proteins BC2GM000870973 VBZ O
Sp1 BC2GM000870973 NNP O
and BC2GM000870973 CC O
Sp3 BC2GM000870973 NNP O
in BC2GM000870973 IN O
addition BC2GM000870973 NN O
to BC2GM000870973 TO O
CBF BC2GM000870973 NNP O
. BC2GM000870973 . O
. . O O

Expression BC2GM026295270 NN O
of BC2GM026295270 IN O
CBP BC2GM026295270 NNP O
/ BC2GM026295270 NNP O
p300 BC2GM026295270 NN O
potentiated BC2GM026295270 VBD O
HS2-mediated BC2GM026295270 JJ O
transactivation BC2GM026295270 NN O
. BC2GM026295270 . O
. . O O

To BC2GM064221348 TO O
assay BC2GM064221348 VB O
for BC2GM064221348 IN O
sequences BC2GM064221348 NNS O
that BC2GM064221348 WDT O
could BC2GM064221348 MD O
potentially BC2GM064221348 RB O
regulate BC2GM064221348 VB O
Xenopus BC2GM064221348 NNP O
proenkephalin BC2GM064221348 NN O
expression BC2GM064221348 NN O
, BC2GM064221348 , O
we BC2GM064221348 PRP O
transfected BC2GM064221348 VBD O
constructs BC2GM064221348 NNS O
that BC2GM064221348 WDT O
contained BC2GM064221348 VBD O
upstream BC2GM064221348 JJ O
genomic BC2GM064221348 JJ O
sequences BC2GM064221348 NNS O
linked BC2GM064221348 VBN O
to BC2GM064221348 TO O
the BC2GM064221348 DT O
CAT BC2GM064221348 NNP O
reporter BC2GM064221348 NN O
gene BC2GM064221348 NN O
into BC2GM064221348 IN O
various BC2GM064221348 JJ O
eukaryotic BC2GM064221348 JJ O
cell BC2GM064221348 NN O
lines BC2GM064221348 NNS O
. BC2GM064221348 . O
. . O O

The BC2GM076347015 DT O
organotins BC2GM076347015 NNS O
. BC2GM076347015 . O
. . O O

Pregnancy BC2GM093052916 NN O
was BC2GM093052916 VBD O
ensued BC2GM093052916 VBN O
in BC2GM093052916 IN O
4 BC2GM093052916 CD O
cases BC2GM093052916 NNS O
in BC2GM093052916 IN O
group BC2GM093052916 NN O
I BC2GM093052916 PRP O
. BC2GM093052916 . O
. . O O

All BC2GM076965048 DT O
sows BC2GM076965048 NNS O
nursed BC2GM076965048 VBN O
nine BC2GM076965048 CD O
pigs BC2GM076965048 NNS O
. BC2GM076965048 . O
. . O O

R BC2GM066692058 NN O
of BC2GM066692058 IN O
the BC2GM066692058 DT O
chest BC2GM066692058 JJS O
wall BC2GM066692058 NN O
was BC2GM066692058 VBD O
maximum BC2GM066692058 JJ O
( BC2GM066692058 ( O
35.6 BC2GM066692058 CD O
cmH2O.L- BC2GM066692058 JJ O
1.sec-1 BC2GM066692058 JJ O
+ BC2GM066692058 NN O
/ BC2GM066692058 NNP O
- BC2GM066692058 : O
2.2 BC2GM066692058 CD O
SE BC2GM066692058 NNP O
) BC2GM066692058 ) O
at BC2GM066692058 IN O
0.2 BC2GM066692058 CD O
Hz-10 BC2GM066692058 JJ O
ml BC2GM066692058 NN O
and BC2GM066692058 CC O
decreased BC2GM066692058 VBN O
with BC2GM066692058 IN O
increasing BC2GM066692058 VBG O
f BC2GM066692058 NN O
and BC2GM066692058 CC O
VT BC2GM066692058 NNP O
, BC2GM066692058 , O
although BC2GM066692058 IN O
the BC2GM066692058 DT O
VT BC2GM066692058 NNP O
effect BC2GM066692058 NN O
diminished BC2GM066692058 VBD O
at BC2GM066692058 IN O
the BC2GM066692058 DT O
higher BC2GM066692058 JJR O
f BC2GM066692058 NN O
. BC2GM066692058 . O
. . O O

Within BC2GM031317365 IN O
any BC2GM031317365 DT O
cell BC2GM031317365 NN O
line BC2GM031317365 NN O
, BC2GM031317365 , O
several BC2GM031317365 JJ O
Tcfs BC2GM031317365 NNP O
and BC2GM031317365 CC O
TLEs BC2GM031317365 NNP O
are BC2GM031317365 VBP O
co-expressed BC2GM031317365 JJ O
. BC2GM031317365 . O
. . O O

Escherichia BC2GM060734859 NNP O
coli BC2GM060734859 NN O
strains BC2GM060734859 NNS O
carrying BC2GM060734859 VBG O
recA730 BC2GM060734859 NN O
( BC2GM060734859 ( O
or BC2GM060734859 CC O
other BC2GM060734859 JJ O
recA* BC2GM060734859 JJ O
alleles BC2GM060734859 NNS O
) BC2GM060734859 ) O
exhibit BC2GM060734859 VBP O
dramatic BC2GM060734859 JJ O
increases BC2GM060734859 NNS O
in BC2GM060734859 IN O
SOS-dependent BC2GM060734859 NNP O
spontaneous BC2GM060734859 JJ O
mutator BC2GM060734859 NN O
activity BC2GM060734859 NN O
. BC2GM060734859 . O
. . O O

Tag BC2GM096526830 NNP O
expression BC2GM096526830 NN O
induced BC2GM096526830 VBD O
apoptosis BC2GM096526830 NN O
in BC2GM096526830 IN O
mammary BC2GM096526830 JJ O
epithelial BC2GM096526830 JJ O
cells BC2GM096526830 NNS O
during BC2GM096526830 IN O
late BC2GM096526830 JJ O
pregnancy BC2GM096526830 NN O
. BC2GM096526830 . O
. . O O

The BC2GM090808370 DT O
delayed BC2GM090808370 JJ O
activation BC2GM090808370 NN O
of BC2GM090808370 IN O
the BC2GM090808370 DT O
prostaglandin BC2GM090808370 NN O
G BC2GM090808370 NNP O
/ BC2GM090808370 NNP O
H BC2GM090808370 NNP O
synthase-2 BC2GM090808370 JJ O
promoter BC2GM090808370 NN O
in BC2GM090808370 IN O
bovine BC2GM090808370 NN O
granulosa BC2GM090808370 NN O
cells BC2GM090808370 NNS O
is BC2GM090808370 VBZ O
associated BC2GM090808370 VBN O
with BC2GM090808370 IN O
down-regulation BC2GM090808370 NN O
of BC2GM090808370 IN O
truncated BC2GM090808370 JJ O
upstream BC2GM090808370 JJ O
stimulatory BC2GM090808370 NN O
factor-2 BC2GM090808370 NN O
. BC2GM090808370 . O
. . O O

Our BC2GM009689602 PRP$ O
studies BC2GM009689602 NNS O
indicate BC2GM009689602 VBP O
no BC2GM009689602 DT O
single BC2GM009689602 JJ O
trans-acting BC2GM009689602 JJ O
factor BC2GM009689602 NN O
is BC2GM009689602 VBZ O
absolutely BC2GM009689602 RB O
essential BC2GM009689602 JJ O
for BC2GM009689602 IN O
enhancer BC2GM009689602 NN O
activity BC2GM009689602 NN O
, BC2GM009689602 , O
and BC2GM009689602 CC O
that BC2GM009689602 IN O
the BC2GM009689602 DT O
enhancer BC2GM009689602 NN O
activity BC2GM009689602 NN O
of BC2GM009689602 IN O
MerI BC2GM009689602 NNP O
is BC2GM009689602 VBZ O
mediated BC2GM009689602 VBN O
via BC2GM009689602 IN O
a BC2GM009689602 DT O
combinatorial BC2GM009689602 JJ O
and BC2GM009689602 CC O
additive BC2GM009689602 JJ O
mechanism BC2GM009689602 NN O
. BC2GM009689602 . O
. . O O

However BC2GM079384236 RB O
, BC2GM079384236 , O
it BC2GM079384236 PRP O
is BC2GM079384236 VBZ O
only BC2GM079384236 RB O
loosely BC2GM079384236 RB O
associated BC2GM079384236 VBN O
, BC2GM079384236 , O
or BC2GM079384236 CC O
not BC2GM079384236 RB O
associated BC2GM079384236 VBN O
, BC2GM079384236 , O
with BC2GM079384236 IN O
viral BC2GM079384236 JJ O
particles BC2GM079384236 NNS O
. BC2GM079384236 . O
gp170 BC2GM079384236 NN O
is BC2GM079384236 VBZ O
generated BC2GM079384236 VBN O
by BC2GM079384236 IN O
an BC2GM079384236 DT O
alternatively BC2GM079384236 RB O
spliced BC2GM079384236 JJ O
Env BC2GM079384236 NNP O
mRNA BC2GM079384236 NN O
using BC2GM079384236 VBG O
a BC2GM079384236 DT O
splice BC2GM079384236 NN O
donor BC2GM079384236 NN O
and BC2GM079384236 CC O
splice BC2GM079384236 NN O
acceptor BC2GM079384236 NN O
pair BC2GM079384236 NN O
localized BC2GM079384236 VBD O
within BC2GM079384236 IN O
the BC2GM079384236 DT O
env BC2GM079384236 NN O
open BC2GM079384236 JJ O
reading BC2GM079384236 NN O
frame BC2GM079384236 NN O
( BC2GM079384236 ( O
ORF BC2GM079384236 NNP O
) BC2GM079384236 ) O
, BC2GM079384236 , O
which BC2GM079384236 WDT O
is BC2GM079384236 VBZ O
normally BC2GM079384236 RB O
used BC2GM079384236 VBN O
to BC2GM079384236 TO O
generate BC2GM079384236 VB O
Bell BC2GM079384236 NNP O
and BC2GM079384236 CC O
Bet BC2GM079384236 NNP O
transcripts BC2GM079384236 NNS O
derived BC2GM079384236 VBN O
from BC2GM079384236 IN O
the BC2GM079384236 DT O
internal BC2GM079384236 JJ O
promoter BC2GM079384236 NN O
within BC2GM079384236 IN O
the BC2GM079384236 DT O
env BC2GM079384236 JJ O
ORF BC2GM079384236 NNP O
. BC2GM079384236 . O
gp170 BC2GM079384236 NN O
is BC2GM079384236 VBZ O
expressed BC2GM079384236 VBN O
at BC2GM079384236 IN O
a BC2GM079384236 DT O
level BC2GM079384236 NN O
30 BC2GM079384236 CD O
to BC2GM079384236 TO O
50 BC2GM079384236 CD O
% BC2GM079384236 NN O
of BC2GM079384236 IN O
the BC2GM079384236 DT O
Env BC2GM079384236 NNP O
precursor BC2GM079384236 NN O
gp130 BC2GM079384236 NN O
. BC2GM079384236 . O
. . O O

43 BC2GM080428035 CD O
% BC2GM080428035 NN O
, BC2GM080428035 , O
6 BC2GM080428035 CD O
/ BC2GM080428035 JJ O
14 BC2GM080428035 CD O
; BC2GM080428035 : O
P BC2GM080428035 NNP O
= BC2GM080428035 NNP O
0.013 BC2GM080428035 CD O
) BC2GM080428035 ) O
, BC2GM080428035 , O
whereas BC2GM080428035 UH O
, BC2GM080428035 , O
in BC2GM080428035 IN O
RCC BC2GM080428035 NNP O
samples BC2GM080428035 NNS O
with BC2GM080428035 IN O
VHL BC2GM080428035 NNP O
methylation BC2GM080428035 NN O
or BC2GM080428035 CC O
mutation BC2GM080428035 NN O
, BC2GM080428035 , O
the BC2GM080428035 DT O
frequency BC2GM080428035 NN O
of BC2GM080428035 IN O
3p14-p21 BC2GM080428035 JJ O
LOH BC2GM080428035 NNP O
did BC2GM080428035 VBD O
not BC2GM080428035 RB O
differ BC2GM080428035 VB O
from BC2GM080428035 IN O
that BC2GM080428035 DT O
of BC2GM080428035 IN O
sp25-p26 BC2GM080428035 NN O
( BC2GM080428035 ( O
72 BC2GM080428035 CD O
% BC2GM080428035 NN O
, BC2GM080428035 , O
18 BC2GM080428035 CD O
/ BC2GM080428035 NN O
25 BC2GM080428035 CD O
vs BC2GM080428035 NN O
. BC2GM080428035 . O
. . O O

Influenza BC2GM043530454 NNP O
virus-induced BC2GM043530454 JJ O
NF-kappaB-dependent BC2GM043530454 JJ O
gene BC2GM043530454 NN O
expression BC2GM043530454 NN O
is BC2GM043530454 VBZ O
mediated BC2GM043530454 VBN O
by BC2GM043530454 IN O
overexpression BC2GM043530454 NN O
of BC2GM043530454 IN O
viral BC2GM043530454 JJ O
proteins BC2GM043530454 NNS O
and BC2GM043530454 CC O
involves BC2GM043530454 VBZ O
oxidative BC2GM043530454 JJ O
radicals BC2GM043530454 NNS O
and BC2GM043530454 CC O
activation BC2GM043530454 NN O
of BC2GM043530454 IN O
IkappaB BC2GM043530454 NNP O
kinase BC2GM043530454 NN O
. BC2GM043530454 . O
. . O O

In BC2GM063365941 IN O
a BC2GM063365941 DT O
previous BC2GM063365941 JJ O
study BC2GM063365941 NN O
of BC2GM063365941 IN O
transforming BC2GM063365941 VBG O
growth BC2GM063365941 NN O
factor-beta1-mediated BC2GM063365941 JJ O
inhibition BC2GM063365941 NN O
of BC2GM063365941 IN O
the BC2GM063365941 DT O
cyclin BC2GM063365941 NN O
A BC2GM063365941 NNP O
promoter BC2GM063365941 NN O
, BC2GM063365941 , O
we BC2GM063365941 PRP O
mapped BC2GM063365941 VBD O
the BC2GM063365941 DT O
inhibitory BC2GM063365941 JJ O
effect BC2GM063365941 NN O
to BC2GM063365941 TO O
the BC2GM063365941 DT O
ATF BC2GM063365941 NNP O
site BC2GM063365941 NN O
; BC2GM063365941 : O
in BC2GM063365941 IN O
the BC2GM063365941 DT O
present BC2GM063365941 JJ O
study BC2GM063365941 NN O
of BC2GM063365941 IN O
IFN-gamma BC2GM063365941 NNP O
treatment BC2GM063365941 NN O
, BC2GM063365941 , O
functional BC2GM063365941 JJ O
analysis BC2GM063365941 NN O
by BC2GM063365941 IN O
transient BC2GM063365941 JJ O
transfection BC2GM063365941 NN O
showed BC2GM063365941 VBD O
that BC2GM063365941 IN O
inhibition BC2GM063365941 NN O
of BC2GM063365941 IN O
the BC2GM063365941 DT O
cyclin BC2GM063365941 NN O
A BC2GM063365941 NNP O
promoter BC2GM063365941 NN O
persisted BC2GM063365941 VBD O
despite BC2GM063365941 IN O
mutation BC2GM063365941 NN O
of BC2GM063365941 IN O
the BC2GM063365941 DT O
ATF BC2GM063365941 NNP O
, BC2GM063365941 , O
NF-Y BC2GM063365941 NNP O
, BC2GM063365941 , O
or BC2GM063365941 CC O
CDE BC2GM063365941 NNP O
elements BC2GM063365941 NNS O
. BC2GM063365941 . O
. . O O

MEASURES BC2GM047460616 NNS O
: BC2GM047460616 : O
SF-36 BC2GM047460616 JJ O
questionnaires BC2GM047460616 NNS O
were BC2GM047460616 VBD O
completed BC2GM047460616 VBN O
by BC2GM047460616 IN O
patients BC2GM047460616 NNS O
at BC2GM047460616 IN O
both BC2GM047460616 DT O
initial BC2GM047460616 JJ O
and BC2GM047460616 CC O
discharge BC2GM047460616 JJ O
examinations BC2GM047460616 NNS O
. BC2GM047460616 . O
. . O O

PEAP BC2GM037222335 NNP O
was BC2GM037222335 VBD O
significantly BC2GM037222335 RB O
higher BC2GM037222335 JJR O
in BC2GM037222335 IN O
IDC BC2GM037222335 NNP O
patients BC2GM037222335 NNS O
compared BC2GM037222335 VBN O
to BC2GM037222335 TO O
controls BC2GM037222335 NNS O
( BC2GM037222335 ( O
48.7 BC2GM037222335 CD O
+ BC2GM037222335 NN O
/ BC2GM037222335 NNP O
- BC2GM037222335 : O
32.6 BC2GM037222335 CD O
vs BC2GM037222335 NN O
. BC2GM037222335 . O
. . O O

This BC2GM008542019 DT O
effect BC2GM008542019 NN O
was BC2GM008542019 VBD O
stronger BC2GM008542019 JJR O
after BC2GM008542019 IN O
multiple BC2GM008542019 JJ O
predoses BC2GM008542019 NNS O
of BC2GM008542019 IN O
sertraline BC2GM008542019 NN O
, BC2GM008542019 , O
when BC2GM008542019 WRB O
imipramine BC2GM008542019 NN O
Cmax BC2GM008542019 NNP O
and BC2GM008542019 CC O
AUC BC2GM008542019 NNP O
( BC2GM008542019 ( O
0-infinity BC2GM008542019 NN O
) BC2GM008542019 ) O
were BC2GM008542019 VBD O
increased BC2GM008542019 VBN O
by BC2GM008542019 IN O
39 BC2GM008542019 CD O
% BC2GM008542019 NN O
and BC2GM008542019 CC O
68 BC2GM008542019 CD O
% BC2GM008542019 NN O
, BC2GM008542019 , O
respectively BC2GM008542019 RB O
. BC2GM008542019 . O
. . O O

CONCLUSION BC2GM046574139 NN O
: BC2GM046574139 : O
DMIPP BC2GM046574139 NNP O
detects BC2GM046574139 VBZ O
regionally BC2GM046574139 RB O
hypoperfused BC2GM046574139 JJ O
myocardium BC2GM046574139 NN O
, BC2GM046574139 , O
in BC2GM046574139 IN O
which BC2GM046574139 WDT O
agreement BC2GM046574139 NN O
between BC2GM046574139 IN O
MBF BC2GM046574139 NNP O
and BC2GM046574139 CC O
fatty BC2GM046574139 JJ O
acid BC2GM046574139 NNS O
uptake BC2GM046574139 JJ O
deteriorates BC2GM046574139 NNS O
. BC2GM046574139 . O
. . O O

After BC2GM022542601 IN O
nine BC2GM022542601 CD O
months BC2GM022542601 NNS O
GFR BC2GM022542601 NNP O
improved BC2GM022542601 VBD O
spontaneously BC2GM022542601 RB O
to BC2GM022542601 TO O
32 BC2GM022542601 CD O
ml BC2GM022542601 NNS O
/ BC2GM022542601 JJ O
min BC2GM022542601 NN O
/ BC2GM022542601 VBD O
1.73 BC2GM022542601 CD O
m2 BC2GM022542601 NNS O
despite BC2GM022542601 IN O
no BC2GM022542601 DT O
improvement BC2GM022542601 NN O
in BC2GM022542601 IN O
his BC2GM022542601 PRP$ O
hypertension BC2GM022542601 NN O
. BC2GM022542601 . O
. . O O

Cloning BC2GM040382030 VBG O
and BC2GM040382030 CC O
sequence BC2GM040382030 NN O
analysis BC2GM040382030 NN O
of BC2GM040382030 IN O
a BC2GM040382030 DT O
chymotrypsinlike BC2GM040382030 JJ O
protease BC2GM040382030 NN O
from BC2GM040382030 IN O
Treponema BC2GM040382030 NNP O
denticola BC2GM040382030 NN O
. BC2GM040382030 . O
. . O O

Genome BC2GM012462768 NNP O
timeline BC2GM012462768 NN O
. BC2GM012462768 . O
. . O O

In BC2GM078700363 IN O
frozen BC2GM078700363 JJ O
sections BC2GM078700363 NNS O
the BC2GM078700363 DT O
spots BC2GM078700363 NNS O
appear BC2GM078700363 VBP O
as BC2GM078700363 IN O
blue BC2GM078700363 JJ O
labelled BC2GM078700363 VBD O
neurones BC2GM078700363 NNS O
with BC2GM078700363 IN O
a BC2GM078700363 DT O
light BC2GM078700363 JJ O
microscope BC2GM078700363 NN O
, BC2GM078700363 , O
or BC2GM078700363 CC O
as BC2GM078700363 IN O
a BC2GM078700363 DT O
brilliant BC2GM078700363 NN O
red BC2GM078700363 JJ O
neurones BC2GM078700363 NNS O
surrounded BC2GM078700363 VBN O
by BC2GM078700363 IN O
reddish BC2GM078700363 JJ O
tissue BC2GM078700363 NN O
with BC2GM078700363 IN O
a BC2GM078700363 DT O
fluorescence BC2GM078700363 NN O
microscope BC2GM078700363 NN O
. BC2GM078700363 . O
. . O O

The BC2GM055829583 DT O
organelles BC2GM055829583 NNS O
synthesize BC2GM055829583 VBP O
their BC2GM055829583 PRP$ O
own BC2GM055829583 JJ O
set BC2GM055829583 NN O
of BC2GM055829583 IN O
Fe BC2GM055829583 NNP O
/ BC2GM055829583 NNP O
S BC2GM055829583 NNP O
proteins BC2GM055829583 VBZ O
, BC2GM055829583 , O
and BC2GM055829583 CC O
they BC2GM055829583 PRP O
initiate BC2GM055829583 VBP O
the BC2GM055829583 DT O
generation BC2GM055829583 NN O
of BC2GM055829583 IN O
extramitochondrial BC2GM055829583 JJ O
Fe BC2GM055829583 NNP O
/ BC2GM055829583 NNP O
S BC2GM055829583 NNP O
proteins BC2GM055829583 VBZ O
. BC2GM055829583 . O
. . O O

Copyright BC2GM037553498 JJ O
1998 BC2GM037553498 CD O
Academic BC2GM037553498 NNP O
Press BC2GM037553498 NNP O
. BC2GM037553498 . O
. . O O

Soft BC2GM039969653 JJ O
independent BC2GM039969653 JJ O
modelling BC2GM039969653 NN O
of BC2GM039969653 IN O
class BC2GM039969653 NN O
analogy BC2GM039969653 NN O
( BC2GM039969653 ( O
SIMCA BC2GM039969653 NNP O
) BC2GM039969653 ) O
is BC2GM039969653 VBZ O
applied BC2GM039969653 VBN O
to BC2GM039969653 TO O
identify BC2GM039969653 VB O
near-infrared BC2GM039969653 JJ O
( BC2GM039969653 ( O
NIR BC2GM039969653 NNP O
) BC2GM039969653 ) O
spectra BC2GM039969653 NN O
of BC2GM039969653 IN O
ten BC2GM039969653 JJ O
excipients BC2GM039969653 NNS O
used BC2GM039969653 VBN O
in BC2GM039969653 IN O
the BC2GM039969653 DT O
pharmaceutical BC2GM039969653 JJ O
industry BC2GM039969653 NN O
. BC2GM039969653 . O
. . O O

Using BC2GM069768430 VBG O
transgenic BC2GM069768430 JJ O
lines BC2GM069768430 NNS O
a BC2GM069768430 DT O
detailed BC2GM069768430 JJ O
analysis BC2GM069768430 NN O
of BC2GM069768430 IN O
the BC2GM069768430 DT O
Hoxa-7 BC2GM069768430 NNP O
enhancer-directed BC2GM069768430 JJ O
expression BC2GM069768430 NN O
during BC2GM069768430 IN O
embryogenesis BC2GM069768430 NN O
was BC2GM069768430 VBD O
performed BC2GM069768430 VBN O
. BC2GM069768430 . O
lacZ BC2GM069768430 JJ O
expression BC2GM069768430 NN O
was BC2GM069768430 VBD O
first BC2GM069768430 RB O
detected BC2GM069768430 VBN O
in BC2GM069768430 IN O
the BC2GM069768430 DT O
allantois BC2GM069768430 NN O
at BC2GM069768430 IN O
day BC2GM069768430 NN O
7.5 BC2GM069768430 CD O
p.c BC2GM069768430 NN O
. BC2GM069768430 . O
and BC2GM069768430 CC O
in BC2GM069768430 IN O
mesoderm BC2GM069768430 NN O
and BC2GM069768430 CC O
ectoderm BC2GM069768430 NN O
at BC2GM069768430 IN O
day BC2GM069768430 NN O
8.5 BC2GM069768430 CD O
of BC2GM069768430 IN O
gestation BC2GM069768430 NN O
. BC2GM069768430 . O
. . O O

Catalase BC2GM020674763 NNP O
plays BC2GM020674763 VBZ O
a BC2GM020674763 DT O
key BC2GM020674763 JJ O
role BC2GM020674763 NN O
as BC2GM020674763 IN O
an BC2GM020674763 DT O
antioxidant BC2GM020674763 NN O
, BC2GM020674763 , O
protecting BC2GM020674763 VBG O
aerobic BC2GM020674763 JJ O
organisms BC2GM020674763 NNS O
from BC2GM020674763 IN O
the BC2GM020674763 DT O
toxic BC2GM020674763 JJ O
effects BC2GM020674763 NNS O
of BC2GM020674763 IN O
hydrogen BC2GM020674763 NN O
peroxide BC2GM020674763 NN O
, BC2GM020674763 , O
and BC2GM020674763 CC O
in BC2GM020674763 IN O
some BC2GM020674763 DT O
cases BC2GM020674763 NNS O
has BC2GM020674763 VBZ O
been BC2GM020674763 VBN O
postulated BC2GM020674763 VBN O
to BC2GM020674763 TO O
be BC2GM020674763 VB O
a BC2GM020674763 DT O
virulence BC2GM020674763 NN O
factor BC2GM020674763 NN O
. BC2GM020674763 . O
. . O O

METHODS BC2GM023106158 NN O
: BC2GM023106158 : O
CD4 BC2GM023106158 NNP O
cell BC2GM023106158 NN O
counts BC2GM023106158 NNS O
and BC2GM023106158 CC O
interview BC2GM023106158 NN O
data BC2GM023106158 NNS O
were BC2GM023106158 VBD O
recorded BC2GM023106158 VBN O
in BC2GM023106158 IN O
a BC2GM023106158 DT O
survey BC2GM023106158 NN O
of BC2GM023106158 IN O
136 BC2GM023106158 CD O
adult BC2GM023106158 NN O
patients BC2GM023106158 NNS O
attending BC2GM023106158 VBG O
a BC2GM023106158 DT O
community BC2GM023106158 NN O
hospital-based BC2GM023106158 JJ O
HIV BC2GM023106158 NNP O
outpatient BC2GM023106158 NN O
clinic BC2GM023106158 NN O
. BC2GM023106158 . O
. . O O

RAP BC2GM077489528 NNP O
has BC2GM077489528 VBZ O
been BC2GM077489528 VBN O
shown BC2GM077489528 VBN O
to BC2GM077489528 TO O
be BC2GM077489528 VB O
a BC2GM077489528 DT O
useful BC2GM077489528 JJ O
vaccine BC2GM077489528 NN O
target BC2GM077489528 NN O
site BC2GM077489528 NN O
, BC2GM077489528 , O
and BC2GM077489528 CC O
RIP BC2GM077489528 NNP O
and BC2GM077489528 CC O
inhibitory BC2GM077489528 JJ O
AIPs BC2GM077489528 NNP O
as BC2GM077489528 IN O
therapeutic BC2GM077489528 JJ O
molecules BC2GM077489528 NNS O
to BC2GM077489528 TO O
prevent BC2GM077489528 VB O
and BC2GM077489528 CC O
suppress BC2GM077489528 VB O
S. BC2GM077489528 NNP O
aureus BC2GM077489528 JJ O
infections BC2GM077489528 NNS O
. BC2GM077489528 . O
. . O O

Precision BC2GM068562414 NN O
of BC2GM068562414 IN O
data BC2GM068562414 NNS O
from BC2GM068562414 IN O
models BC2GM068562414 NNS O
of BC2GM068562414 IN O
sodium BC2GM068562414 NN O
kinetics BC2GM068562414 NNS O
in BC2GM068562414 IN O
hemodialysis BC2GM068562414 NN O
. BC2GM068562414 . O
. . O O

Conventional BC2GM037547379 JJ O
and BC2GM037547379 CC O
digital BC2GM037547379 JJ O
radiography BC2GM037547379 NN O
of BC2GM037547379 IN O
the BC2GM037547379 DT O
heart BC2GM037547379 NN O
, BC2GM037547379 , O
aorta BC2GM037547379 NN O
, BC2GM037547379 , O
and BC2GM037547379 CC O
pulmonary BC2GM037547379 JJ O
vascularity BC2GM037547379 NN O
. BC2GM037547379 . O
. . O O

Response BC2GM055184868 NNP O
surface BC2GM055184868 NN O
methodology BC2GM055184868 NN O
was BC2GM055184868 VBD O
employed BC2GM055184868 VBN O
to BC2GM055184868 TO O
describe BC2GM055184868 VB O
the BC2GM055184868 DT O
relationship BC2GM055184868 NN O
between BC2GM055184868 IN O
soman-induced BC2GM055184868 JJ O
incapacitation BC2GM055184868 NN O
and BC2GM055184868 CC O
the BC2GM055184868 DT O
ATR BC2GM055184868 NNP O
/ BC2GM055184868 NNP O
DZ BC2GM055184868 NNP O
or BC2GM055184868 CC O
ATR BC2GM055184868 NNP O
/ BC2GM055184868 NNP O
SCP BC2GM055184868 NNP O
dosages BC2GM055184868 NNS O
. BC2GM055184868 . O
. . O O

Spongiosa BC2GM094222143 NNP O
regeneration BC2GM094222143 NN O
in BC2GM094222143 IN O
the BC2GM094222143 DT O
millipore BC2GM094222143 NN O
chamber BC2GM094222143 NN O
. BC2GM094222143 . O
. . O O

Blotting BC2GM018845619 VBG O
analysis BC2GM018845619 NN O
of BC2GM018845619 IN O
intestinal BC2GM018845619 JJ O
RNA BC2GM018845619 NNP O
and BC2GM018845619 CC O
hybridization BC2GM018845619 NN O
of BC2GM018845619 IN O
the BC2GM018845619 DT O
blots BC2GM018845619 NNS O
with BC2GM018845619 IN O
carboxy BC2GM018845619 JJ O
apoB BC2GM018845619 NN O
cDNA BC2GM018845619 NN O
probes BC2GM018845619 NNS O
produced BC2GM018845619 VBD O
a BC2GM018845619 DT O
single BC2GM018845619 JJ O
15-kb BC2GM018845619 JJ O
hybridization BC2GM018845619 NN O
band BC2GM018845619 NN O
whereas BC2GM018845619 NNS O
hybridization BC2GM018845619 NN O
with BC2GM018845619 IN O
amino BC2GM018845619 JJ O
terminal BC2GM018845619 JJ O
probes BC2GM018845619 NNS O
produced BC2GM018845619 VBD O
two BC2GM018845619 CD O
hybridization BC2GM018845619 NN O
bands BC2GM018845619 NNS O
of BC2GM018845619 IN O
15 BC2GM018845619 CD O
and BC2GM018845619 CC O
8 BC2GM018845619 CD O
kb BC2GM018845619 NN O
. BC2GM018845619 . O
. . O O

Renal BC2GM030879551 JJ O
dysplasia BC2GM030879551 NN O
with BC2GM030879551 IN O
multisystem BC2GM030879551 NN O
malformation BC2GM030879551 NN O
-- BC2GM030879551 : O
a BC2GM030879551 DT O
study BC2GM030879551 NN O
of BC2GM030879551 IN O
9 BC2GM030879551 CD O
cases BC2GM030879551 NNS O
. BC2GM030879551 . O
. . O O

Paclitaxel BC2GM042404259 NNP O
caused BC2GM042404259 VBD O
a BC2GM042404259 DT O
rapid BC2GM042404259 JJ O
and BC2GM042404259 CC O
transient BC2GM042404259 JJ O
increase BC2GM042404259 NN O
in BC2GM042404259 IN O
c-Jun BC2GM042404259 JJ O
NH2-terminal BC2GM042404259 JJ O
kinase BC2GM042404259 NN O
( BC2GM042404259 ( O
JNK BC2GM042404259 NNP O
) BC2GM042404259 ) O
activity BC2GM042404259 NN O
, BC2GM042404259 , O
a BC2GM042404259 DT O
proposed BC2GM042404259 VBN O
mediator BC2GM042404259 NN O
of BC2GM042404259 IN O
stress BC2GM042404259 JJ O
activation BC2GM042404259 NN O
pathways BC2GM042404259 NNS O
. BC2GM042404259 . O
. . O O

Activated BC2GM085698847 VBN O
FGFR3 BC2GM085698847 NNP O
predominantly BC2GM085698847 RB O
interacts BC2GM085698847 VBZ O
with BC2GM085698847 IN O
GRB2.Sos BC2GM085698847 NNP O
in BC2GM085698847 IN O
complex BC2GM085698847 JJ O
with BC2GM085698847 IN O
a BC2GM085698847 DT O
previously BC2GM085698847 RB O
identified BC2GM085698847 VBN O
90-kDa BC2GM085698847 JJ O
protein BC2GM085698847 NN O
and BC2GM085698847 CC O
designated BC2GM085698847 JJ O
protein BC2GM085698847 NN O
80K-H BC2GM085698847 CD O
. BC2GM085698847 . O
. . O O

Bone BC2GM057651504 NNP O
scintigraphy BC2GM057651504 NN O
is BC2GM057651504 VBZ O
an BC2GM057651504 DT O
excellent BC2GM057651504 JJ O
screening BC2GM057651504 NN O
test BC2GM057651504 NN O
for BC2GM057651504 IN O
bone BC2GM057651504 NN O
lesions BC2GM057651504 NNS O
and BC2GM057651504 CC O
Ga-67 BC2GM057651504 NNP O
scintigraphy BC2GM057651504 NN O
is BC2GM057651504 VBZ O
a BC2GM057651504 DT O
useful BC2GM057651504 JJ O
tool BC2GM057651504 NN O
for BC2GM057651504 IN O
detecting BC2GM057651504 VBG O
inflammatory BC2GM057651504 JJ O
lesions BC2GM057651504 NNS O
. BC2GM057651504 . O
. . O O

The BC2GM030635649 DT O
psychosomatic BC2GM030635649 JJ O
approach BC2GM030635649 NN O
to BC2GM030635649 TO O
temporomandibular BC2GM030635649 JJ O
arthrosis BC2GM030635649 NN O
. BC2GM030635649 . O
. . O O

None BC2GM046615396 NN O
of BC2GM046615396 IN O
the BC2GM046615396 DT O
10 BC2GM046615396 CD O
sequences BC2GM046615396 NNS O
has BC2GM046615396 VBZ O
hitherto BC2GM046615396 VBN O
been BC2GM046615396 VBN O
recognized BC2GM046615396 VBN O
as BC2GM046615396 IN O
part BC2GM046615396 NN O
of BC2GM046615396 IN O
the BC2GM046615396 DT O
p53 BC2GM046615396 NN O
signaling BC2GM046615396 VBG O
pathway BC2GM046615396 NN O
. BC2GM046615396 . O
. . O O

Our BC2GM041444961 PRP$ O
studies BC2GM041444961 NNS O
suggest BC2GM041444961 VBP O
that BC2GM041444961 IN O
the BC2GM041444961 DT O
helicase BC2GM041444961 NN O
assembly BC2GM041444961 NN O
protein BC2GM041444961 NN O
is BC2GM041444961 VBZ O
responsible BC2GM041444961 JJ O
for BC2GM041444961 IN O
loading BC2GM041444961 VBG O
T4 BC2GM041444961 NNP O
gene BC2GM041444961 NN O
41 BC2GM041444961 CD O
helicase BC2GM041444961 NN O
specifically BC2GM041444961 RB O
at BC2GM041444961 IN O
replication BC2GM041444961 NN O
forks BC2GM041444961 NNS O
, BC2GM041444961 , O
and BC2GM041444961 CC O
that BC2GM041444961 IN O
its BC2GM041444961 PRP$ O
binding BC2GM041444961 NN O
sites BC2GM041444961 NNS O
for BC2GM041444961 IN O
each BC2GM041444961 DT O
arm BC2GM041444961 NN O
must BC2GM041444961 MD O
hold BC2GM041444961 VB O
more BC2GM041444961 JJR O
than BC2GM041444961 IN O
six BC2GM041444961 CD O
, BC2GM041444961 , O
but BC2GM041444961 CC O
not BC2GM041444961 RB O
more BC2GM041444961 JJR O
than BC2GM041444961 IN O
12 BC2GM041444961 CD O
nucleotides BC2GM041444961 NNS O
. BC2GM041444961 . O
. . O O

Expression BC2GM045771943 NN O
of BC2GM045771943 IN O
human BC2GM045771943 JJ O
complement BC2GM045771943 NN O
receptor BC2GM045771943 NN O
type BC2GM045771943 NN O
2 BC2GM045771943 CD O
( BC2GM045771943 ( O
CR2 BC2GM045771943 NNP O
/ BC2GM045771943 NNP O
CD21 BC2GM045771943 NNP O
) BC2GM045771943 ) O
is BC2GM045771943 VBZ O
primarily BC2GM045771943 RB O
restricted BC2GM045771943 VBN O
to BC2GM045771943 TO O
mature BC2GM045771943 VB O
B BC2GM045771943 NNP O
cells BC2GM045771943 NNS O
and BC2GM045771943 CC O
follicular BC2GM045771943 JJ O
dendritic BC2GM045771943 JJ O
cells BC2GM045771943 NNS O
. BC2GM045771943 . O
. . O O

However BC2GM098918087 RB O
, BC2GM098918087 , O
in BC2GM098918087 IN O
transient BC2GM098918087 JJ O
transfection BC2GM098918087 NN O
assays BC2GM098918087 NNS O
, BC2GM098918087 , O
a BC2GM098918087 DT O
truncation BC2GM098918087 NN O
of BC2GM098918087 IN O
as BC2GM098918087 RB O
little BC2GM098918087 JJ O
as BC2GM098918087 IN O
15 BC2GM098918087 CD O
Nurr1 BC2GM098918087 NNP O
COOH-terminal BC2GM098918087 NNP O
amino BC2GM098918087 NN O
acids BC2GM098918087 NNS O
diminished BC2GM098918087 VBD O
transcriptional BC2GM098918087 JJ O
activation BC2GM098918087 NN O
of BC2GM098918087 IN O
B1A-thymidine BC2GM098918087 NNP O
kinase-chloramphenicol BC2GM098918087 JJ O
acetyltransferase BC2GM098918087 NN O
reporter BC2GM098918087 NN O
. BC2GM098918087 . O
. . O O

Previous BC2GM083254986 JJ O
analysis BC2GM083254986 NN O
of BC2GM083254986 IN O
this BC2GM083254986 DT O
motif BC2GM083254986 NN O
in BC2GM083254986 IN O
the BC2GM083254986 DT O
lactose BC2GM083254986 JJ O
permease BC2GM083254986 NN O
( BC2GM083254986 ( O
A BC2GM083254986 DT O
. BC2GM083254986 . O
. . O O

It BC2GM052310515 PRP O
is BC2GM052310515 VBZ O
believed BC2GM052310515 VBN O
that BC2GM052310515 IN O
the BC2GM052310515 DT O
operation BC2GM052310515 NN O
is BC2GM052310515 VBZ O
effective BC2GM052310515 JJ O
because BC2GM052310515 IN O
it BC2GM052310515 PRP O
cuts BC2GM052310515 VBZ O
the BC2GM052310515 DT O
spinothalamic BC2GM052310515 JJ O
tract BC2GM052310515 NN O
( BC2GM052310515 ( O
STT BC2GM052310515 NNP O
) BC2GM052310515 ) O
, BC2GM052310515 , O
a BC2GM052310515 DT O
primary BC2GM052310515 JJ O
pathway BC2GM052310515 NN O
carrying BC2GM052310515 VBG O
nociceptive BC2GM052310515 JJ O
information BC2GM052310515 NN O
from BC2GM052310515 IN O
the BC2GM052310515 DT O
spinal BC2GM052310515 JJ O
cord BC2GM052310515 NN O
to BC2GM052310515 TO O
the BC2GM052310515 DT O
brain BC2GM052310515 NN O
in BC2GM052310515 IN O
humans BC2GM052310515 NNS O
. BC2GM052310515 . O
. . O O

Their BC2GM090241856 PRP$ O
central BC2GM090241856 JJ O
projections BC2GM090241856 NNS O
were BC2GM090241856 VBD O
indistinguishable BC2GM090241856 JJ O
from BC2GM090241856 IN O
those BC2GM090241856 DT O
of BC2GM090241856 IN O
control BC2GM090241856 NN O
axons BC2GM090241856 NNS O
in BC2GM090241856 IN O
all BC2GM090241856 DT O
four BC2GM090241856 CD O
trigeminal BC2GM090241856 JJ O
subnuclei BC2GM090241856 NN O
. BC2GM090241856 . O
. . O O

In BC2GM018532054 IN O
addition BC2GM018532054 NN O
, BC2GM018532054 , O
reduced BC2GM018532054 VBD O
metabolism BC2GM018532054 NN O
to BC2GM018532054 TO O
cotinine BC2GM018532054 VB O
from BC2GM018532054 IN O
the BC2GM018532054 DT O
proliposomes BC2GM018532054 NNS O
and BC2GM018532054 CC O
MP BC2GM018532054 NNP O
was BC2GM018532054 VBD O
apparently BC2GM018532054 RB O
responsible BC2GM018532054 JJ O
for BC2GM018532054 IN O
the BC2GM018532054 DT O
sustained BC2GM018532054 JJ O
plasma BC2GM018532054 NN O
nicotine BC2GM018532054 NN O
levels BC2GM018532054 NNS O
. BC2GM018532054 . O
. . O O

Untransformed BC2GM039377977 VBN O
3T3 BC2GM039377977 CD O
cells BC2GM039377977 NNS O
carry BC2GM039377977 VBP O
abundant BC2GM039377977 JJ O
1.9 BC2GM039377977 CD O
kb BC2GM039377977 NN O
Hox BC2GM039377977 NNP O
1.3 BC2GM039377977 CD O
RNA BC2GM039377977 NNP O
, BC2GM039377977 , O
whereas BC2GM039377977 IN O
the BC2GM039377977 DT O
methylcholanthrene-transformed BC2GM039377977 JJ O
MB66 BC2GM039377977 NNP O
and BC2GM039377977 CC O
LTK- BC2GM039377977 NNP O
cells BC2GM039377977 NNS O
or BC2GM039377977 CC O
3T3 BC2GM039377977 CD O
cells BC2GM039377977 NNS O
transformed BC2GM039377977 VBN O
by BC2GM039377977 IN O
the BC2GM039377977 DT O
oncogenes BC2GM039377977 NNS O
src BC2GM039377977 NN O
, BC2GM039377977 , O
fos BC2GM039377977 NN O
or BC2GM039377977 CC O
SV40 BC2GM039377977 NNP O
T BC2GM039377977 NNP O
antigen BC2GM039377977 NN O
express BC2GM039377977 NN O
only BC2GM039377977 RB O
low BC2GM039377977 JJ O
levels BC2GM039377977 NNS O
. BC2GM039377977 . O
. . O O

Optimized BC2GM068969050 VBN O
USF BC2GM068969050 NNP O
and BC2GM068969050 CC O
MYC BC2GM068969050 NNP O
DNA-binding BC2GM068969050 NNP O
sites BC2GM068969050 NNS O
, BC2GM068969050 , O
which BC2GM068969050 WDT O
differ BC2GM068969050 VBP O
in BC2GM068969050 IN O
the BC2GM068969050 DT O
nucleotides BC2GM068969050 NNS O
bordering BC2GM068969050 VBG O
the BC2GM068969050 DT O
hexanucleotide BC2GM068969050 NN O
box BC2GM068969050 NN O
displace BC2GM068969050 VBP O
the BC2GM068969050 DT O
E-C4 BC2GM068969050 NNP O
factor BC2GM068969050 NN O
in BC2GM068969050 IN O
competition BC2GM068969050 NN O
assays BC2GM068969050 NNS O
but BC2GM068969050 CC O
with BC2GM068969050 IN O
lesser BC2GM068969050 JJR O
efficiency BC2GM068969050 NN O
than BC2GM068969050 IN O
the BC2GM068969050 DT O
E-C4 BC2GM068969050 NNP O
site BC2GM068969050 NN O
itself BC2GM068969050 PRP O
. BC2GM068969050 . O
. . O O

After BC2GM066584690 IN O
enzymatic BC2GM066584690 JJ O
hydrolysis BC2GM066584690 NN O
of BC2GM066584690 IN O
the BC2GM066584690 DT O
water BC2GM066584690 NN O
soluble BC2GM066584690 JJ O
fraction BC2GM066584690 NN O
, BC2GM066584690 , O
it BC2GM066584690 PRP O
is BC2GM066584690 VBZ O
shown BC2GM066584690 VBN O
that BC2GM066584690 IN O
28 BC2GM066584690 CD O
% BC2GM066584690 NN O
is BC2GM066584690 VBZ O
again BC2GM066584690 RB O
extractable BC2GM066584690 JJ O
by BC2GM066584690 IN O
DCM BC2GM066584690 NNP O
of BC2GM066584690 IN O
which BC2GM066584690 WDT O
57 BC2GM066584690 CD O
% BC2GM066584690 NN O
consists BC2GM066584690 VBZ O
of BC2GM066584690 IN O
unchanged BC2GM066584690 JJ O
SC4453 BC2GM066584690 NNP O
which BC2GM066584690 WDT O
is BC2GM066584690 VBZ O
therefore BC2GM066584690 IN O
the BC2GM066584690 DT O
main BC2GM066584690 JJ O
partner BC2GM066584690 NN O
of BC2GM066584690 IN O
conjugated BC2GM066584690 JJ O
products BC2GM066584690 NNS O
. BC2GM066584690 . O
. . O O

The BC2GM047538840 DT O
analysis BC2GM047538840 NN O
of BC2GM047538840 IN O
results BC2GM047538840 NNS O
suggests BC2GM047538840 VBZ O
that BC2GM047538840 IN O
seroprevalence BC2GM047538840 NN O
of BC2GM047538840 IN O
Lyme BC2GM047538840 NNP O
borreliosis BC2GM047538840 NN O
in BC2GM047538840 IN O
dogs BC2GM047538840 NNS O
of BC2GM047538840 IN O
the BC2GM047538840 DT O
Kosice BC2GM047538840 NNP O
region BC2GM047538840 NN O
is BC2GM047538840 VBZ O
not BC2GM047538840 RB O
negligible BC2GM047538840 JJ O
. BC2GM047538840 . O
. . O O

The BC2GM055315258 DT O
transition BC2GM055315258 NN O
from BC2GM055315258 IN O
expression BC2GM055315258 NN O
of BC2GM055315258 IN O
early BC2GM055315258 JJ O
meiotic BC2GM055315258 JJ O
genes BC2GM055315258 NNS O
to BC2GM055315258 TO O
expression BC2GM055315258 NN O
of BC2GM055315258 IN O
middle BC2GM055315258 JJ O
sporulation-specific BC2GM055315258 JJ O
genes BC2GM055315258 NNS O
occurs BC2GM055315258 NNS O
at BC2GM055315258 IN O
about BC2GM055315258 IN O
the BC2GM055315258 DT O
time BC2GM055315258 NN O
that BC2GM055315258 WDT O
cells BC2GM055315258 NNS O
exit BC2GM055315258 VBP O
from BC2GM055315258 IN O
pachytene BC2GM055315258 NN O
and BC2GM055315258 CC O
form BC2GM055315258 VB O
the BC2GM055315258 DT O
meiosis BC2GM055315258 NN O
I BC2GM055315258 PRP O
spindle BC2GM055315258 VBP O
. BC2GM055315258 . O
. . O O

Phenotypic BC2GM000008491 NNP O
analysis BC2GM000008491 NN O
demonstrates BC2GM000008491 VBZ O
that BC2GM000008491 IN O
trio BC2GM000008491 NN O
and BC2GM000008491 CC O
Abl BC2GM000008491 NNP O
cooperate BC2GM000008491 NN O
in BC2GM000008491 IN O
regulating BC2GM000008491 VBG O
axon BC2GM000008491 JJ O
outgrowth BC2GM000008491 NN O
in BC2GM000008491 IN O
the BC2GM000008491 DT O
embryonic BC2GM000008491 JJ O
central BC2GM000008491 JJ O
nervous BC2GM000008491 JJ O
system BC2GM000008491 NN O
( BC2GM000008491 ( O
CNS BC2GM000008491 NNP O
) BC2GM000008491 ) O
. BC2GM000008491 . O
. . O O

We BC2GM049661443 PRP O
found BC2GM049661443 VBD O
that BC2GM049661443 IN O
the BC2GM049661443 DT O
central BC2GM049661443 JJ O
nonconserved BC2GM049661443 JJ O
region BC2GM049661443 NN O
of BC2GM049661443 IN O
the BC2GM049661443 DT O
large BC2GM049661443 JJ O
subunit BC2GM049661443 NN O
is BC2GM049661443 VBZ O
not BC2GM049661443 RB O
essential BC2GM049661443 JJ O
for BC2GM049661443 IN O
function BC2GM049661443 NN O
and BC2GM049661443 CC O
likely BC2GM049661443 JJ O
acts BC2GM049661443 NNS O
as BC2GM049661443 IN O
a BC2GM049661443 DT O
spacer BC2GM049661443 NN O
between BC2GM049661443 IN O
the BC2GM049661443 DT O
conserved BC2GM049661443 VBN O
N- BC2GM049661443 NNP O
and BC2GM049661443 CC O
C-terminal BC2GM049661443 JJ O
regions BC2GM049661443 NNS O
. BC2GM049661443 . O
. . O O

We BC2GM042062377 PRP O
conclude BC2GM042062377 VBP O
that BC2GM042062377 IN O
although BC2GM042062377 IN O
the BC2GM042062377 DT O
G3 BC2GM042062377 NNP O
sequence BC2GM042062377 NN O
contains BC2GM042062377 VBZ O
two BC2GM042062377 CD O
protein-binding BC2GM042062377 JJ O
motifs BC2GM042062377 NNS O
, BC2GM042062377 , O
the BC2GM042062377 DT O
organization BC2GM042062377 NN O
of BC2GM042062377 IN O
the BC2GM042062377 DT O
G3 BC2GM042062377 NNP O
enhancer-like BC2GM042062377 JJ O
element BC2GM042062377 NN O
is BC2GM042062377 VBZ O
not BC2GM042062377 RB O
bipartite BC2GM042062377 JJ O
. BC2GM042062377 . O
. . O O

We BC2GM067565355 PRP O
concluded BC2GM067565355 VBD O
that BC2GM067565355 IN O
these BC2GM067565355 DT O
results BC2GM067565355 NNS O
support BC2GM067565355 VBD O
the BC2GM067565355 DT O
feasibility BC2GM067565355 NN O
and BC2GM067565355 CC O
usefulness BC2GM067565355 NN O
of BC2GM067565355 IN O
N-of-1 BC2GM067565355 NNP O
RCT BC2GM067565355 NNP O
in BC2GM067565355 IN O
rheumatology BC2GM067565355 NN O
practice BC2GM067565355 NN O
. BC2GM067565355 . O
. . O O

Sequences BC2GM013192574 NNS O
within BC2GM013192574 IN O
and BC2GM013192574 CC O
flanking BC2GM013192574 VBG O
hypersensitive BC2GM013192574 JJ O
sites BC2GM013192574 NNS O
3 BC2GM013192574 CD O
and BC2GM013192574 CC O
2 BC2GM013192574 CD O
of BC2GM013192574 IN O
the BC2GM013192574 DT O
beta-globin BC2GM013192574 JJ O
locus BC2GM013192574 NN O
control BC2GM013192574 NN O
region BC2GM013192574 NN O
required BC2GM013192574 VBN O
for BC2GM013192574 IN O
synergistic BC2GM013192574 JJ O
versus BC2GM013192574 NN O
additive BC2GM013192574 JJ O
interaction BC2GM013192574 NN O
with BC2GM013192574 IN O
the BC2GM013192574 DT O
epsilon-globin BC2GM013192574 JJ O
gene BC2GM013192574 NN O
promoter BC2GM013192574 NN O
. BC2GM013192574 . O
. . O O

We BC2GM003035581 PRP O
provided BC2GM003035581 VBD O
evidence BC2GM003035581 NN O
that BC2GM003035581 IN O
CaM BC2GM003035581 NNP O
kinase BC2GM003035581 NNP O
II BC2GM003035581 NNP O
played BC2GM003035581 VBD O
a BC2GM003035581 DT O
role BC2GM003035581 NN O
in BC2GM003035581 IN O
regulating BC2GM003035581 VBG O
neurite BC2GM003035581 JJ O
outgrowth BC2GM003035581 NN O
and BC2GM003035581 CC O
growth BC2GM003035581 NN O
cone BC2GM003035581 VBP O
motility BC2GM003035581 NN O
in BC2GM003035581 IN O
these BC2GM003035581 DT O
cells BC2GM003035581 NNS O
, BC2GM003035581 , O
and BC2GM003035581 CC O
that BC2GM003035581 IN O
the BC2GM003035581 DT O
autophosphorylation BC2GM003035581 NN O
is BC2GM003035581 VBZ O
essential BC2GM003035581 JJ O
for BC2GM003035581 IN O
the BC2GM003035581 DT O
kinase BC2GM003035581 NN O
to BC2GM003035581 TO O
sufficiently BC2GM003035581 RB O
exert BC2GM003035581 VB O
its BC2GM003035581 PRP$ O
cellular BC2GM003035581 JJ O
function BC2GM003035581 NN O
in BC2GM003035581 IN O
vivo BC2GM003035581 NN O
[ BC2GM003035581 NN O
Y BC2GM003035581 NNP O
. BC2GM003035581 . O
. . O O

Excess BC2GM067545009 NNP O
recombinant BC2GM067545009 JJ O
PTB BC2GM067545009 NNP O
squelches BC2GM067545009 VBZ O
the BC2GM067545009 DT O
splicing BC2GM067545009 NN O
switch BC2GM067545009 NN O
and BC2GM067545009 CC O
reestablishes BC2GM067545009 NNS O
exon BC2GM067545009 VBP O
skipping BC2GM067545009 VBG O
as BC2GM067545009 IN O
the BC2GM067545009 DT O
predominant BC2GM067545009 NN O
splicing BC2GM067545009 VBG O
pathway BC2GM067545009 NN O
. BC2GM067545009 . O
. . O O

Our BC2GM084545112 PRP$ O
results BC2GM084545112 NNS O
separate BC2GM084545112 JJ O
these BC2GM084545112 DT O
factors BC2GM084545112 NNS O
into BC2GM084545112 IN O
four BC2GM084545112 CD O
regulatory BC2GM084545112 JJ O
classes BC2GM084545112 NNS O
: BC2GM084545112 : O
( BC2GM084545112 ( O
i BC2GM084545112 NN O
) BC2GM084545112 ) O
constitutive BC2GM084545112 NN O
factors BC2GM084545112 NNS O
, BC2GM084545112 , O
such BC2GM084545112 JJ O
as BC2GM084545112 IN O
Oct-1 BC2GM084545112 NNP O
and BC2GM084545112 CC O
probably BC2GM084545112 RB O
Sp1 BC2GM084545112 NNP O
, BC2GM084545112 , O
that BC2GM084545112 WDT O
are BC2GM084545112 VBP O
expressed BC2GM084545112 VBN O
in BC2GM084545112 IN O
thymocytes BC2GM084545112 NNS O
at BC2GM084545112 IN O
all BC2GM084545112 DT O
stages BC2GM084545112 NNS O
; BC2GM084545112 : O
( BC2GM084545112 ( O
ii BC2GM084545112 NN O
) BC2GM084545112 ) O
inducible BC2GM084545112 JJ O
factors BC2GM084545112 NNS O
, BC2GM084545112 , O
such BC2GM084545112 JJ O
as BC2GM084545112 IN O
NF-kappa BC2GM084545112 NNP O
B BC2GM084545112 NNP O
and BC2GM084545112 CC O
complexes BC2GM084545112 NNS O
binding BC2GM084545112 VBG O
to BC2GM084545112 TO O
the BC2GM084545112 DT O
region BC2GM084545112 NN O
of BC2GM084545112 IN O
a BC2GM084545112 DT O
CD28 BC2GM084545112 NNP O
response BC2GM084545112 NN O
element BC2GM084545112 NN O
, BC2GM084545112 , O
that BC2GM084545112 WDT O
can BC2GM084545112 MD O
be BC2GM084545112 VB O
activated BC2GM084545112 VBN O
in BC2GM084545112 IN O
all BC2GM084545112 DT O
thymocytes BC2GM084545112 NNS O
, BC2GM084545112 , O
including BC2GM084545112 VBG O
those BC2GM084545112 DT O
cells BC2GM084545112 NNS O
( BC2GM084545112 ( O
CD4+ BC2GM084545112 NNP O
CD8+ BC2GM084545112 NNP O
TcRlow BC2GM084545112 NNP O
) BC2GM084545112 ) O
that BC2GM084545112 WDT O
can BC2GM084545112 MD O
undergo BC2GM084545112 VB O
selection BC2GM084545112 NN O
; BC2GM084545112 : O
( BC2GM084545112 ( O
iii BC2GM084545112 NN O
) BC2GM084545112 ) O
inducible BC2GM084545112 JJ O
factors BC2GM084545112 NNS O
, BC2GM084545112 , O
such BC2GM084545112 JJ O
as BC2GM084545112 IN O
NF-AT BC2GM084545112 NNP O
and BC2GM084545112 CC O
AP-1 BC2GM084545112 NNP O
, BC2GM084545112 , O
that BC2GM084545112 WDT O
can BC2GM084545112 MD O
be BC2GM084545112 VB O
activated BC2GM084545112 VBN O
in BC2GM084545112 IN O
mature BC2GM084545112 NN O
( BC2GM084545112 ( O
CD4+ BC2GM084545112 NNP O
CD8- BC2GM084545112 NNP O
TcRhigh BC2GM084545112 NNP O
) BC2GM084545112 ) O
and BC2GM084545112 CC O
immature BC2GM084545112 NN O
( BC2GM084545112 ( O
CD4- BC2GM084545112 JJ O
CD8- BC2GM084545112 NNP O
TcR- BC2GM084545112 NNP O
) BC2GM084545112 ) O
thymocytes BC2GM084545112 VBZ O
alike BC2GM084545112 RB O
but BC2GM084545112 CC O
not BC2GM084545112 RB O
in BC2GM084545112 IN O
the BC2GM084545112 DT O
transitional BC2GM084545112 JJ O
stages BC2GM084545112 NNS O
when BC2GM084545112 WRB O
the BC2GM084545112 DT O
cells BC2GM084545112 NNS O
( BC2GM084545112 ( O
CD4+ BC2GM084545112 NNP O
CD8+ BC2GM084545112 NNP O
TcRlow BC2GM084545112 NNP O
) BC2GM084545112 ) O
are BC2GM084545112 VBP O
subject BC2GM084545112 JJ O
to BC2GM084545112 TO O
selection BC2GM084545112 NN O
; BC2GM084545112 : O
and BC2GM084545112 CC O
( BC2GM084545112 ( O
iv BC2GM084545112 NN O
) BC2GM084545112 ) O
a BC2GM084545112 DT O
factor BC2GM084545112 NN O
containing BC2GM084545112 VBG O
CREB BC2GM084545112 NNP O
, BC2GM084545112 , O
which BC2GM084545112 WDT O
can BC2GM084545112 MD O
be BC2GM084545112 VB O
activated BC2GM084545112 VBN O
in BC2GM084545112 IN O
thymocytes BC2GM084545112 NNS O
of BC2GM084545112 IN O
all BC2GM084545112 DT O
developmental BC2GM084545112 JJ O
stages BC2GM084545112 NNS O
by BC2GM084545112 IN O
culture BC2GM084545112 NN O
but BC2GM084545112 CC O
does BC2GM084545112 VBZ O
not BC2GM084545112 RB O
require BC2GM084545112 VB O
specific BC2GM084545112 JJ O
induction BC2GM084545112 NN O
. BC2GM084545112 . O
. . O O

Our BC2GM021392794 PRP$ O
data BC2GM021392794 NNS O
define BC2GM021392794 NN O
Ile BC2GM021392794 NNP O
( BC2GM021392794 ( O
16 BC2GM021392794 CD O
) BC2GM021392794 ) O
, BC2GM021392794 , O
Val BC2GM021392794 NNP O
( BC2GM021392794 ( O
18 BC2GM021392794 CD O
) BC2GM021392794 ) O
, BC2GM021392794 , O
Val BC2GM021392794 NNP O
( BC2GM021392794 ( O
31 BC2GM021392794 CD O
) BC2GM021392794 ) O
, BC2GM021392794 , O
and BC2GM021392794 CC O
Ile BC2GM021392794 NNP O
( BC2GM021392794 ( O
33 BC2GM021392794 CD O
) BC2GM021392794 ) O
as BC2GM021392794 IN O
crucial BC2GM021392794 NN O
for BC2GM021392794 IN O
protein BC2GM021392794 NN O
S BC2GM021392794 NNP O
binding BC2GM021392794 NN O
, BC2GM021392794 , O
with BC2GM021392794 IN O
secondary BC2GM021392794 JJ O
effects BC2GM021392794 NNS O
from BC2GM021392794 IN O
Leu BC2GM021392794 NNP O
( BC2GM021392794 ( O
38 BC2GM021392794 CD O
) BC2GM021392794 ) O
and BC2GM021392794 CC O
Val BC2GM021392794 NNP O
( BC2GM021392794 ( O
39 BC2GM021392794 CD O
) BC2GM021392794 ) O
. BC2GM021392794 . O
. . O O

Northern BC2GM018375556 NNP O
blot BC2GM018375556 NN O
analysis BC2GM018375556 NN O
indicated BC2GM018375556 VBD O
that BC2GM018375556 IN O
both BC2GM018375556 DT O
human BC2GM018375556 JJ O
and BC2GM018375556 CC O
murine BC2GM018375556 JJ O
genes BC2GM018375556 NNS O
encode BC2GM018375556 VBP O
approximately BC2GM018375556 RB O
6-kb BC2GM018375556 JJ O
transcripts BC2GM018375556 NNS O
. BC2GM018375556 . O
. . O O

Fas BC2GM039968036 NNP O
( BC2GM039968036 ( O
APO-1 BC2GM039968036 NNP O
/ BC2GM039968036 NNP O
CD95 BC2GM039968036 NNP O
) BC2GM039968036 ) O
, BC2GM039968036 , O
which BC2GM039968036 WDT O
is BC2GM039968036 VBZ O
a BC2GM039968036 DT O
member BC2GM039968036 NN O
of BC2GM039968036 IN O
the BC2GM039968036 DT O
tumor BC2GM039968036 NN O
necrosis BC2GM039968036 NN O
factor BC2GM039968036 NN O
receptor BC2GM039968036 NN O
superfamily BC2GM039968036 RB O
, BC2GM039968036 , O
is BC2GM039968036 VBZ O
a BC2GM039968036 DT O
cell BC2GM039968036 NN O
surface BC2GM039968036 NN O
receptor BC2GM039968036 NN O
that BC2GM039968036 WDT O
induces BC2GM039968036 VBZ O
apoptosis BC2GM039968036 NN O
. BC2GM039968036 . O
. . O O

Dominant-negative BC2GM025928081 JJ O
upf1 BC2GM025928081 JJ O
mutations BC2GM025928081 NNS O
were BC2GM025928081 VBD O
isolated BC2GM025928081 VBN O
following BC2GM025928081 VBG O
in BC2GM025928081 IN O
vitro BC2GM025928081 JJ O
mutagenesis BC2GM025928081 NN O
of BC2GM025928081 IN O
a BC2GM025928081 DT O
plasmid BC2GM025928081 NN O
containing BC2GM025928081 VBG O
the BC2GM025928081 DT O
UPF1 BC2GM025928081 NNP O
gene BC2GM025928081 NN O
. BC2GM025928081 . O
. . O O

The BC2GM043163295 DT O
deduced BC2GM043163295 JJ O
amino BC2GM043163295 NN O
acid BC2GM043163295 JJ O
sequence BC2GM043163295 NN O
of BC2GM043163295 IN O
PutR BC2GM043163295 NNP O
( BC2GM043163295 ( O
154 BC2GM043163295 CD O
amino BC2GM043163295 NN O
acid BC2GM043163295 NN O
residues BC2GM043163295 NNS O
) BC2GM043163295 ) O
showed BC2GM043163295 VBD O
homology BC2GM043163295 NN O
to BC2GM043163295 TO O
the BC2GM043163295 DT O
small BC2GM043163295 JJ O
regulatory BC2GM043163295 JJ O
proteins BC2GM043163295 NNS O
Lrp BC2GM043163295 NNP O
, BC2GM043163295 , O
BkdR BC2GM043163295 NNP O
, BC2GM043163295 , O
and BC2GM043163295 CC O
AsnC BC2GM043163295 NNP O
. BC2GM043163295 . O
. . O O

RESULTS BC2GM094089829 NN O
: BC2GM094089829 : O
Of BC2GM094089829 IN O
10,709,701 BC2GM094089829 CD O
chemistry BC2GM094089829 NN O
specimens BC2GM094089829 NNS O
submitted BC2GM094089829 VBN O
to BC2GM094089829 TO O
the BC2GM094089829 DT O
participating BC2GM094089829 VBG O
laboratories BC2GM094089829 NNS O
during BC2GM094089829 IN O
the BC2GM094089829 DT O
data BC2GM094089829 NNS O
collection BC2GM094089829 NN O
period BC2GM094089829 NN O
, BC2GM094089829 , O
37,208 BC2GM094089829 CD O
( BC2GM094089829 ( O
0.35 BC2GM094089829 CD O
% BC2GM094089829 NN O
) BC2GM094089829 ) O
were BC2GM094089829 VBD O
rejected BC2GM094089829 VBN O
prior BC2GM094089829 RB O
to BC2GM094089829 TO O
testing BC2GM094089829 VBG O
. BC2GM094089829 . O
. . O O

PKK BC2GM099213570 NNP O
exists BC2GM099213570 VBZ O
in BC2GM099213570 IN O
three BC2GM099213570 CD O
discernible BC2GM099213570 JJ O
forms BC2GM099213570 NNS O
at BC2GM099213570 IN O
steady BC2GM099213570 JJ O
state BC2GM099213570 NN O
: BC2GM099213570 : O
an BC2GM099213570 DT O
underphosphorylated BC2GM099213570 JJ O
form BC2GM099213570 NN O
of BC2GM099213570 IN O
100 BC2GM099213570 CD O
kDa BC2GM099213570 NNS O
; BC2GM099213570 : O
a BC2GM099213570 DT O
soluble BC2GM099213570 JJ O
, BC2GM099213570 , O
cytosolic BC2GM099213570 JJ O
, BC2GM099213570 , O
phosphorylated BC2GM099213570 JJ O
form BC2GM099213570 NN O
of BC2GM099213570 IN O
110 BC2GM099213570 CD O
kDa BC2GM099213570 NN O
; BC2GM099213570 : O
and BC2GM099213570 CC O
a BC2GM099213570 DT O
phosphorylated BC2GM099213570 JJ O
, BC2GM099213570 , O
detergent-insoluble BC2GM099213570 JJ O
form BC2GM099213570 NN O
of BC2GM099213570 IN O
112 BC2GM099213570 CD O
kDa BC2GM099213570 NNS O
. BC2GM099213570 . O
. . O O

CONCLUSIONS BC2GM053864470 NN O
: BC2GM053864470 : O
These BC2GM053864470 DT O
results BC2GM053864470 NNS O
suggest BC2GM053864470 VBP O
that BC2GM053864470 IN O
histamine-2 BC2GM053864470 JJ O
receptor BC2GM053864470 NN O
activation BC2GM053864470 NN O
mechanisms BC2GM053864470 NNS O
may BC2GM053864470 MD O
not BC2GM053864470 RB O
be BC2GM053864470 VB O
involved BC2GM053864470 VBN O
in BC2GM053864470 IN O
postoperative BC2GM053864470 JJ O
IL-6 BC2GM053864470 JJ O
synthesis BC2GM053864470 NN O
. BC2GM053864470 . O
. . O O

DNase BC2GM068132437 NNP O
I BC2GM068132437 PRP O
protection BC2GM068132437 NN O
analysis BC2GM068132437 NN O
as BC2GM068132437 RB O
well BC2GM068132437 RB O
as BC2GM068132437 IN O
oligonucleotide BC2GM068132437 JJ O
competition BC2GM068132437 NN O
experiments BC2GM068132437 NNS O
indicate BC2GM068132437 VBP O
that BC2GM068132437 IN O
this BC2GM068132437 DT O
binding BC2GM068132437 NN O
is BC2GM068132437 VBZ O
sequence BC2GM068132437 JJ O
specific BC2GM068132437 JJ O
. BC2GM068132437 . O
. . O O

Childbirth BC2GM020549068 NN O
and BC2GM020549068 CC O
authoritative BC2GM020549068 JJ O
knowledge BC2GM020549068 NN O
. BC2GM020549068 . O
. . O O

Expression BC2GM072261734 NN O
of BC2GM072261734 IN O
a BC2GM072261734 DT O
cDNA BC2GM072261734 NN O
clone BC2GM072261734 NN O
in BC2GM072261734 IN O
yeast BC2GM072261734 NN O
containing BC2GM072261734 VBG O
a BC2GM072261734 DT O
large BC2GM072261734 JJ O
portion BC2GM072261734 NN O
of BC2GM072261734 IN O
the BC2GM072261734 DT O
open BC2GM072261734 JJ O
reading BC2GM072261734 NN O
frame BC2GM072261734 NN O
produced BC2GM072261734 VBD O
cAMP BC2GM072261734 JJ O
PDEase BC2GM072261734 NNP O
activity BC2GM072261734 NN O
identical BC2GM072261734 NN O
in BC2GM072261734 IN O
properties BC2GM072261734 NNS O
to BC2GM072261734 TO O
the BC2GM072261734 DT O
Drosophila BC2GM072261734 NNP O
enzyme BC2GM072261734 NN O
affected BC2GM072261734 VBN O
by BC2GM072261734 IN O
the BC2GM072261734 DT O
dnc BC2GM072261734 JJ O
mutation BC2GM072261734 NN O
. BC2GM072261734 . O
. . O O

As BC2GM022014688 IN O
to BC2GM022014688 TO O
the BC2GM022014688 DT O
side BC2GM022014688 NN O
effects BC2GM022014688 NNS O
of BC2GM022014688 IN O
SISO BC2GM022014688 NNP O
, BC2GM022014688 , O
cylindruria BC2GM022014688 NN O
with BC2GM022014688 IN O
aggravation BC2GM022014688 NN O
of BC2GM022014688 IN O
microscopic BC2GM022014688 NN O
hematuria BC2GM022014688 NN O
and BC2GM022014688 CC O
elevations BC2GM022014688 NNS O
of BC2GM022014688 IN O
GOT BC2GM022014688 NNP O
, BC2GM022014688 , O
GPT BC2GM022014688 NNP O
and BC2GM022014688 CC O
A1-P BC2GM022014688 NNP O
were BC2GM022014688 VBD O
observed BC2GM022014688 VBN O
each BC2GM022014688 DT O
one BC2GM022014688 CD O
of BC2GM022014688 IN O
them BC2GM022014688 PRP O
, BC2GM022014688 , O
respectively BC2GM022014688 RB O
. BC2GM022014688 . O
. . O O

In BC2GM083904809 IN O
addition BC2GM083904809 NN O
, BC2GM083904809 , O
there BC2GM083904809 EX O
was BC2GM083904809 VBD O
an BC2GM083904809 DT O
increase BC2GM083904809 NN O
in BC2GM083904809 IN O
the BC2GM083904809 DT O
amount BC2GM083904809 NN O
of BC2GM083904809 IN O
p120 BC2GM083904809 JJ O
Ras-specific BC2GM083904809 JJ O
GTPase-activating BC2GM083904809 JJ O
protein BC2GM083904809 NN O
( BC2GM083904809 ( O
GAP BC2GM083904809 NNP O
) BC2GM083904809 ) O
and BC2GM083904809 CC O
GAP-associated BC2GM083904809 JJ O
p190 BC2GM083904809 NN O
. BC2GM083904809 . O
. . O O

In BC2GM049887251 IN O
cells BC2GM049887251 NNS O
stably BC2GM049887251 RB O
transfected BC2GM049887251 VBD O
with BC2GM049887251 IN O
G BC2GM049887251 NNP O
alpha BC2GM049887251 VBP O
i-2 BC2GM049887251 NN O
or BC2GM049887251 CC O
G BC2GM049887251 NNP O
alpha BC2GM049887251 IN O
i-3 BC2GM049887251 JJ O
gene BC2GM049887251 NN O
5'-flanking BC2GM049887251 JJ O
sequences BC2GM049887251 NNS O
fused BC2GM049887251 VBN O
to BC2GM049887251 TO O
firefly BC2GM049887251 VB O
luciferase BC2GM049887251 JJ O
cDNA BC2GM049887251 NN O
reporter BC2GM049887251 NN O
, BC2GM049887251 , O
temporal BC2GM049887251 JJ O
10-15-fold BC2GM049887251 JJ O
transcriptional BC2GM049887251 JJ O
activation BC2GM049887251 NN O
of BC2GM049887251 IN O
both BC2GM049887251 DT O
genes BC2GM049887251 NNS O
occurred BC2GM049887251 VBD O
before BC2GM049887251 IN O
cellular BC2GM049887251 JJ O
polarization BC2GM049887251 NN O
. BC2GM049887251 . O
. . O O

The BC2GM031365198 DT O
Xenopus BC2GM031365198 NNP O
homeobox BC2GM031365198 NN O
gene BC2GM031365198 NN O
twin BC2GM031365198 VBP O
mediates BC2GM031365198 NNS O
Wnt BC2GM031365198 NNP O
induction BC2GM031365198 NN O
of BC2GM031365198 IN O
goosecoid BC2GM031365198 NN O
in BC2GM031365198 IN O
establishment BC2GM031365198 NN O
of BC2GM031365198 IN O
Spemann BC2GM031365198 NNP O
's BC2GM031365198 POS O
organizer BC2GM031365198 NN O
. BC2GM031365198 . O
. . O O

OAT BC2GM086069469 NNP O
has BC2GM086069469 VBZ O
become BC2GM086069469 VBN O
safer BC2GM086069469 NN O
in BC2GM086069469 IN O
recent BC2GM086069469 JJ O
years BC2GM086069469 NNS O
, BC2GM086069469 , O
particularly BC2GM086069469 RB O
if BC2GM086069469 IN O
monitored BC2GM086069469 VBN O
in BC2GM086069469 IN O
special BC2GM086069469 JJ O
anticoagulation BC2GM086069469 NN O
clinics BC2GM086069469 NNS O
. BC2GM086069469 . O
. . O O

Activation BC2GM064814479 NN O
of BC2GM064814479 IN O
the BC2GM064814479 DT O
cytotactin BC2GM064814479 NN O
promoter BC2GM064814479 NN O
by BC2GM064814479 IN O
the BC2GM064814479 DT O
homeobox-containing BC2GM064814479 JJ O
gene BC2GM064814479 NN O
Evx-1 BC2GM064814479 NNP O
. BC2GM064814479 . O
. . O O

Progestins BC2GM045793760 NNS O
: BC2GM045793760 : O
present BC2GM045793760 NN O
and BC2GM045793760 CC O
future BC2GM045793760 NN O
. BC2GM045793760 . O
. . O O

Thirty-five BC2GM000843512 JJ O
pts BC2GM000843512 NNS O
were BC2GM000843512 VBD O
transplanted BC2GM000843512 VBN O
for BC2GM000843512 IN O
constitutional BC2GM000843512 JJ O
disease BC2GM000843512 NN O
: BC2GM000843512 : O
Fanconi BC2GM000843512 NNP O
anemia BC2GM000843512 NN O
( BC2GM000843512 ( O
FA BC2GM000843512 NNP O
) BC2GM000843512 ) O
( BC2GM000843512 ( O
26 BC2GM000843512 CD O
pts BC2GM000843512 NNS O
) BC2GM000843512 ) O
, BC2GM000843512 , O
Dyskeratosis BC2GM000843512 NNP O
congenita BC2GM000843512 NN O
( BC2GM000843512 ( O
2 BC2GM000843512 CD O
pts BC2GM000843512 NNS O
) BC2GM000843512 ) O
, BC2GM000843512 , O
Blackfan-Diamond BC2GM000843512 NNP O
erythroblastopenia BC2GM000843512 NN O
( BC2GM000843512 ( O
2 BC2GM000843512 CD O
pts BC2GM000843512 NNS O
) BC2GM000843512 ) O
, BC2GM000843512 , O
Glanzmann BC2GM000843512 NNP O
thrombasthenia BC2GM000843512 NNP O
( BC2GM000843512 ( O
1 BC2GM000843512 CD O
pt BC2GM000843512 NN O
) BC2GM000843512 ) O
, BC2GM000843512 , O
osteopetrosis BC2GM000843512 NN O
( BC2GM000843512 ( O
1 BC2GM000843512 CD O
pt BC2GM000843512 NN O
) BC2GM000843512 ) O
and BC2GM000843512 CC O
Gaucher BC2GM000843512 NNP O
's BC2GM000843512 POS O
disease BC2GM000843512 NN O
( BC2GM000843512 ( O
1 BC2GM000843512 CD O
pt BC2GM000843512 NN O
) BC2GM000843512 ) O
. BC2GM000843512 . O
. . O O

Deoxyuridine-suppression BC2GM040247589 JJ O
test BC2GM040247589 NN O
and BC2GM040247589 CC O
bone BC2GM040247589 NN O
marrow BC2GM040247589 NN O
culture BC2GM040247589 NN O
for BC2GM040247589 IN O
the BC2GM040247589 DT O
diagnosis BC2GM040247589 NN O
of BC2GM040247589 IN O
macrocytic BC2GM040247589 JJ O
refractory BC2GM040247589 NN O
anaemias BC2GM040247589 NN O
. BC2GM040247589 . O
. . O O

Meq BC2GM095655624 NNP O
/ BC2GM095655624 NNP O
c-Jun BC2GM095655624 JJ O
heterodimers BC2GM095655624 NNS O
bind BC2GM095655624 VBP O
to BC2GM095655624 TO O
an BC2GM095655624 DT O
AP1-like BC2GM095655624 JJ O
sequence BC2GM095655624 NN O
in BC2GM095655624 IN O
the BC2GM095655624 DT O
meq BC2GM095655624 NN O
promoter BC2GM095655624 NN O
region BC2GM095655624 NN O
with BC2GM095655624 IN O
an BC2GM095655624 DT O
affinity BC2GM095655624 NN O
much BC2GM095655624 RB O
greater BC2GM095655624 JJR O
than BC2GM095655624 IN O
that BC2GM095655624 DT O
of BC2GM095655624 IN O
Meq BC2GM095655624 NNP O
/ BC2GM095655624 NNP O
Meq BC2GM095655624 NNP O
or BC2GM095655624 CC O
c-Jun BC2GM095655624 JJ O
/ BC2GM095655624 JJ O
c-Jun BC2GM095655624 JJ O
homodimers BC2GM095655624 NNS O
. BC2GM095655624 . O
. . O O

From BC2GM020218379 IN O
our BC2GM020218379 PRP$ O
own BC2GM020218379 JJ O
investigations BC2GM020218379 NNS O
on BC2GM020218379 IN O
phantoms BC2GM020218379 NNS O
, BC2GM020218379 , O
the BC2GM020218379 DT O
smallest BC2GM020218379 JJS O
signal-to-noise BC2GM020218379 JJ O
ratio BC2GM020218379 NN O
( BC2GM020218379 ( O
delta BC2GM020218379 JJ O
S BC2GM020218379 NNP O
min BC2GM020218379 NN O
/ BC2GM020218379 NNP O
delta BC2GM020218379 NN O
R BC2GM020218379 NNP O
) BC2GM020218379 ) O
was BC2GM020218379 VBD O
obtained BC2GM020218379 VBN O
which BC2GM020218379 WDT O
determines BC2GM020218379 VBZ O
the BC2GM020218379 DT O
minimal BC2GM020218379 JJ O
contrast BC2GM020218379 NN O
, BC2GM020218379 , O
given BC2GM020218379 VBN O
the BC2GM020218379 DT O
film BC2GM020218379 NN O
properties BC2GM020218379 NNS O
( BC2GM020218379 ( O
film BC2GM020218379 NN O
response BC2GM020218379 NN O
S BC2GM020218379 NNP O
, BC2GM020218379 , O
film BC2GM020218379 NN O
gradient BC2GM020218379 NN O
gamma BC2GM020218379 NN O
) BC2GM020218379 ) O
and BC2GM020218379 CC O
the BC2GM020218379 DT O
amount BC2GM020218379 NN O
of BC2GM020218379 IN O
scatter BC2GM020218379 NN O
. BC2GM020218379 . O
. . O O

We BC2GM070452664 PRP O
compared BC2GM070452664 VBN O
retrospectively BC2GM070452664 RB O
the BC2GM070452664 DT O
efficacy BC2GM070452664 NN O
of BC2GM070452664 IN O
granulocyte BC2GM070452664 NN O
colony BC2GM070452664 NN O
stimulating BC2GM070452664 VBG O
factor BC2GM070452664 NN O
( BC2GM070452664 ( O
G-CSF BC2GM070452664 NNP O
) BC2GM070452664 ) O
alone BC2GM070452664 RB O
with BC2GM070452664 IN O
chemotherapy BC2GM070452664 JJ O
plus BC2GM070452664 CC O
G-CSF BC2GM070452664 NNP O
in BC2GM070452664 IN O
mobilizing BC2GM070452664 VBG O
CD34-positive BC2GM070452664 JJ O
cells BC2GM070452664 NNS O
in BC2GM070452664 IN O
patients BC2GM070452664 NNS O
with BC2GM070452664 IN O
malignant BC2GM070452664 JJ O
lymphoma BC2GM070452664 NN O
. BC2GM070452664 . O
. . O O

The BC2GM005932533 DT O
NH BC2GM005932533 NNP O
( BC2GM005932533 ( O
2 BC2GM005932533 CD O
) BC2GM005932533 ) O
-terminus BC2GM005932533 NN O
of BC2GM005932533 IN O
all BC2GM005932533 DT O
three BC2GM005932533 CD O
proteins BC2GM005932533 NNS O
contains BC2GM005932533 VBZ O
a BC2GM005932533 DT O
POZ BC2GM005932533 NNP O
domain BC2GM005932533 NN O
, BC2GM005932533 , O
a BC2GM005932533 DT O
conserved BC2GM005932533 JJ O
120 BC2GM005932533 CD O
amino BC2GM005932533 NN O
acid BC2GM005932533 NN O
motif BC2GM005932533 NN O
involved BC2GM005932533 VBN O
in BC2GM005932533 IN O
transcriptional BC2GM005932533 JJ O
repression BC2GM005932533 NN O
and BC2GM005932533 CC O
protein BC2GM005932533 JJ O
dimerization BC2GM005932533 NN O
. BC2GM005932533 . O
. . O O

This BC2GM053648425 DT O
study BC2GM053648425 NN O
demonstrates BC2GM053648425 VBZ O
a BC2GM053648425 DT O
novel BC2GM053648425 JJ O
link BC2GM053648425 NN O
between BC2GM053648425 IN O
alterations BC2GM053648425 NNS O
in BC2GM053648425 IN O
platelet-derived BC2GM053648425 JJ O
growth BC2GM053648425 NN O
factor BC2GM053648425 NN O
( BC2GM053648425 ( O
PDGF BC2GM053648425 NNP O
) BC2GM053648425 ) O
regulation BC2GM053648425 NN O
of BC2GM053648425 IN O
ornithine BC2GM053648425 JJ O
decarboxylase BC2GM053648425 NN O
( BC2GM053648425 ( O
ODC BC2GM053648425 NNP O
) BC2GM053648425 ) O
expression BC2GM053648425 NN O
during BC2GM053648425 IN O
malignant BC2GM053648425 JJ O
conversion BC2GM053648425 NN O
. BC2GM053648425 . O
. . O O

The BC2GM041754029 DT O
preparative BC2GM041754029 JJ O
regimen BC2GM041754029 NNS O
consisted BC2GM041754029 VBD O
of BC2GM041754029 IN O
fractionated BC2GM041754029 JJ O
total BC2GM041754029 JJ O
body BC2GM041754029 NN O
irradiation BC2GM041754029 NN O
( BC2GM041754029 ( O
TBI BC2GM041754029 NNP O
) BC2GM041754029 ) O
and BC2GM041754029 CC O
cyclophosphamide BC2GM041754029 NN O
( BC2GM041754029 ( O
CY BC2GM041754029 NNP O
) BC2GM041754029 ) O
. BC2GM041754029 . O
. . O O

The BC2GM012988556 DT O
chicken BC2GM012988556 NN O
genome BC2GM012988556 NN O
contains BC2GM012988556 VBZ O
two BC2GM012988556 CD O
functional BC2GM012988556 JJ O
nonallelic BC2GM012988556 JJ O
beta1,4-galactosyltransferase BC2GM012988556 NN O
genes BC2GM012988556 NNS O
. BC2GM012988556 . O
. . O O

The BC2GM017503197 DT O
highest BC2GM017503197 JJS O
incidence BC2GM017503197 NN O
was BC2GM017503197 VBD O
observed BC2GM017503197 VBN O
for BC2GM017503197 IN O
V. BC2GM017503197 NNP O
alginolyticus BC2GM017503197 NN O
( BC2GM017503197 ( O
92-100 BC2GM017503197 CD O
% BC2GM017503197 NN O
) BC2GM017503197 ) O
, BC2GM017503197 , O
followed BC2GM017503197 VBN O
by BC2GM017503197 IN O
V. BC2GM017503197 NNP O
parahaemolyticus BC2GM017503197 NN O
( BC2GM017503197 ( O
67-92 BC2GM017503197 CD O
% BC2GM017503197 NN O
) BC2GM017503197 ) O
, BC2GM017503197 , O
V. BC2GM017503197 NNP O
fluvialis BC2GM017503197 NN O
( BC2GM017503197 ( O
34-67 BC2GM017503197 CD O
% BC2GM017503197 NN O
) BC2GM017503197 ) O
, BC2GM017503197 , O
V. BC2GM017503197 NNP O
vulnificus BC2GM017503197 NN O
( BC2GM017503197 ( O
8-17 BC2GM017503197 CD O
% BC2GM017503197 NN O
) BC2GM017503197 ) O
, BC2GM017503197 , O
V. BC2GM017503197 NNP O
furnissii BC2GM017503197 NN O
( BC2GM017503197 ( O
0-17 BC2GM017503197 CD O
% BC2GM017503197 NN O
) BC2GM017503197 ) O
, BC2GM017503197 , O
V. BC2GM017503197 NNP O
mimicus BC2GM017503197 NN O
( BC2GM017503197 ( O
0-17 BC2GM017503197 CD O
% BC2GM017503197 NN O
) BC2GM017503197 ) O
and BC2GM017503197 CC O
V. BC2GM017503197 NNP O
cholerae BC2GM017503197 VBP O
non-O1 BC2GM017503197 JJ O
( BC2GM017503197 ( O
0-8 BC2GM017503197 CD O
% BC2GM017503197 NN O
) BC2GM017503197 ) O
. BC2GM017503197 . O
. . O O

Pretreatment BC2GM066240715 NN O
of BC2GM066240715 IN O
human BC2GM066240715 JJ O
skin BC2GM066240715 NN O
with BC2GM066240715 IN O
tRA BC2GM066240715 NN O
inhibited BC2GM066240715 VBN O
UV BC2GM066240715 NNP O
induction BC2GM066240715 NN O
of BC2GM066240715 IN O
c-Jun BC2GM066240715 JJ O
protein BC2GM066240715 NN O
and BC2GM066240715 CC O
, BC2GM066240715 , O
consequently BC2GM066240715 RB O
, BC2GM066240715 , O
AP-1 BC2GM066240715 NNP O
. BC2GM066240715 . O
c-Jun BC2GM066240715 JJ O
protein BC2GM066240715 NN O
inhibition BC2GM066240715 NN O
occurred BC2GM066240715 VBD O
via BC2GM066240715 IN O
a BC2GM066240715 DT O
posttranscriptional BC2GM066240715 JJ O
mechanism BC2GM066240715 NN O
, BC2GM066240715 , O
since BC2GM066240715 IN O
tRA BC2GM066240715 NN O
did BC2GM066240715 VBD O
not BC2GM066240715 RB O
inhibit BC2GM066240715 VB O
UV BC2GM066240715 NNP O
induction BC2GM066240715 NN O
of BC2GM066240715 IN O
c-Jun BC2GM066240715 JJ O
mRNA BC2GM066240715 NN O
. BC2GM066240715 . O
. . O O

Henry BC2GM032718257 NNP O
Quastler BC2GM032718257 NNP O
brought BC2GM032718257 VBD O
experience BC2GM032718257 NN O
from BC2GM032718257 IN O
an BC2GM032718257 DT O
actual BC2GM032718257 JJ O
x-ray BC2GM032718257 NN O
treatment BC2GM032718257 NN O
, BC2GM032718257 , O
and BC2GM032718257 CC O
Dr BC2GM032718257 NNP O
. BC2GM032718257 . O
. . O O

The BC2GM019113426 DT O
M-phase BC2GM019113426 NNP O
induction BC2GM019113426 NN O
activity BC2GM019113426 NN O
of BC2GM019113426 IN O
Cdc2-Cdc13 BC2GM019113426 NNP O
is BC2GM019113426 VBZ O
inhibited BC2GM019113426 VBN O
by BC2GM019113426 IN O
Wee1 BC2GM019113426 NNP O
tyrosine BC2GM019113426 NN O
kinase BC2GM019113426 NN O
, BC2GM019113426 , O
which BC2GM019113426 WDT O
phosphorylates BC2GM019113426 VBZ O
Cdc2 BC2GM019113426 NNP O
on BC2GM019113426 IN O
tyrosine-15 BC2GM019113426 NN O
. BC2GM019113426 . O
. . O O

We BC2GM084642529 PRP O
have BC2GM084642529 VBP O
used BC2GM084642529 VBN O
systemic BC2GM084642529 JJ O
application BC2GM084642529 NN O
of BC2GM084642529 IN O
the BC2GM084642529 DT O
ototoxic BC2GM084642529 JJ O
drug BC2GM084642529 NN O
amikacin BC2GM084642529 NN O
, BC2GM084642529 , O
to BC2GM084642529 TO O
induce BC2GM084642529 VB O
total BC2GM084642529 JJ O
cochlear BC2GM084642529 NN O
haircell BC2GM084642529 NN O
loss BC2GM084642529 NN O
in BC2GM084642529 IN O
the BC2GM084642529 DT O
chinchilla BC2GM084642529 NN O
, BC2GM084642529 , O
in BC2GM084642529 IN O
order BC2GM084642529 NN O
to BC2GM084642529 TO O
create BC2GM084642529 VB O
an BC2GM084642529 DT O
animal BC2GM084642529 JJ O
model BC2GM084642529 NN O
of BC2GM084642529 IN O
profound BC2GM084642529 JJ O
deafness BC2GM084642529 NN O
. BC2GM084642529 . O
. . O O

Suspected BC2GM058205876 VBN O
pelvic BC2GM058205876 JJ O
endometriosis BC2GM058205876 NN O
was BC2GM058205876 VBD O
prospectively BC2GM058205876 RB O
evaluated BC2GM058205876 VBN O
in BC2GM058205876 IN O
31 BC2GM058205876 CD O
women BC2GM058205876 NNS O
with BC2GM058205876 IN O
T1- BC2GM058205876 NNP O
and BC2GM058205876 CC O
T2-weighted BC2GM058205876 JJ O
conventional BC2GM058205876 JJ O
spin-echo BC2GM058205876 NN O
( BC2GM058205876 ( O
CSE BC2GM058205876 NNP O
) BC2GM058205876 ) O
magnetic BC2GM058205876 JJ O
resonance BC2GM058205876 NN O
imaging BC2GM058205876 VBG O
alone BC2GM058205876 RB O
and BC2GM058205876 CC O
in BC2GM058205876 IN O
combination BC2GM058205876 NN O
with BC2GM058205876 IN O
T1-weighted BC2GM058205876 JJ O
fat-suppressed BC2GM058205876 JJ O
( BC2GM058205876 ( O
T1FS BC2GM058205876 NNP O
) BC2GM058205876 ) O
and BC2GM058205876 CC O
gadolinium-enhanced BC2GM058205876 JJ O
T1FS BC2GM058205876 NNP O
( BC2GM058205876 ( O
Gd-T1FS BC2GM058205876 NNP O
) BC2GM058205876 ) O
spin-echo BC2GM058205876 NN O
techniques BC2GM058205876 NNS O
. BC2GM058205876 . O
. . O O

Scalp BC2GM053252394 NNP O
blood BC2GM053252394 NN O
flow BC2GM053252394 NN O
was BC2GM053252394 VBD O
recorded BC2GM053252394 VBN O
by BC2GM053252394 IN O
a BC2GM053252394 DT O
laser BC2GM053252394 NN O
Doppler BC2GM053252394 NNP O
flow BC2GM053252394 NN O
sensor BC2GM053252394 NN O
that BC2GM053252394 WDT O
was BC2GM053252394 VBD O
incorporated BC2GM053252394 VBN O
in BC2GM053252394 IN O
the BC2GM053252394 DT O
transcutaneous BC2GM053252394 JJ O
PO2 BC2GM053252394 NNP O
electrode BC2GM053252394 NN O
. BC2GM053252394 . O
. . O O

Mortality BC2GM035733626 NN O
rates BC2GM035733626 NNS O
were BC2GM035733626 VBD O
not BC2GM035733626 RB O
different BC2GM035733626 JJ O
( BC2GM035733626 ( O
chi2 BC2GM035733626 NN O
: BC2GM035733626 : O
0.0298 BC2GM035733626 CD O
, BC2GM035733626 , O
p BC2GM035733626 NN O
> BC2GM035733626 NNP O
0.5 BC2GM035733626 CD O
) BC2GM035733626 ) O
. BC2GM035733626 . O
. . O O

Such BC2GM052589330 JJ O
unique BC2GM052589330 JJ O
recognition BC2GM052589330 NN O
capabilities BC2GM052589330 NNS O
are BC2GM052589330 VBP O
generated BC2GM052589330 VBN O
with BC2GM052589330 IN O
minimal BC2GM052589330 JJ O
alterations BC2GM052589330 NNS O
in BC2GM052589330 IN O
the BC2GM052589330 DT O
CDR3 BC2GM052589330 NNP O
loops BC2GM052589330 NNS O
of BC2GM052589330 IN O
the BC2GM052589330 DT O
TCR BC2GM052589330 NNP O
. BC2GM052589330 . O
. . O O

The BC2GM099774129 DT O
only BC2GM099774129 JJ O
quantities BC2GM099774129 NNS O
which BC2GM099774129 WDT O
were BC2GM099774129 VBD O
significantly BC2GM099774129 RB O
different BC2GM099774129 JJ O
between BC2GM099774129 IN O
appendicitis BC2GM099774129 NN O
and BC2GM099774129 CC O
a BC2GM099774129 DT O
normal BC2GM099774129 JJ O
appendix BC2GM099774129 NN O
were BC2GM099774129 VBD O
sex BC2GM099774129 NN O
, BC2GM099774129 , O
duration BC2GM099774129 NN O
of BC2GM099774129 IN O
symptoms BC2GM099774129 NNS O
, BC2GM099774129 , O
anorexia BC2GM099774129 NN O
and BC2GM099774129 CC O
vomiting BC2GM099774129 NN O
. BC2GM099774129 . O
. . O O

Fig1p BC2GM055422231 NNP O
and BC2GM055422231 CC O
Fig2p BC2GM055422231 NNP O
are BC2GM055422231 VBP O
likely BC2GM055422231 JJ O
to BC2GM055422231 TO O
act BC2GM055422231 VB O
at BC2GM055422231 IN O
the BC2GM055422231 DT O
cell BC2GM055422231 NN O
surface BC2GM055422231 NN O
as BC2GM055422231 IN O
Fig1 BC2GM055422231 NN O
: BC2GM055422231 : O
: BC2GM055422231 : O
beta-gal BC2GM055422231 JJ O
and BC2GM055422231 CC O
Fig2 BC2GM055422231 NNP O
: BC2GM055422231 : O
:beta-gal BC2GM055422231 JJ O
fusion BC2GM055422231 NN O
proteins BC2GM055422231 NNS O
localize BC2GM055422231 VBP O
to BC2GM055422231 TO O
the BC2GM055422231 DT O
periphery BC2GM055422231 NN O
of BC2GM055422231 IN O
mating BC2GM055422231 VBG O
cells BC2GM055422231 NNS O
. BC2GM055422231 . O
. . O O

Because BC2GM054534012 IN O
c-myb BC2GM054534012 JJ O
encodes BC2GM054534012 NNS O
a BC2GM054534012 DT O
transcriptional BC2GM054534012 JJ O
activator BC2GM054534012 NN O
that BC2GM054534012 IN O
functions BC2GM054534012 NNS O
via BC2GM054534012 IN O
DNA BC2GM054534012 NNP O
binding BC2GM054534012 NN O
, BC2GM054534012 , O
it BC2GM054534012 PRP O
is BC2GM054534012 VBZ O
likely BC2GM054534012 JJ O
that BC2GM054534012 IN O
c-myb BC2GM054534012 JJ O
exerts BC2GM054534012 NNS O
its BC2GM054534012 PRP$ O
biological BC2GM054534012 JJ O
activity BC2GM054534012 NN O
by BC2GM054534012 IN O
regulating BC2GM054534012 VBG O
the BC2GM054534012 DT O
transcription BC2GM054534012 NN O
of BC2GM054534012 IN O
genes BC2GM054534012 NNS O
required BC2GM054534012 VBN O
for BC2GM054534012 IN O
DNA BC2GM054534012 NNP O
synthesis BC2GM054534012 NN O
and BC2GM054534012 CC O
cell BC2GM054534012 NN O
cycle BC2GM054534012 NN O
progression BC2GM054534012 NN O
. BC2GM054534012 . O
. . O O

While BC2GM047215943 IN O
some BC2GM047215943 DT O
still BC2GM047215943 RB O
automatically BC2GM047215943 RB O
refuse BC2GM047215943 VB O
all BC2GM047215943 DT O
patients BC2GM047215943 NNS O
with BC2GM047215943 IN O
positive BC2GM047215943 JJ O
mediastinoscopy BC2GM047215943 NN O
, BC2GM047215943 , O
most BC2GM047215943 JJS O
authors BC2GM047215943 NNS O
still BC2GM047215943 RB O
remain BC2GM047215943 VBP O
very BC2GM047215943 RB O
interventionistic BC2GM047215943 JJ O
for BC2GM047215943 IN O
N2 BC2GM047215943 NNP O
patients BC2GM047215943 NNS O
selected BC2GM047215943 VBN O
on BC2GM047215943 IN O
very BC2GM047215943 RB O
accurate BC2GM047215943 JJ O
criteria BC2GM047215943 NNS O
that BC2GM047215943 WDT O
are BC2GM047215943 VBP O
analyzed BC2GM047215943 VBN O
above BC2GM047215943 IN O
. BC2GM047215943 . O
. . O O

In BC2GM071046961 IN O
the BC2GM071046961 DT O
present BC2GM071046961 JJ O
study BC2GM071046961 NN O
, BC2GM071046961 , O
we BC2GM071046961 PRP O
report BC2GM071046961 VBP O
the BC2GM071046961 DT O
entire BC2GM071046961 JJ O
genomic BC2GM071046961 JJ O
structure BC2GM071046961 NN O
of BC2GM071046961 IN O
KCNQ1 BC2GM071046961 NNP O
, BC2GM071046961 , O
which BC2GM071046961 WDT O
consists BC2GM071046961 VBZ O
of BC2GM071046961 IN O
19 BC2GM071046961 CD O
exons BC2GM071046961 NNS O
spanning BC2GM071046961 VBG O
400 BC2GM071046961 CD O
kb BC2GM071046961 NN O
on BC2GM071046961 IN O
chromosome BC2GM071046961 NN O
11p15.5 BC2GM071046961 CD O
. BC2GM071046961 . O
. . O O

The BC2GM010599540 DT O
mutation BC2GM010599540 NN O
also BC2GM010599540 RB O
preferentially BC2GM010599540 RB O
limits BC2GM010599540 NNS O
( BC2GM010599540 ( O
compared BC2GM010599540 VBN O
with BC2GM010599540 IN O
total BC2GM010599540 JJ O
protein BC2GM010599540 JJ O
synthesis BC2GM010599540 NN O
) BC2GM010599540 ) O
translation BC2GM010599540 NN O
of BC2GM010599540 IN O
an BC2GM010599540 DT O
induced BC2GM010599540 JJ O
gene BC2GM010599540 NN O
that BC2GM010599540 WDT O
depends BC2GM010599540 VBZ O
on BC2GM010599540 IN O
five BC2GM010599540 CD O
AGA BC2GM010599540 NNP O
codons BC2GM010599540 NNS O
, BC2GM010599540 , O
i.e. BC2GM010599540 NN O
, BC2GM010599540 , O
the BC2GM010599540 DT O
lambda BC2GM010599540 NN O
cI BC2GM010599540 NN O
repressor BC2GM010599540 NN O
gene BC2GM010599540 NN O
. BC2GM010599540 . O
. . O O

Sequence BC2GM015726285 NNP O
analysis BC2GM015726285 NN O
of BC2GM015726285 IN O
this BC2GM015726285 DT O
region BC2GM015726285 NN O
showed BC2GM015726285 VBD O
it BC2GM015726285 PRP O
contained BC2GM015726285 VBD O
five BC2GM015726285 CD O
potential BC2GM015726285 JJ O
copies BC2GM015726285 NNS O
of BC2GM015726285 IN O
the BC2GM015726285 DT O
sterol BC2GM015726285 NN O
regulatory BC2GM015726285 JJ O
element BC2GM015726285 NN O
( BC2GM015726285 ( O
SRE-1 BC2GM015726285 NNP O
) BC2GM015726285 ) O
( BC2GM015726285 ( O
Smith BC2GM015726285 NNP O
, BC2GM015726285 , O
J.R. BC2GM015726285 NNP O
, BC2GM015726285 , O
Osborne BC2GM015726285 NNP O
, BC2GM015726285 , O
T.F. BC2GM015726285 NNP O
, BC2GM015726285 , O
Brown BC2GM015726285 NNP O
, BC2GM015726285 , O
M.S. BC2GM015726285 NNP O
, BC2GM015726285 , O
Goldstein BC2GM015726285 NNP O
, BC2GM015726285 , O
J.L. BC2GM015726285 NNP O
, BC2GM015726285 , O
and BC2GM015726285 CC O
Gil BC2GM015726285 NNP O
, BC2GM015726285 , O
G BC2GM015726285 NNP O
. BC2GM015726285 . O
. . O O

CONCLUSIONS BC2GM080426101 NN O
: BC2GM080426101 : O
The BC2GM080426101 DT O
present BC2GM080426101 JJ O
study BC2GM080426101 NN O
showed BC2GM080426101 VBD O
it BC2GM080426101 PRP O
is BC2GM080426101 VBZ O
possible BC2GM080426101 JJ O
to BC2GM080426101 TO O
use BC2GM080426101 VB O
a BC2GM080426101 DT O
modified BC2GM080426101 JJ O
Stroop BC2GM080426101 NNP O
task BC2GM080426101 NN O
as BC2GM080426101 IN O
a BC2GM080426101 DT O
measure BC2GM080426101 NN O
of BC2GM080426101 IN O
implicit BC2GM080426101 JJ O
processing BC2GM080426101 NN O
of BC2GM080426101 IN O
alcohol BC2GM080426101 NN O
stimuli BC2GM080426101 NN O
. BC2GM080426101 . O
. . O O

The BC2GM054696358 DT O
second BC2GM054696358 JJ O
patient BC2GM054696358 NN O
was BC2GM054696358 VBD O
successfully BC2GM054696358 RB O
treated BC2GM054696358 VBN O
with BC2GM054696358 IN O
intravenous BC2GM054696358 JJ O
prostaglandin BC2GM054696358 NNS O
F2 BC2GM054696358 NNP O
alpha BC2GM054696358 NN O
( BC2GM054696358 ( O
PGF2 BC2GM054696358 NNP O
alpha BC2GM054696358 RB O
) BC2GM054696358 ) O
. BC2GM054696358 . O
. . O O

Electrophoretic BC2GM083693291 JJ O
mobility BC2GM083693291 NN O
shift BC2GM083693291 NN O
assays BC2GM083693291 NNS O
demonstrated BC2GM083693291 VBD O
that BC2GM083693291 IN O
sequences BC2GM083693291 NNS O
within BC2GM083693291 IN O
this BC2GM083693291 DT O
region BC2GM083693291 NN O
bind BC2GM083693291 IN O
members BC2GM083693291 NNS O
of BC2GM083693291 IN O
the BC2GM083693291 DT O
Sp1 BC2GM083693291 NNP O
family BC2GM083693291 NN O
of BC2GM083693291 IN O
transcription BC2GM083693291 NN O
factors BC2GM083693291 NNS O
. BC2GM083693291 . O
. . O O

Replacement BC2GM074670492 NN O
of BC2GM074670492 IN O
a BC2GM074670492 DT O
valine BC2GM074670492 NN O
( BC2GM074670492 ( O
V68 BC2GM074670492 NNP O
) BC2GM074670492 ) O
in BC2GM074670492 IN O
the BC2GM074670492 DT O
ETS BC2GM074670492 NNP O
domain BC2GM074670492 NN O
of BC2GM074670492 IN O
SAP1a BC2GM074670492 NNP O
by BC2GM074670492 IN O
aspartic BC2GM074670492 JJ O
acid BC2GM074670492 NN O
( BC2GM074670492 ( O
as BC2GM074670492 IN O
found BC2GM074670492 VBN O
in BC2GM074670492 IN O
c-Ets-1 BC2GM074670492 JJ O
, BC2GM074670492 , O
Elk-1 BC2GM074670492 NNP O
, BC2GM074670492 , O
and BC2GM074670492 CC O
Net BC2GM074670492 NNP O
) BC2GM074670492 ) O
enhanced BC2GM074670492 VBD O
ternary BC2GM074670492 JJ O
complex BC2GM074670492 JJ O
formation BC2GM074670492 NN O
by BC2GM074670492 IN O
more BC2GM074670492 JJR O
than BC2GM074670492 IN O
60-fold BC2GM074670492 JJ O
. BC2GM074670492 . O
. . O O

Alfalfa BC2GM040147994 NNP O
phosphorus BC2GM040147994 NN O
release BC2GM040147994 NN O
kinetics BC2GM040147994 NNS O
showed BC2GM040147994 VBD O
high BC2GM040147994 JJ O
bacterial BC2GM040147994 JJ O
phosphorus BC2GM040147994 NN O
contamination BC2GM040147994 NN O
. BC2GM040147994 . O
. . O O

Activated BC2GM028564481 VBN O
Ki-Ras BC2GM028564481 JJ O
suppresses BC2GM028564481 NNS O
12-O-tetradecanoylphorbol-13-acetate-induced BC2GM028564481 JJ O
activation BC2GM028564481 NN O
of BC2GM028564481 IN O
the BC2GM028564481 DT O
c-Jun BC2GM028564481 JJ O
NH2-terminal BC2GM028564481 JJ O
kinase BC2GM028564481 NN O
pathway BC2GM028564481 NN O
in BC2GM028564481 IN O
human BC2GM028564481 JJ O
colon BC2GM028564481 NN O
cancer BC2GM028564481 NN O
cells BC2GM028564481 NNS O
. BC2GM028564481 . O
. . O O

DDD BC2GM007835217 NNP O
( BC2GM007835217 ( O
R BC2GM007835217 NNP O
) BC2GM007835217 ) O
pacing BC2GM007835217 VBG O
with BC2GM007835217 IN O
automatic BC2GM007835217 JJ O
mode BC2GM007835217 NN O
switch BC2GM007835217 NN O
in BC2GM007835217 IN O
patients BC2GM007835217 NNS O
with BC2GM007835217 IN O
paroxysmal BC2GM007835217 JJ O
atrial BC2GM007835217 JJ O
fibrillation BC2GM007835217 NN O
following BC2GM007835217 VBG O
AV BC2GM007835217 NNP O
nodal BC2GM007835217 JJ O
ablation BC2GM007835217 NN O
. BC2GM007835217 . O
. . O O

To BC2GM097372131 TO O
examine BC2GM097372131 VB O
the BC2GM097372131 DT O
functional BC2GM097372131 JJ O
relationship BC2GM097372131 NN O
between BC2GM097372131 IN O
distinct BC2GM097372131 JJ O
cis-active BC2GM097372131 JJ O
elements BC2GM097372131 NNS O
within BC2GM097372131 IN O
the BC2GM097372131 DT O
distal BC2GM097372131 JJ O
enhancer BC2GM097372131 JJ O
region BC2GM097372131 NN O
of BC2GM097372131 IN O
the BC2GM097372131 DT O
rat BC2GM097372131 NN O
PRL BC2GM097372131 NNP O
gene BC2GM097372131 NN O
, BC2GM097372131 , O
we BC2GM097372131 PRP O
have BC2GM097372131 VBP O
used BC2GM097372131 VBN O
deletional BC2GM097372131 JJ O
and BC2GM097372131 CC O
mutational BC2GM097372131 JJ O
analysis BC2GM097372131 NN O
of BC2GM097372131 IN O
that BC2GM097372131 DT O
region BC2GM097372131 NN O
in BC2GM097372131 IN O
transient BC2GM097372131 JJ O
transfection BC2GM097372131 NN O
studies BC2GM097372131 NNS O
in BC2GM097372131 IN O
GH3 BC2GM097372131 NNP O
pituitary BC2GM097372131 JJ O
tumor BC2GM097372131 NN O
cells BC2GM097372131 NNS O
. BC2GM097372131 . O
. . O O

The BC2GM076417003 DT O
non-major BC2GM076417003 JJ O
histocompatibility BC2GM076417003 NN O
complex BC2GM076417003 NN O
( BC2GM076417003 ( O
MHC BC2GM076417003 NNP O
) BC2GM076417003 ) O
-encoded BC2GM076417003 VBD O
CD1 BC2GM076417003 NNP O
family BC2GM076417003 NN O
has BC2GM076417003 VBZ O
recently BC2GM076417003 RB O
emerged BC2GM076417003 VBN O
as BC2GM076417003 IN O
a BC2GM076417003 DT O
new BC2GM076417003 JJ O
antigen-presenting BC2GM076417003 JJ O
system BC2GM076417003 NN O
that BC2GM076417003 WDT O
is BC2GM076417003 VBZ O
distinct BC2GM076417003 JJ O
from BC2GM076417003 IN O
either BC2GM076417003 DT O
MHC BC2GM076417003 NNP O
class BC2GM076417003 NN O
I BC2GM076417003 PRP O
or BC2GM076417003 CC O
class BC2GM076417003 NN O
II BC2GM076417003 NNP O
molecules BC2GM076417003 NNS O
. BC2GM076417003 . O
. . O O

We BC2GM064715787 PRP O
also BC2GM064715787 RB O
show BC2GM064715787 VBP O
that BC2GM064715787 IN O
psbH BC2GM064715787 NN O
and BC2GM064715787 CC O
psbT BC2GM064715787 NN O
are BC2GM064715787 VBP O
transcribed BC2GM064715787 VBN O
from BC2GM064715787 IN O
the BC2GM064715787 DT O
upstream BC2GM064715787 JJ O
psbB BC2GM064715787 NN O
gene BC2GM064715787 NN O
promoter BC2GM064715787 NN O
, BC2GM064715787 , O
and BC2GM064715787 CC O
that BC2GM064715787 IN O
the BC2GM064715787 DT O
psbH BC2GM064715787 NN O
mRNA BC2GM064715787 NN O
has BC2GM064715787 VBZ O
its BC2GM064715787 PRP$ O
own BC2GM064715787 JJ O
target BC2GM064715787 NN O
sequence BC2GM064715787 NN O
for BC2GM064715787 IN O
Mbb1 BC2GM064715787 NNP O
function BC2GM064715787 NN O
. BC2GM064715787 . O
. . O O

E.R.C.P BC2GM016797236 NNP O
. BC2GM016797236 . O
is BC2GM016797236 VBZ O
an BC2GM016797236 DT O
important BC2GM016797236 JJ O
advance BC2GM016797236 NN O
in BC2GM016797236 IN O
diagnosis BC2GM016797236 NN O
. BC2GM016797236 . O
. . O O

Desarrollo BC2GM063573521 NNP O
de BC2GM063573521 FW O
un BC2GM063573521 FW O
modelo BC2GM063573521 FW O
matematico BC2GM063573521 FW O
general BC2GM063573521 JJ O
para BC2GM063573521 NN O
los BC2GM063573521 NN O
procesos BC2GM063573521 NN O
fermentativos BC2GM063573521 NN O
, BC2GM063573521 , O
Cinetica BC2GM063573521 NNP O
de BC2GM063573521 NNP O
la BC2GM063573521 FW O
degradacion BC2GM063573521 NN O
anaerobia BC2GM063573521 NN O
, BC2GM063573521 , O
Ph.D BC2GM063573521 NNP O
. BC2GM063573521 . O
. . O O

Studies BC2GM086734097 NNS O
on BC2GM086734097 IN O
low-dose BC2GM086734097 JJ O
oral BC2GM086734097 JJ O
contraceptives BC2GM086734097 NNS O
: BC2GM086734097 : O
cervical BC2GM086734097 JJ O
mucus BC2GM086734097 NN O
and BC2GM086734097 CC O
plasma BC2GM086734097 VB O
hormone BC2GM086734097 NN O
changes BC2GM086734097 NNS O
in BC2GM086734097 IN O
relation BC2GM086734097 NN O
to BC2GM086734097 TO O
circulating BC2GM086734097 VBG O
D-norgestrel BC2GM086734097 NNP O
and BC2GM086734097 CC O
17alpha BC2GM086734097 CD O
ethynyl-estradiol BC2GM086734097 JJ O
concentrations BC2GM086734097 NNS O
. BC2GM086734097 . O
. . O O

Preface BC2GM026423593 NN O
and BC2GM026423593 CC O
acknowledgements BC2GM026423593 NNS O
. BC2GM026423593 . O
. . O O

Collectively BC2GM019293265 RB O
, BC2GM019293265 , O
a BC2GM019293265 DT O
unique BC2GM019293265 JJ O
mechanism BC2GM019293265 NN O
involving BC2GM019293265 VBG O
NF-ATp BC2GM019293265 NNP O
appears BC2GM019293265 VBZ O
to BC2GM019293265 TO O
regulate BC2GM019293265 VB O
the BC2GM019293265 DT O
cell BC2GM019293265 NN O
type-specific BC2GM019293265 JJ O
and BC2GM019293265 CC O
activation-dependent BC2GM019293265 JJ O
expression BC2GM019293265 NN O
of BC2GM019293265 IN O
the BC2GM019293265 DT O
SCM-1 BC2GM019293265 NNP O
genes BC2GM019293265 NNS O
. BC2GM019293265 . O
. . O O

187-200 BC2GM053682759 CD O
. BC2GM053682759 . O
. . O O

The BC2GM045967019 DT O
expected BC2GM045967019 JJ O
products BC2GM045967019 NNS O
of BC2GM045967019 IN O
the BC2GM045967019 DT O
cloned BC2GM045967019 JJ O
bph BC2GM045967019 NN O
genes BC2GM045967019 NNS O
, BC2GM045967019 , O
except BC2GM045967019 IN O
bphA3 BC2GM045967019 NN O
, BC2GM045967019 , O
were BC2GM045967019 VBD O
observed BC2GM045967019 VBN O
in BC2GM045967019 IN O
E. BC2GM045967019 NNP O
coli BC2GM045967019 NNS O
in BC2GM045967019 IN O
an BC2GM045967019 DT O
in BC2GM045967019 IN O
vitro BC2GM045967019 JJ O
transcription-translation BC2GM045967019 NN O
system BC2GM045967019 NN O
. BC2GM045967019 . O
. . O O

Natl BC2GM020185752 NNP O
. BC2GM020185752 . O
. . O O

Influence BC2GM087700709 NN O
of BC2GM087700709 IN O
long-term BC2GM087700709 JJ O
zimelidine BC2GM087700709 NN O
treatment BC2GM087700709 NN O
on BC2GM087700709 IN O
LSD-induced BC2GM087700709 NNP O
behavioural BC2GM087700709 JJ O
effects BC2GM087700709 NNS O
. BC2GM087700709 . O
. . O O

The BC2GM012129841 DT O
introduction BC2GM012129841 NN O
of BC2GM012129841 IN O
FWD1 BC2GM012129841 NNP O
into BC2GM012129841 IN O
cells BC2GM012129841 NNS O
significantly BC2GM012129841 RB O
promotes BC2GM012129841 VBZ O
ubiquitination BC2GM012129841 NN O
and BC2GM012129841 CC O
degradation BC2GM012129841 NN O
of BC2GM012129841 IN O
IkappaBalpha BC2GM012129841 NNP O
in BC2GM012129841 IN O
concert BC2GM012129841 NN O
with BC2GM012129841 IN O
IkappaB BC2GM012129841 NNP O
kinases BC2GM012129841 NNS O
, BC2GM012129841 , O
resulting BC2GM012129841 VBG O
in BC2GM012129841 IN O
nuclear BC2GM012129841 JJ O
translocation BC2GM012129841 NN O
of BC2GM012129841 IN O
NF-kappaB BC2GM012129841 NNP O
. BC2GM012129841 . O
. . O O

A BC2GM074262156 DT O
mammalian BC2GM074262156 JJ O
protein BC2GM074262156 NN O
called BC2GM074262156 VBN O
RFX BC2GM074262156 NNP O
or BC2GM074262156 CC O
NF-X BC2GM074262156 NNP O
binds BC2GM074262156 NNS O
to BC2GM074262156 TO O
the BC2GM074262156 DT O
X BC2GM074262156 NNP O
box BC2GM074262156 NN O
( BC2GM074262156 ( O
or BC2GM074262156 CC O
X1 BC2GM074262156 NNP O
box BC2GM074262156 NN O
) BC2GM074262156 ) O
in BC2GM074262156 IN O
the BC2GM074262156 DT O
promoters BC2GM074262156 NNS O
of BC2GM074262156 IN O
a BC2GM074262156 DT O
number BC2GM074262156 NN O
of BC2GM074262156 IN O
major BC2GM074262156 JJ O
histocompatibility BC2GM074262156 NN O
( BC2GM074262156 ( O
MHC BC2GM074262156 NNP O
) BC2GM074262156 ) O
class BC2GM074262156 NN O
II BC2GM074262156 NNP O
genes BC2GM074262156 NNS O
. BC2GM074262156 . O
. . O O

Like BC2GM051345201 IN O
pimethixene BC2GM051345201 NN O
and BC2GM051345201 CC O
cyproheptadine BC2GM051345201 NN O
, BC2GM051345201 , O
WA BC2GM051345201 NNP O
335 BC2GM051345201 CD O
has BC2GM051345201 VBZ O
no BC2GM051345201 DT O
distinct BC2GM051345201 JJ O
antagonistic BC2GM051345201 JJ O
qualities BC2GM051345201 NNS O
against BC2GM051345201 IN O
bradykinin BC2GM051345201 NN O
. BC2GM051345201 . O
. . O O

Because BC2GM007219216 IN O
of BC2GM007219216 IN O
the BC2GM007219216 DT O
structural BC2GM007219216 JJ O
similarities BC2GM007219216 NNS O
the BC2GM007219216 DT O
new BC2GM007219216 JJ O
gene BC2GM007219216 NN O
will BC2GM007219216 MD O
be BC2GM007219216 VB O
termed BC2GM007219216 VBN O
scERV2 BC2GM007219216 JJ O
from BC2GM007219216 IN O
now BC2GM007219216 RB O
on BC2GM007219216 IN O
. BC2GM007219216 . O
. . O O

From BC2GM020389288 IN O
the BC2GM020389288 DT O
supposition BC2GM020389288 NN O
that BC2GM020389288 IN O
there BC2GM020389288 EX O
exists BC2GM020389288 VBZ O
a BC2GM020389288 DT O
possible BC2GM020389288 JJ O
connection BC2GM020389288 NN O
between BC2GM020389288 IN O
certain BC2GM020389288 JJ O
psychopathological BC2GM020389288 JJ O
symptoms BC2GM020389288 NNS O
, BC2GM020389288 , O
and BC2GM020389288 CC O
/ BC2GM020389288 NNP O
or BC2GM020389288 CC O
syndromes BC2GM020389288 NNS O
( BC2GM020389288 ( O
e.g. BC2GM020389288 NN O
, BC2GM020389288 , O
hallucinations BC2GM020389288 NNS O
) BC2GM020389288 ) O
and BC2GM020389288 CC O
regional BC2GM020389288 JJ O
cerebral BC2GM020389288 JJ O
dysfunction BC2GM020389288 NN O
, BC2GM020389288 , O
patients BC2GM020389288 NNS O
suffering BC2GM020389288 VBG O
from BC2GM020389288 IN O
auditory BC2GM020389288 NN O
and BC2GM020389288 CC O
tactile BC2GM020389288 JJ O
hallucinations BC2GM020389288 NNS O
were BC2GM020389288 VBD O
investigated BC2GM020389288 VBN O
, BC2GM020389288 , O
in BC2GM020389288 IN O
a BC2GM020389288 DT O
symptom-oriented BC2GM020389288 JJ O
study BC2GM020389288 NN O
, BC2GM020389288 , O
using BC2GM020389288 VBG O
the BC2GM020389288 DT O
method BC2GM020389288 NN O
of BC2GM020389288 IN O
technetium-99m-Hexamethyl-propylenamine BC2GM020389288 JJ O
Oxime BC2GM020389288 NNP O
( BC2GM020389288 ( O
99m-Tc-HMPAO BC2GM020389288 CD O
) BC2GM020389288 ) O
-Single BC2GM020389288 FW O
Photon BC2GM020389288 NNP O
Emission BC2GM020389288 NNP O
Computed BC2GM020389288 NNP O
Tomography BC2GM020389288 NNP O
( BC2GM020389288 ( O
SPECT BC2GM020389288 NNP O
) BC2GM020389288 ) O
and BC2GM020389288 CC O
compared BC2GM020389288 VBN O
with BC2GM020389288 IN O
normal BC2GM020389288 JJ O
controls BC2GM020389288 NNS O
. BC2GM020389288 . O
. . O O

Using BC2GM044666504 VBG O
unidirectional BC2GM044666504 JJ O
PCR BC2GM044666504 NNP O
we BC2GM044666504 PRP O
isolated BC2GM044666504 VBD O
a BC2GM044666504 DT O
361-bp BC2GM044666504 JJ O
5 BC2GM044666504 CD O
' BC2GM044666504 POS O
promoter BC2GM044666504 NN O
region BC2GM044666504 NN O
and BC2GM044666504 CC O
delineated BC2GM044666504 VBD O
the BC2GM044666504 DT O
intronic BC2GM044666504 JJ O
/ BC2GM044666504 NNP O
exonic BC2GM044666504 NN O
boundaries BC2GM044666504 NNS O
which BC2GM044666504 WDT O
include BC2GM044666504 VBP O
a BC2GM044666504 DT O
non-coding BC2GM044666504 JJ O
exon BC2GM044666504 NN O
1 BC2GM044666504 CD O
, BC2GM044666504 , O
a BC2GM044666504 DT O
single BC2GM044666504 JJ O
intron BC2GM044666504 NN O
, BC2GM044666504 , O
and BC2GM044666504 CC O
a BC2GM044666504 DT O
coding BC2GM044666504 NN O
exon BC2GM044666504 NN O
2 BC2GM044666504 CD O
, BC2GM044666504 , O
a BC2GM044666504 DT O
structure BC2GM044666504 NN O
that BC2GM044666504 WDT O
is BC2GM044666504 VBZ O
typical BC2GM044666504 JJ O
of BC2GM044666504 IN O
genes BC2GM044666504 NNS O
of BC2GM044666504 IN O
the BC2GM044666504 DT O
RNase BC2GM044666504 NNP O
A BC2GM044666504 NNP O
superfamily BC2GM044666504 RB O
. BC2GM044666504 . O
. . O O

This BC2GM096948473 DT O
result BC2GM096948473 NN O
, BC2GM096948473 , O
together BC2GM096948473 RB O
with BC2GM096948473 IN O
the BC2GM096948473 DT O
fact BC2GM096948473 NN O
that BC2GM096948473 IN O
unrearranged BC2GM096948473 VBD O
V BC2GM096948473 NNP O
kappa BC2GM096948473 NNP O
genes BC2GM096948473 NNS O
are BC2GM096948473 VBP O
transcriptionally BC2GM096948473 RB O
silent BC2GM096948473 JJ O
, BC2GM096948473 , O
suggests BC2GM096948473 VBZ O
that BC2GM096948473 IN O
structural BC2GM096948473 JJ O
features BC2GM096948473 NNS O
of BC2GM096948473 IN O
both BC2GM096948473 DT O
the BC2GM096948473 DT O
V BC2GM096948473 NNP O
kappa BC2GM096948473 NN O
and BC2GM096948473 CC O
C BC2GM096948473 NNP O
kappa BC2GM096948473 NNP O
loci BC2GM096948473 VBZ O
contribute BC2GM096948473 NN O
to BC2GM096948473 TO O
the BC2GM096948473 DT O
overall BC2GM096948473 JJ O
transcriptional BC2GM096948473 JJ O
efficiency BC2GM096948473 NN O
of BC2GM096948473 IN O
a BC2GM096948473 DT O
rearranged BC2GM096948473 JJ O
V BC2GM096948473 NNP O
kappa-C BC2GM096948473 NN O
kappa BC2GM096948473 NN O
gene BC2GM096948473 NN O
. BC2GM096948473 . O
. . O O

Reduction BC2GM011821006 NN O
of BC2GM011821006 IN O
p53 BC2GM011821006 NN O
protein BC2GM011821006 NN O
was BC2GM011821006 VBD O
detected BC2GM011821006 VBN O
after BC2GM011821006 IN O
1 BC2GM011821006 CD O
day BC2GM011821006 NN O
of BC2GM011821006 IN O
OM BC2GM011821006 NNP O
treatment BC2GM011821006 NN O
and BC2GM011821006 CC O
reached BC2GM011821006 VBD O
maximal BC2GM011821006 JJ O
suppression BC2GM011821006 NN O
of BC2GM011821006 IN O
10-20 BC2GM011821006 JJ O
% BC2GM011821006 NN O
of BC2GM011821006 IN O
control BC2GM011821006 NN O
after BC2GM011821006 IN O
3 BC2GM011821006 CD O
days BC2GM011821006 NNS O
in BC2GM011821006 IN O
H3922 BC2GM011821006 NNP O
and BC2GM011821006 CC O
40 BC2GM011821006 CD O
% BC2GM011821006 NN O
of BC2GM011821006 IN O
control BC2GM011821006 NN O
after BC2GM011821006 IN O
4 BC2GM011821006 CD O
days BC2GM011821006 NNS O
in BC2GM011821006 IN O
MCF-7 BC2GM011821006 NNP O
cells BC2GM011821006 NNS O
. BC2GM011821006 . O
. . O O

Furthermore BC2GM080426712 RB O
, BC2GM080426712 , O
the BC2GM080426712 DT O
rapid BC2GM080426712 JJ O
light-mediated BC2GM080426712 JJ O
increase BC2GM080426712 NN O
of BC2GM080426712 IN O
CPRF BC2GM080426712 NNP O
proteins BC2GM080426712 NNS O
was BC2GM080426712 VBD O
insensitive BC2GM080426712 JJ O
to BC2GM080426712 TO O
transcriptional BC2GM080426712 JJ O
inhibitors BC2GM080426712 NNS O
, BC2GM080426712 , O
suggesting BC2GM080426712 VBG O
that BC2GM080426712 IN O
a BC2GM080426712 DT O
post-transcriptional BC2GM080426712 JJ O
mechanism BC2GM080426712 NN O
controls BC2GM080426712 NNS O
CPRF BC2GM080426712 NNP O
accumulation BC2GM080426712 NN O
. BC2GM080426712 . O
. . O O

We BC2GM008157990 PRP O
have BC2GM008157990 VBP O
previously BC2GM008157990 RB O
demonstrated BC2GM008157990 VBN O
that BC2GM008157990 IN O
pyrene BC2GM008157990 NN O
in BC2GM008157990 IN O
diesel-exhaust BC2GM008157990 JJ O
particles BC2GM008157990 NNS O
( BC2GM008157990 ( O
DEP BC2GM008157990 NNP O
) BC2GM008157990 ) O
has BC2GM008157990 VBZ O
an BC2GM008157990 DT O
adjuvant BC2GM008157990 JJ O
activity BC2GM008157990 NN O
on BC2GM008157990 IN O
immunoglobulin BC2GM008157990 NN O
E BC2GM008157990 NNP O
( BC2GM008157990 ( O
IgE BC2GM008157990 NNP O
) BC2GM008157990 ) O
antibody BC2GM008157990 NN O
production BC2GM008157990 NN O
in BC2GM008157990 IN O
mice BC2GM008157990 NNS O
immunized BC2GM008157990 VBN O
with BC2GM008157990 IN O
Japanese BC2GM008157990 JJ O
cedar BC2GM008157990 NN O
pollen BC2GM008157990 NN O
allergen BC2GM008157990 NN O
( BC2GM008157990 ( O
JCPA BC2GM008157990 NNP O
) BC2GM008157990 ) O
or BC2GM008157990 CC O
ovalbumin BC2GM008157990 $ O
( BC2GM008157990 ( O
OA BC2GM008157990 NNP O
) BC2GM008157990 ) O
intraperitoneally BC2GM008157990 RB O
. BC2GM008157990 . O
. . O O

RESULTS BC2GM068876712 NN O
: BC2GM068876712 : O
Lateral BC2GM068876712 JJ O
PF BC2GM068876712 NNP O
OA BC2GM068876712 NNP O
was BC2GM068876712 VBD O
more BC2GM068876712 RBR O
common BC2GM068876712 JJ O
than BC2GM068876712 IN O
medial BC2GM068876712 JJ O
PF BC2GM068876712 NNP O
OA BC2GM068876712 NNP O
( BC2GM068876712 ( O
P BC2GM068876712 NNP O
< BC2GM068876712 NNP O
0.0001 BC2GM068876712 CD O
) BC2GM068876712 ) O
. BC2GM068876712 . O
. . O O

Moreover BC2GM068884936 RB O
, BC2GM068884936 , O
we BC2GM068884936 PRP O
show BC2GM068884936 VBP O
that BC2GM068884936 IN O
GATA-1 BC2GM068884936 NNP O
and BC2GM068884936 CC O
Sp1 BC2GM068884936 NNP O
synergize BC2GM068884936 VBP O
from BC2GM068884936 IN O
a BC2GM068884936 DT O
distance BC2GM068884936 NN O
in BC2GM068884936 IN O
constructs BC2GM068884936 NNS O
designed BC2GM068884936 VBN O
to BC2GM068884936 TO O
mimic BC2GM068884936 VB O
the BC2GM068884936 DT O
architecture BC2GM068884936 NN O
of BC2GM068884936 IN O
globin BC2GM068884936 JJ O
locus BC2GM068884936 NN O
control BC2GM068884936 NN O
regions BC2GM068884936 NNS O
and BC2GM068884936 CC O
downstream BC2GM068884936 NN O
globin BC2GM068884936 NN O
promoters BC2GM068884936 NNS O
. BC2GM068884936 . O
. . O O

Forty-five BC2GM064660212 JJ O
patients BC2GM064660212 NNS O
with BC2GM064660212 IN O
recent-onset BC2GM064660212 JJ O
hyperthyroidism BC2GM064660212 NN O
( BC2GM064660212 ( O
< BC2GM064660212 JJ O
12 BC2GM064660212 CD O
weeks BC2GM064660212 NNS O
) BC2GM064660212 ) O
were BC2GM064660212 VBD O
sex BC2GM064660212 NN O
and BC2GM064660212 CC O
menopause BC2GM064660212 NN O
stratified BC2GM064660212 VBD O
and BC2GM064660212 CC O
randomly BC2GM064660212 RB O
allocated BC2GM064660212 VBN O
to BC2GM064660212 TO O
treatment BC2GM064660212 NN O
with BC2GM064660212 IN O
carbimazole BC2GM064660212 NN O
( BC2GM064660212 ( O
Neotomizol BC2GM064660212 NNP O
) BC2GM064660212 ) O
, BC2GM064660212 , O
carbimazole BC2GM064660212 JJ O
plus BC2GM064660212 CC O
low BC2GM064660212 JJ O
dose BC2GM064660212 NN O
CT BC2GM064660212 NNP O
( BC2GM064660212 ( O
Calsynar BC2GM064660212 NNP O
; BC2GM064660212 : O
100 BC2GM064660212 CD O
IU BC2GM064660212 NNP O
/ BC2GM064660212 NNP O
day BC2GM064660212 NN O
, BC2GM064660212 , O
2 BC2GM064660212 CD O
days BC2GM064660212 NNS O
/ BC2GM064660212 NNP O
week BC2GM064660212 NN O
) BC2GM064660212 ) O
, BC2GM064660212 , O
or BC2GM064660212 CC O
carbimazole BC2GM064660212 JJ O
plus BC2GM064660212 CC O
high BC2GM064660212 JJ O
dose BC2GM064660212 NN O
CT BC2GM064660212 NNP O
( BC2GM064660212 ( O
Calsynar BC2GM064660212 NNP O
; BC2GM064660212 : O
100 BC2GM064660212 CD O
IU BC2GM064660212 NNP O
/ BC2GM064660212 NNP O
day BC2GM064660212 NN O
, BC2GM064660212 , O
14 BC2GM064660212 CD O
days BC2GM064660212 NNS O
/ BC2GM064660212 NNP O
month BC2GM064660212 NN O
) BC2GM064660212 ) O
. BC2GM064660212 . O
. . O O

The BC2GM001987154 DT O
adenovirus BC2GM001987154 NN O
E1B BC2GM001987154 NNP O
19,000-molecular-weight BC2GM001987154 CD O
( BC2GM001987154 ( O
19K BC2GM001987154 CD O
) BC2GM001987154 ) O
protein BC2GM001987154 NN O
is BC2GM001987154 VBZ O
a BC2GM001987154 DT O
potent BC2GM001987154 JJ O
inhibitor BC2GM001987154 NN O
of BC2GM001987154 IN O
apoptosis BC2GM001987154 NN O
and BC2GM001987154 CC O
cooperates BC2GM001987154 NNS O
with BC2GM001987154 IN O
E1A BC2GM001987154 NNP O
to BC2GM001987154 TO O
transform BC2GM001987154 VB O
primary BC2GM001987154 JJ O
rodent BC2GM001987154 NN O
cells BC2GM001987154 NNS O
. BC2GM001987154 . O
. . O O

There BC2GM095835528 EX O
are BC2GM095835528 VBP O
three BC2GM095835528 CD O
types BC2GM095835528 NNS O
of BC2GM095835528 IN O
problems BC2GM095835528 NNS O
: BC2GM095835528 : O
problems BC2GM095835528 NNS O
arising BC2GM095835528 VBG O
before BC2GM095835528 IN O
the BC2GM095835528 DT O
drug BC2GM095835528 NN O
enters BC2GM095835528 VBZ O
the BC2GM095835528 DT O
body BC2GM095835528 NN O
( BC2GM095835528 ( O
solubilization BC2GM095835528 NN O
, BC2GM095835528 , O
stabilization BC2GM095835528 NN O
and BC2GM095835528 CC O
improved BC2GM095835528 JJ O
acceptability BC2GM095835528 NN O
) BC2GM095835528 ) O
; BC2GM095835528 : O
problems BC2GM095835528 NNS O
associated BC2GM095835528 VBN O
with BC2GM095835528 IN O
the BC2GM095835528 DT O
penetration BC2GM095835528 NN O
and BC2GM095835528 CC O
fate BC2GM095835528 NN O
of BC2GM095835528 IN O
the BC2GM095835528 DT O
drug BC2GM095835528 NN O
in BC2GM095835528 IN O
the BC2GM095835528 DT O
body BC2GM095835528 NN O
( BC2GM095835528 ( O
absorption BC2GM095835528 NN O
, BC2GM095835528 , O
barrier BC2GM095835528 NN O
crossing BC2GM095835528 NN O
, BC2GM095835528 , O
duration BC2GM095835528 NN O
of BC2GM095835528 IN O
action BC2GM095835528 NN O
) BC2GM095835528 ) O
; BC2GM095835528 : O
problems BC2GM095835528 NNS O
relating BC2GM095835528 VBG O
to BC2GM095835528 TO O
the BC2GM095835528 DT O
therapeutic BC2GM095835528 JJ O
target BC2GM095835528 NN O
( BC2GM095835528 ( O
selective BC2GM095835528 JJ O
local BC2GM095835528 JJ O
delivery BC2GM095835528 NN O
) BC2GM095835528 ) O
. BC2GM095835528 . O
. . O O

In BC2GM023474684 IN O
early BC2GM023474684 JJ O
midgestation BC2GM023474684 NN O
embryos BC2GM023474684 IN O
it BC2GM023474684 PRP O
is BC2GM023474684 VBZ O
expressed BC2GM023474684 VBN O
in BC2GM023474684 IN O
telencephalic BC2GM023474684 NN O
, BC2GM023474684 , O
diencephalic BC2GM023474684 JJ O
and BC2GM023474684 CC O
mesencephalic BC2GM023474684 JJ O
regions BC2GM023474684 NNS O
but BC2GM023474684 CC O
from BC2GM023474684 IN O
day BC2GM023474684 NN O
11.75 BC2GM023474684 CD O
of BC2GM023474684 IN O
gestation BC2GM023474684 NN O
its BC2GM023474684 PRP$ O
expression BC2GM023474684 NN O
disappears BC2GM023474684 NNS O
from BC2GM023474684 IN O
dorsal BC2GM023474684 NN O
telencephalon BC2GM023474684 NN O
and BC2GM023474684 CC O
is BC2GM023474684 VBZ O
confined BC2GM023474684 VBN O
to BC2GM023474684 TO O
diencephalic BC2GM023474684 VB O
and BC2GM023474684 CC O
mesencephalic BC2GM023474684 JJ O
regions BC2GM023474684 NNS O
. BC2GM023474684 . O
. . O O

Only BC2GM092441762 RB O
Staphylococcus BC2GM092441762 NNP O
xylosus BC2GM092441762 NNP O
SX63 BC2GM092441762 NNP O
was BC2GM092441762 VBD O
detected BC2GM092441762 VBN O
as BC2GM092441762 IN O
a BC2GM092441762 DT O
strain BC2GM092441762 NN O
with BC2GM092441762 IN O
high BC2GM092441762 JJ O
adherence BC2GM092441762 NN O
activity BC2GM092441762 NN O
. BC2GM092441762 . O
. . O O

Moyamoya BC2GM078287872 NNP O
is BC2GM078287872 VBZ O
an BC2GM078287872 DT O
intriguing BC2GM078287872 JJ O
and BC2GM078287872 CC O
controversial BC2GM078287872 JJ O
syndrome BC2GM078287872 NN O
. BC2GM078287872 . O
. . O O

Plasma BC2GM083038361 NNP O
NE BC2GM083038361 NNP O
and BC2GM083038361 CC O
E BC2GM083038361 NNP O
increased BC2GM083038361 VBD O
to BC2GM083038361 TO O
significantly BC2GM083038361 RB O
higher BC2GM083038361 JJR O
values BC2GM083038361 NNS O
after BC2GM083038361 IN O
15 BC2GM083038361 CD O
min BC2GM083038361 NN O
in BC2GM083038361 IN O
the BC2GM083038361 DT O
young BC2GM083038361 JJ O
subjects BC2GM083038361 NNS O
: BC2GM083038361 : O
1.68 BC2GM083038361 CD O
+ BC2GM083038361 NN O
/ BC2GM083038361 NNP O
- BC2GM083038361 : O
0.18 BC2GM083038361 CD O
vs BC2GM083038361 NN O
. BC2GM083038361 . O
. . O O

Hepatitis BC2GM066102549 NN O
B BC2GM066102549 NNP O
immune BC2GM066102549 NN O
globulins BC2GM066102549 NNS O
and BC2GM066102549 CC O
HIV BC2GM066102549 NNP O
antibodies BC2GM066102549 NNS O
. BC2GM066102549 . O
. . O O

Like BC2GM021031743 IN O
the BC2GM021031743 DT O
human BC2GM021031743 JJ O
gene BC2GM021031743 NN O
, BC2GM021031743 , O
the BC2GM021031743 DT O
Drosophila BC2GM021031743 NNP O
gene BC2GM021031743 NN O
encodes BC2GM021031743 NNS O
at BC2GM021031743 IN O
least BC2GM021031743 JJS O
three BC2GM021031743 CD O
isoforms BC2GM021031743 NNS O
of BC2GM021031743 IN O
full BC2GM021031743 JJ O
length BC2GM021031743 NN O
dystrophin-like BC2GM021031743 JJ O
proteins BC2GM021031743 NNS O
( BC2GM021031743 ( O
dmDLP1 BC2GM021031743 NN O
, BC2GM021031743 , O
dmDLP2 BC2GM021031743 NN O
and BC2GM021031743 CC O
dmDLP3 BC2GM021031743 NN O
, BC2GM021031743 , O
) BC2GM021031743 ) O
, BC2GM021031743 , O
regulated BC2GM021031743 VBN O
by BC2GM021031743 IN O
different BC2GM021031743 JJ O
promoters BC2GM021031743 NNS O
located BC2GM021031743 VBN O
at BC2GM021031743 IN O
the BC2GM021031743 DT O
5 BC2GM021031743 CD O
' BC2GM021031743 POS O
end BC2GM021031743 NN O
of BC2GM021031743 IN O
the BC2GM021031743 DT O
gene BC2GM021031743 NN O
, BC2GM021031743 , O
and BC2GM021031743 CC O
a BC2GM021031743 DT O
smaller BC2GM021031743 JJR O
product BC2GM021031743 NN O
regulated BC2GM021031743 VBN O
by BC2GM021031743 IN O
an BC2GM021031743 DT O
internal BC2GM021031743 JJ O
promoter BC2GM021031743 NN O
( BC2GM021031743 ( O
dmDp186 BC2GM021031743 NN O
) BC2GM021031743 ) O
. BC2GM021031743 . O
. . O O

POPULATION BC2GM061400791 NNP O
AND BC2GM061400791 CC O
METHODS BC2GM061400791 NNP O
: BC2GM061400791 : O
105 BC2GM061400791 CD O
patients BC2GM061400791 NNS O
were BC2GM061400791 VBD O
followed BC2GM061400791 VBN O
prospectively BC2GM061400791 RB O
( BC2GM061400791 ( O
male BC2GM061400791 NN O
: BC2GM061400791 : O
87 BC2GM061400791 CD O
% BC2GM061400791 NN O
; BC2GM061400791 : O
age BC2GM061400791 NN O
: BC2GM061400791 : O
56 BC2GM061400791 CD O
+ BC2GM061400791 NN O
/ BC2GM061400791 NNP O
- BC2GM061400791 : O
10 BC2GM061400791 CD O
) BC2GM061400791 ) O
; BC2GM061400791 : O
clinical BC2GM061400791 JJ O
evaluation BC2GM061400791 NN O
was BC2GM061400791 VBD O
performed BC2GM061400791 VBN O
in BC2GM061400791 IN O
the BC2GM061400791 DT O
1st BC2GM061400791 CD O
, BC2GM061400791 , O
3rd BC2GM061400791 CD O
and BC2GM061400791 CC O
6th BC2GM061400791 CD O
month BC2GM061400791 NN O
, BC2GM061400791 , O
SEKG BC2GM061400791 NNP O
in BC2GM061400791 IN O
the BC2GM061400791 DT O
4th BC2GM061400791 CD O
month BC2GM061400791 NN O
and BC2GM061400791 CC O
recatheterization BC2GM061400791 NN O
for BC2GM061400791 IN O
angiographic BC2GM061400791 JJ O
control BC2GM061400791 NN O
in BC2GM061400791 IN O
the BC2GM061400791 DT O
6th BC2GM061400791 CD O
month BC2GM061400791 NN O
. BC2GM061400791 . O
. . O O

The BC2GM004847396 DT O
effect BC2GM004847396 NN O
of BC2GM004847396 IN O
iron BC2GM004847396 NN O
on BC2GM004847396 IN O
the BC2GM004847396 DT O
toxigenicity BC2GM004847396 NN O
of BC2GM004847396 IN O
Vibrio BC2GM004847396 NNP O
cholerae BC2GM004847396 NN O
. BC2GM004847396 . O
. . O O

The BC2GM061319668 DT O
cells BC2GM061319668 NNS O
arrest BC2GM061319668 VBP O
in BC2GM061319668 IN O
the BC2GM061319668 DT O
G1 BC2GM061319668 NNP O
phase BC2GM061319668 NN O
of BC2GM061319668 IN O
the BC2GM061319668 DT O
cell BC2GM061319668 NN O
cycle BC2GM061319668 NN O
and BC2GM061319668 CC O
grow BC2GM061319668 VB O
a BC2GM061319668 DT O
projection BC2GM061319668 NN O
towards BC2GM061319668 IN O
one BC2GM061319668 CD O
another BC2GM061319668 DT O
forming BC2GM061319668 VBG O
a BC2GM061319668 DT O
shmoo BC2GM061319668 JJ O
projection BC2GM061319668 NN O
. BC2GM061319668 . O
. . O O

We BC2GM096599542 PRP O
show BC2GM096599542 VBP O
that BC2GM096599542 IN O
the BC2GM096599542 DT O
upstream BC2GM096599542 JJ O
region BC2GM096599542 NN O
of BC2GM096599542 IN O
the BC2GM096599542 DT O
beta BC2GM096599542 NN O
-MyHC BC2GM096599542 NNP O
gene BC2GM096599542 NN O
( BC2GM096599542 ( O
-5518 BC2GM096599542 UH O
to BC2GM096599542 TO O
-2490 BC2GM096599542 VB O
relative BC2GM096599542 JJ O
to BC2GM096599542 TO O
the BC2GM096599542 DT O
transcriptional BC2GM096599542 JJ O
start BC2GM096599542 NN O
site BC2GM096599542 NN O
) BC2GM096599542 ) O
directed BC2GM096599542 VBD O
high BC2GM096599542 JJ O
levels BC2GM096599542 NNS O
of BC2GM096599542 IN O
transcriptional BC2GM096599542 JJ O
activity BC2GM096599542 NN O
only BC2GM096599542 RB O
when BC2GM096599542 WRB O
stably BC2GM096599542 RB O
integrated BC2GM096599542 VBN O
, BC2GM096599542 , O
but BC2GM096599542 CC O
not BC2GM096599542 RB O
when BC2GM096599542 WRB O
expressed BC2GM096599542 VBN O
extrachromosomally BC2GM096599542 RB O
in BC2GM096599542 IN O
transient BC2GM096599542 NN O
assays BC2GM096599542 NNS O
. BC2GM096599542 . O
. . O O

Members BC2GM037370433 NNS O
of BC2GM037370433 IN O
the BC2GM037370433 DT O
CRE-binding BC2GM037370433 NNP O
protein BC2GM037370433 NN O
( BC2GM037370433 ( O
CREB BC2GM037370433 NNP O
) BC2GM037370433 ) O
/ BC2GM037370433 VBP O
activating BC2GM037370433 VBG O
transcription BC2GM037370433 NN O
factor BC2GM037370433 NN O
transcription BC2GM037370433 NN O
family BC2GM037370433 NN O
as BC2GM037370433 RB O
well BC2GM037370433 RB O
as BC2GM037370433 IN O
members BC2GM037370433 NNS O
of BC2GM037370433 IN O
the BC2GM037370433 DT O
Jun BC2GM037370433 NNP O
/ BC2GM037370433 NNP O
Fos BC2GM037370433 NNP O
family BC2GM037370433 NN O
have BC2GM037370433 VBP O
been BC2GM037370433 VBN O
shown BC2GM037370433 VBN O
to BC2GM037370433 TO O
bind BC2GM037370433 VB O
to BC2GM037370433 TO O
this BC2GM037370433 DT O
sequence BC2GM037370433 NN O
. BC2GM037370433 . O
. . O O

2 BC2GM050688193 CD O
. BC2GM050688193 . O
. . O O

Soluble BC2GM088223982 JJ O
extracts BC2GM088223982 NNS O
from BC2GM088223982 IN O
FGF-treated BC2GM088223982 NNP O
as BC2GM088223982 IN O
compared BC2GM088223982 VBN O
with BC2GM088223982 IN O
quiescent BC2GM088223982 JJ O
fibroblasts BC2GM088223982 NNS O
exhibited BC2GM088223982 VBD O
up BC2GM088223982 RP O
to BC2GM088223982 TO O
3-fold BC2GM088223982 JJ O
higher BC2GM088223982 JJR O
kinase BC2GM088223982 NN O
activity BC2GM088223982 NN O
towards BC2GM088223982 NNS O
S6 BC2GM088223982 NNP O
in BC2GM088223982 IN O
exogenously BC2GM088223982 RB O
added BC2GM088223982 JJ O
rat BC2GM088223982 NN O
liver BC2GM088223982 RB O
40S BC2GM088223982 CD O
ribosomes BC2GM088223982 NNS O
and BC2GM088223982 CC O
a BC2GM088223982 DT O
synthetic BC2GM088223982 JJ O
peptide BC2GM088223982 NN O
, BC2GM088223982 , O
RRLSSLRA BC2GM088223982 NNP O
. BC2GM088223982 . O
. . O O

Parathyroid BC2GM012456182 NNP O
hormone BC2GM012456182 NN O
responses BC2GM012456182 NNS O
of BC2GM012456182 IN O
cyclic BC2GM012456182 JJ O
AMP- BC2GM012456182 NNP O
, BC2GM012456182 , O
serum- BC2GM012456182 JJ O
and BC2GM012456182 CC O
phorbol BC2GM012456182 JJ O
ester-responsive BC2GM012456182 JJ O
reporter BC2GM012456182 NN O
genes BC2GM012456182 NNS O
in BC2GM012456182 IN O
osteoblast-like BC2GM012456182 JJ O
UMR-106 BC2GM012456182 JJ O
cells BC2GM012456182 NNS O
. BC2GM012456182 . O
. . O O

These BC2GM082412019 DT O
three BC2GM082412019 CD O
chromosomes BC2GM082412019 NNS O
share BC2GM082412019 NN O
the BC2GM082412019 DT O
transferrin BC2GM082412019 NN O
gene BC2GM082412019 NN O
( BC2GM082412019 ( O
TF BC2GM082412019 NNP O
) BC2GM082412019 ) O
, BC2GM082412019 , O
the BC2GM082412019 DT O
myosin BC2GM082412019 NN O
light BC2GM082412019 VBD O
polypeptide BC2GM082412019 RB O
3 BC2GM082412019 CD O
gene BC2GM082412019 NN O
( BC2GM082412019 ( O
MYL3 BC2GM082412019 NNP O
) BC2GM082412019 ) O
, BC2GM082412019 , O
and BC2GM082412019 CC O
the BC2GM082412019 DT O
acylpeptide BC2GM082412019 JJ O
hydrolase BC2GM082412019 NN O
gene BC2GM082412019 NN O
( BC2GM082412019 ( O
APEH BC2GM082412019 NNP O
) BC2GM082412019 ) O
. BC2GM082412019 . O
. . O O

The BC2GM040073608 DT O
101st BC2GM040073608 CD O
annual BC2GM040073608 JJ O
meeting BC2GM040073608 NN O
of BC2GM040073608 IN O
the BC2GM040073608 DT O
Japanese BC2GM040073608 JJ O
Ophthalmological BC2GM040073608 NNP O
Society BC2GM040073608 NNP O
. BC2GM040073608 . O
. . O O

The BC2GM045767472 DT O
pattern BC2GM045767472 NN O
of BC2GM045767472 IN O
net BC2GM045767472 JJ O
RNA BC2GM045767472 NNP O
expression BC2GM045767472 NN O
in BC2GM045767472 IN O
adult BC2GM045767472 NN O
mouse BC2GM045767472 NN O
tissues BC2GM045767472 NNS O
is BC2GM045767472 VBZ O
different BC2GM045767472 JJ O
. BC2GM045767472 . O
. . O O

Moreover BC2GM079747386 RB O
, BC2GM079747386 , O
we BC2GM079747386 PRP O
studied BC2GM079747386 VBD O
the BC2GM079747386 DT O
relationship BC2GM079747386 NN O
between BC2GM079747386 IN O
initial BC2GM079747386 JJ O
percentage BC2GM079747386 NN O
of BC2GM079747386 IN O
bone BC2GM079747386 NN O
marrow BC2GM079747386 NN O
plasma BC2GM079747386 NN O
cells BC2GM079747386 NNS O
and BC2GM079747386 CC O
prognosis BC2GM079747386 NN O
. BC2GM079747386 . O
. . O O

Purified BC2GM095548936 NNP O
preparations BC2GM095548936 NNS O
of BC2GM095548936 IN O
all BC2GM095548936 DT O
four BC2GM095548936 CD O
AGT BC2GM095548936 NNP O
mutants BC2GM095548936 NNS O
showed BC2GM095548936 VBD O
an BC2GM095548936 DT O
approximately BC2GM095548936 RB O
similar BC2GM095548936 JJ O
degree BC2GM095548936 NN O
( BC2GM095548936 ( O
74-120-fold BC2GM095548936 JJ O
) BC2GM095548936 ) O
of BC2GM095548936 IN O
reduction BC2GM095548936 NN O
in BC2GM095548936 IN O
the BC2GM095548936 DT O
rate BC2GM095548936 NN O
of BC2GM095548936 IN O
reaction BC2GM095548936 NN O
with BC2GM095548936 IN O
O6-benzylguanine BC2GM095548936 NNP O
. BC2GM095548936 . O
. . O O

Plasmid BC2GM091451478 NNP O
subclones BC2GM091451478 NNS O
of BC2GM091451478 IN O
the BC2GM091451478 DT O
hr1a-containing BC2GM091451478 JJ O
AcMNPV BC2GM091451478 NNP O
HindIII-N BC2GM091451478 NNP O
fragment BC2GM091451478 NN O
were BC2GM091451478 VBD O
examined BC2GM091451478 VBN O
for BC2GM091451478 IN O
their BC2GM091451478 PRP$ O
ability BC2GM091451478 NN O
to BC2GM091451478 TO O
replicate BC2GM091451478 VB O
in BC2GM091451478 IN O
virus-infected BC2GM091451478 JJ O
( BC2GM091451478 ( O
Spodoptera BC2GM091451478 NNP O
frugiperda BC2GM091451478 NN O
) BC2GM091451478 ) O
Sf9 BC2GM091451478 NNP O
cells BC2GM091451478 NNS O
, BC2GM091451478 , O
and BC2GM091451478 CC O
to BC2GM091451478 TO O
stimulate BC2GM091451478 VB O
transcription BC2GM091451478 NN O
when BC2GM091451478 WRB O
linked BC2GM091451478 VBN O
in BC2GM091451478 IN O
cis BC2GM091451478 NN O
with BC2GM091451478 IN O
a BC2GM091451478 DT O
39K BC2GM091451478 CD O
gene BC2GM091451478 NN O
promoter-beta-glucuronidase BC2GM091451478 JJ O
fusion BC2GM091451478 NN O
and BC2GM091451478 CC O
cotransfected BC2GM091451478 VBD O
into BC2GM091451478 IN O
cells BC2GM091451478 NNS O
along BC2GM091451478 IN O
with BC2GM091451478 IN O
a BC2GM091451478 DT O
plasmid BC2GM091451478 NN O
( BC2GM091451478 ( O
ple-1 BC2GM091451478 JJ O
) BC2GM091451478 ) O
containing BC2GM091451478 VBG O
the BC2GM091451478 DT O
gene BC2GM091451478 NN O
encoding BC2GM091451478 VBG O
the BC2GM091451478 DT O
trans-acting BC2GM091451478 JJ O
factor BC2GM091451478 NN O
IE-1 BC2GM091451478 NNP O
. BC2GM091451478 . O
. . O O

Oral BC2GM037342398 JJ O
hypoglycemic BC2GM037342398 JJ O
agents BC2GM037342398 NNS O
. BC2GM037342398 . O
. . O O

cDNA BC2GM000555540 NN O
cloning BC2GM000555540 NN O
and BC2GM000555540 CC O
transcriptional BC2GM000555540 JJ O
properties BC2GM000555540 NNS O
of BC2GM000555540 IN O
a BC2GM000555540 DT O
novel BC2GM000555540 JJ O
GC BC2GM000555540 NNP O
box-binding BC2GM000555540 NN O
protein BC2GM000555540 NN O
, BC2GM000555540 , O
BTEB2 BC2GM000555540 NNP O
. BC2GM000555540 . O
. . O O

Plasmids BC2GM027554175 NNS O
bearing BC2GM027554175 VBG O
the BC2GM027554175 DT O
P. BC2GM027554175 NNP O
stipitis BC2GM027554175 NN O
URA3 BC2GM027554175 NNP O
gene BC2GM027554175 NN O
and BC2GM027554175 CC O
ARS2 BC2GM027554175 NNP O
element BC2GM027554175 NN O
produced BC2GM027554175 VBD O
more BC2GM027554175 JJR O
than BC2GM027554175 IN O
30,000 BC2GM027554175 CD O
transformants BC2GM027554175 NNS O
per BC2GM027554175 IN O
micrograms BC2GM027554175 NN O
of BC2GM027554175 IN O
plasmid BC2GM027554175 JJ O
DNA BC2GM027554175 NNP O
. BC2GM027554175 . O
. . O O

We BC2GM003267548 PRP O
report BC2GM003267548 VBP O
the BC2GM003267548 DT O
genomic BC2GM003267548 JJ O
organization BC2GM003267548 NN O
of BC2GM003267548 IN O
the BC2GM003267548 DT O
mouse BC2GM003267548 NN O
orphan BC2GM003267548 JJ O
receptor BC2GM003267548 NN O
related BC2GM003267548 VBN O
to BC2GM003267548 TO O
tyrosine BC2GM003267548 VB O
kinases BC2GM003267548 NNS O
( BC2GM003267548 ( O
Ryk BC2GM003267548 NNP O
) BC2GM003267548 ) O
, BC2GM003267548 , O
a BC2GM003267548 DT O
structurally BC2GM003267548 RB O
unclassified BC2GM003267548 JJ O
member BC2GM003267548 NN O
of BC2GM003267548 IN O
the BC2GM003267548 DT O
growth BC2GM003267548 NN O
factor BC2GM003267548 NN O
receptor BC2GM003267548 NN O
family BC2GM003267548 NN O
. BC2GM003267548 . O
. . O O

Analysis BC2GM086442334 NN O
of BC2GM086442334 IN O
deletion BC2GM086442334 NN O
and BC2GM086442334 CC O
substitution BC2GM086442334 NN O
mutations BC2GM086442334 NNS O
in BC2GM086442334 IN O
the BC2GM086442334 DT O
MER2 BC2GM086442334 NNP O
5 BC2GM086442334 CD O
' BC2GM086442334 '' O
exon BC2GM086442334 NN O
demonstrates BC2GM086442334 VBZ O
that BC2GM086442334 IN O
the BC2GM086442334 DT O
unusually BC2GM086442334 RB O
large BC2GM086442334 JJ O
size BC2GM086442334 NN O
of BC2GM086442334 IN O
this BC2GM086442334 DT O
exon BC2GM086442334 NN O
plays BC2GM086442334 VBZ O
an BC2GM086442334 DT O
important BC2GM086442334 JJ O
role BC2GM086442334 NN O
in BC2GM086442334 IN O
splicing BC2GM086442334 VBG O
regulation BC2GM086442334 NN O
. BC2GM086442334 . O
. . O O

EMT BC2GM075120339 NNP O
was BC2GM075120339 VBD O
localized BC2GM075120339 VBN O
to BC2GM075120339 TO O
chromosome BC2GM075120339 VB O
5q31-32 BC2GM075120339 JJ O
, BC2GM075120339 , O
a BC2GM075120339 DT O
region BC2GM075120339 NN O
that BC2GM075120339 WDT O
contains BC2GM075120339 VBZ O
the BC2GM075120339 DT O
genes BC2GM075120339 NNS O
for BC2GM075120339 IN O
several BC2GM075120339 JJ O
growth BC2GM075120339 NN O
factors BC2GM075120339 NNS O
and BC2GM075120339 CC O
receptors BC2GM075120339 NNS O
as BC2GM075120339 RB O
well BC2GM075120339 RB O
as BC2GM075120339 IN O
early BC2GM075120339 JJ O
activation BC2GM075120339 NN O
genes BC2GM075120339 NNS O
, BC2GM075120339 , O
particularly BC2GM075120339 RB O
those BC2GM075120339 DT O
involved BC2GM075120339 VBN O
in BC2GM075120339 IN O
the BC2GM075120339 DT O
hematopoietic BC2GM075120339 JJ O
system BC2GM075120339 NN O
. BC2GM075120339 . O
. . O O

In BC2GM074649255 IN O
dehydrated BC2GM074649255 JJ O
animals BC2GM074649255 NNS O
at BC2GM074649255 IN O
Ta BC2GM074649255 NNP O
38 BC2GM074649255 CD O
degrees BC2GM074649255 NNS O
C BC2GM074649255 NNP O
, BC2GM074649255 , O
Tb BC2GM074649255 NNP O
and BC2GM074649255 CC O
EWL BC2GM074649255 NNP O
were BC2GM074649255 VBD O
both BC2GM074649255 DT O
significantly BC2GM074649255 RB O
altered BC2GM074649255 VBN O
( BC2GM074649255 ( O
P BC2GM074649255 NNP O
less BC2GM074649255 JJR O
than BC2GM074649255 IN O
0.001 BC2GM074649255 CD O
) BC2GM074649255 ) O
from BC2GM074649255 IN O
the BC2GM074649255 DT O
normally BC2GM074649255 RB O
hydrated BC2GM074649255 VBN O
state BC2GM074649255 NN O
and BC2GM074649255 CC O
were BC2GM074649255 VBD O
measured BC2GM074649255 VBN O
at BC2GM074649255 IN O
39.9 BC2GM074649255 CD O
+ BC2GM074649255 NN O
/ BC2GM074649255 NNP O
- BC2GM074649255 : O
0.2 BC2GM074649255 CD O
degree BC2GM074649255 JJ O
C BC2GM074649255 NNP O
and BC2GM074649255 CC O
0.84 BC2GM074649255 CD O
+ BC2GM074649255 NN O
/ BC2GM074649255 NNP O
- BC2GM074649255 : O
0.09 BC2GM074649255 CD O
W BC2GM074649255 NNP O
. BC2GM074649255 . O
kg-1 BC2GM074649255 JJ O
respectively BC2GM074649255 RB O
. BC2GM074649255 . O
. . O O

The BC2GM004773918 DT O
Grb2 BC2GM004773918 NNP O
SH3 BC2GM004773918 NNP O
( BC2GM004773918 ( O
C BC2GM004773918 NNP O
) BC2GM004773918 ) O
binding BC2GM004773918 VBG O
region BC2GM004773918 NN O
of BC2GM004773918 IN O
Gab1 BC2GM004773918 NNP O
has BC2GM004773918 VBZ O
significant BC2GM004773918 JJ O
homology BC2GM004773918 NN O
to BC2GM004773918 TO O
a BC2GM004773918 DT O
region BC2GM004773918 NN O
of BC2GM004773918 IN O
the BC2GM004773918 DT O
adapter BC2GM004773918 NN O
protein BC2GM004773918 NN O
SLP-76 BC2GM004773918 NNP O
. BC2GM004773918 . O
. . O O

Videoanalysis BC2GM097623388 NN O
confirms BC2GM097623388 VBZ O
the BC2GM097623388 DT O
ballistic BC2GM097623388 JJ O
character BC2GM097623388 NN O
of BC2GM097623388 IN O
the BC2GM097623388 DT O
initial BC2GM097623388 JJ O
phase BC2GM097623388 NN O
of BC2GM097623388 IN O
the BC2GM097623388 DT O
reaching BC2GM097623388 VBG O
movement BC2GM097623388 NN O
. BC2GM097623388 . O
. . O O

The BC2GM055969816 DT O
HPV BC2GM055969816 NNP O
E1 BC2GM055969816 NNP O
and BC2GM055969816 CC O
E2 BC2GM055969816 NNP O
proteins BC2GM055969816 VBZ O
along BC2GM055969816 IN O
with BC2GM055969816 IN O
cellular BC2GM055969816 JJ O
factors BC2GM055969816 NNS O
, BC2GM055969816 , O
are BC2GM055969816 VBP O
required BC2GM055969816 VBN O
for BC2GM055969816 IN O
replication BC2GM055969816 NN O
of BC2GM055969816 IN O
the BC2GM055969816 DT O
viral BC2GM055969816 JJ O
genome BC2GM055969816 NN O
. BC2GM055969816 . O
. . O O

Immunoblotting BC2GM040694019 VBG O
with BC2GM040694019 IN O
antiphosphotyrosine BC2GM040694019 NN O
antibody BC2GM040694019 NN O
showed BC2GM040694019 VBD O
that BC2GM040694019 IN O
many BC2GM040694019 JJ O
yeast BC2GM040694019 NN O
proteins BC2GM040694019 NNS O
, BC2GM040694019 , O
including BC2GM040694019 VBG O
the BC2GM040694019 DT O
p34CDC28 BC2GM040694019 NN O
kinase BC2GM040694019 NN O
, BC2GM040694019 , O
became BC2GM040694019 VBD O
phosphorylated BC2GM040694019 VBN O
at BC2GM040694019 IN O
tyrosine BC2GM040694019 NN O
in BC2GM040694019 IN O
cells BC2GM040694019 NNS O
expressing BC2GM040694019 VBG O
v-src BC2GM040694019 NN O
. BC2GM040694019 . O
. . O O

Characterization BC2GM042317082 NN O
of BC2GM042317082 IN O
a BC2GM042317082 DT O
nuclear BC2GM042317082 JJ O
deformed BC2GM042317082 VBN O
epidermal BC2GM042317082 JJ O
autoregulatory BC2GM042317082 JJ O
factor-1 BC2GM042317082 JJ O
( BC2GM042317082 ( O
DEAF-1 BC2GM042317082 NNP O
) BC2GM042317082 ) O
-related BC2GM042317082 VBD O
( BC2GM042317082 ( O
NUDR BC2GM042317082 NNP O
) BC2GM042317082 ) O
transcriptional BC2GM042317082 JJ O
regulator BC2GM042317082 NN O
protein BC2GM042317082 NN O
. BC2GM042317082 . O
. . O O

Deletion BC2GM047688296 NN O
of BC2GM047688296 IN O
the BC2GM047688296 DT O
region BC2GM047688296 NN O
from BC2GM047688296 IN O
amino BC2GM047688296 NN O
acid BC2GM047688296 NN O
residues BC2GM047688296 VBZ O
2-67 BC2GM047688296 JJ O
in BC2GM047688296 IN O
E1A BC2GM047688296 NNP O
, BC2GM047688296 , O
which BC2GM047688296 WDT O
has BC2GM047688296 VBZ O
been BC2GM047688296 VBN O
postulated BC2GM047688296 VBN O
to BC2GM047688296 TO O
interact BC2GM047688296 VB O
with BC2GM047688296 IN O
p300 BC2GM047688296 JJ O
/ BC2GM047688296 NNP O
CBP BC2GM047688296 NNP O
, BC2GM047688296 , O
also BC2GM047688296 RB O
abolished BC2GM047688296 VBD O
the BC2GM047688296 DT O
inhibitory BC2GM047688296 JJ O
effect BC2GM047688296 NN O
of BC2GM047688296 IN O
E1A BC2GM047688296 NNP O
, BC2GM047688296 , O
whereas BC2GM047688296 JJ O
deletion BC2GM047688296 NN O
of BC2GM047688296 IN O
the BC2GM047688296 DT O
region BC2GM047688296 NN O
from BC2GM047688296 IN O
residues BC2GM047688296 NNS O
120 BC2GM047688296 CD O
to BC2GM047688296 TO O
140 BC2GM047688296 CD O
had BC2GM047688296 VBD O
no BC2GM047688296 DT O
effect BC2GM047688296 NN O
. BC2GM047688296 . O
. . O O

In BC2GM021068289 IN O
this BC2GM021068289 DT O
study BC2GM021068289 NN O
, BC2GM021068289 , O
the BC2GM021068289 DT O
case BC2GM021068289 NN O
of BC2GM021068289 IN O
a BC2GM021068289 DT O
patient BC2GM021068289 NN O
presenting BC2GM021068289 VBG O
a BC2GM021068289 DT O
second BC2GM021068289 JJ O
hepatocellular BC2GM021068289 JJ O
carcinoma BC2GM021068289 NN O
13 BC2GM021068289 CD O
years BC2GM021068289 NNS O
after BC2GM021068289 IN O
resection BC2GM021068289 NN O
of BC2GM021068289 IN O
a BC2GM021068289 DT O
first BC2GM021068289 JJ O
tumor BC2GM021068289 NN O
of BC2GM021068289 IN O
the BC2GM021068289 DT O
same BC2GM021068289 JJ O
type BC2GM021068289 NN O
is BC2GM021068289 VBZ O
reported BC2GM021068289 VBN O
. BC2GM021068289 . O
. . O O

To BC2GM007788205 TO O
gain BC2GM007788205 VB O
further BC2GM007788205 JJ O
insights BC2GM007788205 NNS O
into BC2GM007788205 IN O
these BC2GM007788205 DT O
events BC2GM007788205 NNS O
, BC2GM007788205 , O
the BC2GM007788205 DT O
porcine BC2GM007788205 NN O
G BC2GM007788205 NNP O
alpha BC2GM007788205 VBZ O
i-3 BC2GM007788205 JJ O
gene BC2GM007788205 NN O
minimal BC2GM007788205 JJ O
promoter BC2GM007788205 NN O
was BC2GM007788205 VBD O
characterized BC2GM007788205 VBN O
and BC2GM007788205 CC O
found BC2GM007788205 VBN O
67 BC2GM007788205 CD O
base BC2GM007788205 NN O
pairs BC2GM007788205 NNS O
upstream BC2GM007788205 RB O
from BC2GM007788205 IN O
the BC2GM007788205 DT O
major BC2GM007788205 JJ O
transcription BC2GM007788205 NN O
start BC2GM007788205 NN O
site BC2GM007788205 NN O
. BC2GM007788205 . O
. . O O

In BC2GM005993806 IN O
the BC2GM005993806 DT O
absence BC2GM005993806 NN O
of BC2GM005993806 IN O
Mg2+ BC2GM005993806 NNP O
, BC2GM005993806 , O
the BC2GM005993806 DT O
extent BC2GM005993806 NN O
of BC2GM005993806 IN O
destabilization BC2GM005993806 NN O
of BC2GM005993806 IN O
tRNAPhe BC2GM005993806 NN O
is BC2GM005993806 VBZ O
greater BC2GM005993806 JJR O
but BC2GM005993806 CC O
appears BC2GM005993806 VBZ O
to BC2GM005993806 TO O
be BC2GM005993806 VB O
confined BC2GM005993806 VBN O
to BC2GM005993806 TO O
internal BC2GM005993806 JJ O
regions BC2GM005993806 NNS O
of BC2GM005993806 IN O
the BC2GM005993806 DT O
acceptor BC2GM005993806 NN O
and BC2GM005993806 CC O
T BC2GM005993806 NNP O
psi BC2GM005993806 VBP O
C BC2GM005993806 NNP O
helices BC2GM005993806 NNS O
, BC2GM005993806 , O
as BC2GM005993806 IN O
evidenced BC2GM005993806 VBN O
by BC2GM005993806 IN O
the BC2GM005993806 DT O
selectively BC2GM005993806 RB O
enhanced BC2GM005993806 JJ O
exchange BC2GM005993806 NN O
rates BC2GM005993806 NNS O
for BC2GM005993806 IN O
imino BC2GM005993806 NN O
protons BC2GM005993806 NNS O
associated BC2GM005993806 VBN O
with BC2GM005993806 IN O
these BC2GM005993806 DT O
base BC2GM005993806 JJ O
pairs BC2GM005993806 NN O
. BC2GM005993806 . O
. . O O

Influence BC2GM055577023 NN O
of BC2GM055577023 IN O
dietary BC2GM055577023 JJ O
supplementation BC2GM055577023 NN O
with BC2GM055577023 IN O
Streptococcus BC2GM055577023 NNP O
faecium BC2GM055577023 NN O
M-74 BC2GM055577023 NNP O
on BC2GM055577023 IN O
broiler BC2GM055577023 NN O
body BC2GM055577023 NN O
weight BC2GM055577023 NN O
, BC2GM055577023 , O
feed BC2GM055577023 NN O
conversion BC2GM055577023 NN O
, BC2GM055577023 , O
carcass BC2GM055577023 NN O
characteristics BC2GM055577023 NNS O
, BC2GM055577023 , O
and BC2GM055577023 CC O
intestinal BC2GM055577023 JJ O
microbial BC2GM055577023 JJ O
colonization BC2GM055577023 NN O
. BC2GM055577023 . O
. . O O

Both BC2GM095923750 DT O
in BC2GM095923750 IN O
the BC2GM095923750 DT O
Federal BC2GM095923750 NNP O
Republic BC2GM095923750 NNP O
of BC2GM095923750 IN O
Germany BC2GM095923750 NNP O
and BC2GM095923750 CC O
in BC2GM095923750 IN O
some BC2GM095923750 DT O
neighbouring BC2GM095923750 JJ O
countries BC2GM095923750 NNS O
the BC2GM095923750 DT O
epizootic BC2GM095923750 JJ O
situation BC2GM095923750 NN O
of BC2GM095923750 IN O
Aujeszky BC2GM095923750 NNP O
's BC2GM095923750 POS O
disease BC2GM095923750 NN O
has BC2GM095923750 VBZ O
been BC2GM095923750 VBN O
unsatisfactory BC2GM095923750 JJ O
for BC2GM095923750 IN O
a BC2GM095923750 DT O
long BC2GM095923750 JJ O
time BC2GM095923750 NN O
, BC2GM095923750 , O
especially BC2GM095923750 RB O
in BC2GM095923750 IN O
areas BC2GM095923750 NNS O
with BC2GM095923750 IN O
a BC2GM095923750 DT O
high BC2GM095923750 JJ O
pig BC2GM095923750 NN O
density BC2GM095923750 NN O
. BC2GM095923750 . O
. . O O

Hydroxyl BC2GM043911638 NNP O
radical BC2GM043911638 JJ O
footprinting BC2GM043911638 NN O
of BC2GM043911638 IN O
DNA BC2GM043911638 NNP O
complexes BC2GM043911638 NNS O
of BC2GM043911638 IN O
the BC2GM043911638 DT O
ets BC2GM043911638 NNS O
domain BC2GM043911638 VBP O
of BC2GM043911638 IN O
PU.1 BC2GM043911638 NNP O
and BC2GM043911638 CC O
its BC2GM043911638 PRP$ O
comparison BC2GM043911638 NN O
to BC2GM043911638 TO O
the BC2GM043911638 DT O
crystal BC2GM043911638 JJ O
structure BC2GM043911638 NN O
. BC2GM043911638 . O
. . O O

Mean BC2GM024386015 JJ O
disposition BC2GM024386015 NN O
constants BC2GM024386015 NNS O
( BC2GM024386015 ( O
+ BC2GM024386015 JJ O
/ BC2GM024386015 NNP O
- BC2GM024386015 : O
SD BC2GM024386015 NN O
) BC2GM024386015 ) O
were BC2GM024386015 VBD O
obtained BC2GM024386015 VBN O
from BC2GM024386015 IN O
individualized BC2GM024386015 VBN O
fits BC2GM024386015 NNS O
( BC2GM024386015 ( O
V1 BC2GM024386015 NNP O
: BC2GM024386015 : O
0.398 BC2GM024386015 CD O
+ BC2GM024386015 NN O
/ BC2GM024386015 NNP O
- BC2GM024386015 : O
0.336 BC2GM024386015 CD O
LITER BC2GM024386015 NNP O
/ BC2GM024386015 NNP O
KG BC2GM024386015 NNP O
, BC2GM024386015 , O
Vdarea BC2GM024386015 NNP O
: BC2GM024386015 : O
2.53 BC2GM024386015 CD O
+ BC2GM024386015 NN O
/ BC2GM024386015 NNP O
- BC2GM024386015 : O
0.72 BC2GM024386015 CD O
liter BC2GM024386015 NN O
/ BC2GM024386015 NNP O
kg BC2GM024386015 NN O
, BC2GM024386015 , O
alpha BC2GM024386015 NN O
: BC2GM024386015 : O
0.316 BC2GM024386015 CD O
+ BC2GM024386015 NN O
/ BC2GM024386015 NNP O
- BC2GM024386015 : O
0.294 BC2GM024386015 CD O
min BC2GM024386015 NN O
-1 BC2GM024386015 NN O
, BC2GM024386015 , O
beta BC2GM024386015 NN O
: BC2GM024386015 : O
0.00204 BC2GM024386015 CD O
+ BC2GM024386015 NN O
/ BC2GM024386015 NNP O
- BC2GM024386015 : O
0.00262 BC2GM024386015 CD O
min BC2GM024386015 NN O
-1 BC2GM024386015 NN O
, BC2GM024386015 , O
k2 BC2GM024386015 NN O
: BC2GM024386015 : O
0.0305 BC2GM024386015 CD O
+ BC2GM024386015 NN O
/ BC2GM024386015 NNP O
- BC2GM024386015 : O
0.0101 BC2GM024386015 CD O
min BC2GM024386015 NN O
-1 BC2GM024386015 NN O
) BC2GM024386015 ) O
. BC2GM024386015 . O
. . O O

There BC2GM008948246 EX O
was BC2GM008948246 VBD O
no BC2GM008948246 DT O
significant BC2GM008948246 JJ O
correlation BC2GM008948246 NN O
between BC2GM008948246 IN O
serum BC2GM008948246 NN O
amiodarone BC2GM008948246 NN O
or BC2GM008948246 CC O
desethylamiodarone BC2GM008948246 NN O
levels BC2GM008948246 NNS O
and BC2GM008948246 CC O
dosage BC2GM008948246 NN O
of BC2GM008948246 IN O
amiodarone BC2GM008948246 NN O
. BC2GM008948246 . O
. . O O

There BC2GM069051753 EX O
are BC2GM069051753 VBP O
two BC2GM069051753 CD O
regulatory BC2GM069051753 JJ O
regions BC2GM069051753 NNS O
between BC2GM069051753 IN O
the BC2GM069051753 DT O
US3 BC2GM069051753 NNP O
and BC2GM069051753 CC O
the BC2GM069051753 DT O
US6 BC2GM069051753 NNP O
transcription BC2GM069051753 NN O
units BC2GM069051753 NNS O
. BC2GM069051753 . O
. . O O

CD4 BC2GM067510592 NNP O
degradation BC2GM067510592 NN O
mediated BC2GM067510592 VBN O
by BC2GM067510592 IN O
Vpu BC2GM067510592 NNP O
does BC2GM067510592 VBZ O
not BC2GM067510592 RB O
require BC2GM067510592 VB O
the BC2GM067510592 DT O
ER BC2GM067510592 NNP O
chaperone BC2GM067510592 NN O
calnexin BC2GM067510592 NN O
and BC2GM067510592 CC O
is BC2GM067510592 VBZ O
dependent BC2GM067510592 JJ O
on BC2GM067510592 IN O
an BC2GM067510592 DT O
intact BC2GM067510592 JJ O
ubiquitin-conjugating BC2GM067510592 JJ O
system BC2GM067510592 NN O
. BC2GM067510592 . O
. . O O

However BC2GM094523699 RB O
, BC2GM094523699 , O
no BC2GM094523699 DT O
statistical BC2GM094523699 JJ O
difference BC2GM094523699 NN O
in BC2GM094523699 IN O
the BC2GM094523699 DT O
Ca BC2GM094523699 NNP O
/ BC2GM094523699 NNP O
P BC2GM094523699 NNP O
ratio BC2GM094523699 NN O
, BC2GM094523699 , O
carbon BC2GM094523699 NN O
concentration BC2GM094523699 NN O
and BC2GM094523699 CC O
surface BC2GM094523699 NN O
energy BC2GM094523699 NN O
were BC2GM094523699 VBD O
observed BC2GM094523699 VBN O
with BC2GM094523699 IN O
different BC2GM094523699 JJ O
heat BC2GM094523699 NN O
treatments BC2GM094523699 NNS O
. BC2GM094523699 . O
. . O O

To BC2GM057093148 TO O
understand BC2GM057093148 VB O
this BC2GM057093148 DT O
dramatic BC2GM057093148 JJ O
effect BC2GM057093148 NN O
, BC2GM057093148 , O
we BC2GM057093148 PRP O
examined BC2GM057093148 VBD O
the BC2GM057093148 DT O
localization BC2GM057093148 NN O
of BC2GM057093148 IN O
SR BC2GM057093148 NNP O
proteins BC2GM057093148 NNS O
and BC2GM057093148 CC O
found BC2GM057093148 VBD O
that BC2GM057093148 IN O
SC35 BC2GM057093148 NNP O
was BC2GM057093148 VBD O
shifted BC2GM057093148 VBN O
to BC2GM057093148 TO O
the BC2GM057093148 DT O
cytoplasm BC2GM057093148 NN O
in BC2GM057093148 IN O
sky1Delta BC2GM057093148 NN O
yeast BC2GM057093148 NN O
, BC2GM057093148 , O
although BC2GM057093148 IN O
this BC2GM057093148 DT O
phenomenon BC2GM057093148 NN O
was BC2GM057093148 VBD O
not BC2GM057093148 RB O
obvious BC2GM057093148 JJ O
with BC2GM057093148 IN O
ASF BC2GM057093148 NNP O
/ BC2GM057093148 NNP O
SF2 BC2GM057093148 NNP O
, BC2GM057093148 , O
indicating BC2GM057093148 VBG O
that BC2GM057093148 IN O
nuclear BC2GM057093148 JJ O
import BC2GM057093148 NN O
of BC2GM057093148 IN O
SR BC2GM057093148 NNP O
proteins BC2GM057093148 NNS O
may BC2GM057093148 MD O
be BC2GM057093148 VB O
differentially BC2GM057093148 RB O
regulated BC2GM057093148 VBN O
by BC2GM057093148 IN O
phosphorylation BC2GM057093148 NN O
. BC2GM057093148 . O
. . O O

Principles BC2GM011390376 NNS O
of BC2GM011390376 IN O
thyroid BC2GM011390376 JJ O
hormone BC2GM011390376 NN O
treatment BC2GM011390376 NN O
. BC2GM011390376 . O
. . O O

Molecular BC2GM090157482 JJ O
cloning BC2GM090157482 NN O
of BC2GM090157482 IN O
the BC2GM090157482 DT O
alpha-globin BC2GM090157482 JJ O
transcription BC2GM090157482 NN O
factor BC2GM090157482 NN O
CP2 BC2GM090157482 NNP O
. BC2GM090157482 . O
. . O O

Analysis BC2GM049097167 NN O
of BC2GM049097167 IN O
nt BC2GM049097167 JJ O
sequence BC2GM049097167 NN O
was BC2GM049097167 VBD O
carried BC2GM049097167 VBN O
out BC2GM049097167 RP O
on BC2GM049097167 IN O
three BC2GM049097167 CD O
out BC2GM049097167 IN O
of BC2GM049097167 IN O
the BC2GM049097167 DT O
more BC2GM049097167 JJR O
than BC2GM049097167 IN O
15 BC2GM049097167 CD O
of BC2GM049097167 IN O
these BC2GM049097167 DT O
regions BC2GM049097167 NNS O
present BC2GM049097167 VBP O
in BC2GM049097167 IN O
the BC2GM049097167 DT O
mouse BC2GM049097167 NN O
genome BC2GM049097167 NN O
. BC2GM049097167 . O
. . O O

Previously BC2GM021493197 RB O
identified BC2GM021493197 VBN O
mutations BC2GM021493197 NNS O
in BC2GM021493197 IN O
this BC2GM021493197 DT O
variant BC2GM021493197 NN O
have BC2GM021493197 VBP O
been BC2GM021493197 VBN O
within BC2GM021493197 IN O
or BC2GM021493197 CC O
close BC2GM021493197 VB O
to BC2GM021493197 TO O
the BC2GM021493197 DT O
coding BC2GM021493197 VBG O
region BC2GM021493197 NN O
of BC2GM021493197 IN O
exon BC2GM021493197 $ O
1 BC2GM021493197 CD O
of BC2GM021493197 IN O
the BC2GM021493197 DT O
HMBS BC2GM021493197 NNP O
gene BC2GM021493197 NN O
, BC2GM021493197 , O
the BC2GM021493197 DT O
only BC2GM021493197 JJ O
exon BC2GM021493197 NN O
that BC2GM021493197 WDT O
is BC2GM021493197 VBZ O
expressed BC2GM021493197 VBN O
solely BC2GM021493197 RB O
in BC2GM021493197 IN O
the BC2GM021493197 DT O
ubiquitous BC2GM021493197 JJ O
isoform BC2GM021493197 NN O
. BC2GM021493197 . O
. . O O

Absence BC2GM044737613 NN O
of BC2GM044737613 IN O
nitroso BC2GM044737613 JJ O
formation BC2GM044737613 NN O
from BC2GM044737613 IN O
( BC2GM044737613 ( O
14C BC2GM044737613 CD O
) BC2GM044737613 ) O
methomyl BC2GM044737613 NN O
and BC2GM044737613 CC O
sodium BC2GM044737613 NN O
nitrite BC2GM044737613 RB O
under BC2GM044737613 IN O
simulated BC2GM044737613 VBN O
stomach BC2GM044737613 NN O
conditions BC2GM044737613 NNS O
. BC2GM044737613 . O
. . O O

Before BC2GM089348837 IN O
flecainide BC2GM089348837 NN O
, BC2GM089348837 , O
all BC2GM089348837 DT O
patients BC2GM089348837 NNS O
had BC2GM089348837 VBD O
easily BC2GM089348837 RB O
inducible BC2GM089348837 JJ O
VT BC2GM089348837 NNP O
that BC2GM089348837 WDT O
was BC2GM089348837 VBD O
morphologically BC2GM089348837 RB O
identical BC2GM089348837 JJ O
to BC2GM089348837 TO O
their BC2GM089348837 PRP$ O
spontaneously BC2GM089348837 RB O
occurring BC2GM089348837 VBG O
arrhythmia BC2GM089348837 NN O
. BC2GM089348837 . O
. . O O

The BC2GM095197069 DT O
DFGF-R BC2GM095197069 NNP O
protein BC2GM095197069 NN O
may BC2GM095197069 MD O
thus BC2GM095197069 RB O
participate BC2GM095197069 VB O
in BC2GM095197069 IN O
receiving BC2GM095197069 VBG O
spatial BC2GM095197069 JJ O
cues BC2GM095197069 NNS O
that BC2GM095197069 WDT O
guide BC2GM095197069 VBP O
tracheal BC2GM095197069 NN O
cell BC2GM095197069 NN O
outgrowth BC2GM095197069 NN O
. BC2GM095197069 . O
. . O O

Previous BC2GM009479019 JJ O
studies BC2GM009479019 NNS O
using BC2GM009479019 VBG O
partial BC2GM009479019 JJ O
sequences BC2GM009479019 NNS O
have BC2GM009479019 VBP O
suggested BC2GM009479019 VBN O
the BC2GM009479019 DT O
potential BC2GM009479019 NN O
of BC2GM009479019 IN O
26S BC2GM009479019 CD O
or BC2GM009479019 CC O
large-subunit BC2GM009479019 JJ O
( BC2GM009479019 ( O
LSU BC2GM009479019 NNP O
) BC2GM009479019 ) O
rDNA BC2GM009479019 NN O
for BC2GM009479019 IN O
phylogeny BC2GM009479019 NN O
retrieval BC2GM009479019 NN O
at BC2GM009479019 IN O
taxonomic BC2GM009479019 JJ O
levels BC2GM009479019 NNS O
comparable BC2GM009479019 JJ O
to BC2GM009479019 TO O
those BC2GM009479019 DT O
investigated BC2GM009479019 VBN O
with BC2GM009479019 IN O
18S BC2GM009479019 CD O
rDNA BC2GM009479019 NN O
. BC2GM009479019 . O
. . O O

To BC2GM035652683 TO O
examine BC2GM035652683 VB O
the BC2GM035652683 DT O
biochemical BC2GM035652683 JJ O
mechanism BC2GM035652683 NN O
of BC2GM035652683 IN O
Tax1 BC2GM035652683 NNP O
transactivation BC2GM035652683 NN O
, BC2GM035652683 , O
we BC2GM035652683 PRP O
have BC2GM035652683 VBP O
developed BC2GM035652683 VBN O
an BC2GM035652683 DT O
in BC2GM035652683 IN O
vitro BC2GM035652683 JJ O
transactivation BC2GM035652683 NN O
assay BC2GM035652683 NN O
in BC2GM035652683 IN O
which BC2GM035652683 WDT O
wild-type BC2GM035652683 JJ O
Tax1 BC2GM035652683 NNP O
is BC2GM035652683 VBZ O
able BC2GM035652683 JJ O
to BC2GM035652683 TO O
specifically BC2GM035652683 RB O
transactivate BC2GM035652683 VB O
a BC2GM035652683 DT O
polymerase BC2GM035652683 NN O
II BC2GM035652683 NNP O
promoter BC2GM035652683 NN O
through BC2GM035652683 IN O
upstream BC2GM035652683 JJ O
Tax1-responsive BC2GM035652683 JJ O
elements BC2GM035652683 NNS O
. BC2GM035652683 . O
. . O O

DIC BC2GM091426108 NNP O
and BC2GM091426108 CC O
low BC2GM091426108 JJ O
grade BC2GM091426108 NN O
fibrinolysis BC2GM091426108 NN O
may BC2GM091426108 MD O
account BC2GM091426108 VB O
for BC2GM091426108 IN O
the BC2GM091426108 DT O
coagulation BC2GM091426108 NN O
abnormalities BC2GM091426108 NNS O
of BC2GM091426108 IN O
the BC2GM091426108 DT O
syndrome BC2GM091426108 NN O
. BC2GM091426108 . O
. . O O

Biochem BC2GM036083760 NNP O
. BC2GM036083760 . O
. . O O

These BC2GM022278881 DT O
proteins BC2GM022278881 NNS O
were BC2GM022278881 VBD O
detected BC2GM022278881 VBN O
by BC2GM022278881 IN O
an BC2GM022278881 DT O
antibody BC2GM022278881 NN O
which BC2GM022278881 WDT O
recognizes BC2GM022278881 VBZ O
the BC2GM022278881 DT O
N-terminus BC2GM022278881 NNP O
of BC2GM022278881 IN O
SRK3 BC2GM022278881 NNP O
and BC2GM022278881 CC O
, BC2GM022278881 , O
in BC2GM022278881 IN O
an BC2GM022278881 DT O
F2 BC2GM022278881 NNP O
progeny BC2GM022278881 NN O
segregating BC2GM022278881 VBG O
for BC2GM022278881 IN O
the BC2GM022278881 DT O
S3 BC2GM022278881 NNP O
haplotype BC2GM022278881 NN O
, BC2GM022278881 , O
were BC2GM022278881 VBD O
only BC2GM022278881 RB O
expressed BC2GM022278881 VBN O
in BC2GM022278881 IN O
plants BC2GM022278881 NNS O
possessing BC2GM022278881 VBG O
the BC2GM022278881 DT O
S3 BC2GM022278881 NNP O
haplotype BC2GM022278881 NN O
. BC2GM022278881 . O
. . O O

It BC2GM044595672 PRP O
is BC2GM044595672 VBZ O
always BC2GM044595672 RB O
present BC2GM044595672 JJ O
and BC2GM044595672 CC O
has BC2GM044595672 VBZ O
a BC2GM044595672 DT O
discrete BC2GM044595672 JJ O
origin BC2GM044595672 NN O
and BC2GM044595672 CC O
insertion BC2GM044595672 NN O
. BC2GM044595672 . O
. . O O

The BC2GM036882521 DT O
recombinant BC2GM036882521 JJ O
L BC2GM036882521 NNP O
/ BC2GM036882521 NNP O
F-transferase BC2GM036882521 NNP O
is BC2GM036882521 VBZ O
as BC2GM036882521 RB O
active BC2GM036882521 JJ O
as BC2GM036882521 IN O
the BC2GM036882521 DT O
previously BC2GM036882521 RB O
purified BC2GM036882521 VBN O
wild BC2GM036882521 JJ O
type BC2GM036882521 NN O
enzyme BC2GM036882521 NN O
and BC2GM036882521 CC O
contains BC2GM036882521 VBZ O
no BC2GM036882521 DT O
detectable BC2GM036882521 JJ O
RNA BC2GM036882521 NNP O
component BC2GM036882521 NN O
. BC2GM036882521 . O
. . O O

We BC2GM080578931 PRP O
established BC2GM080578931 VBD O
that BC2GM080578931 IN O
, BC2GM080578931 , O
in BC2GM080578931 IN O
unstimulated BC2GM080578931 JJ O
lymphocytes BC2GM080578931 NNS O
, BC2GM080578931 , O
the BC2GM080578931 DT O
Src BC2GM080578931 NNP O
homology BC2GM080578931 NN O
2 BC2GM080578931 CD O
( BC2GM080578931 ( O
SH2 BC2GM080578931 NNP O
) BC2GM080578931 ) O
and BC2GM080578931 CC O
SH3 BC2GM080578931 NNP O
domain-containing BC2GM080578931 JJ O
protein BC2GM080578931 NN O
Grb2 BC2GM080578931 NNP O
and BC2GM080578931 CC O
the BC2GM080578931 DT O
p85 BC2GM080578931 JJ O
subunit BC2GM080578931 NN O
of BC2GM080578931 IN O
phosphatidylinositol BC2GM080578931 JJ O
3-kinase BC2GM080578931 JJ O
, BC2GM080578931 , O
associate BC2GM080578931 JJ O
constitutively BC2GM080578931 RB O
with BC2GM080578931 IN O
Cbl BC2GM080578931 NNP O
via BC2GM080578931 IN O
their BC2GM080578931 PRP$ O
SH3 BC2GM080578931 NNP O
domains BC2GM080578931 NNS O
. BC2GM080578931 . O
. . O O

One BC2GM002667802 CD O
of BC2GM002667802 IN O
the BC2GM002667802 DT O
major BC2GM002667802 JJ O
transcripts BC2GM002667802 NNS O
encodes BC2GM002667802 VBZ O
MEQ BC2GM002667802 NNP O
, BC2GM002667802 , O
a BC2GM002667802 DT O
339-amino-acid BC2GM002667802 JJ O
bZIP BC2GM002667802 NN O
protein BC2GM002667802 NN O
which BC2GM002667802 WDT O
is BC2GM002667802 VBZ O
homologous BC2GM002667802 JJ O
to BC2GM002667802 TO O
the BC2GM002667802 DT O
Jun BC2GM002667802 NNP O
/ BC2GM002667802 NNP O
Fos BC2GM002667802 NNP O
family BC2GM002667802 NN O
of BC2GM002667802 IN O
transcription BC2GM002667802 NN O
factors BC2GM002667802 NNS O
. BC2GM002667802 . O
. . O O

Finally BC2GM024564253 RB O
, BC2GM024564253 , O
we BC2GM024564253 PRP O
demonstrated BC2GM024564253 VBD O
that BC2GM024564253 IN O
although BC2GM024564253 IN O
the BC2GM024564253 DT O
DNA-binding BC2GM024564253 NNP O
domain BC2GM024564253 NN O
of BC2GM024564253 IN O
c-myb BC2GM024564253 NN O
is BC2GM024564253 VBZ O
required BC2GM024564253 VBN O
for BC2GM024564253 IN O
both BC2GM024564253 DT O
the BC2GM024564253 DT O
differentiation BC2GM024564253 NN O
block BC2GM024564253 NN O
and BC2GM024564253 CC O
the BC2GM024564253 DT O
shift BC2GM024564253 NN O
in BC2GM024564253 IN O
cell BC2GM024564253 NN O
cycle BC2GM024564253 NN O
after BC2GM024564253 IN O
PMA BC2GM024564253 NNP O
treatment BC2GM024564253 NN O
, BC2GM024564253 , O
phosphorylation BC2GM024564253 NN O
by BC2GM024564253 IN O
casein BC2GM024564253 NN O
kinase BC2GM024564253 NN O
II BC2GM024564253 NNP O
and BC2GM024564253 CC O
mitogen-activated BC2GM024564253 JJ O
protein BC2GM024564253 NN O
kinase BC2GM024564253 NN O
at BC2GM024564253 IN O
positions BC2GM024564253 NNS O
11 BC2GM024564253 CD O
and BC2GM024564253 CC O
12 BC2GM024564253 CD O
or BC2GM024564253 CC O
532 BC2GM024564253 CD O
of BC2GM024564253 IN O
c-myb BC2GM024564253 NN O
, BC2GM024564253 , O
respectively BC2GM024564253 RB O
, BC2GM024564253 , O
are BC2GM024564253 VBP O
not BC2GM024564253 RB O
. BC2GM024564253 . O
. . O O

A BC2GM035976811 DT O
total BC2GM035976811 NN O
of BC2GM035976811 IN O
4,916 BC2GM035976811 CD O
children BC2GM035976811 NNS O
were BC2GM035976811 VBD O
examined BC2GM035976811 VBN O
and BC2GM035976811 CC O
the BC2GM035976811 DT O
questionnaire BC2GM035976811 NN O
satisfactorily BC2GM035976811 RB O
completed BC2GM035976811 VBN O
by BC2GM035976811 IN O
a BC2GM035976811 DT O
relative BC2GM035976811 JJ O
or BC2GM035976811 CC O
guardian BC2GM035976811 JJ O
( BC2GM035976811 ( O
usually BC2GM035976811 RB O
the BC2GM035976811 DT O
mother BC2GM035976811 NN O
) BC2GM035976811 ) O
of BC2GM035976811 IN O
4,651 BC2GM035976811 CD O
. BC2GM035976811 . O
. . O O

METHODS BC2GM023214186 NNS O
: BC2GM023214186 : O
Two BC2GM023214186 CD O
patients BC2GM023214186 NNS O
developed BC2GM023214186 VBD O
cervical BC2GM023214186 JJ O
myelopathy BC2GM023214186 NN O
or BC2GM023214186 CC O
radiculopathy BC2GM023214186 NN O
after BC2GM023214186 IN O
spinal BC2GM023214186 JJ O
manipulation BC2GM023214186 NN O
therapy BC2GM023214186 NN O
, BC2GM023214186 , O
and BC2GM023214186 CC O
magnetic BC2GM023214186 JJ O
resonance BC2GM023214186 NN O
imaging BC2GM023214186 NN O
showed BC2GM023214186 VBD O
herniated BC2GM023214186 JJ O
cervical BC2GM023214186 JJ O
discs BC2GM023214186 NN O
at BC2GM023214186 IN O
C4-C5 BC2GM023214186 NNP O
and BC2GM023214186 CC O
C6-C7 BC2GM023214186 NNP O
, BC2GM023214186 , O
respectively BC2GM023214186 RB O
. BC2GM023214186 . O
. . O O

An BC2GM078339197 DT O
ethnic BC2GM078339197 JJ O
analysis BC2GM078339197 NN O
was BC2GM078339197 VBD O
made BC2GM078339197 VBN O
of BC2GM078339197 IN O
8947 BC2GM078339197 CD O
cases BC2GM078339197 NNS O
of BC2GM078339197 IN O
primary BC2GM078339197 JJ O
central BC2GM078339197 JJ O
nervous BC2GM078339197 JJ O
system BC2GM078339197 NN O
( BC2GM078339197 ( O
CNS BC2GM078339197 NNP O
) BC2GM078339197 ) O
tumors BC2GM078339197 NNS O
seen BC2GM078339197 VBN O
at BC2GM078339197 IN O
the BC2GM078339197 DT O
Armed BC2GM078339197 NNP O
Forces BC2GM078339197 NNP O
Institute BC2GM078339197 NNP O
of BC2GM078339197 IN O
Pathology BC2GM078339197 NNP O
( BC2GM078339197 ( O
AFIP BC2GM078339197 NNP O
) BC2GM078339197 ) O
, BC2GM078339197 , O
Washington BC2GM078339197 NNP O
, BC2GM078339197 , O
DC BC2GM078339197 NNP O
, BC2GM078339197 , O
from BC2GM078339197 IN O
1971 BC2GM078339197 CD O
to BC2GM078339197 TO O
1985 BC2GM078339197 CD O
. BC2GM078339197 . O
. . O O

There BC2GM075650650 EX O
were BC2GM075650650 VBD O
no BC2GM075650650 DT O
major BC2GM075650650 JJ O
postoperative BC2GM075650650 JJ O
complications BC2GM075650650 NNS O
and BC2GM075650650 CC O
at BC2GM075650650 IN O
follow-up BC2GM075650650 NN O
of BC2GM075650650 IN O
the BC2GM075650650 DT O
13 BC2GM075650650 CD O
patients BC2GM075650650 NNS O
at BC2GM075650650 IN O
10 BC2GM075650650 CD O
to BC2GM075650650 TO O
26 BC2GM075650650 CD O
months BC2GM075650650 NNS O
after BC2GM075650650 IN O
operation BC2GM075650650 NN O
the BC2GM075650650 DT O
results BC2GM075650650 NNS O
were BC2GM075650650 VBD O
satisfactory BC2GM075650650 JJ O
. BC2GM075650650 . O
. . O O

Idealized BC2GM001929746 NNP O
versus BC2GM001929746 NN O
realized BC2GM001929746 VBD O
overall BC2GM001929746 JJ O
treatment BC2GM001929746 NN O
times BC2GM001929746 NNS O
. BC2GM001929746 . O
. . O O

Preventive BC2GM059007743 JJ O
health BC2GM059007743 NN O
counseling BC2GM059007743 NN O
tailored BC2GM059007743 VBN O
to BC2GM059007743 TO O
the BC2GM059007743 DT O
needs BC2GM059007743 NNS O
of BC2GM059007743 IN O
this BC2GM059007743 DT O
group BC2GM059007743 NN O
may BC2GM059007743 MD O
be BC2GM059007743 VB O
most BC2GM059007743 RBS O
beneficial BC2GM059007743 JJ O
. BC2GM059007743 . O
. . O O

However BC2GM022041209 RB O
, BC2GM022041209 , O
to BC2GM022041209 TO O
date BC2GM022041209 NN O
, BC2GM022041209 , O
no BC2GM022041209 DT O
viable BC2GM022041209 JJ O
in BC2GM022041209 IN O
vitro-generated BC2GM022041209 JJ O
deletion BC2GM022041209 NN O
mutant BC2GM022041209 NN O
of BC2GM022041209 IN O
PSTVd BC2GM022041209 NNP O
has BC2GM022041209 VBZ O
been BC2GM022041209 VBN O
reported BC2GM022041209 VBN O
. BC2GM022041209 . O
. . O O

First BC2GM010985473 RB O
, BC2GM010985473 , O
a BC2GM010985473 DT O
GATA-1 BC2GM010985473 NNP O
motif BC2GM010985473 NN O
was BC2GM010985473 VBD O
found BC2GM010985473 VBN O
to BC2GM010985473 TO O
bind BC2GM010985473 VB O
nuclear BC2GM010985473 JJ O
factor BC2GM010985473 NN O
( BC2GM010985473 ( O
s BC2GM010985473 NN O
) BC2GM010985473 ) O
, BC2GM010985473 , O
presumably BC2GM010985473 RB O
the BC2GM010985473 DT O
GATA-1 BC2GM010985473 NNP O
factor BC2GM010985473 NN O
, BC2GM010985473 , O
present BC2GM010985473 JJ O
in BC2GM010985473 IN O
K-562 BC2GM010985473 NNP O
cell BC2GM010985473 NN O
extracts BC2GM010985473 NNS O
and BC2GM010985473 CC O
in BC2GM010985473 IN O
living BC2GM010985473 VBG O
K-562 BC2GM010985473 NNP O
cells BC2GM010985473 NNS O
. BC2GM010985473 . O
. . O O

Immune BC2GM097338310 NNP O
and BC2GM097338310 CC O
clinical BC2GM097338310 JJ O
impact BC2GM097338310 NN O
of BC2GM097338310 IN O
Lactobacillus BC2GM097338310 NNP O
acidophilus BC2GM097338310 CC O
on BC2GM097338310 IN O
asthma BC2GM097338310 NN O
. BC2GM097338310 . O
. . O O

Theophylline BC2GM037104240 NNP O
QID BC2GM037104240 NNP O
, BC2GM037104240 , O
TID BC2GM037104240 NNP O
, BC2GM037104240 , O
BID BC2GM037104240 NNP O
and BC2GM037104240 CC O
now BC2GM037104240 RB O
QD BC2GM037104240 NNP O
? BC2GM037104240 . O
A BC2GM037104240 DT O
report BC2GM037104240 NN O
on BC2GM037104240 IN O
24-hour BC2GM037104240 JJ O
dosing BC2GM037104240 VBG O
with BC2GM037104240 IN O
slow-release BC2GM037104240 JJ O
theophylline BC2GM037104240 NN O
formulations BC2GM037104240 NNS O
with BC2GM037104240 IN O
emphasis BC2GM037104240 NN O
on BC2GM037104240 IN O
analyses BC2GM037104240 NNS O
of BC2GM037104240 IN O
data BC2GM037104240 NNS O
used BC2GM037104240 VBN O
to BC2GM037104240 TO O
obtain BC2GM037104240 VB O
Food BC2GM037104240 NNP O
and BC2GM037104240 CC O
Drug BC2GM037104240 NNP O
Administration BC2GM037104240 NNP O
approval BC2GM037104240 NN O
for BC2GM037104240 IN O
Theo-24 BC2GM037104240 NNP O
. BC2GM037104240 . O
. . O O

Y1 BC2GM033228661 NNP O
, BC2GM033228661 , O
Y2 BC2GM033228661 NNP O
, BC2GM033228661 , O
and BC2GM033228661 CC O
Y4 BC2GM033228661 NNP O
/ BC2GM033228661 NNP O
PP1 BC2GM033228661 NNP O
. BC2GM033228661 . O
. . O O

Prevalence BC2GM010188722 NN O
of BC2GM010188722 IN O
rheumatic BC2GM010188722 JJ O
diseases BC2GM010188722 NNS O
in BC2GM010188722 IN O
a BC2GM010188722 DT O
rural BC2GM010188722 JJ O
population BC2GM010188722 NN O
in BC2GM010188722 IN O
western BC2GM010188722 JJ O
India BC2GM010188722 NNP O
: BC2GM010188722 : O
a BC2GM010188722 DT O
WHO-ILAR BC2GM010188722 JJ O
COPCORD BC2GM010188722 NNP O
Study BC2GM010188722 NNP O
. BC2GM010188722 . O
. . O O

CONCLUSION BC2GM064737481 NN O
: BC2GM064737481 : O
Men BC2GM064737481 NN O
presenting BC2GM064737481 VBG O
with BC2GM064737481 IN O
urethritis BC2GM064737481 NN O
and BC2GM064737481 CC O
women BC2GM064737481 NNS O
presenting BC2GM064737481 VBG O
with BC2GM064737481 IN O
PID BC2GM064737481 NNP O
both BC2GM064737481 DT O
have BC2GM064737481 VBP O
significantly BC2GM064737481 RB O
greater BC2GM064737481 JJR O
peripheral BC2GM064737481 JJ O
blood BC2GM064737481 NN O
mononuclear BC2GM064737481 NN O
cell BC2GM064737481 NN O
proliferative BC2GM064737481 JJ O
responses BC2GM064737481 NNS O
to BC2GM064737481 TO O
the BC2GM064737481 DT O
DK20 BC2GM064737481 NNP O
strain BC2GM064737481 NN O
of BC2GM064737481 IN O
C BC2GM064737481 NNP O
trachomatis BC2GM064737481 NN O
than BC2GM064737481 IN O
controls BC2GM064737481 NNS O
. BC2GM064737481 . O
. . O O

Although BC2GM077806960 IN O
several BC2GM077806960 JJ O
large BC2GM077806960 JJ O
waterborne BC2GM077806960 JJ O
outbreaks BC2GM077806960 NNS O
occurred BC2GM077806960 VBD O
during BC2GM077806960 IN O
the BC2GM077806960 DT O
past BC2GM077806960 JJ O
decade BC2GM077806960 NN O
, BC2GM077806960 , O
most BC2GM077806960 JJS O
were BC2GM077806960 VBD O
in BC2GM077806960 IN O
small BC2GM077806960 JJ O
communities BC2GM077806960 NNS O
. BC2GM077806960 . O
. . O O

ORF3 BC2GM055943127 NNP O
encodes BC2GM055943127 VBZ O
a BC2GM055943127 DT O
putative BC2GM055943127 JJ O
periplasmic BC2GM055943127 JJ O
c-type BC2GM055943127 JJ O
cytochrome BC2GM055943127 NN O
with BC2GM055943127 IN O
a BC2GM055943127 DT O
molecular BC2GM055943127 JJ O
mass BC2GM055943127 NN O
of BC2GM055943127 IN O
94 BC2GM055943127 CD O
, BC2GM055943127 , O
000 BC2GM055943127 CD O
Da BC2GM055943127 NNP O
and BC2GM055943127 CC O
contains BC2GM055943127 NNS O
seven BC2GM055943127 CD O
c-heme-binding BC2GM055943127 JJ O
motifs BC2GM055943127 NNS O
but BC2GM055943127 CC O
shows BC2GM055943127 VBZ O
no BC2GM055943127 DT O
sequence BC2GM055943127 NN O
homology BC2GM055943127 NN O
to BC2GM055943127 TO O
occ BC2GM055943127 VB O
or BC2GM055943127 CC O
ORF1 BC2GM055943127 NNP O
. BC2GM055943127 . O
. . O O

The BC2GM018866489 DT O
temporal BC2GM018866489 JJ O
expression BC2GM018866489 NN O
of BC2GM018866489 IN O
CRAlBP BC2GM018866489 NNP O
is BC2GM018866489 VBZ O
similar BC2GM018866489 JJ O
to BC2GM018866489 TO O
IRBP BC2GM018866489 NNP O
while BC2GM018866489 IN O
bFGF BC2GM018866489 NN O
is BC2GM018866489 VBZ O
not BC2GM018866489 RB O
expressed BC2GM018866489 VBN O
until BC2GM018866489 IN O
after BC2GM018866489 IN O
photoreceptor BC2GM018866489 NN O
differentiation BC2GM018866489 NN O
is BC2GM018866489 VBZ O
complete BC2GM018866489 JJ O
. BC2GM018866489 . O
. . O O

Using BC2GM073047126 VBG O
gel BC2GM073047126 JJ O
retardation BC2GM073047126 NN O
analysis BC2GM073047126 NN O
, BC2GM073047126 , O
four BC2GM073047126 CD O
binding BC2GM073047126 NN O
sites BC2GM073047126 NNS O
for BC2GM073047126 IN O
Rap1p BC2GM073047126 NNP O
have BC2GM073047126 VBP O
been BC2GM073047126 VBN O
identified BC2GM073047126 VBN O
within BC2GM073047126 IN O
the BC2GM073047126 DT O
promoter BC2GM073047126 NN O
of BC2GM073047126 IN O
the BC2GM073047126 DT O
RAP1 BC2GM073047126 NNP O
gene BC2GM073047126 NN O
. BC2GM073047126 . O
. . O O

The BC2GM090582830 DT O
clinical BC2GM090582830 JJ O
picture BC2GM090582830 NN O
, BC2GM090582830 , O
the BC2GM090582830 DT O
light BC2GM090582830 NN O
and BC2GM090582830 CC O
electron BC2GM090582830 NN O
microscopic BC2GM090582830 NN O
appearance BC2GM090582830 NN O
, BC2GM090582830 , O
and BC2GM090582830 CC O
the BC2GM090582830 DT O
histochemical BC2GM090582830 JJ O
findings BC2GM090582830 NNS O
are BC2GM090582830 VBP O
described BC2GM090582830 VBN O
in BC2GM090582830 IN O
six BC2GM090582830 CD O
cases BC2GM090582830 NNS O
of BC2GM090582830 IN O
fibroma BC2GM090582830 NN O
of BC2GM090582830 IN O
tendon BC2GM090582830 JJ O
sheath BC2GM090582830 NN O
. BC2GM090582830 . O
. . O O

Obtaining BC2GM030293079 VBG O
kidney BC2GM030293079 NN O
cells BC2GM030293079 NNS O
from BC2GM030293079 IN O
a BC2GM030293079 DT O
beagle BC2GM030293079 NN O
puppy BC2GM030293079 JJ O
( BC2GM030293079 ( O
RPB-1 BC2GM030293079 NNP O
) BC2GM030293079 ) O
and BC2GM030293079 CC O
the BC2GM030293079 DT O
establishment BC2GM030293079 NN O
of BC2GM030293079 IN O
a BC2GM030293079 DT O
cryopreservation BC2GM030293079 NN O
bank BC2GM030293079 NN O
. BC2GM030293079 . O
. . O O

The BC2GM017837173 DT O
severity BC2GM017837173 NN O
of BC2GM017837173 IN O
the BC2GM017837173 DT O
psychomotor BC2GM017837173 NN O
retardation BC2GM017837173 NN O
varied BC2GM017837173 VBD O
from BC2GM017837173 IN O
mild BC2GM017837173 NN O
to BC2GM017837173 TO O
severe BC2GM017837173 VB O
. BC2GM017837173 . O
. . O O

Results BC2GM073939713 NNS O
indicated BC2GM073939713 VBD O
that BC2GM073939713 IN O
hobbies BC2GM073939713 NNS O
/ BC2GM073939713 VBP O
leisure BC2GM073939713 NN O
activities BC2GM073939713 NNS O
, BC2GM073939713 , O
mobility BC2GM073939713 NN O
, BC2GM073939713 , O
transport BC2GM073939713 NN O
, BC2GM073939713 , O
social BC2GM073939713 JJ O
relationships BC2GM073939713 NNS O
, BC2GM073939713 , O
working BC2GM073939713 VBG O
capacity BC2GM073939713 NN O
, BC2GM073939713 , O
energy BC2GM073939713 NN O
and BC2GM073939713 CC O
doing BC2GM073939713 VBG O
things BC2GM073939713 NNS O
slower BC2GM073939713 JJR O
were BC2GM073939713 VBD O
aspects BC2GM073939713 NNS O
relevant BC2GM073939713 JJ O
to BC2GM073939713 TO O
IPF BC2GM073939713 NNP O
patients BC2GM073939713 NNS O
' BC2GM073939713 POS O
QOL BC2GM073939713 NNP O
. BC2GM073939713 . O
. . O O

The BC2GM069591323 DT O
disease BC2GM069591323 NN O
processes BC2GM069591323 VBZ O
that BC2GM069591323 IN O
affect BC2GM069591323 JJ O
transplant BC2GM069591323 NN O
patients BC2GM069591323 NNS O
both BC2GM069591323 DT O
before BC2GM069591323 IN O
and BC2GM069591323 CC O
after BC2GM069591323 IN O
transplantation BC2GM069591323 NN O
are BC2GM069591323 VBP O
not BC2GM069591323 RB O
seen BC2GM069591323 VBN O
frequently BC2GM069591323 RB O
in BC2GM069591323 IN O
the BC2GM069591323 DT O
general BC2GM069591323 JJ O
practice BC2GM069591323 NN O
of BC2GM069591323 IN O
gastroenterology BC2GM069591323 NN O
. BC2GM069591323 . O
. . O O

In BC2GM080581742 IN O
addition BC2GM080581742 NN O
, BC2GM080581742 , O
Fc BC2GM080581742 NNP O
epsilon BC2GM080581742 VBZ O
R1 BC2GM080581742 NNP O
cross-linking BC2GM080581742 NN O
activates BC2GM080581742 NNS O
PI BC2GM080581742 NNP O
3-kinase BC2GM080581742 CD O
. BC2GM080581742 . O
. . O O

Fluorescence BC2GM075182696 NN O
in BC2GM075182696 IN O
situ BC2GM075182696 JJ O
hybridization BC2GM075182696 NN O
was BC2GM075182696 VBD O
used BC2GM075182696 VBN O
to BC2GM075182696 TO O
investigate BC2GM075182696 VB O
the BC2GM075182696 DT O
physical BC2GM075182696 JJ O
distribution BC2GM075182696 NN O
and BC2GM075182696 CC O
revealed BC2GM075182696 VBD O
that BC2GM075182696 IN O
both BC2GM075182696 DT O
retrotransposon BC2GM075182696 JJ O
families BC2GM075182696 NNS O
are BC2GM075182696 VBP O
present BC2GM075182696 JJ O
on BC2GM075182696 IN O
all BC2GM075182696 DT O
sugar BC2GM075182696 JJ O
beet BC2GM075182696 NN O
chromosomes BC2GM075182696 NNS O
and BC2GM075182696 CC O
largely BC2GM075182696 RB O
excluded BC2GM075182696 VBN O
from BC2GM075182696 IN O
chromosomal BC2GM075182696 JJ O
regions BC2GM075182696 NNS O
harbouring BC2GM075182696 VBG O
the BC2GM075182696 DT O
18S-5.8S-25S BC2GM075182696 JJ O
rRNA BC2GM075182696 NN O
genes BC2GM075182696 NNS O
. BC2GM075182696 . O
. . O O

Oligomers BC2GM000554364 NNS O
corresponding BC2GM000554364 VBG O
to BC2GM000554364 TO O
the BC2GM000554364 DT O
region BC2GM000554364 NN O
of BC2GM000554364 IN O
the BC2GM000554364 DT O
mlc-1 BC2GM000554364 JJ O
/ BC2GM000554364 NN O
3 BC2GM000554364 CD O
enhancer BC2GM000554364 NN O
, BC2GM000554364 , O
which BC2GM000554364 WDT O
encompasses BC2GM000554364 VBZ O
this BC2GM000554364 DT O
conserved BC2GM000554364 JJ O
sequence BC2GM000554364 NN O
, BC2GM000554364 , O
bound BC2GM000554364 IN O
MEF-2 BC2GM000554364 NNP O
and BC2GM000554364 CC O
competed BC2GM000554364 VBN O
for BC2GM000554364 IN O
its BC2GM000554364 PRP$ O
binding BC2GM000554364 NN O
to BC2GM000554364 TO O
the BC2GM000554364 DT O
mck BC2GM000554364 NN O
enhancer BC2GM000554364 NN O
. BC2GM000554364 . O
. . O O

Single BC2GM082775110 NNP O
substitutions BC2GM082775110 NNS O
of BC2GM082775110 IN O
three BC2GM082775110 CD O
highly BC2GM082775110 RB O
conserved BC2GM082775110 VBN O
phenylalanine BC2GM082775110 NN O
residues BC2GM082775110 NNS O
( BC2GM082775110 ( O
Phe-15 BC2GM082775110 NNP O
, BC2GM082775110 , O
Phe-17 BC2GM082775110 NNP O
, BC2GM082775110 , O
Phe-27 BC2GM082775110 NNP O
) BC2GM082775110 ) O
by BC2GM082775110 IN O
alanine BC2GM082775110 NN O
and BC2GM082775110 CC O
substitution BC2GM082775110 NN O
of BC2GM082775110 IN O
one BC2GM082775110 CD O
histidine BC2GM082775110 NN O
( BC2GM082775110 ( O
His-29 BC2GM082775110 NNP O
) BC2GM082775110 ) O
by BC2GM082775110 IN O
glutamine BC2GM082775110 NN O
, BC2GM082775110 , O
all BC2GM082775110 DT O
located BC2GM082775110 VBN O
within BC2GM082775110 IN O
the BC2GM082775110 DT O
putative BC2GM082775110 JJ O
RNA-binding BC2GM082775110 JJ O
sites BC2GM082775110 NNS O
RNP-1 BC2GM082775110 JJ O
and BC2GM082775110 CC O
RNP-2 BC2GM082775110 NNP O
, BC2GM082775110 , O
abolished BC2GM082775110 VBD O
the BC2GM082775110 DT O
nucleic BC2GM082775110 JJ O
acid-binding BC2GM082775110 JJ O
activity BC2GM082775110 NN O
of BC2GM082775110 IN O
CspB BC2GM082775110 NNP O
. BC2GM082775110 . O
. . O O

In BC2GM006324019 IN O
the BC2GM006324019 DT O
studies BC2GM006324019 NNS O
described BC2GM006324019 VBN O
in BC2GM006324019 IN O
this BC2GM006324019 DT O
report BC2GM006324019 NN O
, BC2GM006324019 , O
we BC2GM006324019 PRP O
have BC2GM006324019 VBP O
identified BC2GM006324019 VBN O
two BC2GM006324019 CD O
potential BC2GM006324019 JJ O
Ets BC2GM006324019 NNP O
binding BC2GM006324019 VBG O
sites BC2GM006324019 NNS O
, BC2GM006324019 , O
EBS1 BC2GM006324019 NNP O
and BC2GM006324019 CC O
EBS2 BC2GM006324019 NNP O
, BC2GM006324019 , O
which BC2GM006324019 WDT O
are BC2GM006324019 VBP O
conserved BC2GM006324019 VBN O
in BC2GM006324019 IN O
both BC2GM006324019 DT O
the BC2GM006324019 DT O
human BC2GM006324019 JJ O
and BC2GM006324019 CC O
murine BC2GM006324019 JJ O
interleukin-2 BC2GM006324019 JJ O
enhancers BC2GM006324019 NNS O
. BC2GM006324019 . O
. . O O

The BC2GM036710318 DT O
transcription BC2GM036710318 NN O
start BC2GM036710318 NN O
site BC2GM036710318 NN O
was BC2GM036710318 VBD O
identified BC2GM036710318 VBN O
by BC2GM036710318 IN O
primer BC2GM036710318 JJ O
extension BC2GM036710318 NN O
analysis BC2GM036710318 NN O
and BC2GM036710318 CC O
over BC2GM036710318 IN O
800 BC2GM036710318 CD O
bp BC2GM036710318 NNS O
of BC2GM036710318 IN O
5 BC2GM036710318 CD O
' BC2GM036710318 POS O
flanking BC2GM036710318 VBG O
DNA BC2GM036710318 NN O
was BC2GM036710318 VBD O
sequenced BC2GM036710318 VBN O
. BC2GM036710318 . O
. . O O

It BC2GM073260953 PRP O
produced BC2GM073260953 VBD O
extrapyramidal BC2GM073260953 JJ O
disturbances BC2GM073260953 NNS O
in BC2GM073260953 IN O
nearly BC2GM073260953 RB O
every BC2GM073260953 DT O
subject BC2GM073260953 NN O
, BC2GM073260953 , O
the BC2GM073260953 DT O
most BC2GM073260953 RBS O
common BC2GM073260953 JJ O
being BC2GM073260953 VBG O
akathisia BC2GM073260953 JJ O
and BC2GM073260953 CC O
the BC2GM073260953 DT O
most BC2GM073260953 RBS O
severe BC2GM073260953 JJ O
, BC2GM073260953 , O
in BC2GM073260953 IN O
the BC2GM073260953 DT O
case BC2GM073260953 NN O
of BC2GM073260953 IN O
one BC2GM073260953 CD O
individual BC2GM073260953 NN O
, BC2GM073260953 , O
being BC2GM073260953 VBG O
acute BC2GM073260953 JJ O
dystonia BC2GM073260953 NN O
. BC2GM073260953 . O
. . O O

80 BC2GM069143937 CD O
v-ets-encoded BC2GM069143937 JJ O
amino-acids BC2GM069143937 NNS O
located BC2GM069143937 VBN O
immediately BC2GM069143937 RB O
after BC2GM069143937 IN O
the BC2GM069143937 DT O
v-myb BC2GM069143937 JJ O
/ BC2GM069143937 JJ O
v-ets BC2GM069143937 NNS O
junction BC2GM069143937 NN O
are BC2GM069143937 VBP O
not BC2GM069143937 RB O
found BC2GM069143937 VBN O
in BC2GM069143937 IN O
P54 BC2GM069143937 NNP O
/ BC2GM069143937 NNP O
56c-ets BC2GM069143937 NNS O
, BC2GM069143937 , O
the BC2GM069143937 DT O
translation BC2GM069143937 NN O
product BC2GM069143937 NN O
of BC2GM069143937 IN O
the BC2GM069143937 DT O
c-ets BC2GM069143937 NNS O
proto-oncogene BC2GM069143937 NN O
, BC2GM069143937 , O
nor BC2GM069143937 CC O
in BC2GM069143937 IN O
a BC2GM069143937 DT O
set BC2GM069143937 NN O
of BC2GM069143937 IN O
cellular BC2GM069143937 JJ O
proteins BC2GM069143937 NNS O
of BC2GM069143937 IN O
64 BC2GM069143937 CD O
, BC2GM069143937 , O
62 BC2GM069143937 CD O
, BC2GM069143937 , O
and BC2GM069143937 CC O
60 BC2GM069143937 CD O
kDa BC2GM069143937 NNS O
related BC2GM069143937 VBN O
to BC2GM069143937 TO O
but BC2GM069143937 CC O
distinct BC2GM069143937 JJ O
from BC2GM069143937 IN O
P54 BC2GM069143937 NNP O
/ BC2GM069143937 NNP O
56c-ets BC2GM069143937 NNS O
. BC2GM069143937 . O
. . O O

Concentrations BC2GM096535156 NNS O
of BC2GM096535156 IN O
Co BC2GM096535156 NNP O
, BC2GM096535156 , O
Cu BC2GM096535156 NNP O
, BC2GM096535156 , O
Fe BC2GM096535156 NNP O
, BC2GM096535156 , O
Hg BC2GM096535156 NNP O
, BC2GM096535156 , O
Mn BC2GM096535156 NNP O
, BC2GM096535156 , O
Sb BC2GM096535156 NNP O
, BC2GM096535156 , O
Se BC2GM096535156 NNP O
and BC2GM096535156 CC O
Zn BC2GM096535156 NNP O
in BC2GM096535156 IN O
IAEA BC2GM096535156 NNP O
milk BC2GM096535156 NN O
( BC2GM096535156 ( O
dry BC2GM096535156 JJ O
) BC2GM096535156 ) O
standard BC2GM096535156 JJ O
A-11 BC2GM096535156 NNP O
were BC2GM096535156 VBD O
re-evaluated BC2GM096535156 JJ O
with BC2GM096535156 IN O
the BC2GM096535156 DT O
help BC2GM096535156 NN O
of BC2GM096535156 IN O
instrumental BC2GM096535156 JJ O
and BC2GM096535156 CC O
radiochemical BC2GM096535156 JJ O
neutron BC2GM096535156 NN O
activation BC2GM096535156 NN O
analysis BC2GM096535156 NN O
( BC2GM096535156 ( O
NAA BC2GM096535156 NNP O
) BC2GM096535156 ) O
. BC2GM096535156 . O
. . O O

Anxiogenic BC2GM040965133 JJ O
effects BC2GM040965133 NNS O
of BC2GM040965133 IN O
pentagastrin BC2GM040965133 NN O
in BC2GM040965133 IN O
patients BC2GM040965133 NNS O
with BC2GM040965133 IN O
social BC2GM040965133 JJ O
phobia BC2GM040965133 NN O
and BC2GM040965133 CC O
healthy BC2GM040965133 JJ O
controls BC2GM040965133 NNS O
. BC2GM040965133 . O
. . O O

A BC2GM051722169 DT O
Laboratory BC2GM051722169 NNP O
Manual BC2GM051722169 NNP O
, BC2GM051722169 , O
2nd BC2GM051722169 CD O
ed BC2GM051722169 NN O
. BC2GM051722169 . O
. . O O

The BC2GM070010580 DT O
2.3 BC2GM070010580 CD O
x BC2GM070010580 NN O
10 BC2GM070010580 CD O
( BC2GM070010580 ( O
3 BC2GM070010580 CD O
) BC2GM070010580 ) O
base BC2GM070010580 NN O
SUF12+ BC2GM070010580 NNP O
transcript BC2GM070010580 NN O
contains BC2GM070010580 VBZ O
an BC2GM070010580 DT O
open BC2GM070010580 JJ O
reading BC2GM070010580 NN O
frame BC2GM070010580 NN O
sufficient BC2GM070010580 JJ O
to BC2GM070010580 TO O
encode BC2GM070010580 VB O
a BC2GM070010580 DT O
88 BC2GM070010580 CD O
x BC2GM070010580 NN O
10 BC2GM070010580 CD O
( BC2GM070010580 ( O
3 BC2GM070010580 CD O
) BC2GM070010580 ) O
Mr BC2GM070010580 NNP O
protein BC2GM070010580 NN O
. BC2GM070010580 . O
. . O O

Discriminant BC2GM017164841 JJ O
function BC2GM017164841 NN O
analysis BC2GM017164841 NN O
suggests BC2GM017164841 VBZ O
that BC2GM017164841 IN O
AUDIT BC2GM017164841 NNP O
scores BC2GM017164841 NNS O
can BC2GM017164841 MD O
successfully BC2GM017164841 RB O
identify BC2GM017164841 VB O
SAT-positive BC2GM017164841 JJ O
and BC2GM017164841 CC O
SAT-negative BC2GM017164841 JJ O
patients BC2GM017164841 NNS O
; BC2GM017164841 : O
the BC2GM017164841 DT O
analysis BC2GM017164841 NN O
accounted BC2GM017164841 VBD O
for BC2GM017164841 IN O
42.5 BC2GM017164841 CD O
% BC2GM017164841 NN O
of BC2GM017164841 IN O
the BC2GM017164841 DT O
variance BC2GM017164841 NN O
and BC2GM017164841 CC O
correctly BC2GM017164841 RB O
classified BC2GM017164841 VBD O
84.6 BC2GM017164841 CD O
% BC2GM017164841 NN O
of BC2GM017164841 IN O
the BC2GM017164841 DT O
sample BC2GM017164841 NN O
. BC2GM017164841 . O
. . O O

Electrically BC2GM035320296 RB O
induced BC2GM035320296 JJ O
undulations BC2GM035320296 NNS O
and BC2GM035320296 CC O
their BC2GM035320296 PRP$ O
competition BC2GM035320296 NN O
with BC2GM035320296 IN O
electrically BC2GM035320296 RB O
induced BC2GM035320296 VBN O
convection BC2GM035320296 NN O
in BC2GM035320296 IN O
cholesteric BC2GM035320296 JJ O
liquid BC2GM035320296 NN O
crystals BC2GM035320296 NNS O
. BC2GM035320296 . O
. . O O

4-Hydroxyproline BC2GM018782091 JJ O
assays BC2GM018782091 NNS O
were BC2GM018782091 VBD O
performed BC2GM018782091 VBN O
to BC2GM018782091 TO O
determine BC2GM018782091 VB O
collagen BC2GM018782091 NN O
content BC2GM018782091 NN O
. BC2GM018782091 . O
. . O O

Finally BC2GM049146071 RB O
, BC2GM049146071 , O
we BC2GM049146071 PRP O
demonstrate BC2GM049146071 VBP O
that BC2GM049146071 IN O
animals BC2GM049146071 NNS O
carrying BC2GM049146071 VBG O
a BC2GM049146071 DT O
snf BC2GM049146071 JJ O
mutation BC2GM049146071 NN O
that BC2GM049146071 WDT O
converts BC2GM049146071 VBZ O
SNF BC2GM049146071 NNP O
from BC2GM049146071 IN O
a BC2GM049146071 DT O
bifunctional BC2GM049146071 JJ O
protein BC2GM049146071 NN O
to BC2GM049146071 TO O
a BC2GM049146071 DT O
U1 BC2GM049146071 NNP O
snRNP-specific BC2GM049146071 JJ O
protein BC2GM049146071 NN O
are BC2GM049146071 VBP O
viable BC2GM049146071 JJ O
. BC2GM049146071 . O
. . O O

Additional BC2GM052594867 JJ O
transection BC2GM052594867 NN O
of BC2GM052594867 IN O
both BC2GM052594867 DT O
ADN BC2GM052594867 NNP O
eliminated BC2GM052594867 VBD O
the BC2GM052594867 DT O
remaining BC2GM052594867 VBG O
sigmoidal BC2GM052594867 JJ O
correlation BC2GM052594867 NN O
between BC2GM052594867 IN O
MAP BC2GM052594867 NNP O
and BC2GM052594867 CC O
RSNA BC2GM052594867 NNP O
with BC2GM052594867 IN O
further BC2GM052594867 JJ O
increases BC2GM052594867 NNS O
in BC2GM052594867 IN O
resting BC2GM052594867 VBG O
MAP BC2GM052594867 NNP O
and BC2GM052594867 CC O
RSNA BC2GM052594867 NNP O
. BC2GM052594867 . O
. . O O

It BC2GM072953233 PRP O
tends BC2GM072953233 VBZ O
to BC2GM072953233 TO O
be BC2GM072953233 VB O
higher BC2GM072953233 JJR O
between BC2GM072953233 IN O
frazioni BC2GM072953233 NN O
of BC2GM072953233 IN O
the BC2GM072953233 DT O
same BC2GM072953233 JJ O
community BC2GM072953233 NN O
than BC2GM072953233 IN O
between BC2GM072953233 IN O
communities BC2GM072953233 NNS O
. BC2GM072953233 . O
. . O O

Root BC2GM062280963 NNP O
surface BC2GM062280963 NN O
caries BC2GM062280963 NNS O
incidence BC2GM062280963 NN O
in BC2GM062280963 IN O
the BC2GM062280963 DT O
groups BC2GM062280963 NNS O
inoculated BC2GM062280963 VBD O
with BC2GM062280963 IN O
A. BC2GM062280963 NNP O
viscosus BC2GM062280963 NN O
and BC2GM062280963 CC O
A. BC2GM062280963 NNP O
viscosus BC2GM062280963 NNP O
plus BC2GM062280963 CC O
S. BC2GM062280963 NNP O
sobrinus BC2GM062280963 NN O
did BC2GM062280963 VBD O
not BC2GM062280963 RB O
differ BC2GM062280963 VB O
. BC2GM062280963 . O
. . O O

The BC2GM032034538 DT O
authors BC2GM032034538 NNS O
recommend BC2GM032034538 VBP O
in BC2GM032034538 IN O
cases BC2GM032034538 NNS O
with BC2GM032034538 IN O
an BC2GM032034538 DT O
elevated BC2GM032034538 JJ O
transaminase BC2GM032034538 NN O
serum BC2GM032034538 NN O
activity BC2GM032034538 NN O
more BC2GM032034538 RBR O
frequent BC2GM032034538 JJ O
check-up BC2GM032034538 JJ O
examinations BC2GM032034538 NNS O
to BC2GM032034538 TO O
avoid BC2GM032034538 VB O
missing BC2GM032034538 VBG O
of BC2GM032034538 IN O
a BC2GM032034538 DT O
relapse BC2GM032034538 NN O
, BC2GM032034538 , O
and BC2GM032034538 CC O
to BC2GM032034538 TO O
examine BC2GM032034538 VB O
repeatedly BC2GM032034538 RB O
IgM BC2GM032034538 NNP O
anti-HAV BC2GM032034538 JJ O
as BC2GM032034538 IN O
in BC2GM032034538 IN O
protracted BC2GM032034538 JJ O
forms BC2GM032034538 NNS O
of BC2GM032034538 IN O
hepatitis BC2GM032034538 NN O
IgM BC2GM032034538 NNP O
anti-HAV BC2GM032034538 NN O
may BC2GM032034538 MD O
persist BC2GM032034538 VB O
even BC2GM032034538 RB O
when BC2GM032034538 WRB O
the BC2GM032034538 DT O
transaminase BC2GM032034538 NN O
activity BC2GM032034538 NN O
is BC2GM032034538 VBZ O
normal BC2GM032034538 JJ O
. BC2GM032034538 . O
. . O O

Comparison BC2GM050621994 NN O
with BC2GM050621994 IN O
the BC2GM050621994 DT O
data BC2GM050621994 NNS O
of BC2GM050621994 IN O
clinical BC2GM050621994 JJ O
development BC2GM050621994 NN O
and BC2GM050621994 CC O
hemodynamic BC2GM050621994 JJ O
results BC2GM050621994 NNS O
. BC2GM050621994 . O
. . O O

After BC2GM031587452 IN O
5 BC2GM031587452 CD O
days BC2GM031587452 NNS O
stimulation BC2GM031587452 NN O
with BC2GM031587452 IN O
G-CSF BC2GM031587452 NNP O
( BC2GM031587452 ( O
10 BC2GM031587452 CD O
micrograms BC2GM031587452 NNS O
/ BC2GM031587452 NNP O
kg BC2GM031587452 NN O
) BC2GM031587452 ) O
1l BC2GM031587452 CD O
of BC2GM031587452 IN O
blood BC2GM031587452 NN O
was BC2GM031587452 VBD O
drawn BC2GM031587452 VBN O
, BC2GM031587452 , O
kept BC2GM031587452 VBD O
unprocessed BC2GM031587452 JJ O
for BC2GM031587452 IN O
3 BC2GM031587452 CD O
days BC2GM031587452 NNS O
and BC2GM031587452 CC O
reinfused BC2GM031587452 VBD O
24 BC2GM031587452 CD O
h BC2GM031587452 NN O
after BC2GM031587452 IN O
completion BC2GM031587452 NN O
of BC2GM031587452 IN O
chemotherapy BC2GM031587452 NN O
. BC2GM031587452 . O
. . O O

Thus BC2GM031494591 RB O
, BC2GM031494591 , O
the BC2GM031494591 DT O
pathway BC2GM031494591 NN O
to BC2GM031494591 TO O
Fc BC2GM031494591 NNP O
epsilonRI-mediated BC2GM031494591 JJ O
MEK BC2GM031494591 NNP O
/ BC2GM031494591 NNP O
ERK BC2GM031494591 NNP O
and BC2GM031494591 CC O
ERK BC2GM031494591 NNP O
activation BC2GM031494591 NN O
can BC2GM031494591 MD O
apparently BC2GM031494591 RB O
bypass BC2GM031494591 VB O
Ras BC2GM031494591 NNP O
and BC2GM031494591 CC O
Raf-1 BC2GM031494591 NNP O
. BC2GM031494591 . O
. . O O

New BC2GM055611171 NNP O
protein-free BC2GM055611171 JJ O
products BC2GM055611171 NNS O
for BC2GM055611171 IN O
diet BC2GM055611171 JJ O
therapy BC2GM055611171 NN O
in BC2GM055611171 IN O
chronic BC2GM055611171 JJ O
renal BC2GM055611171 JJ O
insufficiency BC2GM055611171 NN O
. BC2GM055611171 . O
. . O O

In BC2GM040760692 IN O
this BC2GM040760692 DT O
group BC2GM040760692 NN O
of BC2GM040760692 IN O
patients BC2GM040760692 NNS O
, BC2GM040760692 , O
the BC2GM040760692 DT O
mean BC2GM040760692 NN O
LH BC2GM040760692 NNP O
( BC2GM040760692 ( O
9.3 BC2GM040760692 CD O
+ BC2GM040760692 NN O
/ BC2GM040760692 NNP O
- BC2GM040760692 : O
5.9 BC2GM040760692 CD O
IU BC2GM040760692 NNP O
/ BC2GM040760692 NNP O
l BC2GM040760692 NN O
) BC2GM040760692 ) O
and BC2GM040760692 CC O
sex-hormone BC2GM040760692 JJ O
binding BC2GM040760692 NN O
globulin BC2GM040760692 NN O
( BC2GM040760692 ( O
SHBG BC2GM040760692 NNP O
) BC2GM040760692 ) O
( BC2GM040760692 ( O
54.5 BC2GM040760692 CD O
+ BC2GM040760692 NN O
/ BC2GM040760692 NNP O
- BC2GM040760692 : O
22.9 BC2GM040760692 CD O
nmol BC2GM040760692 JJ O
/ BC2GM040760692 NNP O
l BC2GM040760692 NN O
) BC2GM040760692 ) O
concentrations BC2GM040760692 NNS O
were BC2GM040760692 VBD O
significantly BC2GM040760692 RB O
greater BC2GM040760692 JJR O
than BC2GM040760692 IN O
those BC2GM040760692 DT O
of BC2GM040760692 IN O
five BC2GM040760692 CD O
normal BC2GM040760692 JJ O
control BC2GM040760692 NN O
subjects BC2GM040760692 NNS O
( BC2GM040760692 ( O
4.7 BC2GM040760692 CD O
+ BC2GM040760692 NN O
/ BC2GM040760692 NNP O
- BC2GM040760692 : O
1.11 BC2GM040760692 CD O
IU BC2GM040760692 NNP O
/ BC2GM040760692 NNP O
l BC2GM040760692 NN O
and BC2GM040760692 CC O
26.0 BC2GM040760692 CD O
+ BC2GM040760692 NN O
/ BC2GM040760692 NNP O
- BC2GM040760692 : O
7.0 BC2GM040760692 CD O
nmol BC2GM040760692 JJ O
/ BC2GM040760692 NNP O
l BC2GM040760692 NN O
respectively BC2GM040760692 RB O
) BC2GM040760692 ) O
. BC2GM040760692 . O
. . O O

With BC2GM028935369 IN O
this BC2GM028935369 DT O
study BC2GM028935369 NN O
, BC2GM028935369 , O
a BC2GM028935369 DT O
total BC2GM028935369 NN O
of BC2GM028935369 IN O
13 BC2GM028935369 CD O
operators BC2GM028935369 NNS O
for BC2GM028935369 IN O
the BC2GM028935369 DT O
glp BC2GM028935369 NN O
regulon BC2GM028935369 NN O
have BC2GM028935369 VBP O
been BC2GM028935369 VBN O
characterized BC2GM028935369 VBN O
. BC2GM028935369 . O
. . O O

We BC2GM054501592 PRP O
hypothesized BC2GM054501592 VBD O
that BC2GM054501592 IN O
conjugated BC2GM054501592 VBD O
estrogens BC2GM054501592 NNS O
, BC2GM054501592 , O
which BC2GM054501592 WDT O
contain BC2GM054501592 VBP O
several BC2GM054501592 JJ O
vasoactive BC2GM054501592 JJ O
estrogenic BC2GM054501592 JJ O
compounds BC2GM054501592 NNS O
, BC2GM054501592 , O
may BC2GM054501592 MD O
favorably BC2GM054501592 RB O
influence BC2GM054501592 VB O
the BC2GM054501592 DT O
vasomotor BC2GM054501592 NN O
response BC2GM054501592 NN O
to BC2GM054501592 TO O
acetylcholine BC2GM054501592 VB O
in BC2GM054501592 IN O
men BC2GM054501592 NNS O
. BC2GM054501592 . O
. . O O

Several BC2GM082270855 JJ O
studies BC2GM082270855 NNS O
have BC2GM082270855 VBP O
demonstrated BC2GM082270855 VBN O
that BC2GM082270855 IN O
the BC2GM082270855 DT O
corticotropin-releasing BC2GM082270855 JJ O
factor BC2GM082270855 NN O
test BC2GM082270855 NN O
( BC2GM082270855 ( O
CRF BC2GM082270855 NNP O
) BC2GM082270855 ) O
is BC2GM082270855 VBZ O
useful BC2GM082270855 JJ O
for BC2GM082270855 IN O
the BC2GM082270855 DT O
aetiological BC2GM082270855 JJ O
diagnosis BC2GM082270855 NN O
of BC2GM082270855 IN O
Cushing BC2GM082270855 NNP O
's BC2GM082270855 POS O
syndrome BC2GM082270855 NN O
: BC2GM082270855 : O
in BC2GM082270855 IN O
Cushing BC2GM082270855 NNP O
's BC2GM082270855 POS O
disease BC2GM082270855 NN O
, BC2GM082270855 , O
as BC2GM082270855 IN O
opposed BC2GM082270855 VBN O
to BC2GM082270855 TO O
ectopic BC2GM082270855 VB O
ACTH BC2GM082270855 NNP O
secretion BC2GM082270855 NN O
syndrome BC2GM082270855 NN O
, BC2GM082270855 , O
the BC2GM082270855 DT O
hypothalamus-pituitary-adrenal BC2GM082270855 JJ O
( BC2GM082270855 ( O
HPA BC2GM082270855 NNP O
) BC2GM082270855 ) O
axis BC2GM082270855 NN O
can BC2GM082270855 MD O
still BC2GM082270855 RB O
be BC2GM082270855 VB O
stimulated BC2GM082270855 VBN O
by BC2GM082270855 IN O
CRF BC2GM082270855 NNP O
. BC2GM082270855 . O
. . O O

The BC2GM006693980 DT O
methods BC2GM006693980 NNS O
used BC2GM006693980 VBN O
were BC2GM006693980 VBD O
the BC2GM006693980 DT O
AOAC BC2GM006693980 NNP O
method BC2GM006693980 NN O
of BC2GM006693980 IN O
dilution BC2GM006693980 NN O
and BC2GM006693980 CC O
heating BC2GM006693980 NN O
; BC2GM006693980 : O
the BC2GM006693980 DT O
addition BC2GM006693980 NN O
of BC2GM006693980 IN O
mercuric BC2GM006693980 JJ O
chloride BC2GM006693980 NN O
, BC2GM006693980 , O
charcoal BC2GM006693980 NN O
, BC2GM006693980 , O
and BC2GM006693980 CC O
Carrez BC2GM006693980 NNP O
reagents BC2GM006693980 NNS O
at BC2GM006693980 IN O
2 BC2GM006693980 CD O
different BC2GM006693980 JJ O
pH BC2GM006693980 NN O
values BC2GM006693980 NNS O
; BC2GM006693980 : O
and BC2GM006693980 CC O
direct BC2GM006693980 JJ O
analysis BC2GM006693980 NN O
of BC2GM006693980 IN O
sample BC2GM006693980 JJ O
supernatants BC2GM006693980 NNS O
with BC2GM006693980 IN O
no BC2GM006693980 DT O
treatment BC2GM006693980 NN O
( BC2GM006693980 ( O
control BC2GM006693980 NN O
) BC2GM006693980 ) O
. BC2GM006693980 . O
. . O O

One BC2GM058549376 CD O
hundred BC2GM058549376 CD O
cDNA BC2GM058549376 NN O
clones BC2GM058549376 NNS O
were BC2GM058549376 VBD O
sequenced BC2GM058549376 VBN O
and BC2GM058549376 CC O
8 BC2GM058549376 CD O
RTKs BC2GM058549376 NNP O
were BC2GM058549376 VBD O
identified BC2GM058549376 VBN O
, BC2GM058549376 , O
as BC2GM058549376 RB O
well BC2GM058549376 RB O
as BC2GM058549376 IN O
12 BC2GM058549376 CD O
non-RTKs BC2GM058549376 JJ O
and BC2GM058549376 CC O
2 BC2GM058549376 CD O
serine BC2GM058549376 NN O
/ BC2GM058549376 NNP O
threonine BC2GM058549376 NN O
kinases BC2GM058549376 NNS O
. BC2GM058549376 . O
. . O O

We BC2GM067715676 PRP O
show BC2GM067715676 VBP O
that BC2GM067715676 IN O
sae1-1 BC2GM067715676 JJ O
and BC2GM067715676 CC O
sae3-1 BC2GM067715676 JJ O
mutations BC2GM067715676 NNS O
each BC2GM067715676 DT O
confer BC2GM067715676 VBP O
a BC2GM067715676 DT O
distinct BC2GM067715676 JJ O
defect BC2GM067715676 NN O
in BC2GM067715676 IN O
meiotic BC2GM067715676 JJ O
recombination BC2GM067715676 NN O
. BC2GM067715676 . O
sae1-1 BC2GM067715676 JJ O
produces BC2GM067715676 VBZ O
recombinants BC2GM067715676 NNS O
but BC2GM067715676 CC O
very BC2GM067715676 RB O
slowly BC2GM067715676 RB O
and BC2GM067715676 CC O
ultimately BC2GM067715676 RB O
to BC2GM067715676 TO O
less BC2GM067715676 JJR O
than BC2GM067715676 IN O
half BC2GM067715676 PDT O
the BC2GM067715676 DT O
wild-type BC2GM067715676 JJ O
level BC2GM067715676 NN O
; BC2GM067715676 : O
sae3-1 BC2GM067715676 JJ O
makes BC2GM067715676 VBZ O
persistent BC2GM067715676 JJ O
hyper-resected BC2GM067715676 JJ O
meiotic BC2GM067715676 JJ O
double-strand BC2GM067715676 NN O
breaks BC2GM067715676 NNS O
and BC2GM067715676 CC O
has BC2GM067715676 VBZ O
a BC2GM067715676 DT O
severe BC2GM067715676 JJ O
defect BC2GM067715676 NN O
in BC2GM067715676 IN O
formation BC2GM067715676 NN O
of BC2GM067715676 IN O
recombinants BC2GM067715676 NNS O
. BC2GM067715676 . O
. . O O

A BC2GM007032064 DT O
sequence-ready BC2GM007032064 JJ O
3-Mb BC2GM007032064 JJ O
PAC BC2GM007032064 NNP O
contig BC2GM007032064 NN O
covering BC2GM007032064 VBG O
16 BC2GM007032064 CD O
breakpoints BC2GM007032064 NNS O
of BC2GM007032064 IN O
the BC2GM007032064 DT O
Wilms BC2GM007032064 NNP O
tumor BC2GM007032064 NN O
/ BC2GM007032064 NNP O
anirida BC2GM007032064 JJ O
region BC2GM007032064 NN O
of BC2GM007032064 IN O
human BC2GM007032064 JJ O
chromosome BC2GM007032064 NN O
11p13 BC2GM007032064 CD O
. BC2GM007032064 . O
. . O O

For BC2GM054038982 IN O
Thermus BC2GM054038982 NNP O
strain BC2GM054038982 NN O
ZO5 BC2GM054038982 NNP O
dihydroorotase BC2GM054038982 NN O
( BC2GM054038982 ( O
DHOase BC2GM054038982 NNP O
; BC2GM054038982 : O
encoded BC2GM054038982 VBN O
by BC2GM054038982 IN O
pyrC BC2GM054038982 NN O
) BC2GM054038982 ) O
, BC2GM054038982 , O
the BC2GM054038982 DT O
highest BC2GM054038982 JJS O
similarity BC2GM054038982 NN O
scores BC2GM054038982 NNS O
( BC2GM054038982 ( O
about BC2GM054038982 IN O
40 BC2GM054038982 CD O
% BC2GM054038982 NN O
identity BC2GM054038982 NN O
) BC2GM054038982 ) O
were BC2GM054038982 VBD O
obtained BC2GM054038982 VBN O
with BC2GM054038982 IN O
DHOases BC2GM054038982 NNS O
from BC2GM054038982 IN O
B. BC2GM054038982 NNP O
caldolyticus BC2GM054038982 NN O
and BC2GM054038982 CC O
Bacillus BC2GM054038982 NNP O
subtilis BC2GM054038982 NNS O
. BC2GM054038982 . O
. . O O

The BC2GM014013049 DT O
`` BC2GM014013049 `` O
Gregg BC2GM014013049 NNP O
phenomenon BC2GM014013049 NN O
'' BC2GM014013049 '' O
implies BC2GM014013049 NNS O
that BC2GM014013049 IN O
myocardial BC2GM014013049 JJ O
function BC2GM014013049 NN O
and BC2GM014013049 CC O
oxygen BC2GM014013049 NN O
consumption BC2GM014013049 NN O
( BC2GM014013049 ( O
MVO2 BC2GM014013049 NNP O
) BC2GM014013049 ) O
increase BC2GM014013049 NN O
when BC2GM014013049 WRB O
coronary BC2GM014013049 JJ O
perfusion BC2GM014013049 NN O
is BC2GM014013049 VBZ O
enhanced BC2GM014013049 VBN O
within BC2GM014013049 IN O
or BC2GM014013049 CC O
above BC2GM014013049 IN O
the BC2GM014013049 DT O
autoregulatory BC2GM014013049 NN O
range BC2GM014013049 NN O
. BC2GM014013049 . O
. . O O

The BC2GM078153532 DT O
study BC2GM078153532 NN O
of BC2GM078153532 IN O
the BC2GM078153532 DT O
intensity BC2GM078153532 NN O
of BC2GM078153532 IN O
pain BC2GM078153532 NN O
evoked BC2GM078153532 VBN O
by BC2GM078153532 IN O
heat BC2GM078153532 NN O
is BC2GM078153532 VBZ O
relatively BC2GM078153532 RB O
exhaustive BC2GM078153532 JJ O
: BC2GM078153532 : O
the BC2GM078153532 DT O
influence BC2GM078153532 NN O
of BC2GM078153532 IN O
various BC2GM078153532 JJ O
local BC2GM078153532 JJ O
, BC2GM078153532 , O
stimulus-dependent BC2GM078153532 JJ O
or BC2GM078153532 CC O
general BC2GM078153532 JJ O
factors BC2GM078153532 NNS O
upon BC2GM078153532 IN O
threshold BC2GM078153532 NN O
values BC2GM078153532 NNS O
has BC2GM078153532 VBZ O
been BC2GM078153532 VBN O
well BC2GM078153532 RB O
studied BC2GM078153532 VBN O
, BC2GM078153532 , O
as BC2GM078153532 IN O
has BC2GM078153532 VBZ O
the BC2GM078153532 DT O
relation BC2GM078153532 NN O
between BC2GM078153532 IN O
pain BC2GM078153532 NN O
and BC2GM078153532 CC O
stimulus BC2GM078153532 NN O
intensities BC2GM078153532 NNS O
. BC2GM078153532 . O
. . O O

In BC2GM069520528 IN O
patients BC2GM069520528 NNS O
, BC2GM069520528 , O
750 BC2GM069520528 CD O
mL BC2GM069520528 NN O
of BC2GM069520528 IN O
saline BC2GM069520528 NN O
lowered BC2GM069520528 VBN O
DL BC2GM069520528 NNP O
( BC2GM069520528 ( O
CO BC2GM069520528 NNP O
) BC2GM069520528 ) O
( BC2GM069520528 ( O
-8 BC2GM069520528 CD O
% BC2GM069520528 NN O
, BC2GM069520528 , O
P BC2GM069520528 NNP O
< BC2GM069520528 VBZ O
0.01 BC2GM069520528 CD O
versus BC2GM069520528 NN O
baseline BC2GM069520528 NN O
) BC2GM069520528 ) O
, BC2GM069520528 , O
D BC2GM069520528 NNP O
( BC2GM069520528 ( O
M BC2GM069520528 NNP O
) BC2GM069520528 ) O
( BC2GM069520528 ( O
-10 BC2GM069520528 CD O
% BC2GM069520528 NN O
, BC2GM069520528 , O
P BC2GM069520528 NNP O
< BC2GM069520528 VBZ O
0.01 BC2GM069520528 CD O
versus BC2GM069520528 NN O
baseline BC2GM069520528 NN O
) BC2GM069520528 ) O
, BC2GM069520528 , O
aldosterone BC2GM069520528 NN O
( BC2GM069520528 ( O
-29 BC2GM069520528 CD O
% BC2GM069520528 NN O
, BC2GM069520528 , O
P BC2GM069520528 NNP O
< BC2GM069520528 VBZ O
0.01 BC2GM069520528 CD O
versus BC2GM069520528 NN O
baseline BC2GM069520528 NN O
) BC2GM069520528 ) O
, BC2GM069520528 , O
renin BC2GM069520528 NN O
( BC2GM069520528 ( O
-52 BC2GM069520528 CD O
% BC2GM069520528 NN O
, BC2GM069520528 , O
P BC2GM069520528 NNP O
< BC2GM069520528 VBZ O
0.01 BC2GM069520528 CD O
versus BC2GM069520528 NN O
baseline BC2GM069520528 NN O
) BC2GM069520528 ) O
, BC2GM069520528 , O
and BC2GM069520528 CC O
hematocrit BC2GM069520528 NN O
( BC2GM069520528 ( O
-6 BC2GM069520528 CD O
% BC2GM069520528 NN O
, BC2GM069520528 , O
P BC2GM069520528 NNP O
< BC2GM069520528 VBZ O
0.05 BC2GM069520528 CD O
versus BC2GM069520528 NN O
baseline BC2GM069520528 NN O
) BC2GM069520528 ) O
and BC2GM069520528 CC O
increased BC2GM069520528 VBN O
V BC2GM069520528 NNP O
( BC2GM069520528 ( O
C BC2GM069520528 NNP O
) BC2GM069520528 ) O
( BC2GM069520528 ( O
20 BC2GM069520528 CD O
% BC2GM069520528 NN O
, BC2GM069520528 , O
P BC2GM069520528 NNP O
< BC2GM069520528 VBZ O
0.01 BC2GM069520528 CD O
versus BC2GM069520528 NN O
baseline BC2GM069520528 NN O
) BC2GM069520528 ) O
, BC2GM069520528 , O
without BC2GM069520528 IN O
changing BC2GM069520528 VBG O
rap BC2GM069520528 NN O
and BC2GM069520528 CC O
wpp BC2GM069520528 NN O
. BC2GM069520528 . O
. . O O

DESIGN BC2GM017483846 NN O
: BC2GM017483846 : O
Prospective BC2GM017483846 JJ O
case BC2GM017483846 NN O
study BC2GM017483846 NN O
( BC2GM017483846 ( O
Canadian BC2GM017483846 JJ O
Task BC2GM017483846 NNP O
Force BC2GM017483846 NNP O
classification BC2GM017483846 NN O
II-2 BC2GM017483846 NNP O
) BC2GM017483846 ) O
. BC2GM017483846 . O
. . O O

2 BC2GM004506929 CD O
. BC2GM004506929 . O
. . O O

Changes BC2GM030292353 NNS O
in BC2GM030292353 IN O
the BC2GM030292353 DT O
frequency BC2GM030292353 NN O
of BC2GM030292353 IN O
X-chromatin BC2GM030292353 NNP O
in BC2GM030292353 IN O
women BC2GM030292353 NNS O
under BC2GM030292353 IN O
Prednisone BC2GM030292353 NNP O
therapy BC2GM030292353 NN O
. BC2GM030292353 . O
. . O O

INTERNET BC2GM080548139 NNP O
is BC2GM080548139 VBZ O
literally BC2GM080548139 RB O
a BC2GM080548139 DT O
world BC2GM080548139 NN O
of BC2GM080548139 IN O
data BC2GM080548139 NNS O
, BC2GM080548139 , O
dialogue BC2GM080548139 NN O
, BC2GM080548139 , O
and BC2GM080548139 CC O
discourse BC2GM080548139 VB O
on BC2GM080548139 IN O
any BC2GM080548139 DT O
topic BC2GM080548139 NN O
imaginable BC2GM080548139 JJ O
, BC2GM080548139 , O
right BC2GM080548139 JJ O
at BC2GM080548139 IN O
your BC2GM080548139 PRP$ O
fingertips BC2GM080548139 NNS O
. BC2GM080548139 . O
. . O O

These BC2GM006272677 DT O
observations BC2GM006272677 NNS O
suggest BC2GM006272677 VBP O
that BC2GM006272677 IN O
the BC2GM006272677 DT O
AF-1 BC2GM006272677 NNP O
region BC2GM006272677 NN O
of BC2GM006272677 IN O
PPARalpha BC2GM006272677 NNP O
is BC2GM006272677 VBZ O
partially BC2GM006272677 RB O
silenced BC2GM006272677 VBN O
by BC2GM006272677 IN O
corepressor BC2GM006272677 NN O
proteins BC2GM006272677 NNS O
, BC2GM006272677 , O
which BC2GM006272677 WDT O
might BC2GM006272677 MD O
interact BC2GM006272677 VB O
in BC2GM006272677 IN O
a BC2GM006272677 DT O
phosphorylation-dependent BC2GM006272677 JJ O
manner BC2GM006272677 NN O
. BC2GM006272677 . O
. . O O

None BC2GM095222501 NN O
of BC2GM095222501 IN O
these BC2GM095222501 DT O
patients BC2GM095222501 NNS O
developed BC2GM095222501 VBD O
clinical BC2GM095222501 JJ O
events BC2GM095222501 NNS O
before BC2GM095222501 IN O
disappearance BC2GM095222501 NN O
of BC2GM095222501 IN O
the BC2GM095222501 DT O
phospholipid-dependent BC2GM095222501 JJ O
inhibitors BC2GM095222501 NNS O
of BC2GM095222501 IN O
coagulation BC2GM095222501 NN O
. BC2GM095222501 . O
. . O O

The BC2GM030855437 DT O
vaccinia BC2GM030855437 NN O
virus BC2GM030855437 NN O
D6R BC2GM030855437 NNP O
open BC2GM030855437 JJ O
reading BC2GM030855437 NN O
frame BC2GM030855437 NN O
encodes BC2GM030855437 VBZ O
the BC2GM030855437 DT O
small BC2GM030855437 JJ O
subunit BC2GM030855437 NN O
of BC2GM030855437 IN O
the BC2GM030855437 DT O
heterodimeric BC2GM030855437 JJ O
vaccinia BC2GM030855437 NN O
virus BC2GM030855437 NN O
early BC2GM030855437 JJ O
transcription BC2GM030855437 NN O
factor BC2GM030855437 NN O
( BC2GM030855437 ( O
VETF BC2GM030855437 NNP O
) BC2GM030855437 ) O
that BC2GM030855437 WDT O
activates BC2GM030855437 VBZ O
transcription BC2GM030855437 NN O
of BC2GM030855437 IN O
early BC2GM030855437 JJ O
genes BC2GM030855437 NNS O
in BC2GM030855437 IN O
vitro BC2GM030855437 NN O
. BC2GM030855437 . O
. . O O

The BC2GM007629398 DT O
objective BC2GM007629398 NN O
of BC2GM007629398 IN O
this BC2GM007629398 DT O
research BC2GM007629398 NN O
was BC2GM007629398 VBD O
to BC2GM007629398 TO O
determine BC2GM007629398 VB O
if BC2GM007629398 IN O
ergotamine BC2GM007629398 NN O
, BC2GM007629398 , O
an BC2GM007629398 DT O
ergopeptine BC2GM007629398 JJ O
alkaloid BC2GM007629398 NN O
isolated BC2GM007629398 VBN O
from BC2GM007629398 IN O
Neotyphodium-infected BC2GM007629398 JJ O
grasses BC2GM007629398 NNS O
and BC2GM007629398 CC O
associated BC2GM007629398 VBN O
with BC2GM007629398 IN O
toxicoses BC2GM007629398 NNS O
in BC2GM007629398 IN O
livestock BC2GM007629398 NN O
, BC2GM007629398 , O
altered BC2GM007629398 VBD O
plasma BC2GM007629398 JJ O
concentrations BC2GM007629398 NNS O
of BC2GM007629398 IN O
reproductive BC2GM007629398 JJ O
hormones BC2GM007629398 NNS O
in BC2GM007629398 IN O
follicular BC2GM007629398 JJ O
phase BC2GM007629398 NN O
heifers BC2GM007629398 NNS O
and BC2GM007629398 CC O
in BC2GM007629398 IN O
cows BC2GM007629398 NNS O
given BC2GM007629398 VBN O
a BC2GM007629398 DT O
progestin BC2GM007629398 NN O
implant BC2GM007629398 NN O
. BC2GM007629398 . O
. . O O

Plasma BC2GM074781397 NNP O
Pi BC2GM074781397 NNP O
, BC2GM074781397 , O
tibia BC2GM074781397 NN O
breaking BC2GM074781397 VBG O
strength BC2GM074781397 NN O
, BC2GM074781397 , O
and BC2GM074781397 CC O
percentage BC2GM074781397 NN O
of BC2GM074781397 IN O
tibia BC2GM074781397 NN O
ash BC2GM074781397 NN O
were BC2GM074781397 VBD O
increased BC2GM074781397 VBN O
by BC2GM074781397 IN O
raising BC2GM074781397 VBG O
dietary BC2GM074781397 JJ O
Pav BC2GM074781397 NNP O
in BC2GM074781397 IN O
the BC2GM074781397 DT O
presence BC2GM074781397 NN O
of BC2GM074781397 IN O
.392 BC2GM074781397 NNP O
% BC2GM074781397 NN O
A1 BC2GM074781397 NNP O
with BC2GM074781397 IN O
either BC2GM074781397 DT O
level BC2GM074781397 NN O
of BC2GM074781397 IN O
Ca BC2GM074781397 NNP O
. BC2GM074781397 . O
. . O O

A BC2GM069560811 DT O
conventional BC2GM069560811 JJ O
N-terminal BC2GM069560811 JJ O
signal BC2GM069560811 NN O
sequence BC2GM069560811 NN O
was BC2GM069560811 VBD O
not BC2GM069560811 RB O
detected BC2GM069560811 VBN O
in BC2GM069560811 IN O
the BC2GM069560811 DT O
NodO BC2GM069560811 NNP O
protein BC2GM069560811 NN O
. BC2GM069560811 . O
. . O O

Thus BC2GM051178458 RB O
, BC2GM051178458 , O
BCR BC2GM051178458 NNP O
ligation BC2GM051178458 NN O
initiates BC2GM051178458 VBZ O
a BC2GM051178458 DT O
PI BC2GM051178458 NNP O
3-kinase BC2GM051178458 JJ O
/ BC2GM051178458 NNP O
Akt BC2GM051178458 NNP O
/ BC2GM051178458 NNP O
GSK-3 BC2GM051178458 NNP O
signaling BC2GM051178458 VBG O
pathway BC2GM051178458 NN O
. BC2GM051178458 . O
. . O O

Each BC2GM068822744 DT O
patient BC2GM068822744 NN O
was BC2GM068822744 VBD O
seen BC2GM068822744 VBN O
for BC2GM068822744 IN O
5 BC2GM068822744 CD O
to BC2GM068822744 TO O
13 BC2GM068822744 CD O
postsurgical BC2GM068822744 JJ O
maintenance BC2GM068822744 NN O
visits BC2GM068822744 NNS O
. BC2GM068822744 . O
. . O O

We BC2GM006491686 PRP O
have BC2GM006491686 VBP O
analyzed BC2GM006491686 VBN O
herein BC2GM006491686 PDT O
the BC2GM006491686 DT O
roles BC2GM006491686 NNS O
that BC2GM006491686 WDT O
four BC2GM006491686 CD O
different BC2GM006491686 JJ O
PIAS BC2GM006491686 NNP O
proteins BC2GM006491686 NNS O
( BC2GM006491686 ( O
ARIP3 BC2GM006491686 NNP O
/ BC2GM006491686 NNP O
PIASx BC2GM006491686 NNP O
alpha BC2GM006491686 NN O
, BC2GM006491686 , O
Miz1 BC2GM006491686 NNP O
/ BC2GM006491686 NNP O
PIASx BC2GM006491686 NNP O
beta BC2GM006491686 NN O
, BC2GM006491686 , O
GBP BC2GM006491686 NNP O
/ BC2GM006491686 NNP O
PIAS1 BC2GM006491686 NNP O
, BC2GM006491686 , O
and BC2GM006491686 CC O
PIAS3 BC2GM006491686 NNP O
) BC2GM006491686 ) O
play BC2GM006491686 NN O
in BC2GM006491686 IN O
the BC2GM006491686 DT O
regulation BC2GM006491686 NN O
of BC2GM006491686 IN O
steroid BC2GM006491686 JJ O
receptor- BC2GM006491686 JJ O
or BC2GM006491686 CC O
STAT-mediated BC2GM006491686 JJ O
transcriptional BC2GM006491686 JJ O
activation BC2GM006491686 NN O
. BC2GM006491686 . O
. . O O

The BC2GM099918487 DT O
aims BC2GM099918487 NNS O
of BC2GM099918487 IN O
this BC2GM099918487 DT O
study BC2GM099918487 NN O
were BC2GM099918487 VBD O
to BC2GM099918487 TO O
examine BC2GM099918487 VB O
whether BC2GM099918487 IN O
the BC2GM099918487 DT O
EORTC BC2GM099918487 NNP O
( BC2GM099918487 ( O
European BC2GM099918487 JJ O
Organisation BC2GM099918487 NNP O
for BC2GM099918487 IN O
Research BC2GM099918487 NNP O
and BC2GM099918487 CC O
Treatment BC2GM099918487 NNP O
of BC2GM099918487 IN O
Cancer BC2GM099918487 NNP O
) BC2GM099918487 ) O
QLQ-C30 BC2GM099918487 NNP O
core BC2GM099918487 NN O
questionnaire BC2GM099918487 NN O
alone BC2GM099918487 RB O
could BC2GM099918487 MD O
distinguish BC2GM099918487 VB O
between BC2GM099918487 IN O
two BC2GM099918487 CD O
clinically BC2GM099918487 RB O
different BC2GM099918487 JJ O
groups BC2GM099918487 NNS O
of BC2GM099918487 IN O
patients BC2GM099918487 NNS O
and BC2GM099918487 CC O
to BC2GM099918487 TO O
design BC2GM099918487 VB O
a BC2GM099918487 DT O
module BC2GM099918487 NN O
, BC2GM099918487 , O
which BC2GM099918487 WDT O
included BC2GM099918487 VBD O
relevant BC2GM099918487 JJ O
patient-defined BC2GM099918487 JJ O
gastric BC2GM099918487 JJ O
cancer-specific BC2GM099918487 JJ O
variables BC2GM099918487 NNS O
. BC2GM099918487 . O
. . O O

The BC2GM078932858 DT O
mean BC2GM078932858 JJ O
amount BC2GM078932858 NN O
of BC2GM078932858 IN O
blood BC2GM078932858 NN O
loss BC2GM078932858 NN O
prior BC2GM078932858 RB O
to BC2GM078932858 TO O
time BC2GM078932858 NN O
of BC2GM078932858 IN O
injection BC2GM078932858 NN O
was BC2GM078932858 VBD O
4.5 BC2GM078932858 CD O
units BC2GM078932858 NNS O
( BC2GM078932858 ( O
a BC2GM078932858 DT O
range BC2GM078932858 NN O
of BC2GM078932858 IN O
3 BC2GM078932858 CD O
to BC2GM078932858 TO O
10 BC2GM078932858 CD O
units BC2GM078932858 NNS O
) BC2GM078932858 ) O
. BC2GM078932858 . O
. . O O

Like BC2GM057268278 IN O
the BC2GM057268278 DT O
human BC2GM057268278 JJ O
erythrocyte BC2GM057268278 NN O
P4.2 BC2GM057268278 NNP O
, BC2GM057268278 , O
mouse BC2GM057268278 NN O
erythrocyte BC2GM057268278 NN O
P4.2 BC2GM057268278 NNP O
contains BC2GM057268278 VBZ O
regions BC2GM057268278 NNS O
strikingly BC2GM057268278 RB O
homologous BC2GM057268278 JJ O
with BC2GM057268278 IN O
the BC2GM057268278 DT O
transglutaminase BC2GM057268278 NN O
( BC2GM057268278 ( O
TGase BC2GM057268278 NNP O
) BC2GM057268278 ) O
proteins BC2GM057268278 VBZ O
although BC2GM057268278 IN O
it BC2GM057268278 PRP O
too BC2GM057268278 RB O
most BC2GM057268278 RBS O
likely BC2GM057268278 JJ O
lacks BC2GM057268278 NNS O
TGase BC2GM057268278 NNP O
crosslinking BC2GM057268278 NN O
activity BC2GM057268278 NN O
. BC2GM057268278 . O
. . O O

The BC2GM057519691 DT O
largest BC2GM057519691 JJS O
age BC2GM057519691 NN O
adjusted BC2GM057519691 VBD O
differences BC2GM057519691 NNS O
between BC2GM057519691 IN O
men BC2GM057519691 NNS O
with BC2GM057519691 IN O
low BC2GM057519691 JJ O
and BC2GM057519691 CC O
normal BC2GM057519691 JJ O
mood BC2GM057519691 NN O
were BC2GM057519691 VBD O
for BC2GM057519691 IN O
the BC2GM057519691 DT O
AH4 BC2GM057519691 NNP O
( BC2GM057519691 ( O
3 BC2GM057519691 CD O
points BC2GM057519691 NNS O
, BC2GM057519691 , O
t BC2GM057519691 EX O
= BC2GM057519691 JJ O
5.6 BC2GM057519691 CD O
, BC2GM057519691 , O
p BC2GM057519691 NN O
< BC2GM057519691 NNP O
0.0001 BC2GM057519691 CD O
) BC2GM057519691 ) O
and BC2GM057519691 CC O
the BC2GM057519691 DT O
CAMCOG BC2GM057519691 NNP O
( BC2GM057519691 ( O
2 BC2GM057519691 CD O
points BC2GM057519691 NNS O
, BC2GM057519691 , O
t BC2GM057519691 EX O
= BC2GM057519691 JJ O
5.8 BC2GM057519691 CD O
, BC2GM057519691 , O
p BC2GM057519691 NN O
< BC2GM057519691 NNP O
0.0001 BC2GM057519691 CD O
) BC2GM057519691 ) O
. BC2GM057519691 . O
. . O O

It BC2GM077618469 PRP O
thus BC2GM077618469 RB O
seems BC2GM077618469 VBZ O
likely BC2GM077618469 JJ O
that BC2GM077618469 IN O
genistein BC2GM077618469 VBZ O
affects BC2GM077618469 VBZ O
a BC2GM077618469 DT O
common BC2GM077618469 JJ O
pathway BC2GM077618469 NN O
downstream BC2GM077618469 NN O
of BC2GM077618469 IN O
these BC2GM077618469 DT O
signals BC2GM077618469 NNS O
. BC2GM077618469 . O
. . O O

UV-cross-linking BC2GM094112642 JJ O
studies BC2GM094112642 NNS O
suggested BC2GM094112642 VBD O
that BC2GM094112642 IN O
these BC2GM094112642 DT O
two BC2GM094112642 CD O
complexes BC2GM094112642 NNS O
represent BC2GM094112642 VBP O
one BC2GM094112642 CD O
and BC2GM094112642 CC O
two BC2GM094112642 CD O
molecules BC2GM094112642 NNS O
of BC2GM094112642 IN O
ADR1 BC2GM094112642 NNP O
bound BC2GM094112642 NN O
to BC2GM094112642 TO O
DNA BC2GM094112642 NNP O
. BC2GM094112642 . O
. . O O

New BC2GM030067070 NNP O
concepts BC2GM030067070 NNS O
of BC2GM030067070 IN O
condyloma BC2GM030067070 NN O
acuminata BC2GM030067070 NN O
in BC2GM030067070 IN O
children BC2GM030067070 NNS O
. BC2GM030067070 . O
. . O O

We BC2GM083150371 PRP O
tested BC2GM083150371 VBD O
several BC2GM083150371 JJ O
growth BC2GM083150371 NN O
regulatory BC2GM083150371 JJ O
genes BC2GM083150371 NNS O
that BC2GM083150371 WDT O
are BC2GM083150371 VBP O
repressed BC2GM083150371 VBN O
in BC2GM083150371 IN O
senescent BC2GM083150371 NN O
cells BC2GM083150371 NNS O
for BC2GM083150371 IN O
ability BC2GM083150371 NN O
to BC2GM083150371 TO O
restore BC2GM083150371 VB O
activity BC2GM083150371 NN O
to BC2GM083150371 TO O
T BC2GM083150371 NNP O
[ BC2GM083150371 NNP O
K1 BC2GM083150371 NNP O
] BC2GM083150371 NNP O
. BC2GM083150371 . O
. . O O

The BC2GM019410354 DT O
gamma-GCS BC2GM019410354 JJ O
gene BC2GM019410354 NN O
is BC2GM019410354 VBZ O
expressed BC2GM019410354 VBN O
ubiquitously BC2GM019410354 RB O
and BC2GM019410354 CC O
induced BC2GM019410354 VBD O
coordinately BC2GM019410354 RB O
with BC2GM019410354 IN O
NAD BC2GM019410354 NNP O
( BC2GM019410354 ( O
P BC2GM019410354 NNP O
) BC2GM019410354 ) O
H BC2GM019410354 NNP O
: BC2GM019410354 : O
quinone BC2GM019410354 NN O
oxidoreductase BC2GM019410354 NN O
( BC2GM019410354 ( O
1 BC2GM019410354 CD O
) BC2GM019410354 ) O
( BC2GM019410354 ( O
NQO1 BC2GM019410354 NNP O
) BC2GM019410354 ) O
and BC2GM019410354 CC O
glutathione BC2GM019410354 JJ O
S-transferase BC2GM019410354 NNP O
Ya BC2GM019410354 NNP O
( BC2GM019410354 ( O
GST BC2GM019410354 NNP O
Ya BC2GM019410354 NNP O
) BC2GM019410354 ) O
in BC2GM019410354 IN O
response BC2GM019410354 NN O
to BC2GM019410354 TO O
xenobiotics BC2GM019410354 NNS O
and BC2GM019410354 CC O
antioxidants BC2GM019410354 NNS O
. BC2GM019410354 . O
. . O O

It BC2GM047855598 PRP O
appears BC2GM047855598 VBZ O
that BC2GM047855598 IN O
the BC2GM047855598 DT O
K-ABC BC2GM047855598 NNP O
is BC2GM047855598 VBZ O
a BC2GM047855598 DT O
relatively BC2GM047855598 RB O
nonbiased BC2GM047855598 JJ O
test BC2GM047855598 NN O
suitable BC2GM047855598 NN O
for BC2GM047855598 IN O
the BC2GM047855598 DT O
evaluation BC2GM047855598 NN O
of BC2GM047855598 IN O
both BC2GM047855598 DT O
gifted BC2GM047855598 VBN O
and BC2GM047855598 CC O
nongifted BC2GM047855598 VBN O
children BC2GM047855598 NNS O
regardless BC2GM047855598 RB O
of BC2GM047855598 IN O
race BC2GM047855598 NN O
or BC2GM047855598 CC O
gender BC2GM047855598 NN O
. BC2GM047855598 . O
. . O O

The BC2GM025639631 DT O
monkeys BC2GM025639631 NNS O
had BC2GM025639631 VBD O
been BC2GM025639631 VBN O
administered BC2GM025639631 VBN O
a BC2GM025639631 DT O
common BC2GM025639631 JJ O
lead BC2GM025639631 NN O
isotope BC2GM025639631 NN O
`` BC2GM025639631 `` O
mix BC2GM025639631 NN O
'' BC2GM025639631 '' O
at BC2GM025639631 IN O
the BC2GM025639631 DT O
rate BC2GM025639631 NN O
of BC2GM025639631 IN O
about BC2GM025639631 IN O
1300 BC2GM025639631 CD O
micrograms BC2GM025639631 NNS O
Pb BC2GM025639631 NNP O
/ BC2GM025639631 NNP O
kg BC2GM025639631 VB O
body BC2GM025639631 NN O
wt BC2GM025639631 JJ O
/ BC2GM025639631 JJ O
day BC2GM025639631 NN O
from BC2GM025639631 IN O
age BC2GM025639631 NN O
10 BC2GM025639631 CD O
months BC2GM025639631 NNS O
until BC2GM025639631 IN O
the BC2GM025639631 DT O
start BC2GM025639631 NN O
of BC2GM025639631 IN O
the BC2GM025639631 DT O
study BC2GM025639631 NN O
. BC2GM025639631 . O
. . O O

Clinical BC2GM032391801 JJ O
evidence BC2GM032391801 NN O
provides BC2GM032391801 VBZ O
tentative BC2GM032391801 JJ O
suggestions BC2GM032391801 NNS O
on BC2GM032391801 IN O
( BC2GM032391801 ( O
a BC2GM032391801 DT O
) BC2GM032391801 ) O
possible BC2GM032391801 JJ O
additional BC2GM032391801 JJ O
risk BC2GM032391801 NN O
of BC2GM032391801 IN O
cigarette BC2GM032391801 NN O
smoking BC2GM032391801 NN O
( BC2GM032391801 ( O
b BC2GM032391801 NN O
) BC2GM032391801 ) O
avoidance BC2GM032391801 NN O
of BC2GM032391801 IN O
venography BC2GM032391801 NN O
( BC2GM032391801 ( O
c BC2GM032391801 NN O
) BC2GM032391801 ) O
avoidance BC2GM032391801 NN O
of BC2GM032391801 IN O
varicose BC2GM032391801 JJ O
vein BC2GM032391801 NN O
surgery BC2GM032391801 NN O
. BC2GM032391801 . O
. . O O

No BC2GM090376124 DT O
significant BC2GM090376124 JJ O
difference BC2GM090376124 NN O
in BC2GM090376124 IN O
plasma BC2GM090376124 JJ O
ET BC2GM090376124 NNP O
levels BC2GM090376124 NNS O
was BC2GM090376124 VBD O
found BC2GM090376124 VBN O
between BC2GM090376124 IN O
cardiac BC2GM090376124 JJ O
and BC2GM090376124 CC O
peripheral BC2GM090376124 JJ O
sampling BC2GM090376124 NN O
sites BC2GM090376124 NNS O
( BC2GM090376124 ( O
pulmonary BC2GM090376124 JJ O
artery BC2GM090376124 NN O
; BC2GM090376124 : O
1.07 BC2GM090376124 CD O
+ BC2GM090376124 NN O
/ BC2GM090376124 NNP O
- BC2GM090376124 : O
0.28 BC2GM090376124 CD O
, BC2GM090376124 , O
right BC2GM090376124 JJ O
atrium BC2GM090376124 NN O
; BC2GM090376124 : O
1.02 BC2GM090376124 CD O
+ BC2GM090376124 NN O
/ BC2GM090376124 NNP O
- BC2GM090376124 : O
0.28 BC2GM090376124 CD O
, BC2GM090376124 , O
peripheral BC2GM090376124 JJ O
artery BC2GM090376124 NN O
; BC2GM090376124 : O
1.12 BC2GM090376124 CD O
+ BC2GM090376124 NN O
/ BC2GM090376124 NNP O
- BC2GM090376124 : O
0.23 BC2GM090376124 CD O
, BC2GM090376124 , O
peripheral BC2GM090376124 JJ O
vein BC2GM090376124 NN O
; BC2GM090376124 : O
1.14 BC2GM090376124 CD O
+ BC2GM090376124 NN O
/ BC2GM090376124 NNP O
- BC2GM090376124 : O
0.38 BC2GM090376124 CD O
fmol BC2GM090376124 NN O
/ BC2GM090376124 NN O
ml BC2GM090376124 NN O
: BC2GM090376124 : O
N.S BC2GM090376124 NNP O
. BC2GM090376124 . O
) BC2GM090376124 ) O
, BC2GM090376124 , O
or BC2GM090376124 CC O
among BC2GM090376124 IN O
patients BC2GM090376124 NNS O
with BC2GM090376124 IN O
uncomplicated BC2GM090376124 JJ O
MI BC2GM090376124 NNP O
, BC2GM090376124 , O
unstable BC2GM090376124 JJ O
angina BC2GM090376124 NN O
( BC2GM090376124 ( O
1.00 BC2GM090376124 CD O
+ BC2GM090376124 NN O
/ BC2GM090376124 NNP O
- BC2GM090376124 : O
0.32 BC2GM090376124 CD O
fmol BC2GM090376124 NN O
/ BC2GM090376124 NNP O
ml BC2GM090376124 NN O
) BC2GM090376124 ) O
, BC2GM090376124 , O
and BC2GM090376124 CC O
healthy BC2GM090376124 JJ O
subjects BC2GM090376124 NNS O
( BC2GM090376124 ( O
1.01 BC2GM090376124 CD O
+ BC2GM090376124 NN O
/ BC2GM090376124 NNP O
- BC2GM090376124 : O
0.29 BC2GM090376124 CD O
fmol BC2GM090376124 NN O
/ BC2GM090376124 NNP O
ml BC2GM090376124 NN O
) BC2GM090376124 ) O
. BC2GM090376124 . O
. . O O

Typicality BC2GM090248535 NN O
is BC2GM090248535 VBZ O
probably BC2GM090248535 RB O
a BC2GM090248535 DT O
better BC2GM090248535 JJR O
representation BC2GM090248535 NN O
of BC2GM090248535 IN O
Alexander BC2GM090248535 NNP O
, BC2GM090248535 , O
Dunbar BC2GM090248535 NNP O
and BC2GM090248535 CC O
others BC2GM090248535 NNS O
' BC2GM090248535 POS O
conclusions BC2GM090248535 NNS O
than BC2GM090248535 IN O
specificity BC2GM090248535 NN O
, BC2GM090248535 , O
which BC2GM090248535 WDT O
was BC2GM090248535 VBD O
always BC2GM090248535 RB O
too BC2GM090248535 RB O
absolute BC2GM090248535 JJ O
a BC2GM090248535 DT O
term BC2GM090248535 NN O
. BC2GM090248535 . O
. . O O

Ethanol BC2GM008087680 NNP O
preference BC2GM008087680 NN O
in BC2GM008087680 IN O
strains BC2GM008087680 NNS O
of BC2GM008087680 IN O
rats BC2GM008087680 NNS O
selectively BC2GM008087680 RB O
bred BC2GM008087680 VBD O
for BC2GM008087680 IN O
behavioral BC2GM008087680 JJ O
characteristics BC2GM008087680 NNS O
. BC2GM008087680 . O
. . O O

( BC2GM089869328 ( O
1986 BC2GM089869328 CD O
) BC2GM089869328 ) O
described BC2GM089869328 VBD O
optic BC2GM089869328 JJ O
nerve BC2GM089869328 NN O
degenerations BC2GM089869328 NNS O
in BC2GM089869328 IN O
patients BC2GM089869328 NNS O
with BC2GM089869328 IN O
Alzheimer BC2GM089869328 NNP O
's BC2GM089869328 POS O
disease BC2GM089869328 NN O
and BC2GM089869328 CC O
Sadun BC2GM089869328 NNP O
published BC2GM089869328 VBD O
a BC2GM089869328 DT O
dropout BC2GM089869328 NN O
of BC2GM089869328 IN O
retinal BC2GM089869328 JJ O
ganglion BC2GM089869328 NN O
cells BC2GM089869328 NNS O
that BC2GM089869328 WDT O
range BC2GM089869328 VBP O
from BC2GM089869328 IN O
30 BC2GM089869328 CD O
% BC2GM089869328 NN O
to BC2GM089869328 TO O
60 BC2GM089869328 CD O
% BC2GM089869328 NN O
. BC2GM089869328 . O
. . O O

After BC2GM047739640 IN O
cumulative BC2GM047739640 JJ O
occlusions BC2GM047739640 NNS O
of BC2GM047739640 IN O
15 BC2GM047739640 CD O
, BC2GM047739640 , O
30 BC2GM047739640 CD O
, BC2GM047739640 , O
45 BC2GM047739640 CD O
, BC2GM047739640 , O
and BC2GM047739640 CC O
90 BC2GM047739640 CD O
min BC2GM047739640 NN O
, BC2GM047739640 , O
transmural BC2GM047739640 JJ O
needle BC2GM047739640 JJ O
biopsies BC2GM047739640 NNS O
were BC2GM047739640 VBD O
taken BC2GM047739640 VBN O
from BC2GM047739640 IN O
the BC2GM047739640 DT O
ischemic BC2GM047739640 JJ O
area BC2GM047739640 NN O
to BC2GM047739640 TO O
be BC2GM047739640 VB O
analyzed BC2GM047739640 VBN O
for BC2GM047739640 IN O
adenine BC2GM047739640 NN O
nucleotides BC2GM047739640 NNS O
, BC2GM047739640 , O
nucleosides BC2GM047739640 NNS O
, BC2GM047739640 , O
creatine BC2GM047739640 NN O
phosphate BC2GM047739640 NN O
, BC2GM047739640 , O
and BC2GM047739640 CC O
ultrastructural BC2GM047739640 JJ O
changes BC2GM047739640 NNS O
. BC2GM047739640 . O
. . O O

The BC2GM013877363 DT O
myb BC2GM013877363 NN O
proto BC2GM013877363 NN O
oncogene BC2GM013877363 JJ O
product BC2GM013877363 NN O
( BC2GM013877363 ( O
c-Myb BC2GM013877363 JJ O
) BC2GM013877363 ) O
is BC2GM013877363 VBZ O
a BC2GM013877363 DT O
transcriptional BC2GM013877363 JJ O
regulator BC2GM013877363 NN O
and BC2GM013877363 CC O
its BC2GM013877363 PRP$ O
expression BC2GM013877363 NN O
and BC2GM013877363 CC O
function BC2GM013877363 NN O
are BC2GM013877363 VBP O
tightly BC2GM013877363 RB O
linked BC2GM013877363 VBN O
to BC2GM013877363 TO O
the BC2GM013877363 DT O
cellular BC2GM013877363 JJ O
entry BC2GM013877363 NN O
into BC2GM013877363 IN O
S BC2GM013877363 NNP O
phase BC2GM013877363 NN O
and BC2GM013877363 CC O
DNA BC2GM013877363 NNP O
synthesis BC2GM013877363 NN O
. BC2GM013877363 . O
. . O O

The BC2GM086752058 DT O
platelet BC2GM086752058 NN O
membrane BC2GM086752058 NN O
glycoprotein BC2GM086752058 NN O
IIb BC2GM086752058 NNP O
/ BC2GM086752058 NNP O
IIIa BC2GM086752058 NNP O
receptor BC2GM086752058 NN O
inhibitor BC2GM086752058 NN O
abciximab BC2GM086752058 NN O
is BC2GM086752058 VBZ O
used BC2GM086752058 VBN O
for BC2GM086752058 IN O
the BC2GM086752058 DT O
treatment BC2GM086752058 NN O
of BC2GM086752058 IN O
patients BC2GM086752058 NNS O
undergoing BC2GM086752058 VBG O
high-risk BC2GM086752058 JJ O
percutaneous BC2GM086752058 JJ O
coronary BC2GM086752058 JJ O
interventions BC2GM086752058 NNS O
and BC2GM086752058 CC O
is BC2GM086752058 VBZ O
used BC2GM086752058 VBN O
in BC2GM086752058 IN O
approximately BC2GM086752058 RB O
one BC2GM086752058 CD O
third BC2GM086752058 NN O
of BC2GM086752058 IN O
coronary BC2GM086752058 JJ O
interventions BC2GM086752058 NNS O
in BC2GM086752058 IN O
the BC2GM086752058 DT O
United BC2GM086752058 NNP O
States BC2GM086752058 NNPS O
and BC2GM086752058 CC O
a BC2GM086752058 DT O
growing BC2GM086752058 VBG O
number BC2GM086752058 NN O
of BC2GM086752058 IN O
procedures BC2GM086752058 NNS O
in BC2GM086752058 IN O
Europe BC2GM086752058 NNP O
. BC2GM086752058 . O
. . O O

Each BC2GM014615834 DT O
subject BC2GM014615834 NN O
was BC2GM014615834 VBD O
injected BC2GM014615834 VBN O
in BC2GM014615834 IN O
the BC2GM014615834 DT O
antecubital BC2GM014615834 JJ O
vein BC2GM014615834 NN O
with BC2GM014615834 IN O
7 BC2GM014615834 CD O
mg BC2GM014615834 NNS O
/ BC2GM014615834 JJ O
kg BC2GM014615834 NN O
of BC2GM014615834 IN O
sodium BC2GM014615834 NN O
fluorescein BC2GM014615834 NN O
( BC2GM014615834 ( O
25 BC2GM014615834 CD O
% BC2GM014615834 NN O
solution BC2GM014615834 NN O
) BC2GM014615834 ) O
and BC2GM014615834 CC O
measurements BC2GM014615834 NNS O
were BC2GM014615834 VBD O
taken BC2GM014615834 VBN O
1 BC2GM014615834 CD O
hr BC2GM014615834 JJ O
postinjection BC2GM014615834 NN O
at BC2GM014615834 IN O
4.5 BC2GM014615834 CD O
mm BC2GM014615834 NN O
and BC2GM014615834 CC O
7.5 BC2GM014615834 CD O
mm BC2GM014615834 NN O
from BC2GM014615834 IN O
the BC2GM014615834 DT O
retina BC2GM014615834 NN O
. BC2GM014615834 . O
. . O O

Individual BC2GM017483481 JJ O
intolerance BC2GM017483481 NN O
to BC2GM017483481 TO O
betaxolol BC2GM017483481 VB O
will BC2GM017483481 MD O
continue BC2GM017483481 VB O
to BC2GM017483481 TO O
occur BC2GM017483481 VB O
and BC2GM017483481 CC O
care BC2GM017483481 VB O
is BC2GM017483481 VBZ O
always BC2GM017483481 RB O
required BC2GM017483481 VBN O
when BC2GM017483481 WRB O
patients BC2GM017483481 NNS O
with BC2GM017483481 IN O
cardiac BC2GM017483481 JJ O
or BC2GM017483481 CC O
respiratory BC2GM017483481 JJ O
dysfunction BC2GM017483481 NN O
are BC2GM017483481 VBP O
exposed BC2GM017483481 VBN O
to BC2GM017483481 TO O
any BC2GM017483481 DT O
beta-antagonist BC2GM017483481 NN O
. BC2GM017483481 . O
. . O O

After BC2GM096137044 IN O
Northern BC2GM096137044 NNP O
blot BC2GM096137044 NN O
hybridization BC2GM096137044 NN O
, BC2GM096137044 , O
two BC2GM096137044 CD O
Cx31 BC2GM096137044 NNP O
transcripts BC2GM096137044 NNS O
of BC2GM096137044 IN O
2.2 BC2GM096137044 CD O
and BC2GM096137044 CC O
1.8 BC2GM096137044 CD O
kb BC2GM096137044 NNS O
were BC2GM096137044 VBD O
detected BC2GM096137044 VBN O
in BC2GM096137044 IN O
total BC2GM096137044 JJ O
RNA BC2GM096137044 NNP O
of BC2GM096137044 IN O
the BC2GM096137044 DT O
human BC2GM096137044 JJ O
keratinocyte BC2GM096137044 NN O
cell BC2GM096137044 NN O
line BC2GM096137044 NN O
HaCaT BC2GM096137044 NNP O
and BC2GM096137044 CC O
two BC2GM096137044 CD O
transcripts BC2GM096137044 NNS O
of BC2GM096137044 IN O
2.2 BC2GM096137044 CD O
and BC2GM096137044 CC O
1.9 BC2GM096137044 CD O
kb BC2GM096137044 NN O
in BC2GM096137044 IN O
total BC2GM096137044 JJ O
RNA BC2GM096137044 NNP O
of BC2GM096137044 IN O
E6 BC2GM096137044 NNP O
/ BC2GM096137044 NNP O
E7 BC2GM096137044 NNP O
transfected BC2GM096137044 VBD O
human BC2GM096137044 JJ O
keratinocytes BC2GM096137044 NNS O
( BC2GM096137044 ( O
HEK BC2GM096137044 NNP O
cells BC2GM096137044 NNS O
) BC2GM096137044 ) O
. BC2GM096137044 . O
. . O O

The BC2GM012711095 DT O
DFA BC2GM012711095 NNP O
slide BC2GM012711095 NN O
prepared BC2GM012711095 VBD O
from BC2GM012711095 IN O
the BC2GM012711095 DT O
ThinPrep BC2GM012711095 NNP O
Test BC2GM012711095 NNP O
and BC2GM012711095 CC O
the BC2GM012711095 DT O
conventional BC2GM012711095 JJ O
DFA BC2GM012711095 NNP O
sample BC2GM012711095 NN O
prepared BC2GM012711095 VBD O
from BC2GM012711095 IN O
the BC2GM012711095 DT O
endocervical BC2GM012711095 JJ O
swab BC2GM012711095 NN O
were BC2GM012711095 VBD O
evaluated BC2GM012711095 VBN O
independently BC2GM012711095 RB O
. BC2GM012711095 . O
. . O O

IV BC2GM059162976 NNP O
. BC2GM059162976 . O
. . O O

Southern BC2GM046346737 NNP O
blot BC2GM046346737 NN O
analysis BC2GM046346737 NN O
performed BC2GM046346737 VBN O
on BC2GM046346737 IN O
genomic BC2GM046346737 JJ O
DNA BC2GM046346737 NNP O
demonstrated BC2GM046346737 VBD O
altered BC2GM046346737 JJ O
CpG BC2GM046346737 NNP O
methylation BC2GM046346737 NN O
within BC2GM046346737 IN O
intron BC2GM046346737 NN O
1 BC2GM046346737 CD O
in BC2GM046346737 IN O
DNA BC2GM046346737 NN O
from BC2GM046346737 IN O
all BC2GM046346737 DT O
BCC BC2GM046346737 NNP O
compared BC2GM046346737 VBN O
to BC2GM046346737 TO O
normal BC2GM046346737 JJ O
, BC2GM046346737 , O
mortal BC2GM046346737 JJ O
human BC2GM046346737 JJ O
mammary BC2GM046346737 JJ O
epithelial BC2GM046346737 NN O
cells BC2GM046346737 NNS O
( BC2GM046346737 ( O
HMEC BC2GM046346737 NNP O
) BC2GM046346737 ) O
. BC2GM046346737 . O
. . O O

RESULTS BC2GM005153590 NNS O
: BC2GM005153590 : O
All BC2GM005153590 DT O
primary BC2GM005153590 JJ O
tumors BC2GM005153590 NNS O
were BC2GM005153590 VBD O
positive BC2GM005153590 JJ O
for BC2GM005153590 IN O
CAM5.2 BC2GM005153590 NNP O
. BC2GM005153590 . O
. . O O

We BC2GM011632979 PRP O
demonstrate BC2GM011632979 VBP O
that BC2GM011632979 IN O
the BC2GM011632979 DT O
recently BC2GM011632979 RB O
proposed BC2GM011632979 VBN O
synthetic BC2GM011632979 JJ O
imaging BC2GM011632979 NN O
technique BC2GM011632979 NN O
[ BC2GM011632979 NNP O
J BC2GM011632979 NNP O
. BC2GM011632979 . O
. . O O

The BC2GM076394317 DT O
Cryotherapy BC2GM076394317 NNP O
for BC2GM076394317 IN O
Retinopathy BC2GM076394317 NNP O
of BC2GM076394317 IN O
Prematurity BC2GM076394317 NNP O
Study BC2GM076394317 NNP O
has BC2GM076394317 VBZ O
shown BC2GM076394317 VBN O
that BC2GM076394317 IN O
this BC2GM076394317 DT O
number BC2GM076394317 NN O
can BC2GM076394317 MD O
be BC2GM076394317 VB O
halved BC2GM076394317 VBN O
with BC2GM076394317 IN O
treatment BC2GM076394317 NN O
. BC2GM076394317 . O
. . O O

Using BC2GM015923347 VBG O
probes BC2GM015923347 NNS O
from BC2GM015923347 IN O
these BC2GM015923347 DT O
regions BC2GM015923347 NNS O
, BC2GM015923347 , O
rearrangements BC2GM015923347 NNS O
have BC2GM015923347 VBP O
been BC2GM015923347 VBN O
identified BC2GM015923347 VBN O
in BC2GM015923347 IN O
each BC2GM015923347 DT O
of BC2GM015923347 IN O
nine BC2GM015923347 CD O
cases BC2GM015923347 NNS O
of BC2GM015923347 IN O
t BC2GM015923347 NN O
( BC2GM015923347 ( O
8 BC2GM015923347 CD O
; BC2GM015923347 : O
21 BC2GM015923347 CD O
) BC2GM015923347 ) O
AML BC2GM015923347 NNP O
examined BC2GM015923347 VBD O
. BC2GM015923347 . O
. . O O

In BC2GM075933403 IN O
the BC2GM075933403 DT O
latter BC2GM075933403 NN O
, BC2GM075933403 , O
the BC2GM075933403 DT O
cells BC2GM075933403 NNS O
and BC2GM075933403 CC O
adjacent BC2GM075933403 JJ O
matrix BC2GM075933403 NN O
had BC2GM075933403 VBD O
several BC2GM075933403 JJ O
characteristics BC2GM075933403 NNS O
of BC2GM075933403 IN O
fibrocartilage BC2GM075933403 NN O
, BC2GM075933403 , O
including BC2GM075933403 VBG O
chondrocytes BC2GM075933403 NNS O
. BC2GM075933403 . O
. . O O

The BC2GM068076074 DT O
BCL-6 BC2GM068076074 NNP O
POZ BC2GM068076074 NNP O
domain BC2GM068076074 NN O
and BC2GM068076074 CC O
other BC2GM068076074 JJ O
POZ BC2GM068076074 NNP O
domains BC2GM068076074 NNS O
interact BC2GM068076074 NN O
with BC2GM068076074 IN O
the BC2GM068076074 DT O
co-repressors BC2GM068076074 NNS O
N-CoR BC2GM068076074 NNP O
and BC2GM068076074 CC O
SMRT BC2GM068076074 NNP O
. BC2GM068076074 . O
. . O O

Oxalates BC2GM090380328 NNS O
and BC2GM090380328 CC O
the BC2GM090380328 DT O
digestive BC2GM090380328 JJ O
tract BC2GM090380328 NN O
. BC2GM090380328 . O
. . O O

During BC2GM083424933 IN O
chordotonal BC2GM083424933 JJ O
organ BC2GM083424933 NN O
development BC2GM083424933 NN O
, BC2GM083424933 , O
the BC2GM083424933 DT O
3 BC2GM083424933 CD O
' BC2GM083424933 POS O
enhancer BC2GM083424933 NN O
directs BC2GM083424933 NNS O
expression BC2GM083424933 NN O
in BC2GM083424933 IN O
proneural BC2GM083424933 JJ O
clusters BC2GM083424933 NNS O
; BC2GM083424933 : O
whereas BC2GM083424933 NNS O
successive BC2GM083424933 VBP O
modular BC2GM083424933 JJ O
enhancers BC2GM083424933 NNS O
located BC2GM083424933 VBN O
in BC2GM083424933 IN O
the BC2GM083424933 DT O
5 BC2GM083424933 CD O
' BC2GM083424933 POS O
region BC2GM083424933 NN O
drive BC2GM083424933 NN O
tissue-specific BC2GM083424933 JJ O
expression BC2GM083424933 NN O
in BC2GM083424933 IN O
chordotonal BC2GM083424933 JJ O
organ BC2GM083424933 JJ O
precursors BC2GM083424933 NNS O
in BC2GM083424933 IN O
the BC2GM083424933 DT O
embryo BC2GM083424933 NN O
and BC2GM083424933 CC O
larval BC2GM083424933 JJ O
leg BC2GM083424933 NN O
, BC2GM083424933 , O
wing BC2GM083424933 VBG O
and BC2GM083424933 CC O
antennal BC2GM083424933 JJ O
imaginal BC2GM083424933 JJ O
discs BC2GM083424933 NN O
. BC2GM083424933 . O
. . O O

Our BC2GM094775430 PRP$ O
Northern BC2GM094775430 NNP O
and BC2GM094775430 CC O
Southern BC2GM094775430 NNP O
blot BC2GM094775430 NN O
analyses BC2GM094775430 NNS O
of BC2GM094775430 IN O
meningiomas BC2GM094775430 NNS O
clearly BC2GM094775430 RB O
suggest BC2GM094775430 VBP O
the BC2GM094775430 DT O
CLH-22 BC2GM094775430 NNP O
gene BC2GM094775430 NN O
may BC2GM094775430 MD O
be BC2GM094775430 VB O
involved BC2GM094775430 VBN O
in BC2GM094775430 IN O
the BC2GM094775430 DT O
tumor BC2GM094775430 NN O
development BC2GM094775430 NN O
and BC2GM094775430 CC O
can BC2GM094775430 MD O
be BC2GM094775430 VB O
considered BC2GM094775430 VBN O
as BC2GM094775430 IN O
a BC2GM094775430 DT O
candidate BC2GM094775430 NN O
for BC2GM094775430 IN O
a BC2GM094775430 DT O
tumor BC2GM094775430 NN O
suppressor BC2GM094775430 NN O
. BC2GM094775430 . O
. . O O

Alcohol BC2GM054602912 NNP O
and BC2GM054602912 CC O
stomach BC2GM054602912 NN O
diseases BC2GM054602912 NNS O
. BC2GM054602912 . O
. . O O

The BC2GM068846839 DT O
overall BC2GM068846839 JJ O
response BC2GM068846839 NN O
rate BC2GM068846839 NN O
including BC2GM068846839 VBG O
CR BC2GM068846839 NNP O
and BC2GM068846839 CC O
PR BC2GM068846839 NNP O
was BC2GM068846839 VBD O
23.5 BC2GM068846839 CD O
% BC2GM068846839 NN O
( BC2GM068846839 ( O
4 BC2GM068846839 CD O
/ BC2GM068846839 RB O
17 BC2GM068846839 CD O
) BC2GM068846839 ) O
. BC2GM068846839 . O
. . O O

The BC2GM057631357 DT O
immediate BC2GM057631357 JJ O
5'-flanking BC2GM057631357 JJ O
region BC2GM057631357 NN O
was BC2GM057631357 VBD O
GC-rich BC2GM057631357 NNP O
with BC2GM057631357 IN O
3 BC2GM057631357 CD O
SP-1-like BC2GM057631357 JJ O
and BC2GM057631357 CC O
2 BC2GM057631357 CD O
AP-2 BC2GM057631357 JJ O
sites BC2GM057631357 NNS O
identified BC2GM057631357 VBN O
in BC2GM057631357 IN O
close BC2GM057631357 JJ O
proximity BC2GM057631357 NN O
to BC2GM057631357 TO O
the BC2GM057631357 DT O
transcription BC2GM057631357 NN O
start BC2GM057631357 NN O
site BC2GM057631357 NN O
. BC2GM057631357 . O
. . O O

Calcium BC2GM054522727 NN O
bilirubinate BC2GM054522727 NN O
crystals BC2GM054522727 NNS O
were BC2GM054522727 VBD O
seen BC2GM054522727 VBN O
in BC2GM054522727 IN O
gallbladder BC2GM054522727 NN O
bile BC2GM054522727 NN O
or BC2GM054522727 CC O
wall BC2GM054522727 JJ O
scrapings BC2GM054522727 NNS O
of BC2GM054522727 IN O
7 BC2GM054522727 CD O
of BC2GM054522727 IN O
8 BC2GM054522727 CD O
TPN BC2GM054522727 NNP O
animals BC2GM054522727 NNS O
but BC2GM054522727 CC O
in BC2GM054522727 IN O
none BC2GM054522727 NN O
of BC2GM054522727 IN O
the BC2GM054522727 DT O
controls BC2GM054522727 NNS O
( BC2GM054522727 ( O
P BC2GM054522727 NNP O
less BC2GM054522727 JJR O
than BC2GM054522727 IN O
0.001 BC2GM054522727 CD O
) BC2GM054522727 ) O
. BC2GM054522727 . O
. . O O

Further BC2GM001805382 RB O
, BC2GM001805382 , O
we BC2GM001805382 PRP O
will BC2GM001805382 MD O
review BC2GM001805382 VB O
our BC2GM001805382 PRP$ O
evaluation BC2GM001805382 NN O
of BC2GM001805382 IN O
the BC2GM001805382 DT O
survival BC2GM001805382 NN O
rate BC2GM001805382 NN O
and BC2GM001805382 CC O
prognostic BC2GM001805382 JJ O
factors BC2GM001805382 NNS O
for BC2GM001805382 IN O
9,262 BC2GM001805382 CD O
patients BC2GM001805382 NNS O
from BC2GM001805382 IN O
1981 BC2GM001805382 CD O
to BC2GM001805382 TO O
1996 BC2GM001805382 CD O
. BC2GM001805382 . O
. . O O

Thus BC2GM048598667 RB O
, BC2GM048598667 , O
the BC2GM048598667 DT O
potential BC2GM048598667 JJ O
induction BC2GM048598667 NN O
of BC2GM048598667 IN O
this BC2GM048598667 DT O
gene BC2GM048598667 NN O
rearrangement BC2GM048598667 NN O
by BC2GM048598667 IN O
E1A BC2GM048598667 NNP O
gene BC2GM048598667 NN O
therapy BC2GM048598667 NN O
is BC2GM048598667 VBZ O
unlikely BC2GM048598667 JJ O
to BC2GM048598667 TO O
be BC2GM048598667 VB O
clinically BC2GM048598667 RB O
significant BC2GM048598667 JJ O
in BC2GM048598667 IN O
the BC2GM048598667 DT O
treatment BC2GM048598667 NN O
of BC2GM048598667 IN O
advanced BC2GM048598667 JJ O
malignant BC2GM048598667 JJ O
disease BC2GM048598667 NN O
. BC2GM048598667 . O
. . O O

Humoral BC2GM051140215 NNP O
immunity BC2GM051140215 NN O
is BC2GM051140215 VBZ O
altered BC2GM051140215 VBN O
with BC2GM051140215 IN O
the BC2GM051140215 DT O
drop BC2GM051140215 NN O
in BC2GM051140215 IN O
IgG BC2GM051140215 NNP O
levels BC2GM051140215 NNS O
. BC2GM051140215 . O
. . O O

Intensity BC2GM044027057 NNP O
variations BC2GM044027057 NNS O
from BC2GM044027057 IN O
the BC2GM044027057 DT O
variable BC2GM044027057 JJ O
TR BC2GM044027057 NNP O
were BC2GM044027057 VBD O
removed BC2GM044027057 VBN O
, BC2GM044027057 , O
and BC2GM044027057 CC O
the BC2GM044027057 DT O
data BC2GM044027057 NNS O
were BC2GM044027057 VBD O
evaluated BC2GM044027057 VBN O
for BC2GM044027057 IN O
correlation BC2GM044027057 NN O
with BC2GM044027057 IN O
the BC2GM044027057 DT O
lateralized BC2GM044027057 JJ O
stimulus BC2GM044027057 NN O
. BC2GM044027057 . O
. . O O

A BC2GM072047092 DT O
rapid BC2GM072047092 JJ O
mixing BC2GM072047092 NN O
device BC2GM072047092 NN O
for BC2GM072047092 IN O
quasielastic BC2GM072047092 JJ O
light BC2GM072047092 NN O
scattering BC2GM072047092 VBG O
studies BC2GM072047092 NNS O
of BC2GM072047092 IN O
reacting BC2GM072047092 VBG O
systems BC2GM072047092 NNS O
. BC2GM072047092 . O
. . O O

Also BC2GM056849108 RB O
, BC2GM056849108 , O
like BC2GM056849108 IN O
TUB BC2GM056849108 NNP O
, BC2GM056849108 , O
it BC2GM056849108 PRP O
has BC2GM056849108 VBZ O
a BC2GM056849108 DT O
wider BC2GM056849108 NN O
pattern BC2GM056849108 NN O
of BC2GM056849108 IN O
tissue BC2GM056849108 NN O
expression BC2GM056849108 NN O
than BC2GM056849108 IN O
either BC2GM056849108 DT O
TULP1 BC2GM056849108 NNP O
or BC2GM056849108 CC O
TULP2 BC2GM056849108 NNP O
. BC2GM056849108 . O
. . O O

This BC2GM093464345 DT O
enhancer BC2GM093464345 NN O
element BC2GM093464345 NN O
functioned BC2GM093464345 VBN O
in BC2GM093464345 IN O
a BC2GM093464345 DT O
position- BC2GM093464345 JJ O
and BC2GM093464345 CC O
orientation-independent BC2GM093464345 JJ O
manner BC2GM093464345 NN O
both BC2GM093464345 DT O
on BC2GM093464345 IN O
the BC2GM093464345 DT O
Pax-QNR BC2GM093464345 NNP O
P0 BC2GM093464345 NNP O
promoter BC2GM093464345 NN O
and BC2GM093464345 CC O
the BC2GM093464345 DT O
heterologous BC2GM093464345 JJ O
thymidine BC2GM093464345 NN O
kinase BC2GM093464345 NN O
promoter BC2GM093464345 NN O
. BC2GM093464345 . O
. . O O

The BC2GM044965167 DT O
concepts BC2GM044965167 NNS O
were BC2GM044965167 VBD O
developed BC2GM044965167 VBN O
by BC2GM044965167 IN O
Mines BC2GM044965167 NNS O
and BC2GM044965167 CC O
Garrey BC2GM044965167 NNP O
during BC2GM044965167 IN O
the BC2GM044965167 DT O
next BC2GM044965167 JJ O
10 BC2GM044965167 CD O
years BC2GM044965167 NNS O
. BC2GM044965167 . O
. . O O

ER BC2GM029220064 NNP O
beta BC2GM029220064 NN O
was BC2GM029220064 VBD O
less BC2GM029220064 RBR O
potent BC2GM029220064 JJ O
than BC2GM029220064 IN O
ER BC2GM029220064 NNP O
alpha BC2GM029220064 NN O
in BC2GM029220064 IN O
activating BC2GM029220064 VBG O
E2-stimulated BC2GM029220064 JJ O
ERELuc BC2GM029220064 NNP O
activity BC2GM029220064 NN O
( BC2GM029220064 ( O
4-vs BC2GM029220064 JJ O
. BC2GM029220064 . O
. . O O

Both BC2GM076151355 DT O
control BC2GM076151355 NN O
and BC2GM076151355 CC O
Mn-exposed BC2GM076151355 JJ O
quail BC2GM076151355 NN O
accumulated BC2GM076151355 VBD O
5 BC2GM076151355 CD O
to BC2GM076151355 TO O
10 BC2GM076151355 CD O
times BC2GM076151355 NNS O
more BC2GM076151355 RBR O
Mn BC2GM076151355 NNP O
in BC2GM076151355 IN O
their BC2GM076151355 PRP$ O
livers BC2GM076151355 NNS O
than BC2GM076151355 IN O
similarly BC2GM076151355 RB O
treated BC2GM076151355 VBN O
rodents BC2GM076151355 NNS O
. BC2GM076151355 . O
. . O O

The BC2GM074492181 DT O
map BC2GM074492181 NN O
is BC2GM074492181 VBZ O
based BC2GM074492181 VBN O
on BC2GM074492181 IN O
the BC2GM074492181 DT O
CEPH BC2GM074492181 NNP O
reference BC2GM074492181 NN O
pedigrees BC2GM074492181 NNS O
and BC2GM074492181 CC O
includes BC2GM074492181 VBZ O
over BC2GM074492181 IN O
4000 BC2GM074492181 CD O
new BC2GM074492181 JJ O
genotypes BC2GM074492181 NNS O
, BC2GM074492181 , O
our BC2GM074492181 PRP$ O
previously BC2GM074492181 RB O
reported BC2GM074492181 VBN O
data BC2GM074492181 NNS O
plus BC2GM074492181 CC O
29 BC2GM074492181 CD O
allele BC2GM074492181 JJ O
systems BC2GM074492181 NNS O
from BC2GM074492181 IN O
the BC2GM074492181 DT O
published BC2GM074492181 VBN O
CEPH BC2GM074492181 NNP O
version BC2GM074492181 NN O
5 BC2GM074492181 CD O
database BC2GM074492181 NN O
, BC2GM074492181 , O
and BC2GM074492181 CC O
was BC2GM074492181 VBD O
constructed BC2GM074492181 VBN O
using BC2GM074492181 VBG O
the BC2GM074492181 DT O
program BC2GM074492181 NN O
package BC2GM074492181 NN O
CRI-MAP BC2GM074492181 NNP O
. BC2GM074492181 . O
. . O O

Plasma BC2GM056313668 NNP O
prolactin BC2GM056313668 NN O
concentrations BC2GM056313668 NNS O
during BC2GM056313668 IN O
incubation BC2GM056313668 NN O
, BC2GM056313668 , O
25.8 BC2GM056313668 CD O
+ BC2GM056313668 NN O
/ BC2GM056313668 NNP O
- BC2GM056313668 : O
2.3 BC2GM056313668 CD O
ng BC2GM056313668 JJ O
/ BC2GM056313668 NNP O
ml BC2GM056313668 NN O
, BC2GM056313668 , O
decreased BC2GM056313668 VBN O
to BC2GM056313668 TO O
baseline BC2GM056313668 NN O
levels BC2GM056313668 NNS O
, BC2GM056313668 , O
10.8 BC2GM056313668 CD O
+ BC2GM056313668 NN O
/ BC2GM056313668 NNP O
- BC2GM056313668 : O
1.9 BC2GM056313668 CD O
ng BC2GM056313668 JJ O
/ BC2GM056313668 NNP O
ml BC2GM056313668 NN O
, BC2GM056313668 , O
within BC2GM056313668 IN O
24 BC2GM056313668 CD O
hr BC2GM056313668 NN O
after BC2GM056313668 IN O
nestbox BC2GM056313668 JJ O
removal BC2GM056313668 NN O
. BC2GM056313668 . O
. . O O

The BC2GM025770197 DT O
sensitivity BC2GM025770197 NN O
for BC2GM025770197 IN O
ergometry BC2GM025770197 NN O
and BC2GM025770197 CC O
treadmill BC2GM025770197 NN O
testing BC2GM025770197 NN O
was BC2GM025770197 VBD O
75 BC2GM025770197 CD O
and BC2GM025770197 CC O
62 BC2GM025770197 CD O
% BC2GM025770197 NN O
respectively BC2GM025770197 RB O
. BC2GM025770197 . O
. . O O

Radioactively BC2GM052108285 RB O
labeled BC2GM052108285 VBN O
microspheres BC2GM052108285 NNS O
were BC2GM052108285 VBD O
used BC2GM052108285 VBN O
to BC2GM052108285 TO O
determine BC2GM052108285 VB O
and BC2GM052108285 CC O
compare BC2GM052108285 VB O
the BC2GM052108285 DT O
hemodynamic BC2GM052108285 JJ O
effects BC2GM052108285 NNS O
of BC2GM052108285 IN O
sodium BC2GM052108285 NN O
nitroprusside BC2GM052108285 NN O
( BC2GM052108285 ( O
SNP BC2GM052108285 NNP O
) BC2GM052108285 ) O
, BC2GM052108285 , O
nitroglycerin BC2GM052108285 FW O
( BC2GM052108285 ( O
NTG BC2GM052108285 NNP O
) BC2GM052108285 ) O
, BC2GM052108285 , O
and BC2GM052108285 CC O
deep BC2GM052108285 JJ O
enflurane BC2GM052108285 NN O
anesthesia BC2GM052108285 NN O
on BC2GM052108285 IN O
oral BC2GM052108285 JJ O
tissues BC2GM052108285 NNS O
during BC2GM052108285 IN O
controlled BC2GM052108285 VBN O
hypotension BC2GM052108285 NN O
when BC2GM052108285 WRB O
compared BC2GM052108285 VBN O
with BC2GM052108285 IN O
controls BC2GM052108285 NNS O
. BC2GM052108285 . O
. . O O

A BC2GM047130607 DT O
phase BC2GM047130607 NN O
II BC2GM047130607 NNP O
study BC2GM047130607 NN O
was BC2GM047130607 VBD O
initiated BC2GM047130607 VBN O
to BC2GM047130607 TO O
evaluate BC2GM047130607 VB O
the BC2GM047130607 DT O
effect BC2GM047130607 NN O
of BC2GM047130607 IN O
a BC2GM047130607 DT O
combination BC2GM047130607 NN O
of BC2GM047130607 IN O
the BC2GM047130607 DT O
pure BC2GM047130607 JJ O
L-isomer BC2GM047130607 NNP O
of BC2GM047130607 IN O
LV BC2GM047130607 NNP O
and BC2GM047130607 CC O
5-FU BC2GM047130607 JJ O
along BC2GM047130607 IN O
with BC2GM047130607 IN O
epirubicin BC2GM047130607 NN O
in BC2GM047130607 IN O
patients BC2GM047130607 NNS O
with BC2GM047130607 IN O
advanced BC2GM047130607 JJ O
pancreatic BC2GM047130607 JJ O
cancer BC2GM047130607 NN O
. BC2GM047130607 . O
. . O O

BACKGROUND BC2GM018711708 NN O
: BC2GM018711708 : O
Peripheral BC2GM018711708 JJ O
kappa BC2GM018711708 NNS O
receptor BC2GM018711708 NN O
agonists BC2GM018711708 NNS O
may BC2GM018711708 MD O
provide BC2GM018711708 VB O
a BC2GM018711708 DT O
new BC2GM018711708 JJ O
therapeutic BC2GM018711708 JJ O
approach BC2GM018711708 NN O
for BC2GM018711708 IN O
the BC2GM018711708 DT O
treatment BC2GM018711708 NN O
of BC2GM018711708 IN O
functional BC2GM018711708 JJ O
dyspepsia BC2GM018711708 NN O
. BC2GM018711708 . O
. . O O

This BC2GM048973712 DT O
study BC2GM048973712 NN O
demonstrates BC2GM048973712 VBZ O
that BC2GM048973712 IN O
Fluosol BC2GM048973712 NNP O
significantly BC2GM048973712 RB O
attenuates BC2GM048973712 VBZ O
neutrophil BC2GM048973712 JJ O
adherence BC2GM048973712 NN O
, BC2GM048973712 , O
cytotoxicity BC2GM048973712 NN O
, BC2GM048973712 , O
and BC2GM048973712 CC O
enzyme BC2GM048973712 JJ O
release BC2GM048973712 NN O
in BC2GM048973712 IN O
an BC2GM048973712 DT O
in BC2GM048973712 IN O
vitro BC2GM048973712 JJ O
model BC2GM048973712 NN O
of BC2GM048973712 IN O
microvascular BC2GM048973712 JJ O
injury BC2GM048973712 NN O
. BC2GM048973712 . O
. . O O

Our BC2GM097325580 PRP$ O
study BC2GM097325580 NN O
reveals BC2GM097325580 VBZ O
a BC2GM097325580 DT O
consequence BC2GM097325580 NN O
of BC2GM097325580 IN O
adhesion BC2GM097325580 NN O
receptor-mediated BC2GM097325580 JJ O
signaling BC2GM097325580 NN O
in BC2GM097325580 IN O
T BC2GM097325580 NNP O
cells BC2GM097325580 NNS O
, BC2GM097325580 , O
which BC2GM097325580 WDT O
is BC2GM097325580 VBZ O
potentially BC2GM097325580 RB O
important BC2GM097325580 JJ O
in BC2GM097325580 IN O
the BC2GM097325580 DT O
regulation BC2GM097325580 NN O
of BC2GM097325580 IN O
T BC2GM097325580 NNP O
cell BC2GM097325580 NN O
activation BC2GM097325580 NN O
, BC2GM097325580 , O
including BC2GM097325580 VBG O
production BC2GM097325580 NN O
of BC2GM097325580 IN O
cytokines BC2GM097325580 NNS O
and BC2GM097325580 CC O
expression BC2GM097325580 NN O
of BC2GM097325580 IN O
proto-oncogenes BC2GM097325580 NNS O
, BC2GM097325580 , O
many BC2GM097325580 JJ O
of BC2GM097325580 IN O
which BC2GM097325580 WDT O
are BC2GM097325580 VBP O
controlled BC2GM097325580 VBN O
through BC2GM097325580 IN O
3 BC2GM097325580 CD O
' BC2GM097325580 POS O
AU-rich BC2GM097325580 JJ O
elements BC2GM097325580 NNS O
. BC2GM097325580 . O
. . O O

The BC2GM064007116 DT O
average BC2GM064007116 JJ O
coefficient BC2GM064007116 NN O
of BC2GM064007116 IN O
variation BC2GM064007116 NN O
between BC2GM064007116 IN O
assays BC2GM064007116 NNS O
for BC2GM064007116 IN O
gas BC2GM064007116 NN O
chromatography BC2GM064007116 NN O
mass BC2GM064007116 NN O
spectrometry BC2GM064007116 NN O
was BC2GM064007116 VBD O
5.8 BC2GM064007116 CD O
% BC2GM064007116 NN O
and BC2GM064007116 CC O
for BC2GM064007116 IN O
radioimmunoassay BC2GM064007116 NN O
was BC2GM064007116 VBD O
12.3 BC2GM064007116 CD O
% BC2GM064007116 NN O
, BC2GM064007116 , O
while BC2GM064007116 IN O
the BC2GM064007116 DT O
average BC2GM064007116 JJ O
coefficient BC2GM064007116 NN O
of BC2GM064007116 IN O
variation BC2GM064007116 NN O
within BC2GM064007116 IN O
assays BC2GM064007116 NNS O
for BC2GM064007116 IN O
gas BC2GM064007116 NN O
chromatography BC2GM064007116 NN O
mass BC2GM064007116 NN O
spectrometry BC2GM064007116 NN O
was BC2GM064007116 VBD O
4.9 BC2GM064007116 CD O
% BC2GM064007116 NN O
and BC2GM064007116 CC O
for BC2GM064007116 IN O
radioimmunoassay BC2GM064007116 VBP O
6.9 BC2GM064007116 CD O
% BC2GM064007116 NN O
. BC2GM064007116 . O
. . O O

Prolongation BC2GM062170558 NN O
of BC2GM062170558 IN O
prothrombin BC2GM062170558 JJ O
time BC2GM062170558 NN O
was BC2GM062170558 VBD O
not BC2GM062170558 RB O
due BC2GM062170558 JJ O
to BC2GM062170558 TO O
depletion BC2GM062170558 NN O
of BC2GM062170558 IN O
vitamin BC2GM062170558 JJ O
K-dependent BC2GM062170558 JJ O
coagulation BC2GM062170558 NN O
factors BC2GM062170558 NNS O
or BC2GM062170558 CC O
manifest BC2GM062170558 JJS O
fibrinolysis BC2GM062170558 NN O
, BC2GM062170558 , O
but BC2GM062170558 CC O
due BC2GM062170558 JJ O
to BC2GM062170558 TO O
the BC2GM062170558 DT O
presence BC2GM062170558 NN O
of BC2GM062170558 IN O
circulating BC2GM062170558 VBG O
fibrinogen BC2GM062170558 JJ O
fibrinmonomer-FDP BC2GM062170558 JJ O
complexes BC2GM062170558 NNS O
. BC2GM062170558 . O
. . O O

CONCLUSIONS BC2GM072286442 NN O
: BC2GM072286442 : O
These BC2GM072286442 DT O
results BC2GM072286442 NNS O
suggest BC2GM072286442 VBP O
that BC2GM072286442 IN O
, BC2GM072286442 , O
by BC2GM072286442 IN O
interacting BC2GM072286442 VBG O
with BC2GM072286442 IN O
cellular BC2GM072286442 JJ O
transcription BC2GM072286442 NN O
factors BC2GM072286442 NNS O
and BC2GM072286442 CC O
cofactors BC2GM072286442 NNS O
, BC2GM072286442 , O
vIRF-2 BC2GM072286442 NN O
may BC2GM072286442 MD O
modulate BC2GM072286442 VB O
the BC2GM072286442 DT O
expression BC2GM072286442 NN O
of BC2GM072286442 IN O
the BC2GM072286442 DT O
early BC2GM072286442 JJ O
inflammatory BC2GM072286442 NN O
genes BC2GM072286442 NNS O
and BC2GM072286442 CC O
potentially BC2GM072286442 RB O
deregulate BC2GM072286442 VB O
the BC2GM072286442 DT O
immune BC2GM072286442 NN O
system BC2GM072286442 NN O
. BC2GM072286442 . O
. . O O

Human BC2GM021683203 NNP O
CD38 BC2GM021683203 NNP O
, BC2GM021683203 , O
a BC2GM021683203 DT O
leukocyte BC2GM021683203 JJ O
receptor BC2GM021683203 NN O
and BC2GM021683203 CC O
ectoenzyme BC2GM021683203 NN O
, BC2GM021683203 , O
is BC2GM021683203 VBZ O
a BC2GM021683203 DT O
member BC2GM021683203 NN O
of BC2GM021683203 IN O
a BC2GM021683203 DT O
novel BC2GM021683203 JJ O
eukaryotic BC2GM021683203 JJ O
gene BC2GM021683203 NN O
family BC2GM021683203 NN O
of BC2GM021683203 IN O
nicotinamide BC2GM021683203 JJ O
adenine BC2GM021683203 JJ O
dinucleotide+-converting BC2GM021683203 JJ O
enzymes BC2GM021683203 NNS O
: BC2GM021683203 : O
extensive BC2GM021683203 JJ O
structural BC2GM021683203 JJ O
homology BC2GM021683203 NN O
with BC2GM021683203 IN O
the BC2GM021683203 DT O
genes BC2GM021683203 NNS O
for BC2GM021683203 IN O
murine BC2GM021683203 NN O
bone BC2GM021683203 NN O
marrow BC2GM021683203 NN O
stromal BC2GM021683203 NN O
cell BC2GM021683203 NN O
antigen BC2GM021683203 NN O
1 BC2GM021683203 CD O
and BC2GM021683203 CC O
aplysian BC2GM021683203 JJ O
ADP-ribosyl BC2GM021683203 NNP O
cyclase BC2GM021683203 NN O
. BC2GM021683203 . O
. . O O

GAGA BC2GM037059732 NNP O
factor BC2GM037059732 NN O
is BC2GM037059732 VBZ O
known BC2GM037059732 VBN O
to BC2GM037059732 TO O
remodel BC2GM037059732 VB O
the BC2GM037059732 DT O
chromatin BC2GM037059732 NN O
structure BC2GM037059732 NN O
in BC2GM037059732 IN O
concert BC2GM037059732 NN O
with BC2GM037059732 IN O
nucleosome-remodeling BC2GM037059732 JJ O
factor BC2GM037059732 NN O
NURF BC2GM037059732 NNP O
in BC2GM037059732 IN O
a BC2GM037059732 DT O
Drosophila BC2GM037059732 NNP O
embryonic BC2GM037059732 JJ O
S150 BC2GM037059732 NNP O
extract BC2GM037059732 NN O
. BC2GM037059732 . O
. . O O

RXRalpha BC2GM086778872 NNP O
/ BC2GM086778872 NNP O
RARalpha BC2GM086778872 NNP O
heterodimers BC2GM086778872 NNS O
and BC2GM086778872 CC O
HNF-4 BC2GM086778872 NNP O
homodimers BC2GM086778872 NNS O
bind BC2GM086778872 VBP O
to BC2GM086778872 TO O
DR-1 BC2GM086778872 NNP O
motifs BC2GM086778872 NNS O
on BC2GM086778872 IN O
elements BC2GM086778872 NNS O
B BC2GM086778872 NNP O
and BC2GM086778872 CC O
I4 BC2GM086778872 NNP O
, BC2GM086778872 , O
respectively BC2GM086778872 RB O
. BC2GM086778872 . O
. . O O

Treatment BC2GM062721233 NN O
is BC2GM062721233 VBZ O
based BC2GM062721233 VBN O
on BC2GM062721233 IN O
antifungal BC2GM062721233 JJ O
drugs BC2GM062721233 NNS O
, BC2GM062721233 , O
most BC2GM062721233 JJS O
frequently BC2GM062721233 RB O
nystatin BC2GM062721233 RB O
, BC2GM062721233 , O
amphotericin BC2GM062721233 NN O
B BC2GM062721233 NNP O
and BC2GM062721233 CC O
ketoconazole BC2GM062721233 NN O
. BC2GM062721233 . O
. . O O

Thus BC2GM020106641 RB O
, BC2GM020106641 , O
CR2 BC2GM020106641 NNP O
possesses BC2GM020106641 VBZ O
an BC2GM020106641 DT O
essential BC2GM020106641 JJ O
function BC2GM020106641 NN O
besides BC2GM020106641 IN O
pRb-binding BC2GM020106641 NN O
. BC2GM020106641 . O
. . O O

For BC2GM006852575 IN O
evaluation BC2GM006852575 NN O
of BC2GM006852575 IN O
the BC2GM006852575 DT O
model BC2GM006852575 NN O
, BC2GM006852575 , O
simulations BC2GM006852575 NNS O
of BC2GM006852575 IN O
physiological BC2GM006852575 JJ O
excitation BC2GM006852575 NN O
and BC2GM006852575 CC O
of BC2GM006852575 IN O
pathologies BC2GM006852575 NNS O
( BC2GM006852575 ( O
Wolff-Parkinson-White BC2GM006852575 JJ O
syndrome BC2GM006852575 NN O
, BC2GM006852575 , O
complete BC2GM006852575 JJ O
AV-block BC2GM006852575 NNP O
, BC2GM006852575 , O
inferior BC2GM006852575 JJ O
wall BC2GM006852575 NN O
ischaemia BC2GM006852575 NN O
) BC2GM006852575 ) O
were BC2GM006852575 VBD O
examined BC2GM006852575 VBN O
. BC2GM006852575 . O
. . O O

A BC2GM004781079 DT O
positive BC2GM004781079 JJ O
FTA-ABS-19S-IgM BC2GM004781079 JJ O
test BC2GM004781079 NN O
indicates BC2GM004781079 VBZ O
the BC2GM004781079 DT O
necessity BC2GM004781079 NN O
of BC2GM004781079 IN O
treatment BC2GM004781079 NN O
. BC2GM004781079 . O
. . O O

However BC2GM053594335 RB O
, BC2GM053594335 , O
the BC2GM053594335 DT O
relative BC2GM053594335 JJ O
substrate BC2GM053594335 NN O
specificity BC2GM053594335 NN O
of BC2GM053594335 IN O
RSK3 BC2GM053594335 NNP O
differed BC2GM053594335 VBD O
from BC2GM053594335 IN O
that BC2GM053594335 IN O
reported BC2GM053594335 VBN O
for BC2GM053594335 IN O
other BC2GM053594335 JJ O
isoforms BC2GM053594335 NNS O
. BC2GM053594335 . O
. . O O

To BC2GM083943524 TO O
investigate BC2GM083943524 VB O
possible BC2GM083943524 JJ O
roles BC2GM083943524 NNS O
for BC2GM083943524 IN O
HCP BC2GM083943524 NNP O
during BC2GM083943524 IN O
late BC2GM083943524 JJ O
erythroid BC2GM083943524 JJ O
differentiation BC2GM083943524 NN O
, BC2GM083943524 , O
effects BC2GM083943524 NNS O
of BC2GM083943524 IN O
manipulating BC2GM083943524 VBG O
HCP BC2GM083943524 NNP O
expression BC2GM083943524 NN O
or BC2GM083943524 CC O
recruitment BC2GM083943524 NN O
on BC2GM083943524 IN O
EPO-induced BC2GM083943524 JJ O
hemoglobinization BC2GM083943524 NN O
in BC2GM083943524 IN O
erythroleukemic BC2GM083943524 JJ O
SKT6 BC2GM083943524 NNP O
cells BC2GM083943524 NNS O
have BC2GM083943524 VBP O
been BC2GM083943524 VBN O
investigated BC2GM083943524 VBN O
. BC2GM083943524 . O
. . O O

Thus BC2GM045716820 RB O
, BC2GM045716820 , O
the BC2GM045716820 DT O
in BC2GM045716820 IN O
vivo BC2GM045716820 JJ O
function BC2GM045716820 NN O
of BC2GM045716820 IN O
Gle2p BC2GM045716820 NNP O
is BC2GM045716820 VBZ O
strictly BC2GM045716820 RB O
coupled BC2GM045716820 VBN O
to BC2GM045716820 TO O
the BC2GM045716820 DT O
short BC2GM045716820 JJ O
GLEBS BC2GM045716820 NNP O
within BC2GM045716820 IN O
Nup116p BC2GM045716820 NNP O
which BC2GM045716820 WDT O
links BC2GM045716820 VBZ O
this BC2GM045716820 DT O
putative BC2GM045716820 JJ O
mRNA BC2GM045716820 NN O
transport BC2GM045716820 NN O
factor BC2GM045716820 NN O
to BC2GM045716820 TO O
the BC2GM045716820 DT O
nuclear BC2GM045716820 JJ O
pores BC2GM045716820 NNS O
. BC2GM045716820 . O
. . O O

Transcriptional BC2GM063132076 JJ O
analysis BC2GM063132076 NN O
indicates BC2GM063132076 VBZ O
that BC2GM063132076 IN O
human BC2GM063132076 JJ O
TBP BC2GM063132076 NNP O
functions BC2GM063132076 NNS O
poorly BC2GM063132076 RB O
at BC2GM063132076 IN O
promoters BC2GM063132076 NNS O
recognized BC2GM063132076 VBN O
by BC2GM063132076 IN O
RNA BC2GM063132076 NNP O
polymerases BC2GM063132076 NNS O
I BC2GM063132076 PRP O
and BC2GM063132076 CC O
III BC2GM063132076 NNP O
and BC2GM063132076 CC O
at BC2GM063132076 IN O
RNA BC2GM063132076 NNP O
Pol BC2GM063132076 NNP O
II BC2GM063132076 NNP O
promoters BC2GM063132076 NNS O
lacking BC2GM063132076 VBG O
a BC2GM063132076 DT O
conventional BC2GM063132076 JJ O
TATA BC2GM063132076 NNP O
element BC2GM063132076 NN O
. BC2GM063132076 . O
. . O O

Assessment BC2GM097326747 NN O
of BC2GM097326747 IN O
ammonia BC2GM097326747 NN O
and BC2GM097326747 CC O
urea BC2GM097326747 JJ O
blood BC2GM097326747 NN O
content BC2GM097326747 NN O
in BC2GM097326747 IN O
metabolic BC2GM097326747 JJ O
acid-base BC2GM097326747 JJ O
disorders BC2GM097326747 NNS O
in BC2GM097326747 IN O
white BC2GM097326747 JJ O
rats BC2GM097326747 NNS O
. BC2GM097326747 . O
. . O O

NF-kappaB BC2GM043173941 NNP O
only BC2GM043173941 RB O
partially BC2GM043173941 RB O
mediates BC2GM043173941 VBZ O
Epstein-Barr BC2GM043173941 NNP O
virus BC2GM043173941 NN O
latent BC2GM043173941 NN O
membrane BC2GM043173941 NN O
protein BC2GM043173941 VBD O
1 BC2GM043173941 CD O
activation BC2GM043173941 NN O
of BC2GM043173941 IN O
B BC2GM043173941 NNP O
cells BC2GM043173941 NNS O
. BC2GM043173941 . O
. . O O

The BC2GM067799557 DT O
brains BC2GM067799557 NNS O
were BC2GM067799557 VBD O
processed BC2GM067799557 VBN O
according BC2GM067799557 VBG O
to BC2GM067799557 TO O
the BC2GM067799557 DT O
tetramethylbenzidine BC2GM067799557 NN O
( BC2GM067799557 ( O
TMB BC2GM067799557 NNP O
) BC2GM067799557 ) O
protocol BC2GM067799557 NN O
of BC2GM067799557 IN O
Mesulam BC2GM067799557 NNP O
( BC2GM067799557 ( O
'78 BC2GM067799557 POS O
) BC2GM067799557 ) O
and BC2GM067799557 CC O
studied BC2GM067799557 VBN O
with BC2GM067799557 IN O
darkfield BC2GM067799557 JJ O
microscopy BC2GM067799557 NN O
. BC2GM067799557 . O
. . O O

It BC2GM008652234 PRP O
is BC2GM008652234 VBZ O
pathogenetically BC2GM008652234 RB O
proved BC2GM008652234 VBN O
to BC2GM008652234 TO O
use BC2GM008652234 VB O
antithrombin BC2GM008652234 JJ O
III BC2GM008652234 NNP O
concentrate BC2GM008652234 NN O
preparations BC2GM008652234 NNS O
with BC2GM008652234 IN O
anti- BC2GM008652234 JJ O
and BC2GM008652234 CC O
dysaggregatory BC2GM008652234 JJ O
properties BC2GM008652234 NNS O
, BC2GM008652234 , O
fibronectin BC2GM008652234 JJ O
preparations BC2GM008652234 NNS O
, BC2GM008652234 , O
trasylol BC2GM008652234 NN O
or BC2GM008652234 CC O
its BC2GM008652234 PRP$ O
analogs BC2GM008652234 NNS O
during BC2GM008652234 IN O
complex BC2GM008652234 JJ O
preoperative BC2GM008652234 JJ O
preparation BC2GM008652234 NN O
of BC2GM008652234 IN O
patients BC2GM008652234 NNS O
. BC2GM008652234 . O
. . O O

We BC2GM080486141 PRP O
have BC2GM080486141 VBP O
analyzed BC2GM080486141 VBN O
the BC2GM080486141 DT O
role BC2GM080486141 NN O
of BC2GM080486141 IN O
the BC2GM080486141 DT O
HU BC2GM080486141 NNP O
protein BC2GM080486141 NN O
in BC2GM080486141 IN O
invertasome BC2GM080486141 NN O
assembly BC2GM080486141 NN O
when BC2GM080486141 WRB O
the BC2GM080486141 DT O
enhancer BC2GM080486141 NN O
is BC2GM080486141 VBZ O
located BC2GM080486141 VBN O
at BC2GM080486141 IN O
variable BC2GM080486141 JJ O
positions BC2GM080486141 NNS O
close BC2GM080486141 RB O
to BC2GM080486141 TO O
one BC2GM080486141 CD O
of BC2GM080486141 IN O
the BC2GM080486141 DT O
recombination BC2GM080486141 NN O
sites BC2GM080486141 VBZ O
. BC2GM080486141 . O
. . O O

Pneumatic BC2GM076326371 JJ O
dilation BC2GM076326371 NN O
of BC2GM076326371 IN O
the BC2GM076326371 DT O
lower BC2GM076326371 JJR O
esophageal BC2GM076326371 NN O
sphincter BC2GM076326371 NN O
was BC2GM076326371 VBD O
accomplished BC2GM076326371 VBN O
by BC2GM076326371 IN O
endoscopic BC2GM076326371 JJ O
visualization BC2GM076326371 NN O
and BC2GM076326371 CC O
positioning BC2GM076326371 NN O
of BC2GM076326371 IN O
a BC2GM076326371 DT O
modified BC2GM076326371 JJ O
polyurethane BC2GM076326371 NN O
dilator BC2GM076326371 NN O
( BC2GM076326371 ( O
90 BC2GM076326371 CD O
F BC2GM076326371 NNP O
diameter BC2GM076326371 NN O
) BC2GM076326371 ) O
without BC2GM076326371 IN O
fluoroscopy BC2GM076326371 NN O
in BC2GM076326371 IN O
17 BC2GM076326371 CD O
consecutive BC2GM076326371 JJ O
patients BC2GM076326371 NNS O
with BC2GM076326371 IN O
advanced BC2GM076326371 JJ O
symptomatic BC2GM076326371 JJ O
achalasia BC2GM076326371 NN O
. BC2GM076326371 . O
. . O O

Among BC2GM067551044 IN O
women BC2GM067551044 NNS O
, BC2GM067551044 , O
plasma BC2GM067551044 JJ O
factor BC2GM067551044 NN O
VII BC2GM067551044 NNP O
: BC2GM067551044 : O
Ag BC2GM067551044 NNP O
was BC2GM067551044 VBD O
inversely BC2GM067551044 RB O
associated BC2GM067551044 VBN O
with BC2GM067551044 IN O
income BC2GM067551044 NN O
. BC2GM067551044 . O
. . O O

PKCI-1 BC2GM080178845 NNP O
is BC2GM080178845 VBZ O
a BC2GM080178845 DT O
member BC2GM080178845 NN O
of BC2GM080178845 IN O
the BC2GM080178845 DT O
HIT BC2GM080178845 NNP O
family BC2GM080178845 NN O
of BC2GM080178845 IN O
proteins BC2GM080178845 NNS O
, BC2GM080178845 , O
shown BC2GM080178845 VBN O
by BC2GM080178845 IN O
sequence BC2GM080178845 NN O
identity BC2GM080178845 NN O
to BC2GM080178845 TO O
be BC2GM080178845 VB O
conserved BC2GM080178845 VBN O
in BC2GM080178845 IN O
a BC2GM080178845 DT O
broad BC2GM080178845 JJ O
range BC2GM080178845 NN O
of BC2GM080178845 IN O
organisms BC2GM080178845 NNS O
including BC2GM080178845 VBG O
mycoplasma BC2GM080178845 NN O
, BC2GM080178845 , O
plants BC2GM080178845 NNS O
, BC2GM080178845 , O
and BC2GM080178845 CC O
humans BC2GM080178845 NNS O
. BC2GM080178845 . O
. . O O

Causal BC2GM099964294 NNP O
modeling BC2GM099964294 VBG O
combines BC2GM099964294 NNS O
theory BC2GM099964294 NN O
and BC2GM099964294 CC O
research BC2GM099964294 NN O
, BC2GM099964294 , O
and BC2GM099964294 CC O
because BC2GM099964294 IN O
the BC2GM099964294 DT O
interpretation BC2GM099964294 NN O
of BC2GM099964294 IN O
data BC2GM099964294 NNS O
is BC2GM099964294 VBZ O
possible BC2GM099964294 JJ O
only BC2GM099964294 RB O
within BC2GM099964294 IN O
the BC2GM099964294 DT O
context BC2GM099964294 NN O
of BC2GM099964294 IN O
the BC2GM099964294 DT O
proposed BC2GM099964294 VBN O
theory BC2GM099964294 NN O
, BC2GM099964294 , O
it BC2GM099964294 PRP O
offers BC2GM099964294 VBZ O
an BC2GM099964294 DT O
important BC2GM099964294 JJ O
method BC2GM099964294 NN O
for BC2GM099964294 IN O
advancing BC2GM099964294 VBG O
the BC2GM099964294 DT O
science BC2GM099964294 NN O
while BC2GM099964294 IN O
maintaining BC2GM099964294 VBG O
the BC2GM099964294 DT O
specificity BC2GM099964294 NN O
of BC2GM099964294 IN O
the BC2GM099964294 DT O
practice BC2GM099964294 NN O
. BC2GM099964294 . O
. . O O

The BC2GM094026101 DT O
selective BC2GM094026101 JJ O
5-HT2 BC2GM094026101 JJ O
receptor BC2GM094026101 NN O
blocker BC2GM094026101 NN O
ketanserin BC2GM094026101 NN O
was BC2GM094026101 VBD O
found BC2GM094026101 VBN O
to BC2GM094026101 TO O
reduce BC2GM094026101 VB O
maximal BC2GM094026101 JJ O
urethral BC2GM094026101 JJ O
pressures BC2GM094026101 NNS O
in BC2GM094026101 IN O
healthy BC2GM094026101 JJ O
females BC2GM094026101 NNS O
by BC2GM094026101 IN O
about BC2GM094026101 IN O
40 BC2GM094026101 CD O
% BC2GM094026101 NN O
without BC2GM094026101 IN O
reducing BC2GM094026101 VBG O
blood BC2GM094026101 NN O
pressure BC2GM094026101 NN O
. BC2GM094026101 . O
. . O O

These BC2GM019910898 DT O
findings BC2GM019910898 NNS O
indicated BC2GM019910898 VBD O
that BC2GM019910898 IN O
p35 BC2GM019910898 NN O
is BC2GM019910898 VBZ O
a BC2GM019910898 DT O
trans-dominant BC2GM019910898 JJ O
factor BC2GM019910898 NN O
that BC2GM019910898 WDT O
facilitates BC2GM019910898 VBZ O
AcMNPV BC2GM019910898 NNP O
growth BC2GM019910898 NN O
in BC2GM019910898 IN O
a BC2GM019910898 DT O
cell BC2GM019910898 NN O
line-specific BC2GM019910898 JJ O
manner BC2GM019910898 NN O
. BC2GM019910898 . O
. . O O

Platelets BC2GM034677761 NNS O
and BC2GM034677761 CC O
RBCs BC2GM034677761 NNP O
from BC2GM034677761 IN O
each BC2GM034677761 DT O
animal BC2GM034677761 NN O
were BC2GM034677761 VBD O
labeled BC2GM034677761 VBN O
with BC2GM034677761 IN O
51Cr BC2GM034677761 CD O
and BC2GM034677761 CC O
99mTc BC2GM034677761 CD O
, BC2GM034677761 , O
respectively BC2GM034677761 RB O
, BC2GM034677761 , O
and BC2GM034677761 CC O
were BC2GM034677761 VBD O
rapidly BC2GM034677761 RB O
injected BC2GM034677761 VBN O
into BC2GM034677761 IN O
the BC2GM034677761 DT O
right BC2GM034677761 JJ O
atrium BC2GM034677761 NN O
while BC2GM034677761 IN O
blood BC2GM034677761 NN O
was BC2GM034677761 VBD O
sampled BC2GM034677761 VBN O
from BC2GM034677761 IN O
the BC2GM034677761 DT O
ascending BC2GM034677761 VBG O
aorta BC2GM034677761 NN O
. BC2GM034677761 . O
. . O O

METHODOLOGY BC2GM029534167 NN O
: BC2GM029534167 : O
A BC2GM029534167 DT O
case BC2GM029534167 NN O
control BC2GM029534167 NN O
study BC2GM029534167 NN O
of BC2GM029534167 IN O
survivors BC2GM029534167 NNS O
with BC2GM029534167 IN O
gestational BC2GM029534167 JJ O
age BC2GM029534167 NN O
( BC2GM029534167 ( O
GA BC2GM029534167 NNP O
) BC2GM029534167 ) O
< BC2GM029534167 VBD O
28 BC2GM029534167 CD O
weeks BC2GM029534167 NNS O
or BC2GM029534167 CC O
birthweight BC2GM029534167 NN O
( BC2GM029534167 ( O
BW BC2GM029534167 NNP O
) BC2GM029534167 ) O
< BC2GM029534167 NN O
1000 BC2GM029534167 CD O
g BC2GM029534167 NN O
using BC2GM029534167 VBG O
data BC2GM029534167 NNS O
collected BC2GM029534167 VBN O
prospectively BC2GM029534167 RB O
in BC2GM029534167 IN O
our BC2GM029534167 PRP$ O
Neonatal BC2GM029534167 NNP O
Intensive BC2GM029534167 NNP O
Care BC2GM029534167 NNP O
Unit BC2GM029534167 NNP O
database BC2GM029534167 NN O
. BC2GM029534167 . O
. . O O

Promoter BC2GM067523581 NN O
constructs BC2GM067523581 NNS O
containing BC2GM067523581 VBG O
mutations BC2GM067523581 NNS O
in BC2GM067523581 IN O
the BC2GM067523581 DT O
PTRE BC2GM067523581 NNP O
sequence BC2GM067523581 NN O
that BC2GM067523581 WDT O
selectively BC2GM067523581 RB O
abolished BC2GM067523581 VBD O
the BC2GM067523581 DT O
binding BC2GM067523581 NN O
of BC2GM067523581 IN O
either BC2GM067523581 CC O
one BC2GM067523581 CD O
or BC2GM067523581 CC O
both BC2GM067523581 DT O
complexes BC2GM067523581 NNS O
exerted BC2GM067523581 VBD O
opposite BC2GM067523581 JJ O
effects BC2GM067523581 NNS O
on BC2GM067523581 IN O
the BC2GM067523581 DT O
transcriptional BC2GM067523581 JJ O
activity BC2GM067523581 NN O
of BC2GM067523581 IN O
trypsin BC2GM067523581 NN O
promoters BC2GM067523581 NNS O
in BC2GM067523581 IN O
A. BC2GM067523581 NNP O
gambiae BC2GM067523581 NN O
and BC2GM067523581 CC O
Aedes BC2GM067523581 NNP O
aegypti BC2GM067523581 VBP O
cell BC2GM067523581 NN O
lines BC2GM067523581 NNS O
. BC2GM067523581 . O
. . O O

ET-1 BC2GM046561038 NNP O
limited BC2GM046561038 VBD O
the BC2GM046561038 DT O
electrocardiographic BC2GM046561038 JJ O
evidence BC2GM046561038 NN O
of BC2GM046561038 IN O
subendocardial BC2GM046561038 JJ O
ischemia BC2GM046561038 NN O
and BC2GM046561038 CC O
attenuated BC2GM046561038 VBD O
contractile BC2GM046561038 JJ O
dysfunction BC2GM046561038 NN O
compared BC2GM046561038 VBN O
with BC2GM046561038 IN O
mechanical BC2GM046561038 JJ O
stenosis BC2GM046561038 NN O
at BC2GM046561038 IN O
the BC2GM046561038 DT O
same BC2GM046561038 JJ O
coronary BC2GM046561038 JJ O
flows BC2GM046561038 NNS O
, BC2GM046561038 , O
even BC2GM046561038 RB O
though BC2GM046561038 IN O
lactate BC2GM046561038 JJ O
flux BC2GM046561038 NN O
was BC2GM046561038 VBD O
similar BC2GM046561038 JJ O
. BC2GM046561038 . O
. . O O

When BC2GM064306495 WRB O
the BC2GM064306495 DT O
measured BC2GM064306495 VBN O
beta-galactosidase BC2GM064306495 NN O
activity BC2GM064306495 NN O
in BC2GM064306495 IN O
the BC2GM064306495 DT O
pWP-transfected BC2GM064306495 JJ O
cells BC2GM064306495 NNS O
was BC2GM064306495 VBD O
normalized BC2GM064306495 VBN O
to BC2GM064306495 TO O
the BC2GM064306495 DT O
pCH110-transfected BC2GM064306495 JJ O
cells BC2GM064306495 NNS O
( BC2GM064306495 ( O
an BC2GM064306495 DT O
appropriate BC2GM064306495 NN O
control BC2GM064306495 NN O
if BC2GM064306495 IN O
the BC2GM064306495 DT O
SV40 BC2GM064306495 NNP O
early BC2GM064306495 JJ O
region BC2GM064306495 NN O
promoter BC2GM064306495 NN O
functions BC2GM064306495 NNS O
constitutively BC2GM064306495 RB O
in BC2GM064306495 IN O
various BC2GM064306495 JJ O
cell BC2GM064306495 NN O
lines BC2GM064306495 NNS O
) BC2GM064306495 ) O
, BC2GM064306495 , O
the BC2GM064306495 DT O
results BC2GM064306495 NNS O
suggested BC2GM064306495 VBD O
that BC2GM064306495 IN O
the BC2GM064306495 DT O
promoter BC2GM064306495 NN O
region BC2GM064306495 NN O
of BC2GM064306495 IN O
the BC2GM064306495 DT O
PLP BC2GM064306495 NNP O
gene BC2GM064306495 NN O
contains BC2GM064306495 VBZ O
the BC2GM064306495 DT O
information BC2GM064306495 NN O
necessary BC2GM064306495 JJ O
for BC2GM064306495 IN O
initiation BC2GM064306495 NN O
of BC2GM064306495 IN O
transcription BC2GM064306495 NN O
in BC2GM064306495 IN O
a BC2GM064306495 DT O
C6 BC2GM064306495 NNP O
cell-specific BC2GM064306495 JJ O
manner BC2GM064306495 NN O
. BC2GM064306495 . O
. . O O

Transcription BC2GM092059167 NN O
analysis BC2GM092059167 NN O
of BC2GM092059167 IN O
the BC2GM092059167 DT O
EcoRI BC2GM092059167 NNP O
D BC2GM092059167 NNP O
region BC2GM092059167 NN O
of BC2GM092059167 IN O
the BC2GM092059167 DT O
baculovirus BC2GM092059167 NN O
Autographa BC2GM092059167 NNP O
californica BC2GM092059167 NN O
nuclear BC2GM092059167 JJ O
polyhedrosis BC2GM092059167 NN O
virus BC2GM092059167 NN O
identifies BC2GM092059167 VBZ O
an BC2GM092059167 DT O
early BC2GM092059167 JJ O
4-kilobase BC2GM092059167 JJ O
RNA BC2GM092059167 NNP O
encoding BC2GM092059167 VBG O
the BC2GM092059167 DT O
essential BC2GM092059167 JJ O
p143 BC2GM092059167 NN O
gene BC2GM092059167 NN O
. BC2GM092059167 . O
. . O O

However BC2GM091720557 RB O
, BC2GM091720557 , O
sphincter BC2GM091720557 JJR O
length BC2GM091720557 NN O
decreased BC2GM091720557 VBN O
with BC2GM091720557 IN O
age BC2GM091720557 NN O
from BC2GM091720557 IN O
24.3 BC2GM091720557 CD O
to BC2GM091720557 TO O
14.8 BC2GM091720557 CD O
mm. BC2GM091720557 NNS O
, BC2GM091720557 , O
maximal BC2GM091720557 JJ O
urethral BC2GM091720557 JJ O
pressure BC2GM091720557 NN O
from BC2GM091720557 IN O
88.7 BC2GM091720557 CD O
to BC2GM091720557 TO O
55 BC2GM091720557 CD O
cm BC2GM091720557 NN O
. BC2GM091720557 . O
water BC2GM091720557 NN O
and BC2GM091720557 CC O
maximal BC2GM091720557 JJ O
urethral BC2GM091720557 JJ O
pressure BC2GM091720557 NN O
during BC2GM091720557 IN O
voluntary BC2GM091720557 JJ O
contraction BC2GM091720557 NN O
from BC2GM091720557 IN O
221.4 BC2GM091720557 CD O
to BC2GM091720557 TO O
166.3 BC2GM091720557 CD O
cm BC2GM091720557 NN O
. BC2GM091720557 . O
water BC2GM091720557 NN O
. BC2GM091720557 . O
. . O O

The BC2GM005732630 DT O
authors BC2GM005732630 NNS O
investigate BC2GM005732630 VBP O
in BC2GM005732630 IN O
a BC2GM005732630 DT O
group BC2GM005732630 NN O
of BC2GM005732630 IN O
211 BC2GM005732630 CD O
children BC2GM005732630 NNS O
aged BC2GM005732630 VBN O
2-6 BC2GM005732630 CD O
years BC2GM005732630 NNS O
, BC2GM005732630 , O
incl BC2GM005732630 NN O
. BC2GM005732630 . O
in BC2GM005732630 IN O
particular BC2GM005732630 JJ O
a BC2GM005732630 DT O
group BC2GM005732630 NN O
of BC2GM005732630 IN O
33 BC2GM005732630 CD O
2-year-old BC2GM005732630 JJ O
ones BC2GM005732630 NNS O
, BC2GM005732630 , O
in BC2GM005732630 IN O
1990 BC2GM005732630 CD O
and BC2GM005732630 CC O
checked BC2GM005732630 VBD O
in BC2GM005732630 IN O
1991 BC2GM005732630 CD O
at BC2GM005732630 IN O
two BC2GM005732630 CD O
sites BC2GM005732630 NNS O
in BC2GM005732630 IN O
Bratislava BC2GM005732630 NNP O
-- BC2GM005732630 : O
a BC2GM005732630 DT O
town BC2GM005732630 NN O
with BC2GM005732630 IN O
a BC2GM005732630 DT O
varying BC2GM005732630 VBG O
concentration BC2GM005732630 NN O
of BC2GM005732630 IN O
NOX BC2GM005732630 NNP O
, BC2GM005732630 , O
SO2 BC2GM005732630 NNP O
, BC2GM005732630 , O
dustiness BC2GM005732630 NN O
and BC2GM005732630 CC O
dust BC2GM005732630 NN O
fallout BC2GM005732630 NN O
-- BC2GM005732630 : O
their BC2GM005732630 PRP$ O
influence BC2GM005732630 NN O
on BC2GM005732630 IN O
the BC2GM005732630 DT O
incidence BC2GM005732630 NN O
, BC2GM005732630 , O
type BC2GM005732630 NN O
and BC2GM005732630 CC O
course BC2GM005732630 NN O
of BC2GM005732630 IN O
relapsing BC2GM005732630 VBG O
respiratory BC2GM005732630 JJ O
disease BC2GM005732630 NN O
. BC2GM005732630 . O
. . O O

The BC2GM077065468 DT O
crystal BC2GM077065468 JJ O
structure BC2GM077065468 NN O
of BC2GM077065468 IN O
the BC2GM077065468 DT O
yeast BC2GM077065468 JJ O
Phe-tRNAPhe BC2GM077065468 JJ O
ternary BC2GM077065468 NN O
complex BC2GM077065468 NN O
with BC2GM077065468 IN O
Thermus BC2GM077065468 NNP O
aquaticus BC2GM077065468 VB O
EF-Tu-GDPNP BC2GM077065468 NNP O
( BC2GM077065468 ( O
Phe-TC BC2GM077065468 NNP O
) BC2GM077065468 ) O
has BC2GM077065468 VBZ O
previously BC2GM077065468 RB O
been BC2GM077065468 VBN O
determined BC2GM077065468 VBN O
as BC2GM077065468 IN O
one BC2GM077065468 CD O
representative BC2GM077065468 NN O
of BC2GM077065468 IN O
this BC2GM077065468 DT O
general BC2GM077065468 JJ O
yet BC2GM077065468 RB O
highly BC2GM077065468 RB O
discriminating BC2GM077065468 VBG O
complex BC2GM077065468 JJ O
formation BC2GM077065468 NN O
. BC2GM077065468 . O
. . O O

A BC2GM015513463 DT O
transient BC2GM015513463 JJ O
induction BC2GM015513463 NN O
of BC2GM015513463 IN O
both BC2GM015513463 DT O
c-fos BC2GM015513463 JJ O
and BC2GM015513463 CC O
c-jun BC2GM015513463 JJ O
mRNAs BC2GM015513463 NN O
by BC2GM015513463 IN O
TPA BC2GM015513463 NNP O
was BC2GM015513463 VBD O
observed BC2GM015513463 VBN O
in BC2GM015513463 IN O
both BC2GM015513463 DT O
cell BC2GM015513463 NN O
populations BC2GM015513463 NNS O
, BC2GM015513463 , O
together BC2GM015513463 RB O
with BC2GM015513463 IN O
an BC2GM015513463 DT O
associated BC2GM015513463 JJ O
suppression BC2GM015513463 NN O
of BC2GM015513463 IN O
BSP BC2GM015513463 NNP O
mRNA BC2GM015513463 NN O
in BC2GM015513463 IN O
the BC2GM015513463 DT O
fetal BC2GM015513463 JJ O
rat BC2GM015513463 NN O
calvarial BC2GM015513463 JJ O
cells BC2GM015513463 NNS O
. BC2GM015513463 . O
. . O O

Surgical BC2GM054387079 JJ O
methods BC2GM054387079 NNS O
in BC2GM054387079 IN O
the BC2GM054387079 DT O
treatment BC2GM054387079 NN O
of BC2GM054387079 IN O
rhinophyma BC2GM054387079 NN O
. BC2GM054387079 . O
. . O O

The BC2GM060353149 DT O
treatment BC2GM060353149 NN O
with BC2GM060353149 IN O
glucocorticoids BC2GM060353149 NNS O
and BC2GM060353149 CC O
immunosuppressants BC2GM060353149 NNS O
resulted BC2GM060353149 VBD O
in BC2GM060353149 IN O
a BC2GM060353149 DT O
more BC2GM060353149 RBR O
noticeable BC2GM060353149 JJ O
decrease BC2GM060353149 NN O
in BC2GM060353149 IN O
the BC2GM060353149 DT O
levels BC2GM060353149 NNS O
of BC2GM060353149 IN O
T3 BC2GM060353149 NNP O
and BC2GM060353149 CC O
E-RCF BC2GM060353149 NNP O
. BC2GM060353149 . O
. . O O

Deletion BC2GM018602202 NN O
analysis BC2GM018602202 NN O
revealed BC2GM018602202 VBD O
that BC2GM018602202 IN O
only BC2GM018602202 RB O
the BC2GM018602202 DT O
TM BC2GM018602202 NNP O
domain BC2GM018602202 NN O
of BC2GM018602202 IN O
E2 BC2GM018602202 NNP O
was BC2GM018602202 VBD O
required BC2GM018602202 VBN O
for BC2GM018602202 IN O
Golgi BC2GM018602202 NNP O
targeting BC2GM018602202 VBG O
. BC2GM018602202 . O
. . O O

We BC2GM053139054 PRP O
find BC2GM053139054 VBP O
that BC2GM053139054 IN O
Fus3p BC2GM053139054 NNP O
and BC2GM053139054 CC O
Kss1p BC2GM053139054 NNP O
both BC2GM053139054 DT O
control BC2GM053139054 VBP O
G1 BC2GM053139054 NNP O
arrest BC2GM053139054 VBP O
through BC2GM053139054 IN O
multiple BC2GM053139054 JJ O
functions BC2GM053139054 NNS O
that BC2GM053139054 WDT O
operate BC2GM053139054 VBP O
in BC2GM053139054 IN O
parallel BC2GM053139054 NN O
with BC2GM053139054 IN O
Far1p BC2GM053139054 NNP O
. BC2GM053139054 . O
. . O O

In BC2GM006702465 IN O
src-transformed BC2GM006702465 JJ O
cells BC2GM006702465 NNS O
GAP BC2GM006702465 NNP O
forms BC2GM006702465 NNS O
heteromeric BC2GM006702465 JJ O
complexes BC2GM006702465 NNS O
, BC2GM006702465 , O
notably BC2GM006702465 RB O
with BC2GM006702465 IN O
a BC2GM006702465 DT O
highly BC2GM006702465 RB O
tyrosine BC2GM006702465 JJ O
phosphorylated BC2GM006702465 VBN O
62-kDa BC2GM006702465 JJ O
protein BC2GM006702465 NN O
( BC2GM006702465 ( O
p62 BC2GM006702465 NN O
) BC2GM006702465 ) O
. BC2GM006702465 . O
. . O O

Tryptophan BC2GM094661498 NNP O
induction BC2GM094661498 NN O
prevents BC2GM094661498 NNS O
Rho-dependent BC2GM094661498 JJ O
transcription BC2GM094661498 NN O
termination BC2GM094661498 NN O
in BC2GM094661498 IN O
the BC2GM094661498 DT O
leader BC2GM094661498 NN O
region BC2GM094661498 NN O
of BC2GM094661498 IN O
the BC2GM094661498 DT O
operon BC2GM094661498 NN O
. BC2GM094661498 . O
. . O O

Proteins BC2GM051098108 NNS O
PBP-1 BC2GM051098108 NNP O
and BC2GM051098108 CC O
PBP-2 BC2GM051098108 NNP O
bind BC2GM051098108 NN O
to BC2GM051098108 TO O
two BC2GM051098108 CD O
of BC2GM051098108 IN O
the BC2GM051098108 DT O
three BC2GM051098108 CD O
promoter BC2GM051098108 NN O
elements BC2GM051098108 NNS O
in BC2GM051098108 IN O
the BC2GM051098108 DT O
trypanosomatid BC2GM051098108 NN O
Leptomonas BC2GM051098108 NNP O
seymouri BC2GM051098108 NN O
. BC2GM051098108 . O
. . O O

The BC2GM021800196 DT O
model BC2GM021800196 NN O
of BC2GM021800196 IN O
the BC2GM021800196 DT O
complex BC2GM021800196 JJ O
provides BC2GM021800196 VBZ O
a BC2GM021800196 DT O
rationale BC2GM021800196 NN O
for BC2GM021800196 IN O
conserved BC2GM021800196 JJ O
ITAM BC2GM021800196 NNP O
residues BC2GM021800196 NNS O
, BC2GM021800196 , O
substrate BC2GM021800196 JJ O
specificity BC2GM021800196 NN O
, BC2GM021800196 , O
and BC2GM021800196 CC O
suggests BC2GM021800196 VBZ O
that BC2GM021800196 IN O
substrate BC2GM021800196 NN O
binds BC2GM021800196 VBZ O
only BC2GM021800196 RB O
the BC2GM021800196 DT O
active BC2GM021800196 JJ O
conformation BC2GM021800196 NN O
of BC2GM021800196 IN O
the BC2GM021800196 DT O
Src BC2GM021800196 NNP O
family BC2GM021800196 NN O
tyrosine BC2GM021800196 NN O
kinase BC2GM021800196 NN O
, BC2GM021800196 , O
unlike BC2GM021800196 IN O
the BC2GM021800196 DT O
ATP BC2GM021800196 NNP O
cofactor BC2GM021800196 NN O
, BC2GM021800196 , O
which BC2GM021800196 WDT O
can BC2GM021800196 MD O
bind BC2GM021800196 VB O
the BC2GM021800196 DT O
inactive BC2GM021800196 JJ O
form BC2GM021800196 NN O
. BC2GM021800196 . O
. . O O

Transcripts BC2GM060492967 NNS O
appear BC2GM060492967 VBP O
to BC2GM060492967 TO O
be BC2GM060492967 VB O
initiated BC2GM060492967 VBN O
from BC2GM060492967 IN O
an BC2GM060492967 DT O
upstream BC2GM060492967 JJ O
promoter BC2GM060492967 NN O
, BC2GM060492967 , O
P1 BC2GM060492967 NNP O
, BC2GM060492967 , O
located BC2GM060492967 VBN O
in BC2GM060492967 IN O
front BC2GM060492967 NN O
of BC2GM060492967 IN O
the BC2GM060492967 DT O
tRNA BC2GM060492967 NN O
( BC2GM060492967 ( O
met1 BC2GM060492967 NN O
) BC2GM060492967 ) O
gene BC2GM060492967 NN O
and BC2GM060492967 CC O
from BC2GM060492967 IN O
three BC2GM060492967 CD O
internal BC2GM060492967 JJ O
promoters BC2GM060492967 NNS O
: BC2GM060492967 : O
P2 BC2GM060492967 NNP O
is BC2GM060492967 VBZ O
located BC2GM060492967 VBN O
immediately BC2GM060492967 RB O
in BC2GM060492967 IN O
front BC2GM060492967 NN O
of BC2GM060492967 IN O
the BC2GM060492967 DT O
tRNA BC2GM060492967 NN O
( BC2GM060492967 ( O
met2 BC2GM060492967 NN O
) BC2GM060492967 ) O
gene BC2GM060492967 NN O
; BC2GM060492967 : O
PL10 BC2GM060492967 NNP O
is BC2GM060492967 VBZ O
near BC2GM060492967 IN O
the BC2GM060492967 DT O
beginning BC2GM060492967 NN O
of BC2GM060492967 IN O
the BC2GM060492967 DT O
L1-L10 BC2GM060492967 NNP O
intergenic BC2GM060492967 JJ O
space BC2GM060492967 NN O
, BC2GM060492967 , O
and BC2GM060492967 CC O
PL12 BC2GM060492967 NNP O
is BC2GM060492967 VBZ O
at BC2GM060492967 IN O
the BC2GM060492967 DT O
end BC2GM060492967 NN O
of BC2GM060492967 IN O
the BC2GM060492967 DT O
L10 BC2GM060492967 NNP O
gene BC2GM060492967 NN O
sequence BC2GM060492967 NN O
. BC2GM060492967 . O
. . O O

Bodily BC2GM068727128 JJ O
referents BC2GM068727128 NNS O
and BC2GM068727128 CC O
the BC2GM068727128 DT O
experience BC2GM068727128 NN O
of BC2GM068727128 IN O
affect BC2GM068727128 NN O
. BC2GM068727128 . O
. . O O

Time BC2GM066695616 NNP O
dependence BC2GM066695616 NN O
of BC2GM066695616 IN O
frequency BC2GM066695616 NN O
potentiation BC2GM066695616 NN O
in BC2GM066695616 IN O
the BC2GM066695616 DT O
isolated BC2GM066695616 JJ O
guinea-pig BC2GM066695616 NN O
's BC2GM066695616 POS O
atrium BC2GM066695616 NN O
. BC2GM066695616 . O
. . O O

A BC2GM068917661 DT O
wide BC2GM068917661 JJ O
conservation BC2GM068917661 NN O
of BC2GM068917661 IN O
iscSUA BC2GM068917661 JJ O
genes BC2GM068917661 NNS O
in BC2GM068917661 IN O
nature BC2GM068917661 NN O
and BC2GM068917661 CC O
evidence BC2GM068917661 NN O
that BC2GM068917661 IN O
NifU BC2GM068917661 NNP O
and BC2GM068917661 CC O
NifS BC2GM068917661 NNP O
participate BC2GM068917661 VB O
in BC2GM068917661 IN O
the BC2GM068917661 DT O
mobilization BC2GM068917661 NN O
of BC2GM068917661 IN O
iron BC2GM068917661 NN O
and BC2GM068917661 CC O
sulfur BC2GM068917661 NN O
for BC2GM068917661 IN O
nitrogenase-specific BC2GM068917661 JJ O
iron-sulfur BC2GM068917661 JJ O
cluster BC2GM068917661 NN O
formation BC2GM068917661 NN O
suggest BC2GM068917661 VBP O
that BC2GM068917661 IN O
the BC2GM068917661 DT O
products BC2GM068917661 NNS O
of BC2GM068917661 IN O
the BC2GM068917661 DT O
iscSUA BC2GM068917661 NN O
genes BC2GM068917661 NNS O
could BC2GM068917661 MD O
play BC2GM068917661 VB O
a BC2GM068917661 DT O
general BC2GM068917661 JJ O
role BC2GM068917661 NN O
in BC2GM068917661 IN O
the BC2GM068917661 DT O
formation BC2GM068917661 NN O
or BC2GM068917661 CC O
repair BC2GM068917661 NN O
of BC2GM068917661 IN O
iron-sulfur BC2GM068917661 JJ O
clusters BC2GM068917661 NNS O
. BC2GM068917661 . O
. . O O

Twenty-six BC2GM014733001 JJ O
calves BC2GM014733001 NNS O
were BC2GM014733001 VBD O
subjected BC2GM014733001 VBN O
to BC2GM014733001 TO O
a BC2GM014733001 DT O
technique BC2GM014733001 NN O
of BC2GM014733001 IN O
cryoablation BC2GM014733001 NN O
in BC2GM014733001 IN O
order BC2GM014733001 NN O
to BC2GM014733001 TO O
establish BC2GM014733001 VB O
an BC2GM014733001 DT O
animal BC2GM014733001 JJ O
model BC2GM014733001 NN O
of BC2GM014733001 IN O
complete BC2GM014733001 JJ O
cardiac BC2GM014733001 JJ O
denervation BC2GM014733001 NN O
. BC2GM014733001 . O
. . O O

DISCUSSION BC2GM013684936 NN O
: BC2GM013684936 : O
The BC2GM013684936 DT O
higher BC2GM013684936 JJR O
absolute BC2GM013684936 JJ O
knee BC2GM013684936 NN O
extension BC2GM013684936 NN O
strength BC2GM013684936 NN O
measures BC2GM013684936 NNS O
of BC2GM013684936 IN O
leg BC2GM013684936 NN O
and BC2GM013684936 CC O
the BC2GM013684936 DT O
similar BC2GM013684936 JJ O
extension BC2GM013684936 NN O
strength BC2GM013684936 NN O
of BC2GM013684936 IN O
the BC2GM013684936 DT O
trunk BC2GM013684936 NN O
in BC2GM013684936 IN O
the BC2GM013684936 DT O
obese BC2GM013684936 JJ O
sample BC2GM013684936 NN O
compared BC2GM013684936 VBN O
to BC2GM013684936 TO O
the BC2GM013684936 DT O
lean BC2GM013684936 JJ O
might BC2GM013684936 MD O
be BC2GM013684936 VB O
explained BC2GM013684936 VBN O
by BC2GM013684936 IN O
the BC2GM013684936 DT O
training BC2GM013684936 NN O
effect BC2GM013684936 NN O
of BC2GM013684936 IN O
weight BC2GM013684936 NN O
bearing BC2GM013684936 NN O
and BC2GM013684936 CC O
support BC2GM013684936 NN O
of BC2GM013684936 IN O
a BC2GM013684936 DT O
larger BC2GM013684936 JJR O
body BC2GM013684936 NN O
mass BC2GM013684936 NN O
. BC2GM013684936 . O
. . O O

We BC2GM072758555 PRP O
propose BC2GM072758555 VBP O
that BC2GM072758555 IN O
U73 BC2GM072758555 NNP O
is BC2GM072758555 VBZ O
involved BC2GM072758555 VBN O
in BC2GM072758555 IN O
methylation BC2GM072758555 NN O
of BC2GM072758555 IN O
the BC2GM072758555 DT O
G1739 BC2GM072758555 NNP O
residue BC2GM072758555 NN O
of BC2GM072758555 IN O
the BC2GM072758555 DT O
human BC2GM072758555 JJ O
28S BC2GM072758555 CD O
rRNA BC2GM072758555 NN O
. BC2GM072758555 . O
. . O O

Utility BC2GM083051633 NN O
of BC2GM083051633 IN O
thallium-201 BC2GM083051633 JJ O
scintigraphy BC2GM083051633 NN O
in BC2GM083051633 IN O
detecting BC2GM083051633 VBG O
right BC2GM083051633 JJ O
ventricular BC2GM083051633 JJ O
dysfunction BC2GM083051633 NN O
in BC2GM083051633 IN O
pulmonary BC2GM083051633 JJ O
embolism BC2GM083051633 NN O
. BC2GM083051633 . O
. . O O

Unconventional BC2GM017717134 JJ O
mRNA BC2GM017717134 NN O
processing BC2GM017717134 NN O
in BC2GM017717134 IN O
the BC2GM017717134 DT O
expression BC2GM017717134 NN O
of BC2GM017717134 IN O
two BC2GM017717134 CD O
calcineurin BC2GM017717134 NN O
B BC2GM017717134 NNP O
isoforms BC2GM017717134 NNS O
in BC2GM017717134 IN O
Dictyostelium BC2GM017717134 NNP O
. BC2GM017717134 . O
. . O O

CONCLUSION BC2GM021733424 NN O
: BC2GM021733424 : O
Detection BC2GM021733424 NN O
of BC2GM021733424 IN O
recurrent BC2GM021733424 JJ O
head BC2GM021733424 NN O
and BC2GM021733424 CC O
neck BC2GM021733424 NN O
cancer BC2GM021733424 NN O
is BC2GM021733424 VBZ O
feasible BC2GM021733424 JJ O
with BC2GM021733424 IN O
FDG BC2GM021733424 NNP O
PET BC2GM021733424 NNP O
. BC2GM021733424 . O
. . O O

The BC2GM010316325 DT O
Saccharomyces BC2GM010316325 NNPS O
cerevisiae BC2GM010316325 JJ O
targets BC2GM010316325 NNS O
of BC2GM010316325 IN O
rapamycin BC2GM010316325 NN O
, BC2GM010316325 , O
TOR1 BC2GM010316325 NNP O
and BC2GM010316325 CC O
TOR2 BC2GM010316325 NNP O
, BC2GM010316325 , O
signal BC2GM010316325 JJ O
activation BC2GM010316325 NN O
of BC2GM010316325 IN O
cell BC2GM010316325 NN O
growth BC2GM010316325 NN O
in BC2GM010316325 IN O
response BC2GM010316325 NN O
to BC2GM010316325 TO O
nutrient BC2GM010316325 JJ O
availability BC2GM010316325 NN O
. BC2GM010316325 . O
. . O O

Blood BC2GM025874563 NN O
samples BC2GM025874563 NNS O
( BC2GM025874563 ( O
30 BC2GM025874563 CD O
ml BC2GM025874563 NN O
) BC2GM025874563 ) O
were BC2GM025874563 VBD O
collected BC2GM025874563 VBN O
via BC2GM025874563 IN O
an BC2GM025874563 DT O
indwelling BC2GM025874563 JJ O
arm BC2GM025874563 NN O
catheter BC2GM025874563 NN O
at BC2GM025874563 IN O
rest BC2GM025874563 NN O
, BC2GM025874563 , O
and BC2GM025874563 CC O
at BC2GM025874563 IN O
minutes BC2GM025874563 NNS O
13 BC2GM025874563 CD O
and BC2GM025874563 CC O
28 BC2GM025874563 CD O
of BC2GM025874563 IN O
exercise BC2GM025874563 NN O
for BC2GM025874563 IN O
determinations BC2GM025874563 NNS O
of BC2GM025874563 IN O
plasma BC2GM025874563 NN O
EPI BC2GM025874563 NNP O
, BC2GM025874563 , O
serum BC2GM025874563 VBD O
free BC2GM025874563 JJ O
fatty BC2GM025874563 JJ O
acid BC2GM025874563 NN O
( BC2GM025874563 ( O
FFA BC2GM025874563 NNP O
) BC2GM025874563 ) O
, BC2GM025874563 , O
serum BC2GM025874563 JJ O
glycerol BC2GM025874563 NN O
( BC2GM025874563 ( O
GLY BC2GM025874563 NNP O
) BC2GM025874563 ) O
, BC2GM025874563 , O
blood BC2GM025874563 NN O
glucose BC2GM025874563 NN O
( BC2GM025874563 ( O
GLU BC2GM025874563 NNP O
) BC2GM025874563 ) O
, BC2GM025874563 , O
and BC2GM025874563 CC O
blood BC2GM025874563 NN O
lactate BC2GM025874563 NN O
( BC2GM025874563 ( O
LA BC2GM025874563 NNP O
) BC2GM025874563 ) O
concentrations BC2GM025874563 NNS O
. BC2GM025874563 . O
. . O O

In BC2GM018605587 IN O
area BC2GM018605587 NN O
CA1 BC2GM018605587 NNP O
of BC2GM018605587 IN O
the BC2GM018605587 DT O
hippocampus BC2GM018605587 NN O
, BC2GM018605587 , O
numbers BC2GM018605587 NNS O
of BC2GM018605587 IN O
normal BC2GM018605587 JJ O
neurons BC2GM018605587 NNS O
were BC2GM018605587 VBD O
increased BC2GM018605587 VBN O
11- BC2GM018605587 JJ O
to BC2GM018605587 TO O
14-fold BC2GM018605587 JJ O
by BC2GM018605587 IN O
MK-801 BC2GM018605587 NNP O
treatment BC2GM018605587 NN O
( BC2GM018605587 ( O
p BC2GM018605587 JJ O
< BC2GM018605587 NNP O
0.01 BC2GM018605587 CD O
) BC2GM018605587 ) O
. BC2GM018605587 . O
. . O O

Human BC2GM036212227 NNP O
myotonic BC2GM036212227 JJ O
dystrophy BC2GM036212227 NN O
protein BC2GM036212227 NN O
kinase BC2GM036212227 NN O
( BC2GM036212227 ( O
DMPK BC2GM036212227 NNP O
) BC2GM036212227 ) O
is BC2GM036212227 VBZ O
a BC2GM036212227 DT O
member BC2GM036212227 NN O
of BC2GM036212227 IN O
a BC2GM036212227 DT O
novel BC2GM036212227 JJ O
class BC2GM036212227 NN O
of BC2GM036212227 IN O
multidomain BC2GM036212227 NN O
protein BC2GM036212227 NN O
kinases BC2GM036212227 VBZ O
that BC2GM036212227 IN O
regulate BC2GM036212227 NN O
cell BC2GM036212227 NN O
size BC2GM036212227 NN O
and BC2GM036212227 CC O
shape BC2GM036212227 NN O
in BC2GM036212227 IN O
a BC2GM036212227 DT O
variety BC2GM036212227 NN O
of BC2GM036212227 IN O
organisms BC2GM036212227 NNS O
. BC2GM036212227 . O
. . O O

The BC2GM001838288 DT O
results BC2GM001838288 NNS O
were BC2GM001838288 VBD O
subjected BC2GM001838288 VBN O
to BC2GM001838288 TO O
analysis BC2GM001838288 NN O
of BC2GM001838288 IN O
23 BC2GM001838288 CD O
autopsies BC2GM001838288 NNS O
carried BC2GM001838288 VBD O
out BC2GM001838288 RP O
in BC2GM001838288 IN O
children BC2GM001838288 NNS O
dying BC2GM001838288 VBG O
of BC2GM001838288 IN O
intoxication BC2GM001838288 NN O
with BC2GM001838288 IN O
Amanita BC2GM001838288 NNP O
phalloides BC2GM001838288 NNS O
. BC2GM001838288 . O
. . O O

Studies BC2GM019245307 NNS O
with BC2GM019245307 IN O
and BC2GM019245307 CC O
without BC2GM019245307 IN O
attenuating BC2GM019245307 VBG O
media BC2GM019245307 NNS O
were BC2GM019245307 VBD O
performed BC2GM019245307 VBN O
, BC2GM019245307 , O
and BC2GM019245307 CC O
myocardium-to-defect BC2GM019245307 JJ O
count BC2GM019245307 NN O
ratios BC2GM019245307 NNS O
and BC2GM019245307 CC O
defect BC2GM019245307 JJ O
sizes BC2GM019245307 NNS O
from BC2GM019245307 IN O
dual-isotope BC2GM019245307 NN O
SPECT BC2GM019245307 NNP O
images BC2GM019245307 NNS O
were BC2GM019245307 VBD O
compared BC2GM019245307 VBN O
to BC2GM019245307 TO O
myocardium-to-defect BC2GM019245307 JJ O
count BC2GM019245307 NN O
ratios BC2GM019245307 NNS O
and BC2GM019245307 CC O
defect BC2GM019245307 JJ O
sizes BC2GM019245307 NNS O
from BC2GM019245307 IN O
single-isotope BC2GM019245307 NN O
( BC2GM019245307 ( O
201Tl BC2GM019245307 CD O
and BC2GM019245307 CC O
99mTc BC2GM019245307 CD O
) BC2GM019245307 ) O
SPECT BC2GM019245307 NNP O
images BC2GM019245307 NNS O
. BC2GM019245307 . O
. . O O

In BC2GM001711845 IN O
particular BC2GM001711845 JJ O
, BC2GM001711845 , O
MF BC2GM001711845 NNP O
males BC2GM001711845 VBZ O
receiving BC2GM001711845 VBG O
either BC2GM001711845 CC O
a BC2GM001711845 DT O
5.0-mg BC2GM001711845 JJ O
/ BC2GM001711845 NN O
kg BC2GM001711845 NN O
CDP BC2GM001711845 NNP O
dose BC2GM001711845 NN O
or BC2GM001711845 CC O
a BC2GM001711845 DT O
3.0-mg BC2GM001711845 JJ O
/ BC2GM001711845 NN O
kg BC2GM001711845 NN O
RO BC2GM001711845 NNP O
dose BC2GM001711845 NN O
explored BC2GM001711845 VBD O
the BC2GM001711845 DT O
object BC2GM001711845 NN O
more BC2GM001711845 RBR O
often BC2GM001711845 RB O
than BC2GM001711845 IN O
MM BC2GM001711845 NNP O
males BC2GM001711845 NNS O
. BC2GM001711845 . O
( BC2GM001711845 ( O
ABSTRACT BC2GM001711845 NNP O
TRUNCATED BC2GM001711845 NNP O
AT BC2GM001711845 NNP O
250 BC2GM001711845 CD O
WORDS BC2GM001711845 NNP O
) BC2GM001711845 ) O
. BC2GM001711845 . O
. . O O

After BC2GM088461338 IN O
inhibition BC2GM088461338 NN O
of BC2GM088461338 IN O
monoamine BC2GM088461338 JJ O
oxidase BC2GM088461338 NN O
with BC2GM088461338 IN O
pargyline BC2GM088461338 NN O
( BC2GM088461338 ( O
10 BC2GM088461338 CD O
mg BC2GM088461338 NN O
/ BC2GM088461338 NNP O
kg BC2GM088461338 NN O
. BC2GM088461338 . O
i.v BC2GM088461338 NN O
. BC2GM088461338 . O
) BC2GM088461338 ) O
, BC2GM088461338 , O
the BC2GM088461338 DT O
effects BC2GM088461338 NNS O
of BC2GM088461338 IN O
tyramine BC2GM088461338 NN O
( BC2GM088461338 ( O
1000 BC2GM088461338 CD O
micrograms BC2GM088461338 NN O
) BC2GM088461338 ) O
injected BC2GM088461338 VBD O
into BC2GM088461338 IN O
the BC2GM088461338 DT O
hepatic BC2GM088461338 JJ O
artery BC2GM088461338 NN O
were BC2GM088461338 VBD O
potentiated BC2GM088461338 VBN O
. BC2GM088461338 . O
. . O O

Non-suppressed BC2GM018838269 JJ O
thyroidal BC2GM018838269 NN O
radioactive BC2GM018838269 JJ O
iodine BC2GM018838269 NN O
uptake BC2GM018838269 NN O
( BC2GM018838269 ( O
RAIU BC2GM018838269 NNP O
) BC2GM018838269 ) O
in BC2GM018838269 IN O
thyrotoxic BC2GM018838269 JJ O
phase BC2GM018838269 NN O
in BC2GM018838269 IN O
a BC2GM018838269 DT O
case BC2GM018838269 NN O
of BC2GM018838269 IN O
subacute BC2GM018838269 NN O
thyroiditis BC2GM018838269 NN O
with BC2GM018838269 IN O
thyroid-stimulating BC2GM018838269 JJ O
antibodies BC2GM018838269 NNS O
( BC2GM018838269 ( O
TSAb BC2GM018838269 NNP O
) BC2GM018838269 ) O
. BC2GM018838269 . O
. . O O

By BC2GM003255111 IN O
sequencing BC2GM003255111 VBG O
of BC2GM003255111 IN O
exonuclease BC2GM003255111 NN O
III BC2GM003255111 NNP O
deletion BC2GM003255111 NN O
clones BC2GM003255111 NNS O
an BC2GM003255111 DT O
open BC2GM003255111 JJ O
reading BC2GM003255111 NN O
frame BC2GM003255111 NN O
of BC2GM003255111 IN O
405 BC2GM003255111 CD O
nucleotides BC2GM003255111 NNS O
was BC2GM003255111 VBD O
found BC2GM003255111 VBN O
coding BC2GM003255111 VBG O
for BC2GM003255111 IN O
a BC2GM003255111 DT O
protein BC2GM003255111 NN O
of BC2GM003255111 IN O
135 BC2GM003255111 CD O
amino BC2GM003255111 JJ O
acids BC2GM003255111 NNS O
with BC2GM003255111 IN O
a BC2GM003255111 DT O
molecular BC2GM003255111 JJ O
mass BC2GM003255111 NN O
of BC2GM003255111 IN O
15 BC2GM003255111 CD O
kDa BC2GM003255111 NNS O
. BC2GM003255111 . O
. . O O

The BC2GM016378782 DT O
limb BC2GM016378782 NN O
defects BC2GM016378782 NNS O
, BC2GM016378782 , O
oligodactyly BC2GM016378782 NN O
and BC2GM016378782 CC O
syndactyly BC2GM016378782 NN O
, BC2GM016378782 , O
have BC2GM016378782 VBP O
been BC2GM016378782 VBN O
traced BC2GM016378782 VBN O
to BC2GM016378782 TO O
improper BC2GM016378782 VB O
differentiation BC2GM016378782 NN O
of BC2GM016378782 IN O
the BC2GM016378782 DT O
apical BC2GM016378782 JJ O
ectodermal BC2GM016378782 NN O
ridge BC2GM016378782 NN O
( BC2GM016378782 ( O
AER BC2GM016378782 NNP O
) BC2GM016378782 ) O
and BC2GM016378782 CC O
shortening BC2GM016378782 VBG O
of BC2GM016378782 IN O
the BC2GM016378782 DT O
anteroposterior BC2GM016378782 JJ O
limb BC2GM016378782 NN O
axis BC2GM016378782 NN O
. BC2GM016378782 . O
. . O O

A BC2GM017739498 DT O
chest-X BC2GM017739498 JJ O
ray BC2GM017739498 NN O
film BC2GM017739498 NN O
showed BC2GM017739498 VBD O
infiltrative BC2GM017739498 JJ O
shadows BC2GM017739498 NNS O
in BC2GM017739498 IN O
the BC2GM017739498 DT O
right BC2GM017739498 JJ O
middle BC2GM017739498 NN O
and BC2GM017739498 CC O
lower BC2GM017739498 JJR O
lung BC2GM017739498 NN O
fields BC2GM017739498 NNS O
, BC2GM017739498 , O
but BC2GM017739498 CC O
a BC2GM017739498 DT O
chest BC2GM017739498 JJS O
CT BC2GM017739498 NN O
scan BC2GM017739498 NN O
showed BC2GM017739498 VBD O
an BC2GM017739498 DT O
abnormal BC2GM017739498 JJ O
lung BC2GM017739498 NN O
density BC2GM017739498 NN O
in BC2GM017739498 IN O
the BC2GM017739498 DT O
right BC2GM017739498 NN O
lower BC2GM017739498 JJR O
lobe BC2GM017739498 NN O
. BC2GM017739498 . O
. . O O

The BC2GM007950303 DT O
gap BC2GM007950303 NN O
protein BC2GM007950303 NN O
knirps BC2GM007950303 NN O
mediates BC2GM007950303 VBZ O
both BC2GM007950303 DT O
quenching BC2GM007950303 VBG O
and BC2GM007950303 CC O
direct BC2GM007950303 JJ O
repression BC2GM007950303 NN O
in BC2GM007950303 IN O
the BC2GM007950303 DT O
Drosophila BC2GM007950303 NNP O
embryo BC2GM007950303 NN O
. BC2GM007950303 . O
. . O O

T1 BC2GM017736340 NNP O
and BC2GM017736340 CC O
T2 BC2GM017736340 NNP O
values BC2GM017736340 NNS O
were BC2GM017736340 VBD O
calculated BC2GM017736340 VBN O
from BC2GM017736340 IN O
guinea BC2GM017736340 NN O
pig BC2GM017736340 NN O
brain BC2GM017736340 NN O
in BC2GM017736340 IN O
vivo BC2GM017736340 NN O
at BC2GM017736340 IN O
0.5 BC2GM017736340 CD O
T BC2GM017736340 NNP O
. BC2GM017736340 . O
. . O O

Electronic BC2GM058880615 JJ O
structure BC2GM058880615 NN O
and BC2GM058880615 CC O
optical BC2GM058880615 JJ O
properties BC2GM058880615 NNS O
of BC2GM058880615 IN O
the BC2GM058880615 DT O
B12O2 BC2GM058880615 NNP O
crystal BC2GM058880615 NN O
. BC2GM058880615 . O
. . O O

Hydropathy BC2GM090917188 JJ O
analysis BC2GM090917188 NN O
of BC2GM090917188 IN O
deduced BC2GM090917188 JJ O
A4 BC2GM090917188 NNP O
amino BC2GM090917188 NN O
acid BC2GM090917188 NN O
sequence BC2GM090917188 NN O
revealed BC2GM090917188 VBD O
four BC2GM090917188 CD O
putative BC2GM090917188 JJ O
membrane-spanning BC2GM090917188 JJ O
alpha-helices BC2GM090917188 NNS O
. BC2GM090917188 . O
. . O O

This BC2GM045173873 DT O
distinct BC2GM045173873 JJ O
biochemical BC2GM045173873 JJ O
difference BC2GM045173873 NN O
between BC2GM045173873 IN O
STAT5A BC2GM045173873 NNP O
and BC2GM045173873 CC O
STAT5B BC2GM045173873 NNP O
was BC2GM045173873 VBD O
confirmed BC2GM045173873 VBN O
with BC2GM045173873 IN O
purified BC2GM045173873 JJ O
activated BC2GM045173873 VBN O
STAT5 BC2GM045173873 NNP O
recombinant BC2GM045173873 JJ O
proteins BC2GM045173873 NNS O
. BC2GM045173873 . O
. . O O

Ozone BC2GM041250465 NN O
uptake BC2GM041250465 NN O
was BC2GM041250465 VBD O
assessed BC2GM041250465 VBN O
in BC2GM041250465 IN O
awake BC2GM041250465 NN O
, BC2GM041250465 , O
spontaneously BC2GM041250465 RB O
breathing BC2GM041250465 VBG O
Fischer-344 BC2GM041250465 NNP O
Sprague-Dawley BC2GM041250465 NNP O
, BC2GM041250465 , O
and BC2GM041250465 CC O
Long-Evans BC2GM041250465 NNS O
rats BC2GM041250465 NNS O
and BC2GM041250465 CC O
Hartley BC2GM041250465 NNP O
guinea BC2GM041250465 NN O
pigs BC2GM041250465 NNS O
to BC2GM041250465 TO O
provide BC2GM041250465 VB O
data BC2GM041250465 NNS O
on BC2GM041250465 IN O
the BC2GM041250465 DT O
dosimetry BC2GM041250465 NN O
of BC2GM041250465 IN O
O3 BC2GM041250465 NNP O
in BC2GM041250465 IN O
small BC2GM041250465 JJ O
laboratory BC2GM041250465 NN O
animals BC2GM041250465 NNS O
. BC2GM041250465 . O
. . O O

Consistent BC2GM066024326 JJ O
with BC2GM066024326 IN O
other BC2GM066024326 JJ O
experiments BC2GM066024326 NNS O
with BC2GM066024326 IN O
these BC2GM066024326 DT O
compounds BC2GM066024326 NNS O
, BC2GM066024326 , O
cocaine BC2GM066024326 NN O
was BC2GM066024326 VBD O
the BC2GM066024326 DT O
most BC2GM066024326 RBS O
potent BC2GM066024326 NN O
of BC2GM066024326 IN O
the BC2GM066024326 DT O
group BC2GM066024326 NN O
. BC2GM066024326 . O
. . O O

Down-regulation BC2GM089665915 NN O
of BC2GM089665915 IN O
Id1 BC2GM089665915 NNP O
mRNA BC2GM089665915 NN O
correlated BC2GM089665915 VBD O
with BC2GM089665915 IN O
mitogenesis BC2GM089665915 NN O
and BC2GM089665915 CC O
occurred BC2GM089665915 VBD O
when BC2GM089665915 WRB O
quiescent BC2GM089665915 NN O
cells BC2GM089665915 NNS O
were BC2GM089665915 VBD O
treated BC2GM089665915 VBN O
with BC2GM089665915 IN O
growth BC2GM089665915 NN O
factors BC2GM089665915 NNS O
that BC2GM089665915 WDT O
activate BC2GM089665915 VBP O
G BC2GM089665915 NNP O
protein-coupled BC2GM089665915 JJ O
receptors BC2GM089665915 NNS O
and BC2GM089665915 CC O
receptor BC2GM089665915 NN O
protein BC2GM089665915 VBP O
tyrosine BC2GM089665915 JJ O
kinases BC2GM089665915 NNS O
but BC2GM089665915 CC O
not BC2GM089665915 RB O
with BC2GM089665915 IN O
a BC2GM089665915 DT O
non-mitogenic BC2GM089665915 JJ O
cAMP BC2GM089665915 NN O
analog BC2GM089665915 NN O
. BC2GM089665915 . O
. . O O

A BC2GM009609268 DT O
new BC2GM009609268 JJ O
technique BC2GM009609268 NN O
for BC2GM009609268 IN O
the BC2GM009609268 DT O
identification BC2GM009609268 NN O
of BC2GM009609268 IN O
phases BC2GM009609268 NNS O
contained BC2GM009609268 VBN O
within BC2GM009609268 IN O
a BC2GM009609268 DT O
polymer BC2GM009609268 JJ O
blend BC2GM009609268 NN O
is BC2GM009609268 VBZ O
described BC2GM009609268 VBN O
in BC2GM009609268 IN O
this BC2GM009609268 DT O
paper BC2GM009609268 NN O
. BC2GM009609268 . O
. . O O

Recovery BC2GM038386703 NN O
rates BC2GM038386703 NNS O
of BC2GM038386703 IN O
energy BC2GM038386703 NN O
level BC2GM038386703 NN O
and BC2GM038386703 CC O
intracellular BC2GM038386703 JJ O
pH BC2GM038386703 NN O
during BC2GM038386703 IN O
stimulation BC2GM038386703 NN O
at BC2GM038386703 IN O
100Hz BC2GM038386703 CD O
were BC2GM038386703 VBD O
greater BC2GM038386703 JJR O
than BC2GM038386703 IN O
those BC2GM038386703 DT O
observed BC2GM038386703 JJ O
during BC2GM038386703 IN O
stimulation BC2GM038386703 NN O
at BC2GM038386703 IN O
30Hz BC2GM038386703 CD O
. BC2GM038386703 . O
. . O O

Changes BC2GM067379320 NNS O
in BC2GM067379320 IN O
the BC2GM067379320 DT O
size BC2GM067379320 NN O
and BC2GM067379320 CC O
organisation BC2GM067379320 NN O
of BC2GM067379320 IN O
the BC2GM067379320 DT O
brain BC2GM067379320 NN O
in BC2GM067379320 IN O
man BC2GM067379320 NN O
and BC2GM067379320 CC O
his BC2GM067379320 PRP$ O
ancestors BC2GM067379320 NNS O
. BC2GM067379320 . O
. . O O

We BC2GM027725550 PRP O
analyzed BC2GM027725550 VBD O
the BC2GM027725550 DT O
effects BC2GM027725550 NNS O
of BC2GM027725550 IN O
light BC2GM027725550 NN O
on BC2GM027725550 IN O
tubulin BC2GM027725550 NN O
mRNA BC2GM027725550 NN O
abundance BC2GM027725550 NN O
in BC2GM027725550 IN O
Arabidopsis BC2GM027725550 NNP O
seedlings BC2GM027725550 NNS O
using BC2GM027725550 VBG O
RNA BC2GM027725550 NNP O
gel BC2GM027725550 NN O
blot BC2GM027725550 NN O
hybridizations BC2GM027725550 NNS O
and BC2GM027725550 CC O
gene-specific BC2GM027725550 JJ O
probes BC2GM027725550 NNS O
. BC2GM027725550 . O
. . O O

In BC2GM078874950 IN O
vitro BC2GM078874950 NN O
, BC2GM078874950 , O
c-Src BC2GM078874950 JJ O
phosphorylated BC2GM078874950 JJ O
FAK BC2GM078874950 NNP O
Tyr-925 BC2GM078874950 NNP O
in BC2GM078874950 IN O
a BC2GM078874950 DT O
glutathione BC2GM078874950 JJ O
S-transferase-FAK BC2GM078874950 JJ O
C-terminal BC2GM078874950 JJ O
domain BC2GM078874950 NN O
fusion BC2GM078874950 NN O
protein BC2GM078874950 NN O
, BC2GM078874950 , O
whereas BC2GM078874950 JJ O
FAK BC2GM078874950 NNP O
did BC2GM078874950 VBD O
not BC2GM078874950 RB O
. BC2GM078874950 . O
. . O O

In BC2GM088015029 IN O
addition BC2GM088015029 NN O
, BC2GM088015029 , O
mrp17-1 BC2GM088015029 NN O
, BC2GM088015029 , O
in BC2GM088015029 IN O
combination BC2GM088015029 NN O
with BC2GM088015029 IN O
some BC2GM088015029 DT O
mutations BC2GM088015029 NNS O
affecting BC2GM088015029 VBG O
another BC2GM088015029 DT O
mitochondrial BC2GM088015029 JJ O
ribosomal BC2GM088015029 NN O
protein BC2GM088015029 NN O
, BC2GM088015029 , O
caused BC2GM088015029 VBD O
a BC2GM088015029 DT O
synthetic BC2GM088015029 JJ O
defective BC2GM088015029 JJ O
phenotype BC2GM088015029 NN O
. BC2GM088015029 . O
. . O O

Thus BC2GM004675076 RB O
, BC2GM004675076 , O
primate BC2GM004675076 NN O
vs. BC2GM004675076 FW O
rodent BC2GM004675076 NN O
promoter BC2GM004675076 NN O
selectivity BC2GM004675076 NN O
mediated BC2GM004675076 VBN O
by BC2GM004675076 IN O
the BC2GM004675076 DT O
TBP-TAFI BC2GM004675076 NNP O
complex BC2GM004675076 NN O
is BC2GM004675076 VBZ O
likely BC2GM004675076 JJ O
to BC2GM004675076 TO O
be BC2GM004675076 VB O
the BC2GM004675076 DT O
result BC2GM004675076 NN O
of BC2GM004675076 IN O
cumulative BC2GM004675076 JJ O
subtle BC2GM004675076 JJ O
differences BC2GM004675076 NNS O
between BC2GM004675076 IN O
individual BC2GM004675076 JJ O
subunits BC2GM004675076 NNS O
that BC2GM004675076 WDT O
lead BC2GM004675076 VBP O
to BC2GM004675076 TO O
species-specific BC2GM004675076 JJ O
properties BC2GM004675076 NNS O
of BC2GM004675076 IN O
RNA BC2GM004675076 NNP O
polymerase BC2GM004675076 NN O
I BC2GM004675076 PRP O
transcription BC2GM004675076 VBP O
. BC2GM004675076 . O
. . O O

Focal BC2GM091278857 JJ O
glomerulosclerosis-like BC2GM091278857 JJ O
disease BC2GM091278857 NN O
with BC2GM091278857 IN O
nephrotic BC2GM091278857 JJ O
syndrome BC2GM091278857 NN O
in BC2GM091278857 IN O
a BC2GM091278857 DT O
horse BC2GM091278857 NN O
. BC2GM091278857 . O
. . O O

The BC2GM043101437 DT O
Molteno BC2GM043101437 NNP O
implant BC2GM043101437 NN O
is BC2GM043101437 VBZ O
an BC2GM043101437 DT O
effective BC2GM043101437 JJ O
procedure BC2GM043101437 NN O
in BC2GM043101437 IN O
the BC2GM043101437 DT O
treatment BC2GM043101437 NN O
of BC2GM043101437 IN O
complicated BC2GM043101437 VBN O
and BC2GM043101437 CC O
refractory BC2GM043101437 JJ O
cases BC2GM043101437 NNS O
of BC2GM043101437 IN O
glaucoma BC2GM043101437 NN O
in BC2GM043101437 IN O
high-risk BC2GM043101437 JJ O
eyes BC2GM043101437 NNS O
. BC2GM043101437 . O
. . O O

A BC2GM098444070 DT O
selective BC2GM098444070 JJ O
transcriptional BC2GM098444070 JJ O
induction BC2GM098444070 NN O
system BC2GM098444070 NN O
for BC2GM098444070 IN O
mammalian BC2GM098444070 JJ O
cells BC2GM098444070 NNS O
based BC2GM098444070 VBN O
on BC2GM098444070 IN O
Gal4-estrogen BC2GM098444070 NNP O
receptor BC2GM098444070 NN O
fusion BC2GM098444070 NN O
proteins BC2GM098444070 NNS O
. BC2GM098444070 . O
. . O O

Nb2-11C BC2GM090808688 NNP O
cells BC2GM090808688 NNS O
expressed BC2GM090808688 VBD O
three BC2GM090808688 CD O
PNR-related BC2GM090808688 JJ O
mRNA BC2GM090808688 NN O
transcripts BC2GM090808688 NNS O
of BC2GM090808688 IN O
2.5 BC2GM090808688 CD O
, BC2GM090808688 , O
3.0 BC2GM090808688 CD O
and BC2GM090808688 CC O
> BC2GM090808688 $ O
10 BC2GM090808688 CD O
kb BC2GM090808688 NN O
. BC2GM090808688 . O
. . O O

Gel BC2GM005504970 NNP O
shift BC2GM005504970 NN O
and BC2GM005504970 CC O
southwestern BC2GM005504970 JJ O
experiments BC2GM005504970 NNS O
revealed BC2GM005504970 VBD O
nuclear BC2GM005504970 JJ O
proteins BC2GM005504970 NNS O
of BC2GM005504970 IN O
43 BC2GM005504970 CD O
kDa BC2GM005504970 NNS O
and BC2GM005504970 CC O
30 BC2GM005504970 CD O
kDa BC2GM005504970 NN O
in BC2GM005504970 IN O
GC BC2GM005504970 NNP O
and BC2GM005504970 CC O
fish BC2GM005504970 JJ O
cells BC2GM005504970 NNS O
, BC2GM005504970 , O
respectively BC2GM005504970 RB O
, BC2GM005504970 , O
that BC2GM005504970 IN O
bind BC2GM005504970 VBP O
specifically BC2GM005504970 RB O
to BC2GM005504970 TO O
the BC2GM005504970 DT O
tGH BC2GM005504970 NN O
CRE BC2GM005504970 NNP O
, BC2GM005504970 , O
suggesting BC2GM005504970 VBG O
the BC2GM005504970 DT O
involvement BC2GM005504970 NN O
of BC2GM005504970 IN O
CRE-binding-protein BC2GM005504970 NNP O
/ BC2GM005504970 NNP O
activating-transcription-factor-l-related BC2GM005504970 JJ O
peptides BC2GM005504970 NNS O
in BC2GM005504970 IN O
cAMP BC2GM005504970 NN O
response BC2GM005504970 NN O
. BC2GM005504970 . O
. . O O

The BC2GM038917907 DT O
complexity BC2GM038917907 NN O
of BC2GM038917907 IN O
some BC2GM038917907 DT O
of BC2GM038917907 IN O
the BC2GM038917907 DT O
reports BC2GM038917907 NNS O
of BC2GM038917907 IN O
VACURG BC2GM038917907 NNP O
studies BC2GM038917907 NNS O
has BC2GM038917907 VBZ O
led BC2GM038917907 VBN O
some BC2GM038917907 DT O
to BC2GM038917907 TO O
believe BC2GM038917907 VB O
that BC2GM038917907 IN O
this BC2GM038917907 DT O
group BC2GM038917907 NN O
was BC2GM038917907 VBD O
opposed BC2GM038917907 VBN O
to BC2GM038917907 TO O
estrogens BC2GM038917907 NNS O
, BC2GM038917907 , O
but BC2GM038917907 CC O
that BC2GM038917907 DT O
is BC2GM038917907 VBZ O
not BC2GM038917907 RB O
true BC2GM038917907 JJ O
. BC2GM038917907 . O
. . O O

Of BC2GM028423664 IN O
concern BC2GM028423664 NN O
is BC2GM028423664 VBZ O
the BC2GM028423664 DT O
high BC2GM028423664 JJ O
, BC2GM028423664 , O
unexplained BC2GM028423664 JJ O
prevalence BC2GM028423664 NN O
of BC2GM028423664 IN O
BV BC2GM028423664 NNP O
among BC2GM028423664 IN O
African-American BC2GM028423664 JJ O
women BC2GM028423664 NNS O
, BC2GM028423664 , O
who BC2GM028423664 WP O
are BC2GM028423664 VBP O
also BC2GM028423664 RB O
at BC2GM028423664 IN O
extremely BC2GM028423664 RB O
high BC2GM028423664 JJ O
risk BC2GM028423664 NN O
for BC2GM028423664 IN O
preterm BC2GM028423664 JJ O
birth BC2GM028423664 NN O
. BC2GM028423664 . O
. . O O

Mutation BC2GM016145858 NN O
of BC2GM016145858 IN O
K14 BC2GM016145858 NNP O
in BC2GM016145858 IN O
H3 BC2GM016145858 NNP O
, BC2GM016145858 , O
which BC2GM016145858 WDT O
serves BC2GM016145858 VBZ O
as BC2GM016145858 IN O
the BC2GM016145858 DT O
major BC2GM016145858 JJ O
target BC2GM016145858 NN O
of BC2GM016145858 IN O
recombinant BC2GM016145858 JJ O
Gcn5p BC2GM016145858 NNP O
acetylation BC2GM016145858 NN O
in BC2GM016145858 IN O
vitro BC2GM016145858 NN O
, BC2GM016145858 , O
confers BC2GM016145858 VBZ O
a BC2GM016145858 DT O
strong BC2GM016145858 JJ O
, BC2GM016145858 , O
synthetic BC2GM016145858 JJ O
growth BC2GM016145858 NN O
defect BC2GM016145858 NN O
in BC2GM016145858 IN O
gcn5 BC2GM016145858 NN O
cells BC2GM016145858 NNS O
. BC2GM016145858 . O
. . O O

Genotype-phenotype BC2GM043141382 JJ O
correlations BC2GM043141382 NNS O
in BC2GM043141382 IN O
male BC2GM043141382 JJ O
patients BC2GM043141382 NNS O
with BC2GM043141382 IN O
a BC2GM043141382 DT O
partial BC2GM043141382 JJ O
nullisomy BC2GM043141382 NN O
of BC2GM043141382 IN O
the BC2GM043141382 DT O
X BC2GM043141382 NNP O
chromosome BC2GM043141382 NN O
have BC2GM043141382 VBP O
suggested BC2GM043141382 VBN O
that BC2GM043141382 IN O
at BC2GM043141382 IN O
least BC2GM043141382 JJS O
one BC2GM043141382 CD O
locus BC2GM043141382 NN O
involved BC2GM043141382 VBN O
in BC2GM043141382 IN O
MRX BC2GM043141382 NNP O
is BC2GM043141382 VBZ O
on BC2GM043141382 IN O
Xp22.3 BC2GM043141382 NN O
. BC2GM043141382 . O
. . O O

Psychophysical BC2GM085541430 JJ O
evidence BC2GM085541430 NN O
is BC2GM085541430 VBZ O
given BC2GM085541430 VBN O
for BC2GM085541430 IN O
the BC2GM085541430 DT O
existence BC2GM085541430 NN O
of BC2GM085541430 IN O
two BC2GM085541430 CD O
distinct BC2GM085541430 JJ O
systems BC2GM085541430 NNS O
in BC2GM085541430 IN O
human BC2GM085541430 JJ O
vision BC2GM085541430 NN O
: BC2GM085541430 : O
a BC2GM085541430 DT O
fast BC2GM085541430 JJ O
, BC2GM085541430 , O
sign-invariant BC2GM085541430 JJ O
system BC2GM085541430 NN O
concerned BC2GM085541430 VBN O
with BC2GM085541430 IN O
extracting BC2GM085541430 VBG O
contours BC2GM085541430 NNS O
and BC2GM085541430 CC O
a BC2GM085541430 DT O
slower BC2GM085541430 JJR O
, BC2GM085541430 , O
sign-sensitive BC2GM085541430 JJ O
system BC2GM085541430 NN O
concerned BC2GM085541430 VBN O
with BC2GM085541430 IN O
assigning BC2GM085541430 VBG O
surface BC2GM085541430 NN O
color BC2GM085541430 NN O
. BC2GM085541430 . O
. . O O

The BC2GM082632472 DT O
expression BC2GM082632472 NN O
of BC2GM082632472 IN O
cor14b BC2GM082632472 NN O
was BC2GM082632472 VBD O
strongly BC2GM082632472 RB O
impaired BC2GM082632472 VBN O
in BC2GM082632472 IN O
the BC2GM082632472 DT O
barley BC2GM082632472 NN O
albino BC2GM082632472 NN O
mutant BC2GM082632472 VBP O
an BC2GM082632472 DT O
, BC2GM082632472 , O
suggesting BC2GM082632472 VBG O
the BC2GM082632472 DT O
involvement BC2GM082632472 NN O
of BC2GM082632472 IN O
a BC2GM082632472 DT O
plastidial BC2GM082632472 JJ O
factor BC2GM082632472 NN O
in BC2GM082632472 IN O
the BC2GM082632472 DT O
control BC2GM082632472 NN O
of BC2GM082632472 IN O
gene BC2GM082632472 NN O
expression BC2GM082632472 NN O
. BC2GM082632472 . O
. . O O

Prazosin BC2GM020677635 NNP O
in BC2GM020677635 IN O
the BC2GM020677635 DT O
treatment BC2GM020677635 NN O
of BC2GM020677635 IN O
high BC2GM020677635 JJ O
blood BC2GM020677635 NN O
pressure BC2GM020677635 NN O
. BC2GM020677635 . O
. . O O

Maximum BC2GM066160627 JJ O
likelihood BC2GM066160627 NN O
estimation BC2GM066160627 NN O
in BC2GM066160627 IN O
covariance BC2GM066160627 NN O
structure BC2GM066160627 NN O
analysis BC2GM066160627 NN O
with BC2GM066160627 IN O
truncated BC2GM066160627 VBN O
data BC2GM066160627 NNS O
. BC2GM066160627 . O
. . O O

In BC2GM085265641 IN O
the BC2GM085265641 DT O
remaining BC2GM085265641 VBG O
91 BC2GM085265641 CD O
patients BC2GM085265641 NNS O
( BC2GM085265641 ( O
group BC2GM085265641 NN O
2 BC2GM085265641 CD O
) BC2GM085265641 ) O
, BC2GM085265641 , O
Pseudomonas BC2GM085265641 NNP O
( BC2GM085265641 ( O
18 BC2GM085265641 CD O
) BC2GM085265641 ) O
, BC2GM085265641 , O
coagulase-negative BC2GM085265641 JJ O
Staphylococci BC2GM085265641 NNP O
( BC2GM085265641 ( O
15 BC2GM085265641 CD O
) BC2GM085265641 ) O
, BC2GM085265641 , O
Staphylococcus BC2GM085265641 NNP O
epidermidis BC2GM085265641 NN O
( BC2GM085265641 ( O
23 BC2GM085265641 CD O
) BC2GM085265641 ) O
, BC2GM085265641 , O
Staphylococcus BC2GM085265641 NNP O
aureus BC2GM085265641 NN O
( BC2GM085265641 ( O
16 BC2GM085265641 CD O
) BC2GM085265641 ) O
, BC2GM085265641 , O
Corynebacterium BC2GM085265641 NNP O
species BC2GM085265641 NNS O
( BC2GM085265641 ( O
12 BC2GM085265641 CD O
) BC2GM085265641 ) O
, BC2GM085265641 , O
and BC2GM085265641 CC O
others BC2GM085265641 NNS O
( BC2GM085265641 ( O
seven BC2GM085265641 CD O
) BC2GM085265641 ) O
were BC2GM085265641 VBD O
isolated BC2GM085265641 VBN O
. BC2GM085265641 . O
. . O O

However BC2GM085535477 RB O
, BC2GM085535477 , O
ADAR1 BC2GM085535477 NNP O
and BC2GM085535477 CC O
the BC2GM085535477 DT O
related BC2GM085535477 JJ O
deaminase BC2GM085535477 NN O
ADAR2 BC2GM085535477 NNP O
showed BC2GM085535477 VBD O
significant BC2GM085535477 JJ O
expression BC2GM085535477 NN O
in BC2GM085535477 IN O
all BC2GM085535477 DT O
regions BC2GM085535477 NNS O
of BC2GM085535477 IN O
the BC2GM085535477 DT O
brain BC2GM085535477 NN O
examined BC2GM085535477 VBD O
, BC2GM085535477 , O
including BC2GM085535477 VBG O
cortex BC2GM085535477 NN O
, BC2GM085535477 , O
hippocampus BC2GM085535477 NN O
, BC2GM085535477 , O
olfactory BC2GM085535477 NN O
bulb BC2GM085535477 NN O
, BC2GM085535477 , O
and BC2GM085535477 CC O
striatum BC2GM085535477 NN O
, BC2GM085535477 , O
where BC2GM085535477 WRB O
the BC2GM085535477 DT O
5-HT2CR BC2GM085535477 JJ O
pre-mRNA BC2GM085535477 NN O
was BC2GM085535477 VBD O
extensively BC2GM085535477 RB O
edited BC2GM085535477 VBN O
. BC2GM085535477 . O
. . O O

The BC2GM099313539 DT O
human BC2GM099313539 JJ O
CA11 BC2GM099313539 NNP O
gene BC2GM099313539 NN O
appears BC2GM099313539 VBZ O
to BC2GM099313539 TO O
be BC2GM099313539 VB O
located BC2GM099313539 VBN O
between BC2GM099313539 IN O
the BC2GM099313539 DT O
secretor BC2GM099313539 NN O
type BC2GM099313539 NN O
alpha BC2GM099313539 NN O
( BC2GM099313539 ( O
1,2 BC2GM099313539 CD O
) BC2GM099313539 ) O
-fucosyltransferase BC2GM099313539 NN O
gene BC2GM099313539 NN O
cluster BC2GM099313539 NN O
( BC2GM099313539 ( O
FUT1-FUT2-FUT2P BC2GM099313539 NNP O
) BC2GM099313539 ) O
and BC2GM099313539 CC O
the BC2GM099313539 DT O
D-site BC2GM099313539 NNP O
binding BC2GM099313539 NN O
protein BC2GM099313539 NN O
gene BC2GM099313539 NN O
( BC2GM099313539 ( O
DBP BC2GM099313539 NNP O
) BC2GM099313539 ) O
on BC2GM099313539 IN O
chromosome BC2GM099313539 NN O
19q13.3 BC2GM099313539 CD O
. BC2GM099313539 . O
. . O O

In BC2GM038727625 IN O
this BC2GM038727625 DT O
paper BC2GM038727625 NN O
, BC2GM038727625 , O
the BC2GM038727625 DT O
authors BC2GM038727625 NNS O
used BC2GM038727625 VBD O
measured BC2GM038727625 VBN O
weight BC2GM038727625 NN O
for BC2GM038727625 IN O
1,259 BC2GM038727625 CD O
white BC2GM038727625 JJ O
women BC2GM038727625 NNS O
aged BC2GM038727625 VBN O
65-74 BC2GM038727625 JJ O
years BC2GM038727625 NNS O
from BC2GM038727625 IN O
the BC2GM038727625 DT O
Epidemiologic BC2GM038727625 NNP O
Follow-up BC2GM038727625 NNP O
Study BC2GM038727625 NNP O
of BC2GM038727625 IN O
the BC2GM038727625 DT O
First BC2GM038727625 NNP O
National BC2GM038727625 NNP O
Health BC2GM038727625 NNP O
and BC2GM038727625 CC O
Nutrition BC2GM038727625 NNP O
Examination BC2GM038727625 NNP O
Survey BC2GM038727625 NNP O
to BC2GM038727625 TO O
examine BC2GM038727625 VB O
the BC2GM038727625 DT O
effect BC2GM038727625 NN O
of BC2GM038727625 IN O
overweight BC2GM038727625 NN O
on BC2GM038727625 IN O
coronary BC2GM038727625 JJ O
heart BC2GM038727625 NN O
disease BC2GM038727625 NN O
incidence BC2GM038727625 NN O
( BC2GM038727625 ( O
mean BC2GM038727625 JJ O
length BC2GM038727625 NN O
of BC2GM038727625 IN O
follow-up BC2GM038727625 NN O
, BC2GM038727625 , O
14 BC2GM038727625 CD O
years BC2GM038727625 NNS O
) BC2GM038727625 ) O
. BC2GM038727625 . O
. . O O

Synthetic BC2GM064897549 JJ O
studies BC2GM064897549 NNS O
on BC2GM064897549 IN O
furan BC2GM064897549 NN O
derivatives BC2GM064897549 NNS O
by BC2GM064897549 IN O
the BC2GM064897549 DT O
wittig BC2GM064897549 JJ O
reaction BC2GM064897549 NN O
. BC2GM064897549 . O
. . O O

Overexpression BC2GM081593003 NN O
of BC2GM081593003 IN O
eIF4E BC2GM081593003 NN O
transforms BC2GM081593003 NNS O
cells BC2GM081593003 NNS O
, BC2GM081593003 , O
and BC2GM081593003 CC O
mutations BC2GM081593003 NNS O
in BC2GM081593003 IN O
eIF4E BC2GM081593003 JJ O
arrest BC2GM081593003 NN O
cells BC2GM081593003 NNS O
in BC2GM081593003 IN O
G BC2GM081593003 NNP O
, BC2GM081593003 , O
in BC2GM081593003 IN O
cdc33 BC2GM081593003 JJ O
mutants BC2GM081593003 NNS O
. BC2GM081593003 . O
. . O O

Lung BC2GM033997989 NNP O
transplantation BC2GM033997989 NN O
is BC2GM033997989 VBZ O
warranted BC2GM033997989 VBN O
for BC2GM033997989 IN O
stable BC2GM033997989 JJ O
, BC2GM033997989 , O
ventilator-dependent BC2GM033997989 JJ O
recipients BC2GM033997989 NNS O
. BC2GM033997989 . O
. . O O

The BC2GM079066948 DT O
authors BC2GM079066948 NNS O
report BC2GM079066948 VBP O
two BC2GM079066948 CD O
cases BC2GM079066948 NNS O
of BC2GM079066948 IN O
orbital BC2GM079066948 JJ O
cavernous BC2GM079066948 JJ O
hemangioma BC2GM079066948 NN O
diagnosed BC2GM079066948 VBN O
by BC2GM079066948 IN O
Tc-99m BC2GM079066948 NNP O
RBC BC2GM079066948 NNP O
SPECT BC2GM079066948 NNP O
. BC2GM079066948 . O
. . O O

The BC2GM095732578 DT O
authors BC2GM095732578 NNS O
report BC2GM095732578 VBP O
a BC2GM095732578 DT O
case BC2GM095732578 NN O
of BC2GM095732578 IN O
a BC2GM095732578 DT O
painful BC2GM095732578 JJ O
wrist BC2GM095732578 NN O
related BC2GM095732578 VBN O
to BC2GM095732578 TO O
a BC2GM095732578 DT O
`` BC2GM095732578 `` O
Manieux BC2GM095732578 NNP O
muscle BC2GM095732578 NN O
'' BC2GM095732578 '' O
of BC2GM095732578 IN O
the BC2GM095732578 DT O
dorsal BC2GM095732578 NN O
aspect BC2GM095732578 NN O
of BC2GM095732578 IN O
the BC2GM095732578 DT O
hand BC2GM095732578 NN O
. BC2GM095732578 . O
. . O O

Essential BC2GM001365084 JJ O
fatty BC2GM001365084 JJ O
acid BC2GM001365084 JJ O
deficiency BC2GM001365084 NN O
in BC2GM001365084 IN O
childhood BC2GM001365084 NN O
. BC2GM001365084 . O
. . O O

Furthermore BC2GM083586381 RB O
the BC2GM083586381 DT O
aldosterone BC2GM083586381 NN O
stimulating BC2GM083586381 VBG O
effect BC2GM083586381 NN O
of BC2GM083586381 IN O
low BC2GM083586381 JJ O
sodium BC2GM083586381 NN O
diet BC2GM083586381 NN O
( BC2GM083586381 ( O
17 BC2GM083586381 CD O
children BC2GM083586381 NNS O
) BC2GM083586381 ) O
, BC2GM083586381 , O
severe BC2GM083586381 JJ O
and BC2GM083586381 CC O
prolonged BC2GM083586381 JJ O
vomiting BC2GM083586381 NN O
( BC2GM083586381 ( O
19 BC2GM083586381 CD O
children BC2GM083586381 NNS O
) BC2GM083586381 ) O
and BC2GM083586381 CC O
synthetic BC2GM083586381 JJ O
ACTH BC2GM083586381 NNP O
( BC2GM083586381 ( O
10 BC2GM083586381 CD O
children BC2GM083586381 NNS O
) BC2GM083586381 ) O
has BC2GM083586381 VBZ O
been BC2GM083586381 VBN O
studied BC2GM083586381 VBN O
by BC2GM083586381 IN O
our BC2GM083586381 PRP$ O
modified BC2GM083586381 JJ O
method BC2GM083586381 NN O
. BC2GM083586381 . O
. . O O

Experiment BC2GM002326238 NN O
B BC2GM002326238 NN O
: BC2GM002326238 : O
Clinical BC2GM002326238 JJ O
, BC2GM002326238 , O
biochemical BC2GM002326238 JJ O
, BC2GM002326238 , O
and BC2GM002326238 CC O
histological BC2GM002326238 JJ O
variables BC2GM002326238 NNS O
were BC2GM002326238 VBD O
measured BC2GM002326238 VBN O
over BC2GM002326238 IN O
a BC2GM002326238 DT O
12-day BC2GM002326238 JJ O
period BC2GM002326238 NN O
after BC2GM002326238 IN O
the BC2GM002326238 DT O
zymosan BC2GM002326238 NN O
had BC2GM002326238 VBD O
been BC2GM002326238 VBN O
given BC2GM002326238 VBN O
. BC2GM002326238 . O
. . O O

A BC2GM004792351 DT O
DNA BC2GM004792351 NN O
binding BC2GM004792351 VBG O
protein BC2GM004792351 NN O
was BC2GM004792351 VBD O
identified BC2GM004792351 VBN O
which BC2GM004792351 WDT O
binds BC2GM004792351 VBZ O
to BC2GM004792351 TO O
two BC2GM004792351 CD O
novel BC2GM004792351 JJ O
target-like BC2GM004792351 JJ O
sequences BC2GM004792351 NNS O
: BC2GM004792351 : O
( BC2GM004792351 ( O
i BC2GM004792351 NN O
) BC2GM004792351 ) O
at BC2GM004792351 IN O
the BC2GM004792351 DT O
5 BC2GM004792351 CD O
' BC2GM004792351 POS O
flanking BC2GM004792351 VBG O
site BC2GM004792351 NN O
of BC2GM004792351 IN O
the BC2GM004792351 DT O
breakpoint BC2GM004792351 NN O
junction BC2GM004792351 NN O
of BC2GM004792351 IN O
chromosome BC2GM004792351 NN O
8 BC2GM004792351 CD O
in BC2GM004792351 IN O
a BC2GM004792351 DT O
patient BC2GM004792351 NN O
with BC2GM004792351 IN O
T-acute BC2GM004792351 NNP O
lymphoblastic BC2GM004792351 JJ O
leukemia BC2GM004792351 NN O
( BC2GM004792351 ( O
ALL BC2GM004792351 NNP O
) BC2GM004792351 ) O
carrying BC2GM004792351 VBG O
the BC2GM004792351 DT O
t BC2GM004792351 NN O
( BC2GM004792351 ( O
8 BC2GM004792351 CD O
; BC2GM004792351 : O
14 BC2GM004792351 CD O
) BC2GM004792351 ) O
( BC2GM004792351 ( O
q24 BC2GM004792351 NN O
; BC2GM004792351 : O
q11 BC2GM004792351 CC O
) BC2GM004792351 ) O
rearrangement BC2GM004792351 NN O
and BC2GM004792351 CC O
( BC2GM004792351 ( O
ii BC2GM004792351 NN O
) BC2GM004792351 ) O
on BC2GM004792351 IN O
chromosome BC2GM004792351 NN O
1 BC2GM004792351 CD O
in BC2GM004792351 IN O
three BC2GM004792351 CD O
of BC2GM004792351 IN O
five BC2GM004792351 CD O
T-ALL BC2GM004792351 JJ O
patients BC2GM004792351 NNS O
with BC2GM004792351 IN O
the BC2GM004792351 DT O
t BC2GM004792351 NN O
( BC2GM004792351 ( O
1 BC2GM004792351 CD O
; BC2GM004792351 : O
14 BC2GM004792351 CD O
) BC2GM004792351 ) O
( BC2GM004792351 ( O
p32 BC2GM004792351 NN O
; BC2GM004792351 : O
q11 BC2GM004792351 CC O
) BC2GM004792351 ) O
rearrangement BC2GM004792351 NN O
. BC2GM004792351 . O
. . O O

PrRP BC2GM076704194 NNP O
rapidly BC2GM076704194 RB O
and BC2GM076704194 CC O
transiently BC2GM076704194 RB O
activated BC2GM076704194 VBD O
extracellular BC2GM076704194 JJ O
signal-regulated BC2GM076704194 JJ O
protein BC2GM076704194 NN O
kinase BC2GM076704194 NN O
( BC2GM076704194 ( O
ERK BC2GM076704194 NNP O
) BC2GM076704194 ) O
in BC2GM076704194 IN O
both BC2GM076704194 DT O
types BC2GM076704194 NNS O
of BC2GM076704194 IN O
cells BC2GM076704194 NNS O
. BC2GM076704194 . O
. . O O

Finally BC2GM081450660 RB O
, BC2GM081450660 , O
synthetic BC2GM081450660 JJ O
peptides BC2GM081450660 NNS O
corresponding BC2GM081450660 VBG O
to BC2GM081450660 TO O
the BC2GM081450660 DT O
mutant BC2GM081450660 JJ O
proteins BC2GM081450660 NNS O
were BC2GM081450660 VBD O
assessed BC2GM081450660 VBN O
for BC2GM081450660 IN O
the BC2GM081450660 DT O
ability BC2GM081450660 NN O
to BC2GM081450660 TO O
act BC2GM081450660 VB O
as BC2GM081450660 IN O
substrates BC2GM081450660 NNS O
for BC2GM081450660 IN O
PR BC2GM081450660 NNP O
. BC2GM081450660 . O
. . O O

Risk BC2GM053578806 NNP O
ratios BC2GM053578806 NNS O
decreased BC2GM053578806 VBD O
with BC2GM053578806 IN O
increasing BC2GM053578806 VBG O
age BC2GM053578806 NN O
and BC2GM053578806 CC O
increased BC2GM053578806 VBD O
with BC2GM053578806 IN O
number BC2GM053578806 NN O
of BC2GM053578806 IN O
breast BC2GM053578806 NN O
biopsies BC2GM053578806 NNS O
, BC2GM053578806 , O
family BC2GM053578806 NN O
history BC2GM053578806 NN O
of BC2GM053578806 IN O
breast BC2GM053578806 NN O
cancer BC2GM053578806 NN O
, BC2GM053578806 , O
estrogen BC2GM053578806 NN O
use BC2GM053578806 NN O
, BC2GM053578806 , O
time BC2GM053578806 NN O
between BC2GM053578806 IN O
screenings BC2GM053578806 NNS O
, BC2GM053578806 , O
no BC2GM053578806 DT O
comparison BC2GM053578806 NN O
with BC2GM053578806 IN O
previous BC2GM053578806 JJ O
mammograms BC2GM053578806 NNS O
, BC2GM053578806 , O
and BC2GM053578806 CC O
the BC2GM053578806 DT O
radiologist BC2GM053578806 NN O
's BC2GM053578806 POS O
tendency BC2GM053578806 NN O
to BC2GM053578806 TO O
call BC2GM053578806 VB O
mammograms BC2GM053578806 NNS O
abnormal BC2GM053578806 JJ O
. BC2GM053578806 . O
. . O O

Medical BC2GM016319405 JJ O
management BC2GM016319405 NN O
of BC2GM016319405 IN O
early-stage BC2GM016319405 JJ O
breast BC2GM016319405 NN O
cancer BC2GM016319405 NN O
. BC2GM016319405 . O
. . O O

Cytostatic BC2GM067535411 JJ O
activity BC2GM067535411 NN O
of BC2GM067535411 IN O
some BC2GM067535411 DT O
essential BC2GM067535411 JJ O
oils BC2GM067535411 NNS O
against BC2GM067535411 IN O
HEp-2 BC2GM067535411 NNP O
cells BC2GM067535411 NNS O
. BC2GM067535411 . O
. . O O

Ribosome BC2GM060572853 NNP O
association BC2GM060572853 NN O
of BC2GM060572853 IN O
GCN2 BC2GM060572853 NNP O
protein BC2GM060572853 NN O
kinase BC2GM060572853 NN O
, BC2GM060572853 , O
a BC2GM060572853 DT O
translational BC2GM060572853 JJ O
activator BC2GM060572853 NN O
of BC2GM060572853 IN O
the BC2GM060572853 DT O
GCN4 BC2GM060572853 NNP O
gene BC2GM060572853 NN O
of BC2GM060572853 IN O
Saccharomyces BC2GM060572853 NNP O
cerevisiae BC2GM060572853 NN O
. BC2GM060572853 . O
. . O O

Pyridostigmine BC2GM042178518 NNP O
pretreatment BC2GM042178518 NN O
was BC2GM042178518 VBD O
supplemented BC2GM042178518 VBN O
by BC2GM042178518 IN O
therapy BC2GM042178518 NN O
with BC2GM042178518 IN O
two BC2GM042178518 CD O
doses BC2GM042178518 NNS O
of BC2GM042178518 IN O
an BC2GM042178518 DT O
antidotal BC2GM042178518 JJ O
combination BC2GM042178518 NN O
( BC2GM042178518 ( O
A BC2GM042178518 NNP O
, BC2GM042178518 , O
TM BC2GM042178518 NNP O
, BC2GM042178518 , O
B BC2GM042178518 NNP O
) BC2GM042178518 ) O
consisting BC2GM042178518 NN O
of BC2GM042178518 IN O
0.05 BC2GM042178518 CD O
mg BC2GM042178518 NNS O
/ BC2GM042178518 JJ O
kg BC2GM042178518 FW O
atropine BC2GM042178518 NN O
, BC2GM042178518 , O
2.24 BC2GM042178518 CD O
mg BC2GM042178518 NN O
/ BC2GM042178518 NNP O
kg BC2GM042178518 VBZ O
TMB-4 BC2GM042178518 NNP O
, BC2GM042178518 , O
and BC2GM042178518 CC O
0.4 BC2GM042178518 CD O
mg BC2GM042178518 NN O
/ BC2GM042178518 NNP O
kg BC2GM042178518 NNP O
benactyzine BC2GM042178518 NN O
which BC2GM042178518 WDT O
assured BC2GM042178518 VBD O
survival BC2GM042178518 NN O
in BC2GM042178518 IN O
five BC2GM042178518 CD O
of BC2GM042178518 IN O
six BC2GM042178518 CD O
animals BC2GM042178518 NNS O
following BC2GM042178518 VBG O
three BC2GM042178518 CD O
separate BC2GM042178518 JJ O
exposures BC2GM042178518 NNS O
to BC2GM042178518 TO O
10 BC2GM042178518 CD O
LD50 BC2GM042178518 NNP O
soman BC2GM042178518 NN O
. BC2GM042178518 . O
. . O O

Of BC2GM085373279 IN O
these BC2GM085373279 DT O
four BC2GM085373279 CD O
PP2C BC2GM085373279 NNP O
genes BC2GM085373279 NNS O
, BC2GM085373279 , O
the BC2GM085373279 DT O
expression BC2GM085373279 NN O
of BC2GM085373279 IN O
the BC2GM085373279 DT O
PP2Cbeta BC2GM085373279 NNP O
gene BC2GM085373279 NN O
has BC2GM085373279 VBZ O
been BC2GM085373279 VBN O
reported BC2GM085373279 VBN O
to BC2GM085373279 TO O
be BC2GM085373279 VB O
tissue-specific BC2GM085373279 JJ O
and BC2GM085373279 CC O
development-dependent BC2GM085373279 JJ O
. BC2GM085373279 . O
. . O O

HCVR-L BC2GM069896778 NNP O
significantly BC2GM069896778 RB O
increased BC2GM069896778 VBD O
dVAS BC2GM069896778 JJ O
/ BC2GM069896778 NNP O
dPCO2 BC2GM069896778 NN O
to BC2GM069896778 TO O
4.9 BC2GM069896778 CD O
+ BC2GM069896778 NNS O
/ BC2GM069896778 SYM O
- BC2GM069896778 : O
0.7 BC2GM069896778 CD O
mm BC2GM069896778 NN O
/ BC2GM069896778 NNP O
Torr BC2GM069896778 NNP O
compared BC2GM069896778 VBN O
to BC2GM069896778 TO O
HCVR-S BC2GM069896778 NNP O
( BC2GM069896778 ( O
p BC2GM069896778 JJ O
< BC2GM069896778 NNP O
0.05 BC2GM069896778 CD O
) BC2GM069896778 ) O
. BC2GM069896778 . O
. . O O

Purified BC2GM045058559 NNP O
phosphorylated BC2GM045058559 VBD O
PhoP BC2GM045058559 NNP O
( BC2GM045058559 ( O
PhoPP BC2GM045058559 NNP O
) BC2GM045058559 ) O
had BC2GM045058559 VBD O
a BC2GM045058559 DT O
half-life BC2GM045058559 NN O
of BC2GM045058559 IN O
approximately BC2GM045058559 RB O
2.5 BC2GM045058559 CD O
h BC2GM045058559 NN O
, BC2GM045058559 , O
which BC2GM045058559 WDT O
was BC2GM045058559 VBD O
reduced BC2GM045058559 VBN O
to BC2GM045058559 TO O
about BC2GM045058559 IN O
15 BC2GM045058559 CD O
min BC2GM045058559 NNS O
by BC2GM045058559 IN O
addition BC2GM045058559 NN O
of BC2GM045058559 IN O
the BC2GM045058559 DT O
same BC2GM045058559 JJ O
molar BC2GM045058559 JJ O
amount BC2GM045058559 NN O
of BC2GM045058559 IN O
*PhoR BC2GM045058559 NNP O
( BC2GM045058559 ( O
the BC2GM045058559 DT O
cytoplasmic BC2GM045058559 JJ O
region BC2GM045058559 NN O
of BC2GM045058559 IN O
PhoR BC2GM045058559 NNP O
) BC2GM045058559 ) O
. BC2GM045058559 . O
. . O O

These BC2GM021272736 DT O
data BC2GM021272736 NNS O
show BC2GM021272736 VBP O
that BC2GM021272736 IN O
the BC2GM021272736 DT O
processing BC2GM021272736 NN O
of BC2GM021272736 IN O
specific BC2GM021272736 JJ O
target BC2GM021272736 NN O
transcripts BC2GM021272736 NNS O
, BC2GM021272736 , O
such BC2GM021272736 JJ O
as BC2GM021272736 IN O
the BC2GM021272736 DT O
P-element BC2GM021272736 NNP O
mRNA BC2GM021272736 NN O
, BC2GM021272736 , O
is BC2GM021272736 VBZ O
regulated BC2GM021272736 VBN O
by BC2GM021272736 IN O
a BC2GM021272736 DT O
functional BC2GM021272736 JJ O
PSI-U1 BC2GM021272736 NNP O
snRNP BC2GM021272736 NN O
interaction BC2GM021272736 NN O
in BC2GM021272736 IN O
Drosophila BC2GM021272736 NNP O
. BC2GM021272736 . O
. . O O

Since BC2GM079186421 IN O
the BC2GM079186421 DT O
early BC2GM079186421 JJ O
1900s BC2GM079186421 CD O
, BC2GM079186421 , O
a BC2GM079186421 DT O
genetic BC2GM079186421 JJ O
hypothesis BC2GM079186421 NN O
has BC2GM079186421 VBZ O
been BC2GM079186421 VBN O
suggested BC2GM079186421 VBN O
. BC2GM079186421 . O
. . O O

Purified BC2GM038525158 NNP O
fER BC2GM038525158 NN O
exhibited BC2GM038525158 VBD O
a BC2GM038525158 DT O
distribution BC2GM038525158 NN O
constant BC2GM038525158 NN O
( BC2GM038525158 ( O
KD BC2GM038525158 NNP O
) BC2GM038525158 ) O
for BC2GM038525158 IN O
17 BC2GM038525158 CD O
beta-estradiol BC2GM038525158 NN O
of BC2GM038525158 IN O
0.45 BC2GM038525158 CD O
nM BC2GM038525158 NNS O
. BC2GM038525158 . O
. . O O

We BC2GM087392570 PRP O
now BC2GM087392570 RB O
report BC2GM087392570 VBP O
that BC2GM087392570 IN O
both BC2GM087392570 DT O
HSCR BC2GM087392570 NNP O
mutations BC2GM087392570 NNS O
impair BC2GM087392570 VBP O
the BC2GM087392570 DT O
fixation BC2GM087392570 NN O
of BC2GM087392570 IN O
Shc BC2GM087392570 NNP O
to BC2GM087392570 TO O
RET BC2GM087392570 NNP O
and BC2GM087392570 CC O
consequently BC2GM087392570 RB O
prevent BC2GM087392570 VB O
its BC2GM087392570 PRP$ O
phosphorylation BC2GM087392570 NN O
. BC2GM087392570 . O
. . O O

Phenotypic BC2GM029775114 NNP O
responses BC2GM029775114 NNS O
of BC2GM029775114 IN O
additional BC2GM029775114 JJ O
mutants BC2GM029775114 NNS O
, BC2GM029775114 , O
including BC2GM029775114 VBG O
exo1 BC2GM029775114 NN O
, BC2GM029775114 , O
srs2 BC2GM029775114 NN O
, BC2GM029775114 , O
rad5 BC2GM029775114 NN O
, BC2GM029775114 , O
and BC2GM029775114 CC O
rdh54 BC2GM029775114 NN O
strains BC2GM029775114 NNS O
, BC2GM029775114 , O
suggest BC2GM029775114 VBP O
roles BC2GM029775114 NNS O
in BC2GM029775114 IN O
recombinational BC2GM029775114 JJ O
repair BC2GM029775114 NN O
, BC2GM029775114 , O
but BC2GM029775114 CC O
not BC2GM029775114 RB O
in BC2GM029775114 IN O
NHEJ BC2GM029775114 NNP O
. BC2GM029775114 . O
. . O O

A BC2GM075408371 DT O
drop BC2GM075408371 NN O
of BC2GM075408371 IN O
methylprednisolone BC2GM075408371 NN O
acetate BC2GM075408371 NN O
or BC2GM075408371 CC O
vehicle BC2GM075408371 NN O
constituent BC2GM075408371 NN O
was BC2GM075408371 VBD O
placed BC2GM075408371 VBN O
on BC2GM075408371 IN O
the BC2GM075408371 DT O
dissected BC2GM075408371 JJ O
plantar BC2GM075408371 NN O
nerve BC2GM075408371 NN O
proximal BC2GM075408371 NN O
to BC2GM075408371 TO O
the BC2GM075408371 DT O
stimulating BC2GM075408371 NN O
electrodes BC2GM075408371 NNS O
after BC2GM075408371 IN O
recording BC2GM075408371 VBG O
control BC2GM075408371 NN O
responses BC2GM075408371 NNS O
( BC2GM075408371 ( O
A-fibre BC2GM075408371 NNP O
volley BC2GM075408371 NN O
in BC2GM075408371 IN O
the BC2GM075408371 DT O
sciatic BC2GM075408371 JJ O
nerve BC2GM075408371 NN O
and BC2GM075408371 CC O
C-fibre BC2GM075408371 NNP O
evoked BC2GM075408371 VBD O
reflex BC2GM075408371 JJ O
discharge BC2GM075408371 NN O
in BC2GM075408371 IN O
flexor BC2GM075408371 JJ O
motoneurons BC2GM075408371 NNS O
) BC2GM075408371 ) O
. BC2GM075408371 . O
. . O O

Salt BC2GM081449509 NNP O
wars BC2GM081449509 NNS O
. BC2GM081449509 . O
. . O O

The BC2GM023099486 DT O
Rep78 BC2GM023099486 NNP O
protein BC2GM023099486 NN O
of BC2GM023099486 IN O
adeno-associated BC2GM023099486 JJ O
virus BC2GM023099486 NN O
( BC2GM023099486 ( O
AAV BC2GM023099486 NNP O
) BC2GM023099486 ) O
contains BC2GM023099486 VBZ O
amino BC2GM023099486 JJ O
acid BC2GM023099486 JJ O
sequence BC2GM023099486 NN O
motifs BC2GM023099486 NNS O
common BC2GM023099486 JJ O
to BC2GM023099486 TO O
rolling-circle BC2GM023099486 JJ O
replication BC2GM023099486 NN O
( BC2GM023099486 ( O
RCR BC2GM023099486 NNP O
) BC2GM023099486 ) O
initiator BC2GM023099486 NN O
proteins BC2GM023099486 NNS O
. BC2GM023099486 . O
. . O O

These BC2GM071814520 DT O
findings BC2GM071814520 NNS O
suggest BC2GM071814520 VBP O
that BC2GM071814520 IN O
T3R BC2GM071814520 NNP O
can BC2GM071814520 MD O
repress BC2GM071814520 VB O
or BC2GM071814520 CC O
activate BC2GM071814520 VB O
transcription BC2GM071814520 NN O
while BC2GM071814520 IN O
tethered BC2GM071814520 VBN O
to BC2GM071814520 TO O
the BC2GM071814520 DT O
LBD BC2GM071814520 NNP O
of BC2GM071814520 IN O
GAL4-RXR BC2GM071814520 NNP O
and BC2GM071814520 CC O
that BC2GM071814520 IN O
heterodimerization BC2GM071814520 NN O
can BC2GM071814520 MD O
occur BC2GM071814520 VB O
in BC2GM071814520 IN O
vivo BC2GM071814520 NN O
without BC2GM071814520 IN O
stabilization BC2GM071814520 NN O
by BC2GM071814520 IN O
hormone BC2GM071814520 NN O
response BC2GM071814520 NN O
elements BC2GM071814520 NNS O
. BC2GM071814520 . O
. . O O

METHODS BC2GM079255764 NN O
: BC2GM079255764 : O
Single BC2GM079255764 NNP O
white BC2GM079255764 JJ O
flash BC2GM079255764 NN O
ERG BC2GM079255764 NNP O
, BC2GM079255764 , O
photopic BC2GM079255764 NN O
ERG BC2GM079255764 NNP O
, BC2GM079255764 , O
scotopic BC2GM079255764 NN O
ERG BC2GM079255764 NNP O
and BC2GM079255764 CC O
flicker BC2GM079255764 NN O
ERG BC2GM079255764 NNP O
were BC2GM079255764 VBD O
recorded BC2GM079255764 VBN O
in BC2GM079255764 IN O
30 BC2GM079255764 CD O
cases BC2GM079255764 NNS O
of BC2GM079255764 IN O
unilateral BC2GM079255764 JJ O
CRVO BC2GM079255764 NNP O
. BC2GM079255764 . O
. . O O

It BC2GM064119241 PRP O
is BC2GM064119241 VBZ O
an BC2GM064119241 DT O
untested BC2GM064119241 JJ O
argument BC2GM064119241 NN O
that BC2GM064119241 IN O
conventional BC2GM064119241 JJ O
beta-adrenoceptor BC2GM064119241 JJ O
antagonists BC2GM064119241 NNS O
possess BC2GM064119241 RB O
unwanted BC2GM064119241 JJ O
metabolic BC2GM064119241 JJ O
effects BC2GM064119241 NNS O
that BC2GM064119241 WDT O
may BC2GM064119241 MD O
counter BC2GM064119241 VB O
some BC2GM064119241 DT O
of BC2GM064119241 IN O
their BC2GM064119241 PRP$ O
potential BC2GM064119241 JJ O
cardiac BC2GM064119241 JJ O
benefits BC2GM064119241 NNS O
. BC2GM064119241 . O
. . O O

Earlier BC2GM071451741 RBR O
nonoptical BC2GM071451741 JJ O
methods BC2GM071451741 NNS O
probably BC2GM071451741 RB O
did BC2GM071451741 VBD O
not BC2GM071451741 RB O
include BC2GM071451741 VB O
the BC2GM071451741 DT O
portion BC2GM071451741 NN O
of BC2GM071451741 IN O
the BC2GM071451741 DT O
film BC2GM071451741 NN O
that BC2GM071451741 WDT O
contained BC2GM071451741 VBD O
mucus BC2GM071451741 NN O
. BC2GM071451741 . O
. . O O

Sleeping BC2GM029453791 VBG O
position BC2GM029453791 NN O
and BC2GM029453791 CC O
sudden BC2GM029453791 JJ O
infant BC2GM029453791 NN O
death BC2GM029453791 NN O
syndrome BC2GM029453791 NN O
( BC2GM029453791 ( O
SIDS BC2GM029453791 NNP O
) BC2GM029453791 ) O
: BC2GM029453791 : O
effect BC2GM029453791 NN O
of BC2GM029453791 IN O
an BC2GM029453791 DT O
intervention BC2GM029453791 NN O
programme BC2GM029453791 NN O
to BC2GM029453791 TO O
avoid BC2GM029453791 VB O
prone BC2GM029453791 NN O
sleeping BC2GM029453791 NN O
. BC2GM029453791 . O
. . O O

Differential BC2GM089407597 NNP O
decay BC2GM089407597 NN O
of BC2GM089407597 IN O
a BC2GM089407597 DT O
polycistronic BC2GM089407597 JJ O
Escherichia BC2GM089407597 NNP O
coli BC2GM089407597 NN O
transcript BC2GM089407597 NN O
is BC2GM089407597 VBZ O
initiated BC2GM089407597 VBN O
by BC2GM089407597 IN O
RNaseE-dependent BC2GM089407597 NNP O
endonucleolytic BC2GM089407597 JJ O
processing BC2GM089407597 NN O
. BC2GM089407597 . O
. . O O

Studies BC2GM000680250 NNS O
of BC2GM000680250 IN O
fetal BC2GM000680250 JJ O
maturity BC2GM000680250 NN O
. BC2GM000680250 . O
. . O O

The BC2GM004777845 DT O
QCS BC2GM004777845 NNP O
appears BC2GM004777845 VBZ O
comparable BC2GM004777845 JJ O
with BC2GM004777845 IN O
the BC2GM004777845 DT O
MMSE BC2GM004777845 NNP O
and BC2GM004777845 CC O
is BC2GM004777845 VBZ O
quicker BC2GM004777845 JJR O
to BC2GM004777845 TO O
administer BC2GM004777845 VB O
. BC2GM004777845 . O
. . O O

This BC2GM050378714 DT O
article BC2GM050378714 NN O
expands BC2GM050378714 VBZ O
the BC2GM050378714 DT O
analysis BC2GM050378714 NN O
of BC2GM050378714 IN O
a BC2GM050378714 DT O
numeric BC2GM050378714 JJ O
example BC2GM050378714 NN O
included BC2GM050378714 VBD O
in BC2GM050378714 IN O
the BC2GM050378714 DT O
SAS BC2GM050378714 NNP O
GLM BC2GM050378714 NNP O
procedure BC2GM050378714 NN O
to BC2GM050378714 TO O
cover BC2GM050378714 VB O
several BC2GM050378714 JJ O
crucial BC2GM050378714 JJ O
statistical BC2GM050378714 JJ O
aspects BC2GM050378714 NNS O
relevant BC2GM050378714 VBP O
to BC2GM050378714 TO O
ANCOVA BC2GM050378714 NNP O
, BC2GM050378714 , O
and BC2GM050378714 CC O
to BC2GM050378714 TO O
highlight BC2GM050378714 VB O
the BC2GM050378714 DT O
meaning BC2GM050378714 NN O
of BC2GM050378714 IN O
the BC2GM050378714 DT O
statistical BC2GM050378714 JJ O
results BC2GM050378714 NNS O
obtained BC2GM050378714 VBD O
. BC2GM050378714 . O
. . O O

In BC2GM077752729 IN O
this BC2GM077752729 DT O
paper BC2GM077752729 NN O
we BC2GM077752729 PRP O
review BC2GM077752729 VBP O
evidence BC2GM077752729 NN O
on BC2GM077752729 IN O
smoking BC2GM077752729 NN O
and BC2GM077752729 CC O
lung BC2GM077752729 NN O
cancer BC2GM077752729 NN O
among BC2GM077752729 IN O
Latinos BC2GM077752729 NNP O
, BC2GM077752729 , O
including BC2GM077752729 VBG O
findings BC2GM077752729 NNS O
from BC2GM077752729 IN O
several BC2GM077752729 JJ O
unpublished BC2GM077752729 JJ O
studies BC2GM077752729 NNS O
and BC2GM077752729 CC O
technical BC2GM077752729 JJ O
reports BC2GM077752729 NNS O
. BC2GM077752729 . O
. . O O

Antibodies BC2GM071468863 NNS O
specific BC2GM071468863 VBP O
to BC2GM071468863 TO O
the BC2GM071468863 DT O
different BC2GM071468863 JJ O
members BC2GM071468863 NNS O
of BC2GM071468863 IN O
the BC2GM071468863 DT O
Jun BC2GM071468863 NNP O
and BC2GM071468863 CC O
Fos BC2GM071468863 NNP O
family BC2GM071468863 NN O
of BC2GM071468863 IN O
transcription BC2GM071468863 NN O
factors BC2GM071468863 NNS O
show BC2GM071468863 VBP O
that BC2GM071468863 IN O
, BC2GM071468863 , O
in BC2GM071468863 IN O
gel BC2GM071468863 JJ O
retardation BC2GM071468863 NN O
assays BC2GM071468863 NNS O
, BC2GM071468863 , O
a BC2GM071468863 DT O
Jun-like BC2GM071468863 JJ O
factor BC2GM071468863 NN O
is BC2GM071468863 VBZ O
a BC2GM071468863 DT O
component BC2GM071468863 NN O
of BC2GM071468863 IN O
the BC2GM071468863 DT O
H3.2 BC2GM071468863 NNP O
specific BC2GM071468863 JJ O
complex BC2GM071468863 NN O
. BC2GM071468863 . O
. . O O

The BC2GM052219408 DT O
region BC2GM052219408 NN O
surrounding BC2GM052219408 VBG O
the BC2GM052219408 DT O
ZNF35 BC2GM052219408 NNP O
zinc BC2GM052219408 NNP O
finger BC2GM052219408 NN O
protein BC2GM052219408 NN O
gene BC2GM052219408 NN O
on BC2GM052219408 IN O
3p21 BC2GM052219408 CD O
is BC2GM052219408 VBZ O
of BC2GM052219408 IN O
particular BC2GM052219408 JJ O
interest BC2GM052219408 NN O
, BC2GM052219408 , O
as BC2GM052219408 IN O
this BC2GM052219408 DT O
region BC2GM052219408 NN O
of BC2GM052219408 IN O
chromosome BC2GM052219408 NN O
3 BC2GM052219408 CD O
is BC2GM052219408 VBZ O
frequently BC2GM052219408 RB O
involved BC2GM052219408 VBN O
in BC2GM052219408 IN O
rearrangements BC2GM052219408 NNS O
and BC2GM052219408 CC O
/ BC2GM052219408 NN O
or BC2GM052219408 CC O
deletions BC2GM052219408 NNS O
associated BC2GM052219408 VBN O
with BC2GM052219408 IN O
various BC2GM052219408 JJ O
human BC2GM052219408 JJ O
tumors BC2GM052219408 NNS O
including BC2GM052219408 VBG O
lung BC2GM052219408 NN O
and BC2GM052219408 CC O
renal BC2GM052219408 JJ O
carcinoma BC2GM052219408 NN O
. BC2GM052219408 . O
. . O O

Also BC2GM012559118 RB O
, BC2GM012559118 , O
the BC2GM012559118 DT O
absence BC2GM012559118 NN O
of BC2GM012559118 IN O
PdNi BC2GM012559118 NNP O
between BC2GM012559118 IN O
the BC2GM012559118 DT O
segments BC2GM012559118 NNS O
reduces BC2GM012559118 VBZ O
the BC2GM012559118 DT O
heat BC2GM012559118 NN O
production BC2GM012559118 NN O
of BC2GM012559118 IN O
the BC2GM012559118 DT O
seed BC2GM012559118 NN O
. BC2GM012559118 . O
. . O O

The BC2GM097255960 DT O
mean BC2GM097255960 JJ O
serum BC2GM097255960 NN O
CDT BC2GM097255960 NNP O
increased BC2GM097255960 VBD O
from BC2GM097255960 IN O
8.5 BC2GM097255960 CD O
( BC2GM097255960 ( O
SD BC2GM097255960 NNP O
2.2 BC2GM097255960 CD O
) BC2GM097255960 ) O
U BC2GM097255960 NNP O
/ BC2GM097255960 NNP O
l BC2GM097255960 NN O
to BC2GM097255960 TO O
16.6 BC2GM097255960 CD O
( BC2GM097255960 ( O
SD BC2GM097255960 NNP O
7.2 BC2GM097255960 CD O
) BC2GM097255960 ) O
U BC2GM097255960 NNP O
/ BC2GM097255960 NNP O
l BC2GM097255960 NN O
( BC2GM097255960 ( O
P BC2GM097255960 NNP O
< BC2GM097255960 NNP O
0.001 BC2GM097255960 CD O
) BC2GM097255960 ) O
. BC2GM097255960 . O
. . O O

Protein BC2GM026311034 NNP O
metabolism BC2GM026311034 NN O
disorders BC2GM026311034 NNS O
in BC2GM026311034 IN O
burns BC2GM026311034 NNS O
. BC2GM026311034 . O
. . O O

Although BC2GM080710806 IN O
the BC2GM080710806 DT O
occurrence BC2GM080710806 NN O
of BC2GM080710806 IN O
any BC2GM080710806 DT O
ventricular BC2GM080710806 JJ O
ectopic BC2GM080710806 NN O
activity BC2GM080710806 NN O
, BC2GM080710806 , O
as BC2GM080710806 IN O
detected BC2GM080710806 VBN O
by BC2GM080710806 IN O
either BC2GM080710806 DT O
or BC2GM080710806 CC O
both BC2GM080710806 DT O
methods BC2GM080710806 NNS O
, BC2GM080710806 , O
was BC2GM080710806 VBD O
common BC2GM080710806 JJ O
, BC2GM080710806 , O
the BC2GM080710806 DT O
incidence BC2GM080710806 NN O
was BC2GM080710806 VBD O
significantly BC2GM080710806 RB O
higher BC2GM080710806 JJR O
( BC2GM080710806 ( O
P BC2GM080710806 NNP O
less BC2GM080710806 JJR O
than BC2GM080710806 IN O
0.001 BC2GM080710806 CD O
) BC2GM080710806 ) O
in BC2GM080710806 IN O
patients BC2GM080710806 NNS O
with BC2GM080710806 IN O
coronary BC2GM080710806 JJ O
heart BC2GM080710806 NN O
disease BC2GM080710806 NN O
( BC2GM080710806 ( O
86 BC2GM080710806 CD O
percent BC2GM080710806 NN O
; BC2GM080710806 : O
77 BC2GM080710806 CD O
/ BC2GM080710806 IN O
90 BC2GM080710806 CD O
) BC2GM080710806 ) O
, BC2GM080710806 , O
as BC2GM080710806 IN O
compared BC2GM080710806 VBN O
to BC2GM080710806 TO O
that BC2GM080710806 DT O
in BC2GM080710806 IN O
normal BC2GM080710806 JJ O
subjects BC2GM080710806 NNS O
( BC2GM080710806 ( O
40 BC2GM080710806 CD O
percent BC2GM080710806 NN O
; BC2GM080710806 : O
12 BC2GM080710806 CD O
/ BC2GM080710806 IN O
30 BC2GM080710806 CD O
) BC2GM080710806 ) O
. BC2GM080710806 . O
. . O O

These BC2GM015085481 DT O
data BC2GM015085481 NNS O
also BC2GM015085481 RB O
demonstrate BC2GM015085481 VBP O
that BC2GM015085481 IN O
insulin BC2GM015085481 NN O
and BC2GM015085481 CC O
TPA BC2GM015085481 NNP O
activate BC2GM015085481 VBP O
MBP BC2GM015085481 NNP O
/ BC2GM015085481 NNP O
MAP2 BC2GM015085481 NNP O
kinase BC2GM015085481 NN O
activity BC2GM015085481 NN O
by BC2GM015085481 IN O
de BC2GM015085481 FW O
novo BC2GM015085481 FW O
phosphorylation BC2GM015085481 NN O
of BC2GM015085481 IN O
threonine BC2GM015085481 NN O
and BC2GM015085481 CC O
tyrosine BC2GM015085481 NN O
residues BC2GM015085481 NNS O
via BC2GM015085481 IN O
a BC2GM015085481 DT O
very BC2GM015085481 RB O
similar BC2GM015085481 JJ O
pathway BC2GM015085481 NN O
. BC2GM015085481 . O
. . O O

Normal BC2GM070631455 JJ O
replication BC2GM070631455 NN O
of BC2GM070631455 IN O
DNA BC2GM070631455 NN O
A BC2GM070631455 NNP O
still BC2GM070631455 RB O
carrying BC2GM070631455 VBG O
the BC2GM070631455 DT O
AC3 BC2GM070631455 NNP O
ORF BC2GM070631455 NNP O
mutation BC2GM070631455 NN O
was BC2GM070631455 VBD O
found BC2GM070631455 VBN O
in BC2GM070631455 IN O
extracts BC2GM070631455 NNS O
from BC2GM070631455 IN O
these BC2GM070631455 DT O
plants BC2GM070631455 NNS O
. BC2GM070631455 . O
. . O O

The BC2GM059966403 DT O
KEMAR BC2GM059966403 NNP O
measurements BC2GM059966403 NNS O
show BC2GM059966403 VBP O
that BC2GM059966403 IN O
the BC2GM059966403 DT O
two BC2GM059966403 CD O
models BC2GM059966403 NNS O
give BC2GM059966403 VBP O
an BC2GM059966403 DT O
improvement BC2GM059966403 NN O
of BC2GM059966403 IN O
the BC2GM059966403 DT O
signal-to-noise BC2GM059966403 JJ O
ratio BC2GM059966403 NN O
of BC2GM059966403 IN O
approximately BC2GM059966403 RB O
7.5 BC2GM059966403 CD O
dB BC2GM059966403 NNS O
in BC2GM059966403 IN O
a BC2GM059966403 DT O
diffuse BC2GM059966403 NN O
sound BC2GM059966403 JJ O
field BC2GM059966403 NN O
. BC2GM059966403 . O
. . O O

This BC2GM049397374 DT O
inhibition BC2GM049397374 NN O
was BC2GM049397374 VBD O
due BC2GM049397374 JJ O
to BC2GM049397374 TO O
competition BC2GM049397374 NN O
from BC2GM049397374 IN O
the BC2GM049397374 DT O
EMC BC2GM049397374 NNP O
virus BC2GM049397374 NN O
IRES BC2GM049397374 NNP O
present BC2GM049397374 JJ O
in BC2GM049397374 IN O
pEP-2A BC2GM049397374 JJ O
transcripts BC2GM049397374 NNS O
, BC2GM049397374 , O
as BC2GM049397374 RB O
well BC2GM049397374 RB O
as BC2GM049397374 IN O
the BC2GM049397374 DT O
expression BC2GM049397374 NN O
of BC2GM049397374 IN O
proteolytically BC2GM049397374 RB O
active BC2GM049397374 JJ O
2Apro BC2GM049397374 CD O
. BC2GM049397374 . O
. . O O

The BC2GM056160161 DT O
centromeric BC2GM056160161 JJ O
dodeca-satellite BC2GM056160161 NN O
of BC2GM056160161 IN O
Drosophila BC2GM056160161 NNP O
forms BC2GM056160161 NNS O
altered BC2GM056160161 VBD O
DNA BC2GM056160161 NNP O
structures BC2GM056160161 NNS O
in BC2GM056160161 IN O
vitro BC2GM056160161 NN O
in BC2GM056160161 IN O
which BC2GM056160161 WDT O
its BC2GM056160161 PRP$ O
purine-rich BC2GM056160161 JJ O
strand BC2GM056160161 NN O
( BC2GM056160161 ( O
G-strand BC2GM056160161 NNP O
) BC2GM056160161 ) O
forms BC2GM056160161 VBZ O
stable BC2GM056160161 JJ O
fold-back BC2GM056160161 JJ O
structures BC2GM056160161 NNS O
, BC2GM056160161 , O
while BC2GM056160161 IN O
the BC2GM056160161 DT O
complementary BC2GM056160161 JJ O
C-strand BC2GM056160161 NNP O
remains BC2GM056160161 VBZ O
unstructured BC2GM056160161 JJ O
. BC2GM056160161 . O
. . O O

MGF BC2GM033980745 NNP O
is BC2GM033980745 VBZ O
a BC2GM033980745 DT O
novel BC2GM033980745 JJ O
member BC2GM033980745 NN O
of BC2GM033980745 IN O
the BC2GM033980745 DT O
cytokine-regulated BC2GM033980745 JJ O
transcription BC2GM033980745 NN O
factor BC2GM033980745 NN O
gene BC2GM033980745 NN O
family BC2GM033980745 NN O
. BC2GM033980745 . O
. . O O

Ultraviolet BC2GM086763772 NNP O
crosslinking BC2GM086763772 VBG O
experiments BC2GM086763772 NNS O
using BC2GM086763772 VBG O
element BC2GM086763772 NN O
B BC2GM086763772 NNP O
revealed BC2GM086763772 VBD O
the BC2GM086763772 DT O
specific BC2GM086763772 JJ O
binding BC2GM086763772 NN O
of BC2GM086763772 IN O
two BC2GM086763772 CD O
proteins BC2GM086763772 NNS O
of BC2GM086763772 IN O
approximately BC2GM086763772 RB O
43 BC2GM086763772 CD O
and BC2GM086763772 CC O
80 BC2GM086763772 CD O
kDa BC2GM086763772 NN O
. BC2GM086763772 . O
. . O O

When BC2GM044659370 WRB O
severe BC2GM044659370 JJ O
hypoxia BC2GM044659370 NN O
was BC2GM044659370 VBD O
acutely BC2GM044659370 RB O
produced BC2GM044659370 VBN O
by BC2GM044659370 IN O
ventilation BC2GM044659370 NN O
with BC2GM044659370 IN O
low-oxygen BC2GM044659370 JJ O
mixtures BC2GM044659370 NNS O
in BC2GM044659370 IN O
experimental BC2GM044659370 JJ O
( BC2GM044659370 ( O
PaO2 BC2GM044659370 NNP O
, BC2GM044659370 , O
23.7 BC2GM044659370 CD O
+ BC2GM044659370 NN O
/ BC2GM044659370 NNP O
- BC2GM044659370 : O
1.7 BC2GM044659370 CD O
torr BC2GM044659370 NN O
) BC2GM044659370 ) O
and BC2GM044659370 CC O
control BC2GM044659370 NN O
animals BC2GM044659370 NNS O
( BC2GM044659370 ( O
PaO2 BC2GM044659370 NNP O
, BC2GM044659370 , O
26.3 BC2GM044659370 CD O
+ BC2GM044659370 NN O
/ BC2GM044659370 NNP O
- BC2GM044659370 : O
1.0 BC2GM044659370 CD O
torr BC2GM044659370 NN O
) BC2GM044659370 ) O
, BC2GM044659370 , O
plasma BC2GM044659370 JJ O
insulin BC2GM044659370 NN O
responses BC2GM044659370 NNS O
were BC2GM044659370 VBD O
markedly BC2GM044659370 RB O
inhibited BC2GM044659370 VBN O
in BC2GM044659370 IN O
both BC2GM044659370 DT O
. BC2GM044659370 . O
. . O O

Reasons BC2GM042452037 NNS O
are BC2GM042452037 VBP O
presented BC2GM042452037 VBN O
to BC2GM042452037 TO O
support BC2GM042452037 VB O
the BC2GM042452037 DT O
contention BC2GM042452037 NN O
that BC2GM042452037 IN O
this BC2GM042452037 DT O
increase BC2GM042452037 NN O
is BC2GM042452037 VBZ O
in BC2GM042452037 IN O
part BC2GM042452037 NN O
real BC2GM042452037 JJ O
. BC2GM042452037 . O
. . O O

These BC2GM089338443 DT O
findings BC2GM089338443 NNS O
suggest BC2GM089338443 VBP O
that BC2GM089338443 IN O
NMDA BC2GM089338443 NNP O
receptor BC2GM089338443 NN O
blockade BC2GM089338443 NN O
may BC2GM089338443 MD O
ameliorate BC2GM089338443 VB O
the BC2GM089338443 DT O
dyskinetic BC2GM089338443 JJ O
complications BC2GM089338443 NNS O
of BC2GM089338443 IN O
long-term BC2GM089338443 JJ O
levodopa BC2GM089338443 NN O
therapy BC2GM089338443 NN O
, BC2GM089338443 , O
without BC2GM089338443 IN O
diminishing BC2GM089338443 VBG O
the BC2GM089338443 DT O
beneficial BC2GM089338443 JJ O
effects BC2GM089338443 NNS O
on BC2GM089338443 IN O
parkinsonian BC2GM089338443 JJ O
signs BC2GM089338443 NNS O
. BC2GM089338443 . O
. . O O

Effect BC2GM083230779 NN O
of BC2GM083230779 IN O
TNF BC2GM083230779 NNP O
, BC2GM083230779 , O
IL-1 BC2GM083230779 NNP O
, BC2GM083230779 , O
and BC2GM083230779 CC O
IL-6 BC2GM083230779 NNP O
on BC2GM083230779 IN O
the BC2GM083230779 DT O
proliferation BC2GM083230779 NN O
of BC2GM083230779 IN O
human BC2GM083230779 JJ O
Tenon BC2GM083230779 NNP O
's BC2GM083230779 POS O
capsule BC2GM083230779 NN O
fibroblasts BC2GM083230779 NNS O
in BC2GM083230779 IN O
tissue BC2GM083230779 NN O
culture BC2GM083230779 NN O
. BC2GM083230779 . O
. . O O

We BC2GM057358124 PRP O
have BC2GM057358124 VBP O
analyzed BC2GM057358124 VBN O
the BC2GM057358124 DT O
function BC2GM057358124 NN O
of BC2GM057358124 IN O
these BC2GM057358124 DT O
putative BC2GM057358124 JJ O
SL BC2GM057358124 NNP O
structures BC2GM057358124 NNS O
in BC2GM057358124 IN O
RNA BC2GM057358124 NNP O
translation BC2GM057358124 NN O
by BC2GM057358124 IN O
constructing BC2GM057358124 VBG O
chimeric BC2GM057358124 JJ O
chloramphenicol BC2GM057358124 NN O
acetyltransferase BC2GM057358124 NN O
( BC2GM057358124 ( O
CAT BC2GM057358124 NNP O
) BC2GM057358124 ) O
RNAs BC2GM057358124 NNP O
, BC2GM057358124 , O
flanked BC2GM057358124 VBD O
either BC2GM057358124 CC O
by BC2GM057358124 IN O
both BC2GM057358124 DT O
5'- BC2GM057358124 JJ O
and BC2GM057358124 CC O
3'-terminal BC2GM057358124 JJ O
sequence BC2GM057358124 NN O
domains BC2GM057358124 NNS O
from BC2GM057358124 IN O
the BC2GM057358124 DT O
RV BC2GM057358124 NNP O
genome BC2GM057358124 NN O
or BC2GM057358124 CC O
several BC2GM057358124 JJ O
deletion BC2GM057358124 NN O
derivatives BC2GM057358124 NNS O
of BC2GM057358124 IN O
the BC2GM057358124 DT O
same BC2GM057358124 JJ O
sequences BC2GM057358124 NNS O
. BC2GM057358124 . O
. . O O

The BC2GM080802212 DT O
decision BC2GM080802212 NN O
support BC2GM080802212 NN O
system BC2GM080802212 NN O
uses BC2GM080802212 VBZ O
the BC2GM080802212 DT O
network BC2GM080802212 NN O
at BC2GM080802212 IN O
its BC2GM080802212 PRP$ O
core BC2GM080802212 NN O
and BC2GM080802212 CC O
helps BC2GM080802212 VBZ O
not BC2GM080802212 RB O
only BC2GM080802212 RB O
in BC2GM080802212 IN O
reaching BC2GM080802212 VBG O
a BC2GM080802212 DT O
diagnosis BC2GM080802212 NN O
but BC2GM080802212 CC O
also BC2GM080802212 RB O
in BC2GM080802212 IN O
finding BC2GM080802212 VBG O
the BC2GM080802212 DT O
optimal BC2GM080802212 JJ O
way BC2GM080802212 NN O
to BC2GM080802212 TO O
reach BC2GM080802212 VB O
that BC2GM080802212 DT O
diagnosis BC2GM080802212 NN O
. BC2GM080802212 . O
. . O O

NSD1 BC2GM034218044 NNP O
contains BC2GM034218044 VBZ O
a BC2GM034218044 DT O
SET BC2GM034218044 NNP O
domain BC2GM034218044 NN O
and BC2GM034218044 CC O
multiple BC2GM034218044 JJ O
PHD BC2GM034218044 NNP O
fingers BC2GM034218044 NNS O
. BC2GM034218044 . O
. . O O

Fusion BC2GM062196323 NN O
of BC2GM062196323 IN O
mouse BC2GM062196323 NN O
CD8+ BC2GM062196323 NNP O
class BC2GM062196323 NN O
I BC2GM062196323 PRP O
MHC-restricted BC2GM062196323 JJ O
T BC2GM062196323 NNP O
cells BC2GM062196323 NNS O
with BC2GM062196323 IN O
the BC2GM062196323 DT O
BW5147 BC2GM062196323 NNP O
thymoma BC2GM062196323 NN O
invariably BC2GM062196323 RB O
yields BC2GM062196323 VBZ O
CD8- BC2GM062196323 NNP O
hybridomas BC2GM062196323 NN O
in BC2GM062196323 IN O
which BC2GM062196323 WDT O
RNA BC2GM062196323 NNP O
transcribed BC2GM062196323 VBD O
from BC2GM062196323 IN O
the BC2GM062196323 DT O
CD8 BC2GM062196323 NNP O
alpha BC2GM062196323 NN O
( BC2GM062196323 ( O
Lyt-2 BC2GM062196323 NNP O
) BC2GM062196323 ) O
gene BC2GM062196323 NN O
is BC2GM062196323 VBZ O
undetectable BC2GM062196323 JJ O
. BC2GM062196323 . O
. . O O

Chronic BC2GM067940878 NNP O
active BC2GM067940878 JJ O
hepatitis BC2GM067940878 NN O
and BC2GM067940878 CC O
pregnancy BC2GM067940878 NN O
. BC2GM067940878 . O
. . O O

Both BC2GM084800882 DT O
proteins BC2GM084800882 NNS O
share BC2GM084800882 NN O
sequence BC2GM084800882 NN O
similarity BC2GM084800882 NN O
with BC2GM084800882 IN O
the BC2GM084800882 DT O
myelin-associated BC2GM084800882 JJ O
glycoprotein BC2GM084800882 NN O
, BC2GM084800882 , O
an BC2GM084800882 DT O
adhesion BC2GM084800882 NN O
molecule BC2GM084800882 NN O
of BC2GM084800882 IN O
oligodendrocytes BC2GM084800882 NNS O
and BC2GM084800882 CC O
Schwann BC2GM084800882 NNP O
cells BC2GM084800882 NNS O
that BC2GM084800882 WDT O
has BC2GM084800882 VBZ O
been BC2GM084800882 VBN O
implicated BC2GM084800882 VBN O
in BC2GM084800882 IN O
the BC2GM084800882 DT O
process BC2GM084800882 NN O
of BC2GM084800882 IN O
myelination BC2GM084800882 NN O
, BC2GM084800882 , O
raising BC2GM084800882 VBG O
the BC2GM084800882 DT O
important BC2GM084800882 JJ O
question BC2GM084800882 NN O
of BC2GM084800882 IN O
whether BC2GM084800882 IN O
myelin-associated BC2GM084800882 JJ O
glycoprotein BC2GM084800882 NN O
is BC2GM084800882 VBZ O
also BC2GM084800882 RB O
a BC2GM084800882 DT O
sialic BC2GM084800882 JJ O
acid-binding BC2GM084800882 JJ O
protein BC2GM084800882 NN O
. BC2GM084800882 . O
. . O O

The BC2GM034188692 DT O
site BC2GM034188692 NN O
of BC2GM034188692 IN O
acetylation BC2GM034188692 NN O
of BC2GM034188692 IN O
Tat BC2GM034188692 NNP O
was BC2GM034188692 VBD O
mapped BC2GM034188692 VBN O
to BC2GM034188692 TO O
the BC2GM034188692 DT O
double-lysine BC2GM034188692 JJ O
motif BC2GM034188692 NN O
in BC2GM034188692 IN O
a BC2GM034188692 DT O
highly BC2GM034188692 RB O
conserved BC2GM034188692 JJ O
region BC2GM034188692 NN O
, BC2GM034188692 , O
( BC2GM034188692 ( O
49 BC2GM034188692 CD O
) BC2GM034188692 ) O
RKKRRQ BC2GM034188692 NNP O
( BC2GM034188692 ( O
54 BC2GM034188692 CD O
) BC2GM034188692 ) O
, BC2GM034188692 , O
of BC2GM034188692 IN O
the BC2GM034188692 DT O
basic BC2GM034188692 JJ O
RNA-binding BC2GM034188692 JJ O
motif BC2GM034188692 NN O
of BC2GM034188692 IN O
Tat BC2GM034188692 NNP O
. BC2GM034188692 . O
. . O O

On BC2GM026280361 IN O
day BC2GM026280361 NN O
1 BC2GM026280361 CD O
at BC2GM026280361 IN O
3500 BC2GM026280361 CD O
m BC2GM026280361 NN O
, BC2GM026280361 , O
RI BC2GM026280361 NNP O
showed BC2GM026280361 VBD O
a BC2GM026280361 DT O
significant BC2GM026280361 JJ O
fall BC2GM026280361 NN O
in BC2GM026280361 IN O
body BC2GM026280361 NN O
weight BC2GM026280361 NN O
( BC2GM026280361 ( O
BW BC2GM026280361 NNP O
) BC2GM026280361 ) O
with BC2GM026280361 IN O
respect BC2GM026280361 NN O
to BC2GM026280361 TO O
SL BC2GM026280361 NNP O
but BC2GM026280361 CC O
AI BC2GM026280361 NNP O
maintained BC2GM026280361 VBD O
it BC2GM026280361 PRP O
. BC2GM026280361 . O
. . O O

Histological BC2GM087023573 NNP O
and BC2GM087023573 CC O
immunophenotypic BC2GM087023573 JJ O
studies BC2GM087023573 NNS O
revealed BC2GM087023573 VBD O
12 BC2GM087023573 CD O
large BC2GM087023573 JJ O
cell BC2GM087023573 NN O
lymphomas BC2GM087023573 NN O
( BC2GM087023573 ( O
11 BC2GM087023573 CD O
B BC2GM087023573 NNP O
cell BC2GM087023573 NN O
and BC2GM087023573 CC O
one BC2GM087023573 CD O
T BC2GM087023573 NNP O
cell BC2GM087023573 NN O
) BC2GM087023573 ) O
, BC2GM087023573 , O
two BC2GM087023573 CD O
small BC2GM087023573 JJ O
noncleaved BC2GM087023573 VBD O
cell BC2GM087023573 NN O
lymphomas BC2GM087023573 NN O
( BC2GM087023573 ( O
B-cell BC2GM087023573 NNP O
phenotype BC2GM087023573 NN O
) BC2GM087023573 ) O
, BC2GM087023573 , O
and BC2GM087023573 CC O
five BC2GM087023573 CD O
low BC2GM087023573 JJ O
grade BC2GM087023573 NN O
B-cell BC2GM087023573 NNP O
lymphomas BC2GM087023573 NN O
( BC2GM087023573 ( O
two BC2GM087023573 CD O
small BC2GM087023573 JJ O
lymphocytic BC2GM087023573 JJ O
and BC2GM087023573 CC O
three BC2GM087023573 CD O
follicular BC2GM087023573 JJ O
mixed BC2GM087023573 JJ O
lymphomas BC2GM087023573 NN O
) BC2GM087023573 ) O
. BC2GM087023573 . O
. . O O

In BC2GM072960583 IN O
previous BC2GM072960583 JJ O
studies BC2GM072960583 NNS O
, BC2GM072960583 , O
we BC2GM072960583 PRP O
showed BC2GM072960583 VBD O
that BC2GM072960583 IN O
the BC2GM072960583 DT O
nuclear BC2GM072960583 JJ O
import BC2GM072960583 NN O
of BC2GM072960583 IN O
SREBP-2 BC2GM072960583 NNP O
occurs BC2GM072960583 NNS O
via BC2GM072960583 IN O
the BC2GM072960583 DT O
direct BC2GM072960583 JJ O
interaction BC2GM072960583 NN O
of BC2GM072960583 IN O
importin BC2GM072960583 JJ O
beta BC2GM072960583 NN O
with BC2GM072960583 IN O
the BC2GM072960583 DT O
HLH-Zip BC2GM072960583 NNP O
domain BC2GM072960583 NN O
. BC2GM072960583 . O
. . O O

Recombinant BC2GM015638731 JJ O
protein BC2GM015638731 NN O
encoded BC2GM015638731 VBN O
by BC2GM015638731 IN O
ESX BC2GM015638731 NNP O
( BC2GM015638731 ( O
for BC2GM015638731 IN O
epithelial-restricted BC2GM015638731 JJ O
with BC2GM015638731 IN O
serine BC2GM015638731 JJ O
box BC2GM015638731 NN O
) BC2GM015638731 ) O
exhibits BC2GM015638731 VBZ O
Ets-like BC2GM015638731 JJ O
DNA BC2GM015638731 NNP O
binding BC2GM015638731 NN O
specificity BC2GM015638731 NN O
in BC2GM015638731 IN O
electrophoretic BC2GM015638731 JJ O
mobility BC2GM015638731 NN O
shift BC2GM015638731 NN O
assays BC2GM015638731 NNS O
and BC2GM015638731 CC O
, BC2GM015638731 , O
in BC2GM015638731 IN O
transient BC2GM015638731 JJ O
transfection BC2GM015638731 NN O
assays BC2GM015638731 NNS O
, BC2GM015638731 , O
transactivates BC2GM015638731 VBZ O
Ets-responsive BC2GM015638731 JJ O
promoter BC2GM015638731 NN O
elements BC2GM015638731 NNS O
including BC2GM015638731 VBG O
that BC2GM015638731 DT O
found BC2GM015638731 VBD O
in BC2GM015638731 IN O
the BC2GM015638731 DT O
HER2 BC2GM015638731 NNP O
/ BC2GM015638731 NNP O
neu BC2GM015638731 JJ O
oncogene BC2GM015638731 NN O
. BC2GM015638731 . O
. . O O

The BC2GM047470331 DT O
human BC2GM047470331 JJ O
SHBG BC2GM047470331 NNP O
proximal BC2GM047470331 NN O
promoter BC2GM047470331 NN O
was BC2GM047470331 VBD O
analyzed BC2GM047470331 VBN O
by BC2GM047470331 IN O
DNase BC2GM047470331 NNP O
I BC2GM047470331 PRP O
footprinting BC2GM047470331 VBP O
, BC2GM047470331 , O
and BC2GM047470331 CC O
the BC2GM047470331 DT O
functional BC2GM047470331 JJ O
significance BC2GM047470331 NN O
of BC2GM047470331 IN O
6 BC2GM047470331 CD O
footprinted BC2GM047470331 JJ O
regions BC2GM047470331 NNS O
( BC2GM047470331 ( O
FP1-FP6 BC2GM047470331 NNP O
) BC2GM047470331 ) O
within BC2GM047470331 IN O
the BC2GM047470331 DT O
proximal BC2GM047470331 JJ O
promoter BC2GM047470331 NN O
was BC2GM047470331 VBD O
studied BC2GM047470331 VBN O
in BC2GM047470331 IN O
human BC2GM047470331 JJ O
HepG2 BC2GM047470331 NNP O
hepatoblastoma BC2GM047470331 NN O
cells BC2GM047470331 NNS O
. BC2GM047470331 . O
. . O O

Electronic BC2GM008458026 JJ O
structure BC2GM008458026 NN O
of BC2GM008458026 IN O
Si BC2GM008458026 NNP O
( BC2GM008458026 ( O
111 BC2GM008458026 CD O
) BC2GM008458026 ) O
-NiSi2 BC2GM008458026 NN O
( BC2GM008458026 ( O
111 BC2GM008458026 CD O
) BC2GM008458026 ) O
A-type BC2GM008458026 NN O
and BC2GM008458026 CC O
B-type BC2GM008458026 JJ O
interfaces BC2GM008458026 NNS O
. BC2GM008458026 . O
. . O O

Anatomical BC2GM011249269 JJ O
considerations BC2GM011249269 NNS O
in BC2GM011249269 IN O
transsphenoidal BC2GM011249269 JJ O
hypophysectomy BC2GM011249269 NN O
. BC2GM011249269 . O
. . O O

Off-shell BC2GM035650199 NNP O
effect BC2GM035650199 NN O
in BC2GM035650199 IN O
Rydberg-atom-alkali-metal-atom BC2GM035650199 NNP O
scattering BC2GM035650199 NN O
. BC2GM035650199 . O
. . O O

Second BC2GM044561188 JJ O
, BC2GM044561188 , O
overexpression BC2GM044561188 NN O
of BC2GM044561188 IN O
RIM11 BC2GM044561188 NNP O
can BC2GM044561188 MD O
suppress BC2GM044561188 VB O
an BC2GM044561188 DT O
ime1 BC2GM044561188 NN O
missense BC2GM044561188 NN O
mutation BC2GM044561188 NN O
( BC2GM044561188 ( O
ime1-L321F BC2GM044561188 JJ O
) BC2GM044561188 ) O
but BC2GM044561188 CC O
not BC2GM044561188 RB O
an BC2GM044561188 DT O
ime1 BC2GM044561188 JJ O
deletion BC2GM044561188 NN O
. BC2GM044561188 . O
. . O O

Acute BC2GM012340535 JJ O
intoxication BC2GM012340535 NN O
with BC2GM012340535 IN O
cypermethrin BC2GM012340535 NN O
( BC2GM012340535 ( O
NRDC BC2GM012340535 NNP O
149 BC2GM012340535 CD O
) BC2GM012340535 ) O
. BC2GM012340535 . O
. . O O

Should BC2GM047847482 MD O
we BC2GM047847482 PRP O
use BC2GM047847482 VB O
thiazide BC2GM047847482 JJ O
diuretics BC2GM047847482 NNS O
in BC2GM047847482 IN O
hypertensive BC2GM047847482 JJ O
patients BC2GM047847482 NNS O
with BC2GM047847482 IN O
non-insulin-dependent BC2GM047847482 JJ O
diabetes BC2GM047847482 NNS O
mellitus BC2GM047847482 NN O
? BC2GM047847482 . O
. BC2GM047847482 . O
. . O O

CYP51P1 BC2GM009549697 NNP O
is BC2GM009549697 VBZ O
96.5 BC2GM009549697 CD O
% BC2GM009549697 NN O
identical BC2GM009549697 JJ O
to BC2GM009549697 TO O
the BC2GM009549697 DT O
human BC2GM009549697 JJ O
CYP51 BC2GM009549697 NNP O
coding BC2GM009549697 NN O
sequence BC2GM009549697 NN O
and BC2GM009549697 CC O
is BC2GM009549697 VBZ O
not BC2GM009549697 RB O
interrupted BC2GM009549697 VBN O
with BC2GM009549697 IN O
introns BC2GM009549697 NNS O
but BC2GM009549697 CC O
has BC2GM009549697 VBZ O
six BC2GM009549697 CD O
in-frame BC2GM009549697 JJ O
stop BC2GM009549697 NN O
codons BC2GM009549697 NNS O
resulting BC2GM009549697 VBG O
from BC2GM009549697 IN O
point BC2GM009549697 NN O
mutations BC2GM009549697 NNS O
. BC2GM009549697 . O
. . O O

For BC2GM018288795 IN O
il8ra BC2GM018288795 NN O
, BC2GM018288795 , O
it BC2GM018288795 PRP O
is BC2GM018288795 VBZ O
formed BC2GM018288795 VBN O
from BC2GM018288795 IN O
two BC2GM018288795 CD O
exons BC2GM018288795 NNS O
, BC2GM018288795 , O
whereas BC2GM018288795 NNS O
for BC2GM018288795 IN O
il8rb BC2GM018288795 NN O
, BC2GM018288795 , O
seven BC2GM018288795 CD O
distinct BC2GM018288795 JJ O
neutrophil BC2GM018288795 JJ O
mRNAs BC2GM018288795 NN O
are BC2GM018288795 VBP O
formed BC2GM018288795 VBN O
by BC2GM018288795 IN O
alternative BC2GM018288795 JJ O
splicing BC2GM018288795 NN O
of BC2GM018288795 IN O
11 BC2GM018288795 CD O
exons BC2GM018288795 NNS O
. BC2GM018288795 . O
. . O O

We BC2GM051838944 PRP O
speculate BC2GM051838944 VBP O
that BC2GM051838944 IN O
the BC2GM051838944 DT O
enhancing BC2GM051838944 VBG O
effect BC2GM051838944 NN O
of BC2GM051838944 IN O
glucose BC2GM051838944 NN O
and BC2GM051838944 CC O
galactose BC2GM051838944 VB O
on BC2GM051838944 IN O
fructose BC2GM051838944 JJ O
absorption BC2GM051838944 NN O
may BC2GM051838944 MD O
be BC2GM051838944 VB O
due BC2GM051838944 JJ O
to BC2GM051838944 TO O
activation BC2GM051838944 NN O
of BC2GM051838944 IN O
the BC2GM051838944 DT O
fructose BC2GM051838944 NN O
carrier BC2GM051838944 NN O
. BC2GM051838944 . O
. . O O

Finally BC2GM094127714 RB O
, BC2GM094127714 , O
the BC2GM094127714 DT O
conservation BC2GM094127714 NN O
of BC2GM094127714 IN O
the BC2GM094127714 DT O
two BC2GM094127714 CD O
residues BC2GM094127714 NNS O
most BC2GM094127714 RBS O
sensitive BC2GM094127714 JJ O
to BC2GM094127714 TO O
mutations BC2GM094127714 NNS O
( BC2GM094127714 ( O
Y949 BC2GM094127714 NNP O
and BC2GM094127714 CC O
Y953 BC2GM094127714 NNP O
) BC2GM094127714 ) O
in BC2GM094127714 IN O
TM11 BC2GM094127714 NNP O
, BC2GM094127714 , O
and BC2GM094127714 CC O
in BC2GM094127714 IN O
the BC2GM094127714 DT O
homologous BC2GM094127714 JJ O
TM5 BC2GM094127714 NNP O
, BC2GM094127714 , O
of BC2GM094127714 IN O
all BC2GM094127714 DT O
mammalian BC2GM094127714 JJ O
P-gps BC2GM094127714 NNP O
and BC2GM094127714 CC O
also BC2GM094127714 RB O
in BC2GM094127714 IN O
other BC2GM094127714 JJ O
ABC BC2GM094127714 NNP O
transporters BC2GM094127714 NNS O
, BC2GM094127714 , O
suggests BC2GM094127714 VBZ O
that BC2GM094127714 IN O
these BC2GM094127714 DT O
residues BC2GM094127714 NNS O
and BC2GM094127714 CC O
domains BC2GM094127714 NNS O
may BC2GM094127714 MD O
play BC2GM094127714 VB O
an BC2GM094127714 DT O
important BC2GM094127714 JJ O
role BC2GM094127714 NN O
in BC2GM094127714 IN O
structural BC2GM094127714 JJ O
as BC2GM094127714 RB O
well BC2GM094127714 RB O
as BC2GM094127714 IN O
mechanistic BC2GM094127714 JJ O
aspects BC2GM094127714 NNS O
common BC2GM094127714 JJ O
to BC2GM094127714 TO O
this BC2GM094127714 DT O
family BC2GM094127714 NN O
of BC2GM094127714 IN O
proteins BC2GM094127714 NNS O
. BC2GM094127714 . O
. . O O

Arterial BC2GM079148945 JJ O
compliance BC2GM079148945 NN O
measurements BC2GM079148945 NNS O
using BC2GM079148945 VBG O
intraarterial BC2GM079148945 JJ O
pulse BC2GM079148945 JJ O
contour BC2GM079148945 NN O
analysis BC2GM079148945 NN O
and BC2GM079148945 CC O
a BC2GM079148945 DT O
modified BC2GM079148945 JJ O
Windkessel BC2GM079148945 NNP O
model BC2GM079148945 NN O
were BC2GM079148945 VBD O
carried BC2GM079148945 VBN O
out BC2GM079148945 IN O
in BC2GM079148945 IN O
19 BC2GM079148945 CD O
patients BC2GM079148945 NNS O
with BC2GM079148945 IN O
isolated BC2GM079148945 JJ O
systolic BC2GM079148945 JJ O
hypertension BC2GM079148945 NN O
( BC2GM079148945 ( O
> BC2GM079148945 CD O
or BC2GM079148945 CC O
= BC2GM079148945 VB O
160 BC2GM079148945 CD O
/ BC2GM079148945 JJ O
< BC2GM079148945 NN O
or BC2GM079148945 CC O
= BC2GM079148945 $ O
90 BC2GM079148945 CD O
mm BC2GM079148945 NN O
Hg BC2GM079148945 NNP O
) BC2GM079148945 ) O
and BC2GM079148945 CC O
compared BC2GM079148945 VBN O
to BC2GM079148945 TO O
measurements BC2GM079148945 NNS O
in BC2GM079148945 IN O
29 BC2GM079148945 CD O
patients BC2GM079148945 NNS O
with BC2GM079148945 IN O
essential BC2GM079148945 JJ O
hypertension BC2GM079148945 NN O
( BC2GM079148945 ( O
diastolic BC2GM079148945 JJ O
blood BC2GM079148945 NN O
pressure BC2GM079148945 NN O
[ BC2GM079148945 NNP O
BP BC2GM079148945 NNP O
] BC2GM079148945 NNP O
> BC2GM079148945 NNP O
or BC2GM079148945 CC O
= BC2GM079148945 $ O
95 BC2GM079148945 CD O
mm BC2GM079148945 NN O
Hg BC2GM079148945 NNP O
) BC2GM079148945 ) O
and BC2GM079148945 CC O
47 BC2GM079148945 CD O
normotensive BC2GM079148945 JJ O
control BC2GM079148945 NN O
subjects BC2GM079148945 NNS O
. BC2GM079148945 . O
. . O O

One BC2GM066107969 CD O
cytoplasmic BC2GM066107969 NN O
target BC2GM066107969 NN O
which BC2GM066107969 WDT O
reflects BC2GM066107969 VBZ O
the BC2GM066107969 DT O
functional BC2GM066107969 JJ O
state BC2GM066107969 NN O
of BC2GM066107969 IN O
the BC2GM066107969 DT O
plastids BC2GM066107969 NNS O
is BC2GM066107969 VBZ O
protein BC2GM066107969 JJ O
kinase BC2GM066107969 NN O
C BC2GM066107969 NNP O
. BC2GM066107969 . O
. . O O

Additionally BC2GM066585108 RB O
, BC2GM066585108 , O
the BC2GM066585108 DT O
members BC2GM066585108 NNS O
of BC2GM066585108 IN O
this BC2GM066585108 DT O
family BC2GM066585108 NN O
display BC2GM066585108 NN O
strong BC2GM066585108 JJ O
sequence BC2GM066585108 NN O
homologies BC2GM066585108 NNS O
between BC2GM066585108 IN O
their BC2GM066585108 PRP$ O
larger BC2GM066585108 JJR O
C-terminal BC2GM066585108 JJ O
effector BC2GM066585108 NN O
binding BC2GM066585108 VBG O
/ BC2GM066585108 JJ O
oligomerization BC2GM066585108 NN O
domains BC2GM066585108 NNS O
. BC2GM066585108 . O
. . O O

A BC2GM092243053 DT O
novel BC2GM092243053 JJ O
protein BC2GM092243053 NN O
kinase BC2GM092243053 NN O
C BC2GM092243053 NNP O
( BC2GM092243053 ( O
PKC BC2GM092243053 NNP O
) BC2GM092243053 ) O
-interacting BC2GM092243053 VBG O
protein BC2GM092243053 NN O
was BC2GM092243053 VBD O
identified BC2GM092243053 VBN O
by BC2GM092243053 IN O
the BC2GM092243053 DT O
yeast BC2GM092243053 JJ O
two-hybrid BC2GM092243053 JJ O
screening BC2GM092243053 NN O
using BC2GM092243053 VBG O
the BC2GM092243053 DT O
regulatory BC2GM092243053 JJ O
domain BC2GM092243053 NN O
of BC2GM092243053 IN O
PKC BC2GM092243053 NNP O
beta BC2GM092243053 NN O
I BC2GM092243053 PRP O
as BC2GM092243053 IN O
a BC2GM092243053 DT O
bait BC2GM092243053 NN O
. BC2GM092243053 . O
. . O O

Activation BC2GM024271469 NN O
of BC2GM024271469 IN O
tyrosine BC2GM024271469 JJ O
kinase-containing BC2GM024271469 JJ O
receptors BC2GM024271469 NNS O
, BC2GM024271469 , O
heterotrimeric BC2GM024271469 JJ O
G BC2GM024271469 NNP O
proteins BC2GM024271469 NNS O
, BC2GM024271469 , O
and BC2GM024271469 CC O
protein BC2GM024271469 JJ O
kinase BC2GM024271469 NN O
C BC2GM024271469 NNP O
enhanced BC2GM024271469 VBD O
the BC2GM024271469 DT O
activities BC2GM024271469 NNS O
of BC2GM024271469 IN O
both BC2GM024271469 DT O
MEK BC2GM024271469 NNP O
isoforms BC2GM024271469 NNS O
in BC2GM024271469 IN O
293 BC2GM024271469 CD O
and BC2GM024271469 CC O
PC12 BC2GM024271469 NNP O
cells BC2GM024271469 NNS O
. BC2GM024271469 . O
. . O O

Hepatitis BC2GM032192885 NN O
B BC2GM032192885 NNP O
markers BC2GM032192885 NNS O
in BC2GM032192885 IN O
Lancashire BC2GM032192885 NNP O
police BC2GM032192885 NN O
officers BC2GM032192885 NNS O
. BC2GM032192885 . O
. . O O

The BC2GM066700172 DT O
N-terminal BC2GM066700172 JJ O
exon1 BC2GM066700172 NN O
had BC2GM066700172 VBD O
no BC2GM066700172 DT O
homology BC2GM066700172 NN O
at BC2GM066700172 IN O
the BC2GM066700172 DT O
amino BC2GM066700172 NN O
acid BC2GM066700172 JJ O
level BC2GM066700172 NN O
with BC2GM066700172 IN O
NGFI-B BC2GM066700172 NNP O
, BC2GM066700172 , O
the BC2GM066700172 DT O
mammalian BC2GM066700172 JJ O
homologue BC2GM066700172 NN O
. BC2GM066700172 . O
. . O O

Cotransfection BC2GM041907191 NN O
of BC2GM041907191 IN O
expression BC2GM041907191 NN O
plasmids BC2GM041907191 NNS O
encoding BC2GM041907191 VBG O
the BC2GM041907191 DT O
protein BC2GM041907191 NN O
kinase BC2GM041907191 VBD O
A BC2GM041907191 NNP O
inhibitor BC2GM041907191 NN O
, BC2GM041907191 , O
or BC2GM041907191 CC O
an BC2GM041907191 DT O
inactive BC2GM041907191 JJ O
protein BC2GM041907191 NN O
kinase BC2GM041907191 VB O
A BC2GM041907191 NNP O
( BC2GM041907191 ( O
PKA BC2GM041907191 NNP O
) BC2GM041907191 ) O
catalytic BC2GM041907191 JJ O
beta BC2GM041907191 NN O
subunit BC2GM041907191 NN O
, BC2GM041907191 , O
inhibited BC2GM041907191 VBD O
both BC2GM041907191 DT O
forskolin BC2GM041907191 NN O
and BC2GM041907191 CC O
PACAP BC2GM041907191 NNP O
activation BC2GM041907191 NN O
of BC2GM041907191 IN O
chromogranin BC2GM041907191 NN O
A BC2GM041907191 DT O
transcription BC2GM041907191 NN O
, BC2GM041907191 , O
revealing BC2GM041907191 VBG O
that BC2GM041907191 IN O
PACAP-induced BC2GM041907191 NNP O
trans-activation BC2GM041907191 NN O
is BC2GM041907191 VBZ O
highly BC2GM041907191 RB O
dependent BC2GM041907191 JJ O
on BC2GM041907191 IN O
PKA BC2GM041907191 NNP O
. BC2GM041907191 . O
. . O O

Although BC2GM051190318 IN O
several BC2GM051190318 JJ O
other BC2GM051190318 JJ O
signal BC2GM051190318 JJ O
transduction BC2GM051190318 NN O
molecules BC2GM051190318 NNS O
also BC2GM051190318 RB O
contain BC2GM051190318 VBP O
tandemly BC2GM051190318 RB O
occurring BC2GM051190318 VBG O
SH3 BC2GM051190318 NNP O
and BC2GM051190318 CC O
SH2 BC2GM051190318 NNP O
domains BC2GM051190318 NNS O
, BC2GM051190318 , O
the BC2GM051190318 DT O
function BC2GM051190318 NN O
of BC2GM051190318 IN O
these BC2GM051190318 DT O
closely BC2GM051190318 RB O
spaced BC2GM051190318 JJ O
domains BC2GM051190318 NNS O
is BC2GM051190318 VBZ O
not BC2GM051190318 RB O
well BC2GM051190318 RB O
understood BC2GM051190318 RB O
. BC2GM051190318 . O
. . O O

Detection BC2GM030669575 NN O
of BC2GM030669575 IN O
sinusoidal BC2GM030669575 JJ O
gratings BC2GM030669575 NNS O
by BC2GM030669575 IN O
pattern-specific BC2GM030669575 JJ O
detectors BC2GM030669575 NNS O
: BC2GM030669575 : O
further BC2GM030669575 JJ O
evidence BC2GM030669575 NN O
for BC2GM030669575 IN O
the BC2GM030669575 DT O
correlation BC2GM030669575 NN O
principle BC2GM030669575 NN O
in BC2GM030669575 IN O
human BC2GM030669575 JJ O
vision BC2GM030669575 NN O
. BC2GM030669575 . O
. . O O

Both BC2GM092152216 DT O
the BC2GM092152216 DT O
arterial BC2GM092152216 JJ O
and BC2GM092152216 CC O
venous BC2GM092152216 JJ O
thrombi BC2GM092152216 NN O
were BC2GM092152216 VBD O
clearly BC2GM092152216 RB O
discernible BC2GM092152216 JJ O
at BC2GM092152216 IN O
2 BC2GM092152216 CD O
to BC2GM092152216 TO O
8 BC2GM092152216 CD O
h BC2GM092152216 NN O
after BC2GM092152216 IN O
injection BC2GM092152216 NN O
of BC2GM092152216 IN O
99Tcm-SZ-51 BC2GM092152216 CD O
. BC2GM092152216 . O
. . O O

Members BC2GM096403627 NNS O
of BC2GM096403627 IN O
the BC2GM096403627 DT O
steroid BC2GM096403627 JJ O
/ BC2GM096403627 NNP O
hormone BC2GM096403627 NN O
nuclear BC2GM096403627 JJ O
receptor BC2GM096403627 NN O
superfamily BC2GM096403627 RB O
regulate BC2GM096403627 VB O
target BC2GM096403627 NN O
gene BC2GM096403627 NN O
transcription BC2GM096403627 NN O
via BC2GM096403627 IN O
recognition BC2GM096403627 NN O
and BC2GM096403627 CC O
association BC2GM096403627 NN O
with BC2GM096403627 IN O
specific BC2GM096403627 JJ O
cis-acting BC2GM096403627 JJ O
sequences BC2GM096403627 NNS O
of BC2GM096403627 IN O
DNA BC2GM096403627 NN O
, BC2GM096403627 , O
called BC2GM096403627 VBD O
hormone BC2GM096403627 NN O
response BC2GM096403627 NN O
elements BC2GM096403627 NNS O
( BC2GM096403627 ( O
HREs BC2GM096403627 NNP O
) BC2GM096403627 ) O
. BC2GM096403627 . O
. . O O

Buspirone BC2GM048642261 NNP O
therapy BC2GM048642261 NN O
for BC2GM048642261 IN O
Type BC2GM048642261 NNP O
A BC2GM048642261 NNP O
behavior BC2GM048642261 NN O
, BC2GM048642261 , O
hostility BC2GM048642261 NN O
, BC2GM048642261 , O
and BC2GM048642261 CC O
perceived BC2GM048642261 VBD O
stress BC2GM048642261 NN O
in BC2GM048642261 IN O
cardiac BC2GM048642261 JJ O
patients BC2GM048642261 NNS O
. BC2GM048642261 . O
. . O O

The BC2GM026944266 DT O
transcription BC2GM026944266 NN O
start BC2GM026944266 NN O
site BC2GM026944266 NN O
was BC2GM026944266 VBD O
localized BC2GM026944266 VBN O
224 BC2GM026944266 CD O
bp BC2GM026944266 JJ O
upstream BC2GM026944266 RB O
the BC2GM026944266 DT O
ATG BC2GM026944266 NNP O
codon BC2GM026944266 NN O
by BC2GM026944266 IN O
RNase BC2GM026944266 NNP O
protection BC2GM026944266 NN O
and BC2GM026944266 CC O
primer BC2GM026944266 NN O
extension BC2GM026944266 NN O
mapping BC2GM026944266 NN O
. BC2GM026944266 . O
. . O O

Effect BC2GM034354079 NN O
of BC2GM034354079 IN O
infantile BC2GM034354079 JJ O
undernutrition BC2GM034354079 NN O
on BC2GM034354079 IN O
adult BC2GM034354079 NN O
sucrose BC2GM034354079 JJ O
solution BC2GM034354079 NN O
consumption BC2GM034354079 NN O
in BC2GM034354079 IN O
the BC2GM034354079 DT O
rat BC2GM034354079 NN O
. BC2GM034354079 . O
. . O O

Portions BC2GM009197562 NNS O
of BC2GM009197562 IN O
the BC2GM009197562 DT O
3'-coding BC2GM009197562 JJ O
and BC2GM009197562 CC O
3'-untranslated BC2GM009197562 JJ O
regions BC2GM009197562 NNS O
were BC2GM009197562 VBD O
found BC2GM009197562 VBN O
to BC2GM009197562 TO O
be BC2GM009197562 VB O
missing BC2GM009197562 VBG O
from BC2GM009197562 IN O
the BC2GM009197562 DT O
7.2- BC2GM009197562 JJ O
and BC2GM009197562 CC O
4.8-kb BC2GM009197562 JJ O
topo BC2GM009197562 NN O
II BC2GM009197562 NNP O
alpha BC2GM009197562 NN O
mRNAs BC2GM009197562 NN O
by BC2GM009197562 IN O
Northern BC2GM009197562 NNP O
blot BC2GM009197562 NN O
analysis BC2GM009197562 NN O
. BC2GM009197562 . O
. . O O

Here BC2GM006399626 RB O
, BC2GM006399626 , O
we BC2GM006399626 PRP O
analyzed BC2GM006399626 VBD O
the BC2GM006399626 DT O
interaction BC2GM006399626 NN O
of BC2GM006399626 IN O
CYT-18 BC2GM006399626 NNP O
with BC2GM006399626 IN O
a BC2GM006399626 DT O
small BC2GM006399626 JJ O
RNA BC2GM006399626 NNP O
( BC2GM006399626 ( O
P4-P6 BC2GM006399626 NNP O
RNA BC2GM006399626 NNP O
) BC2GM006399626 ) O
corresponding BC2GM006399626 VBG O
to BC2GM006399626 TO O
the BC2GM006399626 DT O
isolated BC2GM006399626 JJ O
P4-P6 BC2GM006399626 NNP O
domain BC2GM006399626 NN O
of BC2GM006399626 IN O
the BC2GM006399626 DT O
N. BC2GM006399626 NNP O
crassa BC2GM006399626 NN O
mitochondrial BC2GM006399626 JJ O
large BC2GM006399626 JJ O
subunit BC2GM006399626 NN O
ribosomal BC2GM006399626 JJ O
RNA BC2GM006399626 NNP O
intron BC2GM006399626 NN O
. BC2GM006399626 . O
. . O O

These BC2GM023719948 DT O
sequences BC2GM023719948 NNS O
were BC2GM023719948 VBD O
further BC2GM023719948 RB O
tested BC2GM023719948 VBN O
for BC2GM023719948 IN O
the BC2GM023719948 DT O
presence BC2GM023719948 NN O
of BC2GM023719948 IN O
an BC2GM023719948 DT O
enhancer BC2GM023719948 NN O
element BC2GM023719948 NN O
, BC2GM023719948 , O
by BC2GM023719948 IN O
their BC2GM023719948 PRP$ O
ability BC2GM023719948 NN O
to BC2GM023719948 TO O
activate BC2GM023719948 VB O
a BC2GM023719948 DT O
fusion BC2GM023719948 NN O
reporter BC2GM023719948 NN O
gene BC2GM023719948 NN O
consisting BC2GM023719948 VBG O
of BC2GM023719948 IN O
the BC2GM023719948 DT O
CAT BC2GM023719948 NNP O
gene BC2GM023719948 NN O
linked BC2GM023719948 VBD O
to BC2GM023719948 TO O
the BC2GM023719948 DT O
gamma-globin BC2GM023719948 JJ O
gene BC2GM023719948 NN O
promoter BC2GM023719948 NN O
, BC2GM023719948 , O
in BC2GM023719948 IN O
erythroid BC2GM023719948 NN O
( BC2GM023719948 ( O
K562 BC2GM023719948 NNP O
) BC2GM023719948 ) O
and BC2GM023719948 CC O
non-erythroid BC2GM023719948 JJ O
( BC2GM023719948 ( O
HeLa BC2GM023719948 NNP O
) BC2GM023719948 ) O
cells BC2GM023719948 NNS O
. BC2GM023719948 . O
. . O O

Mouse BC2GM016224723 NNP O
embryo BC2GM016224723 NN O
cells BC2GM016224723 NNS O
( BC2GM016224723 ( O
C57BL BC2GM016224723 NNP O
/ BC2GM016224723 NNP O
6 BC2GM016224723 CD O
, BC2GM016224723 , O
H-2b BC2GM016224723 NNP O
) BC2GM016224723 ) O
transformed BC2GM016224723 VBN O
by BC2GM016224723 IN O
the BC2GM016224723 DT O
E1A BC2GM016224723 NNP O
and BC2GM016224723 CC O
E1B BC2GM016224723 NNP O
genes BC2GM016224723 NNS O
of BC2GM016224723 IN O
adenovirus BC2GM016224723 NN O
type BC2GM016224723 NN O
5 BC2GM016224723 CD O
( BC2GM016224723 ( O
Ad5E1 BC2GM016224723 NNP O
MEC BC2GM016224723 NNP O
) BC2GM016224723 ) O
are BC2GM016224723 VBP O
highly BC2GM016224723 RB O
immunogenic BC2GM016224723 JJ O
. BC2GM016224723 . O
. . O O

When BC2GM083535249 WRB O
cotransfected BC2GM083535249 VBN O
with BC2GM083535249 IN O
the BC2GM083535249 DT O
HIV BC2GM083535249 NNP O
LTR BC2GM083535249 NNP O
CAT BC2GM083535249 NNP O
into BC2GM083535249 IN O
CV-1 BC2GM083535249 NNP O
cells BC2GM083535249 NNS O
, BC2GM083535249 , O
both BC2GM083535249 CC O
the BC2GM083535249 DT O
pCD41 BC2GM083535249 NN O
and BC2GM083535249 CC O
pGD41 BC2GM083535249 JJ O
clones BC2GM083535249 NNS O
trans-activated BC2GM083535249 VBD O
the BC2GM083535249 DT O
HIV BC2GM083535249 NNP O
LTR BC2GM083535249 NNP O
. BC2GM083535249 . O
. . O O

This BC2GM068782112 DT O
vector BC2GM068782112 NN O
should BC2GM068782112 MD O
be BC2GM068782112 VB O
applicable BC2GM068782112 JJ O
for BC2GM068782112 IN O
high-throughput BC2GM068782112 JJ O
characterization BC2GM068782112 NN O
of BC2GM068782112 IN O
new BC2GM068782112 JJ O
open BC2GM068782112 JJ O
reading BC2GM068782112 NN O
frames BC2GM068782112 NNS O
found BC2GM068782112 VBN O
in BC2GM068782112 IN O
genome BC2GM068782112 JJ O
sequencing BC2GM068782112 NN O
. BC2GM068782112 . O
. . O O

When BC2GM020852658 WRB O
medical BC2GM020852658 JJ O
aid BC2GM020852658 NN O
was BC2GM020852658 VBD O
sought BC2GM020852658 VBN O
a BC2GM020852658 DT O
false BC2GM020852658 JJ O
history BC2GM020852658 NN O
was BC2GM020852658 VBD O
given BC2GM020852658 VBN O
and BC2GM020852658 CC O
the BC2GM020852658 DT O
true BC2GM020852658 JJ O
nature BC2GM020852658 NN O
of BC2GM020852658 IN O
the BC2GM020852658 DT O
child BC2GM020852658 NN O
's BC2GM020852658 POS O
illness BC2GM020852658 NN O
, BC2GM020852658 , O
heat BC2GM020852658 NN O
stroke BC2GM020852658 NN O
, BC2GM020852658 , O
was BC2GM020852658 VBD O
not BC2GM020852658 RB O
determined BC2GM020852658 VBN O
until BC2GM020852658 IN O
after BC2GM020852658 IN O
death BC2GM020852658 NN O
. BC2GM020852658 . O
. . O O

The BC2GM052216512 DT O
effects BC2GM052216512 NNS O
of BC2GM052216512 IN O
erythrosine BC2GM052216512 NN O
( BC2GM052216512 ( O
Red BC2GM052216512 NNP O
3 BC2GM052216512 CD O
) BC2GM052216512 ) O
, BC2GM052216512 , O
rose BC2GM052216512 VBD O
bengal BC2GM052216512 JJ O
B BC2GM052216512 NNP O
( BC2GM052216512 ( O
Red BC2GM052216512 NNP O
105 BC2GM052216512 CD O
) BC2GM052216512 ) O
and BC2GM052216512 CC O
thyroidectomy BC2GM052216512 $ O
on BC2GM052216512 IN O
the BC2GM052216512 DT O
development BC2GM052216512 NN O
of BC2GM052216512 IN O
thyroid BC2GM052216512 JJ O
tumor BC2GM052216512 NN O
were BC2GM052216512 VBD O
examined BC2GM052216512 VBN O
in BC2GM052216512 IN O
male BC2GM052216512 JJ O
Wistar BC2GM052216512 NNP O
rats BC2GM052216512 NNS O
treated BC2GM052216512 VBD O
with BC2GM052216512 IN O
N-bis BC2GM052216512 NNP O
( BC2GM052216512 ( O
2-hydroxypropyl BC2GM052216512 JJ O
) BC2GM052216512 ) O
nitrosamine BC2GM052216512 NN O
( BC2GM052216512 ( O
DHPN BC2GM052216512 NNP O
) BC2GM052216512 ) O
. BC2GM052216512 . O
. . O O

We BC2GM077438111 PRP O
have BC2GM077438111 VBP O
demonstrated BC2GM077438111 VBN O
that BC2GM077438111 IN O
the BC2GM077438111 DT O
specific BC2GM077438111 JJ O
determination BC2GM077438111 NN O
and BC2GM077438111 CC O
identification BC2GM077438111 NN O
of BC2GM077438111 IN O
plasma BC2GM077438111 JJ O
FbDP BC2GM077438111 NNP O
alone BC2GM077438111 RB O
is BC2GM077438111 VBZ O
not BC2GM077438111 RB O
sufficient BC2GM077438111 JJ O
to BC2GM077438111 TO O
follow BC2GM077438111 VB O
the BC2GM077438111 DT O
effectiveness BC2GM077438111 NN O
of BC2GM077438111 IN O
thrombolytic BC2GM077438111 JJ O
therapy BC2GM077438111 NN O
. BC2GM077438111 . O
. . O O

We BC2GM019782679 PRP O
therefore BC2GM019782679 RB O
investigated BC2GM019782679 VBD O
whether BC2GM019782679 IN O
the BC2GM019782679 DT O
promoter BC2GM019782679 NN O
activity BC2GM019782679 NN O
of BC2GM019782679 IN O
the BC2GM019782679 DT O
mouse BC2GM019782679 NN O
TRH BC2GM019782679 NNP O
gene BC2GM019782679 NN O
is BC2GM019782679 VBZ O
directly BC2GM019782679 RB O
regulated BC2GM019782679 VBN O
by BC2GM019782679 IN O
RA BC2GM019782679 NNP O
using BC2GM019782679 VBG O
a BC2GM019782679 DT O
transient BC2GM019782679 JJ O
transfection BC2GM019782679 NN O
assay BC2GM019782679 VBP O
into BC2GM019782679 IN O
CV-1 BC2GM019782679 NNP O
cells BC2GM019782679 NNS O
. BC2GM019782679 . O
. . O O

Type BC2GM083885285 NNP O
II BC2GM083885285 NNP O
neuroleptanalgesia BC2GM083885285 NN O
in BC2GM083885285 IN O
odonto-stomatology BC2GM083885285 NN O
. BC2GM083885285 . O
. . O O

Titres BC2GM064870034 NNS O
of BC2GM064870034 IN O
antistreptolysin BC2GM064870034 NN O
O BC2GM064870034 NNP O
in BC2GM064870034 IN O
mothers BC2GM064870034 NNS O
of BC2GM064870034 IN O
children BC2GM064870034 NNS O
affected BC2GM064870034 VBN O
with BC2GM064870034 IN O
Down BC2GM064870034 NNP O
's BC2GM064870034 POS O
syndrome BC2GM064870034 NN O
. BC2GM064870034 . O
. . O O

VLA-4 BC2GM096905196 JJ O
integrin BC2GM096905196 JJ O
cross-linking BC2GM096905196 NN O
on BC2GM096905196 IN O
human BC2GM096905196 JJ O
monocytic BC2GM096905196 JJ O
THP-1 BC2GM096905196 NNP O
cells BC2GM096905196 NNS O
induces BC2GM096905196 VBZ O
tissue BC2GM096905196 NN O
factor BC2GM096905196 NN O
expression BC2GM096905196 NN O
by BC2GM096905196 IN O
a BC2GM096905196 DT O
mechanism BC2GM096905196 NN O
involving BC2GM096905196 VBG O
mitogen-activated BC2GM096905196 JJ O
protein BC2GM096905196 NN O
kinase BC2GM096905196 NN O
. BC2GM096905196 . O
. . O O

Acidic BC2GM022660122 JJ O
carboxyl-terminal BC2GM022660122 JJ O
domain BC2GM022660122 NN O
of BC2GM022660122 IN O
gene BC2GM022660122 NN O
2.5 BC2GM022660122 CD O
protein BC2GM022660122 NN O
of BC2GM022660122 IN O
bacteriophage BC2GM022660122 NN O
T7 BC2GM022660122 NNP O
is BC2GM022660122 VBZ O
essential BC2GM022660122 JJ O
for BC2GM022660122 IN O
protein-protein BC2GM022660122 JJ O
interactions BC2GM022660122 NNS O
. BC2GM022660122 . O
. . O O

This BC2GM054051105 DT O
difference BC2GM054051105 NN O
between BC2GM054051105 IN O
SP-1 BC2GM054051105 NNP O
and BC2GM054051105 CC O
SP-2 BC2GM054051105 NNP O
peptides BC2GM054051105 NNS O
was BC2GM054051105 VBD O
not BC2GM054051105 RB O
due BC2GM054051105 JJ O
to BC2GM054051105 TO O
their BC2GM054051105 PRP$ O
differential BC2GM054051105 JJ O
uptake BC2GM054051105 NN O
by BC2GM054051105 IN O
cell BC2GM054051105 NN O
, BC2GM054051105 , O
since BC2GM054051105 IN O
approximately BC2GM054051105 RB O
100 BC2GM054051105 CD O
times BC2GM054051105 NNS O
more BC2GM054051105 RBR O
SP-2 BC2GM054051105 JJ O
peptide BC2GM054051105 NN O
could BC2GM054051105 MD O
be BC2GM054051105 VB O
found BC2GM054051105 VBN O
in BC2GM054051105 IN O
cytoplasmic BC2GM054051105 JJ O
extracts BC2GM054051105 NNS O
than BC2GM054051105 IN O
SP-1 BC2GM054051105 NNP O
peptide BC2GM054051105 NN O
in BC2GM054051105 IN O
experiments BC2GM054051105 NNS O
using BC2GM054051105 VBG O
radiolabeled BC2GM054051105 JJ O
peptides BC2GM054051105 NNS O
. BC2GM054051105 . O
. . O O

A BC2GM051388825 DT O
DNA BC2GM051388825 NN O
fragment BC2GM051388825 NN O
that BC2GM051388825 WDT O
complements BC2GM051388825 VBZ O
the BC2GM051388825 DT O
uvs-2 BC2GM051388825 JJ O
mutation BC2GM051388825 NN O
was BC2GM051388825 VBD O
subcloned BC2GM051388825 VBN O
by BC2GM051388825 IN O
monitoring BC2GM051388825 VBG O
its BC2GM051388825 PRP$ O
ability BC2GM051388825 NN O
to BC2GM051388825 TO O
transform BC2GM051388825 VB O
the BC2GM051388825 DT O
uvs-2 BC2GM051388825 JJ O
mutant BC2GM051388825 NN O
to BC2GM051388825 TO O
MMS BC2GM051388825 NNP O
resistance BC2GM051388825 NN O
. BC2GM051388825 . O
. . O O

For BC2GM013864172 IN O
O3 BC2GM013864172 NNP O
, BC2GM013864172 , O
the BC2GM013864172 DT O
correlation BC2GM013864172 NN O
between BC2GM013864172 IN O
personal BC2GM013864172 JJ O
exposures BC2GM013864172 NNS O
and BC2GM013864172 CC O
ambient BC2GM013864172 NN O
levels BC2GM013864172 NNS O
was BC2GM013864172 VBD O
weakest BC2GM013864172 JJS O
in BC2GM013864172 IN O
the BC2GM013864172 DT O
winter BC2GM013864172 NN O
for BC2GM013864172 IN O
residential BC2GM013864172 JJ O
microenvironments BC2GM013864172 NNS O
( BC2GM013864172 ( O
rs BC2GM013864172 VB O
= BC2GM013864172 RB O
0.05 BC2GM013864172 CD O
, BC2GM013864172 , O
p BC2GM013864172 NN O
> BC2GM013864172 NNP O
0.05 BC2GM013864172 CD O
) BC2GM013864172 ) O
, BC2GM013864172 , O
and BC2GM013864172 CC O
was BC2GM013864172 VBD O
strongest BC2GM013864172 VBN O
in BC2GM013864172 IN O
the BC2GM013864172 DT O
summer BC2GM013864172 NN O
for BC2GM013864172 IN O
outdoor BC2GM013864172 JJ O
near-roadway BC2GM013864172 JJ O
microenvironments BC2GM013864172 NNS O
( BC2GM013864172 ( O
rs BC2GM013864172 VB O
= BC2GM013864172 RB O
0.91 BC2GM013864172 CD O
, BC2GM013864172 , O
p BC2GM013864172 NN O
< BC2GM013864172 NNP O
0.05 BC2GM013864172 CD O
) BC2GM013864172 ) O
. BC2GM013864172 . O
. . O O

Coronary BC2GM005484781 JJ O
vasoconstriction BC2GM005484781 NN O
caused BC2GM005484781 VBN O
by BC2GM005484781 IN O
endothelin-1 BC2GM005484781 NN O
is BC2GM005484781 VBZ O
enhanced BC2GM005484781 VBN O
by BC2GM005484781 IN O
ischemia-reperfusion BC2GM005484781 NN O
and BC2GM005484781 CC O
by BC2GM005484781 IN O
norepinephrine BC2GM005484781 JJ O
present BC2GM005484781 NN O
in BC2GM005484781 IN O
concentrations BC2GM005484781 NNS O
typically BC2GM005484781 RB O
observed BC2GM005484781 VBD O
after BC2GM005484781 IN O
neonatal BC2GM005484781 JJ O
cardiopulmonary BC2GM005484781 JJ O
bypass BC2GM005484781 NN O
. BC2GM005484781 . O
. . O O

To BC2GM063978181 TO O
study BC2GM063978181 VB O
the BC2GM063978181 DT O
signaling BC2GM063978181 NN O
pathways BC2GM063978181 VBZ O
that BC2GM063978181 IN O
regulate BC2GM063978181 NN O
cytoskeletal BC2GM063978181 JJ O
rearrangements BC2GM063978181 NNS O
in BC2GM063978181 IN O
T BC2GM063978181 NNP O
lymphocytes BC2GM063978181 NNS O
, BC2GM063978181 , O
we BC2GM063978181 PRP O
set BC2GM063978181 VBP O
up BC2GM063978181 RP O
a BC2GM063978181 DT O
conjugate BC2GM063978181 NN O
formation BC2GM063978181 NN O
assay BC2GM063978181 VBP O
using BC2GM063978181 VBG O
Jurkat BC2GM063978181 NNP O
T BC2GM063978181 NNP O
cells BC2GM063978181 NNS O
as BC2GM063978181 IN O
effectors BC2GM063978181 NNS O
and BC2GM063978181 CC O
cell-sized BC2GM063978181 JJ O
latex BC2GM063978181 NN O
beads BC2GM063978181 NNS O
coated BC2GM063978181 VBN O
with BC2GM063978181 IN O
various BC2GM063978181 JJ O
antibodies BC2GM063978181 NNS O
as BC2GM063978181 IN O
artificial BC2GM063978181 JJ O
APCs BC2GM063978181 NNP O
. BC2GM063978181 . O
. . O O

In BC2GM005637228 IN O
both BC2GM005637228 DT O
RAW BC2GM005637228 NNP O
cells BC2GM005637228 NNS O
and BC2GM005637228 CC O
the BC2GM005637228 DT O
microglia BC2GM005637228 NN O
cell BC2GM005637228 NN O
line BC2GM005637228 NN O
EOC20 BC2GM005637228 NNP O
, BC2GM005637228 , O
two BC2GM005637228 CD O
IFN-gamma-activated BC2GM005637228 JJ O
transcription BC2GM005637228 NN O
factors BC2GM005637228 NNS O
, BC2GM005637228 , O
STAT-1alpha BC2GM005637228 NNP O
and BC2GM005637228 CC O
IRF-1 BC2GM005637228 NNP O
, BC2GM005637228 , O
bind BC2GM005637228 IN O
the BC2GM005637228 DT O
GAS BC2GM005637228 NNP O
and BC2GM005637228 CC O
IRF BC2GM005637228 NNP O
elements BC2GM005637228 NNS O
, BC2GM005637228 , O
respectively BC2GM005637228 RB O
. BC2GM005637228 . O
. . O O

The BC2GM000222745 DT O
findings BC2GM000222745 NNS O
are BC2GM000222745 VBP O
discussed BC2GM000222745 VBN O
with BC2GM000222745 IN O
reference BC2GM000222745 NN O
to BC2GM000222745 TO O
possible BC2GM000222745 JJ O
mechanisms BC2GM000222745 NNS O
by BC2GM000222745 IN O
which BC2GM000222745 WDT O
parasite BC2GM000222745 NN O
development BC2GM000222745 NN O
might BC2GM000222745 MD O
be BC2GM000222745 VB O
controlled BC2GM000222745 VBN O
. BC2GM000222745 . O
. . O O

Results BC2GM048894159 NNS O
demonstrated BC2GM048894159 VBD O
that BC2GM048894159 IN O
for BC2GM048894159 IN O
both BC2GM048894159 DT O
S. BC2GM048894159 NNP O
europaea BC2GM048894159 NN O
and BC2GM048894159 CC O
A. BC2GM048894159 NNP O
prostrata BC2GM048894159 NN O
, BC2GM048894159 , O
the BC2GM048894159 DT O
total BC2GM048894159 JJ O
number BC2GM048894159 NN O
of BC2GM048894159 IN O
seeds BC2GM048894159 NNS O
that BC2GM048894159 WDT O
germinated BC2GM048894159 VBD O
decreased BC2GM048894159 VBN O
throughout BC2GM048894159 IN O
the BC2GM048894159 DT O
growing BC2GM048894159 VBG O
season BC2GM048894159 NN O
. BC2GM048894159 . O
. . O O

The BC2GM038288477 DT O
goal BC2GM038288477 NN O
of BC2GM038288477 IN O
this BC2GM038288477 DT O
investigation BC2GM038288477 NN O
was BC2GM038288477 VBD O
to BC2GM038288477 TO O
determine BC2GM038288477 VB O
whether BC2GM038288477 IN O
BMIPP BC2GM038288477 NNP O
uptake BC2GM038288477 NN O
can BC2GM038288477 MD O
be BC2GM038288477 VB O
used BC2GM038288477 VBN O
to BC2GM038288477 TO O
differentiate BC2GM038288477 VB O
viable BC2GM038288477 JJ O
myocardium BC2GM038288477 NN O
from BC2GM038288477 IN O
scar BC2GM038288477 NN O
tissue BC2GM038288477 NN O
soon BC2GM038288477 RB O
after BC2GM038288477 IN O
coronary BC2GM038288477 JJ O
thrombolysis BC2GM038288477 NN O
for BC2GM038288477 IN O
acute BC2GM038288477 JJ O
myocardial BC2GM038288477 JJ O
infarction BC2GM038288477 NN O
. BC2GM038288477 . O
. . O O

For BC2GM077166085 IN O
the BC2GM077166085 DT O
target BC2GM077166085 NN O
stimuli BC2GM077166085 NN O
, BC2GM077166085 , O
P3 BC2GM077166085 NNP O
amplitude BC2GM077166085 NN O
and BC2GM077166085 CC O
latency BC2GM077166085 NN O
were BC2GM077166085 VBD O
negatively BC2GM077166085 RB O
correlated BC2GM077166085 VBN O
and BC2GM077166085 CC O
most BC2GM077166085 JJS O
tightly BC2GM077166085 RB O
coupled BC2GM077166085 VBN O
over BC2GM077166085 RP O
the BC2GM077166085 DT O
frontal-central BC2GM077166085 JJ O
and BC2GM077166085 CC O
right BC2GM077166085 JJ O
medial BC2GM077166085 NN O
/ BC2GM077166085 NNP O
lateral BC2GM077166085 JJ O
recording BC2GM077166085 NN O
sites BC2GM077166085 NNS O
. BC2GM077166085 . O
. . O O

AIMS BC2GM040722108 NNS O
: BC2GM040722108 : O
We BC2GM040722108 PRP O
postulated BC2GM040722108 VBD O
that BC2GM040722108 IN O
perhexiline BC2GM040722108 NN O
, BC2GM040722108 , O
a BC2GM040722108 DT O
novel BC2GM040722108 JJ O
anti-ischaemic BC2GM040722108 JJ O
agent BC2GM040722108 NN O
with BC2GM040722108 IN O
an BC2GM040722108 DT O
oxygen-sparing BC2GM040722108 JJ O
metabolic BC2GM040722108 JJ O
effect BC2GM040722108 NN O
in BC2GM040722108 IN O
the BC2GM040722108 DT O
myocardium BC2GM040722108 NN O
( BC2GM040722108 ( O
via BC2GM040722108 IN O
inhibition BC2GM040722108 NN O
of BC2GM040722108 IN O
carnitine BC2GM040722108 JJ O
palmitoyltransferase-1 BC2GM040722108 NN O
) BC2GM040722108 ) O
and BC2GM040722108 CC O
no BC2GM040722108 DT O
adverse BC2GM040722108 JJ O
haemodynamic BC2GM040722108 NN O
effects BC2GM040722108 NNS O
, BC2GM040722108 , O
may BC2GM040722108 MD O
improve BC2GM040722108 VB O
symptomatic BC2GM040722108 JJ O
status BC2GM040722108 NN O
in BC2GM040722108 IN O
elderly BC2GM040722108 JJ O
patients BC2GM040722108 NNS O
with BC2GM040722108 IN O
severe BC2GM040722108 JJ O
aortic BC2GM040722108 JJ O
stenosis BC2GM040722108 NN O
. BC2GM040722108 . O
. . O O

MRS BC2GM000665827 NN O
allowed BC2GM000665827 VBD O
the BC2GM000665827 DT O
differentiation BC2GM000665827 NN O
of BC2GM000665827 IN O
the BC2GM000665827 DT O
following BC2GM000665827 JJ O
metabolites BC2GM000665827 NNS O
in BC2GM000665827 IN O
5 BC2GM000665827 CD O
patients BC2GM000665827 NNS O
: BC2GM000665827 : O
N-acetyl-aspartate BC2GM000665827 NNP O
( BC2GM000665827 ( O
NAA BC2GM000665827 NNP O
) BC2GM000665827 ) O
, BC2GM000665827 , O
creatine BC2GM000665827 NN O
and BC2GM000665827 CC O
phosphocreatine BC2GM000665827 NN O
, BC2GM000665827 , O
phosphorylcholine BC2GM000665827 NN O
and BC2GM000665827 CC O
glycerophosphorylcholine BC2GM000665827 NN O
, BC2GM000665827 , O
beta- BC2GM000665827 JJ O
and BC2GM000665827 CC O
gamma-glutamate BC2GM000665827 JJ O
( BC2GM000665827 ( O
GLU BC2GM000665827 NNP O
) BC2GM000665827 ) O
. BC2GM000665827 . O
. . O O

Two BC2GM075521296 CD O
putative BC2GM075521296 JJ O
ATP-binding BC2GM075521296 JJ O
domains BC2GM075521296 NNS O
were BC2GM075521296 VBD O
identified BC2GM075521296 VBN O
, BC2GM075521296 , O
one BC2GM075521296 CD O
in BC2GM075521296 IN O
the BC2GM075521296 DT O
amino-terminal BC2GM075521296 JJ O
half BC2GM075521296 NN O
of BC2GM075521296 IN O
the BC2GM075521296 DT O
argA-encoded BC2GM075521296 JJ O
protein BC2GM075521296 NN O
and BC2GM075521296 CC O
the BC2GM075521296 DT O
other BC2GM075521296 JJ O
in BC2GM075521296 IN O
the BC2GM075521296 DT O
carboxy-terminal BC2GM075521296 JJ O
half BC2GM075521296 NN O
. BC2GM075521296 . O
. . O O

We BC2GM022720719 PRP O
suggest BC2GM022720719 VBP O
that BC2GM022720719 IN O
this BC2GM022720719 DT O
effect BC2GM022720719 NN O
of BC2GM022720719 IN O
Myc BC2GM022720719 NNP O
is BC2GM022720719 VBZ O
mediated BC2GM022720719 VBN O
by BC2GM022720719 IN O
its BC2GM022720719 PRP$ O
action BC2GM022720719 NN O
upstream BC2GM022720719 NN O
of BC2GM022720719 IN O
cyclin BC2GM022720719 JJ O
E-CDK2 BC2GM022720719 NNP O
, BC2GM022720719 , O
and BC2GM022720719 CC O
occurs BC2GM022720719 VBZ O
via BC2GM022720719 IN O
the BC2GM022720719 DT O
neutralization BC2GM022720719 NN O
of BC2GM022720719 IN O
p27 BC2GM022720719 NN O
( BC2GM022720719 ( O
Kip1 BC2GM022720719 NNP O
) BC2GM022720719 ) O
family BC2GM022720719 NN O
proteins BC2GM022720719 NNS O
, BC2GM022720719 , O
rather BC2GM022720719 RB O
than BC2GM022720719 IN O
induction BC2GM022720719 NN O
of BC2GM022720719 IN O
Cdc25A BC2GM022720719 NNP O
. BC2GM022720719 . O
. . O O

Lamivudine BC2GM098636877 NNP O
therapy BC2GM098636877 NN O
for BC2GM098636877 IN O
acute BC2GM098636877 JJ O
hepatitis BC2GM098636877 NN O
B BC2GM098636877 NNP O
infection BC2GM098636877 NN O
following BC2GM098636877 VBG O
peripheral BC2GM098636877 JJ O
blood BC2GM098636877 NN O
stem BC2GM098636877 NN O
cell BC2GM098636877 NN O
transplantation BC2GM098636877 NN O
. BC2GM098636877 . O
. . O O

These BC2GM071919705 DT O
results BC2GM071919705 NNS O
demonstrate BC2GM071919705 VBP O
the BC2GM071919705 DT O
extensive BC2GM071919705 JJ O
homology BC2GM071919705 NN O
in BC2GM071919705 IN O
sequence BC2GM071919705 NN O
among BC2GM071919705 IN O
light BC2GM071919705 JJ O
chains BC2GM071919705 NNS O
of BC2GM071919705 IN O
IgM BC2GM071919705 NNP O
kappa BC2GM071919705 NNP O
autoantibodies BC2GM071919705 NNS O
and BC2GM071919705 CC O
indicate BC2GM071919705 VBP O
that BC2GM071919705 IN O
a BC2GM071919705 DT O
particular BC2GM071919705 JJ O
V BC2GM071919705 NNP O
kappa BC2GM071919705 NNP O
germ BC2GM071919705 FW O
line BC2GM071919705 NN O
gene BC2GM071919705 NN O
, BC2GM071919705 , O
kappa BC2GM071919705 FW O
IIIb BC2GM071919705 NNP O
, BC2GM071919705 , O
is BC2GM071919705 VBZ O
expressed BC2GM071919705 VBN O
as BC2GM071919705 IN O
a BC2GM071919705 DT O
phylogenetic BC2GM071919705 JJ O
response BC2GM071919705 NN O
to BC2GM071919705 TO O
certain BC2GM071919705 JJ O
self BC2GM071919705 NN O
antigens BC2GM071919705 NNS O
or BC2GM071919705 CC O
as BC2GM071919705 IN O
part BC2GM071919705 NN O
of BC2GM071919705 IN O
a BC2GM071919705 DT O
selection BC2GM071919705 NN O
process BC2GM071919705 NN O
by BC2GM071919705 IN O
which BC2GM071919705 WDT O
these BC2GM071919705 DT O
autoimmune BC2GM071919705 NN O
responses BC2GM071919705 NNS O
are BC2GM071919705 VBP O
regulated BC2GM071919705 VBN O
. BC2GM071919705 . O
. . O O

Characterization BC2GM004472936 NN O
of BC2GM004472936 IN O
a BC2GM004472936 DT O
tonB-phoA BC2GM004472936 JJ O
gene BC2GM004472936 NN O
fusion BC2GM004472936 NN O
suggests BC2GM004472936 VBZ O
that BC2GM004472936 IN O
the BC2GM004472936 DT O
amino-terminal BC2GM004472936 JJ O
41 BC2GM004472936 CD O
amino BC2GM004472936 JJ O
acids BC2GM004472936 NNS O
of BC2GM004472936 IN O
TonB BC2GM004472936 NNP O
are BC2GM004472936 VBP O
sufficient BC2GM004472936 JJ O
to BC2GM004472936 TO O
promote BC2GM004472936 VB O
export BC2GM004472936 NN O
of BC2GM004472936 IN O
the BC2GM004472936 DT O
fusion BC2GM004472936 NN O
protein BC2GM004472936 NN O
and BC2GM004472936 CC O
presumably BC2GM004472936 RB O
TonB BC2GM004472936 NNP O
as BC2GM004472936 RB O
well BC2GM004472936 RB O
. BC2GM004472936 . O
. . O O

It BC2GM017310347 PRP O
also BC2GM017310347 RB O
produces BC2GM017310347 VBZ O
an BC2GM017310347 DT O
NH2 BC2GM017310347 NNP O
terminus BC2GM017310347 NN O
that BC2GM017310347 WDT O
corresponds BC2GM017310347 VBZ O
to BC2GM017310347 TO O
an BC2GM017310347 DT O
equivalent BC2GM017310347 JJ O
NH2 BC2GM017310347 NNP O
terminus BC2GM017310347 NN O
on BC2GM017310347 IN O
the BC2GM017310347 DT O
processed BC2GM017310347 VBN O
matrix BC2GM017310347 NN O
form BC2GM017310347 NN O
of BC2GM017310347 IN O
the BC2GM017310347 DT O
similar BC2GM017310347 JJ O
alpha1 BC2GM017310347 NN O
( BC2GM017310347 ( O
XI BC2GM017310347 NNP O
) BC2GM017310347 ) O
chain BC2GM017310347 NN O
, BC2GM017310347 , O
thus BC2GM017310347 RB O
suggesting BC2GM017310347 VBG O
physiological BC2GM017310347 JJ O
significance BC2GM017310347 NN O
. BC2GM017310347 . O
. . O O

Although BC2GM015002604 IN O
immunoglobulin BC2GM015002604 NN O
and BC2GM015002604 CC O
CRP BC2GM015002604 NNP O
concentration BC2GM015002604 NN O
increased BC2GM015002604 VBD O
, BC2GM015002604 , O
anemia BC2GM015002604 NN O
obviously BC2GM015002604 RB O
improved BC2GM015002604 VBN O
with BC2GM015002604 IN O
hemoglobin BC2GM015002604 NN O
levels BC2GM015002604 NNS O
increasing BC2GM015002604 VBG O
from BC2GM015002604 IN O
4.8 BC2GM015002604 CD O
g BC2GM015002604 NNS O
/ BC2GM015002604 JJ O
dl BC2GM015002604 NN O
to BC2GM015002604 TO O
8.5 BC2GM015002604 CD O
g BC2GM015002604 NNS O
/ BC2GM015002604 JJ O
dl BC2GM015002604 NN O
without BC2GM015002604 IN O
any BC2GM015002604 DT O
side BC2GM015002604 NN O
effects BC2GM015002604 NNS O
. BC2GM015002604 . O
. . O O

The BC2GM014101305 DT O
genes BC2GM014101305 NNS O
on BC2GM014101305 IN O
each BC2GM014101305 DT O
chromosome BC2GM014101305 NN O
involved BC2GM014101305 VBN O
in BC2GM014101305 IN O
this BC2GM014101305 DT O
translocation BC2GM014101305 NN O
have BC2GM014101305 VBP O
been BC2GM014101305 VBN O
identified BC2GM014101305 VBN O
as BC2GM014101305 IN O
the BC2GM014101305 DT O
transcription BC2GM014101305 NN O
factor-encoding BC2GM014101305 JJ O
genes BC2GM014101305 NNS O
PAX3 BC2GM014101305 NNP O
and BC2GM014101305 CC O
FKHR BC2GM014101305 NNP O
. BC2GM014101305 . O
. . O O

In BC2GM030876064 IN O
this BC2GM030876064 DT O
report BC2GM030876064 NN O
, BC2GM030876064 , O
we BC2GM030876064 PRP O
identify BC2GM030876064 VBP O
Tyr319 BC2GM030876064 NNP O
as BC2GM030876064 IN O
a BC2GM030876064 DT O
functionally BC2GM030876064 RB O
important BC2GM030876064 JJ O
phosphorylation BC2GM030876064 NN O
site BC2GM030876064 NN O
in BC2GM030876064 IN O
the BC2GM030876064 DT O
ZAP-70 BC2GM030876064 NNP O
interdomain BC2GM030876064 NN O
B BC2GM030876064 NNP O
region BC2GM030876064 NN O
. BC2GM030876064 . O
. . O O

This BC2GM098968246 DT O
region BC2GM098968246 NN O
does BC2GM098968246 VBZ O
not BC2GM098968246 RB O
contain BC2GM098968246 VB O
a BC2GM098968246 DT O
consensus BC2GM098968246 NN O
estrogen BC2GM098968246 NN O
response BC2GM098968246 NN O
element BC2GM098968246 NN O
, BC2GM098968246 , O
and BC2GM098968246 CC O
ER BC2GM098968246 NNP O
binding BC2GM098968246 VBG O
to BC2GM098968246 TO O
this BC2GM098968246 DT O
DNA BC2GM098968246 NN O
sequence BC2GM098968246 NN O
was BC2GM098968246 VBD O
not BC2GM098968246 RB O
observed BC2GM098968246 VBN O
. BC2GM098968246 . O
. . O O

At BC2GM083493191 IN O
the BC2GM083493191 DT O
first BC2GM083493191 JJ O
phase BC2GM083493191 NN O
( BC2GM083493191 ( O
1-43 BC2GM083493191 JJ O
ms BC2GM083493191 NN O
for BC2GM083493191 IN O
the BC2GM083493191 DT O
VMN BC2GM083493191 NNP O
and BC2GM083493191 CC O
1-10 BC2GM083493191 JJ O
ms BC2GM083493191 NN O
for BC2GM083493191 IN O
the BC2GM083493191 DT O
LN BC2GM083493191 NNP O
) BC2GM083493191 ) O
the BC2GM083493191 DT O
hypothalamic-cortical BC2GM083493191 JJ O
responses BC2GM083493191 NNS O
completely BC2GM083493191 RB O
inhibited BC2GM083493191 VBD O
the BC2GM083493191 DT O
formation BC2GM083493191 NN O
of BC2GM083493191 IN O
the BC2GM083493191 DT O
VC BC2GM083493191 NNP O
response BC2GM083493191 NN O
to BC2GM083493191 TO O
the BC2GM083493191 DT O
light BC2GM083493191 JJ O
stimulus BC2GM083493191 NN O
. BC2GM083493191 . O
. . O O

The BC2GM075805410 DT O
analysis BC2GM075805410 NN O
of BC2GM075805410 IN O
the BC2GM075805410 DT O
organization BC2GM075805410 NN O
of BC2GM075805410 IN O
the BC2GM075805410 DT O
sequence BC2GM075805410 NN O
of BC2GM075805410 IN O
the BC2GM075805410 DT O
human BC2GM075805410 JJ O
ABP BC2GM075805410 NNP O
/ BC2GM075805410 NNP O
DAO BC2GM075805410 NNP O
gene BC2GM075805410 NN O
reveals BC2GM075805410 NNS O
that BC2GM075805410 IN O
the BC2GM075805410 DT O
2.4-kilobase BC2GM075805410 JJ O
messenger BC2GM075805410 NN O
RNA BC2GM075805410 NNP O
is BC2GM075805410 VBZ O
transcribed BC2GM075805410 VBN O
from BC2GM075805410 IN O
two BC2GM075805410 CD O
close BC2GM075805410 JJ O
origins BC2GM075805410 NNS O
identifying BC2GM075805410 VBG O
the BC2GM075805410 DT O
proximal BC2GM075805410 JJ O
promoter BC2GM075805410 NN O
. BC2GM075805410 . O
. . O O

INTERVENTIONS BC2GM087773567 NN O
: BC2GM087773567 : O
Postoperative BC2GM087773567 JJ O
follow-up BC2GM087773567 NN O
consisted BC2GM087773567 VBN O
of BC2GM087773567 IN O
serial BC2GM087773567 JJ O
determination BC2GM087773567 NN O
of BC2GM087773567 IN O
different BC2GM087773567 JJ O
biochemical BC2GM087773567 JJ O
markers BC2GM087773567 NNS O
( BC2GM087773567 ( O
CK BC2GM087773567 NNP O
, BC2GM087773567 , O
CK-MB BC2GM087773567 NNP O
, BC2GM087773567 , O
cTnI BC2GM087773567 NN O
) BC2GM087773567 ) O
, BC2GM087773567 , O
ECGs BC2GM087773567 NNP O
, BC2GM087773567 , O
and BC2GM087773567 CC O
echocardiography BC2GM087773567 NN O
. BC2GM087773567 . O
. . O O

In BC2GM005310044 IN O
one BC2GM005310044 CD O
trial BC2GM005310044 NN O
, BC2GM005310044 , O
116 BC2GM005310044 CD O
subjects BC2GM005310044 NNS O
with BC2GM005310044 IN O
transfusion-related BC2GM005310044 JJ O
chronic BC2GM005310044 JJ O
hepatitis BC2GM005310044 NN O
C BC2GM005310044 NNP O
were BC2GM005310044 VBD O
treated BC2GM005310044 VBN O
with BC2GM005310044 IN O
lymphoblastoid BC2GM005310044 JJ O
interferon BC2GM005310044 NN O
( BC2GM005310044 ( O
5 BC2GM005310044 CD O
MU BC2GM005310044 NNP O
/ BC2GM005310044 NNP O
m2 BC2GM005310044 VBD O
three BC2GM005310044 CD O
times BC2GM005310044 NNS O
a BC2GM005310044 DT O
week BC2GM005310044 NN O
for BC2GM005310044 IN O
2 BC2GM005310044 CD O
mo BC2GM005310044 NNS O
, BC2GM005310044 , O
then BC2GM005310044 RB O
3 BC2GM005310044 CD O
MU BC2GM005310044 NNP O
/ BC2GM005310044 NNP O
m2 BC2GM005310044 VBD O
three BC2GM005310044 CD O
times BC2GM005310044 NNS O
a BC2GM005310044 DT O
week BC2GM005310044 NN O
for BC2GM005310044 IN O
4 BC2GM005310044 CD O
or BC2GM005310044 CC O
10 BC2GM005310044 CD O
mo BC2GM005310044 NN O
) BC2GM005310044 ) O
. BC2GM005310044 . O
. . O O

Heating BC2GM011130797 NNP O
had BC2GM011130797 VBD O
no BC2GM011130797 DT O
effect BC2GM011130797 NN O
upon BC2GM011130797 IN O
either BC2GM011130797 DT O
force BC2GM011130797 NN O
decline BC2GM011130797 NN O
or BC2GM011130797 CC O
slowing BC2GM011130797 NN O
of BC2GM011130797 IN O
relaxation BC2GM011130797 NN O
during BC2GM011130797 IN O
fatiguing BC2GM011130797 VBG O
contractions BC2GM011130797 NNS O
. BC2GM011130797 . O
. . O O

The BC2GM020275127 DT O
use BC2GM020275127 NN O
of BC2GM020275127 IN O
self-measured BC2GM020275127 JJ O
blood BC2GM020275127 NN O
pressure BC2GM020275127 NN O
determinations BC2GM020275127 NNS O
in BC2GM020275127 IN O
assessing BC2GM020275127 VBG O
dynamics BC2GM020275127 NNS O
of BC2GM020275127 IN O
drug BC2GM020275127 NN O
compliance BC2GM020275127 NN O
in BC2GM020275127 IN O
a BC2GM020275127 DT O
study BC2GM020275127 NN O
with BC2GM020275127 IN O
amlodipine BC2GM020275127 NN O
once BC2GM020275127 RB O
a BC2GM020275127 DT O
day BC2GM020275127 NN O
, BC2GM020275127 , O
morning BC2GM020275127 NN O
versus BC2GM020275127 NN O
evening BC2GM020275127 NN O
. BC2GM020275127 . O
. . O O

The BC2GM028962331 DT O
aim BC2GM028962331 NN O
of BC2GM028962331 IN O
this BC2GM028962331 DT O
study BC2GM028962331 NN O
was BC2GM028962331 VBD O
to BC2GM028962331 TO O
evaluate BC2GM028962331 VB O
the BC2GM028962331 DT O
impact BC2GM028962331 NN O
of BC2GM028962331 IN O
the BC2GM028962331 DT O
ESRD BC2GM028962331 NNP O
treatment BC2GM028962331 NN O
modality BC2GM028962331 NN O
on BC2GM028962331 IN O
the BC2GM028962331 DT O
quality BC2GM028962331 NN O
of BC2GM028962331 IN O
life BC2GM028962331 NN O
in BC2GM028962331 IN O
patients BC2GM028962331 NNS O
with BC2GM028962331 IN O
Type BC2GM028962331 NNP O
I BC2GM028962331 PRP O
( BC2GM028962331 ( O
insulin-dependent BC2GM028962331 JJ O
) BC2GM028962331 ) O
diabetes BC2GM028962331 VBZ O
mellitus BC2GM028962331 NN O
. BC2GM028962331 . O
. . O O

In BC2GM005102149 IN O
an BC2GM005102149 DT O
effort BC2GM005102149 NN O
to BC2GM005102149 TO O
identify BC2GM005102149 VB O
factors BC2GM005102149 NNS O
involved BC2GM005102149 VBN O
in BC2GM005102149 IN O
the BC2GM005102149 DT O
expression BC2GM005102149 NN O
of BC2GM005102149 IN O
this BC2GM005102149 DT O
important BC2GM005102149 JJ O
erythroid-specific BC2GM005102149 JJ O
regulatory BC2GM005102149 JJ O
protein BC2GM005102149 NN O
, BC2GM005102149 , O
we BC2GM005102149 PRP O
have BC2GM005102149 VBP O
isolated BC2GM005102149 VBN O
the BC2GM005102149 DT O
mouse BC2GM005102149 NN O
EKLF BC2GM005102149 NNP O
gene BC2GM005102149 NN O
and BC2GM005102149 CC O
systematically BC2GM005102149 RB O
analyzed BC2GM005102149 VBD O
the BC2GM005102149 DT O
promoter BC2GM005102149 NN O
region BC2GM005102149 NN O
. BC2GM005102149 . O
. . O O

In BC2GM035505674 IN O
pituitary BC2GM035505674 JJ O
GH3 BC2GM035505674 NNP O
cells BC2GM035505674 NNS O
, BC2GM035505674 , O
vitamin BC2GM035505674 FW O
D BC2GM035505674 NNP O
increases BC2GM035505674 VBZ O
the BC2GM035505674 DT O
levels BC2GM035505674 NNS O
of BC2GM035505674 IN O
PRL BC2GM035505674 NNP O
transcripts BC2GM035505674 NNS O
and BC2GM035505674 CC O
stimulates BC2GM035505674 VBZ O
the BC2GM035505674 DT O
PRL BC2GM035505674 NNP O
promoter BC2GM035505674 NN O
. BC2GM035505674 . O
. . O O

In BC2GM007444164 IN O
CYP7A1 BC2GM007444164 NNP O
transgenic BC2GM007444164 JJ O
mice BC2GM007444164 NN O
, BC2GM007444164 , O
livers BC2GM007444164 NNS O
contained BC2GM007444164 VBD O
approximately BC2GM007444164 RB O
3-fold BC2GM007444164 JJ O
more BC2GM007444164 JJR O
sterol BC2GM007444164 JJ O
response BC2GM007444164 NN O
element-binding BC2GM007444164 JJ O
protein-2 BC2GM007444164 JJ O
mRNA BC2GM007444164 NN O
. BC2GM007444164 . O
. . O O

Comparisons BC2GM039151408 NNS O
of BC2GM039151408 IN O
defective BC2GM039151408 JJ O
HTLV-I BC2GM039151408 NNP O
proviruses BC2GM039151408 NNS O
predict BC2GM039151408 VBP O
the BC2GM039151408 DT O
mode BC2GM039151408 NN O
of BC2GM039151408 IN O
origin BC2GM039151408 NN O
and BC2GM039151408 CC O
coding BC2GM039151408 VBG O
potential BC2GM039151408 NN O
of BC2GM039151408 IN O
internally BC2GM039151408 RB O
deleted BC2GM039151408 VBN O
genomes BC2GM039151408 NNS O
. BC2GM039151408 . O
. . O O

These BC2GM092675349 DT O
findings BC2GM092675349 NNS O
suggest BC2GM092675349 VBP O
that BC2GM092675349 IN O
the BC2GM092675349 DT O
mechanism BC2GM092675349 NN O
of BC2GM092675349 IN O
ribosomal BC2GM092675349 JJ O
frameshifting BC2GM092675349 NN O
at BC2GM092675349 IN O
the BC2GM092675349 DT O
PVM BC2GM092675349 NNP O
signal BC2GM092675349 NN O
is BC2GM092675349 VBZ O
different BC2GM092675349 JJ O
from BC2GM092675349 IN O
the BC2GM092675349 DT O
one BC2GM092675349 CD O
described BC2GM092675349 VBN O
by BC2GM092675349 IN O
the BC2GM092675349 DT O
'simultaneous BC2GM092675349 JJ O
slippage BC2GM092675349 NN O
' BC2GM092675349 '' O
model BC2GM092675349 NN O
in BC2GM092675349 IN O
that BC2GM092675349 DT O
only BC2GM092675349 RB O
the BC2GM092675349 DT O
string BC2GM092675349 NN O
of BC2GM092675349 IN O
four BC2GM092675349 CD O
adenosine BC2GM092675349 NN O
nucleotides BC2GM092675349 NNS O
represents BC2GM092675349 VBZ O
the BC2GM092675349 DT O
slippery BC2GM092675349 NN O
sequence BC2GM092675349 NN O
involved BC2GM092675349 VBN O
in BC2GM092675349 IN O
a BC2GM092675349 DT O
-1 BC2GM092675349 JJ O
P-site BC2GM092675349 JJ O
slippage BC2GM092675349 NN O
. BC2GM092675349 . O
. . O O

The BC2GM034659182 DT O
arrangement BC2GM034659182 NN O
of BC2GM034659182 IN O
amino BC2GM034659182 JJ O
acids BC2GM034659182 NNS O
in BC2GM034659182 IN O
the BC2GM034659182 DT O
helix BC2GM034659182 NN O
1 BC2GM034659182 CD O
and BC2GM034659182 CC O
helix BC2GM034659182 $ O
2 BC2GM034659182 CD O
regions BC2GM034659182 NNS O
is BC2GM034659182 VBZ O
quite BC2GM034659182 RB O
similar BC2GM034659182 JJ O
to BC2GM034659182 TO O
those BC2GM034659182 DT O
of BC2GM034659182 IN O
Mxi BC2GM034659182 NNP O
and BC2GM034659182 CC O
Mad BC2GM034659182 NNP O
, BC2GM034659182 , O
but BC2GM034659182 CC O
different BC2GM034659182 JJ O
from BC2GM034659182 IN O
those BC2GM034659182 DT O
of BC2GM034659182 IN O
E2F-1 BC2GM034659182 NNP O
and BC2GM034659182 CC O
DP-1 BC2GM034659182 NNP O
. BC2GM034659182 . O
. . O O

This BC2GM004484072 DT O
raises BC2GM004484072 VBZ O
the BC2GM004484072 DT O
possibility BC2GM004484072 NN O
that BC2GM004484072 IN O
recombination BC2GM004484072 NN O
occurred BC2GM004484072 VBD O
between BC2GM004484072 IN O
corresponding BC2GM004484072 VBG O
LTR BC2GM004484072 NNP O
and BC2GM004484072 CC O
vif BC2GM004484072 JJ O
loci BC2GM004484072 NN O
of BC2GM004484072 IN O
the BC2GM004484072 DT O
quasi-species BC2GM004484072 NNS O
present BC2GM004484072 NN O
in BC2GM004484072 IN O
the BC2GM004484072 DT O
isolates BC2GM004484072 NNS O
described BC2GM004484072 VBD O
here BC2GM004484072 RB O
. BC2GM004484072 . O
. . O O

A BC2GM032527280 DT O
ready-made BC2GM032527280 JJ O
prosthesis BC2GM032527280 NN O
is BC2GM032527280 VBZ O
placed BC2GM032527280 VBN O
on BC2GM032527280 IN O
the BC2GM032527280 DT O
external BC2GM032527280 JJ O
side BC2GM032527280 NN O
of BC2GM032527280 IN O
the BC2GM032527280 DT O
ribs BC2GM032527280 NN O
vertically BC2GM032527280 RB O
bridging BC2GM032527280 VBG O
the BC2GM032527280 DT O
flailed BC2GM032527280 VBN O
chest BC2GM032527280 NN O
segment BC2GM032527280 NN O
, BC2GM032527280 , O
and BC2GM032527280 CC O
fixed BC2GM032527280 VBN O
to BC2GM032527280 TO O
the BC2GM032527280 DT O
first BC2GM032527280 JJ O
upper BC2GM032527280 NN O
and BC2GM032527280 CC O
first BC2GM032527280 JJ O
lower BC2GM032527280 JJR O
intact BC2GM032527280 JJ O
rib BC2GM032527280 NN O
as BC2GM032527280 RB O
well BC2GM032527280 RB O
as BC2GM032527280 IN O
to BC2GM032527280 TO O
the BC2GM032527280 DT O
mobile BC2GM032527280 JJ O
segments BC2GM032527280 NNS O
of BC2GM032527280 IN O
the BC2GM032527280 DT O
affected BC2GM032527280 JJ O
ribs BC2GM032527280 NN O
. BC2GM032527280 . O
. . O O

In BC2GM096784284 IN O
the BC2GM096784284 DT O
other BC2GM096784284 JJ O
two BC2GM096784284 CD O
cases BC2GM096784284 NNS O
, BC2GM096784284 , O
fluoxetine BC2GM096784284 JJ O
adjunct BC2GM096784284 NN O
produced BC2GM096784284 VBD O
benefits BC2GM096784284 NNS O
with BC2GM096784284 IN O
no BC2GM096784284 DT O
additional BC2GM096784284 JJ O
side BC2GM096784284 NN O
effects BC2GM096784284 NNS O
. BC2GM096784284 . O
. . O O

To BC2GM006556353 TO O
better BC2GM006556353 RBR O
understand BC2GM006556353 VB O
the BC2GM006556353 DT O
relationship BC2GM006556353 NN O
between BC2GM006556353 IN O
expression BC2GM006556353 NN O
of BC2GM006556353 IN O
an BC2GM006556353 DT O
oncogene BC2GM006556353 NN O
and BC2GM006556353 CC O
genetic BC2GM006556353 JJ O
instability BC2GM006556353 NN O
, BC2GM006556353 , O
we BC2GM006556353 PRP O
have BC2GM006556353 VBP O
studied BC2GM006556353 VBN O
a BC2GM006556353 DT O
cell BC2GM006556353 NN O
line BC2GM006556353 NN O
expressing BC2GM006556353 VBG O
an BC2GM006556353 DT O
activated BC2GM006556353 JJ O
human BC2GM006556353 JJ O
Ha-ras BC2GM006556353 NNP O
under BC2GM006556353 IN O
the BC2GM006556353 DT O
control BC2GM006556353 NN O
of BC2GM006556353 IN O
bacterial BC2GM006556353 JJ O
lactose BC2GM006556353 JJ O
operon BC2GM006556353 NN O
regulatory BC2GM006556353 JJ O
elements BC2GM006556353 NNS O
for BC2GM006556353 IN O
changes BC2GM006556353 NNS O
in BC2GM006556353 IN O
methotrexate BC2GM006556353 NN O
resistance BC2GM006556353 NN O
and BC2GM006556353 CC O
dihydrofolate BC2GM006556353 VB O
reductase BC2GM006556353 NN O
( BC2GM006556353 ( O
dhfr BC2GM006556353 NN O
) BC2GM006556353 ) O
gene BC2GM006556353 NN O
amplification BC2GM006556353 NN O
following BC2GM006556353 VBG O
mutant BC2GM006556353 JJ O
Ha-ras BC2GM006556353 JJ O
induction BC2GM006556353 NN O
. BC2GM006556353 . O
. . O O

METHODS BC2GM058126841 NN O
: BC2GM058126841 : O
Children BC2GM058126841 NN O
with BC2GM058126841 IN O
attention-deficit BC2GM058126841 JJ O
/ BC2GM058126841 NNP O
hyperactivity BC2GM058126841 NN O
disorder BC2GM058126841 NN O
( BC2GM058126841 ( O
ADHD BC2GM058126841 NNP O
; BC2GM058126841 : O
n BC2GM058126841 CC O
= BC2GM058126841 VB O
282 BC2GM058126841 CD O
) BC2GM058126841 ) O
, BC2GM058126841 , O
all BC2GM058126841 DT O
subtypes BC2GM058126841 NNS O
, BC2GM058126841 , O
ages BC2GM058126841 VBZ O
6 BC2GM058126841 CD O
to BC2GM058126841 TO O
12 BC2GM058126841 CD O
years BC2GM058126841 NNS O
, BC2GM058126841 , O
were BC2GM058126841 VBD O
randomized BC2GM058126841 VBN O
to BC2GM058126841 TO O
placebo BC2GM058126841 VB O
( BC2GM058126841 ( O
n BC2GM058126841 JJ O
= BC2GM058126841 NNP O
90 BC2GM058126841 CD O
) BC2GM058126841 ) O
, BC2GM058126841 , O
immediate-release BC2GM058126841 JJ O
methylphenidate BC2GM058126841 NN O
( BC2GM058126841 ( O
IR BC2GM058126841 NNP O
MPH BC2GM058126841 NNP O
) BC2GM058126841 ) O
3 BC2GM058126841 CD O
times BC2GM058126841 NNS O
a BC2GM058126841 DT O
day BC2GM058126841 NN O
( BC2GM058126841 ( O
tid BC2GM058126841 NN O
; BC2GM058126841 : O
dosed BC2GM058126841 VBN O
every BC2GM058126841 DT O
4 BC2GM058126841 CD O
hours BC2GM058126841 NNS O
; BC2GM058126841 : O
n BC2GM058126841 CC O
= BC2GM058126841 VB O
97 BC2GM058126841 CD O
) BC2GM058126841 ) O
, BC2GM058126841 , O
or BC2GM058126841 CC O
OROS BC2GM058126841 NNP O
MPH BC2GM058126841 NNP O
once BC2GM058126841 RB O
a BC2GM058126841 DT O
day BC2GM058126841 NN O
( BC2GM058126841 ( O
qd BC2GM058126841 NN O
; BC2GM058126841 : O
n BC2GM058126841 CC O
= BC2GM058126841 VB O
95 BC2GM058126841 CD O
) BC2GM058126841 ) O
in BC2GM058126841 IN O
a BC2GM058126841 DT O
double-blind BC2GM058126841 JJ O
, BC2GM058126841 , O
28-day BC2GM058126841 JJ O
trial BC2GM058126841 NN O
. BC2GM058126841 . O
. . O O

We BC2GM092341620 PRP O
have BC2GM092341620 VBP O
isolated BC2GM092341620 VBN O
and BC2GM092341620 CC O
determined BC2GM092341620 VBN O
the BC2GM092341620 DT O
complete BC2GM092341620 JJ O
nucleotide BC2GM092341620 JJ O
sequence BC2GM092341620 NN O
of BC2GM092341620 IN O
another BC2GM092341620 DT O
operon BC2GM092341620 NN O
, BC2GM092341620 , O
cpeCD BC2GM092341620 NN O
, BC2GM092341620 , O
that BC2GM092341620 WDT O
encodes BC2GM092341620 VBZ O
the BC2GM092341620 DT O
linker BC2GM092341620 NN O
proteins BC2GM092341620 VBZ O
associated BC2GM092341620 VBN O
with BC2GM092341620 IN O
phycoerythrin BC2GM092341620 NN O
hexamers BC2GM092341620 NNS O
in BC2GM092341620 IN O
the BC2GM092341620 DT O
phycobilisome BC2GM092341620 NN O
. BC2GM092341620 . O
. . O O

However BC2GM036083685 RB O
, BC2GM036083685 , O
differential BC2GM036083685 JJ O
utilization BC2GM036083685 NN O
of BC2GM036083685 IN O
these BC2GM036083685 DT O
determinants BC2GM036083685 NNS O
mediate BC2GM036083685 VBP O
RAR-RXR BC2GM036083685 JJ O
heterodimer BC2GM036083685 NN O
binding BC2GM036083685 NN O
to BC2GM036083685 TO O
DR-2 BC2GM036083685 NNP O
and BC2GM036083685 CC O
DR-5 BC2GM036083685 NNP O
RAREs BC2GM036083685 NNP O
. BC2GM036083685 . O
. . O O

Plasmid BC2GM084248034 NNP O
pSP64E6E7 BC2GM084248034 NN O
which BC2GM084248034 WDT O
contains BC2GM084248034 VBZ O
the BC2GM084248034 DT O
reading BC2GM084248034 NN O
frames BC2GM084248034 NNS O
of BC2GM084248034 IN O
both BC2GM084248034 DT O
E6 BC2GM084248034 NNP O
and BC2GM084248034 CC O
E7 BC2GM084248034 NNP O
was BC2GM084248034 VBD O
constructed BC2GM084248034 VBN O
in BC2GM084248034 IN O
order BC2GM084248034 NN O
to BC2GM084248034 TO O
study BC2GM084248034 VB O
the BC2GM084248034 DT O
expression BC2GM084248034 NN O
of BC2GM084248034 IN O
both BC2GM084248034 DT O
proteins BC2GM084248034 NNS O
in BC2GM084248034 IN O
a BC2GM084248034 DT O
coupled BC2GM084248034 JJ O
transcription BC2GM084248034 NN O
/ BC2GM084248034 NNP O
rabbit BC2GM084248034 NN O
reticulocyte BC2GM084248034 NN O
translation BC2GM084248034 NN O
system BC2GM084248034 NN O
. BC2GM084248034 . O
. . O O

The BC2GM058702886 DT O
fusion BC2GM058702886 NN O
of BC2GM058702886 IN O
AML1 BC2GM058702886 NNP O
to BC2GM058702886 TO O
MDS1 BC2GM058702886 NNP O
is BC2GM058702886 VBZ O
in BC2GM058702886 IN O
frame BC2GM058702886 NN O
, BC2GM058702886 , O
and BC2GM058702886 CC O
adds BC2GM058702886 VBZ O
127 BC2GM058702886 CD O
codons BC2GM058702886 NNS O
to BC2GM058702886 TO O
the BC2GM058702886 DT O
interrupted BC2GM058702886 JJ O
AML1 BC2GM058702886 NNP O
. BC2GM058702886 . O
. . O O

Mortality BC2GM097865195 NNP O
among BC2GM097865195 IN O
patients BC2GM097865195 NNS O
with BC2GM097865195 IN O
CAVB BC2GM097865195 NNP O
is BC2GM097865195 VBZ O
still BC2GM097865195 RB O
high BC2GM097865195 JJ O
and BC2GM097865195 CC O
has BC2GM097865195 VBZ O
not BC2GM097865195 RB O
declined BC2GM097865195 VBN O
within BC2GM097865195 IN O
the BC2GM097865195 DT O
last BC2GM097865195 JJ O
decade BC2GM097865195 NN O
. BC2GM097865195 . O
. . O O

Together BC2GM005272522 RB O
with BC2GM005272522 IN O
a BC2GM005272522 DT O
number BC2GM005272522 NN O
of BC2GM005272522 IN O
phase BC2GM005272522 NN O
II BC2GM005272522 NNP O
trials BC2GM005272522 NNS O
, BC2GM005272522 , O
phase BC2GM005272522 NN O
I BC2GM005272522 PRP O
trials BC2GM005272522 VBP O
utilizing BC2GM005272522 VBG O
escalating BC2GM005272522 VBG O
doses BC2GM005272522 NNS O
of BC2GM005272522 IN O
carboplatin BC2GM005272522 NN O
and BC2GM005272522 CC O
paclitaxel BC2GM005272522 NN O
with BC2GM005272522 IN O
growth BC2GM005272522 NN O
factor BC2GM005272522 NN O
or BC2GM005272522 CC O
growth BC2GM005272522 NN O
factor BC2GM005272522 NN O
and BC2GM005272522 CC O
blood BC2GM005272522 NN O
stem-cell BC2GM005272522 JJ O
support BC2GM005272522 NN O
have BC2GM005272522 VBP O
shown BC2GM005272522 VBN O
that BC2GM005272522 IN O
substantial BC2GM005272522 JJ O
increases BC2GM005272522 NNS O
in BC2GM005272522 IN O
dose BC2GM005272522 JJ O
intensity BC2GM005272522 NN O
can BC2GM005272522 MD O
be BC2GM005272522 VB O
achieved BC2GM005272522 VBN O
. BC2GM005272522 . O
. . O O

D. BC2GM008679879 NNP O
, BC2GM008679879 , O
and BC2GM008679879 CC O
Long BC2GM008679879 NNP O
, BC2GM008679879 , O
C BC2GM008679879 NNP O
. BC2GM008679879 . O
. . O O

Human BC2GM024341758 NNP O
recombinant BC2GM024341758 NN O
erythropoietin BC2GM024341758 NN O
( BC2GM024341758 ( O
r-HuEPO BC2GM024341758 JJ O
, BC2GM024341758 , O
EprexR BC2GM024341758 NNP O
) BC2GM024341758 ) O
was BC2GM024341758 VBD O
administered BC2GM024341758 VBN O
to BC2GM024341758 TO O
8 BC2GM024341758 CD O
children BC2GM024341758 NNS O
with BC2GM024341758 IN O
chronic BC2GM024341758 JJ O
renal BC2GM024341758 JJ O
failure BC2GM024341758 NN O
and BC2GM024341758 CC O
high BC2GM024341758 JJ O
transfusion BC2GM024341758 NN O
requirement BC2GM024341758 NN O
. BC2GM024341758 . O
. . O O

In BC2GM040656099 IN O
a BC2GM040656099 DT O
series BC2GM040656099 NN O
of BC2GM040656099 IN O
papers BC2GM040656099 NNS O
, BC2GM040656099 , O
the BC2GM040656099 DT O
staging BC2GM040656099 NN O
system BC2GM040656099 NN O
for BC2GM040656099 IN O
melanoma BC2GM040656099 NN O
was BC2GM040656099 VBD O
critically BC2GM040656099 RB O
analyzed BC2GM040656099 VBN O
, BC2GM040656099 , O
and BC2GM040656099 CC O
many BC2GM040656099 JJ O
shortcomings BC2GM040656099 NNS O
were BC2GM040656099 VBD O
identified BC2GM040656099 VBN O
. BC2GM040656099 . O
. . O O

The BC2GM033539828 DT O
shift BC2GM033539828 NN O
from BC2GM033539828 IN O
complex BC2GM033539828 JJ O
I BC2GM033539828 PRP O
to BC2GM033539828 TO O
complex BC2GM033539828 VB O
II BC2GM033539828 NNP O
seen BC2GM033539828 VBN O
only BC2GM033539828 RB O
in BC2GM033539828 IN O
SCM-1-producer BC2GM033539828 NNP O
T BC2GM033539828 NNP O
cell BC2GM033539828 NN O
lines BC2GM033539828 NNS O
upon BC2GM033539828 IN O
activation BC2GM033539828 NN O
was BC2GM033539828 VBD O
completely BC2GM033539828 RB O
suppressed BC2GM033539828 VBN O
by BC2GM033539828 IN O
cyclosporin BC2GM033539828 NN O
A BC2GM033539828 NNP O
. BC2GM033539828 . O
. . O O

Is BC2GM089212224 VBZ O
exposure BC2GM089212224 NN O
to BC2GM089212224 TO O
a BC2GM089212224 DT O
patient BC2GM089212224 NN O
with BC2GM089212224 IN O
Crohn BC2GM089212224 NNP O
's BC2GM089212224 POS O
disease BC2GM089212224 NN O
an BC2GM089212224 DT O
environmental BC2GM089212224 JJ O
factor BC2GM089212224 NN O
for BC2GM089212224 IN O
developing BC2GM089212224 VBG O
the BC2GM089212224 DT O
disease BC2GM089212224 NN O
. BC2GM089212224 . O
. . O O

Of BC2GM000611082 IN O
81 BC2GM000611082 CD O
girls BC2GM000611082 NNS O
cured BC2GM000611082 VBN O
from BC2GM000611082 IN O
the BC2GM000611082 DT O
bacteriuria BC2GM000611082 NN O
24 BC2GM000611082 CD O
recurred BC2GM000611082 VBD O
, BC2GM000611082 , O
5 BC2GM000611082 CD O
with BC2GM000611082 IN O
a BC2GM000611082 DT O
symptomatic BC2GM000611082 JJ O
pyelonephritis BC2GM000611082 NN O
and BC2GM000611082 CC O
3 BC2GM000611082 CD O
with BC2GM000611082 IN O
cystitis BC2GM000611082 NN O
. BC2GM000611082 . O
. . O O

In BC2GM048068707 IN O
phase BC2GM048068707 NN O
II BC2GM048068707 NNP O
studies BC2GM048068707 NNS O
, BC2GM048068707 , O
MDL BC2GM048068707 NNP O
72,974A BC2GM048068707 CD O
is BC2GM048068707 VBZ O
proving BC2GM048068707 VBG O
to BC2GM048068707 TO O
be BC2GM048068707 VB O
a BC2GM048068707 DT O
useful BC2GM048068707 JJ O
adjunct BC2GM048068707 NN O
to BC2GM048068707 TO O
conventional BC2GM048068707 JJ O
therapy BC2GM048068707 NN O
. BC2GM048068707 . O
. . O O

Therefore BC2GM087006265 RB O
, BC2GM087006265 , O
a BC2GM087006265 DT O
structural BC2GM087006265 JJ O
interaction BC2GM087006265 NN O
between BC2GM087006265 IN O
PsaL BC2GM087006265 NNP O
and BC2GM087006265 CC O
PsaI BC2GM087006265 NNP O
may BC2GM087006265 MD O
stabilize BC2GM087006265 VB O
the BC2GM087006265 DT O
association BC2GM087006265 NN O
of BC2GM087006265 IN O
PsaL BC2GM087006265 NNP O
with BC2GM087006265 IN O
the BC2GM087006265 DT O
photosystem BC2GM087006265 NN O
I BC2GM087006265 PRP O
core BC2GM087006265 VBP O
. BC2GM087006265 . O
. . O O

Our BC2GM070908421 PRP$ O
experience BC2GM070908421 NN O
suggests BC2GM070908421 VBZ O
that BC2GM070908421 IN O
T2 BC2GM070908421 NNP O
weighting BC2GM070908421 NN O
is BC2GM070908421 VBZ O
adequate BC2GM070908421 JJ O
and BC2GM070908421 CC O
is BC2GM070908421 VBZ O
the BC2GM070908421 DT O
method BC2GM070908421 NN O
of BC2GM070908421 IN O
choice BC2GM070908421 NN O
for BC2GM070908421 IN O
the BC2GM070908421 DT O
early BC2GM070908421 JJ O
recognition BC2GM070908421 NN O
of BC2GM070908421 IN O
necrosis BC2GM070908421 NN O
of BC2GM070908421 IN O
the BC2GM070908421 DT O
lunate BC2GM070908421 NN O
. BC2GM070908421 . O
. . O O

The BC2GM068680235 DT O
DNA-binding BC2GM068680235 JJ O
proteins BC2GM068680235 NNS O
are BC2GM068680235 VBP O
without BC2GM068680235 IN O
effect BC2GM068680235 NN O
on BC2GM068680235 IN O
the BC2GM068680235 DT O
transcription BC2GM068680235 NN O
of BC2GM068680235 IN O
plasmids BC2GM068680235 NNS O
lacking BC2GM068680235 VBG O
binding BC2GM068680235 VBG O
sites BC2GM068680235 NNS O
or BC2GM068680235 CC O
when BC2GM068680235 WRB O
the BC2GM068680235 DT O
binding BC2GM068680235 NN O
sites BC2GM068680235 NNS O
are BC2GM068680235 VBP O
located BC2GM068680235 VBN O
further BC2GM068680235 JJ O
upstream BC2GM068680235 NN O
. BC2GM068680235 . O
. . O O

The BC2GM098593892 DT O
cyanobacterial BC2GM098593892 JJ O
phycobilisome BC2GM098593892 NN O
is BC2GM098593892 VBZ O
a BC2GM098593892 DT O
large BC2GM098593892 JJ O
protein BC2GM098593892 NN O
complex BC2GM098593892 NN O
located BC2GM098593892 VBN O
on BC2GM098593892 IN O
the BC2GM098593892 DT O
photosynthetic BC2GM098593892 JJ O
membrane BC2GM098593892 NN O
. BC2GM098593892 . O
. . O O

Tritiated BC2GM057882399 VBN O
1,24,25-trihydroxyvitamin BC2GM057882399 JJ O
D3 BC2GM057882399 NNP O
was BC2GM057882399 VBD O
synthesized BC2GM057882399 VBN O
biologically BC2GM057882399 RB O
and BC2GM057882399 CC O
used BC2GM057882399 VBD O
as BC2GM057882399 IN O
tracer BC2GM057882399 NN O
to BC2GM057882399 TO O
monitor BC2GM057882399 VB O
the BC2GM057882399 DT O
recovery BC2GM057882399 NN O
of BC2GM057882399 IN O
endogenous BC2GM057882399 JJ O
metabolite BC2GM057882399 NN O
during BC2GM057882399 IN O
isolation BC2GM057882399 NN O
from BC2GM057882399 IN O
serum BC2GM057882399 NN O
. BC2GM057882399 . O
. . O O

Individual BC2GM012909505 NNP O
and BC2GM012909505 CC O
combined BC2GM012909505 VBN O
effects BC2GM012909505 NNS O
of BC2GM012909505 IN O
fumonisin BC2GM012909505 NN O
B1 BC2GM012909505 NNP O
present BC2GM012909505 NN O
in BC2GM012909505 IN O
Fusarium BC2GM012909505 NNP O
moniliforme BC2GM012909505 JJ O
culture BC2GM012909505 NN O
material BC2GM012909505 NN O
and BC2GM012909505 CC O
diacetoxyscirpenol BC2GM012909505 NN O
or BC2GM012909505 CC O
ochratoxin BC2GM012909505 VB O
A BC2GM012909505 DT O
in BC2GM012909505 IN O
turkey BC2GM012909505 NN O
poults BC2GM012909505 NNS O
. BC2GM012909505 . O
. . O O

RESEARCH BC2GM043004762 NNP O
DESIGN BC2GM043004762 NNP O
AND BC2GM043004762 NNP O
METHODS BC2GM043004762 NNP O
: BC2GM043004762 : O
A BC2GM043004762 DT O
total BC2GM043004762 NN O
of BC2GM043004762 IN O
26 BC2GM043004762 CD O
IDDM BC2GM043004762 NNP O
patients BC2GM043004762 NNS O
with BC2GM043004762 IN O
normoalbuminuria BC2GM043004762 NNS O
were BC2GM043004762 VBD O
randomized BC2GM043004762 VBN O
into BC2GM043004762 IN O
two BC2GM043004762 CD O
groups BC2GM043004762 NNS O
, BC2GM043004762 , O
with BC2GM043004762 IN O
one BC2GM043004762 CD O
group BC2GM043004762 NN O
receiving BC2GM043004762 VBG O
placebo BC2GM043004762 NN O
( BC2GM043004762 ( O
n BC2GM043004762 JJ O
= BC2GM043004762 NN O
13 BC2GM043004762 CD O
, BC2GM043004762 , O
age BC2GM043004762 NN O
36 BC2GM043004762 CD O
+ BC2GM043004762 NN O
/ BC2GM043004762 NNP O
- BC2GM043004762 : O
3 BC2GM043004762 CD O
years BC2GM043004762 NNS O
, BC2GM043004762 , O
BMI BC2GM043004762 NNP O
24.5 BC2GM043004762 CD O
+ BC2GM043004762 NNP O
/ BC2GM043004762 NNP O
- BC2GM043004762 : O
1.1 BC2GM043004762 CD O
kg BC2GM043004762 NN O
/ BC2GM043004762 NNP O
m2 BC2GM043004762 NN O
) BC2GM043004762 ) O
and BC2GM043004762 CC O
the BC2GM043004762 DT O
other BC2GM043004762 JJ O
group BC2GM043004762 NN O
receiving BC2GM043004762 VBG O
an BC2GM043004762 DT O
average BC2GM043004762 NN O
of BC2GM043004762 IN O
15 BC2GM043004762 CD O
mg BC2GM043004762 NNS O
lisinopril BC2GM043004762 JJ O
daily BC2GM043004762 JJ O
( BC2GM043004762 ( O
n BC2GM043004762 JJ O
= BC2GM043004762 NN O
13 BC2GM043004762 CD O
, BC2GM043004762 , O
age BC2GM043004762 NN O
34 BC2GM043004762 CD O
+ BC2GM043004762 NN O
/ BC2GM043004762 NNP O
- BC2GM043004762 : O
2 BC2GM043004762 CD O
years BC2GM043004762 NNS O
, BC2GM043004762 , O
BMI BC2GM043004762 NNP O
24.4 BC2GM043004762 CD O
+ BC2GM043004762 NNP O
/ BC2GM043004762 NNP O
- BC2GM043004762 : O
0.9 BC2GM043004762 CD O
kg BC2GM043004762 NN O
/ BC2GM043004762 NNP O
m2 BC2GM043004762 NN O
) BC2GM043004762 ) O
. BC2GM043004762 . O
. . O O

In BC2GM071553689 IN O
addition BC2GM071553689 NN O
, BC2GM071553689 , O
measurements BC2GM071553689 NNS O
of BC2GM071553689 IN O
shielded BC2GM071553689 JJ O
and BC2GM071553689 CC O
unshielded BC2GM071553689 JJ O
syringes BC2GM071553689 NNS O
containing BC2GM071553689 VBG O
99mTc-labelled BC2GM071553689 JJ O
radiopharmaceuticals BC2GM071553689 NNS O
were BC2GM071553689 VBD O
carried BC2GM071553689 VBN O
out BC2GM071553689 RP O
. BC2GM071553689 . O
. . O O

In BC2GM033438467 IN O
the BC2GM033438467 DT O
absence BC2GM033438467 NN O
of BC2GM033438467 IN O
c-fos BC2GM033438467 JJ O
gene BC2GM033438467 NN O
expression BC2GM033438467 NN O
, BC2GM033438467 , O
c-Fos BC2GM033438467 JJ O
protein BC2GM033438467 NN O
appears BC2GM033438467 VBZ O
to BC2GM033438467 TO O
be BC2GM033438467 VB O
replaced BC2GM033438467 VBN O
by BC2GM033438467 IN O
proteins BC2GM033438467 NNS O
of BC2GM033438467 IN O
Fos BC2GM033438467 NNP O
family BC2GM033438467 NN O
( BC2GM033438467 ( O
Fra-1 BC2GM033438467 NNP O
) BC2GM033438467 ) O
and BC2GM033438467 CC O
ATF BC2GM033438467 NNP O
family BC2GM033438467 NN O
( BC2GM033438467 ( O
ATF-2 BC2GM033438467 NNP O
and BC2GM033438467 CC O
ATFa BC2GM033438467 NNP O
) BC2GM033438467 ) O
. BC2GM033438467 . O
. . O O

A BC2GM048845063 DT O
nationwide BC2GM048845063 JJ O
record BC2GM048845063 NN O
linkage BC2GM048845063 NN O
of BC2GM048845063 IN O
the BC2GM048845063 DT O
Finnish BC2GM048845063 NNP O
Twin BC2GM048845063 NNP O
Cohort BC2GM048845063 NNP O
Study BC2GM048845063 NNP O
( BC2GM048845063 ( O
FTCS BC2GM048845063 NNP O
) BC2GM048845063 ) O
with BC2GM048845063 IN O
the BC2GM048845063 DT O
Hospital BC2GM048845063 NNP O
Discharge BC2GM048845063 NNP O
Registry BC2GM048845063 NNP O
and BC2GM048845063 CC O
the BC2GM048845063 DT O
Registry BC2GM048845063 NNP O
of BC2GM048845063 IN O
Rights BC2GM048845063 NNPS O
for BC2GM048845063 IN O
Free BC2GM048845063 JJ O
medication BC2GM048845063 NN O
is BC2GM048845063 VBZ O
presented BC2GM048845063 VBN O
. BC2GM048845063 . O
. . O O

Thus BC2GM014908370 RB O
, BC2GM014908370 , O
Shp2 BC2GM014908370 NNP O
regulates BC2GM014908370 VBZ O
phosphotyrosine-signalling BC2GM014908370 JJ O
events BC2GM014908370 NNS O
during BC2GM014908370 IN O
the BC2GM014908370 DT O
complex BC2GM014908370 JJ O
ectodermal-mesenchymal BC2GM014908370 JJ O
interactions BC2GM014908370 NNS O
that BC2GM014908370 WDT O
regulate BC2GM014908370 VBP O
mammalian BC2GM014908370 JJ O
budding BC2GM014908370 NN O
morphogenesis BC2GM014908370 NN O
. BC2GM014908370 . O
. . O O

Increased BC2GM036319950 VBN O
platelet-derived BC2GM036319950 JJ O
growth BC2GM036319950 NN O
factor BC2GM036319950 NN O
production BC2GM036319950 NN O
and BC2GM036319950 CC O
intimal BC2GM036319950 JJ O
thickening BC2GM036319950 NN O
during BC2GM036319950 IN O
healing BC2GM036319950 NN O
of BC2GM036319950 IN O
Dacron BC2GM036319950 NNP O
grafts BC2GM036319950 NNS O
in BC2GM036319950 IN O
a BC2GM036319950 DT O
canine BC2GM036319950 NN O
model BC2GM036319950 NN O
. BC2GM036319950 . O
. . O O

A BC2GM006085106 DT O
Drosophila BC2GM006085106 NNP O
subobscura BC2GM006085106 NN O
genomic BC2GM006085106 JJ O
fragment BC2GM006085106 NN O
containing BC2GM006085106 VBG O
all BC2GM006085106 PDT O
the BC2GM006085106 DT O
exons BC2GM006085106 NNS O
and BC2GM006085106 CC O
the BC2GM006085106 DT O
late BC2GM006085106 JJ O
and BC2GM006085106 CC O
early BC2GM006085106 JJ O
promotors BC2GM006085106 NNS O
in BC2GM006085106 IN O
the BC2GM006085106 DT O
Sxl BC2GM006085106 NNP O
gene BC2GM006085106 NN O
of BC2GM006085106 IN O
D. BC2GM006085106 NNP O
melanogaster BC2GM006085106 NN O
was BC2GM006085106 VBD O
isolated BC2GM006085106 VBN O
. BC2GM006085106 . O
. . O O

Thus BC2GM069088909 RB O
, BC2GM069088909 , O
the BC2GM069088909 DT O
predicted BC2GM069088909 JJ O
M3 BC2GM069088909 NNP O
ORF BC2GM069088909 NNP O
is BC2GM069088909 VBZ O
a BC2GM069088909 DT O
functional BC2GM069088909 JJ O
gene BC2GM069088909 NN O
that BC2GM069088909 WDT O
encodes BC2GM069088909 VBZ O
an BC2GM069088909 DT O
abundant BC2GM069088909 JJ O
secreted BC2GM069088909 VBN O
protein BC2GM069088909 NN O
which BC2GM069088909 WDT O
is BC2GM069088909 VBZ O
a BC2GM069088909 DT O
candidate BC2GM069088909 NN O
for BC2GM069088909 IN O
interacting BC2GM069088909 VBG O
with BC2GM069088909 IN O
host BC2GM069088909 NN O
cellular BC2GM069088909 JJ O
receptors BC2GM069088909 NNS O
or BC2GM069088909 CC O
cytokines BC2GM069088909 NNS O
. BC2GM069088909 . O
. . O O

But BC2GM026059945 CC O
it BC2GM026059945 PRP O
is BC2GM026059945 VBZ O
possible BC2GM026059945 JJ O
that BC2GM026059945 IN O
the BC2GM026059945 DT O
two BC2GM026059945 CD O
hemispheres BC2GM026059945 NNS O
differ BC2GM026059945 VBP O
in BC2GM026059945 IN O
the BC2GM026059945 DT O
manner BC2GM026059945 NN O
in BC2GM026059945 IN O
which BC2GM026059945 WDT O
they BC2GM026059945 PRP O
make BC2GM026059945 VBP O
use BC2GM026059945 NN O
of BC2GM026059945 IN O
semantic BC2GM026059945 JJ O
structures BC2GM026059945 NNS O
: BC2GM026059945 : O
the BC2GM026059945 DT O
left BC2GM026059945 NN O
hemisphere BC2GM026059945 NN O
in BC2GM026059945 IN O
a BC2GM026059945 DT O
selective BC2GM026059945 JJ O
manner BC2GM026059945 NN O
, BC2GM026059945 , O
appropriate BC2GM026059945 NN O
for BC2GM026059945 IN O
the BC2GM026059945 DT O
solution BC2GM026059945 NN O
of BC2GM026059945 IN O
a BC2GM026059945 DT O
specific BC2GM026059945 JJ O
task BC2GM026059945 NN O
, BC2GM026059945 , O
and BC2GM026059945 CC O
the BC2GM026059945 DT O
right BC2GM026059945 NN O
hemisphere BC2GM026059945 NN O
in BC2GM026059945 IN O
a BC2GM026059945 DT O
more BC2GM026059945 RBR O
diffuse BC2GM026059945 NN O
and BC2GM026059945 CC O
global BC2GM026059945 JJ O
manner BC2GM026059945 NN O
. BC2GM026059945 . O
. . O O

During BC2GM011299853 IN O
seed BC2GM011299853 NN O
maturation BC2GM011299853 NN O
, BC2GM011299853 , O
the BC2GM011299853 DT O
transcriptional BC2GM011299853 JJ O
activity BC2GM011299853 NN O
of BC2GM011299853 IN O
napin BC2GM011299853 NN O
genes BC2GM011299853 NNS O
is BC2GM011299853 VBZ O
regulated BC2GM011299853 VBN O
by BC2GM011299853 IN O
developmental BC2GM011299853 JJ O
signals BC2GM011299853 NNS O
involving BC2GM011299853 VBG O
the BC2GM011299853 DT O
transcriptional BC2GM011299853 JJ O
activator BC2GM011299853 NN O
ABI3 BC2GM011299853 NNP O
and BC2GM011299853 CC O
abscisic BC2GM011299853 JJ O
acid BC2GM011299853 NN O
( BC2GM011299853 ( O
ABA BC2GM011299853 NNP O
) BC2GM011299853 ) O
. BC2GM011299853 . O
. . O O

These BC2GM096315697 DT O
data BC2GM096315697 NNS O
demonstrate BC2GM096315697 NN O
that BC2GM096315697 IN O
CCTalpha BC2GM096315697 NNP O
can BC2GM096315697 MD O
be BC2GM096315697 VB O
regulated BC2GM096315697 VBN O
by BC2GM096315697 IN O
lipids BC2GM096315697 NNS O
by BC2GM096315697 IN O
two BC2GM096315697 CD O
independent BC2GM096315697 JJ O
domains BC2GM096315697 NNS O
: BC2GM096315697 : O
( BC2GM096315697 ( O
i BC2GM096315697 NN O
) BC2GM096315697 ) O
the BC2GM096315697 DT O
three BC2GM096315697 CD O
amphipathic BC2GM096315697 JJ O
alpha-helical BC2GM096315697 JJ O
repeats BC2GM096315697 NNS O
that BC2GM096315697 WDT O
interact BC2GM096315697 VBP O
with BC2GM096315697 IN O
both BC2GM096315697 DT O
neutral BC2GM096315697 JJ O
and BC2GM096315697 CC O
anionic BC2GM096315697 JJ O
lipid BC2GM096315697 JJ O
mixtures BC2GM096315697 NNS O
and BC2GM096315697 CC O
( BC2GM096315697 ( O
ii BC2GM096315697 NN O
) BC2GM096315697 ) O
the BC2GM096315697 DT O
last BC2GM096315697 JJ O
57 BC2GM096315697 CD O
residues BC2GM096315697 NNS O
that BC2GM096315697 IN O
interact BC2GM096315697 NN O
with BC2GM096315697 IN O
anionic BC2GM096315697 JJ O
lipids BC2GM096315697 NNS O
. BC2GM096315697 . O
. . O O

Brainstem BC2GM081451242 NNP O
auditory BC2GM081451242 NN O
evoked BC2GM081451242 VBD O
potential BC2GM081451242 JJ O
responses BC2GM081451242 NNS O
( BC2GM081451242 ( O
BAEPs BC2GM081451242 NNP O
) BC2GM081451242 ) O
were BC2GM081451242 VBD O
recorded BC2GM081451242 VBN O
from BC2GM081451242 IN O
CZ-A1 BC2GM081451242 NNP O
and BC2GM081451242 CC O
CZ-A2 BC2GM081451242 NNP O
scalp BC2GM081451242 NN O
regions BC2GM081451242 NNS O
in BC2GM081451242 IN O
23 BC2GM081451242 CD O
hypertensive BC2GM081451242 JJ O
and BC2GM081451242 CC O
14 BC2GM081451242 CD O
normotensive BC2GM081451242 JJ O
subjects BC2GM081451242 NNS O
. BC2GM081451242 . O
. . O O

Southern BC2GM029012322 NNP O
zoo BC2GM029012322 NN O
blot BC2GM029012322 NN O
analysis BC2GM029012322 NN O
indicated BC2GM029012322 VBD O
that BC2GM029012322 IN O
ZNF236 BC2GM029012322 NNP O
is BC2GM029012322 VBZ O
conserved BC2GM029012322 VBN O
in BC2GM029012322 IN O
the BC2GM029012322 DT O
genomes BC2GM029012322 NNS O
of BC2GM029012322 IN O
all BC2GM029012322 DT O
mammalian BC2GM029012322 JJ O
species BC2GM029012322 NNS O
tested BC2GM029012322 VBN O
, BC2GM029012322 , O
but BC2GM029012322 CC O
not BC2GM029012322 RB O
in BC2GM029012322 IN O
yeast BC2GM029012322 NN O
. BC2GM029012322 . O
. . O O

Upstream BC2GM072719765 NNP O
tissue BC2GM072719765 NN O
inhibitor BC2GM072719765 NN O
of BC2GM072719765 IN O
metalloproteinases-1 BC2GM072719765 JJ O
( BC2GM072719765 ( O
TIMP-1 BC2GM072719765 NNP O
) BC2GM072719765 ) O
element-1 BC2GM072719765 NN O
, BC2GM072719765 , O
a BC2GM072719765 DT O
novel BC2GM072719765 NN O
and BC2GM072719765 CC O
essential BC2GM072719765 JJ O
regulatory BC2GM072719765 JJ O
DNA BC2GM072719765 NNP O
motif BC2GM072719765 NN O
in BC2GM072719765 IN O
the BC2GM072719765 DT O
human BC2GM072719765 JJ O
TIMP-1 BC2GM072719765 NNP O
gene BC2GM072719765 NN O
promoter BC2GM072719765 NN O
, BC2GM072719765 , O
directly BC2GM072719765 RB O
interacts BC2GM072719765 VBZ O
with BC2GM072719765 IN O
a BC2GM072719765 DT O
30-kDa BC2GM072719765 JJ O
nuclear BC2GM072719765 JJ O
protein BC2GM072719765 NN O
. BC2GM072719765 . O
. . O O

Relationship BC2GM044020511 NN O
between BC2GM044020511 IN O
age-associated BC2GM044020511 JJ O
endocrine BC2GM044020511 NN O
deficiencies BC2GM044020511 NNS O
and BC2GM044020511 CC O
muscle BC2GM044020511 NN O
function BC2GM044020511 NN O
in BC2GM044020511 IN O
elderly BC2GM044020511 JJ O
women BC2GM044020511 NNS O
: BC2GM044020511 : O
a BC2GM044020511 DT O
cross-sectional BC2GM044020511 JJ O
study BC2GM044020511 NN O
. BC2GM044020511 . O
. . O O

Using BC2GM087723838 VBG O
mammalian BC2GM087723838 JJ O
expression BC2GM087723838 NN O
vectors BC2GM087723838 NNS O
( BC2GM087723838 ( O
pRSV-neo BC2GM087723838 JJ O
and BC2GM087723838 CC O
pSV2-neo BC2GM087723838 JJ O
) BC2GM087723838 ) O
, BC2GM087723838 , O
antisense BC2GM087723838 JJ O
constructs BC2GM087723838 NNS O
for BC2GM087723838 IN O
perforin BC2GM087723838 NN O
and BC2GM087723838 CC O
granzyme BC2GM087723838 NN O
B BC2GM087723838 NNP O
were BC2GM087723838 VBD O
independently BC2GM087723838 RB O
electroporated BC2GM087723838 VBN O
into BC2GM087723838 IN O
YT-INDY BC2GM087723838 NNP O
, BC2GM087723838 , O
a BC2GM087723838 DT O
human BC2GM087723838 JJ O
non-MHC-restricted BC2GM087723838 JJ O
, BC2GM087723838 , O
IL-2-independent BC2GM087723838 JJ O
, BC2GM087723838 , O
cytotoxic BC2GM087723838 JJ O
lymphocyte BC2GM087723838 NN O
. BC2GM087723838 . O
. . O O

In BC2GM046827862 IN O
addition BC2GM046827862 NN O
, BC2GM046827862 , O
mutations BC2GM046827862 NNS O
within BC2GM046827862 IN O
the BC2GM046827862 DT O
Ubx BC2GM046827862 NNP O
unit BC2GM046827862 NN O
exons BC2GM046827862 NNS O
are BC2GM046827862 VBP O
known BC2GM046827862 VBN O
and BC2GM046827862 CC O
most BC2GM046827862 JJS O
of BC2GM046827862 IN O
these BC2GM046827862 DT O
behave BC2GM046827862 VBP O
as BC2GM046827862 IN O
null BC2GM046827862 JJ O
alleles BC2GM046827862 NNS O
. BC2GM046827862 . O
. . O O

The BC2GM048824639 DT O
observed BC2GM048824639 JJ O
alterations BC2GM048824639 NNS O
in BC2GM048824639 IN O
lung BC2GM048824639 NN O
functions BC2GM048824639 NNS O
in BC2GM048824639 IN O
these BC2GM048824639 DT O
subjects BC2GM048824639 NNS O
indicate BC2GM048824639 VBP O
that BC2GM048824639 IN O
individuals BC2GM048824639 NNS O
performing BC2GM048824639 VBG O
heavy BC2GM048824639 JJ O
continuous BC2GM048824639 JJ O
exercise BC2GM048824639 NN O
are BC2GM048824639 VBP O
more BC2GM048824639 RBR O
likely BC2GM048824639 JJ O
to BC2GM048824639 TO O
be BC2GM048824639 VB O
affected BC2GM048824639 VBN O
by BC2GM048824639 IN O
lower BC2GM048824639 JJR O
O3 BC2GM048824639 NNP O
levels BC2GM048824639 NNS O
. BC2GM048824639 . O
. . O O

To BC2GM026833170 TO O
explore BC2GM026833170 VB O
the BC2GM026833170 DT O
effect BC2GM026833170 NN O
of BC2GM026833170 IN O
persistent BC2GM026833170 JJ O
cardiomegaly BC2GM026833170 NN O
on BC2GM026833170 IN O
cardiovascular BC2GM026833170 JJ O
function BC2GM026833170 NN O
, BC2GM026833170 , O
groups BC2GM026833170 NNS O
of BC2GM026833170 IN O
newborn BC2GM026833170 JJ O
rats BC2GM026833170 NNS O
inhaled BC2GM026833170 VBD O
up BC2GM026833170 RB O
to BC2GM026833170 TO O
500 BC2GM026833170 CD O
ppm BC2GM026833170 NNS O
CO BC2GM026833170 NNP O
for BC2GM026833170 IN O
33 BC2GM026833170 CD O
days BC2GM026833170 NNS O
, BC2GM026833170 , O
after BC2GM026833170 IN O
which BC2GM026833170 WDT O
development BC2GM026833170 NN O
continued BC2GM026833170 VBD O
in BC2GM026833170 IN O
ambient BC2GM026833170 JJ O
air BC2GM026833170 NN O
. BC2GM026833170 . O
. . O O

Spen BC2GM071296895 NNP O
is BC2GM071296895 VBZ O
the BC2GM071296895 DT O
only BC2GM071296895 JJ O
known BC2GM071296895 JJ O
homeotic BC2GM071296895 JJ O
protein BC2GM071296895 NN O
with BC2GM071296895 IN O
RNP BC2GM071296895 NNP O
binding BC2GM071296895 VBG O
motifs BC2GM071296895 NNS O
, BC2GM071296895 , O
which BC2GM071296895 WDT O
indicates BC2GM071296895 VBZ O
that BC2GM071296895 IN O
splicing BC2GM071296895 VBG O
, BC2GM071296895 , O
transport BC2GM071296895 NN O
, BC2GM071296895 , O
or BC2GM071296895 CC O
other BC2GM071296895 JJ O
RNA BC2GM071296895 NNP O
regulatory BC2GM071296895 JJ O
steps BC2GM071296895 NNS O
are BC2GM071296895 VBP O
involved BC2GM071296895 VBN O
in BC2GM071296895 IN O
the BC2GM071296895 DT O
diversification BC2GM071296895 NN O
of BC2GM071296895 IN O
segmental BC2GM071296895 JJ O
morphology BC2GM071296895 NN O
. BC2GM071296895 . O
. . O O

First BC2GM069042705 RB O
, BC2GM069042705 , O
the BC2GM069042705 DT O
amino-terminal BC2GM069042705 JJ O
regulatory BC2GM069042705 JJ O
arm BC2GM069042705 NN O
of BC2GM069042705 IN O
the BC2GM069042705 DT O
GDI BC2GM069042705 NNP O
binds BC2GM069042705 VBZ O
to BC2GM069042705 TO O
the BC2GM069042705 DT O
switch BC2GM069042705 NN O
I BC2GM069042705 PRP O
and BC2GM069042705 CC O
II BC2GM069042705 NNP O
domains BC2GM069042705 NNS O
of BC2GM069042705 IN O
Cdc42 BC2GM069042705 NNP O
leading BC2GM069042705 VBG O
to BC2GM069042705 TO O
the BC2GM069042705 DT O
inhibition BC2GM069042705 NN O
of BC2GM069042705 IN O
both BC2GM069042705 DT O
GDP BC2GM069042705 NNP O
dissociation BC2GM069042705 NN O
and BC2GM069042705 CC O
GTP BC2GM069042705 NNP O
hydrolysis BC2GM069042705 NN O
. BC2GM069042705 . O
. . O O

87 BC2GM049355866 CD O
, BC2GM049355866 , O
7270-7274 BC2GM049355866 JJ O
) BC2GM049355866 ) O
. BC2GM049355866 . O
. . O O

Stamps BC2GM006359930 NNS O
in BC2GM006359930 IN O
cardiology BC2GM006359930 NN O
: BC2GM006359930 : O
de BC2GM006359930 FW O
Musset BC2GM006359930 NNP O
sign BC2GM006359930 NN O
. BC2GM006359930 . O
. . O O

The BC2GM004377989 DT O
effect BC2GM004377989 NN O
of BC2GM004377989 IN O
betamethasone BC2GM004377989 NN O
on BC2GM004377989 IN O
duodenal BC2GM004377989 JJ O
calcium BC2GM004377989 NN O
absorption BC2GM004377989 NN O
and BC2GM004377989 CC O
1,25-dihydroxy BC2GM004377989 JJ O
vitamin BC2GM004377989 NN O
D3 BC2GM004377989 NNP O
production BC2GM004377989 NN O
in BC2GM004377989 IN O
the BC2GM004377989 DT O
chick BC2GM004377989 NN O
. BC2GM004377989 . O
. . O O

All BC2GM086709432 DT O
patients BC2GM086709432 NNS O
were BC2GM086709432 VBD O
peritonitis-free BC2GM086709432 JJ O
at BC2GM086709432 IN O
least BC2GM086709432 JJS O
6 BC2GM086709432 CD O
weeks BC2GM086709432 NNS O
before BC2GM086709432 IN O
each BC2GM086709432 DT O
PET BC2GM086709432 NNP O
. BC2GM086709432 . O
. . O O

When BC2GM062642302 WRB O
O-2A BC2GM062642302 NNP O
/ BC2GM062642302 NNP O
c-myc BC2GM062642302 JJ O
cells BC2GM062642302 NNS O
underwent BC2GM062642302 JJ O
terminal BC2GM062642302 JJ O
differentiation BC2GM062642302 NN O
APprog BC2GM062642302 NNP O
complexes BC2GM062642302 NNS O
were BC2GM062642302 VBD O
lost BC2GM062642302 VBN O
and BC2GM062642302 CC O
conventional BC2GM062642302 JJ O
AP-1 BC2GM062642302 JJ O
DNA-binding BC2GM062642302 JJ O
activity BC2GM062642302 NN O
became BC2GM062642302 VBD O
evident BC2GM062642302 JJ O
, BC2GM062642302 , O
particularly BC2GM062642302 RB O
in BC2GM062642302 IN O
astrocytes BC2GM062642302 NNS O
. BC2GM062642302 . O
. . O O

Oligo- BC2GM008441714 JJ O
[ BC2GM008441714 NNP O
alpha BC2GM008441714 NN O
] BC2GM008441714 NNP O
-deoxynucleotides BC2GM008441714 NNS O
can BC2GM008441714 MD O
be BC2GM008441714 VB O
derived BC2GM008441714 VBN O
by BC2GM008441714 IN O
stabilizing BC2GM008441714 VBG O
( BC2GM008441714 ( O
intercalating BC2GM008441714 VBG O
) BC2GM008441714 ) O
agents BC2GM008441714 NNS O
or BC2GM008441714 CC O
reactive BC2GM008441714 JJ O
groups BC2GM008441714 NNS O
( BC2GM008441714 ( O
cleaving BC2GM008441714 VBG O
reagents BC2GM008441714 NNS O
, BC2GM008441714 , O
cross-linkers BC2GM008441714 NNS O
... BC2GM008441714 : O
) BC2GM008441714 ) O
. BC2GM008441714 . O
. . O O

For BC2GM039082460 IN O
the BC2GM039082460 DT O
population BC2GM039082460 NN O
of BC2GM039082460 IN O
patients BC2GM039082460 NNS O
with BC2GM039082460 IN O
melanoma BC2GM039082460 NN O
levels BC2GM039082460 NNS O
III BC2GM039082460 NNP O
and BC2GM039082460 CC O
IV BC2GM039082460 NNP O
significant BC2GM039082460 JJ O
differences BC2GM039082460 NNS O
in BC2GM039082460 IN O
survival BC2GM039082460 JJ O
rate BC2GM039082460 NN O
were BC2GM039082460 VBD O
associated BC2GM039082460 VBN O
with BC2GM039082460 IN O
thickness BC2GM039082460 NN O
( BC2GM039082460 ( O
less BC2GM039082460 JJR O
than BC2GM039082460 IN O
2 BC2GM039082460 CD O
mm BC2GM039082460 NN O
or BC2GM039082460 CC O
greater BC2GM039082460 JJR O
than BC2GM039082460 IN O
or BC2GM039082460 CC O
equal BC2GM039082460 JJ O
to BC2GM039082460 TO O
2 BC2GM039082460 CD O
mm BC2GM039082460 NN O
; BC2GM039082460 : O
p BC2GM039082460 CC O
less BC2GM039082460 JJR O
than BC2GM039082460 IN O
0,001 BC2GM039082460 CD O
) BC2GM039082460 ) O
, BC2GM039082460 , O
though BC2GM039082460 IN O
not BC2GM039082460 RB O
with BC2GM039082460 IN O
level BC2GM039082460 NN O
. BC2GM039082460 . O
. . O O

Sequence BC2GM029377540 NN O
analysis BC2GM029377540 NN O
identifies BC2GM029377540 VBZ O
a BC2GM029377540 DT O
ras-associating BC2GM029377540 NN O
( BC2GM029377540 ( O
RA BC2GM029377540 NNP O
) BC2GM029377540 ) O
-like BC2GM029377540 NN O
domain BC2GM029377540 NN O
in BC2GM029377540 IN O
the BC2GM029377540 DT O
N-termini BC2GM029377540 NNP O
of BC2GM029377540 IN O
band BC2GM029377540 NN O
4.1 BC2GM029377540 CD O
/ BC2GM029377540 NN O
JEF BC2GM029377540 NNP O
domains BC2GM029377540 NNS O
and BC2GM029377540 CC O
in BC2GM029377540 IN O
the BC2GM029377540 DT O
Grb7 BC2GM029377540 NNP O
/ BC2GM029377540 NNP O
10 BC2GM029377540 CD O
/ BC2GM029377540 VBD O
14 BC2GM029377540 CD O
adapter BC2GM029377540 JJ O
family BC2GM029377540 NN O
. BC2GM029377540 . O
. . O O

Evasion BC2GM021235622 NN O
of BC2GM021235622 IN O
host BC2GM021235622 NN O
immunity BC2GM021235622 NN O
by BC2GM021235622 IN O
Toxocara BC2GM021235622 NNP O
canis BC2GM021235622 NN O
infective BC2GM021235622 JJ O
larvae BC2GM021235622 NN O
is BC2GM021235622 VBZ O
mediated BC2GM021235622 VBN O
by BC2GM021235622 IN O
the BC2GM021235622 DT O
nematode BC2GM021235622 JJ O
surface BC2GM021235622 NN O
coat BC2GM021235622 NN O
, BC2GM021235622 , O
which BC2GM021235622 WDT O
is BC2GM021235622 VBZ O
shed BC2GM021235622 VBN O
in BC2GM021235622 IN O
response BC2GM021235622 NN O
to BC2GM021235622 TO O
binding BC2GM021235622 NN O
by BC2GM021235622 IN O
host BC2GM021235622 NN O
antibody BC2GM021235622 NN O
molecules BC2GM021235622 NNS O
or BC2GM021235622 CC O
effector BC2GM021235622 NN O
cells BC2GM021235622 NNS O
. BC2GM021235622 . O
. . O O

Macrophages BC2GM092456996 NNS O
: BC2GM092456996 : O
modulators BC2GM092456996 NNS O
of BC2GM092456996 IN O
immunity BC2GM092456996 NN O
. BC2GM092456996 . O
. . O O

Reversible BC2GM076789342 JJ O
topology BC2GM076789342 NN O
of BC2GM076789342 IN O
a BC2GM076789342 DT O
bifunctional BC2GM076789342 JJ O
transmembrane BC2GM076789342 NN O
protein BC2GM076789342 NN O
depends BC2GM076789342 VBZ O
upon BC2GM076789342 IN O
the BC2GM076789342 DT O
charge BC2GM076789342 NN O
balance BC2GM076789342 NN O
around BC2GM076789342 IN O
its BC2GM076789342 PRP$ O
transmembrane BC2GM076789342 NN O
domain BC2GM076789342 NN O
. BC2GM076789342 . O
. . O O

However BC2GM031146030 RB O
, BC2GM031146030 , O
microinjection BC2GM031146030 NN O
of BC2GM031146030 IN O
reconstituted BC2GM031146030 JJ O
mRNPs BC2GM031146030 NN O
into BC2GM031146030 IN O
Xenopus BC2GM031146030 NNP O
oocytes BC2GM031146030 VBZ O
demonstrates BC2GM031146030 VBZ O
that BC2GM031146030 IN O
although BC2GM031146030 IN O
translational BC2GM031146030 JJ O
repression BC2GM031146030 NN O
occurs BC2GM031146030 VBZ O
in BC2GM031146030 IN O
the BC2GM031146030 DT O
absence BC2GM031146030 NN O
of BC2GM031146030 IN O
consensus BC2GM031146030 NN O
RNA BC2GM031146030 NNP O
binding BC2GM031146030 NN O
sequences BC2GM031146030 NNS O
for BC2GM031146030 IN O
FRGY2 BC2GM031146030 NNP O
, BC2GM031146030 , O
the BC2GM031146030 DT O
presence BC2GM031146030 NN O
of BC2GM031146030 IN O
FRGY2 BC2GM031146030 NNP O
recognition BC2GM031146030 NN O
elements BC2GM031146030 NNS O
within BC2GM031146030 IN O
mRNA BC2GM031146030 NN O
potentiates BC2GM031146030 NNS O
translational BC2GM031146030 JJ O
repression BC2GM031146030 NN O
. BC2GM031146030 . O
. . O O

Our BC2GM054841165 PRP$ O
data BC2GM054841165 NNS O
suggest BC2GM054841165 VBP O
that BC2GM054841165 IN O
association BC2GM054841165 NN O
of BC2GM054841165 IN O
TBP BC2GM054841165 NNP O
with BC2GM054841165 IN O
the BC2GM054841165 DT O
TATA BC2GM054841165 NNP O
box BC2GM054841165 NN O
may BC2GM054841165 MD O
be BC2GM054841165 VB O
regulated BC2GM054841165 VBN O
, BC2GM054841165 , O
directly BC2GM054841165 RB O
or BC2GM054841165 CC O
indirectly BC2GM054841165 RB O
, BC2GM054841165 , O
by BC2GM054841165 IN O
a BC2GM054841165 DT O
substrate BC2GM054841165 NN O
of BC2GM054841165 IN O
Snf1 BC2GM054841165 NNP O
. BC2GM054841165 . O
. . O O

A BC2GM009721363 DT O
structural BC2GM009721363 JJ O
model BC2GM009721363 NN O
for BC2GM009721363 IN O
Vpu BC2GM009721363 NNP O
is BC2GM009721363 VBZ O
proposed BC2GM009721363 VBN O
in BC2GM009721363 IN O
which BC2GM009721363 WDT O
the BC2GM009721363 DT O
membrane BC2GM009721363 NN O
anchor BC2GM009721363 NN O
precedes BC2GM009721363 VBZ O
a BC2GM009721363 DT O
region BC2GM009721363 NN O
comprising BC2GM009721363 VBG O
two BC2GM009721363 CD O
amphipathic BC2GM009721363 JJ O
alpha-helices BC2GM009721363 NNS O
of BC2GM009721363 IN O
opposed BC2GM009721363 JJ O
polarity BC2GM009721363 NN O
, BC2GM009721363 , O
joined BC2GM009721363 VBN O
by BC2GM009721363 IN O
a BC2GM009721363 DT O
strongly BC2GM009721363 RB O
acidic BC2GM009721363 JJ O
turn BC2GM009721363 VBP O
that BC2GM009721363 WDT O
protrudes BC2GM009721363 VBZ O
into BC2GM009721363 IN O
the BC2GM009721363 DT O
cytoplasm BC2GM009721363 NN O
and BC2GM009721363 CC O
contains BC2GM009721363 VBZ O
the BC2GM009721363 DT O
CK-2 BC2GM009721363 JJ O
phosphorylation BC2GM009721363 NN O
sites BC2GM009721363 NNS O
. BC2GM009721363 . O
. . O O

Supportive BC2GM058564521 JJ O
therapy BC2GM058564521 NN O
with BC2GM058564521 IN O
xenogenous BC2GM058564521 JJ O
peptides BC2GM058564521 NNS O
in BC2GM058564521 IN O
patients BC2GM058564521 NNS O
with BC2GM058564521 IN O
metastatic BC2GM058564521 JJ O
breast BC2GM058564521 NN O
cancer BC2GM058564521 NN O
undergoing BC2GM058564521 VBG O
aggressive BC2GM058564521 JJ O
chemotherapy BC2GM058564521 NN O
( BC2GM058564521 ( O
modified BC2GM058564521 VBN O
AC-protocol BC2GM058564521 NNP O
) BC2GM058564521 ) O
: BC2GM058564521 : O
a BC2GM058564521 DT O
prospective BC2GM058564521 JJ O
, BC2GM058564521 , O
randomized BC2GM058564521 VBN O
double-blind BC2GM058564521 NN O
study BC2GM058564521 NN O
. BC2GM058564521 . O
. . O O

This BC2GM071895729 DT O
article BC2GM071895729 NN O
focuses BC2GM071895729 VBZ O
on BC2GM071895729 IN O
a BC2GM071895729 DT O
general BC2GM071895729 JJ O
approach BC2GM071895729 NN O
to BC2GM071895729 TO O
the BC2GM071895729 DT O
use BC2GM071895729 NN O
of BC2GM071895729 IN O
ARV BC2GM071895729 NNP O
agents BC2GM071895729 NNS O
. BC2GM071895729 . O
. . O O

However BC2GM011718278 RB O
, BC2GM011718278 , O
no BC2GM011718278 DT O
significant BC2GM011718278 JJ O
difference BC2GM011718278 NN O
in BC2GM011718278 IN O
either BC2GM011718278 CC O
the BC2GM011718278 DT O
Valsalva BC2GM011718278 NNP O
ratio BC2GM011718278 NN O
or BC2GM011718278 CC O
delta BC2GM011718278 NN O
SBP BC2GM011718278 NNP O
was BC2GM011718278 VBD O
found BC2GM011718278 VBN O
between BC2GM011718278 IN O
diabetic BC2GM011718278 JJ O
patients BC2GM011718278 NNS O
and BC2GM011718278 CC O
controls BC2GM011718278 NNS O
. BC2GM011718278 . O
. . O O

The BC2GM095844038 DT O
structure BC2GM095844038 NN O
elucidation BC2GM095844038 NN O
of BC2GM095844038 IN O
the BC2GM095844038 DT O
iridoid BC2GM095844038 JJ O
compounds BC2GM095844038 VBZ O
2 BC2GM095844038 CD O
and BC2GM095844038 CC O
3 BC2GM095844038 CD O
are BC2GM095844038 VBP O
discussed BC2GM095844038 VBN O
in BC2GM095844038 IN O
detail BC2GM095844038 NN O
. BC2GM095844038 . O
. . O O

The BC2GM008286757 DT O
effect BC2GM008286757 NN O
of BC2GM008286757 IN O
pneumoperitoneum BC2GM008286757 NN O
on BC2GM008286757 IN O
dissemination BC2GM008286757 NN O
and BC2GM008286757 CC O
scar BC2GM008286757 NN O
implantation BC2GM008286757 NN O
of BC2GM008286757 IN O
intra-abdominal BC2GM008286757 JJ O
tumor BC2GM008286757 NN O
cells BC2GM008286757 NNS O
. BC2GM008286757 . O
. . O O

Of BC2GM064815025 IN O
the BC2GM064815025 DT O
private BC2GM064815025 JJ O
practices BC2GM064815025 NNS O
accredited BC2GM064815025 VBN O
in BC2GM064815025 IN O
August BC2GM064815025 NNP O
1995 BC2GM064815025 CD O
, BC2GM064815025 , O
40.6 BC2GM064815025 CD O
per BC2GM064815025 IN O
cent BC2GM064815025 NN O
( BC2GM064815025 ( O
122 BC2GM064815025 CD O
) BC2GM064815025 ) O
participated BC2GM064815025 VBD O
. BC2GM064815025 . O
. . O O

This BC2GM089636250 DT O
is BC2GM089636250 VBZ O
a BC2GM089636250 DT O
consensus BC2GM089636250 NN O
casein BC2GM089636250 NN O
kinase BC2GM089636250 NN O
II BC2GM089636250 NNP O
( BC2GM089636250 ( O
CKII BC2GM089636250 NNP O
) BC2GM089636250 ) O
site BC2GM089636250 NN O
and BC2GM089636250 CC O
, BC2GM089636250 , O
using BC2GM089636250 VBG O
purified BC2GM089636250 VBN O
wild-type BC2GM089636250 JJ O
and BC2GM089636250 CC O
mutant BC2GM089636250 JJ O
proteins BC2GM089636250 NNS O
, BC2GM089636250 , O
we BC2GM089636250 PRP O
show BC2GM089636250 VBP O
that BC2GM089636250 IN O
it BC2GM089636250 PRP O
is BC2GM089636250 VBZ O
the BC2GM089636250 DT O
main BC2GM089636250 JJ O
CKII BC2GM089636250 NNP O
site BC2GM089636250 NN O
in BC2GM089636250 IN O
the BC2GM089636250 DT O
body BC2GM089636250 NN O
of BC2GM089636250 IN O
the BC2GM089636250 DT O
N-terminal BC2GM089636250 JJ O
complex-forming BC2GM089636250 JJ O
region BC2GM089636250 NN O
. BC2GM089636250 . O
. . O O

The BC2GM064277567 DT O
effects BC2GM064277567 NNS O
of BC2GM064277567 IN O
different BC2GM064277567 JJ O
sources BC2GM064277567 NNS O
of BC2GM064277567 IN O
commercial BC2GM064277567 JJ O
rations BC2GM064277567 NNS O
on BC2GM064277567 IN O
the BC2GM064277567 DT O
humoral BC2GM064277567 JJ O
immune BC2GM064277567 JJ O
response BC2GM064277567 NN O
of BC2GM064277567 IN O
broilers BC2GM064277567 NNS O
to BC2GM064277567 TO O
Newcastle BC2GM064277567 NNP O
disease BC2GM064277567 NN O
vaccination BC2GM064277567 NN O
. BC2GM064277567 . O
. . O O

Here BC2GM017907484 RB O
we BC2GM017907484 PRP O
demonstrate BC2GM017907484 VBP O
that BC2GM017907484 IN O
a BC2GM017907484 DT O
region BC2GM017907484 NN O
of BC2GM017907484 IN O
high BC2GM017907484 JJ O
homology BC2GM017907484 NN O
between BC2GM017907484 IN O
the BC2GM017907484 DT O
members BC2GM017907484 NNS O
of BC2GM017907484 IN O
this BC2GM017907484 DT O
class BC2GM017907484 NN O
of BC2GM017907484 IN O
proteins BC2GM017907484 NNS O
contains BC2GM017907484 VBZ O
a BC2GM017907484 DT O
type BC2GM017907484 NN O
A BC2GM017907484 NNP O
nucleotide BC2GM017907484 RB O
binding BC2GM017907484 VBG O
site BC2GM017907484 NN O
consensus BC2GM017907484 NN O
sequence BC2GM017907484 NN O
which BC2GM017907484 WDT O
has BC2GM017907484 VBZ O
ATPase BC2GM017907484 NNP O
activity BC2GM017907484 NN O
and BC2GM017907484 CC O
is BC2GM017907484 VBZ O
sufficient BC2GM017907484 JJ O
to BC2GM017907484 TO O
bind BC2GM017907484 VB O
DNA BC2GM017907484 NNP O
containing BC2GM017907484 VBG O
specific BC2GM017907484 JJ O
mismatched BC2GM017907484 VBN O
residues BC2GM017907484 NNS O
. BC2GM017907484 . O
. . O O

There BC2GM021968476 EX O
was BC2GM021968476 VBD O
a BC2GM021968476 DT O
highly BC2GM021968476 RB O
significant BC2GM021968476 JJ O
decrease BC2GM021968476 NN O
in BC2GM021968476 IN O
serum BC2GM021968476 NN O
eosinophil BC2GM021968476 NN O
cationic BC2GM021968476 JJ O
protein BC2GM021968476 NN O
in BC2GM021968476 IN O
patients BC2GM021968476 NNS O
with BC2GM021968476 IN O
elevated BC2GM021968476 JJ O
AGA BC2GM021968476 NNP O
. BC2GM021968476 . O
. . O O

The BC2GM056206368 DT O
Aspergillus BC2GM056206368 NNP O
uvsH BC2GM056206368 JJ O
gene BC2GM056206368 NN O
encodes BC2GM056206368 VBZ O
a BC2GM056206368 DT O
product BC2GM056206368 NN O
homologous BC2GM056206368 JJ O
to BC2GM056206368 TO O
yeast BC2GM056206368 VB O
RAD18 BC2GM056206368 NNP O
and BC2GM056206368 CC O
Neurospora BC2GM056206368 NNP O
UVS-2 BC2GM056206368 NNP O
. BC2GM056206368 . O
. . O O

Three BC2GM084095947 CD O
modern BC2GM084095947 JJ O
hematology BC2GM084095947 NN O
analyzers BC2GM084095947 NNS O
( BC2GM084095947 ( O
Abbott BC2GM084095947 NNP O
Cell-Dyn BC2GM084095947 NNP O
3000 BC2GM084095947 CD O
, BC2GM084095947 , O
Coulter BC2GM084095947 NNP O
STKS BC2GM084095947 NNP O
, BC2GM084095947 , O
and BC2GM084095947 CC O
Sysmex BC2GM084095947 NNP O
NE-8000 BC2GM084095947 NNP O
) BC2GM084095947 ) O
with BC2GM084095947 IN O
high BC2GM084095947 JJ O
throughput BC2GM084095947 NN O
and BC2GM084095947 CC O
5-part BC2GM084095947 JJ O
differential BC2GM084095947 JJ O
capability BC2GM084095947 NN O
were BC2GM084095947 VBD O
evaluated BC2GM084095947 VBN O
using BC2GM084095947 VBG O
a BC2GM084095947 DT O
protocol BC2GM084095947 NN O
designed BC2GM084095947 VBN O
by BC2GM084095947 IN O
a BC2GM084095947 DT O
quality BC2GM084095947 NN O
team BC2GM084095947 NN O
. BC2GM084095947 . O
. . O O

International BC2GM012710435 NNP O
efforts BC2GM012710435 NNS O
are BC2GM012710435 VBP O
now BC2GM012710435 RB O
being BC2GM012710435 VBG O
made BC2GM012710435 VBN O
to BC2GM012710435 TO O
standardize BC2GM012710435 VB O
haemolytic BC2GM012710435 JJ O
test BC2GM012710435 NN O
conditions BC2GM012710435 NNS O
and BC2GM012710435 CC O
the BC2GM012710435 DT O
present BC2GM012710435 JJ O
study BC2GM012710435 NN O
is BC2GM012710435 VBZ O
meant BC2GM012710435 VBN O
as BC2GM012710435 IN O
a BC2GM012710435 DT O
contribution BC2GM012710435 NN O
to BC2GM012710435 TO O
this BC2GM012710435 DT O
. BC2GM012710435 . O
. . O O

Electrophoretic BC2GM000534680 JJ O
mobility-shift BC2GM000534680 NN O
assays BC2GM000534680 NNS O
with BC2GM000534680 IN O
nuclear BC2GM000534680 JJ O
extracts BC2GM000534680 NNS O
from BC2GM000534680 IN O
COS-1 BC2GM000534680 NNP O
cells BC2GM000534680 NNS O
transfected BC2GM000534680 VBN O
with BC2GM000534680 IN O
expression BC2GM000534680 NN O
vectors BC2GM000534680 NNS O
for BC2GM000534680 IN O
SMADs BC2GM000534680 NNP O
1-5 BC2GM000534680 JJ O
indicate BC2GM000534680 NN O
that BC2GM000534680 IN O
SMAD3 BC2GM000534680 NNP O
forms BC2GM000534680 VBZ O
a BC2GM000534680 DT O
complex BC2GM000534680 JJ O
with BC2GM000534680 IN O
a BC2GM000534680 DT O
migration BC2GM000534680 NN O
similar BC2GM000534680 JJ O
to BC2GM000534680 TO O
that BC2GM000534680 DT O
of BC2GM000534680 IN O
the BC2GM000534680 DT O
endogenous BC2GM000534680 JJ O
TGF-beta-specific BC2GM000534680 NNP O
complex BC2GM000534680 NN O
observed BC2GM000534680 VBD O
in BC2GM000534680 IN O
fibroblast BC2GM000534680 JJ O
extracts BC2GM000534680 NNS O
. BC2GM000534680 . O
. . O O

A BC2GM035315423 DT O
new BC2GM035315423 JJ O
B-cell-specific BC2GM035315423 JJ O
enhancer BC2GM035315423 NN O
element BC2GM035315423 NN O
has BC2GM035315423 VBZ O
been BC2GM035315423 VBN O
identified BC2GM035315423 VBN O
3 BC2GM035315423 CD O
' BC2GM035315423 '' O
of BC2GM035315423 IN O
E4 BC2GM035315423 NNP O
and BC2GM035315423 CC O
the BC2GM035315423 DT O
octamerlike BC2GM035315423 NN O
motifs BC2GM035315423 NNS O
in BC2GM035315423 IN O
the BC2GM035315423 DT O
human BC2GM035315423 JJ O
immunoglobulin BC2GM035315423 NN O
heavy-chain BC2GM035315423 NN O
gene BC2GM035315423 NN O
enhancer BC2GM035315423 NN O
. BC2GM035315423 . O
. . O O

We BC2GM031634103 PRP O
present BC2GM031634103 VBP O
the BC2GM031634103 DT O
case BC2GM031634103 NN O
of BC2GM031634103 IN O
a BC2GM031634103 DT O
patient BC2GM031634103 NN O
who BC2GM031634103 WP O
presented BC2GM031634103 VBD O
an BC2GM031634103 DT O
unusually BC2GM031634103 RB O
large BC2GM031634103 JJ O
mucoid BC2GM031634103 JJ O
cyst BC2GM031634103 NN O
measuring BC2GM031634103 VBG O
38 BC2GM031634103 CD O
x BC2GM031634103 JJ O
25 BC2GM031634103 CD O
mm BC2GM031634103 NN O
in BC2GM031634103 IN O
an BC2GM031634103 DT O
uncommon BC2GM031634103 JJ O
localization BC2GM031634103 NN O
, BC2GM031634103 , O
the BC2GM031634103 DT O
right BC2GM031634103 JJ O
maxillary BC2GM031634103 NN O
. BC2GM031634103 . O
. . O O

To BC2GM023966802 TO O
study BC2GM023966802 VB O
the BC2GM023966802 DT O
mechanisms BC2GM023966802 NNS O
and BC2GM023966802 CC O
the BC2GM023966802 DT O
signaling BC2GM023966802 NN O
pathways BC2GM023966802 NNS O
involved BC2GM023966802 VBN O
, BC2GM023966802 , O
IGF-1R BC2GM023966802 NNP O
promoter BC2GM023966802 NN O
reporter BC2GM023966802 NN O
constructs BC2GM023966802 NNS O
were BC2GM023966802 VBD O
transiently BC2GM023966802 RB O
transfected BC2GM023966802 VBN O
in BC2GM023966802 IN O
CHO-AT1 BC2GM023966802 NNP O
cells BC2GM023966802 NNS O
that BC2GM023966802 IN O
overexpress BC2GM023966802 JJ O
angiotensin BC2GM023966802 NN O
AT1 BC2GM023966802 NNP O
receptors BC2GM023966802 NNS O
. BC2GM023966802 . O
. . O O

The BC2GM049429395 DT O
CydDC BC2GM049429395 NNP O
system BC2GM049429395 NN O
appears BC2GM049429395 VBZ O
to BC2GM049429395 TO O
be BC2GM049429395 VB O
the BC2GM049429395 DT O
first BC2GM049429395 JJ O
prokaryotic BC2GM049429395 JJ O
example BC2GM049429395 NN O
of BC2GM049429395 IN O
a BC2GM049429395 DT O
heterodimeric BC2GM049429395 JJ O
ABC BC2GM049429395 NNP O
transport BC2GM049429395 NN O
system BC2GM049429395 NN O
in BC2GM049429395 IN O
which BC2GM049429395 WDT O
each BC2GM049429395 DT O
polypeptide BC2GM049429395 NN O
contains BC2GM049429395 VBZ O
both BC2GM049429395 DT O
hydrophobic BC2GM049429395 JJ O
and BC2GM049429395 CC O
ATP-binding BC2GM049429395 JJ O
domains BC2GM049429395 NNS O
. BC2GM049429395 . O
. . O O

The BC2GM022748890 DT O
avian BC2GM022748890 JJ O
carcinoma BC2GM022748890 NN O
virus BC2GM022748890 NN O
MH2 BC2GM022748890 NNP O
contains BC2GM022748890 VBZ O
a BC2GM022748890 DT O
hybrid BC2GM022748890 JJ O
gene BC2GM022748890 NN O
delta BC2GM022748890 JJ O
gag-mht BC2GM022748890 JJ O
with BC2GM022748890 IN O
a BC2GM022748890 DT O
contiguous BC2GM022748890 JJ O
open BC2GM022748890 JJ O
reading BC2GM022748890 NN O
frame BC2GM022748890 NN O
of BC2GM022748890 IN O
2682 BC2GM022748890 CD O
base BC2GM022748890 NN O
pairs BC2GM022748890 NN O
as BC2GM022748890 RB O
well BC2GM022748890 RB O
as BC2GM022748890 IN O
v-myc BC2GM022748890 NN O
and BC2GM022748890 CC O
avian BC2GM022748890 JJ O
helper BC2GM022748890 NN O
virus-related BC2GM022748890 JJ O
sequences BC2GM022748890 NNS O
. BC2GM022748890 . O
delta BC2GM022748890 NN O
gag BC2GM022748890 NN O
is BC2GM022748890 VBZ O
a BC2GM022748890 DT O
partial BC2GM022748890 JJ O
retroviral BC2GM022748890 NN O
core BC2GM022748890 NN O
protein BC2GM022748890 NN O
gene BC2GM022748890 NN O
while BC2GM022748890 IN O
v-mht BC2GM022748890 JJ O
and BC2GM022748890 CC O
v-myc BC2GM022748890 JJ O
are BC2GM022748890 VBP O
cell-drived BC2GM022748890 JJ O
sequences BC2GM022748890 NNS O
. BC2GM022748890 . O
. . O O

To BC2GM098375429 TO O
investigate BC2GM098375429 VB O
its BC2GM098375429 PRP$ O
transcription BC2GM098375429 NN O
, BC2GM098375429 , O
1.1 BC2GM098375429 CD O
kilobases BC2GM098375429 NNS O
of BC2GM098375429 IN O
the BC2GM098375429 DT O
5'-flanking BC2GM098375429 JJ O
sequence BC2GM098375429 NN O
were BC2GM098375429 VBD O
fused BC2GM098375429 VBN O
to BC2GM098375429 TO O
a BC2GM098375429 DT O
luciferase BC2GM098375429 NN O
reporter BC2GM098375429 NN O
gene BC2GM098375429 NN O
. BC2GM098375429 . O
. . O O

Following BC2GM038644966 VBG O
40 BC2GM038644966 CD O
min BC2GM038644966 JJ O
`` BC2GM038644966 `` O
ischemia BC2GM038644966 NN O
'' BC2GM038644966 '' O
, BC2GM038644966 , O
preparations BC2GM038644966 NNS O
treated BC2GM038644966 VBD O
with BC2GM038644966 IN O
PC BC2GM038644966 NN O
recovered BC2GM038644966 VBN O
from BC2GM038644966 IN O
transmural BC2GM038644966 JJ O
conduction BC2GM038644966 NN O
block BC2GM038644966 NN O
more BC2GM038644966 RBR O
rapidly BC2GM038644966 RB O
( BC2GM038644966 ( O
PC1 BC2GM038644966 NNP O
group BC2GM038644966 NN O
, BC2GM038644966 , O
4 BC2GM038644966 CD O
min BC2GM038644966 NN O
, BC2GM038644966 , O
P BC2GM038644966 NNP O
less BC2GM038644966 JJR O
than BC2GM038644966 IN O
0.05 BC2GM038644966 CD O
; BC2GM038644966 : O
PC2 BC2GM038644966 NNP O
group BC2GM038644966 NN O
, BC2GM038644966 , O
23 BC2GM038644966 CD O
min BC2GM038644966 NN O
, BC2GM038644966 , O
ns BC2GM038644966 NN O
) BC2GM038644966 ) O
, BC2GM038644966 , O
compared BC2GM038644966 VBN O
to BC2GM038644966 TO O
control BC2GM038644966 VB O
. BC2GM038644966 . O
( BC2GM038644966 ( O
ABSTRACT BC2GM038644966 NNP O
TRUNCATED BC2GM038644966 NNP O
AT BC2GM038644966 NNP O
250 BC2GM038644966 CD O
WORDS BC2GM038644966 NNP O
) BC2GM038644966 ) O
. BC2GM038644966 . O
. . O O

MATERIALS BC2GM040449829 NNP O
AND BC2GM040449829 CC O
METHODS BC2GM040449829 NNP O
: BC2GM040449829 : O
A BC2GM040449829 DT O
seven-wavelength BC2GM040449829 JJ O
frequency-domain BC2GM040449829 JJ O
photon BC2GM040449829 NN O
migration BC2GM040449829 NN O
probe BC2GM040449829 NN O
was BC2GM040449829 VBD O
used BC2GM040449829 VBN O
to BC2GM040449829 TO O
perform BC2GM040449829 VB O
noninvasive BC2GM040449829 JJ O
NIR BC2GM040449829 NNP O
measurements BC2GM040449829 NNS O
in BC2GM040449829 IN O
the BC2GM040449829 DT O
breasts BC2GM040449829 NNS O
of BC2GM040449829 IN O
28 BC2GM040449829 CD O
healthy BC2GM040449829 JJ O
women BC2GM040449829 NNS O
, BC2GM040449829 , O
both BC2GM040449829 DT O
pre- BC2GM040449829 JJ O
and BC2GM040449829 CC O
postmenopausal BC2GM040449829 NN O
, BC2GM040449829 , O
aged BC2GM040449829 VBN O
18-64 BC2GM040449829 CD O
years BC2GM040449829 NNS O
. BC2GM040449829 . O
. . O O

Profilins BC2GM068294994 NNS O
IIa BC2GM068294994 NNP O
and BC2GM068294994 CC O
IIb BC2GM068294994 NNP O
are BC2GM068294994 VBP O
also BC2GM068294994 RB O
present BC2GM068294994 JJ O
in BC2GM068294994 IN O
humans BC2GM068294994 NNS O
, BC2GM068294994 , O
suggesting BC2GM068294994 VBG O
that BC2GM068294994 IN O
all BC2GM068294994 DT O
mammals BC2GM068294994 NNS O
have BC2GM068294994 VBP O
three BC2GM068294994 CD O
profilin BC2GM068294994 NN O
isoforms BC2GM068294994 NNS O
. BC2GM068294994 . O
. . O O

A BC2GM078123829 DT O
species BC2GM078123829 NNS O
comparison BC2GM078123829 NN O
of BC2GM078123829 IN O
cDNA BC2GM078123829 NN O
sequences BC2GM078123829 NNS O
and BC2GM078123829 CC O
isolation BC2GM078123829 NN O
of BC2GM078123829 IN O
a BC2GM078123829 DT O
genomic BC2GM078123829 JJ O
clone BC2GM078123829 NN O
. BC2GM078123829 . O
. . O O

In BC2GM057663917 IN O
this BC2GM057663917 DT O
first-person BC2GM057663917 JJ O
account BC2GM057663917 NN O
, BC2GM057663917 , O
the BC2GM057663917 DT O
author BC2GM057663917 NN O
chronicles BC2GM057663917 VBZ O
her BC2GM057663917 PRP$ O
experience BC2GM057663917 NN O
of BC2GM057663917 IN O
being BC2GM057663917 VBG O
mentally BC2GM057663917 RB O
ill BC2GM057663917 JJ O
and BC2GM057663917 CC O
homeless BC2GM057663917 NN O
in BC2GM057663917 IN O
New BC2GM057663917 NNP O
York BC2GM057663917 NNP O
and BC2GM057663917 CC O
New BC2GM057663917 NNP O
Jersey BC2GM057663917 NNP O
in BC2GM057663917 IN O
the BC2GM057663917 DT O
early BC2GM057663917 JJ O
1980s BC2GM057663917 CD O
. BC2GM057663917 . O
. . O O

The BC2GM020276784 DT O
enzyme BC2GM020276784 NN O
encoded BC2GM020276784 VBN O
by BC2GM020276784 IN O
the BC2GM020276784 DT O
cloned BC2GM020276784 JJ O
fragment BC2GM020276784 NN O
is BC2GM020276784 VBZ O
equally BC2GM020276784 RB O
active BC2GM020276784 JJ O
on BC2GM020276784 IN O
pyruvate BC2GM020276784 NN O
and BC2GM020276784 CC O
hydroxypyruvate BC2GM020276784 NN O
, BC2GM020276784 , O
indicating BC2GM020276784 VBG O
that BC2GM020276784 IN O
the BC2GM020276784 DT O
enzyme BC2GM020276784 NN O
has BC2GM020276784 VBZ O
both BC2GM020276784 DT O
D-lactate BC2GM020276784 NNP O
and BC2GM020276784 CC O
D-glycerate BC2GM020276784 NNP O
dehydrogenase BC2GM020276784 NN O
activities BC2GM020276784 NNS O
. BC2GM020276784 . O
. . O O

Northern BC2GM090069165 NNP O
blot BC2GM090069165 NN O
analysis BC2GM090069165 NN O
linked BC2GM090069165 VBD O
Plk BC2GM090069165 NNP O
expression BC2GM090069165 NN O
to BC2GM090069165 TO O
the BC2GM090069165 DT O
proliferative BC2GM090069165 JJ O
activity BC2GM090069165 NN O
of BC2GM090069165 IN O
cells BC2GM090069165 NNS O
and BC2GM090069165 CC O
tissues BC2GM090069165 NNS O
. BC2GM090069165 . O
. . O O

The BC2GM010471023 DT O
maximal BC2GM010471023 JJ O
rise BC2GM010471023 NN O
in BC2GM010471023 IN O
plasma BC2GM010471023 JJ O
adrenaline BC2GM010471023 NN O
was BC2GM010471023 VBD O
of BC2GM010471023 IN O
similar BC2GM010471023 JJ O
magnitude BC2GM010471023 NN O
in BC2GM010471023 IN O
all BC2GM010471023 DT O
three BC2GM010471023 CD O
groups BC2GM010471023 NNS O
but BC2GM010471023 CC O
a BC2GM010471023 DT O
lower BC2GM010471023 JJR O
plasma BC2GM010471023 NN O
glucose BC2GM010471023 NN O
was BC2GM010471023 VBD O
required BC2GM010471023 VBN O
to BC2GM010471023 TO O
stimulate BC2GM010471023 VB O
this BC2GM010471023 DT O
hormonal BC2GM010471023 JJ O
response BC2GM010471023 NN O
in BC2GM010471023 IN O
the BC2GM010471023 DT O
'unaware BC2GM010471023 NNP O
' BC2GM010471023 POS O
patients BC2GM010471023 NNS O
, BC2GM010471023 , O
in BC2GM010471023 IN O
whom BC2GM010471023 WP O
the BC2GM010471023 DT O
plasma BC2GM010471023 NN O
adrenaline BC2GM010471023 NN O
concentration BC2GM010471023 NN O
was BC2GM010471023 VBD O
lower BC2GM010471023 JJR O
at BC2GM010471023 IN O
the BC2GM010471023 DT O
time BC2GM010471023 NN O
of BC2GM010471023 IN O
the BC2GM010471023 DT O
reaction BC2GM010471023 NN O
. BC2GM010471023 . O
. . O O

Within BC2GM052769911 IN O
the BC2GM052769911 DT O
final BC2GM052769911 JJ O
11 BC2GM052769911 CD O
amino BC2GM052769911 NN O
acids BC2GM052769911 NNS O
there BC2GM052769911 EX O
are BC2GM052769911 VBP O
5 BC2GM052769911 CD O
aromatic BC2GM052769911 JJ O
, BC2GM052769911 , O
2 BC2GM052769911 CD O
basic BC2GM052769911 JJ O
, BC2GM052769911 , O
and BC2GM052769911 CC O
no BC2GM052769911 DT O
acidic BC2GM052769911 JJ O
residues BC2GM052769911 NNS O
and BC2GM052769911 CC O
it BC2GM052769911 PRP O
has BC2GM052769911 VBZ O
been BC2GM052769911 VBN O
proposed BC2GM052769911 VBN O
that BC2GM052769911 IN O
these BC2GM052769911 DT O
residues BC2GM052769911 NNS O
stack BC2GM052769911 VBP O
with BC2GM052769911 IN O
and BC2GM052769911 CC O
electrostatically BC2GM052769911 RB O
interact BC2GM052769911 JJ O
with BC2GM052769911 IN O
the BC2GM052769911 DT O
kinked BC2GM052769911 VBN O
DNA BC2GM052769911 NN O
at BC2GM052769911 IN O
the BC2GM052769911 DT O
site BC2GM052769911 NN O
of BC2GM052769911 IN O
a BC2GM052769911 DT O
pyrimidine BC2GM052769911 JJ O
dimer BC2GM052769911 NN O
. BC2GM052769911 . O
. . O O

The BC2GM014990106 DT O
term BC2GM014990106 NN O
Kartagener BC2GM014990106 NNP O
syndrome BC2GM014990106 NN O
applies BC2GM014990106 NNS O
to BC2GM014990106 TO O
this BC2GM014990106 DT O
syndrome BC2GM014990106 NN O
when BC2GM014990106 WRB O
accompanied BC2GM014990106 VBN O
by BC2GM014990106 IN O
infertility BC2GM014990106 NN O
and BC2GM014990106 CC O
dextrocardia BC2GM014990106 NN O
or BC2GM014990106 CC O
situs BC2GM014990106 NN O
inversus BC2GM014990106 NN O
. BC2GM014990106 . O
. . O O

Similar BC2GM087115294 JJ O
observations BC2GM087115294 NNS O
were BC2GM087115294 VBD O
obtained BC2GM087115294 VBN O
when BC2GM087115294 WRB O
these BC2GM087115294 DT O
mutated BC2GM087115294 VBD O
versions BC2GM087115294 NNS O
of BC2GM087115294 IN O
site BC2GM087115294 NN O
A BC2GM087115294 NNP O
were BC2GM087115294 VBD O
evaluated BC2GM087115294 VBN O
by BC2GM087115294 IN O
transient BC2GM087115294 JJ O
cotransfection BC2GM087115294 NN O
assays BC2GM087115294 NNS O
in BC2GM087115294 IN O
CV1 BC2GM087115294 NNP O
cells BC2GM087115294 NNS O
. BC2GM087115294 . O
. . O O

Important BC2GM045195775 NNP O
prognostic BC2GM045195775 JJ O
factors BC2GM045195775 NNS O
for BC2GM045195775 IN O
the BC2GM045195775 DT O
results BC2GM045195775 NNS O
of BC2GM045195775 IN O
physiotherapeutic BC2GM045195775 JJ O
exercises BC2GM045195775 NNS O
in BC2GM045195775 IN O
intermittent BC2GM045195775 JJ O
claudication BC2GM045195775 NN O
. BC2GM045195775 . O
. . O O

Computer BC2GM089535838 NNP O
analysis BC2GM089535838 NN O
revealed BC2GM089535838 VBD O
that BC2GM089535838 IN O
the BC2GM089535838 DT O
human BC2GM089535838 JJ O
protein BC2GM089535838 NN O
P1 BC2GM089535838 NNP O
sequence BC2GM089535838 NN O
corresponding BC2GM089535838 VBG O
to BC2GM089535838 TO O
amino BC2GM089535838 VB O
acid BC2GM089535838 NN O
residues BC2GM089535838 NNS O
within BC2GM089535838 IN O
the BC2GM089535838 DT O
N-terminal BC2GM089535838 JJ O
RNA BC2GM089535838 NNP O
binding BC2GM089535838 NN O
domain BC2GM089535838 NN O
displays BC2GM089535838 NNS O
high BC2GM089535838 JJ O
homology BC2GM089535838 NN O
( BC2GM089535838 ( O
greater BC2GM089535838 JJR O
than BC2GM089535838 IN O
54 BC2GM089535838 CD O
% BC2GM089535838 NN O
identity BC2GM089535838 NN O
; BC2GM089535838 : O
61 BC2GM089535838 CD O
to BC2GM089535838 TO O
94 BC2GM089535838 CD O
% BC2GM089535838 NN O
similarity BC2GM089535838 NN O
) BC2GM089535838 ) O
with BC2GM089535838 IN O
two BC2GM089535838 CD O
animal BC2GM089535838 JJ O
virus BC2GM089535838 NN O
proteins BC2GM089535838 NNS O
which BC2GM089535838 WDT O
possess BC2GM089535838 VBP O
RNA BC2GM089535838 NNP O
binding BC2GM089535838 NN O
activity BC2GM089535838 NN O
( BC2GM089535838 ( O
vaccinia BC2GM089535838 JJ O
virus BC2GM089535838 NN O
E3L BC2GM089535838 NNP O
; BC2GM089535838 : O
rotavirus BC2GM089535838 VB O
VP2 BC2GM089535838 NNP O
) BC2GM089535838 ) O
and BC2GM089535838 CC O
two BC2GM089535838 CD O
proteins BC2GM089535838 NNS O
of BC2GM089535838 IN O
unknown BC2GM089535838 JJ O
function BC2GM089535838 NN O
( BC2GM089535838 ( O
murine BC2GM089535838 JJ O
TIK BC2GM089535838 NNP O
; BC2GM089535838 : O
rotavirus BC2GM089535838 VB O
NS34 BC2GM089535838 NNP O
) BC2GM089535838 ) O
, BC2GM089535838 , O
but BC2GM089535838 CC O
which BC2GM089535838 WDT O
are BC2GM089535838 VBP O
likely BC2GM089535838 JJ O
RNA BC2GM089535838 NNP O
binding BC2GM089535838 NN O
proteins BC2GM089535838 NNS O
. BC2GM089535838 . O
. . O O

The BC2GM057332311 DT O
CHL BC2GM057332311 NNP O
1 BC2GM057332311 CD O
( BC2GM057332311 ( O
CTF BC2GM057332311 NNP O
1 BC2GM057332311 CD O
) BC2GM057332311 ) O
gene BC2GM057332311 NN O
product BC2GM057332311 NN O
of BC2GM057332311 IN O
Saccharomyces BC2GM057332311 NNP O
cerevisiae BC2GM057332311 NN O
is BC2GM057332311 VBZ O
important BC2GM057332311 JJ O
for BC2GM057332311 IN O
chromosome BC2GM057332311 NN O
transmission BC2GM057332311 NN O
and BC2GM057332311 CC O
normal BC2GM057332311 JJ O
cell BC2GM057332311 NN O
cycle BC2GM057332311 NN O
progression BC2GM057332311 NN O
in BC2GM057332311 IN O
G2 BC2GM057332311 NNP O
/ BC2GM057332311 NNP O
M BC2GM057332311 NNP O
. BC2GM057332311 . O
. . O O

At BC2GM018687842 IN O
least BC2GM018687842 JJS O
one BC2GM018687842 CD O
such BC2GM018687842 JJ O
complex BC2GM018687842 NN O
is BC2GM018687842 VBZ O
eliminated BC2GM018687842 VBN O
by BC2GM018687842 IN O
preincubating BC2GM018687842 VBG O
the BC2GM018687842 DT O
nuclear BC2GM018687842 JJ O
extract BC2GM018687842 NN O
with BC2GM018687842 IN O
an BC2GM018687842 DT O
antibody BC2GM018687842 NN O
with BC2GM018687842 IN O
broad BC2GM018687842 JJ O
cross-reactivity BC2GM018687842 NN O
with BC2GM018687842 IN O
Ets-1 BC2GM018687842 NNP O
and BC2GM018687842 CC O
Ets-2 BC2GM018687842 NNP O
proteins BC2GM018687842 NNS O
, BC2GM018687842 , O
thus BC2GM018687842 RB O
confirming BC2GM018687842 VBG O
that BC2GM018687842 IN O
an BC2GM018687842 DT O
ETS BC2GM018687842 NNP O
transcription BC2GM018687842 NN O
factor BC2GM018687842 NN O
( BC2GM018687842 ( O
s BC2GM018687842 PRP O
) BC2GM018687842 ) O
recognizes BC2GM018687842 VBZ O
the BC2GM018687842 DT O
-12 BC2GM018687842 NN O
motif BC2GM018687842 NN O
. BC2GM018687842 . O
. . O O

During BC2GM015636298 IN O
normoxic BC2GM015636298 JJ O
exercise BC2GM015636298 NN O
, BC2GM015636298 , O
at BC2GM015636298 IN O
a BC2GM015636298 DT O
mean BC2GM015636298 JJ O
O2 BC2GM015636298 NNP O
uptake BC2GM015636298 NN O
( BC2GM015636298 ( O
VO2 BC2GM015636298 NNP O
) BC2GM015636298 ) O
of BC2GM015636298 IN O
4.0 BC2GM015636298 CD O
l BC2GM015636298 NN O
/ BC2GM015636298 NNP O
min BC2GM015636298 NN O
, BC2GM015636298 , O
almitrine BC2GM015636298 NN O
increased BC2GM015636298 VBD O
arterial BC2GM015636298 JJ O
PO2 BC2GM015636298 NNP O
( BC2GM015636298 ( O
PaO2 BC2GM015636298 NNP O
) BC2GM015636298 ) O
( BC2GM015636298 ( O
P BC2GM015636298 NNP O
< BC2GM015636298 NNP O
0.05 BC2GM015636298 CD O
) BC2GM015636298 ) O
, BC2GM015636298 , O
SaO2 BC2GM015636298 NNP O
( BC2GM015636298 ( O
P BC2GM015636298 NNP O
< BC2GM015636298 NNP O
0.01 BC2GM015636298 CD O
) BC2GM015636298 ) O
, BC2GM015636298 , O
and BC2GM015636298 CC O
VE BC2GM015636298 NNP O
( BC2GM015636298 ( O
P BC2GM015636298 NNP O
< BC2GM015636298 NNP O
0.05 BC2GM015636298 CD O
) BC2GM015636298 ) O
and BC2GM015636298 CC O
decreased BC2GM015636298 VBN O
arterial BC2GM015636298 JJ O
PCO2 BC2GM015636298 NNP O
( BC2GM015636298 ( O
P BC2GM015636298 NNP O
< BC2GM015636298 NNP O
0.01 BC2GM015636298 CD O
) BC2GM015636298 ) O
, BC2GM015636298 , O
without BC2GM015636298 IN O
affecting BC2GM015636298 VBG O
pulmonary BC2GM015636298 JJ O
hemodynamics BC2GM015636298 NNS O
or BC2GM015636298 CC O
ventilation-perfusion BC2GM015636298 NN O
distributions BC2GM015636298 NNS O
. BC2GM015636298 . O
. . O O

JCAHO BC2GM063881420 NNP O
moves BC2GM063881420 VBZ O
to BC2GM063881420 TO O
rewrite BC2GM063881420 VB O
many BC2GM063881420 JJ O
rules BC2GM063881420 NNS O
to BC2GM063881420 TO O
lessen BC2GM063881420 VB O
hospitals BC2GM063881420 NNS O
' BC2GM063881420 POS O
regulatory BC2GM063881420 JJ O
burden BC2GM063881420 NN O
. BC2GM063881420 . O
. . O O

Convergence BC2GM062223441 NN O
of BC2GM062223441 IN O
trigeminal BC2GM062223441 JJ O
input BC2GM062223441 NN O
with BC2GM062223441 IN O
visceral BC2GM062223441 JJ O
and BC2GM062223441 CC O
phrenic BC2GM062223441 JJ O
inputs BC2GM062223441 NNS O
on BC2GM062223441 IN O
primate BC2GM062223441 JJ O
C1-C2 BC2GM062223441 JJ O
spinothalamic BC2GM062223441 JJ O
tract BC2GM062223441 NN O
neurons BC2GM062223441 NNS O
. BC2GM062223441 . O
. . O O

At BC2GM026460390 IN O
D28 BC2GM026460390 NNP O
, BC2GM026460390 , O
149 BC2GM026460390 CD O
of BC2GM026460390 IN O
386 BC2GM026460390 CD O
patients BC2GM026460390 NNS O
( BC2GM026460390 ( O
49 BC2GM026460390 CD O
% BC2GM026460390 NN O
) BC2GM026460390 ) O
had BC2GM026460390 VBD O
had BC2GM026460390 VBN O
episodes BC2GM026460390 NNS O
of BC2GM026460390 IN O
automatic BC2GM026460390 JJ O
mode BC2GM026460390 NN O
switch BC2GM026460390 NN O
prompted BC2GM026460390 VBN O
by BC2GM026460390 IN O
atrial BC2GM026460390 JJ O
arrhythmias BC2GM026460390 NN O
. BC2GM026460390 . O
. . O O

Csk BC2GM033988822 NNP O
( BC2GM033988822 ( O
C-terminal BC2GM033988822 JJ O
Src BC2GM033988822 NNP O
kinase BC2GM033988822 NN O
) BC2GM033988822 ) O
is BC2GM033988822 VBZ O
a BC2GM033988822 DT O
protein BC2GM033988822 JJ O
tyrosine BC2GM033988822 NN O
kinase BC2GM033988822 NN O
that BC2GM033988822 WDT O
phosphorylates BC2GM033988822 VBZ O
Src BC2GM033988822 NNP O
family BC2GM033988822 NN O
member BC2GM033988822 NN O
C-terminal BC2GM033988822 NNP O
tails BC2GM033988822 NNS O
, BC2GM033988822 , O
resulting BC2GM033988822 VBG O
in BC2GM033988822 IN O
downregulation BC2GM033988822 NN O
of BC2GM033988822 IN O
Src BC2GM033988822 NNP O
family BC2GM033988822 NN O
members BC2GM033988822 NNS O
. BC2GM033988822 . O
. . O O

Because BC2GM066642984 IN O
the BC2GM066642984 DT O
wa-2 BC2GM066642984 JJ O
mutation BC2GM066642984 NN O
was BC2GM066642984 VBD O
mapped BC2GM066642984 VBN O
previously BC2GM066642984 RB O
to BC2GM066642984 TO O
the BC2GM066642984 DT O
vicinity BC2GM066642984 NN O
of BC2GM066642984 IN O
the BC2GM066642984 DT O
EGF BC2GM066642984 NNP O
/ BC2GM066642984 NNP O
TGF-alpha BC2GM066642984 NNP O
receptor BC2GM066642984 NN O
( BC2GM066642984 ( O
EGFR BC2GM066642984 NNP O
) BC2GM066642984 ) O
gene BC2GM066642984 NN O
on BC2GM066642984 IN O
mouse BC2GM066642984 NN O
chromosome BC2GM066642984 NN O
11 BC2GM066642984 CD O
, BC2GM066642984 , O
we BC2GM066642984 PRP O
hypothesized BC2GM066642984 VBD O
that BC2GM066642984 IN O
the BC2GM066642984 DT O
wa-2 BC2GM066642984 JJ O
phenotype BC2GM066642984 NN O
might BC2GM066642984 MD O
result BC2GM066642984 VB O
from BC2GM066642984 IN O
a BC2GM066642984 DT O
defect BC2GM066642984 NN O
in BC2GM066642984 IN O
either BC2GM066642984 CC O
the BC2GM066642984 DT O
expression BC2GM066642984 NN O
or BC2GM066642984 CC O
activity BC2GM066642984 NN O
of BC2GM066642984 IN O
EGFR BC2GM066642984 NNP O
, BC2GM066642984 , O
or BC2GM066642984 CC O
both BC2GM066642984 DT O
. BC2GM066642984 . O
. . O O

Sequence BC2GM043410270 NN O
and BC2GM043410270 CC O
deletion BC2GM043410270 NN O
analysis BC2GM043410270 NN O
of BC2GM043410270 IN O
the BC2GM043410270 DT O
recombination BC2GM043410270 NN O
enhancement BC2GM043410270 NN O
gene BC2GM043410270 NN O
( BC2GM043410270 ( O
ref BC2GM043410270 JJ O
) BC2GM043410270 ) O
of BC2GM043410270 IN O
bacteriophage BC2GM043410270 NN O
P1 BC2GM043410270 NNP O
: BC2GM043410270 : O
evidence BC2GM043410270 NN O
for BC2GM043410270 IN O
promoter-operator BC2GM043410270 NN O
and BC2GM043410270 CC O
attenuator-antiterminator BC2GM043410270 NN O
control BC2GM043410270 NN O
. BC2GM043410270 . O
. . O O

Coexpression BC2GM024208708 NN O
of BC2GM024208708 IN O
a BC2GM024208708 DT O
dominant BC2GM024208708 JJ O
negative BC2GM024208708 JJ O
c-jun BC2GM024208708 NN O
antagonized BC2GM024208708 VBD O
the BC2GM024208708 DT O
ras-dependent BC2GM024208708 JJ O
stimulation BC2GM024208708 NN O
of BC2GM024208708 IN O
the BC2GM024208708 DT O
92-kDa BC2GM024208708 JJ O
gelatinase BC2GM024208708 NN O
B BC2GM024208708 NNP O
promoter-driven BC2GM024208708 JJ O
CAT BC2GM024208708 NNP O
reporter BC2GM024208708 NN O
. BC2GM024208708 . O
. . O O

Results BC2GM044671212 NNS O
of BC2GM044671212 IN O
these BC2GM044671212 DT O
studies BC2GM044671212 NNS O
indicate BC2GM044671212 VBP O
that BC2GM044671212 IN O
binding BC2GM044671212 NN O
of BC2GM044671212 IN O
biotin BC2GM044671212 NN O
to BC2GM044671212 TO O
the BC2GM044671212 DT O
protein BC2GM044671212 NN O
results BC2GM044671212 NNS O
in BC2GM044671212 IN O
protection BC2GM044671212 NN O
of BC2GM044671212 IN O
regions BC2GM044671212 NNS O
of BC2GM044671212 IN O
the BC2GM044671212 DT O
central BC2GM044671212 JJ O
domain BC2GM044671212 NN O
in BC2GM044671212 IN O
the BC2GM044671212 DT O
vicinity BC2GM044671212 NN O
of BC2GM044671212 IN O
the BC2GM044671212 DT O
active BC2GM044671212 JJ O
site BC2GM044671212 NN O
and BC2GM044671212 CC O
the BC2GM044671212 DT O
C-terminal BC2GM044671212 JJ O
domain BC2GM044671212 NN O
from BC2GM044671212 IN O
chemical BC2GM044671212 JJ O
cleavage BC2GM044671212 NN O
. BC2GM044671212 . O
. . O O

After BC2GM068890496 IN O
5,850 BC2GM068890496 CD O
C14 BC2GM068890496 NNP O
BP BC2GM068890496 NNP O
, BC2GM068890496 , O
the BC2GM068890496 DT O
decrease BC2GM068890496 NN O
in BC2GM068890496 IN O
Acer BC2GM068890496 NNP O
stands BC2GM068890496 NNS O
could BC2GM068890496 MD O
be BC2GM068890496 VB O
attributed BC2GM068890496 VBN O
to BC2GM068890496 TO O
fire BC2GM068890496 VB O
as BC2GM068890496 IN O
suggested BC2GM068890496 VBN O
by BC2GM068890496 IN O
the BC2GM068890496 DT O
strong BC2GM068890496 JJ O
increase BC2GM068890496 NN O
in BC2GM068890496 IN O
Betula BC2GM068890496 NNP O
and BC2GM068890496 CC O
by BC2GM068890496 IN O
the BC2GM068890496 DT O
delayed BC2GM068890496 JJ O
expansion BC2GM068890496 NN O
of BC2GM068890496 IN O
Pinus BC2GM068890496 NNP O
cembra BC2GM068890496 NN O
. BC2GM068890496 . O
. . O O

Truncations BC2GM011003396 NNS O
from BC2GM011003396 IN O
Hip BC2GM011003396 NNP O
's BC2GM011003396 POS O
N BC2GM011003396 NNP O
terminus BC2GM011003396 NN O
resulted BC2GM011003396 VBD O
in BC2GM011003396 IN O
an BC2GM011003396 DT O
apparent BC2GM011003396 JJ O
loss BC2GM011003396 NN O
of BC2GM011003396 IN O
Hip BC2GM011003396 NNP O
homo-oligomerization BC2GM011003396 NN O
, BC2GM011003396 , O
but BC2GM011003396 CC O
these BC2GM011003396 DT O
mutants BC2GM011003396 NNS O
retained BC2GM011003396 VBD O
association BC2GM011003396 NN O
with BC2GM011003396 IN O
hsp70 BC2GM011003396 NN O
and BC2GM011003396 CC O
were BC2GM011003396 VBD O
recovered BC2GM011003396 VBN O
in BC2GM011003396 IN O
receptor BC2GM011003396 NN O
complexes BC2GM011003396 NNS O
. BC2GM011003396 . O
. . O O

More BC2GM012674132 RBR O
important BC2GM012674132 JJ O
, BC2GM012674132 , O
ligand-activated BC2GM012674132 JJ O
insulin BC2GM012674132 NN O
and BC2GM012674132 CC O
IGF-I BC2GM012674132 JJ O
receptors BC2GM012674132 NNS O
phosphorylate BC2GM012674132 VBP O
SHC BC2GM012674132 NNP O
proteins BC2GM012674132 NNS O
in BC2GM012674132 IN O
vitro BC2GM012674132 NN O
, BC2GM012674132 , O
indicating BC2GM012674132 VBG O
that BC2GM012674132 IN O
SHC BC2GM012674132 NNP O
proteins BC2GM012674132 NNS O
could BC2GM012674132 MD O
be BC2GM012674132 VB O
direct BC2GM012674132 JJ O
substrates BC2GM012674132 NNS O
for BC2GM012674132 IN O
insulin BC2GM012674132 NN O
and BC2GM012674132 CC O
IGF-I BC2GM012674132 JJ O
receptors BC2GM012674132 NNS O
. BC2GM012674132 . O
. . O O

A BC2GM045785731 DT O
physical BC2GM045785731 JJ O
and BC2GM045785731 CC O
genetic BC2GM045785731 JJ O
map BC2GM045785731 NN O
covering BC2GM045785731 VBG O
the BC2GM045785731 DT O
entire BC2GM045785731 JJ O
RP12 BC2GM045785731 NNP O
candidate BC2GM045785731 NN O
gene BC2GM045785731 NN O
region BC2GM045785731 NN O
was BC2GM045785731 VBD O
constructed BC2GM045785731 VBN O
. BC2GM045785731 . O
. . O O

In BC2GM029138982 IN O
this BC2GM029138982 DT O
study BC2GM029138982 NN O
, BC2GM029138982 , O
the BC2GM029138982 DT O
effect BC2GM029138982 NN O
of BC2GM029138982 IN O
the BC2GM029138982 DT O
antibiotic BC2GM029138982 JJ O
lasalocid BC2GM029138982 NN O
on BC2GM029138982 IN O
the BC2GM029138982 DT O
rumen BC2GM029138982 NNS O
anaerobic BC2GM029138982 VBP O
fungus BC2GM029138982 JJ O
Neocallimastix BC2GM029138982 NNP O
frontalis BC2GM029138982 NN O
RK BC2GM029138982 NNP O
21 BC2GM029138982 CD O
was BC2GM029138982 VBD O
examined BC2GM029138982 VBN O
. BC2GM029138982 . O
. . O O

The BC2GM020677655 DT O
results BC2GM020677655 NNS O
suggest BC2GM020677655 VBP O
that BC2GM020677655 IN O
proenzyme BC2GM020677655 NN O
processing BC2GM020677655 NN O
is BC2GM020677655 VBZ O
not BC2GM020677655 RB O
essential BC2GM020677655 JJ O
for BC2GM020677655 IN O
secretion BC2GM020677655 NN O
of BC2GM020677655 IN O
PC2 BC2GM020677655 NNP O
, BC2GM020677655 , O
but BC2GM020677655 CC O
peptides BC2GM020677655 NNS O
containing BC2GM020677655 VBG O
mutations BC2GM020677655 NNS O
that BC2GM020677655 WDT O
affect BC2GM020677655 VBP O
the BC2GM020677655 DT O
ability BC2GM020677655 NN O
of BC2GM020677655 IN O
the BC2GM020677655 DT O
propeptide BC2GM020677655 NN O
( BC2GM020677655 ( O
and BC2GM020677655 CC O
cleavage BC2GM020677655 VB O
sites BC2GM020677655 NNS O
) BC2GM020677655 ) O
to BC2GM020677655 TO O
fold BC2GM020677655 VB O
within BC2GM020677655 IN O
the BC2GM020677655 DT O
catalytic BC2GM020677655 JJ O
pocket BC2GM020677655 NN O
are BC2GM020677655 VBP O
not BC2GM020677655 RB O
transferred BC2GM020677655 VBN O
beyond BC2GM020677655 IN O
the BC2GM020677655 DT O
early BC2GM020677655 JJ O
stages BC2GM020677655 NNS O
of BC2GM020677655 IN O
the BC2GM020677655 DT O
secretory BC2GM020677655 JJ O
pathway BC2GM020677655 NN O
. BC2GM020677655 . O
. . O O

Small BC2GM064087768 JJ O
t BC2GM064087768 NN O
also BC2GM064087768 RB O
inhibited BC2GM064087768 VBD O
the BC2GM064087768 DT O
dephosphorylation BC2GM064087768 NN O
of BC2GM064087768 IN O
cAMP-dependent BC2GM064087768 JJ O
protein BC2GM064087768 NN O
kinase BC2GM064087768 NN O
( BC2GM064087768 ( O
PKA BC2GM064087768 NNP O
) BC2GM064087768 ) O
-phosphorylated BC2GM064087768 VBD O
CREB BC2GM064087768 NNP O
in BC2GM064087768 IN O
rat BC2GM064087768 NN O
liver BC2GM064087768 NN O
nuclear BC2GM064087768 JJ O
extracts BC2GM064087768 NNS O
. BC2GM064087768 . O
. . O O

Neurological BC2GM042374200 JJ O
toxicity BC2GM042374200 NN O
occurred BC2GM042374200 VBD O
in BC2GM042374200 IN O
8 BC2GM042374200 CD O
/ BC2GM042374200 JJ O
219 BC2GM042374200 CD O
patients BC2GM042374200 NNS O
treated BC2GM042374200 VBN O
with BC2GM042374200 IN O
fludarabine BC2GM042374200 NN O
( BC2GM042374200 ( O
FAMP BC2GM042374200 NNP O
) BC2GM042374200 ) O
, BC2GM042374200 , O
30 BC2GM042374200 CD O
mg BC2GM042374200 NN O
/ BC2GM042374200 NNP O
m2 BC2GM042374200 NN O
per BC2GM042374200 IN O
day BC2GM042374200 NN O
and BC2GM042374200 CC O
cytosine BC2GM042374200 NN O
arabinoside BC2GM042374200 NN O
( BC2GM042374200 ( O
Ara-C BC2GM042374200 NNP O
) BC2GM042374200 ) O
, BC2GM042374200 , O
0.5 BC2GM042374200 CD O
g BC2GM042374200 NN O
/ BC2GM042374200 NNP O
m2 BC2GM042374200 FW O
per BC2GM042374200 IN O
hour BC2GM042374200 NN O
for BC2GM042374200 IN O
2-6 BC2GM042374200 JJ O
hours BC2GM042374200 NNS O
for BC2GM042374200 IN O
5 BC2GM042374200 CD O
days BC2GM042374200 NNS O
, BC2GM042374200 , O
for BC2GM042374200 IN O
new BC2GM042374200 JJ O
or BC2GM042374200 CC O
relapsed BC2GM042374200 VBN O
acute BC2GM042374200 JJ O
leukemia BC2GM042374200 NN O
or BC2GM042374200 CC O
myelodysplasia BC2GM042374200 NN O
. BC2GM042374200 . O
. . O O

Vectorcardiography BC2GM092131835 NN O
in BC2GM092131835 IN O
coronary BC2GM092131835 JJ O
patients BC2GM092131835 NNS O
with BC2GM092131835 IN O
the BC2GM092131835 DT O
electrocardiographic BC2GM092131835 JJ O
RS BC2GM092131835 NNP O
segment BC2GM092131835 NN O
in BC2GM092131835 IN O
the BC2GM092131835 DT O
V1 BC2GM092131835 NNP O
lead BC2GM092131835 NN O
. BC2GM092131835 . O
. . O O

Peripheral BC2GM013849593 NNP O
neuropathy BC2GM013849593 NN O
in BC2GM013849593 IN O
the BC2GM013849593 DT O
cherry-red BC2GM013849593 JJ O
spot-myoclonus BC2GM013849593 JJ O
syndrome BC2GM013849593 NN O
( BC2GM013849593 ( O
sialidosis BC2GM013849593 NN O
type BC2GM013849593 NN O
I BC2GM013849593 PRP O
) BC2GM013849593 ) O
. BC2GM013849593 . O
. . O O

We BC2GM051498268 PRP O
reviewed BC2GM051498268 VBD O
81 BC2GM051498268 CD O
patients BC2GM051498268 NNS O
with BC2GM051498268 IN O
dementia BC2GM051498268 NN O
and BC2GM051498268 CC O
autopsy BC2GM051498268 JJ O
findings BC2GM051498268 NNS O
of BC2GM051498268 IN O
Alzheimer BC2GM051498268 NNP O
's BC2GM051498268 POS O
disease BC2GM051498268 NN O
( BC2GM051498268 ( O
AD BC2GM051498268 NNP O
) BC2GM051498268 ) O
to BC2GM051498268 TO O
identify BC2GM051498268 VB O
patients BC2GM051498268 NNS O
with BC2GM051498268 IN O
seizures BC2GM051498268 NNS O
or BC2GM051498268 CC O
myoclonus BC2GM051498268 NNS O
after BC2GM051498268 IN O
onset BC2GM051498268 NN O
of BC2GM051498268 IN O
dementia BC2GM051498268 NN O
. BC2GM051498268 . O
. . O O

CONCLUSIONS BC2GM013965440 NN O
: BC2GM013965440 : O
The BC2GM013965440 DT O
number BC2GM013965440 NN O
of BC2GM013965440 IN O
Spanish BC2GM013965440 JJ O
articles BC2GM013965440 NNS O
published BC2GM013965440 VBN O
in BC2GM013965440 IN O
Anesthesiology BC2GM013965440 NNP O
, BC2GM013965440 , O
BJA BC2GM013965440 NNP O
, BC2GM013965440 , O
and BC2GM013965440 CC O
Anesth BC2GM013965440 NNP O
Analg BC2GM013965440 NNP O
is BC2GM013965440 VBZ O
low BC2GM013965440 JJ O
, BC2GM013965440 , O
although BC2GM013965440 IN O
the BC2GM013965440 DT O
comparison BC2GM013965440 NN O
of BC2GM013965440 IN O
our BC2GM013965440 PRP$ O
productivity BC2GM013965440 NN O
with BC2GM013965440 IN O
that BC2GM013965440 DT O
of BC2GM013965440 IN O
other BC2GM013965440 JJ O
EU BC2GM013965440 NNP O
countries BC2GM013965440 NNS O
in BC2GM013965440 IN O
function BC2GM013965440 NN O
of BC2GM013965440 IN O
GNPpc BC2GM013965440 NNP O
places BC2GM013965440 NNS O
us BC2GM013965440 PRP O
in BC2GM013965440 IN O
an BC2GM013965440 DT O
intermediate BC2GM013965440 JJ O
position BC2GM013965440 NN O
. BC2GM013965440 . O
. . O O

Routine BC2GM059205443 NNP O
and BC2GM059205443 CC O
default BC2GM059205443 NN O
retrieval BC2GM059205443 NN O
home BC2GM059205443 NN O
visits BC2GM059205443 NNS O
were BC2GM059205443 VBD O
given BC2GM059205443 VBN O
to BC2GM059205443 TO O
ensure BC2GM059205443 VB O
maximal BC2GM059205443 JJ O
drug BC2GM059205443 NN O
compliance BC2GM059205443 NN O
. BC2GM059205443 . O
. . O O

In BC2GM048391096 IN O
EGF BC2GM048391096 NNP O
receptor-mediated BC2GM048391096 JJ O
signaling BC2GM048391096 NN O
, BC2GM048391096 , O
the BC2GM048391096 DT O
protein BC2GM048391096 NN O
kinase BC2GM048391096 NN O
PKB BC2GM048391096 NNP O
/ BC2GM048391096 NNP O
Akt BC2GM048391096 NNP O
and BC2GM048391096 CC O
the BC2GM048391096 DT O
mitogen-activated BC2GM048391096 JJ O
protein BC2GM048391096 NN O
kinase BC2GM048391096 VBD O
c-Jun BC2GM048391096 JJ O
N-terminal BC2GM048391096 JJ O
kinase BC2GM048391096 NN O
, BC2GM048391096 , O
but BC2GM048391096 CC O
not BC2GM048391096 RB O
extracellular BC2GM048391096 JJ O
signal-regulated BC2GM048391096 JJ O
kinase BC2GM048391096 NN O
2 BC2GM048391096 CD O
, BC2GM048391096 , O
function BC2GM048391096 NN O
downstream BC2GM048391096 NN O
of BC2GM048391096 IN O
phosphatidylinositol BC2GM048391096 JJ O
3-kinase BC2GM048391096 JJ O
( BC2GM048391096 ( O
PI BC2GM048391096 NNP O
3-kinase BC2GM048391096 NNP O
) BC2GM048391096 ) O
. BC2GM048391096 . O
. . O O

98 BC2GM074209039 CD O
, BC2GM074209039 , O
93-98 BC2GM074209039 CD O
) BC2GM074209039 ) O
. BC2GM074209039 . O
. . O O

Unlike BC2GM086417938 IN O
JNK BC2GM086417938 NNP O
activation BC2GM086417938 NN O
, BC2GM086417938 , O
ERK BC2GM086417938 NNP O
activation BC2GM086417938 NN O
could BC2GM086417938 MD O
not BC2GM086417938 RB O
be BC2GM086417938 VB O
mapped BC2GM086417938 VBN O
to BC2GM086417938 TO O
specific BC2GM086417938 JJ O
reovirus BC2GM086417938 NN O
gene BC2GM086417938 NN O
segments BC2GM086417938 NNS O
, BC2GM086417938 , O
suggesting BC2GM086417938 VBG O
that BC2GM086417938 IN O
ERK BC2GM086417938 NNP O
activation BC2GM086417938 NN O
and BC2GM086417938 CC O
JNK BC2GM086417938 NNP O
activation BC2GM086417938 NN O
are BC2GM086417938 VBP O
triggered BC2GM086417938 VBN O
by BC2GM086417938 IN O
different BC2GM086417938 JJ O
events BC2GM086417938 NNS O
during BC2GM086417938 IN O
virus-host BC2GM086417938 NN O
cell BC2GM086417938 NN O
interaction BC2GM086417938 NN O
. BC2GM086417938 . O
. . O O

Primers BC2GM020087373 NNS O
were BC2GM020087373 VBD O
developed BC2GM020087373 VBN O
for BC2GM020087373 IN O
specific BC2GM020087373 JJ O
amplification BC2GM020087373 NN O
of BC2GM020087373 IN O
9804 BC2GM020087373 CD O
gene BC2GM020087373 NN O
fragments BC2GM020087373 NNS O
. BC2GM020087373 . O
. . O O

The BC2GM053457298 DT O
highest BC2GM053457298 JJS O
TTX BC2GM053457298 NN O
content BC2GM053457298 NN O
is BC2GM053457298 VBZ O
10.0 BC2GM053457298 CD O
microg BC2GM053457298 NN O
/ BC2GM053457298 NNP O
g BC2GM053457298 NN O
in BC2GM053457298 IN O
N. BC2GM053457298 NNP O
livescens BC2GM053457298 NNS O
. BC2GM053457298 . O
. . O O

The BC2GM080062282 DT O
deduced BC2GM080062282 JJ O
gene BC2GM080062282 NN O
product BC2GM080062282 NN O
was BC2GM080062282 VBD O
found BC2GM080062282 VBN O
to BC2GM080062282 TO O
have BC2GM080062282 VB O
significant BC2GM080062282 JJ O
sequence BC2GM080062282 NN O
similarity BC2GM080062282 NN O
to BC2GM080062282 TO O
the BC2GM080062282 DT O
yeast BC2GM080062282 NN O
and BC2GM080062282 CC O
prokaryotic BC2GM080062282 JJ O
RNA BC2GM080062282 NNP O
polymerase BC2GM080062282 NN O
subunits BC2GM080062282 NNS O
involved BC2GM080062282 VBN O
with BC2GM080062282 IN O
subunit BC2GM080062282 NN O
assembly BC2GM080062282 NN O
. BC2GM080062282 . O
. . O O

Human BC2GM096376764 NNP O
parvovirus BC2GM096376764 NN O
B19 BC2GM096376764 NNP O
gene BC2GM096376764 NN O
expression BC2GM096376764 NN O
from BC2GM096376764 IN O
the BC2GM096376764 DT O
viral BC2GM096376764 JJ O
p6 BC2GM096376764 NN O
promoter BC2GM096376764 NN O
( BC2GM096376764 ( O
B19p6 BC2GM096376764 NNP O
) BC2GM096376764 ) O
is BC2GM096376764 VBZ O
restricted BC2GM096376764 VBN O
to BC2GM096376764 TO O
primary BC2GM096376764 JJ O
human BC2GM096376764 JJ O
hematopoietic BC2GM096376764 JJ O
cells BC2GM096376764 NNS O
undergoing BC2GM096376764 VBG O
erythroid BC2GM096376764 JJ O
differentiation BC2GM096376764 NN O
. BC2GM096376764 . O
. . O O

Response BC2GM092742899 NNP O
properties BC2GM092742899 NNS O
of BC2GM092742899 IN O
single BC2GM092742899 JJ O
units BC2GM092742899 NNS O
in BC2GM092742899 IN O
the BC2GM092742899 DT O
accessory BC2GM092742899 NN O
optic BC2GM092742899 JJ O
system BC2GM092742899 NN O
of BC2GM092742899 IN O
the BC2GM092742899 DT O
dark-reared BC2GM092742899 JJ O
cat BC2GM092742899 NN O
. BC2GM092742899 . O
. . O O

We BC2GM086681787 PRP O
recently BC2GM086681787 RB O
described BC2GM086681787 VBD O
the BC2GM086681787 DT O
isolation BC2GM086681787 NN O
and BC2GM086681787 CC O
characterization BC2GM086681787 NN O
of BC2GM086681787 IN O
nontoxic BC2GM086681787 JJ O
PAP BC2GM086681787 NNP O
mutants BC2GM086681787 NNS O
, BC2GM086681787 , O
NT123-2 BC2GM086681787 NNP O
, BC2GM086681787 , O
which BC2GM086681787 WDT O
has BC2GM086681787 VBZ O
a BC2GM086681787 DT O
point BC2GM086681787 NN O
mutation BC2GM086681787 NN O
( BC2GM086681787 ( O
E176V BC2GM086681787 NNP O
) BC2GM086681787 ) O
in BC2GM086681787 IN O
the BC2GM086681787 DT O
active BC2GM086681787 JJ O
site BC2GM086681787 NN O
that BC2GM086681787 WDT O
abolishes BC2GM086681787 VBZ O
enzymatic BC2GM086681787 JJ O
activity BC2GM086681787 NN O
, BC2GM086681787 , O
and BC2GM086681787 CC O
NT124-3 BC2GM086681787 NNP O
, BC2GM086681787 , O
which BC2GM086681787 WDT O
has BC2GM086681787 VBZ O
a BC2GM086681787 DT O
nonsense BC2GM086681787 JJ O
mutation BC2GM086681787 NN O
that BC2GM086681787 WDT O
results BC2GM086681787 NNS O
in BC2GM086681787 IN O
deletion BC2GM086681787 NN O
of BC2GM086681787 IN O
the BC2GM086681787 DT O
C-terminal BC2GM086681787 JJ O
25 BC2GM086681787 CD O
aa BC2GM086681787 NN O
( BC2GM086681787 ( O
W237Stop BC2GM086681787 NNP O
) BC2GM086681787 ) O
. BC2GM086681787 . O
. . O O

During BC2GM062613921 IN O
the BC2GM062613921 DT O
last BC2GM062613921 JJ O
three BC2GM062613921 CD O
days BC2GM062613921 NNS O
of BC2GM062613921 IN O
the BC2GM062613921 DT O
study BC2GM062613921 NN O
, BC2GM062613921 , O
mean BC2GM062613921 JJ O
urine BC2GM062613921 JJ O
osmolality BC2GM062613921 NN O
( BC2GM062613921 ( O
Uosm BC2GM062613921 NNP O
) BC2GM062613921 ) O
and BC2GM062613921 CC O
free BC2GM062613921 JJ O
water BC2GM062613921 NN O
reabsorption BC2GM062613921 NN O
( BC2GM062613921 ( O
TCH2O BC2GM062613921 NNP O
) BC2GM062613921 ) O
increased BC2GM062613921 VBD O
significantly BC2GM062613921 RB O
: BC2GM062613921 : O
[ BC2GM062613921 JJ O
formula BC2GM062613921 NN O
: BC2GM062613921 : O
see BC2GM062613921 VB O
text BC2GM062613921 JJ O
] BC2GM062613921 NN O
. BC2GM062613921 . O
. . O O

Because BC2GM003857556 IN O
controlled-release BC2GM003857556 JJ O
niacin BC2GM003857556 NN O
seems BC2GM003857556 VBZ O
to BC2GM003857556 TO O
be BC2GM003857556 VB O
more BC2GM003857556 RBR O
potent BC2GM003857556 JJ O
than BC2GM003857556 IN O
crystalline BC2GM003857556 NN O
niacin BC2GM003857556 NN O
, BC2GM003857556 , O
product BC2GM003857556 NN O
substitution BC2GM003857556 NN O
without BC2GM003857556 IN O
dose BC2GM003857556 JJ O
adjustment BC2GM003857556 NN O
should BC2GM003857556 MD O
be BC2GM003857556 VB O
avoided BC2GM003857556 VBN O
. BC2GM003857556 . O
. . O O

They BC2GM052917492 PRP O
cause BC2GM052917492 VBP O
temporary BC2GM052917492 JJ O
disability BC2GM052917492 NN O
, BC2GM052917492 , O
invalidity BC2GM052917492 NN O
and BC2GM052917492 CC O
mortality BC2GM052917492 NN O
of BC2GM052917492 IN O
a BC2GM052917492 DT O
great BC2GM052917492 JJ O
part BC2GM052917492 NN O
of BC2GM052917492 IN O
the BC2GM052917492 DT O
productive BC2GM052917492 JJ O
population BC2GM052917492 NN O
, BC2GM052917492 , O
significantly BC2GM052917492 RB O
damaging BC2GM052917492 VBG O
the BC2GM052917492 DT O
economic BC2GM052917492 JJ O
status BC2GM052917492 NN O
of BC2GM052917492 IN O
the BC2GM052917492 DT O
country BC2GM052917492 NN O
. BC2GM052917492 . O
. . O O

Furthermore BC2GM013429399 IN O
we BC2GM013429399 PRP O
elucidate BC2GM013429399 VBP O
the BC2GM013429399 DT O
subtle BC2GM013429399 JJ O
highly BC2GM013429399 RB O
anisotropic BC2GM013429399 JJ O
interchain BC2GM013429399 NN O
correlations BC2GM013429399 NNS O
and BC2GM013429399 CC O
reveal BC2GM013429399 VB O
the BC2GM013429399 DT O
detailed BC2GM013429399 JJ O
atomic BC2GM013429399 JJ O
structure BC2GM013429399 NN O
of BC2GM013429399 IN O
the BC2GM013429399 DT O
low-temperature BC2GM013429399 NN O
( BC2GM013429399 ( O
8x2 BC2GM013429399 CD O
) BC2GM013429399 ) O
phase BC2GM013429399 NN O
. BC2GM013429399 . O
. . O O

Lactate BC2GM019146982 NNP O
, BC2GM019146982 , O
pyruvate BC2GM019146982 NN O
and BC2GM019146982 CC O
actual BC2GM019146982 JJ O
pH BC2GM019146982 NN O
values BC2GM019146982 NNS O
in BC2GM019146982 IN O
the BC2GM019146982 DT O
venous BC2GM019146982 JJ O
blood BC2GM019146982 NN O
of BC2GM019146982 IN O
newborn BC2GM019146982 JJ O
calves BC2GM019146982 NNS O
. BC2GM019146982 . O
. . O O

These BC2GM038659549 DT O
results BC2GM038659549 NNS O
are BC2GM038659549 VBP O
discussed BC2GM038659549 VBN O
in BC2GM038659549 IN O
the BC2GM038659549 DT O
context BC2GM038659549 NN O
of BC2GM038659549 IN O
a BC2GM038659549 DT O
model BC2GM038659549 NN O
of BC2GM038659549 IN O
the BC2GM038659549 DT O
myogenic BC2GM038659549 JJ O
lineage BC2GM038659549 NN O
that BC2GM038659549 WDT O
is BC2GM038659549 VBZ O
based BC2GM038659549 VBN O
on BC2GM038659549 IN O
the BC2GM038659549 DT O
expression BC2GM038659549 NN O
of BC2GM038659549 IN O
desmin BC2GM038659549 NN O
. BC2GM038659549 . O
. . O O

Using BC2GM035984243 VBG O
community BC2GM035984243 NN O
development BC2GM035984243 NN O
approaches BC2GM035984243 NNS O
. BC2GM035984243 . O
. . O O

These BC2GM067698579 DT O
tiny BC2GM067698579 JJ O
premature BC2GM067698579 NN O
infants BC2GM067698579 NNS O
also BC2GM067698579 RB O
received BC2GM067698579 VBD O
PN BC2GM067698579 NNP O
for BC2GM067698579 IN O
significantly BC2GM067698579 RB O
longer BC2GM067698579 JJR O
periods BC2GM067698579 NNS O
of BC2GM067698579 IN O
time BC2GM067698579 NN O
, BC2GM067698579 , O
and BC2GM067698579 CC O
the BC2GM067698579 DT O
longer BC2GM067698579 JJR O
the BC2GM067698579 DT O
infusions BC2GM067698579 NNS O
were BC2GM067698579 VBD O
administered BC2GM067698579 VBN O
the BC2GM067698579 DT O
greater BC2GM067698579 JJR O
was BC2GM067698579 VBD O
the BC2GM067698579 DT O
risk BC2GM067698579 NN O
of BC2GM067698579 IN O
cholestasis BC2GM067698579 NN O
developing BC2GM067698579 NN O
. BC2GM067698579 . O
. . O O

This BC2GM002856642 DT O
mutant BC2GM002856642 NN O
also BC2GM002856642 RB O
functions BC2GM002856642 NNS O
in BC2GM002856642 IN O
vivo BC2GM002856642 NN O
as BC2GM002856642 IN O
a BC2GM002856642 DT O
trans-acting BC2GM002856642 JJ O
dominant BC2GM002856642 JJ O
negative BC2GM002856642 JJ O
regulator BC2GM002856642 NN O
: BC2GM002856642 : O
the BC2GM002856642 DT O
transcriptional BC2GM002856642 JJ O
inducibility BC2GM002856642 NN O
of BC2GM002856642 IN O
the BC2GM002856642 DT O
HIV BC2GM002856642 NNP O
long BC2GM002856642 JJ O
terminal BC2GM002856642 JJ O
repeat BC2GM002856642 NN O
( BC2GM002856642 ( O
which BC2GM002856642 WDT O
contains BC2GM002856642 VBZ O
two BC2GM002856642 CD O
potential BC2GM002856642 JJ O
NF-kappa BC2GM002856642 NNP O
B BC2GM002856642 NNP O
binding BC2GM002856642 VBG O
sites BC2GM002856642 NNS O
) BC2GM002856642 ) O
by BC2GM002856642 IN O
phorbol BC2GM002856642 NN O
ester BC2GM002856642 NN O
( BC2GM002856642 ( O
PMA BC2GM002856642 NNP O
) BC2GM002856642 ) O
is BC2GM002856642 VBZ O
inhibited BC2GM002856642 VBN O
when BC2GM002856642 WRB O
it BC2GM002856642 PRP O
is BC2GM002856642 VBZ O
co-transfected BC2GM002856642 JJ O
into BC2GM002856642 IN O
CD4+ BC2GM002856642 NNP O
T BC2GM002856642 NNP O
cells BC2GM002856642 NNS O
with BC2GM002856642 IN O
the BC2GM002856642 DT O
delta BC2GM002856642 NN O
SP BC2GM002856642 NNP O
mutant BC2GM002856642 NN O
. BC2GM002856642 . O
. . O O

Hypoxia BC2GM099382056 NNP O
decreased BC2GM099382056 VBD O
the BC2GM099382056 DT O
rate BC2GM099382056 NN O
of BC2GM099382056 IN O
spontaneous BC2GM099382056 JJ O
impulse BC2GM099382056 JJ O
initiation BC2GM099382056 NN O
in BC2GM099382056 IN O
SA BC2GM099382056 NNP O
nodal BC2GM099382056 JJ O
fibers BC2GM099382056 NNS O
by BC2GM099382056 IN O
decreasing BC2GM099382056 VBG O
the BC2GM099382056 DT O
slope BC2GM099382056 NN O
of BC2GM099382056 IN O
diastolic BC2GM099382056 JJ O
depolarization BC2GM099382056 NN O
. BC2GM099382056 . O
. . O O

Effect BC2GM038768942 NN O
of BC2GM038768942 IN O
isobarin BC2GM038768942 NN O
on BC2GM038768942 IN O
electrocardiographic BC2GM038768942 JJ O
indices BC2GM038768942 NNS O
in BC2GM038768942 IN O
hypertensive BC2GM038768942 JJ O
disease BC2GM038768942 NN O
. BC2GM038768942 . O
. . O O

Therefore BC2GM035284828 RB O
prostaglandin BC2GM035284828 JJ O
E2 BC2GM035284828 NNP O
is BC2GM035284828 VBZ O
characterized BC2GM035284828 VBN O
in BC2GM035284828 IN O
relation BC2GM035284828 NN O
to BC2GM035284828 TO O
prostaglandin BC2GM035284828 VB O
F2-alpha BC2GM035284828 NNP O
not BC2GM035284828 RB O
only BC2GM035284828 RB O
by BC2GM035284828 IN O
a BC2GM035284828 DT O
stronger BC2GM035284828 JJR O
uterine BC2GM035284828 JJ O
effectiveness BC2GM035284828 NN O
, BC2GM035284828 , O
but BC2GM035284828 CC O
also BC2GM035284828 RB O
at BC2GM035284828 IN O
the BC2GM035284828 DT O
same BC2GM035284828 JJ O
time BC2GM035284828 NN O
a BC2GM035284828 DT O
pronounced BC2GM035284828 JJ O
influence BC2GM035284828 NN O
on BC2GM035284828 IN O
the BC2GM035284828 DT O
cardiovascular BC2GM035284828 JJ O
system BC2GM035284828 NN O
. BC2GM035284828 . O
. . O O

A BC2GM047096684 DT O
plasma BC2GM047096684 JJ O
cell-rich BC2GM047096684 JJ O
infiltrate BC2GM047096684 NN O
was BC2GM047096684 VBD O
present BC2GM047096684 JJ O
in BC2GM047096684 IN O
the BC2GM047096684 DT O
connective BC2GM047096684 JJ O
tissue BC2GM047096684 NN O
cores BC2GM047096684 NNS O
of BC2GM047096684 IN O
the BC2GM047096684 DT O
papillae BC2GM047096684 NN O
. BC2GM047096684 . O
. . O O

Fos BC2GM037804373 NNP O
/ BC2GM037804373 NNP O
Jun BC2GM037804373 NNP O
bound BC2GM037804373 NN O
to BC2GM037804373 TO O
an BC2GM037804373 DT O
unacetylated BC2GM037804373 JJ O
nucleosome BC2GM037804373 NN O
with BC2GM037804373 IN O
only BC2GM037804373 RB O
a BC2GM037804373 DT O
4- BC2GM037804373 JJ O
to BC2GM037804373 TO O
5-fold BC2GM037804373 JJ O
reduction BC2GM037804373 NN O
in BC2GM037804373 IN O
DNA BC2GM037804373 NNP O
binding BC2GM037804373 VBG O
affinity BC2GM037804373 NN O
compared BC2GM037804373 VBN O
with BC2GM037804373 IN O
naked BC2GM037804373 JJ O
DNA BC2GM037804373 NN O
. BC2GM037804373 . O
. . O O

After BC2GM037081508 IN O
30 BC2GM037081508 CD O
weeks BC2GM037081508 NNS O
of BC2GM037081508 IN O
amifostine BC2GM037081508 JJ O
therapy BC2GM037081508 NN O
, BC2GM037081508 , O
the BC2GM037081508 DT O
morphology BC2GM037081508 NN O
of BC2GM037081508 IN O
the BC2GM037081508 DT O
MDS BC2GM037081508 NNP O
switched BC2GM037081508 VBD O
to BC2GM037081508 TO O
a BC2GM037081508 DT O
chronic BC2GM037081508 JJ O
myelomonocytic BC2GM037081508 JJ O
leukemia BC2GM037081508 NN O
( BC2GM037081508 ( O
CMML BC2GM037081508 NNP O
) BC2GM037081508 ) O
-like BC2GM037081508 NN O
appearance BC2GM037081508 NN O
, BC2GM037081508 , O
with BC2GM037081508 IN O
continuously BC2GM037081508 RB O
increasing BC2GM037081508 VBG O
leukocytes BC2GM037081508 NNS O
, BC2GM037081508 , O
so BC2GM037081508 IN O
that BC2GM037081508 IN O
we BC2GM037081508 PRP O
discontinued BC2GM037081508 VBD O
amifostine BC2GM037081508 JJ O
therapy BC2GM037081508 NN O
for BC2GM037081508 IN O
1 BC2GM037081508 CD O
month BC2GM037081508 NN O
to BC2GM037081508 TO O
exclude BC2GM037081508 VB O
a BC2GM037081508 DT O
possible BC2GM037081508 JJ O
side BC2GM037081508 NN O
effect BC2GM037081508 NN O
of BC2GM037081508 IN O
amifostine BC2GM037081508 NN O
. BC2GM037081508 . O
. . O O

In BC2GM048997766 IN O
order BC2GM048997766 NN O
to BC2GM048997766 TO O
investigate BC2GM048997766 VB O
the BC2GM048997766 DT O
effect BC2GM048997766 NN O
of BC2GM048997766 IN O
the BC2GM048997766 DT O
local BC2GM048997766 JJ O
direct BC2GM048997766 JJ O
action BC2GM048997766 NN O
of BC2GM048997766 IN O
danazol BC2GM048997766 NN O
upon BC2GM048997766 IN O
endometriosis BC2GM048997766 NN O
, BC2GM048997766 , O
intravaginal BC2GM048997766 JJ O
and BC2GM048997766 CC O
intrauterine BC2GM048997766 JJ O
application BC2GM048997766 NN O
were BC2GM048997766 VBD O
tried BC2GM048997766 VBN O
. BC2GM048997766 . O
. . O O

11:5801-5812 BC2GM028574302 CD O
, BC2GM028574302 , O
1991 BC2GM028574302 CD O
) BC2GM028574302 ) O
present BC2GM028574302 JJ O
evidence BC2GM028574302 NN O
that BC2GM028574302 IN O
the BC2GM028574302 DT O
Vps18 BC2GM028574302 NNP O
/ BC2GM028574302 NNP O
Pep3 BC2GM028574302 NNP O
protein BC2GM028574302 NN O
colocalizes BC2GM028574302 VBZ O
with BC2GM028574302 IN O
the BC2GM028574302 DT O
Vps11 BC2GM028574302 NNP O
/ BC2GM028574302 NNP O
Pep5 BC2GM028574302 NNP O
protein BC2GM028574302 NN O
to BC2GM028574302 TO O
the BC2GM028574302 DT O
cytosolic BC2GM028574302 JJ O
face BC2GM028574302 NN O
of BC2GM028574302 IN O
the BC2GM028574302 DT O
vacuolar BC2GM028574302 JJ O
membrane BC2GM028574302 NN O
. BC2GM028574302 . O
. . O O

Furthermore BC2GM083470342 RB O
, BC2GM083470342 , O
ERK BC2GM083470342 NNP O
phosphorylation BC2GM083470342 NN O
was BC2GM083470342 VBD O
substantially BC2GM083470342 RB O
prolonged BC2GM083470342 VBN O
in BC2GM083470342 IN O
LC BC2GM083470342 NNP O
/ BC2GM083470342 NNP O
BRY-treated BC2GM083470342 NNP O
cells BC2GM083470342 NNS O
compared BC2GM083470342 VBN O
to BC2GM083470342 TO O
those BC2GM083470342 DT O
exposed BC2GM083470342 VBN O
to BC2GM083470342 TO O
BRY BC2GM083470342 NNP O
alone BC2GM083470342 RB O
, BC2GM083470342 , O
and BC2GM083470342 CC O
pretreatment BC2GM083470342 NN O
with BC2GM083470342 IN O
the BC2GM083470342 DT O
highly BC2GM083470342 RB O
specific BC2GM083470342 JJ O
MEK BC2GM083470342 NNP O
inhibitors BC2GM083470342 NNS O
, BC2GM083470342 , O
PD98059 BC2GM083470342 NNP O
, BC2GM083470342 , O
U0126 BC2GM083470342 NNP O
, BC2GM083470342 , O
and BC2GM083470342 CC O
SL327 BC2GM083470342 NNP O
, BC2GM083470342 , O
opposed BC2GM083470342 VBD O
ERK BC2GM083470342 NNP O
activation BC2GM083470342 NN O
while BC2GM083470342 IN O
protecting BC2GM083470342 VBG O
cells BC2GM083470342 NNS O
from BC2GM083470342 IN O
LC BC2GM083470342 NNP O
/ BC2GM083470342 NNP O
BRY-induced BC2GM083470342 NNP O
lethality BC2GM083470342 NN O
. BC2GM083470342 . O
. . O O

Those BC2GM096003316 DT O
participating BC2GM096003316 VBG O
in BC2GM096003316 IN O
this BC2GM096003316 DT O
investigation BC2GM096003316 NN O
( BC2GM096003316 ( O
65 BC2GM096003316 CD O
centers BC2GM096003316 NNS O
= BC2GM096003316 VBP O
79 BC2GM096003316 CD O
% BC2GM096003316 NN O
) BC2GM096003316 ) O
received BC2GM096003316 VBD O
a BC2GM096003316 DT O
series BC2GM096003316 NN O
of BC2GM096003316 IN O
computer BC2GM096003316 NN O
disks BC2GM096003316 NNS O
containing BC2GM096003316 VBG O
50 BC2GM096003316 CD O
99mTc-DMSA BC2GM096003316 JJ O
studies BC2GM096003316 NNS O
. BC2GM096003316 . O
. . O O

Serum BC2GM087479423 NNP O
pituitary BC2GM087479423 JJ O
and BC2GM087479423 CC O
steroid BC2GM087479423 JJ O
hormone BC2GM087479423 NN O
levels BC2GM087479423 NNS O
in BC2GM087479423 IN O
the BC2GM087479423 DT O
adult BC2GM087479423 NN O
male BC2GM087479423 NN O
: BC2GM087479423 : O
one BC2GM087479423 CD O
value BC2GM087479423 NN O
is BC2GM087479423 VBZ O
as BC2GM087479423 RB O
good BC2GM087479423 JJ O
as BC2GM087479423 IN O
the BC2GM087479423 DT O
mean BC2GM087479423 NN O
of BC2GM087479423 IN O
three BC2GM087479423 CD O
. BC2GM087479423 . O
. . O O

We BC2GM050190565 PRP O
investigated BC2GM050190565 VBD O
the BC2GM050190565 DT O
pattern BC2GM050190565 NN O
of BC2GM050190565 IN O
evolution BC2GM050190565 NN O
of BC2GM050190565 IN O
bronchial BC2GM050190565 JJ O
albumin BC2GM050190565 NN O
, BC2GM050190565 , O
IgA BC2GM050190565 NNP O
, BC2GM050190565 , O
and BC2GM050190565 CC O
IgG BC2GM050190565 NNP O
levels BC2GM050190565 NNS O
in BC2GM050190565 IN O
ventilated BC2GM050190565 JJ O
ICU BC2GM050190565 NNP O
patients BC2GM050190565 NNS O
in BC2GM050190565 IN O
relation BC2GM050190565 NN O
to BC2GM050190565 TO O
nosocomial BC2GM050190565 JJ O
pneumonia BC2GM050190565 NN O
. BC2GM050190565 . O
. . O O

The BC2GM068735966 DT O
human BC2GM068735966 JJ O
lbc BC2GM068735966 NN O
oncogene BC2GM068735966 NN O
product BC2GM068735966 NN O
is BC2GM068735966 VBZ O
a BC2GM068735966 DT O
guanine BC2GM068735966 JJ O
nucleotide BC2GM068735966 JJ O
exchange BC2GM068735966 NN O
factor BC2GM068735966 NN O
that BC2GM068735966 WDT O
specifically BC2GM068735966 RB O
activates BC2GM068735966 VBZ O
the BC2GM068735966 DT O
Rho BC2GM068735966 NNP O
small BC2GM068735966 JJ O
GTP BC2GM068735966 NNP O
binding BC2GM068735966 NN O
protein BC2GM068735966 NN O
, BC2GM068735966 , O
thus BC2GM068735966 RB O
resulting BC2GM068735966 VBG O
in BC2GM068735966 IN O
biologically BC2GM068735966 RB O
active BC2GM068735966 JJ O
, BC2GM068735966 , O
GTP-bound BC2GM068735966 NNP O
Rho BC2GM068735966 NNP O
, BC2GM068735966 , O
which BC2GM068735966 WDT O
in BC2GM068735966 IN O
turn BC2GM068735966 NN O
mediates BC2GM068735966 NNS O
actin BC2GM068735966 VBP O
cytoskeletal BC2GM068735966 JJ O
reorganization BC2GM068735966 NN O
, BC2GM068735966 , O
gene BC2GM068735966 NN O
transcription BC2GM068735966 NN O
, BC2GM068735966 , O
and BC2GM068735966 CC O
entry BC2GM068735966 NN O
into BC2GM068735966 IN O
the BC2GM068735966 DT O
mitotic BC2GM068735966 JJ O
S BC2GM068735966 NNP O
phase BC2GM068735966 NN O
. BC2GM068735966 . O
. . O O

Only BC2GM073857956 RB O
viable BC2GM073857956 JJ O
bacteria BC2GM073857956 NNS O
at BC2GM073857956 IN O
a BC2GM073857956 DT O
high BC2GM073857956 JJ O
concentration BC2GM073857956 NN O
induced BC2GM073857956 VBD O
purulent BC2GM073857956 JJ O
otitis BC2GM073857956 NN O
media BC2GM073857956 NNS O
, BC2GM073857956 , O
which BC2GM073857956 WDT O
was BC2GM073857956 VBD O
culture BC2GM073857956 NN O
positive BC2GM073857956 JJ O
in BC2GM073857956 IN O
58 BC2GM073857956 CD O
% BC2GM073857956 NN O
of BC2GM073857956 IN O
the BC2GM073857956 DT O
cases BC2GM073857956 NNS O
on BC2GM073857956 IN O
day BC2GM073857956 NN O
4 BC2GM073857956 CD O
. BC2GM073857956 . O
. . O O

Improvement BC2GM044052355 NN O
of BC2GM044052355 IN O
some BC2GM044052355 DT O
pharmaceutical BC2GM044052355 JJ O
properties BC2GM044052355 NNS O
of BC2GM044052355 IN O
clofibrate BC2GM044052355 NN O
by BC2GM044052355 IN O
cyclodextrin BC2GM044052355 JJ O
complexation BC2GM044052355 NN O
. BC2GM044052355 . O
. . O O

268 BC2GM006409741 CD O
, BC2GM006409741 , O
6858-6861 BC2GM006409741 JJ O
) BC2GM006409741 ) O
. BC2GM006409741 . O
. . O O

Sequence BC2GM094631984 NNP O
analysis BC2GM094631984 NN O
of BC2GM094631984 IN O
AEBP2 BC2GM094631984 NNP O
cDNA BC2GM094631984 NN O
revealed BC2GM094631984 VBD O
that BC2GM094631984 IN O
it BC2GM094631984 PRP O
encodes BC2GM094631984 VBZ O
a BC2GM094631984 DT O
protein BC2GM094631984 NN O
containing BC2GM094631984 VBG O
three BC2GM094631984 CD O
Gli-Kruppel BC2GM094631984 NNP O
( BC2GM094631984 ( O
Cys2-His2 BC2GM094631984 NNP O
) BC2GM094631984 ) O
-type BC2GM094631984 VBZ O
zinc BC2GM094631984 JJ O
fingers BC2GM094631984 NNS O
. BC2GM094631984 . O
. . O O

Cutting BC2GM074443347 VBG O
the BC2GM074443347 DT O
intraorbital BC2GM074443347 JJ O
nerves BC2GM074443347 NNS O
produced BC2GM074443347 VBD O
a BC2GM074443347 DT O
temporary BC2GM074443347 JJ O
retrieval BC2GM074443347 NN O
impairment BC2GM074443347 NN O
that BC2GM074443347 WDT O
was BC2GM074443347 VBD O
indistinguishable BC2GM074443347 JJ O
from BC2GM074443347 IN O
that BC2GM074443347 DT O
produced BC2GM074443347 VBN O
by BC2GM074443347 IN O
intramystacial BC2GM074443347 JJ O
lidocaine BC2GM074443347 NN O
injection BC2GM074443347 NN O
. BC2GM074443347 . O
. . O O

Characterization BC2GM028014715 NN O
of BC2GM028014715 IN O
the BC2GM028014715 DT O
chromosome BC2GM028014715 NN O
19 BC2GM028014715 CD O
breakpoint BC2GM028014715 NN O
region BC2GM028014715 NN O
revealed BC2GM028014715 VBD O
that BC2GM028014715 IN O
the BC2GM028014715 DT O
transcription BC2GM028014715 NN O
factor-encoding BC2GM028014715 JJ O
USF2 BC2GM028014715 NNP O
gene BC2GM028014715 NN O
is BC2GM028014715 VBZ O
affected BC2GM028014715 VBN O
. BC2GM028014715 . O
. . O O

Interestingly BC2GM000227172 RB O
, BC2GM000227172 , O
basal BC2GM000227172 NN O
MAPK BC2GM000227172 NNP O
, BC2GM000227172 , O
but BC2GM000227172 CC O
not BC2GM000227172 RB O
Raf-1 BC2GM000227172 NNP O
, BC2GM000227172 , O
activity BC2GM000227172 NN O
was BC2GM000227172 VBD O
constitutively BC2GM000227172 RB O
enhanced BC2GM000227172 VBN O
in BC2GM000227172 IN O
Jak1-deficient BC2GM000227172 NNP O
HeLa BC2GM000227172 NNP O
cells BC2GM000227172 NNS O
. BC2GM000227172 . O
. . O O

To BC2GM002134546 TO O
clone BC2GM002134546 VB O
cDNAs BC2GM002134546 NN O
for BC2GM002134546 IN O
the BC2GM002134546 DT O
beta BC2GM002134546 NN O
subunit BC2GM002134546 NN O
of BC2GM002134546 IN O
rabbit BC2GM002134546 NN O
eIF-2B BC2GM002134546 JJ O
, BC2GM002134546 , O
amino BC2GM002134546 JJ O
acid BC2GM002134546 NN O
sequence BC2GM002134546 NN O
data BC2GM002134546 NNS O
was BC2GM002134546 VBD O
first BC2GM002134546 JJ O
obtained BC2GM002134546 VBN O
and BC2GM002134546 CC O
used BC2GM002134546 VBN O
to BC2GM002134546 TO O
design BC2GM002134546 VB O
redundant BC2GM002134546 JJ O
oligonucleotide BC2GM002134546 NN O
primers BC2GM002134546 NNS O
for BC2GM002134546 IN O
use BC2GM002134546 NN O
in BC2GM002134546 IN O
PCR BC2GM002134546 NNP O
. BC2GM002134546 . O
. . O O

Phosphorylation BC2GM081507457 NN O
of BC2GM081507457 IN O
the BC2GM081507457 DT O
ras BC2GM081507457 JJ O
GTPase-activating BC2GM081507457 NNP O
protein BC2GM081507457 NN O
( BC2GM081507457 ( O
GAP BC2GM081507457 NNP O
) BC2GM081507457 ) O
by BC2GM081507457 IN O
the BC2GM081507457 DT O
p93c-fes BC2GM081507457 JJ O
protein-tyrosine BC2GM081507457 JJ O
kinase BC2GM081507457 NN O
in BC2GM081507457 IN O
vitro BC2GM081507457 NN O
and BC2GM081507457 CC O
formation BC2GM081507457 NN O
of BC2GM081507457 IN O
GAP-fes BC2GM081507457 NNP O
complexes BC2GM081507457 NNS O
via BC2GM081507457 IN O
an BC2GM081507457 DT O
SH2 BC2GM081507457 NNP O
domain-dependent BC2GM081507457 NN O
mechanism BC2GM081507457 NN O
. BC2GM081507457 . O
. . O O

Whereas BC2GM043187885 IN O
Sprague-Dawleys BC2GM043187885 NNP O
displayed BC2GM043187885 VBD O
lights-off BC2GM043187885 NN O
and BC2GM043187885 CC O
lights-on BC2GM043187885 JJ O
peaks BC2GM043187885 NNS O
of BC2GM043187885 IN O
ingestive BC2GM043187885 JJ O
activity BC2GM043187885 NN O
, BC2GM043187885 , O
only BC2GM043187885 RB O
a BC2GM043187885 DT O
minority BC2GM043187885 NN O
of BC2GM043187885 IN O
Fisher-344s BC2GM043187885 NNP O
displayed BC2GM043187885 VBD O
a BC2GM043187885 DT O
consistent BC2GM043187885 JJ O
lights-on BC2GM043187885 JJ O
peak BC2GM043187885 NN O
of BC2GM043187885 IN O
ingestive BC2GM043187885 JJ O
activity BC2GM043187885 NN O
. BC2GM043187885 . O
. . O O

The BC2GM022946300 DT O
fusion BC2GM022946300 NN O
gene BC2GM022946300 NN O
cassette BC2GM022946300 NN O
was BC2GM022946300 VBD O
placed BC2GM022946300 VBN O
under BC2GM022946300 IN O
the BC2GM022946300 DT O
control BC2GM022946300 NN O
of BC2GM022946300 IN O
a BC2GM022946300 DT O
vaccinia BC2GM022946300 NN O
virus BC2GM022946300 NN O
early BC2GM022946300 JJ O
promoter BC2GM022946300 NN O
and BC2GM022946300 CC O
cloned BC2GM022946300 VBN O
in BC2GM022946300 IN O
a BC2GM022946300 DT O
host-restricted BC2GM022946300 JJ O
fowlpox BC2GM022946300 JJ O
viral BC2GM022946300 JJ O
vector BC2GM022946300 NN O
. BC2GM022946300 . O
. . O O

Triaxiality BC2GM019604417 NN O
in BC2GM019604417 IN O
the BC2GM019604417 DT O
proton-neutron BC2GM019604417 NN O
interacting BC2GM019604417 VBG O
boson BC2GM019604417 JJ O
model BC2GM019604417 NN O
: BC2GM019604417 : O
Perturbed BC2GM019604417 VBN O
O BC2GM019604417 NNP O
( BC2GM019604417 ( O
6 BC2GM019604417 CD O
) BC2GM019604417 ) O
symmetry BC2GM019604417 NN O
with BC2GM019604417 IN O
application BC2GM019604417 NN O
to BC2GM019604417 TO O
the BC2GM019604417 DT O
mass BC2GM019604417 NN O
A BC2GM019604417 NNP O
. BC2GM019604417 . O
. . O O

During BC2GM081059742 IN O
subsequent BC2GM081059742 JJ O
CS-alone BC2GM081059742 JJ O
trials BC2GM081059742 NNS O
, BC2GM081059742 , O
the BC2GM081059742 DT O
responses BC2GM081059742 NNS O
of BC2GM081059742 IN O
( BC2GM081059742 ( O
+ BC2GM081059742 JJ O
) BC2GM081059742 ) O
MK-801-injected BC2GM081059742 JJ O
mice BC2GM081059742 NN O
were BC2GM081059742 VBD O
extinguished BC2GM081059742 VBN O
as BC2GM081059742 RB O
easily BC2GM081059742 RB O
as BC2GM081059742 IN O
those BC2GM081059742 DT O
of BC2GM081059742 IN O
saline-injected BC2GM081059742 JJ O
mice BC2GM081059742 NN O
. BC2GM081059742 . O
. . O O

Mutational BC2GM031957537 JJ O
analysis BC2GM031957537 NN O
of BC2GM031957537 IN O
the BC2GM031957537 DT O
IME2 BC2GM031957537 NNP O
UAS BC2GM031957537 NNP O
reveals BC2GM031957537 VBZ O
two BC2GM031957537 CD O
critical BC2GM031957537 JJ O
sequence BC2GM031957537 NN O
elements BC2GM031957537 NNS O
: BC2GM031957537 : O
a BC2GM031957537 DT O
G+C-rich BC2GM031957537 JJ O
sequence BC2GM031957537 NN O
( BC2GM031957537 ( O
called BC2GM031957537 VBN O
URS1 BC2GM031957537 NNP O
) BC2GM031957537 ) O
, BC2GM031957537 , O
previously BC2GM031957537 RB O
identified BC2GM031957537 VBN O
at BC2GM031957537 IN O
many BC2GM031957537 JJ O
meiotic BC2GM031957537 JJ O
genes BC2GM031957537 NNS O
, BC2GM031957537 , O
and BC2GM031957537 CC O
a BC2GM031957537 DT O
newly BC2GM031957537 RB O
described BC2GM031957537 VBN O
element BC2GM031957537 NN O
, BC2GM031957537 , O
the BC2GM031957537 DT O
T4C BC2GM031957537 NNP O
site BC2GM031957537 NN O
, BC2GM031957537 , O
that BC2GM031957537 IN O
we BC2GM031957537 PRP O
found BC2GM031957537 VBD O
at BC2GM031957537 IN O
a BC2GM031957537 DT O
subset BC2GM031957537 NN O
of BC2GM031957537 IN O
meiotic BC2GM031957537 JJ O
genes BC2GM031957537 NNS O
. BC2GM031957537 . O
. . O O

Treatment BC2GM025047286 NN O
with BC2GM025047286 IN O
ACE BC2GM025047286 NNP O
inhibitors BC2GM025047286 NNS O
after BC2GM025047286 IN O
acute BC2GM025047286 JJ O
myocardial BC2GM025047286 JJ O
infarction BC2GM025047286 NN O
. BC2GM025047286 . O
. . O O

Rat BC2GM080956637 NNP O
p8 BC2GM080956637 NN O
mRNA BC2GM080956637 NN O
was BC2GM080956637 VBD O
discovered BC2GM080956637 VBN O
because BC2GM080956637 IN O
of BC2GM080956637 IN O
its BC2GM080956637 PRP$ O
strong BC2GM080956637 JJ O
activation BC2GM080956637 NN O
in BC2GM080956637 IN O
pancreas BC2GM080956637 NNS O
during BC2GM080956637 IN O
the BC2GM080956637 DT O
acute BC2GM080956637 JJ O
phase BC2GM080956637 NN O
of BC2GM080956637 IN O
pancreatitis BC2GM080956637 NN O
. BC2GM080956637 . O
. . O O

Multivariable BC2GM062932226 JJ O
logistic BC2GM062932226 JJ O
regression BC2GM062932226 NN O
showed BC2GM062932226 VBD O
that BC2GM062932226 IN O
mean BC2GM062932226 JJ O
blood BC2GM062932226 NN O
glucose BC2GM062932226 JJ O
level BC2GM062932226 NN O
for BC2GM062932226 IN O
the BC2GM062932226 DT O
first BC2GM062932226 JJ O
2 BC2GM062932226 CD O
days BC2GM062932226 NNS O
( BC2GM062932226 ( O
p BC2GM062932226 JJ O
= BC2GM062932226 NNP O
0.002 BC2GM062932226 CD O
) BC2GM062932226 ) O
, BC2GM062932226 , O
obesity BC2GM062932226 NN O
( BC2GM062932226 ( O
p BC2GM062932226 JJ O
< BC2GM062932226 NNP O
0.002 BC2GM062932226 CD O
) BC2GM062932226 ) O
, BC2GM062932226 , O
and BC2GM062932226 CC O
use BC2GM062932226 NN O
of BC2GM062932226 IN O
the BC2GM062932226 DT O
internal BC2GM062932226 JJ O
mammary BC2GM062932226 JJ O
artery BC2GM062932226 NN O
( BC2GM062932226 ( O
p BC2GM062932226 JJ O
< BC2GM062932226 NNP O
0.02 BC2GM062932226 CD O
) BC2GM062932226 ) O
were BC2GM062932226 VBD O
all BC2GM062932226 DT O
independent BC2GM062932226 JJ O
predictors BC2GM062932226 NNS O
of BC2GM062932226 IN O
deep BC2GM062932226 JJ O
wound BC2GM062932226 NN O
infection BC2GM062932226 NN O
. BC2GM062932226 . O
. . O O

OBJECTIVE BC2GM083712853 NN O
: BC2GM083712853 : O
To BC2GM083712853 TO O
report BC2GM083712853 VB O
a BC2GM083712853 DT O
case BC2GM083712853 NN O
of BC2GM083712853 IN O
fulminant BC2GM083712853 JJ O
neuropathy BC2GM083712853 JJ O
with BC2GM083712853 IN O
severe BC2GM083712853 JJ O
quadriparesis BC2GM083712853 NN O
associated BC2GM083712853 VBN O
with BC2GM083712853 IN O
vincristine BC2GM083712853 JJ O
chemotherapy BC2GM083712853 NN O
. BC2GM083712853 . O
. . O O

Finally BC2GM016129428 RB O
, BC2GM016129428 , O
gel BC2GM016129428 JJ O
shift BC2GM016129428 NN O
assays BC2GM016129428 NNS O
showed BC2GM016129428 VBD O
that BC2GM016129428 IN O
ORF2 BC2GM016129428 NNP O
was BC2GM016129428 VBD O
able BC2GM016129428 JJ O
to BC2GM016129428 TO O
bind BC2GM016129428 VB O
to BC2GM016129428 TO O
promoter BC2GM016129428 VB O
fragment BC2GM016129428 JJ O
566-888 BC2GM016129428 JJ O
. BC2GM016129428 . O
. . O O

CONCLUSIONS BC2GM099821771 NN O
: BC2GM099821771 : O
This BC2GM099821771 DT O
initial BC2GM099821771 JJ O
experience BC2GM099821771 NN O
indicates BC2GM099821771 VBZ O
that BC2GM099821771 IN O
there BC2GM099821771 EX O
is BC2GM099821771 VBZ O
short- BC2GM099821771 JJ O
to BC2GM099821771 TO O
middle-term BC2GM099821771 JJ O
efficiency BC2GM099821771 NN O
and BC2GM099821771 CC O
safety BC2GM099821771 NN O
when BC2GM099821771 WRB O
using BC2GM099821771 VBG O
GKS BC2GM099821771 NNP O
to BC2GM099821771 TO O
treat BC2GM099821771 VB O
MTLE BC2GM099821771 NNP O
. BC2GM099821771 . O
. . O O

Flicker BC2GM056889976 NNP O
thresholds BC2GM056889976 NNS O
were BC2GM056889976 VBD O
measured BC2GM056889976 VBN O
from BC2GM056889976 IN O
1 BC2GM056889976 CD O
to BC2GM056889976 TO O
40 BC2GM056889976 CD O
Hz BC2GM056889976 NNP O
with BC2GM056889976 IN O
a BC2GM056889976 DT O
vertical-line BC2GM056889976 JJ O
target BC2GM056889976 NN O
used BC2GM056889976 VBN O
for BC2GM056889976 IN O
the BC2GM056889976 DT O
asynchrony BC2GM056889976 NN O
thresholds BC2GM056889976 NNS O
. BC2GM056889976 . O
. . O O

Cardiovascular BC2GM082079771 JJ O
effects BC2GM082079771 NNS O
in BC2GM082079771 IN O
man BC2GM082079771 NN O
of BC2GM082079771 IN O
intravenous BC2GM082079771 JJ O
prizidilol BC2GM082079771 NNS O
hydrochloride BC2GM082079771 NN O
( BC2GM082079771 ( O
SK BC2GM082079771 NNP O
& BC2GM082079771 CC O
F BC2GM082079771 NNP O
92657 BC2GM082079771 CD O
) BC2GM082079771 ) O
; BC2GM082079771 : O
a BC2GM082079771 DT O
new BC2GM082079771 JJ O
antihypertensive BC2GM082079771 JJ O
agent BC2GM082079771 NN O
. BC2GM082079771 . O
. . O O

Localized BC2GM050646541 VBN O
Bicaudal-C BC2GM050646541 NNP O
RNA BC2GM050646541 NNP O
encodes BC2GM050646541 VBZ O
a BC2GM050646541 DT O
protein BC2GM050646541 NN O
containing BC2GM050646541 VBG O
a BC2GM050646541 DT O
KH BC2GM050646541 NNP O
domain BC2GM050646541 NN O
, BC2GM050646541 , O
the BC2GM050646541 DT O
RNA BC2GM050646541 NNP O
binding BC2GM050646541 VBG O
motif BC2GM050646541 NN O
of BC2GM050646541 IN O
FMR1 BC2GM050646541 NNP O
. BC2GM050646541 . O
. . O O

In BC2GM029330776 IN O
uraemic BC2GM029330776 JJ O
patients BC2GM029330776 NNS O
, BC2GM029330776 , O
similar BC2GM029330776 JJ O
maximum BC2GM029330776 NN O
serum BC2GM029330776 NN O
concentrations BC2GM029330776 NNS O
were BC2GM029330776 VBD O
found BC2GM029330776 VBN O
after BC2GM029330776 IN O
a BC2GM029330776 DT O
single BC2GM029330776 JJ O
7.5 BC2GM029330776 CD O
mg BC2GM029330776 NN O
/ BC2GM029330776 NNP O
kg BC2GM029330776 NNP O
iv BC2GM029330776 NN O
dose BC2GM029330776 NN O
. BC2GM029330776 . O
. . O O

This BC2GM056227993 DT O
study BC2GM056227993 NN O
demonstrates BC2GM056227993 VBZ O
that BC2GM056227993 IN O
the BC2GM056227993 DT O
exposure BC2GM056227993 NN O
to BC2GM056227993 TO O
sulphur BC2GM056227993 VB O
mustard BC2GM056227993 JJ O
results BC2GM056227993 NNS O
in BC2GM056227993 IN O
very BC2GM056227993 RB O
low BC2GM056227993 JJ O
androgen BC2GM056227993 NN O
levels BC2GM056227993 NNS O
and BC2GM056227993 CC O
hypo-responsiveness BC2GM056227993 NN O
to BC2GM056227993 TO O
GnRH BC2GM056227993 NNP O
in BC2GM056227993 IN O
the BC2GM056227993 DT O
first BC2GM056227993 JJ O
five BC2GM056227993 CD O
weeks BC2GM056227993 NNS O
and BC2GM056227993 CC O
normalization BC2GM056227993 NN O
by BC2GM056227993 IN O
the BC2GM056227993 DT O
twelfth BC2GM056227993 NN O
week BC2GM056227993 NN O
after BC2GM056227993 IN O
injury BC2GM056227993 NN O
. BC2GM056227993 . O
. . O O

In BC2GM008474326 IN O
addition BC2GM008474326 NN O
, BC2GM008474326 , O
two BC2GM008474326 CD O
cis-acting BC2GM008474326 JJ O
elements BC2GM008474326 NNS O
direct BC2GM008474326 VBP O
the BC2GM008474326 DT O
first BC2GM008474326 JJ O
zygotic BC2GM008474326 JJ O
expression BC2GM008474326 NN O
of BC2GM008474326 IN O
Kr BC2GM008474326 NNP O
in BC2GM008474326 IN O
a BC2GM008474326 DT O
striped BC2GM008474326 JJ O
subpattern BC2GM008474326 NN O
within BC2GM008474326 IN O
the BC2GM008474326 DT O
central BC2GM008474326 JJ O
region BC2GM008474326 NN O
of BC2GM008474326 IN O
the BC2GM008474326 DT O
blastoderm BC2GM008474326 JJ O
embryo BC2GM008474326 NN O
. BC2GM008474326 . O
. . O O

This BC2GM014519920 DT O
indicates BC2GM014519920 VBZ O
changes BC2GM014519920 NNS O
in BC2GM014519920 IN O
postvaccination BC2GM014519920 NN O
allergy BC2GM014519920 NN O
to BC2GM014519920 TO O
BCG BC2GM014519920 NNP O
. BC2GM014519920 . O
. . O O

Alignment BC2GM023639868 NN O
of BC2GM023639868 IN O
the BC2GM023639868 DT O
rat BC2GM023639868 NN O
and BC2GM023639868 CC O
human BC2GM023639868 JJ O
WIN BC2GM023639868 NNP O
cDNAs BC2GM023639868 NN O
and BC2GM023639868 CC O
their BC2GM023639868 PRP$ O
comparison BC2GM023639868 NN O
with BC2GM023639868 IN O
mouse BC2GM023639868 NN O
genomic BC2GM023639868 JJ O
sequence BC2GM023639868 NN O
revealed BC2GM023639868 VBD O
that BC2GM023639868 IN O
the BC2GM023639868 DT O
WIN BC2GM023639868 NNP O
DNA BC2GM023639868 NNP O
binding BC2GM023639868 VBG O
domain BC2GM023639868 NN O
is BC2GM023639868 VBZ O
encoded BC2GM023639868 VBN O
by BC2GM023639868 IN O
four BC2GM023639868 CD O
exons BC2GM023639868 NNS O
, BC2GM023639868 , O
two BC2GM023639868 CD O
of BC2GM023639868 IN O
which BC2GM023639868 WDT O
( BC2GM023639868 ( O
exons BC2GM023639868 NNS O
4 BC2GM023639868 CD O
and BC2GM023639868 CC O
6 BC2GM023639868 CD O
) BC2GM023639868 ) O
are BC2GM023639868 VBP O
alternatively BC2GM023639868 RB O
spliced BC2GM023639868 VBN O
to BC2GM023639868 TO O
generate BC2GM023639868 VB O
at BC2GM023639868 IN O
least BC2GM023639868 JJS O
three BC2GM023639868 CD O
classes BC2GM023639868 NNS O
of BC2GM023639868 IN O
mRNA BC2GM023639868 NN O
transcripts BC2GM023639868 NNS O
. BC2GM023639868 . O
. . O O

Any BC2GM068345268 DT O
opacity BC2GM068345268 NN O
on BC2GM068345268 IN O
a BC2GM068345268 DT O
chest BC2GM068345268 NN O
radiograph BC2GM068345268 NN O
has BC2GM068345268 VBZ O
a BC2GM068345268 DT O
wide BC2GM068345268 JJ O
differential BC2GM068345268 JJ O
diagnosis BC2GM068345268 NN O
. BC2GM068345268 . O
. . O O

The BC2GM025094237 DT O
melanoma BC2GM025094237 NN O
growth BC2GM025094237 NN O
stimulatory BC2GM025094237 NN O
activity BC2GM025094237 NN O
/ BC2GM025094237 NNP O
growth-regulated BC2GM025094237 JJ O
protein BC2GM025094237 NN O
, BC2GM025094237 , O
CXCL1 BC2GM025094237 NNP O
, BC2GM025094237 , O
is BC2GM025094237 VBZ O
constitutively BC2GM025094237 RB O
expressed BC2GM025094237 VBN O
at BC2GM025094237 IN O
high BC2GM025094237 JJ O
levels BC2GM025094237 NNS O
during BC2GM025094237 IN O
inflammation BC2GM025094237 NN O
and BC2GM025094237 CC O
progression BC2GM025094237 NN O
of BC2GM025094237 IN O
melanocytes BC2GM025094237 NNS O
into BC2GM025094237 IN O
malignant BC2GM025094237 JJ O
melanoma BC2GM025094237 NN O
. BC2GM025094237 . O
. . O O

Treatment BC2GM041269018 NN O
of BC2GM041269018 IN O
steroid BC2GM041269018 NN O
resistant BC2GM041269018 JJ O
rejection BC2GM041269018 NN O
following BC2GM041269018 VBG O
renal BC2GM041269018 JJ O
transplantation BC2GM041269018 NN O
: BC2GM041269018 : O
benefits BC2GM041269018 NNS O
and BC2GM041269018 CC O
risks BC2GM041269018 NNS O
of BC2GM041269018 IN O
OKT3 BC2GM041269018 NNP O
therapy BC2GM041269018 NN O
. BC2GM041269018 . O
. . O O

The BC2GM018490469 DT O
plasma BC2GM018490469 NN O
steroid BC2GM018490469 NN O
levels BC2GM018490469 NNS O
in BC2GM018490469 IN O
the BC2GM018490469 DT O
CAPD BC2GM018490469 NNP O
patients BC2GM018490469 NNS O
after BC2GM018490469 IN O
each BC2GM018490469 DT O
infusion BC2GM018490469 NN O
rate BC2GM018490469 NN O
were BC2GM018490469 VBD O
equal BC2GM018490469 JJ O
to BC2GM018490469 TO O
or BC2GM018490469 CC O
greater BC2GM018490469 JJR O
than BC2GM018490469 IN O
the BC2GM018490469 DT O
levels BC2GM018490469 NNS O
in BC2GM018490469 IN O
normal BC2GM018490469 JJ O
subjects BC2GM018490469 NNS O
. BC2GM018490469 . O
. . O O

The BC2GM047579187 DT O
feasibility BC2GM047579187 NN O
of BC2GM047579187 IN O
creating BC2GM047579187 VBG O
CR1 BC2GM047579187 NNP O
/ BC2GM047579187 NNP O
Ig BC2GM047579187 NNP O
chimeras BC2GM047579187 NN O
makes BC2GM047579187 VBZ O
possible BC2GM047579187 JJ O
a BC2GM047579187 DT O
new BC2GM047579187 JJ O
strategy BC2GM047579187 NN O
of BC2GM047579187 IN O
targeting BC2GM047579187 VBG O
complement BC2GM047579187 JJ O
inhibition BC2GM047579187 NN O
by BC2GM047579187 IN O
the BC2GM047579187 DT O
use BC2GM047579187 NN O
of BC2GM047579187 IN O
Ig BC2GM047579187 NNP O
fusion BC2GM047579187 NN O
partners BC2GM047579187 NNS O
having BC2GM047579187 VBG O
particular BC2GM047579187 JJ O
antigenic BC2GM047579187 JJ O
specificities BC2GM047579187 NNS O
. BC2GM047579187 . O
. . O O

Treatment BC2GM048018983 NN O
of BC2GM048018983 IN O
cells BC2GM048018983 NNS O
for BC2GM048018983 IN O
10 BC2GM048018983 CD O
min BC2GM048018983 NNS O
with BC2GM048018983 IN O
TNF-alpha BC2GM048018983 NNP O
resulted BC2GM048018983 VBD O
in BC2GM048018983 IN O
activation BC2GM048018983 NN O
of BC2GM048018983 IN O
p44 BC2GM048018983 NN O
/ BC2GM048018983 $ O
42 BC2GM048018983 CD O
MAPK BC2GM048018983 NNP O
, BC2GM048018983 , O
p38 BC2GM048018983 NN O
, BC2GM048018983 , O
and BC2GM048018983 CC O
JNK BC2GM048018983 NNP O
. BC2GM048018983 . O
. . O O

Both BC2GM048243610 DT O
claR BC2GM048243610 NN O
and BC2GM048243610 CC O
car BC2GM048243610 NN O
are BC2GM048243610 VBP O
expressed BC2GM048243610 VBN O
as BC2GM048243610 IN O
monocistronic BC2GM048243610 JJ O
transcripts BC2GM048243610 NNS O
; BC2GM048243610 : O
the BC2GM048243610 DT O
level BC2GM048243610 NN O
of BC2GM048243610 IN O
transcript BC2GM048243610 NN O
declined BC2GM048243610 VBD O
rapidly BC2GM048243610 RB O
after BC2GM048243610 IN O
48h BC2GM048243610 CD O
in BC2GM048243610 IN O
complex BC2GM048243610 JJ O
media BC2GM048243610 NNS O
, BC2GM048243610 , O
but BC2GM048243610 CC O
low BC2GM048243610 JJ O
sustained BC2GM048243610 JJ O
levels BC2GM048243610 NNS O
of BC2GM048243610 IN O
both BC2GM048243610 DT O
transcripts BC2GM048243610 NNS O
were BC2GM048243610 VBD O
observed BC2GM048243610 VBN O
in BC2GM048243610 IN O
defined BC2GM048243610 JJ O
GSPG BC2GM048243610 NNP O
medium BC2GM048243610 NN O
until BC2GM048243610 IN O
96h BC2GM048243610 CD O
. BC2GM048243610 . O
claR BC2GM048243610 NN O
and BC2GM048243610 CC O
car BC2GM048243610 NN O
were BC2GM048243610 VBD O
not BC2GM048243610 RB O
significantly BC2GM048243610 RB O
expressed BC2GM048243610 VBN O
in BC2GM048243610 IN O
mutants BC2GM048243610 NNS O
disrupted BC2GM048243610 VBN O
in BC2GM048243610 IN O
the BC2GM048243610 DT O
ccaR BC2GM048243610 NN O
gene BC2GM048243610 NN O
, BC2GM048243610 , O
a BC2GM048243610 DT O
regulatory BC2GM048243610 JJ O
gene BC2GM048243610 NN O
that BC2GM048243610 WDT O
controls BC2GM048243610 VBZ O
positively BC2GM048243610 RB O
clavulanic BC2GM048243610 JJ O
acid BC2GM048243610 NN O
and BC2GM048243610 CC O
cephamycin BC2GM048243610 JJ O
biosynthesis BC2GM048243610 NN O
. BC2GM048243610 . O
. . O O

Measures BC2GM095821650 NNS O
of BC2GM095821650 IN O
sedation BC2GM095821650 NN O
, BC2GM095821650 , O
BIS BC2GM095821650 NNP O
, BC2GM095821650 , O
deltaBIS BC2GM095821650 NN O
( BC2GM095821650 ( O
absolute BC2GM095821650 JJ O
change BC2GM095821650 NN O
of BC2GM095821650 IN O
BIS BC2GM095821650 NNP O
after BC2GM095821650 IN O
a BC2GM095821650 DT O
painful BC2GM095821650 JJ O
stimulus BC2GM095821650 NN O
) BC2GM095821650 ) O
, BC2GM095821650 , O
memory BC2GM095821650 NN O
, BC2GM095821650 , O
and BC2GM095821650 CC O
drug BC2GM095821650 NN O
concentration BC2GM095821650 NN O
were BC2GM095821650 VBD O
obtained BC2GM095821650 VBN O
at BC2GM095821650 IN O
each BC2GM095821650 DT O
target BC2GM095821650 NN O
drug BC2GM095821650 NN O
concentration BC2GM095821650 NN O
. BC2GM095821650 . O
. . O O

U.S.A BC2GM077073177 NNP O
. BC2GM077073177 . O
. . O O

The BC2GM022444174 DT O
content BC2GM022444174 NN O
of BC2GM022444174 IN O
monoamine BC2GM022444174 NN O
metabolites BC2GM022444174 NNS O
, BC2GM022444174 , O
5-hydroxyindoleacetic BC2GM022444174 JJ O
acid BC2GM022444174 NN O
, BC2GM022444174 , O
5-HIAA BC2GM022444174 JJ O
, BC2GM022444174 , O
and BC2GM022444174 CC O
homovanillic BC2GM022444174 JJ O
acid BC2GM022444174 NN O
( BC2GM022444174 ( O
HVA BC2GM022444174 NNP O
) BC2GM022444174 ) O
, BC2GM022444174 , O
and BC2GM022444174 CC O
-- BC2GM022444174 : O
for BC2GM022444174 IN O
17 BC2GM022444174 CD O
patients BC2GM022444174 NNS O
-- BC2GM022444174 : O
tryptophan BC2GM022444174 NN O
, BC2GM022444174 , O
in BC2GM022444174 IN O
the BC2GM022444174 DT O
cerebrospinal BC2GM022444174 JJ O
fluid BC2GM022444174 NN O
was BC2GM022444174 VBD O
determined BC2GM022444174 VBN O
. BC2GM022444174 . O
. . O O

The BC2GM077560209 DT O
same BC2GM077560209 JJ O
high BC2GM077560209 JJ O
degree BC2GM077560209 NN O
of BC2GM077560209 IN O
sequence BC2GM077560209 NN O
homology BC2GM077560209 NN O
between BC2GM077560209 IN O
the BC2GM077560209 DT O
two BC2GM077560209 CD O
F. BC2GM077560209 NNP O
diplosiphon BC2GM077560209 JJ O
PC BC2GM077560209 NN O
alpha BC2GM077560209 NN O
and BC2GM077560209 CC O
PC BC2GM077560209 NN O
beta BC2GM077560209 NN O
sequences BC2GM077560209 NNS O
( BC2GM077560209 ( O
85 BC2GM077560209 CD O
and BC2GM077560209 CC O
77 BC2GM077560209 CD O
% BC2GM077560209 NN O
, BC2GM077560209 , O
respectively BC2GM077560209 RB O
) BC2GM077560209 ) O
was BC2GM077560209 VBD O
found BC2GM077560209 VBN O
at BC2GM077560209 IN O
both BC2GM077560209 DT O
the BC2GM077560209 DT O
nucleotide BC2GM077560209 NN O
and BC2GM077560209 CC O
amino BC2GM077560209 NN O
acid BC2GM077560209 NN O
levels BC2GM077560209 NNS O
, BC2GM077560209 , O
and BC2GM077560209 CC O
similar BC2GM077560209 JJ O
results BC2GM077560209 NNS O
were BC2GM077560209 VBD O
obtained BC2GM077560209 VBN O
for BC2GM077560209 IN O
interspecies BC2GM077560209 NNS O
comparisons BC2GM077560209 NNS O
. BC2GM077560209 . O
. . O O

IRA2 BC2GM040811399 NNP O
, BC2GM040811399 , O
a BC2GM040811399 DT O
second BC2GM040811399 JJ O
gene BC2GM040811399 NN O
of BC2GM040811399 IN O
Saccharomyces BC2GM040811399 NNS O
cerevisiae BC2GM040811399 VBP O
that BC2GM040811399 IN O
encodes BC2GM040811399 VBZ O
a BC2GM040811399 DT O
protein BC2GM040811399 NN O
with BC2GM040811399 IN O
a BC2GM040811399 DT O
domain BC2GM040811399 NN O
homologous BC2GM040811399 JJ O
to BC2GM040811399 TO O
mammalian BC2GM040811399 JJ O
ras BC2GM040811399 VB O
GTPase-activating BC2GM040811399 NNP O
protein BC2GM040811399 NN O
. BC2GM040811399 . O
. . O O

Adult-onset BC2GM043010172 JJ O
parkinsonism BC2GM043010172 NN O
has BC2GM043010172 VBZ O
appeared BC2GM043010172 VBN O
in BC2GM043010172 IN O
several BC2GM043010172 JJ O
previously BC2GM043010172 RB O
unaffected BC2GM043010172 JJ O
members BC2GM043010172 NNS O
in BC2GM043010172 IN O
families BC2GM043010172 NNS O
with BC2GM043010172 IN O
DRD BC2GM043010172 NNP O
suggesting BC2GM043010172 VBG O
that BC2GM043010172 IN O
this BC2GM043010172 DT O
may BC2GM043010172 MD O
be BC2GM043010172 VB O
an BC2GM043010172 DT O
additional BC2GM043010172 JJ O
phenotypical BC2GM043010172 JJ O
expression BC2GM043010172 NN O
of BC2GM043010172 IN O
the BC2GM043010172 DT O
disease BC2GM043010172 NN O
. BC2GM043010172 . O
. . O O

The BC2GM084109623 DT O
tro BC2GM084109623 NN O
operon BC2GM084109623 NN O
is BC2GM084109623 VBZ O
flanked BC2GM084109623 VBN O
by BC2GM084109623 IN O
a BC2GM084109623 DT O
Holliday BC2GM084109623 NNP O
structure BC2GM084109623 NN O
DNA BC2GM084109623 NNP O
helicase BC2GM084109623 NN O
homolog BC2GM084109623 NN O
( BC2GM084109623 ( O
upstream BC2GM084109623 JJ O
) BC2GM084109623 ) O
and BC2GM084109623 CC O
two BC2GM084109623 CD O
ORFs BC2GM084109623 NNP O
representing BC2GM084109623 VBG O
a BC2GM084109623 DT O
purine BC2GM084109623 JJ O
nucleoside BC2GM084109623 JJ O
phosphorylase BC2GM084109623 NN O
homolog BC2GM084109623 NN O
and BC2GM084109623 CC O
tpp15 BC2GM084109623 NN O
, BC2GM084109623 , O
a BC2GM084109623 DT O
previously BC2GM084109623 RB O
characterized BC2GM084109623 VBN O
gene BC2GM084109623 NN O
encoding BC2GM084109623 VBG O
a BC2GM084109623 DT O
membrane BC2GM084109623 NN O
lipoprotein BC2GM084109623 NN O
( BC2GM084109623 ( O
downstream BC2GM084109623 NN O
) BC2GM084109623 ) O
. BC2GM084109623 . O
. . O O

Reduced BC2GM022050616 VBN O
cell BC2GM022050616 NN O
numbers BC2GM022050616 NNS O
72 BC2GM022050616 CD O
h BC2GM022050616 NN O
after BC2GM022050616 IN O
insonation BC2GM022050616 NN O
were BC2GM022050616 VBD O
recorded BC2GM022050616 VBN O
when BC2GM022050616 WRB O
the BC2GM022050616 DT O
cells BC2GM022050616 NNS O
were BC2GM022050616 VBD O
insonated BC2GM022050616 VBN O
at BC2GM022050616 IN O
an BC2GM022050616 DT O
antinode BC2GM022050616 NN O
but BC2GM022050616 CC O
not BC2GM022050616 RB O
when BC2GM022050616 WRB O
they BC2GM022050616 PRP O
were BC2GM022050616 VBD O
at BC2GM022050616 IN O
a BC2GM022050616 DT O
node BC2GM022050616 NN O
. BC2GM022050616 . O
. . O O

Two BC2GM043554799 CD O
of BC2GM043554799 IN O
the BC2GM043554799 DT O
proteins BC2GM043554799 NNS O
UPRF-1 BC2GM043554799 NNP O
and BC2GM043554799 CC O
UPRF-2 BC2GM043554799 NNP O
( BC2GM043554799 ( O
which BC2GM043554799 WDT O
is BC2GM043554799 VBZ O
apparently BC2GM043554799 RB O
a BC2GM043554799 DT O
proteolytic BC2GM043554799 JJ O
degradation BC2GM043554799 NN O
product BC2GM043554799 NN O
of BC2GM043554799 IN O
UPRF-1 BC2GM043554799 NNP O
) BC2GM043554799 ) O
bind BC2GM043554799 NN O
inefficiently BC2GM043554799 RB O
to BC2GM043554799 TO O
mutant BC2GM043554799 VB O
versions BC2GM043554799 NNS O
of BC2GM043554799 IN O
the BC2GM043554799 DT O
UPR BC2GM043554799 NNP O
that BC2GM043554799 WDT O
are BC2GM043554799 VBP O
unable BC2GM043554799 JJ O
to BC2GM043554799 TO O
confer BC2GM043554799 VB O
responsiveness BC2GM043554799 NN O
to BC2GM043554799 TO O
unfolded BC2GM043554799 JJ O
proteins BC2GM043554799 NNS O
to BC2GM043554799 TO O
the BC2GM043554799 DT O
( BC2GM043554799 ( O
CYC1 BC2GM043554799 NNP O
) BC2GM043554799 ) O
promoter BC2GM043554799 NN O
. BC2GM043554799 . O
. . O O

A BC2GM008773952 DT O
lead BC2GM008773952 JJ O
phthalocyanin BC2GM008773952 NN O
method BC2GM008773952 NN O
for BC2GM008773952 IN O
the BC2GM008773952 DT O
demonstration BC2GM008773952 NN O
of BC2GM008773952 IN O
acid BC2GM008773952 JJ O
hydrolases BC2GM008773952 NNS O
in BC2GM008773952 IN O
plant BC2GM008773952 NN O
and BC2GM008773952 CC O
animal BC2GM008773952 NN O
tissues BC2GM008773952 NNS O
. BC2GM008773952 . O
. . O O

As BC2GM097801700 IN O
usual BC2GM097801700 JJ O
tests BC2GM097801700 NNS O
, BC2GM097801700 , O
such BC2GM097801700 JJ O
as BC2GM097801700 IN O
`` BC2GM097801700 `` O
time BC2GM097801700 NN O
'' BC2GM097801700 '' O
of BC2GM097801700 IN O
cephalin BC2GM097801700 NN O
are BC2GM097801700 VBP O
slightly BC2GM097801700 RB O
sensible BC2GM097801700 JJ O
to BC2GM097801700 TO O
LMW-Hep BC2GM097801700 NNP O
, BC2GM097801700 , O
only BC2GM097801700 RB O
anti-Xa BC2GM097801700 JJ O
activity BC2GM097801700 NN O
can BC2GM097801700 MD O
be BC2GM097801700 VB O
used BC2GM097801700 VBN O
. BC2GM097801700 . O
. . O O

Recently BC2GM049476497 RB O
we BC2GM049476497 PRP O
have BC2GM049476497 VBP O
performed BC2GM049476497 VBN O
a BC2GM049476497 DT O
detailed BC2GM049476497 JJ O
analysis BC2GM049476497 NN O
of BC2GM049476497 IN O
specific BC2GM049476497 JJ O
neuronal BC2GM049476497 JJ O
populations BC2GM049476497 NNS O
affected BC2GM049476497 VBN O
by BC2GM049476497 IN O
the BC2GM049476497 DT O
mutation BC2GM049476497 NN O
which BC2GM049476497 WDT O
shed BC2GM049476497 VBD O
new BC2GM049476497 JJ O
light BC2GM049476497 NN O
on BC2GM049476497 IN O
the BC2GM049476497 DT O
role BC2GM049476497 NN O
of BC2GM049476497 IN O
Krox-20 BC2GM049476497 NNP O
in BC2GM049476497 IN O
the BC2GM049476497 DT O
segmentation BC2GM049476497 NN O
and BC2GM049476497 CC O
on BC2GM049476497 IN O
the BC2GM049476497 DT O
physiological BC2GM049476497 JJ O
consequences BC2GM049476497 NNS O
of BC2GM049476497 IN O
its BC2GM049476497 PRP$ O
inactivation BC2GM049476497 NN O
. BC2GM049476497 . O
. . O O

B BC2GM044292594 NNP O
and BC2GM044292594 CC O
C1 BC2GM044292594 NNP O
fusions BC2GM044292594 NNS O
with BC2GM044292594 IN O
yeast BC2GM044292594 JJ O
GAL4 BC2GM044292594 NNP O
DNA-binding BC2GM044292594 NNP O
and BC2GM044292594 CC O
transcriptional BC2GM044292594 JJ O
activation BC2GM044292594 NN O
domains BC2GM044292594 NNS O
were BC2GM044292594 VBD O
also BC2GM044292594 RB O
found BC2GM044292594 VBN O
to BC2GM044292594 TO O
interact BC2GM044292594 VB O
when BC2GM044292594 WRB O
synthesized BC2GM044292594 VBN O
and BC2GM044292594 CC O
assayed BC2GM044292594 VBN O
in BC2GM044292594 IN O
yeast BC2GM044292594 NN O
. BC2GM044292594 . O
. . O O

SYC1 BC2GM096199881 NNP O
( BC2GM096199881 ( O
suppressor BC2GM096199881 NN O
of BC2GM096199881 IN O
yeast BC2GM096199881 JJ O
cbf5-1 BC2GM096199881 NN O
) BC2GM096199881 ) O
was BC2GM096199881 VBD O
identified BC2GM096199881 VBN O
as BC2GM096199881 IN O
a BC2GM096199881 DT O
multicopy BC2GM096199881 NN O
suppressor BC2GM096199881 NN O
of BC2GM096199881 IN O
cbf5-1 BC2GM096199881 NN O
and BC2GM096199881 CC O
subsequently BC2GM096199881 RB O
was BC2GM096199881 VBD O
found BC2GM096199881 VBN O
to BC2GM096199881 TO O
be BC2GM096199881 VB O
identical BC2GM096199881 JJ O
to BC2GM096199881 TO O
RRN3 BC2GM096199881 NNP O
, BC2GM096199881 , O
an BC2GM096199881 DT O
RNA BC2GM096199881 NNP O
polymerase BC2GM096199881 NN O
I BC2GM096199881 PRP O
transcription BC2GM096199881 VBP O
factor BC2GM096199881 NN O
. BC2GM096199881 . O
. . O O

The BC2GM053000072 DT O
repeats BC2GM053000072 NNS O
are BC2GM053000072 VBP O
highly BC2GM053000072 RB O
conserved BC2GM053000072 VBN O
both BC2GM053000072 DT O
within BC2GM053000072 IN O
a BC2GM053000072 DT O
given BC2GM053000072 VBN O
element BC2GM053000072 NN O
as BC2GM053000072 RB O
well BC2GM053000072 RB O
as BC2GM053000072 IN O
between BC2GM053000072 IN O
different BC2GM053000072 JJ O
members BC2GM053000072 NNS O
of BC2GM053000072 IN O
the BC2GM053000072 DT O
family BC2GM053000072 NN O
( BC2GM053000072 ( O
less BC2GM053000072 JJR O
than BC2GM053000072 IN O
10 BC2GM053000072 CD O
% BC2GM053000072 NN O
divergence BC2GM053000072 NN O
) BC2GM053000072 ) O
. BC2GM053000072 . O
. . O O

Mutations BC2GM022478425 NNS O
in BC2GM022478425 IN O
Saccharomyces BC2GM022478425 NNP O
cerevisiae BC2GM022478425 NN O
that BC2GM022478425 WDT O
block BC2GM022478425 VBZ O
meiotic BC2GM022478425 JJ O
prophase BC2GM022478425 NN O
chromosome BC2GM022478425 NN O
metabolism BC2GM022478425 NN O
and BC2GM022478425 CC O
confer BC2GM022478425 NN O
cell BC2GM022478425 NN O
cycle BC2GM022478425 NN O
arrest BC2GM022478425 NN O
at BC2GM022478425 IN O
pachytene BC2GM022478425 JJ O
identify BC2GM022478425 VB O
two BC2GM022478425 CD O
new BC2GM022478425 JJ O
meiosis-specific BC2GM022478425 JJ O
genes BC2GM022478425 NNS O
SAE1 BC2GM022478425 NNP O
and BC2GM022478425 CC O
SAE3 BC2GM022478425 NNP O
. BC2GM022478425 . O
. . O O

Along BC2GM033064195 IN O
with BC2GM033064195 IN O
these BC2GM033064195 DT O
species BC2GM033064195 NNS O
, BC2GM033064195 , O
F. BC2GM033064195 NNP O
graminearum BC2GM033064195 NNP O
group BC2GM033064195 NN O
2 BC2GM033064195 CD O
( BC2GM033064195 ( O
ZON BC2GM033064195 NNP O
, BC2GM033064195 , O
DON BC2GM033064195 NNP O
and BC2GM033064195 CC O
/ BC2GM033064195 NNP O
or BC2GM033064195 CC O
3AcDON BC2GM033064195 CD O
or BC2GM033064195 CC O
15AcDON BC2GM033064195 CD O
) BC2GM033064195 ) O
; BC2GM033064195 : O
F. BC2GM033064195 NNP O
chlamydosporum BC2GM033064195 NN O
; BC2GM033064195 : O
F. BC2GM033064195 NNP O
acuminatum BC2GM033064195 NN O
( BC2GM033064195 ( O
type-A BC2GM033064195 JJ O
trichothecene BC2GM033064195 NN O
derivatives BC2GM033064195 NNS O
) BC2GM033064195 ) O
; BC2GM033064195 : O
and BC2GM033064195 CC O
F. BC2GM033064195 NNP O
semitectum BC2GM033064195 NN O
were BC2GM033064195 VBD O
often BC2GM033064195 RB O
found BC2GM033064195 VBN O
to BC2GM033064195 TO O
be BC2GM033064195 VB O
associated BC2GM033064195 VBN O
. BC2GM033064195 . O
. . O O

Endodontic BC2GM047517578 JJ O
treatment BC2GM047517578 NN O
of BC2GM047517578 IN O
deciduous BC2GM047517578 JJ O
teeth BC2GM047517578 NNS O
using BC2GM047517578 VBG O
the BC2GM047517578 DT O
formocresol BC2GM047517578 JJ O
amputation BC2GM047517578 NN O
method BC2GM047517578 NN O
. BC2GM047517578 . O
. . O O

Since BC2GM007134922 IN O
UmuD BC2GM007134922 NNP O
protein BC2GM007134922 NN O
is BC2GM007134922 VBZ O
proteolytically BC2GM007134922 RB O
processed BC2GM007134922 VBN O
to BC2GM007134922 TO O
an BC2GM007134922 DT O
active BC2GM007134922 JJ O
form BC2GM007134922 NN O
( BC2GM007134922 ( O
UmuD* BC2GM007134922 NNP O
) BC2GM007134922 ) O
in BC2GM007134922 IN O
a BC2GM007134922 DT O
RecA*-dependent BC2GM007134922 JJ O
fashion BC2GM007134922 NN O
, BC2GM007134922 , O
and BC2GM007134922 CC O
MucA BC2GM007134922 NNP O
shares BC2GM007134922 NNS O
extensive BC2GM007134922 VBP O
amino BC2GM007134922 NN O
acid BC2GM007134922 NN O
homology BC2GM007134922 NN O
with BC2GM007134922 IN O
UmuD BC2GM007134922 NNP O
, BC2GM007134922 , O
we BC2GM007134922 PRP O
examined BC2GM007134922 VBD O
whether BC2GM007134922 IN O
MucA BC2GM007134922 NNP O
is BC2GM007134922 VBZ O
similarly BC2GM007134922 RB O
processed BC2GM007134922 VBN O
in BC2GM007134922 IN O
the BC2GM007134922 DT O
cell BC2GM007134922 NN O
, BC2GM007134922 , O
using BC2GM007134922 VBG O
antiserum BC2GM007134922 NN O
against BC2GM007134922 IN O
a BC2GM007134922 DT O
LacZ'-'MucA BC2GM007134922 JJ O
fusion BC2GM007134922 NN O
protein BC2GM007134922 NN O
. BC2GM007134922 . O
. . O O

During BC2GM015535650 IN O
an BC2GM015535650 DT O
observation BC2GM015535650 JJ O
period BC2GM015535650 NN O
of BC2GM015535650 IN O
12 BC2GM015535650 CD O
weeks BC2GM015535650 NNS O
after BC2GM015535650 IN O
halving BC2GM015535650 VBG O
atenolol BC2GM015535650 NN O
from BC2GM015535650 IN O
a BC2GM015535650 DT O
mean BC2GM015535650 JJ O
dose BC2GM015535650 NN O
of BC2GM015535650 IN O
82 BC2GM015535650 CD O
mg BC2GM015535650 NNS O
to BC2GM015535650 TO O
41 BC2GM015535650 CD O
mg BC2GM015535650 NNS O
, BC2GM015535650 , O
no BC2GM015535650 DT O
significant BC2GM015535650 JJ O
changes BC2GM015535650 NNS O
in BC2GM015535650 IN O
systolic BC2GM015535650 NN O
and BC2GM015535650 CC O
diastolic BC2GM015535650 JJ O
blood BC2GM015535650 NN O
pressure BC2GM015535650 NN O
or BC2GM015535650 CC O
in BC2GM015535650 IN O
response BC2GM015535650 NN O
rate BC2GM015535650 NN O
( BC2GM015535650 ( O
defined BC2GM015535650 VBN O
as BC2GM015535650 IN O
a BC2GM015535650 DT O
diastolic BC2GM015535650 JJ O
blood BC2GM015535650 NN O
pressure BC2GM015535650 NN O
of BC2GM015535650 IN O
95 BC2GM015535650 CD O
mm BC2GM015535650 NNS O
Hg BC2GM015535650 NNP O
or BC2GM015535650 CC O
less BC2GM015535650 JJR O
) BC2GM015535650 ) O
were BC2GM015535650 VBD O
observed BC2GM015535650 VBN O
. BC2GM015535650 . O
. . O O

The BC2GM075057659 DT O
single-copy BC2GM075057659 JJ O
U20 BC2GM075057659 NNP O
sequence BC2GM075057659 NN O
is BC2GM075057659 VBZ O
located BC2GM075057659 VBN O
on BC2GM075057659 IN O
the BC2GM075057659 DT O
same BC2GM075057659 JJ O
DNA BC2GM075057659 NNP O
strand BC2GM075057659 NN O
as BC2GM075057659 IN O
the BC2GM075057659 DT O
nucleolin BC2GM075057659 NN O
mRNA BC2GM075057659 NN O
. BC2GM075057659 . O
. . O O

The BC2GM073438143 DT O
Rep BC2GM073438143 NNP O
proteins BC2GM073438143 NNS O
of BC2GM073438143 IN O
adeno-associated BC2GM073438143 JJ O
virus BC2GM073438143 NN O
type BC2GM073438143 NN O
2 BC2GM073438143 CD O
( BC2GM073438143 ( O
AAV BC2GM073438143 NNP O
) BC2GM073438143 ) O
are BC2GM073438143 VBP O
known BC2GM073438143 VBN O
to BC2GM073438143 TO O
bind BC2GM073438143 VB O
to BC2GM073438143 TO O
Rep BC2GM073438143 NNP O
recognition BC2GM073438143 NN O
sequences BC2GM073438143 NNS O
( BC2GM073438143 ( O
RRSs BC2GM073438143 NNP O
) BC2GM073438143 ) O
in BC2GM073438143 IN O
the BC2GM073438143 DT O
AAV BC2GM073438143 NNP O
inverted BC2GM073438143 VBD O
terminal BC2GM073438143 JJ O
repeats BC2GM073438143 NNS O
( BC2GM073438143 ( O
ITRs BC2GM073438143 NNP O
) BC2GM073438143 ) O
, BC2GM073438143 , O
the BC2GM073438143 DT O
AAV BC2GM073438143 NNP O
p5 BC2GM073438143 NN O
promoter BC2GM073438143 NN O
, BC2GM073438143 , O
and BC2GM073438143 CC O
the BC2GM073438143 DT O
preferred BC2GM073438143 JJ O
AAV BC2GM073438143 NNP O
integration BC2GM073438143 NN O
site BC2GM073438143 NN O
in BC2GM073438143 IN O
human BC2GM073438143 JJ O
chromosome BC2GM073438143 NN O
19 BC2GM073438143 CD O
, BC2GM073438143 , O
called BC2GM073438143 VBN O
AAVS1 BC2GM073438143 NNP O
. BC2GM073438143 . O
. . O O

We BC2GM082914643 PRP O
investigated BC2GM082914643 VBD O
whether BC2GM082914643 IN O
two BC2GM082914643 CD O
WT1 BC2GM082914643 NNP O
splice BC2GM082914643 NN O
variants BC2GM082914643 NNS O
lacking BC2GM082914643 VBG O
or BC2GM082914643 CC O
including BC2GM082914643 VBG O
a BC2GM082914643 DT O
three-amino-acid BC2GM082914643 NN O
( BC2GM082914643 ( O
KTS BC2GM082914643 NNP O
) BC2GM082914643 ) O
insertion BC2GM082914643 NN O
between BC2GM082914643 IN O
the BC2GM082914643 DT O
third BC2GM082914643 JJ O
and BC2GM082914643 CC O
fourth BC2GM082914643 JJ O
zinc BC2GM082914643 NN O
finger BC2GM082914643 NN O
in BC2GM082914643 IN O
the BC2GM082914643 DT O
DNA-binding BC2GM082914643 NNP O
domain BC2GM082914643 NN O
could BC2GM082914643 MD O
repress BC2GM082914643 VB O
the BC2GM082914643 DT O
IR BC2GM082914643 NNP O
promoter BC2GM082914643 NN O
in BC2GM082914643 IN O
vitro BC2GM082914643 NN O
. BC2GM082914643 . O
. . O O

Exit BC2GM056337043 NN O
from BC2GM056337043 IN O
mitosis BC2GM056337043 NN O
in BC2GM056337043 IN O
Drosophila BC2GM056337043 NNP O
syncytial BC2GM056337043 JJ O
embryos BC2GM056337043 NN O
requires BC2GM056337043 VBZ O
proteolysis BC2GM056337043 NN O
and BC2GM056337043 CC O
cyclin BC2GM056337043 NN O
degradation BC2GM056337043 NN O
, BC2GM056337043 , O
and BC2GM056337043 CC O
is BC2GM056337043 VBZ O
associated BC2GM056337043 VBN O
with BC2GM056337043 IN O
localized BC2GM056337043 JJ O
dephosphorylation BC2GM056337043 NN O
. BC2GM056337043 . O
. . O O

Deep BC2GM094893147 NNP O
bite BC2GM094893147 NN O
CL BC2GM094893147 NNP O
II BC2GM094893147 NNP O
Div BC2GM094893147 NNP O
. BC2GM094893147 . O
. . O O

Hematopoietic BC2GM054430010 JJ O
progenitor BC2GM054430010 NN O
kinase BC2GM054430010 NN O
1 BC2GM054430010 CD O
( BC2GM054430010 ( O
HPK1 BC2GM054430010 NNP O
) BC2GM054430010 ) O
is BC2GM054430010 VBZ O
a BC2GM054430010 DT O
member BC2GM054430010 NN O
of BC2GM054430010 IN O
the BC2GM054430010 DT O
mitogen-activated BC2GM054430010 JJ O
protein BC2GM054430010 NN O
kinase BC2GM054430010 NN O
kinase BC2GM054430010 VB O
kinase BC2GM054430010 NN O
kinase BC2GM054430010 NN O
( BC2GM054430010 ( O
MAP4K BC2GM054430010 NNP O
) BC2GM054430010 ) O
family BC2GM054430010 NN O
and BC2GM054430010 CC O
an BC2GM054430010 DT O
upstream BC2GM054430010 JJ O
activator BC2GM054430010 NN O
of BC2GM054430010 IN O
the BC2GM054430010 DT O
c-Jun BC2GM054430010 JJ O
N-terminal BC2GM054430010 JJ O
kinase BC2GM054430010 NN O
( BC2GM054430010 ( O
JNK BC2GM054430010 NNP O
) BC2GM054430010 ) O
signaling BC2GM054430010 VBG O
cascade BC2GM054430010 NN O
. BC2GM054430010 . O
. . O O

However BC2GM038571179 RB O
, BC2GM038571179 , O
strains BC2GM038571179 NNS O
in BC2GM038571179 IN O
which BC2GM038571179 WDT O
both BC2GM038571179 DT O
of BC2GM038571179 IN O
the BC2GM038571179 DT O
two BC2GM038571179 CD O
most BC2GM038571179 JJS O
highly BC2GM038571179 RB O
related BC2GM038571179 JJ O
genes BC2GM038571179 NNS O
, BC2GM038571179 , O
DdPIK1 BC2GM038571179 NNP O
and BC2GM038571179 CC O
DdPIK2 BC2GM038571179 NNP O
, BC2GM038571179 , O
were BC2GM038571179 VBD O
disrupted BC2GM038571179 VBN O
showed BC2GM038571179 VBD O
both BC2GM038571179 DT O
growth BC2GM038571179 NN O
and BC2GM038571179 CC O
developmental BC2GM038571179 JJ O
defects BC2GM038571179 NNS O
, BC2GM038571179 , O
while BC2GM038571179 IN O
double BC2GM038571179 JJ O
knockouts BC2GM038571179 NNS O
of BC2GM038571179 IN O
DdPIK1 BC2GM038571179 NNP O
and BC2GM038571179 CC O
DdPIK3 BC2GM038571179 NNP O
and BC2GM038571179 CC O
DdPIK2 BC2GM038571179 NNP O
and BC2GM038571179 CC O
DdPIK3 BC2GM038571179 NNP O
appear BC2GM038571179 VBP O
to BC2GM038571179 TO O
be BC2GM038571179 VB O
lethal BC2GM038571179 JJ O
. BC2GM038571179 . O
. . O O

The BC2GM014406229 DT O
132-bp BC2GM014406229 JJ O
PHO8p BC2GM014406229 NNP O
fragment BC2GM014406229 NN O
, BC2GM014406229 , O
connected BC2GM014406229 VBN O
at BC2GM014406229 IN O
position BC2GM014406229 NN O
-281 BC2GM014406229 NN O
of BC2GM014406229 IN O
the BC2GM014406229 DT O
5 BC2GM014406229 CD O
' BC2GM014406229 POS O
upstream BC2GM014406229 JJ O
region BC2GM014406229 NN O
of BC2GM014406229 IN O
a BC2GM014406229 DT O
HIS5'-'lacZ BC2GM014406229 NNP O
fused BC2GM014406229 JJ O
gene BC2GM014406229 NN O
, BC2GM014406229 , O
could BC2GM014406229 MD O
sense BC2GM014406229 VB O
Pi BC2GM014406229 NNP O
signals BC2GM014406229 NNS O
in BC2GM014406229 IN O
vivo BC2GM014406229 NN O
, BC2GM014406229 , O
but BC2GM014406229 CC O
a BC2GM014406229 DT O
20-bp BC2GM014406229 JJ O
synthetic BC2GM014406229 JJ O
oligonucleotide BC2GM014406229 NN O
having BC2GM014406229 VBG O
the BC2GM014406229 DT O
same BC2GM014406229 JJ O
sequence BC2GM014406229 NN O
from BC2GM014406229 IN O
-544 BC2GM014406229 NN O
to BC2GM014406229 TO O
-525 BC2GM014406229 VB O
of BC2GM014406229 IN O
the BC2GM014406229 DT O
PHO8p BC2GM014406229 NNP O
DNA BC2GM014406229 NNP O
could BC2GM014406229 MD O
not BC2GM014406229 RB O
. BC2GM014406229 . O
. . O O

We BC2GM091026320 PRP O
propose BC2GM091026320 VBP O
that BC2GM091026320 IN O
optimal BC2GM091026320 JJ O
transcription BC2GM091026320 NN O
of BC2GM091026320 IN O
the BC2GM091026320 DT O
gD BC2GM091026320 JJ O
gene BC2GM091026320 NN O
depends BC2GM091026320 VBZ O
on BC2GM091026320 IN O
the BC2GM091026320 DT O
interaction BC2GM091026320 NN O
of BC2GM091026320 IN O
ICP4 BC2GM091026320 NNP O
with BC2GM091026320 IN O
multiple BC2GM091026320 JJ O
binding BC2GM091026320 VBG O
sites BC2GM091026320 NNS O
across BC2GM091026320 IN O
the BC2GM091026320 DT O
gene BC2GM091026320 NN O
and BC2GM091026320 CC O
cellular BC2GM091026320 JJ O
factors BC2GM091026320 NNS O
that BC2GM091026320 IN O
recognize BC2GM091026320 VBP O
specific BC2GM091026320 JJ O
sequence BC2GM091026320 NN O
elements BC2GM091026320 NNS O
in BC2GM091026320 IN O
the BC2GM091026320 DT O
promoter BC2GM091026320 NN O
. BC2GM091026320 . O
. . O O

The BC2GM009169433 DT O
sections BC2GM009169433 NNS O
were BC2GM009169433 VBD O
stained BC2GM009169433 VBN O
with BC2GM009169433 IN O
anti-polymorphonuclear BC2GM009169433 JJ O
leukocyte BC2GM009169433 NN O
antibody BC2GM009169433 NN O
, BC2GM009169433 , O
the BC2GM009169433 DT O
endothelial BC2GM009169433 JJ O
marker BC2GM009169433 NN O
factor BC2GM009169433 NN O
VIII-related BC2GM009169433 JJ O
antigen BC2GM009169433 NN O
, BC2GM009169433 , O
and BC2GM009169433 CC O
with BC2GM009169433 IN O
hematoxylin BC2GM009169433 NN O
and BC2GM009169433 CC O
eosin BC2GM009169433 NN O
. BC2GM009169433 . O
. . O O

Treatment BC2GM091292121 NN O
with BC2GM091292121 IN O
polyinosinic-polycytidylic BC2GM091292121 JJ O
acid BC2GM091292121 NN O
to BC2GM091292121 TO O
induce BC2GM091292121 VB O
expression BC2GM091292121 NN O
of BC2GM091292121 IN O
Cre BC2GM091292121 NNP O
resulted BC2GM091292121 VBD O
in BC2GM091292121 IN O
complete BC2GM091292121 JJ O
disruption BC2GM091292121 NN O
of BC2GM091292121 IN O
the BC2GM091292121 DT O
Arnt BC2GM091292121 NNP O
gene BC2GM091292121 NN O
and BC2GM091292121 CC O
loss BC2GM091292121 NN O
of BC2GM091292121 IN O
ARNT BC2GM091292121 NNP O
messenger BC2GM091292121 NN O
RNA BC2GM091292121 NNP O
( BC2GM091292121 ( O
mRNA BC2GM091292121 NN O
) BC2GM091292121 ) O
expression BC2GM091292121 NN O
in BC2GM091292121 IN O
liver BC2GM091292121 NN O
. BC2GM091292121 . O
. . O O

The BC2GM075371550 DT O
full-length BC2GM075371550 JJ O
cDNA BC2GM075371550 NN O
was BC2GM075371550 VBD O
cloned BC2GM075371550 VBN O
and BC2GM075371550 CC O
sequenced BC2GM075371550 VBN O
, BC2GM075371550 , O
and BC2GM075371550 CC O
the BC2GM075371550 DT O
inferred BC2GM075371550 JJ O
amino BC2GM075371550 NN O
acid BC2GM075371550 NN O
sequence BC2GM075371550 NN O
was BC2GM075371550 VBD O
found BC2GM075371550 VBN O
to BC2GM075371550 TO O
encode BC2GM075371550 VB O
a BC2GM075371550 DT O
novel BC2GM075371550 JJ O
protein BC2GM075371550 NN O
, BC2GM075371550 , O
which BC2GM075371550 WDT O
we BC2GM075371550 PRP O
named BC2GM075371550 VBD O
cystatin BC2GM075371550 NN O
M BC2GM075371550 NNP O
, BC2GM075371550 , O
with BC2GM075371550 IN O
40 BC2GM075371550 CD O
% BC2GM075371550 NN O
homology BC2GM075371550 NN O
to BC2GM075371550 TO O
human BC2GM075371550 JJ O
family BC2GM075371550 NN O
2 BC2GM075371550 CD O
cystatins BC2GM075371550 NNS O
and BC2GM075371550 CC O
similar BC2GM075371550 JJ O
overall BC2GM075371550 JJ O
structure BC2GM075371550 NN O
. BC2GM075371550 . O
. . O O

Dynamic BC2GM041011754 NNP O
expression BC2GM041011754 NN O
of BC2GM041011754 IN O
broad-complex BC2GM041011754 JJ O
isoforms BC2GM041011754 NNS O
mediates BC2GM041011754 VBZ O
temporal BC2GM041011754 JJ O
control BC2GM041011754 NN O
of BC2GM041011754 IN O
an BC2GM041011754 DT O
ecdysteroid BC2GM041011754 JJ O
target BC2GM041011754 NN O
gene BC2GM041011754 NN O
at BC2GM041011754 IN O
the BC2GM041011754 DT O
onset BC2GM041011754 NN O
of BC2GM041011754 IN O
Drosophila BC2GM041011754 NNP O
metamorphosis BC2GM041011754 NN O
. BC2GM041011754 . O
. . O O

We BC2GM044066999 PRP O
assessed BC2GM044066999 VBD O
cardiovascular BC2GM044066999 JJ O
variables BC2GM044066999 NNS O
and BC2GM044066999 CC O
blood BC2GM044066999 NN O
O2 BC2GM044066999 NNP O
contents BC2GM044066999 NNS O
in BC2GM044066999 IN O
order BC2GM044066999 NN O
to BC2GM044066999 TO O
characterize BC2GM044066999 VB O
O2 BC2GM044066999 NNP O
transport BC2GM044066999 NN O
in BC2GM044066999 IN O
ponies BC2GM044066999 NNS O
during BC2GM044066999 IN O
treadmill BC2GM044066999 JJ O
exercise BC2GM044066999 NN O
. BC2GM044066999 . O
. . O O

Amongst BC2GM045278199 $ O
53 BC2GM045278199 CD O
`` BC2GM045278199 `` O
inoperable BC2GM045278199 JJ O
'' BC2GM045278199 '' O
( BC2GM045278199 ( O
T4 BC2GM045278199 NNP O
, BC2GM045278199 , O
N0 BC2GM045278199 NNP O
, BC2GM045278199 , O
N1 BC2GM045278199 NNP O
, BC2GM045278199 , O
T. BC2GM045278199 NNP O
, BC2GM045278199 , O
N2 BC2GM045278199 NNP O
, BC2GM045278199 , O
N3 BC2GM045278199 NNP O
) BC2GM045278199 ) O
cases BC2GM045278199 NNS O
, BC2GM045278199 , O
5 BC2GM045278199 CD O
( BC2GM045278199 ( O
10 BC2GM045278199 CD O
% BC2GM045278199 NN O
) BC2GM045278199 ) O
had BC2GM045278199 VBD O
a BC2GM045278199 DT O
positive BC2GM045278199 JJ O
scan BC2GM045278199 NN O
and BC2GM045278199 CC O
5 BC2GM045278199 CD O
a BC2GM045278199 DT O
doubtful BC2GM045278199 JJ O
scan BC2GM045278199 NN O
. BC2GM045278199 . O
. . O O

However BC2GM092239807 RB O
, BC2GM092239807 , O
the BC2GM092239807 DT O
blend BC2GM092239807 NN O
of BC2GM092239807 IN O
Metanil BC2GM092239807 NNP O
yellow BC2GM092239807 NNP O
and BC2GM092239807 CC O
Orange BC2GM092239807 NNP O
II BC2GM092239807 NNP O
( BC2GM092239807 ( O
1:1 BC2GM092239807 CD O
) BC2GM092239807 ) O
resulted BC2GM092239807 VBD O
in BC2GM092239807 IN O
the BC2GM092239807 DT O
D1 BC2GM092239807 NNP O
50.value BC2GM092239807 CD O
of BC2GM092239807 IN O
288 BC2GM092239807 CD O
min BC2GM092239807 NN O
. BC2GM092239807 . O
. . O O

Two BC2GM074572349 CD O
genes BC2GM074572349 NNS O
from BC2GM074572349 IN O
the BC2GM074572349 DT O
family BC2GM074572349 NN O
encoding BC2GM074572349 VBG O
mouse BC2GM074572349 NN O
ribosomal BC2GM074572349 JJ O
protein BC2GM074572349 NN O
S16 BC2GM074572349 NNP O
were BC2GM074572349 VBD O
cloned BC2GM074572349 VBN O
, BC2GM074572349 , O
sequenced BC2GM074572349 VBN O
, BC2GM074572349 , O
and BC2GM074572349 CC O
analyzed BC2GM074572349 VBD O
. BC2GM074572349 . O
. . O O

The BC2GM061646727 DT O
human BC2GM061646727 JJ O
PAX8 BC2GM061646727 NNP O
gene BC2GM061646727 NN O
generates BC2GM061646727 NNS O
at BC2GM061646727 IN O
least BC2GM061646727 JJS O
five BC2GM061646727 CD O
different BC2GM061646727 JJ O
alternatively BC2GM061646727 RB O
spliced BC2GM061646727 VBD O
transcripts BC2GM061646727 NNS O
encoding BC2GM061646727 VBG O
different BC2GM061646727 JJ O
PAX8 BC2GM061646727 NNP O
isoforms BC2GM061646727 NNS O
. BC2GM061646727 . O
. . O O

Since BC2GM073846842 IN O
simian BC2GM073846842 JJ O
virus BC2GM073846842 NN O
40 BC2GM073846842 CD O
( BC2GM073846842 ( O
SV40 BC2GM073846842 NNP O
) BC2GM073846842 ) O
large BC2GM073846842 JJ O
T BC2GM073846842 NNP O
antigen BC2GM073846842 NN O
and BC2GM073846842 CC O
human BC2GM073846842 JJ O
papillomavirus BC2GM073846842 NN O
type BC2GM073846842 NN O
16 BC2GM073846842 CD O
( BC2GM073846842 ( O
HPV16 BC2GM073846842 NNP O
) BC2GM073846842 ) O
E7 BC2GM073846842 NNP O
protein BC2GM073846842 NN O
also BC2GM073846842 RB O
bind BC2GM073846842 VBZ O
host BC2GM073846842 NN O
regulatory BC2GM073846842 JJ O
factors BC2GM073846842 NNS O
, BC2GM073846842 , O
we BC2GM073846842 PRP O
investigated BC2GM073846842 VBD O
whether BC2GM073846842 IN O
these BC2GM073846842 DT O
viral BC2GM073846842 JJ O
proteins BC2GM073846842 NNS O
can BC2GM073846842 MD O
complement BC2GM073846842 VB O
E1A BC2GM073846842 NNP O
mutants BC2GM073846842 NNS O
which BC2GM073846842 WDT O
are BC2GM073846842 VBP O
defective BC2GM073846842 JJ O
in BC2GM073846842 IN O
early BC2GM073846842 JJ O
gene BC2GM073846842 NN O
activation BC2GM073846842 NN O
. BC2GM073846842 . O
. . O O

STUDY BC2GM065655704 NNP O
OBJECTIVE BC2GM065655704 NNP O
: BC2GM065655704 : O
to BC2GM065655704 TO O
characterize BC2GM065655704 VB O
gas BC2GM065655704 NN O
exchange BC2GM065655704 NN O
and BC2GM065655704 CC O
cardiopulmonary BC2GM065655704 JJ O
performance BC2GM065655704 NN O
during BC2GM065655704 IN O
maximal BC2GM065655704 JJ O
progressive BC2GM065655704 JJ O
arm BC2GM065655704 NN O
crank BC2GM065655704 NN O
exercise BC2GM065655704 NN O
. BC2GM065655704 . O
. . O O

Prospects BC2GM042361998 NNS O
of BC2GM042361998 IN O
chemosterilant BC2GM042361998 NN O
and BC2GM042361998 CC O
genetic BC2GM042361998 JJ O
control BC2GM042361998 NN O
of BC2GM042361998 IN O
rodents BC2GM042361998 NNS O
. BC2GM042361998 . O
. . O O

Here BC2GM028887515 RB O
, BC2GM028887515 , O
we BC2GM028887515 PRP O
identify BC2GM028887515 VBP O
the BC2GM028887515 DT O
analytical BC2GM028887515 JJ O
form BC2GM028887515 NN O
of BC2GM028887515 IN O
the BC2GM028887515 DT O
PDF BC2GM028887515 NNP O
of BC2GM028887515 IN O
one BC2GM028887515 CD O
such BC2GM028887515 JJ O
measure BC2GM028887515 NN O
, BC2GM028887515 , O
the BC2GM028887515 DT O
order BC2GM028887515 NN O
parameter BC2GM028887515 NN O
in BC2GM028887515 IN O
the BC2GM028887515 DT O
low BC2GM028887515 JJ O
temperature BC2GM028887515 NN O
phase BC2GM028887515 NN O
of BC2GM028887515 IN O
the BC2GM028887515 DT O
2D BC2GM028887515 CD O
XY BC2GM028887515 NNP O
model BC2GM028887515 NN O
. BC2GM028887515 . O
. . O O

As BC2GM073356328 IN O
anticipated BC2GM073356328 VBN O
, BC2GM073356328 , O
both BC2GM073356328 DT O
intracellular BC2GM073356328 JJ O
p54-SAPKbeta BC2GM073356328 NN O
activation BC2GM073356328 NN O
and BC2GM073356328 CC O
Bcl-2 BC2GM073356328 NNP O
phosphorylation BC2GM073356328 NN O
are BC2GM073356328 VBP O
blocked BC2GM073356328 VBN O
by BC2GM073356328 IN O
co-transfection BC2GM073356328 NN O
with BC2GM073356328 IN O
the BC2GM073356328 DT O
MAP BC2GM073356328 NNP O
kinase BC2GM073356328 NN O
specific BC2GM073356328 JJ O
phosphatase BC2GM073356328 NN O
MKP3 BC2GM073356328 NNP O
/ BC2GM073356328 NNP O
PYST1 BC2GM073356328 NNP O
. BC2GM073356328 . O
. . O O

Using BC2GM013614335 VBG O
a BC2GM013614335 DT O
dominant BC2GM013614335 JJ O
negative BC2GM013614335 JJ O
form BC2GM013614335 NN O
of BC2GM013614335 IN O
Sp3 BC2GM013614335 NNP O
and BC2GM013614335 CC O
transcriptional BC2GM013614335 JJ O
activation BC2GM013614335 NN O
assays BC2GM013614335 NNS O
in BC2GM013614335 IN O
Schneider BC2GM013614335 NNP O
SL-2 BC2GM013614335 NNP O
insect BC2GM013614335 NN O
cells BC2GM013614335 NNS O
, BC2GM013614335 , O
it BC2GM013614335 PRP O
was BC2GM013614335 VBD O
confirmed BC2GM013614335 VBN O
that BC2GM013614335 IN O
ERalpha-Sp3 BC2GM013614335 NNP O
interactions BC2GM013614335 NNS O
define BC2GM013614335 VBP O
a BC2GM013614335 DT O
pathway BC2GM013614335 NN O
for BC2GM013614335 IN O
E2-mediated BC2GM013614335 JJ O
inhibition BC2GM013614335 NN O
of BC2GM013614335 IN O
gene BC2GM013614335 NN O
expression BC2GM013614335 NN O
, BC2GM013614335 , O
and BC2GM013614335 CC O
this BC2GM013614335 DT O
represents BC2GM013614335 VBZ O
a BC2GM013614335 DT O
new BC2GM013614335 JJ O
mechanism BC2GM013614335 NN O
for BC2GM013614335 IN O
decreased BC2GM013614335 JJ O
gene BC2GM013614335 NN O
expression BC2GM013614335 NN O
by BC2GM013614335 IN O
E2 BC2GM013614335 NNP O
. BC2GM013614335 . O
. . O O

In BC2GM071413005 IN O
this BC2GM071413005 DT O
study BC2GM071413005 NN O
, BC2GM071413005 , O
we BC2GM071413005 PRP O
cloned BC2GM071413005 VBD O
the BC2GM071413005 DT O
full-length BC2GM071413005 JJ O
cDNA BC2GM071413005 NN O
of BC2GM071413005 IN O
mouse BC2GM071413005 NN O
PAX4 BC2GM071413005 NNP O
by BC2GM071413005 IN O
RACE BC2GM071413005 NNP O
( BC2GM071413005 ( O
rapid BC2GM071413005 JJ O
amplification BC2GM071413005 NN O
of BC2GM071413005 IN O
cDNA BC2GM071413005 NN O
ends BC2GM071413005 NNS O
) BC2GM071413005 ) O
using BC2GM071413005 VBG O
RNA BC2GM071413005 NNP O
from BC2GM071413005 IN O
MIN6 BC2GM071413005 NNP O
cells BC2GM071413005 NNS O
, BC2GM071413005 , O
a BC2GM071413005 DT O
mouse BC2GM071413005 NN O
insulinoma BC2GM071413005 NN O
cell BC2GM071413005 NN O
line BC2GM071413005 NN O
. BC2GM071413005 . O
. . O O

A BC2GM009539472 DT O
novel BC2GM009539472 JJ O
serine BC2GM009539472 NN O
kinase BC2GM009539472 NN O
activated BC2GM009539472 VBN O
by BC2GM009539472 IN O
rac1 BC2GM009539472 JJ O
/ BC2GM009539472 JJ O
CDC42Hs-dependent BC2GM009539472 JJ O
autophosphorylation BC2GM009539472 NN O
is BC2GM009539472 VBZ O
related BC2GM009539472 VBN O
to BC2GM009539472 TO O
PAK65 BC2GM009539472 NNP O
and BC2GM009539472 CC O
STE20 BC2GM009539472 NNP O
. BC2GM009539472 . O
. . O O

Phosphorylation BC2GM023056895 NN O
by BC2GM023056895 IN O
Cdc28 BC2GM023056895 NNP O
activates BC2GM023056895 VBZ O
the BC2GM023056895 DT O
Cdc20-dependent BC2GM023056895 JJ O
activity BC2GM023056895 NN O
of BC2GM023056895 IN O
the BC2GM023056895 DT O
anaphase-promoting BC2GM023056895 JJ O
complex BC2GM023056895 NN O
. BC2GM023056895 . O
. . O O

The BC2GM012126360 DT O
in-plane BC2GM012126360 JJ O
orientational BC2GM012126360 JJ O
anisotropy BC2GM012126360 NN O
of BC2GM012126360 IN O
the BC2GM012126360 DT O
8CB BC2GM012126360 CD O
films BC2GM012126360 NNS O
grown BC2GM012126360 VBN O
on BC2GM012126360 IN O
unidirectionally BC2GM012126360 RB O
photopolymerized BC2GM012126360 VBN O
PVCN BC2GM012126360 NNP O
substrates BC2GM012126360 NNS O
is BC2GM012126360 VBZ O
considerably BC2GM012126360 RB O
lower BC2GM012126360 JJR O
than BC2GM012126360 IN O
the BC2GM012126360 DT O
intrinsic BC2GM012126360 JJ O
surface BC2GM012126360 NN O
orientational BC2GM012126360 JJ O
anisotropy BC2GM012126360 NN O
of BC2GM012126360 IN O
these BC2GM012126360 DT O
substrates BC2GM012126360 NNS O
, BC2GM012126360 , O
which BC2GM012126360 WDT O
can BC2GM012126360 MD O
explain BC2GM012126360 VB O
the BC2GM012126360 DT O
generally BC2GM012126360 RB O
found BC2GM012126360 VBN O
weak BC2GM012126360 JJ O
surface BC2GM012126360 NN O
anchoring BC2GM012126360 NN O
of BC2GM012126360 IN O
liquid BC2GM012126360 JJ O
crystals BC2GM012126360 NNS O
on BC2GM012126360 IN O
PVCN BC2GM012126360 NNP O
alignment BC2GM012126360 NN O
layers BC2GM012126360 NNS O
. BC2GM012126360 . O
. . O O

In BC2GM012033196 IN O
addition BC2GM012033196 NN O
, BC2GM012033196 , O
we BC2GM012033196 PRP O
found BC2GM012033196 VBD O
that BC2GM012033196 IN O
the BC2GM012033196 DT O
transactivation BC2GM012033196 NN O
mediated BC2GM012033196 VBN O
by BC2GM012033196 IN O
the BC2GM012033196 DT O
p68c-ets-1 BC2GM012033196 JJ O
pr BC2GM012033196 NN O
p55erg BC2GM012033196 NN O
through BC2GM012033196 IN O
the BC2GM012033196 DT O
Polyomavirus BC2GM012033196 NNP O
enhancer BC2GM012033196 NN O
sequence BC2GM012033196 NN O
is BC2GM012033196 VBZ O
specifically BC2GM012033196 RB O
inhibited BC2GM012033196 VBN O
by BC2GM012033196 IN O
the BC2GM012033196 DT O
p46kDaPax-QNR BC2GM012033196 NN O
in BC2GM012033196 IN O
transient BC2GM012033196 JJ O
transfection BC2GM012033196 NN O
assay BC2GM012033196 NN O
. BC2GM012033196 . O
. . O O

Is BC2GM083427683 VBZ O
conventional BC2GM083427683 JJ O
sperm BC2GM083427683 JJ O
analysis BC2GM083427683 NN O
of BC2GM083427683 IN O
any BC2GM083427683 DT O
use BC2GM083427683 NN O
? BC2GM083427683 . O
The BC2GM083427683 DT O
computerised BC2GM083427683 JJ O
records BC2GM083427683 NNS O
of BC2GM083427683 IN O
867 BC2GM083427683 CD O
couples BC2GM083427683 NNS O
were BC2GM083427683 VBD O
used BC2GM083427683 VBN O
to BC2GM083427683 TO O
investigate BC2GM083427683 VB O
the BC2GM083427683 DT O
prognostic BC2GM083427683 JJ O
significance BC2GM083427683 NN O
of BC2GM083427683 IN O
semen BC2GM083427683 NNS O
volume BC2GM083427683 NN O
, BC2GM083427683 , O
motility BC2GM083427683 NN O
, BC2GM083427683 , O
density BC2GM083427683 NN O
and BC2GM083427683 CC O
morphology BC2GM083427683 NN O
. BC2GM083427683 . O
. . O O

FDP-1 BC2GM052669347 NNP O
( BC2GM052669347 ( O
200 BC2GM052669347 CD O
micrograms.kg-1 BC2GM052669347 NN O
) BC2GM052669347 ) O
of BC2GM052669347 IN O
intracoronary BC2GM052669347 JJ O
injection BC2GM052669347 NN O
increased BC2GM052669347 VBD O
collateral BC2GM052669347 NN O
flow BC2GM052669347 NN O
, BC2GM052669347 , O
reduced BC2GM052669347 VBN O
systemic BC2GM052669347 JJ O
artery BC2GM052669347 NN O
resistance BC2GM052669347 NN O
, BC2GM052669347 , O
and BC2GM052669347 CC O
coronary BC2GM052669347 JJ O
systolic BC2GM052669347 JJ O
pressure BC2GM052669347 NN O
in BC2GM052669347 IN O
infarcted BC2GM052669347 JJ O
region BC2GM052669347 NN O
and BC2GM052669347 CC O
the BC2GM052669347 DT O
area BC2GM052669347 NN O
of BC2GM052669347 IN O
infarction BC2GM052669347 NN O
decreased BC2GM052669347 VBN O
from BC2GM052669347 IN O
28.9 BC2GM052669347 CD O
+ BC2GM052669347 NNS O
/ BC2GM052669347 SYM O
- BC2GM052669347 : O
1.3 BC2GM052669347 CD O
% BC2GM052669347 NN O
to BC2GM052669347 TO O
15.3 BC2GM052669347 CD O
+ BC2GM052669347 NNS O
/ BC2GM052669347 SYM O
- BC2GM052669347 : O
1.2 BC2GM052669347 CD O
% BC2GM052669347 NN O
( BC2GM052669347 ( O
P BC2GM052669347 NNP O
< BC2GM052669347 NNP O
0.01 BC2GM052669347 CD O
, BC2GM052669347 , O
n BC2GM052669347 RB O
= BC2GM052669347 VBZ O
6 BC2GM052669347 CD O
) BC2GM052669347 ) O
. BC2GM052669347 . O
. . O O

Complete BC2GM052299815 JJ O
activation BC2GM052299815 NN O
of BC2GM052299815 IN O
signal BC2GM052299815 JJ O
transducer BC2GM052299815 NN O
and BC2GM052299815 CC O
activator BC2GM052299815 NN O
of BC2GM052299815 IN O
transcription BC2GM052299815 NN O
1 BC2GM052299815 CD O
( BC2GM052299815 ( O
STAT1 BC2GM052299815 NNP O
) BC2GM052299815 ) O
requires BC2GM052299815 VBZ O
phosphorylation BC2GM052299815 NN O
at BC2GM052299815 IN O
both BC2GM052299815 DT O
Y701 BC2GM052299815 NNP O
and BC2GM052299815 CC O
a BC2GM052299815 DT O
conserved BC2GM052299815 VBN O
PMS BC2GM052299815 NNP O
( BC2GM052299815 ( O
727 BC2GM052299815 CD O
) BC2GM052299815 ) O
P BC2GM052299815 NNP O
sequence BC2GM052299815 NN O
. BC2GM052299815 . O
. . O O

Deletion BC2GM029897790 NN O
mutants BC2GM029897790 NNS O
of BC2GM029897790 IN O
the BC2GM029897790 DT O
human BC2GM029897790 JJ O
CHOP BC2GM029897790 NNP O
promoter BC2GM029897790 NN O
identify BC2GM029897790 VB O
a BC2GM029897790 DT O
region BC2GM029897790 NN O
comprising BC2GM029897790 VBG O
nucleotides BC2GM029897790 NNS O
-75 BC2GM029897790 VBP O
to BC2GM029897790 TO O
-104 BC2GM029897790 VB O
required BC2GM029897790 VBN O
for BC2GM029897790 IN O
both BC2GM029897790 DT O
constitutive BC2GM029897790 JJ O
and BC2GM029897790 CC O
ER-stress-inducible BC2GM029897790 JJ O
expression BC2GM029897790 NN O
. BC2GM029897790 . O
. . O O

In BC2GM036305978 IN O
this BC2GM036305978 DT O
study BC2GM036305978 NN O
, BC2GM036305978 , O
transcriptional BC2GM036305978 JJ O
fusions BC2GM036305978 NNS O
were BC2GM036305978 VBD O
constructed BC2GM036305978 VBN O
between BC2GM036305978 IN O
the BC2GM036305978 DT O
xcpP BC2GM036305978 NNP O
and BC2GM036305978 CC O
xcpR BC2GM036305978 NNP O
genes BC2GM036305978 NNS O
and BC2GM036305978 CC O
the BC2GM036305978 DT O
lacZ BC2GM036305978 JJ O
reporter BC2GM036305978 NN O
. BC2GM036305978 . O
. . O O

New BC2GM023843160 NNP O
, BC2GM023843160 , O
selective BC2GM023843160 JJ O
catechol-O-methyltransferase BC2GM023843160 NN O
inhibitors BC2GM023843160 NNS O
as BC2GM023843160 IN O
therapeutic BC2GM023843160 JJ O
agents BC2GM023843160 NNS O
in BC2GM023843160 IN O
Parkinson BC2GM023843160 NNP O
's BC2GM023843160 POS O
disease BC2GM023843160 NN O
. BC2GM023843160 . O
. . O O

We BC2GM009701774 PRP O
recently BC2GM009701774 RB O
reported BC2GM009701774 VBD O
the BC2GM009701774 DT O
cloning BC2GM009701774 NN O
and BC2GM009701774 CC O
sequencing BC2GM009701774 NN O
of BC2GM009701774 IN O
the BC2GM009701774 DT O
alpha BC2GM009701774 NN O
7 BC2GM009701774 CD O
integrin BC2GM009701774 NN O
chain BC2GM009701774 NN O
and BC2GM009701774 CC O
its BC2GM009701774 PRP$ O
regulated BC2GM009701774 JJ O
expression BC2GM009701774 NN O
during BC2GM009701774 IN O
the BC2GM009701774 DT O
development BC2GM009701774 NN O
of BC2GM009701774 IN O
skeletal BC2GM009701774 JJ O
muscle BC2GM009701774 NN O
( BC2GM009701774 ( O
Song BC2GM009701774 NNP O
et BC2GM009701774 RB O
al BC2GM009701774 NN O
. BC2GM009701774 . O
. . O O

Present BC2GM035562452 JJ O
investigation BC2GM035562452 NN O
was BC2GM035562452 VBD O
undertaken BC2GM035562452 VBN O
to BC2GM035562452 TO O
elucidate BC2GM035562452 VB O
what BC2GM035562452 WP O
pharmacokinetic BC2GM035562452 JJ O
parameters BC2GM035562452 NNS O
in BC2GM035562452 IN O
animal BC2GM035562452 JJ O
experiment BC2GM035562452 NN O
could BC2GM035562452 MD O
be BC2GM035562452 VB O
of BC2GM035562452 IN O
more BC2GM035562452 RBR O
predictable BC2GM035562452 JJ O
for BC2GM035562452 IN O
human BC2GM035562452 JJ O
clinical BC2GM035562452 JJ O
trial BC2GM035562452 NN O
of BC2GM035562452 IN O
beta-blocking BC2GM035562452 JJ O
agents BC2GM035562452 NNS O
. BC2GM035562452 . O
. . O O

The BC2GM081844353 DT O
CBS-1 BC2GM081844353 NNP O
gene BC2GM081844353 NN O
was BC2GM081844353 VBD O
mapped BC2GM081844353 VBN O
to BC2GM081844353 TO O
human BC2GM081844353 JJ O
chromosome BC2GM081844353 NN O
10p12 BC2GM081844353 CD O
between BC2GM081844353 IN O
markers BC2GM081844353 NNS O
WI-8535 BC2GM081844353 NNP O
and BC2GM081844353 CC O
WI-4724 BC2GM081844353 NNP O
, BC2GM081844353 , O
and BC2GM081844353 CC O
is BC2GM081844353 VBZ O
tightly BC2GM081844353 RB O
linked BC2GM081844353 VBN O
to BC2GM081844353 TO O
the BC2GM081844353 DT O
two BC2GM081844353 CD O
STRP BC2GM081844353 NNP O
markers BC2GM081844353 NNS O
of BC2GM081844353 IN O
D10S1789 BC2GM081844353 NNP O
and BC2GM081844353 CC O
D10S550 BC2GM081844353 NNP O
. BC2GM081844353 . O
. . O O

LiF BC2GM077681760 NNP O
thermoluminescence BC2GM077681760 NN O
dosimeters BC2GM077681760 NNS O
( BC2GM077681760 ( O
TLD BC2GM077681760 NNP O
) BC2GM077681760 ) O
in BC2GM077681760 IN O
chip BC2GM077681760 NN O
form BC2GM077681760 NN O
were BC2GM077681760 VBD O
placed BC2GM077681760 VBN O
onto BC2GM077681760 IN O
1 BC2GM077681760 CD O
eyelid BC2GM077681760 NNS O
, BC2GM077681760 , O
the BC2GM077681760 DT O
skin BC2GM077681760 NN O
over BC2GM077681760 IN O
the BC2GM077681760 DT O
thyroid BC2GM077681760 NN O
, BC2GM077681760 , O
and BC2GM077681760 CC O
the BC2GM077681760 DT O
patient BC2GM077681760 NN O
's BC2GM077681760 POS O
clothes BC2GM077681760 NNS O
covering BC2GM077681760 VBG O
the BC2GM077681760 DT O
region BC2GM077681760 NN O
of BC2GM077681760 IN O
breasts BC2GM077681760 NNS O
and BC2GM077681760 CC O
ovaries BC2GM077681760 NNS O
of BC2GM077681760 IN O
female BC2GM077681760 JJ O
patients BC2GM077681760 NNS O
and BC2GM077681760 CC O
the BC2GM077681760 DT O
testicles BC2GM077681760 NNS O
of BC2GM077681760 IN O
male BC2GM077681760 JJ O
patients BC2GM077681760 NNS O
. BC2GM077681760 . O
. . O O

Yet BC2GM006513676 RB O
testosterone BC2GM006513676 NN O
was BC2GM006513676 VBD O
predominant BC2GM006513676 JJ O
in BC2GM006513676 IN O
the BC2GM006513676 DT O
plasma BC2GM006513676 NN O
of BC2GM006513676 IN O
the BC2GM006513676 DT O
Type BC2GM006513676 NNP O
II BC2GM006513676 NNP O
male BC2GM006513676 NN O
morph BC2GM006513676 NN O
which BC2GM006513676 WDT O
neither BC2GM006513676 CC O
courts BC2GM006513676 NNS O
females BC2GM006513676 NNS O
nor BC2GM006513676 CC O
nests BC2GM006513676 NNS O
, BC2GM006513676 , O
but BC2GM006513676 CC O
instead BC2GM006513676 RB O
parasitizes BC2GM006513676 VBZ O
Type BC2GM006513676 NNP O
I BC2GM006513676 PRP O
males BC2GM006513676 VBP O
with BC2GM006513676 IN O
sneak BC2GM006513676 NN O
or BC2GM006513676 CC O
satellite BC2GM006513676 NN O
spawning BC2GM006513676 NN O
tactics BC2GM006513676 NNS O
. BC2GM006513676 . O
. . O O

Advisory BC2GM052166427 NNP O
Committee BC2GM052166427 NNP O
report BC2GM052166427 NN O
recommends BC2GM052166427 VBZ O
that BC2GM052166427 IN O
US BC2GM052166427 NNP O
make BC2GM052166427 VB O
amends BC2GM052166427 NNS O
for BC2GM052166427 IN O
human BC2GM052166427 JJ O
radiation BC2GM052166427 NN O
experiments BC2GM052166427 NNS O
. BC2GM052166427 . O
. . O O

In BC2GM064852247 IN O
addition BC2GM064852247 NN O
, BC2GM064852247 , O
a BC2GM064852247 DT O
double BC2GM064852247 JJ O
mutant BC2GM064852247 NN O
( BC2GM064852247 ( O
E482A BC2GM064852247 NNP O
, BC2GM064852247 , O
D489A BC2GM064852247 NNP O
) BC2GM064852247 ) O
which BC2GM064852247 WDT O
removed BC2GM064852247 VBD O
negative BC2GM064852247 JJ O
charges BC2GM064852247 NNS O
along BC2GM064852247 IN O
one BC2GM064852247 CD O
side BC2GM064852247 NN O
of BC2GM064852247 IN O
the BC2GM064852247 DT O
helix BC2GM064852247 NN O
had BC2GM064852247 VBD O
negligible BC2GM064852247 JJ O
effects BC2GM064852247 NNS O
on BC2GM064852247 IN O
fusion BC2GM064852247 NN O
activity BC2GM064852247 NN O
. BC2GM064852247 . O
. . O O

When BC2GM067017397 WRB O
single-point BC2GM067017397 JJ O
mutation BC2GM067017397 NN O
was BC2GM067017397 VBD O
introduced BC2GM067017397 VBN O
to BC2GM067017397 TO O
each BC2GM067017397 DT O
GC BC2GM067017397 NNP O
box BC2GM067017397 NN O
, BC2GM067017397 , O
EBS BC2GM067017397 NNP O
, BC2GM067017397 , O
and BC2GM067017397 CC O
GT BC2GM067017397 NNP O
box BC2GM067017397 NN O
in BC2GM067017397 IN O
PFP9a20 BC2GM067017397 NNP O
, BC2GM067017397 , O
at BC2GM067017397 IN O
least BC2GM067017397 JJS O
3-fold BC2GM067017397 JJ O
less BC2GM067017397 JJR O
CAT BC2GM067017397 NNP O
activity BC2GM067017397 NN O
was BC2GM067017397 VBD O
observed BC2GM067017397 VBN O
in BC2GM067017397 IN O
CTLL-R8 BC2GM067017397 NNP O
cells BC2GM067017397 NNS O
. BC2GM067017397 . O
. . O O

A BC2GM052715311 DT O
regression BC2GM052715311 NN O
analysis BC2GM052715311 NN O
showed BC2GM052715311 VBD O
that BC2GM052715311 IN O
86 BC2GM052715311 CD O
% BC2GM052715311 NN O
of BC2GM052715311 IN O
the BC2GM052715311 DT O
variance BC2GM052715311 NN O
in BC2GM052715311 IN O
weight BC2GM052715311 JJ O
gain BC2GM052715311 NN O
was BC2GM052715311 VBD O
predicted BC2GM052715311 VBN O
by BC2GM052715311 IN O
two BC2GM052715311 CD O
leading BC2GM052715311 VBG O
indicators BC2GM052715311 NNS O
in BC2GM052715311 IN O
the BC2GM052715311 DT O
middle BC2GM052715311 JJ O
phase BC2GM052715311 NN O
of BC2GM052715311 IN O
treatment BC2GM052715311 NN O
. BC2GM052715311 . O
. . O O

The BC2GM083448203 DT O
effect BC2GM083448203 NN O
of BC2GM083448203 IN O
guaiphenesin BC2GM083448203 NN O
on BC2GM083448203 IN O
absorption BC2GM083448203 NN O
and BC2GM083448203 CC O
bioavailability BC2GM083448203 NN O
of BC2GM083448203 IN O
paracetamol BC2GM083448203 NN O
from BC2GM083448203 IN O
composite BC2GM083448203 JJ O
analgesic BC2GM083448203 JJ O
preparations BC2GM083448203 NNS O
. BC2GM083448203 . O
. . O O

A BC2GM065421759 DT O
third BC2GM065421759 JJ O
GEF BC2GM065421759 NNP O
, BC2GM065421759 , O
GRP3 BC2GM065421759 NNP O
( BC2GM065421759 ( O
KIAA0846 BC2GM065421759 NNP O
) BC2GM065421759 ) O
, BC2GM065421759 , O
activated BC2GM065421759 VBD O
both BC2GM065421759 DT O
Ras BC2GM065421759 NNP O
and BC2GM065421759 CC O
Rap1 BC2GM065421759 NNP O
and BC2GM065421759 CC O
shared BC2GM065421759 VBD O
significant BC2GM065421759 JJ O
sequence BC2GM065421759 NN O
homology BC2GM065421759 NN O
with BC2GM065421759 IN O
the BC2GM065421759 DT O
calcium- BC2GM065421759 JJ O
and BC2GM065421759 CC O
diacylglycerol-activated BC2GM065421759 JJ O
GEFs BC2GM065421759 NNP O
, BC2GM065421759 , O
GRP1 BC2GM065421759 NNP O
and BC2GM065421759 CC O
GRP2 BC2GM065421759 NNP O
. BC2GM065421759 . O
. . O O

The BC2GM033795205 DT O
tensile BC2GM033795205 JJ O
strengths BC2GM033795205 NNS O
of BC2GM033795205 IN O
an BC2GM033795205 DT O
adhesive BC2GM033795205 JJ O
luting BC2GM033795205 NN O
resin BC2GM033795205 NN O
'Panavia BC2GM033795205 POS O
EX BC2GM033795205 NNP O
' BC2GM033795205 POS O
to BC2GM033795205 TO O
the BC2GM033795205 DT O
bovine BC2GM033795205 NN O
dentin BC2GM033795205 NN O
decreased BC2GM033795205 VBN O
significantly BC2GM033795205 RB O
by BC2GM033795205 IN O
the BC2GM033795205 DT O
zinc BC2GM033795205 NN O
iontophoresis BC2GM033795205 NN O
. BC2GM033795205 . O
. . O O

Elements BC2GM025748861 NNS O
regulating BC2GM025748861 VBG O
cell- BC2GM025748861 JJ O
and BC2GM025748861 CC O
stage-specific BC2GM025748861 JJ O
expression BC2GM025748861 NN O
of BC2GM025748861 IN O
the BC2GM025748861 DT O
C. BC2GM025748861 NNP O
elegans BC2GM025748861 VBZ O
MyoD BC2GM025748861 NNP O
family BC2GM025748861 NN O
homolog BC2GM025748861 NN O
hlh-1 BC2GM025748861 NN O
. BC2GM025748861 . O
. . O O

The BC2GM090212976 DT O
cost BC2GM090212976 NN O
and BC2GM090212976 CC O
effectiveness BC2GM090212976 NN O
of BC2GM090212976 IN O
nurse BC2GM090212976 JJ O
education BC2GM090212976 NN O
-- BC2GM090212976 : O
1 BC2GM090212976 CD O
. BC2GM090212976 . O
. . O O

An BC2GM011289618 DT O
81-nt BC2GM011289618 JJ O
tandem BC2GM011289618 NN O
duplication BC2GM011289618 NN O
of BC2GM011289618 IN O
the BC2GM011289618 DT O
C-terminal BC2GM011289618 JJ O
coding BC2GM011289618 NN O
region BC2GM011289618 NN O
is BC2GM011289618 VBZ O
located BC2GM011289618 VBN O
adjacent BC2GM011289618 JJ O
to BC2GM011289618 TO O
the BC2GM011289618 DT O
termination BC2GM011289618 NN O
codon BC2GM011289618 NN O
of BC2GM011289618 IN O
the BC2GM011289618 DT O
CyIIIb BC2GM011289618 NNP O
gene BC2GM011289618 NN O
, BC2GM011289618 , O
a BC2GM011289618 DT O
potential BC2GM011289618 JJ O
relic BC2GM011289618 NN O
of BC2GM011289618 IN O
a BC2GM011289618 DT O
slipped BC2GM011289618 JJ O
mispairing BC2GM011289618 NN O
and BC2GM011289618 CC O
replication BC2GM011289618 NN O
event BC2GM011289618 NN O
. BC2GM011289618 . O
. . O O

Nitroglycerin BC2GM076429520 NNP O
( BC2GM076429520 ( O
glyceryl BC2GM076429520 JJ O
trinitrate BC2GM076429520 NN O
) BC2GM076429520 ) O
as BC2GM076429520 IN O
a BC2GM076429520 DT O
monoamine BC2GM076429520 NN O
oxidase BC2GM076429520 NN O
inhibitor BC2GM076429520 NN O
. BC2GM076429520 . O
. . O O

By BC2GM069744943 IN O
computed BC2GM069744943 JJ O
homology BC2GM069744943 NN O
search BC2GM069744943 NN O
, BC2GM069744943 , O
we BC2GM069744943 PRP O
noticed BC2GM069744943 VBD O
significant BC2GM069744943 JJ O
similarities BC2GM069744943 NNS O
between BC2GM069744943 IN O
US3 BC2GM069744943 NNP O
PK BC2GM069744943 NNP O
and BC2GM069744943 CC O
p21-activated BC2GM069744943 JJ O
kinase BC2GM069744943 NN O
( BC2GM069744943 ( O
PAK BC2GM069744943 NNP O
) BC2GM069744943 ) O
, BC2GM069744943 , O
which BC2GM069744943 WDT O
is BC2GM069744943 VBZ O
activated BC2GM069744943 VBN O
by BC2GM069744943 IN O
the BC2GM069744943 DT O
Cdc42 BC2GM069744943 NNP O
or BC2GM069744943 CC O
Rac BC2GM069744943 NNP O
. BC2GM069744943 . O
. . O O

Recombinant BC2GM014138510 JJ O
Human BC2GM014138510 NNP O
Erythropoietin BC2GM014138510 NNP O
and BC2GM014138510 CC O
Platinum-Based BC2GM014138510 JJ O
Chemotherapy BC2GM014138510 NNP O
In BC2GM014138510 IN O
Advanced BC2GM014138510 NNP O
Ovarian BC2GM014138510 NNP O
Cancer BC2GM014138510 NNP O
. BC2GM014138510 . O
. . O O

The BC2GM092826848 DT O
molecular BC2GM092826848 JJ O
dynamics BC2GM092826848 NNS O
simulations BC2GM092826848 NNS O
provide BC2GM092826848 VBP O
insight BC2GM092826848 RB O
into BC2GM092826848 IN O
the BC2GM092826848 DT O
conformational BC2GM092826848 JJ O
flexibility BC2GM092826848 NN O
of BC2GM092826848 IN O
these BC2GM092826848 DT O
analogs BC2GM092826848 NNS O
. BC2GM092826848 . O
. . O O

This BC2GM078538527 DT O
finding BC2GM078538527 NN O
is BC2GM078538527 VBZ O
of BC2GM078538527 IN O
importance BC2GM078538527 NN O
because BC2GM078538527 IN O
it BC2GM078538527 PRP O
completes BC2GM078538527 VBZ O
an BC2GM078538527 DT O
explanation BC2GM078538527 NN O
for BC2GM078538527 IN O
central BC2GM078538527 JJ O
near-location BC2GM078538527 JJ O
errors BC2GM078538527 NNS O
in BC2GM078538527 IN O
the BC2GM078538527 DT O
partial-report BC2GM078538527 JJ O
bar-probe BC2GM078538527 NN O
task BC2GM078538527 NN O
. BC2GM078538527 . O
. . O O

Immunologic BC2GM021508246 JJ O
tolerance BC2GM021508246 NN O
in BC2GM021508246 IN O
rats BC2GM021508246 NNS O
during BC2GM021508246 IN O
13 BC2GM021508246 CD O
weeks BC2GM021508246 NNS O
of BC2GM021508246 IN O
inhalation BC2GM021508246 NN O
exposure BC2GM021508246 NN O
to BC2GM021508246 TO O
trimellitic BC2GM021508246 JJ O
anhydride BC2GM021508246 NN O
. BC2GM021508246 . O
. . O O

The BC2GM096394711 DT O
atopic BC2GM096394711 NN O
disposition BC2GM096394711 NN O
, BC2GM096394711 , O
indicated BC2GM096394711 VBN O
by BC2GM096394711 IN O
positive BC2GM096394711 JJ O
skin BC2GM096394711 NN O
reactions BC2GM096394711 NNS O
and BC2GM096394711 CC O
IgE BC2GM096394711 NNP O
antibody BC2GM096394711 NN O
titers BC2GM096394711 NNS O
etc. BC2GM096394711 VBP O
, BC2GM096394711 , O
and BC2GM096394711 CC O
the BC2GM096394711 DT O
bronchial BC2GM096394711 JJ O
reactivity BC2GM096394711 NN O
to BC2GM096394711 TO O
inhaled BC2GM096394711 VB O
acetylcholine BC2GM096394711 NN O
were BC2GM096394711 VBD O
examined BC2GM096394711 VBN O
on BC2GM096394711 IN O
the BC2GM096394711 DT O
following BC2GM096394711 JJ O
three BC2GM096394711 CD O
groups BC2GM096394711 NNS O
: BC2GM096394711 : O
( BC2GM096394711 ( O
1 BC2GM096394711 CD O
) BC2GM096394711 ) O
20 BC2GM096394711 CD O
young BC2GM096394711 JJ O
adults BC2GM096394711 NNS O
with BC2GM096394711 IN O
a BC2GM096394711 DT O
history BC2GM096394711 NN O
of BC2GM096394711 IN O
childhood BC2GM096394711 NN O
asthma BC2GM096394711 NN O
who BC2GM096394711 WP O
have BC2GM096394711 VBP O
been BC2GM096394711 VBN O
symptom-free BC2GM096394711 JJ O
for BC2GM096394711 IN O
more BC2GM096394711 JJR O
than BC2GM096394711 IN O
4 BC2GM096394711 CD O
yr BC2GM096394711 NN O
; BC2GM096394711 : O
( BC2GM096394711 ( O
2 BC2GM096394711 CD O
) BC2GM096394711 ) O
20 BC2GM096394711 CD O
current BC2GM096394711 JJ O
asthmatics BC2GM096394711 NNS O
, BC2GM096394711 , O
and BC2GM096394711 CC O
( BC2GM096394711 ( O
3 BC2GM096394711 CD O
) BC2GM096394711 ) O
20 BC2GM096394711 CD O
healthy BC2GM096394711 JJ O
young BC2GM096394711 JJ O
adults BC2GM096394711 NNS O
. BC2GM096394711 . O
. . O O

Sailer BC2GM081815204 NNP O
, BC2GM081815204 , O
K BC2GM081815204 NNP O
. BC2GM081815204 . O
. . O O

Using BC2GM066315892 VBG O
in BC2GM066315892 IN O
vivo BC2GM066315892 JJ O
genomic BC2GM066315892 JJ O
dimethyl BC2GM066315892 NN O
sulfate BC2GM066315892 NN O
and BC2GM066315892 CC O
KMnO4 BC2GM066315892 NNP O
footprinting BC2GM066315892 NN O
, BC2GM066315892 , O
we BC2GM066315892 PRP O
showed BC2GM066315892 VBD O
that BC2GM066315892 IN O
the BC2GM066315892 DT O
promoter BC2GM066315892 NN O
region BC2GM066315892 NN O
is BC2GM066315892 VBZ O
differentially BC2GM066315892 RB O
protected BC2GM066315892 VBN O
, BC2GM066315892 , O
depending BC2GM066315892 VBG O
upon BC2GM066315892 IN O
which BC2GM066315892 WDT O
holoenzyme BC2GM066315892 NN O
is BC2GM066315892 VBZ O
bound BC2GM066315892 VBN O
. BC2GM066315892 . O
. . O O

Gastrointestinal BC2GM085878325 JJ O
accumulation BC2GM085878325 NN O
of BC2GM085878325 IN O
indium-111 BC2GM085878325 NN O
labelled BC2GM085878325 VBN O
granulocytes BC2GM085878325 NNS O
in BC2GM085878325 IN O
reactive BC2GM085878325 JJ O
arthritis BC2GM085878325 NN O
. BC2GM085878325 . O
. . O O

Basal BC2GM009941081 NNP O
level BC2GM009941081 NN O
expression BC2GM009941081 NN O
was BC2GM009941081 VBD O
reduced BC2GM009941081 VBN O
to BC2GM009941081 TO O
20 BC2GM009941081 CD O
and BC2GM009941081 CC O
50 BC2GM009941081 CD O
% BC2GM009941081 NN O
when BC2GM009941081 WRB O
the BC2GM009941081 DT O
UGA BC2GM009941081 NNP O
stop BC2GM009941081 NN O
codon BC2GM009941081 NN O
was BC2GM009941081 VBD O
replaced BC2GM009941081 VBN O
by BC2GM009941081 IN O
UAG BC2GM009941081 NNP O
or BC2GM009941081 CC O
UAA BC2GM009941081 NNP O
, BC2GM009941081 , O
respectively BC2GM009941081 RB O
, BC2GM009941081 , O
consistent BC2GM009941081 JJ O
with BC2GM009941081 IN O
the BC2GM009941081 DT O
finding BC2GM009941081 NN O
that BC2GM009941081 IN O
in BC2GM009941081 IN O
E. BC2GM009941081 NNP O
coli BC2GM009941081 NNS O
translation BC2GM009941081 NN O
terminates BC2GM009941081 VBZ O
more BC2GM009941081 RBR O
efficiently BC2GM009941081 RB O
at BC2GM009941081 IN O
UAG BC2GM009941081 NNP O
and BC2GM009941081 CC O
UAA BC2GM009941081 NNP O
than BC2GM009941081 IN O
at BC2GM009941081 IN O
UGA BC2GM009941081 NNP O
. BC2GM009941081 . O
. . O O

The BC2GM035866321 DT O
Gastrointestinal BC2GM035866321 NNP O
Tumor BC2GM035866321 NNP O
Study BC2GM035866321 NNP O
Group BC2GM035866321 NNP O
( BC2GM035866321 ( O
GITSG BC2GM035866321 NNP O
) BC2GM035866321 ) O
protocol BC2GM035866321 VBD O
GI-7175 BC2GM035866321 NNP O
randomized BC2GM035866321 VBD O
227 BC2GM035866321 CD O
patients BC2GM035866321 NNS O
between BC2GM035866321 IN O
1975 BC2GM035866321 CD O
and BC2GM035866321 CC O
1980 BC2GM035866321 CD O
following BC2GM035866321 VBG O
complete BC2GM035866321 JJ O
surgical BC2GM035866321 JJ O
resection BC2GM035866321 NN O
of BC2GM035866321 IN O
stages BC2GM035866321 NNS O
B2 BC2GM035866321 NNP O
and BC2GM035866321 CC O
C BC2GM035866321 NNP O
rectal BC2GM035866321 JJ O
adenocarcinoma BC2GM035866321 NN O
to BC2GM035866321 TO O
four BC2GM035866321 CD O
treatment BC2GM035866321 NN O
arms BC2GM035866321 NNS O
: BC2GM035866321 : O
( BC2GM035866321 ( O
1 BC2GM035866321 CD O
) BC2GM035866321 ) O
no BC2GM035866321 DT O
adjuvant BC2GM035866321 JJ O
therapy BC2GM035866321 NN O
, BC2GM035866321 , O
( BC2GM035866321 ( O
2 BC2GM035866321 CD O
) BC2GM035866321 ) O
chemotherapy BC2GM035866321 NN O
only BC2GM035866321 RB O
, BC2GM035866321 , O
( BC2GM035866321 ( O
3 BC2GM035866321 CD O
) BC2GM035866321 ) O
radiotherapy BC2GM035866321 NN O
only BC2GM035866321 RB O
, BC2GM035866321 , O
and BC2GM035866321 CC O
( BC2GM035866321 ( O
4 BC2GM035866321 CD O
) BC2GM035866321 ) O
radiotherapy BC2GM035866321 NN O
and BC2GM035866321 CC O
chemotherapy BC2GM035866321 NN O
( BC2GM035866321 ( O
combined BC2GM035866321 JJ O
modality BC2GM035866321 NN O
) BC2GM035866321 ) O
. BC2GM035866321 . O
. . O O

Two BC2GM095573888 CD O
mutants BC2GM095573888 NNS O
, BC2GM095573888 , O
mapping BC2GM095573888 VBG O
at BC2GM095573888 IN O
the BC2GM095573888 DT O
HindIII BC2GM095573888 NNP O
site BC2GM095573888 NN O
( BC2GM095573888 ( O
between BC2GM095573888 IN O
the BC2GM095573888 DT O
consensus BC2GM095573888 NN O
sequences BC2GM095573888 VBZ O
) BC2GM095573888 ) O
of BC2GM095573888 IN O
the BC2GM095573888 DT O
pSC101 BC2GM095573888 NN O
tetA BC2GM095573888 NN O
promoter BC2GM095573888 NN O
, BC2GM095573888 , O
were BC2GM095573888 VBD O
studied BC2GM095573888 VBN O
: BC2GM095573888 : O
MA2 BC2GM095573888 NNP O
corresponds BC2GM095573888 VBZ O
to BC2GM095573888 TO O
a BC2GM095573888 DT O
4 BC2GM095573888 CD O
bp BC2GM095573888 NN O
deletion BC2GM095573888 NN O
between BC2GM095573888 IN O
positions BC2GM095573888 NNS O
-12 BC2GM095573888 NNP O
and BC2GM095573888 CC O
-15 BC2GM095573888 NNP O
; BC2GM095573888 : O
B30 BC2GM095573888 NNP O
bears BC2GM095573888 VBZ O
a BC2GM095573888 DT O
44 BC2GM095573888 CD O
bp BC2GM095573888 NN O
insertion BC2GM095573888 NN O
C BC2GM095573888 NNP O
( BC2GM095573888 ( O
TA BC2GM095573888 NNP O
) BC2GM095573888 ) O
21 BC2GM095573888 CD O
G BC2GM095573888 NNP O
at BC2GM095573888 IN O
the BC2GM095573888 DT O
HindIII BC2GM095573888 NNP O
site BC2GM095573888 NN O
. BC2GM095573888 . O
. . O O

AU-rich BC2GM052871586 JJ O
elements BC2GM052871586 NNS O
in BC2GM052871586 IN O
the BC2GM052871586 DT O
3'-untranslated BC2GM052871586 JJ O
region BC2GM052871586 NN O
of BC2GM052871586 IN O
a BC2GM052871586 DT O
new BC2GM052871586 JJ O
mucin-type BC2GM052871586 JJ O
gene BC2GM052871586 NN O
family BC2GM052871586 NN O
of BC2GM052871586 IN O
Trypanosoma BC2GM052871586 NNP O
cruzi BC2GM052871586 NN O
confers BC2GM052871586 NNS O
mRNA BC2GM052871586 VBP O
instability BC2GM052871586 NN O
and BC2GM052871586 CC O
modulates BC2GM052871586 VBZ O
translation BC2GM052871586 NN O
efficiency BC2GM052871586 NN O
. BC2GM052871586 . O
. . O O

The BC2GM081102567 DT O
three BC2GM081102567 CD O
respective BC2GM081102567 JJ O
time BC2GM081102567 NN O
control BC2GM081102567 NN O
groups BC2GM081102567 NNS O
( BC2GM081102567 ( O
C5 BC2GM081102567 NNP O
, BC2GM081102567 , O
C10 BC2GM081102567 NNP O
, BC2GM081102567 , O
and BC2GM081102567 CC O
C15 BC2GM081102567 NNP O
) BC2GM081102567 ) O
were BC2GM081102567 VBD O
injected BC2GM081102567 VBN O
with BC2GM081102567 IN O
saline BC2GM081102567 JJ O
solution BC2GM081102567 NN O
. BC2GM081102567 . O
. . O O

Binding BC2GM041356222 NNP O
of BC2GM041356222 IN O
C BC2GM041356222 NNP O
/ BC2GM041356222 NNP O
EBPs BC2GM041356222 NNP O
to BC2GM041356222 TO O
all BC2GM041356222 DT O
three BC2GM041356222 CD O
spi BC2GM041356222 VBD O
2.3 BC2GM041356222 CD O
3 BC2GM041356222 CD O
' BC2GM041356222 '' O
UTR BC2GM041356222 NNP O
repressor BC2GM041356222 NN O
sites BC2GM041356222 NNS O
, BC2GM041356222 , O
although BC2GM041356222 IN O
rather BC2GM041356222 RB O
weak BC2GM041356222 JJ O
, BC2GM041356222 , O
was BC2GM041356222 VBD O
confirmed BC2GM041356222 VBN O
by BC2GM041356222 IN O
electrophoretic BC2GM041356222 JJ O
mobility BC2GM041356222 NN O
shift BC2GM041356222 NN O
assays BC2GM041356222 VBZ O
that BC2GM041356222 IN O
otherwise BC2GM041356222 RB O
failed BC2GM041356222 VBD O
to BC2GM041356222 TO O
reveal BC2GM041356222 VB O
specific BC2GM041356222 JJ O
interactions BC2GM041356222 NNS O
with BC2GM041356222 IN O
other BC2GM041356222 JJ O
liver BC2GM041356222 JJ O
nuclear BC2GM041356222 JJ O
proteins BC2GM041356222 NNS O
in BC2GM041356222 IN O
vitro BC2GM041356222 NN O
. BC2GM041356222 . O
. . O O

Large BC2GM006829575 JJ O
volumes BC2GM006829575 NNS O
of BC2GM006829575 IN O
bone BC2GM006829575 NN O
marrow BC2GM006829575 NN O
may BC2GM006829575 MD O
be BC2GM006829575 VB O
required BC2GM006829575 VBN O
for BC2GM006829575 IN O
certain BC2GM006829575 JJ O
types BC2GM006829575 NNS O
of BC2GM006829575 IN O
autologous BC2GM006829575 JJ O
bone BC2GM006829575 NN O
marrow BC2GM006829575 NN O
transplants BC2GM006829575 NNS O
. BC2GM006829575 . O
. . O O

In BC2GM016633318 IN O
two BC2GM016633318 CD O
separate BC2GM016633318 JJ O
studies BC2GM016633318 NNS O
, BC2GM016633318 , O
specimens BC2GM016633318 NNS O
of BC2GM016633318 IN O
saliva BC2GM016633318 NN O
from BC2GM016633318 IN O
57 BC2GM016633318 CD O
individuals BC2GM016633318 NNS O
over BC2GM016633318 IN O
the BC2GM016633318 DT O
age BC2GM016633318 NN O
of BC2GM016633318 IN O
65 BC2GM016633318 CD O
years BC2GM016633318 NNS O
( BC2GM016633318 ( O
mean BC2GM016633318 JJ O
age BC2GM016633318 NN O
, BC2GM016633318 , O
76.7 BC2GM016633318 CD O
years BC2GM016633318 NNS O
) BC2GM016633318 ) O
and BC2GM016633318 CC O
37 BC2GM016633318 CD O
persons BC2GM016633318 NNS O
under BC2GM016633318 IN O
the BC2GM016633318 DT O
age BC2GM016633318 NN O
of BC2GM016633318 IN O
40 BC2GM016633318 CD O
years BC2GM016633318 NNS O
( BC2GM016633318 ( O
mean BC2GM016633318 JJ O
age BC2GM016633318 NN O
, BC2GM016633318 , O
28.8 BC2GM016633318 CD O
years BC2GM016633318 NNS O
) BC2GM016633318 ) O
were BC2GM016633318 VBD O
examined BC2GM016633318 VBN O
for BC2GM016633318 IN O
concentrations BC2GM016633318 NNS O
of BC2GM016633318 IN O
IgA BC2GM016633318 NNP O
as BC2GM016633318 IN O
functions BC2GM016633318 NNS O
of BC2GM016633318 IN O
volume BC2GM016633318 NN O
, BC2GM016633318 , O
total BC2GM016633318 JJ O
protein BC2GM016633318 NN O
, BC2GM016633318 , O
and BC2GM016633318 CC O
electrolyte BC2GM016633318 JJ O
conductivity BC2GM016633318 NN O
; BC2GM016633318 : O
some BC2GM016633318 DT O
were BC2GM016633318 VBD O
also BC2GM016633318 RB O
tested BC2GM016633318 VBN O
for BC2GM016633318 IN O
IgG BC2GM016633318 NNP O
and BC2GM016633318 CC O
IgM BC2GM016633318 NNP O
content BC2GM016633318 NN O
. BC2GM016633318 . O
. . O O

Elevated BC2GM051322057 JJ O
potassium BC2GM051322057 NN O
stimulation BC2GM051322057 NN O
of BC2GM051322057 IN O
GAL BC2GM051322057 NNP O
mRNA BC2GM051322057 NN O
was BC2GM051322057 VBD O
completely BC2GM051322057 RB O
blocked BC2GM051322057 VBN O
, BC2GM051322057 , O
but BC2GM051322057 CC O
pituitary BC2GM051322057 JJ O
adenylyl BC2GM051322057 NN O
cyclase-activating BC2GM051322057 JJ O
polypeptide BC2GM051322057 NN O
and BC2GM051322057 CC O
histamine BC2GM051322057 JJ O
stimulations BC2GM051322057 NNS O
were BC2GM051322057 VBD O
only BC2GM051322057 RB O
partially BC2GM051322057 RB O
blocked BC2GM051322057 VBN O
, BC2GM051322057 , O
by BC2GM051322057 IN O
cycloheximide BC2GM051322057 NN O
. BC2GM051322057 . O
. . O O

Signaling BC2GM099774461 VBG O
through BC2GM099774461 IN O
mitogen-activated BC2GM099774461 JJ O
protein BC2GM099774461 NN O
kinase BC2GM099774461 NN O
and BC2GM099774461 CC O
Rac BC2GM099774461 NNP O
/ BC2GM099774461 NNP O
Rho BC2GM099774461 NNP O
does BC2GM099774461 VBZ O
not BC2GM099774461 RB O
duplicate BC2GM099774461 VB O
the BC2GM099774461 DT O
effects BC2GM099774461 NNS O
of BC2GM099774461 IN O
activated BC2GM099774461 JJ O
Ras BC2GM099774461 NNP O
on BC2GM099774461 IN O
skeletal BC2GM099774461 JJ O
myogenesis BC2GM099774461 NN O
. BC2GM099774461 . O
. . O O

Two BC2GM096590375 CD O
genes BC2GM096590375 NNS O
( BC2GM096590375 ( O
ptsI BC2GM096590375 NN O
and BC2GM096590375 CC O
ptsA BC2GM096590375 NN O
) BC2GM096590375 ) O
that BC2GM096590375 WDT O
encode BC2GM096590375 VBP O
homologues BC2GM096590375 NNS O
of BC2GM096590375 IN O
the BC2GM096590375 DT O
energy BC2GM096590375 NN O
coupling BC2GM096590375 VBG O
Enzyme BC2GM096590375 NNP O
I BC2GM096590375 PRP O
of BC2GM096590375 IN O
the BC2GM096590375 DT O
phosphoenolpyruvate-dependent BC2GM096590375 JJ O
sugar-transporting BC2GM096590375 JJ O
phosphotransferase BC2GM096590375 NN O
system BC2GM096590375 NN O
( BC2GM096590375 ( O
PTS BC2GM096590375 NNP O
) BC2GM096590375 ) O
have BC2GM096590375 VBP O
previously BC2GM096590375 RB O
been BC2GM096590375 VBN O
identified BC2GM096590375 VBN O
on BC2GM096590375 IN O
the BC2GM096590375 DT O
Escherichia BC2GM096590375 NNP O
coli BC2GM096590375 VBZ O
chromosome BC2GM096590375 NN O
. BC2GM096590375 . O
. . O O

Since BC2GM019141094 IN O
1988 BC2GM019141094 CD O
Modulit-SZ-20 BC2GM019141094 NNP O
has BC2GM019141094 VBZ O
been BC2GM019141094 VBN O
tested BC2GM019141094 VBN O
for BC2GM019141094 IN O
localization BC2GM019141094 NN O
of BC2GM019141094 IN O
nephroliths BC2GM019141094 NNS O
and BC2GM019141094 CC O
ureteroliths BC2GM019141094 NNS O
. BC2GM019141094 . O
. . O O

This BC2GM068393922 DT O
pathway BC2GM068393922 NN O
has BC2GM068393922 VBZ O
been BC2GM068393922 VBN O
reported BC2GM068393922 VBN O
to BC2GM068393922 TO O
mediate BC2GM068393922 VB O
heterodimer BC2GM068393922 JJ O
interactions BC2GM068393922 NNS O
with BC2GM068393922 IN O
the BC2GM068393922 DT O
proapoptotic BC2GM068393922 JJ O
regulator BC2GM068393922 NN O
, BC2GM068393922 , O
Bad BC2GM068393922 NNP O
. BC2GM068393922 . O
. . O O

To BC2GM004241014 TO O
investigate BC2GM004241014 VB O
this BC2GM004241014 DT O
issue BC2GM004241014 NN O
, BC2GM004241014 , O
we BC2GM004241014 PRP O
used BC2GM004241014 VBD O
a BC2GM004241014 DT O
recognition BC2GM004241014 NN O
task BC2GM004241014 NN O
in BC2GM004241014 IN O
which BC2GM004241014 WDT O
two BC2GM004241014 CD O
strings BC2GM004241014 NNS O
of BC2GM004241014 IN O
letters BC2GM004241014 NNS O
are BC2GM004241014 VBP O
presented BC2GM004241014 VBN O
sequentially BC2GM004241014 RB O
. BC2GM004241014 . O
. . O O

DNMT2 BC2GM061129675 NNP O
binds BC2GM061129675 VBZ O
AdoHcy BC2GM061129675 NNP O
in BC2GM061129675 IN O
the BC2GM061129675 DT O
same BC2GM061129675 JJ O
conformation BC2GM061129675 NN O
as BC2GM061129675 IN O
confirmed BC2GM061129675 VBN O
m BC2GM061129675 NN O
( BC2GM061129675 ( O
5 BC2GM061129675 CD O
) BC2GM061129675 ) O
C BC2GM061129675 NNP O
MTases BC2GM061129675 NNP O
and BC2GM061129675 CC O
, BC2GM061129675 , O
while BC2GM061129675 IN O
DNMT2 BC2GM061129675 NNP O
shares BC2GM061129675 NNS O
all BC2GM061129675 DT O
sequence BC2GM061129675 NN O
and BC2GM061129675 CC O
structural BC2GM061129675 JJ O
features BC2GM061129675 NNS O
with BC2GM061129675 IN O
m BC2GM061129675 NN O
( BC2GM061129675 ( O
5 BC2GM061129675 CD O
) BC2GM061129675 ) O
C BC2GM061129675 NNP O
MTases BC2GM061129675 NNP O
, BC2GM061129675 , O
it BC2GM061129675 PRP O
has BC2GM061129675 VBZ O
failed BC2GM061129675 VBN O
to BC2GM061129675 TO O
demonstrate BC2GM061129675 VB O
detectable BC2GM061129675 JJ O
transmethylase BC2GM061129675 NN O
activity BC2GM061129675 NN O
. BC2GM061129675 . O
. . O O

Significance BC2GM050066357 NN O
of BC2GM050066357 IN O
esophagocardiac BC2GM050066357 JJ O
reflexes BC2GM050066357 NNS O
for BC2GM050066357 IN O
inducing BC2GM050066357 VBG O
thoracic BC2GM050066357 NN O
pain BC2GM050066357 NN O
. BC2GM050066357 . O
. . O O

In BC2GM091017201 IN O
the BC2GM091017201 DT O
promoters BC2GM091017201 NNS O
of BC2GM091017201 IN O
many BC2GM091017201 JJ O
immediate BC2GM091017201 VBP O
early BC2GM091017201 JJ O
genes BC2GM091017201 NNS O
, BC2GM091017201 , O
including BC2GM091017201 VBG O
c-fos BC2GM091017201 NN O
, BC2GM091017201 , O
CArG BC2GM091017201 NNP O
DNA BC2GM091017201 NNP O
regulatory BC2GM091017201 JJ O
elements BC2GM091017201 NNS O
mediate BC2GM091017201 VBP O
basal BC2GM091017201 JJ O
constituitive BC2GM091017201 JJ O
expression BC2GM091017201 NN O
and BC2GM091017201 CC O
rapid BC2GM091017201 JJ O
and BC2GM091017201 CC O
transient BC2GM091017201 JJ O
serum BC2GM091017201 NN O
induction BC2GM091017201 NN O
. BC2GM091017201 . O
. . O O

Comparison BC2GM003905153 NNP O
of BC2GM003905153 IN O
the BC2GM003905153 DT O
therapeutic BC2GM003905153 JJ O
effectiveness BC2GM003905153 NN O
of BC2GM003905153 IN O
membrane BC2GM003905153 NN O
and BC2GM003905153 CC O
centrifugation BC2GM003905153 NN O
plasmapheresis BC2GM003905153 NN O
. BC2GM003905153 . O
. . O O

Our BC2GM034925448 PRP$ O
results BC2GM034925448 NNS O
showed BC2GM034925448 VBD O
that BC2GM034925448 IN O
the BC2GM034925448 DT O
5-hydroxytryptamine BC2GM034925448 JJ O
( BC2GM034925448 ( O
5-HT BC2GM034925448 JJ O
) BC2GM034925448 ) O
content BC2GM034925448 NN O
in BC2GM034925448 IN O
platelets BC2GM034925448 NNS O
was BC2GM034925448 VBD O
: BC2GM034925448 : O
( BC2GM034925448 ( O
1 BC2GM034925448 CD O
) BC2GM034925448 ) O
increased BC2GM034925448 VBN O
in BC2GM034925448 IN O
the BC2GM034925448 DT O
subgroup BC2GM034925448 NN O
of BC2GM034925448 IN O
anti-social BC2GM034925448 JJ O
alcoholics BC2GM034925448 NNS O
; BC2GM034925448 : O
( BC2GM034925448 ( O
2 BC2GM034925448 CD O
) BC2GM034925448 ) O
transiently BC2GM034925448 RB O
and BC2GM034925448 CC O
differently BC2GM034925448 RB O
altered BC2GM034925448 VBN O
in BC2GM034925448 IN O
alcoholics BC2GM034925448 NNS O
compared BC2GM034925448 VBN O
to BC2GM034925448 TO O
opiate BC2GM034925448 VB O
addicts BC2GM034925448 NNS O
; BC2GM034925448 : O
and BC2GM034925448 CC O
( BC2GM034925448 ( O
3 BC2GM034925448 CD O
) BC2GM034925448 ) O
lowered BC2GM034925448 VBD O
in BC2GM034925448 IN O
drinking BC2GM034925448 NN O
alcoholics BC2GM034925448 NNS O
and BC2GM034925448 CC O
normal BC2GM034925448 JJ O
in BC2GM034925448 IN O
alcoholics BC2GM034925448 NNS O
who BC2GM034925448 WP O
were BC2GM034925448 VBD O
drinking BC2GM034925448 VBG O
as BC2GM034925448 RB O
well BC2GM034925448 RB O
as BC2GM034925448 IN O
smoking BC2GM034925448 NN O
( BC2GM034925448 ( O
that BC2GM034925448 WDT O
may BC2GM034925448 MD O
occur BC2GM034925448 VB O
via BC2GM034925448 IN O
MAO-B BC2GM034925448 NNP O
inhibition BC2GM034925448 NN O
by BC2GM034925448 IN O
smoke BC2GM034925448 NN O
) BC2GM034925448 ) O
. BC2GM034925448 . O
. . O O

The BC2GM053114631 DT O
Polycomb BC2GM053114631 NNP O
group BC2GM053114631 NN O
proteins BC2GM053114631 NNS O
are BC2GM053114631 VBP O
involved BC2GM053114631 VBN O
in BC2GM053114631 IN O
maintenance BC2GM053114631 NN O
of BC2GM053114631 IN O
the BC2GM053114631 DT O
silenced BC2GM053114631 JJ O
state BC2GM053114631 NN O
of BC2GM053114631 IN O
several BC2GM053114631 JJ O
developmentally BC2GM053114631 RB O
regulated BC2GM053114631 VBN O
genes BC2GM053114631 NNS O
. BC2GM053114631 . O
. . O O

Earlier BC2GM046485760 JJR O
reports BC2GM046485760 NNS O
have BC2GM046485760 VBP O
localized BC2GM046485760 VBN O
mutations BC2GM046485760 NNS O
which BC2GM046485760 WDT O
affect BC2GM046485760 VBP O
the BC2GM046485760 DT O
processing BC2GM046485760 NN O
and BC2GM046485760 CC O
transport BC2GM046485760 NN O
of BC2GM046485760 IN O
herpes BC2GM046485760 NNS O
simplex BC2GM046485760 JJ O
virus BC2GM046485760 NN O
1 BC2GM046485760 CD O
glycoproteins BC2GM046485760 NNS O
to BC2GM046485760 TO O
a BC2GM046485760 DT O
region BC2GM046485760 NN O
located BC2GM046485760 VBN O
between BC2GM046485760 IN O
the BC2GM046485760 DT O
genes BC2GM046485760 NNS O
specifying BC2GM046485760 VBG O
glycoprotein BC2GM046485760 NN O
B BC2GM046485760 NNP O
and BC2GM046485760 CC O
the BC2GM046485760 DT O
major BC2GM046485760 JJ O
viral BC2GM046485760 JJ O
DNA-binding BC2GM046485760 NNP O
protein BC2GM046485760 NN O
( BC2GM046485760 ( O
beta BC2GM046485760 IN O
8 BC2GM046485760 CD O
) BC2GM046485760 ) O
. BC2GM046485760 . O
. . O O

This BC2GM013779301 DT O
communication BC2GM013779301 NN O
presents BC2GM013779301 VBZ O
two BC2GM013779301 CD O
patients BC2GM013779301 NNS O
with BC2GM013779301 IN O
clinically BC2GM013779301 RB O
massive BC2GM013779301 JJ O
PE BC2GM013779301 NNP O
of BC2GM013779301 IN O
recent BC2GM013779301 JJ O
onset BC2GM013779301 NN O
( BC2GM013779301 ( O
confirmed BC2GM013779301 VBN O
by BC2GM013779301 IN O
lung BC2GM013779301 NN O
perfusion BC2GM013779301 NN O
scans BC2GM013779301 NNS O
) BC2GM013779301 ) O
who BC2GM013779301 WP O
were BC2GM013779301 VBD O
successfully BC2GM013779301 RB O
treated BC2GM013779301 VBN O
with BC2GM013779301 IN O
a BC2GM013779301 DT O
single BC2GM013779301 JJ O
i.v BC2GM013779301 NN O
. BC2GM013779301 . O
dose BC2GM013779301 NN O
of BC2GM013779301 IN O
30 BC2GM013779301 CD O
mg BC2GM013779301 NN O
of BC2GM013779301 IN O
anisoylated BC2GM013779301 JJ O
lys-plasminogen BC2GM013779301 JJ O
streptokinase BC2GM013779301 NN O
activator BC2GM013779301 NN O
complex BC2GM013779301 NN O
( BC2GM013779301 ( O
APSAC BC2GM013779301 NNP O
, BC2GM013779301 , O
comparable BC2GM013779301 JJ O
to BC2GM013779301 TO O
1,500,000 BC2GM013779301 CD O
U BC2GM013779301 NNP O
of BC2GM013779301 IN O
streptokinase BC2GM013779301 NN O
) BC2GM013779301 ) O
followed BC2GM013779301 VBN O
by BC2GM013779301 IN O
systemic BC2GM013779301 JJ O
heparinization BC2GM013779301 NN O
for BC2GM013779301 IN O
7 BC2GM013779301 CD O
days BC2GM013779301 NNS O
. BC2GM013779301 . O
. . O O

The BC2GM089043766 DT O
present BC2GM089043766 JJ O
study BC2GM089043766 NN O
demonstrates BC2GM089043766 VBZ O
that BC2GM089043766 IN O
the BC2GM089043766 DT O
proto-oncogene BC2GM089043766 JJ O
c-jun BC2GM089043766 JJ O
represses BC2GM089043766 NNS O
transcription BC2GM089043766 NN O
of BC2GM089043766 IN O
the BC2GM089043766 DT O
human BC2GM089043766 JJ O
CG BC2GM089043766 NNP O
alpha BC2GM089043766 NN O
and BC2GM089043766 CC O
CG BC2GM089043766 NNP O
beta BC2GM089043766 NN O
promoters BC2GM089043766 NNS O
. BC2GM089043766 . O
c-Jun BC2GM089043766 NN O
repressed BC2GM089043766 VBD O
the BC2GM089043766 DT O
CG BC2GM089043766 NNP O
alpha BC2GM089043766 NN O
promoter BC2GM089043766 NN O
through BC2GM089043766 IN O
a BC2GM089043766 DT O
canonical BC2GM089043766 JJ O
cAMP BC2GM089043766 NN O
response BC2GM089043766 NN O
element BC2GM089043766 NN O
( BC2GM089043766 ( O
CRE BC2GM089043766 NNP O
) BC2GM089043766 ) O
that BC2GM089043766 WDT O
is BC2GM089043766 VBZ O
known BC2GM089043766 VBN O
to BC2GM089043766 TO O
bind BC2GM089043766 VB O
c-Jun BC2GM089043766 JJ O
and BC2GM089043766 CC O
other BC2GM089043766 JJ O
members BC2GM089043766 NNS O
of BC2GM089043766 IN O
the BC2GM089043766 DT O
B-Zip BC2GM089043766 NNP O
transcription BC2GM089043766 NN O
factor BC2GM089043766 NN O
family BC2GM089043766 NN O
. BC2GM089043766 . O
. . O O

Simulations BC2GM054881964 NNS O
of BC2GM054881964 IN O
velocities BC2GM054881964 NNS O
, BC2GM054881964 , O
vorticity BC2GM054881964 NN O
, BC2GM054881964 , O
pressure BC2GM054881964 NN O
and BC2GM054881964 CC O
certain BC2GM054881964 JJ O
stress BC2GM054881964 NN O
values BC2GM054881964 NNS O
were BC2GM054881964 VBD O
developed BC2GM054881964 VBN O
by BC2GM054881964 IN O
a BC2GM054881964 DT O
computer BC2GM054881964 NN O
and BC2GM054881964 CC O
displayed BC2GM054881964 VBD O
for BC2GM054881964 IN O
man-machine BC2GM054881964 JJ O
interaction BC2GM054881964 NN O
. BC2GM054881964 . O
. . O O

Two-dimensional BC2GM000816999 JJ O
echocardiographic BC2GM000816999 JJ O
parasternal BC2GM000816999 JJ O
long- BC2GM000816999 NN O
and BC2GM000816999 CC O
short-axis BC2GM000816999 JJ O
views BC2GM000816999 NNS O
were BC2GM000816999 VBD O
obtained BC2GM000816999 VBN O
during BC2GM000816999 IN O
graded BC2GM000816999 JJ O
bleeding BC2GM000816999 NN O
by BC2GM000816999 IN O
rapid BC2GM000816999 JJ O
withdrawal BC2GM000816999 NN O
of BC2GM000816999 IN O
blood BC2GM000816999 NN O
from BC2GM000816999 IN O
an BC2GM000816999 DT O
arterial BC2GM000816999 JJ O
cannula BC2GM000816999 NN O
, BC2GM000816999 , O
with BC2GM000816999 IN O
increments BC2GM000816999 NNS O
of BC2GM000816999 IN O
5 BC2GM000816999 CD O
% BC2GM000816999 NN O
each BC2GM000816999 DT O
up BC2GM000816999 RB O
to BC2GM000816999 TO O
30 BC2GM000816999 CD O
% BC2GM000816999 NN O
of BC2GM000816999 IN O
calculated BC2GM000816999 JJ O
blood BC2GM000816999 NN O
volume BC2GM000816999 NN O
. BC2GM000816999 . O
. . O O

We BC2GM027029005 PRP O
present BC2GM027029005 VBP O
here BC2GM027029005 RB O
a BC2GM027029005 DT O
statistical BC2GM027029005 JJ O
technique BC2GM027029005 NN O
we BC2GM027029005 PRP O
developed BC2GM027029005 VBD O
to BC2GM027029005 TO O
identify BC2GM027029005 VB O
the BC2GM027029005 DT O
sequence BC2GM027029005 NN O
elements BC2GM027029005 NNS O
that BC2GM027029005 WDT O
may BC2GM027029005 MD O
be BC2GM027029005 VB O
responsible BC2GM027029005 JJ O
for BC2GM027029005 IN O
this BC2GM027029005 DT O
cell BC2GM027029005 NN O
cycle BC2GM027029005 NN O
regulation BC2GM027029005 NN O
. BC2GM027029005 . O
. . O O

The BC2GM045755791 DT O
recruitment BC2GM045755791 NN O
of BC2GM045755791 IN O
constitutively BC2GM045755791 RB O
phosphorylated BC2GM045755791 VBN O
p185 BC2GM045755791 NN O
( BC2GM045755791 ( O
neu BC2GM045755791 JJ O
) BC2GM045755791 ) O
and BC2GM045755791 CC O
the BC2GM045755791 DT O
activated BC2GM045755791 JJ O
mitogenic BC2GM045755791 JJ O
pathway BC2GM045755791 NN O
proteins BC2GM045755791 VBZ O
to BC2GM045755791 TO O
this BC2GM045755791 DT O
membrane-microfilament BC2GM045755791 JJ O
interaction BC2GM045755791 NN O
site BC2GM045755791 NN O
provides BC2GM045755791 VBZ O
a BC2GM045755791 DT O
physical BC2GM045755791 JJ O
model BC2GM045755791 NN O
for BC2GM045755791 IN O
integrating BC2GM045755791 VBG O
the BC2GM045755791 DT O
assembly BC2GM045755791 NN O
of BC2GM045755791 IN O
the BC2GM045755791 DT O
mitogenic BC2GM045755791 JJ O
pathway BC2GM045755791 NN O
with BC2GM045755791 IN O
the BC2GM045755791 DT O
transmission BC2GM045755791 NN O
of BC2GM045755791 IN O
growth BC2GM045755791 NN O
factor BC2GM045755791 NN O
signal BC2GM045755791 NN O
to BC2GM045755791 TO O
the BC2GM045755791 DT O
cytoskeleton BC2GM045755791 NN O
. BC2GM045755791 . O
. . O O

Membrane BC2GM050480913 NNP O
depolarization BC2GM050480913 NN O
is BC2GM050480913 VBZ O
a BC2GM050480913 DT O
critical BC2GM050480913 JJ O
element BC2GM050480913 NN O
of BC2GM050480913 IN O
neuronal BC2GM050480913 JJ O
signaling BC2GM050480913 NN O
. BC2GM050480913 . O
. . O O

The BC2GM083528781 DT O
sequence BC2GM083528781 NN O
of BC2GM083528781 IN O
the BC2GM083528781 DT O
127 BC2GM083528781 CD O
residue BC2GM083528781 JJ O
NrfF BC2GM083528781 NNP O
polypeptide BC2GM083528781 NN O
, BC2GM083528781 , O
M BC2GM083528781 NNP O
( BC2GM083528781 ( O
r BC2GM083528781 NN O
) BC2GM083528781 ) O
14,522 BC2GM083528781 CD O
, BC2GM083528781 , O
is BC2GM083528781 VBZ O
strikingly BC2GM083528781 RB O
similar BC2GM083528781 JJ O
to BC2GM083528781 TO O
the BC2GM083528781 DT O
CcI2 BC2GM083528781 NNP O
protein BC2GM083528781 NN O
of BC2GM083528781 IN O
R. BC2GM083528781 NNP O
capsulatus BC2GM083528781 NN O
, BC2GM083528781 , O
especially BC2GM083528781 RB O
in BC2GM083528781 IN O
the BC2GM083528781 DT O
putative BC2GM083528781 JJ O
haem-binding BC2GM083528781 NN O
motif BC2GM083528781 NN O
, BC2GM083528781 , O
RCPQCQNQN BC2GM083528781 NNP O
. BC2GM083528781 . O
( BC2GM083528781 ( O
ABSTRACT BC2GM083528781 NNP O
TRUNCATED BC2GM083528781 NNP O
AT BC2GM083528781 NNP O
400 BC2GM083528781 CD O
WORDS BC2GM083528781 NNP O
) BC2GM083528781 ) O
. BC2GM083528781 . O
. . O O

In BC2GM042107668 IN O
7 BC2GM042107668 CD O
men BC2GM042107668 NNS O
and BC2GM042107668 CC O
1 BC2GM042107668 CD O
woman BC2GM042107668 NN O
who BC2GM042107668 WP O
died BC2GM042107668 VBD O
suddenly BC2GM042107668 RB O
the BC2GM042107668 DT O
functionally BC2GM042107668 RB O
important BC2GM042107668 JJ O
areas BC2GM042107668 NNS O
of BC2GM042107668 IN O
myocardium BC2GM042107668 NN O
in BC2GM042107668 IN O
the BC2GM042107668 DT O
sino-auricular BC2GM042107668 JJ O
area BC2GM042107668 NN O
and BC2GM042107668 CC O
the BC2GM042107668 DT O
subendocardial BC2GM042107668 JJ O
layers BC2GM042107668 NNS O
of BC2GM042107668 IN O
left BC2GM042107668 JJ O
ventricle BC2GM042107668 NN O
were BC2GM042107668 VBD O
obtained BC2GM042107668 VBN O
by BC2GM042107668 IN O
necropsy BC2GM042107668 JJ O
no BC2GM042107668 DT O
more BC2GM042107668 JJR O
than BC2GM042107668 IN O
3 BC2GM042107668 CD O
h BC2GM042107668 NN O
after BC2GM042107668 IN O
death BC2GM042107668 NN O
, BC2GM042107668 , O
and BC2GM042107668 CC O
then BC2GM042107668 RB O
prepared BC2GM042107668 VBD O
for BC2GM042107668 IN O
study BC2GM042107668 NN O
by BC2GM042107668 IN O
electron BC2GM042107668 NN O
microscopy BC2GM042107668 NN O
. BC2GM042107668 . O
. . O O

Single BC2GM066721015 NNP O
oblique-view BC2GM066721015 NN O
mammography BC2GM066721015 NN O
for BC2GM066721015 IN O
periodic BC2GM066721015 JJ O
screening BC2GM066721015 NN O
for BC2GM066721015 IN O
breast BC2GM066721015 NN O
cancer BC2GM066721015 NN O
in BC2GM066721015 IN O
women BC2GM066721015 NNS O
. BC2GM066721015 . O
. . O O

The BC2GM024643868 DT O
three-dimensional BC2GM024643868 JJ O
structure BC2GM024643868 NN O
of BC2GM024643868 IN O
the BC2GM024643868 DT O
E. BC2GM024643868 NNP O
coli BC2GM024643868 NNS O
CR BC2GM024643868 NNP O
domain BC2GM024643868 NN O
indicates BC2GM024643868 VBZ O
that BC2GM024643868 IN O
this BC2GM024643868 DT O
sequence BC2GM024643868 NN O
conservation BC2GM024643868 NN O
is BC2GM024643868 VBZ O
likely BC2GM024643868 JJ O
to BC2GM024643868 TO O
result BC2GM024643868 VB O
in BC2GM024643868 IN O
a BC2GM024643868 DT O
conserved BC2GM024643868 JJ O
structural BC2GM024643868 JJ O
motif BC2GM024643868 NN O
. BC2GM024643868 . O
. . O O

Plasma BC2GM003098775 NNP O
LH BC2GM003098775 NNP O
and BC2GM003098775 CC O
progesterone BC2GM003098775 NN O
levels BC2GM003098775 NNS O
after BC2GM003098775 IN O
single BC2GM003098775 JJ O
or BC2GM003098775 CC O
multiple BC2GM003098775 JJ O
injections BC2GM003098775 NNS O
of BC2GM003098775 IN O
synthetic BC2GM003098775 JJ O
LH-RH BC2GM003098775 NNP O
in BC2GM003098775 IN O
anoestrous BC2GM003098775 JJ O
ewes BC2GM003098775 NN O
and BC2GM003098775 CC O
comparison BC2GM003098775 NN O
with BC2GM003098775 IN O
levels BC2GM003098775 NNS O
during BC2GM003098775 IN O
the BC2GM003098775 DT O
oestrous BC2GM003098775 JJ O
cycle BC2GM003098775 NN O
. BC2GM003098775 . O
. . O O

Thirty BC2GM033539277 NNP O
minutes BC2GM033539277 NNS O
after BC2GM033539277 IN O
reperfusion BC2GM033539277 NN O
, BC2GM033539277 , O
lung BC2GM033539277 NN O
lymph BC2GM033539277 NN O
flow BC2GM033539277 NN O
( BC2GM033539277 ( O
QL BC2GM033539277 NNP O
) BC2GM033539277 ) O
increased BC2GM033539277 VBD O
from BC2GM033539277 IN O
4.3 BC2GM033539277 CD O
to BC2GM033539277 TO O
8.3 BC2GM033539277 CD O
ml BC2GM033539277 NNS O
/ BC2GM033539277 VBD O
30 BC2GM033539277 CD O
minutes BC2GM033539277 NNS O
( BC2GM033539277 ( O
p BC2GM033539277 NN O
less BC2GM033539277 JJR O
than BC2GM033539277 IN O
0.05 BC2GM033539277 CD O
) BC2GM033539277 ) O
, BC2GM033539277 , O
lymph BC2GM033539277 JJ O
/ BC2GM033539277 NNP O
plasma BC2GM033539277 NN O
protein BC2GM033539277 NN O
ratio BC2GM033539277 NN O
was BC2GM033539277 VBD O
unchanged BC2GM033539277 JJ O
from BC2GM033539277 IN O
0.6 BC2GM033539277 CD O
, BC2GM033539277 , O
and BC2GM033539277 CC O
the BC2GM033539277 DT O
lymph BC2GM033539277 NN O
protein BC2GM033539277 JJ O
clearance BC2GM033539277 NN O
increased BC2GM033539277 VBD O
from BC2GM033539277 IN O
2.6 BC2GM033539277 CD O
to BC2GM033539277 TO O
4.6 BC2GM033539277 CD O
ml BC2GM033539277 NNS O
/ BC2GM033539277 VBD O
30 BC2GM033539277 CD O
minutes BC2GM033539277 NNS O
( BC2GM033539277 ( O
p BC2GM033539277 NN O
less BC2GM033539277 JJR O
than BC2GM033539277 IN O
0.05 BC2GM033539277 CD O
) BC2GM033539277 ) O
, BC2GM033539277 , O
data BC2GM033539277 NNS O
consistent BC2GM033539277 NN O
with BC2GM033539277 IN O
increased BC2GM033539277 JJ O
microvascular BC2GM033539277 JJ O
permeability BC2GM033539277 NN O
. BC2GM033539277 . O
. . O O

Tubular BC2GM010453739 JJ O
dysfunction BC2GM010453739 NN O
in BC2GM010453739 IN O
renal BC2GM010453739 JJ O
lithiasis BC2GM010453739 NN O
: BC2GM010453739 : O
cause BC2GM010453739 NN O
or BC2GM010453739 CC O
consequence BC2GM010453739 NN O
? BC2GM010453739 . O
] BC2GM010453739 NN O
To BC2GM010453739 TO O
investigate BC2GM010453739 VB O
whether BC2GM010453739 IN O
overall BC2GM010453739 JJ O
tubular BC2GM010453739 JJ O
dysfunction BC2GM010453739 NN O
is BC2GM010453739 VBZ O
encountered BC2GM010453739 VBN O
in BC2GM010453739 IN O
a BC2GM010453739 DT O
particular BC2GM010453739 JJ O
subgroup BC2GM010453739 NN O
of BC2GM010453739 IN O
patients BC2GM010453739 NNS O
with BC2GM010453739 IN O
urolithiasis BC2GM010453739 NN O
, BC2GM010453739 , O
the BC2GM010453739 DT O
following BC2GM010453739 VBG O
parameters BC2GM010453739 NNS O
of BC2GM010453739 IN O
renal BC2GM010453739 JJ O
tubular BC2GM010453739 JJ O
function BC2GM010453739 NN O
have BC2GM010453739 VBP O
been BC2GM010453739 VBN O
measured BC2GM010453739 VBN O
in BC2GM010453739 IN O
fasting BC2GM010453739 VBG O
morning BC2GM010453739 NN O
urine BC2GM010453739 NN O
in BC2GM010453739 IN O
124 BC2GM010453739 CD O
male BC2GM010453739 NN O
stone BC2GM010453739 NN O
formers BC2GM010453739 NNS O
: BC2GM010453739 : O
excretion BC2GM010453739 NN O
of BC2GM010453739 IN O
lysozyme BC2GM010453739 NN O
and BC2GM010453739 CC O
gamma-glutamyl BC2GM010453739 JJ O
transpeptidase BC2GM010453739 NN O
( BC2GM010453739 ( O
gamma-GT BC2GM010453739 JJ O
) BC2GM010453739 ) O
, BC2GM010453739 , O
fractional BC2GM010453739 JJ O
excretion BC2GM010453739 NN O
( BC2GM010453739 ( O
FE BC2GM010453739 NNP O
) BC2GM010453739 ) O
or BC2GM010453739 CC O
glucose BC2GM010453739 JJ O
, BC2GM010453739 , O
insulin BC2GM010453739 NN O
, BC2GM010453739 , O
bicarbonate BC2GM010453739 NN O
after BC2GM010453739 IN O
an BC2GM010453739 DT O
alkali BC2GM010453739 JJ O
load BC2GM010453739 NN O
, BC2GM010453739 , O
and BC2GM010453739 CC O
theoretical BC2GM010453739 JJ O
phosphate BC2GM010453739 NN O
threshold BC2GM010453739 NN O
( BC2GM010453739 ( O
TmP BC2GM010453739 NNP O
/ BC2GM010453739 NNP O
GFR BC2GM010453739 NNP O
) BC2GM010453739 ) O
. BC2GM010453739 . O
. . O O

The BC2GM097227201 DT O
MALDI-TOF BC2GM097227201 NNP O
experiment BC2GM097227201 NN O
, BC2GM097227201 , O
however BC2GM097227201 RB O
, BC2GM097227201 , O
proved BC2GM097227201 VBD O
to BC2GM097227201 TO O
be BC2GM097227201 VB O
superior BC2GM097227201 JJ O
to BC2GM097227201 TO O
the BC2GM097227201 DT O
GC BC2GM097227201 NNP O
experiment BC2GM097227201 NN O
, BC2GM097227201 , O
particularly BC2GM097227201 RB O
with BC2GM097227201 IN O
regard BC2GM097227201 NN O
to BC2GM097227201 TO O
baseline BC2GM097227201 VB O
resolution BC2GM097227201 NN O
of BC2GM097227201 IN O
unsaturated BC2GM097227201 JJ O
acids BC2GM097227201 NNS O
. BC2GM097227201 . O
. . O O

The BC2GM006621209 DT O
aim BC2GM006621209 NN O
of BC2GM006621209 IN O
this BC2GM006621209 DT O
work BC2GM006621209 NN O
was BC2GM006621209 VBD O
to BC2GM006621209 TO O
organize BC2GM006621209 VB O
chemical BC2GM006621209 JJ O
data BC2GM006621209 NNS O
in BC2GM006621209 IN O
a BC2GM006621209 DT O
client-server BC2GM006621209 JJ O
environment BC2GM006621209 NN O
using BC2GM006621209 VBG O
Database BC2GM006621209 NNP O
Management BC2GM006621209 NNP O
System BC2GM006621209 NNP O
and BC2GM006621209 CC O
Web BC2GM006621209 NNP O
fashion BC2GM006621209 NN O
for BC2GM006621209 IN O
the BC2GM006621209 DT O
client BC2GM006621209 NN O
interface BC2GM006621209 NN O
. BC2GM006621209 . O
. . O O

Significance BC2GM069590110 NN O
of BC2GM069590110 IN O
the BC2GM069590110 DT O
determination BC2GM069590110 NN O
of BC2GM069590110 IN O
vascular BC2GM069590110 JJ O
tonus BC2GM069590110 NN O
in BC2GM069590110 IN O
the BC2GM069590110 DT O
differential BC2GM069590110 JJ O
diagnosis BC2GM069590110 NN O
of BC2GM069590110 IN O
rheumatic BC2GM069590110 JJ O
and BC2GM069590110 CC O
arteriosclerotic BC2GM069590110 JJ O
lesions BC2GM069590110 NNS O
of BC2GM069590110 IN O
the BC2GM069590110 DT O
heart BC2GM069590110 NN O
and BC2GM069590110 CC O
vessels BC2GM069590110 NNS O
in BC2GM069590110 IN O
middle-aged BC2GM069590110 JJ O
and BC2GM069590110 CC O
elderly BC2GM069590110 JJ O
persons BC2GM069590110 NNS O
with BC2GM069590110 IN O
fibrillation BC2GM069590110 NN O
arrhythmia BC2GM069590110 NN O
. BC2GM069590110 . O
. . O O

The BC2GM026075633 DT O
results BC2GM026075633 NNS O
reveal BC2GM026075633 JJ O
preferences BC2GM026075633 NNS O
for BC2GM026075633 IN O
particular BC2GM026075633 JJ O
initiating BC2GM026075633 NN O
nucleotides BC2GM026075633 NNS O
( BC2GM026075633 ( O
ATP BC2GM026075633 NNP O
> BC2GM026075633 NNP O
or BC2GM026075633 CC O
= BC2GM026075633 NNP O
GTP BC2GM026075633 NNP O
> BC2GM026075633 NNP O
UTP BC2GM026075633 NNP O
> BC2GM026075633 NNP O
> BC2GM026075633 NNP O
CTP BC2GM026075633 NNP O
) BC2GM026075633 ) O
and BC2GM026075633 CC O
for BC2GM026075633 IN O
starting BC2GM026075633 VBG O
positions BC2GM026075633 NNS O
downstream BC2GM026075633 NN O
of BC2GM026075633 IN O
the BC2GM026075633 DT O
Pribnow BC2GM026075633 NNP O
box BC2GM026075633 NN O
( BC2GM026075633 ( O
7 BC2GM026075633 CD O
> BC2GM026075633 NNP O
> BC2GM026075633 VBD O
6 BC2GM026075633 CD O
and BC2GM026075633 CC O
8 BC2GM026075633 CD O
> BC2GM026075633 NNS O
9 BC2GM026075633 CD O
> BC2GM026075633 $ O
10 BC2GM026075633 CD O
) BC2GM026075633 ) O
. BC2GM026075633 . O
. . O O

We BC2GM065423133 PRP O
have BC2GM065423133 VBP O
determined BC2GM065423133 VBN O
the BC2GM065423133 DT O
molecular BC2GM065423133 JJ O
organization BC2GM065423133 NN O
and BC2GM065423133 CC O
transcription BC2GM065423133 NN O
start BC2GM065423133 NN O
points BC2GM065423133 NNS O
( BC2GM065423133 ( O
tsp BC2GM065423133 NN O
) BC2GM065423133 ) O
for BC2GM065423133 IN O
the BC2GM065423133 DT O
murine BC2GM065423133 NN O
gene BC2GM065423133 NN O
( BC2GM065423133 ( O
TK BC2GM065423133 NNP O
) BC2GM065423133 ) O
encoding BC2GM065423133 VBG O
thymidine BC2GM065423133 JJ O
kinase BC2GM065423133 NN O
. BC2GM065423133 . O
. . O O

Time BC2GM011442958 NN O
for BC2GM011442958 IN O
action BC2GM011442958 NN O
on BC2GM011442958 IN O
hepatitis BC2GM011442958 NN O
B BC2GM011442958 NNP O
immunisation BC2GM011442958 NN O
. BC2GM011442958 . O
. . O O

Evidence BC2GM075340311 NN O
that BC2GM075340311 IN O
the BC2GM075340311 DT O
AT1A BC2GM075340311 NNP O
receptor BC2GM075340311 NN O
activates BC2GM075340311 VBZ O
transcription BC2GM075340311 JJ O
factor-Stat91 BC2GM075340311 JJ O
and BC2GM075340311 CC O
/ BC2GM075340311 JJ O
or BC2GM075340311 CC O
a BC2GM075340311 DT O
related BC2GM075340311 JJ O
protein BC2GM075340311 NN O
. BC2GM075340311 . O
. . O O

ATF6 BC2GM019974743 NNP O
, BC2GM019974743 , O
a BC2GM019974743 DT O
basic-leucine BC2GM019974743 JJ O
zipper BC2GM019974743 NN O
protein BC2GM019974743 NN O
, BC2GM019974743 , O
was BC2GM019974743 VBD O
isolated BC2GM019974743 VBN O
by BC2GM019974743 IN O
binding BC2GM019974743 VBG O
to BC2GM019974743 TO O
SRF BC2GM019974743 NNP O
and BC2GM019974743 CC O
in BC2GM019974743 IN O
particular BC2GM019974743 JJ O
to BC2GM019974743 TO O
its BC2GM019974743 PRP$ O
transcriptional BC2GM019974743 JJ O
activation BC2GM019974743 NN O
domain BC2GM019974743 NN O
. BC2GM019974743 . O
. . O O

Renal BC2GM015383059 NNP O
cell BC2GM015383059 NN O
carcinoma BC2GM015383059 NN O
induced BC2GM015383059 VBD O
Coombs BC2GM015383059 NNP O
negative BC2GM015383059 JJ O
autoimmune BC2GM015383059 NN O
hemolytic BC2GM015383059 JJ O
anemia BC2GM015383059 NN O
and BC2GM015383059 CC O
severe BC2GM015383059 JJ O
thrombocytopenia BC2GM015383059 NN O
responsive BC2GM015383059 NN O
to BC2GM015383059 TO O
nephrectomy BC2GM015383059 VB O
. BC2GM015383059 . O
. . O O

Experimental BC2GM080877738 JJ O
studies BC2GM080877738 NNS O
and BC2GM080877738 CC O
clinical BC2GM080877738 JJ O
application BC2GM080877738 NN O
of BC2GM080877738 IN O
plasma BC2GM080877738 NN O
ACTH BC2GM080877738 NNP O
radioimmunoassay BC2GM080877738 VBP O
kit BC2GM080877738 NN O
without BC2GM080877738 IN O
extraction BC2GM080877738 NN O
process BC2GM080877738 NN O
. BC2GM080877738 . O
. . O O

Transcriptional BC2GM023122487 JJ O
analysis BC2GM023122487 NN O
of BC2GM023122487 IN O
this BC2GM023122487 DT O
gene BC2GM023122487 NN O
cluster BC2GM023122487 NN O
was BC2GM023122487 VBD O
performed BC2GM023122487 VBN O
by BC2GM023122487 IN O
detecting BC2GM023122487 VBG O
the BC2GM023122487 DT O
presence BC2GM023122487 NN O
of BC2GM023122487 IN O
mRNAs BC2GM023122487 NN O
spanning BC2GM023122487 VBG O
adjacent BC2GM023122487 JJ O
genes BC2GM023122487 NNS O
as BC2GM023122487 RB O
well BC2GM023122487 RB O
as BC2GM023122487 IN O
by BC2GM023122487 IN O
using BC2GM023122487 VBG O
a BC2GM023122487 DT O
promoterless BC2GM023122487 NN O
lacZ BC2GM023122487 NN O
reporter BC2GM023122487 NN O
gene BC2GM023122487 NN O
fused BC2GM023122487 VBD O
to BC2GM023122487 TO O
each BC2GM023122487 DT O
of BC2GM023122487 IN O
the BC2GM023122487 DT O
seven BC2GM023122487 CD O
genes BC2GM023122487 NNS O
contained BC2GM023122487 VBN O
in BC2GM023122487 IN O
the BC2GM023122487 DT O
tol-oprL BC2GM023122487 JJ O
locus BC2GM023122487 NN O
. BC2GM023122487 . O
. . O O

The BC2GM011847629 DT O
maternal BC2GM011847629 JJ O
par BC2GM011847629 NN O
genes BC2GM011847629 NNS O
and BC2GM011847629 CC O
the BC2GM011847629 DT O
segregation BC2GM011847629 NN O
of BC2GM011847629 IN O
cell BC2GM011847629 NN O
fate BC2GM011847629 NN O
specification BC2GM011847629 NN O
activities BC2GM011847629 NNS O
in BC2GM011847629 IN O
early BC2GM011847629 JJ O
Caenorhabditis BC2GM011847629 NN O
elegans BC2GM011847629 NNS O
embryos BC2GM011847629 VBP O
. BC2GM011847629 . O
. . O O

PCC BC2GM026213346 NN O
6803 BC2GM026213346 CD O
mutant BC2GM026213346 NN O
impaired BC2GM026213346 VBN O
in BC2GM026213346 IN O
cytochrome BC2GM026213346 JJ O
c BC2GM026213346 JJ O
maturation BC2GM026213346 NN O
. BC2GM026213346 . O
. . O O

The BC2GM005575827 DT O
transcriptional BC2GM005575827 JJ O
start BC2GM005575827 NN O
site BC2GM005575827 NN O
, BC2GM005575827 , O
identified BC2GM005575827 VBN O
by BC2GM005575827 IN O
primer BC2GM005575827 JJ O
extension BC2GM005575827 NN O
and BC2GM005575827 CC O
S1 BC2GM005575827 NNP O
nuclease BC2GM005575827 NNP O
assay BC2GM005575827 NN O
, BC2GM005575827 , O
is BC2GM005575827 VBZ O
34 BC2GM005575827 CD O
nt BC2GM005575827 JJ O
upstream BC2GM005575827 NN O
of BC2GM005575827 IN O
the BC2GM005575827 DT O
translation BC2GM005575827 NN O
initiation BC2GM005575827 NN O
codon BC2GM005575827 NN O
. BC2GM005575827 . O
. . O O

Northern BC2GM024533099 NNP O
analyses BC2GM024533099 VBZ O
further BC2GM024533099 JJ O
confirm BC2GM024533099 NN O
that BC2GM024533099 IN O
the BC2GM024533099 DT O
expression BC2GM024533099 NN O
of BC2GM024533099 IN O
endogenous BC2GM024533099 JJ O
alpha-ENaC BC2GM024533099 JJ O
gene BC2GM024533099 NN O
in BC2GM024533099 IN O
salivary BC2GM024533099 JJ O
Pa-4 BC2GM024533099 NNP O
cells BC2GM024533099 NNS O
is BC2GM024533099 VBZ O
suppressed BC2GM024533099 VBN O
by BC2GM024533099 IN O
an BC2GM024533099 DT O
ectopic BC2GM024533099 JJ O
HMGI-C BC2GM024533099 JJ O
overexpression BC2GM024533099 NN O
. BC2GM024533099 . O
. . O O

Five BC2GM049289655 CD O
sequence BC2GM049289655 NN O
variants BC2GM049289655 NNS O
were BC2GM049289655 VBD O
identified BC2GM049289655 VBN O
. BC2GM049289655 . O
. . O O

Between BC2GM090228241 JJ O
1988 BC2GM090228241 CD O
and BC2GM090228241 CC O
1995 BC2GM090228241 CD O
, BC2GM090228241 , O
341 BC2GM090228241 CD O
children BC2GM090228241 NNS O
with BC2GM090228241 IN O
acute BC2GM090228241 JJ O
myeloid BC2GM090228241 NN O
leukaemia BC2GM090228241 NN O
( BC2GM090228241 ( O
AML BC2GM090228241 NNP O
) BC2GM090228241 ) O
were BC2GM090228241 VBD O
treated BC2GM090228241 VBN O
on BC2GM090228241 IN O
the BC2GM090228241 DT O
Medical BC2GM090228241 NNP O
Research BC2GM090228241 NNP O
Council BC2GM090228241 NNP O
Acute BC2GM090228241 NNP O
Myeloid BC2GM090228241 NNP O
Leukaemia BC2GM090228241 NNP O
Trial BC2GM090228241 NNP O
( BC2GM090228241 ( O
MRC BC2GM090228241 NNP O
AML10 BC2GM090228241 NNP O
) BC2GM090228241 ) O
. BC2GM090228241 . O
. . O O

Low-affinity BC2GM020792074 JJ O
E2-binding BC2GM020792074 NNP O
site BC2GM020792074 NN O
mediates BC2GM020792074 NNS O
downmodulation BC2GM020792074 NN O
of BC2GM020792074 IN O
E2 BC2GM020792074 NNP O
transactivation BC2GM020792074 NN O
of BC2GM020792074 IN O
the BC2GM020792074 DT O
human BC2GM020792074 JJ O
papillomavirus BC2GM020792074 NN O
type BC2GM020792074 VBD O
8 BC2GM020792074 CD O
late BC2GM020792074 JJ O
promoter BC2GM020792074 NN O
. BC2GM020792074 . O
. . O O

The BC2GM054094309 DT O
two BC2GM054094309 CD O
ORFs BC2GM054094309 NNP O
had BC2GM054094309 VBD O
significant BC2GM054094309 JJ O
similarity BC2GM054094309 NN O
with BC2GM054094309 IN O
the BC2GM054094309 DT O
putative BC2GM054094309 JJ O
replication BC2GM054094309 NN O
protein BC2GM054094309 NN O
from BC2GM054094309 IN O
plasmid BC2GM054094309 JJ O
pTiK12 BC2GM054094309 NN O
of BC2GM054094309 IN O
Thiobacillus BC2GM054094309 NNP O
intermedius BC2GM054094309 NN O
and BC2GM054094309 CC O
other BC2GM054094309 JJ O
CoIE2-related BC2GM054094309 JJ O
plasmids BC2GM054094309 NNS O
. BC2GM054094309 . O
. . O O

Control BC2GM009859517 NN O
of BC2GM009859517 IN O
ovulation BC2GM009859517 NN O
in BC2GM009859517 IN O
mares BC2GM009859517 NNS O
in BC2GM009859517 IN O
the BC2GM009859517 DT O
early BC2GM009859517 JJ O
breeding BC2GM009859517 NN O
season BC2GM009859517 NN O
with BC2GM009859517 IN O
ovarian BC2GM009859517 JJ O
steroids BC2GM009859517 NNS O
and BC2GM009859517 CC O
prostaglandin BC2GM009859517 NN O
. BC2GM009859517 . O
. . O O

Reaction BC2GM089809726 NN O
of BC2GM089809726 IN O
aromatic BC2GM089809726 JJ O
/ BC2GM089809726 NNP O
heterocyclic BC2GM089809726 NN O
sulfonamides BC2GM089809726 NNS O
possessing BC2GM089809726 VBG O
free BC2GM089809726 JJ O
amino BC2GM089809726 NN O
, BC2GM089809726 , O
imino BC2GM089809726 NN O
or BC2GM089809726 CC O
hydrazino BC2GM089809726 NN O
moieties BC2GM089809726 NNS O
with BC2GM089809726 IN O
7-chloro-4-chloromethylcoumarin BC2GM089809726 NNP O
afforded BC2GM089809726 VBD O
a BC2GM089809726 DT O
series BC2GM089809726 NN O
of BC2GM089809726 IN O
N- BC2GM089809726 NNP O
[ BC2GM089809726 NNP O
( BC2GM089809726 ( O
7-chloro-4-coumarinyl BC2GM089809726 JJ O
) BC2GM089809726 ) O
-methyl BC2GM089809726 FW O
] BC2GM089809726 SYM O
- BC2GM089809726 : O
derivatives BC2GM089809726 NNS O
which BC2GM089809726 WDT O
showed BC2GM089809726 VBD O
effective BC2GM089809726 JJ O
inhibition BC2GM089809726 NN O
of BC2GM089809726 IN O
three BC2GM089809726 CD O
carbonic BC2GM089809726 JJ O
anhydrase BC2GM089809726 NN O
( BC2GM089809726 ( O
CA BC2GM089809726 NNP O
) BC2GM089809726 ) O
isozymes BC2GM089809726 NNS O
. BC2GM089809726 . O
. . O O

Transforming BC2GM005625314 VBG O
growth BC2GM005625314 NN O
factor-beta BC2GM005625314 JJ O
( BC2GM005625314 ( O
TGF-beta BC2GM005625314 NNP O
) BC2GM005625314 ) O
inhibits BC2GM005625314 VBZ O
cell BC2GM005625314 NN O
cycle BC2GM005625314 NN O
progression BC2GM005625314 NN O
, BC2GM005625314 , O
in BC2GM005625314 IN O
part BC2GM005625314 NN O
through BC2GM005625314 IN O
up-regulation BC2GM005625314 NN O
of BC2GM005625314 IN O
gene BC2GM005625314 NN O
expression BC2GM005625314 NN O
of BC2GM005625314 IN O
the BC2GM005625314 DT O
p21 BC2GM005625314 NN O
( BC2GM005625314 ( O
WAF1 BC2GM005625314 NNP O
/ BC2GM005625314 NNP O
Cip1 BC2GM005625314 NNP O
) BC2GM005625314 ) O
( BC2GM005625314 ( O
p21 BC2GM005625314 NN O
) BC2GM005625314 ) O
cell BC2GM005625314 NN O
cycle BC2GM005625314 NN O
inhibitor BC2GM005625314 NN O
. BC2GM005625314 . O
. . O O

Also BC2GM083262968 RB O
, BC2GM083262968 , O
the BC2GM083262968 DT O
RVW BC2GM083262968 NNP O
hypertrophy BC2GM083262968 NN O
, BC2GM083262968 , O
the BC2GM083262968 DT O
IVS BC2GM083262968 NNP O
hypertrophy BC2GM083262968 NN O
, BC2GM083262968 , O
and BC2GM083262968 CC O
the BC2GM083262968 DT O
RV BC2GM083262968 NNP O
high BC2GM083262968 JJ O
pressure BC2GM083262968 NN O
load BC2GM083262968 NN O
to BC2GM083262968 TO O
the BC2GM083262968 DT O
LV BC2GM083262968 NNP O
through BC2GM083262968 IN O
the BC2GM083262968 DT O
IVS BC2GM083262968 NNP O
may BC2GM083262968 MD O
be BC2GM083262968 VB O
related BC2GM083262968 VBN O
to BC2GM083262968 TO O
the BC2GM083262968 DT O
small BC2GM083262968 JJ O
LV BC2GM083262968 NNP O
, BC2GM083262968 , O
high BC2GM083262968 JJ O
EF BC2GM083262968 NNP O
, BC2GM083262968 , O
and BC2GM083262968 CC O
abnormal BC2GM083262968 JJ O
two BC2GM083262968 CD O
chamber BC2GM083262968 NN O
inflow BC2GM083262968 NN O
in BC2GM083262968 IN O
the BC2GM083262968 DT O
PS BC2GM083262968 NNP O
group BC2GM083262968 NN O
before BC2GM083262968 IN O
BV BC2GM083262968 NNP O
. BC2GM083262968 . O
. . O O

However BC2GM075161698 RB O
, BC2GM075161698 , O
neither BC2GM075161698 DT O
SF-1 BC2GM075161698 JJ O
nor BC2GM075161698 CC O
NGF-IB BC2GM075161698 JJ O
alone BC2GM075161698 NN O
, BC2GM075161698 , O
binding BC2GM075161698 VBG O
as BC2GM075161698 IN O
monomers BC2GM075161698 NNS O
, BC2GM075161698 , O
increases BC2GM075161698 NNS O
transcription BC2GM075161698 NN O
. BC2GM075161698 . O
. . O O

Cost BC2GM013293084 NN O
analysis BC2GM013293084 NN O
and BC2GM013293084 CC O
the BC2GM013293084 DT O
HSA BC2GM013293084 NNP O
: BC2GM013293084 : O
a BC2GM013293084 DT O
framework BC2GM013293084 NN O
. BC2GM013293084 . O
. . O O

Such BC2GM014618195 JJ O
tetranucleotides BC2GM014618195 NNS O
are BC2GM014618195 VBP O
common BC2GM014618195 JJ O
in BC2GM014618195 IN O
promoter BC2GM014618195 NN O
regions BC2GM014618195 NNS O
, BC2GM014618195 , O
particularly BC2GM014618195 RB O
in BC2GM014618195 IN O
activating BC2GM014618195 VBG O
transcription BC2GM014618195 NN O
factor BC2GM014618195 NN O
/ BC2GM014618195 NNP O
cyclic BC2GM014618195 NN O
AMP BC2GM014618195 NNP O
response BC2GM014618195 NN O
element-binding BC2GM014618195 NN O
protein BC2GM014618195 NN O
( BC2GM014618195 ( O
ATF BC2GM014618195 NNP O
/ BC2GM014618195 NNP O
CREB BC2GM014618195 NNP O
) BC2GM014618195 ) O
and BC2GM014618195 CC O
E-box BC2GM014618195 NNP O
motifs BC2GM014618195 NNS O
, BC2GM014618195 , O
suggesting BC2GM014618195 VBG O
that BC2GM014618195 IN O
PIF BC2GM014618195 NNP O
may BC2GM014618195 MD O
modulate BC2GM014618195 VB O
the BC2GM014618195 DT O
transcription BC2GM014618195 NN O
of BC2GM014618195 IN O
many BC2GM014618195 JJ O
genes BC2GM014618195 NNS O
. BC2GM014618195 . O
. . O O

The BC2GM054086435 DT O
carboxy-proximal BC2GM054086435 JJ O
regions BC2GM054086435 NNS O
of BC2GM054086435 IN O
the BC2GM054086435 DT O
VP1 BC2GM054086435 NNP O
, BC2GM054086435 , O
which BC2GM054086435 WDT O
contain BC2GM054086435 VBP O
very BC2GM054086435 RB O
low BC2GM054086435 JJ O
amino BC2GM054086435 NN O
acid BC2GM054086435 NN O
homology BC2GM054086435 NN O
, BC2GM054086435 , O
displayed BC2GM054086435 VBD O
evidence BC2GM054086435 NN O
of BC2GM054086435 IN O
conservation BC2GM054086435 NN O
in BC2GM054086435 IN O
structural BC2GM054086435 JJ O
features BC2GM054086435 NNS O
such BC2GM054086435 JJ O
as BC2GM054086435 IN O
a BC2GM054086435 DT O
hydrophilic BC2GM054086435 NN O
, BC2GM054086435 , O
highly BC2GM054086435 RB O
basic BC2GM054086435 JJ O
domain BC2GM054086435 NN O
. BC2GM054086435 . O
. . O O

We BC2GM066316127 PRP O
conclude BC2GM066316127 VBP O
that BC2GM066316127 IN O
these BC2GM066316127 DT O
cDNAs BC2GM066316127 NNS O
belong BC2GM066316127 VBP O
to BC2GM066316127 TO O
a BC2GM066316127 DT O
novel BC2GM066316127 JJ O
GST BC2GM066316127 NNP O
class BC2GM066316127 NN O
hereby BC2GM066316127 NN O
designated BC2GM066316127 VBN O
Kappa BC2GM066316127 NNP O
, BC2GM066316127 , O
with BC2GM066316127 IN O
the BC2GM066316127 DT O
rat BC2GM066316127 NN O
GST BC2GM066316127 NNP O
subunit BC2GM066316127 VBZ O
13 BC2GM066316127 CD O
gene BC2GM066316127 NN O
designated BC2GM066316127 VBN O
rGSTK1 BC2GM066316127 NN O
and BC2GM066316127 CC O
the BC2GM066316127 DT O
human BC2GM066316127 JJ O
gene BC2GM066316127 NN O
being BC2GM066316127 VBG O
called BC2GM066316127 VBN O
hGSTK1 BC2GM066316127 NN O
. BC2GM066316127 . O
. . O O

Mutating BC2GM002989216 VBG O
bases BC2GM002989216 NNS O
-142 BC2GM002989216 VBP O
to BC2GM002989216 TO O
-151 BC2GM002989216 VB O
abolishes BC2GM002989216 NNS O
formation BC2GM002989216 NN O
of BC2GM002989216 IN O
complex BC2GM002989216 JJ O
VII BC2GM002989216 NNP O
and BC2GM002989216 CC O
partially BC2GM002989216 RB O
inhibits BC2GM002989216 NNS O
complex BC2GM002989216 JJ O
IV BC2GM002989216 NNP O
, BC2GM002989216 , O
suggesting BC2GM002989216 VBG O
that BC2GM002989216 IN O
the BC2GM002989216 DT O
proteins BC2GM002989216 NNS O
forming BC2GM002989216 VBG O
these BC2GM002989216 DT O
complexes BC2GM002989216 NNS O
bind BC2GM002989216 VBP O
neighboring BC2GM002989216 JJ O
segments BC2GM002989216 NNS O
of BC2GM002989216 IN O
DNA BC2GM002989216 NNP O
. BC2GM002989216 . O
. . O O

Moclobemide BC2GM023797731 NNP O
is BC2GM023797731 VBZ O
a BC2GM023797731 DT O
well-tolerated BC2GM023797731 JJ O
alternative BC2GM023797731 JJ O
antidepressant BC2GM023797731 NN O
, BC2GM023797731 , O
but BC2GM023797731 CC O
there BC2GM023797731 EX O
is BC2GM023797731 VBZ O
a BC2GM023797731 DT O
need BC2GM023797731 NN O
for BC2GM023797731 IN O
prospective BC2GM023797731 JJ O
controlled BC2GM023797731 VBN O
trials BC2GM023797731 NNS O
to BC2GM023797731 TO O
evaluate BC2GM023797731 VB O
its BC2GM023797731 PRP$ O
long-term BC2GM023797731 JJ O
efficacy BC2GM023797731 NN O
. BC2GM023797731 . O
. . O O

In BC2GM045276080 IN O
5 BC2GM045276080 CD O
cases BC2GM045276080 NNS O
, BC2GM045276080 , O
combined BC2GM045276080 VBN O
sensitization BC2GM045276080 NN O
to BC2GM045276080 TO O
mercury BC2GM045276080 NN O
and BC2GM045276080 CC O
other BC2GM045276080 JJ O
metal BC2GM045276080 NN O
salts BC2GM045276080 NNS O
, BC2GM045276080 , O
particularly BC2GM045276080 RB O
gold BC2GM045276080 JJ O
sodium BC2GM045276080 NN O
thiosulfate BC2GM045276080 NN O
( BC2GM045276080 ( O
GST BC2GM045276080 NNP O
) BC2GM045276080 ) O
and BC2GM045276080 CC O
palladium BC2GM045276080 JJ O
chloride BC2GM045276080 NN O
( BC2GM045276080 ( O
PDC BC2GM045276080 NNP O
) BC2GM045276080 ) O
, BC2GM045276080 , O
was BC2GM045276080 VBD O
observed BC2GM045276080 VBN O
. BC2GM045276080 . O
. . O O

A BC2GM032318705 DT O
single BC2GM032318705 JJ O
dose BC2GM032318705 NN O
of BC2GM032318705 IN O
Cef BC2GM032318705 NNP O
was BC2GM032318705 VBD O
administered BC2GM032318705 VBN O
intravenously BC2GM032318705 RB O
to BC2GM032318705 TO O
11 BC2GM032318705 CD O
patients BC2GM032318705 NNS O
with BC2GM032318705 IN O
autoimmune BC2GM032318705 JJ O
diseases BC2GM032318705 NNS O
and BC2GM032318705 CC O
varying BC2GM032318705 VBG O
degrees BC2GM032318705 NNS O
of BC2GM032318705 IN O
renal BC2GM032318705 JJ O
impairment BC2GM032318705 NN O
( BC2GM032318705 ( O
Group BC2GM032318705 NNP O
I BC2GM032318705 PRP O
CLCR BC2GM032318705 NNP O
less BC2GM032318705 JJR O
than BC2GM032318705 IN O
50 BC2GM032318705 CD O
ml BC2GM032318705 JJ O
/ BC2GM032318705 NNP O
min BC2GM032318705 NN O
, BC2GM032318705 , O
Group BC2GM032318705 NNP O
II BC2GM032318705 NNP O
CLCR BC2GM032318705 NNP O
greater BC2GM032318705 JJR O
than BC2GM032318705 IN O
50 BC2GM032318705 CD O
ml BC2GM032318705 JJ O
/ BC2GM032318705 NNP O
min BC2GM032318705 NN O
) BC2GM032318705 ) O
. BC2GM032318705 . O
. . O O

In BC2GM005683824 IN O
Types BC2GM005683824 NNP O
I BC2GM005683824 PRP O
and BC2GM005683824 CC O
II BC2GM005683824 NNP O
, BC2GM005683824 , O
capillary BC2GM005683824 JJ O
walls BC2GM005683824 NNS O
became BC2GM005683824 VBD O
thinner BC2GM005683824 JJR O
and BC2GM005683824 CC O
more BC2GM005683824 RBR O
capillary BC2GM005683824 JJ O
lumens BC2GM005683824 NNS O
were BC2GM005683824 VBD O
visiable BC2GM005683824 JJ O
. BC2GM005683824 . O
. . O O

Changes BC2GM041736875 NNS O
in BC2GM041736875 IN O
tension BC2GM041736875 NN O
were BC2GM041736875 VBD O
monitored BC2GM041736875 VBN O
isometrically BC2GM041736875 RB O
on BC2GM041736875 IN O
spiral BC2GM041736875 JJ O
strips BC2GM041736875 NNS O
of BC2GM041736875 IN O
freshly BC2GM041736875 RB O
obtained BC2GM041736875 VBN O
bovine BC2GM041736875 NN O
basilar BC2GM041736875 JJ O
arteries BC2GM041736875 NNS O
. BC2GM041736875 . O
. . O O

LIP BC2GM083917947 NNP O
and BC2GM083917947 CC O
DIP BC2GM083917947 NNP O
are BC2GM083917947 VBP O
less BC2GM083917947 RBR O
common BC2GM083917947 JJ O
IIPs BC2GM083917947 NNP O
, BC2GM083917947 , O
both BC2GM083917947 DT O
characterized BC2GM083917947 VBN O
by BC2GM083917947 IN O
ground-glass BC2GM083917947 JJ O
attenuation BC2GM083917947 NN O
. BC2GM083917947 . O
. . O O

Animals BC2GM072883448 NNS O
were BC2GM072883448 VBD O
divided BC2GM072883448 VBN O
into BC2GM072883448 IN O
six BC2GM072883448 CD O
equal BC2GM072883448 JJ O
groups BC2GM072883448 NNS O
as BC2GM072883448 IN O
follows BC2GM072883448 VBZ O
: BC2GM072883448 : O
( BC2GM072883448 ( O
1 BC2GM072883448 CD O
) BC2GM072883448 ) O
no BC2GM072883448 DT O
oral BC2GM072883448 JJ O
drug BC2GM072883448 NN O
( BC2GM072883448 ( O
water BC2GM072883448 NN O
) BC2GM072883448 ) O
, BC2GM072883448 , O
no BC2GM072883448 DT O
hemodilution BC2GM072883448 NN O
, BC2GM072883448 , O
no BC2GM072883448 DT O
IV BC2GM072883448 NNP O
drug BC2GM072883448 NN O
( BC2GM072883448 ( O
saline BC2GM072883448 NN O
) BC2GM072883448 ) O
; BC2GM072883448 : O
( BC2GM072883448 ( O
2 BC2GM072883448 CD O
) BC2GM072883448 ) O
oral BC2GM072883448 JJ O
water BC2GM072883448 NN O
, BC2GM072883448 , O
hemodilution BC2GM072883448 NN O
, BC2GM072883448 , O
IV BC2GM072883448 NNP O
saline BC2GM072883448 NN O
; BC2GM072883448 : O
( BC2GM072883448 ( O
3 BC2GM072883448 CD O
) BC2GM072883448 ) O
oral BC2GM072883448 JJ O
water BC2GM072883448 NN O
, BC2GM072883448 , O
no BC2GM072883448 DT O
hemodilution BC2GM072883448 NN O
, BC2GM072883448 , O
IV BC2GM072883448 NNP O
propranolol BC2GM072883448 NN O
; BC2GM072883448 : O
( BC2GM072883448 ( O
4 BC2GM072883448 CD O
) BC2GM072883448 ) O
oral BC2GM072883448 JJ O
water BC2GM072883448 NN O
, BC2GM072883448 , O
hemodilution BC2GM072883448 NN O
, BC2GM072883448 , O
IV BC2GM072883448 NNP O
propranolol BC2GM072883448 NN O
; BC2GM072883448 : O
( BC2GM072883448 ( O
5 BC2GM072883448 CD O
) BC2GM072883448 ) O
oral BC2GM072883448 JJ O
propranolol BC2GM072883448 NN O
, BC2GM072883448 , O
no BC2GM072883448 DT O
hemodilution BC2GM072883448 NN O
, BC2GM072883448 , O
IV BC2GM072883448 NNP O
saline BC2GM072883448 NN O
; BC2GM072883448 : O
and BC2GM072883448 CC O
( BC2GM072883448 ( O
6 BC2GM072883448 CD O
) BC2GM072883448 ) O
oral BC2GM072883448 JJ O
propranolol BC2GM072883448 NN O
, BC2GM072883448 , O
hemodilution BC2GM072883448 NN O
, BC2GM072883448 , O
IV BC2GM072883448 NNP O
saline BC2GM072883448 NN O
. BC2GM072883448 . O
. . O O

Further BC2GM049662793 RB O
comparative BC2GM049662793 JJ O
analysis BC2GM049662793 NN O
identified BC2GM049662793 VBD O
an BC2GM049662793 DT O
ADNP BC2GM049662793 NNP O
paralog BC2GM049662793 NN O
( BC2GM049662793 ( O
33 BC2GM049662793 CD O
% BC2GM049662793 NN O
identity BC2GM049662793 NN O
and BC2GM049662793 CC O
46 BC2GM049662793 CD O
% BC2GM049662793 NN O
similarity BC2GM049662793 NN O
) BC2GM049662793 ) O
, BC2GM049662793 , O
indicating BC2GM049662793 VBG O
that BC2GM049662793 IN O
these BC2GM049662793 DT O
genes BC2GM049662793 NNS O
belong BC2GM049662793 VBP O
to BC2GM049662793 TO O
a BC2GM049662793 DT O
novel BC2GM049662793 JJ O
protein BC2GM049662793 NN O
family BC2GM049662793 NN O
with BC2GM049662793 IN O
a BC2GM049662793 DT O
nine-zinc BC2GM049662793 JJ O
finger BC2GM049662793 NN O
motif BC2GM049662793 NN O
followed BC2GM049662793 VBN O
by BC2GM049662793 IN O
a BC2GM049662793 DT O
homeobox BC2GM049662793 NN O
domain BC2GM049662793 NN O
. BC2GM049662793 . O
. . O O

In BC2GM013825160 IN O
cases BC2GM013825160 NNS O
of BC2GM013825160 IN O
intracapsular BC2GM013825160 JJ O
prostatic BC2GM013825160 JJ O
cancer BC2GM013825160 NN O
the BC2GM013825160 DT O
level BC2GM013825160 NN O
of BC2GM013825160 IN O
prostatic BC2GM013825160 JJ O
acid BC2GM013825160 NN O
phosphatase BC2GM013825160 NN O
( BC2GM013825160 ( O
PAP BC2GM013825160 NNP O
) BC2GM013825160 ) O
measured BC2GM013825160 VBN O
by BC2GM013825160 IN O
radioimmunoassay BC2GM013825160 NN O
was BC2GM013825160 VBD O
1.4 BC2GM013825160 CD O
+ BC2GM013825160 JJ O
/ BC2GM013825160 NNP O
- BC2GM013825160 : O
0.8 BC2GM013825160 CD O
micrograms BC2GM013825160 NNS O
/ BC2GM013825160 JJ O
l BC2GM013825160 NN O
. BC2GM013825160 . O
. . O O

M. BC2GM035763240 NNP O
, BC2GM035763240 , O
Apps BC2GM035763240 NNP O
, BC2GM035763240 , O
D BC2GM035763240 NNP O
. BC2GM035763240 . O
. . O O

Aggravation BC2GM095985725 NN O
of BC2GM095985725 IN O
peripheral-blood BC2GM095985725 JJ O
cytopenia BC2GM095985725 NN O
during BC2GM095985725 IN O
the BC2GM095985725 DT O
first BC2GM095985725 JJ O
weeks BC2GM095985725 NNS O
and BC2GM095985725 CC O
hypocellularity BC2GM095985725 NN O
of BC2GM095985725 IN O
bone-marrow BC2GM095985725 JJ O
aspirates BC2GM095985725 NNS O
at BC2GM095985725 IN O
the BC2GM095985725 DT O
end BC2GM095985725 NN O
of BC2GM095985725 IN O
therapy BC2GM095985725 NN O
suggest BC2GM095985725 VBP O
that BC2GM095985725 IN O
low-dose BC2GM095985725 JJ O
Ara BC2GM095985725 NNP O
C BC2GM095985725 NNP O
exerts BC2GM095985725 VBZ O
its BC2GM095985725 PRP$ O
main BC2GM095985725 JJ O
activity BC2GM095985725 NN O
by BC2GM095985725 IN O
suppression BC2GM095985725 NN O
of BC2GM095985725 IN O
leukaemic BC2GM095985725 JJ O
growth BC2GM095985725 NN O
, BC2GM095985725 , O
rather BC2GM095985725 RB O
than BC2GM095985725 IN O
by BC2GM095985725 IN O
induction BC2GM095985725 NN O
of BC2GM095985725 IN O
differentiation BC2GM095985725 NN O
in BC2GM095985725 IN O
malignant BC2GM095985725 JJ O
cells BC2GM095985725 NNS O
. BC2GM095985725 . O
. . O O

Ras BC2GM055859383 NNP O
involvement BC2GM055859383 NN O
in BC2GM055859383 IN O
signal BC2GM055859383 JJ O
transduction BC2GM055859383 NN O
by BC2GM055859383 IN O
the BC2GM055859383 DT O
serotonin BC2GM055859383 JJ O
5-HT2B BC2GM055859383 JJ O
receptor BC2GM055859383 NN O
. BC2GM055859383 . O
. . O O

There BC2GM041118324 EX O
remains BC2GM041118324 VBZ O
the BC2GM041118324 DT O
physiological BC2GM041118324 JJ O
problem BC2GM041118324 NN O
-- BC2GM041118324 : O
one BC2GM041118324 CD O
which BC2GM041118324 WDT O
has BC2GM041118324 VBZ O
always BC2GM041118324 RB O
been BC2GM041118324 VBN O
foremost BC2GM041118324 VBN O
in BC2GM041118324 IN O
Moruzzi BC2GM041118324 NNP O
's BC2GM041118324 POS O
thinking BC2GM041118324 NN O
about BC2GM041118324 IN O
the BC2GM041118324 DT O
intrinsic BC2GM041118324 JJ O
regulation BC2GM041118324 NN O
of BC2GM041118324 IN O
brain BC2GM041118324 NN O
activity BC2GM041118324 NN O
-- BC2GM041118324 : O
of BC2GM041118324 IN O
how BC2GM041118324 WRB O
the BC2GM041118324 DT O
separate BC2GM041118324 JJ O
actions BC2GM041118324 NNS O
of BC2GM041118324 IN O
the BC2GM041118324 DT O
different BC2GM041118324 JJ O
arousal BC2GM041118324 NN O
systems BC2GM041118324 NNS O
are BC2GM041118324 VBP O
brought BC2GM041118324 VBN O
together BC2GM041118324 RB O
into BC2GM041118324 IN O
a BC2GM041118324 DT O
functional BC2GM041118324 JJ O
whole BC2GM041118324 NN O
. BC2GM041118324 . O
. . O O

Analysis BC2GM076028870 NN O
of BC2GM076028870 IN O
exon BC2GM076028870 JJ O
2 BC2GM076028870 CD O
of BC2GM076028870 IN O
the BC2GM076028870 DT O
factor BC2GM076028870 NN O
IX BC2GM076028870 NNP O
gene BC2GM076028870 NN O
revealed BC2GM076028870 VBD O
a BC2GM076028870 DT O
C BC2GM076028870 NNP O
-- BC2GM076028870 : O
> BC2GM076028870 JJ O
T BC2GM076028870 NNP O
mutation BC2GM076028870 NN O
in BC2GM076028870 IN O
codon BC2GM076028870 JJ O
10 BC2GM076028870 CD O
of BC2GM076028870 IN O
the BC2GM076028870 DT O
propeptide BC2GM076028870 JJ O
region BC2GM076028870 NN O
, BC2GM076028870 , O
resulting BC2GM076028870 VBG O
in BC2GM076028870 IN O
the BC2GM076028870 DT O
substitution BC2GM076028870 NN O
of BC2GM076028870 IN O
alanine BC2GM076028870 NN O
by BC2GM076028870 IN O
valine BC2GM076028870 NN O
. BC2GM076028870 . O
. . O O

The BC2GM062054764 DT O
vaccine BC2GM062054764 NN O
was BC2GM062054764 VBD O
highly BC2GM062054764 RB O
immunogenic BC2GM062054764 JJ O
, BC2GM062054764 , O
since BC2GM062054764 IN O
111 BC2GM062054764 CD O
of BC2GM062054764 IN O
113 BC2GM062054764 CD O
patients BC2GM062054764 NNS O
( BC2GM062054764 ( O
98 BC2GM062054764 CD O
% BC2GM062054764 NN O
) BC2GM062054764 ) O
produced BC2GM062054764 VBD O
anti-HBs BC2GM062054764 JJ O
( BC2GM062054764 ( O
10 BC2GM062054764 CD O
mIU BC2GM062054764 NN O
/ BC2GM062054764 NNP O
ml BC2GM062054764 NN O
or BC2GM062054764 CC O
more BC2GM062054764 JJR O
) BC2GM062054764 ) O
. BC2GM062054764 . O
. . O O

Secretion BC2GM027314864 NN O
of BC2GM027314864 IN O
cuticle BC2GM027314864 NN O
over BC2GM027314864 IN O
and BC2GM027314864 CC O
between BC2GM027314864 IN O
the BC2GM027314864 DT O
domed BC2GM027314864 JJ O
apical BC2GM027314864 JJ O
surfaces BC2GM027314864 NNS O
of BC2GM027314864 IN O
these BC2GM027314864 DT O
cells BC2GM027314864 NNS O
leads BC2GM027314864 VBZ O
to BC2GM027314864 TO O
a BC2GM027314864 DT O
honeycomb-like BC2GM027314864 JJ O
structure BC2GM027314864 NN O
and BC2GM027314864 CC O
gives BC2GM027314864 VBZ O
the BC2GM027314864 DT O
superficial BC2GM027314864 JJ O
wart-like BC2GM027314864 JJ O
phenotype BC2GM027314864 NN O
of BC2GM027314864 IN O
mitotic BC2GM027314864 JJ O
clones BC2GM027314864 NNS O
on BC2GM027314864 IN O
the BC2GM027314864 DT O
adult BC2GM027314864 NN O
. BC2GM027314864 . O
. . O O

RESULTS BC2GM062143954 NN O
: BC2GM062143954 : O
In BC2GM062143954 IN O
the BC2GM062143954 DT O
test BC2GM062143954 NN O
data BC2GM062143954 NN O
set BC2GM062143954 NN O
, BC2GM062143954 , O
the BC2GM062143954 DT O
single-sample BC2GM062143954 JJ O
model BC2GM062143954 NN O
was BC2GM062143954 VBD O
confirmed BC2GM062143954 VBN O
to BC2GM062143954 TO O
give BC2GM062143954 VB O
excellent BC2GM062143954 JJ O
estimation BC2GM062143954 NN O
of BC2GM062143954 IN O
the BC2GM062143954 DT O
AUC BC2GM062143954 NNP O
: BC2GM062143954 : O
AUC BC2GM062143954 NNP O
( BC2GM062143954 ( O
mg BC2GM062143954 JJ O
/ BC2GM062143954 NNP O
ml BC2GM062143954 NN O
x BC2GM062143954 NNP O
min BC2GM062143954 NN O
) BC2GM062143954 ) O
= BC2GM062143954 VBZ O
0.93 BC2GM062143954 CD O
x BC2GM062143954 NN O
C3h BC2GM062143954 NNP O
+ BC2GM062143954 VBZ O
0.47 BC2GM062143954 CD O
( BC2GM062143954 ( O
MPE BC2GM062143954 NNP O
% BC2GM062143954 NN O
= BC2GM062143954 VBZ O
4.4 BC2GM062143954 CD O
% BC2GM062143954 NN O
, BC2GM062143954 , O
RMSE BC2GM062143954 NNP O
% BC2GM062143954 NN O
= BC2GM062143954 VBZ O
8.9 BC2GM062143954 CD O
% BC2GM062143954 NN O
) BC2GM062143954 ) O
. BC2GM062143954 . O
. . O O

Beyond BC2GM012794802 IN O
the BC2GM012794802 DT O
first BC2GM012794802 JJ O
year BC2GM012794802 NN O
post-renal BC2GM012794802 JJ O
transplantation BC2GM012794802 NN O
there BC2GM012794802 EX O
was BC2GM012794802 VBD O
no BC2GM012794802 DT O
difference BC2GM012794802 NN O
in BC2GM012794802 IN O
C BC2GM012794802 NNP O
( BC2GM012794802 ( O
IO BC2GM012794802 NNP O
) BC2GM012794802 ) O
between BC2GM012794802 IN O
LRD BC2GM012794802 NNP O
and BC2GM012794802 CC O
CAD BC2GM012794802 NNP O
allografts BC2GM012794802 NNS O
. BC2GM012794802 . O
. . O O

Mutations BC2GM070361623 NNS O
in BC2GM070361623 IN O
nifR1 BC2GM070361623 NN O
( BC2GM070361623 ( O
ntrC BC2GM070361623 JJ O
) BC2GM070361623 ) O
and BC2GM070361623 CC O
nifR4 BC2GM070361623 $ O
( BC2GM070361623 ( O
rpoN BC2GM070361623 NN O
, BC2GM070361623 , O
encoding BC2GM070361623 VBG O
sigma54 BC2GM070361623 NN O
) BC2GM070361623 ) O
had BC2GM070361623 VBD O
no BC2GM070361623 DT O
influence BC2GM070361623 NN O
on BC2GM070361623 IN O
xdh BC2GM070361623 NNP O
gene BC2GM070361623 NN O
expression BC2GM070361623 NN O
. BC2GM070361623 . O
. . O O

The BC2GM035498745 DT O
amount BC2GM035498745 NN O
of BC2GM035498745 IN O
overlap BC2GM035498745 NN O
in BC2GM035498745 IN O
VFI BC2GM035498745 NNP O
, BC2GM035498745 , O
EF BC2GM035498745 NNP O
, BC2GM035498745 , O
and BC2GM035498745 CC O
RVF BC2GM035498745 NNP O
values BC2GM035498745 NNS O
among BC2GM035498745 IN O
the BC2GM035498745 DT O
clinical BC2GM035498745 JJ O
groups BC2GM035498745 NNS O
was BC2GM035498745 VBD O
considerable BC2GM035498745 JJ O
. BC2GM035498745 . O
. . O O

Authors BC2GM099658397 NNS O
present BC2GM099658397 VBP O
the BC2GM099658397 DT O
anatomical BC2GM099658397 JJ O
variations BC2GM099658397 NNS O
of BC2GM099658397 IN O
the BC2GM099658397 DT O
course BC2GM099658397 NN O
of BC2GM099658397 IN O
the BC2GM099658397 DT O
inferior BC2GM099658397 JJ O
mesenteric BC2GM099658397 JJ O
artery BC2GM099658397 NN O
and BC2GM099658397 CC O
its BC2GM099658397 PRP$ O
branches BC2GM099658397 NNS O
in BC2GM099658397 IN O
62 BC2GM099658397 CD O
human BC2GM099658397 JJ O
fetus BC2GM099658397 NN O
. BC2GM099658397 . O
. . O O

A BC2GM034704877 DT O
case BC2GM034704877 NN O
of BC2GM034704877 IN O
bilateral BC2GM034704877 JJ O
testicular BC2GM034704877 JJ O
germ BC2GM034704877 NN O
cell BC2GM034704877 NN O
tumors BC2GM034704877 NNS O
in BC2GM034704877 IN O
a BC2GM034704877 DT O
23-year-old BC2GM034704877 JJ O
male BC2GM034704877 NN O
is BC2GM034704877 VBZ O
reported BC2GM034704877 VBN O
. BC2GM034704877 . O
. . O O

Plasma BC2GM061570261 NNP O
enteroglucagon BC2GM061570261 NN O
was BC2GM061570261 VBD O
measured BC2GM061570261 VBN O
before BC2GM061570261 IN O
and BC2GM061570261 CC O
during BC2GM061570261 IN O
three BC2GM061570261 CD O
hours BC2GM061570261 NNS O
after BC2GM061570261 IN O
a BC2GM061570261 DT O
standard BC2GM061570261 JJ O
meal BC2GM061570261 NN O
in BC2GM061570261 IN O
21 BC2GM061570261 CD O
untreated BC2GM061570261 JJ O
adult BC2GM061570261 NN O
patients BC2GM061570261 NNS O
with BC2GM061570261 IN O
suspected BC2GM061570261 JJ O
coeliac BC2GM061570261 JJ O
disease BC2GM061570261 NN O
who BC2GM061570261 WP O
all BC2GM061570261 DT O
had BC2GM061570261 VBD O
villous BC2GM061570261 JJ O
atrophy BC2GM061570261 NN O
of BC2GM061570261 IN O
the BC2GM061570261 DT O
small BC2GM061570261 JJ O
intestinal BC2GM061570261 JJ O
mucosa BC2GM061570261 NN O
and BC2GM061570261 CC O
malabsorption BC2GM061570261 NN O
, BC2GM061570261 , O
and BC2GM061570261 CC O
in BC2GM061570261 IN O
nine BC2GM061570261 CD O
control BC2GM061570261 NN O
subjects BC2GM061570261 NNS O
. BC2GM061570261 . O
. . O O

E1A BC2GM090825486 NNP O
+ BC2GM090825486 NNP O
cHa-ras BC2GM090825486 NN O
transformed BC2GM090825486 VBD O
rat BC2GM090825486 JJ O
embryo BC2GM090825486 NN O
fibroblast BC2GM090825486 NN O
cells BC2GM090825486 NNS O
are BC2GM090825486 VBP O
characterized BC2GM090825486 VBN O
by BC2GM090825486 IN O
high BC2GM090825486 JJ O
and BC2GM090825486 CC O
constitutive BC2GM090825486 JJ O
DNA BC2GM090825486 NNP O
binding BC2GM090825486 NN O
activities BC2GM090825486 NNS O
of BC2GM090825486 IN O
AP-1 BC2GM090825486 NNP O
dimers BC2GM090825486 NNS O
with BC2GM090825486 IN O
significantly BC2GM090825486 RB O
altered BC2GM090825486 VBN O
composition BC2GM090825486 NN O
. BC2GM090825486 . O
. . O O

Despite BC2GM034839336 IN O
this BC2GM034839336 DT O
loss BC2GM034839336 NN O
, BC2GM034839336 , O
YEpFAS1 BC2GM034839336 NNP O
is BC2GM034839336 VBZ O
still BC2GM034839336 RB O
able BC2GM034839336 JJ O
to BC2GM034839336 TO O
complement BC2GM034839336 VB O
a BC2GM034839336 DT O
fas1 BC2GM034839336 JJ O
mutation BC2GM034839336 NN O
at BC2GM034839336 IN O
the BC2GM034839336 DT O
enoyl BC2GM034839336 JJ O
reductase BC2GM034839336 NN O
domain BC2GM034839336 NN O
. BC2GM034839336 . O
. . O O

In BC2GM099522196 IN O
the BC2GM099522196 DT O
postoperative BC2GM099522196 JJ O
patient BC2GM099522196 NN O
with BC2GM099522196 IN O
tetralogy BC2GM099522196 NN O
of BC2GM099522196 IN O
Fallot BC2GM099522196 NNP O
with BC2GM099522196 IN O
symptomatic BC2GM099522196 JJ O
ventricular BC2GM099522196 NN O
arrhythmias BC2GM099522196 NN O
, BC2GM099522196 , O
it BC2GM099522196 PRP O
is BC2GM099522196 VBZ O
concluded BC2GM099522196 VBN O
that BC2GM099522196 IN O
electrophysiologic BC2GM099522196 NN O
study BC2GM099522196 NN O
is BC2GM099522196 VBZ O
useful BC2GM099522196 JJ O
in BC2GM099522196 IN O
reproducing BC2GM099522196 VBG O
clinical BC2GM099522196 JJ O
episodes BC2GM099522196 NNS O
of BC2GM099522196 IN O
VT BC2GM099522196 NNP O
and BC2GM099522196 CC O
in BC2GM099522196 IN O
selecting BC2GM099522196 VBG O
effective BC2GM099522196 JJ O
antiarrhythmic BC2GM099522196 JJ O
medication BC2GM099522196 NN O
; BC2GM099522196 : O
a BC2GM099522196 DT O
small BC2GM099522196 JJ O
number BC2GM099522196 NN O
of BC2GM099522196 IN O
patients BC2GM099522196 NNS O
with BC2GM099522196 IN O
ventricular BC2GM099522196 JJ O
premature BC2GM099522196 NN O
complexes BC2GM099522196 NNS O
alone BC2GM099522196 RB O
will BC2GM099522196 MD O
have BC2GM099522196 VB O
inducible BC2GM099522196 JJ O
sustained BC2GM099522196 VBN O
VT BC2GM099522196 NNP O
during BC2GM099522196 IN O
electrophysiologic BC2GM099522196 JJ O
study BC2GM099522196 NN O
; BC2GM099522196 : O
prognosis BC2GM099522196 NN O
of BC2GM099522196 IN O
these BC2GM099522196 DT O
patients BC2GM099522196 NNS O
may BC2GM099522196 MD O
be BC2GM099522196 VB O
improved BC2GM099522196 VBN O
by BC2GM099522196 IN O
treatment BC2GM099522196 NN O
that BC2GM099522196 WDT O
results BC2GM099522196 NNS O
in BC2GM099522196 IN O
prevention BC2GM099522196 NN O
of BC2GM099522196 IN O
VT BC2GM099522196 NNP O
induction BC2GM099522196 NN O
; BC2GM099522196 : O
and BC2GM099522196 CC O
in BC2GM099522196 IN O
patients BC2GM099522196 NNS O
with BC2GM099522196 IN O
right BC2GM099522196 JJ O
ventricular BC2GM099522196 JJ O
hypertension BC2GM099522196 NN O
, BC2GM099522196 , O
VT BC2GM099522196 NNP O
is BC2GM099522196 VBZ O
likely BC2GM099522196 JJ O
to BC2GM099522196 TO O
be BC2GM099522196 VB O
refractory BC2GM099522196 JJ O
to BC2GM099522196 TO O
drug BC2GM099522196 NN O
treatment BC2GM099522196 NN O
. BC2GM099522196 . O
. . O O

Fus3p BC2GM038819274 NNP O
and BC2GM038819274 CC O
Kss1p BC2GM038819274 NNP O
together BC2GM038819274 RB O
increase BC2GM038819274 VB O
the BC2GM038819274 DT O
expression BC2GM038819274 NN O
of BC2GM038819274 IN O
CLN3 BC2GM038819274 NNP O
and BC2GM038819274 CC O
PCL2 BC2GM038819274 NNP O
genes BC2GM038819274 NNS O
that BC2GM038819274 WDT O
promote BC2GM038819274 VBP O
budding BC2GM038819274 NN O
, BC2GM038819274 , O
and BC2GM038819274 CC O
Kss1p BC2GM038819274 NNP O
inhibits BC2GM038819274 VBZ O
the BC2GM038819274 DT O
MAP BC2GM038819274 NNP O
kinase BC2GM038819274 NN O
cascade BC2GM038819274 NN O
. BC2GM038819274 . O
. . O O

In BC2GM062590002 IN O
a BC2GM062590002 DT O
rat BC2GM062590002 NN O
model BC2GM062590002 NN O
of BC2GM062590002 IN O
SAH BC2GM062590002 NNP O
, BC2GM062590002 , O
we BC2GM062590002 PRP O
assessed BC2GM062590002 VBD O
BBB BC2GM062590002 NNP O
changes BC2GM062590002 NNS O
by BC2GM062590002 IN O
means BC2GM062590002 NNS O
of BC2GM062590002 IN O
the BC2GM062590002 DT O
quantitative BC2GM062590002 JJ O
[ BC2GM062590002 NN O
14C BC2GM062590002 CD O
] BC2GM062590002 NNP O
-alpha-aminoisobutyric BC2GM062590002 JJ O
acid BC2GM062590002 NN O
technique BC2GM062590002 NN O
. BC2GM062590002 . O
. . O O

Comparison BC2GM074705876 NNP O
between BC2GM074705876 IN O
the BC2GM074705876 DT O
Ricketts BC2GM074705876 NNP O
and BC2GM074705876 CC O
Bimler BC2GM074705876 NNP O
therapeutic BC2GM074705876 JJ O
technics BC2GM074705876 NNS O
in BC2GM074705876 IN O
the BC2GM074705876 DT O
treatment BC2GM074705876 NN O
of BC2GM074705876 IN O
cases BC2GM074705876 NNS O
of BC2GM074705876 IN O
class BC2GM074705876 NN O
II BC2GM074705876 NNP O
, BC2GM074705876 , O
division BC2GM074705876 NN O
I BC2GM074705876 PRP O
mmalocclusion BC2GM074705876 VBP O
. BC2GM074705876 . O
. . O O

TFEC BC2GM096877178 NNP O
RNA BC2GM096877178 NNP O
is BC2GM096877178 VBZ O
found BC2GM096877178 VBN O
in BC2GM096877178 IN O
many BC2GM096877178 JJ O
tissues BC2GM096877178 NNS O
of BC2GM096877178 IN O
adult BC2GM096877178 NN O
rats BC2GM096877178 NNS O
, BC2GM096877178 , O
but BC2GM096877178 CC O
the BC2GM096877178 DT O
relative BC2GM096877178 JJ O
concentrations BC2GM096877178 NNS O
of BC2GM096877178 IN O
TFEC BC2GM096877178 NNP O
and BC2GM096877178 CC O
TFE3 BC2GM096877178 NNP O
RNAs BC2GM096877178 NNP O
vary BC2GM096877178 NN O
considerably BC2GM096877178 RB O
in BC2GM096877178 IN O
these BC2GM096877178 DT O
different BC2GM096877178 JJ O
tissues BC2GM096877178 NNS O
. BC2GM096877178 . O
. . O O

Radiological BC2GM090980905 JJ O
imaging BC2GM090980905 NN O
such BC2GM090980905 JJ O
as BC2GM090980905 IN O
UGI BC2GM090980905 NNP O
series BC2GM090980905 NN O
and BC2GM090980905 CC O
CT BC2GM090980905 NNP O
scan BC2GM090980905 NN O
was BC2GM090980905 VBD O
useful BC2GM090980905 JJ O
to BC2GM090980905 TO O
arrive BC2GM090980905 VB O
at BC2GM090980905 IN O
an BC2GM090980905 DT O
accurate BC2GM090980905 JJ O
diagnosis BC2GM090980905 NN O
. BC2GM090980905 . O
. . O O

Modified BC2GM092831891 NNP O
Grocott BC2GM092831891 NNP O
's BC2GM092831891 POS O
methenamine BC2GM092831891 NN O
silver BC2GM092831891 NN O
nitrate BC2GM092831891 NN O
method BC2GM092831891 NN O
for BC2GM092831891 IN O
quick BC2GM092831891 JJ O
staining BC2GM092831891 NN O
of BC2GM092831891 IN O
Pneumocystis BC2GM092831891 NNP O
carinii BC2GM092831891 NN O
. BC2GM092831891 . O
. . O O

CHIEF BC2GM003943388 NNP O
OUTCOME BC2GM003943388 NNP O
MEASURES BC2GM003943388 NNP O
: BC2GM003943388 : O
Endoluminal BC2GM003943388 JJ O
release BC2GM003943388 NN O
of BC2GM003943388 IN O
prostacyclin BC2GM003943388 NN O
( BC2GM003943388 ( O
6-Keto-PGF1 BC2GM003943388 JJ O
alpha BC2GM003943388 NN O
) BC2GM003943388 ) O
and BC2GM003943388 CC O
thromboxane BC2GM003943388 JJ O
B2 BC2GM003943388 NNP O
( BC2GM003943388 ( O
TxB2 BC2GM003943388 NNP O
) BC2GM003943388 ) O
, BC2GM003943388 , O
patency BC2GM003943388 NN O
, BC2GM003943388 , O
EC BC2GM003943388 NNP O
coverage BC2GM003943388 NN O
and BC2GM003943388 CC O
cell BC2GM003943388 NN O
identity BC2GM003943388 NN O
. BC2GM003943388 . O
. . O O

Multiple BC2GM055980217 NNP O
organ BC2GM055980217 JJ O
failure BC2GM055980217 NN O
( BC2GM055980217 ( O
MOF BC2GM055980217 NNP O
) BC2GM055980217 ) O
following BC2GM055980217 VBG O
major BC2GM055980217 JJ O
trauma BC2GM055980217 NN O
occurs BC2GM055980217 VBZ O
in BC2GM055980217 IN O
response BC2GM055980217 NN O
to BC2GM055980217 TO O
perfusion BC2GM055980217 NN O
deficits BC2GM055980217 NNS O
, BC2GM055980217 , O
a BC2GM055980217 DT O
persistent BC2GM055980217 JJ O
inflammatory BC2GM055980217 NN O
focus BC2GM055980217 NN O
, BC2GM055980217 , O
or BC2GM055980217 CC O
a BC2GM055980217 DT O
persistent BC2GM055980217 JJ O
focus BC2GM055980217 NN O
of BC2GM055980217 IN O
dead BC2GM055980217 JJ O
and BC2GM055980217 CC O
/ BC2GM055980217 JJ O
or BC2GM055980217 CC O
injured BC2GM055980217 JJ O
tissue BC2GM055980217 NN O
. BC2GM055980217 . O
. . O O

During BC2GM072370465 IN O
hexamethylene BC2GM072370465 JJ O
bisactamide BC2GM072370465 NN O
( BC2GM072370465 ( O
HMBA BC2GM072370465 NNP O
) BC2GM072370465 ) O
-induced BC2GM072370465 VBD O
differentiation BC2GM072370465 NN O
of BC2GM072370465 IN O
murine BC2GM072370465 NN O
erythroleukemia BC2GM072370465 NN O
( BC2GM072370465 ( O
MEL BC2GM072370465 NNP O
) BC2GM072370465 ) O
cells BC2GM072370465 NNS O
erythroid BC2GM072370465 JJ O
genes BC2GM072370465 NNS O
are BC2GM072370465 VBP O
transcriptionally BC2GM072370465 RB O
activated BC2GM072370465 VBN O
while BC2GM072370465 IN O
c-myb BC2GM072370465 JJ O
and BC2GM072370465 CC O
several BC2GM072370465 JJ O
other BC2GM072370465 JJ O
nuclear BC2GM072370465 JJ O
proto-oncogenes BC2GM072370465 NNS O
are BC2GM072370465 VBP O
down-regulated BC2GM072370465 JJ O
. BC2GM072370465 . O
. . O O

Furthermore BC2GM007514824 RB O
, BC2GM007514824 , O
the BC2GM007514824 DT O
cognate BC2GM007514824 NN O
binding BC2GM007514824 NN O
protein BC2GM007514824 NN O
is BC2GM007514824 VBZ O
present BC2GM007514824 JJ O
in BC2GM007514824 IN O
both BC2GM007514824 DT O
rat BC2GM007514824 NN O
and BC2GM007514824 CC O
human BC2GM007514824 NN O
( BC2GM007514824 ( O
HeLa BC2GM007514824 NNP O
) BC2GM007514824 ) O
cell BC2GM007514824 NN O
nuclear BC2GM007514824 JJ O
extracts BC2GM007514824 NNS O
. BC2GM007514824 . O
. . O O

They BC2GM079386869 PRP O
are BC2GM079386869 VBP O
both BC2GM079386869 DT O
insensitive BC2GM079386869 JJ O
to BC2GM079386869 TO O
inhibitors BC2GM079386869 NNS O
of BC2GM079386869 IN O
serine BC2GM079386869 NN O
and BC2GM079386869 CC O
aspartyl BC2GM079386869 JJ O
proteinases BC2GM079386869 NNS O
but BC2GM079386869 CC O
are BC2GM079386869 VBP O
sensitive BC2GM079386869 JJ O
to BC2GM079386869 TO O
sulfhydryl BC2GM079386869 VB O
reagents BC2GM079386869 NNS O
and BC2GM079386869 CC O
0.5 BC2GM079386869 CD O
mM BC2GM079386869 NN O
ZnCl2 BC2GM079386869 NNP O
. BC2GM079386869 . O
. . O O

Blood BC2GM039478548 NNP O
pressure BC2GM039478548 NN O
was BC2GM039478548 VBD O
controlled BC2GM039478548 VBN O
long BC2GM039478548 JJ O
term BC2GM039478548 NN O
( BC2GM039478548 ( O
with BC2GM039478548 IN O
/ BC2GM039478548 NN O
without BC2GM039478548 IN O
diuretics BC2GM039478548 NNS O
/ BC2GM039478548 JJ O
beta-adrenoreceptor BC2GM039478548 JJ O
blocking BC2GM039478548 VBG O
drugs BC2GM039478548 NNS O
) BC2GM039478548 ) O
in BC2GM039478548 IN O
sixteen BC2GM039478548 JJ O
out BC2GM039478548 IN O
of BC2GM039478548 IN O
nineteen BC2GM039478548 JJ O
patients BC2GM039478548 NNS O
with BC2GM039478548 IN O
mild-moderate BC2GM039478548 JJ O
hypertension BC2GM039478548 NN O
. BC2GM039478548 . O
. . O O

Trimethylcolchicinic BC2GM085145891 JJ O
acid BC2GM085145891 NN O
methyl BC2GM085145891 NN O
ether BC2GM085145891 RB O
d-tartrate BC2GM085145891 NN O
( BC2GM085145891 ( O
TMCA BC2GM085145891 NNP O
; BC2GM085145891 : O
NSC-36351 BC2GM085145891 NNP O
) BC2GM085145891 ) O
was BC2GM085145891 VBD O
administered BC2GM085145891 VBN O
daily BC2GM085145891 RB O
by BC2GM085145891 IN O
mouth BC2GM085145891 NN O
to BC2GM085145891 TO O
71 BC2GM085145891 CD O
patients BC2GM085145891 NNS O
with BC2GM085145891 IN O
malignant BC2GM085145891 JJ O
lymphomas BC2GM085145891 NN O
. BC2GM085145891 . O
. . O O

The BC2GM032564148 DT O
authors BC2GM032564148 NNS O
suggest BC2GM032564148 VBP O
that BC2GM032564148 IN O
alprazolam BC2GM032564148 NN O
may BC2GM032564148 MD O
have BC2GM032564148 VB O
enhanced BC2GM032564148 VBN O
specificity BC2GM032564148 NN O
for BC2GM032564148 IN O
a BC2GM032564148 DT O
subpopulation BC2GM032564148 NN O
of BC2GM032564148 IN O
benzodiazepine BC2GM032564148 NN O
receptors BC2GM032564148 NNS O
. BC2GM032564148 . O
. . O O

Cloning BC2GM020687268 NNP O
, BC2GM020687268 , O
sequence BC2GM020687268 NN O
analysis BC2GM020687268 NN O
, BC2GM020687268 , O
and BC2GM020687268 CC O
expression BC2GM020687268 NN O
of BC2GM020687268 IN O
the BC2GM020687268 DT O
gene BC2GM020687268 NN O
encoding BC2GM020687268 VBG O
formaldehyde BC2GM020687268 JJ O
dismutase BC2GM020687268 NN O
from BC2GM020687268 IN O
Pseudomonas BC2GM020687268 NNP O
putida BC2GM020687268 NN O
F61 BC2GM020687268 NNP O
. BC2GM020687268 . O
. . O O

Characterization BC2GM030204205 NN O
of BC2GM030204205 IN O
insertion BC2GM030204205 NN O
mutations BC2GM030204205 NNS O
in BC2GM030204205 IN O
the BC2GM030204205 DT O
Saccharomyces BC2GM030204205 NNP O
cerevisiae BC2GM030204205 NN O
MSH1 BC2GM030204205 NNP O
and BC2GM030204205 CC O
MSH2 BC2GM030204205 NNP O
genes BC2GM030204205 NNS O
: BC2GM030204205 : O
evidence BC2GM030204205 NN O
for BC2GM030204205 IN O
separate BC2GM030204205 JJ O
mitochondrial BC2GM030204205 NN O
and BC2GM030204205 CC O
nuclear BC2GM030204205 JJ O
functions BC2GM030204205 NNS O
. BC2GM030204205 . O
. . O O

Cytokine-mediated BC2GM027258079 JJ O
I BC2GM027258079 PRP O
kappa BC2GM027258079 VBP O
B BC2GM027258079 NNP O
alpha BC2GM027258079 NN O
reappearance BC2GM027258079 NN O
was BC2GM027258079 VBD O
completely BC2GM027258079 RB O
blocked BC2GM027258079 VBN O
by BC2GM027258079 IN O
the BC2GM027258079 DT O
protein BC2GM027258079 NN O
synthesis BC2GM027258079 NN O
inhibitor BC2GM027258079 NN O
cycloheximide BC2GM027258079 NN O
. BC2GM027258079 . O
. . O O

Repression BC2GM091983873 NN O
of BC2GM091983873 IN O
the BC2GM091983873 DT O
herpes BC2GM091983873 NNS O
simplex BC2GM091983873 VBP O
virus BC2GM091983873 NN O
1 BC2GM091983873 CD O
alpha BC2GM091983873 NN O
4 BC2GM091983873 CD O
gene BC2GM091983873 NN O
by BC2GM091983873 IN O
its BC2GM091983873 PRP$ O
gene BC2GM091983873 NN O
product BC2GM091983873 NN O
( BC2GM091983873 ( O
ICP4 BC2GM091983873 NNP O
) BC2GM091983873 ) O
within BC2GM091983873 IN O
the BC2GM091983873 DT O
context BC2GM091983873 NN O
of BC2GM091983873 IN O
the BC2GM091983873 DT O
viral BC2GM091983873 JJ O
genome BC2GM091983873 NN O
is BC2GM091983873 VBZ O
conditioned BC2GM091983873 VBN O
by BC2GM091983873 IN O
the BC2GM091983873 DT O
distance BC2GM091983873 NN O
and BC2GM091983873 CC O
stereoaxial BC2GM091983873 JJ O
alignment BC2GM091983873 NN O
of BC2GM091983873 IN O
the BC2GM091983873 DT O
ICP4 BC2GM091983873 NNP O
DNA BC2GM091983873 NNP O
binding BC2GM091983873 VBG O
site BC2GM091983873 NN O
relative BC2GM091983873 NN O
to BC2GM091983873 TO O
the BC2GM091983873 DT O
TATA BC2GM091983873 NNP O
box BC2GM091983873 NN O
. BC2GM091983873 . O
. . O O

These BC2GM083857019 DT O
two BC2GM083857019 CD O
enhancer BC2GM083857019 NN O
elements BC2GM083857019 NNS O
also BC2GM083857019 RB O
enhanced BC2GM083857019 VBD O
transcription BC2GM083857019 NN O
when BC2GM083857019 WRB O
fused BC2GM083857019 VBD O
separately BC2GM083857019 RB O
to BC2GM083857019 TO O
the BC2GM083857019 DT O
basal BC2GM083857019 NN O
promoter BC2GM083857019 NN O
region BC2GM083857019 NN O
of BC2GM083857019 IN O
the BC2GM083857019 DT O
chicken BC2GM083857019 NN O
vimentin BC2GM083857019 NN O
gene BC2GM083857019 NN O
. BC2GM083857019 . O
. . O O

Effect BC2GM042332667 NN O
of BC2GM042332667 IN O
family BC2GM042332667 NN O
visits BC2GM042332667 NNS O
on BC2GM042332667 IN O
the BC2GM042332667 DT O
blood BC2GM042332667 NN O
pressure BC2GM042332667 NN O
and BC2GM042332667 CC O
heart BC2GM042332667 NN O
rate BC2GM042332667 NN O
of BC2GM042332667 IN O
patients BC2GM042332667 NNS O
in BC2GM042332667 IN O
the BC2GM042332667 DT O
coronary-care BC2GM042332667 JJ O
unit BC2GM042332667 NN O
. BC2GM042332667 . O
. . O O

Surprisingly BC2GM071848637 RB O
, BC2GM071848637 , O
in BC2GM071848637 IN O
adult BC2GM071848637 NN O
animals BC2GM071848637 NNS O
, BC2GM071848637 , O
the BC2GM071848637 DT O
suprabasal BC2GM071848637 JJ O
expression BC2GM071848637 NN O
of BC2GM071848637 IN O
dnRXR BC2GM071848637 NN O
alpha BC2GM071848637 NN O
significantly BC2GM071848637 RB O
reduced BC2GM071848637 VBD O
the BC2GM071848637 DT O
ability BC2GM071848637 NN O
of BC2GM071848637 IN O
topically BC2GM071848637 RB O
applied BC2GM071848637 VBN O
tRA BC2GM071848637 NN O
to BC2GM071848637 TO O
stimulate BC2GM071848637 VB O
proliferation BC2GM071848637 NN O
of BC2GM071848637 IN O
undifferentiated BC2GM071848637 JJ O
keratinocytes BC2GM071848637 NNS O
in BC2GM071848637 IN O
the BC2GM071848637 DT O
basal BC2GM071848637 NN O
layer BC2GM071848637 NN O
of BC2GM071848637 IN O
epidermis BC2GM071848637 NN O
. BC2GM071848637 . O
. . O O

We BC2GM011718257 PRP O
report BC2GM011718257 VBP O
here BC2GM011718257 RB O
on BC2GM011718257 IN O
an BC2GM011718257 DT O
eight-year-old BC2GM011718257 JJ O
boy BC2GM011718257 NN O
who BC2GM011718257 WP O
first BC2GM011718257 RB O
developed BC2GM011718257 VBD O
acute BC2GM011718257 VB O
intravascular BC2GM011718257 JJ O
hemolysis BC2GM011718257 NN O
following BC2GM011718257 VBG O
therapy BC2GM011718257 NN O
with BC2GM011718257 IN O
amphotericin BC2GM011718257 NN O
B BC2GM011718257 NNP O
( BC2GM011718257 ( O
AmB BC2GM011718257 NNP O
) BC2GM011718257 ) O
and BC2GM011718257 CC O
subsequently BC2GM011718257 RB O
a BC2GM011718257 DT O
delayed BC2GM011718257 JJ O
hemolytic BC2GM011718257 JJ O
transfusion BC2GM011718257 NN O
reaction BC2GM011718257 NN O
due BC2GM011718257 JJ O
to BC2GM011718257 TO O
alloantibodies BC2GM011718257 NNS O
. BC2GM011718257 . O
. . O O

The BC2GM020608832 DT O
relationship BC2GM020608832 NN O
between BC2GM020608832 IN O
polymorphonuclear BC2GM020608832 JJ O
granulocytes BC2GM020608832 NNS O
and BC2GM020608832 CC O
cartilage BC2GM020608832 NN O
destruction BC2GM020608832 NN O
in BC2GM020608832 IN O
rheumatoid BC2GM020608832 JJ O
arthritis BC2GM020608832 NN O
. BC2GM020608832 . O
. . O O

Somatic BC2GM044076816 JJ O
and BC2GM044076816 CC O
visceral BC2GM044076816 JJ O
inputs BC2GM044076816 NNS O
to BC2GM044076816 TO O
the BC2GM044076816 DT O
thoracic BC2GM044076816 JJ O
spinal BC2GM044076816 JJ O
cord BC2GM044076816 NN O
of BC2GM044076816 IN O
the BC2GM044076816 DT O
cat BC2GM044076816 NN O
: BC2GM044076816 : O
effects BC2GM044076816 NNS O
of BC2GM044076816 IN O
noxious BC2GM044076816 JJ O
stimulation BC2GM044076816 NN O
of BC2GM044076816 IN O
the BC2GM044076816 DT O
biliary BC2GM044076816 JJ O
system BC2GM044076816 NN O
. BC2GM044076816 . O
. . O O

Deletion BC2GM031489380 NN O
of BC2GM031489380 IN O
CDC5 BC2GM031489380 NNP O
was BC2GM031489380 VBD O
lethal BC2GM031489380 JJ O
and BC2GM031489380 CC O
resulted BC2GM031489380 VBD O
in BC2GM031489380 IN O
a BC2GM031489380 DT O
dumbbell-shaped BC2GM031489380 JJ O
terminal BC2GM031489380 JJ O
morphology BC2GM031489380 NN O
, BC2GM031489380 , O
with BC2GM031489380 IN O
the BC2GM031489380 DT O
nuclei BC2GM031489380 NN O
almost BC2GM031489380 RB O
divided BC2GM031489380 VBD O
but BC2GM031489380 CC O
still BC2GM031489380 RB O
connected BC2GM031489380 VBN O
. BC2GM031489380 . O
. . O O

The BC2GM070904413 DT O
translational BC2GM070904413 JJ O
product BC2GM070904413 NN O
of BC2GM070904413 IN O
UL26.5 BC2GM070904413 NNP O
is BC2GM070904413 VBZ O
infected-cell BC2GM070904413 JJ O
protein BC2GM070904413 NN O
35c BC2GM070904413 CD O
, BC2GM070904413 , O
d BC2GM070904413 NN O
( BC2GM070904413 ( O
ICP35c BC2GM070904413 NNP O
, BC2GM070904413 , O
d BC2GM070904413 NN O
) BC2GM070904413 ) O
( BC2GM070904413 ( O
F BC2GM070904413 NNP O
. BC2GM070904413 . O
. . O O

Sequencing BC2GM083317663 VBG O
of BC2GM083317663 IN O
this BC2GM083317663 DT O
fragment BC2GM083317663 NN O
showed BC2GM083317663 VBD O
that BC2GM083317663 IN O
the BC2GM083317663 DT O
MRP13 BC2GM083317663 NNP O
coding BC2GM083317663 VBG O
region BC2GM083317663 NN O
specifies BC2GM083317663 VBZ O
a BC2GM083317663 DT O
324-amino-acid BC2GM083317663 JJ O
basic BC2GM083317663 JJ O
protein BC2GM083317663 NN O
with BC2GM083317663 IN O
a BC2GM083317663 DT O
calculated BC2GM083317663 JJ O
Mr BC2GM083317663 NNP O
of BC2GM083317663 IN O
37,366 BC2GM083317663 CD O
. BC2GM083317663 . O
. . O O

The BC2GM020770465 DT O
IGFBP-1 BC2GM020770465 NNP O
IRS BC2GM020770465 NNP O
and BC2GM020770465 CC O
PEPCK BC2GM020770465 NNP O
IRS BC2GM020770465 NNP O
both BC2GM020770465 DT O
bind BC2GM020770465 IN O
the BC2GM020770465 DT O
alpha BC2GM020770465 NN O
and BC2GM020770465 CC O
beta BC2GM020770465 NN O
forms BC2GM020770465 NNS O
of BC2GM020770465 IN O
hepatic BC2GM020770465 JJ O
nuclear BC2GM020770465 JJ O
factor BC2GM020770465 NN O
3 BC2GM020770465 CD O
( BC2GM020770465 ( O
HNF-3 BC2GM020770465 NNP O
) BC2GM020770465 ) O
, BC2GM020770465 , O
although BC2GM020770465 IN O
the BC2GM020770465 DT O
latter BC2GM020770465 NN O
does BC2GM020770465 VBZ O
so BC2GM020770465 RB O
with BC2GM020770465 IN O
a BC2GM020770465 DT O
sixfold-lower BC2GM020770465 JJ O
relative BC2GM020770465 JJ O
affinity BC2GM020770465 NN O
. BC2GM020770465 . O
. . O O

Expression BC2GM053394099 NN O
of BC2GM053394099 IN O
Msx-1 BC2GM053394099 NNP O
and BC2GM053394099 CC O
Msx-2 BC2GM053394099 NNP O
has BC2GM053394099 VBZ O
been BC2GM053394099 VBN O
studied BC2GM053394099 VBN O
during BC2GM053394099 IN O
development BC2GM053394099 NN O
of BC2GM053394099 IN O
the BC2GM053394099 DT O
osteoblast BC2GM053394099 NN O
phenotype BC2GM053394099 NN O
, BC2GM053394099 , O
but BC2GM053394099 CC O
the BC2GM053394099 DT O
role BC2GM053394099 NN O
of BC2GM053394099 IN O
Dlx BC2GM053394099 NNP O
in BC2GM053394099 IN O
this BC2GM053394099 DT O
context BC2GM053394099 NN O
and BC2GM053394099 CC O
in BC2GM053394099 IN O
the BC2GM053394099 DT O
regulation BC2GM053394099 NN O
of BC2GM053394099 IN O
bone-expressed BC2GM053394099 JJ O
genes BC2GM053394099 NNS O
is BC2GM053394099 VBZ O
unknown BC2GM053394099 JJ O
. BC2GM053394099 . O
. . O O

The BC2GM069948018 DT O
LIF BC2GM069948018 NNP O
appeared BC2GM069948018 VBD O
to BC2GM069948018 TO O
be BC2GM069948018 VB O
released BC2GM069948018 VBN O
by BC2GM069948018 IN O
the BC2GM069948018 DT O
patient BC2GM069948018 NN O
's BC2GM069948018 POS O
peripheral BC2GM069948018 JJ O
blood BC2GM069948018 NN O
lymphocytes BC2GM069948018 NNS O
when BC2GM069948018 WRB O
cultured BC2GM069948018 VBN O
with BC2GM069948018 IN O
optimal BC2GM069948018 JJ O
doses BC2GM069948018 NNS O
of BC2GM069948018 IN O
propranolol BC2GM069948018 NN O
. BC2GM069948018 . O
. . O O

Similar BC2GM084547844 JJ O
tissue-specific BC2GM084547844 NN O
patterns BC2GM084547844 NNS O
are BC2GM084547844 VBP O
observed BC2GM084547844 VBN O
with BC2GM084547844 IN O
a BC2GM084547844 DT O
fusion BC2GM084547844 NN O
between BC2GM084547844 IN O
the BC2GM084547844 DT O
caufliflower BC2GM084547844 NN O
mosaic BC2GM084547844 NN O
virus BC2GM084547844 NN O
35S BC2GM084547844 CD O
RNA BC2GM084547844 NNP O
promotor BC2GM084547844 NN O
and BC2GM084547844 CC O
the BC2GM084547844 DT O
GUS BC2GM084547844 NNP O
gene BC2GM084547844 NN O
. BC2GM084547844 . O
. . O O

The BC2GM085686844 DT O
immune BC2GM085686844 JJ O
response BC2GM085686844 NN O
seems BC2GM085686844 VBZ O
to BC2GM085686844 TO O
be BC2GM085686844 VB O
partially BC2GM085686844 RB O
responsible BC2GM085686844 JJ O
for BC2GM085686844 IN O
both BC2GM085686844 DT O
protection BC2GM085686844 NN O
and BC2GM085686844 CC O
the BC2GM085686844 DT O
destructive BC2GM085686844 JJ O
consequences BC2GM085686844 NNS O
of BC2GM085686844 IN O
chlamydial BC2GM085686844 JJ O
infection BC2GM085686844 NN O
. BC2GM085686844 . O
. . O O

OBJECTIVE BC2GM070662634 NN O
: BC2GM070662634 : O
The BC2GM070662634 DT O
audiologic BC2GM070662634 JJ O
presentation BC2GM070662634 NN O
of BC2GM070662634 IN O
vestibular BC2GM070662634 JJ O
schwannoma BC2GM070662634 NN O
( BC2GM070662634 ( O
VS BC2GM070662634 NNP O
) BC2GM070662634 ) O
associated BC2GM070662634 VBN O
with BC2GM070662634 IN O
neurofibromatosis BC2GM070662634 NN O
type BC2GM070662634 NN O
2 BC2GM070662634 CD O
( BC2GM070662634 ( O
NF2 BC2GM070662634 NNP O
) BC2GM070662634 ) O
has BC2GM070662634 VBZ O
not BC2GM070662634 RB O
been BC2GM070662634 VBN O
well BC2GM070662634 RB O
characterized BC2GM070662634 VBN O
. BC2GM070662634 . O
. . O O

Early BC2GM024107686 JJ O
attempts BC2GM024107686 NNS O
for BC2GM024107686 IN O
modifying BC2GM024107686 VBG O
growth BC2GM024107686 NN O
functions BC2GM024107686 NNS O
to BC2GM024107686 TO O
annual BC2GM024107686 JJ O
variations BC2GM024107686 NNS O
dating BC2GM024107686 VBG O
back BC2GM024107686 RB O
up BC2GM024107686 RB O
to BC2GM024107686 TO O
2 BC2GM024107686 CD O
decades BC2GM024107686 NNS O
are BC2GM024107686 VBP O
recalled BC2GM024107686 VBN O
together BC2GM024107686 RB O
with BC2GM024107686 IN O
examples BC2GM024107686 NNS O
for BC2GM024107686 IN O
their BC2GM024107686 PRP$ O
application BC2GM024107686 NN O
showing BC2GM024107686 VBG O
rather BC2GM024107686 RB O
different BC2GM024107686 JJ O
degrees BC2GM024107686 NNS O
of BC2GM024107686 IN O
approximation BC2GM024107686 NN O
. BC2GM024107686 . O
. . O O

Characterization BC2GM088026149 NN O
of BC2GM088026149 IN O
human BC2GM088026149 JJ O
activating BC2GM088026149 VBG O
transcription BC2GM088026149 NN O
factor BC2GM088026149 NN O
4 BC2GM088026149 CD O
, BC2GM088026149 , O
a BC2GM088026149 DT O
transcriptional BC2GM088026149 JJ O
activator BC2GM088026149 NN O
that BC2GM088026149 WDT O
interacts BC2GM088026149 VBZ O
with BC2GM088026149 IN O
multiple BC2GM088026149 JJ O
domains BC2GM088026149 NNS O
of BC2GM088026149 IN O
cAMP-responsive BC2GM088026149 JJ O
element-binding BC2GM088026149 JJ O
protein BC2GM088026149 NN O
( BC2GM088026149 ( O
CREB BC2GM088026149 NNP O
) BC2GM088026149 ) O
-binding BC2GM088026149 VBG O
protein BC2GM088026149 NN O
. BC2GM088026149 . O
. . O O

The BC2GM019812857 DT O
MEE BC2GM019812857 NNP O
was BC2GM019812857 VBD O
significantly BC2GM019812857 RB O
greater BC2GM019812857 JJR O
than BC2GM019812857 IN O
the BC2GM019812857 DT O
BEE BC2GM019812857 NNP O
and BC2GM019812857 CC O
significantly BC2GM019812857 RB O
less BC2GM019812857 JJR O
than BC2GM019812857 IN O
the BC2GM019812857 DT O
calculated BC2GM019812857 JJ O
energy BC2GM019812857 NN O
expenditure BC2GM019812857 NN O
. BC2GM019812857 . O
. . O O

No BC2GM037653411 DT O
effect BC2GM037653411 NN O
of BC2GM037653411 IN O
4 BC2GM037653411 CD O
beta-phorbol BC2GM037653411 JJ O
12-myristate BC2GM037653411 JJ O
13-acetate BC2GM037653411 NN O
was BC2GM037653411 VBD O
observed BC2GM037653411 VBN O
on BC2GM037653411 IN O
the BC2GM037653411 DT O
expression BC2GM037653411 NN O
of BC2GM037653411 IN O
hnRNP BC2GM037653411 NN O
H BC2GM037653411 NNP O
. BC2GM037653411 . O
. . O O

Interconversions BC2GM037219569 NNS O
between BC2GM037219569 IN O
haloperidol BC2GM037219569 NN O
and BC2GM037219569 CC O
reduced BC2GM037219569 JJ O
haloperidol BC2GM037219569 NN O
in BC2GM037219569 IN O
schizophrenic BC2GM037219569 JJ O
patients BC2GM037219569 NNS O
and BC2GM037219569 CC O
guinea BC2GM037219569 NN O
pigs BC2GM037219569 NNS O
: BC2GM037219569 : O
a BC2GM037219569 DT O
steady-state BC2GM037219569 JJ O
study BC2GM037219569 NN O
. BC2GM037219569 . O
. . O O

The BC2GM021675012 DT O
nucleoporin BC2GM021675012 JJ O
98 BC2GM021675012 CD O
gene BC2GM021675012 NN O
( BC2GM021675012 ( O
NUP98 BC2GM021675012 NNP O
) BC2GM021675012 ) O
, BC2GM021675012 , O
which BC2GM021675012 WDT O
is BC2GM021675012 VBZ O
rearranged BC2GM021675012 VBN O
in BC2GM021675012 IN O
several BC2GM021675012 JJ O
acute BC2GM021675012 JJ O
myeloid BC2GM021675012 NN O
leukemia BC2GM021675012 NN O
translocations BC2GM021675012 NNS O
, BC2GM021675012 , O
is BC2GM021675012 VBZ O
located BC2GM021675012 VBN O
within BC2GM021675012 IN O
this BC2GM021675012 DT O
region BC2GM021675012 NN O
. BC2GM021675012 . O
. . O O

The BC2GM037203350 DT O
RNA BC2GM037203350 NNP O
, BC2GM037203350 , O
whether BC2GM037203350 IN O
antisense BC2GM037203350 NN O
, BC2GM037203350 , O
ribozyme BC2GM037203350 NN O
, BC2GM037203350 , O
or BC2GM037203350 CC O
RNA BC2GM037203350 NNP O
aptamer BC2GM037203350 NN O
, BC2GM037203350 , O
must BC2GM037203350 MD O
be BC2GM037203350 VB O
efficiently BC2GM037203350 RB O
transcribed BC2GM037203350 VBN O
, BC2GM037203350 , O
stabilized BC2GM037203350 VBN O
against BC2GM037203350 IN O
rapid BC2GM037203350 JJ O
degradation BC2GM037203350 NN O
, BC2GM037203350 , O
folded BC2GM037203350 VBN O
correctly BC2GM037203350 RB O
, BC2GM037203350 , O
and BC2GM037203350 CC O
directed BC2GM037203350 VBD O
to BC2GM037203350 TO O
the BC2GM037203350 DT O
part BC2GM037203350 NN O
of BC2GM037203350 IN O
the BC2GM037203350 DT O
cell BC2GM037203350 NN O
where BC2GM037203350 WRB O
it BC2GM037203350 PRP O
can BC2GM037203350 MD O
be BC2GM037203350 VB O
most BC2GM037203350 RBS O
effective BC2GM037203350 JJ O
. BC2GM037203350 . O
. . O O

Calculation BC2GM050006872 NN O
of BC2GM050006872 IN O
energy BC2GM050006872 NN O
levels BC2GM050006872 NNS O
, BC2GM050006872 , O
E1 BC2GM050006872 NNP O
transition BC2GM050006872 NN O
amplitudes BC2GM050006872 NNS O
, BC2GM050006872 , O
and BC2GM050006872 CC O
parity BC2GM050006872 NN O
violation BC2GM050006872 NN O
in BC2GM050006872 IN O
francium BC2GM050006872 NN O
. BC2GM050006872 . O
. . O O

Since BC2GM068080836 IN O
it BC2GM068080836 PRP O
is BC2GM068080836 VBZ O
often BC2GM068080836 RB O
necessary BC2GM068080836 JJ O
to BC2GM068080836 TO O
resort BC2GM068080836 VB O
to BC2GM068080836 TO O
thoracotomy BC2GM068080836 VB O
as BC2GM068080836 IN O
a BC2GM068080836 DT O
final BC2GM068080836 JJ O
step BC2GM068080836 NN O
in BC2GM068080836 IN O
making BC2GM068080836 VBG O
such BC2GM068080836 JJ O
a BC2GM068080836 DT O
diagnosis BC2GM068080836 NN O
, BC2GM068080836 , O
we BC2GM068080836 PRP O
have BC2GM068080836 VBP O
sought BC2GM068080836 VBN O
a BC2GM068080836 DT O
procedure BC2GM068080836 NN O
that BC2GM068080836 WDT O
is BC2GM068080836 VBZ O
simpler BC2GM068080836 JJR O
while BC2GM068080836 IN O
capable BC2GM068080836 JJ O
of BC2GM068080836 IN O
providing BC2GM068080836 VBG O
the BC2GM068080836 DT O
same BC2GM068080836 JJ O
information BC2GM068080836 NN O
. BC2GM068080836 . O
. . O O

This BC2GM026151864 DT O
clone BC2GM026151864 NN O
will BC2GM026151864 MD O
be BC2GM026151864 VB O
useful BC2GM026151864 JJ O
for BC2GM026151864 IN O
identifying BC2GM026151864 VBG O
the BC2GM026151864 DT O
genetic BC2GM026151864 JJ O
determinants BC2GM026151864 NNS O
of BC2GM026151864 IN O
FIV-Oma BC2GM026151864 NNP O
's BC2GM026151864 POS O
biological BC2GM026151864 JJ O
activities BC2GM026151864 NNS O
. BC2GM026151864 . O
. . O O

These BC2GM053776586 DT O
results BC2GM053776586 NNS O
suggest BC2GM053776586 VBP O
that BC2GM053776586 IN O
repetitive BC2GM053776586 JJ O
GAA BC2GM053776586 NNP O
sequences BC2GM053776586 NNS O
enhance BC2GM053776586 RB O
splicing BC2GM053776586 VBG O
by BC2GM053776586 IN O
binding BC2GM053776586 VBG O
a BC2GM053776586 DT O
protein BC2GM053776586 NN O
complex BC2GM053776586 JJ O
containing BC2GM053776586 VBG O
a BC2GM053776586 DT O
sequence-specific BC2GM053776586 JJ O
RNA BC2GM053776586 NNP O
binding BC2GM053776586 NN O
protein BC2GM053776586 NN O
and BC2GM053776586 CC O
a BC2GM053776586 DT O
general BC2GM053776586 JJ O
splicing BC2GM053776586 NN O
activator BC2GM053776586 NN O
that BC2GM053776586 IN O
, BC2GM053776586 , O
in BC2GM053776586 IN O
turn BC2GM053776586 NN O
, BC2GM053776586 , O
recruit BC2GM053776586 VBP O
additional BC2GM053776586 JJ O
SR BC2GM053776586 NNP O
proteins BC2GM053776586 NNS O
. BC2GM053776586 . O
. . O O

The BC2GM035233185 DT O
more BC2GM035233185 RBR O
sustained BC2GM035233185 JJ O
effect BC2GM035233185 NN O
of BC2GM035233185 IN O
cyclofenil BC2GM035233185 NN O
on BC2GM035233185 IN O
prolactin BC2GM035233185 JJ O
secretion BC2GM035233185 NN O
with BC2GM035233185 IN O
a BC2GM035233185 DT O
reduced BC2GM035233185 JJ O
frequency BC2GM035233185 NN O
of BC2GM035233185 IN O
relapse BC2GM035233185 NN O
, BC2GM035233185 , O
and BC2GM035233185 CC O
the BC2GM035233185 DT O
lower BC2GM035233185 JJR O
oestradiol BC2GM035233185 JJ O
level BC2GM035233185 NN O
, BC2GM035233185 , O
which BC2GM035233185 WDT O
might BC2GM035233185 MD O
indicate BC2GM035233185 VB O
a BC2GM035233185 DT O
reduced BC2GM035233185 JJ O
risk BC2GM035233185 NN O
of BC2GM035233185 IN O
thromboembolism BC2GM035233185 NN O
, BC2GM035233185 , O
suggest BC2GM035233185 VBP O
that BC2GM035233185 IN O
this BC2GM035233185 DT O
drug BC2GM035233185 NN O
has BC2GM035233185 VBZ O
some BC2GM035233185 DT O
advantage BC2GM035233185 NN O
over BC2GM035233185 IN O
bromocriptine BC2GM035233185 NN O
in BC2GM035233185 IN O
the BC2GM035233185 DT O
inhibition BC2GM035233185 NN O
of BC2GM035233185 IN O
postpartum BC2GM035233185 NN O
lactation BC2GM035233185 NN O
. BC2GM035233185 . O
. . O O

Furthermore BC2GM064960643 RB O
, BC2GM064960643 , O
the BC2GM064960643 DT O
social BC2GM064960643 JJ O
learning BC2GM064960643 NN O
theory BC2GM064960643 NN O
of BC2GM064960643 IN O
depression BC2GM064960643 NN O
, BC2GM064960643 , O
developed BC2GM064960643 VBN O
by BC2GM064960643 IN O
Lewinsohn BC2GM064960643 NNP O
, BC2GM064960643 , O
is BC2GM064960643 VBZ O
described BC2GM064960643 VBN O
. BC2GM064960643 . O
. . O O

It BC2GM083575704 PRP O
is BC2GM083575704 VBZ O
very BC2GM083575704 RB O
probable BC2GM083575704 JJ O
that BC2GM083575704 IN O
this BC2GM083575704 DT O
change BC2GM083575704 NN O
was BC2GM083575704 VBD O
due BC2GM083575704 JJ O
to BC2GM083575704 TO O
mechanical BC2GM083575704 JJ O
effects BC2GM083575704 NNS O
induced BC2GM083575704 VBN O
by BC2GM083575704 IN O
injecting BC2GM083575704 VBG O
a BC2GM083575704 DT O
hypertonic BC2GM083575704 JJ O
solution BC2GM083575704 NN O
of BC2GM083575704 IN O
MT-141 BC2GM083575704 NNP O
at BC2GM083575704 IN O
a BC2GM083575704 DT O
rate BC2GM083575704 NN O
of BC2GM083575704 IN O
70 BC2GM083575704 CD O
-- BC2GM083575704 : O
130 BC2GM083575704 CD O
ml BC2GM083575704 NN O
/ BC2GM083575704 NNP O
dog BC2GM083575704 NN O
. BC2GM083575704 . O
. . O O

Fractional BC2GM056924608 NNP O
Ca BC2GM056924608 NNP O
retention BC2GM056924608 NN O
was BC2GM056924608 VBD O
measured BC2GM056924608 VBN O
from BC2GM056924608 IN O
the BC2GM056924608 DT O
72-h BC2GM056924608 JJ O
postdose BC2GM056924608 NN O
WBR BC2GM056924608 NNP O
divided BC2GM056924608 VBN O
by BC2GM056924608 IN O
WBR BC2GM056924608 NNP O
at BC2GM056924608 IN O
time BC2GM056924608 NN O
0 BC2GM056924608 CD O
. BC2GM056924608 . O
. . O O

( BC2GM072636195 ( O
We BC2GM072636195 PRP O
observed BC2GM072636195 VBD O
a BC2GM072636195 DT O
ferritin BC2GM072636195 JJ O
value BC2GM072636195 NN O
as BC2GM072636195 RB O
high BC2GM072636195 JJ O
as BC2GM072636195 IN O
47 BC2GM072636195 CD O
mg BC2GM072636195 NN O
/ BC2GM072636195 NNP O
L BC2GM072636195 NNP O
in BC2GM072636195 IN O
one BC2GM072636195 CD O
patient BC2GM072636195 NN O
. BC2GM072636195 . O
) BC2GM072636195 ) O
Results BC2GM072636195 NNS O
with BC2GM072636195 IN O
all BC2GM072636195 PDT O
these BC2GM072636195 DT O
kits BC2GM072636195 NNS O
did BC2GM072636195 VBD O
not BC2GM072636195 RB O
inter-compare BC2GM072636195 JJ O
well BC2GM072636195 NN O
for BC2GM072636195 IN O
ferritin BC2GM072636195 NN O
concentrations BC2GM072636195 NNS O
greater BC2GM072636195 JJR O
than BC2GM072636195 IN O
300 BC2GM072636195 CD O
micrograms BC2GM072636195 NNS O
/ BC2GM072636195 JJ O
L BC2GM072636195 NNP O
, BC2GM072636195 , O
a BC2GM072636195 DT O
finding BC2GM072636195 NN O
that BC2GM072636195 WDT O
casts BC2GM072636195 VBZ O
further BC2GM072636195 RB O
doubt BC2GM072636195 NN O
on BC2GM072636195 IN O
the BC2GM072636195 DT O
controversial BC2GM072636195 JJ O
use BC2GM072636195 NN O
of BC2GM072636195 IN O
serum BC2GM072636195 NN O
ferritin BC2GM072636195 NN O
measurement BC2GM072636195 NN O
in BC2GM072636195 IN O
cases BC2GM072636195 NNS O
of BC2GM072636195 IN O
iron BC2GM072636195 NN O
overload BC2GM072636195 NN O
. BC2GM072636195 . O
. . O O

Two BC2GM081464048 CD O
SH2 BC2GM081464048 NNP O
domains BC2GM081464048 NNS O
of BC2GM081464048 IN O
p120 BC2GM081464048 JJ O
Ras BC2GM081464048 NNP O
GTPase-activating BC2GM081464048 NNP O
protein BC2GM081464048 NN O
bind BC2GM081464048 NN O
synergistically BC2GM081464048 RB O
to BC2GM081464048 TO O
tyrosine BC2GM081464048 VB O
phosphorylated BC2GM081464048 VBN O
p190 BC2GM081464048 JJ O
Rho BC2GM081464048 NNP O
GTPase-activating BC2GM081464048 NNP O
protein BC2GM081464048 NN O
. BC2GM081464048 . O
p120 BC2GM081464048 JJ O
GTPase-activating BC2GM081464048 NNP O
protein BC2GM081464048 NN O
( BC2GM081464048 ( O
GAP BC2GM081464048 NNP O
) BC2GM081464048 ) O
is BC2GM081464048 VBZ O
a BC2GM081464048 DT O
negative BC2GM081464048 JJ O
regulator BC2GM081464048 NN O
of BC2GM081464048 IN O
Ras BC2GM081464048 NNP O
that BC2GM081464048 IN O
functions BC2GM081464048 NNS O
at BC2GM081464048 IN O
a BC2GM081464048 DT O
key BC2GM081464048 JJ O
relay BC2GM081464048 NN O
point BC2GM081464048 NN O
in BC2GM081464048 IN O
signal BC2GM081464048 JJ O
transduction BC2GM081464048 NN O
pathways BC2GM081464048 NNS O
that BC2GM081464048 WDT O
control BC2GM081464048 VBP O
cell BC2GM081464048 NN O
proliferation BC2GM081464048 NN O
. BC2GM081464048 . O
. . O O

The BC2GM057310449 DT O
rate BC2GM057310449 NN O
for BC2GM057310449 IN O
Arm BC2GM057310449 NNP O
III BC2GM057310449 NNP O
( BC2GM057310449 ( O
CAF BC2GM057310449 NNP O
therapy BC2GM057310449 NN O
) BC2GM057310449 ) O
was BC2GM057310449 VBD O
61.5 BC2GM057310449 CD O
% BC2GM057310449 NN O
( BC2GM057310449 ( O
32 BC2GM057310449 CD O
/ BC2GM057310449 RB O
52 BC2GM057310449 CD O
) BC2GM057310449 ) O
, BC2GM057310449 , O
a BC2GM057310449 DT O
little BC2GM057310449 JJ O
higher BC2GM057310449 JJR O
than BC2GM057310449 IN O
that BC2GM057310449 DT O
for BC2GM057310449 IN O
the BC2GM057310449 DT O
other BC2GM057310449 JJ O
two BC2GM057310449 CD O
. BC2GM057310449 . O
. . O O

Spinophilin BC2GM002404692 NNP O
, BC2GM002404692 , O
a BC2GM002404692 DT O
novel BC2GM002404692 JJ O
protein BC2GM002404692 NN O
phosphatase BC2GM002404692 NN O
1 BC2GM002404692 CD O
binding BC2GM002404692 NN O
protein BC2GM002404692 NN O
localized BC2GM002404692 VBD O
to BC2GM002404692 TO O
dendritic BC2GM002404692 JJ O
spines BC2GM002404692 NNS O
. BC2GM002404692 . O
. . O O

The BC2GM084597422 DT O
cause BC2GM084597422 NN O
for BC2GM084597422 IN O
the BC2GM084597422 DT O
increase BC2GM084597422 NN O
in BC2GM084597422 IN O
plasma BC2GM084597422 JJ O
ANP BC2GM084597422 NNP O
levels BC2GM084597422 NNS O
in BC2GM084597422 IN O
the BC2GM084597422 DT O
active BC2GM084597422 JJ O
phase BC2GM084597422 NN O
remains BC2GM084597422 VBZ O
to BC2GM084597422 TO O
be BC2GM084597422 VB O
determined BC2GM084597422 VBN O
. BC2GM084597422 . O
. . O O

It BC2GM078836227 PRP O
is BC2GM078836227 VBZ O
of BC2GM078836227 IN O
interest BC2GM078836227 NN O
that BC2GM078836227 IN O
, BC2GM078836227 , O
aside BC2GM078836227 RB O
from BC2GM078836227 IN O
starvation BC2GM078836227 NN O
, BC2GM078836227 , O
the BC2GM078836227 DT O
nutrition BC2GM078836227 NN O
catastrophes BC2GM078836227 NNS O
of BC2GM078836227 IN O
the BC2GM078836227 DT O
past BC2GM078836227 JJ O
, BC2GM078836227 , O
including BC2GM078836227 VBG O
scurvy BC2GM078836227 NN O
( BC2GM078836227 ( O
vitamin BC2GM078836227 JJ O
C BC2GM078836227 NNP O
deficiency BC2GM078836227 NN O
) BC2GM078836227 ) O
resulting BC2GM078836227 VBG O
from BC2GM078836227 IN O
lack BC2GM078836227 NN O
of BC2GM078836227 IN O
fresh BC2GM078836227 JJ O
vegetables BC2GM078836227 NNS O
and BC2GM078836227 CC O
fruit BC2GM078836227 NN O
and BC2GM078836227 CC O
beriberi BC2GM078836227 NN O
( BC2GM078836227 ( O
vitamin BC2GM078836227 JJ O
B1 BC2GM078836227 NNP O
deficiency BC2GM078836227 NN O
) BC2GM078836227 ) O
from BC2GM078836227 IN O
consumption BC2GM078836227 NN O
of BC2GM078836227 IN O
polished BC2GM078836227 JJ O
rice BC2GM078836227 NN O
, BC2GM078836227 , O
are BC2GM078836227 VBP O
forgotten BC2GM078836227 VBN O
and BC2GM078836227 CC O
only BC2GM078836227 RB O
of BC2GM078836227 IN O
interest BC2GM078836227 NN O
as BC2GM078836227 IN O
history BC2GM078836227 NN O
. BC2GM078836227 . O
. . O O

Synergy BC2GM008228861 NNP O
between BC2GM008228861 IN O
interferon-gamma BC2GM008228861 JJ O
and BC2GM008228861 CC O
tumor BC2GM008228861 JJ O
necrosis BC2GM008228861 NN O
factor-alpha BC2GM008228861 NN O
in BC2GM008228861 IN O
transcriptional BC2GM008228861 JJ O
activation BC2GM008228861 NN O
is BC2GM008228861 VBZ O
mediated BC2GM008228861 VBN O
by BC2GM008228861 IN O
cooperation BC2GM008228861 NN O
between BC2GM008228861 IN O
signal BC2GM008228861 JJ O
transducer BC2GM008228861 NN O
and BC2GM008228861 CC O
activator BC2GM008228861 NN O
of BC2GM008228861 IN O
transcription BC2GM008228861 NN O
1 BC2GM008228861 CD O
and BC2GM008228861 CC O
nuclear BC2GM008228861 JJ O
factor BC2GM008228861 NN O
kappaB BC2GM008228861 NN O
. BC2GM008228861 . O
. . O O

For BC2GM006482394 IN O
more BC2GM006482394 JJR O
detailed BC2GM006482394 JJ O
mapping BC2GM006482394 NN O
, BC2GM006482394 , O
we BC2GM006482394 PRP O
constructed BC2GM006482394 VBD O
mouse BC2GM006482394 RB O
A9 BC2GM006482394 NNP O
cells BC2GM006482394 NNS O
containing BC2GM006482394 VBG O
STFs BC2GM006482394 NNP O
derived BC2GM006482394 VBD O
from BC2GM006482394 IN O
human BC2GM006482394 JJ O
chromosome BC2GM006482394 NN O
2 BC2GM006482394 CD O
tagged BC2GM006482394 VBN O
with BC2GM006482394 IN O
pSTneo BC2GM006482394 NN O
at BC2GM006482394 IN O
different BC2GM006482394 JJ O
regions BC2GM006482394 NNS O
in BC2GM006482394 IN O
2q31-qter BC2GM006482394 JJ O
. BC2GM006482394 . O
. . O O

In BC2GM044172582 IN O
this BC2GM044172582 DT O
study BC2GM044172582 NN O
, BC2GM044172582 , O
we BC2GM044172582 PRP O
sought BC2GM044172582 VBD O
to BC2GM044172582 TO O
determine BC2GM044172582 VB O
the BC2GM044172582 DT O
specific BC2GM044172582 JJ O
effect BC2GM044172582 NN O
of BC2GM044172582 IN O
HIV BC2GM044172582 NNP O
protease BC2GM044172582 NN O
inhibitors BC2GM044172582 NNS O
on BC2GM044172582 IN O
patient BC2GM044172582 JJ O
weight BC2GM044172582 NN O
. BC2GM044172582 . O
. . O O

Sixteen BC2GM090366403 JJ O
patients BC2GM090366403 NNS O
on BC2GM090366403 IN O
maintenance BC2GM090366403 NN O
hemodialysis BC2GM090366403 NN O
underwent BC2GM090366403 JJ O
dialysis BC2GM090366403 NN O
with BC2GM090366403 IN O
either BC2GM090366403 DT O
cuprophane BC2GM090366403 NN O
( BC2GM090366403 ( O
n BC2GM090366403 JJ O
= BC2GM090366403 NNP O
8 BC2GM090366403 CD O
) BC2GM090366403 ) O
or BC2GM090366403 CC O
polymethylmethacrylate BC2GM090366403 NN O
( BC2GM090366403 ( O
PMMA BC2GM090366403 NNP O
; BC2GM090366403 : O
n BC2GM090366403 CC O
= BC2GM090366403 VB O
8 BC2GM090366403 CD O
) BC2GM090366403 ) O
membranes BC2GM090366403 NNS O
for BC2GM090366403 IN O
1 BC2GM090366403 CD O
week BC2GM090366403 NN O
and BC2GM090366403 CC O
then BC2GM090366403 RB O
switched BC2GM090366403 VBD O
to BC2GM090366403 TO O
the BC2GM090366403 DT O
opposite BC2GM090366403 JJ O
membrane BC2GM090366403 NN O
during BC2GM090366403 IN O
the BC2GM090366403 DT O
second BC2GM090366403 JJ O
week BC2GM090366403 NN O
. BC2GM090366403 . O
. . O O

Synchronous BC2GM025305972 JJ O
multicentric BC2GM025305972 NN O
giant BC2GM025305972 NN O
cell BC2GM025305972 NN O
tumour BC2GM025305972 NN O
: BC2GM025305972 : O
a BC2GM025305972 DT O
case BC2GM025305972 NN O
report BC2GM025305972 NN O
with BC2GM025305972 IN O
review BC2GM025305972 NN O
of BC2GM025305972 IN O
literature BC2GM025305972 NN O
. BC2GM025305972 . O
. . O O

In BC2GM033814986 IN O
addition BC2GM033814986 NN O
, BC2GM033814986 , O
renal BC2GM033814986 JJ O
sympathetic BC2GM033814986 JJ O
activity BC2GM033814986 NN O
was BC2GM033814986 VBD O
measured BC2GM033814986 VBN O
in BC2GM033814986 IN O
a BC2GM033814986 DT O
separate BC2GM033814986 JJ O
group BC2GM033814986 NN O
of BC2GM033814986 IN O
rats BC2GM033814986 NNS O
. BC2GM033814986 . O
. . O O

Molecular BC2GM052850405 JJ O
cloning BC2GM052850405 NN O
of BC2GM052850405 IN O
cDNAs BC2GM052850405 JJ O
encoding BC2GM052850405 VBG O
alpha-subunits BC2GM052850405 NNS O
of BC2GM052850405 IN O
guanine BC2GM052850405 JJ O
nucleotide-binding BC2GM052850405 JJ O
regulatory BC2GM052850405 JJ O
proteins BC2GM052850405 NNS O
( BC2GM052850405 ( O
G-proteins BC2GM052850405 NNP O
) BC2GM052850405 ) O
has BC2GM052850405 VBZ O
revealed BC2GM052850405 VBN O
the BC2GM052850405 DT O
existence BC2GM052850405 NN O
of BC2GM052850405 IN O
nine BC2GM052850405 CD O
species BC2GM052850405 NNS O
of BC2GM052850405 IN O
alpha-subunits BC2GM052850405 NNS O
. BC2GM052850405 . O
. . O O

Experimental BC2GM097083223 JJ O
production BC2GM097083223 NN O
of BC2GM097083223 IN O
a BC2GM097083223 DT O
syndrome BC2GM097083223 JJ O
analogous BC2GM097083223 JJ O
to BC2GM097083223 TO O
hydramnios BC2GM097083223 VB O
in BC2GM097083223 IN O
the BC2GM097083223 DT O
rat BC2GM097083223 NN O
fetus BC2GM097083223 NN O
. BC2GM097083223 . O
. . O O

To BC2GM026003128 TO O
define BC2GM026003128 VB O
the BC2GM026003128 DT O
molecular BC2GM026003128 JJ O
mechanism BC2GM026003128 NN O
regulating BC2GM026003128 VBG O
FGFR-1 BC2GM026003128 NNP O
gene BC2GM026003128 NN O
expression BC2GM026003128 NN O
in BC2GM026003128 IN O
proliferating BC2GM026003128 VBG O
myoblasts BC2GM026003128 NNS O
and BC2GM026003128 CC O
post-mitotic BC2GM026003128 JJ O
muscle BC2GM026003128 NN O
fibers BC2GM026003128 NNS O
, BC2GM026003128 , O
we BC2GM026003128 PRP O
have BC2GM026003128 VBP O
isolated BC2GM026003128 VBN O
and BC2GM026003128 CC O
partially BC2GM026003128 RB O
characterized BC2GM026003128 VBD O
the BC2GM026003128 DT O
avian BC2GM026003128 JJ O
FGFR-1 BC2GM026003128 NNP O
gene BC2GM026003128 NN O
promoter BC2GM026003128 NN O
. BC2GM026003128 . O
. . O O

Comparisons BC2GM094423214 NNS O
of BC2GM094423214 IN O
the BC2GM094423214 DT O
efficacy BC2GM094423214 NN O
of BC2GM094423214 IN O
benazepril BC2GM094423214 NN O
and BC2GM094423214 CC O
hydrochlorothiazide BC2GM094423214 VB O
alone BC2GM094423214 RB O
and BC2GM094423214 CC O
in BC2GM094423214 IN O
combination BC2GM094423214 NN O
have BC2GM094423214 VBP O
shown BC2GM094423214 VBN O
that BC2GM094423214 IN O
benazepril BC2GM094423214 NN O
20 BC2GM094423214 CD O
mg BC2GM094423214 NN O
once BC2GM094423214 RB O
daily BC2GM094423214 JJ O
is BC2GM094423214 VBZ O
as BC2GM094423214 RB O
effective BC2GM094423214 JJ O
as BC2GM094423214 IN O
or BC2GM094423214 CC O
more BC2GM094423214 RBR O
effective BC2GM094423214 JJ O
in BC2GM094423214 IN O
lowering BC2GM094423214 VBG O
diastolic BC2GM094423214 JJ O
blood BC2GM094423214 NN O
pressure BC2GM094423214 NN O
than BC2GM094423214 IN O
hydrochlorothiazide BC2GM094423214 RB O
25 BC2GM094423214 CD O
mg BC2GM094423214 NNS O
once BC2GM094423214 RB O
daily BC2GM094423214 JJ O
and BC2GM094423214 CC O
that BC2GM094423214 IN O
the BC2GM094423214 DT O
combination BC2GM094423214 NN O
of BC2GM094423214 IN O
benazepril BC2GM094423214 $ O
20 BC2GM094423214 CD O
mg BC2GM094423214 NN O
and BC2GM094423214 CC O
hydrochlorothiazide BC2GM094423214 VB O
25 BC2GM094423214 CD O
mg BC2GM094423214 NN O
has BC2GM094423214 VBZ O
a BC2GM094423214 DT O
possibly BC2GM094423214 RB O
synergistic BC2GM094423214 JJ O
effect BC2GM094423214 NN O
on BC2GM094423214 IN O
diastolic BC2GM094423214 JJ O
blood BC2GM094423214 NN O
pressure BC2GM094423214 NN O
. BC2GM094423214 . O
. . O O

Metabolic BC2GM061513457 NNP O
studies BC2GM061513457 NNS O
of BC2GM061513457 IN O
tetrabenazine BC2GM061513457 NN O
, BC2GM061513457 , O
a BC2GM061513457 DT O
psychotropic BC2GM061513457 JJ O
drug BC2GM061513457 NN O
in BC2GM061513457 IN O
animals BC2GM061513457 NNS O
and BC2GM061513457 CC O
man BC2GM061513457 NN O
. BC2GM061513457 . O
. . O O

When BC2GM079539609 WRB O
the BC2GM079539609 DT O
same BC2GM079539609 JJ O
single-amino-acid BC2GM079539609 JJ O
mutations BC2GM079539609 NNS O
were BC2GM079539609 VBD O
directly BC2GM079539609 RB O
introduced BC2GM079539609 VBN O
into BC2GM079539609 IN O
the BC2GM079539609 DT O
parental BC2GM079539609 JJ O
PV BC2GM079539609 NNP O
/ BC2GM079539609 NNP O
CBV4-2A BC2GM079539609 NNP O
genome BC2GM079539609 NN O
, BC2GM079539609 , O
chimeric BC2GM079539609 JJ O
viruses BC2GM079539609 NNS O
with BC2GM079539609 IN O
a BC2GM079539609 DT O
large-plaque BC2GM079539609 JJ O
phenotype BC2GM079539609 NN O
and BC2GM079539609 CC O
a BC2GM079539609 DT O
wild-type BC2GM079539609 JJ O
PV-like BC2GM079539609 JJ O
growth BC2GM079539609 NN O
pattern BC2GM079539609 NN O
were BC2GM079539609 VBD O
obtained BC2GM079539609 VBN O
upon BC2GM079539609 IN O
transfection BC2GM079539609 NN O
, BC2GM079539609 , O
an BC2GM079539609 DT O
observation BC2GM079539609 NN O
demonstrating BC2GM079539609 VBG O
that BC2GM079539609 IN O
these BC2GM079539609 DT O
point BC2GM079539609 NN O
mutations BC2GM079539609 NNS O
alone BC2GM079539609 RB O
had BC2GM079539609 VBD O
a BC2GM079539609 DT O
drastic BC2GM079539609 JJ O
effect BC2GM079539609 NN O
on BC2GM079539609 IN O
the BC2GM079539609 DT O
growth BC2GM079539609 NN O
of BC2GM079539609 IN O
the BC2GM079539609 DT O
PV BC2GM079539609 NNP O
/ BC2GM079539609 NNP O
CBV4 BC2GM079539609 NNP O
chimeric BC2GM079539609 JJ O
virus BC2GM079539609 NN O
. BC2GM079539609 . O
. . O O

The BC2GM026829531 DT O
amino-terminal BC2GM026829531 JJ O
gag-encoded BC2GM026829531 JJ O
region BC2GM026829531 NN O
of BC2GM026829531 IN O
P140gag-fps BC2GM026829531 NNP O
contains BC2GM026829531 VBZ O
a BC2GM026829531 DT O
phosphotyrosine BC2GM026829531 NN O
residue BC2GM026829531 NN O
in BC2GM026829531 IN O
addition BC2GM026829531 NN O
to BC2GM026829531 TO O
normal BC2GM026829531 JJ O
gag BC2GM026829531 JJ O
phosphorylation BC2GM026829531 NN O
sites BC2GM026829531 NNS O
. BC2GM026829531 . O
. . O O

This BC2GM023227858 DT O
increased BC2GM023227858 VBD O
frequency BC2GM023227858 NN O
of BC2GM023227858 IN O
infection BC2GM023227858 NN O
has BC2GM023227858 VBZ O
been BC2GM023227858 VBN O
accompanied BC2GM023227858 VBN O
by BC2GM023227858 IN O
significant BC2GM023227858 JJ O
excess BC2GM023227858 JJ O
mortality BC2GM023227858 NN O
. BC2GM023227858 . O
. . O O

When BC2GM099015286 WRB O
they BC2GM099015286 PRP O
were BC2GM099015286 VBD O
exposed BC2GM099015286 VBN O
to BC2GM099015286 TO O
intermittent BC2GM099015286 JJ O
schedules BC2GM099015286 NNS O
of BC2GM099015286 IN O
punishment BC2GM099015286 NN O
( BC2GM099015286 ( O
fixed-interval BC2GM099015286 JJ O
[ BC2GM099015286 NNP O
FI BC2GM099015286 NNP O
] BC2GM099015286 VBD O
120 BC2GM099015286 CD O
s BC2GM099015286 NN O
or BC2GM099015286 CC O
FI BC2GM099015286 NNP O
300 BC2GM099015286 CD O
s BC2GM099015286 NN O
) BC2GM099015286 ) O
, BC2GM099015286 , O
SIB BC2GM099015286 NNP O
for BC2GM099015286 IN O
all BC2GM099015286 DT O
but BC2GM099015286 CC O
1 BC2GM099015286 CD O
of BC2GM099015286 IN O
the BC2GM099015286 DT O
participants BC2GM099015286 NNS O
increased BC2GM099015286 VBD O
to BC2GM099015286 TO O
levels BC2GM099015286 NNS O
similar BC2GM099015286 JJ O
to BC2GM099015286 TO O
those BC2GM099015286 DT O
observed BC2GM099015286 VBN O
during BC2GM099015286 IN O
baseline BC2GM099015286 NN O
. BC2GM099015286 . O
. . O O

Using BC2GM028143170 VBG O
a BC2GM028143170 DT O
simulated BC2GM028143170 JJ O
cough BC2GM028143170 NN O
machine BC2GM028143170 NN O
, BC2GM028143170 , O
we BC2GM028143170 PRP O
analyzed BC2GM028143170 VBD O
the BC2GM028143170 DT O
effect BC2GM028143170 NN O
of BC2GM028143170 IN O
adding BC2GM028143170 VBG O
tensio-active BC2GM028143170 JJ O
liquids BC2GM028143170 NNS O
as BC2GM028143170 IN O
sol BC2GM028143170 JJ O
phase BC2GM028143170 NN O
simulant BC2GM028143170 NN O
on BC2GM028143170 IN O
the BC2GM028143170 DT O
clearance BC2GM028143170 NN O
of BC2GM028143170 IN O
gel BC2GM028143170 JJ O
mucus BC2GM028143170 NN O
simulant BC2GM028143170 NN O
by BC2GM028143170 IN O
cough BC2GM028143170 NN O
. BC2GM028143170 . O
. . O O

All BC2GM019485774 DT O
rights BC2GM019485774 NNS O
reserved BC2GM019485774 VBN O
. BC2GM019485774 . O
. . O O

To BC2GM099329110 TO O
determine BC2GM099329110 VB O
the BC2GM099329110 DT O
role BC2GM099329110 NN O
of BC2GM099329110 IN O
elevated BC2GM099329110 JJ O
FAK BC2GM099329110 NNP O
expression BC2GM099329110 NN O
in BC2GM099329110 IN O
facilitating BC2GM099329110 VBG O
epidermal BC2GM099329110 JJ O
growth BC2GM099329110 NN O
factor BC2GM099329110 NN O
( BC2GM099329110 ( O
EGF BC2GM099329110 NNP O
) BC2GM099329110 ) O
-stimulated BC2GM099329110 VBD O
human BC2GM099329110 JJ O
adenocarcinoma BC2GM099329110 NN O
( BC2GM099329110 ( O
A549 BC2GM099329110 NNP O
) BC2GM099329110 ) O
cell BC2GM099329110 NN O
motility BC2GM099329110 NN O
, BC2GM099329110 , O
antisense BC2GM099329110 JJ O
oligonucleotides BC2GM099329110 NNS O
were BC2GM099329110 VBD O
used BC2GM099329110 VBN O
to BC2GM099329110 TO O
reduce BC2GM099329110 VB O
FAK BC2GM099329110 NNP O
protein BC2GM099329110 NN O
expression BC2GM099329110 NN O
> BC2GM099329110 VBD O
75 BC2GM099329110 CD O
% BC2GM099329110 NN O
. BC2GM099329110 . O
. . O O

PURPOSE BC2GM070319467 NN O
: BC2GM070319467 : O
Second BC2GM070319467 JJ O
malignant BC2GM070319467 JJ O
neoplasms BC2GM070319467 NNS O
( BC2GM070319467 ( O
SMNs BC2GM070319467 NNP O
) BC2GM070319467 ) O
are BC2GM070319467 VBP O
a BC2GM070319467 DT O
rare BC2GM070319467 JJ O
occurrence BC2GM070319467 NN O
after BC2GM070319467 IN O
the BC2GM070319467 DT O
successful BC2GM070319467 JJ O
treatment BC2GM070319467 NN O
of BC2GM070319467 IN O
childhood BC2GM070319467 NN O
cancer BC2GM070319467 NN O
. BC2GM070319467 . O
. . O O

A BC2GM032982135 DT O
wound BC2GM032982135 NN O
model BC2GM032982135 NN O
for BC2GM032982135 IN O
decubitus BC2GM032982135 NN O
and BC2GM032982135 CC O
leg BC2GM032982135 NN O
ulcers BC2GM032982135 NNS O
consisting BC2GM032982135 VBG O
of BC2GM032982135 IN O
human BC2GM032982135 JJ O
dermal BC2GM032982135 JJ O
fibroblasts BC2GM032982135 NNS O
in BC2GM032982135 IN O
type BC2GM032982135 NN O
I BC2GM032982135 PRP O
collagen BC2GM032982135 VBP O
dermal BC2GM032982135 JJ O
`` BC2GM032982135 `` O
equivalent BC2GM032982135 JJ O
'' BC2GM032982135 '' O
matrix BC2GM032982135 NN O
( BC2GM032982135 ( O
DEM BC2GM032982135 NNP O
) BC2GM032982135 ) O
was BC2GM032982135 VBD O
exposed BC2GM032982135 VBN O
in BC2GM032982135 IN O
vitro BC2GM032982135 NN O
to BC2GM032982135 TO O
electric BC2GM032982135 VB O
fields BC2GM032982135 NNS O
similar BC2GM032982135 JJ O
to BC2GM032982135 TO O
postulated BC2GM032982135 VB O
endogenous BC2GM032982135 JJ O
fields BC2GM032982135 NNS O
in BC2GM032982135 IN O
wounds BC2GM032982135 NNS O
. BC2GM032982135 . O
. . O O

Compression BC2GM007067197 NN O
of BC2GM007067197 IN O
pulmonary BC2GM007067197 JJ O
artery BC2GM007067197 NN O
and BC2GM007067197 CC O
right BC2GM007067197 JJ O
ventricular BC2GM007067197 NN O
outflow BC2GM007067197 IN O
tract BC2GM007067197 NN O
by BC2GM007067197 IN O
aneurysm BC2GM007067197 NN O
of BC2GM007067197 IN O
ascending BC2GM007067197 VBG O
aorta BC2GM007067197 NN O
. BC2GM007067197 . O
. . O O

Both BC2GM097016872 DT O
RNA14 BC2GM097016872 NNP O
and BC2GM097016872 CC O
RNA15 BC2GM097016872 NNP O
wild-type BC2GM097016872 JJ O
genes BC2GM097016872 NNS O
, BC2GM097016872 , O
when BC2GM097016872 WRB O
cloned BC2GM097016872 VBN O
on BC2GM097016872 IN O
a BC2GM097016872 DT O
multicopy BC2GM097016872 NN O
plasmid BC2GM097016872 NN O
, BC2GM097016872 , O
are BC2GM097016872 VBP O
able BC2GM097016872 JJ O
to BC2GM097016872 TO O
suppress BC2GM097016872 VB O
the BC2GM097016872 DT O
temperature-sensitive BC2GM097016872 JJ O
phenotype BC2GM097016872 NN O
of BC2GM097016872 IN O
strains BC2GM097016872 NNS O
bearing BC2GM097016872 VBG O
either BC2GM097016872 CC O
the BC2GM097016872 DT O
rna14 BC2GM097016872 NN O
or BC2GM097016872 CC O
the BC2GM097016872 DT O
rna15 BC2GM097016872 JJ O
mutation BC2GM097016872 NN O
, BC2GM097016872 , O
suggesting BC2GM097016872 VBG O
that BC2GM097016872 IN O
the BC2GM097016872 DT O
encoded BC2GM097016872 JJ O
proteins BC2GM097016872 NNS O
could BC2GM097016872 MD O
interact BC2GM097016872 VB O
with BC2GM097016872 IN O
each BC2GM097016872 DT O
other BC2GM097016872 JJ O
. BC2GM097016872 . O
. . O O

Sequential BC2GM036281424 JJ O
immunoprecipitation BC2GM036281424 NN O
showed BC2GM036281424 VBD O
all BC2GM036281424 DT O
detectable BC2GM036281424 JJ O
p53 BC2GM036281424 NN O
to BC2GM036281424 TO O
be BC2GM036281424 VB O
of BC2GM036281424 IN O
the BC2GM036281424 DT O
PAb246+ BC2GM036281424 NNP O
class BC2GM036281424 NN O
in BC2GM036281424 IN O
each BC2GM036281424 DT O
LPV-transformed BC2GM036281424 NNP O
cell BC2GM036281424 NN O
line BC2GM036281424 NN O
, BC2GM036281424 , O
suggesting BC2GM036281424 VBG O
that BC2GM036281424 IN O
the BC2GM036281424 DT O
stable BC2GM036281424 JJ O
p53 BC2GM036281424 NN O
was BC2GM036281424 VBD O
indeed BC2GM036281424 RB O
wild BC2GM036281424 JJ O
type BC2GM036281424 NN O
. BC2GM036281424 . O
. . O O

The BC2GM076272520 DT O
results BC2GM076272520 NNS O
corroborate BC2GM076272520 VBP O
the BC2GM076272520 DT O
proposed BC2GM076272520 VBN O
physiological BC2GM076272520 JJ O
function BC2GM076272520 NN O
of BC2GM076272520 IN O
CCoAOMT BC2GM076272520 NNP O
in BC2GM076272520 IN O
elicited BC2GM076272520 JJ O
plant BC2GM076272520 NN O
cells BC2GM076272520 NNS O
and BC2GM076272520 CC O
may BC2GM076272520 MD O
shed BC2GM076272520 VB O
new BC2GM076272520 JJ O
light BC2GM076272520 NN O
on BC2GM076272520 IN O
the BC2GM076272520 DT O
sequential BC2GM076272520 JJ O
action BC2GM076272520 NN O
of BC2GM076272520 IN O
trans-active BC2GM076272520 JJ O
factors BC2GM076272520 NNS O
in BC2GM076272520 IN O
the BC2GM076272520 DT O
regulation BC2GM076272520 NN O
of BC2GM076272520 IN O
phenylpropanoid BC2GM076272520 JJ O
genes BC2GM076272520 NNS O
. BC2GM076272520 . O
. . O O

Adequacy BC2GM055691020 NN O
of BC2GM055691020 IN O
the BC2GM055691020 DT O
Haldane BC2GM055691020 NNP O
transformation BC2GM055691020 NN O
in BC2GM055691020 IN O
the BC2GM055691020 DT O
computation BC2GM055691020 NN O
of BC2GM055691020 IN O
exercise BC2GM055691020 NN O
V BC2GM055691020 NNP O
O2 BC2GM055691020 NNP O
in BC2GM055691020 IN O
man BC2GM055691020 NN O
. BC2GM055691020 . O
. . O O

Cerebellar BC2GM007318409 JJ O
functional BC2GM007318409 JJ O
compensation BC2GM007318409 NN O
after BC2GM007318409 IN O
its BC2GM007318409 PRP$ O
complete BC2GM007318409 JJ O
destruction BC2GM007318409 NN O
by BC2GM007318409 IN O
a BC2GM007318409 DT O
neoplasm BC2GM007318409 NN O
. BC2GM007318409 . O
. . O O

These BC2GM031428839 DT O
involve BC2GM031428839 VBP O
( BC2GM031428839 ( O
1 BC2GM031428839 CD O
) BC2GM031428839 ) O
subcloning BC2GM031428839 VBG O
a BC2GM031428839 DT O
promoterless BC2GM031428839 NN O
sucCD BC2GM031428839 NN O
fragment BC2GM031428839 JJ O
downstream BC2GM031428839 NN O
of BC2GM031428839 IN O
the BC2GM031428839 DT O
lac BC2GM031428839 NN O
promoter BC2GM031428839 NN O
in BC2GM031428839 IN O
M13mp10 BC2GM031428839 NNP O
, BC2GM031428839 , O
and BC2GM031428839 CC O
( BC2GM031428839 ( O
2 BC2GM031428839 CD O
) BC2GM031428839 ) O
precise BC2GM031428839 NN O
splicing BC2GM031428839 NN O
of BC2GM031428839 IN O
the BC2GM031428839 DT O
suc BC2GM031428839 NN O
coding BC2GM031428839 VBG O
regions BC2GM031428839 NNS O
with BC2GM031428839 IN O
the BC2GM031428839 DT O
efficient BC2GM031428839 JJ O
atpE BC2GM031428839 JJ O
ribosome-binding BC2GM031428839 JJ O
site BC2GM031428839 NN O
and BC2GM031428839 CC O
expression BC2GM031428839 NN O
from BC2GM031428839 IN O
the BC2GM031428839 DT O
thermoinducible BC2GM031428839 JJ O
lambda BC2GM031428839 NN O
promoters BC2GM031428839 NNS O
in BC2GM031428839 IN O
the BC2GM031428839 DT O
pJLA503 BC2GM031428839 NN O
vector BC2GM031428839 NN O
. BC2GM031428839 . O
. . O O

To BC2GM062716898 TO O
study BC2GM062716898 VB O
structural BC2GM062716898 JJ O
diversity BC2GM062716898 NN O
of BC2GM062716898 IN O
the BC2GM062716898 DT O
three BC2GM062716898 CD O
homologous BC2GM062716898 JJ O
loci BC2GM062716898 NN O
encoding BC2GM062716898 VBG O
a BC2GM062716898 DT O
KN1-like BC2GM062716898 JJ O
homeobox BC2GM062716898 NN O
protein BC2GM062716898 NN O
in BC2GM062716898 IN O
the BC2GM062716898 DT O
hexaploid BC2GM062716898 JJ O
wheat BC2GM062716898 NN O
genome BC2GM062716898 NN O
, BC2GM062716898 , O
we BC2GM062716898 PRP O
isolated BC2GM062716898 VBD O
clones BC2GM062716898 NNS O
from BC2GM062716898 IN O
a BC2GM062716898 DT O
cDNA BC2GM062716898 JJ O
library BC2GM062716898 NN O
of BC2GM062716898 IN O
young BC2GM062716898 JJ O
spikes BC2GM062716898 NNS O
of BC2GM062716898 IN O
Japanese BC2GM062716898 JJ O
common BC2GM062716898 JJ O
wheat BC2GM062716898 NN O
cultivar BC2GM062716898 NN O
'Norin BC2GM062716898 POS O
26 BC2GM062716898 CD O
' BC2GM062716898 POS O
. BC2GM062716898 . O
. . O O

Removal BC2GM094364440 NN O
of BC2GM094364440 IN O
cyclin-dependant BC2GM094364440 JJ O
kinases BC2GM094364440 NNS O
( BC2GM094364440 ( O
cdks BC2GM094364440 NN O
) BC2GM094364440 ) O
or BC2GM094364440 CC O
cdk2 BC2GM094364440 NN O
from BC2GM094364440 IN O
these BC2GM094364440 DT O
extracts BC2GM094364440 NNS O
using BC2GM094364440 VBG O
affinity BC2GM094364440 NN O
matrices BC2GM094364440 NNS O
severely BC2GM094364440 RB O
inhibits BC2GM094364440 JJ O
initiation BC2GM094364440 NN O
of BC2GM094364440 IN O
S BC2GM094364440 NNP O
phase BC2GM094364440 NN O
. BC2GM094364440 . O
. . O O

Paraplegia BC2GM018703043 NNP O
associated BC2GM018703043 VBD O
with BC2GM018703043 IN O
intraaortic BC2GM018703043 JJ O
balloon BC2GM018703043 NN O
pump BC2GM018703043 NN O
counterpulsation BC2GM018703043 NN O
. BC2GM018703043 . O
. . O O

Human BC2GM055133205 NNP O
psychophysical BC2GM055133205 JJ O
analysis BC2GM055133205 NN O
of BC2GM055133205 IN O
receptive BC2GM055133205 JJ O
field-like BC2GM055133205 JJ O
properties BC2GM055133205 NNS O
-- BC2GM055133205 : O
II BC2GM055133205 NNP O
. BC2GM055133205 . O
. . O O

The BC2GM063706036 DT O
B. BC2GM063706036 NNP O
aphidicola BC2GM063706036 VBD O
argS-rrn BC2GM063706036 JJ O
DNA BC2GM063706036 NNP O
fragments BC2GM063706036 NNS O
from BC2GM063706036 IN O
endosymbionts BC2GM063706036 NNS O
from BC2GM063706036 IN O
seven BC2GM063706036 CD O
species BC2GM063706036 NNS O
of BC2GM063706036 IN O
aphids BC2GM063706036 NNS O
had BC2GM063706036 VBD O
promoter BC2GM063706036 NN O
activities BC2GM063706036 NNS O
in BC2GM063706036 IN O
E. BC2GM063706036 NNP O
coli BC2GM063706036 NNS O
which BC2GM063706036 WDT O
ranged BC2GM063706036 VBD O
from BC2GM063706036 IN O
6 BC2GM063706036 CD O
to BC2GM063706036 TO O
135 BC2GM063706036 CD O
% BC2GM063706036 NN O
of BC2GM063706036 IN O
that BC2GM063706036 DT O
observed BC2GM063706036 VBD O
with BC2GM063706036 IN O
a BC2GM063706036 DT O
comparable BC2GM063706036 JJ O
DNA BC2GM063706036 NNP O
fragment BC2GM063706036 NN O
of BC2GM063706036 IN O
E. BC2GM063706036 NNP O
coli BC2GM063706036 NNS O
rrnB BC2GM063706036 NN O
. BC2GM063706036 . O
. . O O

On BC2GM037537411 IN O
the BC2GM037537411 DT O
basis BC2GM037537411 NN O
of BC2GM037537411 IN O
these BC2GM037537411 DT O
findings BC2GM037537411 NNS O
we BC2GM037537411 PRP O
suggest BC2GM037537411 VBP O
that BC2GM037537411 IN O
the BC2GM037537411 DT O
acceptor BC2GM037537411 NN O
peptide BC2GM037537411 NN O
binds BC2GM037537411 VBZ O
the BC2GM037537411 DT O
transferase BC2GM037537411 NN O
in BC2GM037537411 IN O
a BC2GM037537411 DT O
beta-like BC2GM037537411 JJ O
conformation BC2GM037537411 NN O
and BC2GM037537411 CC O
that BC2GM037537411 DT O
penultimate BC2GM037537411 NN O
residue BC2GM037537411 JJ O
side BC2GM037537411 NN O
chain BC2GM037537411 NN O
steric BC2GM037537411 JJ O
interactions BC2GM037537411 NNS O
may BC2GM037537411 MD O
play BC2GM037537411 VB O
a BC2GM037537411 DT O
role BC2GM037537411 NN O
in BC2GM037537411 IN O
determining BC2GM037537411 VBG O
extent BC2GM037537411 NN O
that BC2GM037537411 IN O
a BC2GM037537411 DT O
given BC2GM037537411 VBN O
Ser BC2GM037537411 NNP O
or BC2GM037537411 CC O
Thr BC2GM037537411 NNP O
is BC2GM037537411 VBZ O
glycosylated BC2GM037537411 VBN O
. BC2GM037537411 . O
. . O O

Capillary BC2GM013781370 JJ O
tortuosity BC2GM013781370 NN O
was BC2GM013781370 VBD O
a BC2GM013781370 DT O
function BC2GM013781370 NN O
of BC2GM013781370 IN O
sarcomere BC2GM013781370 JJ O
length BC2GM013781370 NN O
in BC2GM013781370 IN O
all BC2GM013781370 DT O
animals BC2GM013781370 NNS O
and BC2GM013781370 CC O
this BC2GM013781370 DT O
relationship BC2GM013781370 NN O
was BC2GM013781370 VBD O
not BC2GM013781370 RB O
changed BC2GM013781370 VBN O
by BC2GM013781370 IN O
hypoxia BC2GM013781370 NN O
. BC2GM013781370 . O
. . O O

The BC2GM016841080 DT O
strangulated BC2GM016841080 JJ O
intestinal BC2GM016841080 JJ O
pathologies BC2GM016841080 NNS O
of BC2GM016841080 IN O
horses BC2GM016841080 NNS O
are BC2GM016841080 VBP O
accompanied BC2GM016841080 VBN O
by BC2GM016841080 IN O
a BC2GM016841080 DT O
local BC2GM016841080 JJ O
activation BC2GM016841080 NN O
of BC2GM016841080 IN O
the BC2GM016841080 DT O
neutrophils BC2GM016841080 NNS O
, BC2GM016841080 , O
that BC2GM016841080 WDT O
can BC2GM016841080 MD O
be BC2GM016841080 VB O
revealed BC2GM016841080 VBN O
by BC2GM016841080 IN O
measuring BC2GM016841080 VBG O
the BC2GM016841080 DT O
tissular BC2GM016841080 JJ O
enzymatic BC2GM016841080 JJ O
activity BC2GM016841080 NN O
of BC2GM016841080 IN O
the BC2GM016841080 DT O
granulocytic BC2GM016841080 JJ O
enzyme BC2GM016841080 NN O
myeloperoxidase BC2GM016841080 NN O
( BC2GM016841080 ( O
MPO BC2GM016841080 NNP O
) BC2GM016841080 ) O
. BC2GM016841080 . O
. . O O

Kluyveromyces BC2GM092963902 NNS O
lactis BC2GM092963902 NN O
, BC2GM092963902 , O
a BC2GM092963902 DT O
budding BC2GM092963902 NN O
yeast BC2GM092963902 RB O
related BC2GM092963902 VBN O
to BC2GM092963902 TO O
Saccharomyces BC2GM092963902 NNP O
cerevisiae BC2GM092963902 NN O
, BC2GM092963902 , O
can BC2GM092963902 MD O
grow BC2GM092963902 VB O
on BC2GM092963902 IN O
a BC2GM092963902 DT O
wider BC2GM092963902 JJR O
variety BC2GM092963902 NN O
of BC2GM092963902 IN O
substrates BC2GM092963902 NNS O
and BC2GM092963902 CC O
shows BC2GM092963902 VBZ O
less BC2GM092963902 JJR O
sensitivity BC2GM092963902 NN O
to BC2GM092963902 TO O
glucose BC2GM092963902 VB O
repression BC2GM092963902 NN O
than BC2GM092963902 IN O
does BC2GM092963902 VBZ O
Saccharomyces BC2GM092963902 NNPS O
cerevisiae BC2GM092963902 NN O
. BC2GM092963902 . O
. . O O

Localization BC2GM012663791 NN O
of BC2GM012663791 IN O
the BC2GM012663791 DT O
porcine BC2GM012663791 NN O
enzyme BC2GM012663791 NN O
in BC2GM012663791 IN O
the BC2GM012663791 DT O
endoplasmic BC2GM012663791 JJ O
reticulum BC2GM012663791 NN O
is BC2GM012663791 VBZ O
consistent BC2GM012663791 JJ O
with BC2GM012663791 IN O
immuno-electron-microscopic BC2GM012663791 JJ O
studies BC2GM012663791 NNS O
using BC2GM012663791 VBG O
pig BC2GM012663791 NN O
hepatocytes BC2GM012663791 NNS O
. BC2GM012663791 . O
. . O O

Co-expression BC2GM074332613 NN O
of BC2GM074332613 IN O
a BC2GM074332613 DT O
gag-TRalpha BC2GM074332613 JJ O
fusion BC2GM074332613 NN O
protein BC2GM074332613 NN O
in BC2GM074332613 IN O
AEV-transformed BC2GM074332613 NNP O
cells BC2GM074332613 NNS O
and BC2GM074332613 CC O
addition BC2GM074332613 NN O
of BC2GM074332613 IN O
ligand BC2GM074332613 NN O
derepresses BC2GM074332613 NNS O
CAII BC2GM074332613 NNP O
transcription BC2GM074332613 NN O
. BC2GM074332613 . O
. . O O

In BC2GM052850929 IN O
all BC2GM052850929 DT O
cases BC2GM052850929 NNS O
, BC2GM052850929 , O
a BC2GM052850929 DT O
large BC2GM052850929 JJ O
fraction BC2GM052850929 NN O
of BC2GM052850929 IN O
soluble BC2GM052850929 JJ O
Al BC2GM052850929 NNP O
became BC2GM052850929 VBD O
insoluble BC2GM052850929 JJ O
in BC2GM052850929 IN O
the BC2GM052850929 DT O
stomach BC2GM052850929 NN O
after BC2GM052850929 IN O
ingestion BC2GM052850929 NN O
. BC2GM052850929 . O
. . O O

Basic BC2GM058996965 JJ O
helix-loop-helix BC2GM058996965 JJ O
proteins BC2GM058996965 NNS O
can BC2GM058996965 MD O
act BC2GM058996965 VB O
at BC2GM058996965 IN O
the BC2GM058996965 DT O
E-box BC2GM058996965 NNP O
within BC2GM058996965 IN O
the BC2GM058996965 DT O
serum BC2GM058996965 NN O
response BC2GM058996965 NN O
element BC2GM058996965 NN O
of BC2GM058996965 IN O
the BC2GM058996965 DT O
c-fos BC2GM058996965 JJ O
promoter BC2GM058996965 NN O
to BC2GM058996965 TO O
influence BC2GM058996965 VB O
hormone-induced BC2GM058996965 JJ O
promoter BC2GM058996965 NN O
activation BC2GM058996965 NN O
in BC2GM058996965 IN O
Sertoli BC2GM058996965 NNP O
cells BC2GM058996965 NNS O
. BC2GM058996965 . O
. . O O

High BC2GM007100869 JJ O
expression BC2GM007100869 NN O
of BC2GM007100869 IN O
p51A BC2GM007100869 NN O
( BC2GM007100869 ( O
TAp63gamma BC2GM007100869 NNP O
) BC2GM007100869 ) O
in BC2GM007100869 IN O
the BC2GM007100869 DT O
skeletal BC2GM007100869 JJ O
muscle BC2GM007100869 NN O
tissue BC2GM007100869 NN O
drove BC2GM007100869 VBD O
us BC2GM007100869 PRP O
to BC2GM007100869 TO O
investigate BC2GM007100869 VB O
a BC2GM007100869 DT O
differentiation-inducible BC2GM007100869 JJ O
myoblastic BC2GM007100869 JJ O
cell BC2GM007100869 NN O
line BC2GM007100869 NN O
which BC2GM007100869 WDT O
showed BC2GM007100869 VBD O
increased BC2GM007100869 VBD O
p51A BC2GM007100869 JJ O
expression BC2GM007100869 NN O
after BC2GM007100869 IN O
differentiation BC2GM007100869 NN O
induction BC2GM007100869 NN O
. BC2GM007100869 . O
. . O O

Of BC2GM011651930 IN O
the BC2GM011651930 DT O
CSF BC2GM011651930 NNP O
tested BC2GM011651930 VBD O
, BC2GM011651930 , O
24 BC2GM011651930 CD O
stimulated BC2GM011651930 VBD O
oxygen BC2GM011651930 NN O
consumption BC2GM011651930 NN O
above BC2GM011651930 IN O
our BC2GM011651930 PRP$ O
cut BC2GM011651930 NN O
off BC2GM011651930 RP O
, BC2GM011651930 , O
and BC2GM011651930 CC O
8 BC2GM011651930 CD O
did BC2GM011651930 VBD O
not BC2GM011651930 RB O
( BC2GM011651930 ( O
0.84 BC2GM011651930 CD O
+ BC2GM011651930 NN O
/ BC2GM011651930 NNP O
- BC2GM011651930 : O
0.34 BC2GM011651930 CD O
, BC2GM011651930 , O
n BC2GM011651930 RB O
= BC2GM011651930 VBZ O
24 BC2GM011651930 CD O
compared BC2GM011651930 VBN O
with BC2GM011651930 IN O
the BC2GM011651930 DT O
rate BC2GM011651930 NN O
of BC2GM011651930 IN O
0.27 BC2GM011651930 CD O
+ BC2GM011651930 NNS O
/ BC2GM011651930 SYM O
- BC2GM011651930 : O
0.1 BC2GM011651930 CD O
mumol BC2GM011651930 NN O
/ BC2GM011651930 NNP O
min BC2GM011651930 NN O
/ BC2GM011651930 NNP O
g BC2GM011651930 NN O
dry BC2GM011651930 JJ O
wt BC2GM011651930 NN O
, BC2GM011651930 , O
respectively BC2GM011651930 RB O
; BC2GM011651930 : O
SD BC2GM011651930 NNP O
n BC2GM011651930 VBD O
= BC2GM011651930 NNP O
8 BC2GM011651930 CD O
) BC2GM011651930 ) O
at BC2GM011651930 IN O
180 BC2GM011651930 CD O
minutes BC2GM011651930 NNS O
. BC2GM011651930 . O
. . O O

3-5-fold BC2GM097330592 JJ O
increases BC2GM097330592 NNS O
in BC2GM097330592 IN O
EGF BC2GM097330592 NNP O
receptor BC2GM097330592 NN O
but BC2GM097330592 CC O
not BC2GM097330592 RB O
p185 BC2GM097330592 VB O
( BC2GM097330592 ( O
neu BC2GM097330592 NN O
) BC2GM097330592 ) O
tyrosine BC2GM097330592 NN O
phosphorylation BC2GM097330592 NN O
occur BC2GM097330592 IN O
following BC2GM097330592 VBG O
Gi-coupled BC2GM097330592 JJ O
receptor BC2GM097330592 NN O
stimulation BC2GM097330592 NN O
. BC2GM097330592 . O
. . O O

The BC2GM064633844 DT O
human BC2GM064633844 JJ O
cDNA BC2GM064633844 NN O
was BC2GM064633844 VBD O
cloned BC2GM064633844 VBN O
and BC2GM064633844 CC O
sequenced BC2GM064633844 VBN O
; BC2GM064633844 : O
it BC2GM064633844 PRP O
was BC2GM064633844 VBD O
shown BC2GM064633844 VBN O
to BC2GM064633844 TO O
have BC2GM064633844 VB O
an BC2GM064633844 DT O
open BC2GM064633844 JJ O
reading BC2GM064633844 NN O
frame BC2GM064633844 NN O
encoding BC2GM064633844 VBG O
a BC2GM064633844 DT O
296-amino-acid BC2GM064633844 JJ O
protein BC2GM064633844 NN O
in BC2GM064633844 IN O
which BC2GM064633844 WDT O
could BC2GM064633844 MD O
be BC2GM064633844 VB O
identified BC2GM064633844 VBN O
four BC2GM064633844 CD O
peptides BC2GM064633844 NNS O
previously BC2GM064633844 RB O
identified BC2GM064633844 VBN O
by BC2GM064633844 IN O
micro-sequencing BC2GM064633844 JJ O
purified BC2GM064633844 JJ O
protein BC2GM064633844 NN O
. BC2GM064633844 . O
. . O O

Two BC2GM070219691 CD O
patient BC2GM070219691 JJ O
groups BC2GM070219691 NNS O
were BC2GM070219691 VBD O
studied BC2GM070219691 VBN O
: BC2GM070219691 : O
Type BC2GM070219691 NN O
I BC2GM070219691 PRP O
-- BC2GM070219691 : O
with BC2GM070219691 IN O
a BC2GM070219691 DT O
new BC2GM070219691 JJ O
ePTFE BC2GM070219691 NN O
graft BC2GM070219691 NN O
; BC2GM070219691 : O
and BC2GM070219691 CC O
Type BC2GM070219691 NNP O
II BC2GM070219691 NNP O
-- BC2GM070219691 : O
with BC2GM070219691 IN O
thrombectomy BC2GM070219691 NN O
and BC2GM070219691 CC O
/ BC2GM070219691 NN O
or BC2GM070219691 CC O
revision BC2GM070219691 NN O
of BC2GM070219691 IN O
a BC2GM070219691 DT O
previously BC2GM070219691 RB O
placed BC2GM070219691 VBN O
ePTFE BC2GM070219691 NN O
graft BC2GM070219691 NN O
. BC2GM070219691 . O
. . O O

Indeed BC2GM045795328 RB O
, BC2GM045795328 , O
DEX BC2GM045795328 NNP O
also BC2GM045795328 RB O
enhanced BC2GM045795328 VBD O
the BC2GM045795328 DT O
RA-dependent BC2GM045795328 JJ O
increase BC2GM045795328 NN O
in BC2GM045795328 IN O
RARbeta BC2GM045795328 NNP O
mRNA BC2GM045795328 NN O
in BC2GM045795328 IN O
a BC2GM045795328 DT O
cycloheximide-sensitive BC2GM045795328 JJ O
manner BC2GM045795328 NN O
. BC2GM045795328 . O
. . O O

Percentage BC2GM070291312 NN O
incremental BC2GM070291312 JJ O
18-OHB BC2GM070291312 JJ O
responses BC2GM070291312 NNS O
to BC2GM070291312 TO O
metoclopramide BC2GM070291312 VB O
were BC2GM070291312 VBD O
greater BC2GM070291312 JJR O
( BC2GM070291312 ( O
P BC2GM070291312 NNP O
less BC2GM070291312 JJR O
than BC2GM070291312 IN O
0.01 BC2GM070291312 CD O
) BC2GM070291312 ) O
in BC2GM070291312 IN O
the BC2GM070291312 DT O
subjects BC2GM070291312 NNS O
after BC2GM070291312 IN O
5 BC2GM070291312 CD O
days BC2GM070291312 NNS O
on BC2GM070291312 IN O
a BC2GM070291312 DT O
200-meq BC2GM070291312 JJ O
sodium BC2GM070291312 NN O
intake BC2GM070291312 NN O
than BC2GM070291312 IN O
after BC2GM070291312 IN O
5 BC2GM070291312 CD O
days BC2GM070291312 NNS O
on BC2GM070291312 IN O
a BC2GM070291312 DT O
10-meq BC2GM070291312 JJ O
sodium BC2GM070291312 NN O
intake BC2GM070291312 NN O
. BC2GM070291312 . O
. . O O

Immunoprecipitation BC2GM082800985 NN O
of BC2GM082800985 IN O
spinophilin BC2GM082800985 NN O
or BC2GM082800985 CC O
neurabin BC2GM082800985 NN O
from BC2GM082800985 IN O
crude BC2GM082800985 NN O
brain BC2GM082800985 NN O
extracts BC2GM082800985 NNS O
selectively BC2GM082800985 RB O
coprecipitated BC2GM082800985 VBN O
PP1gamma BC2GM082800985 NNP O
( BC2GM082800985 ( O
1 BC2GM082800985 CD O
) BC2GM082800985 ) O
over BC2GM082800985 IN O
PP1beta BC2GM082800985 NNP O
. BC2GM082800985 . O
. . O O

Interactions BC2GM018362321 NNS O
were BC2GM018362321 VBD O
also BC2GM018362321 RB O
detected BC2GM018362321 VBN O
between BC2GM018362321 IN O
full-length BC2GM018362321 JJ O
HSF1 BC2GM018362321 NNP O
and BC2GM018362321 CC O
the BC2GM018362321 DT O
small BC2GM018362321 JJ O
subunit BC2GM018362321 NN O
( BC2GM018362321 ( O
gamma BC2GM018362321 NN O
) BC2GM018362321 ) O
of BC2GM018362321 IN O
TFIIA BC2GM018362321 NNP O
. BC2GM018362321 . O
. . O O

The BC2GM090334902 DT O
study BC2GM090334902 NN O
was BC2GM090334902 VBD O
carried BC2GM090334902 VBN O
out BC2GM090334902 RP O
according BC2GM090334902 VBG O
to BC2GM090334902 TO O
the BC2GM090334902 DT O
BSI BC2GM090334902 NNP O
( BC2GM090334902 ( O
1980 BC2GM090334902 CD O
) BC2GM090334902 ) O
recommendations BC2GM090334902 NNS O
for BC2GM090334902 IN O
testing BC2GM090334902 VBG O
restorative BC2GM090334902 JJ O
materials BC2GM090334902 NNS O
in BC2GM090334902 IN O
vivo BC2GM090334902 NN O
. BC2GM090334902 . O
. . O O

Plasmid BC2GM036804385 NNP O
subclones BC2GM036804385 NNS O
of BC2GM036804385 IN O
recombinant BC2GM036804385 JJ O
phage BC2GM036804385 NN O
lambda BC2GM036804385 NN O
Asm152 BC2GM036804385 NNP O
were BC2GM036804385 VBD O
able BC2GM036804385 JJ O
to BC2GM036804385 TO O
complement BC2GM036804385 VB O
both BC2GM036804385 DT O
Escherichia BC2GM036804385 NNP O
coli BC2GM036804385 NN O
gltB BC2GM036804385 NN O
and BC2GM036804385 CC O
A. BC2GM036804385 NNP O
sesbaniae BC2GM036804385 VBD O
Asm- BC2GM036804385 NNP O
Vi BC2GM036804385 NNP O
mutants BC2GM036804385 NNS O
; BC2GM036804385 : O
NADPH-glutamate BC2GM036804385 NNP O
synthase BC2GM036804385 NN O
activity BC2GM036804385 NN O
was BC2GM036804385 VBD O
detected BC2GM036804385 VBN O
in BC2GM036804385 IN O
all BC2GM036804385 DT O
such BC2GM036804385 JJ O
strains BC2GM036804385 NNS O
complemented BC2GM036804385 VBN O
to BC2GM036804385 TO O
Asm+ BC2GM036804385 NNP O
. BC2GM036804385 . O
. . O O

They BC2GM013098163 PRP O
contain BC2GM013098163 VBP O
a BC2GM013098163 DT O
large BC2GM013098163 JJ O
( BC2GM013098163 ( O
0.9 BC2GM013098163 CD O
X BC2GM013098163 RB O
10 BC2GM013098163 CD O
( BC2GM013098163 ( O
3 BC2GM013098163 CD O
) BC2GM013098163 ) O
to BC2GM013098163 TO O
1.88 BC2GM013098163 CD O
X BC2GM013098163 NNS O
10 BC2GM013098163 CD O
( BC2GM013098163 ( O
3 BC2GM013098163 CD O
) BC2GM013098163 ) O
base-pairs BC2GM013098163 NN O
) BC2GM013098163 ) O
intron BC2GM013098163 NN O
in BC2GM013098163 IN O
the BC2GM013098163 DT O
middle BC2GM013098163 NN O
of BC2GM013098163 IN O
the BC2GM013098163 DT O
gene BC2GM013098163 NN O
and BC2GM013098163 CC O
are BC2GM013098163 VBP O
further BC2GM013098163 RB O
interrupted BC2GM013098163 VBN O
close BC2GM013098163 RB O
to BC2GM013098163 TO O
the BC2GM013098163 DT O
5 BC2GM013098163 CD O
' BC2GM013098163 POS O
end BC2GM013098163 NN O
of BC2GM013098163 IN O
the BC2GM013098163 DT O
gene BC2GM013098163 NN O
. BC2GM013098163 . O
. . O O

MADS-box BC2GM062141275 JJ O
genes BC2GM062141275 NNS O
in BC2GM062141275 IN O
plants BC2GM062141275 NNS O
are BC2GM062141275 VBP O
a BC2GM062141275 DT O
diverse BC2GM062141275 JJ O
class BC2GM062141275 NN O
of BC2GM062141275 IN O
transcription BC2GM062141275 NN O
factors BC2GM062141275 NNS O
that BC2GM062141275 WDT O
are BC2GM062141275 VBP O
involved BC2GM062141275 VBN O
in BC2GM062141275 IN O
regulating BC2GM062141275 VBG O
developmental BC2GM062141275 JJ O
processes BC2GM062141275 NNS O
, BC2GM062141275 , O
particularly BC2GM062141275 RB O
meristem BC2GM062141275 NN O
and BC2GM062141275 CC O
organ BC2GM062141275 JJ O
identity BC2GM062141275 NN O
during BC2GM062141275 IN O
floral BC2GM062141275 JJ O
development BC2GM062141275 NN O
. BC2GM062141275 . O
. . O O

G-CSF BC2GM026427859 NNP O
( BC2GM026427859 ( O
10 BC2GM026427859 CD O
microg BC2GM026427859 NN O
/ BC2GM026427859 NNP O
kg BC2GM026427859 NN O
) BC2GM026427859 ) O
was BC2GM026427859 VBD O
started BC2GM026427859 VBN O
on BC2GM026427859 IN O
day BC2GM026427859 NN O
+1 BC2GM026427859 NNP O
and BC2GM026427859 CC O
all BC2GM026427859 DT O
patients BC2GM026427859 NNS O
engrafted BC2GM026427859 VBN O
within BC2GM026427859 IN O
a BC2GM026427859 DT O
median BC2GM026427859 JJ O
day BC2GM026427859 NN O
number BC2GM026427859 NN O
of BC2GM026427859 IN O
12 BC2GM026427859 CD O
( BC2GM026427859 ( O
range BC2GM026427859 NN O
, BC2GM026427859 , O
10-22 BC2GM026427859 JJ O
) BC2GM026427859 ) O
until BC2GM026427859 IN O
leukocytes BC2GM026427859 NNS O
> BC2GM026427859 VBP O
1.0 BC2GM026427859 CD O
x BC2GM026427859 JJ O
10 BC2GM026427859 CD O
( BC2GM026427859 ( O
9 BC2GM026427859 CD O
) BC2GM026427859 ) O
/ BC2GM026427859 NN O
l BC2GM026427859 NN O
and BC2GM026427859 CC O
a BC2GM026427859 DT O
median BC2GM026427859 JJ O
day BC2GM026427859 NN O
number BC2GM026427859 NN O
of BC2GM026427859 IN O
56 BC2GM026427859 CD O
( BC2GM026427859 ( O
range BC2GM026427859 NN O
, BC2GM026427859 , O
10-180 BC2GM026427859 JJ O
) BC2GM026427859 ) O
until BC2GM026427859 IN O
platelets BC2GM026427859 NNS O
> BC2GM026427859 VBP O
20.0 BC2GM026427859 CD O
x BC2GM026427859 JJ O
10 BC2GM026427859 CD O
( BC2GM026427859 ( O
9 BC2GM026427859 CD O
) BC2GM026427859 ) O
/ BC2GM026427859 NN O
l BC2GM026427859 NN O
( BC2GM026427859 ( O
ie BC2GM026427859 JJ O
platelet BC2GM026427859 NN O
transfusion BC2GM026427859 NN O
independence BC2GM026427859 NN O
) BC2GM026427859 ) O
. BC2GM026427859 . O
. . O O

Pancreatic BC2GM050204231 JJ O
expression BC2GM050204231 NN O
of BC2GM050204231 IN O
the BC2GM050204231 DT O
glucagon BC2GM050204231 NN O
gene BC2GM050204231 NN O
depends BC2GM050204231 VBZ O
on BC2GM050204231 IN O
multiple BC2GM050204231 JJ O
transcription BC2GM050204231 NN O
factors BC2GM050204231 NNS O
interacting BC2GM050204231 VBG O
with BC2GM050204231 IN O
at BC2GM050204231 IN O
least BC2GM050204231 JJS O
three BC2GM050204231 CD O
DNA BC2GM050204231 NNP O
control BC2GM050204231 NN O
elements BC2GM050204231 NNS O
: BC2GM050204231 : O
G1 BC2GM050204231 NNP O
, BC2GM050204231 , O
the BC2GM050204231 DT O
upstream BC2GM050204231 JJ O
promoter BC2GM050204231 NN O
element BC2GM050204231 NN O
, BC2GM050204231 , O
and BC2GM050204231 CC O
G2 BC2GM050204231 NNP O
and BC2GM050204231 CC O
G3 BC2GM050204231 NNP O
, BC2GM050204231 , O
two BC2GM050204231 CD O
enhancer-like BC2GM050204231 JJ O
sequences BC2GM050204231 NNS O
. BC2GM050204231 . O
. . O O

Eighteen BC2GM056619320 JJ O
patients BC2GM056619320 NNS O
with BC2GM056619320 IN O
advanced BC2GM056619320 JJ O
epidermoid BC2GM056619320 JJ O
carcinoma BC2GM056619320 NN O
of BC2GM056619320 IN O
the BC2GM056619320 DT O
head BC2GM056619320 NN O
and BC2GM056619320 CC O
neck BC2GM056619320 NN O
were BC2GM056619320 VBD O
entered BC2GM056619320 VBN O
into BC2GM056619320 IN O
a BC2GM056619320 DT O
phase BC2GM056619320 NN O
II BC2GM056619320 NNP O
trial BC2GM056619320 NN O
of BC2GM056619320 IN O
N-Methylformamide BC2GM056619320 NNP O
( BC2GM056619320 ( O
NMF BC2GM056619320 NNP O
) BC2GM056619320 ) O
, BC2GM056619320 , O
800 BC2GM056619320 CD O
mg BC2GM056619320 NN O
/ BC2GM056619320 NNP O
M2 BC2GM056619320 NNP O
IV BC2GM056619320 NNP O
daily BC2GM056619320 RB O
for BC2GM056619320 IN O
5 BC2GM056619320 CD O
days BC2GM056619320 NNS O
every BC2GM056619320 DT O
4 BC2GM056619320 CD O
weeks BC2GM056619320 NNS O
. BC2GM056619320 . O
. . O O

Cytokine BC2GM003163464 NNP O
inducibility BC2GM003163464 NN O
of BC2GM003163464 IN O
VCAM1 BC2GM003163464 NNP O
in BC2GM003163464 IN O
endothelial BC2GM003163464 JJ O
cells BC2GM003163464 NNS O
utilizes BC2GM003163464 VBZ O
the BC2GM003163464 DT O
interaction BC2GM003163464 NN O
of BC2GM003163464 IN O
heterodimeric BC2GM003163464 JJ O
p50 BC2GM003163464 NN O
/ BC2GM003163464 NNP O
p65 BC2GM003163464 NN O
proteins BC2GM003163464 NNS O
with BC2GM003163464 IN O
IRF-1 BC2GM003163464 NNP O
. BC2GM003163464 . O
. . O O

This BC2GM043009268 DT O
experience BC2GM043009268 NN O
would BC2GM043009268 MD O
recommend BC2GM043009268 VB O
consideration BC2GM043009268 NN O
of BC2GM043009268 IN O
home BC2GM043009268 NN O
nutritional BC2GM043009268 JJ O
support BC2GM043009268 NN O
in BC2GM043009268 IN O
patients BC2GM043009268 NNS O
with BC2GM043009268 IN O
systemic BC2GM043009268 JJ O
scleroderma BC2GM043009268 NN O
when BC2GM043009268 WRB O
the BC2GM043009268 DT O
disease BC2GM043009268 NN O
is BC2GM043009268 VBZ O
relatively BC2GM043009268 RB O
stable BC2GM043009268 JJ O
and BC2GM043009268 CC O
no BC2GM043009268 DT O
major BC2GM043009268 JJ O
organ BC2GM043009268 JJ O
failure BC2GM043009268 NN O
is BC2GM043009268 VBZ O
present BC2GM043009268 JJ O
. BC2GM043009268 . O
. . O O

Both BC2GM043507962 DT O
oligonucleotide BC2GM043507962 JJ O
cross-competition BC2GM043507962 NN O
and BC2GM043507962 CC O
antibody BC2GM043507962 NN O
supershift BC2GM043507962 NN O
experiments BC2GM043507962 NNS O
established BC2GM043507962 VBD O
that BC2GM043507962 IN O
the BC2GM043507962 DT O
double-strand BC2GM043507962 NN O
binding BC2GM043507962 NN O
protein BC2GM043507962 NN O
is BC2GM043507962 VBZ O
equivalent BC2GM043507962 JJ O
to BC2GM043507962 TO O
Sp1 BC2GM043507962 NNP O
. BC2GM043507962 . O
. . O O

Because BC2GM096119161 IN O
of BC2GM096119161 IN O
the BC2GM096119161 DT O
data BC2GM096119161 NNS O
, BC2GM096119161 , O
we BC2GM096119161 PRP O
suggest BC2GM096119161 VBP O
that BC2GM096119161 IN O
LAC9 BC2GM096119161 NNP O
contacts BC2GM096119161 NNS O
positions BC2GM096119161 NNS O
6 BC2GM096119161 CD O
, BC2GM096119161 , O
7 BC2GM096119161 CD O
, BC2GM096119161 , O
and BC2GM096119161 CC O
8 BC2GM096119161 CD O
, BC2GM096119161 , O
both BC2GM096119161 DT O
plus BC2GM096119161 CC O
and BC2GM096119161 CC O
minus BC2GM096119161 CC O
, BC2GM096119161 , O
of BC2GM096119161 IN O
the BC2GM096119161 DT O
UAS BC2GM096119161 NNP O
, BC2GM096119161 , O
which BC2GM096119161 WDT O
are BC2GM096119161 VBP O
separated BC2GM096119161 VBN O
by BC2GM096119161 IN O
more BC2GM096119161 JJR O
than BC2GM096119161 IN O
one BC2GM096119161 CD O
turn BC2GM096119161 NN O
of BC2GM096119161 IN O
the BC2GM096119161 DT O
DNA BC2GM096119161 NNP O
helix BC2GM096119161 NN O
, BC2GM096119161 , O
and BC2GM096119161 CC O
twists BC2GM096119161 NNS O
part BC2GM096119161 NN O
way BC2GM096119161 NN O
around BC2GM096119161 IN O
the BC2GM096119161 DT O
DNA BC2GM096119161 NNP O
, BC2GM096119161 , O
thus BC2GM096119161 RB O
protecting BC2GM096119161 VBG O
the BC2GM096119161 DT O
broad BC2GM096119161 JJ O
region BC2GM096119161 NN O
of BC2GM096119161 IN O
the BC2GM096119161 DT O
minor BC2GM096119161 JJ O
groove BC2GM096119161 NN O
between BC2GM096119161 IN O
the BC2GM096119161 DT O
major-groove BC2GM096119161 JJ O
contacts BC2GM096119161 NNS O
. BC2GM096119161 . O
. . O O

Thus BC2GM075375859 RB O
, BC2GM075375859 , O
oxyR BC2GM075375859 JJ O
mutants BC2GM075375859 NNS O
are BC2GM075375859 VBP O
locked BC2GM075375859 VBN O
on BC2GM075375859 IN O
for BC2GM075375859 IN O
Ag43 BC2GM075375859 NNP O
expression BC2GM075375859 NN O
, BC2GM075375859 , O
whereas BC2GM075375859 WP O
dam BC2GM075375859 NN O
mutants BC2GM075375859 NNS O
are BC2GM075375859 VBP O
locked BC2GM075375859 VBN O
off BC2GM075375859 RP O
for BC2GM075375859 IN O
Ag43 BC2GM075375859 NNP O
expression BC2GM075375859 NN O
. BC2GM075375859 . O
. . O O

Substitution BC2GM000160086 NN O
of BC2GM000160086 IN O
cholinergic BC2GM000160086 JJ O
drugs BC2GM000160086 NNS O
in BC2GM000160086 IN O
the BC2GM000160086 DT O
treatment BC2GM000160086 NN O
of BC2GM000160086 IN O
Alzheimer BC2GM000160086 NNP O
type BC2GM000160086 NN O
dementia BC2GM000160086 NN O
( BC2GM000160086 ( O
AD BC2GM000160086 NNP O
/ BC2GM000160086 NNP O
SDAT BC2GM000160086 NNP O
) BC2GM000160086 ) O
has BC2GM000160086 VBZ O
hitherto BC2GM000160086 VBN O
not BC2GM000160086 RB O
been BC2GM000160086 VBN O
very BC2GM000160086 RB O
successful BC2GM000160086 JJ O
. BC2GM000160086 . O
. . O O

Mutations BC2GM079348328 NNS O
in BC2GM079348328 IN O
the BC2GM079348328 DT O
beta-galactosidase BC2GM079348328 JJ O
gene BC2GM079348328 NN O
result BC2GM079348328 NN O
in BC2GM079348328 IN O
the BC2GM079348328 DT O
lysosomal BC2GM079348328 JJ O
storage BC2GM079348328 NN O
disorders BC2GM079348328 NNS O
GM1-gangliosidosis BC2GM079348328 NNP O
and BC2GM079348328 CC O
Morquio BC2GM079348328 NNP O
B BC2GM079348328 NNP O
syndrome BC2GM079348328 NN O
. BC2GM079348328 . O
. . O O

The BC2GM063124230 DT O
largest BC2GM063124230 JJS O
one BC2GM063124230 NN O
probably BC2GM063124230 RB O
corresponds BC2GM063124230 VBZ O
to BC2GM063124230 TO O
the BC2GM063124230 DT O
precursor BC2GM063124230 NN O
form BC2GM063124230 NN O
of BC2GM063124230 IN O
PS2 BC2GM063124230 NNP O
in BC2GM063124230 IN O
E. BC2GM063124230 NNP O
coli BC2GM063124230 NNS O
. BC2GM063124230 . O
. . O O

On BC2GM086512279 IN O
guanidine BC2GM086512279 NN O
and BC2GM086512279 CC O
the BC2GM086512279 DT O
treatment BC2GM086512279 NN O
of BC2GM086512279 IN O
botulism BC2GM086512279 NN O
. BC2GM086512279 . O
. . O O

It BC2GM083166259 PRP O
is BC2GM083166259 VBZ O
our BC2GM083166259 PRP$ O
conclusion BC2GM083166259 NN O
that BC2GM083166259 IN O
Sonoclot BC2GM083166259 NNP O
coagulation BC2GM083166259 NN O
analysis BC2GM083166259 NN O
is BC2GM083166259 VBZ O
unlikely BC2GM083166259 JJ O
to BC2GM083166259 TO O
identify BC2GM083166259 VB O
patients BC2GM083166259 NNS O
with BC2GM083166259 IN O
prolonged BC2GM083166259 JJ O
bleeding BC2GM083166259 NN O
time BC2GM083166259 NN O
in BC2GM083166259 IN O
whom BC2GM083166259 WP O
platelet BC2GM083166259 NN O
count BC2GM083166259 NN O
and BC2GM083166259 CC O
other BC2GM083166259 JJ O
coagulation BC2GM083166259 NN O
factors BC2GM083166259 NNS O
are BC2GM083166259 VBP O
normal BC2GM083166259 JJ O
. BC2GM083166259 . O
. . O O

There BC2GM036511457 EX O
is BC2GM036511457 VBZ O
no BC2GM036511457 DT O
indication BC2GM036511457 NN O
from BC2GM036511457 IN O
these BC2GM036511457 DT O
experiments BC2GM036511457 NNS O
that BC2GM036511457 WDT O
linker BC2GM036511457 VBP O
histones BC2GM036511457 NNS O
bind BC2GM036511457 IN O
fundamentally BC2GM036511457 RB O
differently BC2GM036511457 RB O
to BC2GM036511457 TO O
5 BC2GM036511457 CD O
S BC2GM036511457 NNP O
and BC2GM036511457 CC O
bulk BC2GM036511457 JJ O
nucleosomes BC2GM036511457 NNS O
. BC2GM036511457 . O
. . O O

The BC2GM025327018 DT O
POU-specific BC2GM025327018 NNP O
domain BC2GM025327018 NN O
of BC2GM025327018 IN O
Pit-1 BC2GM025327018 NNP O
is BC2GM025327018 VBZ O
essential BC2GM025327018 JJ O
for BC2GM025327018 IN O
sequence-specific BC2GM025327018 JJ O
, BC2GM025327018 , O
high BC2GM025327018 JJ O
affinity BC2GM025327018 NN O
DNA BC2GM025327018 NNP O
binding BC2GM025327018 NN O
and BC2GM025327018 CC O
DNA-dependent BC2GM025327018 JJ O
Pit-1-Pit-1 BC2GM025327018 JJ O
interactions BC2GM025327018 NNS O
. BC2GM025327018 . O
. . O O

1 BC2GM035707050 CD O
. BC2GM035707050 . O
. . O O

This BC2GM014758643 DT O
deletion BC2GM014758643 NN O
disrupts BC2GM014758643 VBZ O
the BC2GM014758643 DT O
PU.1 BC2GM014758643 NNP O
Ets BC2GM014758643 NNP O
domain BC2GM014758643 NN O
. BC2GM014758643 . O
. . O O

For BC2GM049160960 IN O
this BC2GM049160960 DT O
interaction BC2GM049160960 NN O
, BC2GM049160960 , O
the BC2GM049160960 DT O
C-terminal BC2GM049160960 JJ O
part BC2GM049160960 NN O
of BC2GM049160960 IN O
Sp1 BC2GM049160960 NNP O
and BC2GM049160960 CC O
the BC2GM049160960 DT O
N BC2GM049160960 NNP O
terminus BC2GM049160960 NN O
of BC2GM049160960 IN O
E2F1 BC2GM049160960 NNP O
, BC2GM049160960 , O
a BC2GM049160960 DT O
domain BC2GM049160960 NN O
also BC2GM049160960 RB O
present BC2GM049160960 JJ O
in BC2GM049160960 IN O
E2F2 BC2GM049160960 NNP O
and BC2GM049160960 CC O
E2F3 BC2GM049160960 NNP O
but BC2GM049160960 CC O
absent BC2GM049160960 NN O
in BC2GM049160960 IN O
E2F4 BC2GM049160960 NNP O
and BC2GM049160960 CC O
E2F5 BC2GM049160960 NNP O
, BC2GM049160960 , O
were BC2GM049160960 VBD O
essential BC2GM049160960 JJ O
. BC2GM049160960 . O
. . O O

This BC2GM027072594 DT O
dip BC2GM027072594 NN O
also BC2GM027072594 RB O
occurred BC2GM027072594 VBD O
during BC2GM027072594 IN O
prednisone BC2GM027072594 NN O
and BC2GM027072594 CC O
vitamin BC2GM027072594 NN O
D BC2GM027072594 NNP O
treatment BC2GM027072594 NN O
, BC2GM027072594 , O
but BC2GM027072594 CC O
did BC2GM027072594 VBD O
not BC2GM027072594 RB O
occur BC2GM027072594 VB O
when BC2GM027072594 WRB O
calcium BC2GM027072594 NN O
was BC2GM027072594 VBD O
added BC2GM027072594 VBN O
to BC2GM027072594 TO O
prednisone BC2GM027072594 VB O
, BC2GM027072594 , O
although BC2GM027072594 IN O
the BC2GM027072594 DT O
baseline BC2GM027072594 NN O
value BC2GM027072594 NN O
was BC2GM027072594 VBD O
lower BC2GM027072594 JJR O
at BC2GM027072594 IN O
the BC2GM027072594 DT O
start BC2GM027072594 NN O
of BC2GM027072594 IN O
combined BC2GM027072594 JJ O
treatment BC2GM027072594 NN O
with BC2GM027072594 IN O
prednisone BC2GM027072594 NN O
and BC2GM027072594 CC O
calcium BC2GM027072594 NN O
. BC2GM027072594 . O
. . O O

Human BC2GM013042173 NNP O
CR2 BC2GM013042173 NNP O
has BC2GM013042173 VBZ O
a BC2GM013042173 DT O
restricted BC2GM013042173 VBN O
cellular BC2GM013042173 JJ O
distribution BC2GM013042173 NN O
, BC2GM013042173 , O
being BC2GM013042173 VBG O
expressed BC2GM013042173 VBN O
on BC2GM013042173 IN O
B BC2GM013042173 NNP O
lymphocytes BC2GM013042173 NNS O
, BC2GM013042173 , O
dendritic BC2GM013042173 JJ O
cells BC2GM013042173 NNS O
of BC2GM013042173 IN O
the BC2GM013042173 DT O
spleen BC2GM013042173 NN O
, BC2GM013042173 , O
pharyngeal BC2GM013042173 JJ O
epithelial BC2GM013042173 JJ O
cells BC2GM013042173 NNS O
, BC2GM013042173 , O
and BC2GM013042173 CC O
at BC2GM013042173 IN O
low BC2GM013042173 JJ O
levels BC2GM013042173 NNS O
on BC2GM013042173 IN O
some BC2GM013042173 DT O
T BC2GM013042173 NNP O
lymphocytes BC2GM013042173 NNS O
. BC2GM013042173 . O
. . O O

An BC2GM070296233 DT O
additional BC2GM070296233 JJ O
stimulation BC2GM070296233 NN O
of BC2GM070296233 IN O
D1 BC2GM070296233 NNP O
receptors BC2GM070296233 NNS O
by BC2GM070296233 IN O
giving BC2GM070296233 VBG O
SKF38393 BC2GM070296233 NNP O
30 BC2GM070296233 CD O
min BC2GM070296233 NN O
later BC2GM070296233 RB O
produced BC2GM070296233 VBD O
an BC2GM070296233 DT O
almost BC2GM070296233 RB O
continuous BC2GM070296233 JJ O
pattern BC2GM070296233 NN O
of BC2GM070296233 IN O
jaw BC2GM070296233 JJ O
openings BC2GM070296233 NNS O
but BC2GM070296233 CC O
less BC2GM070296233 JJR O
closure BC2GM070296233 NN O
movements BC2GM070296233 NNS O
from BC2GM070296233 IN O
the BC2GM070296233 DT O
rest BC2GM070296233 NN O
position BC2GM070296233 NN O
, BC2GM070296233 , O
and BC2GM070296233 CC O
the BC2GM070296233 DT O
openings BC2GM070296233 NNS O
were BC2GM070296233 VBD O
accompanied BC2GM070296233 VBN O
by BC2GM070296233 IN O
frequent BC2GM070296233 JJ O
tongue BC2GM070296233 NN O
protrusions BC2GM070296233 NNS O
. BC2GM070296233 . O
. . O O

Detailed BC2GM083452156 JJ O
comparison BC2GM083452156 NN O
of BC2GM083452156 IN O
the BC2GM083452156 DT O
urinary BC2GM083452156 JJ O
excretion BC2GM083452156 NN O
of BC2GM083452156 IN O
purines BC2GM083452156 NNS O
in BC2GM083452156 IN O
a BC2GM083452156 DT O
patient BC2GM083452156 NN O
with BC2GM083452156 IN O
the BC2GM083452156 DT O
Lesch-Nyhan BC2GM083452156 NNP O
syndrome BC2GM083452156 NN O
and BC2GM083452156 CC O
a BC2GM083452156 DT O
control BC2GM083452156 NN O
subject BC2GM083452156 NN O
. BC2GM083452156 . O
. . O O

For BC2GM022311934 IN O
all BC2GM022311934 DT O
samples BC2GM022311934 NNS O
, BC2GM022311934 , O
the BC2GM022311934 DT O
sensitivity BC2GM022311934 NN O
of BC2GM022311934 IN O
the BC2GM022311934 DT O
blast BC2GM022311934 NN O
flag BC2GM022311934 NN O
on BC2GM022311934 IN O
the BC2GM022311934 DT O
CD3500 BC2GM022311934 NNP O
was BC2GM022311934 VBD O
85 BC2GM022311934 CD O
% BC2GM022311934 NN O
with BC2GM022311934 IN O
a BC2GM022311934 DT O
specificity BC2GM022311934 NN O
of BC2GM022311934 IN O
91 BC2GM022311934 CD O
% BC2GM022311934 NN O
( BC2GM022311934 ( O
STKS BC2GM022311934 NNP O
: BC2GM022311934 : O
sensitivity BC2GM022311934 NN O
, BC2GM022311934 , O
75 BC2GM022311934 CD O
% BC2GM022311934 NN O
; BC2GM022311934 : O
specificity BC2GM022311934 NN O
, BC2GM022311934 , O
85 BC2GM022311934 CD O
% BC2GM022311934 NN O
) BC2GM022311934 ) O
; BC2GM022311934 : O
the BC2GM022311934 DT O
sensitivity BC2GM022311934 NN O
of BC2GM022311934 IN O
the BC2GM022311934 DT O
CD3500 BC2GM022311934 NNP O
IG BC2GM022311934 NNP O
flag BC2GM022311934 NN O
was BC2GM022311934 VBD O
72 BC2GM022311934 CD O
% BC2GM022311934 NN O
with BC2GM022311934 IN O
a BC2GM022311934 DT O
specificity BC2GM022311934 NN O
of BC2GM022311934 IN O
76 BC2GM022311934 CD O
% BC2GM022311934 NN O
( BC2GM022311934 ( O
STKS BC2GM022311934 NNP O
: BC2GM022311934 : O
sensitivity BC2GM022311934 NN O
, BC2GM022311934 , O
75 BC2GM022311934 CD O
% BC2GM022311934 NN O
: BC2GM022311934 : O
specificity BC2GM022311934 NN O
, BC2GM022311934 , O
73 BC2GM022311934 CD O
% BC2GM022311934 NN O
) BC2GM022311934 ) O
; BC2GM022311934 : O
and BC2GM022311934 CC O
the BC2GM022311934 DT O
sensitivity BC2GM022311934 NN O
of BC2GM022311934 IN O
the BC2GM022311934 DT O
NRBC BC2GM022311934 NNP O
flag BC2GM022311934 NN O
was BC2GM022311934 VBD O
43 BC2GM022311934 CD O
% BC2GM022311934 NN O
with BC2GM022311934 IN O
a BC2GM022311934 DT O
specificity BC2GM022311934 NN O
of BC2GM022311934 IN O
94 BC2GM022311934 CD O
% BC2GM022311934 NN O
( BC2GM022311934 ( O
STKS BC2GM022311934 NNP O
sensitivity BC2GM022311934 NN O
, BC2GM022311934 , O
37 BC2GM022311934 CD O
% BC2GM022311934 NN O
; BC2GM022311934 : O
specificity BC2GM022311934 NN O
, BC2GM022311934 , O
88 BC2GM022311934 CD O
% BC2GM022311934 NN O
) BC2GM022311934 ) O
. BC2GM022311934 . O
. . O O

Evaluation BC2GM099337674 NN O
of BC2GM099337674 IN O
materials BC2GM099337674 NNS O
and BC2GM099337674 CC O
technics BC2GM099337674 NNS O
in BC2GM099337674 IN O
vascular BC2GM099337674 JJ O
surgery BC2GM099337674 NN O
using BC2GM099337674 VBG O
111-Indium BC2GM099337674 JJ O
. BC2GM099337674 . O
. . O O

Slowly BC2GM038263382 RB O
adapting BC2GM038263382 VBG O
type BC2GM038263382 NN O
I BC2GM038263382 PRP O
mechanoreceptor BC2GM038263382 VBP O
discharge BC2GM038263382 NN O
as BC2GM038263382 IN O
a BC2GM038263382 DT O
function BC2GM038263382 NN O
of BC2GM038263382 IN O
dynamic BC2GM038263382 JJ O
force BC2GM038263382 NN O
versus BC2GM038263382 NN O
dynamic BC2GM038263382 JJ O
displacement BC2GM038263382 NN O
of BC2GM038263382 IN O
glabrous BC2GM038263382 JJ O
skin BC2GM038263382 NN O
of BC2GM038263382 IN O
raccoon BC2GM038263382 NN O
and BC2GM038263382 CC O
squirrel BC2GM038263382 NN O
monkey BC2GM038263382 JJ O
hand BC2GM038263382 NN O
. BC2GM038263382 . O
. . O O

Searching BC2GM086765060 VBG O
the BC2GM086765060 DT O
human BC2GM086765060 JJ O
DNA BC2GM086765060 NNP O
data BC2GM086765060 NN O
base BC2GM086765060 NN O
of BC2GM086765060 IN O
expressed BC2GM086765060 VBN O
sequence BC2GM086765060 NN O
tags BC2GM086765060 NN O
( BC2GM086765060 ( O
EST BC2GM086765060 NNP O
) BC2GM086765060 ) O
revealed BC2GM086765060 VBD O
novel BC2GM086765060 JJ O
partial BC2GM086765060 JJ O
sequences BC2GM086765060 NNS O
similar BC2GM086765060 JJ O
to BC2GM086765060 TO O
, BC2GM086765060 , O
but BC2GM086765060 CC O
distinct BC2GM086765060 JJ O
from BC2GM086765060 IN O
, BC2GM086765060 , O
the BC2GM086765060 DT O
sequences BC2GM086765060 NNS O
of BC2GM086765060 IN O
the BC2GM086765060 DT O
previously BC2GM086765060 RB O
known BC2GM086765060 VBN O
PEF BC2GM086765060 NNP O
proteins BC2GM086765060 NNS O
. BC2GM086765060 . O
. . O O

Radiographic BC2GM031753625 JJ O
spatial BC2GM031753625 JJ O
frequencies BC2GM031753625 NNS O
essential BC2GM031753625 JJ O
to BC2GM031753625 TO O
the BC2GM031753625 DT O
diagnosis BC2GM031753625 NN O
of BC2GM031753625 IN O
incipient BC2GM031753625 NN O
interproximal BC2GM031753625 JJ O
lesions BC2GM031753625 NNS O
. BC2GM031753625 . O
. . O O

Conventional BC2GM066788416 JJ O
toxicological BC2GM066788416 JJ O
considerations BC2GM066788416 NNS O
suggest BC2GM066788416 VBP O
that BC2GM066788416 IN O
the BC2GM066788416 DT O
adverse BC2GM066788416 JJ O
health BC2GM066788416 NN O
effects BC2GM066788416 NNS O
of BC2GM066788416 IN O
any BC2GM066788416 DT O
necessary BC2GM066788416 JJ O
increase BC2GM066788416 NN O
in BC2GM066788416 IN O
coal BC2GM066788416 NN O
combustion BC2GM066788416 NN O
effluents BC2GM066788416 NNS O
would BC2GM066788416 MD O
be BC2GM066788416 VB O
greatest BC2GM066788416 JJS O
per BC2GM066788416 IN O
unit BC2GM066788416 NN O
of BC2GM066788416 IN O
coal BC2GM066788416 NN O
in BC2GM066788416 IN O
those BC2GM066788416 DT O
areas BC2GM066788416 NNS O
which BC2GM066788416 WDT O
are BC2GM066788416 VBP O
most BC2GM066788416 RBS O
heavily BC2GM066788416 RB O
populated BC2GM066788416 VBN O
and BC2GM066788416 CC O
have BC2GM066788416 VBP O
the BC2GM066788416 DT O
highest BC2GM066788416 JJS O
preexisting BC2GM066788416 NN O
levels BC2GM066788416 NNS O
of BC2GM066788416 IN O
the BC2GM066788416 DT O
gas-aerosol BC2GM066788416 JJ O
complex BC2GM066788416 NN O
. BC2GM066788416 . O
. . O O

The BC2GM012196374 DT O
22-d BC2GM012196374 JJ O
orbital BC2GM012196374 JJ O
flight BC2GM012196374 NN O
of BC2GM012196374 IN O
rats BC2GM012196374 NNS O
onboard BC2GM012196374 VBP O
the BC2GM012196374 DT O
Cosmos-605 BC2GM012196374 NNP O
biosatellite BC2GM012196374 NN O
was BC2GM012196374 VBD O
followed BC2GM012196374 VBN O
by BC2GM012196374 IN O
inhibition BC2GM012196374 NN O
of BC2GM012196374 IN O
erythroblastosis BC2GM012196374 NN O
, BC2GM012196374 , O
alteration BC2GM012196374 NN O
in BC2GM012196374 IN O
the BC2GM012196374 DT O
morphology BC2GM012196374 NN O
of BC2GM012196374 IN O
megakaryocytes BC2GM012196374 NNS O
, BC2GM012196374 , O
and BC2GM012196374 CC O
stimulation BC2GM012196374 NN O
of BC2GM012196374 IN O
myelopoiesis BC2GM012196374 NN O
. BC2GM012196374 . O
. . O O

These BC2GM016660026 DT O
motifs BC2GM016660026 NNS O
, BC2GM016660026 , O
and BC2GM016660026 CC O
their BC2GM016660026 PRP$ O
cognate BC2GM016660026 JJ O
transcription BC2GM016660026 NN O
factors BC2GM016660026 NNS O
, BC2GM016660026 , O
appear BC2GM016660026 VBP O
to BC2GM016660026 TO O
act BC2GM016660026 VB O
in BC2GM016660026 IN O
concert BC2GM016660026 NN O
, BC2GM016660026 , O
with BC2GM016660026 IN O
partial BC2GM016660026 JJ O
redundancy BC2GM016660026 NN O
, BC2GM016660026 , O
so BC2GM016660026 IN O
that BC2GM016660026 DT O
discrete BC2GM016660026 JJ O
mutations BC2GM016660026 NNS O
were BC2GM016660026 VBD O
only BC2GM016660026 RB O
partially BC2GM016660026 RB O
effective BC2GM016660026 JJ O
in BC2GM016660026 IN O
reducing BC2GM016660026 VBG O
transcriptional BC2GM016660026 JJ O
activity BC2GM016660026 NN O
. BC2GM016660026 . O
. . O O

Sequence BC2GM051932987 NN O
analysis BC2GM051932987 NN O
revealed BC2GM051932987 VBD O
that BC2GM051932987 IN O
Hv-p68 BC2GM051932987 NNP O
belongs BC2GM051932987 NNS O
to BC2GM051932987 TO O
the BC2GM051932987 DT O
large BC2GM051932987 JJ O
family BC2GM051932987 NN O
of BC2GM051932987 IN O
FAD-dependent BC2GM051932987 NNP O
glucose BC2GM051932987 JJ O
methanol BC2GM051932987 NNS O
choline BC2GM051932987 VBP O
oxidoreductases BC2GM051932987 NNS O
and BC2GM051932987 CC O
that BC2GM051932987 IN O
it BC2GM051932987 PRP O
shares BC2GM051932987 NNS O
significant BC2GM051932987 JJ O
sequence BC2GM051932987 NN O
identity BC2GM051932987 NN O
( BC2GM051932987 ( O
> BC2GM051932987 JJ O
67 BC2GM051932987 CD O
% BC2GM051932987 NN O
) BC2GM051932987 ) O
with BC2GM051932987 IN O
the BC2GM051932987 DT O
alcohol BC2GM051932987 NN O
oxidases BC2GM051932987 NNS O
of BC2GM051932987 IN O
the BC2GM051932987 DT O
methylotrophic BC2GM051932987 JJ O
yeasts BC2GM051932987 NNS O
. BC2GM051932987 . O
. . O O

1995 BC2GM014978613 CD O
. BC2GM014978613 . O
. . O O

We BC2GM060480858 PRP O
concluded BC2GM060480858 VBD O
that BC2GM060480858 IN O
HFV BC2GM060480858 NNP O
can BC2GM060480858 MD O
achieve BC2GM060480858 VB O
values BC2GM060480858 NNS O
of BC2GM060480858 IN O
CO2 BC2GM060480858 NNP O
elimination BC2GM060480858 NN O
close BC2GM060480858 RB O
to BC2GM060480858 TO O
the BC2GM060480858 DT O
estimated BC2GM060480858 VBN O
metabolic BC2GM060480858 JJ O
CO2 BC2GM060480858 NNP O
production BC2GM060480858 NN O
in BC2GM060480858 IN O
normal BC2GM060480858 JJ O
unintubated BC2GM060480858 JJ O
subjects BC2GM060480858 NNS O
over BC2GM060480858 IN O
short BC2GM060480858 JJ O
periods BC2GM060480858 NNS O
of BC2GM060480858 IN O
time BC2GM060480858 NN O
. BC2GM060480858 . O
. . O O

Effects BC2GM039227487 NNS O
of BC2GM039227487 IN O
acute BC2GM039227487 JJ O
exposure BC2GM039227487 NN O
to BC2GM039227487 TO O
cold BC2GM039227487 VB O
on BC2GM039227487 IN O
pulmonary BC2GM039227487 JJ O
arterial BC2GM039227487 JJ O
blood BC2GM039227487 NN O
pressure BC2GM039227487 NN O
in BC2GM039227487 IN O
awake BC2GM039227487 NN O
rats BC2GM039227487 NNS O
. BC2GM039227487 . O
. . O O

Thus BC2GM007356608 RB O
, BC2GM007356608 , O
the BC2GM007356608 DT O
antibody BC2GM007356608 NN O
class BC2GM007356608 NN O
switch BC2GM007356608 NN O
appears BC2GM007356608 VBZ O
to BC2GM007356608 TO O
be BC2GM007356608 VB O
directed BC2GM007356608 VBN O
by BC2GM007356608 IN O
induction BC2GM007356608 NN O
of BC2GM007356608 IN O
accessibility BC2GM007356608 NN O
, BC2GM007356608 , O
as BC2GM007356608 IN O
assayed BC2GM007356608 VBN O
by BC2GM007356608 IN O
transcription BC2GM007356608 NN O
of BC2GM007356608 IN O
germ BC2GM007356608 JJ O
line BC2GM007356608 NN O
CH BC2GM007356608 NNP O
genes BC2GM007356608 NNS O
. BC2GM007356608 . O
. . O O

A BC2GM020478123 DT O
novel BC2GM020478123 JJ O
alternative BC2GM020478123 NN O
spliced BC2GM020478123 VBD O
variant BC2GM020478123 NN O
of BC2GM020478123 IN O
the BC2GM020478123 DT O
transcription BC2GM020478123 NN O
factor BC2GM020478123 NN O
AP2alpha BC2GM020478123 NNP O
is BC2GM020478123 VBZ O
expressed BC2GM020478123 VBN O
in BC2GM020478123 IN O
the BC2GM020478123 DT O
murine BC2GM020478123 NN O
ocular BC2GM020478123 JJ O
lens BC2GM020478123 NNS O
. BC2GM020478123 . O
. . O O

It BC2GM072306591 PRP O
has BC2GM072306591 VBZ O
been BC2GM072306591 VBN O
demonstrated BC2GM072306591 VBN O
that BC2GM072306591 IN O
stimulation BC2GM072306591 NN O
of BC2GM072306591 IN O
the BC2GM072306591 DT O
pontomesencephalic BC2GM072306591 JJ O
parabrachial BC2GM072306591 JJ O
region BC2GM072306591 NN O
( BC2GM072306591 ( O
PBR BC2GM072306591 NNP O
) BC2GM072306591 ) O
by BC2GM072306591 IN O
microinjection BC2GM072306591 NN O
of BC2GM072306591 IN O
cholinergic BC2GM072306591 JJ O
drugs BC2GM072306591 NNS O
or BC2GM072306591 CC O
electricity BC2GM072306591 NN O
in BC2GM072306591 IN O
the BC2GM072306591 DT O
cat BC2GM072306591 NN O
produces BC2GM072306591 VBZ O
potent BC2GM072306591 JJ O
pain BC2GM072306591 NN O
suppression BC2GM072306591 NN O
which BC2GM072306591 WDT O
is BC2GM072306591 VBZ O
not BC2GM072306591 RB O
antagonized BC2GM072306591 VBN O
by BC2GM072306591 IN O
the BC2GM072306591 DT O
opiate BC2GM072306591 JJ O
antagonist BC2GM072306591 NN O
, BC2GM072306591 , O
naloxone BC2GM072306591 NN O
. BC2GM072306591 . O
. . O O

To BC2GM076697045 TO O
increase BC2GM076697045 VB O
the BC2GM076697045 DT O
number BC2GM076697045 NN O
of BC2GM076697045 IN O
circulating BC2GM076697045 VBG O
polymorphonuclear BC2GM076697045 JJ O
neutrophils BC2GM076697045 NNS O
, BC2GM076697045 , O
the BC2GM076697045 DT O
patient BC2GM076697045 NN O
was BC2GM076697045 VBD O
treated BC2GM076697045 VBN O
with BC2GM076697045 IN O
recombinant BC2GM076697045 JJ O
granulocyte-macrophage BC2GM076697045 JJ O
colony-stimulating BC2GM076697045 JJ O
factor BC2GM076697045 NN O
( BC2GM076697045 ( O
GM-CSF BC2GM076697045 NNP O
) BC2GM076697045 ) O
at BC2GM076697045 IN O
a BC2GM076697045 DT O
dose BC2GM076697045 NN O
of BC2GM076697045 IN O
2 BC2GM076697045 CD O
micrograms BC2GM076697045 NNS O
protein BC2GM076697045 VBP O
/ BC2GM076697045 JJ O
kg BC2GM076697045 NN O
bodyweight BC2GM076697045 VBD O
s.c. BC2GM076697045 JJ O
/ BC2GM076697045 NNP O
12 BC2GM076697045 CD O
h BC2GM076697045 NN O
. BC2GM076697045 . O
. . O O

Taken BC2GM080784888 VBN O
together BC2GM080784888 RB O
, BC2GM080784888 , O
these BC2GM080784888 DT O
results BC2GM080784888 NNS O
indicate BC2GM080784888 VBP O
that BC2GM080784888 IN O
ICSBP BC2GM080784888 NNP O
and BC2GM080784888 CC O
PU.1 BC2GM080784888 NNP O
are BC2GM080784888 VBP O
critical BC2GM080784888 JJ O
elements BC2GM080784888 NNS O
for BC2GM080784888 IN O
IL-18 BC2GM080784888 NNP O
gene BC2GM080784888 NN O
expression BC2GM080784888 NN O
. BC2GM080784888 . O
. . O O

The BC2GM086763162 DT O
mean BC2GM086763162 JJ O
times BC2GM086763162 NNS O
to BC2GM086763162 TO O
LNR BC2GM086763162 VB O
in BC2GM086763162 IN O
these BC2GM086763162 DT O
groups BC2GM086763162 NNS O
were BC2GM086763162 VBD O
42.0 BC2GM086763162 CD O
months BC2GM086763162 NNS O
( BC2GM086763162 ( O
range BC2GM086763162 NN O
, BC2GM086763162 , O
3.0-194.5 BC2GM086763162 JJ O
months BC2GM086763162 NNS O
) BC2GM086763162 ) O
and BC2GM086763162 CC O
49.0 BC2GM086763162 CD O
months BC2GM086763162 NNS O
( BC2GM086763162 ( O
range BC2GM086763162 NN O
, BC2GM086763162 , O
3.6-209.0 BC2GM086763162 JJ O
months BC2GM086763162 NNS O
) BC2GM086763162 ) O
respectively BC2GM086763162 RB O
. BC2GM086763162 . O
. . O O

Consistently BC2GM018016290 RB O
, BC2GM018016290 , O
we BC2GM018016290 PRP O
show BC2GM018016290 VBP O
that BC2GM018016290 IN O
phosphorylation BC2GM018016290 NN O
by BC2GM018016290 IN O
protein BC2GM018016290 NN O
kinase BC2GM018016290 NN O
A BC2GM018016290 NNP O
inhibits BC2GM018016290 VBZ O
Sfl1 BC2GM018016290 NNP O
DNA BC2GM018016290 NNP O
binding BC2GM018016290 NN O
in BC2GM018016290 IN O
vitro BC2GM018016290 NN O
, BC2GM018016290 , O
and BC2GM018016290 CC O
that BC2GM018016290 IN O
a BC2GM018016290 DT O
tpk2Delta BC2GM018016290 JJ O
mutation BC2GM018016290 NN O
increases BC2GM018016290 VBZ O
the BC2GM018016290 DT O
levels BC2GM018016290 NNS O
of BC2GM018016290 IN O
Sfl1 BC2GM018016290 NNP O
protein BC2GM018016290 NN O
associated BC2GM018016290 VBN O
with BC2GM018016290 IN O
specific BC2GM018016290 JJ O
promoter BC2GM018016290 NN O
elements BC2GM018016290 NNS O
in BC2GM018016290 IN O
vivo BC2GM018016290 NN O
. BC2GM018016290 . O
. . O O

The BC2GM031784532 DT O
pcaR BC2GM031784532 NN O
regulatory BC2GM031784532 JJ O
locus BC2GM031784532 NN O
has BC2GM031784532 VBZ O
been BC2GM031784532 VBN O
found BC2GM031784532 VBN O
to BC2GM031784532 TO O
be BC2GM031784532 VB O
required BC2GM031784532 VBN O
for BC2GM031784532 IN O
both BC2GM031784532 DT O
induction BC2GM031784532 NN O
of BC2GM031784532 IN O
all BC2GM031784532 DT O
of BC2GM031784532 IN O
the BC2GM031784532 DT O
genes BC2GM031784532 NNS O
within BC2GM031784532 IN O
the BC2GM031784532 DT O
pca BC2GM031784532 NN O
regulon BC2GM031784532 NN O
( BC2GM031784532 ( O
pcaBDC BC2GM031784532 NN O
, BC2GM031784532 , O
pcaIJ BC2GM031784532 NN O
, BC2GM031784532 , O
and BC2GM031784532 CC O
pcaF BC2GM031784532 NN O
) BC2GM031784532 ) O
and BC2GM031784532 CC O
the BC2GM031784532 DT O
chemotactic BC2GM031784532 JJ O
response BC2GM031784532 NN O
of BC2GM031784532 IN O
the BC2GM031784532 DT O
bacteria BC2GM031784532 NNS O
to BC2GM031784532 TO O
aromatic BC2GM031784532 JJ O
compounds BC2GM031784532 NNS O
. BC2GM031784532 . O
. . O O

Additional BC2GM001896188 NNP O
genetic BC2GM001896188 JJ O
analyses BC2GM001896188 NNS O
described BC2GM001896188 VBD O
herein BC2GM001896188 JJ O
suggest BC2GM001896188 VBP O
that BC2GM001896188 IN O
Skb1 BC2GM001896188 NNP O
is BC2GM001896188 VBZ O
a BC2GM001896188 DT O
component BC2GM001896188 NN O
of BC2GM001896188 IN O
the BC2GM001896188 DT O
morphology BC2GM001896188 NN O
control BC2GM001896188 NN O
branch BC2GM001896188 NN O
of BC2GM001896188 IN O
the BC2GM001896188 DT O
Ras BC2GM001896188 NNP O
signaling BC2GM001896188 VBG O
cascade BC2GM001896188 NN O
in BC2GM001896188 IN O
S. BC2GM001896188 NNP O
pombe BC2GM001896188 NN O
and BC2GM001896188 CC O
that BC2GM001896188 IN O
it BC2GM001896188 PRP O
positively BC2GM001896188 RB O
modulates BC2GM001896188 VBZ O
Shk1 BC2GM001896188 NNP O
function BC2GM001896188 NN O
. BC2GM001896188 . O
. . O O

Endothelial BC2GM027981774 JJ O
purine BC2GM027981774 NN O
content BC2GM027981774 NN O
. BC2GM027981774 . O
. . O O

CONCLUSIONS BC2GM011974374 NN O
: BC2GM011974374 : O
Patients BC2GM011974374 NNS O
' BC2GM011974374 POS O
attainment BC2GM011974374 NN O
of BC2GM011974374 IN O
TGB BC2GM011974374 NNP O
monotherapy BC2GM011974374 NN O
was BC2GM011974374 VBD O
associated BC2GM011974374 VBN O
with BC2GM011974374 IN O
their BC2GM011974374 PRP$ O
achievement BC2GM011974374 NN O
of BC2GM011974374 IN O
positive BC2GM011974374 JJ O
changes BC2GM011974374 NNS O
of BC2GM011974374 IN O
varying BC2GM011974374 VBG O
degree BC2GM011974374 NN O
on BC2GM011974374 IN O
psychological BC2GM011974374 JJ O
tests BC2GM011974374 NNS O
. BC2GM011974374 . O
. . O O

On BC2GM011317190 IN O
the BC2GM011317190 DT O
other BC2GM011317190 JJ O
hand BC2GM011317190 NN O
, BC2GM011317190 , O
V3 BC2GM011317190 NNP O
'' BC2GM011317190 '' O
values BC2GM011317190 NNS O
were BC2GM011317190 VBD O
not BC2GM011317190 RB O
significantly BC2GM011317190 RB O
correlated BC2GM011317190 VBN O
with BC2GM011317190 IN O
the BC2GM011317190 DT O
degree BC2GM011317190 NN O
of BC2GM011317190 IN O
tremor BC2GM011317190 NN O
, BC2GM011317190 , O
seborrhea BC2GM011317190 NN O
, BC2GM011317190 , O
and BC2GM011317190 CC O
duration BC2GM011317190 NN O
of BC2GM011317190 IN O
the BC2GM011317190 DT O
illness BC2GM011317190 NN O
. BC2GM011317190 . O
. . O O

Oral BC2GM037434431 JJ O
basal BC2GM037434431 NN O
body BC2GM037434431 NN O
temperature BC2GM037434431 NN O
( BC2GM037434431 ( O
BBT BC2GM037434431 NNP O
) BC2GM037434431 ) O
recordings BC2GM037434431 NNS O
of BC2GM037434431 IN O
46 BC2GM037434431 CD O
women BC2GM037434431 NNS O
that BC2GM037434431 WDT O
conceived BC2GM037434431 VBN O
by BC2GM037434431 IN O
donor BC2GM037434431 JJ O
insemination BC2GM037434431 NN O
and BC2GM037434431 CC O
who BC2GM037434431 WP O
had BC2GM037434431 VBD O
midcycle BC2GM037434431 NN O
monitoring BC2GM037434431 NN O
of BC2GM037434431 IN O
luteinising BC2GM037434431 VBG O
hormone BC2GM037434431 NN O
( BC2GM037434431 ( O
LH BC2GM037434431 NNP O
) BC2GM037434431 ) O
were BC2GM037434431 VBD O
analysed BC2GM037434431 VBN O
to BC2GM037434431 TO O
establish BC2GM037434431 VB O
features BC2GM037434431 NNS O
associated BC2GM037434431 VBN O
with BC2GM037434431 IN O
an BC2GM037434431 DT O
optimal BC2GM037434431 JJ O
cycle BC2GM037434431 NN O
. BC2GM037434431 . O
. . O O

The BC2GM068628850 DT O
embryology BC2GM068628850 NN O
of BC2GM068628850 IN O
the BC2GM068628850 DT O
vertebral BC2GM068628850 JJ O
column BC2GM068628850 NN O
is BC2GM068628850 VBZ O
reviewed BC2GM068628850 VBN O
briefly BC2GM068628850 NN O
, BC2GM068628850 , O
and BC2GM068628850 CC O
the BC2GM068628850 DT O
origin BC2GM068628850 NN O
of BC2GM068628850 IN O
each BC2GM068628850 DT O
anomaly BC2GM068628850 NN O
of BC2GM068628850 IN O
the BC2GM068628850 DT O
C2 BC2GM068628850 NNP O
vertebra BC2GM068628850 NN O
is BC2GM068628850 VBZ O
traced BC2GM068628850 VBN O
to BC2GM068628850 TO O
one BC2GM068628850 CD O
of BC2GM068628850 IN O
the BC2GM068628850 DT O
two BC2GM068628850 CD O
early BC2GM068628850 JJ O
stages BC2GM068628850 NNS O
in BC2GM068628850 IN O
development BC2GM068628850 NN O
as BC2GM068628850 IN O
follows BC2GM068628850 VBZ O
: BC2GM068628850 : O
1 BC2GM068628850 CD O
) BC2GM068628850 ) O
the BC2GM068628850 DT O
formation BC2GM068628850 NN O
of BC2GM068628850 IN O
the BC2GM068628850 DT O
mesenchymal BC2GM068628850 JJ O
vertebra BC2GM068628850 NN O
or BC2GM068628850 CC O
2 BC2GM068628850 CD O
) BC2GM068628850 ) O
its BC2GM068628850 PRP$ O
induction BC2GM068628850 NN O
to BC2GM068628850 TO O
cartilage BC2GM068628850 VB O
. BC2GM068628850 . O
. . O O

The BC2GM030532264 DT O
signs BC2GM030532264 NNS O
of BC2GM030532264 IN O
enterocolitis BC2GM030532264 NN O
, BC2GM030532264 , O
pathological BC2GM030532264 JJ O
microbial BC2GM030532264 NN O
flora BC2GM030532264 NN O
in BC2GM030532264 IN O
the BC2GM030532264 DT O
stool BC2GM030532264 NN O
and BC2GM030532264 CC O
changes BC2GM030532264 NNS O
in BC2GM030532264 IN O
the BC2GM030532264 DT O
colon BC2GM030532264 NN O
mucosa BC2GM030532264 NN O
were BC2GM030532264 VBD O
absent BC2GM030532264 JJ O
. BC2GM030532264 . O
. . O O

Here BC2GM039101947 RB O
we BC2GM039101947 PRP O
show BC2GM039101947 VBP O
that BC2GM039101947 IN O
the BC2GM039101947 DT O
sck1 BC2GM039101947 JJ O
gene BC2GM039101947 NN O
, BC2GM039101947 , O
cloned BC2GM039101947 VBN O
as BC2GM039101947 IN O
a BC2GM039101947 DT O
high BC2GM039101947 JJ O
copy BC2GM039101947 NN O
number BC2GM039101947 NN O
suppressor BC2GM039101947 NN O
of BC2GM039101947 IN O
a BC2GM039101947 DT O
mutation BC2GM039101947 NN O
in BC2GM039101947 IN O
git3 BC2GM039101947 NN O
, BC2GM039101947 , O
is BC2GM039101947 VBZ O
able BC2GM039101947 JJ O
to BC2GM039101947 TO O
suppress BC2GM039101947 VB O
the BC2GM039101947 DT O
defects BC2GM039101947 NNS O
conferred BC2GM039101947 VBN O
by BC2GM039101947 IN O
a BC2GM039101947 DT O
mutation BC2GM039101947 NN O
in BC2GM039101947 IN O
any BC2GM039101947 DT O
of BC2GM039101947 IN O
these BC2GM039101947 DT O
git BC2GM039101947 JJ O
genes BC2GM039101947 NNS O
. BC2GM039101947 . O
. . O O

The BC2GM050518839 DT O
Fugu BC2GM050518839 NNP O
rubripes BC2GM050518839 NNS O
( BC2GM050518839 ( O
Fugu BC2GM050518839 NNP O
) BC2GM050518839 ) O
gene BC2GM050518839 NN O
fragment BC2GM050518839 NN O
was BC2GM050518839 VBD O
used BC2GM050518839 VBN O
to BC2GM050518839 TO O
isolate BC2GM050518839 VB O
the BC2GM050518839 DT O
GH BC2GM050518839 NNP O
gene BC2GM050518839 NN O
from BC2GM050518839 IN O
a BC2GM050518839 DT O
Fugu BC2GM050518839 NNP O
genomic BC2GM050518839 JJ O
library BC2GM050518839 NN O
. BC2GM050518839 . O
. . O O

The BC2GM023703398 DT O
activity BC2GM023703398 NN O
of BC2GM023703398 IN O
plasminogen BC2GM023703398 NN O
activator BC2GM023703398 NN O
has BC2GM023703398 VBZ O
been BC2GM023703398 VBN O
measured BC2GM023703398 VBN O
in BC2GM023703398 IN O
tissue BC2GM023703398 NN O
sections BC2GM023703398 NNS O
with BC2GM023703398 IN O
the BC2GM023703398 DT O
aid BC2GM023703398 NN O
of BC2GM023703398 IN O
a BC2GM023703398 DT O
modified BC2GM023703398 JJ O
Todd BC2GM023703398 NNP O
technique BC2GM023703398 NN O
. BC2GM023703398 . O
. . O O

A BC2GM074570108 DT O
factor BC2GM074570108 NN O
present BC2GM074570108 NN O
in BC2GM074570108 IN O
nuclear BC2GM074570108 JJ O
extracts BC2GM074570108 NNS O
of BC2GM074570108 IN O
wounded BC2GM074570108 JJ O
potato BC2GM074570108 NN O
tubers BC2GM074570108 NNS O
was BC2GM074570108 VBD O
found BC2GM074570108 VBN O
to BC2GM074570108 TO O
bind BC2GM074570108 VB O
specifically BC2GM074570108 RB O
to BC2GM074570108 TO O
nucleotides BC2GM074570108 NNS O
located BC2GM074570108 VBN O
between BC2GM074570108 IN O
-135 BC2GM074570108 NN O
to BC2GM074570108 TO O
-105 BC2GM074570108 VB O
, BC2GM074570108 , O
suggesting BC2GM074570108 VBG O
that BC2GM074570108 IN O
this BC2GM074570108 DT O
region BC2GM074570108 NN O
contains BC2GM074570108 VBZ O
important BC2GM074570108 JJ O
cis-regulatory BC2GM074570108 JJ O
elements BC2GM074570108 NNS O
. BC2GM074570108 . O
. . O O

The BC2GM059635373 DT O
requirement BC2GM059635373 NN O
for BC2GM059635373 IN O
an BC2GM059635373 DT O
essential BC2GM059635373 JJ O
interaction BC2GM059635373 NN O
between BC2GM059635373 IN O
NPH BC2GM059635373 NNP O
I BC2GM059635373 PRP O
and BC2GM059635373 CC O
H4L BC2GM059635373 NNP O
provides BC2GM059635373 VBZ O
an BC2GM059635373 DT O
explanation BC2GM059635373 NN O
for BC2GM059635373 IN O
the BC2GM059635373 DT O
observed BC2GM059635373 JJ O
restriction BC2GM059635373 NN O
of BC2GM059635373 IN O
transcription BC2GM059635373 NN O
termination BC2GM059635373 NN O
to BC2GM059635373 TO O
early BC2GM059635373 JJ O
viral BC2GM059635373 JJ O
genes BC2GM059635373 NNS O
. BC2GM059635373 . O
. . O O

Several BC2GM077691653 JJ O
positive BC2GM077691653 JJ O
clones BC2GM077691653 NNS O
were BC2GM077691653 VBD O
isolated BC2GM077691653 VBN O
, BC2GM077691653 , O
one BC2GM077691653 CD O
of BC2GM077691653 IN O
which BC2GM077691653 WDT O
encoded BC2GM077691653 VBD O
the BC2GM077691653 DT O
C-terminal BC2GM077691653 JJ O
253 BC2GM077691653 CD O
amino BC2GM077691653 JJ O
acids BC2GM077691653 NNS O
of BC2GM077691653 IN O
a BC2GM077691653 DT O
putative BC2GM077691653 JJ O
RNA BC2GM077691653 NNP O
helicase BC2GM077691653 NN O
, BC2GM077691653 , O
a BC2GM077691653 DT O
DEAD BC2GM077691653 NNP O
box BC2GM077691653 NN O
protein BC2GM077691653 NN O
designated BC2GM077691653 VBD O
DDX3 BC2GM077691653 NNP O
. BC2GM077691653 . O
. . O O

We BC2GM068581710 PRP O
exposed BC2GM068581710 VBD O
Dorper-cross BC2GM068581710 NNP O
ewes BC2GM068581710 NN O
at BC2GM068581710 IN O
approximately BC2GM068581710 RB O
120-135 BC2GM068581710 JJ O
days BC2GM068581710 NNS O
of BC2GM068581710 IN O
gestation BC2GM068581710 NN O
to BC2GM068581710 TO O
a BC2GM068581710 DT O
hot BC2GM068581710 JJ O
( BC2GM068581710 ( O
40 BC2GM068581710 CD O
degrees BC2GM068581710 NNS O
C BC2GM068581710 NNP O
, BC2GM068581710 , O
60 BC2GM068581710 CD O
% BC2GM068581710 NN O
relative BC2GM068581710 JJ O
humidity BC2GM068581710 NN O
) BC2GM068581710 ) O
and BC2GM068581710 CC O
a BC2GM068581710 DT O
cold BC2GM068581710 JJ O
( BC2GM068581710 ( O
4 BC2GM068581710 CD O
degrees BC2GM068581710 NNS O
C BC2GM068581710 NNP O
, BC2GM068581710 , O
90 BC2GM068581710 CD O
% BC2GM068581710 NN O
relative BC2GM068581710 JJ O
humidity BC2GM068581710 NN O
) BC2GM068581710 ) O
environment BC2GM068581710 NN O
and BC2GM068581710 CC O
to BC2GM068581710 TO O
treadmill BC2GM068581710 VB O
exercise BC2GM068581710 NN O
( BC2GM068581710 ( O
2.1 BC2GM068581710 CD O
km BC2GM068581710 NN O
/ BC2GM068581710 NN O
h BC2GM068581710 NN O
, BC2GM068581710 , O
5 BC2GM068581710 CD O
degrees BC2GM068581710 NNS O
gradient BC2GM068581710 NN O
) BC2GM068581710 ) O
and BC2GM068581710 CC O
measured BC2GM068581710 VBN O
fetal BC2GM068581710 JJ O
lamb BC2GM068581710 NN O
and BC2GM068581710 CC O
ewe BC2GM068581710 VB O
body BC2GM068581710 NN O
temperatures BC2GM068581710 NNS O
using BC2GM068581710 VBG O
previously BC2GM068581710 RB O
implanted BC2GM068581710 VBN O
abdominal BC2GM068581710 JJ O
radiotelemeters BC2GM068581710 NNS O
. BC2GM068581710 . O
. . O O

Analysis BC2GM007331951 NN O
of BC2GM007331951 IN O
the BC2GM007331951 DT O
DNA BC2GM007331951 NNP O
sequence BC2GM007331951 NN O
upstream BC2GM007331951 NN O
of BC2GM007331951 IN O
the BC2GM007331951 DT O
narQ BC2GM007331951 JJ O
gene BC2GM007331951 NN O
, BC2GM007331951 , O
which BC2GM007331951 WDT O
encodes BC2GM007331951 VBZ O
the BC2GM007331951 DT O
second BC2GM007331951 JJ O
nitrate-responsive BC2GM007331951 JJ O
sensor-transmitter BC2GM007331951 NN O
protein BC2GM007331951 NN O
in BC2GM007331951 IN O
Escherichia BC2GM007331951 NNP O
coli BC2GM007331951 NN O
, BC2GM007331951 , O
revealed BC2GM007331951 VBD O
an BC2GM007331951 DT O
open BC2GM007331951 JJ O
reading BC2GM007331951 NN O
frame BC2GM007331951 NN O
( BC2GM007331951 ( O
ORF BC2GM007331951 NNP O
) BC2GM007331951 ) O
whose BC2GM007331951 WP$ O
product BC2GM007331951 NN O
shows BC2GM007331951 VBZ O
a BC2GM007331951 DT O
high BC2GM007331951 JJ O
degree BC2GM007331951 NN O
of BC2GM007331951 IN O
similarity BC2GM007331951 NN O
to BC2GM007331951 TO O
a BC2GM007331951 DT O
number BC2GM007331951 NN O
of BC2GM007331951 IN O
iron-sulfur BC2GM007331951 JJ O
proteins BC2GM007331951 NNS O
as BC2GM007331951 RB O
well BC2GM007331951 RB O
as BC2GM007331951 IN O
to BC2GM007331951 TO O
the BC2GM007331951 DT O
beta BC2GM007331951 NN O
subunit BC2GM007331951 NN O
of BC2GM007331951 IN O
glutamate BC2GM007331951 JJ O
synthase BC2GM007331951 NN O
( BC2GM007331951 ( O
gltD BC2GM007331951 NN O
) BC2GM007331951 ) O
of BC2GM007331951 IN O
E. BC2GM007331951 NNP O
coli BC2GM007331951 NNS O
. BC2GM007331951 . O
. . O O

Recurrent BC2GM037252566 JJ O
infections BC2GM037252566 NNS O
, BC2GM037252566 , O
episodic BC2GM037252566 JJ O
lymphopenia BC2GM037252566 NN O
and BC2GM037252566 CC O
impaired BC2GM037252566 JJ O
cellular BC2GM037252566 JJ O
immunity BC2GM037252566 NN O
. BC2GM037252566 . O
. . O O

This BC2GM078528949 DT O
paper BC2GM078528949 NN O
describes BC2GM078528949 VBZ O
a BC2GM078528949 DT O
longitudinal BC2GM078528949 JJ O
study BC2GM078528949 NN O
in BC2GM078528949 IN O
which BC2GM078528949 WDT O
clinical BC2GM078528949 JJ O
parameters BC2GM078528949 NNS O
and BC2GM078528949 CC O
aspartate BC2GM078528949 JJ O
aminotransferase BC2GM078528949 NN O
( BC2GM078528949 ( O
AST BC2GM078528949 NNP O
) BC2GM078528949 ) O
in BC2GM078528949 IN O
gingival BC2GM078528949 NN O
crevicular BC2GM078528949 JJ O
fluid BC2GM078528949 NN O
( BC2GM078528949 ( O
GCF BC2GM078528949 NNP O
) BC2GM078528949 ) O
were BC2GM078528949 VBD O
monitored BC2GM078528949 VBN O
bimonthly BC2GM078528949 RB O
over BC2GM078528949 IN O
a BC2GM078528949 DT O
6-12 BC2GM078528949 JJ O
months BC2GM078528949 NNS O
period BC2GM078528949 NN O
in BC2GM078528949 IN O
970 BC2GM078528949 CD O
sites BC2GM078528949 NNS O
from BC2GM078528949 IN O
7 BC2GM078528949 CD O
treated BC2GM078528949 JJ O
periodontitis BC2GM078528949 NN O
patients BC2GM078528949 NNS O
. BC2GM078528949 . O
. . O O

An BC2GM006351577 DT O
enhancement BC2GM006351577 NN O
of BC2GM006351577 IN O
benign BC2GM006351577 JJ O
liver BC2GM006351577 NN O
tumors BC2GM006351577 NNS O
( BC2GM006351577 ( O
tumorigenic BC2GM006351577 JJ O
effect BC2GM006351577 NN O
) BC2GM006351577 ) O
was BC2GM006351577 VBD O
observed BC2GM006351577 VBN O
only BC2GM006351577 RB O
in BC2GM006351577 IN O
CF1 BC2GM006351577 NNP O
male BC2GM006351577 NN O
mice BC2GM006351577 NN O
( BC2GM006351577 ( O
17 BC2GM006351577 CD O
/ BC2GM006351577 RB O
56 BC2GM006351577 CD O
at BC2GM006351577 IN O
the BC2GM006351577 DT O
only BC2GM006351577 RB O
tested BC2GM006351577 VBN O
dose BC2GM006351577 NN O
: BC2GM006351577 : O
400 BC2GM006351577 CD O
ppm BC2GM006351577 NN O
vs BC2GM006351577 NN O
. BC2GM006351577 . O
. . O O

Antibiotics BC2GM064553826 NNS O
and BC2GM064553826 CC O
CDCA-mediation BC2GM064553826 NNP O
are BC2GM064553826 VBP O
essential BC2GM064553826 JJ O
for BC2GM064553826 IN O
symptomatic BC2GM064553826 JJ O
therapy BC2GM064553826 NN O
. BC2GM064553826 . O
. . O O

In BC2GM066299877 IN O
situ BC2GM066299877 JJ O
hybridization BC2GM066299877 NN O
reveals BC2GM066299877 NNS O
strong BC2GM066299877 JJ O
signals BC2GM066299877 NNS O
for BC2GM066299877 IN O
Zep BC2GM066299877 NNP O
mRNA BC2GM066299877 NN O
in BC2GM066299877 IN O
the BC2GM066299877 DT O
cerebellum BC2GM066299877 NN O
and BC2GM066299877 CC O
olfactory BC2GM066299877 NN O
bulb BC2GM066299877 NN O
with BC2GM066299877 IN O
moderate BC2GM066299877 JJ O
signals BC2GM066299877 NNS O
detected BC2GM066299877 VBN O
in BC2GM066299877 IN O
the BC2GM066299877 DT O
hippocampus BC2GM066299877 NN O
and BC2GM066299877 CC O
cortex BC2GM066299877 NN O
. BC2GM066299877 . O
. . O O

Site-directed BC2GM048437284 JJ O
mutagenesis BC2GM048437284 NN O
shows BC2GM048437284 NNS O
that BC2GM048437284 WDT O
sites BC2GM048437284 VBZ O
throughout BC2GM048437284 IN O
the BC2GM048437284 DT O
IRE BC2GM048437284 NNP O
alter BC2GM048437284 NN O
negative BC2GM048437284 JJ O
control BC2GM048437284 NN O
and BC2GM048437284 CC O
IRE-BP BC2GM048437284 NNP O
binding BC2GM048437284 NN O
reflecting BC2GM048437284 VBG O
the BC2GM048437284 DT O
fact BC2GM048437284 NN O
that BC2GM048437284 IN O
the BC2GM048437284 DT O
footprint BC2GM048437284 NN O
of BC2GM048437284 IN O
the BC2GM048437284 DT O
IRE-BP BC2GM048437284 NNP O
is BC2GM048437284 VBZ O
over BC2GM048437284 IN O
the BC2GM048437284 DT O
entire BC2GM048437284 JJ O
IRE BC2GM048437284 NNP O
. BC2GM048437284 . O
. . O O

Results BC2GM030020218 NNS O
obtained BC2GM030020218 VBD O
from BC2GM030020218 IN O
the BC2GM030020218 DT O
tritium BC2GM030020218 NN O
test BC2GM030020218 NN O
and BC2GM030020218 CC O
direct BC2GM030020218 JJ O
chemical BC2GM030020218 NN O
analysis BC2GM030020218 NN O
were BC2GM030020218 VBD O
compared BC2GM030020218 VBN O
. BC2GM030020218 . O
. . O O

This BC2GM038940991 DT O
increase BC2GM038940991 NN O
is BC2GM038940991 VBZ O
not BC2GM038940991 RB O
the BC2GM038940991 DT O
result BC2GM038940991 NN O
of BC2GM038940991 IN O
alterations BC2GM038940991 NNS O
in BC2GM038940991 IN O
the BC2GM038940991 DT O
deposition BC2GM038940991 NN O
of BC2GM038940991 IN O
inhaled BC2GM038940991 JJ O
particles BC2GM038940991 NNS O
of BC2GM038940991 IN O
capsaicin BC2GM038940991 NN O
brought BC2GM038940991 VBN O
about BC2GM038940991 IN O
by BC2GM038940991 IN O
volume BC2GM038940991 NN O
restriction BC2GM038940991 NN O
. BC2GM038940991 . O
. . O O

When BC2GM036119481 WRB O
expressed BC2GM036119481 VBN O
in BC2GM036119481 IN O
Escherichia BC2GM036119481 NNP O
coli BC2GM036119481 NN O
, BC2GM036119481 , O
SH-PTP2 BC2GM036119481 NNP O
displays BC2GM036119481 VBZ O
tyrosine-specific BC2GM036119481 JJ O
phosphatase BC2GM036119481 NN O
activity BC2GM036119481 NN O
. BC2GM036119481 . O
. . O O

This BC2GM035114288 DT O
action BC2GM035114288 NN O
could BC2GM035114288 MD O
be BC2GM035114288 VB O
antagonized BC2GM035114288 VBN O
by BC2GM035114288 IN O
aminophylline BC2GM035114288 NN O
, BC2GM035114288 , O
a BC2GM035114288 DT O
competitive BC2GM035114288 JJ O
antagonist BC2GM035114288 NN O
on BC2GM035114288 IN O
P1 BC2GM035114288 NNP O
purinoceptors BC2GM035114288 NNS O
. BC2GM035114288 . O
. . O O

The BC2GM071297366 DT O
existence BC2GM071297366 NN O
of BC2GM071297366 IN O
universal BC2GM071297366 JJ O
non-specific BC2GM071297366 JJ O
mechanism BC2GM071297366 NN O
of BC2GM071297366 IN O
action BC2GM071297366 NN O
of BC2GM071297366 IN O
external BC2GM071297366 JJ O
factors BC2GM071297366 NNS O
upon BC2GM071297366 IN O
the BC2GM071297366 DT O
living BC2GM071297366 NN O
tissue BC2GM071297366 NN O
based BC2GM071297366 VBN O
on BC2GM071297366 IN O
the BC2GM071297366 DT O
DEL-reaction BC2GM071297366 NNP O
is BC2GM071297366 VBZ O
suggested BC2GM071297366 VBN O
. BC2GM071297366 . O
. . O O

In BC2GM004529705 IN O
the BC2GM004529705 DT O
healing BC2GM004529705 NN O
tendons BC2GM004529705 NNS O
, BC2GM004529705 , O
the BC2GM004529705 DT O
rate BC2GM004529705 NN O
of BC2GM004529705 IN O
collagen BC2GM004529705 NN O
synthesis BC2GM004529705 NN O
decreased BC2GM004529705 VBN O
and BC2GM004529705 CC O
the BC2GM004529705 DT O
rate BC2GM004529705 NN O
of BC2GM004529705 IN O
noncollagen BC2GM004529705 NN O
protein BC2GM004529705 NN O
synthesis BC2GM004529705 NN O
remained BC2GM004529705 VBD O
unchanged BC2GM004529705 JJ O
. BC2GM004529705 . O
. . O O

Ectopic BC2GM051891413 NNP O
expression BC2GM051891413 NN O
of BC2GM051891413 IN O
cyclin BC2GM051891413 NN O
D1 BC2GM051891413 NNP O
in BC2GM051891413 IN O
progestin-inhibited BC2GM051891413 JJ O
cells BC2GM051891413 NNS O
led BC2GM051891413 VBN O
to BC2GM051891413 TO O
the BC2GM051891413 DT O
reappearance BC2GM051891413 NN O
of BC2GM051891413 IN O
the BC2GM051891413 DT O
120-kDa BC2GM051891413 JJ O
active BC2GM051891413 JJ O
form BC2GM051891413 NN O
of BC2GM051891413 IN O
cyclin BC2GM051891413 JJ O
E-Cdk2 BC2GM051891413 NNP O
preceding BC2GM051891413 VBG O
the BC2GM051891413 DT O
resumption BC2GM051891413 NN O
of BC2GM051891413 IN O
cell BC2GM051891413 NN O
cycle BC2GM051891413 NN O
progression BC2GM051891413 NN O
. BC2GM051891413 . O
. . O O

Three BC2GM058516621 CD O
experiments BC2GM058516621 NNS O
using BC2GM058516621 VBG O
20 BC2GM058516621 CD O
microM BC2GM058516621 JJ O
2- BC2GM058516621 JJ O
( BC2GM058516621 ( O
hydroxyamino BC2GM058516621 NN O
) BC2GM058516621 ) O
-1-methyl-6-phenylimidazo BC2GM058516621 VBZ O
[ BC2GM058516621 JJ O
4,5-b BC2GM058516621 JJ O
] BC2GM058516621 NN O
pyridine BC2GM058516621 NN O
( BC2GM058516621 ( O
N-OH-PhIP BC2GM058516621 NNP O
) BC2GM058516621 ) O
were BC2GM058516621 VBD O
performed BC2GM058516621 VBN O
to BC2GM058516621 TO O
induce BC2GM058516621 VB O
mutations BC2GM058516621 NNS O
in BC2GM058516621 IN O
the BC2GM058516621 DT O
dihydrofolate BC2GM058516621 NN O
reductase BC2GM058516621 NN O
( BC2GM058516621 ( O
DHFR BC2GM058516621 NNP O
) BC2GM058516621 ) O
gene BC2GM058516621 NN O
of BC2GM058516621 IN O
a BC2GM058516621 DT O
hemizygous BC2GM058516621 JJ O
Chinese BC2GM058516621 JJ O
hamster BC2GM058516621 NN O
ovary BC2GM058516621 JJ O
( BC2GM058516621 ( O
CHO BC2GM058516621 NNP O
) BC2GM058516621 ) O
cell BC2GM058516621 NN O
line BC2GM058516621 NN O
( BC2GM058516621 ( O
UA21 BC2GM058516621 NNP O
) BC2GM058516621 ) O
. BC2GM058516621 . O
. . O O

However BC2GM005174218 RB O
massive BC2GM005174218 JJ O
necrosis BC2GM005174218 NN O
of BC2GM005174218 IN O
the BC2GM005174218 DT O
renal BC2GM005174218 JJ O
tubules BC2GM005174218 NNS O
had BC2GM005174218 VBD O
been BC2GM005174218 VBN O
found BC2GM005174218 VBN O
with BC2GM005174218 IN O
more BC2GM005174218 JJR O
than BC2GM005174218 IN O
15mg BC2GM005174218 CD O
of BC2GM005174218 IN O
DSM BC2GM005174218 NNP O
administration BC2GM005174218 NN O
. BC2GM005174218 . O
. . O O

Seroconversion BC2GM026278190 NN O
after BC2GM026278190 IN O
hepatitis BC2GM026278190 NN O
B BC2GM026278190 NNP O
vaccination BC2GM026278190 NN O
. BC2GM026278190 . O
. . O O

The BC2GM024059771 DT O
Ca2+ BC2GM024059771 NNP O
concentration BC2GM024059771 NN O
in BC2GM024059771 IN O
rats BC2GM024059771 NNS O
serum BC2GM024059771 VBP O
after BC2GM024059771 IN O
intragastrically BC2GM024059771 RB O
fenarimol BC2GM024059771 JJ O
administration BC2GM024059771 NN O
( BC2GM024059771 ( O
doses BC2GM024059771 VBZ O
1 BC2GM024059771 CD O
/ BC2GM024059771 NN O
40 BC2GM024059771 CD O
, BC2GM024059771 , O
1 BC2GM024059771 CD O
/ BC2GM024059771 NN O
20 BC2GM024059771 CD O
and BC2GM024059771 CC O
1 BC2GM024059771 CD O
/ BC2GM024059771 NNS O
10 BC2GM024059771 CD O
LD50 BC2GM024059771 NNP O
) BC2GM024059771 ) O
during BC2GM024059771 IN O
5 BC2GM024059771 CD O
days BC2GM024059771 NNS O
was BC2GM024059771 VBD O
investigated BC2GM024059771 VBN O
. BC2GM024059771 . O
. . O O

The BC2GM021289219 DT O
predicted BC2GM021289219 JJ O
proteins BC2GM021289219 NNS O
show BC2GM021289219 VBP O
strong BC2GM021289219 JJ O
homology BC2GM021289219 NN O
to BC2GM021289219 TO O
an BC2GM021289219 DT O
ABA-inducible BC2GM021289219 JJ O
glycine-rich BC2GM021289219 JJ O
protein BC2GM021289219 NN O
from BC2GM021289219 IN O
maize BC2GM021289219 JJ O
embryos BC2GM021289219 NN O
and BC2GM021289219 CC O
to BC2GM021289219 TO O
the BC2GM021289219 DT O
mammalian BC2GM021289219 JJ O
RNA-binding BC2GM021289219 NNP O
protein BC2GM021289219 NN O
A1 BC2GM021289219 NNP O
of BC2GM021289219 IN O
the BC2GM021289219 DT O
heterogeneous BC2GM021289219 JJ O
nuclear BC2GM021289219 JJ O
ribonucleoprotein BC2GM021289219 NN O
complex BC2GM021289219 JJ O
involved BC2GM021289219 VBN O
in BC2GM021289219 IN O
pre-mRNA BC2GM021289219 JJ O
splicing BC2GM021289219 NN O
. BC2GM021289219 . O
. . O O

Men BC2GM026141578 NN O
and BC2GM026141578 CC O
women BC2GM026141578 NNS O
entering BC2GM026141578 VBG O
psychotherapy BC2GM026141578 NN O
more BC2GM026141578 RBR O
often BC2GM026141578 RB O
had BC2GM026141578 VBD O
negative BC2GM026141578 JJ O
Wish BC2GM026141578 JJ O
elements BC2GM026141578 NNS O
than BC2GM026141578 IN O
others BC2GM026141578 NNS O
. BC2GM026141578 . O
. . O O

Four BC2GM056512837 CD O
cDNAs BC2GM056512837 NN O
( BC2GM056512837 ( O
Kox4 BC2GM056512837 NNP O
, BC2GM056512837 , O
Kox7 BC2GM056512837 NNP O
, BC2GM056512837 , O
Kox12 BC2GM056512837 NNP O
, BC2GM056512837 , O
and BC2GM056512837 CC O
Kox15 BC2GM056512837 NNP O
) BC2GM056512837 ) O
were BC2GM056512837 VBD O
identified BC2GM056512837 VBN O
that BC2GM056512837 IN O
match BC2GM056512837 VBP O
one BC2GM056512837 CD O
or BC2GM056512837 CC O
more BC2GM056512837 JJR O
genomic BC2GM056512837 JJ O
clones BC2GM056512837 NNS O
; BC2GM056512837 : O
these BC2GM056512837 DT O
matches BC2GM056512837 NNS O
were BC2GM056512837 VBD O
confirmed BC2GM056512837 VBN O
by BC2GM056512837 IN O
nucleotide BC2GM056512837 JJ O
sequence BC2GM056512837 NN O
analysis BC2GM056512837 NN O
. BC2GM056512837 . O
. . O O

The BC2GM043540576 DT O
Xenopus BC2GM043540576 NNP O
annexin BC2GM043540576 NN O
II BC2GM043540576 NNP O
heavy BC2GM043540576 NN O
chain BC2GM043540576 NN O
lacks BC2GM043540576 VBZ O
the BC2GM043540576 DT O
highly BC2GM043540576 RB O
conserved BC2GM043540576 JJ O
tyrosine BC2GM043540576 NN O
at BC2GM043540576 IN O
position BC2GM043540576 NN O
23 BC2GM043540576 CD O
which BC2GM043540576 WDT O
is BC2GM043540576 VBZ O
the BC2GM043540576 DT O
site BC2GM043540576 NN O
of BC2GM043540576 IN O
src BC2GM043540576 JJ O
oncogene BC2GM043540576 JJ O
tyrosine BC2GM043540576 NN O
kinase BC2GM043540576 NN O
phosphorylation BC2GM043540576 NN O
in BC2GM043540576 IN O
the BC2GM043540576 DT O
murine BC2GM043540576 NN O
protein BC2GM043540576 NN O
. BC2GM043540576 . O
. . O O

In BC2GM091999980 IN O
both BC2GM091999980 DT O
liver BC2GM091999980 NN O
and BC2GM091999980 CC O
pancreatic BC2GM091999980 JJ O
islet BC2GM091999980 NN O
, BC2GM091999980 , O
glucokinase BC2GM091999980 NN O
is BC2GM091999980 VBZ O
subject BC2GM091999980 JJ O
to BC2GM091999980 TO O
inhibition BC2GM091999980 NN O
by BC2GM091999980 IN O
a BC2GM091999980 DT O
regulatory BC2GM091999980 JJ O
protein BC2GM091999980 NN O
( BC2GM091999980 ( O
GCKR BC2GM091999980 NNP O
) BC2GM091999980 ) O
. BC2GM091999980 . O
. . O O

The BC2GM020495057 DT O
residual BC2GM020495057 JJ O
small BC2GM020495057 JJ O
rRNAs BC2GM020495057 NN O
in BC2GM020495057 IN O
[ BC2GM020495057 NNP O
poky BC2GM020495057 NN O
] BC2GM020495057 NN O
appear BC2GM020495057 VBP O
to BC2GM020495057 TO O
be BC2GM020495057 VB O
synthesized BC2GM020495057 VBN O
via BC2GM020495057 IN O
the BC2GM020495057 DT O
upstream BC2GM020495057 JJ O
promoter BC2GM020495057 NN O
( BC2GM020495057 ( O
s BC2GM020495057 NN O
) BC2GM020495057 ) O
, BC2GM020495057 , O
but BC2GM020495057 CC O
are BC2GM020495057 VBP O
missing BC2GM020495057 VBG O
37-44 BC2GM020495057 JJ O
nucleotides BC2GM020495057 NNS O
from BC2GM020495057 IN O
their BC2GM020495057 PRP$ O
5 BC2GM020495057 CD O
' BC2GM020495057 '' O
ends BC2GM020495057 NNS O
, BC2GM020495057 , O
indicating BC2GM020495057 VBG O
either BC2GM020495057 CC O
that BC2GM020495057 IN O
pre-rRNAs BC2GM020495057 NN O
are BC2GM020495057 VBP O
processed BC2GM020495057 VBN O
abnormally BC2GM020495057 RB O
or BC2GM020495057 CC O
that BC2GM020495057 IN O
abnormal BC2GM020495057 JJ O
5 BC2GM020495057 CD O
' BC2GM020495057 POS O
RNA BC2GM020495057 NNP O
ends BC2GM020495057 NNS O
are BC2GM020495057 VBP O
unstable BC2GM020495057 JJ O
. BC2GM020495057 . O
. . O O

Mean BC2GM057600455 NNP O
total BC2GM057600455 JJ O
homocysteine BC2GM057600455 NN O
( BC2GM057600455 ( O
tHcy BC2GM057600455 NN O
) BC2GM057600455 ) O
was BC2GM057600455 VBD O
21.1 BC2GM057600455 CD O
+ BC2GM057600455 JJ O
/ BC2GM057600455 NNP O
-9.5 BC2GM057600455 NNP O
micromol BC2GM057600455 NN O
/ BC2GM057600455 NNP O
L BC2GM057600455 NNP O
and BC2GM057600455 CC O
median BC2GM057600455 JJ O
concentration BC2GM057600455 NN O
was BC2GM057600455 VBD O
19 BC2GM057600455 CD O
micromol BC2GM057600455 NN O
/ BC2GM057600455 NNP O
L BC2GM057600455 NNP O
. BC2GM057600455 . O
. . O O

In BC2GM020447854 IN O
a BC2GM020447854 DT O
subsequent BC2GM020447854 JJ O
phase-II BC2GM020447854 JJ O
clinical BC2GM020447854 JJ O
trial BC2GM020447854 NN O
safety BC2GM020447854 NN O
and BC2GM020447854 CC O
efficacy BC2GM020447854 NN O
of BC2GM020447854 IN O
transrectal BC2GM020447854 JJ O
HIFU BC2GM020447854 NNP O
as BC2GM020447854 IN O
a BC2GM020447854 DT O
novel BC2GM020447854 NN O
minimally BC2GM020447854 RB O
invasive BC2GM020447854 JJ O
treatment BC2GM020447854 NN O
modality BC2GM020447854 NN O
for BC2GM020447854 IN O
patients BC2GM020447854 NNS O
with BC2GM020447854 IN O
symptomatic BC2GM020447854 JJ O
benign BC2GM020447854 NN O
prostatic BC2GM020447854 JJ O
hyperplasia BC2GM020447854 NN O
( BC2GM020447854 ( O
BPH BC2GM020447854 NNP O
; BC2GM020447854 : O
n BC2GM020447854 CC O
= BC2GM020447854 VB O
102 BC2GM020447854 CD O
) BC2GM020447854 ) O
was BC2GM020447854 VBD O
determined BC2GM020447854 VBN O
. BC2GM020447854 . O
. . O O

It BC2GM047717064 PRP O
was BC2GM047717064 VBD O
found BC2GM047717064 VBN O
that BC2GM047717064 IN O
on BC2GM047717064 IN O
the BC2GM047717064 DT O
14th BC2GM047717064 CD O
and BC2GM047717064 CC O
21st BC2GM047717064 CD O
day BC2GM047717064 NN O
after BC2GM047717064 IN O
cimetidine BC2GM047717064 JJ O
administration BC2GM047717064 NN O
serum BC2GM047717064 NN O
gastrin BC2GM047717064 NN O
levels BC2GM047717064 NNS O
were BC2GM047717064 VBD O
significantly BC2GM047717064 RB O
elevated BC2GM047717064 VBN O
. BC2GM047717064 . O
. . O O

Dual BC2GM081030617 JJ O
signal BC2GM081030617 NN O
peptides BC2GM081030617 NNS O
mediate BC2GM081030617 VBP O
the BC2GM081030617 DT O
signal BC2GM081030617 JJ O
recognition BC2GM081030617 NN O
particle BC2GM081030617 NN O
/ BC2GM081030617 NNP O
Sec-independent BC2GM081030617 NNP O
insertion BC2GM081030617 NN O
of BC2GM081030617 IN O
a BC2GM081030617 DT O
thylakoid BC2GM081030617 JJ O
membrane BC2GM081030617 NN O
polyprotein BC2GM081030617 NN O
, BC2GM081030617 , O
PsbY BC2GM081030617 NNP O
. BC2GM081030617 . O
. . O O

The BC2GM082413558 DT O
preference BC2GM082413558 NN O
for BC2GM082413558 IN O
third BC2GM082413558 JJ O
base BC2GM082413558 NN O
codon BC2GM082413558 NN O
in BC2GM082413558 IN O
Y BC2GM082413558 NNP O
position BC2GM082413558 NN O
prolines BC2GM082413558 NNS O
is BC2GM082413558 VBZ O
U BC2GM082413558 NNP O
for BC2GM082413558 IN O
the BC2GM082413558 DT O
alpha BC2GM082413558 NN O
2 BC2GM082413558 CD O
( BC2GM082413558 ( O
VI BC2GM082413558 NNP O
) BC2GM082413558 ) O
collagen BC2GM082413558 NN O
as BC2GM082413558 IN O
it BC2GM082413558 PRP O
is BC2GM082413558 VBZ O
for BC2GM082413558 IN O
the BC2GM082413558 DT O
human BC2GM082413558 JJ O
fibrillar BC2GM082413558 JJ O
collagen BC2GM082413558 NN O
genes BC2GM082413558 NNS O
. BC2GM082413558 . O
. . O O

Parameters BC2GM042242435 NNS O
of BC2GM042242435 IN O
sperm BC2GM042242435 JJ O
quality BC2GM042242435 NN O
were BC2GM042242435 VBD O
evaluated BC2GM042242435 VBN O
before BC2GM042242435 IN O
and BC2GM042242435 CC O
after BC2GM042242435 IN O
freezing BC2GM042242435 VBG O
/ BC2GM042242435 JJ O
thawing BC2GM042242435 NN O
. BC2GM042242435 . O
. . O O

Noise BC2GM089582706 NN O
in BC2GM089582706 IN O
STM BC2GM089582706 NNP O
due BC2GM089582706 JJ O
to BC2GM089582706 TO O
atoms BC2GM089582706 NNS O
moving BC2GM089582706 VBG O
in BC2GM089582706 IN O
the BC2GM089582706 DT O
tunneling BC2GM089582706 JJ O
space BC2GM089582706 NN O
. BC2GM089582706 . O
. . O O

The BC2GM039225135 DT O
phosphoprotein BC2GM039225135 NN O
pUL69 BC2GM039225135 NN O
of BC2GM039225135 IN O
human BC2GM039225135 JJ O
cytomegalovirus BC2GM039225135 NN O
( BC2GM039225135 ( O
HCMV BC2GM039225135 NNP O
) BC2GM039225135 ) O
, BC2GM039225135 , O
which BC2GM039225135 WDT O
is BC2GM039225135 VBZ O
a BC2GM039225135 DT O
herpesvirus BC2GM039225135 NN O
of BC2GM039225135 IN O
considerable BC2GM039225135 JJ O
medical BC2GM039225135 JJ O
importance BC2GM039225135 NN O
in BC2GM039225135 IN O
immunosuppressed BC2GM039225135 JJ O
patients BC2GM039225135 NNS O
and BC2GM039225135 CC O
newborns BC2GM039225135 NNS O
, BC2GM039225135 , O
has BC2GM039225135 VBZ O
previously BC2GM039225135 RB O
been BC2GM039225135 VBN O
identified BC2GM039225135 VBN O
as BC2GM039225135 IN O
an BC2GM039225135 DT O
early-late BC2GM039225135 JJ O
viral BC2GM039225135 JJ O
protein BC2GM039225135 NN O
that BC2GM039225135 WDT O
can BC2GM039225135 MD O
stimulate BC2GM039225135 VB O
several BC2GM039225135 JJ O
viral BC2GM039225135 JJ O
and BC2GM039225135 CC O
cellular BC2GM039225135 JJ O
promoters BC2GM039225135 NNS O
and BC2GM039225135 CC O
thus BC2GM039225135 RB O
exerts BC2GM039225135 VBZ O
a BC2GM039225135 DT O
rather BC2GM039225135 RB O
broad BC2GM039225135 JJ O
activation BC2GM039225135 NN O
pattern BC2GM039225135 NN O
. BC2GM039225135 . O
. . O O

We BC2GM028707148 PRP O
show BC2GM028707148 VBP O
that BC2GM028707148 IN O
Fos BC2GM028707148 NNP O
down BC2GM028707148 RB O
regulates BC2GM028707148 VBZ O
several BC2GM028707148 JJ O
immediate-early BC2GM028707148 JJ O
genes BC2GM028707148 NNS O
( BC2GM028707148 ( O
c-fos BC2GM028707148 JJ O
, BC2GM028707148 , O
Egr-1 BC2GM028707148 NNP O
, BC2GM028707148 , O
and BC2GM028707148 CC O
Egr-2 BC2GM028707148 NNP O
) BC2GM028707148 ) O
after BC2GM028707148 IN O
mitogenic BC2GM028707148 JJ O
stimulation BC2GM028707148 NN O
. BC2GM028707148 . O
. . O O

Gallstone-formation BC2GM022884107 NN O
has BC2GM022884107 VBZ O
traditionally BC2GM022884107 RB O
been BC2GM022884107 VBN O
attributed BC2GM022884107 VBN O
to BC2GM022884107 TO O
supersaturation BC2GM022884107 NN O
of BC2GM022884107 IN O
bile BC2GM022884107 NN O
with BC2GM022884107 IN O
cholesterol BC2GM022884107 NN O
. BC2GM022884107 . O
. . O O

Fourteen BC2GM014590821 JJ O
eyes BC2GM014590821 NNS O
( BC2GM014590821 ( O
38.9 BC2GM014590821 CD O
% BC2GM014590821 NN O
) BC2GM014590821 ) O
developed BC2GM014590821 VBD O
DLK BC2GM014590821 NNP O
after BC2GM014590821 IN O
an BC2GM014590821 DT O
epithelial BC2GM014590821 JJ O
defect BC2GM014590821 NN O
, BC2GM014590821 , O
representing BC2GM014590821 VBG O
an BC2GM014590821 DT O
odds BC2GM014590821 JJ O
ratio BC2GM014590821 NN O
of BC2GM014590821 IN O
13 BC2GM014590821 CD O
times BC2GM014590821 NNS O
. BC2GM014590821 . O
. . O O

OBJECTIVE BC2GM074908707 NN O
: BC2GM074908707 : O
To BC2GM074908707 TO O
summarise BC2GM074908707 VB O
quantitatively BC2GM074908707 RB O
the BC2GM074908707 DT O
association BC2GM074908707 NN O
between BC2GM074908707 IN O
moderate BC2GM074908707 JJ O
alcohol BC2GM074908707 NNS O
intake BC2GM074908707 NN O
and BC2GM074908707 CC O
biological BC2GM074908707 JJ O
markers BC2GM074908707 NNS O
of BC2GM074908707 IN O
risk BC2GM074908707 NN O
of BC2GM074908707 IN O
coronary BC2GM074908707 JJ O
heart BC2GM074908707 NN O
disease BC2GM074908707 NN O
and BC2GM074908707 CC O
to BC2GM074908707 TO O
predict BC2GM074908707 VB O
how BC2GM074908707 WRB O
these BC2GM074908707 DT O
changes BC2GM074908707 NNS O
would BC2GM074908707 MD O
lower BC2GM074908707 VB O
the BC2GM074908707 DT O
risk BC2GM074908707 NN O
. BC2GM074908707 . O
. . O O

CVO2 BC2GM076683276 NNP O
saturation BC2GM076683276 NN O
is BC2GM076683276 VBZ O
a BC2GM076683276 DT O
reliable BC2GM076683276 JJ O
and BC2GM076683276 CC O
sensitive BC2GM076683276 JJ O
method BC2GM076683276 NN O
for BC2GM076683276 IN O
detecting BC2GM076683276 VBG O
blood BC2GM076683276 NN O
loss BC2GM076683276 NN O
. BC2GM076683276 . O
. . O O

Renal BC2GM027491434 JJ O
function BC2GM027491434 NN O
was BC2GM027491434 VBD O
evaluated BC2GM027491434 VBN O
in BC2GM027491434 IN O
a BC2GM027491434 DT O
group BC2GM027491434 NN O
of BC2GM027491434 IN O
24 BC2GM027491434 CD O
patients BC2GM027491434 NNS O
( BC2GM027491434 ( O
21 BC2GM027491434 CD O
men BC2GM027491434 NNS O
and BC2GM027491434 CC O
3 BC2GM027491434 CD O
women BC2GM027491434 NNS O
, BC2GM027491434 , O
mean BC2GM027491434 JJ O
age BC2GM027491434 NN O
47 BC2GM027491434 CD O
years BC2GM027491434 NNS O
) BC2GM027491434 ) O
who BC2GM027491434 WP O
had BC2GM027491434 VBD O
survived BC2GM027491434 VBN O
the BC2GM027491434 DT O
malignant BC2GM027491434 JJ O
phase BC2GM027491434 NN O
of BC2GM027491434 IN O
hypertension BC2GM027491434 NN O
during BC2GM027491434 IN O
the BC2GM027491434 DT O
period BC2GM027491434 NN O
of BC2GM027491434 IN O
1969-1979 BC2GM027491434 JJ O
. BC2GM027491434 . O
. . O O

The BC2GM030350925 DT O
induction BC2GM030350925 NN O
by BC2GM030350925 IN O
dexamethasone BC2GM030350925 NN O
of BC2GM030350925 IN O
rat BC2GM030350925 NN O
liver BC2GM030350925 NN O
CYP3A1 BC2GM030350925 NNP O
differs BC2GM030350925 NNS O
from BC2GM030350925 IN O
classical BC2GM030350925 JJ O
glucocorticoid BC2GM030350925 NN O
gene BC2GM030350925 NN O
regulation BC2GM030350925 NN O
in BC2GM030350925 IN O
part BC2GM030350925 NN O
because BC2GM030350925 IN O
both BC2GM030350925 DT O
glucocorticoids BC2GM030350925 NNS O
and BC2GM030350925 CC O
antiglucocorticoids BC2GM030350925 NNS O
such BC2GM030350925 JJ O
as BC2GM030350925 IN O
pregnenolone BC2GM030350925 NN O
16 BC2GM030350925 CD O
alpha-carbonitrile BC2GM030350925 NN O
( BC2GM030350925 ( O
PCN BC2GM030350925 NNP O
) BC2GM030350925 ) O
induce BC2GM030350925 NN O
CYP3A1 BC2GM030350925 NNP O
through BC2GM030350925 IN O
transcriptional BC2GM030350925 JJ O
gene BC2GM030350925 NN O
activation BC2GM030350925 NN O
. BC2GM030350925 . O
. . O O

In BC2GM027121414 IN O
this BC2GM027121414 DT O
reconstituted BC2GM027121414 JJ O
system BC2GM027121414 NN O
, BC2GM027121414 , O
RNAP BC2GM027121414 NNP O
IIA BC2GM027121414 NNP O
, BC2GM027121414 , O
but BC2GM027121414 CC O
not BC2GM027121414 RB O
RNAP BC2GM027121414 NNP O
IIB BC2GM027121414 NNP O
, BC2GM027121414 , O
can BC2GM027121414 MD O
transcribe BC2GM027121414 VB O
from BC2GM027121414 IN O
the BC2GM027121414 DT O
DHFR BC2GM027121414 NNP O
promoter BC2GM027121414 NN O
. BC2GM027121414 . O
. . O O

Acyclovir BC2GM045289936 NNP O
( BC2GM045289936 ( O
3 BC2GM045289936 CD O
% BC2GM045289936 NN O
ointment BC2GM045289936 NN O
) BC2GM045289936 ) O
used BC2GM045289936 VBD O
topically BC2GM045289936 RB O
one BC2GM045289936 CD O
to BC2GM045289936 TO O
five BC2GM045289936 CD O
times BC2GM045289936 NNS O
a BC2GM045289936 DT O
day BC2GM045289936 NN O
on BC2GM045289936 IN O
acute BC2GM045289936 NN O
ocular BC2GM045289936 JJ O
HSV BC2GM045289936 NNP O
infection BC2GM045289936 NN O
gave BC2GM045289936 VBD O
beneficial BC2GM045289936 JJ O
results BC2GM045289936 NNS O
as BC2GM045289936 IN O
measured BC2GM045289936 VBN O
by BC2GM045289936 IN O
a BC2GM045289936 DT O
reduction BC2GM045289936 NN O
in BC2GM045289936 IN O
corneal BC2GM045289936 JJ O
involvement BC2GM045289936 NN O
, BC2GM045289936 , O
conjunctivitis BC2GM045289936 NN O
, BC2GM045289936 , O
iritis BC2GM045289936 NN O
, BC2GM045289936 , O
and BC2GM045289936 CC O
corneal BC2GM045289936 NN O
clouding BC2GM045289936 NN O
. BC2GM045289936 . O
. . O O

Indeed BC2GM016116401 RB O
, BC2GM016116401 , O
ectopic BC2GM016116401 JJ O
expression BC2GM016116401 NN O
of BC2GM016116401 IN O
MOX4 BC2GM016116401 NNP O
in BC2GM016116401 IN O
aerobic BC2GM016116401 JJ O
cells BC2GM016116401 NNS O
resulted BC2GM016116401 VBD O
in BC2GM016116401 IN O
partially BC2GM016116401 RB O
constitutive BC2GM016116401 JJ O
expression BC2GM016116401 NN O
of BC2GM016116401 IN O
DAN1 BC2GM016116401 NNP O
. BC2GM016116401 . O
. . O O

In BC2GM018110366 IN O
vitro BC2GM018110366 JJ O
kinase BC2GM018110366 NN O
assays BC2GM018110366 NNS O
on BC2GM018110366 IN O
isolated BC2GM018110366 JJ O
microvilli BC2GM018110366 NN O
and BC2GM018110366 CC O
microvillar BC2GM018110366 JJ O
fractions BC2GM018110366 NNS O
enriched BC2GM018110366 VBN O
in BC2GM018110366 IN O
the BC2GM018110366 DT O
putative BC2GM018110366 JJ O
signal BC2GM018110366 JJ O
transduction BC2GM018110366 NN O
particle BC2GM018110366 NN O
showed BC2GM018110366 VBD O
a BC2GM018110366 DT O
high BC2GM018110366 JJ O
specific BC2GM018110366 JJ O
activity BC2GM018110366 NN O
of BC2GM018110366 IN O
tyrosine BC2GM018110366 JJ O
kinase BC2GM018110366 NN O
activity BC2GM018110366 NN O
compared BC2GM018110366 VBN O
to BC2GM018110366 TO O
that BC2GM018110366 DT O
of BC2GM018110366 IN O
membranes BC2GM018110366 NNS O
from BC2GM018110366 IN O
EGF BC2GM018110366 NNP O
receptor-overexpressing BC2GM018110366 JJ O
A431 BC2GM018110366 NNP O
cells BC2GM018110366 NNS O
maximally BC2GM018110366 RB O
activated BC2GM018110366 VBN O
by BC2GM018110366 IN O
EGF BC2GM018110366 NNP O
. BC2GM018110366 . O
. . O O

Various BC2GM095055828 JJ O
stimuli BC2GM095055828 NNS O
inactivate BC2GM095055828 VBP O
IkappaB BC2GM095055828 NNP O
alpha BC2GM095055828 NN O
by BC2GM095055828 IN O
triggering BC2GM095055828 VBG O
phosphorylation BC2GM095055828 NN O
of BC2GM095055828 IN O
the BC2GM095055828 DT O
N-terminal BC2GM095055828 JJ O
residues BC2GM095055828 NNS O
Ser32 BC2GM095055828 NNP O
and BC2GM095055828 CC O
Ser36 BC2GM095055828 NNP O
. BC2GM095055828 . O
. . O O

This BC2GM071024994 DT O
combination BC2GM071024994 NN O
is BC2GM071024994 VBZ O
considered BC2GM071024994 VBN O
pathognomonic BC2GM071024994 JJ O
for BC2GM071024994 IN O
factitious BC2GM071024994 JJ O
hyperinsulinism BC2GM071024994 NN O
. BC2GM071024994 . O
. . O O

The BC2GM061410736 DT O
practice BC2GM061410736 NN O
of BC2GM061410736 IN O
measuring BC2GM061410736 NN O
of BC2GM061410736 IN O
AChE BC2GM061410736 NNP O
levels BC2GM061410736 NNS O
in BC2GM061410736 IN O
acute BC2GM061410736 NN O
poisoning BC2GM061410736 NN O
is BC2GM061410736 VBZ O
limited BC2GM061410736 VBN O
. BC2GM061410736 . O
. . O O

Heart BC2GM017309998 NNP O
rate BC2GM017309998 NN O
and BC2GM017309998 CC O
oxygen BC2GM017309998 NN O
consumption BC2GM017309998 NN O
increased BC2GM017309998 VBD O
75+ BC2GM017309998 CD O
/ BC2GM017309998 NNP O
-4 BC2GM017309998 NNP O
bpm BC2GM017309998 NN O
and BC2GM017309998 CC O
26.3+ BC2GM017309998 CD O
/ BC2GM017309998 NN O
-1.4 BC2GM017309998 NNP O
ml BC2GM017309998 NN O
O2 BC2GM017309998 NNP O
/ BC2GM017309998 NNP O
kg BC2GM017309998 NNP O
x BC2GM017309998 NNP O
min BC2GM017309998 NN O
( BC2GM017309998 ( O
-1 BC2GM017309998 JJ O
) BC2GM017309998 ) O
from BC2GM017309998 IN O
supine BC2GM017309998 NN O
resting BC2GM017309998 VBG O
values BC2GM017309998 NNS O
, BC2GM017309998 , O
respectively BC2GM017309998 RB O
. BC2GM017309998 . O
. . O O

This BC2GM044384474 DT O
evidence BC2GM044384474 NN O
, BC2GM044384474 , O
together BC2GM044384474 RB O
with BC2GM044384474 IN O
the BC2GM044384474 DT O
ability BC2GM044384474 NN O
of BC2GM044384474 IN O
a BC2GM044384474 DT O
carboxyl-terminal BC2GM044384474 JJ O
coding BC2GM044384474 NN O
sequence BC2GM044384474 NN O
starting BC2GM044384474 VBG O
from BC2GM044384474 IN O
the BC2GM044384474 DT O
BamHI BC2GM044384474 NNP O
site BC2GM044384474 NN O
to BC2GM044384474 TO O
complement BC2GM044384474 VB O
a BC2GM044384474 DT O
shy1 BC2GM044384474 NN O
mutant BC2GM044384474 NN O
, BC2GM044384474 , O
suggests BC2GM044384474 VBZ O
that BC2GM044384474 IN O
the BC2GM044384474 DT O
Shy1p BC2GM044384474 NNP O
contains BC2GM044384474 VBZ O
two BC2GM044384474 CD O
domains BC2GM044384474 NNS O
that BC2GM044384474 WDT O
can BC2GM044384474 MD O
be BC2GM044384474 VB O
separately BC2GM044384474 RB O
expressed BC2GM044384474 VBN O
to BC2GM044384474 TO O
form BC2GM044384474 VB O
a BC2GM044384474 DT O
functional BC2GM044384474 JJ O
protein BC2GM044384474 NN O
. BC2GM044384474 . O
. . O O

Having BC2GM014548210 VBG O
demonstrated BC2GM014548210 VBN O
proper BC2GM014548210 JJ O
localization BC2GM014548210 NN O
of BC2GM014548210 IN O
GFP-calmodulin BC2GM014548210 NNP O
in BC2GM014548210 IN O
budding BC2GM014548210 VBG O
yeast BC2GM014548210 NN O
, BC2GM014548210 , O
we BC2GM014548210 PRP O
examined BC2GM014548210 VBD O
the BC2GM014548210 DT O
localization BC2GM014548210 NN O
of BC2GM014548210 IN O
a BC2GM014548210 DT O
fusion BC2GM014548210 NN O
between BC2GM014548210 IN O
GFP BC2GM014548210 NNP O
and BC2GM014548210 CC O
calmodulin BC2GM014548210 NN O
( BC2GM014548210 ( O
GFP-Camlp BC2GM014548210 NNP O
) BC2GM014548210 ) O
in BC2GM014548210 IN O
fission BC2GM014548210 NN O
yeast BC2GM014548210 NN O
, BC2GM014548210 , O
where BC2GM014548210 WRB O
calmodulin BC2GM014548210 NN O
had BC2GM014548210 VBD O
not BC2GM014548210 RB O
been BC2GM014548210 VBN O
localized BC2GM014548210 VBN O
by BC2GM014548210 IN O
any BC2GM014548210 DT O
method BC2GM014548210 NN O
. BC2GM014548210 . O
. . O O

In BC2GM097292555 IN O
female BC2GM097292555 JJ O
toads BC2GM097292555 NNS O
, BC2GM097292555 , O
Bufo BC2GM097292555 NNP O
bufo BC2GM097292555 NN O
, BC2GM097292555 , O
feeding BC2GM097292555 VBG O
at BC2GM097292555 IN O
different BC2GM097292555 JJ O
rates BC2GM097292555 NNS O
, BC2GM097292555 , O
the BC2GM097292555 DT O
uncorrected BC2GM097292555 JJ O
value BC2GM097292555 NN O
of BC2GM097292555 IN O
n BC2GM097292555 NN O
was BC2GM097292555 VBD O
0.44 BC2GM097292555 CD O
, BC2GM097292555 , O
when BC2GM097292555 WRB O
metabolism BC2GM097292555 NN O
and BC2GM097292555 CC O
growth BC2GM097292555 NN O
were BC2GM097292555 VBD O
expressed BC2GM097292555 VBN O
as BC2GM097292555 IN O
kJ BC2GM097292555 JJ O
kJ-1 BC2GM097292555 NN O
. BC2GM097292555 . O
. . O O

The BC2GM084802462 DT O
predicted BC2GM084802462 JJ O
5 BC2GM084802462 CD O
' BC2GM084802462 POS O
and BC2GM084802462 CC O
3 BC2GM084802462 CD O
' BC2GM084802462 '' O
ends BC2GM084802462 NNS O
of BC2GM084802462 IN O
the BC2GM084802462 DT O
transcript BC2GM084802462 NN O
are BC2GM084802462 VBP O
in BC2GM084802462 IN O
very BC2GM084802462 RB O
good BC2GM084802462 JJ O
agreement BC2GM084802462 NN O
with BC2GM084802462 IN O
the BC2GM084802462 DT O
previously BC2GM084802462 RB O
determined BC2GM084802462 VBN O
size BC2GM084802462 NN O
of BC2GM084802462 IN O
the BC2GM084802462 DT O
LEU3 BC2GM084802462 NNP O
message BC2GM084802462 NN O
. BC2GM084802462 . O
. . O O

The BC2GM076693165 DT O
elevated BC2GM076693165 JJ O
levels BC2GM076693165 NNS O
of BC2GM076693165 IN O
inositol BC2GM076693165 NN O
phosphates BC2GM076693165 NNS O
resulting BC2GM076693165 VBG O
from BC2GM076693165 IN O
N BC2GM076693165 NNP O
( BC2GM076693165 ( O
epi BC2GM076693165 NN O
) BC2GM076693165 ) O
alpha BC2GM076693165 NN O
qQ209L BC2GM076693165 JJ O
expression BC2GM076693165 NN O
were BC2GM076693165 VBD O
similar BC2GM076693165 JJ O
to BC2GM076693165 TO O
those BC2GM076693165 DT O
obtained BC2GM076693165 VBN O
with BC2GM076693165 IN O
carbachol BC2GM076693165 JJ O
activation BC2GM076693165 NN O
of BC2GM076693165 IN O
the BC2GM076693165 DT O
M1 BC2GM076693165 NNP O
muscarinic BC2GM076693165 JJ O
acetylcholine BC2GM076693165 NN O
receptor BC2GM076693165 NN O
. BC2GM076693165 . O
. . O O

When BC2GM079564376 WRB O
the BC2GM079564376 DT O
VBP-1 BC2GM079564376 NNP O
protein BC2GM079564376 NN O
was BC2GM079564376 VBD O
solely BC2GM079564376 RB O
expressed BC2GM079564376 VBN O
, BC2GM079564376 , O
it BC2GM079564376 PRP O
located BC2GM079564376 VBD O
to BC2GM079564376 TO O
the BC2GM079564376 DT O
cytoplasm BC2GM079564376 NN O
and BC2GM079564376 CC O
did BC2GM079564376 VBD O
not BC2GM079564376 RB O
localize BC2GM079564376 VB O
to BC2GM079564376 TO O
the BC2GM079564376 DT O
nucleus BC2GM079564376 NN O
. BC2GM079564376 . O
. . O O

The BC2GM095563020 DT O
cholesterol BC2GM095563020 NN O
7alpha-hydroxylase BC2GM095563020 JJ O
gene BC2GM095563020 NN O
( BC2GM095563020 ( O
CYP7A BC2GM095563020 NNP O
) BC2GM095563020 ) O
is BC2GM095563020 VBZ O
transcriptionally BC2GM095563020 RB O
regulated BC2GM095563020 VBN O
by BC2GM095563020 IN O
a BC2GM095563020 DT O
number BC2GM095563020 NN O
of BC2GM095563020 IN O
factors BC2GM095563020 NNS O
, BC2GM095563020 , O
including BC2GM095563020 VBG O
hormones BC2GM095563020 NNS O
, BC2GM095563020 , O
bile BC2GM095563020 JJ O
acids BC2GM095563020 NNS O
, BC2GM095563020 , O
and BC2GM095563020 CC O
diurnal BC2GM095563020 JJ O
rhythm BC2GM095563020 NN O
. BC2GM095563020 . O
. . O O

100 BC2GM015089402 CD O
and BC2GM015089402 CC O
51 BC2GM015089402 CD O
p BC2GM015089402 NN O
. BC2GM015089402 . O
. . O O

Antisense BC2GM083462824 NNP O
oligonucleotides BC2GM083462824 VBZ O
complementary BC2GM083462824 JJ O
to BC2GM083462824 TO O
the BC2GM083462824 DT O
5 BC2GM083462824 CD O
' BC2GM083462824 POS O
end BC2GM083462824 NN O
of BC2GM083462824 IN O
PKC-zeta BC2GM083462824 NNP O
mRNA BC2GM083462824 NN O
sequences BC2GM083462824 NNS O
significantly BC2GM083462824 RB O
reduced BC2GM083462824 VBD O
the BC2GM083462824 DT O
collagen BC2GM083462824 NN O
lattice-stimulated BC2GM083462824 JJ O
alpha2 BC2GM083462824 NN O
and BC2GM083462824 CC O
MMP-1 BC2GM083462824 NNP O
mRNA BC2GM083462824 NN O
levels BC2GM083462824 NNS O
. BC2GM083462824 . O
. . O O

Our BC2GM048938799 PRP$ O
results BC2GM048938799 NNS O
admit BC2GM048938799 VBP O
that BC2GM048938799 IN O
a BC2GM048938799 DT O
ribosome BC2GM048938799 JJ O
scanning BC2GM048938799 NN O
mechanism BC2GM048938799 NN O
of BC2GM048938799 IN O
the BC2GM048938799 DT O
MP BC2GM048938799 NNP O
gene BC2GM048938799 NN O
expression BC2GM048938799 NN O
from BC2GM048938799 IN O
I BC2GM048938799 PRP O
( BC2GM048938799 ( O
2 BC2GM048938799 CD O
) BC2GM048938799 ) O
sgRNA BC2GM048938799 NN O
operates BC2GM048938799 VBZ O
concurrently BC2GM048938799 RB O
. BC2GM048938799 . O
. . O O

Engineering BC2GM055876986 VBG O
temperature-sensitive BC2GM055876986 JJ O
SH3 BC2GM055876986 NNP O
domains BC2GM055876986 NNS O
. BC2GM055876986 . O
. . O O

In BC2GM091282092 IN O
addition BC2GM091282092 NN O
, BC2GM091282092 , O
both BC2GM091282092 DT O
activated BC2GM091282092 VBN O
Ral-GDS-like BC2GM091282092 NNP O
factor BC2GM091282092 NN O
and BC2GM091282092 CC O
Raf BC2GM091282092 NNP O
stimulate BC2GM091282092 VBP O
cyclin BC2GM091282092 NN O
D BC2GM091282092 NNP O
( BC2GM091282092 ( O
1 BC2GM091282092 CD O
) BC2GM091282092 ) O
transcription BC2GM091282092 NN O
and BC2GM091282092 CC O
E2F BC2GM091282092 NNP O
activity BC2GM091282092 NN O
and BC2GM091282092 CC O
act BC2GM091282092 NN O
in BC2GM091282092 IN O
synergy BC2GM091282092 NN O
with BC2GM091282092 IN O
PI BC2GM091282092 NNP O
3-kinase BC2GM091282092 NNP O
. BC2GM091282092 . O
. . O O

Similarly BC2GM096832130 RB O
, BC2GM096832130 , O
TAM-67 BC2GM096832130 NNP O
reverted BC2GM096832130 VBD O
the BC2GM096832130 DT O
morphology BC2GM096832130 NN O
of BC2GM096832130 IN O
the BC2GM096832130 DT O
AdoMetDC-antisense BC2GM096832130 JJ O
expressors BC2GM096832130 NNS O
. BC2GM096832130 . O
. . O O

A BC2GM083303978 DT O
decrease BC2GM083303978 NN O
was BC2GM083303978 VBD O
also BC2GM083303978 RB O
found BC2GM083303978 VBN O
of BC2GM083303978 IN O
the BC2GM083303978 DT O
levels BC2GM083303978 NNS O
of BC2GM083303978 IN O
total BC2GM083303978 JJ O
cholesterol BC2GM083303978 NN O
and BC2GM083303978 CC O
LDL-cholesterol BC2GM083303978 NNP O
. BC2GM083303978 . O
. . O O

Elimination BC2GM000570200 NN O
of BC2GM000570200 IN O
brush BC2GM000570200 JJ O
border BC2GM000570200 NN O
as BC2GM000570200 RB O
well BC2GM000570200 RB O
as BC2GM000570200 IN O
of BC2GM000570200 IN O
glomerular BC2GM000570200 JJ O
marker BC2GM000570200 NN O
proteins BC2GM000570200 NNS O
was BC2GM000570200 VBD O
significantly BC2GM000570200 RB O
lower BC2GM000570200 JJR O
after BC2GM000570200 IN O
intravenous BC2GM000570200 JJ O
injection BC2GM000570200 NN O
of BC2GM000570200 IN O
low-osmolar BC2GM000570200 JJ O
CM BC2GM000570200 NNP O
iopamidol BC2GM000570200 NN O
370 BC2GM000570200 CD O
( BC2GM000570200 ( O
832 BC2GM000570200 CD O
mOsm BC2GM000570200 NN O
/ BC2GM000570200 NNP O
kg BC2GM000570200 NN O
) BC2GM000570200 ) O
than BC2GM000570200 IN O
after BC2GM000570200 IN O
meglumine BC2GM000570200 JJ O
diatrizoate BC2GM000570200 NN O
76 BC2GM000570200 CD O
( BC2GM000570200 ( O
2100 BC2GM000570200 CD O
mOsm BC2GM000570200 NN O
/ BC2GM000570200 NNP O
kg BC2GM000570200 NN O
) BC2GM000570200 ) O
. BC2GM000570200 . O
. . O O

Protection BC2GM038029406 NN O
levels BC2GM038029406 NNS O
of BC2GM038029406 IN O
33.3 BC2GM038029406 CD O
% BC2GM038029406 NN O
, BC2GM038029406 , O
36.6 BC2GM038029406 CD O
% BC2GM038029406 NN O
and BC2GM038029406 CC O
37.0 BC2GM038029406 CD O
% BC2GM038029406 NN O
were BC2GM038029406 VBD O
achieved BC2GM038029406 VBN O
in BC2GM038029406 IN O
groups BC2GM038029406 NNS O
which BC2GM038029406 WDT O
had BC2GM038029406 VBD O
received BC2GM038029406 VBN O
, BC2GM038029406 , O
respectively BC2GM038029406 RB O
, BC2GM038029406 , O
1000 BC2GM038029406 CD O
20-krad BC2GM038029406 JJ O
cercariae BC2GM038029406 NN O
, BC2GM038029406 , O
1000 BC2GM038029406 CD O
10-krad BC2GM038029406 JJ O
cercariae BC2GM038029406 NN O
, BC2GM038029406 , O
2000 BC2GM038029406 CD O
40-krad BC2GM038029406 JJ O
cercariae BC2GM038029406 NN O
and BC2GM038029406 CC O
2000 BC2GM038029406 CD O
60-krad BC2GM038029406 JJ O
cercariae BC2GM038029406 NN O
. BC2GM038029406 . O
. . O O

In BC2GM023981862 IN O
summary BC2GM023981862 JJ O
, BC2GM023981862 , O
the BC2GM023981862 DT O
only BC2GM023981862 JJ O
treatment-related BC2GM023981862 JJ O
effect BC2GM023981862 NN O
noted BC2GM023981862 VBN O
in BC2GM023981862 IN O
this BC2GM023981862 DT O
study BC2GM023981862 NN O
was BC2GM023981862 VBD O
hydrocarbon BC2GM023981862 VBN O
nephropathy BC2GM023981862 RB O
in BC2GM023981862 IN O
male BC2GM023981862 JJ O
rats BC2GM023981862 NNS O
, BC2GM023981862 , O
which BC2GM023981862 WDT O
is BC2GM023981862 VBZ O
not BC2GM023981862 RB O
considered BC2GM023981862 VBN O
relevant BC2GM023981862 NN O
for BC2GM023981862 IN O
human BC2GM023981862 JJ O
health BC2GM023981862 NN O
. BC2GM023981862 . O
. . O O

A BC2GM086826510 DT O
new BC2GM086826510 JJ O
direct BC2GM086826510 JJ O
hemagglutination BC2GM086826510 NN O
test BC2GM086826510 NN O
( BC2GM086826510 ( O
HI-GONAVIS BC2GM086826510 NNP O
) BC2GM086826510 ) O
for BC2GM086826510 IN O
urinary BC2GM086826510 JJ O
LH BC2GM086826510 NNP O
was BC2GM086826510 VBD O
compared BC2GM086826510 VBN O
with BC2GM086826510 IN O
the BC2GM086826510 DT O
serum BC2GM086826510 JJ O
radioimmuno-assay BC2GM086826510 NN O
of BC2GM086826510 IN O
LH BC2GM086826510 NNP O
. BC2GM086826510 . O
. . O O

In BC2GM078078489 IN O
vitro BC2GM078078489 NN O
, BC2GM078078489 , O
SHIP BC2GM078078489 NNP O
catalyzes BC2GM078078489 VBZ O
the BC2GM078078489 DT O
conversion BC2GM078078489 NN O
of BC2GM078078489 IN O
the BC2GM078078489 DT O
phosphoinositide BC2GM078078489 JJ O
3-kinase BC2GM078078489 NNP O
( BC2GM078078489 ( O
PI3K BC2GM078078489 NNP O
) BC2GM078078489 ) O
product BC2GM078078489 NN O
phosphatidylinositol BC2GM078078489 NN O
3,4 BC2GM078078489 CD O
, BC2GM078078489 , O
5-trisphosphate BC2GM078078489 JJ O
( BC2GM078078489 ( O
PIP3 BC2GM078078489 NNP O
) BC2GM078078489 ) O
into BC2GM078078489 IN O
phosphatidylinositol BC2GM078078489 JJ O
3,4-bisphosphate BC2GM078078489 JJ O
. BC2GM078078489 . O
. . O O

Successive BC2GM042151214 JJ O
5 BC2GM042151214 CD O
' BC2GM042151214 POS O
deletions BC2GM042151214 NNS O
of BC2GM042151214 IN O
the BC2GM042151214 DT O
[ BC2GM042151214 NNP O
-326 BC2GM042151214 NNP O
; BC2GM042151214 : O
+20 BC2GM042151214 NNP O
] BC2GM042151214 NNP O
type BC2GM042151214 NN O
II BC2GM042151214 NNP O
sPLA2 BC2GM042151214 NN O
promoter BC2GM042151214 NN O
indicated BC2GM042151214 VBD O
that BC2GM042151214 IN O
the BC2GM042151214 DT O
region BC2GM042151214 NN O
upstream BC2GM042151214 NN O
of BC2GM042151214 IN O
position BC2GM042151214 NN O
-195 BC2GM042151214 NNP O
inhibits BC2GM042151214 VBZ O
the BC2GM042151214 DT O
transcription BC2GM042151214 NN O
activity BC2GM042151214 NN O
sixfold BC2GM042151214 NN O
in BC2GM042151214 IN O
HepG2 BC2GM042151214 NNP O
cells BC2GM042151214 NNS O
but BC2GM042151214 CC O
not BC2GM042151214 RB O
in BC2GM042151214 IN O
HeLa BC2GM042151214 NNP O
cells BC2GM042151214 NNS O
. BC2GM042151214 . O
. . O O

Static BC2GM015656322 JJ O
and BC2GM015656322 CC O
dynamic BC2GM015656322 JJ O
MRI BC2GM015656322 NNP O
of BC2GM015656322 IN O
the BC2GM015656322 DT O
normal BC2GM015656322 JJ O
and BC2GM015656322 CC O
pathological BC2GM015656322 JJ O
female BC2GM015656322 NN O
pelvic BC2GM015656322 JJ O
floor BC2GM015656322 NN O
. BC2GM015656322 . O
. . O O

Crude BC2GM065525497 NNP O
drugs BC2GM065525497 NNS O
from BC2GM065525497 IN O
aquatic BC2GM065525497 JJ O
plants BC2GM065525497 NNS O
. BC2GM065525497 . O
. . O O

The BC2GM016049892 DT O
benzo-pyrone BC2GM016049892 JJ O
drug BC2GM016049892 NN O
Venalot BC2GM016049892 NNP O
had BC2GM016049892 VBD O
a BC2GM016049892 DT O
considerable BC2GM016049892 JJ O
effect BC2GM016049892 NN O
in BC2GM016049892 IN O
reducing BC2GM016049892 VBG O
the BC2GM016049892 DT O
protein BC2GM016049892 NN O
concentration BC2GM016049892 NN O
in BC2GM016049892 IN O
the BC2GM016049892 DT O
air BC2GM016049892 NN O
spaces BC2GM016049892 NNS O
and BC2GM016049892 CC O
the BC2GM016049892 DT O
interstitial BC2GM016049892 JJ O
tissue BC2GM016049892 NN O
, BC2GM016049892 , O
and BC2GM016049892 CC O
of BC2GM016049892 IN O
the BC2GM016049892 DT O
oedema BC2GM016049892 NN O
in BC2GM016049892 IN O
the BC2GM016049892 DT O
latter BC2GM016049892 NN O
. BC2GM016049892 . O
. . O O

Removal BC2GM013294615 NN O
of BC2GM013294615 IN O
ink4a BC2GM013294615 NN O
dramatically BC2GM013294615 RB O
reduces BC2GM013294615 VBZ O
the BC2GM013294615 DT O
lymphoid BC2GM013294615 NN O
and BC2GM013294615 CC O
neurological BC2GM013294615 JJ O
defects BC2GM013294615 NNS O
seen BC2GM013294615 VBN O
in BC2GM013294615 IN O
bmi-1-deficient BC2GM013294615 JJ O
mice BC2GM013294615 NN O
, BC2GM013294615 , O
indicating BC2GM013294615 VBG O
that BC2GM013294615 IN O
ink4a BC2GM013294615 NN O
is BC2GM013294615 VBZ O
a BC2GM013294615 DT O
critical BC2GM013294615 JJ O
in BC2GM013294615 IN O
vivo BC2GM013294615 NN O
target BC2GM013294615 NN O
for BC2GM013294615 IN O
Bmi-1 BC2GM013294615 NNP O
. BC2GM013294615 . O
. . O O

The BC2GM091638425 DT O
technique BC2GM091638425 NN O
used BC2GM091638425 VBN O
by BC2GM091638425 IN O
this BC2GM091638425 DT O
system BC2GM091638425 NN O
involves BC2GM091638425 VBZ O
a BC2GM091638425 DT O
transient BC2GM091638425 NN O
, BC2GM091638425 , O
externally BC2GM091638425 RB O
applied BC2GM091638425 JJ O
increase BC2GM091638425 NN O
in BC2GM091638425 IN O
resistance BC2GM091638425 NN O
to BC2GM091638425 TO O
breathing BC2GM091638425 NN O
. BC2GM091638425 . O
. . O O

These BC2GM089958574 DT O
proteins BC2GM089958574 NNS O
, BC2GM089958574 , O
called BC2GM089958574 VBN O
variant BC2GM089958574 JJ O
surface BC2GM089958574 NN O
glycoproteins BC2GM089958574 NNS O
( BC2GM089958574 ( O
VSGs BC2GM089958574 NNP O
) BC2GM089958574 ) O
, BC2GM089958574 , O
are BC2GM089958574 VBP O
expressed BC2GM089958574 VBN O
from BC2GM089958574 IN O
a BC2GM089958574 DT O
specific BC2GM089958574 JJ O
locus BC2GM089958574 NN O
, BC2GM089958574 , O
the BC2GM089958574 DT O
VSG BC2GM089958574 NNP O
gene BC2GM089958574 NN O
expression BC2GM089958574 NN O
site BC2GM089958574 NN O
( BC2GM089958574 ( O
ES BC2GM089958574 NNP O
) BC2GM089958574 ) O
. BC2GM089958574 . O
. . O O

Furthermore BC2GM072515083 RB O
, BC2GM072515083 , O
mutations BC2GM072515083 NNS O
in BC2GM072515083 IN O
element BC2GM072515083 NN O
II BC2GM072515083 NNP O
result BC2GM072515083 NN O
in BC2GM072515083 IN O
changes BC2GM072515083 NNS O
in BC2GM072515083 IN O
the BC2GM072515083 DT O
RNA BC2GM072515083 NNP O
structure BC2GM072515083 NN O
near BC2GM072515083 IN O
element BC2GM072515083 JJ O
III BC2GM072515083 NNP O
, BC2GM072515083 , O
consistent BC2GM072515083 NN O
with BC2GM072515083 IN O
a BC2GM072515083 DT O
long-range BC2GM072515083 JJ O
interaction BC2GM072515083 NN O
that BC2GM072515083 WDT O
may BC2GM072515083 MD O
promote BC2GM072515083 VB O
translation BC2GM072515083 NN O
. BC2GM072515083 . O
. . O O

The BC2GM041958370 DT O
uap100 BC2GM041958370 JJ O
cis-acting BC2GM041958370 NN O
, BC2GM041958370 , O
up-promoter BC2GM041958370 JJ O
, BC2GM041958370 , O
constitutive BC2GM041958370 JJ O
mutation BC2GM041958370 NN O
is BC2GM041958370 VBZ O
a BC2GM041958370 DT O
duplication BC2GM041958370 NN O
that BC2GM041958370 WDT O
comprises BC2GM041958370 VBZ O
two BC2GM041958370 CD O
GATA BC2GM041958370 NNP O
sites BC2GM041958370 NNS O
and BC2GM041958370 CC O
suppresses BC2GM041958370 NNS O
weakly BC2GM041958370 VBP O
the BC2GM041958370 DT O
AREA BC2GM041958370 NNP O
zinc BC2GM041958370 NNP O
finger BC2GM041958370 NN O
mutation BC2GM041958370 NN O
but BC2GM041958370 CC O
does BC2GM041958370 VBZ O
not BC2GM041958370 RB O
alleviate BC2GM041958370 VB O
the BC2GM041958370 DT O
need BC2GM041958370 NN O
for BC2GM041958370 IN O
functional BC2GM041958370 JJ O
UAY BC2GM041958370 NNP O
and BC2GM041958370 CC O
AREA BC2GM041958370 NNP O
proteins BC2GM041958370 NNS O
. BC2GM041958370 . O
. . O O

RESULTS BC2GM068742708 NN O
: BC2GM068742708 : O
There BC2GM068742708 EX O
were BC2GM068742708 VBD O
no BC2GM068742708 DT O
significant BC2GM068742708 JJ O
differences BC2GM068742708 NNS O
in BC2GM068742708 IN O
the BC2GM068742708 DT O
mean BC2GM068742708 JJ O
serum BC2GM068742708 NN O
vitamin BC2GM068742708 NN O
A BC2GM068742708 NNP O
, BC2GM068742708 , O
E BC2GM068742708 NNP O
concentrations BC2GM068742708 NNS O
and BC2GM068742708 CC O
vitamin BC2GM068742708 NN O
E BC2GM068742708 NNP O
/ BC2GM068742708 NNP O
cholesterol BC2GM068742708 NN O
ratio BC2GM068742708 NN O
between BC2GM068742708 IN O
pregnant BC2GM068742708 JJ O
women BC2GM068742708 NNS O
with BC2GM068742708 IN O
normal BC2GM068742708 JJ O
hemoglobin BC2GM068742708 NN O
and BC2GM068742708 CC O
hemoglobinopathies BC2GM068742708 NNS O
, BC2GM068742708 , O
while BC2GM068742708 IN O
confounding BC2GM068742708 VBG O
variables BC2GM068742708 NNS O
that BC2GM068742708 WDT O
might BC2GM068742708 MD O
affect BC2GM068742708 VB O
serum BC2GM068742708 JJ O
vitamin BC2GM068742708 NN O
levels BC2GM068742708 NNS O
i.e BC2GM068742708 VBP O
. BC2GM068742708 . O
maternal BC2GM068742708 JJ O
age BC2GM068742708 NN O
, BC2GM068742708 , O
gravida BC2GM068742708 NN O
, BC2GM068742708 , O
BMI BC2GM068742708 NNP O
, BC2GM068742708 , O
gestational BC2GM068742708 JJ O
age BC2GM068742708 NN O
, BC2GM068742708 , O
hematocrit BC2GM068742708 NN O
, BC2GM068742708 , O
hemoglobin BC2GM068742708 NN O
, BC2GM068742708 , O
mean BC2GM068742708 JJ O
corpuscular BC2GM068742708 JJ O
hemoglobin BC2GM068742708 NN O
concentration BC2GM068742708 NN O
and BC2GM068742708 CC O
blood BC2GM068742708 NN O
group BC2GM068742708 NN O
were BC2GM068742708 VBD O
not BC2GM068742708 RB O
different BC2GM068742708 JJ O
. BC2GM068742708 . O
. . O O

The BC2GM053438621 DT O
overall BC2GM053438621 JJ O
rate BC2GM053438621 NN O
of BC2GM053438621 IN O
biohydrogenation BC2GM053438621 NN O
of BC2GM053438621 IN O
C18:2 BC2GM053438621 NNP O
was BC2GM053438621 VBD O
14.3 BC2GM053438621 CD O
% BC2GM053438621 NN O
/ BC2GM053438621 NN O
h BC2GM053438621 NN O
, BC2GM053438621 , O
but BC2GM053438621 CC O
declined BC2GM053438621 VBD O
1.2 BC2GM053438621 CD O
% BC2GM053438621 NN O
/ BC2GM053438621 NN O
h BC2GM053438621 NN O
for BC2GM053438621 IN O
each BC2GM053438621 DT O
percentage BC2GM053438621 NN O
unit BC2GM053438621 NN O
increase BC2GM053438621 NN O
in BC2GM053438621 IN O
C18:2 BC2GM053438621 NNP O
added BC2GM053438621 VBD O
to BC2GM053438621 TO O
the BC2GM053438621 DT O
substrate BC2GM053438621 NN O
. BC2GM053438621 . O
. . O O

The BC2GM024468009 DT O
peptides BC2GM024468009 NNS O
are BC2GM024468009 VBP O
generated BC2GM024468009 VBN O
in BC2GM024468009 IN O
the BC2GM024468009 DT O
cytosol BC2GM024468009 NN O
, BC2GM024468009 , O
then BC2GM024468009 RB O
translocated BC2GM024468009 VBN O
across BC2GM024468009 IN O
the BC2GM024468009 DT O
membrane BC2GM024468009 NN O
of BC2GM024468009 IN O
the BC2GM024468009 DT O
endoplasmic BC2GM024468009 JJ O
reticulum BC2GM024468009 NN O
by BC2GM024468009 IN O
the BC2GM024468009 DT O
transporter BC2GM024468009 NN O
associated BC2GM024468009 VBN O
with BC2GM024468009 IN O
antigen BC2GM024468009 NN O
processing BC2GM024468009 NN O
( BC2GM024468009 ( O
TAP BC2GM024468009 NNP O
) BC2GM024468009 ) O
. BC2GM024468009 . O
. . O O

Tax BC2GM050923022 NN O
was BC2GM050923022 VBD O
demonstrated BC2GM050923022 VBN O
to BC2GM050923022 TO O
interact BC2GM050923022 VB O
directly BC2GM050923022 RB O
with BC2GM050923022 IN O
CREB1 BC2GM050923022 NNP O
but BC2GM050923022 CC O
not BC2GM050923022 RB O
with BC2GM050923022 IN O
other BC2GM050923022 JJ O
bZIP BC2GM050923022 NN O
proteins BC2GM050923022 NNS O
, BC2GM050923022 , O
including BC2GM050923022 VBG O
CREB2 BC2GM050923022 NNP O
and BC2GM050923022 CC O
Jun BC2GM050923022 NNP O
. BC2GM050923022 . O
. . O O

Our BC2GM048321842 PRP$ O
results BC2GM048321842 NNS O
suggest BC2GM048321842 VBP O
that BC2GM048321842 IN O
Sp1 BC2GM048321842 NNP O
binding BC2GM048321842 VBG O
site BC2GM048321842 NN O
can BC2GM048321842 MD O
function BC2GM048321842 VB O
as BC2GM048321842 IN O
a BC2GM048321842 DT O
distinct BC2GM048321842 JJ O
TGF-beta BC2GM048321842 NNP O
responsive BC2GM048321842 NN O
element BC2GM048321842 NN O
for BC2GM048321842 IN O
TGF-beta BC2GM048321842 NNP O
mediated BC2GM048321842 VBD O
promoter BC2GM048321842 NN O
expression BC2GM048321842 NN O
and BC2GM048321842 CC O
Sp1 BC2GM048321842 NNP O
per BC2GM048321842 IN O
se BC2GM048321842 NN O
can BC2GM048321842 MD O
mediate BC2GM048321842 VB O
this BC2GM048321842 DT O
response BC2GM048321842 NN O
. BC2GM048321842 . O
. . O O

Low BC2GM054416322 JJ O
temperature BC2GM054416322 NN O
( BC2GM054416322 ( O
8 BC2GM054416322 CD O
degrees BC2GM054416322 NNS O
C BC2GM054416322 NNP O
) BC2GM054416322 ) O
impairs BC2GM054416322 VBZ O
secretory BC2GM054416322 JJ O
activity BC2GM054416322 NN O
, BC2GM054416322 , O
again BC2GM054416322 RB O
independently BC2GM054416322 RB O
of BC2GM054416322 IN O
the BC2GM054416322 DT O
photoperiod BC2GM054416322 NN O
selected BC2GM054416322 VBN O
. BC2GM054416322 . O
. . O O

The BC2GM016026210 DT O
community-acquired BC2GM016026210 JJ O
bacteremia BC2GM016026210 NN O
was BC2GM016026210 VBD O
mainly BC2GM016026210 RB O
due BC2GM016026210 JJ O
to BC2GM016026210 TO O
E. BC2GM016026210 NNP O
coli BC2GM016026210 NNS O
. BC2GM016026210 . O
. . O O

The BC2GM051756783 DT O
gene BC2GM051756783 NN O
encoding BC2GM051756783 VBG O
the BC2GM051756783 DT O
cellulase BC2GM051756783 NN O
( BC2GM051756783 ( O
Avicelase BC2GM051756783 NNP O
) BC2GM051756783 ) O
Cel1 BC2GM051756783 NNP O
from BC2GM051756783 IN O
Streptomyces BC2GM051756783 NNP O
reticuli BC2GM051756783 NN O
and BC2GM051756783 CC O
analysis BC2GM051756783 NN O
of BC2GM051756783 IN O
protein BC2GM051756783 NN O
domains BC2GM051756783 NNS O
. BC2GM051756783 . O
. . O O

Using BC2GM084178776 VBG O
a BC2GM084178776 DT O
combined BC2GM084178776 JJ O
pharmacokinetic-pharmacodynamic BC2GM084178776 JJ O
model BC2GM084178776 NN O
, BC2GM084178776 , O
the BC2GM084178776 DT O
impact BC2GM084178776 NN O
of BC2GM084178776 IN O
various BC2GM084178776 JJ O
factors BC2GM084178776 NNS O
on BC2GM084178776 IN O
the BC2GM084178776 DT O
effective BC2GM084178776 JJ O
bioavailability BC2GM084178776 NN O
and BC2GM084178776 CC O
on BC2GM084178776 IN O
its BC2GM084178776 PRP$ O
estimation BC2GM084178776 NN O
, BC2GM084178776 , O
using BC2GM084178776 VBG O
the BC2GM084178776 DT O
intravenous-to-oral BC2GM084178776 JJ O
dose BC2GM084178776 JJ O
ratio BC2GM084178776 NN O
required BC2GM084178776 VBN O
to BC2GM084178776 TO O
produce BC2GM084178776 VB O
the BC2GM084178776 DT O
same BC2GM084178776 JJ O
area BC2GM084178776 NN O
under BC2GM084178776 IN O
the BC2GM084178776 DT O
response BC2GM084178776 NN O
time BC2GM084178776 NN O
curve BC2GM084178776 NN O
after BC2GM084178776 IN O
acute BC2GM084178776 JJ O
administration BC2GM084178776 NN O
, BC2GM084178776 , O
are BC2GM084178776 VBP O
explored BC2GM084178776 VBN O
. BC2GM084178776 . O
. . O O

The BC2GM027429119 DT O
nucleotide BC2GM027429119 JJ O
sequence BC2GM027429119 NN O
of BC2GM027429119 IN O
the BC2GM027429119 DT O
gene BC2GM027429119 NN O
encoding BC2GM027429119 VBG O
this BC2GM027429119 DT O
product BC2GM027429119 NN O
was BC2GM027429119 VBD O
determined BC2GM027429119 VBN O
and BC2GM027429119 CC O
the BC2GM027429119 DT O
amino BC2GM027429119 NN O
acid BC2GM027429119 JJ O
sequence BC2GM027429119 NN O
deduced BC2GM027429119 VBD O
. BC2GM027429119 . O
. . O O

Diclofenac BC2GM068927372 NNP O
sodium BC2GM068927372 NN O
: BC2GM068927372 : O
blood BC2GM068927372 NN O
concentration BC2GM068927372 NN O
of BC2GM068927372 IN O
the BC2GM068927372 DT O
slow-release BC2GM068927372 JJ O
form BC2GM068927372 NN O
and BC2GM068927372 CC O
influence BC2GM068927372 NN O
on BC2GM068927372 IN O
the BC2GM068927372 DT O
metabolism BC2GM068927372 NN O
of BC2GM068927372 IN O
kallikrein BC2GM068927372 NN O
. BC2GM068927372 . O
. . O O

DESIGN BC2GM069010582 NN O
: BC2GM069010582 : O
Intradermally BC2GM069010582 RB O
injected BC2GM069010582 VBN O
human BC2GM069010582 JJ O
squamous BC2GM069010582 JJ O
cell BC2GM069010582 NN O
carcinoma BC2GM069010582 NN O
cells BC2GM069010582 NNS O
were BC2GM069010582 VBD O
grown BC2GM069010582 VBN O
to BC2GM069010582 TO O
40 BC2GM069010582 CD O
to BC2GM069010582 TO O
80 BC2GM069010582 CD O
mm3 BC2GM069010582 NNS O
in BC2GM069010582 IN O
athymic BC2GM069010582 JJ O
nude BC2GM069010582 JJ O
mice BC2GM069010582 NN O
and BC2GM069010582 CC O
irradiated BC2GM069010582 VBN O
with BC2GM069010582 IN O
675-nm BC2GM069010582 JJ O
light BC2GM069010582 NN O
( BC2GM069010582 ( O
75 BC2GM069010582 CD O
J BC2GM069010582 NNP O
/ BC2GM069010582 NNP O
cm2 BC2GM069010582 NN O
, BC2GM069010582 , O
75 BC2GM069010582 CD O
mW BC2GM069010582 NN O
/ BC2GM069010582 NNP O
cm2 BC2GM069010582 NN O
) BC2GM069010582 ) O
24 BC2GM069010582 CD O
hours BC2GM069010582 NNS O
after BC2GM069010582 IN O
the BC2GM069010582 DT O
intraperitoneal BC2GM069010582 JJ O
injection BC2GM069010582 NN O
of BC2GM069010582 IN O
SiPc BC2GM069010582 NNP O
IV BC2GM069010582 NNP O
( BC2GM069010582 ( O
1.0 BC2GM069010582 CD O
mg BC2GM069010582 NN O
/ BC2GM069010582 NNP O
kg BC2GM069010582 NN O
) BC2GM069010582 ) O
. BC2GM069010582 . O
. . O O

Analysis BC2GM067850977 NN O
of BC2GM067850977 IN O
WT1 BC2GM067850977 NNP O
target BC2GM067850977 NN O
gene BC2GM067850977 NN O
expression BC2GM067850977 NN O
in BC2GM067850977 IN O
stably BC2GM067850977 RB O
transfected BC2GM067850977 VBN O
cell BC2GM067850977 NN O
lines BC2GM067850977 NNS O
. BC2GM067850977 . O
. . O O

We BC2GM097874818 PRP O
conclude BC2GM097874818 VBP O
that BC2GM097874818 IN O
in BC2GM097874818 IN O
the BC2GM097874818 DT O
presence BC2GM097874818 NN O
of BC2GM097874818 IN O
fatty BC2GM097874818 JJ O
acids BC2GM097874818 NNS O
in BC2GM097874818 IN O
the BC2GM097874818 DT O
medium BC2GM097874818 NN O
transcription BC2GM097874818 NN O
of BC2GM097874818 IN O
SPS19 BC2GM097874818 NNP O
is BC2GM097874818 VBZ O
directly BC2GM097874818 RB O
regulated BC2GM097874818 VBN O
by BC2GM097874818 IN O
both BC2GM097874818 DT O
Pip2p-Oaf1p BC2GM097874818 NNP O
and BC2GM097874818 CC O
Adr1p BC2GM097874818 NNP O
. BC2GM097874818 . O
. . O O

Starches BC2GM033742253 NNS O
had BC2GM033742253 VBD O
no BC2GM033742253 DT O
effect BC2GM033742253 NN O
. BC2GM033742253 . O
. . O O

The BC2GM091705287 DT O
protein BC2GM091705287 NN O
contains BC2GM091705287 VBZ O
a BC2GM091705287 DT O
SHAQKYF BC2GM091705287 NNP O
amino BC2GM091705287 NN O
acid BC2GM091705287 NN O
signature BC2GM091705287 NN O
motif BC2GM091705287 NN O
in BC2GM091705287 IN O
the BC2GM091705287 DT O
second BC2GM091705287 JJ O
myb-like BC2GM091705287 JJ O
repeat BC2GM091705287 NN O
, BC2GM091705287 , O
which BC2GM091705287 WDT O
is BC2GM091705287 VBZ O
highly BC2GM091705287 RB O
conserved BC2GM091705287 VBN O
in BC2GM091705287 IN O
a BC2GM091705287 DT O
number BC2GM091705287 NN O
of BC2GM091705287 IN O
recently BC2GM091705287 RB O
identified BC2GM091705287 VBN O
plant BC2GM091705287 NN O
myb-related BC2GM091705287 JJ O
genes BC2GM091705287 NNS O
, BC2GM091705287 , O
thus BC2GM091705287 RB O
defining BC2GM091705287 VBG O
a BC2GM091705287 DT O
new BC2GM091705287 JJ O
class BC2GM091705287 NN O
of BC2GM091705287 IN O
plant BC2GM091705287 NN O
DNA-binding BC2GM091705287 NNP O
proteins BC2GM091705287 NNS O
. BC2GM091705287 . O
. . O O

A BC2GM079864843 DT O
genomic BC2GM079864843 JJ O
clone BC2GM079864843 NN O
of BC2GM079864843 IN O
the BC2GM079864843 DT O
chicken BC2GM079864843 JJ O
osteopontin-encoding BC2GM079864843 JJ O
gene BC2GM079864843 NN O
( BC2GM079864843 ( O
opn BC2GM079864843 PRP O
) BC2GM079864843 ) O
was BC2GM079864843 VBD O
isolated BC2GM079864843 VBN O
and BC2GM079864843 CC O
found BC2GM079864843 VBN O
to BC2GM079864843 TO O
be BC2GM079864843 VB O
organized BC2GM079864843 VBN O
as BC2GM079864843 IN O
follows BC2GM079864843 VBZ O
: BC2GM079864843 : O
an BC2GM079864843 DT O
untranslated BC2GM079864843 JJ O
5 BC2GM079864843 CD O
' BC2GM079864843 POS O
exon BC2GM079864843 NN O
; BC2GM079864843 : O
a BC2GM079864843 DT O
signal BC2GM079864843 JJ O
peptide BC2GM079864843 NN O
; BC2GM079864843 : O
a BC2GM079864843 DT O
recognition BC2GM079864843 NN O
sequence BC2GM079864843 NN O
for BC2GM079864843 IN O
phosphorylation BC2GM079864843 NN O
by BC2GM079864843 IN O
casein BC2GM079864843 NN O
kinase BC2GM079864843 NN O
II BC2GM079864843 NNP O
; BC2GM079864843 : O
a BC2GM079864843 DT O
domain BC2GM079864843 NN O
containing BC2GM079864843 VBG O
a BC2GM079864843 DT O
possible BC2GM079864843 JJ O
O-linkage BC2GM079864843 JJ O
site BC2GM079864843 NN O
for BC2GM079864843 IN O
glycosylation BC2GM079864843 NN O
; BC2GM079864843 : O
a BC2GM079864843 DT O
second BC2GM079864843 JJ O
casein BC2GM079864843 NN O
kinase BC2GM079864843 NN O
II BC2GM079864843 NNP O
phosphorylation BC2GM079864843 NN O
site BC2GM079864843 NN O
; BC2GM079864843 : O
an BC2GM079864843 DT O
exon BC2GM079864843 NN O
containing BC2GM079864843 VBG O
three BC2GM079864843 CD O
functional BC2GM079864843 JJ O
regions BC2GM079864843 NNS O
, BC2GM079864843 , O
the BC2GM079864843 DT O
poly-Asp BC2GM079864843 JJ O
sequence BC2GM079864843 NN O
of BC2GM079864843 IN O
seven BC2GM079864843 CD O
consecutive BC2GM079864843 JJ O
Asp BC2GM079864843 NNP O
residues BC2GM079864843 NNS O
, BC2GM079864843 , O
the BC2GM079864843 DT O
RGD BC2GM079864843 NNP O
integrin BC2GM079864843 NN O
recognition BC2GM079864843 NN O
site BC2GM079864843 NN O
and BC2GM079864843 CC O
a BC2GM079864843 DT O
potential BC2GM079864843 JJ O
N-linkage BC2GM079864843 NN O
site BC2GM079864843 NN O
for BC2GM079864843 IN O
glycosylation BC2GM079864843 NN O
; BC2GM079864843 : O
and BC2GM079864843 CC O
a BC2GM079864843 DT O
large BC2GM079864843 JJ O
C-terminal BC2GM079864843 NNP O
exon BC2GM079864843 NN O
which BC2GM079864843 WDT O
also BC2GM079864843 RB O
contains BC2GM079864843 VBZ O
a BC2GM079864843 DT O
potential BC2GM079864843 JJ O
N-linkage BC2GM079864843 NN O
site BC2GM079864843 NN O
for BC2GM079864843 IN O
glycosylation BC2GM079864843 NN O
. BC2GM079864843 . O
. . O O

Both BC2GM047731031 DT O
PMP20 BC2GM047731031 NNP O
gene BC2GM047731031 NN O
products BC2GM047731031 NNS O
contain BC2GM047731031 VBP O
the BC2GM047731031 DT O
carboxyl-terminal BC2GM047731031 JJ O
sequence BC2GM047731031 NN O
AKL BC2GM047731031 NNP O
, BC2GM047731031 , O
similar BC2GM047731031 JJ O
to BC2GM047731031 TO O
the BC2GM047731031 DT O
putative BC2GM047731031 JJ O
SKL BC2GM047731031 NNP O
peroxisomal BC2GM047731031 NN O
sorting BC2GM047731031 VBG O
sequence BC2GM047731031 NN O
( BC2GM047731031 ( O
Gould BC2GM047731031 NNP O
, BC2GM047731031 , O
S BC2GM047731031 NNP O
. BC2GM047731031 . O
. . O O

Glucose BC2GM016014528 NNP O
may BC2GM016014528 MD O
reduce BC2GM016014528 VB O
slightly BC2GM016014528 RB O
the BC2GM016014528 DT O
pool BC2GM016014528 NN O
of BC2GM016014528 IN O
amino BC2GM016014528 NN O
nitrogen BC2GM016014528 NN O
available BC2GM016014528 JJ O
for BC2GM016014528 IN O
albumin BC2GM016014528 NN O
and BC2GM016014528 CC O
urea BC2GM016014528 JJ O
synthesis BC2GM016014528 NN O
by BC2GM016014528 IN O
diverting BC2GM016014528 VBG O
some BC2GM016014528 DT O
of BC2GM016014528 IN O
the BC2GM016014528 DT O
infused BC2GM016014528 JJ O
amino BC2GM016014528 NN O
acids BC2GM016014528 NNS O
from BC2GM016014528 IN O
protein BC2GM016014528 JJ O
synthesis BC2GM016014528 NN O
by BC2GM016014528 IN O
the BC2GM016014528 DT O
liver BC2GM016014528 NN O
to BC2GM016014528 TO O
muscle BC2GM016014528 NN O
. BC2GM016014528 . O
. . O O

The BC2GM046993980 DT O
TDx BC2GM046993980 NNP O
assay BC2GM046993980 NN O
for BC2GM046993980 IN O
cyclosporine BC2GM046993980 NN O
and BC2GM046993980 CC O
its BC2GM046993980 PRP$ O
metabolites BC2GM046993980 NNS O
in BC2GM046993980 IN O
blood BC2GM046993980 NN O
samples BC2GM046993980 NNS O
compared BC2GM046993980 VBN O
with BC2GM046993980 IN O
HPLC BC2GM046993980 NNP O
and BC2GM046993980 CC O
RIA BC2GM046993980 NNP O
methods BC2GM046993980 NNS O
. BC2GM046993980 . O
. . O O

The BC2GM099460087 DT O
availability BC2GM099460087 NN O
of BC2GM099460087 IN O
a BC2GM099460087 DT O
commercial BC2GM099460087 JJ O
program BC2GM099460087 NN O
( BC2GM099460087 ( O
PCNONLIN BC2GM099460087 NNP O
) BC2GM099460087 ) O
is BC2GM099460087 VBZ O
needed BC2GM099460087 VBN O
to BC2GM099460087 TO O
carry BC2GM099460087 VB O
out BC2GM099460087 RP O
matrix BC2GM099460087 JJ O
handling BC2GM099460087 VBG O
calculations BC2GM099460087 NNS O
. BC2GM099460087 . O
. . O O

By BC2GM067441518 IN O
contrast BC2GM067441518 NN O
, BC2GM067441518 , O
footprint BC2GM067441518 NN O
II BC2GM067441518 NNP O
at BC2GM067441518 IN O
position BC2GM067441518 NN O
-125 BC2GM067441518 NN O
is BC2GM067441518 VBZ O
common BC2GM067441518 JJ O
to BC2GM067441518 TO O
both BC2GM067441518 DT O
HeLa BC2GM067441518 NNP O
and BC2GM067441518 CC O
GH3 BC2GM067441518 NNP O
cell BC2GM067441518 NN O
extracts BC2GM067441518 NNS O
and BC2GM067441518 CC O
overlies BC2GM067441518 VBZ O
a BC2GM067441518 DT O
15-base-pair BC2GM067441518 JJ O
sequence BC2GM067441518 NN O
found BC2GM067441518 VBN O
in BC2GM067441518 IN O
all BC2GM067441518 DT O
members BC2GM067441518 NNS O
of BC2GM067441518 IN O
the BC2GM067441518 DT O
growth BC2GM067441518 NN O
hormone BC2GM067441518 NN O
gene BC2GM067441518 NN O
family BC2GM067441518 NN O
. BC2GM067441518 . O
. . O O

In BC2GM091634210 IN O
addition BC2GM091634210 NN O
, BC2GM091634210 , O
putative BC2GM091634210 JJ O
binding BC2GM091634210 NN O
sites BC2GM091634210 NNS O
for BC2GM091634210 IN O
SH3 BC2GM091634210 NNP O
and BC2GM091634210 CC O
SH2 BC2GM091634210 NNP O
domains BC2GM091634210 NNS O
are BC2GM091634210 VBP O
present BC2GM091634210 JJ O
in BC2GM091634210 IN O
the BC2GM091634210 DT O
amino-terminal BC2GM091634210 JJ O
half BC2GM091634210 NN O
of BC2GM091634210 IN O
the BC2GM091634210 DT O
molecule BC2GM091634210 NN O
. BC2GM091634210 . O
. . O O

Antigen BC2GM035217555 NNP O
dose-response BC2GM035217555 JJ O
curves BC2GM035217555 NNS O
were BC2GM035217555 VBD O
drawn BC2GM035217555 VBN O
, BC2GM035217555 , O
and BC2GM035217555 CC O
the BC2GM035217555 DT O
cumulative BC2GM035217555 JJ O
dose BC2GM035217555 NN O
required BC2GM035217555 VBN O
for BC2GM035217555 IN O
a BC2GM035217555 DT O
35 BC2GM035217555 CD O
% BC2GM035217555 NN O
reduction BC2GM035217555 NN O
in BC2GM035217555 IN O
specific BC2GM035217555 JJ O
airway BC2GM035217555 NN O
conductance BC2GM035217555 NN O
was BC2GM035217555 VBD O
calculated BC2GM035217555 VBN O
and BC2GM035217555 CC O
designated BC2GM035217555 VBN O
Provocation BC2GM035217555 NNP O
Dose BC2GM035217555 NNP O
( BC2GM035217555 ( O
PD35 BC2GM035217555 NNP O
) BC2GM035217555 ) O
. BC2GM035217555 . O
. . O O

The BC2GM034359599 DT O
analysis BC2GM034359599 NN O
showed BC2GM034359599 VBD O
that BC2GM034359599 IN O
the BC2GM034359599 DT O
morning BC2GM034359599 NN O
active BC2GM034359599 JJ O
( BC2GM034359599 ( O
MA BC2GM034359599 NNP O
) BC2GM034359599 ) O
individuals BC2GM034359599 NNS O
rose BC2GM034359599 VBD O
earlier BC2GM034359599 RBR O
and BC2GM034359599 CC O
went BC2GM034359599 VBD O
to BC2GM034359599 TO O
bed BC2GM034359599 NN O
earlier BC2GM034359599 RBR O
than BC2GM034359599 IN O
the BC2GM034359599 DT O
evening BC2GM034359599 NN O
active BC2GM034359599 JJ O
( BC2GM034359599 ( O
EA BC2GM034359599 NNP O
) BC2GM034359599 ) O
individuals BC2GM034359599 NNS O
, BC2GM034359599 , O
and BC2GM034359599 CC O
the BC2GM034359599 DT O
former BC2GM034359599 JJ O
had BC2GM034359599 VBD O
a BC2GM034359599 DT O
longer BC2GM034359599 RBR O
sleep BC2GM034359599 JJ O
length BC2GM034359599 NN O
than BC2GM034359599 IN O
the BC2GM034359599 DT O
latter BC2GM034359599 JJ O
during BC2GM034359599 IN O
days BC2GM034359599 NNS O
with BC2GM034359599 IN O
a BC2GM034359599 DT O
morning BC2GM034359599 NN O
shift BC2GM034359599 NN O
, BC2GM034359599 , O
while BC2GM034359599 IN O
the BC2GM034359599 DT O
opposite BC2GM034359599 NN O
was BC2GM034359599 VBD O
true BC2GM034359599 JJ O
for BC2GM034359599 IN O
afternoon BC2GM034359599 NN O
and BC2GM034359599 CC O
night BC2GM034359599 NN O
shifts BC2GM034359599 NNS O
. BC2GM034359599 . O
. . O O

In BC2GM045681720 IN O
late BC2GM045681720 JJ O
October BC2GM045681720 NNP O
, BC2GM045681720 , O
1974 BC2GM045681720 CD O
, BC2GM045681720 , O
Staphylococcus BC2GM045681720 NNP O
aureus BC2GM045681720 VBP O
postoperative BC2GM045681720 JJ O
wound BC2GM045681720 NN O
infection BC2GM045681720 NN O
was BC2GM045681720 VBD O
recorded BC2GM045681720 VBN O
in BC2GM045681720 IN O
a BC2GM045681720 DT O
nonhuman BC2GM045681720 JJ O
primate BC2GM045681720 NN O
( BC2GM045681720 ( O
Macaca BC2GM045681720 NNP O
mulatta BC2GM045681720 NN O
) BC2GM045681720 ) O
which BC2GM045681720 WDT O
had BC2GM045681720 VBD O
recently BC2GM045681720 RB O
undergone BC2GM045681720 JJ O
surgical BC2GM045681720 JJ O
operation BC2GM045681720 NN O
. BC2GM045681720 . O
. . O O

At BC2GM066396358 IN O
11.5 BC2GM066396358 CD O
years BC2GM066396358 NNS O
of BC2GM066396358 IN O
follow-up BC2GM066396358 NN O
, BC2GM066396358 , O
521 BC2GM066396358 CD O
major BC2GM066396358 JJ O
coronary BC2GM066396358 JJ O
disease BC2GM066396358 NN O
events BC2GM066396358 NNS O
had BC2GM066396358 VBD O
occurred BC2GM066396358 VBN O
, BC2GM066396358 , O
261 BC2GM066396358 CD O
fatal BC2GM066396358 NN O
and BC2GM066396358 CC O
260 BC2GM066396358 CD O
non-fatal BC2GM066396358 JJ O
. BC2GM066396358 . O
. . O O

An BC2GM008024280 DT O
infant BC2GM008024280 NN O
of BC2GM008024280 IN O
8 BC2GM008024280 CD O
months BC2GM008024280 NNS O
with BC2GM008024280 IN O
congenital BC2GM008024280 JJ O
glaucoma BC2GM008024280 NN O
and BC2GM008024280 CC O
hemophilia BC2GM008024280 VB O
A BC2GM008024280 DT O
lost BC2GM008024280 JJ O
one BC2GM008024280 CD O
eye BC2GM008024280 NN O
due BC2GM008024280 JJ O
to BC2GM008024280 TO O
haemorrhages BC2GM008024280 NNS O
after BC2GM008024280 IN O
trabeculotomy BC2GM008024280 NN O
in BC2GM008024280 IN O
an BC2GM008024280 DT O
eye BC2GM008024280 NN O
hospital BC2GM008024280 NN O
. BC2GM008024280 . O
. . O O

In BC2GM069174792 IN O
this BC2GM069174792 DT O
technique BC2GM069174792 NN O
, BC2GM069174792 , O
the BC2GM069174792 DT O
posterior BC2GM069174792 JJ O
wall BC2GM069174792 NN O
of BC2GM069174792 IN O
the BC2GM069174792 DT O
neopharynx BC2GM069174792 NN O
consists BC2GM069174792 VBZ O
only BC2GM069174792 RB O
of BC2GM069174792 IN O
the BC2GM069174792 DT O
prevertebral BC2GM069174792 JJ O
tissue BC2GM069174792 NN O
, BC2GM069174792 , O
while BC2GM069174792 IN O
the BC2GM069174792 DT O
flap BC2GM069174792 NN O
forms BC2GM069174792 VBZ O
the BC2GM069174792 DT O
anterior BC2GM069174792 JJ O
and BC2GM069174792 CC O
lateral BC2GM069174792 JJ O
walls BC2GM069174792 NNS O
. BC2GM069174792 . O
. . O O

Here BC2GM062761406 RB O
we BC2GM062761406 PRP O
report BC2GM062761406 VBP O
that BC2GM062761406 IN O
components BC2GM062761406 NNS O
of BC2GM062761406 IN O
the BC2GM062761406 DT O
Ras BC2GM062761406 NNP O
/ BC2GM062761406 NNP O
Raf BC2GM062761406 NNP O
/ BC2GM062761406 NNP O
MAPK BC2GM062761406 NNP O
pathway BC2GM062761406 NN O
are BC2GM062761406 VBP O
constitutively BC2GM062761406 RB O
activated BC2GM062761406 VBN O
in BC2GM062761406 IN O
these BC2GM062761406 DT O
lck-transformed BC2GM062761406 JJ O
immature BC2GM062761406 NN O
thymoblasts BC2GM062761406 NNS O
. BC2GM062761406 . O
p56 BC2GM062761406 NN O
( BC2GM062761406 ( O
lck BC2GM062761406 NN O
) BC2GM062761406 ) O
utilizes BC2GM062761406 VBZ O
Shc BC2GM062761406 NNP O
and BC2GM062761406 CC O
Grb2 BC2GM062761406 NNP O
adaptors BC2GM062761406 NNS O
to BC2GM062761406 TO O
mediate BC2GM062761406 VB O
activation BC2GM062761406 NN O
of BC2GM062761406 IN O
p21 BC2GM062761406 NN O
( BC2GM062761406 ( O
ras BC2GM062761406 NNS O
) BC2GM062761406 ) O
in BC2GM062761406 IN O
the BC2GM062761406 DT O
thymoblast BC2GM062761406 NN O
lines BC2GM062761406 NNS O
by BC2GM062761406 IN O
promoting BC2GM062761406 VBG O
tyrosine BC2GM062761406 JJ O
phosphorylation BC2GM062761406 NN O
of BC2GM062761406 IN O
the BC2GM062761406 DT O
Shc BC2GM062761406 NNP O
protein BC2GM062761406 NN O
and BC2GM062761406 CC O
constitutive BC2GM062761406 JJ O
interaction BC2GM062761406 NN O
between BC2GM062761406 IN O
Shc BC2GM062761406 NNP O
and BC2GM062761406 CC O
Grb2 BC2GM062761406 NNP O
. BC2GM062761406 . O
. . O O

Resistance BC2GM094961159 NN O
to BC2GM094961159 TO O
Mup BC2GM094961159 NNP O
was BC2GM094961159 VBD O
classified BC2GM094961159 VBN O
as BC2GM094961159 IN O
low BC2GM094961159 JJ O
( BC2GM094961159 ( O
minimal BC2GM094961159 JJ O
inhibitory BC2GM094961159 NN O
concentration BC2GM094961159 NN O
[ BC2GM094961159 NNP O
MIC BC2GM094961159 NNP O
] BC2GM094961159 NNP O
> BC2GM094961159 NNP O
or BC2GM094961159 CC O
= BC2GM094961159 $ O
8 BC2GM094961159 CD O
microg BC2GM094961159 NN O
/ BC2GM094961159 NNP O
mL BC2GM094961159 NN O
) BC2GM094961159 ) O
or BC2GM094961159 CC O
high BC2GM094961159 JJ O
( BC2GM094961159 ( O
MIC BC2GM094961159 NNP O
> BC2GM094961159 NNP O
or BC2GM094961159 CC O
= BC2GM094961159 $ O
512 BC2GM094961159 CD O
microg BC2GM094961159 NN O
/ BC2GM094961159 NNP O
mL BC2GM094961159 NN O
) BC2GM094961159 ) O
degree BC2GM094961159 NN O
. BC2GM094961159 . O
. . O O

Continuous BC2GM096399526 JJ O
arterial BC2GM096399526 JJ O
blood BC2GM096399526 NN O
sampling BC2GM096399526 VBG O
method BC2GM096399526 NNS O
based BC2GM096399526 VBN O
on BC2GM096399526 IN O
the BC2GM096399526 DT O
microsphere BC2GM096399526 JJ O
model BC2GM096399526 NN O
was BC2GM096399526 VBD O
used BC2GM096399526 VBN O
as BC2GM096399526 IN O
a BC2GM096399526 DT O
quantitative BC2GM096399526 JJ O
rCBF BC2GM096399526 NN O
measurement BC2GM096399526 NN O
. BC2GM096399526 . O
. . O O

Further BC2GM084745915 JJ O
interventions BC2GM084745915 NNS O
were BC2GM084745915 VBD O
: BC2GM084745915 : O
nephrectomy BC2GM084745915 NN O
( BC2GM084745915 ( O
2x BC2GM084745915 CD O
) BC2GM084745915 ) O
, BC2GM084745915 , O
resection BC2GM084745915 NN O
and BC2GM084745915 CC O
ligation BC2GM084745915 NN O
of BC2GM084745915 IN O
the BC2GM084745915 DT O
inferior BC2GM084745915 JJ O
vena BC2GM084745915 NN O
cava BC2GM084745915 NN O
( BC2GM084745915 ( O
1x BC2GM084745915 CD O
) BC2GM084745915 ) O
, BC2GM084745915 , O
resection BC2GM084745915 NN O
and BC2GM084745915 CC O
replacement BC2GM084745915 NN O
of BC2GM084745915 IN O
the BC2GM084745915 DT O
left BC2GM084745915 JJ O
renal BC2GM084745915 JJ O
vein BC2GM084745915 NN O
( BC2GM084745915 ( O
1x BC2GM084745915 CD O
) BC2GM084745915 ) O
. BC2GM084745915 . O
. . O O

The BC2GM065134610 DT O
specificity BC2GM065134610 NN O
of BC2GM065134610 IN O
the BC2GM065134610 DT O
transcriptional BC2GM065134610 JJ O
activation BC2GM065134610 NN O
by BC2GM065134610 IN O
ISGF3 BC2GM065134610 NNP O
is BC2GM065134610 VBZ O
mediated BC2GM065134610 VBN O
by BC2GM065134610 IN O
specific BC2GM065134610 JJ O
elements BC2GM065134610 NNS O
termed BC2GM065134610 VBD O
IFN-stimulatory BC2GM065134610 JJ O
response BC2GM065134610 NN O
element BC2GM065134610 NN O
( BC2GM065134610 ( O
ISRE BC2GM065134610 NNP O
) BC2GM065134610 ) O
located BC2GM065134610 VBN O
in BC2GM065134610 IN O
the BC2GM065134610 DT O
promoter BC2GM065134610 NN O
region BC2GM065134610 NN O
of BC2GM065134610 IN O
IFN-inducible BC2GM065134610 JJ O
genes BC2GM065134610 NNS O
. BC2GM065134610 . O
. . O O

Database BC2GM033547721 NNP O
searches BC2GM033547721 VBZ O
revealed BC2GM033547721 VBD O
a BC2GM033547721 DT O
50-63 BC2GM033547721 JJ O
% BC2GM033547721 NN O
similarity BC2GM033547721 NN O
and BC2GM033547721 CC O
34-42 BC2GM033547721 CD O
% BC2GM033547721 NN O
identity BC2GM033547721 NN O
with BC2GM033547721 IN O
several BC2GM033547721 JJ O
families BC2GM033547721 NNS O
of BC2GM033547721 IN O
serine BC2GM033547721 NN O
proteases BC2GM033547721 NNS O
, BC2GM033547721 , O
in BC2GM033547721 IN O
particular BC2GM033547721 JJ O
the BC2GM033547721 DT O
trypsin-like BC2GM033547721 JJ O
proteases BC2GM033547721 NNS O
, BC2GM033547721 , O
members BC2GM033547721 NNS O
of BC2GM033547721 IN O
the BC2GM033547721 DT O
glandular BC2GM033547721 JJ O
kallikrein BC2GM033547721 NNS O
family BC2GM033547721 NN O
( BC2GM033547721 ( O
including BC2GM033547721 VBG O
prostate-specific BC2GM033547721 JJ O
antigen BC2GM033547721 NN O
, BC2GM033547721 , O
nerve BC2GM033547721 NN O
growth BC2GM033547721 NN O
factor BC2GM033547721 NN O
gamma BC2GM033547721 NN O
, BC2GM033547721 , O
and BC2GM033547721 CC O
epidermal BC2GM033547721 JJ O
growth BC2GM033547721 NN O
factor-binding BC2GM033547721 JJ O
protein BC2GM033547721 NN O
) BC2GM033547721 ) O
and BC2GM033547721 CC O
the BC2GM033547721 DT O
activators BC2GM033547721 NNS O
for BC2GM033547721 IN O
the BC2GM033547721 DT O
kringle BC2GM033547721 NN O
family BC2GM033547721 NN O
proteins BC2GM033547721 NNS O
( BC2GM033547721 ( O
including BC2GM033547721 VBG O
the BC2GM033547721 DT O
human BC2GM033547721 JJ O
tissue BC2GM033547721 NN O
plasminogen BC2GM033547721 NN O
activator BC2GM033547721 NN O
and BC2GM033547721 CC O
human BC2GM033547721 JJ O
hepatocyte BC2GM033547721 NN O
growth BC2GM033547721 NN O
factor BC2GM033547721 NN O
activator BC2GM033547721 NN O
) BC2GM033547721 ) O
. BC2GM033547721 . O
. . O O

The BC2GM041631891 DT O
primary BC2GM041631891 JJ O
structures BC2GM041631891 NNS O
of BC2GM041631891 IN O
the BC2GM041631891 DT O
human BC2GM041631891 JJ O
KB BC2GM041631891 NNP O
cell BC2GM041631891 NN O
( BC2GM041631891 ( O
FR-KB1 BC2GM041631891 NNP O
) BC2GM041631891 ) O
folate BC2GM041631891 NN O
receptor BC2GM041631891 NN O
( BC2GM041631891 ( O
FR BC2GM041631891 NNP O
) BC2GM041631891 ) O
and BC2GM041631891 CC O
of BC2GM041631891 IN O
a BC2GM041631891 DT O
human BC2GM041631891 JJ O
placental BC2GM041631891 NN O
( BC2GM041631891 ( O
FR-P2 BC2GM041631891 NNP O
) BC2GM041631891 ) O
FR BC2GM041631891 NNP O
, BC2GM041631891 , O
proteins BC2GM041631891 VBZ O
important BC2GM041631891 JJ O
in BC2GM041631891 IN O
cellular BC2GM041631891 JJ O
accumulation BC2GM041631891 NN O
of BC2GM041631891 IN O
folates BC2GM041631891 NNS O
, BC2GM041631891 , O
have BC2GM041631891 VBP O
been BC2GM041631891 VBN O
deduced BC2GM041631891 VBN O
from BC2GM041631891 IN O
cDNA BC2GM041631891 NN O
sequences BC2GM041631891 NNS O
. BC2GM041631891 . O
. . O O

The BC2GM053748645 DT O
role BC2GM053748645 NN O
of BC2GM053748645 IN O
the BC2GM053748645 DT O
medical BC2GM053748645 JJ O
facilities BC2GM053748645 NNS O
in BC2GM053748645 IN O
the BC2GM053748645 DT O
prognosis BC2GM053748645 NN O
of BC2GM053748645 IN O
the BC2GM053748645 DT O
patient BC2GM053748645 NN O
with BC2GM053748645 IN O
tetanus BC2GM053748645 NN O
specially BC2GM053748645 RB O
the BC2GM053748645 DT O
importance BC2GM053748645 NN O
of BC2GM053748645 IN O
considering BC2GM053748645 VBG O
at BC2GM053748645 IN O
the BC2GM053748645 DT O
same BC2GM053748645 JJ O
time BC2GM053748645 NN O
the BC2GM053748645 DT O
severity BC2GM053748645 NN O
of BC2GM053748645 IN O
the BC2GM053748645 DT O
disease BC2GM053748645 NN O
and BC2GM053748645 CC O
the BC2GM053748645 DT O
characteristics BC2GM053748645 NNS O
of BC2GM053748645 IN O
the BC2GM053748645 DT O
therapy BC2GM053748645 NN O
deserve BC2GM053748645 NN O
further BC2GM053748645 RBR O
study BC2GM053748645 NN O
in BC2GM053748645 IN O
order BC2GM053748645 NN O
to BC2GM053748645 TO O
contribute BC2GM053748645 VB O
to BC2GM053748645 TO O
the BC2GM053748645 DT O
development BC2GM053748645 NN O
of BC2GM053748645 IN O
the BC2GM053748645 DT O
medical BC2GM053748645 JJ O
assistance BC2GM053748645 NN O
to BC2GM053748645 TO O
the BC2GM053748645 DT O
patients BC2GM053748645 NNS O
with BC2GM053748645 IN O
tetanus BC2GM053748645 NN O
. BC2GM053748645 . O
. . O O

HBO BC2GM086777586 NNP O
had BC2GM086777586 VBD O
marked BC2GM086777586 VBN O
effects BC2GM086777586 NNS O
on BC2GM086777586 IN O
these BC2GM086777586 DT O
enzymes BC2GM086777586 NNS O
: BC2GM086777586 : O
lung BC2GM086777586 NN O
SOD BC2GM086777586 NNP O
increased BC2GM086777586 VBD O
( BC2GM086777586 ( O
guinea BC2GM086777586 NN O
pigs BC2GM086777586 NNS O
47 BC2GM086777586 CD O
% BC2GM086777586 NN O
, BC2GM086777586 , O
rats BC2GM086777586 VBZ O
88 BC2GM086777586 CD O
% BC2GM086777586 NN O
) BC2GM086777586 ) O
and BC2GM086777586 CC O
CAT BC2GM086777586 NNP O
and BC2GM086777586 CC O
GSHPx BC2GM086777586 NNP O
activities BC2GM086777586 NNS O
decreased BC2GM086777586 VBD O
( BC2GM086777586 ( O
33 BC2GM086777586 CD O
% BC2GM086777586 NN O
) BC2GM086777586 ) O
in BC2GM086777586 IN O
brain BC2GM086777586 NN O
and BC2GM086777586 CC O
lung BC2GM086777586 NN O
. BC2GM086777586 . O
. . O O

Furthermore BC2GM073834099 RB O
, BC2GM073834099 , O
rubella BC2GM073834099 NN O
IgM BC2GM073834099 NNP O
antibody BC2GM073834099 NN O
was BC2GM073834099 VBD O
never BC2GM073834099 RB O
detected BC2GM073834099 VBN O
after BC2GM073834099 IN O
immunization BC2GM073834099 NN O
in BC2GM073834099 IN O
women BC2GM073834099 NNS O
who BC2GM073834099 WP O
were BC2GM073834099 VBD O
HAI-negative BC2GM073834099 JJ O
and BC2GM073834099 CC O
LA-positive BC2GM073834099 JJ O
during BC2GM073834099 IN O
pregnancy BC2GM073834099 NN O
. BC2GM073834099 . O
. . O O

We BC2GM045948715 PRP O
reviewed BC2GM045948715 VBD O
the BC2GM045948715 DT O
different BC2GM045948715 JJ O
published BC2GM045948715 VBN O
cases BC2GM045948715 NNS O
of BC2GM045948715 IN O
acute BC2GM045948715 JJ O
high BC2GM045948715 JJ O
dose BC2GM045948715 NN O
methotrexate BC2GM045948715 NN O
neurotoxicity BC2GM045948715 NN O
and BC2GM045948715 CC O
the BC2GM045948715 DT O
different BC2GM045948715 JJ O
underlying BC2GM045948715 JJ O
mechanisms BC2GM045948715 NNS O
. BC2GM045948715 . O
. . O O

Low BC2GM083364353 JJ O
serum BC2GM083364353 NN O
C3 BC2GM083364353 NNP O
values BC2GM083364353 NNS O
were BC2GM083364353 VBD O
observed BC2GM083364353 VBN O
in BC2GM083364353 IN O
all BC2GM083364353 DT O
11 BC2GM083364353 CD O
children BC2GM083364353 NNS O
at BC2GM083364353 IN O
some BC2GM083364353 DT O
stage BC2GM083364353 NN O
of BC2GM083364353 IN O
their BC2GM083364353 PRP$ O
illness BC2GM083364353 NN O
. BC2GM083364353 . O
. . O O

Elements BC2GM063198333 NNS O
of BC2GM063198333 IN O
the BC2GM063198333 DT O
hAT BC2GM063198333 NN O
transposon BC2GM063198333 VBD O
family BC2GM063198333 NN O
, BC2GM063198333 , O
such BC2GM063198333 JJ O
as BC2GM063198333 IN O
the BC2GM063198333 DT O
maize BC2GM063198333 NN O
activator BC2GM063198333 NN O
( BC2GM063198333 ( O
Ac BC2GM063198333 NNP O
) BC2GM063198333 ) O
, BC2GM063198333 , O
have BC2GM063198333 VBP O
been BC2GM063198333 VBN O
discovered BC2GM063198333 VBN O
in BC2GM063198333 IN O
a BC2GM063198333 DT O
large BC2GM063198333 JJ O
number BC2GM063198333 NN O
of BC2GM063198333 IN O
eukaryotic BC2GM063198333 JJ O
species BC2GM063198333 NNS O
. BC2GM063198333 . O
. . O O

We BC2GM019927220 PRP O
found BC2GM019927220 VBD O
remarkable BC2GM019927220 JJ O
differences BC2GM019927220 NNS O
in BC2GM019927220 IN O
the BC2GM019927220 DT O
expression BC2GM019927220 NN O
patterns BC2GM019927220 NNS O
of BC2GM019927220 IN O
MTB-Zf BC2GM019927220 NNP O
mRNA BC2GM019927220 NN O
and BC2GM019927220 CC O
two BC2GM019927220 CD O
other BC2GM019927220 JJ O
hybridizable BC2GM019927220 JJ O
mRNAs BC2GM019927220 NN O
of BC2GM019927220 IN O
5kb BC2GM019927220 CD O
and BC2GM019927220 CC O
8.5 BC2GM019927220 CD O
kb BC2GM019927220 NN O
when BC2GM019927220 WRB O
human BC2GM019927220 JJ O
brain BC2GM019927220 NN O
and BC2GM019927220 CC O
primary BC2GM019927220 JJ O
brain BC2GM019927220 NN O
tumors BC2GM019927220 NNS O
were BC2GM019927220 VBD O
compared BC2GM019927220 VBN O
. BC2GM019927220 . O
. . O O

As BC2GM051293681 IN O
expected BC2GM051293681 VBN O
, BC2GM051293681 , O
the BC2GM051293681 DT O
QOLS-N BC2GM051293681 NNP O
had BC2GM051293681 VBD O
a BC2GM051293681 DT O
lower BC2GM051293681 JJR O
correlation BC2GM051293681 NN O
with BC2GM051293681 IN O
physical BC2GM051293681 JJ O
health BC2GM051293681 NN O
( BC2GM051293681 ( O
r BC2GM051293681 VB O
= BC2GM051293681 RB O
0.24 BC2GM051293681 CD O
, BC2GM051293681 , O
p BC2GM051293681 NN O
< BC2GM051293681 NNP O
0.000 BC2GM051293681 CD O
) BC2GM051293681 ) O
and BC2GM051293681 CC O
self-reported BC2GM051293681 JJ O
symptoms BC2GM051293681 NNS O
( BC2GM051293681 ( O
r BC2GM051293681 VB O
= BC2GM051293681 NNP O
-0.20 BC2GM051293681 NNP O
, BC2GM051293681 , O
p BC2GM051293681 NN O
< BC2GM051293681 NNP O
0.001 BC2GM051293681 CD O
) BC2GM051293681 ) O
, BC2GM051293681 , O
and BC2GM051293681 CC O
a BC2GM051293681 DT O
higher BC2GM051293681 JJR O
correlation BC2GM051293681 NN O
with BC2GM051293681 IN O
mental BC2GM051293681 JJ O
health BC2GM051293681 NN O
( BC2GM051293681 ( O
r BC2GM051293681 VB O
= BC2GM051293681 RB O
0.52 BC2GM051293681 CD O
, BC2GM051293681 , O
p BC2GM051293681 NN O
< BC2GM051293681 NNP O
0.000 BC2GM051293681 CD O
) BC2GM051293681 ) O
. BC2GM051293681 . O
. . O O

A BC2GM042126877 DT O
preterm BC2GM042126877 JJ O
formula BC2GM042126877 NN O
with BC2GM042126877 IN O
a BC2GM042126877 DT O
traditional BC2GM042126877 JJ O
corn BC2GM042126877 NN O
oil BC2GM042126877 NN O
/ BC2GM042126877 NNP O
MCT BC2GM042126877 NNP O
blend BC2GM042126877 VBP O
containing BC2GM042126877 VBG O
38 BC2GM042126877 CD O
% BC2GM042126877 NN O
MCTs BC2GM042126877 NNP O
( BC2GM042126877 ( O
MCT BC2GM042126877 NNP O
group BC2GM042126877 NN O
) BC2GM042126877 ) O
was BC2GM042126877 VBD O
compared BC2GM042126877 VBN O
to BC2GM042126877 TO O
a BC2GM042126877 DT O
new BC2GM042126877 JJ O
fat BC2GM042126877 JJ O
blend BC2GM042126877 NN O
, BC2GM042126877 , O
designed BC2GM042126877 VBN O
to BC2GM042126877 TO O
resemble BC2GM042126877 VB O
human BC2GM042126877 JJ O
milk BC2GM042126877 NN O
more BC2GM042126877 RBR O
, BC2GM042126877 , O
containing BC2GM042126877 VBG O
6 BC2GM042126877 CD O
% BC2GM042126877 NN O
MCTs BC2GM042126877 NNP O
( BC2GM042126877 ( O
LCT BC2GM042126877 NNP O
group BC2GM042126877 NN O
) BC2GM042126877 ) O
. BC2GM042126877 . O
. . O O

In BC2GM003020957 IN O
this BC2GM003020957 DT O
study BC2GM003020957 NN O
, BC2GM003020957 , O
we BC2GM003020957 PRP O
report BC2GM003020957 VBP O
the BC2GM003020957 DT O
cloning BC2GM003020957 NN O
and BC2GM003020957 CC O
sequencing BC2GM003020957 NN O
of BC2GM003020957 IN O
several BC2GM003020957 JJ O
overlapping BC2GM003020957 VBG O
cDNAs BC2GM003020957 NN O
encoding BC2GM003020957 VBG O
approximately BC2GM003020957 RB O
4.1 BC2GM003020957 CD O
kb BC2GM003020957 NNS O
of BC2GM003020957 IN O
the BC2GM003020957 DT O
human BC2GM003020957 JJ O
homologue BC2GM003020957 NN O
of BC2GM003020957 IN O
Wnt-5A BC2GM003020957 NNP O
. BC2GM003020957 . O
. . O O

Our BC2GM065118476 PRP$ O
data BC2GM065118476 NNS O
provide BC2GM065118476 VB O
the BC2GM065118476 DT O
first BC2GM065118476 JJ O
evidence BC2GM065118476 NN O
that BC2GM065118476 IN O
differential BC2GM065118476 JJ O
splicing BC2GM065118476 NN O
in BC2GM065118476 IN O
the BC2GM065118476 DT O
extracellular BC2GM065118476 JJ O
region BC2GM065118476 NN O
of BC2GM065118476 IN O
a BC2GM065118476 DT O
receptor BC2GM065118476 NN O
gene BC2GM065118476 NN O
generates BC2GM065118476 NNS O
receptor BC2GM065118476 VBP O
variants BC2GM065118476 NNS O
with BC2GM065118476 IN O
different BC2GM065118476 JJ O
ligand-binding BC2GM065118476 JJ O
specificities BC2GM065118476 NNS O
. BC2GM065118476 . O
. . O O

We BC2GM033034738 PRP O
demonstrate BC2GM033034738 VBP O
inhibition BC2GM033034738 NN O
of BC2GM033034738 IN O
2-deoxyglucose BC2GM033034738 JJ O
uptake BC2GM033034738 NN O
in BC2GM033034738 IN O
isolated BC2GM033034738 JJ O
primary BC2GM033034738 JJ O
rat BC2GM033034738 NN O
adipocytes BC2GM033034738 NNS O
and BC2GM033034738 CC O
3T3-L1 BC2GM033034738 JJ O
adipocytes BC2GM033034738 NNS O
pretreated BC2GM033034738 VBN O
with BC2GM033034738 IN O
U73122 BC2GM033034738 NNP O
. BC2GM033034738 . O
. . O O

When BC2GM091202887 WRB O
lipid BC2GM091202887 JJ O
X BC2GM091202887 NN O
was BC2GM091202887 VBD O
combined BC2GM091202887 VBN O
with BC2GM091202887 IN O
ticarcillin BC2GM091202887 NN O
, BC2GM091202887 , O
survival BC2GM091202887 JJ O
differences BC2GM091202887 NNS O
were BC2GM091202887 VBD O
both BC2GM091202887 DT O
significant BC2GM091202887 JJ O
and BC2GM091202887 CC O
prolonged BC2GM091202887 JJ O
. BC2GM091202887 . O
. . O O

Cryoglobulinaemia BC2GM044133796 NNP O
among BC2GM044133796 IN O
maintenance BC2GM044133796 JJ O
haemodialysis BC2GM044133796 NN O
patients BC2GM044133796 NNS O
and BC2GM044133796 CC O
its BC2GM044133796 PRP$ O
relation BC2GM044133796 NN O
to BC2GM044133796 TO O
hepatitis BC2GM044133796 VB O
C BC2GM044133796 NNP O
infection BC2GM044133796 NN O
. BC2GM044133796 . O
. . O O

The BC2GM015227811 DT O
ferric BC2GM015227811 JJ O
uptake BC2GM015227811 JJ O
regulation BC2GM015227811 NN O
( BC2GM015227811 ( O
fur BC2GM015227811 NN O
) BC2GM015227811 ) O
gene BC2GM015227811 NN O
product BC2GM015227811 NN O
participates BC2GM015227811 NNS O
in BC2GM015227811 IN O
regulating BC2GM015227811 VBG O
expression BC2GM015227811 NN O
of BC2GM015227811 IN O
the BC2GM015227811 DT O
manganese- BC2GM015227811 JJ O
and BC2GM015227811 CC O
iron-containing BC2GM015227811 JJ O
superoxide BC2GM015227811 NN O
dismutase BC2GM015227811 NN O
genes BC2GM015227811 NNS O
of BC2GM015227811 IN O
Escherichia BC2GM015227811 NNP O
coli BC2GM015227811 NN O
. BC2GM015227811 . O
. . O O

CSEn BC2GM092572255 NNP O
stimulated BC2GM092572255 VBD O
transcription BC2GM092572255 NN O
of BC2GM092572255 IN O
a BC2GM092572255 DT O
variety BC2GM092572255 NN O
of BC2GM092572255 IN O
promoters BC2GM092572255 NNS O
, BC2GM092572255 , O
including BC2GM092572255 VBG O
the BC2GM092572255 DT O
hCS BC2GM092572255 NN O
, BC2GM092572255 , O
human BC2GM092572255 JJ O
growth BC2GM092572255 NN O
hormone BC2GM092572255 NN O
, BC2GM092572255 , O
thymidine BC2GM092572255 JJ O
kinase BC2GM092572255 NN O
, BC2GM092572255 , O
and BC2GM092572255 CC O
Rous BC2GM092572255 NNP O
sarcoma BC2GM092572255 VBP O
virus BC2GM092572255 NN O
promoters BC2GM092572255 NNS O
, BC2GM092572255 , O
in BC2GM092572255 IN O
human BC2GM092572255 JJ O
choriocarcinoma BC2GM092572255 NN O
cell BC2GM092572255 NN O
lines BC2GM092572255 NNS O
( BC2GM092572255 ( O
BeWo BC2GM092572255 NNP O
and BC2GM092572255 CC O
JEG-3 BC2GM092572255 NNP O
) BC2GM092572255 ) O
but BC2GM092572255 CC O
not BC2GM092572255 RB O
HeLa BC2GM092572255 NNP O
cells BC2GM092572255 NNS O
or BC2GM092572255 CC O
rat BC2GM092572255 NN O
somatolactotrophes BC2GM092572255 NNS O
( BC2GM092572255 ( O
GC BC2GM092572255 NNP O
) BC2GM092572255 ) O
. BC2GM092572255 . O
. . O O

This BC2GM073122143 DT O
enzyme BC2GM073122143 NN O
is BC2GM073122143 VBZ O
distinct BC2GM073122143 JJ O
from BC2GM073122143 IN O
other BC2GM073122143 JJ O
known BC2GM073122143 VBN O
E3s BC2GM073122143 NNP O
, BC2GM073122143 , O
including BC2GM073122143 VBG O
E3 BC2GM073122143 NNP O
alpha BC2GM073122143 NN O
/ BC2GM073122143 NNP O
UBR1 BC2GM073122143 NNP O
, BC2GM073122143 , O
E3 BC2GM073122143 NNP O
beta BC2GM073122143 NN O
, BC2GM073122143 , O
and BC2GM073122143 CC O
E6-AP BC2GM073122143 NNP O
. BC2GM073122143 . O
. . O O

This BC2GM043298820 DT O
region BC2GM043298820 NN O
shows BC2GM043298820 VBZ O
46 BC2GM043298820 CD O
% BC2GM043298820 NN O
identity BC2GM043298820 NN O
with BC2GM043298820 IN O
the BC2GM043298820 DT O
calmodulin-binding BC2GM043298820 JJ O
region BC2GM043298820 NN O
of BC2GM043298820 IN O
rat BC2GM043298820 NN O
brain BC2GM043298820 NN O
Ca2+ BC2GM043298820 NNP O
/ BC2GM043298820 NNP O
calmodulin-dependent BC2GM043298820 JJ O
protein BC2GM043298820 NN O
kinase BC2GM043298820 NN O
II BC2GM043298820 NNP O
and BC2GM043298820 CC O
32 BC2GM043298820 CD O
% BC2GM043298820 NN O
identity BC2GM043298820 NN O
with BC2GM043298820 IN O
the BC2GM043298820 DT O
equivalent BC2GM043298820 JJ O
region BC2GM043298820 NN O
of BC2GM043298820 IN O
chicken BC2GM043298820 NN O
smooth BC2GM043298820 JJ O
muscle BC2GM043298820 NN O
myosin BC2GM043298820 NN O
light BC2GM043298820 NN O
chain BC2GM043298820 NN O
kinase BC2GM043298820 NN O
. BC2GM043298820 . O
. . O O

Conversely BC2GM036087490 RB O
, BC2GM036087490 , O
as BC2GM036087490 IN O
a BC2GM036087490 DT O
GAL-4 BC2GM036087490 NNP O
chimera BC2GM036087490 NN O
, BC2GM036087490 , O
the BC2GM036087490 DT O
isolated BC2GM036087490 JJ O
LAZ3 BC2GM036087490 NNP O
/ BC2GM036087490 NNP O
BCL6 BC2GM036087490 NNP O
BTB BC2GM036087490 NNP O
/ BC2GM036087490 NNP O
POZ BC2GM036087490 NNP O
domain BC2GM036087490 NN O
appears BC2GM036087490 VBZ O
nearly BC2GM036087490 RB O
as BC2GM036087490 RB O
efficient BC2GM036087490 JJ O
as BC2GM036087490 IN O
the BC2GM036087490 DT O
entire BC2GM036087490 JJ O
protein BC2GM036087490 NN O
at BC2GM036087490 IN O
inducing BC2GM036087490 VBG O
transcriptional BC2GM036087490 JJ O
repression BC2GM036087490 NN O
. BC2GM036087490 . O
. . O O

The BC2GM035316486 DT O
mutants BC2GM035316486 NNS O
retained BC2GM035316486 VBD O
the BC2GM035316486 DT O
parental BC2GM035316486 JJ O
ability BC2GM035316486 NN O
to BC2GM035316486 TO O
participate BC2GM035316486 VB O
in BC2GM035316486 IN O
intergeneric BC2GM035316486 JJ O
coaggregation BC2GM035316486 NN O
with BC2GM035316486 IN O
human BC2GM035316486 JJ O
oral BC2GM035316486 JJ O
actinomyces BC2GM035316486 NNS O
, BC2GM035316486 , O
indicating BC2GM035316486 VBG O
the BC2GM035316486 DT O
specificity BC2GM035316486 NN O
of BC2GM035316486 IN O
the BC2GM035316486 DT O
mutation BC2GM035316486 NN O
in BC2GM035316486 IN O
altering BC2GM035316486 VBG O
intrageneric BC2GM035316486 JJ O
coaggregations BC2GM035316486 NNS O
. BC2GM035316486 . O
. . O O

By BC2GM036392527 IN O
RT-PCR BC2GM036392527 NNP O
, BC2GM036392527 , O
different BC2GM036392527 JJ O
levels BC2GM036392527 NNS O
of BC2GM036392527 IN O
E75 BC2GM036392527 NNP O
expression BC2GM036392527 NN O
can BC2GM036392527 MD O
be BC2GM036392527 VB O
detected BC2GM036392527 VBN O
in BC2GM036392527 IN O
the BC2GM036392527 DT O
epidermis BC2GM036392527 NN O
, BC2GM036392527 , O
nerve BC2GM036392527 NN O
cord BC2GM036392527 NN O
and BC2GM036392527 CC O
the BC2GM036392527 DT O
eyestalk BC2GM036392527 NN O
of BC2GM036392527 IN O
early BC2GM036392527 JJ O
pre-molt BC2GM036392527 JJ O
shrimp BC2GM036392527 NN O
. BC2GM036392527 . O
. . O O

In BC2GM058534127 IN O
addition BC2GM058534127 NN O
, BC2GM058534127 , O
we BC2GM058534127 PRP O
show BC2GM058534127 VBP O
that BC2GM058534127 DT O
expression BC2GM058534127 NN O
of BC2GM058534127 IN O
antisense BC2GM058534127 NN O
mRNA BC2GM058534127 NN O
for BC2GM058534127 IN O
p130CAS BC2GM058534127 NN O
resulted BC2GM058534127 VBD O
in BC2GM058534127 IN O
reversion BC2GM058534127 NN O
of BC2GM058534127 IN O
the BC2GM058534127 DT O
transformed BC2GM058534127 JJ O
phenotype BC2GM058534127 NN O
of BC2GM058534127 IN O
all BC2GM058534127 PDT O
these BC2GM058534127 DT O
cell BC2GM058534127 NN O
lines BC2GM058534127 NNS O
. BC2GM058534127 . O
. . O O

Exon BC2GM081998478 NNP O
A1a BC2GM081998478 NNP O
encodes BC2GM081998478 VBZ O
most BC2GM081998478 JJS O
of BC2GM081998478 IN O
the BC2GM081998478 DT O
5'-untranslated BC2GM081998478 JJ O
region BC2GM081998478 NN O
. BC2GM081998478 . O
. . O O

Bilateral BC2GM050477465 NNP O
renal BC2GM050477465 JJ O
oncocytoma BC2GM050477465 NN O
in BC2GM050477465 IN O
a BC2GM050477465 DT O
Greyhound BC2GM050477465 NNP O
dog BC2GM050477465 NN O
. BC2GM050477465 . O
. . O O

Iomazenil-SPECT BC2GM035992425 NNP O
revealed BC2GM035992425 VBD O
a BC2GM035992425 DT O
highly BC2GM035992425 RB O
significant BC2GM035992425 JJ O
increase BC2GM035992425 NN O
in BC2GM035992425 IN O
the BC2GM035992425 DT O
benzodiazepine BC2GM035992425 NN O
receptor BC2GM035992425 NN O
uptake BC2GM035992425 NN O
in BC2GM035992425 IN O
all BC2GM035992425 DT O
studied BC2GM035992425 JJ O
cortical BC2GM035992425 JJ O
regions BC2GM035992425 NNS O
except BC2GM035992425 IN O
temporal BC2GM035992425 JJ O
cortices BC2GM035992425 NNS O
. BC2GM035992425 . O
. . O O

A BC2GM090984958 DT O
case BC2GM090984958 NN O
of BC2GM090984958 IN O
acquired BC2GM090984958 VBN O
immune BC2GM090984958 JJ O
deficiency BC2GM090984958 NN O
syndrome BC2GM090984958 NN O
before BC2GM090984958 IN O
1980 BC2GM090984958 CD O
. BC2GM090984958 . O
. . O O

Amplification BC2GM085429283 NN O
of BC2GM085429283 IN O
4q21-q22 BC2GM085429283 JJ O
and BC2GM085429283 CC O
the BC2GM085429283 DT O
MXR BC2GM085429283 NNP O
gene BC2GM085429283 NN O
in BC2GM085429283 IN O
independently BC2GM085429283 RB O
derived BC2GM085429283 VBN O
mitoxantrone-resistant BC2GM085429283 JJ O
cell BC2GM085429283 NN O
lines BC2GM085429283 NNS O
. BC2GM085429283 . O
. . O O

K. BC2GM072323236 NNP O
, BC2GM072323236 , O
Weiss BC2GM072323236 NNP O
, BC2GM072323236 , O
M BC2GM072323236 NNP O
. BC2GM072323236 . O
. . O O

Implantation BC2GM040040983 NN O
is BC2GM040040983 VBZ O
contraindicated BC2GM040040983 VBN O
for BC2GM040040983 IN O
severe BC2GM040040983 JJ O
dysplasia BC2GM040040983 NN O
of BC2GM040040983 IN O
the BC2GM040040983 DT O
cochlea BC2GM040040983 NN O
and BC2GM040040983 CC O
for BC2GM040040983 IN O
the BC2GM040040983 DT O
recently BC2GM040040983 RB O
described BC2GM040040983 VBN O
variety BC2GM040040983 NN O
of BC2GM040040983 IN O
x-linked BC2GM040040983 JJ O
deafness BC2GM040040983 NN O
with BC2GM040040983 IN O
deficient BC2GM040040983 JJ O
bone BC2GM040040983 NN O
at BC2GM040040983 IN O
the BC2GM040040983 DT O
fundus BC2GM040040983 NN O
of BC2GM040040983 IN O
the BC2GM040040983 DT O
internal BC2GM040040983 JJ O
auditory BC2GM040040983 NN O
meatus BC2GM040040983 NN O
. BC2GM040040983 . O
. . O O

A BC2GM070333070 DT O
p53 BC2GM070333070 NN O
cDNA BC2GM070333070 NN O
deletion BC2GM070333070 NN O
mutant BC2GM070333070 NN O
( BC2GM070333070 ( O
delta BC2GM070333070 JJ O
pro BC2GM070333070 FW O
AE BC2GM070333070 NNP O
) BC2GM070333070 ) O
, BC2GM070333070 , O
which BC2GM070333070 WDT O
lacks BC2GM070333070 VBZ O
this BC2GM070333070 DT O
entire BC2GM070333070 JJ O
proline-rich BC2GM070333070 JJ O
domain BC2GM070333070 NN O
( BC2GM070333070 ( O
deleted BC2GM070333070 VBN O
for BC2GM070333070 IN O
amino BC2GM070333070 JJ O
acids BC2GM070333070 NNS O
62-91 BC2GM070333070 JJ O
) BC2GM070333070 ) O
, BC2GM070333070 , O
was BC2GM070333070 VBD O
created BC2GM070333070 VBN O
and BC2GM070333070 CC O
characterized BC2GM070333070 VBN O
for BC2GM070333070 IN O
a BC2GM070333070 DT O
variety BC2GM070333070 NN O
of BC2GM070333070 IN O
p53 BC2GM070333070 NN O
functions BC2GM070333070 NNS O
. BC2GM070333070 . O
. . O O

PATIENTS BC2GM010484925 NNP O
-- BC2GM010484925 : O
125 BC2GM010484925 CD O
women BC2GM010484925 NNS O
consulting BC2GM010484925 VBG O
the BC2GM010484925 DT O
general BC2GM010484925 JJ O
practitioner BC2GM010484925 NN O
for BC2GM010484925 IN O
symptomatic BC2GM010484925 JJ O
bacterial BC2GM010484925 JJ O
vaginosis BC2GM010484925 NN O
. BC2GM010484925 . O
. . O O

Action BC2GM016387762 NN O
against BC2GM016387762 IN O
Vibrio BC2GM016387762 NNP O
cholerae BC2GM016387762 NN O
O1 BC2GM016387762 NNP O
Tox+ BC2GM016387762 NNP O
of BC2GM016387762 IN O
chemical BC2GM016387762 NN O
products BC2GM016387762 NNS O
used BC2GM016387762 VBN O
in BC2GM016387762 IN O
the BC2GM016387762 DT O
lemon BC2GM016387762 JJ O
production BC2GM016387762 NN O
. BC2GM016387762 . O
. . O O

The BC2GM022798605 DT O
recent BC2GM022798605 JJ O
concept BC2GM022798605 NN O
of BC2GM022798605 IN O
a BC2GM022798605 DT O
bioartificial BC2GM022798605 JJ O
organ BC2GM022798605 NN O
is BC2GM022798605 VBZ O
an BC2GM022798605 DT O
attempt BC2GM022798605 NN O
to BC2GM022798605 TO O
avoid BC2GM022798605 VB O
such BC2GM022798605 JJ O
disadvantages BC2GM022798605 NNS O
. BC2GM022798605 . O
. . O O

Amino-terminal BC2GM068583518 JJ O
polymorphisms BC2GM068583518 NN O
of BC2GM068583518 IN O
the BC2GM068583518 DT O
human BC2GM068583518 JJ O
beta BC2GM068583518 NN O
2-adrenergic BC2GM068583518 JJ O
receptor BC2GM068583518 NN O
impart BC2GM068583518 JJ O
distinct BC2GM068583518 JJ O
agonist-promoted BC2GM068583518 JJ O
regulatory BC2GM068583518 JJ O
properties BC2GM068583518 NNS O
. BC2GM068583518 . O
. . O O

Using BC2GM098192106 VBG O
the BC2GM098192106 DT O
interaction-trap BC2GM098192106 JJ O
assay BC2GM098192106 NN O
to BC2GM098192106 TO O
identify BC2GM098192106 VB O
candidate BC2GM098192106 NN O
proteins BC2GM098192106 NNS O
that BC2GM098192106 WDT O
bind BC2GM098192106 VBP O
the BC2GM098192106 DT O
cytoplasmic BC2GM098192106 JJ O
region BC2GM098192106 NN O
of BC2GM098192106 IN O
the BC2GM098192106 DT O
LAR BC2GM098192106 NNP O
transmembrane BC2GM098192106 NN O
protein BC2GM098192106 NN O
tyrosine BC2GM098192106 JJ O
phosphatase BC2GM098192106 NN O
( BC2GM098192106 ( O
PT-Pase BC2GM098192106 NNP O
) BC2GM098192106 ) O
, BC2GM098192106 , O
we BC2GM098192106 PRP O
isolated BC2GM098192106 VBD O
a BC2GM098192106 DT O
cDNA BC2GM098192106 NN O
encoding BC2GM098192106 VBG O
a BC2GM098192106 DT O
2861-amino BC2GM098192106 JJ O
acid BC2GM098192106 NN O
protein BC2GM098192106 NN O
termed BC2GM098192106 VBD O
Trio BC2GM098192106 NNP O
that BC2GM098192106 IN O
contains BC2GM098192106 VBZ O
three BC2GM098192106 CD O
enzyme BC2GM098192106 NN O
domains BC2GM098192106 NNS O
: BC2GM098192106 : O
two BC2GM098192106 CD O
functional BC2GM098192106 JJ O
GEF BC2GM098192106 NNP O
domains BC2GM098192106 NNS O
and BC2GM098192106 CC O
a BC2GM098192106 DT O
protein BC2GM098192106 NN O
serine BC2GM098192106 NN O
/ BC2GM098192106 NNP O
threonine BC2GM098192106 NN O
kinase BC2GM098192106 NN O
( BC2GM098192106 ( O
PSK BC2GM098192106 NNP O
) BC2GM098192106 ) O
domain BC2GM098192106 NN O
. BC2GM098192106 . O
. . O O

In BC2GM064809845 IN O
NIH BC2GM064809845 NNP O
3T3 BC2GM064809845 CD O
fibroblasts BC2GM064809845 VBZ O
the BC2GM064809845 DT O
high BC2GM064809845 JJ O
affinity BC2GM064809845 NN O
IL-2R BC2GM064809845 NNP O
bearing BC2GM064809845 NN O
a BC2GM064809845 DT O
deletion BC2GM064809845 NN O
of BC2GM064809845 IN O
a BC2GM064809845 DT O
region BC2GM064809845 NN O
rich BC2GM064809845 JJ O
in BC2GM064809845 IN O
acidic BC2GM064809845 JJ O
amino BC2GM064809845 NN O
acids BC2GM064809845 NNS O
( BC2GM064809845 ( O
the BC2GM064809845 DT O
`` BC2GM064809845 `` O
acidic BC2GM064809845 JJ O
'' BC2GM064809845 '' O
region BC2GM064809845 NN O
) BC2GM064809845 ) O
in BC2GM064809845 IN O
the BC2GM064809845 DT O
IL-2R BC2GM064809845 NNP O
beta-chain BC2GM064809845 NN O
failed BC2GM064809845 VBD O
to BC2GM064809845 TO O
induce BC2GM064809845 VB O
the BC2GM064809845 DT O
tyrosine BC2GM064809845 JJ O
phosphorylation BC2GM064809845 NN O
of BC2GM064809845 IN O
MAP BC2GM064809845 NNP O
kinase BC2GM064809845 NN O
as BC2GM064809845 RB O
well BC2GM064809845 RB O
as BC2GM064809845 IN O
the BC2GM064809845 DT O
expression BC2GM064809845 NN O
of BC2GM064809845 IN O
the BC2GM064809845 DT O
all BC2GM064809845 DT O
three BC2GM064809845 CD O
nuclear BC2GM064809845 JJ O
proto-oncogenes BC2GM064809845 NNS O
. BC2GM064809845 . O
. . O O

No BC2GM033557862 DT O
bafilomycin-sensitive BC2GM033557862 JJ O
ATPase BC2GM033557862 NNP O
is BC2GM033557862 VBZ O
detected BC2GM033557862 VBN O
in BC2GM033557862 IN O
a BC2GM033557862 DT O
vacuolar BC2GM033557862 JJ O
fraction BC2GM033557862 NN O
. BC2GM033557862 . O
. . O O

19 BC2GM073006220 CD O
, BC2GM073006220 , O
4967-4973 BC2GM073006220 JJ O
) BC2GM073006220 ) O
. BC2GM073006220 . O
. . O O

Repeated BC2GM053136580 VBN O
interferon-beta BC2GM053136580 JJ O
( BC2GM053136580 ( O
IFN-beta BC2GM053136580 NNP O
) BC2GM053136580 ) O
silencer BC2GM053136580 NN O
B BC2GM053136580 NNP O
motifs BC2GM053136580 NN O
and BC2GM053136580 CC O
a BC2GM053136580 DT O
lysozyme BC2GM053136580 JJ O
silencer BC2GM053136580 NN O
1 BC2GM053136580 CD O
motif BC2GM053136580 NNS O
have BC2GM053136580 VBP O
been BC2GM053136580 VBN O
found BC2GM053136580 VBN O
in BC2GM053136580 IN O
the BC2GM053136580 DT O
CD95 BC2GM053136580 NNP O
gene BC2GM053136580 NN O
at BC2GM053136580 IN O
approximately BC2GM053136580 RB O
-1,600 BC2GM053136580 JJ O
and BC2GM053136580 CC O
-1,100 BC2GM053136580 JJ O
, BC2GM053136580 , O
respectively BC2GM053136580 RB O
. BC2GM053136580 . O
. . O O

Nine BC2GM074564112 JJ O
individuals BC2GM074564112 NNS O
who BC2GM074564112 WP O
were BC2GM074564112 VBD O
stable BC2GM074564112 JJ O
after BC2GM074564112 IN O
1 BC2GM074564112 CD O
month BC2GM074564112 NN O
of BC2GM074564112 IN O
therapy BC2GM074564112 NN O
at BC2GM074564112 IN O
low BC2GM074564112 JJ O
dosage BC2GM074564112 NN O
were BC2GM074564112 VBD O
randomized BC2GM074564112 VBN O
to BC2GM074564112 TO O
a BC2GM074564112 DT O
further BC2GM074564112 JJ O
month BC2GM074564112 NN O
of BC2GM074564112 IN O
therapy BC2GM074564112 NN O
at BC2GM074564112 IN O
low BC2GM074564112 JJ O
or BC2GM074564112 CC O
high BC2GM074564112 JJ O
dosage BC2GM074564112 NN O
, BC2GM074564112 , O
during BC2GM074564112 IN O
which BC2GM074564112 WDT O
one BC2GM074564112 CD O
of BC2GM074564112 IN O
four BC2GM074564112 CD O
at BC2GM074564112 IN O
high BC2GM074564112 JJ O
dosage BC2GM074564112 NN O
had BC2GM074564112 VBD O
a BC2GM074564112 DT O
partial BC2GM074564112 JJ O
response BC2GM074564112 NN O
, BC2GM074564112 , O
and BC2GM074564112 CC O
none BC2GM074564112 NN O
of BC2GM074564112 IN O
five BC2GM074564112 CD O
at BC2GM074564112 IN O
low BC2GM074564112 JJ O
dosage BC2GM074564112 NN O
manifested BC2GM074564112 VBN O
response BC2GM074564112 NN O
. BC2GM074564112 . O
. . O O

